<SEC-DOCUMENT>0001193125-15-142145.txt : 20150422
<SEC-HEADER>0001193125-15-142145.hdr.sgml : 20150422
<ACCEPTANCE-DATETIME>20150422171035
ACCESSION NUMBER:		0001193125-15-142145
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		30
CONFORMED PERIOD OF REPORT:	20150416
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Changes in Registrant's Certifying Accountant
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150422
DATE AS OF CHANGE:		20150422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rosewind CORP
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-EDUCATIONAL SERVICES [8200]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53121
		FILM NUMBER:		15786285

	BUSINESS ADDRESS:	
		STREET 1:		16200 WCR 18E
		CITY:			LOVELAND
		STATE:			CO
		ZIP:			80537
		BUSINESS PHONE:		(970) 635-0346

	MAIL ADDRESS:	
		STREET 1:		16200 WCR 18E
		CITY:			LOVELAND
		STATE:			CO
		ZIP:			80537
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d912919d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION&nbsp;13 OR 15(d)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): April&nbsp;16, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ROSEWIND CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Colorado</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-53121</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>47-0883144</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>373 Inverness Parkway</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 200</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Englewood,
Colorado</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>80112</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:&nbsp;(720) 437-6500 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page<BR>No.</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_1">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_2">Item&nbsp;1.01 Entry into a Material Definitive Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_3">Item&nbsp;2.01 Completion of Acquisition of Disposition of Assets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_4">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_5">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_6">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_7">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_8">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_9">Security Ownership of Certain Beneficial Owners and Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_10">Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_11">Description of Our Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_12">Market Price of and Dividends on Registrant&#146;s Common Stock and Related Stockholder Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_13">Recent Sales of Unregistered Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_14">Indemnification of Directors and Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_15">Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_16">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_17">Item&nbsp;3.02 Unregistered Sales of Equity Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_18">Item&nbsp;4.01 Changes in Registrant&#146;s Certifying Accountant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_19">Item&nbsp;5.01 Changes in Control of Registrant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_20">Item&nbsp;
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_21">Item&nbsp;5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_22">Item&nbsp;8.01 Other Events</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx912919_23">Item&nbsp;9.01 Financial Statements and Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Current Report on Form 8-K, unless the context indicates or otherwise requires, all references to
&#147;Rosewind&#148; refer to Rosewind Corporation, a Colorado corporation; all references to &#147;Vyrix&#148; refer to Vyrix Pharmaceuticals, Inc., a Delaware corporation; all references to &#147;Luoxis&#148; refer to Luoxis Diagnostics, Inc., a
Delaware corporation; all references to &#147;Ampio&#148; refer to Ampio Pharmaceuticals, Inc.; all references to the &#147;Combined Company,&#148; &#147;we,&#148; &#147;our&#148; and &#147;us&#148; refer to Rosewind from and after the closing of
the Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Form 8-K includes industry and market data and other information, which we have obtained from, or is based upon, market research,
independent industry publications or other publicly available information. Although we believe each such source to have been reliable as of its respective date, we have not independently verified the information contained in such sources. Any such
data and other information is subject to change based on various factors, including those described below under the heading &#147;Risk Factors&#148; and elsewhere in this Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including Zertane, Vyrix, RedoxSYS and
Luoxis. All other trademarks or trade names referred to in this Form 8-K are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 8-K may be referred to without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We
do not intend or use or display of other companies&#146; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_1"></A>SPECIAL NOTE REGARDING FORWARD LOOKING-STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form 8-K, including the sections entitled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and &#147;Business,&#148; contains forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. Although we believe that
the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements
in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">our need for, and ability to raise, additional capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">the number, designs, results and timing of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">the regulatory review process and any regulatory approvals that may be issued or denied by the Food and Drug Administration or other regulatory agencies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">our need to secure collaborators to license, manufacture, market and sell any products for which we receive regulatory approval in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">the therapeutic benefits, effectiveness and safety of our products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">the accuracy of our estimates of the size and characteristics of the markets that may be addressed by our products and product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture sufficient amounts of our product candidates for clinical trials and products for commercialization activities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">the commercial success and market acceptance of any of our product candidates that are approved for marketing in the United States or other countries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">the safety and efficacy of medicines or treatments introduced by competitors that are targeted to indications which our product candidates have been developed to treat; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">our current or prospective collaborators&#146; compliance or non-compliance with their obligations under our agreements with them; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">other factors discussed elsewhere in this Form 8-K or the documents incorporated by reference herein. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some
cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current
expectations include, among other things, those listed under &#147;Risk factors&#148; and elsewhere in this Form 8-K. If one or more of these risks or uncertainties occur, or if our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a
guarantee of future performance. You should read this Form 8-K and the documents that we reference in this Form 8-K and have filed with the Securities and Exchange Commission as exhibits to this Form 8-K completely and with the understanding that
our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
forward-looking statements in this Form 8-K represent our views as of the date of this Form 8-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking
statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent
to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_2"></A>Item&nbsp;1.01. Entry into a Material Definitive Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the disclosure set forth under Item&nbsp;2.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2015, we entered into a Voting Agreement with Ampio Pharmaceuticals, Inc., or Ampio, a Delaware corporation. Pursuant to the Voting
Agreement, Ampio agreed to vote all of the shares of our common stock beneficially owned by Ampio at a special meeting of our stockholders or by written consent in favor of the following proposals approved by our Board of Directors and authorizing
us to (1)&nbsp;re-incorporate into the State of Delaware through a plan of conversion; (2)&nbsp;effectuate a reverse stock split of our common stock, at a ratio of one new share for every approximately 12.174 shares currently outstanding;
(3)&nbsp;change our name from &#147;Rosewind Corporation&#148; to &#147;Aytu Bioscience, Inc.&#148;; and (4)&nbsp;approve a new stock option and incentive plan. The Voting Agreement will remain in effect until our stockholders approve the foregoing
proposals. Ampio is the holder of approximately 81.5% of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of the Voting Agreement set forth herein does not purport to
be complete and is qualified in its entirety by reference to the full text thereof, which is attached hereto as Exhibit 10.13. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_3"></A>Item&nbsp;2.01 Completion of Acquisition or Disposition of Assets. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, pursuant to an Agreement and Plan of Merger, or the Merger Agreement, entered into among Rosewind, Luoxis, Vyrix, and two subsidiaries
of Rosewind created solely for the purposes of the Merger, and which did not survive the Merger, the Merger occurred in two stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first stage,
each of Vyrix and Luoxis merged with one of Rosewind&#146;s merger subsidiaries. Vyrix and Luoxis survived these mergers. The outstanding shares of stock of Vyrix and the outstanding shares of stock of Luoxis were converted into the right to receive
shares of common stock in the Combined Company. The Vyrix stock and the Luoxis stock were each converted at an exchange factor. The exchange factor for each of them was determined upon the basis of a relative value opinion obtained by Ampio, the
parent company of Vyrix and Luoxis. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Vyrix were converted into shares of Vyrix as the surviving corporation. The outstanding shares of Rosewind&#146;s merger subsidiary that
merged with Luoxis were converted into shares of Luoxis as the surviving corporation. After completion of the first stage, Vyrix and Luoxis became subsidiaries of Rosewind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the second stage, which occurred on the same day as the first stage, each of Vyrix and Luoxis merged with Rosewind with Rosewind surviving. The first and
second stage mergers are referred to collectively as the &#147;Merger.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Merger: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The board of directors of Rosewind, whose sole member was James Wiegand, increased the number of directors by one, and appointed Michael Macaluso to fill the vacancy created by that increase. James Wiegand resigned from
the board immediately thereafter. The board of directors of Rosewind, whose sole member is Michael Macaluso, then appointed Joshua Disbrow as Chief Executive Officer, Jarrett Disbrow as Chief Operating Officer and Gregory A. Gould as Chief Financial
Officer of the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ampio purchased 57,970,000&nbsp;shares of common stock of the Combined Company for (i)&nbsp;issuance to Rosewind of a promissory note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of
the Merger; (ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Wiegand entered into a consulting agreement with the Combined Company with a one year duration, providing for compensation of $50,000 to him. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of James Wiegand and Michael Wiegand executed a release in favor of the Combined Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of Ampio, James Wiegand and Michael Wiegand entered into a lock-up agreement with the Combined Company agreeing not to sell its shares of the Combined Company for two years (except for the one with Ampio, for more
than three years). The lock-up agreements other than the one with Ampio release 25% of the shares subject to it on June&nbsp;30, 2015. The Ampio lock-up agreement terminates upon a change-in-control event of either the Combined Company or Ampio.
Each other lock-up agreement terminates upon a change-of-control event of the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Joshua Disbrow entered into an employment agreement with the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Jarrett Disbrow entered into an employment agreement with the Combined Company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement
contemplates the reincorporation of the Combined Company in Delaware, as a corporation, with the name Aytu Biosciences, Inc. as soon as is reasonably practicable after the closing of the Merger. The reincorporation is also expected to result in the
reduction of the number of shares of stock outstanding in the Combined Company equivalent to a reverse stock split at the rate of approximately 12.174 to 1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger has been accounted for
as a reverse-merger and recapitalization. Vyrix and Luoxis, collectively, is the acquirer for financial reporting purposes and Rosewind is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in
the historical financial statements prior to the Merger will be those of Vyrix and Luoxis and will be recorded at the historical cost basis of Vyrix and Luoxis, and the consolidated financial statements after completion of the Merger will include
the assets and liabilities of Rosewind, Vyrix and Luoxis, the historical operations of Vyrix and Luoxis and the operations of the Combined Company from and after the closing date of the Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Treatment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger is intended to constitute a
tax-free reorganization under Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background of Rosewind </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rosewind was incorporated on August&nbsp;9, 2002 in the State of Colorado. Rosewind filed a registration statement on Form SB-2 (File No.&nbsp;333-139933) that
was declared effective by the SEC on May&nbsp;11, 2011, and sold an aggregate of 239,000 shares of its common stock under that registration statement. Prior to the Merger, Rosewind intended to develop a sailing school. Upon the closing of the
Merger, the Combined Company has abandoned those business plans and is now pursuing the business of Vyrix and Luoxis. Upon closing the Merger, our executive offices are relocated to those of Luoxis and Vyrix at 373 Inverness Parkway, Suite 200,
Englewood, Colorado 80112. Our telephone number is (720)&nbsp;437-6580, and our corporate website is <I>www.aytubio.com</I>. The information on, or accessible through, our website does not constitute part of, and is not incorporated by reference
into, this Form 8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_4"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rosewind was incorporated on
August&nbsp;9, 2002 in the State of Colorado. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix was incorporated under the laws of the State of Delaware on November&nbsp;18, 2013 and was wholly
owned by Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), or Ampio, immediately prior to the completion of the Merger. Vyrix was previously a carve-out of the sexual dysfunction treatment business, including the late-stage men&#146;s health product
candidates, Zertane and Zertane-ED, from Ampio, which was announced in December 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis was incorporated under the laws of the State of Delaware on
January&nbsp;24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger. Luoxis is focused on developing and advancing the RedoxSYS system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2015, Rosewind formed Rosewind Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of
the Merger, and on April&nbsp;16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis, and Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and
Luoxis merged with and into Rosewind with Rosewind as the surviving corporation. Concurrent with the closing of the Merger, Rosewind abandoned its pre-merger business plans to develop a sailing school, and we now solely pursue the business of Vyrix
and Luoxis in the healthcare industry. The following discussion describes the business being pursued by the Combined Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a specialty healthcare company concentrating on developing and commercializing products for redox-modulated conditions with an initial focus on
urological indications and related conditions. We are focused primarily on the urological disorders market and specifically sexual dysfunction and male infertility and expect to seek expansion opportunities in other urological indications such as
urological cancers. Our Luoxis division maintains a focus on the RedoxSYS oxidation-reduction potential system. Through the Luoxis division, we are focused on commercializing the RedoxSYS system into the global research market while developing
numerous clinical applications for this potential first-in-class diagnostic device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global urological disorders market is forecast to exceed $10
billion by 2017. With a Compound Annual Growth Rate, or CAGR, of 7.9% between 2002 and 2010, the urology market is a substantial growth market with significant medical needs still unaddressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The premature ejaculation market alone is expected to reach over $1.3 billion in annual sales in 2015, representing an increase of 10.3% since 2010. According
to recent published analyses, premature ejaculation, or PE, is a highly prevalent male sexual dysfunction affecting 20-30% of men worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more
prevalent than erectile dysfunction, or ED. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to our knowledge, only two other prescription products have been approved elsewhere in the world. Treatment
options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive behavior therapy or counseling, all of which have had limited effectiveness in treating the disorder. PE
therefore represents an area of significant unmet medical need. In addition, approximately 32% of the more than 12,000 men with PE surveyed in a 2007 study published in <I>European Urology</I> also suffered from ED. Accordingly, we believe that a
combination product candidate to treat both PE and ED represents another significant worldwide market opportunity for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are actively developing the
global market for the RedoxSYS system across a range of applications. Specifically, we have begun commercializing RedoxSYS system for research use through direct selling, distribution partners, and academic collaborators. Over the past 18 months, we
have engaged in over 60 trials around the world whereby prominent researchers are implementing oxidation-reduction potential as a marker in both chronic and acute illnesses and disorders in both clinical research as well as basic science research.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our extensive network of researchers, RedoxSYS system has demonstrated the potential to have broad
clinical applications. Studies are now underway at a major U.S. university in the area of male infertility. This condition is prevalent, underserved, and oxidative stress is widely implicated in its pathophysiology. As such, we expect to bolster our
research focus in this area with RedoxSYS system to complement our focus on urologic conditions. The male infertility market is expected to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2013 to 2020. Oxidative stress is broadly
implicated in the pathophysiology of oxidative stress, yet very few diagnostic tools exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of
the RedoxSYS system, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative stress and monitor patients&#146; responses to antioxidant therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our most advanced development programs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_263.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">505(b)(2) regulatory pathway </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">510(k) de novo regulatory pathway </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zertane </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our premature ejaculation product candidate, Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for
the on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section&nbsp;505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA, as the active ingredient is already well characterized for the
treatment of pain, and we are relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we believe it will be the first commercial
product approved by the United States Food and Drug Administration, or FDA, for PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of significant development work performed by a previous
partner of Ampio, Zertane has already been evaluated outside the United States in two Phase 1 clinical trials, two Phase 2 clinical trials and two Phase 3 clinical trials. The two Phase 1 safety trials were conducted to characterize the
concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane ODT (89 mg) in healthy volunteers. Two randomized, placebo-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controlled, blinded Phase 2 clinical trials were conducted in a total of 102 patients. These trials evaluated doses of tramadol hydrochloride between 25 and 120 mg in male subjects with PE. Two
placebo-controlled, randomized and double-blind Phase 3 clinical trials were conducted in Europe to investigate tramadol hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between two and eight hours before a sexual
event. This development work has demonstrated a favorable safety and efficacy profile of Zertane in men with PE. Furthermore, the safety and pharmacology of the drug substance in Zertane, tramadol hydrochloride, is well characterized, which will
eliminate the need for us to conduct additional pre-clinical studies and safety trials. Based on guidance received at a recent consultation meeting with the FDA, we believe we are well positioned to initiate a Phase 3 clinical program with Zertane
in the United States. Specifically, we believe the meeting clarified specific aspects of the trial, including the primary efficacy endpoints and patient inclusion and exclusion criteria. The FDA agreed to review a draft study protocol in advance of
us submitting our Investigational New Drug application, or IND. Upon completion of the program, if successful, we plan to submit a New Drug Application, or NDA, and subsequently market Zertane in the United States, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zertane-ED </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Zertane, we also have
an early-stage combination product candidate, Zertane-ED, which is a combination of Zertane and an FDA-approved phosphodiesterase type 5, or PDE-5, inhibitor, a category of drug that is found in commonly used treatments for ED (e.g., Viagra, Cialis,
Levitra, or Stendra), designed to treat both PE and ED. In light of the fact that approximately 32% of men with PE also suffer from ED, according to a 2007 study published in <I>European Urology</I>, we believe that a combination of tramadol
hydrochloride with a PDE-5 inhibitor, if approved, would benefit men that experience both distinct problems. If, and when, the FDA accepts filing of our NDA for Zertane, we will commence developing the Zertane-ED fixed dose combination product
candidate. Formulation development, stability studies and analytical work as well as manufacturing of clinical supplies in compliance with current good manufacturing practices, or cGMP, have already been completed by a contract manufacturer, and our
collaboration with Daewoong Pharmaceutical Co., Ltd., or Daewoong, in South Korea will provide development support to complement our U.S. development efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RedoxSYS system for Research Use </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We completed the
development of the RedoxSYS system during the two years preceding the Merger. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. This enabled the launch of the
RedoxSYS system into the research market around the world. We also received a CE marking in Europe and Health Canada clearance to begin the market development of the RedoxSYS system as a clinical diagnostic in Europe, Canada, and elsewhere around
the world where CE marking is recognized. We launched sales efforts into the research market in late 2014 and since that time have already placed the RedoxSYS system at a number of prominent research centers in the United States, Europe, and Israel.
These research placements are depicted below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_265a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prominent U.S. Research Centers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_265b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prominent Centers in Europe and Israel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to leverage these research relationships and build numerous applications in areas where researchers are studying oxidative stress. Currently, there
are no available research platforms that measure oxidation-reduction potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal fluid, tissue, and cells). While oxidative stress is commonly studied in research
settings around the world (both academia and industry), the current assessment methods are incomplete, time consuming, and often impractical for assessing oxidative stress completely. To position RedoxSYS system effectively in the research market,
we have placed key personnel in the United States, Europe, and Asia to develop direct research business relationships as well as distribution networks. From these networks, we expect to realize product revenues for the RedoxSYS system for research
applications in 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RedoxSYS system for Reproductive Health </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our strategy to develop future clinical applications of the RedoxSYS system, we have conducted initial studies in reproductive health. Male
infertility is a significant medical condition in which oxidative stress is well known to play a substantial role. As such, we believe developing a clinical application to assess oxidative stress levels with the RedoxSYS system represents a
significant commercial opportunity. Oxidative stress is well established as a leading contributing factor to male infertility. Further, a significant proportion of male infertility remains unexplained in part because of the lack of standardized
tests available to clinicians and researchers to assess oxidative stress in semen and plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis around the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have conducted proof-of-concept studies in male infertility with a leading research center in the United States, which demonstrate that oxidation-reduction
potential effectively measures oxidative stress levels in semen and seminal plasma. Semen analysis studies are routinely conducted to assess causes of infertility, so we expect clinicians and oxidative stress researchers to readily integrate the
RedoxSYS system into routine use. Additional studies are now in the late planning stages that will evaluate the RedoxSYS system&#146;s performance in the detection of oxidative stress levels in healthy and infertile males. Of the approximately $300
million male infertility market, the North American market and Asia Pacific market dominate due to prevalence, awareness of treatment, and availability of treatment resources. Thus, it is important that we have already established distribution
relationships and direct access to major oxidative stress researchers in both markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An attractive aspect of the reproductive health market relates to
reimbursement as infertility treatments and the associated diagnostic tests are generally paid directly by patients. The current infertility treatments could cost in excess of $10,000 per treatment cycle, so the addition of a moderately priced
oxidative stress test would consume nominal relative costs while providing specific, actionable information needed to improve the oxidative status of infertile patients. The current infertility treatments include antioxidant supplements and
lifestyle modifications that lower oxidative stress (e.g., smoking cessation, exercise, dietary changes, etc.), so the measurements reported by the RedoxSYS system could effectively guide treatment in the infertile patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an extensive range of intellectual property across our two primary, near-term assets. We have patent protection in the United States and several other
large markets worldwide for the oxidation-reduction potential products and product candidates. Further, we have patent protection in the United States and several other large markets worldwide for the use of tramadol hydrochloride to treat PE. We
also have intellectual property specifically covering Zertane-ED, and methods of using Zertane-ED to treat comorbid PE and ED that has issued patents in several large markets worldwide and is pending in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key elements of our strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"><I>Develop a pipeline of therapeutics and diagnostics focused on urological conditions, with a focus on the initiation and completion of two Phase 3 clinical trials for Zertane in the United States and the development
of worldwide commercialization and marketing partnerships.</I> <I></I> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead therapeutic product candidate is Zertane, a Phase 3-ready
oral product for the treatment of PE. Zertane is in advanced clinical studies, and we have already completed pivotal study-enabling studies in Europe that demonstrate favorable efficacy and safety in more than 600 patients with PE. We intend to
initiate and complete Phase 3 clinical trials in order to obtain FDA approval for Zertane. We expect to use a similar development approach for the combination product candidate, and we have a clinical development collaboration in place with our
South Korean partner for Zertane-ED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to maximize the value of Zertane in the United States via either securing a licensing arrangement or
commercializing it ourselves. We also expect to seek collaboration agreements to commercialize Zertane in the rest of world, or ROW, markets. We already have such agreements in place to commercialize Zertane in South Korea and Brazil, Canada, the
Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America which will &#150; if approved&#151;provide royalty and milestone-based revenue for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"><I>Build our Luoxis division by initially positioning the RedoxSYS system as a research tool and expanding its application to other indications.</I> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead diagnostic product candidate is RedoxSYS system, which is currently being studied in clinical trials at a major U.S. academic center to evaluate its
utility in measuring oxidative stress in infertile males. If successful, these clinical trials are expected to pave the way for our RedoxSYS system in entering the male infertility market around the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RedoxSYS system is expected to be commercialized initially as a research tool, and pending the outcome of our clinical studies &#150; oxidative stress as a
key indicator of male infertility &#150; be commercialized for additional indications, if approved. Internationally, we intend to commercialize RedoxSYS system for multiple potential indications where oxidative stress is implicated, if approved. The
United States will be our primary focus in terms of commercialization opportunities. However, we intend to leverage ROW opportunities to drive incremental revenue and adoption of our RedoxSYS system as well as to facilitate research to develop
further redox-modulated application for our RedoxSYS system. We intend to utilize distribution partners in Europe, Asia, and elsewhere to launch and grow sales in both research and diagnostic applications. We have established research collaborations
with over 20 leading academic centers around the world. Further, the RedoxSYS system has been used in numerous clinical studies supported by pharmaceutical companies. As oxidative stress is widely studied in both academic and industry settings, the
research application of RedoxSYS system spans a wide range of applications in clinical research, basic science research, and health and wellness research. We seek, either directly or through distributors, to commercialize RedoxSYS system across a
broad range of potential customers. To date, we have signed distribution agreements for the research market with four companies, including EuroBio in France, Una Health in the United Kingdom, THP Medical in Austria, and KYS Technologies in Taiwan.
We expect to significantly expand our distribution network throughout 2015 to enable entry into major markets in Europe and Asia. We plan to commercialize directly in the United States. We expect these research collaborations will generate new
findings and potential clinical applications for the RedoxSYS system. In turn, we believe this development of new data and publications will enable us to pursue adjunct conditions where oxidative stress is implicated. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"><I>Acquire established marketed products and late-stage development assets within our focus</I> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to
diversify our product portfolio and create more value, we intend to seek to acquire complementary products or product candidates to develop and/or commercialize including marketed assets. Initially, the focus will be on acquiring products or product
candidates for urological conditions but we will opportunistically consider other products or product candidates based on their ability to create value and complement our focus. We plan to pursue product acquisitions, inclusive of therapeutics,
diagnostics, and devices, which will be evaluated for their strategic fit and potential for near-term and/or accretive value to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product
Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Therapeutic Product Candidates &#150; Zertane and Zertane-ED </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead therapeutic product candidate, Zertane, is a specifically formulated orally disintegrating tablet, or ODT, of tramadol hydrochloride patented for the
on-demand treatment of PE. Zertane is being developed utilizing a regulatory pathway pursuant to Section&nbsp;505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA, as the active ingredient is already well characterized for the
treatment of pain, and we are relying on the FDA&#146;s finding of safety of tramadol hydrochloride to support its use in a new indication, PE, at a lower dose. If we receive marketing approval for Zertane, we believe it will be the first commercial
product approved by the United States Food and Drug Administration, or FDA, for PE. In addition to Zertane, we also have an early-stage combination product candidate, Zertane-ED, which is a combination of Zertane and an FDA-approved
phosphodiesterase type 5, or PDE-5, inhibitor, a category of drug that is found in commonly used treatments for erectile dysfunction, or ED (e.g., Viagra, Cialis, Levitra or Stendra), designed to treat both PE and ED. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to recent published analyses, PE is a highly prevalent male sexual dysfunction affecting 20-30% of men
worldwide. Based on internal market research and published reports, we believe that PE is up to 1.5-times more prevalent than erectile dysfunction. Currently, there are no FDA-approved prescription products in the United States to treat PE, and to
our knowledge, only one oral prescription product has been approved elsewhere in the world. Treatment options for PE have traditionally included antidepressant drugs prescribed &#147;off label,&#148; topical numbing medications, and cognitive
behavior therapy or counseling, all of which have had limited effectiveness in treating the disorder. PE therefore represents an area of significant unmet medical need. In addition, approximately 32% of the more than 12,000 men with PE surveyed in a
2007 study published in <I>European Urology </I>also suffered from ED. Accordingly, we believe that a combination product candidate to treat both PE and ED, such as Zertane-ED, represents another significant worldwide market opportunity for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By virtue of significant development work performed by a previous partner of Ampio, Zertane has already been evaluated outside the United States in two Phase
1 clinical trials, two Phase 2 clinical trials and two Phase 3 clinical trials. This development work has demonstrated a favorable safety and efficacy profile of Zertane in men with PE and helped inform the design and endpoints of the Phase 3
clinical trials we will need to obtain FDA approval. Furthermore, the safety and pharmacology of the drug substance in Zertane, tramadol hydrochloride, is well characterized, which we believe will eliminate the need for us to conduct additional
pre-clinical studies and safety trials. We believe we are well positioned to initiate Phase 3 clinical trials with Zertane in the United States. Upon completion of the trials, if successful, we plan to submit a New Drug Application, or NDA, and
subsequently market Zertane in the United States, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy for Zertane is focused on the initiation and completion of the Phase 3
clinical program in the United States and the development of worldwide commercialization and marketing partnerships. We expect to finalize clinical development of Zertane, seek FDA marketing approval and &#150; if approved&#151;commercialize the
product candidate in the United States either directly or via partnerships. We will seek partnerships to commercialize Zertane in rest of world, or ROW, markets. We already have partnerships in place to market Zertane in South Korea and Brazil,
which could provide near-term revenue for us if, working with our partners, we are able to successfully obtain regulatory approval in those countries. In addition, we recently entered into an agreement with Endo Ventures Limited, which recently
acquired Paladin Labs Inc., or Paladin, a leading Canadian specialty pharmaceutical company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa,
Colombia and Latin America. We also intend to build awareness of PE in the United States with the intention of paving the way for successful product introduction and initiate pre-clinical work on Zertane-ED as a potential combination treatment for
PE and ED. We expect to use a similar clinical and commercial approach for Zertane-ED and we have a clinical development collaboration in place with our South Korean partner for the combination product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PE Market Opportunity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>What is PE? </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medical literature contains several one-dimensional and multi-dimensional operational definitions of PE. The Diagnostic and Statistical Manual of Mental
Disorders defines PE as persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the person wishes it, with the disturbance causing marked distress or interpersonal difficulty.
Alternately, the International Society for Sexual Medicine, or the ISSM, has adopted a new and evidence-based definition for lifelong PE: &#147;premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly
always occurs prior to or within a minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual
intimacy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE may be classified as lifelong (primary) or acquired (secondary). Lifelong PE is characterized by onset from the first sexual
experience and remains a problem throughout life. Acquired PE is characterized by either a gradual or subtle onset, with ejaculation being considered normal before onset of PE. Time to ejaculation is short but not usually as fast as in lifelong
(less than 1 minute in almost all encounters). We believe acquired PE and/or situational PE suggests a psychological cause and behavioral therapy and/or relationship counseling may be the most appropriate initial therapy. In contrast, we believe
lifelong PE suggests a biogenic cause and pharmacologic treatment is the most appropriate initial therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ejaculation latency, most commonly quantified using intravaginal ejaculation latency time, or IELT, is a dominant
component of PE assessment in clinical trials. IELT is defined as the time between vaginal intromission and intravaginal ejaculation. Although a standard cut-off for ejaculatory latency does not exist, it has been suggested that an IELT of 2 minutes
or less may serve as an adequately sensitive criterion for defining PE and some studies have used IELT values from 1 to 2&nbsp;minutes for defining PE. In a pre-IND meeting with FDA, we agreed to use an IELT of less than or equal to 1 minute as one
of the enrollment criteria for our planned Phase 3 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, IELT is not the sole criteria used to diagnose PE. We believe diagnosis of
PE should also include a subject&#146;s perceived control over ejaculation, as well as distress and interpersonal difficulty due to the condition. The need to objectively assess and diagnose PE beyond IELT has led to the development of several
questionnaires within the male sexual dysfunction medical community including the Premature Ejaculation Diagnostic Tool (PEDT), Premature Ejaculation Profile, or PEP, the Index of Premature Ejaculation (IPE), and the Male Sexual Health Questionnaire
Ejaculatory Dysfunction (MSHQ-EjD). In collaboration with the FDA, Ampio has also developed a modified version of PEP known as the Patient Outcome for Premature Ejaculation, referred to as the POPE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prevalence of PE </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE is a significant unmet medical need
in the United States and worldwide as it causes significant emotional distress for affected men and their partners. According to an article published in <I>European Urology</I> in 2010 and a survey published in the <I>Journal of the American Medical
Association (JAMA)</I> in 1999, PE is a highly prevalent male sexual dysfunction affecting 20-30% of men worldwide. However, most prevalence data on PE is based on patient surveys, which are inherently subjective, and therefore some of the men
surveyed may not have PE as it is defined by the medical societies noted above. In a 2007 study published in <I>European Urology</I>, the incidence of PE was assessed via a web-based survey of 12,133 men ages 18-70 in the United States, Germany and
Italy. In this survey 2,754, or 22.7%, of the men reported that they suffer from PE. The vast majority (87.9%)&nbsp;of men with PE wished that they had more control over time to climax. Additionally, a majority (57.6%)&nbsp;of the men surveyed
reported that they would seek medical treatment if they knew that a pill to control ejaculation were available. We believe men would also ask their doctor about treatment options if their partner suggested it. Additional primary company market
research indicated that over 66% of patients that see a urologist for PE were self-referred, which we believe further demonstrates that PE is a condition for which patients are actively seeking treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Existing therapies do not satisfy the significant PE market need </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently, there are no approved prescription pharmaceuticals in the United States to treat PE and only two pharmaceuticals known to be approved elsewhere in
the world. Current &#147;off label&#148; or unapproved therapies used to treat PE carry with them unwanted side effects and inconsistent or limited effectiveness. Topical over-the-counter, or OTC, options are not preferred due to route of
administration and may also have an impact on partner satisfaction. Oral therapeutics, specifically selective serotonin reuptake inhibitors, or SSRIs, carry potentially significant side effects most notably of which is diminished libido. PDE-5
inhibitors have been prescribed &#147;off label&#148; for PE but have not demonstrated efficacy. Outside of oral or topical therapeutics, non-medical options include behavioral therapy and relationship counseling, both of which can be time consuming
and stressful and frequently ineffective for men and their partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates the current methods used to treat patients with PE
and the associated issues based upon our sponsored market research: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Pharmacologic Treatment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Issues</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tricyclic antidepressants*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Fatigue, nausea, dizziness, dry mouth, hypotension</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-acting SSRIs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nausea, diarrhea, headache, dizziness, risk of suicidal ideation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-acting SSRIs*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ED, decreased libido, fatigue, nausea, increased perspiration</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Topical desensitizing agents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Messy, numbing of vagina, skin irritation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PDE-5 inhibitors*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ineffectiveness, headache, flushing, nausea</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Non-Pharmacologic Treatment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Issues</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Stop-Start&#148; strategy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Requires an understanding partner</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;Squeeze&#148; method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Requires an understanding partner</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Psychological therapy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Time consuming for patients; costly, long-term benefits unknown</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Pharmacologic Treatment</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Issues</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Relationship counseling</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Time consuming, costly, requires an understanding partner</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">NOT approved for treatment of PE </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe patients and their partners are generally dissatisfied with
existing pharmacologic and non-pharmacologic treatments for PE. Based on primary market research commissioned by Ampio, our parent company, which included discussions with a cross section of clinicians that treat patients with PE, we believe that
there are significant issues with existing PE treatments demonstrating a real need for a safe and effective, FDA-approved product to treat PE that does not have a ramp-up period. This primary market research supports that ideal product
characteristics include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fewer side effects than anti-depressants, such as SSRIs, that are used &#147;off-label&#148; for PE; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Quick onset/on-demand usage. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Zertane </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead therapeutic product candidate, Zertane for premature ejaculation, contains 89 mg tramadol hydrochloride in an orally dissolving tablet, or ODT.
Tramadol hydrochloride is a well-established, centrally acting synthetic analgesic and has been used for more than 30&nbsp;years as a treatment for moderate to severe pain. The drug and its active metabolite (M1, <I>O</I>-desmethyltramadol) act as
an opiate agonist, apparently by selective activity at the &micro;-receptor. Although the mechanism by which tramadol hydrochloride delays ejaculation has not been identified, numerous laboratory studies have shown that tramadol hydrochloride also
acts as an <I>N</I>-methyl-D-aspartate receptor antagonist, 5-hydroxytryptamine type 2C receptor antagonist, 5 nicotinic acetylcholine receptor antagonist, M1 and M3 muscarinic acetylcholine receptor antagonist, and a serotonin and norepinephrine
modulator. It is possible that one or a combination of these effects leads to a delay in ejaculation. The relative contribution of tramadol hydrochloride versus its M1 metabolite to delay ejaculation is unknown. However, the metabolite is six times
more potent than the parent drug in producing analgesia in animal models and 200 times more potent in &micro;-receptor binding. As a pain medication, tramadol hydrochloride has been associated with certain adverse effects including dizziness,
nausea, constipation, vertigo, headache, vomiting and drowsiness. However, we intend that our labeling for Zertane, if regulatory approval is obtained, will suggest &#147;as required&#148; dosing before sexual intercourse and not to exceed one
tablet per day. Based on previous clinical studies, we believe that limiting the dosing to no more than once per day will minimize any side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
an alternative to antidepressant and anxiolytic medication, tramadol hydrochloride has been recognized as a potential therapy for treatment of PE, after an association was observed between its use and improvements in ejaculation latency time. The
combination of completed clinical trials, primarily performed in Europe, planned clinical trials in the United States, and literature are intended to establish the safety and efficacy of Zertane in the treatment of the condition and standardize the
dose and dosing regimen. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>History of Zertane </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;David Bar-Or discovered the utility of tramadol hydrochloride for the treatment of PE in June 1999, and this discovery and accompanying intellectual
property were the property of&nbsp;DMI BioSciences, Inc., or DMI BioSciences.&nbsp;DMI BioSciences conducted two Phase 2 clinical studies in male subjects with PE using a pharmacy-compounded gelatin capsule preparation.&nbsp;A proof-of-concept Phase
2 study was initiated in March 2003, and final patient assessments were on July&nbsp;7, 2003.&nbsp;A dose-ranging study Phase 2 study was initiated in September 2004 and final patient assessments were in October 2005. In 2007, DMI BioSciences
licensed the worldwide rights to tramadol hydrochloride for PE to Biovail Laboratories International, or Biovail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biovail had previously entered into a
product development and licensing agreement with Ethypharm S.A., or Ethypharm, in 2002, which had developed an ODT formulation of tramadol hydrochloride using its proprietary FLASHTAB technology.&nbsp;In this agreement, Biovail acquired the rights
to develop and market Ethypharm&#146;s tramadol hydrochloride ODT product for use in the management of pain. In March of 2004, Biovail submitted a Section&nbsp;505(b)(2) NDA (US NDA 21,639) to FDA for market registration of tramadol hydrochloride
ODT 50&nbsp;mg (RYBIX) for the management of moderate to moderately severe pain, and this NDA was granted approval in May 2005. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biovail decided not to launch the RYBIX 50&nbsp;mg ODT product in the United States, and in 2009, signed an NDA
agreement with Ethypharm pursuant to which Ethypharm acquired all the rights to RYBIX 50&nbsp;mg ODT and Biovail acquired the rights to develop, manufacture and market a FLASHTAB ODT product containing tramadol hydrochloride for the symptomatic
treatment of PE.&nbsp;In this agreement, Biovail assigned to Ethypharm all of Biovail&#146;s rights, title and interest in and to the approved NDA for RYBIX, the regulatory documentation and product rights to enable Ethypharm to develop and market
RYBIX in the United States for the management of pain.&nbsp;In addition, the agreement granted Biovail the right to reference and use all data, regulatory filings and regulatory communication, including the approved NDA for RYBIX, the product rights
(including any information, data, know-how, formulas, assays, or intellectual property contained in the approved NDA) and any and all related regulatory documentation that would be relevant for the purposes of developing, manufacturing or marketing
the tramadol hydrochloride ODT product for PE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using the newly acquired FLASHTAB technology and manufacturing processes obtained in the NDA agreement
with Ethypharm, Biovail developed two strengths of tramadol hydrochloride ODT (62 and 89&nbsp;mg) for use in four NDA-enabling clinical trials: two Phase 1 pharmacokinetic/bioavailability and two Phase 3 placebo-controlled pivotal trials.&nbsp;These
trials were initiated in the latter half of 2009.&nbsp;In&nbsp;July 2010, Biovail terminated the clinical trials in Europe as a direct result of a merger with Valeant Pharmaceuticals International, or Valeant, which was announced in June 2010 but
was finalized in September 2010. Following the merger, Valeant adopted a new research and development model and began identifying product development programs that did not align with this new R&amp;D model. In connection with this new R&amp;D model,
Valeant decided to terminate Biovail&#146;s licensing agreement for tramadol hydrochloride for PE and also to terminate the ongoing Phase 3 studies. The Valeant model did not include compounds that had any regulatory or clinical risk (i.e., were
still in development) and instead was focused solely on &#147;commercially ready&#148; products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biovail withdrew from its licensing agreement with DMI
Biosciences and the worldwide rights to tramadol hydrochloride for PE reverted back to DMI Biosciences, which was acquired in March 2011 by Ampio. In December of 2011, the Ethypharm-Biovail NDA Agreement was transferred to Ampio in an asset purchase
from Valeant, providing Ampio access to all data, regulatory filings and rights to develop, manufacture and market tramadol hydrochloride ODT for PE. Ampio completed clinical study reports for the European Phase&nbsp;3 studies and submitted tramadol
hydrochloride 89&nbsp;mg ODT for marketing authorization in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2013, Ampio spun out the assets and agreements associated with its
sexual dysfunction treatment portfolio, including Zertane, to us, a wholly-owned subsidiary of Ampio at that time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical Data </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Six European clinical trials have been completed with Zertane: two Phase 1 trials in healthy volunteers and two Phase 2 and two Phase&nbsp;3 trials in men with
lifelong PE. The two Phase&nbsp;1 safety trials were conducted to characterize the concentration of tramadol hydrochloride in plasma after oral administration of a single Zertane ODT (89&nbsp;mg)&nbsp;in healthy volunteers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two randomized, placebo-controlled, blinded Phase 2 clinical trials were conducted in a total of 102&nbsp;patients. The first of these showed that a single
25-mg dose of conventionally formulated immediate release tramadol hydrochloride (i.e., immediate-release gelatin capsules) was safe, well-tolerated and prolonged time to ejaculation in some, but not all, patients. The second trial evaluated three
higher doses of tramadol hydrochloride: 65 mg, 85 mg and 120 mg. In this trial, a clear dose response was seen for both efficacy and safety, leading DMI Biosciences to conclude that the optimal tramadol hydrochloride dose to treat PE was likely to
be in the range 60-90 mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two placebo-controlled, randomized and double-blind Phase 3 clinical trials were conducted in Europe to investigate tramadol
hydrochloride 62 mg and 89 mg ODT for the treatment of PE when taken as needed between two and eight&nbsp;hours before a sexual event. A total of 677 patients were randomized in the trials and received either the 62 or 89 mg ODT or a matching
placebo ODT. Our claim that Zertane was efficacious in the Phase 3 trials is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based on at least one of the two doses resulting in statistically significant improvements in both IELT and PEP measures (i.e., co-primary endpoints) from baseline to the end of the trial. Using
IELT in combination with a self-report questionnaire (e.g., PEP or POPE) has gained acceptance as meaningful measures of pharmacoactivity and efficacy in the scientific and regulatory communities. The results of the Phase 3 trials suggest that
tramadol hydrochloride 89&nbsp;mg ODT is consistently more effective as a treatment for PE than tramadol hydrochloride 62&nbsp;mg ODT. In accordance with the definitions from the clinical trial protocols, only the tramadol hydrochloride 89 mg ODT
dose satisfied the claim for effective treatment of PE in both Phase 3 trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the six prior clinical trials of Zertane.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:51.90pt; font-size:8pt; font-family:Times New Roman">Trial Name<BR>(Dates/Sponsor)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Demographic<BR>(Age)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Enrollment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Design</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Duration&nbsp;of<BR><FONT STYLE="white-space:nowrap">Double-blind</FONT><BR>Treatment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Zertane<BR>Dose&nbsp;(mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Noteworthy Findings</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-101</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(June&nbsp;26,&nbsp;2009</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to July&nbsp;5, 2009/</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthy&nbsp;male</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and females (18-55
yr)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">0</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comparative</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">bioavailability study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">89</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall systemic exposure of tramadol hydrochloride and 2 metabolites were similar following 89&nbsp;mg ODT and the reference 89&nbsp;mg
tramadol hydrochloride solution.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">13 subjects experienced a total of 37 adverse events
(AEs) during the study. Most common AEs were GI disorders (nausea) and central nervous system disorders (sleepiness, dizziness, headache).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-102</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(July 14, 2009</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to July&nbsp;30,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2009/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthy&nbsp;males</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(19-55&nbsp;yr)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alcohol</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">interaction</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">study</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">NA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">89</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no significant difference in the peak and total systemic exposures of tramadol hydrochloride compared to when tramadol
hydrochloride 89&nbsp;mg ODT was taken with water, or with either strength of alcohol.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tramadol hydrochloride was well tolerated with alcohol. 7&nbsp;subjects experienced 11&nbsp;AEs, most frequently decreased blood pressure and
dizziness.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNL 40237</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(March&nbsp;13,&nbsp;2003</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to July&nbsp;7,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2003/ DMI**)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Men with PE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(18-70&nbsp;yr)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Double-blind,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">randomized</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">placebo- controlled</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3&nbsp;weeks</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">25</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with tramadol hydrochloride 25 mg had no statistically different effect than placebo in subjects with a baseline IELT of 2 minutes
or less (n=30; <I>P</I>=0.4560) or in a subpopulation of subjects with a baseline IELT of 1 minute or less (n=19; <I>P</I>=0.1796).</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">46 AEs emerged during treatment (28 with tramadol hydrochloride and 18 with placebo). There were no deaths, serious or other significant AEs. All AEs were of
mild intensity. Most common AEs were GI disorders (nausea) and central nervous system disorders (headache).</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:51.90pt; font-size:8pt; font-family:Times New Roman">Trial Name<BR>(Dates/Sponsor)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Demographic<BR>(Age)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Enrollment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Design</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Duration&nbsp;of<BR><FONT STYLE="white-space:nowrap">Double-blind</FONT><BR>Treatment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Zertane<BR>Dose&nbsp;(mg)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Noteworthy Findings</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNL 40491</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(September&nbsp;28, 2004 to
October&nbsp;18, 2005/ DMI**)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Men with PE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(18-70&nbsp;yr)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Double-blind,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">randomized</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">placebo- controlled</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">12&nbsp;weeks</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">65,&nbsp;85,&nbsp;120</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tramadol hydrochloride significantly increased the median IELT compared to both Baseline and placebo. Statistically significant increases in
IELT compared to Baseline were observed to be 3.0-fold (<I>P</I>=0.0013), 4.2-fold (<I>P</I>&lt;0.0001), and 5.1-fold (<I>P</I> &lt;0.0001) for the 65-, 85-, and 120-mg dose levels, respectively.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Doses of 65 and 85 mg were generally well tolerated. 120&nbsp;mg was less well tolerated
with adverse events known to be associated with tramadol hydrochloride (headache, dizziness, somnolence, insomnia) and related to sexual function (penile hypoaesthesia, anorgasmia, and ED).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-301</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(August 17, 2009 to
September&nbsp;9, 2010/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Men with PE (18-65&nbsp;yr)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Double-blind, randomized placebo- controlled</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">12 weeks</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">62, 89</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 89&nbsp;mg compared
to placebo (p&nbsp;=&nbsp;0.002). The significant difference was apparent at the first visit during the double-blind treatment period and each visit thereafter (p <U>&lt;</U> 0.05 for all Visits). Tramadol hydrochloride 62 mg and 89&nbsp;mg ODT
demonstrated statistically significant improvements in PEP measures compared with placebo.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">During the double-blind treatment or open-label extension periods, 21&nbsp;subjects experienced at least 1 treatment-emergent AE. There were no deaths or
serious AEs during the study.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVF-324-302</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(September&nbsp;30, 2009 to
August&nbsp;23, 2010/ Biovail*)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Men&nbsp;with PE (18-65&nbsp;yr)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">56</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Double-blind, randomized placebo- controlled</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">12 weeks</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">62, 89</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was a statistically significant change in IELT from Baseline to the end of the study for tramadol hydrochloride ODT 62 and 89&nbsp;mg
compared to placebo (p&nbsp;= 0.01 and p&nbsp;=&nbsp;0.02). Tramadol hydrochloride 62&nbsp;mg and 89 mg ODT demonstrated statistically significant improvements in both IELT and PEP measures compared with placebo.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A total of 28 out of 399&nbsp;subjects (7.5%) experienced at least 1 treatment-emergent AE
during the double-blind or open-label treatment period. No subject died or experienced a severe AE.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Biovail Laboratories International, SRL </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">DMI Biosciences, Inc. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Planned Phase 3 Clinical Program in United States </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the size of the U.S. market opportunity for Zertane, FDA approval is a critical value driver for us in the near term. We believe we are well
positioned to quickly move into NDA-enabling Phase 3 clinical development in order to complete and submit our Section&nbsp;505(b)(2) NDA for Zertane. Ampio met with the FDA in a pre-IND meeting on June&nbsp;20, 2012 and we subsequently met with the
FDA on October&nbsp;23, 2014. As a result of these meetings, we have been able to define the number and key aspects of necessary trials to progress Zertane to an NDA that may be accepted for filing by the FDA. Furthermore, the results from the
European trials will inform the design, endpoints and inclusion criteria for the U.S. Phase 3 program as well as recommendations by FDA: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patients as those with a subset of disease symptoms described by the ISSM Ad Hoc Committee for the Definition of PE; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Two tramadol hydrochloride doses (62 and 89&nbsp;mg)&nbsp;will be evaluated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The patient reported outcome questionnaire, or PEP, from the European Phase 3 trials, was modified to capture the most clinically significant aspects of PE from the ISSM definition &#150; now termed Patient Outcomes in
Premature Ejaculation, or POPE &#150; and this 4-question questionnaire will be validated during the first trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Key efficacy assessments will include intravaginal ejaculation latency time, or IELT and the subject&#146;s frustration or bother due to PE; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total enrollment for each trial will be approximately 350 &#150; 400 subjects. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in the Phase 3 trials
conducted in Europe, co-primary endpoints will be used for determination of efficacy. Both improvement in IELT, which will be captured by the partner in a blinded diary, and PE-related frustration or bother, which will be assessed after each sexual
intercourse attempt as well as at the final study visit by a single question in the POPE, will be evaluated as co-primary endpoints to determine efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently expect to file the IND for Zertane in the first half of 2015. We are prepared to commence our Phase 3 clinical program soon after the IND becomes
effective because our supplies are already manufactured and packaged and only require appropriate clinical labeling of the product candidate. Importantly, our manufacturing process has already been validated at the site of commercial manufacture.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ROW Opportunity </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond seeking U.S. NDA approval,
we plan to leverage partnerships to gain approval and eventual marketing authorization for Zertane in several key markets around the world. We already have partnerships in place with Daewoong Pharmaceuticals Co., Ltd. in South Korea and FBM
Industria Farmaceutica Ltda. in Brazil, thereby providing potential royalty and milestone-based revenue if, working with our partners, we are successfully able to obtain regulatory approval in those countries. In addition, our recent agreement with
Paladin provides Paladin with exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sub-Saharan Africa, Colombia and Latin America. Before marketing any products in Brazil and South Korea, approval must be received from the Brazilian Health Surveillance Agency (Anvisa) and the
Ministry of Food and Drug Safety (MFDS, previously the Korean Food and Drug Administration), respectively. We intend to leverage the expertise of our local collaborators in these jurisdictions to navigate the regulatory requirements and help
determine an efficient and effective pathway to bringing Zertane to market. If required regulatory approvals are obtained, partnerships in ROW markets will potentially provide additional revenue to us and help to establish the Zertane brand and the
role of tramadol hydrochloride in PE around the world. Such clinical experience will be useful as we seek to impact treatment guidelines for PE and gather post-marketing data to better inform our U.S. NDA submission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Zertane-ED </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the fact that approximately 32%
of men with PE also suffer from ED, according to a 2007 study published in <I>European Urology</I>, we believe that a combination of tramadol hydrochloride with a PDE-5 inhibitor, if approved, would benefit men that experience both distinct
problems. If, and when, the FDA accepts filing of our NDA for Zertane, we will commence developing the Zertane-ED fixed dose combination product candidate. Formulation development, stability studies and analytical work as well as manufacturing of
clinical supplies in compliance with current good manufacturing practices, or cGMPs, have already been completed by a contract manufacturer, and our collaboration with Daewoong Pharmaceutical Co., Ltd., or Daewoong, in South Korea will provide
development support to complement our U.S. development efforts. For additional information about our collaboration with Daewoong, see &#147;Material Collaborations&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All analytical methods were developed and validated and five current cGMP clinical lots were made. The clinical lots have been released and have been on
stability since October 2013 thereby enabling pharmacokinetic/pre-clinical work to be initiated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commercial Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>U.S. Commercial Strategy </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the population and the
anticipated pricing, the United States represents the largest PE opportunity and we will seek to maximize the market potential for Zertane in one or more of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>License U.S. promotional rights to Zertane to an established pharmaceutical company &#150; </I>We will seek to secure a milestone and royalty-based agreement with a company to market Zertane to high-value U.S.
prescribers. Potential partners may already have a commercial presence in urology (the single largest prescriber population for PE drugs) as well as primary care physicians (the single largest category of physicians in the United States).
Alternatively, we may attempt to secure agreements with multiple partners to promote Zertane to different specialties: e.g., one for urology and one for primary care physicians. We may also consider divesting Zertane as an alternative to a licensing
agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialize Zertane via our own commercial infrastructure &#150; </I>Our management has experience with all aspects of commercialization and we may deploy a specialized sales force to initiate promotion of Zertane
specifically to urologists. We may expand our commercial presence into primary care and other relevant physician specialties. Alternatively we may deploy a sales force of our own focused on urologists, while also seeking a partner for the larger
primary care segment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ROW Commercial Strategy </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated previously, we intend to leverage partnerships to market Zertane around the world. We will seek to collaborate in the largest viable markets with
companies that are well positioned to maximize sales of Zertane. Considerations for collaborations will include the prospective collaborator&#146;s presence in the therapeutic category of men&#146;s health, its ability to invest in the regulatory
and commercialization activities necessary, and its commitment to Zertane, our management team and economic terms. Countries will be prioritized for partnering based on viability of Zertane in the market, including but not limited to regulatory
pathway (i.e., the amount of regulatory work required for the partner to submit for approval); market conditions (markets that accept sexual health products); economic factors (pricing); and market size, as well as deal teams, including but not
limited to royalty and/or milestone based economic terms; upfront payments based on market; and commitment to marketing and/or regulatory investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We already have entered into collaboration agreements in South Korea and Brazil, which represent two of the
larger ROW market opportunities. In addition, our recent agreement with Paladin provides Paladin with exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia
and Latin America. We will seek to enter into similar arrangements in additional countries with additional companies in order to capitalize on the sizable opportunity for Zertane, and later, Zertane-ED. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Diagnostic Product Candidate &#150; The RedoxSYS system </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our leading diagnostic product candidate, the RedoxSYS system, is now fully developed for research use. RedoxSYS is a novel, portable device that measures
oxidation-reduction potential, or ORP, a global measure of oxidative stress. This system is the first and only system that measures ORP in biologic specimens to provide a complete measure of redox balance, which is broadly implicated across a wide
range of both acute and chronic conditions. To date, Canadian and European regulators have characterized RedoxSYS system as Class II medical device and regulated them accordingly. Classification of a medical device as Class II in Europe and Canada
indicates that the device is generally regarded as posing medium risk, and non-invasive medical devices that come into contact with injured skin are generally classified as Class II. As we have conducted initial validation studies with the RedoxSYS
system across a range of conditions and obtained a CE marking in Europe and Health Canada clearance to begin the market development of the RedoxSYS system as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is
recognized, we are now initiating commercialization for use of the RedoxSYS system as a research tool. By employing a focused commercial infrastructure and a growing network of distributors around the world, we believe we can efficiently penetrate
the academic and industry-based research centers who study oxidative stress. With this growth in the research market, we intend to develop clinical applications for the RedoxSYS system. An early potential opportunity that has presented promise
through our research is the application of ORP in the study of male infertility. ORP represents a unique approach to assessing oxidative stress in male infertility, and early proof-of-concept studies have been conducted. We are now beginning
clinical studies with a globally recognized U.S.-based university in male infertility. Oxidative stress is widely assessed in male infertility laboratories, and we believe the RedoxSYS system, if proven effective, will provide a simple,
comprehensive solution to oxidative stress detection and management of antioxidant and lifestyle intervention in this underserved market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy
for the RedoxSYS system is to continue deployment of this system at leading academic centers around the world, develop research collaborations with key opinion leaders in oxidative stress research, identify clinical applications for the platform,
and aggressively pursue infertility studies to establish efficacy of the system in this setting of care. Our plans include introduction of the RedoxSYS system to researchers in the United States through a direct commercial effort while engaging with
distributors in major markets around the world, including Canada, Europe, and Asia (with a focus on Japan, Korea, Taiwan, Singapore, and Malaysia). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Oxidative Stress and the Male Infertility Market Opportunity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oxidative stress plays a pivotal role in the pathogenesis of male infertility. The presence of excess levels of reactive oxygen species, or ROS, is associated
with both the structural and functional integrity of sperm. Moreover, these increased levels of ROS &#150; the increase of oxidative stress &#150; directly interfere with capacitation and fertilization. It is widely estimated that total infertility
is driven by male infertility in half of the cases, and the major factors influencing the rise in infertility among men are the change in lifestyle, increasing age, and environmental effects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prevalence of Male Infertility </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of all sexually active
adults, 12-15% are infertile and male infertility is the sole cause or contributing factor 50% of the time. The male infertility market is large and growing. The market is expected to grow to more than $300 million globally by 2020, with a CAGR of
nearly 5% from 2013 to 2020. Despite the prevalence of male infertility, difficulties remain in effectively diagnosis root causes. Oxidative stress assessment is considered a standard practice but due to various factors is not effectively used
routinely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Potential Role of ORP in Male Infertility </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oxidation-reduction potential is defined in the published literature as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;ORP in a biological system is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents contribute to
the ORP. Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric oxide, peroxynitrite, transition metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include
thiols, vitamin C, tocopherol, &szlig;-carotene, lycopene, uric acid, bilirubin, and flavinoids. Enzymes such as SOD, catalase, and glutathione peroxidase, are involved in the conversion of ROS into less reactive species. ORP monitoring of plasma
represents a single measurement that integrates the overall quantitative balance among the oxidants and reductants of the system.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that
ORP represents a single, global measure of oxidative stress in a biological system, we believe the potential for ORP to serve as a standardized marker in semen analysis and other aspects of infertility assessment is significant. A major limitation
of oxidative stress assays relates to the fact that there is poor standardization in testing. As many factors contribute to oxidative stress (e.g., free radical proliferation, antioxidant depletion, DNA damage, etc.), it is important to have an
integrated measure that combines all known and unknown oxidants and reductants in the respective system into one measurement. We believe ORP is an integrated measure of oxidative stress that can be easily and quickly measured with the RedoxSYS
system. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_277.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the context of infertility, having an integrated value representing all relevant biologic constituents contributing to
oxidative stress will enable simple, robust analysis in a four-minute test.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Existing infertility assessment tools do not satisfy the clinical need
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are various techniques in use to assess semen in cases of male infertility. The most commonly implemented techniques involve DNA fragmentation,
oxidative stress analysis, microscopic examination, sperm penetration assays, sperm agglutination, computer assisted semen analysis, and others. The currently available oxidative stress analysis tools are widely considered expensive and cumbersome
to use in routine clinical practice. In both developed countries as well as in the developing world, expensive analysis tools and recurring reagent expenses make routine testing nearly impossible to implement with regularity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Market Opportunity for RedoxSYS system </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the
market opportunity for the RedoxSYS system is significant as scientists implicate oxidative stress in numerous diseases and acute conditions. Our initial focus of commercializing the RedoxSYS system for use in research enables us to rapidly build a
base of clinical validation and utility data across a range of illnesses. As such, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we expect to generate early revenues from oxidative stress researchers implementing the RedoxSYS system into their routine oxidative stress research programs while generating published clinical
data demonstrating ORP&#146;s usefulness in disease monitoring and prognostic assessment. From a clinical perspective, we plan to continue our research efforts in male infertility while expanding future applications in acute and chronic illnesses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The male infertility market is in excess of $300 million, while the broader <I>in vitro</I> diagnostics market is expected to grow to more than $80
billion by 2017. With a substantial base of conditions for which the RedoxSYS system may present utility, we expect to realize significant revenue potential from this first-in-class system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our collaborative research efforts our scientific team has identified several diagnoses in which we believe the ORP technology derives distinct values
that may be useful in better identifying a patient&#146;s risk for the development of more severe illness &#150; beyond reproductive health and infertility. Further, we believe the ORP technology has the potential to better stratify patients
according to clinical characteristics detected uniquely by ORP measurements. Specific diseases where the RedoxSYS system have been initially studied include trauma, critical illness, stroke, heart failure, diabetes, and pregnancy. Multiple other
clinical areas exist where the system could be studied and potentially applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diagnostics serve a key role in the health value chain by influencing the
quality of patient care, health outcomes and downstream resource requirements across a wide range of clinical conditions. From consumer-friendly at-home pregnancy and glucose monitoring tests to more complex automated laboratory-based systems, these
tests are often first-line health decision tools. While diagnostics comprise less than 5% of hospital costs and about 1.6% of all Medicare costs, their findings are commonly believed to influence as much as 60-70% of health care decision-making. The
value of diagnostics accrues not only to clinicians and patients, but to health care managers, third-party payors and quality assurance organizations that use diagnostic performance to measure and improve health care quality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORP is a tightly controlled measurement, much like the vital signs routinely measured in medical practice&#151;temperature, heart rate, respiratory rate,
blood pressure and oxygen saturation of blood. Abnormal changes in oxidation-reduction potential are closely associated with poor outcomes in critically ill patients, including traumatic brain injury, multi-trauma injury, stroke, sepsis, and
pneumonia. Rapid results are essential for optimal treatment adjustments in critical care areas such as emergency and intensive care departments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORP
results may also help determine which patients are at high risk of early readmission at hospital discharge, especially patients with heart attack, heart failure, stroke, and pneumonia, and this represents an incremental assessment not afforded by
currently available diagnostic tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numerous scientific studies confirm the clinical value of measuring oxidative stress. Recently, a large assortment
of blood and cell tests have been used in research studies to measure separate biomarkers of oxidative stress, such as lipid peroxidation, protein oxidation and total antioxidants, but currently many of these separate biomarker test results are
needed to start to assess total oxidative stress. Despite the importance of assessing oxidative stress, we are not aware of any practical or efficient method for measuring these oxidative stress biomarkers in a point-of-care setting. Oxidative
stress is often a marker for inflammation, which in turn indicates the presence of disease-related processes or developing conditions across a wide array of diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The worldwide IVD market was $44 billion in 2010 and is projected to grow to $82 billion by 2017. The IVD market includes all laboratory and hospital-based
sales and home-use, or OTC, product sales covering immunoassays, clinical chemistry, microbiology, hematology, histology/cytology, point-of-care testing, and over-the-counter diagnostics. The professional point-of-care testing worldwide market is a
significant opportunity and was in excess of $5 billion in 2009 and is expected to grow to almost $7 billion by 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, critical care (an
application for which the RedoxSYS system is targeted) constituted 14% ($700 million) of sales in 2009 with expected CAGR of 5%, and cardiac markers constituted 9% ($435 million) of sales in 2009 with expected CAGR of 8%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Background on the RedoxSYS system </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the RedoxSYS system is the first and only research and clinical diagnostic platform that provides an accurate, easy, and complete real-time
assessment of redox status. Through the development and commercialization of the RedoxSYS system, we are pioneering the true measurement of redox potential, also called oxidation-reduction potential, a novel measure of oxidative stress, which has
been implicated in numerous critical injuries, illnesses, and chronic conditions with significant appreciation of the role of oxidative stress in infertility. We believe the RedoxSYS platform has a broad range of potential in both research and
clinical settings where no other methods exist to measure oxidation-reduction potential in biologic specimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through research directed by
Dr.&nbsp;David Bar-Or and Raphael Bar-Or at Ampio, we believe we have developed the first and only clinical diagnostic device that measures ORP in biologic specimens (i.e., plasma, serum, semen, seminal plasma, cells, tissues, cell cultures, and
others). This device, called the RedoxSYS system, rapidly measures ORP and antioxidant capacity, a global marker of antioxidant reserve and concentration to provide a global picture of oxidative status. The system uses a small, bench top analyzer in
conjunction with small, disposable sensors that work electrochemically without any liquid reagents or difficult sample preparation. The RedoxSYS system has been CE marked and approved for use in Europe and Canada, and we are now collaborating with
major medical centers around the world. The RedoxSYS system is an easy-to-use diagnostic device that can be used in various research settings. Further, this portable device can be decentralized to multiple research sites and enable real-time
reporting of oxidative stress values at the patient&#146;s point of care or in a clinical laboratory setting. We received ISO 13485:2003 medical device certification in 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS system has been developed over an 18-year period by Dr.&nbsp;David Bar-Or, Raphael Bar-Or, and their colleagues, and the research and development
work has focused on both the technical and clinical development of various applications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The RedoxSYS system Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS system is comprised of two distinct, patented components that enable a system capable of measuring the ORP and antioxidant capacity of a
biological fluid: an analyzer and sensor strips. In mechanical terms, ORP is defined as the potential between a working electrode and a reference electrode at equilibrium. The RedoxSYS system has been specifically studied in human whole blood,
serum, plasma, semen, and other biological fluids. The RedoxSYS system measures two distinct elements to determine a patient&#146;s oxidation reduction potential: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Static ORP &#150; the standard potential between a working electrode and a reference electrode with no driving current (or extremely small current). This is proportional to the balance of redox agents and is what is
classically defined as ORP. Low ORP values mean that the biological sample is in the normal range of oxidative stress. Higher than normal ORP values means that the biological sample is in a higher oxidation state. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Capacity &#150; the measure of antioxidant reserve available in the body&#146;s system. High capacity values mean that the biological sample has levels of antioxidant reserves. Lower than normal capacity values means
that the biological sample has below normal antioxidant reserves. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The RedoxSYS Analyzer </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS analyzer is a portable, lightweight desktop platform that may be used in a clinical or research laboratory or near a patient care area. The
analyzer is a small device that accepts an inserted sensor that has collected a small specimen as obtained by traditional specimen collection procedures. The analyzer is battery powered and equipped with a custom 5 lead strip connector. The reader
consists of a Galvanostat analog circuit with &gt; 1012 M<FONT STYLE="FONT-FAMILY:SYMBOL">&#087;</FONT> input impedance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The analyzer contains a 10 MHz external crystal (internal 4X PLL for 40 MHz operation), and a programming/serial
header is externally accessible. The device has internal power/heart-beat indicator LED, primary storage of 128Mbit (16Mbyte)&nbsp;SPI Flash (3.3V)&nbsp;(Bulk data storage), and secondary storage of 2Mbit (256Kbyte)&nbsp;SPI FRAM
(3.3V)&nbsp;(Hi-Speed Storage). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS analyzer contains a user-friendly interface that is flexibly designed to accommodate multiple endpoints
depending upon the specific clinical condition being considered. The interface is LCD, 16x2, with a white backlight, variable delay auto-off time-out. Two status LED indicators are visible through front panel mounted lenses. Further, the reader
contains three DPDT push-button switches (Left, Center, Right), power on button(s) for battery mode operation, switch usage switch, audible alerts, strip detection, and test completion signals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the RedoxSYS analyzer enables data transfer, has USB serial communication, and is configured for data download to a connected PC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS analyzer&#146;s power management consists of an external 5VDC power jack with input capacitance and filtering, a boost converter supplied by
external 5VDC power or internal Li-Ion battery, and provides main 5VDC digital board supply. The reader functions with or without the battery connected. The battery lasts in excess of 24 hours with continuous operation to enable prolonged use
outside of a laboratory setting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Image of the RedoxSYS Analyzer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_280a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The RedoxSYS Sensor Strips </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ORP sensor strips, via standard biological specimen collection techniques, receive 20-40 microliters of a specimen from which the ORP clinical analysis is
performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated
with the sensors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Image of the Sensor Strips </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_280b.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical Studies for Male Infertility </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have begun
clinical studies in male infertility with a prominent, U.S.-based university medical center utilizing the RedoxSYS system. If successful, we anticipate we will demonstrate RedoxSYS system&#146;s ability to measure oxidative stress in semen samples
as an adjunctive measure of infertility. These studies are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:14.65pt; font-size:8pt; font-family:Times New Roman"><B>Aim</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hypothesis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Methods and Procedures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expected outcome</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The RedoxSYS system will be able to detect oxidation-reduction potential (ORP) in fresh seminal ejaculates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Standardize the instrument for inter/intra observer and assay
variability</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Standardize the system for fresh ejaculate and seminal plasma measurements</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Test the
ability of the system to measure the effect of exogenous ROS in semen</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establish the effect of time on ORP measurements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The assumption that RedoxSYS system can measure ORP in semen shall be confirmed</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ORP values can be detected in fresh and frozen semen samples</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compare the effect of rapid freezing on the ORP of the seminal
ejaculate and seminal plasma</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The effect of exogenous ROS addition to the ORP and capacitance of both
ejaculate and seminal plasma after rapid freezing</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establish the effect of different subzero storage temperatures and storage time
on ORP measurement in frozen seminal ejaculate and seminal plasma samples</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comparing the effect of storage time after rapid freezing on the ORP of both the
seminal ejaculate and seminal plasma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">It shall be confirmed that ORP can be measured in both fresh and frozen semen samples and that n differences will exist</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Establish ORP values in ejaculates of healthy men.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establish ORP values in seminal ejaculates and of healthy men
with normal semen parameters i.e normal concentration, motility and morphology according to WHO, 2010</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establish the effect of varying sperm concentration 0, 10, 20, 40 and 100 X 10<SUP
STYLE="font-size:85%; vertical-align:top">6</SUP>/ mL on ORP levels (concentration response).</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ORP values in ejaculates of healthy men will be established</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Establish ORP values in ejaculates of with different clinical characteristics.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establish the ORP values in seminal ejaculates in infertile
men in the absence or presence of leukocytes (Endtz negative and Endtz positive) samples.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establishing ORP in healthy normozoospermic donors and infertile men with an
abnormal spermiogram</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Examine effect of abstinence on ORP in semen samples from normozoospermic
donors</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ORP levels in infertile men with varicocele</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Specific and different ORP values will be established in the ejaculates from men with different pathologies</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The ORP values correlate with ROS-TAC scores in ejaculates of healthy men.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comparative study between ORP and. ROS&#150;TAC scores as measured by chemiluminescence and total
antioxidant capacity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">A positive correlation will be found between ORP values and ROS-TAC scores</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results from these clinical studies could validate that the RedoxSYS system can be used for detection of ORP in
human ejaculates and seminal plasma without requiring large sample volumes. Furthermore, it can show that the results obtained are comparable to the current parameters measured. This will validate the use of the RedoxSYS system in the clinical
andrology setting as a tool to provide real time information on oxidative status. If successful, these studies will provide substantial clinical validation for use of the RedoxSYS system in male infertility and enable a specific clinical application
in the field of andrology and male infertility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Clinical Study for Other Indications </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond male infertility, we have generated robust clinical data with ORP. As much of our initial research efforts focused on trauma, research beginning in 2014
has expanded into research and clinical applications in the areas of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stroke </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sepsis </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ventilator-Associated Pneumonia </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Athletic exertion </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hemodialysis </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Post cardiac surgery </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Congestive heart failure </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hip Fracture </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Frailty </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Diabetic Kidney Disease </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pulmonary Arterial Hypertension </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have conducted numerous pre-clinical studies looking at
various neurodegenerative conditions including Parkinson&#146;s disease and multiple sclerosis. We have active research in place with over 20 key opinion leaders around the world with over 80 studies in various stages or planning or execution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>U.S. Research&nbsp;&amp; Development </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2013 and 2014,
we deployed the RedoxSYS system around the world in the development of numerous future clinical applications. While many areas of study have been undertaken, we have focused research resources on high-value areas where significant medical needs
remain unmet. Given our initial orientation around trauma, the studies completed thus far have focused on large conditions related to critical care. These initial studies demonstrated the initial clinical validation for the RedoxSYS system and
represent substantial opportunities as growth applications and markets following initial entry into the research and infertility markets. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_283.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initiated over 80 studies across a range of study types, ranging from studies in trauma, liver disease,
diabetes, cardiac conditions, wellness/exercise, and fertility. From this research has presented unique opportunities to deploy RedoxSYS system to users in multiple markets around the world in various conditions. With a CE marking now in place and
research instruments now manufactured and ready for use, we are positioned to begin commercializing the RedoxSYS system. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919dsp_284.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Select Published Clinical Trials with Oxidation-Reduction Potential </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant research has been performed on the ORP diagnostic platform, and numerous peer-reviewed publications demonstrate the various
considerations made in the development of this application in a clinical setting. Further, the research conducted to date demonstrates the clinical relevance of ORP as a diagnostic marker in trauma, the development of TRALI via blood transfusions,
and other conditions. Over the past 20 years, Ampio employees, Dr.&nbsp;Bar-Or, Raphael Bar-Or, Leonard Rael, and their colleagues, have employed the resources of two Level 1 trauma centers in the state of Colorado. Specific, select studies
reporting on the clinical role of ORP as it relates to trauma, acute lung injury related to blood transfusions, and traumatic brain injury include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Study Summary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Phase</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Demographic</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Outcome/Findings</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Oxidation-Reduction Potential in Trauma Patients</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthy&nbsp;= 39</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Trauma&nbsp;= 10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Trauma patients admitted to a Level 1 trauma center</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Plasma ORP in multi-trauma patients increased during the first few days of hospitalization and approached normal ORP levels upon discharge</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effect of Storage on Oxidative Biomarkers on Packed Red Blood Cells</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">10 patient specimens</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Critically ill patients with a risk of&nbsp;developing transfusion-related acute lung injury</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Oxidation-reduction potential significantly increased (p &lt; 0.05) in the day 42 sample versus the day 1 sample. The oxidation of human serum albumin increased by 63.6% during the storage time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plasma Oxidation-Reduction Potential and Protein Oxidation in Traumatic Brain Injury</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-head injury trauma patients = 26</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderate ITBI patients = 18</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthy patients =</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">22</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Isolated traumatic brain injury</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Admission plasma ORP was significantly elevated in all traumatized patients compared to controls. Maximum ORP was detected on day 6 for severe ITBI and non-head injury traumatized patients. Maximum ORP values were significantly
higher p&lt;0.05) in the severe ITBI group compared to the non-head injury group</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Oxidation-reduction potential in trauma patients</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Clinical Proof of Concept</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trauma patients = 39</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Healthy patients = 10</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Critically injured patients</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The presence of an oxidative environment in the plasma of the critically injured as measured by ORP. ORP can differentiate the degree of oxidative stress based on the severity of the trauma and degree of inflammation</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulatory Pathway </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
achieved ISO 13485: 2003 in early 2014 following the successful development of a compliant medical device quality system. Following the issuance of our ISO certification, we were awarded a CE marking for the RedoxSYS system, which has enabled
initial market development in Europe and markets that accept a CE marking. We also received Health Canada clearance, and we are now working with multiple centers in Canada in research projects. In the United States, we intend to pursue 510k <I>de
novo</I> clearance with the FDA. We have had initial discussions with FDA and have confirmed RedoxSYS system&#146;s eligibility for the 510k <I>de novo</I> pathway in early 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commercial Strategy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>U.S. Commercial Strategy </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the clinical studies to measure oxidative stress in male infertility are successful, we expect to pursue that intended use for the RedoxSYS system via the
FDA 510K de novo pathway. If cleared for the intended use we intend to seek to commercialize RedoxSYS system as a new tool for the assessment of oxidative stress in infertility in men. We envision pursuing a direct sales efforts to high priority
infertility clinics and reference centers across the United States. We have identified the primary, influential centers in the United States and believe our commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deployment will be efficient through a focused sales and marketing effort. We intent to seek to sell the RedoxSYS system into individual centers and laboratories but will focus our revenue model
on the repeat ordering of the disposable, single use RedoxSYS sensor strips. We expect to realize a substantial gross margin and profit margin on the basis of low cost of goods sold on both components of the system. We envision an average selling
price for the disposable sensors of approximately $40. We envision selling the RedoxSYS analyzers for $5,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we will leverage our urology
commercialization efforts with other products with a focus on urology centers, infertility clinics, and reproductive health laboratories around the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe a focused sales force (initially) will enable effective representation of our products and penetration of the reproductive health market. Our sales
efforts into the research markets will be enabled initially through a full-time business development professional who will focus on collaborative research and research sales to major oxidative stress centers in the United States. We expect identical
pricing in the research market as we will pursue in the clinical diagnostics markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ROW Commercial Strategy </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intent to undertake a similar strategy outside the United States for the RedoxSYS system while complementing our efforts in infertility and research with
adjunct applications in critical care conditions. To efficiently execute across our strategy, we intent to utilize a network of established distributors in the target markets in Europe and Asia. We have already engaged with distributors in three
European countries and one Asian country, while many other potential distributors are in advanced stages of discussions with us. We anticipate slightly reduced pricing outside the United States for the disposable sensors (~$32 vs. $40) given the
anticipated lower pricing observed ex-US for diagnostic and research products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to augment our core development and commercial assets through efficient identification of complementary therapeutics, devices, and diagnostics related
to urological disorders. We intend to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through asset purchases, licensing, co-development, or collaborative commercial
arrangements (co-promotions, co-marketing, etc.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team has extensive experience across a wide range of business development activities and
have in-licensed or acquired products from large, mid-sized, and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect that we will rapidly advance our internal products as well
as externally sourced assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with Ampio </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into
various collaboration agreements and arrangements with Ampio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note and Debt Cancellations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, Ampio purchased 57,970,000 shares of common stock of the Combined Company for (i)&nbsp;issuance to the Combined Company of a promissory
note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii)&nbsp;cancellation of indebtness of Luoxis to Ampio in the amount of $8,000,000, and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio
in the amount of $4,000,000. Unpaid principal amounts under the promissory note bear simple interest equal to the greater of (i)&nbsp;0.4% and (ii)&nbsp;any other minimum rate of interest required by applicable rules and regulations of the Internal
Revenue Service. The promissory note is repayable, in whole or in part, at any time and from time to time, without penalty. In connection with the closing of the Merger, the loan agreements entered into by Ampio and Vyrix and Luoxis, respectively,
were terminated. See &#147;Related Party Transactions&#148; for further discussion regarding the loan agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assignment and Assumption Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2013, Vyrix entered into an assignment and assumption agreement with Ampio. Pursuant to the assignment and assumption agreement, Ampio assigned to
Vyrix all its rights under a certain manufacturing and supply agreement, license agreement, distribution agreement, services agreement and other agreements related to Vyrix&#146; product candidates. Such agreements were assigned to the Combined
Company upon the closing of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2013, Ampio transferred to Luoxis certain intellectual property, including registered and unregistered patents, related to the Luoxis ORP
technology. In December 2013, Ampio transferred to Vyrix certain intellectual property, including registered and unregistered patents, related to Vyrix product candidates. Such intellectual property was transferred to the Combined Company upon the
closing of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2013, Luoxis entered into a services agreement with Ampio whereby Ampio provides corporate overhead services and a shared facility with Luoxis in
exchange for $15,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. In January 2014, Vyrix entered into a services agreement with Ampio whereby Ampio
provides corporate overhead services to Vyrix in exchange for $7,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. Both agreements were assigned to the
Combined Company upon the closing of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with TRLLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer,
Dr.&nbsp;Bar-Or. The agreement, amended in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and development of Luoxis&#146; RedoxSYS system. In March 2014, Luoxis also agreed
to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be
terminated prior to March 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with Valeant Pharmaceuticals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;2, 2011, Ampio entered into an asset purchase agreement with Valeant International (Barbados) SRL (formerly BioVail Laboratories International
SRL), or Valeant. Under the agreement, which was assigned to us, Valeant sold and transferred all of Valeant&#146;s rights, title and interest in and to a license agreement covering patented technology, specified data, information, manufacturing
rights and know-how relating to an ODT formulation for Zertane, including samples of the Zertane product candidate, in exchange for cash of $2,000,000 and 3% of the aggregate annual net sales of Zertane. This product license is a major component for
documenting the manufacturing process for regulatory approval and accelerating the timeline for commercialization of Zertane. The agreement may no longer be terminated by either party other than by mutual agreement to terminate and our royalty
obligations under the agreement continue indefinitely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with Ethypharm </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;10, 2012, Ampio entered into a manufacturing and supply agreement with Ethypharm S.A., a society anonyme organized under the laws of France,
or Ethypharm, pursuant to which Ampio agreed to purchase all of its requirements of Zertane ODT exclusively from Ethypharm during the term of the agreement. The agreement, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was assigned to us, sets out fixed bulk pricing for the Zertane ODT product manufactured and supplied by Ethypharm. The term is a period of ten years from the effective date, automatically
renewing for three-year periods unless terminated. The agreement may also be terminated in the event of a material breach by either party, upon a bankruptcy or in the event that regulatory approval is withdrawn once obtained. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with Daewoong Pharmaceuticals Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;8, 2011, Ampio entered into a license, development and commercialization agreement, effective as of August&nbsp;23, 2011, with Daewoong
Pharmaceuticals Co., Ltd., or Daewoong, a major Korean pharmaceutical company. The agreement, which was assigned to us, grants Daewoong exclusive rights to develop, market and sell Zertane in South Korea for the treatment of PE and Zertane-ED for
the treatment of PE and ED. Upon signing of the agreement, Daewoong paid Ampio a $500,000 upfront payment, the net proceeds of which were $417,500 after withholding of Korean tax. The upfront payment has been deferred and is being recognized as
license revenue over a ten year period. Daewoong agreed to make milestone payments totaling up to $3,200,000 contingent upon achievement of regulatory approvals and cumulative net sales targets, which may take several years. In addition, we will
earn a royalty based on 25% of net sales, as defined in the agreement, if the royalty exceeds the transfer price of the Zertane product. The agreement has a term of ten years from the date of the first commercial sale of the first product in South
Korea, which will renew automatically renewal for successive two-year periods, subject to the right of either party to terminate upon 90 days written notice prior to the commencement of any renewal term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with FBM Farmaceutica </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;1, 2012, Ampio entered into a distribution agreement with FBM Industria Farmaceutica, Ltda., or FBM. The agreement, which was assigned to us, provides FBM with exclusive rights to market, distribute and sell Zertane in Brazil for the
treatment of PE and sets a fixed transfer price per tablet FBM will pay for supplying the product. FBM is responsible for obtaining and maintaining required product registration in Brazil. For the first three years following the first commercial
sale of Zertane in Brazil, FBM has a minimum marketing expenditure commitment. The agreement has a term of twenty years from the date of the first commercial delivery of Zertane to FBM and may be terminated by us on 120 days&#146; notice, subject to
early termination payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration with Paladin </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;9, 2014, we entered into a distribution and license agreement with Endo Ventures Limited, which recently acquired Paladin Labs Inc., or Paladin,
a leading Canadian specialty pharmaceutical company. The agreement grants Paladin exclusive rights to market and sell Zertane in Canada, the Republic of South Africa, Colombia and certain countries in Sub Saharan Africa and Latin America. Pursuant
to the agreement, Paladin has the right of first negotiation to include Zertane-ED as an additional product under the agreement. Upon signing of the agreement, Paladin made an upfront payment to us in the amount of $250,000. The agreement sets a
fixed transfer price that Paladin will pay per tablet and provides for milestone payments by Paladin to us upon the achievement of certain regulatory approvals and net sales targets, up to $3,025,000 in the aggregate, and for royalty payments by
Paladin to us based on net sales. The agreement has an initial term that expires on a country-by-country basis on the later of (i)&nbsp;the expiration of market exclusivity for the product in that country or (ii)&nbsp;15 years after the first
commercial sale of the product in that country, and automatically renews for successive three-year terms, unless we deliver notice of termination at least six months prior to the end of the then-current term. Either party may terminate the agreement
in the event of a material breach, subject to a cure period, or upon a bankruptcy or dissolution and may remove a country from the covered territory if regulatory approval is not obtained in that country. After the fourth anniversary of the
agreement, we may terminate for convenience on 60 days&#146; notice, subject to early termination payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current Vyrix patent portfolio consists of 77 issued patents and 15 pending applications worldwide. The portfolio primarily consists of three families
filed in the United States and throughout the world. The first family includes 30 issued patents for the use of tramadol to treat premature ejaculation. The standard 20-year expiration for patents in this family is in 2022. The other two families
are for the use of a combination of tramadol and a phosphodiesterase inhibitor to treat comorbid premature ejaculation and erectile dysfunction and to treat sexual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dysfunction side effects associated with administration of tramadol. These two families include issued patents in Europe, Australia, Canada, China, Mexico, New Zealand, Japan, the Philippines and
South Africa and pending applications in the United States, Brazil, China, India, Japan, Korea, and the Philippines. The standard 20-year expiration for patents in these families is in 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current Luoxis patent portfolio consists of 27 issued patents and 50 pending applications worldwide. The portfolio primarily consists of four families
filed in the United States and throughout the world. The first family includes three issued patents and six pending applications with claims directed to the measurement of the ORP of a patient sample to evaluate various conditions. The standard
20-year expiration for patents in this family is in 2028. The second family includes two pending United States applications, pending applications in Canada, Singapore, South Africa and Australia and a PCT international application with claims
directed to the measurement of the ORP capacity of a patient sample to evaluate various conditions. The standard 20-year expiration for patents in this family is in 2033. The third family includes five issued patents and 18 pending applications with
claims directed to devices and methods for the measurement of ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2032. The fourth family includes one pending United States application and 16 pending applications
worldwide with claims directed to multiple layer gel test strip measurement devices and methods of making for use in measuring ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2033. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain trade secrets and proprietary know-how that we seek to protect through confidentiality and nondisclosure agreements. These agreements may not
provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary information. If we do not adequately protect our trade secrets and proprietary know-how, our competitive position and
business prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to seek United States and foreign patent protection for drug and diagnostic products we
discover, as well as therapeutic and diagnostic products and processes. We expect also to seek patent protection or rely upon trade secret rights to protect certain other technologies which may be used to discover and characterize drugs and
diagnostic products and processes, and which may be used to develop novel therapeutic and diagnostic products and processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of
companies such as ours involve complex legal and factual questions and, therefore, their enforceability cannot be predicted with any certainty. Our issued and licensed patents, and those that may be issued to us in the future, may be challenged,
invalidated or circumvented, and the rights granted under the patents or licenses may not provide us with meaningful protection or competitive advantages. Our competitors may independently develop similar technologies or duplicate any technology
developed by us, which could offset any advantages we might otherwise realize from our intellectual property. Furthermore, even if our product candidates receive regulatory approval, the time required for development, testing, and regulatory review
could mean that protection afforded us by our patents may only remain in effect for a short period after commercialization. The expiration of patents or license rights we hold could adversely affect our ability to successfully commercialize our
pharmaceutical drugs or diagnostics, thus harming our operating results and financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be able to protect our proprietary intellectual
property rights from unauthorized use by third parties primarily to the extent that such rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. If we must litigate to protect our intellectual property
from infringement, we may incur substantial costs and our officers may be forced to devote significant time to litigation-related matters. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the
laws of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pending patent applications, or those we may file or license from third parties in the future, may not result in patents
being issued. Until a patent is issued, the claims covered by an application for patent may be narrowed or removed entirely, thus depriving us of adequate protection. As a result, we may face unanticipated competition, or conclude that without
patent rights the risk of bringing product candidates to market exceeds the returns we are likely to obtain. We are generally aware of the scientific research being conducted in the areas in which we focus our research and development efforts, but
patent applications filed by others are maintained in secrecy for at least 18 months and, in some cases in the United States, until the patent is issued. The publication of discoveries in scientific literature often occurs substantially later than
the date on which the underlying discoveries were made. As a result, it is possible that patent applications for products similar to our drug or diagnostic candidates may have already been filed by others without our knowledge. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and
other intellectual property rights, and it is possible that our development of product candidates could be challenged by other pharmaceutical or biotechnology companies. If we become involved in litigation concerning the enforceability, scope and
validity of the proprietary rights of others, we may incur significant litigation or licensing expenses, be prevented from further developing or commercializing a product candidate, be required to seek licenses that may not be available from third
parties on commercially acceptable terms, if at all, or subject us to compensatory or punitive damage awards. Any of these consequences could materially harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The healthcare industry is highly
competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Significant competitive factors in our industry include product efficacy and safety; quality
and breadth of an organization&#146;s technology; skill of an organization&#146;s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals; government reimbursement rates for, and the average selling
price of, products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual property and patent rights and their protection; and sales and marketing capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that any of our products that we successfully develop will be clinically superior or scientifically preferable to products developed or
introduced by our competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PE has traditionally been treated by behavioral or psychosexual therapy, antidepressant drugs, such as SSRIs, or topical
desensitizing agents, all of which have significant drawbacks. Behavioral and psychosexual therapy as a treatment for PE requires an understanding partner and can be frustrating, embarrassing, time consuming and expensive, among other things.
Antidepressant drugs are sometimes prescribed &#147;off-label&#148; and have numerous shortcomings, including side effects such as nausea, headaches, drop of libido, and ED, need for chronic dosing, ramp up periods, variable responses and unwanted
drug-drug interactions. Topical agents, including lidocaine-based products affect spontaneity, can numb a partner and be messy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dapoxetine (brand name
Priligy, owned by Furiex Pharmaceuticals, Inc.) is currently the only approved oral prescription drug to treat PE, with approval in several European countries. Priligy is not approved in the United States. In addition, we are aware of a topical
product in late-stage development for PE by Plethora Solutions referred to as PSD502 and studies of Botox for the treatment of PE are being conducted in the United States. These products &#150; if approved in the United States &#150; would represent
competition and alternative choices for physicians and potential patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, generic tramadol hydrochloride is available in the United States
and abroad for treatment of pain. Although the generic drug is not available in the same dosage as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off label&#148; for the treatment of
PE instead of Zertane, if Zertane is approved for commercialization. Patients could use generic tramadol hydrochloride dosages that are either higher or lower than what will be approved for Zertane or they could attempt to split dosages to arrive at
the dosages approved for Zertane. While any such &#147;off label&#148; use of generic tramadol hydrochloride for treatment of PE may constitute infringement of the Vyrix patent portfolio, liability in that circumstance would be at the level of the
physician or the patient making enforcement difficult or impractical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are other oxidative stress diagnostic tests available throughout the world,
although none are approved in the United States for clinical use. Diagnostic systems that are marketed for clinical use outside the United States include the FRAS 4 system (H&amp;D srl), FREE Carpe Diem (Diacron International), and the FORM and
FORMPlus systems (Callegari srl). These systems are used in both research and clinical settings but do not generate significant sales in the clinical setting. If approved in the United States for clinical use, these systems could present competition
to the RedoxSYS system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitors may also succeed in obtaining FDA or other regulatory approvals for their product candidates more
rapidly than we are able to do, which could place us at a significant competitive disadvantage or deny us marketing exclusivity rights. Market acceptance of our product candidates will depend on a number of factors, including: (i)&nbsp;potential
advantages over existing or alternative therapies or tests, (ii)&nbsp;the actual or perceived safety of similar classes of products, (iii)&nbsp;the effectiveness of sales, marketing, and distribution capabilities, and (iv)&nbsp;the scope of any
approval provided by the FDA or foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe our product candidates possess attractive attributes, we cannot
assure you that our product candidates will achieve regulatory or market acceptance, or that we will be able to compete effectively in the pharmaceutical drug markets. If our product candidates fail to gain regulatory approvals and acceptance in
their intended markets, we may not generate meaningful revenues or achieve profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategy is to minimize fixed overhead by outsourcing much of our research and development activities. We believe we will benefit from Ampio&#146;s
research and development experience as well as regulatory expertise. Additionally, we intend to utilize consultants with domain experience for research, development and regulatory guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have consulting agreements in place with two such companies who are actively participating with us on the impending clinical trials for Zertane. For
Zertane-ED, we intend to collaborate on pre-clinical studies and clinical trials with our partner in Korea, Daewoong Pharmaceuticals Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our RedoxSYS
system has been developed in conjunction with numerous medical device and diagnostic development consultants. Further, we have relationships with regulatory consultants who are actively assisting in the development of our regulatory strategy with
the FDA. To complement our internal clinical research efforts with the RedoxSYS system, we have engaged with numerous universities around the world to identify and develop research and clinical applications for the RedoxSYS system. Through these
engagements we have access to data and analyses that enable us to develop new uses for the RedoxSYS system. Additionally, we have formal research agreements in place with two prominent U.S.-based universities and one prominent European university
for which we are paying a research fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business strategy is to use cGMP compliant contract manufacturers for the manufacture of clinical supplies as well as for commercial supplies if required
by our commercialization plans, and to transfer manufacturing responsibility to our collaboration partners when possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to a 10-year
supply agreement with an established manufacturer of tramadol hydrochloride for Zertane. Importantly, product supply has been produced for our planned clinical trials for Zertane. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have completed the technical development of the RedoxSYS system by engaging contract development and manufacturing companies in the United States. We
secured supply and quality agreements with manufacturers for both the RedoxSYS instrument as well as the RedoxSYS sensor strips. Both manufacturers hold long-standing ISO 13485:2003 certifications and are established medical device manufacturers.
Both manufacturers have high volume manufacturing capacity such that production volumes can be easily scaled. Both manufacturers have been audited by our quality engineers and are fully compliant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Approval Process for
Pharmaceutical Products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>FDA Approval Process for Pharmaceutical Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and
other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil
penalties, and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharmaceutical product development in the United States typically involves the performance of satisfactory
nonclinical, also referred to as pre-clinical, laboratory and animal studies under the FDA&#146;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated current good
manufacturing requirements, or cGMP, including a quality system regulating manufacturing, the submission and acceptance of an IND application, which must become effective before human clinical trials may begin in the United States, obtaining the
approval of Institutional Review Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical trials to establish the safety and
effectiveness of the drug for each indication for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time required may vary
substantially based upon the type, complexity, and novelty of the product or disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pre-clinical tests generally include laboratory evaluation of a
product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical
data and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an
IND, which must become effective before human clinical trials can begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to
various FDA laws and regulations, as well as international scientific standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity of clinical trial data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the
intended conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is no guarantee that an IND based on those studies will become effective, allowing clinical
testing to begin. In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by an independent IRB or Ethics Committee, or EC. The IRB considers, among
other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA&#146;s GCP requirements. The FDA and/or IRB may order the temporary, or permanent, discontinuation of a
clinical trial or that a specific clinical trial site to be halted at any time, or impose other sanctions for failure to comply with requirements under the appropriate entity jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1 clinical
trials, a product candidate is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to be used. The main purpose of the trial is to assess a product candidate&#146;s safety
and the ability of the human body to tolerate the product candidate. Phase 1 clinical trials generally include less than 50 subjects or patients. During Phase 2 trials, a product candidate is studied in an exploratory trial or trials in a limited
number of patients with the disease or medical condition for which it is intended to be used in order to: (i)&nbsp;further identify any possible adverse side effects and safety risks, (ii)&nbsp;assess the preliminary or potential efficacy of the
product candidate for specific target diseases or medical conditions, and (iii)&nbsp;assess dosage tolerance and determine the optimal dose for Phase 3 trials. Phase 3 trials are generally undertaken to demonstrate clinical efficacy and to further
test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase 3 trials are generally designed to reach a specific goal or endpoint, the achievement of which is
intended to demonstrate the candidate product&#146;s clinical efficacy and adequate information for labeling of the approved drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are three main
types of NDAs, which are covered by Section&nbsp;505 of the FDC Act: (1)&nbsp;an application that contains full reports of investigations of safety and efficacy (Section 505(b)(1)); (2)&nbsp;an application that contains full reports of
investigations of safety and effectiveness but where at least some of the information required for approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comes from studies not conducted by or for the applicant and for which the application has not obtained a right of reference (Section 505(b)(2)); and (3)&nbsp;an application that contains
information to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product
(Section 505(j)). Section&nbsp;505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by the applicant. In the pre-IND briefing meeting with Ampio and in June, 2012, the FDA agreed that our NDA may be submitted
under Section&nbsp;505(b)(2). As such, we intend to rely on studies published in the scientific literature and reference FDA-approved NDAs for tramadol-containing products (NDAs 21-693, 20-281 and 21-692) to support the safety and efficacy
demonstrated in our clinical program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the
NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture,
and controls. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2.3 million and the manufacturer and/or
sponsor under an approved NDA are also subject to annual product and establishment user fees, currently approximately $0.1 million per product and $0.6 million per establishment. These fees are typically increased annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the FDA&#146;s threshold
determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications
for standard review drug products are reviewed within ten months; most applications for priority review drugs are reviewed in six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, or provide a
treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by FDA for three additional months to consider certain late-submitted information, or information intended to clarify information
already provided in the submission. The FDA may also refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and
other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an
NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance
with cGMP is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter
generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#146;s
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial
marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the
potential risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU
can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially
affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if
compliance with regulatory standards is not maintained or problems are identified following initial marketing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Regulatory Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside of the United States, our ability to market our product candidates will be contingent also upon our receiving marketing authorizations from the
appropriate foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries generally encompasses risks similar to those we will encounter in the FDA approval
process. The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite approvals, may vary widely from country to country and differ from those required for FDA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized or decentralized procedure. The centralized
procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of
a national marketing authorization may submit an application to the remaining member states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval. The mutual recognition
process results in separate national marketing authorizations in the reference member state and each concerned member state. We will seek to choose the appropriate route of European regulatory filing in an attempt to accomplish the most rapid
regulatory approvals for our product candidates when ready for review. However, the chosen regulatory strategy may not secure regulatory approvals or approvals of the chosen product indications. In addition, these approvals, if obtained, may take
longer than anticipated. We can provide no assurance that any of our product candidates will prove to be safe or effective, will receive required regulatory approvals, or will be successfully commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the registration of Zertane in Australia, an application in common technical document (CTD) format was submitted to the Therapeutic Goods Administration
(TGA) in August 2013. This was a Category 1 Type C submission for a new indication, as well as a Type F major variation for a new dosage strength. The submission included original data from the clinical trials and medical literature, given the prior
approvals for tramadol hydrochloride in products used in the management of pain. A pre-planning form, or PPF, was submitted to the TGA first, which included only summaries of the clinical, nonclinical and chemistry, manufacturing and control (CMC)
sections as well as administrative documents. Within 2.5 months from the PPF submission, the full registration dossier with all supporting and source documentation was provided, which initiated the TGA review process. A consolidated list of
questions from TGA was received after approximately 4-5 months of the review cycle and these questions were required to be addressed by us within 60 days receipt of the questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have addressed these questions and expect to receive final TGA evaluation reports for all disciplines in approximately 1 month. While there may be some
unresolved issues that come back to us as a second round of questions, the Delegate&#146;s Overview is typically issued about 1 month after the TGA evaluation reports are received. The Delegate&#146;s Overview triggers a request for advice from an
Advisory Committee on Prescription Medicines, or ACPM, obtained at formal pre-scheduled meetings held once every two months. After the ACPM meeting, TGA notifies us of the outcome (called the ACPM resolution) and a decision letter is issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Hatch-Waxman Act </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In seeking approval for a drug
through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#146;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#146;s
Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or
ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed
drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are
commonly referred to as &#147;generic equivalents&#148; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#146;s Orange Book that: 1) the
required patent information has not been filed; 2) the listed patent has expired; 3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or 4) the listed patent is invalid or will
not be infringed by the new product. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the applicant does not
challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice
of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV
certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of
the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ANDA application also will not be approved until any
non-patent exclusivity listed in the Orange Book for the referenced product has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients during which ANDAs for generic
versions of those drugs cannot be submitted, unless the submission contains a Paragraph IV challenge to a listed patent&#151;in which case the submission may be made four years following the original product approval. Federal law provides for a
period of three years of exclusivity during which FDA cannot grant effective approval of an ANDA based on the approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of
administration or combination, or for a new use; the approval of which was required to be supported by new clinical trials conducted by, or for, the applicant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product candidate
receives regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions on
its use or even complete withdrawal of the product from the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or
experiences. Further, drug manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which
impose rigorous procedural and documentation requirements upon us and our contract manufacturers. We cannot be certain that we or our present or future contract manufacturers or suppliers will be able to comply with cGMP regulations and other FDA
regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation
of marketing approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA approves one or more of our product candidates, we and the contract manufacturers we use for manufacture of clinical
supplies and commercial supplies must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing process or facilities where the manufacturing occurs or other post-approval changes may
necessitate additional FDA review and approval. The labeling, advertising, promotion, marketing and distribution of a drug or biologic product or medical devices, also must be in compliance with FDA and Federal Trade Commission, or FTC, requirements
which include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very
broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing us to correct deviations from regulatory standards and enforcement actions that can include
seizures, fines, injunctions and criminal prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Approval Process for Medical Devices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the FDCA, FDA regulations and other federal and state statutes and regulations govern, among other things, medical device design and
development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. The FDA
regulates the design, manufacturing, servicing, sale and distribution of medical devices, including molecular diagnostic test kits and instrumentation systems. Failure to comply with applicable U.S. requirements may subject a company to a variety of
administrative or judicial sanctions, such as FDA refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and
criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless an exemption applies, each medical device we wish to distribute commercially in the United States will
require marketing authorization from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also called 510(k) clearance, and premarket approval, also called PMA
approval. The type of marketing authorization is generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated
with a device and the level of regulatory control deemed necessary to ensure the device&#146;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are
deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling, premarket notification and adherence to the FDA&#146;s current Good Manufacturing Practices, or cGMP, known
as the Quality System Regulations, or QSR. Class II devices are intermediate risk devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents, special
labeling requirements, patient registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety and effectiveness solely through general or special controls and include life-sustaining,
life-supporting or implantable devices, devices of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most Class I devices and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior
authorization from the FDA. Some Class I devices that have not been so exempted and Class II devices are eligible for marketing through the 510(k) clearance pathway. By contrast, devices placed in Class III generally require PMA approval or 510(k)
de novo clearance prior to commercial marketing. The PMA approval process is more stringent, time-consuming and expensive than the 510(k) clearance process, however, the 510(k) clearance process has also become increasingly stringent and expensive.
The FDA has provided initial guidance to us that the RedoxSYS system is appropriate for the 510(k) clearance process, likely through the de novo pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>510(k) Clearance.</I> To obtain 510(k) clearance for a medical device, an applicant must submit a premarket notification to the FDA demonstrating that the
device is &#147;substantially equivalent&#148; to a device legally marketed in the United States that is not subject to PMA approval, commonly known as the &#147;predicate device.&#148; A device is substantially equivalent if, with respect to the
predicate device, it has the same intended use and has either (i)&nbsp;the same technological characteristics or (ii)&nbsp;different technological characteristics and the information submitted demonstrates that the device is as safe and effective as
a legally marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires clinical data. Generally, the 510(k) clearance process can exceed 90 days and may
extend to a year or more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Application fees must accompany medical device submissions. Such fees under the Medical Device User Fees Act, or MDUFA, for
2015 are approximately $258,000 for a full fee application and approximately $5,000 for a 510(k). Fees are adjusted annually. There are also establishment registration and reporting fees of approximately $4,000 and $9,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness,
such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a modification could
significantly affect the device&#146;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product at any time
and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can submit a medical device for 510(k) clearance, we may have to perform a series of generally short
studies over a period of months, including method comparison, reproducibility, interference and stability studies to ensure that users can perform the test successfully. Some of these studies may take place in clinical environments, but are not
usually considered clinical trials. For PMA submissions, we would generally be required to conduct a longer clinical trial over a period of years that supports the clinical utility of the device and how the device will be used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although clinical investigations of most devices are subject to the investigational device exemption, or IDE, requirements, clinical investigations of
diagnostic tests, including our products and products under development, are generally exempt from the IDE requirements. Thus, clinical investigations by intended users for intended uses of our products generally do not require the FDA&#146;s prior
approval but may require approval of an Institutional Review Board, or IRB, and written informed consent by the patient, provided the clinical evaluation testing is non-invasive, does not require an invasive sampling procedure that presents a
significant risk, does not intentionally introduce energy into the subject and is not used as a diagnostic procedure without confirmation by another medically established test or procedure. In addition, our products must be labeled per FDA
regulations &#147;for research use only-RUO&#148; or &#147;for investigational use only-IUO,&#148; and distribution controls must be established to assure that our products distributed for research, method comparisons or clinical evaluation studies
are used only for those purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Regulation After FDA Clearance or Approval. </I>Any devices we manufacture or distribute pursuant to clearance or
approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. We are required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which include, among
other things, testing, control and documentation requirements. Non-compliance with these standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production,
refusal of the government to grant 510(k) clearance or PMA approval of devices, withdrawal of marketing approvals and criminal prosecutions, fines and imprisonment. We have designed and implemented our manufacturing facilities under the FDA&#146;s
cGMP requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Regulatory Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the European Union, we are required under the European Medical Device Directive (Council Directive 93/42/EEC) to affix the CE mark to our certain of our products in order to sell the products in member countries of the European Union. The CE mark is
an international symbol that represents adherence to certain essential principles of safety and effectiveness mandated in the European Medical Device Directive, which are referred to as the &#147;essential requirements&#148;. Once affixed, the CE
mark enables a product to be sold within the European Economic Area, or EEA, which is composed of the 28 member states of the EU plus Norway, Iceland and Liechtenstein as well as other countries that accept the CE mark. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To demonstrate compliance with the essential requirements, we must undergo a conformity assessment procedure which varies according to the type of medical
device and its classification. Except for low risk medical devices (Class I with no measuring function and which are not sterile) where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its
products with the essential requirements of the Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a notified body.
Depending on the relevant conformity assessment procedure, the notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. The notified body issues a CE
certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the essential requirements. This certificate entitles the
manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we modify our
devices we may need to apply for permission to affix the CE mark to the modified product. Additionally, we may need to apply for a CE mark for any new products that we may develop in the future. Certain products regulated as medical devices
according to EC-Directives are subject to vigilance requirements for reporting of adverse events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be subject to additional regulations in other countries in which we market, sell and import our products,
including Canada. We or our distributors must receive all necessary approvals or clearance prior to marketing and/or importing our products in those markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The International Standards Organization, or ISO, promulgates internationally recognized standards, including those for the requirements of quality systems.
To support ISO certifications, surveillance audits are conducted by a notified body yearly and recertification audits every three years that assess continued compliance with the relevant ISO standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Regulatory Matters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing, sales,
promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare&nbsp;&amp; Medicaid Services, other
divisions of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental
Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid
rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA. If products are made
available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled
Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and
state consumer protection and unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements and regulations,
including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet
applicable regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or
refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to
modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to
be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and other specific aspects of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited
patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for
patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term
restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an
approved drug is eligible for the extension and the application for the extension must be submitted prior to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we
intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond the current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing
of the relevant NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The
FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any
other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. Recently FDA stated that it may change its interpretation of 5-year NCE exclusivity determinations to apply to each drug
substance in a fixed-combination drug product, not for the drug product as a whole. If this change is implemented, for example, a fixed-combination drug product that contains a drug substance with a single, new active moiety would be eligible for 5
year NCE exclusivity, even if the fixed-combination also contains a drug substance with a previously approved active moiety. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a
Section&nbsp;505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the
applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non- infringement to one of the patents
listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or
sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug
received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not
delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to
demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the
United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the
voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not anticipate that the sales of our product candidates, once approved for sale, will be heavily dependent upon reimbursement by third-party payors.
Traditionally, sales of pharmaceutical products that are not &#147;life style&#148; indications depend, in part, on the extent to which products will be covered by third-party payors, such as government health programs, commercial insurance and
managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. Lack of third-party reimbursement for our product candidate or a decision by a third-party payor to not cover our
product candidates could reduce physician usage of the product candidate and have a material adverse effect on our sales, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug
pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control
the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products
launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;16, 2015, we employ seven full-time employees and utilize the services of a number of consultants on a temporary basis, including various
Ampio employees pursuant to a services agreement. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our services agreements with
Ampio, we use a portion of Ampio&#146;s office space as our office space, which is located in Englewood, Colorado. We also expect to open an office in Raleigh, North Carolina. Ampio&#146;s lease expires in 2024 and our cost for the office space is
included in our quarterly payment under the services agreements. We believe our current office space is sufficient to meet our current needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this Form 8-K, we are not party to any legal matters or claims, and none of our property is subject to any legal
proceedings. In the future we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations
or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before investing in our common stock you should carefully consider the following risks,
together with the financial and other information contained in this Form 8-K. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be adversely affected. In that case, the
trading price of our common stock would likely decline and you may lose all or a part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition
and Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited operating history, have incurred losses, and can give no assurance of profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage healthcare company with a limited operating history. We have not generated material revenue to date and are not profitable, and have
incurred losses in each year since our inception. Our net loss for the years ended December&nbsp;31, 2014 and 2013 was $7.1 million and $3.9 million, respectively. We have not demonstrated the ability to be a revenue-generating enterprise, and
without significant financing, there is substantial doubt about our ability to continue as a going concern. We expect to incur substantial losses for the foreseeable future. Our ability to generate revenue is uncertain, and we may never achieve
profitability. We have a very limited operating history on which investors can evaluate our potential for future success. Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered
by early-stage businesses, many of which will be beyond our control. These risks include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of sufficient capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated problems, delays, and expense relating to product development and implementation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of intellectual property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">licensing and marketing difficulties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">technological changes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertain market acceptance of our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of our limited operating history, and the
increasingly competitive nature of the markets in which we compete, our historical financial data, which consists of allocations of expenses from Ampio, is of limited value in anticipating future operating expenses. Our planned expense levels will
be based in part on our expectations concerning future operations, which is difficult to forecast accurately based on our stage of development. We may be unable to adjust spending in a timely manner to compensate for any unexpected budgetary
shortfall. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not received any material revenues from the commercialization of our product candidates and might not receive significant revenues
from the commercialization of our product candidates in the near term. In September 2011, Ampio entered into an agreement to license, develop and commercialize Zertane in South Korea with a Korean pharmaceutical company, which provided for a
$500,000 upfront payment and an agreement to make future milestone payments contingent upon regulatory approvals and cumulative net sales targets. We may enter into additional licensing and collaboration arrangements, which may provide us with
potential milestone payments and royalties, and those arrangements, if obtained, will be our primary source of revenues for the coming years. We cannot be certain that any other licensing or collaboration arrangements will be concluded, or that the
terms of those arrangements will result in our receiving material revenues. To obtain revenues from product candidates, we must succeed, either alone or with others, in a range of challenging activities, including completing clinical trials of our
product candidates, obtaining positive results from the clinical trials, achieving marketing approval for these product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, manufacturing, marketing and selling those products for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining
reimbursement for our products from private insurance or government payors. We, and our collaborators, may never succeed in these activities and, even if we do, or one of our collaborators does, we may never generate revenues that are large enough
for us to achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to
obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
currently advancing our product candidates through clinical development. Developing product candidates is expensive, lengthy and risky, and we expect our research and development expenses to increase substantially in connection with our ongoing
activities, particularly as we advance Zertane into two planned Phase 3 clinical trials in the United States and develop RedoxSYS system for additional applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014, our cash and cash equivalents were $160,905. Our operating plan may change as a result of many factors currently unknown to us,
and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and
licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, our product candidates. Raising funds in the current economic environment may
present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and
commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or
the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible
securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur
additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through
arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidate or otherwise agree to terms unfavorable to us,
any of which may have a material adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis,
we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate or be unable to expand our operations or otherwise capitalize on our business
opportunities, as desired, which could materially affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain the
capital necessary to fund our operations, we will be unable to successfully develop, obtain regulatory approval of, and commercialize, our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development of pharmaceutical products and medical devices is capital-intensive. We anticipate we may require additional financing to continue to fund our
operations. Our future capital requirements will depend on, and could increase significantly as a result of, many factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">progress in, and the costs of, our pre-clinical studies and clinical trials and other research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, prioritization and number of our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of securing manufacturing arrangements for commercial production; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory clearances to market our product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through collaboration arrangements, sales of our securities,
debt financings, or by licensing one or more of our product candidates. Dislocations in the financial markets have generally made equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet our
fundraising needs. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or
development programs or our commercialization efforts. Additional funding, if obtained, may significantly dilute existing shareholders if that financing is obtained through issuing equity or instruments convertible into equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs associated with, and our management will need to devote substantial time and effort to, compliance with public company
reporting and other requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that Vyrix and Luoxis did
not incur as private companies. In addition, the rules and regulations of the SEC and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our
corporate governance practices, with which we will need to comply. Further, we will be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results. Based on currently available
information and assumptions, we estimate that we will incur approximately $500,000 in expenses on an annual basis as a direct result of the requirements of being a publicly traded company. Our management and other personnel will need to devote
substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those requirements could be expensive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development, Regulatory Approval and Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot be certain that the FDA will consider premature ejaculation to be a treatable medical condition or that we will be able to obtain regulatory
approval for, or successfully commercialize, Zertane. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no drug products approved for sale and may never be able to develop
marketable drug products. Zertane will require substantial additional clinical development, testing, and regulatory approval before we are permitted to commence its commercialization. Our other drug product candidate, Zertane-ED, is still in
pre-clinical development. The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by numerous government authorities in the
United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through pre-clinical testing and
clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial
resources. Of the large number of drugs in development in the United States, only a small percentage successfully completes the U.S. Food and Drug Administration, or FDA, regulatory approval process and is commercialized. Accordingly, even if we are
able to obtain the requisite financing to continue to fund our development and clinical programs, we cannot assure you that Zertane or any other of our product candidates will be successfully developed or commercialized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not permitted to market Zertane in the United States until we receive approval of a New Drug Application,
or an NDA, from the FDA, or in any foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of
Zertane for many reasons, including, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to demonstrate that Zertane is safe and effective in treating premature ejaculation, to the satisfaction of the FDA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may require that we conduct additional clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may not approve the formulation, labeling or specifications of Zertane; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate that Zertane&#146;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients
or the public in general; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may disagree with our interpretation of data from our pre-clinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may not accept data generated at our clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval
of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or the applicable foreign regulatory agency may not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA may change its approval policies or adopt new regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Ampio obtained guidance from
FDA on our NDA-enabling Phase 3 trials at a pre-IND meeting held in June 2012, including information to help us define the target patient population, select co-primary endpoints and design an acceptable patient-reported outcome measure. As a result
of direction provided at the meeting, along with the existing data from six clinical trials of Zertane conducted to date, we believe we are positioned to advance Zertane into Phase 3 clinical trials in the United States. However, we can provide no
assurance that the FDA will not change its guidance about our planned Phase 3 clinical trials and require us to significantly modify the design of, or endpoints for, our planned clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market Zertane.
Moreover, because our business is almost entirely dependent upon this one product candidate, any such setback in our pursuit of regulatory approval would have a material adverse effect on our business and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Favorable results in the prior clinical trials of Zertane outside of the United States may not be
predictive of the results in our planned Phase 3 clinical trials of Zertane in the United States or the designs of our Phase 3 clinical trials may be inadequate for FDA approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving
promising results in earlier-stage development. The prior clinical trials of Zertane showed favorable safety and efficacy data; however, we will have different enrollment criteria in our planned Phase 3 clinical trials. In the Phase 2 clinical
trials, we were able to enroll patients utilizing a broader definition of premature ejaculation, or PE. In our Phase 3 clinical trials, we will be utilizing the definition of lifelong PE adopted by the International Society for Sexual Medicine, or
the ISSM: &#147;premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within a minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal
penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.&#148; As a result, we may encounter difficulty enrolling a sufficient number of patients in a timely fashion and we may
not observe a similarly favorable safety and efficacy profile as our prior clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not secure collaborations with strategic
partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop products and generate meaningful revenues. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key aspect of our current strategy is to selectively enter into collaborations with third parties to conduct clinical testing, as well as to commercialize
and manufacture product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. We currently have two
collaboration agreements in effect, which relate to sales of Zertane in South Korea and Brazil and were entered into by Ampio. Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and
safety, obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety are demonstrated. The current economic environment may result in potential collaborators electing to reduce
their external spending, which may prevent us from developing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we succeed in securing collaborators, the collaborators may
fail to develop or effectively commercialize products using our product candidates. Collaborations involving our product candidates pose a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not have sufficient resources or decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may believe our intellectual property is not valid, is not infringed by potential competitors or is unenforceable or the product candidate infringes on the intellectual property rights of others;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay the development or commercialization of our product candidates in favor of developing or commercializing another party&#146;s product candidate; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may decide to terminate or not to renew the collaboration for these or other reasons. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, collaboration agreements may not lead to development or commercialization of product candidates in the most
efficient manner or at all. For example, our former collaborator that licensed Zertane conducted clinical trials which we believe demonstrated efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic
focus and thereafter terminated the collaboration agreement. The merger also created a potential conflict with a principal customer of the acquired company, which sells a product to treat premature ejaculation in certain European markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration agreements are generally terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to
commercialization of a product candidate. We also face competition in seeking out collaborators. If we are unable to secure new collaborations that achieve the collaborator&#146;s objectives and meet our expectations, we may be unable to advance our
product candidates and may not generate meaningful revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are expected to undergo clinical trials that are time-consuming
and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we, or our
collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pre-clinical testing and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any
clinical studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical testing and clinical development necessary to commercialize a drug or biologic, and delays or failure can occur
at any stage. Interim results of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be certain that we will not face similar setbacks. The design of a clinical trial
can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An unfavorable outcome in one or more trials would be a major
set-back for our product candidates and for us. Due to our limited financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more product development programs, which could
have a material adverse effect on our business and financial condition and on the value of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with clinical
testing and trials, we face a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate is ineffective, inferior to existing approved medicines, unacceptably toxic, or has unacceptable side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patients may die or suffer other adverse effects for reasons that may or may not be related to the product candidate being tested; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not confirm the positive results of earlier testing or trials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not meet the level of statistical significance required by the FDA or other regulatory agencies to establish the safety and efficacy of our product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of pre-clinical studies do not necessarily predict clinical success, and larger and later-stage clinical trials may not produce the same results
as earlier-stage clinical trials. Frequently, product candidates developed by pharmaceutical companies have shown promising results in early pre-clinical studies or clinical trials, but have subsequently suffered significant setbacks or failed in
later clinical trials. In addition, clinical trials of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not successfully complete pre-clinical and clinical development, we will be unable to market and sell products derived from our product candidates
and generate revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before an NDA may be submitted to the FDA. Although there are a large number
of drugs and biologics in development in the United States and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved for commercialization, and only a small number achieve widespread
physician and consumer acceptance following regulatory approval. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not receive regulatory approval of any
of these product candidates and our business and financial condition will be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays, suspensions and terminations in our clinical trials could result in increased costs to us and delay
or prevent our ability to generate revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are very expensive, time-consuming, and difficult to design, implement and
complete. We currently expect clinical trials of our product candidates could take up to 24 months to complete, but the completion of trials for our product candidates may be delayed for a variety of reasons, including delays in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement on acceptable terms with prospective contract research organizations and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">validating test methods to support quality testing of the drug substance and drug product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining sufficient quantities of the drug substance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing sufficient quantities of a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining approval of an Investigational New Drug application, or IND, from the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining dosing and clinical design and making related adjustments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective
treatments for the relevant disease and the eligibility criteria for the clinical trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commencement and completion of clinical trials
for our product candidates may be delayed, suspended or terminated due to a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of effectiveness of product candidates during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse events, safety issues or side effects relating to the product candidates or their formulation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to raise additional capital in sufficient amounts to continue clinical trials or development programs, which are very expensive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to sequence clinical trials as opposed to conducting them concomitantly in order to conserve resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to enter into collaborations relating to the development and commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or our collaborators to conduct clinical trials in accordance with regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability or the inability of our collaborators to manufacture or obtain from third parties materials sufficient for use in pre-clinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect
to clinical trial results; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our collaborators to advance our product candidates through clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in patient enrollment, especially in the United States where the screening requirements for participation in our trials are expected to be more stringent than the previous European trials of Zertane, variability
in the number and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in patient monitoring and data collection due to failure of patients to maintain contact after treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a regional disturbance where we or our collaborative partners are enrolling patients in our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of our data, and regulatory commitments and requirements by the FDA and similar foreign regulatory agencies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of these factors may also ultimately lead to denial of our NDA for a current or potential product candidate. If we experience delay, suspensions or
terminations in a clinical trial, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may encounter delays or product candidate rejections based on new governmental regulations, future legislative or administrative actions, or
changes in FDA policy or interpretation during the period of product development. If we obtain required regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diminishment of any competitive advantages that such product candidates may have or attain. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, if
we fail to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diminishment of any competitive advantages that such product candidates may have or attain; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays or termination in clinical trials or commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements to approved applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls or seizures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of manufacturing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawals of previously approved marketing applications; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, civil penalties, and criminal prosecutions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our product candidates are not approved by the FDA, we
will be unable to commercialize them in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA must approve any new medicine before it can be commercialized, marketed, promoted or
sold in the United States. We must provide the FDA with data from pre-clinical studies and clinical trials that demonstrate that our product candidates are safe and effective for a defined indication before they can be approved for commercial
distribution. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We must provide data to ensure the identity, strength, quality and purity of the drug
substance and drug product. Also, we must assure the FDA that the characteristics and performance of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical batches will be replicated consistently in the commercial batches. We will not obtain approval for a product candidate unless and until the FDA approves an NDA for a drug. The processes
by which regulatory approvals are obtained from the FDA to market and sell a new or repositioned product are complex, require a number of years and involve the expenditure of substantial resources. We cannot assure you that any of our product
candidates will receive FDA approval in the future, and the time for receipt of any such approval is currently incapable of estimation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or our
collaborators intend to seek FDA approval for most of our product candidates using an expedited process established by the FDA. If we, or our collaborators, are unable to secure clearances to use expedited development pathways from the FDA for
certain of our drug product candidates, we, or they, may be required to conduct additional pre-clinical studies or clinical trials beyond those that we, or they, contemplate, which could increase the expense of obtaining, and delay the receipt of,
necessary marketing approvals and of any product revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming successful completion of clinical trials, we expect to submit NDAs to the FDA
at various times in the future under Section&nbsp;505(b)(2) of the Food, Drug and Cosmetic Act, as amended, or the FDCA. NDAs submitted under this section are eligible to receive FDA approval by relying in part on the FDA&#146;s findings of safety
and efficacy for a previously approved drug. The FDA&#146;s 1999 guidance on Section&nbsp;505(b)(2) applications states that new indications for a previously approved drug, a new combination product, a modified active ingredient, or changes in
dosage form, strength, formulation, and route of administration of a previously approved product are encompassed within the Section&nbsp;505(b)(2) NDA process. Relying on Section&nbsp;505(b)(2) is advantageous because we or our collaborators may not
be required (i)&nbsp;to perform the full range of safety and efficacy trials that is otherwise required to secure approval of a new drug, and (ii)&nbsp;obtain a &#147;right of reference&#148; from the applicant that obtained approval of the
previously approved drug. However, a Section&nbsp;505(b)(2) application must support the proposed change of the previously approved drug by including necessary and adequate information, as determined by the FDA, and the FDA may still require us to
perform a portion or the full range of safety and efficacy trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If one of our product candidates achieves clinical trial objectives, we must prepare
and submit to the FDA a comprehensive NDA. Review of the application may lead the FDA to request more information or require us to perform additional clinical trials, thus adding to product development costs and timelines and subsequently delaying
any marketing approval from the FDA. Additionally, the review period may vary significantly based on the disease to be treated, availability of alternate treatments, severity of the disease, and the risk/benefit profile of the proposed product. Even
if one of our products receives FDA marketing approval, we could be required to conduct post-marketing Phase IV studies and surveillance to monitor for adverse effects. If we experience delays in NDA application processing, requests for additional
information or further clinical trials, or are required to conduct post-marketing studies or surveillance, our product development costs could increase substantially, and our ability to generate revenues from a product candidate could be postponed,
perhaps indefinitely. The resulting negative impact on our operating results and financial condition may cause the value of our common stock to decline, and you may lose all or a part of your investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The approval process outside the United States varies among countries and may limit our ability to develop, manufacture and sell our products
internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market and sell our products in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional testing. We may conduct clinical trials for, and seek regulatory approval to market, our product
candidates in countries other than the United States. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may decide to first seek regulatory approvals of a product candidate in
countries other than the United States, or we may simultaneously seek regulatory approvals in the United States and other countries. If we or our collaborators seek marketing approvals for a product candidate outside the United States, we will be
subject to the regulatory requirements of health authorities in each country in which we seek approvals. With respect to marketing authorizations in Europe, we will be required to submit a European marketing authorization application, or MAA, to the
European Medicines Agency, or EMA, which conducts a validation and scientific approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries and may involve additional testing, and the
time required to obtain approvals may differ from that required to obtain FDA approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Obtaining regulatory approvals from health authorities in countries outside the United States is likely to subject us to all of the risks associated with obtaining FDA approval described above.
In addition, marketing approval by the FDA does not ensure approval by the health authorities of any other country, and approval by foreign health authorities does not ensure marketing approval by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products
may limit how we or they market our products, which could materially impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory
approval for a product candidate, this approval may carry conditions that limit the market for the product or put the product at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the
indicated uses for which we can market a product or the patient population that may utilize the product, or may be required to carry a warning in its labeling and on its packaging. Products with boxed warnings are subject to more restrictive
advertising regulations than products without such warnings. These restrictions could make it more difficult to market any product candidate effectively. Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of
our product candidates, we, and our collaborators will continue to expend time, money and effort in all areas of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any of our
product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if
we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of our product candidates for which we, or our collaborators, obtain marketing approval in the future, as well as the manufacturing processes,
post-approval studies and measures, labeling, advertising and promotional activities for such products, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements
include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents,
requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed
or to the conditions of approval, including the FDA requirement to implement a REMS to ensure that the benefits of a drug or biological product outweigh its risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The
FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in
accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding off-label use and if we, or our collaborators, do not market any of our product candidates for which we,
or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the
promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our
product candidates may be delayed, and our business will be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We sometimes estimate for planning purposes the timing of the accomplishment
of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies, clinical trials, the submission of regulatory
filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of
marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the
milestones to vary considerably from our estimates, including: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our available capital resources or capital constraints we experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to
identify and enroll patients who meet clinical trial eligibility criteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our receipt of approvals by the FDA and other regulatory agencies and the timing thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other actions, decisions or rules issued by regulators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to access sufficient, reliable and affordable supplies of compounds used in the manufacture of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efforts of our collaborators with respect to the commercialization of our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our
business and results of operations may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials and perform data collection and analysis,
which may result in costs and delays that prevent us from successfully commercializing product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely, and will rely in the future,
on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical
trials conducted in reliance on third parties may be delayed, suspended, or terminated if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the third parties do not successfully carry out their contractual duties or fail to meet regulatory obligations or expected deadlines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we replace a third party; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the quality or accuracy of the data obtained by third parties is compromised due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the
commercialization of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements
without incurring delays or additional costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, for Zertane, we are currently using, and relying on, single suppliers and single manufacturers
for drug supply for our planned Phase 3 clinical trials and our commercial products. Although there are potential alternative suppliers and manufacturers for Zertane if need be, we have not qualified these vendors to date. If we were required to
change vendors, it could result in a failure to meet regulatory requirements or projected timelines and necessary quality standards for successful manufacturing of the various required lots of material for our development and commercialization
efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if collaborators with which we contract in the future successfully complete clinical trials of our product candidates, those
candidates may not be commercialized successfully for other reasons. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we contract with collaborators that successfully complete clinical
trials for one or more of our product candidates, those candidates may not be commercialized for other reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to receive regulatory clearances required to market them as drugs; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being subject to proprietary rights held by others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being difficult or expensive to manufacture on a commercial scale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">having adverse side effects that make their use less desirable; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failing to compete effectively with products or treatments commercialized by competitors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Relying on
third-party manufacturers may result in delays in our clinical trials and product introductions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing and commercializing new medicines
entails significant risks and expenses. Our clinical trials may be delayed if third-party manufacturers are unable to assure a sufficient quantity of the drug product to meet our study needs. If our clinical trials are delayed, our commercialization
efforts may be impeded, or our costs may increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once regulatory approval is obtained, a marketed product and its manufacturer are subject to continual
review. The discovery of previously unknown problems with a product or manufacturer may result in restrictions on the product, manufacturer or manufacturing facility, including withdrawal of the product from the market. Any manufacturers with which
we contract are required to operate in accordance with FDA-mandated current good manufacturing practices, or cGMPs. A failure of any of our contract manufacturers to establish and follow cGMPs and to document their adherence to such practices may
lead to significant delays in the launch of products based on our product candidates into the market. Failure by third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines,
injunctions, civil penalties, revocation or suspension of marketing approval for any products granted pre-market approvals, seizures or recalls of products, operating restrictions, and criminal prosecutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to enter into agreements with third parties to sell and market any products we develop and for which we obtain regulatory approvals, which may
affect the sales of our products and our ability to generate revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently maintain an organization for the sale, marketing and
distribution of pharmaceutical products and may contract with, or license, third parties to market any products we develop that receive regulatory approvals. Outsourcing sales and marketing in this manner may subject us to a variety of risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to exercise control over sales and marketing activities and personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or inability of contracted sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes with third parties concerning sales and marketing expenses, calculation of royalties, and sales and marketing strategies; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with sales and marketing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to partner with a third
party that has adequate sales, marketing, and distribution capabilities, we may have difficulty commercializing our product candidates, which would adversely affect our business, financial condition, and ability to generate product revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition from companies with considerably more resources and experience than we have, which may result in others discovering,
developing, receiving approval for, or commercializing products before or more successfully than us. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our potential competitors have
substantially greater financial, technical, personnel and marketing resources than we do. In addition, many of these competitors have significantly greater resources devoted to product development and pre-clinical research. Our ability to compete
successfully will depend largely on our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discover and develop product candidates that are superior to other products in the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain qualified personnel; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain patent and/or other proprietary protection for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain required regulatory approvals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain collaboration arrangements to commercialize our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Established pharmaceutical
companies devote significant financial resources to discovering, developing or licensing novel compounds that could make our product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines
before us. Other companies are engaged in the discovery of compounds that may compete with the product candidates we are developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any new product that
competes with a currently-approved treatment or medicine must demonstrate compelling advantages in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful. If we are not able to compete
effectively against our current and future competitors, our business will not grow and our financial condition and operations will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if
any of our product candidates are commercialized, they may not be accepted by physicians, patients, or the medical community in general. Even if we, or our collaborators, are able to commercialize our product candidates, the products may become
subject to market conditions that could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the medical community accepts a product as safe and efficacious for its
indicated use, physicians may choose to restrict the use of the product if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to any existing
medicines or treatments. We cannot predict the degree of market acceptance of any product candidate that receives marketing approval, which will depend on a number of factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demonstration of the clinical efficacy and safety of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approved labeling for the product and any required warnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the advantages and disadvantages of the product compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our and any collaborator&#146;s ability to educate the medical community about the safety and effectiveness of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reimbursement policies of government and third-party payors pertaining to the product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the market price of our product relative to competing treatments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of Zertane, tramadol
hydrochloride is a well-established centrally acting synthetic analgesic that has been used for more than 30 years as a treatment for moderate to severe pain. As an opioid, tramadol hydrochloride has been associated with certain adverse effects
including dizziness, nausea, constipation, vertigo, headache, vomiting and drowsiness. As a result, physicians may be reluctant to prescribe Zertane to treat premature ejaculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Generic tramadol hydrochloride is available in the United States and abroad for treatment of pain. Although the generic drug is not available in the
same dosage as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off label&#148; for the treatment of PE instead of Zertane, which would adversely affect our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zertane is a specifically formulated tramadol hydrochloride, generic tramadol hydrochloride is commercially available in the United States and abroad
for treatment of pain. Although the generic drug is not available in the same dosage as Zertane for treatment of PE, it is possible that physicians could prescribe the generic version of the drug &#147;off label&#148; for the treatment of PE instead
of Zertane, which would adversely affect our business. Patients could use generic tramadol hydrochloride dosages that are either higher or lower than what will be approved for Zertane or they could attempt to split dosages to arrive at the dosages
approved for Zertane. While any such &#147;off label&#148; use of generic tramadol hydrochloride for treatment of PE may constitute infringement of our patent portfolio, liability in that circumstance would be at the level of the physician or the
patient making enforcement difficult or impractical. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment
initiatives, may negatively impact our ability to generate revenues if we obtain regulatory approval to market a product. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The continuing efforts
of the government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care may adversely affect one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our or our collaborators&#146; ability to set a price we believes is fair for our products, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to generate revenues and achieve profitability; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of capital. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2010 enactments of the Patient Protection and Affordable Care Act, or PPACA,
and the Health Care and Education Reconciliation Act are expected to significantly impact the provision of, and payment for, health care in the United States. Various provisions of these laws take effect over the next several years, and are designed
to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide
additional support for medical research. Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and
reduce demand and prices for our products, if approved. This could harm our or our collaborators&#146; ability to market any products and generate revenues. Although we do not expect to receive significant revenues from reimbursement of our products
by commercial third-party payors and government payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any
of our product candidates approved in the future, and could cause an increase in our compliance, manufacturing, or other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs is subject to government control
and reimbursement may in some cases be unavailable. We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which may make it difficult for us to sell our potential products that
may be approved in the future at a price acceptable to us or any of our future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in some foreign countries, the proposed
pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of
medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a
system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In the case of Zertane, a member state may require that physicians prescribe the generic drug tramadol hydrochloride instead of
our branded drug Zertane, if our product candidate is approved for marketing. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing
arrangements for any of our products. Historically, pharmaceutical products launched in the European Union do not follow price structures of the United States and generally tend to have significantly lower prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an
approved label, or result in significant negative consequences following marketing approval, if any. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date six clinical trials of Zertane have
been conducted outside of the United States to evaluate the safety and efficacy of the product candidate for the treatment of PE. Adverse events observed in these clinical trials have primarily involved gastrointestinal disorders, such as nausea,
and central nervous system disorders, such as vertigo, dizziness, drowsiness and headaches. These events have not been reported to be severe and were observed to be reversible after stopping or delaying treatment. Formulation development, stability
studies and analytical work has been completed for Zertane-ED, but no clinical trials for the product candidate have been conducted to date. We expect that undesirable side effects of Zertane-ED will include those observed for Zertane as well as
those commonly observed for PDE-5 inhibitors, such as headaches, dizziness, flushing, dyspepsia and nasal congestion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt,
delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Further, if Zertane receives marketing approval and we or others identify
undesirable side effects caused by the product (or any other similar product) after the approval, or if drug abuse is determined to be a significant problem with an approved product, a number of potentially significant negative consequences could
result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw or limit their approval of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may decide to remove the products from the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market
acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates and significantly impact our ability to successfully commercialize our product candidates and generate revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other
risks and uncertainties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future profitability will depend, in part, on our ability to commercialize Zertane in foreign markets for which we
intend to rely on collaboration with third parties. If we commercialize Zertane in foreign markets, we would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to directly control commercial activities because we are relying on third parties </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">import or export licensing requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer accounts receivable collection times; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer lead times for shipping; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">language barriers for technical training; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency exchange rate fluctuations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our customers&#146; ability to obtain reimbursement for Zertane in foreign markets; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign sales of Zertane could also be adversely affected by the imposition of governmental controls, political
and economic instability, trade restrictions and changes in tariffs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may use hazardous chemicals and biological materials in our business. Any
claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development
processes may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for
any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use,
manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and
regulations may be expensive and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures
for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future
laws and regulations are interpreted and enforced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product development programs for candidates other than Zertane may require substantial
financial resources and may ultimately be unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and
commercialize products to treat PE and/or ED. In addition to the development of Zertane, we may pursue development of our other development programs, including Zertane-ED. None of our other potential product candidates has commenced any clinical
trials, and there are a number of FDA requirements that we must satisfy before we can commence clinical trials. Satisfaction of these requirements will entail substantial time, effort and financial resources. We may never satisfy these requirements.
Any time, effort and financial resources we expend on our other development programs may adversely affect our ability to continue development and commercialization of Zertane, and we may never commence clinical trials of such development programs
despite expending significant resources in pursuit of their development. If we do commence clinical trials of our other potential product candidates, such product candidates may never be approved by the FDA. If any of these events occur, we may be
forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may fail to receive favorable clinical results related to the RedoxSYS System, and even if we were to receive favorable clinical results, we may
still fail to receive the necessary clearances or approvals to market the RedoxSYS System. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are investing in the research and development of
the RedoxSYS System. To commercialize, we are required to undertake time-consuming and costly development activities, including clinical trials for which the outcome is uncertain. Full clinical trials have not been completed for the RedoxSYS System
as it is currently configured. Product candidates that appear promising during early development and preclinical studies may, nonetheless, fail to demonstrate the results needed to support regulatory approval or commercial viability. As such,
clinical trials involve inherent risks including the possibility of demonstrating lack of effectiveness, safety concerns, or inability to demonstrate a clinical benefit with available company and partner resources. Even if we were to receive
favorable clinical results, we may still fail to obtain the necessary FDA clearance and approvals. Any such failure, or any material delay in obtaining the necessary clearance or approvals, could materially adversely affect our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory clearance or approval process is expensive, time consuming and uncertain, and the failure to
obtain and maintain required clearances or approvals could prevent us from commercializing the RedoxSYS System. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RedoxSYS System is subject to 510(k) clearance or pre-market approval by the FDA prior to its marketing for
commercial use in the United States, and to any approvals required by foreign governmental entities prior to its marketing outside the United States. In addition, any changes or modifications to a device that has received regulatory clearance or
approval that could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, may require the submission of a new application for 510(k) clearance, pre-market approval, or foreign regulatory approvals.
The 510(k) clearance and pre-market approval processes, as well as the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve months from submission to obtain 510(k) clearance,
and from one to three years from submission to obtain pre-market approval; however, it may take longer, and 510(k) clearance or pre-market approval may never be obtained. We have limited experience in filing FDA applications for 510(k) clearance and
pre-market approval. In addition, we are required to continue to comply with applicable FDA and other regulatory requirements even after obtaining clearance or approval. There can be no assurance that we will obtain or maintain any required
clearance or approval on a timely basis, or at all. Any failure to obtain or any material delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial results will depend on the acceptance among hospitals, third-party payors and the medical community of the
RedoxSYS System. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success depends on the acceptance by our target customers, third-party payors and the medical community that the
RedoxSYS System is a reliable, accurate and cost-effective solution. Our business success depends on our ability to convince our target customers to replace their current testing method with the RedoxSYS System. Many factors may affect the market
acceptance and commercial success of the RedoxSYS System, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability convince our potential customers of the advantages and economic value of the RedoxSYS System over existing technologies and products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative convenience and ease of testing of the RedoxSYS System over existing technologies and products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the introduction of new technologies and competing products that may make the RedoxSYS System a less attractive solution for our target customers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in training medical personnel on the proper use of the RedoxSYS System; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of third-party payors to reimburse our target customers that adopt the </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">RedoxSYS System; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the acceptance in the medical community of the RedoxSYS System; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent and success of our marketing and sales efforts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third-party payors do not reimburse our customers for the use of the
RedoxSYS System or if reimbursement levels are set too low for us to sell the RedoxSYS System at a profit, our ability to sell the RedoxSYS System and our results of operations will be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a diagnostic product candidate is approved and reaches the market, the product may not achieve physician, hospital, or laboratory acceptance, or it
may not obtain adequate reimbursement from third party payors. We expect to sell the RedoxSYS System to target customers substantially all of whom receive reimbursement for the health care services they provide to their patients from third-party
payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each
third-party payor&#146;s determination that use of a product is: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate and medically necessary for the specific indication; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors may deny reimbursement for covered products if
they determine that a medical product was not used in accordance with cost-effective diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse for procedures
and devices deemed to be experimental. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining coverage and reimbursement approval for a product from each government or third- party payor is a time
consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party payor. We may not be able to provide data sufficient to
gain acceptance with respect to coverage and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that allows our potential customers to make a
profit or even cover their costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of
reimbursement for medical products and services. Increasingly, Medicare, Medicaid and other third-party payors are challenging the prices charged for medical services, including clinical diagnostic tests. Levels of reimbursement may decrease in the
future, and future legislation, regulation or reimbursement policies of third-party payors may adversely affect the demand for and reimbursement available for the RedoxSYS System, which in turn, could negatively impact pricing. If our customers are
not adequately reimbursed for the RedoxSYS System, they may reduce or discontinue purchases of the RedoxSYS System, which would result in a significant shortfall in achieving revenue expectations for the RedoxSYS System. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing risks and inefficiencies may adversely affect our ability to produce the RedoxSYS System. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to engage third parties to manufacture components of the RedoxSYS System in sufficient quantities and on a timely basis, while maintaining product
quality, acceptable manufacturing costs and complying with regulatory requirements, such as quality system regulations. In determining the required quantities of the RedoxSYS System and the manufacturing schedule, we must make significant judgments
and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing the RedoxSYS System, there could be significant differences between our
estimates and the actual amounts of product we require. If we do not secure collaborations with manufacturing and development partners to enable to production scale of the RedoxSYS System, we may not be successful in commercializing the RedoxSYS
System in the event we receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we
manufactured these components ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reliance on third parties for regulatory compliance and quality assurance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible breaches of manufacturing agreements by the third parties because of factors beyond our control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible regulatory violations or manufacturing problems experienced by our suppliers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible termination or non-renewal of agreements by third parties, based on their own business priorities, at times that are costly or inconvenient for us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to meet the demand for the RedoxSYS System if one or more of these third-party manufacturers is not able to supply us with the necessary
components that meet our specifications. It may be difficult to find alternate suppliers in a timely manner and on terms acceptable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party manufacturers we engage and our potential customers are subject to various governmental
regulations, and we may incur significant expenses to comply with, and experience delays in our product commercialization as a result of these regulations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing processes and facilities of third-party manufacturers we engage are required to comply with the federal Quality System Regulation, or QSR,
which covers procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of
manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown
problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administrative or judicially imposed sanctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall or seizure of the product in question; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production or distribution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s refusal to grant pending future clearance or pre-market approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal or suspension of marketing clearances or approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical holds; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to permit the export of the product in question; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">criminal prosecution. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these actions, in combination or alone, could prevent us from marketing,
distributing or selling the RedoxSYS System and would likely harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a product defect or regulatory violation could lead to a
government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have similar
authority to recall devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims,
and harm our reputation with customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in sales and marketing and may be unable to successfully commercialize the
RedoxSYS System </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited marketing, sales and distribution experience and capabilities. Our ability to achieve profitability depends on
attracting customers for the RedoxSYS System and building brand loyalty. To successfully perform sales, marketing, distribution and customer support functions, we will face a number of risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain skilled support team, marketing staff and sales force necessary to commercialize and gain market acceptance for the RedoxSYS System; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our sales and marketing team to identify and penetrate the potential customer base; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the difficulty of establishing brand recognition and loyalty for the RedoxSYS System. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may seek to enlist one or more third parties to assist with sales, distribution and customer
support globally or in certain regions of the world. If we do seek to enter into these arrangements, we may not be successful in attracting desirable sales and distribution partners, or we may not be able to enter into these arrangements on
favorable terms, or at all. If our sales and marketing efforts, or those of any third-party sales and distribution partners, are not successful, the RedoxSYS System may not gain market acceptance, which would materially impact our business and
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will be subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral,
false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our anticipated relationship with
healthcare providers and institutions are subject to various federal and state laws intended to prevent health care fraud and abuse. The federal anti-kickback statute prohibits the knowing offer, receipt or payment of remuneration in exchange for or
to induce the referral of patients or the use of products or services that would be paid for in whole or in part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value,
including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply their state health care programs as well as private payors. Violations of the anti-kickback laws can result in exclusion from
federal health care programs and substantial civil and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal False Claims Act, or FCA, imposes liability on persons who, among
other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services
not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful
claims. If our marketing or other arrangements were determine to violate anti-kickback or related laws, including the FCA, then our anticipated revenues could be adversely affected, which would likely have a material adverse effect on our business,
financial conditions and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the RedoxSYS System does not perform as expected or the reliability of the technology on which
the RedoxSYS System is based is questioned, our operating results and business will suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends on the market&#146;s confidence
that we can provide reliable, high-quality diagnostics product. We believe that customers in our target markets are likely to be particularly sensitive to product defects and errors. As a result, our reputation and the public image of our product or
technologies will be impaired if the RedoxSYS System fails to perform as expected. Although the RedoxSYS System is designed to be user-friendly, the functions it performs are quite complex, and the RedoxSYS System may develop or contain undetected
defects or errors. If we experience a sustained material defect or error, this could result in loss or delay of anticipated revenues, delayed market acceptance, damaged reputation, diversion of development and management resources, legal claims,
increased insurance costs or increased service and warranty costs, any of which could materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development, manufacture and sale
of diagnostic products involve inherent risks of adverse side effects or reactions that can cause bodily injury or even death. Any product we succeed in commercializing could adversely affect consumers even after obtaining regulatory approval and,
if so, we could be required to withdraw from the market or be subject to administrative or other proceedings. As we are not now manufacturing, marketing or distributing diagnostics, we have elected not to obtain product liability insurance at the
current time. We expect to obtain clinical trial liability coverage for any human clinical trials, and appropriate product liability insurance coverage for any product that receives regulatory approval and is licensed to collaborators, if any. The
amount, nature and pricing of such insurance coverage will likely vary due to a number of factors. We may not be able to obtain sufficient insurance coverage to address our exposure to product recall or liability actions, or the cost of that
coverage may be such that we will be limited in the types or amount of coverage we can obtain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face intense competition from established and new companies in the in-vitro diagnostics field.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compete with companies that design, manufacture and market already-existing and new in-vitro diagnostics systems and tests. We anticipate that
we will face increased competition in the future as new companies enter the market with new technologies and our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our
technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater
resources to invest in new technologies, more substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are not
able to compete successfully, we may not generate sufficient revenue to become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unsuccessful in our long-term goal of
expanding sales of the RedoxSYS System outside the United States. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming we receive the applicable regulatory approvals, we intend to market
the RedoxSYS System outside the United States through third-party distributors. These distributors may not commit the necessary resources to market and sell the RedoxSYS System to the level of our expectations. If distributors do not perform
adequately or in compliance with applicable laws and regulations in particular geographic areas, or we are unable to locate distributors in particular geographic areas, our ability to realize long-term international revenue potential would be
materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market the RedoxSYS System in the European Union and many other foreign jurisdictions, we, or our distributors
or partners, must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical studies and commercial sales and
distribution of the RedoxSYS System. The approval procedure varies among countries and can involve additional testing. The regulatory approval process outside the United States may include all of the risks associated with obtaining FDA approval, as
well as additional risks. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from
regulatory authorities outside the United States on a timely basis, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete may decline if we do not adequately protect our proprietary rights. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends on obtaining and maintaining proprietary rights to our product candidates and compounds for the treatment of sexual
dysfunctions and devices and methods for measurement of ORP, as well as successfully defending these rights against third-party challenges. We will only be able to protect our product candidates, compounds, devices, and their uses from unauthorized
use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent protection for our product candidates, compounds, and devices is uncertain due to a number of
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have been the first to make the inventions covered by pending patent applications or issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have been the first to file patent applications for our product candidates, the compositions, or the devices we developed or for their uses; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may independently develop identical, similar or alternative products, compositions or devices and uses thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any or all of our pending patent applications may not result in issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not seek or obtain patent protection in countries that may eventually provide us a significant business opportunity; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents issued to us may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our compositions, devices and methods may not be patentable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may design around our patent claims to produce competitive products which fall outside of the scope of our patents; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may identify prior art or other bases which could invalidate our patents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we have or obtain
patents covering our product candidates, compositions, or devices, we may still be barred from making, using and selling our product candidates, devices, or technologies because of the patent rights of others. Others may have filed, and in the
future may file, patent applications covering compositions, devices, or products that are similar or identical to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices, and some
of these relate to products we intend to commercialize. Numerous U.S. and foreign issued patents and pending patent applications owned by others exist in the sexual dysfunction treatment field and in the diagnostic field in which we are developing
products. These could materially affect our ability to develop our product candidates or sell our products if approved. Because patent applications can take many years to issue, there may be currently pending applications unknown to us that may
later result in issued patents that our product candidates, compositions, or devices may infringe. These patent applications may have priority over patent applications filed by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees,
annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent
application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process
can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse
purposefully or inadvertently, our competitive position could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal actions to enforce our patent rights can be expensive and may involve the
diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or
other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property
rights successfully, our competitive position could suffer, which could harm our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical and medical device patents
and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical and medical device companies can be highly uncertain and involve complex legal and factual questions. The
interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions
and the related patent claims. The standards of the United States Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty.
Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to reexamination proceedings, post-grant review and/or inter
partes review in the USPTO. Foreign patents may be subject also to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or
reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, reexamination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights under any
issued patents may not provide us with sufficient protection against competitive products or processes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, changes in or different interpretations of patent laws in the United States and foreign countries
may permit others to use our discoveries or to develop and commercialize our technology and products without providing any compensation to us, or may limit the number of patents or claims we can obtain. The laws of some countries do not protect
intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to obtain and maintain patent protection and trade secret protection of our product candidates, we could lose our competitive advantage and
competition we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developments in patent law could have a negative impact on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the United States Supreme Court, or the Supreme Court, other federal courts, the United States Congress or the USPTO may change the
standards of patentability and any such changes could have a negative impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Leahy-Smith America Invents Act, or the
America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a &#147;first-to-invent&#148; system to a &#147;first-to-file&#148; system, changes to the
way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application
filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and,
in particular, the first-to-file provisions, became effective on March&nbsp;16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them.
Accordingly, it is not clear what, if any, impact the America Invents Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend any
patents that may issue from our patent applications, all of which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect
the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patent protection, because we
operate in the highly technical field of drug discovery, development of therapies and medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to
protect. We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that
the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#146;s relationship with us. These agreements also generally
provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security
measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent
an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Trade secrets may be
independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was
independently developed by a competitor, our competitive position could be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to enforce our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have
encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other
intellectual property protection, especially those relating to pharmaceuticals. This could make it difficult for us to stop the infringement of some of our patents, if obtained, or the misappropriation of our other intellectual property rights. For
example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or
government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly,
we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may
be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert ownership or commercial rights to inventions we develop. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have written agreements with
collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with collaborators with respect to joint inventions or inventions made
by our collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration. If we
cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&#146;s materials where required, or if disputes otherwise arise with respect to the intellectual
property developed with the use of a collaborator&#146;s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees,
contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property
we have developed or will develop and interfere with our ability to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain
intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at universities or other biopharmaceutical or medical device companies, including our
competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against
these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A dispute concerning the infringement or misappropriation of our
proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant litigation in the pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not
currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims that our product candidates, devices, technologies or activities infringe the intellectual property rights of others. If our development activities are found to infringe any such patents,
we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs, compositions or devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade
secrets, or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in one or more areas similar to the activities
conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of
our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a
material adverse impact on our cash position and stock price. Any legal action against us or our collaborators could lead to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&#146;s patent rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">us or our collaborators having to enter into license arrangements that may not be available on commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and
business and financial condition. As a result, we could be prevented from commercializing current or future product candidates. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Our Organization, Structure and Operation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ampio controls us, including having the ability to control the election of our directors,
and its interests may conflict with or differ from your interests as stockholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ampio owns 81.5% of our outstanding common stock as of the
closing of the Merger. If Ampio were to choose so, as a result of its stock ownership, Ampio may be able to influence our management and affairs and control all matters submitted to our stockholders for approval, including the election of directors
and approval of any merger, consolidation, or sale of all or substantially all of our assets. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might affect the market price of our
common stock. This control may delay, deter or prevent acts that would be favored by our other stockholders, as the interests of Ampio may not always coincide with our interests or the interests of our other stockholders. For example, Ampio may seek
to cause us to take courses of action that, in its judgment, could enhance its investment in us, but which might involve risks to our other stockholders or adversely affect us or our other stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to achieve some or all of the benefits that we expect to achieve from our separation from Ampio. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a stand-alone, independent public company, we believe that our business will benefit from, among other things, allowing our management to design and
implement corporate policies and strategies that are based primarily on the characteristics of our business, allowing us to focus our financial resources wholly on our own operations and implement and maintain a capital structure designed to meet
our own specific needs. However, as a result of our separation from Ampio there is a risk that we may be more susceptible to market fluctuations and other adverse events than we would have been were we still a part of Ampio. We may not be able to
achieve some or all of the benefits that we expect to achieve as a stand-alone healthcare company or such benefits may be delayed or may not occur at all. For example, there can be no assurance that analysts and investors will place a greater value
on our company as a stand-alone healthcare company than on our business as a part of Ampio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our historical financial information as a business conducted by Ampio may not be representative of our
results as an independent public company. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical financial information included herein does not necessarily reflect what our financial
position, operating results or cash flows would have been had we been an independent entity during the historical periods presented. The historical costs and expenses reflected in our financial statements include amounts for certain corporate
functions historically provided by Ampio, including costs of finance and other administrative services, and income taxes. These expense allocations were developed on the basis of what we and Ampio considered to be reasonable prices for the
utilization of services provided or the benefits received by us. The historical financial information in our audited financial statements may not be indicative of what our results of operations, financial position, changes in equity and cash flows
would have been had we been a separate stand-alone entity during the periods presented or will be in the future. We have not made adjustments to reflect many significant changes that will occur in our cost structure, funding and operations as a
result of our separation from Ampio, including changes in our employee base, changes in our tax structure, potential increased costs associated with reduced economies of scale and increased costs associated with being a publicly traded, stand-alone
company, such as audit fees, directors and officers insurance costs and compliance costs, nor have we made offsetting adjustments to reflect the benefits of this offering, as these factors are presently difficult to quantify. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have received better terms from unaffiliated third parties than the terms we received in our agreements with Ampio. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements related to our separation from Ampio, including the assignment and assumption agreement, services agreement and the other agreements, were
negotiated in the context of our separation from Ampio while we were still part of Ampio and, accordingly, may not reflect terms that would have resulted from arm&#146;s-length negotiations among unaffiliated third parties. The terms of the
agreements we negotiated in the context of our separation related to, among other things, allocation of assets, liabilities, rights, indemnifications and other obligations among Ampio and us. We may have received better terms from third parties
because third parties may have competed with each other to win our business. Our sole director is also a member of the Ampio board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to
operate our business effectively may suffer if we or Ampio terminate our services agreement, or if we are unable to establish on a cost-effective basis our own administrative and other support functions in order to operate as a stand-alone company
after the expiration or termination of our services agreement with Ampio. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Merger, we have relied on administrative and other
resources of Ampio to operate our business. We have entered into a services agreement to retain the ability for specified periods to use certain Ampio resources. We may elect to continue this agreement for an indefinite period of time. Any decision
by us to terminate this agreement would be approved by disinterested members of our management and board of directors under our procedures regarding related party transactions. After the termination of this agreement, we will need to create our own
administrative and other support systems or contract with third parties to replace Ampio&#146;s services. These services may not be provided at the same level, and we may not be able to obtain the same benefits that we received prior to the
separation. These services may not be sufficient to meet our needs, and after our agreement with Ampio is terminated, we may not be able to replace these services at all or obtain these services at prices and on terms as favorable as we currently
have with Ampio. Any failure or significant downtime in our own administrative systems or in Ampio&#146;s administrative systems during the transitional period could result in unexpected costs, impact our results or prevent us from paying our
suppliers or employees and performing other administrative services on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may seek to hold us responsible for
liabilities of Ampio that we did not assume in our agreements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our separation from Ampio, Ampio has generally agreed to retain
all liabilities that did not historically arise from our business. Third parties may seek to hold us responsible for Ampio&#146;s retained liabilities. Under our agreements with Ampio, Ampio has agreed to indemnify us for claims and losses relating
to these retained liabilities. However, if those liabilities are significant and we are ultimately liable for them, we cannot assure you that we will be able to recover the full amount of our losses from Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any disputes that arise between us and Ampio with respect to our past and ongoing relationships could harm our business operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may arise between Ampio and us in a number of areas relating to our past and ongoing relationships, including: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with non-compete provisions applicable to Ampio and us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">labor, tax, employee benefit, indemnification and other matters arising from our separation from Ampio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distribution and supply obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee retention and recruiting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business combinations involving us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales or distributions by Ampio of all or any portion of its ownership interest in us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the nature, quality and pricing of transitional services Ampio has agreed to provide us; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business opportunities that may be attractive to both Ampio and us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to resolve any
potential conflicts, and even if we do, the resolution may be less favorable than if we were dealing with an unaffiliated party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreements we have
entered into with Ampio may be amended upon agreement between the parties. While we are controlled by Ampio, Ampio may be able to require us to agree to amendments to these agreements that may be less favorable to us than the original terms of the
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of our directors and executive officers may have conflicts of interest because of their ownership of Ampio common stock, options
to acquire Ampio common stock and positions with Ampio. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our director and executive officers own Ampio common stock and options to
purchase Ampio common stock. In addition, our sole director is also a director of Ampio. Ownership of Ampio common stock and options to purchase Ampio common stock by our director and officers and the presence of a director of Ampio on our board of
directors could create, or appear to create, conflicts of interest with respect to matters involving both us and Ampio. For example, corporate opportunities may arise that are applicable or complementary to both of our businesses and that each
business would be free to pursue, such as the potential acquisition of a particular business or technology. However, we do not believe that Ampio intends to acquire businesses that are focused on urological disorders. We have not established at this
time any procedural mechanisms to address actual or perceived conflicts of interest of these directors and officers and expect that our board of directors, in the exercise of its fiduciary duties, will determine how to address any actual or
perceived conflicts of interest on a case-by-case basis. If any corporate opportunity arises and if our directors and officers do not pursue it on our behalf, we may not become aware of, and may potentially lose, a significant business opportunity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt
our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of April&nbsp;16, 2015, we have seven full-time employee, and in connection with becoming a public company, we
expect to increase our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these
development activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to
operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other
projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue
could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to
effectively manage the future development and expansion of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on key personnel and attracting qualified management personnel and our business could be harmed
if we lose personnel and cannot attract new personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends to a significant degree upon the technical and management skills of
our officers and key personnel, including in particular those of Josh Disbrow, our Chief Executive Officer, and Jarrett Disbrow, our Chief Operating Officer. The loss of the services of any of these individuals would likely have a material adverse
effect on us. Our success also will depend upon our ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our officers or key
personnel. The loss of any of our key executives, or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compete for such personnel against numerous companies, including larger, more established companies with significantly greater financial resources than we
possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure to do so could have a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in
insider trading, which could significantly harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct. Misconduct by
employees could include intentional failures to comply with the regulations of the FDA and applicable non-U.S. regulators, provide accurate information to the FDA and applicable non-U.S. regulators, comply with healthcare fraud and abuse laws and
regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and
serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or
unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product
candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical
products. Side effects of, or manufacturing defects in, products that we develop which are commercialized by any collaborators could result in the deterioration of a patient&#146;s condition, injury or even death. Once a product is approved for sale
and commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups seeking to represent a class. These lawsuits may divert our management from
pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could
materially harm our business, financial condition and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we expect to maintain general liability and product liability insurance, this
insurance may not fully cover potential liabilities. In addition, inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or administrative liability claims
could prevent or inhibit the commercial production and sale of any of our product candidates that receive regulatory approval, which could adversely affect our business. Product liability claims could also harm our reputation, which may adversely
affect our collaborators&#146; ability to commercialize our products successfully. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In order to satisfy our obligations as a public company, we will need to hire qualified accounting and
financial personnel with appropriate public company experience. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we will need to establish and maintain effective disclosure
and financial controls and make changes in our corporate governance practices. We will need to hire additional accounting and financial personnel with appropriate public company experience and technical accounting knowledge, and it may be difficult
to recruit and maintain such personnel. Even if we are able to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment and the indirect consequences related to the diversion
of management resources from product development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our third-party contractors or consultants,
may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation
of security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. While we do not believe that we have not experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a loss of clinical trial data
for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our
data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product
candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits
of such acquisitions. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with
our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected
benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Merger and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is not now, and there may never be, an active, liquid and orderly trading market for our common stock, which may make it difficult for you to sell
your shares of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is not now, nor has there been since our inception, any substantial trading activity in our common stock
or a market for shares of our common stock, and an active trading market for our shares may never develop or be sustained. As a result, investors in our common stock must bear the economic risk of holding those shares for an indefinite period of
time. Although our common stock is quoted on the OTCQB, an over-the-counter quotation system, trading of our common stock is extremely limited and sporadic and at very low volumes. We do not now, and may not in the future, meet the initial listing
standards of any national securities exchange, and we presently anticipate that our common stock will continue to be quoted on the OTCQB or another over-the-counter quotation system in the foreseeable future. In those venues, our stockholders may
find it difficult to obtain accurate quotations as to the market value of their shares of our common stock, and may find few buyers to purchase their stock and few market makers to support its price. As a result of these and other factors, you may
be unable to resell your shares of our common stock at or above the price for which you purchased them, or at all. Further, an inactive market may also impair our ability to raise capital by selling additional equity in the future, and may impair
our ability to enter into strategic partnerships or acquire companies or products by using shares of our common stock as consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our share price is volatile and may be influenced by numerous factors, some of which are beyond our
control. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our common stock is likely to be highly volatile, and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this report, these factors include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the product candidates we seek to pursue, and our ability to obtain rights to develop, commercialize and market those product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated adverse results or delays in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to commercialize our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated serious safety concerns related to the use of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to patents and other proprietary rights and our ability to obtain patent protection for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our dependence on third parties, including CROs as well as our potential partners that produce companion diagnostic products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in quarterly operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed the estimates and projections of the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar
companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions or trends in the biotechnology and biopharmaceutical industries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of new products offered by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain an adequate rate of growth and manage such growth; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuances of debt or equity securities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us or our stockholders in the future, or the perception that such sales could occur; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general political and economic conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effects of natural or man-made catastrophic events; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other events or factors, many of which are beyond our control. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and
the stocks of small-cap biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry
factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#147;Risk
Factors,&#148; could have a dramatic and material adverse impact on the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FINRA sales practice requirements may
limit a stockholder&#146;s ability to buy and sell our stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Financial Industry Regulatory Authority (FINRA) has adopted rules requiring
that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain information about the customer&#146;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief
that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to
recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any
trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any trading market for our common stock that may develop will depend in part on the research and reports that
securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no securities or industry analysts commence coverage of our company, the
trading price for our stock would be negatively affected. If securities or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price
would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have material liabilities that are not discovered until after the closing of the Merger. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Merger, the former business plan and management of Rosewind have been abandoned and replaced with the business and management team of Vyrix
and Luoxis. Prior to the Merger, there were no relationships or other connections among the businesses or individuals associated with Rosewind and Vyrix and Luoxis. As a result, Rosewind may have material liabilities that are not discovered until
after the Merger is completed. The Combined Company could experience losses as a result of any such undisclosed liabilities that are discovered following the Merger, which could materially harm our business and financial condition. Although the
Merger Agreement contains customary representations and warranties from Rosewind concerning its assets, liabilities, financial condition and affairs, there may be limited or no recourse against Rosewind&#146;s pre-merger stockholders or principals
in the event those representations prove to be untrue. As a result, the stockholders of the Combined Company following the closing of the Merger will bear some, or all, of the risks relating to any such unknown or undisclosed liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be exposed to additional risks as a result of &#147;going public&#148; by means of a merger
transaction. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be exposed to additional risks because the business of Vyrix and Luoxis has become a public company through a &#147;reverse
merger&#148; transaction. There has been increased focus by government agencies on transactions such as the Merger in recent years, and we may be subject to increased scrutiny by the SEC and other government agencies and holders of our securities as
a result of the completion of that transaction. Additionally, our &#147;going public&#148; by means of a reverse merger transaction may make it more difficult for us to obtain coverage from securities analysts of major brokerage firms following the
Merger because there may be little incentive to those brokerage firms to recommend the purchase of our common stock. The occurrence of any such event could cause our business or stock price to suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we became public by means of a &#147;reverse merger,&#148; it may be more difficult to list on a national exchange such as the NASDAQ, NYSE or
NYSE Amex. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It may be more difficult to list on a major exchange because we have conducted a reverse merger. In 2011, the Securities and Exchange
Commission approved new rules of the three major U.S. listing markets that toughen the standards that companies going public through a reverse merger must meet to become listed on those exchanges. Under the new rules, NASDAQ, NYSE and NYSE Amex will
impose more stringent listing requirements for companies that become public through a reverse merger. Specifically, the new rules prohibit a reverse merger company from applying to list on either the NASDAQ, NYSE or NYSE Amex until: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the company has completed a one-year &#147;seasoning period&#148; by trading in the U.S. over the counter market or on another regulated U.S. or foreign exchange following the reverse merger, and filed all required
reports with the Commission, including audited financial statements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the company maintains the requisite minimum share price for a sustained period, and for at least 30 of the 60 trading days, immediately prior to its listing application and the exchange&#146;s decision to list.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible for a reverse merger company to be exempt from these special requirements, but only if a listing is in connection with a
substantial, firm commitment underwritten public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and
will be able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A certain large stockholder owns a significant percentage
of our outstanding capital stock. As of the date of this report, the large stockholder owns approximately 81.5% of our outstanding voting stock. Accordingly, our large stockholder has significant influence over our affairs due to its substantial
ownership and has substantial voting power to approve matters requiring the approval of our stockholders. For example, these stockholders will be able to control elections of directors, amendments of our organizational documents, or approval of any
merger, sale of assets, or other major corporate transactions. This concentration of ownership in our large stockholder may prevent or discourage unsolicited acquisition proposals or offers for our common stock that some of our stockholders may
believe is in their best interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we issue additional shares of our capital stock in the future, our existing stockholders will be diluted.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Articles of Incorporation authorize the issuance of up to 300,000,000 shares of our common stock and up to 5,000,000 shares of preferred
stock with the rights, preferences and privileges that our Board of Directors may determine from time to time. Upon the closing of the Merger on April&nbsp;16, 2015, we issued an aggregate of 154,161,963 shares of our common stock, which equals
approximately 88.8% of our currently issued and outstanding capital stock. In addition to capital raising activities, which we expect to continue to pursue in order to raise the funding we will need in order to continue our operations, other
possible business and financial uses for our authorized capital stock include, without limitation, future stock splits, acquiring other companies, businesses or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products in exchange for shares of our capital stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances, attracting and retaining
employees by the issuance of additional securities under our equity compensation plans, or other transactions and corporate purposes that our Board of Directors deems are in the best interest of our company. Additionally, shares of our capital stock
could be used for anti-takeover purposes or to delay or prevent changes in control or our management. Any future issuances of shares of our capital stock may not be made on favorable terms or at all, they may not enhance stockholder value, they may
have rights, preferences and privileges that are superior to those of our common stock, and they may have an adverse effect on our business or the trading price of our common stock. The issuance of any additional shares of our common stock will
reduce the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common stock. Additionally, any such issuance will reduce the proportionate ownership and voting power of all of our current
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur,
could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock
in the public market after the legal restrictions on resale discussed in this report lapse or after those shares become registered for resale pursuant to an effective registration statement, the trading price of our common stock could decline. As of
the date of this report, a total of 173,597,365 shares of our common stock are outstanding. Of those shares, only approximately 1.4% are currently freely tradable, without restriction, in the public market. We have agreed to file, as soon as is
reasonably practicable, one registration statement to register for resale under the Securities Act as many shares of our common stock held by persons who are not affiliates of Ampio as we determine we can reasonably include with such registration
statement. Upon the effectiveness of any such registration statement, or any other registration we could elect to file with respect to any other outstanding shares of our common stock, those shares that become registered would be freely tradable
without restriction, except for shares held by our affiliates, and any sales of those shares or any perception in the market that such sales may occur could cause the trading price of our common stock to decline. Additional, 158,522,319 shares
subject to the lock-up agreement will become freely tradeable upon expiration of the lock-up agreements. See &#147;Market Price and Dividends on Our Common Stock and Related Shareholder Matters&#148; for further information regarding the lock-up
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, shares of common stock that are reserved for future issuance under our future equity incentive plans will become eligible for
sale in the public market to the extent permitted by the provisions of various vesting schedules, Rule 144 and Rule 701 under the Securities Act, and any future registration of such shares under the Securities Act. If these additional shares of
common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our future equity incentive plans or otherwise,
could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that significant
additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in
material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock. Further, any future sales of our common stock by us or resales of our common stock by our
existing stockholders could cause the market price of our common stock to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any
sales of such shares in the market, could have an adverse effect on the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some provisions of our charter documents and Colorado law may discourage an acquisition of us by others,
even if the acquisition may be beneficial to some of our stockholders. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions in our Articles of Incorporation and Bylaws as in effect upon
the closing of the Merger, as well as certain provisions of Colorado law, could make it more difficult for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include the authorization of 5,000,000
shares of &#147;blank check&#148; preferred stock, the rights, preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time to time and without stockholder approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any provision of our Articles of Incorporation or Bylaws or of Colorado law that is applicable to us that has the effect of delaying or deterring a
change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors
are willing to pay for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The elimination of personal liability against our directors and officers under Colorado law and the
existence of indemnification rights held by our directors, officers and employees may result in substantial expenses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Articles of
Incorporation and our Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Colorado law. Further, our
Articles of Incorporation and our Bylaws and individual indemnification agreements we intend to enter with each of our directors and executive officers provide that we are obligated to indemnify each of our directors or officers to the fullest
extent authorized by the Colorado law and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations could
expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our stockholders from
bringing a lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay cash dividends on our capital stock in the foreseeable future. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of
cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate laws, results of operations, anticipated cash requirements and other factors and will be at the discretion
of the our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our common stock is subject to the &#147;penny stock&#148; rules of the SEC and the trading market in the securities is limited, which makes
transactions in the stock cumbersome and may reduce the value of an investment in the stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted Rule 15g-9 which establishes the
definition of a &#147;penny stock,&#148; for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any
transaction involving a penny stock, unless exempt, the rules require: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that a broker or dealer approve a person&#146;s account for transactions in penny stocks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to approve a person&#146;s account for transactions in penny stocks, the broker or dealer must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain financial information and investment experience objectives of the person; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of
transactions in penny stocks. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule
prescribed by the SEC relating to the penny stock market, which, in highlight form sets forth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the basis on which the broker or dealer made the suitability determination; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that the broker or dealer received a signed, written agreement from the investor prior to the transaction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, brokers may be less willing to execute transactions in securities subject to the &#147;penny stock&#148; rules. This may make it more difficult for
investors to dispose of common stock and cause a decline in the market value of stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disclosure also has to be made about the risks of investing in
penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor
in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_6"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our
combined financial statements and the related notes and other financial information attached as exhibits to this report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information
with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading &#147;Special Note Regarding Forward-Looking Statements&#148; elsewhere in this report.
You should review the &#147;Risk Factors&#148; section of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in
the following discussion and analysis. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>All references to &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and &#147;the combined Vyrix and Luoxis
company&#148; in this discussion and analysis refer solely to Vyrix Pharmaceuticals, Inc., a Delaware corporation, or Vyrix, and Luoxis Diagnostics, Inc., a Delaware corporation, or Luoxis, Vyrix, on a combined basis. The Merger is accounted for as
a reverse merger and recapitalization, with the combined Vyrix and Luoxis company as the acquirer and Rosewind as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that will be
reflected in the historical financial statements prior to the Merger will be those of the combined Vyrix and Luoxis company and will be recorded at the historical cost basis of the combined Vyrix and Luoxis company, and the consolidated financial
statements after completion of the Merger will include the assets and liabilities of Rosewind and the combined Vyrix and Luoxis company, the historical operations of the combined Vyrix and Luoxis company and the operations of the combined enterprise
of Rosewind and the combined Vyrix and Luoxis company from and after the closing date of the Merger. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a specialty healthcare company concentrating on developing and commercializing products for redox-modulated conditions with an initial focus on
urological indications and related conditions. We are focused primarily on the urological disorders market and specifically sexual dysfunction and male infertility and expect to seek expansion opportunities in other urological indications such as
urological cancers. Our Luoxis division maintains a focus on the RedoxSYS oxidation-reduction potential system. Through the Luoxis division, we are focused on commercializing the RedoxSYS system into the global research market while developing
numerous clinical applications for this potential first-in-class diagnostic device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix was incorporated under the laws of the State of Delaware on
November&nbsp;18, 2013 and was wholly owned by Ampio, immediately prior to the completion of the Merger. Vyrix was previously a carve-out of the sexual dysfunction treatment business, including the late-stage men&#146;s health product candidates,
Zertane and Zertane-ED, from Ampio, which was announced in December 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis was incorporated under the laws of the State of Delaware on
January&nbsp;24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger. Luoxis is focused on developing and advancing the RedoxSYS system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have financed operations through a combination of private and public grants and contracts, debt and equity financings including the net proceeds
from the private placement of Luoxis stock. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating requirements for at least the
next 12 months. See &#147;&#151;Liquidity and Capital Resources.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not received any material revenues from the commercialization of our
product candidates and do not expect to receive significant revenues from the commercialization of our product candidates in the near term. We have incurred accumulated net losses since our inception, and as of December&nbsp;31, 2014, we had a
deficit accumulated of $10.1 million. Our net loss was $7.1 million for the year ended December&nbsp;31, 2014, $3.9 million for the year ended December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Significant Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis
and Vyrix are governed by a common board of directors and they are both majority owned by Ampio Pharmaceuticals, Inc., or Ampio. Therefore, the accompanying combined financial statements include the accounts of Luoxis and Vyrix, collectively
&#147;the combined Vyrix and Luoxis company&#148;. All significant intercompany transactions have been eliminated in this combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
combined Vyrix and Luoxis company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. The combined Vyrix and
Luoxis company&#146;s investment policy is to preserve principal and maintain liquidity. The combined Vyrix and Luoxis company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests.
Periodically, throughout the year, the combined Vyrix and Luoxis company has maintained balances in excess of federally insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Product&nbsp;&amp; Service Sales </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
recognize revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>License Agreements and Royalties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or
patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval in the territory, cumulative sales targets, and other projected milestones and are recognized at the time the milestone requirements are achieved. Royalties
will be recognized as revenue when earned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are recorded at their net realized value. We evaluate collectability of accounts receivable on a quarterly basis and record a valuation
allowance accordingly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. We periodically review the composition of our
inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the
impairment is first recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on
management&#146;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are taken into consideration, including the current status in the regulatory approval process, potential impediments to the
approval process such as safety or efficacy, anticipated research and development initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. For product candidates that
have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs related to purchases of the active
pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research and development expense. Currently, our ORP product is available for sale for research purposes and our Zertane product is not currently being
capitalized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fixed Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fixed assets are recorded at cost and after being placed in service, are depreciated using the straight-line method over estimated useful lives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In-Process Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In-process research and development, or IPRD, relates to the Zertane product and clinical trial data acquired in connection with the 2011 acquisition of
BioSciences Inc. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written
down if impaired. Once the Zertane product obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If we decided to abandon the Zertane product,
the IPRD would be expensed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents,
determined by an independent, third party appraisal to be $500,000, acquired in connection with the 2011 acquisition of BioSciences is being amortized over the remaining U.S. patent lives of approximately 11 years. The fair value of the Luoxis
patents was $380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent lives of approximately 15 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation
of combined financial statements in accordance with Generally Accepted Accounting Principles in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
disclosures of contingent assets and liabilities as of the date of the combined financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include
the fair value of valuation allowances, stock-based compensation, useful lives of fixed assets and assumptions in evaluating impairment of indefinite lived assets. Actual results could differ from these estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis and Vyrix are
included in the combined tax returns of Ampio. The combined Vyrix and Luoxis company&#146;s taxes are computed and reported on a &#147;separate return&#148; basis for these combined financial statements. Deferred taxes are provided on an asset and
liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences
are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the
deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of income taxes and related income tax positions taken would be subject to audits by federal and state tax authorities if we filed these taxes on a
separate basis. The combined Vyrix and Luoxis company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the
position, and the measurement of the benefit is calculated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as the largest amount that is more than 50% likely to be realized upon recognition of the benefit. The combined Vyrix and Luoxis company believes that it has no material uncertain tax positions.
The combined Vyrix and Luoxis company&#146;s policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-10, Accounting for Uncertainty in Income Taxes&#151;an interpretation
of FASB Statement No.&nbsp;109, or ASC 740-10, and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the
determination is made. The combined Vyrix and Luoxis company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the combined Vyrix and Luoxis company has concluded that no
significant tax position requires recognition under ASC 740-10.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards
on the date of grant. The combined Vyrix and Luoxis company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the vesting period using the graded method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research
and development costs are expensed as incurred with expense recorded in the respective periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments, including cash and cash equivalents, accounts payable and other current assets and liabilities are
carried at cost which approximates fair value due to the short maturity of these instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ampio routinely performs an annual evaluation of the recoverability of the carrying value of its long-lived assets to determine if facts and
circumstances indicate that the carrying value of assets or intangible assets may be impaired and if any adjustment is warranted. Based on Ampio&#146;s evaluation as of December&nbsp;31, 2014, no impairment existed for long-lived assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Newly Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board or FASB, issued Accounting Standards Update or ASU, 2014-09 regarding Accounting Standards Codification,
or ASC, Topic 606, &#147;Revenue from Contracts with Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be
entitled in exchange for those goods or services. The guidance will be effective for reporting periods beginning after December&nbsp;15, 2016. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure
requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2014, the FASB issued ASU 2014-10,
&#147;Development Stage Entities (Topic 915)&#148;. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from GAAP for development stage entities, primarily
presentation of inception to date financial statements. The provisions of the amendments are effective for calendar year 2015; however, early adoption is permitted and, accordingly, we elected to implement the guidance for our financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, &#147;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties
about an Entity&#146;s Ability to Continue as a Going Concern&#148;, or ASU 2014-15. ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue
as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December&nbsp;15, 2016, with early adoption permitted. Management is currently assessing the impact the
adoption of ASU 2014-15 will have on our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, the FASB issued ASU 2015-01, &#147;Extraordinary and Unusual Items (Subtopic 225-20):
Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.&#148; The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately
classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December&nbsp;15, 2015 and subsequent interim periods with early application permitted. Management is
currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations&#151;Year Ended
December&nbsp;31, 2014 and 2013 See Notes to Combined Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of operations for the years ended December&nbsp;31, 2014 and 2013
reflected losses of $7.1 million and $3.9 million, respectively. These losses include non-cash charges related to stock-based compensation, depreciation and amortization expense, amortization of prepaid research and development-related party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated material revenue in
our operating history. The total revenue recognized during 2014 and 2013 was $90,000 and $50,000, respectively. Included in the revenues are $77,000 and $50,000 license revenue recognized during 2014 and 2013, respectively, which represents the
amortization of the upfront payments received on our license agreements. From an agreement entered into in 2012, the initial payment of $500,000 from the license agreement of Zertane with a Korean pharmaceutical company was deferred and is being
recognized over 10 years. As well as from an agreement entered into in 2014 with a Canadian-based supplier, the initial payment of $250,000 from the license agreement of Zertane was deferred and is being recognized over seven years. We also
recognized $13,000 related to Luoxis product and service revenue in fiscal year 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development
costs consist of labor, stock-based compensation, clinical trials and sponsored research, consultants and sponsored research &#150; related party. These costs relate solely to research and development without an allocation of general and
administrative expenses and are summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trials and sponsored research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,534,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,432,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Labor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored Research&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consultants and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,446,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,003,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of Years Ended December&nbsp;31, 2014 and 2013 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses increased $1,443,000, or 48%, in 2014 over 2013. This was due primarily to labor and clinical trial and sponsored research
costs associated with the Luoxis&#146; development of its RedoxSYS system. We expect research and development expenses to at least maintain the 2014 level or possible increase in 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During fiscal year 2014, we spent $2,984,000 on Luoxis&#146; development of its RedoxSYS system and $1,462,000 on Vyrix&#146;s Zertane drug. During fiscal
year 2013, we spent $1,780,000 on Luoxis&#146; development of its RedoxSYS system and $1,223,000 on Vyrix&#146;s Zertane drug. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and
Administrative </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of personnel costs for employees in executive, business development and operational
functions and director fees; stock-based compensation; patents and intellectual property; professional fees include legal, auditing and accounting; occupancy, travel and other includes rent, governmental and regulatory compliance, insurance,
investor/public relations and professional subscriptions. These costs are summarized as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Labor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">715,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Occupancy, travel and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of Years Ended December&nbsp;31, 2014 and 2013 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative costs increased $1,642,000, or 101%, in 2014 over 2013. The increase in labor costs and stock-based compensation primarily relates
to increased professional staffing, bonuses earned and stock options granted in Luoxis and Vyrix as well as the continuing vesting of stock option awards granted in previous years. The increase in professional fees relates to the expensed legal
costs associated with Vyrix trying to complete an initial public offering during 2014. We expect general and administrative expenses to increase in 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2014, our operating activities used $7.2 million in cash. The use of cash was approximately $106,000 higher than the net loss due primarily to non-cash
charges for stock-based compensation, depreciation and amortization. Cash provided in operating activities also included a $630,000 decrease in deferred tax liability and a $615,000 increase in research and development related party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2013, our operating activities used approximately $4.0 million in cash. The use of cash was $39,000 higher than the net loss due primarily to non-cash
charges for stock-based compensation, depreciation and amortization. Net cash provided in operating activities also included a $227,000 decrease in accounts payable and a $620,000 decrease in deferred tax liability which were partially offset by an
increase of $206,000 in related party payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2013, cash was used to acquire ORP patents on behalf of Luoxis and the purchase of a Luoxis ORP manufacturing device. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash from Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2014 was $5.4 million which reflects proceeds from the convertible notes to Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2013 was $6.4 million which reflects proceeds and costs from the Luoxis&#146; private financing of $4.7 million
and $672,000, respectively. Net cash provided by financing activities in 2013 also included $300,000 in proceeds from a convertible note to Ampio and $2.0 million contribution by Ampio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commitments and contingencies are described below and summarized by the following table for the years ending December&nbsp;31: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 91,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 91,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical research and trial obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research agreement with related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,106,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">770,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis has entered into an agreement with a local manufacturing company to build its RedoxSYS system, the current remaining commitment is $91,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Research and Trial Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with upcoming clinical trials, Vyrix has a remaining commitment of $193,000 on contracts related to the Zertane drug and Luoxis has entered into
research agreements with a remaining commitment of $138,000 related to the RedoxSYS system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement with
Related Party </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis entered into a Sponsored Research Agreement with TRLLC, a related party, in June 2013. Under the terms of the Sponsored
Research Agreement, TRLLC agreed to work collaboratively in advancing the ORP diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146; notice (see
Note 8&#151;Related Party Transactions). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Management Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January of 2013, Luoxis entered into an agreement with Ampio whereby Luoxis agreed to pay Ampio $15,000 per month for shared overhead which includes costs
related to the shared facility, corporate staff, and other miscellaneous overhead expenses. Vyrix entered into a similar agreement with Ampio in January of 2014, at a rate of $7,000 per month. These agreements will be in effect until they have been
terminated in writing by both parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated significant revenue as our primary activities are focused on research and development, advancing our primary product candidates, and
raising capital. As of December&nbsp;31, 2014, we had cash and cash equivalents totaling $161,000 available to fund our operations and $445,000 in accounts payable and accrued compensation. Based upon the $6.3 million of cash received from January
2015 to April 2015 from Ampio to the combined Vyrix and Luoxis company plus the Ampio commitment to fund the combined Vyrix and Luoxis company operation with another $10.0 million, we believe we have adequate capital to continue operations into the
second half of 2016. This projection is based on a number of assumptions that may prove to be wrong, and we could exhaust our available cash and cash equivalents earlier than presently anticipated. We intend to seek additional capital within the
next 12 months to expand our clinical development activities for Zertane and RedoxSYS. In addition, we intend to evaluate the capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or
otherwise, depending on market conditions relative to our need for funds at such time, and we will seek to raise additional capital during the next 12 months at such time as we conclude that such capital is available on terms that we consider to be
in the best interests of us and our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have prepared a budget for 2015 which reflects cash requirements for fixed, on-going expenses such as payroll,
legal and accounting, patents and overhead at an average cash burn rate of approximately $0.4 million per month. Additional funds are planned for regulatory approvals, clinical trials, outsourced research and development and commercialization
consulting. Accordingly, it will be necessary to raise additional capital and/or enter into licensing or collaboration agreements. At this time, we expect to satisfy our future cash needs through Ampio&#146;s contributions to us and private or
public sales of our securities or debt financings. We cannot be certain that financing will be available to us on acceptable terms, or at all. Over the last three years, volatility in the financial markets has adversely affected the market
capitalizations of many bioscience companies and generally made equity and debt financing more difficult to obtain. This volatility, coupled with other factors, may limit our access to additional financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot raise adequate additional capital in the future when we require it, we will be required to delay, reduce the scope of, or eliminate one or more
of our research or development programs or our commercialization efforts. We also may be required to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose.
This may lead to impairment or other charges, which could materially affect our balance sheet and operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative
Disclosures about Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not currently exposed to material market risk arising from financial instruments, changes in interest rates or
commodity prices, or fluctuations in foreign currencies. We have no need to hedge against any of the foregoing risks and therefore currently engage in no hedging activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have
off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &#147;variable interest entities.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_7"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table sets forth the names and ages of all of our directors and executive officers following consummation of the Merger. Our Board of Directors is currently comprised of one member, who is elected annually to serve for one year or until his
successor is duly elected and qualified, or until his earlier resignation or removal. Executive officers serve at the discretion of the Board of Directors and are appointed by the Board of Directors. Each of the director and executive officers
listed below joined us upon the closing of the Merger on April&nbsp;16, 2015. Also provided herein are brief descriptions of the business experience of each of the directors and executive officers during the past five years, and an indication of
directorships held by the director in other companies subject to the reporting requirements under the federal securities law. As of the date of this Form 8-K, the member of our Board of Directors and our executive officers are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation and Areas of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Relevant Experience For Directors</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joshua&nbsp;R.&nbsp;Disbrow&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief&nbsp;Executive&nbsp;Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joshua R. Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Luoxis since January 2013. Mr. Disbrow was also the Chief Operating Officer of Ampio
since December 2012. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company, from May 2007 through October 2012. He joined Arbor as that company&#146;s second
full-time employee. Mr. Disbrow led the company&#146;s commercial efforts from inception to the company&#146;s acquisition in 2010 and growth to over $127 million in net sales in 2011. By the time Mr. Disbrow departed Arbor in late 2012, he had led
the growth of the commercial organization to comprise over 150 people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years in the pharmaceutical, diagnostic and
medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional Sales Manager with Cyberonics,
Inc., a medical device company focused on neuromodulation therapies from June 2005 through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience, an in vitro diagnostics company. Mr. Disbrow holds an MBA from Wake
Forest University and BS in Management from North Carolina State University.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation and Areas of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Relevant Experience For Directors</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jarrett&nbsp;T.&nbsp;Disbrow&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief&nbsp;Operating&nbsp;Officer, Secretary and Treasurer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jarrett Disbrow has been employed by us since April&nbsp;16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix since November 2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or
Eurus Pharma, where he held the position of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to
2010. Following Arbor Pharmaceuticals&#146; acquisition in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Prior to founding Arbor Pharmaceuticals in 2006, he was head of marketing for Accentia
Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcom, Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing. Mr. Disbrow received a
BS in business management from North Carolina State University in Raleigh, NC.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation and Areas of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Relevant Experience For Directors</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gregory&nbsp;A.&nbsp;Gould&nbsp;(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief&nbsp;Financial&nbsp;Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gregory A. Gould has been our Chief Financial Officer since April&nbsp;16, 2015. Mr. Gould is also the Chief Financial Officer of Ampio where he has been employed since June 2014. Prior to joining Ampio, he provided financial and
operational consulting services to the biotech industry through his consulting company, Gould LLC from April 2012 until June 2014.&nbsp;Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare from November 2006 until the company
was sold to Linden Capital Partners in April 2012.&nbsp;During the period from July 2011 until April 2012 Mr. Gould also served as the Interim President and Chief Executive Officer of SeraCare Life Sciences.&nbsp;Mr. Gould has held several other
executive positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould&#146;s tenure at
Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855 million. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo
of the Eligard<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products. Mr. Gould was the Chief Financial Officer at Colorado MedTech, Inc., a publicly traded medical device design and manufacturing company where he negotiated the
transaction to sell the company to KRG Capital Partners.&nbsp;Mr. Gould began his career as an auditor with Arthur Andersen, LLP.&nbsp;He currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company
pursuing anti-viral agents for the treatment of HIV.&nbsp;Mr. Gould graduated from the University of Colorado with a BS in Business Administration and is a Certified Public Accountant.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Principal Occupation and Areas of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Relevant Experience For Directors</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael&nbsp;Macaluso&nbsp;(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Macaluso has become a member of our Board of Directors since April&nbsp;16, 2015. Mr. Macaluso is also the Chief Executive Officer of
Ampio where he founded Life Sciences and has been a member of the board of directors of Life Sciences, Ampio&#146;s predecessor, since its inception. Mr. Macaluso has also been a member of our Board of Directors since the merger with Chay
Enterprises in March 2010 and our Chief Executive Officer since January&nbsp;9, 2012. Mr. Macaluso was appointed president of Isolagen, Inc. (AMEX: ILE) and served in that position from June 2001 to August 2001, when he was appointed chief executive
officer. In June 2003, Mr. Macaluso was re-appointed as president of Isolagen and served as both chief executive officer and president until September 2004. Mr. Macaluso also served on the board of directors of Isolagen from June 2001 until April
2005. From October 1998 until June 2001, Mr. Macaluso was the owner of Page International Communications, a manufacturing business. Mr. Macaluso was a founder and principal of International Printing and Publishing, a position Mr. Macaluso held from
1989 until 1997, when he sold that business to a private equity firm.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mr.
Macaluso&#146;s experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion of our Board of Directors that he should serve as a director of our
Combined Company in light of our business and structure.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Joshua R. Disbrow was appointed the Chief Executive Officer of Luoxis in January 2013. In connection with the Merger, he resigned from Luoxis and was appointed the Chief Executive Officer of the Combined Company upon
the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Jarrett T. Disbrow was appointed the Chief Executive Officer of Vyrix in November 2013. In connection with the Merger, he resigned from Vyrix and was appointed the Chief Operating Officer, Secretary and Treasurer of the
Combined Company upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Gregory A. Gould was appointed the Chief Financial Officer of Luoxis and Vyrix in June 2014. In connection with the Merger, he resigned from Luoxis and Vyrix and was appointed the Chief Financial Officer of the Combined
Company upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Michael Macaluso was appointed a Director of Luoxis in January 2013 and a Director of Vyrix in November 2013. In connection with the Merger, he resigned from the boards of Luoxis and Vyrix and was appointed a Director
of the Combined Company upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Former Directors and Executive Officers </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Former Positions with the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Company</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Date&nbsp;Assumed<BR>Positions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Date&nbsp;Resigned<BR>Positions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James B. Wiegand (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Former President, Chief Financial Officer, Secretary and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">9-Aug-02</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24-Mar-15</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary V. Cantrell (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1-Feb-14</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24-Mar-15</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John A. Donofrio Jr (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1-Feb-14</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24-Mar-15</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas J. Leb (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1-Feb-14</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24-Mar-15</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Vaughan Clift (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11-May-14</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13-May-15</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Wiegand was appointed President, Chief Executive Officer and Secretary and a director on August&nbsp;9, 2002. In connection with the Merger, he resigned from all of his positions with us on April&nbsp;16, 2015.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Cantrell was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Donofrio was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Leb was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Clift was appointed Chief Medical Officer of Vyrix in May 2014. In connection with the Merger, he resigned from this position on March&nbsp;13, 2015 as we continue to assess the appropriate management
structure. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships and Other Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow, our Chief Operating Officer, is the brother of Joshua R. Disbrow, our Chief Executive Officer. There are no other family relationships
among or between any of our current or former executive officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Involvement in Certain Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our directors, executive officers, significant employees, promoters or control persons has been involved in any legal proceeding in the past 10 years
that would require disclosure under Item&nbsp;401(f) of Regulation S-K promulgated under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Director
Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors is currently comprised of a sole director, Michael Macaluso, who is an executive officer and director of Ampio and
is not an independent director. We look to our director to guide us through our next phase as a public company and continue and manage our growth. Our director brings leadership experience from a variety of corporate, technology and professional
backgrounds which we require to continue to grow and to add stockholder value. Our director also has worked with startup through public companies and bring depth of knowledge in building stockholder value, growing a company from inception,
developing leading edge products, and navigating mergers and acquisitions and the public company process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has not established a separate standing audit committee within the meaning of Section&nbsp;3(a)(58)(A) of the Exchange Act or separate
standing nominating or compensation committees, or committees performing similar functions, nor has it adopted charters for any such committee. Due to the present and prior size of our Board of Directors, our Board of Directors believes that it is
not necessary to have separate standing audit, nominating or compensation committees at this time because the functions of each such committee are adequately performed by our full Board of Directors. However, it is anticipated that our Board of
Directors will form separate standing audit, nominating and compensation committees, with the audit committee including an audit committee financial expert and the audit and compensation committees consisting solely of independent directors, if and
when our Board of Directors determines that the establishment of such committees is advisable as we seek to further develop our business and operations and potentially expand the size of our Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominations to the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director
candidates are considered based upon various criteria, including without limitation their broad-based business and professional skills and experiences, knowledge of the industry in which we operate and ability to add perspectives relating to that
industry, expertise in the healthcare field, concern for the long-term interests of our stockholders, diversity, and personal integrity and judgment. Our Board of Directors has a critical role in guiding our strategic direction and overseeing the
management of our business, and accordingly, we seek to attract and retain highly qualified directors who have sufficient time to engage in the activities of our Board of Directors and to understand and enhance their knowledge of our industry and
business plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although
we do not have a formal policy regarding stockholder communications with our Board of Directors, stockholders may communicate with our Board of Directors, or any individual director on our Board of Directors, by writing to us at the address of our
principal executive offices, addressing the communication to the attention of our Chief Executive Officer, and specifying the Board of Directors or, if applicable, the individual member thereof as the intended recipient of the communication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure and Board&#146;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The positions of our Chairman of the Board of Directors and Chief Executive Officer are presently separated at our company. Separating these positions allows
our Chief Executive Officer to focus on our day-to-day business, while allowing the Chairman to lead the Board of Directors in its fundamental role of providing advice to and oversight of management. Our Board of Directors recognizes the time,
effort and energy that the Chief Executive Officer must devote to his position in the current business environment, as well as the commitment required to serve as our Chairman, particularly as the Board of Directors&#146; oversight responsibilities
continue to grow. Our Board of Directors believes its administration of its risk oversight function has not affected its leadership structure. Our Board of Directors believes that having separate positions is the appropriate leadership structure for
us at this time and demonstrates our commitment to good corporate governance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The role of our Board of Directors is to oversee our risk management
function. Members of our management team report to our Board of Directors on areas of material risk to us, including operational, financial, legal and regulatory, and strategic and other risks, and provide it with all information necessary to enable
our directors to develop a fulsome understanding of the applicable risk and conduct an evaluation of the risk and management&#146;s manner of addressing it. If an identified area of risk poses an actual or potential conflict with management, our
non-employee directors may conduct the evaluation. It is anticipated that our Board of Directors will in the future establish more formal procedures regarding the scope and administration of its risk oversight role. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has not established a separate standing compensation committee. None of our current or former executive officers serves, or during our
last completed fiscal year has served, as a member of the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our
Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have not adopted a written code of ethics that applies to our officers, directors and employees, including our principal executive officer and
principal accounting officer. Our Board of Directors intends to adopt such a formal code of ethics when it deems appropriate based on the size of our operations and personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In establishing director
compensation, our Board of Directors is guided by the following goals: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation should consist of a combination of cash and equity awards that are designed to fairly pay the directors for work required for a company of our size and scope; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation should align the directors&#146; interests with the long-term interests of stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation should assist with attracting and retaining qualified directors. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to pay our
non-employee directors $1,500 per meeting for each in-person Board meeting attended and $1,000 per meeting for each telephonic meeting attended. We will reimburse them for expenses incurred in connection with their service as director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow, who served as a member of Vyrix&#146;s board of directors during 2014, did not receive any compensation, equity awards or non-equity
awards for his service as a director, although Mr.&nbsp;Disbrow did receive compensation in 2014 from and with respect to his employment with Vyrix. James B. Wiegand, who served as the sole director of Rosewind in 2014, did not receive any
compensation, equity awards or non-equity awards for his service as a director. Mr.&nbsp;Wiegand was appointed President, Chief Executive Officer and Secretary and a director of Rosewind on August&nbsp;9, 2002. He resigned from all of his positions
with us on April&nbsp;16, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding all compensation paid to non-employee directors of Vyrix and Luoxis
during the fiscal year ended December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid in Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Stock&nbsp;Option<BR>Awards (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>All Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Micael Macaluso (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary V. Cantrell (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John A. Donofrio Jr (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas J. Leb (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value computed in accordance with FASB ASC Topic 718. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Michael Macaluso was appointed a Director of Luoxis in January 2013 and a Director of Vyrix in November 2013. In connection with the Merger, he resigned from the boards of Luoxis and Vyrix and was appointed a Director
of the Combined Company upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Gary V. Cantrell was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">John A. Donofrio Jr. was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Nicholas J. Leb was appointed a director of Vyrix in February 2014. In connection with the Merger, he resigned from this position on April&nbsp;16, 2015 as we continue to assess the appropriate corporate governance
structure. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_8"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From fiscal year 2012 to the completion of the Merger on April&nbsp;16, 2015, no compensation was earned by or paid to James B. Wiegand, the former President,
Chief Financial Officer and Secretary of Rosewind. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Discussion and Analysis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Philosophy and Objectives</I>. Vyrix&#146; and Luoxis&#146; executive compensation program is designed to retain the executive officers and to
motivate them to increase stockholder value on both an annual and longer term basis. These objectives are to be accomplished primarily by positioning Vyrix and Luoxis to maximize their product development efforts and to transform, over time, those
efforts into collaboration revenues and income. To that end, compensation packages include significant incentive forms of stock-based compensation to ensure that each executive officer&#146;s interest is aligned with the interests of the
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Executive Compensation Components. </I>Vyrix&#146; and Luoxis&#146; respective compensation program for their named executive officers,
consists of three components: (i)&nbsp;a base salary, (ii)&nbsp;discretionary bonuses based on performance, and (iii)&nbsp;equity compensation. Each of these components is reflected in the Summary Compensation Table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Why Each Element of Compensation is Paid; How the Amount of Each Element is Determined</I>. Vyrix and Luoxis intend to pay each of these elements in order
to ensure that a desirable overall mix is established between base compensation and incentive compensation, cash and non-cash compensation, and annual and long-term compensation. Vyrix and Luoxis also intend to evaluate on a periodic basis the
overall competitiveness of the executive compensation packages as compared to packages offered in the marketplace for which they compete with executive talent. Overall, Vyrix and Luoxis believe that the executive compensation packages are currently
appropriately balanced and structured to retain and motivate the named executive officers, while necessarily taking into account our presently limited financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk Assessment</I>. Vyrix and Luoxis have reviewed the compensation program and believe that the program, including the cash incentive compensation and
equity incentive compensation, does not encourage the named executive officers to engage in any unnecessary or excessive risk-taking. As a result, Vyrix and Luoxis have to date not implemented a provision for recovery by them of cash or incentive
compensation bonuses paid to the named executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the compensation earned in each of Vyrix&#146; and Luoxis&#146; fiscal years ended
December&nbsp;31, 2014, 2013 and 2012 by its named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>(a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)<BR>(d)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Award&nbsp;($)<BR>(e)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Award</B><br><B>($)(1)<BR>(f)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive Plan<BR>Compensation&nbsp;($)<BR>(g)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change in<BR>Pension Value<BR>and<BR>Nonqualified<BR>Deferred<BR>Compensation<BR>Earnings ($)<BR>(h)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)<BR>(i)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)<BR>(j)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I><U>Named Exective Officers</U></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Joshua R. Disbrow (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>since December 2012</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jarrett T. Disbrow (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Chief Operating Officer, Secretary and Treasurer since November 2013</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gregory A. Gould (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Chief Financial Officer since June 2014</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vaughan Clift, M.D. (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Former Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the grant date fair value of option awards as determined in accordance with FASB ASC Topic 718, excluding the effect of any estimated forfeitures. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Joshua R. Disbrow was appointed the Chief Executive Officer of Luoxis in January 2013. In connection with the Merger, he resigned from Luoxis and was appointed the Chief Executive Officer of the Combined Company upon
the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Jarrett T. Disbrow was appointed the Chief Executive Officer of Vyrix in November 2013. In connection with the Merger, he resigned from Vyrix and was appointed the Chief Operating Officer, Secretary and Treasurer of the
Combined Company upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Gregory A. Gould was appointed the Chief Financial Officer of Luoxis and Vyrix in June 2014. In connection with the Merger, he resigned from Luoxis and Vyrix was appointed the Chief Financial Officer of the Combined
Company upon the closing of the Merger on April&nbsp;16, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Vaughan Clift was appointed the Chief Medical Officer of Vyrix in May 2014. In connection with the Merger, he resigned from this position on March&nbsp;13, 2015 as we continue to assess the appropriate
management structure. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2014 Grants of Plan-Based Awards Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During fiscal year 2014, stock options were granted to our named executive officers as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>All&nbsp;Other&nbsp;Option<BR>Awards:&nbsp;Number&nbsp;of<BR>Securities<BR>Underlying Options<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Exercise&nbsp;Price&nbsp;of<BR>Option Awards<BR>($/Share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant&nbsp;Date&nbsp;Fair<BR>Value of Option<BR>Awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>($)(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Named Exective Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vaughan Clift M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/11/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value computed in accordance with FASB ASC 718, excluding the effect of any estimated forfeitures and may not correspond to the actual value
that will be realized by the named executive officer. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These Vyrix options were accelerated and cancelled in connection with the merger. Because the consideration paid to holders of common stock of Vyrix was less than the exercise price of such options, no amount was paid
to the option holder in connection with the cancellation. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">These Luoxis options were accelerated and cancelled in connection with the merger. Because the consideration paid to holders of common stock of Luoxis was less than the exercise price of such options, no amount was paid
to the option holder in connection with the cancellation. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2014 Fiscal Year-End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the current holdings of equity awards by our named executive officers on December&nbsp;31, 2014. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Exercisable&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>Unexercisable<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Equity&nbsp;Incentive<BR>Plan Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number&nbsp;of<BR>Shares or<BR>Units&nbsp;of&nbsp;Stock<BR>That&nbsp;Have&nbsp;Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Market&nbsp;Value<BR>of Shares or<BR>Units&nbsp;of&nbsp;Stock<BR>That&nbsp;Have&nbsp;Not<BR>Vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Equity<BR>Incentie&nbsp;Plan<BR>Awards:<BR>Number of<BR>Unearned<BR>Shares,<BR>Units
or<BR>Other Rights<BR>That<BR>Have&nbsp;Not</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vested&nbsp;(#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Equity<BR>Incentive<BR>Plan&nbsp;Awards:<BR>Market or<BR>Payout Value<BR>of Unearned<BR>Shares, Units<BR>or Other<BR>Rights That<BR>Have Not<BR>Vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>(a)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(d)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(e)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(f)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(g)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(h)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(i)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(j)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I><U>Named Exective Officers</U></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Joshua R. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/15/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Joshua R. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jarrett T. Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/18/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/11/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vaughan Clift, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/11/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">James B. Wiegand</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Unexercisable options vest annually and become fully vested on June&nbsp;14, 2016. These Luoxis options were accelerated and cancelled in connection with the merger, and option holders received a cash payment per option
share equal to the difference between the consideration payable per share of common stock of Luoxis pursuant to the merger and the exercise price of the option. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Unexercisable options vest monthly and become fully vested on August&nbsp;11, 2018. These Luoxis options were accelerated and cancelled in connection with the merger. Because the consideration paid to holders of common
stock of Luoxis was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Unexercisable options vest annually and become fully vested on November&nbsp;18, 2016. These Vyrix options were accelerated and cancelled in connection with the merger. Because the consideration paid to holders of
common stock of Vyrix was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Unexercisable options vest monthly and become fully vested on August&nbsp;11, 2018. These Luoxis options were accelerated and cancelled in connection with the merger. Because the consideration paid to holders of common
stock of Luoxis was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Unexercisable options vest annually and become fully vested on March&nbsp;11, 2017. These Vyrix options were accelerated and cancelled in connection with the merger. Because the consideration paid to holders of common
stock of Vyrix was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option Exercises and Stock Vested in 2014 </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the
fiscal year 2014, none of our named executive officers exercised any options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment and Consulting Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an
employment agreement with Joshua Disbrow in connection with his employment as our Chief Executive Officer. The agreement is for a term of 24 months beginning on April&nbsp;16, 2015, subject to termination by us with or without Cause or as a result
of officer&#146;s disability, or by the officer with or without Good Reason (as discussed below). Mr.&nbsp;Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary and
600,000 stock options with 50% vesting upon grant and the remainder vesting on the following two anniversaries of the grant date. Mr.&nbsp;Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to
the terms and conditions of such plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an employment agreement with Jarrett Disbrow, our Chief Operating Officer, in connection with his
employment with us. The agreement is for a term of 24 months beginning on April&nbsp;16, 2015, subject to termination by us with or without Cause or as a result of the officer&#146;s disability, or by the officer with or without Good Reason (as
discussed below). Mr.&nbsp;Disbrow is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary and 600,000 stock options with 50% vesting upon grant and the remainder vesting on
the following two anniversaries of the grant date. Mr.&nbsp;Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payments Provided Upon Termination for Good Reason or Without Cause </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreements, in the event Mr.&nbsp;Joshua Disbrow&#146;s or Mr.&nbsp;Jarrett Disbrow&#146;s employment is terminated without Cause by
us or either officer terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal to two times his base salary in effect at the date of termination, as well as continued
participation in the health and welfare plans for up to two years. All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long as a Change in Control is not in effect,
then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to 1/24th the number of option shares multiplied by the
number of full months of such officer&#146;s employment shall be deemed vested and immediately exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be
exercisable by such officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Good Reason&#148; means, without the officer&#146;s written consent, there is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material reduction in the officer&#146;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a
reduction in the officer&#146;s responsibilities or authority); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material reduction of the level of the officer&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally, provided, however, that in no case may
the base salary be reduced below certain specified amounts); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material change in the principal geographic location at which the officer must perform his services. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conviction of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than a traffic violation which is a misdemeanor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful malfeasance or willful misconduct by the officer in connection with his employment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gross negligence in performing any of his duties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful and deliberate violation of any of our policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unintended but material breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable satisfaction of the board; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unauthorized use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure as a result of the officer&#146;s relationship with us;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful and deliberate breach of his obligations under the employment agreement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The severance benefits described above are contingent on each officer executing a general release of claims. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payments Provided Upon a Change in Control </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
the employment agreements, in the event of a Change in Control of us, all stock options, restricted stock and other stock-based grants granted or may be granted in the future by us to the officers will immediately vest and become exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; means: the occurrence of any of the following events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the acquisition by any individual, entity, or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act) (the &#147;Acquiring Person&#148;), other than us, or any of our Subsidiaries, of
beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding voting securities of us entitled to vote generally in the election
of directors (excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes); or; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the acquisition of us by another entity by means of any transaction or series of related transactions to which we are party (including, without limitation, any stock acquisition, reorganization, merger or consolidation
but excluding any issuance of securities by us in a transaction or series of transactions made principally for bona fide equity financing purposes ) other than a transaction or series of related transactions in which the holders of the voting
securities of us outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of shares in us held by such holders prior to such
transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such other surviving or resulting entity is
a wholly-owned subsidiary immediately following such acquisition, its parent); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sale or other disposition of all or substantially all of the assets of us in one transaction or series of related transactions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payments Provided Upon Termination for Cause or Without Good Reason, Death or Disability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreements, in the event we end the officer&#146;s employment for Cause, if such officer resigns as an employee for reasons other
than an event of Good Reason, such officer dies or disability occurs , then we shall pay to the officer the accrued compensation but shall have no obligation to pay the officer any amount, whether for salary, benefits, bonuses, or other compensation
or expense reimbursements of any kind, accruing after the end of the employment, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be forfeited immediately upon the end of the
employment. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date we end the employment for Cause, or the date of the
officer&#146;s death or disability, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the officer or his personal representative or executor. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:73.70pt; font-size:8pt; font-family:Times New Roman"><B>Recipient and Benefit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cause;&nbsp;Without<BR>good&nbsp;reason;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Cause;<BR>Good&nbsp;reason</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Death;&nbsp;Disability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;in&nbsp;Control</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Disbrow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of health benefits provided after termination (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jarrett Disbrow</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salary</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of health benefits provided after termination (1)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">556,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The value of such benefits is determined based on the estimated cost of providing health benefits to the named executive officer for a period of two years. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_9"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of April&nbsp;16, 2015 for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each beneficial owner of more than 5%&nbsp;of our outstanding common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our director and named executive officers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our directors and executive officers as a group. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with
the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include common stock that can be acquired within 60
days of April&nbsp;16, 2015. The percentage ownership information shown in the table is based upon 173,597,365 shares of common stock outstanding as of April&nbsp;16, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and
investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of
common stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of April&nbsp;16, 2015. We did not deem these shares outstanding, however, for the purpose of computing the percentage
ownership of any other person. Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the table below is based on information known to us or ascertained by us from public filings made by the stockholders.
Except as otherwise indicated in the table below, addresses of the director, executive officers and named beneficial owners are in care of Rosewind Corporation, 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio Pharmaceuticals, Inc.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,535,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua R. Disbrow<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jarrett T. Disbrow<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Macaluso</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James B. Wiegand<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (five persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,340,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The address of Ampio Pharmaceuticals, Inc. is 373 Inverness Parkway, Suite 200, Englewood, CO 80112. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">6,800,000 shares were purchased and held by an irrevocable trust for estate planning in which Mr.&nbsp;Disbrow is a beneficiary. Mr.&nbsp;Disbrow does not have or share investment control over the shares held by the
trust, Mr.&nbsp;Disbrow is not the trustee of the trust (nor is any member of Mr.&nbsp;Disbrow&#146;s immediate family) and Mr.&nbsp;Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules,
Mr.&nbsp;Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">6,800,000 shares were purchased and held by an irrevocable trust for estate planning in which Mr.&nbsp;Disbrow is a beneficiary. Mr.&nbsp;Disbrow does not have or share investment control over the shares held by the
trust, Mr.&nbsp;Disbrow is not the trustee of the trust (nor is any member of Mr.&nbsp;Disbrow&#146;s immediate family) and Mr.&nbsp;Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules,
Mr.&nbsp;Disbrow does not have beneficial ownership over the shares purchased and held by the trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Wiegand was appointed President, Chief Executive Officer and Secretary and a director on August&nbsp;9, 2002. In connection with the closing of the Merger, he resigned from all of his positions on
April&nbsp;16, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_10"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We describe below all transactions and series of similar transactions, other than compensation arrangements, during the last three fiscal years, to which we
were a party or will be a party, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation arrangements for our directors and named executive officers are described elsewhere in this Form 8-K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, pursuant to the Merger
Agreement entered into among Rosewind, Luoxis, Vyrix and two subsidiaries of Rosewind created solely for the purposes of the Merger, and which did not survive the Merger, the Merger occurred in two stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first stage, each of Vyrix and Luoxis merged with one of Rosewind&#146;s merger subsidiaries. Vyrix and Luoxis survived these mergers. The outstanding
shares of stock of Vyrix and the outstanding shares of stock of Luoxis were converted into the right to receive shares of common stock in the Combined Company. The Vyrix stock and the Luoxis stock were each converted at an exchange factor. The
exchange factor for each of them was determined upon the basis of a relative value opinion obtained by Ampio, the parent company of Vyrix and Luoxis. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Vyrix were converted
into shares of Vyrix as the surviving corporation. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as the surviving corporation. After completion of the first stage, Vyrix and
Luoxis became subsidiaries of Rosewind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the second stage, which occurred on the same day as the first stage, each of Vyrix and Luoxis merged with
Rosewind with Rosewind surviving. The first and second stage mergers are referred to collectively as the &#147;Merger.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the
Merger: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The board of directors of Rosewind, whose sole member was James Wiegand, increased the number of directors by one, and appointed Michael Macaluso to fill the vacancy created by that increase. James Wiegand resigned from
the board immediately thereafter. The board of directors of Rosewind, whose sole member is Michael Macaluso, then appointed Joshua Disbrow as Chief Executive Officer, Jarrett Disbrow as Chief Operating Officer and Gregory A. Gould as Chief Financial
Officer of the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ampio purchased 57,970,000 shares of common stock of the Combined Company for (i)&nbsp;issuance to Rosewind of a promissory note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the
Merger; (ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Wiegand entered into a consulting agreement with the Combined Company with a one year duration, providing for compensation of $50,000 to him. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of James Wiegand and Michael Wiegand executed a release in favor of the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of Ampio, James Wiegand, Michael Wiegand, a trust affiliated with Joshua Disbrow and a trust affiliated with Jarrett Disbrow entered into a lock-up agreement with the Combined Company agreeing not to sell its
shares of the Combined Company for two years (except for the one with Ampio, more than three years). The lock-up agreements other than the one with Ampio release 25% of the shares subject to it on or prior to June&nbsp;30, 2015. The Ampio lock-up
agreement terminates upon a change-in-control event of either the Combined Company or Ampio. Each other lock-up agreement terminates upon a change-of-control event of the Combined Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Joshua Disbrow entered into an employment agreement with the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Jarrett Disbrow entered into an employment agreement with the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The sailing boat owned by Rosewind was transferred to James Wiegand upon the closing of the Merger in exchange for cancellation of indebtedness owing to James Wiegand in the amount of approximately $30,000 (being the
approximate value of the sailing boat). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement contemplates the reincorporation of the Combined Company in Delaware, as a
corporation, with the name Aytu Biosciences, Inc. as soon as is reasonably practicable after the closing of the Merger. The reincorporation is also expected to result in the reduction of the number of shares of stock outstanding in the Combined
Company equivalent to a reverse stock split at the rate of approximately 12.174 to 1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rosewind </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of August&nbsp;31, 2014, Rosewind has a secured promissory note to the sole officer and director for $30,985 for working capital. The loan carries a 6%
interest rate, matures on demand and is secured by the sailing vessel. Accrued interest payable on the loan totaled $17,607 as of August&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended August&nbsp;31, 2014 and 2013 the sole officer of Rosewind contributed services valued at $3,690 and $4,980, respectively. This amount has
been booked to additional paid in capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of
which Joshua Disbrow and Jarrett Disbrow are beneficiaries. None of such persons have or share investment control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such
trusts. None of such persons have or share power to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Luoxis and Vyrix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales and Purchases of Securities
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, pursuant to a subscription agreement, Ampio purchased 20,000,000 shares of Vyrix common stock at a purchase price of $0.0001 per
share plus the transfer of certain intellectual property described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ampio Loan Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agrees to lend Vyrix up to an aggregate amount of
$3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of the
Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any outstanding
balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the board of
directors, as of such conversion date. As of December&nbsp;31, 2014 the amount advanced was $2,700,000 with interest rates from 2.17%&#151;3.32%. On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its
obligation in the amount of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March
2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for
long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may
repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined
by the board of directors, as of such conversion date. As of December&nbsp;31, 2014 the amount outstanding remained $3,000,000 with interest rates from 2.17% - 3.32%. On April&nbsp;16, 2015, in connection with the closing of the Merger, Ampio
released Luoxis from its obligation in the amount of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assignment and Assumption Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December
2013, Vyrix entered into an assignment and assumption agreement with Ampio. Pursuant to the assignment and assumption agreement, Ampio assigned to Vyrix all its rights under a certain manufacturing and supply agreement, license agreement,
distribution agreement, services agreement and other agreements related to Vyrix&#146; product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Intellectual Property
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2013, Ampio transferred to Luoxis certain intellectual property, including registered and unregistered patents, related to the Luoxis
ORP technology. In December 2013, Ampio transferred to Vyrix certain intellectual property, including registered and unregistered patents, related to Vyrix product candidates. Such intellectual property was transferred to the Combined Company upon
the closing of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2013, Luoxis entered into a services agreement with Ampio whereby Ampio provides corporate overhead services and a shared facility with Luoxis in
exchange for $15,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. In January 2014, Vyrix entered into a services agreement with Ampio whereby Ampio
provides corporate overhead services to Vyrix in exchange for $7,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated at any time by either party. Both agreements were assigned to the
Combined Company upon the closing of the Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer,
Dr.&nbsp;Bar-Or. The agreement, which was amended in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and development of Luoxis&#146; RedoxSYS system. In March 2014, Luoxis
also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019
and cannot be terminated prior to March 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review, Approval or Ratification of Transactions with Related Persons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the small size of our company, we do not at this time have a formal written policy regarding the review of related party transactions, and rely on our
full Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest. Our Board of Directors reviews any such transaction in light of the particular affiliation and interest of any involved director,
officer or other employee or stockholder and, if applicable, any such person&#146;s affiliates or immediate family members. Management aims to present transactions to our Board of Directors for approval before they are entered into or, if that is
not possible, for ratification after the transaction has occurred. If our Board of Directors finds that a conflict of interest exists, then it will determine the appropriate action or remedial action, if any. Our Board of Directors approves or
ratifies a transaction if it determines that the transaction is consistent with our best interests and the best interest of our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_11"></A>DESCRIPTION OF OUR SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 300,000,000
shares of common stock, no par value per share, and 5,000,000 shares of non-voting preferred stock, no par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;16, 2015, a
total of 173,597,365 shares of our common stock were issued and outstanding and no shares of our preferred stock were issued and outstanding. All of the outstanding and issued capital stock is, and will be, fully paid and non-assessable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to
one vote per share. Our Articles of Incorporation does not provide for cumulative voting. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available
funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption
or conversion rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights
of the holders of any series of preferred stock, which may be designated solely by action of the Board of Directors and issued in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Articles of Incorporation vests our
Board of Directors with authority to divide the preferred stock into series and to fix and determine the relative rights and preferences of the shares of any such series so established to the full extent permitted by the laws of the State of
Colorado and the Articles of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the preferred stock are not entitled to any voting rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;16, 2015, we have 465,250
outstanding warrants. Such warrants were originally issued by Luoxis in 2013 and were cancelled and exchanged for warrants to purchase shares of common stock of the Combined Company in connection with the Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of the Merger, each of
Vyrix and Luoxis had an option plan and had made equity grants thereunder. On April&nbsp;16, 2015, upon the closing of the Merger, all equity compensation plans of Vyrix and Luoxis were terminated and all the awards granted thereunder were
cancelled. See the section titled &#147;Market Price of and Dividends on Our Common Stock and Related Stockholder Matters &#150; Securities Authorized for Issuance under Equity Compensation Plans&#148; for further information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, we
have agreed to file, as soon as is reasonably practicable, one registration statement to register for resale under the Securities Act as many shares of our common stock held by persons who are not affiliates of Ampio as we determine we can
reasonably include with such registration statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent of our common stock is Standard Registrar and Transfer Agency. Their business address is 673 Bluebird Lane Northeast, Albuquerque, NM 87122
and their telephone number is (505)&nbsp;828-2839. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_12"></A>MARKET PRICE OF AND DIVIDENDS ON OUR COMMON STOCK AND RELATED
STOCKHOLDER MATTERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
common stock is quoted on the OTCQB under the symbol &#147;RSWN.&#148; The OTCQB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities. The OTCQB is a
quotation medium for subscribing members, not an issuer listing service, and should not be confused with the NASDAQ, NYSE or any other national exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;16, 2015, immediately prior to the closing of the Merger, there were 19,435,402 shares of our common stock outstanding and held by 131
stockholders of record. We have no shares of preferred stock issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, there is only a very limited public market for our common
stock on the OTCQB. You should also note that the OTCQB is not a listing service or exchange, but is instead a dealer quotation service for subscribing members. If our common stock is not quoted on the OTCQB or if a public market for our common
stock does not develop, then investors may not be able to resell the shares of our common stock that they have purchased and may lose all of their investment. If we do establish a trading market for our common stock, the market price of our common
stock may be significantly affected by factors such as actual or anticipated fluctuations in our operation results, general market conditions and other factors. In addition, the stock market has from time to time experienced significant price and
volume fluctuations that have particularly affected the market prices for the shares of developmental stage companies, which may materially adversely affect the market price of our common stock. Accordingly, investors may find that the price for our
securities may be highly volatile and may bear no relationship to our actual financial condition or results of operation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth
the range of high and low closing bid quotations for our common stock during our most recent two fiscal years on the OTCQB. The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent
actual transactions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:112.80pt; font-size:8pt; font-family:Times New Roman">Fiscal Year ended August&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Low</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:112.80pt; font-size:8pt; font-family:Times New Roman">Fiscal Year ended August 31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Low</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
not paid any cash dividends on our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in our operations. The declaration and payment of dividends in the future, of which there can be
no assurance, will be determined by the Board of Directors in light of conditions then existing, including earnings, financial condition, capital requirements and other factors. The Colorado law prohibits us from declaring dividends where, if after
giving effect to the distribution of the dividend: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we would not be able to pay our debts as they become due in the usual course of business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our total assets would be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as set forth above, there are no restrictions that currently materially limit our ability to pay dividends or which we reasonably
believe are likely to limit materially the future payment of dividends on common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has the right to authorize the issuance of
preferred stock, without further stockholder approval, the holders of which may have preferences over the holders of our common stock as to payment of dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Eligible for Future Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;16,
2015, there are 173,597,365 shares of our common stock outstanding, of which the former named executive officer of Rosewind beneficially own an aggregate of 2,340,569 shares. Of the outstanding shares of our common stock, only 201,152 shares are
freely tradeable, without restriction, as of April&nbsp;16, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rule 144 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, persons who have beneficially owned restricted ordinary shares for at least six months, and any affiliate of the company who owns either restricted
or unrestricted ordinary shares, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by Rule 144 under the Securities Act. A non-affiliated person who has beneficially owned
restricted securities within the meaning of Rule 144 for at least one year would be entitled to sell those shares without regard to the provisions of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a person who has beneficially owned restricted ordinary shares for at least six months would be entitled to sell their securities pursuant to Rule
144 under the Securities Act provided that (1)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (2)&nbsp;we have been subject to the Exchange Act periodic
reporting requirements for at least 90 days before the sale. Such sale by non-affiliates must also comply with the current public information provision of Rule 144. Persons who have beneficially owned restricted ordinary shares for at least six
months, but who are our affiliates at the time of, or at any time during the 90 days preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of
securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1.0% of the number of ordinary shares then outstanding, in the form of ADSs or otherwise, which will equal approximately ordinary shares immediately after the completion of the global offering based on the number of
ordinary shares outstanding as of , 2015; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of the ADSs on NASDAQ during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales by
affiliates must also comply with the manner of sale, current public information and notice provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lock-Up Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ampio entered into a lock-up agreement with the Combined Company agreeing not to sell its shares in the Combined Company until they are released. Ampio&#146;s
lock-up agreement releases Ampio&#146;s shares on the following schedule: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% on April&nbsp;16, 2017; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% on October&nbsp;16, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% on April&nbsp;16, 2018; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all remaining shares are released on October&nbsp;16, 2018. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ampio&#146;s lock-up agreement terminates upon a
change-of-control event of either the Combined Company or Ampio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of James Wiegand, a trust affiliated with Joshua Disbrow and a trust affiliated
with Jarrett Disbrow entered into a lock-up agreement with the Combined Company agreeing not to sell its shares in the Combined Company until they are released. Each of their lock-up agreements releases its shares on the following schedule: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% on June&nbsp;30, 2015; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all remaining shares are released on April&nbsp;16, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Wiegand entered into a lock-up agreement
with the Combined Company agreeing not to sell his shares in the Combined Company agreeing not to sell his shares in the Combined Company until they are released. His lock-up agreement releases his shares on the following schedule: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">25% as soon as Michael Wiegand may sell his shares without restriction under all applicable laws; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all remaining shares on April&nbsp;16, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under his lock-up agreement Michael Wiegand has agreed that he
is solely responsible for determining whether his shares are freely tradable and that the Combined Company makes no representations to him in that regard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the lock-up agreements for James Wiegand, the trust affiliated with Joshua Disbrow, the trust affiliated with Jarrett Disbrow and Michael Wiegand
terminates upon a change-of-control event of the Combined Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Penny Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities
with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided
by the exchange or system. Our stock is currently a &#147;penny stock.&#148; The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, deliver a standardized risk disclosure
document prepared by the SEC, which: (a)&nbsp;contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b)&nbsp;contains a description of the broker&#146;s or dealer&#146;s
duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws; (c)&nbsp;contains a brief, clear, narrative description of a dealer market,
including bid and ask prices for penny stocks and significance of the spread between the bid and ask price; (d)&nbsp;contains a toll-free telephone number for inquiries on disciplinary actions; (e)&nbsp;defines significant terms in the disclosure
document or in the conduct of trading in penny stocks; and (f)&nbsp;contains such other information and is in such form as the SEC shall require by rule or regulation. The broker-dealer also must provide to the customer, prior to effecting any
transaction in a penny stock, (a)&nbsp;bid and offer quotations for the penny stock; (b)&nbsp;the compensation of the broker-dealer and its salesperson in the transaction; (c)&nbsp;the number of shares to which such bid and ask prices apply, or
other comparable information relating to the depth and liquidity of the market for such stock; and (d)&nbsp;monthly account statements showing the market value of each penny stock held in the customer&#146;s account. In addition, the penny stock
rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the
purchaser&#146;s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitably statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These disclosure requirements may have the effect of reducing the trading activity in the secondary market for
our stock as it is subject to these penny stock rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Authorized for Issuance Under Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding the common stock that may be issued upon the exercise of options, warrants and other rights that
have been or may be granted to employees, directors or consultants under our existing equity compensation plans, as of April&nbsp;15, 2015. On April&nbsp;16, 2015, upon the closing of the Merger, all equity compensation plans of Vyrix and Luoxis
were terminated and all the awards granted thereunder were cancelled. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:49.10pt; font-size:8pt; font-family:Times New Roman"><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>to be issued upon<BR>exercise of<BR>outstanding options,<BR>warrants and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding&nbsp;options,<BR>warrants and rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities<BR>remaining&nbsp;available&nbsp;for<BR>future issuance under<BR>equity compensation<BR>plans (excluding<BR>securities
reflected in<BR>column (a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity compensation plans approved by security holders for Luoxis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,835,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity compensation plans approved by security holders for Vyrix</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Equity compensation plans not approved by security holders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,785,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,215,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_13"></A>RECENT SALES OF UNREGISTERED SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rosewind </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;17, 2012, Rosewind issued Craig
K. Olson 20,000 shares of our common stock in consideration of $3,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2012, Rosewind issued Ruth Harrison Revocable Trust 11,500 shares
of our common stock in consideration of $1,725. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;23, 2012, Rosewind issued Katherine Gould 33,334 shares of our common stock in
consideration for $5,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2013, Rosewind issued Sonja Gouak 8,000 shares of our common stock in exchange for services valued at $2,000.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2013, Rosewind issued Craig K. Olson 20,000 shares of our common stock in consideration for $3,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2014, Rosewind issued Ruth Harrison Revocable Trust 18,000 shares of our common stock in consideration for $2,700. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;19, 2014, Rosewind issued James B. Wiegand 600,000 shares of our common stock in consideration of cancelation of notes totaling $90,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2014, Rosewind issued Michael Wiegand 100,000 shares of our common stock in consideration of services valued at $15,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;8, 2014, Rosewind issued Larry Willis 100,000 shares of our common stock in consideration for $15,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2014, Rosewind issued Craig K. Olson 100,000 shares of our common stock in consideration of $15,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2015, Rosewind accepted a cash investment from two irrevocable trusts for estate planning of which Joshua Disbrow and Jarrett Disbrow are
beneficiaries. None of such persons have or share investment control over our shares held by such trusts. None of such persons, nor members of their respective immediate families, are trustees of such trusts. None of such persons have or share power
to revoke such trusts. Accordingly, under Rule 16a-8(b) and related rules, none of such persons has beneficial ownership over our shares purchased and held by such trusts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales and issuances
of the securities described in this section were exempt from registration either (a)&nbsp;under Section&nbsp;4(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any public
offering within the meaning of Section&nbsp;4(2), (b)&nbsp;Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c)&nbsp;under Regulation S promulgated
under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their relationships with Rosewind
to information about Rosewind. The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the
disclosure set forth under Item&nbsp;3.02 of this Current Report on Form 8-K regarding the issuance of shares of Rosewind&#146;s common stock to former stockholders of Vyrix and Luoxis upon the closing of the Merger, which disclosure is incorporated
herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vyrix </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2013, Vyrix issued 20,000,000 shares of its common stock to Ampio at a purchase price of $0.0001 per share, and in consideration of the transfer of certain intellectual property assets of Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, Vyrix has granted stock options to purchase 950,000 shares of its common stock at an exercise price of $0.70 per share to its officers and
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales
and issuances of the securities described in this section were exempt from registration either (a)&nbsp;under Section&nbsp;4(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did not involve any
public offering within the meaning of Section&nbsp;4(2), (b)&nbsp;Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c)&nbsp;under Regulation S
promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their relationships
with Vyrix, to information about Vyrix. The sales of these securities were made without any general solicitation or advertising. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Luoxis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2013, a total of 4,652,500 shares of Luoxis common stock were issued at $1.00 per share resulting in $4,653,000 of gross proceeds. Net proceeds were
$3,980,000 after placement agent and legal fees. The placement agent also received 465,250 warrants to purchase Luoxis common stock valued at $313,000 in connection with the closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, Luoxis has granted stock options to purchase 2,835,000 shares of its common stock at an exercise price of $1.00&#151;$1.60 per share to its
officers and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The
offers, sales and issuances of the securities described in this section were exempt from registration either (a)&nbsp;under Section&nbsp;4(2) of the Securities Act in that the transactions were between an issuer and sophisticated investors and did
not involve any public offering within the meaning of Section&nbsp;4(2), (b)&nbsp;Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans or contracts relating to compensation or (c)&nbsp;under
Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. All recipients had adequate access, through their
relationships with Luoxis, to information about Luoxis. The sales of these securities were made without any general solicitation or advertising. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_14"></A>INDEMNIFICATION OF OFFICERS AND DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Articles of Incorporation limit the liability of directors to the maximum extent permitted by Colorado law. Colorado law provides that directors of a
corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of their duty of loyalty to the corporation or its stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Bylaws provide that we will
indemnify our directors, officers, employees and other agents to the fullest extent permitted by law. We believe that indemnification under our Bylaws covers at least negligence and gross negligence on the part of indemnified parties. Our Bylaws
also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our Bylaws permit such indemnification.
We currently do not have directors&#146; and officers&#146; liability insurance, but we expect to have it in place within 60 days following this filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to enter into separate indemnification agreements with each of our directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required or permitted, and we are not
aware of any threatened litigation or proceedings that may result in a claim for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as an indemnification for liabilities arising
under the Securities Act may be permitted for directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC each indemnification is against public policy as expressed in the
Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and officers are indemnified by our Bylaws against amounts actually and necessarily incurred
by them in connection with the defense of any action, suit or proceeding in which they are a party by reason of being or having been our directors or officers or of our subsidiaries. Our Articles of Incorporation provide that none of our directors
or officers shall be personally liable for damages for breach of any fiduciary duty as a director or officer involving any act or omission of any such director or officer. Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to such directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that a claim for indemnification against such liabilities, other than the payment by us of expenses
incurred or paid by such director, officer or controlling person in the successful defense of any action, suit or proceeding, is asserted by such director, officer or controlling person in connection with the securities being registered, we will,
unless in the opinion of counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_15"></A>FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the financial statements and pro forma financial information contained in Item&nbsp;9.01 of this Current Report on Form 8-K, which is
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx912919_16"></A>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ON ACCOUNTING AND FINANCIAL DISCLOSURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the disclosure set forth in Item&nbsp;4.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_17"></A>Item&nbsp;3.02. Unregistered Sales of Equity Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the disclosure set forth under Item&nbsp;2.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference.
Upon the closing of the Merger, we issued 154,161,963 shares of our common stock to approximately 50 former stockholders of Vyrix and Luoxis in exchange for all of the outstanding shares of capital stock of Vyrix and Luoxis. The issuance and sale of
such securities was not registered under the Securities Act, and such securities were issued in reliance upon an exemption from registration afforded by Section&nbsp;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder
or under Regulation S promulgated under the Securities Act. In determining that the issuance of such securities qualified for an exemption under Section&nbsp;4(a)(2) of the Securities Act, we relied on the following facts: the securities were issued
to recipients that each represented that it was an &#147;accredited investor&#148; as defined in Rule 501 promulgated under the Securities Act, it was acquiring the securities for investment purposes and without a view toward disposition thereof,
and it had sufficient investment experience to evaluate the risks of the investment; we used no advertising or general solicitation in connection with the issuance and sale of the securities; and the securities were issued as restricted securities.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_18"></A>Item&nbsp;4.01. Changes in Registrant&#146;s Certifying Accountant. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Effective on April&nbsp;16, 2015 and with the approval of our Board of Directors, we dismissed HJ&nbsp;&amp; Associates, LLC, or HJ, as our independent
registered public accounting firm engaged to audit our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The report issued by HJ dated November&nbsp;26, 2014 relating to its audits
of our balance sheets as of August&nbsp;31, 2014 and 2013, and the related statements of operations, changes in stockholders&#146; equity (deficit) and cash flows for each of the fiscal years then ended, contained an explanatory paragraph stating
that there was substantial doubt about our ability to continue as a going concern. Other than as disclosed above, such reports did not contain an adverse opinion or disclaimer of opinion and were not qualified as to uncertainty, audit scope or
accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our decision to dismiss HJ is not the result of any disagreement between us and HJ on matters of accounting principles or
practices, financial statement disclosure or auditing scope or procedures. During our two most recent fiscal years, there were no disagreements with HJ on any matter of accounting principles or practices, financial statement disclosure or auditing
scope or procedures, which disagreements, if not resolved to the satisfaction of HJ, would have caused HJ to make a reference to the subject matter of the disagreement in connection with its reports. Pursuant to the rules of the SEC applicable to
smaller reporting companies, HJ was not required to provide an attestation as to the effectiveness of our internal control over financial reporting for any period since our inception. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as disclosed above, there were no reportable events (as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation S-K) during our two most
recent fiscal years. Our Board of Directors discussed the subject matter referred to above with HJ. We authorized HJ to respond fully and without limitation to all requests of our successor accountant concerning all matters related to the annual and
interim periods audited and reviewed by HJ, including with respect to the subject matter of any reportable event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provided HJ with a copy of the above
disclosures it is making in response to Item&nbsp;4.01 of this Current Report on Form 8-K and requested that HJ furnish a letter addressed to the SEC stating whether or not it agrees with the above statements, and, if not, stating the respects in
which it does not agree. A copy of the letter dated April&nbsp;22, 2015, is filed as Exhibit 16.1 to this Current Report on Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Effective on
April&nbsp;16, 2015 and with the approval of our Board of Directors, we have engaged EKS&amp;H LLLP, or EKS&amp;H, as our new independent registered public accounting firm. EKS&amp;H was engaged by Vyrix and Luoxis prior to the Merger to audit their
financial statements for the years ended December&nbsp;31, 2014 and 2013 and the related statements of operations, changes in stockholders&#146; deficit and cash flows for each of the years then ended and for the period through December&nbsp;31,
2014, which are filed as Exhibit 99.1 to this Current Report on Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During our two most recent fiscal years and through the date of our engagement
of EKS&amp;H, neither we nor anyone on our behalf consulted with EKS&amp;H regarding either (i)&nbsp;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be
rendered with respect to our financial statements, and no written report or oral advice was provided to us by EKS&amp;H that was an important factor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considered by us in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii)&nbsp;any matter that was the subject of a disagreement (as that term is defined in
Item&nbsp;304(a)(1)(iv) of Regulation S-K promulgated under the Securities Act and the related instructions) or a reportable event (as that term is defined in Item&nbsp;304(a)(1)(v) of Regulation S-K) relating to our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_19"></A>Item&nbsp;5.01. Changes in Control of Registrant. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the disclosure set forth under Item&nbsp;2.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_20"></A>Item&nbsp;5.02. Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangement of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Merger on April&nbsp;16, 2015, James B. Wiegand resigned from all his
executive positions and the Board of Directors of our company. Following such resignation, the member of our Board of Directors that was elected in connection with the closing of the Merger, as described below, the individuals appointed as the
executive officers of our company set forth under the heading &#147;Management&#151;Directors and Executive Officers&#148; in Item&nbsp;2.01 of this Current Report on Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information regarding compensation of our director and executive officers, see the disclosure under the heading &#147;Management&#148; and &#147;Related
Party Transactions&#148; in Item&nbsp;2.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information
regarding our equity incentive plans, see the disclosure under the heading &#147;Market Price of and Dividends on the Registrant&#146;s Common Equity and Related Stockholder Matters&#148; in Item&nbsp;2.01 of this Current Report on Form 8-K, which
disclosure is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For certain biographical, related party and other information regarding our newly appointed executive
officers, see the disclosure under the heading &#147;Management&#148; and &#147;Related Party Transactions&#148; in Item&nbsp;2.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Merger, Michael Macaluso was elected to the Board of Directors of our company to serve until the next annual stockholder
meeting or his earlier resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information regarding compensation of our directors, see the disclosure under the heading
&#147;Management.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the disclosure under the heading &#147;Security Ownership of Certain Beneficial Owners and Management&#148; for information
about the current beneficial ownership in our common stock of our director and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No standing committees of our Board of Directors have
been established and, as a result, no director is a member of any such committee. Because of Ampio&#146;s substantial equity ownership interest, we have agreed to appoint additional Ampio designees to our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For certain biographical, related party and other information regarding our newly appointed director, see the disclosure under the heading
&#147;Management&#148; and &#147;Related Party Transactions&#148; in Item&nbsp;2.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_21"></A>Item&nbsp;5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the approval of our Board of Directors, our fiscal year end has been changed from August&nbsp;31 to June&nbsp;30. The Merger is being accounted for
as a reverse acquisition, with Vyrix and Luoxis, collectively, regarded as the accounting acquirer. As a result, we filed with the this Form 8-K the financial statements of Vyrix and Luoxis as of the years ended December&nbsp;31, 2014 and 2013, and
commencing with the first periodic report we are to file under the Exchange Act, we intend to file annual and quarterly reports based on the June&nbsp;30 fiscal year end. Such financial statements will depict the operating results of Vyrix and
Luoxis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_22"></A>Item&nbsp;8.01. Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, the Combined Company issued a press release announcing that it had completed the Merger and the new management will host an investor
conference call on Friday, April&nbsp;24th, at 11:00am Mountain Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the press release is being furnished as Exhibit 99.3 to this Form 8-K and
is incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information under this Item&nbsp;8.01 and Exhibit 99.3 attached hereto is intended to be furnished and shall not
be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx912919_23"></A>Item&nbsp;9.01.&nbsp;Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) <U>Financial Statements of Businesses Acquired</U>. In accordance with Item&nbsp;9.01(a), the following are filed as exhibits to this Current Report on
Form 8-K: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Audited financial statements of Vyrix and Luoxis for the years ended December&nbsp;31, 2014 and 2013 are filed as Exhibit 99.1. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Forma Financial Information</U>. In accordance with Item&nbsp;9.01(b), the unaudited pro forma financial information of Rosewind and Vyrix and
Luoxis, as of and for the fiscal year ended December&nbsp;31, 2014 are filed as Exhibit 99.2 to this Current Report on Form 8-K. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Exhibits</U>.
Reference is made to the Exhibit Index following the signature page of this Current Report on Form 8-K, which is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;22, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua R. Disbrow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL>&nbsp;N<SMALL>O</SMALL>.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:87.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>ESCRIPTION</SMALL> <SMALL>OF</SMALL>
E<SMALL>XHIBIT</SMALL></B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement and Plan of Merger among Rosewind, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind, dated as of April 16, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Merger</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Articles of Incorporation, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant&#146;s Form SB-2/A filed March 7, 2007;<BR>File No. 333-139933)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement, to be entered into between the Registrant and its directors and officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between the Registrant and Joshua R. Disbrow, dated as of April 16, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement between the Registrant and Jarrett Disbrow, dated as of April 16, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Valeant International (Barbados) SRL, effective as of December 2, 2011 (incorporated by reference to Exhibit 10.24 to Ampio&#146;s<BR>Form 10-K
filed February 9, 2012; File No. 001-35182)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Manufacturing and Supply Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Ethypharm S.A., dated September 10, 2012 (incorporated by reference to Exhibit 10.2 to Ampio&#146;s Form 10-Q filed November 2, 2012;
File No. 001-35182)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License, Development and Commercialization Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011 (incorporated by reference to Exhibit 10.1 to
Ampio&#146;s Form 8-K/A filed October 5, 2011; File No. 001-35182)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Distribution Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and FBM Industria Farmaceutica, Ltda., dated as of March 1, 2012</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Distribution and License Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated September 1, 2009 (incorporated by reference to Exhibit 10.5 to Ampio Pharmaceuticals, Inc.&#146;s<BR>Form 8-K/A
filed March 17, 2010; File No. 333-146542)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Addendum No. 4 to Sponsor Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated March 17, 2014 (incorporated by reference to Exhibit 10.2 to Ampio Pharmaceuticals, Inc.&#146;s
Form 10-Q filed May 7, 2014; File No. 001-35182)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Promissory Note issued by Ampio to the Registrant on April 16, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subscription Agreement between the Registrant and Ampio, dated April 16, 2015</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Voting Agreement between the Registrant and Ampio, dated April&nbsp;21, 2015 (incorporated by reference to Exhibit 10.1 to Ampio&#146;s Form 8-K filed April&nbsp;22, 2015; File No. 001-35182)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Letter from HJ &amp; Associates, LLC, dated April 22, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Audited Combined Financial Statements of Vyrix and Luoxis, for the fiscal years ended December 31, 2014 and 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Pro Forma Financial Information giving effect to the acquisition of Vyrix and Luoxis</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.3</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Press Release issued by the Registrant on April 16, 2015, furnished herewith</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Application has been made to the Securities and Exchange Commission for confidential treatment of certain provisions. Omitted material for which confidential treatment has been requested has been filed separately with
the Securities and Exchange Commission. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Indicates a management contract or any compensatory plan, contract or arrangement. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d912919dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>This Agreement and Plan of Merger (the &#147;Agreement&#148;) contains representations, warranties and covenants that: were made only for purposes of
the Agreement and as of specific dates; were solely for the benefit of the parties to the Agreement; may be subject to limitations agreed upon by the parties to the Agreement, including being qualified by confidential disclosures made for the
purposes of allocating contractual risk among the parties to the Agreement instead of establishing those matters as facts; and may be subject to standards of materiality applicable to the parties to the Agreement that differ from those applicable to
investors. Rosewind&#146;s shareholders and other investors are not third-party beneficiaries under the Agreement and should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual
state of facts or condition of Rosewind or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Agreement, which subsequent
information may or may not be fully reflected in public disclosures by Rosewind. </I></B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>This <B>AGREEMENT AND PLAN OF MERGER</B> (this &#147;<B>Agreement</B>&#148;), dated as of April&nbsp;16, 2015 is made by and among
James&nbsp;B. Wiegand and Michael&nbsp;B. Wiegand (each, a &#147;<B>Parent Major Stockholder</B>&#148; and collectively, the &#147;<B>Parent Major Stockholders</B>&#148;), Rosewind Corporation, a Colorado corporation (&#147;<B>Parent</B>&#148;),
Rosewind Merger Sub V, Inc., a Delaware corporation (&#147;<B>Vyrix Merger Sub</B>&#148;), Vyrix Pharmaceuticals, Inc., a Delaware corporation (&#147;<B>Vyrix</B>&#148;), Rosewind Merger Sub L, Inc., a Delaware corporation (&#147;<B>Luoxis Merger
Sub</B>&#148; and, collectively with Vyrix Merger Sub, the &#147;<B>Merger Subs</B>&#148; and each, a &#147;<B>Merger Sub</B>&#148;), and Luoxis Diagnostics, Inc., a Delaware corporation (&#147;<B>Luoxis</B>&#148; and, collectively with Vyrix, the
&#147;<B>Companies</B>&#148; and each, a &#147;<B>Company</B>&#148;).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Parent has approved, and the respective
Boards of Directors of Vyrix Merger Sub and Vyrix have adopted, approved and declared advisable, this Agreement and the merger of Vyrix Merger Sub with and into Vyrix with Vyrix surviving (the &#147;<B>Vyrix Merger</B>&#148;), on the terms and
subject to the conditions provided for in this Agreement;<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Parent has approved, and the respective Boards of
Directors of Luoxis Merger Sub and Luoxis have adopted, approved and declared advisable, this Agreement and the merger of Luoxis Merger Sub with and into Luoxis with Luoxis surviving (the &#147;<B>Luoxis Merger</B>&#148; and, collectively with the
Vyrix Merger, the &#147;<B>Mergers</B>&#148; and each, a &#147;<B>Merger</B>&#148;), on the terms and subject to the conditions provided for in this Agreement;<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, immediately following approval and adoption of this Agreement by the Board of Directors of Vyrix (the &#147;<B>Vyrix
Board</B>&#148;), the holders of the outstanding voting securities of Vyrix will unanimously adopt and approve this Agreement and the Vyrix Merger as required under the General Corporation Law of the State of Delaware (the &#147;<B>DGCL</B>&#148;)
and will execute and deliver an action by written consent evidencing the same (the &#147;<B>Vyrix Stockholder Consent</B>&#148;);<B> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, immediately following approval and adoption of this Agreement by the Board of
Directors of Luoxis (the &#147;<B>Luoxis Board</B>&#148;), the holders of a sufficient number of the outstanding voting securities of Luoxis will adopt and approve this Agreement and the Luoxis Merger as required under the DGCL and will execute and
deliver an action by written consent evidencing the same (the &#147;<B>Luoxis Stockholder Consent</B>&#148; and, collectively with the Vyrix Stockholder Consent, the &#147;<B>Company Stockholder Consents</B>&#148; and each, a &#147;<B>Company
Stockholder Consent</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Parent Major Stockholders, Parent, the Merger Subs and the Companies desire that
each of the Mergers, taken together with the merger of the Surviving Corporations (as defined in <U>Section&nbsp;2.1(ii)</U>) with and into Parent, with Parent surviving (as described in <U>Section&nbsp;2.5(c)</U>), qualify as a tax-free
reorganization under Section&nbsp;368(a)(1)(A) of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW,
THEREFORE</B>, for and in consideration of the foregoing and the representations, warranties, covenants and agreements set forth in this Agreement, the Parties agree as follows:<B> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
AND USAGE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>Defined Terms</U>. For the purposes of this Agreement, the following terms have the meanings set forth
below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly or indirectly controlling,
controlled by, or under common control with such Person. For purposes of this definition, a Person is deemed to &#147;control&#148; an Entity if such Person, directly or indirectly: (i)&nbsp;has the power to direct the management or policies of such
Entity; or (ii)&nbsp;owns, beneficially or of record (a)&nbsp;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity&#146;s Board of
Directors or other governing body, or (b)&nbsp;at least fifty percent (50%)&nbsp;of the outstanding equity or financial interests of such Entity. The Parent Major Stockholders are deemed to be Affiliates of Parent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning ascribed thereto in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Applicable Law</B>&#148; means, with respect to any Person, any international, federal, state, local or foreign statute, code,
ordinance, rule, regulation, consent, approval, judgment, Order, writ, decree, injunction or other authorization, treaty, convention, or governmental requirement of any Governmental Authority that is binding upon, or applicable to, such Person.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Assignment and Assumption Agreement</B>&#148; means the Assignment and Assumption Agreement to be entered into on the
Closing Date among the Companies and Parent, and to be consented to by Company Parent, in substantially the form of <U>Exhibit&nbsp;F</U>.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Business Day</B>&#148; means any day other than a Saturday, Sunday or any day on which banks in the State of&nbsp;New York are
authorized or required by federal law to be closed.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Claim</B>&#148; means claims, demands, charges, complaints,
actions, causes of action, suits, proceedings, hearings or administrative proceedings.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Code</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Companies Balance Sheet</B>&#148; means the balance sheet of the Companies included in the Companies Financial Statements.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company</B>&#148; and &#147;<B>Companies</B>&#148; have the meaning ascribed to them in the Preamble.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Acquisition Proposal</B>&#148; means any proposal for a merger or other business combination involving either of the
Companies or for the acquisition of a substantial equity interest in either of them or any material part of the assets of either of them.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Board</B>&#148; and &#147;<B>Company Boards</B>&#148; mean the Vyrix Board and the Luoxis Board, or either or both of
them, as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Companies Financial Statements</B>&#148; means the unaudited, combined financial
statements as at December&nbsp;31, 2014 of the Companies.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Material Adverse Effect</B>&#148; means a
Material Adverse Effect with respect to either of the Companies.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Parent</B>&#148; means Ampio
Pharmaceuticals, Inc., a Delaware corporation.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Parent Board</B>&#148; means the Board of Directors of
Company Parent.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Parent Stock Purchase</B>&#148; means the purchase by Company Parent of Parent Common
Stock from Parent at the Closing for (i)&nbsp;issuance to Parent by Company Parent of a promissory note in the principal amount of $10,000,000, (ii)&nbsp;Company Parent cancellation of indebtedness of Luoxis to Company Parent in the amount of
$8,000,000 and (iii)&nbsp;Company Parent cancellation of indebtedness of Vyrix to Company Parent in the amount of $4,000,000, all on terms, and subject to conditions and documentation, satisfactory to each of Company Parent and Parent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Stock</B>&#148; means Vyrix Stock and Luoxis Stock, or either or both of them, as the context may require.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company Stockholder Consent</B>&#148; and &#147;<B>Company Stockholder Consents</B>&#148; have the meaning ascribed to them in
the Recitals.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Consulting Agreement</B>&#148; means the Consulting Agreement to be entered into at the Closing
between Parent and James B. Wiegand substantially in the form of <U>Exhibit D</U>.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Contract</B>&#148; means any
agreement, arrangement, commitment or instrument, written or oral, including, any loan or credit agreement or other agreement evidencing Indebtedness, promissory note, bond, mortgage, indenture, guarantee, permit, lease, sublease, license, agreement
to render services, or other agreement, arrangement, commitment or instrument evidencing rights or obligations of any kind or nature, including all amendments, modifications, supplements and options relating thereto.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>DGCL</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Disclosure Letter</B>&#148; and &#147;<B>Disclosure Letters</B>&#148; mean the Parent Disclosure Letter and the Company
Disclosure Letter, or either or both of them, as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Employment Agreement</B>&#148; and
&#147;<B>Employment Agreements</B>&#148; mean the employment agreements to be entered into at the Closing between Parent and each of Joshua Disbrow and Jarrett Disbrow, in substantially the form of <U>Exhibit&nbsp;E</U>, or either or both of them,
as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Entity</B>&#148; means any corporation (including any non-profit corporation), general
partnership, limited partnership, limited liability partnership, limited liability company, joint venture, estate, trust, company (including any limited liability company or joint stock company), firm or other enterprise, association, organization
or entity.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Environmental, Health and Safety Laws</B>&#148; means any present or future Applicable Laws relating to
(a)&nbsp;emissions, discharges, releases or threatened releases of Hazardous Materials into the environment, including into ambient air, soil, sediments, land surface or subsurface, buildings or facilities, surface water, groundwater, publicly-owned
treatment works, or septic systems, (b)&nbsp;the generation, treatment, storage, disposal, use, handling, manufacturing, recycling, transportation or shipment of Hazardous Materials, (c)&nbsp;occupational health and safety, or (d)&nbsp;the pollution
of the environment, solid waste handling, treatment or disposal, reclamation or remediation activities, or protection of environmentally sensitive areas.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Equity Interests</B>&#148; means (a)&nbsp;with respect to a corporation, any and all shares, equity securities, interests,
profit participations, stock appreciation rights, phantom stock plans or other equivalents (however designated) of corporate stock, including all common stock, preferred stock and other equity and voting interests, and warrants, options, calls,
subscriptions or other convertible securities or other rights to acquire any of the foregoing, and (b)&nbsp;with respect to a partnership, limited liability company or similar Person, any and all units, membership or other interests, including
rights to purchase, warrants, options, calls, subscriptions or other equivalents of, or other interests convertible into, any beneficial or legal ownership interest in such Person.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>GAAP</B>&#148; means generally accepted accounting principles, as recognized by the U.S. Financial Accounting Standards Board
(or any generally recognized successor).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Governmental Authority</B>&#148; means (a)&nbsp;the United States of
America, (b)&nbsp;any state, county, municipality, or other governmental subdivision within the U.S., (c)&nbsp;any court or any governmental department, commission, board, bureau, agency, or other instrumentality of the U.S. or of any state, county,
municipality, water rights, taxing, or zoning authority, or other governmental subdivision within the U.S. and (d)&nbsp;any foreign government or agency having jurisdiction over any Party.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Hazardous Material</B>&#148; means any chemical, pollutant, contaminant, material, waste or substance regulated by any Governmental
Authority under Environmental, Health and Safety Law, including, but not limited to, any hazardous waste, hazardous substance, toxic substance, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
radioactive material (including any naturally occurring radioactive material), asbestos-containing materials in any form or condition, polychlorinated biphenyls in any form or condition, or
petroleum, petroleum hydrocarbons, petroleum products or any fraction or byproducts thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>&#147;<I></I><B>Indebtedness</B><I></I>&#148; of any Person means and includes any obligations consisting of (a)&nbsp;the outstanding
principal amount of and accrued and unpaid interest on, and other payment obligations for, borrowed money, or payment obligations issued or incurred in substitution or exchange for payment obligations for borrowed money, (b)&nbsp;amounts owing as
deferred purchase price for property or services, including &#147;earn out&#148; payments, (c)&nbsp;payment obligations evidenced by any promissory note, bond, debenture, mortgage or other debt instrument or debt security, (d)&nbsp;commitments or
obligations by which such Person assures a creditor against loss, including contingent reimbursement obligations with respect to letters of credit, (e)&nbsp;payment obligations secured by a Lien, other than a Permitted Lien, on assets or properties
of such Person, (f)&nbsp;obligations to repay deposits or other amounts advanced by and owing to third parties, (g)&nbsp;obligations under capitalized leases, (h)&nbsp;obligations under any interest rate, currency or other hedging agreement or
derivatives transaction, (i)&nbsp;guarantees or other contingent liabilities with respect to any amounts of a type described in clauses&nbsp;(a) through (h)&nbsp;above, and (j)&nbsp;any change of control payments or prepayment premiums, penalties,
charges or equivalents thereof with respect to any indebtedness, obligation or liability of a type described in clauses (a)&nbsp;through (i)&nbsp;above that are required to be paid at the time of, or the payment of which would become due and payable
solely as a result of, the execution of this Agreement or the consummation of the transactions contemplated by this Agreement at such time, in each case determined in accordance with GAAP; <I>provided, however</I>, that Indebtedness shall not
include accounts payable to trade creditors and accrued expenses arising in the ordinary course of business consistent with past practices and shall not include the endorsement of negotiable instruments for collection in the ordinary course of
business.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Intellectual Property</B>&#148; means all U.S. and foreign (a)&nbsp;patents and patent applications and
all reissues, renewals, divisions, extensions, provisional patents, continuations and continuations in part thereof, (b)&nbsp;inventions (regardless of whether patentable), invention disclosures, trade secrets, proprietary information, industrial
designs and registrations and applications, mask works and applications and registrations therefor, (c)&nbsp;copyrights and copyright applications and corresponding rights, (d)&nbsp;trade dress, trade names, logos, URLs, common law trademarks and
service marks, registered trademarks and trademark applications, registered service marks and service mark applications, (e)&nbsp;domain name rights and registrations, (f)&nbsp;databases, customer lists, data collections and rights therein, and
(g)&nbsp;confidentiality rights or other intellectual property rights of any nature, in each case throughout the world.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Knowledge</B>&#148; means, with respect to any Person, the actual (but not constructive) knowledge of such Person or such
Person&#146;s officers after reasonable inquiry. With respect to Parent, &#147;Knowledge&#148; also includes the Knowledge of the Parent Major Stockholders and of the Merger Subs. With respect to each of the Companies, &#147;Knowledge&#148; includes
the Knowledge of the other Company.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; means any lien, mortgage, security interest, indenture, deed of trust,
pledge, deposit, restriction, burden, encumbrance, license, lease, sublease, right of first refusal, right of first offer, charge, privilege, easement, right of way, reservation, option, preferential purchase right, preemptive right, right of a
vendor under any title retention or conditional sale agreement, or other arrangement substantially equivalent thereto, in each case regardless of whether relating to the extension of credit or the borrowing of money. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Lock-up Agreement</B>&#148; and &#147;<B>Lock-up Agreements</B>&#148; mean
(i)&nbsp;with respect to the Parent Major Stockholders, Lock-up Agreements substantially in the form of <U>Exhibit&nbsp;B-1</U>, and (ii)&nbsp;with respect to Company Parent, a Lock-up Agreement substantially in the form of <U>Exhibit&nbsp;B-2</U>,
or any or all of them, as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis</B>&#148; has the meaning ascribed thereto in the
Preamble.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Board</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Common Stock</B>&#148; means common stock, $0.0001 par value per share, of Luoxis.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Merger</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Merger Sub</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Merger Sub Board</B>&#148; means the Board of Directors of Luoxis Merger Sub.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Merger Sub Common Stock</B>&#148; means the common stock of Luoxis Merger Sub, $0.001 par value per share.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Preferred Stock</B>&#148; means preferred stock, $0.0001 par value per share, of Luoxis.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Stock</B>&#148; means Luoxis Common Stock and Luoxis Preferred Stock, or either or both of them, as the context may
require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Luoxis Stockholder Consent</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Material Adverse Effect</B>&#148; means, with respect to any of the Parties, any change, event, circumstance or effect whether
or not such change, event, circumstance or effect is caused by or arises in connection with a breach of a representation, warranty, covenant or agreement of such Party or Parties in this Agreement or any of the Transaction Documents that is or is
reasonably likely to be materially adverse to the business, assets (including intangible assets), capitalization, financial condition, operations or results of operations of such Party or Parties, except to the extent that any such change, event,
circumstance or effect results from (i)&nbsp;changes in general economic conditions that do not have a disproportionate effect on such Party or (ii)&nbsp;changes affecting the industry generally in which such Party or Parties operate that do not
have a disproportionate effect on such Party.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Merger</B>&#148; and &#147;<B>Mergers</B>&#148; has the meaning
ascribed to them in the Recitals.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Merger Sub</B>&#148; and &#147;<B>Merger Subs</B>&#148; have the meaning
ascribed to them in the Preamble.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Merger Sub Common Stock</B>&#148; means Luoxis Merger Sub Common Stock and Vyrix
Merger Sub Common Stock, or either or both of them, as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Order</B>&#148; means any order,
writ, fine, injunction, decree, judgment, award or enforceable determination of any Governmental Authority.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent</B>&#148; has the meaning ascribed thereto in the Preamble.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Acquisition Proposal</B>&#148; means any proposal for a merger or other business combination involving Parent or either
of the Merger Subs or for the acquisition of a substantial equity interest in any of them or any material part of the assets of any of them.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Board</B>&#148; means the Board of Directors of Parent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Common Stock</B>&#148; means common stock, no par value per share, of Parent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Major Stockholder</B>&#148; and &#147;<B>Parent Major Stockholders</B>&#148; have the meaning ascribed to them in the
Preamble.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Major Stockholder Indebtedness</B>&#148; means all Indebtedness of Parent to James&nbsp;B.
Wiegand.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Major Stockholder Release</B>&#148; and &#147;<B>Parent Major Stockholder Releases</B>&#148; mean,
with respect to each of the Parent Major Stockholders, the release executed by such Parent Major Stockholder in substantially the form of <U>Exhibit&nbsp;C</U>, or either of both of them, as the context may require.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Material Adverse Effect</B>&#148; means a Material Adverse Effect with respect to any of Parent, the Merger Subs and
the Parent Major Stockholders.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Permitted Payables</B>&#148; means all of the following, up to the aggregate
amount of $25,000 and in each case as of the Closing Date: (i)&nbsp;accrued expenses of Parent, (ii)&nbsp;accounts payable of Parent not representing any out-of-pocket expenses, travel expenses or payments to Parent Major Stockholders or other
holders of Parent Stock, (iii)&nbsp;Parent Major Stockholder Indebtedness and (iv)&nbsp;other Indebtedness of Parent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Preferred Stock</B>&#148; means preferred stock, no par value per share, of Parent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Quarterly Report</B>&#148; means the Quarterly Report on Form 10-Q of Parent for Parent&#146;s fiscal quarter ended
February&nbsp;28, 2015.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Parent Stock</B>&#148; means Parent Common Stock and Parent Preferred Stock, or either or
both of them, as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Party</B>&#148; or &#147;<B>Parties</B>&#148; means, the Parent Major
Stockholders, Parent, the Merger Subs and the Companies, or any or all of them, as the context may require.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Permitted Liens</B>&#148; means (a)&nbsp;Liens for Taxes, assessments or other
governmental charges or levies that are not yet due and payable or that are being contested in good faith by appropriate proceedings and for which adequate reserves have been established and described in the applicable Disclosure Letter,
(b)&nbsp;Liens in connection with workmen&#146;s compensation, unemployment insurance or other social security, old age pension or public liability obligations not yet due or which are being contested in good faith by appropriate proceedings and for
which adequate reserves in accordance with GAAP have been established and described in the applicable Disclosure Letter, (c)&nbsp;operators&#146;, vendors&#146;, suppliers&#146;, carriers&#146;, warehousemen&#146;s, repairmen&#146;s,
mechanics&#146;, workmen&#146;s, materialmen&#146;s, or construction Liens (during repair or upgrade periods) or other like Liens arising by operation of Applicable Law in the ordinary course of business or statutory landlord&#146;s Liens, each of
which is in respect of obligations that have not been outstanding more than 90 days (so long as no action has been taken to file or enforce such Liens within said 90-day period) or which are being contested in good faith, or (d)&nbsp;any other Lien,
encumbrance or other imperfection of title that does not materially affect the value or use of the property subject thereto or has been incurred in the ordinary course of business.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Person</B>&#148; means any natural person or Entity.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Preamble</B>&#148; means the preamble to this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Recitals</B>&#148; means the recitals to this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Securities Laws</B>&#148; means the Securities Act, the Exchange Act, SOX, the Investment Company Act of 1940, the Investment
Advisors Act of 1940, the Trust Indenture Act of 1939, each as amended, and the rules and regulations of any Governmental Authority promulgated thereunder.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>SOX</B>&#148; means the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated thereunder.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, (a)&nbsp;any corporation of which such Person owns, either
directly or through its Subsidiaries, more than 50% of the total combined voting power of all classes of voting securities of such corporation, or (b)&nbsp;any partnership, association, joint venture, limited liability company or other business
organization, regardless of whether such business organization constitutes a legal entity, in which such Person directly or indirectly owns more than 50% of the total Equity Interests.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; or &#147;<B>Taxes</B>&#148; (including with correlative meaning, &#147;<B>Taxable</B>&#148;) means any federal,
foreign, state or local tax, including any income, gross income, gross receipts, ad valorem, excise, sales, use, value added, admissions, business, occupation, license, franchise, margin, capital, net worth, customs, premium, real property, personal
property, intangibles, capital stock, transfer, profits, windfall profits, severance, fuel, utility, payroll, social security, employment, withholding, disability, stamp, rent, recording, registration, alternative minimum, add-on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
minimum, or other tax, assessment, duty, fee, levy or other governmental charge of any kind whatsoever imposed by a Governmental Authority (a &#147;<B>Tax Authority</B>&#148;), together with and
including any and all interest, fines, penalties, assessments and additions to tax resulting from, relating to, or incurred in connection with any such tax or any contest or dispute thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Tax Return</B>&#148; means any report, return, document, declaration or other information (including any attached schedules
and any amendments to such report, return, document, declaration or other information) required to be supplied to or filed with any Tax Authority with respect to any Tax, including an information return and any document with respect to or
accompanying payments, deposits or estimated Taxes, or with respect to or accompanying requests for the extension of time in which to file any such report, return, document, declaration or other information.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Third Party</B>&#148; means any Person other than any of the Parties and their respective Affiliates.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Transaction Documents</B>&#148; means this Agreement, the Parent Disclosure Letter, the Company Disclosure Letter, the
Employment Agreements, the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements, the Parent Major Stockholder Releases, the Consulting Agreement, the Assignment and Assumption Agreement and any and all other documents and agreements entered
into by any of the Parties in connection with the Merger and the other transactions contemplated hereunder.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Transfer Agent</B>&#148; means Standard Registrar and Transfer Agency or any other transfer agent or trust company designated
by the Companies prior to the Effective Time.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vessel</B>&#148; means the vessel &#147;Six String&#148; registered
in the United States with official number 1092464.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vessel Mortgage</B>&#148; means the undocumented mortgage in
favor of James&nbsp;B. Wiegand constituting a Lien against the Vessel as security for payment of the Parent Major Stockholder Indebtedness.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix</B>&#148; has the meaning ascribed thereto in the Preamble.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Board</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Common Stock</B>&#148; means common stock, $0.0001 par value per share, of Vyrix.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Merger</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Merger Sub</B>&#148; has the meaning ascribed thereto in the Recitals.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Merger Sub Board</B>&#148; means the board of directors of Vyrix Merger Sub.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Merger Sub Common Stock</B>&#148; means the common stock of Vyrix Merger Sub, $0.001 par value per share.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Preferred Stock</B>&#148; means preferred stock, $0.0001 par value per share, of Vyrix.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Stock</B>&#148; means Vyrix Common Stock and Vyrix Preferred Stock, or
either of both of them, as the context may require.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Vyrix Stockholder Consent</B>&#148; has the meaning ascribed
thereto in the Recitals.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>References and Titles</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) All references in this Agreement to Exhibits, Schedules, Articles, Sections, subsections and other subdivisions refer to the corresponding
Exhibits, Schedules, Articles, Sections, subsections and other subdivisions of or to this Agreement, unless expressly provided otherwise. Titles appearing at the beginning of any Articles, Sections, subsections or other subdivisions of this
Agreement are for convenience only, do not constitute any part of this Agreement, and shall be disregarded in construing the language hereof. The words &#147;this Agreement,&#148; &#147;herein,&#148; &#147;hereby,&#148; &#147;hereunder&#148; and
&#147;hereof,&#148; and words of similar import, refer to this Agreement as a whole and not to any particular Article, Section, subsection or subdivision unless expressly so limited. The words &#147;this Article&#148; and &#147;this Section,&#148;
and words of similar import, refer only to the Article, Section&nbsp;or subsection hereof in which such words occur. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The word
&#147;or&#148; is not exclusive, and the word &#147;including&#148; (in its various forms) means including without limitation. Pronouns in masculine, feminine or neuter genders shall be construed to state and include any other gender, and words,
terms and titles (including terms defined herein) in the singular form shall be construed to include the plural and vice versa, unless the context otherwise requires. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) A reference in this Agreement to any statute shall be to such statute as amended from time to time, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE MERGERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>The Mergers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(i) Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, at the
Effective Time Luoxis Merger Sub shall be merged with and into Luoxis, the separate corporate existence of Luoxis Merger Sub shall thereupon cease and Luoxis shall continue as the corporation surviving the Luoxis Merger (the &#147;<B>Luoxis
Surviving Corporation</B>&#148;). <B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(ii) Upon the terms and subject to the conditions set forth in this
Agreement, and in accordance with the DGCL, at the Effective Time Vyrix Merger Sub shall be merged with and into Vyrix, the separate corporate existence of Vyrix Merger Sub shall thereupon cease and Vyrix shall continue as the corporation surviving
the Vyrix Merger (the &#147;<B>Vyrix Surviving Corporation</B>&#148; and, collectively with the Luoxis Surviving Corporation, the &#147;<B>Surviving Corporations</B>&#148; and each, a &#147;<B>Surviving Corporation</B>&#148;). <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Effective Time</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(i) Subject to the terms and conditions of this Agreement, the Luoxis Merger shall become effective upon the filing of a
Certificate of Merger in respect thereof with the Secretary of State of the State of Delaware in substantially the form of <U>Exhibit A-1</U> (the &#147;<B>Luoxis Certificate of Merger</B>&#148;) in accordance with Section&nbsp;252 of the DGCL. Such
time of filing the Luoxis Certificate of Merger is referred to in this Agreement as the &#147;<B>Luoxis Effective Time</B>.&#148;<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(ii) Subject to the terms and conditions of this Agreement, the Vyrix Merger shall become effective upon the filing of a
Certificate of Merger in respect thereof with the Secretary of State of the State of Delaware in substantially the form of <U>Exhibit A-2</U> (the &#147;<B>Vyrix Certificate of Merger</B>&#148; and, collectively with the Luoxis Certificate of
Merger, the &#147;<B>Certificates of Merger</B>&#148; and each, a &#147;<B>Certificate of Merger</B>&#148;) in accordance with Section&nbsp;252 of the DGCL. Such time of filing the Vyrix Certificate of Merger is referred to in this Agreement as the
&#147;<B>Vyrix Effective Time</B>.&#148;<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(iii) The Parties agree that neither of the Certificates of Merger
will be filed unless both of them will be filed. Subject to the terms and conditions of this Agreement, the Parties intend to file the Certificates of Merger simultaneously. Accordingly, the Luoxis Effective Time and the Vyrix Effective Time are
referred to in this Agreement collectively as the &#147;<B>Effective Time</B>.&#148;<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Closing</U>. The closing
of the Mergers (the &#147;<B>Closing</B>&#148;) shall occur at the Effective Time. The date of the Closing is referred to in this Agreement as the &#147;<B>Closing Date</B>.&#148; The Closing shall occur at the offices of Goodwin Procter LLP, 620
Eighth Avenue, New York, New York 10018. At the Closing, all of the documents, certificates, agreements and instruments referenced in <U>Article 7</U> will be executed and delivered as described in this Agreement. At the Effective Time, all actions
taken at the Closing shall be deemed to be taken simultaneously. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Effects of the Mergers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The Luoxis Merger shall have the effects set forth in this Agreement and the DGCL. Without limiting the generality of the
foregoing, and subject thereto, at the Effective Time all of the respective properties, rights, privileges, powers and franchises of Luoxis and Luoxis Merger Sub shall vest in the Luoxis Surviving Corporation, and all of the respective debts,
liabilities and duties of Luoxis and Luoxis Merger Sub shall become the debts, liabilities and duties of the Luoxis Surviving Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) The Vyrix Merger shall have the effects set forth in this Agreement and the DGCL. Without limiting the generality of the
foregoing, and subject thereto, at the Effective Time all of the respective properties, rights, privileges, powers and franchises of Vyrix and Vyrix Merger Sub shall vest in the Vyrix Surviving Corporation, and all of the respective debts,
liabilities and duties of Vyrix and Vyrix Merger Sub shall become the debts, liabilities and duties of the Vyrix Surviving Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <U>Post-Closing Actions</U>. The Parties intend that, as soon as is reasonably
practicable after the Effective Time: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Parent Board will increase the size of Parent Board by one (1)&nbsp;member and appoint the
individual listed on <U>Schedule 2.5(a)</U> to fill the vacancy created by such increase, after which the Parent Major Stockholder member of Parent Board will resign from Parent Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Parent will adopt a stock option plan approved by the Parent Board and Parent shall reserve up to 10,000,000 shares of Parent Common Stock
for allocation among management and former holders of Luoxis Options and Vyrix Options pursuant to such stock option plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) each of the
Surviving Corporations will merge with and into Parent, with Parent surviving; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Parent will conduct a reverse stock split of all
outstanding shares of Parent Common Stock at a ratio, and on other terms, determined by the Parent Board; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Parent will re-domicile as a
Delaware corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Parent will adopt as its Certificate of Incorporation an amended and restated Certificate of Incorporation
approved by the Parent Board and renaming Parent as Aytu Bioscience, Inc.; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Parent will adopt as its Bylaws amended and restated Bylaws
approved by the Parent Board; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) the Parent Board will appoint as officers of Parent the individuals listed on <U>Schedule 2.5(h)</U>
and will remove from office all other officers of Parent. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGER CONSIDERATION AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EFFECT OF THE MERGERS ON CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <U>Effect on Capital Stock of Luoxis</U>. At the Effective Time, by virtue of the Luoxis Merger and without any action on the
part of the holder of any shares of capital stock of Luoxis or Luoxis Merger Sub: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Conversion of the Luoxis Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Each share of Luoxis Merger Sub Common Stock outstanding immediately prior to the Effective Time shall, by virtue of the
Merger and without any action on the part of the holder thereof, be converted into the right to receive one (1)&nbsp;share of common stock, $0.001 par value per share, of the Luoxis Surviving Corporation, so that at the Effective Time, Parent shall
be the holder of all of the outstanding shares of the Luoxis Surviving Corporation; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(ii) Each outstanding share, other than Dissenting Shares, of Luoxis Stock
shall be converted into and represent the right to receive 2.685 (the &#147;<B>Luoxis Exchange Factor</B>&#148;) validly issued, fully paid and nonassessable shares of Parent Common Stock (the &#147;<B>Luoxis Merger Consideration</B>&#148;). No
fractional shares of Parent Common Stock will be issued. All Luoxis Stock, including any treasury shares, shall no longer be outstanding and shall be automatically canceled and retired and shall cease to exist, and each holder of a certificate
representing any shares of outstanding Luoxis Stock (the &#147;<B>Luoxis Share Certificates</B>&#148;) shall cease to have any rights with respect thereto, except (i)&nbsp;for all shares of outstanding Luoxis Stock other than Dissenting Shares, the
right to receive the Luoxis Merger Consideration, without interest, and (ii)&nbsp;for Dissenting Shares, rights pursuant to <U>Section&nbsp;3.1(e)</U>.<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Luoxis Treasury Shares</U>. Each share of Luoxis Stock held in the treasury of Luoxis shall be cancelled in the Luoxis Merger and cease
to exist. No Luoxis Merger Consideration shall be paid or payable in respect of any shares of Luoxis Stock held in the treasury of Luoxis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Luoxis Options.</U> All options to purchase shares of Luoxis Stock, whether vested or unvested (the &#147;<B>Luoxis Options</B>&#148;),
shall be cancelled without further action by the holder thereof. Prior to the Closing, Luoxis shall make cash payments to holders of Luoxis Options, the exercise price of which exceeds the per share value of Luoxis Common Stock (as determined by
Luoxis), in consideration of the cancellation of such Luoxis Options, provided, that the aggregate of such cash payments, combined with the aggregate of cash payments in respect of Vyrix Options made pursuant to <U>Section&nbsp;3.2(c)</U>, shall not
exceed $30,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Luoxis Warrants</U>. All warrants to purchase shares of Luoxis Stock (the &#147;<B>Luoxis Warrants</B>&#148;),
shall be cancelled and exchanged for warrants to purchase shares of Parent Common Stock (&#147;<B>Parent Warrants</B>&#148;) without further action by the holder thereof. Each Parent Warrant exchanged for a Luoxis Warrant shall constitute a warrant
to acquire such number of shares of Parent Common Stock as is equal to the number of shares of Luoxis Stock subject to the unexercised portion of such Luoxis Warrant multiplied by the Luoxis Exchange Factor (with any fraction resulting from such
multiplication to be rounded to the nearest whole number, and with 0.5 shares rounded upward to the nearest whole number). The exercise price per share of each such Parent Warrant shall be equal to the exercise price of such Luoxis Warrant prior to
conversion divided by the Luoxis Exchange Factor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Shares of Dissenting Stockholders</U>. Notwithstanding anything in this Agreement
to the contrary, shares of Luoxis Stock that are outstanding immediately prior to the Effective Time and which are held by a stockholder who did not vote in favor of the Luoxis Merger (or consent thereto in writing) and who is entitled to demand and
properly demands appraisal of such shares pursuant to, and who, in all respects, complies with the provisions of, Section&nbsp;262 of the DGCL (&#147;<B>Dissenting Shares</B>&#148;), shall not be converted into or be exchangeable for the right to
receive the Luoxis Merger Consideration, but instead each holder of Dissenting Shares (the &#147;<B>Dissenting Stockholders</B>&#148;), shall be entitled to payment of the fair value of such Dissenting Stockholder&#146;s Dissenting Shares in
accordance with the provisions of Section&nbsp;262 of the DGCL (and at the Effective Time, such Dissenting Shares shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and such Dissenting Stockholder shall
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cease to have any rights with respect thereto, except the right to receive the fair value of such Dissenting Shares in accordance with the provisions of Section&nbsp;262 of the DGCL), unless and
until such Dissenting Stockholder shall have failed to perfect or shall have effectively waived, withdrawn or lost rights to appraisal under the DGCL (or a court of competent jurisdiction shall determine that such Dissenting Stockholder is not
entitled to the relief provided by Section&nbsp;262 of the DGCL). If any Dissenting Stockholder shall have failed to perfect or shall have effectively waived, withdrawn or lost such right (or a court of competent jurisdiction shall determine that
such Dissenting Stockholder is not entitled to the relief provided by Section&nbsp;262 of the DGCL), such Dissenting Stockholder&#146;s shares of Luoxis Stock shall thereupon be treated as if they had been converted into and become exchangeable for
the right to receive, as of the Effective Time, the Luoxis Merger Consideration for each such share of Luoxis Stock, as provided herein, without any interest thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <U>Effect on Capital Stock of Vyrix</U>. At the Effective Time, by virtue of the Vyrix Merger and without any action on the
part of the holder of any shares of capital stock of Vyrix or Vyrix Merger Sub: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Conversion of the Vyrix Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Each share of Vyrix Merger Sub Common Stock outstanding immediately prior to the Effective Time shall, by virtue of the
Merger and without any action on the part of the holder thereof, be converted into the right to receive one (1)&nbsp;share of common stock, $0.001 par value per share, of the Vyrix Surviving Corporation, so that at the Effective Time, Parent shall
be the holder of all of the outstanding shares of the Vyrix Surviving Corporation; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(ii) Each outstanding share
of Vyrix Stock shall be converted into and represent the right to receive 1.5 (the &#147;<B>Vyrix Exchange Factor</B>&#148;) validly issued, fully paid and nonassessable shares of Parent Common Stock (the &#147;<B>Vyrix Merger
Consideration</B>&#148; and, collectively with the Luoxis Merger Consideration the &#147;<B>Merger Consideration</B>&#148;). No fractional shares of Parent Common Stock will be issued. All Vyrix Stock, including any treasury shares, shall no longer
be outstanding and shall be automatically canceled and retired and shall cease to exist, and each holder of a certificate representing any shares of outstanding Vyrix Stock (the &#147;<B>Vyrix Share Certificates</B>&#148; and, collectively with the
Luoxis Share Certificates the &#147;<B>Company Share Certificates</B>&#148; and each, a &#147;<B>Company Share Certificate</B>&#148;) shall cease to have any rights with respect thereto, except for the right to receive the Merger Consideration,
without interest.<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Vyrix Treasury Shares</U>. Each share of Vyrix Stock held in the treasury of Vyrix shall be cancelled in
the Vyrix Merger and cease to exist. No Vyrix Merger Consideration shall be paid or payable in respect of any shares of Vyrix Stock held in the treasury of Vyrix. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Vyrix Options</U>. All options to purchase shares of Vyrix Stock, whether vested or unvested (the &#147;<B>Vyrix Options</B>&#148;),
shall be canceled without further action by the holder thereof. Prior to the Closing, Vyrix shall make cash payments to holders of Vyrix Options, the exercise price of which exceeds the per share value of Vyrix Common Stock (as determined by Vyrix),
in consideration of the cancellation of such Vyrix Options, provided, that the aggregate of such cash payments, combined with the aggregate of cash payments in respect of Luoxis Options made pursuant to <U>Section&nbsp;3.1(c)</U>, shall not exceed
$30,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Exchange of Company Share Certificates</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Exchange Agent</U>. Prior to the Effective Time, Parent shall designate the Transfer Agent to act as agent for the holders of Company
Stock (the &#147;<B>Exchange Agent</B>&#148;) to receive in trust the Merger Consideration to which such holders become entitled hereunder. From time to time, Parent shall make available, or cause the applicable Surviving Corporation to make
available, to the Exchange Agent certificates (or evidence of book-entry shares of Parent Common Stock) representing the aggregate number of shares of Parent Common Stock to be issued as Merger Consideration in exchange for Company Stock in amounts
and at times necessary for the prompt payment of the Merger Consideration upon surrender of Company Share Certificates as provided herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange Procedure</U>. As soon as is reasonably practicable after the Effective Time, the Exchange Agent (with respect to Company
Stock) and Parent (with respect to Luoxis Warrants) shall mail to each holder of record of a Company Share Certificate or Luoxis Warrant a letter of transmittal in form satisfactory to the Companies specifying that delivery shall be effected, and
risk of loss and title to Company Share Certificates or Luoxis Warrants, as applicable, shall pass, only upon delivery of Company Share Certificates or Luoxis Warrants, as applicable, to the Exchange Agent including instructions for surrendering of
Company Share Certificates or Luoxis Warrants, as applicable, in exchange for the Merger Consideration or Parent Warrants, as applicable. Upon surrender of a Company Share Certificate or Luoxis Warrant, as applicable, to the Exchange Agent, together
with such letter of transmittal, duly executed, and such other documents as may reasonably be required by the Exchange Agent, the holder of such Company Share Certificate or Luoxis Warrant, as applicable, shall be entitled to receive the Merger
Consideration or Parent Warrants, as applicable, as provided herein and such Company Share Certificate or Luoxis Warrant, as applicable, shall be deemed canceled. In the event of a transfer of ownership of shares of Company Stock that is not
registered in the transfer records of the applicable Company, payment may be made to a Person other than the Person in whose name the surrendered Company Share Certificate or Luoxis Warrant, as applicable, is registered, if such Company Share
Certificate or Luoxis Warrant, as applicable, is properly endorsed or otherwise in proper form for transfer and the Person requesting such payment shall pay any transfer or other taxes required by reason of the payment of Merger Consideration or
Parent Warrants, as applicable, to a Person other than the registered holder of such Company Share Certificate or Luoxis Warrant, as applicable, or establish to the satisfaction of the Surviving Corporation that such tax has been paid or is not
applicable. Until surrendered as contemplated by this <U>Section&nbsp;3.3</U>, each Company Share Certificate or Luoxis Warrant, as applicable, shall be deemed at any time after the Effective Time to represent only the right to receive upon
surrender the Merger Consideration or Parent Warrants, as applicable, without interest, which the shares of Company Stock or Luoxis Warrants, as applicable, theretofore represented by such Company Share Certificate or Luoxis Warrant, as applicable,
shall have been entitled to receive pursuant to <U>Section&nbsp;3.1</U> or <U>Section&nbsp;3.2</U>, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>No Further Ownership Rights; Transfer Books</U>. The Merger Consideration or Parent
Warrants, as applicable, paid upon surrender of Company Share Certificates or Luoxis Warrants, as applicable, in accordance with this <U>Article 3</U> shall be deemed to have been paid in full satisfaction of all rights pertaining to the Company
Stock theretofore represented by such Company Share Certificates or Luoxis Warrants, as applicable. At the Effective Time, the stock transfer books of each of the Companies shall be closed, and there shall be no further transfers of Company Stock or
Luoxis Warrants. If, after the Effective Time, Company Share Certificates or Luoxis Warrants, as applicable, representing shares of Company Stock or Luoxis Warrants, as applicable, outstanding prior to the Effective Time, other than Dissenting
Shares, are presented to Parent or the Surviving Corporation, such Company Share Certificates or Luoxis Warrants, as applicable, shall be canceled and exchanged for Merger Consideration or Parent Warrants, as applicable, in respect thereof pursuant
to this Agreement in accordance with the procedures set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Lost, Stolen or Destroyed Certificates</U>. In the event any
Company Share Certificates representing shares of Company Stock outstanding prior to the Effective Time, other than Dissenting Shares, or Luoxis Warrants, have been lost, stolen or destroyed, the Exchange Agent shall pay to the holder thereof the
Merger Consideration or Parent Warrants, as applicable, required pursuant to <U>Section&nbsp;3.1</U> or <U>Section&nbsp;3.2</U>, as applicable in exchange for such lost, stolen or destroyed Company Share Certificates or Luoxis Warrants, as
applicable, upon the making of an affidavit of that fact by such holder with such assurances as the Exchange Agent in its discretion and as a condition precedent to the payment of the Merger Consideration or Parent Warrants, as applicable, may
reasonably require of such holder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>As an inducement for the Companies to enter into this Agreement, Parent, the Merger Subs and the Parent Major Stockholders hereby
jointly and severally make the following representations and warranties to the Companies; <B></B><I>provided, however</I><B></B>, that such representations and warranties are subject to and qualified by the disclosure letter delivered by Parent to
the Companies on the date hereof, each section of which qualifies the correspondingly numbered representation and warranty to the extent specified therein (the &#147;<B>Parent Disclosure Letter</B>&#148;), it being understood that (i)&nbsp;the
disclosure of any fact or item in any Section&nbsp;of the Parent Disclosure Letter shall, should the existence of such fact or item be relevant to any other section, be deemed to be disclosed with respect to that other Section&nbsp;to the extent
that such disclosure is made in a manner that makes its relevance to the other Section&nbsp;reasonably apparent and (ii)&nbsp;the disclosure of any matter or item in the Parent Disclosure Letter shall not be deemed to constitute an acknowledgement
that such matter or item is required to be disclosed therein or is material to a representation or warranty set forth in this Agreement and shall not be used as a basis for interpreting the terms &#147;material,&#148; &#147;materially,&#148;
&#147;materiality,&#148; &#147;Parent Material Adverse Effect&#148; or any word or phrase of similar import and does not mean that such matter or item, alone or together with any other matter or item, would constitute a Parent Material Adverse
Effect.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <U>Corporate Existence; Good Standing; Corporate Authority</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Parent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Parent is a corporation duly incorporated, validly existing and in good standing under the Applicable Laws of the State of
Colorado. Parent is duly qualified to conduct business and is in good standing in each jurisdiction in which the ownership, operation or lease of its property or the nature of its business requires such qualification, except for jurisdictions in
which any failures to be so qualified or to be in good standing, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Parent Material Adverse Effect. Parent has all requisite corporate
power and authority to own or lease and operate its properties and assets and to carry on its business as it is currently being conducted. Each of the Articles of Incorporation and Bylaws of Parent (the &#147;<B>Parent Charter Documents</B>&#148;)
is in full force and effect, has not been amended or modified and has not been terminated, superseded or revoked. Parent is not in violation of the Parent Charter Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) The minute books of Parent provided to the Companies each contain true, correct and complete minutes and records of all
meetings, proceedings and other actions of the stockholders of Parent, the Parent Board and committees of the Parent Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Luoxis
Merger Sub</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Luoxis Merger Sub is a corporation duly incorporated, validly existing and in good standing under the
laws of the State of Delaware. Luoxis Merger Sub does not carry on any business or other operations. Each of the Certificate of Incorporation and Bylaws of Luoxis Merger Sub (the &#147;Luoxis Merger Sub Charter Documents&#148;) is in full force and
effect, has not been amended or modified and has not been terminated, superseded or revoked. Luoxis Merger Sub is not in violation of the Luoxis Merger Sub Charter Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) The minute books of Luoxis Merger Sub provided to the Companies prior to the date of this Agreement each contain true,
correct and complete minutes and records of all meetings, proceedings and other actions of the stockholders of Luoxis Merger Sub, the Luoxis Merger Sub Board and committees of the Luoxis Merger Sub Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Vyrix Merger Sub</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(i) Vyrix Merger Sub is a corporation duly incorporated, validly existing and in good standing under the laws of the
State of Delaware. Vyrix Merger Sub does not carry on any business or other operations. Each of the Certificate of Incorporation and Bylaws of Vyrix Merger Sub (the &#147;<B>Vyrix Merger Sub Charter Documents</B>&#148; and, collectively with the
Luoxis Merger Sub Charter Documents, the &#147;<B>Merger Sub Charter Documents</B>&#148;) is in full force and effect, has not been amended or modified and has not been terminated, superseded or revoked. Vyrix Merger Sub is not in violation of the
Vyrix Merger Sub Charter Documents.<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) The minute books of Vyrix Merger Sub provided to the Companies prior to
the date of this Agreement each contain true, correct and complete minutes and records of all meetings, proceedings and other actions of the stockholders of Vyrix Merger Sub, the Vyrix Merger Sub Board and committees of the Vyrix Merger Sub Board.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Authorization, Validity and Effect of Agreement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Authority</U>. Each of Parent and the Merger Subs has the requisite corporate power and authority to execute and deliver this Agreement
and all other Transaction Documents to which it is, or is contemplated to become, a party, to perform its obligations hereunder and thereunder and to consummate the Mergers and all other transactions contemplated hereunder and thereunder. The
execution, delivery and performance of this Agreement and the Transaction Documents and the consummation of the Mergers and the other transactions contemplated hereunder and thereunder have been duly authorized by all requisite corporate and
stockholder action on behalf of Parent and the Merger Subs, and require no other corporate proceedings by Parent or the Merger Subs or action or approval by stockholders of Parent, except for the filing of the Certificates of Merger pursuant to the
DGCL. Each of the Parent Board and the Merger Sub Boards, by unanimous written consents, (i)&nbsp;determined that this Agreement, the Transaction Documents to which Parent, or such Merger Sub, as applicable, is, or is contemplated to become, a
party, the Mergers and the other transactions contemplated hereby and thereby are advisable, fair to and in the best interests of Parent and Parent&#146;s stockholders, and each of the Merger Subs and Parent (as the sole stockholder of each of the
Merger Subs), and (ii)&nbsp;approved this Agreement, such Transaction Documents, the Merger and the other transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Binding Obligations</U>. This Agreement and each of the Transaction Documents to which any of Parent and the Merger Subs is, or is
contemplated to become, a party, have been or will at or before the Closing be duly executed by it and, assuming the due authorization, execution and delivery hereof and thereof by the Companies to the extent a party hereof and thereof, constitute
its valid and legally binding obligations, enforceable against it in accordance with their respective terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Applicable Laws relating to or affecting the rights and
remedies of creditors generally and to general principles of equity (regardless of whether considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>Capitalization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Of Parent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Authorized and Outstanding Shares</U>. The authorized capital stock of Parent consists of 300,000,000 shares of Parent
Common Stock and 5,000,000 shares of Parent Preferred Stock. There are 19,435,402 shares of Parent Common Stock outstanding. The offer, issuance and sale of such outstanding shares of Parent Common Stock were (A)&nbsp;either made pursuant to a
registration statement effective under the Securities Laws or exempt from the registration and prospectus delivery requirements of the Securities Act, (B)&nbsp;registered or qualified (or were exempt from registration or qualification) under the
registration or qualification requirements of all applicable state securities laws and (C)&nbsp;accomplished in conformity with all other applicable Securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Laws. None of such outstanding shares of Parent Common Stock are subject to a right of withdrawal or a right of rescission under any federal or state securities or &#147;Blue Sky&#148; law. The
Parent Common Stock is eligible for registration under the Exchange Act. There are no shares of Parent Stock held in Parent&#146;s treasury. There are no outstanding shares of Parent Preferred Stock. There are no outstanding options, warrants,
convertible securities or similar rights to acquire Parent Stock (&#147;<B>Parent Equity Rights</B>&#148;) and no shares of Parent Stock are reserved for issuance in respect of Parent Equity Rights. There are no outstanding or authorized stock
appreciation, phantom stock, profit participation or other similar rights with respect to Parent Stock. All outstanding shares of Parent Common Stock are duly authorized, validly issued, fully paid and nonassessable, and free and clear of all Liens.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <U>Other Equity Interests</U>. Other than the outstanding shares of Parent Common Stock referenced in
<U>Section&nbsp;4.3(a)(i)</U>, Parent has not issued, sold, granted or delivered, and has no outstanding, Equity Interests, bonds, debentures, promissory notes or other Indebtedness, the holders of which have the right to vote with the stockholders
of Parent on any matter, or which are convertible or exercisable for Equity Interests having the right to vote. Parent is not obligated to issue, sell, grant or deliver (or to cause to be issued, sold, granted or delivered), and is not party to any
Contract or other obligation to issue, sell, grant or deliver, any Equity Interest (including, any securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind pursuant to which a Person is entitled
to acquire an Equity Interest) of any nature or any additional shares of capital stock or any other Equity Interest in Parent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Parent Equity Rights</U>. There are no outstanding or authorized (i)&nbsp;contractual or other obligations of Parent
to repurchase, redeem or otherwise acquire any Equity Interest of Parent or any Parent Equity Rights, or (ii)&nbsp;voting trusts or similar agreements to which Parent or any Parent Major Stockholder is a party with respect to voting of the capital
stock of Parent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <U>Share Quotation</U>. The shares of Parent Common Stock are quoted on the OTCQB Market under the
symbol &#147;RSWN&#148;. Parent is in compliance in all material respects with all of the respective rules and regulations of OTC Markets, Inc. applicable to it and to the Parent Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) <U>No Orders, Proceedings or Investigations</U>. No order suspending the effectiveness of any registration statement in
respect of Parent Common Stock has been issued by the SEC and, to Parent&#146;s Knowledge, no proceedings for that purpose have been initiated by the SEC. Parent is not, and has not ever been, and none of Parent&#146;s past or present directors,
officers, employees or Affiliates are, or have ever been, the subject of any civil, criminal or administrative proceeding or investigation by any Governmental Authority, including any such proceeding or investigation with respect to any alleged
violation of any of the Securities Laws. None of Parent, the Merger Subs and the Parent Major Stockholders has any reason to believe that Parent or any of its officers, directors, employees or Affiliates will be the subject of any such proceeding or
investigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) <U>Parent Stockholders</U>. Section&nbsp;4.3(a)(vi) of the Parent Disclosure
Letter contains a true and complete list of the names of the record owners of all of the outstanding shares of Parent Common Stock and other Equity Interests of Parent, together with the number of securities held or to which such Person has rights
to acquire. To Parent&#146;s Knowledge, there is no voting trust, agreement or arrangement among any of the beneficial holders of Parent Common Stock affecting the nomination or election of directors or the exercise of the voting rights of Parent
Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Of Luoxis Merger Sub.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Authorized and Outstanding Shares</U>. The authorized capital stock of Luoxis Merger Sub consists of 1,000 shares of
Luoxis Merger Sub Common Stock. There are 100 shares of Luoxis Merger Sub Common Stock outstanding and no shares of Luoxis Merger Sub Common Stock are held in Luoxis Merger Sub&#146;s treasury. There are no outstanding options, warrants, convertible
securities or similar rights to acquire Luoxis Merger Sub Common Stock (&#147;<B>Luoxis Merger Sub Equity Rights</B>&#148;). There are no shares of Luoxis Merger Sub Common Stock reserved for issuance with respect to any Luoxis Merger Sub Equity
Rights. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Luoxis Merger Sub Common Stock. All outstanding shares of Luoxis Merger Sub Common Stock are owned by
Parent and are duly authorized, validly issued, fully paid and nonassessable, and free and clear of all Liens. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Other Equity Interests</U>. Other than the outstanding shares of Luoxis Merger Sub Common Stock referenced in <U>Section&nbsp;4.3(b)(i)</U>, Luoxis Merger Sub has not issued, sold, granted or delivered, and has no outstanding, Equity Interests,
bonds, debentures, promissory notes or other Indebtedness, the holders of which have the right to vote with the stockholders of Luoxis Merger Sub on any matter, or which are convertible or exercisable for Equity Interests having the right to vote.
Luoxis Merger Sub is not obligated to issue, sell, grant or deliver (or to cause to be issued, sold, granted or delivered), and is not party to any Contract or other obligation to issue, sell, grant or deliver, any Equity Interest (including, any
securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind pursuant to which a Person is entitled to acquire an Equity Interest) of any nature or any additional shares of capital stock or any
other Equity Interest in Luoxis Merger Sub. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Luoxis Merger Sub Equity Rights</U>. There are no outstanding or
authorized (i)&nbsp;contractual or other obligations of Luoxis Merger Sub to repurchase, redeem or otherwise acquire any Equity Interest of Luoxis Merger Sub or any Luoxis Merger Sub Equity Rights, or (ii)&nbsp;voting trusts or similar agreements to
which Luoxis Merger Sub or Parent is a party with respect to voting of the capital stock of Luoxis Merger Sub. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Of Vyrix Merger Sub</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Authorized and Outstanding Shares</U>. The authorized capital stock of Vyrix Merger Sub consists of 1,000 shares of
Vyrix Merger Sub Common Stock. There are 100 shares of Vyrix Merger Sub Common Stock outstanding and no shares of Vyrix Merger Sub Common Stock are held in Vyrix Merger Sub&#146;s treasury. There are no outstanding options, warrants, convertible
securities or similar rights to acquire Vyrix Merger Sub Common Stock (&#147;<B>Vyrix Merger Sub Equity Rights</B>&#148; and, collectively with the Luoxis Merger Sub Equity Rights, the &#147;<B>Merger Sub Equity Rights</B>&#148;). There are no
shares of Vyrix Merger Sub Common Stock reserved for issuance with respect to any Vyrix Merger Sub Equity Rights. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to
Vyrix Merger Sub Common Stock. All outstanding shares of Vyrix Merger Sub Common Stock are owned by Parent and are duly authorized, validly issued, fully paid and nonassessable, and free and clear of all Liens. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <U>Other Equity Interests</U>. Other than the outstanding shares of Vyrix Merger Sub Common Stock referenced in
<U>Section&nbsp;4.3(c)(i)</U>, Vyrix Merger Sub has not issued, sold, granted or delivered, and has no outstanding, Equity Interests, bonds, debentures, promissory notes or other Indebtedness, the holders of which have the right to vote with the
stockholders of Vyrix Merger Sub on any matter, or which are convertible or exercisable for Equity Interests having the right to vote. Vyrix Merger Sub is not obligated to issue, sell, grant or deliver (or to cause to be issued, sold, granted or
delivered), and is not party to any Contract or other obligation to issue, sell, grant or deliver, any Equity Interest (including, without limitation, any securities, options, warrants, calls, rights, commitments, agreements, arrangements or
undertakings of any kind pursuant to which a Person is entitled to acquire an Equity Interest) of any nature or any additional shares of capital stock or any other Equity Interest in Vyrix Merger Sub. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Vyrix Merger Sub Equity Rights</U>. There are no outstanding or authorized (i)&nbsp;contractual or other obligations
of Vyrix Merger Sub to repurchase, redeem or otherwise acquire any Equity Interest of Vyrix Merger Sub or any Vyrix Merger Sub Equity Rights, or (ii)&nbsp;voting trusts or similar agreements to which Vyrix Merger Sub or Parent is a party with
respect to voting of the capital stock of Vyrix Merger Sub. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4 <U>Subsidiaries</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Of Parent</U>. Parent has no Subsidiaries other than the Merger Subs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Of Luoxis Merger Sub</U>. Luoxis Merger Sub has no Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Of Vyrix Merger Sub</U>. Vyrix Merger Sub has no Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5 <U>Compliance with Laws; Permits</U>. Except for (x)&nbsp;matters relating to Taxes, which are treated exclusively in
<U>Section&nbsp;4.10</U>, (y)&nbsp;matters relating to employment, which are treated exclusively under <U>Section&nbsp;4.11</U> and (z)&nbsp;matters arising under Environmental, Health and Safety Laws, which are treated exclusively in
<U>Section&nbsp;4.13</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) None of Parent and the Merger Subs is in material violation of any Applicable Law relating to the ownership
or operation of any of its assets, and no Claim is pending or, to the Knowledge of Parent, threatened with respect to any such matters; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>(b) Each of Parent and the Merger Subs holds all permits, licenses, certifications,
variations, exemptions, Orders, franchises, registrations, filings, approvals, authorizations or other required grant of operating authority required by any Governmental Authority necessary for the conduct of its business and the ownership or lease,
as applicable, of its properties (the &#147;<B>Parent Permits</B>&#148;). All Parent Permits are in full force and effect and there exists no default thereunder or breach thereof. Parent has not received any notice and has no Knowledge (i)&nbsp;that
any Parent Permit is being, is threatened to be, or will be, terminated, cancelled or reformed, (ii)&nbsp;that any Parent Permit will not be renewed or (iii)&nbsp;of any condition or requirement that must be satisfied or met in order for any Parent
Permit to be renewed.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6 <U>No Conflict; Consents</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>No Conflict</U>. The execution and delivery by each of Parent, the Merger Subs and the Parent Major Stockholders of this Agreement and
the Transaction Documents to which it is, or is contemplated to become, a party, the performance of its obligations hereunder and thereunder and the consummation by it of the Mergers and the other transactions contemplated hereby and thereby in
accordance with the terms hereof and thereof will not, as applicable, (i)&nbsp;conflict with or result in a breach of the Parent Charter Documents or the Merger Sub Charter Documents, (ii)&nbsp;violate, conflict with, result in a breach of any
provision of, constitute a default (or an event which, with notice or lapse of time or both, would constitute a default) under, impair its rights under, alter the rights or obligations of third parties under, result in the termination of or in a
right of termination or cancellation of, give rise to a right of purchase under, or accelerate the performance required by, any Parent Contract or other Contract to which it is a party or by which any of its properties or assets are bound,
(iii)&nbsp;result in the creation of any Lien (other than Permitted Liens) upon any of its properties or assets under any Parent Contract or other Contract to which it is a party or by which any of its properties or assets are bound,
(iv)&nbsp;result in any Parent Contract or other Contract to which it is a party or by which any of its properties or assets are bound being declared void, voidable, or without further binding effect, or (v)&nbsp;contravene, conflict with or
constitute a violation of any provision of any Applicable Law binding upon or applicable to it, other than any such violations, conflicts, breaches, defaults, impairments, alterations, terminations, cancellations, purchase rights, accelerations or
Liens that, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Parent Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Required Consents</U>. Neither the execution and delivery by each of Parent and the Merger Subs of this Agreement and the other
Transaction Documents to which it is, or is contemplated to become, a party, nor the consummation by it of the Mergers and the other transactions contemplated hereby and thereby in accordance with the terms hereof or thereof will require any
consent, approval or authorization of, notice to or filing or registration with any Governmental Authority, other than the filing of the Certificates of Merger with the Secretary of State of the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7 <U>SEC Documents</U>. Parent has filed with the SEC all documents required to be so filed by it, pursuant to
Sections&nbsp;13(a), 14(a) and 15(d) of the Exchange Act (collectively, the &#147;<B>Parent Reports</B>&#148;). As of its respective date or, if amended by a subsequent filing prior to the date hereof, on the date of such filing, each Parent Report
has complied in all material respects with all applicable requirements of the Exchange Act, SOX and the rules and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations promulgated thereunder, and did not (i)&nbsp;contain any untrue statement of a material fact or (ii)&nbsp;omit to state a material fact required to be stated therein or necessary to
make the statements made therein, in the light of the circumstances under which they were made, not misleading. Each of the balance sheets included in or incorporated by reference into the Parent Reports (including the related notes and schedules)
fairly presents in all material respects the financial position of Parent as of its date, and each of the statements of operations, cash flows and changes in stockholders&#146; equity included in or incorporated by reference into the Parent Reports
(including any related notes and schedules) fairly presents in all material respects the results of operations, cash flows or changes in stockholders&#146; equity, as the case may be, of Parent for the periods set forth therein (such balance sheets
and statements of operations, cash flows and changes in stockholders&#146; equity, each including the notes and schedules thereto, the &#147;<B>Parent Financial Statements</B>&#148;). The Parent Financial Statements (i)&nbsp;complied as to form in
all material respects with the published rules and regulations of the SEC and (ii)&nbsp;were prepared in accordance with GAAP consistently applied during the periods involved, except as may be noted in the Parent Financial Statements or as permitted
by <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> or <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> Except as and to the extent adequately accrued or reserved against in the audited
balance sheet of Parent as at August&nbsp;31, 2014, Parent does not have any liability, indebtedness, expense, claim, deficiency, guaranty or obligation of any type or nature, whether accrued, absolute, contingent, matured, unmatured or otherwise,
whether known or unknown and whether or not required by GAAP to be reflected in a balance sheet of Parent or disclosed in the notes thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8 <U>Litigation</U>. There is not now, nor has there ever been, any litigation, arbitration, mediation, action, suit, Claim,
proceeding or investigation, whether legal or administrative, pending against any of Parent and the Merger Subs or, to Parent&#146;s Knowledge, threatened against any of Parent and the Merger Subs or any of their respective assets, properties or
operations, at Applicable Law or in equity, before or by any Governmental Authority or any Order of any Governmental Authority in respect of which the amount in contention exceeds $10,000 for any one matter or $25,000 in the aggregate. None of
Parent, the Merger Subs and the Parent Major Stockholders is, or has ever been, the subject of any voluntary or involuntary bankruptcy or insolvency proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9 <U>Absence of Certain Changes</U>. Since August&nbsp;31, 2014, there has not been (a)&nbsp;any Parent Material Adverse
Effect, (b)&nbsp;any event or occurrence that could reasonably be expected to have or cause a Parent Material Adverse Effect, (c)&nbsp;any material change by any of Parent and the Merger Subs in accounting or Tax methods, principles or practices, or
(d)&nbsp;any declaration, setting aside or payment of any dividend or distribution in respect of any capital stock of any of Parent and the Merger Subs or any redemption, purchase or other acquisition of any of capital stock of any of Parent and the
Merger Subs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <U>Taxes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In all material respects: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Each of Parent and the Merger Subs has filed, or has caused to be filed on its behalf, all Tax Returns required to be filed
by or on behalf of it in the manner prescribed by Applicable Law. All such Tax Returns are complete and correct. Each of Parent and the Merger Subs has timely paid all Taxes due and owing, and, in accordance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with GAAP, the most recent Parent Financial Statements contained in the Parent Reports reflect a reserve (excluding any reserve for deferred Taxes established to reflect timing differences
between book and Tax income) for all Taxes payable by any of Parent and the Merger Subs for all Taxable periods and portions thereof through the date of such Parent Financial Statements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) No Tax Return of any of Parent and the Merger Subs is under audit or examination by any Governmental Authority, and no
written or, to the Knowledge of Parent, unwritten notice of such an audit or examination has been received by any of Parent and the Merger Subs. There is no assessed deficiency, refund litigation, proposed adjustment or matter in controversy with
respect to any Taxes due and owing by any of Parent and the Merger Subs; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Since August&nbsp;31, 2014, none of Parent
and the Merger Subs has made or rescinded any election relating to Taxes or settled or compromised any Claim, action, suit, litigation, proceeding, arbitration, investigation, audit or controversy relating to any Taxes, or made any change to any of
its methods of reporting income or deductions for federal income Tax purposes from those employed in the preparation of their most recently filed federal Tax Returns; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) There are no agreements or other documents extending, or having the effect of extending, the period of assessment or
collection of any material Taxes and no power of attorney with respect to any such Taxes has been executed or filed with any Tax Authority by or on behalf of any of Parent and the Merger Subs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) Except for statutory Liens for Taxes not yet due, no Liens for Taxes exist with respect to any assets or properties of any
of Parent and the Merger Subs; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) Except for any agreements or arrangements (A)&nbsp;with customers, vendors, lessors or
similar Persons entered into in the ordinary course of business, the principal purpose of which is not related to Tax, or (B)&nbsp;among Parent and the Merger Subs, none of Parent and the Merger Subs is a party to or bound by any Tax sharing
agreement, Tax indemnity obligation or agreement or arrangement with respect to Taxes (including any advance pricing agreement, closing agreement or other agreement relating to Taxes with any Governmental Authority); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) Each of Parent and the Merger Subs has complied with all Applicable Law relating to the payment and withholding of Taxes
and has, within the time and the manner prescribed by such Applicable Law withheld from and paid over to the proper Governmental Authorities all amounts required to be so withheld and paid over under Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) None of Parent and the Merger Subs knows of any fact, agreement, plan, or other circumstance, or has taken or failed to take any action,
that could reasonably be expected to prevent either of the Mergers from qualifying as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11 <U>Employment Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Parent has no employees other than James B. Wiegand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Neither of the Merger Subs has any employees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) None of Parent and the Merger Subs has any employee benefit plans; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Neither the execution and delivery of this Agreement and the other Transaction Documents nor the consummation of the Mergers and the other
transactions contemplated hereby and thereby will (either alone or in conjunction with any other event, such as termination of employment), result in, cause the accelerated vesting, funding or delivery of, or increase the amount or value of, any
payment or benefit to any employee, officer or director of any of Parent and the Merger Subs; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) There are no payments to be paid or
payable (whether in cash, property or benefits, acceleration of payment of cash, property or benefits, or otherwise) by any of Parent, the Merger Subs and the Parent Major Stockholders in connection with this Agreement and the other Transaction
Documents, the Mergers or the other transactions contemplated hereby and thereby that were or will be an &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12 <U>Labor Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Collective Bargaining</U>. None of Parent and the Merger Subs is a party to, or bound by, any collective bargaining agreement or similar
Contract, agreement or understanding with a labor union or similar labor organization. There are no organizational efforts with respect to the formation of a collective bargaining unit presently being made or threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Unfair Labor Practices</U>. None of Parent and the Merger Subs has received any written complaint of any unfair labor practice or other
unlawful employment practice or any written notice of any material violation of any federal, state or local statutes, Applicable Laws, ordinances, rules, regulations, Orders or directives with respect to the employment of individuals by it, or its
employment practices, or the work conditions, terms and conditions of employment, wages or hours of its businesses. There are no unfair labor practice charges or other employee related complaints against any of Parent and the Merger Subs pending or
threatened before any Governmental Authority by or concerning any employees working in its businesses. There is no labor dispute, strike, slowdown or work stoppage pending or threatened against any of Parent and the Merger Subs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13 <U>Environmental Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and the Merger Subs has been and is in compliance with all applicable Environmental, Health and Safety Laws and possesses
and is in compliance with any permits or licenses required under Environmental, Health and Safety Laws. To the Knowledge of Parent, there are no past or present facts, conditions or circumstances that interfere with or preclude, or could interfere
with or preclude if known to a Governmental Authority, the respective businesses any of Parent and the Merger Subs as now conducted or which interfere with continued compliance with applicable Environmental, Health and Safety Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) No proceedings or investigations of any Governmental Authority are pending or, to the
Knowledge of Parent, threatened against any of Parent and the Merger Subs that allege the violation of or seek to impose liability pursuant to any Environmental, Health and Safety Laws, and, to the Knowledge of Parent, there are no past or present
facts, conditions or circumstances at, on or arising out of, or otherwise associated with, any current (or, to the Knowledge of Parent, former) businesses, assets or properties of any of Parent and the Merger Subs, which constitute a material
violation of Environmental, Health and Safety Laws or are reasonably likely to give rise to (i)&nbsp;costs, expenses, liabilities or obligations for any cleanup, remediation, disposal or corrective action under any Environmental, Health and Safety
Laws, (ii)&nbsp;Claims arising for personal injury, property damage or damage to natural resources or (iii)&nbsp;fines, penalties or injunctive relief. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) None of Parent and the Merger Subs has (i)&nbsp;received any written notice of noncompliance with, violation of, or liability or potential
liability under any Environmental, Health and Safety Laws or (ii)&nbsp;entered into or become subject to any consent decree, Order or agreement with any Governmental Authority or other Persons pursuant to any Environmental, Health and Safety Laws or
relating to the cleanup of any Hazardous Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.14 <U>Intellectual Property</U>. None of Parent and the Merger Subs
owns, licenses or uses any Intellectual Property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.15 <U>Insurance</U>. None of Parent and the Merger Subs has or maintains
any insurance policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.16 <U>Ownership and Condition of Assets; Operations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Of Parent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Parent (A)&nbsp;has good and marketable title to all the properties and assets (1)&nbsp;reflected in the Parent Financial
Statements as being owned by Parent or (2)&nbsp;acquired after the date thereof which are material to Parent&#146;s business (except properties sold or otherwise disposed of since the date thereof in the ordinary course of business), free and clear
of all Liens except Permitted Liens, and (B)&nbsp;is the lessee of all leasehold estates reflected in the Parent Financial Statements or acquired after the date thereof which are material to its business (except for leases that have expired by their
terms since the date thereof) and is in possession of the properties purported to be leased thereunder, and each such lease is valid without default thereunder by the lessee or, to Parent&#146;s Knowledge, the lessor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Parent owns the Vessel free and clear of all Liens other than the Vessel Mortgage. There are no permits, licenses,
registrations, recordings and Orders, of any kind, from, by or of any Governmental Authority or other organization or association relating to the Vessel (&#147;<B>Vessel Permits</B>&#148;), other than the Vessel&#146;s United States Registration.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Parent (A)&nbsp;has never had or carried on any operations or activities,
of any kind, other than those described in the Parent Reports, and (B)&nbsp;currently, neither has nor carries on any operations or activities of any kind, other than those described in the Parent Reports filed on and after November&nbsp;26, 2014.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Of the Merger Subs</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Neither of the Merger Subs owns or leases any properties or assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Neither of the Merger Subs has, or has ever had, or carries on, or has ever carried on, any operations or activities of
any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.17 <U>Undisclosed Liabilities</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Of Parent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) As of the date of this Agreement, Parent has no liabilities or obligations of any nature, regardless of whether fixed,
accrued, contingent or otherwise, other than the Parent Permitted Payables. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) The discontinuation of Parent&#146;s
current business at or before the Effective Time will not result in any Parent Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Of the Merger Subs</U>.
Neither of the Merger Subs has any liabilities or obligations of any nature, regardless of whether fixed, accrued, contingent or otherwise, including notes payable, accounts payable or other Indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.18 <U>Contracts</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Of Parent</U>. Section&nbsp;4.18(a) of the Parent Disclosure Letter lists all Contracts to which Parent is a party or by which it or any
of its property is bound, other than this Agreement and the other Transaction Documents (the &#147;<B>Parent Contracts</B>&#148;). All of the Parent Contracts are filed as exhibits to Parent Reports filed prior to the date of this Agreement. Each
Parent Contract is in full force and effect. Parent has no knowledge of, and has received no notice of, any breach or violation of, or default under any Parent Contract. Parent has no Knowledge of any condition which, with the passage of time or the
giving of notice, or both, would result in any breach or violation of, or default under, any Parent Contract. Parent has not received any notice of the desire of the other party or parties to any Parent Contract to exercise any rights to cancel,
terminate or repudiate such Parent Contract or exercise remedies thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Of the Merger Subs</U>. Neither of the Merger Subs is
party to any Contracts. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.19 <U>No Brokers</U>. None of Parent, the Merger Subs and the Parent Major Stockholders has entered
into any Contract with any Person that may result in the obligation of any of Parent, the Merger Subs and any Parent Major Stockholder to pay any finder&#146;s fees, brokerage, severance, change of control or other like payments in connection with
this Agreement, the other Transaction Documents, the Mergers or the other transactions contemplated hereby and thereby, including to any Parent Major Stockholder or other stockholder of Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.20 <U>Improper Payments</U>. (a)&nbsp;No funds, assets or properties of any of
Parent, the Merger Subs and their respective Affiliates have been used or offered for illegal purposes; (b)&nbsp;no accumulation or use of any funds, assets or properties of any of Parent, the Merger Subs and their respective Affiliates has been
made without being properly accounted for in its financial books and records; (c)&nbsp;all payments by or on behalf of any of Parent, the Merger Subs and their respective Affiliates have been duly and properly recorded and accounted for in its
financial books and records and such books and records accurately and fairly reflect all transactions and dispositions of its assets; (d)&nbsp;Parent has devised and maintained systems that provide reasonable assurances that transactions are and
have been executed in accordance with management&#146;s general or specific authorization; (e)&nbsp;none of Parent, the Merger Subs and their respective Affiliates, or any of their respective directors, officers, agents, employees, other associated
Persons or Persons acting on behalf of any of them, has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or payment of anything of value relating to political activity, (ii)&nbsp;made any direct or indirect
unlawful payment to any employee, agent, officer, director, representative or stockholder of any Governmental Authority or political party, or official or candidate thereof, or any immediate family member of the foregoing or (iii)&nbsp;made any
bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment in connection with the conduct of the respective businesses of each of Parent, the Merger Subs and their respective Affiliates; (f)&nbsp;none of Parent, the Merger
Subs and their respective Affiliates, or any of their respective agents received any bribes, kickbacks or other improper payments from vendors, suppliers or other Persons; and (g)&nbsp;Parent has no Knowledge that any payment made to any Person
would be or has thereafter been offered, given or provided to any foreign official, political party or official thereof, or to any candidate for public office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.21 <U>No Ownership of the Company Stock</U>. None of Parent, the Merger Subs, the Parent Major Stockholders and their
respective Affiliates owns, directly or indirectly, any Company Stock or any securities convertible into or exercisable to acquire Company Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.22 <U>State Takeover Statutes</U>. To Parent&#146;s Knowledge, except for Section&nbsp;203 of the DGCL (which has been rendered
inapplicable), no &#147;moratorium,&#148; &#147;control share,&#148; &#147;fair price&#148; or other anti-takeover law or regulation is applicable to this Agreement, the other Transaction Documents, the Mergers or the other transactions contemplated
hereby and thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.23 <U>Interested Party Transactions</U>. No officer, director, stockholder or &#147;associate&#148;
(as such term is defined in Rule&nbsp;405 under the Securities Act) of any of Parent, the Merger Subs and their respective Affiliates, has or has had, either directly or indirectly, (a)&nbsp;an interest in any Person that (i)&nbsp;furnishes or sells
services or products that are furnished or sold or are proposed to be furnished or sold by the Companies or Parent or (ii)&nbsp;purchases from or sells or furnishes to the Companies or Parent any goods or services, or (b)&nbsp;any beneficial
interest in any Contract to which any of the Companies or Parent is a party or by which it may be bound or affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.24
<U>Obligations to or by Stockholders</U>. Parent has no liability or obligation or commitment to any holder of Parent Common Stock or any Affiliate or &#147;associate&#148; (as such term is defined in Rule&nbsp;405 under the Securities Act) of any
holder of Parent Common Stock, nor does any such holder or any such Affiliate or associate have any liability, obligation or commitment to Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.25 <U>Disclosure</U>. There is no fact relating to any of Parent, the Merger Subs
and the Parent Major Stockholders that Parent has not disclosed to the Companies in writing that has had or is currently having a Parent Material Adverse Effect or, insofar as any of Parent, the Merger Subs and the Parent Major Stockholders can now
foresee, could reasonably be expected to have a Parent Material Adverse Effect. No representation or warranty by any of Parent, the Merger Subs and the Parent Major Stockholders herein, in any of the other Transaction Documents or in any of the
other documents delivered by any of them to any of Company Parent, the Companies or their respective counsel, agents or representatives contains any untrue statement of a material fact or omits to state a material fact necessary to make the
statements contained herein or therein not misleading. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an inducement for Parent, the Merger Subs and the Parent Major Stockholders to enter into this Agreement, the Companies hereby jointly and
severally make the following representations and warranties to Parent, the Merger Subs and the Parent Major Stockholders; <I>provided, however</I>, that such representations and warranties are subject to and qualified by the disclosure letter
delivered by the Company to Parent on the date hereof, each Section&nbsp;of which qualifies the correspondingly numbered representation and warranty or covenant to the extent specified therein (the &#147;<B>Company Disclosure Letter</B>&#148;), it
being understood that (i)&nbsp;the disclosure of any fact or item in any section of the Company Disclosure Letter shall, should the existence of such fact or item be relevant to any other section, be deemed to be disclosed with respect to that other
section to the extent that such disclosure is made in a manner that makes its relevance to the other Section&nbsp;reasonably apparent and (ii)&nbsp;the disclosure of any matter or item in the Company Disclosure Letter shall not be deemed to
constitute an acknowledgement that such matter or item is required to be disclosed therein or is material to a representation or warranty set forth in this Agreement and shall not be used as a basis for interpreting the terms &#147;material,&#148;
&#147;materially,&#148; &#147;materiality,&#148; &#147;Company Material Adverse Effect&#148; or any word or phrase of similar import and does not mean that such matter or item, alone or together with any other matter or item, would constitute a
Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Corporate Existence; Good Standing; Corporate Authority</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Each of the Companies is a corporation duly incorporated, validly existing and in good standing under the Applicable Laws of the State of
Delaware. Each of the Companies is duly qualified to conduct business and is in good standing in each jurisdiction in which the ownership, operation or lease of its property or the nature of its business requires such qualification, except for
jurisdictions in which any failures to be so qualified or to be in good standing, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Company Material Adverse Effect. Each of the Companies
has all requisite corporate power and authority to own or lease and operate its properties and assets and to carry on its business as it is currently being conducted. Each of the Certificate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Incorporation and Bylaws of each of the Companies (the &#147;<B>Company Charter Documents</B>&#148;), is in full force and effect, has not been amended or modified and has not been terminated,
superseded or revoked. Neither of the Companies is in violation of its Company Charter Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The respective minute books of each
of the Companies provided to Parent prior to the date of this Agreement (to the extent requested by Parent) each contain true, correct and complete minutes and records of all meetings, proceedings and other actions of the stockholders of such
Company, the Company Board of such Company and committees of the Company Board of such Company, if any, except where such would not have a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Authorization, Validity and Effect of Agreements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Authority</U>. Each of the Companies has the requisite corporate power and authority to execute and deliver this Agreement and the other
Transaction Documents to which it is, or is contemplated to become, a party, to perform its obligations hereunder and thereunder and to consummate the Mergers and all other transactions contemplated hereunder and thereunder. The execution, delivery
and performance of this Agreement and the other Transaction Documents to which it is, or is contemplated to become, a party and the consummation of the Mergers and the other transactions contemplated hereunder and thereunder have been duly
authorized by all requisite corporate action on behalf of each of the Companies, respectively, and no other corporate proceedings by either of the Companies are necessary to authorize the execution and delivery of this Agreement and the other
Transaction Documents to which it is, or is contemplated to become, a party, or to consummate the Mergers and the other transactions contemplated hereunder and thereunder, except for the filing of the Certificates of Merger pursuant to the DGCL.
Each of the Company Boards, by unanimous written consents, (i)&nbsp;determined that this Agreement, the Transaction Documents to which such Company is, or is contemplated to be, a party, the Mergers and the other transactions contemplated hereby and
thereby are advisable, fair to and in the best interests of such Company and its stockholders, (ii)&nbsp;approved this Agreement and the Transaction Documents to which such Company is, or is contemplated to become, a party, the Mergers and the other
transactions contemplated hereby and thereby, and (iii)&nbsp;resolved to recommend that such Company&#146;s stockholders approve and adopt this Agreement, the Transaction Documents to which such Company is, or is contemplated to become, a party, the
Mergers and the other transactions contemplated hereby and thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Binding Obligations</U>. Each of this Agreement and the
Transaction Documents to which either of the Companies is, or is contemplated to become, a party has been, or will be, duly executed by such Company and, assuming the due authorization, execution and delivery hereof and thereof by each of Parent,
the Merger Subs and the Parent Major Stockholders party hereto and thereto, constitute the valid and legally binding obligations of such Company, enforceable against such Company in accordance with their respective terms, subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other Applicable Laws relating to or affecting the rights and remedies of creditors generally and to general principles of equity (regardless of whether considered in a proceeding in equity or at
law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>Capitalization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Authorized and Outstanding Shares of Luoxis</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The authorized capital stock of Luoxis consists of 60,000,000 shares of Luoxis Common Stock and 10,000,000 shares of Luoxis
Preferred Stock. There are 24,652,500 outstanding shares of Luoxis Common Stock, no outstanding shares of Luoxis Preferred Stock, and no shares of Luoxis Stock held by Luoxis in its treasury. Section&nbsp;5.3(d) of the Company Disclosure Letter sets
forth a true, correct and complete list of all outstanding options, warrants, convertible securities or similar rights to acquire Luoxis Stock (collectively, the &#147;<B>Luoxis Equity Rights</B>&#148;), and the number of shares of Luoxis Stock
reserved for future issuance in respect of Luoxis Equity Rights. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Luoxis Stock. All outstanding shares of
Luoxis Stock are, duly authorized, validly issued, fully paid and nonassessable shares, and free and clear of all Liens. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Section&nbsp;5.3(a)(ii) of the Company Disclosure Letter contains a true and complete list of the names of the record
owners, other than Company Parent, of all of the outstanding shares of Luoxis Stock and other Equity Interests in Luoxis (the &#147;<B>Luoxis Minority Stockholders</B>&#148;), together with the number of securities held or to which such Person has
rights to acquire. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized and Outstanding Shares of Vyrix</U>. The authorized capital stock of Vyrix consists of 60,000,000
shares of Vyrix Common Stock and 10,000,000 shares of Vyrix Preferred Stock. There are 20,000,000 outstanding shares of Vyrix Common Stock, no outstanding shares of Vyrix Preferred Stock, and no shares of Vyrix Stock held by Vyrix in its treasury.
Section&nbsp;5.3(d) of the Company Disclosure Letter sets forth a true, correct and complete list of all outstanding options, warrants, convertible securities or similar rights (collectively, the &#147;<B>Vyrix Equity Rights</B>&#148; and, together
with the Luoxis Equity Rights, the &#147;<B>Company Equity Rights</B>&#148;) and the number of shares of Vyrix Stock reserved for future issuance in respect of Vyrix Equity Rights. There are no outstanding or authorized stock appreciation, phantom
stock, profit participation or other similar rights with respect to Vyrix Stock. All outstanding shares of Vyrix Stock are duly authorized, validly issued, fully paid and nonassessable, and free and clear of all Liens. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Other Equity Interests</U>. Except as provided in <U>Section&nbsp;5.3(a)</U> and <U>Section&nbsp;5.3(b)</U>, neither of the Companies
has issued, sold, granted or delivered, and neither of the Companies has any outstanding, Equity Interests, bonds, debentures, promissory notes or other Indebtedness, the holders of which have the right to vote with the stockholders of such Company
on any matter or which are convertible or exercisable for Equity Interests having the right to vote. Neither of the Companies is obligated to issue, sell, grant or deliver (or to cause to be issued, sold, granted or delivered), nor is a party to any
Contract or other obligation to issue, sell, grant or deliver, any Equity Interest (including any securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind pursuant to which a Person is entitled
to acquire an Equity Interest) of any nature or any additional shares of capital stock or any other Equity Interest in such Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Company Equity Rights</U>. Section&nbsp;5.3(d) of the Company Disclosure Letter sets forth
a true, correct and complete list of all outstanding Company Equity Rights, including grantee name, exercise price (if any), vesting schedule and other vesting conditions to the extent not fully vested and expiration date. Since December&nbsp;31,
2014 neither of the Companies has (i)&nbsp;granted, conferred or awarded any Company Equity Rights that will not be exercised, converted or terminated by their terms by the Effective Time, (ii)&nbsp;granted or issued any restricted stock or
securities, or (iii)&nbsp;amended or otherwise modified any Company Equity Rights. There are no outstanding or authorized (i)&nbsp;contractual or other obligations of either of the Companies to repurchase, redeem or otherwise acquire any Equity
Interest of such Company or any Company Equity Rights of such Company or (ii)&nbsp;voting trusts or similar agreements to which such Company is a party with respect to the voting of the capital stock of such Company, except repurchases, redemptions
or acquisitions that would have an immaterial effect on such Company. At the Effective Time, all outstanding Company Equity Rights will be converted or exercised in accordance with <U>Section&nbsp;3.1</U> or <U>Section&nbsp;3.2</U>, as applicable,
or otherwise terminated and of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>Subsidiaries</U>. The respective subsidiaries of each of
the Companies are listed in Section&nbsp;5.4 of the Company Disclosure Letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5 <U>Compliance with Laws; Permits</U>.
Except for such matters that, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Company Material Adverse Effect, and except for (x)&nbsp;matters relating to Taxes, which are treated
exclusively in <U>Section&nbsp;5.9</U>, (y)&nbsp;matters relating to employment, which are treated exclusively under <U>Section&nbsp;5.11</U> and (z)&nbsp;matters arising under Environmental, Health and Safety Laws, which are treated exclusively in
<U>Section&nbsp;5.13</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Neither of the Companies is in violation of any Applicable Law relating to the ownership or operation of any
of its assets and no Claim is pending or, to the Companies&#146; Knowledge, threatened with respect to any such matters; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each of the
Companies holds all permits, licenses, certifications, variations, exemptions, Orders, franchises, registrations, filings, approvals, authorizations or other required grant of operating authority required by any Governmental Authority necessary for
the conduct of its business and the ownership or lease, as applicable, of its properties (the &#147;<B>Company Permits</B>&#148;). All Company Permits are in full force and effect and there exists no default thereunder or breach thereof. Neither of
the Companies has received any notice and has no Knowledge (i)&nbsp;that any Company Permit is being, is threatened to be, or will be, terminated, cancelled or reformed, (ii)&nbsp;that any Company Permit will not be renewed or (iii)&nbsp;of any
condition or requirement that must be satisfied or met in order for any Company Permit to be renewed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6 <U>No Conflict;
Consents</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>No Conflict</U>. The execution and delivery by each of the Companies of this Agreement and the Transaction Documents
to which it is, or is contemplated to become, a party, the performance of the respective obligations of each of the Companies hereunder and thereunder and the consummation by each of the Companies of the Mergers and the other transactions
contemplated hereby and thereby in accordance with the terms hereof and thereof </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will not (i)&nbsp;conflict with or result in a breach of any provisions of its Company Charter Documents, (ii)&nbsp;violate, conflict with, result in a breach of any provision of, constitute a
default (or an event which, with notice or lapse of time or both, would constitute a default) under, impair its rights under, alter the rights or obligations of third parties under, result in the termination of or in a right of termination or
cancellation of, give rise to a right of purchase under, or accelerate the performance required by, any Company Material Contract, (iii)&nbsp;result in the creation of any Lien (other than Permitted Liens) upon any of its properties or assets under
any Company Material Contract, (iv)&nbsp;result in any Company Material Contract being declared void, voidable, or without further binding effect, or (v)&nbsp;contravene, conflict with or constitute a violation of any provision of any Applicable Law
binding upon or applicable to it, other than any such violations, conflicts, breaches, defaults, impairments, alterations, terminations, cancellations, purchase rights, accelerations or Liens that, individually or in the aggregate, have not had or
caused and could not reasonably be expected to have or cause a Company Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Required Consents</U>. Neither the
execution and delivery by each of the Companies of this Agreement or any of the Transaction Documents to which it is, or is contemplated to become, a party, nor the consummation by each of the Companies of the Mergers and the other transactions
contemplated hereby and thereby in accordance with the terms hereof or thereof will require any consent, approval or authorization of, notice to or filing or registration with any Governmental Authority, other than the filing of the Certificates of
Merger with the Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7 <U>Litigation</U>. There is no litigation, arbitration,
mediation, action, suit, Claim, proceeding or investigation, whether legal or administrative, pending against either of the Companies or, to the Companies&#146; Knowledge, threatened against either of the Companies or any of their assets, properties
or operations, at Applicable Law or in equity, before or by any Governmental Authority or any Order of any Governmental Authority that, individually or in the aggregate, and taking into consideration the aggregate amounts reserved for any such
matters in the Company Balance Sheets, has had or caused or could reasonably be expected to have or cause a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8 <U>Absence of Certain Changes</U>. Since December&nbsp;31, 2014, there has not been (a)&nbsp;any event or occurrence that has
had or caused or could reasonably be expected to have or cause a Company Material Adverse Effect, (b)&nbsp;any material change by either of the Companies in accounting or Tax methods, principles or practices, or (c)&nbsp;any declaration, setting
aside or payment of any dividend or distribution in respect of any capital stock of either of the Companies or any redemption, purchase or other acquisition of any capital stock of either of the Companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.9 <U>Taxes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) In all material respects: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Each of the Companies has filed, or has caused to be filed on its behalf, all Tax Returns required to be filed by or on its
behalf, in the manner prescribed by Applicable Law. All such Tax Returns are complete and correct. Each of the Companies has timely paid all Taxes due and owing, and, in accordance with GAAP, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Companies Financial Statements reflect a reserve (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) for all Taxes payable by each of
the Companies, respectively, for all Taxable periods and portions thereof through the date of the Companies Financial Statements; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) No Tax Return of either of the Companies is under audit or examination by any Governmental Authority, and no written or,
to the Companies&#146; Knowledge, unwritten notice of such an audit or examination has been received by either of the Companies. There is no assessed deficiency, refund litigation, proposed adjustment or matter in controversy with respect to any
Taxes due and owing by either of the Companies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Since December&nbsp;31, 2014, neither of the Companies has made or
rescinded any election relating to Taxes or settled or compromised any Claim, action, suit, litigation, proceeding, arbitration, investigation, audit or controversy relating to any Taxes, or made any change to any of its methods of reporting income
or deductions for federal income Tax purposes from those employed in the preparation of its most recently filed federal Tax Returns; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) There is no agreement or other document extending, or having the effect of extending, the period of assessment or
collection of any material Taxes and no power of attorney with respect to any such Taxes has been executed or filed with any Governmental Authority by or on behalf of either of the Companies; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) Except for statutory Liens for Taxes not yet due, no Liens for Taxes exist with respect to any assets or properties of
either of the Companies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) Except for any agreements or arrangements with customers, vendors, lessors or similar
Persons entered into in the ordinary course of business, the principal purpose of which is not related to Tax, neither of the Companies is a party to or bound by any Tax sharing agreement, Tax indemnity obligation or agreement or arrangement with
respect to Taxes (including any advance pricing agreement, closing agreement or other agreement relating to Taxes with any Tax Authority); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) Each of the Companies has complied with all Applicable Law relating to the payment and withholding of Taxes and has,
within the time and the manner prescribed by any such Applicable Law, withheld from and paid over to the proper Governmental Authorities all amounts required to be so withheld and paid over under Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Neither of the Companies know of any fact, agreement, plan, or other circumstance, or has taken or failed to take any action, that would
reasonably be expected to prevent either of the Mergers from qualifying as a reorganization within the meaning of Section&nbsp;368(a) of the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10 <U>Financial Statements; No Undisclosed Liabilities</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;5.10(a) of the Company Disclosure Letter includes true and complete copies of the Companies Financial Statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The Companies Financial Statements (i)&nbsp;are correct and complete and have been prepared in accordance with the respective books and
records of the Companies; (ii)&nbsp;have been prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated and consistent with each other (except as may be indicated in the notes thereto); and (iii)&nbsp;fairly
present, in all material respects, the financial position, results of operations and cash flows of the Companies on a combined basis, as the case may be, as at the dates thereof and for the periods indicated therein, except as otherwise noted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Except as and to the extent adequately accrued or reserved against in the Companies Balance Sheet, neither of the Companies has any
liability, indebtedness, expense, claim, deficiency, guaranty or obligation of any type or nature, whether accrued, absolute, contingent, matured, unmatured or otherwise, whether known or unknown and whether or not required by GAAP to be reflected
in a balance sheet of the Companies on a combined basis or disclosed in the notes thereto, except for (i)&nbsp;liabilities and obligations, incurred in the ordinary course of business consistent with past practice since the date of the Companies
Balance Sheet, that are not, individually or in the aggregate, material in amount, (ii)&nbsp;liabilities for performance under Company Material Contracts that do not exceed $250,000 individually or $1,500,000 in the aggregate, and
(iii)&nbsp;liabilities described in Section&nbsp;5.10(c) of the Company Disclosure Letter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The books of account and financial records
of each of the Companies are true and correct and have been prepared and are maintained in accordance with GAAP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) To the Knowledge of
the Companies, the Companies Financial Statements are in the form, in all material respects, that will be filed, together with the report of the Companies&#146; auditors thereon, as audited financial statements with Parent&#146;s <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> as soon as is reasonably practicable after the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11 <U>Employment
Matters</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Section&nbsp;5.11(a) of the Company Disclosure Letter contains a list of all the employee benefit plans maintained by
either of the Companies (each a &#147;<B>Company Benefit Plan</B>&#148; and collectively, the &#147;<B>Company Benefit Plans</B>&#148;). To the extent applicable, the Company Benefit Plans comply in all material respects with the requirements of
ERISA and the Code or with the Applicable Laws and regulations of any applicable jurisdiction. The Company Benefit Plans have been maintained and operated in compliance in all material respects with their terms. To the Companies&#146; Knowledge,
there are no breaches of fiduciary duty in connection with the Company Benefit Plans for which the Company could be liable. There are no pending or, to the Companies&#146; Knowledge, threatened Claims against or otherwise involving any Company
Benefit Plan that, individually or in the aggregate, have had or caused or could reasonably be expected to have or cause a Company Material Adverse Effect, and no suit, action or other litigation (excluding claims for benefits incurred in the
ordinary course of the Company Benefit Plan activities) has been brought against or with respect to any such Company Benefit Plan for which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicable Company could be liable that, individually or in the aggregate, have had or caused or could reasonably be expected to have or cause a Company Material Adverse Effect. All material
contributions required to be made as of the date hereof to the Company Benefit Plans have been made or have been properly accrued and are reflected in the Companies Financial Statements as of the date thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Neither of the Companies contributes to, or has an obligation to contribute to, and has not within six years prior to the Effective Time
contributed to, or had an obligation to contribute to, or has any material liability, contingent or otherwise, with respect to, (i)&nbsp;a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;3(37) of ERISA, (ii)&nbsp;any plan that is
covered by Title&nbsp;IV of ERISA, (iii)&nbsp;any plan subject to Section&nbsp;412 of the Code or (iv)&nbsp;any plan funded by a &#147;voluntary employees&#146; benefits association&#148; within the meaning of Section&nbsp;501(c)(9) of the Code.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) No Company Benefit Plan maintained by either of the Companies provides medical, surgical, hospitalization, death or similar benefits
(regardless of whether insured) for employees or former employees of such Company for periods extending beyond their retirement or other termination of service other than coverage mandated by Applicable Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) All accrued material obligations of each of the Companies, whether arising by operation of Applicable Law, Contract, or past custom, for
compensation and benefits, including, but not limited to, bonuses and accrued vacation, and benefits under the Company Benefit Plans, have been paid or adequate accruals for such obligations are reflected on the Companies Financial Statements as of
the date thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Neither the execution and delivery of this Agreement and the other Transaction Documents to which it is, or is
contemplated to become, a party, or the consummation of the Merger and the other transactions contemplated hereby and thereby will (either alone or in conjunction with any other event, such as termination of employment), result in, cause the
accelerated vesting, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer or director of either of the Companies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Section&nbsp;5.11(f) of the Company Disclosure Letter contains a description that is accurate and correct in all material respects, of all
amounts estimated to be paid or payable (whether in cash, in property, or in the form of benefits, accelerated cash, property, or benefits, or otherwise) in connection with the transactions contemplated hereby (solely as a result thereof) that were
or will be an &#147;excess parachute payment&#148; within the meaning of Section&nbsp;280G of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Each Company Benefit Plan
which is or reasonably could be determined to be an arrangement subject to Section&nbsp;409A of the Code has been operated in good faith compliance with Section&nbsp;409A of the Code since each Company&#146;s formation through a shared service with
Company Parent, and has been, or may be, timely amended with the consent of the participant, if necessary, to comply in good faith with Section&nbsp;409A of the Code and any applicable guidance, whether proposed or final, issued by the IRS with
respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) No Company Benefit Plan is a multiple employer plan within the meaning of Section&nbsp;413(c)
of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) No Company Benefit Plan that is not subject to ERISA has any material liabilities thereunder which are not otherwise
fully funded, if applicable, or properly accrued and reflected under the Companies Financial Statements as of the date thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12 <U>Labor Matters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Neither of the Companies is a party to, or bound by, any collective bargaining agreement or similar Contract, agreement or understanding
with a labor union or similar labor organization. To the Companies&#146; Knowledge there are no organizational efforts with respect to the formation of a collective bargaining unit presently being made or threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Except for such matters that, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or
cause a Company Material Adverse Effect, (i)&nbsp;neither of the Companies has received any written complaint of any unfair labor practice or other unlawful employment practice or any written notice of any material violation of any federal, state or
local statutes, Applicable Laws, ordinances, rules, regulations, Orders or directives with respect to the employment of individuals by, or the employment practices of, such Company, or the work conditions, terms and conditions of employment, wages
or hours of its business, (ii)&nbsp;there are no unfair labor practice charges or other employee related complaints against either of the Companies pending or, to the Companies&#146; Knowledge, threatened before any Governmental Authority by or
concerning the employees working in either of the Companies business, and (iii)&nbsp;there is no labor dispute, strike, slowdown or work stoppage against either of the Companies pending or, to the Companies&#146; Knowledge, threatened against either
of the Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13 <U>Environmental Matters</U>. Except for such matters that, individually or in the aggregate, have
not had or caused and could not reasonably be expected to have or cause a Company Material Adverse Effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Each of the Companies has
been and is in compliance with all applicable Environmental, Health and Safety Laws and possess and is in compliance with any permits or licenses required under Environmental, Health and Safety Laws. To the Companies&#146; Knowledge, there are no
past or present facts, conditions or circumstances that interfere with or preclude, or could interfere with or preclude if known to a Governmental Authority, the conduct of any of the Companies&#146; respective businesses as now conducted or which
interfere with continued compliance with applicable Environmental, Health and Safety Laws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) No proceedings or investigations of any
Governmental Authority are pending or, to the Companies&#146; Knowledge, threatened against either of the Companies that allege the violation of or seek to impose liability pursuant to any Environmental, Health and Safety Laws, and, to the
Companies&#146; Knowledge, there are no past or present facts, conditions or circumstances at, on or arising out of, or otherwise associated with, any current (or, to the Companies&#146; Knowledge, former) businesses, assets or properties of either
of the Companies, which constitute a material violation of Environmental, Health and Safety Laws or are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably likely to give rise to (i)&nbsp;costs, expenses, liabilities or obligations for any cleanup, remediation, disposal or corrective action under any Environmental, Health and Safety Laws,
(ii)&nbsp;Claims arising for personal injury, property damage or damage to natural resources, or (iii)&nbsp;fines, penalties or injunctive relief; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Neither of the Companies has (i)&nbsp;received any written notice of noncompliance with, violation of, or liability or potential liability
under any Environmental, Health and Safety Laws or (ii)&nbsp;entered into or become subject to any consent decree, Order or agreement with any Governmental Authority or other Persons pursuant to any Environmental, Health and Safety Laws or relating
to the cleanup of any Hazardous Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.14 <U>Intellectual Property</U>. Except for such matters that, individually or
in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Company Material Adverse Effect, (a)&nbsp;the products, services and operations of each of the Companies does not infringe upon, violate or
misappropriate the Intellectual Property of any Third Party, (b)&nbsp;each of the Companies owns or possesses valid licenses or other valid rights to use the Intellectual Property that it uses, exercises or exploits in, or that may be necessary or
desirable for, its business as currently being conducted, free and clear of all Liens (other than Permitted Liens), and (c)&nbsp;to the Companies&#146; Knowledge, there is no infringement of any Intellectual Property owned by or licensed by or to
either of the Companies. To the Companies&#146; Knowledge, there is no unauthorized use, disclosure, infringement or misappropriation of any Intellectual Property of either of the Companies by any Person, including, any employee or independent
contractor (present or former) of either of the Companies that, individually or in the aggregate, has had or caused or could reasonably be expected to have or cause a Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.15 <U>Insurance</U>. Section&nbsp;5.15 of the Company Disclosure Letter sets forth a description of all material insurance
policies maintained by either of the Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.16 <U>Ownership and Condition of Assets</U>. Except as could not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Companies (i)&nbsp;have good and marketable title to all the properties and assets reflected in the Companies Financial Statements as being
owned by the Companies or acquired after the date thereof which are material to the Companies&#146; business on a combined basis, to the extent applicable (except properties sold or otherwise disposed of since the date thereof in the ordinary course
of business), free and clear of all Liens except Permitted Liens, and (ii)&nbsp;are the lessee of all leasehold estates reflected in the Companies Financial Statements as leased by the Companies or acquired after the date thereof which are material
to the Companies&#146; business on a combined basis, to the extent applicable (except for leases that have expired by their terms since the date thereof), and are in possession of the properties purported to be leased thereunder, and each such lease
is valid without default thereunder by the lessee or, to Companies&#146; Knowledge, the lessor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.17 <U>Material
Contracts</U>. Section&nbsp;5.17 of the Company Disclosure Letter lists all material Contracts to which either of the Companies is a party or by which they or any of their property is bound as of the date of this Agreement, other than this Agreement
or any Transaction Document (the &#147;<B>Company Material Contracts</B>&#148;). As of the date of this Agreement, each of the Company Material Contracts is, to the Companies&#146; Knowledge, in full </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
force and effect. Except for such matters that, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Company Material Adverse Effect,
neither of the Companies knows of, or has received written notice of, any breach or violation of, or default under (nor, to the Companies&#146; Knowledge, does there exist any condition which with the passage of time or the giving of notice or both
would result in such a violation or default under), any Company Material Contract, or has received written notice of the desire of the other party or parties to any such Company Material Contract to exercise any rights such party has to cancel,
terminate or repudiate such Contract or exercise remedies thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.18 <U>No Brokers; Investment Advisor</U>. Neither of
the Companies has entered into any Contract with any Person that may result in the obligation of such Company to pay any finder&#146;s fees, brokerage or other like payments in connection with the negotiations leading to this Agreement, the other
Transaction Documents, the Mergers or the other transactions contemplated hereby and thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.19 <U>Improper Payments</U>.
Except for such matters that, individually or in the aggregate, have not had or caused and could not reasonably be expected to have or cause a Company Material Adverse Effect: (a)&nbsp;no funds, assets or properties of any of the Companies and their
respective Affiliates have been used or offered for illegal purposes; (b)&nbsp;no accumulation or use of any funds, assets or properties of any of the Companies and their respective Affiliates has been made without being properly accounted for in
its financial books and records; (c)&nbsp;all payments by or on behalf of any of the Companies and their respective Affiliates have been duly and properly recorded and accounted for in its financial books and records and such books and records
accurately and fairly reflect all transactions and dispositions of its assets; (d)&nbsp;each of the Companies has devised and maintained systems that provide reasonable assurances that transactions are and have been executed in accordance with
management&#146;s general or specific authorization; (e)&nbsp;none of the Companies and their respective Affiliates, or any of their respective directors, officers, agents, employees, other associated Persons or Persons acting on behalf of any of
them, has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or payment of anything of value relating to political activity, (ii)&nbsp;made any direct or indirect unlawful payment to any employee, agent, officer,
director, representative or stockholder of any Governmental Authority or political party, or official or candidate thereof, or any immediate family member of the foregoing or (iii)&nbsp;made any bribe, unlawful rebate, payoff, influence payment,
kickback or other unlawful payment in connection with the conduct of the respective businesses of each of the Companies and their respective Affiliates; (f)&nbsp;none of the Companies and their respective Affiliates, or any of their respective
agents has received any bribes, kickbacks or other improper payments from vendors, suppliers or other Persons; and (g)&nbsp;the Companies have no Knowledge that any payment made to a Person would be or has thereafter been offered, given or provided
to any foreign official, political party or official thereof, or to any candidate for public office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.20 <U>State Takeover
Statutes</U>. To the Companies&#146; Knowledge, except for Section&nbsp;203 of the DGCL (which has been rendered inapplicable), no &#147;moratorium,&#148; &#147;control share,&#148; &#147;fair price&#148; or other anti-takeover law or regulation is
applicable to this Agreement, the other Transaction Documents, the Mergers or the other transactions contemplated hereby and thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.21 <U>Interested Party Transactions</U>. To the Companies&#146; Knowledge, no
officer, director, stockholder, or &#147;associate&#148; (as such term is defined in Rule&nbsp;405 under the Securities Act) of any of the Companies and their respective Affiliates, has or has had, either directly or indirectly, (a)&nbsp;an interest
in any Person that (i)&nbsp;furnishes or sells services or products that are furnished or sold or are proposed to be furnished or sold by the Companies or Parent or (ii)&nbsp;purchases from or sells or furnishes to the Companies or Parent any goods
or services, or (b)&nbsp;any beneficial interest in any Contract to which any of the Companies or Parent is a party or by which it may be bound or affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.22 <U>No Obligations to Stockholders</U>. Neither of the Companies has any liability or obligation or commitment to any holder
of its Company Stock or any Affiliate or &#147;associate&#148; (as such term is defined in Rule&nbsp;405 under the Securities Act) of any holder of its Company Stock, nor does any such holder or any such Affiliate or associate have any liability,
obligation or commitment to such Company, other than arm&#146;s-length Contracts between such Company and Company Parent or any of Company Parent&#146;s Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.23 <U>Disclosure</U>. There is no fact relating to either of the Companies that the Companies have not disclosed to Parent in
writing that has had or is currently having a Company Material Adverse Effect or, insofar as either of the Companies can now foresee, could reasonably be expected to have a Company Material Adverse Effect. No representation or warranty by either of
the Companies herein, in any of the other Transaction Documents or in any of the other documents delivered by either them to any of Parent, the Merger Subs and the Parent Major Stockholders or their respective counsel, agents or representatives
contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained herein or therein not misleading. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDUCT
PENDING THE MERGERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <U>Conduct of Business by the Companies Pending the Mergers</U>. Prior to the Effective Time,
unless Parent otherwise agrees in writing or as otherwise contemplated by this Agreement, each of the Companies: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) conduct its business only in the ordinary course; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) use its best efforts to preserve intact its business organization, to keep available the services of its present officers
and key employees, and to preserve the good will of those having business relationships with it; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) promptly advise
Parent orally and in writing of any Company Acquisition Proposal and the substance thereof; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) immediately cease and
terminate any existing activities, discussions, negotiations or Contract with any Person other than the other Parties with respect to any Company Acquisition Proposal; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) shall not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) directly or indirectly redeem, purchase or otherwise acquire any of its Company Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) amend its Company Charter Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) split, combine or reclassify any of its Company Stock or declare, set aside or pay any dividend payable in cash, stock or
property or make any distribution with respect to any of its Company Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) issue any additional shares of its
Company Stock or Company Equity Rights of such Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) acquire or dispose of any fixed assets or acquire or dispose
of any other substantial assets other than in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) incur additional Indebtedness, or
incur any other liabilities other than in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) enter into any Contract other than in the
ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) dissolve, or merge or consolidate with or into any Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) and shall not authorize any Person to, make, solicit, encourage any inquiries with respect to, or engage in any
negotiations or enter into any Contract concerning, any Company Acquisition Proposal; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) enter into any new employment
agreements with any of its officers or employees or grant any increases in the compensation or benefits of its officers and employees or amend any Company Benefit Plan of such Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) agree to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <U>Conduct of Business by Parent Pending the Mergers</U>. Prior to the Effective Time, unless the Companies otherwise agree
in writing or as otherwise contemplated by this Agreement, Parent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) conduct its business only in the ordinary course; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) continue to satisfy the filing requirements of the Exchange Act and all other requirements of applicable Securities Laws
and of the OTC Bulletin Board; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) promptly advise the Companies orally and in writing of any Parent Acquisition
Proposal and the substance thereof; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) immediately cease and terminate any existing activities, discussions,
negotiations or Contract with any Person other than the other Parties with respect to any Parent Acquisition Proposal; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) shall not:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) directly or indirectly redeem, purchase or otherwise acquire any Parent Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) amend the Parent Charter Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) split, combine or reclassify any Parent Stock or declare, set aside or pay any dividend payable in cash, stock or
property or make any distribution with respect to any Parent Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) issue any additional Parent Stock or Parent
Equity Rights; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) acquire or dispose of any assets other than in the ordinary course of business, except for the transfer
of the Vessel and the Vessel Permits to James B. Wiegand prior to the Closing Date, in consideration of a reduction in the outstanding balance of the Parent Major Stockholder Indebtedness in the amount of $27,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) incur additional Indebtedness, or incur any other liabilities other than in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) enter into any Contract other than in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) dissolve, or merge or consolidate with or into any Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) and shall not authorize any Person to, make, solicit, encourage any inquiries with respect to, or engage in any
negotiations or enter into any Contract concerning, any Parent Acquisition Proposal; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) hire or terminate any employees,
enter into any employment agreements with any of its officers or employees or grant any increases in the compensation or benefits of its officers and employees; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) agree to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3 <U>Conduct of Business by the Merger Subs Pending the Merger</U>. Prior to the Effective Time, unless the Companies otherwise
agree in writing or as otherwise contemplated by this Agreement, each of the Merger Subs: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) promptly advise the Companies orally and in writing of any Parent Acquisition Proposal and the substance thereof; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) immediately cease and terminate any existing activities, discussions,
negotiations or Contract with any Person other than the other Parties with respect to any Parent Acquisition Proposal; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) shall not:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) conduct any business or other operations; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) directly or indirectly redeem, purchase or otherwise acquire any Merger Sub Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) amend its Merger Sub Charter Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) split, combine or reclassify any of its Merger Sub Common Stock or declare, set aside or pay any dividend payable in cash,
stock or property or make any distribution with respect to any of its Merger Sub Common Stock </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) issue any additional
shares of its Merger Sub Common Stock or any Merger Sub Equity Rights in it; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) acquire or dispose of any assets; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) incur any Indebtedness or any other liabilities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) enter into any Contract; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) dissolve, or merge or consolidate with or into any Person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) and shall not authorize any Person to, make, solicit, encourage any inquiries with respect to, or engage in any
negotiations or enter into any Contract concerning, any Parent Acquisition Proposal; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) hire any employees; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xii) agree to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.4 <U>Actions by the Parent Major Stockholders Pending the Mergers</U>. Prior to the Effective Time, unless the Companies
otherwise agree in writing or as otherwise contemplated by this Agreement, each of the Parent Major Stockholders: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) promptly advise the Companies orally and in writing of any Parent Acquisition Proposal and the substance thereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) immediately cease and terminate any existing activities, discussions, negotiations or Contract with any Person other than
the other Parties with respect to any Parent Acquisition Proposal; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) shall not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) directly or indirectly acquire any Parent Stock or Merger Sub Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) vote or resolve to amend the Parent Charter Documents; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) and shall not authorize any Person to, make, solicit, encourage any inquiries with respect to, or engage in any
negotiations or enter into any Contract concerning, any Parent Acquisition Proposal; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) agree to do any of the
foregoing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO PARTIES&#146; OBLIGATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <U>Conditions to Parent, Merger Sub and Parent Major Stockholder Obligations</U>. The obligations of Parent, the Merger Subs
and the Parent Major Stockholders under this Agreement and the other Transaction Documents are subject to the fulfillment, at or prior to the Closing, of the following conditions, any of which may be waived in whole or in part by Parent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The representations and warranties of each of the Companies under this Agreement and the other Transaction Documents to which it is a party
(i)&nbsp;shall have been true and correct as of the date of this Agreement, and (ii)&nbsp;shall be deemed to have been made again on the Closing Date and shall then be true and correct in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each of the Companies shall have performed and complied in all material respects with all agreements and conditions required by this
Agreement and the other Transaction Documents to which it is a party to be performed or complied with by it on or before the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) No action or proceeding before any Governmental Authority shall have been threatened, asserted or instituted to restrain or prohibit, or to
obtain substantial damages in respect of, this Agreement or any of the other Transaction Documents or the carrying out of any of the Mergers and the other transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Parent shall have received from each of the Companies a certificate of the Secretary of such Company certifying as to and attaching where
applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) copies of (A)&nbsp;the Company Stockholder Consent of such Company (B)&nbsp;resolutions of the Company
Parent Board, and (C)&nbsp;resolutions of the Company Board of such Company, in each case, authorizing and approving the execution, delivery and performance of this Agreement and the other Transaction Documents to which such Company is a party and
the consummation of the Mergers and the other transactions contemplated hereby and thereby; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) the incumbency and signatures of the officers authorized to execute this
Agreement and the other Transaction Documents to which such Company is a party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) the Certificate of Incorporation and
By-laws of such Company and that there have been no changes in either of them since the date of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv)
evidence as of a recent date of the good standing and corporate existence of such Company issued by the Secretary of State of the State of Delaware; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) such additional supporting documentation and other information with respect to the Mergers and the other transactions
contemplated hereby as Parent may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) All corporate and other proceedings and actions taken in connection with the
transactions contemplated hereby and all certificates, opinions, agreements, instruments and documents mentioned herein or incident to any such transactions shall be reasonably satisfactory in form and substance to Parent, the Merger Subs and the
Parent Major Stockholders. The Companies shall furnish to Parent such supporting documentation and evidence of satisfaction of any or all of the conditions specified in this <U>Section&nbsp;7.1</U> as Parent may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Parent shall have received a certificate from an officer of Company Parent under Treasury Regulation Section&nbsp;1.1445-2(b) stating that
Company Parent is not a foreign person for purposes of Section&nbsp;1445 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <U>Conditions to the
Companies&#146; Obligations</U>. The obligations of the Companies under this Agreement and the other Transaction Documents are subject to the fulfillment, at or prior to the Closing, of the following conditions, any of which may be waived in whole
or in part by the Companies: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The representations and warranties of each of Parent, the Merger Subs and the Parent Major Stockholders
under this Agreement and the Transaction Documents to which it is a party (i)&nbsp;shall have been true and correct as of the date of this Agreement, and (ii)&nbsp;shall be deemed to have been made again on the Closing Date and shall then be true
and correct in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent, the Merger Subs and the Parent Major Stockholders shall have performed and
complied in all material respects with all agreements and conditions required by this Agreement and the other Transaction Documents to which it is a party to be performed or complied with by it on or before the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) No action or proceeding before any Governmental Authority shall have been threatened, asserted or instituted to restrain or prohibit, or to
obtain substantial damages in respect of, this Agreement or any of the other Transaction Documents or the carrying out of any of the Mergers and the other transactions contemplated hereby and thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Parent shall have no liabilities, indebtedness, expenses, claims, deficiencies, guaranties or
obligations of any type or nature, whether accrued, absolute, contingent, matured, unmatured or otherwise, whether known or unknown and whether or not required by GAAP to be reflected in a balance sheet of Parent or disclosed in the notes thereto,
other than the Parent Permitted Payables, and the Companies shall have received a certificate to that effect by the President and by the Secretary of Parent to that effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The Companies shall have received a certificate by the President and by the Secretary of Parent certifying as to and attaching as
applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) copies of resolutions of (A)&nbsp;the Parent Board, (B)&nbsp;the Luoxis Merger Sub Board and (C)&nbsp;the
Vyrix Merger Sub Board, in each case, authorizing and approving the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the Mergers and the other transactions contemplated hereby and
thereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) copies of resolutions of the Parent Board authorizing and approving all actions necessary to appoint to the
Parent Board at the Closing a director or directors chosen by the Companies; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) the incumbency and signatures of the
respective officers of each of Parent and the Merger Subs authorized to execute this Agreement and the other Transaction Documents to which it is a party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) the Parent Charter Documents and the Merger Sub Charter Documents and that there have been no changes in any of them since
the date of this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) evidence as of a recent date of the good standing and corporate existence of Parent issued
by the Secretary of State of the State of Colorado; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) evidence as of a recent date of the good standing and corporate
existence of each of the Merger Subs issued by the Secretary of State of the State of Delaware; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) that except for the
filing of the Certificates of Merger, all consents, authorizations, orders and approvals of, and filings and registrations with any Governmental Authority that are required for the execution, delivery and performance of this Agreement and the other
Transaction Documents and the consummation of the Mergers and the other transactions contemplated hereby and thereby have been duly made or obtained; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) that all material consents by third parties required for the Mergers have been obtained; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) that since the date of this Agreement there has been no Parent Material Adverse Effect; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) that no action or proceeding before any Governmental Authority has been
threatened, asserted or instituted to restrain or prohibit, or to obtain substantial damages in respect of, this Agreement, the other Transaction Documents or the consummation of any of the Mergers and the other transactions contemplated hereby and
thereby; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) that no severance, change of control or similar payments are due to any Person in connection with the
consummation of either of the Mergers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xii) that all of the Parent Contracts have been terminated other than
(A)&nbsp;Parent Contracts that have been assigned to one of the Parent Major Stockholders and (B)&nbsp;Parent Contracts with OTC Markets Group, Inc. or any of its Affiliates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiii) the executed resignations of all directors and officers of each of Parent and the Merger Subs, with the director
resignations to take effect on the Closing Date; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiv) copies of executed Lock-up Agreements from Company Parent and from
each of the Parent Major Stockholders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xv) the amount of the Parent Permitted Payables; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xvi) copies of all income Tax Returns of Parent that were required to be filed prior to the Closing Date, in form and
substance satisfactory to the Companies; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xvii) such additional supporting documentation and other information with
respect to the transactions contemplated hereby as the Companies may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) All corporate and other proceedings and
actions taken in connection with the transactions contemplated hereby and all certificates, opinions, agreements, instruments and documents mentioned herein or incident to any such transactions shall be satisfactory in form and substance to the
Companies. Each of Parent, the Merger Subs and the Parent Major Stockholders shall furnish to the Companies such supporting documentation and evidence of satisfaction of any or all of the conditions specified in this <U>Section&nbsp;7.2</U> as the
Companies may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Company Parent shall have made the Company Parent Closing Stock Purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) Company Parent Board shall have approved this Agreement, the other Transaction Documents, the Mergers and the other transactions
contemplated hereby and thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The Companies shall have received the executed Parent Major Stockholder Releases. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) The Companies shall have received the executed Consulting Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) The Companies shall have received the executed Employment Agreements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) The Companies shall have received the executed Assignment and Assumption Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) The Companies shall have received the resignation of James B. Wiegand as a director of Parent and from all offices held by him with Parent.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) The Companies shall have received the resignation of Michael Wiegand from all positions of any kind held by him with Parent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) Parent shall have filed the Parent Quarterly Report prior to the Closing, in form and substance satisfactory to the Companies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p) No action or proceeding before any Governmental Authority shall have been threatened, asserted or instituted to restrain or prohibit, or to
obtain substantial damages in respect of, this Agreement or any of the other Transaction Documents or the carrying out of any of the Mergers and the other transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(q) The Vessel and the Vessel Permits shall have been transferred to James B. Wiegand, on terms and pursuant to documentation satisfactory to
the Companies and in accordance with this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1 <U>Indemnification by Parent Major Stockholders</U>. The Parent Major Stockholders, jointly and severally, shall indemnify
and hold harmless each of Company Parent and its officers, directors, employees and agents (the &#147;<B>Indemnified Parties</B>&#148; and each, an &#147;<B>Indemnified Party</B>&#148;), and shall reimburse the Indemnified Parties for, any loss,
liability, claim, damage, expense (including, but not limited to, costs of investigation and defense and reasonable attorneys&#146; fees) or diminution of value (&#147;<B>Damages</B>&#148;) arising from or in connection with (a)&nbsp;any inaccuracy
in any of the representations and warranties of any of Parent, the Merger Subs and the Parent Major Stockholders in this Agreement or any of the other Transaction Documents or in any certificate delivered by or on behalf of any of them pursuant
hereto or thereto, or any actions, omissions or statements of fact inconsistent with any such representation or warranty, (b)&nbsp;any failure by any of Parent, the Merger Subs and the Parent Major Stockholders to perform or comply with any covenant
or agreement made by it in this Agreement or any of the other Transaction Documents, (c)&nbsp;any Claim for brokerage or finder&#146;s fees, severance payments, change of control payments, commissions or similar payments based upon any agreement or
understanding made or alleged to have been made by or on behalf of any of Parent, the Merger Subs and the Parent Major Stockholders in connection with any of the Mergers and the other transactions contemplated by this Agreement and the other
Transaction Documents, (d)&nbsp;Taxes attributable to any transaction or event occurring on or prior to the Effective Time, (e)&nbsp;any Claim relating to or arising out of any liabilities reflected in the latest Parent Financial Statements or with
respect to accounting Fees arising after the date hereof (f)&nbsp;any litigation, action, Claim, proceeding or investigation by any Third Party relating to or arising out of the business or operations of any of Parent and the Merger Subs, or any
actions of any of Parent, the Merger Subs, the Parent Major Stockholders and any holder of Parent Stock prior to the Effective Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2 <U>Survival</U>. The representations and warranties set forth in
<U>Section&nbsp;4.1</U>, <U>Section&nbsp;4.2</U> and <U>Section&nbsp;4.3</U> shall survive indefinitely. The representations and warranties set forth in <U>Section&nbsp;4.10</U> shall survive until sixty days after the expiration of the applicable
statute of limitations. All other representations, warranties, covenants and agreements of each of Parent, the Merger Subs and the Parent Major Stockholders in this Agreement and the other Transaction Documents or in any certificate delivered
pursuant hereto or thereto shall survive until the second anniversary of the Closing Date, provided, that such survival shall be indefinite in the event of any fraud, intentional misrepresentation or willful breach on the part of any of Parent, the
Merger Subs and the Parent Major Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3 <U>Time Limitations</U>. Any of the Indemnified Parties seeking
indemnification pursuant to <U>Section&nbsp;8.1</U> must notify the Parent Major Stockholders of its indemnification Claim on or before the later of the second anniversary of the Closing Date or the date on which the subject matter of the Claim
ceases to survive pursuant to <U>Section&nbsp;8.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4 <U>Effect of Investigation</U>. The representations and
warranties of each of Parent, the Merger Subs and the Parent Major Stockholders, and the rights of the Indemnified Parties to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on
behalf of any of the Indemnified Parties or by reason of the fact that any of the Indemnified Parties knew or should have known that any such representation or warranty is, was or might be inaccurate, or by reason of any waiver by any of the
Indemnified Parties of any condition set forth in <U>Section&nbsp;7.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5 <U>Effect of Qualification</U>. For purposes
of this <U>Article 8</U>, any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar qualification contained in or otherwise applicable to such
representation or warranty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.6 <U>Limitation on Liability</U>. The obligations of each of the Parent Major Stockholders to
the Indemnified Parties set forth in <U>Section&nbsp;8.1</U> shall be subject to the following limitations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Neither of the Parent
Major Stockholders shall be obligated to make any payment pursuant to this <U>Article&nbsp;8</U> until the aggregate Damages of the Indemnified Parties for the matters indemnified in <U>Section&nbsp;8.1</U> exceed $100,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The aggregate liability of the Parent Major Stockholders to the Indemnified Parties under this Agreement other than for Claims
(i)&nbsp;based on fraud, intentional misrepresentation or willful breach, (ii)&nbsp;for specific performance, injunctive or other equitable relief, or (iii)&nbsp;for breaches of the representations set forth in <U>Section&nbsp;4.1</U>,
<U>Section&nbsp;4.2</U> and <U>Section&nbsp;4.3</U> shall be limited to the value of the shares of Parent Common Stock held by the Parent Major Stockholders immediately following the Effective Time. The Parties agree that the value of such shares is
$1,300,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Other than Claims (i)&nbsp;based on fraud, intentional misrepresentation or willful breach,
(ii)&nbsp;for specific performance, injunctive or other equitable relief, or (iii)&nbsp;for breaches of the representations set forth in <U>Section&nbsp;4.1</U>, <U>Section&nbsp;4&nbsp;.2</U> and <U>Section&nbsp;4.3</U>, the indemnity provided in
this <U>Article&nbsp;8</U> shall be the sole and exclusive monetary remedy of the Indemnified Parties against Parent, the Merger Subs and the Parent Major Stockholders for any matter covered by <U>Section&nbsp;8.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.7 <U>Notice of Claims</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) To assert a Claim for indemnification pursuant to <U>Section&nbsp;8.1</U>, an Indemnified Party shall notify the Parent Major Stockholders
of such Claim, stating in such notice (i)&nbsp;that an Indemnified Party incurred or reasonably believes it may incur Damages and the reasonable estimate of the amount of any such Damages; (ii)&nbsp;in reasonable detail, the facts alleged as the
basis for such claim and the section or sections of this Agreement or other Transaction Document alleged as the basis or bases for the claim; and (iii)&nbsp;if the Damages have actually been incurred, amount of such Damages. If the Claim is for
Damages which the Indemnified Parties reasonably believe may be incurred or are otherwise un-liquidated, the written Claim of the applicable Indemnified Party shall state the reasonable estimate of such Damages, in which event a Claim shall be
deemed to have been asserted under this <U>Article&nbsp;8</U> in the amount of such estimated Damages. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) In the event that any action,
suit or proceeding is brought against any Indemnified Party with respect to which the Parent Major Stockholders may have liability under this <U>Article&nbsp;8</U>, the Companies shall control the defense of such action, suit or proceeding. In
connection with any action, suit or proceeding subject to this <U>Article&nbsp;8</U>, the Parent Major Stockholders and each Indemnified Party agree to render to each other such assistance as may reasonably be required in order to ensure proper and
adequate defense of such action, suit or proceeding. Neither of the Parent Major Stockholders shall, without the prior written consent of the applicable Indemnified Party, which consent shall not be unreasonably withheld, settle or compromise any
Claim or demand if such settlement or compromise does not include an irrevocable and unconditional release of such Indemnified Party for any liability arising out of such Claim or demand. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION
PRIOR TO CLOSING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1 <U>Termination of Agreement</U>. This Agreement may be terminated at any time prior to the Closing:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) by the mutual written consent of the Parties; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) by the Company, if any of Parent, the Merger Subs and the Parent Major Stockholders (i)&nbsp;fails to perform in any material respect any
of its agreements contained in this Agreement or in any of the other Transaction Documents to which it is a party required to be performed by it on or prior to the Closing Date, or (ii)&nbsp;materially breaches any of its representations,
warranties, covenants or agreements contained in this Agreement or in any of the other Transaction Documents to which it is a party, which failure or breach is not cured within ten (10)&nbsp;days after the Companies have notified Parent of their
intent to terminate this Agreement pursuant to this <U>Section&nbsp;9.1(b)</U>; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) by Parent if either of the Companies (i)&nbsp;fails to perform in any material respect any of
its agreements contained in this Agreement or in any of the other Transaction Documents to which it is a party required to be performed by it on or prior to the Closing Date or (ii)&nbsp;materially breaches any of its representations, warranties,
covenants or agreements contained in this Agreement or in any of the other Transaction Documents to which it is a party, which failure or breach is not cured within ten (10)&nbsp;days after Parent has notified the Companies of its intent to
terminate this Agreement pursuant to this <U>Section&nbsp;9.1(c)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) by either the Companies, on the one hand, or Parent, on the
other hand, if there shall be any Order, writ, injunction or decree of any Governmental Authority binding on any of Parent, the Merger Subs, the Parent Major Stockholders or the Companies that prohibits or materially restrains it from consummating
any of the Mergers and the other transactions contemplated by this Agreement and the other Transaction Documents; <I>provided</I> that the Parties have used their best efforts to have any such order, writ, injunction or decree lifted and the same
has not been lifted within ninety (90)&nbsp;days after entry by any such Governmental Authority; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) by either Parent, by notice to
the Companies, or by the Companies, by notice to Parent, at any time after the date which is thirty (30)&nbsp;days after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2 <U>Termination of Obligations</U>. Termination of this Agreement pursuant to this <U>Article&nbsp;9</U> shall terminate all
obligations of the Parties hereunder, except for the obligations under <U>Section&nbsp;10.12</U>, <U>Section&nbsp;10.14</U> and <U>Section&nbsp;10.15</U>; <I>provided</I>, <I>however</I>, that termination pursuant to <U>Section&nbsp;9.1(b)</U> or<U>
Section&nbsp;9.1(c)</U> shall not relieve the defaulting or breaching Party or Parties from any liability to the other Parties. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
10 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.1 <U>Further Actions</U>. Subject to the terms and conditions of this Agreement, each of the Parties agrees to execute and
deliver any additional instruments or documents necessary to consummate the Mergers and the other transactions contemplated by this Agreement and the other Transaction Documents and to do any and all such further things as may be necessary to
implement and carry out the intent of this Agreement, including any actions by James B. Wiegand necessary to transfer the Vessel and the Vessel Permits to James B. Wiegand in accordance with this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.2 <U>Amendment</U>. This Agreement may be amended by the Parties at any time by mutual consent; <I>provided</I>,
<I>however</I>, that no amendment may be made that by Applicable Law requires approval by any of the holders of Company Stock beyond the Company Stockholder Consents, without such further approval being obtained. This Agreement may not be amended
except by a written instrument signed by an authorized representative of each of the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.3 <U>Notices</U>. Any notice or other communication required or permitted
hereunder shall be in writing and, unless delivery instructions are otherwise expressly set forth above herein, either delivered personally (effective upon delivery), by email or facsimile transmission (effective on upon confirmation of after
transmission), by recognized overnight delivery service (effective on the next day after delivery to the service), or by registered or certified mail, postage prepaid and return receipt requested (effective on the third Business Day after the date
of mailing), at the following addresses or facsimile transmission numbers (or at such other address(es) or facsimile transmission number(s) for a Party as shall be specified by like notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">To the Companies: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Ampio
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email: <U>ggould@ampiopharma.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">620 Eighth
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">New York, New York 10018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Andrew Goodman. Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (212)&nbsp;355-3333 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email: AGoodman@goodwinprocter.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">To any of Parent, the Merger Subs and the Parent Major Stockholders: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Rosewind Corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">16200 West
County Road 18E </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Loveland, Colorado 80537 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Mr.&nbsp;James&nbsp;B. Wiegand </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email: shellgamer@aol.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">with a
copy (which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Roger V. Davidson, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">2540 Westward Dr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Lafeyette,
Colorado 80026 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Email: rogetd@comcast.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.4 <U>Counterparts; Facsimile Signature</U>. This Agreement may be executed in one or more counterparts, all of which shall be
considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties, it being understood that all Parties need not sign the same counterpart. This
Agreement may be executed by facsimile signature and a facsimile signature shall constitute an original for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.5 <U>Severability</U>. Any term or provision of this Agreement that is invalid or
unenforceable in any jurisdiction shall, as to such jurisdiction, be deemed modified to the minimum extent necessary to make such term or provision valid and enforceable; <I>provided</I> that if such term or provision is incapable of being so
modified, then such term or provision shall be deemed ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or
enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.6 <U>Entire Agreement; No Third Party Beneficiaries</U>. This Agreement and the other Transaction Documents constitute the
entire agreement, and supersede all other prior agreements and understandings, both written and oral, among the Parties with respect to the subject matter hereof and are solely for the benefit of the Parties and their respective successors, legal
representatives and assigns and does not confer on any Person other than the Parties any rights or remedies hereunder. The Indemnified Parties are third party beneficiaries of this Agreement to the extent of the rights accorded to them in
<U>Article&nbsp;8</U>. The representations, warranties, covenants and other agreements in this Agreement are the product of negotiations among the Parties and are for the sole benefit of the Parties and the Indemnified Parties. Any inaccuracies in
such representations, warranties, covenants or agreements are subject to waiver by the Party for whose benefit such representation, warranty, covenant or agreement was made, in accordance with <U>Section&nbsp;10.8</U> without notice of liability to
any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.7 <U>Assignment</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder
shall be assigned by any of the Parties (whether by operation of Applicable Law or otherwise) without the prior written consent of the other Parties, and any such attempted assignment without such consent shall be immediately null and void. Subject
to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.8 <U>Waivers</U>. At any time prior to the Effective Time, to the extent legally allowed: (a)&nbsp;any Party may extend the
time for the performance of any of the obligations or other acts of the other Parties, (b)&nbsp;any Party for whose benefit a representation or warranty was made may waive any inaccuracies in the representations and warranties of the other Parties
contained herein or in any document delivered pursuant hereto, and (c)&nbsp;any Party may waive performance of any of the covenants or agreements of the other Parties, or satisfaction of any of the conditions to its obligations to effect the
Mergers, contained herein. Any agreement on the part of a Party to any such extension or waiver shall be valid only if set forth in a written instrument signed by an authorized representative of such Party. Except as provided in this Agreement, no
action taken pursuant to this Agreement, including any investigation by or on behalf of any Party, shall be deemed to constitute a waiver by the Party taking such action of compliance with any representations, warranties, covenants or agreements
contained in this Agreement. The waiver by any Party of a breach of any provision hereof shall not operate or be construed as a waiver of any prior or subsequent breach of the same or any other provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.9 <U>Incorporation</U>. The Exhibits and Schedules to this Agreement are hereby incorporated into this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.10 <U>No Remedy in Certain Circumstances</U>. Each Party agrees that should any
Governmental Authority hold any provision of this Agreement or part hereof to be null, void or unenforceable, or order any Party to take any action inconsistent herewith or not to take an action consistent herewith or required hereby, the validity,
legality and enforceability of the remaining provisions and obligations contained or set forth herein shall not in any way be affected or impaired thereby. Except as otherwise contemplated by this Agreement, to the extent that a Party took an action
inconsistent herewith or failed to take action consistent herewith or required hereby pursuant to an Order or judgment of a court or other competent Governmental Authority, such Party shall not incur any liability or obligation unless such Party did
not in good faith seek to resist or object to the imposition or entering of such Order or judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.11 <U>No Strict
Construction</U>. Each of the Parties hereto acknowledges that this Agreement has been prepared jointly by the Parties hereto, and shall not be strictly construed against any Party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.12 <U>Expenses</U>. Each Party shall pay its own costs and expenses incident to preparing for, entering into and carrying out
this Agreement and the other Transaction Documents and the consummation of the Mergers and the other transactions contemplated hereby and thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.13 <U>Resale Registration Rights</U>. Parent hereby undertakes that, as soon as is reasonably practicable, Parent shall file a
registration statement with the SEC (i)&nbsp;naming each of the holders of Parent Common Stock identified in Section&nbsp;4.3(a)(vi) of the Parent Disclosure Letter as a Selling Stockholder and (ii)&nbsp;allowing for the resale of as many shares of
Parent Common Stock held by Persons who are not Affiliates of Company Parent as Parent determines in good faith, after the Closing, Parent can reasonably include in such registration statement, not including any Dissenting Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.14 <U>Governing Law</U>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of
Delaware, without regard to any conflicts or choices of laws provisions thereof that would operate to apply the laws of any other state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.15 <U>Jurisdiction; Waiver of Jury Trial</U>. The Parties agree that any suit, action or proceeding seeking to enforce any
provision of, or based on any matter arising out of or in connection with, any of this Agreement, the other Transaction Documents, the Mergers and the other transactions contemplated hereby and thereby shall be exclusively brought in any federal
court located in the State of Delaware or any Delaware state court, and each of the Parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and
irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in
any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any Party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing,
each Party agrees that service of process on such Party in the manner provided in <U>Section&nbsp;10.3</U> shall be deemed effective service of process on such Party. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A
TRIAL BY JURY IN ANY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE MERGERS AND THE OTHER TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the Parties has executed this Agreement as of the date first
written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><I>/s/ James B. Wiegand</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND MERGER</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>SUB L, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><I>/s/ James B. Wiegand</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND MERGER</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><B>SUB V, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ James B. Wiegand</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ James B. Wiegand</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">James B. Wiegand</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Michael B. Wiegand</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Michael B. Wiegand</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LUOXIS DIAGNOSTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><I>/s/ Joshua R. Disbrow</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Name: Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Agreement and Plan of Merger] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VYRIX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><I>/s/ Jarrett T. Disbrow</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Name: Jarrett T. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Agreement and Plan of Merger] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.5(a) </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Parent Board </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Macaluso </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.5(h) </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Parent Officers </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joshua Disbrow</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jarret Disbrow</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A-1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF MERGER </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ROSEWIND MERGER SUB L, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WITH
AND INTO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LUOXIS DIAGNOSTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;251 of
the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), the undersigned corporation does hereby certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The
constituent corporations (the &#147;<B><I>Constituent Corporations</I></B>&#148;) participating in the merger herein certified (the &#147;<B><I>Merger</I></B>&#148;) are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Rosewind Merger Sub L, Inc., which is incorporated under the laws of the State of Delaware (&#147; <B><I>Merger Sub</I></B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Luoxis Diagnostics, Inc., which is incorporated under the laws of the State of Delaware (&#147;<B><I>Luoxis</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. An Agreement and Plan of Merger (the &#147;<B><I>Merger Agreement</I></B>&#148;), dated as of April&nbsp;16, 2015, by and among the individuals identified
therein as Parent Major Stockholders, Rosewind Corporation, a Colorado corporation, Merger Sub, Luoxis, Rosewind Merger Sub V, Inc., a Delaware corporation, and Vyrix Pharmaceuticals, Inc., a Delaware corporation, has been approved, adopted,
certified, executed and acknowledged by each of the Constituent Corporations in accordance with Section&nbsp;251 and 228 of the DGCL. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The name of the
surviving corporation in the Merger is Luoxis Diagnostics, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The certificate of incorporation of the surviving corporation at the effective time of
the Merger shall be amended and restated as set forth on <U>Exhibit A</U> hereto, and as so amended and restated, shall be the certificate of incorporation of the surviving corporation until thereafter amended as provided therein or pursuant to the
provisions of the laws of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The Merger shall be effective upon the filing of this Certificate of Merger with the Secretary of the
State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. An executed copy of the Merger Agreement is on file at an office of the aforesaid surviving corporation, the address of which is as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Luoxis Diagnostics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. A copy of the Merger Agreement will be furnished by the aforesaid surviving corporation, on request, and
without cost, to any stockholder of either of the Constituent Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Luoxis Diagnostics, Inc. has caused this Certificate of Merger to be executed
by its duly authorized officer this 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of April, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LUOXIS DIAGNOSTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>OSEWIND</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> L C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> M<SMALL>ERGER</SMALL> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED<U> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATE OF INCORPORATION</U> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LUOXIS DIAGNOSTICS,
INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIRST</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The name of this corporation shall be: Luoxis Diagnostics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SECOND</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its registered office in the State of Delaware is to be located at:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is: The Corporation Trust Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>THIRD</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The purpose or purposes of the corporation shall be:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">To carry on any and all business and to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FOURTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The total number of shares of stock which this corporation is authorized to issue is:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">One Thousand (1,000) shares of Common Stock, par value $0.001 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIFTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to adopt, amend or repeal the by-laws of the corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SIXTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Elections of directors need not be by written ballot unless the by-laws of the corporation shall so provide.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SEVENTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s
duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section 174 of the Delaware General Corporation Law, or
(iv)&nbsp;for any transaction from which the director derived any improper personal benefit. If the Delaware General Corporation Law is amended after the effective date of this Certificate of Incorporation to authorize corporate action further
eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware. No amendment,
modification or repeal of this Article EIGHTH shall adversely affect the rights and protection afforded to a director of the corporation under this Article EIGHTH Section for acts or omissions occurring prior to such amendment, modification or
repeal.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">EIGHTH:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The corporation reserves the right to amend or repeal this Certificate of Incorporation in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein
are granted subject to this reservation. Whenever any vote of the holders of capital stock of the corporation is required to amend or repeal any provision of this Certificate of Incorporation, and in addition to any other vote of holders of capital
stock that is required by this Certificate of Incorporation or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the
affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit A-2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF MERGER </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ROSEWIND MERGER SUB V, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WITH
AND INTO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VYRIX PHARMACEUTICALS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;251 of
the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), the undersigned corporation does hereby certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The
constituent corporations (the &#147;<B><I>Constituent Corporations</I></B>&#148;) participating in the merger herein certified (the &#147;<B><I>Merger</I></B>&#148;) are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Rosewind Merger Sub V, Inc., which is incorporated under the laws of the State of Delaware (&#147; <B><I>Merger Sub</I></B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Vyrix Pharmaceuticals, Inc., which is incorporated under the laws of the State of Delaware (&#147;<B><I>Vyrix</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. An Agreement and Plan of Merger (the &#147;<B><I>Merger Agreement</I></B>&#148;), dated as of April&nbsp;16, 2015, by and among the individuals identified
therein as Parent Major Stockholders, Rosewind Corporation, a Colorado corporation, Rosewind Merger Sub L, Inc., a Delaware corporation, Luoxis Diagnostics, Inc., a Delaware corporation, Merger Sub and Vyrix, has been approved, adopted, certified,
executed and acknowledged by each of the Constituent Corporations in accordance with Section&nbsp;251 and 228 of the DGCL. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The name of the surviving
corporation in the Merger is Vyrix Pharmaceuticals, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The certificate of incorporation of the surviving corporation at the effective time of the
Merger shall be amended and restated as set forth on <U>Exhibit A</U> hereto, and as so amended and restated, shall be the certificate of incorporation of the surviving corporation until thereafter amended as provided therein or pursuant to the
provisions of the laws of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The Merger shall be effective upon the filing of this Certificate of Merger with the Secretary of the
State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. An executed copy of the Merger Agreement is on file at an office of the aforesaid surviving corporation, the address of which is as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Vyrix Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. A copy of the Merger Agreement will be furnished by the aforesaid surviving corporation, on request, and
without cost, to any stockholder of either of the Constituent Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page follows.</I>]<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Vyrix Pharmaceuticals, Inc. has caused this Certificate of Merger to be
executed by its duly authorized officer this 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of April, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VYRIX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Jarrett Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>OSEWIND</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> V C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> M<SMALL>ERGER</SMALL> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATE OF INCORPORATION</U> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VYRIX
PHARMACEUTICALS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIRST</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The name of this corporation shall be: Vyrix Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SECOND</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its registered office in the State of Delaware is to be located at:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is: The Corporation Trust Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>THIRD</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The purpose or purposes of the corporation shall be:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">To carry on any and all business and to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FOURTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The total number of shares of stock which this corporation is authorized to issue is:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">One Thousand (1,000) shares of Common Stock, par value $0.001 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIFTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to adopt, amend or repeal the by-laws of the corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SIXTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Elections of directors need not be by written ballot unless the by-laws of the corporation shall so provide.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SEVENTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s
duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section 174 of the Delaware General Corporation Law, or
(iv)&nbsp;for any transaction from which the director derived any improper personal benefit. If the Delaware General Corporation Law is amended after the effective date of this Certificate of Incorporation to authorize corporate action further
eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware. No amendment,
modification or repeal of this Article EIGHTH shall adversely affect the rights and protection afforded to a director of the corporation under this Article EIGHTH Section for acts or omissions occurring prior to such amendment, modification or
repeal.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="83%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>EIGHTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The corporation reserves the right to amend or repeal this Certificate of Incorporation in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein
are granted subject to this reservation. Whenever any vote of the holders of capital stock of the corporation is required to amend or repeal any provision of this Certificate of Incorporation, and in addition to any other vote of holders of capital
stock that is required by this Certificate of Incorporation or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the
affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B-1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LOCKUP AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LOCKUP AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made and entered into as of April&nbsp;[&#149;], 2015, by and among Rosewind
Corporation, a Colorado corporation (together with any successors and assigns thereto, &#147;<U>Parent</U>&#148;), and the undersigned holder of Parent&#146;s capital stock (&#147;<U>Seller</U>&#148;). Each capitalized term used, but not otherwise
defined, herein has the respective meaning ascribed to such term in the Agreement and Plan of Merger, dated as of April&nbsp;[&#149;], 2015, by and among Seller, Parent, and the other parties thereto (the &#147;<U>Merger Agreement</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the transactions contemplated by the Merger Agreement and for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged and agreed, Seller and Parent hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The execution and
delivery of this Agreement is a condition to the performance of the parties&#146; obligations under the Merger Agreement, including the delivery of the shares of Parent Common Stock issued to the Seller pursuant thereto (the
&#147;<U>Shares</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Seller hereby acknowledges and agrees that during the Lockup Period (as defined below), as applicable to
those Shares which remain subject to the Lockup Period from time to time (as set forth below), it shall not, without the prior written consent of Parent, (A)&nbsp;sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option
to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section&nbsp;16 of the Securities
Exchange Act of 1934 (the &#147;<U>Exchange Act</U>&#148;) with respect to any portion of such Shares or any securities convertible into or exercisable or exchangeable for Parent Common Stock now owned or hereafter acquired by the undersigned,
(B)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any such Shares or securities convertible into or exercisable or exchangeable for Parent Common Stock,
whether any such transaction is to be settled by delivery of such Shares or such other securities, in cash or otherwise, or (C)&nbsp;publicly announce any intention to effect any transaction specified in clause (A)&nbsp;or (B). As used herein, the
term &#147;<U>Lockup Period</U>&#148; means the period beginning on the date hereof and ending on the earlier of: (a)&nbsp;(i) with respect to twenty-five percent (25%)&nbsp;of the Shares, June&nbsp;30, 2015, and (ii)&nbsp;with respect to the
remaining seventy-five percent (75%)&nbsp;of the Shares, April&nbsp;[&#149;], 2017, and (b)&nbsp;the date that Parent, the corporate parent of Parent, consummates a liquidation, merger, stock exchange or other similar transaction that results in all
of the holders of Parent Common Stock having the right to exchange their shares of Parent Common Stock for cash, securities or other property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Notwithstanding the provisions of paragraph 2, above, Seller may transfer any or all of its Shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to the officers, directors or employees of Parent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift to any member of the immediate family to Seller&#146;s immediate family members (as defined below) and trusts for estate planning purposes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift to a charity or educational institution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">by virtue of the laws of descent and distribution upon Seller&#146;s death; or </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">transfers by operation of law, including pursuant to domestic relations or court orders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">transfers consented to, in writing, by Parent; </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that in the case of any transfer described
in clauses (a)&nbsp;through (e)&nbsp;above, it shall be a condition to the transfer that (A)&nbsp;the transferee executes and delivers to Parent not later than three (3)&nbsp;business days prior to such transfer, a written agreement, in
substantially the form of this Agreement (it being understood that any references to &#147;immediate family&#148; in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the
immediate family of the transferee) and otherwise satisfactory in form and substance to Parent. For purposes of this paragraph, &#147;immediate family&#148; shall mean a spouse, child, grandchild or other lineal descendant (including by adoption),
father, mother, brother or sister of the undersigned. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. In furtherance of the foregoing, Seller hereby (a)&nbsp;further agrees that
(i)&nbsp;it will not, during the Lockup Period, make any demand or request for or exercise any right with respect to the registration under the Securities Act of any Shares or any securities convertible into or exercisable or exchangeable for Parent
Common Stock, and (b)&nbsp;authorizes Parent during the Lockup Period to cause the transfer agent for the Parent Common Stock to decline to transfer any Shares or securities convertible into or exercisable or exchangeable for Parent Common Stock,
and to place restrictive legends and note stop transfer restrictions on the Shares, the stock register and other records relating to the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Seller hereby represents and warrants to Parent that (i)&nbsp;it has full power and authority to enter into this Agreement and
(ii)&nbsp;this Agreement constitutes the legal, valid and binding obligation of the undersigned, enforceable in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and
supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Agreement may not be
changed, amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. No
party hereto may assign this Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported assignment in violation of this paragraph 7 shall be void and ineffectual and
shall not operate to transfer or assign any interest or title to the purported assignee. This Agreement shall be binding on each party&#146;s respective successors, heirs, personal representatives and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without giving effect
to conflicts of law principles that&middot; would result in the application of the substantive laws of another jurisdiction. The parties hereto (i)&nbsp;agree that any action, proceeding, claim or dispute arising out of, or relating in any way to,
this Agreement shall be brought and enforced in the courts of the State of Delaware, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii)&nbsp;waive any objection to such exclusive
jurisdiction and venue or that such courts represent an inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Any notice, consent or request to be given in connection with any of the terms or provisions
of this Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery, or by electronic or facsimile transmission, to the address, email or
facsimile number indicated on the books and records of Parent or such other address as a party shall subsequently provide. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. Upon
request by Parent, Seller will execute any additional documents necessary in connection with enforcement hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Lockup Agreement on the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STOCKHOLDERS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> W<SMALL>IEGAND</SMALL>
L<SMALL>OCKUP</SMALL> A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit B-2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LOCKUP AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LOCKUP AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made and entered into as of April&nbsp;[&#149;], 2015, by and among Rosewind
Corporation, a Colorado corporation (together with any successors and assigns thereto, &#147;<U>Parent</U>&#148;), and Ampio Pharmaceuticals, Inc., a Delaware corporation (together with any successors and assigns thereto, &#147;<U>Seller</U>&#148;).
Each capitalized term used, but not otherwise defined, herein has the respective meaning ascribed to such term in the Agreement and Plan of Merger, dated as of April&nbsp;[&#149;], 2015, by and among certain subsidiaries of Seller, Parent, and the
other parties thereto (the &#147;<U>Merger Agreement</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the transactions contemplated by
the Merger Agreement and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and agreed, Seller and Parent hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The execution and delivery of this Agreement is a condition to the performance of the parties&#146; obligations under the Merger Agreement,
including the delivery of the shares of Parent Common Stock issued to the Seller pursuant thereto (the &#147;<U>Shares</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
Seller hereby acknowledges and agrees that during the Lockup Period (as defined below), as applicable to those Shares which remain subject to the Lockup Period from time to time (as set forth below), it shall not, without the prior written consent
of Parent, (A)&nbsp;sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or
liquidate or decrease a call equivalent position within the meaning of Section&nbsp;16 of the Securities Exchange Act of 1934 (the &#147;<U>Exchange Act</U>&#148;) with respect to any portion of such Shares or any securities convertible into or
exercisable or exchangeable for Parent Common Stock now owned or hereafter acquired by the undersigned, (B)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of any such Shares or securities convertible into or exercisable or exchangeable for Parent Common Stock, whether any such transaction is to be settled by delivery of such Shares or such other securities, in cash or otherwise, or (C)&nbsp;publicly
announce any intention to effect any transaction specified in clause&nbsp;(A) or (B). As used herein, the term &#147;<U>Lockup Period</U>&#148; means the period beginning on the date hereof and ending on the earlier of: (a)&nbsp;with respect to
twenty-five percent (25%)&nbsp;of the Shares, April&nbsp;[&#149;], 2017, (b)&nbsp;with respect to twenty-five percent (25%)&nbsp;of the Shares, October&nbsp;[&#149;], 2017, (c)&nbsp;with respect to twenty-five percent (25%)&nbsp;of the Shares,
April&nbsp;[&#149;], 2018, (d)&nbsp;October [&#149;], 2018, (e)&nbsp;the date that Parent consummates a liquidation, merger, stock exchange or other similar transaction that results in all of the holders of Parent Common Stock having the right to
exchange their shares of Parent Common Stock for cash, securities or other property, and (f)&nbsp;the date that a person or group of persons or entities obtains a controlling interest in Seller&#146;s capital stock. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Notwithstanding the provisions of paragraph 2, above, Seller may transfer any or all of its
Shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to the officers, directors or employees of Parent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift to any member of the immediate family to Seller&#146;s immediate family members (as defined below) and trusts for estate planning purposes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift to a charity or educational institution; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">by virtue of the laws of descent and distribution upon Seller&#146;s death; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">transfers by operation of law, including pursuant to domestic relations or court orders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">transfers consented to, in writing, by Parent; </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that in the case of any transfer described
in clauses&nbsp;(a) through (e)&nbsp;above, (A)&nbsp;it shall be a condition to the transfer that the transferee executes and delivers to Parent not later than three (3)&nbsp;business days prior to such transfer, a written agreement, in
substantially the form of this Agreement (it being understood that any references to &#147;immediate family&#148; in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the
immediate family of the transferee) and otherwise satisfactory in form and substance to Parent and (B)&nbsp;acceptance of Shares by any transferee shall constitute such transferee&#146;s agreement to be bound by this Agreement. For purposes of this
paragraph, &#147;immediate family&#148; shall mean a spouse, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. In furtherance of the foregoing, Seller hereby (a)&nbsp;further agrees that (i)&nbsp;it will not, during the Lockup Period, make any demand
or request for or exercise any right with respect to the registration under the Securities Act of any Shares or any securities convertible into or exercisable or exchangeable for Parent Common Stock, and (b)&nbsp;authorizes Parent during the Lockup
Period to cause the transfer agent for the Parent Common Stock to decline to transfer any Shares or securities convertible into or exercisable or exchangeable for Parent Common Stock, and to place restrictive legends and note stop transfer
restrictions on the Shares, the stock register and other records relating to the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Seller hereby represents and warrants to
Parent that (i)&nbsp;it has full power and authority to enter into this Agreement and (ii)&nbsp;this Agreement constitutes the legal, valid and binding obligation of the undersigned, enforceable in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. This Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and
supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Agreement may not be
changed, amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. No
party hereto may assign this Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported assignment in violation of this paragraph 7 shall be void and ineffectual and
shall not operate to transfer or assign any interest or title to the purported assignee. This Agreement shall be binding on each party&#146;s respective successors, heirs, personal representatives and assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. This Agreement shall be governed by and construed and enforced in accordance with the laws of
the State of Delaware, without giving effect to conflicts of law principles that&middot; would result in the application of the substantive laws of another jurisdiction. The parties hereto (i)&nbsp;agree that any action, proceeding, claim or dispute
arising out of, or relating in any way to, this Agreement shall be brought and enforced in the courts of the State of Delaware, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and
(ii)&nbsp;waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Any notice,
consent or request to be given in connection with any of the terms or provisions of this Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand
delivery, or by electronic or facsimile transmission, to the address, email or facsimile number indicated on the books and records of Parent or such other address as a party shall subsequently provide. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. Upon request by Parent, Seller will execute any additional documents necessary in connection with enforcement hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Lockup Agreement on the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMPIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Gregory A. Gould</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>MPIO</SMALL>
L<SMALL>OCKUP</SMALL> A<SMALL>GREEMENT</SMALL>] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS RELEASE
(this &#147;<U>Release</U>&#148;), dated as of April [&#149;], 2015 is made by the undersigned holder of capital stock of Rosewind Corporation, a Colorado corporation (&#147;<U>Parent</U>&#148;), for the benefit of Parent. Capitalized terms used
herein but not defined herein have the respective meanings ascribed to them in the Merger Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
undersigned, as a Parent Major Stockholder, the other Parent Major Stockholder, Parent, Rosewind Merger Sub L, Inc., a Delaware corporation (&#147;<U>Luoxis Merger Sub</U>&#148;) and Rosewind Merger Sub V, Inc., a Delaware corporation
(&#147;<U>Vyrix Merger Sub</U>&#148;), and Luoxis Diagnostics, Inc. (&#147;<U>Luoxis</U>&#148;) and Vyrix Pharmaceuticals, Inc. (&#147;<U>Vyrix</U>,&#148; and, together with Luoxis, the &#147;<U>Companies</U>&#148;), have entered into an Agreement
and Plan of Merger (the &#147;<U>Merger Agreement</U>&#148;) on or about the date hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the undersigned owns shares of Parent
Common Stock and will benefit from the consummation of the transactions contemplated by the Merger Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent is
indebted to the undersigned in the amount of approximately $30,000 pursuant to an un-documented loan made by the undersigned to Parent (the &#147;<U>Loan</U>&#148;), and the Loan is secured by an un-documented security interest in the Vessel (the
&#147;<U>Vessel Mortgage</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce the Companies to enter into the Merger Agreement and consummate the
transactions contemplated thereby, the undersigned wishes to grant this Release in accordance with Section&nbsp;7.2 of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the undersigned hereby agrees as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B>Release</B>. Effective upon the Closing, the undersigned, on behalf of
himself and his successors, assigns and heirs, hereby unconditionally and irrevocably waives, releases and forever discharges Parent and each of its past and present directors, officers, managers, employees, agents, predecessors, successors,
assigns, equityholders, members, partners, insurers, representatives and Affiliates (collectively, the &#147;<U>Released Parties</U>&#148;) from any and all liabilities of any kind whatsoever, in each case whether absolute or contingent, liquidated
or unliquidated, known or unknown, including any liabilities or obligations under the Loan and the Vessel Mortgage, or either of them, and the undersigned shall not seek to recover any amounts owed to the undersigned pursuant to any agreement or
other arrangement entered into prior to the Closing, other than the Merger Agreement and the other Transaction Documents. The undersigned understands that this is a full and final release of all claims, demands, causes of actions and liabilities of
any nature whatsoever, whether or not known, suspected or claimed, that could have been asserted in any legal or equitable proceeding against any of the Released Parties, except as expressly set forth in this Section&nbsp;1. The undersigned
represents that he is not aware of any claim by him other than the claims that are waived, released and forever discharged by this Section&nbsp;1. The undersigned hereby releases the Vessel Mortgage. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2. </I><B>Miscellaneous</B><I></I>. The following provisions of the Merger Agreement are
hereby incorporated into and specifically made applicable to this Release (provided that, in construing such incorporated provisions, any reference to &#147;this Agreement&#148; shall be deemed to refer to this Release: Section&nbsp;1.2
(<I>References and Titles</I>), Section&nbsp;10.3 (<I>Notices</I>), Section&nbsp;10.4 (<I>Counterparts, Facsimile Signatures</I>), Section&nbsp;10.5 (<I>Severability</I>), Section&nbsp;10.6 (<I>Entire Agreement, No Third Party Beneficiaries</I>),
Section&nbsp;10.7 (<I>Assignment</I>), Section&nbsp;10.14 (<I>Governing Law</I>) and Section&nbsp;10.15 (<I>Jurisdiction, Waiver of Jury Trial</I>).<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has executed this Release as of the date first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Name: James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(P<SMALL>ARENT</SMALL> M<SMALL>AJOR</SMALL> S<SMALL>TOCKHOLDER</SMALL>) R<SMALL>ELEASE</SMALL> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ROSEWIND CORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">c/o Ampio
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">373 Inverness Parkway, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Englewood, Colorado 80112 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April&nbsp;[&#149;], 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James B. Wiegand </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16200 WCR 18E </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loveland, Colorado 80537 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Wiegand: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>This letter agreement (this
&#147;<B>Agreement&#148;</B>) sets forth the terms and conditions whereby you agree to provide certain services (as described on Schedule 1) to Rosewind Corporation (the &#147;<B>Company&#148;</B>).<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>S<SMALL>ERVICES</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top">The Company hereby engages you, and you hereby accept such engagement, as an independent contractor to provide certain services to the Company on the terms and conditions set forth in this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top">You shall provide to the Company the services set forth on Schedule 1 (the &#147;<B>Services</B>&#148;). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top">The Company shall not control the manner or means by which you perform the Services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top">To the extent you perform any Services on the Company&#146;s premises or using the Company&#146;s equipment, you shall comply with all applicable policies of the Company relating to business and office conduct, health
and safety and use of the Company&#146;s facilities, supplies, information technology, equipment, networks and other resources. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>T<SMALL>ERM</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The term of this Agreement shall commence on the date set forth
above and shall continue through the first anniversary of such date, unless earlier terminated in accordance with <U>Section&nbsp;9</U> (the &#147;<B>Term&#148;</B>). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>F<SMALL>EE</SMALL> <SMALL>AND</SMALL> E<SMALL>XPENSES</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top">As full compensation for the Services and the rights granted to the Company in this Agreement, the Company shall pay you a fixed fee of $50,000 (the &#147;<B>Fee&#148;</B>). $25,000 of the Fee is payable upon execution
of this Agreement, and the remaining $25,000 of the Fee is payable at the end of the Term, subject to any applicable adjustment pursuant to <U>Section&nbsp;9.1</U> in the event of an early termination without cause. You acknowledge that you will
receive an IRS Form 1099-MISC from the Company, and that you shall be solely responsible for all federal, state and local taxes, as set out in <U>Section&nbsp;4.2</U>. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top">The Company will reimburse you for any reasonable out-of-pocket expenses that you incur for travel (including meals and lodging) at the request of the Company in performance of the Services. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>R<SMALL>ELATIONSHIP</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>ARTIES</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top">You are an independent contractor of the Company, and this Agreement shall not be construed to create any association, partnership, joint venture, employee or agency relationship between you and the Company for any
purpose. You have no authority (and shall not hold yourself out as having authority) to bind the Company and you shall not make any agreements or representations on the Company&#146;s behalf without the Company&#146;s prior written consent.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top">Without limiting <U>Section&nbsp;4.1</U>, you will not be eligible under this Agreement to participate in any vacation, group medical or life insurance, disability, profit sharing or retirement benefits or any other
fringe benefits or benefit plans offered by the Company to its employees, and the Company will not be responsible for withholding or paying any income, payroll, Social Security or other federal, state or local taxes, making any insurance
contributions, including unemployment or disability, or obtaining worker&#146;s compensation insurance on your behalf. You shall be responsible for, and shall indemnify the Company against, all such taxes or contributions, including penalties and
interest. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> R<SMALL>IGHTS</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top">The Company is and shall be, the sole and exclusive owner of all right, title and interest throughout the world in and to all the results and proceeds of the Services performed under this Agreement, including all
patents, copyrights, trademarks, trade secrets and other intellectual property rights (collectively &#147;<B>Intellectual Property</B>&#148;) therein. You agree that any and all Intellectual Property is deemed to be &#147;work made for hire&#148; as
defined in 17&nbsp;U.S.C. &#167;&nbsp;101 for the Company. If, for any reason, any of the Intellectual Property does not constitute a &#147;work made for hire,&#148; you hereby irrevocably assign to the Company, in each case without additional
consideration, all right, title and interest throughout the world in and to the Intellectual Property. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top">Upon the request of the Company, you shall promptly take such further actions, including execution and delivery of all appropriate instruments of conveyance, as may be necessary to assist the Company to prosecute,
register, perfect, record or enforce its rights in any of the Intellectual Property. In the event the Company is unable, after reasonable effort, to obtain your signature on any such documents, you hereby irrevocably designate and appoint the
Company as your agent and attorney-in-fact, to act for and on your behalf solely to execute and file any such application or other document and do all other lawfully permitted acts to further the prosecution and issuance of any of the Intellectual
Property with the same legal force and effect as if you had executed them. You agree that this power of attorney is coupled with an interest. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>C<SMALL>ONFIDENTIALITY</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>6.1</TD>
<TD ALIGN="left" VALIGN="top">You acknowledge that you will have access to information that is treated as confidential and proprietary by the Company, including, without limitation, the existence and terms of this Agreement, trade secrets,
technology, and information pertaining to business operations and strategies, customers, pricing, marketing, finances, sourcing, personnel, operations of the Company, its affiliates or their suppliers or customers, in each case whether spoken,
written, printed, electronic or in any other form or medium (collectively, the &#147;<B>Confidential Information&#148;</B>). Any Confidential Information that you develop in connection with the Services, including but not limited to any Intellectual
Property, shall be subject to the terms and conditions of this Section. You agree to treat all Confidential Information as strictly confidential, not to disclose Confidential Information or permit it to be disclosed, in whole or part, to any third
party without the prior written consent of the Company in each instance, and not to use any Confidential Information for any purpose except as required in the performance of the Services. You shall notify the Company immediately in the event you
become aware of any loss or disclosure of any Confidential Information.<B> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top">Confidential Information shall not include information that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">is or becomes generally available to the public other than through your breach of this Agreement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">is communicated to you by a third party that had no confidentiality obligations with respect to such information. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Nothing herein shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to
the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
extent of disclosure required by such law, regulation or order. You agree to provide written notice of any such order to an authorized officer of the Company within five days of receiving such
order, but in any event sufficiently in advance of making any disclosure to permit the Company to contest the order or seek confidentiality protections, as determined in the Company&#146;s sole discretion. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top">You represent and warrant to the Company that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">you have the right to enter into this Agreement, to grant the rights granted herein and to perform fully all of your obligations in this Agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">your entering into this Agreement with the Company and your performance of the Services do not and will not conflict with or result in any breach or default under any other agreement to which you are subject;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">you shall perform the Services in a professional and workmanlike manner in accordance with generally recognized industry standards for similar services and you shall devote sufficient resources to ensure that the
Services are performed in a timely and reliable manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">you shall perform the Services in compliance with all applicable federal, state and local laws and regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">the Company will receive good and valid title to all Intellectual Property, free and clear of all encumbrances and liens of any kind; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">all Intellectual Property is and shall be your original work (except for material in the public domain or provided by the Company) and does not and will not violate or infringe upon the intellectual property right or
any other right whatsoever of any person, firm, corporation or other entity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top">The Company hereby represents and warrants to you that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">the execution of this Agreement by its representative whose signature is set forth at the end hereof has been duly authorized by all necessary corporate action. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NDEMNIFICATION</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top">You shall defend, indemnify and hold harmless the Company and its affiliates and their officers, directors, employees, agents, successors and assigns from and against all losses, damages, liabilities, deficiencies,
actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind (including reasonable attorneys&#146; fees) arising out of or resulting from: </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">bodily injury, death of any person or damage to real or tangible, personal property resulting from your acts or omissions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">your breach of any representation, warranty or obligation under this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top">The Company may satisfy such indemnity (in whole or in part) by way of deduction from any payment due to you. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>T<SMALL>ERMINATION</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top">The Company may terminate this Agreement without cause upon thirty days&#146; written notice to you. If the Company terminates this Agreement pursuant to this <U>Section&nbsp;9.1</U>, the Company shall pay you the pro
rata portion of the Fee corresponding to the portion of the Term completed through the date of such termination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top">The Company may terminate this Agreement, effective immediately upon written notice to you and without any liability to pay the Fee or otherwise, in the event that you materially breach this Agreement.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top">Upon expiration or termination of this Agreement for any reason, or at any other time upon the Company&#146;s written request, you shall promptly after such expiration or termination: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">deliver to the Company all Intellectual Property (whether complete or incomplete) and all hardware, software, tools, equipment or other materials provided for your use by the Company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">deliver to the Company all tangible documents and materials (and any copies) containing, reflecting, incorporating or based on the Confidential Information; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">permanently erase all of the Confidential Information from your computer systems; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">certify in writing to the Company that you have complied with the requirements of this Section. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top">The terms and conditions of this <U>Section&nbsp;9</U>, <U>Section&nbsp;4</U>, <U>Section&nbsp;5</U>, <U>Section&nbsp;6</U>, <U>Section&nbsp;7</U>, <U>Section&nbsp;8</U>, <U>Section&nbsp;7.3</U>, <U>Section&nbsp;11</U>,
<U>Section&nbsp;12</U> and <U>Section&nbsp;13</U> shall survive the expiration or termination of this Agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>O<SMALL>THER</SMALL> B<SMALL>USINESS</SMALL> A<SMALL>CTIVITIES</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may be
engaged or employed in any other business, trade, profession or other activity which does not place you in a conflict of interest with the Company; provided, that, during the Term, you shall not be engaged in any business activities that do or may
compete with the business of the Company without the Company&#146;s prior written consent. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>SSIGNMENT</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You shall not assign any rights, or delegate or subcontract
any obligations, under this Agreement without the Company&#146;s prior written consent. Any assignment in violation of the foregoing shall be deemed null and void. The Company may freely assign its rights and obligations under this Agreement at any
time. Subject to the limits on assignment stated above, this Agreement will inure to the benefit of, be binding on, and be enforceable against each of the parties hereto and their respective successors and assigns. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>M<SMALL>ISCELLANEOUS</SMALL> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top">You shall not export, directly or indirectly, any technical data acquired from the Company, or any products utilizing any such data, to any country in violation of any applicable export laws or regulations.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>12.2</TD>
<TD ALIGN="left" VALIGN="top">All notices, requests, consents, claims, demands, waivers and other communications hereunder (each, a &#147;<B>Notice&#148;</B>) shall be in writing and addressed to the parties at the addresses set forth on the first
page of this Agreement (or to such other address that may be designated by the receiving party from time to time in accordance with this section). All Notices shall be delivered by personal delivery, nationally recognized overnight courier (with all
fees pre-paid), facsimile or e-mail of a PDF document (with confirmation of transmission) or certified or registered mail (in each case, return receipt requested, postage prepaid). Except as otherwise provided in this Agreement, a Notice is
effective only if (a)&nbsp;the receiving party has received the Notice and (b)&nbsp;the party giving the Notice has complied with the requirements of this Section.<B> </B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top">This Agreement and together with Schedule 1, constitutes the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersedes all prior and contemporaneous
understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top">This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto, and any of the terms thereof may be waived, only by a written document signed by each party to this
Agreement or, in the case of waiver, by the party or parties waiving compliance. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top">This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule. Each party irrevocably submits to
the exclusive jurisdiction and venue of the federal and state courts located in New York, New York in any legal suit, action or proceeding arising out of or based upon this Agreement or the Services provided hereunder. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top">If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or
invalidate or render unenforceable such term or provision in any other jurisdiction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top">This Agreement may be executed in multiple counterparts and by facsimile signature, each of which shall be deemed an original and all of which together shall constitute one instrument. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this letter accurately sets forth our understanding, kindly execute the enclosed copy of this letter and
return it to the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ROSEWIND CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACCEPTED AND AGREED:</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James B. Wiegand</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature page to Consulting Agreement] </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Services: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">Transition services related to the mergers of the Company with Luoxis Diagnostics, Inc. and Vyrix Pharmaceuticals, Inc. (the &#147;<B>Merger</B>&#148;), including: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">communications with third parties (vendors, service providers, etc.) with whom the Company has done or does business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">transfer of the Company&#146;s sailing vessel and related licenses, agreements and other documents into your own name or that of your designee; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">Change of leadership communications as required with the SEC, financial reporting groups, and any other parties the Company needs to notify; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">Assistance with OTCQB transition and communication as requested by the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">Assistance in securing historical documents, data, figures, etc. as relevant to the Merger and the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">Being available for questions from the Company&#146;s senior management, accounting firm, attorneys, etc. as required throughout the Term; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top">assistance with other general business needs. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Employment
Agreement (the &#147;Agreement&#148;), is effective as of April [&#149;], 2015 (the &#147;Effective Date&#148;), between Rosewind Corporation, a Colorado corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA,
hereinafter referred to as the &#147;Company&#148;, and [&nbsp;&nbsp;&nbsp;&nbsp;] (&#147;Employee&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Company is a duly organized Colorado corporation, with its principal place of business within the State of Colorado, and
is in the business of developing and marketing pharmaceutical products; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Company desires assurance of the
continued association and services of the Employee in order to continue to retain the Employee&#146;s experience, skills, abilities, background and knowledge, and is willing to continue to engage the Employee&#146;s services on the terms and
conditions set forth in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Employee desires to be in the continued employ of the Company, and is willing
to accept such continued employment on the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> the parties hereto agree to the terms
and conditions of this Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Employment for Term. </B>The Company hereby agrees to employ Employee and Employee hereby accepts such
employment with the Company for the period of 24 months beginning on the Effective Date. The term of this Agreement (the &#147;Term&#148;) shall continue until the termination of Employee&#146;s employment in accordance with the provisions of this
Agreement. The termination of Employee&#146;s employment under this Agreement shall end the Term but shall not terminate Employee&#146;s or the Company&#146;s other obligations that are intended to survive the termination of this Agreement
(including without limitation, the payments under Section&nbsp;7 and 8 and Employee&#146;s obligations under Section&nbsp;9). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Position and
Duties.</B> During the Term, Employee shall serve as Chief Executive Officer (CEO) of the Company, and perform such duties as are consistent with this position. The Employee shall report to the Board of Directors of the Company. During the Term,
Employee shall also hold such additional positions and titles as the Board of Directors of the Company (the &#147;Board&#148;) may determine from time to time. During the Term, Employee shall devote as much time as is necessary to satisfactorily
perform his duties as CEO of the Company. Employee may engage in any civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the
Company During the Term of this Agreement, Employee agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Employee to be adverse or antagonistic to the Company, its business or
prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of
which Employee is or becomes a member of during the term hereof. Employee shall provide written disclosure to the Compensation Committee of the Company&#146;s Board of Directors as to all advisory boards on which Employee sits, and will provide the
Company with written notice within 10 business days of Employee agreeing to sit on any additional advisory boards. On termination of Employee&#146;s employment, regardless of the reason for such termination, Employee shall immediately (and with
contemporaneous effect) resign any directorships, offices or other positions that Employee may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Compensation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Base Salary.</B> The Company shall pay Employee a base salary of $[&#149;] per annum, payable at least monthly on the Company&#146;s
regular pay cycle for professional employees (the &#147;Base Salary&#148;). Except as specifically otherwise provided herein, the Base Salary may be increased only by recommendation of the Compensation Committee of the Board and ratified by the
Compensation Committee or a majority of the independent members of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Annual Review.</B> The Base Salary shall be reviewed
at the end of each calendar year (the first such review to occur at the end of calendar year 2015). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Equity Compensation.</B> In
connection with the execution of this Agreement, the Company hereby agrees to grant on or promptly after April&nbsp;1, 2015 initial equity compensation to Employee in the aggregate amount of [&#149;] options to purchase shares of Company Common
Stock. These options shall be granted subject to the terms and conditions of the Company&#146;s stock option plan then in effect, and the terms and conditions of the applicable option agreement, and will vest in accordance with the terms and
schedule set forth in Exhibit A hereto. Such vesting schedule will be accelerated, to the extent provided in Section&nbsp;8 of this agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Other and Additional Compensation.</B> Subsections (a)&nbsp;and (c)&nbsp;above establish Employee&#146;s compensation during the Term
which shall not preclude the Board from awarding Employee a higher salary or any bonuses or stock options, restricted stock or other forms of additional equity awards in the discretion of the Board during the Term at any time. The Employee shall be
eligible for an annual discretionary bonus (hereinafter referred to as the &#147;Bonus&#148;) with a target amount of [&#149;] ([&#149;]%)&nbsp;of the Base Salary<B>, </B>subject to standard deductions and withholdings, based on the Compensation
Committee&#146;s determination, in good faith, and based upon the Employee&#146;s individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Employee has met such performance
milestones as are established for the Employee by the Board or the Compensation Committee, in good faith, in consultation with the Employee (hereinafter referred to as the &#147;Performance Milestones&#148;). The Performance Milestones will be based
on certain factors including, but not limited to, the Employee&#146;s performance and the Company&#146;s financial performance. The Employee&#146;s Bonus target will be reviewed annually and may be adjusted by the Board or the Compensation Committee
in its discretion, provided however, that the Bonus target may only be reduced upon Employee&#146;s written consent. The Employee must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions
hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of
partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Employee Benefits.</B> During the Term, Employee shall
be entitled to participate at the same level as other senior executive officers of the Company in any group insurance, hospitalization, medical, health and accident, disability, fringe benefit and tax-qualified retirement plans or programs of the
Company now existing or hereafter established to the extent that he is eligible under the general provisions thereof. For the term of this Agreement, Employee shall be entitled to paid vacation at the rate of (4)&nbsp;weeks per annum. In accordance
with Company policy, unused vacation may not be carried over from year to year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Expenses.</B> The Company shall reimburse Employee for actual, reasonable out-of-pocket expenses incurred
by him in the performance of his services for the Company upon the receipt of appropriate documentation of such expenses which shall be submitted in such form, and with such supporting documentation, as called for or required by Company policy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Termination. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>General. </B>The Term shall end immediately upon Employee&#146;s death. Employee&#146;s employment may also be terminated by the Company with or without Cause or as a result of Employee&#146;s Disability, as defined
in Section&nbsp;7 or by Employee with or without Good Reason (as such terms are defined below). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notice of Termination.</B> Either party shall give written notice of termination to the other party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(c)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notification of New Employer</B>. In the event that Employee leaves the employ of the Company, Employee grants consent to notification by the Company to Employee&#146;s new employer about his rights and obligations
under this Agreement and the PIA (hereinafter defined). </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Severance Benefits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Cause Defined.</B> &#147;Cause&#148; means (i)&nbsp;willful malfeasance or willful misconduct by Employee in connection with his
employment; (ii)&nbsp;Employee&#146;s gross negligence in performing any of his duties under this Agreement; (iii)&nbsp;Employee&#146;s conviction of, or entry of a plea of guilty to, or entry of a plea of <I>nolo contendere</I> with respect to, any
crime other than a traffic violation or infraction which is a misdemeanor; (iv)&nbsp;Employee&#146;s willful and deliberate violation of a Company policy, (v)&nbsp;Employee&#146;s unintended but material breach of any written policy applicable to
all employees adopted by the Company which is not cured to the reasonable satisfaction of the Board of Directors within thirty (30)&nbsp;business days after notice thereof; (vi)&nbsp;the Employee&#146;s unauthorized use or disclosure of any
proprietary information or trade secrets of the Company or any other party as to which the Employee owes an obligation of nondisclosure as a result of the Employee&#146;s relationship with the Company, (vii)&nbsp;the Employee&#146;s willful and
deliberate breach of his obligations under this Agreement, or (viii)&nbsp;any other material breach by Employee of any of his obligations in this Agreement which is not cured to the reasonable satisfaction of the Board of Directors within thirty
(30)&nbsp;business days after notice thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Disability Defined. </B>&#147;Disability&#148; shall mean (i)&nbsp;Employee&#146;s
incapacity due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable accommodation, that results in Employee being substantially unable to perform his duties hereunder for six consecutive months
(or for six months out of any nine month period) or (ii)&nbsp;a qualified independent physician mutually acceptable to the Company and Employee determines that Employee is incapacitated due to a physical or mental condition and, if reasonable
accommodation is required by law, after any reasonable accommodation so as to be unable to regularly perform the duties of his position and such condition is expected to be of a permanent or near-permanent duration. Until such time as Employee is
terminated for Disability under this paragraph (b), Employee shall continue to receive his Base Salary hereunder, provided that if the Company provides Employee with disability insurance coverage, payments of Employee&#146;s Base Salary shall be
reduced by the amount of any disability insurance payments received by Employee due to such coverage. The Company shall give Employee written notice of termination due to Disability which shall take effect sixty (60)&nbsp;days after the date it is
sent to Employee unless Employee shall have returned to the performance of his duties hereunder during such sixty (60)&nbsp;day period (whereupon such notice shall become void). In the event that the Company terminates Employee&#146;s employment as
a result of his Disability, Employee shall be entitled to the same benefits as if his employment had been terminated by the Company without Cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Good Reason Defined.</B> For purposes of this Agreement, &#147;Good Reason&#148; shall
mean, without Employee&#146;s written consent: (i)&nbsp;there is a material reduction of the level of Employee&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally,
provided, however, that in no case may the Base Salary be reduced below the amount stated in Section&nbsp;3(a)), (ii)&nbsp;there is a material reduction in Employee&#146;s overall responsibilities or authority, or scope of duties (it being
understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in Employee&#146;s responsibilities or authority); or (iii)&nbsp;there is a material change in the principal geographic location at which
Employee must perform his services (it being understood that the relocation of Employee to a facility or a location within forty (40)&nbsp;miles of the State Capitol Building in Denver, Colorado shall not be deemed material for purposes of this
Agreement). No event shall be deemed to be &#147;Good Reason&#148; if the Company has cured the event (if susceptible to cure) within 30 days of receipt of written notice from Employee specifying the event or events which, absent cure, would
constitute &#147;Good Cause.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Accrued Compensation Defined. </B>Accrued Compensation shall mean an amount which shall include
all amounts earned or accrued by Employee through the date of termination of this Agreement but not paid as of such date, including (i)&nbsp;Base Salary, (ii)&nbsp;reimbursement for business expenses incurred by the Employee on behalf of the
Company, pursuant to the Company&#146;s expense reimbursement policy in effect at such time, (iii)&nbsp;any expense allowance pursuant to Company policy, (iv)&nbsp;accrued but unused vacation pay per Company policy, and (v)&nbsp;bonuses and
incentive compensation earned and awarded prior to the date of termination. Accrued Compensation shall be paid on the first regular pay date after the date of termination (or earlier, if required by applicable law). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Termination. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Cause; Without Good Reason; Death; Disability.</B> If the Company ends the Term for Cause, if Employee resigns as an
employee of the Company for reasons other than an event of Good Reason, the Employee dies or Disability occurs , then the Company shall pay to Employee the Accrued Compensation but shall have no obligation to pay Employee any amount, whether for
salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after the end of the Term, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be
forfeited immediately upon the end of the Term. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date the Company ends the Term
for Cause, or the date of Employee&#146;s death or Disability, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the Employee or his personal representative or executor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Without Cause; Good Reason.</B> In the event that the Company terminates Employee&#146;s employment hereunder without
Cause, or the Employee terminates his employment with Good Reason, he shall be entitled to the Accrued Compensation and, subject to Section&nbsp;21 and 22 below, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) A lump sum payment equal to two times his Base Salary in effect at the date of termination, less applicable withholding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(B) To the extent permitted by the Company&#146;s health insurance carrier and if such coverage
would not result in penalties to the Company under the Patient Protection and Affordable Care Act, continued participation (via state or federal insurance continuation laws such as COBRA, to the extent available) in the health and welfare plans (or
comparable plans, if continued participation in the Company&#146;s plans is not available) provided by the Company to Employee at the time of termination for a period of two years from the date of termination or, if earlier, until he is eligible for
comparable coverage with a subsequent employer. The Company agrees to reimburse the payments Employee makes for such coverage, whether via continuation or separate comparable policy. Premium reimbursements shall be made by the Company to Employee
consistent with the Company&#146;s normal expense reimbursement policy, provided that Employee submits documentation to the Company substantiating his payments for insurance coverage. Employee shall give the Company prompt notice of his eligibility
for comparable coverage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(C) All vested stock options shall remain exercisable from the date of termination until the expiration date of
the applicable award. So long as the Section&nbsp;8&nbsp;below does not apply, then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of
option shares equal to 1/24<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> the number of option shares multiplied by the number of full months of Employee&#146;s employment hereunder shall be deemed vested and immediately exercisable by the
Employee. Any unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be exercisable by the Employee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(D) Any severance payments and/or other separation benefits contemplated by this Agreement are conditional on Employee: (i)&nbsp;continuing to
comply with the terms of this Agreement and the PIA (as defined herein); (ii)&nbsp;delivering prior to or contemporaneously with any such severance payments, and not revoking, (x)&nbsp;a customary general release of claims relating to
Employee&#146;s employment and/or this Agreement against the Company or its successor, its subsidiaries and their respective directors, officers and stockholders and (y)&nbsp;a customary affirmation of Employee&#146;s continuing obligations
hereunder and under the PIA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise required by law, no severance payments and/or benefits under this Agreement will be paid and/or provided
until after the expiration of any relevant revocation period. Subject to the effectiveness of the release, the severance payments shall be paid on the first payroll date that begins 30 days after Employee&#146;s termination of employment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Change in Control Payments.</B> The provisions of this paragraph 8 set forth the terms of an agreement reached between Employee and the Company regarding
Employee&#146;s rights and obligations upon the occurrence of a &#147;Change in Control&#148; (as hereinafter defined) of the Company during the Term. These provisions are intended to assure and encourage in advance Employee&#146;s continued
attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such Change in Control. The following provisions shall apply in the event of a Change in Control, in addition to any payment or
benefit that may be required pursuant to Section&nbsp;7. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Equity.</B> Upon the occurrence of a Change in Control, all stock options,
restricted stock and other stock-based grants to Employee by the Company or that may be granted in the future shall, irrespective of any provisions of his award agreements, immediately and irrevocably vest and become exercisable and any restrictions
thereon shall lapse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Definitions.</B> For purposes of this paragraph 8, the following terms shall have the
following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the acquisition by any individual, entity, or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act) (the
&#147;Acquiring Person&#148;), other than the Company, or any of its Subsidiaries, of beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of
the then outstanding voting securities of the Company entitled to vote generally in the election of directors (excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona fide equity
financing purposes ; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the acquisition of the Company by another entity by means of any transaction or series of related transactions
to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona
fide equity financing purposes ) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain,
immediately after such transaction or series of related transactions, as a result of shares in the Company held by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power represented by
the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) the sale or other disposition of all or substantially all of the assets of the Company in one transaction or series of related
transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Proprietary Information and Inventions Agreement</B>. As a condition of Employee&#146;s employment with the Company, Employee agrees
to sign the Company&#146;s standard form of Proprietary Information and Inventions Agreement (&#147;PIA&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Successors and Assigns. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Employee.</B> This Agreement is a personal contract, and the rights and interests that the Agreement accords to Employee may not be
sold, transferred, assigned, pledged, encumbered, or hypothecated by him. All rights and benefits of Employee shall be for the sole personal benefit of Employee, and no other person shall acquire any right, title or interest under this Agreement by
reason of any sale, assignment, transfer, claim or judgment or bankruptcy proceedings against Employee. Except as so provided, this Agreement shall inure to the benefit of and be binding upon Employee and his personal representatives, distributees
and legatees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) The Company.</B> This Agreement shall be binding upon the Company and inure to the benefit of the Company and of its
successors and assigns, including (but not limited to) any Company that may acquire all or substantially all of the Company&#146;s assets or business or into or with which the Company may be consolidated or merged. Any such successor of the Company
will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#147;successor&#148; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or
otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Entire Agreement.</B> This Agreement (together with the equity award agreements referred to herein)
represents the entire agreement between the parties concerning Employee&#146;s employment with the Company and supersedes all prior negotiations, discussions, understanding and agreements, whether written or oral, between Employee and the Company
relating to the subject matter of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Amendment or Modification, Waiver.</B> No provision of this Agreement may be amended or waived
unless such amendment or waiver is agreed to in writing signed by Employee and by a duly authorized officer of the Company. No waiver by any party to this Agreement or any breach by another party of any condition or provision of this Agreement to be
performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Notices.</B> Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or
certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to
Employee:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the address specified in the payroll records of the Company. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rosewind Corporation</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 200</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by
registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Severability.</B> If any
provision of this Agreement or the application of any such provision to any party or circumstances shall be determined by any court of competent jurisdiction or arbitrator acting pursuant to Section&nbsp;19 below to be invalid and unenforceable to
any extent, the remainder of this Agreement or the application of such provision to such person or circumstances other than those to which it is so determined to be invalid and unenforceable shall not be affected, and each provision of this
Agreement shall be validated and shall be enforced to the fullest extent permitted by law. If for any reason any provision of this Agreement containing restrictions is held to cover an area or to be for a length of time that is unreasonable or in
any other way is construed to be too broad or to any extent invalid, such provision shall not be determined to be entirely null, void and of no effect; instead, it is the intention and desire of both the Company and Employee that, to the extent that
the provision is or would be valid or enforceable under applicable law, any court of competent jurisdiction or arbitrator acting pursuant to Section&nbsp;19 below shall construe and interpret or reform this Agreement to provide for a restriction
having the maximum enforceable area, time period and such other constraints or conditions (although not greater than those contained currently contained in this Agreement) as shall be valid and enforceable under the applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Survivorship.</B> The respective rights and obligations of the parties hereunder shall survive any
termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Headings.</B> All descriptive
headings of sections and paragraphs in this Agreement are intended solely for convenience of reference, and no provision of this Agreement is to be construed by reference to the heading of any section or paragraph. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Withholding Taxes.</B> All salary, benefits, reimbursements and any other payments to Employee under this Agreement shall be subject to all applicable
payroll and withholding taxes and deductions required by any law, rule or regulation of and federal, state or local authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Counterparts.</B>
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together constitute one and same instrument. The parties agree that facsimile signatures shall have the same force and
effect as original signatures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Applicable Law; Arbitration.</B> The validity, interpretation and enforcement of this Agreement and any amendments
or modifications hereto shall be governed by the laws of the State of Colorado, as applied to a contract executed within and to be performed in such State. The parties agree that any disputes shall be definitively resolved by binding arbitration
before the American Arbitration Association in Denver, Colorado in accordance with its rules of arbitration procedure then in effect. The parties consent to the jurisdiction to the federal courts of the District of Colorado or, if there shall be no
jurisdiction, to the state courts located in Arapahoe County, Colorado, to enforce any arbitration award rendered with respect thereto. Each party shall choose one arbitrator and the two arbitrators shall choose a third arbitrator. All costs and
fees related to such arbitration (and judicial enforcement proceedings, if any) shall be borne by the Company unless Employee&#146;s claim is deemed to be frivolous by the arbitrator(s) or judge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Legal Fees.</B> The Company shall pay the reasonable expenses of Employee&#146;s counsel in negotiating this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Section&nbsp;409A. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Anything in
this Agreement to the contrary notwithstanding, if at the time of Employee&#146;s separation from service within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), the Company determines that
Employee is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#146;s separation
from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment
shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after Employee&#146;s separation from service, or (B)&nbsp;Employee&#146;s death. If any such delayed cash payment is
otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All in-kind benefits provided and expenses eligible for
reimbursement under this Agreement shall be provided by the Company or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any
reimbursement be paid after the last day of the taxable year following the taxable year in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses
eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another
benefit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes &#147;non-qualified deferred
compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#146;s termination of employment, then such payments or benefits shall be payable only upon Employee&#146;s
&#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&nbsp;1.409A 1(h). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this
Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&nbsp;1.409A 2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully
comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Application of Internal Revenue Code Section&nbsp;280G. </B>If any payment or benefit Employee would receive pursuant to a Change in Control from the
Company or otherwise (&#147;<I>Payment</I>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by
Section&nbsp;4999 of the Code (the &#147;<I>Excise Tax</I>&#148;), then such Payment shall be equal to the Reduced Amount. The &#147;Reduced Amount&#148; shall be either (x)&nbsp;the largest portion of the Payment that would result in no portion of
the Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the
Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#146;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.
If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Employee. If more
than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event it is subsequently
determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x)&nbsp;in the preceding paragraph is subject to the Excise Tax, Employee agrees to promptly return to the Company a sufficient
amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y)&nbsp;in the preceding paragraph, Employee will have no obligation to
return any portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless Employee and the Company agree on an alternative accounting firm, the
accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as
accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with
respect to the determinations by such accounting firm required to be made hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Employee and the Company within fifteen (15)&nbsp;calendar days after the date on which Employee&#146;s right to a Payment is triggered (if
requested at that time by the Employee or the Company) or such other time as requested by Employee or the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Indemnification.</B> As a
condition to the effectiveness of this Agreement, the Company and Employee shall enter into a mutually acceptable indemnification agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement as of the date first written above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>EMPLOYEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Michael Macaluso</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chairman,</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Board of Directors</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Employment Agreement] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Terms of Equity Compensation </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management equity grant</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">[&#149;] total options to purchase shares of the Company&#146;s common stock. The strike price for all options will be the last sale price of the Company&#146;s common stock as reported on April [&#149;], 2015 and in
accordance with the terms of the Company&#146;s Stock and Incentive Plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All options fully vest upon Change in Control, death, Disability, termination with or without Cause, termination for Good Reason </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">[&#149;] options are fully vested on the Effective Date of this agreement </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">[&#149;] options vest 365 days thereafter </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">[&#149;] options vest 730 days thereafter </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT AND ASSUMPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This ASSIGNMENT AND ASSUMPTION AGREEMENT (this &#147;<U>Assignment</U>&#148;) is dated as of April [&#149;], 2015, by and between Vyrix
Pharmaceuticals, Inc., a Delaware corporation (&#147;<U>Vyrix</U>&#148;), Luoxis Diagnostics, a Delaware corporation (&#147;<U>Luoxis</U>&#148; and, together with Vyrix, each an &#147;<U>Assignor</U>&#148;), Rosewind Corporation, a Colorado
corporation (&#147;<U>Assignee</U>&#148;), and Ampio Pharmaceuticals, Inc., a Delaware corporation (&#147;<U>Counterparty</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with that certain Agreement and Plan of Merger by and among Assignors, Assignee, and the other parties thereto, dated
April [&#149;], 2015, each Assignor desires, for good and valuable consideration, the receipt and adequacy which are acknowledged, to assign and transfer all of its rights and interests in and under the Contracts (as defined below) to Assignee and
Assignee desires to accept such assignment and transfer and to assume the Contracts as of the date hereof, each in accordance with the terms and conditions of this Assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each Contract provides that such Contract may not be assigned without the prior written consent of the parties to the Contract. As
such, this Assignment requires the written consent of Counterparty as the counterparty to each Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration
of the mutual promises, covenants and conditions set forth herein, the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Assignment</U>. Each
Assignor hereby sells, assigns, transfers and conveys to Assignee, its successors and assigns, effective as of the date hereof, all of Assignor&#146;s rights, title and interest in and under the following contracts: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Services Agreement between Ampio Pharmaceuticals, Inc. and Vyrix Pharmaceuticals, Inc., dated as of January&nbsp;1, 2014 (the
&#147;<U>Vyrix Contract</U>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Services Agreement between Ampio Pharmaceuticals, Inc. and Luoxis Diagnostics, Inc., dated as
of January&nbsp;1, 2013 (the &#147;<U>Luoxis Contract</U>&#148; and, together with the Vyrix Contract, the &#147;<U>Contracts</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Assumption</U>. Assignee, for itself and its successors and assigns, hereby accepts each Assignor&#146;s assignment and assumes and
agrees to be bound by and solely perform, effective as of the date hereof, all of the obligations, liabilities and duties of Assignor under each of the Contracts. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Consent</U>. Counterparty consents and agrees that each Contract shall remain in full force and effect in accordance with its terms
notwithstanding this Assignment and that Counterparty waives any termination or other rights that it may have under the Contracts that arise solely by virtue of this Assignment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Governing Law</U>. This Assignment shall be governed by, construed and enforced in accordance with the laws of the State of Delaware.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Counterparts</U>. This Assignment may be signed in any number of counterparts, all of which together shall constitute one and the
same instrument. Any party may execute and deliver this Assignment by an executed signature page transmitted by electronic scan (pdf) or a facsimile machine. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Binding Effect</U>. If and when this Assignment becomes effective, this Assignment shall be
binding upon each Assignor, its successors and assigns, and shall inure to the benefit of Assignee, its successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page follows.</I>]<I> </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed by their
respective officers thereunto duly authorized, as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ASSIGNORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">VYRIX PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:&nbsp;&nbsp;Jarrett Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LUOXIS DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:&nbsp;&nbsp;Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ASSIGNEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ROSEWIND, CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:&nbsp;&nbsp;James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:&nbsp;&nbsp;&nbsp;&nbsp;President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COUNTERPARTY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMPIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:&nbsp;&nbsp;Gregory A. Gould</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>SSIGNMENT</SMALL>
<SMALL>AND</SMALL> A<SMALL>SSUMPTION</SMALL> A<SMALL>GREEMENT</SMALL>] </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>3
<FILENAME>d912919dex22.htm
<DESCRIPTION>EX-2.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF MERGER </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ROSEWIND MERGER SUB L, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WITH
AND INTO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LUOXIS DIAGNOSTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;251 of
the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), the undersigned corporation does hereby certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The
constituent corporations (the &#147;<B><I>Constituent Corporations</I></B>&#148;) participating in the merger herein certified (the &#147;<B><I>Merger</I></B>&#148;) are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Rosewind Merger Sub L, Inc., which is incorporated under the laws of the State of Delaware (&#147; <B><I>Merger Sub</I></B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Luoxis Diagnostics, Inc., which is incorporated under the laws of the State of Delaware (&#147;<B><I>Luoxis</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. An Agreement and Plan of Merger (the &#147;<B><I>Merger Agreement</I></B>&#148;), dated as of April&nbsp;16, 2015, by and among the individuals identified
therein as Parent Major Stockholders, Rosewind Corporation, a Colorado corporation, Merger Sub, Luoxis, Rosewind Merger Sub V, Inc., a Delaware corporation, and Vyrix Pharmaceuticals, Inc., a Delaware corporation, has been approved, adopted,
certified, executed and acknowledged by each of the Constituent Corporations in accordance with Section&nbsp;251 and 228 of the DGCL. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The name of the
surviving corporation in the Merger is Luoxis Diagnostics, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The certificate of incorporation of the surviving corporation at the effective time of
the Merger shall be amended and restated as set forth on <U>Exhibit A</U> hereto, and as so amended and restated, shall be the certificate of incorporation of the surviving corporation until thereafter amended as provided therein or pursuant to the
provisions of the laws of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The Merger shall be effective upon the filing of this Certificate of Merger with the Secretary of the
State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. An executed copy of the Merger Agreement is on file at an office of the aforesaid surviving corporation, the address of which is as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Luoxis Diagnostics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. A copy of the Merger Agreement will be furnished by the aforesaid surviving corporation, on request, and
without cost, to any stockholder of either of the Constituent Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>.] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Luoxis Diagnostics, Inc. has caused this Certificate of Merger to be executed
by its duly authorized officer this 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of April, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">LUOXIS DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua R. Disbrow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Joshua R. Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>OSEWIND</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> L C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> M<SMALL>ERGER</SMALL> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATE OF INCORPORATION </U></B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LUOXIS DIAGNOSTICS,
INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIRST:</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The name of this corporation shall be: Luoxis Diagnostics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SECOND</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its registered office in the State of Delaware is to be located at:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is: The Corporation Trust Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>THIRD</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The purpose or purposes of the corporation shall be:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">To carry on any and all business and to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FOURTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The total number of shares of stock which this corporation is authorized to issue is:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">One Thousand (1,000)&nbsp;shares of Common Stock, par value $0.001 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIFTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to adopt, amend or repeal the by-laws of the corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SIXTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Elections of directors need not be by written ballot unless the by-laws of the corporation shall so provide.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SEVENTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s
duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section 174 of the Delaware General Corporation Law, or
(iv)&nbsp;for any transaction from which the director derived any improper personal benefit. If the Delaware General Corporation Law is amended after the effective date of this Certificate of Incorporation to authorize corporate action further
eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware. No amendment,
modification or repeal of this Article EIGHTH shall adversely affect the rights and protection afforded to a director of the corporation under this Article EIGHTH Section for acts or omissions occurring prior to such amendment, modification or
repeal.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>EIGHTH:</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The corporation reserves the right to amend or repeal this Certificate of Incorporation in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein
are granted subject to this reservation. Whenever any vote of the holders of capital stock of the corporation is required to amend or repeal any provision of this Certificate of Incorporation, and in addition to any other vote of holders of capital
stock that is required by this Certificate of Incorporation or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the
affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF MERGER </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ROSEWIND MERGER SUB V, INC.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WITH AND INTO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VYRIX
PHARMACEUTICALS, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;251 of the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), the undersigned corporation does
hereby certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The constituent corporations (the &#147;<B><I>Constituent Corporations</I></B>&#148;) participating in the merger herein certified
(the &#147;<B><I>Merger</I></B>&#148;) are: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Rosewind Merger Sub V, Inc., which is incorporated under the laws of the State of Delaware
(&#147; <B><I>Merger Sub</I></B>&#148;); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Vyrix Pharmaceuticals, Inc., which is incorporated under the laws of the State of Delaware
(&#147;<B><I>Vyrix</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. An Agreement and Plan of Merger (the &#147;<B><I>Merger Agreement</I></B>&#148;), dated as of April&nbsp;16, 2015,
by and among the individuals identified therein as Parent Major Stockholders, Rosewind Corporation, a Colorado corporation, Rosewind Merger Sub L, Inc., a Delaware corporation, Luoxis Diagnostics, Inc., a Delaware corporation, Merger Sub and Vyrix,
has been approved, adopted, certified, executed and acknowledged by each of the Constituent Corporations in accordance with Section&nbsp;251 and 228 of the DGCL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. The name of the surviving corporation in the Merger is Vyrix Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The certificate of incorporation of the surviving corporation at the effective time of the Merger shall be amended and restated as set forth on <U>Exhibit
A</U> hereto, and as so amended and restated, shall be the certificate of incorporation of the surviving corporation until thereafter amended as provided therein or pursuant to the provisions of the laws of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The Merger shall be effective upon the filing of this Certificate of Merger with the Secretary of the State of Delaware. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. An executed copy of the Merger Agreement is on file at an office of the aforesaid surviving corporation, the address of which is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Vyrix Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">373
Inverness Parkway, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. A copy of the Merger Agreement will be furnished by the aforesaid surviving corporation, on request, and
without cost, to any stockholder of either of the Constituent Corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature page follows.</I>]<I> </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Vyrix Pharmaceuticals, Inc. has caused this Certificate of Merger to be
executed by its duly authorized officer this 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of April, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VYRIX PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jarrett Disbrow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Jarrett Disbrow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> R<SMALL>OSEWIND</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> V C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> M<SMALL>ERGER</SMALL> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATE OF INCORPORATION</U> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VYRIX
PHARMACEUTICALS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIRST:</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The name of this corporation shall be: Vyrix Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SECOND</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Its registered office in the State of Delaware is to be located at:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">1209 Orange Street, in the City of Wilmington, County of New Castle, 19801, and its registered agent at such address is: The Corporation Trust Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>THIRD</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The purpose or purposes of the corporation shall be:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">To carry on any and all business and to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FOURTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The total number of shares of stock which this corporation is authorized to issue is:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">One Thousand (1,000) shares of Common Stock, par value $0.001 per share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>FIFTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly authorized to adopt, amend or repeal the by-laws of the corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SIXTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Elections of directors need not be by written ballot unless the by-laws of the corporation shall so provide.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>SEVENTH</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">A director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the director&#146;s
duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section 174 of the Delaware General Corporation Law, or
(iv)&nbsp;for any transaction from which the director derived any improper personal benefit. If the Delaware General Corporation Law is amended after the effective date of this Certificate of Incorporation to authorize corporate action further
eliminating or limiting the personal liability of directors, then the liability of a director of the corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware. No amendment,
modification or repeal of this Article EIGHTH shall adversely affect the rights and protection afforded to a director of the corporation under this Article EIGHTH Section for acts or omissions occurring prior to such amendment, modification or
repeal.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>EIGHTH:</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The corporation reserves the right to amend or repeal this Certificate of Incorporation in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein
are granted subject to this reservation. Whenever any vote of the holders of capital stock of the corporation is required to amend or repeal any provision of this Certificate of Incorporation, and in addition to any other vote of holders of capital
stock that is required by this Certificate of Incorporation or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the
affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Document processing fee</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If document is filed on paper</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$150.00</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If document is filed electronically</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Currently Not Available</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees&nbsp;&amp; forms/cover sheets are subject to change.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To file electronically, access instructions for this form/cover sheet and other information or print copies of filed documents, visit
www.sos.state.co.us and select Business.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paper documents must be typewritten or machine printed.</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" NOWRAP>ABOVE SPACE FOR OFFICE USE ONLY</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement of Merger </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Surviving Entity is a Domestic Entity) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">filed pursuant to &#167; 7-90-203.7 of the Colorado Revised Statutes (C.R.S.) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">For each <U>merging</U> entity, its ID number (if applicable), entity name or true name, form of entity, jurisdiction under the law of which it is formed, and principal address are </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID Number</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">20131023976</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5">&nbsp;&nbsp;&nbsp;&nbsp;<I>(Colorado Secretary of State ID number)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Entity name or true name</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Luoxis Diagnostics, Inc.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Form of entity</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Corporation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jurisdiction</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Delaware</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Street</U> address</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Englewood</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">CO</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">80112</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">USA</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Mailing</U> address</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(<B>leave blank </B>if same as street address)</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name or Post Office Box information)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGE_DOM</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">Page 1 of 4</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Rev. 5/29/2007</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID Number</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">20131624127</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><I>&nbsp;&nbsp;&nbsp;&nbsp;(Colorado Secretary of State ID number)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Entity name or true name</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Vyrix Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Form of entity</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Corporation</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jurisdiction</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Delaware</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Street</U> address</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Englewood</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">CO</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">80112</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">USA</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Mailing</U> address</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(<B>leave blank </B>if same as street address)</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name or Post Office Box information)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID Number</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><I>&nbsp;&nbsp;&nbsp;&nbsp;(Colorado Secretary of State ID number)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Entity name or true name</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Form of entity</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jurisdiction</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Street</U> address</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Mailing</U> address</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(<B>leave blank </B>if same as street address)</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name or Post Office Box information)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>(If the following statement applies, adopt the statement by marking the box and include an attachment.)
</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">There are more than three merging entities and the ID number (if applicable), entity name or true name, form of entity, jurisdiction under the law of which it is formed, and the principal address of each additional
merging entity is stated in an attachment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGE_DOM</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">Page 2 of 4</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Rev. 5/29/2007</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">For the <U>surviving</U> entity, its entity ID number (if applicable), entity name or true name, form of entity, jurisdiction under the law of which it is formed, and principal address are </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID Number</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">20021219479</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><I>&nbsp;&nbsp;&nbsp;&nbsp;(Colorado Secretary of State ID number)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Entity name or true name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Rosewind Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Form of entity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Colorado</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Street</U> address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">16200 West County Road 18E</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Loveland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">CO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">80537</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">USA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Mailing</U> address</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(<B>leave blank </B>if same as street address)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><I>(Street number and name or Post Office Box information)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Each merging entity has been merged into the surviving entity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><I>(If the following statement applies, adopt the statement by marking the box.) </I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">The plan of merger provides for amendments to a constituent filed document of the surviving entity and an appropriate statement of change or other document effecting the amendments will be delivered to the Secretary of
State for filing pursuant to Part 3 of Article 90 of Title 7, C.R.S. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><I>(If the following statement applies, adopt the statement by marking the box and state the appropriate document number(s).) </I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">One or more of the merging entities is a registrant of a trademark described in a filed document in the records of the secretary of state and the document number of each filed document is </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Document number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Document number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Document number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><I>(If the following statement applies, adopt the statement by marking the box and include an attachment.)
</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">There are more than three trademarks and the document number of each additional trademark is stated in an attachment. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"><I>(If applicable, adopt the following statement by marking the box and include an attachment.)</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">This document contains additional information as provided by law. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><I>(</I><B><I>Caution:</I></B><I> <U>Leave blank</U> if the document does not have a delayed effective date. Stating a delayed effective date has significant legal consequences. Read instructions before entering a
date.) </I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>(If the following statement applies, adopt the statement by entering a date and, if applicable, time using
the required format.) </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">The delayed effective date and, if applicable, time of this document are</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>.</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:10pt"><I>(mm/dd/yyyy hour:minute am/pm)</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGE_DOM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Page 3 of 4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Rev. 5/29/2007</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Causing this document to be delivered to the Secretary of State for filing shall constitute the affirmation or acknowledgment of each individual causing such
delivery, under penalties of perjury, that such document is such individual&#146;s act and deed, or that such individual in good faith believes such document is the act and deed of the person on whose behalf such individual is causing such document
to be delivered for filing, taken in conformity with the requirements of part 3 of article 90 of title 7, C.R.S. and, if applicable, the constituent documents and the organic statutes, and that such individual in good faith believes the facts stated
in such document are true and such document complies with the requirements of that Part, the constituent documents, and the organic statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
perjury notice applies to each individual who causes this document to be delivered to the Secretary of State, whether or not such individual is identified in this document as one who has caused it to be delivered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. The true name and mailing address of the individual causing this document to be delivered for filing are </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Gomez</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Christina</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">M</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>(Last)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(First)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Middle)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(Suffix)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">c/o Goodwin Procter LLP</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7" ALIGN="center"><I>(Street number and name or Post Office Box information)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Three Embarcadero Center, 24th Floor</P></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">San Francisco</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">CA</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">94111</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><I>(ZIP/Postal Code)</I></TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="10%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><I>(Province &#150; if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><I>(Country)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>(If applicable, adopt the following statement by marking the box and include an attachment.)</I> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">This document contains the true name and mailing address of one or more additional individuals causing the document to be delivered for filing. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimer: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This form/cover sheet, and any related
instructions, are not intended to provide legal, business or tax advice, and are furnished without representation or warranty. While this form/cover sheet is believed to satisfy minimum legal requirements as of its revision date, compliance with
applicable law, as the same may be amended from time to time, remains the responsibility of the user of this form/cover sheet. Questions should be addressed to the user&#146;s legal, business or tax advisor(s). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MERGE_DOM</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">Page 4 of 4</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Rev. 5/29/2007</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Business Information Survey (Optional)</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">For office use only</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Submit with your form if you want to add, change, or remove survey information</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Survey information can be added, changed, or removed when you file a form with our office. The information on this survey is associated with the entity&#146;s record- it does not become a part of the document that you file with
us.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">This survey is voluntary. Any information that you enter will be available to the public. The information is being gathered as required by law- see House Bill 13-1167 for information.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Entity information </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID number</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Entity name</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">20021219479</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">Rosewind Corporation</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Choose one: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> 1. Remove all survey information from this entity&#146;s record. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt"> 2. Add or update the survey information on this entity&#146;s record as follows: </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">a) Gender </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> Male </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt"> Female </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> Choose not to answer / Remove this information </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">b) Veteran? </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> Yes </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt"> No </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> Choose not to answer / Remove this information </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">c) Person with a disability? </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> Yes </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt"> No </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:14pt"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> Choose not to answer / Remove this information </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">d) Race </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> African American</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> Latino</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> Anglo</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> Native American</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> Asian</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> Other</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-size:14pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#111;</FONT></FONT> Choose not to answer / Remove this information</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SurveyInfo</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">Page 1 of 2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Rev. 12/11/2013</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Entity information continued </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">e)&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9">NAICS code(s)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="9"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enter up to five. For more information, see the NAICS Association site at <U>www.naics.com/search.htm</U>.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Filer&#146;s information </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Middle</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Last</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Suffix</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">Christina</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">M</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Gomez</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address 1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Address 2</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">c/o Goodwin Procter LLP</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">Three Embarcadero Center, 24th Floor</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">City</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">State</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">ZIP code</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Province</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Country</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt">San Francisco</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">CA</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">94111</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8pt">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SurveyInfo</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="center">Page 2 of 2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">Rev. 12/11/2013</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mail form with correct payment to: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Colorado Secretary of State </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1700
Broadway Ste 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Denver, CO 80290 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Make checks payable to:</B> Colorado Secretary of State </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Include a separate check for each form submitted for filing. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">If a document is rejected, this will allow us to return the check at </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">the time of rejection (if applicable). The document can be </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">corrected and resubmitted with the returned check. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Checks must be written for the exact amount</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>or the document may be rejected and returned.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Do not include this page with your filing. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF OWNERSHIP AND MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MERGING </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VYRIX
PHARMACEUTICALS, INC., a Delaware Corporation </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LUOXIS DIAGNOSTICS, INC., a Delaware Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITH AND INTO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROSEWIND
CORPORATION, a Colorado Corporation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;16, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;253 of the Delaware General Corporation Law (the&nbsp;<B>&#148;</B><U>DGCL</U><B>&#148;</B>), Rosewind Corporation, a
Colorado corporation (the &#147;<U>Corporation</U>&#148;), does hereby certify to the following information relating to the mergers (the&nbsp;&#147;<U>Mergers</U><B>&#148;</B>) of Luoxis Diagnostics, Inc., a Delaware corporation
(&#147;<U>Luoxis</U>&#148;), and Vyrix Pharmaceuticals, Inc., a Delaware corporation (<B>&#147;</B><U>Vyrix</U><B>&#148;</B>), with and into the Corporation, with the Corporation remaining as the surviving corporation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Both Luoxis and Vyrix are incorporated pursuant to the DGCL, the provisions of which permit a merger of a corporation of that jurisdiction with a corporation of another jurisdiction. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The Corporation is incorporated pursuant to the Colorado Business Corporation Act (the &#147;<U>CBCA</U>&#148;), the provisions of which permit a merger of a corporation of that jurisdiction with a corporation of
another jurisdiction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Corporation is the owner of all of the issued and outstanding shares of capital stock of each of Luoxis and Vyrix that, absent Section&nbsp;253 of the DGCL, would be entitled to vote on the Merger.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Board of Directors of the Corporation, by resolutions duly adopted by unanimous written consent on March&nbsp;24, 2015, determined to merge each of Luoxis and Vyrix with and into the Corporation pursuant to
Section&nbsp;253 of the DGCL, which resolutions are as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>WHEREAS:</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The Corporation owns all of the issued and outstanding shares of each class of capital stock of each of Luoxis and Vyrix.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>WHEREAS</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">It is deemed advisable and in the best interest of the Corporation that the Corporation merge each of Luoxis and Vyrix with and into the Corporation.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, BE IT: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESOLVED:</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">That, as a result of the Mergers, the Corporation shall be the surviving corporation possessed of all the estate, property, rights, privileged and franchises of each of Luoxis and Vyrix, and the Corporation shall assume all of the
liabilities and obligations of each of Luoxis and Vyrix pursuant to and in the manner prescribed by Section 253 of the DGCL.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESOLVED</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">The separate existence of each of Luoxis and Vyrix shall cease as soon as the Mergers shall become effective, and the Corporation shall continue as the surviving corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESOLVED</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">That the proper officers of the Company be, and each of them acting singly hereby is, authorized, empowered and directed in the name and on behalf of the Corporation, to execute and file or cause to be filed and/or recorded the
documents prescribed by the (i) laws of the State of Delaware, including, without limitation, an appropriate Certificate of Ownership and Merger (the &#147;<U>Certificate of Merger</U>&#148;) embodying these resolutions as required by Section 253 of
the DGCL and any and all additional documents and information required to be filed therewith, filed with the Secretary of State of the State of Delaware, (ii) by the laws of the State of Colorado, and by the laws of any other appropriate
jurisdiction and will cause to be performed all necessary acts within the jurisdiction of organization of Luoxis, Vyrix and of the Corporation and in any other appropriate jurisdiction.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESOLVED</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">That the Mergers shall be effective upon the filing of the Certificate of Merger with the Secretary of the State of Delaware.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>RESOLVED</U>:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">That, upon the proposed Mergers becoming effective, each outstanding share of capital stock of each of Luoxis and Vyrix owned of record by the Corporation shall cease to be outstanding, without any payment being made in respect
thereof.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The Corporation shall be the surviving corporation of the Mergers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">The Certificate of Incorporation of the Corporation, as in effect immediately prior to the Merger, shall be the Certificate of Incorporation of the surviving corporation. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">This Certificate of Ownership and Merger and the Mergers shall become effective upon the filing of such Certificate of Ownership and Merger with the Delaware Secretary of State. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">The Corporation agrees that it may be served with process in the State of Delaware in any proceeding for enforcement of any obligation of any constituent corporation of Delaware, as well as the enforcement of any
obligation of the Corporation arising from the Merger, and irrevocably appoints the Secretary of State of Delaware as its agent to accept services of process in any such suit or proceeding. The Secretary of State shall mail a copy of any such
process to the Corporation at: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rosewind Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">c/o Ampio Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">373 Inverness Parkway, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: <U>ggould@ampiopharma.com</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">The Mergers have been adopted, approved, certified, executed and acknowledged by the Corporation pursuant to and in accordance with the CBCA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page is intentionally left blank </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has caused this Certificate of Ownership and Merger to
be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James B. Wiegand</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Date: President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> C<SMALL>ERTIFICATE</SMALL>
<SMALL>OF</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">O<SMALL>WNERSHIP</SMALL> <SMALL>AND</SMALL> M<SMALL>ERGER</SMALL> <SMALL>RE</SMALL>: R<SMALL>OSEWIND</SMALL>
M<SMALL>ERGER</SMALL> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>4
<FILENAME>d912919dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919g10v78.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Department of State Certificate </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">I, WAYNE W.
WILLIAMS, SECRETARY OF STATE OF THE STATE OF COLORADO HEREBY CERTIFY THAT ACCORDING TO THE RECORDS OF THIS OFFICE, THE ATTACHED IS A FULL, TAKE AND COMPLETE COPY OF THE ARTICLES OF INCORPORATION AND ALL AMENDMENTS THERETO OF ROSEWIND CORPORATION
(COLORADO CORPORATION) AS FILED IN THIS OFFICE AND ADMITTED TO RECORD. I FURTHER CERTIFY THAT SAID ENTITY HAS COMPLIED WITH ALL APPLICABLE REQUIREMENTS OF THIS OFFICE, AND IS IN GOOD STANDING WITH THIS OFFICE. Dated: April&nbsp;9, 2015 SECRETARY OF
STATE </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g912919g15i50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLES OF INCORPORATION </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rosewind Corporation </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, who if a natural person, is more than eighteen years of age, hereby establishes a corporation pursuant to the Statutes of
Colorado and adopts the following Articles of Incorporation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST: The name of the corporation is Rosewind Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND: The corporation shall have perpetual existence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD: (a)&nbsp;Purposes. The nature, objects and purposes of the business to be transacted shall be to transact all lawful business for which
corporations may be incorporated pursuant to the Colorado Business Corporation Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Powers. In furtherance of the foregoing purposes,
the corporation shall have and may exercise all of the rights, powers and privileges now or thereafter conferred upon corporations organized under the laws of Colorado. In addition, it may do everything necessary, suitable or proper for the
accomplishment of any of its corporation purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOURTH: (a)&nbsp;The aggregate number of shares which the corporation shall have
authority to issue is 20,000,000 shares of common stock having no par value per share. The shares of this class of common stock shall have unlimited voting rights and shall constitute the sole voting group of the corporation, except to the extent
any additional voting group or groups may hereafter be established in accordance with the Colorado Business Corporation Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The
corporation may also issue up to 5,000,000 shares of non-voting preferred stock having no par value. The preferred stock of the corporation shall be issued in one or more series as may be determined from time to time by the Board of Directors. In
establishing a series, the Board of Directors shall give to it a distinctive designation so as to distinguish it from the shares of all other series and classes, shall fix the number of shares in such series, and the preferences, rights and
restrictions thereof. All shares in a series shall be alike. Each series may vary in the following respects: (1)&nbsp;the rate of the dividend; (2)&nbsp;the price at the terms and conditions on which shares shall be redeemed; (3)&nbsp;the amount
payable upon shares in the event of involuntary liquidation; (4)&nbsp;the amount payable upon shares in the event of voluntary liquidation; (5)&nbsp;sinking fund provisions for the redemption of shares; (6)&nbsp;the terms and conditions on which
shares may be converted if the shares of any series are issued with the privilege of conversion; and (7)&nbsp;voting powers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Each
shareholder of record shall have one vote for each share of stock standing in his name on the books of the corporation and entitled to vote. Cumulative voting shall not be permitted in the election of directors or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) At all meetings of shareholders, a majority of the shares of a voting group entitled to vote at such meeting, represented in person or by
proxy, shall constitute a quorum of that voting group. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Shareholders of the corporation shall not have preemptive rights to subscribe
for any additional unissued or treasury shares of stock or for other securities of any class, or for rights, warrants or options to purchase stock, or for scrip, or for securities of any kind convertible into stock or carrying stock purchase
warrants or privileges. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIFTH: The number of directors of the corporation shall be fixed by the bylaws. One director
shall constitute the initial board of directors. The names and addresses of the initial directors are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="text-indent:2.00em; font-size:10pt; font-family:Times New Roman">James B. Wiegand</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">10077 E<SUP STYLE="font-size:85%; vertical-align:top"></SUP>. County Line Rd.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Longmont, CO 80501</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SIXTH: The address of the initial registered office of the corporation is 10077 E. County Line Rd., Longmont,
Colorado 80501. The name of its initial registered agent at such address is James B. Wiegand. The corporation may conduct part or all of its business in any other part of Colorado, of the United States or of the world. It may hold, purchase,
mortgage, lease and convey real and personal property in any of such places. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEVENTH: The address of the initial principal office of the
corporation is 10077 E. County Line Rd., Longmont, CO 80501. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EIGHTH: The following provisions are inserted for the management of the
business and for the conduct of the affairs of the corporation, and the same are in furtherance of and not in limitation or exclusion of the powers conferred by law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Conflicting Interest Transactions. As used in this paragraph, &#147;conflicting interest transaction&#148; means any of the following: (i)
a loan or other assistance by the corporation to a director of the corporation or to an entity in which a director of the corporation is a director or officer or has a financial interest; (ii) a guaranty by the corporation of an obligation of a
director of the corporation or of an obligation of an entity in which a director of the corporation is a director or officer or has a financial interest; or (iii)&nbsp;a contract or transaction between the corporation and a director of the
corporation or between the corporation and an entity in which a director of the corporation, is a director or officer or has a financial interest. No conflicting interest transaction shall be void or voidable, be enjoined, be set aside or give rise
to an award of damages or other sanctions in a proceeding by a shareholder or by or in the right of the corporation, solely because the conflicting interest transaction involves a director of the corporation or an entity in which a director of the
corporation is a director or officer or has a financial interest, or solely because the director is present at or participates in the meeting of the corporation&#146;s board of directors or of the committee of the board of directors which
authorizes, approves or ratifies a conflicting interest transaction, or solely because the director&#146;s vote is counted for such purpose if: (A)&nbsp;the material facts as to the director&#146;s relationship or interest and as to the conflicting
interest transaction are disclosed or are known to the board of directors or the committee, and the board of directors or committee in good faith authorizes, approves or ratifies the conflicting interest transaction by the affirmative vote of a
majority of the disinterested directors, even though the disinterested directors are less than a quorum; or (B)&nbsp;the material facts as to the director&#146;s relationship or interest and as to the conflicting interest transaction are disclosed
or are known to the shareholders entitled to vote thereon, and the conflicting interest transaction is specifically authorized, approved or ratified in good faith by a vote of the shareholders; or (C)&nbsp;a conflicting interest transaction is fair
as to the corporation as of the time it is authorized, approved or ratified by the board of directors, a committee thereof or the shareholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the
board of directors or of a committee which authorizes, approves or ratifies the conflicting interest transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Loans and Guaranties
for the Benefit of Directors. Neither the board of directors nor any committee thereof shall authorize a loan by the corporation to a director of the corporation or to an entity in which a director of the corporation is a director or officer or has
a financial interest, or a guaranty by the corporation of an obligation of a </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
director of the corporation or of an obligation of an entity in which a director of the corporation is a director or officer or has a financial interest, until at least ten days after written
notice of the proposed authorization of the loan or guaranty has been given to the shareholders who would be entitled to vote thereon if the issue of the loan or guaranty were submitted to a vote of the shareholders. The requirements of this
paragraph (b) are in addition to, and not in substitution for, the provisions of paragraph (a)&nbsp;of Article EIGHTH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)
Indemnification. The corporation shall indemnify, to the maximum extent permitted by law, any person who is or was a director, officer, agent, fiduciary or employee of the corporation against any claim, liability or expense arising against or
incurred by such person made party to a proceeding because he is or was a director, officer, agent, fiduciary or employee of the corporation or because he is or was serving another entity as a director, officer, partner, trustee, employee, fiduciary
or agent at the corporation&#146;s request. The corporation shall further have the authority to the maximum extent permitted by law to purchase and maintain insurance providing such indemnification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Limitation on Director&#146;s Liability. No director of this corporation shall have any personal liability for monetary damages to the
corporation or its shareholders for breach of his fiduciary duty as a director, except that this provision shall not eliminate or limit the personal liability of a director to the corporation or its shareholders for monetary damages for:
(i)&nbsp;any breach of the director&#146;s duty of loyalty to the corporation or its shareholders; (ii)&nbsp;acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii)&nbsp;voting for or
assenting to a distribution in violation of Colorado Revised Statutes Section&nbsp;7-106-401 or these Articles of Incorporation if it is established that the director did not perform his duties in compliance with Colorado Revised Statutes
Section&nbsp;7-108-401, provided that the personal liability of a director in this circumstance shall be limited to the amount of the distribution which exceeds what could have been distributed without violation of Colorado Revised Statutes
Section&nbsp;7-106-401 or these Articles of Incorporation; or (iv)&nbsp;any transaction from which the director directly or indirectly derives an improper personal benefit. Nothing contained herein will be construed to deprive any director of his
right to all defenses ordinarily available to a director nor will anything herein be construed to deprive any director of any right he may have for contribution from any other director or other person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Negation of Equitable Interests in-Shares or Rights. Unless a person is recognized as a shareholder through procedures established by the
corporation pursuant to Colorado Revised Statutes Section&nbsp;7-107-204 or any similar law, the corporation shall be entitled to treat the registered holder of any shares of the corporation as the owner thereof for all purposes permitted by the
Colorado Business Corporation Act including without limitation all rights deriving from such shares, and the corporation shall not be bound to recognize any equitable or other claim to or interest in such shares or rights deriving from such shares
on the part of any other person, including without limitation a purchaser, assignee or transferee of such shares, unless and until such other person becomes the registered holder of such shares or is recognized as such, whether or not the
corporation shall have either actual or constructive notice of the claimed interest of such other person. By way of example and not of limitation, until such other person has become the registered holder of such shares or is recognized pursuant to
Colorado Revised Statutes Section&nbsp;7-107-204 or any similar applicable law, he shall not be entitled: (i)&nbsp;to receive notice of the meetings of the shareholders; (ii)&nbsp;to vote at such meetings; (iii)&nbsp;to examine a list of the
shareholders; (iv)&nbsp;to be paid dividends or other distributions payable to shareholders; or (v)&nbsp;to own, enjoy and exercise any other rights deriving from such shares against the corporation. Nothing contained herein will be construed to
deprive any beneficial shareholder, as defined in Colorado Revised Statutes Section&nbsp;7-113-101(1), of any right he may have pursuant to Article 113 of the Colorado Business Corporation Act or any subsequent law. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5">NINTH: The name and address of the incorporator is:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James&nbsp;B.&nbsp;Wiegand</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">10077 E. County Line Rd.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Longmont, CO 80501</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5">DATED the 9th day of August, 2002.</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">


<IMG SRC="g912919g75a85.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">/s/ James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">James B. Wiegand, Incorporator</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">James B. Wiegand hereby consents to the appointment as the initial registered agent for the corporation. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">


<IMG SRC="g912919g06e15.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">/s/ James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">Initial Registered Agent</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name [or names] and mailing address [or addresses] of the individual[s] who causes [cause] this document to be delivered
for filing is [are] <B><I></I></B> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">James B. Wiegand</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">10077 E. County Line Rd.</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Longmont CO 80501</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g912919g23c35.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Colorado Secretary of State</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date and Time: 08/02/2010 08:44 AM</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Document must be filed electronically.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">ID Number: 20021219479</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Paper documents will not be accepted.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Document processing fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$25.00&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Document number: 20101429194</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees&nbsp;&amp; forms/cover sheets are subject to change.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amount Paid: $25.00</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To access other information or print copies of filed documents, visit <U>www.sos.state.co.us</U> and select Business.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="text-indent:6.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">ABOVE SPACE FOR OFFICE USE ONLY</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Articles of Amendment </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">filed pursuant to &#167;7-90-301, et seq. and &#167;7-110-106 of the Colorado Revised Statutes (C.R.S.) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID number:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>20021219479&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;Entity name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">ROSEWIND CORPORATION</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;(If changing the name of the corporation, indicate name BEFORE the name change)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.&nbsp;New Entity name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(if applicable)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.&nbsp;Use of Restricted Words <I>(if any of these terms are contained in an entity name, true name of an entity, trade name or
trademark stated in this document, mark the applicable box):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&#147;bank&#148; or &#147;trust&#148; or any derivative thereof</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&#147;credit union&#148;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp; &#147;savings and loan&#148;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&#147;insurance&#148;, &#147;casualty&#148;, &#147;mutual&#148;, or
&#147;surety&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.&nbsp;Other amendments, if any, are attached.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.&nbsp;If the amendment provides for an exchange, reclassification or cancellation of issued shares, the attachment states
the provisions for implementing the amendment.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.&nbsp;If the corporation&#146;s period of duration as amended is less than perpetual, state the date on which the period of duration
expires:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mm/dd/yyyy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;If the corporation&#146;s period of duration as amended is perpetual, mark this box:&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.<I>&nbsp;(Optional)</I> Delayed effective date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mm/dd/yyyy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Causing this document
to be delivered to the secretary of state for filing shall constitute the affirmation or acknowledgment of each individual causing such delivery, under penalties of perjury, that the document is the individual&#146;s act and deed, or that the
individual in good faith believes the document is the act and deed of the person on whose behalf the individual is causing the document to be delivered for filing, taken in conformity with the requirements of part 3 of article 90 of title 7, C.R.S.,
the constituent documents, and the organic statutes, and that the individual in good faith believes the facts stated in the document are true and the document complies with the requirements of that Part, the constituent documents, and the organic
statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This perjury notice applies to each individual who causes this document to be delivered to the secretary of state, whether or not such
individual is named in the document as one who has caused it to be delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMD_PC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 1 of 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Rev. 5/01/2010</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.30em; text-indent:-1.30em; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;Name(s) and address(es) of the individual(s) causing the &nbsp;document to be delivered for filing:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Sawyer</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Jon</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(Last)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(First)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(Middle)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(Suffix)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">600 17th Street</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7" ALIGN="center"><I>(Street name and number or Post Office information)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Suite 2700</P>
<P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Denver</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">CO</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">80202</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>(Postal/Zip Code)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">United States</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(Province</I> &#150; <I>if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><I>(Country &#150; if not US)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>(The document need not state the true name and address of more than one individual. However, if you wish to
state the name and address of any additional individuals causing the document to be delivered for filing, mark this box </I><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><I></I><I> and include an attachment stating the name and address of such
individuals.) </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimer: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This form, and any
related instructions, are not intended to provide legal, business or tax advice, and are offered as a public service without representation or warranty. While this form is believed to satisfy minimum legal requirements as of its revision date,
compliance with applicable law, as the same may be amended from time to time, remains the responsibility of the user of this form. Questions should be addressed to the user&#146;s attorney. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMD_PC</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center">Page 2 of 2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">Rev. 5/01/2010</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF AMENDMENT TO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROSEWIND
CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of the Colorado Business Corporation Act, ROSEWIND CORPORATION adopts the following Articles
of Amendment to its Articles of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST:</B> The name of the Corporation is ROSEWIND CORPORATION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND:</B> The following amendment was adopted on June&nbsp;18, 2010, by the Board of Directors, and on June&nbsp;25, 2010, by a vote of
the Shareholders of the Corporation, in the manner prescribed by the Colorado Business Corporation Act. The number of shares voted for the amendment was sufficient for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article FOURTH (a)&nbsp;shall be amended to read as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;FOURTH: (a)&nbsp;The aggregate number of shares which the corporation shall have authority to issue is 50,000,000 shares
of common stock having no par value per share. The shares of this class of common stock shall have unlimited voting rights and shall constitute the sole voting group of the corporation, except to the extent any additional voting group or groups may
hereafter be established in accordance with the Colorado Business Corporation Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="right">


<IMG SRC="g912919g23c35.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Colorado Secretary of State</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date and Time: 03/14/2011 03:42 PM</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Document must be filed electronically.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">ID Number: 20021219479</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Paper documents will not be accepted.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Document processing fee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$25.00&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Document number: 20111155398</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fees&nbsp;&amp; forms/cover sheets are subject to change.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amount Paid: $25.00</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">To access other information or print copies of filed documents, visit <U>www.sos.state.co.us</U> and select Business.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ABOVE SPACE FOR OFFICE USE ONLY</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Articles of Amendment </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">filed pursuant to &#167;7-90-301, et seq. and &#167;7-110-106 of the Colorado Revised Statutes (C.R.S.) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ID number:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>20021219479&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.&nbsp;Entity name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">ROSEWIND CORPORATION</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;(If changing the name of the corporation, indicate name BEFORE the name change)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.&nbsp;New Entity name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; font-size:10pt; font-family:Times New Roman">(if applicable)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.&nbsp;Use of Restricted Words <I>(if any of these terms are contained in an entity name, true name of an entity, trade name or
trademark stated in this document, mark the applicable box):</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&#147;bank&#148; or &#147;trust&#148; or any derivative thereof</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&#147;credit union&#148;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp; &#147;savings and loan&#148;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&#147;insurance&#148;, &#147;casualty&#148;, &#147;mutual&#148;, or
&#147;surety&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.&nbsp;Other amendments, if any, are attached.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.&nbsp;If the amendment provides for an exchange, reclassification or cancellation of issued shares, the attachment states
the provisions for implementing the amendment.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.&nbsp;If the corporation&#146;s period of duration as amended is less than perpetual, state the date on which the period of duration
expires:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(mm/dd/yyyy)</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>OR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;If the corporation&#146;s period of duration as amended is perpetual, mark this box:&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.<I>&nbsp;(Optional)</I> Delayed effective date:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mm/dd/yyyy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Causing this document
to be delivered to the secretary of state for filing shall constitute the affirmation or acknowledgment of each individual causing such delivery, under penalties of perjury, that the document is the individual&#146;s act and deed, or that the
individual in good faith believes the document is the act and deed of the person on whose behalf the individual is causing the document to be delivered for filing, taken in conformity with the requirements of part 3 of article 90 of title 7, C.R.S.,
the constituent documents, and the organic statutes, and that the individual in good faith believes the facts stated in the document are true and the document complies with the requirements of that Part, the constituent documents, and the organic
statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This perjury notice applies to each individual who causes this document to be delivered to the secretary of state, whether or not such
individual is named in the document as one who has caused it to be delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMD_PC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Page 1 of 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Rev. 5/01/2010</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.&nbsp;Name(s) and address(es) of the individual(s)<BR>causing the document to be delivered for filing:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Sawyer</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Jon</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(Last)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>(First)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>(Middle)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>(Suffix)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">600 17th St.,</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7" ALIGN="center"><I>(Street name and number or Post Office information)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Suite 2700S</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">Denver</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">CO</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">80202</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(City)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><I>(State)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><I>(Postal/Zip Code)</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center"><I>(Province</I> &#150; <I>if applicable)</I></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="5"><I>(Country &#150; if not US)</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>(The document need not state the true name and address of more than one individual. However, if you wish to
state the name and address of any additional individuals causing the document to be delivered for filing, mark this box </I><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><I></I><I> and include an attachment stating the name and address of such
individuals.) </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclaimer: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This form, and any
related instructions, are not intended to provide legal, business or tax advice, and are offered as a public service without representation or warranty. While this form is believed to satisfy minimum legal requirements as of its revision date,
compliance with applicable law, as the same may be amended from time to time, remains the responsibility of the user of this form. Questions should be addressed to the user&#146;s attorney. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMD_PC</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="center">Page 2 of 2</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">Rev. 5/01/2010</TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF AMENDMENT TO </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ROSEWIND
CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of the Colorado Business Corporation Act, ROSEWIND CORPORATION adopts the following Articles
of Amendment to its Articles of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of the Corporation is ROSEWIND CORPORATION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The following amendment was adopted on February&nbsp;7, 2011, by the Board of Directors, and on February&nbsp;18, 2011, by a
vote of the Shareholders of the Corporation, in the manner prescribed by the Colorado Business Corporation Act. The number of shares voted for the amendment was sufficient for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article FOURTH (a)&nbsp;shall be amended to read as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;FOURTH: (a)&nbsp;The aggregate number of shares which the corporation shall have authority to issue is 300,000,000
shares of common stock having no par value per share. The shares of this class of common stock shall have unlimited voting rights and shall constitute the sole voting group of the corporation, except to the extent any additional voting group or
groups may hereafter be established in accordance with the Colorado Business Corporation Act. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d912919dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (&#147;<U>Agreement</U>&#148;) is effective as of [&#149;], 2015, by and between Rosewind Corporation, a
Colorado corporation (the &#147;<U>Company</U>&#148;), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&#147;<U>Indemnitee</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce Indemnitee to provide, or continue to provide, services to the Company, the Company wishes to provide for the
indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Indemnitee does not
regard the current protection available as adequate under the present circumstances, and the Indemnitee may not be willing to continue to serve in such capacity without additional protection; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and Indemnitee recognize the continued difficulty in obtaining liability insurance for the Company&#146;s directors,
officers, employees, agents and fiduciaries, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and Indemnitee further recognize the substantial increase in corporate litigation in general, subjecting directors,
officers, employees, agents and fiduciaries to expensive litigation risks at the same time as the availability and coverage of liability insurance has been severely limited; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on
behalf of, Indemnitee to the fullest extent permitted by applicable law so that Indemnitee will serve or continue to serve the Company free from undue concern that he will not be so indemnified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and Indemnitee&#146;s agreement to provide, or continue to provide, services to the Company,
the Company and Indemnitee hereby agree as set forth below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><I>Certain Definitions</I>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Claim</U>&#148; shall mean any
threatened, pending or completed action, suit, proceeding or alternative dispute resolution mechanism, or any hearing, inquiry or investigation that Indemnitee in good faith believes might lead to the institution of any such action, suit, proceeding
or alternative dispute resolution mechanism, whether civil, criminal, administrative, whether formal or informal, investigative or other. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) References to the &#147;Company&#148; shall include, in addition to Rosewind Corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or merger to which Rosewind Corporation (or any of its wholly owned subsidiaries) is a party which, if its separate existence had continued, would have had power and authority
to indemnify its directors, officers, employees, agents or fiduciaries, so that if Indemnitee is or was a director, officer, employee, agent or fiduciary of such constituent corporation, or is or was serving at the request of such constituent
corporation as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement
with respect to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Expenses</U>&#148; shall mean any and all expenses (including attorneys&#146; fees, expert witness fees, and all
other costs, expenses and obligations incurred in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to defend, to be a witness in or to participate in, any action, suit, proceeding,
alternative dispute resolution mechanism, hearing, inquiry or investigation, whether formal or informal), judgments, fines, penalties and amounts paid in settlement (if such settlement is approved in advance by the Company, which approval shall not
be unreasonably withheld) of any Claim regarding any Indemnifiable Event and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Expense Advance</U>&#148; shall mean an advance payment of Expenses to Indemnitee pursuant to Section&nbsp;3(a).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Indemnifiable Event</U>&#148; shall mean any event or occurrence
related to the fact that Indemnitee is or was a director, officer, employee, agent or fiduciary of the Company, or any subsidiary of the Company, or is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary
of another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of lndemnitee while serving in such capacity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Independent Legal Counsel</U>&#148; shall mean an attorney or firm of attorneys, selected in accordance with the
provisions of Section&nbsp;2(b) hereof, who shall not have otherwise performed services for the Company or Indemnitee within the last three years (other than with respect to matters concerning the rights of Indemnitee under this Agreement, or of
other indemnitees under similar indemnity agreements). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) References to &#147;<U>other enterprises</U>&#148; shall
include employee benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to &#147;serving at the request of the Company&#148; shall include any
service as a director, officer, employee, agent or fiduciary of the Company which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee benefit plan, its participants or its
beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner
&#147;not opposed to the best interests of the Company&#148; as referred to in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Sale
Event</U>&#148; shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to which the holders of the
Company&#146;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its
ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any other transaction in which
the owners of the Company&#146;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction
other than as a result of the acquisition of securities directly from the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Voting
Securities</U>&#148; shall mean any securities of the Company that vote generally in the election of directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><I>Indemnification</I>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of Expenses</I>. The Company
shall indemnify Indemnitee to the fullest extent permitted by law if Indemnitee was or is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, any Claim by reason of (or
arising in part out of) any Indemnifiable Event against Expenses, including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses. Such payment of Expenses shall be made by the Company as soon
as practicable but in any event no later than five (5)&nbsp;business days after written demand by Indemnitee therefor is presented to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Sale Event</I>. The Company agrees that if there is a Sale Event (other than a Sale Event which has been approved by a
majority of the Company&#146;s Board of Directors who were directors immediately prior to such Sale Event), then with respect to all matters thereafter arising concerning the rights of Indemnitee to payments of Expenses and Expense Advances under
this Agreement or any other agreement or under the Certificate of Incorporation or Articles of Incorporation as the case may be, of the Company as now or hereafter in effect (the &#147;Charter&#148;) or Bylaws of the Company as now or hereafter in
effect (the &#147;Bylaws&#148;), Independent Legal Counsel, if desired by Indemnitee, shall be selected by Indemnitee and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things, shall render its
written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified under applicable law and the Company agrees to abide by such opinion. The Company agrees to pay the reasonable fees of the
Independent Legal Counsel referred to above and to indemnify fully such counsel against any and all Expenses (including attorneys&#146; fees), claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant
hereto. Notwithstanding any other provision of this Agreement, the Company shall not be required to pay Expenses of more than one Independent Legal Counsel in connection with all matters concerning a single Indemnitee, and such Independent Legal
Counsel shall be the Independent Legal Counsel for any or all other Indemnitees unless (i)&nbsp;the Company otherwise determines, or (ii)&nbsp;any Indemnitee shall provide a written statement setting forth in detail a reasonable objection to such
Independent Legal Counsel representing other Indemnitees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Mandatory Payment of Expenses</I>. Notwithstanding any other provision of
this Agreement other than Section&nbsp;9 hereof, to the extent that Indemnitee has been successful on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in defense of any Claim regarding any
Indemnifiable Event, Indemnitee shall be indemnified against all Expenses incurred by Indemnitee in connection therewith. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><I>Expenses; Indemnification Procedure</I>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Advancement of
Expenses</I>. The Company shall advance all Expenses incurred by Indemnitee. The advances to be made hereunder shall be paid by the Company to Indemnitee as soon as practicable but in any event no later than 30 days after written demand by
Indemnitee therefor to the Company. Indemnitee hereby agrees to repay to the Company all amounts advanced to Indemnitee hereunder if it is ultimately determined that Indemnitee is not entitled to indemnification hereunder. The Company&#146;s
obligation to advance Expenses shall terminate with respect to any Claim as to which the Indemnitee shall have entered a plea of guilty or nolo contendere, or an equivalent plea acknowledging guilt. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Notice/Cooperation by Indemnitee</I>. Indemnitee shall, as a condition precedent to Indemnitee&#146;s right to be
indemnified under this Agreement, give the Company notice in writing as soon as practicable of any Claim made against Indemnitee for which indemnification will or could be sought under this Agreement; provided however that the failure to so provide
notice to the Company shall not relieve the Company from any liability that it may have to Indemnitee hereunder unless the Company&#146;s ability to participate in the defense of such claim was materially and adversely affected by such failure.
Notice to the Company shall be directed to the Chief Executive Officer of the Company at the headquarters office of the Company (or such other address as the Company shall designate in writing to Indemnitee). In addition, Indemnitee shall give the
Company such information and cooperation as it may reasonably require and as shall be within Indemnitee&#146;s power, to the extent that doing so is consistent with the exercise of the Indemnitee&#146;s rights under the federal and state
Constitutions. The Company shall provide Indemnitee with such information and cooperation as Indemnitee may reasonably require, to the extent that doing so is consistent with the Company&#146;s obligation to cooperate with regulatory or law
enforcement agencies. Indemnitee understands that such obligation may include, as deemed necessary or advisable by the Company, a waiver of any attorney-client or other privilege held by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Presumptions; Burden of Proof</I>. For purposes of this Agreement, the termination of any Claim by judgment, order,
settlement (whether with or without court approval) or conviction, or upon a plea of <I>nolo contendere</I>, or its equivalent, shall not create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular
belief or that a court has determined that indemnification is not permitted by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to
Insurers</I>. If, at the time of the receipt by the Company of a notice of a Claim pursuant to Section&nbsp;3(b) hereof, the Company has liability insurance in effect which may cover such Claim, the Company shall give prompt notice of the
commencement of such Claim to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all
amounts payable as a result of such Claim in accordance with the terms of such policies. The Company shall keep Indemnitee reasonably informed as to the status of all relevant insurance matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Selection of Counsel</I>. In the event the Company shall be obligated hereunder to pay the Expenses of any Claim the
Company, if appropriate, shall be entitled to assume the defense of such Claim with counsel approved by Indemnitee (not to be unreasonably withheld) upon the delivery to Indemnitee of written notice of the Company&#146;s election so to do. After
delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with
respect to the same Claim; provided that, (i)&nbsp;Indemnitee shall have the right to employ Indemnitee&#146;s separate counsel in any such Claim at Indemnitee&#146;s Expense, and (ii)&nbsp;if (A)&nbsp;the employment of separate counsel by
Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense, or (C)&nbsp;the Company
shall not continue to retain such counsel to defend such Claim, then the fees and Expenses of Indemnitee&#146;s separate counsel shall be at the Expense of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><I>Additional Indemnification Rights; Non-Exclusivity.</I> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Scope</I>.
The Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Charter, the Bylaws or by statute.
In the event of any change after the date of this Agreement in any applicable law, statute or rule which expands the right of a corporation organized under the laws of the Governing Law State (as defined in Section&nbsp;17) to indemnify a member of
its board of directors or an officer, employee, agent or fiduciary, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits afforded by such change. In the event of any change in any applicable law,
statute or rule which narrows the right of a corporation organized under the laws of the Governing Law State to indemnify a member of its board of directors or an officer, employee, agent or fiduciary, such change, to the extent not otherwise
required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties&#146; rights and obligations hereunder except as set forth in Section&nbsp;9(a) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Non-Exclusivity</I>. The indemnification provided by this Agreement shall be in addition to any rights to which
Indemnitee may be entitled under the Charter, the Bylaws, any other agreement, any vote of stockholders or disinterested directors, the laws of the Governing Law State, or otherwise. The indemnification provided under this Agreement shall continue
as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though Indemnitee may have ceased to serve in such capacity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>5. <I>No Duplication of Payments.</I> The Company shall not be liable under this Agreement to make any payment in connection with any
Claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment (under any insurance policy, provision of the Charter, the Bylaws or otherwise) of the amounts otherwise indemnifiable hereunder.<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>6. <I>Partial Indemnification. </I>If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for
some or a portion of Expenses incurred in connection with any Claim, but not, however, for the entire total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such Expenses to which Indemnitee is entitled.<I>
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>7. <I>No Imputation. </I>The knowledge or actions, or failure to act, of any director, officer, agent or employee of the
Company or the Company itself shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Liability Insurance. </I>For the duration of lndemnitee&#146;s service as a director or officer or other agent of the Company, and
thereafter for so long as Indemnitee shall be subject to any pending or possible Claim by reason of any Indemnifiable Event, the Company shall use reasonable efforts, taking into account the scope and amount of coverage available relative to the
cost thereof, to obtain and maintain in effect policies of liability insurance providing coverage for directors and officers of the Company. Indemnitee acknowledges that at the date hereof, the Company maintains no such policy in effect. To the
extent the Company in the future maintains liability insurance applicable to directors, officers, employees, agents or fiduciaries, Indemnitee shall be covered by such policies in such a manner as to provide Indemnitee the same rights and benefits
as are provided to the most favorably insured of the Company&#146;s directors, if lndemnitee is a director; or of the Company&#146;s officers, if Indemnitee is not a director of the Company but is an officer; or of the Company&#146;s key employees,
agents or fiduciaries, if lndemnitee is not an officer or director but is a key employee, agent or fiduciary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>9. <I>Exceptions.</I>
Notwithstanding any other provision of this Agreement, the Company shall not be obligated pursuant to the terms of this Agreement:<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Excluded Action or Omissions</I>. To indemnify Indemnitee for acts, omissions or transactions if a final decision by a
court having jurisdiction in the matter shall determine that such indemnification is prohibited by applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Claims Initiated by Indemnitee</I>. To indemnify or advance Expenses to Indemnitee with respect to Claims initiated or brought voluntarily by Indemnitee and not by way of defense, except (i)&nbsp;with respect to actions or proceedings brought to
establish or enforce a right to indemnification under this Agreement or any other agreement or insurance policy or under the Charter or Bylaws relating to Claims for Indemnifiable Events, (ii)&nbsp;in specific cases if the Board of Directors has
approved the initiation or bringing of such Claim, or (iii)&nbsp;as otherwise required under, if Delaware is the Governing Law State, Section&nbsp;145 of the Delaware General Corporation Law, regardless of whether Indemnitee ultimately is determined
to be entitled to such indemnification, advance Expense payment or insurance recovery, as the case may be. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Lack of Good Faith</I>. To indemnify Indemnitee for any Expenses incurred
by the Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction determines that each of the material assertions made by the Indemnitee in such proceeding was not
made in good faith or was frivolous. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Claims Under Section&nbsp;16(b)</I>. To indemnify Indemnitee for expenses and
the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute; provided that the Company shall advance
expenses in connection with Indemnitee&#146;s defense of a claim under Section&nbsp;16(b), which advances shall be repaid to the Company if it is ultimately determined that Indemnitee is not entitled to indemnification of such expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>10. <I>Period of Limitations.</I> No legal action shall be brought and no cause of action shall be asserted by or in the right of the
Company against Indemnitee, Indemnitee&#146;s estate, spouse, heirs, executors or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action, and any claim or cause of action of the Company
shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such two-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such
shorter period shall govern.<I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>11. <I>Counterparts.</I> This Agreement may be executed in one or more counterparts, each of
which shall constitute an original.<I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>12. <I>Binding Effect; Successors and Assigns.</I> This Agreement shall be binding upon
and inure to the benefit of and be enforceable by the parties hereto and their respective successors, assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or
assets of the Company), spouses, heirs and personal and legal representatives. The Company shall require and cause any successor (whether direct or indirect, and whether by purchase, merger, consolidation or otherwise) to all, substantially all, or
a substantial part, of the business or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company
would be required to perform if no such succession had taken place. This Agreement shall continue in effect regardless of whether Indemnitee continues to serve as a director, officer, employee, agent or fiduciary (as applicable) of the Company or of
any other enterprise at the Company&#146;s request.<I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Attorneys&#146; Fees. </I>In the event that any action is instituted by
Indemnitee under this Agreement or under any liability insurance policies maintained by the Company to enforce or interpret any of the terms hereof or thereof, Indemnitee shall be entitled to be paid all Expenses incurred by Indemnitee with respect
to such action, regardless of whether Indemnitee is ultimately successful in such action, and shall be entitled to the advancement of Expenses with respect to such action, unless as a part of such action a court of competent jurisdiction over such
action determines that each of the material assertions made by Indemnitee as a basis for such action was not made in good faith or was frivolous. In the event of an action instituted by or in the name of the Company under this Agreement to enforce
or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all Expenses incurred by Indemnitee in defense of such action (including costs and Expenses incurred with respect to Indemnitee&#146;s counterclaims and
cross-claims made in such action), and shall be entitled to the advancement of Expenses with respect to such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Notice.
</I>All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed duly given (i)&nbsp;if delivered by hand and signed for by the party addressed, on the date of such delivery, or (ii)&nbsp;if
mailed by domestic certified or registered mail with postage prepaid, on the third business day after the date postmarked. The address for notice to Indemnitee is as shown on the signature page of this Agreement, and the address for the Company is
its headquarters office, or as subsequently modified by either party by written notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Consent to Jurisdiction.</I> The Company
and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the Governing Law State for all purposes in connection with any action or proceeding which arises out of or relates to this Agreement and agree that, if the
Governing Law State is Delaware, any action instituted under this Agreement shall be commenced, prosecuted and continued only in the Court of Chancery of the State of Delaware in and for New Castle County, which shall be the exclusive and only
proper forum for adjudicating such a claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <I>Severability.</I> The provisions of this Agreement shall be severable in the event that
any of the provisions hereof (including any provision within a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain enforceable
to the fullest extent permitted by law. Furthermore, to the fullest extent possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement containing any provision held to be invalid, void or otherwise
unenforceable, that is not itself invalid, void or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <I>Choice of Law.</I> This Agreement shall be governed by and its provisions construed and enforced in accordance with the laws of the
State of incorporation of the Company, as it may change from time to time (the &#147;<U>Governing Law State</U>&#148;), as applied to contracts between residents of the Governing Law State entered into and to be performed entirely within the
Governing Law State. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>18. <I>Subrogation.</I> In the event of payment under this Agreement, the Company shall be subrogated to the
extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such
rights.<I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <I>Amendment and Termination.</I> Due to the uncertain application of any statutes of limitations that may govern any
Claim, this Agreement shall be of indefinite duration. No amendment, modification, termination or cancellation of this Agreement shall be effective unless it is in writing signed by both the parties hereto. No waiver of any of the provisions of this
Agreement shall be deemed to be or shall constitute a waiver of any other provisions hereof (whether or not similar), nor shall such waiver constitute a continuing waiver. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>20. <I>Integration and Entire Agreement. </I>This Agreement sets forth the entire understanding between the parties hereto and
supersedes and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the parties hereto.<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>21. <I>No Construction as Employment Agreement.</I> Nothing contained in this Agreement shall be construed as giving Indemnitee any
right to be retained in the employ of the Company or any of its subsidiaries or affiliated entities.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows]
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ROSEWIND CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AGREED TO AND ACCEPTED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">INDEMNITEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(signature)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(address)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page to Indemnification Agreement] </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>d912919dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION COPY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Employment
Agreement (the &#147;Agreement&#148;), is effective as of April&nbsp;16, 2015 (the &#147;Effective Date&#148;), between Rosewind Corporation, a Colorado corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA,
hereinafter referred to as the &#147;Company&#148;, and Joshua R. Disbrow (&#147;Employee&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Company is a duly organized Colorado corporation, with its principal place of business within the State of Colorado, and
is in the business of developing and marketing pharmaceutical products; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Company desires assurance of the
continued association and services of the Employee in order to continue to retain the Employee&#146;s experience, skills, abilities, background and knowledge, and is willing to continue to engage the Employee&#146;s services on the terms and
conditions set forth in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Employee desires to be in the continued employ of the Company, and is willing
to accept such continued employment on the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> the parties hereto agree to the terms
and conditions of this Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Employment for Term. </B>The Company hereby agrees to employ Employee and Employee hereby accepts such
employment with the Company for the period of 24 months beginning on the Effective Date. The term of this Agreement (the &#147;Term&#148;) shall continue until the termination of Employee&#146;s employment in accordance with the provisions of this
Agreement. The termination of Employee&#146;s employment under this Agreement shall end the Term but shall not terminate Employee&#146;s or the Company&#146;s other obligations that are intended to survive the termination of this Agreement
(including without limitation, the payments under Section&nbsp;7 and 8 and Employee&#146;s obligations under Section&nbsp;9). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Position and
Duties.</B> During the Term, Employee shall serve as Chief Executive Officer (CEO) of the Company, and perform such duties as are consistent with this position. The Employee shall report to the Board of Directors of the Company. During the Term,
Employee shall also hold such additional positions and titles as the Board of Directors of the Company (the &#147;Board&#148;) may determine from time to time. During the Term, Employee shall devote as much time as is necessary to satisfactorily
perform his duties as CEO of the Company. Employee may engage in any civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the
Company During the Term of this Agreement, Employee agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Employee to be adverse or antagonistic to the Company, its business or
prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of
which Employee is or becomes a member of during the term hereof. Employee shall provide written disclosure to the Compensation Committee of the Company&#146;s Board of Directors as to all advisory boards on which Employee sits, and will provide the
Company with written notice within 10 business days of Employee agreeing to sit on any additional advisory boards. On termination of Employee&#146;s employment, regardless of the reason for such termination, Employee shall immediately (and with
contemporaneous effect) resign any directorships, offices or other positions that Employee may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Compensation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Base Salary.</B> The Company shall pay Employee a base salary of $250,000 per annum, payable at least monthly on the Company&#146;s
regular pay cycle for professional employees (the &#147;Base Salary&#148;). Except as specifically otherwise provided herein, the Base Salary may be increased only by recommendation of the Compensation Committee of the Board and ratified by the
Compensation Committee or a majority of the independent members of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Annual Review.</B> The Base Salary shall be reviewed
at the end of each calendar year (the first such review to occur at the end of calendar year 2015). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Equity Compensation.</B> In
connection with the execution of this Agreement, the Company hereby agrees to grant on or promptly after April&nbsp;1, 2015 initial equity compensation to Employee in the aggregate amount of 600,000 options to purchase shares of Company Common
Stock. These options shall be granted subject to the terms and conditions of the Company&#146;s stock option plan then in effect, and the terms and conditions of the applicable option agreement, and will vest in accordance with the terms and
schedule set forth in Exhibit A hereto. Such vesting schedule will be accelerated, to the extent provided in Section&nbsp;8 of this agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Other and Additional Compensation.</B> Subsections (a)&nbsp;and (c)&nbsp;above establish Employee&#146;s compensation during the Term
which shall not preclude the Board from awarding Employee a higher salary or any bonuses or stock options, restricted stock or other forms of additional equity awards in the discretion of the Board during the Term at any time. The Employee shall be
eligible for an annual discretionary bonus (hereinafter referred to as the &#147;Bonus&#148;) with a target amount of one hundred and twenty five percent (125%)&nbsp;of the Base Salary<B>, </B>subject to standard deductions and withholdings, based
on the Compensation Committee&#146;s determination, in good faith, and based upon the Employee&#146;s individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Employee has met such
performance milestones as are established for the Employee by the Board or the Compensation Committee, in good faith, in consultation with the Employee (hereinafter referred to as the &#147;Performance Milestones&#148;). The Performance Milestones
will be based on certain factors including, but not limited to, the Employee&#146;s performance and the Company&#146;s financial performance. The Employee&#146;s Bonus target will be reviewed annually and may be adjusted by the Board or the
Compensation Committee in its discretion, provided however, that the Bonus target may only be reduced upon Employee&#146;s written consent. The Employee must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the
termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses
calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Employee Benefits.</B> During
the Term, Employee shall be entitled to participate at the same level as other senior executive officers of the Company in any group insurance, hospitalization, medical, health and accident, disability, fringe benefit and tax-qualified retirement
plans or programs of the Company now existing or hereafter established to the extent that he is eligible under the general provisions thereof. For the term of this Agreement, Employee shall be entitled to paid vacation at the rate of (4)&nbsp;weeks
per annum. In accordance with Company policy, unused vacation may not be carried over from year to year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Expenses.</B> The Company shall reimburse Employee for actual, reasonable out-of-pocket expenses incurred
by him in the performance of his services for the Company upon the receipt of appropriate documentation of such expenses which shall be submitted in such form, and with such supporting documentation, as called for or required by Company policy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Termination. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) General. </B>The
Term shall end immediately upon Employee&#146;s death. Employee&#146;s employment may also be terminated by the Company with or without Cause or as a result of Employee&#146;s Disability, as defined in Section&nbsp;7 or by Employee with or without
Good Reason (as such terms are defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Notice of Termination.</B> Either party shall give written notice of termination to
the other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Notification of New Employer</B>. In the event that Employee leaves the employ of the Company, Employee grants
consent to notification by the Company to Employee&#146;s new employer about his rights and obligations under this Agreement and the PIA (hereinafter defined). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Severance Benefits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Cause
Defined.</B> &#147;Cause&#148; means (i)&nbsp;willful malfeasance or willful misconduct by Employee in connection with his employment; (ii)&nbsp;Employee&#146;s gross negligence in performing any of his duties under this Agreement;
(iii)&nbsp;Employee&#146;s conviction of, or entry of a plea of guilty to, or entry of a plea of <I>nolo contendere</I> with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iv)&nbsp;Employee&#146;s willful
and deliberate violation of a Company policy, (v)&nbsp;Employee&#146;s unintended but material breach of any written policy applicable to all employees adopted by the Company which is not cured to the reasonable satisfaction of the Board of
Directors within thirty (30)&nbsp;business days after notice thereof; (vi)&nbsp;the Employee&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the Employee owes an
obligation of nondisclosure as a result of the Employee&#146;s relationship with the Company, (vii)&nbsp;the Employee&#146;s willful and deliberate breach of his obligations under this Agreement, or (viii)&nbsp;any other material breach by Employee
of any of his obligations in this Agreement which is not cured to the reasonable satisfaction of the Board of Directors within thirty (30)&nbsp;business days after notice thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Disability Defined. </B>&#147;Disability&#148; shall mean (i)&nbsp;Employee&#146;s incapacity due to a physical or mental condition and,
if reasonable accommodation is required by law, after any reasonable accommodation, that results in Employee being substantially unable to perform his duties hereunder for six consecutive months (or for six months out of any nine month period) or
(ii)&nbsp;a qualified independent physician mutually acceptable to the Company and Employee determines that Employee is incapacitated due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable
accommodation so as to be unable to regularly perform the duties of his position and such condition is expected to be of a permanent or near-permanent duration. Until such time as Employee is terminated for Disability under this paragraph (b),
Employee shall continue to receive his Base Salary hereunder, provided that if the Company provides Employee with disability insurance coverage, payments of Employee&#146;s Base Salary shall be reduced by the amount of any disability insurance
payments received by Employee due to such coverage. The Company shall give Employee written notice of termination due to Disability which shall take effect sixty (60)&nbsp;days after the date it is sent to Employee unless Employee shall have
returned to the performance of his duties hereunder during such sixty (60)&nbsp;day period (whereupon such notice shall become void). In the event that the Company terminates Employee&#146;s employment as a result of his Disability, Employee shall
be entitled to the same benefits as if his employment had been terminated by the Company without Cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Good Reason Defined.</B> For purposes of this Agreement, &#147;Good Reason&#148; shall
mean, without Employee&#146;s written consent: (i)&nbsp;there is a material reduction of the level of Employee&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally,
provided, however, that in no case may the Base Salary be reduced below the amount stated in Section&nbsp;3(a)), (ii)&nbsp;there is a material reduction in Employee&#146;s overall responsibilities or authority, or scope of duties (it being
understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in Employee&#146;s responsibilities or authority); or (iii)&nbsp;there is a material change in the principal geographic location at which
Employee must perform his services (it being understood that the relocation of Employee to a facility or a location within forty (40)&nbsp;miles of the State Capitol Building in Denver, Colorado shall not be deemed material for purposes of this
Agreement). No event shall be deemed to be &#147;Good Reason&#148; if the Company has cured the event (if susceptible to cure) within 30 days of receipt of written notice from Employee specifying the event or events which, absent cure, would
constitute &#147;Good Cause.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Accrued Compensation Defined. </B>Accrued Compensation shall mean an amount which shall include
all amounts earned or accrued by Employee through the date of termination of this Agreement but not paid as of such date, including (i)&nbsp;Base Salary, (ii)&nbsp;reimbursement for business expenses incurred by the Employee on behalf of the
Company, pursuant to the Company&#146;s expense reimbursement policy in effect at such time, (iii)&nbsp;any expense allowance pursuant to Company policy, (iv)&nbsp;accrued but unused vacation pay per Company policy, and (v)&nbsp;bonuses and
incentive compensation earned and awarded prior to the date of termination. Accrued Compensation shall be paid on the first regular pay date after the date of termination (or earlier, if required by applicable law). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Termination. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Cause; Without Good Reason; Death; Disability.</B> If the Company ends the Term for Cause, if Employee resigns as an
employee of the Company for reasons other than an event of Good Reason, the Employee dies or Disability occurs , then the Company shall pay to Employee the Accrued Compensation but shall have no obligation to pay Employee any amount, whether for
salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after the end of the Term, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be
forfeited immediately upon the end of the Term. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date the Company ends the Term
for Cause, or the date of Employee&#146;s death or Disability, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the Employee or his personal representative or executor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Without Cause; Good Reason.</B> In the event that the Company terminates Employee&#146;s employment hereunder without
Cause, or the Employee terminates his employment with Good Reason, he shall be entitled to the Accrued Compensation and, subject to Section&nbsp;21 and 22 below, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) A lump sum payment equal to two times his Base Salary in effect at the date of termination, less applicable withholding
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(B) To the extent permitted by the Company&#146;s health insurance carrier and if such coverage would not result in penalties to the
Company under the Patient Protection and Affordable Care Act, continued participation (via state or federal insurance continuation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
laws such as COBRA, to the extent available) in the health and welfare plans (or comparable plans, if continued participation in the Company&#146;s plans is not available) provided by the Company
to Employee at the time of termination for a period of two years from the date of termination or, if earlier, until he is eligible for comparable coverage with a subsequent employer. The Company agrees to reimburse the payments Employee makes for
such coverage, whether via continuation or separate comparable policy. Premium reimbursements shall be made by the Company to Employee consistent with the Company&#146;s normal expense reimbursement policy, provided that Employee submits
documentation to the Company substantiating his payments for insurance coverage. Employee shall give the Company prompt notice of his eligibility for comparable coverage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(C) All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable award. So long
as the Section&nbsp;8&nbsp;below does not apply, then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to 1/24<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> the number of option shares multiplied by the number of full months of Employee&#146;s employment hereunder shall be deemed vested and immediately exercisable by the Employee. Any unvested options
over and above the foregoing shall be cancelled and of no further force or effect, and shall not be exercisable by the Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(D) Any
severance payments and/or other separation benefits contemplated by this Agreement are conditional on Employee: (i)&nbsp;continuing to comply with the terms of this Agreement and the PIA (as defined herein); (ii)&nbsp;delivering prior to or
contemporaneously with any such severance payments, and not revoking, (x)&nbsp;a customary general release of claims relating to Employee&#146;s employment and/or this Agreement against the Company or its successor, its subsidiaries and their
respective directors, officers and stockholders and (y)&nbsp;a customary affirmation of Employee&#146;s continuing obligations hereunder and under the PIA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise required by law, no severance payments and/or benefits under this Agreement will be paid and/or provided until after the expiration of any
relevant revocation period. Subject to the effectiveness of the release, the severance payments shall be paid on the first payroll date that begins 30 days after Employee&#146;s termination of employment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Change in Control Payments.</B> The provisions of this paragraph 8 set forth the terms of an agreement reached between Employee and the Company regarding
Employee&#146;s rights and obligations upon the occurrence of a &#147;Change in Control&#148; (as hereinafter defined) of the Company during the Term. These provisions are intended to assure and encourage in advance Employee&#146;s continued
attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such Change in Control. The following provisions shall apply in the event of a Change in Control, in addition to any payment or
benefit that may be required pursuant to Section&nbsp;7. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Equity.</B> Upon the occurrence of a Change in Control, all stock options,
restricted stock and other stock-based grants to Employee by the Company or that may be granted in the future shall, irrespective of any provisions of his award agreements, immediately and irrevocably vest and become exercisable and any restrictions
thereon shall lapse. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Definitions.</B> For purposes of this paragraph 8, the following terms shall have the following meanings: </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the acquisition by any individual, entity, or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act) (the
&#147;Acquiring Person&#148;), other than the Company, or any of its Subsidiaries, of beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of
the then outstanding voting securities of the Company entitled to vote generally in the election of directors (excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona fide equity
financing purposes ; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the acquisition of the Company by another entity by means of any transaction or series of related transactions
to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona
fide equity financing purposes ) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain,
immediately after such transaction or series of related transactions, as a result of shares in the Company held by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power represented by
the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) the sale or other disposition of all or substantially all of the assets of the Company in one transaction or series of related
transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Proprietary Information and Inventions Agreement</B>. As a condition of Employee&#146;s employment with the Company, Employee agrees
to sign the Company&#146;s standard form of Proprietary Information and Inventions Agreement (&#147;PIA&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Successors and Assigns. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Employee.</B> This Agreement is a personal contract, and the rights and interests that the Agreement accords to Employee may not be
sold, transferred, assigned, pledged, encumbered, or hypothecated by him. All rights and benefits of Employee shall be for the sole personal benefit of Employee, and no other person shall acquire any right, title or interest under this Agreement by
reason of any sale, assignment, transfer, claim or judgment or bankruptcy proceedings against Employee. Except as so provided, this Agreement shall inure to the benefit of and be binding upon Employee and his personal representatives, distributees
and legatees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) The Company.</B> This Agreement shall be binding upon the Company and inure to the benefit of the Company and of its
successors and assigns, including (but not limited to) any Company that may acquire all or substantially all of the Company&#146;s assets or business or into or with which the Company may be consolidated or merged. Any such successor of the Company
will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#147;successor&#148; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or
otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Entire Agreement.</B> This Agreement (together with the equity award agreements referred to herein)
represents the entire agreement between the parties concerning Employee&#146;s employment with the Company and supersedes all prior negotiations, discussions, understanding and agreements, whether written or oral, between Employee and the Company
relating to the subject matter of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Amendment or Modification, Waiver.</B> No provision of this Agreement may be amended or waived
unless such amendment or waiver is agreed to in writing signed by Employee and by a duly authorized officer of the Company. No waiver by any party to this Agreement or any breach by another party of any condition or provision of this Agreement to be
performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Notices.</B> Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or
certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Employee:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">205 Albion Street</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Denver, Colorado 80220</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the address specified in the payroll records of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Rosewind Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">373 Inverness Parkway</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Suite 200</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Englewood, Colorado 80112</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by
registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Severability.</B> If any
provision of this Agreement or the application of any such provision to any party or circumstances shall be determined by any court of competent jurisdiction or arbitrator acting pursuant to Section&nbsp;19 below to be invalid and unenforceable to
any extent, the remainder of this Agreement or the application of such provision to such person or circumstances other than those to which it is so determined to be invalid and unenforceable shall not be affected, and each provision of this
Agreement shall be validated and shall be enforced to the fullest extent permitted by law. If for any reason any provision of this Agreement containing restrictions is held to cover an area or to be for a length of time that is unreasonable or in
any other way is construed to be too broad or to any extent invalid, such provision shall not be determined to be entirely null, void and of no effect; instead, it is the intention and desire of both the Company and Employee that, to the extent that
the provision is or would be valid or enforceable under applicable law, any court of competent jurisdiction or arbitrator acting pursuant to Section&nbsp;19 below shall construe and interpret or reform this Agreement to provide for a restriction
having the maximum enforceable area, time period and such other constraints or conditions (although not greater than those contained currently contained in this Agreement) as shall be valid and enforceable under the applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Survivorship.</B> The respective rights and obligations of the parties hereunder shall survive any termination of this Agreement to the extent necessary
to the intended preservation of such rights and obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Headings.</B> All descriptive headings of sections and paragraphs in this Agreement are intended solely
for convenience of reference, and no provision of this Agreement is to be construed by reference to the heading of any section or paragraph. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.
Withholding Taxes.</B> All salary, benefits, reimbursements and any other payments to Employee under this Agreement shall be subject to all applicable payroll and withholding taxes and deductions required by any law, rule or regulation of and
federal, state or local authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Counterparts.</B> This Agreement may be executed in one or more counterparts, each of which shall be deemed to
be an original but all of which together constitute one and same instrument. The parties agree that facsimile signatures shall have the same force and effect as original signatures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Applicable Law; Arbitration.</B> The validity, interpretation and enforcement of this Agreement and any amendments or modifications hereto shall be
governed by the laws of the State of Colorado, as applied to a contract executed within and to be performed in such State. The parties agree that any disputes shall be definitively resolved by binding arbitration before the American Arbitration
Association in Denver, Colorado in accordance with its rules of arbitration procedure then in effect. The parties consent to the jurisdiction to the federal courts of the District of Colorado or, if there shall be no jurisdiction, to the state
courts located in Arapahoe County, Colorado, to enforce any arbitration award rendered with respect thereto. Each party shall choose one arbitrator and the two arbitrators shall choose a third arbitrator. All costs and fees related to such
arbitration (and judicial enforcement proceedings, if any) shall be borne by the Company unless Employee&#146;s claim is deemed to be frivolous by the arbitrator(s) or judge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Legal Fees.</B> The Company shall pay the reasonable expenses of Employee&#146;s counsel in negotiating this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Section&nbsp;409A. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Anything in
this Agreement to the contrary notwithstanding, if at the time of Employee&#146;s separation from service within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), the Company determines that
Employee is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#146;s separation
from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment
shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after Employee&#146;s separation from service, or (B)&nbsp;Employee&#146;s death. If any such delayed cash payment is
otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All in-kind benefits provided and expenses eligible for
reimbursement under this Agreement shall be provided by the Company or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any
reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind
benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to
liquidation or exchange for another benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes
&#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#146;s termination of employment, then such payments or benefits shall be payable only upon
Employee&#146;s &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&nbsp;1.409A 1(h). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this
Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&nbsp;1.409A 2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully
comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Application of Internal Revenue Code Section&nbsp;280G. </B>If any payment or benefit Employee would receive pursuant to a Change in Control from the
Company or otherwise (&#147;<I>Payment</I>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by
Section&nbsp;4999 of the Code (the &#147;<I>Excise Tax</I>&#148;), then such Payment shall be equal to the Reduced Amount. The &#147;Reduced Amount&#148; shall be either (x)&nbsp;the largest portion of the Payment that would result in no portion of
the Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the
Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#146;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.
If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Employee. If more
than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event it is subsequently
determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x)&nbsp;in the preceding paragraph is subject to the Excise Tax, Employee agrees to promptly return to the Company a sufficient
amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y)&nbsp;in the preceding paragraph, Employee will have no obligation to
return any portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless Employee and the Company agree on an alternative accounting firm, the
accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as
accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with
respect to the determinations by such accounting firm required to be made hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Employee and the Company within fifteen (15)&nbsp;calendar days after the date on which Employee&#146;s right to a Payment is triggered (if
requested at that time by the Employee or the Company) or such other time as requested by Employee or the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Indemnification.</B> As a
condition to the effectiveness of this Agreement, the Company and Employee shall enter into a mutually acceptable indemnification agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement as of the date first written above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Macaluso</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joshua R. Disbrow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Michael Macaluso</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sole Director</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Joshua R. Disbrow</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Employment Agreement] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Terms of Equity Compensation </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management equity grant: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,000 total options to purchase shares of the Company&#146;s common stock. The strike price for all options will be the last sale price of the Company&#146;s common stock as reported on April&nbsp;1, 2015 and in
accordance with the terms of the Company&#146;s Stock and Incentive Plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All options fully vest upon Change in Control, death, Disability, termination with or without Cause, termination for Good Reason </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">300,000 options are fully vested on the Effective Date of this agreement </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">150,000 options vest 365 days thereafter </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">150,000 options vest 730 days thereafter </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>d912919dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION COPY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Employment
Agreement (the &#147;Agreement&#148;), is effective as of April&nbsp;16, 2015 (the &#147;Effective Date&#148;), between Rosewind Corporation, a Colorado corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA,
hereinafter referred to as the &#147;Company&#148;, and Jarrett T. Disbrow (&#147;Employee&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Company is a duly organized Colorado corporation, with its principal place of business within the State of Colorado, and
is in the business of developing and marketing pharmaceutical products; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the Company desires assurance of the
continued association and services of the Employee in order to continue to retain the Employee&#146;s experience, skills, abilities, background and knowledge, and is willing to continue to engage the Employee&#146;s services on the terms and
conditions set forth in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Employee desires to be in the continued employ of the Company, and is willing
to accept such continued employment on the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> the parties hereto agree to the terms
and conditions of this Agreement as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Employment for Term. </B>The Company hereby agrees to employ Employee and Employee hereby accepts such
employment with the Company for the period of 24 months beginning on the Effective Date. The term of this Agreement (the &#147;Term&#148;) shall continue until the termination of Employee&#146;s employment in accordance with the provisions of this
Agreement. The termination of Employee&#146;s employment under this Agreement shall end the Term but shall not terminate Employee&#146;s or the Company&#146;s other obligations that are intended to survive the termination of this Agreement
(including without limitation, the payments under Section&nbsp;7 and 8 and Employee&#146;s obligations under Section&nbsp;9). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Position and
Duties.</B> During the Term, Employee shall serve as Chief Operating Officer (COO) of the Company, and perform such duties as are consistent with this position. The Employee shall report to the Chief Executive Officer (CEO) of the Company. During
the Term, Employee shall also hold such additional positions and titles as the CEO of the Company may determine from time to time. During the Term, Employee shall devote as much time as is necessary to satisfactorily perform his duties as COO of the
Company. Employee may engage in any civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company. During the Term of this
Agreement, Employee agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Employee to be adverse or antagonistic to the Company, its business or prospects, its financial position,
or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of which Employee is or becomes a member
of during the Term. Employee shall provide written disclosure to the Compensation Committee of the Company&#146;s Board of Directors as to all advisory boards on which Employee sits, and will provide the Company with written notice within 10
business days of Employee agreeing to sit on any additional advisory boards. On termination of Employee&#146;s employment, regardless of the reason for such termination, Employee shall immediately (and with contemporaneous effect) resign any
directorships, offices or other positions that Employee may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Compensation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Base Salary.</B> The Company shall pay Employee a base salary of $250,000 per annum, payable at least monthly on the Company&#146;s
regular pay cycle for professional employees (the &#147;Base Salary&#148;). Except as specifically otherwise provided herein, the Base Salary may be increased only by recommendation of the CEO and ratified by the Compensation Committee or a majority
of the independent members of the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Annual Review.</B> The Base Salary shall be reviewed at the end of each calendar year (the
first such review to occur at the end of calendar year 2015). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Equity Compensation.</B> In connection with the execution of this
Agreement, the Company hereby agrees to grant on or promptly after April&nbsp;1, 2015 initial equity compensation to Employee in the aggregate amount of 600,000 options to purchase shares of Company Common Stock. These options shall be granted
subject to the terms and conditions of the Company&#146;s stock option plan then in effect, and the terms and conditions of the applicable option agreement, and will vest in accordance with the terms and schedule set forth in Exhibit A hereto. Such
vesting schedule will be accelerated, to the extent provided in Section&nbsp;8 of this agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Other and Additional
Compensation.</B> Subsections (a)&nbsp;and (c)&nbsp;above establish Employee&#146;s compensation during the Term which shall not preclude the Board from awarding Employee a higher salary or any bonuses or stock options, restricted stock or other
forms of additional equity awards in the discretion of the Board during the Term at any time. The Employee shall be eligible for an annual discretionary bonus (hereinafter referred to as the &#147;Bonus&#148;) with a target amount of one hundred and
twenty five percent (125%)&nbsp;of the Base Salary<B>, </B>subject to standard deductions and withholdings, based on the Compensation Committee&#146;s determination, in good faith, and based upon the Employee&#146;s individual achievement and
company performance objectives as set by the Board or the Compensation Committee, of whether the Employee has met such performance milestones as are established for the Employee by the Board or the Compensation Committee, in good faith, in
consultation with the Employee (hereinafter referred to as the &#147;Performance Milestones&#148;). The Performance Milestones will be based on certain factors including, but not limited to, the Employee&#146;s performance and the Company&#146;s
financial performance. The Employee&#146;s Bonus target will be reviewed annually and may be adjusted by the Board or the Compensation Committee in its discretion, provided however, that the Bonus target may only be reduced upon Employee&#146;s
written consent. The Employee must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which
such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Employee Benefits.</B> During the Term, Employee shall be entitled to participate at the same level as other senior executive officers of the Company in
any group insurance, hospitalization, medical, health and accident, disability, fringe benefit and tax-qualified retirement plans or programs of the Company now existing or hereafter established to the extent that he is eligible under the general
provisions thereof. For the term of this Agreement, Employee shall be entitled to paid vacation at the rate of (4)&nbsp;weeks per annum. In accordance with Company policy, unused vacation may not be carried over from year to year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Expenses.</B> The Company shall reimburse Employee for actual, reasonable out-of-pocket expenses incurred
by him in the performance of his services for the Company upon the receipt of appropriate documentation of such expenses which shall be submitted in such form, and with such supporting documentation, as called for or required by Company policy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Termination. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) General. </B>The
Term shall end immediately upon Employee&#146;s death. Employee&#146;s employment may also be terminated by the Company with or without Cause or as a result of Employee&#146;s Disability, as defined in Section&nbsp;7 or by Employee with or without
Good Reason (as such terms are defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Notice of Termination.</B> Either party shall give written notice of termination to
the other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Notification of New Employer</B>. In the event that Employee leaves the employ of the Company, Employee grants
consent to notification by the Company to Employee&#146;s new employer about his rights and obligations under this Agreement and the PIA (hereinafter defined). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Severance Benefits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Cause
Defined.</B> &#147;Cause&#148; means (i)&nbsp;willful malfeasance or willful misconduct by Employee in connection with his employment; (ii)&nbsp;Employee&#146;s gross negligence in performing any of his duties under this Agreement;
(iii)&nbsp;Employee&#146;s conviction of, or entry of a plea of guilty to, or entry of a plea of <I>nolo contendere</I> with respect to, any crime other than a traffic violation or infraction which is a misdemeanor; (iv)&nbsp;Employee&#146;s willful
and deliberate violation of a Company policy, (v)&nbsp;Employee&#146;s unintended but material breach of any written policy applicable to all employees adopted by the Company which is not cured to the reasonable satisfaction of the Board of
Directors within thirty (30)&nbsp;business days after notice thereof; (vi)&nbsp;the Employee&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party as to which the Employee owes an
obligation of nondisclosure as a result of the Employee&#146;s relationship with the Company, (vii)&nbsp;the Employee&#146;s willful and deliberate breach of his obligations under this Agreement, or (viii)&nbsp;any other material breach by Employee
of any of his obligations in this Agreement which is not cured to the reasonable satisfaction of the Board of Directors within thirty (30)&nbsp;business days after notice thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Disability Defined. </B>&#147;Disability&#148; shall mean (i)&nbsp;Employee&#146;s incapacity due to a physical or mental condition and,
if reasonable accommodation is required by law, after any reasonable accommodation, that results in Employee being substantially unable to perform his duties hereunder for six consecutive months (or for six months out of any nine month period) or
(ii)&nbsp;a qualified independent physician mutually acceptable to the Company and Employee determines that Employee is incapacitated due to a physical or mental condition and, if reasonable accommodation is required by law, after any reasonable
accommodation so as to be unable to regularly perform the duties of his position and such condition is expected to be of a permanent or near-permanent duration. Until such time as Employee is terminated for Disability under this paragraph (b),
Employee shall continue to receive his Base Salary hereunder, provided that if the Company provides Employee with disability insurance coverage, payments of Employee&#146;s Base Salary shall be reduced by the amount of any disability insurance
payments received by Employee due to such coverage. The Company shall give Employee written notice of termination due to Disability which shall take effect sixty (60)&nbsp;days after the date it is sent to Employee unless Employee shall have
returned to the performance of his duties hereunder during such sixty (60)&nbsp;day period (whereupon such notice shall become void). In the event that the Company terminates Employee&#146;s employment as a result of his Disability, Employee shall
be entitled to the same benefits as if his employment had been terminated by the Company without Cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Good Reason Defined.</B> For purposes of this Agreement, &#147;Good Reason&#148; shall
mean, without Employee&#146;s written consent: (i)&nbsp;there is a material reduction of the level of Employee&#146;s compensation (excluding any bonuses) (except where there is a general reduction applicable to the management team generally,
provided, however, that in no case may the Base Salary be reduced below the amount stated in Section&nbsp;3(a)), (ii)&nbsp;there is a material reduction in Employee&#146;s overall responsibilities or authority, or scope of duties (it being
understood that the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in Employee&#146;s responsibilities or authority); or (iii)&nbsp;there is a material change in the principal geographic location at which
Employee must perform his services (it being understood that the relocation of Employee to a facility or a location within forty (40)&nbsp;miles of the State Capitol Building in Raleigh, North Carolina shall not be deemed material for purposes of
this Agreement). No event shall be deemed to be &#147;Good Reason&#148; if the Company has cured the event (if susceptible to cure) within 30 days of receipt of written notice from Employee specifying the event or events which, absent cure, would
constitute &#147;Good Cause.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Accrued Compensation Defined. </B>Accrued Compensation shall mean an amount which shall include
all amounts earned or accrued by Employee through the date of termination of this Agreement but not paid as of such date, including (i)&nbsp;Base Salary, (ii)&nbsp;reimbursement for business expenses incurred by the Employee on behalf of the
Company, pursuant to the Company&#146;s expense reimbursement policy in effect at such time, (iii)&nbsp;any expense allowance pursuant to Company policy, (iv)&nbsp;accrued but unused vacation pay per Company policy, and (v)&nbsp;bonuses and
incentive compensation earned and awarded prior to the date of termination. Accrued Compensation shall be paid on the first regular pay date after the date of termination (or earlier, if required by applicable law). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Termination. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Cause; Without Good Reason; Death; Disability.</B> If the Company ends the Term for Cause, if Employee resigns as an
employee of the Company for reasons other than an event of Good Reason, the Employee dies or Disability occurs , then the Company shall pay to Employee the Accrued Compensation but shall have no obligation to pay Employee any amount, whether for
salary, benefits, bonuses, or other compensation or expense reimbursements of any kind, accruing after the end of the Term, and such rights shall, except as otherwise required by law or pursuant to the applicable award agreement or plan, be
forfeited immediately upon the end of the Term. For the sake of clarity, any stock options, restricted stock or other equity compensation shall, to the extent vested on the date of resignation without Good Reason, the date the Company ends the Term
for Cause, or the date of Employee&#146;s death or Disability, remain outstanding and exercisable to the extent provided in the applicable award agreement or plan, by the Employee or his personal representative or executor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Without Cause; Good Reason.</B> In the event that the Company terminates Employee&#146;s employment hereunder without
Cause, or the Employee terminates his employment with Good Reason, he shall be entitled to the Accrued Compensation and, subject to Section&nbsp;21 and 22 below, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) A lump sum payment equal to two times his Base Salary in effect at the date of termination, less applicable withholding
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(B) To the extent permitted by the Company&#146;s health insurance carrier and if such coverage would not result in penalties to the
Company under the Patient Protection and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Affordable Care Act, continued participation (via state or federal insurance continuation laws such as COBRA, to the extent available) in the health and welfare plans (or comparable plans, if
continued participation in the Company&#146;s plans is not available) provided by the Company to Employee at the time of termination for a period of two years from the date of termination or, if earlier, until he is eligible for comparable coverage
with a subsequent employer. The Company agrees to reimburse the payments Employee makes for such coverage, whether via continuation or separate comparable policy. Premium reimbursements shall be made by the Company to Employee consistent with the
Company&#146;s normal expense reimbursement policy, provided that Employee submits documentation to the Company substantiating his payments for insurance coverage. Employee shall give the Company prompt notice of his eligibility for comparable
coverage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(C) All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable
award. So long as the Section&nbsp;8&nbsp;below does not apply, then all options which are unvested at the date of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares
equal to 1/24<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> the number of option shares multiplied by the number of full months of Employee&#146;s employment hereunder shall be deemed vested and immediately exercisable by the Employee. Any
unvested options over and above the foregoing shall be cancelled and of no further force or effect, and shall not be exercisable by the Employee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(D) Any severance payments and/or other separation benefits contemplated by this Agreement are conditional on Employee: (i)&nbsp;continuing to
comply with the terms of this Agreement and the PIA (as defined herein); (ii)&nbsp;delivering prior to or contemporaneously with any such severance payments, and not revoking, (x)&nbsp;a customary general release of claims relating to
Employee&#146;s employment and/or this Agreement against the Company or its successor, its subsidiaries and their respective directors, officers and stockholders and (y)&nbsp;a customary affirmation of Employee&#146;s continuing obligations
hereunder and under the PIA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise required by law, no severance payments and/or benefits under this Agreement will be paid and/or provided
until after the expiration of any relevant revocation period. Subject to the effectiveness of the release, the severance payments shall be paid on the first payroll date that begins 30 days after Employee&#146;s termination of employment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Change in Control Payments.</B> The provisions of this paragraph 8 set forth the terms of an agreement reached between Employee and the Company regarding
Employee&#146;s rights and obligations upon the occurrence of a &#147;Change in Control&#148; (as hereinafter defined) of the Company during the Term. These provisions are intended to assure and encourage in advance Employee&#146;s continued
attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such Change in Control. The following provisions shall apply in the event of a Change in Control, in addition to any payment or
benefit that may be required pursuant to Section&nbsp;7. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Equity.</B> Upon the occurrence of a Change in Control, all stock options,
restricted stock and other stock-based grants to Employee by the Company or that may be granted in the future shall, irrespective of any provisions of his award agreements, immediately and irrevocably vest and become exercisable and any restrictions
thereon shall lapse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Definitions.</B> For purposes of this paragraph 8, the following terms shall have the
following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; shall mean any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the acquisition by any individual, entity, or group (within the meaning of Section&nbsp;13(d)(3) or 14(d)(2) of the Exchange Act) (the
&#147;Acquiring Person&#148;), other than the Company, or any of its Subsidiaries, of beneficial ownership (within the meaning of Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of
the then outstanding voting securities of the Company entitled to vote generally in the election of directors (excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona fide equity
financing purposes); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the acquisition of the Company by another entity by means of any transaction or series of related transactions
to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by the Company in a transaction or series of transactions made principally for bona
fide equity financing purposes ) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain,
immediately after such transaction or series of related transactions, as a result of shares in the Company held by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power represented by
the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) the sale or other disposition of all or substantially all of the assets of the Company in one transaction or series of related
transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Proprietary Information and Inventions Agreement</B>. As a condition of Employee&#146;s employment with the Company, Employee agrees
to sign the Company&#146;s standard form of Proprietary Information and Inventions Agreement (&#147;PIA&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Successors and Assigns. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Employee.</B> This Agreement is a personal contract, and the rights and interests that the Agreement accords to Employee may not be
sold, transferred, assigned, pledged, encumbered, or hypothecated by him. All rights and benefits of Employee shall be for the sole personal benefit of Employee, and no other person shall acquire any right, title or interest under this Agreement by
reason of any sale, assignment, transfer, claim or judgment or bankruptcy proceedings against Employee. Except as so provided, this Agreement shall inure to the benefit of and be binding upon Employee and his personal representatives, distributees
and legatees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) The Company.</B> This Agreement shall be binding upon the Company and inure to the benefit of the Company and of its
successors and assigns, including (but not limited to) any Company that may acquire all or substantially all of the Company&#146;s assets or business or into or with which the Company may be consolidated or merged. Any such successor of the Company
will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, &#147;successor&#148; means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or
otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Entire Agreement.</B> This Agreement (together with the equity award agreements referred to herein)
represents the entire agreement between the parties concerning Employee&#146;s employment with the Company and supersedes all prior negotiations, discussions, understanding and agreements, whether written or oral, between Employee and the Company
relating to the subject matter of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Amendment or Modification, Waiver.</B> No provision of this Agreement may be amended or waived
unless such amendment or waiver is agreed to in writing signed by Employee and by a duly authorized officer of the Company. No waiver by any party to this Agreement or any breach by another party of any condition or provision of this Agreement to be
performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same time, any prior time or any subsequent time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Notices.</B> Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or
certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Employee:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">3516 Rock Creek Drive</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Raleigh, NC 27609</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the address specified in the payroll records of the Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to the Company:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Rosewind Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">373 Inverness Parkway</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Suite 200</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Englewood, Colorado 80112</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by
registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Severability.</B> If any
provision of this Agreement or the application of any such provision to any party or circumstances shall be determined by any court of competent jurisdiction or arbitrator acting pursuant to Section&nbsp;19 below to be invalid and unenforceable to
any extent, the remainder of this Agreement or the application of such provision to such person or circumstances other than those to which it is so determined to be invalid and unenforceable shall not be affected, and each provision of this
Agreement shall be validated and shall be enforced to the fullest extent permitted by law. If for any reason any provision of this Agreement containing restrictions is held to cover an area or to be for a length of time that is unreasonable or in
any other way is construed to be too broad or to any extent invalid, such provision shall not be determined to be entirely null, void and of no effect; instead, it is the intention and desire of both the Company and Employee that, to the extent that
the provision is or would be valid or enforceable under applicable law, any court of competent jurisdiction or arbitrator acting pursuant to Section&nbsp;19 below shall construe and interpret or reform this Agreement to provide for a restriction
having the maximum enforceable area, time period and such other constraints or conditions (although not greater than those contained currently contained in this Agreement) as shall be valid and enforceable under the applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Survivorship.</B> The respective rights and obligations of the parties hereunder shall survive any
termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Headings.</B> All descriptive
headings of sections and paragraphs in this Agreement are intended solely for convenience of reference, and no provision of this Agreement is to be construed by reference to the heading of any section or paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Withholding Taxes.</B> All salary, benefits, reimbursements and any other payments to Employee under this Agreement shall be subject to all applicable
payroll and withholding taxes and deductions required by any law, rule or regulation of and federal, state or local authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Counterparts.</B>
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together constitute one and same instrument. The parties agree that facsimile signatures shall have the same force and
effect as original signatures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Applicable Law; Arbitration.</B> The validity, interpretation and enforcement of this Agreement and any amendments
or modifications hereto shall be governed by the laws of the State of Colorado, as applied to a contract executed within and to be performed in such State. The parties agree that any disputes shall be definitively resolved by binding arbitration
before the American Arbitration Association in Denver, Colorado in accordance with its rules of arbitration procedure then in effect. The parties consent to the jurisdiction to the federal courts of the District of Colorado or, if there shall be no
jurisdiction, to the state courts located in Arapahoe County, Colorado, to enforce any arbitration award rendered with respect thereto. Each party shall choose one arbitrator and the two arbitrators shall choose a third arbitrator. All costs and
fees related to such arbitration (and judicial enforcement proceedings, if any) shall be borne by the Company unless Employee&#146;s claim is deemed to be frivolous by the arbitrator(s) or judge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Legal Fees. </B>The Company shall pay the reasonable expenses of Employee&#146;s counsel in negotiating this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Section&nbsp;409A. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Anything in
this Agreement to the contrary notwithstanding, if at the time of Employee&#146;s separation from service within the meaning of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), the Company determines that
Employee is a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#146;s separation
from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment
shall not be payable and such benefit shall not be provided until the date that is the earlier of (A)&nbsp;six months and one day after Employee&#146;s separation from service, or (B)&nbsp;Employee&#146;s death. If any such delayed cash payment is
otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All in-kind benefits provided and expenses eligible for
reimbursement under this Agreement shall be provided by the Company or incurred by Employee during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any
reimbursement be paid after the last day of the taxable year following the taxable year in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses
eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another
benefit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent that any payment or benefit described in this Agreement constitutes &#147;non-qualified deferred
compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#146;s termination of employment, then such payments or benefits shall be payable only upon Employee&#146;s
&#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&nbsp;1.409A 1(h). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. Each payment pursuant to this
Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section&nbsp;1.409A 2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully
comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. Application of Internal Revenue Code Section&nbsp;280G. </B>If any payment or benefit Employee would receive pursuant to a Change in Control from the
Company or otherwise (&#147;<I>Payment</I>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by
Section&nbsp;4999 of the Code (the &#147;<I>Excise Tax</I>&#148;), then such Payment shall be equal to the Reduced Amount. The &#147;Reduced Amount&#148; shall be either (x)&nbsp;the largest portion of the Payment that would result in no portion of
the Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the
Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#146;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.
If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Employee. If more
than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event it is subsequently
determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to clause (x)&nbsp;in the preceding paragraph is subject to the Excise Tax, Employee agrees to promptly return to the Company a sufficient
amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y)&nbsp;in the preceding paragraph, Employee will have no obligation to
return any portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless Employee and the Company agree on an alternative accounting firm, the
accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as
accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with
respect to the determinations by such accounting firm required to be made hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Employee and the Company within fifteen (15)&nbsp;calendar days after the date on which Employee&#146;s right to a Payment is triggered (if
requested at that time by the Employee or the Company) or such other time as requested by Employee or the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. Indemnification.</B> As a
condition to the effectiveness of this Agreement, the Company and Employee shall enter into a mutually acceptable indemnification agreement (the &#147;Indemnification Agreement&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement as of the date first written above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ROSEWIND CORPORATION</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Macaluso</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jarrett T. Disbrow</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: MICHAEL MACALUSO</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">JARRETT T. DISBROW</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Sole Director</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Employment Agreement] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Terms of Equity Compensation </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management equity grant</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">600,000 total options to purchase shares of the Company&#146;s common stock. The strike price for all options will be the last sale price of the Company&#146;s common stock as reported on April&nbsp;1, 2015 and in
accordance with the terms of the Company&#146;s Stock and Incentive Plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All options fully vest upon Change in Control, death, Disability, termination with or without Cause, termination for Good Reason </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">300,000 options are fully vested on the Effective Date of this agreement </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">150,000 options vest 365 days thereafter </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">150,000 options vest 730 days thereafter </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>d912919dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>***Text Omitted and Filed Separately with the Securities and Exchange Commission </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DISTRIBUTION AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>DATED</SMALL> <SMALL>AS</SMALL> <SMALL>OF</SMALL> M<SMALL>ARCH</SMALL>&nbsp;1, 2012 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>BETWEEN</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>MPIO</SMALL> <SMALL>PHARMACEUTICALS</SMALL>, <SMALL>INC</SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SMALL>AND</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F<SMALL>BM</SMALL> <SMALL>INDUSTRIA</SMALL> <SMALL>FARMACEUTICA</SMALL>, <SMALL>LTDA</SMALL>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">D<SMALL>ISTRIBUTION</SMALL> A<SMALL>GREEMENT</SMALL> (this &#147;<I>Agreement</I>&#148;), dated
as of March&nbsp;1, 2012 (the &#147;<I>Effective Date</I>&#148;), between Ampio Pharmaceuticals, Inc., a Delaware corporation (&#147;Ampio&#148;), and FBM Industria Farmaceutica, Ltda., VP 3D, Qd, 8B, Mod. 9112 CEP 75132-095, Anapolis - GO, Brazil
(&#147;<I>Distributor</I>&#148;). Each of Ampio and Distributor are referred to herein as a &#147;<I>Party</I>&#148; or the &#147;<I>Parties</I>.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Introduction </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ampio has rights
to market, distribute and sell the Product. Ampio wishes to distribute the Product by appointment of distributors to make sales in certain territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ampio wishes to appoint Distributor as its exclusive distributor to promote, advertise, market, distribute and sell the Product in Brazil (the
&#147;<I>Territory</I>&#148;) and Distributor wishes to act as distributor on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms shall have the meanings ascribed to such terms in Section&nbsp;12.2 or as otherwise provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For good and valuable consideration, and in reliance upon the covenants, promises, and representations and warranties contained herein, the
Parties, intending legally to be bound, hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>PPOINTMENT</SMALL> <SMALL>OF</SMALL> D<SMALL>ISTRIBUTOR</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <U>Appointment.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions of this Agreement, Ampio hereby appoints Distributor to act as its exclusive distributor to promote,
advertise, market, distribute and sell the Product in the Field in the Territory during the Term. Distributor hereby accepts the appointment and agrees to use commercially reasonable efforts to promote, advertise, market, distribute and sell the
Product in the Field in the Territory during the Term in accordance with the terms and conditions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to
Article 8, Ampio hereby retains all rights outside the Territory and outside the Field with respect to the Product in all respects, including the right to appoint other distributors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Ampio shall forward to Distributor all inquiries, requests for information and purchase orders from Persons in the Field in the Territory
relating to the Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) At all times during the Term, Distributor shall obtain, hold and Maintain, at its own cost and expense, all
applicable Brazilian Governmental Authority authorizations to label, package, promote, advertise, market, distribute and sell the Product in the Territory, including, without limitation, licenses, registrations and/or authorizations that are
required from a distributor of pharmaceutical products, probiotics, enzymes, cosmetics and contraceptives. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.2 <U>Exclusivity.</U> The appointment in Section&nbsp;1.1(a) shall be exclusive to
Distributor in the Field in the Territory during the Term until the Exclusivity Termination Date (if any). During the Term until the Exclusivity Termination Date, Ampio shall not (directly or indirectly) appoint as its distributor any Person to, nor
shall itself, promote, advertise, market, distribute or sell the Product, or any versions thereof, or any competitive Product in the Field in the Territory, nor shall supply any Third Party for promotion, advertisement, marketing, distribution or
sale of the Product, or any versions thereof, or any competitive Product, in the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.3 <U>Limitations
on Appointment.</U> Distributor shall not, and, if permitted under applicable Laws, shall cause each of its Sub-Distributors not to, (i)&nbsp;actively promote, advertise, market, distribute or sell the Product outside the Field or outside the
Territory; or (ii)&nbsp;support by its own actions any Third Party in doing any of the foregoing (which support includes, for example and without limitation, providing any written marketing materials, conducting or financing any clinical trials or
otherwise providing any consideration in support of same). In addition, once Distributor learns of any conduct by a Sub-Distributor of these prohibited activities, Distributor shall, if permitted under applicable Laws, use commercially reasonable
efforts to end all such prohibited activities by such Sub-Distributor within a commercially reasonable time period, which in all events shall be within 6 months of first learning of any such prohibited activities by such Sub-Distributor, and if
unable to end all such prohibited activities by such efforts: if permitted under applicable Laws, (a)&nbsp;terminate the appointment of such Sub-Distributor; and (b)&nbsp;stop selling (directly or indirectly through other Sub-Distributors or
otherwise) the Product to such Sub-Distributor. If Ampio notifies Distributor in writing of any conduct by a non-Affiliated Sub-Distributor of any such prohibited activities, Distributor shall thereafter confirm in writing to Ampio that Distributor
has complied with the immediately preceding sentence with respect to such Sub-Distributor. The Parties agree that if Distributor breaches its obligations under this Section&nbsp;1.3, Ampio shall have the right, in Ampio&#146;s sole discretion, to
either (a)&nbsp;provide written notice to convert Distributor&#146;s appointment pursuant to Section&nbsp;1.1 from exclusive distributor to non-exclusive distributor and the date of receipt of such notice shall be treated as an Exclusivity
Termination Date; or (b)&nbsp;terminate this Agreement pursuant to Section&nbsp;10.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.4 <U>No Compensation.</U> Ampio is
not obligated to pay compensation for Distributor&#146;s performance of its obligations hereunder, and Distributor&#146;s sole compensation shall arise from its resale of the Product. Ampio shall not provide Distributor with any other compensation
or benefits, and Ampio shall not be responsible for reimbursement of any out-of-pocket expenses, except as expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.5 <U>Relationship.</U> In the exercise of their respective rights and the performance of their respective obligations
hereunder, the Parties are and shall remain independent contractors. Nothing in this Agreement shall be construed: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to give either Party the right or power to direct or control the daily activities of the
other Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to create the relationship between the Parties of principal and agent, franchiser and franchisee, partners, joint
ventures, co-owners or otherwise as participants in a joint undertaking; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) to authorize either Party to bind the other Party to, or
assume or create any contract and obligation of any kind, express or implied, on behalf of the other Party or to any other Person; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
to waive any right, interest and claim that one of the Parties may have against any other Person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ARKETING</SMALL> <SMALL>AND</SMALL> P<SMALL>ROMOTION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <U>Steering Committee.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties shall appoint a committee (the &#147;<I>Steering Committee</I>&#148;) comprised of one member designated by Ampio and one
member designated by Distributor. The initial members of the Steering Committee shall be Bruce Miller, Zertane Product Manager, for Ampio and Dr.&nbsp;Alexandre Feliciano Ferreira, for Distributor. Each Party may replace its Steering Committee
member at any time upon written notice to the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Steering Committee shall meet at least on a calendar quarterly basis,
which meeting can be a teleconference, and shall be responsible for reviewing and steering the promotion, advertising and marketing activities relating to the Product and the performance of the Agreement by the Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Party may invite, with the approval of the other Party (which shall not be unreasonably withheld), additional individuals to attend
one or more meetings of the Steering Committee as ad hoc guests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <U>Promotion, Advertising and Marketing.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Term, Distributor shall actively promote, advertise, market, distribute and sell the Product only in the Field and only in the
Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor shall commercialize the Product in accordance with the Business Plans attached as Exhibit A and such additional
Business Plans to be developed by Distributor during the Term of this Agreement. Distributor shall update the Business Plans at least annually and present them to Ampio for review no later than October&nbsp;1 of each year preceding the
implementation of such plan. Such Business Plan shall include, at a minimum: (i)&nbsp;Distributor&#146;s proposed promotion, advertising and marketing efforts; and (ii)&nbsp;a list of planned promotional activities, such as training sessions for the
education and training of Customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Distributor shall produce promotion, advertising and marketing materials for the Product in
the Territory. In connection therewith, Distributor shall conduct such activities, including development, translation, printing and communication of marketing, sales, medical education or other related materials (e.g., sales literature, advertising
materials and promotional programs) as commercially necessary for the distribution and sale of the Product in the Territory (along with all other documents and other materials intended for public distribution created by or on behalf of Distributor
or any Sub-Distributor regarding Ampio or any Product, collectively, &#147;<I>Distributor Materials</I>&#148;). Ampio shall provide such support (e.g., regarding technical information relating to the Product or printed materials such as product
labels) as is reasonably necessary to permit Distributor to fulfill any relevant regulatory requirements with regard to the Distributor Materials. Distributor shall bear its own costs associated with Distributor Materials, and shall provide all
Distributor Materials that would entail public communication regarding the Product to Ampio (translated in English, if applicable) for its prior review and prompt approval insofar as the material relates to the Product, which approval shall not be
unreasonably withheld, <I>provided</I> that any accurate translation of any such materials previously approved by Ampio, or any materials provided by Ampio, shall not require Ampio&#146;s separate approval. Unless Ampio has notified Distributor of
any objections within 10 Business Days after receipt of such Distributor Materials, Ampio shall be deemed to have approved the Distributor Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <U>Sub-Distributors.</U> Distributor shall be entitled to appoint one or more Sub-Distributors to promote, advertise, market,
distribute or sell the Product in the Territory in accordance with the terms and conditions of this Agreement; <I>provided, however,</I> that Distributor shall not utilize or engage any Competitor of Ampio as a Sub-Distributor, without the prior
written consent of Ampio. Distributor shall remain jointly and severally liable under this Agreement for the actions and omissions of each of its Sub-Distributors, and Distributor shall be solely responsible for any commitments, obligations or
liabilities made by any of its Sub-Distributors. Distributor hereby acknowledges that the appointment of any such Sub-Distributor does not reduce, impair or negatively affect its ability to perform each one of its obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <U>Customer Information.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within 20 days of the end of each Calendar Quarter during the Term, Distributor shall provide Ampio with a quarterly report, which shall
include the following information: (i)&nbsp;the number of new Customers added in the Calendar Quarter ; (ii)&nbsp;the number of unit sales of each Product ; (iii)&nbsp;the average price paid by each Customer for each Product ; (iv)&nbsp;any
information required by Law, such as Customer complaint information; and (v)&nbsp;any such other information that may be reasonably requested by Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <U>Rights and Obligations of Distributor.</U> Consistent with applicable Laws, Distributor shall actively promote the sale
and distribution of the Product in the Territory. Without limiting any other obligation of Distributor hereunder, in particular, Distributor shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) appoint and train appropriately qualified staff to carry out its duties under this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) undertake debtor collection; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) check product availability and confirm delivery dates to Customers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) take orders from Customers and place such orders with Ampio; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) track Customers&#146; orders and respond to Customers&#146; inquiries on orders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) undertake key account management; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) provide other customer service activities as requested by Ampio and agreed to by Distributor; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) assume no obligation or liability in Ampio&#146;s name; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) refrain from acting in such a manner as to be construed an employee or agent of Ampio; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) make no representations or claims with respect to the Product, except in accordance with Section&nbsp;3.1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) maintain sufficient inventory to fulfill its obligations under this Agreement and to Customers; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) keep Ampio informed on a reasonably regular basis on sales activity, and promptly disclose to Ampio all material information relating to
the Product obtained concerning purchasing plans of existing and prospective Customers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) within 30 days of expiration or termination of
this Agreement, return to Ampio, at Ampio&#146;s expense, all samples, catalogs, literature, correspondence, sales records, market data or information and other similar documents or materials on hand relating to the Product; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) submit marketing materials relating to the Product to the Brazilian Governmental Authorities, whenever required or necessary by applicable
Law, or as directed by Ampio or any Governmental Authority in the Territory, and provide reasonable assistance to Ampio in connection with Ampio&#146;s submission of marketing materials relating to the Product in any country or jurisdiction in which
Ampio is required by Laws to make such submissions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) maintain facilities, including warehousing and distribution facilities, in the
Territory suitable for the conduct of Distributor&#146;s business and in compliance with all applicable legal requirements; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)
obtain, hold and Maintain all Product Registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributor may agree to provide other incidental services and perform other administrative
functions in connection with or incidental to its duties hereunder, consistent with applicable Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6 <U>Competing Product.</U> During the Term, Distributor shall not, and, if
permitted under applicable Laws, shall cause its Sub-Distributors not to, directly or indirectly engage in the manufacture, sale, offer for sale, marketing, promotion, distribution, solicitation of order or service of any competitive product in the
Territory other than the Product as provided in this Agreement. In addition, once Distributor learns of any conduct by a Sub-Distributor of such activities, Distributor shall, unless such activities have been approved by Ampio and unless prohibited
by applicable Laws, use commercially reasonable efforts to promptly end all such activities by such Sub-Distributor within a commercially reasonable time period, which in all events shall be within 6 months of first learning of any such prohibited
activities by such Sub-Distributor, and if unable to end all such prohibited activities by such efforts: if permitted under applicable Laws (a)&nbsp;terminate the appointment of such Sub-Distributor; and (b)&nbsp;stop selling (directly or indirectly
through other Sub-Distributors or otherwise) the Product to such Sub-Distributor. If Ampio notifies Distributor in writing of any conduct by a non-Affiliated Sub-Distributor of any such prohibited activities, Distributor shall thereafter confirm in
writing to Ampio that Distributor has complied with the immediately preceding sentence with respect to such Sub-Distributor. The Parties agree that if Distributor breaches its obligations under this Section&nbsp;2.6, Ampio shall have the right, in
Ampio&#146;s sole discretion, to either (a)&nbsp;provide written notice to convert Distributor&#146;s appointment pursuant to Section&nbsp;1.1 from exclusive distributor to non-exclusive distributor the date of receipt of such notice shall be
treated as an Exclusivity Termination Date; or (b)&nbsp;terminate this Agreement pursuant to Section&nbsp;10.2. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>ISTRIBUTION</SMALL> <SMALL>OF</SMALL> P<SMALL>RODUCT</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <U>Distributor Covenants.</U> Distributor hereby covenants and agrees for the benefit of Ampio that Distributor shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) conduct any promotion, advertising, marketing, distribution or sale of the Product in accordance with all applicable Laws and in material
conformance with applicable industry codes, guidelines and standards, including each as amended and in force from time to time, and shall cultivate good relationships with Customers and potential customers in the Territory in accordance with sound
commercial principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) observe and comply with such storage, stock control and operational practices and procedures with respect to
the Product as may be legally required and as Ampio may specify or approve from time to time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) not make any representation to Customers
nor give any warranties other than those printed on the Product&#146; packaging or labeling or included within marketing or sales aid material or other Product information provided or agreed to by Ampio; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) during the Term of this Agreement and for 3 years following expiration or termination of this Agreement, or such longer period as may be
required by applicable Laws, maintain complete and accurate books of account and records showing orders placed, sales and services stock with respect to the Product; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) not use the services of any Person debarred or suspended under section 306 of the Federal Food, Drug, and Cosmetic Act, as amended, or
under the Brazilian ANVISA regulation, in performing its obligations or exercising its rights under this Agreement. Distributor shall promptly notify Ampio if any Person whose services Distributor is using in the performance of its obligations or
exercise of its rights under this Agreement becomes debarred or suspended; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) submit marketing materials relating to the Product, if any, to local Governmental Authorities
in the Territory where such submissions are required or necessary or as directed by Ampio or any Governmental Authority; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) be
responsible for all reimbursement activity relating to the Product; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) promote, advertise, market, distribute and sell the Product in the
Territory in substantially the same manner as other of Distributor&#146;s businesses; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) execute trade terms, quantity discount,
settlement terms, etc. in substantially the same manner as other of Distributor&#146;s businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <U>Branding.</U>
Distributor shall have the right to choose the trademarks, logos and/or trade dress (the &#147;<I>Product Branding</I>&#148;) pursuant to which the Product are marketed and sold in the Territory, <I>provided, however</I>, that Ampio&#146;s
&#147;Zertane&#148; trademark shall be included in the Product Branding in a manner to be mutually agreed upon by the Steering Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <U>Insurance.</U> The Parties shall maintain adequate insurance, in such amounts and with such insurance companies as is
customary in accordance with sound business practices consistent with the nature of the Product. Each Party shall upon the request of the other Party furnish certificates of such insurance. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P<SMALL>URCHASE</SMALL>, S<SMALL>ALE</SMALL> <SMALL>AND</SMALL> D<SMALL>ELIVERY</SMALL> <SMALL>OF</SMALL> P<SMALL>RODUCT</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <U>Supply of Product.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Ampio shall use commercially reasonable efforts to manufacture and supply the Product with the Product Branding for Distributor during the
Term with such quantities of the Product as Distributor shall order from Ampio on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Ampio shall have the right to satisfy its supply obligations under this Agreement either in whole or in part through arrangements with
Affiliates or Third Parties engaged by Ampio, <I>provided</I> that Ampio remains solely liable for the performance of such obligations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Ampio shall notify Distributor as soon as commercially reasonable, taking due account of Distributor&#146;s need to be informed, in the
event Ampio anticipates any problems with supplying the quantities of the Product set forth in any forecast provided pursuant to Section&nbsp;4.3, and the Parties shall agree on appropriate measures to address any such problems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <U>Forecasts.</U> Upon execution of this Agreement, and for each Calendar Quarter thereafter, Distributor shall provide to
Ampio, fifteen (15)&nbsp;days before the start of each Calendar Quarter a written forecast of its best estimate Order forecast for the 12-month period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beginning with the start of the next Calendar Quarter, such forecast to be broken down Product-by-Product and month-by-month. Except as provided in Section&nbsp;4.5(c), the forecasted amounts for
the first 4 quarters of the forecast shall be deemed a binding and firm purchase order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <U>Orders.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All orders from Distributor to Ampio shall be initiated by a written purchase order specifying the quantities of the Product and requested
dates of shipment (each, an &#147;<I>Order</I>&#148;) and shall be deemed accepted within 5 Calendar Days after receipt by Ampio, unless Ampio notifies Distributor in writing within those 5 Calendar Days. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Ampio shall not refuse to accept an Order which falls within the committed forecasts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4 <U>Order of Precedence.</U> Any inconsistency in any documents relating to the purchase of the Product shall be resolved by
giving precedence in the following order: (i)&nbsp;the terms and conditions of this Agreement (including the Exhibits attached hereto); (ii)&nbsp;the provisions and text appearing on the face of the applicable Order insofar as they refer to the
specific Order; and (iii)&nbsp;other documents, exhibits and attachments which accompany such Order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.5 <U>Taxes and
Governmental Charges.</U> Prices do not include any taxes or other governmental charges, including import or export duties, value-added, sales, use or privileges taxes, property or excise, or similar taxes levied by any government. Distributor shall
pay all such taxes or charges on or before the due date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.6 <U>Shipment, Delivery and Title</U>. Ampio shall deliver the
Product EXW (Incoterms 2000) at a facility designated by Ampio in Europe on the date as specified in the Order, provided, that such dates specified in the Orders shall allow for a delivery time of at least thirty (30)&nbsp;days from date of Order.
The product shall be delivered as bulk tablets and with Distributor responsible for labeling and packaging in final trade dress suitable for distribution to final users. Title to each of the Product shall pass to Distributor when delivery is made to
the carrier at such point of shipment. Ampio shall be entitled to change the point of shipment, provided, however, that Ampio shall be responsible for any additional costs or expenses incurred by Distributor in connection with such changed point of
shipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.7 <U>Rejection of Delivery.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Within 30 days of delivery of the Product to Distributor, Distributor shall notify Ampio in writing of any physical damage or issue which
is apparent from an external review of the packaged Product, and within 15 days of Distributor&#146;s receipt of notice from a Customer that any Product has a defect and/or does not conform to the Specifications for the Product, Distributor shall
notify Ampio in writing of such claims by the Customer. In each case, Distributor shall, if possible, include with its notice sufficient samples to permit Ampio to evaluate Distributor&#146;s or the Customer&#146;s claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Within 30 days of receipt of those samples, Ampio will inform Distributor in writing whether
it accepts or rejects Distributor&#146;s or the Customer&#146;s claims. If the claim is accepted, then Ampio shall use its commercially reasonable efforts to replace the Product free of charge DDP (Incoterms 2010) destination as indicated by
Distributor in writing or, at Distributor&#146;s discretion, credit Distributor the amount actually paid by Distributor for such Product including transport and any taxes or other governmental charges. Distributor shall return all non-conforming
Product (less reasonable samples) in its possession at Ampio&#146;s expense within 30 days of the date of Ampio&#146;s written confirmation that it accepts the claim, <I>provided</I> that such shipment can be made in accordance with applicable Laws,
including export Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If Ampio does not accept the claim, the Parties shall submit samples of the non-conforming Product for testing
to an independent expert agreed upon by both Parties acting reasonably. If the Parties are unable to agree on the identity of the expert, the Parties shall jointly apply to a mutually agreed Third Party for the appointment of an expert. The
expert&#146;s determination will be final absent of manifest error. The costs associated with such expert determination shall be borne by the losing Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.8 <U>Terms of Payment.</U> Ampio shall issue invoices for each shipment upon delivery in accordance with Section&nbsp;4.6.
Terms of payment shall be net thirty (30)&nbsp;days from date of the invoice. All payments shall be in United States Dollars and shall be fully net, without set-off, deduction or counterclaim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.9 <U>Payment and Pricing</U>. Distributor shall pay to Ampio for Product supplied hereunder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Within thirty (30)&nbsp;days after supply by Ampio to Distributor, its Affiliates or its Subdistributors of any Product, Distributor shall pay
to Ampio an amount equal to Transfer Price. &#147;Transfer Price&#148; means US$[&#133;***&#133;] per tablet, subject to annual adjustment on each anniversary of the date of first commercial sale of the Product in the Territory; provided that from
and after the date upon which Distributor has bought and paid for [&#133;***&#133;] pills, the Transfer Price shall be reduced by US$[&#133;***&#133;] per tablet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.10 <U>Withholding Tax</U>. (a)&nbsp;All payments by Distributor hereunder shall be made without any deduction and free and
clear of and without deduction for or on account of any withholding tax or similar tax deduction (the &#147;<I>Withholding Taxes</I>&#148;) , except to the extent that Distributor is required by law to make payment subject to such Withholding Taxes.
If any amounts in respect of Withholding Tax must be deducted, or any other deductions for or on account of Withholding Tax must be made, from any amounts payable or paid by Distributor hereunder, Distributor shall pay such additional amounts as may
be necessary to ensure that Ampio receives a net amount equal to the full amount which it would have received had payment not been made subject to deduction of such Withholding Tax. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">(b) Without affecting item (a)&nbsp;above, if Ampio is required to make any payment on account of Withholding Tax on or in relation to any
amount received or receivable hereunder or any liability in respect of such payment is asserted, imposed, levied or assessed against Ampio, Distributor shall, on demand by Ampio, indemnify and hold harmless Ampio against that payment or liability.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Distributor shall maintain official receipts related to any Withholding Taxes and forward copies of such
receipts to Ampio, as instructed by Ampio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.11 <U>Marketing Expenditures</U>. For three years following the first
commercial sale of the Product in the Territory, Distributor shall invest and spend at least $1,000,000 in Marketing Expenses on the Product in the Territory. Distributor shall draft a &#147;Sales and Marketing Expenditure Plan&#148; to be submitted
to Ampio for its review and comment not later than three (3)&nbsp;months prior to the planned commercial launch of the Product in the Territory. Thereafter, Distributor shall prepare annual updates to the Sales and Marketing Expenditure Plan for
each calendar year before September&nbsp;15 of the prior year. Each draft of the Sales and Marketing Expenditure Plans shall be reviewed by the Steering Committee, and Distributor shall in good faith take into account any comments from the Steering
Committee in connection with the finalization of each Sales and Marketing Expenditure Plan. Following the receipt of comments, if any, from the Steering Committee, Distributor shall finalize the Sales and Marketing Expenditure Plan with the terms
and expenditures, including (i)&nbsp;a budget for aggregate annual sales and marketing expenditures (the &#147;<I>Budget</I>&#148;) and (ii)&nbsp;the targeted number of sales calls to physicians, determined appropriate by Distributor in its sole
discretion (&#147;<I>Target Sales Calls</I>&#148;). Distributor shall submit each such final Sales and Marketing Expenditure Plan to the Steering Committee for its official records retention (which, in the case of annual updates, shall be submitted
not later than November&nbsp;15 of the prior year); provided, however that Distributor may amend and revise any such final Sales and Marketing Expenditure Plan to reflect any material change in condition not reasonably within the control of
Distributor (including, but not limited to, Product safety issues, recalls, changes in regulatory requirements, interruption of supply and backorders). Upon written request from Ampio, Distributor shall affirm to Ampio its compliance with the
foregoing minimum marketing expenditures and sales calls. If, however, Distributor fails to spend the minimum Budget amount or conduct such minimum Target Sales Calls, and Distributor further fails to cure such deficiencies within the first six
(6)&nbsp;months of the following period, Ampio may elect to convert the appointment in Section&nbsp;1.1. of this Agreement to non-exclusive in the Territory by providing written notice to Distributor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.12 <U>Late Charges.</U> If Distributor fails to pay the price or any other payment due to Ampio promptly and when due, Ampio
may recover, in addition to the price or payment, interest thereon at a rate of one percent (1%)&nbsp;per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.13
<U>Trade Price.</U> Distributor shall set the trade prices in consultation with the Steering Committee. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>OMPLIANCE</SMALL> <SMALL>WITH</SMALL> L<SMALL>AWS</SMALL>; R<SMALL>EGULATORY</SMALL> M<SMALL>ATTERS</SMALL>; R<SMALL>ECYCLING</SMALL>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <U>Export and Trade Regulations.</U> Both Parties shall endeavor to at all times carry out the transactions contemplated
by this Agreement in conformity with all applicable Laws (including the United States Export Administration Acts), and shall obtain all necessary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permits and licenses required in connection with the purchase, installation, sale, shipment, service or use of the Product. Shipments by Ampio are or may be subject to restrictions and
limitations imposed by United States export controls and other trade sanctions. Each Party shall at all times use commercially reasonable efforts to keep the other Party informed of, and both Parties shall at all times use commercially reasonable
efforts to comply with, such sanctions, controls and regulations, as well as the United States Foreign Corrupt Practices Act, in its respective use and disposition of the Product. If Ampio learns, or has reasonable cause to believe, or if any branch
or agency of the government of the United States claims that a violation of any applicable export regulation or other trade sanction, export control or trade regulation by Distributor has occurred or is likely to occur because of any shipment by
Ampio to Distributor, Ampio shall promptly notify Distributor and may, in addition to any other remedy it may have, suspend all shipments to Distributor until Ampio is satisfied that such violation did not occur or has ceased to occur, or such claim
is withdrawn or otherwise resolved in favor of Ampio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <U>Customer Complaints and Product Safety.</U> The Parties will
cooperate in and each Party is responsible for full compliance with its requirements regarding Vigilance, Product complaint, Field Safety Notices, Product Recall&nbsp;requirements. Distributor shall promptly notify Ampio of any customer complaints
of which it may become aware in relation to the Product or any component thereof. Distributor will provide such Product to Ampio for evaluation. Ampio will perform evaluations of such customer complaints and supply the results of such evaluations to
Distributor, including, but not limited to, corrective action(s) and investigations. Distributor will respond directly to the Customer regarding the results of these evaluations. Ampio will be responsible for creating and implementing any corrective
or preventive action that concerns the Product, and shall bear all cost relating to such corrective or preventive action, including all reasonable direct cost and expenses incurred by Distributor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <U>Pharmacovigilance</U>. Under overall Ampio oversight, Distributor shall at its own cost and expense, carry out
pharmacovigilance procedures by means of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of the Product with a view to identifying new information about hazards
associated with Product and preventing harm resulting from Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>Recalls.</U> In the event any component of the
Product is subject to a recall or withdrawal or other field correction of Product in the Territory, the Parties will cooperate, under overall Ampio oversight, to manage the process in a commercially reasonable manner. In the event of a recall or
potential recall or withdrawal or other field correction of any component of the Product, Ampio will notify and consult with Distributor with regard to the measures to be taken consistent with good business practices. Ampio shall be responsible for
implementing any recall that concerns the Product, and shall bear all cost relating to such recall, including all reasonable direct cost and expenses incurred by Distributor, and Ampio will provide all replacement Product to Distributor or to
Customers free of charge DDP (Incoterms 2010) destination as indicated by Distributor in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.4 <U>Regulatory Interface.</U> Distributor shall be responsible for obtaining
Registration of the Product in the Territory and shall exercise commercially reasonable efforts to obtain and Maintain any Product Registrations in the Territory during the Term. As between the Parties hereto, it is agreed that the Product
Registrations shall be held in the name of Distributor, who shall be the beneficial owner of all Product Registrations and Ampio may not use the Product Registrations, or any of them, on or in respect of any product other than the Product or use any
authorization other than one or more of the Product Registrations on or in respect of the Product, except as may be approved in writing by Distributor. Ampio agrees to use its commercially reasonable efforts to assist Distributor, at
Distributor&#146;s costs, in obtaining and Maintaining the Product Registrations. All costs to obtain or Maintain the Product Registrations shall be borne by Distributor. If any Governmental Authority gives notice to Distributor that its Product
Registration may be invalid or may be revoked, limited, or conditioned, Distributor shall promptly inform Ampio, but in any case not more than 5 Business Days following Distributor&#146;s receipt of such notice. In support of Distributor&#146;s
Registration of the Product, Ampio will (a)&nbsp;shall supply to Distributor efficacy, quality and safety data as specified by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
(ICH), (b)&nbsp;perform or cause to be performed and will supply to Distributor data from Zone 4 stability testing of the Product, and (c)&nbsp;will provide suitable evidence that the site at which the Product is manufactured complies with the
Agency requirements (ANVISA), including, if required, inspection by the Brazilian Regulatory Authorities at manufacturing site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.5 <U>Failure to Maintain.</U> At any time during the Term, if Distributor fails to Maintain an existing Product Registration or
any of the Product Registrations becomes invalid or not in full force and effect with the appropriate authorities in the Territory, then Ampio may either assume, to the extent permitted by applicable law, Distributor&#146;s responsibilities under
this Article V at Distributor&#146;s costs or terminate this Agreement with regard to such Product with immediate effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.6 <U>Regulatory Requirements.</U> Distributor shall at all times label, package, promote, advertise, market distribute and sell
the Product in accordance with all applicable Laws. Distributor shall also follow all relevant current written regulatory, quality assurance instructions and guidelines agreed by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.7 <U>Labeling.</U> Subject to Section&nbsp;3.2 hereof, all labeling and package inserts used in any way in connection with the
Product shall comply with the Product labeling supplied or approved in writing by Ampio and with all applicable Laws. Distributor shall comply with any local legal requirements affecting the labeling and package inserts of the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.8 <U>Local Laws.</U> Distributor shall keep Ampio informed of any Laws (including new published Laws or regulations as well as
bills) of the Territory which might be applicable to, or affect the use or sale of, the Product in the Territory. Distributor shall inform Ampio of any instructions or requests inconsistent with these Laws, <I>provided</I>, <I>however</I>, that
Ampio remains independently obligated to be aware of regulatory requirements in all jurisdictions where it has obtained and Maintains a Product Registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> R<SMALL>IGHTS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <U>Grant of License; Ownership of Intellectual Property Rights.</U> Ampio hereby grants Distributor a non-exclusive,
royalty-free, limited license during the Term and under the Intellectual Property Rights of Ampio relating to the Product solely to purchase Product from Ampio and to promote, advertise, market, distribute and sell Product to Customers in the
Territory in accordance with the terms and conditions of this Agreement. Distributor hereby grants Ampio a non-exclusive, royalty-free, limited license during the Term and under the Intellectual Property Rights of Distributor to use the Product
Branding solely for the purposes of this Agreement and for no other purpose whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <U>Use of Intellectual Property
Rights.</U> Distributor shall not alter, deface, remove, cover, mutilate, or add to, in any manner whatsoever, any patent notice, copyright notice, trademark, trade name, serial number, model number or legend that Ampio may attach or affix to the
Product. Distributor also agrees that during the Term, it will not otherwise register or use any of Ampio&#146;s Intellectual Property Rights or any word, symbol or design confusingly similar thereto, unless agreed by Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3 <U>Assistance.</U> Distributor shall, at the expense of Ampio, take such steps as Ampio may reasonably require to assist
Ampio in maintaining the validity and enforceability of the Intellectual Property Rights of Ampio, and Distributor will not do, or allow or authorize any Person to do, any act which could invalidate or be inconsistent with the Intellectual Property
Rights of Ampio and shall not omit, or allow or authorize any Person to omit, to do any act which, by its omission, could invalidate or be inconsistent with the Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.4 <U>Notice of Claims of Infringement.</U> Distributor shall promptly notify Ampio of (a)&nbsp;any claims or objections that
its use of the Intellectual Property Rights in connection with the promotion, advertising, marketing, distribution or sale of the Product may or will infringe the copyrights, patents, trademarks or other proprietary rights of another Person, and
(b)&nbsp;any and all infringements, imitations, illegal use, or misuse, by any Person, of the Intellectual Property Rights of Ampio which come to its attention; <I>provided</I>, <I>however</I>, that Distributor will not take any legal action
relating to the protection of any Intellectual Property Rights of Ampio without the prior written approval of Ampio; and <I>provided further</I>, that Distributor shall render Ampio, at Ampio&#146;s expense, all reasonable assistance in connection
with any matter pertaining to the protection of the Intellectual Property Rights, whether in courts, administrative agencies, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.5 <U>Notice of Infringement.</U> Distributor shall promptly notify Ampio of any infringement, violation, claim or objection in
the Territory of or relating to the Intellectual Property Rights or Confidential Information (including trademarks, patents, know-how, etc.) of Ampio which come to Distributor&#146;s attention, and shall, at the expense of Ampio, cooperate in taking
such action as Ampio may reasonably deem necessary in connection with any such infringement, violation, claim or objection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.6 <U>Reservation of Rights.</U> Except as otherwise expressly set forth herein,
either Party reserves all right, title and interest in the Intellectual Property Rights of it or any of its Affiliates, and the other Party shall not acquire, or be deemed to have acquired, any right, title or interest whatsoever as a result of this
Agreement in the Intellectual Property Rights of either Party or any of its Affiliates. Subject to Section&nbsp;11.3, upon expiration or termination of this Agreement for any reason, the Parties agree to immediately discontinue any further use of
the Intellectual Property Rights of the other Party granted under this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C<SMALL>ONFIDENTIALITY</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <U>Non-Disclosure Obligations.</U> During the Term, a Party may, at its sole discretion, disclose certain Confidential
Information to the other Party. This information will be used solely to permit the receiving Party to exercise its rights and perform its obligations under this Agreement. The receiving Party shall not disclose any Confidential Information to a
Third Party and shall refrain from using or exploiting any and all Confidential Information for any purpose or activities other than those specifically authorized in this Agreement. The receiving Party shall keep such Confidential Information secret
during the Term of this Agreement and for 10 years after the expiration or termination hereof. For clarity, the terms of this Agreement shall be deemed the confidential information of Ampio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <U>Ownership of Material</U><U>.</U> Except as otherwise expressly provided for herein, all files, lists, records, documents,
drawings and specifications which incorporate or refer to all or a portion of the Confidential Information shall remain the sole property of the disclosing Party. Such materials shall be promptly returned upon the earlier of (a)&nbsp;the disclosing
Party&#146;s reasonable request, or (b)&nbsp;expiration or termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <U>Exceptions.</U> The
provisions of this Article VII shall not apply, or shall cease to apply, to data and information supplied by a Party if such data or information (a)&nbsp;was already known to the receiving Party, (b)&nbsp;becomes part of the public domain without a
breach of confidence by the receiving Party or any other Person, (c)&nbsp;was received by the receiving Party from a Third Party without restrictions on such Third Party&#146;s use in favor of the disclosing Party, or (d)&nbsp;was required to be
disclosed pursuant to any statutory or regulatory provision or court order (in which case only such portion of Confidential Information shall be disclosed as is required, and the provisions of this Article VII shall not apply for disclosure in
accordance with the respective statutory or regulatory provision or court order only), <I>provided</I> that the receiving Party shall have the burden of establishing any of the foregoing exceptions. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>ARTICLE VIII<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>R<SMALL>EPRESENTATIONS</SMALL>, W<SMALL>ARRANTIES</SMALL> <SMALL>AND</SMALL> L<SMALL>IABILITIES</SMALL> <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.1 <U>By Ampio.</U> Ampio represents and warrants to Distributor that (i)&nbsp;Ampio has the full right and authority to enter
into this Agreement and grant the rights granted herein; (ii)&nbsp;Ampio has not previously granted and will not grant any right in conflict with any of the rights granted herein; and (iii)&nbsp;to Ampio&#146;s knowledge on the Effective Date, there
is no existing or threatened action, suit or claim pending against it with respect to its right to enter into and perform any of its obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.2 <U>By Distributor.</U> Distributor represents and warrants to Ampio that
(i)&nbsp;Distributor has the full right and authority to enter into this Agreement and grant the rights granted herein; (ii)&nbsp;Distributor has not previously granted and will not grant any right in conflict with any of the rights granted herein;
and (iii)&nbsp;to Distributor&#146;s knowledge on the Effective Date, there is no existing or threatened action, suit or claim pending against it with respect to its right to enter into and perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.3 <U>Product Warranty and Remedies.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;8.3(b), Ampio hereby warrants that the Product shall be free from material defects in material and workmanship
under normal use and maintenance as provided in the applicable instructions and fulfills the Specifications, for a period of 12 months from the date of shipment of the Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor shall maintain inventory of Product on a first in, first out (FIFO) basis. For Product with expiration date, Distributor shall
distribute such Product by lowest expiration date first. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Subject to Section&nbsp;4.9, the obligation of Ampio under the warranties set
forth in this Section&nbsp;8.3 is limited to replacement or credit of Product that prove defective. The foregoing notwithstanding, Ampio shall not be responsible for damage to any Product resulting from misuse, negligence or accident by any Person
other than Ampio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.4 <U>No Implied Warranties.</U> THE EXPRESS REPRESENTATIONS AND WARRANTIES GIVEN IN THIS AGREEMENT ARE
THE ONLY REPRESENTATIONS OR WARRANTIES GIVEN BY AMPIO WITH RESPECT TO THE PRODUCT AND ARE GIVEN IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF NONINFRINGEMENT, TITLE, MERCHANTABILITY, COURSE OF DEALING,
USAGE OF TRADE, AND FITNESS FOR A PARTICULAR PURPOSE. DISTRIBUTOR&#146;S EXCLUSIVE REMEDIES AND AMPIO&#146;S SOLE LIABILITY FOR ANY NONCONFORMITY OR DEFECT IN ANY PRODUCT SHALL BE THOSE EXPRESSED IN THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.5 <U>Limitation of Liability.</U> An essential purpose of the limited exclusive liabilities and remedies in this Agreement is
allocation of risk between Ampio and Distributor, which allocation of risks is reflected in the purchase price for the Product. EXCEPT FOR AMPIO&#146;S INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 9 AND/OR AMPIO&#146;S LIABILITY ARISING OUT OF
TERMINATION OF THIS AGREEMENT BY DISTRIBUTOR PURSUANT TO SECTION 10.2, OR AS A RESULT OF A BREACH OF SECTION 7, UNDER NO CIRCUMSTANCES SHALL AMPIO&#146;S LIABILITY ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR AMPIO&#146;S PERFORMANCE OR
ASSERTED FAILURE TO PERFORM HEREUNDER, IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EXCEED THE PURCHASE PRICE OF THE PRODUCT OR PART THEREOF TO WHICH SUCH LIABILITY RELATES. EXCEPT </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FOR LIABILITY ARISING AS A RESULT OF A PARTY&#146;S INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 9 OR AS A RESULT OF A BREACH OF SECTIONS 6.1 AND/OR 7, IN NO EVENT SHALL EITHER PARTY BE
LIABLE FOR SPECIAL, INCIDENTAL, PUNITIVE, CONSEQUENTIAL, TORT OR ANALOGOUS DAMAGES, INCLUDING DAMAGES RESULTING FROM LOSS OF USE, PROFITS, REVENUES, BUSINESS OR GOODWILL, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY THEREOF. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>NDEMNIFICATION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.1 <U>Indemnity. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Ampio Indemnity</U>. Ampio will indemnify, defend, and hold harmless Distributor, and each of its officers, directors, agents,
employees, representatives, successors, and authorized assigns (collectively, &#147;<I>Distributor Indemnitees</I>&#148;), from and against any and all liabilities, losses, damages, and expenses , including without limitation reasonable
attorney&#146;s fees and expenses (the &#147;<I>Losses</I>&#148;) relating to any demand, claim, suit or proceeding brought by a Third Party to the extent arising from or occurring as a result of: (i)&nbsp;Ampio&#146;s material breach of this
Agreement, (ii)&nbsp;any negligent or willful act or omission by or on behalf of Ampio, (iii)&nbsp;violation of any applicable Law by Ampio, (iv)&nbsp;the actual or alleged infringement of a claim of a patent or the actual or alleged infringement or
misappropriation of a Third Party Intellectual Property Right by the Product, (v)&nbsp;physical injury (including death) and/or property damage actually or allegedly caused by the Product, or (vi)&nbsp;any other representation, act or omission by or
on behalf of Ampio, including Ampio&#146;s performance of or failure to perform any term or condition of this Agreement. Ampio shall not be liable for any Losses resulting from the negligent or willful misconduct of any Distributor Indemnitee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Distributor Indemnity</U>. Ampio shall not be liable for any Losses to the extent incurred by Distributor or any other person or entity,
and Distributor shall indemnify, defend, and hold harmless Ampio and its Affiliates and their officers, directors, agents, employees, representatives, successors, and authorized assigns (collectively, &#147;<I>Ampio Indemnitees</I>&#148;) from and
against any and all Losses relating to any demand, claim, suit or proceeding brought by a Third Party to the extent arising from or occurring as a result of (i)&nbsp;Distributor&#146;s material breach of this Agreement, (ii)&nbsp;any negligent or
willful act or omission by or on behalf of Distributor; (iii)&nbsp;violation of any applicable Law by Distributor, (iv)&nbsp;the labeling, packaging, use, offer for sale, sale or distribution of any Product, (v)&nbsp;any modification made to the
Product without Ampio&#146;s prior written consent including physical injury (including death) and/or property damage actually or allegedly caused by it, (vi)&nbsp;any termination or expiration of any Sub-Distributor (to the extent not attributable
to any direct relationship, including any relationship preceding this Agreement, entered into between Ampio and such Sub-Distributor independently from this Agreement), or (vii)&nbsp;any other representation, act or omission by or on behalf of
Distributor, including Distributor&#146;s performance of or failure to perform any term or condition of this Agreement. Distributor shall not be liable for any Losses resulting from the negligent or willful misconduct of any Ampio Indemnitee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.2 <U>Indemnification Procedure. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A Party that intends to claim indemnification under this Section&nbsp;9 shall promptly notify the indemnifying Party of any such claims in
respect of which such Party intends to claim such indemnification, and if applicable such indemnifying Party shall assume the defense thereof with counsel mutually satisfactory to the Parties; <I>provided</I> that such Party shall have the right to
retain its own counsel and, in case compensation for fees and expenses are not otherwise awarded, compensation for such reasonable costs shall be paid by such indemnifying Party <I>provided</I> such indemnifying Party is responsible for the defense
thereof, if representation of such Party by the counsel retained by such indemnifying Party would be inappropriate due to actual or potential conflicting interests between such Party and any other Party represented by such counsel. The
indemnification provided for by this Section&nbsp;9 shall not apply to amounts paid in settlement of any such claim if such settlement is effected without the consent of the indemnifying Party, which consent shall not be unreasonably withheld. The
failure to deliver notice to the indemnifying Party within a reasonable time after the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve the indemnifying Party of any liability to the
other Party under this Section&nbsp;9.3 to the extent so prejudiced, but the omission so to deliver notice to such indemnifying Party shall not otherwise relieve it of any liability that it may have to such other Party. The indemnified Party shall
cooperate fully with the other Party in the investigation of any such claim covered by this indemnification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If Distributor receives a
demand, claim, suit or proceeding subject to Ampio indemnification under Section&nbsp;9.1(a)(iv), Distributor shall notify Ampio promptly in writing and give Ampio information, assistance and exclusive authority to evaluate, defend and settle such
claim. Ampio shall then at its own expense and option, (i)&nbsp;settle the claim (which settlement shall include for Distributor the right to sell and use the Product pursuant to this Agreement); (ii)&nbsp;procure for Distributor the right to sell
and use the Product pursuant to this Agreement; (iii)&nbsp;replace or modify the Product to avoid infringement; (iv)&nbsp;defend against such claim; or (v)&nbsp;remove the Product and indemnify and hold harmless Distributor. Should any court of
competent jurisdiction hold in a final decision that the sale, manufacture, or use of such Product constitutes infringement, Ampio shall pay any costs and damages finally awarded against Distributor on the account of such infringement, and if the
use of such Product is enjoined, Ampio shall take one more of the actions under clauses (ii), (iii)&nbsp;or (v)&nbsp;above. Ampio reserves the right, at its sole option, to notify Distributor in writing that as a result of a claim, suit or
proceeding or threat of same in the Territory, Distributor may not market or sell the Product in such Territory, effective as of such written notice, subject to full indemnification of Distributor. The foregoing states the entire and complete
liability of Ampio for any patent infringement or claimed infringement by reason of the sale, manufacture or use of the Product or any part thereof. This Section&nbsp;9.3(b) shall also apply in the event Ampio receives a claim, suit or proceeding
relating to an actual or alleged infringement of a claim of a patent or an actual or alleged infringement or misappropriation of a Third Party Intellectual Property Right by the Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE X </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>ERM</SMALL> <SMALL>AND</SMALL> T<SMALL>ERMINATION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.1 <U>Term and Renewal</U> The term of this Agreement shall be for a period of twenty (20)&nbsp;years from the date of the
first commercial delivery of Product, unless earlier terminated under the provisions of this Agreement (the &#147;<I>Term</I>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.2 <U>Termination for Cause.</U> This Agreement may be terminated by Ampio or Distributor in the event of any of the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) immediately upon written notice to the other, if the other Party becomes insolvent or seeks protection under any bankruptcy,
receivership, &#147;<I>recupera&ccedil;&atilde;o judicial/extrajudicial</I>&#148;, trust deed, creditors arrangement, composition or comparable proceeding, or if any such proceeding is instituted against the other Party which proceeding remains
undismissed for a period of 30 days; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in the event that the other Party fails to perform or otherwise materially breaches any of its
obligations hereunder, and does not cure such failure or breach within 60 days of receipt of written notice from the non-breaching Party of such failure or breach. In no event, however, shall such notice of intention to terminate be deemed to waive
any rights to damages or any other remedy which the Party giving notice of breach may have as a consequence of such failure or breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For clarity, the date of any notice of termination for cause under this Section&nbsp;10.2 shall also be an Exclusivity Termination Date
notwithstanding any wind-down period provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Ampio shall have the right, in its sole discretion
to in lieu of terminating the Agreement in full pursuant to Section&nbsp;10.2, convert Distributor&#146;s appointment pursuant to Section&nbsp;1.1 from exclusive to non-exclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Ampio terminates this Agreement pursuant to this Section&nbsp;10.2 due to Distributor&#146;s breach of Section&nbsp;2.6 hereof, Ampio shall
have, the right to collect damages equal to the quantity of Product as set forth in the most recent Forecast multiplied by the Transfer Price; further claims are excluded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.3 <U>Termination without Cause</U>. This Agreement may be terminated by Ampio without cause upon one hundred twenty
(120)&nbsp;days written notice. In the event Ampio terminates this Agreement under this Section&nbsp;10.3, it shall be obligated to pay the following compensation to Distributor: (a)&nbsp;if Termination without Cause occurs prior to the time the
Product is selling in the Territory, Ampio shall pay Distributor an amount equal to five (5)&nbsp;times Distributor&#146;s out-of-pocket expenditures for commercialization of the Product through date of Termination; and (b)&nbsp;if Termination
without Cause occurs after the Product is selling in the Territory, Ampio shall pay Distributor an amount equal to three (3)&nbsp;years&#146; projected net income to Distributor (the &#147;Projected Income Amount&#148;). The Projected Income Amount
shall be determining utilizing the Distributor&#146;s most recent annual forecast submitted under Section&nbsp;4.2 hereof, subtracting the Distributor&#146;s costs for the most recent calendar year that are directly related to its distribution of
the Product, and multiplying the result by three. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE XI </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RIGHTS AND OBLIGATIONS UPON TERMINATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.1 <U>Cessation of Rights<B>.</B></U> Upon expiration, non-renewal or termination (collectively,
&#147;<I>Termination</I>&#148;) of this Agreement for any reason whatsoever, no Party and none of its directors, officers, stockholders, Sub-Distributor or Affiliates shall have any further obligation to the other Party under this Agreement, except
with respect to Sections 2.5(m), 3.1(d), 4.4., 4.6, 4.7, 4.10, 6.2, 6.6, 8.4, 8.5, 10.2, 10.4, 10.5 and 10.5, Articles 7, 9, 11 and 12 and the definitions in Exhibit I (which shall survive Termination of this Agreement), except that nothing in this
Section&nbsp;10.5 shall prejudice any rights, claims, or causes of action that may have accrued hereunder or with respect hereto prior to the date of such Termination, including for breach of this Agreement (whether based upon the Termination or
otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.2 <U>No Penalties; Survival.</U> Without prejudice to any rights or right of action which may have accrued
during the Term, and subject to Sections 10.2, 10.4 and 10.5, neither Party shall be entitled to any compensation or other penalty arising out of Termination, <I>provided</I> this Agreement has expired or been terminated in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.3 <U>Return of Product and Information.</U> Upon Termination of this Agreement, Distributor shall promptly and at
the cost of Ampio return to Ampio or a Third Party designated by Ampio, all Product samples, Confidential Information and all other information supplied by Ampio; <I>provided</I> that in the event that this Agreement terminates as a result of a
material uncured breach by Distributor, Ampio shall not be responsible for such return costs; and <I>provided further</I>, that Distributor may maintain a copy of Ampio&#146;s Confidential Information for as long as reasonably necessary to comply
with applicable Laws. Upon Termination of this Agreement, Ampio may, at its option, elect to purchase any remaining Product from Distributor at cost or allow Distributor to sell its remaining supply of Product in the Territory within reasonable
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.4 <U>Obligations of Distributor upon Termination.</U> Upon Termination of this Agreement and subject to
Section&nbsp;11.3, Distributor shall immediately cease any and all use of the Product Registrations and shall reasonably cooperate in the execution of any documents and the taking of any actions reasonable requested by Ampio to enable Ampio or its
designees to obtain its own Product Registrations upon the cancellation of Product Registrations held by Distributor without interruption or disruption to the distribution, marketing or sales of the Product in the Territory. In addition to the
foregoing, upon any expiration or termination of this Agreement, Distributor shall provide to Ampio or its designees written authorization for Ampio or its designees to market and sell the Product in the Territory under the Product Registration held
by Distributor, until such time as Ampio or its designees obtains all required Regulatory Approvals for the same, at which time Distributor shall cause its Product Registrations to be cancelled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE XII </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.1 <U>Notices</U> All notices, requests, claims, demands, waivers and other communications under this Agreement shall be in
writing and shall be by facsimile, courier services or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a Party in accordance with this Section&nbsp;12.1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Distributor: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">FBM Industria
Farmaceutica, Ltda. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">VP 1-B Qd, 8B Mod. 9/21 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75133-600 DAIA, Anapolis &#150; GO, Brazil </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Moises Alves de Oliveira Neto. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Marcelo Reis Perillo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">FBM Industria Farmaceutica, Ltda. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">VP 1-B Qd, 8B Mod. 9/21 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">75133-600 DAIA, Anapolis &#150; GO, Brazil </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Dr.&nbsp;Alexandre Feliciano Ferreira </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to Ampio: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Ampio
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">5445 DTC Parkway, Suite 925 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Greenwood Village, CO 80111 USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: +1 720-437-6501 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with
a copy (which shall not constitute notice) to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Exchange Place </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Boston, MA 02109
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Larry Wittenberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: 617-523-1231 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All notices and
communications under this Agreement shall be deemed to have been duly given (x)&nbsp;when delivered by hand, if personally delivered, (y)&nbsp;1 Business Day after when delivered to a courier, if delivered by commercial one-day overnight courier
service or (z)&nbsp;when sent, if sent by facsimile, with an acknowledgment of sending being produced by the sending facsimile machine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.2 <U>Definitions.</U> For the purposes of this Agreement, the following terms
have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Active Ingredient</I>&#148; means the chemical compound known as (i)&nbsp;tramadol (base)
(ii)&nbsp;any salt of tramadol; (iii)&nbsp;any metabolites, isomers, enantiomers, polymorphs or pro-drugs of tramadol or of any salt of tramadol and (iv)&nbsp;any compounds obtained by forming or breaking a non-covalent bond with or of any of (i),
(ii)&nbsp;or (iii)&nbsp;if such compounds retain the activity of tramadol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; means, with respect to any
Person, any other Person controlling, controlled by or under direct or indirect common control with such first Person. For purposes of this definition, a Person shall be deemed to control another Person if it owns or controls 50% or more of the
voting equity of the other Person (or other comparable ownership if the Person is not a corporation), or otherwise possesses the power to direct the management or policies of the other Person, whether through ownership of voting securities or by
contract or otherwise; <I>provided</I> that solely for purposes of this Agreement, no Party shall be deemed to be an &#147;Affiliate&#148; of any other Party (or any of its Affiliates). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Business Day</I>&#148; means any day other than a Saturday or Sunday or a day on which banking institutions at the domicile of Ampio
or Distributor are permitted or required by Law, executive order or decree of a Governmental Authority to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>&#147;Business Plan&#148;</I> means a description of the plan for marketing the Product in the Territory during the Term, including at
least: (1)&nbsp;the projected minimum sales quantities per quarter during the Term; (2)&nbsp;the distribution route (direct or indirect), (3)&nbsp;the projected reimbursement for the Product, (4)&nbsp;and any other information reasonably necessary
for the Parties to assess the commercialization of the Product in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Competitor</I>&#148; means any Third Party
which, by itself or through any of its Affiliates, is engaged or otherwise participating in any business or other activity involving the manufacture for commercial sale or distribution of Product that compete with Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Confidential Information</I>&#148; means all data and information of a confidential or proprietary nature, including know-how and
trade secrets relating to the business, the affairs and the Product of a Party. Confidential Information may be communicated orally, in writing or in any other recorded or tangible form. Data and information shall be considered to be Confidential
Information, (a)&nbsp;if a Party has advised the receiving Party of such confidential nature, or (b)&nbsp;if, due to such character or nature, a reasonable person in a like position and under like circumstances as the receiving Party would treat
such as secret and confidential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Customer</I>&#148; means a Person who (a)&nbsp;is resident in the Territory; and (b)&nbsp;has
entered into an agreement (oral or written, including purchase orders) for the purchase of Product with Distributor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Field</I>&#148; means persistent or recurrent ejaculation sooner than desired either
before or shortly after penetration, typically reflecting an IELT (intravaginal ejaculatory latency time) of two minutes or less, over which the sufferer has minimal or no control, or such substantially similar description as may be adopted by the
Governmental Authority in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Force Majeure</I>&#148; has the meaning as set forth in Section&nbsp;12.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Governmental Authority</I>&#148; means any nation, state, province, county, city or political subdivision and any official, agency,
arbitrator, authority, court, department, commission, board, bureau, instrumentality or other governmental entity of any thereof, whether domestic or foreign. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Intellectual Property Rights</I>&#148; means, collectively, all rights in, to and under patents, trade secret rights, copyrights,
mask works, trademarks, service marks, trade dress and similar rights of any type under the laws of any Governmental Authority, including, without limitation, all applications and registrations relating to the foregoing, which either Party may at
any time own, control, license, adopt, use or register with respect to the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Laws</I>&#148; means any law, statute, rule,
regulation, guideline, ordinance or other pronouncement of any Governmental Authority having the effect of law or guidances of any Governmental Authority in the United States and in the Territory, or any province, county, city or other political
sub-division thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Maintain</I>&#148; means that: (a)&nbsp;Distributor shall exercise commercially reasonable efforts to
maintain the Product Registrations as valid and in force with the appropriate Governmental Authorities, (b)&nbsp;Distributor shall use commercially reasonable efforts to the extent possible to minimize the number and extent of any changes to the
Product Registrations, and (c)&nbsp;Distributor shall notify Ampio of any change to any of the Product Registrations during the Term and any such change requested or required by appropriate Governmental Authorities in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Marketing Expenses</I>&#148; means the specific direct marketing, promotion and advertising costs incurred directly on account of the
Product, including promotional materials, professional education, product-related public relations, relationships with opinion leaders and professional societies, market research, and other similar activities related to the Product. Such costs will
include both internal overhead costs (e.g., salaries, benefits, supplies and materials, etc.) and costs of outside services and expenses (e.g., consultants, agency fees, meeting costs, etc.), in all cases only to the extent directly applicable to
the Product. Notwithstanding anything to the contrary in the foregoing, Marketing Expenses shall specifically exclude the cost of activities that promote a party&#146;s business as a whole without being specific to the Product relating disease
(e.g., corporate image advertising). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Person</I>&#148; means and includes any individual, corporation, trust, estate,
partnership, limited liability company, joint venture company, association, league, governmental bureau or agency, or any other entity regardless of the type or nature thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Product Registrations</I>&#148; means existing and future marketing and regulatory authorizations relating to the Product in the
Territory including such authorizations relating to any and all existing and future uses for the Product, necessary for import, labeling, packaging, advertisement, marketing, distribution and sale of the Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Product</I>&#148; means an orally disintegrating tablet formulation of the Active
Ingredient that is suitable for use in the Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Specifications</I>&#148; shall mean the specifications for the Product that
are included in the User Manual for such Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Sub-Distributor</I>&#148; means any Third Party or any Affiliate of
Distributor that has entered into a written agreement with Distributor for the distribution of Product anywhere in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Third Party</I>&#148; means any Person other than Ampio, Distributor or their respective Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<I>Zertane</I>&#148; means Ampio&#146;s trademark and/or trade dress for the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.3 <U>Descriptive Headings; Certain Interpretations.</U> The table of contents and headings contained in this Agreement are for
reference purposes only and shall not control or affect the meaning or construction of this Agreement. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a)&nbsp;&#147;or&#148;
is not exclusive and &#147;include,&#148; &#147;includes&#148; and &#147;including&#148; are not limiting; (b)&nbsp;&#147;hereof,&#148; &#147;hereto,&#148; &#147;hereby,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of similar import
when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (c)&nbsp;&#147;date hereof&#148; refers to the date of this Agreement; (d)&nbsp;&#147;extent&#148; in the phrase &#147;to the
extent&#148; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#147;if&#148;; (e)&nbsp;definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms;
(f)&nbsp;references to an agreement or instrument mean such agreement or instrument as from time to time amended, modified or supplemented, and all exhibits, appendices, schedules or other attachments thereto; (g)&nbsp;references to a Person are
also to its permitted successors and assigns; (h)&nbsp;references to an &#147;Article,&#148; &#147;Section,&#148; &#147;Clause,&#148; &#147;Exhibit&#148; or &#147;Schedule&#148; refer to an Article, Section or Clause of, or an Exhibit or Schedule
to, this Agreement; (i)&nbsp;words importing the masculine gender include the feminine or neuter and, in each case, vice versa; (j)&nbsp;references to a Law include any amendment or modification to such Law and any rules or regulations issued
thereunder, whether such amendment or modification is made, or issuance of such rules or regulations occurs, before or after the date of this Agreement; and (k)&nbsp;references to monetary amounts shall be denominated in United States Dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.4 <U>Waivers</U>. The waiver by either Party of a breach or default in any of the provisions of this Agreement by the other
Party shall not be construed as a waiver of any succeeding breach of the same of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder nor operates as a waiver of any breach or default by the
other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.5 <U>Entire Agreement and Amendments</U>. This Agreement constitutes the entire
agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements between the Parties, whether written or oral, relating to the same subject matter. No modification, amendment or supplements to this
Agreement shall be effective for any purpose unless in writing, signed by each Party. Approvals or consents hereunder of a Party shall also be in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.6 <U>Severability.</U> In the event that any provision herein shall be determined to be void or unenforceable in whole or in
part for any reason whatsoever, such unenforceability or invalidity shall not affect the enforceability or validity of the remaining provisions or part thereof contained in this Agreement and such void or unenforceable provisions shall be deemed to
be severable from any other provisions or part thereof herein contained. In the event that any of the provisions herein contained are held to be unreasonable by reason of the duration or type or scope of services covered by the said provision then
the said provision shall be given effect only to the extent as may be enforceable or deemed enforceable by any court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.7 <U>Assignments</U><U>.</U> Neither Party shall transfer or assign the Agreement or delegate the performance of its
obligations hereunder without the express written consent of the other Party. Notwithstanding the foregoing, either Party may assign this Agreement (a)&nbsp;to any of its Affiliates; or (b)&nbsp;to any Third Party in connection with the sale or
transfer, by merger, reorganization, consolidation or otherwise, of all or substantially all of the Party&#146;s business or assets to which this Agreement relates. This Agreement and the provisions hereof shall be binding upon and inure to the
benefit of the Parties hereto and their respective successors and permitted assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.8 <U>Force Majeure</U><U>.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither Party shall be liable to the other Party for any delay or omission in the performance of any obligation hereunder, where the delay
or omission is due to any cause or conditions beyond the reasonable control of the Party obligated to perform, including strike or other labor difficulties, acts of God, acts of government, war (declared or undeclared), acts of terrorism, fire,
epidemic of disease, riots, civil commotion, embargoes, government requisition or impoundment or other acts of any Governmental Authority or inability to obtain supplies (&#147;<I>Force Majeure</I>&#148;). For clarification, failure to obtain or
maintain a Product Registration shall not be considered a Force Majeure event. If Force Majeure prevents or delays the performance by a Party of any obligation under this Agreement, then the Party claiming Force Majeure shall notify the other Party
thereof in writing within 15 days of the occurrence of such Force Majeure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the performance of this Agreement shall be prevented for
a continuous period exceeding six months from the date of notice given pursuant to Section&nbsp;12.8(a) due to an event of Force Majeure, the Party receiving notice of an event of Force Majeure shall be entitled to terminate this Agreement by giving
written notice to the other. Distributor, if it is the Party receiving notice of an event of Force Majeure (instead of exercising its rights in the preceding sentence) may elect to extend the Term of this Agreement for one additional year. As
regards the supply of Product for the remainder of the Term, absent termination by the Party receiving notice of an event of Force Majeure, this Agreement shall continue in full force and effect in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.9 <U>No Third-Party Beneficiaries.</U> This Agreement is for the sole benefit of
the Parties hereto and their permitted successors and assigns and nothing herein express or implied shall give or be construed to give to any Person, other than the Parties hereto and such successors and assigns, any legal or equitable rights or
remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.10 <U>Counterparts.</U> This Agreement may be executed in counterparts, each of which shall be deemed an
original but all of which shall constitute one and the same instrument. Delivery of an executed counterpart of this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually executed counterpart of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.11 <U>Further Assurance.</U> Each Party undertakes, at the request and cost and expense of the other Party, to
sign all documents and to do all other acts, which may be necessary to give full effect to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.12
<U>Governing Law.</U> This Agreement shall be governed by, and construed in accordance with, the Laws of the State of New York, excluding its conflicts of laws principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.13 <U>Governing Language.</U> The official text of this Agreement shall be the English language, and any interpretation or
construction of this Agreement shall be based thereon. If this Agreement or any documents or notices relating to it are translated into another language the English version shall be controlling in the event of discrepancy between the two. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.14 <U>Arbitration.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties recognize that disputes as to certain matters may from time to time arise which relate to either Party&#146;s rights or
obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation. To accomplish this objective, the Parties agree to
follow the procedures set forth in this Section&nbsp;12.14, if and when a dispute arises under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event of a
dispute between the Parties, the Parties shall first attempt in good faith to resolve such dispute by negotiation and consultation between themselves. In the event that such dispute is not resolved on an informal basis within 30 days either Party
may commence arbitration as set forth below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) All disputes arising out of or in connection with this Agreement shall be finally settled
under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with the said Rules. Such arbitration shall take place in New York, New York. The language of the arbitration shall be
English. The arbitration award so given shall be a final and binding determination of the dispute and shall not include any damages expressly prohibited by Section&nbsp;8.5. Except in a proceeding to enforce the results of the arbitration or as
otherwise required by Law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding the foregoing dispute resolution procedure, in the event of an actual or
threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific performance or other injunctive relief) without submitting to such dispute resolution procedure if there is a reasonable likelihood of
the occurrence of irreparable harm during the period of the dispute resolution procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.15 <U>Press Releases.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;12.15(b), press releases or other similar public communications by a Party relating to this Agreement shall be
subject to a right of reasonable prior review and approval by the other Party, which approval shall not be unreasonably withheld or delayed, <I>provided</I> that such right of approval shall not apply to communications required by applicable Law,
disclosures of information for which consent has previously been obtained, or information that has been previously disclosed publicly, and <I>provided, further</I>, that any draft press release or other public communication submitted to a Party for
its approval shall be deemed approved if such Party fails to notify the submitting Party within 5 Business Days of receipt thereof as to whether or not it has been approved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor understands and agrees that Ampio may submit a copy of this Agreement to the United States Securities and Exchange Commission.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties have caused this Agreement to be executed by their respective duly authorized officers as of the date
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">A<SMALL>MPIO</SMALL> P<SMALL>HARMACEUTICALS</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Macaluso</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Michael Macaluso</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FBM I<SMALL>NDUSTRIA</SMALL> F<SMALL>ARMACEUTICA</SMALL>, L<SMALL>TDA</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Moises Alves de Oliveira Neto</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Moises Alves de Oliveira Neto</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FBM I<SMALL>NDUSTRIA</SMALL> F<SMALL>ARMACEUTICA</SMALL>, L<SMALL>TDA</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marcelo Reis Perillo</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name: Marcelo Reis Perillo</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title: Director</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>9
<FILENAME>d912919dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*** Text Omitted and Filed Separately with the Securities and Exchange Commission </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISTRIBUTION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS AGREEMENT </B>is made on 9&nbsp;April, 2014 (the &#147;<B>Effective Date</B>&#148;), between: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vyrix Pharmaceuticals, Inc.</B> of 5445 DTC Parkway, Suite 925 Greenwood Village, CO 80111 USA (&#147;<B>Vyrix</B>&#148;)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ENDO VENTURES LIMITED</B>, of No.&nbsp;33 Fitzwilliam Square, Dublin 2, Ireland (&#147;<B>Endo</B>&#148;) <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">Vyrix is the registration, trademark holder and manufacturer of an orally disintegrating tablet containing 89 mg tramadol hydrochloride for treating premature ejaculation, known by Parties as the
&#147;<B>Product</B>&#148;. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">The parties wish for Endo to commercialize the Product in the Territory (as defined below). </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreed Terms:
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTERPRETATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Definitions</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Affiliate&#148;</B> means, with respect to a party to this Agreement, any other entity that Controls, is Controlled by, or is under
common Control with that party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Business Day&#148;</B> means a day on which Banks are open for general banking business in
Greenwood Village, Colorado, USA and Dublin, Ireland, excluding Saturdays, Sundays and public holidays in either Colorado, USA or Dublin, Ireland. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Calendar Year&#148; </B>shall mean any period of twelve consecutive calendar months commencing on January&nbsp;1st and ending on
December&nbsp;31st. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Control&#148;</B> means the power of a person to secure either by means of the holding of a majority
(&gt;50%) of shares, by contract, by reason of managerial powers or mandate or the possession of decisive voting power in or in relation to the company or corporation concerned or by virtue of any decisive powers conferred by the articles of
association or constitution or other document regulating that company or that corporation that its affairs are conducted in accordance with the wishes of that person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Field&#148;</B> means the treatment of premature ejaculation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Force Majeure&#148;</B> means events or occurrences beyond the reasonable control of the party affected, the effects of which could
not, by the exercise of reasonable diligence by that party, have been avoided and which affect the ability of that party to observe or perform its obligations under this Agreement, except for the failure or inability to pay any sum of money, such
events including: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">war, invasion, riot, civil or military disturbances or sabotage; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">strikes, picketing or other labour disputes or disturbances or work to rule; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">lightning, fire, flood or threat of floods, earthquake and vulcanic smoke, storm, cyclone or explosion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">outbreak of diseases and pandemia restricting normal commerce, travel and transport of freight; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">governmental restrictions or other governmental actions or inactions (unless such restrictions, action or inactions arise out of the failure of the party affected to comply with any governmental requirements).
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Health Canada&#148;</B>, means the Canadian regulatory agency responsible for the evaluation and approval of
pharmaceutical drugs for human use and having the authority to grant Marketing Authorization in Canada. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Improvements</B>&#148;,
in respect of the Product means any changes to the Product including, without limitation, in dosage strength, form, packaging or other advances in modifications or changes made by Vyrix to the Product to be used in the Field. For the avoidance of
doubt, the Parties agree that &#147;Improvements&#148; does not include Vyrix&#146;s proposed tramadol-sildenafil combination tablet. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Intellectual Property Rights&#148;</B> means intellectual property rights of any nature whatsoever including such rights comprised in
patents, copyright, designs, trade marks whether or not registered, trade secrets and know-how and in goodwill and reputation, and all other similar rights, whether existing at common law or conferred by statute, rights to apply for registration
under law in respect of these or like rights and rights to protect trade secrets and know-how. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Launch</B>&#148; and
&#147;<B>Launch Date</B>&#148; shall mean the first commercial sale and the date of the first commercial sale of the Product to third party customers in the Territory by Endo or its Affiliates or licensees following the issuance of the Marketing
Authorization, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Long term Inability to Supply&#148;</B> means inability to supply at least seventy percent
(70%)&nbsp;of the volumes of Product indicated in the purchase orders provided by and confirmed by Endo, that continues for more than one hundred and twenty (120)&nbsp;days, to start after the stipulated delivery date, defined in Section&nbsp;6.5.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Marketing Authorization&#148;</B> shall mean (i)&nbsp;with respect to Canada, the final regulatory approval granted by the
regulatory authorities in the form of a notice of compliance issued to and in the name of Endo in respect of the Product on the basis of the New Drug Submission, authorizing Endo to lawfully market and sell the Product in Canada, and (ii)&nbsp;for
all other countries in the Territory, final approval of a new drug application, health registration, marketing authorization application, common technical document, regulatory submission, notice of compliance or equivalent (but in no event to
include any applicable pricing or reimbursement approval) necessary to authorize Endo to lawfully market and sell the Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;MCC&#148; </B>shall mean the Medicines Control Council of South Africa and/or any other
regulatory authority in South Africa responsible for the evaluation and approval of pharmaceutical drugs for human use and having the authority to grant Marketing Authorization. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Net Sales&#148;</B> means with respect to a Product, the gross amount invoiced for sales of any Product in the Territory in arm&#146;s
length sales by Endo (and its authorized affiliates and/or sublicensees) to Third Parties, less the following deductions from such gross amounts which are actually incurred, allowed, accrued or specifically allocated to such Product:
(i)&nbsp;credits, price adjustments or allowances for damaged products, returns or rejections of Product; (ii)&nbsp;normal and customary trade, cash and quantity discounts, allowances and credits (other than price discounts granted at the time of
invoicing which have already been included in the gross amount invoiced); (iii)&nbsp;chargeback payments, repayments and rebates (or the equivalent thereof) granted to or imposed by group purchasing organizations, managed health care organizations
or federal, state/provincial, local and other governments, including any or all of their regulatory authorities, agencies, review boards or tribunals, or trade customers; (iv)&nbsp;any invoiced freight, postage, shipping, insurance and other
transportation charges; (v)&nbsp;sales, value-added (to the extent not refundable in accordance with applicable law), and excise taxes, tariffs and duties, and other taxes directly related to the sale (but not including taxes assessed against the
income derived from such sale); (vi)&nbsp;stocking allowances; and (vii)&nbsp;any other payment which reduces gross revenue and is permitted to be deducted in calculating net sales in accordance with GAAP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Pack&#148;</B> shall mean commercial packaged Product in final, finished goods form, consisting of six (6)&nbsp;tablets in a printed
foil blister tray, in a four (4)&nbsp;color box with a one (1)&nbsp;black&nbsp;&amp; white package insert. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product&#148;</B>
shall mean orally disintegrating tablets containing 89mg tramadol hydrochloride as the active ingredient, suitable for distribution in accordance with the Specifications listed under Schedule 1 of this Agreement and all Improvements thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulatory Approval&#148;</B> means, for each country, each considered separately, an authorisation from the relevant regulatory
authority for the import, distribution, marketing and/or sale of the Product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Regulatory Approval Date&#148;</B> means the date
that the relevant regulatory agencies in a given Country in the Territory granted Regulatory Approval to the Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Royalties&#148;</B> shall have the meaning ascribed in Section&nbsp;9.5 of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Short Term Inability to Supply&#148; </B>means inability to supply at least seventy percent (70%)&nbsp;of the volumes of Product
indicated in the purchase orders provided by and confirmed by Endo, that continues for more than thirty (30)&nbsp;days but less than one hundred and twenty (120)&nbsp;days, starting after the stipulated delivery date, defined in Section&nbsp;6.5.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Specifications&#148;</B> means the specifications for the Product as set forth in Schedule 1 attached to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Sponsor&#148;</B> means the party holding the Regulatory Approval for the Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sublicense</B>&#148; has the meaning ascribed thereto in Section 3.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Term&#148;</B> has the meaning ascribed thereto in Section&nbsp;2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Territory&#148;</B> means Canada, the Republic of South Africa, Sub Saharan Africa,
Colombia and Latin America, as described in Schedule 3 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Trade Marks&#148;</B> means the trade marks as listed
in Schedule 2 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Transfer Price&#148;</B> has the meaning ascribed thereto in Section&nbsp;9.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Upfront Payment</B>&#148; has the meaning ascribed thereto in Section 9.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Vyrix IP&#148;</B> means all Intellectual Property Rights that subsist in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">the Product, including methods and processes for its production and storage and its use in the life sciences; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix&#146;s marketing and informational materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">the Improvements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">the Vyrix Patents, the Vyrix Know-How and the Trade Marks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">the colour scheme and the art work on the Pack (if not designed by Endo); </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and all other
intellectual property rights that Vyrix owns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Vyrix Know-How&#148;</B> means Confidential Information relating to the manufacture
and sale of the Product owned or Controlled by Vyrix. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Vyrix Patents&#148;</B> means those patents in Vyrix&#146;s name (or
otherwise assigned to Vyrix) that claim the Product or an aspect of the process of making it and any other aspect of it, and all patents that derive priority from the same priority document and all other patents and patent applications in the same
patent family, including all corresponding national phase filing, divisional application and continuations. These are listed in Schedule 2 of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Interpretation</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In this Agreement, unless the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">words importing natural persons include corporations, firms, unincorporated associations, partnerships, trusts and any other entities or groups recognized by law; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">reference to any legislation or to any provision of any legislation includes any amendment, modification, consolidation or re-enactment of, or any legislative provision substituted for, and all legislative and statutory
instruments issued under, such legislation or such provision; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">the words &#147;written&#148; and &#147;in writing&#148; include any means of visible reproduction of words in a tangible and permanently visible form; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">reference to any party to this Agreement or any other agreement or document includes the party&#146;s successors and permitted assigns; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">reference to any document or agreement includes references to such document or agreement as novated, supplemented, varied or replaced from time to time except to the extent excluded by the terms of this agreement or
that other document or agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">no rule of construction applies to the disadvantage of a party because that party was responsible for the preparation of this Agreement or any part of it; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">where the day on, or by, which any thing is to be done is not a Business Day, that thing shall be done on, or by, the next following Business Day; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">the headings to sections, clauses or schedules are for ease of reference only and do not form part of this Agreement or affect its interpretation. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><B>TERM</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Agreement commences on the Effective Date and will, subject to the provisions
for termination herein, expire on a country-by-country basis the later of (i)&nbsp;the expiration of market exclusivity for the Product in that country, or (ii)&nbsp;fifteen (15)&nbsp;years after the first commercial sale of the Product in that
country. The term of this Agreement shall automatically continue after expiry hereof on a country-by-country basis for consecutive three (3)&nbsp;year periods, unless Vyrix delivers to Endo written notice of termination in respect of that country at
least six (6)&nbsp;months prior to the end of that term. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><B>APPOINTMENT AND GRANT OF RIGHTS</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Appointment</B>. Vyrix appoints Endo as Vyrix&#146;s exclusive distributor for marketing and selling the Product in the Territory and Endo accepts such appointment and agrees to use commercially reasonable efforts to
market, distribute and sell the Product subject to the terms and conditions set out in this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Grant of Rights &#150; the Product</B>. Subject to the terms and conditions in this Agreement, Vyrix grants to Endo an exclusive license to the Vyrix IP in the Territory, as per the stipulations made in
Section&nbsp;3.1, with the right to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">market, promote, import into the Territory, offer for sale and sell the Product for use in the Field; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">use the Trade Marks and reproduce the Vyrix marketing materials in accordance with the provisions of Section&nbsp;11; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">design its own packaging for the Product, and market the Product under its own trademark or any other trademark in the Territory; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">use the Vyrix Know-How to exercise its rights and perform its obligations set out in this Agreement </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(the <B>&#147;License&#148;</B>); and provided that Vyrix may continue to use the Vyrix IP in the Territory for any purpose other than
marketing, distributing and selling the Product in the Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>The Right to Grant Sublicenses</B>. Endo is entitled to grant
sublicenses under the License that comply with Section&nbsp;3.4 (&#147;<B>Sublicense</B>&#148;) to its Affiliates and third parties. When Endo wishes to enter into a Sublicense with a third party (but not an Affiliate), subject to written consent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of Vyrix which shall not be unreasonably withheld, Endo shall deliver to Vyrix at least one (1)&nbsp;month&#146;s advance written notice of its intention to enter into a Sublicense agreement, by
which Endo shall inform Vyrix of all the principal terms of such agreement, including the identity of the proposed sublicensee. Endo does not need to notify Vyrix upon granting a sublicence to an Affiliate in the Territory. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>The Content of Sublicenses</B>. Endo is entitled to grant Sublicenses under the License, that in all material respects: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">are in writing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">contain a scope of rights which are no greater than the scope of rights granted under Section&nbsp;3.2; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">contain express provisions that: (i)&nbsp;require the sublicensee to comply with Section&nbsp;5 (Marketing and Commercialization) and Section&nbsp;11 (Intellectual Property), (ii)&nbsp;automatically terminate the
Sublicense agreement upon termination of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Endo to Remain Liable. </B>Endo shall be liable to Vyrix for its Sublicensees acts and omissions under each Sublicense agreement. If a Sublicensee makes a claim against Vyrix whether by way of damages, costs or
expenses or otherwise, Endo agrees to be voluntarily joined as a party to such claim. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>License Qualifications and Clarifications. </B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">This Agreement shall not grant to Endo or to any Affiliate of Endo or to its Sublicensees any rights or licenses other than the rights and licenses expressly provided for in this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix hereby represents that it owns the Vyrix IP and, Endo acknowledges that, subject to the express grant of the licenses hereunder to Endo, Vyrix has the right to use and otherwise exploit the Vyrix IP in the Field
outside the Territory and outside the Field in the Territory. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">For the avoidance of doubt, Vyrix shall be entitled to supply Product and enter into licences and other types of transaction for or related to the supply of Product: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">to any third party outside the Territory for any use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">to third parties in the Territory for non-commercial use in the Field, such as research partners. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix shall not use the Product Trade Mark in the Territory. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">If Endo knows or reasonably suspects that any person outside the Territory has or will import the Product into the Territory, for use in the Field, Vyrix shall use commercially reasonable efforts to assist Endo to stop
such unauthorized import and sale activities and to mitigate any losses suffered by Endo. Subject to Vyrix complying with such covenant, Vyrix shall not be liable to Endo if third parties import the Product into the Territory or offer the Product
for sale in the Territory in the Field. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Endo will not at any time during the Term seek customers in any place which is outside the Territory. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">Endo will not at any time during the Term, supply the Product to any person outside the Territory or for use outside the Field or within the Territory if Endo knows or has reason to believe that such person intends to
resell or re-supply the Product outside the Territory. In the event that Endo becomes aware of any person selling the Product that has been supplied by Endo outside the Territory, Endo shall notify Vyrix in writing and shall take reasonable steps to
prevent such re-sale. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"><B>Improvements</B>. Vyrix grants Endo an exclusive license in the Territory for all Improvements to the Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Right of First Negotiation</B>. Endo has the right of first negotiation to include Vyrix&#146;s tramadol-sildenafil combination tablet (&#147;<B>Zertane-ED</B>&#148;) as an additional product under this Agreement,
subject to separate economic considerations. Vyrix will notify Endo by registered mail or courier no less than six (6)&nbsp;months prior to the anticipated filing date for the regulatory dossier for Zertane-ED in the United States. During a period
of ninety (90)&nbsp;days, the parties will negotiate in good faith an amendment to the Definitive Agreement, with respect to Zertane-ED. If the Parties are unable to agree on such amendment within the ninety (90)&nbsp;day period, starting from
postdate of notice, Vyrix is free to solicit a third party for Zertane-ED and to sell and market such product in the Territory, unless both Parties agree on extending the negotiation period. For clarity, a New Product does not include Improvements
to the Product, which are listed in the Improvements section of this Agreement. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The foregoing Section&nbsp;3.7 shall not be
construed to allow Endo to make use of Vyrix&#146;s Know-How without prior written consent of Vyrix. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"><B>PRODUCT REGISTRATION</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Marketing Authorisation and Launch</B>. Endo shall use commercially reasonable efforts to apply for Regulatory Approval, and launch the Product in the Territory. Endo shall solely bear all the costs and expenses of,
and related to, preparing, filing and prosecuting such regulatory applications and maintaining the corresponding approvals. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulatory Approval</B>. Endo shall be responsible for maintaining the Regulatory approval/license in Canada and all equivalent registrations in other countries in the Territory. Subject to the provisions for
termination in Section&nbsp;12, Endo shall retain ownership of the said approval/license and equivalent registrations. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Assistance. </B>Within sixty (60)&nbsp;days of the Effective Date, Vyrix will deliver to Endo all data, records and reports (including pre-clinical and clinical reports) necessary for Endo to make a regulatory
submission to Health Canada as well as all other regulatory filings required to commercialize the Product in the other countries in the Territory. In addition, Vyrix will provide Endo with all reasonable assistance during the Term, in support of
Endo&#146;s applications for Regulatory Approval for the Product in the Territory, including: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">reasonable telephone and email communication; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">modular based and sales focused comprehensive product training material; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">additional information that may be requested by Health Canada (including, by way of example, stability information); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">facilitating an inspection of Vyrix&#146;s manufacturing facilities if required by regulatory authorities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">making its personnel available by email and telephone as reasonably required. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The assistance
to be provided by Vyrix under this Section&nbsp;4.3 is in support of Endo&#146;s performance of its obligations under Section&nbsp;4.1 for which Endo shall retain primary responsibility. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><B>MARKETING AND COMMERCIALIZATION</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Comply with Laws</B>. Endo will be responsible for all the duties and responsibilities laid down for marketing authorization holders by the laws and regulations in the Territory, which shall be considered on a
country by country basis. Endo shall be responsible for compliance with any and all applicable laws, rules and regulations of the Territory with respect to the marketing, distribution, promotion and sale of Product. Endo shall be responsible at its
own cost and expense to obtain and maintain throughout the Term all import licenses, registrations, licenses, permits, and approvals that are necessary to carry out all such activities. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Diligence - General.</B> Endo will use reasonable commercial efforts to promote, market and sell the Product in the Territory consistent with products of similar commercial value as determined by Endo. Endo shall
also use reasonable commercial efforts to maintain a quantity of inventory for the Product necessary to meet Product demand in the Territory as determined by Endo from time to time. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Promote Reputation</B>. Endo shall not knowingly: (i) disparage in any manner the Product, (ii)&nbsp;nor the Trade Marks, nor (iii)&nbsp;attempt to register or otherwise assert any rights in or to any Trade Marks.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Information Exchange</B>. Each party shall communicate to the other information relevant to the distribution, marketing and sale of the Product in the Territory, including: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">customer complaints in relation to the Product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">in the case of Endo: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">any inquiries made by any person regarding sales or potential sales of the Product outside the Territory or outside the Field; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">monthly sales of Product in the Territory reported on an a quarterly basis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">stock levels at the end of the quarter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">scientific and other information that such party generates or of which it becomes aware; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">facts or opinions likely to be relevant in relation to the marketing of the Product; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Endo will notify Vyrix of any potential clinical collaborators or research endeavors related to the Product that they become aware of. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>6.</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>ORDERING AND SUPPLY OF PRODUCT</B><B> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Ordering</B>. Endo shall order Product from Vyrix by delivering to Vyrix a written order that specifies: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">the quantity of Product being ordered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">whether the Product is to be received in bulk tablet or as finished Pack format; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Endo&#146;s requirements for the Pack labelling, which must comply with Sections 11<B>.</B>2 through 11<B>.</B>7; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">the port(s) of destination for delivery. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Forecasts</B>. Three (3)&nbsp;months prior to the Launch Date reasonably expected by Endo in the Territory and within the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;month of each Calendar
Year thereafter, Endo shall provide to Vyrix a good faith forecast setting forth amounts of Product that Endo expects in good faith to order for the first twelve (12)&nbsp;calendar months following the expected Launch Date with respect to the first
such forecast and for the twelve (12)&nbsp;calendar month period following the delivery of the forecast thereafter. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>First Order. </B>The first order placed by Endo shall have a lead time of four (4)&nbsp;months after approval of printing proofs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Delivery</B>. Subject to Endo being in compliance with its payment obligations under Section 9.7, Ethypharm shall deliver to Endo Product that Endo orders in accordance with Section&nbsp;6.1. Delivery shall be
Ex-works (Incoterms 2010) Ethypharm&#146;s facility (Saint-Cloud, France) with the delivery designated for a port to be specified by Endo: (i)&nbsp;for Canada, the Port of Montreal, (ii)&nbsp;for Africa, in Durban (Kwazulu-Natal) and (iii)&nbsp;for
Mexico, to be determined upon Endo placing the first order. Endo shall be responsible for and bear all freight, insurance and other shipping expenses and all applicable taxes or duties that may be assessed against the Product after delivery.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Time for Delivery</B>. The time for delivery under Section&nbsp;6.4 shall be the later of three (3)&nbsp;months after Vyrix&#146;s receipt of Endo&#146;s order or three (3)&nbsp;months after Endo&#146;s approval of
packaging artwork, except for the first order which is described in Section&nbsp;6.3. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"><B>Change of Manufacturer</B>. Provided it has no negative impact on the Regulatory Approval in the Territory, Vyrix has the right to subcontract manufacturing by providing Endo with no less than six (6)&nbsp;months
advance notice of any change in manufacturer not listed in the regulatory dossier for the Product as of the Effective Date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Title and Risk</B>. Risk of loss for Product shall pass to Endo upon delivery under Section&nbsp;6.4. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DELAY AND FAILURE TO SUPPLY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"><B>Short Term Inability to Supply</B>. Vyrix acknowledges that punctual delivery is key to successful execution of the Agreement and that it shall deliver the Product in a timely manner. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the event that Vyrix experiences a Short Term Inability to Supply, for any reason other than as a result of Force Majeure, Vyrix shall
rescind the requirements for payment of Royalties to Vyrix as listed in Section&nbsp;9.5 for an equivalent period of time of any resulting direct loss of sales (by virtue of a product backorder). The foregoing shall be without prejudice to any other
rights or remedies available to Endo under the Agreement and the applicable law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"><B>Long Term Inability to Supply</B>. In the event of any Long Term Inability to Supply the Product in the Territory, the parties agree to act in good faith and make all commercially reasonable efforts to find a
mutually acceptable solution to the Long Term Inability to Supply. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event of (i)&nbsp;a Long Term
Inability to Supply or (ii)&nbsp;the happening of any of the events set out in Sections&nbsp;12.1(b) to 12.1(d) in respect of Vyrix, the following shall occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">In the event that Vyrix experiences a Long Term Inability to Supply, for any reason other than as a result of Force Majeure, Vyrix shall rescind the requirements for payment of Royalties to Vyrix as listed in
Section&nbsp;9.5 for an equivalent period of time of any resulting direct loss of sales (by virtue of a product backorder). The foregoing shall be without prejudice to any other rights or remedies available to Endo under the Agreement and the
applicable law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix shall transfer/initiate production of the Product at a secondary manufacturer as specified in the Quality Agreement in order to manufacture and supply the Product for the Territory. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Any costs for the transfer and/or initiation of production at the referred to in Section&nbsp;7.2 (b), to the extent required for the Territory, shall be borne by Vyrix. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">The supply price for Product manufactured and supplied to Endo by the secondary manufacturer shall be the same or lower than the prices paid by Endo as per Section&nbsp;9.1 of this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">The minimum order quantities shall be no larger than those set out in Section&nbsp;9.1 of this Agreement, and may be smaller based on the batch size of the third party manufacturer, which shall be provided to Endo. In
the case that batch sizes are larger than those listed in Section&nbsp;9.1, Endo shall have the right to purchase a partial batch, with any additional costs due to this partial batch production to be borne by Vyrix. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"><B>No diversion of Product</B>. In no event shall Vyrix ship Product originally destined to be shipped to Endo due to a valid purchase order placed by Endo to countries outside the Territory. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Multiple Inability to Supply issues</B>. If Endo is faced with two (2)&nbsp;or more Short or Long Term Inability events in two (2)&nbsp;consecutive
years that result in a direct loss of sales (by virtue of a product backorder), Vyrix will reduce Endo&#146;s obligation to pay Vyrix Royalties as listed in Section&nbsp;9.5 by fifty percent (50%)&nbsp;for a period of time equal to the longest
period of product backorder during the previous two (2)&nbsp;years. This is in addition to any remedy owing to an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Inability to Supply issue as outlined in Sections 7.1 and 7.2. The reduction in Royalty payment described in this Section owing to multiple Inability to Supply issues will start no earlier than
at the end of any other period of Royalty reduction outlined in Sections 7.1 and 7.2. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TESTING AND INSPECTION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"><B>Sampling and Quality Control</B>. Prior to each delivery of Product to Endo, Vyrix shall be responsible for all sampling and quality control testing of the Product in accordance with the methods of analysis set forth
in the Specifications, required to determine whether the Product conforms to the Specifications. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"><B>Certificates</B>. For each batch of Product to be delivered to Endo hereunder, Vyrix shall provide copies of the complete certificate of analysis and certificate of compliance at time of delivery, as well as copies
of any other documents required by any governmental authority. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Defective Product.</B> Endo will inspect the Product delivered for damages of the outer packaging material identifiable by means of a sight test (&#147;<B>Apparent Defects</B>&#148;), shortages in order quantity, or
failure in any material way to comply with the Warranty set forth in Section&nbsp;13.1 and will notify Vyrix of any Apparent Defects, shortage, or failure with respect to Section&nbsp;13.1 within thirty (30)&nbsp;days of receipt by Endo. Endo will
notify Vyrix of any hidden or latent defects (i.e. defects other than Apparent Defects), of which it becomes aware, within thirty (30)&nbsp;days following discovery of the defect. Within the above-mentioned time-frames Endo is entitled to reject the
defective Product or the batch containing defective Product. In the event of a Product rejection, the parties shall immediately endeavor to agree whether or not the delivery in question is defective. If the parties fail to agree, the matter shall be
determined by an independent expert or laboratory and the decision of the independent expert shall be final and binding on the parties. The independent expert shall act as an expert and not as an arbitrator and its fees shall be borne by Vyrix if it
is determined that defects exist and by Endo if it is determined that no defects exist. In order to avoid further delays, Endo shall be entitled to request that Vyrix supplies a supplementary delivery of the same kind and amount of Product
(&#147;<B>Supplementary Delivery</B>&#148;) as soon as reasonably possible (at Endo&acute;s sole discretion and cost by airfreight), but in no event later than within one (1)&nbsp;month following notification by Endo to Vyrix of the nature of the
defect in the Product, and Vyrix shall comply with such request. The results obtained by such independent expert or laboratory shall be binding upon the parties, and the costs of such analyses shall be borne by the party whose test results are not
upheld by such independent laboratory testing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top">If Vyrix agrees or the independent expert finds that any delivery of the Product is defective, then Vyrix shall promptly replace the delivery in question (and in no event any later than within one (1)&nbsp;month) by
airfreight or the fastest possible means of transport under the circumstances, at no additional cost to Endo. If Endo requested a Supplementary Delivery in accordance with the foregoing paragraph, such Supplementary Delivery shall be considered to
be a replacement delivery in accordance with the foregoing sentence. All costs and expenses incurred by Endo in connection with Defective delivery (including, without limitation, the cost of the Supplementary Delivery, and return or disposal of the
defective Product) shall be borne by Vyrix. Vyrix shall promptly inform Endo whether the Defective delivery shall be disposed of or returned to Vyrix. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top">If a delivery of the Product is found by the independent expert not to be defective, Endo shall pay for such delivery in accordance with the payment provisions contained in this Agreement. If Endo requested a
Supplementary Delivery in accordance with this Section&nbsp;8, such Supplementary Delivery must be paid for by Endo separately. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.6<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Recall.</B> In the event that Endo is required by Health Canada or any regulatory authority in the Territory to recall a Product or in the event
either party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal in the Territory, the party notified of such recall or similar action, or the party that desires such recall
or similar action, shall within twenty-four (24)&nbsp;hours, advise the other party thereof by telephone or facsimile (with written confirmation notice to follow). Endo, in consultation with Vyrix, shall decide whether to conduct any recall in the
Territory, although Endo shall have final decision-making authority on whether to conduct such recall (except in the case of a government mandated recall, in which case either party may act without such advance notice but, shall notify the other
party as soon as possible) and the manner in which any such recall shall be conducted; provided however that Endo shall initiate a recall upon Vyrix&#146;s request in the event that Vyrix reasonably believes that such a recall is required due to
non-compliance with applicable laws and regulations in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Territory. Vyrix will make available to Endo, upon request, all of Vyrix&#146;s pertinent disclosable records that Endo may reasonably request to assist Endo in effecting any recall. If such a
recall arises as a result of an act of omission,an infringement or a misrepresentation in Endo&#146;s storage, handling, promotion, advertising or distribution of the Product, Endo shall bear the costs and expenses of the recall for the Territory.
In all circumstances due to any act or omission on behalf of Vyrix, Vyrix shall bear all the costs and expenses associated with such a recall. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PRICES AND PAYMENTS </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Transfer Price. </B>The price payable by Endo for Product (the &#147;<B>Transfer Price</B>&#148;) shall not exceed the prices set forth below: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Batch size of approximately [&#133;***&#133;] tablets: Not to exceed USD$ [&#133;***&#133;]/tablet (bulk packaged). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Batch size of approximately [&#133;***&#133;] tablets: Not to exceed USD$ [&#133;***&#133;]/tablet (bulk packaged). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Batch size of approximately [&#133;***&#133;] tablets: Not to exceed USD$ [&#133;***&#133;]/tablet (bulk packaged). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The above pricing shall be reflective of the pricing provided to Vyrix by Ethypharm, with no additional mark-up on pricing by Vyrix except for
any necessary taxes costs to be billed as incurred. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"><B>Price Adjustments</B>. Vyrix shall not increase the prices in Section&nbsp;9.1 for a period of two (2)&nbsp;years following the Launch Date of the Product provided that Vyrix is not losing money either directly or as
a result of currency exchange. At any time after the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>)&nbsp;anniversary of the Launch Date of the Product in each country in the Territory, Vyrix shall be entitled to increase the
prices specified in Section&nbsp;9.1, but not more than once per Calendar Year. Vyrix shall consult with Endo in relation to the reasons for its intended price increase and deliver to Endo at least six (6)&nbsp;months advance written notice of a
proposed increase in price and demonstrate based on reasonable documentary evidence that the proposed price increase corresponds exclusively to an increase in the prices of Ethypharm&#146;s raw materials, production and manufacturing processes. If
the prices of Ethypharms&#146;s raw materials, production and manufacturing processes decrease by more than five percent (5%), Vyrix shall pass on those price decreases to Endo. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"><B>Upfront Payments.</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon signing of this Agreement, within five (5)&nbsp;Business Days
Endo will pay via wire to Vyrix two hundred and fifty-thousand US Dollars ($USD 250,000). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Milestone Payments.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Upon regulatory approval of the Product in Canada, within five (5)&nbsp;Business Days Endo will pay via wire to Vyrix [&#133;***&#133;]. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Upon regulatory approval of the Product in the Republic of South Africa, within five (5)&nbsp;Business Days Endo will pay via wire to Vyrix [&#133;***&#133;]. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">If Net Sales of the Product in any Calendar Year exceed [&#133;***&#133;] (the &#147;<B>First Net Sales Threshold</B>&#148;), Endo shall pay Vyrix [&#133;***&#133;]. This Milestone Payment shall only be due once, if at
all, and shall be due and payable sixty (60)&nbsp;days following the end of the applicable Calendar Year in which the First Net Sales Threshold is achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">If Net Sales of the Product in any Calendar Year exceed [&#133;***&#133;] (the &#147;<B>Second Net Sales Threshold</B>&#148;), Endo shall pay Vyrix [&#133;***&#133;]. This Milestone Payment shall only be due once, if at
all, and shall be due and payable sixty (60)&nbsp;days following the end of the applicable Calendar Year in which the Second Net Sales Threshold is achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">If Net Sales of the Product in any Calendar Year exceed [&#133;***&#133;] (the &#147;<B>Third Net Sales Threshold</B>&#148;), Endo shall pay Vyrix [&#133;***&#133;]. This Milestone Payment shall only be due once, if at
all, and shall be due and payable sixty (60)&nbsp;days following the end of the applicable Calendar Year in which the Third Net Sales Threshold is achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">If Net Sales of the Product in any Calendar Year exceed [&#133;***&#133;] (the &#147;<B>Fourth Net Sales Threshold</B>&#148;), Endo shall pay Vyrix [&#133;***&#133;]. This Milestone Payment shall only be due once, if at
all, and shall be due and payable sixty (60)&nbsp;days following the end of the applicable Calendar Year in which the Fourth Net Sales Threshold is achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">If Net Sales of the Product in any Calendar Year exceed [&#133;***&#133;] (the &#147;<B>Fifth Net Sales Threshold</B>&#148;), Endo shall pay Vyrix [&#133;***&#133;]. This Milestone Payment shall only be due once, if at
all, and shall be due and payable sixty (60)&nbsp;days following the end of the applicable Calendar Year in which the Fifth Net Sales Threshold is achieved. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">If Net Sales of the Product in any Calendar Year exceed [&#133;***&#133;] (the &#147;<B>Sixth Net Sales Threshold</B>&#148;), Endo shall pay Vyrix [&#133;***&#133;]. This Milestone Payment shall only be due once, if at
all, and shall be due and payable sixty (60)&nbsp;days following the end of the applicable Calendar Year in which the Sixth Net Sales Threshold is achieved. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Net Sales Thresholds are cumulative, meaning that (a)&nbsp;should they all be achieved Endo shall owe Vyrix a
total aggregate amount of (and never exceeding) three million and twenty five thousand US dollars ($USD 3,025,000), and (b)&nbsp;such First, Second, Third, Fourth, Fifth, Sixth, and Seventh Net Sales Thresholds may be achieved in one or more
Calendar Years as applicable. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Royalties.</B> Commencing with the calendar quarter in which Launch of the Product is made in the Territory, Endo shall pay Vyrix a non-creditable, non-refundable Royalty, in immediately available funds, in an amount
equal to one of the following (the &#147;<B>Royalties</B>&#148;): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] percent ([&#133;***&#133;]%) of Net Sales in any Calendar Year should the Net Sales in that Calendar Year be less than or equal to [&#133;***&#133;] or; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">[&#133;***&#133;] percent ([&#133;***&#133;]%) of Net Sales should the Net Sales in that Calendar Year exceed [&#133;***&#133;]. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">No later than forty-five (45)&nbsp;days after the end of each calendar quarter, Endo shall report to Vyrix the Net Sales of the Product sold by
Endo in the Territory and the Royalties due to Vyrix for such period. The payment by Endo to Vyrix shall be made within sixty (60)&nbsp;days after the end of each calendar quarter, subject to a true-up within sixty (60)&nbsp;days of the end of the
Calendar Year should Net Sales cross the [&#133;***&#133;] threshold. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"><B>Royalty Term</B>. Endo shall pay to Vyrix the Royalties described in Section&nbsp;9.8 above on a country-by-country basis in the Territory until the later of (i)&nbsp;the expiration of market exclusivity for the
Product in that country, or (ii)&nbsp;fifteen (15)&nbsp;years after the Launch of the Product in that country. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Payment. </B>All amounts due to Vyrix shall be payable within thirty (30)&nbsp;days of receipt of an invoice from Vyrix, with the exception of Royalty payments to be paid as per Section&nbsp;9.5 of this Agreement.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.8<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Manner of Payment</B>. All payments to Vyrix under this Agreement shall be made in United States Dollars by way of wire transfer to Vyrix&#146;s nominated bank account. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"><B>Withholding Tax</B>. If Endo is required by the applicable laws of any jurisdiction to deduct or withhold from any payment to Vyrix any taxes or charges which may be levied against Vyrix, Endo shall deduct or
withhold such taxes or charges in accordance with such applicable laws, and shall forthwith provide to Vyrix the reasons therefore. Endo shall promptly furnish Vyrix with copies of any tax certificate or other documentation evidencing such
withholding. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.10</TD>
<TD ALIGN="left" VALIGN="top"><B>Currency Conversion</B>. Payments under this Agreement based on sales amounts in a currency other than Canadian dollars shall first be calculated in the foreign currency and then the payment owing shall be converted
to Canadian dollars on the basis of the exchange rate in effect for the purchase of Canadian dollars with such foreign currency quoted by the Bank of Canada on the date that the payment is made. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RECORDS AND INSPECTION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Endo to Report. </B>Within forty-five (45)&nbsp;days of each calendar quarter during the Term, Endo shall deliver to Vyrix a written report of all the Net Sales of Product recorded by it and by its Affiliates, as
well as the stock level at the end of the quarter, on a country by country basis during the calendar quarter preceding the date of the report. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Vyrix&#146;s Right to Inspect Records</B>. Endo must maintain the records described in Section 10.1 for a minimum of three (3)&nbsp;years and make them available for inspection by Vyrix&#146;s accountants or auditors
upon reasonable written request from Vyrix. Vyrix acknowledges that all records are Confidential Information of Endo and that it shall be entitled to inspect those records once every twenty four (24<B>)</B>&nbsp;months. Vyrix must pay the costs
associated with the audit; provided that if any such audit shows that payments to Vyrix have been understated by five percent (5%)&nbsp;or more, the cost of such audit shall be borne by Endo. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INTELLECTUAL PROPERTY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Ownership</B>. Endo acknowledges and agrees that, as between the parties, Vyrix owns all of the Vyrix IP and that Vyrix shall retain ownership of all the Vyrix IP. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Use of the Trade Marks</B>. Endo agrees that each Pack of Product shall bear the following language, and that Endo shall not market, promote, offer for sale or sell the Product without each Pack bearing the following
language: &#147;Licensed from Vyrix Pharmaceuticals, Inc.&#148; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Pack Modifications</B>. Subject to Endo complying with Sections 11.1, 11.2 and 11.4, Endo may modify the Pack, with Endo assuming such costs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quality Standards</B>. Vyrix shall be entitled to prescribe from time to time such reasonable standards of manufacture, quality and performance as appear to Vyrix to be necessary to ensure the maintenance of the good
quality and reputation of the Product and Endo shall use reasonable efforts to observe each and every one of the said quality standards provided they do not impact the Regulatory Approval in the Territory. Endo shall not market, promote nor sell
Product which does not comply with the said quality standards without Vyrix&#146;s informed prior written consent. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Maintenance of Trade Marks and Domain Name. </B>Vyrix shall, at its expense, take all such steps as Vyrix deems reasonably required to maintain the validity and enforceability of the Trade Marks in the Territory
during the Term, including paying on or before the due date all registration and renewal fees. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.6<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Infringement of Rights</B>. Endo shall promptly report to Vyrix any suspected infringement in the Territory of the Vyrix IP by third parties which it suspects or of which it becomes aware. Endo may take action in
respect of such infringement except if such action involves a counterclaim against the validity or existence of any Vyrix IP or IP licensed to Vyrix for the Product, in which case Vyrix shall assume the care and conduct of such proceedings. Endo
shall provide to Vyrix with all reasonable assistance in support of actions or suits that Vyrix initiates, including in the case of trade mark proceedings, with evidence of use. Any damages and costs recovered shall be split between Vyrix and Endo
on a 50/50 basis after first deducting all costs for such proceedings borne by Endo. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Vyrix&#146;s Representations. </B>Vyrix warrants that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">at the Effective Date, Vyrix owns or has been assigned the Vyrix IP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to the best of its knowledge, the use of the Trade Marks and the exploitation of the Vyrix IP does not infringe the rights of any third party; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix has not misappropriated and is not aware of any misappropriation of any trade secrets of any third parties relating to the Product or the Vyrix IP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix has not granted to any other third party any right or licence to market, distribute or sell the Product in the Territory which right is still in force and effect on the Effective Date; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix and/or its Affiliates is/are direct and exclusive owner(s) of all Vyrix IP as of the Effective Date, and do not license the Vyrix IP from any other party; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">All Product manufactured and delivered to Endo shall comply in all material respects with all GMPs, Specifications and other regulations as required by Health Canada, MCC or other regulatory authorities in the
Terrritory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">All Product supplied by Vyrix to Endo hereunder shall, as of the time that such Product is delivered to Endo, have a minimum shelf life (at the time of delivery to the carrier&#146;s vehicle by Vyrix for shipment at the
shipping point pursuant to Section&nbsp;6.4) of the <U>greater</U> of (i)&nbsp;twenty (20)&nbsp;months, and (ii)&nbsp;four (4)&nbsp;months less than the shelf life set forth in the Regulatory Approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">As of the date hereof and during the immediately preceding five (5)&nbsp;year period, there have not been any claims, lawsuits, arbitrations, legal or administrative or regulatory proceedings, charges, complaints or
investigations by any government authority or other third party threatened, commenced or pending against Vyrix and Vyrix has not received any notice of intellectual property infringement with respect to, the Product or the Vyrix IP, including
Vyrix&#146;s right to manufacture, use, sell or license the Product. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Either party shall inform the other party in writing
without delay if any notice from a third party should be received by such party during the Term claiming such infringement, violation or misappropriation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.8<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>No Challenge by Endo.</B> Endo shall not directly or indirectly challenge the validity or ownership of the Vyrix IP or challenge that the use of the Vyrix IP by Endo during the Term is only on behalf of Vyrix as a
licensee under its control. Endo shall not knowingly do, or authorize any third party to do, any act, which would or might invalidate or infringe any Intellectual Property of Vyrix and shall not knowingly omit or authorize any third party to omit to
do any act which, by its omission, would have that effect. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TERMINATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Termination by either Party.</B> Either party may terminate this Agreement with immediate effect by written notice to such effect to the other party upon the happening of any of the following events:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">if the other party commits any material breach of the provisions contained in this Agreement and does not remedy the breach within sixty (60)&nbsp;days after receipt of written notice requiring it to do so and provided
that if the breaching party has proposed a course of action to cure the breach and is acting in good faith to cure same but has not cured same by the sixtieth (60th)&nbsp;day, such period shall be extended by a further period of up to an additional
thirty (30)&nbsp;days to permit the breach to be cured; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a petition or other application being presented or resolution being passed for the winding up, liquidation or dissolution of the other party or notice of intention to propose such a resolution being given or the entry
of the other party into a scheme of arrangement or compromise with any of its creditors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">the appointment of an administrator or a receiver or receiver and manager or official manager or agent of a secured creditor to any of the other party&#146;s property; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">the other party ceasing to carry on business or stopping or wrongfully suspending payment to any of its creditors or stating its intention so to do. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Either Party can remove a country from the Territory in the Definitive Agreement in the instance that the health authorities in the specified country in the Territory has refused regulatory approval (or equivalent in
the country in the Territory) of the Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix has the right to (partially) terminate the Definitive Agreement with respect to Canada, South Africa, or Mexco in the event that Endo has not applied for regulatory approvals to distribute the Product in such
jurisdiction prior to the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;anniversary of the Effective Date, assuming sufficiency of the existing regulatory dossier unless Endo requires additional documentation and/or data from
Vyrix for the filing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix has the right to terminate this Agreement entirely or partially with respect to a Country as determined by Vyrix for convenience without fault of Endo at any time following the fourth (4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the Effective Date by giving Endo not less than sixty (60)&nbsp;Calendar Days prior written notice. In such event, Vyrix shall be obliged to pay the greater of (a)&nbsp;all
sales and marketing costs incurred by Endo as of the Effective Date, or (b)&nbsp;two (2)&nbsp;times Endo&#146;s Net Sales of the Product in the Country of termination in the preceeding twelve (12)&nbsp;month period, provided that all outstanding
sales (including orders received, but not yet processed or shipped) and backorders are included in the calculation of Net Sales. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">In case of termination, Endo shall notify the health authorities in the specific country(ies) in the Territory if applicable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">On the earlier of expiry or termination of the Agreement in relation to the Territory, Endo shall transfer to Vyrix ownership of the regulatory dossier(s) in the Territory and provide to Vyrix details of the amount of
Product in Endo&#146;s possession. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"><B>Right of (Partial) Termination by either Party for lack of Regulatory Approval.</B> Either Party can partially terminate the Agreement with a respect to a country from the Territory where the competent regulatory
authority has refused Regulatory Approval (or equivalent in the country in the Territory) of the Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"><B>Non-renewal by Vyrix.</B> Should Vyrix elect not to renew the Agreement, Vyrix shall provide six (6)&nbsp;months written notice prior to the end of the current term of such intention. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"><B>Right of Termination by Endo.</B> Endo may terminate the Agreement at any time, giving Vyrix not less than six (6)&nbsp;months written notice. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Consequences of (Partial) Termination. </B>On the earlier of expiry or termination of this Agreement in relation to the entire Territory or partially, on a country by country basis as the case may be:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Endo&#146;s rights and licenses under Section&nbsp;3 shall expire and cease being of force or effect and Endo shall not promote or market the Product, except as provided under Section&nbsp;12.7; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Endo shall transfer to Vyrix or any party it designates the Regulatory Approval for the Production the Territory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Endo shall provide to Vyrix details of the amount of Product in Endo&#146;s possession. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"><B>Termination by Endo due to Inability to Supply.</B> Endo may terminate this Agreement with immediate effect by written notice to such effect to Vyrix should there be a Long Term Inability to Supply that persists for
six (6)&nbsp;months after the scheduled delivery of the goods as described in 6.5. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"><B>Sell-Off Period.</B> Notwithstanding any termination of the Agreement (in whole or in respect of a particular country), Endo shall be entitled to continue to enjoy its rights and licenses and be entitled to continue
to sell existing inventory of the Product in the relevant country or countries for a further period of nine (9)&nbsp;months. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"><B>Stock Purchase.</B> Subject to Section 12.4, Vyrix shall be entitled, at its option, exercisable by written notice to Endo within a period of thirty (30)&nbsp;days following the date of termination or expiration of
this Agreement, to repurchase from Endo any unsold Product. The repurchase price shall be the same price at which Vyrix originally sold such Product to Endo provided that Vyrix is responsible for arranging, and for the cost of, transport and
insurance arising from the repurchase. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.9<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Survival.</B> Expiry or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, including the payment obligation specified in Section&nbsp;9.9.
Without limiting the foregoing, Sections 3.3 and 3.4 and Sections&nbsp;7 through 18 (both inclusive), shall survive the termination or expiry of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>WARRANTIES, INDEMNITIES AND LIMITATION OF LIABILITY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Product Warranty</B>. Vyrix warrants to Endo that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix shall maintain in effect all required approvals regarding the Product and the manufacturing facility and, as the case may be, ensure that at all times such approvals remain valid with respect to any additional
manufacturing facility, including without limitation in both cases, the maintenance of GMPs with respect thereto. Vyrix shall manufacture<B>, </B>test, store and ship the Product in accordance with (i)&nbsp;the Specifications, (ii)&nbsp;applicable
law, including GMPs, and (iii)&nbsp;required approvals in France or the country in which the manufacturing site resides; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">the Product delivered to Endo hereunder shall conform, in all material respects, to the Specifications; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Endo&#146;s remedy under the warranty under this Section&nbsp;13.1 is for Vyrix to replace any Product found to be defective during the warranty period and returned to Vyrix in accordance with Section&nbsp;8, except in
the case of bodily injury or death, in which case such remedies shall not be exhaustive and shall be subject to Section&nbsp;13.4. Except for the warranty provided in this Section&nbsp;13.1 and Section&nbsp;11, Vyrix makes no other warranties,
whether express or implied, regarding the Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Qualifications. </B>The warranty set out in Section&nbsp;13.1 does not apply to any Product that (i)&nbsp;has had any identification markings removed or rendered illegible, or (ii) has been damaged by transportation,
storage or maintenance after delivery to Endo under temperature and other conditions that are contrary to Vyrix&#146;s specifications<B>,</B> or (iii)&nbsp;has been the subject of misuse, accident or neglect, or from any other cause beyond
Vyrix&#146;s reasonable control after the delivery of Product in accordance with Section&nbsp;6.4<B>,</B> or (iv)&nbsp;has been used in a manner not in accordance with the instructions supplied by Vyrix or in a manner other than for which it was
intended as indicated in the Product label claims. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Endo&#146;s Indemnity</B>. Endo shall indemnify, defend, and hold harmless Vyrix and its officers, directors, employees, Affiliates, and agents and their respective successors, heirs and assigns (the &#147;<B>Vyrix
Indemnitees</B>&#148;), against any and all liability, damage, loss and expense, including reasonable attorneys&#146; fees and expenses of litigation, incurred by or imposed upon any of the Vyrix Indemnitees in connection with any claims, suits,
actions, demands or judgments </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(<B></B>the <B></B>&#147;<B>Endo Indemnifying Claims</B>&#148;) arising out of any theory of
liability, including without limitation actions in the form of tort, warranty, or strict liability and regardless of whether such action has any factual basis, concerning Endo&#146;s or its Affiliates&#146;, distributors&#146;, agents&#146; or
licensees&#146; exploitation or sale of the Product and/or the manufacture of Product, the marketing, offering for sale and sale, use and/or promotion, importation and export of the Product, except to the extent that any Endo Indemnifying Claims are
the result of Vyrix&#146;s breach of Section&nbsp;11.7 or Vyrix&#146;s failure to comply with its obligations hereunder, gross negligence or wilful misconduct. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Vyrix&#146;s Indemnity. </B>Subject to the terms of this Agreement, Vyrix shall indemnify, defend, and hold harmless Endo and its officers, directors, employees, Affiliates, and agents and their respective
successors, heirs and assigns (<B></B>the<B> &#147;Endo Indemnitees&#148;</B>), against any and all liability, damage, loss and expense, including reasonable attorneys&#146; fees and expenses of litigation, incurred by or imposed upon any of the
Endo Indemnitees in connection with any claims, suits, actions, demands or judgments (<B></B>the<B> &#147;Vyrix Indemnifying Claims</B><B></B>&#148;) arising out of any theory of liability, including without limitation actions in the form of tort,
warranty, or strict liability and regardless of whether such action has any factual basis, concerning </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix&#146;s breach of the Section&nbsp;11.1 warranty; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix&#146;s breach of the Section&nbsp;13 warranty; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Vyrix&#146;s breach of any of its representations or warranties of this Agreement, or breach of any other provision of this Agreement by Vyrix; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">any claim that the exercise by Endo of its rights under this Agreement relating (directly or indirectly) to Vyrix IP infringes the intellectual property of the other person; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">any claim that the use of the Product in conformity with the applicable marketing authorization has caused damage or loss to any person, </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">except to the extent that any Vyrix Indemnifying Claims are the result of Endo&#146;s failure to comply its obligations hereunder or its gross
negligence or wilful misconduct. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notice</B>. If a party receives notice of any Vyrix Indemnifying Claim or if Vyrix receives notice of any Endo Indemnifying Claim (each, an <B>&#147;Indemnifying Party&#148;</B>), the other party (the
&#147;<B>Indemnitee</B>&#148;) shall, as promptly as is reasonably possible, give the Indemnifying Party notice thereof; provided, however, that failure to give such notice promptly shall only relieve the Indemnifying Party of any indemnification
obligation hereunder to the extent such failure diminishes the ability of the Indemnifying Party to respond to or to defend the Indemnitee against such indemnifying claim of the Indemnifying Party. The parties shall consult and cooperate with each
other regarding the response to and the defense of any such indemnifying claim and the Indemnifying Party shall assume the defense or represent the interests of the Indemnitee in respect of such indemnifying claim of the Indemnifying Party, that
shall include the right to select and direct legal counsel and other consultants to appear in proceedings on behalf of the Indemnitee and to propose, accept or reject offers of settlement, all at its sole cost; provided, however, that no such
settlement shall be made without the prior written consent of the Indemnitee, such consent not to be unreasonably withheld. Nothing herein shall prevent the Indemnitee from retaining its own counsel and participating in its own defence at its own
cost and expense. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.6<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Settlements</B>. Neither party may settle a claim or action related to its indemnity obligations hereunder without the consent of the Indemnitee, if such settlement would impose any monetary obligation on the
Indemnitee or require the Indemnitee to submit to an injunction or otherwise limit the Indemnitee, its Affiliates, employees, agents, officers or directors; provided that this restriction shall not apply to any settlement by Vyrix of litigation
relating to the Vyrix IP. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Limitation of Liability. </B>Subject only to Sections 7.1 and 7.2, neither party shall have any liability to the other party or its Affiliates for any loss of profits, direct, special, indirect, consequential,
exemplary, punitive or incidental damages arising out of or relating to this Agreement however caused and on any theory of liability (including negligence), whether or not a party has been advised of the possibility of such damages.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.8<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Endo Insurance. </B>Endo shall be responsible at its own cost to effect and maintain throughout the Term comprehensive and product liability insurance policy that a reasonable and prudent person engaged in the
relevant industry would effect and maintain, and including without limitation contractual liability coverage for Endo&#146;s indemnification obligations hereunder. Such insurance policy shall be insurance cover of not less than CAD$5,000,000. Endo
shall deliver to Vyrix a copy thereof at Vyrix&#146;s request. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.9<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Vyrix Insurance. </B>Vyrix either directly or via its parent company Ampio Pharmaceuticals now has in effect and shall maintain in good standing throughout the Term, comprehensive civil and product liability
insurance with a single limit of USD$ 5,000,000&nbsp;per loss and per insurance year aggregated, during the Term, from a reputable and financially secure insurance carrier, to cover any physical or material damage injury to third parties arising
under or related to Vyrix&#146;s performance of its obligations under this Agreement. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONFIDENTIALITY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Confidential Information</B>. &#147;<B>Confidential Information</B>&#148; means any scientific, technical, trade or business information or material related to a party&#146;s (the &#147;<B>Discloser</B>&#148;)
technology or business that is the subject of efforts that are reasonable under the circumstances to maintain its secrecy, and is disclosed to the other party or to that other party&#146;s Affiliates (collectively, the <B>&#147;Recipient&#148;</B>)
in connection with this Agreement. Without limiting the foregoing, a party&#146;s Confidential Information includes information in which such party owns the intellectual property rights and interests in accordance with the terms herein. Confidential
Information does not include information that: (i)&nbsp;is now or subsequently becomes generally available to the public through no wrongful act or omission of Recipient; (ii)&nbsp;Recipient can demonstrate to have had rightfully in its possession
prior to disclosure to Recipient by Discloser; (iii)&nbsp;is independently developed by Recipient without use, directly or indirectly, of any Confidential Information of Discloser as can be demonstrated by Recipient; or (iv)&nbsp;Recipient
rightfully obtains from a third party (except such third parties who act for or on behalf of the Discloser) who has the unrestricted right to transfer or disclose it. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Non-Disclosure</B>. Except as specifically authorized in this Agreement or as has otherwise been specifically authorized by Discloser in writing, Recipient shall not directly or indirectly reproduce, use, distribute,
disclose or otherwise disseminate the Discloser&#146;s Confidential Information<B>.</B> If required by law, the Recipient may disclose the Discloser&#146;s Confidential Information to a governmental authority or by order of a court of competent
jurisdiction, provided that: (i)&nbsp;such disclosure is subject to all applicable governmental or judicial protection available for like information; (ii)&nbsp;reasonable advance notice is given to the Discloser; and (iii)&nbsp;the Discloser is
provided with a reasonable opportunity to avail itself of legal process to prevent or minimize such disclosure. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Return of Information</B>. Upon expiry or termination of this Agreement, or upon request by Discloser, Recipient shall promptly deliver to Discloser or at Recipient&#146;s option destroy all Confidential Information
of Discloser and all embodiments and/or copies thereof then in its custody, control or possession and shall deliver within one (1)&nbsp;month after such expiration or termination or request a written statement to Discloser certifying such action.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Disclosure to Employees and Consultants</B>. Recipient agrees that access to Confidential Information will be limited to those employees and other authorized representatives and consultants of Recipient who
(i)&nbsp;need to know such Confidential Information in order to conduct their work in connection with the terms of this Agreement, and (ii)&nbsp;have signed agreements with Recipient obligating them to maintain the confidentiality of Confidential
Information disclosed to them and to take all reasonably necessary steps to ensure that the terms of this Agreement are not violated by them. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Press Releases and Other Disclosures</B>. Neither party shall publish any information or make public disclosure of the terms of this Agreement without the consent of the other party, such consent not to be
unreasonably withheld (with failure to respond to any request for consent beyond one (1)&nbsp;week from the request to be deemed consent). Notwithstanding the foregoing, a party may disclose the terms of, or activities under, this Agreement:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to the extent required by law or regulation or court order, or by the rules of any stock exchange on which the stock or shares of the party are listed; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">in confidence to its professional advisors, and its existing or potential investors, acquirers or merger partners. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The parties agree that press releases relating to this Agreement shall be made upon the Effective Date by each of them. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PHARMACOVIGILANCE </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Appropriate Reporting of Adverse Events</B>. The parties agree that appropriate reporting of adverse events and other safety data relating to the Product is critical. Specific details regarding the management of
information of adverse events, medical inquiries and Product complaints related to the use of the Product in the Territory and outside will be set out in a separate document, to be agreed to by the parties at least three (3)&nbsp;months before the
first scheduled launch date in the Territory. The Pharmacovigilance and product labelling representatives of each party will work in good faith together to develop a document that identifies and/or provides: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">which safety information will be exchanged; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">when such information will be exchanged; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Endo will have regulatory reporting responsibilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Endo will manage the safety database for the Territory only; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Endo will be obligated to obtain follow-up information on incomplete safety reports for the Territory only; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">that Endo will review the literature for safety report information for the Territory only; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">that Endo will prepare required periodic safety updates for the Territory only; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top">the identification of any other details required to appropriately manage safety information for the Product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quality and Pharmacovigilance Agreements</B>. Within ninety (90)&nbsp;days after Regulatory Approval in Canada, the parties will begin to negotiate in good faith a mutually acceptable quality agreement and
pharmacovigilance agreement with respect to the Product including the matters set forth in Section&nbsp;15.1 above. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DISPUTE RESOLUTION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Conditions Prior to Litigation</B> A party must not start arbitration or court proceedings (except proceedings seeking interlocutory relief) in respect of a Dispute unless it has complied with this clause.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Dispute. </B>For the purpose of this Section&nbsp;16, &#147;<B>Dispute</B>&#148; means any dispute or material difference arising out of or in connection with this Agreement, between the parties. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>No Court Proceedings</B>. No party may commence or initiate any court proceedings (except applications for urgent interim injunctive relief) until the procedures set out below have been followed. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"><B>Notice of Dispute.</B> A party that considers a Dispute has arisen or exists shall be entitled to send written notice to the other <B>party</B> involved in the Dispute (the &#147;<B>Dispute Notice</B>&#148;) setting
out a full description of the matters in dispute. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Dispute Resolution</B>. Any Dispute between the parties shall be brought to the attention of the managing directors (or equivalent of each party) who shall attempt in good faith to achieve a resolution. If any
Dispute is not resolved by the parties&#146; managing directors (or their designees, as the case may be) within four (4)&nbsp;weeks after such dispute is referred to them, then either party shall have the right to refer such dispute to mediation,
provided that in the case of a dispute which primarily relates to the ownership or infringement of intellectual rights or issues relating to the supply of the Product by Vyrix, the parties shall be entitled to commence litigation in a court of
competent jurisdiction after the expiry of such four (4)&nbsp;weeks. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.6<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Mediation</B>. A Dispute which is not resolved in accordance with Section&nbsp;16.5 shall be submitted by the parties to non-binding mediation following a process to be agreed upon by the parties. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Failure of Mediation</B>. If the parties do not resolve the Dispute by mediation within a period of ninety (90) days after the case has been referred to mediation either party may enter the dispute in any court
having jurisdiction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.8<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Costs.</B> The expenses of mediation and/or litigation shall be borne by the parties in such proportion as determined by the mediator or otherwise in such proportion to which each party is defeated or prevails in
litigation.<B> </B> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.9</TD>
<TD ALIGN="left" VALIGN="top">If a party does not comply with any provision of Sections 16.1 to 16.6, the other party involved in the Dispute will not be bound by Sections 16.1 to 16.6. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FORCE MAJEURE </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"><B>Failure Due to Force Majeure.</B> Notwithstanding anything to the contrary in this Agreement, no party is responsible or liable to the other party for, nor will this Agreement be terminated (except as provided under
Section&nbsp;17.5) as a result of that first mentioned party&#146;s failure to perform any of its obligations hereunder, with the exception of payment of monies due and owing, if such failure results from Force Majeure. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exceptions. </B>A party is not entitled to the benefit of the provisions of Section&nbsp;17.1 under any of the following circumstances: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that the failure was caused by the contributory negligence of that party; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to the extent that the failure was caused by that party having failed to take reasonable steps to remedy the condition and to resume the performance of such obligations as soon as practicable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">unless as soon as possible after the occurrence relied upon or as soon as possible after determining that the occurrence was in the nature of Force Majeure and would affect that party&#146;s ability to observe and
perform its obligations contained in this Agreement that party has given to the other party written notice that the former party is unable by reason of Force Majeure (the nature of which must be specified therein) to perform the particular
obligations. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Avoidance of Force Majeure. </B>The party claiming Force Majeure shall use reasonable efforts to avoid or remove any such causes and resume performance under this Agreement as soon as feasible whenever such cause is
removed, provided however that the foregoing is not to be construed to require a party to settle any labour dispute or to commence, continue or settle any litigation. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notice of Force Majeure. </B>The party claiming Force Majeure shall likewise give notice as soon as possible after the Force Majeure condition has been remedied or ceased to exist to the effect that the same has been
remedied and that the party has resumed or is then in a position to resume the performance of such obligations. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Termination for Force Majeure. </B>If the cause of the delay continues for a period of more than ninety (90)&nbsp;days the party not claiming Force Majeure may terminate this Agreement by written notice to the other
party without penalty. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>GENERAL</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notices</B>. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the <B>parties</B> to the other shall be in writing (by registered mail or facsimile or e-mail
message) and addressed to such other <B>party</B> at its address indicated above, or to such other address as the addressee shall have last furnished in writing to the addressor, and shall be effective upon receipt by the addressee. If to Endo, a
copy should be sent to: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ENDO VENTURES LIMITED. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">No.&nbsp;33 Fitzwilliam Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dublin 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ireland </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to
Vyrix, a copy should be sent to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vyrix Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5445 DTC Parkway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Suite 925 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Greenwood Village, CO 80111 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Waiver. </B>A waiver by any party of any breach or a failure to enforce or to insist upon the observance of a condition of this Agreement will not be a waiver of any other or of any subsequent breach. No waiver under
this agreement will be binding unless in writing and signed by the parties giving the waiver. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Severance. </B>If any part of this Agreement is invalid, unenforceable, illegal, void or voidable for any reason, this Agreement will be construed and be binding on the parties as if the invalid, unenforceable,
illegal, void or voidable part had been deleted from this Agreement or read down to the extent necessary to overcome the difficulty. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.4<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Successors and Assigns</B>. This Agreement will be binding on and continue for the benefit of each party, its successors and permitted assigns. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.5<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Further Assurances. </B>The parties will do everything reasonably necessary to give effect to this Agreement and to the transactions contemplated by it and will use all reasonable endeavours to cause relevant third
parties to do likewise. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.6<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Assignment. </B>Neither party may assign any of its rights or obligations under this Agreement without first obtaining the other party&#146;s advance written consent to such effect, except that either party may do so
as part of a corporate restructure and either Party may assign this Agreement to an Affiliate, in either case without having to obtain the other party&#146;s advance written consent. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.7<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing Obligations. </B>The expiration or termination of this Agreement does not operate to terminate any of the continuing obligations under this Agreement and they will remain in full force and effect and
binding on the party concerned. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.8<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Variation.</B> No variation of this Agreement (other than a waiver which is governed by Section&nbsp;18.2) will be binding on the parties unless in writing and signed by all parties. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.9<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Applicable Law. </B>This Agreement is governed by and construed in accordance with the laws of the Courts of New York State, USA. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.10<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>No Agency. </B>Nothing contained in this Agreement shall be deemed to create an agency, joint venture, amalgamation, partnership or similar relationship between the parties. Neither party shall at any time enter
into, incur or hold itself out to third parties as having authority to enter into, or incur, any commitment, expense or liability on behalf of the other party. All contracts, undertakings, expenses and liabilities undertaken or incurred by one party
in the performance of this Agreement shall be undertaken or incurred exclusively by that party and not as an agent or representative of the other party. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.11<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Costs. </B>Each<B></B> party shall pay their own legal, accounting and other costs in relation to the negotiation, preparation, execution and implementation of this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.12<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entire Agreement. </B>This Agreement (including the schedules) constitutes the entire agreement and basis of the transaction between the parties in relation to its subject matter and supersedes all other
communications, negotiations, arrangements and agreements between Vyrix and Endo, whether oral or in writing including, as from the Effective Date in relation to the subject matter of this Agreement, the confidentiality agreement dated 24&nbsp;July
2013 between Vyrix and Endo (which confidentiality agreement remains in full force and effect in relation to any other subject matter covered by this confidentiality agreement and in relation to any breach of that confidentiality agreement in
relation to the subject matter of this Agreement occurring on or prior to the Effective Date). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AND THE PARTIES HAVE SIGNED: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VYRIX PHARMACEUTICALS, INC.</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>ENDO VENTURES LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jarrett T. Disbrow</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Blaine T. Davis</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jarrett T. Disbrow</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>President &amp;
CEO</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Blaine T. Davis</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By:</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To the Distribution and License Agreement between Vyrix and Endo </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Product Specifications </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Release Specifications for Tramadol 89&nbsp;mg Drug Product </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Australia &#150; Commercial Product) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:13pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:13pt"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD style="width:21pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:21pt"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:14.65pt; font-size:8pt; font-family:Times New Roman"><B>Test</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Method</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Specification</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="middle">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">&#133;***&#133;]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#133;***&#133;]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To the Distribution and License Agreement between Vyrix and Endo </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Intellectual Property </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licensed Patents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman">Country</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Patent #</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Issue&nbsp;Date</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Use of Tramadol to Delay Ejaculation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,440,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/24/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mexico</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Method of Delaying Ejaculation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/28/2007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">South&nbsp;Africa</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Method of Delaying Ejaculation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003/08067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/30/2005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licensed Trademarks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZERTANE </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definition of Sub Saharan Africa and Latin America </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sub Saharan Africa </B>shall mean the following countries: Angola, Botswana, Cameroon, DR Congo, Gabon, Kenya, Lesotto, Madagascar, Malawi, Mozambique,
Mierz, Nigeria, Swaziland, Uganda, Zimbabwe, Tanzania </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Latin America</B> shall mean the following countries: Antigua and Barbuda, Aruba, Bahamas,
Barbados, Belize, Bermuda, British Virgin Islands, Cayman Islands, Costa Rica, Curacao, Dominica, Dominican Republic, El Salvador, Grenada, Guadeloupe, Guatemala, Haiti, Honduras, Jamaica, Martinique, Mexico, Monserrat, Nicaragua, Panama, Saint
Lucia, Saint Vincent and the Grenadines, Trinidad&nbsp;&amp; Tobago, Turks&nbsp;&amp; Caicos. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>10
<FILENAME>d912919dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROMISSORY NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$10,000,000</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">April&nbsp;16,&nbsp;2015</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>FOR VALUE RECEIVED, Ampio Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), hereby promises to pay to the order of Rosewind Corporation, a Colorado corporation (&#147;<B>Lender</B>&#148;), Lender&#146;s successors, endorsees and assigns, the principal amount of $10,000,000 plus interest from and
including the date hereof on the principal balance from time to time outstanding, computed daily, at a rate per annum equal to the greater of (i)&nbsp;four-tenths of one percent (0.4%) and (ii)&nbsp;any other minimum rate of interest required by
applicable rules and regulations of the Internal Revenue Service, on or before April&nbsp;16, 2016 (the &#147;<B>Maturity Date</B>&#148;). Interest shall be calculated on the basis of the actual number of days elapsed over a year of
365&nbsp;days.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>This Promissory Note (this &#147;<B>Note</B>&#148;) will be registered on the books of the Company or its
agent as to principal and interest. Any transfer of this Note will be effected only by surrender of this Note to the Company and reissuance of a new note to the transferee. This Note may be prepaid in whole or in part at any time, without premium or
penalty. This Note is a general unsecured obligation of the Company. This Note is prepayable, in whole or in part, at any time and from time to time, without penalty.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby waives presentment, demand, notice of dishonor, protest, notice of protest and all other demands, protests and notices in
connection with the execution, delivery, performance, collection and enforcement of this Note. The Company shall pay all costs of collection when incurred, including reasonable attorneys&#146; fees, costs and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable, in whole or
in part or in any respect, or in the event that any one or more of the provisions of this Note operate or would prospectively operate to invalidate this Note, then and in any such event, such provision(s) only shall be deemed null and void and shall
not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and in full force and effect and in no way shall be affected, prejudiced, or disturbed thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note may only be amended, modified or terminated by an agreement in writing signed by the party to be charged. This Note shall be binding
upon the successors and assigns of the Company and inure to the benefit of the Lender and his permitted successors, endorsees and assigns. This Note shall be governed by and construed and enforced in accordance with the laws of the State of
New&nbsp;York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EXECUTED</B> as of the date set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMPIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory A. Gould</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Gregory A. Gould</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>11
<FILENAME>d912919dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ampio Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as
subscriber </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April 16, 2015 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ROSEWIND CORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16200 WCR
18E, LOVELAND, CO 80537 PHONE 970-635-0346 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SUBSCRIPTION AGREEMENT FOR COMMON SHARES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby subscribes for 57,970,000 shares of common stock, no par value (the &#147;Shares&#148;) of Rosewind Corporation, a
corporation organized under the laws of the State of Colorado (the &#147;Company&#148;), for $0.3795 per share (the &#147;Share Price&#148;) and agrees to pay the Consideration (as defined below) for the Shares upon acceptance by the Company of this
subscription. The Company shall issue a Certificate for the Shares to the undersigned as fully paid and non-assessable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The undersigned
represents and warrants as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) The Shares are being acquired by the undersigned for the undersigned&#146;s own account and not on
behalf of any other person. The Shares are being acquired for investment purposes only and not for distribution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The undersigned has
been given the opportunity to review (and to have the undersigned&#146;s attorney, accountant, and/or financial advisor review) the Company&#146;s Annual Report on Form 10-K together with its Articles of Incorporation and Bylaws as filed with the
U.S. Securities and Exchange Commission (&#147;SEC&#148;), and are available for viewing and copying on the SEC&#146;s website: www.sec.gov. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The undersigned has been given the opportunity to discuss the business, financial condition, and affairs of the Company with its
management. The undersigned has reviewed this information and its contemplated investment with its legal, investment, financial, and tax and accounting advisors to the extent the undersigned deems such review necessary. As a result, the undersigned
is cognizant of the financial condition, capitalization, and proposed operations and financing of the Company, and the undersigned has available full information concerning its affairs and has been able to evaluate the merits and risks of the
investment in the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) The undersigned understands the special risks of an investment in the Shares, in particular, those special
risks due to its lack of operating history, and due to its limited capitalization. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) The undersigned acknowledges that an investment in
the Shares is one of high risk and is suitable only for investors who can withstand the risk of loss of their entire investment. The undersigned further acknowledges that it will only make an investment in the Shares after having completed its own
due diligence investigation and after consulting with its own legal, financial and investment advisors to the extent the undersigned deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) The undersigned acknowledges and understands that there is currently only a limited market
for the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) The Company has given the undersigned the opportunity to ask questions of and to receive answers from persons acting
on the Company&#146;s behalf concerning the terms and conditions of this transaction and the undersigned also has been given the opportunity to obtain any additional information regarding the Company which the Company possesses or can acquire
without unreasonable effort or expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) The undersigned acknowledges and represents that it is a knowledgeable investor who can fend
for itself and has adequate means to make the investment in the Shares; and that, in connection with the purchase of the Shares, it has obtained investment advice from outside sources, including its investment adviser and private attorney and/or
accountant as it deemed necessary to make an informed investment decision. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The undersigned is not a member of the National Association
of Securities Dealers, Inc., nor affiliated with an NASD member broker-dealer firm. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. As consideration for the issuance by the Company of
the Shares to the undersigned pursuant to this Subscription Agreement, the undersigned shall, as of the date hereof (collectively, the &#147;Consideration&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) issue to the Company a promissory note in the principal amount of $10,000,000, in substantially the form attached hereto as <U>Exhibit
A</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) cancel the outstanding principal amount of the indebtedness of Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;), a majority-owned
subsidiary of the undersigned to be merged with and into a subsidiary of the Company on or about the date hereof, to the undersigned pursuant to that certain Intercompany Loan Agreement dated as of March&nbsp;6, 2014 by and between the undersigned
and Luoxis, which outstanding principal amount of is $8,000,000 as of the date hereof; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) cancel the outstanding principal amount of
the indebtedness of Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;), a wholly-owned subsidiary of the undersigned to be merged with and into a subsidiary of the Company on or about the date hereof, to the undersigned pursuant to that certain
Intercompany Loan Agreement dated as of November&nbsp;18, 2013 by and between the undersigned and Vyrix, which outstanding principal amount is $4,000,000 as of the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. This Subscription may be amended or modified only in writing signed by the undersigned and the Company. No evidence shall be admissible in
any court concerning any alleged oral amendment hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This Subscription binds and inures to the benefit of the successors and assigns
of the undersigned. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. This Subscription is made under, shall be construed in accordance with and shall be governed by the laws of the
State of Colorado. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. The undersigned acknowledges that the Company is relying upon the accuracy and completeness
hereof in complying with certain obligations under applicable securities laws and that the sale of the Shares by the Company will be based upon its representations and warranties set forth herein and the statements made by it herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, subject to acceptance by the Company, the undersigned has completed this
Subscription Agreement to evidence the undersigned&#146;s subscription to purchase the Shares as of the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AMPIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregory A. Gould</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ACCEPTED AND AGREED BY:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ROSEWIND CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">James B. Wiegand</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Subscription for Common Shares] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Promissory Note </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROMISSORY NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$10,000,000</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;16, 2015</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>FOR VALUE RECEIVED, Ampio Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), hereby promises to pay to the order of Rosewind Corporation, a Colorado corporation (&#147;<B>Lender</B>&#148;), Lender&#146;s successors, endorsees and assigns, the principal amount of $10,000,000 plus interest from and
including the date hereof on the principal balance from time to time outstanding, computed daily, at a rate per annum equal to the greater of (i)&nbsp;four-tenths of one percent (0.4%) and (ii)&nbsp;any other minimum rate of interest required by
applicable rules and regulations of the Internal Revenue Service, on or before April&nbsp;16, 2016 (the &#147;<B>Maturity Date</B>&#148;). Interest shall be calculated on the basis of the actual number of days elapsed over a year of
365&nbsp;days.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>This Promissory Note (this &#147;<B>Note</B>&#148;) will be registered on the books of the Company or its
agent as to principal and interest. Any transfer of this Note will be effected only by surrender of this Note to the Company and reissuance of a new note to the transferee. This Note may be prepaid in whole or in part at any time, without premium or
penalty. This Note is a general unsecured obligation of the Company. This Note is prepayable, in whole or in part, at any time and from time to time, without penalty.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby waives presentment, demand, notice of dishonor, protest, notice of protest and all other demands, protests and notices in
connection with the execution, delivery, performance, collection and enforcement of this Note. The Company shall pay all costs of collection when incurred, including reasonable attorneys&#146; fees, costs and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable, in whole or
in part or in any respect, or in the event that any one or more of the provisions of this Note operate or would prospectively operate to invalidate this Note, then and in any such event, such provision(s) only shall be deemed null and void and shall
not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and in full force and effect and in no way shall be affected, prejudiced, or disturbed thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note may only be amended, modified or terminated by an agreement in writing signed by the party to be charged. This Note shall be binding
upon the successors and assigns of the Company and inure to the benefit of the Lender and his permitted successors, endorsees and assigns. This Note shall be governed by and construed and enforced in accordance with the laws of the State of
New&nbsp;York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EXECUTED</B> as of the date set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMPIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory A. Gould</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>12
<FILENAME>d912919dex161.htm
<DESCRIPTION>EX-16.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-16.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 16.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 22, 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities
and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">450 Fifth Street N.W. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington,
D.C. 20549 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have read the
statements of Rosewind Corporation pertaining to our firm included in Item 4.01 of the Form 8-K dated April&nbsp;22, 2015 and are in agreement with the statements contained in that document pertaining to our firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ HJ &amp; Associates, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HJ &amp; Associates, LLC </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g912919img002.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>13
<FILENAME>d912919dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix
Pharmaceuticals, Inc. and Luoxis Diagnostics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greenwood Village, Colorado </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying combined balance sheets of Vyrix Pharmaceuticals, Inc. and Luoxis Diagnostics, Inc. (the &#147;combined Vyrix and Luoxis
company&#148;) as of December 31, 2014 and 2013, and the related statements of operations, changes in stockholder&#146;s equity, and cash flows for each of the years then ended, and for the period December 31, 2014. The combined Vyrix and Luoxis
company&#146;s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The combined Vyrix and Luoxis company is not required to have nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the combined Vyrix and Luoxis company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements include carve-out adjustments for Vyrix Pharmaceuticals Inc. and were prepared for the purpose of
complying with the rules and regulations of the Securities and Exchange Commission (for inclusion in the Form 8-K). The activities of Vyrix Pharmaceuticals, Inc. are a carve-out from Ampio Pharmaceuticals, Inc., its Parent, as of December 31, 2013
and for the period from January 1, 2013 through November 17, 2013. The carve-out financial statements are combined with the operations of the combined Vyrix and Luoxis company from November 18, 2013 through December 31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the combined financial position of Vyrix Pharmaceuticals,
Inc. and Luoxis Diagnostics, Inc. as of December 31, 2014 and 2013, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">/s/ EKS&amp;H LLLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EKS&amp;H LLLP
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 22, 2015 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, Colorado </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vyrix and Luoxis Combined Balance Sheets </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December 31,<BR>2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December 31,<BR>2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,001,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,070,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets, net (Note 2)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In-process research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion of prepaid research and development - related party (Note 9)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,606,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,305,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,941,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,376,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Liabilities and Stockholders' Equity</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">350,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payable to Ampio</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to Ampio</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,385,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deferred revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent deferred tax liability</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">629,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,854,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,195,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,519,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated Deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,112,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,979,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,544,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,941,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,376,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these combined financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vyrix and Luoxis Combined Statements of Operations </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product and service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,254,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,956,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,625,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,712,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,627,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss, before income tax</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,743,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,577,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax benefit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,132,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,957,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these combined financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vyrix and Luoxis Combined Statements of Stockholders&#146; Equity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Parent&#146;s</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Additional</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">paid-in</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Accumulated</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Total<BR>Stockholders&#146;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Equity</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">capital</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Deficit</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Equity</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance - December 31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,715,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,715,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss prior to purchase of Vyrix Aquired Assets by Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(977,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(977,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution of parent to Luoxis and Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,065,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,065,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in exchange for Vyrix Aquired Assets by Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,803,356</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,801,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment from parent in Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Luoxis common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock of Luoxis for cash net of offering costs of $985,274 (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,652,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,979,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,980,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock of Luoxis in exchange for patents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,979,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,979,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance - December 31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,652,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,519,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,979,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,544,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,132,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,132,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance - December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,652,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,195,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,112,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these combined financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vyrix and Luoxis Combined Statements of Cash Flows </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years Ended December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,132,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,957,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,906</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) in inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) in prepaid research and development - related party (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(615,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) in deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) increase in related party payable (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(629,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(619,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,238,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,995,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in investing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of fixed assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of patents</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(330,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(419,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible note to Parent</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contribution of Parent</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,137,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of Luoxis common stock (Note 6)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,652,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs related to sale of Luoxis common stock (Note 6)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(672,210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,417,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,840,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,001,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,001,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,001,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash transactions:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Luoxis stock for patents</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant compensation from Luoxis common stock offering costs (Note 6)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">313,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in exchange for Vyrix acquired assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,803,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these combined financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Vyrix and Luoxis Combined Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#150; Business, Basis of Presentation and Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements represent the combined financial statements of Luoxis Diagnostics, Inc. (&#147;Luoxis&#148;) a 80.9% owned subsidiary of Ampio
Pharmaceuticals, Inc. (&#147;Ampio&#148;) and Vyrix Pharmaceuticals, Inc. (&#147;Vyrix&#148;) a wholly owned subsidiary of Ampio. The combined companies are called the combined Vyrix and Luoxis company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis was incorporated in the state of Delaware on January&nbsp;24, 2013 and was a wholly-owned subsidiary of Ampio. Luoxis&#146; focus is on the development
and commercialization of the Oxidation Reduction Potential (&#147;ORP&#148;) technology platform. The ORP technology indicates disease severity and progression across a wide range of critical and chronic illnesses. Luoxis was funded through a
private placement launched in 2013. The combined Vyrix and Luoxis company also paid Trauma Research LLC (&#147;TRLLC&#148;) $330,000 and 50,000 shares of Luoxis common stock valued at $50,000 were issued to the Institute for Molecular Medicine,
Inc., both related parties, for assignment of all patents previously licensed by Ampio. As a result of the 2013 private placement and the TRLLC transaction, Ampio owns 80.9% of Luoxis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix was incorporated in the state of Delaware on November&nbsp;18, 2013. Vyrix is a specialty pharmaceutical company focused on developing and
commercializing late-stage prescription drug products to improve men&#146;s health and quality of life. Vyrix&#146;s principal asset is Zertane, a repurposed drug (tramadol Hydrochloride) to treat male sexual dysfunction pertaining to premature
ejaculation (&#147;PE&#148;). Vyrix acquired the worldwide rights to Zertane, combination product with Zertane and an erectile dysfunction product to address co-morbid PE and erectile dysfunction (&#147;Zertane-ED&#148;), patents, distribution and
manufacturing contracts, and all Ampio&#146;s clinical trial and research data related to Zertane and Zertane-ED (collectively the &#147;Vyrix Acquired Assets&#148;), from Ampio in November of 2013 in exchange for 20,000,000 shares of Vyrix common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements include the financial statements of Luoxis from January 2013 as well as the financial statements of Vyrix from its
inception in November 2013, combined with the carve-out financial statements related to the Vyrix Acquired Assets from March&nbsp;23, 2011, the date Ampio originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc.
(&#147;BioSciences&#148;). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The combined Vyrix and Luoxis company&#148; referred to in these financial statements includes Luoxis,
Vyrix, and the Vyrix Acquired Assets, collectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity Disclosure&#151;Company Discusses Liquidity Issues but Believes Actions It Has Taken
Will Enable It to Continue as a Going Concern over the Next Year </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, the combined Vyrix and Luoxis company had cash and
cash equivalents of $161,000, a working capital deficit of $6,050,000 and an accumulated deficit of $10,112,000. Additionally, as a development stage company we have not generated any material revenue to date and are not profitable, and have
incurred losses in each year since our inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has taken several actions to ensure that the Vyrix and Luoxis company will continue as a
going concern through June&nbsp;30, 2016, including, obtaining a $5.0 million cash infusion from Ampio during the first half of 2015 and an additional $10 million commitment from Ampio which will be funded prior to April&nbsp;15, 2016. Further, the
combined Vyrix and Luoxis company intends to file an S-1 and go out to increase their market presence and possibly obtain additional third party financing. Lastly, we have entered into numerous distribution agreements and we intent to start
generating revenue during 2015 as we generate sales of our RedoxSYS system. Management believes that these actions will enable the combined Vyrix and Luoxis company to continue as a going concern through June&nbsp;30, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#150; Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis
and Vyrix are governed by a common Board of Directors and they are both majority owned by Ampio Pharmaceuticals, Inc. Therefore, the accompanying combined financial statements include the accounts of Luoxis and Vyrix (collectively, &#147;the
combined Vyrix and Luoxis company&#148;). All significant intercompany transactions have been eliminated in this combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash
and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company considers all highly liquid instruments purchased with an original maturity of three
months or less to be cash equivalents. Cash equivalents consist primarily of money market fund investments. The combined Vyrix and Luoxis company&#146;s investment policy is to preserve principal and maintain liquidity. The combined Vyrix and Luoxis
company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, the combined Vyrix and Luoxis company has maintained balances in excess of federally
insured limits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Product&nbsp;&amp; Service Sales </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
recognize revenue from product and service sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>License Agreements and Royalties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or
patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval in the territory, cumulative sales targets, and other projected milestones and are recognized at the time the milestone requirements are achieved. Royalties
will be recognized as revenue when earned. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are recorded at their net realized value. We evaluate collectability of accounts receivable on a quarterly basis and record a valuation
allowance accordingly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventories are recorded at the lower of cost or market, with cost determined on a first-in, first-out basis. We periodically review the composition of our
inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the
impairment is first recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on
management&#146;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are taken into consideration, including the current status in the regulatory approval process, potential impediments to the
approval process such as safety or efficacy, anticipated research and development initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. For product candidates that
have not been approved by the FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For products that have been approved by the FDA, inventory used in clinical trials is
expensed at the time the inventory is packaged for the clinical trial. Prior to receiving FDA approval, costs related to purchases of the active pharmaceutical ingredient and the manufacturing of the product candidate are recorded as research and
development expense. Currently, our ORP product is available for sale for research purposes and our Zertane product is not currently being capitalized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fixed Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fixed assets are
recorded at cost and after being placed in service, are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Estimated</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Useful&nbsp;Lives&nbsp;in&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;-&nbsp;5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company recorded the following depreciation expense in the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>In-Process Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In-process research and development (&#147;IPRD&#148;) relates to the Zertane product and clinical trial data acquired in connection with the 2011 acquisition
of BioSciences Inc. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written
down if impaired. Once the Zertane product obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If the combined Vyrix and Luoxis company
decided to abandon the Zertane product, the IPRD would be expensed. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents,
determined by an independent, third party appraisal to be $500,000, acquired in connection with the 2011 acquisition of BioSciences is being amortized over the remaining U.S. patent lives of approximately 11 years. The cost of the Luoxis patents was
$380,000 when they were acquired in connection with the 2013 formation of Luoxis and is being amortized over the remaining U.S. patent lives of approximately 15 years. Patents consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated armortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(216,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">664,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">735,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company recorded the following amortization expense in the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future amortization is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;664,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of combined financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#147;GAAP&#148;)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the combined financial statements and the reported amounts of
revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, useful lives of fixed assets and assumptions in evaluating impairment of
indefinite lived assets. Actual results could differ from these estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis and Vyrix are included in the consolidated tax returns of Ampio. The combined Vyrix and Luoxis company&#146;s taxes are computed and reported on a
&#147;separate return&#148; basis for these combined financial statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for
deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and
liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of income taxes and related income tax
positions taken would be subject to audits by federal and state tax authorities if we filed these taxes on a separate basis. The combined Vyrix and Luoxis company has adopted accounting guidance for uncertain tax positions which provides that in
order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon recognition of
the benefit. The combined Vyrix and Luoxis company believes that it has no material uncertain tax positions. The combined Vyrix and Luoxis company&#146;s policy is to record a liability for the difference between the benefits that are both
recognized and measured pursuant to FASB ASC 740-10, Accounting for Uncertainty in Income Taxes&#151;an interpretation of FASB Statement No.&nbsp;109 (&#147;ASC 740-10&#148;) and tax position taken or expected to be taken on the tax return. Then, to
the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The combined Vyrix and Luoxis company reports tax-related interest and penalties as a component of
income tax expense. During the periods reported, management of the combined Vyrix and Luoxis company has concluded that no significant tax position requires recognition under ASC 740-10.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
combined Vyrix and Luoxis company accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The combined Vyrix and Luoxis company determines the estimated grant fair
value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research
and development costs are expensed as incurred with expense recorded in the respective periods as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;4,445,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3,003,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments, including cash and cash equivalents, accounts payable and other current assets and notes payable to Ampio and
other liabilities are carried at cost which approximates fair value due to the short maturity of these instruments. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company routinely performs an annual evaluation of the recoverability of the carrying value of its long-lived assets to determine
if facts and circumstances indicate that the carrying value of assets or intangible assets may be impaired and if any adjustment is warranted. Based on our evaluation as of December&nbsp;31, 2014 and 2013, no impairment existed for long-lived
assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Newly Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2014-09 regarding Accounting
Standards Codification (&#147;ASC&#148;) Topic 606, &#147;Revenue from Contracts with Customers&#148;. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to
which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for reporting periods beginning after December&nbsp;15, 2016. Early adoption is not permitted. We are currently evaluating the
accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June
2014, the FASB issued ASU 2014-10, &#147;Development Stage Entities (Topic 915)&#148;. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from GAAP for development
stage entities, primarily presentation of inception to date financial statements. The provisions of the amendments are effective for calendar year 2015; however, early adoption is permitted and, accordingly, we elected to implement the guidance for
our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, &#147;Presentation of Financial Statements-Going Concern (Subtopic 205-40):
Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern&#148; (&#147;ASU 2014-15&#148;). ASU 2014-15 is intended to define management&#146;s responsibility to evaluate whether there is substantial doubt about an
organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December&nbsp;15, 2016, with early adoption permitted. Management
is currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, the FASB issued ASU 2015-01,
&#147;Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.&#148; The purpose of this amendment is to eliminate the concept of extraordinary items. As a
result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December&nbsp;15, 2015 and subsequent interim
periods with early application permitted. Management is currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#150; License Agreement/Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2011, Ampio entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix
when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&#147;PE&#148;) and for a combination drug to be developed, utilizing Zertane
and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $500,000 upfront payment, the net proceeds of which were $418,000 after withholding of Korean tax. The upfront payment has been deferred and is being recognized as
license revenue over a ten year period. Milestone payments of $3,200,000 may be earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which may take several years. In addition, Vyrix may earn a
royalty based on 25% of net sales, as defined, if the royalty exceeds the transfer price of the Zertane product. No royalties have been earned to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, Vyrix entered into a Distribution and License Agreement (the &#147;Paladin Agreement&#148;) with Endo Ventures Limited, which recently acquired
Paladin Labs Inc. (&#147;Paladin&#148;), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement
expires on a country by country basis the later of fifteen years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $250,000 to Vyrix upon signing the Paladin
Agreement and may make milestone payments aggregating up to $3,025,000 based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment has been deferred and is being recognized as
license revenue over a seven year period. In addition, the Paladin Agreement provides that Paladin pays royalties based on sales volume. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#150; Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously discussed in Note 2 &#150; Summary of Significant Accounting Policies, The combined Vyrix and Luoxis company is included in Ampio&#146;s
consolidated tax returns. For purposes of these financial statements, the combined Vyrix and Luoxis company&#146;s taxes are computed and reported on a &#147;separate return&#148; basis. Ampio and the combined Vyrix and Luoxis company do not have a
tax sharing agreement. Accordingly, certain tax attributes, e.g., net operating loss carryforwards, reflected in these financial statements, may or may not be available to the combined Vyrix and Luoxis company. In the event that Ampio&#146;s
ownership interest in the combined Vyrix and Luoxis company falls below 80% and the combined Vyrix and Luoxis company is deconsolidated from Ampio&#146;s consolidated income tax return, the net operating loss carryforwards originated prior to
deconsolidation would no longer be available to the combined Vyrix and Luoxis company and the related deferred income tax asset would be removed and recorded as a deemed dividend to the parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax benefit resulting from applying statutory rates in jurisdictions in which the combined Vyrix and Luoxis company is taxed (Federal and State of
Colorado) differs from the income tax provision (benefit) in the combined Vyrix and Luoxis company&#146;s financial statements. The following table reflects the reconciliation for the respective periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years&nbsp;Ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State, net of federal income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial
reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current deferred income tax asset:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue short term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current deferred income tax asset</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deferred income tax assets (liabilities):</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,959,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,374,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section 197 intangible</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">589,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue long term</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired patents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired in-process research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,779,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,779,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,005,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(881,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term deferred income tax assets (liabilities)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(630,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred income tax assets (liabilities)</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(611,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company has recorded income tax benefits in its statements of operations since inception,
stemming from its operating losses, and is expected to incur operating losses for the foreseeable future. In 2014, the net deferred tax liability was reduced to zero based upon the operating losses, thus the combined Vyrix and Luoxis company
established a valuation allowance offsetting any future net deferred tax asset. As such, the combined Vyrix and Luoxis company would no longer record income tax benefits in its results of operations after 2014 because management is unable to
conclude that it is more likely than not that a benefit will be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have made our best estimates of certain income tax amounts included in the
combined financial statements. Application of our accounting policies and estimates, however, involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at our
estimates, factors we consider include how accurate the estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. The Company is no longer
subject to income tax examinations for federal income taxes before 2011 or for Colorado before 2010. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#150; Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commitments and contingencies are described below and summarized by the following table for the years ended December&nbsp;31: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical research and trial obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research agreement with related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,106,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">770,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis has entered into an agreement with a local manufacturing company to build their RedoxSYS system, the current remaining commitment is $91,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Research and Trial Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with upcoming clinical trials, Vyrix has a remaining commitment of $193,000 on contracts related to the Zertane drug and Luoxis has entered into
research agreements with a remaining commitment of $138,000 related to the RedoxSYS system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement with
Related Party </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis entered into a Sponsored Research Agreement with TRLLC, a related party, in June 2013. Under the terms of the Sponsored
Research Agreement, TRLLC agreed to work collaboratively in advancing the ORP diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days&#146; notice (see
Note 8 - Related Party Transactions). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Management Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January of 2013, Luoxis entered into an agreement with Ampio whereby Luoxis agreed to pay Ampio $15,000 per month for shared overhead which includes costs
related to the shared facility, corporate staff, and other miscellaneous overhead expenses. Vyrix entered into a similar agreement with Ampio in January of 2014, at a rate of $7,000 per month. These agreements will be in effect until they are
terminated in writing by both parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#150; Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Capital Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31,
2014 and 2013, Vyrix and Luoxis each had 60&nbsp;million shares of common stock authorized with a par value of $0.0001 per share and Vyrix and Luoxis each had 10&nbsp;million shares of preferred stock authorized with a par value of $0.0001 per
share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement &#150; Luoxis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2013, Ampio completed a private placement for its Luoxis subsidiary. A total of 4,652,500 shares of Luoxis common stock were issued at $1.00 per share
resulting in $4,653,000 of gross proceeds. Net proceeds were $3,980,000 after placement agent and legal fees. The placement agent also received 465,250 warrants to purchase Luoxis common stock valued at $313,000 in connection with the closing, which
amount has been included in total offering costs in the combined statement of changes in stockholders&#146; equity (deficit). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#150; Equity Instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Luoxis
2013 Stock Option Plan (the &#147;2013 Plan&#148;), 5.0&nbsp;million shares of its common stock were reserved for issuance. In June&nbsp;2013, Luoxis granted 1,800,000 shares to officers, employees and consultants. The shares have an exercise price
of $1.00 which is the same as the private placement offering price. Twenty-five percent of the shares vested immediately and the remainder vest annually on the grant date at a rate of 25% over the next three years. The fair value of these options
totaling $1.3 million was also calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the
underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. We estimate the expected term based on the average of the
vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. During the first quarter of 2014, Luoxis granted
150,000 options to officers and consultants. The options have an exercise price of $1.00 and the same vesting schedule as those granted in 2013. The fair value of these options totaling $101,000 was also calculated using the Black-Scholes option
pricing model utilizing the same methodology as described above. During the third quarter of 2014, Luoxis granted 885,000 options to officers and consultants. The options have an exercise price of $1.60 and vest at a rate of 25% over the next four
years starting on the one year anniversary of the grant date. Luoxis has estimated a forfeiture rate of 5.9% based upon historical experience; this is an estimate of options granted that are expected to be forfeited or cancelled before becoming
fully vested. All Luoxis options expire 10 years after the date of grant. The fair value of these options totaling $1.2 million was also calculated using the Black-Scholes option pricing model utilizing the same methodology as described above
including the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years&nbsp;Ended&nbsp;December&nbsp;31,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">79% - 108%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">85-86%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.75%&nbsp;-&nbsp;2.09%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.04%&nbsp;-&nbsp;1.53%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 - 7.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0-6.5</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Luoxis stock option activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted&nbsp;Average<BR>Remaining<BR>Contractual Life</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<br>Intrinsic&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,272,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,035,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,835,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,541,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">661,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available for grant at December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,165,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix has also adopted a 2013 Stock Option Plan (the &#147;Vyrix 2013 Plan&#148;) which reserved 5.0&nbsp;million shares of
its common stock for issuance to officers, employees and consultants. As of December 2014, 950,000 shares had been granted to a director, officers and consultants. Twenty-five percent or 237,500 shares vested immediately and the remainder vest
annually over three years. In November&nbsp;2013, 500,000 of these shares were granted to the Vyrix Chief Executive Officer and the exercise price was to be based upon a future private equity offering. Management estimated a price of $1.75 per
common share for valuing the option grant. The grant was valued utilizing the Black-Scholes option pricing model using the same methodology as described above for Luoxis. The valuation resulted in a charge of $140,000 in 2013. In the first quarter
of 2014, Vyrix engaged an independent third party consulting firm to perform a valuation. Based on the valuation, the exercise price was fixed at $0.70 per share. All 950,000 options have been valued utilizing the $0.70 per share. As a result of the
previous charge in the fourth quarter of 2013 and the revision of the exercise price, a reduction of stock compensation expense of $84,000 was reflected in the first quarter of 2014. Assumptions are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Years&nbsp;Ended&nbsp;December&nbsp;31,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63% -&nbsp;76%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">66% - 76%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.90%&nbsp;-&nbsp;2.02%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.33%&nbsp;-&nbsp;2.02%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 - 6.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.0 - 6.5</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vyrix stock option activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted&nbsp;Average<BR>Remaining<BR>Contractual Life</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<br>Intrinsic&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">557,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">416,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available for grant at December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to the fair value of stock options was included in the combined statements of
operations as research and development expenses and general and administrative expenses as set forth in the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes
stock-based compensation expense for the years ended 2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Years Ended December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">294,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">676,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">619,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized expense at December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining years to vest</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luoxis</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vyrix</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luoxis issued warrants in conjunction with its 2013 Private Placement. A summary of all Luoxis warrants is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of<br>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<BR>Average<BR>Exercise&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted&nbsp;Average<BR>Remaining<BR>Contractual Life</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued - Private Placements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2013</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding December 31, 2014</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants,
certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause
significant adjustments to valuation. The combined Vyrix and Luoxis company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity. The offering costs and the additional paid-in capital for the warrants associated with the common stock offering was valued at $313,000 using the Black-Scholes
valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions in valuing the Luoxis warrants were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.52</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#150; Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales and Purchases of Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November
2013, pursuant to a subscription agreement, Ampio purchased 20,000,000 shares of Vyrix common stock at a purchase price of $0.0001 per share plus the transfer of certain intellectual property described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ampio Loan Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, Vyrix
entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple
interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this
loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into
shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of December&nbsp;31, 2014 the amount advanced was $2,700,000 with interest rates
from 2.17% - 3.32%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis
$3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the &#147;Applicable Federal Rate&#148; for long-term obligations prescribed under Section&nbsp;1274(d) of the Internal Revenue Code of 1986, as
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may
repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined
by the Ampio board of directors, as of such conversion date. As of December&nbsp;31, 2014 the amount outstanding remained $3,000,000 with interest rates from 2.17% - 3.32%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assignment and Assumption Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December
2013, Vyrix entered into an assignment and assumption agreement with Ampio. Pursuant to the assignment and assumption agreement, Ampio assigned to Vyrix all its rights under a certain manufacturing and supply agreement, license agreement,
distribution agreement, services agreement and other agreements related to Vyrix&#146; product candidates in exchange for 20&nbsp;million shares of Vyrix stock, making Ampio the sole owner as of that date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Intellectual Property </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January
2013, Ampio transferred to Luoxis certain intellectual property, including registered and unregistered patents, related to the Luoxis ORP technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2013, Ampio transferred to Vyrix certain intellectual property, including registered and unregistered patents, related to Vyrix product candidates in exchange for stock as described above in the assignment and assumptions agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis
company each have service agreements with Ampio which are described in Note 5. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#146;s director and Chief Scientific Officer,
Dr.&nbsp;Bar-Or. The agreement, which was amended in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and development of Luoxis&#146; Oxidation Reduction Potential platform. In
March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to
expire March 2019 and cannot be terminated prior to March 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9 &#150; Subsequent Event </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F</B>rom January&nbsp;1, 2015 through April&nbsp;22, 2015, the combined Vyrix and Luoxis company received $6.3 million from Ampio. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>14
<FILENAME>d912919dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Unaudited Pro Forma Condensed Combined Balance Sheet as of February&nbsp;28, 2015 and the following Unaudited Pro Forma Condensed Combined
Statements of Operations for the year ended August&nbsp;31, 2014 and for the six months ended February&nbsp;28, 2015 are based on the historical financial statements of the combined Vyrix and Luoxis company and Rosewind Corporation
(&#147;Rosewind&#148;) after giving effect to the acquisition of Rosewind by the combined Vyrix and Luoxis company (as discussed in Note 2) as if it had occurred for the Balance Sheet on February&nbsp;28, 2015 and the Statements of Operations at
September&nbsp;1, 2013, and after applying the assumptions and adjustments described in Note 3 to the Unaudited Pro Forma Condensed Combined Financial Statements. This acquisition became effective on April&nbsp;16, 2015 (the &#147;Closing
Date&#148;) and is considered a reverse triangular merger in which the combined Vyrix and Luoxis company is the accounting acquirer as its shareholders hold a majority of the stock and management positions after the acquisition was complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These Unaudited Pro Forma Condensed Combined Financial Statements have been developed from, and should be read in conjunction with, (1)&nbsp;the unaudited
interim consolidated financial statements of Rosewind contained in the Company&#146;s Quarterly Report on Form 10-Q for the six months ended February&nbsp;28, 2015, (2)&nbsp;the audited consolidated financial statements of Rosewind contained in the
Company&#146;s Annual Report on Form 10-K for the fiscal year ended August&nbsp;31, 2014, and (3)&nbsp;the audited combined financial statements of Luoxis and Vyrix, collectively &#147;the combined Vyrix and Luoxis company&#148; for the fiscal year
ended December&nbsp;31, 2014 contained in Exhibit 99.1 to this Current Report on Form 8-K. The Unaudited Pro Forma Condensed Combined Financial Statements are provided for informational purposes only and do not purport to represent the combined
Vyrix and Luoxis company&#146;s actual consolidated results of operations or consolidated financial position had the acquisition occurred on the dates assumed, nor are these financial statements necessarily indicative of the combined Vyrix and
Luoxis company&#146;s future consolidated results of operations or consolidated financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combined Vyrix and Luoxis company expects to
incur costs and realize benefits associated with integrating the operations of the combined Vyrix and Luoxis company and Rosewind. The Unaudited Pro Forma Condensed Combined Financial Statements do not reflect the costs of any integration activities
or any benefits that may result from operating efficiencies. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;28, 2015 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vyrix&nbsp;and&nbsp;Luoxis<BR>Combined (1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Rosewind&nbsp;(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,999,900</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,160,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,803</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,029</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,001,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,344,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In-process research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion of prepaid research and development - related party</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(481</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,606,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,606,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,941,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,950,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Liabilities and Stockholders' Equity</B></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">445,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">450,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes to related parties</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,727,000</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;(b)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest to related parties</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,903</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,385,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,735,903</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deferred revenue</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,854,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,735,903</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,179,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(557,766</TD>
<TD NOWRAP VALIGN="bottom">)(b)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,195,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,638,431</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;(b)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,882,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ampio stock subscription</P></TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,000,000</TD>
<TD NOWRAP VALIGN="bottom">)(b)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,000,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,112,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(656,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">656,056</TD>
<TD NOWRAP VALIGN="bottom">(b)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,112,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,736,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,771,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,941,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,950,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This Balance Sheet is as of December 31, 2014 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">This Balance Sheet is as of February 28, 2015 </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of
the Unaudited Pro Forma Condensed Combined </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Financial Statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the year ended August&nbsp;31, 2014 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vyrix&nbsp;and&nbsp;Luoxis<BR>Combined (1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Rosewind (2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,290,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,290,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development - related party</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,076,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,511</TD>
<TD NOWRAP VALIGN="bottom">(d)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,336,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,527,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401,981</TD>
<TD NOWRAP VALIGN="bottom">(e)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss, before income tax</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,536,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,399,163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,827,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(61,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,689,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,273,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,986,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,259,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For the twelve months ended September 30, 2014 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For the twelve months ended August 31, 2014 </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the
Unaudited Pro Forma Condensed Combined </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Financial Statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the six months ended February&nbsp;28, 2015 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Vyrix&nbsp;and&nbsp;Luoxis<BR>Combined (1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Rosewind (2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Adjustments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Pro Forma<BR>Combined</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,723,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,723,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development - related party</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,898,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,308</TD>
<TD NOWRAP VALIGN="bottom">(f)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,003,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,730,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,835,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest (expense) income</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,787</TD>
<TD NOWRAP VALIGN="bottom">(g)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(937</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss, before income tax</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,749,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,779,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(3,725,772)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,755,922</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,824,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,434,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,259,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For the six months ended December 31, 2014 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">For the six months ended February 28, 2015 </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of the
Unaudited Pro Forma Condensed Combined </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Financial Statements. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Note 1: Basis of Pro Forma Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Unaudited Pro Forma Condensed Combined Balance Sheet gives effect to the acquisition as if it had occurred on February&nbsp;28, 2015 and includes estimated
pro forma adjustments. The Unaudited Pro Forma Condensed Combined Statements of Operations gives effect to the acquisition as if it had occurred at September&nbsp;1, 2013. The Unaudited Pro Forma Condensed Combined Financial Statements do not
reflect the costs of any integration activities or benefits that may result from operating efficiencies expected to result from the deal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Note 2: Acquisition of Rosewind by the Combined Vyrix and Luoxis Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, pursuant to an Agreement and Plan of Merger, or the Merger Agreement, entered into among Rosewind, Luoxis, Vyrix, two major
stockholders of Rosewind and two subsidiaries of Rosewind created solely for the purposes of the Merger, and which did not survive the Merger, the Merger occurred in two stages. The two major stockholders of Rosewind were James Wiegand, founder of
Rosewind, and his son, Michael Wiegand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first stage, each of Vyrix and Luoxis merged with one of Rosewind&#146;s merger subsidiaries. Vyrix and
Luoxis survived these mergers. The outstanding shares of stock of Vyrix and the outstanding shares of stock of Luoxis were converted into the right to receive shares of common stock in the Combined Company. The Vyrix stock and the Luoxis stock were
each converted at an exchange factor. The exchange factor for each of them was determined upon the basis of a relative value opinion obtained by Ampio, the parent company of Vyrix and Luoxis, prior to the Merger. The outstanding shares of
Rosewind&#146;s merger subsidiary that merged with Vyrix were converted into shares of Vyrix as the surviving corporation. The outstanding shares of Rosewind&#146;s merger subsidiary that merged with Luoxis were converted into shares of Luoxis as
the surviving corporation. After completion of the first stage, Vyrix and Luoxis became wholly-owned subsidiaries of Rosewind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the second stage, which
occurred on the same day as the first stage, each of Vyrix and Luoxis merged with Rosewind with Rosewind surviving. The first and second stage mergers are referred to collectively as the &#147;Merger.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the Merger: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The board of directors of Rosewind, whose sole member was James Wiegand, increased the number of directors by one, and appointed Michael Macaluso to fill the vacancy created by that increase. James Wiegand resigned from
the board immediately thereafter. The board of directors of Rosewind, whose sole member is Michael Macaluso, then appointed Joshua Disbrow as Chief Executive Officer, and Jarrett Disbrow as Chief Operating Officer, of the Combined Company.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ampio purchased 57,970,000 shares of common stock of the Combined Company for (i)&nbsp;issuance to Rosewind of a promissory note of Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the
Merger; (ii)&nbsp;cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii)&nbsp;cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James Wiegand entered into a consulting agreement with the Combined Company with a one year duration, providing for compensation of $50,000 to him. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of James Wiegand and Michael Wiegand executed a release in favor of the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of Ampio, James Wiegand, Michael Wiegand, a trust affiliated with Joshua Disbrow and a trust affiliated with Jarrett Disbrow entered into a lock-up agreement with the Combined Company agreeing not to sell its
shares of the Combined Company for two years (except the one for Ampio, more than three years). The lock-up agreements other than the one with Ampio release 25% of the shares subject to it on June&nbsp;30, 2015. The Ampio lock-up agreement
terminates upon a change-in-control event of either the Combined Company or Ampio. Each other lock-up agreement terminates upon a change-in-control event of the Combined Company. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Joshua Disbrow entered into an employment agreement with the Combined Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Jarrett Disbrow entered into an employment agreement with the Combined Company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement
contemplates the reincorporation of the Combined Company in Delaware, as a corporation, with the name Aytu Biosciences, Inc. as soon as is reasonably practicable after the closing of the Merger. The reincorporation is also expected to result in the
reduction of the number of shares of stock outstanding in the Combined Company equivalent to a reverse stock split at the rate of 12.174 to 1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Note 3: Pro Forma Adjustments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Unaudited Pro Forma Condensed Combined Statements of Operations do not include any material non-recurring charges that will result from the acquisition. The Unaudited Pro Forma Condensed Combined Financial Statements reflect adjustments directly
attributable to this transaction, factually supportable and expected to have a continuing impact. A detail of the adjustments are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Adjustments to exclude assets that the combined Vyrix and Luoxis company did not acquire and liabilities that the combined Vyrix and Luoxis company did not assume pursuant to the Merger Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Adjustments to record the common stock and equity changes pursuant to the Merger Agreement, including contributions to be made on conversion of note payable to Ampio. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">An adjustment due to Rosewind Corporation not generating any sailing school revenue. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Adjustments to exclude costs associated with the sailing school and activities not pursuant to the Merger Agreement. Additionally, adjustments to increase general and administrative costs including taking the full
compensation of our CEO which was partially paid by Ampio and to Rosewind&#146;s prior CEO for a 12-month period consulting agreement of $50,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr. Disbrow&#146;s Salary paid by Ampio</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting agreement with Mr. Wiegand</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less Rosewind general and administrative expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Adjustment to exclude interest pertaining to related party notes payable and include interest income related to the promissory note from Ampio for one year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Adjustments to exclude costs associated with the sailing school and activities not pursuant to the Merger Agreement. Additionally, adjustments to increase general and administrative costs including taking the full
compensation of our CEO which was partially paid by Ampio. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr. Disbrow&#146;s Salary paid by Ampio</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;105,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less Rosewind general and administrative expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">Adjustment to exclude interest pertaining to related party notes payable. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>15
<FILENAME>d912919dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Completes Reverse Merger Combining Assets of Vyrix Pharmaceuticals and Luoxis Diagnostics </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conference Call to be Held April&nbsp;24th </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LOVELAND, Colo.,
April&nbsp;16, 2015 /PRNewswire/ &#151; Rosewind Corporation (OTCMKTS: RSWN) announced today that it has completed a reverse merger with a newly formed specialty healthcare company focused on redox-modulated conditions, with an initial focus on
addressing urological disorders. The merged company, which is expected to be re-named Aytu BioScience Inc., has commenced operations and incorporates the pipeline assets of both Vyrix Pharmaceuticals and Luoxis Diagnostics. The Company&#146;s
strategy is to build a late-stage and commercial pipeline of therapeutics and diagnostics, including its lead therapeutic candidate Zertane&#153;, a first-in-class treatment for premature ejaculation (PE) that is nearing commercial-stage, and the
RedoxSYS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> System, which has CE Marking for Europe and medical device approval by Health Canada and is currently being studied in male infertility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development pathway for Zertane is significantly de-risked following success in two European Phase 3, two Phase 2, and two Phase 1 trials for PE. The
Company is currently preparing to initiate a pivotal clinical study in the U.S. and already has secured commercialization agreements for Zertane with strategic partners in Canada, South Korea, South Africa, and Latin America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In parallel with its development of Zertane, the Company will continue to leverage the RedoxSYS System through its Luoxis research division, which will focus
on developing additional therapeutic markets where a redox imbalance is implicated. The Company recently initiated a clinical study in collaboration with a prominent U.S. research hospital using the RedoxSYS System to measure oxidative stress levels
in semen, which has been broadly implicated as a cause of male infertility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Josh Disbrow, Chief Executive Officer of Rosewind, added, &#147;We are proud
to launch our urology-focused organization and intend to rapidly progress our late-state assets toward commercialization. The men&#146;s health market is very large, yet many medical needs remain. As such we look forward to entering the $10 billion
urology market by advancing Zertane through pivotal trials, while supporting our urology focus with the recently initiated RedoxSYS studies in male infertility. As a management team, we have a track record of building successful commercial-stage
companies, and we are excited to hit the ground running as we advance our internal assets and seek to in-license and acquire complementary commercialized urology products.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger between Rosewind Corporation, Vyrix Pharmaceuticals and Luoxis Diagnostics was effected pursuant to the terms and conditions of an agreement and
plan of merger dated April&nbsp;16, 2015. Rosewind will file a Current Report on Form 8-K with the SEC on April&nbsp;22, 2015, providing information about the Company&#146;s post-merger business, plan of operations, financial condition, and
management team. The Current Report on Form 8-K will be available at the SEC&#146;s website at <U>www.sec.gov.</U> The new management team of Rosewind will also host an investor conference call on Friday, April&nbsp;24<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>, at 11:00 am Mountain Time. To join the call dial the conference line below. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: Friday, April&nbsp;24, 2015 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: 11:00 a.m. Mountain
Time, 1:00 p.m. Eastern Time </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Conference call numbers: </U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Domestic/Canada: 1-(719)-867-0487 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Passcode: 4050753995 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Rosewind Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rosewind Corporation is a
specialty healthcare company focused on redox-modulated conditions, with an initial focus on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic
candidate Zertane, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company&#146;s therapeutic pipeline is supported in part by its Luoxis division, whose first-in-class
RedoxSYS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> System provides the only complete assessment of patients&#146; redox status and enables identification of a broad variety of disorders where redox is implicated. Initial studies are
underway utilizing the RedoxSYS system in male fertility. The company&#146;s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.
Rosewind expects to formally change its name to Aytu BioScience in the near future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Investors&nbsp;&amp; Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Tiberend Strategic Advisors, Inc. </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joshua Drumm, Ph.D.:
<U>jdrumm@tiberend.com;</U> (212)&nbsp;375-2664 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Wheeler: <U>awheeler@tiberend.com</U>; (646)&nbsp;362-5750 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SOURCE Rosewind Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g912919dsp_263.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_263.jpg
M_]C_X1>,17AI9@``34T`*@````@`"`$2``,````!``$```$:``4````!````
M;@$;``4````!````=@$H``,````!``(```$Q``(````>````?@$R``(````4
M````G`$[``(````&````L(=I``0````!````N````.0`+<;````G$``MQL``
M`"<0061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP-#HR,B`Q
M-CHP.#HR,`!J=V%N9P`````#H`$``P````'__P``H`(`!`````$```).H`,`
M!`````$```%+``````````8!`P`#`````0`&```!&@`%`````0```3(!&P`%
M`````0```3H!*``#`````0`"```"`0`$`````0```4("`@`$`````0``%D(`
M````````2`````$```!(`````?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!:`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#NNM]&ZAGYM5V+DOQF,I=4XUWVU&;+*6OO935^KNNQL+[=]F?<RS]9
MNI_T:KTX?UW%@-^=CNK;Z9V,`:7%E+O4K=:[&LV^OG[&9%K:?Z)^EQ*L*[]"
MMUV'B.<7.HK+G&22T$DGY)OL.%_W'J_S&_W)*>;JQOK^YEK79=++:O8U[Q66
M6`N]7=2UF-O9<RFWT&Y5OZ#U<;_DN[U/MB/;T_ZXW@5VYE(8UQ;OJ<:R]KFY
M-7JOK^SO>S9OP[/LS,G^>]?];_F5N_8<+_N/5_F-_N2^PX7_`''J_P`QO]R2
MG!S>F?6?*Z=359:RW)&2ZVX-R;,5AK].RNFNN[I^-3E,QV93Z\GT'/MOV5^G
M;FY"G3@?71@<U_4L=\.<QA-8UK:W=1<89_/76LIJRJ=WL9;FVT7?T2O&T;L/
M%^V-:*:P#7^Z(^DU<_C_`%FZ-931;D]/OQ?M(8ZH&CU);:VVZFS]'^E]]>+D
M?X'_``/Z+UJ_1LM2D[\+Z\T5C*^UU7WMK'JTMU#_`$R^]M;:GUUT?I?6NQ+/
M1^PVW^E@7?:J?1NJ>:KI_P!="*S;U)C-NW<T"I[B#O\`5]9_V&EMCFN])]7H
M5XGZ+?C_`,[^NJK_`,XNAD;ABN+2&N:YK*WM(>UKPYSZ7V5MKWV5T^HRR[_M
MKWJ=/U@Z!?D48U5)==D/V-9Z;1$6UXKG6>[=5M?;N]*UE5WZ.S]&DI([`^O+
M\9XLZA0+G,L`%0#&[GLO8/>[&ML_07MP[,3;]"NV_P"U?:_L]?V@N7T+KMO4
M;,RCJ3J6L=35C,:YQBD!C,VVYC_4PK,A[;<RREC\&W]9JP;;,CTOU=6Z\;&]
M6_\`0L@.9'M'^C8LS(ZST[&SK\6[I]@IHN9COS&L::@YU7VI[OS7[:J_I^EZ
MW\O9_A$I:RKZ^,LII;>RQUA>YUK17Z3"P,=^L.=CMM^S9#FOJHQZ:OM>-ZOJ
MVYV;_-TV7X'UR=D/8SJ-;,4>DVJR*S<[:U[;[;&_8_08ZZQ]=OHL_P!#Z55E
M._U%3QOK+]6\J^C'IJ>;<E]==8-&DV^LUA<\%S?3:[%MWV?]M^HS>M3%^QY3
M+'MQFL]*ZVAS7M;.ZEWI.?[-S=EGTV)*2=(Q_K#5DV'JF0R_'--0K#=LBX-_
M67>S'Q_8Y_T7;O\`K%2UED4XN,6NFEA_26_FCM98LD]?Z77?97D]/MHIKMOJ
M&46,-;OL]GV6Q^IK?L=?L9O;ZE3/5J_2_P!(^S)3UJ2XT_6OZMFMSJJ7.>UC
MK`VRH5-AM->;^DOM/IT[J[V,]W^$_P`&MRFC%LKKL^SM9ZC6OV.:TD;@'[7>
MF7U[F[OS'[$E.LDL/9AX_31DV4-<VG'%KP&C<0ROU7?2_.=M68SZR=&:&_;<
M&W">[TPUME37;C8]E30S;MM]OK57[+::K?L[]_I_SE:2GKTER#/K+T"W!R\W
M'H+VX5#<FQEE;:9#W.K;4VVX^EZVZO\`S_T5?Z7U?3W:\;%%E;FU,Y:YIV@'
M6'-_JI*?_]#TPV7&\TMOI%D;Q402_9,;BWU?^EM4MN;_`*2K_,=_Z565U/I6
M-G9CKKLJ]FT,:VMC"`STWB[]';76VW;;8QCKOTGZ3TJ/]!3LK-^KW3&VA[;K
MFM`(%3*W-8'&/TWL8U[K_4;Z_JO?[,C]*DFAW=QKLISW,;=27LC>T-,B=6[A
MZOMW*6W-_P!)5_F._P#2JJ=,KQ>FX;<2M]MK6%Q#[&6.<=[G6^YSFG=[GJW]
MLH_E_P#;;_\`R"2&ID&YN6T66UAQJ,`5O<2`YN[VLL_-EB7JVCBYNNO\S;_Z
M42NO#L]EM3]I92YI#JK'2'.9K[=G^C1/M5_^D;_VQ;_Y))3`6W'BYI_ZS;_Z
M43NLO`AUS0#XTW:_^"(&3CTY=C;<@[K*Q#'MKO86Z[IK-=C=COY2A7A8]37-
M:]Y#BQQ%@R;-:CZE.WU;';-EGO\`T:2DE?J^K?-C='-G]!;_`*-G\M%W7C_"
M-&G^@NX_[<6=7TW#-EC7.L<VHM:T$Y1_P;!N?^E]S]OLW_Z/]&B_L_'VEAMM
M+38+6C]9]KFC8W:[U-VSW.MVO_PO_%UI*;I?D09M$=_T-W_I1,?6[O;I_P`!
M=_Z452O`QJG^I6^P/DF2<HR2'5G<#;[G;7_33.Z;B.(E]G>1.5!!!]G\[]#\
M_P!B2D]!M]-Q+VC]);S1;_I'_P#"(H?=,"ULCD"FV?\`SXJ&+T_$8UY:Y\E]
MP,G*=])UE3G:V^VWTW.;ZOTT3[!BQ&YX!()VC)$[6LI9OVV?I-E=3-OJ)*;A
MMO'-S1X33=_Z40_4MW@;F>F`2^TU6!K-0UN[=:/I?O?X-1Q*FX8=Z%KB7QO=
M:W(M)VCG]+8YK/Y?IHQS+]VPPX.:?T@JL`:01RUV_>YS7>Q)2V)C9?V6@^I6
M(K9^8Z=&M_X9&%&:.+:Q_8?_`.EU#`R,>K!QZV[]K:F`2QYT#1WV(_VRC^7_
M`-MO_P#()*1^AFS/JUZ<>Q__`*72;C9(>USK*R`03#'3S_QQ1/ME'\O_`+;?
M_P"03C+I<0T;I)@>QXY_LI*?_]'O.HYW6J,\MPL5V10UE8+7`-8XO>/5LKR&
M%[V?9Z1_-/I_2^MZG_:?],)O4OK(+?3=@,>V"\V@.8WL]M#6[[;'V;?T'K[:
MZ_5_3>GZ2L=7ZEB=,?6;SDO]466O]'W"JFK:<G+M&YOZOC^K5O\`2]2[])^B
MIL4'=9Z)6'&[/-18WU"U]FIKE[1>W;NWT[*7W[V_S>/^FN]-B2=.Q^U&<WZR
M6TTV#%%%CJ\CU:F@/VV-=MQ6[K7T;M]7Z3\QGJ?X1:?3CF'&#\W2YSB=D-&U
MH.VN=FYN][&^K;[[/TMC_P#!JDWJW0W.+1U'46&H_I"(<T^F[=^[7ZKF4>K_
M`#7VA]>/_/V>FA'KO1/T99FVO9<QMC7M+]I98+_1>UQ`]7UG8=U=55/J7V?H
M_P!%^D20OUS+R\?-H&/8^MKZ;"\L8'R6OIV3NKM_-?8J!ZKU3MD7:_\`!-_]
MYU=R.K],QLRNNRW(%5E5=C\W=&/6RXV_9?7>Y[=GKNQ[MMGI;*_\-95ZM6^9
MZY]7Q3Z[NJ!M6ON-A`&WT]^Z?H^GZU?J_P"B_P`)_-6I*:'[5ZI_W(N\OT3/
M_>=-^U>J?]R+O^VF_P#O.KS>N=$VO+\VRLUO>PL<YVXFNS[.[TVLW>K[O3M_
M1^_[/D8U_P#-9%2<]=^KP=8W]J`FH$NBTG@[/9_I7.?[*VU_SK]_I_S:2G/9
MU/J(<\C(NW$@V?HVG6`![?L_M]@3CJO5/^Y%W_;3?_>=:5/4^B6Y#:,?/===
M?8VMHJ>ZP.<ZNRYD.K#Z]GH8MOZ7^:_1_P"D53!^M'0<SU"W+MK#7N967O!%
MNW3=1Z#KO^#_`$%GIY=?KXGK8]?VS%]9*0?M7JG_`'(N\OT3?_>="OSLNW8<
MB^R*7;ZW.:VN'AKF[VO;57]%CG^U:S>M=!<]C&]2W/L+!6T/)+C86-K8R![W
M[K:_8WZ'YZ&[JWU:OLI8_J#;'[PZD%Y,6;[,1I_K^JVYGO\`W/5_P?J)*='I
M+[[,)K[V[+'/L+A!'Y[]2P[MF[]Q7%0P#@YF,W)P<E]V/87%MC'DM<2X[W-)
M_-WJQ]E'^EM_SRDI.D@?91_I;?\`/*7V4?Z6W_/*2E87]#H_XMG_`%(1U79A
M,8UK&V6AK0&M&\\#1/\`91_I;?\`/*2DZ2!]E'^EM_SRG&,`0?4L,&8+C&B2
MG__2]$S^F8F=D4WY6)Z[\4GT27D-@NJM]]37-KM;ZN-CV[+F/_24UV*C=]5.
MDV0:\-V.=U1L=38&N>RECL=F.]YW/]&RA_HW^EZ;[ZO9:];Z22G)_8G3O499
M^SV[ZXV'?^ZVME;3[O<VO[-CV5,=_-Y%%63_`$BOU5!OU>Z4UFQO3PT;=H+;
M"""'>OZS'A^]F3ZWZ7[6W]:]3_#+9224XN3TGI-N8ZW(Z>+;K*?3?N?N8:P'
M8T>B]_I>IZ-]M7J^GZGHVVU^I^D3'I/1R&AW36.V^CM+BTD?9]_V8[G/W?H_
M6N_XSU;?4_G%?R`3EB!_@C_U35E7].ZV[J+\K&ZEZ.._TQ]ELJ]1K6L#?5],
M$[?5O=ZGZ3_6E*7MZ#T>Q]3FX3JO2<'`56!@=%;L;:[:_=[Z_3];T_3LR/LV
M+]H]6JAC$6SI'1K*S2_IK#601LW-`$N;=[&M?^CVVUMLK]/^:_P:K5X'UI'I
M>KU6@@%GJ[<0!Q:&,KMV;MS=]EWJW?\`J/\`1*S@8G5:;+'YV6W*98UNVMM>
MP,>T-:]];@UGZ.WW/]+_`-2/M2F5.'TVO)%U.`*[L=Y+7M<UL&P7W.V[7_1_
MRAE?V[?^+4'U]#<:^G.HJ%F)CBNK'%S&V54!U3ZWU-%K;:=MN-BOKR&?I&6T
MT6>I_-JU6UWK7Z'Z3/\`SW6L;J--#\[).1T6S-`])K;:@\V6`U65^HVR*Z&5
MTMNNQJZFY'JU9'ZS=Z'J4Y*2FS1TCHN/F6.]`.LM:75XKK*@RMC6?9[G8^.P
MLV,?5F[<FW_">O3ZK_YI$PNG="KI9]BPF&ECCL=78U[=]=C;'>[U';GU96-[
MO^%K_P",6.^KI^/183]6\IHL;MO#2XP&;<EHW-?O]-V337Z7V??;ZGJ;Z:_4
M]+)WNELC!K8S#=@,K<^NO%=J6L:]PK/[OZ5OZ7V^I_QB2DO3_LV%C?9\/%-5
M+7V2W>TDOWN]:QSW/<][K+=[][T2_K&-CO8S(<RA]@)K;9;6TN#8WEC7O]VW
M<H4M=L=H?YVW_P`^6+"ZK9==DOIR.A9&6`30+:;'MKLJ:]EC76MK=2RW]'?Z
MF*V_^9R_MGZ2G^?24](,^7;17+O#>SX?OI,S_48VRNO>QX#F/:]A:0>'-<'>
MY<=]DP'-=3_S6R179[+BUU@::]S]C=LL<]WIX]-EWT/YW_#V?S_0]*M>^GT1
M@78%6,&5T,N@[F`0W9JY_LV?X3W_`,VDIT*\]UE;+!2Z'M#A+F3#AN_>0G=9
MQ6W_`&9SJVY&A]$VUA\.DL_1[]WOVN4<9KOLM&A_FJ_^I:LCKN%C^H'GI-G4
MCD3;8QC[6L]2EK*F/LKKW4-N=B%[&VNK]7(91]D_2_HDE.X[J=;6.L<UK6,!
M<]YLK`:!NW.<XO\`HMV/_P`Q$;E/+PTTD20#[FZ2?ZRY#"Z?TW*R*\/,^KMN
M*VUYM8XV6;`ZL6_I;&![=GL=757_`,+=73]#T[%UC0XV-)!U<"=/-)3_`/_3
M[WJ]?4F9%5G3\>JY@:]UM;VB7O.WTF[]IV?R_<S_`$GZ?9]GLI"WZP^X_LR@
MG8W:S:`W?M<7`V^IOV.?L]_H_H7_`*OZ617^OJQURKI]N;CC-M^SW%CQ06V%
MLM:ZNUS[#Z%E;/2M91:SU'_SC%3Q\/HM5=F/^T?5:\4O<;,TN@,%CVNK?Z>U
MGVAGJVY/I>^W^=23IXIPWK)%A&.P'?9L#J&26;"^CTVLLV?S[646>M?^D]3U
M/U=:/3,1[L9MN:P"Y[1NI<VN&%LMW#TF-]UOT[/>_P#X-87V'H366,=DV;/4
M>0'7V%HLK$Y3\=KL?TW6;76VY5E7^ER,C_A%K=&P&XS3E8;C;3D-!8RRQX`D
MNL?;M=4W]+=O;O\`T;/934DHTKJ=^/@Y=48K+O5J?S#0`QU?\BS=N]55OVO5
M_P"5U7^</_2*O9>(W+RF?:::W^G6=GZ5[8W.;NU8QO[C%']CX7_<>O\`[?L_
MN20T_P!KU?\`E=5K_*'_`*12_:]43^SJO+W#_P!(JY^Q\+7]7K_[?L_\BE^Q
M\+_N/7_V_9_Y%)309U.IK[''`J(>0?I#2&M9M_F?Y*G^UJ?_`"NJ\_</_2*L
M5=)Q#9<TT,(8X!H]>S26,=X?RD3]CX7_`'&K_P"W[/\`R*2G/NZH7L`HPZ:+
M-S2'F'B`0Y[7,])O\XW]']):W3W8&=1ZK,=C7-.RQA:#M>`"6[H]WTE5OZ)0
M]FVEC<=Y+3ZC;7N,`@O:&O;L][/9[OH*_0UV/4VFFJIE;!#6BP_^DTE,<3$Q
M34XFFL_I;?S1_I+/)&^QXG^@K_S1_<JE>8<=C&V^FTW7VUUR\P7;[7;7'TO9
M]'_/_1JYNRO]&S_//_I))2WV/$_T%?\`FC^Y+[)B?Z&O_-']R?=E?Z.O_//_
M`*22W97^C9_GG_TDDI!AXF*<.@FFLGTV?FC]T>2-]CQ/]#7_`)H_N0L-V3]D
MHBMA'IL_//[H_P""1MV5_HZ_\\_^DDE+?9,6(]&N#S[1_<G&+B@@BE@(,@AH
MD$?)+=E?Z-G^>?\`TDD'9,B:V`=R'DZ?]MI*?__4[WK-3;[ZZSA#,:YCFDZ]
MR`ZGU&AS*&[?YU]O\[5OH_2?S:RGX];:';N@WO<0*Q2VQSF%KG.86NW?H_1_
MP^0S\^]_K_IK?UJS>?\`3=_1>3]+GG\[^4F_]A$DZN7L=7>ZEG2[[O6MM#GM
M>X!H:ST6OLR,C_3T6/\`2^SO]*OUO2_G?7L6OTC8SIN.!0[#W,#CC6'<]A=^
MD>VQ\NWV;G>]WT_WU#_V$2_]A$E&VIUO`MSLZ@TMJ>*J;`X6.CZ;Z=I;[+/]
M$Y43T#,_T6-_G_\`J!;/?_M)PE_[")(<?]@9G^AQO\__`-0)?L#,_P!#C?Y_
M_J!;'_L(E_[")*<5G1,ISGL%./-9`,O')`L_T/\`+3CH&9WIQO\`/_\`4"V?
M'^B)?^PB2G&_8&9_HL;_`#__`%`E^P,R?YG&\O?_`.H%L_\`L(E_[")*<(],
MR6E@;14?6>^D!A!U9OW^M^C;MI_1/_\`2?J+IL2MU&-73;=ZSV"#8[D_^<_1
M]WO_`-(J[?HG^B_+CGNF_P#81)3?W-\0EN;XA4/_`&$2_P#81)38PG-^QX^H
M_FF?]2$?<WQ"H#@?T3A+_P!A$E-_<WQ"6YOB%0_]A$[?I-_HO(XYY_-_E)*?
M_]G_[1^V4&AO=&]S:&]P(#,N,``X0DE-!`0``````!D<`5H``QLE1QP"```"
M2,`<`E``!6IW86YG`#A"24T$)0``````$!NH)*085-8RVF9[HBDU7]8X0DE-
M!#H``````.4````0`````0``````"W!R:6YT3W5T<'5T````!0````!0<W13
M8F]O;`$`````26YT965N=6T`````26YT90````!#;')M````#W!R:6YT4VEX
M=&5E;D)I=&)O;VP`````"W!R:6YT97).86UE5$585`````$```````]P<FEN
M=%!R;V]F4V5T=7!/8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'``````
M``IP<F]O9E-E='5P`````0````!";'1N96YU;0````QB=6EL=&EN4')O;V8`
M```)<')O;V9#35E+`#A"24T$.P`````"+0```!`````!```````2<')I;G1/
M=71P=71/<'1I;VYS````%P````!#<'1N8F]O;```````0VQB<F)O;VP`````
M`%)G<TUB;V]L``````!#<FY#8F]O;```````0VYT0V)O;VP``````$QB;'-B
M;V]L``````!.9W1V8F]O;```````16UL1&)O;VP``````$EN=')B;V]L````
M``!"8VMG3V)J8P````$```````!21T)#`````P````!29"`@9&]U8D!OX```
M`````````$=R;B!D;W5B0&_@````````````0FP@(&1O=6)`;^``````````
M``!"<F1456YT1B-2;'0```````````````!";&0@56YT1B-2;'0`````````
M``````!2<VQT56YT1B-0>&Q`<L````````````IV96-T;W)$871A8F]O;`$`
M````4&=0<V5N=6T`````4&=0<P````!09U!#`````$QE9G15;G1&(U)L=```
M`````````````%1O<"!5;G1&(U)L=````````````````%-C;"!5;G1&(U!R
M8T!9````````````$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P4F5C
M=$)O='1O;6QO;F<`````````#&-R;W!296-T3&5F=&QO;F<`````````#6-R
M;W!296-T4FEG:'1L;VYG``````````MC<F]P4F5C=%1O<&QO;F<``````#A"
M24T#[0``````$`$L`````0`"`2P````!``(X0DE-!"8```````X`````````
M````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S
M```````)```````````!`#A"24TG$```````"@`!``````````(X0DE-`_4`
M`````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@``
M``$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@``````'``
M`/____________________________\#Z`````#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z```.$))300````````"```X0DE-!`(`````
M``(``#A"24T$,````````0$`.$))300M```````&``$````".$))300(````
M```0`````0```D````)``````#A"24T$'@``````!``````X0DE-!!H`````
M`UL````&``````````````%+```"3@```!,`.0`Q`#(`.0`Q`#D`7P`P`#``
M,0!?`'``80!R`'0`7P`Y`"T`.`````$``````````````````````````0``
M```````````"3@```4L``````````````````````0``````````````````
M```````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```4L`````4F=H=&QO;F<```).````!G-L:6-E<U9L3',`
M```!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````
M````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R
M:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y
M<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$````
M`%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```%+
M`````%)G:'1L;VYG```"3@````-U<FQ415A4`````0```````&YU;&Q415A4
M`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!````
M```.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!````
M```):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L
M=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A
M=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90``
M``!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG
M``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO
M;F<``````#A"24T$*```````#`````(_\````````#A"24T$$0```````0$`
M.$))3004```````$`````CA"24T$#``````67@````$```"@````6@```>``
M`*C````60@`8``'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;
M`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01
M#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``
M$0@`6@"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,`
M`0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#
M`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$
M!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[KK?
M1NH9^;5=BY+\9C*75.-=]M1FRREK[V4U?J[KL;"^W?9GW,L_6;J?]&J].']=
MQ8#?G8[JV^F=C`&EQ92[U*W6NQK-OKY^QF1:VG^B?I<2K"N_0K==AXCG%SJ*
MRYQDDM!))^2;[#A?]QZO\QO]R2GFZL;Z_N9:UV72RVKV->\5EE@+O5W4M9C;
MV7,IM]!N5;^@]7&_Y+N]3[8CV]/^N-X%=N92&-<6[ZG&LO:YN35ZKZ_L[WLV
M;\.S[,S)_GO7_6_YE;OV'"_[CU?YC?[DOL.%_P!QZO\`,;_<DIP<WIGUGRNG
M4U66LMR1DNMN#<FS%8:_3LKIKKNZ?C4Y3,=F4^O)]!S[;]E?IVYN0ITX'UT8
M'-?U+'?#G,836-:VMW47&&?SUUK*:LJG=[&6YMM%W]$KQM&[#Q?MC6BFL`U_
MNB/I-7/X_P!9NC64T6Y/3[\7[2&.J!H]26VMMNIL_1_I??7BY'^!_P`#^B]:
MOT;+4I._"^O-%8ROM=5][:QZM+=0_P!,OO;6VI]=='Z7UKL2ST?L-M_I8%WV
MJGT;JGFJZ?\`70BLV]28S;MW-`J>X@[_`%?6?]AI;8YKO2?5Z%>)^BWX_P#.
M_KJJ_P#.+H9&X8KBTAKFN:RM[2'M:\.<^E]E;:]]E=/J,LN_[:]ZG3]8.@7Y
M%&-52779#]C6>FT1%M>*YUGNW5;7V[O2M95=^CL_1I*2.P/KR_&>+.H4"YS+
M`!4`QNY[+V#WNQK;/T%[<.S$V_0KMO\`M7VO[/7]H+E]"Z[;U&S,HZDZEK'4
MU8S&N<8I`8S-MN8_U,*S(>VW,LI8_!M_6:L&VS(]+]75NO&QO5O_`$+(#F1[
M1_HV+,R.L].QLZ_%NZ?8*:+F8[\QK&FH.=5]J>[\U^VJOZ?I>M_+V?X1*6LJ
M^OC+*:6WLL=87N=:T5^DPL#'?K#G8[;?LV0YKZJ,>FK[7C>KZMN=F_S=-E^!
M]<G9#V,ZC6S%'I-JLBLW.VM>V^VQOV/T&.NL?7;Z+/\`0^E593O]14\;ZR_5
MO*OHQZ:GFW)?776#1I-OK-87/!<WTVNQ;=]G_;?J,WK4Q?L>4RQ[<9K/2NMH
M<U[6SNI=Z3G^S<W99]-B2DG2,?ZPU9-AZID,OQS34*PW;(N#?UEWLQ\?V.?]
M%V[_`*Q4M99%.+C%KII8?TEOYH[66+)/7^EUWV5Y/3[:*:[;ZAE%C#6[[/9]
MEL?J:W['7[&;V^I4SU:OTO\`2/LR4]:DN-/UK^K9K<ZJESGM8ZP-LJ%38;37
MF_I+[3Z=.ZN]C/=_A/\`!K<IHQ;*Z[/L[6>HUK]CFM)&X!^UWIE]>YN[\Q^Q
M)3K)+#V8>/TT9-E#7-IQQ:\!HW$,K]5WTOSG;5F,^LG1FAOVW!MPGN],-;94
MUVXV/94T,V[;?;ZU5^RVFJW[._?Z?\Y6DIZ])<@SZR]`MP<O-QZ"]N%0W)L9
M96VF0]SJVU-MN/I>MNK_`,_]%7^E]7T]VO&Q196YM3.6N:=H!UAS?ZJ2G__0
M],-EQO-+;Z19&\5$$OV3&XM]7_I;5+;F_P"DJ_S'?^E5E=3Z5C9V8ZZ[*O9M
M#&MK8P@,]-XN_1VUUMMVVV,8Z[])^D]*C_04[*S?J]TQMH>VZYK0"!4RMS6!
MQC]-[&->Z_U&^OZKW^S(_2I)H=W<:[*<]S&W4E[(WM#3(G5NX>K[=REMS?\`
M25?YCO\`TJJG3*\7IN&W$K?;:UA<0^QECG'>YUON<YIW>YZM_;*/Y?\`VV__
M`,@DAJ9!N;EM%EM8<:C`%;W$@.;N]K+/S98EZMHXN;KK_,V_^E$KKP[/9;4_
M:64N:0ZJQTASF:^W9_HT3[5?_I&_]L6_^224P%MQXN:?^LV_^E$[K+P(=<T`
M^--VO_@B!DX].78VW(.ZRL0Q[:[V%NNZ:S78W8[^4H5X6/4US6O>0XL<18,F
MS6H^I3M]6QVS99[_`-&DI)7ZOJWS8W1S9_06_P"C9_+1=UX_PC1I_H+N/^W%
MG5]-PS98USK'-J+6M!.4?\&P;G_I?<_;[-_^C_1HO[/Q]I8;;2TV"UH_6?:Y
MHV-VN]3=L]SK=K_\+_Q=:2FZ7Y$&;1'?]#=_Z43'UN[VZ?\``7?^E%4KP,:I
M_J5OL#Y)DG*,DAU9W`V^YVU_TTSNFXCB)?9WD3E000?9_._0_/\`8DI/0;?3
M<2]H_26\T6_Z1_\`PB*'W3`M;(Y`IMG_`,^*AB]/Q&->6N?)?<#)RG?2=94Y
MVMOMM]-SF^K]-$^P8L1N>`2"=HR1.UK*6;]MGZ3974S;ZB2FX;;QS<T>$TW?
M^E$/U+=X&YGI@$OM-5@:S4-;NW6CZ7[W^#4<2IN&'>A:XE\;W6MR+2=HY_2V
M.:S^7Z:,<R_=L,.#FG](*K`&D$<M=OWN<UWL24MB8V7]EH/J5B*V?F.G1K?^
M&1A1FCBVL?V'_P#I=0P,C'JP<>MN_:VI@$L>=`T=]B/]LH_E_P#;;_\`R"2D
M?H9LSZM>G'L?_P"ETFXV2'M<ZRL@$$PQT\_\<43[91_+_P"VW_\`D$XRZ7$-
M&Z28'L>.?[*2G__1[SJ.=UJC/+<+%=D4-96"UP#6.+WCU;*\AA>]GV>D?S3Z
M?TOK>I_VG_3";U+ZR"WTW8#'M@O-H#F-[/;0UN^VQ]FW]!Z^VNOU?TWI^DK'
M5^I8G3'UF\Y+_5%EK_1]PJIJVG)R[1N;^KX_JU;_`$O4N_2?HJ;%!W6>B5AQ
MNSS46-]0M?9J:Y>T7MV[M].RE]^]O\WC_IKO38DG3L?M1G-^LEM--@Q118ZO
M(]6IH#]MC7;<5NZU]&[?5^D_,9ZG^$6GTXYAQ@_-TN<XG9#1M:#MKG9N;O>Q
MOJV^^S]+8_\`P:I-ZMT-SBT=1U%AJ/Z0B'-/INW?NU^JYE'J_P`U]H?7C_S]
MGIH1Z[T3]&69MKV7,;8U[2_:66"_T7M<0/5]9V'=7553ZE]GZ/\`1?I$D+]<
MR\O'S:!CV/K:^FPO+&!\EKZ=D[J[?S7V*@>J]4[9%VO_``3?_>=7<CJ_3,;,
MKKLMR!59578_-W1CULN-OV7UWN>W9Z[L>[;9Z6RO_#65>K5OF>N?5\4^N[J@
M;5K[C80!M]/?NGZ/I^M7ZO\`HO\`"?S5J2FA^U>J?]R+O+]$S_WG3?M7JG_<
MB[_MIO\`[SJ\WKG1-KR_-LK-;WL+'.=N)KL^SN]-K-WJ^[T[?T?O^SY&-?\`
MS614G/7?J\'6-_:@)J!+HM)X.SV?Z5SG^RMM?\Z_?Z?\VDISV=3ZB'/(R+MQ
M(-GZ-IU@`>W[/[?8$XZKU3_N1=_VTW_WG6E3U/HEN0VC'SW777V-K:*GNL#G
M.KLN9#JP^O9Z&+;^E_FOT?\`I%4P?K1T',]0MR[:PU[F5E[P1;MTW4>@Z[_@
M_P!!9Z>77Z^)ZV/7]LQ?62D'[5ZI_P!R+O+]$W_WG0K\[+MV'(OLBEV^MSFM
MKAX:YN]KVU5_18Y_M6LWK707/8QO4MS["P5M#R2XV%C:V,@>]^ZVOV-^A^>A
MNZM]6K[*6/Z@VQ^\.I!>3%F^S$:?Z_JMN9[_`-SU?\'ZB2G1Z2^^S":^]NRQ
MS["X01^>_4L.[9N_<5Q4,`X.9C-R<')?=CV%Q;8QY+7$N.]S2?S=ZL?91_I;
M?\\I*3I('V4?Z6W_`#RE]E'^EM_SRDI6%_0Z/^+9_P!2$=5V83&-:QMEH:T!
MK1O/`T3_`&4?Z6W_`#RDI.D@?91_I;?\\IQC`$'U+#!F"XQHDI__TO1,_IF)
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MQ7\@$Y8@?X(_]4U95_3NMNZB_*QNI>CCO],?9;*O4:UK`WU?3!.WU;W>I^D_
MUI2E[>@]'L?4YN$ZKTG!P%5@8'16[&VNVOW>^OT_6]/T[,C[-B_:/5JH8Q%L
MZ1T:RLTOZ:PUD$;-S0!+FW>QK7_H]MM;;*_3_FO\&JU>!]:1Z7J]5H(!9ZNW
M$`<6AC*[=F[<W?9=ZMW_`*C_`$2LX&)U6FRQ^=EMRF6-;MK;7L#'M#6O?6X-
M9^CM]S_2_P#4C[4IE3A]-KR1=3@"N['>2U[7-;!L%]SMNU_T?\H97]NW_BU!
M]?0W&OISJ*A9B8XKJQQ<QME5`=4^M]31:VVG;;C8KZ\AGZ1EM-%GJ?S:M5M=
MZU^A^DS_`,]UK&ZC30_.R3D=%LS0/2:VVH/-E@-5E?J-LBNAE=+;KL:NIN1Z
MM61^LW>AZE.2DILT=(Z+CYECO0#K+6EU>*ZRH,K8UGV>YV/CL+-C'U9NW)M_
MPGKT^J_^:1,+IW0JZ6?8L)AI8X['5V->W?78VQWN]1VY]65C>[_A:_\`C%CO
MJZ?CT6$_5O*:+&[;PTN,!FW):-S7[_3=DTU^E]GWV^IZF^FOU/2R=[I;(P:V
M,PW8#*W/KKQ7:EK&O<*S^[^E;^E]OJ?\8DI+T_[-A8WV?#Q352U]DMWM)+][
MO6L<]SW/>ZRW>_>]$OZQC8[V,R',H?8":VV6UM+@V-Y8U[_=MW*%+7;':'^=
MM_\`/EBPNJV779+Z<CH61E@$T"VFQ[:[*FO98UUK:W4LM_1W^IBMO_F<O[9^
MDI_GTE/2#/EVT5R[PWL^'[Z3,_U&-LKKWL>`YCVO86D'AS7!WN7'?9,!S74_
M\ULD5V>RXM=8&FO<_8W;+'/=Z>/39=]#^=_P]G\_T/2K7OI]$8%V!5C!E=#+
MH.Y@$-V:N?[-G^$]_P#-I*="O/=96RP4NA[0X2YDPX;OWD)W6<5M_P!F<ZMN
M1H?1-M8?#I+/T>_=[]KE'&:[[+1H?YJO_J6K(Z[A8_J!YZ39U(Y$VV,8^UK/
M4I:RIC[*Z]U#;G8A>QMKJ_5R&4?9/TOZ))3N.ZG6UCK'-:UC`7/>;*P&@;MS
MG.+_`*+=C_\`,1&Y3R\--)$D`^YNDG^LN0PNG]-RLBO#S/J[;BMM>;6.-EFP
M.K%OZ6Q@>W9['5U5_P#"W5T_0].Q=8T.-C20=7`G3S24_P#_T^]ZO7U)F159
MT_'JN8&O=;6]HE[SM])N_:=G\OW,_P!)^GV?9[*0M^L/N/[,H)V-VLV@-W[7
M%P-OJ;]CG[/?Z/Z%_P"K^ED5_KZL=<JZ?;FXXS;?L]Q8\4%MA;+6NKM<^P^A
M96STK646L]1_\XQ4\?#Z+579C_M'U6O%+W&S-+H#!8]KJW^GM9]H9ZMN3Z7O
MM_G4DZ>*<-ZR181CL!WV;`ZADEFPOH]-K+-G\^UE%GK7_I/4]3]76CTS$>[&
M;;FL`N>T;J7-KAA;+=P])C?=;].SWO\`^#6%]AZ$UEC'9-FSU'D!U]A:+*Q.
M4_':[']-UFUUMN595_I<C(_X1:W1L!N,TY6&XVTY#06,LL>`)+K'V[75-_2W
M;V[_`-&SV4U)*-*ZG?CX.75&*R[U:G\PT`,=7_(LW;O55;]KU?\`E=5_G#_T
MBKV7B-R\IGVFFM_IUG9^E>V-SF[M6,;^XQ1_8^%_W'K_`.W[/[DD-/\`:]7_
M`)75:_RA_P"D4OVO5$_LZKR]P_\`2*N?L?"U_5Z_^W[/_(I?L?"_[CU_]OV?
M^124T&=3J:^QQP*B'D'Z0TAK6;?YG^2I_M:G_P`KJO/W#_TBK%72<0V7--#"
M&.`:/7LTEC'>'\I$_8^%_P!QJ_\`M^S_`,BDIS[NJ%[`*,.FBS<TAYAX@$.>
MUS/2;_.-_1_26MT]V!G4>JS'8US3LL86@[7@`ENZ/=])5;^B4/9MI8W'>2T^
MHVU[C`(+VAKV[/>SV>[Z"OT-=CU-IIJJ96P0UHL/_I-)3'$Q,4U.)IK/Z6W\
MT?Z2SR1OL>)_H*_\T?W*I7F''8QMOIM-U]M=<O,%V^UVUQ]+V?1_S_T:N;LK
M_1L_SS_Z224M]CQ/]!7_`)H_N2^R8G^AK_S1_<GW97^CK_SS_P"DDMV5_HV?
MYY_]))*08>)BG#H)IK)]-GYH_='DC?8\3_0U_P":/[D+#=D_9*(K81Z;/SS^
MZ/\`@D;=E?Z.O_//_I))2WV3%B/1K@\^T?W)QBXH((I8"#((:)!'R2W97^C9
M_GG_`-))!V3(FM@'<AY.G_;:2G__U.]ZS4V^^NLX0S&N8YI.O<@.I]1H<RAN
MW^=?;_.U;Z/TG\VLI^/6VAV[H-[W$"L4ML<YA:YSF%KMWZ/T?\/D,_/O?Z_Z
M:W]:LWG_`$W?T7D_2YY_._E)O_81).KE['5WNI9TN^[UK;0Y[7N`:&L]%K[,
MC(_T]%C_`$OL[_2K];TOYWU[%K](V,Z;C@4.P]S`XXUAW/87?I'ML?+M]FYW
MO=]/]]0_]A$O_81)1MJ=;P+<[.H-+:GBJFP.%CH^F^G:6^RS_1.5$]`S/]%C
M?Y__`*@6SW_[2<)?^PB2''_8&9_H<;_/_P#4"7[`S/\`0XW^?_Z@6Q_[")?^
MPB2G%9T3*<Y[!3CS60#+QR0+/]#_`"TXZ!F=Z<;_`#__`%`MGQ_HB7_L(DIQ
MOV!F?Z+&_P`__P!0)?L#,G^9QO+W_P#J!;/_`+")?^PB2G"/3,EI8&T5'UGO
MI`80=6;]_K?HV[:?T3__`$GZBZ;$K=1C5TVW>L]@@V.Y/_G/T?=[_P#2*NWZ
M)_HORXY[IO\`V$24W]S?$);F^(5#_P!A$O\`V$24V,)S?L>/J/YIG_4A'W-\
M0J`X']$X2_\`81)3?W-\0EN;XA4/_81.WZ3?Z+R..>?S?Y22G__9.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V````
M`0`X0DE-!`8```````<`"`````$!`/_A$;)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL
M;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(B!X;6QN<SIP9&9X/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9G@O,2XS+R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X;7`Z0W)E871E1&%T
M93TB,C`Q-2TP-"TR,E0P,3HR,SHP,2TP-3HP,"(@>&UP.DUE=&%D871A1&%T
M93TB,C`Q-2TP-"TR,E0Q-CHP.#HR,"LP-3HS,"(@>&UP.D-R96%T;W)4;V]L
M/2)4;V]L:VET(&AT='`Z+R]W=W<N86-T:79E<&1F+F-O;2(@>&UP.DUO9&EF
M>41A=&4](C(P,34M,#0M,C)4,38Z,#@Z,C`K,#4Z,S`B('AM<$U-.D1O8W5M
M96YT240](GAM<"YD:60Z-4)%-C0P.$-"0T4X130Q,3E$,#$X-S1#03,Y1C-#
M14$B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z-4-%-C0P.$-"0T4X130Q
M,3E$,#$X-S1#03,Y1C-#14$B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB
M=75I9#HP.&)B-CDS9BTQ8SDY+30P-34M.&0Y-RTU-F0T,3`P,6(P.#<B(&1C
M.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&1F.E!R;V1U8V5R/2)4;V]L:VET(&AT
M='`Z+R]W=W<N86-T:79E<&1F+F-O;2(@<&1F>#I3;W5R8V5-;V1I9FEE9#TB
M1#HR,#$U,#0R,C`T-38U,2(@<&1F>#I#;VUP86YY/2)!;G-L;W<F86UP.TIA
M8VQI;B(@<&1F>#I$;V-)1#TB04-4259%+S@Q,C8X,C4W+C$P(B!P9&9X.D%0
M5$M615(](C4N-2XP+C$U,#(X(%!R;R!0<F]D=6-T:6]N+3,R(B!P:&]T;W-H
M;W`Z0V]L;W)-;V1E/2(S(CX@/'AM<$U-.G-U8FIE8W0^(#QR9&8Z4V5Q/B`\
M<F1F.FQI/C$Q/"]R9&8Z;&D^(#PO<F1F.E-E<3X@/"]X;7!-33IS=6)J96-T
M/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)C;VYV97)T960B('-T179T.G!A<F%M971E<G,](F9R;VT@87!P;&EC
M871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`B
M+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC
M94E$/2)X;7`N:6ED.C5"138T,#A#0D-%.$4T,3$Y1#`Q.#<T0T$S.48S0T5!
M(B!S=$5V=#IW:&5N/2(R,#$U+3`T+3(R5#$V.C`X.C(P*S`U.C,P(B!S=$5V
M=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S
M*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB
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M/2)X;7`N:6ED.C5#138T,#A#0D-%.$4T,3$Y1#`Q.#<T0T$S.48S0T5!(B!S
M=$5V=#IW:&5N/2(R,#$U+3`T+3(R5#$V.C`X.C(P*S`U.C,P(B!S=$5V=#IS
M;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@
M<W1%=G0Z8VAA;F=E9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R
M>3X@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI
M:60Z-4)%-C0P.$-"0T4X130Q,3E$,#$X-S1#03,Y1C-#14$B('-T4F5F.F1O
M8W5M96YT240](GAM<"YD:60Z-4)%-C0P.$-"0T4X130Q,3E$,#$X-S1#03,Y
M1C-#14$B('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HP.&)B-CDS
M9BTQ8SDY+30P-34M.&0Y-RTU-F0T,3`P,6(P.#<B+SX@/&1C.F-R96%T;W(^
M(#QR9&8Z4V5Q/B`\<F1F.FQI/FIW86YG/"]R9&8Z;&D^(#PO<F1F.E-E<3X@
M/"]D8SIC<F5A=&]R/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\
M+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@
M96YD/2)W(C\^_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!2P).`P$1``(1`0,1`?_=
M``0`2O_$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!
M````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042
M!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"
M\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA9
M6F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4
MU=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%
M,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F
M-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E
M]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FI
MN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=52_S1?D!_
M-$Z+P?3[_P`LKX:=?_+C<&X\KO#_`$NIV-O7!;/Q>P\'B:+!':KX[^+]I]7R
MY&OW%7Y"LUF.:K6"*A(9%,JM[]U[JB7^7]_.F_G\_P`P9M@=A=0_RU_BWFOC
M3EN[L;U3V!W91[VK\/C=K8_&;AP-#V/N#%XO<WR!Q^X=QTFT,'EWJ148[&Y"
M"HDA:*`3RH\0]U[JY/X8?S.M[?)CYJ?S0^J]Y;?ZIZ]^)?P*[,V3TKM+NJOR
M64V]F-U]G5,68HNQL/NK,[EW`NT_#M?/[>GB0TM-2:8ZNDNTIE#'W7NKG()X
M*J"&IIIHJBFJ(HYZ>H@D2:">"9!)%-#+&6CEBEC8,K*2&!N./?NO=);:6_\`
M8F_HLI/L7>VT=Z0X/)2X;-3;2W)AMQQ8?,0*&GQ64DP];6)C\E"K`O!*4E4'
ME??NO=0*GM3J^BJ=YT=9V1L*DJ^N:2ER'85+4[PV]!4[$H*VG-515N\X)<BD
MNUZ2KI5,D4E<($DC&I21S[]U[K/N+LOKC9^VZ+>6[>P-D[7VADDHI,=NK<6Z
M\%A-MY!,E"M1CGHLYDZ^FQE4F0@</`8Y6$J$%;@W]^Z]U+W%OO8^T-M'>F[-
MY;4VQLX1T,IW9N+<6(PNVA%E)(8L9*<[DJRFQ8CR,M1&L#>6TS2*$N6%_=>Z
MR4N]]EUVXWV?1;NVQ6;MCP]/N*3:U+G\54;C3;]6ZQTN=?"15;Y-</4R,%CJ
MC%X')`#$^_=>ZY;MWIL[8&$GW+OO=FVME;<I9:>"IS^[<[B]N82GGJY5@I(9
M\KF*JCH89:J=PD:M("[D`7)]^Z]U/GS^"I<%-NBIS6)I]LT^)DS\^XI\C1Q8
M*#!149R$N:FR\DRX^/$QT"F=JEI!"(1K+:>??NO=,$G977,.RAV5-O\`V5%U
MR:2*O&_Y-U8)-E&AGJTH(*P;J:O&"-)-72+"DGGT-*P0'40/?NO=$9^9_P#-
M&^*WPGRWQ^V9OS>>*W1V?\G^TMA=7]1=?[8W)M=*NI7?>2QM(O9.\,UE,O28
M?974FW:+*15=;G*J0QM"ZBFCJ&+:/=>ZS]J_(3Y<0_.OXI]*="]5])[Z^)G8
M&P-V[_\`DEW7G.TMGIV'L3'QX[.2]>_Z..N:3LO&;TW%BMRY3&4L#Y6+;F7Q
M/^Y!/\IA\4I'NO='KR.^=DX?<N$V9EMX[6Q>\-S0U51MO:F1W#B:'<NX(*)7
M>MGPF"J:N+*96&D1&,K012+&`2Q%O?NO=*GW[KW6J9\GOYQ7\VG</\Q#Y;?#
M3^5U\$.EOEEL_P"(T/6./[$W?O//Y':66PNYM\[/HLU64&4RNXNW>L=JSE,]
M]_1T=-2"6IEBQLTIU*&*>Z]T<O\`E@_S@.W?E%\D.U_@)\[_`(FY3X5_.[J3
M8>/[3&PH<\V[^O\`L_K65\+093=NRMQ0K64%,V-RN=IK4T.3S%-4TTS/3UTT
ME+6QT_NO=7=9K?\`L/;>?V]M3<6]MHX#=&[I98=J;;S6Y,-BL_N>:%D2:+;V
M'KJV#(YJ6)Y5#+31RE2P!^H]^Z]UDKM];(QFZL-L7);QVKC][[CI*JOV]LVN
MW#B*3=6>H:&.IFK:W#;>J*R/+Y2DHX:*9Y9((72-8G+$!6M[KW7LIOK9.#W)
MM[9V:WCM7#[NW<*UMJ;5RFX<1C]R;G&-@>IR)V]@ZNKAR>:%!31M)-]M%+XD
M4LU@"??NO=<:S?NQL=NS%["R&]-IT.^<W12Y+"[,K-QX>EW9E\=`*@SU^+V[
M/6)F*^BA%++KEBA=%\;W/I-O=>ZJF_G#?S&NT?Y?>QOBG0=!]?;*[2[U^5WR
MUZV^.6R-F;]BW/)@Y<5NN')_WAS<;;5R.+KUR>,KVQD$.N7P@5CR,K^/2?=>
MZM6W=V!L3KZEQM9O_>^T-DTN7KXL1BZO=VY,-MFERF6F1GBQF-FS5=1QUE?,
MB,R01L\I`-@;>_=>Z<]P;GVUM/!5VZ-T[AP>VMLXRG2KR6XMP9:@PV"Q]++)
M'%'4UV7R-138^DIY)9D57DD52S@`W(]^Z]TV4G8.PJ_+8+`T&]]H5N=W1MY-
MV[9PM)N7#5.6W%M215=-S8+'0UKUF7V\ZL"*VG22F((]?OW7NI5=O/9^+W+@
M]F9/=>VL=O#<\&0JMM;4KL[BZ3<NX:;$P/596IP>"J*J/*9:#&4L325#T\4B
MPQJ6<@`GW[KW392]G=;5VU<IOJB["V/6;(P<F0BS>\J7=F!J-JX>7$R>'*QY
M3<,60?$8^3&2^FH$LR&%N'L??NO=*O&Y+'9G'4&8P^0HLMB<K14N2Q>4QM5!
M78[)8ZN@CJJ*OH*ZEDEIJRBK*:59(I8V:.1&#*2"#[]U[I/;5[`V'OILTFR-
M[;1WB^V\E)AMQ)M7<F&W"V!R\1<2XK-+B*VL.+R49C8-!/XY05-UX/OW7NL,
MG9'7<.4W5A)M^[+BS6Q<;!F=[8B3=.#CRFSL14THK:;*[JH&KA5[>QM11,)D
MGJTAB>(ZPQ7GW[KW28[`[[Z6ZLZFS'>V_P#M'8^V>G<%MVLW77]C5VXL8VU'
MP-%CZG*25N-RM/43T^9:>BI)&IXJ,SS5173"CN0I]U[H!/@+\ZNH_P"8C\?,
M+\DNEX:_&;(W/F]U4>!P>Y<EMY]]P8+;^ZL[M7%9_>&V,#E<Q)LJ;=S[=J*Z
M@H*R4U)Q[Q2O8N43W7NJUOYQG\TKY>_#3OGX6_$WX!_'3K_Y1?)KY8)VUF$Z
MYWW-G:$4FV.N\=A*RCR&+RE#O#8V#QRU*OEYZRIR5>E/34V++'2&U#W7NBC=
M(_SNOYFW2_S#^*WQC_FX_P`NC87Q?VQ\T]_MU5TEVGUCV9C,]34N_'J<)A\?
MC\UBL?O[MC&Y6"NW+NC%44J')8BJIDR*3I%4JC+[]U[K9YJ>V.K*)MZI6=E[
M`I'ZVCHINQ4J=Y;=@;8,.2223'2[U67(H=K1U\<+M"U=X!*%)6X!]^Z]U(W'
MV9UQL[&87-[N[`V1M7#;DJ*2DV[E]Q[KP.#QF?JJ^#[JAIL+7Y.OI:7*U%;3
M?N1)`\C2)ZE!'/OW7NEJCI(BR1LKHZJZ.C!D=&`965E)#*P-P1P1[]U[I`U?
M;/5=!A=R[DKNR^OZ/;NS,M_`=X9^KWEMRGPNT\[YZ6E_@NY<K-DDH<%EONJZ
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M#K;!?!+^1U\8LMNNFAQ-+@/C9N'Y3=@R5&6@\6CL.CS_`'ODJFJRE0$HZ&.F
MVYFX8CJ_:I4A"LS!"Q]U[K5V^$GP&^+6^OY&GST_FU?.S9&X^Y=V]T97Y8?(
M+J+9>[NVM\879&S-S05^Y^MMH[JQ&!Q6=PV$K.U]X=L?<4CYK(09"JFHXJ&"
MF1-4J5'NO=8._P#L?Y2=/_R>/^$^OP*H<=\D=^;=^;]=E=]=U8/I'=[X/M;M
MGIF7=F'[`V3\9=B[\R^I<#/N787;=(4H9XWIH%QM-#:6DBD@?W7NC<?"+H'Y
M`=2?S;/AQW%\)OY0WRA_EG?%NHV=O_JSYKX;LO?U1E.JNP=FR;?S^3VIN_<2
M9+<N6\6:V;DDAJH:B:22:MR,%*B@$3//[KW3-_*?_EK]:?SF.Q?YHOS;^56Z
M>P,G\8OD#\[=Y4FR>D=@[_R.U,5V/)U7EJ_+[7S_`&3O';53#N+=^S=D;:WS
M2X[;V)CJ8<;!4/65-G=*1H?=>ZD_*O?'Q`^=7>_R<^2G3_\`*R^2O\R_X\?!
M78.Z_CIF<QV1\L>K_B[\"^C:?HG;4.=WA6?'[8E?/A]P553B=M8Z.:>:GFEF
MGHJN.>.AC\M%(?=>ZK>S$?8,?_":'^7K\8^R.Q*O!T7\PC^9OB-O]?KOG++E
M(.H?C51[NSF.B7;LU971/!M+;V_=O4>:_P`KD5(X\Q*+1I)$4]U[JSO^<-_+
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MED,@P6[RHWNO=64?ST>N=H_'W^59_+&_DR]>9+#8[L+Y)=W_`!,^.-%MF@RD
MU'/E,%LJOP3]@;_R&(IY*JOKL-7=PY/#5%6Y;2*_(K(I9X[#W7NDM\EOY>WP
MZ^:'_"E;I[XWY'X^;>W#TU\:?@+C.P/DYAHAF,;C=Y9>EVRW4_1NVMT5]!G:
M.J7#;)VA5;-?&P8\4;&2E82F:-IA[]U[I/[3[DH]B_S(_P#A0?\`S'>L]DX?
M)X+^5]\+MJ_$CXY8+%`;AP^T]S;2V,]))1X+#44BXO%;1V]NOJNL.5IH@!04
M,]0I*EI[^Z]TU?'/^4__`"^?D%_*'ZB^;/SZ^1^5ZV^9GS&K=H=J9#^8WVSW
M+EJ+L3879V[NP#EMD[0Z^JMP[SP6SJ*(;8P;8J.BD1Y=4]74(T?AIDI/=>ZW
M/NO\:>M>HMF8C=O8V4W[_<+KS`T&X^V=[38ZFS6[X]L;=I8,IO\`W=544-'B
MHLGG(Z)\A7RQ1Q0"61V"JO`]U[K6F_X3$R1=@=5?S&OYAF\Z_'8^M^<7SV[>
MWWC<OF-S1UM9%UAL*LKY]LT.4K:N9*:CH=LYG?6;I:8`A$HXT(TQ>)1[KW16
M,=W]B?EG_P`*`_F!_,-^+=+E^WNC/Y5O\M/LCKS*[VV/41938_='>F*Q?9^?
MQ'6>ULE1S^#=5'FZC=><CHI:60TM54[8-3#,T$M+)/[KW5(?0G6'8OSO^#'<
M/R"[4_E+?.CYW?./Y7Q]O;GZV_F+8WM*:/9O7^^,)NK=6$ZL'4.WZ;-X^#:^
MP>J=Z88I7XF*F)J9*>JHHGCHUHX:7W7NK?\`NC*]U?&O<O\`PF%^?G\P8UO5
MG</4M?VO\9OE=G^UJVF@RV#V_NK8>9VYMW??:.^I)JCQ9V/8E)D,U74M4\E3
M/6U]2MQ/YM7NO="7UGV+VOW/UI_,D_X4Q;WZ\FRVX-B=`]Q];_RC^O-R8"'*
MU'3G0G75-NW`S_(*KV_EHZB/'9G?>XZ^KR.3F7QU,6'3.0H\F-R%./?NO=4>
M[-^-W;GR-_EVT/8>U/Y1W\PWO+^8KW1287OG:'\U2N[?R>2SE7OK)[OQ>ZL9
MNO9,])N>DKZ?9"[.I6H:&D,+57DG:H#K4E)H_=>ZO?[`R/;WR^_G)_\`"?SX
M\_(BBDQ7:_Q2^$K?.+Y4;)KL\F3DVYWUFMCX^DCQV<Q^&G:@AWIMOL[KW&57
ME=C&(<@?$S1M:7W7ND3_`"J?B9\=_P"=MO+^8I_,!_F=;;R/>V9P'RT[1^._
M4G37:&]]W[=V=\7.F>OL)M;<L&,Q.T]O[IP5-M/,2T&XZ>DK*R1M2S8>HJ1)
M]S4ULLGNO=5&9?Y(]BX?_A.-\\.FF[#;<7QEW?\`S2*#XC?"W>?9NXJS<>6;
MHVBW=@.W*S#X+-9/Q-7;1VY0[)3(4U:-<<<E5DT41K!'''[KW1__`.=1_*T^
M('\LSX3?"/M3X<4F7P_\Q3#?);XR==]+=[Q=G[]SG:W=>[,=@)Z.JJY,77[J
MR]!68#RX3'204V,HZ>AQ$)I*&F$--,E/+[KW1C^X_C%MC^;!_P`*5L_UYWID
M*O)=,_R[O@UL'&=J[9V'V#N+;6,WEV+V;15N5R^Q6RVT\CC-Q8S:^=C[GJZ;
M.TB5E+/7X[#&AJV:"HDA/NO=5U_`KX=?"S>WP]_GM_-#M'8F<S/P&Z7[Z^1%
M3\4?B=3=S;UHNBX-Y=-[+S5;M7L`XK%[BQ\>[-^U.,W?M_`;;R-=5U<-/#D*
MJ)8IW>&2/W7NDGV%OOY/_'7^0Q_(T^&6ST[XW'1?S".[]V9;M.@Z+W2,!V7N
MWI?-=J1;NV=\:^O-ZY(/%M?-=N;6[,H):2%HGI7GQT]/,):(SP5'NO='`^)'
MQS[_`.J?YIWP#[;^`W\G'Y:?RV^C<:=T=0_-B/L/L.JSG6_:W4^:H8%V_N#=
M]-D-Q9;S9G8)^_R9JJF2:HR>53'*@$T`>7W7NIO\N'X:?&?^93W_`/SM?YH'
MS.H,]V-\6V^379.R]H]757:.X\)U=N[;GQZQLF\7WOO]]JYK;R;PH]C[(;`+
MMP5-8</CS-5R&&1XJ:6#W7NB18?"[)H/^$B>\\YO;JRESC=U?.+==;\*=IY?
M+[BW35;)S^[.UAU;A:W&+59&BCI,[MS:N!WM24(C#4<CNM8T+U%1+J]U[K=W
M_EC?R]^A?Y=/Q<Z\ZFZ=ZPPVP=W9C876%;WOGZ1ZFKS_`&3VW@-@8/;^YMW[
MIR%36UT;Y&NRM+4S?;TAAQU/+42_;0QJ[`^Z]UJ\?-3$?S%?F5_PHU[CS_\`
M+!WMT5MWM7^7/\5NN.L9=S]]Y*3,;#P4W;F+S6<WB-LX:#9^^:2EWI6)VC5X
MFKUTD<B18^8/+<1Q^_=>ZLH^-/\`*?\`YA_:_P`O^@?GE_.>^8O4_<>2^'V*
MW%N/H+HCH_;D>V>K=B;\S4:G)[]W7FI]I[$H:J?$4^-I:TR1T,D]154-&9*R
M.FH?MY_=>ZJW_DY_RQ>L/YOU3_,.^='R^W%OO<?Q]^2WSXWYNO9'0VTMYUVU
M-O[[JNN-T9;/;>W-VKN+;<E-F]];9V=0[[DPNW,,:F+&8[_<C4)&TE1`T'NO
M="U_*9^'GQH_G0;B_F"_.K^9'LMNWVV5\INQ/C%T=T'OO=6YMF==?$GHCJW;
M>T<SB=N[8V)M3<NW<;LBL@PN=I,?45'I\4F%GJ%?[FIK99/=>ZK!VW\V?DQT
ME_(0^5'7?3G;V_Z7H_L;^;1F?@E\/>[*C<66S.\=E_&'<>*K=\[JI<3O*I:D
MGI-D5.$P!Q])DH)#+]SG\E!`:<Q1F#W7NC1?SM_Y2GQ+^(N#_EK_``R^$\>Y
M.NNS/G)\A.M/CAWYMZ+MO>LLGRDV#@-R;+R=-V/W1M;(9S)8+(9W:':-;2Y&
MER])14:X^HRU3%"GA\44'NO=&H[R^*M'_,J_X4B;AZ!P/8.Y.K/CK_+M^!.S
M.K-\S=5;@@QF[9,5V)B:Y,AUAL+=%,M37]8Y3=VWNWVPF;R-%X\J,!C*VB26
M)JI'B]U[I2_-_J+X&[8WU\;OY'OQ1^%'RX^9.3^)>)J_E#O?X?\`2/R#V;T9
MT3FL7NO*XO)4N7^8':?950N2WUDZROW91U=.K5=)]I!F:>&.J45*TH]U[HB'
M\M#LW._%Z@_X4F?*79/3=5\*/CQ\?^IUZAVQ\/-L=X4':77VQ/E%@]J[EV54
MM@NS*3)9#&Y?>./WOA0YK<6YI'EW9]K3-*E/2JGNO=$T[W_EE]$?'S_A/-\#
M=^97;-9N_P"?7SF[SZ:_T%;NW%V7O&"#J7'=^YINP<;C>N-EQ9B+:V#PM?UW
MMC#19V=,9-7/F,T\\D[+%21P^Z]U;O\`(7X&=*='_P`]+^21TATE_>O='RL5
M-Y?)SYA_*#?O;6[MV]O]Y8'K?;%-3TV6[&J,SF:Z.`[B'6&=IX::DI<?CI:6
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MX<5MG<U9/LG<-%NC#41R69V]NB@.-;,XV"6:-J1F8Q*59&`/OW7NA![F^+G6
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M4S&`HY5008V-(XD3W7NJXOE[_*VP^X_G9_(V_EFX'ISL_MO^7=\4^M/D+O;L
MS>/9&R\QO/:,U-EL9G:K$[,[+[2P&W]O;-I,YFZW9E/245,OV%5":Z"2)"[1
MGW[KW5QWQ2_D@?"#XF?("C^4&#_TY]W=V;6QV5V_U-O+Y.]U;K[QJNBMH9:*
M>F?:/4,.YRL6W<90T%744M+550K\O!35=1&*S343!_=>ZS?+#^29\-?ECWKE
M/DQ69GY#_'GO/=M!@,+VAV)\3^\MT=%9?N/`;9A2DQ.'[1I\%'68S<BPX^&&
ME:M2"GRC4U-!%]UH@B">Z]T]]O?R6/@-W1\(L+\`MT]?[UINC-K;P3LK9^4H
M^T=[9;M/:O:6C+Q5'9.+[%WIE=V9BKW171;AR"3I7BMQTD=9(GVH0(J>Z]T$
MVP?Y`'P'Z\[O^*OR0QT_R"W+W?\`$_-9+<.WNR>R>[,[V?NKM/+55#14.'?M
M_,;^H=PUV4QNR_L_-A,=@I-O8W'3SS.E.?,X/NO="?V3_)A^(/8GSUP_\QNE
MSGR"ZR^0J9C86:W_``=2]U;@V3U[W7/UHVVQM+']N[5@IZNHW#MVFI]G8J"J
MQ='68[&Y&&AC6K@GU2%_=>Z&?XC_`,M3XV?#G;?RHVKL6#=_8.)^9?<O8O=O
M?,?<>1V[O'^].X>TZ$X_=VW/!CMK;<H&V/5TL]2JX^IAJ6M63AY762P]U[HD
M?6?_``G+_EJ];=H[4WX^"[T[(V)UINS^_73?QD[=[VWIV#\7>F=UBJGKERVP
MNI<O+X)=-9522?;YFLR](S.=41X`]U[JZ#M3KO#]N=7]C=3[@KLUBMO]G;#W
M=UYG,EMJLAQNXL=AMZ;?R&V\G6X#(5%)708_,TM#DG>EF>"98IU5BC`:3[KW
M6LE@?^$>/\IG#UM#+6[E^86Y,322M)4;8S7=^V:;!91)%(DIZ\;:ZMV]EXX9
M&LS&FJZ>0E1ZK7!]U[K8(^)OPN^,7P<Z7QWQ_P#B]U%MKJWJZBDGJZW"XU*K
M)U^Z,Q64E/0Y'<6]=P9NHR.>WCN')TE)%%/69&HJ)FAC2(%88XXU]U[JL"3_
M`(3F_P`NJ#>^9R^VZKY2;`Z@W%G\CNC/?$KK;Y1=I;`^*^2SV6RJYC)5J=:;
M5RF,R>(I:FJ14%!C\M1XV&!5CBIXT1`ONO='6^?G\LGXS?S'_C?LWXK]^IO_
M`!/5&P]];)W]MR#K7=--MS/T^1V%@,[M?#8J?-9K#;H>HPD^!W'4T]2C1_<R
M75UF25`_OW7NCC87J+K#;W4^-Z)Q&P]KTO3>)V!3]5T/6C8FEJMG1]<4NWUV
MK%LJ;"5B5%'5[>;;B_924TRR)+3DHX8$W]U[JFC9?_"=7^7GL3>-!D\)EOEH
M>I<%N*EW7M7XKS?+3N.#XS[1SU%FWW'35>#V#B\]C<V::/,OYC25>7JZ-R-+
M1,C.K>Z]T?38W\O?HK87SV[E_F-8W(]A9/Y`]V]2;9Z4W#1YW<&(KNOMN['V
MM_=,TD.R]O0[<I,MALA7R;-HWJI9LC5)([3%43RM[]U[HD7??_">[^7OWUW#
MV;W"_P#LPW3$W?.4K,S\C.M?CSWUN[J3I_Y#9+(PU463JNUM@X19:+(295\A
M535AQTF,^\JJRIGG\DM1,[^Z]T0#^;7\`-K[Q[D_D6?RW_C]\6<I3?!G8_R@
MW!VIWAM_9'5.Z=Q].[.V%UX-M5D&"[)WA2Q5>,Q0[3H,_NNFR%1F*W[_`"U3
M625,D\M0S&3W7NK*_C[_`"&_@!\>/D)M'Y(XC$]U=I;OZEGE?XZ;5[[[NWMW
M!UM\8:1HJ>&CQO1>T=UU51'M^CPL5)%_#6R4^6J,;)#%+32Q30PR1^Z]T9GH
M?^6[T'\=>X_G'WUL#.=HS=F_/[<-!N+N;/;AW1A\C)MN?$T.[*#$X_JS[7:^
M.FVMB\9'O"H:&.JDR3AX*;4[+"J^_=>Z`';/\DWX@[/_`)9^ZOY4^W-P=X8K
MXV[VRU=F=S[BI=Z;7B[@RU7D.Q,7V55"IW<FPUP#PR9?"TM(5.'.K&0+`Q;E
MS[KW1A>^OY9WQ"^3'Q/ZQ^&G<?7U;N7J+I;$];T/4M?19_([9[$ZXRO4^!I=
MM;)WALS?>V7Q&8V]NW'X>E,,M32F..JBFFBEB>&5XS[KW01_$K^3]\9/B!N/
M<?8>UNQ/E9V]W%N#9.?ZZB[G^1/R1W]VUOS;>SMQF1Z[$;5H\C/0;!PYCF,<
MD-0,(]4CP(?(;R"3W7NG?HK^4M\8_CI_+R[#_EH]9Y[N#']"=G[<[:VQNS<]
M9N[;\O;M30=TQY"EWI/!NRCV;08.*N?%Y%J*F=L2ZQTB(CK(06/NO=([M?\`
MDG_![NCX#](?RZM]8CLJHZ3^.3X')=.[KP^^O[O]M;/W9M^FSM)3;Y@W/A\/
M28"OW/60;GR(J34XB:AE>L=_MED$;)[KW1[/BU\<=I_$SHO9'0FR]X]K=A8+
M8\67$>]^[^P<OVCVGN>MSF<R6X,EE-W;VS0CJLK6/791TA2.*"EI*5(J>"**
M&)$'NO=`S\6?Y>O1'Q$[T^8OR*ZTK^P<SV7\X.R\9VAW'7[[S^(SE%C\KAI]
MT5&+P6Q(,?MS"56`VK1/NZJ"4M1/72:%B4RD1*/?NO=&V['V/C.SNO=^=;9N
MNR^,PW86S-T;'RV2V_618_/X_&;LP==@:^NPE?-35D-#EZ2EKWDIIGAE6*95
M8HP&D^Z]T7SX,_"SIG^7O\8NN?B9T%_>F7K+K)MTS8:OWQE:#.[QRM;O'=^=
MWKFLAN',8S#X"AKZR3+;@F2,QT<"14L<406T8)]U[JO#OO\`X3W?R]^^NX>S
MNX7'R%Z9G[ZRE9F?D9UM\>>^MW=2=/\`R&R61AJHLG4]K[!P8EHLC)E9,A53
MUAQTF,-955E3//Y):B9W]U[H*_YK?Q=V-U%\#>G?AWTO_*MJOE]\#*/-5V"[
M:Z4^.>]Z[8W?O1./QHCW#LKNGHW#K1Y#(=D;SH-Q5&7JLJ*FN^_RN0J(DK7J
M*?(9"6/W7NJA/Y:_\N>H[^_FC_$7Y:]>_$+Y]?'CXH?"OJ3=E3D.U/YFV=S4
MWR=^07=61BW5M;9&`H]K[DW1NBGP?7_7-+E(JS&PX*DQ6)I9*.ID*I45L?E]
MU[K:M^,O\O;HCXI?(;YB_)WKJN[`S':GS@WSMS??<%;OC<&*SF,Q=7M0;E&%
MP6P*6AV]AJK;^VJ9=TS@T]145\K+%`IEM"H]^Z]T`?RN_DO_``O^7WR=V]\O
M-^'O#KSNN@VI1;`WMG^@N[MZ=*#N3K_'2QR46RNU:G9%5C\[E</%%%'`TN-K
ML57S4T,$,M2\5-3+#[KW0$[4_P"$\GP1V+\-?D_\$MG[G^1V`Z$^6?:^U^W>
MR*.D[+VU-NG%9?9^=V]N#![<VCN"OZ]J_M=I0UFU:!9(<E!E*R:.`:ZDN2Y]
MU[HXO>_\L'XU_(C/_`_-;\J>Q*:B_EV[SV[OKH7:FW=PX6@VGDLWM*AVAC]N
M+V/BZ[;&3EW+0XB#9-'X8Z:;',-4PU%)2OOW7NE13_R\NB(OYA%=_,MJ<EV)
MDOD+4]#1_'6@Q>2W!AZCK/;VPDRU-F9*G;^VUVW'FZ'<=15Q3"2H;*20E*RH
M`A!DN/=>Z(?V1_PG9_E^;W[(WUO[9N<^5/QWPO;.Y,UNSN+IWXV_)7?75'27
M:V;W'`*?/3[LV!0&O@I*;*QM():?$3XN#3,Z*@CTHONO=6]]`=`]/?%OIW8?
M0706P\+UGU'UIAA@MF;,P*3_`&.+HGJJBOK)I:FLGJLCD\KELI63UE=6U4TU
M775D\L\\DDLCN?=>Z&'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]+>SW[W
M!U)U6*`]G]I===<#*LR8L[]WOMG9XR3HLC.M!_>')X[[QD6)B1'J("G^A]^Z
M]T'7^S?_`!+_`.\HOCK_`.CLZT_^R;W[KW7O]F_^)?\`WE%\=?\`T=G6G_V3
M>_=>Z]_LW_Q+_P"\HOCK_P"CLZT_^R;W[KW7O]F_^)?_`'E%\=?_`$=G6G_V
M3>_=>Z]_LW_Q+_[RB^.O_H[.M/\`[)O?NO=>_P!F_P#B7_WE%\=?_1V=:?\`
MV3>_=>Z]_LW_`,2_^\HOCK_Z.SK3_P"R;W[KW7O]F_\`B7_WE%\=?_1V=:?_
M`&3>_=>Z]_LW_P`2_P#O*+XZ_P#H[.M/_LF]^Z]U[_9O_B7_`-Y1?'7_`-'9
MUI_]DWOW7NO?[-_\2_\`O*+XZ_\`H[.M/_LF]^Z]U[_9O_B7_P!Y1?'7_P!'
M9UI_]DWOW7NO?[-_\2_^\HOCK_Z.SK3_`.R;W[KW7O\`9O\`XE_]Y1?'7_T=
MG6G_`-DWOW7NO?[-_P#$O_O*+XZ_^CLZT_\`LF]^Z]U$E^9WP^AK*3'S?*WX
MVQ5U?#5U%%1R=Y=8I45<%"(C6RT\3;G#S)2B93(5!TAKGW[KW4G_`&<+XD?]
MY2_'/_T=W6?_`-D_OW7NO?[.%\2/^\I?CG_Z.[K/_P"R?W[KW7O]G"^)'_>4
MOQS_`/1W=9__`&3^_=>Z]_LX7Q(_[RE^.?\`Z.[K/_[)_?NO=>_V<+XD?]Y2
M_'/_`-'=UG_]D_OW7NO?[.%\2/\`O*7XY_\`H[NL_P#[)_?NO=>_V<+XD?\`
M>4OQS_\`1W=9_P#V3^_=>Z]_LX7Q(_[RE^.?_H[NL_\`[)_?NO=>_P!G"^)'
M_>4OQS_]'=UG_P#9/[]U[KW^SA?$C_O*7XY_^CNZS_\`LG]^Z]U[_9POB1_W
ME+\<_P#T=W6?_P!D_OW7NO?[.%\2/^\I?CG_`.CNZS_^R?W[KW7O]G"^)'_>
M4OQS_P#1W=9__9/[]U[J+5_-#X>4"02UORN^-E)'4UU%C*=Y^\NL8EGR&2G6
MEH**$MN@>2JK*APD:"[.WT'OW7NI7^SA?$C_`+RD^.?_`*.[K/\`^R?W[KW7
MO]G"^)'_`'E+\<__`$=W6?\`]D_OW7NO?[.%\2/^\I?CG_Z.[K/_`.R?W[KW
M7O\`9POB1_WE+\<__1W=9_\`V3^_=>Z]_LX7Q(_[RE^.?_H[NL__`+)_?NO=
M>_V<+XD?]Y2_'/\`]'=UG_\`9/[]U[KW^SA?$C_O*7XY_P#H[NL__LG]^Z]U
M[_9POB1_WE+\<_\`T=W6?_V3^_=>Z]_LX7Q(_P"\I?CG_P"CNZS_`/LG]^Z]
MU[_9POB1_P!Y2_'/_P!'=UG_`/9/[]U[KW^SA?$C_O*7XY_^CNZS_P#LG]^Z
M]U[_`&<+XD?]Y2_'/_T=W6?_`-D_OW7NO?[.%\2/^\I?CG_Z.[K/_P"R?W[K
MW6&I^9?Q!HZ:HK*KY5?&^GI:2":JJJB;O#K*.&GIJ>-I9YYI&W.%CBBC4LS'
M@`7]^Z]USB^8_P`1)XH9X?E1\<98:B**>"6/O#K)HYH)D66&:-QN<J\<L;!E
M8<$&X]^Z]US_`-G"^)'_`'E+\<__`$=W6?\`]D_OW7NO?[.%\2/^\I?CG_Z.
M[K/_`.R?W[KW7O\`9POB1_WE+\<__1W=9_\`V3^_=>Z]_LX7Q(_[RE^.?_H[
MNL__`+)_?NO=>_V<+XD?]Y2_'/\`]'=UG_\`9/[]U[KW^SA?$C_O*7XY_P#H
M[NL__LG]^Z]U[_9POB1_WE+\<_\`T=W6?_V3^_=>Z]_LX7Q(_P"\I?CG_P"C
MNZS_`/LG]^Z]U[_9POB1_P!Y2_'/_P!'=UG_`/9/[]U[KW^SA?$C_O*7XY_^
MCNZS_P#LG]^Z]U[_`&<+XD?]Y2_'/_T=W6?_`-D_OW7NO?[.%\2/^\I?CG_Z
M.[K/_P"R?W[KW78^8/Q))`'RD^.A)-@!W=UH22?H`/[S<D^_=>ZAT7S0^'F1
M@^ZH/E=\;*RF^XK*7STW>76,T7W./JYJ"M@$B;H*F2EK*:2)Q?TNA!Y'OW7N
MI?\`LX7Q(_[RE^.?_H[NL_\`[)_?NO=>_P!G"^)'_>4OQS_]'=UG_P#9/[]U
M[KW^SA?$C_O*7XY_^CNZS_\`LG]^Z]U[_9POB1_WE+\<_P#T=W6?_P!D_OW7
MNO?[.%\2/^\I?CG_`.CNZS_^R?W[KW7O]G"^)'_>4OQS_P#1W=9__9/[]U[K
MW^SA?$C_`+RE^.?_`*.[K/\`^R?W[KW7O]G"^)'_`'E+\<__`$=W6?\`]D_O
MW7NO?[.%\2/^\I?CG_Z.[K/_`.R?W[KW7O\`9POB1_WE+\<__1W=9_\`V3^_
M=>Z]_LX7Q(_[RE^.?_H[NL__`+)_?NO=>_V<+XD?]Y2_'/\`]'=UG_\`9/[]
MU[KW^SA?$C_O*7XY_P#H[NL__LG]^Z]TLZ3OOHNOV5E>RJ'NGJ:MZYP53346
M;W_2=C;/J=E8>LK*^GQ5'297=4.8?!8^IJLI5Q4T<<TZ,]1*D:@NP!]U[K__
MT]]#<6R-E[P^W_O;M#:^Z/LR32?WBP&*S?VI8,":?^)TE3X"0YOIM]3_`%]^
MZ]TF?]"?3/\`SZ/K'_T`MJ__`%I]^Z]U[_0GTS_SZ/K'_P!`+:O_`-:??NO=
M>_T)],_\^CZQ_P#0"VK_`/6GW[KW7O\`0GTS_P`^CZQ_]`+:O_UI]^Z]U[_0
MGTS_`,^CZQ_]`+:O_P!:??NO=>_T)],_\^CZQ_\`0"VK_P#6GW[KW7O]"?3/
M_/H^L?\`T`MJ_P#UI]^Z]U[_`$)],_\`/H^L?_0"VK_]:??NO=>_T)],_P#/
MH^L?_0"VK_\`6GW[KW7O]"?3/_/H^L?_`$`MJ_\`UI]^Z]U[_0GTS_SZ/K'_
M`-`+:O\`]:??NO=>_P!"?3/_`#Z/K'_T`MJ__6GW[KW7O]"?3/\`SZ/K'_T`
MMJ__`%I]^Z]U[_0GTS_SZ/K'_P!`+:O_`-:??NO=>_T)],_\^CZQ_P#0"VK_
M`/6GW[KW1#OD'U+U-1_,/X>4U/U5UBM/4]=?+B6HIWZ]V?-!/)1[8ZPEI6EB
MGPTD<GAD8D`@CU$?0D'W7NA:_P!&/5/_`#Z'I[_T4W77_P!C/OW7NO?Z,>J?
M^?0]/?\`HINNO_L9]^Z]U[_1CU3_`,^AZ>_]%-UU_P#8S[]U[KW^C'JG_GT/
M3W_HINNO_L9]^Z]U[_1CU3_SZ'I[_P!%-UU_]C/OW7NO?Z,>J?\`GT/3W_HI
MNNO_`+&??NO=>_T8]4_\^AZ>_P#13==?_8S[]U[KW^C'JG_GT/3W_HINNO\`
M[&??NO=>_P!&/5/_`#Z'I[_T4W77_P!C/OW7NO?Z,>J?^?0]/?\`HINNO_L9
M]^Z]U[_1CU3_`,^AZ>_]%-UU_P#8S[]U[KW^C'JG_GT/3W_HINNO_L9]^Z]U
M[_1CU3_SZ'I[_P!%-UU_]C/OW7NBJ_+[K'JU=F]"O%U3U53-)\Y?A=12M1]9
M[%HFEI*SNG$I54\II,!"9(JB-`K!K@H2OT9@?=>Z-8W6/5.IO^,0]/?J/_-)
MNNOZ_P#AL^_=>ZX_Z,>J?^?0]/?^BFZZ_P#L9]^Z]U[_`$8]4_\`/H>GO_13
M==?_`&,^_=>Z]_HQZI_Y]#T]_P"BFZZ_^QGW[KW7O]&/5/\`SZ'I[_T4W77_
M`-C/OW7NO?Z,>J?^?0]/?^BFZZ_^QGW[KW7O]&/5/_/H>GO_`$4W77_V,^_=
M>Z]_HQZI_P"?0]/?^BFZZ_\`L9]^Z]U[_1CU3_SZ'I[_`-%-UU_]C/OW7NO?
MZ,>J?^?0]/?^BFZZ_P#L9]^Z]U[_`$8]4_\`/H>GO_13==?_`&,^_=>Z]_HQ
MZI_Y]#T]_P"BFZZ_^QGW[KW7O]&/5/\`SZ'I[_T4W77_`-C/OW7N@6^2G6?5
MD?QL^14L74O4D$L/1/;4L,U/U7U]3S12IL7.%)(IH=N)+'(C<JRD%2`1R/?N
MO=*SJ?K#JK_1'U`S=2=1R/)U'U?-))/U7U_/+)+-L3`2RN\LVW))'9I')Y/'
MXX]^Z]TO?]&/5/\`SZ'I[_T4W77_`-C/OW7NO?Z,>J?^?0]/?^BFZZ_^QGW[
MKW7O]&/5/_/H>GO_`$4W77_V,^_=>Z]_HQZI_P"?0]/?^BFZZ_\`L9]^Z]U[
M_1CU3_SZ'I[_`-%-UU_]C/OW7NO?Z,>J?^?0]/?^BFZZ_P#L9]^Z]U[_`$8]
M4_\`/H>GO_13==?_`&,^_=>Z]_HQZI_Y]#T]_P"BFZZ_^QGW[KW7O]&/5/\`
MSZ'I[_T4W77_`-C/OW7NO?Z,>J?^?0]/?^BFZZ_^QGW[KW7O]&/5/_/H>GO_
M`$4W77_V,^_=>Z]_HQZI_P"?0]/?^BFZZ_\`L9]^Z]U+H.KNJ'KJ)&ZAZ?TO
M5TRMIZHZ\1K-,@-G3;2NIL?J""/Q[]U[HH?PDZVZOG^/PEJ.J.IJF4][_+B,
MRU75VP*F7QP_*WN6*"(23[=D<100JL<:WTI&JHH"JH'NO=&Q_P!&/5/_`#Z'
MI[_T4W77_P!C/OW7NO?Z,>J?^?0]/?\`HINNO_L9]^Z]U[_1CU3_`,^AZ>_]
M%-UU_P#8S[]U[KW^C'JG_GT/3W_HINNO_L9]^Z]U[_1CU3_SZ'I[_P!%-UU_
M]C/OW7NO?Z,>J?\`GT/3W_HINNO_`+&??NO=>_T8]4_\^AZ>_P#13==?_8S[
M]U[KW^C'JG_GT/3W_HINNO\`[&??NO=>_P!&/5/_`#Z'I[_T4W77_P!C/OW7
MNO?Z,>J?^?0]/?\`HINNO_L9]^Z]U[_1CU3_`,^AZ>_]%-UU_P#8S[]U[KW^
MC'JG_GT/3W_HINNO_L9]^Z]U[_1CU3_SZ'I[_P!%-UU_]C/OW7NA9H-F;'@Z
M@S>#@V'L*#`5N3IWKMMP;'VI#MFND@S>.J()J[;D6'3!UDT-2BRH\M.SK*JN
M"'52/=>Z_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T0#Y&_]EE?#;_Q&WS!
M_P#>4ZN]^Z]T)_OW7NBO?)GYM?$7X84^S*OY8?(/8'0D'8SYR/8;[Z.?ONMM
ML_PW^\7\*3`8/-R%<+_&:03M*(P#4Q@7OPQ]3!]5]%XH^K\,2:?/06*AO2A9
M6`S6JG%!T\+>8VQNQ&?IA)X9;RUZ=6G[=-#]AZQ_&CYQ?#GYFC=:_%'Y*=6=
M]5>Q$H)MYXK8V6K_`..[<H\J[Q8S)Y#;^>QF$S;8>MJ(VB2LBIY*43*8VD5[
M*5OT\_T_U?@L;77HU#(#4J%-/A)'PZJ!J$*25("3QX?'%L9`+@H7"G!*@T)7
M^(*2-5*E=2DT!!)IRCK:Z,+G2+J1=O\`4BX^O^'MGIWKS*R&S*RGZV8$&W];
M&WOW7NLD=/4321110R/+.ZQPH%L9'<@*JEM*DL3_`%]Z8A5=F-%4$GY`"I/Y
M`5Z]Z=$ZF_F"_!NGZBD[_G^4W54/2,7;[?'^3M"6JW!'M=.[4=P_69=\`,E_
M>)8HVF)%/]J(%,GFT"_O=O6Z?EV.V4O)NX!L@.-R"6`\+UJ48#5IR#UJ<_3-
MS$EQV/M`)O0?^(H!0$R^0H70&E<L.CBR4]1%(8I89$E5BI0K=@R_4>FX)`_I
M?W[S(\Q7^6#_`#Z\K*ZHZFJ,`0?4$5!_,&O0-=R?(+H_X\4G7]=WKVAMCJRB
M[6['PG3_`%M4[I;(I'O/M'<B32X'8^'_`(;C\@W\:R<4#M'YA#``IU2+[]"/
MJ;^TVN#OW&X!\*,?$^DHITUQAI$7)%6=0*D]>E*V]G>;A.P2QMU!D<FBH"&-
M3YG"LU`"=*L3@'H99*>>*26*2&1)8'>*="MS%)&2KH^FX#*P(//X]^J*5\NM
M^=//K&J.]]*LUOKI4FW^O8&WOW7N@D["[YZ6ZDWGT]UUV?V9MG8V^_D)NC);
M)Z.VKG'R*Y7M'=V'@H*C*;?VPM'05E,:ZABRM+K-5)31:JF,!R6L-0'ZF_7:
M[?OW$V\DXC'Q>#$"9)/32@#$YK@XZ]-_BUC+N5P=&WQS11-(?A$LQ(B0^>J0
MJ0N/+-.A:(*DJPL5)!!^H(-B/]@??@00".'6R""01D=%5^7W_'E]!?\`B]_P
ME_\`?UXSWOK71JW_`%M_P9O][/OW7NN/OW7NLD,,M1+'!!&TLTSK'%$MM4DC
MD*B+<@79C;D^_=>ZK%W%_.C_`)3.T=RYW9^Y_GYT1A-S[8SF3VUN'#UIWZ*C
M$9["U\^+RV,JY(MD2THFH,C3212,LC1W0D,1S[;M)H;Z&VN+.97MYE5D<&BL
MK@%6JU**00:FE!DTZ<N(9K26>"YB9)XF974BI5E)#*0*Y!!%!7/#HX.X/E#\
M;]K;GZ`V;G>\.O*7<ORM^Y/QFQ]'F),W#WHE'0X[)5$_7F7P%+E,'E*1*+,4
MCB:6I@B;[F,!BQ("GP)_WG/LO@M^]HHFE>*G>L:AV9SY:0L;L#7N5&9:BA*=
M9H6VN/>EE4[0\J1K+^`R2&B(//4Q(%",$T-#7H=W1XV*.C(P^JL"#_3Z'_'V
MT#7ATX014'CUYD=+:E9;_34I6_\`K7`O[]U[KQ1U`9D8*?HQ4@&_/!(L>/?N
MO=>T-IUZ6T`V+6.F_P#35:U_?NO=<0"2``220``+DDFP``Y))][`)(`%3UXD
M`$DXZ"C!]\=*;F[H[`^.6V^TMGY_OOJ?;6"WCV?U+B:^:LW=L#;.YC3#!93=
M$,5,<=CCD17TS"F-0U7&E3$TD2!P?=;=A=P7MU:GQ+6WG6&5URJ2L"5C)X%B
M%;X:@%64D,I'6[@&TGLK:Z'AW%S"TT2MAI(D(5I%'\()`S0FH(!!!Z%?WOK7
M7O?NO=`K\E_^R:?D=_X@7MS_`-X3.>_=>Z5W5'_,HNG?_$/]5?\`O`;=]^Z]
MTO/?NO=>]^Z]T5;Y,_.3X>?#!MEI\L/D3U]T))V/#G*C846^CN'R;KI]LRXZ
M#<,^*3`8'-L8L//EZ5)C+X[-.@%[\,BX@-P]H)1]2L:N5S4(Q958XI1F1P,U
M.EL4'3O@3>`+KPS].7*!O(N`K%?6H5E)Q2C#J%T/\^/A+\H=K=E[U^/'RDZC
M[=VQTQA:C<W;>0VKF,BM5UYM>DQU9EJG=.X\%F<5BMQ1;;BQ^.J'^]AI)J<O
M`\08RC07+QEV_;9=XO3X>U1DAI3\"D"I#4J5-,BH[A4BNEJ-6_\`C=_#M=MW
M[E)31$/B?4VD::T#=Q"FA[25U4U"HX]0=O=7?('K':?=/2&^<)V?U)OREK:W
M9O8&V?OFP&XJ7&92MP>2EH&R5%CZY?L,UC:BEE66"-EFA86(`)4W%M<6DB17
M4125HTD`/$I(H>-OL=2&'R/3%O<V]VLKVTRNB2O&Q'E)&:.I^:GCT(X1V!*H
MQ`^I"D@?GD@6''MCI_KRH[WT*S6^NE2UK_2]@??NO==!68Z54EO]2`2?]L.?
M?NO=(GLKLKKKIC8.[.U>W]];6ZPZRV'BI,UO/?N]\O38';.W,;&ZQ+-7Y"K9
M=5155#K#34T*RU574.L4$<DK*A8N+JWM(Q+<S!$+J@K6K.QHJ*`"69CP`!/$
M\`2'H+>:YE\&",L]"3P`"CBS$T"JM15F(45%3GH*?C=\OOBO\Q=N;AW;\5>_
M^MN^L!M#*4^%W95;"RU3/6[8R5;`:J@ASV"R]#B=P8RGR4"L::IDI12U)C=8
MY&>-U5:]O.D$-TT1^FD9E5^*EEH66HX,`0VDT)4A@",](DN;=[B:T64?51JK
M,O`A6)"M0\5)!74*@,"#0XZ,7[9Z?Z][]U[J;C?^+C0?]1M+_P!;X_?NO=$^
M^$'_`&3TO_B>OE[_`/!8=S>_=>Z-I[]U[KWOW7NBG_)GYW?#3X85NS<;\K_D
M=UYT+D.P\?E\KL:CWS_>0S[GQF!JZ6@S-=C1@-OYM13XZMK8HI#*8SK<:01<
MAD7$#7$EHLH-TB*[+YA'+A&/R8QN!_I#^;I@F$$=R8R+=G95;R+(%+*/FH="
M?],.L'2_SZ^$?R,Z^[2[6Z)^4G4?:77G1V(KMQ=R;DVSF,C_`,8SVWC<159V
MMW+NO!Y3%8W<M)MV'$T%1,*V.BEII#3RQH[2HR!V\(V_;CN]Z?#VP-I,ARH>
MH`0TJ0Q)&E2`6!J*@$ANT4WVX1;3:?J;FX!6,?$P)(!%:`BHH:'!I6E14>^J
M^TNN.\^MMG]Q].;RQ'8W578.+.;V1OS;OWIP6Y<4E74X^2MQYR%)05RQQ9"B
MF@9988G$D3"WT)?N+>>UD6*YB*2E$<`\2DBAXV^QT8,/D1TQ!<072/);RAXU
M=T)'`/&Q5U^U6!!^8Z7P1V!948J/JP4D#_7(%A[9Z>Z\J.]]*LUOKI4FW^O8
M>_=>ZZ"LQTJI9N>`"3Q]>!SQ[]U[KQ!!((((X(/!!_Q'OW7NBE]__/7X2?%'
M>>T.N?DO\J>F>C]^[\I:?(;7VCOS<TE'FZO%5E:F.HLWDZ;'T.17:^"K:QRL
M%;EFH:698Y'1S'%(ZZM66]O3MUHXDO@5!0$"A?**2:*&89"E@U""0`PK>:-[
M>T^OG4K9G51CYZ:ZBJBK,%I0E5(![:ZL=&R5DDCBFBEAJ(*B&&IIJFFGAJJ2
MKI:F))Z6KHZNG>6FJZ2J@D62*6-VCDC8,I*D'W=T>-WCD0K(I(((H00:$$'(
M(."#D'II'25$EB=6B8`JP((((J"",$$9!'7?NO5NO>_=>Z$>E_YEGDO^UC'_
M`.[:@]^Z]U__U=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1`/D;_V65\-O_$;
M?,'_`-Y3J[W[KW0G^_=>ZUE/Y^N:W3MSYF?R0LYLKX[4WRUW5C>\OD'487XW
M5F2VSAJ;MVI&W-AJVUYLMO/%YK:V.5H&:?S5M+-"AAO:X!!5M32)[DHT5KX[
M_P!6+L:,8!:X#2Y!'Z*UE]>WM(-#TNW!4;DB4/<>$O[]MSJR:D+"0F,_J&D?
MIW9!%1T&74OQ?^9>5^8/S/\`YJN\OA)M?^4OM+K;^7!WGT_L3J'8N]=DY;L7
MLSLP=>93*T7:LW^CC$X3;5$NV9J2&;[\X^BTU&+QT2)4R)-,M-UN).6N1/=/
M<(]SD:^W"!3#&G;]/X;VY,]23I>L-$H%UM,[!5T,TKML/W]S5[<;8-KB%I8W
MA>:1S43AUF004`&H`2GXB=*"A8ZT6,IB?)W^8_\`&?\`DK]+?S#J_P">GR)[
M\^0?SQS?7?QLV5AMY3;9R6POC!M_<.]M[4<W8^QJ#<;4>,S'>V9V_P!<KC(M
MP9JII8H9\O43/*98HJA1#O<`M>8.3N388)';>9[6::>,TG"?2B8VEH"0D7C_
M`%$0D)/>;=F!C,C,H>V69[W;>:>9YI$6'9TN(XH6J8V?QTC%Q<@*6D6$I-I4
M!@OC0JRR!='1N^LODE_-;^"&ROYB>Z>WL#\L.T/CWU+\)]T][=!;M_F';@^.
M>[OD-LCY,;=K=K;76AR.)Z1[9[#S&7Z1RDN>JLK&E9?'%<0J:H&DFDJ"W=[_
M`,/EK>#"\46YINEG#:R*M76VNI5BE%QC0;A#()8=8([5XH=`,]JLF?F#EYIE
MDEL9;.YDO(2VE&>V@GN%>W);6L+>"EM+I!;5,6(5HZDV'\M;K/YM[2[$_E[_
M`",[6_G)1]Z[2^:/1-7VCVC\6/D=D=N5U7OS<>=VQM_>L%#\/<#1Y&CCQ)ZS
MK]SQ)E9Z+P-110)#]I+#5?;TI[?6=KL^Y<X<MRPM=6UKMJE*$_5"0JP^H+$L
MPM9`WZ;'Q/%`=7R$F0AL[ZXWW9=DYC&JSN)KUU=2H$&C4P%N5H!]32-J@:3&
MQ5E:@>.2EW8O8^^NK?Y&6?W%U]N.JVMG*W^?9E-MU>0IJ##Y"27"YOL58<C0
MM3YS&Y2D02F*-PZQK*CQK9@-08IV!BT_W7;9C6VFMT21?)U,EU52>(!]5(/S
MZ-M^/A[O]YVX3$\2R.C>:MKMEU#R)HS"A!&>'"EI_;N"^=7RZ_G)?S(/B5U5
M_,=^0WQ%^/\`TM\9^B.W<?@>J5QF3KJ+=N1V/@)\?C=GY#*-!6]?X/-;@JZK
M);@;%S15F9*K3R2")O0'MON+E^5_<C?9+AI;C:]WE2%&)"ZC!+(BNP[C"BQL
M/!':7=9?CC%3&8PKN/MKMJVZK'?[5JG=0-1"W(0L%/;XQU(JR&FF-&CX.>B&
MX;YX?*SOG^4__)D[A[.[2J<YVYNK^<!US\>^PNPY,3@ZC.=B[#VWO#=NWZ23
M=CY#%U<%1GZG%4L$55D84AK*HP++)(97D9I!VV.VO^?_`&I=(%A@W';KB65%
MPI>.58=0&=.M(JR!"JZI)"@6JZ2Z\LY]KY6][-OENVEGVB;PHI#DT`22A+`E
M@KR'P]56"JBDD`U-;OC=WSM^>WR4_FW;WV!_-$W#_+EV3_+3[LQ73O377L&1
MPVTNAX<;M>;+9'<7;7R?R%8LU=F]J[UFV]-)%4U=-6PJ*CP:)*6+P.$-@GF_
MJYM?-LL\;7=UO<MN8IZ&".&&>*)(?#P#/(LOA@&ADN%*%B&4PF.YQP-S#)RK
M%;OX,>RP76N$GQI);FW:4MJK41P,H\0KA(2&"JX8RROYFGR6[1RG9<W4G6_S
MB^;G9'<W3OPCP_8>;Z7_`)2?7=/UQL3%=NYK9==NV;Y?_)SY(9C===LFA^/F
M;BQL4]#LE)Y'I\?7TO@K//,8YZ[K*8[OGO<]KCF2WLI]""=M-MM\:1F9X;A*
M%KFZ?S9:,L2F-%+H\B^VF'Q[?D>PO;B&26^`)\%=5UN#/,L"O;D=D$:`^=(S
M*K2/IC=5Z"JF[_[2^4N&_P"$FW?O=N=AW5VQV+\B>W:S?.ZH\?1XN7<V7PE!
MB=L1YZOH<=!2X^/+Y+'X2&2L>"**.:J,D@1==O8ECBAB]W[<V\*QQR<GW4NA
M<*K2VGB/I'X5+LS!>"@Z1@`=!$W<]U[7<S+<2:V@YIL(58U+%(KFY5-1.68*
M`I8Y:E2222=N>;_/2_\`+1_^AC[*D^!/L'0CE_M)/],?\/14OE]_QY?07_B]
M_P`)?_?UXSW?JG1JW_6W_!F_WL^_=>ZX^_=>Z>-O_P#%]P__`&LZ+_W(C]Z;
MX)/](W^`]:/E]H_PCK07^%5?\E]T]$_S4NC^D/Y+>T?Y@%)VM\Y/F/M"C^2^
MZ=U]/X:DZUW/NZ+$[?\`[JU6)WAMI]\UT&R8I*;/12T&;QL<=17+XY8)`\I0
M)8W&]>V'MSM*H+!Y-FC5+JN6K,6^H&G25:%@R(7U#5&I(9%T=+Y[NWVSW&YO
MW*5S=+%>ZGMJ8HIG[#6H99ZT<*`=.H<6!!@>Y/A%\COBO-_PF,^$$??F.Z\^
M26VNP/E;A:SN[;F&Q796/ZFRW8M7@MSYFBV-C=R4IP6Z<CUY@MP3T&'J*F)J
M`Y.&.?08%`]F\MQ#O/NG&+61HH(^4/!:1*J\JV\,R3:2P!3QE1X4D(#)&5?2
M&%.B:.VDVKVVW6:ZA4R3<TP3+$3V0M*X,1;2Q#LK%9YD!TO)KC#:37HT71_R
MU^1_Q)S7\]KXN?)7^8[O#*;.^#>)Z-RG2'S<^0'7K=U]F]4Y7OFE;&/!!LC'
M5M'6]B9Z>HR-'38+$FH%%'FXUJ%2.&66-2R2Z7<N0ENBWTV[KS";!9(E9I)8
M6DF_3500PE\*V=O&)_0$DLE=$2T.S8R;?SC81JHN;"XV5[YXI"%BCDC6(!S0
M$+'XDU&B44G"Q1A1(YJ&_P`%/EK\TML_S"=P?'#:/:WSVWAUCVA_+:[=[]ZR
MIOYN$^VZ'/;N[UZ\?<N/V)W]LK!UU4<YTG\?]\;BQ4;18C+U,1%"]3]R984I
M7C6RM>-M'N986]K%%NUC:)/9(S*]S:R.\$,<%U-VQ22'QG,BL%`D$6I8])U(
M(A8"]]NMTN;N:3:KW<9;6\D12EO/''#]1));0U:1=(TZ'4$&)NUY-3%0A_E]
M_,#YP];?-CX<[/\`GU\K_P"9'U!O?O?LK=W7/8NQ_E1U'M;M[X%_)+=.6W)0
MX3"=?_%GL[8.Y,7B=EY*KRU>(Z3-8JDR>,PU4M-$E0:*9T=9LK6<[7UC91_4
ML-FEG6WGU1WC2PQR2&6*1^X(-'B+XBJ9A6&K%D8H=^:]@A7<KG3`B[HB&:VT
MO:K$[(OA2(A*DT9E8J[+$!XYIH<!#;,^9G\ZSY6R]X_-GXWY;Y@UNY^MOF!N
M3KCKKHG!YOXL[6_EO;?ZBZ[S.,Q6<ZB[FQ'9';VU.P:SLZIPN7"RY";$>6NJ
M:F*6&I$S1RTQ?RS/X6T\B;Q?Q&Z_>D0GNUETZ98I-0T6`4ZHV5D"H#I<*K-W
M&KR&6_10R;OS?LEM,;4;<WA6[1U,D<BO7Q+S4%5T9*EJ%D+D+V+IC3=@SM#E
M=]=<9;%4N6W%U/N'L#K6JQG\>VS-22[PZHW#O/:#4M3E]K554:K'R;HZ_P`K
MDWEQTSF6`U5)&Y+IR=[S80S?O7;+7<)5M3(\:31G3)X8?#*2`4=T&DF@*ZF(
M`(Z:V:]EC&T;C>V$3W"B*22%^Z)G`#-&P!S&6J*`D%30$\>M;/\`E0_%SK/X
M;?SO?YI?0'5%=OG.;9VM\3?C-ELANWL[=^2WUV+OS>.\/[H;LWMOS>^Y\H_D
MR&Y=W;HS-5757A2&FCDFT0QHB@>[\OW2W/+?/,<-K';V4',$$,,48HD421W(
M5%\R!DU.22?*@#?,%LT.^^WEQ-<R3WMULE[--*YJTDAN@FH^0I&B(`/):FK$
MD[/'O73G7O?NO=`K\E_^R:?D=_X@7MS_`-X3.>_=>Z5W5'_,HNG?_$/]5?\`
MO`;=]^Z]TO/?NO=>]^Z]UJ_?SW\YNS;7\Q3^2#G=B_&JE^8>[,;N?Y338?XS
MUN3VMA:;MF1L#M"*HPDN6WMB<[M3'"@I'DKA+6TDT:&E!`#:6"/9'E3GK<S%
M8?4$\N,",=@+W@,F0?[,5?&>W!!ITMW14;DF`27/A#]^1FN<D"U(3&?U#2/T
M[L@BHZ2'2/PZ^5>\?E7_`#`_YE?<'P>V/_+`ZPD_EN=Y?'W;WQJVYNG9FX=S
M]O[HFZVJ\ED.R-Q4W7.-P>UX,?0TN(59*LT%!Y9Z6CACCFDCJ*ADVZR1;)[>
M>ZBW-T;B7=8U,<(^&W1#$#(:U`<M'50NDNT\SZ0!61ZQD?=.=?;%(=O2.+;;
MM2\Q/=*7:0"):#('BYJ2$2)`2Q91'79\?LS\\OAA_*S_`)0WSLZ\^>W9+;&W
MA\E^MOCU!\+<=M?`XKX_#IS>_97:=)E*/<E%"C5>^]\9JOPE=45^4R<<LZ?Q
M2-*-X/X?3NPTF<V_N)R'L=\GUL.\6UO%+KP(U:V@$*P*M-'AP,!KKXC7"B0D
MIV=`RU47/)/N'NED?I)-GEN;A"AJTCI/&LGBL14K)(X81U,:Q!TTAY&8'`_F
M]_,ONC;_`&I\^MX_%?YG?S$]V[R^'G]U,;M_9'PZV!2]3_!7X8U^TJK`2[QQ
M/S([*WKE:S#_`"5WUV!79*>**AHJ=:BAGIJBE\-7!"R0@6RN[BVLSO<+>/&=
MW,33W!'TA1+A+=;."VRS2`L1-+4B25ED;3"P5QO-:17%[;[3*@B8[49?IX"3
M=:FMI;DW<TXHJ0@1@JG;IB.A"9QTY?S'?D;_`#-]P[M^-78V!WA\ZMM_%'<O
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M!+@"8\SEJ_)4T-/+)+`DH07EW8;?8\H<W;E;PMS)8W4J^#$GBP334B$+QQNJ
MJ\LBF6!U4J%C#F4Z7DD<QM(;VZW#FGEK:WE78[^RB/C3$)/`FLR3?JJQ:)%*
MQ2Q.5;5D1_Z'&AAOY3_QUW[O;Y;_`"^_FPY;XSP_!_I/Y4]?;&Z4^,/QFAVQ
M1;&W/N7J_:55@\O%\@.W=D86FH\'M7<N]*;;E(V*I!&E08*JH<"6`0UM:NL+
M:\V/E[<=LW>96WS<]P2[E@5M:V*PQR1K!K.3*[2,\RT!23Q"VDR>%&57D]IO
M&^;7>;3$1L6V6+V\4Q70;MI7#&0**4@10!$:L'40:21"&>_#VCZ7=>]^Z]U-
MQO\`Q<:#_J-I?^M\?OW7NB??"#_LGI?_`!/7R]_^"P[F]^Z]T;3W[KW7O?NO
M=:MG\[_<&\MK?S:/Y*&>Z_\`BO2?-?=V/V1\O7Q/QAKLIM'"4O:7FPL5/74D
MN6WWAMP;3Q_]W<=--EUEK*295;'C1IDT.ON6WE3F3GCPMM%P&Y>MPQ-/T5^H
MNOUL@DZ31:+1CJH#QZ>WM4;E;8Q)=F$#=W(.>XAK$A,4_M#1,X[L@BO2`ZR^
M'GRFKNU/YM_\RKNKX7;+_EH];[X_EE][_'[:'Q2VONC9V?SW8>>CZQAR.2[8
MW1!U[C\1M.E@IH]M:#4K08YJJJ9$2&1H9ZF<AYB$6T>V7N-:7%R+F;<[NWG2
M/-+6.*9%-":T=SW``G4T\[T1=(*[:8VW?G[VXD@LUACVUM+S&FJ9VUMX:TH2
MFE@&)J%6"W6K&H0FG1&X/GC\)?@9_(T^8FT/GGV9N+KWO;Y!]+_&2L^%T.V-
MO87X^8KI;>VY-YT9QM1C*2/[G=V^*RDQE5-D,UDDEKC7Y%&I988Z&G##X,(_
M<+E+E^_C^KMMTL84D+D@H7@M$@\$#$?@12J-0.IY8E<G3(Z@)01-<\B<[[U9
M2?2S;////&%SK(N)!+XK'+B67N\,_IK"SH`'HW0Z_P`V[YP=X;3W_P#/;M?X
ME_-/^8AO[=GQ$WWM7;.#Q'Q:V!0=3?RZ/APVS=V[3P6Z^NOE3NK>N0R&-^3W
M9N^:[.U$!CHH!-!D8GB:&HHHS&H"V^^NK6TL=^AD6>VEW8JTMUFVFA+^%#:V
MMOEM2=K2S@E)M:2?II(&89W5A#=WLFQRHT,R[69!#;@_4HPMY+A[J>XJ%56T
M52(YCC5XE#RK1%C_`#0/D+_,R?N#8N_,5OCY[[*^(M1\&>N>T\/E?Y65'L3<
MVZ-G]Y9_KO";S[(W9\GNMUS6.WMCNO*',96)TJ,A58N@I,(\!H)GD-4OLWW@
M1;/S)[@0R7$D$%IN`CLFE&NTCMD**PG-0!*93(.]O%(0`QF,A@4[3,VZ\N\A
M36R137%W:%[Q5HMT]PP<KX"D$F(1B,T5?#+,_?K`7IM[S_F-_+7Y![?_`)0/
MQM^,OR3^1O;V(^5O3';/:?>?R:^&76W6?0_RT[\RW26;W9M:JV5LG;'<G8&W
MME==[CV35[.GFW;#39I5S<RM4TZR4[1T\QI?6K3\Z<P630O%M=GLUI>QI;E2
MDCW:NOCOJTL(-256W74T+-*C*2BO$76EX+/E3;[J21&W*YW>:S9K@,#$D1A<
M0CXJS,DP"SL5$J"&16`D;Q+I_P"3[N_Y[9KH7M?8O\P3#;R;?G4?=65VETWV
M#V?FNJ<SW%V%TC5T35NW8N[GZ@WIOC;=/VQL^HA-+DC45*5KB9!*U0T9G>TK
MPW6T[%>M'"F\.'2X6&O@NR>&4GB[54*VMXV"U%8PS4+9VJM#NV[VT$DK[.`D
MD!EIXJ:S)KB>A)P`CIJ_B8*=("K6]_-NZ*^,OR`VK_,TS'P\F^-FY/G!U]LG
M!Y7^9[)W9'O')=N[6^->PMB2U]#M/XTY/LG`9CJCJSL++83"4WVN4Q$28\&E
M@$TZU3TS*#KLV]IL<VZJ7')(WB.:_:"GU3WJW*K$H=E:0)6.Y22%5_5TA(Q)
MH\-A1;"6ZW:UVN2G]:_W6\5BLBDVZVLD1:1G5*#4?%@=9C4Q:B[E-1D6\#^7
MAOSK3L[X!_"[?'3.&WEMWJ;+?&WK''=?[?[$RL>>WYA-N[3P<>SH<;NW<$--
M14VXLS35.`E#Y"&&""L73+''&C*BC_FA[B;?]QN[IE:6Y\.XJHTC1/%'-&-)
M9B&".H8%F.H$EFKJ((Y<6*/9;6WA4A87FB-2#WQS2+(5H%&@N&*`*H52$TC3
M0'#]D/1WU[W[KW0CTO\`S+/)?]K&/_W;4'OW7NO_UM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW1`/D;_V65\-O_$;?,'_`-Y3J[W[KW0G^_=>Z+-W1\0^D?D!
MW1\6^_\`LO';KJ^ROAOO#<F^NBZO!;KJ<%@L=N'=E-C*7,R[MP<-)40[KHY$
MPU/XXGD@,85U#%9'!K:*+'=SOEN!^\3926E2-0\&4.'`'DQ$CT:O$J:$HO5K
MAC=;8VT3?[A&Z2XH,-XL>G2:_P`/8M5X'/KT..^]G8+LG8F^^MMV15D^U.R=
MF[GV#NR#&ULF+R4^VMXX>LP.=AQN3A5YL97RXVND$-0BLT,A#@$BWM'N6W6V
M[;;>[3>!C9W$91P#1M)H<-Q!J!GI39WMQ87]KN5L5%W#('4D5&H5XCS&>'14
M*7^7?\1Q\'<7_+DSW6];OGXEX;:DFT<=LO?&XZW-;HHZ;^\61W;09ZCWQ!%C
MLKCMX;>W+E):O%Y&F6&2B8(BJT0*,8;PQWU[>7</[>%85C9.QH_`B$,;*17N
M\(:)*U656=74AB.D.THNRBX2Q_LII)7D5^]7\:3Q75@?PZP&4"A1E5D(*@A"
M?$G^5+\&?A7B.W<;U%U5EMUUW?>U)NN^W]V=\;QRO<V\=Z]65.*BPU1U-5YK
M<:01T/6]50Q`3XZF@A-0P0RR.(:=8=WCK?[7=;+=1(VW3R>),M#6:4!@DDC5
MU%XPQ$9!&@DL.\ENO6L?T>YV6\6[LNX6R!(&KB!=0<B):476P4OQU!0#VU!#
M;XL_R3/Y<OPY[SV_\B>F.I=Z5?8^Q%SB=3P]I=J[I[.V9TO_`'BJJFIR4_5F
MTL\RTFWJ](ZN6"GJ9Y*R>FBD=D83L9O=[6XGLX)X89F\:6`0M,:&?P@K(4$M
M`5#*[*Q4`E25PCNK4N[:"]>,S1`6Z2^*(EJL7BZE<2::DDJZ!@"Q751B"50J
MK#_*,^$I^-4_Q).WNUSTK4?)[_9P)<?_`*6,E_>H]WC)?Q/^(#=/\)\XVMYO
M^7;X;:OW/+Y/7[8M0+*3DF6W`#\O*!95R%`+D>*/]%S(WQ4\AY#IVZ'ULO.D
M]QF3F!2+VF-08H3X7^^C6-3VU\QYGHT.T_BCTSLGY1]^_,?`8_=$7>GR9Z[V
MAU9VSDJS=%36;2K=G['QU+B<!!MS:;TJ0;=R4=#0Q"6H2>7R.'<*K2/=+%8V
MT.U<P;+&I&W[I<FXN!7O,AC>/L?BBZ9'H,Y*Y[1TZTC/=;#>'_<C;;<P0>@C
M,@E(<?C.M1W8Q4<#T53;W\H#X/;6^/W0'QAP^V^TX^H_C)\E:;Y;=2T%1VE7
MU&X:#NFDR=?EX,AG]P'$))GMLK69*4G&M#$I!'[E^?9G!<S6]_R[N<1`O-J@
M>&W-*`)))XK!U%-9,F:U';5""I(-+D_5P\U6\Y8Q;U+XEUW&K-I5.PUJHTJ,
M'5W=_P`5"&/Y8_R5?Y=OS4[OSOR'[QZLWQ!V5O>FV_1]J/U;VMNCK#:G<M/M
M>:D;"?Z4MK8'R46X:RFI*&&D>IA:DJ)::*/6YEC24(;*WM["21H(5:!YA,8G
MJT)E#,QDT5%"S,68`A2Q+`!G<L[=W$]Y#'%+(5D2)HUE6BRB-@!HUT-0H`"U
M!(%%RH4*_P#;'\GSX%]O;_I>P*_8/9761GZ=VU\>=\[`^/W=>_\`HSJGN/HC
M9>.AQ&S^INX]D;#R%!'O79FW\11TU)'3?<TWGIJ*F2<R>%3[W+$+BXWRXN6:
M0[C.L\ZME&N470ET$II6>(4:)J%8W56"98-I)I(H=KA@I&UE$\4,BXE6&1M4
MD)D^)HY"6#@]S!VJWPE51LC^5M\1>O\`;/P@VC@<?VQ48;^7;O?>78'Q:7-]
MI5^4J]NYW?=?_$\W2;QJ6Q,/]],!352JM#22+3_:4ZF$.T;,"N-W*=[MN80J
M#=(MM:P#:>TV[1^$VI>!DT8$G$8(%1DO^AMAM.Y;&$(VZZOX[QU!SX\3,Z%6
MXJFIV+)G43D]6'LQ9F8_5B6/XY)N?]Y]I0```.`Z6$EB6/$GHJOR^_X\OH+_
M`,7O^$O_`+^O&>]]:Z-6_P"MO^#-_O9]^Z]UQ]^Z]UGI:F6CJ8*N`J)J::.>
M(NNM1)$P="RW&I=0Y'Y]^\B/(@C]N.O=%7^*?PYZ+^%NW.U]J="8W=>+PO=7
M=N\?D+OZ/=VZZC=U55=F[[@Q]-N&LQ-544=$V)PDL&,A$5$JN(V#,79F)]WB
MD:':-AV./_DG;;;^!`#EA&6+49OQ&OG0?S/6I@+C=-TWB7_<Z\<-*10*2I<B
MBCAF1O,XH."CK+W-\0.C^_>[_BY\B.R<=NNK[0^&^YMU;OZ+K,'NNIP>!QN;
MWE2XVESLF[,##23P[KII(\13^*-Y(3$`ZABLC`MV@%CNK[U;@?7M:/;$D5'A
M2"0,`/)B)7[@?-202B]7NF-YM+[+/FP:ZBN"!AO%A(*'5_#4"J\#GUZ!7?G\
MK;X5]I;F^;6Z>R.O-R;TJ_YA6)Z_Q7R9QF9WODS@LFW5BP/U]FNO:&DIZ:?K
M[<>UJ^EAK*6L@FG9*N)7*E=2%,+.%=J?9HRZVIOQ>A@:2)<@RL'1_P`(/CRH
MR4(>)S$^I!3I0UY.^XVVZ.P-S%9-:4SH:W<1AD9*T)_2C(8$%77Q%HYU=(3J
M+^3S\).G>U\3WC247?7:_:E+U)OCH3<^Z/D3\@=[]Z+VCTMOS!-M2OZO[1Q6
M^/N\=N+9.`VDPQF(Q]*F/IJ.DCC#)*\:M[72R>.N_+-&KKND"Q76JI,VF1)3
M,S5U>.[Q1:Y=52L:`!:5*)%,4NPS02O&^US"2UTF@A(5T5$6FD1+XDC!*4U2
M,:Y%$IT'_(Z_EQ?&ON39?=W6G6O9U9GNK=SY+>O3^Q>PN[-[]@=.]/[PKZV6
MOI=S=>];YN8X['9G;L\[G&354U8:5V$I\DZ)*KEA=7.W`M#.SW/TS0"62CS+
M$X"NJO0:2Z`1L0,I48)KTWN%K;;EJ2>W1;9IQ,T2#3$TBG4I9,U`<ZPM:!J?
MA[>N>^_Y&_\`+,[)^1V9^3V[^BLY6[OW7O\`I>V-\=94?8NX\9\=M_\`9U*U
M1.=[[RZ6HS'@<OE<CDJEJVNB$T5'6UC2/+"4GGCE3[,%V![9]L0+]/(9+<-5
MUMG(`U0`FB:`*1@ZA&**H"JBJHW5GWI)TW!RS31B.5E.EYD#:J2L,OJX.<%A
MDG42QMLDD>9VDD(+-;A42-%4`*D<<4:K'%%&@"HB@*B@````>]DDEF9B6)))
M)J23DDDY))R2<DYZJJJBHB*%C4```4``%``/(```#R'19-D_$7I+KWY6=Z?-
M/;&.W5#WW\CMD;(Z\[3R=?NNIK]GUNV.O:/$4&VH=O[/>DCIL!714V!I1-,D
MTGE99&"J97)I9(NWV>Z6%L*6UY=BYEKDF9=8!#<0OZC]N?(5[1U>]8[A<;-=
M7.9K"TDMH:8`BED\1PP_$VK@QR!CHS'NW5>O>_=>Z!7Y+_\`9-/R._\`$"]N
M?^\)G/?NO=*[JC_F473O_B'^JO\`W@-N^_=>Z7GOW7NO>_=>Z+%V]\/^C^\^
M_P#XN?)OL/';KJNV_AQEMY9OHNNPNZZC#;=QM?OVDHJ+<;;KV[%23P;JAEAQ
M\7A5Y(3%9@"0S`^L_P#$=RN-VM\7LMH;9B<KX3>*"`ODU)I,UI4J2*HI&[HF
M\VY-JG/^)K<K<`#!\53&02?-:Q)VT_B%:,>A\WCM;#[]V;O38.Y(ZJ;;78&T
M-T;%W-#05<F.R$VW-XX2NV[G8<?D8E:7'5TN+R,JPU"@M#(0X!(M[1[A86VZ
M;?>;9=AC:3QZ'TFC:20<'R-0,]*+2[GL;VTW"W(%U!*LB$BHU*:BH\Q7R\^B
M'Y;^5C\/<W\1_CU\'LA@^S6^/GQ=[,VYV]U#C:;LROI=Z4&^-K9O=.X<55;A
MWE'B_/G\4F3WGD&-&:>&-4>((4,*'V;37EQ/ONP<R.5_>VV",6[`#2OA(D::
ME_$0L:5-02:U^(]%MO9V]KM',FQ1*?W;NRR+<@FK$2R+(^ACE.Y%I2M!4=!W
MWG_)=^!'R([`[\W]V%MSO+'4WRCJHL_W]U5US\A^QNO.BNSNQJ&F>'!]O;FZ
MFP%9'@,KV;MJMD;(T%94F>CARK/5-2R-)(KE,%A;6]J]E&I-J+F2XC5CJ%O-
M*P::2`&HC::C)(2&)CD>,:05T&<M[<33I=,P%Q]/'`[*-+301"D<4Q6A=$[2
MH&G**34ZM6'O#^2M\!?D$O3N0WQMCN7!;ZZ1Z?VWT'MKM[K'N_=/77;>[>I]
MGXFBPNV-L=K[OP=/H["DPN.Q\4<-944L544&AW>,(B+;P_6[KO.\.`EQN#Z[
ME$%(I7THOB,F1KTHJL00'`&H$JNE):UM-NV[:XR6M;.O@%LO"I+-X<;X(C#.
MQ1.$=3HTZGU+;L[^43_+Y[6^,/3/Q"R_1LNT^G_CIEFW!T56];;OSNS.T^LM
MQUM:,CN;<6#[0IY*O<55F=^9`?<9Z6L^X&1J@D^F.6&!X_;@S[ENEIO-PY6_
M@A,,9C[`L#"AM](P8?Q!34ZZN6)9]7K)4L+*]L(D#V]S(LDOB5=GE6NF8L3_
M`&B@Z0111'2,*$"@!UNC^2!_+MW1\2<-\(_]'_9NVNA:#MEN]MR0[2[;S>,[
M![6[;?$Y#"?WT[BW_64&4R>_JR"@R3K30S1PTU(8H3#&GB7W6[5+R;9Y98U5
M-O1UMT0:8XBX57E"?[^95TF6NL(SQ@B,A1>V8VB[KX1)FO2OCR,2TCJC%TBU
M'A"KG6(@-.L"0U?4Q%/X:_RL_BO\#^PMT]H=#9?Y%9'=6\-C2]=YB/N/O_=G
M;&W4VU+F,)G"<=MW-TU-04>;AK-O4J0UOKFIZ;RPQZ4FDNL6^G6SO+'M,,\J
M2.2`7UQ^)I(?B`?$8N/QFA/PCI*UK"T]G<4(>`,$`-%`9-!!'F`OPC@#0^0Z
ML7]I.E'7O?NO=3<;_P`7&@_ZC:7_`*WQ^_=>Z)]\(/\`LGI?_$]?+W_X+#N;
MW[KW1M/?NO=>]^Z]T6/L[X@=']P?)?XR_+G?&-W14]V?$.EWY1](Y+%[HFQ>
MV,;!V1CY<9ND;GVRE'-%N5YZ6=A"6FA\1M^JP]VLG.WW>Z7UJ2+B\LQ:RU)*
MF%6=@`N`&K(_=GBII50>M78^ML;7;KC-K#<>.M,'Q*Q-EO-:PQ]OR85[CT-7
M8^PMM]L=<=B=4;TAKZC9?:>Q=V=<;QI\5D),3E:C:N]L'6[=W!!B\M"DDV*R
M,N+R$JP5**SP2$.`2+>T.XV%MNEA=;;>*3:S`!@#0T5E<9_TRBOJ*CSZ66%[
M<;;?6FXVI`NH7#K45%149'F,]$LSO\L#XB[D^-_Q/^)^5PG9#=,_"CLO9_;G
M05%3=C5E-NG%;XV-6YG(8"KW5N=<6TNY\;%5Y^I+TI@IU*E%5E"#V;/>W#[]
ML_,I*C=K!(TA-.P")8534GXB!!'4U%:-7XCT6PVT,&S;]L$8;]V;EK\<:CJ/
MB.TCZ6_""S&@H0,4RH/0/]T_R2/Y???F\>_=U[[VOWECL1\GMP5&_>Z^H=@?
M(GL78?0N[NWID`@[OJ.HL+5+MN7M7&U32U=-750JZ2.MJ9YC2L92/95!8V]O
M9)MT88V<=PTT*DU%O(Y!D\"N(Q(H,38)\!C"I5`FDRGO;BXN'NW8"YD@2&5E
M&DS11?V23$9<1FCKP_44.:L6U2^_OY*WP#^2.:Z^W?OW:W<>W.Q^O.IML]'K
MVMU/W=NGK3LGL/K39N#Q.V]KX?N#<.$IV@[#R6)PN$IJ<5\]-#5311JDK/''
M"D:NZ_QS=-]W:;$VYRF6YC7$,LI%#(8\@,5[30T*TJ*@'I):UL]KV;:8S6WV
M^/1;LV98TJ6T!\$J&)90:E230]S56W<?\HO^7YW;\>^B?C%N#I&HV9UC\8*B
MHJ_CWD>IMXYWK_LSJJHRE0M;NF7!=DT<E;N"M??>17[S.FN-2<AD`M42D\:.
MMK]FW'=DWN=BFXK%X0,9*+X(30L!48,4:_V:FI0EJ-WR:Z6,:;=MMQM,"!K*
M67Q7#][--6IFU&GZI^%FX%0%T@*FDQ_Q,^(/QX^#O3E#T1\9=A+L38,&:R&Z
MLU+6Y2MW)O#?6]<Q'30YC?/8.[\HS93=>Z\C3T<,)GET104T,<,$442!/:BY
MO);F*RMV"I:6T7AQ1H-*1I6I"K4T+-W.226/R``;BMHX9;NX!9KF=]<CN2SL
M<T!)_"E3H48%6.69F)7?F!_)Y^`7SJ[;Q_>7R#ZOW?/V6NW<9L[>&;ZT[+W)
MUA!VYL_"U=!58?;?;]#MT^/>E%C8\=%31S7IJPTBI$TS>&G:(MM+2ULKNZNX
MH%/CRI+)&U3$\J"BRL@(_4P-3`C50$YJ2NN+F:ZM;>TDD(\&-XXY%Q+'&]2T
M:/FB$L2`0=))I@TZL8VGM3:VPMJ;7V'L3;>$V9L;9&WL1M+9FS]M4$.*V[M;
M:^`HHL=A<!A,;`/%1XW&T,"1QKRQMJ8LQ))A=W=S?W4][>3&2ZE;4S'B3P^P
M````"@```%!TBMK:"S@BM;:()`@H`*^9)))-22S$LS$DLQ)))/3_`.T_3W7O
M?NO="/2_\RSR7_:QC_\`=M0>_=>Z_]??QFJJ:GM]Q4P0:OT^::.+5]?IK9;_
M`$/OW7NL'\3QO_.PH?\`SKI_^OGOW7NO?Q/&_P#.PH?_`#KI_P#KY[]U[KW\
M3QO_`#L*'_SKI_\`KY[]U[KW\3QO_.PH?_.NG_Z^>_=>Z]_$\;_SL*'_`,ZZ
M?_KY[]U[KW\3QO\`SL*'_P`ZZ?\`Z^>_=>Z]_$\;_P`["A_\ZZ?_`*^>_=>Z
M]_$\;_SL*'_SKI_^OGOW7NO?Q/&_\["A_P#.NG_Z^>_=>Z]_$\;_`,["A_\`
M.NG_`.OGOW7NO?Q/&_\`.PH?_.NG_P"OGOW7NO?Q/&_\["A_\ZZ?_KY[]U[K
MW\3QO_.PH?\`SKI_^OGOW7NO?Q/&_P#.PH?_`#KI_P#KY[]U[KW\3QO_`#L*
M'_SKI_\`KY[]U[H@OR*KJ"3YD?#=ER&."KUO\OU+/7T<:@OM7JX+<R3J!<_[
M#@_T]^Z]T*?W-#_SM,-_Y^L5_P#5GOW7NO?<T/\`SM,-_P"?K%?_`%9[]U[K
MWW-#_P`[3#?^?K%?_5GOW7NO?<T/_.TPW_GZQ7_U9[]U[KWW-#_SM,-_Y^L5
M_P#5GOW7NO?<T/\`SM,-_P"?K%?_`%9[]U[KWW-#_P`[3#?^?K%?_5GOW7NO
M?<T/_.TPW_GZQ7_U9[]U[KWW-#_SM,-_Y^L5_P#5GOW7NO?<T/\`SM,-_P"?
MK%?_`%9[]U[KWW-#_P`[3#?^?K%?_5GOW7NO?<T/_.TPW_GZQ7_U9[]U[KWW
M-#_SM,-_Y^L5_P#5GOW7NBJ_+ZJHO[F=!`9+%.?]GM^$[D1Y7'261.Z\7K9M
M%4VE5#7-_P`7/T!]^Z]T:QZFAUM_N4PWZF_Y?6*_J?\`IL]^Z]UQ^YH?^=IA
MO_/UBO\`ZL]^Z]U[[FA_YVF&_P#/UBO_`*L]^Z]U[[FA_P"=IAO_`#]8K_ZL
M]^Z]U[[FA_YVF&_\_6*_^K/?NO=>^YH?^=IAO_/UBO\`ZL]^Z]U[[FA_YVF&
M_P#/UBO_`*L]^Z]U[[FA_P"=IAO_`#]8K_ZL]^Z]U[[FA_YVF&_\_6*_^K/?
MNO=>^YH?^=IAO_/UBO\`ZL]^Z]U[[FA_YVF&_P#/UBO_`*L]^Z]U[[FA_P"=
MIAO_`#]8K_ZL]^Z]U[[FA_YVF&_\_6*_^K/?NO=`K\EJBB/QI^1H&3Q#$]"]
MN`*N8Q;,Q.Q,Y8*JU99F)^@`N??NO=*WJ>JH?]$73W^Y3$`CJ#JP$-F,6K`K
ML';P(*M5@@@CW[KW2]^YH?\`G:8;_P`_6*_^K/?NO=>^YH?^=IAO_/UBO_JS
MW[KW7ON:'_G:8;_S]8K_`.K/?NO=>^YH?^=IAO\`S]8K_P"K/?NO=>^YH?\`
MG:8;_P`_6*_^K/?NO=>^YH?^=IAO_/UBO_JSW[KW7ON:'_G:8;_S]8K_`.K/
M?NO=>^YH?^=IAO\`S]8K_P"K/?NO=>^YH?\`G:8;_P`_6*_^K/?NO=>^YH?^
M=IAO_/UBO_JSW[KW7ON:'_G:8;_S]8K_`.K/?NO=>^YH?^=IAO\`S]8K_P"K
M/?NO=3<;4T/\1H/]RF&_X&TO_+YQ7_'>/_IL]^Z]T3_X0U%$OQ[4-DL0A_T]
M?+STOE\8C6/RP[F(.EJL'2P-P?H0;CCW[KW1L_N:'_G:8;_S]8K_`.K/?NO=
M>^YH?^=IAO\`S]8K_P"K/?NO=>^YH?\`G:8;_P`_6*_^K/?NO=>^YH?^=IAO
M_/UBO_JSW[KW7ON:'_G:8;_S]8K_`.K/?NO=>^YH?^=IAO\`S]8K_P"K/?NO
M=>^YH?\`G:8;_P`_6*_^K/?NO=>^YH?^=IAO_/UBO_JSW[KW7ON:'_G:8;_S
M]8K_`.K/?NO=>^YH?^=IAO\`S]8K_P"K/?NO=>^YH?\`G:8;_P`_6*_^K/?N
MO=>^YH?^=IAO_/UBO_JSW[KW7ON:'_G:8;_S]8K_`.K/?NO="3234QZQR;BM
MQ[1+D8]50N0HFI4OEJ``/5+.:9&)X`+`DV'U(]^Z]U__T-Y3M?X\](]Z?PG_
M`$P=8;1[$_@3O)B/[T8N/(_P]W69':FUD>,LM0X_Y"/]??NO=`Y_PWM\)/\`
MO&/J3_T&*?\`Z.]^Z]U[_AO;X2?]XQ]2?^@Q3_\`1WOW7NO?\-[?"3_O&/J3
M_P!!BG_Z.]^Z]U[_`(;V^$G_`'C'U)_Z#%/_`-'>_=>Z]_PWM\)/^\8^I/\`
MT&*?_H[W[KW7O^&]OA)_WC'U)_Z#%/\`]'>_=>Z]_P`-[?"3_O&/J3_T&*?_
M`*.]^Z]U[_AO;X2?]XQ]2?\`H,4__1WOW7NO?\-[?"3_`+QCZD_]!BG_`.CO
M?NO=>_X;V^$G_>,?4G_H,4__`$=[]U[KW_#>WPD_[QCZD_\`08I_^CO?NO=>
M_P"&]OA)_P!XQ]2?^@Q3_P#1WOW7NO?\-[?"3_O&/J3_`-!BG_Z.]^Z]U[_A
MO;X2?]XQ]2?^@Q3_`/1WOW7NO?\`#>WPD_[QCZD_]!BG_P"CO?NO=%%[0^"W
MPYH_F-\3MO0?&WJA<1F^NOD]/DZ+^[<9IZJ;%T?4IH))8/-X)'I17SA"RL5$
MS6Y/'NO=&U_X;O\`@Y_WBWTW_P"@A0_\4]^Z]U[_`(;O^#G_`'BWTW_Z"%#_
M`,4]^Z]U[_AN_P"#G_>+?3?_`*"%#_Q3W[KW7O\`AN_X.?\`>+?3?_H(4/\`
MQ3W[KW7O^&[_`(.?]XM]-_\`H(4/_%/?NO=>_P"&[_@Y_P!XM]-_^@A0_P#%
M/?NO=>_X;O\`@Y_WBWTW_P"@A0_\4]^Z]U[_`(;O^#G_`'BWTW_Z"%#_`,4]
M^Z]U[_AN_P"#G_>+?3?_`*"%#_Q3W[KW7O\`AN_X.?\`>+?3?_H(4/\`Q3W[
MKW7O^&[_`(.?]XM]-_\`H(4/_%/?NO=>_P"&[_@Y_P!XM]-_^@A0_P#%/?NO
M=>_X;O\`@Y_WBWTW_P"@A0_\4]^Z]T3SYH_!3X;[:VCT1+@_C7U+CI<I\ROB
M/A*V2EVO3P/-C,OW;M:@R5(YA=/)#64-1)#(C:D:.1@1]+>Z]T</_AN_X.?]
MXM]-_P#H(4/_`!3W[KW7O^&[_@Y_WBWTW_Z"%#_Q3W[KW7O^&[_@Y_WBWTW_
M`.@A0_\`%/?NO=>_X;O^#G_>+?3?_H(4/_%/?NO=>_X;O^#G_>+?3?\`Z"%#
M_P`4]^Z]U[_AN_X.?]XM]-_^@A0_\4]^Z]U[_AN_X.?]XM]-_P#H(4/_`!3W
M[KW7O^&[_@Y_WBWTW_Z"%#_Q3W[KW7O^&[_@Y_WBWTW_`.@A0_\`%/?NO=>_
MX;O^#G_>+?3?_H(4/_%/?NO=>_X;O^#G_>+?3?\`Z"%#_P`4]^Z]U[_AN_X.
M?]XM]-_^@A0_\4]^Z]U[_AN_X.?]XM]-_P#H(4/_`!3W[KW0(?)KX!?"K#?&
M[Y"9?&?&/J"CR.+Z/[8R-#50;3HXIJ:LH=AYZJI:B*2,J\<L,\2LK*000"#?
MW[KW2FZ9_E_?"?*=/=39&N^,'3U165W66PJJIFDVG2222S3[5Q,DCN\A>1V9
MF/+$D_DGW[KW0D_\-W_!S_O%OIO_`-!"A_XI[]U[KW_#=_P<_P"\6^F__00H
M?^*>_=>Z]_PW?\'/^\6^F_\`T$*'_BGOW7NO?\-W_!S_`+Q;Z;_]!"A_XI[]
MU[KW_#=_P<_[Q;Z;_P#00H?^*>_=>Z]_PW?\'/\`O%OIO_T$*'_BGOW7NO?\
M-W_!S_O%OIO_`-!"A_XI[]U[KW_#=_P<_P"\6^F__00H?^*>_=>Z]_PW?\'/
M^\6^F_\`T$*'_BGOW7NO?\-W_!S_`+Q;Z;_]!"A_XI[]U[KW_#=_P<_[Q;Z;
M_P#00H?^*>_=>Z('U[U?\29>X>X=J=R_#;XX;:ZDPW?U=T5U!VIMK:4T=+%N
M/&[9V?D8MG=SQ9-Y:;`[DW5E]QR#!9>F<8G(:HJ"7[:O\"5GNO=']7^7C\'E
M8,OQ<Z<5E(92-H4(((-P0;<$'W[KW13/A/\``WX8[DZ&DRF9^,_45=6GO7Y:
MT"S5&U::=XZ'"_+#NO"8FC22=Y9C!C\3CH*>(,QTQ1*+\>_=>Z-E_P`-W_!S
M_O%OIO\`]!"A_P"*>_=>Z]_PW?\`!S_O%OIO_P!!"A_XI[]U[KW_``W?\'/^
M\6^F_P#T$*'_`(I[]U[KW_#=_P`'/^\6^F__`$$*'_BGOW7NO?\`#=_P<_[Q
M;Z;_`/00H?\`BGOW7NO?\-W_``<_[Q;Z;_\`00H?^*>_=>Z]_P`-W_!S_O%O
MIO\`]!"A_P"*>_=>Z]_PW?\`!S_O%OIO_P!!"A_XI[]U[KW_``W?\'/^\6^F
M_P#T$*'_`(I[]U[KW_#=_P`'/^\6^F__`$$*'_BGOW7NO?\`#=_P<_[Q;Z;_
M`/00H?\`BGOW7NO?\-W_``<_[Q;Z;_\`00H?^*>_=>Z]_P`-W_!S_O%OIO\`
M]!"A_P"*>_=>Z$O'_%/XWXKK#/=+8[I?8%%U/N>NH\GN'K^GP--'MC,5^/RU
M%GJ&KKL:!X9YJ7,XZ"I0GZ2Q*WU'OW7NO__1W^/?NO=$1[D_F@?R[/CQV-N#
MJ'O3YJ_&WJ;M':@QIW+L'?G:^T]N;JP7\9Q5%G,4,KALCD8:VB.0PV1IZJ(.
MH+P3(X]+`EF"Y@N1(UO*KJCLAH:T9#1E/S4X(\C4<>GI;>>#PC-$RB1`ZU%-
M2FH##U!H:'Y=#Q\??E!\=?E?L_)=@?&?NSK/O;9&'W!4[3RVZ^K-WX;>>"QN
MYJ/'XW*U6`K<CA*JKIJ;+4^,S%+4/`["18:B-R-+J2LDMKB**WGEA98902C$
M4#!6*DJ?,!@0:>8ITD6>%YI;=)5,Z!2RURH:NDD>0.DT]:'TZ';VST[TBLSV
M1U_MS>>RNN<]O3;&'W]V1#N:IV!LO)9O'TFZ-YTVS*&ER>[JK;6#FG3(YFEV
MSCZZ"6OD@C=*5)XS(5\B7U&1++-!%W31P^*X&2L7B)%XC#R3Q)$0,:`LP49Z
MLRLD23N*0M*(PQP#(4>0(#YL4CD?2,Z48\`>EK[WU7KWOW7NO>_=>Z+)\COE
MUTK\5*CJ&E[BRFX\7-WEV7B>HNNA@=G[BW2,OOS-PS3XO!RM@J"L%+55T5/(
MT,;7FG$;F-'$<A3=K_CFZ6VSPG_'I8Y'0'`(B4LU&."0!P&<@F@SU2Y;Z2PF
MW*53]'')&CL*=GBMH5FJ11-5`6.*D**L0"9OWKJ_7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW57/SJ[.W+U!\@_B5O+9>!P>Y=Z5N([;Z[VCB=TY>NP6U1N
M+M??/QVZ[QF5W/E,5B\UEX,#@JC<0K*E*2EEJ9HX3'&`S!A[KW0Y???S%?\`
MGF/A7_Z'7>8_WC_1T;>_=>Z]]]_,5_YYCX5_^AWWG_\`:Z]^Z]U[[[^8K_SS
M'PK_`/0[[S_^UU[]U[KWWW\Q7_GF/A7_`.AWWG_]KKW[KW7OOOYBO_/,?"O_
M`-#OO/\`^UU[]U[KWWW\Q7_GF/A7_P"AWWG_`/:Z]^Z]U[[[^8K_`,\Q\*__
M`$.^\_\`[77OW7NN(R'\Q,D@;:^%)*\,!OSO(E3_`(@==<>_=>ZY???S%?\`
MGF/A7_Z'?>?_`-KKW[KW7OOOYBO_`#S'PK_]#OO/_P"UU[]U[KWWW\Q7_GF/
MA7_Z'?>?_P!KKW[KW71K_P"8H+`[9^%0+&POOOO+DV)L/^,=<FP)_P!8>_=>
MZ[^^_F*_\\Q\*_\`T.^\_P#[77OW7NB?_,ZM^=YVCT4-S;:^(:1#YD_$=L6<
M/O?NB65LTO=NUCBHJE:O8$")0RY#Q">12[QP>0K&[Z1[]U[HX'WW\Q7_`)YC
MX5_^AWWG_P#:Y]^Z]U[[[^8K_P`\Q\*__0[[S_\`M=>_=>ZZ%?\`S%#]-L?"
MH_ZV^^\O_M=>_=>Z[^^_F*_\\Q\*_P#T.^\__M=>_=>Z]]]_,5_YYCX5_P#H
M=]Y__:Z]^Z]U[[[^8K_SS'PK_P#0[[S_`/M=>_=>Z]]]_,5_YYCX5_\`H=]Y
M_P#VNO?NO=="O_F*'Z;8^%1L;&V^^\OJ/J/^9=?7W[KW7?WW\Q7_`)YCX5_^
MAWWG_P#:Z]^Z]U[[[^8K_P`\Q\*__0[[S_\`M=>_=>Z]]]_,5_YYCX5_^AWW
MG_\`:Z]^Z]U[[[^8K_SS'PK_`/0[[S_^UU[]U[KWWW\Q7_GF/A7_`.AWWG_]
MKKW[KW0)?)BM_F!'XW_((9K;7PV3$'I#M<91Z#?'=LE<F._N)GOOGHXZCKZ&
M"2J6EUF-7=%+V!8"Y]^Z]TING*W^8,.H>J!B]K_#3^'#K380HOO-\]WK5?;#
M:F)$1G2/KQT20KR5#-I^FH_4^."0>/7N.1PZ$?[[^8K_`,\Q\*__`$.^\_\`
M[77OW7NNOO\`^8I<#^['PJN?H/[]]Y7-OK;_`(QU^/?NO==_??S%?^>8^%?_
M`*'?>?\`]KKW[KW7'^(_S$M6C^[7PIU?ZG^_O>6KZ7^G^CJ_T]^Z]UR^^_F*
M_P#/,?"O_P!#OO/_`.UU[]U[KWWW\Q7_`)YCX5_^AWWG_P#:Z]^Z]U[[[^8K
M_P`\Q\*__0[[S_\`M=>_=>Z]]]_,5_YYCX5_^AWWG_\`:Z]^Z]U[[[^8K_SS
M'PK_`/0[[S_^UU[]U[KWWW\Q7_GF/A7_`.AWWG_]KKW[KW7OOOYBO_/,?"O_
M`-#OO/\`^UU[]U[IQ^/_`,?]VX?8/>^!^1]%U?NNO[^[?WWV%NG:>RX\]F-A
M4VWMU[>VKMFGVT\^[Z''Y3+S_9;8\U3,]-`GFG(B50BGW[KW43:>Z-S?&;<N
M"ZF[5S63W-TUN;*4FWND^Z,[52U^5VWE*^9*;"]-=QY>H)DER<\SI2[8W)4,
M?XT-%!7.,H(9LG[KW6?X'1R0_'F:&:-XIHOD'\RHY8I%*21R)\Q>^%>.1&`9
M'1@00>01[]U[HX_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__2W^/?NO=4V_S&>]\J_96R?@_\
M--C]9;K_`)B/R.P4F?B["W/L3;>\\%\/^A,960X3='RR[AAR&-K%J8-ON3CM
ME8:N98]Q[E\5.%F@@FIY2];*??+FZVNQN3:[9!H>_NE%##&_"""A7Q+^Z`TQ
M1HP:&+5=3/#&L;LJEN;?:+6VW"^MA<WDY9+.U8E?J77XGD89BL[>NJ>4!F<T
M@@221F\,B?S13)?RE>A?@!_+J^#&)^2&/;Y+]G]K3]P]L_&3K38G=GS6WYC>
MM>OW[+[JWMLG;_8=7A]C9'NWN'.UU,U=N/(FHIMJX6&H>AQ\B4E%30F%]?Q[
MIO\`9;5%:R6W+MGM<LD4%NP!BC@EMH+:$.P/Z(DN3+=N%\2:32"5-R["EM8S
M6NR\P<Q/)#<<Q7>Z6ZRRS*0CRW:SR3S"-#\:0VK1VL5?#C!5F8^%W%UW=\T?
MYF_5_P#+Z^;=>LOS-ZB;JWNSX/XGX7_)3Y\=*=2[#^2.ZL=WU\@=F]?]N;#[
M3VGL2IS/7/8.)ZZJJQC3Y6+'XNHR.(S"TTL:M3I,RBVM9=SW?VUVR>[B@N[_
M`)E^CE,(!$ED]L[Q/)"P.B97\2-RKZ93##.-#O*@+;JZ3;+7FR^%M/<[=!L4
MMUW40V]S;R1ZD28?VD=PI1DU1EHM=Q$2P6)@/_8?PT[2ZO\`YQG\IK&[I_F$
M_-#N7*R]9_-C?&1S'8F1Z.030;';H_<&X=BX^@VITUMJAQ'7_:<&2BQ^=I!'
M-6+08VD2BJZ297G.N7)H(-ZY\$2:;:#ERW8ZV+-(K;BL2I/)VZUB9A<(0%(F
MC5F+*67I[F&UDN>7^6YY90L\W,/AUC4*(F&VWLK20J0Y1B%:`!GD40S2"FL!
M^B;][?S$?D%L#,-\G>FOGA\L_E#OK;GRXZ[V/V)L[J7XFQ;;_E$[&ZDWGWWB
M^EFV55]J]C]<8?=&ZJ:7'UU1B:#>6VMX;DJLCN^F,BP0TLB5*)N3!)>;E[;6
M-V3<VV[7$$5W-*IA\4W,;-JL(>R2.E8Y+74)4>")I9Y&,X1_<W2"PV_GF:)_
MI[S;K>YDM(DH[H;0%F6]>C1R,-#K=@&)HGD$<4?Z!H>[=D'SF^3GR;_G&83:
M_P#,4[O^-W5OPIWAUY7=`[+ZFV3TU75=+O;+?$79W9^1AWYG][]?[ERVY>I$
MSE2)O[MPRT<M555-5(]=&/"BD4=W=V/(-WSMXWC;A;;AO4<<<@'@M'8SJX69
M1F0D%8HF!3P8U?4)C)V",6EI>\Z[1RQX)BV^YL=J:9E8^)KNO%C9H6.(L*SR
M5#^(Y328ECHY6NU?YH/R^^0>!_EK]5XN+YKX.7N[^7%LGYS_`"7SW\KWI;JK
MLCY$[JW5O#,8O8&W-OX"/NBMFVET_P!3T&YZ:ORN7KJ>ERM?65%10XR):>!Y
M9R,-YL8(.9N888XYUVVUM=O>%4/:L]_'-.XG=JM)%%%$8[=`%,C&265R8%5@
MSM<UU)RQM-Z3`]U<;IN=K*T@)?P=MDBB5H572BRS/,C32%=**NB-!XITW*_R
MP\OWU\F/C+D$_F`]![X7>74W=>]=F=.[G^5G3>Q-C]S]H]-8F+:FX.L^XM_]
M=8+([JVGLKL^I%5_#LJ^)FA@GR6#-9%'"9O&E98UBAY>W8R0+S!X+F4P558Y
MEGD4/"#5H!-"D$[1!W\*1GC1VC1#TTC.;K=]NI+)L]4:(RJ*E)(R'ADIVRM"
MQEC$NA/%@>,LHD:4=6Y^T'2WKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JG
M_P#F5_\`,\_@U_XDS'?_``1'Q1]^Z]U<![]U[KWOW7NO>_=>Z][]U[KWOW7N
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MMV[[G:VT,`0/%;V\-VNXSSR`D`O;6-E)#;Z131)=^.2CJ.@_9FXV[89=TOK1
M[B]VNSN+VXG5AXK3-:S6\<40<MICFOKJ.64L6$9BMA%&VDE#/2_-GNO9Q[,Z
M$QW><N7DV1\I^V.M-J]H;5ZLZ4H>P:?HGXR?'_JK=_?\.`INR=Y[(^/>#J^L
M.Y=_4V`AK-P3Y'(3X(5(%'5U].U9$67VYS7=@_,VXAX;6*#=KZZ9=)+6L&X2
M65I.68:3KF2X^H2".I$,100B1STLL]IFL9UV&Q\*62FU6L`)D*BXNK=KF2!,
M^(2MFD3H\[E5GE<,\RB->@OV?_,Q^5?86U?A=OJM[2Z\V-@-^]5?'S+=L3[)
MV/L_LO)8'MKY&=D4C]$T'R;Z?DS\?;.QNF?D7TU44$6!W1UW)70XC>%;7-7_
M`.XJE@]GIM;6VWT6EX"Q(M8C&C5A-VNVM?;M91R!6GCNX-<1LO'3P'5D6=F=
MC6DQB?8-QNK*=O$A>]E$DB`2?1QWC6=C=:=2V\L$DL4XO5A?Z@!0ULHJ:#_\
M(?G-\LOD'\A>F9=Z)08S8W?N&^0V^LYTGE!T3%#TSU1L+/R8+J;<.Q<WL;L+
M<?=.Y]UC*T]#B-Y+N[%XVC;+9>?^'T]&M`86*]KB>2T*W#I-*-HM;R617'Z<
MUVT+PQQ*@,;VKQ23HK.YGUVJR%J221+;>6-I>^%%#X:C=9K)5XATM4F6XE9G
M(?QO&BCD"QIX2QS^$U6"2MP_FR4W3.^L/N'=6T=XX[=?R`ZJWWT-T5F]N8GL
M[<D?=70<':>_]J9W'[]^*74%/D:';U5\H,I'N/%9*AKZE8#DL/BC3?=/#!+2
MR4V!9'YCV"XL)0;>[W>"&20$&1'M75G@76IT6GAR.VYHHJUHS3D2"*,!Z](&
MU[Q;74<;-!M5Q<+#+B"02Q2+'-(5()N$>+3M[5(6ZI'13*QZ7?\`,5^9O?O3
M_=D73/5&X)NJMF[#^)V\_D]V#W,N*Z+SM=79JGW9+L'K_9M5C>^]_P"P-N1=
M>T&1Q]7D=UU&$3)[CD\V-I*%:-JDRRE[W5R9=_NH4C+6@M8X(';0EQ=7C3^$
MLI&J<0$PK`C0`,9I7U/6()(HM+*&.UV"VF:5Q<33":;!DCM[2.`RO&"%A,S?
M4"1FF*Q)'"W8=>J(J/?_`,F/E7VWDMJ9O.[MZXV9C.I_F-_*DZ>QW16#PF$S
M>)WQ\NMR9KK3NSY2;6R?9^1K*O<`VKU;L'>8?%4>'B7)/D<"[3S20/-3L;"[
MY=VS<1<[[N;CENYW_<;2%HQ62*UVZUD$DDG9^JSWUM=0HR*B_HE2C!P8R*8[
MQ?[$&V*P<\P6_+]G>S*\?:\U[=!8`FIP%0V\EL\HJ2L<VM7#+5D'W%_-([>D
MPO>->_9^)DZL[.^#'S!^06T9MX[:ZRZ^V1LGKV/=.SNF?B9O/8F3VAV%N3O*
MBKM[;J[+QT6XQOJ+&2251G?&TU"8/MT*OW;>WNT;CL.[*/WU/:;3$U/PW>]7
MB01QJ(R4^G%JUTZ@R&<-;1EI*/)01I/'M^^6.Y66J2R@W&^"K&NIFAVBUFN;
MMVU@MXPGABC5Q&+<BXIH-$8K"/>78FWL?L/X([Z[PV[W#U)U)\C_`(+[6I>T
M\&M#US44>V^@>C]Q?*KY)]929_;>8,>]<#UGMWHO;M=45+22Y5:3=OV>6J*B
M11(QENF^6$.[GFV>=HK?;-PWW<(WTJ[SVFW;:C0.T"#PXV7<[Z.RJ/T-<00`
M2Q2$DUIMDQV$;#;P22[GN>U[59R0IDP7>Y;CX$@$Y[@;BQAGN]3-X@37*K".
M5*8XOFU\P)^E,[V'L?LKK/K>?KWXD]#]Z[UV9M#J;9&9R?8'R\^=O<^8S?Q\
MZMKWRF0;%X3!978U5B:?<K4B',9*7<<==2U-/.NJ2T=G=P75CL]M2:^AW/9]
MHC@D0P))=-#;S;U3N#+%"+Q&ABC"M'HD<DHI1O7EY:BUO+^6.2VMFL]YW$SO
M1BMC;O+#M=0*CQI!:2`%ZZU"I(H9U=#$;2^9GRD[([V^*T&"[HZKVNOR*^8G
M>W5.[?B?7[6VWF=V]8="_$G%]IT?9V8I-TTLJ[MF[(W%N_K_`!IRDV1`QF.H
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MO`5O"BFA5J)<1+<),MY$I^IT+']-W%CT3WX]?.S<?2>`S7:F]_D/CMR]9;HZ
M]^>W\Q7MW+]HTVTJ*>MV>>WSTG\3^D>M<WCI\;2XVEE&T*BH^UACJZZ2I2"B
M58Q41Q%!(U]:<LO";33N<>P;5],QTF2XW7?I9;F`RHN-(HUM&BT7]6)20(A1
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MTJW<DQD\/2BS<I;$2W<EO*_[MFDW>6.=Y(_%BL]LGDV^`Z"HC)7P&N9_&;4(
M1;1(J"4OT=;K3YJ]Y;Z^?N`ZPR/:6RL=U5O???8FS.N-H[2P6Q^S^L]W0])]
M8XE^_.L-R;_VIDE[GZ6^7/3_`'`N5>:FW-1ILC-[7H--"3D9!H.-MM[>3]YL
MUP;FW,5U/`XC:-)K+ZE(;*]M9"=#QC4D%_;S+XZ7,KF$B*+HOO9)Q8[1/'''
M!<@6,5RNL2-%?2Q2RW5K.F&"M$OC6,\!*>&J"XS+4B!W-\I.U<A\FNXM@;-^
M177'Q]Q7QPW;\<=E8#K;>FS,'O#)_*G?7<V)HNP\OM=HZN:+?5!CLALUS@MN
M':WBJQG$KJNJDJ*>C-(I-;W3Q6-WODEL]VBWUU;I9QT65TLK-+F=@:$K-()6
M>!I/T!'`K.CB8E#*2!99K?;UG2V#623M<N"4C>>ZFMH0PU*IA1X5\95'C/X]
M(WC9%UDPRW\RWY";/ZYVSWC_`*;.K^Q:[OSX@_)'Y#TW0V$VUM2HP_Q6R6&@
MVOA_C+C:[=>!)W9G\EG.UM\X?8^>IMQU#'+;CFJSC8J1:*:E56]K>(M[M-DX
MN]R>RVXQ7&G1$M]N5W;V]O$JK59K647-Q+#I8SM;[>9BQ$K@,1R1_O"VNKVW
M:WVN'<[Z*>`@M,;/;8+J6[EK4$3QFTCUT"PJ]ZD)`(B=IN^/E9_,!Z\W3WOM
M2;Y)=<[RS_QYW#_+LZKKL1B^DMHXJF[0^87R?S>V*#L;I#;U?/D)Y,;TC3[-
MW3BLT@TMO>BJ,I(XR/VE-'3S+;$V$M_:RR!GV2[YKDL;1]2C78V\$=SN,EQI
M#:)+2-I5@,9H&MYDN!*P#=%]R;J':IV<F/<HN5VOK@4#-;W,DL\.WHB_"XN)
M8A'.')U"6!K94UFB9S7\Q/OQ^NLCW/+\A-@;]V3W1UG_`#'][X'I/!["V_M>
MHZ:Z;ZDR>Z=J?&C>^8[$@R']YJ/>N2WJ^W-N5TF5*8[-5NX=-!2QU%&9)@U<
MVUS?;"-GN5U;A?<NV32RZ@O@7^ZW%E;V<*1IW$3QWTH\$DS&2REDC9425.A'
M;']W;]#>2$Q6]CS!-%X934TUMM]M=2WTK*P-!#/9&0,OZ:P7,4<U7>,]`]NC
MY0_)OI[JC?G1&!8T'5'QV:D^#F)ZNW/)TQ6TO<^WNM/C709+Y&=D;OWONOLI
M_D5%V@*3(Y?/[=7%X#^[\V+PE,U:U7_$I)HA%=;G;WVXWFZI<JVWS2[JX'96
MUV_;#=00S1QQJVN</:Q&XAGHGA3+''1PLT@=CV^]L-H@M&M&7=/IMND)+$^+
M?;H]O/+#*6(\.$)<ND9A+2^,DC#]-?"C0?QV^6WS2Z:^,_56T-J=Q9#<DNS/
MB/\`'?Y.9CLK>&"^/<U'W'WM\S]V;AW%UYTQNR?L3L'9FXL7T9@,/B:/:\5;
MLR@R6YOXIE'C%1$,9%2SV\&.+<HMBL+</)MNX6.TQPRR5:[D>&WN+R>:5*S"
M9C=&.R**8Y/"EEG:8@Z'))"]K=;W<H8X]TAW+<PRR(S6UO!)):VD2HRB$*H@
M$]R&:J*\$$0C+DDW_9_R1[M^3G8GQCVE/VYL3;N'[H_F:#I:O^'>,BQ:=B;:
MZC^%.=W;V-VSO'-;KQ=73;ZDWQ%O?I>%\U#(1MG^ZV7HX4IS-4+55*?EY+>Y
MWCE/<'E::"2QW#=HI-)C6W%LEQ;V`TU*R"22:U2X2;4ZWTICC"B$CKV\2SQ[
M3S3:1P)$5.W;=)4Z_$>_6TFO&C8+J#"%[KZ26/0BV\!EEUM)V&?^?'RO[<ZS
M[F[!VITO1];U&[NMOC%L*BZQR^[,!B=P93$_+/YG_(3%=!=`X^-'K:7-G!P8
M?;><RF3Q,#1+F*2!09%\`94&WK+N6YW%I:[U!;W$VZ;7MT:R(W"4W&X;FY8$
M!E@V^WAETD@(U')R*F%[/9[=8VL][;W?@)8;I?RF--:-':Q06]D.':TE]<M$
M&'$%D--0Z6G4ORK[7V'U3_,NWSW7V?A>T]C?"O<>],5MCN";:FU>OZK-9GKC
MX^[8['[;P%7M[;-0V!I\)LGL#+2XS&O,SUY59(*N:HEA\[M\PW<;<EW.Z;>&
MM=QGFOX+8,VIBJ3_`$=G(S4"&22\$T(*!49(XG,<;,XZOL5E/-SA9[)N#K-9
MB';WG:-6"J\R&:X534L%2V,$S`EFC:5QK9`M"+?$+K&K^&_Q"PWRB[:ZJ^#N
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M_O+<+6SVV*:,.K*L49OIC1O$N1`GP*VKI-0?S&N\ME;0V#W]N/OK`;WPNZ]P
M?,G;N=^,/^C;9..WMU[TY\3MD=O-DN]^P<SMZ,[BP?:&#W9U=B9]UX^1:;;*
MR[M3%T-%!/'2RS!1[V\EV?ZBRC1KV^Y<-^KC]2&RGF%LME$I4CQE>>>.SD64
M^(URUPT95+<Q`2M8"VW^+:KDAXK7?[>Q<*X\:[B)=KEA&5JCF$2W5N8^Q;6*
MW\:KW!<,.:^>?S>ZQPV!Z_I^WMA_)3M/M7K3X14&YMY[,ZVZYV[M?XP]U_)/
M=NY,;N_'X5,CO':6S=R+5=>[9K\IMK";NS4%4,O%0M6U)H<C%2D27]K'#OFY
M\O1R/]-;[L;878:-6D%M97-W>PQ+(IB>73#;20%=8BCO&63ZB2)-0?VN>YNM
MJL]^:.-FGVJ2Z%LP=0OBW5K;V4DC*6D6.MU*D^1XS6;>#X(:0I:U_+Q[H[;[
MMZG[$S/:N8I-WQ;0[S[%Z\Z_[!;_`$:P;EWOLS:LF,IY:G?F-Z<SVYNJZ#>F
MUMWS97`5;8&L;'5:XJ.H5(GED0-`>)MFSW[1QH]S%(X\-F>-XA/+'!,I<!@9
MHD5W3*K)J*-X;(%=U.FZ[Q8@.8+=H5J^@.LK6\4D\15":".1B$+4<H0KJ'5B
M3\^V>E'7O?NO=>]^Z]U[W[KW3'N7;.W]Y;?R^U=UX;';AVWGZ"HQ>:PF6I8J
MW'9*@JD,<]+5TTRM')&ZG^EU(!!!`/OW7NJMOY5NY=QXO9_:_15)'E-W]8]/
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MMU::!8U#5*!$C5=`,G4K1<K^V>[PV.][O[IK:;PUA!&\*;7<R-#'#6,0!@XB
M:7Q"9V*%8I8FDG>7ZG1:E49+^6MO#>G25%U#VMF/G+W9NS;7:E'W=TI\G.V_
MFCUE_LT7QO[)_@D>`P.1ZC[,V%U9MR@VUB*##I5Q[BQM5B\[0235[+%!EX6#
M4]Y]RWV63:+JVY96VW*T$ZK<1SHLSQ7002V\S4=7MW2,)/&%(H1H\0A717'R
M/[21IND-Y[V/<65P8M</[INWB#6I<^-;AFB*SF20/82LT9=4;ZHV68Y8=%_*
MRP,W1G<'3.\NMOE#VYF_D+V/T;VGW5\BNY_E[L?=_P`E.Q\MT%OS`;QZ2P.Y
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M;+K8=P?ETW>Y[9+;O!-<7*S2HMH0%@U/0/$\2QVX9P)F@CT&6`EBZ?=.0_:/
M>4W^V/O8;>RW1)TFC3:+F%'-Z"?&D6,OX3Q2:YKM8#)#%<.C6T5_DQ6+;2^.
M^Z=C[R^9>]\3\?=W3YWYS9?;N3[M\G?VR:C$4-=M;J#$=0M)UK$VU<?683&U
MNP,1"M(]9]Q43[C,HJ$I*`15/LIE;>9.5KCD]N73^ZI+B_E9A<1^)KW$A[G2
MY4=@``MZJ"KU5^RC]&EORS[3Q<PVW-$7O0POHH;5$5]HNM(2T+K:AT65@)!(
MS/=A'9/I=$D+37)>V!6=T_RP,;F^I?BKUGL7KOY*=!;Z^&W6\?2G1'R@Z-^7
M.QM@_(?$=65&)H:?(;(WCND=?9[:.\-F;DQF(I?XS35NWJM:3<$*-BH%@:3(
M`QO-UYDO=YEWS]PF&^FM(;27P[E`D]O;J/`CG!#%UB8"4-76ER24K&S-T56W
M(?L]9[7^[?\`7E::V2ZFO$#;1=-)%//*WU+V[>(@621G98U:D<MAFX>.Y5+8
MGV^!?QUI?BCUU7=0;;ZLWUMK#93.9SM7>W:W;?=-'W1V_P!U=L;\JJ>7=6^^
MU=SQ1"IRO9N<^P27,RQB+$4I2"FQODID`A,K7<MQNTLK&;88[':[2W$<")('
M55+M(5I5GUM(\DLK,[5DD.EV'PACF7E;DC8H)=PY?]QVWW>[JZ/CCZ&:UIX<
M:H)%>0(AM]*QQ6BI''(8XV:>&W?$A]?:WH%=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=5!?S+:3.U'</Q`K]O;2W;OJLVGF<]O_(;5V#A?[R[UR6V-A=T_
M%_=.[)ML[;6IHY]P9+%[?QM14BCAD$\ZQ%8PSV4^Z]T9\_.3!?\`>,OS>/\`
MK?%?L?\`^I??NO=>_P!GDP7_`'C)\WO_`$E?L?\`^I??NO=>_P!GDP7_`'C)
M\WO_`$E?L?\`^I??NO=>_P!GDP7_`'C)\WO_`$E?L?\`^I??NO=>_P!GDP7_
M`'C)\WO_`$E?L?\`^I??NO=>_P!GDP7_`'C)\WO_`$E?L?\`^I??NO=,N>^8
M&P-TT4.-W/\`$;YB;CQU/D<7F(*#/?$+?.7HH,OA*^GRN%RD-+D,=401Y'$9
M2DBJ:6=5$M//&DD;*Z@CP&F6"=<3Q/J1OQ(U"NI3Q5M+,*BAH2.!/7CW1S0G
M,,B%77R930E6'!E)`)!J,#KK-_+_`*_W,F,CW)\1?F'N"/"YK&[DPT>;^(6^
M,LF)W%A9C48?/XQ:_'5"T&:Q-0?)3546B>!_4C*>??AVNDBXD6M#YC4K(U#Q
M&I&9#3BK,IP2.O'*21',;@!AY,`RN`1P-'56%>#*K#(!Z0.X^Z?C=O&@CQ>[
MOY?GR%W3C(MW9#L"+';C^".7SE!%OW+^;^*[VCH\GMVJITW=D_N9/N,D%%;-
MY&UR-J-ZA$`@4(`L4;QICX$D8LZ+_"CL2SJ*!F))!)ZOXDE)E\1M,A0MD]QC
M`5"WJ44!4)KI``%`!UX=T_&Y=R;,WDO\OSY"KN_KC#TVWNO-UCX(Y<;DV'@*
M):M*/![,S@V[_%-KX>D3(3B*FH98(8Q/(%4:VNZDCQRS3QN5GD4*[`T9E"Z`
MK$990G:`:C3V\,=,^''X*6V@?3JY<+0:0Y8.6"\`Q<!RU*E@&K4`]/FU/DAT
MGL3.[NW1L?X._*'9NYNP,@F6W[N+:GPGW-M[.[VRL4M7-'D]W9?$86CR&Y,A
M'-7SNLU;)-(&FD(-W:[<*K;VR6<`"6BL6"+A`S&K,%%%!8Y)I4GCU>3]687$
MO=/ITZCEM..W4<TP,5I@>@ZQY/Y%=&YO?N#[5S/P8^3N6[0VQ0OC-M=D9/X2
M;CK]^[>QLJ5L<F/P>\*K!R[AQ-#(F2J5:*GJ(XR*B0$>MKZA5;>6>>W4)/*N
MEV7M9UI2C$4+"F*&HICKTOZ\<44_?%&VI5;(5J@ZE!P#4`U&:@'CUDWE\D.D
MNQ<CM3+]@_!WY0[ZRVP\NFX-C93>7PGW-N?([,ST<U)41YO:E;F\)75.W<ND
M]!`XJ:-H9@\,9U712-Q@0W*7D0TW:H5#C#A6IJ4,.X*U!45H:"O#K4@$L$EM
M*-5L_P`2'*M@C*G!P2,C@2/,]%3^7WR)ZJK=K](OC?B)\F=N5-+\\/BSVD]7
M6_$/<&%-=OL]P;;BRFXZ:JGH:5Y=_;@Q+3T0KD+Y"K$_VQ=EF(/BJL(`R@B+
M5HJ*Z-;,SZ/X=3.[-IIJ+N34LU71-,&F99G#2*JO0D:U4*JJV>Y55$"@U`"(
M`**M!^Q_9_Q5Q$FX9,5_+F[RQDF[)*R7=4F.^`=91ON:7(9:FS]?+N!Z;;$9
MS3UV=HH:V9JGR&6KA29KR*K#R`1Q10(`L*!0JC"J%KI"C@`NHZ:<*FG$]49B
M\TEPY)G?5J8Y9M0`:IXG4``U3D``].N)[L^..!PF(VS@_P"7_P#(C"[;V\NZ
MTP&W\3\$\QCL)@TWW2U=%OA<1BJ/;L-!C5WE15\\.5$,:#(Q32)4>178&\CO
M*GA2N6C\`PT)J/!+*YBH<>&756,?PEE5J5`/6T=XY6GC<K,9EF+`T8S*I192
M>/B*C,JO\04E0:$CIXB^1W2$,%32P_!OY014U;5[1R%93Q?";<L<%77]?PXZ
MGV'6U,*X01SU>R8,/2)B)'!?&I2PK3F,1(%O+/-/,EQ-,SW"SO,&8DL)G72\
MH8Y$KKVM(#J9<$D=-*B)$T"(!`8!"5`HIA!)$1'`Q@LQ"?""Q-*D]%/ZDV_T
M'U9\@JKY-U_17\QGM/MN#&;UPFU-S=C_`!1,F7VEB^PLABZK=$8W!LOK39FZ
M-\Y2HQF!QV'ILENFNSN3HL)CX:.&H5#.TU-N;]V6=Y:VP`>XBCBE?@7CB<R@
M%%TQ!I)CXT\BQB2:4!W8T(-]P_W97L%Y,`JQ2-(B+A5=D,8[C60I'&SI!$SF
M*%9'"(*KI-3GOD+T1NG>^V^S-S_!3Y,[C[(V;"*?:'8.>^$.X<OO?:E.):B<
M0;;W7D,%49[!PB>KE?32U$2ZY'-KL;ZA)MY)9H#HF==+,N"RE2I#$4)&EF6A
MQI8C@3UZ3]6-(9>Z)6U!3D!JJ=0!P#5$-1FJJ>*BB/R'87Q)RU#M[&97^6WW
M3D\;M&HS57M3'9#^7W/6T.V*K<N6&?W'4[>I*G:LE/A:C/YU16UKTRQ-558\
MTI:3U>ZQ@0O#+$`LD:1HA&"J1$M$JD958V),:B@0DE0">K2,TWC^,Q?Q9'=Z
MYUO(`LCM7XF=0%=C4LH`8D`=*6N[V^/64WS)V=D_@/\`([(]E34D6/F[#KO@
MQFZO?,M!!CZC$0T4F[:C;\F?>DAQ59-2K&:@HM/*\8&AF4T$406Z01KHG#"0
M4%)`Z:'#C\89`$8-4,@TFHQU[6^NUDU'Q("IC-<QE7\12AXH5?O4K2C]PSGK
MJJ[T^/%=D^O\W6_`;Y&UF9ZFI(,?U7EZKX+YNHR?6=!30P4]-1=?U\NWWJMF
M4E/!2Q(D>.>F1$C4``*`'@[BZGO0Y^LE32\E>]U[NUF^)E[VP21W-ZGIO0GT
MZVFD?2J^H)3L#5!U!>`:JJ:TK4`\0.I>%^0?0VV]][A[2V[\$ODQ@.S=W0&F
MW9V+A?A!N'%;[W/3'[*]/N'=U#@H-P9J`_PRFNE342K_`)/'QZ%MJ,F&*2"$
MZ(';4RC"LU6;40,$ZF8U.:LQXD]6E`GDAEG[Y8Q12V2HIIHI.0-.*"F,<.IM
M?\E>E\KOO"=I93X0_*7)=F[:QE3A=N=BU_PJW16;[P&&K%JUK,3A-W5&&DW!
MBL95+D)Q)!!41Q.)Y-2G6UZQ`0/<20C1),H60K@NJD$*Y&6`(!`:H!`(ZU(!
M,L"3#6D3ET!R$8BA90?A8C!(H2,5ITP8GNOXWX'^]_\``_Y?OR&PO^D+-T&Y
M=_?PGX)9?'?WXW'BLJV=QF?W?]GMV'^\N;QV;<UD%56^>>&K)F1A(=7O=O\`
MXK':PVOZ<4#ZXU3M$;X[D`H$;`[EH<#/5I29IY;F8Z[F1"C.V69&%&1F.2K`
MD%2:$&A'4G=?R!Z;W;A-UX>J^'7S!QE1O#(R;BR6XL)\.MTT6YZ?>Z8./;N*
M['Q^7DP52\/8>W,930)C<Q(LM71BEA"-HC50BO+&&]VZYVQF:.VDCG6L9T,G
MU*2).T9'P/(LLFMAEM;:JZC53;7;VU_;[B426>-H320:U<6[K)"C@_%'&RJ5
M0FBT&FA`/0>=5;I^*G3W6^-ZOVI\!_E!4X"GV1U[L+<.0S_PES>6W'V)ANKL
M=1X_9E5V;F7VU%-OK+XIZ):E*BO60QUCO-&(V;V<37L\L[SJ?#K.)@J555D4
M@HZBN&32H1JEUTKW5%>BV*VBB15H6(CECU,2S&.8LTR%FJ2DI9C(GPM4U!Z9
M_DEW_P!(U_6/R,[&A^$WR4Q?:FX/COVKLVO[9K?A=GZ'>+;=JMB96F&*S&_)
ML/%G&VU3>"%I()JO[9(X5)4!`0B15B2ZCC4+'.090!02$`*#(.#D*`!JK@`<
M!TI8EVMW8DO":QGS0]V4/%3WME:?$WJ>IO3G;_QOQO6WQQKH_@)WY/F>I>M-
MH4W6>?Q_P6R#U&PXZO;V/J*U^O<E2X&5]IT^1J)GFD&-EA61Y"6N227`[K/)
M=*Y%T\2Q,]>]HE!58RWQ%%4D*A.D`D`4)ZIH0PBWT#Z<2&0)3M#LP=G"\-9=
M58M2I8!B:@'H4J/OSX_X[?\`7=KX_P"!GR3H>TLG(TN2[)H_@YGJ7?\`D)7Q
ML>%>2NWC!@4W%5R/AX4I"9*EB:9!%^@!?=(@($>.$!$8L2%P"7(9B0.)9@&8
M^9`)J0.KRDSLCSG6ZJH!;)`6ND`G@%U-I`P*FG$]/-?\GNH,KF)=PY3X4_*S
M);@J,AMC+SYRO^%^ZZS,3979$E=-LS)RY.HP\E;)D-HS92I?%S%S)0-42F!H
MS(]]I^F0T?:P=FJ,=SQ^"[8_$\/Z3'BT?8:KCJQDD92C.2A0)2IIH63Q56G\
M(E_4"\!)W@:L]=U'R@ZAJ]O[IVG5?"KY6U.U=\5&<J]Z[9J/AANR;;^\*K=&
MO^\M3NG#28AL=N"HW#Y&^^>KCF:KU'RE[^Z/'')#%;21JUNGPJ0"J]YD[5.!
M^H2^!\9+?$:];CFFBF^HBE9;C'<"0V%"#N&<(`@S\("\!3H/=H=B?$OKZ;-5
M&POY;O=>R)]RX"MVIN.?:'\ORHVU-G]K9+1_$=M9J3#;5HGRN`R'B7ST<YDI
MY=(U(;#W=P)89K>7NMY*:U.5:E::E.&I4TJ#2I]>F0B":"X"@3Q$E&IW(3@E
M3Q4D8-".GW9W=OQQZ[BQL'7_`/+_`/D1L6#"Y=]P8>'9WP3S&V(L3GY<#+M6
M3.8V/";=H4H<O)MB=\:U3$$F-`[4Y;Q$H;B20!5#D*H<#/`2%&D`]!(T:,X_
M&40M4J*:,<9#J4!5BA.!DQ%C&3ZF,NY0GX"S:::C4-.W,]\8.X=J]L[9RGPE
M^8.S:[O*#"T7;&_.M?AUN+9?96^L9AMP8;</\*W-OB@VS)F<YCLK)A8Z6LCJ
MWG\U%++$"I8,K42)";,1J!!#>PW7AC$;S03"X0NHIJK*"7X,P9QJ[VJ^99"T
M\C,3-):36VNIUK%/"8'"-6JTC("T-`43!"@="9#W=\<Z?9^Z>O8/@#\B8-@[
MZRM;G=[;'A^"F9CV?O'.9&:DJ,AF=T[:3;RX7<.5KYZ"!YJBK@FFE>&,LQ**
M1J2..6&WMI8U:WB(**0"J:6UKH4X6C]XH!1NX9STU&!%+)-$-,SKI9AAF4+H
M`)&2-/;0XTXX8Z7>W/F#L#9^!Q&U=I?$;YB;6VQM['TN(P&W-N?$/?.$P.#Q
M-#$M/18S$8?&8ZEQ^-Q]'`@2*&&-(XT`"J`/;\LLLSM+-(SRGB6))/VDY/58
MXXXET1(%6I-``!5B6)QYDDDGS)).3T]?[/)@O^\9/F]_Z2OV/_\`4OMOJ_7O
M]GDP7_>,GS>_])7['_\`J7W[KW7O]GDP7_>,GS>_])7['_\`J7W[KW0[=&=[
M[+^0.U\WN?9M!O+"-M?>.;V!NO;/8.S\UL7>.V-W;?CH*G(8?-[=SM/3UE-(
M:#*TM3#(NN&:GJ8W1R#Q[KW09[SW[NSNG>>9Z5Z0S55M_;^U<B,5WSWKBQ&Y
MV?.@AGK>HNJZJ1):3(]QY*CF5<ED`):79M),))!)E)*:FC]U[I'?RY-L[>V9
M\5,-M+:6)CP>V=M=U_+K"8+$QU5;7FBQF-^7?>E)213Y')U%7D\G6&*(-/55
M,LM153,TLKL[L3[KW1Y??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U-_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW1+NV8I&^;OP[D6-S&G6ORLUR!&*)>CZ9`U,!I6Y8#G\GW[K
MW1T??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=$B^=:R-LWX]^-78+\W?ANTF@,0L8[ZV>"SZ?HFHCD\7M
M[]U[H[OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7N@$^588_%[Y(A`Q<]!]PA0H)8L>O-Q!0H')8GZ>_=>
MZ5'1@9>DNG5<,''5G7P<."&##:6(#!@>0P/UOS?W[KW0I^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ?J6+N/>G8GR_
MZ4V+1;UZMP60^6&\=Q=E=[UV`R."FH=FY[KOK#^'[6Z%K<S1QTFZ=_[FI:1E
MFS].E1B]JTK&0-/DC3TZ>Z]U9;L;8VTNM=I8+8NQ<%0[:VGMNB%!A\-CUD\-
M-"9)*B>::>>2:KK\C7UDTE15U=1)+55E5+)//))-([M[KW18_@;&\7QXDCE1
MXY$^0/S(5T=2CJ1\Q.][AE8!E(_Q]^Z]T<?W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_5WD>V
MN@>M>[UQ2]@1;YE&%9WH/[F]N]N=7$-()%;[P]7;YV:<FMI3857F`-B+$"WN
MO=`M_L@'QJ_Y5.\O_2NOES_]O+W[KW7O]D`^-7_*IWE_Z5U\N?\`[>7OW7NO
M?[(!\:O^53O+_P!*Z^7/_P!O+W[KW7O]D`^-7_*IWE_Z5U\N?_MY>_=>Z]_L
M@'QJ_P"53O+_`-*Z^7/_`-O+W[KW7O\`9`/C5_RJ=Y?^E=?+G_[>7OW7NO?[
M(!\:O^53O+_TKKY<_P#V\O?NO=>_V0#XU?\`*IWE_P"E=?+G_P"WE[]U[KW^
MR`?&K_E4[R_]*Z^7/_V\O?NO=>_V0#XU?\JG>7_I77RY_P#MY>_=>Z]_L@'Q
MJ_Y5.\O_`$KKY<__`&\O?NO=>_V0#XU?\JG>7_I77RY_^WE[]U[KW^R`?&K_
M`)5.\O\`TKKY<_\`V\O?NO=>_P!D`^-7_*IWE_Z5U\N?_MY>_=>Z]_L@'QJ_
MY5.\O_2NOES_`/;R]^Z]T43M#X/?'FB^8_Q-P<%)W,*+,]=_)Z>N:7Y4_*:H
MK->,H^I?M!29*H[EER>-C'WTOE2FFB2HNOE#^--/NO=&[_V0#XU?\JG>7_I7
M7RY_^WE[]U[KW^R`?&K_`)5.\O\`TKKY<_\`V\O?NO=>_P!D`^-7_*IWE_Z5
MU\N?_MY>_=>Z]_L@'QJ_Y5.\O_2NOES_`/;R]^Z]U[_9`/C5_P`JG>7_`*5U
M\N?_`+>7OW7NO?[(!\:O^53O+_TKKY<__;R]^Z]U[_9`/C5_RJ=Y?^E=?+G_
M`.WE[]U[KW^R`?&K_E4[R_\`2NOES_\`;R]^Z]U[_9`/C5_RJ=Y?^E=?+G_[
M>7OW7NO?[(!\:O\`E4[R_P#2NOES_P#;R]^Z]U[_`&0#XU?\JG>7_I77RY_^
MWE[]U[KW^R`?&K_E4[R_]*Z^7/\`]O+W[KW7O]D`^-7_`"J=Y?\`I77RY_\`
MMY>_=>Z)U\TOA!\?-O;2Z'FQM+W,),C\ROB3A:C[WY3?*3*H*++=V;6H*PP1
M9;N2NCI*S[:=Q#4PB.JIG(DADCD56'NO='%_V0'XU_\`*IWE_P"E=?+G_P"W
ME[]U[KW^R`?&K_E4[R_]*Z^7/_V\O?NO=>_V0#XU?\JG>7_I77RY_P#MY>_=
M>Z]_L@'QJ_Y5.\O_`$KKY<__`&\O?NO=>_V0#XU?\JG>7_I77RY_^WE[]U[K
MW^R`?&K_`)5.\O\`TKKY<_\`V\O?NO=>_P!D`^-7_*IWE_Z5U\N?_MY>_=>Z
M]_L@'QJ_Y5.\O_2NOES_`/;R]^Z]U[_9`/C5_P`JG>7_`*5U\N?_`+>7OW7N
MO?[(!\:O^53O+_TKKY<__;R]^Z]U[_9`/C5_RJ=Y?^E=?+G_`.WE[]U[IGW#
M\&?C'MS`9S<-70][2TN"P^3S-3'%\N_EN)9*?%T4]=,D9?O-4$CQP$"Y`O\`
M7W[KW0`?%#JOX0_,#J3$]K==XSY*;=FD^SH=Y];;\^5GRMPG9W5>Z:K$8W.M
MLSL?;-)\@<F-O;CCP^8I*M8O-(DU)50S1LR2`^_=>Z5'R;^"/QTQ/QM^0F5H
MZ7NO[O&]']L5]+]U\K_E=7TWW%'L+/U,/W%#7]UU5#6P>6,:XIHI(I%NKJRD
M@^Z]TI.E_@;\<<AT[U-7U%)W;YZSK+855-X/EG\L:6$23[5Q,CB&EI.[8*6G
MB#-Z4C1$0<*H``]^Z]T)?^R`?&K_`)5.\O\`TKKY<_\`V\O?NO=>_P!D`^-7
M_*IWE_Z5U\N?_MY>_=>Z]_L@'QJ_Y5.\O_2NOES_`/;R]^Z]U[_9`/C5_P`J
MG>7_`*5U\N?_`+>7OW7NO?[(!\:O^53O+_TKKY<__;R]^Z]U[_9`/C5_RJ=Y
M?^E=?+G_`.WE[]U[KW^R`?&K_E4[R_\`2NOES_\`;R]^Z]U[_9`/C5_RJ=Y?
M^E=?+G_[>7OW7NO?[(!\:O\`E4[R_P#2NOES_P#;R]^Z]U[_`&0#XU?\JG>7
M_I77RY_^WE[]U[KW^R`?&K_E4[R_]*Z^7/\`]O+W[KW663X#_'&98DEB[WE2
M"/Q0+)\OOEXZPQ:F?QQ*W>9$<>IB;"PN3[]U[K&/@#\:P012=Y7!!'_.77RY
M^HY'_-<??NO=%*^$OP;^/&X.A7R60I.YQ4?Z=/EI0`4/RI^4^*IQ2X;Y7]UX
M:A'VF*[FH:,SBAH(Q--X_-4RZIIFDFDDD;W7NC:?[(!\:O\`E4[R_P#2NOES
M_P#;R]^Z]U[_`&0#XU?\JG>7_I77RY_^WE[]U[KW^R`?&K_E4[R_]*Z^7/\`
M]O+W[KW7O]D`^-7_`"J=Y?\`I77RY_\`MY>_=>Z]_L@'QJ_Y5.\O_2NOES_]
MO+W[KW7O]D`^-7_*IWE_Z5U\N?\`[>7OW7NO?[(!\:O^53O+_P!*Z^7/_P!O
M+W[KW7O]D`^-7_*IWE_Z5U\N?_MY>_=>Z]_L@'QJ_P"53O+_`-*Z^7/_`-O+
MW[KW7O\`9`/C5_RJ=Y?^E=?+G_[>7OW7NO?[(!\:O^53O+_TKKY<_P#V\O?N
MO=>_V0#XU?\`*IWE_P"E=?+G_P"WE[]U[KW^R`?&K_E4[R_]*Z^7/_V\O?NO
M=";C_B_U%B^L<_U!1P]D#9&YJRBKLM'4][=ZU^ZVJ,?E:/-4O\.[&KNR*GL;
M!P"OH8_)#0Y6GBFAU0R*T+O&WNO=?__6W^/?NO=)^NW9M;&54E%DMR[?Q]9"
M$,M)79G'4E5$)%#QF2GGJ8Y4#H;BX%QR/>@0U:&M#3\_3K9!%*CIQQ^5QF7@
M:IQ.1H,G3+(T35&/K*>M@650K-&TM-)+&)%#`D7N`1[M0@`D8/5:BI%<]3_>
MNM]8WFBC>*-Y8TDG9D@C=U5YF1&E=8E)#2,L:%B!<A03]![]7-/.E?RP*_94
MC]H]>MT-*TQUD]^ZUU[W[KW7O?NO=>]^Z]TG*K>&TJ&HFHZW=.W*.KIW,=12
MU6;QE/402``E)H):I)8G`/T8`^]`@Y!QUL@BE13K/+N?;4%#392;<.#AQE8S
M)1Y&7+4$=#5.A8.M-5O4"GG9"AN%8D6/]/>S@A3@D5_+K0[@Q&0#0_(_/K+3
M9_!5M!596BS6*K,90B<UN1I,A25-%2"EA6HJ?N:J":2"`P4[!WU,-*$$\'WI
MF"*7<T0`DDX%!Q-?0=616D=8T4F0D``9))X"GJ?+I"=4]W]0=YXC+9[ISLK9
MO9F&P6;K=N9G);,SU!G:7%YS'R-'5XRNDH9I13U2%=2AK"2,AT+(RL7%CD:T
MLK\(?H[E-<3T[76M*J?.AP?,'CTUXD?U%W::A]3`Y21?-&!(H1]H-#P-#0GH
M4O=.K]>]^Z]U[W[KW557SS^2W7'Q/^2WPD[/[.I-[97&;D_TZ].[0VWUOLW+
M;_WSO#LWL>CZR_N9M';FT\&KY/)Y'.?P"K2(1@_NJB&VL$>Z]U.R/\V/I+$K
MD7R/1GS`IH<2F^9LC5#H.OJ:."DZTR%)@=]9"*KH\_44U?C<'NVOBP,-13--
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M^6Z$^8U!#B!OM\I52]`9"6CHZ;J^>DQW8M?]Y39Z>EJL9M/<=?#A)*F!Y:>M
MW#)_":%ZK(I)3)[KW7*7^:OT[335=/6="?,.@EQU5G*/+??]$3T<6'FVCM2+
M>^^WRU3/N5*6@H^N]M5,,FX*F1Q38:MJ(L;521Y21*(^Z]US7^:EU*:BFHY/
MCS\T:2MJ<E@L**3)?'C*8J>ES6X=H2=BTV(R@R>=I$PM=A^N(QN#.+6&!=LX
MF6&7,&@,\*2>Z]U&Q?\`->Z<S9Q:X?X__,[(S9L;*&'I8?CQE8JW(U'9,M:>
MOL?%0U><IZR'*[LQ6-J,O#1S)%54NWXCEZR.FQC)5M[KW72?S7^F9Z2GKZ3H
M'YGU]'6X["9;&3X_XZ9NN_B^-W;NVHV)L2IQ$-+EY:C)MV/NNBJ*?;D,*/49
MRFI9J^CCFQL3UB^Z]UCF_FR](P0UE2W1?S!EI:&EW#7SU5'T'79&"7'[9W+3
M['KZ_'OC\_5?Q>DR6_:I<%A6HQ/_`'ERRR4^'%>T,QC]U[J7D?YK'3F(_B1R
MO0GS%Q\>&._?XO4S=!5TE'CH.JHJ`=G5T]=39^>CDQ>Q,ME*;$5M7%))32[A
MG7#TKU&4#4B^Z]T6;Y1?S!=B]JX7JK`;;Z`^6]-E=@_*KX_;^W53Y_I)]OQ8
M/`=.[FVWW5VO/E*O*[DIJ.A;K3K6D^]SXDD48:KJ*?'59AR4Z49]U[HS]/\`
MS3NJ:J:BIHOCK\U%JLA7;8Q=-257QURV/J4R^\-K5._<+B*^+(9RE;$9*'KR
ME?<65BK/`VWL(8ZO+_8QS0F3W7NH-!_-AZ9RJXTXOH'YFY!\S#LV7#4\'QXR
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M:R-30YRJCQ"2295OLQ[KW7!OYJ_3\56U!5=`?,C'5L60.)K*?*]!5F).+R=+
ML\=@YZDS,N2W%2T^&_N7LAX\CN*6J>*#;BSPTV3>EK9HZ9O=>ZR4'\U#J?)R
MX^GH?CM\TY:O*UFT,;0T<GQVRM)5OEM][?K]Y;7P]7!6YRGDQ66J-A8R?<5?
M3U@IY,%M]!D,L*&FDBD?W7NF^D_FS])Y"+'38[H7YF5ZYFCVA78:.F^.V::J
MR\'8F:J\%UQ'CZ%\Q'6S5_8%1CZBKQ-(8Q5U&%IWRYB3$C[T^Z]UG7^:[TU)
M3-64W07S*R%+]C_$X)\3\>\IF%R&.J=[#K7`5F(3%9RLFS$>^.PM>(VTM*LT
MFYJB&67%+64D4E0ONO=<*[^;%TIC%R$E=T5\PH(<5'O2HKZE>@Z^JI8J/KO*
M4FW=Y9""IH\_40Y''XS>%?%@::>E:>/,YYFQV+-;5QRQ)[KW4JJ_FJ]/4#UZ
M9#H3YA4`Q$F[TS$M5T/4+2XA.N=OT6YNRZO)5B;DDI*;&=;X[)TL&;JR_P!K
M0Y:ICQ+2'*M]D/=>Z2V]_P":#U7F=L[NVE%\??F7C\_EL3E-HQ4&7Z#K]O34
M.Y<QUO6[[DQ&7JLMGJ6FVY5;8V/+%E=PRUK00;5IIX5S+T,\L<+>Z]U6/\:8
M.SNH=M=`[[ZFIDP'<>R.INI.O'V9/MIMG;5[$V]DL!4[DPO16Z]A_<RYO#1[
MII*O+978U/4U*[Q@EGR/9>_,G0[<2#&5/NO=7-YOY)]?_)KX._(S>&SJE*'-
MX_H'MFAWWL2LJHIMP[$W#+UMN63[#(!$B3*8#+Q1FLP.=I5?#[FPLM/E,9/4
M4-3#,WNO=&MZ)_YDATW_`.(JZ\_]Y'$>_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-?@5_V3JW
M_BP'S(_^#$[X]^Z]T<KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_7W^/?NO=:\W\W+H?^7WC-
MY;;K5_E__&_Y@_S/?F1F8MC?'/8G8FSZ?*U.\L]M/`8[&Y+MGNG*4\T-?B>A
M>C-GT-/6;BR!:)I*.FAH(98Y:A982E;*ZN;F?8N65BBOY`;BXE;^RL[=WTRW
ML]`U-352WC"L]U=%8XXY*2Z5\US##9)NV^R3/M\16"&-"!-<RFI2UMM7:&SK
MEE>D-M%665A6-7+5V%EMB?\`"<GX4_$_XB=+;WZQV7V]\MNYM\YKMKY2]J=9
M]D;VZGV;N7&;+HMU=W=N8[HCI:FK-XYS[*DI<-MK8>SL;]ECX8FI7R=<D=/6
M5-0>;IN<-[NFS<M;?<2P;'8[=(R22+X\[1PR1*!)1@#<7L\YDEE9S'"BRJ@;
M3"A066VM!8\R\W7=DDNZ75]`AAA;PX8WN?%T*A856ULX89"JJOB324(13*^E
M.83^>;\B\C\(OFIOOK/,],_)/N'XE]M?#[;76WR&QW1_=_171'R3VK\J.Y]N
M]=Q86MZM[2;$[RV%OO85545^-SGV&4RE`B/1UM/(S/+`GH;6^W"]Y#M(+=+:
M?=.8#MKAV+QM'],TT=S&XHZAZ@21LA,<T$JKKADB;I-<7=GMR\PO>W+2VT&S
M27T;QH=<302(L\$ZM^F6I0PNL@$D<Z,55X9`PG]A=>_S)<)_."_E.8_O+Y>_
M'+?64J^O/FEN>IQ^POBQNG9&`Q^S\/%TK)VKM"AAR?>>Z:C)YW=6U,A28[`Y
MZ>2"7!R4U3/+25BU;4_NW+?TR[YSNG=(D7+L&MF`#R1ON,:HJ*`RP/XZQ2R,
MK-XD<9A(':POO\=V_+_+\\)$+2[^%106=8Y!MU\Y+FJ>,BP^+&JLB'Q)$EKV
M%.@W^0_\Y;Y/_&[M?%[JWK\H/Y=NX*N;Y4;8Z2SO\L;J*GW%W3\@]E[`W!V5
MC>LYZ_L#Y-;"WS7[4Z^[=Q6/R@S\]'G]LXC!+4PR8F.HFK(S#(CY39]WO^2=
MMNPLTV[3)%<20']"Q>4,`$E(9;GP)/#BD!\-[AOJ&A5(XPZ7YD8[7MW-=_;%
M8EVV"26!9?[2\2)==7BU*T'CH':,KXBPJ8/&8L[`FKW_`/*C^:MVW\A_YH77
M7QCW[\/^J^LO@!N;9%;M#.=M]1=@=A;O[4J]Q?&G:O<-1U1G(L!V;M3%;5V[
M#DJZ:2HW/'%4UZBNA@@HG6GED8JAW">VY1GYVO566TMK[=(3`M5,Z6$X))D/
M]DRPE8T"AQ,[.[&$(H<\.WVUSS5MG*UK(\;75GM\C2M0^"]WXB=J4_5!92YU
M%/"5411*78H73Y'_`,^C<<6Q_P"7WA]O]D=-?"+<ORW^&NV?FAVSW%V[TQW7
M\J\#UW@MRG'X';/575?5?2\.-S>[=S;GWH,D]1E<[68K&XO!8TN//75,,*"3
M=K..TYDWK;(;QEL;.VM)HZIJ>=KU'D2&0@A(1;PIJFD&II)7B2)-'B,I#MTT
ML_+NW;K)9>)<7.XWMFQ#Z$A_=[JDTP7N:0S.Z+%%JHB&1I)"537;/_*3^=VX
MOG]\9MP]C;RQN';>'5W<.]NC\[O_`&=M'L/8O67=R[.HMOY?!]V]6;5[5P^%
MW[M[9>_]N[FI)AC\C'+-CLC%5THFGCB25W+FU=+#9MQDMA!+=P,[PZQ((72:
M6%E63!>)_#$T+,J/X,J+(HE5^D\5P/WAN>W>.LRP,A24*5\2*5`Z:U-0DT;:
MX9D5G7Q(C(A\.1.M=CJ?IOXZ;_\`DE_-%SO;O\D_L_\`F3[H3^9_\F\?3_('
M9N$^/N9Q.&PU-CNO'H>J6J.X.Z>N=SP5>RY)I99(H*!\>OWX,4SN9`J"RCB3
MEKE=H]M,#M%>%G.G_&&_>NX#QQ0DT(`B[@#6(XI0D4\SDG?I!JP-NVN@SV_[
MK+3%*::DU<T))#C52B]'<^4WQE^-79&Y_P"09\<=T?"3%='_`!TW;\C?E'-F
MOA5V7A-HOC-GR_[+3W5O!,;N?!;#W/NC9]17C=Z#.)]KDJN(SSJ\A+&2,&%M
M;QW_`#F%O+I;KP>5+YXV%2$*-M.E!J`[H03"<$`AC&Q[7Z#$\C6O(^[7%K:M
M:S2\R[8'^$,X,UU"SDJ3VS1J&&03&RA@IJH&/N#XL=&_RO\`YP?RW=__``:V
M/0=`[3^67R!W!\.ODCT#UO6UN$ZJ[;V=NGJ#L?L/:/:&2V$U=+@J/L?IK=6P
MHY:?.T5/#D9L9D)Z*HEDIS&BIMDGGO.8+SE"XFU;+?['N5T58DO#<;?'!+'+
M;$$&-ID9H+CBK1E655D&LWWQ(+7EZVYAAAT[K:;WMT`<"@EAOI)89(;B@)D5
M#2:W!*A)5))93IZN]Z&^.73/QCVKFMC]&[)I-@[3W!O#/[_RN$H,AEZ^DJ-X
M[JD@J=SYY3F<AD9X*S<.0A-95A'5)JV:6=E\LTC,WXC_`$]G:U_0MXQ'&/)4
M%2%'R!)_;T[X:?475W3_`!F=M4C5)+OPUL3Q:E%K_"J+P4=#=[IU?KWOW7NO
M>_=>ZH%_G2Y!L3WK_*QR`R;8>.#Y.=A1U60_T@Q=60)0UO2^Z:"OH\AO9*')
M9^FQ.6I*IZ2KQFWX3NO<5-.^(P;Q92NIIH_=>Z`])Y8*X%ZAL+48>KF%FR&#
MZHK<!6=9X"1)%625,ALOI.JZ7VCD/%4,OW>V/C/MBL^UI/XSVCF28O=>Z?J=
M&QL=+34])4X]Z-]NXV@I*/;&(VW-C*K;VW)M_;1PN%VUO"LK<3L2OV/B<A+N
M;:^V-SRSXGJC%5$O9W9\M=N^OQF+C]U[INIV&4DHJ.E2&:*K_@&*Q^-Q6+R6
M;CK(=SULN]]J8+;^S^R)J?*[M;>.7@EW1MW;FZ9X<AV-DH9^T.SYZ3;5'C<:
MWNO=3RU/54:LT=-F*+,T4+L7I,KVWAMP8SLC=-3`]I**;&;T[FV_W+NW#+J(
M%%NCY.;HHO\`ES=587_*/=>Z3=;DOOVJ:BMKZ:>*HI\[E\A6YG<>5S<-?#GJ
MJ#86[=P9[=6QJ:#);QAWEDZ:':VX=T[4BBR78N1A@ZMZN@H]LT>2R;>Z]TIG
MD;&)6555-5T,E#-NFMK<AE,K@<%4XZJV;B\5LK=F9S6\.O/N\-L/*[%P>33;
M6Y]S;8AJ,3U)B*B+K+K.*OWED,GDXO=>ZARU4U)5>&-VP,F*K`D:@8OJBIP5
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MU=#48IMQUU56SYG;6T9\%4[#V]3;;W%D\GN#:HK<%UAF>M-NY2+`[BW#@8JG
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M6`SM1DMK]59'J[;E;+F<#A,T]7@N@\%52;VWO+E.Q,K14</NO=1,52BLEHJ.
MDA6H::?:^)QV+P^+BR$K?Q.>HW]L[#879'9]33R92KKYDFW;M3:V[*A7R;K4
M=M=M3QT4>*Q3>Z]UCJ*F&NIJ>.."FS,6;H,='!3KA-P=D4>XL=V1EZG+44%/
M1UT]!NGN7`=N[NH3D:6AR#4FZ/DGN6C;<.?;$=7X>GIIO=>Z:XJB/+)65]97
M4N8BR=)F<G655=N7);ZI\[2[RR])L_<.8S.XMN0X[<G:.&[)W'2Q8#,9O;\=
M-N'O#/TT.P-@Q8[8F-R&0?W7NE+DJXT!KJFMGF@EII]TU]=7YK(TV*JXJC"/
M2]>[QS&8WWU<*C'XBMPF.,.T]U;JVG$]'M2B:'J7J:&?+2Y;+CW7NH$<LM-5
MO+-4S8B?#U%:T@_BF`ZMKL!5]:[?:FJS]TJ5^TNEZWIS:5<*6NJ:9:S;7QNV
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MV)M+/+1'</7O:O5U%1;5[#Z[W%48BLR>`K-P;+W%1RT-;)CJRLHON8G5)F*L
M%]U[HT/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NB:_`K_LG5O_%@/F1_\&)WQ[]U[HY7OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z__T-_CW[KW6M3V+\(/GYMOYX_)SY=]$_,7=&WM\]T38;KC#UN_?Y<.
MQ>^JCJOJ'9S56?VUTIU'V-F_DUL1,/U5)'6RYG)3T>.H:7/9^*+[[7F`D9#-
MCNM[L]K?[2-NO)S+?RSRRK$`97>GA(S:Z-%;6ZK'!P53K']K*5ZEI/;/:^88
MMEY@N/<GERT1-OC$5O+=2:[="2DSF(0DI=3W1I-&=4OA%9D'T49DZ66]/B_\
MQ>Y-D]9[D[C^0_>^?^:?QY[6SG;'Q*^6/5_P?Z^Z?Q?6E+OK9<>R,GU-V1TG
MF.[]XX#L[K_MG;+UW]XH:O+X*?&#[:"NJ,?/'&)]R;Z5NMJW+;>7MPBW6*&X
M@E9T$D-Q;730-X#PLRJC`VZR1S5UVTRHY,;"CKT]I+7Z7=;"_P#>+E/]U22V
M\@5+R4203V@F6:YCDBA<S+$9_"$(5EW")Y3:+<1%GCA;]^&'R`[U^-/<W3WR
M3^0GS,[[[1[S[6^-G9N1[1J_CQM3K_J#K[!_'WMW:N_MA[-Z1^,%/VI4XGJY
M=\U>U'QNY\A59>HR[5,R9K*A:"*FC9;9\S16&[\D;K;<L;B[;1NXW%BZKKN7
M,;0K`'[?`@4:0D>AFB;Q9I2PFU`NN_9>.^VWFRQO/>;E&!MPVU[!4CNY72W5
M:2SRL%B9+F8*QD$BR&.Z'AV=D3<0M&#0?)KK3?\`W=\H_AO\L.NJ7Y"=);V^
M*64[.PF;Q>2^.^W.V-N]K=)=N#9&/[6V8U#)V#MG-[(W5E<KL.FQN)S=%+55
ME)!42Y):"KQMYU+[/>S;WV]3S[%N3;?N6V&QN8U0)(8EE$T4D,RL6ADCN!FB
MLTBA673$&=C'=/:"WO=DM]KM?=WE`7]M>K=V[F]?2MPT$T/ARJT*I)&UG,TS
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ME.D[FRNZ:`]&%LJU#!J3DZ%[P5Z.[7VPL(N;;'FN/W=Y1DCAMK%$B:[FCU+9
M-((&):W#H;N9C$\<B![-5^JN-%HZ2`H&/^`?:75^P/AE5_$[LKY-]`_+#X@_
M&?$?#1>^\K\9=@=E=;=[=&TJ4.X8MJ]J]&;@[6PE/3JN3P\>X\%7TFY:;^[>
M3EGQU;-45DRTGL\O^:[^\WN^W:VV7<(TN[.TMIX7C62-Q91L+>9"7407'=(S
M3*N8Y7M9.XJ`1V7LUMEGLL&VWOO!RI(EO?7E]$\=W.LD;7LX^JC9%MV$\:N(
M[?P2=<WA1[E;*;9#*+5/@9M;LKK3K[(;#[9W_P#*+O;LG-YK+]J]@]Y_(O;^
M*V7CLYN'>\E)IP/5?7F'S>6PW4?75!%CV.*V30%O[M4X*UK?>5#-,KM=WBOD
ML[&UV2\MK:VMP!)<4,LI9WD+RR`+KD9G8!="^#"L4)5=`J&.9>0!RG;S;I<>
MX&P[K=W5VR>!MT\DH@\)%0JJ,E$A0*@^H\21+R9Y9H))4U%"683^6=\_NF.T
M/D_NCXE?S/\`8G2?6GR9^2_9/RARO6N]_@)M3NS+;8WOVC%@J?/X^E[!K_D/
MLNLRN(@I]N4J0*^/@\>EC;U>UEN]W'MNW;9<W"R0V@F2(A`A$<MU/=:6H3J9
M7N'&LY(H,```+[I>)N5^=P$`CD:VM8F%:U^FMHK8-6@(U+$&*\%)-/,E8]W_
M`,N?YI=W[6^'>[,Q_,0V9C/EW\/NVNT^S=O?(>'X3;9K-D;LH^S=A[DZS?;E
M?T!)WI!B,7-A-F[FFACR"YVH>2H45`BBD"Z7F<1;G8;GMP,#KMEQ9SJ3K$_U
M$L,C2`T4Q4%O$NA=0:C$G2Q3HO(:?:MSVF]826\VXVMU&0-!B^E5M,9X^)JE
M=I"QTD+1*&FKI>=%?RZ^Y8OD;U]\K?G=\R*SYJ=L]$X3>>"^-V#V_P!#[5^-
M?373<W8V,I<+OG?T/7.WMX]C9'=_;><P,4N*CS5?FOMJ'$5,D%/0QS,:DNVD
ML-BM_-!;UW.YB\$S,=31V^I'>&`4`B$TB(UQ("9)E1(BPA4HS-W'/>"RMI;D
MC:X)1-X*B@EG4.J2SFI\7P5<^`A`6&0M*H\0ZA:[[3=*.O>_=>Z][]U[KWOW
M7NM?[^=;EZ7`=X_RL,U6YE-N4F-^3W8=54[AEW)U_L:FP=+#TCN^6NRM?V3V
M=JVMU5B:''I++7;I@CJ-Q8*A2:JV_#+G$QZ'W7NBKXSMSJJ(8>GP_:?6I(/7
M$&'HMK=A=-P,DM%2;CW=U9B-L[*["W#58O:>1Q^-:HW'L+:NY:BJQG7>--5V
M?V1+D]X5>,Q47NO=-5+VWTW514D-+VWT?/3U>+VQ!C:?&;RVMEZ/*XK=>X9\
MWLFBV_@-Z[MBK]]X?L/>]--E=L[>W3+#7]H[GAJ.Q>RJFDV]1XW$-[KW3^_;
M_3T]'5!NXNF<MC\A0YT5,M/W1LSMW`9;#;HW[C,7G:BL.4SV'WGV[M7L;L6@
M2@K9I&Q^Y?DAO6GBI'.#ZPQ&FH]U[IIRW<O3\DF2J<QW3TO3A_[]Y3,5^Y>X
M=KSW3S4^TNT\UNS>O7>=ILKG9FJ13;;WSN3:]-#7;RJA2]8=;P8_;--D<I)[
MKW4V3N#J_'254LO<?6-%54-7N.HKY1\@>IMO5N(RVV^MXL5O/(9S-;8RE7C>
MOLUUYL+(0XW=NX]LQ3XCIO:M1'U[UI!7;LR&2R\7NO=1_P#2WU335M+`G:_4
MV&K:/*8.CHZ?^^W5'5F6Q.7VCM'^+[8H*>GI-T979G3N7Z[Z^JI,G@Z=?O\`
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MO7JW.4DM;78ZG:FVWO\`W+MJGCFK8OM>J>K(*7$QY+,/[KW3C3=N=4X^H:4=
MT=38^OQE?7M-(O?_`%=U[E\%E=K;#J:?/2U^1PN6R6W^K\YUQUW4QTV=R^"2
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M,5L'%4.-E]U[K/\`Z7^F:JFRE57=V=&U\-90[UJ\M49'OK;^[(,C0Y?*TFWM
M]Y#/97&YJ@S_`&?A=U;RBI\'N7*XM:'<O>VZ(8=F;:3"]>8VJJYO=>Z<<[W3
MU7'+F*G+]Q=7Q24U5OS)9VOW3W!U?--1RXZCQ.U.RLMN+>_6.:IV@K]NX5Z3
M;V_=S;5@C_A6.EI>J^JJ=(Y,KF3[KW3?2=M=3TN00MW+U!C:_&Y:*)U/>O6?
M4^9P63VCLN=JQ3D<9E\SM#J',]9]95`%?D*".MP'QXV75)@=I1YGL3+U-;#[
MKW7.D[=ZOB7&08_M+KBGGI_[B4>'I*+>'3&V9Z&IV_LZMW-UYB]O87-;DKL)
MUKF=J[5J:K<&RMOYEJS`]+;<EJ-][QES78>2I:.#W7NH^'[8Z:J8\;%B^W^C
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MU`[8[(83:F!VQV)E-P;TZ[RJ1;>R>S-J3T^#WSNC:,#T^Q,#/3=6]4T\F1J,
MOF_?NO=8J7MKJ:GR:Q'N+IS#Y"AS%#2_;OVSUIT[7X?+;1VF:FDI5J,=N'-;
M3ZCRO6G6U8:B.:F2KP'QRV34?;XE<WV3E99XO=>Z<J'MWJR*/%TV+[5ZTU1_
MW`I\-1[?W]TS0_;RX[#YS=O6>)VWM;>NY*S%;(RN'PLU5N+8NVMP2U6)ZQQ#
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M2^6P>/EV6_S*7;=/_`L_N#`BHVA\<-KM_<S:"R[B?+92G]U[K8+^+NS]H;`^
M-W0^S]A;7PNR]H8/J38%-@]L;>I?L\1B*63;&-JG@I8BSRR-+4SO)+-*\D]1
M,[RRN\KN[>Z]T._OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NB:_`K_LG5O_%@/F1_\&)WQ[]U[HY7OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z__T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1#OD!M7;&]/
MF/\`$';N\MM;?W=MZKZZ^4=14X/=&%QNX,/-4T,/3%3154F,R]+64355'.NJ
M*71Y(R3I(U&_NO=&(D^-OQVE#B7H/I:02BK602=6;&<2#(3)45X<-@CK%;41
MJ\U_\XZAFN0#[]U[KDWQO^/#ERW0O3#&4U32%NKMCDR-7Q+#7%[X(ZS60HJ2
MW_SB@!K@>_=>ZZ/QO^/!;6>A>ER_D$NH]7;'+>44GV`EU'!7\@H3X=7U\/H_
M3Q[]U[KT?QO^/$1C:+H7I>,Q-2O$8^KMCH8WH8F@HGC*X(%&HX'*1$<QH2%L
M#[]U[KH?&WX[*J*O0?2RK&E+'&HZLV,%CCH:AJNB1`,%94HZIS+$!Q'(2RV)
MO[]U[KH?&WXZA2@Z#Z5"%#&5'5FQM)C-5]\8RO\``K:#6_O6^GE]?ZN??NO=
M=R?&[X[2B02]"=+2B45BRB3JW8SB5<@Z29`2!L$=8KI(U::]_*P!:Y'OW7NN
MS\;_`([L79NA>EV,C5+2$]6[')D:LA6FJV<G!79JJG18Y"?UH`K7`M[]U[KE
M_LN/QZ#!_P#0/TSK62.97_T7[(U"6&D-!#*&_@=Q)%0L85;ZK$=`]/'OW7NN
M$?QM^.T/C,70G2T1A-(8C'U;L9/$:!'CH3'IP0T&BCD98;6\88A;`^_=>Z\/
MC;\=E54'0G2P1$IXT4=6[&"I'25#5E+&JC!65*:K8RQ@<)(2PLW/OW7NNC\;
M/CH0RGH+I4JRR(RGJS8UF26J^^E5A_`K%9:W]YA]&E]9]7/OW7NN3_&_X[RB
M02="]+R"45HE#]6['<2C)%#D1(&P1UBO,:^:]_+I&J]A[]U[HEWSAZ"Z(QVT
M.@Y*#I'J"DDK_FQ\0J6LEI^M-EPR5%/D>[-GXW(1RR1X17=:[&_Y--<_NTY,
M370E3[KW1TQ\<?CR&5QT/TR'22&57'5^R`RRT],:*"16&#N)(*-C$A^JQ'2+
M+Q[]U[K@GQM^.L7C\70?2T?A^T\.CJS8R>+^'Z_L/'IP0\?V7E;PVMX]1TVN
M??NO==CXW?'95"#H3I<(L<,*H.K=C!5BIZHUM/$%&"L(X*TF9%^BRG6+-S[]
MU[KBWQL^.KAP_0?2K"03JX;JS8S!UJJE:VI5[X(ZA4UBB60']<H#&[<^_=>Z
MY/\`&_X\2>3R="]+OY?O/+KZNV.WD_B*JN0\FK!'7]\J*)KW\H`U7M[]U[KQ
M^-WQW9F=NA.EV=W>1F/5NQBS22THH9'9C@KEY*%1"Q/)B&@^GCW[KW7)?CC\
M>D9&3H?IE&CDIY8V7J_9"LDM)3M24LB$8,%9*:E<Q1D<I&2HL./?NO=8U^-G
MQU3QZ.@^E4\*TB1:>K-C+XEQ\DDM`L=L$-"T,LK-"!81,Q*V)/OW7NNQ\;?C
ML%"#H/I8((TB"#JS8P411U7WT<848*PCCK3YE'T$OK'JY]^Z]UT_QL^.LFL2
M=!]*R"05*R!^K-C-K6MG2JK%?5@CJ%74QK)*#_G)%#-<B_OW7NN;?&_X\/Y"
M_0O2[>4UAEU=7;';R'(1K%7F2^".LUT2!9KW\J@!K@>_=>Z1'9OQT^/D?7/8
M51'T-TP9UV5NV97/5.RJEFF_NID,=J:%,()*@MCS]N5!U/`?%?2;>_=>ZH9^
M#O4V_/E'L7J/9'5>Y\_LS8FS-A==0=Z_)/;.^1N3-;(W#1]?4^ULSU%TIO\`
MP]/0[:W3\O:[9U4,#G-WX*`;2^/FT96VKLU3N.HR>3IO=>ZO.[AZRZ_Z9^#G
M<W5?5>T<'L/KO8GQG[6V[M':.W**.@PV#P]#UQN-8*6EITNS.[%I)II&>:HG
M=Y97>1W<^Z]T,/1/_,D.F_\`Q%77G_O(XCW[KW0J^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)K\"O\`
MLG9O_%@/F1_\&)WQ[]U[HY7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__2WD>VNHLOVC_"1C.[
M.Y>HABW=Y?\`1/E]F8HY?6LRZ,L=V;&WB947R@CQ>&Q1?\;^Z]T#7^RC[K_[
MS4^97_H8=-__`&C??NO=>_V4?=?_`'FI\RO_`$,.F_\`[1OOW7NO?[*/NO\`
M[S4^97_H8=-__:-]^Z]U[_91]U_]YJ?,K_T,.F__`+1OOW7NO?[*/NO_`+S4
M^97_`*&'3?\`]HWW[KW7O]E'W7_WFI\RO_0PZ;_^T;[]U[KW^RC[K_[S4^97
M_H8=-_\`VC??NO=>_P!E'W7_`-YJ?,K_`-##IO\`^T;[]U[KW^RC[K_[S4^9
M7_H8=-__`&C??NO=>_V4?=?_`'FI\RO_`$,.F_\`[1OOW7NO?[*/NO\`[S4^
M97_H8=-__:-]^Z]U[_91]U_]YJ?,K_T,.F__`+1OOW7NO?[*/NO_`+S4^97_
M`*&'3?\`]HWW[KW7O]E'W7_WFI\RO_0PZ;_^T;[]U[KW^RC[K_[S4^97_H8=
M-_\`VC??NO=(G+?`BJS6_P#9'9%?\S/F5+N3K_#;TP6W9O[Y=0"*"BW['A(L
M_P"6%>DE@GDF7;]-H9T8QM&"I!'OW7NEM_LH^Z_^\U/F5_Z&'3?_`-HWW[KW
M7O\`91]U_P#>:GS*_P#0PZ;_`/M&^_=>Z]_LH^Z_^\U/F5_Z&'3?_P!HWW[K
MW7O]E'W7_P!YJ?,K_P!##IO_`.T;[]U[KW^RC[K_`.\U/F5_Z&'3?_VC??NO
M=>_V4?=?_>:GS*_]##IO_P"T;[]U[KW^RC[K_P"\U/F5_P"AATW_`/:-]^Z]
MU[_91]U_]YJ?,K_T,.F__M&^_=>Z]_LH^Z_^\U/F5_Z&'3?_`-HWW[KW7O\`
M91]U_P#>:GS*_P#0PZ;_`/M&^_=>Z]_LH^Z_^\U/F5_Z&'3?_P!HWW[KW7O]
ME'W7_P!YJ?,K_P!##IO_`.T;[]U[KW^RC[K_`.\U/F5_Z&'3?_VC??NO=(;?
M_P`!)^R<?MK&[G^9/S)K*7:O8>P>S<4O]\>GT,>YNN-QTFZ=MRNT7241DIH<
MO0Q221-JCDT`,I`M[]U[I<_[*/NO_O-3YE?[#=_3?_VCO?NO=>_V4?=?_>:G
MS*_]##IO_P"T;[]U[KW^RC[K_P"\U/F5_P"AATW_`/:-]^Z]U[_91]U_]YJ?
M,K_T,.F__M&^_=>Z]_LH^Z_^\U/F5_Z&'3?_`-HWW[KW7O\`91]U_P#>:GS*
M_P#0PZ;_`/M&^_=>Z]_LH^Z_^\U/F5_Z&'3?_P!HWW[KW7O]E'W7_P!YJ?,K
M_P!##IO_`.T;[]U[KW^RC[K_`.\U/F5_Z&'3?_VC??NO=>_V4?=?_>:GS*_]
M##IO_P"T;[]U[KW^RC[K_P"\U/F5_P"AATW_`/:-]^Z]UAJ?A]N.LIZBCK/F
M=\QJFDJX)J6JII=W].&*HIJB-H9X)-/1ZOHEB<J;$,`>"#S[]U[I-[&^!>/Z
MNV?MOKOK'Y/_`"AZYZ^V;B:7`[1V/LK+='[?VOMK"T2E:7&8?$T/14<%-31`
MDD^IY'8N[,[,Q]U[J1O#X/Y?>^T=U;*SGS/^9<^$WCMO.;5S,(WCT\CRXK<&
M,J<5D(XY(^D(Y(G>DJW`965A?@@^_=>ZG8+X7Y[;N#PFWL9\T/F3#C=OX;%8
M+'1#>'3I*4&'H*?&T:N[]'N\LOV],NMV)9VN223[]U[IT_V4?=?_`'FI\RO_
M`$,.F_\`[1OOW7NO?[*/NO\`[S4^97_H8=-__:-]^Z]U[_91]U_]YJ?,K_T,
M.F__`+1OOW7NO?[*/NO_`+S4^97_`*&'3?\`]HWW[KW7O]E'W7_WFI\RO_0P
MZ;_^T;[]U[KW^RC[K_[S4^97_H8=-_\`VC??NO=>_P!E'W7_`-YJ?,K_`-##
MIO\`^T;[]U[KW^RC[K_[S4^97_H8=-__`&C??NO=>_V4?=?_`'FI\RO_`$,.
MF_\`[1OOW7NO?[*/NO\`[S4^97_H8=-__:-]^Z]U[_91]U_]YJ?,K_T,.F__
M`+1OOW7NO?[*/NO_`+S4^97_`*&'3?\`]HWW[KW7)?B1NM65A\T_F02K!@'W
M=TTRFQO9E/1MF4_D?D>_=>Z0W7GP'JNL=LMM/:_S-^9M/BFW-OK=KI+O3J":
M5\SV)OC</8.Y9VEGZ2EE856X]SU4H!:RZ[``6`]U[I;_`.RC[K_[S4^97_H8
M=-__`&C??NO=>_V4?=?_`'FI\RO_`$,.F_\`[1OOW7NO?[*/NO\`[S4^97_H
M8=-__:-]^Z]U[_91]U_]YJ?,K_T,.F__`+1OOW7NO?[*/NO_`+S4^97_`*&'
M3?\`]HWW[KW7O]E'W7_WFI\RO_0PZ;_^T;[]U[KW^RC[K_[S4^97_H8=-_\`
MVC??NO=>_P!E'W7_`-YJ?,K_`-##IO\`^T;[]U[KW^RC[K_[S4^97_H8=-__
M`&C??NO=>_V4?=?_`'FI\RO_`$,.F_\`[1OOW7NO?[*/NO\`[S4^97_H8=-_
M_:-]^Z]U[_91]U_]YJ?,K_T,.F__`+1OOW7NO?[*/NO_`+S4^97_`*&'3?\`
M]HWW[KW0EX_HK.4/6.>ZX?Y#_(#(9#-UU'60=HY#.[`D[.P"4F6H\H]#@LG3
M];TVV8**MBI#1S+/BJAS232!660K(ONO=?_3W^/?NO=>]^Z]T0/L+^:K_+5Z
MFWWNCK#L_P"=WQ3V!V+LC.5.VMX;)W?W?L#`;EVSGZ)UCK</F\1DLW3UF-R%
M'(VF6.55:-KAK$&WNO='3V5OG9/9.V<7O3KK>.UM_;.S<<LV%W9LK<&)W3MG
M+PPSRTLTN+SV#JZ[%U\<53"\;-%*X5T93R"/?NO=(/J?Y$=$=\9#L?$]+=O=
M>=J9+I_>F0ZX[3HMA[KP^YY^O]_8J6H@R>SMV)B:JJ.$W%03TDJ34D^B:-HV
M#*"#[]U[H9??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<7=(D>21UCC
MC5GDD=@B(B`LSNS$*JJHN2>`/?NO=`[OSY$=$]7=B=5]1=C=O=>;([2[QK<O
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MZ][]U[KWOW7NN*NCEU5U9HF"2*K`F-RB2!'`)*,8Y%:QYTL#]"/?NO=%[^0O
MRU^,'Q+P^W-P?)WO[J3H+![ORE7A=K9;MK?6WMBX_<&6H*05];CL35;@KJ&&
MNJZ2C(DD2,DHA!/U%_=>Z1?0WS]^#WRCW'6;.^.7RY^.G=V[J"G^[JMJ=9=O
M[&W?N5*00U%0]6F!PV:JLK/20P4DCR2QQ,D:H2Q'OW7NC=>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO_U-_CW[KW31N#.8W;&!S>Y<S4)28C;V(R
M6<RM7*RI'2XW$T4U?75$CNRHB0TM.S$D@`#D^_=>ZTL?Y$/\KSX6?S.OCM\C
MOYB?SD^..#[P[&^6_P`U/D#V%LK*;]W-NN7([>ZVASU/2TF%T;7SV`H(ZV'>
MLV<CJ'\;&9(8""$2-%]U[H0OY3^=P7\M3^9=_/<^&?4\6\:KX,?%GK#:?ROV
M9L_*[LJ,UMWJG<_^C/;V^=W;/PV4S<U5/0U.ZL?N2JHTFJ)99GH]J0&JDEFB
M>5O=>Z-G_*F[Z[*VE_)RWE\^^A/Y<FPLI\@/E#V;VEW#@OC-\5LSN'`T?:N?
MJ-[5O7V,WMO;<7;^^-XUV$J6&V*JNR\M-/*):6%30T'W-0(6]U[J?T3_`#;_
M`.81L'^8W\;O@=_,$^//Q-AJ/F-MS>>X>K,G\,>TMV=B;HZ4DV;@LEGZW$][
M8S<=9EJ7*10P8F2&IR6-&/H8QKJ8&JHH)D3W7NL6*_G+_._Y,=F_*#LKX`_"
MGJOMSX"_"#?F[]A]N=H=I]HYK9';7R-R_6N.FRW9-!\7*"DI'VEC<IM_%PK4
MT2;@2HILE3U=%KGHIJIJ>G]U[H!MH_\`"AKY"[@_D\?-W^:MDNE>GL-C]C_)
M>HZ8^%NPZN#=4,NZ=JY+=VQMMX/*]V4T78-?+D]R82DW?/49%,'6XR"J?%SK
M`D4963W[KW2QWK_.@_FB],Q_RU>X._O@S\<>IOCA\X.U_C]\?\W@]Q=Q;G@^
M1U%OSN+$8ZJR'8D&THXJC;'5FPJ;Q9'(4.'R4VY,K%1+24^4JL?65#)'[KW1
MN_E-_-+^6.\?G#O_`/EL?RL/CSU-W1\A^D^O\#V'\BNZ_DEO#<FU?CKTA%N>
MEQF3VWLVNH-DQQ;OWKN_.8K-4;K'15D'V\M25$<ZTN0:D]U[IG^*_P#.RW/D
M\+_,<ZR^<_05'T]\MOY7VQ*[L_NOKWI'<-3V3LWMKKB/9]1NW%;RZ<FK(UW#
M31Y6&.E$E'DA(*"GR^/FGJE:2JAH_=>Z)U\>/YS7\W?Y8;'V5\JOC%\,O@7\
MDOCSN>OQ_P#'?BUTY\L*^O\`G/UU@Z_=U=MLY/L2LW0VW.N=K5=)'0AY*>;#
MEE6HBG8K!Y6B]U[H,?YZ/>?\TWMG^8?\!_Y>7Q0BZ@VOLGN7);:^2.W=DYO=
MW8>$W!V5+TA&V^MZ[2^7-9LZK6BQWQ_AKL'/3?P?$-4R9::@FDEJ&<4B0^Z]
MT;3(?(C']L_SQ]@=2_(CX_?&"LW#_+B_EX1_)?O3Y3-6]DON/I[LW=^WJ";?
M=%TU')O./;U'UB*;>M/,L6=PE?FC1+-4?<(R0CW[KW0:Q?SI?YJOR`Z/W?\`
MS!/A+_+CZQWK_+ZV-NK/T&W]O]G[Y[!;YB_)C9>V]P0;3RN]NFMC]?8C*[>V
MO3TN?%5&]+5TN>G9J*>.`3M$S'W7NMFKIKL2H[<ZEZT[1K-C;VZPK>PMC;8W
MC7=;]E89]O=@[!KMPX>DR=;LW>N$D9SC-T;:JJEZ.MB#.BU$+:69;,?=>ZU"
M_AE\)?B]_.%_FZ?SJ/DS\O\`J3`]\]5=)]S=??$SHS";GW-G/X7B<AU5C<MM
M3?.7QM-M+)X-#352[&Q]51O+*[1KEZA"I<R-[]U[I3]+]`=4_P`K#_A2_P!4
M?&CX5;?SO6_QH^8?P0W3V;W[U#C]W97+=<[$W%L*H[@J=O=@O2;CR&2K<901
MUW5])2TS3U$KTE7N.L6!XZ6I,"^Z]T-^1_G5_P`R#Y)]5_(+YM?RZ_AG\=MU
M?R]OBYE^TCF]^?(_M/=FVNY?DWM+I?%56=[$W1T3M;:T=)B-C8W&X>ADFIY,
M^,@U666**-JR.IHH/=>Z'JI_G9;UWWVQ_)"W+TQL'847Q2_FLCM#`;[KM]TF
MX<AV=U7V+L/'8NEBV7@MT;>W1C]C1UZ;UR<N,9:S'U<E><=.8$B)(C]U[H<]
MQ_S1M\[M_F7]H?%SHVAZD/Q$^!O2&;[@_F8?)#?%%N[+UW7NX*K"Y[+[0Z<Z
MIJ=L9^AP5-O6@QV#ER>:ER5'DH4HJ+*4R)!78_QU'NO=5SY[^>1_,ZW?\:]T
M?S1^D/@-T-1_RO\`8&0S.0EQ/<7<.X<5\ONX.K-N[LIMG9GM?8E)MV&7KK8N
M+@RYJ4&/R5+EJHM1S>%JJ(PSR^Z]TGOYUW=^T/YBM3_(*^,_5=749+K7^8-\
MG>M/E!N#'5N0HZ7R=&=>[=VIN+,XC=%%0O72-E%V]V5D6$44K0QY#$2Q,Q8(
MR^Z]T<+=W\U7Y\?+7Y3?)7XT?RAOC+\?>P-M?##>T/7/?GR8^76^]Y;<ZKSO
M9E)4UE'N#JGJO;?7"T^X\CF\178JLIY,K-4S4D;4CO)3QPS4,U7[KW0<Q_\`
M"@K-Y'^5;\]_ECE^G-F=-?,[X!=E5WQY[9^/^^-QU6^.OJ?O-M^8K8>WOX7F
M=JY+`YS<.S]P9*LK(HT2>CF6NQ59"L\M/$E;-[KW02=S_P`ZO^;?\5/C+\9/
MG]\G?Y?/QQVA\.-^TG3E%W;@=N]Q[ORGR3V^W9]-02Q=B8S:]72TVUMA[?R8
MF9\=MNLEW'F*>2JI:;)5=',:@P>Z]T:_YN_SAODGU=_,G^$/P4^#?QTZT^6"
M_)?H;)]\[N_CF],CL7(TFTMP4^[DV!N"AW\E75X3KO9^!I]IR9S/5>2P&=JZ
M[$R)38RE:ODACE]U[HM/QV_G(_S:N^M\?/CXH8'X0?%++_*WX4[NJJ/=O;]-
MW)O/;?POV/MP4NXIZ?%;QS.47+=B[N[$FJ,"\>/H:'^#T^1@IZ^HK9<+]AXJ
MGW7NE]U)_P`*)I:G^3YTY_,-[A^/*Y'Y!=Y]U9/XR=-_'/JG.5M-C>[.[8=R
M97`8@[5RVX8LYE-H;/K8\/4S5;U?\4FHI:<TL;U4TU/Y/=>Z$7KS^:7_`#$?
MCO\`-GXG?%K^:E\:/C%UCM7Y_P"3WGMWXW;Y^,/:&Y]W5W7/8&TJ3;=5_HO[
MJH]Y5-12[@S-55[MQN-_BN$-+02U]=&:5*J(3F#W7NDKC?YO/\POOS^93_,(
M^"7PK^(72/:FW/B9CMH[=VSVWV9OS<_7^R]H;]JJ;&C<N0[OW9B:C<\^8H\M
MFX<O0[>VWMW!PY:I;'2S559#!3U4L7NO=!%%_.J^<G:W\D_YD?-O:'6OQ=ZU
M^4?Q'[T[+^/_`&FD^[MV[DZHHZ+KVAVO!N#?_7>*IZBOR\^\Z[+[UI*+;F'R
M63JJ"HJ1%63U,M+(*=O=>Z.+_P`)R]F_/3:G\O\`VKE_G!7['STG;34G?G5&
M\H]R[^W=WWO?"]YS9?LW-[B^1V;WG55%"V[Q'N/&T>+I\<JK28JECBG+2("/
M=>ZIZ_X45_(3X79G^<!_+)^.W\P+<KXWX6=']6]H?(3OS%C';VW10;BS?8D6
MY=O];;4K-L=88W);XFJ*K<O5..6I>-1%_"LK*;JHEU>Z]T2_![7_`)7?R\_F
MI?RO\!_PG\Z@W=LC<_1O>2]V?+#OO:&R^W=K[!VSTCMS)[8K:[$[AQ_<.1I*
MV>HRV,QV5Q@>2DHJ>J;+Q4*25DE5X8/=>ZN7Q_\`.U_F2_(+Y=_S(?BA\#?@
MOUI\C,Q\7>V\3U'U#O');EK=D=>[+BP5=NC;_8G8GR-[&W%O_#[3W0F8W)MT
M)M3:VV9<1FZRE6MDF<K0N\ONO=#,W\U+^9%\LN^^[?C+_+!^-WQ;[*R?PORF
MW>N?EA\H?D9O3L/:?Q^W%WQ2TKT?875W0FT]GSR;ZJX<7N7%9*"GR60KJI((
M:3541".6BJ*WW7NGKJ3_`(4,]9M_+V^8WRU^3/3.4ZB[T^!';>:^.OR"^-NW
M-U8W=<F1[SCW$-H;+PFP]W11-')MC>NYS+1R5]33M_"WQN2>U93TD<]3[KW1
M,_EO_//_`)MOP0^)6`^1'RH^`?QTV?D?E'4;7Q?Q!H]G=C[NW=_HQWIGQB-S
MP=;?+?9V3S6U,Q4Y[.]9IF:['UVV,E3QTV2QPHZ^DIRS,ONO=&U^;?\`.6^6
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M9+L';_76*V_TKUM3Y:KSV0W5MW<V5FH,SN2OS`H&GIYFHL-.*2K2'W7NCW;\
M_G/_`#^V%\D/Y9TV\OA'U1UG\2OYDW8NSNM>O-H;Q[/S>4^96WSNV+9KR;WW
MG@L-!2];;*HL53;OCKH\*!F:R:D,<5;4XNLD:GB]U[K-\BOYU7RIWM\_/D+_
M`"]/Y?NP_A-MSLGXRC9U'N?=_P#,"[GW=U:.X=T;DI**NR&T^B.M]MPX#.;F
M?$KD8(!729/QU'E2ICB-++3RS^Z]U<K_`"_^]OE;\@>AEW;\SOB77_#GO+$[
MMSVU\SUP^^-N[_V_N+&8K[4X[?NT,U@:ZMGI<!G&GEA6CK[54,M*[J\U/)!/
M)[KW1W_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__5W^/?NO=5]?S6
MZ3O;+?RX_F-MCXS[!S79W>6^^CMV];;`V5MZ"BJ<SE:[LN&+865J:&/(Y'%4
M@DPFW]Q5=>7:=3&M*659'"QM[KW6KY\!>\_^%#WQ1^('4'P2^/G\EC9>SZGK
M'866VQ@.Y>U>SL%@=NG<V6R>8SV6[$W5@:C=^W<769/([@SDM;/2)D2:B=C]
M8[JONO=#QN7^4O\`,+XA_P`FS^8\:6ES'S,_FM?S*YL6WR)W#L@195)J+?&[
M:7$;@V7MFJS,^UXJO;FQ]A;IW+5O5I!2+)DLB8X:<T5-1Q+[KW4W^95_++^8
MU-\#/Y0_Q\Z/ZFWS\G?C'\4-O=?[>^<_PLZ_[2I^C]Z_(6&DVEL"@>LK=SX[
M/8M,A04>?I]PBMHZ6>62GJ<L*M`XC:HIO=>Z!K^7%_+F[`Z9_G*;T^5_:?\`
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M_,/Z`_F+S=<;K>AV-W-M/KSM7I?M#:TFX9*C;>XJ??R5<=5L.NRFZ,F\=720
M2TE%CWQZ&6$TLL,GNO=*KX@_`+^9ITIMW^9)_,@SVS/C!5?S3_G=E,)D-G?'
M;?V:RFY.C^J>I]EL*/$=.YS?6U*[&G,[PS6W(X:=YHJ^3"2S8C&?=52"6LDI
M_=>ZJBWG_*^^6'RX^0_Q]W9\=OY.DO\`)I^3'7/=>S=Y]^_-WKGY1;0H^HZ+
M;>.:MGW]2=2=);`J3B]W5FZ,O6+68UJ"G>*.&F&/KY7IJJ6>+W7NK4^_.G?G
MKL3_`(44]>_-2F^%&Z?E!\::CXY;/^+W26_MG=O[0VWB.@ZC>.XL#4=L=L]A
MX;/Q3Y#&+MNCW'NJ-Z""E(RM!4PR4]2]2&IH_=>Z:OB;_+:^07?7;G_"BGLG
MY%[6WKT#GOY@^Z-W?&CX];MRM'C\=D(^AMM;0WYL;8G9.).+RN8KY<9GL/D\
M`]=3N8?.,65"@N5C]U[H)?AS!_/N^.GQ2^.W\K;HOX+=>]"[ZZ`R]'MS>WS^
M[1[:V+V=\<<AU/-OW-[EK\[L7K3%P4&[]S;ESV.W#'&]")6K:9:>?R0TLLZO
M1>Z]UM>;URF[=I=6[MS6!QM3OW?6V=@Y[*8;#T%%3T]7O3=N&V[5U>.QM%CV
MK:6D@J=Q9BF2*.$U$<:M,%\BJ-0]U[K14_E8;^_G^_RZ^G]Y]';'_DJ+V)NS
MN7O;??=F\^VM_=B838;97=W84>(A8;A$6X5H:?"[?BQ($1EKTM&[`:78E_=>
MZN8_ER_RE?DYGNR_EM\^/YL&\]N9WYM?,?J?<'0&,V7U+EII-I_%SH3<6%DP
MF4V?LG,4==68V'<M=!'3)$V/GK8\=#1F3^(UM7D:^4>Z]UK[=,_R&M]?'JD;
MXS]Z_P`C'=OSP[3P^[MWP8+Y?[(_F3Y[XZ_'KM#KW(;FK)MN;AW3M:CS/WW6
ME7@L#5)#-BEQSY2M2G#"*261G;W7NKM_YKO\M#M/JG^6I\!MG_RN/CID<7W?
M\!?E3U5WYTMTGM+<X[5QFT=S9&IWINC?5;DMQ]G56-KNPL;A>SMSID9*VM:G
M^Z8&22GCIV>&/W7NCI_%K^3[2]7_`,ICO+X3]B[SER7R0^:O7O;VZ_EQWT)9
M*G-;K^2W?N"R$VY]R5V3H9TJ,[M_8^7R$&.IT1H8\E14$D[QQRUU1J]U[K6.
M^/?\C7<>R\7L3XV=_?\`"?C=_?'<FUW3`]A?*ND_FH[FZG^-&_L&^:JI(^SL
M;CL!79'+8&H_@TD8_N_189ZX30K(])$9&B3W7NKT^L?Y>G8^WOY['QGW-M?X
M^97K+X!_RZ/Y='^B+XX;LF>GSNU,GV3N4-@<AM;'9_-[@R6[<UG\?M_L;(/+
MDJFF6HEFPLK32%YEDE]U[HO7Q?Z=_FE?R6.R/G#TG\>_Y>T_S_ZG^57R8WK\
MA/CKWAMSY`;(Z^_NKD][XNFI8]J?(.@WR[YRFI]N0TE"M3D$:ECK*FGK'AJ)
M/NHC3^Z]U5M_,*_E_=X?#S^5_P!<?$_M+>.Q=Q_S`OYT_P#-9V-V'WQ)MJDJ
MZW9>+R6>JLIFH=EXNMHL:^1RFVM@]A9_#U]?4Q12JE9EJR.D$].(YG]U[JUS
MY>=.?S9_YPNW>F?Y=O?/P7V]\(?CML/MCKS='S)^2A[OVAV7M3M;;O6,;S46
M%^,.W,/2T>XFPN^*F)Z^C&2IIJC&3O0TV0DI3358J/=>Z-1\-OB;WO3?SR?Y
MDWSB[9Z%S.P^G-A]`]1_&#X:U#X/`1TF^-BX+%8.3=.0Z^\>9JZFD:FK^O/#
M%=**.6FSB1$(%91[KW1(OAA\0?GGT9_)@_FX[_SWQSWK3?S!_G_V]\DM\+T\
MV&VZN]VH^W_X?L+&Q4RQ;EEIIJ+$4^[=QYZF$E>33).YB21K>;W7NF?Y7?R&
M^W>U/Y-'\JCIC8/6>.WYW=\&*C8W;7:WQ;S>_(NF8^[:7L^.@W?\D.GH^P<1
M7'#;0['?<E4U)39Z2J'@CCK7@J?/+%Y/=>ZG_P`L_P#E(]%2_)O8'>F[?Y#7
M8OPOPG0N5C[2V)VYW-_,8WKW-OZ/M_8];#E]H4&T_CUC\GDL9G<?0YRACJH<
MCF*RBIFJ(X98DF"%&]U[HS7\G7XV_,?XK?`3^9O\FNT^A=X;=^>_RR[S^5/R
M/Q'4U=AMNQ[TS6Y)-LY*OZ@VO31P;FFH:FDRW866R<])%49*"&$9)[.J$S/[
MKW5?NXOY4OSUV?\`\)?=C?"_IOI/,Y?Y.]H=QTW<WREZDJMP[>V1V'6;5JNR
ML[O#)86EJ*C)28K=F[::BVGM"F>EJ:Y)IZ&&30'E@BI']U[K;+^"6\-_[U^*
MW4N2[&^+NY/AKF,3@%V=AOCSN_>V!W_N78VS-D2-M/9BY;/;<I:/&K-E=NX>
MGJHZ8IYZ>"5%FM+K5?=>ZI>^-'\O_>W?_P#.O_FC_,#YN_%3:N9Z039_370G
MQ.7NKKO86^MK;\VU@*>*+<F_-HXW<,VZ?M*FBGV)"YJVIJ626#/Z`%(EC7W7
MNK]\?U]L/H#K+=D'0W3.RMJQ8/;6;S&#Z[ZLV7MG9E%N#,8K&5]?BL+18?;]
M+@<6U9DZX^&(,8E\DYNZW+>_=>ZIH_X3C_#KNOXG?!3>.<^477-?UG\GODQ\
ME.YN_>X]M9RAQU)G\95YS-P[>V[05;X_(917QT^,V^V5I(WG9H%RSJ0"23[K
MW1"/B_T[_-)_DK]D_.'I7X^?R]JC^8!U-\J_DOO7Y"?';N_;7?\`LCKX[5RF
M]L73TL>U/D'0;Y9\W2T^W8:2A6IR"-2Q5E13UCPU$GW47V_NO=%5^17\C7OW
M!_RB.T.E]Y]N=*97^:'\SOG'3?/'<O7)[&VIU]M_N3L:B_C%/D_CEUYD-UUF
M#AWY)MC%;_KLS'"S"A&XZO0DZTW@JG]U[J%\[.[/FS_,M^>G\D?X7_*SX7XC
MX=[0W'W[3_)S=G360[*VYW1VGNC'=&P/6[JW7NK;^`Q5%B^LNJ*G;>+W%C<7
M2Y*6IR%>'JIIT1::))?=>ZN(^'WQ1^0>YOY^'\R+YY]\].YG9'66W^G>JOC7
M\1]U9_'XD4.^-K>#"S[ZW7M>HAS&2R$4D&3V1)KE:*F\M+G=&E2'3W[KW1./
MYO/P5^8?>?\`-,ZG[>WW\*]W?S1?@`W2--LWKKXP8+Y)T7Q]V'T[W_\`Q+3D
M=_\`:5-D\U0464HZNA>HG_B;P2PSP54-/,]\;!3U/NO=$0^*_P#+O^<GQ\^#
M/_"@')[9_EX97HSY'?*ZMP?1OQZZ-ZMK,=N7:R])[LRVY]D[QQ74>?R.ZZ>3
M-[9VSM;>-=7R9.H^VFK!!!/#`S$4J>Z]T>#YN?RTODOGOY6'\E[^6%T]TMG]
MQ[2I>YOC'4_,_.8[#[:6@ZIVS@*"',]M9[=]*^?IZ$Q/OOL'*9&J$"U[5KXZ
M;U-*Z^;W7NCH?);XD=\?(C_A0+_+][4R/3>=I/A9\&?C5V-O/"]D'&8-=D5_
M?N]X]T8&BVG1`Y$U=/)@*1-LY"D$5"A@J<6VEM-F3W7NB%?S$OCY\O?DMV7V
M]L;YJ_R`^F/G=D\EN#+83XL?+?XC?(7#=!;A@Z_BCC79^.[=W7NS,5/9.WLK
MB9J2">J?)2IA(7GJ:6FI9X$\]5[KW5W_`/)0^(OR9^#_`/+NZ7^/ORW[1J>S
MNY=O2[ES&1BEW#4;OHNM,%N#+RY#;W4V'W;6%ZK<.-V70,%\NJ2FIZB>6EHW
M:A@I6/NO=6O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__6W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]TQ[GVSMW>NVMP[-WA@\3N?:6[<'EML[HVUGJ"FR
MN#W#MW/4%1BLW@\SC*V.:CR.)RV,JY:>H@E1HIH9&1@5)'OW7NJ&\/\`\)G/
MY5F'W-15/]Q^\<MU+C-RQ;PQ?Q=S_P`B>T<U\9Z#<4.6;-+7#K6NS4LV1A>N
M=_)25M?4T<T<CI)"RLP/NO=7\4E)2T%+34-#34]'14=/#24='20QT]+24M/&
ML-/34U/"J104\$2!410%50```/?NO=2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
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MG\'WXPF<M;5X?X[';5]A'Y_=>ZX)UE\H5AB1_E)MYYEIJ>.68?'S`():F/'8
M*GJ*D1#?A$:U&1H:^I"`D(M>L0)%.K2>Z]URJ^M/D]*E2*3Y1;>I'DIJF.F=
MOC]@:G[6IDQ6XJ6FJ65M]QBH6FRN0QU68SI$BXYH20*EGC]U[KE/UI\G9),@
MT'R@V_3QSU&2DQ\9^/\`@9CCZ>I.]CC:>1VWTGWK8Q<UA`SD(9_X))<+]^_@
M]U[K*>M_DQYRX^3>WQ!]Z9A!_H#P1(HC7+.*+S?WYN7%"#!Y;7+'R:;^GW[K
MW6&#K3Y.I)0-/\H=OSQP38]Z^-?C_@837PP#:'\0@1QOIS1G(?PC,:7`<P_Q
MA+!OLD\WNO==4_6?R?C2F6H^46WJAXHJ-*EU^/N!@%5+#0[<AK)51=]N*<5E
M=CLE.%!;Q#)+&"PI5:3W7NN#]9?*$T\T:?*7;R5#TE1%#4?[+W@&6&KDQ6?I
M:>K,)WV%E6FRM?CZLQD@.N/:$D"I9X_=>ZR5'6GR=D-4:?Y0[?IQ*:\TH;X_
MX&?[43R[[:@#$[Z0U'\/BSF!5KZ?-_`9"=/\0D$'NO=2).N/DLTZO'\F<!'`
M)(V:`]"X-RT:UU1/)'YCOA2#)0R1P:K>DQF2UVTCW7NL-/UK\G(Y:9ZCY/[?
MJ(HVQAJ8EZ`P,!J5IJG:DF359!OES!_$Z;%9:)2`WVYRR,-1HT$ONO==4O6G
MR=BAB2J^4&WZJ98\6LLR_'_`TXEDIH=J)E)!$N^G$8RDV*RSJMS]O_%D4%A1
MH9?=>ZCS=8_*5X"D/RHV[#/XM(G/QXP$JB7^&YRG\OA._5!'\2K:&ITWMIH6
MBO:H9H_=>ZE3];?)IWJ6@^3NWX$DDKVID/0."F--'/+O=J"-G.^4,YH(LU@T
M9B%\W\#D)T_?N(/=>Z[/6WR9,[./DYM\0FIDD6#_`$!8(E:9LE7U,=,9?[\W
M9H\;/3TWDM=FIS+:\A5?=>Z+'V5G?EUL#O[XX=7P?)+9V3PG9&WN\]Q[MFJ>
M@,/3U54G5V+ZJRV*H,>T&]Y#CQ7K7Y>&64,Y7^(QL%)I5$GNO=+>$?*U(J-9
MODGLR:6&"CCK)1T#CXA73PP[-2LG2,;X84JUTV%S+A`6\0SD:@G[%#-[KW7!
MD^6!A=%^2^RTF:D>%9?]E_Q[!*MJ/(0I6>,[Y`98ZRIIY_%>Q%,4O:4E?=>Z
MS3GY52"N$'R/V93F>.O6A)Z$H)ACY*B3=S4$CAM\+]X,?'F,0I#:?-_!7)T_
M>OXO=>Z[F/RI>29H?D=LR&-YZAX8CT+02&""2ORM13P&0[W4RFGH*NEIBY`+
MM2&0@&8JONO==QM\J%E@>3Y&[-EB2>EDGA'0U!&9Z>'(;7J:JG$HWNQB:LQ^
M*RE,'`)C.624`FD19/=>ZX1?[-6OA\OR0V9+H6C$UNA*"/SM#3[+BK&%M[GQ
M"NJ,)FI0!?Q#.QH+_8(9O=>ZP+'\LA!(C?)C91G>.=8Y_P#9?<<%BDDHIH()
M3#_?JT@IZUTG*W&L)X^`VH>Z]UGJ?]FKE2I6F^2.S*5Y?XG]M(W0>/J!2_=1
M[N3&:D;?"><XJ3,XAVN1]P,*X.G[U_%[KW7<_P#LU4E0TL'R0V93TYGKY%I6
MZ$H)F6">JSDM!3^<[X4DX^EKZ&$O:\QQ[.0IJ&">Z]UE@?Y2QSP23_(O9M1`
MDL#STZ]$4,)GB2JV[+/"LPWLQA,]+C<C"&`.@Y-7L32J)/=>ZBP+\KXXJ=9_
MDKLNHEBAH4J)5Z`Q\(JIH*?9<5=.L8WRPIQ7U&#S4H0$B$9V-`6^P0S>Z]UT
M4^6'A,8^2VR_,:;Q"H_V7_'D"I_A@I?N_#_?D*5_B8-5X[VTGQ7MZO?NO=9J
MS_9JIOO/L_DALRA\T=8M'KZ$H*O[*2>CW?#12-JWQ']T*&LS.(G93I\PPKH2
MHK7,7NO=`OWYV-\O^M<)UUF,!\A=BN=[_)WH#J.>FJ^A<?(N/VOV[V9EML91
MHY3O4FHKL5A\UCUCD(4R/C&?TFJ81^Z]T-L;?*:.1/+\BMFS(E;232(.B*&(
MRT<%7AY:RB##>Q,;UM+15D(EY,1KE<`F!0_NO=1J=?E=']A]Q\E-EU/VYQYK
M]/0./@_B(IZ;9L605-.^7^R_B-3A,S*I&OP#.(@U?8H9O=>Z\J_*X0QHWR4V
M6\RTZ1R3?Z`,>HDJ%QD%*]2(AODA%DR<;U6BY"K((KV74?=>ZY3#Y6.E0(?D
MELR!Y(ZQ:=ST%CY13R34^[XZ.1D.^5\XH:C,X>0J2!*,*ZFWWKF+W7NNV_V:
MLF33\D=F(&>H:,?Z`Z!C&DM5N:6G0D[X&LTM+E,9"3QY#BF<V-6XC]U[K*C_
M`"F6:!Y/D7LV2&.:F>>`=$4"-40Q9+'5-3")?[[$PFJQM-4TH8`F-JH2V)B"
MM[KW6&E'RLB:E-5\DMF58B7%"J5>@L?3_=M2?W)_BKJ5WP_VPS'\#S>D#5]M
M_'H[:OL$\WNO==1#Y6I2&*7Y)[+FJ_MJ2(58Z"Q\2_<PT%'3U=5]L-\,NFLK
MX9J@1ZK1+.(P2$#'W7NN-2OROEBJ%IODKLNEED2I6GE;X_X^<4SRQ;H2F=HV
MWTHG%++E<6Y!(\@Q+@V^[<Q>Z]UGF;Y4/+.\/R-V;#$\]7)!">AJ"4P035>Z
M9J2G,IWNIE-'29;%0ER`93B'<@&L<1>Z]US#_*7[I93\BMFFE%:DYI/]!%"&
M:B&8HZQZ'[C^^I8,^(AFHO-IU!IQ/IU($/NO=1Z%?E=!'1+7?)39F0D@-$:V
M1.@<?1BN$$FR6K0B)OB04GW\>"S:BQ;P_P`?C(O_``]/-[KW72+\KQ#"C_)7
M9;S)2QQ33CH#'J)ZI:7&1250A_OR1$LM72U4WC!(4582Y$0+>Z]T'O<.Z?EY
ML3J/M[?V(^1^QI,ELCJGLG=F'IJCH''O`<U@MI;RRF#EJ&.]SY:>AR$V->2,
MBTZXUU)`JF,?NO=/VR\O\M=R[`V5N.I^2&R*?([KZ^VON2;1T#CVBH\ENG;6
M9S:LD?\`?A1-#C9MS8I`ATB485R=/WK^+W7NE7J^4_F9_P#9C-FB$U/E6#_0
M-0$K3?QBEK/M#+_?8$M_!XI:+R6OJF$]M2!#[KW6.#_9JX_MO/\`)+9E1XC0
M&IMT%00_="!MEFO"Z=\-]O\`Q!<)F@I&KP_QV,C5]@GF]U[KUOE7I`_V9+9F
MH1Q*6_T!X\:I%H\+!++;^^_`EK:&MG"_V17K'R*=2_NO=8YD^5[QU*P_);9<
M$DL=8M-*?C_CY12R34&<IZ.5HSOE14"BKZ^AJ2I(\JT#1G2*AF3W7NL]0WRH
ME%5]O\C=FTIEGR<E*6Z&H*C[2"J_OM_#*=@V]T^Y.*.=PFISI-1_`9+A?X@_
MA]U[KIC\J35),OR/V8M(M3-*]'_H%H&9Z:2NCJ(:45)WN&1J>@5J<R:279O)
M8$:??NO==TI^5$3TS57R.V;5I$:3[E%Z%H*<U8A.T35Z67>[_;FL&&RX%K^+
M^-):_P!DGE]U[K!&ORO6"..3Y*[+EG6G@CDG'Q_Q\:RU$=!@*>>I$(WT1&M1
M7X_(5`CN0@R*QW(IE:3W7NN+I\L3321+\E]E)4M23PQU7^R_8]EBJWQ>:I(*
MTP'?0#I!E:ZBK#%<!UH&AN!4,R>Z]UGJS\JIFJVI/D=LRB6;[W[1&Z%H*K[/
MSG?'V6IFWO']S]@,]@P;Z?-_=^2^G^(/X/=>ZY%OE1YY)!\C=FB!JKS1T_\`
MH&H"T=+][-/]F9O[[`NWV;I!Y;`W3R6NVD>Z]UW3M\IHQ3_<?(W9M3XZC'25
M&GH:@@^YIZ9]K-D:=;;V?P-E$Q.557%S!_%T(#?9IY?=>Z[QL'RMDJ,735/R
M5V9.3+C(*R1>@,?#]T4@VO35\B(N^6^V^_JL;DYE`+>$95$%Q2*9/=>Z`CXZ
M=C_,7MKJH;TSOR+V'290]C=\;+T4G0./\`I>M.WNU^L,'6:/[[(/)-!@L96R
MK_::D>.]IV=?=>Z'.?\`V:J0U1@^1^S*<2FO-*&Z$H)OM%J&WP<>&)WNOW!Q
MJ9[!AB=/G_N_(3I_B#^'W7NNU/RJ#AF^1^S&3S%RG^@2@4F$U]=4"'6-[FQ&
M/G@IM7UU4YDM>0JONO==T[?*B.2D:H^1NS*F.%Z`U:+T+0P&L2GK-KS5Z*XW
MP_VQR-'BLI`I`;P'+I(-1HT$ONO=1X$^6$?V_G^2^RZCQTN.BJ+?'['0_<U5
M-#M9,C5K;?3>!<G-B<K(L8N(!ET4%OLT,ONO=<F7Y7FGFC7Y*;+6H>D>**I_
MT`X]E@JFHZ^%*LP'?($JQUE13S^,D`BG*7M(2ONO=<JL?*R850I/DELRC,K5
MII2W06/JA2+.^]FHE8-OB/[G[%,[A%).GS?P&0G3]^_A]U[K,S?*8U+2K\B]
MFBF-7),M+_H'H2RTC9/*54=']Q_?;4S1XRJI:3R6NS4AFM>8JONO==1M\IUG
MBDD^1FS9($J*>66G'0]`C34\5?MBHJ:43C>Q,1JJ#%92G$@4F,Y9)+$TBK)[
MKW6"F7Y711TZU/R5V752Q+2BHE7H#'TXJFBBVFE4RQC?+^`5<N(RS@`GQC,H
M!?[)/+[KW7;CY7-2B)/DGLM*H4]3&:L]`X]@9Y:&6"FJ?MO[\!0*6N=*@IJM
M(J>,D!M0]U[KJI7Y7RM5&F^2NRZ198<HE*AZ`Q]1]I-5G>?\+F9FWRAJ1B!F
M\*&4Z?N?X%)?3]^_A]U[K/*WRG>6=XOD7LR&*2:J>"$]#T,IIX9<EF:JEA,I
MWLIF-'C:VCI2Q`,C4+2D`SLJ>Z]UP7_9J@4+?)#9C`/`SK_H#H!K2.JV[+/&
M#_?CT^>DQN1A!_L')J_)I5$GNO="_BT[K3I#<@K^W,!7=F2QTM!A.P8^L:2C
MQ&%K$CP^,J<E/LA=Q2P945-<*BK$#5D:H*A8@Q6,,WNO=?_0W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=$`^1O_997PV_\1M\P?\`WE.KO?NO="?[]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HJWR^_P"/+Z"_\7O^$O\`[^O&>_=>Z-6_ZV_X,W^]GW[KW7'W[KW7O?NO
M=:XG\WGY_?);XT_.KXU_'3J_YW]$?`3I[LWXQ[N[6W;VIWSTAMSM[;M;OS`[
MZKL%CL%3ODMNYS,4-;F,7&@@CCDIJ1/!(S%Y'126;;<2W?,'->WW%XD=I9V5
MG+"I7NDDF=TE16'$Z0)>XA0L;`&I`Z6WT:6VS<NWD-H[W%U>744K`X1(HT>-
MV4^6H^'VY+2*2**3TG/AK_/$S&U?B-VUW7\XLAEOE!MW87SMQ?PPZ4^2GQ#Z
M5_@M)\H7W?MS)[BP^Y,!U;F)MD4]3_=^LQ1HI'Q4"S5)KZ.%:>::\TIPTL<U
MKR1&NU30[]N]Q>6Z05#>)]+H\*X74595NM;1HN?U(VJ(BLB1E@CDBON;%_>$
M4VT[;:6MR\M-(C%PQ22%F%4)@-'-370&(9P8RUCG8G\UKK;KB?K+9-1\1_G9
MO?Y,]E=>[E[AK?A9UIU%LC>'R9Z?Z<VSFLKMYNS.[<12=F1[`V3A-PY7%>/$
M4J9VKR60^YA5(!(X3VQ/+!"^Y:9Q)9V,$<MW.@8P6OBHLBQ2.0"\X1M3Q1!V
M0#4>TJ2]`#,ED9!X$MW.\5K'+19;DQMI:2-`24BXT>8H#0@=RL`[[G_FU?#K
M']%?&[O7K6K[7^1LGS#SN7VK\8^B.ANO7W+\BNU-U;0G>F[-P"=?YW+;=H-H
M3=0S0R#<M5F,A24-!I4B9UEC9GY[>XBW"#;+:!KJYDM?JU,-&C^CH3]49&*J
M(L,H4_JF1)8PFJ*0+6V=)K*_O[AOI8;6X%M*)@RNETU0EL4`8F22E4(["K1O
MJI(E:_?YA'\Z_+[:_E\;C[Q^"VP^Y<#\@(/DEMGXJ=EX'M'I;;&0W_\`"_LM
M\YCH]S;?[DZMW+NI\!5[XW)15<>/VF\+Y;!9*OGD5YXGA)5#2:\W+D*VV^<R
M;3O-TZB>%1(S>$H$EG&DFFE]K8,89-'Z,4C>(FI"7XYK>UM.<;C<+;3>[3:K
M(8I6*)IF_LKMW35_B14'3,A;]5HU\-UU@6J1?)+`_%'X(;3^2GSA[*[$H!M+
MKS;V:[4W7VGU#M#K;N_,;SW=D33;;V'E^A.G<IN/96"[8RV1R%+B8,'@:ZKH
MVE`F:H">:15V]3VEE>P6UM&LLTKQ011VY>8W%P8ZD1:@I+.5=W%`D6EZ'0@/
M23:H;J>WN)+J?2L7C2R23!85B@60T9J$C0JE1&<R2@I4&1Z=%5S'\X;8%9U1
M\KY,%\8/EQU9\LOCM\:\O\C]N_$7Y(=4;>V1VQV#UO54'V6`[CVSC,7V%D\!
MN3JO:.YZI#NN.+*0YC%T=%5`TCRH(B4<Q37FW\O;_N>V/')=V,J03TJXL9):
M%)KD`4:V5#XC2Q>(B]BOIUK4UV6&VO\`>>7K.[646&X`R6[JI`O%C)UPV['A
M<N!2..70S`EEJ$8A\_DK=^?*7Y3_``?VQ\B_EMO+L/=N_>V,O3[BVU%OKH?J
M;H;"8?9]1@L?5TS]0TG5&7RH[)ZFR]57%J'<6?CQ^:GJ:>>,T<4`C+"O=K&W
MVZ#:((P3<O;B61F)\7]14*K)&!X:`=SPM&3XL,B/($8:`'+"\EO[G<YS1;59
M2B*@K""DDJMX<C$R.XHJ3(^(I%THS@EC;/[)NC3KWOW7N@5^2_\`V33\CO\`
MQ`O;G_O"9SW[KW2NZH_YE%T[_P"(?ZJ_]X#;OOW7NEY[]U[KWOW7NO>_=>ZK
M6_F>?,'N/XI]9=$[+^,&T-E[R^6?S+^0^UOBW\=HNRWJ/]&VS-S;EH*K(Y[L
MW?-+221U.3Q&S,9'&\=,HDC>>822QS1Q&"5B*"]W7?=HY<V^YCMY;B*XN)IG
M&H0VEH@DG9$H=<K`A8P010.0&8*I>DFL=MV?=M_W)&>VMF@BCB4T,US<R:((
MBV-*'2Q8ZEJ=*ZT!+J7W:\_\ZWXTXSY0Y'Y1=T_%;Y3]*[2^'/=/;^P_D3LG
MKK`]/=A=4_('KW8VY<OMK92]2XW'4-#V/M.JJL7%6U,E?2FFEB((JHBCT4Z+
MF'<X]MY3YMW!`\.XVD*R6DH`<3%G1626-B50(NHD\5+(!XNMO`4;+82WO-?*
M5E)23;KN]2*[BKI\)":5AD%&8R,RH*5P'8B,HIF+K\4_YMF6CV5UQVG\INX^
MU=[9C`?R:\9_,&[OZ1V'\>^EL5L/-_:]I5^ULMVOL_MNCW!MW>T?9^0HE@H?
M[DMCZ':21:JM*I)@8P(=S>QV^UYJO1`SV]K=;+`"31H9=QL[>0I&H-)HI)IC
M(\DI#0CLB#*O1%M3W>Y#8(FG5)[BXW<87$D=B]P55_X#%%`0AB#&1J>+IU@D
MX_5?\XKXX=[;NQG5F&ZQ^7W0^X^V_BYO_P"3'QR[#[PZ-P6V]K=T;'V;L2LW
M;N'-=1TK;US,FX\]LG'QR5T='EZ?'X[++1@I,U)54\TQ?O<$^W[;SE(UUX%Y
MM%E]3,`NJ9+=CI2Y6)P$8%J`12,KY(904D"F6SRPW]YRD%@$MKNM]]+%5],;
M7"4:2W>5:L"!AI(PRBHT%JBJ$Z=_FV]4XGXL?"K.3P_+KY[?(;Y4=<;\[$V1
ML3J#XV]:;7^2._\`K_KW=>Z<+NWM[?W4FS]]T'2G56V,#6888N!://3?Q:6-
M&IDDF>9$5;V\5ANMQMZ694VNTVM]<^&QD2"WGB0QSREZ/6X<FD4:N$?4B]H4
ME+M8>ZVYMQGNU$,NY3VL'B!8S++$]'AB"U!6!>YI9"I*=[<#0=MR?S7_`([4
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MFY;EOX674`[*\T:N*A9%*O'H9'&FJ.-+!U<4N98!RKNFX0`IO%KO]E92`T(5
M)QJ=>TM&VN,HZNI)4,,@AAU?(?J?]?VEZV10D?/KKW[K74W&_P#%QH/^HVE_
MZWQ^_=>Z)]\(/^R>E_\`$]?+W_X+#N;W[KW1M/?NO=>]^Z]U[W[KW1+/YBWS
M#IO@+\+.\/E@VTH=_P"<ZZQ^V\+L'8E543TF/W=V;V%N;&;*V%B<S4TDD-9%
MM],[ETJ:_P`#I.])`Z1LK,&".Z;<))MIVO9X5DWK<+V*U@#4T!Y229&JR@B-
M%=PI90[!5+*"6"RRBLF^ONMSN?!VNSM)KF9ZT.B):Z`U&TF1RJ!BK:02U"0`
M2@_'/9O\_797>WQZS/R2[=^%OR7Z+[4JQ%\E^JMI[%QO2^<^+N/S-%2YFBK.
MK=[X[&T>=[7K,'-5/CHHI36K5-`L4ZJ)CD8#N..PM+O<]NOY9)+.*VG*7:BC
M_40(VA?"[04FDIW%`-"LQ\%@J2$<UQ=WNWV6Z[;&(KJ26(FU;X/IY2"SF1BS
M+)%&*Z`S?J.%'BK5D*'\&OYG?=?<F\_B)MWY`?('=U-NONGYN?S'>F\1L+K_
M`../3%5L3N3K/XNX';F9VQMOLW?]5E,!O#I>?8]'7SST&0VQ0Y.OSTTRP9)A
M'%YF*]JN(I-@V+=KM#+=/R2^ZW*_"OB13W8>>(KGQ/#MPJV[!8"0"6#2='.Y
M0-'NW/-C:@1V=GS78[=;/EG1+D46)U(TNDCD&2=F\6(#]-6%:&RZ%_GN?$'O
MK.?&,XGI#YG;*ZT^5_;<G0G5G?'9W3>#V]T34]Z+F,CA\=U#D]Z8??N:RL^>
MW!58X)#68Z@J\="TS)).LM)7)3&-K8RW-U9V6I8[JZV][R!7JIGBB75+X=`<
MQY6K461@!&6#*2BW"5-MM=VO)ZF"PO1:W)7(@=R!&\A-`$=3KQ5D0$R!>'4+
MJ+^:KU-LOIGNW?\`VAV3\B_DWN^E_F(]N_"[I;J7!?&KK/9'>V\^T]L/@YJ3
MX]],;%ZTW=5;9W]M/9F/KWJ(][;GR.(KZJ$LN06*40I(707"7&T^WAL[=[C<
M-XVV2Z4IB26"*1A->3QDB*VC@72)%C9E"E6/<6HHNX6MM[YV@N95@LMLN(8F
M![HXI95<1V\4@!EN)9W1M(=5)(JM5(/1@]L_S2NC=Y="[Q[IVKTC\PL]O;KS
MOBB^+V_/B/B^AZNM^56SN_LE-$<?L;<VV(,X_7>#PU9BIA7)N>IW'%MD1?LF
MM%5:$O3#1#LUS:TN;6^\70\9`2,VX)NDG:0H(9+:E)(WH[$CPP^:-Q:FFW:"
MZ4VTUE"LSB3BT4A(A>()J,JSD=FG@.]]*4)KT^2G\Z^C[)^(^W.Y_@W7;TZD
M[,V9_,E^.OP\^0&Q^[M@]<;AW/M;!=A9+<$>Y<(K83<79/6^0BW+28U/!D\1
ME*FII/!-$'@E.OWJR1[GF'VN,,L<_+.\[G+;3$:E+>'$':,%E5U*AE=98ZHX
M9=+-0CK=T1:[5[CI+"T>^[3LXN8PU"$9YXXT<@$AO]%1HWHRLM648ZV0,M3Q
M4F4R-+`I6&GK:J")2Q8K'%,Z(I9B68A5^IY/OWK]O6O)#ZJ#^T`]-_OW7NO>
M_=>Z$>E_YEGDO^UC'_[MJ#W[KW7_T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW1`/D;_V65\-O_$;?,'_`-Y3J[W[KW0G^_=>Z][]U[JJ;^:3\\>^OA-+\/-J
M_'+I_IKN'LCY;=U[BZ<Q>/[RW_E>M=G;?K,/MBGW!05TFZ:')XC'T"5SRR1S
M25LXC30BQJS/[202W5US)9;#;QQZ9=NN[HLS:2/I3&2HK@ZD9R!\3.%502W3
MTXM[78[O>;B1_P!.^MK<*JZJFYU@,:9&EU4$_"JEF8@+7H-/A+_,T^0':7R^
M[-^$7S>Z'Z`Z*[2VA\;?]FNV[V'\?.^\?V]T_'U=C=R?W8W-1=G;BGS.6I-C
M9B@E/WL$\]9#']JC&:)8Y*>>0SMEL[G9>9-V%R8_W3-"MQX@TQZ)HU=61S0$
MH&#/D@J32AC.I'/]7!N.Q60@$B[D)%A"&LOBQENTQUU%9-)52%%'`6K%B$.W
M\>/YB/P4^6><W[MKXY?*;J_L[.]8X2JW7O?'P2;CV>V+V3054]%D>PL;5=A;
M?VE1;KZXQM33L*G<&'EK\/3J4>2H5)$9F2K)M<^]2*4VN(`R._9X09/$4RHU
M)(@R94NJ@\!W$`V$T9W&':4</N,M?#1._P`0JP1EC9:I(RL0"J,6S6E,],_Q
MW_F7_`#Y:]H5?2GQN^5O6_:_:\&/R>7H=D8VBWMMO([IP^&J)Z;+9;KZNWSM
M3:^%[+QN.:EEDEFV_59)!31/."84>17(;>XN+>:ZBA8PQHKO4:61'II=T:CJ
MA)4%RH52RAB"RUK<7$%K-#!/*JO([(AK5'=!5HUD6L;2`5(0,68`E00#1WZL
M_F)_!/O#OG-?%_J#Y3]7]@]]X.HW%12=?8.3<:?QS(;/-MVXO8F\<GM_']?]
ME9;;&ES7TNWLMDYZ98I6=`(I"K=@C[K9R7^W(9;14$A88)C+:!*JM1FB+#^U
M52E*-JTFO5[V2/;;N.QOV$5VTAC"GRD"ZC$Q%5273_H;E7K5::A3I/[8_F>?
MR]-Z?(!?BUM/Y;]89[OB;>]=UC1;/H:7>O\``LKV7C(W>NZ\P?:D^TX>H,[O
M2"2-H!CJ//SU,E4/MT5IK(:[?_NUB2?;2)HGA:5"#3Q(D^.6(-0RQJ.XO&&7
M1W@E<]6OR-K++N!$15U1JY".YHJ2%:B-R>W2^DJW:P!!`<=C_P`R3X%]D]S;
MI^/.Q?E#L'<'<^PY>S(NP-EIBM]XN+KT=-)62=HU._=WYO:.-V)L['[/CQU2
MTM5D<I3TU2*>4TKSZ&LU;S0W6U3;[;RJVS1VXG::M$$)94#U-":LZ44`O1E;
M3I(/5[R.6PW"/:;N%UW1YQ"L04L[2E/$"@*&KVU);X`0R%@ZE0'&)_FH_#+N
M;IWY6[X^'W?_`%A\BNQ_C!T3V5W36];P1[[VJ^<I=C8#+U^.K8$W/M?;.5W/
MUYE,YC4HJC.;>&0I(3/':8-+%K0[[>7.T\K;IS/!:E[>V"5!!!5I-)021U61
M"T;%XPX0.5H#QZ6;/!9[AS)M?+UU>"-[B1EU*000FH/X;YCD*LM&56)`S2F>
MD3_+Z_FZ?$WYR;0Z!VJG<W4V`^8/;73^-[+W+\;]M5>\)(\/ECC:C+[CVKLO
M=6Y,/%M_=V7VOC:=I:_&4V5K,M1-#4+-"/"^D2SV"F6^7;9#<0VL$+S'`*>)
M'&9#IP6BCE<Q>*@9.WN:H:A##>L(K=MQ1899KB6.,5J&T2ND8+"H226-5D$;
M%6.L:11EK:M[+>C#KWOW7NBK?+[_`(\OH+_Q>_X2_P#OZ\9[]U[HU;_K;_@S
M?[V??NO=<??NO=>]^Z]U67W;\!)^\?YG/QW^9V^,9TKOSH7I_P"*'9O1.Y>K
M.R=N0;RW+E-^;PW'6YW;NY\+MK<&V<SLR;#8L5,?EJ9JF&LA*.J1R+)<)MI@
M%CN_.>XW`5X]QVZTMX0!5HY+>?Q'=J_"&2J*4JQJ0W:3TYN4C7FW<JV4#,C6
M.X7,\N2!)'/`8D1:<2KT=@PTB@([@.N_YB_P4W1\LNH?B1U3T+4]2]1XOXV_
M-/HSY*5>$R&*EV;L^/875N1RN1SVVMCX38>W*C'X_<V2J<B)::$TU+232:S)
M-&S:_;]OKCYMY+YBG<O;[9<N\@K5V0QJBJE<&@4@*64+4,*T*GTAC/*_.FPP
MQA9]SM!$A``19/$UL\E,Y\R`6)X^O3#\E_B5\PL#\\<Q_,7_`)>F]_C1%VQV
M;\?Z'XU=T=/?,!.RL=UYD-N;5S[[JZ][0V/O'J?&Y[<./W5@<C3TM-78:HI1
M0UU/$[">-Y-2,V27=E;\T[7%<*NV[O-#.\@6LUM<P0FW6:-3^G,AA8TB<I20
ML2S#2%<NFM;V;E^]G63ZW;4FB513P[BWGD\5XG/Q1,LE6$J!B1I6@HQ8IVVO
MY-O<WQMV+\#.QOB?W[U=N[YI_"/?'R1W[N+,?(7;6Z-O_'SY'5/S(DD?OS;U
M5!U]#EMX=4TF'%04VU6TE)6N$354PZG`199S'8GM;38+5/ZOIL,>T-#,S"1K
M>&=KF*X$BZB)4N'>3PB2K)X4;2'1(94DT*;J-WNM[>F]76\_O59(5JD5QX:Q
M&`([#5%)''$KR-W!A(R(FM0B8[7_`)-?R-[>^,7R3I=X=T='UWS5^:?S?Z#^
M87?>7P]-O;!?''8F!Z2RS#`]/]5SU&%R6^MPC;6W7>.'+9*AI)\O-(%G$)3S
M/K:%M]DN/;>WMF>7:]DWZXW2=W`6:>:[5OJ/"1241-17PT9C2CDL`RHM=S-S
MNMM[@F8HEYN^R0[;`JU,<4=LR>"\SGN9V56,I10`=`5?B)M6_F3?#N'^8'\9
M-W=#X_?YZFWB-_\`7G<?4_8M9A3N3$[5[2ZGW"NY=H2[JVY%/"^:VME)#-15
MT<;F6*.H\R*[1!&2.+N#=>7M_P!LD1=UVK<%NX!("8V8*Z&-Z9`97-&%=+JI
M*LNI2H@%NVU[KLE^KG;[[;S:3&,@.%/AMK34"#I>,$J::E)4,I(8$9/\OGYJ
M_(OM3O[Y6?./LKXMX[Y%;D^!/</P1^._6WQ@7L^NZ/VE0]PX;-3;I[A[0WEV
M1A<9OG(YG,[IS;QQXBAHIJ7%XT%EDJ)PI]I-XVJVN-CYYMMJJN][_#!!(TI_
M2M[6WE65+>,K4R%G'B&=HU=2632RE=*W;=PD@W;D:7<&U[5L=XUT&04GN9W7
MPVD=21'$HB`7PE+`M1@R:6#V$?`SH#=?Q1^$OQ6^,>^\QMS<.]>ANFMN=;;H
MSNSY\C5;4RV8PT^0EGK-O5.7H,5E*G&.E6H1YZ6GD8J28UX'L3;O>Q;A??4P
MJPC%O;Q]U`28;>*%C0$T#,A*YKI(KGH/;59R6%F]O*RES<W,E16FF:>251FF
M0K@-Y:@:5'1L?99T8]>]^Z]T"OR7_P"R:?D=_P"(%[<_]X3.>_=>Z5W5'_,H
MNG?_`!#_`%5_[P&W??NO=+SW[KW7O?NO=>]^Z]U7_P#S&?@W7?.?J3K?%;#[
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M7$D96KECWJ5((8,/$9]$0C>VJ^GL>8N5-QDH-MVZ\%Q*R?V]T`0#$]:(%&D2
M*<4>H4*&<L37`?R/ODQBMA9[:=1VOT')6Y;^1I)_*V@EARV^FI8^[I.TI]]C
M?LT[[+21>IDQ,H@-4(FRK5)_X`A!<K]U/UVV\V6,&)+_`'+8;F,MP";3;VT,
MZO3(>1H7,--0*LNLJ0>BO:(#M\O+LD[AA9OO)?3YC<Q="+37XBGCQ^)73IT/
MIUZETG`S7\LGN_*]H?RR]\KV'U3_``WX0?R]^\_B%V33SUFZS7;J["[2Z#_T
M283<VP(1@&@J-F4.<5*FKEKI:*M2A2R022$*JCFN<;_N'N[>6@T)S%LBV4&O
M!CE%P\Q>>A/Z9#4JA9M5<4STSRQ9_N*P]K[2Y(9]AWH7DVG(DB$:IHB)`K(-
M/X@BT/$<.@$Z)_E.?-CX>[6^`';WQJ[1^*&Y/E[\2_BQV=\.>W-D=V5';%)\
M<>UNI^PNT=X]IX?-;1W[LO;<W86WMU;+SFX83(LF%CCR80IK@1#Y?;C>W$F^
M[QN.V:5L=QV?;[.82#OAFV^*-4N(@N)!(R:6C=E7PP"`'8LKUE:Q+LEEM=\2
M)[/>;R^B:/*RK>]DD4NJA1EB^!E##Q,D$"A67R0_EC_/CO3/?!OM?LKY"_$C
MYM=J_'W%]G4W>'6GS$ZTW/M7XGYW>78N;FS>U.V.LNI^H=O/BMP;HZ0H*F/"
M4"[AQZSYZ@QT<D\],]3((D"6L%KNVXRV;DV5QM,=DMQ,JRW-M*CZYKZ"$@6_
MB7.H@Q#0B*JJ2[:9(U<ES<7&U01S@I>1;B]U]/"[1VT\;1"..SFF.J<QPE2Z
MR,';7(S`!59)4#\1?Y,_R0^.F>_E5R[M[7Z$W/BOY>?R6^<?;&_,CM+^^&(J
M>RMD_)Z#%-L>38^VJC:E-CL%N7%5U/4C*8F>>&AH8&A6FJJG2P*[:Y8K"YVB
MX*2>';\JOM;*7,K>*;BZE5A(Y#/'HFCU2O1RZ2#P^Y65F]$EU9<VVU8Q)N',
M5GN*%4$:+';Q(DL;("0CEE/A(FI`I`+#3G8Y/)/^O[3].$U)/77OW6NIN-_X
MN-!_U&TO_6^/W[KW1/OA!_V3TO\`XGKY>_\`P6'<WOW7NC:>_=>Z][]U[KWO
MW7NBL?-SXC]??/#XI]Q?$OL[,9?;&V.V</BXZ/>6WX4JLYL3>6ULU0[GV/O;
M'4,L]+%E&V[N3&02ST;2PBKI3+$)(V975#?VMQ<+9S6-X;?=+6X2X@E%>R6.
MM*T(.AU9D?20X5BR,&`/2VPNTLY9_&MQ-9S020RQFG?%**,`6#`.I`="5(#*
M-0*DCH@WQ[^-7\[R#NKX]5'RO_F&_'./XY_'3,TV0S-/\9.L]PT7<WRYQ>"I
M8<)A=N=]C>>`H-J8:AS.)IQ/7RX^1S3332F"-JL4]93GT=W!/?[CO.Z6H:YG
MMIT^E2@M?%N%(:<D@,&B>DD>D4^)5$:LP))/9O#MUOLNTW&FU26(BX<4N%BA
M.(5'<I61:QOJ)-`KLTA&2T_&S^31\BNENW?A#V)N3LWHS(XGXO\`RV_F/?(+
M>F.V]D]\2U^;VE\SMGX/;G7>&VBN1VE2PU6X=L5F)DDS<57+2P00R)]O-5,K
M7)+&WDM=AM]I=P;A.1I]D+?A-S+)=NLHX$0#ZA-39<:'`C-58'=Y=+<;CS7=
MQJ1#N'-NW;L@/%8+,@R1N:T\9LA`*H:@LZTH7/J?^3M\B=@?"7^5%\8,OVET
MG7;P^`7\Q'!?,3M+-X_([VDVEO#KO$]F[YWO+M?KJ6IVI3Y.KWN^-W7'%''D
M*:@HON5DO.%L6$IW2)N9.3=[\-OI]NV*>QD7&HRRQ+&KIFC1J10DE6IW!?P]
M$^YPR7VQ>Y.UH0+C>[\3Q$X55'$2<2I)HVE0XH-&JIUB/@/Y./R8V'MVO[+Z
MZ[DZ%Q_RKZF_FQ?(C^9#\:8]UP[\R_1^Z=B]\8_;6`RO2G=M;C,+0[MVGG<C
MA,(7FR>'H\FE!(HCA:0R>>(.[8+K:;/VN,`CDO\`8]@N=JN58E8Y8KQV:66!
MP"VM`1X?B*`26#`T6IENQ@W;<O<)W9H]NW?<K2^A8`&6.:S\4Q+*A(4QL9`'
M"L2=.H$`E0(ORL_EY_S*/F5\<]KXOO[Y,?&#L?N+;WRYV[\@9/BE6X/?^UO@
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MLE5)6Y&NK(U=(ZJKJ*A%DL'5)I7D57"DJ&`;FQ(O[9]?MZ?\E'HH'[`!U"]^
MZ]U[W[KW0CTO_,L\E_VL8_\`W;4'OW7NO__2W^/?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=$`^1O_997PV_\1M\P?\`WE.KO?NO="?[]U[KWOW7NJ8?YN_P/W!\
M]>P_Y9&T:[I=N[/CUUC\L<[N[Y7XA]RQ;9H,#T]EMH4N+FR64J:?<6W-S5-'
M4U<+1Z,/)+6A@/2%.H)K"T@?G+;]PW&/_=0FS[A$7-:+<2"-K844ZB3(@(--
M(*]^#F^X7-RO*M]9[:W^[5]TL9`N,P(SBY-3V@"-B#G4:]N1T0_9_P#)Z[C^
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M'EHTD)ONLZW^W<_7MM`IN=YL5@2"<M]6U)TN]%W=#"I#)J2&2/\`4,RF2BK*
MZ1DVV0R;=><CVS2%5VC<3<FXAT^`A"&`36D#4)N)UH\L;J8O".C5K17?)\#O
M@C_,3ZL^0'2NT<9UU\F?BM\3-M=5]V===^[*^5'R(Z*^5_3NP<?G=GYG9_7N
M!_EQ;CP=+E?D#L:BK=SYA\W/)53X,C'HL-1)4Q1"&9+=0/NNR<TV=W?AOJ]D
M^GA::.EZ+EXF1$:2)M'TEJ:)I8NIAP(A+H=5"2G;;W9+BSL`;JVWA;DK$];$
MP).LDK:)>\7-R@JK*-2S:B7T,R@+_P"7;_*)^773G;WP8Z^[TZ8[SPFUO@QV
M=OGLC*=^[Y^>%9O?XC2UU'E\IE-B9CX8?&K9LQS^(W#V?69F,[JHLY2XVA^U
MAK6F,DE2T:F-M?RSRR;[&JVFYILT]I&EP/J)UGFM3:%8W%$^AK'',X.EA$R1
MH`T"M*AO]OBBM[K94K=V,N[Q71DB_0B>**?ZD23(:NMZ@9HHBID'BJ7D+)(P
MC0N*_EW?S2MV]R?#??/R"^,';?8?9WQG_F8[:[\[=[[D^3W64WQYR/1LW:U5
MDY9/AG\2\!N3;FTM@;3.#>GSFZ9JC"T^X34X^!H))VK9Z:F3<EO!MM_R7<W,
M,EK%%MUS:W1F/C3+-+$XCD:1.U+*)E;PT@C0%[J@BTIJ#O.MO-NVU\_;=82I
M,+FXBGLU2L<7A1E-49#=TE[+6FN9GI%"0TFHU>P?IS^6O\E-S?"/^>I\8]ZX
M6AZ-W_\`/7YI_*#L3X^[PW!F<1/B=Y];[RJ=NY;K7<>XLMM.?/Y/#;(W948B
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M6DEG:I@6,0F%9[90#)]7,0&DJN@1FA8L`6#GJ3X"_*K:47_":F*NZ/FPD/P%
MP_:R_+Q*;,;'A_T+Y3>/7]'CH7RZT&<;^\=3N'<,<IJ7PQR/EJ29)B=1D]F\
MLBGW$FWQ6_W5'E1K/Q/+ZGZ1(1%3XB0]4#%=-"QU`'N*XHBG($FRZ*;JW,R7
M?A^9MUO))O%)^$`1L&I75FE*XZV1#R3_`*Y]HQP'2L\3UU[WU[HJWR^_X\OH
M+_Q>_P"$O_OZ\9[]U[HU;_K;_@S?[V??NO=<??NO=>]^Z]U3Q\F/YH7>>U_D
MIV;\2?Y?W\O7?W\PWN#X\8#;>X/E#DZ3M7;?2'6'3L^],1_'=I[%HMW;AI,A
M_?#LFLQ7^43XV%8GT:HZ9:B6"I$*2VN)[J#<=TCM&_J_:SO`T]:M+/%_;)!$
M`6E6'*.5U,)1I*!6C:13<16UK)MMA+>+^^KN$3)"."0$Z5>=R0(C(2C1JQ4&
M-M5<8-AT1\[NINT_AKMWYM=RX7<WPCZYJQDJ+?&#^6ZT_5V4Z\S^&SDNV:ND
MJJW-K0+G<+F\Y3NN#JX($J,G%Q]M'*DJ*8[F++;OH9!N,;VEU&CPMP9O%)"(
MR9_4(&JBZE*,LBMX;!ND&W&\OS>PM8LMW;2.DH&4!C4,[JYI6-:Z230AU>,C
M6I'0CT_S*^'U9T=%\G:7Y3]"U/QMESE+M<]\0=C82;J^FW/6Y6/!4NV\EN6.
M5HL1G9LQ*M.*6K2"76RD@(RL:RQ202V$$Z%);I@(`<>,2&8",_"QHCDY[=#:
MJ4/5EECDCO98W#1VREIJ9,0&G+@9`.M*&G=J736O3]TO\H/C+\D<AOG$_'?Y
M$=+]YY3K"OAQO9-!U;V#@-V3[%JJB6OIZ=MR&@JC%18^HJ,35(E:&>B+4[_O
M<"]61TLOWFZE=NJP\4X0%5UL"QIIHG=W4JN16AI?4OU0L0P-X0"$!JQ!(6H`
MK7N(4@5(8@&AZ@=)?+7XI_)C<>\]G?''Y+='][[MZYTMOS;/5O86#W5FMJ4[
MY&7$+D,I14DX<X@96%J=JV'S4B2Z0T@#H6U$#/8C<X>[;B1^J/@&I2ZZB::0
MRJS*6H"%:GPFGIB+>Z-C.=-[W=A^(Z2`P`%=14D`A:D5&.L74WR]^)??FZ]_
M;$Z+^3O17<>]^JX:VJ[(VEUQV-@=SY_9M%C*R?'93)96@H:AGFQ>,R%,\-15
M4IJ*>&0`,X#*6;62-]NDWA'!VE%#--_H:J5+*S'\*LJLRL0`0#3-!U=T>._C
MVJ12-S=BJQ?C9E(5E`\V5F`91D$Y&#1-]7_.[X.=W[YVKU?TQ\Q?C;VKV5OK
M"UVX=E;"V/VIMW-;JW7AL7)DHLE5X/%1SI-624+8:L,E/Q5:*61Q$4&HJ5MY
MW%P5A8K#$)7-,)$55A(W]$*RLQ%=*L"U!6B>:X@MC$+B94+RF)0QIJD4E2@K
M^(LK!:TU$44D]![\6OYE7PS^:/;_`'OT?\<.W\-O[?7Q[RW\+W330U%+3+O"
MCHDI(=R[SZWH7G;*[CZXVGGJ^#$U.;:*&FGR$H$(:%HI96-M/[VV&+F2R!;;
M7F9,@A@HIX4S#@L5R"QMR3J=48D#AT]?_P"ZS>9=AO.W<5C5J<5)(8O$K><L
M&DB=*?ID@5->CV>]]>Z][]U[H%?DO_V33\CO_$"]N?\`O"9SW[KW2NZH_P"9
M1=._^(?ZJ_\`>`V[[]U[I>>_=>Z][]U[HAGR4^;E9\9_EW\#?CGN;J>GRO5O
MSFW5OSK"C[]_O?/CGZM[@VMC(LKM;9%=LXX6IH\]3[_BK:>.FG-?2RI*T@5'
M$1OO:].Y;[>[`Q,=T-KEO+<@%O'^GU&XB-,1^$H1BY)KXJ`+Q(KN;#;MCAWW
M4K6Z[C#:S@G28UN"JPR+QUEW+@K0`",U:K*"@L5_,XZGIODY\Z^INU/]'_1?
MQM^!K]0[,WU\ONS^S*?;^U=W=]=KXZGR_P#H>PV#K<9%0)4[:H'F662"MJJY
MJB)5>FC216]L;?/%>;+<[W-*D4#;K+8VJZ@QNC;AOJ7H,HT+JH*`,"CA]0TN
M%>O(9+;=+':8%,TYVP7ER0"!:K(P%NC$BC>,IU*U0*J44%J`QODA_-)Z0ZKZ
M/^/'R`^.^3ZX^8W7G?GS0Z<^&[9[JWLRFFP^TLOVG6Y2ER>X_O,5C<M45^XM
MHICD=,)4Q49K14QMYDC(<NJLW]8>3]BE@*1[Q+*J2G@HC6NM1\+C5J5P64KH
M;SH"U(\*[%SEO,<Z-+L]B+AHJT+DO&@1CQC!#A@]&&*>M!GV5\V>JJ;JSO#N
M7Y%=I_%+I3K?I;Y$[[Z%K-_[5^2>&[*Z^67:N0Q^-PE-OG<]1@]LC9G=.9J*
MT_Q'944-?4XK]MC/(KL4HL\`VGEC<II0LNY6XD"C,;,6<4M9?^),05"QF"H`
M0P(&FO6PLS[GOFWP1ZULBM2#^HJD9:XCI^@P8JH4LVHF@)/$$OC;_-0Z*^07
M8/\`,$HZ_/\`4>P/CO\`!'-]301_*I^Y,'F^KNUMH=K;3J-T4F])<R*>EV]M
MFGQ[1)2PT]+79&2KFF6-;3@Q>U(B\'ERWW[<F^FFDW:ZL1"_&MNRJDBGBQGU
M`J@7`(()&0G$XGYBFV"P'U"IMEM>>*OI.&+HPX*(-#:G+>1J!3(D[T_FC?R]
M]F_&CM#Y>4ORNZD[)Z)Z@K*;!;PW#U%N:@WYEWWOE*1JS;/7&(P%)-2UU1O?
M>$:G^&03_;TTRI)(TZ1PS,B'<[D;5;[?<7,+E;N?P8`HJ990"S(N:5C0-++7
MX(E:0B@RNLX&OYKR"W=/$MX/&EJ:"..NE7;'!WI$E/BE94XD==_'CY\=:_*?
MM_9.U>E-T_'?>/46_P#XOTOR)PNY,/\`(;"Y3Y"4&4.XX=MYW:^>^/\`287[
M>@Z]V=D3-097=O\`&O#2YJFDHGIP59U.KG;9;$\R"\D&BPEB"RQ]\$D4BEA.
M\AT^"K`%H`P/BQT>HK0((;N.ZM-AN[5'_P`=9T*2+X<D<B*6\)5[O$F4:/%0
M&L=6XZ.X:^G?F#\1_D3N7>^R_C_\H.B.[-X=:P5-9O[:W6?8^`W1G=K8^CJY
MZ"MRE=CZ.H\U5B:*MIGCFJZ3[BFB8#4X#(6*UD1MODW=6!VI%#-+^!5(+!F/
M%5*@D%@`:&F<=*G4QWT6UN*;E(Q58N+LP(!50,,P)`(!)%?0$A(;`_F!_`GM
MC>NQ^M>K/FK\8NQ>Q>S(Z^3KO8NS^VMMYC=.]#BZC*TE=38+$Q3K439"&IP5
M:BTLGBJ9C2OXHW&DLHA@GN#*((F<I")6TBM(R-6O'$!>YJ5*C+`#K5Q2T&J[
M/A+XQBJW;20$*4->!U,H!-`2P`)Z-S_O'^!X/^Q!^GMKKWV]3<;_`,7&@_ZC
M:7_K?'[]U[HGWP@_[)Z7_P`3U\O?_@L.YO?NO=&T]^Z]U[W[KW7O?NO=>]^Z
M]T2OY4?,)_C+W3\#.GUZY@WPOS>^0^5Z#DW%+N:;`R=7KB]JKN;^]E-C(\5D
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M?G\XOK&'I7>'R/Z$I?C_`-Z=2[=^".[OF9C-MQ_).BPWR+K]R[.W%1[?S?4N
M8Z5Q6T\U-C=I;7J:Y:7<&[(*^H7%9B&:B%)(8_(RW>9)=DFW>&=8I3;7%E&C
M1/J66.\N$MQ.33LB#,YB)_M2@4A2YT,;?X&Y6^SSQ/)$UR]VKK,HC:,VUFUX
M(TRWB7#*%$L6/"C<2AG%`7FN_G!=(]8]8=A=Z_)NLZ9ZHZHV3\<?C!WE1;<V
M!W=!VO\`)G(;N^2_76%WYB.HMS]"#;VWJG954T^4EIMO92?)209NBIS7S"D@
M$OB5<PM:<N[EOFUW%SXUS;;X=MA$0#&9E61V>3/Z$B1QM+)%W:84D>I*`,QL
M_C[UMNP[G#!X4-WM<M[)XO8(Q'.T*K$3_;QR,`JR]OZS+%ISJ!S.BOG1\._D
MKL7=G8?2WR3Z;WYM[K78^%[$[B?;N^L3EWZ6VMF\'5[@3(]F34C>#!4>/HL9
M6B>HNT0>@J!P8RH=W6`;-#?7EY<1_NN"5XVN`3X)*Y!#$`Z76CI4#4C`CJNW
M2-NC[?!9V\IO;J,/'"5I,1725T9[D?L=03I?M/1@MB;\V1VGLK:W976>[<#O
M[KK?.'I]Q;*WQM:M&2VUNS`5;2+2YK`Y$)&M=C:EHF$<H`5])MQS[;EBE@<1
MS1E'*JU#@Z74.C?8R,&7U!!ZW%-%.ADAD#H&9:C(U(Q1U^U6!5AY$$=*OVWT
MYU[W[KW7O?NO="/2_P#,L\E_VL8__=M0>_=>Z__3W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=$`^1O_997PV_\1M\P?\`WE.KO?NO="?[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJWR^
M_P"/+Z"_\7O^$O\`[^O&>_=>Z-6_ZV_X,W^]GW[KW7'W[KW78-B"/P;_`.V]
MV5BC*PX@UZ\14$=:^6X:?YR?RTOG1\Z>X^H_@IV1_,%^,'\P/>>S.]<-+T'N
MG$8OM;I7N?:&U1MW/['["PV6H<G4/LW."MJ)*'(10^%((HA"S3&:)$.U3W%C
MR_<\KM:,)[?<KN\M)ZUAE2]*O)',,M')"Z1K@@LJLX+*](E&X017F\0\Q170
M!FVVTL[F$CO0V89(I(JD!U=2[,*$5=58QF,&9K^4O7G\QGY(=6?RPOF'\I_A
MMMKL?L+XF?*7='>WR5_E]=(;AQF^=QY_K3/X:/!]9[NPNW=^YV;;6]>[^FZ5
M/NI=N)E9]<\I\<M.QJ4@61Q6^R<Y<O;R;F6XM$V>\M;AH4U""]N-*I/"NH%X
MB45F<:C`U!&[(IE*5Y;C=>6.8MJBA2WFEW.UGMUE<J9;.`LTD,S!:!GULH5E
M42)EHP[>%T0CY2_`WY==_?%S^;9W#UW\..TNJ]N_/?Y4_"G>_0WP2R.!V]1]
MRXW;_26[*&D[?[P[%ZOVUG<GM_K[/]G1AZNLH(ZIJ@PHTU0SQF&9[[+9P[<G
MMMMFYI#+%%S=<7\X4B2&UL[F"90CM0`^(63QT[A$VB/@2!O>+V3<?ZX7FV1R
M6MR.5H[".1JK)>74<T$BNJ#506RJZ0N!652[!0P.HZ_R*_E\][=B?/7^8Q0?
M'WJF/ICJWY#_`,E''?%[JCM?#X7&;`Z:K>^/XYB(X.NZS+X**"FH,E-M^@_A
MDTPIG>@QRGZ1QQJ46[VTVY;%[I6J/KGN>9MLO(4=LW5O;(C3K'J(5A)I>,AR
MJ,[$.0C,>J[8ZV&\^U-RR,L%GL5_;3,H-;6:?Q%A=Z9U1LR2"A+T`*58"B6Z
M=Z+[N^0'4>R>AMI_RIMQ?!SNOI7^6)VS\/-R?,WO*MP_4DVW>T=R]3576V&V
M'\<TZVSF7I^\]B;]WHDV6R&Y<M'3G#4M=45D3K4-']R8<UK'S`ON)O6TD6UM
MN=I!'#:FBRW`2Y2Y.WRQ$>';V<4:"%9R`7!$1B1!H%^67_J[>\@6.Y1_5G;=
MTEGEG4:HH04>/ZZ)\M-=3%JM`>P4+:I*LW0#?RQ/@I\FMJ]]_#7<G:_27SRZ
MV7X"_%KNS8'9&Z?E!N'X\;/Z,P^X]Q]=Y[9\O5/Q-Q'4/7\&\?D-U?O2O=LM
M+D-P9E_X3!2PS&HGG?74L[[>VLVP^Y6\H@2WON6OI(TGK]4[)&6,,D:!$CAL
M])>&>E9&HIB0TZIMUI<0[MR3LY56F@YB^I:2$@V\:&=2LT4IJS3W8/AS0C2H
M5G[V4&A/?Y<O2W<GR?\`@3_*2Z-Z4^#N]-B[CZL^??\`LX&[OYBHQFQ<7U%3
M=-]?=M]BC=U2.P\;G)=_57;>?DH8MO2;4JZ!?+#B**17DADA%.(X*V_-GMOO
MEP?HMOVG9@;B'M;ZI9XJBWB`&F5+O4))RW?$Y*LI0,W1=NABNMH]UMIC3ZR\
MW;=)(H":?XM+%)'_`(Q*33PFM`K+#1:/$Y>-_%TH]_7\MGJ/M#X[_-_^;'L?
ML+XU=D[/VM\@/EINKY0=(?(Z#9>VTZ(W=U?G,=BJ*FV%BNP<9DAE:;>\M9DA
M4+A&HA`%I:EGDCFC99`GRK;R6G(-IM%T1#N%EN=ZS1GM,D=S*#`8:"CI&L1+
M`42-)(]`)+!37?OU.<#ND/ZUE=[581!USX<UM"_U'B@FL9=WT*U"TC*VJBE&
M:ZKVIZUU[W[KW0*_)?\`[)I^1W_B!>W/_>$SGOW7NE=U1_S*+IW_`,0_U5_[
MP&W??NO=+SW[KW7O?NO=5G?S<OCGO[Y$_##*UW2.V7W;\F?C'VOU)\N_C#A*
M2F-3E\SVQTAO''9R?:6%6-XJ@U^^=FR9'')&CCRS/$"#8#VD>YO=JWGE;F3;
M8&EO-NW!&:,$KXMM-^C<1/IRT05EFD0@AEB(I4]*HX+?<MKYEY>O+GP;7<MO
MEB\3%8YE'B6\BZNT/XB^&&-*"4]P%>J?]R_%'YX]<_`GXZ=ACI'LC<7>7R+_
M`)C.\/Y@'\Q?;70W6O5797S/Z.D[,R>5GVG'\;=N]Z8G.[1Q>_NM]IPTF(JJ
MA:8UE`TQB0Q4TM0P5F"SV6^]OMCADFFY>VS:;N&6:`*)9K^[B,DAF=*%89G=
MH+N6-@93`C!M1C7I$)KW=[;GO=;B*&/>;Z]M5A@G+-&FW6<@B6.-:A7D5$$]
MJKT"K*VJI5F!5>L/@!\Q<%UYOW;-!\-?E+LNERW\_'X6_+O:^#[5K\9V)OT?
M&3#8/=4V>[0WKOC%9S(XW.9G:JR4S;M\$LW\&R.12E=F\;F.VRP26#>U$=Y/
M;JVW;_NTEPL=?#@BF@MDA.NGZD7:R)<FGU7@O,%#2*A:WJ4;G#[NW%I'._[R
MY3LXK<R@"6XN%N6>2/0,12D'Q#;F@@5O"!/AD]"KBO@K\MMBX/9W?.Z?A[VI
MW/M+XW_S[?E_\O-Z?$ZAPF!KM_=W?'[MBEVEC.N^^NK^O]Q9*CP_9%;LG(XN
M:IQ--+/`\QDD(:.#R3JFV&=MG@]E+JZBFTV7*%[MURD:AY;2ZN9)&A:1*C2H
MH/$<$E#X16F2'MR@:_?W4L[9XQ)>;UM]Y`SDK%<06RR+/"KT-3(L@!4@AD+5
MJ04,/*?&[Y\U6UOYR'9G2O\`+T[`Z,H/D[\ROAGVYL?I'=O5W3&Z.T,IT)M.
M3=&3[3WYT'L+/2[LZ>J_D?B<O/C<_)23+6'!UV0J8T>2M@9A6WBFVSE_V[L+
MF8@6?-=]<W?TM)+BWMI43Z<VK,HHH8FW\1`J&,$#1`6*ZF9-PYCYUW&"/ON>
M5+.VM?J-4<$MQ&S"5+D*:Y3]01L2=="U90H*3VO_`"]_E?OK8_\`/FH<!\3O
MF!MBE^:GQBZ`W%\9IOF'6;"SG=7<>]M@9"IR.[Z7>F1VWD3LK:'<FX,HE554
M6U::.C7!T]1'24R4\2Q*=;A"?ZA;CLZQQ+N$/-5E=I%$&<"T#LY,4C%I)6CB
M:MRVIF$CM`6D(?I?:W`FYLV&_DEE-M_5Z^LWEDTH#<,J1Q*T0HD"LR!8CA7C
MC6Y[`X`%ZK^''R_^5?<?:&7V%\9^[_B=0]G?\)[Y_A%MS<7=VS<5U/0X3Y*[
M>[2P"Y?K7,UF&RV4H<+3]EXK;U7X*U6'EPN3%5(D=VB!MS5#^];+W9-G.A&Z
M;_M.XV\18!I;6%EFEM2M0BR!`8GC)\%7&EGT-4H>7I#MEA[36MRC+/M4-];7
M$@J1'*]G/!'=J02[1B61)$D($K?A76I"C]\=^A^]>Z/DC_*JSFW?Y=/:/\O;
M$?RS>B^S]D_)S?\`V7@=@;)Q7<63W)TY3]94/1W0E5LC<.5J.^-D;GWCCJO,
MU&:KXH(((JYZ@Z9YA]PGWTIN6Y>XG-5B2NT;AR_=V4&WD:9;B68,;:*2+_08
MMN)5K=\"1@$\.,JFEFPBDL=NY1Y7F57W"UWRUNGO@08X(X)`9YEDR[2WZDB9
M%/:`=3RH7;HFW3?\N/Y-[._EL_R>=HI\/-Y;9^1O4/\`-SQ7?'R'HZ78>(QW
M:FR>J(.SM^U4O8^_\O3NF8BVPFUAB`\[U#J:2GI%TE88@H@VRYLK3G+VINED
M6/:K+8)X+AAB..5PM5D\M4AK)1A4BH(#=G3F\*EYL?O'#]/KNK_<HY+52`6=
M4`HT7'"]T8*8#,3\)9QN<Y.2.7)9"6%E>&2NJY(G3]#QO42,C)]/2RD$?X>P
MO""L,2L*$*/\'3\AU.[5XD]=8W_BXT'_`%&TO_6^/VYU3HGWP@_[)Z7_`,3U
M\O?_`(+#N;W[KW1M/?NO=>]^Z]U[W[KW7O?NO=4\_P`W?J'Y,;@J/@%\IOBU
MTM4_)3=_P1^6T7=^].@,'F:7![X[#Z\SVVDVKFVV#-6!HLCN'##U_;(DLP27
MSB*9(9(RDM))-LYPV7F`V[RV:[=N%E($IJ0WR0JLI'$J@C:M,:R@8JC%U=O(
M%W3EC=]D2X2*\:[M+J,O70WTAE<QU%*%BR\2"5U:*OI5J[<Q\8/G%\Z,-_/!
M^4&_/ASNKXP9WY@?#;KWXV?%_P"-O;6<V]DNW][[GZ>VY55T^XLA32)28C`M
MF<JL=+B)IA3":KFTP/>`SNCN]J^AY1WR%9Q/N>X<QV6X^'&"3##:.J,.))=X
M]3!/C-'&G0R:EEG>K=<T[%(Z^!M]ILE[8M+(:(\MY5T.!4)&V':A51H:I;4J
M%K[+^*WR[[SPK[BVE\%?DKUC%C/^$Z._?@Q/M;?76.(VEG,G\H]L=AX:DJ-H
MXG$X/,Y*#(U._:>@DR^&G8Q5.3QT@E>*.77$B_FE'OMZ]S-QLT,EMNNX[-=6
MX%-2Q1W\,LL3+^%X(U9Y434B*A(-"@8IV&-[#ECVPV6Z(^NVN?=$N&!JA\79
MW@AF#8JDTS+$K,-9E-'S5CQW]_+D^9_8'4?\U/:%)\9>P(-P=O\`\K?^5-UW
MT_#G\/BJ5=\]N_'+KGJ.;MKKG:=55ULM/4[^VA5[9R.,FI499A74[0HQUQLZ
MCFY%O)?="XLY%E-Q[AVNX0:02TUG&THDFB--7AA7#,5^)&T9JRA5RR%MX_:R
M.Z?PQ:\F[G9SUP(KJ>>9X(9*T"N]492<*"&J*5ZS?S+-B=P5N8^#N[?C?U3N
M_P".787\V7XU4'\HCY+]`]OX'$=>=M;07%;SV568[N&LZQVME\A#+_#MIXO/
M0G*"5Z9-NSTAD$7W0B]K+NQ@W[W#W[ES]Y`<L;_<6N^2&,IXEN=LG6>=7-.U
MWL2ML\/<E5GT$L$/1=M][+R]R+LN^RV1',7+\<NV(2&TW/[PM'AA6-P:E%O1
MXT<A"N9#%K*JC#K<&V;L3:75>RME=5;`QE-A=A=7;/VSUSLG$4<,=/28[:VR
ML-1[=PM/!!"J11`T6/5V"@`NQ/Y]^W'<)MVW"_W6X_M[F9Y"/(:R2%'R1:*/
MD!UO;[%-LL++;8W++!$J%CQ9@.]SQR[ZF-234Y).>E%[1]*^O>_=>Z][]U[H
M1Z7_`)EGDO\`M8Q_^[:@]^Z]U__4WK=]]E#8LD$?]P>R]X^=L6NO8FU#N*.+
M^)U-?3ZIV%=2>-<?]AY*H_[ICFB;G78>Z]T$\'R@$XIS_LO/RCA^X%!Q/U&\
M9@^^.Q1_E'^YT^(T?]^?W_KX_P"#Y/Z_:>OW7NN,?RC$D$4_^R[_`"E3RTU/
M4^&3J%UGC^XQV!R/@EC_`(\=%3!_'O!(E_34T=4G^Z;M[KW7=7\H121U4G^R
M\?*2I^VIJFIT4G43S25'VV*W%E?MZ5?X\OEJ:C^[OVT2<:ZNNI([CS77W7NN
M4_R@$$F1C_V7GY13?P^?)P:X.HWDCKOX8=[CS8YOXZ/N8,A_<F],W'E&7QOT
M^[]'NO=9O]F:'G,'^R_?)SBM-%YO]$[^`VKUH/NQ)_'.:(ZO,)+?Y@%[?CW[
MKW6&#Y/B>2@C_P!EZ^44/W\^/@US]1O''1_Q#^YW[U>QSI^V@HO[X?Y0W/B_
MA>0^OVWK]U[KC3?*$5*4K_[+Q\I(/NH:.714]1/$]/\`>4&VZ[Q52_QYO%-2
M_P!X_#,O.B>@K$Y\%V]U[KA)\I!'3S5'^R[?*=_#25-7X(^H':HE^VQ.X<K]
MM#%_'AKJZC^[_P!M$E_75UM)'<>:Z^Z]UEJ/D^*<U0_V7KY13_:G("]/U&\H
MJ/X?+OV*]*?XZOE%;_</53_3RIF<6>/O!X_=>ZD2?)@1SK!_H`^33ZI(X_-'
MU.[0#R5U10ZVD_C@M&GV_F8VX@='_M6'NO=8*;Y/"IFIHO\`9>_E#!]RV+7R
MU/4CQ0P?Q.IVE3:JE_XZWB7'_P![/)5&Q\,6-KVY^VL_NO=>I?D^*J"*?_9>
MOE#3^6/%R>&JZC>*>/\`BD&TI_'+'_'6T28[^]FBJ%_V7QM>.?MO7[KW4:;Y
M3B&`S_[+G\JI;1>7PP]/O).?]QF=R7C$?\?%Y?\`<%]O:_\`P)K*6/\`W==?
M=>ZES_)P0/4I_LOGR?F^VDKX]<'4KR)/]A+OF+73-_'1Y8ZW^X^JG/'D3,8P
M\?=^CW7NNS\FP)VA_P!E]^3QTU,E-Y1U*Y@;QY+(8W[A9/X[S3/_``_[A7MS
M33Q/;UV'NO=$H[E[TGW1\N/AO7TO1/R.HI%V5\J,8<?E.LDQ]>@S>#Z/QD>0
M>&;.Z5QV/GW`CU4FHF**EJ6`/BLWNO=#+#VYE9HZ24?'?Y1Q"M@HJA8Y^J:2
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MV.R$EC]M:3W7NN$7;65E\/\`SCU\GX_,M$P\O5=*GB^]I]EU*K./[SGQM2C?
M$<<XY\4N)RJ\_9WE]U[K`.X<H8)*C_9<_E0!''/(86ZFI!42"GH9J\I%%_>G
MURS+!X8UN-=0ZIQ>_OW7NL]3VUE:5*ES\>?E!4"E_B=TI.JZ2:2H_A<>[I7^
MT7^\Z^?^(C9SK1_3SOE,8/3]W^W[KW7<_;.5IZAJ8_'KY/S%9ZZ#STW5=)+2
MDT%7G*1I5F_O.MZ>L.!:2G>W[L-92/8>>R>Z]UD@[4RU1-#`/C]\FH3/-#")
M:CJZDBIXC/5[=I!)42_WF;Q00G<BR2-8Z8:&M>Q^WL_NO=1H.WLK/%3RCX[?
M*6$5,-#.(ZCJBDBF@%?3[+J5BJH_[TMX:BC7?$<=0MSXI<3E5N?L[R^Z]UU_
MI?RO@,_^RZ_*6PI35>'_`$44GW!`QBY3[<1?WI_X&%&^W$=_^!8,5_[7OW7N
MLU;VUE:'[P-\>?E!5_91UDC&@ZKI*D50HJ/=]:T=#_OYT^XEJUV:\4`]/DGR
MF,3C[N\?NO=%?^7/:&0DVKTM2R]'_(7'_P`*^</Q"KWJ<GUU24E'D4P'=U9%
M)!B)_P"\4GWM3EI,!IH00BSG)8^Y3[H:/=>Z-,G:F5FE51\?ODU%Y:ZEHP\W
M5](B(:VLP](M5,PW,VBAI3FEDGDY\<-+5/8^&S>Z]U%I^W<K4_86^._RD@_B
M#8]5^ZZHI(OLOXC3[,J4.2_W]#?:+1+O:..J/J\,N)RB\_9WE]U[KI.WLJ\*
M3?[+M\I5$E/'4"-^J*19T$F,@RG@DB_O0=-4B5`IV2YM5H\=_3J/NO=<Y>W<
MM3I._P#LO/RDD\$=9(RTW55+)).**#=]0T=,HW0OFEJALQT@''DERF,7C[O]
MOW7NNV[;RJ,X_P!EZ^4+&-ZE"R=5TI#FFJMSTA>,_P!YQJCJ&VL\D1_MPY"@
M?C[FT?NO=9H^ULO)/!%_LO\`\FT:HFIH!-)U?2K!%]UDL;BQ+43#<Q\4$#9,
M3RM8Z*2GGDL?'I;W7NL%+VYEJLTBCX\?*.G%6N*<?>=54D"TW\7_`+DZ%K#_
M`'H?P28W^_4?WHY\'\(RWZOLOW?=>Z]'V[EIZ7[O_9>/E'&HIJ2I^VGZJI4K
M=-904>0$`@_O0P^[I5K!#.E_VZF*6.YT7/NO=8J[MO)+25T=1\=/E)6TQI,C
M355+!U12SM6TC4>[(ZRCBB_O2GF7(4NV9844$>0Y.@6X^ZO&W-##<PS6]Q$K
MV\B,CJ<AE8%64_)@2#\CU>*62&6*:%RLR,&5AQ5E(*L/F"`1\QT@.IJ/KWX[
M=>83ICHSX<]Z]5]4[*J=P1[8V#L3J&*CVEAI,EN'>V2SM5AJ>?=]3+XL]G,'
M55^LN?-_%Z&2R_=Z8U4]Q/<F%KB5G:.)8U)S1$%%4?):FGVGIA(HXC,T<84R
M2%VI^)VH"Q^=`!C````%.A,':F7-2M)_LO\`\F>:Y*$3GK"E%&K/F*/#?=M-
M_>8VH%>M%4TNGBABEFMZ-)9Z<ZBT/;N4KXZ*1?CO\I*,5QH0J9'JFDI9:3[Z
M39,:FO3^]$GVPH_[]QM4?J\2XC+'G[+]WW7NND[>RKPPS_[+M\I5$]+'5")^
MJ*1:B(2TF,K/MZB+^])\57&,H(F2YM-3U"7_`&[M[KW0._(_M;*3_';Y#4)Z
M!^2]*9^A>Y?\MK>KZ6#'0_;=?[\E;SU(W,[(9UVZXB`1B[5M&/\`=_H]U[I4
M]7=MY2'J/JP#X_?)FL&/ZDV%$TF/ZPI*J&L.&V7D:.0X]_[RQ_<FO;9,CTP(
M4RIE,9>QJ_V_=>Z$'_2MEO,T/^R^_)LE:G[7R_Z+J3P,W\7I<-]PLO\`>?FC
MUU8JO);_`(`QR36].D^Z]UCI^VLK4&F`^//RAA^Z-"`:GJNDB$'W[;+535'^
M\[>`4?\`?B,U/U\0Q.5^OV?[ONO==#MS*V5_]EX^47,<4H'^BJD#J):+"5P0
MC^]'$T0SBQ.O]FHI*I/]TW;W7NN$O<&6ACJ9O]EV^4\GVT=9*R0=44KSSBCQ
M^<R#1TJ?WI'FFJEP+0P"X\E364D?'GU+[KW4BI[9R],*HGX_?)Z?[2;)TY%+
MU;2S&I.,_OL9):,?WG7STV1_N+)]HW'G_B^)X7[W]KW7NNF[:RZ5<=+_`++Y
M\GV9ZF:E6J3JVE-'&8*Z/'FH>H_O/=*25I/-&]O53!GMQ;W[KW7=+VSEZIZ5
M!\?/D_3FI-)I>LZMI8$IOO#M`#[MO[SOX/MO[Y)Y_KX_X7D_K]I^Y[KW6"/N
M'+2P1S_[+M\IT$D$%4(9>J*5:F/[B@P&0$,L7]Z3HJX5W`L,J7.BIHJR.Y\%
MW]U[KB_<65%-)4M\=?E2ZQTDU::=>IZ5JIQ!BLUEC310_P!ZO772I@VIHX[C
M565=+%<>;4ONO=9ZSMK+T;U<;_'OY/U?V?WMVHNK*6ICJ/L3O@-]DW]Z%^X^
M[_N%)]O]/*,QB/I][^U[KW7(]L9<5$L'^R^_)TLE3]F9QU=2_;R'[R6A^XCF
M_O/ZZ+5#Y?)8?Y.RO;FWOW7NO4_:V6J/MR/CY\G(/N*C&TX%3U=20F`Y-]JH
MD]3_`+^=O%2T'][$-6_/A7'9$V/VO[GNO=<\5W#DGJ\3.WQW^4E.D]1B9B*G
MJFCA>E6LAVM76K0VZ;4[42;H6.H!)$4^/KTN?MKO[KW13_ACV?E<;T']L>AO
MDADF3NWY95S38CK.FK*=?NODIWQG6H#(VY(6&4H?X8]!40Z;1Y26*#4=>L>Z
M]T:J?MG*P&J!^/7R?F^U.04FGZKI914?PYM\*QI#_>=?.M;_`'#D-,>/,,QB
M#Q][^U[KW7E[9RK.$_V7KY/B\QAU-U72J@(R%=CO*6_O.;0%J`SAOS330R?V
M](]U[KE3]KY:H>DC'Q\^3L)K&H$5ZGJRDBCICD:S:U$C5K?WG;[=*)MV)+4F
MS>*GQV0?G[6TGNO=1H.X,I/]O;XZ?*>'[FEQ]6/N.IZ2+P+DH=K3I350_O2W
MBK:$;L1*J/GPR8[(K=OM;R>Z]US/;V52GEJ?]EW^4I\-*]7X4ZHI352*E'7U
MOV\,7]Z1Y*QEQYB6.XO/-"E_7<>Z]URJ^W<M2?=,_P`>?E'5?:-6J?LNJZ6H
M:I^PDWM&S4=]T)YUJSL61J<^GRKE\2>/O?VO=>ZSMVOF5J6IO]E^^3C,M7)2
M>=>L*4TK/%D\GBONEG_O/S1.V*-0DEN:.HIY;?NZ5]U[KJ/M?+RSPT_^R_?)
MU#+4T].LTO5]*E-$U57[7H!432_WG/CIH'W4DTKV]%-CLA)8_;6D]U[H!_[A
M]$Y?O[$?+>M^!/<-1\G*':5#LO"]YYOHZEG[)V]M27';>H8<-05]5O&>DP;4
M>)W_`"4<D\$"5<4-'E8A*13GR[MF:S&X?2'P_J_[?3@R_`*.>-"(XP0*`A%!
MJ*UU<`78L5NAXBVW]D&X1Y9NT?)G=AJK0L2*&E!P?MW*I3"J_P!EW^4;AJ>I
MJ/MX^J:5ZP"EH9:\PM#_`'H%JFH6$PQ)?UU#*EQ>XUUOKU3V]E:5JI3\=OE)
M4?:0Y29FI.J:2=:@8G^^?DBHV_O0GW$^1_N1)]DOI\_\6Q7Z?O/VO=>ZD2]J
MY:&6>$_'WY-R^":JA,D/5U))#,:3)9C&-)3R?WF7RP5+85JB%K#R4E52R6'F
MTK[KW6)>VLJQ0?[+S\GUUO`EVZKI0%\]7MVD#.?[S^F.%MRK)(?[,-#7/S]O
M9_=>Z&C%;ZK*KHC<NZ3U7W+1U&,2DRPV'7[*@I^R<M#.N&S?V>$VR,R\5?DX
M*>J,$D/W*::N":*YT7/NO=?_U=_CW[KW18OF=\I-H_"?XM]U?*O?NWMQ[LVA
MTALV?>>=VWM$8P[ES-)#74./6AP_\9KL9B_O)9Z]+>>>)``;GVGN)V@^D6.!
MI)I[JWMT5:5+W,\=O'Q(%-<JDYX5I4XZ66-D]_-+"CJI2":4DUII@ADF88KD
MK&0/F16@SU7CN+^;UV#T[BL5V-\K_P"6;\S/B_\`'C^-[9Q.^OD+NW._&W?V
MRNJ*'=^5HL#A=W=@8#JGNS>.^\;LNGS64I8\CD(<9.N-BE\LJV4@F=M:B?<[
M3:9)TBO+B<01EJ^&T[G3'$TBAE3Q9*11NY$9E>-&=0^H%2W#7&VR[KM]K+=6
MZ6QN"L2ZI6A5?$=TB-'D*1UD9%!<1J[!3I(ZMWW7V1UWL0X)=\;]V7LUMT5J
MXS;*[KW3@]O'<62<PA<?@AEZZC.7K6-3':*G\DA\B\>H72JK-<1VBJ3=N2%0
M?&U"`:+Q-"R@T'$@<2.GU='MC>HX-G0'Q`:I1@64ZOAH5!(-<@$C`/4[=V]-
MG=?X2HW-OS=FV=D[;I9:>"JW!N[/8O;>$IIZN9:>DAJ,MF:JBH(9:J=PD:M(
M"[D`7)M[;:2-&C5Y`&=M*@D`L:%J#U.E2:#-`3P!Z=6-W#LB$JHJU!6@J!4^
M@J0*GS('GT7?H?Y<[%[ZWQ\L-E8?"9[:W^RC]NT74>]-Q[HGPE/M_<E37]5;
M&[=@W=MFLH\I5D;3.VM^4P\]8M,Q:)W"F+2[:M)5N=B._2?HVZ[EN%FZ2=KI
M)MTJQ3,_DJL6JM3J`!UA3CJLX\+>1LL7ZLS6%C=HZ=RNE^CO$J4RS`)0T%"2
M-!89Z&K'=O=3Y?:$W8.)[/Z[RFPJ>MCQM1O?';UVU6[0@R,M;2XV+'S;EILG
M+AHJV3(UT-.L33"0SS(@&IU!?,<@:U0QD/.0(Q0UD))4!!^(EE8`+6I!'$'J
MH8-XI4@B,$M_1"KJ);T`7N)/!<G'25[T^1W2GQMZ][)[/[D[`P.T-K=2];YO
MMO?*S5(KMP8SK_;[-#7;AI]K8X56XLG2R9`+1T_V]-*:FND2GCU3.J%%>7<=
ME;27,BLRB2*,!15FDG?PX(P/XYI.R,$C4U<T!(7V.W76X7,%M`H!DUD,QTH%
MB77*Y8X"Q1G7(?P+0GB*UO[<_F]'';EZJJ?D9\$/F7\2.B^]-Y[4Z^ZL^17=
MF!ZM?93;N[)K::DZIQ':NU-A]E[P['Z-??\`+5Q4L4NYL510X[*SQ4-<]/,_
MI-K>S>3<H=BNI([??Y2ZQ0NRGQ9HT9WMHY4+1/<Z58Q1*Q,VB3PRQ2A)+G<+
M>':Y]\M]5QLD6EI)HU)5(G8(+EE;2_TP)!:;3I571F`#CHX'QZ^:>SN\^YOD
M]\=LWLG>'3/=_P`6=W8^BW5L'L6;;_W.].J-V4<N0ZS^0?764P&6RN+W'U1V
M#34E5#%,)(Z[%9&AJ*+)4]+4HJ.B@DMY]B&^K<*L,,CPW:,0&LYT7Q/#G)-%
M62$B>"4T2>+4\9948@PO(S9[S'LQ(>2:VCN+=UJ5N(78QL8P0&+P2CPKA`#X
M,C1JS$R+T6R#^;YT#-\<MW_*N#K[N'*]/5_R$?XT?%>;;&`PNZ-Z_.?L:7.5
M.SL&_P`9]FXG/2U>9V[O7>^)R=#@Z[+S8J*NI,949%_!0JLQHHO6M^7PNW3#
M>-T5Y(+5AHE%N$:9+BXUZ1:Q-;(UVYN/#,5MH>0!I8T:^BW%YO<37B';]M"B
MXN$#O&LNM8I88@JE[B2*XDCM3X"R))<EHHW;PW8.G3'\S6;>?>FU/C%\A?B3
M\@?A-WCV[M;>>Y?CMA^_JGK#/[*[WEZ\Q3YK?6VMG[_Z1WWVAA*3>6S\/HR-
M=B*[[:N;%O\`<TZ3@%0]2.6WW+Z68/N-K;F=X=+AC!J6,2QG3IE`E94DCC+2
MQ:XW9-#A@PQ>!K*:Y@<;7-.L/C+I*I*P+)')W#PVE4-X#/ICE9'C#AP%9![?
M^:W\P_*;8ZQS64^`3X/*[L^3F:ZFWO@ZS,;_`#5]?=+T-0D>*[XRB0;(J#4;
M:S4&2H)(4I#65R+-+]Q14S4>12A>L(X9KKEB&^D,<=U8227++0BWN0:10Y(&
MEZC4S$!<]VD%@FO9)XH=^ELP)&MKU%@4J:W%J0Q>116JR(%(TL`7*]BEI(5D
MN)]I^E77O?NO=>]^Z]T2SMHG_9W_`(<BYM_HU^5IM^/^`737X]^Z]T=/W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW1'_G:?\`?F_'C_'YP?#8'_'_`(SSM`\_[$>_=>Z/![]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB$?.?Y+]N_&^;XU2]0[)P79-;V;
MWDVRMV[`K:3,S;MWALRAZWWWO/,87JZMQ]518'`]@@[92JAR.Y)Z/:U%CZ6K
MER=720J)T]U[HT72O=?6_P`A.N=O]J]4;ACW'L[<<+/2U34M7CLA1546D56+
MS.(R$-/D<3E:-F&N&:-249)$+Q21R/[KW0J^_=>Z][]U[KWOW7N@"^5O_9+G
MR3_\0%W%_P"^[W%[]U[I4=$_\R0Z;_\`$5=>?^\CB/?NO="K[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MHFWP*)/QV8DW)^0'S(N3R?\`LL3OCW[KW1R??NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__UM_C
MW[KW5/\`_/XECA_DX?S`GE\6ENBJR$&9M*I)4;GVW!#(IU*/-'-(K1@\&0*"
M#]"AO:?4<O`W!AKO>U#Q`0"E=SM!K!.*KQ%<5`KCH^Y=!-]>T%?]UNX8]:6%
MR:?9Z_+JJ+Y^?%+M#XX8_P"+?9GS/^='R\^9_P#*DW!V7UEM?YL=5=IY?JC:
M<.P*G/YO"MTOV_V3F.I^K=E5V^?C-@NR?X;2[PVY+-#.CRT=9]Q71K+3(>0R
MPV//]I:[HL0'U$AL)W.E(-UA<O;?4BJQ/',%<022K';V]RL;RAM4:@%;:EW?
M\A17>SF1)_H(FN(8*^))M\D(6Y%HPU31R0*WB.(B\TUL)55DTNY+=\Z\/D.V
M?YI'S_QG?6[/Y0L&RMM]+]"?Z`J'^;5M;L_<>+H?B_G.J%R>[-\?#K*;:[+Z
M_P!GX:.I[6GSJ[@S6$:?=%/E:>G5:F"%*92%[2V7]P<Y/N$WA;S^^+F*[,8E
M&XPQI#']%X=/U!'X+.\*VJU:Z,_CZIC$%%5T;?Z[DIME0MMS;1&T!K$;%YC<
MS?4%A3PC(`MLI-S53:B+P*1"<D3^H<+T#N#L?^4MLW^9WW7U_P#*?X;?\-O=
MI9+XV=N?)_:FZ=B?'/N?Y/4_:^/IESF]-E_)"DQ$M;O_``'Q-FQT.U9M\TAJ
M:^E:NR%%JJYDD]C#<GC?FWG%;RU$.[#9-F*),822-,W[SN(#^&[FN!92WL<7
MZ\,;JLJHHF`#T`4<K<KMMUQ(VW?OW=?&:(R!!7PQMMO)4YM8P;Z.TU:HY6B0
MQLPTEBHX5OBMB/C]\N]I=0[KG;^5Q)_PH2Z4V%\F,UM3<F<EZ[H?AS4]%[`@
MW1MC/;KI:ULA2?%J/OD87$-5PU(QC;;=4IYVH&1R1<O37$UK[?2<WT%G)OG,
M!A-Q7]2[6&NT?6^)VLSD1O*;_)F6U-S^HV5N\P1#>O<<;&JZQRWLC/X%2Z5N
M@NY&U$7>'6#Z@*ML*)'XJVZZ54='BR>-_E?[6^67\QK9G6D'25'_`"CA_*TQ
M6XOGQMGH&3;+?&3"?)&3M.>EZGJMD4.P9'V)@_DKF^H*:H:BBVX(,M45]-B)
ME5LF(']I;F.T/)_/+;F+ED_?6UBQK_;?6F&<21[<)OTS64;;JT@PB\*+,<R+
MT9V#%>9^1AL\B#?&MK_ZD$#Z;]W`P:'OC$"U0S7HI-WFQ:Y9:QA.@K^'F[-L
M=?\`Q`_F29G^9/T#WM\F_FU!T+T?3?(+I/?E3M:3NW<W\KG+;8VYA>F<IU13
M8*JQ^-3!]<;3R>=S78HQ$L>8'9.,RDF1E_B#8YO9YS"L4O+WTO,,]O%=R[^%
MYBN+35X5MO)9#%=@P*?\5@@^G?;VCU")!=2)I1)Z$^P!H>8K,\O+(^W)LCGE
M^*709+C:QXP-M)K(=[NXG$D5V)A5TDLD(.I5Z7F_>^Z3XB=>]*=K?`_^<I0_
MS&NO-U]B=+[%V+_+A^1F8Z=^4/97>6*[![1P%!@-F=5=C;1H<%\@^N]^==;:
MR-75TU7N>AS34LV)C7+/"*;2##;!<R\U[)L^]0B[-W=11RSK030+H<2;CXT7
MZ#)#&5N9W<1QR*KN)6DDC1RZ[>R3EC>-UV9VM5M;2>2.)M7A2$%0MB()%,X\
M60&WC1!(\:N%$81'D4\/\^3X_;7W17_![M/`[WWKTWV;W)\K.G?Y;W:6_NL<
MO1[<W1V1\.OF3NJ3!]T])9[(3TM0U905<F'AR.%GL]1@\F)JBC\<D\KD-[?8
MVEUS5MVVW:"3:]U@N(KR!O[.YCL+2[W*W5B"'7]:W,$AC93):W-S#)K5U`/[
MV[N8N5]YN[=W3<-I`O+.5"==M<2O%8R2@5TLO@S^(588E@@D1XRA)';^:YC/
MA?TG\2_C9TO\A.M.P>N?B+C^YNG.L=K=]]![CJNMJW^7QN/:&&K:+X_=[XS>
M&#UYOK7"[0W!C*3!0YV)6H\8<BB5HDIYVBE>N[R;=.:MMENMT-GO$_U<L5Y5
M(T6X\!@;8X\,?61231)&Z?3T!5]`",M+"T_=G+^ZC;]M%Y90)"LUH0TCRVQF
M1I;@U822FVD6.XDTLUS(PUJ)&#]$\ZA[^[#Z&^=OP[Z(ZM_F;;+_`)N75GR+
MW9O;#YWK+=6)Z0[#^1OQ=VSMCJK(Y?,_)2F[^^/]/B\##U]!F<52X>LH-Q8G
M'R57\:\5#-6U+3R0K]I>:_WC<MJO+)5ACVVZNC=HK1BW,;1B&VE45CD%[*S1
M)3PF214P4302O=*V>TV-_874CZK^T@^F9DD$ZR,^N=":2A[2(+,Q_54H'9C&
M65NMF_VCZ7]>]^Z]U[W[KW7O?NO=5/?S$.XMV]!]P_&;L[8&SCV!OJCVMW)L
M_:&SQ1YK)G,9_LK>WQVV#0:<3MRGJ,_F&H9=P?<?:TOB:81G7-3Q!YX_=>Z`
MFE_F`?..=*1ZC9_PR@@FI\#45F3H,]W_`+BQ,%%7YRNP.=SN#FP>T:NMWOMZ
M'<U-'M79DN,IWJNUMYR5%#MJGFH:"JRB^Z]UCG_F!?.VE@DEKMB?"K&-!15-
M3D&GWUW1D<;A)<5N./#;Y?(9O"[7KZ&OVYU#!/#0YW-8[[RARF_*E-F[?_BV
M7CJ9(?=>ZE3?/CYWQK7>3K_X=XN:D;=44D.Z=T=U;;I\55[:JZ)\E2[NR[X'
M(8K:M)UWM&L7.]CY&22?';`GJ*/;L\M?N2L3'I[KW7J[Y\_.^EDJ8J?KOX@U
M4Z3YVGHL?7;B[OVUEZBNH\'%G]KX'-T.>V[2Q[)W-GMM,^Z=S4N3EB3J[97V
M^2W1+2UE;38MO=>ZQT_S_P#G-531I0]??%#+I/5XR#&QX^I[^AR>X!F]JRY[
M9M#A\/E-NT-9!NWM:N@GJ-O8:O\`LZNCV+1S[USIP^$,*R^Z]USA^?GSDE_A
M[KL_X8Y*BK9-KE,CM;<'?^YER>-W#'4TM'G-GXR#:%%EMW0[]WE3OM[K:ABB
M@R79)I:W/T,-)MND;)R>Z]UBHOY@'SGJ(::6KV5\,Z&)J/$5>1KZ+<7?.Y\1
MCJ>HW%/MW<^4QU?MW:M9-O';^!SR1;:V[4XN":7LS?,LN&VQ#5Q4=3D5]U[K
MNK^?GSNHJ6>HK-C?";&-34F1J,B,COSNG[#`383/0XW>W\<S..VMD*#^`=.8
MZI@AW7FJ,UF/.]JR#9>%;,9WSB'W7NL4_P#,"^=L1KX_]'7Q"HJFB;>$34NY
M-R=T;:7'56V115KTF\LE5X2HQFR(=G[/JO[Q]CUU3)+C^LJ:6DP^1FJ]PUL6
M-7W7NIM1\]OG<DE1'1=>_$*NE2IRE+0X^MSW>FV,Y7U<>"7.[/PN0Q&X]M43
M[0W3O/`I/NG+T&4DA_T:[`BBSN[)<>]928Z3W7NL=)\_?G-63T\=%L+XF9B.
MJJL'%COX'4]_U>0W%!N#;U1E-K?W<PE;MS&Y&HSO:68II4VGB*I:2MJMHTE1
MO/*#$X!(VE]U[K)!\^/G+*M'*-I?"VMI:A=KRM7;=W'\@-R1UN.SSS4`S>T*
M*CV;!D]\T>[-Z)_=?KFEHXDR':.2@K,IB88=NT4N6;W7NFV'^83\Y6CC>NV/
M\-,>HHL=5Y&LI-T=Y[HP^+4[J?;.[ZVER>WML50W7M_9F3\.`QE=BHJC_2%O
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MX5JI\!3C!T%1EA[KW4;_`(<$^=4<0>NV+\+\?XZ**JR-3#O'NS<&&Q+4NZ!M
M[>LZYO`;9K*;<FW>MZF2'#OE,4E7!N[?U1_=7;29.K@J:N+W7NIU1\]_G=3Q
MUIJ=B_"_#3T46X35Q;IWEW5@*/"5.W,M#3[FAW5FUVUDL3@\7U'MF:/(]A95
M)*G'[7SM72[0IWRFYIC1Q^Z]U%K?Y@/SOI):R!>MOB(M33R;I@BH<SN3NK;%
M9!7X7$TV<P^$W7_&<%%1[$S`VG*^Y][C(3"FZIVV:;^\$PR];!BO?NO=2D^?
M/SJGF\-!U]\2\C)+5+3XRBDK^_,#G,Y+7[7BS^R,1!A,]MNDGP6[^T8VGS%)
MB<I)22[6Z\I&WAN>3$XZHI:>7W7N@`[G[B^2/R<RW4%)VO@OC?+LWKW?6+WK
M2T_4L_=6^).Q!N_8>Y=J[4:/8^=QNSH>S-K[YW7EYO[B;0R4M-'V;!B%W#D(
M*+9D-3/5^Z]TZ]:=C]C]%]@5/=75TE1N9MRMB\GVUU8F=DSE!\@L+5Y>HVO%
MO6EWA#`*'=/>,V;5\-M[?,-%+/W/N^"GVAM/&4VS<#'F*7W7NKZ.FNXMA=\]
M>8/LWKC+KE=NYE\C0SQ2&"/+;=W'@,E58+=>S=ST$$]3_!]W;.W'CZG&Y2B=
MV>DKJ:2,DZ;GW7NA1]^Z]U[W[KW0!?*W_LESY)_^("[B_P#?=[B]^Z]TJ.B?
M^9(=-_\`B*NO/_>1Q'OW7NA5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T37X%?\`9.K?^+`?,C_X,3OC
MW[KW1RO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U__7W^/?NO=!=W)UG3=O]?YGK^OGP28O/FE@
MR]#NK9&V>Q]K9K%)41O7X;<.RMW4M7@<Y05L`.E)EM%4+%+9A&8W27L%Q/%&
M+2[,%RDB.KZ5?2R,&4@-^)6`9&!!1PK@U7H1\K;ML^S;H;K?>7QN>V-#)&\'
MCRVQ.M"H*S1=RT.'6C+)&7C(&O4H,[H^.&^]Y;8S.R=V=Z3[RV9G<-7[?RVS
M]]=1=8[NVGG\,(C18?%;LVYDL4,5N/%SXR:6/.4\D<<>8E\4D0H5C,;D<^Q[
MI<J5N.87E6H:DD,3@LC!HF8$=S*PU,<%G"NIC*YD:W]Q/;2W2..+V.L(8P%4
MB#<+Z'2CK2X2&CL(E)"K:`AUM8O$BD%WKU*&_8OP'VCV[C-EX+M;)];=KX+K
M!U_T6XKM;XR=!]B4W7<./HZ!,&=IQ[DVA508"L^[Q\,64EQ\=&,ABZ>"DA2C
M>$5+*#MN^&_;=#S1,VYDD^.T4;3?%K!:6@=B9.^0U[\4",-93?UY]KVLUL7]
MC-N6S*J&BCOKY(236.0)#K9$18#IM$HWTTQ>5VN(V%NJH[.^'TW=^UI-@=W=
MBX/N3KNHR5'D:K8?:70_3&_]J334D<M?!5#;V[=L9G`KEL;N24OCZDTC?98@
MFA$;RD5P9?9MUDEBFFYBD>1)-:DPPEE8JP+*2ITO5F`8<(F:,@UU].K[@>VT
M5H]I;^R&WQQF$)I6_OPA",JHK()!JB\!1XD=07O`MTKH@^E//&_$;(XO!;BV
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MHD8N--PVE5GM`ELJ0,IN&$8_&O>W]]*;LP=U02=F4&W*[:5#V#5]+=6U.[X=
MJU.4@JXMFR;C.+CS\FQ)8J=*RLQ`JTIZK<4<>3!B"?:%I=JWI!+HYED!?3J_
M1BH^@N(P^!K5%DDH"<2.SJ5#%"HDY^]L)S$)_8^R,:5"TW&^#('`:9HF+$1S
M23*BK(%HMDHM'25PMRH5;+_EX]>]8=@Y?MWJM>G>N>W<S%N),AVMM#XF_';;
MG9&8DS%=#D1/N7>VW-F83<F<ESM8KR[G)J83N"41,AH/&PDW#MF]VMN]K9\S
MRQ6Y33I6*(*55@T895"A@&`,@H`Y"E?#IEI^>?:^YN8KN_\`8ZQEF$BN3^\;
M\,"R,EQX3,[M'VD+9%C)]*ID$OUFL%!9W'\;-Z[N7#P[J[QJ=W4NV=RX?=NU
M8=Y=2]7;I;;NX]IELGLW=&-;*862*CWCAMR3RR292GC@J),:RTM.*2936MI-
MJWJ*5)HN9YEE35I;PXM2AD9#1@`:N'=)2*>)"[146I8NS>X/MI=0/!=>QNVL
MD@'B*M]?*C,7&OL,C4C6-(VMD)8P7B_5,\RD6ZN^2Z+[1SV/K\)N/Y$9S/;?
MS-+7XK/8/*=8]9Y#&YC!9ZDE;<6+K*#)X>OQM3'4Y.3QT@G@FAI<.7H9(JF1
M_O%;?9-TF1HI^89'A:H93#"00<L*%2/B^`D$*G91CWB_^N+[<H-5O[)V"3J`
M58;AN`H\9T1$Z958J8*_4*&4SW5+E7AC!MF"7I3X&[2^.4V1EZ&K>J^CTW,V
M`_OO3])?%[H7J2+=\./FJ'R=/E'V3M;%U4R0PSM'@6GEJ'P:S3EVKC*IC5"Q
MW_PXX'YIF-L&#%!'&$)X.0N:$K18SDQBM2]11#)SG[6Z[F>V]C[%+QDE6.5K
M^]>1/.WUG4HD"N2]VI"K=L$\-;32VL_(%@!SP+<\G_8G\GV>=1(<YZ[]^Z]U
M[W[KW7O?NO=49_SEJ2BKZSXYX_)4.)RE!D:VOQ]7BL_M??6^<+E8Z[Y`_$^E
M3%Y'875]50]C[_CR,\J0QX##3P5>;G=*)Y8Z>>9U]U[H`\KDDQTU?6UE;+3R
MT]7N'*U^0R>YVP<T-5AXCUKO7,YG>^P*>:@P-7A,;/#M+=>[MIPO0;0H7@ZE
MZDAFS-1F<PONO=08(JF&H>><U.)DPLT[R,\FW>LZK`5G5>`6GJCYZ!<AM7I6
MOZ4V;D%@J:JG6LVQ\;MLUBX^@7,=GYAVB]U[IY`&&,5)2PS8F;&38?'4-%CL
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M,KE4]U[IH=JJ.I"(:K$RX:;2NEMN=9U>`J^JL`TB7^Y_B.U.DZWI/9>0++&Y
MK-K_`!MVQ5F64YCL_,+XO=>ZE0T:XE(*6CI)Z":CGPF,H*/%[:AVQ4TE7@:(
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MV#2TNS-UY3*;NV*E?@.N,IUKM_(Q[>W'N3`0U.&Z1PE5'UYUW%D]_P"3K\A#
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MW%CNRL[_`':R=9697;'\-WAVQ@>W-WXQ<37U^'6DW+\D=RT:[8VRF(ZSQ%75
MS>Z]UBR&8'^63U%>S,PS>6RN3RVYC4->6*FZSWMFLUO#KZE"U%35B.#:&[-W
M[/A"N!!U%U%3K`N6RS^Z]U/IJ:;%M-6UC5&)J\--DZFIJJRJPNP:W;M7UOB(
M-O9^JK=P;57(;7ZFRO4FU\M'B<SG,.E5@/C]M^LCVAM*/+=D9>IJH/=>ZY5%
M2^)DBHZ-)\158>;'T=-34=%C.OJK;U7UUBYMS8"EH=N;L?);6ZJRO4^V,I)E
M\+A,Q)58'X_X"KDWAO"3+=D9:FI8/=>ZA8[$%VI*>FH'E9A@<3B<;B]LQU[`
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MP8_;^`G[RJMKXW#8G)08S:^W9UVOUAV=\=MGPT-;G\C35,/7W4.QJ"FVAEY\
MWO#(R2T?NO=;)OOW7NO>_=>Z`+Y6_P#9+GR3_P#$!=Q?^^[W%[]U[I4=$_\`
M,D.F_P#Q%77G_O(XCW[KW0J^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)K\"O^R=6_\`%@/F1_\`!B=\
M>_=>Z.5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO_0W^/?NO=5*?STJG-4_P#*K^5T6WMW;BV#
ME\KC.JMNTF\]J9C)8#<&VQN?O/K';M1EL;E<15T-?3R4M+E'9U255ECU1O='
M924;G93;I?\`)^TV]PT4MYO^V6X8&E/&O88\Y';W=P."*UZ41WR[79<Q;JT"
MR"UV?<9M)%0?"L;B2E/7MP>(-",CJGOY\_(WO/L7^4#@OC%!V+O+:?R2ZWI>
M\=H_*WL#:.X<OB=XT6U_Y:>3Q:=EYY=U8ZKILO19#O+/)L=TJDF455)NN079
M792:<R[BE]N6Q\VPVZ0[=+'!N+PZU`%Q/N,.T&T:-"M$3<IKS0*=JV!9:A=0
M9V6S.U66^\NFY9]PA>2RMY'0%C!]!+NJ72ER0Y&V11K)4$F2X(-#DFE_F.?S
M<OD=\(<G5Q;`RG\N>#:G672VQNQLGUKWOWOW!GOE[WI!E=LTF9R#]<=&=#]?
M[TS75VWC5PRX6EW#O$?P:;)2)4U$]+1)))[?WN_AM.9.:?J(?$L;7=)(3#;D
M-*J"DADED(\"#4DE(XWS1`Y/Z\*%'RW;-=\L\I%9&CN;G;89#--_9EF!C"QK
M7QK@H4\25XZDARJ(6AD;H'=]_P`TZ7XN=I_/KY@U.'S.7A[AZ;_D]XSI#J7?
MN\-XU77W7^_?DWL#NK*BOW5%LG#;[R6)VSM+%QS97<TNU<#7Y;,PXCPTT$U0
M\#)7<X9]EN=ZY<A9)+@\XW=D+AU?PXTM]HL)Y)75`TOAA8W98EXRR`%D#O(I
MM$G[ZVCDSF@0,EK'RDUY+`A7Q9#-NK0QQJQTQ-+KD2/Q)"`D=6%0HC8_G\HO
M^:=N?^8!7=V]<]C8GJW*;[Z8I=F;B@[=^.VW?D3@OC_V1MK?4F=ITQ>`H?DS
MUCUCV5@=^;#R&"-/F:*>GK*2:*LI:JEJ6626&!8ELL^U2[C'%+&T%T('$FBD
MNN/Q8Y[<J:M$1XD,@8!XYH6)JDL1),]Q)#N<-C(R2)/;M,C('_2,<@BD@GU`
M`2]T<T;(2LD4M**\3U`CY+_+KLKX??*C^<=WYM+'S=FU?1/PO_EZ[MV+U)NK
M=.?H]CY#<>Z-_?(/;F0I:*GIYYZ3;5?N02T\<U93P(9)886G+)'P3P7-Q;<M
M;W):VGU%Y-SK8VB@M0A+FUVB`A6-0@7ZAY:84OE@:D]']_:0W&[\EI),885Y
M6WFX<@5!:UN))E+**:S^GHK\>@E5/`=%^^<'ST_F<X7XI_S-_C[VML#XU=&_
M);K?X5[8^4?6_8_0W:?;.;VQB.@>T-T;PZYWUMYMQ9+;^`W9B?DEUTNVJK^%
M9"B@3`Y"LFAF5J:-+O:_V]-RV]X;:[U?2<T[=MEVPU1I<1WQ1X'MN,J0R./!
MNQ-HE6!Y#$ID"UIRU>2#?MJ(M5_QS9+N^M@]&\":TTB1+FHT.ZI()H/"$D7B
M*BRL5+@`IO'^:SOC^5OCNN/@)UQM/XH;-W_\?>HMA]F?()^WNP?YA?=NSNP]
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MGN;1BH/Z5#`_C@L7B4JH4R5IJTW.WN;38':VF3<+QKU60CMB-A<6L,[!R!XB
M-XY$/:GB=DM52HZK@^*/R/\`DCNCX??R[*WY5M@NRNY^YL%_-DEV+WGM7N7O
M*GW/M#;&P.D^U,G%FMU86HR&$VUV!OG(9_'U^+IDRM-74&#PU/056.,&060H
M5<XZ(M@WGZ0&.<>W!NI'!(+$_N7PZ9.F6:.XAN;F==,J7:S1PM]/*^L2<JAG
MYHVE+T*\7]?TMHTI55"_O;Q`:TK%$\$L%O$VM'M6A>9?'C4H%78GR8^0.T_Y
M;':E3\?Z]MI?(;9'\GS^4/V!E_D9NCNCNN;=>>V]V3E]V8;<]-28:#+Y7;F`
MWQCUH9FCSE)30Y/.?Q2=<I52BGI-`EN([RXYEYBCVV&WCLX_</:[26-]16;Q
MK6T,9."8XGE>*WNH8RL;6C3R*IN2-0=C-I;I9K>R32W3<J[]<Q.**81!N5\&
M5:$"1XXDDEMI9`9$N$@C+?3Z@MQ&_P#^:#V]\5:'YM;,^6G675T'</QL^+O2
M?R)Z*Q/3F8WE6;2^21[9@?J8;/VY)NRD_O'1U6,^6]-#M(.T(G&.SF*JI(5D
MG*$NN1)?V6Y?U;M)Y=Z3?X-MCCE"`.=R"';)@%8%D?3>"YT'M-C<:,!25-AX
M=O<[(W,-Y#%LT^T3WLLT9<B+]WEFW"+5(`OB"!K66V5LR?4JKD:6;JX?K&J[
M"K>M]@5O;>-VSANU*S9>V*KLG#[+JJ^NV?B=^5&%HIMVXS:U;E?]R=;MZ@SS
MSQ4<U0!-+3HC.`Q(]J=RCL8=QOH=LN&EVY)76-V&EG0,0KE<:2PHU.(K0])-
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M>Z=X)>Y0AJ8OA_\`.$ULC39&$9#I[:^"S<V3K*>FV%B9:K<>RM\04FR=X938
MT<W\0S.`IEI.JNMPNS=@4ZYNOR&;]^Z]U&F;NJF838WX@?-%A0+'68L;8Z/V
M_L&M:;9DC[=V"FUJ!][Y';/6V1?'UD\?7]((ZO!]+;5^ZR2IE=^Y%JV/W7NI
M4*=LXZ,14OQ`^9D46,%/#1/@_CMM1Z):'8D=1F-KR[/VWNWL/(46/Q]#O/(-
M#UKMW//6X[$9W[OL;?<F:S[8^BA]U[IKK<?W++_D;?#[Y9QT=IL55"DZ(;<>
M$@Q:&+?66^WPV\.QCD-][3BWN%)Q>?G;(=M=DD[LWW4#;U#08@>Z]U.I(.WZ
MI&AROP[^9$;91)*7*Q[HZ:I>P<2HWQ6P[@[#IMV5D78>*W1O_`QICH*CL6LC
MEI,[W9N9J3`PR878&.:CG]U[KJID[NR'[TOP_P#F@]3D9#558SO5:1Y&6MWO
M&^!W+)N[<>S]\8^HEW'/M"DB?L'/X!*2HFVS]IUYL"+%89:^LE]U[KG32]S1
M(:F+X??.3[U1-D*,KU!M/:^5DR:4G]PMMO%E-M[U;'=?;NR6T'E1<MA(&H.G
MNMU.W=DTS[HR-;FE]U[J-6+W32C7B/B!\R&7&"*IP_\`=;H3;^P*J4[#J!BN
MOAM7$S[\RNVNOJV-*VHBZRQLPJ\%TY@Q6;CKES._\BE3%[KW2:S.ZMX=9TV#
MGWA\7?E]MO%5^\=G==[=J\;\?=OY'$Y#.OG4J.N\5M7:>\]_Y."HQU;VCEXZ
M+KS`[FDGH&WA-4]C=C5&3KUQV.C]U[I730=PR1?8S_#_`.6<<$L4F+K]?0\N
M[,3'25BKO?<L%729_L9<MV/LZ'>:(^4I<O-'ENZ>QF7.[OG@VECZ+$>_=>ZQ
M4\7<=;K3+?#OYG*^622'*C<O4D.]:0MOZ2&N["I=Z9.E[#Q.Y-]XJ.AQ\4_9
M.0I'HLWVYE?LMJ8N3";%HIXI_=>ZR54G=M>6J!\0OF@:O(SFNJ'S?4E-BLZU
M9O`S;6S$NX]U;#WM1_8;IK-B4T9WSG]N0TSXK9(INN>N8,;2-DLE+[KW4"@7
MNRC85D/P\^<0JZ<?Q'&OB^H]I[+R_P#$,122;'V=_"JO#[UJ<-UENG([;FDC
MQ-9BH9L1TEUVLF,VK356\LC4Y9/=>Z=9'[AQREL1\0OF+IQ`@;#-MOX[[<V9
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MXW[',]C.M%LG;3839=)4F;W7NN\OOC<&`RVW*7L/IOY"]/C?&0SW\&W=W[L7
M']8X:?<E1@J^A.(S_8O6NXLM)M[LK=76F"--DLAMK'+-@MI/1]9=84M/65=?
ME9/=>ZS9;.Y3$97;F"P.W]U;K[-W1NL[-ZQZPV5)B=D=C[M[%V9@?X='M?:T
M%'!D=H]/9GJ':61$.=RT?GV=\7-F5+4%`^2[%R<\\/NO=7(_#;X;4/QVH*OL
M#L&LVUO3Y';SVUB-L;LW9MC$5&'V#UKL'#U$F0VY\>_CWMS(25%=LCHO8]=4
MR2HDTCYC=&7>?.9R>JR=23#[KW1YO?NO=>]^Z]T`7RM_[)<^2?\`X@+N+_WW
M>XO?NO=*CHG_`)DATW_XBKKS_P!Y'$>_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-?@5_V3JW_
M`(L!\R/_`(,3OCW[KW1RO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]'?X]^Z]T6+YD?%K9_S
M3^.'8GQHW[N3=6TMI]D':)RNX=E28B'<V/\`[G;ZVSOVA_ALF=Q>:Q2_=9+:
M\,,WEII+T\CA=+Z66BH%W#8=QXR[?N-K>(/PM):3I.BOYZ&9`&H0:5H0<]5F
M7QK+=K%C2.[L;FU8CBJ74$EN[+Y:E60LM01J`J"*@E.[5_E)_'[M7?7SO[#K
M]Y=I8#<'SZZ9V[TKO^/!Y7;PQ'6V&Q>,I,;N?</5.)K]N5E)AMS=E'"XBHW!
M/6BOCKJG#TKZ%TL&+AM4"[3?;.KL+6?>+?<*X+1O;2I.L,9(.F![@33R)DM+
M<RL".P*9'<KAK^RW!@/&AVNXLCQI*MQ&T)EESW2Q0%((6%`D42(0PZ#GOO\`
MDS[`[P["[]W5B_EI\M>C=F_+/:VSMM_*/K+I+</56VJ#N)MD=<X[JO'U=1OS
M.]4[G[1V9CLWLK`8VBS.'PF9HL+EX*5TGI66IJ/(KNK5+JWW6Q=C^[+F_N;Q
M83E(I[JC2T(H\L?B*)!'<-*H8LO]DPC!=M8_="[$]GB]L;&WM%E.7:"V+F,9
MJL<E)''BPB-P=$BE9463I]K/Y-_0F6V9O_:^6[2[O&;WAU=\)=C[8[(VYG]M
M;.["Z>WU\",!GL/T=WIU/G-N;6HH]M=GI5Y^2LR!DAJ<54%33"C6CEGIY%^Z
M7$VY;G?[RK^#N<N^3;HKJ`PCGN+6*RFB"/J22WEMXWBDCE#EDGE&H'0R6M"+
M3:=FV(`MM%IM'[N*:F4RP+=?61,\B%76:&8(\<D;)1HT8@D&IN?BE\6-U_'&
M/?.2W_\`+'Y-_+/>F_:K"&MW/\@MV[9EQ6V<5MVFJZ;%X;8'6O6VT]@=8;,C
MG-=+-D:VDQ`RF6FT&KJ94@IXXK&:,6B6L5LBGQ&D=S5G=RJH`&8GPXU1%`BC
MTQZR\I4R2,Q8\.1K@SR3$@($10`JJM2QJ%H)'+,WZKZG":8P0B`=`Q\A?Y97
M4OR,S/S&S6Z.PNSL!4?-+J3X]]/;]BVW4[5CAVE@_CGN_=V\MK9390R>VLDT
M.8SM?O">+)&N-;"T,48ACB8,S)(4$-HUHI)C.^VNZ5/'QK4682/_`)I-]%'K
M'Q][Z6';1?-<O-<;?<,`&M]HO]O4>1BO_$\60^?B)XA\.A"X&I6S7+\F_P"6
M?U/\I-R?)'<V\.P>S-NU7R:^'6%^%V[:;:]1M:*DV_L+";XW7ON#=FV1E=MY
M.:/>D^1W;/!(]4]30_;Q1@4X?4[7MZV\.Y0IPNM[V[<V)XK-MM/"C7_A4E/U
M`:L?PLO3%BYL+G9+J++V.VWEDE>#1WBHKNW]--`*4HM2=2MTP=[_`,LC'=F]
MNU7>73'RU^57PX['WCUMM+J;NS+?''<O7U#1=X[1V#'5TVQ,CO/"=C=>=@8?
M&=A[)QN5KJ+%[EQ$./R]+15C0&5XXX5C]+2>_P!ZN)2WT.X71N)X%8H/&*+$
M[PRJ1/`TD*112>'(`1#`X"R1ZV8M(S9;9LEC"U;G;K1;>"5QKI$A+JDD1_1E
M596>4!XS0RRK71(5Z,%UU\-]C]:_(:E^1N-WQVAN3==)\4NO/B1]GOS=<F]G
MR>S>N=Z;AWOCMZ[EW;N&GK=][I[)S62W',N2R60R=1]X%$C)Y2[M<NK+S8A@
MC";Q=6TTH10BH;6&YA1(E6@5"MRY8$%JJM&&:M_2K78V\60M80W4:EF+E_JG
MMI'9V8DDJ;5-%**`S"E-.DHO6/\`)\ZGZSVSU!LN'O;OG=>U/C]NCY<Y+I?%
M;IK.O:F;8VROE]UMF>NMU]8ID\=L3&U^=VSL@[AKLMA*FO>?*#(5++55-33+
M'`B+<+7]Y;6^V74[LS\MOLKRXUO;F2R:.8XTB>*.Q@@0JHC,>HM&SD,#:SO/
MH=WAW:WMT5H]_3=EC[M`N`MX'C%6+>#*][+(RZM8<+I<#4#PJOY-G05?TQV9
MTC7=G]T2[>[-^$GQD^#];F8,KM&BW#@MH_%%MQU?6W8^$JJ;:24B]@U68W`*
MO(B>&;%5#TL<:T<<32(YE)=W)FWVY@F,-U?;_:;OK6E8KFSC@2)8]0(\*MNC
M,&#,26HP!%"Y(8/J=NGGA$D4&UWVWE#73)!N$]Q//JI0AQ]2Z1LI`50I96()
M(3]I_"'M_P"1GSM^!L7;/6VX-R=._P`N_$U'86=^:G9.].KQO+Y?;[J]J[4;
M9/7O^BKK(8R7'TNU^W<+2[QSU3F,)BL7'EMMTG\)AM5,ZL[9)&.:-YYK:U%F
M\5C)9P6ZDNES).L>F];)$8LHS>""KB9;F[)CC$*L3K<8I#R[M_+45P]Q%/>"
MYFE=C6WAC:8/9A2/UFO!],DS:=#6L)661YB%ZO2]UZ=Z][]U[KWOW7NB7=M1
MN?F[\.I`C&->MOE:&<`Z031],V!/T!Y'OW7NCH^_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)#\[`YV9\
M>BH8A?F]\-BY`-@G^GK9ZW:WT74P'/Y(]^Z]T=[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=51?S2\;ORKC^'U;UUUMV?VCNC&_)&L7#[=ZEV
M]0UFZ5S&9Z8[2P&*J9.P\W!4;<^/&!:IR9BRG9%2DE7M#%25-3BD;,-C[>Z]
MT.GPS^&E#\=,?4]@=A5NV]Z_(_>.V,/M7=>[=M8NJQ>P^M>O\+/)D-M_'KX^
M8'*2U62V7T9L>MJ'F43RR9G=68>?.YV>IR=23#[KW1Z??NO=>]^Z]U[W[KW0
M!_*Q2WQ=^22J"S-T'W"J@"Y)/7FX@``/J2??NO=*CHH$=(].`@@CJOKT$'@@
MC:.(N"/P1[]U[H5/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$W^!BLGQWD1U*LOR!^9*LK`AE(^8G?`(
M(/((]^Z]T<CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_2WL-\]2[#['>&3=^+R.0>G?&/$:+=
M&Z]OA6P]17U6/)7;N;Q*R>*?)3%@P(E#!9-2H@7W7N@E_P!E"^.V,ACGDVUN
M"EI\>M"ZSU/;G;:Q0)C#L@TCS2U&_2A6(]=8C49"1)]O)KU?=5?G\2!QZV`3
M@#/390_%CXNU1I\;CL=75<BTT5-3TM+W7VG55+4]#C,'C455C[#DJ)3%C]LT
M@9S=B8GD8EY9FDV`36@X?\5U6H%*GCT\5?PZ^/M<E3'4[4W*Z5E-4TE0$[8[
M>A+P5>*W#A9U5H-^1M$S8[=-<@9"KJTJ2*1)#`\>NM]<JCX>?'ZJDKY9MJ;E
M9\G49*IK2O:_;L8DFRYWJU>T:Q[[1:993V'EM*Q!%B\\?C"_:TG@]U[KR?$O
MX^3U,TT6W,]+4P9`U50(^V.UW,->U9'E2)H4WV4B)J-+^(J$T$+IT'3[\,BH
MX5I^8X_LZ]P-#Q_S]>@^'GQ^II*"6':FY5?&34%11ENU^W9!'+C/[H?9,ZR;
M[=:A8_[B8S4L@=9/#)K#?<U/F]U[KC3_``Z^/E*E-'!M/<JI20T<%.&[7[>E
M*14%#MW'4JLTN_':4I1[4H5+.69VB=V+//.TGNO=-L7Q,^,U>U;AZ?"Y:JG2
MEK**NH:;N7MB2L@IYL;GMOUB31P]@FJIG6BW161%_2\<DJ.")886CW0E2P':
M#2OE4U_S']AZ\<&AX]2U^)'QSRZ5DT.WLY71U$^5AJY:3MWMEX_N:NIWX<I!
MJI=_:()4J>Q\R"BZ3"9XU4+]I2"GUQ5'_"PJ#Y$>H]1\QU[S9?Q*:$>A]#Z'
MY=2/]E1^/-76U&G`9J:NH):9ZR*+MGM0R4<IJ9LQ3"JIH]]V@\DM6TJJZ@/&
MP%C&%`T2`I<GL%<^6,G/RJ*^E>O>>G\7^K_,?V=0\1\4?C94F*LPN%R]>*"7
M&!)J/N'M7(10S8B;:5=CTET;_GB9HI-EXQF5[^58G$@9:BH$UJ&@-,'K514B
MN>IM-\//C]1P14U/M3<J0PQXR*-6[7[=E8)AX-J4^/!DEWV\CF*'9.-#$DF4
MPN9-1J*DRZZWU'F^&7QWJ(#32[2W.T)B\)4=M]Q(WC_AN<Q%O)'OY9+_`&&X
MZQ+WU:I%>_DBA:/W7NI<_P`0.@*EZB2;:NY&>JDKY9RO:O;D89\G+O>:M*K'
MOI%B$DG8N7*A0HC%1&$TBEI!![KW79^(/0)F:H.U=R>5ZF2K9O\`2KVV%,\N
M2R&6=O&-]>,*:_*3MI`T!6"`>-$5?=>Z*#V+\6^D<+\R_AQAL=MK<$-"-C?)
MS*K')V7V?5R"MQ4'0<]%)]S6;QJ*PQQR8*F+1>3Q2A&$BL))0_NO=&XA^'7Q
M\IXJ*&+:>Y5CQ]/14M(#VQV^YCAQT.RJ>D5WDWXSSM'%U[B0S2%FD,$A<L:J
MK,_NO=<&^&WQZ>)X&VGN8Q24<E`RCMGN`$TLM%D<>Z!QOT.KFERTZZP1(&8.
M#K1&7W7NL\_P_P"@*E:]9MJ[D89./(15NGM7MR/R)E)=XS5HC,6^D-,9)-_9
M4J8M!C\\832*:E$/NO==S?$#H">2:67:NY&>HGJ*B4CM7MQ`TU5D<ME9V"IO
MI416KLW4L%4!55U10$CC5/=>Z[B^(/0,,T$\>U=R"6FJ*2JA)[5[;=5FH<CM
M7+4S,C[Z:.14KME8UBK`JZPNC`I45"R^Z]UPB^'OQ^A\'CVIN5?MUHDBOVMV
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ME:.GZYQ`9G+-(:>1G+-559G]U[KH_#?X]&`TQVGN;PFE-$5_TL]P!OMCBUPV
MCR#?OD#?PY0FN^O7^Y?R>OW[KW66N^'WQ_R/WOW>U-R2?Q"*MAJ]':W;M/KC
MR-%O+'U83[??<7@,E)O_`"JJ8])C:>-D*O34K0^Z]T3[YK_&3IC![6Z/K,;M
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M,K]NB[U=7NFNG(`WV`H>IWID6`%@HF15LM/3B+W7NLT?Q#Z"BGIZE-J[C$U+
M-35$+'M3MIE66DR>,S$#-&V^3'(%R&'IW*L"KJAC8&-Y%;W7NL%)\._C[0M2
M-3;4W*AHDQ,=,7[7[>FT)@_[BC&!Q/ON03&'_1OA]9?49OMY/)K^[J_/[KW7
MH?AU\?8*3[&+:FY5IOMJ.CT'MCMYW^WH*"BQE*GF??C3ZDHL?$I;5K=E+L2[
M.S>Z]USE^'_04T%=2MMG=:P9*"IIJZ.'MWN*F%33U:;I2>)S3[^B8(PWGD"`
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MJOS^Z]UU_LG?Q]TJG]U-RZ5CBB`_TK]O<1P4.#QT8O\`W\N2*3;E&I/U9HV<
MDO+,TGNO=<)OAO\`'JHBJ8)=I[F:.LBK8:A1VSW`A>/(8_/8NJ"O'OU7B,E%
MN:M4%"I1I%="KPPM'[KW6>J^(/0-8*M:C:NY'%;/E*FIT]J]MQ:YLS_?G^(L
MIAWU&85E_P!)&8T*FE8?N(O&$^TH_![KW73?#_H!ZQ*]MJ[E-5'53UB/_I6[
M<""HJ<A'E)G,`WT(&5JV)6"%2BJ-``0E3[KW7=+\0.@*)Z62FVKN1'HS1FG+
M=J]N3:/L#LTTNH3;ZD670=@8J^L-K\$FJ_W-5YO=>ZP1_#?X]1014R;3W,(8
M::GI(U/;/<#,(*7'[>Q<"F1M^M*[+1;6H5+DEV:-W8EYIVD]U[KBWPT^/+TT
ME&VTMS&GEHYZ!U';7<(8TM3B<Y@YD$J[^$R.V-W'6('#"17D60,)(H7C]U[J
M16?#_H#(/6256U=R.]?]]]T4[6[<@#_Q$[]-7H6#?42P>0]F9G3XPOC^XBT:
M?M*/[?W7NN7^R@]`F>2I_NKN3S2U?WSM_I4[;TFI-;+D=8C_`+]>)4^[G9M`
M`32=-M`"CW7NNZ?XA=!4GVX@VKN1?M:G&5<&KM3MJ73/AWVG)CW;R[Y?R+$^
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M'9&-#.^IY3"YD+&HJ3-[KW7-OAQ\>WIYJ1MI[F,$](]#*O\`I9[?#-32460Q
MSH)1OP2HQI,I.NM6#@L&!UHC+[KW7*L^'?Q]KQ5K5;4W*XKFKFJ=':_;T.ML
MD^^9*PH8-]QF'R/V1F"NC3X_N(@FD4E'X/=>ZSM\0^@VJ6K#M7<9J&JY*YG_
M`-*?;04U,N4RF9=_$-\B$(<CFJA]`7QA76,#QQQHGNO==1_$+H**>&ICVKN0
M305--5Q,>U.VV59Z/(;5RE.QC??+1NJ5NR\<Q5@4=871@4J*A9?=>ZCTOPX^
M/=%%30TVT]S)'2+2I`&[8[?E*K11;0AI@SS;\D>4I'L3%@ERQ<P2%KFIJ3-[
MKW7;_#KX^24HHGVGN4TRTU32!!VQV\K>"LH)L94)YEWX)BST4[*&U:D8AU(<
M!A[KW755\./CW6M5O4;3W,[5T.6IZDKVQV_"'BS9WN<DJ"'?D:PF;_2-E]#)
MI:'[B/QE/M:3P>Z]U)E^(?04\L\\FU=R&2IFJYYB.U.VD5I:[)YK,515$WRL
M<:OD-PU;A5`5%D6-0(XHE3W7NL2_#WX_H49=J;E!C>"1/^,K=NFSTU7MNNA)
M!WV0P6IVE0$@W#")U-UGG$ONO=+FAZ%ZNQO7.:ZGH\)EX]B[@Q]/B\KC'WMO
MNHR,]#2XW'XB"*'<]1N67=5#(M!BX4,E/6Q2LREV8R.[-[KW7__3W^/?NO=5
M"?S\RR_R<OY@92<TY_T"Y(%E=XVD4[AV^'I5:/U:JU"80.`==B0"3[+MQ2.5
M]CBEM6GB;>=K#1C!D4[C:@QC(RXJHR,GB.C[ETTOKPCC^[K_`#Z?XC<Y_+C^
M76NCV_TY\<-R;XZ&^*OPK_DR=Q_RS?YB_<6:VKOWXN?+/M.KZHZ9VSUA!U1N
M#`;D[5W_`(+>VP>[]]Y'L[.;:V5'4Q5FQX:*JK\O19)6JJ9(&U^Q-M4A?G&V
M6VNO"@V^Y2[O$J06V\2^'/$L"U2Z6X5C;/%J\*,2F:1U6($@N*2*#DZ&?<[;
MZXWEG]-"5<QB2]>WUPO]3_:6A5U^HBFTB21HO"0%G8"QO^8#_.PWAU'\RNZO
MBMUG\GOBI\3(OC%MG8*YS/?)CX^_)+OVO^0G;F_]GT'85)M'!4_0@IJ'J7J[
M;6W,G04V4SE5+D<O+D*]Q24#14I>4-6>X&ZM]UWF"`3QP7LL$-F"RO,+=5,S
MR3E2(M<K&WMU1)"?#EFE*AHE(AN-OGVY=DL+UFUW%A'<270"]GB22Q(L=N&H
MYTQ-/*7DC5=<,2:JRLH[[(_F:?+KYYP_##JCX6;0ZS^,O;W?_P`2=Q_,CO[>
MGR8V=O3L?%](;)VQV4.DL;L78G6^(S'665W[N'L#MBAR/VF1R==B:>EVS0FL
M-/)4U,,,9_N>V/!ON\VEO=Z=KL;+;KD,55VF?=(YI8;5BKTB>WBAD:Y<!P9%
M2-!1F(+[6X`V+;+VZMB^X7NX7UJFABL:)MS1B:[(92S).9K<6\1(<"8ER=!Z
M)OT!\L?EU\:*7^8=!+UOTQE?GS\H?YQW6/PWV/B8\UO4_&?#]K;N^*G4]?2=
MX9/[RHJ.PX>HUZQV35[JEP<<S985##&K,"1*I1RVUMN6P<O\O['(T277,/,M
MS*TFF62TAMV2XO0M%B6[:!D$,#$0"7QHI'1`KIU;=O%L>9N9MQW33<S67+>P
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MN63?;/=/=66[7D,^VA28);C9XY`)!+\6BZW$I<11A70VT<89U)EUK?8;_P"@
MWZUL-XLECW#;+>:+=#02QP;FT8,:P=Q$UO8JT=Q(SH%G:01J65'ZKQV)UY\*
M_C?OGXVR=L?R^OF#_)9^3VU.S^KZ:/YU[>\/=W1?86\$WKCML;MZJ[I^4NT-
MZ;KP^_MA?(>IFCH:NM["Q6)3*U.3CKV*20&1C[;9(;SF/;?W!2U@EDTKMKJ(
MTNH9(92=O527B:2+PZPM%)]4KQ1O`RM(00WNL,UKRYN`W^0W4B1ZWW"-M3V\
MR2(5OSP>-6,A:6-U,`1I(9%81C2?OY?YON#^3S\B=Y=\_%'J&?N/I'^9?O:C
MZYD^.^-RF-PV)Z\_FG=A?[A>E^X(6RF;P]'ANH_DL:9<=V(:0+4TF4Q--DT>
M22I-.0_MZ[E(C\BV<JH]RS/M4\@U16+!6EO[>6E'^D2$2[I`E9`KV]U;QK;1
M2A^A#N(MY7'.=QJ9[.$)N4:L5DNK6)52SEA[)%^K24I8N1H\2.X@E9+B2%B,
MGR(_EJ]Y]8_RV\1T?U+NA/D'\F.TOD;L[Y,?/O!5/:YZ#WG_`#+*NHKI]S_)
M7H[;W;%(N-J^M,'O7%4]-BL%3P+2TF/VE@X<9,8XIJF5U>X_NN&^Y8LK/;9+
MGDS;/%'TS4:28-#*OUUQ&[.+N;ZV1+^YAFD83O2+Q2(X5--L?<+F/F/<+^]6
MUYEW)$59U9Q%9DS1>':P2T+P0Q6B265O(B`H6,XC5GD(!GX/8OX,]6?S`.B<
M3U5\6_EM_)E[RW!@^R=K9?XV]C=:T&V/CE\_<#)L6FW#CL#3[SVQN_L7IK='
M8G2^2J9LWB9L77X_<\4<-72U"24\G@1=MTZR2[Q:6FX?4*]JY-G)J5T\&6-C
M?01-BJ(PCG>$O6)Z.?#A9NBZ^18[2PEN]O\`!G%S#HO$(95,GB*UG*ZT)6X*
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MLR+U$'7$L4E!A-]5\.">9"\<V;D%#`9:H&(>Z]UW7_S6?A9BI,G%E-Z=D8Q\
M++OB#-??_'[OFD3#R=7T%%D^SSDYINN5AHH>MZ7)TRYV5V$6,JJB*EF9:MU@
M/NO=9V_FG?#>.HDI)MU=GT]5#D*K%5--5_'GORDFHLGC=DKV9FJ#()5=<0G'
MU6VNN73.Y=9_'_!\9)'-6_;B1`WNO=8J7^:K\,JZ>@I*/=G:,]9E*O:./QU&
MOQU^0"5E9DM_[>J]X;)QD=+-UK'.N2W+LJ@FSD$#JLJ82,U\RQ4A$Q]U[KC0
M?S6/A?EHL9-B=W]G96/-P[+J,(<=\=_D!6/F8NRLM78+K8XN*#K5YJZ3L7*8
MRI3!QQJTF4AII:BG5Z9&F'NO=1S_`#8_A+]JM:N^>QY:*3'19F"KI_CYW[54
M]7AZK>G^C;&92ADINMI17T.?[$#8+%/!Y!E\HCP47W#1OI]U[K-5_P`USX4T
M$.2J:W>_8M+2X>GWG696JEZ![X-+0477.;H=K[]KZBICZY>'[#:>[LG3X:KG
M5FB_C4RT$;25=X1[KW66O_FJ_##%39&GRN\>R\7-AZG>='F$R/Q\[[HAB*GK
M;"T>XNRX\G)4=<1Q4*];8;(TTNX'D98\1)414]2T=2ZPGW7NLJ?S3?AP]2*,
M;I[12L_B$6)>DG^._?U+44^5DV6W9,V-K(JGK>%Z&MQG7*_Q[(1S>-L7B66H
MK/`CIJ]U[K%2?S5/AG7RXZ"BW7VE55&8GV528FGB^.GR"^YR%=V3B:S<77V/
MIJ=^M%F;([RVOCY\O0P%1*^&B:O=4H[3'W7NL-!_-<^%>5BQ\^*WIV7E(<O2
M;0KL0^.^/7?U:<O1]A[CJMH==3XJ.GZV>7(#L3<U#44F!6)6?,&GEEI%EIXV
ME'NO=%5^6W\QKXJ]C;-Z=.SMQ=F9Q-I?)[XU]L9Z:BZ"[QDIZ+K;KOY([;VS
MN[>RU#=?I#6[?Q^[*";#T\M*9Y,IEXVI,>E5,KJONO=&MK/YK7PKQZY.2OWM
MV-1Q86/?,V7GGZ`[X6GQM/UC6T6*['JZJH'7)A2BV/G,E3XW(SAC##E9EH0S
M5A\`]U[K-7?S4?AIC)ZZER>[>SL948JKW509:/(_'KONB_A-9L+;=+O#L&#*
M/4]<1QX\]>[7KZ>MSS3,B8=*B*.K:*:1(C[KW7H/YJ/PUJ:J"@BW7VA]_4Y'
M&8>*BE^._?U-5#+YC9LO8]#BIX*GK:&2DR*]=0MN"JAF$;X_#::NK$$+HS>Z
M]UBHOYJWPQR38M,=NWM&ODSC[$BPT-+\=?D#+496H[2I*[)]9TE#3CK3S35V
M_L+BZG)8N#2)JG$T[U^D4:^?W[KW6"D_FP?"?(4]'5X[>_9&2I<C0[=RF,GQ
M_P`>^_:U,ICMY;JJ-C;(K<8*;K:1\A#OK>%'-CL'X0[9B>"5J,311O(/=>ZY
MU/\`-=^%-)35%;4;V['2BI*#+Y6HK%^/O?<]*F*P6\8NNLGE(YZ?K>:.IQZ=
MBS+M^GFB+I79N]%2F>=61?=>Z[KOYKGPJQ?\3_B>]^Q<>N$&^VS,E7T!WQ##
MBH^K#0Q=G5%?.W77@IZ3KVMR=-1Y>8MX:/)5$=$S?>-X/?NO=2:G^:?\-J*H
MJJ2NW9V?05-!79_&9&&N^//?E&^,K]H[0INP-Z4N3-1UO&F-DV-L>N@RN=,Y
MC7"TM1%]Z8))$1O=>ZX4W\U/X:5E52T--NSM"2NK:[;^*I:(_'?O^&KERNZM
MIS[_`-OXIJ>?K:*6GR60Z_IGS[02A)*3"`5M2(:=ED;W7NN-#_-5^&>4&+.+
MW9VCDOXX-C?P5*'XZ?(&IER[]H/7CK.#'PQ]:--4U785/B:JJP\*KY:['TTM
M9&II$,_OW7NHL/\`-D^$E334]92[Z[&K*2LH,1EJ&IH_CYW[619#%[CWC-UY
MM6OQQINMI6R%-O+?E-+B,(80YS-;#(M$)TC=U]U[K-5?S7/A314]965>]^QH
M:/'T>YLC6U@^/_?4U+3XW9NZZ78.Y\D9Z?KB6.;'XKL&MBV_YHR\=3G'^PIS
M-5!HA[KW7*N_FL_"W%R9./)[T[(QSX23?46:^^^/_?%,F'?JZEH:OL]LE+)U
MR(:.'KA<G30YN5V$6.K:B.DE9:MQ`?=>Z"KY$?S)?BIN[HKO;8>!S7:M7N[<
M?5G;FR,5@I/CUWO0ULN['Z8RN\JS!5!R/7E'38VNP6S<E3Y;+?=201X>@GCD
MKFIM:@^Z]T]=/_S./B+ANM>I=GUVX^TX=RT>R>H-JS85_COWZN0CW-N?K:FW
M3M[;TE/_`*.#X\SD]HXRHS/VY.J##PM73>.D*S-[KW1+OE5\C>C_`)E]R=&2
M=5P[N[%ZUQG1/;])VFVYNF^P,1U[DMG_`"#R_6V%Z@P&Y*#<6"VGV#VI3=T9
MS8M:VV>O]E5%'F.Q:K&0?<U]'MRFR%4WNO=&8^'OS&R77^7V]T%W[NJNW!M7
M.5-/B^E.]]TY^CW#D?/49R3:%#U1W5OS&T]+M3<NZX]W0QX3$;_H4QVTM[;I
MJ*C;N"^_J\1)6Y#W7NKC??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T37X%?]DZM_XL!\R/\`X,3OCW[KW1RO?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U__U-_CW[KW1%?YEOQ]C^6'P@[_`/C//F=W;8I>[]IP["J=V;(V
M&W9V?VK'79C&UL>:BV)#F]O56X:5*G'I!,D-7$T,<YF8K'&[*7[A-]-^[+PQ
M3.+;<+.XI$NMS]-=17`4+_3,00M1M&K65(4CH6\E[<VZ[Q/8Q[G86DTEE=HK
MWDXMH*RV\D1!F8%%95D:1%<J)&01*VMU!+#\ZNGJ#YJ?'G;/5)V1\E^CNV^H
MMW]?]Q_'WY'[>ZBQ>[]V=`=W].5]/44O8&$V['NFF@W9!C4:7&5V,BJ/%N?%
M9.I3&O4!#/"777,]W)S#8<SV>RWMON=O=/+F#Q$:&4E;RTE59%:6WFB;0\88
MI,PCD"S+$5Z&FU>REC8<NMRY/[I<H7]F]I'`%^O:`O(J`V-S&[PUM9=:&82,
MR/9:3%>/;&8!R\]J_&CY5)W9V5\B_B#\@N__`(@=J_(K9G7.V_EOA<E\+]F_
M(CJ_L/?_`%;M.CVICNY.J=O9[M3"U75O8FVM@EHGD%=G,'N&GAH:-*:NR='(
MC5;?%5-WVNWV7<X>6;B^FN5@"UGMY)UC2<07*MI`>*-)'8Q,7N%#PMJ+1#W^
MM(6&R7LONER==;S;V*6XG-ZT:3QJ\KVYN;9XD;ONY'B1/%1[2%Y'N5BM62X:
M5V1\2NU1+\:NS?C%V[\T^JOF+\=>JL]\>ZCY*]]].X#Y.S_(CJ3>.1I-[9O:
MGR*VWGM\[$.YLC-G,7%NC!Y2ARN)IMMY+RXV51-+'CEW-S#*=YO]QVW8;RVM
M[NU@MIH#`'1X[0.UK(&+CP[M-;O)=`5F$L\,U'E"BR>SULNT6EGN7NSRG<2V
MUQ+=QS+?R*\;W#+'>*L?@MKMFD5+=;4EI!'%!=VFJUB:X8%,7_+6S4W3O?FU
MMT]M?-C>GR`[;^96S/YAG4_RJ/0FQMM;ZZ9^5&V=B[3VAL7-T^S)<_\`W&S.
MP,J-O9"D.VJV"AH,%M2M_@V3DHIO#6/6WW_]V6^RQ\O<O7UO+8;E?W4)>(R"
M6+<5\-[:\!:/QS-&TIN9?TE:9DD>*`1QQ]73V?2:]WRYY@]V.4)HKW;;.QN%
M2^92B[>QEDEMG2.5U-K*(#:A#+)-H_Q*2^"R2A9P_#;Y(9Z+Y+=J=G?)'Y,[
MX^:GR*Z/V]\6<#\IMH?$#!]3[7Z`^,,F[OXYG-J]&]'TO:E?D=O]@=BY^KR`
MK-PYC/561P^5:BRYIJ7%T47W&[O=[*YVFYV%-AW5=LO[ZWN-P8(#)<Q0!XH[
M:`R5%K$\4DD#KH8J9Y[EU!9)%;M/:>\M[^RWJ;W4Y-&YV%K/%9P_7$Q07$A2
M6:XG\)=%W+"J17$;JZQSI%'MT+23B6$^'\LCX]8W;?R,Z&VEU;\FNO?@]\GN
MC^M-A[^^,&U.J(X)]D]Y]&C;V"V?\O.J=^P;KJY-M=DT\&S\)19BA&$K9]U9
MG$4>XY6JZ6*IEF>W'FF\W**]\3:]RMYUW5-PL7MX1$VV2J29X[41D4M7E6%D
M@))C/U/A5M[F2F[3V;M[*]VR:/W.Y.N2-M>RO!/N&K]Y1RZVA%T[PK2Y-O/<
MO+=$K&%:*UG\*^BACZ:MP_#OYG]W;=PW1_S;^97R7^1OP_PV?VAN+=W4.V/@
MAUWU+W!W!C.J-U8S=N,V-W7WK@.UMVP;HV_C,GAL8VX9-KX#$UV]WB)Q%1I^
MZ0J;3FSZ;=-NWV[Y:O)-QM)$N(UCA\.!;N$JPG:$,P=8)!XT4"MX33:&B5UB
M"!!+[+R3V%WLNW^[?*:6=W');/)+N!>5K6Y!2-(YGAC>%[J,O&\\R)+9Q@C<
M/IWG5R?/YG;+K?E]B_CEB*K8GR'ZUE^._P`Q/CS\JF>FZDQN[5W=6="[BJ=W
M9#KHR1;SQ]/C*;,8.M6?^,1/50F531TJ560#4JH[+F)[3>MIWAMAW`M:"Z&C
MPQWFYL;FS8:@Q`\)+GQZBHD*>"I\1NTPO?9VUN=FWC;(/=CE!H[Z!$#F]D!1
M%N89(Y-#0HVJ2>`V_AMI>!6%Y.BV=)7;?G-U5B_F[L7KO%TVS_EYT1W3TAVC
MB^YOCA\@.MM@[:?=_4O;N%QN5HMO9)\1NK*S;7W7LW>6RLQ6PY_#991BYJ.8
MX^O>ER1@B5/'O]Y:[G9;UMFT7T6[P13PHS0*Z-%=1Z)8)49Q6*>,*ST9&0HJ
M,ZL3&RI_:';9-MO]KW3W0Y0FVF8PR2(-PD#*]O(&$\31V[,L]K<_I1%%9YE=
M[BV66U#7"ESZR^.'R<WQWST5W-\^>^^\_EK2?'#>,G8?QWZWZX^%&VOBSUEA
M.TMU[=SVP<'VUVO2KVMV3NG>6X,=MK<F0CQ5,:G%46U&EJ*C*0HU1!<PLN8X
M+*_EW6WY=W#][O:S6L<I0A(;>[T+,%2H.NX1!&[2M((8@:I%(PD))?\`LW+<
MV`L+SW2Y0_=T$J7,L8O0\TMQ8UDHLJ1,K);N0\:PZ/KY646K721/&E_8N0+B
MQL+B]['\B_YM[..HM/$T..N_?NM=>]^Z]U[W[KW5`'\ZHTW^G?\`E2Q5:8V>
M.K^5^[:&*ARV,WMN&DRU;6]4;@@QV%CV;U])3[B[#R>6KVC@HMMSS4V!SU8T
M='G)X<++7N/=>Z!NNS%7E9:NLK\E+-3U?\?RF3R6:S6:ST-;%N/*1[-W9GMQ
M[RZ[BAR>[3O#-TT.V=Q[EVK!%7=CY2&#J[JV"CVW29/)M[KW2@3,5E`E353Y
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MN3@SE/F,?6QR219W-=EX_<.*[`W#04DVNHACQ6\^Y=N=N[UI!23U-$*/<WR6
MW31C$888?JW#U,\_NO=<\MG:ZL>OGK,C5S)+)N?)Y')YG-U>0,HRU;3;'WEF
M\]O7K**.?,568K88-J;IW/M2!)MP5,5/U1U/!#C(,IE&]U[J1'DJO%R3U<V8
MJL95XR;.Y"JJZG=F+Z_R&"J]K;=?;.[\ED]P8&&NP'6>8ZZV]4PX/<FX,`M5
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M8:JQE7D):J2MW!C^KJ_`5.R\*V`W+43Y?%1Y3:7462ZJVM5)B\YE<;'6;=^/
M&WJM-J[73+]EY>HJ(?=>Z=#ELECQ34\#Y3&U6+DP-)2TT&-PNR9\!5;$VU+G
MMO8_'8//U-?M[JO+]7[7R4F9P&#S;U6`Z&P%5)O7>\F4[$RM)1P^Z]U`QSU0
MDH8*=Y5EU;9H<7B\?BZY)&EEFDWOLC$X'979=2K5M;6!YMU[3VKNV=6R&F?M
MGMF>.ACQ6*;W7NN51EIJJDCIJ9VS5)EJ.AIJ2FAARO:F)S^,W_NNKSN*IZ:B
MKYL5O3N';G;F[L<V1H:2N-'N;Y([GHSG]P-B.K\/34T_NO=-*5TV06JK,CE%
MR$&4I<O7UE1F<]N+=E)G:'=^3&WL[E\QN#9\='GNS,3V-NJ@CP66SFW8Z;.=
MY;@IH]A;`BQNQ<;7Y!_=>Z4U;N"NIUK:NLR>2#++NK)Y+(9/<^-B>.HI<?C=
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M<$\&"QN.IL1A<YN:GR5/N+(56\]JX?;^V]Y55)F=^TV^<Q!/N3`[?W++3YCM
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MNLOUON':_P`;^_<UFLAMW.;ACZZZ%[@WCB:;;VXZG>"XN/-TWQ[[?PT&4RC8
M#M'%X1VGQ<7FR4V+P9Q>)W5DUWI/-35?NO=7">_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)K\"O\`LG5O_%@/F1_\&)WQ[]U[
MHY7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z__5W^/?NO=%T^6GR=Z[^&WQX[.^2/:46=KMI=:8
M6FJ_[O[4QQS&[]Y[ESF6Q^V-D;`V;B?)"N2W?OW>>:H,/C(7DBA:MK8_+)'$
M'D5//+.)+&TLK8S[I=W,5O;P@@&6>9PD:5.%6IU2.01'&KR$:4/2RRMH[F25
MKF[2WL889)IIGKHA@A1I)97IFB(I-!EC11DCHB>POFG_`#"MJ]H]*4'R]_EY
M87K#I;Y#[UQW7>W=X="=[5?R/W_T!O3=%'49#9.-^3NS,/UAMG#87;&5>!L9
MDMS[;RN;P&$RR**F?[2H@JB8010M>-M=Q<`7K12O'*F;5F@C::2$R/X<@=XU
M8P,8M,KH4[&D0=%LLK&T?<[:)OHD>)6C<:;DK-*D"3+&*KI5W1IHR_BQ1R:Z
M,(9BHN;^_F7?&&?);MZ[Z)^1_P`5-Z]W=?[JZ]Q._=D=@=RU6R\+L[%[I[NV
MYTIF:;<6XMM[1WU-B-]G<N:.+PF%J*6.3*;@EI*.62EBJ?ND9VI3N]QL<ED/
M%VJYO[>W=X^Z3_&899H4MX\":XD2,O'"7C#1K(Q<:*&V[2+L\6]0WK"'=;:T
MGE5).Q`8'C60SODPPIX@URA'HS(`K!J@&^O/YNG37>NX_DULOIW=/1>-W3\5
MOFEU?\4]\P=Q=OY#9N,SV&WWNC;&SVWKMFLP>PMSR'<^Y-Y5^:VUM3`3HHS&
MX\#+!/64<,R3*QM,T>[VG)FY6[`V6[7DT(`(,I55O'@^G2M)I;F"U6\CC+1C
MZ21GUF2,QE5N\)VBXYGL)C_CNW6"7!-&$2MJMDG6X8@&&.VEN!;S2J):3Z%T
M:7U='4IOG+\/:SY,5'PUI?DET_4?*6DQ\F2J.BX=ZXB3L*&.'%+GYJ)\*LY<
M9N';[C(OCM7\07'_`.5&$0`R>WK%6W);][!&E2UKXI4$A`I56->!",ZHY6H5
MZHQ#*P#%Z1MQL1?'PC<T\+5C7J#%:>FH(Q6M-0H5K5:H&I_F;_R^:3Y&1?$B
MH^8/0L?R/FW+'LM.IO[_`.';<@WI-&7BV9*Z3-BX-WR2@0+BWJ%KS5LM-XON
M&6,UVTC>`YVL_4!0QJG<"$%7*$8<(`=135ITO6A1Z>OR-J19-Q(A0A3W8H'(
M"%O--501JI565OA924STU\_]J[IZ-^:?R#[IPV.ZCZY^&?R&^5W4V[,Q2Y>N
MW2*_8?QARU12UF_YJ9,-CJR#+;@QE*\W\)IXZIHYM,,4LS,+I+F_@LN5>7>9
MKH,!?67C&-15@YNY[5(4K36TC1(%KIJ\@4T`U$SBVR:YYANM@M64NAMP'8Z5
MI-8VUX[OQTI$)V#-GLC+FE:`J6"_F,?S`:'!=9?)#M#^6?5;:^&7:N>V#2JF
MR.ZYNS/FAU'L+M'*8W#[-[=[8^..!ZUCP,^!I9<I1UNXL'M[<N7S^V\;D/+/
M#*^/KXXS^#:KBVWR#EK?YHK;=Y)FMRT;>+;0W5=*P33D1Z4+@PM<A3`)*'48
MV5R'SN%O=[3=[]M#&3;(8&N`)`5FN;=1J+VT<?BZG9#XL44C(\B*1VRLL?1T
MNU_YG/\`+XZ+[NQOQO[>^870O7W>63K-OXZ/K;<>_L12;@Q^1W5/%!M['[A4
M2R4>UJ_+&HBDBAR<U)(8)XIBHBEC=BK;W3=;B2UVYUFN%D,9"D']0<8QY&2O
M;X8JY8A`NH@$QO(I-OMX[J^0Q0,FL%^WL_WYG(CX_J'LH&.JBM1?YGYR?$';
MWR$Q'Q/S/R(ZNH?DGG)ZRGQO2<FY:5^PY#C]DQ]CU=14;>A$E7CZ"+8LHRGW
M-0(J=J0,ZN=#`>MV2ZBO)X'#06\<KRM4!8T@.F5I&-%0(<'414@TK0]:D5H5
MMGD%!,T0C\S(9G,<6@#+ZY%*`J"`U`:$BL#X\?/KX6?+3>6_NO?C1\GNF>[]
MZ]8,YWQMKKK>^(W'E,-2QY*;$/EHH:.=AF-OKDX?!_$:$U-!Y'C'F_=BUW@5
M[JR7<8$9K(E1KH:`L-2:O-=8!*Z@-6EM-=+4:N)([2]&VW+K'?D$B-B`QTT#
MT'F4)`D`J4)`<`D5-U[UU?KWOW7NO>_=>Z][]U[K7Y_G:97&X;NO^5G4YC.X
MG;N+K/D_OW!5M?G]\YSK_!54.X.F]T8@[?R^1VI3U.\MXT.YS5_P]MEX7PY7
M?QJ!MZ&>F&2>>/W7N@$3=.WL5.:JHW?MO$UF.K*[(5]7D.R\5UKE,)6[-P=;
ML[?&4S6YMJ#(;<Z\RG7&V:NGP&[-R;<CJ</TU@:J#K7K6*NWED<GE(O=>ZRI
MG8(&@096'&2X>7'PPHU7L+K^MP.3ZKVD,C1TT$`KJ_;?2V:Z:Z\R1KZ&FJ/O
M=K_'#9U:<G7G,=FYD+%[KW4F@R^W*$TM#C\YMB">F;;>*Q6.PTM!LS(1U&-J
M8]_]?X;;FPNQ<A6XC`UV.QCU.[-F[2W5-+0[1H34]L]J35.:EQ.)7W7NHKYG
M&9N&"DHLGA\Y0Y.'$8K'T^/&/[,Q>;H]_;AR&\]F8G!;?W1E,?NGM#"=J;NH
M:G.;;Q&>EI\YW7N2DJ-_=@2X_96-Q^.?W7NH#;BVG50U,L^Z=CY2#,8[+U-1
M-7;KS.[*7/XOLB<8G)5-76XN>@W%W+M_MK?M"F+KJZB%%NCY-;NI(\%AQANL
M,1433>Z]TXU^[,?6_P`0K:S=%#4T]]U9O,Y7-[\VYN6G6&M&(ZS[%S^XM\=>
MM1UV<\U6M)L_>^YMIT\-1DIS2]2]400XZ/*Y5O=>ZEPY_!86K\U?N?;>#K<5
M7U=76SY?>6'ZER6W:[8&-_NQNRMRFZMJ29/;76&5ZKV?4Q8G<.?PT57A.A-M
M5<6Q]CQ9/?\`DZZOB]U[K&-PTL'VE+C\Q#0S8IL/#3TN/R>P-EU."R76>UZK
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M,UD:_LS;N4C@$.)Q76O8N<W%O#8HA>`XV`T^T=\;IVA'_N,A>FZCZG@#'*Y=
MO=>Z;WRV'P]<\N5W%A-NUV&KI9*XYK.X#J>OV]D>ML?38//O7;EVI/EMJ]19
MGIS8^26CS&9QL53@?CAM2J3;6V(\OV5EZBIB]U[J50;BHJ7^'T.&S-#356)3
M;\-!C]NYG9FV:O!U/7^.S.\]KX[$;0WO55VW^J\QUELS(S;CVWMS.RU6$Z)V
MS4S[]WM+E>PLI1T</NO=8:.MP12EIH<GMU?/2[?QN%Q]!BH*J&IARQJ>Q^N\
M-MO:^]\JT^6CW-4K-NK9>T]VR"3-U"U';7:M0F/CQ6*/NO=3)-R[?R,0IL;N
M':NX*/.1R4U)3XC=O^EG$;BQG9.[*6OQ4$&+W148S=W;FWNY=^8<SX^FR34>
MX_DMNZC.8SK8CK/#T]+/[KW314YW`5WFR.9W+MJHI<K_`!K*5^2W%FZG>%!E
MZ/>N8.R-Y9W/;MZ_J:3<F_L;OK=V.CVWN7-[<A@S7=^XJ>'KW846,V/C<A7R
M>Z]U+?>6%HTJZJ7>&#IWIFS&3R]94]K8+'ST-3AMKQ=>]BYO<FY-G*])MVKV
MIC*R#:N]MV;3B>@V/CI8.INJ()LM/ELP/=>ZS'+4./J&FR&8Q^!JL)6,LS9"
MJV?UGD-O97J[;]/2UL-17X&MR6SNE,STQL/+HL]91K5[<^-NT*Q:"@3,=F9I
MI8O=>ZETNX<-CGHZ7#9["TM7CY=MT&-H-K9G;FU,C05VTVR.^=CX?`[$['JZ
MO![%S&S=M5$NZ-I;7W%-48CJ7!33=E]BRY'>F0Q^.B]U[IC%?B:Q*6GAKL%4
MP5-%@,9B:7'X:BW?3Y"DW//6=B]?8;;NU]WY:GK-Y4&_,M1U&Z-H[:W7+%D=
M]Y.&H[4[0GI\!18W%M[KW7--S[5KJ:2.FW1LK-4N;H\DBBAWQDNQL?N+$]EY
MG&!`:3-2XW=G=&W.Y=_8QHU$K4.Y_E!O*B+3-ANK,*D<_NO=2ZO<&-R<E7D,
MSN+$U%/D&W+FLEE=R;BHMXPUU+N;+P=>;]W%N#=76U11YK>4&Y=QTL.U-WY[
M;D,.2[)S,,'5_6D-#M>CR&2?W7NIC;MV_C?/4U.[MN8VIH)\K7Y*JK.S\/L;
M(8JLVMM^IV3OG+Y[<&TEKL)LBOV#@*ZGVYN_<VV(I<7U5A:B#K'K*&KW37Y3
M+1^Z]TW56:IJ5U>7+0XF7"U,$2-4U&P^NJ_`Y/JG:\-3#`BT5?D=K])YKI;K
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MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[HFOP*_[)U;_`,6`^9'_`,&)WQ[]U[HY
M7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z__];?X]^Z]T1/^9-\9M^?+/X@=B]4]2YO";>[DQF=
MZQ[>Z9R6Z#4+M1^V>B.SMH]R;`P^ZWI%DJ8-L;DW'LB#&U\\:224U-5O,B.T
M84IVFN]OW3EOF+;X!-?[5N,5VD1.D3*H:.>'42`K2VTLT<;$A4E9'8Z5/2NW
M6UNK3>]FOYFBV_<K"XM))%&IHQ/&524#S\*41R,M#J566AU=%BV!\S_YBGR$
M[#Z7ZOVK_+D[+^(;XO>N!ROR\[<^4^?ZQW5U-MSK_;TR/O;8?QDR/4G9^2W%
MW3O??60ADQV#W!68S#XC'47^Y&II)/)'`IA`EO/>"Z69EV%(Y&(D71=2.T3B
M"(0@ND8$I62>4RD+'$T:JTDR%2Z8SV]E-:R*LF^L45&B)-J@U@RSL[*'>D>(
M;?2K/)(-<B)#)J)C/\->^Z'^7!W%UM@_CUG\=VWOC^;56=_U>U*)-I0;JW5U
MNW\QK;G9=/VAE\E#FHJ+*TR]1XJ/)K)45/WHQU*D8B#HD(2\IZ[$?=D^N.AM
MG>V-]7_B-I?<R_B<2Q431`Z->'4`D`TUS/']:OWA/I1XC;FDZV9\[@%-O"".
MOP@^%(`&T`:&X5%6[=WQQ^3LF^?F-UW3?&'L>J@RG\ZOX0_.'9G8E`-AOUWV
M9T$F\OC=#O*IVUE(]T0YL[CZLI.JLI7;BH,A0TQA@EC>F:JDD=0WLRM_S#%9
M*P_NW?-V$Y;&B.\7?IH+E:$ZH0+NVC8J-:RR+&`0K>'KFN#ZZW]SA:N)'W3E
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M"UQ;K[2;CNFF`;5?1-<B84CMRS%72RAA[4AA=YFBN3K_`,68B2)I)F?KW.ZQ
M3;=[J;7M1,\6Z6$B6A3+W($*D-?RRD$2R!55X%.GQHXO#<(@07*]6_!?L;N/
MX2_S7_BKVIB,QT_6?+/Y>_S!,AUSN++B@K1)LWN'<\U5U;VC34N(R-8]3MVN
MJ#!6BFE:"KEIXGC>.)F'MF_ANI>4.1[7;[E8]\L+=)1JR([FWW:YO85D[6[6
MI"6*ANQ\`MCHYM-P@L^;MRW*12^W2K:QL5XM$=GLK2XT5([T83(M2!XB?PY+
M1M?YB?S6]T[*ZW^,>`_EP;OZE^6%!6[,V1V[\I.U=Q]:;I^!&T=M;?J:&E[`
M[JZ\RVT.T:'MOMF;=&WJ7[C;NT?X/AJVFR&32&OJO'C:HS'\ES9;[S!%NJQM
M9<OR77CW44II<QQ&35+:6P7Q(YIB288IV98BO^,,`G;T$K.QFY?V/]TR2)=;
MG!9^#:O&2T,LBQA()KEBL;0(`/&FC".X9?IT[G#BIC^:%T5_-'[ZJOYC_P`>
M]K_&KY-9/;G</9"[IZ+VK\5=H_"+JSXC=I=6[:VEMI8>POD_\@-Z//\`)OM_
MN;=%#BYX<CLAZ7'I)EL9C:>@R24PADC"EA:(]MM<=PKL;;>A<RQS(%MXXUW`
MS@V]O"RBZDEB6UF\=Y%DBNFN)9%D6(Q$67<\%O>W$MC<O_C6S?3+(AI<&9[3
MPF$LSAA;PPR&XB550K):>%&IC>8R=6DUWPB[K[9R_P#/$QF,V3+U-N?YE_'W
MH'JCH;MO<T&*HGS\M%\+3U]EL3+D\/797<.+P.TNP,I4X_(QNJ>"6>HD@$U]
M;/\`,VWS7/*_-NU6TD4]S/S9N%V(P2$N+<+M;0AG*J#'<?3SQH6!"!G+(`64
MA_D2?]T[MR+>[G;LMO9\NV$!U`-]//X^XF;2M6I)$)+>5]'QE8@')4%2I?RN
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MH<;7R97'P1Q_P/0D%%EI6K(D`TQUC&<`2G7[]U[KB?Y??P8,;Q'X@_'!HI(*
MFEEC;IW8C1S4U;DAFJ^GF1L(5F@R.845=2C`K4U2B64/(`P]U[K)/\`?@[4^
M?[KXC?'2J^[_`(H:LU/4&QJ@U9SC1-G&JC-A7-0^<^WC%:7U&K6-5EUJH`]U
M[KS?`'X/-)),?B/\=3-+-65$DW^B'8XE>IR./3#U]2THPH<U-9AHUHI)+ZWH
MP("?%Z/?NO=<A\!/@^K1NOQ(^.J/%)230NG4.QD>&7'XYL/C98&7"AH9,7B'
M:EI66QI:9FBBT(2I]U[K'#_+^^#5.8#3?$+XX4YIOX1]M]OT[L2`4W]W_,=O
MBG$6$00+@7J)'H0MA1R2,\.AF)/NO==K_+_^#:I'$OQ#^./BBBIX(XO]#VQ#
M$E/2Y%\S3TZQG"%!!#F9&K0EM/WI,]O-Z_?NO=<'_E]_!B1)(Y/B#\;Y8YH:
MRFG23IS8<BST^2R"9;*03J^#83PY7*1)4U:/=:J=%DE#LH(]U[K+-\`O@_4^
M<U/Q'^.M2:ILJ]4:CJ'8\[5+YV.&'.R5#2X5S/)G*>GCBK6>[5<,:QRET4*/
M=>ZZ;X`_!UI&F/Q&^.GF::HJ6F'4&QEF-358U<+45/E7"B05,N%441D!U_9?
ML7\7H]^Z]URC^`?P?B,31?$CXZQ-`]!)`8NH=CQ&GDQ-#)C,.].4PJ^!\-CI
MGIZ,II-)"[)#H5F!]U[K'%_+]^#,'@\'Q"^.$(IOX4*80].;#B6G&!EEJ,$M
M.J8-1"F$JIWFHPMA2SNTD6ER6]^Z]UV/Y?\`\&UC6$?$3XY>%88Z80GI_8K1
M?;1Y,YQ:8QMA"AISG#]\R$:&K?\`*&!F]?OW7NB<_-7X1?#C;^S^C7POQ:Z"
MQCYWYC_%?;N9DH>J]G4KY;`;O[YVF=WX7*/3XJ-LEB-W!R,M2S^2GR8/^5)+
M86]U[HY,OP#^$$[3M/\`$GX[S-5/DY:EYNH]D2O42YNGBH\U+.SX9FEES%#`
ME/5,UVJ*9%AD+1J%'NO=<3\`?@Z9/*?B-\=/+YGJ!*.H-C+*M1)C/X(:A9%P
MH=*A<)_D2N"&2C_84B(E/?NO=<HO@'\'Z<PFG^)'QUIS3/C)*;P=0['A^U?!
MTLM%@GI1%A5%,V"HYY(J$II^S21A#H#-?W7NL4?\OWX,1+"L7Q!^-T24RXQ*
M=(^F]A(E.F%J9:[#1P(N#"Q18BOF>II54!:>I=IHPLA+>_=>Z['\OWX-"+P#
MXA_'+P&!J4PGI[8IA:FDR?\`&YJ9XCA#&]/49L"ME0@K+6`3N&E`<>Z]UU/_
M`"_?@S5+.M5\0OCC4K5)DHZH5/3VQ*@529JHBJ\VM5YL(_W*YNI@1ZW7J^[9
M%,VO2+>Z]UD?X!_!^1IG?XD?'9WJ)<E/4.W46R&>>?,T<>-R\\SG#%I9\KBX
MEI*EV):>D40.6B`3W[KW7O\`9`O@]Y!*/B-\=!*LJ5"2KU!L99(ZB/&'"03Q
MR+A0\<]-A2:*%U(:&D)A0K$2OOW7NNJ?X`?!VD,!I/B-\=*0TS8EJ4TO4&QJ
M;[5L!#)3X`TWAPJ?;_P"&9Q0:-/V6MC#H+$GW7NN*?R_O@S&L2)\0OC@B0)0
MQP(O3FPQ'#%BZV3)XV*)!@],<./RDK54*`!8JIC,H$I+^_=>ZZ_X;\^#/C:+
M_90OC@8G@GI9(FZ=V(T4M-59,9NLII8VPA26GK\THK*A&!6HJU$T@:0!A[KW
M7*?^7_\`!NJ%0*KXB?'.J^[&4%6:KI_8M0:O^.R12YTU1FPCFI;.O3Q_?%]1
MK!&HFUA0![KW7)O@%\'GDDE;XC_'4S335U1-+_HAV/Y9:C)T"8G(U,D@PNMZ
MBNQ$2T<LA.N2C40$F+T>_=>Z!'Y,_!;X88/XX?('.8;XJ]`8K,8;I/L_+XC*
MXWJK9M!DL5E,)UCN"APF2QE?28F&KQU?A*!!!130/'+1P?MPM&O'OW7NE'TG
M\#_A16=/]/Y.?XF_'EZ^3K/JNL:K/4FR?N?N<-M/'/A9_N#AS,9L-+4R24CE
MBU-+(\D95V9C[KW5>?SOZ;^/OQG^0GQ:R/4?5NP>FYLOUI\@8)%ZDVK3[4WC
MN7)[6R_5&;V5C]G8S!XE]COO7;V:SF0K,1N+=%)7X_9,F0K\ICJ.KW%/B@ON
MO='1^&/PQJ=M5>#[R[PP>+I=^4N,IZ/K#K*CI9H]M=,[76HJ<GCJ*EH,A-6U
MO]Y%K,C45<LE9/59!LA55&1R-159FJJ*B/W7NK0/?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T37X%?\`9.K?^+`?,C_X
M,3OCW[KW1RO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__7WF=\9/O2DW'!!UUM'K3-[4.&H9:C
M([LWGN'`YQ,\^8GBR5'#C,7M+-T<F,@P0CFAG-0LDE2S1M&J`2'W7ND'!G_E
M\13_`'/6G0J%A0_=>'M/>T@C+_W(_B/AU];1^00"KW%XKZ?)]E0ZM/W4WVWN
MO=<4W!\P#!$9.L^@UJ#3T[3(G:F]FB6J;'X)ZJ.-SUJK/#'E)LE&C$`M#!3N
M0&E=(_=>ZY5>?^7RI4FBZTZ%ED6FJ6I!4]I[VA22K7%[ADI(YVCZVE,4$F9@
MQ<3LH8K3U%3(`6AC27W7NNY\_P#+T29`4W6O0KQ)/DAC&F[2WK&]131G>O\`
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M2^Z]UEGS_P`O%-3]MUKT-(%:O^T\W:6]8S(J2[[&,,^GK>3Q&>&CVV9M.KQM
M75X75]K`:GW7NL\F>^6@G41=<=&-3>2,,[]G;S641&MG21A&.NBI<8\1.!JL
M969;@`,?=>ZPTV?^7;2TXJ^M>AXX6;&?=-!VEO622-9*G:BY<P(_6\:R&FI*
MG--!J*^5Z6D5M`J)3![KW75-G_EXT$1J^M>AHJ@QXPS1P=I;UEB262':AS"Q
MR/UO$SI35%3FEIR5!E2EI"P0U$H@]U[K!-N'YBB`F#K'H!ZGQ7"2]K;X2$S_
M`,-SD@4R+UF[B/\`BT..COIOX)YWMJB1)/=>ZE3Y[Y<J]3]MUMT1)&LE<*0R
M]H;TC>2))=[#&M.%ZXD$3SPTFWC,`6$;5M<%+"EA-1[KW79SWRW\S!>M^B?M
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M>AUNM%]QX^T=ZMH=Z;9#9`1:NN%UK#5U>XEB)MK2BH&.DU4PIO=>ZCC<'S%\
M$A/6/0`J1'4&)!VMO@PM*M#,],KR?Z,]:QR9$1HY"DK"S.`6`4^Z]U(J<_\`
M+Q8ZHTG6O0TLBG*?9K/VCO6))1'%O$X?[ADZXD,7W4U+@14:0WB6LK2NLTT(
MJ/=>Z]49_P"7:U)6FZUZ'DI//7@23=H[UBG-,E7GEQCF).MY$$T]##C7F75:
M.2>H52PB1I?=>ZS4^>^6K3PBIZXZ*CIS-"*AX>S]YR3)`:O;BU#1(W7,:R2I
M13Y9U4LH:2GIE)`FD:+W7NHL&X/F"8J<U/6?0:3-!0FK2'M3>TD<=0]-LALB
MD#OUK&TD4%75[B6%F"F2.BH68*:J84WNO=='<'S"\!(ZRZ#^X^U+!/\`2IO;
MQ?>?PM9!$9/]&NK[?^,7BUZ=7V_KMJ]'OW7NLM;G_EVAK?X?UKT/,%CK3C_N
MNT=ZP>:5*/>+8]:KQ=;S>!)Z^EP*2E=9CBK*U@&:FA6H]U[H#/D)U_\`+[N/
M$=?8F@V1T/CTV+\C.DNVTGJ.S-Z,]=M[JGLZLWE4TC1KUX%I\IE,7@\0@YDC
MCEK*H>H01-+[KW0\Q9[Y:F2,3=;]%I&:VC24Q]G[S=UQ[UF&6OF0-UR@>JAH
M9:]XD-E>2&!2RB5VC]U[J+3[@^8!_A_W76?0D>LX[^)^#M/>TGVZO3;);*&C
MU];1_<FGJZO<*P:_'Y(Z*A9M!J9A3^Z]UY-P?,`PQE^L^@Q.::-I$7M3>QB6
MK.+@DEC1SUJ&:!<RTL08@$TZK)8,2@]U[KE/G_E\$J#3]:="O(L=::42]I;V
M1))4IMY-CUF9>MG,:3U5+@%E(#&-*RM(#&FA%1[KW7)L_P#+P-)HZUZ&*AZD
M1%NTMZ@M&M7NA:1G`ZV(5Y**GPSR`7"R554H)$$33>Z]UECSWRU,].)>N.BE
MIVGI15.G9^\VECIVR>,CK'A0]<JLDL>'DJY8U)4-41Q(2%=G3W7NL%)G_E\Q
MI/O>M.A8E9,2:TT_:>]I3%))_<;^-BF$G6T0F6D^\W']L6*F;[&@U^/[J?[;
MW7NNHL_\OS2:I^M.A%KOMJ-O#'VGO9Z;[MJ"C>NB\S=;+)X(<FT\<3:-3PHC
MD*S%5]U[KC4[@^8*Q5!I.L^@Y)E2I^U6?M3>\4<CK%NHT@F9.M93&DDU-A1(
M0&*K559`)IXA/[KW4F;/?+<2U`I^M^B7A6>L%,\O:&]$DDIEK-V+0O,B]<.L
M<TU!381Y%!8)+5UB@L*>)I_=>ZY#._+3[I5/7'18HOOD1I1V=O,U`QYS%%%)
M.L/^CH1FJ7`O43"/5I-4B1Z@C&1?=>ZC4&X/F`\=$<EUGT)!*YH?X@M'VGO:
MH2$/)L49$TC2];0-.8(JS<9AU!/(U#0!M/W4YIO=>ZZ7/_,'P0%^L^@Q4FEB
M:H1>T][F%*PTF+::*)SUJ&>G6NDK$5R`QBBB8J#(RI[KW0>=Q8OYC=C]3=L=
M=T/7G0-+4;\ZN['V;CJR?M+>_C@R^Y=H[UPF$DJD7K@$4)KI\3]RRMKCCGJB
MH8PQB7W7NGG8T7R_V9U_L_:*]=]"5E5M/9&#VXM0>T=[1P5F0P&$W#BX93;K
M9G@I*R7%X1V_6T2UM8!K--$:CW7NF#=?6/<.^^RNMNV-X=`_';<&_NFZC=,7
M5VZ<AVGO^2JVA1[VK\%CMTU=#C%V`,3+E<CMC$)(DLT<LE+50+'!)&LLDOOW
M7NA,I\_\O3]M]SUKT-'J-!]WX>TMZR>,.VR/XD8-?6\?E\"U>XO#JT^0T5#J
MT_=3?;>Z]U[^/_+W2/\`C&O0NOQQ%A_I2WMI$IHL&\Z@_P"C8DHN0FR**;7,
M4$#$!I76/W7NL<VX/F$(JDP=9]!/.L58:1)>U-[I'+,F/SST"3NO6KM%'-E(
M<;'*5#%(9ZAP&:)$E]U[J14Y[Y<**K[3K?HF5EGRBT8G[0WI$):>,;Y_@TE0
M4ZYE\4M2:/;GW"KJ$7WU?I+_`&L'W/NO==-GOES]VBIUMT0:$U,ZR3-VCO05
M(I!7QI3RK".N#&T[XPM(Z%PJS`(&*DL/=>Z]2Y[Y<L]**WK;HB*-C1_>-3]H
M;TE>(,=F_??;K)UQ$)3"*K/>+45U_9T5]/W,WV_NO=8(]P?,(P1&7K/H-:DT
MU.TR)VIO9HEJVH-OO51QR-UJK/!'DYLI&C%0S0T],Y`::18O=>ZXMN#YB"FD
M9.LN@35BCG:*-NU=[B!J\8G.24T+RCK0NM,^;AQT3N%++33SR!2\2))[KW4F
MLSWRY5ZL4'6W0\T:_??8M5=H;UA:;0=^?P[[E8NN)A#YEH]M>727\9K\AIU?
M:0?<^Z]UV<]\N/N)`.M^B33"K*QR?Z3]Z>9J+[V9/*\?^CG0M1_#Q&^@,5\I
M9=5@&/NO==TV>^6[?;_==;]%1EJG&+5>'L_><GCI)'VF,O)#KZYC\DU,E3FS
M`ITB4TM&&*?<2^#W7NL5)G_EZWV7WO6?0L>K^'_Q`4W:F]I/%KI=K-E!2&3K
M1/-X*RHS*PE@ODCI:1F"F>58?=>Z`_X\;*^973/5[;'KMA_'[(UK=B=Z[X\]
M/VAOB.F5.U.W.VNUL;0KJZYEDTT%1NW&T<CDDF,SR6U1HDGNO=#C49_Y=J:K
M[;K7H:0*<A]F9NT=ZQF54??@Q9J`G6[^$U$='MHSZ=7C-=D-.O[2#[GW7NNU
MS_RZUJ&ZUZ'">8AF7M'>I80?Q&O17`/6X!E.+2FD*_3SR2)?2BNWNO=<J;/?
M+AI*,5?6W1,<;OCQ7-!VAO21X4>MVHF4-,K]<QB=J?'U.:>$,4$LM+2*V@5$
MK0>Z]U&@W!\PS]O]QUET#'JI,<U5XNU=[R>.M>#:9RL4&KK2/R4]/45.;6!V
MTM*E+2%E0U$H@]U[KDV?^8'V\S+UIT&:H4CM!&>T][B%ZX460>.*20=:ETIC
MD$I4+A2PBDD;3=%5O=>ZYU>?^7JBK^QZTZ%F96KOLA4]I;VA$JH^^1CC4F/K
M:;PF>.CVX90NOQFNKPNK[6`U/NO=9FSWRU^Y95ZXZ*-)]Y(J2'L_>8G-",IE
M8XIFB'7)05+8>.BE9`Q45$LL88K&KO[KW74>>^6QJ(5EZWZ*6F-33+/(G:&]
M&F2D;(;62KDCC/7"H\\>,J,S)&I8!IJ6D0D+/*\/NO=1Z7<'S`:*F-9UGT'%
M,RTIJUI^U-[31QNT6T#6B!GZUB:58IZG.B,L%UK249.DU$H@]U[KM]P?+\4H
M:/K/H0UGV]2QB?M/>RT_W2T$KTD8E'6Q<P29((DC:05A)<`L`I]U[KJJW!\P
M%:J%'UGT'*BPY8T1J.U-[1-+41G>_P#!$J!'UM*(8JH4FW?N2I<P_>UVD/\`
M:P_<>Z]U)ESWRV$U0(.M^BG@$U6*5Y.S]YI*\"Y/-1T+S(O7++'++B(L?+(H
M+!)YIT!98D>3W7NL2Y_Y=W35UKT.`7@#E>T=ZDB,U>VUJ&4'K<79**?+.@XU
M24U*IL)I&A]U[I4X;+?(J79.[ZO/[)ZFH^PJ:FQK;%PN+WYN>MVKEZN3;V(G
MRT>Y<[4[*H\GAH*;=$M=3P-3T569:*&&9@DDCQ1^Z]U__]#?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
FO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g912919dsp_265a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_265a.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X1A$17AI9@``34T`*@````@`"`$2``,`
M```!``$```$:``4````!````;@$;``4````!````=@$H``,````!``(```$Q
M``(````;````?@$R``(````4````F0$[``(````&````K8=I``0````!````
MM````.````$L`````0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O
M=W,`,C`Q-3HP-#HR,B`Q,3HR,#HS,@!J=V%N9P````.@`0`#`````?__``"@
M`@`$`````0```3*@`P`$`````0```3(`````````!@$#``,````!``8```$:
M``4````!```!+@$;``4````!```!-@$H``,````!``(```(!``0````!```!
M/@("``0````!```6_@````````!(`````0```$@````!_]C_X``02D9)1@`!
M`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`*``
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.WMJ.7B_;\D
M^IZGZ1E;G$5UU&?0:RH>SU?H/ON?ZEG\Y_@O2I4*\+#,[L=@(V^V"8D3^=[O
MHJUBEKNE8U(<!99CLV`Z`D!O=0],UY%@W%P!@./A`VMY*K92;W+-`"D?V'!_
M[CL^[_:E]AP?^X[/N_VHR2BXI=S]JZAV0_8<'_N.S[O]J7V'!_[CL^[_`&HR
M27%+N?M50[(?L.#_`-QV?=_M2^PX/_<=GW?[49)+BEW/VJH=D/V'!_[CL^[_
M`&I?8<'_`+CL^[_:C))<4NY^U5#LA^PX<@-QV%QT:(Y*M,Z5TYC0W[/6XCEQ
M$DGQ]Q3XXFX=X:XCX^UO_?E94N.ZNRLG5U36_9G3O^XM7^:HGI/3C5Z8H8#^
M_$NYGE6TD^SW6N=?T_!;<8QV!KA+1&DC1\?]!0^PX/\`W'9]W^U7,H.)82/8
MV3N'B?;[OW6H*AF2)'4LD0*V".C"Z?N+;<>IL$NKG@CZ#@__`+Y6E?@8`O+6
MX[&[0V8;IN,_V?H;=R)`)D@$\:^"0``@:!+W)55GS5P"[53B]-L.Q^+2RW73
M;HX"/<S[_H)[Z&X(&9A_H140;J6D^F^LD-M_0SL;<QGZ2JVOW[V>F_\`1)B#
M+2#!:X.'<2/WOY*;/R7.P+VN9JYL2TZ:D:NW>Y28\NH!*V<--'__T.^Z=7NQ
M\)[A[68S-IC\X^?[S6I[/YVR.-Q^^!N1.F_\FXG_`!+/R(=EC++7.806D-@C
MO`U<JV7;ZLT/V,4DDE"O4DDDDI22222E))))*46AP@JS7DUEK=[@'Q#IX#N#
M+OHJLG3HR,4$6W4E38]]>C"`#KM(D3_T=J(<MP$FL0-3[OR>U2#)'KHL,"V"
M`001(.A'B"J,%KG,.NPEH/C'=6[WOKK+F#4&)_='[\?R54B-/R\H9"-`F'52
M222B7J0,Z?L=L&/;KI.DA'0<W^AW?U?XM3H_,/,(EL?)_]'T/IO_`";B?\2S
M\B"^KT[?3;(`UK$B#N&FZ?\`A&^EO1NF_P#)N)_Q+/R)LT$A@$#1QD^'M!:J
M^2J)[%EANB!#A(X*21)>YSV$AKR7!KAX^[R<FEW=I^+=?[G*$LBZ28.:3`(G
MPX/W%204LDDDDI22222E))))*4EIP>.Z222D^+8ZT.KLVG:`T@$[N-ONW?2W
M-_/0`(TF8EL^,>V4CKW(.H!'(G0I``"`('@G2E8'<(`HE22<`GA*#X)J5`$D
M`"22`!QJ4/J%6W#N`>U[@R7-#H(@M^BSZ3MO\M__`%M3$R8F6_G>'CM_E_R_
M\&@9GMQ+06C8&PV.Q,!KD^%7'K9"V5T?)__2]#Z;_P`FXG_$L_(HY#MUVAT8
M-O\`:/N<E@V"OI6*_DBFO:/$D>T(8T&ID]SXGN56RGIW9H#JI)))0KU'40=1
MX'5-L:.);_5)'_F*=))2T.[.^\`_DVJ6R[]T'Y$?^33'0$^`/Y%5;5C>A0QF
M)8+16QS[OL[KF/&P.EKFO'TG?]<3X8S.Z-4HD`6;^@;>VW_1GY'^\-319_HW
M?A_>JGI``/.,7-%@:YHPK`=A[^Z_=]%C_=7^?Z7L_,?-].)]AOG&>W(9798+
MC2ZEHVN]FSW.V_\`!^_?^^GG`0+L+8SB2!KJ:V_]"3;R#JTAL<\Z_!NY2!#O
MHF8Y4G_3=\2H$,<X;P8[N`W$#^2H0N7`<20UI<6B70/P_K_R$CHXM.CART\H
MHO#"QM3"REL[ARX_)Q_]2H>9<+/2J9N8Y]K6A\AKH.[R>]K'_04G#$Z`Z[(!
M).VBR2K6%](>,BUM-K6[A4_,:#_:WX[=K/Y:5'JY#]E%K;G@!VVO,:XP?I.A
MN-^:C[$_#[5<</WOP2VTMOMQZ7;??8Z"YH>`15:6N]-_M>@OP7AUC1CN`8=H
M<,3',Q/Z1GO]^_\`J)]]9K?7D569#:K+6[G5>H"&/>QCIC:[:SVH5M6`;,*,
M>H>O8?3#JVMWS3:^-NW=_*]S4H9.`48WJR&$CH)2CPB7R['AXI_U6P_"97]F
MO=6*G66[0P5,I<W;5>VP_H2]WZ9[?5_G?H>FHY;IPK03[]L$=Y!;V_Z2)5C8
M]3M[*:VV'3<QC0==-C-K=R)F4EG3\A[_`.<-1&G`$M]O\I(>N8-4-&.9J-$F
M6E67_]/O,=P_9F$SOZ3''R`;'_5.3H>-_0L3Q^S5RD<C'#BWU!N:8<!)@CEI
MVA4\FLRV,8)B*!*1)0]>KF2?@QY_(Q.VVM[BQI]X;.TM<TQ]&?TC6?G)M'LN
MX3U!'T6;<U[0YC+7-<):13:00>#_`#:?U/\`@[O^V;?_`$FJQ%;V5$URX5L:
M\/IR@YK@UK7.FENQ_NKJ_P#2B@]M5C=K6,<ZLN#B:LR6N/O#=S1ZFVRI]3GU
M[O9_PBF]K'^_^(6DR!(&.1K^7[K<%C2_TR'M<X$@/8]D@?2VFUC6^W<ITVYM
M--=++JRVMH8TFHS#1MU_3JO3M'H55LV-J%I(;7;6P;]A`_61])S]_P!%'49/
M!(B,OJNZ#2KUJ0$O^DUQA@.:YOI!S3N8?3L(!`VM]OVOZ'M_FT1V3FY=-N+D
M65UOV[;F-K,[7?X2E[KO=59_@[-G_!V?ID11LI]7;M=LM9/I6@26D_2:YO\`
MA*;/\-5^?_QGIV)>Y/\`>*HT.@':7#'T_P#-7MMVN'M<]UCB`UNWL'6.+G6N
MK8UK6M_>43:X#<:7;8F=]$1_[$*#+#8S%R#3ZK#[[:6EI]ME;V%OZ9U;7MW/
M0+&.W,BB+'[@''&QG#2;1MC(;L:S;^>Y.A'&1ZI452XA0$0=-;/4?X3:+W?I
M&FMU=E;0[:_;J';MCFNK?:S\QZ)?7[64C]'MV6/=7[7&SL[<=W_2^F@/<1O=
M51Z+"VBBFIQ:!H75?X`W[*V>LU-=U%CGFR:6CZ+I=;R!O_[C?N.2$3ZN#770
MH.X.@^OZ5!/6'%MDY-Y>T$M&YNNT3MGTT&UUE6USLC(L<9#2'5,@?2=NLL94
MQC?H)A>][F!WI-K.]QL]0AH](L9:RSUJZ?;^F_-4LENXUFIKKFC<'.AAG<V-
MS:+G5U.J_KN2N5@2)C6^J1]#8)&U:*-?I,-+J[7.DN(<^D&7.]6Y[W?:-[G?
MI?;]#9[%+':VND4,8^MM$4[+"'.&T-VR\.LW^QS??O0'-R'.<\5D/,0\X^,7
M2`1+C]H]RFRECG66V-LI#G@A@L<P!H;75_-XUKJF-]GT6)9!"@8FS:HF1XN/
M0?-IZO5Y<398]M=C7O,,:3N)[2"W<I]1(=TV]PX-<CMH85?I+WW8]-WIO</<
M/4OW->(<]O\`-VMW;_;_`"_^.5GJ7_)^1_4/Y0G8A5>;'E%2(ZQ/#]C_`/_4
M[AHROV=TUU#:RT5M;:;'.;`+/9LV,L^E8U)MM8QJJ[K&UWNOOV,]:RICOTK]
MS66U;'.=N<SZ3?\`A/31\5N[I&,>[*6/']EO_D4+T6`N+76-W$N(9;8P2=7.
MVUV-:W<JYEP9":W#.*ECX3I1W_E_>:S;PT[W6U^HSWP[)R]`9^F+6NV\._-^
M@K;_`+-ZM`Q7;J13:UIDNU%E.^762]SMR;TQ^_=_V_=_Z53MJ8'[QN+R-NY[
MWO,$[MH]5[]ON"$\PE$BCJJ$!$W?0]._^$NJXOIIOR&VOV%UC7`%KC(]*ENX
M;6N_.:B,O8]H>QMKF.$M<*;2"#PYI])2%Y`T9>!_Q-W_`*247">Q9`"+N)[=
MD%O4\"EH=9=`<2&@,L<20#9#6MK_`'&*;'ON]:RIUOI5.8W:QE;"`6>J^VS[
M<VOVZJ.797<QE-C7SZM-C6VLL9.RZKW-]5K-VQSVHQ;=OM<RT!MVWU&/K%@)
M:-O=[$Z'")>H:)D`(Z`QD;^?U1_1V'`Q]/*'TFY36AVUSRW$(;P-[MCG.V^Y
M.&Y%5U0M+P+66.].P5AS2QU3&.W8XV>YMOT?>A'"J=]*O&.LZXK.?WOYSS10
MRPO8^RP.;4QU=;&5BMK0XL/9S_\`1-VI\Y8C$\(U61XK]4HD4=!'_P!`5CU>
MA173O=9Z30SU'1N='YSMOM2?359;5:]LV4%QJ,D07M]-_M:=K_9^^II*%/$;
M)O4WMI\WS,;`XM&R-S7L>`XD`['MMVDM#OI;/W4KGY5SR\M#"1$5Y-K1_FC'
M4E$6M).UMCPTEI+*K'"6G:X;V5N:[:Y/C.8TC^2N'B%&/%7G_P!RMD,.98TY
ME-+JV5OK#"3;.\LW%WJU5[?;4AW>H'558[W4^G#GM94UX-<.JKJ_2%C:O>WV
M^G_HT]%MY:_UZK`X6/%>RBX#TP?T+G;F._2.9]-,[;<7D5NL:0QH=LK)8^M]
MIL8ZG.->W<VS]U(>J5STO<[+CQ1!`'R:1!^37^^O6[*;8YMK+;&$-],^FQKM
MTO\`4;M8_P!WLV.1<=XNN%1:YCFF7!PCV@OX(EOTJG,?^XJ8Q[6@[**P^0YC
M_L^."TZ'>-F5]/<WU/\`C%<PZQ]K#FU>@QE#:V-A@!<USW6O:S'?8RO^=3S#
M'IPRLWLL))$B0(Z?HD?]%T"23)5;J7_)^1_4/Y0K"K]2_P"3\C^H?RA2#<>;
M"7__U?0^G`'IF*")!H8"/(M4;J?3]S=:^-=2W_S!2Z;_`,FXG_$L_(K!&X%O
M[P(^_103B#;)$TT4[?I!0;ZFT3M.FO(_\DI!P,QR.0>0J[*U1?DNPZL5[6>B
MRNH;'TY(>US!7OW64MVN=O:_8ZM-6RNM]=K&`6L<2'.9F.B/4V?3'Z3VO_._
MX56TE-[\NP080))J6NN__H*&VRW-MQG7$AU+7NL]-CV,)WT/I9NR:][OYK?^
MC1E&USVL!8`7N<QC=TQ+WMJEVW]W>H/?DLL-;FF6F);CWN:>1[7U[F_FIM3R
M$R`7:"(%T!8%_P",63[Z*SMMMKK<1(#WM:8\8<4)_4,46,IK=]IML/\`-XY;
M8YK-?T]K`_V4;AZ?J?Z1*;V/LN@NWBMI`Q<DD;?4VN@^YW]G_OZ)2,BZT,:U
MK7ND!S\>]FC=73;9L;M]WL;N]Z7LS_=_$)$L0W-Z=^O^*C]:G;:^_(=BOW[:
M:K7-I:0UE+G_`)K_`,Z[]_WJ'K``%^50UI`<'?;1!:1NWAQQ?YM%H'J5B[<^
MIUHW/;78]K=P_1R&S_P:)Z9_TM__`&\__P`DG1GC``,+/79$KXM)<-:5PCHB
M:^DLJ=7E>I?ZC!=2VUMK0UQV.]PKKW-_E_OJ-C&%@]GZ866A^]F1!8ZQSV.K
MLQ?;]!R-Z32YKG/L>6D.`?8YPD?1EKC[MJ(`X\`GX(>X!*X"M*I!HQJ6NMW\
MK4KKI#]MM<U/::[@T9<N9[8^DW^1]#_C/W[%8K.XVO@@/M>YNX%IVDC:=KH<
MGN<ZFE]I87;0(;Q))#0-Q_K*+?MAN++,8,J#2?5%F\[P[;Z7I>FS\SW^JA/(
M9BC7T5&``)C_`,Z4>G;Y6:)CU;KO5@@-$!PT!(ENT_O_`$DU59?9M,AK=7D:
M?U63_*5L`-`:!``@`=@$L<>JV4NBE7ZE_P`GY']0_E"L*OU+_D_(_J'\H4PW
M'FQE_];T/IO_`";B?\2S\BL*OTW_`)-Q/^)9^16%"=RO:CFM^T;"`6^H-#Q#
MO=_WY-=4UEFT3$!S#.HF0Z'?)%RS48:2/4$0WN6N,._\FH/+GTML.KJB66'R
M@'?_`-0HI#YA_A,@.Q^B+WC]UWW@_P#?DOTFOT1X#4_](0G24:Y@\.>R&$-L
M8YCANU`<Q[;1NVQ[7[$%N+:P0PM8T&0UMV4&ZG=]!M^U6#H0[P!!CF#_`.12
M#IU8-P\01K_53HSE'8TK0BB`?-#Z%^D>FV!MEMF0"1+G0XMM]_N>_P"DDRB^
MMX>TLD.#];<DB0=_T77%OTOS4<$$2-0>$D[W9_O?DJH_NAA36:J65N(<6B"0
M(!))<=H/Q4TX!)#0"XG@`3PG-=@YK?X\3I\DRB>BB==3NQ4!B'*RBT>G+*FD
M&VOU6ZNL'T-]?[O[ZD'-+VC>T,<0"Z>)^]O]5&=T[&>[=<#81QNB1XMD#Z*?
MC!L2JZ5Q`6+(L;QW:5^*&.MK?34&M$!U>`^R7?2W#WVL>W_7]&IX^$_(?:QK
M,9A8!!?@V,DF?=^EOVN;[4?]EXVZ-K-GCM]WP_<_M(3\''8[8^IATD$#D<?V
M5*<E"S!:-=/=G_+_``VUAL;6RVM@#6,N>&M:(`^B?:W\UJ.@X@K;2&,:&;"0
MX-$`D^[?I^_^<C)7>O=;(W(^:E7ZE_R?D?U#^4*PJ_4O^3\C^H?RA$;CS6E_
M_]?T/IO_`";B?\2S\BL*OTW_`)-Q/^)9^16%"=RO8VU"P`$P1]%P[3SI^<@4
MEU=WIN`]WM=X3$L>/Y-C595;)#V6>KR/;M([%OYG]O\`\P39:5+MOY+HZZ,;
M*S6[;'L).PCC][9_68H*U;6V]K75N&D[#RTSR'?<JH,C\H\".0HYQH^!7Q-A
M22228E;AT=G:CR/YW^=])38PO>&`Q,DGP`Y=^*B1(\.X([%3QM_K\`C:=Q`(
MB8V^/TMJ=$60%'8MBJEE4P2YQT+G<QX:*:22G85_X\IDDDE*0<IA(%@UV3N`
M_=/?^RC)($6*2#1MJT.+;0.S]#\0"YCE:0FXP98'M,,:9:R.--OTOW45"`(%
M%,B";"E7ZE_R?D?U#^4*PJ_4O^3\C^H?RA/&X\UI?__0]#Z;_P`FXG_$L_(K
M"I47MP6##S/T/H>VJUP/IV5@_H7-NC9ZNSV74OV6>I_P/IV(O[1Z=_W)J_SE
M$0;V7`AL)$`@APEIT(/<*O\`M'IW_<FK_.2_:/3O^Y-7^<A1[)M+14:F%KG;
MR3,\=H_@AY-?^%:/^,`\/])_9_.3?M'IW_<FK_.2/4>FD$')J(.A&[L@86*I
M(EK:%)`;FX>T3>SCN=?FG^VX7^G9]Y_N4'#+L?L9+'<)D?%XL^(_(J7VW"_T
M[/O/]R+C]1P6N<'7U@.`,D]Q[83X`\6Q^Q$B*W;Z2K_M'IW_`')J_P`Y+]H]
M._[DU?YREH]F.VPDJK^J]/;$7L>3^Z?RH1ZOCSI;4!X$N/Y`U`FNA^Q(%M])
M5F]3Z>6M)R*VD@$MW<$]D_[1Z=_W)J_SD:/9%MA)5_VCT[_N35_G)?M'IW_<
MFK_.2H]E6V%7ZE_R?D?U#^4)?M'IW_<FK_.0K[QG`8>'-PM(%UP!]-E8(=;^
ME(V.N>W]'557[][_`%'_`*)&(-A!+__9_^T=$%!H;W1O<VAO<"`S+C``.$))
M300$```````1'`(```(``AP"4``%:G=A;F<`.$))300E```````06L2Z+NU8
M0NV"C>O;'[&8?3A"24T#[0``````$`$L`````0`!`2P````!``$X0DE-!"8`
M``````X`````````````/X```#A"24T$#0``````!````!XX0DE-!!D`````
M``0````>.$))30/S```````)```````````!`#A"24T$"@```````0``.$))
M32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@``
M`````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@```````0`U````
M`0`M````!@```````3A"24T#^```````<```________________________
M_____P/H`````/____________________________\#Z`````#_________
M____________________`^@`````_____________________________P/H
M```X0DE-!`@``````!`````!```"0````D``````.$))300>```````$````
M`#A"24T$&@`````#70````8``````````````3(```$R````%``Y`#$`,@`Y
M`#$`.0!?`#``,``Q`%\`<`!A`'(`=`!?`#D`,``Q`#`````!````````````
M``````````````$``````````````3(```$R``````````````````````$`
M````````````````````````$`````$```````!N=6QL`````@````9B;W5N
M9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG``````````!,
M969T;&]N9P``````````0G1O;6QO;F<```$R`````%)G:'1L;VYG```!,@``
M``9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````!W-L
M:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU
M;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E96YU
M;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`````
M``!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````````
M`$)T;VUL;VYG```!,@````!29VAT;&]N9P```3(````#=7)L5$585`````$`
M``````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A;'14
M86=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E
M>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L
M:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T
M06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E
M0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG``````````IL
M969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P`````````+
M<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_`````````X
M0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`````%QH````!
M````H````*````'@``$L````%OX`&``!_]C_X``02D9)1@`!`@$`2`!(``#_
M[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1
M"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`*``H`,!(@`"$0$#
M$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%
M`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"
M$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:B
MLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q
M$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"
MTD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.WMJ.7B_;\D^IZGZ1E;G$5U
MU&?0:RH>SU?H/ON?ZEG\Y_@O2I4*\+#,[L=@(V^V"8D3^=[OHJUBEKNE8U(<
M!99CLV`Z`D!O=0],UY%@W%P!@./A`VMY*K92;W+-`"D?V'!_[CL^[_:E]AP?
M^X[/N_VHR2BXI=S]JZAV0_8<'_N.S[O]J7V'!_[CL^[_`&HR27%+N?M50[(?
ML.#_`-QV?=_M2^PX/_<=GW?[49)+BEW/VJH=D/V'!_[CL^[_`&I?8<'_`+CL
M^[_:C))<4NY^U5#LA^PX<@-QV%QT:(Y*M,Z5TYC0W[/6XCEQ$DGQ]Q3XXFX=
MX:XCX^UO_?E94N.ZNRLG5U36_9G3O^XM7^:HGI/3C5Z8H8#^_$NYGE6TD^SW
M6N=?T_!;<8QV!KA+1&DC1\?]!0^PX/\`W'9]W^U7,H.)82/8V3N'B?;[OW6H
M*AF2)'4LD0*V".C"Z?N+;<>IL$NKG@CZ#@__`+Y6E?@8`O+6X[&[0V8;IN,_
MV?H;=R)`)D@$\:^"0``@:!+W)55GS5P"[53B]-L.Q^+2RW73;HX"/<S[_H)[
MZ&X(&9A_H140;J6D^F^LD-M_0SL;<QGZ2JVOW[V>F_\`1)B#+2#!:X.'<2/W
MOY*;/R7.P+VN9JYL2TZ:D:NW>Y28\NH!*V<--'__T.^Z=7NQ\)[A[68S-IC\
MX^?[S6I[/YVR.-Q^^!N1.F_\FXG_`!+/R(=EC++7.806D-@CO`U<JV7;ZLT/
MV,4DDE"O4DDDDI22222E))))*46AP@JS7DUEK=[@'Q#IX#N#+OHJLG3HR,4$
M6W4E38]]>C"`#KM(D3_T=J(<MP$FL0-3[OR>U2#)'KHL,"V"`001(.A'B"J,
M%KG,.NPEH/C'=6[WOKK+F#4&)_='[\?R54B-/R\H9"-`F'52222B7J0,Z?L=
ML&/;KI.DA'0<W^AW?U?XM3H_,/,(EL?)_]'T/IO_`";B?\2S\B"^KT[?3;(`
MUK$B#N&FZ?\`A&^EO1NF_P#)N)_Q+/R)LT$A@$#1QD^'M!:J^2J)[%EANB!#
MA(X*21)>YSV$AKR7!KAX^[R<FEW=I^+=?[G*$LBZ28.:3`(GPX/W%204LDDD
MDI22222E))))*4EIP>.Z222D^+8ZT.KLVG:`T@$[N-ONW?2W-_/0`(TF8EL^
M,>V4CKW(.H!'(G0I``"`('@G2E8'<(`HE22<`GA*#X)J5`$D`"22`!QJ4/J%
M6W#N`>U[@R7-#H(@M^BSZ3MO\M__`%M3$R8F6_G>'CM_E_R_\&@9GMQ+06C8
M&PV.Q,!KD^%7'K9"V5T?)__2]#Z;_P`FXG_$L_(HY#MUVAT8-O\`:/N<E@V"
MOI6*_DBFO:/$D>T(8T&ID]SXGN56RGIW9H#JI)))0KU'40=1X'5-L:.);_5)
M'_F*=))2T.[.^\`_DVJ6R[]T'Y$?^33'0$^`/Y%5;5C>A0QF)8+16QS[OL[K
MF/&P.EKFO'TG?]<3X8S.Z-4HD`6;^@;>VW_1GY'^\-319_HW?A_>JGI``/.,
M7-%@:YHPK`=A[^Z_=]%C_=7^?Z7L_,?-].)]AOG&>W(9798+C2ZEHVN]FSW.
MV_\`!^_?^^GG`0+L+8SB2!KJ:V_]"3;R#JTAL<\Z_!NY2!#OHF8Y4G_3=\2H
M$,<X;P8[N`W$#^2H0N7`<20UI<6B70/P_K_R$CHXM.CART\HHO#"QM3"REL[
MARX_)Q_]2H>9<+/2J9N8Y]K6A\AKH.[R>]K'_04G#$Z`Z[(!).VBR2K6%](>
M,BUM-K6[A4_,:#_:WX[=K/Y:5'JY#]E%K;G@!VVO,:XP?I.AN-^:C[$_#[5<
M</WOP2VTMOMQZ7;??8Z"YH>`15:6N]-_M>@OP7AUC1CN`8=H<,3',Q/Z1GO]
M^_\`J)]]9K?7D569#:K+6[G5>H"&/>QCIC:[:SVH5M6`;,*,>H>O8?3#JVMW
MS3:^-NW=_*]S4H9.`48WJR&$CH)2CPB7R['AXI_U6P_"97]FO=6*G66[0P5,
MI<W;5>VP_H2]WZ9[?5_G?H>FHY;IPK03[]L$=Y!;V_Z2)5C8]3M[*:VV'3<Q
MC0==-C-K=R)F4EG3\A[_`.<-1&G`$M]O\I(>N8-4-&.9J-$F6E67_]/O,=P_
M9F$SOZ3''R`;'_5.3H>-_0L3Q^S5RD<C'#BWU!N:8<!)@CEIVA4\FLRV,8)B
M*!*1)0]>KF2?@QY_(Q.VVM[BQI]X;.TM<TQ]&?TC6?G)M'LNX3U!'T6;<U[0
MYC+7-<):13:00>#_`#:?U/\`@[O^V;?_`$FJQ%;V5$URX5L:\/IR@YK@UK7.
MFENQ_NKJ_P#2B@]M5C=K6,<ZLN#B:LR6N/O#=S1ZFVRI]3GU[O9_PBF]K'^_
M^(6DR!(&.1K^7[K<%C2_TR'M<X$@/8]D@?2VFUC6^W<ITVYM--=++JRVMH8T
MFHS#1MU_3JO3M'H55LV-J%I(;7;6P;]A`_61])S]_P!%'49/!(B,OJNZ#2KU
MJ0$O^DUQA@.:YOI!S3N8?3L(!`VM]OVOZ'M_FT1V3FY=-N+D65UOV[;F-K,[
M7?X2E[KO=59_@[-G_!V?ID11LI]7;M=LM9/I6@26D_2:YO\`A*;/\-5^?_QG
MIV)>Y/\`>*HT.@':7#'T_P#-7MMVN'M<]UCB`UNWL'6.+G6NK8UK6M_>43:X
M#<:7;8F=]$1_[$*#+#8S%R#3ZK#[[:6EI]ME;V%OZ9U;7MW/0+&.W,BB+'[@
M''&QG#2;1MC(;L:S;^>Y.A'&1ZI452XA0$0=-;/4?X3:+W?I&FMU=E;0[:_;
MJ';MCFNK?:S\QZ)?7[64C]'MV6/=7[7&SL[<=W_2^F@/<1O=51Z+"VBBFIQ:
M!H75?X`W[*V>LU-=U%CGFR:6CZ+I=;R!O_[C?N.2$3ZN#770H.X.@^OZ5!/6
M'%MDY-Y>T$M&YNNT3MGTT&UUE6USLC(L<9#2'5,@?2=NLL94QC?H)A>][F!W
MI-K.]QL]0AH](L9:RSUJZ?;^F_-4LENXUFIKKFC<'.AAG<V-S:+G5U.J_KN2
MN5@2)C6^J1]#8)&U:*-?I,-+J[7.DN(<^D&7.]6Y[W?:-[G?I?;]#9[%+':V
MND4,8^MM$4[+"'.&T-VR\.LW^QS??O0'-R'.<\5D/,0\X^,72`1+C]H]RFRE
MCG66V-LI#G@A@L<P!H;75_-XUKJF-]GT6)9!"@8FS:HF1XN/0?-IZO5Y<398
M]M=C7O,,:3N)[2"W<I]1(=TV]PX-<CMH85?I+WW8]-WIO</</4OW->(<]O\`
M-VMW;_;_`"_^.5GJ7_)^1_4/Y0G8A5>;'E%2(ZQ/#]C_`/_4[AHROV=TUU#:
MRT5M;:;'.;`+/9LV,L^E8U)MM8QJJ[K&UWNOOV,]:RICOTK]S66U;'.=N<SZ
M3?\`A/31\5N[I&,>[*6/']EO_D4+T6`N+76-W$N(9;8P2=7.VUV-:W<JYEP9
M":W#.*ECX3I1W_E_>:S;PT[W6U^HSWP[)R]`9^F+6NV\._-^@K;_`+-ZM`Q7
M;J13:UIDNU%E.^762]SMR;TQ^_=_V_=_Z53MJ8'[QN+R-NY[WO,$[MH]5[]O
MN"$\PE$BCJJ$!$W?0]._^$NJXOIIOR&VOV%UC7`%KC(]*ENX;6N_.:B,O8]H
M>QMKF.$M<*;2"#PYI])2%Y`T9>!_Q-W_`*247">Q9`"+N)[=D%O4\"EH=9=`
M<2&@,L<20#9#6MK_`'&*;'ON]:RIUOI5.8W:QE;"`6>J^VS[<VOVZJ.797<Q
ME-C7SZM-C6VLL9.RZKW-]5K-VQSVHQ;=OM<RT!MVWU&/K%@):-O=[$Z'")>H
M:)D`(Z`QD;^?U1_1V'`Q]/*'TFY36AVUSRW$(;P-[MCG.V^Y.&Y%5U0M+P+6
M6.].P5AS2QU3&.W8XV>YMOT?>A'"J=]*O&.LZXK.?WOYSS10RPO8^RP.;4QU
M=;&5BMK0XL/9S_\`1-VI\Y8C$\(U61XK]4HD4=!'_P!`5CU>A173O=9Z30SU
M'1N='YSMOM2?359;5:]LV4%QJ,D07M]-_M:=K_9^^II*%/$;)O4WMI\WS,;`
MXM&R-S7L>`XD`['MMVDM#OI;/W4KGY5SR\M#"1$5Y-K1_FC'4E$6M).UMCPT
MEI+*K'"6G:X;V5N:[:Y/C.8TC^2N'B%&/%7G_P!RMD,.98TYE-+JV5OK#"3;
M.\LW%WJU5[?;4AW>H'558[W4^G#GM94UX-<.JKJ_2%C:O>WV^G_HT]%MY:_U
MZK`X6/%>RBX#TP?T+G;F._2.9]-,[;<7D5NL:0QH=LK)8^M]IL8ZG.->W<VS
M]U(>J5STO<[+CQ1!`'R:1!^37^^O6[*;8YMK+;&$-],^FQKMTO\`4;M8_P!W
MLV.1<=XNN%1:YCFF7!PCV@OX(EOTJG,?^XJ8Q[6@[**P^0YC_L^."TZ'>-F5
M]/<WU/\`C%<PZQ]K#FU>@QE#:V-A@!<USW6O:S'?8RO^=3S#'IPRLWLL))$B
M0(Z?HD?]%T"23)5;J7_)^1_4/Y0K"K]2_P"3\C^H?RA2#<>;"7__U?0^G`'I
MF*")!H8"/(M4;J?3]S=:^-=2W_S!2Z;_`,FXG_$L_(K!&X%O[P(^_103B#;)
M$TT4[?I!0;ZFT3M.FO(_\DI!P,QR.0>0J[*U1?DNPZL5[6>BRNH;'TY(>US!
M7OW64MVN=O:_8ZM-6RNM]=K&`6L<2'.9F.B/4V?3'Z3VO_._X56TE-[\NP08
M0))J6NN__H*&VRW-MQG7$AU+7NL]-CV,)WT/I9NR:][OYK?^C1E&USVL!8`7
MN<QC=TQ+WMJEVW]W>H/?DLL-;FF6F);CWN:>1[7U[F_FIM3R$R`7:"(%T!8%
M_P",63[Z*SMMMKK<1(#WM:8\8<4)_4,46,IK=]IML/\`-XY;8YK-?T]K`_V4
M;AZ?J?Z1*;V/LN@NWBMI`Q<DD;?4VN@^YW]G_OZ)2,BZT,:UK7ND!S\>]FC=
M73;9L;M]WL;N]Z7LS_=_$)$L0W-Z=^O^*C]:G;:^_(=BOW[::K7-I:0UE+G_
M`)K_`,Z[]_WJ'K``%^50UI`<'?;1!:1NWAQQ?YM%H'J5B[<^IUHW/;78]K=P
M_1R&S_P:)Z9_TM__`&\__P`DG1GC``,+/79$KXM)<-:5PCHB:^DLJ=7E>I?Z
MC!=2VUMK0UQV.]PKKW-_E_OJ-C&%@]GZ866A^]F1!8ZQSV.KLQ?;]!R-Z32Y
MKG/L>6D.`?8YPD?1EKC[MJ(`X\`GX(>X!*X"M*I!HQJ6NMW\K4KKI#]MM<U/
M::[@T9<N9[8^DW^1]#_C/W[%8K.XVO@@/M>YNX%IVDC:=KH<GN<ZFE]I87;0
M(;Q))#0-Q_K*+?MAN++,8,J#2?5%F\[P[;Z7I>FS\SW^JA/(9BC7T5&``)C_
M`,Z4>G;Y6:)CU;KO5@@-$!PT!(ENT_O_`$DU59?9M,AK=7D:?U63_*5L`-`:
M!``@`=@$L<>JV4NBE7ZE_P`GY']0_E"L*OU+_D_(_J'\H4PW'FQE_];T/IO_
M`";B?\2S\BL*OTW_`)-Q/^)9^16%"=RO:CFM^T;"`6^H-#Q#O=_WY-=4UEFT
M3$!S#.HF0Z'?)%RS48:2/4$0WN6N,._\FH/+GTML.KJB66'R@'?_`-0HI#YA
M_A,@.Q^B+WC]UWW@_P#?DOTFOT1X#4_](0G24:Y@\.>R&$-L8YCANU`<Q[;1
MNVQ[7[$%N+:P0PM8T&0UMV4&ZG=]!M^U6#H0[P!!CF#_`.12#IU8-P\01K_5
M3HSE'8TK0BB`?-#Z%^D>FV!MEMF0"1+G0XMM]_N>_P"DDRB^MX>TLD.#];<D
MB0=_T77%OTOS4<$$2-0>$D[W9_O?DJH_NAA36:J65N(<6B"0(!))<=H/Q4TX
M!)#0"XG@`3PG-=@YK?X\3I\DRB>BB==3NQ4!B'*RBT>G+*FD&VOU6ZNL'T-]
M?[O[ZD'-+VC>T,<0"Z>)^]O]5&=T[&>[=<#81QNB1XMD#Z*?C!L2JZ5Q`6+(
ML;QW:5^*&.MK?34&M$!U>`^R7?2W#WVL>W_7]&IX^$_(?:QK,9A8!!?@V,DF
M?=^EOVN;[4?]EXVZ-K-GCM]WP_<_M(3\''8[8^IATD$#D<?V5*<E"S!:-=/=
MG_+_``VUAL;6RVM@#6,N>&M:(`^B?:W\UJ.@X@K;2&,:&;"0X-$`D^[?I^_^
M<C)7>O=;(W(^:E7ZE_R?D?U#^4*PJ_4O^3\C^H?RA$;CS6E__]?T/IO_`";B
M?\2S\BL*OTW_`)-Q/^)9^16%"=RO8VU"P`$P1]%P[3SI^<@4EU=WIN`]WM=X
M3$L>/Y-C595;)#V6>KR/;M([%OYG]O\`\P39:5+MOY+HZZ,;*S6[;'L).PCC
M][9_68H*U;6V]K75N&D[#RTSR'?<JH,C\H\".0HYQH^!7Q-A22228E;AT=G:
MCR/YW^=])38PO>&`Q,DGP`Y=^*B1(\.X([%3QM_K\`C:=Q`(B8V^/TMJ=$60
M%'8MBJEE4P2YQT+G<QX:*:22G85_X\IDDDE*0<IA(%@UV3N`_=/?^RC)($6*
M2#1MJT.+;0.S]#\0"YCE:0FXP98'M,,:9:R.--OTOW45"`(%%,B";"E7ZE_R
M?D?U#^4*PJ_4O^3\C^H?RA/&X\UI?__0]#Z;_P`FXG_$L_(K"I47MP6##S/T
M/H>VJUP/IV5@_H7-NC9ZNSV74OV6>I_P/IV(O[1Z=_W)J_SE$0;V7`AL)$`@
MAPEIT(/<*O\`M'IW_<FK_.2_:/3O^Y-7^<A1[)M+14:F%KG;R3,\=H_@AY-?
M^%:/^,`\/])_9_.3?M'IW_<FK_.2/4>FD$')J(.A&[L@86*I(EK:%)`;FX>T
M3>SCN=?FG^VX7^G9]Y_N4'#+L?L9+'<)D?%XL^(_(J7VW"_T[/O/]R+C]1P6
MN<'7U@.`,D]Q[83X`\6Q^Q$B*W;Z2K_M'IW_`')J_P`Y+]H]._[DU?YREH]F
M.VPDJK^J]/;$7L>3^Z?RH1ZOCSI;4!X$N/Y`U`FNA^Q(%M])5F]3Z>6M)R*V
MD@$MW<$]D_[1Z=_W)J_SD:/9%MA)5_VCT[_N35_G)?M'IW_<FK_.2H]E6V%7
MZE_R?D?U#^4)?M'IW_<FK_.0K[QG`8>'-PM(%UP!]-E8(=;^E(V.N>W]'557
M[][_`%'_`*)&(-A!+__9.$))300A``````!3`````0$````/`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<``@`$,`4P````$`.$))300&```````'``@````!`0#_X1O1
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X]
M)^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\>#IX;7!M
M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM<'1K/2=835`@=&]O
M;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F.E)$1B!X;6QN<SIR
M9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C0S93DS8SDV+64X
M8C,M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIE>&EF/2=H='1P
M.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X:68Z0V]L;W)3<&%C
M93XT,CDT.38W,CDU/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX96Q8
M1&EM96YS:6]N/C,P-CPO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X:68Z
M4&EX96Q91&EM96YS:6]N/C,P-CPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\
M+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TG=75I9#HT,V4Y,V,Y-BUE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G
M"B`@>&UL;G,Z<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*
M("`\<&1F.E!R;V1U8V5R/E1O;VQK:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N
M8V]M/"]P9&8Z4')O9'5C97(^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT,V4Y,V,Y-BUE.&(S+3$Q
M930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z<&1F>#TG:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&9X+S$N,R\G/@H@(#QP9&9X.E-O=7)C94UO9&EF:65D
M/D0Z,C`Q-3`T,C(P-#4V-3$\+W!D9G@Z4V]U<F-E36]D:69I960^"B`@/'!D
M9G@Z0V]M<&%N>3Y!;G-L;W<F86UP.TIA8VQI;CPO<&1F>#I#;VUP86YY/@H@
M(#QP9&9X.D1O8TE$/D%#5$E612\X,3(V.#(U-RXQ,#PO<&1F>#I$;V-)1#X*
M("`\<&1F>#I!4%1+5D52/C4N-2XP+C$U,#(X(%!R;R!0<F]D=6-T:6]N+3,R
M/"]P9&9X.D%05$M615(^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT,V4Y,V,Y-BUE.&(S+3$Q930M
M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O
M;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P.DAI
M<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T:6]N
M/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C0S93DS8SDV
M+64X8C,M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIT:69F/2=H
M='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I96YT
M871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU=&EO
M;CXS,#`O,3PO=&EF9CI84F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO
M;CXS,#`O,3PO=&EF9CI94F5S;VQU=&EO;CX*("`\=&EF9CI297-O;'5T:6]N
M56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@/"]R9&8Z1&5S8W)I<'1I
M;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z-#-E.3-C
M.38M93AB,RTQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.GAA<#TG
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R<^"B`@/'AA<#I#<F5A=&5$
M871E/C(P,34M,#0M,C)4,3$Z,C`Z,S(K,#4Z,S`\+WAA<#I#<F5A=&5$871E
M/@H@(#QX87`Z365T861A=&%$871E/C(P,34M,#0M,C)4,3$Z,C`Z,S(K,#4Z
M,S`\+WAA<#I-971A9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B
M92!0:&]T;W-H;W`@0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@(#QX
M87`Z36]D:69Y1&%T93XR,#$U+3`T+3(R5#$Q.C(P.C,R*S`U.C,P/"]X87`Z
M36]D:69Y1&%T93X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C0S93DS8SDV+64X8C,M,3%E-"TY-V)F
M+3DV.3(W8S8W-60V9"<*("!X;6QN<SIS=%)E9CTG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R<*("!X;6QN<SIX87!-
M33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-
M.DEN<W1A;F-E240^=75I9#HY,3DR8V(P.2TU86%F+31F9#<M.#AD8RTW83$R
M8S(T,#DU,3`\+WAA<$U-.DEN<W1A;F-E240^"B`@/'AA<$U-.G-U8FIE8W0^
M"B`@(#QR9&8Z4V5Q/@H@("`@/')D9CIL:3XQ,3PO<F1F.FQI/@H@("`\+W)D
M9CI397$^"B`@/"]X87!-33IS=6)J96-T/@H@(#QX87!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2=297-O=7)C92<^"B`@(#QS=%)E9CII;G-T86YC
M94E$/G5U:60Z-#-E.3-C.3(M93AB,RTQ,64T+3DW8F8M.38Y,C=C-C<U9#9D
M/"]S=%)E9CII;G-T86YC94E$/@H@("`\<W12968Z9&]C=6UE;G1)1#YU=6ED
M.C`X8F(V.3-F+3%C.3DM-#`U-2TX9#DW+34V9#0Q,#`Q8C`X-SPO<W12968Z
M9&]C=6UE;G1)1#X*("`\+WAA<$U-.D1E<FEV961&<F]M/@H@(#QX87!-33I$
M;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HT,V4Y,V,Y-2UE.&(S
M+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0\+WAA<$U-.D1O8W5M96YT240^"B`\
M+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TG=75I9#HT,V4Y,V,Y-BUE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G
M"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*("`\9&,Z
M8W)E871O<CX*("`@/')D9CI397$^"B`@("`\<F1F.FQI/FIW86YG/"]R9&8Z
M;&D^"B`@(#PO<F1F.E-E<3X*("`\+V1C.F-R96%T;W(^"B`\+W)D9CI$97-C
M<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@
M96YD/2=W)S\^_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!,@$R`P$1``(1`0,1`?_=
M``0`)__$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!
M````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042
M!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"
M\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA9
M6F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4
MU=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%
M,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F
M-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E
M]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FI
MN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W".Y.Z>U.P.TLS\=
M?CCE,?M"KV;0XJN[T[WR>)IMQ4_68S]/]_@=A[$V_7$8G</:>=Q0^[D-;KH,
M-0R1S31RR2QQA'?[A;[;'$91KN9`="#B0.+'T`_GU>"*:XF6.-.P$%B>%*Y7
M[2/V5Z)AOCH';K[MW/0Y_M_OG=V4Q*8;'5.Y-[?(;LVDJ*C(9C&C(2UM#BMB
MY'#XFGJZ2EQ]=.,?3444,`CB72-:JT9;QSKS(-PW`65];6UGI54&A6I05)."
M:GUX]#:UY7VE-OLGFMYY9Y"S/WFM*X`]`*@8QTU_[+=U?-6XN/$[Z[HS-!#E
MZ?!U>0I^^>ZZ),M6KB\GE,U.*6HWS)54$5%42Q4\,3$.J4NIR79F]D&X^X?,
MT,ZQV.Y0M'X:U?0,M3-!3]O1O!R;M!C,U[MTL;UH.\X7T(KQ/'/2L/Q5ZO/T
MW!WCP?J?D-W5S_Z^WLN'N1SG_P!'2#_G&/\`-UN3E'ES%()1_MCUU_LJO6'_
M`#T'>'_I0W=7_P!FWO?^N3SG_P!'.#_G&/\`-TU_5+EW_?,W^]'KW^RJ]8?\
M]!WA_P"E#=U?_9M[]_KD\Y_]'.#_`)QC_-U[^J7+O^^9O]Z/7O\`95>L/^>@
M[P_]*&[J_P#LV]^_UR><_P#HYP?\XQ_FZ]_5+EW_`'S-_O1Z]_LJO6'_`#T'
M>'_I0W=7_P!FWOW^N3SG_P!'.#_G&/\`-U[^J7+O^^9O]Z/7O]E5ZP_YZ#O#
M_P!*&[J_^S;W[_7)YS_Z.<'_`#C'^;KW]4N7?]\S?[T>O?[*KUA_ST'>'_I0
MW=7_`-FWOW^N3SG_`-'.#_G&/\W7OZI<N_[YF_WH]>_V57K#_GH.\/\`TH;N
MK_[-O?O]<GG/_HYP?\XQ_FZ]_5+EW_?,W^]'KW^RJ]8?\]!WA_Z4-W5_]FWO
MW^N3SG_T<X/^<8_S=>_JER[_`+YF_P!Z/7O]E5ZP_P">@[P_]*&[J_\`LV]^
M_P!<GG/_`*.<'_.,?YNO?U2Y=_WS-_O1Z]_LJO6'_/0=X?\`I0W=7_V;>_?Z
MY/.?_1S@_P"<8_S=>_JER[_OF;_>CU[_`&57K#_GH.\/_2ANZO\`[-O?O]<G
MG/\`Z.<'_.,?YNO?U2Y=_P!\S?[T>O?[*KUA_P`]!WA_Z4-W5_\`9M[]_KD\
MY_\`1S@_YQC_`#=>_JER[_OF;_>CU[_95>L/^>@[P_\`2ANZO_LV]^_UR><_
M^CG!_P`XQ_FZ]_5+EW_?,W^]'KW^RJ]8?\]!WA_Z4-W5_P#9M[]_KD\Y_P#1
MS@_YQC_-U[^J7+O^^9O]Z/7O]E5ZP_YZ#O#_`-*&[J_^S;W[_7)YS_Z.<'_.
M,?YNO?U2Y=_WS-_O1Z]_LJO6'_/0=X?^E#=U?_9M[]_KD\Y_]'.#_G&/\W7O
MZI<N_P"^9O\`>CUTWQ7ZLC5Y)-Q]W1QQJTDDC_(CNI4CC07>1W.]M*(@Y))X
M'OW^N3SF>&YP_P#.,?YNO#E+EVH_1F_WH]*[K?X4=8;BPM+NK-[X[RKZ?*U%
M=58K&8OY"]Q4N.AQ`JY8*&&MJ5W<];6U\:0DRLDJ1LQ%@.1['>V<P\S2VUO=
MWVZ,9&/PF)`/SH*TZ#^X;7M$5Y-:65LYB3SU<?SKT*'^R/\`17_*]WB?_+DN
M]_\`B-^^SH\Q[O\`[_B_W@=%W[KM/^49_P#>O]GKW^R/]%?\KO>/_I27?'_V
M>^]?UBW?_?\`%_O`Z]^Z[3_E&?\`WK_9Z8MS_!_JIL%7IM:O[G7..D(HFJ_D
MMWG%$/\`*8#56EGWO4PQS&C$@C+1.H>Q(M[3WG,V_BV=+.]A2Y)Q6,''[.G+
M?:MG-S%]?;RB#SHQ_P`AZR;?^#'4=-BXDW!G>Z\EEGEGGJIZ;Y%=ZTM+#YY#
M)%14L8WX)&IZ*,B-9)/W);%B!?2/6F_[W'`HEO8I)3DG0./IP\NMS[7MWBM]
M/;2>#Y5?R_;TD9OA;U[%V32X[[COE]G5..GKHZF/Y#=WR444M)C_``RT576#
M?AGIZM\I)')&K\2H3H)".`E3F/F3]\`23Q?0^'CM'\\=+4VKE_\`=C_H2?7^
M)GO-/RSZ=,&[/B#UQM_<\="FX^Z)L5FZ6MRF,3_9B>[4KL4**7&TL]!4#^^C
M15-&\U;K@DU"5>4<,0'(<YCYQYPVJ\1H=U@\*88'ACM`_+I?M'+O+]Y:R^);
M3>(&.=3>OV]-'^RJ]8?\]!WA_P"E#=U?_9M[(/\`7)YS_P"CG!_SC'^;HP_J
MER[_`+YF_P!Z/7O]E5ZP_P">@[P_]*&[J_\`LV]^_P!<GG/_`*.<'_.,?YNO
M?U2Y=_WS-_O1ZQ2_%#K*0^C<_?41,;1VA^17<UKL0?(H?>+_`+B`67ZBQ-P?
MJ*O[D<YZ3_NT@IY_IC_-U>+E#ELR+6":O^F/2AP7P]ZTWEM3(8_$;K[GQ.[L
M/GH:'+9B?Y`=WUE*M#-6/6J]!!!OI::2HDPLBQJDEFCF0^4`$%AOM?.6_P"X
M[:'AW"+Q5(#/H&*^5*9KZ]$EYR_MMI?E9K9_"(.GN/#]M.A@7X0='(D8.0[Q
ME9(T5I'^1_>BM*R`*TKB/?BH&<C4;``$\6%O9^O,.]!$\66(/3^$9^?#S].B
M=]JVK6_Z,G'R8_Y^B_9OXE;`HLUN'!)N?N^CJ,7DHJRBKXOD%W)6TDN/R;U%
M=C,?54\V]A()*>B"15$=UDL5D23U"P$W?G[FO;]T:.'<H!`&P#&IH/GC_#T)
MK'ECEZ]M82UO,&IDZC_GZ7.TOC%T1EYSA]QU'<6(SA+R43TOR5[]_A&8IHXO
M)/)0U-9OQ'AK*,(YFII'9Q&/(A9-140[7[B;EN?:]Q`MY_I5`(^7`=$^Y<IP
M6;+HMY&LZ\0QK_AKT)/^R0=$GZ5W>!_UODGWN?\`Y?O9W_6'>/\`?T?^\#I!
M^Z[2I'TSU_TW^SUR7X2],4[>;'9_O_$UJ<T^1QOR6[QCK:.0?IGI7J-ZU4`E
M1N1KC=?Z@CWL<R[HM"\T9_V@X_LZU^ZK,X-NX!\]7#Y\>N%-V+VY\1,[@6[2
M[!S/=GQ@W%F\7M>L["WG3T"]J]"YC.5D>.P&1WOGL524-%O_`*QR>3J8J2IR
ME1!#D\5-(DD[S0:F4]VW=?KP8980EVHJ:'#5]!Z_9T675D;*72DYDMSP)XC[
M3Z?;GJRGR1_\=$_1Y/U+_F_^.GU_1_C]/9KTQU__T-LSX3_[E.G]S[XJ_P!W
M/]F=[=^[SW/6MS/6923M/<NWZ59)?U-#C<'@:2DIU^D4$"HM@`/8(YAF<;R2
MJ$B)0!\P1GH^V8GZ/]3!9B1]G4CO;;&,QM9AJN+%Y>7'9S/5V9SDE*U*:$;A
MDIZ.%<_65$F13-3U>(Q%`[14,5/)C?!Y#.4'#1QS#%;6[QSK#I\8TKY5/0SV
MB>2X#*.$8J#\ESP]/7I#'##:&<V1C,GCS@*F7#M693[O))DC79J=]QX>/*_Q
M$3U4<AS,;Q,MY&\321PJ3P"$=ZL#MTUE;LFES&21]O1_M]Z-PMKR97U#Q13[
M*'_!T(_^^_WUOI[*.GR".(Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KEB<#4[
MRS<FW7CC@P])!C,IG*AZF59\ACI*V;_<7004Y23_`"J:@,53)(\82&3TK(3[
M$7+&UIN5^UQ+BTB^)?GZ_GT5[G=FS5$!H\@-/GT:2RCA51%_"1HD:K?FP5%5
M1S_A[E#H"=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0,]M8I:2&CWNM1/''A4AQV
M<A;PR42[<J*N2:JKF1U^XBFH:V6-V>(DF(&Z,%%@QS/8O<0"\A4M(!3'IT(-
MAO/!E-I(:1MFI]?+H/\`\`@@@@,"""""+@@C@@CW&G0OZ][]U[J)745/DJ.H
MH*M9'I:N)H9UBGJ*61HW%F"5%++#40M_M2,K#^OOW7NHVVLACNK\YA(\/!C,
M?@<PZXW/8]ZJ:GD%+]W!(^Y8$8M3U-9BO(?/-4.A,$C7=FTJ1-RUN?[ON6#-
M2-CDGRZ+-VV]+VS9N,R\!YTZ,?AM\;5SRU34.9IPU%YI*B&M2;&52TE/"E1)
MD8Z3)QTE3+BS3R!Q4A/%I/+`@@2#!N%M=)<R1W"MH6N#T$)[*:W:W5XF`8TS
MT7*FK,IFLON3<U?/3-2[BK:>?%4L$%5&]'CL=%)CJ)&GJYG:IIZREA2JCM%`
M4:=P0P((B3<+EMPO;J60]K.?LZ'=K`EM!%$A[0!U$W#@J?<&,GHY5I_N5AJS
MCIJM9YJ6EK:BDFHUJIJ.*HITK5BBJ&M'(2I_%CS[2KVNA!X$4_(]/$5P>'0B
M;3[4;%5F/VKO>IQE.L>%22EW-##7TE+**22*B@AS:RK4T&/JJF)2PE6H\9>-
M@54O'JD7:^9H;I1;7<HB9/Q-@/\`9]O06W39V@8RV:^)JXT\AT/J.DBJ\;*Z
M.JNCJ0RNC`,K*PN&5E-P1P1[%8R"1PZ#95A6HX=!]VYM7#[YZJ[+V=GZ:.LP
MNYM@;QPN2II5#K)35^WLC`64$$"6%V61#]5=01R/:_:IS;[E82#CXJC]IZ3W
M:L]C>HHJQC-!ZGJFO_9GNU_^>@K/^W*G]]O^!4__`!_'_/6?]KC_`)N_K_Q]
MRU]-%ZC_`')T_E_FZ!&J?T/^XW_&O\_7_]';,^"O_9-^$_\`$C=[?^_LW_[!
M&^FF[WA/H/\``.C_`&X5M;,?(]+[OB"9Z;:\\,JAWFS^)AIT114SU67Q/A@T
M.Q;RTS-%H:'3ZYGB;5Z+-'/-=)8-MA0CQ!,,?:<4Z%G+\@A%UXAHH0Y\OS/1
M<<E09F#M'(;/W#D\E5I08K(IN')Y.@QE+-D-O4N(H8Z#(4M=%+5RTV&FGJU2
M"D>0*C4C3A5:VD';S!<V^Y7$=QXC%0.XCM%1@`]"VSF@FL+=H$C5<U"GB?4]
M";MZHJJK"8V>MN:J6F1FD96CDJ(@66EK9(7]<+Y"E"3E#RADTGZ>RL]7?RZ>
M?>NF^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KM1<@'_?<>_=>Z$[JBAB-'G\VUC5Y#-3XHJ!
MQ3T&WV>EIH`QN6:6>>6=[6%Y0+>D'W)O*T,=MMJ7/E+4M]@-.@9S"\S7CJGP
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MIQE1.8Y'EQF0AD:.>$^ET;\,`1:*>ZC9],I",*'/5T,1JLT08#(^WIUN2+&W
M^L/H/];^@_P_'O6D+VJ:KU2I;)%#U[W[KW2?W13;BK<-/0[8JL=29&KDCIY9
M\HLKT\>/FO%7F+PI(ZUAIV/B8JP5[&WO:N(V61JZ0033CQZJPJI`XTZ&C`]J
M;,I,72468>HVC-CL?1TXH\M23?;M'31?:LV,JZ*.HBKJ6%X=(8+'Z60Z1J'N
M6K+?=KN(25N-%0H[AIR/+/0.GV?<*RLL.H$^1J:?/I;[AJZ6OV1N'(T4\550
M56T\Y4T]7`WDIYH)<+6/'*DJ^@HZ$$&_Y]G5E(C7=E*#^F)4-?(Y\O7HEEC>
M-9E<494)(_+K7)TG_P!H96_XW_K>YP\%_E_N9IX^?0&\1?\`JE7K_]+:M^'V
M5GP7Q,.9IHHYY\;O'Y`UL$,NKQR3P]S[_,(DT,L@A$A!DL;Z`>1]?<>\TW1M
M;K=KM%JT:B@^=!3\J]"38D6X7;D)HNH@_96AZ&[KW?F*[(>'$9W$TN2W-MFK
MK\G+7T^*E;;\$V.R4F,H,KC:C(%Y:*NKHW)2(%RK1RZ790"0EMNYP[]$DMQ;
MQ^-'QH.!\J?GT(=RM+K:9)$BT_32`TKYX^7IT@>SL8N?WQ74T.4S!IZ%,=29
MJEG&+CQU-23T$53-BL0JTK960Y>&2(U%1(RA5:2.-R"5`5YG>);DQZY3.V34
MC1^SC7HXV%)X[.!I1'0@TTUKY>O63^O`%SP`+`?X`?@>PKT>,P-.N_?NJ]>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7)/U#_8_P"]'W[KW0B=9YW"4&"KZ6NR^+HJ[^]6?:2A
MK,C14=4C55;JI=4%5/#*14THCDC*A@Z,"">?<H[`\/[BA5KA`R:A0G)U&O00
MWN*X:^E*0,0R#^7GT,'^^_WQ_/L^=]+*H%:]$BQ%D9RP%.O>[]-=>]^Z]U[W
M[KW7O?NO=>]^Z]TE]U;4H=UT=/!4U-9055!/)5XW(T+1F:DJ)8'IY"]/.DE+
M64\L4A#Q2*0P^A4V8%NX[9;[I;F"XKJ\B/+TZ66M_<VS+H8`?Y.@+RF-RFW<
MHN%S)HZB2II)*[%9/'P34])DJ6"18JQ'IJB:HDHZ['O+&9(Q)(I29&4VN%C?
M=]FGVB9(I)5D5EKJ4$#[,^?0XL;N.^BDD04930CB?M^SJ+[)^E?7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UU[T=0!TD:OGU[KL$J=2DW_UR/K]?Z_\`&_?D`U!I
MAJ^7E7UZVI*FH8@_+I$[KVWCJK;V6\T^5DIZ#!;A,-!)DZN7'&FFQ>0E.-:A
MDE:F_A:5DOW`A"_Y]$8DZ0`<[=N%Z+ZPC6X;PO&3M/`=PX=%^XPP/97SM`E1
M"YJ!DG3YGJH#_P"\76_/^W_5]?\`>?\`'WF3XC>O_$FOY]0)J3^'_0:_['7_
MT]HSXUUD=!\+*ZJF9UIUWKW=#4B-=<CT]9W]O"CJ840$,6J*>=H^"/U?@>XR
MYX5Z[Y%$*R-I`KZD"G\^A;RG&KR[6KFB'4Q_VIK3HW?6N!JL+MNGER]`:+<>
M4FGKL\)7BDJ3,)YXL?!(T#RP01T>,$2)!$[Q0G5I+%F9BC:-N%A:P6\D"I.4
M!8@UU'Y]&&ZW,L]W<DW!DA_""/A'RZ#+>M-)1]@9:6J#ELUBL1/B:B34?)08
MV*2GKL?3,!XPE!D9#,Z?K_RM6Y!X`W-<>G<0U?PTZ$.QRB6R44`*8^VOF>F?
MV&>CGKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHE704=?'+%5TT$HFADIFED@A
MDF6&5&C=$D=&8#2QL!]/Q[T%C5@RJPR#34:$C/5&0O*)&?RI3Y=#[U[DY<KL
M["5%2RO5TL,N'K'!_P`Y58.HEQ,TQ_M*U0:,2$&Q!?\`V\R;5<)>6D<_JN?D
MWIU'^Y(\%U)`J]H:@^:^O[.EI[7](^O>_=>Z][]U[KWOW7NO>_=>Z][]U[I!
M]BX&3-;>>HHX]>8V^\N:Q(^AFD@@D6NQS-=0(LKCC)#_`$60HY_2+$^^V*[A
MM[H<2H=0(XGY?9T:;3?/9WFJ@,<@TD>E?,?,=`71UM)D*>*KH*F*JII5NLL,
MB2`&P+1N8W<)-&39U/J5N#[B8I(CRHZTTGH=,RU30:J1U*]ZZWU[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]TC-]9#+46W\PF,P,N8CGP.X%JIXZZDIEH%3%
M3E'>"=EGJA,':PC'!0@_477[6FO<;'/^C)_QX=)-P_Y)VX_\T'_P=4^_[?\`
M[<7?T_/]/K_QKWFEH'K_`,2>L?/^V?K_U-JSX@;>I=V_$Q-M5LDD%-F=[]^4
M+U,(C::E,O=F_&BJH4D!1Y::6-7`;@Z;<7N`%S-#'<[CN$4M=#:2:8.`.!Z$
M>S2R6\-C)$>X*P_;QZ.K20?:TE-3>62<TU-!3F>8@RU!@A2(SRZ0J^2;3J:W
M&HGV3(2FC).D4SG'1@R`^(QXMQZ+[OEYE[`K17&=?+A,<-MBH#"GEH8$#Y]<
M>W^98Q9*6-JGD2\QW&@+:.^:HY?KED;^S(Z$^P/#](\:_P!KJSTQ7OS_`%Y_
MI]?\#S["W1[U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NM=9<1G-Q[=.;I,
M&,7!39JJHZ\Y"K,U3+CYX:):.M--B`J4T]55B&(B5YM`*W=)#Q[$&V<P3;58
MRV44=7<U#$5`/S^7RZ+I]LBNKI+FZ!*A:$#%1_G^?2FQ78FY\4X7+T\6ZJ!K
MDS4RT6(SU-]?]T_Y-ALG#^;:J21/I^Y[-K/G`@JE[%5CYJ*#I#<<NQ3,38,5
M7T8U/[>A4VYO#![H^XBQTU1%7481ZW%Y*G:@R=+%+Q%,]+(6$M+(P(6:)Y8F
M:ZZKBWL66FXV]ZM8)`6I6GF.B">QDMG*3(0/7I4>UP-1TDE0)2G77NW377O?
MNO=>]^Z]U"R.1I<305^3K7"4F.H:NOJF)``IJ2%YIC<\7T+8?U)'MN21(8Y)
M9/@523TY%&\LL<4?QL:#[>BGX2@AHJ,RK24]!49#PUE504=/%1T-!(T$:1T%
M%1P*D,$%#"JQ7YDD92\C,QO[ANZNI+B21W`H[FE!3`ZDE(!%!;*"=07N\\].
M_M+U;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IGW'_`,>WN3_PWLY_[JJO
MVNVQBNXV-/\`?R?\>'23</\`DG;C_P`T'_P=4Q?_`'B_WFCJ/_9QUCW_`-:.
MO__5VS/@M_V3?A/_`!(W>W_O[-_^P/OW_)7O/L'^`='^W?[BV?V'HWM_]];V
M2:-8*KQH?\'2LS,@+,V.@)[?KHAFMBXJIHE,<U;E*ZCR(CIJBI&1BQ\U-'00
MH":ZCI?MZB2>><+X6*1QDW/`(YM8"*R0C]0Y)]:="+EL!O%E#>7#I&V`X%[#
M@7^MO\?\?8&Z%?7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][L'905!P
M>K^(_P#%UU_R/_B??M;:2E>WJGXM7XNL4BU"U-#D*&LFQ^5QDCRX[(0+$\D!
ME0QST\L4Z20U5#6(;30N"DEE/ZE4A19WEQ82M-;3A'(H:^8XTZ;N8H;N/P[I
MNT</MZ65%V1NR@*ME*#&;BI(P#,^,27#9DH.6:"DFGJ\75S``D(9*</]`02+
MBJTYON*B.]@0+_$O\Z]!V?8!)J>*X-1P'2R/:^S]"O"V?J=04Z(-KYWR*6`)
M1Q+11('0FQ]1`(//LZ/,^UBG^.T^6@M_,?X.BZ/9-P8$F#SZ<\%O_;^X*]<7
M2C*T5?)%+-34^7Q-1CC61TX5JC[2677#-)`C:VCU"0)=M)`)"_;]WL-RD,45
MS5O6E/Y>75)]IN+=0\JD5Z6GXO<#B]R;`<7N2?H![-6TKJ!;M'G\O7HK(.K2
M.->B[;LW4=YSMC\=,&V=0U,3R3H23NRMI7699%D`L=N450@\84VK9DUD^%5$
MD=\P<QFX8V%BQ^G&"X_&/0]"[:-J-OHN)%U7(S0_@^?V],C&Y)YY_KR?]N;_
M`)]A$YTU\N'RZ$)9C6IZZ]^ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
MS[C_`./;W)_X;^;_`/=55^UFW?\`)0L/^:R?\>'23</^2=N/_-!_\'5,7_WB
M_P!YI?\`;1UCY_UHZ__6VS/@M_V3?A/_`!(W>W_O[-_^P/OW_)7O/L7_``#H
M^V[_`'%M/]*>C2;BJ*NCV_G*N@JJ*AK:3$Y"II*W)`G'TD\%+)+'4UH`8FEA
M9-3\-P/H?H2*5Y(XI9(F`<*2"?+''\N-//HPMA&9HQ**QDYZ*7C<WN#=-?3Y
M'*F@@SDV.?%4E9GHZO#T>Y*?&R3Y&EBHJI:!$P^6,-5*=#4T=/D$16"K+&X,
M;211[^$:6_)N$#9(TB6A^*A^$CAIQ7H9V\<FT(H5:P2&M,5%?\G3Y0U*UU#1
M5ZH8UKJ2FJUB8AFB6IA298V8&S%0]KC@_7V&G3PII(2>'1RQJJG@3Y=2O?NJ
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]Z(!XBO6B`>(ZZL/
MZ#WOKP`'`==DW^O-OI?WX8X=6U-_$>I&+J8Z'<VTZRH;QTR9Y:6:<FRPG*8W
M)8RE=S?B)Z^MAC)-@"XOQ[.N76`WN$DT71_/_/T@W74;"8@5;HSWT^ON50R$
M4U`^O4>!@NFK4..BZ[NV[3[3SM+'CE,&#W%%6S4U)^J'&9JC:.>KHJ._J@H\
ME23>>.$72-X9=(4,`(YYHVE;6=+U*!'-*#A_FZ'>QWGUD$L;-W1BOS/^?IC]
MA;HVZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z\.?IS_K>]Z6I72:=>.!4X
M'3-N5E3;.Y7=@B+M[.%G8A54#%5A)9C8``?4GVKV[.XV%/\`?R?\>'22_P`[
M=N-,_H/_`(.J8O\`[Q=?_8?U]YH:E]1_N1UCY_UHZ__7VS/@M_V3?A/_`!(W
M>W_O[-_^P/OW_)7O/L7_``#H^V[_`'%M/]*>C<30Q5$4L$\4<\$\;PS0S(DL
M4L4BE)(Y(Y%9)(W0D$$$$'GV2G0<.FI3BGV]+$$A8>$U'\C]F>BL;SV[AL#N
M.79XA2OP&Z:"NS*84T4K4N`A5_MI:%V!-)%AJN6)FI2IC>&HU)Q>,^XWYBL!
MME]&T;BC$MI_(Y],=#39[V7<+=2\1+1D#5_DZ8L918_;^)V['!75$$+5&ZL-
MDJ?)5324E*NV)H1C*BGJZN9VIZV7'5],)8P?#+$#+I1D8N6W]O"MEMMVA_6=
M2''I3A7]O2R">6:]O4?X5"TK\Z]*+V3@@\.EG7O>^M]>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3;F(9*C%UT4,;2S>`R0QQL%D
MDF@9*B%(BW`E:6(:?IZK<CZ^[P2FWFBD`X2`G[/7JXCBE29)&`K&0/F3T(FU
M^S=Y9FNQ53D-GO)@,_7/2T]1A()\C+A-<CQJV5R%+5UM&7Q\BA:Z.HCQ\L%V
M8(=.DRA8[IN-Y<+XVVH-MQ^H@'[3YU]<=`BYVRPM[7Q+>=6O0U"KUK\Z?Y.E
MWV)@JK-;=,F.ION\MA*VDS>.I5*B2K:CUQ5M%$6('EK,743QQ@\&5E]^WZR:
M^V^:)%+.CEE'KTSM=P]M?4<4@)R?+H#HJB"KBBJJ9B\%1&DL3,K(^EA]'C<*
M\<BD$,I`*L"#R/<5L=+:&^*I_EQZ'94CB/\`4>LGO?6NO>_=>Z][]U[KWOW7
MNO>_=>Z\;!69B%1069V("HJC4S,20`J@7/\`A[TS!06/#JR4U"O#IRP>V]P;
MJB%7AUIL5A9#:+/96&HG>OC)]4^%Q$)@>K@%CHGGFAAD-B@E3DBFTY7OKA(Y
M9[B2*`TJ`*FA^7H?7HEO=]%JS+"JR`8->`_V1TF=_8P[7Q>\#5;*SF>QN/P>
M723=>\\G.=NU$QQ$[I64.$V_15.,HJ.GE>PGK(8U\@-](&LG=O9;;M.[;?X6
MT2F)9HZS$U!SZ>5#\NBF>YNMRM;M([Z)',+T1<$XX9_S]4P7_P`!_P!N,=7Z
MA_Q7]/\`M7T]Y*T'\!_MO]0ZA[PI?7_B/I_VW7__T-LSX+?]DWX3_P`2-WM_
M[^S?_L#[]_R5[S[%_P``Z/MN_P!Q;3_2GHWGLD9%D&AV(4^G2L$@U''I`]A;
M8FW#B8*C&_90YW#5D>1Q]95PU$O^31C_`'*8X&EO,$RU$IB(TR('TMH+*I!5
MO>V+NEFZ8UQC4#YD#R_V.C/:KTV<RI7])N/V]`-A9(<[0T^#K*6@J,)V3$E/
MHK:.#*MMO=>3PSTM#FJ!Y`BRQI)"M+4HI1Q*$=&4EU(0V6^%SKV.YM@%<&A8
M4(T_YZ]">^@>%VW2&0:XP#I!^(>=>N\4U7+22BJEBJ)J6ORE`\\4!I5D&,R%
M30ZY*5IJAJ69_MB6C+L5N+\^P]?1QQ7#Q1?V:F@_;Y]&2.TL<<KJ`[J"0/*O
M3A[2=6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MNOZ?X&X_P(]^Z]U@P%7G]I;@RNX,97'*4^52EBK-L31P4-'-#2I99*:MB1G&
M;#?IJ9UD#I:)M*`,IYLF]3;7,4=BUH>/R_+I#N=A#?JH0:7`_:>A3W1V11G:
M=#6;=DKI:S=$-=14%5CUQ]57;<JH:!IZB;(XVHJ$+5^,9@'I`3.75M`8J+CJ
M]W2SBL3<>-AUQ3)_9T&(+2XEN9(!"=<9S7`QZ$\>@@PI!Q&-TTTE(JT<48II
M3(9(O$/%9FG2*H8.4U`R*DK!@74,2!%;!6[C\>H_SZ'+.&R/X5'[.G3W7IOK
MWOW7NO>_=>Z][]U[KWOW#KW39DU?(0M@**.2LRN7$-/!CJ:-YZB6FGJXJ:KF
MF2-7$%"D!<232:8@+@M?CVOVVUEN[FU"0ED+BOH!QSZ#IF\(BM99&D"U7&<G
M[!Y]"YN3LB:GR$^*VA2X^M_A\CTN0RM?YOX/1U$1\:X['T]$8I<E5TP'[Q$D
M4$)'C+-)=5'>^<UC;Y%M[2,,P4#Y"G&I]>@O8[+]2)))G/ADX]?^*Z160[`W
M,*#(46<;$Y3'9K$YS$214.*GQ]92U%;@\F*:HA8Y*N%7212H/.C+J6$M)JLA
MNUR]S1<[EN]C:W-HO@-(H)^=13IO>-DAM-MN[N*X(DC7]M<=49W/]1_VXOM_
MQOZ>\G]?]$?[F5_V/LZB7'J?[#TZ_]';,^"W_9-^$_\`$C=[?^_LW_[`^_?\
ME>\^Q?\``.C[;O\`<6T_TIZ-Y[)NE73)N:MJ\9MS/Y*A5&K<?ALG6THD&I!4
M4U%-+"S+<:E6102/R!;_`!]I[N1H;2YF0]ZH2.E%I`MQ=6T3'!<=%.Q,;;?S
M>-S^3K<KDL'3UT6Y<FU)%CY*YZZ%9*DUM52NU,CP^9_-*])XYFT!7BD;]SW&
M>TWT-QN,5U>(?&UTJ*`9Z&FXP'Z">.VJ*J0:GTIP_P!GJ9E,%@ZO<N[J_$FI
MQPK,\*VGK\+53X^605^(Q.1J)94(:GJ?NJRJ>9XZB!]#NRV!'"??4A7=KWZ<
M4B+5'[.G]OU_0VKN:DK^RF*?RZPB/<M$1X9\;GHUN6CKT;#5^GZ+HJZ2*JQ\
M[G\EH(>?[0'LIZ6=='<=+3'3EJ+)X0@V::NI?-CP3]2,ICGK*)$']93%_K>_
M=>Z>Z2II:Z+ST5535D/)$M'/%51$#\^2%W7_`'GCW[K766]_?NJ!B30K3KOW
M[ISKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ]^^WAU[[.H3XV@:OAR8
MHX%KX1(J5:*8Y2)4,;F3QE4F?1PK.&9038BYO<M50A+:!P%>'507J6J-1XFG
M'J=>_)Y/NG5NO>_=>Z][]U[KWOW7NO>_=>ZY*`;EF"*O+,?HH')8\CA0+^]@
M$D`<3UX4)H>'43&YFJAP\V-P\\M-D-S1P97=F;@<Q5&/Q-3&_P#=[:N&D`#P
M5<N$9*BIG_5"M42EI)5,8MNK\[380VMC07CIWN>'V`<0>BE+9-PN)I;JIAB:
MD:_9YGU'4>J$F/QCIB,>)Y*2G6.AQL++$CD,%2-6>1!H0L78%M3`'DL>0H:2
ML`TFG4U6)SGHT50F%^'ILILY-C#F,AF<-4U8?;>6V_2SHD>+BP];N&EK:)JN
MCIY*G+_QN=XUA5Y4FB2""5U4.QD"C/ENXL+/=MOME_5EDEC`<8`.KS!S^SHC
MWZUN;S;;E5<1JBLQ!SJ`'R_R]4U:3_M/_;C#3_QK_@GO*7PW_P!^?\2*>?'U
MZA34G\/^@U_+TZ__TMLSX+?]DWX3_P`2-WM_[^S?_L#[]_R5[S[%_P``Z/MN
M_P!Q;3_2GHWGLFZ5=)/?E9!0;)W;55#Z(H]NY=2UU!US4,\$2H&*AG>65547
MN2;"YX*3<"B[=N#.U`(C^WI=MBEK^U`%>\=%PK<5'E\4N/J9JBD21:!WDHY%
M27_)9:>I,22R1L#%*8=#>D$H3]#8B%0E%&AR*D-7J05*]V*Y8$'YTZFT]-#2
MQF.!7"M)),[2335$LLTSF26::HJ9)JB>61VN6=F8_P!?;\LC3.9'/<>JHH1%
M11VCJ1[;ZMUVK%22#:X(/U^A^HX_K[]U[IFK-OX.MD$\N,IXJH<BMHO)CJX'
M^HK,>]-47_UV-_S[]UX8(/448C*4Q_W'[CKBJ@Z8,W34N9@M_93[A10Y0VO]
M6J&('OW5]2'!6@ZYM6;EI@$FP^.RBCDS8G)_9R'_`%J'*Q*EQ?\`Y63?^M_?
MNM'13M.>N)W)1P`?Q*BS.(/Y>NQ-6],.;:FKL>M?0HG^U-(H]^ZKU.H\SB,@
M;4&5QM8UKE*:MIII!^#>-)#("#_4>_=75014].=FXNIY_J"+_P"MQ[WTT^L,
M0H%.O6-[6-[7M;FWO76_MX]>]^ZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2
M([(WB>OMB[GWHN*?./MW&BNCQ"5L>.;(S/5TU'#2"OD@JDHQ)+5"\AC<(`38
M_3V]!"]S-!;Q?VSO0='G+.RCF'?MOV>6\%M!-KK+I+E0D;R-2,%=7:O#4/3Y
M]2%Q/R0D-7X>I>IY?X>DLE>8_D91/]BD-54T,SU@7K4FF2*MHYH6+V"RQ.A]
M2D`>M[9\P@_'`/\`3/0_X#TH-][*BE/<C=S]FRC\_P#EH^O3M_<GY7_\^*Z^
M_P#1]K_]K#W7_6TYBK3Q+?\`WL_]`]:_>'LM_P"%%W?_`+DZC_O(]-4NS_E+
MF<74IC^F>M)X*M6I?NJ7Y`Q5,#+Y%CJH/-!UF5!DBU1-9@REK\$>[Q^VW,"N
MC^+;$!@?C/D:^G6FOO94@H?<C>!44QLHQ7%?^2CT@LWNOM;KB?;8WWU=M%<3
MN+LV@ZVS&0V#VU1;VRV"WKN6BKLW!25>VH=F8:0>*"%%,+5$4D%,\1(T`7+>
M8>3]ZV>VDW3<I8O!>:BA22<\!GI9M^T^W.];?O*<I<^7MSN^W6+7)AGVSZ99
M(D=5;]07LVER&!%58$U%.A=Q^1I,G%)+2/+>"9J>IIZB"6EK*.I0*S4]72S!
M9890C!A<:71@RDJ0?8/4@5JH((Z"/35NVCCJ]L9Y6DJ('I\1E*R">DGDI:B&
MIIL;5O#+'-$0RLC?[#VLVAO`W/:G0=R7"'[<@4/23<,[=N(_X0_^#JFVY_J?
M^W%_^\_ZK_@W^/U]YF>'_2/]O_J/6/G_`%HZ_]/;,^"W_9-^$_\`$C=[?^_L
MW_[`^_?\E>\^Q?\``.C[;O\`<6T_TIZ-Y[):@9/#I8H!8`]`WW+.:S%8O:D5
M0*>;.5DE=/40K&]?CZ+"1BJBR%"9`R4M4F8>F6.9E;2UP`3>P1YJOGAM&L@:
M/(<_Z7S_`,F>COEVW9KDW#_@!(^WRZ#N-3'!#&TTE1)''&CSS!!-.R(%::7Q
M(D7EE8:FT@+<\`#W'8&E54<`.A@%"L[#BQJ>N7O?5NO>_=>Z][]U[KWOW7NN
MO?NM$5%#UZUO?NM!0O"O7,2.OZ6(XM<<&W]+CW[JW396XC%9'_BX8S'UQ_U5
M714U0_\`KAY8F8'_`!!!]^ZV&(X=01MC$Q*#1-D\6ZCTC%YG*445QP":9*IJ
M-BH^EXR/?NK:V^77?\*RL7_`3=&42_)7(4>'R48/]-7V5+5$?]/#[]U0FIKU
MV(MS0_IR&WJ\?@5&,R>,D-OJ#+3Y'(QW/]?'[]UO7$<`9^WKL56Y$N'P>*G/
MX-'GYE)/U/HK</3J!;_:_?NM==-ELG'I\NULKJ'ZA35^"JK_`.`U9*F9O]@+
M_P"'OW7NO#.L"/+MW=$?];4%'46-_P"M'7U!_P!X/OW7NN/]Y*--7FQ>YHN?
MHVVLS);Z6&J"EE1C_B#;W[KW7!]T8W2VFEW$KZ6*AMJ[C/(4D?IQC+]1_7Z>
M]].!00#UPVQF*W*XNG.7I8\?GH$IX\KCXR]DJ)Z."NCEIX9O\I2GGIJA6`<!
MD;4AY0GWZG6]*^G2F*L+74K?Z:AIU?FXU6N+>]=-==>_=>ZQRS04T,U35314
MU+3Q//45,\BPP4\,8U233S2%8XHHT!+,Q``%S[LHU,%\SU4AR*KP''[.FW^(
MSQ4^#K:S%9.EI-T^(;7FCCAR"9Z2J_<I*6C2ADFFCR%13'RK%*J:H@SJ65&(
M6S[7>P+"[1$I(:#IN.[M)BZ+*%9%):OH.G"GG6I68JDT,E-43TE535<$M)5T
ME73,%GIJJEG5)H)XR1Z6'*D,+J02CDBE@=HIE(D4YZ=5D=$DC8%&%13K-[IU
MOKWOW7NO>_=>Z][]U[KWOW7N@5^1G_,D.Q/Z?PF@O<7%OX]B;\?GV:;)C=K%
MAQ#BG[:=#CVXSSCM0]4N!^VUFX>AQQZ'WO;H?HWK^BW)W1OO(]J+B*?/BOR$
M^V-P+31;/@W5O"7.Y"HI*.AIZ2JJ,/5;JSM7Y_,]7/%#E9HDM`=*99-([$5<
MX%.L3F4.:R=Q'F<FG&E3Y#R'`=%0Q'^R(9^CW+G:;N'Y+U\FXH8\+EZ6HJ^W
MMS/L_.&EW'A%BH@NU\CCJ')8)<K+!"\9FI()((G4DN7DKJ?^,_R_S=>"J,!1
M3[!TJMIR?#K"[GW!AMH=P=N9:A[`Q[["JL+B,5OB26HWCV5FL!@COROW(^%H
M\)4Y&HH,5II9:B,E<?/D68RT[+%%[4W\9_EUH11$T\-?V="UWIT]M3I+8/1F
MUMH-E)*3*?++:&Y,I69FL6OR>1S62VMN6GKJZKJDB@5WE7'1Z0%`C`TK90``
M![DOIY5FP#_C$0%16@)-:>A^?4T^S"J+KW`(4`_U;NN`I_HL'&G'CU@911;I
M#6'BS^,$6HZ1;)8-F>.,LQN9:K&5KD<_II3_`$'O'KHQZR[E98]L[E9V5$3;
MN=9W=E5%5<36,69V(4*%%R;VMS[,-J4-N-C7_?T?_'QTDW#_`))VX_\`-!_\
M'5,EQ_4?]N+K_7^S_7_6_P`?>:6D?]G/6/>?^J'7_]3;,^"W_9-^$_\`$C=[
M?^_LW_[`^_?\E>\^Q?\``.C[;O\`<6T_TIZ-TQ`4LQ"JHU,Q(4*HY9F8\*J@
M7)_`]DC4TL2,`5_9G_)TIR<`Y./VXZ*W/E'W%D\EN:1F>/*2BGQ(<$>';M#)
M+'BA&IYC6O!:L<?VGJ.?H+1!NU])N5_-=ER8JT4>0`\AU(MC:"QM8;9E_6`J
MQ\S7UZ][+NE?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW0=U&X^QLMV)7]==:=8TV_,EA]EX;>N:K,AOS$[+I:&BSV;SF$QU+3IDL9
MD9*^>2;`S.[+H5%*C\CV*=DY8O\`?3,NWM$'C4,?$%>/EQZ$`VW8=OV"SYBY
MBW]K**YNI($00/<`F)48M5"NDD2#%2?+J=D*;Y(8F6FARG1&RL9-6?\``2+(
M?(79U%+5?Y70X^]-'4[>C:<??Y2F@]-_WJF)/U2*"<_ZV.^'_1T_WOHK^K]M
M0<<_25_Z5\__`%LZG0X3Y13O41P?'G;$LE'.*:J2/OG:SM33M%#.L,ZIMDM%
M*]/41N%8`E74_D>_?ZV&^?[^3_>^K?7>VX_\&!+_`-R^?_K9UB?%_)Q*V+'2
M?'_:29*>)IZ>@?O_`&FM=/$@?7-#3';8FDCC\;`L`0-)_I[]_K8;Y_O]/][Z
MU]=[;_\`A0)?^Y?-_P!;.L-;2?)3&56*H:_H3:%'79ZMEQ^%I*GO[:D-3EJZ
M"AJ<G-2X^)]M"2JGAQU'-.RH"1%&S'@>_?ZV&^?[_3_>^O?7>V__`(4"7_N7
MS_\`6SIEW[D_D5UOLS<^_P#=GQXQ5/MO:&&K,_G)\?W5MFOKH\9CHS/6/2T2
M[<A:JJ%A4E4#@N0%!N?;-UR!O6W6-S>320&WB4L?Q-0<:&O\NCC8+/D7F3>M
MLY=VWGB22_O)A''_`(E-'W,"`-9=@`33\/0EJ=2H_!\B(]P+'2ZAUO\`7G21
M?\>P-(H1J#A0']HKT'"&0E"<C'VTQ7\^/3978+#9-C)7XRDJ9RL:+5-$L=;&
ML3%H_#71!*R`Q%B4T.I4DV^I]TZUJ/KU";;5)3`/@:BJPE9:QE26?(4=40;H
MF1H<A4S)5('/ZE>*=03ID'OW7ER1U@GR&YJ*)ZFNQN!BA@TI+IS=<#/(Q5$:
MDC&&F<"HD8".%BTS,0HN;7<12[!%%7.!]O3Z^&"2X[`,]"EM'KZKW"E-EM^X
M84%&((YJ#:4];+/*T_W"S"NW&M*U/2U"^&)4CH7$B*LCF8%[(@YV;ED0@3;@
M@-S2H0\`/XN@KN>\T=K:S)$'\8XG^C]GGT-:T6(D6"B6DQLBXAZ.2GI4BI7_
M`(7+3QE<?)#`FK[&2"&_A("E4OIX]BX+#*J1F,%8R"/D?(]!F3Q(W:36:N"#
M\QYC[.D/N7KJ+-YA\U09F;`RUL,$.9C@H*:M7(&E]%/71_<RI'1Y".G_`&FE
M*RK)&B!EN@/LIW'E^RW"YANI9M$C5P/Q$>O1IMN\RV40M3;AH1P8^5?+[!T4
M7*]V=8;-RV0VAOC?V"P>\=N3+0;CP]::H5M!6&)*FG>ICHZ2>&-,A0315,)4
MZ7BE#*`#81O=V%S#<S0M"ZL&.!'(13RH0*</3J9]I]N^=>8-JVW?-IV"5]LN
MU+1/JC02@,5)0R.HPP*G'$'J#_LR/0W_`#]3:_\`K_[E?_K=[8^EO_*QDI_S
M3E_S=+#[4>Y`)']4KK'SMS_/ZC/V]>_V9'H;_GZFU_\`UJ__`%N]^^EW#_E!
MD_YQR_YNM?ZU'N1_TR5U^VW_`.VCKW^S(]#?\_4VO_ZU?_K=[]]+N'_*#)_S
MCE_S=>_UJ/<C_IDKK]MO_P!M'6*;Y+=`T\,M1/VQM.&""-I9YYI<A!!!$@+/
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MF:HK47=D!\\&R!Z#;?O>7R?Z_P!O0YH87XH5D>0WAM#`S4E+U]V-2:ZK>^[L
M9MYLG*_]\V$CP569^XEN"\NEA?4U_>A[K;CFNWVU*?Q/_FZ$?+GMK[1\QW=]
M:B'F.%(MMN;K4;RQ/^XT+S%"/HQ0D(17RK6AZ5;[]^3-##4-)1_#^DI34MD:
MN1NM>PX(/N1*)GR%2QWLL?G$HUF5O5JYO?WX^ZU^`2=OM_\`>G_S=$(Y7]GC
M2FW<S?\`998_]L?28W#F?D/W0_6\_8V8Z:H=J[/["QO8BTVS=J[[H]PY4X.E
MSF.Q<$53N'=61H*.DR5/E!.Q:`R!"!^J_LCW[GC<.8]N&W7%E'#&662HXL%K
M2G[>A%LZ^VW*D',IY<V[?/WQ?;=):CZJYM6C19&1C)HBME+4T8`=:\>A(R6.
MH\O3/25L/EB9E>)E]-12U*`B&LHIAZJ:MIV;5'(I!!_J"00030'H'J*LOI7J
M/MW;/]XL7OV?<E9D]SX;%[;R-1B:AJ"CQNV*NNIL7E(:FAK(HH&;/5=%4P)4
M,RRO2ZV`=`4"^Q[R7M=M<7%G--:R%O&3+Y4]WX?GY]!SF7</#5[:%M*E&!`\
MQ3JES6W]?^Z&-_I^?Z^\I-8]3_N5U#7ACU_T*G7_U=LSX+?]DWX3_P`2-WM_
M[^S?_L#;^VG=;UO0`_R'1]M_^XEI_I6Z&[L_.I3X9]L4CR',;G@:F'@;2:#"
M">"/,Y.>46,2&ED:"$`ZY9Y0%L%9E`O-%]]%MS1JWZDRC[>(_/H3[/9>)/%.
MRU13Z8\^@FTJED152-`$1$`6-40!45%'`15`M;BWN+]%?U*\?+_8Z&1-<GCU
MW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I`[1
M[$@ZH[I[NW]4;=SN[$P7Q_Z;5=N;9CI9MP9B?+=N;ZP=+1XF"MJ*2FGK7J<F
MA2-I$UD:0;D>YB]J<INM?XEZ?]P,^UW)H\OWU??]6K7IM[/^5WPU[\RNV\'N
MS-]BP08@[KH,K5[<QNY<;34V*;,8;(4U#EYZ;"5$N4H]P97:&-K8DH'%923T
MT:2%5,Z>Y@TCT'4`]!#NBO\`Y>==6X3:\N\.[*=WWS+MNNQE%N3L3;=#MK)8
MF:BK"U=2_:18\TVWYJJGQT<8+"@IJQR6B$/DC]I7T'7NF'L__9+\9C-FY?;%
M9WDV-[0VYCMV]>;XP55755-MREH=P4/46\UP>,R/\,SFW,_B-J4^2S5;5"T\
MD&,GFB>HE"4T_M*_PCKW0][7[V^%</>&W^TML5N_LUF=Q8F7-XK-Y*@W&F!V
MW/5X:AV;28?$;?S&(ILC#693%9:-/(S>"F@X298BT?OVE?X1U[H5.YOD-U_W
M]\4OEC5=;U%5E,%M+KG<6)FSLU-4T,%?DW@S]#D:2FI:R""I`QE5A6!ELT4Z
MR*T;%3?V3\Q`#8=W-,?32?\`'3U)?LV/^8I<BG_I(1_Y>HM-_P`!J;_J'@_Z
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MP4/W]-!X!HI6)G4<B1ED<ZK;%O\`9@?2RSLI(J9"/C/SKPIZ=>W/:[R67Q8P
M%CX!!0A!]OSZ6^0[9CDE>/;."ES-*@5/XOD:F;"4#U!74R4])/CY\K50T[$*
M\GBB1FN$+6)'KOFRR6=E^G\4+@,<?L_S])H=CEE2LMV4:O`"O0`=7U7=>XJG
MY!YCJBEP]!O"E^4FT:S<6"K\K0T>#S6UZ7IW8<.1Q]1GJW%Y#(4>.JK0SK]M
M3/5%@(BH1I&]RCR/=IN&VO=!*1-*:"M:=H'^$='/NS;O9;=[6VOC%E'+RD<1
MQO+HUIC.<T'ET+>ULA\VY<GM.#>Z]`X1JC<NUIMVX'"5-1E<S)MR7-3?Q^/;
MLF1R5+'3-5[<Q<S0Q-%.ZSBH=)G$:I[&/=\Z=0Z#+0$EOY]8LEE_GGKQ$.Q=
MD]"9C%4.(RU+FLQOK=-5)6YS<-)NK)QTM3B6VA31TE!BI]NQ01&*:`S0U.K7
MRC*VJGSX]>U.,%C7[3U+CKOGJ=R9>E3"_&"JP>/@@J*7Q2[KBRE342S9!UPN
M4C7+S-AUEHGIG-4(YO2-21DNR1^[OGUO5)_$U/SZ:=_U'R'J_CO\L?\`3GA.
ML\3B(NE]S?W"DV5)6396K5]@9F3<TFZ(YJ[(4--41Y%46!*9F0(#9Y.""K??
M^2+NI(R+>2G^\'J1_9XR'W8]M5J2S;Y9`"O$F=/7'V_SQT6';?R.ZC7;>VXW
MS&ZT>+;N!AD4=8=GL!)%B:.-[.FSV1UU+PRDJ1R"1[Q25"$BR*E1U/&X>T_/
M[;CN$IVVV.N9R"+NS2H+&F%N1Y>H!^72HPG?W4^XL]3;6Q6X\FVX:W'UV6H<
M/D-E[XPU;D,?C&@3(5-`F7VY1"K6D>JC#B/45U`GWNA`!U#\NBG<_;OG/8-J
M_>NY[.D>TBX2'Q8IK:8"66I0.8YG91VFE0`:&E:'I&?(?<3#K_%,N/EH:=NU
MNE5CK]QSTN`H7J!VIM.:&%(JR;^(SZO&2UH%L@)O8'WL:CJXX'1[[5PSW.^;
M[%!;N[KL.[`JH+D?XE,,T!P3P^WH=I<1D,C54\NXYL;5P4,\M1!B:+'R#'O5
ME)H4J:R3(2U$M::996,2>.)$DL]BRK:M3YGJ--7$:NE$26(_'T'^'U^IL/H+
M^_*:,I/ETE8`*:8Q3\NG':VTZC>M3D*ALKE,?M>*"FHXI*&DI8X\[.SUIR8H
MLC4Q25$24T?AC-13WC+,P1M:ZE&.P<L07*"[W!66(,&`-021PX^7\NB7=]T\
M!DA0@X\NAKW#1TN/V5GZ&BIXJ2CHMI9REI*6!%CAIJ>'"5:10Q(HLJ(B@?[W
M[D>VD5MPV]85TP"5`!P\^@?.YE\5V-3I/^#K7(_^\8^YE_[:N@3_`-`=?__6
MVR_@M_V3?A/_`!(W>W_O[-_^P-OXU;K>KZ@?X!T(-M(%M9$G`!Z5^[G>;?6X
MY'#7I*?!XF'7R!2PX[^)@Q_2WEJ\K(S<#D#W#',TTD^YR*Z_IH@`/SZD;91I
MVP`C)>O3/[#G1CU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW770#4O^S3=GI4O`%/0'5SA9FB()C[$[*=&"27!*2*"#:X:UK&
MWN8O:PB)-R\1@NIEI4@5H<]*N?XY#[7\G:48TWF^X"HS#:TR,?E6O1]6QFV'
MD65Z/"/,CK*DKTF->5)4\NB5)&A++(GGDLU[CR-_JC[F'J`?"F_WR_\`O)_S
M=%3[>;Y!X;>.6R73^Q-C;VPCXC;5/@L#E\EL;;VVJJIK\Q4)O^NWMD*^D;>\
M^9HL;]O-B8,;+%CZG0XJG\@4-[K?A3?[Y?\`WD_YND9DMT?.#'Y3&0XKI?X[
M93!2Q>"=!NJ;%IMY5DS53&T4\F5EGR'E\U#"R1TT2*\<TJ\2A(MTKPZ]X4W^
M^7_WEO\`-T<_&XC"''TB9?'[4.3?%8^DR@H<?01T+RP0*9Z>EAJ!/,F,BJ7?
MPQ.\FA#]2;DZ^?6Q!.140O3_`$I_S=%_^8D>'H?B?\A(J`8ZE63JO=K-'2K2
MTZR.V/G8L4@6-7=G)/TN2?\`'V2<QLHV/=5+@,;>0`5&3I/4D^SL4J^Z/(Y,
M34&X1UP?YXZ!2F_X#4W_`%#0?[S"A]XJ1@A%!X@=#"[!6ZN5/$2-_A/6;_B/
M=^DZ$25"9(_;^SKOW[K>/XA^T?Y^NPQ%K$\&X-SJ%N!Z[Z^!_C[]U['\0_:/
M\_71-S<_GW[KPH65006/SZBUE:F/II:IPS^,*(X(R!+4U$K"&EI(K_[NJZJ1
M(T'Y9A[=A$DDL=NF`[4KZ'_5^75P_A0-<%28Q\N-.-.E[A^L,O6-+)O/.4,N
M+*4D\..V_P#<4(J?+`KUM+E<G))+,]!23N8T-,\/W4?JD*A@@'MARK;VL?BW
M\@E`.?E\O^*Z"MYO\LS&*TM/#/KT!_4W>W7_`$3O_P"1N,K]C]LR8/=';=#G
M]J5NQ.H-^;NVWD,1!UOLG`5=1093#XFJIBD6>PM7$5#6_;NHTLI]CC8>9N6]
MIMKBT-[X2B4D+IQ32/A('"M>/GU(G-?(V\<[\O\`ME?[?O.V>);;)X$R37D$
M4B2"ZN6T,C$,IT.C9K4'K%V1V1\>N[]SKN;+;6^8"-C\=AL)E<;M;HWLS%T=
M<V#J<[DL!+6U<.T6S=)44E+O')Q%::JIXZFGKF$JOHC*B6UYHVN^0R6MYK0&
MA[#Q.:9\^H_F]GM]M%B$^^;"FKA7<;?@,>3=!'N>#XRT[8#);AR_\P[#T.$F
M414L^T.Z\;A,AX\;E5R8KZ6/;-/3R292"=IJR4%6<0?54:4.W<<W[-:)XES?
MJBZM-3&>/IUNW]GM_NM8M]ZV)](J:;C;?]!?X.FW%9+XSXS<F`W;MC.?,V3)
MG<J[CK:BMZH[2S+9/92[EIMP5NQ,=-C\#12T.V:ZKC2B<2O-_D4TH.J7Q2Q-
M-SMR_'H\3<U&H5'Z9R.KGV9YD[R-UV,!31J[A;BE:^IZ,IWM\P.O]_=*=M[(
MVUU_\@JK<>[NN-Y[<PE/4=`=FTL%1E\S@*_'X^"6IJ<''3T\4U74*K2.RHBD
MDFP]E>X\]<N2[?N$,6X"68PN`NEA4E2!Y'SZ&_MS[7[SR[S_`,D[]NV][)'M
M=KN=M/*PW"`D11RJSL*$DZ5!.`2:<.L&&R,U)A,%B815U^<I-L85:C!TCO+7
MP&CP5/)5/51>0&AIZ6.%S))*``!9=3%5:!(XI;MQX$3,VD8H13]M.BS<9]L2
MZOITFC,#7,@!U!\EB1W#XJC(Z*1G<[VW'\F_CQ6X_J7)[IVAGL!V;5;Q[.QV
M6$V%V;1[JCHH,/BZPR1L(EQ&*P5*RQWC^ZFJY/&NM7O3&B@XAC7Y$8IU-?+F
MU<GS>QGN1<7_`#Y:VG-#;C9-;;<\?ZDXA$E)$:H!KXK"E01I^8Z&OOOX\]:_
M)/:N*V7VC2YJJP>%W/C-W4*X3,U&$JUR^+AJ:>(2U-,KF6DFIZR5'0B]FNI5
M@"-!J!A3!Z"OM?[J<V>T6[;YN_*)M!<WNWR6DGBQ"1?"F%'T*P-)!ZU'VD=#
M:BI%%%#&NF*"*.&)=3.5BB18XU+NS.Y5$`N22?SS[IZGJ.W=I'>1C5F))Q3)
M-3CR^SKBM",OD<%@FU/%F<W04M9"&=?+BH&?(Y=3XRCF.7'44D;@$762Q^OL
MTV6V%WN5K$T>J*M6_P!+Z](;^0Q65S(.(7HU$<44$:0PQQQ0Q(L4,,*+'#!%
M&`D<44:`(D4:*`H```_'N72I;PR'HB"@7_5Z=1_)(96U'IBW9_QZFZ?_``VM
MP?\`NGK?:BT_W.L/^:R?X>FV^"3_`$I_P=:W_P#]XQ]S/_VU=`S_`*`Z_]?;
M)^#3QQ?&O#RS.L4,?8??$LLLC!4CBC[J[`>21V)`5(XU+,3P`.?8%YBD6'=-
MRD<T5`M?V#H_VM&N+&S,8K74OYU(_P`/3NV1_C==F-PD2*F>R<U?11R`AX\5
M'%!C\3K5N4>;'4<<S*0"K2D'D>X%WBX,^XR.#V$]2?90O;VD4,E-8XTZY>T'
M2GKWOW7NO>_=>Z][]U[KWOW7NDKN[>VV-AXZERNZ\F<70UV3I<+0NE!DLG45
MN6K8ZB6DQ])08BCKZ^IJ9XZ61@J1-PA)L![<ABEN)A!;1F28MI`7))'IY]&^
MR[!O',-S>VFT67BSVT7B2U>.-4C!`+L\CHJJ"0*D@5-.D/\`Z>^KO^=ON+_T
M7/97_P!B'LS_`*O[[_T9[C_>#T>?ZW_-'^^+/_LNL?\`MIZ]_I[ZM_YW&X?_
M`$7/97_V(^]_U>W[_HSW'^\'_-UO_6_YH_WQ9_\`9=8_]M/7O]/?5W_.WW%_
MZ+GLK_[$/>OZO[]_T9[C_>#UK_6_YH_WQ9_]EUC_`-M/7O\`3WU=^,ON(_ZW
M7/97_P!B/OW]7]]_Z-%Q_O!_S=;_`-;_`)F'Q1V0^V^L?^VCIXV[V]UYNK.T
MFV<+G*M\]7TM=6T&-R>V=UX":NIL8D4N1DHY,_@\93U)HHID:14=G56!M;VC
MN["^L/#-Y:21ZC0:A3(%>D6Y\G[[M&W2;K>16YL4D5&:.YMYBK/70&6*5V&J
MA"XR1U*W9U1UGOK(T^6WIL+:FZ,I24@Q]-D<WAZ:NK8:!9I*A:*.ID7RBE6>
M5W"7TAF)M<^TT<E`"6<J>%"5I7JO+O/'.'+-A+9\N\SWUG9RRM(4BE9$U,`"
MY6@[B%7_``=)K_9=>AO^?/\`7_\`Z#M'_P`4]W\>?_?G_'O^@NCS_7;]T?\`
MIOMW_P"RANO?[+KT-_SY_K__`-!VC_XI[]X\_P#OS_CW_077O]=OW1_Z;[=_
M^RANO#X[="A@3T_U\;<\[<HR+_BXM8^_>/-_OS_CW_075']V?=*1&C'N'O"5
M\_J&Q3-:#-1^'-`U":BHZ+QF>C.INC<Y7YS.]7;2W)T9G\B]7D,G7X093.=+
M9G)S?O5-7*1+59#J6NJY+M(2TV`E8DZJ)C]M?QI6%1(=7IW?M^/_`%?9U*MK
M[F^X?N-M]O8;1SUN%I[A10Z%@$Y6+<HXQ4:?PC<`M20`JW/!/U`%<P:_'?H"
M:.*9.HNN*FGFC@JH)4P&/J::>&54GIJB)@)()X9$*NC#4K"Q''MLS2MVNS4]
M0QI^PD_X>HRD]T_=.-&BNN>]V$%60UF9"I%597!J0:EE((!Z&@```#@*``/Z
M`"P'^L![;H%P#4=1K$&5*.#JJ:U-2:DFI)_BX_GT';;IW]F-\;FV1UUU'D-_
M3[.PVTLON+*_WZV;M"BI?[YG-##4=-%N2L@J:Z<C`S&0H`J%E47)]B;8N5=S
MYAAN)K!X@D9`.LE34UX4!]./0MEV[ES;MAV/>N9N;H[&#<'G6&/Z:XG8_3LB
M2%GC=-`+.-(S4`^73^F-^2+LBK\:*MFDC$T:KW/U<S/"2H$R!<@2\1+#U"Z\
M_7V<_P"MMS'YK#_O1_Z!Z*OJO;+_`,*/_P!TRZ_ZV]<GQ/R4C**_QFK5:1M$
M8;N;J]3(^EGT(#D`7?0A-A<V!/X]Z/MOS"#0F#_>S_T#U[ZKVS_\*-_W3+K_
M`*V])W-;C[2V5F-CT/971^4V5BM^;KCV9B<\.P]C[E@ILY/A<SG:=*S'82LE
MKUII:3!S*9%4A7*W%C?V5[QR?NVQV1O[TQ>`&"]K5-3PQ0=&ECM?*^]66]W'
M+'.XNKRQM3.\1LIH=48=$-'D=EJ&=<8-*D<*=/6Z<;E,M#04F-JXJ1*JK_AD
MTA\@J_/G3%@L?+0LJO''-#+D7/D8:HKB1/W$4J3;6C_O&U1:%I#ISP&K-?M'
M02N6'T<RL6TA:Z2:@>M/D?,=#)V?04U%@]G[*IM:[>EDEH:C'J[+]SC-O891
M04U0R,'-)%4B)G`/JD5`>/8OYIDDM;&RABE(8G2#ZA?,_/H/;"4EN;B22(&-
M5J/6IQT@:2FCI::"CI@4IZ6&."!&=Y2L40TJ#)*SRR-_5F)9CR23[`3D%C0D
MCY]"$PJ362)-?Y_YNGO9F[\-MC+9ZMRU36TM#DUQM!$E/25-7%)/A)ZZ#*[@
MJQ`&-%B\::N*B>H<`/)#(%U"(E1KR[<P;=:PK>RK&9YM25]`//T^71#NUD;L
MVXAA%8ZUPO[!VY]>E!VK*U5G-JTDI27&-B\]7PJ0L\%5D?\`<=1#R7+Q2PIB
MLC+I4W5A,Q_'O7.4SAK%$@`MY!J)^?RZ]RY&H%U*J`,.VA"X/J1IX=`MOG<^
M-ZZV9NK?-1B)*^GVSA:G,55!BDHZ:OR*4:62DAFF\-.)I2X56E8(M[D@#V"8
M1<3RI#(1J9@J_GPKZ=#WES:9N8=\VW9%N8H6N9-.LJ2%HI8D@*3A5/E\NLV-
MQ'R&RU;4C(_'G-#&4SQ*V.VWW1U,F39WABG6++Y*;*&;'>1)01#!''*4*MYA
M<CW)MK[;7L3>)>)&].`20C(]3IX?+HOO;[D?6R6?N5&95&&?;+G6OEIQ(0>&
M#0?9TL\5+W1M5<E4;2^)F6CS.:A2D27,_(#KFM2MGQPJ3!%/)+FJV=THD:5G
M6`"2P()`%U$T?+^YVEO)%8;?"K'S:34?R.G%/3HENK/D7<9H#N'NOKAC:JC]
MV7-!Z@#5FIIY]!PU%\B=I[;KJNN^-M>]#MS&Y#(9*2F[>ZO!@IJ&&;*3Q048
MR<DB+3T1`BC9V<QA;LQ.H@RX]O=^I/<NUN%`9B-9K@5.-/[.A9MX]N[V\LK"
MV]R%^MEF2*$G:YZ*7(4&NL4-2*M3`R*]*7:V?IMV;8VWNJBBFIZ/<^`PVX:2
MGJ?']S3TV:QU-DH(*D1L\8J(8JD*^DE=0-C;W'H8,`PX'HNW:UDVK==TVJZF
M#W-K<RPNP#`,T3LA8:A6A*U%<TZ?+^]G`)/#I-'')*"50T'KUB6JFQF4P&;I
MXZB1L-F*>KK!11Q3U[8J2*>ERL-)2RR0I5O4T=0R&/6&*G4@9U52:;5N,%CN
M%M>2%EMF`%*=WYCT_/I%?Q//97,2+5V7'V]&&PN\ML;BKI\=@\O3Y.KIL90Y
M>ICIA*ZT]%DI)HZ,SRM&J15+M`VJ!B)X[>M%]RK;WEM=O,MM,'\.FHC@*\.@
M)+9W-O&LL\10,2`#@FG''6?=G_'J;I_\-K<'_NGK?9A:?[G6'_-9/\/25O@D
M_P!*?\'6M_\`_>,?<S_]M70,_P"@.O_0VCOC-2RU?PVLA?QTO8G<^2K(58JM
M9C<;W[O.MRE%*%*M)#/CHI=27LX%B"#[B_GM994WKPI-+@J2?4`#'0NY4F2(
M68DCU(20!Z&IS^VAZ%1M)(T%2@`"%;:&6WI*6`&FWT]P3I<L&=JGJ2>O>[]>
MZ][]U[KWOW7NO>_=>ZZ]^ZUTC\W?_2)\=;$@COS;0N#;AMG;\!!_J"/8MY&C
M5.;-I:,?I-JJ#QJ5+`U^70GV=-'*7NH@I0;!08!('U=F?B.:ZB3]AIT(]2WR
M9J]_[KVOU9W'U%79G%;LS];OZFW7G\KNW+83:V<I,I4=94>)Z_I,=C:/KZ;$
MQU%/#5I)4U?\8,`J!(+R*^2PH"3HK_MFZQ@5:$FA/^V/^;I246`^=E+5U-+4
M;^Z8R=!/D)<C'F:G$5U)5T])!APM/MZCP]+B%ABILEF8U>6KGJ*B:EB\ND2Z
MHUCW5?\`?8_WINK8J>W_`(T?\W24RV+^9F;^UI-K=[])4G;>U]C;*??77R8R
MMR&VEW@])O\`3(YVH5)$SN$P6=BRF(EIJ:2%A42T1D)CB4)+K%:Z/^--UJ@K
M72?]Z-/\'3?+L/\`F`;CRHRTO=O4>!@I-R4M-]EM&AKJO#SX3"UL]<$R=%D\
M9/(,I-DP:2KAAJ(&FI'$<LC&$:_&AH=&?M/6ZT_T,'\S_FZ?/DN*_P#TJ_%D
MY1X'R/\`#^Y_OC2:S1BM_N5ML59I/(?)]L:C5X]7JT6O[B?W8U?0[&HH$^H-
M>)/P^IZF_P!KR/ZD>Z)IW+)M;`^C+<2TI4<,Y'GTRGZG_7/N$P```.'2BI.2
M:GUZZ][Z]U[W[KW7O?NO=<9$CGBEAGBCJ()XI()X)T2:">"9&CF@GAD5XY89
M8W*LK`JRD@@CWL&G#J\<LL,D<T,S)*C!E(P4<&JR(1D.IX9I0D\0#T6G15?&
MVI;_`($5WQTK9PJ@B2KK^AZZLF_2H&NHK.GZJ=^#9I-NR.?K0$"GN:,*@=WG
MU*\BP>Z\!D,<8]T5`+**(N[1H*LWDB7ZJ.!'^-TKB6NHRL<D4L<<T$T51!-'
M'+#402++!/#*BR130S(6CEAEC8,K*2K*002.?;?432E4,[4<1H77N4JX=/\`
M0V0]RMY9],CIAZJV$O9'9_R5VTN:J]N5:[>^,><QF<H:2CKJC'9?;U?V/E\?
M4-0UZ24==3FHI=,L,@TNC'D&Q$X^UKH^V[FH6E)5_P`!ZK[GLK<@>U;1ZUJ^
MZ'B?]_P>O#[/RZ0&4VST5MR>OV;M[Y4?(.([0VEFXL_D]I;F%0FS\#MO.8/9
M&1IJO,5],J4$4V:W-C$IXJ'_`"=#B9)(?&(ZC7)P5P:^*W4"^&/0?S_S],59
MBOBO/BTQ>;^?>^<N-OX"6HS5)N/L7*RUM35)DJ1\9N3)QU,@S.'I\3)XH$>C
M-,S4DI$LLBOJ-ZR?Q#]G7O"7T'\_\_0U=Y;.SNQ.O/B)MK=&\LGV#N*C[^Q\
M^<W=EJF>IJ,SD:_8?:%?-)$T[.RX^D^Y%/2KQIIXDN-1/N/_`'+U?U7DU$?V
MZ?SU=39[,J%7W%\O]T+_`/:3;?/IWH(Q/GMJ4[<K+NO#2,+_`*OLFGR*+_R%
M+1J/<-;+!)+NUEI';&X)X^0IY=/WVM;6YD$3%%B)8@$Z5X:C3YXZ$+M>CF5]
MMYQ4+TM#5U>%K5#V,"[CDH(Z&K"<:PN2H(XGL;A9M5B%/L5<X6KFUM9B:(CD
MG!S7\O+H,;!<0+-+;JS,[H#A&-,DYQQIY>70<$Z21]".#<V/N-R\=31_Y'_-
MT,3W&M"/D00?\'46GH,?2O5O!2JKY!W>N)9G-1Y#(TB_N,YBBD:9V,:V36[-
M:[$GWAO(4)CDE53VU&!]G5U\`@LI&D-1B:"C>FEJ,?M`ITRXS<LV>Q6-J<A5
M4R8S8W\4V?C6@85+9.;'UL6%GR]34J"9I:Q**&&GIXE)!+7+NZA#K<MVO=V6
MPLC`:1#2`<&O[/Y=((+..P:ZDAE#F5JL:4`'V=(/Y!8W<-;T1VU+3[=RE)1T
MVQ\K5U>0SU#4XBE2FB:G.FDAJHTK*ZMG)(1%142Q:1EL`5>S;+?M<Q7=U#X,
M$3!JGSIP`^WH9>W.YV:<]\MQB5FD,S@!#0U,,@K7T'$_RZ76*S/0O4_<NZ=_
MMW)N3:VX=T9'L:LJ=GU.$AAV[6SON&';>Z8<;2)(]//N$[FV(9(\A7,=:3(D
M(B68K)DZ*4U**&IXY].L99E!#URWB'))KYX^SH/G@^+4N9J9JGYT;JGS&'BR
MF\X8MN[D&,AVWF-RTFY*[-[NQ]!M^@:AQU,T-?73BG5!3P+-+]QY0\03=9/X
MA^SI-X2^@_G_`)^A-V3DNE<E%NJ+K?O7=VY\SM[IOM#`Y[9.>R%?63;P3(8G
M'YFEW[GZC)).^Z*S;."%!BJ/+033+]KHII*AW41A/?*#9W#-Q\)_S[>A#R@Z
M)S;RL@8!_P!XVU14U*^,F4'F1]O[.BU]3[E[\3JKK!*+J+8E311]<['CHZB?
MN&2EGJ*5-L8M:>>:E'7LPII9H@&:/6^@G3J-K^\1J**"AX=9C\X;1[8/S?S8
M\WN-NR3'=+LLO[ID?2?'DJ-7U0U4X5H*^G2P7M+LG!;MV%MW?W6.W\)0=@9[
M([<QV2VUV%4;QR--DL?MO,[FNV`AV7BJBJIIJ?"/$SQR$QO(MUL>'88)IIH8
M(HRTS\`,_9^WH/WG*'(]QRWO^_\`+G.MW=S[='%(\<MB]JK"2XC@_MGN)%!!
MD#4TYH5&37HT&'V!G-RU%-59>/,[7V_#&\G@BJ8J'.9F28QQK%54XAJI,3CH
MHS(2&:.J=RA`BT@^QCL_*DC%Y]\B`\P@X]0U=[S#`2MJ^J;R)!IT,V!VKMW:
MZ5<6WL+C\1'63"HJS1QMYZNH`*&>MJI6DJJR:Q_5([-R?Z^QI!'%"NB&!$'G
MI%*TX5]3T%;EY98T,LSNX)^(UX^GIU[=G_'J;I_\-K<'_NGK?:ZT_P!SK#_F
MLG^'I"WP2?Z4_P"#K6__`/O&/N9_^VKH&?\`0'7_T=I/XPLZ?#.K*7`DWKWG
M23,/I'35O>^]*2LE+"Q40T<TC$_A02>/<7\]F2,[V(TJITUKZ$#H2\J?J)9&
M0T.LT_;T*<M@]E%E``51R%4<!1_@![@Y%#,`3CJ420JLS,``"<F@Q\^@SS_<
M?4FU<K58'<O9FQ\%GJ'Q?>X7*;EQ=)E*/SQ1SP"JH9:@5-.9H)5==:C4K`C@
MCVYX$SJ9(;>1HAYA2W^#H2[7R;S5OEK'?;1L%W-9R$E'$4@#)P!%5&KN#"HQ
MCIG_`-F"Z--BO:^QY`38>+-P3EC>UD,`EU'_`'O\>]"VNGKH@DJ/6-^CN/VK
M]Q'%?ZHWA'EV%?\`CW'\NNO]F`Z9MZ.PL+/<&QI*?,U@9N;`?:XR6X-O;J6-
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M`J3@\!FO27EB2VW';.?=DDO8+6[O]D=(#/((UD=+FU?2"1BJQL03C'4#M/=W
M0/<&3W#F=V]!?,>'*;FQ^)QF0K=O;=7`SPTN&J\35TPQ\E#O1&H)Y3AH8Y98
MR)'BUJ"`[>YH_P!<#E/_`*.9_P"<4O\`T!U&/^M/OG_1\V;_`++(_P#-T']?
MA/C'EZ;(19+HWYR5N4R=#7X@[DFHI#N2DQ>1>$/C<?E$WBKT=)#2Q&F157_@
M-+*C%O+(6]_K@<J>6YG_`)QR_P#0'7A[3;Z<#?-FK_SVQ"OV5ITWYG,_&KMJ
M'"YG%]8_,^;!T-!BMC9D8C;GA&Y,7UCA<]UU'BLI5KO*CDKLM39!;5U;6I6S
MU+T*QJ4C)OL\_P#*H-/WF?\`G%+_`-`=+MR]E.:MHNC9;ANVS1W816*_70D@
M.H=*TKQ4@C[?(XZX4>ROB12U]=7R?'7YI5YR5)!25E%7XMY<9.8:Q\B]:^/C
MWG#3OD:K(R/43S$%Y9F+L2;$:_UP.4_^CF?^<<O_`$!TA_UI]\_Z/FS?]ED?
M^;H6<WOFA[`WO\?,1LSJ_N+:&T^I-N]BXZLRG9FW:;$00T>3VS@\'MZACR`S
MV5J,C72O0E>5OH6Y;^H!]P>8MGWRSVN+;+HR2I*6."*"E,A@#T/^5^79.4>4
MN>+/=MVL'GW"2Q$*PSK*S>%+([87A2HR:<<="D?J;?U]Q<05)!XCHEHZ]L@H
MXX_;UU[UUOKWOW7NO>_=>Z][]U[KIDCFCEIYHXYH*B.2">&:-)89H)D:.:&:
M*0-'+%+&Q5E8$,I((M[]4C(Z<666`PS6\K),AU*RFC!@1I8,,C214`8)H3P'
M0$]"44&$Q?9>U,;Y8-N[,[@W;MW:N*>:6>GP&WAC-N9FGP6,,[R/3XC'UV7G
M^U@!T4\+"*.T:JH<D^+]G^#J1_<N0WNX\I[Q*JC<=PV.UGG<``R3EI0TS#@9
M'6-0[4JYJQ[B3TM,1D^[NL^S=^;TZQQO4^=Q6_MM[`Q%?2;]S.\,1D\97;&&
MZ462D.WL)E:.IHLA'N0'ULLBM$>+'V-N5>;H>6K>Y@$!<RL&-<4(K@4^WH.[
ME#R?S3RMRYM.^76YV][M<UV2T$44D;+<R1OFK@@KH/RIZ4ZE0[V[Y@?+O3]'
M_#^*3<,]34YPQU^^4.:J*VHHJNKERI&Q0*]ZFKQM/+(9=6J6%'-V4'V)Q[K>
MNT-3[>@G_4;VUR3ON]4^5O;'^7C9Z#+;6^NP-XG>>(@^,7PLCAV3NO([`R"5
ML>YI8:V>C@P^XYY*-5Z_9QCIILK&^A[,98RS`<>]GW4*G.SM^WH\WOVJ]N]D
M78WDYCWIUO[".[6EM;C2DA8`,3/QJO2]WMG?D%VUF>K(]^X7I3;NV.O-_P!/
MOJ9]F9W?.3S=<U%MC<FWZ?%TE-F=O8W&PPN<_P"1W>2ZK%902;>P[S+SR>8]
ML.V_0&(&16+5_AK@?;7I_8[/DOE2QYG_`'+>[I<[C?;>UNBRQ0I&"9(Y-3%)
M':@$=.`&>/2=W;-3S]FL^X-]]H[2VEL/IC-]D/1]79G#8;*Y'<Z]B;:VGB)Z
MRMSF+K:%(8*;-/'Y9YJ:EID=IIW6)&9;\@[7:[O?7OU9D&A0P*.5R6"D&G$9
MZ7WV[6O+'ML_,`Y8VN_W*;>4M-=Y"TP2(6SRNL8$B`:I`I8FOPXZP-OKXZ9&
MOR^R=_\`RI^3FVMQX6LIGR&W:K>F$W131O%4XYL15P[AV3U]F]MUCU^7F6"C
MCAK'FGG30JEF53*=UR7L]['X4\ER8Z\/%;J-+?W<EMI7DA]N.5!)7C]`WF./
M]N/7I.8C?/P]S5734\'RS^3JC,O.^U&3,3U4^Z,70P8QLCF:#'4O5TN1H\=C
MY\@Z.U5%#>.FEG6\*E_9:?;3E<FOA7'_`#E;I:/>W<P*#D'E7_N7U_ZS=8-]
MXO;%?U1E^QNC.^^[<O\`PCN[K;JB#)]@;JPTVR\S!NS,[-I<S6ST4VS\77)A
M?X3NVRS,8W+1^1+@K</\V\D;%M.U->V,4B7"21@5D:AU,!4^M*UX]#OD'G^+
MG&_Y@V??.1-@@L_W'N%SXEM9F*X#06[R(R2"5B#J0"E"-.*=&LVWA-L[.F7/
M[NW-ALKD(Y:*JV_A<!D1F7FJZ*A2E^^CQV,I:!<KD8X88D@*4B4U(L8D+!G:
M0!J*SM-JFN=SW2[BGN`*BGD?Z('^7J+;F:]O@J6%A.EG2DC>2DY!)-``?-2"
MW2![NBW?W+UQO;9\-=2[:3<F!KJ#"X:9YA1I6R:9:&IW=D:`3U=:B21(TE/2
M@0(?^.S*K$GW'F.6]GB,>H6*D$JO$T./]GH;\@R[9RMS)LO,6[QRR6]M(3+H
MT:PC(R,5UD+J`:HKY^74%MW]W2U>3R,W1OQ`FR6;J(*O-Y":MWO)69>LIDIT
MBJLE4/L=IZR=#21E7D9F!0&]Q?V/![IB@*;*[/YC52G[>BUN1/;EJR_OO>PC
M$G-O;4R21GQ^-./4$9OMM5JT7X^_#)$R&,EPE<D<F\8TK,/.U<T^+J438:K-
M0SME*G7$P*/YWN#J-_?ZZ<G_`$8'_P![7JG]1?;C_H^[S_S@MO\`K=TV2UW=
M5-/N;)[=Z<^*FV=P;FV%6==SY;"[@[&H13;=J83&M)34%+L^"BA172`R%$5Y
M4I($9M,,86D_NB);>2%MG=696%*U-&%/+'1GM?*GMSM6X[5NTF][V8;6YCE_
MW'MJ4C<.U#XV#C/2UV)@:C:FQ]F;7JIX:RLVSL_;FWZBHIQ)%3UE3@\+18Z6
M6G$P62.*IEI24UBX#"_N(6.312!Z'C^?2K?MT7=]]WO=HHRD5W>33!3I)`ED
M9P#0D<&\B>B?]V]]8K97;_Q4VWB=N[NR6X\WVIE6SV]-K[>?<F;Q.0K]B9;;
M=7@OX=XZPX/"X*;>T,8#0O)(*2HJ50F,%S\7ZVBVUGL<!%YC]2E34C(].)QU
M)_M?R'<\V>V7OUS5?<P6=K:66WV^FUGG$+L4NX[BJ1Z0928K=CV>;**Y-#\[
M;V3OG-5M/D9,QO+:]!!4TU1)D\]N'+U.XLI'!4)*]-2;>EKI<?1T56J:'>N0
M'QL0M-]&`AVVQWR2Y@N-POF"JU2C4J1Z=8X[CN&T".2*RM@[D8<<!\^C+<7:
MPL"20/PH)N%'^`_'L7!:=!II2PH1TG]V?\>ING_PVMP?^Z>M]J;3_<ZP_P":
MR?X>FF^"3_2G_!UK?_\`WC'W,_\`VU=`S_H#K__2VO?A52)7_%RFH9*:"L2M
MWM\@J1J2J<QTU4*CN/L.(4]1(JNT4,VO2SA254D@'Z>P+S)%]5?[E:,*K(`*
M?.@IGH0;2ZV]O92%M*+4D@5I0U)IFOV>?6#:F<3(A\0MJNOP,U9@,S/3UU!7
MFDSVWC0TF8I*Z.AGJ6I[5-4!!([?Y4$<@#3<P%/87-H'%P%!!<<<X-!CJ6KN
M.6WJ$CF21H5E7Q(S'JC=<.A?34'B#0CTZ5WQOPF0R\WS+QF`?'X[==5V!10;
M>S%;203G$YK(]';'BQ.0E,E-/)X:/(".4C2_"FRGZ&<_;0!N7F9E&H3$5H.`
M"TKZ\>DOO%+*+;VW<3R:CL=#D^5W<^C4\\TZX4E;\KX,UN;'8[LCXWP9O;J5
MF[,GL'-Y:LR>4V7AZ]*Z:AI-TYC"4&(FJ\-!#.1'))04RP)'%+:0VO(11&XH
M/V#J$6=G%)"6^TDT^RO7#%U/S)WW_'#C^^OC<M'0[L?'M3;.H\BU/3[+J8<C
M74.2K\G>ORE-NF;&97#S1T\,\$*$L)&*R+KV%`P,#Y=4HO\`".E-M.B^9>;V
M?E=N3=L]9_WSP6],1@AN.3%XV>IR^S*;9])4YW<DT.'Q<M#_`!6OW3F@:>%:
M*@+XZDA8M2S3.3L8Z]^?39\D<!F]J]4?$O;^X\Y4[GW%MONOJ+#[AW%63RU$
M^X<W3;#WCB<KF:B6=4DFDR>0E>8EU4DOR!]/<>>YR#^JQ()%+F,X-.):O^'J
M;/9)$,WN5514<KW1!\P?J+/(]#QZ@@D7M^3_`*_O'\=JR)Q#&IKG(Z6ZFQG@
MH`P,`>GI7S]?/KO6?]]?_BOOW6];_P`77.)V\L7_`"T3_>Q[WU21!,I23(_P
M>51\^@$^-S$=6K_AV)W0/]A_IAWP?K]?S[<F_M'QYGJ1/=,!.=KQD%&:RLJG
MUI:0@=#QK/\`OK_\5]M=1]K?^+KHL2+'Z>[*Q0DJ!7K3$M34:TX8&.NO>LD_
M,GK0!)51ECC[3T".*[^VAGL=2YC`;2[JSV&KU:7'YC"]&=JY/%9*G262'[K'
M9"CVK+2UU)(\9T2QLR.!<$CV;GEO?V2WFM]HNI(91J4A12GV]2%=^V^\;==2
MVFX[[R[;WB"DD,NZ6JR1O2I0CQ!1E\PU,X/4_P#TSX?_`)]U\@?_`$GOM[_[
M$/=OZM<Q?]&.Z_WD=(?ZCW?_`$T_+O\`W-K'_K?U[_3/A_\`GW7R!_\`2>^W
MO_L0]^_JUS%_T8[K_>1U[^H]W_TT_+O_`'-K'_K?UX]T88`D]=]_BPOS\?.W
M@3R!Q_OT>>3[U_5GF0M&HV.Z`8TKI&">K?U%O"E%YIY:$C,`"^[V84?.BRDG
MA\NE=L??NWNP*3+U>`7.4KX#.U&V<WC]S;<S>U,SB,W2T5#D9J*OPVX:''9&
MG9:')P2AFC"LD@(/LONK2>RN);2YB=)T-&#``U^P>715S+RYN7+,MG:[C]*Y
MNK<3P203+/$\)++X@=&92K.CCC4:3T7;XK]A9G>^9^2E+E^M-Z=?IA.^MP/C
MJK=M"]'!N2DK<9C,:M3B&>.(5"TXV\)9&C,L/CJXK2$D^VI*:L<.I5]]>6-O
MY5C]K3MO.6V;H9^6;5G^F<O].RNQ:%_Z06;-<@HW1N?>G<N`&`Q\NH'9%+4+
M%HP30'@>(R//!/'_`"=<ETAE+"Z@@D7M<7Y%_P`7'Y_'O6MOXC^WKQ0,"I.#
MCC3C\^BR?'CJ_N/KG-=YUW:V_P#;N]J'L+M3(;XV138+%28^7`XJNI8Z.6GR
M;R4M,/N9:2CHXA"AF2/[8OY&,I`N\KNU=1_U8ZF;W;YO]O\`FFWY!M^2.5+O
M;IMMV6&TNGFF\03R1<#'FH%=9-/45X#HS-O;>IC@D]0ZJU28!F'8>!/7NGJ>
M&K^4S4]13QU4$_QMW-!/3S1I-!403]H[9CE@GBE#12Q2I=65@05N/I?W*WM8
M!]9NC:23X:\/],.E_/+5]GH#J[_ZS@Z13@+)\@5_;\ST,G<>`[5Q61V^G3&S
M,'%BXML9R"*;";<V!)64N[J:IQ]1M&BS?]ZI\;'BMBT\*5%0TN,2>M3(10CQ
MB.^J:1(HJ&1JU/E7\\'K'=6CH&TN:T/EC`^8STCMIO\`(^#<>UX]R]`]7T6#
M%?3XC(9G"R[>J:_#[?JJJ.*JKVH%?'2'(2)3N\_VDWVD4=2K"FF:-D._$3^%
MO]Y/^?K99/)7_P",_P#076'YP[5PK]"T>#HJ)\#09GN[I'[]MLL=MUZS9'M;
M;`K,C35^'6EJ:7)RL]_N8R)]=CJN/8,]PA*_*U^T8&H-$<GT<?S'4X?=XO;G
M;N>]TO(%C>XBY>W<HLB"53_B4N&0G0RGT/VGHCV3^&_7M9VOU;VS!O?MVDR_
M564K<GC\14]@YG/8C.RU2A1!EQG'K*J*E!_SJ0.@J4)22X]XZ%R:$DD@^>>/
M4Z6'OYS!%R'SIR.O)_+PV[>Q$))X[%(9H'B^(1F,:=;5($AX#AT/G9W86W^I
MNOMY=F;HBR<VW-D8*MW#EX<+1-D<K+142@R1T-%Y(A-.[N`-3HB@W9E4$^[(
M[>)J#!30Y_XKJ/>2>5=WY\YLV'DW8VB7=]RN%@B,CB.,.YP78XTCS&*C%>@7
MV5\O^E]];4P.\<4W8L&,W#C*?)4E-4]3=C5-3"DPY26HP^W,IBZAD92I>GJ9
MXB1Z7(]^$3R'62&KZGH6\Q^S'//+^^[KL6XC;VOK:[>*1X[R#3J4T;35Q1":
M$*PU#A6G0L[([;V%V)DLKAMK5^6ERV%Q]#ELCC<UM;=.UJR+&Y*HJ*2BKHJ?
M<V(Q,E52S5-+)'KB#@,A!]U>/134BYZ!',')_,'+-K97N[01I;S,T:E)8Y@T
MD8U.:QDA>TCM/V@="0%)Y'X/]?I_M[>ZJ2C:D)'V<.@_&[Q%7''B//#+3[#@
M_P"7KBS+&&:1E1$!9V9@%15!9V9B;!54$D_0`7^GOTCF3X?[7SZUDTJ23\^A
MFZOH33;/QE=+`J56:FR&=>1H565XLM73U%"6=D$O&+,(Y^@]RYL=K])L]G"T
M2^/)DF@KZX/$=`'>'CN]PEJQ(I2E>V@H.'#R_F?7H0OZ_P!2;D_F_LSH.)R?
M4Y/190#X<#Y8'7O=NM],&[/^/4W3_P"&UN#_`-T];[?M/]SK#_FLG^'K3?!)
M_I3_`(.M;_\`^\8^YG_[:N@9_P!`=?_3VS?@HQ7XX8-A]5['[U/Y_'=F_O\`
M4D-_MN?8(WPTWB[/R7_`.C[;PQM;,(:/0T\\^719=N_!/H?JW>'9M+2X/>,U
M9O;>-?V#+4U78F\J6)Z'/U%3+3Q4']WLSAE^VHZ\5$1%4)JGR)?R,A2T$[W8
MS[7N=PKDU=BPKF@;-!7RZRYWK[QGN1[@0<N?O&\LXEVK;8[.-8K2VU,D2Z0S
MJ5H25%,XZ'/XTY7;_P`>,+\TLU@MNYW,8/8^\]C;B&WZ?.UF6R]:M;U7M#[M
MDRVZ\G65)2,WE<-,Y6.-A$CMIC:9/;)W;:-P5FP+IJ?+M7AU%OOKN5]O.W^U
M^Z[@X>>3:IUJ$1,+>S4&E`%Q7IBW+O/XD]XC?]'BM]]QY2F7(YWNG<&RMCO6
M8K:E5O/86SQN+,''[NGVU&9JS<V"Q'[5,^3%'.::0QQPGR`R3UCUT&^/@^"6
MVZ[:+;GZW[OHMZ[H6IK9MHUF&W7F*D9'#8_;N8G?/-]GC(:Q\)B*R&0S./MW
M\,B,99::G6/W7NA*Z\W[\*.INT<+NS9^*[/PV;7$9S"[2A,VX:G;$]#N'+8;
M"YFF7"UM:F"V[*)<)32)3SO3R111,TL,4VA&]U[H4?D#VOM/N;J+I3?>R_XI
M_!E^4G6^-4YG&38NK%52U.9H)P(96<-&RUJV96;228WTRI)&D?\`N<#_`%7D
MS_H\?^$]33[*MHO^?T(P_+%X/^JELW^3K,?J;?3WCYTNZ][]U[KE&0)(R?H'
M4D_2P!%_?AU92`LK'!",0:5`(%14>8)%#T3_`*I[+I.N-J5FS]T;![G3,8_?
MG:=7*^)Z?WWF\744F;[+W7G,75T&7QN)J*"OIZS%Y&&57C=A9P/K[4/&TC,R
MD4)/GU-?.O*O]9=_;>MJYAV=K&:SLRK/N$$35%K$KH8WJ5T.&6E!PZ$C_9@]
MJ?\`/"][_P#HB^R/_K'[KX#^J_MZ"G^MON/_`$?]C_[FEK_T#T&G:_S3V!U)
MMN@W)E^LN_<G35^X<1M]8H^I-TX%89<K,\:U,F1W+28S&Z81&2(1(9IF]**3
MR-&)@"21C\^AIR)[`<Q\_P"[7NU[9S7R[$UM8SW#!]R@<L(U!`41J6KY#]O6
M#K7Y:9_L.LWW2M\7^_L-3[-W76[;H\@,)AJFES])`C/3Y6)LME=NF%JB(!_'
M#]W$J2+^\22!;PU#,#)0@CB#GI_G+V5MN39^4'B]T>6[UK^QCGDBCN0'@=G!
M\,]CAF6NBI=#4'`Z-7T%MCNK=7Q`^+53T_O3%[)GBZQACS@W%)7JL$D^=VWG
M,;D?L<=1U\>6JZ"FV[6XR:DDEIXW@RLK";T:7R@Y;_Y(.STX?3I_@'6+7O,H
M7W8]PP:8W6XX?Z<Y_P!GIT7,_*_+XB3+;!^3?QGS%#4;RH=O5&<KL%E\M3RY
M9<KB-OTV"HEH*ML70UV7BK(FFB@7Q"N95ATBI,J'G47T'4W>.'^=.W:?)[OQ
M_<?3V73;6/CJJ?$_PP8W'9K'2;<A3(Y'=E/74L&.QF*PVXISD/-15,-6<:FD
MRR,%IY/=;QT-^&VOWKN+M+"[NRG:FT\ATSA:N3,8+`;6I:RARVYHLALRIQ=(
M=RS10K22TD&5R`KUI_/-$SZ'&@(L?O1\OMZT0ND]H.#_`(.BE[:]7:ORHU<V
M^0F27GG@=9=;`#_6`'O&7G7'-6]?\U%_XXG657,/9RK[1A,?\AJ,_P#9Y>="
M$23:Y)TC2`22`OUL`38#GV%Z]`Q@&4JP!4BE/E2E/V8^SKKW[KP````P.O>_
M=;Z][]ULLQ&DG%:_GG_.?V]>]^ZT"16AXCH/MW=7;'WSD\?F=R8_*R9;%8^J
MQ-#DL-NK=>U:Z/&5M7#756/EJ=JYO"RU5'+64T<OCF,@5U!'M5:7MW8NTMG<
M/%(10E20:5K3]O0CVKFO?=HV^?:K*Y3]VR3B8QR)%(OBJI0.!(C4;02M13!S
MTFO]`/6'_''?G_HW^W/_`+.>/:W]_;U_T=)_][;_`#]+ASQS`.'T7_9/:_\`
M6KKK_0!U?]?!ON_U_P"9O=N?7_T./K[W^_\`>_\`HZ3_`.]M_GZ]_7GF'UL_
M^R>U_P"M762GZ"ZMIJ[&9%L7N:OGP^5QN<Q\>:[([)SU#3Y;#U"5N+KCB\UN
MVOQE1/0UD2R1>6&14=00+@>VKK>=UO;<VEW?RR6QI568D&AJ*CY'JC^X'-"K
M/9PW,%LTL,D3F.&V0O%*I61"5B!TR*2&%<@]#&3>Y/U/)/\`L?9:N33H&R*2
MK,M=8'&E>'R\\=!AO+=>Y*/=&W=C[9VUM+.U&Y-O[BSM?5[WWI_<S;]!CL/E
MMK[?2DFJ$VSNF2OJ<QD]V4\$41A2,L2"3>WL1<O<N7/,%Y/96TZI-#$"2=5,
M^NG-3T*[.PV*PY=W#G#=^8+RUM[:^AMXOIH1-(TDR2R:JF2+3H$+<'!!.`>G
M'#P]]9""BBP.SN@ZFED@JUH8,9\AZY::.FQ#I2UD<$4'4ZP4ZT$C!#'9"H!L
M+`V%O^M5N^/]V$'[).@^W,'ME,97EYBWEYW'Q-M\):NH,22;PFI(XG)Z0M7L
MSOS!]BY;M+-8/X_46.R.P=O[+,%9\B:F.&E7&[BR^>&6FR4G6!A@HJE<NL?J
M5$0)J:2S6%F]J]XTHOU]O05\I/,]">ZY[]JKCE*QY=._[S]3#N$]R3^[X/AF
MB$:C_<RN"#Y4^?2DW]@^_J#9N:K]R[.Z)P>V4QE96Y/)U7R"RII7Q%%2"OR5
MA2]5I4U<?\/8,Z0DN49;`AA?W^M=NJ`@WML2/^:G^3H-MO\`[7L8PW,N]*%1
M5QM\!.!3_E-''J3MG/;HR.\<[U]V5M'#X',[)W)U5#F*?"[GEW7B,[BM[0Q9
M.CD^ZJ=N;8F@($06III*4J02-1!(]A:XV%MEYEL-JN&1V=E<TKI*E349S3&:
M^?2[F';]KMN6-DYCY?W.YN-NOXKAE::!8)$>W<QE=*O(&!(K\9^>>CXBX"C_
M`%*A1].`HL!;Z"WN2!C13&D4'R'RZACN#:W_`+;S/`U\^O>]]>Z][]U[I@W9
M_P`>ING_`,-K<'_NGK?;]I_N=8?\UD_P]:;X)/\`2G_!UK?_`/WC'W,__;5T
M#/\`H#K_U-LOX+<_&_"#ZW[&[V_I_P`_LW__`%X]@;F`TW6^(XZ1_@'0@VS_
M`''L:\*'_#TMM[44N.WO6U$QDD3<6+H:VAGD]1U8>,8_(8J,WLD5(98JI4`M
M>JD(OS[AWFNU>VW#ZI@Q26,`')%?0?/H?;-<)/MLEL%I*KGX0`V<5^SY^G0'
MIM7L_`[F[%S6P.T<'MK#]G2[=JMR[:W!U;AM\TSU6W=OP;=B:*IR><H5:FK*
M*FC:2&2!QK7@\GW78N;][V"V:VLQ"8V->\$_X,UZD>YW3E+>-BY9V;FSDRXO
M+[;(YHTEAOS;Q%))C-1E^EE)8%L$$#CT[0R_).`S>#Y#;=QZSM(\ZXWX\]?4
MXG>9&CF:8S9:I,K21G221=EN#[/1[F<R-Q2U_)&/_/P_R]$K;;[7#X?;Z['V
M[I(_^"T3_+U+^\^33,'/RBJ8G`8!J3H[JF%AKT:[-44E6XU"-0>>=(_I[H_N
M1S,Q[8H*?)/\[UZ;:S]MT(\+VY=A3\>X7!S_`+5%'\NN%OD1)J,_RCW$=9<N
M(.H.E(`WED6:75KVE4L3+*@=N?4P!-R/;#^XW-!XSJGR$2G^>H]/11^VZ'4_
MMA`Q]'O+T_S65/\`!TS9G978>\)MM1]@=];YWIA=L;OPF]Z7;=1M?K';^+JL
MUMZJDK<8:J;;6S\9E/MXZJ4NRI.I<_J)Y]D^Z<X[_NEE-87M[6)SY+Z</6GY
M='%MS-RWLUGNXY:]O]NV^[O+:2U:5)+Z6=89-/B:1+<21U.F@)3SQT)GL/=!
M(J17!H/]6>O>_=4U+_$.O>_=>U+_`!#KUR/H2/\`8_[#W[KQ96I4@]=W/]3_
M`+<^_=:_3^7\N@M[PVM0[ZZ9[3V?E*G(TF/SNP]RTM168FK>AR=,(L9/6134
M-8@+4\Z3TR\CZBX/!/MV*H8&AT\"?D?GT._;/F2?E+W"Y%Y@L+6WFGMMUMV*
M2KJ1JR*FEE'Q*0^0?MZ8OC1M"BV)\>.E]J8ZOR^2HL=UUMB:*LSM=)D<C))F
M,;%FJH35,ECX(ZO).L,8`2*%4119?;:D55J]N.G?<W?;K?\`W2YOY@N[:"*6
M;=9G"6RB.-%5S'I"X`%!7A\^EE\:_DWM7K'X^]9]5[XZM^0`W#M/:,>VMQTE
M#TKO#*8YJN&2KCJDI<A2024U;231R>B1&*.C7'UXR`VOG7ENTVS;[66[;6D2
M>1_9^7^#HD]QO:O=.9.>.:^8MLYIV%MMO;Z6:(MN$8?1(U5U+2H(KD$`CI`9
MFJ^)6XEV_%GNN/F?EJ;:6+@P>UJ2JV+VB(-OX3'RA\'A\:8(898\=M]+QTL;
M,VI"/N#.T<31F/\`7[EG_E,/^\GH%CV2YD%:<V;!_P!S&+_-TF\IMOX49>GQ
M]/4]2?,B,XZBS%&DM-L/M&`UCYU<2F1K,I3K":#)S/'AH4CBFA>E@C&B.)$6
M-4]_7[EG_E,/^\GK?^LGS+_TUFP?]S&/_-T8+J3OGX]](8C,878G5WRFI\=F
MLJN8JXLQU#V)FI$GBHJ;'PP4\U9`[I3Q4E*BC5JE<W:1W-B/#GWEK)6[-:?P
M_P"?K:^R',;%1_6CE]GKBNXQ8/#TZ0/6&8J-T[D[XWR=N;LVQB=]=U9/<6VZ
M+>FWZS:^=J\*-B;%PZY"7#9`"LIH)<CBJA$+@%_&3;GW"/-UW;WW,.XW5K+K
MA9A0_P"U&/RZDCG*"/;K#D'8AN-K<W6W[''!,UO,)XA)]3<R%0Z@"H6120*T
MKQZ%OV&^@/U[W[KW7O?NO=>]^Z]U[W[KW7O?NM5%0*YZZ]^ZMI:@-#0BH^8Z
MXLZ(K/(P2-$>1W:VE4C1G=C<@`*JDDFP'U]^!!.G4-73D8=KFWBAFK>2418_
M(U-!J]*G`]3@=!EU5W/UAW=A<MN'JS>&/WCB,%N"MVQEZO'QU42T.:H522:D
MD2L@IW99(95DBE0&*:-@R,0??B5'XU_;T)^<?;[G?VZWBRVCG7EN:PNWMUGC
MC=@`T<@JK]FHT-?/@<&AZ$_WY&4LH#"M>@M&"'7[>DI@-K8;>_R,V/M7<$,\
M^(S'27;]/5"DK*K'5D30[LZHK:2JH<C0305M!745;31SPS1.CQRQJP/'N4_:
MTD;E>GS\$@_[WY_E_+HWYH4I[,;M&ZD,.8K*H./^(EZ1CH%'?XUT=/$^_P#X
M9]D86CW#D\Z]/64NX\CEGS^(P.ZS0_WIS\^0S.V:IY=PRQ5<KQ3O-4U%)'.I
MUTLJL\XU;U/6-W4#:&0^`5=MZ"GDZ$[1Q%#MZ;+8+:E!#A]X5M=N6AW%3;=Q
MM)1URQY:)Y-P9*FQ,+PT&08K"*26JA9HU:?W[4W\1Z]09-,]";U!B_BGV]N3
M;_1<'5/8>X,;L.NWS(^[-TTU3C<=2;\W)DJ_>>Y=K;FQV*R\M+1%:"FADH(I
METTJTD5(8X@L2R>J?4]>Z5=?`U;\X.Y,:]1&*5Y.A:R2@#@O*</L3=&:%88+
M?MP0U&-AB+@V/DTM]%O"_,D<C\]%UC8J+=<T)`[6\^LB=Q)'LQ[:U.-.Y?\`
M:<O^'/\`/HZ@^@_/LVZA]JZFKQKU[W[K77O?NO=,&[/^/4W3_P"&UN#_`-T]
M;[?M/]SK#_FLG^'K3?!)_I3_`(.M;_\`^\8^YG_[:N@9_P!`=?_5VS/@K_V3
M?@__`!(W>W_O[-_^P3O>G]\W6H]O;7]@Z/MN%;6T']$]#=VQ3*VVJ/)@1B?"
M;APE3$Y.F=X<A5C#5E+3$W0M4P9"Q5@%('U!"D`3FJ%)MHDE<YA:H_,@?Y>A
M+L\LL6YE2I\%DI7_`%?9T%#?J/\`@;<?X<?XV/N,/#<)XE.SH9!U)H#GKKW3
MJW7O?NO=>]^Z]U[W[K72"["W=E-GXG"S8';4>[=P;FWKL[8F`PD^=AVU2U.9
MWIFX,)02UF:GQ^42BHZ>:<22-X)#I4V'M;MUC-N=W!9VPK-(U!FGG0U/D!YG
M]G0@Y9V3;][O[U-POQMVW6=C-<S2)$TY"0KJ:BQM&6:E`!ZD=/IVA\M!_P!R
M^[$_]*"H_P#6'_-,?S[''^MKS!Z1?\YC_P!`].?6>S__`(4W</\`N5R_]M?4
M''X3Y0Y>!JK$]&];92E2>HI6J<=\C<96TZU5),U/5TS34W6DD:U%+.C)(A.I
M'4@@$6]^_P!;7F'TB_YS'_H'KWUOL_6G^N;N'_<JE_[:NL-1C?DS235E/5=*
M]84T^.I(Z_(0U'R2Q,,M!0RLR15M;')ULKTM)*ZD+(X5&((!X]^_UM>8?2+_
M`)S'_H'KWUOL_P#^%-W#_N52_P#;5TYC:/RS-[?'W8AL;'_G(*CX/]#_`,8Q
M^OOW^MKS!Z1?\YC_`-`]>^L]G_\`PINX?]RJ7_MJZ"W?.?[2V[6YWKKM/J[#
M[+J=S=/=G;OP.3P79%-OB*>':E-B\9DZ&MI4VKMR2CED.Y87B</(K!6!`/L.
M[YRMN'+KVK74V9R>T-J%%H#GC^(<>A5R[LW+5X^S<S\H<X27]O!OME:RQS6L
MEH5\4M*KAC-,LA/A,*$*10>72QZ?_P"9/=3_`/B--A_^\MB_8;`"@`<!T%><
M*#FWF<+P_>%Q_P!76Z$;RO\`U_WD_P#%?>^@W0>G7O*_]?\`>3_Q7W[KU!Z=
M>\K_`-?]Y/\`Q7W[KU!Z=>\K_P!?]Y/_`!7W[KU!Z=<&8L;GZ_3W[KW7'WL`
MG@">K,"FG5C4I8?8./\`@X<>O?[?_;'W[2WH>MZ'_@/[">O?[?\`VQ_XI[]I
M/IUK0_\``W[#_FZ]_M_]L?\`BGOVD^G7M#_P-^P_YNO?[[Z'WL(QK1>O$$?%
MC[<?LK2OV#KQM_7_`'W]?>A7NQP&>M"2BX4T4U)KY`4TD4J:_:.@SP6=[>WM
MD-Z+L+K#:&4P&SMZY38YR^YNX*3:%;E,GAZ'`5E?4T^&?9>8,5%&^XZ>%6-0
MQ9R+@:E!&.T<E[MO-DM[:*O@DD"LFFM*>0!QGH6;EM'(G+4&R1\P<[W%K>WE
ME'="**P:=425G"@R>,G=5#4!:#&3TL8]G_*.8SQIT=U]4-!)X:B-.^J:012F
M..4P5"?Z,V:*1X)E;20#H8'Z$7,_];?F6O9].%^<K5_XYTC&[>U`6+1[D7Z%
M:`D;5)J-#4$$70IH:A`\_+H(>F?CM\B>F\)N#:F!Z`Z?QYSV^=[;_GI=O]ST
M>'!@W5N*KK:"*HHH^M3).<3CY(:/S6T6A"H`H"^[-[<<R,S$"V`/_#&_Z`Z&
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M+W8K/>=E-Y#,IG$\;(8X6$;KX4T;@NDYJLC/3A7'0A?;]Z6`_P!FL[=_U_[K
M]*W/T_)ZQ/\`3V=?ZX7-/_*:G_.->@Q];R5_X2S:O^<M]_VU]>^W[TO?_9K.
MW>/^S8Z5_P#M9"_OW^N%S3_RFI_SC7KQO>2C_P""LVH?\W;[_MKZ:\1MKMG`
M155/@ODGV1A8:_(565K8L7LCHK'QUN4KF5JS(U:TW5L0J*ZJ91Y)7N[V%R;#
MWL^XG-39-\I_YMCKWUG)7G[6[7_SEOO^VORZ4_4NWLUMCM3(YS.;_P!V=B[@
M[/BBCW#D-R4&UX:@0[2V]+3;?DIJ3:VW<#38^BI$5XI)-($DTZ!M3%?;FU;]
MN.[;R;B[JS>'1F`H*^6!T3<Z;M;[OLNSV5AR_9;?;;<72*.$S$TFE,KN[2RR
M%J$^IH.`Z.$/H/I]!]/I]/Q_A[''47DL22QJWF?4]=^]]:Z][]U[I@W9_P`>
MING_`,-K<'_NGK?;]I_N=8?\UD_P]:;X)/\`2G_!UK?_`/WC'W,__;5T#/\`
MH#K_UMLSX+?]DWX3_P`2-WM_[^S?_L#[]_R5[S[%_P``Z/\`;32VLS\CT://
MX*CW%B:K$5S3I!4F"5)Z64PU-)54D\=51UE+(4D19Z:IA5QJ5D:VE@5)'L/7
M5K%>V\EK-_9N*'_#T=0W9BE22(?J`XKT`&XL)D=FU%-'EJREKL/6NT%'N`0&
M@-/5@-)%CLY#Y7I*>HJHE/AGC*PS."FB-B@:-]WV.2Q_4A.J&M*="RPW-;O]
M!T"R\:^1Z;8Y8YD66)TEC<!DDC=)$D4_1T=&970_@@D'V'<U((-1T:M&4`)(
M(/IUD]^ZIU[W[KW7O?NO=!?V9_P.Z3']?DKT&/Z\_P!_J#^G/L3\FC1S%M`/
M$RG_`(\.A5RJ`UKS[*K`Q_U=W"A'G^DG#HQ+_P`P7XT4>\LEL7<VZLCLS*XK
M.;BVQD*G=&'J*/%TVXL#O*JVC3X>2JI'K)%J-QQ4;Y;'OH$,F%_RF1XAZ?>3
MNEOX&_8?\W6+BZR`=%/]LG_071'(:3X89;";SDC^4'R`ZRVYMJOW3AJJEPN[
M<QL_;-%C\IN!"N:H=N8'`F+`8*IRV4IH:!:J.E>>*D.A?"U1JWI;^%OV'_-U
M;OJ1H_XTG_073MN#KSXN1PY7<&_>XN_]O;1S^&Z_W!O3<NY=\8,X^JHMX4-7
M3;.V-GU$E9O/>%;GZ'+/&U32TM?%"@1/N898]2:TM_"?V'_-U6K5IH_FO_07
M1R]N_,[XH;"Q^W-@3]OU[C&8W&X7#Y;=&#WI-49TT\.5AIX5R]5@%;,9$46"
MDF>0:@].\,H9EFC9]Z6_A;]A_P`W6^[^#_C2_P#070!_,V7>6ZNY>FEZSQ^V
M,C4[L^/7>=*/[\9'/[8IZ3$9[)=61I7^*@P>3R*Y*#[J,_:SP0D#4'*L-/N'
M?=9TCDV%61R2)>`]#&?/[#UE%[*77+ME[?<R;CS%/<QVUMS1M4J^`D4A9HX;
MMM+ZV6@-,:2?GT_;&P51M78VRMJUDT-16[9VEMO;]744VO[:HJL+AJ/&U$U/
MY0LO@EEIBR:@&TD7`]P\RE6*GB#T5;]N$>Z[WO&Z0H5BN;J650:`@.Y8`@8!
M`/`=*?W7HJZ][]U[KWOW7NO>_=>ZZ]^ZNJ,U*>A_E_G\N@_WYE=X4L^P-O[$
M;;$&X]_=BX78]-7;NI<I787&PY+%YW*5%?/18>MQU=52Q+A@B(LR"[W)L/9W
ML6TOO-_#MZ730RR5TL,\.-?\G0KY8VG9KF#FC<N94OUVO;-M:\TVK"*21Q)%
M$J%Y49-)\6K4KCRKT_[QZX^06P,9297=79?0%#35^1I\/CH:'K#M_.Y/)Y6I
M@J:F''8K"8+=N3S.3K#244TS1P02,D$,DC`(C,)`_P!:J<G.YPD^IC:I^9HW
M$^?10W//L@"=/+O-)'SNK$G\R;;H-J?.[KJL979F#Y'_`!0?%X[$UF;JJQMH
M]E1Q''4+Y1:AZ7R;X1JZJT86JECIX0]1+3Q&5$:,AC[_`%J9_P#HXV__`#C;
M_H+JO]>O9+/_`"&^:?\`LIL/^V?I6R83LJ%:=YODA\,8EJYJ>GI&E7<,8J9Z
MRDCKZ2"G+]GCS355#,DT:K=GB8.`5(/OW^M3/_T<;?\`YQM_T%UO^O/LC_TS
MO-'_`&4V/_;-TL\/T[\CMQ4/\2V_VG\9<WCS45=(*_$;4W[DZ,5>/J9*.OI?
MN:/L&>#[BBJX7BFCU:HY%*L`P(]V7VH8U\7<8<#%(VX_/OX=5?GGV7T-X.P<
MT*__`#U6`K\B?IB1^72(V[5=A8OL;LWK/L>?9.1RNQ*38F3H\QL?'9[$X^MH
M]Z8[,5O@JJ+/97,5"5-$^*L&24(P?Z<>P!S)LS<N7S[=+.DCF(&J*5`U$@5J
M37A\J=&V]6O*]QRORQS+RI%?16>XFZ0I=/$[JUNR+4-$B`@ZOQ"N.L_5W4VV
M.RNO^^<ANG/;JP6,VKWIV[-E3M&;'P9#*[<FVMU7G\MBQ45U#62T<KU^T:&>
M&HI6@J8Y:>RR*KL#-WMX=7+4``-1(P_DO0$]["/WKR/4C/+=IYC_`'Y<=`[1
MY;X8;HP^WY$^4GR*V=-4T&%WUCMJT^]=V#.O@3DIJS;^1W%0;?QV8J:$-C\5
M-`*?(5$571TI0U<<,BQ%1SI?^!OV'J&<&O>G^]+_`)^NMY8WXH?W=&[=L_*'
MMS'YNKGV=/AYY\IN6ORO6%%FY-M=?9+,R459CZ;+[>R;G*I/,M;4C5D9="02
M+(U/+K2W\#?L/7L?QI_O2_Y^CY=:=8=0[[[(B^0NS]_;NWK_``3-Y/&X/'Y#
M*UE1M?:^;HML5&Q,]046/R5'!6Q9#'T-7+2S"5FEI:D2PL0_E0>H?X37[.JL
MRKQ9:?:#Y_(]%'Z!_P"9583_`,.+LO\`]^EO7_8^\2MU/^[7<5((832<?E*_
M^?K*[W$HG.6]1NP$NFW.FM33Z:'.*@?F>AD]H.@5U[W[KW7:B["_/_(O?NO=
M)S&[2K\[N;+T^V*?.8:JDK<#+N/<5%N2KQZ#&SR_<M(:$UA2LH98Z&6)8X@)
M/N4L51"784\OV6Z7MQ"UO<A;1/B`^+]GG^WHOW::U@M!',A,CBHP".CE-RQX
MMR>!:PY^@MQ8>Y)IIQZ=`$\3UQ]^ZUU[W[KW3!NS_CU-T_\`AM;@_P#=/6^W
M[3_<ZP_YK)_AZTWP2?Z4_P"#K6__`/O&/N9_^VKH&?\`0'7_U]LSX+?]DWX3
M_P`2-WM_[^S?_L#[]_R5[S[%_P``Z/MN_P!Q;3_2GHWGLC<%E(4T/2Q&TL&Z
MQS0P5$;0U,,-3"]M<%1#'/#(%-P'BE5T<`\\CW98H&1TGBU]O\_7I\7#AE,0
MHU?Y=%JSVWI=GY?^'@F3`YBHJZO`U7A6&.CJYZFJK:S;DX1S'Y*=',M*X5?)
M3ADMJB):+=\VU[25IP/TBU.'#H;;9>B\C\)C21*>=:UZ@^R#@SKZ&GV]&++I
M-*]=^_=:Z][]UKI`=B[7W#N;%;;DVKD\)B]P[1[#V)V!BIMQ4-=7X:KJ]DYZ
M#.)B\C!C*NBK_MLAX/&S12*R7N+_`$]F>U[B=LW"TOUA#M"Q8`F@))!%:9IC
MH3\M;OM.VW-_'OEC/+M%UMMQ:.MNZQ2*)U"^*A=)$+)2H5E(/#I]J-[=^U4_
MW53M7XF5%3]W'7BHJ.O]]3S_`'T4@FBK?-)GC)]W%*`RR7UAA<&_N0?]=3<?
M^C5!_O3]%?\`57V3Q_RM7_.>Q_[9.FG^,=Q^".F_T>_#7[:(RF*G_P!%N[_!
M&9Y8IYS'%_&O&AFG@1WL/4Z*3R![]_KJ;C_T:K?_`'I^M_U6]DO_``ZO^<]C
M_P!LG3C7;O[XR<E/-D=G_$?(34E!'B::6NZ\WQ5R4^*BG2J3&4[SYUV@H(ZF
M-9%A4B-74,%N`??O]=/</^C5!_O3]:_JK[)_^'5_SGL/^V3KJHW?WQ5U,%95
M;/\`B-45=+I^VJ:CKO?$]33Z59%-/429PR0Z4=E&DBP)'Y]^_P!=3<?^C5!_
MO3];_JK[)_\`AU?\Y['_`+9.FBKB[9WMVAMKL;LK(=9I!M#8^[-G8C#[`PNZ
M:"28[MRVU<E45E=4[AR^0B$5&FUT1(XE4MY22;`>PGS/S3=\S_2)<0)%%$K@
M!"2:N`*U.<4Z-9+CD[9>4K_EGDVUW,I=;C!=2/>RV\E/IXIHU6-88(BI)EKJ
M+'X:4SA?DW-_Z^PO2F*D_;QZ"^IG[W-7.3]O7O?NO=<78(CNQLJ*SN?Z*@+,
M?]@H][`J0!Q/5XHVFEB@3^T=@H^TF@KZ"OGT`&,^1^T\WCZ/+X787>F7Q.1@
M6KQN4QW3F[JK'Y&CD)\-90U4=.8ZBEG4:HW'#*01[OX?],?S_P`W4D7?M9O5
MA<RV5]S!L$%[&:/')N=FCH<893+4'U!`IU,?O[#1QO+_`*,/D"PB1Y"J]*;P
MU$1HSD+J@5;D+87(Y]^$=336.F(_;3=)IHH(>9^7#([`?\E:S\R!6GB$D"M3
MT5[KK=G<GRYW5M7O;J;L[?/0'5>TIMV;!W7U/O?8U!DLCN7<6-D>2/=%+2UD
MJ8S(T53!7P1,:AEDH9J5T0,Y8^_'2!I&:5\N/4S<W[-[<^RFQ[[[5<\<H;=S
M+SO=-!>0;I9W\RQ16[J/\7_2P6#(]36O<*XZ,I3[6['Q/;'QQK=T]N-O'%+W
MQMR-L)_H\VSMD/42;3WN(:LY3$U4M6!3%2?';1)?GZ#V+>1W9>:=H0)53J\^
M&/,=1>^^<H;CR/[L6VS<C';K@<OEO$^OGN`H%Y9@#1+3XL_9Y5Z%G>GRE?<^
M+J]L=G?%GM?<M;2;MRM/M,]='=`I9<[@JO=F/H<ACMXP0;7R^%IXL911QU66
M@>.&V5>G5)%2H4Y*%&J:`TZPP*Y[6!7[&_R+3]G0<U.*^.>:VEAM^X;X-[JI
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ML;X^9%L?7HBUU`:O:^ZJ@T-:D3R1+64GDT2JK,`X(!/U]X\^YJB3F4T)_P!Q
MX_+YL>LB+,%_:?VQ93V"XW/[#66$8/RZQ;+R'=_5TW86.V15].Y3:^^M^9C?
M1IM[8/><F7I)<[B,)BZS%5)PV9I\;5TJ+A@RMXP660AAQ[KLG/5UL=@MA!81
MN@8M5F8&IIZ8\NC??6]N.;H]AGYEM=ZBW.RV^.T/TTUMX3K$TC*X$MN[JQ\0
M@C41@4X].Z[O[O2IGK4V5\2TJZJ/Q5-6FP]Z+55$6IW\4\XRHEFCUR,;,2+L
M3^3[./\`73W'_HU0?[T_1!_53V7]>9_^<UE_VR]0X\_W!#J,/7GP_B+R-,YC
MZZW:FN5Z>&E:5M&2&J1J6GCC+'DQHJ_10![_`%T]Q_Z-4'^]/U[^JGLQY'F?
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M2+#&\LII&!Q]>A<V=UW-@LS_`'FR^5@K\R<9-BXX,=1-18^EIJB:">='FGFG
MKLHZRTX\;RF)(P6*QJSD^Y+V7E^'9FD<SNT[<:&@K\AGH&[GNR[AX82'2J8K
M6M?Y?Y^A1]GW1,>O>_=>Z][]U[I@W9_QZFZ?_#:W!_[IZWV_:?[G6'_-9/\`
M#UIO@D_TI_P=:W__`-XQ]S/_`-M70,_Z`Z__T-LSX+?]DWX3_P`2-WM_[^S?
M_L#[]_R5[S[%_P``Z/MN_P!Q;3_2GHWGLFZ5=>]^ZO')X;%@H..@V[;)CV+D
M:I:62J./R.WLAHA$1JD6FSV.\TM(9GBC6<4TDB\NH9&87Y]DG,L/C;)=A$&M
M2I_(<>C?9&'[RBD9R,\/(U]>@"&XZ2,%JZ@SV,%R`:W"9`QDJ2&_RC'Q9&FL
MMOKJ`/X]Q1DT/D>'SZ',NDR.RG!->G"AR^)R8D&.R-+620A6EBBD`FB5CI5I
M*=PLZ*6XN5`OQ]??NF^G#W[KW77OW7N&>O6'^^)]^KU;6WK_`"'7K#_?$^_5
MZ]K;U_D.O6'^^)]^KU[6WK_(=>L/]\3[]7KVMO7^0ZQS2Q4\,U1,VB"GAEGF
M?DZ(8(VEE<@`DA$4GCGWL9H.MVD37%]'#JJTK*B+0YE8T4%N"KZU'0,XSOK9
M^;H*++83;/<^8Q.3I8*[&93&=#]N5^/R5!4HLM+6T-93[2:"KI*F)P\<B$HZ
MD$$CV=1\N;]-&DT6TRM$P!!'`@\",<#T.KSVYWJPNKBRO]\Y?AO8G*21ONED
MC(ZFC*RM*&5E."I`(.#U,_TSX'C_`'Y'>GJ-E_YQ][BY)_`']T+^[?U9YA_Z
M,TW^K\NFOZAWO'^LO+O_`'-K'_K;UCF[GP30SK_<CO6[0S(/^<?>XOUM&R*#
M;9[6&MA<V]W3E?F'4/\`=/-Q_P!7ET[!R-<)/`\O,_+H175B?WM8F@5@<?J\
M<8Z#KIGLB#:?4/6VU\_L#O.ASNW]GX3%9>B7H/MRH%+7TM*(ZB$34^TY()0C
MBVI&93^"?>CRQS#4D;--3_5\NA'SMRPF[<X\S;KM7-/+9L[F[DD4_O6Q)(+'
M))E/`4X="1_IIP0^NRN]+C_P'WN*X^@_&T/P3[U_5GF'_HS3?ZORZ";\A7<A
MK)S+RXP`_P"CK8#_``2CTZ\>Y\#Q?9'>@`O8#X^=P@`ZB6X79X`.N]_ZGW[^
MK/,7_1FF_P!7Y=/CDK<-)7^M/+Q!XUW>Q))^TRUX>7485>T.\Z.2##9SL?9V
M<ZUWOA\F]92XG-]=;WVKNNGPDE;C'^RW?@!.D%7@=P%AKI9(I8Y^#?VCA-_R
M_NBW"Q-#N,7$'CD8K^75TAW/V\G:.ZM=JNK;>;!U))2]M;BW\0:CK@>@9)8M
M(H]%(((KTI?[D[Z_[R9^2O\`Z'VWO_L+]G8YYYG``_>1_8/\W13%S)LCQQM_
MK;<MY4'_`'$;S'_-7KW]R=]?]Y,_)3_T/MO?_87[W_7KF?\`Z.)_8/\`-TY_
M6+9/_";<M_\`9(W_`%MZ]_<G?7_>3/R4_P#0^V]_]A?OW]>N9_\`HXG]@_S=
M>_K%LG_A-N6_^R1O^MO6*;8>\ZF*2"I^2/R,JH)5TR05>]MLU5/(+@@203[(
MDBD"L`1<&Q'NK<\<S,*'<FI]@_S=5;F#9&H#[;\N4K_RB-GY?VO3AM+84.T\
MSNG<E3N[?&^-R;R&"CSF?WYFZ7-9)Z;;5+5T>&HZ5J+&8FGI:6EAKY?2(R69
M[DGV1;EN=[NUP+J^F+S!`M?D.DV]<Q2;Q9;5ML>TV-EMMD93%%:Q>$H,S!I"
MW<Q8DJ*$G`%.EQ;V@Z(`S`4'7K#_`'Q/OU>O:V]?Y#KUA_OC[]7KWB$9)`'V
M#IFR&XMN8B6.#+[AP.)GEC\T<&5S6,QL\D))`ECAK:J"5XR01J`(N/>Z&G#'
M1E8;-OFZ0F:PVZYN+<,%9X;>65-14L0"@/#%?MZ1F2[HZAQ&?VMM7(]G;%I]
MR;WKY,7M#"KN3&5-=G\E&%)HJ&.DJ)U-02Z@!RFIB%6[$#WLJ0`2"!T?6WMU
MSYN&T;MO]GRG?C8]O4-<W#V\PCA0FFMPR(0H/')IT)@O]"+'\C_'_7]UZ!H'
M8K,P$E2-/GC\5>%&X@<?7J/5U/VL#2K#+4S%X8::D@&J>LJZF5*:CHX5M;RU
M55(D:D\`M<\`GW>&&:XFCAA6I)ZV3''$\LK44=#1M'K^DPK4.9S$LN3W1%$[
M/.\\IQN*FJ(GCJ*?#4`*T\:QQ2-"*AQ)4R)JNX#E?<J;1L]OMT2LM3,PR32H
M^S'ET`=QW"XO&,;'3$#@#S^WH1_9R`0`"Q)]3T6FE<"@Z][MU[KWOW7NO>_=
M>Z8-V?\`'J;I_P##:W!_[IZWV_:?[G6'_-9/\/6F^"3_`$I_P=:W_P#]XQ]S
M/_VU=`S_`*`Z_]';,^"W_9-^$_\`$C=[?^_LW_[`^_?\E>\^Q?\``.C[;O\`
M<6T_TIZ-Y[)NE77O?NO=-&X<<F7P&;Q;Q^89#$Y"D6,`$F2:DF2$H#_NU9BI
M0_A@/;%U$T]I=0)\31G_``=*+:1XIHW0T;4!^WHLN,J/NL=CJE7#-445+*[*
M[$>9HU$UR3=6252I!Y!!N+^X9D0QK%">*`C^9ZD4"A;TQ_@Z;ZY,1F*UL;.U
M1'E\<SM2UE,M315M),:>&IF7'9-8A%.\5-4Q/40*TB!)%\J6/OVB3P]?TYT?
MQ9I_J'5D>-9"'.K^B./\L]0_XID,+J7/HE3CT'HW#10&*.,7`5<UCXQ*V/?G
MFHB5J0_5A#]/;=!Z].D(Q+*M%/EZ=*5'CE1)8I$EBE0212Q.LD<L;?HDCD0L
MCQN.002#[UTUUR]^Z]U[W[KW7O?NO=>]^Z]TVYH7PN:'(OALO]"0>,=4\7!!
ML?>E8^/"OD3T9[*O^[G9&U'_`',@Q4T-9`,C@<=.>TLY0S?%;XC;"H>S</L3
M>.YNN^LLKB,)EMR9_:$>_L)MS:&-;/;7?=.V&BSVWJ>8UL$IJ*619G>%8;/'
M)(IRRV/LV?:@O`6\?_'!U&_NTH7W1]Q%50%&]7E!Z?XQ)TFX.F_EOBJ&IQE)
M\QMCUL=94U>.J,QFJ>JGRL6VLL<=_%Z*F62MJ8XMQTU?6@TF2$BS0BI@11&%
M(G-"Y/D/V=1UH7/SZ5T.,^2XS]/M(_,;KA*A:.JRV,I*/:&TZ_<N6V]MMZ.F
MRE3DEJ</44M//34-9&]:T7D>>J/GC^WA5Z?WK4?0=;"@4^72:.T_D+W7UWM3
M+8;YA[6Q68J'[&?(;BV'C,IM;%YKKG?=5B$V[+08N=L=6TF>VE2X2L_A&;>-
MF1I6=#*#(S;UGY?LZV0&Q0#[`!U"R.WOE=+FMF09GYF]-_Q?'4V[]X4T-!@Z
M3!8W*8%:N:@HJFLQU()8<IC<;29&E5)ZNJ>**9'+05I5I1X,17AU4H#3CCHP
M712=F1;LW=N[M+O?K_L+;^XZ?"8KKG"[2JH:.FP^/:KKI8)*J14QE!N')9JJ
M6;PUT-+&U5$FF.\2(JZU'Y=;TBM>BY$W^1?RS%R0.P>M!R;_`$Z3V-Q?^@M[
MQP]Q>WF?<'''3'_U;7K)F5`OM_[4LI(+;=<@T/$?O"ZX^O2R]@D9`Z#PX"@I
MU[WOK?7O?NO=>]^Z]U[W[KW37F<WAMNX^?+[@R^,P>)I0GW.4S%?28S'4WDD
M6*/[FNK98*:#R2N%74PNQ`')'NR@$]P8C^B*GI=MFW;AO%]%M>V;9/<WL@)5
M84,CD#XCX:YHOR_R=(3_`$V],?\`/WNKC_K;_P!J'_>LM[L4KE%[?Z1TM^8I
MCH1_ZWO/_GR%O'_9+.*_.GAMQX\3U[_3;TQ_S][J_P#]#[:O_P!=O>O#?T7_
M`'H?YNO?ZWG/QQ_4/>,_\NLY_EX.?LZ+L=W_`!SW5\@.Q<AN_<_26Y*.#JSJ
M>CQ%=N7+[%S-+#4Q[@[0ER--C:C*U%3#',L<L#3K$0VEHR_&GVZ4D"IA:4_C
M'J?EU)YV3W1VWVWY3AV38^8;1Y-RW%I%MXKJ$D:+81:UC`HI[]."!4@=*2NV
M_P#!S);DVAO"H_V7&#<VP\D<QM/+XS-[%PM1B,G=&2L"8>OH8*V6"6))(ON%
ME$4J!U`87]TI(>(4_P"V_P!CI!;[G]X>TV/?N6X+?F@;)ND8CNHC'=.LR`UT
MMKB8@'STD5&#4=#!4]Z]*TZ&9^V>MY]4D4214N^-K33R25$R11A(URR\%W%V
M8A5')('/ORV]Q*&6&(L_]'NI]N,#Y]`!^0/<"AFDY"W<0I4L?I9\#SQX0R<`
M<:>71@NN]MMN";&[SK7A;!1K#DMI4D4M)6)DWJ*>]+N>JJ:2IJJ9J989B:")
M&)N?.YOXPH[Y=V2>T5+R\A`F_#FN/.HX=15O5\PEFVHQO')&=,BN"KB0<58%
M5*E<`CH>/]X]C'6).Y>@M(K*U&XTZ][WU3KWOW7NO>_=>Z][]U[I@W9_QZFZ
M?_#:W!_[IZWV_:?[G6'_`#63_#UIO@D_TI_P=:W_`/\`>,?<S_\`;5T#/^@.
MO__2VS/@M_V3?A/_`!(W>W_O[-_^P/OW_)7O/L7_``#H^V[_`'%M/]*>C>>R
M;I5U[W[KW78N""/K<6_'^\^[)4L`.)-/R/'JZX#'S!'16ZVC&+SVZ<0%,<=!
MG*JIID(&H4.:1,U3L".'7RULJC\@)8\CF(-\MC:[O?1GX==1\@1U(%BYDM8F
M8U:G^#I9=>X3$;BQ.Z\5F\;39.BI]W+5P^?R+)'456W</+K@JH6CGIZFEU>/
M7&ZMH:U_J/8UY7AAOMKBMKN!3`)&H2*\:G_#T'M\EEL[IKFUF83&,8!\ZT_P
M=)?,X2?:N>.#6N:NQ]5CYLMBJB?R?Q"FIHZ_[2;&5TK22"N-(9$\<YTNR&S@
ML-3!/>MOCVFZ6$`&.2I6OH>%/ET>[??R7EJ^O$PXGI'S8>?'N]3MIX:34[23
MX.HU)@ZUWLTLD*0JTF&K)'%_)`#$S$F2)R;@AZ,5XCKDV>GB(^]VWN*C)L&,
M%)39>$,0"=+X>JK)2G/!,:W_`*#Z>]].,!0XZY+NK;X95GR*43-QIR4%3C64
MCDAAD(:8`@?U/O75$H3U$QV>R^2IER-'M^"JQ]0T[4,D&?IA45-+'4SPPU)@
MJ:&&G45440D4+,PT,.3?WOK;@"E!TY4F96HJEH:S'UN'KI(WEIJ>N-'(E:D(
M!G-#5T-75TM0\`-WCU+,J>HIIN1KJG4G*0RU&+RE-"-4U3C,E30*#8M-444\
M,2W^@N[CG\>]K0.K4R#TNVJY6TW3;+FX0K!'=Q,S-\/AA@2P^8->BY4M?LK=
MO3_3G7O=7PJ[SWEGNKNK*7KA<OC,UU;2T\457M[&X3=0PE=#V[C:X4&;&.3U
M/''(T04,H^GN<=L]P]@M=ML+6X=_'CA16P>*J`?Y]*^?/;JSYCYWYNY@V_GS
M9_H+W<KB>/6TP;PY96=0P$1`:C"M"<\.F&IV%\:*MZF23X$?).-ZRD%#,:;?
M&PZ55HA4XJL%+3PT_><4%)"U3AH9'$2IY7+-)K+7]K_]<OEK^-_V'H)_ZT/_
M`(?NR?[W/_UIZ$_:^X^HMG9C&YW;WP9^0=!D<*\DN%E7,=3RC$35.%I,!7RX
MY9>Y6^V?*XVBC6JL;3N"S`LS$^_UR^6OXW_8>O?ZT)_Z;W9/][G_`.M/27R-
M'T/D8T@7X(_(S%4L>"Q>VXZ7;^ZNMMO4\>&QF+BPCT:PX?NND4C+8B!*>N8^
MJK347)=W9O?ZY?+7\;U^P]>_UH<_\K[LE/\`3S_]:>H.8P/QZSE5#4U_P,^1
MGC@J**IBQ])N[KK'XI9*"II*N%1C:+NZ"E^V:;'T^J#3X2(5LH);5[_7+Y:_
MC?\`8>O?ZT/_`(?NR?[W/_UJZ>,3_H/P^2QV7IO@K\BY,AB*G'5V+FJ]T=9U
MHQ^0Q:+'1Y"E2?NDQQ5L<44:!PMU6,:=-VU>_P!<OEO^-_V'K?\`K0_^'[LG
M^]S_`/6GI:[(R>XMU]B=\]CYS8FYNNZ/L/>VT\CM_`[MGVY-GFQVW^MML;8K
M*RK7:V<W#C*>.;*8V7Q+]R9"@!('N(>:]SMMZWN[O[0DVSA*5_HH%/\`,=#W
M?4L]MY=Y$Y<M=S@O+K;[&0320EC'KEO)Y452P5OA<:L4K7H5/8<Z"8U4&M:/
MYCT/F.O>_=;Z][]U[KWOW7NO>_=>Z"KMJ&GJ,?UY3U<$-52S=[=#1U%-40I/
M3SQOVQM16BF@DCE2:)QPRE6!'X/L_P"4L\Q[<A^%I%!'D17@>AGR3))#/S3<
M0R,EQ'L&XE64E64_3.:JP((-<U!'0CT60^6&%GJJ>H^*G7V]8:BJS]549C(9
M?KG;28F6FQM!+0X;;.!P\==49?!G)RU"4=3D*Z.LK(HE\QIGDM'DY]+:FO\`
MBT?'^$?YNL;AS)S#0`;_`'M/^:\O_073;F.Q?DI3[FH=K4?PTZ_GR[[>S&ZY
M:3&Y7`U6,CI**DR4&,Q&6W97XNEV_2U^1S"4R-!#(9Q%)Y%;TLA]]):_\HT?
M^\C_`#=;',G,8X;_`'W_`#GE_P"@^G?,R?+3%;]I<SB/C5U/N7K[-;<Z\279
MD^5V;B\EL[<61QF!J>Q91GUQ9GRT>!R536TD'$L5:$$JK`L/^5;^EM?^4:/_
M`'D?YNO#F3F,#2-_OJ?\UY?^@^DKC^V?E-DMS0[6B^!W7D.1I8TK-PRUFZ<+
M387%8R7(I34-13;C7#3X?+Y+)TSEGH:9Y9*`PLTCRW*IKZ2U_P"4:/\`WE?\
MW6OZR<Q?]'^^_P"<\O\`T'T,FSY.[<ENW(8+LWXV]4[?V-/MS/5+;PVU4X3(
MC$U]'@:`TE'-35K"LR<69RKUH!2EA:FB2(.'U-(/-:VPBFI`@.G^$9_ETNVW
MF/F([CM]=_OO[=/]'E_C']/KOXQ*$^.O2"*`%7J[9R@*+*`N)A`"@<`6'N+[
M;-I;$\2E3\S4]2![JJ(_<WGU4%%&[7-/^<K#_`!^SH=/;JJJBBB@Z`+,S&K$
MD]>]VZUU[W[KW7O?NO=>]^Z]TP;L_P"/4W3_`.&UN#_W3UOM^T_W.L/^:R?X
M>M-\$G^E/^#K6_\`_O&/N9_^VKH&?]`=?__3VS/@M_V3?A/_`!(W>W_O[-_^
MP/OW_)7O/L7_``#H^V[_`'%M/]*>C>>R;I5U[W[KW7?O:R%'44X_RZV8P\;D
MGA3\^@&[(PE9B<O5[MTI4X/)18NDR[PZVJL15TJ-14]?/'ITRX>J22*-Y%(:
MGD4,P*,S+'_-.W7J%]Q@;_%P:-_G^SY]##9[^%XXK%J+*34$X%:</MQ6G6;K
M3+TN+RV6V[6%J>3.Y`9;!RR6$%9.F)I:3*8U)+^FOC7'"H2-K&2)G*W*.`OY
M4O(_!:T5Q@5X^N>J<Q6LK.EVYJV`:>5,#IP[3I?'5;7S2HV@5&0V_52!5T1C
M*015M`SDC4/)78GQ@_IU2`$78'W3FVU#VMK=D]T;D?E_FZURZZFYN145:/`]
M?LZ#O_??[[Z>P!T(NO>_=>ZY:N"&]2D6*MRI'^(-P1;W[KW7```64!5'`50`
MJC\``6``'OW7NH62H(<E2-32EXI%DCJ:2LA.FIH*V`EJ:NI'^L<\#$_[2Z$H
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MM_&@=XXJNUM(J+XDI1*N3109,G`%3T<-?FM\:K$_Z0*^P9@6_P!'_9JB^H\_
M\><1S[GT<W<MM\&\1$?[<_S`I^SJ*/\`6/\`<Y<'E^`G_GOV\?\`:WT4#<NZ
M/COG=V[IW10_*SM#:\.X*O+55%A\!U[V!24E"FX*[^*9RARSG:A3<^-J*^23
MPT]3&L,,+Z"LC*KBQYQY75=3[O`%\S^I2O2A?9/W,(%.7("?^>^P_P"VOI-2
M9;J9\G75O_#@'R1-%-A,EB<;A?[K]@4N.Q,\D69I<'7PKB=H8R6HDV]35](5
M#MY*F>A62:0^1E&OZY\JZ0W[W@T^OZE/V]6_UDO<SSY:@K_SW6'_`&U]*?J3
ML3J+JOL:FW'+\LNQMX[.EQ68J\_MO/;*[26'.[WR-)AL71YB3&1;1EP^+QV/
MHJ.MJ/%1BG$]=7>25)&B23WX\X\L$=N[P:?7]3_-3JC^R7N:RXY;@K7_`)3[
M#_MKZ-=DOF;\<JZAR%%1;[R55638VN,5'!U_V;)/,I@:'4L2[.+,OED1=1&D
M%A?ZCW:+FGE^XUQ0[JC.5_`&)_F/\'GU:S]E/<:WO]OFN=E@BB6=#J-_84H&
M!-?\;'EGS^SIB^-M)64/Q^Z6H\A1U>/K:;K/:$550UU/-25E+,,3`7@J:6H2
M.>FGCO9HW574\,`?8*M`PL[34"/T_,4/$\0<@]/>Z,UO/[D<\RVDD;6YW2YH
M4(93^J_<K@E75N*LK,I&0>AK]J.@)U[W[KW7O?NO=>]^Z]U[W[KW3!NS_CU-
MT_\`AM;@_P#=/6^W[3_<ZP_YK)_AZTWP2?Z4_P"#K6__`/O&/N9_^VKH&?\`
M0'7_U-LSX+?]DWX3_P`2-WM_[^S?_L#[]_R5[S[%_P``Z/MN_P!Q;3_2GHWG
MLFZ5=>]^Z]U[W[KW6"KI*:OI*J@K((ZFCK:>:DJZ>0#1/35,3P3PL3R%EBD8
M'_7]T:$3AXGCUPNI5AZ#UZ>B+*!*E-:&JY''HJN1Q>0Q5;7X#SF3*[;R&.K<
M+D*Q=7W-+%-!E-NUM68-+>0B`T]24"L3'*1:_N(YTDV?>#%;L1#$U:\-0.:4
M^7#H?0LM_8$NV77/V^?0QY&7_23UW/54-.U%DYDEK:2B>IAF-%N/;]=(\=%-
M,JB.6+^(4+(0RJ6A<$A2>)"NHAONT"XB6JM_(^8SZ=!.W\7;MP50*4-.@>I*
MJ*NHZ2NA5UBK*>&IC62PD59T$JI(H+:9$#V;DBXX]Q5Q=XQ\8X]#:OKQZD^_
M=;Z][]U[KWOW7NO>_=>Z3^7D2AR6"R\PT4M+-6XRNJ.-%/39F*!(*B=_I%`F
M2I8$9VNJ![FPN??NO=*(JVIEL258@@`DWU:?Z?D^_=;TD^72>;=>W%=D_B$K
MZ7>/R0X[*5%.[1NT;F&JIZ"6FGC61"NM'9+@\\>]T/3OT\W\'^#IYIJFFKJ:
M*LHIXZJDG4F*HA<21OI9D8!E^C(ZE6!L58$$`@CWKIIE9#1A0]9O?NM=>]^Z
M]U[W[KW7@+\#W[KW7K6_IR;?4?6]K?Z_/OQH.+#]HZH'4F@/7(HXL2IL?S:X
M_P!B1P/]C[]^8_:.K`U(`!K]AZXD6_I]-1L02!<"Y`-P+FW^OQ^#[]P\^KB-
MS^`]-^2GKH((FQM+]W,\VB4620PP^.5O*L+UF/$Q,JHEO,FD/J-PI!>A1')#
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MQ\@8-I2#.TM75QT^,<K8FHB:2G(N=*,`C!.ZY0NH9/!@8S6S'U&*_:1PZ/[;
M?;.>(_47+Q2!?GW&GRX5/3LW6V[%Q[5D>Y(6SP/F7!QP1IMUXUX_AW\5EB7+
M_=R+>U7Z8O):\/CN/9F_)ZBP\.&35<`87U/I4X_GT70[\AF0-:Z$KQ#$D?,=
M(:ERDU298W:JI*VE?P9#&U3-#7XZI%]5/64Q=GB:X.A^8Y5&I&92#[`TBRP/
MX+(0N1GU'0D2<2*'CED(/H1_GZRMDLCBZS';@H#//7X*H-7'3QR-KKJ*1#%E
M,42;D_Q&C9E0?BH6)O[(]F.TW_[OO(YV?3'4!C]I^6>F[F'ZRUN+<EM;#M+4
M-"/,?/HS=!74>5HJ3*X^H%719*FAK:6I4ZA/!4+YDD_-G(>S#ZJP(/(M[E_Q
M4F59$:H(K^WJ/)(S"?IW?4Z8)ZE^_=-]>]^Z]U[W[KW7O?NO=>]^Z]TP;L_X
M]3=/_AM;@_\`=/6^W[3_`'.L/^:R?X>M-\$G^E/^#K6__P#O&/N9_P#MJZ!G
M_0'7_]7;,^"W_9-^$_\`$C=[?^_LW_[`^_?\E>\^Q?\``.C[;O\`<6T_TIZ-
MY[)NE77O?NO=>]^Z]T'O8L6[8L5%FMIYNIQTV!^YKLGBX:*AKAG,8(E:IBCC
MJZ&L?[^BBC:2G1=(E;4A()5E*MT2^6(W&WW1291P\B/\_1CMIM3,([B`,#YU
MI3H%*:HFKWJ<[59=L[6Y=HYFRH6GCAEI8;QT-+204EJ6&CHX254*+EBQ:[,3
M[BZ\N9KVYDN+EQXQH#7'`4Z'<<,,*+'`FF(#AQ_GT('5V0IZ7+;FP\S-'/DV
MH=PXZ*P6.J2"CAQ67>$WTFI@G@@,@_45E5N0#I'/*%W6R:RD;N$A(]*=!CF"
M)DEBG08ID_/IHWGM:3:E95YG%X^HEVI4P/6UU-0@U/\`=RO1YI<A6QX_FH7"
M5D3"1Q!K%-*KMXPCW4LYBV9H+F6YLHJPT)-/YGI9M6X"8:96.H\.DX"&564@
MJZAU(((*L+@BWX(]@WH^Z[]^Z]U[W[KW7O?NO=<7CCECDAFC66&:.2&:*15D
MCEBD0I)%)&X*21R*2"#P0??NO=)23"YF*"3$X_)QKA:I%IB]8]2^8Q-$[**J
MEQU6BNE<DE/JCA-1IDIM5]<@50-].:QTJXDBIXH8*>,004\<<,4,=TCCAA18
MXHD4&P2-%``_H/>NO>-+Y-TGYXQA<M!74Y*8S/5T-#E*2]HH\K5#PX_+0`?H
MDJYXTIZA1Q,S(_ZD);W5BZ-&=0)E]>E$;7X^G_&N1_L#[]TSU[W[KW71_P!8
MG_`"Y_VWOW5@I.:]=2RQTJR3U#B.""*2>>9C:.&*-&=WD8VTJJ*2?\/=HU,K
MF-/[0>7GTV31RI4A?XOPG[#TM=D]:8W)8:FS6YH\W45&6DJ\FF'J\U70T--2
MU]9-/CFDHJ9X)4F;%&'5`TK11$D!$8M>1=MY8VOP89;NT#.R@G.:D5^7GT$[
M_>[GQ9([>@"DBOV&E?/I<R]8["DC"1[<IJ-UOXZG'5%=CZR)BI`=:NEJHJEB
M#_JF8#^GLWEV+9)(W3Z`"HIT7KNFX!@3?-3[!TT3=3;9_ATU/0K64>7:62II
MMRRULV0S<-28UBABJ*FJO]]BECC5&I);Q,E[!9/W`DDY?V\VCVD=JJ@T[JY%
M/R\^E";S>!U:2Z=E\Q_J/2.'7>_V/A\VT(-2&,Y)*[+S")CZ?N4Q4F'0R2*/
M6L35&FXTEC^KV'AR6S34-WHMSQTFII]AI_AZ-)-_LVA4^`[7"FHJ`%K\R#_D
MZ4^T=H[TVAN&:DCS5)F]E9`UN0JI*N*GH\O39.2")(RE/3P!7GK)8E$K1M]N
MR`D11.!K$^V;?<[9.MNDJOM@'$_'7[*4_GT4WE_:WL&IX"MV>-,K_G_ET+?L
MW5`A?2Q*EB17_!T4DUT_(4Z][MUKKW^^_P!Y!_WL>_=>Z]]/>B:`GK8TDC57
M3\N@9[6I88Z_9^16%!4RUN6Q,TR(JRRTLN'EKHZ>:3TM(D=1C@Z*20EB1;4?
M8-YT5#;[:_@@/G*C!'S^?0BY:']N7<EO+[/\G0?G\VXO_K'B][?GV`,$@-\/
MG_DZ%JD`@GAT)O5%7&E+N3"%V1\?F4R-+2M<I#C,U14T^NF(&G[=LS%6Z@+"
M.0D<7'N2N6+[ZBP9)&K+&U/RIBG0*Y@A$%R)E7]-AY="S[$X-17HE(I3YBO7
MO>^M=>]^Z]U[W[KW7O?NO=,&[/\`CU-T_P#AM;@_]T];[?M/]SK#_FLG^'K3
M?!)_I3_@ZUO_`/[QC[F?_MJZ!G_0'7__UMLSX+?]DWX3_P`2-WM_[^S?_L#[
M]_R5[S[%_P``Z/MN_P!Q;3_2GHWGLFZ5=>]^Z]U[W[KW7B+@CZ7X_P!O_MO>
MTTAB774I%*=61RC:AQZ!C=_6^0<Y;,;-K8Z*KJ(:K(S8&6C2JI<CF`_W+/0/
M+54\6+DRANE0MGB=R'41N68AK=N6K2Z@N;R,Z9`#V@5KC[13H166]&-8H)(J
MJ3@UX#]F>@UIL[)CJC$;MQ-%5Y.;#ULS28FG2*/(UM#5))B\SBTCK)*>&#*4
MZ2%@DCIHGI]+<'V!MHW`;5N5LTRD)725]*8K7H0[C"EYMY@3^T;(;T_+HQDC
M8[>^TZ@4T]3#C-SX.H@6I5/#64\.1II('NC7"5-,6*NA)`8%3[EB13>VLD4$
MP6&:)LTKQ!^SH!0R26MS)J%!"XK\Z?X/Y]%[>"MQM=4X++QT\&7QL=.THIW'
MVF0HYPXH\KCE:T@I*A8B&C(U4\JM&;V#&'+ZSGVZY:WN4I7X#_%_F_GU(5M-
M'=VZW$+5!XCS'7/VEZ=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH>1H:?)T%3CJ
MK6(:E`IDC?QRP2(Z2PU$$EKQSTTT:R(P^CJ#[]UL"IIU!PV2FJXI:'(!4S6,
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M,"1:IE-1T9[1<_3W:UQ&2:_(=`;25E-71>>F>ZZF62)@T<]+,&/DI:NG>TU)
M50,"KQ2!9$868#\P^T<D<\JR`JPQI]/SZ'1*&AC?4A''J0N7GVYD*/<]("7Q
M8,>2I[_MY#;\KHV3I9+#B6E2,5-._P#8FBM^EVN=['>&QO(YV.J+4`5X5J:5
MK\OLZ0;A9+>PB,M1LT-/05Z-.I#"ZE64\JRFZLI%PP-AP1[ER0`2.%-17_9Z
M`#'A\L?LZ[]TZUU[W[KW7O?NO=>]^Z]TP;L_X]3=/_AM;@_]T];[?M/]SK#_
M`)K)_AZTWP2?Z4_X.M;_`/\`O&/N9_\`MJZ!G_0'7__7VS/@M_V3?A/_`!(W
M>W_O[-_^P/OW_)7O/L7_``#H^V[_`'%M/]*>C>>R;I5U[W[KW7O?NO=>]^Z]
MU[_6)'TY'!X]^^W(Z\U3X9K33T7S>])3XW?-0U)I09S"T^7KX$72L>1I*R3&
MBLL+*),C2!0Q^K&F!-S[C7G%8H]QCT0(/$0`XX?,?/H=['*SVI9LT/2ZZKJZ
M>7;#XV.3_*<)E\S15<##2\"U&2J\E0NJGDT]305D;QM^EA<#])]C+E^=)-HM
ME#$K&A!/G7TZ#^]1^#N%R2@*LX:GJHX]-_;T./."HI6I(7W%49.EQ^V,DT<8
MFQE<&?)550U1;R?8ICJ&<S0@VJ!Z.+Z@AYK>SCL5^JA9IF`T,/PY''TQU;83
M))=LT4A$%35?E3H,V-V)_!-Q]/TGE?IP.+>XR[M1(IX7\^AEUU[WU[KWOW7N
MO>_=>Z][]U[KWOW7NNO?NO`T->F#(E<?F,+EG(2GG2JP%;*2`L/\0DBJ<4\E
MR"(FR--X=7T#U`^@/O?5QWU!Z4)#7-U(N2+$?X_3FW/^V]ZZTR@4IT(_45.R
M4V\*J1Q)+4;I2$,J+&@IJ'`8=*6$1JOU@%0X+$DNS$\?02/RFBMM;FE&\9L^
M?`=`WF"1OJDC_#H!_F>A>]BH"@IT0DU-3U[WOK77O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[WHDC(/7L^1H>@0[)P#8W))O+'TDTE+7)#C
M]UPT5+)4SJ\&O^%[A^VI8GGG\",U-4D!F$)B<\1M8&<T;9XJ1WMM$-88ZZ>:
MT\OG7H4;%N&D26UR_P"F!53YU]"?3_+T&>6FA?;^7J$>.:"3"9":)XW62*:)
M\?,Z.C*2K)(K"QO[`@J)$(-%JI'KAO/H3L5(0H<5/_'3T:S$JR8G%1N=4D>+
MQT<C?ZMTHH%9N?ZD>YKC)*ACQ-#_`"'48GB?M/\`A/4_VYUKKWOW7NO>_=>Z
M][]U[I@W9_QZFZ?_``VMP?\`NGK?;]I_N=8?\UD_P]:;X)/]*?\`!UK?_P#W
MC'W,_P#VU=`S_H#K_]#;,^"W_9-^$_\`$C=[?^_LW_[`^_?\E>\^Q?\``.C[
M;O\`<6T_TIZ-Y[)NE77O?NO=>]^Z]U[W[KW7O?NO=`'V-AJW$9R?=DTCUF&R
MXH*"MG9/W-M-1PBGH5D?R>/^`UD\LC,^A3!52W=BD@*`'FS;+R26+<`?$BKI
MTC_0Q_$:<?SZ&&P7=OX9LY!X<AX'UZD=8S20;HW)0`C_`"[!X7*2`VU^>AKJ
MW'.RV!(1J>ICX_U7/Y-UO)]P@3<;5?[(,,<<]5YB.@6]R/[8=M?*GV<.A@S6
M$Q6X<=48K,T-/D*"I1T>"IC5PK,C(LT+,K&&HB#DHXY1N1^?8NEMXKR-K:=0
M8V]?VX]/RZ#-O<R6\PFC/=7RZ+YFMH979/\`#HGJZ/*;;GJ8,'C*I8Y*;-4,
MII7;'Q92!5^PJ8&2E:'S0E&UA"T?J-HQWWEYMK?ZQ9*P,VD#YG/^3H8[?NJW
MI\$Q4E"U)_E3J!_ON/\`?'V'NC;KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ3T]
M/5P34M7"E135,3PSP2+JCEBD%F1U-K@C_8@\CGW[K8)'#IC&)R5%QBL_5K3J
M?11YB`9J.,``*L-7)+2Y-8PHMI>:0_T(^GO?5E[JUZ$SIVNS*9G>&'RE/0I$
MT&&SD<^.J)98&JY368>H8TLT0EQXJH,9"WB9Y3KCD(8CDR%R<[-:7D9^!74C
M_;8/02YBB075HX&6%#]@Z'OV,7`5V`X`]!LX)'SZ][KUKKWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][UU[KL$@@J2"#<$'FX]Z**P.I>SS
MZLC:6!\N@7EZ@AJ*K*PS9V>FVW6U==/2X7&45/35$%-DY'FJL=+DJIJP?91R
M32>-88(75'L&X]AD\H6C74EX;D&.0UTU]#Y4^?1_^_6AA2*.+4_\7IBG^JO0
MQQ((HTC50B1JL<:ABUHXU"(+GDV51[$X`4!5%`!T'CQ.>LGO?7NO>_=>Z][]
MU[KWOW7NF#=G_'J;I_\`#:W!_P"Z>M]OVG^YUA_S63_#UIO@D_TI_P`'6M__
M`/>,?<S_`/;5T#/^@.O_T=LSX+?]DWX3_P`2-WM_[^S?_L#[]_R5[S[%_P``
MZ/MN_P!Q;3_2GHWGLFZ5=>]^Z]U[W[KW7O?NO=>]^Z]UCG@@JH)Z6JABJ::I
MAEIZBGG19()X9D:.6&:)U99(I8W*L#]0?=2JL'5E!5A0_,>AZMK>JMK.H</E
MT6;=FRI=IUV/>&MR"X&LJ):#"9&AR%;09O`5-5&THP557TT\=3D,54QTP-*S
MZR'A6.8,1&YC_>-INMC=KO;IV6!SFA(_/'0TVR^MMT"VEQ"KLF:D5J!]O0T;
M!W!/N#`+]_*DF:Q%7-A\PVCQ&HJ:=%EILD(@`L:9;'RQ5``](9V`^EO8SVG<
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MP]OPPFY:*!<,TBY^7F/SZ]XJQJ]1FG1D=J[8Q6U<338_'45-!/\`;TJY*KCB
MC6KR=;!`L<U;7U"J)*FHFF+OJ<D^L_U]S%;6L%HGAP0*AH*T`%2/,TX]1Q=7
M,MQ<2-)(S:6-*DX^STZ4OM222:GCTGZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOWD5_">/7NO>Z"-!2B`4ZV&900I(!Z]
M[OUKKWOW7NO>_=>Z][]U[KWOW7NF#=G_`!ZFZ?\`PVMP?^Z>M]OVG^YUA_S6
M3_#UIO@D_P!*?\'6M_\`_>,?<S_]M70,_P"@.O_2VS/@M_V3?A/_`!(W>W_O
M[-_^P/OW_)7O/L7_``#H^V[_`'%M/]*>C>>R;I5U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=)O=>W(]TX9\4]8^/F6KH:^BKXH$J7HJW'U25,$WV\K1Q5"'24=&8
M!D8B_M'?V,>X6BV<A_3!_;TNLKUK*Z>[459A3KCMC:F/VK2SPT4M54U-;4+5
M9+(5LBO55]0D(IXV=(5AIJ>&"%0D<42+&BCZ$DD[L+.UV^W-O"A^WKUW?->%
MF89/2F]JND/0;=A[3GS5)39G$0/4;BPA;[:%91&V4Q,\H?)84AY$IFDF6TM.
M7L%J8UNRJS$D>_[5^\[%S$?\;C^#\^/^`=&NSWGTEVA8TC;B?+H&J6JAK8%J
M*=F:-BZ,KQO#-#-"YCGIJF"0++3U--*I22-@&1A8^XL:-XCX<D961<&HI4^O
MV=#HL')8-4'J1[KU[KWOW7NO>_=>Z][]U[KWOW7NFC/6&$R[<7BQU94)<'3K
MI8'JH[V_YN0CV]:FE[9,30>(.K)PF_YI-_DZ-Q3S?<T]/4E2C5%/!.RG^RTT
M*2:;?C0&L?\`$>YL-<5]!_@ZC&3XC]I_P]9??NJ=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW3!NS_CU-T_\`AM;@_P#=/6^W[3_<ZP_YK)_AZTWP2?Z4
M_P"#K6__`/O&/N9_^VKH&?\`0'7_T]LSX-`Q?'FBH9!HJ\9VIW]C,A`;B2EK
MZ3NW?@J:692`4EB,BW4\BX]@;?R!N]WQ/`8SY#T_P\.C[;.ZS@9>":@?ET;S
MV3]*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KQ^G^W_P!Z
M][2FM=7P=;)I&]/CQ3HO&]Z%<9O?(,($B@W%B\?DJ9U70M56XQI:'+R.1Z7K
MHXY:0N3ZFC=3S8VC3FVV^FOHYJ?HNM`?G4X]>%.AIL=SXUF59N].(]!TP>PN
M13!Z.000".'7O?NM]>]^Z]U[W[KW7O?NO=,VX1_N!S)_IB\@6%P+I]I-J'^Q
M'MR($RVQ\O%7JRT`F)_WVPZ-O2\T\)'Z?##I%K:0(D`7_D'Z>YP8@A*'\(_P
M=1C)\;#S!/4CW7JG7O?NO=>]^Z]U[W[KW7O>B:<>MJK-\(Z][\"#Y];*,I`(
MR>O$@"_X_P!8_P"]?7W<HP753MZ\RE#1B`?M'7K_`.^L?]>W^O8>Z@$BH!IU
M4"H8@B@XY'7O>NM<<]>][ZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=)G>U53T.R]XUU9-'3T=%M+<]753RL$CAIZ?!U\TTKN>%2*)"Q/]
M![?LP3?V``J?&7_#UI\0S/Y!37]G6O/_`'5W%_SJ*S_MQ9Y_\T?\U_JO^-?7
MW-'_`&U=`GQ%^?\`95X'AU__U-L+>LF3^&O:_86\<SB<KD/BGW9NB7L'.;KP
ME!5Y:7X^]MY:&EH]VU^[,5CXJBO_`-%?8E1315\F2ABD7$94S><)!.LBEVY;
M6VXJKVHI<Z"K`4JZK4@BN*UP<U(X5Z46=Y]%*?%K].^,?A)\S\O.O1EMN=A[
M`WAB:3/;2WSL[<^$KHDGH\M@=T8/*8^IB<`JT531U\L9^O(X(/!`/L"3P3VT
M@CF@D#'^BW^;H\6:!QJBG1Q\C_GIT^_QO"_\[G#_`/GUQ_\`]4^VL_PM_O+?
MYNO>(/\`41_GZ]_&\+_SN</_`.?7'_\`U3[]G^%O]Y;_`#=>\0?ZB/\`/U[^
M-X7_`)W.'_\`/KC_`/ZI]^S_``M_O+?YNO>(/]1'^?KW\;PO_.YP_P#Y]<?_
M`/5/OV?X6_WEO\W7O$'^HC_/U[^-X7_G<X?_`,^N/_\`JGW[/\+?[RW^;KWB
M#_41_GZ]_&\+_P`[G#_^?7'_`/U3[]G^%O\`>6_S=>\0?ZB/\_7OXWA?^=SA
M_P#SZX__`.J??L_PM_O+?YNO>(/]1'^?KW\;PO\`SN</_P"?7'__`%3[]G^%
MO]Y;_-U[Q!_J(_S]>_C>%_YW.'_\^N/_`/JGW[/\+?[RW^;KWB#_`%$?Y^@9
M[3W)@I\CM?$P9'$O74TE;GIJS^+8\+1XU8)<2],-%06>7*U%6+*;)IIV8\JO
ML)<V*MQ;VL"P2&=6U5T-2G#TX]"?ET&MS*SH(B--"R@UX\">'2!_B^(_.7Q-
M_P`_[DZ'_P"J/8!-K>$FEE.1_P`TW_S="QI(2>R1--!^)?3_`$W7OXOA_P#G
M<8G_`,^=#_\`5'O7TM[_`,H$_P#SC?\`S=5UI_OQ/]Z7_/U[^+X?_G<8G_SY
MT/\`]4>_?2WO_*!/_P`XW_S=>UI_OQ/]Z7_/U[^+X?\`YW&)_P#/G0__`%1[
M]]+>_P#*!/\`\XW_`,W7M:?[\3_>E_S]>_B^'_YW&)_\^=#_`/5'OWTM[_R@
M3_\`.-_\W7M:?[\3_>E_S]<),G@YHWAFR>&FAF1XIHGR5`R2Q2(T<D3J9[,D
MD;D$?T/O1MK\$%;&?'_"WX^7EU99(@>Z1"M/XE_S]#!UANRBJ\!58^NSF+GD
MV]E9<)3U4^8H&JJB@BHJ&LH?O-=0'>HI:>L$!E/,ZQ"3DL3[E'EZ>XN-LC:Z
MBE6=25-4;RID8X=`'>8X[>]94*Z6`."#QK\^A'_C>%_YW.'_`//KC_\`ZI]G
MF?X6_P!Y;_-T5>(/]1'^?KW\;PO_`#N</_Y]<?\`_5/OV?X6_P!Y;_-U[Q!_
MJ(_S]>_C>%_YW.'_`//KC_\`ZI]^S_"W^\M_FZ]X@_U$?Y^O?QO"_P#.YP__
M`)]<?_\`5/OV?X6_WEO\W7O$'^HC_/UPDS^"ACDFES6(6**.221_XI0-I2-#
M([$+4$V"J?=7J$9M#FF?A;_-TIMF#,14#'F0/\O0+5'=C5D:382@P-)3SQK+
M356X]ST6MX95#Q2MB\29F77&P.AZA6%[&Q!`"L_-,D)DBLMHFD8<2T;4!^5`
M>A#%LJR:))[B+Y4=2:?MZ2M9O7+9-V.0[!AAAEL)*'`5^)P5(B'ZQ0SQ2U.9
ML1]6-9J/X(]AN[WGF.Z+,EM-"/X5C<C[>'$]&B[9MR@!HXG/J76OV<>F2;==
M=A*&6MH^Q\C+48]&_AL%5N'&5=,T;3DT6(FI)BZ9)'FE6$2S^2K=2!Y=5B*6
MNX\Q"\V^&1[G0WQ?IMZ_9U:YLMIALVI;0^(P\G7'\^C8#-X?2NK,8A6TKJ7^
M*X_TL5&I?^!1/I/'U]RD`U!J5]7^E;_-T`6=`S!:4!]1_GZ[_C>%_P"=SA__
M`#ZX_P#^J?>\_P`+?[RW^;JOB#_41_GZ]_&\+_SN</\`^?7'_P#U3[]G^%O]
MY;_-U[Q!_J(_S]>_C>%_YW.'_P#/KC__`*I]^S_"W^\M_FZ]X@_U$?Y^O?QO
M"_\`.YP__GUQ_P#]4^_9_A;_`'EO\W7O$'^HC_/U[^-X7_G<X?\`\^N/_P#J
MGW[/\+?[RW^;KWB#_41_GZ]_&\+_`,[G#_\`GUQ__P!4^_9_A;_>6_S=>\0?
MZB/\_7OXWA?^=SA__/KC_P#ZI]^S_"W^\M_FZ]X@_P!1'^?KW\;PO_.YP_\`
MY]<?_P#5/OV?X6_WEO\`-U[Q!_J(_P`_6&HW)MRC@EJJS<6WZ.E@0R35-5G,
M534\,8_4\L\U8D4:*/J20`/?@LC$+'#(S'R"-7_!U[Q8QEW"KZDBG1,.P=^'
MY@3Y/XV_'?*2Y_9V=F_@GR&[[P&N;8>PNOY'T[DV+LK=27Q>[NTMZT0?'I'C
MY*B'$TTTL]0ZL$3V,MCVB:SFBW"^BTL!5%/Q!O5AY#HIO;Z.=3#:3!EKW,.!
M'F`?7JP__1!UK_SR.)_YEM_H@_S!_P"9:_\`/(_J_P"+3_M'^\^Q'XTO\9^+
M5_MO7[>B_2OIY4_+K__5W[ZW_@'5_P#`;_@-/_P-_P"`?^:?_@7_`-,W_'3_
M`&B_O8XCKQZUAOD3_P`S4W-_VYR_XN%3^C_B_P#ZF_X^C_J\_P#'?_FYJ]G2
M?V8_M_S_`,G16_\`:C^R_+CT!?\`Z:"][_YR].?[QU[_`--!>_?\Y>O?[QU[
M_P!-!>_?\Y>O?[QU[_TT%[]_SEZ]_O'7O_307OW_`#EZ]_O'7O\`TT%[]_SE
MZ]_O'7O_`$T%[]_SEZ]_O'7O_307OW_.7KW^\=>_]-!>_?\`.7KW^\=<3]3_
M`-N?_P"S]?K_`&OK_A_3_8^T5Q_:#[/Q<?\`BNJ/Y?#UU_Z9]]WC^!>/Y<.J
M?[SU[_TS[[O_`+UU[_>>O?\`IGWW[_>NO?[SU[_TS[[]_O77O]YZ]_Z9]]^_
MWKKW^\]>_P#3/OOW^]=>_P!YZY+^?^W/_P"/T?\`!1]?\?Z?X6]N)P_'^73B
M\/P]=_\`IH+W?_G+U;_>.O?^F@O?O^<O7O\`>.O?^F@O?O\`G+U[_>.O?^F@
MO?O^<O7O]XZ]_P"F@_H?];Z'Z_X?\1[\?A;^UZ8GX)_9\?/KC_97_MS]]/\`
MD'Z#]/\`A_Q'M##\4O#CY?Y>O#@/@ZZ_],^^W_\`>NM_[SU[^G_;GWZK]?\`
M@Z_3_:O]3_M5O=5_MH^/'\_R^?34WPG^S_/K(?\`S$'_`+'VJ/$_VO2E/@7X
M.`ZZ_P#307O7_.7JW^\=>_\`307OW_.7KW^\=>_]-!>_?\Y>O?[QU[_TT%[]
M_P`Y>O?[QU[_`--!>_?\Y>O?[QU[_P!-!>_?\Y>O?[QU[_TT%[]_SEZ]_O'7
MO_307OW_`#EZ]_O'3_MG_B^8S_MS5_P*A_XOW_%K_P`ZG_`K_:?=D^+_`$?_
M`&O'\NO>3?!P\^'6T/TO_P`RPV=_S*__`(M$'_,E_P#F6'Y_X\[_`*M'^H]D
@LO\`:/\`%Q_%Q_/Y]*X/[)?@_P!K\/Y="A[;Z=Z__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g912919dsp_265b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_265b.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X16917AI9@``34T`*@````@`"`$2``,`
M```!``$```$:``4````!````;@$;``4````!````=@$H``,````!``(```$Q
M``(````;````?@$R``(````4````F0$[``(````&````K8=I``0````!````
MM````.````$L`````0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O
M=W,`,C`Q-3HP-#HR,B`Q,3HR,3HT-0!J=V%N9P````.@`0`#`````?__``"@
M`@`$`````0```AN@`P`$`````0```1\`````````!@$#``,````!``8```$:
M``4````!```!+@$;``4````!```!-@$H``,````!``(```(!``0````!```!
M/@("``0````!```44P````````!(`````0```$@````!_]C_X``02D9)1@`!
M`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`%4`
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/1*:FV5,LL+
MGOL:'N)>[EPWPT-<&M;JI_9Z?`_Y[_\`R:6-_1J?^+9_U+4KGO8R6-DF03^[
MI]-1&1UU7@6LZFAH+G2`.27O_P#)I&B@;29$F&_I'@$G^W[E6L.0YH#G;F.=
M(:1R`-&.V^[W?3_E_P!M6ZJFU-VB)Y<X#GS_`,U-$R3U28@+?9ZOW7?Y[_\`
MR:%>**VD-!=9V;O>=?Y7Z3VH+W^K+[!,_1KG0#\UNWZ+G)V5D-<1PT#<X\:]
M@F'*=H_:N&,=46VWASW#0&6.,".5:QV5V,&\.%@^D-[_`/.TL0G1.DPZ!KSY
M_P#G*DP["QX<'.!G;P>^G[ON:U",Y`ZDD>:91!&U);<9I86UR+.0#8\&)U_/
M4;&T[7,][+!`(WV#^MMLWH6I:&DZ#S\]W/\`6_-^@G:`#IW.J)RGI?VH$!U2
M7-LS>C!CZW9+GPUS6V&DNVOB76U[7-W;?TFU9U'16FY@NZ;=743L<_[=8X>X
M`OO=4VP;W>ST]_\`._\`6U;R/0_8;?7]?T_4&N-)LGU#MC9[MKOYMZS17TKU
M&GTNLA]C@UK3]JT(:[;^DW?H_P";=7O=;^YZOZ/TE9&P8BG=T4AUK&]/LL87
ML>'/SK=36^RUCJ][[GU[?6?_`*/_`*WZ=:6/T*JUY9DX%]+;OIO.;;89&_\`
M2.:+-GK6;][W*C8>A6LI:_%ZN?38_P!.[9D!P9<YF19N=_._SSO39N;ZOZ-]
M=/ZNC@](%=K:<3JV.+[:[7"JN]NUX=ZC#76WV5;;+M][6U_I/0_6/4V(H=,?
M5?IK;-[;,D-VO#F'(M<'.>]EWJOLL>^YUE3ZOT7Z7TO^#4_^;/2)8=EP%;@]
MK1D7[9&GOK];98S_`(.SV+'KIZ;:V*F=;M:UWI.LWY+"]GIY'Z1SK;*7W5,V
MV,]3^>]>S&_X-&?G=/MN&0:>K-#CN>X57-9L;[/TE9#=U=7J6^S9ZMW\Y^G]
M.I)3?9]5.C,>7[+G.=4:7;[[G2TM=2Z=]KOTOI.V>M_.J=?U9Z340:VW-+7-
M<S]/<0W86;6M8^US-GZ)FYBJXKL,L>QM/4`VT/867EY(8W8YK_2O>_\`1NW_
M`*/V?\'?6A@X%C6@-ZJW<-+2;P8<=S6>YV[W.]GT?T?_``:2GHTED8V7CXA`
M;7F6&]K7!KFNMVB'/]+=[_3V3Z?O?_U",.N8Y=M=1DL(B=]+F@$C<UFX^W<D
MI__0]'QOZ-3_`,6S_J6J3G$0&EH>?HAW!CZ7"K8F1-=37:,V,`)T(]K8<[^2
MY$RH]C3]+4QW@?\`F2KF0HD=&01.@*&AMIR2Q['.<'!QLB&N9RS;9O?ZOI^W
M>_\`/5BS)J94^P/:=IV\_G$[!_TE4M#G5D-U(!VATD<1]'<WVJ-4.9[P'D:%
MSF[6O<.7,:_<]E6_Z.[_`-2*,3JZ&[*8WJ>E:!)Z@?L)(+OHZ-VZN,[8:BO#
M64LKW.<7'>#M('A[N-F[_![D/'NNKJ8"=YC7<22?Y/J^W_/]+_K:@YSWN<7:
MO<?<.W\EW?;M_-2L43N3HBC==`RT)YEHC:0"`?CN_=22;P.T:1\$DQ*DXY"9
M..0DI=UCJ^CL<S*&&\V;6VEGJZNL+=GI?G;_`/H?SBSCU)C16]WUJQQ4TAUA
MV8^XL+'/U?NV4^UU5S+/3_L;+/T6B]@?T45FRJG<XP^\-<T$6%_T;=U>]NW<
MQ5*QA2U]_4.G74VDF]OIU-;;`YW>J_W^@?\`A%>CL&N4=K\^G8;?K/0P$1+J
M*0TO&QGTC9Y._1;]_J7?SGT*TPS'Z-_YU8V^:Y&S'G4M;JSU-S?7=6YC/Z[_
M`.0BONHL>/4ZKT]SF^VG<RISH>&O?7)M^C<ST'?H_P#!^E]/^=LEC680L!R\
M[IU];PWU`QM;"Z7>I6W5]FYGKW4VU_\`#6_\(BAJ#J+7L<YWUKQ@_>VT$,H8
MUK-MGZ'8^QSW5O;=1;[[/5_1_P"CN4AGO<]S6_6K&=()]M5!`&YS-'-L_,V^
MF[^HM7UOJVRPP_";8RS:Z#5+;'M<Z'?NVV5UV?V&)FV_5ESAM?@EP)B#5,AS
MI_\`!'6?VTE-$]7QA8YA^L&.RUE=9((K]TULO]>ICG#?ZS'^M^A]7]'96KW3
MW7Y+?5HZK7F4M+F.-;*R-VUOTGUEWZ2IWZ3;_P`(IF_ZO!WKFS##I##:753N
M(+&,W_O>G4YK/Y%:G5U+HE<54Y6*R3HQME8U`'YK7?NI*8#!ZL&_\HP0?:/1
M:0!$!KMSG6/_`.W$;#Q\^I_ZUE#);M@>QK#N]ON]G]I6*KJKZFW4O;;58`YE
MC"'-<#PYKF^URFDI_]'NJ`!17YL;)_LA3&XNVZN)^CW,#\S^PI8V.XTTDD!N
MQFNLQM;_`*_25EK=KM&,:`-'-Y\Q]%5!`V;TU9^(5W:3B7:#41)`('/T>4P+
MS&_:'-$F?@K-NT^IL:V*X+W1#IGW:H%E8VU/,`/EAYC<TN=N_M)IC7BD&V+7
MM`\NPT)'\C:%(!P'CJ21\?-,#NC>1J`6CB2?^JVI20\-&YQ(G;R=`[_R*:N7
M;()!Y=J/_(ITTM<TF-P:)<(U'];]Q.V8$S\#RDA1('/)[`3^11+FD$-,SH"/
M[PG8"26@$OY<!J3X.T4@>#V24N^NNSHC6/\`0:PN`G*:'5`^K^CWUN+6N?ZF
MSTV;OYQ5'XV'0QUF2[I=60Q['X]FQC-IEP:7/LW?I?T_\XQO^%?L]/UE;VN?
MT>LLQ?MK@\.;3N##(LEMC7OAOZ/Z?TEGT].%+J6U?5C'K+2&!PLHV5M&][7_
M`$=^UMW[E7J?IO\`C&5WAL&N67[)I(:QE71R0T,<W[.(:SZ=C6#U/H>S=Z:N
M8N#TD-]/+IZ>;'/`8VJM@!+1N8UK7R[?L&]468GJ[_6^K5++';7^]U-F[>]G
MVACWAI9OK<ZQ[&^IL]*O_!_S2`[&]$5D_5-@:T5-J-3Z26['M]"O]'[F;'VV
MOW_S'I_S]B*'<'3_`*O-J?4,;#;4'38P,K#0YNYVY[8V[F>K9_VXHG"^K=I%
MIHPK"2:P_9422P^ZO='^#>WZ"I/KOL]-SN@;W[#OWW5'9ZC:;;JJG.<[W>H^
MYCMGIL?=1_.?IO53U,OOH]+*Z`RFIK#MK-M3QN>:M]=;*Q[6N]SGO_X+^6DI
MNU])^K[#;:S&QHL#!9[6ED,#JZO9_-L]ECV^U29TCH-H#Z\+$L`(+7-JK,$#
M8V"&_P"C?M_J*J*'T^I71T5K:;##MME;`YK2ZRO=6W_A'(HMRL&F,;IL5AC'
M&JMX]KH<Q]5;&M^C5Z=+&>FWZ"2G3KKKJ8*ZF-K8WZ+6@`#X-:I+/JS>INL:
MVSIYJK+MKGFUCH'&_97N6@DI_]+T;&_HU/\`Q;/^I:BH6-_1J?\`BV?]2U%4
M)W7C9@/2I'@'NU)DZG]XJN`T,O`A]$$$\\#>QS?WMGT5:<T/:6G@\_!(@%I;
MP""-.P.FB:1?T2"YHVS[O>:Y/8EL?2^C]';N:K>*:VM+RX!W\HB6M\C^Z]#;
MCVLIM;VL]NW;N`+1`LW-_?;[6*#2P@.;&O"C'IHTR'U6&R**+`XL)U.I:3'B
MT.KT;M_K(#@YCBU[2".XU!\]$A,R)!\1H5&S7W$^[B7$\<?UD)2!&U%0!'5L
M5`OH+:C#YUCEVOM]WYNYJK$M.T1,B&@B)XV[=_\`U2)BRRP!P:SVD:'DSQ_W
M]/:TLN(&N[W>$2?H_P"<B=8@]M%#21'?5'E&C]@AV2<AM?J,#G89<+ANN#!L
M]#]+M]WZ7T_?Z.]9'J=)87/.;UJQIK<XO_62VL#]*SV>GN]9K7U^G^CM]3]$
MMO?8SI##5E,PG[]+K&A[8WNWMVN+/I,_E*D,R[]'_P!DF&6.=J[TZMSQM<YS
M:W>OLW[=EW\V_P#PG^#_`)NV-@P%I&[HA<VDW]6#FLKKM)9D!Q:/594_)?Z/
MJV>O-C_Y;_TE?_:A2K9AT6M)S>L6AU0=54X76;?5#@'W,>Q^ZWU1^C^TLV5V
M5HXS\EM=C7_67`+K&,#+=E0V/'I/L<RKU_<RRAV_]);_`(=G^#3Y6=FM>PX_
M7\$-:TV&NUC"Y],FYV3ZE=K?YC%JO_FJ?2N]'Z>-_.U%#7MLZ4?>,KK3G->Z
M-HR1N>6.O8QC7U-9_-.=Z6W]'^98KK+NG&FK9DYQIMJ!;9-CG[0\O]]A:[*W
M?I/^V_\`K:3.I"UC&5_6##=<UK6/<T5$.>T,9=9Z7J_H7/L_P7J/1L?.+KJ@
M.LXM[=[&NK#62_=ZK&5L>RW^=M?CW_\`;%G^CL24UZ\GIU1+S;U'BP[7BYS=
MD;'W':W;LV_S>_W_`-M)C<*P'T\CJ+655%P8WU&R*_=[';=FZZNO]%6SZ=?]
M=*OJ9=Z19U_#>VU_LWBMKBUWNK#6^HWU7/\`8RO^:_1OW_\`'7,/JF*S>[)Z
MMBY+36;6EKJV0UO\[9[;'_H:]U?O24CQ>I=/PG.KWY=K[-KBVQC[7"3L9#FM
M=N:_Z'J?S?Z/^<6EAYM.8U[J@\!CMIWM+#\=K_=_G(7[8Z3HX9E):Z1O#VEH
M+=FYKWSM8[]-7[7_`.D3LZOTE\;,W'=N+6MBUADO(94T>[_".>QM?[Z2G__3
M]&QOZ-3_`,6S_J6HJ%C?T6C_`(IG_4M15"=UXV4DDDDIB:V%V^/=P2"1(_E;
M?I)/8'-<`&@D`21II]'Z.WZ*DH6%PK<6?2&OCQ]+_HH'9+4M]'U"T%KO2:&V
M$0`'?3VN:W\_8YG\M,&MDRT:Z:CLF'N<YW+B\ES]->W(3P0/;P/S?[E`39)9
M5-U;KJ>#/\5)H`(A1'NL8T>W<=I<X&->RF6EMFQWTI^_S:E6EJM<ULMZ,VNP
MTAKG:_:`TLTLW_1LEF_V[J_Y:J>A7Z@O;=TS8QP?4\U-+@YH<]S_`%6O9[VL
MNL_2,]/^<]7_``GI*S979;T1K:\2O/=N!&-:X-:Z+)W[GM>W]'_.J@,?+]2M
M_P#S6Q0YCP0_U:):0ZUC;F_HOS:SZO\`I/UC_C5=&P:Y9.Z?A.K!:_I0]&AE
M>2#166-)(L]3Z37,JL_1.KH>HLQ\<N<*KND%V.!6&MJ8"RIS/:S^<=Z7K8[[
MOS?2]&S\]B:SIUE36MJ^K6*]CZPRRIEE0K&VX>GNWLJ:]C:JZ\K^8_X'_!J=
MU.;F/?\`:_JSC6N`)99=;2\.,4T[?YJRQFZB[)9]'_M-Z?\`AV(H=*O"^KPL
MV,HP_5<"XM:RK<=IVN?MC=[',3G$Z!ZC+#5BBQI9:QT5@RQKVT6?]:JNL]']
MSU%D,Q;Z[VOI^J]%-LN?ZK+J6<AS+-SZF;M[FY65[/Y?^9991>[';8_H-/K6
M-!MI=96YP+2]E+'7[=EGIU#_`*WZGL24Z+\7H@+G/IQ@;M'N+:_=Z0]'W&/?
MZ+/T/_!_S:BS!Z``&5X^(`6FIK6LK^BZ-U(`'T'[&?HU4-=[:?3'1*W,K+_2
MJ%E>W<X>H][6ENQC+;-_]OW^FIV8[J+#]EZ/4\5O::K&/KK)!]SK(V[F;7-_
M2?Z1)3?_`&=T\@`XM,-W!H]-NF\!MD>W_"-8W>HMZ3TI@:&X=#0PM<T"I@@L
M+'5N;[?S'44N9_Q-7^C1L=]UE+775^E9J',G=$&/I(J2G__4]'/V#<[9ZT;C
M/I>MLW3[]OH_HOI_3V?GI?J?_=G_`-F5\QI)I^BGZ<_4_P#NS_[,I?J?_=G_
M`-F5\QI)?8I^G/U/_NS_`.S*7ZG_`-V?_9E?,:27V*?I<_LN=?7^7VC^"7^2
M_P#NQ_[,KYH23#O^@O\`\9^EC^RH,^O'>?M*F_\`9_IGU/M'IQKN^T1']I?,
MR2,>OR?1!Z;_`%?I7KG[._9#?M'J?9/4Q]GV7F?5J^S[=OL]#?Z?J?X/T5B?
MY*].S_ES@^C_`$F9](_T+_T'W_\`7?I_K*\%24BU]^R_V+ZK(_:_VG[,S?\`
M9_M7J^ELRO2^U;?=ZOJ_:?YS_M5Z/J?X%,/V7%GK?MS9&OJ_:MNW?=ZNV?[>
M_P#PGH?9_0_P*\"224^_Y?V#UJ_4_;.W7T?1]7;.ROU-WH_I_6_\-?I_Z3Z?
MZ#U%'_)7VEN[]MSM;,_:]NW_``NZ/=]+^D[/TG\U_@_17@222GZ&?^SO0J]7
M]I3Z3-W\[ZGI[G?TC9[]F[=O_P"#_P"#4_U2=/VIN]3W?SL_3K]/Z7M]'?\`
M0_Z_ZB^=DDE/T9D_8O5?/[2_GW;O1];;/NW[?3_[3;OW?T>]:^#L^R5^GOV1
M[?4^E$Z?^8KY<224_P#_V?_M&F90:&]T;W-H;W`@,RXP`#A"24T$!```````
M$1P"```"``(<`E``!6IW86YG`#A"24T$)0``````$%K$NB[M6$+M@HWKVQ^Q
MF'TX0DE-`^T``````!`!+`````$``0$L`````0`!.$))300F```````.````
M`````````#^````X0DE-!`T```````0````>.$))3009```````$````'CA"
M24T#\P``````"0```````````0`X0DE-!`H```````$``#A"24TG$```````
M"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F
M``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`+0````8`
M``````$X0DE-`_@``````'```/____________________________\#Z```
M``#_____________________________`^@`````____________________
M_________P/H`````/____________________________\#Z```.$))300(
M```````0`````0```D````)``````#A"24T$'@``````!``````X0DE-!!H`
M`````UT````&``````````````$?```"&P```!0`.0`Q`#(`.0`Q`#D`7P`P
M`#``,0!?`'``80!R`'0`7P`Y`#``,0`P`````0``````````````````````
M```!``````````````(;```!'P`````````````````````!````````````
M`````````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P``
M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`
M`````````$)T;VUL;VYG```!'P````!29VAT;&]N9P```AL````&<VQI8V5S
M5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N
M9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L
M:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L
M:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0``
M``0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N
M9P```1\`````4F=H=&QO;F<```(;`````W5R;%1%6%0````!````````;G5L
M;%1%6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585```
M``$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585```
M``$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D
M969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````
M!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4
M>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E
M=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T
M<V5T;&]N9P``````.$))300H```````,`````3_P````````.$))3001````
M```!`0`X0DE-!!0```````0````".$))300,`````!1O`````0```*````!5
M```!X```GV```!13`!@``?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E
M7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!5`*`#`2(``A$!`Q$!_]T`!``*
M_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``
M```````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H`#`,!``(1`Q$`/P#T2FIME3++"Y[[&A[B7NY<-\-#7!K6ZJ?V
M>GP/^>__`,FEC?T:G_BV?]2U*Y[V,EC9)D$_NZ?341D==5X%K.IH:"YT@#DE
M[_\`R:1HH&TF1)AOZ1X!)_M^Y5K#D.:`YVYCG2&D<@#1CMON]WT_Y?\`;5NJ
MIM3=HB>7.`Y\_P#-31,D]4F("WV>K]UW^>__`,FA7BBMI#076=F[WG7^5^D]
MJ"]_JR^P3/T:YT`_-;M^BYR=E9#7$<-`W./&O8)ARG:/VKAC'5%MMX<]PT!E
MCC`CE6L=E=C!O#A8/I#>_P#SM+$)T3I,.@:\^?\`YRI,.PL>'!S@9V\'OI^[
M[FM0C.0.I)'FF401M26W&:6%M<BSD`V/!B=?SU&QM.US/>RP0"-]@_K;;-Z%
MJ6AI.@\_/=S_`%OS?H)V@`Z=SJB<IZ7]J!`=4ES;,WHP8^MV2Y\-<UMAI+MK
MXEUM>US=VW])M6=1T5IN8+NFW5U$['/^W6.'N`+[W5-L&]WL]/?_`#O_`%M6
M\CT/V&WU_7]/U!KC2;)]0[8V>[:[^;>LT5]*]1I]+K(?8X-:T_:M"&NV_I-W
MZ/\`FW5[W6_N>K^C])61L&(IW=%(=:QO3[+&%['AS\ZW4UOLM8ZO>^Y]>WUG
M_P"C_P"M^G6EC]"JM>69.!?2V[Z;SFVV&1O_`$CFBS9ZUF_>]RHV'H5K*6OQ
M>KGTV/\`3NV9`<&7.9D6;G?SO\\[TV;F^K^C?73^KHX/2!7:VG$ZMCB^VNUP
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MJN*[#+'L;3U`-M#V%EY>2&-V.:_TKWO_`$;M_P"C]G_!WUH8.!8UH#>JMW#2
MTF\&''<UGN=N]SO9]']'_P`&DIZ-)9&-EX^(0&UYEAO:UP:YKK=HAS_2W>_T
M]D^G[W_]0C#KF.7;749+"(G?2YH!(W-9N/MW)*?_T/1\;^C4_P#%L_ZEJDYQ
M$!I:'GZ(=P8^EPJV)D374UVC-C`"="/:V'._DN1,J/8T_2U,=X'_`)DJYD*)
M'1D$3H"AH;:<DL>QSG!P<;(AKF<LVV;W^KZ?MWO_`#U8LR:F5/L#VG:=O/YQ
M.P?])5+0YU9#=2`=H=)'$?1W-]JC5#F>\!Y&A<YNUKW#ES&OW/95O^CN_P#4
MBC$ZNANRF-ZGI6@2>H'["2"[Z.C=NKC.V&HKPUE+*]SG%QW@[2!X>[C9N_P>
MY#Q[KJZF`G>8UW$DG^3ZOM_S_2_ZVH.<][G%VKW'W#M_)=WV[?S4K%$[DZ(H
MW70,M">9:(VD`@'X[OW4DF\#M&D?!),2I..0F3CD)*7=8ZOH[',RAAO-FUMI
M9ZNKK"W9Z7YV_P#Z'\XLX]28T5O=]:L<5-(=8=F/N+"QS]7[ME/M=5<RST_[
M&RS]%HO8']%%9LJIW.,/O#7-!%A?]&W=7O;MW,52L84M??U#IUU-I)O;Z=36
MVP.=WJO]_H'_`(17H[!KE':_/IV&WZST,!$2ZBD-+QL9](V>3OT6_?ZEW\Y]
M"M,,Q^C?^=6-OFN1LQYU+6ZL]3<WUW5N8S^N_P#D(K[J+'CU.J]/<YOMIW,J
M<Z'AKWUR;?HW,]!WZ/\`P?I?3_G;)8UF$+`<O.Z=?6\-]0,;6PNEWJ5MU?9N
M9Z]U-M?_``UO_"(H:@ZBU['.=]:\8/WMM!#*&-:S;9^AV/L<]U;VW46^^SU?
MT?\`H[E(9[W/<UOUJQG2"?;500!N<S1S;/S-OIN_J+5];ZMLL,/PFV,LVN@U
M2VQ[7.AW[MME==G]AB9MOU9<X;7X)<"8@U3(<Z?_``1UG]M)31/5\86.8?K!
MCLM9762"*_=-;+_7J8YPW^LQ_K?H?5_1V5J]T]U^2WU:.JUYE+2YCC6RLC=M
M;])]9=^DJ=^DV_\`"*9O^KP=ZYLPPZ0PVEU4[B"QC-_[WIU.:S^16IU=2Z)7
M%5.5BLDZ,;96-0!^:UW[J2F`P>K!O_*,$'VCT6D`1`:[<YUC_P#MQ&P\?/J?
M^M90R6[8'L:P[O;[O9_:5BJZJ^IMU+VVU6`.98PAS7`\.:YOM<II*?_1[J@`
M45^;&R?[(4QN+MNKB?H]S`_,_L*6-CN--))`;L9KK,;6_P"OTE9:W:[1C&@#
M1S>?,?1500-F]-6?B%=VDXEV@U$20"!S]'E,"\QOVAS1)GX*S;M/J;&MBN"]
MT0Z9]VJ!96-M3S`#Y8>8W-+G;O[2:8UXI!MBU[0/+L-"1_(VA2`<!XZDD?'S
M3`[HWD:@%HXDG_JMJ4D/#1N<2)V\G0._\BFKEVR"0>7:C_R*=-+7-)C<&B7"
M-1_6_<3MF!,_`\I(42!SR>P$_D42YI!#3,Z`C^\)V`DEH!+^7`:D^#M%('@]
MDE+OKKLZ(UC_`$&L+@)RFAU0/J_H]];BUKG^IL]-F[^<51^-AT,=9DNZ75D,
M>Q^/9L8S:9<&ES[-WZ7]/_.,;_A7[/3]96]KG]'K+,7[:X/#FT[@PR+);8U[
MX;^C^G])9]/3A2ZEM7U8QZRTA@<+*-E;1O>U_P!'?M;=^Y5ZGZ;_`(QE=X;!
MKEE^R:2&L95T<D-#'-^SB&L^G8U@]3Z'LW>FKF+@])#?3RZ>GFQSP&-JK8`2
MT;F-:U\NW[!O5%F)ZN_UOJU2RQVU_O=39NWO9]H8]X:6;ZW.L>QOJ;/2K_P?
M\T@.QO1%9/U38&M%3:C4^DENQ[?0K_1^YFQ]MK]_\QZ?\_8BAW!T_P"KS:GU
M#&PVU!TV,#*PT.;N=N>V-NYGJV?]N*)POJW:1::,*PDFL/V5$DL/NKW1_@WM
M^@J3Z[[/3<[H&]^P[]]U1V>HVFVZJISG.]WJ/N8[9Z;'W4?SGZ;U4]3+[Z/2
MRN@,IJ:P[:S;4\;GFK?76RL>UKO<Y[_^"_EI*;M?2?J^PVVLQL:+`P6>UI9#
M`ZNKV?S;/98]OM4F=(Z#:`^O"Q+`""US:JS!`V-@AO\`HW[?ZBJBA]/J5T=%
M:VFPP[;96P.:TNLKW5M_X1R*+<K!IC&Z;%88QQJK>/:Z',?56QK?HU>G2QGI
MM^@DITZZZZF"NIC:V-^BUH``^#6J2SZLWJ;K&MLZ>:JR[:YYM8Z!QOV5[EH)
M*?_2]&QOZ-3_`,6S_J6HJ%C?T:G_`(MG_4M15"=UXV8#TJ1X![M29.I_>*K@
M-#+P(?1!!//`WL<W][9]%6G-#VEIX//P2(!:6\`@C3L#IHFD7]$@N:-L^[WF
MN3V);'TOH_1V[FJWBFMK2\N`=_*(EK?(_NO0VX]K*;6]K/;MV[@"T0+-S?WV
M^UB@TL(#FQKPHQZ:-,A]5ALBBBP.+"=3J6DQXM#J]&[?ZR`X.8XM>T@CN-0?
M/1(3,B0?$:%1LU]Q/NXEQ/'']9"4@1M14`1U;%0+Z"VHP^=8Y=K[?=^;N:JQ
M+3M$3(AH(B>-NW?_`-4B8LLL`<&L]I&AY,\?]_3VM++B!KN]WA$GZ/\`G(G6
M(/;10TD1WU1Y1H_8(=DG(;7ZC`YV&7"X;K@P;/0_2[?=^E]/W^CO61ZG26%S
MSF]:L::W.+_UDMK`_2L]GI[O6:U]?I_H[?4_1+;WV,Z0PU93,)^_2ZQH>V-[
MM[=KBSZ3/Y2I#,N_1_\`9)AECG:N].K<\;7.<VMWK[-^W9=_-O\`\)_@_P";
MMC8,!:1NZ(7-I-_5@YK*Z[269`<6CU65/R7^CZMGKS8_^6_])7_VH4JV8=%K
M2<WK%H=4'55.%UFWU0X!]S'L?NM]4?H_M+-E=E:.,_);78U_UEP"ZQC`RW94
M-CQZ3[',J]?W,LH=O_26_P"'9_@T^5G9K7L./U_!#6M-AKM8PN?3)N=D^I7:
MW^8Q:K_YJGTKO1^GC?SM10U[;.E'WC*ZTYS7NC:,D;GECKV,8U]36?S3G>EM
M_1_F6*ZR[IQIJV9.<:;:@6V38Y^T/+_?86NRMWZ3_MO_`*VDSJ0M8QE?U@PW
M7-:UCW-%1#GM#&76>EZOZ%S[/\%ZCT;'SBZZH#K.+>W>QKJPUDOW>JQE;'LM
M_G;7X]__`&Q9_H[$E->O)Z=42\V]1XL.UXN<W9&Q]QVMV[-O\WO]_P#;28W"
ML!]/(ZBUE51<&-]1LBOW>QVW9NNKK_15L^G7_72KZF7>D6=?PWMM?[-XK:XM
M=[JPUOJ-]5S_`&,K_FOT;]__`!US#ZIBLWNR>K8N2TUFUI:ZMD-;_.V>VQ_Z
M&O=7[TE(\7J73\)SJ]^7:^S:XML8^UPD[&0YK7;FO^AZG\W^C_G%I8>;3F->
MZH/`8[:=[2P_':_W?YR%^V.DZ.&926ND;P]I:"W9N:]\[6._35^U_P#I$[.K
M])?&S-QW;BUK8M89+R&5-'N_PCGL;7^^DI__T_1L;^C4_P#%L_ZEJ*A8W]%H
M_P"*9_U+450G=>-E))))*8FMA=OCW<$@D2/Y6WZ23V!S7`!H)`$D::?1^CM^
MBI*%A<*W%GTAKX\?2_Z*!V2U+?1]0M!:[TFAMA$`!WT]KFM_/V.9_+3!K9,M
M&NFH[)A[G.=RXO)<_37MR$\$#V\#\W^Y0$V2653=6ZZG@S_%2:`"(41[K&-'
MMW':7.!C7LIEI;9L=]*?O\VI5I:K7-;+>C-KL-(:YVOV@-+-+-_T;)9O]NZO
M^6JGH5^H+VW=,V,<'U/-32X.:'/<_P!5KV>]K+K/TC/3_G/5_P`)Z2LV5V6]
M$:VO$KSW;@1C6N#6NBR=^Y[7M_1_SJH#'R_4K?\`\UL4.8\$/]6B6D.M8VYO
MZ+\VL^K_`*3]8_XU71L&N63NGX3JP6OZ4/1H97D@T5EC22+/4^DUS*K/T3JZ
M'J+,?'+G"J[I!=C@5AK:F`LJ<SVL_G'>EZV.^[\WTO1L_/8FLZ=94UK:OJUB
MO8^L,LJ994*QMN'I[M[*FO8VJNO*_F/^!_P:G=3FYCW_`&OZLXUK@"6676TO
M#C%-.W^:LL9NHNR6?1_[3>G_`(=B*'2KPOJ\+-C*,/U7`N+6LJW':=KG[8W>
MQS$YQ.@>HRPU8HL:66L=%8,L:]M%G_6JKK/1_<]19#,6^N]KZ?JO13;+G^JR
MZEG(<RS<^IF[>YN5E>S^7_F6647NQVV/Z#3ZUC0;:765N<"TO92QU^W99Z=0
M_P"M^I[$E.B_%Z("YSZ<8&[1[BVOW>D/1]QCW^BS]#_P?\VHLP>@`!E>/B`%
MIJ:UK*_HNC=2`!]!^QGZ-5#7>VGTQT2MS*R_TJA97MW.'J/>UI;L8RVS?_;]
M_IJ=F.ZBP_9>CU/%;VFJQCZZR0?<ZR-NYFUS?TG^D24W_P!G=/(`.+3#=P:/
M3;IO`;9'M_PC6-WJ+>D]*8&AN'0T,+7-`J8(+"QU;F^W\QU%+F?\35_HT;'?
M=92UUU?I6:AS)W1!CZ2*DI__U/1S]@W.V>M&XSZ7K;-T^_;Z/Z+Z?T]GYZ7Z
MG_W9_P#9E?,:2:?HI^G/U/\`[L_^S*7ZG_W9_P#9E?,:27V*?IS]3_[L_P#L
MRE^I_P#=G_V97S&DE]BGZ7/[+G7U_E]H_@E_DO\`[L?^S*^:$DP[_H+_`/&?
MI8_LJ#/KQWG[2IO_`&?Z9]3[1Z<:[OM$1_:7S,DC'K\GT0>F_P!7Z5ZY^SOV
M0W[1ZGV3U,?9]EYGU:OL^W;[/0W^GZG^#]%8G^2O3L_Y<X/H_P!)F?2/]"_]
M!]__`%WZ?ZRO!4E(M??LO]B^JR/VO]I^S,W_`&?[5ZOI;,KTOM6WW>KZOVG^
M<_[5>CZG^!3#]EQ9ZW[<V1KZOVK;MWW>KMG^WO\`\)Z'V?T/\"O`DDE/O^7]
M@]:OU/VSMU]'T?5VSLK]3=Z/Z?UO_#7Z?^D^G^@]11_R5]I;N_;<[6S/VO;M
M_P`+NCW?2_I.S])_-?X/T5X$DDI^AG_L[T*O5_:4^DS=_.^IZ>YW](V>_9NW
M;_\`@_\`@U/]4G3]J;O4]W\[/TZ_3^E[?1W_`$/^O^HOG9))3]&9/V+U7S^T
MOY]V[T?6VS[M^WT_^TV[]W]'O6O@[/LE?I[]D>WU/I1.G_F*^7$DE/\`_]D`
M.$))300A``````!3`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P````$`.$))300&```````'``@````!`0#_X1O1:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\>#IX;7!M971A('AM;&YS.G@])V%D
M;V)E.FYS.FUE=&$O)R!X.GAM<'1K/2=835`@=&]O;&MI="`S+C`M,C@L(&9R
M86UE=V]R:R`Q+C8G/@H\<F1F.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H
M='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2=U=6ED.C0S93DS8SEA+64X8C,M,3%E-"TY-V)F+3DV
M.3(W8S8W-60V9"<*("!X;6QN<SIE>&EF/2=H='1P.B\O;G,N861O8F4N8V]M
M+V5X:68O,2XP+R<^"B`@/&5X:68Z0V]L;W)3<&%C93XT,CDT.38W,CDU/"]E
M>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX96Q81&EM96YS:6]N/C4S.3PO
M97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X:68Z4&EX96Q91&EM96YS:6]N
M/C(X-SPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT,V4Y,V,Y
M82UE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z<&1F/2=H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*("`\<&1F.E!R;V1U8V5R
M/E1O;VQK:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N8V]M/"]P9&8Z4')O9'5C
M97(^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TG=75I9#HT,V4Y,V,Y82UE.&(S+3$Q930M.3=B9BTY-CDR-V,V
M-S5D-F0G"B`@>&UL;G,Z<&1F>#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&9X
M+S$N,R\G/@H@(#QP9&9X.E-O=7)C94UO9&EF:65D/D0Z,C`Q-3`T,C(P-#4V
M-3$\+W!D9G@Z4V]U<F-E36]D:69I960^"B`@/'!D9G@Z0V]M<&%N>3Y!;G-L
M;W<F86UP.TIA8VQI;CPO<&1F>#I#;VUP86YY/@H@(#QP9&9X.D1O8TE$/D%#
M5$E612\X,3(V.#(U-RXQ,#PO<&1F>#I$;V-)1#X*("`\<&1F>#I!4%1+5D52
M/C4N-2XP+C$U,#(X(%!R;R!0<F]D=6-T:6]N+3,R/"]P9&9X.D%05$M615(^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#HT,V4Y,V,Y82UE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D
M-F0G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H
M;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H
M;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C0S93DS8SEA+64X8C,M,3%E-"TY-V)F
M+3DV.3(W8S8W-60V9"<*("!X;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N
M8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/
M<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU=&EO;CXS,#`O,3PO=&EF9CI8
M4F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXS,#`O,3PO=&EF9CI9
M4F5S;VQU=&EO;CX*("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E
M<V]L=71I;VY5;FET/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z-#-E.3-C.6$M93AB,RTQ,64T+3DW
M8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,34M,#0M,C)4
M,3$Z,C$Z-#4K,#4Z,S`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z365T861A
M=&%$871E/C(P,34M,#0M,C)4,3$Z,C$Z-#4K,#4Z,S`\+WAA<#I-971A9&%T
M841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W`@0U,@
M5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@(#QX87`Z36]D:69Y1&%T93XR
M,#$U+3`T+3(R5#$Q.C(Q.C0U*S`U.C,P/"]X87`Z36]D:69Y1&%T93X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2=U=6ED.C0S93DS8SEA+64X8C,M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*
M("!X;6QN<SIS=%)E9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-.DEN<W1A;F-E240^=75I
M9#HY,3DR8V(P.2TU86%F+31F9#<M.#AD8RTW83$R8S(T,#DU,3`\+WAA<$U-
M.DEN<W1A;F-E240^"B`@/'AA<$U-.G-U8FIE8W0^"B`@(#QR9&8Z4V5Q/@H@
M("`@/')D9CIL:3XQ,3PO<F1F.FQI/@H@("`\+W)D9CI397$^"B`@/"]X87!-
M33IS=6)J96-T/@H@(#QX87!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E
M/2=297-O=7)C92<^"B`@(#QS=%)E9CII;G-T86YC94E$/G5U:60Z,3EB8F9A
M-&8M93)E9BTT-#)D+6(V.&8M-&0P-64T9C$P-3)A/"]S=%)E9CII;G-T86YC
M94E$/@H@("`\<W12968Z9&]C=6UE;G1)1#YU=6ED.C`X8F(V.3-F+3%C.3DM
M-#`U-2TX9#DW+34V9#0Q,#`Q8C`X-SPO<W12968Z9&]C=6UE;G1)1#X*("`\
M+WAA<$U-.D1E<FEV961&<F]M/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E
M.F1O8VED.G!H;W1O<VAO<#HT,V4Y,V,Y.2UE.&(S+3$Q930M.3=B9BTY-CDR
M-V,V-S5D-F0\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT,V4Y,V,Y
M82UE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z9&,])VAT
M='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z9F]R;6%T
M/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*("`\9&,Z8W)E871O<CX*("`@/')D
M9CI397$^"B`@("`\<F1F.FQI/FIW86YG/"]R9&8Z;&D^"B`@(#PO<F1F.E-E
M<3X*("`\+V1C.F-R96%T;W(^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^X`#D%D
M;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!'P(;`P$1``(1`0,1`?_=``0`1/_$`:(````&`@,!
M``````````````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<"
M"`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E1
M0A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597
M&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)
MBI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U
M]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!
M(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2
MXO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V
M9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZ
MRMKJ^O_:``P#`0`"$0,1`#\`W6NZ_D7)L'<N+ZIZSV;4]L]X[@Q+9ZCV729*
M#"8#:.V/.]&N]NS=V5$533[1VO)6QM#3@13UV0G1HZ6"0J[+J66WM8#=7DNB
MW!IZECZ*/,^OD/,]4K(\@@MX]<Y%:<`!ZL?(?S/ET$!K/GGD;5<W9?Q;VK)*
MH9L'0=8]F;J@H20"81GJS?."ER+(>#(*2!6M<(/9(W,^W!B$L)F7U+J"?RH:
M?MZ5C:MP(!-Q$#Z:2?YU'^#KCH^=_P".[/C/?_Q"'8/_`-L_W7^M%C_T;I?]
M[7_H'K?[JW#_`)2HO]Y/_0778'SPMSW1\9#_`(_Z$^Q!_P#-.]^_K18?]&Z7
M_G(O_0/7OW5?_P#*5'_O)_Z"Z]_SGA_S^CXR?^B4[$_^V=[]_6BQ_P"C=+_S
MD7_H'KW[JO\`_E*C_P!Y/_077O\`G/#_`)_1\9/_`$2G8G_VSO?OZT6/_1NE
M_P"<B_\`0/7OW5?_`/*5'_O)_P"@NO?\YX?\_H^,G_HE.Q/_`+9WOW]:+'_H
MW2_\Y%_Z!Z]^ZK__`)2H_P#>3_T%U[_G/$'CN;XQ,+?1NE>QAS_7T]G>_?UH
ML/\`HW2_[VO_`$#U[]U7_P#RE1?[R?\`H+KO5\\?^?Q_&#_T2W9'_P!L[W[^
ML]A_T;I?][7_`*!ZW^ZK_P#Y28O]Y/\`T%U[5\\?^?Q_&#_T2W9'_P!L[W[^
ML]A_T;I?][7_`*!Z]^ZK_P#Y28O]Y/\`T%U[5\\?^?Q_&#_T2W9'_P!L[W[^
ML]A_T;I?][7_`*!Z]^ZK_P#Y28O]Y/\`T%U@JJSYT45-45M;W9\6*.CI(9*F
MJJZOISL6GI:6GA4O+45,\G:"QPP1("69B`H%S[TW-.W(K.]A*$`J29%``]2=
M/6UVC<78*D\9<F@`0DD^@[N/2?VON;YZ;GIZ_(0=G?&2DQ,61GH\+D:CIOLQ
M#GZ.F)AFRL-%)V3#54=*U6CI%Y%M/&HEC+1NI+-MS=8W`E?]U3+$&HI\1>X#
M\5--1FH%>(R,'IZYV*_MS&AOHC*5JPT'M)X+750FF33@<'(Z4WD^>?\`S^#X
MN?\`HF>S/_MG>U']9]O_`.C?-_O:_P#0/2;]U;A_RE1?[R?^@NO>3YY_\_@^
M+G_HF>S/_MG>_?UGV_\`Z-\W^]K_`-`]>_=6X?\`*5%_O)_Z"Z]Y/GG_`,_@
M^+G_`*)GLS_[9WOW]9]O_P"C?-_O:_\`0/7OW5N'_*5%_O)_Z"Z\)?GF#SV[
M\6V%OH>FNS5Y_KQV;[]_6?;_`/HWS?[VO_0/6_W5N'_*3%_O)_Z"ZY>;YX_\
M_:^+7_HG.S__`+9OOW]9]O\`^C?-_O:_]`]>_=6X?\I,7^\G_/U[S?/'_G[7
MQ:_]$YV?_P#;-]^_K/M__1OF_P![7_H'KW[JW#_E)B_WD_Y^O>;YX_\`/VOB
MU_Z)SL__`.V;[]_6?;_^C?-_O:_]`]>_=6X?\I,7^\G_`#]0ZS+_`#AQQI4K
M^ZOB90/7U*45`E=U/V12M6UL@O'24JS=HHU14/\`A$!:WX]U;FO;$T:[*12Q
MH*R**GT&,G[.K+L^YN&,<J,%%31&-!ZG.!TQ2]A?+^"JQE!)\@OALU;F9Y:;
M%4L/6?9%3/73TXD\ZPQTW:,I"Q&%PS-90RVO?CVP><]C#1H86UN:*/%0DD5K
M2@^1_9T\.7M[*R/I&A!5CH8`5X5J?.O26S7>?RCP-'B,C6_(3XBS8_-SI3T5
M9C>HNT\C`CR2P0H]<:;LUFH(F>I2QE"DK=@"JL0EFY_Y=@6!WBD*2&BE7##\
MZ+VCYFG2F'E/F&=ID14#H*D,I!_*K9./+I]PW9WR^W!D*_&8;O3XG5L^+HOX
MA7U"],=O08RFI/.M,LK9>J[%@QI$LCJ8[2GRQL'2ZF_MZ#GC8KF22*"WD9D'
M<0XTBAI\6G36OE7AGATU-RWOEO''),44.:`%3J.*_"&)_E@XZ6OW/SR(!':_
MQ5((!!'4':1!!Y!!'9MB"/:[^L^W_P#*!+_O:_\`0/2/]U;A_P`I,7^\G_/U
M[[GYZ`_\S5^*A%O^?0]J`W_V'99]^_K/MW_*!-_O:_\`0/7OW5N'_*3%_O)_
MZ"Z[^Z^>?_/T_BI_Z*/M3_[97O7]9MO_`.4&;_>U_P"@>O?NJ_\`^4F+_>3_
M`-!=>^Z^>?\`S]/XJ?\`HH^U/_ME>_?UFV__`)09O][7_H'KW[JO_P#E)B_W
MD_\`077ONOGG_P`_3^*G_HH^U/\`[97OW]9MO_Y09O\`>U_Z!Z]^ZK__`)28
MO]Y/_0722W9O3YY;6&$U=A_%FN_C62GQR.O5/:,$=*:?'U&1>235V0\DK/%3
M%455M?\`4R\7+-VYZVW:;=+A]IN)`SZ:"1!3!-<K\NE^W\N;CN$DL2WT*%4U
M91C7-*8;Y^?6;:N\/GGNBFKZV+?_`,5Z*CH\C+C*>>7JSM27^(2TB1_?31(O
M8J>."FJG,())UNC?0#FVU\[;?N=K]7^Z)XT+$*#(A)`XG"\*X'6K_E^_L9E@
M^OA=]()HC"E>`^+C3/2H^[^>?_/S_BG_`.BF[6_^V1[,OZS;=_R@S?[VO_0/
M2']U[A_RD1?[RW_077:U7SS9E`[/^*5RP'_,INUOR;?CLCW[^LVW?\H$W^]K
M_P!`]>.U[@`3]1%_O+?]!=);:WS.[%Z_R=/1_*'8VT\=LFLSTNW8>].I<AE<
MCL7!5RY.3$4LW8NV<^&W!LK"Y"M0+'E(Y\ACXF=1/)"#J#6T<V;#OE[-MEI*
M\6YHS`1RT_4T\?#<=K'STFC>@/2B_P!EW7:K>.[NXU>S95)=*]FH"GB*<KQI
MJ%5]2.K'XY(YHTEB=)8I462*6-E>.2-U#(Z.I*NCJ000;$>Q#T7=<_?NO=:R
M/RJ^4??GR*^9W75+\7/CUWCM_P"2GP)Z[_F:5NX-H;^ZTW?3[!K]P93I3';/
M^-6Z,+O^IQ..ZK[+QO<&ZA2U6&QN.RU76+&Y2K2GLS>RVQGNWV/FOF.U#Q--
ML4<#+2LT$_[WA\:-(V_MIX[2":Y30KQO14!=JIT<,]C#/:<LWI5WDWRTFC;4
M1%-;0V=R[2/*M3!$TMS#`^NDB,6;0*`]$BI=]_,+Y'=#;IV)M3OGYM]T;!?N
M;^61F9.[_D3\<)>LNT.D?E=G/DIB%^0>Q^LMOUG4G6\6[^L^KL'2T>3F%9AL
MOA<+*BQG)UT$LA]B*"SMY]XY:6UNC'LT?,12RNP1]1<V!VR\-Q).&!6-@WA)
M!,\<9,L[CPV\)20\+JYBVSF4W$*G>'Y9OFO;7)@ANEFMQ;10%0"WBJ9PZ1S2
M,4BC>D1>A]\V/E'_`#(ND_BI4]1===C_`,P3?GR$V!\N_FWL+ICN[:VR]NH_
M:FQ.E,C@*KK?#=]MM3XM=E3;URNX,1G*F;`IBL=LW!YJ.BF2HRT`CC,9.+XR
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M`(V]M_PSXL_W7BQ^Q]N9Z+<NY\#42^%,U7U0W!"L24Z:%LP1BEN8>4+V*=F>
M_'+^RWCST_626YN(X[X1*%8%H;-V?P?"E<31M*5?4(P++JVM9.;IFC=8]NAY
MDN+-(5(\&6#Z"6>!G<U95^JC6-I5<)HD"DJ5)8I/4ORR_FU[L_EM?+'?F1^1
M/:F$K-G=M?',;5["SW7_`'SG^],=!F,CDI>_^O,=N>G_`)=>U*[;>&K8VQ)Q
MN0HNO-V4NW6::EGK94J8G]F^Z+;06'+$\3DQ2;E.H*,09K86Q\$NY5B=%QWZ
MFA@^H0F,%63HEV@RS[AOD,J`3KM9=@ZU6*Y\5*>'&'11J@\56033F-@DH4K7
MJS3M?>OR&^1/\F7XC[Z['V%\L\KMO)]F=-5?SFV7#'DZKY.]D?$_;^\LWB^U
MLE3T/7VS>G]Z;@P>[\91X_*55-1;=P.?R>UWD\M`DLDT3J.8$VF+F;EZXW>V
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M^$ZRM;QB.1B&45T](O&N(=SWUI[51=0[-NDSPL#X2SQ0R-9B)4U`-XH9=(N'
M,RA=*U6I&;Y%9'Y+;'K>JML]\?)GYUR;/^,W\S?Y1]?4WS`ZZZ/3L?Y'X7X^
M93X8XK<6)W-)A=A=+[@VKG,6F\][5V'BSE+M*LBI81HAA,U/="X7%6Y<O=3P
M7,FQ[U"_AI42S0;K%%9+-6N@SQPPU-4\:@&N))6D5=<VTEO9<T6$;K<VYNMA
MN$UT!C$L4C78C(*ZA"P9Q\;(6HRO15(&]]_-3^>#B:/^7Q&N5[3ZXJMZ?'[:
M>XL#N*OZXWMA:?N/NVK[9W'@::B^1^R^M_BA\BJ]*O*=6T^W*[(;8FGV%%"^
M4GG2O\A9(#"R2:?G/Z/<;:"*_P##VXO:1N7M5\2"-]Q$<ATJQCNC-`)#<J8%
M6,B(JVMD%]]%#R_+/9W,\FUBZW!5N*:;DQ1S,M@2"M1KM]$H_P`6/CL7#4*@
M$U^XNP/YA>VNC-V_('M?Y6_-?9NU>POYF&\.@NY:?JWJ7`[OR_Q8^)VR]_=A
MTF(WCT-L*EZ/W=O_`"\N[MV4.%QE1N"KQ^X@N"JXU@HA9YW1;6UND?(MO<32
MO#>VUY<-*R@R-=Q/<IM]E*JC3'!,$5IRVDR.JUF1)-)4WBWKR\V36]M";ZT2
MRC2%25B\*:VL9+^Z34299X&DE\%`5"@R$JSQ8P'LC^9A\S?Y17R/V[C]D47R
M$V7NO:'RWQ4'=68WK6[3^5F7W=UG\D-^8[:&P\7\>-L=:TVVM4.T-I4=*%CS
MU+5QREX13F2-4E?GN4VZUY&W[=+3PXH8=BOG%O6<RTFM)[MR-6`%$S#0T@94
M6A8/J5;L$T,?,N[6UG<M+;BZOK;]<"+PXVLG2"GJ[R.E0ZQG4Y++&1H#MVQ\
ME.X?DOO_`.1WR8^"E5\E^LL$_2?\M7XLX?N#+=!=B;$W'B>P=P_,C*UO=&.V
MQUYW/U_15.?_`+D=6[U1\WDEQ=3B8XIK?<O&I<*H+%Y]QDB>]$6V;MS?;J&4
MBKV<.WW'CRC4#X2,\B)&TBJPD`;1@5#]E<+;\O;-8FWU[OLW*NZ2R*X)1;F1
M+06L>I6`EEUVLC%$9NW31B6PH=N8_P">VZNXNH_C;D>]._<]F-G_`"-_FQ]#
M;'^5.^NMMHCL?'[5POQTV'FOCUV#N/>%#UIC-KPOC]\[AJ(:7(4-)CZ+-14Q
MI2DHCT*C87%YL=W=62)#O;<K2NH6J+)=6V_B*)7J21X]K"@E2M6C=I5`8AP(
MA#8V!OX;V=YMM_?NSM3!9+>YVR9[E4TBA\&9B5D*DI)16QV$J?R2^8_\X[=7
MQ\R/R*V7'W]TWLK;>\N@OA]W#M;&[4RN"WEMC<?7G7NXLU\G?D1MJHQ707>V
M\J+%;P[SJ,3MJ@W!CMG[BH_X72NU/"L=2]1&FO[FRENK7=$D:'9MZO+BYM4&
MH-;PQ0QQV=I*`DIC,]RU\\BL5UBVM8WEBK25#;6T\,-WM09)]WV>T6">2E4N
M99;EC+<1EG19/!M([4H11D-W<MX<FA=)@_B?O'^:M\@*O+;H[9^5/=W6-5U'
M_+FC[@Z[I-F=3YFMZU[?[:W#N_Y`;9ZZW%VSA=Y?'+:7:.]=P879N%P=?F<%
M@L!@JW+Y!(*F.C6*1*:=[>5>QV[G2\0TW&%=OB6,C].-I[,R7<L*H96!)0%"
M2ZVLCL7C8`*&]K\&ZO>3;0@G:IKN^=W)_6>*WN;,0Q2N_@II/B7"`T0S0JH6
M4-JDZ"'X>]Y?.;Y&]-_$[:/8VY?E=E]T4_\`,-W%L'<7R-W=MB#-5]5M/<?P
MH[HR$F?ZES'8/Q,Z`W=L7';)["^UC^[RFUC'192>*EAR=9%))&5=_`MS$KV7
MB6KMRWO@321X[R1BW>V?Q$8UUEC"E4ADE9)*1,JQOUZTN)+0\P1W>F?1=;*]
M-)$(U;G&EQ&8RM01$OBN/$E2.-D8,K:NB&_&GOKY=[:WW_+HV!U]E?YB&X=Z
M]?=H='[7^5^XN_.H$DZ[?;&Y>Y,WM3?E;@I,K\1*G=6Z%Z<@WQ7T[;BSF_J!
M,7+6)-01Y"(U)6_*XM]SW#88W5;3:9]H@@8"D<D<TFT:(Y$!"K$#<4LXGD\6
M5S;A9HS$PE=!OHDVW:^;%9I)=WAO+VXB(.I)5COVG6*0C69"4CCN7CC6-/\`
M&7\.59%6-+.<!L3M7(_R1/YFW3.]MZ_*WNSN"@^5W<.S=U8CN+;FZINP:;$U
MOR6VJF,BV/6TNQ]N5V[=O[JZ^DBS4M9C),E0QSUM0D#T\,0IH0Y;6HW3DCV6
MMKFV2(SS62W)%=:.VYDW'BAFUC0'\4M)DEW+.U.P0PRFPY[]T+F*6JB*]DMP
M:&)H_P!U.+=HR!I.ME\,(K8"1@(I-7![KK;WR-B^:_P=[%W?UI\@LI0_R[\G
MWE\&\5%BMK[J:OWW%UI\;/DCO?(]@[=3/41VQN"/>V*.Q<;A\O6F:@K<M`*?
M7(UU8Z3=7=><N;KA'%_N7+=V&2+2)4?;FV^"4(&70)9KZ2_FC!!U1HK*-((Z
M)FVR$67+G+-L\7T=GO%E.I<DIIW*626-&9"LBB"SC@BF2H,;.156->DY\1/E
M-_,"[DJZZBW]5?*W>75C?S#OY9&[.FJOY*]<Q[F[)QG5F^>T>R<+WI0Y3,S_
M`!DZ*P^.@VDNW<=#ESCL--2[=K1(]'F)X95G)GLT4*GED74T+WD=UNJR21Z@
M&MSLDLEG)K8ARLLXDT.R1.[5C:.FD-[<ID,'.!LUF2&7EZ5Q&]"8[J+<+-6B
M5%#*&5)7!0R3AT1'!#*U#.=6]J_.G9&!I^U/D3\J?G#E^M^]/BQ_,=W7O_;N
MS^KMHKO+H#-_'GO7!X+H)^@X*?IO)5U%VANW:.6F@I5W#3YE,R"DB0B&(LH8
MCE>VY4O8[DR3;JFR;#>(ZT662]NG"SVOPE5B8&..=2NJ+]29G74-![N%LC\U
M7#6DD4>VKS#?V1CIJA6R%K+)'<UKK+P/&6C97*R%D0*2-+V[?R7>R]S]J?!W
M:&Y>P.]N\?D#V?)N7<+=C[K[\ZZWAUKN[;.Y<@:/,1=;8_&;PZMZAGSV&V%A
M,C24#9BCQ/\`#\G7QU,\$FAA%$*-UMH[>':5A,3Q?3@&9,">16832^&S-)$A
MEU+$DE'\%4)%220EM]P;B[WG5XJD7)TQ/GPHBH,*:PH1W,6EYC&642NZ`]O5
ML?LGZ->O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_0VX?BUIW+BNW>XLC_
M`)3NOMKO3M%\M7S>NI@VWUMNS*=:;%VQ#*]Y$Q.WL)MDM#$#I6:JE?\`4Y/L
M'\T3N^XBVK^E#&H`^;`,Q^TD_P`AT9[+&!;27'^B22-7[%.D#[`!T:+V'.CG
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J'7X^ARM#
M5XS*4=-D<=7P/35U!61+/25=-)Q)!40N"DL,@'*G@^ZNB2(T<B!HV%"#D$>A
M'5D=XG62-RLBFH(P0?4=2U545$10B1HD4:*`J1QQJ$CC11PJ1HH"@<`"P]VX
M4`X=5]2>/7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H(NT,MN'`-B\E2;PJ
M]L8.;713'&;1Q.Y:R+))Y*X5]=_%<A3S38UJ6G,"TM%#-52ROP#<6+-PDGA,
M3I=F.$XPBN=7&IU$8H*:5!8DXZ,]OC@F\2-[423#.79!3A04'&IKJ8A0.B4>
M6GEW;D\W/4UNYJO/PY[&967)T-5B<A@:G<,%%'A\EA\+CZ[*2PU%1)**B%H/
M&[B=*<S!2T*QY+?V\=S<78G,[R*X*L"FEF[=2T+$-BM!I[32OET.$MY6MH;<
MQB%8V4@@A@P6I*L2%!'EFN033SZR9'`[5HLG2U&$;/Y6NK,)2U[9"D?&4+XR
M'`/-DY_O,S4^&3%9C*TL$@$4$)G187)')()A=2(T;1FC*,:>VE.'"G#)\ZG)
MKTM"LZ.LH`752AJ:UQP\Q\_LIT)\FP=EUU-!69''"II$DDSJ1YB4RP4AJ:6&
M4?<BH&LPT$<2L!(YTE3J+"X]V:61]3.Y+,!4GB:<*GC4>O'I,LCH=*8IC'\Z
M?;_JSTDTPV#CH!"TVY<?'FH8Z<[BR$7VV"S-#BEDR=/%-A*;(Q-'"M)1R/2"
M2%2H52."B^[+=N`8J$0,`"F0K4R*T-3G/J3CACJ[(2P?M,BY'`LI.#0D4^1I
M_GZ.)U=E,OD-O34V4I\B8<-4PX[$Y7(XN?$S9;$FCAFI&DI9Z:CU5&/5OMWD
M2)8Y0JL/46]RGL5Q?7%B/KX&29&TU*Z=0H*&GRX?ET`-WAMH;NMK*K(XU$!M
M6DUR*YX\1Z5Z$GV<=%G7O?NO=>]^Z]U[W[KW16NV\K7[9WUBJW-TE3D,+GVB
MQNV:V*LF^VP<JTD"9&A%!+$F/_B=9,))R4D-544RG2"(]!`/-D%X;F.9I:V>
MGM7-`0.[RTZCQ&:D5IPIT,>7VMWM9(XU`N5-7.*D$]OSTC`X4!.>->A(ZMRE
M-3IF-JU$B0U\&5K\UC8I"$?(XO*,E342TQ:WW4N-R)ECG47:-#&Q&E@?9IRG
M>126!LBP$\3$TX$JQJ"/6AJ#T6[_`&[BX2["DQ.H!/HPQ0^E10CUST+OL5=$
M'3'N:+,S;=S<.W95ASLF-J4Q4K2QP:*MEL"D\R20T\QCU".1U*QR$,18>V+H
M3M;7"VK`7)0Z">`:F.GK8P+<0-<J3;AAJ'R\^BNTV-P>XMLIAJW%Q56V\]A9
M,17X7(K'4PU>&R=,]%6X^M4F2.H6IIY75VN=9;5>Y]PTLLUO,L\4A6XC?4&!
MR&4U#`^M16O4B21),KPRJ&C<4((P010BGI0TIT,OP%W%E<U\;=OX3,5]5E:O
MK+=_9/4$&4KI7GK*_#]8[[SVTMNS54TA9Y9X]OXVEB9CRQCN>>?>75M<F]LM
MOOV%'GMXY"/Z3H"W\Z]008A;RW-J#58970?8K$#^5.CG>W>M]5]=L_S!-G=7
M;UV[@%Z^W'NC:.5^3VW/BSF^PL9F,-3XG;F[Z_9.6WAN_/RXR4RY&OV]UW+!
M0X[)NFA_O:V0("M'.1O;5;<;S;[50$2[6Z:%ZBC"U<0$M6@0276JVBR2TB_"
M`T>N]TAMK/>KL`N;""VDE5:5_P`9D0!!GXHK:07DE0`(2M"23I=*'Y]]?/O?
MY';2K^O>UIZ3X^]C;1ZUBRFQ=D;E[4R78F5W%M'*;FR^2V]M+K[#9S<&,PFT
M:S;N4Q];55L<<'GH'(<!X@["SQ_NFUW:8E(I9KM0"#B.T$9:9F':$D617BS5
MT*%:ZJ!1+:/'>)9(RM(UK#+Q`JTTC1B)17O=3I#4^%F96`\-SU!_X<H^,IBP
M.0HLYN7<^*WYC]@UW5L&P.ONR=^;O[`??_7NZNSZ"AH-C[=V559O'UU)L_9N
M0J98I=3Q_;21S"&51&RF5#`;A92-<7C,U,J(H(K6:28L,:%2[B8GAI8$$Y"M
M10M-!'<1D",X;51"LGU4EGX6EC77]1&T=*5#`XTC41%VG\WNA]\[VZ:V1M.J
M[!SDOR!VK+O/J/=M#U3V))UUNW`TFW/[U9.HBW]_=T;8QD^%Q3(M=%65%/)2
M54L=-*%J)$C9WZ6;ZW<+!E"W-M$97#$`&+]("1&)I(C&>((4)UEJ+4@T1&XC
M%M;7=&,,LW@X4ZEEK*#'(M-4;*8)=88#2%JU`1T,O=?;F`Z,ZUW!V5N/'YK-
MTN'DPV-QFW-M4U/6;DW7NC=.=QNU=H;2V]2U=514<N:W/NC,TE#3^>>&!))P
M\LD<:NZHV:0RVEM;PF2[N)EBC6H%78\23A410TDKFNB)'>ATTZ5HBE+F:5]%
MM!#)+(U"=,<2%W:@R2%4Z5&68A1DCH`:'Y:9_8]%O;(_*/IJMZ"Q.U<1MW+X
MW<V'WOC.X=I[GJ]T9VEVMAM@8^NVUAL-GE[<K]Q9"FIJ7;\>,J&R'W41HJBI
M)D6.^J,0CN9KTS1Q+$JLS2M('(^GH-4H3PV\74L;1C2[+H8LM`LC2CM"VGT\
MDSR,RJL*Q$:_').F/M961@SH]'4-J6C1<E_,+^,^*QN'K*S-;^&2R8['?([2
M@ZE[)J][[*BZAI\-6]F3]B[2I=LS9K8,&S<=N*@JJMLI%3`TM9#+'Y$D4FDL
MT$2S2M.AM8[5KAY0:Q)$LAA=G<552DP,3(3J5QI('5H8I9WCB2-A<O=);K&1
M21I9(S+&%0T+*\8+JX["OXJXZ9MA?S*OBEV-N/#;8V_N#L6EKL]6XK'T%7N3
MI3MO:V'^YW-U]6=J[&2HS&?V;CZ"F_TC]?8VIR>W=3@YF&GD2F#RKXRKFMIK
M?ZL3QE9(/J`Z_C$EH%>YA""K-/#&Z3/$H+^"RR`%#7I-%.D[0B$%DD\`JP'8
M4N7,4$VLT40R3`P"4D()AX9(;'68_P`Q_P",<-/E4R-7VSA-QXO=_76QEZ]S
MG0W<>)[,R^X>W<1N?-]7PX#K^LV7%NC,46^J+9F4%!4PTS4YFHI(I'CD&GVR
MJO(T21+KE:2:/2M"P>W@2ZF5@#CP[>1923C16A)5@%@@<M<`T$<=NL^HD!6B
M:X%J'0GXQ]0RQT6IJRXHP/2VVC\YOC3OG!RY[;F^ZNHABHNKJLX^MVEN_%9Q
MINX]\YWK'8V*3!Y#!T^6ES=1V-MC(X2NHTA:IQ62HIH:M(60^_:'D,*VVF1I
M9HHHR&&AVGM8[R%M>0L4EM*LPF:D81926'@RA4LLH@^K-Q&Z&WBGDD!4ZD6U
ME:"X!7CKBD4*R#NI)"P!6:,L,'3';6-[CVE6Y^EQE3M[-[=W7NG8.]]J5U3#
M65VT][[+R\^&W!@YZVF5*:OB66%*BEJ8P$J:.HAF`77I%M*M;6-Y$2;:XA$B
M$C2>+(ZLIRK1RI)&P/$H2*J5)<<Z+J^M377#*4K0T92`\;K7BLD3I(*5IJTD
MU!Z%KW3KW0#_`",^,?0_RVZWFZC^1?7&'[1Z[FS.*W$VV\S59B@BBSF%:9L9
MDZ7(8#)8C+T572BHD4-#4)JCD=&U(S*6);6">2WFEC!EB)*GS&I2K<.(*D@@
MU!P:5`(>BN)X$N(XI"J2H%<?Q*&5P#]C(K?:.E3TQTMU5\>.L=H=,]([%P'6
MO5VPL8,/M'96V*4TF'PM`9YJJ2.!'>:HGGJ:NHDFFFFDDGGFD:21V=BQ7W-U
M<7DBR7$FIE14'``(BA450``JJH`````'2*WM8+1'C@CTJSLYR269V+,S$DEF
M9B2222>A/]I^G^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_T=M_X;_\
MR._\J_\`(?\`]_GO[V">9?\`DLW7^EC_`..+T;[+_P`DZ+_3/_QX]&D]D71K
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW33F<[A]OT4^0S.0IZ&FI
MXA,_D;74.C31TZ?;440>LJW>HF5%6)'8NP%KGVS/<06L3S7$H2)14D^G^$_E
MT[#!-<2+%!&6<F@IZ\>/`8]>O83.X?<F/CRN!R--E,=)+/3I5TI<Q^>E?Q5,
M#"1(W2:"0:74@$'WN"X@NHEFMI5>$\",C'']G7IH)K:0PSQ%)1Y'CGA^WIV]
MN]-=8WFAC95EG@B=U9D26:*-Y%0HKM&CNK.J-(H)`(!8`\D>_5`XD5Z\`34@
M&G63W[KW7O?NO=>]^Z]U[W[KW6.26&+Q^::&'RR)#%YI8XO+/)?QP1>1E\LT
MECI1;LUN![T2!2I`KUL`FM`33H.-Z[]&&:LP6!3[K<T<<!J*B6%7P^VXJE1,
M:W+32O'%/51T8,L5&A:1[J9-$9N2'>=]@VQ'AC.J_*X%*A:\"W^;B?LZ-MMV
MF2]*32]MG4YKEJ>2_G@MP&?/HL67G;?$T"T&;S&ZJO'RU%>,SE<D?[MXJIRL
M$E/.J4'VAIZFHFB4,**GACCC1$N\:MZXXN]SOMP&FXN6D%216E%)_AQCY4\L
M>?0UM[6"R!*0+'4`4`[F`]37^9XGUIA7T.`P^/BHHX*"F:2@8RP5D\2SUWW3
MQ+#/6M5S>2?[JH5?4VK@6`L``$@512@ZL9'8L2QH?+RIZ4Z9MUXW'18#(20T
ME-!/]XN0@C@IT3^)9FJ_R`4T\<05JE\U%4M2R']6B4M<%;BK@:2?/J\3,9%!
M)X4^P<?Y<?RZXU&TZF=OLI-PY9]OS14IKL552QU]9//1RQ/%2IE*B-VAQ3QQ
M*DT2(&ET7U@,]_:#PU'3UX3`=WACQ/(\/Y>O^JG4'=%'DMW92+;E'514.$QS
MP9#<V1%-'4U4E83Y<=A<9YX7IZ>J2.T\[W)6*1!P20?-J9@%-`,D_P"#JT12
M%#(PK(<`?+S)^7ETI=LQ9#9FX<!DVS^]LUA*),A%EHI:^;<F6K/NU)@@FIJ^
MJAA&(C8!B*9/,DPU@'42!%L^[O;7B2W]]<-"`1QU@U\B#FE<@KD4].BG<;-+
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MW^ZT2@*6:(`7N`?9?;;)MME)X]K:A;@5H22:$@^IX9S\NET^[7UU'X%Q-6`D
M:@`HJ*CT''&/GTAL/V%O3:U5+M3?6V,IF\Q348R=-GJ*LPM-2Y*ADJ/MY"9I
M9**"I$52UH7CBC8Q'3*BR(2Y3^_+K:0+;?+=FGR5=--'7UH=-*5`Z,6VJUW#
M_&=KN%2'@4;5533\^(SQ^PYZ6-#VOMYIA%G*7);4+7\%9E5I:K%2,+>DY3%S
M5D%+,`=5JA8E(!LQM[66G,VUW+:&D,3_`-.@!_,$C\C3I)<;%?1*6C"RK_1K
M7]A`/[*]!)_"IMI'"P39&CSVWLLT9PFZ\133OCJFOJ<C()\;D9HJBOIZ:NEE
MJ$>-]<<,A=D4*4T^P5O6SS67^-1S>/:R5;6!@$G@:$C-10\"<="6POTO"T;1
M^%<(0"A.:`<14`XID9(X]++^7H+=);T_\6.^2%_]?_2[N?WDQM'_`"0]A_YX
M8/\`JV.H;N?]S]T_YZI?^/GH]?M?TUU6%-\&*_>F7[,V/O2OK<-U[3?(7N'Y
M`]<;JQ4F%R%7GY?D=U7OC:F[=NY''R319'!9CK/?&]JW*4-6\<L55"M$BMJ2
M;0EAAD3:K*VBN'AO[.UNK2)P%)59;Q+^VND.1XMO(!'H=15X1(2P?"YKW_';
MYI;=)["[^@>1&P#](D,$MLZTS'/%;H2X8FDTBD+H4,D<E_*OHI<!CL31]Y5N
M7F>JZOR&^:+LGKF@WWL3MG,;"V)N[:F9SW9_7U+NS:F)WGDMQ[DWA-N:FIZZ
M6?$8[-0PO)0UL4:QA=>&&Z`MX[9(MN#7&B)140I/#:PKX&L,J30K:TCF=)2%
MFF"HK%75+'--'';%KB1KN-5U2:M+2L+F>Y;Q=`4M'*9M,J(T9?PU)?271E#T
M%_+"VUT-E^BLIC^X=Q[C'16/VGBL13U6T-NX5,YC]G].]F].8V&MCPL]/08T
MR8GLAJIUI*>.!9J)(XXDC>R5OW;<?KFG/ZUQ:W$+MD]US;[?`\@J2:CZ!7`)
M-3*P)[036JBW%LJT077C>7'Z^>_T@``!=4YC%."*#QKU`Z-_E^=S_&?,X7.]
M9?);:V[(-E]([5Z2V1M[LSHIZZHP&U=JKE,Q68O`[HP':V&AV_!O[>]=%D\W
M4/B:^KG^TIH0YBIH%1VZO+J9MWG"H;FZ,1J:CMM[=8+>,G-8XCXLH5534\\N
MHU(8,M;P27%M(698TFN9*88![NZ>YG=1@AW5HX-18@)"A`%6#'U[=Z@H>\NI
M<CUIO3+Y+!UN4BVSE8MU[+D@HLQM7?6T<SB-V;:WAM1LO2Y6DCK=M[QPE-74
MD=9!4P2>$1SQRQLZ,U<A1>Q7>VR/&UO<B6!FHS#2319!\+J\9:*9<!XW=05J
M"'+1W6V>&^C5UGMVBG5255UE0I*JL.Y:@G0P[E(5AD=5U]C?RH,#WKN'?'87
M>W9VS]T=G[CVUM?!XC/[%^.77.PML5.6V9V!LWLO`;P[@VAE,CONH[RSJ[@V
M'CZ2HI\KDZ?$-AC44D%%3-.9UI!_BBRR6D<:W3744U&77`IC2="JPDBGBK=7
M'B2&1INZ,I(K1*QO*[7,4=I>.[VBPRQ5!T3D2!1F8#'AF.-HT2-8PZDNCHQ0
M"UMG^7G@L-MZOQM3N[9.$R6:ZL^1/666BZ>Z%V%TIL58N_Z79^/FR^(V+M.K
MJ!#4;1H-G0I$V1R&5KJ]YG,]9H6*.-B[MH[F&^A5W5)[`6QJVJA^I^I:110(
M*FB:0H&D!F+N68WLIVL[[;;[0A>VW&.Z``TZO"MS`$9LL:ZF<L2:$Z454`40
M-P_RW\-G,3#CJ3NK>VV:REW'TGN6@W#MS$X['[@Q&0Z4^.N?^/>)JL+D/O)#
MC<CD*3._QA:E59Z.LA5(PR^L&FYWC[C>W%\!X<KW6XS@`F@;<+46I4D:6*Q@
M:L$%P2E4J&%[*X^CLK&Q:,210V-I;=U.Y;7</KPQ%*!G;LID+0/GX2'/2O\`
M*DPO4O8&)['F[:QM9F:+?G0F_LICME]/X78.(W#F.A,+W3@J#)YRIDW9NS=N
MXMV;\I^YZJIW!F\QE<KD*ROI1(K1Q.L$58+GP)[698E$4,MW(L:@+&AO-O&W
MR)$B@".)$2.2-.Y@RMXCR,[/TCE#S0M%).[N;2.W+L=4CK'?V^X*\KG+R%X&
MC)&E!&ZJB((@&F[8_E_U&TOD%\7,ACZG<61V#\>U[ZW_`+PWA7MM7'8OMC</
M:?:.Z^R>LNOJC;U'F:_<4L_36\=X9#-4]744]+1+*:=HII9I)HH6-OF:SEGN
MF5C]/LEI81)BLDMM`MJ+L9"HRV;7EMWL/]S9%"E0)`]NI%^)0*!KO>9[V0@?
MV4<CB9K<L1J827,=I,-`X6@UD:@A.;\7NLMT]?[<[)W#OFCCQ&\NY^YM^]Q9
MS;<-929"/:<.Y9J#%;<VU)7XZIJ\;79#&[3V_0?>RT\CP/7/-XW=`KM6*..U
MV[;+!&5I(HY&D9=6EIKB>6YETA@&"H\QC%>.C4*!@!6Y=Y]SW*[:GALT<<?&
MIBMX8X(V;/Q.(S)3%`X4@,#T9GWKK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U_]+;?^&__,CO_*O_`"'_`/?Y[^]@GF7_`)+-
MU_I8_P#CB]&^R_\`).B_TS_\>/1I/9%T:]>]^Z]U[W[KW7O?NO=>]^Z]UV`6
M-@"3_0`D_P"\>_=>ZZL;VL;_`-+<\?7C_#W[KW4>JJ8:*EJJVH9EIZ.FGJZA
MDCDF=8*:)II62&)7FF<1H;(BLS'@`GCWIF"*SM\(!)^P=;52[*B_$30?GT4'
MLZNP4V[MF5]#)0=AS[NJ*K))1[DHZ'(KM?">#$B@P%'']JF1VCCJB6=ZB?4L
M>1,H9M7[97V#M[NK>"2UN#HGCDU,5<*2%HNF-0:%`2:M^+]G0MVF">2&ZB.J
M`QT6J$C4U6J['@Y`%!^'R\^GB/?F[,)6T3U.<VWCTQL;20[&PN(DH-M5.'8R
M4MYIXJ:JRD%752P^2&9CIIY@ZVE0L?95#S-N1N(GCME^D3C&BFE"/4`D'!*_
MLSTHDV6Q:*12SF9^$CM5JC/`D`BAHWY''0V]?YS>^X:;+Y7=VW:';./K*NEJ
M-G4$%6:O)/M^:G9UGW!JTFER\CZ6>$(JQ:M(+@:B.;&:\N%EENK=8XV(,8KW
M:2/Q^C5XCR^?07OH;.!HHK6X,D@!$AI1=0/X/5?0^?RZ8\KT]M_=/8478.]B
MNY9]OO1?W`PT@JZ7&;3^WCIY*NOEACJ_'ELM79&$2EI%$"!([1EUU>VI-KAN
M+_Z^[/B,@`C7(5*9)I7N8G-3C`Q45Z=CW2:WL38VGZ:O7Q&P2]:@"M.U0,>N
M3FF.A>)+$DFY)))/U)/)/^Q]F?19TR;@W!B-K8FIS><JUHL?3%(S(59WFJ9M
M0I:*FB0%IJRLD71$G&IN+@<^V9[B*VB::=],8_F3P`]2>`'F>G8();F5884K
M(?Y`<2?0#B3T#51\CMB_9Z\9C]SY#+.GD@P57B)L+4R#[RGHU+5M6)J$).\Y
M,+QM*DOB<`AA8D;\T;6(6EB+NX![::3BE14XK0U`K4T/GT<IRYN!DT2%%2OQ
M5U#-<T&:8H?2HZ2,_=N_:+=%1D:S:PCZYAHLI'30R8TT.Y)\U5QT@V[35YFR
M-4T='35@>*>I@0I*);B,&,:BY>:@]Z4C37:%6T@*0Q:G8I)-.(()&#44&.EW
M]7HOI!66EYJ6IU`J%%=1%`/*A`.13CGIMJ=WY[=KJ^=S]#24..RV.KZ6-,7A
MJ+^'9R&.H;'/M?--5UTU/5Q13LLYE9ZY&T@"$LR^R6_W_=F<QS^$C:E90H5C
M&16E#4T?UKD?*O2ZVVJQB`:%)&JI4U+4<8KJ6@JN,4[3\Z=-;PRYALE@Z2"6
MEP\.6JJ7<F3JZYY\KF*D"&IR5'$&::L+9(SJD]7/(':$D1KR"`Y)))/)(\CE
MG)JQ)J2>C5`L*QD``Z1I`%`!Y?+'D!Y\>ED+!550%1%"HB@*B(H"JB*.%55`
M`'X`]^Z;Z][]U[I,9M?XAE,%AD>73%6+GLHD(5&BH\;Y&QLDE2RLT!GS*QJJ
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M`+?GW*J,LBJZ,"A%01D$'S'0$961F1U(<&A!X@^AZ#K!]HXK*9)<+DL+N';6
M7.8J<"U/EJ.)Z),I%(WVE(V2I9Y(A+DJ<+)#J14;6JZB2NHH@WNSEN_H)%>*
M]U$:6'F.'<*CN&1T9S;3<1P?51R));:0U5.:>>#G!P>F3?6T=UY_>6)R.(J/
MX918_%4PI=RMD1$NV*N"OK*O+5JXL31O75-91&&)49332QAA.RHMF3;GM^Y7
M>YV$]K<>%;1J:M7@:U/;P-1C.*5KT_M][8VUA=17$6N9V^&GQ"@`[O*AJ?7T
MZ;]X=WX6AJZ;`[-K\#E<[55E#229+,3U=/MK'K65M+2"I$]+'&<T=,LDA%-*
ML*)!(6E&FWO=[O\`;QSPVEDR2W+R:2:]B<*EB.-`:X-/4CK=ILD[QRW-Y&\<
M"H6``&MN.`#P\N(KD4&>GK*=K1!<A3;9Q%9E*J*5Z+&9Z;[--KU%9!,::LKV
M9*_^)RXNBD1VC98B*PII1M)U^V+WFFRMC<PP*SW*8!IV%O/-:T!^6>`]>MVV
MPW$HADG=4A;)&=84Y&*4J?MQY^G0+8Y:]S08NIH13Q;>RFZ,JN8\=1#+EI-S
M5TLCX^G5ZRIIH<2#_ECPQ`1),T:*J&-M8-OMS^LL;.W:-?&5W=F`."Q/:*UP
M>)H:<!04Z$L-JL,]Q,KG0R(H6H.%'Q&@'</A!.:5-37I2@D7L2+\&Q^H_P`?
M91TIZ;5Q$)KJ.:GJ*NAA7*TV4K<=2S:,9E*VF#+2U-;0L&@6JIW?5YHA'*Y%
MG9A[=^HG2VEM5E;Z=LE?*HR#3R/V<?/KP5#(LC(#*!0-Y@'B*^GR/#RZ7O\`
M+T_YDCO3_P`6.^1__OW=S^\K]H_Y(>P_\\,'_5L=0;<_[G[I_P`]4O\`Q\]'
MK]K^FNJNZC^9SMB'K_NK?J]1;DEAZ9_F$[=_E_5F+7<V)6?/[CW#V=UKUG%V
M325+4'BHL%35?9$56U!('J&CI702:G4AVQB^M3D5PVD;X\RK7/A>"UXIU4^+
M5]&Q%*4UCT-7MQB.W2<U(YU?NO:(K]CP\19+9+GPU_A8!].HX)%:>73$/YT'
MP9S.3[OVKLS?FY<QO7I#K7Y&=C96AW)U=V_LC9VXHOBQ+DJ7N;`[8[#RG7=5
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ME`[F(6SS2L%`6*K-I"U(?=<_SK_C#G.HL9W3VO2Y?J+:]7T1\0^Z\GBX:'>O
M9>ZL$_S(SF\=M=:;4J,/LWKV2'+U$F<V?)3I/C*BNEE>3]ZFI0(S,OW.U7;;
MJXM#(TDZ[F+%`B$M).UE'?!`HJVLQR:54!E9@`'+-I%4#.AEH$A6/<9&9V50
ML6W7BV<LE:D:2[*U"5*@T`<`L)^^?YT'QDQG3]#W1UC2Y[LC!9'ISYH]ITNU
M,SB-\]5=BIE_A!A\/D>T^N\OM#>G7T<^T=SP568B@FCSDN+GI@\<D4%6'*HB
MF62$,X59(3:V-PC(RLKPWU\EA&X8&E%E9M0!9M2,I51W=+=JLQNES!:)*8YC
MN\>WN'1@8YI+>6Y`(-&)\.*HP$(;^T!&DG1ZF^8?6/=O478?;G7<.:S>(ZOP
M=15;G88S)4V!J-SXW8U)O7<&T-J[QJ\?!@MY5.UWJQB\E5XUJFEI,I%+3NPF
MBDC6N^NNR6.[[D#XUG;-=A2.TS"T9T>1%.?"=T98Y*%'*L4+*M>B_8F_?=SM
M5FH\.YN$MBRGN\(W(5EC<C'B*K*SI74JNA8+J`ZI-Z@_X4;8WLO:67WED_AQ
M6XS%_P"RS[S^4NUH.OOE?T#WAF)M@];5^R9M^T'9^W>N*FNW/T9N'$;3WE_$
MJ>CW)0T]56RT%11B))XWT+'MO!6X\:0"6"YV^.0K1XECW"Z2T$JSJ3$_@O(K
MR(&J8@S!L`&[*YN3;P(78RWD2+@3/-:P7$RHL%?$*S?3M&LJAD5WBJ2)%J<W
M*?SD>OH.R^\.M<'TEO;<=9UQW!\9^G^JLU1;GVY'BOD)DOD'O['=<YC-;*)B
MFJ,3C>I]PU50F26J622J^T;Q:-0LUM\,M])80,HBN)MYGL2IR8TABO9!=/0?
MV3G;KM<87PU9FHU%2WEU':VES?1_K6\6RK?MHH3K8V?^*T)`\11N%F[,"5TR
M-0%DTL`/97\[SN[I;>GR6P_;W\MS=NQM@_$G=73&"[O[/JOEAT1D</M;"?(/
M=^)VWU-N[^$4$#Y&NQ>=QF57)U:0&1L3`C)6-"P)#&R/%ND>QRWTRV4=[N!L
M:N0RQW2)%)+&S`@:8TE4^+41N<*:]&5Y:S0WUU96"&Z\.QN+P%>TO;01W3+(
MJM1M4LEJT0C_`+12P<KI&;._C?\`.[ICY5]Z_(WI[I3<&S^Q<#\=\'TKE:_M
MCKOL7:78FR-V5O<6+WEDQ@\;6;1J\E24&2VD-H-'6))4R.S5*'2@'J41032;
M?/N+1LD*WTELM0:/X<%M,9%/`K6X\.@K1D:I\@CN)(X+C:;99%>2YLWN"`16
M+3.T.AQQU-02#AVD8\^@ZV%_,EZWWQ\UOD-\.O[B[NQ(Z&V17[GI.W#?+[7[
M.S^R\9L_+]Q;"V5@L305&=K=S=34?8F#^_AB%1+425^B*/5&0R2QF%[LV][S
MX<BQV<M`FDL\T`>:%KB)5J6074$MM10Q,BC-3I"F[MY+7<]CVP%6DO8QW5`2
M*9P)(X)'/8CR6S+<#4RTCJ2**6Z1.*_G/?`O*]:]B=EG>G:V(7K#LK8O4&Y>
MM=R?'7O?;?>M1V+V=C*K-=?;8VWT7FNOZ+M3=-=N_#XZKJJ'[#%3K+3T51)<
M+"Y#T@*6VV72CQ(KN6:./P_U&UVZ+)<:U344$,;+)(S@*BL"3D=:6&0S7T$B
M^&;>W6=V?L0QM(859':BOJF'A`(2=95>)'0?[K_GE_";9/86QL'N++;T3JSL
MKX_["[^V?W+A>O\`L3<V)BPV]>TMQ]4UV.W[M3`[+KMQ=44>QL_M\+G,IN,8
MVBQT]0E--HF%B]9P&\W.[V>.2/ZU;BRCB(8-%,M_$\EM(DZDQ:9BHCAJWZK-
MV_"U&;IDMMOMMR.HQ-]>)%TL)8FV\P^.IB(\1BHE)8*AT",DX93T:!/YF/PX
ME^3M1\1HNS,G+V[39NHV=)51[`W\W5[=CTN#.YI^IH>Y1MS_`$73=L1[?'W?
M]W%RQRIBX$)?T^T5K,MY;[A<P*QAMHYW)*E2Z6W^Y#0A@#,L)#"0Q!@ICD_@
M:EKI39M9K/3];P2""&""X_L#*5J(A+5-!DT@^)'_`!K5I^)O\TCX9_-GL#)=
M8_'[?VZ\]NV@V-4]D4E-NGJGLWKO&[FV;C=S+LS/9K9.<WWM7;^'WK2[9W9(
MF/R38N:J%%5.(Y"#>RJTB>^VZ3=+;NLU6W8G@VBZC:2WDTFC>',J/H>FDE2*
MUZI?,NW;E^Z;MM-[XMQ'0=RF2U94N$#K5-<3,NI:US6E`>E;VW\U<9UYLSOO
M=FT>LMS=L5G3N^ML=-[5VKM;,86DSW<W>VXX\,TO5VR8J]O%3U6!DW)115M;
M4L(HY15`(WV<I)?)=,EK9W21:EN+B2.(`FICMVD6YF:@.A(3!<X-6?Z=Z4#1
MEU<=NC75U;RSB-+>U6:5SP1I0#!#09+RAX#PHHN83W`OHX;E_F!]"[-ZBZU[
MNW)3=EKUYV)U]B>S*S<VV>L=Y[VV[USM?)/CJ:JK.R=Q[7Q&1PNUSALE7/35
M4<DQG1J6H?Q^.%W!M<VZ0[N=IBG$FJ6!(I*:8Y1=2".U9"WE,2I`SH5U,FD,
M"4=J+F?;S>O:LDR>,)(JAI(WME)N$*C/Z)5E+4`9A1"QQTS=K_S$>F>N=B=X
M[ZPF$[!W[C^A<I@<3N:MQ&R-VT.T]QUM=V9@NK=S8_8&^I]OU&V]\9O8FY,T
M8,EC\;)4U:5,#0*A8Z@DAU3MM&A#HO+^WMEQW4N)F@29$^*2(NCZ62H?34&C
M(640Q>/)<PQ2(9([">YPPT@0VOU?AN]=,<C1-&VER"JR`D=K`.%5_,6^-=)@
M8,M-6=CC-C<&_=O9SKC_`$5[X':FSI.KH,+6]A9C>77KXA-Q[=VUM/&[GQ57
M4Y":$4QILI2/&S^=`?,T2B"1ID%J\32M+7]**-)I+9FF?X8PMQ%+%W4):-Z`
MJC,*:)-4\1C87"R)&L9!#RO+"MQ&L*FAD+0,)!I_#@T;'3WM_P"?GQIW7VGC
M>I]N;FW-F<EE]WX?KW'[TH=@[QEZHJM^[DZYQ_;6U]G0=H_P<;,J,]N?KS)Q
M9*@BBJW6>,F,,)AX_:B"VGG=XUC(D!N0`W:7-FQ6Y"5^+P:%FI@KW*6'34\D
M=O;VMTT@,,L4$@*]Q6.YD,4#.!E!)*/#&JA#D!@*BHQ]\]T4G2.T,3F8]L9;
M?6[-X[QV[UQUQL/!U-!C\AO+?V[)IX\-B&R^5EAQ>!Q5-2TE379&OJ"4HL=1
MSRK'-(J0R)"9Y)[:TM(0]U+KI4Z458XWE>21@&98T5#4JCMJ*JJ,S`=*%1!#
M=W4S,+:!%9RHU,=4B1(J+5=3/)(B`%E`U:F95#,`2B^8-7L/";GJ/DEU56]4
M[AQ&[MJ[,VEC.O=U1=ZXKMS<&\J;)U&)VUU;68/;VU=VYS>N-&$K#E<15X&@
MFH8814*\U,QF6_B1,EOX/B-<R2R((]!U$1QK*TRZ2P,`1CJD)72Z2(RCL,C1
M6199Q*$6U2!)#*6HBEY/"6)Z@%96DT*B`,'$D95B2P5.;C_F8?%#;."AW+4[
MDWOD\-#UUN+M7=%7MWJ_?FX!U[LS:&X\YLW==7V)'BL'4R;0R>WMZ;=JL158
M^J"UZ9!!$(3J#'Q:/6RI*CQ?XMID4AHW-Z[1VJHXPS3NCJBC(9'#Z2I`O'&\
M@C[2LK23H4;$B&U2.2<NARJQQS1N6/:RNK(6!!,W9_\`,:^.&]-P9+:N/C[A
MQNX,5_I`HZO$[AZ+[4PM<^Z.LL!C]W[JV#04E7MA:G+=@1[-R]'EZ3$4B35=
M=CJJ.6!9+E18J?!FG7N"1L^E>YV$=R+.;2HJ6,%R1#/04B8@L0G=TS#()Y8(
MT!`D>-=3=J+XT1G@9G-%5)X@SQ,31]+*.\:>FZ3^99\:XJ18GI.Z3O([[W3U
MM+U3!T5V=5]LTN\-F]?8OM;/8VMV)2;=GRU)#3]<9>#+QU,@6FFIB521IE,7
MMN22*.)IWE7Z=89Y7>HTQQVLR07#NW`"*61%;C76I74#7I5%;33230JA$RFV
M`4X9_K/$^FT`Y;Q3%(HI\)1M>FG0D[=^;/0F_,13UG7&ZCN[*9K<6P=G;/Q'
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ML.A/]M=7Z][]U[KWOW7NO>_=>Z][]U[K_]/;?^&__,CO_*O_`"'_`/?Y[^]@
MGF7_`)+-U_I8_P#CB]&^R_\`).B_TS_\>/1I/9%T:]>]^Z]U[W[KW7O?NO==
MA6;Z*3:U[`FU^!]/ZGWNA/6N@![=R&5KLWB-F15$&/QAIJ/<U<\-?D:?)9:"
MFK*FAK<)/#0U%*!1%'CE&IFN^ER-*V8&\V7]Q;I#9Q55)!JU*Q#5!H5-/(C/
M&O0FY?M87$UVXU.IT@$`J*BH85\QD?\`%]!9N'=W84D^$VO039.IAQVWY:>6
MIP^YX<)+6N*R2/!9K-R5L(K9*Z*.D9)88)I5F:+6=*LRD.W7,FXRP6L$,CQR
M(E&(([Z<&-1J!QG.<]'=OM%@CW%Q*BD,]0"I.G'<HH:4S@D"GY=.&9[RWQLK
MK"GR>?J=IR]A8?.8_'9:FKZ+*+0Y^AR,$XQ;85,")9):_)U,#!YK4Z4UBS(-
M/(@AYDG.TI=%XC>I*%<$,`01VA=/%F]<`9QT6G8;:7<V@C6463QEE(*DJ017
M5J\AZ9)]>D1U3C*`4.7W)00YN@FW/E*JLR>.R:LD7\2ED66>6.:?579AZ9F-
M,*V8JTWC8Z+DL0/.==Q,_A:&+$D5+&I-<L<DCA7'0BD+!(HF<,JJ`"!3`%,`
M8`/&@KT*."KI-F[IAR>#IVFR&Z*JDH<W@H?/)4[AIO)#`E;21+Y&IJW"*QE$
MMDIS'K64C4&!UR[?W5G?I#!&9(Y2`RCCQ^/Y:?GBE>BK=;:&[LV,SA3$"58\
M!CX?GJX4XUI3HT[<,PU:K,?5_JN?U?['W*70#ZZ]ZZWUX"YM[]U[HG&\]XY+
MLG+1UVW:&?([+VYDHJ2'$Y:'([=DW%--"8LCG(X:R1*7)TF-F-J&22-!Q):Y
M/N-N8=Y6_E-M;R'Z1*>HJX)KJ!X@$#2:`@^O0ZVC;181>)<`"Z<<<-I7R`(X
M$_B&:XZ=J/%8W'F(T=)%%)!3O1Q5!#250I7G>J:!JJ9GJ'C>HD:0@L?42?89
M9F8EF8EB:DGS/KT95)%/+TZS5T]/2T-;55BJ])2TE14U*.B.KP4\+S2J4D_;
M?4B6`/!/NII0UX=>4$LH7B3TGL7A(ZN$Y'/4E/55E=%.L%!4".KH<)B*LEX,
M/0T[0QTT#I3%5J9$0/+(#ZBH'NH4'+#/3CN0=,;$`>?`D^I_R>G3]C\?18NE
MCH<?`M-2Q%V2,-)(2\CEY)))97DFFED<W9W9F/Y/NP``H.'3;,SG4QJ>IOO?
M6NG7;&TZC>=5735-?4XW;6*JVQ55#1&G7(9W)4[03Y&D-19JO$XV"FE2(RQ%
M)Y7=])4`-[%7+^P1[@AO+MC],&HJ@_$0>X-Y@>6,G/1-NNZ&Q*P0(#<,M236
MB@_"1Y$^><#'3-F=MT&TMW-28[/2YJ+*XF19Z*KEHIZ_;K8&I@-'0U,U-IJ9
M8IZ/.#0U2#.VD$D@ZBFY@VFUVR6)K64E9"U5)!TTH0!3-*'SSPZ4;7?SWT#_
M`%$05DI1@"`VJH)SBM5\L=>E"M#.&.E#!.';5ITIXGUOJN-.E;F_X]A[HQ'$
M=)3'4$F6V'C<=%--0RU>W**&GGIYI:.6FF%/&]+*DM*8YH5\J*S:+%E)_J?>
MDH%0D5`ICUZ=<Z9Y#_2/S_P].&&KJY<9M\YV)::JS.-@J,;7+/\`<T&::.-D
MK(X*OQQ+%EZ2:%Q44D@69"-2ZE-PMNK&:U2"=E_Q:50R,,BA_"3Y,.!!_*O2
M9)HII)XXS^I&Q##@1\Z>:GR(_.G3_P`@\7!!_P!8@C_>00?:/ISH1NHV<4^Z
MZ)&E;'4&X(%HX`VJCI)JW&4U=DZ:D=O3`7KYFDEB!T122$V!8CW(_*$DK[;*
MCLQC24A:\`*`D#Y5KCRZ"7,*H+J%@`)&CJ?4Y(!/Y4SYCH,-OXU-Y[ES=#N?
M*U6U:BJKZS/34B)11U-1E*3-QI7XF3)9)9?LSMFGAHTC,2K)*KB:-PBV]E-C
M9Q;KO6Y/?R/%=I(&5`0#@C\1]*`4'K6M.C2ZN'V_;K,6D2RP%-);)P5XT'\1
M+<?2ASU.SFXLOOFIGJ*G(?;[/F^[IJ/;>/8K3Y:*FR-1'#E<[D!:HKUK88[B
MEC9*0QLNL2$7]H]ZW^[O)9[:%_#M`Q7M.7H:5)]#Z#!'&O3NW;7;V<<<C)JN
MZ`U/X:@&BCY>IR#PIU%E@IYHUBFIZ>:)-.B*:"*6)-`(31%(C1KH!.FPXOQ[
M#5!PICHTJ0:@FO7)$2-$CC1(XXU"1QQJJ1QHHLJ(B`*B*.````/?NO<<GCUS
M]^Z]U[W[KW62'_/1?\M8_P#H8>]-\)^SK:\1]O2C_EW(\?1F\(Y9FJ)%^1OR
M0#3.J(TA_P!+^Z2&*1@(I`-N!^/>6NT?\D/8/^>&#_JV.H,NL[ANI`Q]5+_Q
M\]'O]K^FNJ;-Q?RAX<U\A=Q[]H?EIV_A/C)OOY6;/^;/8?P[IMG=8U6T=T_(
MS9F5P&YJ'<<7;-3M\]J8/:.1W?M'%9.LP5/5_:SS4C)K"2$+?99)-H.U"1S<
M1[<]VUF'H/IS=K,&%0/U5B:YG>%7^`N.)6I]O+/NZ;B%D,$E[96]I<LI)\6W
MMU5`@#$B,R11I'*R"KKJX:AIY[A_DZ]?[@ZWPW7,O=6\Z:FQ&U_YD.V?XK#M
M?;IJJQ/YCM5F:G=]=/`95B6HZS_C)7&`&U<(U^X*^TB6ZIML&VJU(X]FL-O!
M_HV%Y!>++3AKE>$*XX`,6%3T:0[H\._R[^L*^*V_0[GH\@\-K):B*O'05DUE
MN((`X=,FS?Y*?4^P._<K\F]I]P;VQ'<^:H]@;,RNZJ?`8:V:Z6VI\7=O_&?<
M?3&?QQJS1Y?:F[_[LT6ZUF*QU>+W!2PO`S1*RNJW%OWA;\S6HK'!NYW7ZD`X
M<;E*)X_]M8S*&@;@RM*CK^I4%5MJMX>5XZZI-HALTMW."C6MS--(V*"EU%.]
MO,AU+I"..]%I!ZY_DF];]>838.$@[RWMEH-A[-_EU[.@DJ]J;=B_BE-_+P[(
MW9V/M2KJHUJI4B?LJMW6]-DD6XHHX5:`LQ(]F3;HYW==W\(>(-W:_"DXUG:Q
MM@2M`:!`)M7'7@`#/3=S$MQM]YMY)"366YVY."0NYWT=\[4H`3$R>&HX,IJ:
M''3IV;_)AZ\[+E[$FJ^\=\8INPF_F1O5?:[8V_/_``P_S'L=M+';O%,9*E#,
M.LDVG&V,UV-:9F$^BP]D<%LD6U6^TL=4*;;:69)XLEINK;H&/SD=C"P&`G<.
M['1W;[M);[E%N21#6NZV5]2N-5EMS;<J<.#HWB$\0PTT(ST9[XI?R]-@_#[I
M?N'XZ=4[TW!3=(=DQ5$NS^O:C'T9QG3F2W'L"BVEV(^QJEJB:M;";WW+2R[D
M;'5+O%0Y6NJQ"_AE"(IWUFWW9[S9YV*Q/]6D;<6BM[EW>.W%<%+5I)%A-`?#
M*1M70&)-LJ?N7<;'<HNZ6-+8R#($T]OAKAA4A9)T$:RA0%+1^)34[DECZ2_D
MF]!_'NGV50=6[OK=J8FL^&==\+OD[@L'L+9F(PGRQVG'M>;!;4[*["Q]!!"F
M&[:VED*^MJTS%*9ILA%6R4U69D",N][*;U#S?9-$L6U;M#'^BM=%O<0C3'<P
M@$!6\,LCQT"-57`5P691:3-:;CL>[*`VY6.X7$XD.&D@N96FDM)"M"T8D\,Q
MM74@0K0JVE973'\F3JWJ&L^`62;N;L+>>1^#-5V?EZROSV'V\M7\@MQ=@93)
M[CPV<[+J(4>:CJ^OMVY,Y+&?:,6,T2*[%0;KDW&5-ZGWE44.^SI8Z,Z5<!E>
MY7.))%GO0PR/\<D-:J*EYM$.S-LXH(SN@O-8%&5%\/3;+FBQ?XO9ZN.H6R=H
MJ-(D_(7^5AU]\B9?FV-S=F;AH<?\W,U\1,KO'$_W8V_E\=M>F^)>?PF<QF'H
M:7(N8<]CNP$PWVV22L73%#,X0,."7;>D5B-C22)9HK+?I=STN`5D>6&&$PL"
M"-`$(8&A))X8Z-3=R"XN+F,E)9-DFVX$&A59?JOU0?XU^J:@X=HSG!@/CQ\&
M^G?B_P!Z_(ON;IS";9V%B_D/@^E\1DNKMB;#VGL/9&UJKIS%[QQD.:Q5%M2B
MQL%;DMU#>#R5CRPA@U.@#,#P['--'MUSMWBEHWO9+E234(9(+>`HJ\-/^+B0
M\*L[5]2CN$CGN-IN1&J26MF]N:`5D#SM-K<_Q+70./:!]G5>&#_D.]1[8WU!
MW;MOY+?)+;WR,SN[_DMN7M+N3$=@;KC.]Z'Y08+=N"WEBMM]<5N[*_KCJ?(X
M:/.XV>@RV`QU/D?N,#2/,\MAI*[6P:RV>/9+.Y:.U_=$EE(1EY7>2.X%P7)+
MQGZR/ZF2&%HXY6=T848GI9=7/UNZ2;K=0H\XW2*[C%`%C2-&@\`*M%>MHWTP
MFD#2J@!!)QT%_2W_``GJVKT-M'>LO7WS*[?P_>^X>V^D?D'MGOVDZTZDCR^T
M>\>E-O=@;,BWI4[$J,-6;,WO0[_VEV)6P[AHLQ#4RY&O+5LE2TLKK[-S=W4,
M>WIM[I;-;3W3KH1=/AW]O#;WT`C/:D<@A5H-`4VV%74!E"T,5R\QW%3<H]M'
M$=9.O7;W'U%K.9*ZVEA(",7+"5=6H"HTFOWG_*5H>R-I=I8CLCY2=P=A[U[B
M^&NVOB-OGM/>6&VCD=WY487MG<O;N0[+*4%+BL139#)YC<ST4.'@IX<;08^F
M@CBN4N;0306D\DEG:+'$=SVJ\"U+&NU4\-&=B6D,YJTLC'5J9BH'`++>ZGC6
MT^H?Q9(HMU2M`HINBQ(RJJX1(%B41(N"#0G`Z##`?R)/C]MG^83F/GIBMZ)-
M49[?N2[>K^L\[T]U1N+)4O;&5VRN!J=R[>[IR^$J>S=MX-:V)<A%B:6=(X:A
MI%CF2.1E]H+"$;?8[S80G]*XBNHX2`%:!;PL9:LM#,5\68(9,A&5&+A!5'?1
M_7_NHS&IA6U$M>X3?2A50Z6J(BPCC+Z!EE++I+8-%\5_Y:^S_BSNCXT[GP?:
M&Y]V3?&SXP]E_&3$4F5P.%QT.ZL3V5VIMOM2OW=E7H)&>AS&.K]N+2QP0WAD
MBF9V.L#V9QWAB7<46)0MQ8;9:T\E7;(I8D8?.42DL#A=(`XGI1N4AW&2.1U"
ME=WO[_'\=^Q9X_\`2QU[6XMY]-Q^`.)W]V;NK$]QI7Y[HO;OR-WS\I^NL!0Y
MR3&T^[.P^W-J18VO3=<V#R.*W1C*SI_<TN:K,0T+B"J3-TSF3RT13V76$:0V
MMDL\>JYLX;NVAK\/A75T;OQ10_V@222R96`_2\1N_P`<Z+7UQ/<37*H]+:Z^
MD>7`K6TMQ;"`XKX;&&VNPP))E30P54&L#^POY+^Q-W;:S?6F$[HRF$Z<J\7V
M7MW9776Z>M]O=IT_26`[&W1D=\3R=)5>^LUD,9L_>.-W+FZV-<_68[*Y,8>6
M.AIGI/$)V>M))[63;IQ+6[M/IO"DH!(!9S^+;1:QPMUC6&&2-`CS"%7>7+*=
MF51+</'&5BF:9I(]1,;M<PI%/(R\&D8J\L1-4ADE=A&Q"D&6_P!D%R#=>]J=
M+R=][A_T,;\WKC^Q=L[*BV+MJ/);(WC4]S8/O+>-<^[GJILIN3'YG=V*GAQU
M(R4D>*H*Z6-S62)#+&]%,D;[!(T08[9?6TT&:`0VL[316[4'<:,L3RDU9(HR
M$5S(TB.&%;=;Q825^JL+BWG\_$DN+-+-IQ7"$*K2^&O:99)*G3H5$'VK_*UV
M-V%V/NKMZAWAM7_2!NGL7LO=TLG:W1'77>VS<=MSM/:G5.W<[MJ@V5OHB@I\
MWALCU#CLCBLVDJ302S5%/4T]72RM#[20)X$5K;@@PK%)'(=*ZV5[Z[OD*.0?
M#:-KV:/*NCH070NJ,BRZF%U=/=R(?$!MRBAF"`PVL=HVM009%E2)'(U*R.JF
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MS?\`F]X]H=A[ZV)G^\]S;LZ\W?39W&?&KJS"],+E.NJC?,E/5;RZ-J9<V.SL
MINZG[+S46:R.:W#45\OEIGHIJ"2DC9M0(ME#%%9(JTGDD(<:TI)#X#1QIVB)
M1&`RLGZGBC6SLA,9M/))>:EO)&9/!"`J=,FH213*[N=1<AXE&@@1>$731J82
M`6)OY<FU:WK7?/7U3O\`AQ3=A?'\]%YRKV%U3UUUIMN@$_8VX^QZO=&VM@[)
MQ^)VWAF^^W&U'%2LL\IIH(WJ:JJJ6EGD>#(ER9XE;3]1M<H#,6-=LEFE4$T"
M@3O,Y<(B*GX%%:=;MI6MY(Y=*:U&X"BC2*7\<$1'FQ\%+=-+.SL]3K:@`'#M
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M`%0".6W81JJJH27202FIDUK,UM=VUZ1JFCDL6-2>_P"@^L$9=F+.SR"[;Q7+
M$DH"*`Z1`Z>^#&0Z<^0/5.^<71;ESFR_BQ\0MO\`2NU7K<GLS'_Z>^S,+03X
MK:^^3A*/)2G`YW8NR*W,X%:K*O01L=P,(0]/!Y@NEW"62YYMW<6Z_67W@I%%
M4]A1`+B8/P7ZM8;&%AW$I:`LJ:4\1&+2-DV#;C/2WBN[JXED*@BD\SO%"1\;
M"V::YF0K@>,P&IW;0=3XK]4YWIWI?![7W;+22;TS.?WUV+O=,=*9L90[O[1W
MON#L'/X?&3:F6?'X"NW&U##*+"=*82V!<CVG\*&TM-KVRVDUVUG:10*U"-91
M?U)`#W!9)3)(JM4HK!">WIPO)<7FY[A,@6:ZN7DTC.E<)$I/FRPI&'(PT@9E
MHI`!B/=.K=>]^Z]U[W[KW7O?NO=>]^Z]U__4VWOAL=71H;GGM[Y#$7_Q[SW\
M?^)]@GF7_DLW7^EC_P".+T<;-_R3HO\`3/\`\>/1I?9%T:=>]^Z]U[W[KW7O
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M"OD2>'V=-S7\5A"TD[,(V.D`9R?.GG0#/Y=3\Q1[HV]35N)>IPM?C,O--6]E
MKMS[/<.=VH)Y*:EV_2UT<\9J\?@Z;'49C-=3P&9*F5W6-0!*!++:[GM.VM:6
M)BD<U,^GN=2U--`<@`"E:5KD`4KT4QSV5]=+<3K(E*"'754>E2V>!8DUH32E
M!4\.D=NG;V,W!C<=DZ'(U,%%!C),.J8FH5*7+;?S=1CH):!"RO&DZR4\34LV
MDO%*"#^IO81@CC>XACD0E68*0#0Y('[?M'V]'WBO$LM*:AW9%:%02/R]:>71
MQL%M';NU?.F#Q<5%--'%35-8\D]7D*F*G&F..HKZR:HJGC#`L4#A-1)M?W,-
MM8V=B&2TMU0'C09/VGCU'%Q>7-X5-Q,7`X`\!7T`QTH/:KI/U[W[KW0#=\;H
MR>*PV,V]A,G24&0W%-(M0E/FJK&[GJ:*)XHXZ3`TU#']W40Y"ID\57)'+%-%
M3AC%=KE2'?[V2UME2*6-68U:KE6T5`.D*"QJ30TH?3/1WL=I'<7#RS1,R(,4
M4,NK^D6P*#(K4$\>@GVGM6BP%)2U'AJ5RTM`D5<U56O5M%+,4GK(8R&,11ZL
M%M1UN3]7)))C&21Y35R.)\J<?,^9/S))Z&3'B%^'_53_`%"@Z6'MOJO24S<]
M-7Y7"[=>ICECJ:B>LR^/@='JVI:"F^^QZUL8)>GQ=361*)"0/*0B`V9O=&H2
MJUZ=0%5>2G#@?MP:?.G2K))))^I-S_KGW?IKJ/`]7D<FF#PM#/D<O(T2D-#5
M08FA26-YS4Y7+K3RTM)##3H7*`M/("H1&+"RZPVZ[W&98K>,Z2:%C\*XJ:G[
M/+B?+IBXN8+2)I9Y``!PQJ/V#SSY\!Y]*G);,3!14-7O?>]!BL)69/'8F1\-
MBZS'R2Y#)S>"BH),Y55E8,315$PT-5&.)@#;7&2#[%:<J6EJ\4NX;@3!J`H%
MT@L>`+5-%/KC[1T2_ON:X$B6-E^L%)RVJ@&20M!4CTS]AZRR;ZH*?$18'K/&
M28K'1O/&-PUE&$HH8FG<SUF%I:N2>IS]?7OJ=:JHM"-7D<R&R&][S)965N;/
M9HAJ4E0:41<Y(!^(UX>7F2>JP;-<7$QN=UEJ30Z:U9L8!(PH'F!GR%./2(IL
M514M=D,J$DJ,QEC"<MF:V4U65R9IUT0&MK'`:184X1%"QH.%4```$33S7,K3
MW$I>5N)/'H1(JQQI%&H6)>`'`=-6YD^Y3"8N10U%E\[2TN12[%YJ2G@J<B:7
MQ*Z>6GJY*-4GN2%A+7!!M[8;.D>1/3L6"[_B"X_P?Y<?/I3*!=5`"*-*J%`"
MHHLJA5%@JJ!8`?0>[=-=+[8&-P[;'R-=N?\`A$F$S^>R&5?&9D4G\)Q+1U(P
MJQO)7:(%KZRJH#-*ZE1YIK(;W+2;R_;11['%]2ZO!(2]&II6II3..(_:<=!'
M=YI6W0K;*RS1J%JM=38K7&:4-!\AGIEW3L;%;5HFK_[P;E?#S5L%#CMMXZ/&
MME)YZYG:#%46Y:TM/1T*QHY\\@>6"!3:0D+[+MQV#9[!9=PFDE%L&'Z:TR2<
M*#Q`/VX'GTKLMVO[QTM4BB\?2:NU:`#\148)_P`)\ND34UV[J.D@JMLU%)@J
MW$"'^`;9QE95TNUZ:G^Y6?(4V4:5*B7<.0RL1<5%75)J>4@KXA=B0-S!>+<6
M[V@$-I%@1+\.FN=5?B)]?(\.C5=MM&25;JLLLGQ2-\5:8*T^$`\`/SKUBIL>
MM700#.4=-6UU1)+D\DM8D&04Y>OD>IR$RO)&T;,9YF4,H`T``>D#V3SS/<3S
M3R$F1V)/YGI<BB)5CBPB@`4]!@=.P`4!55550%55`554"RJJJ`JJH%@!P![:
MZWUW[]U[KWOW7NO>_=>Z][]U[K)#_GHO^6B?]##WIOA;[.MK\0^WI3_R]/\`
MF2.]/_%COD?_`._=W/[RUVC_`)(>P_\`/#!_U;'4&7/^Y^Z?\]4O_'ST>OVO
MZ:ZJNJ/YGF*AZ][NWZG3&4E7IC^8IMS^7W-B1O>B23<65W%VEUEUDG:,-8=M
ME,9CJ6?LE*PXIHYI62D:/[H&0.CMC%]:G(;ZM`WQYE'GX/@M>K4_QZOHR133
M3Q`,Z<O;E#^[I.:T9M7[KV>*_)X>();9+GPAQTD!]&HU!(KI%:=)>+^=E\*,
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MO\0W33#41%'%%&9VD8E?`*R@E&!)''>QM87M^ZTBM]M@OFIG5#<'1%X.`97:
M6L(C4:S,K1Z=8(Z2FU?YR/P/WGN[NG9^`[!WE43=);([8["R&Y:KJO?V-V+V
M5MGHFDK:SN&HZ/WOD<'2[:[?JNO5Q\J9&'"U%1(CKZ`Z@L"9;^`[%><QLKIM
ML$*3-K4I)]/+((X[@1-1S"[,FE]-"LB-P8='+6%PN^6?+VD'<)K@6XH:QK<%
M=7@/(*HDM`W83QC<"I4])/:?\[7X4;URO0F"V_CODY69KY(_[DNM,./BCWJ<
MN^Q9]R8G:6+[:W)B8]F29+;74NX,]EUAQ^?JHEHJQ89I(V,<>LG<.W74^YMM
M`4+?)&K.'(41%_%\..9FH(I9!"[*CE3HTL:*P/10U[;+MC;P)-5AJ949>XRZ
M$1Y&A"U,JH)$#,@(#MH!+`@-G_#R?32?(_K3XS0]5]M;EW9V?WW\H.AL?NO8
M6RM^;MV'MG-_&'(-A]QU.Z\S%L6AJHJNKR;1?=P8^GR%+BZ.053U<T+1&4GL
MIY-Q6U-I$*R;!-N@+DJ&CBD>,1QT5G<L8V&K0H60Q1$&2>(.9[M"NT,JW#$D
M[C8VE%`+*;VWBN%D;N"JJK,N-56199246&;0#^<_G^_'/;77N[]W9/I7Y'U6
M[MC]X]$=$[FZAH>E.Y,3V;@<UWF)X\+NS.;3W]UALC/4.RZBMP^4@PU0E)-4
M9^>CC@A@BJJ@0(LME-Y/RI#;93==S:S5B0%B=8XY6$E"3XHCDU"$`LP!(;2L
MC1I[X/M\',4URFEMOVXW9'E,!,T)$+_`Z!Q'KE!(3Q!5<Q^(.6^_YS'QHQNT
M_FOE>JMK=O=J[A^$/6G9^_-]1U'6'8?7_5NZ<SU*8J3>/7^V^\,_LZKV-)NS
M#9N7[&KIU,T\$\<NF*7Q/9F-S-MUINL`#64U]:VZDD*76ZNA:I/$#3Q8@VIP
MRFC*`:@-J!A96'U.^6&P32&.\GC+4"ES&?`%P$E`Q')X;+57*D$Z3W#3TX[K
M_FV=2XW*=!P;-V-G]Y;:[G[`[NZUR._)*VNP.T=L[AZ'^-VZ?D'O:IVS7MMC
M*2=J8+&5&U:C;=56XI$@ARL50(S4/3/`U[QTM#NTI)^AM]NO[Q)""/&CL;J"
MU+*F7$<S3%HI*$,J:E5T=7Z1;2C;IMT5XJE;KZK:8'B%&T2;JX54,E57Q(`R
MM*GEJ56*-4*SXS^=M\*$SO1NR]U9;L7%;Q[LV-\8M\QU&W^I^T=U]:;'QGRV
MQ]'-TY5[V[139F)P6U,1N7,5L>.@GR\>,G>KD1&IT8NJ&7[NDDYAW+ENV8M?
MVUX]J=0T`W"P"Y$*M4H9)(2SH@8DA'.`I/22ZN4L=L&[79I:%)Y.VKL(K>Z>
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M@B*]94@K_3+,`Z<4_%T!73/\]/\`E\=[=C];=4[+W7W+C]X]J;VVOL+;--O?
MXZ]S[%Q=/FNPMH?WXZKGW#G]S[/QV%V]BNW=O)--M>HJIT&:6FF>`&)/(5\5
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MDGD0SQ*R:*]MY=HVW?=17:[LGPW8%0557+2'52D2F-HS(>WQ!H!+`@*9;.>'
M<[[9SI;<+9`TBJP;26$)5,',A6>-Q&*OHU/30I/33O+^>%_+\V0>HILEO;LW
M*8?N?JKJKN_;FY]K=)=G;HVKMWJ?N'=E=L;:N^>R-PX7;M7C>N,%2[NH#C\A
M)EWI31U4D<9#,UO9O#8W$V_S<MJ`-R2YMX#4TC\6[C$MJ@D^`FX4_I`&K$,"
M!I)!=-<1P;0N]2AA:Z+MBND^*HL6"W>J&GB#P68!^WS'J*X4_G$=,4"_+B@S
MW679U9N_XG[\^3&`S.R>LL-D^UMP9[8?QJQ>TJK*]H9:';^$I4V'A=YY;=T6
M.Q=/6F9IJF"<I++'!.T)'?;@EGRXF_JFNEC)<2(2$2(B\N+.**29NQ6F:V>4
M$@:(5DE<".)G)X-K?^L%CL33`&Y%KX;4J7%Q:+=R,L8J66!'5&(/?+)%&HUR
MJO7'X^_SD>@.U/C=+W]VCM/??260P?1W5_R'WQUY7[9WON#)[6ZU[I['W%UE
MUK7P9#*[&V/5;DJLYG=MS.PI,>:?[5HZF&6>EDBG<33[3)'>PV$,HDN&O+*S
M/X0MU?Q1RPQFIJ!ID4.S!2AJ&44Z(+.Y-[`MTL16W>&_FC)(J\&VA3<R8JN*
M]@5G#_A8D$!!_)7^?-\2_CQF^V-IT'6'RK[BW/TGW5M;H/L>7K3XZ]EY78&V
M^Q-S[BP.%BP=9VDN`DV7-E129U*JEH*:HJ,AD3H@IX6EFC!(K&?]XR[&MLA$
M-]N0LD=ZH#(LTD,V@$:I6B,3G1&"7(501JJ%M\GT$.Z/*RF:UVT7K(I!/AR0
MI-#K-:1"02)5G("`DFNFA/EW_P#,'!]*8_+MC-GUV\\[MWXZ]H?)S<>WZS*K
MLRIV]UOUSA8YZ1LU_$L7D*V@RV[=T5D.+IJ=Z;7`8JR>46I&C=C=KS]U+OKM
MX;KMZQ>*0XTZYY9(H%5@&!5_!G=I`=*1Q$]S/&K/;9;_`+S;8E36IOYBL8*D
M.$2-9)G*'2:Q>+`A3XC)/&N%#L@-=??S$\#ENN).T]\473.>V[D,[UKLO:^'
M^)7>F1^6&],CV)VE'+)MG8^=V_B^I.N(-L9:N9%BA>6JFB:769##&AD]G%U;
M?27:6!8O<R7DEO&4%8Y##')+*PD)``2*,RY']GDD'2K%MI<"[M7O1ICMH[-+
MB0.U)$65XXXU,8!)+/)HP:ZQ0`BI"SWG_,>^/W6NX=U;>[-PW<W7+[7Z][)[
M+3)[OZDW3C<?NG;O3^-QV5[+39L44-5E\_7[7I,B"%2E6+)>*4X^2K5=10K*
MCI-(C5T&/`^(K-=)9Q.%X@//+&H#!7TNLA4)W`QCM;B2;;(1'0W4HB4D@*)6
M@>X$;-72&\*-R2"55E*,P<%>D/N7^:7T)M6OV>FX,)OG9^/RO8VX^M-ZP=BX
M'([*WGLG.T74?^EW8L='L2>AR67WM5]M8JKH*7;]'CW^ZK*FO2-4,ZO`'")!
M>1V0B9YWAN2JH-;M<6MQ:V\EJ$'&6MT')!*!$+5*DLK,0CGM)[J*9=$?TSU;
ML3Z>Y%P1<ZVH!$GT\BM4:@RE2%(`+SU1_,.P/8GR"[$Z1W)T[V+U51;9W3'L
M78^YM[T59#E.P=WXOIND[QWQ0/MFCP\U%M2BVGLW(P`2U&5GGJZF31X8B5U,
M"ZMTV_=;Z>90UJ]\2J'6&@V^:&WGG#"@(:6>,1(NHNA+ZA2G7DCFFOK6TMXB
M5D2S!+=A26_5GMXBIR*HCEV;3H92M#QZ1?:'\USI_:VR*+>'5W5?>7>*U=!\
M>LY6?W/V!D*##;=V]\D\KMZFZ\KMPYW,FEIZ7)5^)SC524$233F6G,$I@:1'
M]KX[:5M[L]ED&AY-TCL&<_"LTB12$*.+E(YHF(%`=8&JM:)I[B.':[_<E.OP
M;&ZN=`XE;66>!@QX(&FMI44FI(4N%*]'F[T[FQW1W6=;V!6[>S6ZLC-E=J[5
MVELG"-0TV>WAOO?NXL7M'96TJ.HR=138S'3YC<F:IX9:FHE6"DA+S.2L9!3,
M)6NK2QMD$EW/-X:9TI6C.SN]#IBCC1Y9&"LPC1BJ.U$*J,*T%U=RZEM8('FD
M(6K*B"IHM1J<FBJM15V`)`-07Z7YA9SK&AW[5_)_K/;G646TALNGP>3ZK[9Q
M_=F&WIN;?F;7;.!ZQQT%=M3J[>N-[4J<]-!''CZC"#'3P5,<T60<+.L/M<9B
M01AWO6N%A2-5KXK,CR%H6K0K&L<GC>*(C&%U4*$L*:760F0*EFMLTSR,:"$*
MZKIE%,%]:>&8S(KEBE0P`9BR7\R[XV8[$8[)I%V=EJI]M=K[NW7M_!=?9+,Y
MWK+!=&U%+2=M579,%#42T6VI=E5&0I5FA^XFFJEJHGI%J(WU>VY9[>&.XN#.
MK6,5LD[3"IC$<DLD"YIJ+&:*6(H%+*\;!@`*].0Q23206X0K>RW?TRQ'$AE\
M))L#AH,4D<@>NE@ZT)8TZQ;"_F8_';L'=6/VC08'O+!9#(Y7^`QU6Z>E]YXB
M@CSM?U54]W;0PA=:2JJZO,=B]544V8P-+30SSUL<1@*QU;)3LKGMYK87JRQD
M3VXN@T8%9#)9,BW<*J*EY8%DCD=5J#$XD1F4-I1V]S'=&U,&89A;LKFBIX5V
MQCMYRS$!899@8`YIHF!20)QZCQ_S-?C\5R&,J=I]\T/8-!V+L[JV/J"IZ?W`
MW:60W=V%L/=W9&R*>DVY22U5-#1[AVKL3+2B>IJJ=*.:BDAK/MI;*6@"Y18A
MK<FZ!"D-I-G%!-<U()4B.*XCDJI8."0A9E(Z6F)DDN$F(C6."*:KU4-'-<?2
MQLH(U'5/1-)4,*AB`N>A`V;\^?CGV!A8,QM7<&?JFKTZ2&(QN1VGG\5D\K4_
M(+,Y?;/7=-1T-30FKF?^\^W<GC\IHC<XJIQE4LX'BN?%)&=8;8+),]QX*4)"
MEC91WZ.6H=$+VLJR"5@%H)!\4;`,,WAI/+/&Z+%"\CB@+J(KIK.9-%:F6*=0
MC1CN_4B(J)%)37^SKY3^[/\`>;_0_/XOXK_HF_AW]]Z?^)?[-)_I=_T1_P"A
M#P?W9M_"?O/]RO\`>2_B_A7[OV5_3[:^KL=/C?XU]+^Z_K]?@X\'5X7ATU_[
MD?4?H>#QU9K3I7].OB_3>,OUG[R^ET9KX?A^/]5P_L?IOU]7PZ<:O/K_U=M[
MX:_\R*C_`/$M_(/_`-_COWV"N9?^2S<_Z6/_`(XO1QLW_).B_P!,_P#Q\]&E
M]D/1IU[W[KW7O?NO=>]^Z]TG=P;4V_NF."/.8Y:MJ7RBDJHJBKH:ZE6<`3I3
MUU!/35<<4P4:T#Z&(!(N![27=C9WRJEW;K(!PKQ'V$9'2FVO+FS9FMIBI/'@
M0?M!J.@OR75^:QC4B[2RJY6C8I2U%%N^L8S8V(,=&0ILK042U61A@C],E/,I
MFDX*R@W!"M]RA&S1MMTV@$]P<DT'J",X]#Q]>CZVYAJ'%[#W4J"@I4^A!-!7
MU'#TZ]F<QB>D=N2R^&NW7O/<LRRP4E/15"3;CR5&E+3O2TQHZ:I3%8K%44A:
M&%F:0HK'UR,Q]F)-ERMMVE:O,QKFM7;`.0"%`'`'R]3TE1+GF&\J2([=!3B.
MQ34\"1J)/$_X!TR;VR&U,I2XB/:%)B9ZC=N6I-R[T;'TJT[UV,I4JZ4G<-;H
MAG:H@S*66DG0O4M3M=%4%O9=S'>V7T"K92H)KDAV*#+J/XF%#QQGC0BG2W:+
M>[%RYO`WAP*434<*QSVC(X>8X5&>H>WL/2YG<V`V_(L=-BX8JK.U-+`B0I51
M;?FH9:+&1(BJD<#Y"HBEE"`$Q0E>`Q/LCY;LX[S=$\4]D2ZZ>I!%/RJ:G[.E
M^[W+VUC(Z"LCD)7TU`U/VT%!]O1FB2Q+$W)))/\`4GDGW*/0&ZZ]^Z]U[W[K
MW1?.T*:FQF[Z'-UR*E#E<+#3C(UL*&CH,OAJF=*:FI:UPRT5168_)2NRL8PV
M@E6)+``+G"U?Q[6[56*%"I-*@4-1]E:GY8Z%O+TP:WFMJ@.KU`\R&&?M`('[
M>D@F3IYUEDHH<CE*>F8"MJ\-BLAEJ.A!8*7JJN@IYH`$+#4J,\@_*VO["L-E
M>7$;RP6DCQ+Q(4D?[/Y5Z.GEAB94EF1'/`%@"?R_STZ88MR9`2UE)48&J.3_
M`(Q546-PT9%-7MCZ.GHIIZ[+M7-'3XIH/NQK$A7EXT`+$^VIXI+:3P94(F`%
M1P(J*T/S`(_P=/1B.5!)'(/"I\7$')&*<:T_E7IUPM#4TJ5M;D!`N3S%9]_6
MQTX#0TEJ>GI:;'Q3'UU"TE+2H&D-A)+J8``@>V@.)/$];=@=*K72HH/GYUZ<
M:J:>*-$I(!5Y"KJ*>@QE&21]WDJV58*2!BOJ6+R-KD8?IB5F_'M^W@DN9X;>
M(5D=@!^?^0<3\NF7=(T>21J1J"2?D/\`+Z?/HPFTML0;3Q/\/2I-?75-1)7Y
MG*-&(7RF2E`5YO$K.(J:FB58:>.Y$4"*/K<F7=NL(=MM4M8<TR6\V8\2?\`]
M!3H!7MY)?3F=Q04HH_A'I_E/J>@N[(KTRVYJ/"7,]!MRA6NR%,ZJU(V?RP!Q
M_FC:ZU$U#APTBJP*Q&I5AZK$!#F^]+26^WHYTJ-3CYGX:^M!4T^8/0@Y?M]$
M,MVR]['2I\Z#XJ>E30?E3I*<"P```%@````.``!P`![!?0@Z[]^Z]TF,QKES
MFVJ>H;[?'BIFK:>JCCU35&=I89Q38IY]0^RIYZ"260D*34:#%=?HU3\2UX?Y
M>G$_LY2/BI2GR/G\\T^SCTIP;$'^G]/K_L/KS[MTWTUUE5'+M&FVQEYMNPS;
M)F3<.!;*?=T5'N['BBRL&5H)?(M?3R[KCJ:Q9`%#>>2962-!J(%27,>[;(VW
M22Q02V]&6I(#HH-?]M7RSDUIT5&%[/<_K8TDDCGJK4`)1B13T[:#Y4`I7K*U
M9N>7;F'VM+5X_)8B@K,#64U=E::>EW)B:3%M'(*"!Z`_85<HIU,&N90^B1U8
MMQ[02;]=7&V';;B)'6BT;(90M*?(G''CTH3;[:*]:]B9ED(:JBA5BU:GU`\Z
M<,#J?[).EO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW62'_`#T7_+1/^AA[
MTWPM]G6U^(?;TI_Y>8/^@_>)/]KY&?(]A_K?Z7MT#_B/>6VT?\D38?\`GA@_
MZMKU!ES_`+G[I_SU2_\`'ST>OVNZ:ZIUW%_*&PV;^0VX.QJ3Y4]VX3XY[W^4
MNS_FEV#\.J3`]85'76[/D=LO)X+<6-W:>Q:O:4O;6%VY6[MVIB\G68.DRD=#
M4U%)9AH>RVV5Y-G;;"TAN$V][IK,/CZ8W:S!P-('B+&;B=H5DU",N-.5J=[R
MTF[I?KK,#WMI;VMRR$UFM[<*@CHQ(C\2)%CE*4+KJK\6,NX/Y/'6.X>N<-US
M/W'O^FHL/MC^8SMD9.#"[6^\JXOYC=3F:G?-;/&:7P"HZX.99<0%`%2(U^YU
M<^TJVZIML.VJU(DV>PV\'ST6%Y#>))3AKD>$*XX48D=V>C.'=)(=_EW]8E\9
MM]AW/1^$20VLEJ(J\=!60L2>ZH`X=+_'?RJ.F*+Y-_&WY,R[TWI5Y3X\]3[$
MV!-U_)'B(]C]G[SZHV+N/K?JGN;>E$E,:D;^Z_V?O7-4E"U.Z0:*Y"RDT\1!
MG)=F7>>;MW>,']ZF=O#.5@DNE2*ZEB/$//:QQVKG!\)30]QZ(C;D[-R]LWBD
M16&A2X`#3Q0N)H(9:4!2&Z!N4&:2DD4QT3+I_P#X3L?&'I/?'R6W-L[L+*QX
M7OGJSOWJ_:V)GZ=Z+7>74-)\A\=FL9N[+8[N>FV/!VQOB7%4>X:J*@I\OE)(
M5@9(I?*D:CV31V93E>\Y9>8L)8(H!*`$86\,BNL;)'I1V(CB5Y&6KZ"Y&MBP
M-S>_\BG;>9UA4/;WGU1B-61IZ<0S5:--1=E1"-.J@.D4(X?+;^2]UI\M3\-H
M-P=V;NV52_$#:NR-G8K([<ZOZ4R._P#<V+V/6;4K*2MP';6X=D9'LWJ+.Y%]
MK(L]3MS*4R*)2T422`NYV;QFYPO>;W4^-/,)#&K-&*K(\@0R1E9&B8N5>-F(
M=-2$Z78$HAMQ!RC'RFC5@1'0.P#8>(1%O#:L8<``JZ@,K`')5:/5=_*#VU#N
MC;6\-E?);N'KS<."^3/S$^0=7E=M8O9SY'*8;YKT%/C.T^L(Z_*8VOJL+2XZ
MDHH/X5G:1H\S22Q^59/(=0)VLXY(-OMY7;3!R]=[2=)"%H[JX%V)@4`,<D-P
MD;QB,JI"!&[21T:3W;32&;0/%%]MMTA;OHVW68L55@U0ZSV_B++JJ09"RD,J
MD%@ZD_X3R===-=9=T[0VO\N>ZG[`[GW?\9>R<EW)5;%Z@3=.)[.^*N_LYO;K
M_?<V(I-JT^W]VYO.)FS3YZ?,PUU5EZB/[R>=IG8$S2X9#RTPBC4;9O*;E&JJ
M%C\;Z9K:=!&.U(95(98T"B)@=.K6W1;/;I<C<TN7>2.ZVJ>P;4Q9_!EFAFC8
MR'O>2%H$4,Y.M.T@46B[WE_(7ZMWYW=\PN[L_P#(??M/F/E[TKVSTYN/%;0Z
MKZ.ZXBQB=R8S#X_<^Z]VY;KK9.U<OW-EL7)BC/B8]SR5B4,\[RZI)OW2@M;:
M"UVRYVI$K:R74,NFI"!(;Q;L((@?"UL4$1GT^((S($T^(U39=PG_`'OR_O#F
MMS8!2#^)W6V>UJ7(+K'I<N80=&L)Y(H`F8/^2ITMLZFZVVKL3M3?NT>ING>Q
M.Z>QNJ^IZ#%;=J-L]?U??WQEW#\=NQ]M[8J*F%J_'[1KLCN>MW=34)9TI,U5
MSQH?MI0B/[@9-RMKZVN)F*R[=?V*'B8[:]NH;I(Q7XA:M$8H*T_1*HU?#4E)
MM4K;5"L,(!!NMJN9/+Q+C:Y-?C-QHUV!&)PM%U(9%`>1R7C;7\G3J_;76.<Z
MQI^XNP*B@SG7G\NOKN;*RX;;*UT&/_EU9G&YK8]=%&E/X6J.Q)L:JY9&NE,'
M)I[&WLSEW.27F"/F`Q+XZ[^^ZZ?(R/:1VGA$\=`6,.#QU$CATGDC$EE/9'X7
MVO<+&OGHW"ZFNI'_`--&TQ51P*J"V>@VWY_(=^/G9&9Q.X]T=I=B3;CV;N_Y
MB=G]6;CH<=MZAS_5/;_RO[RVWWU0=I;+R,<+-2;HZ8W1MI*;#&19(:RCJ)DJ
MU8.1[*ML\79XMI:PG9-PL;#;[6&;&I5L+B:8DC@RW2S/!<)A6AJH^(]+]QN5
MW1MS2\@5[*\O!/-$2=+Z=N3;PE5*NND(MPCJP=)E4@T`Z:_D!_(SQ/R#[`[5
MW'G?F?WQM[KWN+LW#][;RZ5P6TNJVV/6=[4W1L_0^=[(3)5VVZC>40SNV95J
M$Q*9%,;1U2ZDC?@JS]+$(;NT!8V?B;@;=&-?I5W%_$G1#@N`^8S)J*U:F7<F
MANIV^EEDD)O/HK2VGD%`;@63:H&90*(.)D5*!WTL31%4#KB?Y1G6F)W3M;=4
M7;F^Y*O:W;?P:[;A@;"[85*[(_!GI:OZ6VAA:J5:7S#';XQ>0:NR3*1)3U(T
MT^E"03ZZW:6[W=MW>,"4[MNM]IJ::]UMOI9$]=,*]T9XDX;'17!9K!RY%RX)
M&-NFRVFVA_Q".TOOKED`X:Y'[&'#3D9I0T&V_@KT=B_E-WE\L]S[8VMV)V/W
M'5=-UN*GWML/9N<K>J:KIG:4NU<1/U[N2OQ55N#$S95I!6SLDT;1U2!HR+7]
ME-A_NNM)K:V&F62^GN3(.UZSPP0F,L*$HJP8J?\`1''`FJ[<"-R:P%P@,-O9
MBW"$:E8"XFN0Y!KW:IJ8Q1$/$=$P[E_DR;![@^,E;\8Y/D1VYM3;.6^6?;7R
MFW%D,7A]C9C'[P7N;=F[]S[MZHWOL7<V%R^R=X[(@&\)8Z$Y&CJ)::IIJ>K`
M::,>RX;;#]+RE8RL6M=JL)+32?\`18Y'=]?_``J=&8&*9.Z*A*49B0MEW"9[
MSF6_B`CN]QN8)]2D@Q/!!%`%!!!DBD2*LL3]LA:C550"U;:_DC=1[8Z)W+T+
M1=V=D3;?SOQ`Z9^&U+FJG";2;-8K8O2/<.[NW=M[C7QT<='6;DR-3NLT%8&C
M2E>*F25(T=B`)4W:X^M_>,RJUVVY[5?.0-(:3:XHHD6E31)?"#,*DJ6.D]%T
M");1QQ0K2)(=XC4>B[N5\3\X`H$>!J_%Y=*7!?R9^GMH]T?(COW9G:F_-K=D
M?*;._)D=W97&XO;WAWYUS\C=EXK;M+UEGZ:2$I7XWIW<>(3.[8KCIJZ>KJ*J
M*7R05+J`]=6,=SRQN_*FHKMM]MEQ:RT_%+-<331W@'`3P+<2VZFE'@8HU./1
MB+]QO6P;[X8-]MLU@T1J<1V=NL#P&E*QW7AQR25!*21JT9!J2@.X?Y(>WNS\
M3U_MK;WR\[TZMVGA?BUT#\4NU]M;5VYUEDJ'O/9?QJW4F\>KLENBJW)MO*9/
M:]=1YF6I-:F#GH16PU!B=Q&I5CFVO'MN9KKF'+PR[I9[@;<G](75F-,;@BCT
M9*!T+%6*JQ!*K0HBMQ#R_M^Q1R,KV]I?6JS"@?P-P`\=*4T@Z@*.!J"ZD%`Q
M/0^=E?RLMH[]Z0^3_4&,[O[#V3D_D;\NZ/YFT/8>%PFT,AFNK^SL1N3KW=.!
MH<#ALWC:[`;AP.+RG7=,?%D89#.LSA[@#V5Q0>"O)OAR$2;+N3WL1H#KD>ZN
M+HJX(II#7#**9H`3YCI;*\=Q+S$UQ"'@W+:8+"5*D`1P6T=L&4@@AF$:NV:5
M)`H*$"IW=\3=Q=E]E5>8;.U>2P7<WQ*WS\1>[-R1-AL;GL#05<E;N39W9VW\
M+)3KB:VM.<S&7I:V@C58U_B%-(B&.GD4TN[2&]/,MF4,.V[@;690O=X4MG+*
M5C)8EV26&X*ZJDJT"5_M697;6]NK*#EUA)XUS8S3:M0"^*MU%`LDG:`%=)+6
M$A1I4I++0%D128;>?0F#WEMGIS;4V:R&,@Z<W_UIV!CJJAI*#SYVLZSII:;'
MX[)H\7CBI,DDO[S1`.EK(0/9G?W!O]\3>W0+*MS<S:!736Y@N8&'K11<LP]2
MHKBO1;96XLME?9E<M&UM!#J/Q4@F@F!]*L8`I\J,:>75=^[OY06SM[;[[`WO
MFN[MR?=[UIOD3C1D(.NM@R;^DP_R0HJNEW%C-Y=HY&ER&\M[4>QA)3P[8I6F
MH<=BZ"E6G-+*3YE0V47T=C#8AJHJ6Z&@TAQ;7EM>12.!EYV>V"SS,29`[%5C
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M<Z,K8_*R:HU>`&!DUQ96TZWL*1>%:W*;A'(B</"W&:">1$)J4,4MO&8F[J+J
M5@P-0[82S63^,\K2S@V#*S\?%V])(X7>GQAEE?Q5[=348%2,X</_`"VMJ;<Z
M%W!T?@^VMY0'*[=^+>'Q>\J_";;R&1Q&1^*=)M6#9^:FQ`IZ3&95]QU&TX9<
MG3MXHCY76$QC38RFN&DWFWWI5"SQ[ZFYA>*EUBM8#":YT&.U'=\0:0G\('20
MVZ&PW"P)/AW&W7-H3Y@7-Q>W)<>6I'O6`![2L:@Y)/1I]_=+9+NGJS<G77:V
MYY:6OJ]WP[FV=O+KJ)<!N+9-9M/=E%NSK#<>(ERD67H?[V;3R>)I*AGE@FHZ
MB2,QR0R1,ZLDHZC;+F&0IN=O(9`]`5UZY*#0?BB:W80S(W]HIE%5#BBN-]+;
MA!,@DV^>,Q,E2I:)XD60$@U5C)K964]O8>(IT1C>'\J/:7;&X-\=D]S=HX[>
MG<>Y<?LZDPN\<)T-U!L_;&/KMB;XQ'8>#W%OCK]<1G*/M_.U>?PL4%><_6U%
M)+BV>FIZ>D9C-[M$/I8F%HB+.URDQ++KCJL5Q"46(D!0Z7=SK?49BTBL)5,2
M4]([7*I;WCL]JL+QBATR]YB;490">QK>$QH%6(:&#(RNPZ%G%?R]MLT^S\[M
MO)[]ABKMT=`]Y=#9JIV!U1UGU1MB+']Y9''UV3W!@MC;'P^/P^-J]M0XV*"C
M2H>MGJ$!:KJ9WLP9N[:.Z6\0,ZK-!:1DDZB/I9YKC4*T4&1YF#*JJH"@T+EF
M:UI*UK>;7>A5+VM\]RH`"@EXHH=!.6("PAM3,S:F(%$"HN#??\NC:&^,;DZ`
M]M=C;8GR.^-I;[AS6USB\7G\1D]H?%3*?%2A_@N42%IL=/)@,F<Q]PG[T601
M50B/VLW"9[^[DO2`LIEW.0"E5KN0CUJPJ"R1^&!I)'B*S(QH<:VZ3]WVEA9T
M\2*"RLK;."5LKUKU7X8=W;34?!1645%"'W17\K'9W2O8F![+B[0EK,QB-_\`
M6G853@=H=5]?]9[.K\OU?UEW)U7BBV(VY3SY*:LSN#[BJ*O+9"NKLAD:[)4B
MS-.$D,27CN#&P8+50MZ%7@J?76D%K*(U`"I&BVT;1(!12"&+DEBEEB,T(BDE
M9F^GMX=1[G9;>]2]1I&-2\K2*RNY.48!570!UUL#X`+U]W[\6LOC&W'D.O?B
MEU=V53R;ERN2VS$.YMX[XW3G,SL'"Y/;-!4&LIWZ:GW/GJ^DJZJ.FIQ59>$P
M,[I,8ZV]U+!<;QN)2LW[KM+*"/'<]O"L+70.%1VMA):9-2EQ,-(0*Q?W!4O8
M[>WHH6;=KJ^E:GPB>9IQ;DTU,OU!AG730+]*H8L9"HQ?[+E\@_[M>+^X^!_O
M3_IT_P!GI^\_OAB?X?\`Z9?]+/WO^@#Q>75]K_H<_P`A_C]OL/XI^Y?3ZO:3
MZ27]W?N;]X0_0_N[17PY*_7?7?O3ZFE:^#]7V^%6NC-*=G2SQ+;]X_OBK_5_
MO'3IQ3Z#Z']V5K3^W^F_5U<->/#Z_];;>^&O_,BH_P#Q+?R#_P#?X[]]@KF7
M_DLW/^EC_P".+T<;-_R3HO\`3/\`\?/1I?9#T:=>]^Z]U[W[KW7O?NO=>]^Z
M]TR;DI,]78'*4NV*R''9R>F\>/KZA'>.FD+H974I!5&.H:G#B)S%*$E*L48"
MQ8N4N)+>9+20)<E>UB*@'UI_@^?3UN]ND\3W2%H`>X`T)'^KC\NBS4FXLCNN
MCP<V7W!4Y$4<4V3HL/718ZCR5+4L9\9+6Y6&EAI*NLGH'\U/'(\,2HQ:Z^3Z
M17?[ON-]$MI>2@JC9[=))%15N'#RP/V]#Z#:X;/7=V]JPB?MU]Q2M`VE6-5J
M10D:B:?+K+38R@HZO)5U+31P568FIZC)RQZ@:N>EIQ2P32(6,8D6G4*2H!:U
MVN>?95TH+,0JDX'#I;=>4#Y'=U1D]+_9;8QDM*)`C".3.9T1ZZ;R&P=J+#1"
M1@MP#4K?FP]C+D^T9I[F^8'0BZ%^9.6_8`/V]!_F"X"6\5J#WNVHCT5>'[3_
M`(.AY]C[H)]>]^Z]U[W[KW29S>\=I;?K:+#[AS^(Q=9EP%IJ+)3I&*B.7R*C
M3B16@@IYC&RJTY2-R"`2>/:6>]L[>2."XN8TE?@K$"O^Q\SCI1#9W5PCS6]N
M[HG$@</]G[,]8]O[SVIG9LCCMMY6DF;!4\=34I%255%C:6FG,P@K(9Y*6FH)
M\>\D+WD@=E]#F_%_>K6_LKII4M+A'\/C3@/SX4^SJUQ97=N(WN8677PKDG\J
MDU^WY=%>VSC*18YMQ,)Y\WN(&MS.1JJFHJ6K:R1P*JJIO.[)#2UTL"R)XPJR
M1+&;6"@0_<.\MS<2RR:Y6<U:M0<^7R]/E3J0A1(XH473$B@`4I04\_F//YUZ
M4LT@AAFF*22"&&68QPH9)I!$C2&.&,<R2OILJCZL0/;76AD@=)W^\-)4XY,W
MC*D4N2P;T^?HXJB:*EK*:>@8S@,/*4D@K:598-:,\4BR,M_J`KAEEVV[MYZZ
M71@PIYKYT/`@BHQU1XEN(I(2*QN"IQY_/T(-#0Y%.C>_=F?'_P`0H:=ZAI\?
M]_0TC7ADJ&EI/NJ2E8'F*28LJ&_*D^YDU536BUJM0.%<5`ZCG31]#M2C4)],
MT)Z*SC*F7(4O\6JI_N<AFII<ME)RGBODJK2M53B'ZT\>.,0I4C/,:0A3R#[A
MB[GFN;J>XN?[=F-1Z$8I^5*?EU(T<4<$<<,0_250!\QZ_.O&OSZ</:?J_7%F
M5%=W942-&DD=V")'&BEGD=V(5$10222``/?NO=)59FW/4T,E+&T>`QE?#D?O
MYE,<^8KJ5'-)%04S6FAQL3S"1YY0IFLHC4H2_NE=5*?"#T[3P@U?[0BE/0?/
MY_+RZ5GN_377$JK:=2JVE@Z:E5M#K^F1-0.EUOP1R/?NO<.N7OW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZR0_YZ+_`):)_P!##WIOA;[.MK\0
M^WI4?R]/^9&[M_\`%B?D=_[^#=7O+;:?^2)L7_/#!_U;7J#+G_<_=/\`GJE_
MX^>CU>UW3754M1_,]IH>N^\=^ITK52_Z&/YC>VOY?38G^_L"'<=7N+M3K#K%
M>U%K3M(KBJ6DD[)6L.',50[BC,7W@\FM';&+ZU.07U:?WX\RCS\'P6O5K_PS
M5]'7\%/$IG3W/[E#^[I.;$+:_P!U[-%?GR\02VT=SX7GI*Z]&ONK35I%:=)=
M/YV?P]S.0[NVWM:#MU=P].=:?*#L&#+[\Z=[(V-U;O\`JOB)/E:3NS:NQ>S)
MMLY7%;MSFS)<:L]=#BH<A-!1SQR"-Y&$)00727>R?OVUH;3P;68!JJ[07=PM
MK',J4+-&+AO!9@*>*K+72K,%*[>Z\Q;?RW.Q^KGOOHZH`ZK/X(G\-FJ%5S"0
MX5F6H(]1T+.'_FI?&*LVQ79;(OOVDW'BNV_CGT55[)H]CYVKW#F>ROE)M':N
M]>I(=ET-738RNW+M#<&W]U)5KF##301TU)5/*L9IY54VEM"FX6U@CC7+NE]8
MC454I)MWB/=/,-1\**.&,W!<DCP&2455E)(HKU7L+N_="(H=MM[TTSXD5RWA
MPK#6AED>>MN(P`QG5H@-0(Z1>TOYTGP.WON[N?:.W][[YJ#TSL7M[L1MTU76
MFZL?L;MC;70E#7U_<4O1>[JVD@P_:-9L"/&RK70T+AM2WB\B`N"<7T)V*]YB
M973;X((YV#*5D^GE<1QW`C:CF)V9"&I73(C$`'!R;&X&]V>P4!OIKD6P(-8U
MN2-7@/(*JLM`_:30F-P"2,L.UOYV7Q`W?G_CWM;$;*^68W+\FHDS76>WZWXK
M]M4N=/7=7N3$[3PG<&X\*^%.5P?4VYLUEE3&9EH7BK8H998U,2AV.HMNN9=U
MDV8@)?1QJTH<Z1"S^*4BF8XBE=87<(]*(59BH/1.U_;#:FWI'UV&ME0KW&;0
MB/(T(']HB"1`S+4:FTBI!HVP_P`XOK27Y(]9?&>@Z4[CWAN/M#Y`?*CH2CWK
MUYLO>N[-@[4S/Q<KABMR5.Z\K'LVCK163Y"6%JZ"@IZVFQ=#*M4:J>-XA(3V
M4\FXK:&UC`,NP3;H"Y90R1RO"(X@%9Y"SH4+:5TRO!%I+SQ`FF[0IL[!;ABQ
M_>5C:$*!J4WMM'<K(U6"JJ)*&IJS$DTK%%@ET@YG/Y^W26V]B;WW#D/CM\FZ
M_?W7O?'070>[NEL?TSVGB>T-MYKO=ZBDPF[,_M;>VP=J9G'[1J\IALI2X1Q3
M25N=JJ6*F6GIZFH$,:NV`O9^48K4ADW;=&LE<D:8G2..5A)2OZPCDU+"*E@I
M(?2LC(EOR^W6_,<URA#[=MK7=,_KJLS0GP6I1HPWAZI1A?%7M.J/6-N^OYSO
MQVH=I?./*]3;$[C[/W#\&.MNT=[[W;*]=;SZ[ZHW;N'J5EH]W==[?[FRVVLK
MMV+<^(SK&AJHVII)(YX9O''-XF]M1R>/MEGN\%#83WUK;HQ(4NMU="U6>('^
MTB!U."#W*`>U3J!I9;>;G?K#E^>0QWD\>LT4N8CX`N`DH%/#DT,H*L11CI)U
M=IG[H_FY]74M=\>GV+U_FMY[/[OW_P!Y]<5O8L^5J<'L_!YGH/XV[M[_`-Z9
M+959%MO,S]L;;QV2VC4[8J*Z@2EACRD%3X34M3M"][QDM#N\I)^BM]MOKR.1
M@1XT5E<P6P=4%6$5P9B\,G=J1`RJR.K](-H1MUVV.[4:;OZO:;=XA1@DNZ2!
M/#,E57Q;8%3*E.+*C,C:@K9BOYV_P]7+]([4W/3]N4FX^X=B_%G?-=G-I]0=
MC;OZDZWQOR_Q])+TU6=@]IIMK%8G9^'W+FZQ,9!-EH,?425DB)]NK%PAE^[G
MDYAW+ERV:MY;7K6A+@(K7*P"Y6%6J5,LD.IT0,20CDT"U*.ZN4L=L&ZW7^XW
MAW$M$!=UAMKM[.65D4:@BRI1FII&H4)!!+/5_P`Z#IO;_:>U=A[HV96K@=SU
MOS"VY2[AVQE,WG=S9'L;XJ_(#87Q]H>J]F]<5FR,+F]\[X[/W1OI/LX:*<0T
M\E.RQR5<+-4QENVM^\K6WGA1VFN+#;KF"-1J:8[A-<Q!%!*E5A6V>621P`L0
M=W$:H6)INEJ-K^M::91#;7XMYF;M6-3MHW#Q68:@=6I(41-1=W72=9$?1A.T
M?YIWQ/Z<VOV?NW?N3W]B\9T]W[#\:=]PP;&R%?78OM:7J%>[GQD,%)/*E;BZ
M?8Q+25L3M`M6#""3S[I<2Q6]M:WC2!K:;Z[0RU(8;=*\5R1YTUHWAXJXH0.F
MX;6XEFFMO"*W$=E:73*U`5CO65(0?+7J8!UK5//H$.G/YY_P3[N[&ZWZLVR?
MD/M[=?:&^=E]?X$]A_&OMO8>"QN:[2V7_?\`Z;J=T;CW#MVDPNWL3W3MJ.>?
M:DT\P;,)2S21(($\I,(;"YFO9=O50+J/ZI6#'3IELPS3P'50^.L:^-X0JWAE
M2VDG2"^6ZBALUOS5K4Q0RZE&H>#-(L*S5%1X*SL('D!*"8Z`6X]%J^9G\^"M
M^)GRV[P^-=+\=.J-^8[H23I%\[-FOFAL+K#Y`]FTW<6W\#N.2'X]?%W/=<93
M=W=F;VQ2YHQ/1XO*`U$\81G@U^E'RY_N^NK2!NQ)MV:P'ATFD5@T:":2)=+)
M#60%G)H$61@3H(Z,MVMOW9:V4XF35-MLEY65A!"HCEN(_",[576WTY(P#5U6
MAP38`_\`-5^(\/R4F^,53E.SJ7<E'OD=1Y'M.?J'?B_';%]YC;;;NDZ%R/>P
MP[=?4O<<6WT,[81JOS`_M:O+^W[;@FAN(;^Y24+;0I<NCM51<)9U^J>UU`&X
M6$+(6,8-1%)IU:<I)#+%'8O);R!YH[9W0"K6PNR!;_5`5^G,C/&H\2@#21AB
M-717=V?SZ/BU3_&3??RDZOZ>^67;>Q=F=K=9=4T/\(^/N_L!3[WJNTMS/MS`
M;QV7FLQB?X?G=E-+`^BHAU5,]5-24R0>6LAO=EG63E.)H"LF[WT=M&K5#QEP
MCU=*%JF-_P!)%#&62D0*DU#LRK#_`%G'BJS;79S3R%35&\%FC*+)\`(D%)&)
M"QQAY3J5*$R&'_FU_#S+=_1_'J3)]K8+,ONV;K%^SMR],]@X+H*F[NH=K-O/
M,]`UO===AH]B4?=FW\!%+)7X"2J6HII:>6!CYD,?NR&*1-RF%P@M[=+J17)T
MI<Q6;%;F:T)I]3%%I<EXJAEC=DU**EES)&MCJMI3),ML74*6:W-V%^F6Z45-
MN\I>-0LE"'D1&TLU.@$S7\\KXQUW6TG9G6FS>ULOM^D[I^-?7DV8[?V)O?X]
M;2W#U;\D.V8NK,/\C>M-Y;]VA+ANR.J,--%65HJZ$K'4QTNEY:9)4F]N6T8>
M?:([UQ:I/)(LPE[9K4)8W%^CSPL0RB6.`B.I%:L<LA0JG@(_?T<!\:ZL[&YG
MC$??'<-:R1PRPQRCLU))(JL<T)%`PJ0>\?,?869^/&U_D-LS;VZ\MA.S-S[>
MV;TWM_<^-DV+F.SL[O;=\.SMA5N*BR\<]3C]J;PFJ$RE)D)X-38,_>B%ETHU
M'AN5FV>S:+PK^]TZ8Y:HT58WG<3BC&-HH(Y)7C(+KIT$"3M"59K=X=WNDE#V
M=F)-4B=R2%&$:^$U0'$D[)!&]1&78-J$??T7NG_F![L7?]1B<AU[TB-ETORC
MG^+[X_#_`"/K<K\@9<NF^FZ]AWA2=)S=-X['U6)_BX^_GI5W']S!A$EJ_5XF
MC]M;7-%N,6TSL^B*]6[9"*,(EM6NZM<&JB-2MHS.RZQ&9$'<*L-[AXEDNY:4
MU26B6S.IJ#(;B.U<K`*$RLIN@J@Z3)X;84D#I<Y/^9G\:\)B<YGLU'V5AL'#
M0C*==YG,;'GQ.)[TQ7]_<+UBV4Z=R>1R%-0YW'1;VW+C*5YLC)BHT@R-/6L1
M02?=#<;-*L2+$PO7\(^"U%E$<X9H965BH6-U1CW,&4@(ZK(\:.]+&87N];#Z
M>`3:Y15HU>W!,T55!)D2C#2JD/I<QEEC=E;J_P#F-[,PO9<NS]Q].=V;;VPO
MQ]VQW33[DS6S*BFSV1W-O+MR;IS:_3N.V.LDF7K]Z[AW6D,.-EIGGQ^1>ICD
M@G-(5JGO&K22[K;QH7N8)+)(T45:<WD=S+10=.@PI;.THET%`DQD\,0G4S(Z
MQK82.P$$JWS2.?@A2Q^GU.S+J#I)]0NAHM88F-5UM)1%S@_G[TSN+/;3V5B-
MK=RUW9.<W+G=M;LZNHNL\IDNPNGO[LY;:V%SNX>VMO8JIKGV[M*AK-\X9UR-
M))D(*FER,=33F6F2>6*ULBWDD8M9E>V*U,HJ(E<R2PB)W8#1*9H9H]+`:3$[
ML5BI(=3LUK!-+<Q,DBM01FGB2#PQ,7B4$^(@B*N64GXEC`,I$?4[XV?-C87R
M2WGV/USMS!Y6'>G5&_.VME]@P8>9=S;;V.W779VXNO=MQ[RW1%2XRBP6[.RZ
M#;TF:QV#"3UD..O)*1$8)IVMM8;GL>V[Y%VP3VT<AKP$DC.&@C;_`$5X557F
M(`$8EC#49@"HW&)MNW.;;9160,NDCB8S!#*)67\",TK11DD^(T4A7"MI6/=7
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M:,Y0B-7-`?`Q.D<L4Z/$T5H^H'M`OC&+5230!I3*G'"!@9"@ZY[+_F1=(=B;
M,SN\]E;'[YST.(V[UEO:@P*]6U>+W#N7KWMN#<,VT.QL7!G<IBL9B-B-)M'*
MPUF2S=7B(:*HH6CETM-2B=1<Q/;*S/0A)VB>A%(SX"W,;.Q(54G@='@SJEU:
M%7Q`R#UL'N7$8C=&:)V4,""[13"WGB5:%S+!,0DR:1H^.IB!<,F)_FF_%_/P
M;&R6!I^V<SMW>6TNM=[Y'=E!UKE9=K]<[<[8[)W/T_M&L[&S#U$<.$EE[+VC
M78FHAIA6S4[QB<J:0_<"\-O)<7`MXA5C);QJ:$!I+NU2\MHU!&K5+#(I`*@*
M_9(4;'5)W6VM)KN8T\-KL.E0746#JEVQ`)71#K#%@Q#)5DU:31=YKYY=6-L6
M?>^Q<7N'>7\&V'NOMK=V`FQ]=@,SM7K+K3LD]:]IY/*03T%:*;=>U,I09-Z?
M#S>&3(_PFI1)DT!BD2:(BSN)&(V^5+%S*!553<58VQK\)((_7&H&%`[M4II*
MGP)3)+;+$S7VN\C2,4+/-9A2\>"2/%UH(&`82L\:J.\'H[5#74F3H:/)4%1'
M5T&0I:>NHJJ%@\-325<*3TU1$XX:.:&164_D'VHFADMYI8)D*S(Q5@>((-"#
M]A%.DD$T=Q##<0MJAD4,I]0PJ#^8/4KVWT[U_]?;>^&O_,BH_P#Q+?R#_P#?
MX[]]@KF7_DLW/^EC_P".+T<;-_R3HO\`3/\`\?/1I?9#T:=>]^Z]U[W[KW7O
M?NO=,6Y\9D<SM_+8O#YBHV_E:VD:+'YJFU&;'50=)(Y]*,DCQDII<*RL48@,
M#S[9N8I)K>:**8QRLI`8<5/D>GK:2.&XBEEA$D2M4J>!'IT7;<&V-TTV4_A&
MY3NSL`B@6NQ&4QL.6DI8Z=O(F0A^VCJA28O*T$L0/D,IFGBDC*<ZE]@3=MNY
M@-S'"MS/<QZ*AAVT/F"`0*^F22.A987NU>`TJQ16YU4*FA)]""020?LH",]`
M+@>@-F)WD_R96OS5;O\`RFP3L;R1Y+(1[?KMOU-0M7_$:O"U51/!'G*B7F4P
MB&#S,SB(2,3["MS)]1<&X>,+,11B*]S>;$'@3Y@8KGJ73[I\V)[40^RIFMOZ
MBQ[L=P5?`C^H6X*Z:?4`:S$!D*:FF-6D`=&`9'4<J4+*2A=3:]O2UN-2@D7%
M^?;74<AE:M"#3I<=/5<E/!FL!D8(?XVCTN?K,G3U$T\6:BKE..^X:.>*#[*2
MADQXA$**(EB*$$G43(W*EU!):3VL4&AXV!.:ZM0^*M!0U%*<`*=!;F"!UGBN
M#)JB8%0*4TTS3%:\:UXUKT-'L5=!_KWOW7NF;<.;@VW@\GG:B"6JBQE-Y_M8
M2HDJ96D2"G@#N0D2RU$J*SMZ8U)8\#VQ=7"6=M/=2`E(U+$#B:>73UO`UU/#
M;HP#.U*G@.B>YW!8]DR6X-PU$=3N+)4U3_$):ZOG;&9#(2F6LIZ,TTQE\6-H
MZM`(U@$0$,7JXU>XAN+VZNY;EW<L\M:BE<5U:1@D**#`H,=2+!''"L$<2TBC
MI0\*8I7YDCS-<G'0G'96+VCU?597!U^\(&SFS]KX;)4&;R]34K,E=5X^DEK*
MZCJQ(]%E(Z*MDIM4;JD-,Q4+J]1'L]G;[9L5Y-8^(A>`5!/FU.X@\&H:8P!@
M#H+QW<M_N\$5T(V"3,00!P%30$<5J`<\3Y^73855244!53T(H%@J)Z54#\!5
M%O<;\,="CKNCH\IF<K38/"+1_?RTU1D*FIR!J?L,;CJ:T8J*L4@,Y>MJV6"!
M01J?4W(C8>S+:]LFW6X:")@JJM2Q!('IP\R>'YGI+>7<5E#XTP)!-`!2I/GQ
M\@,G\AY]"[M?8&.Q6+6GW!287/Y)\K79@SR8N&:CQU17F$O2XA:Y)JF*E4P!
MV9B#+.[R%5+6$D;;M,5C90VLVF9U)-2H-"<T6M2!_EST$+[<I+FY>:`M$A4+
M0,02!YM2@)_R4'0A7L;EE7D6)94YOP`20+D_0>S;HMZ`W<6QL]3Y_+5N#CP-
M309VL&4BQ]7F5P=;1UDU+#'DC%#/23TU32U57`U071E822O=">2"]YY:N;R^
MEN[22(+)0E6.DUI0G@:UXG\^A-M^\P16L<%RLFN,4J!J!%<#C44!I^0ZAMU_
MOU(C/IVE(X%_X6F2RJ5+?G2N4EQBT)=A]+PJG/ZK<^T)Y.OA&6^KB\7THU/]
MZ_V.E(Y@LBP!AE">O;_QVM?Y]`UF<9N&MI=T4NZ5DPV5PL2S1[9QU;25U#!`
MU'%E*66MGA5_XW4U-/=#K!I(I#Z8W*'V&;NRGL;GZ:]4:Q0E0?(_/UI^0Z/K
M>Y@F2*:T-8V)&HBAJ,</(`_F?7/0N[JVMB=MP[7SNW:>*BP^7I\=A,E2*[RO
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M,\%N%18VJ3H#QHL<ICTF1`0U:]9<_P#R@.F=P]>8?KFJ[2[0AQN'VS_,+VQ'
MD*=-HBOJ*;^8M4YBJ[+JYPVWVIS5;$;,N,%I0*0B_=B?FZ9;=5V^#;@3X4>T
M6.W@^?AV%W#=QR>GB2/`JR8TZ6:@#4/1G#NDL.^R;\L:_4-OD.YZ<Z?%AM9+
M58_7PRDA8YU:@*-3'2]Q_P#*QZ&H?DO\</DZ^X]]U>Y?CGU)L_K2BV=-5X@;
M%[#SW6VRMP=>=9=M;ZQ,>+6:J[&V!M#>6;HL=4TTM/`D63<-&WBAT&4EVTN\
M<V[NZ`MNWBEHS4I"]QH2YDAK4J\]O'%;2&N8D`&222-K?5M'+VS&0^!M^@!A
MAIHXF$L,4I%`T<-R/J4%,3'5P``*!U/_`,)Z?B/TQO7Y(;GV3NW<U%B._>L.
M]^K\3@6ZQ^/"Y_J;&_(2@R^.WIDML]Q4W4=/W?N>JH:7.U4>/AS^XLC30PNL
M4B2Q1QJI1':%.5[WEAYV:*:&*'Q0`CB"%PZ1E8PD;FB1J\CHS/HU']1F;HW-
M\W]9]OYG6)1-!=_4^%\4;3TRW=J=%J78)&R!2U!113H9OEC_`"9>F/EW3_$3
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M^(\D+0H%=V8LO:V`M%YO7^0]T5V%W5\L>\MU]X=JU.Z/EATOVKTQN2/!;(Z!
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MUR-M42PP`%?J=JN'_P"&7&UOK69L_'=`1K<Z:!BFM0KN[,\;<_D]]+[:ZTS7
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MMPNANC;DE[`CV=W=B>:(ZM#TVY=N"&A#`!$6=&5@Z3JK*P``Z:>^OY&?7OR!
M[`[/W9N;Y:_)?![/[=[%Q'=>].G=NGJZ'KC(=WTG24O1.9[/\-=L*MW+'DL]
MM203&@7(KBZ6K77%`!8*S]+"(;NU&HVC27[0(Q+?2KN+^)<)$<%EU93Q-96K
M$&KN6;-S.WTDDDA-VME:6TTF`UPMDVJ!I```*5.M4"K(VEF%42@Y8O\`E)].
MXK<VV-T0]F]F25NU^U_A1VW30R)M3PUF7^#W3=;TOL+%5;+@5F;%;NPE<U9E
M]+"45@'VS0QW0GEUNLUUNYW=XU$QW3=+[2*Z?$W6V^FE3C71$G='^+5\188Z
M+(+-+?EV'EQ78VJ;-:;:&/Q>%:7OUJ2>FMY.Q\:='`!L]9N]?Y1_07?'8'R3
M[>SFZM[;;[B[WWS\>>T=D=L[7IMITO8'QM[*^-6U:3:NP]W=,;CJ\!5UM%-7
MTE,YRE)D&K*&OCJ9H)(C#(4]E-B'VV':UL7T7-INL]\LE`2YN1$LUO**:9+9
MXXS&T;#*NQKJ"D&]Y=+N$/TM[;I)9':S9-&>!3ZB:Z24-\231S2JZ.A6ABC]
M#6!COY2^P:3Y!IW%5?(;ORLZYJ>]:+Y99WXQ)6;%HNEL[\LJ;;T&"F[QG>#9
MW]_Z26JJZ:/*G;D69&VURR+.*/TA1>T$=G5(HZPP"\6Q5J-^[TO?%\98"1^I
MI%Q<B(SB4QBXDI6N2^XC>YB"2N/$FCM%O6"J#?&S\(Q/,`*1NQM[8R-!X3.(
M$6H7'1==G?R`NB=F;.^6.W\9W_W%1[C^4^>ZUW'/O;:^ROC[UK/USF>INU3W
M%L[/8;9O5W46R^N]Y;MCW<J?=YC<6*R>0JZ6,0M($+`MVZM:6&PV5M(R/M^Y
M6E[&XS^K9@B)5B;5#$AU,9!%&C2$KK8B-`JJ]==QW'=;^^C$B7EC=VDB$GNC
MO=/C:I!25V&A?#+NV@:J9=B1QQO\G?JU>Y1O[<_R`[^WGU'/W'D_DUE?BWE\
MAL6DZ9S/R@W#M>HVUNGNFNGP^S*#?XES\U?5Y1MO1YA-N4V6J6J(*./3&B^6
M&U$$]I+:K)9)!>06:-7_`!&WOO%$T4#`AFHD]Q'$\QDDC29P&)-2RS7&J*:&
M?P[EVM'NG54!O);+PC#+*-)5'+V]N\IA$?B&%`W;5>D52?R1^L,CTBWQI[3^
M4'R7[U^/F%WCT%7];]-=LY78>;Z\ZZZO^/O82[^P73M)MK&[+P^.W?A=V1I'
MALUFL\F2W%586&.F6L15.I29FNIMMN]X5;W<(9C))+(,S'Z26S0%11(PB2F4
MF%4,DP5Y"VE0+H5M?WM'M2_1V=S9W$"Q1=J0_4RI*\B5J69&0"$.62%"ZHH#
M'HS$GP>GZI^*?7/173&Z<[O"I^.';VVNX.@,;V+EJ2%<9B-E]AU.[=N]*U>?
MHJ"*1]HX39V3J]LXBJJ4EJ*.B6D,SR^`EM/>7;WO+>XW3O<75FJQ3.2/%N8V
MMI;*21V8Z?'^GEUEL"6:,,Y#2,W3<<,<=OS+:6FFWM[\2-&BC].!S)'<HB`Z
MF$)N8@6'<R1R.L=`L:J]97^7=TW793$]A[>EJ=B]YX'Y`[O^0VW.[L-MK8TG
M8^'R78V<K*_?W6^2RLV!G3<O7&Z]M92IP-=05;3&2A,<B2K44\$T::RMH-M3
M:[6$"2TMH;FWD4U"W5O=2S2RQS#&"\JNC`*\;PPN*,IKZ[>7<8=R\<:9K@VT
MB$T9K:>UAABAEA)J`ZB$AAE7669""CT":H_Y<V,H<=/B8N]=]5V*VGL;<_67
M0V'W%LKJK=>"Z=Z_WMNK!;EWAM>MP6Y=H93$]L46?H]M46$D?<<55-%A(FBB
M=*F1ZL^D1YHIC<N)KV6*""621582VUNP9(FCH$!8JC22H%=Y(XGJH0JR@2A)
M]5NIAMA-/.B1G3X=S.KJTR/\0">+((HC6-5D=65QI*IW;?\`*TZ]VA@=OX?;
M';6_\!/M[8D6W,?68C$;,I*/#[LPG>Z?(O8>\]G[?.%EPFS,;L'L$R14&VZ*
M%<`<,XHGIRBZR]')-;RB>VE9;A([-8W?]1@UG'>0ZG9ZF7QX+ZXAE5S0(RB+
MP]"T2/#',K17$:FWD:[\5%&A72[6T!50N(S$]C;S1NG=XRM(VHL>ESM7X`G9
MO8>.[JV_\A.R\=WEG,UN*J[L[-@V_P!?25/<>V-SY+8]=5[+J-LUNW*W;.QL
M7B:;KK%T>,J,33QUE'2BHO)++4O*+V30[>?!MH?]UK4:2%B2))A--.)6?#U\
M2XF4HI"&%EB`70K"UVKWT3FYD_QX`K%*H"M"AB6'0BY5AI1'K('/C()*TJG3
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M!E=48O&:'"NC,VEQG0\B&JN0'?&U010N#6*;Q8F#%6CD*Z&(I@AT[6#`Y"LI
M5E!Z);1?RD>JMO#$9S9O8N2P/9$F0["JM];XR/4G1&[<?NVF[0S6`W%N2CPO
M6^XNNJSKKKDXG,;;II<)+AL=!)0*9$G^\61[JHG\'Z6&(4LHXHT9#1F?PY9Y
M@YE(+J3)=7&I4I'HETJB^'&48D)G,TUP`UV9"RL*JJ5AC@*Z`:.-$,))<ER\
M>K5WN&-%!\,=CTV<VWG(]U[J$VV?DGE_DQ1TXBP$---N?,=0YGIV;;LT-)B*
M:&';L6%S4E4BP)%*M4J@,(OV_:(6J!;A02!):[G`>)HNYS/-*02228F<B.I.
M`->HU)V23%+#7#KMX)Q7_=?X/AX`"_J>"OB4`&3H"B@!=]S_`,J_KK-8O8-)
MCNT]XT=9UUU[T'UWB(]Q;8V#OS:.;QOQ_I>U*/;E9O;8&Y\!4[7W=/D5[8JZ
MAHJN)J:DKZ*CJ8(TDB.I6SL=PO+_`+=4]RLK@@&FFTBM/T]50DFF)766A="T
MBKV2,O2FXNFN8I(I%I66XDJI*FMS>+>.I((+1:UT-'6CKI+=R*1)V/\`RKNJ
M=C=7;EZJHNS^R\CA]R;*ZIV*^3KH-ET^2H<1U)\@=]_(?!2TL.'VQC,1'4UV
MY-_5-!4!*5(5H(8A%''("Q4VEY)9W5C=H`TL%W87`J2=3;?:QVD08UK1HHT+
MGB6!((KT@NXEO%OU?'U$6YHU``!^]`OCLH``&AE+1+32M:$$`=-6'^'78>/V
MW\]\[@<*FV][?-3?>0VMA-OYS<N)S6+ZDZJS6/;:FZ=TT<U#)+1?<;CS&XMS
M;WDQ=,SR25^4AIY2)$D*%,=E#)R[M7+MR1]++>/-=&AJ('E,BV8IIU+#`#;Q
M%2%B>XE9&,:BI@UT8]_N-]@5?&M;*..U!`TO<11@>.12JK+(L)E5B2ZVP)TM
M(0MG^VL!0;4VYM_:^+5DQFV\)BL!CD=M3K08>@@QU&KL>69:>G4$_D^S6^NY
M+^]N[Z:GC32O(U/5V+'^9Z*[*U2QL[2RC),<,2H#\D4*/Y#I[]I>E/7_T-M[
MX:_\R*C_`/$M_(/_`-_COWV"N9?^2S<_Z6/_`(XO1QLW_).B_P!,_P#Q\]&E
M]D/1IU[W[KW7O?NO=>]^Z]T%,7;VVAN?/[?R`.,HL#DFPTNY)ZRFFQ#Y6.@I
M<BU)4M3Z_L!-3U8\3NS*SHR/XWTJ27]_6*;C/MT[>&R4[R1H)H#2M<'.*\>C
M;]S79LX+R+OUBN@`Z@*D5^?#-/MST(V2S&+PM#)D\KDZ/&XZ'PO)6U=3'#3(
M)I$B@<R%K%99)5"D7!+#V;R2Q0(999%2,>9-!GAGHLCBDF<1Q1EI#Y`5../1
M0ODI\1<#WOMVDQU!NC=&S\=B=T[>['3"[&RU3A9-P[CVQ6U.1AI8\K%5214&
M-S]/5,DL4<)C\Z12II.HD+;QRO!?M)<VCB*;23I`P[UK4FN*\,?(]3/[/>]F
M^>S^^;AO.W;+MNX3W6W7%BPOH!<)'#<J$9T0TI+'0%6KPU*P(/02],=/4?7V
M\=[8S;/8V]ZZ?NK?N3WQE_\`2)+7;IR>S,M/12NNW-NX.L?''#X;PQR7J)O*
MHDC16&D*2#=LVDW-^+*Y:6%WJ<H3D"M,TI@<<CH2>YWNQ>\^[1R0MURQL]G'
MR_M*6$9L8E@-RBM43W)%?$E)I@4`JQ'Q'H_&U-FT.U%JY8ZVNRV3R"T\=;E<
MC]NDTD%)Y#34E-2T<4%)14D3S.^A%N\CEF8FUI,VS:K7:HY$M]19S5F;B:<!
MC``]!UC_`'VX3W[(90JHM:*.`KQ.<D_,])OLOL^GZ^.+H(,3)G<]F15/2T"U
M(I*:@IX*>1H*_+3B*>>*DJZX)!&L<;2.S,PLJ,?=-SW:';/#5UU3.K$"O!5%
M2QXFE:#`J2<<.G=MVR3</$</IA0@$\:DG@.`K3)J:#\^I>W^S=NY'%4D^X*[
M';5SH2CAS&#R56\`H,E5,\8@HZRL@I$RM#)+$WCJ8@8ROZM)X]ZL]ZV^[@27
MZE$?`92:48\!FE:^1\^M76U7=O,T:0N\>2K`5JH\\5I\P>D9W]GSB\)A\8,W
M28**>L_CF;ES-52XG;U=MS%LL;4&:SE;)%#0T5?F:BFA"H=4KN+^A65BOFZ[
M:WL([>.4K)*V13#(/B!/EDC[>CCE#:KK=MR\&RVZ6ZNJ41(D:676035(T#,Q
M"AB:#M`)Z+OA*W*UVX:++_8U\&8SV1GS6#:MHI$I<1A*!,8V'R/WM*]*V0IB
MAF+0QU4E)6E@CQE6O["-K<7&V!9C#0%`R$K2KD@@ZA0E0*U6ND\",]']S!%.
M'@\3X"5<`YQ4,"IKI:M,D!ER0<=+<[LW7N')?P'*[ARF7V=18YLOD:[*8Z@Q
MO\5KJ')RT]&XR5#3TBY#`1U5+,TAL$EGIP+E$8,Y>;QN]Q9K!=R_HRBH[0"R
M@G-1^$MCYD>G2:#;MO@E,T$(%PII2I(4D#R/!J$?8#Z]2ZS=6WZ"BK,E6Y2&
MFI**CFR$\M0LU.STL`O(]*E3'"U8Q+`!8M1)9?ZCV321RQ`&6)E!X5!%?LKQ
MZ6(ID;3'1C6F"#^VG#\^G?8.XMWX_9VY=]1;=:*#=5;@:'9]&^(K\CN'*5-5
M4+14^2J**FD#0[8Q-),WV\3!&JIQ-.[I'(@]CK9Q=;=LT]S!:ZI)*:!I.J1S
M@$CRC'!:TK0L2`1T'MS2UNMQ@M9;B@C#:SJ`5%&2`?-R>)%:"BBI!Z&W8F/W
MO3T<E?O3<E1E*K)Q)-#@)L/AJ'^[;&:5_MS7XI%DR$\D#()%>Z1,-*$VN1'M
MT=^L"/N-QJG85*A5`0\:`CC3AGHBOY+%I2EC;Z8E--6ICK^=#P_+H-NW,7O3
M?M?6[*VUCX9L3B:+#Y.JK*J3'TM(-R2U%:]+!)D7JQ7P1TU&@$Z0PM(JRZA9
MPOLLWJ'<K^06-G"AME"LY9M/=6H`(-<`9%//HQVB6QL8Q>74C"=BP4`5[:`$
MD$4R>!KY=(&BQCU9K%W;015F[:2J--N:3(TSU#KDM"S(E)/5B37BS1O&:7QM
MH,!7\D^P%N?UHO[@7S-]0&]?+RT_T:4I\NA/;-`+>'Z.@MB.VG\Z_P!*O&OG
MU.&Y-V8!Z?;FT,[61>>*.9Z/(T]+E\=M[$FK"35M'4Y!7JZ*5PLD=)3AJB,N
M#:-40D*;;F+=K./P(IPRTH-8U:1Z@\?L!J.F9=JV^Y8W$\%&K^$E=1]"!C[3
M@_/KA78?^)UL>1R>7SF2K40QFKKZR"HJ'BT3)'")/M$-+3Q_<,?%!XHW)]8?
MVBN;^\O`PNIS)7U"U%/X32J_,#CY]/PPPVP`@A5`/(5`_/.?M-:>762*AKG3
M%IEL_E\['AE_W&4N0:F6@H:C[>.B6JI*2G@C$3PT,0BB5F=8KNRV=V8VNMSO
MKR)(+BX+0J:A<`#``X>0`P#7-3QZI';6T#O)#`JNPR<U.:^?J>)%*X'`=.GM
M#T_U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UDA_ST
M7_+1/^AA[TWPM]G6U^(?;TJ/Y>G_`#(W=O\`XL3\CO\`W\&ZO>6VT_\`)$V+
M_GA@_P"K:]09<_[G[I_SU2_\?/1ZO:[IKJHG'?S%_DAOSY`9[;_2/P+W3VY\
M2MB_)3_95>P?D3A^X=LXSL#';^Q&4I]O;_WOMKH:LVV[9[IOK7<5:E/E,U4;
MDQU28Z>JE@HY%A7R:V<C<(=HO+W_`!;;]Q%PUM)0R`I"9T26<"G@Q7$ENZ1D
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M,O\`B=#<ZSP01*?$9CV>'5M5`>DS?I#>3=@P?0QV\DGB`H2EU+X$)0'XR\WZ
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M;Q2MM$NXW<9BFCN%61'[&A29`ULLJ,=0DD*35(.D%0E%85=F=@NZQ6%N?$A=
M&6-U!999HF83K$XPP13$0M-1!:0$KA+%-H=N]4=A5=7CM@=G=>;YR-!2"OK<
M?L_>NV]S5M'1&185JZJEPN2K9Z>E:9@@D=0A8@7O[:F+Q6L]T(R8XP:GRK0D
M`G@":&GV'TZV&74B%AJ;A\_6GK3JLKK/^:M2[\Z9^%/<>3Z9DV_C?EMWAW_U
M%D\9!O8Y>;KC'=$8?O\`S59NF"<;5H3NV;.TO1;!*$1T'A;(@>:3P_NVNG@L
MFM&N7(MWY:;=V8"I54MK6Y,(6HU&ESI#U'P5T]U`875A+#=<SVD)#S;?OEMM
MRU[1*UQ<QVPE)SH"F35I[JTIJ''I&X#^>=\4>Q>KNP>Q>N]O=QX<['V[\>-_
M8ZE[MZCWYU70=A]8?(KN';W2^U^Q.N*R7#9NJWAM6DWEFWH):VEIVIOOH2H<
MP!YT6VEA/=76T6Z4K<[G!9$9$B/<V[W-NQ0@46>!#)$6*U7+:25!+O$B$]];
MEB6BL=PN0RC5&PVX,+E0XP6C<:7`JPR0#2G1CJ?^:=\5)'V%2UM;O_"Y??G>
M'R$Z$_@.:V9-09K9>ZOBSC=P9OO+<'8-&]>PVML/96`VZ]?)E)&=)J2JI7B1
MS41J2I+NW>UVZ^,H6SN-GFW,N2*0VT#B*3Q@*E)1<,MKX0#-]21#ANG1%,7O
M(EB)N(=RMK$(*:I9KM5DA,(--<;0-]27P!;@RD:0>@$VK_/?^`V[NI>\NY,=
ME.XJ7;?0V!V9O;.8;*]2YW'[RWQUGV'O7&]?[*[2ZKVS)4-6[VV-N'=&6@@@
MFB,56-:ZZ=2Z!GY/&BM+.YDM91+-?069ATDS1W%R"8(Y(Q4@R$,HIJHR,IH:
M5]&J27=Q;+/'X26US<"8FD+Q6BE[@I(:`^$@#L#I[75A45(%#K;^;=\=.T?D
M1LGXM8;K3Y28'N3=NR\+O7.X#>O0&ZMM1=14VY\%G-S[7PW=$E1++6;`SV=V
M[@S71PRP31T]-4P-4R0EF";F4I;<PW221F+;89'D;5V%XHHY985<`@R1B55=
M?]^512ST!3M,D<&U7#JVF\<"-0.\H9F@64KQ$;NK:6XE5+T"T)+WU1_.TVGW
M'O':?7FQ/C1WYN[-[P^&N\/EYA=X[/ZXW_N;KK,4&V]RY7;=#LK`/C-HS;WS
M-?F,AA9Z)9X\0#_&6BH$BD=RZ-SF6*;F%?"I'MMMMTSAL22+?A'!B0`@JL;,
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MMRMW$]L@M3&(SJ>X6]8QV[VZ8:1))U:W#4"^*I%=`U]:6*4WL-A)$T<IEFB<
MN"J0R01&XD29N$;?3#ZD`Y,)!IJ95+QM[^=K\+]T]/-VI@\=W_D]R?Z8MM=$
M4WQVQO2&Z<Q\F\CV5O#;^0WGMO#XKI_"-DLIE*;+;#Q%9G8ZF">2`8RDF=F$
MJ>(N3K)$-N\.)IC<_48C&OPQ:!6N6FI_9K`KQ,['MI+'I))(#,3I(M^[L(HX
M(HI*R=@E6=_#A\$G^T,LH:-%&=:/J"J-70*]*_SV.K^RNL>TNVLWT'W9+A>J
M]DXCL3<6R>GMB[U[<[1Q&R,YW/WIU32;PW%M0[5VA_!,!CJ'I.?*9@R2^?!K
M-)%5H@B$DFKEH;+:+7=KB4?3O]-K=.Z&(W&WQ7_=+@%`L@1)`-,A*THS:0I\
M!I;]K&U#,YGO(T5P4ED-I/;V[!8S4A]<_>A-5"D@LN>A?J/YSOQRPN#S_8&[
M-I]M[=Z^Q_3/Q/[AQ>)GZUW75=SU6.^7W8>\.NNK*&NZPHZ">2.IRV4VQ%)%
M3TE;69`Q52EJ="8Q(]<0R6LLMG(C/N(W6/;UCC!<FXDLEO%B-/\`1*$QE155
MDHK,#6B>)X;BSM-PCE"64EE?71>3L406,T4,DBMD,C>*'5B1J2C+4&O3UVE_
M-HZTPO\`+A[Z_F$=3=:[VW'3=#9C.;-W3TKW31Y3X_;\V[V)M?L/!=>[FV9V
M/#G<'N2MV!6X*JSD=74224=6(Z:Q902P1+?EK1.69HI;>2UW62!8I3(%B"32
MM"79R**(Y$=7J*54T-*$K-GMUW3<-WVZ3Q89K**=I`4):L-H;P!5J-0DC*!6
M!IW8K2G1:?CS_/IZJW?U]\D]_?(C:G5FTL/\>\CTSB:/<_Q&^1>W/FWUYVON
M;O5\[1[)ZOV!NS:&TM@5==W$N3V^\=7A&H/!315,$CU@#2"-9<11P[587Z"9
M[F?<I;)(A&=4CQ0QW#2Q&M'@2%RTDAT!/#?CBI;;R2SW1C;PDM1MYNV<O1H4
M$@AT3I2L<CR,JQ*"Y>N0H%296E_G0_$/-[6^.^X-D[>^0_9.<^2^_NQ.K-D]
M9]>=([BW5VGMKL/J1,#4=E[5[(V905!K-FU>RL=N*"MKYY7EHH:$//YC&`S-
M&.1KVUL8`)'GL&O$<']+P$E$$CO(<1^',?"?6!1ABH*DVDF2';]PW"XK&MM<
MQV[1L*2M+-%)/"L:<9/&BB:2/23J6G`Z@H.];_SQ^F<GUC+VWW'L7,=:[>Q'
M0._>_MT8/:\F>[-W1B]M;.^86=^(E%_#8<?M3!X_._QC<6,@K6@AE6NA%0T:
M03+&)G=FB2&TBNB[.779@`JD_J[S;F:&,>;:6'AAE!U<2J&B]&UUMLMO?WMD
M"`L-YN<)=Z("FV6T-S-(<L$/ARFJ$T!7#-4TL3^('S3ZF^:FU^PMP]98'M?9
M63ZH[&R'5G8NP.[NML_U/V5M'=='AL+N6DBS6S-QHF3HJ+.;:W%19"AE>QGI
M:E&*J;J-O:2)96&X:D:VN/%`*L"5D@E:&:)P/ADBE1D=<T(I4]$J74;W5S9Z
M6$\21/E2`T<\8EBD0G#(Z&H8>A'ET;KVFZ4]>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7__T=MWX9BW0]/_`+5VM\@&_P!OWAOWV">9?^2S
M=?Z5/^.+T;[+_P`D^+_3/_QX]&F]D71KU[W[KW7O?NO==@V((^H-_>Q@@]:Z
M*QDMLTVT<SF-IP/*V+K:09K%22I!'4S4>6\M/F89IX*>!*VIH\F&U2,K2".:
M+66/)BKF';5V^^*Q:O`E74"<Y)[A6GD>'R/0^VR]:]M4F>GC(=)I\OA-*FE1
M^50:=-.1%?G(,+A<OCZ9GV]1RT-%O.CT4M7-MT1TGV&W_P"'+,T,61AKZ9)Y
MYS&8I$IDT:6D=1N]WIK[;HK2:`?5#M+C`\,4(`'J2!7[,<>MVUBEI=2W$4I\
M)N[0<]YJ"U?2A-!\_D.E_@NR<AB,5A\!'LV6H;!XR/'UM3'71XC&RK0R-18\
MX/[I*W[O[J@A2>59'C\#/HNQ'L^AYMMH;:SC-HQD"48+@*1@::\01GCCAT4S
M;`\T]Q+]6`K/5:BI-<G52E*''#/'IFW1N_=^<J*W+8FJRNVCC<:R[<Q:5V.,
MTV12GDDJ*K.NB5=%605$^B**!W:)(5)(#M<%FY\T7D]PDFW2/%`BX!I5CYZN
M((\@/SZ66.RVD,7AW:+)(S9(K@>07@0?,FG\ND=F=^=JYO:^`J=O9V>6FK:K
M#YC)UV.Q>(PFZCAX(Y9<EBZ&*1VQK_Q8,`I4>9"H",0P(8?FK=9;5DUA9B00
MRJ`:9J"#49\C2N*=*8]CVR*Y8O'50&&EB2M<4->./V?LITT3UVRH7QF8J<G4
M4PSN/^]6>HDKIY\W1)/1UR+F:BHBJZZ:1:V.+1$\B/+*OB`<>CV2&]G/CE[A
MB9EHQ.2P!K0DU(%?(4KPZ,1;DZ46$?I-@"@"FA%0!0<*YH:<?GU*H,34YR2/
M/;E@@CJI\-5XS'XZGCJH6QF.S'JR'W;51\KY2JB"(QTJL2@A0"S63#4PJW`^
M7^KSZNS*E4B\CD^M/2GE_AZ2'9W0W6G<VT,UL/LW'9K=6UMQ4.+QV8H*S<N8
MCDJ8<+D:;*8N:.IAJ$EI*JCJJ1`K1:$,8TE2/;]Q--=FMS,SGYG_``>G`<.A
M=[=>X7-GM/S7MG._(.X)8\RV?B>%+X4<@`E1HY`R."K!E8\14'(/7.6LZZZN
MP6&BW[6YO"XFAJ,+U_L:AR'9>*VGL>CQ<=1XL#LC;<^2K5S%6^9HH4$D$Q:2
M2=-"&)%#^SF&_P!H^DMTW..XGFCH%!8!%%?A7-2I'$'CPQT1VVQ<\<\[YO=Q
MRYMDM]NDHGO;HP6SS3$5+SW,JQJ0BJS$E@`JZO/AT8JD.V.SMKY#*83KRI*;
M:I#C=DQYDU&VJ?/PT43O!BE^VGIIH\)'6T_BF@G,D1O^J[-I&@6RWBU:>/;-
M0AQ#K&@/0572>(2M!G'4;EKO;+A(I-Q`\4UET=Y6IH2?(M0U!&>A?^T7/8K'
M?WJPN,GK&HH9*S&5<--EZ3'UU32+'D*6EDJ8I(VB0NT6I0-<?'(]G6GQXH_J
M8E+Z14&C`$C(%?S%?,=%.KP))/II6"5P1520#@FG[?MZ=8U6%$CA58HXXUAC
MCB`CCCA1!&D2(@"I$D:A0H```L./;HP`!@=-')).3T%?:F^(-JT.,Q$>8I<+
MEMSO5QPY">>*&;'8C'I$V6R%&);AJX^>."G:Q$<LOD/Z.2#F+=3M=FHB8"ZE
M)53Z#\3?EY?,]'.R[=]=<.[QEH(Z$CU)^$'Y>9^0IY]!AM/*T6TLK%N##XM\
MQC*["UV-J(\+4TDLU?6-44U?BJVLK*FIC2M7SI-'-4/(\T7W!<AAJ'L&;#NT
M>VW5S/<EVCD3-,DL#45KZY%?+H1;I8O?6\<"%4D1P17``I0@`?D:>=.DK58J
MOIZE]S4L<E9N>NRTF4W%!3UKQTN;3)S?[D:*..NJ$H8_X=$R"C<B(J(%!(#,
M"37<\EW=3WC_`-K(Q)_/R_(4`^SHR@6.*&.U&(46BU&13SQG)X_;URVW4/E*
MS.9UJ2>ACJIJ7$T])7E%RE+_``0U<%9%64\3/'1+)5S&1(]3LRD2$V=0$ZFI
M8TZO(-"I'JKYXX9I3[<=*SW?IKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZR0_YZ+_`):)_P!##WIOA;[.MK\0^WI4
M?R].>C=VG_P(GY'?^_@W5[RVVG_DB;%_SPP?]6UZ@RY_W/W3_GJE_P"/GH]7
MM=TUU55D?Y4FQC\A*WN':?R;^5O7/5^X>_L5\I=[_%38G8F&PG1^\N^<95TV
M4J=Y5U6NUI>T\/BMR9K'TU;E\%C=Q4>$R51$3+2E9)%;6T@;4NWQZ1/;V7C_
M`$J2@,MO]0)0X4"FM$,TK11R^(D;.2J^76MU'[T2[R89[I(4N'CPTR0"-4!K
M4(Y2)$DECT2R*!J>H!ZAY?\`E#]&9K9&U]B3]G=TT&.VICOG7CJ#*X'/[?P&
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MC=CEJ6-W]7":G)8G3%(S:F=%U$^(S.1.R?\`**Z9K=[XK?E%VUW-A<M1_+GY
M%_*_+TV/J]D/C-TCY4[5H=E=S]+9REKMFU;-UCN/;-`M+')3M!G*57=HJ]7(
M8%*6=K]+M%C<P":RM-DOMK*-6DMO?S_42,Y6C"2.54:)D*@:%U!LU-;W<+F[
MEEN4?P;LW>VW*.G&.7:X/IH2H;4I$D1<2JP(;6=.G%$G\&?Y(GQ%^"M3W)3;
M3BD[5V?W%L*JZFK]C]H=5_'88K'=49"MDJ<IL'+9O8G3>S-Y=G8G+TX@IJR3
M=V2SDU7#3J9F>5I)&6^(TNR_N>_5+C5)$\CLH7Q&A6D9,2!8`0U9*K&#K-10
M"G2&ABWF+>+)WMY(BYB5&/Z32&K,DC5E!`[%[Z!"13T/7T1\'_AI\7<_F=U?
M&SXI_'CH/<VXL0NW\_N#IWI[8/7&9S6"2KAR"8?*Y+:6!Q-77XQ:ZGCF$$KM
M&)45K7`/OWC2_336?BM])(P9DKVLRA@I9>!*AV`)&`S`<3U0Q1-)',T:F9`0
MK4R*TK0\16@K3C0=$;ZW_DT]0];]FX7=--\@ODAN3J3KK/\`>F\NAOC-N7<&
MPZOI[H??'R&P>[L!O[=.R)J/85#V#E9X:+L#._PNDS>;R=#CFRDICAX6R%+7
M_=+>;//.\KR;.^UK.YK-%9R&.L:FFEF"111"1U9_#C"ZJ=+KB\FN-X&['LU[
MI%N$\2U$=Q<PT:-I,ZM`D`E\-6">(%;3VCJ;N/\`DV=![EZ\VIUO5]F=OT^)
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M[L7I<;>JE0/AEEC'APS3+P>2&`M;QDC$+,O$D]$SZ0_X3X_$[HCJ?NGJ':W8
M'8<^$[@DZDHXL]'L+XX;2WGLK:W3G9VW^TMN;8H=V==]([/SV\X<CF=KT4&0
MK=SU&:R%1#$9/,M0[S$S@O+B*+8A+)KN;+<[>^+T"":6V_LU>./3$J%BS,(T
M0U8A2H`'2-X8C<;I-&NF&YL+NT"5U")+R-XY&1WU2%U1J)J<J`HU*W1FN^/Y
M3?2OR&^<73_SEWSV)V+!N_IB?:N0VWL3!X'IO&X>HRNS8,Q%A7J>RH^KCWY2
MX&:?,--786FW9%B*]TTRTYBDDC8NM;=;1][E5B9;V*9":TT>-`;=C1-(ETHQ
M*).)45]+:3H32]?,;_:[#:932V@*\,E@LR3XU:O#8N@#/%X;%:BN22"E=_(S
MZ1DZZZ^ZSP/R*^3&S<%LGXE[\^'>6J-J9[K_`!V2WYUOO#L&O[3Q65W+52;`
MJ33;DV7OJO-91G'BCHZN-!3UT%3`SQN]?(M]=;E>.H$MS:;5#2@95.SOJM9-
M+5#E@TD<R/JBD25@4&"%=S>O=7:WCJ%E^OW.Z.DE2?WL*740(.I5!"-$Z%98
MVC4AR:U[Z._D9=$?'3:W5NW^IN]N]]J9+JCY:O\`,+"[FQ%'TOAZNOW[GNJZ
M#J+L;:M9MS!=3XK8M!L/L3;-"354>/Q5'-133R&CF@#6"HW&J\V*[,8IM]IN
M%K$M20;?<2&EC8DECX;@M$P(*ZM!JBH%*9;?Q[?=X9WU27C6+L]`&66P>5X9
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MK)?W?%8I(0\6U;=8QR$*Q0;7,9K>;2X:-I"YI*KJT3K5?#`)Z-I-SFFOY[Z1
M`?%W.:\=*L%8W%E]!)#4'4(_"[E*L)%DHP>@`Z#SK;^0]T#U)TGANM.N^[^X
M-@]E[2[XPOR$V'\C^M=C_&7JKL_9V\\'M#+[`@H:;`];=#;6ZJW%@ZO9FY,G
M0U$>:V_DII!6LXD5XXBAK-=W#-M;VTS026\=S&Q0G]:.\"BX1U8E5#".*AB"
M.IB4AJUJ3Q6T"IN45Q$L\4X@TB0`^"]LQ>&6-@`_B*S.279@P=U(TL062B_D
M'=08+J/MGJ?:?RQ^5FV_]->R.O.O^PM^19/J?*[WW!MS8'=7;/>LU-DJO-=8
M5^(R']^-V]NUL&=2>CD@KZ"FB@,:K)4>9IW/T^UVEO2&UM+RTN41<J7L;.*T
MME8-JU)'X$<]&KJF4,U5[>EIGD:2>>5V>[D2^4R$G7_NQEADN2K`@JQ$/AH5
MH8XW95IVD#ZG\I/8F9S51O#LWY&]]]L]@9.B^(-'N#?.ZXNI\9EL_P#[)CWG
MNGO;K>:LQ^S>MML[=IFS68W0V+RBTM'!&V,IHA`L-1KG=7!>FVOK>_BA7QDW
M-;\U+-KG&WG;V+%F)(="9FH0?&/:0G9TB,&K:AM#R$VZ[=?V2FB@I!?S0RE5
M"@*/`\%(X<4"5UAS0]"-V3_+)ZE[+^+WR]^*^0["[,Q&T_F-W9OKO7>NZL7-
MM-]U[0W7OO>>UM\5=%LW^([8KL$,-B\MM*G2FCR%'72&%W$KR$@@L*.+/E2T
MAF*-L\BO"X`+%DNIKL%PP*G]29EH%`T@8K4DV@W"2#=-SW7PU:6[MO`=372$
M^@3;ZK0U!\)`_$CQ"<::+T4;</\`(,^/O9NQ>\,!\@.^N]>_=^]T4G4%##VS
MOG`?'S$9CKZDZ+W#FMU]>P;;Z_V)TIM3IS/PTN?W'725R;AV[F$R-/4&GG#0
M@+[]/#%)%']/&L5Z+Y+IY::VD9(7ME1DDUQ*G@2RIV(KUD\35K2,HBMV,!2-
MR7LDL9+5(ZE0B221S,P==,A<20Q,I9R`$*TTNX)D?C+_`"F^BOBW4?%?(;)W
M=NRMRGQ8K?D%E<-4P[1Z9Z_QW8&8^1>%P&W]V9/>>UNH^LNOMI03X;%[:I(\
M><70T#>B]29SR%L]P9KB68+I5MI^@TU8@1FXCNFD&HFDC2QYI1`K$!*T/25;
M>EI-:/(6U[E%>%J*&U0P3P1QX`K&$G;C5]0!U4J.@@Q_\CCXYX[9DVR8NUNZ
MY,=/TGE.C&JI:S8IK!MO+?,:;YI3Y4%=EK!_&X^P)SBU)3P?P8:3&:G_`"CV
M[:WTEJ;`HBGZ>;9I%KYG9(C#;@_*536:E"3\!08Z.+[<IK^;<9Y44-<S[K*U
M*T!W:UCM9P*DXC2,-%6I#$ZRXQU9'TO\;MI](]B?)3LG;V<W'E<M\GNU<+VU
MO"AS4F-?'8#-X/K/9/5U-C=LK0X^CJ8L3+AMBTU0XJI*F7[J:4APA5%2P.;?
M:;/:%S!#<7<P8_$6NYVN'!\J*S%4Q72!4DYZ07!-S>I?/B065O;4'#1;>)H;
MUU-XAU9I@4`ST8GW3K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U__2VN?C-N&/:?Q<RVY)/%_N(["^0M3"LXD:*6L;O#?<%#!(L7[A6>MF
MC4A;&Q^H^H`'.5P+2^W.Z/\`H<2G\Q&M!^9IT?\`+5N;J&SMQ7OE88]-9J?R
M%>A,C[3W;BXY6S.`PV7IZ1)*ZLR>,K9L0YH(HE:II*?$51R+-E("KR(S3B"6
M,!;H_N,8.<F"H+JR&K5DJ:`+Z@&IJ/2M".AO)R[$S'Z>Z88P&%<_:*8/V5!]
M>AZBECGAAJ(6UPU$$-3"]K:X:B))H7MS;7&X/^Q]CH$$`C@1T%2""0>(-.LG
MOW7NO>_=>Z+UV17U5=V#A\;%3R_P_;>VZRIK:MJJ#[=LAN2:%:2GAH@HJA51
MTN+8R2,QA,;J`H<7]@+G&Y#3VEH*U12YX4[L#YUQZTH>A;R]#IM;B<D5=PH]
M>W)SPIG[:CTZ8_8,Z/NO>_=>Z[4V(/\`0@_U^A_I[]UKHOF_=Z=C;!ZQ['K>
MLNLINQM_[*JQ)MK9M3F*##8W.QY[,&IIJ>DRK52RNF)Q%9]RZR"&20D1*;B_
MMJK*K`+5@?\`#U(/MSR_R=S1SSR[LO/W.8V#E&Z9A<7_`(1F,`6-BI,8'^B2
M`)7(6NHCI$?''L3L3=^[=^X+??3&[]B18##;?R.)WWE:_&UNSMS3;AJ)LGE]
MN[07'TM-3O'A,N\KM/&9`^CGQV0-6&IU:@:_R_+H0^X/(7)_+7*G*O,G+7NE
MM^]76XWEY')911O'=6D5O(4@GN`Y)7ZF,*P0A2NH!=8U$&Y]O]0]U[W[KW02
M]H;!Z8[;.W]A]L8K:.[*C$Y6D[$VWM3.Y*&+)PU^VY&6+<U#C8JVER$]%CVF
M*3/I:G*L5DN./=656H&^WJ0.1N;_`'*]NUWGFWD'<-PVZWGMWV^YNX(R8C'<
M"IMI)2C1J\@74@J)`1J2AZ76Q-Q[UQW]Y*K$YW%G;N4W+79#"4E7AZ>O@>)2
M*6JJ*>2EDQLM)0UTM.&4))*9&#2AAKM[/-NY@OMN@$%N$:#431@3GSTD$$`X
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MM1$$4.8@T1D2S>P+O6ZG=+J*0J%18P``:C)J<T&>`/E48J.A18[<+"V:.-R]
M6)8TIY4&!7'$@^AS0]<ZO;4!FDK<+53;<R<VO[BKQD<)AJU>,HPJ\;.LF.DF
MU:6$_B\RLOZCR/9.5\U-#TL$IH%<:D^?^?C^7#K-ALL\]--!EGI:7+8F<X_+
M+]S&M-+4P4D-6:VEDD$&JEK:*9:@#2#$K%6`TD^_*21W?$./6G0`@I4H<C_-
M]H./GU%VC-3UF-KJ^DGCKJ:NW#GJB+)Q/K3)1_?O!#57'"A8(%B46`T1*0+'
MWI,@D>IZM,"&52*$*,>F.E1[OTUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9(?\]%_P`M$_Z&'O3?"WV=;7XA]O2I
M_EZ_\R,W5_XL-\C?_?P;K]Y;;3_R1-A_YX8/^K:]09<_[G[G_P`]4O\`Q]NC
MT^UW376N%\GO#OK.X+>W;%3U[2Q4/\TOLC8F_:KO'J[<O<G4>T.L>L_C[VE@
M^G<1N_KC%[GVNLN#S..R5#F:*9ZZCIGR^>6I<R$QK[0[3X0N>4KJ98@;G:]Z
MDG+("#<K=M;QH22/U(HH4AA))HJ,\:5E8L87E/`YNBA:1GB79DC"$J1"QL[F
M8TR&0SS3F5E`UA51V_0%`=V5VE\O.MMJ=3]=;2WUA>E.IJ+$]L97X_[^7$=S
MXG8/=&\JGY([RBVXNV.L\-U+WINJ?K4=>56'.W>MZJMQ4ZX>MU45;4PQK+3&
MEB+V:7:8KYF_?26FWQ^!.3([J0Z7,DQ`C\61],9,AE1[1)$,B*0SDMO5MT_>
MLMH5.W2W=[))+&/#6)Q'#)#%%J+B-48W`.E)8KN:*30V5C(\?(G_`&8^NP.Y
MNT,QNSM7>.ZZ'N7YW[:VGM"3:L57L/9>U]D]%]OXG8$>V]GC:FK*4&5KGC6"
MIS'WYR):".S.HU-[4T:MLTA4ZKB&<NSD,ZA>8+:!$JO:O^*1JW:*FC2JP!KT
M=;=IFN+E+EU6..YVA=*51#JLX)IW%>^OCO+6K=E?#8`BG0[=-=G_`".V[\@M
MH;V[([4[3K^L=W_('YW]?;WVAN[;>%QW5_7W3G2M)F]Q=2Y_%_8;0Q>2PL]&
M,"$CS%57S#*4E2\3>73$R*+%K9=IAN]PE`>39;BZD=SE;B+=X[6.AQIU6KL3
M$02^)1D5Z(IE9[6P-I&5ECN=J@"J,.EQLOU%RS"E21=@'4"%C:L>`2.C5?.(
MX3,T?QURW85#EMT?$T=D5>9^05+@\?F<_M^NV_)L//3]9Y+L?$[=AJZ[-=.4
M^^9*2;,Q2PSXLG[62OC:D24A"\,,&ZM%ND(!2VN%C$H_16[#Q"/Q@00&T"=8
M"P(2Y,96DGAD*XY/'VBYDL)'-P\D#5C-':V[VFT9!(/Z1D"][0B0`%2XZJ7J
M>[>VMGX*;;W0NU,%\;?B?D?D-NE,[W3U]OWO'#]*5Z574E!FML474&6S7QRW
M#7=1;.J]^4T]+EX\/MJKVO6;@@E@AKJ>:JD2;:-<-:;6;ZZ>,K#>&%'JSR2K
M-`8QJ*M)+!I>Z:WMY/"+"$K%KC")UJ2.W6YW!]NB69Y9+7QBH`6.(K<1N2JL
M$CG)CM!--&7*+,K2JK%Y`.N>W/\`-3=&V<MN.M^0/:^-W'B8OY?6RL54=5;`
MJ-M;(S%-W?V#MS%=W]A4VUNQ.M*;=]1EZG:$X9_XA34:X&1IIQ2TX<)&IM4,
MO,%I97<>BWFWP6\PJ`%@3:H+F18B&;P5>[>55D9G=!IB9BR,"F9F79KNXAD#
M2P;'=W$34)9YA>W<4'B55?%9;>.+"HJ2']505=3TA<KW!\J>D\9D6W=VY\H>
MQ-M[MV_\D]H5F8JZ;9VVZW8"=6_-#9G3W46])]\#J/+8S8U+4]5Y^JGW+N*7
M%9.>LQB/DJ6D^XACD""QN6N[2UAO/#CF>PVBY:1B8D^HF-TMQ&Q`9HXI%BA4
MPQ@R?4,@5HUF-#*ZLH;&YW"X@DDFBM[NXC6,`2,T+6$5RI12RB22&XD94D9M
M/@HPD$A0U#S8O<_SD[%V!N^FF[O[VPXZDZI_F`[]VKFMG;::NE[%S?46\^LL
MM\:X<GN_?O2&U-P;]V[6[<W#61TCIA<5)NK&R:V270LOM66,-LUX4+745EMY
MTNND>.^Z7]O=!X02=7TT4`9*C0-,I578]-(D#[FNV*1]#<;LD8D#:F2W?:XI
M6T2TTT6[9Z/1@KH8U9D&3L]?;\[O[B[J[!^,G=V>SS]98'J;-?(SL#<M=A,=
M@\;D^K?D'L#&8OK#K4Y1<;`^'R/6'8E!O:H5D>.MB@P%!)+*3?R-;Q'#;[?S
MI/'>-$-FDN;59015IS<&^L[M:CN-O8K&A9>P389&J&Z1;/<71/)4G@Z[W=(K
M:Y,=&&E([?Z6\MB*<)[MTD\.OB+&XTD9"V&_#S>.\.P?BO\`'[>V_P!YY]X[
MFZGV7EL[752>*JR]5586E://5,15/#49^F$=:Z6&AJ@BPM[--U31>L6MQ#,\
M<;R1`U$4KQ(\T((XB&5GC!_H])K`1K#)%!<&:TBGFCBD)!,D,<TD<,E0`&\2
M)4?4``VJHP>C(^R[I;U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=?__3V.NJ-QYFJZ-CQ6,?7@]I=P=PY'.XZ*GEF;/Y8]\;SRM-
M3UE73S13X[$;>IA%4SLBRZWD&M&1"I@OW3W24;[=;9"U(@D;2?.J*0OR`%"?
MMZDCD&QB_=D5Y*/U7>4(?X0&8$T\RQJ!\A\^C3ADE19$*RQ3QK+&_#1S0S*'
M1QQI>.5&N/P0?<8="_(QY]*[K[<<^%R%#M&NEC?!Y%JJ+;4\IE^XQ5>J_<Q[
M<>5W>.;'5,*RFAN%>)D,/J4QV'7+&\N[)M=RP/:?#8G)I^`_8/A\\4].@YO6
MW*4>_A4AQ36!P]-?RS35Y9KZ]#I[&W07Z][]U[HLNZ\K493LO<E,F*CHJ+;>
M,Q6&ES$=:*@;BK*N"'+QQ2T@111S;>CJ9(B=3EUJ`#;2`(WYKN(Y=Q$(B`DB
M4`M7+`@$`CRTU/[>AKLD)BV]9#*2)&)"TIIH2I(/GJH/V=8/87Z-NO>_=>Z]
M[]U[H+.PMMM7O3Y`2TK4=;/B</DZ.O.FDCGEK/L\5G&M$ZU/\+_B$H>GE9(Y
M0RG6K*+M2+4@^1Q_L]*K>735:'4*D$<?4C\Z#/3KN7M#K[:&Z]F]=9_=^W<%
MOOL-,K!USM+)5#TM7N>JQ-.7J(,;3PQ.J4\$A56Y0GE8]3"WNY8`A:Y/#H1[
M)R'S?S#L',G..T<MWESRELQB.XW42!DM4E:BF0DC)%2*`@8+47/2;Z+JN]*S
M82S?(K$[%PO8_P#>#/I]EUY5SUNW_P"[*5I&W9WEGFG(R4U'<RJKG@*6"N64
M>37I[P-71U[JV_M5;<VF+V:W#=;GDOZ.W.O<$5+CZDI_C"@*%_3#_"2.-0"5
M"DC%[MU''0([WZ=ZMKM]P=\93:=+7=K[=V/F-@;<W')5Y-95P^X5J*7^#)04
MT_VM145<^0>*.0Q-*HF8`B]PVZKEZ=U.A]MWN9SS8<@;I[46>_.G(%]N$=[/
M:Z(R'N(M.F365\0`:%)4,%)4$C'0S4D4E/1T=/+(9I:>DI8)9654,LD,$<<D
MA1/0AD=22HX%[#VX,`#H!,:LQ]3U(]^ZUTVY'#XW+>$U]*DLU*S24=9&ST^0
MH9'`#RT-?`T=72.X4!M#@,``P(X]Z*J>(SU97=*Z3@^7E^SI(;B@RN/Q\,N1
MR<&5VQC\E05V8:K44N>7&TU2K1)]\CI15ZPUC0L[:*>=HHR-3,>:-4"I-4K^
M?3T15F(52)2"!3A7[.(Q]HZ4^7SU!BZ.2I:II:JIDBC?'T$-93_<Y6:JE6GH
M8J-`[/+'5U,BJ)%5E`)/X]V9@!QZ:2-G:E"!YFG#U_9TV4VUJ:JGK\EN>APN
M4RV2:D61$HUGH\?28]--'04DU7&*B<1RL\DDS!&D9[:0BJOO6D&I8`GJQE("
MK$S!!\^->)QUWD=MG^(3YW!UR8'*/0U,58\-#3S4V4=3!/3/D4=6LL34H1W1
M/*8F8*58ZO>RN=0-#UY9:*(W74E?7A]G3YB:\97%XW)B%J<9"BIJP0,VLQ?<
M1K)I#V&M.;J;`E;$@'CWL&H!ZHZZ'9*UH:=.'O?5>O>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZR0_P">B_Y:)_T,/>F^%OLZ
MVOQ#[>E5_+U_YD9NK_Q8;Y&_^_@W7[RVVG_DB;#_`,\,'_5M>H,N?]S]S_YZ
MI?\`C[='H]KNFND=A]B[-V_NO=^^,+A:'&[IWX,#%O++TLDT<FX)=L4<V-P,
MV2IQ.:*2OQ^/J#3K.(UG:$)&[,L<8748\*-X4)$32F334TULJHS`'"EEC0-I
MIJT@FI%>O.!)(DS@&58Q&#YZ`S.JD^85G<K6NG4VF@8U5[NL:L[LJ(BEG=R%
M55479F8D!5`')/O?7N.!UV"&`92&5@"K`@@@BX((X((]^Z]U'K*.DR-)4T%?
M2T];0UL$M+64=7#'44M533HT4]/402J\4T$T;%65@5938BWNK*KJ4=05/D<C
MJRLR,&1B&'F.LT44<,<<,,:10Q(D4442+''%'&H1(XT4!41%``````]N.[.S
M.[$N34DY))XDGS)Z;1%C5410$44`&``.``\@.NEEB<,4DC<([1N5=6"NGZT8
M@G2Z?D'D>ZU%`?+JWG3SZ\DT4@)CECD`TW*.K@:@&6Y4FVI3<?U'OW7NN9(4
M$L0`.220`!_4D\#W[KW73.BB[.J@@D%F`!`&HFY/T"B_^M[]U[H)I.C^JJZF
M[1BGVRM=#W<T3]FSU&<W#63[LI(\8N(I\9)7S9>6JQVWH,9KBBQU#)38^-9Y
MRD(-1.9-!0L,5KH'@I.90I`-9"RL7:OQFJ(._4-")'3PU50XLLBW/UBN1<>$
M(P?1%#`*HX+\;&J@$LQ<DN:]"A114-+34]%CTI:>CHX4HZ6DHUBCIZ6"C58(
MZ6"&&T<,5,B!`B@!``+#W=W>1VDD8L[&I)R23Q)/G4^?3$<:0HD,:A8U``'H
M`,#]G4OW7J_7O?NO=<2R@A2RAFOI4D`M;ZV'U-O?NO==DA02Q``^I)``_P!<
MGCW[KW7BRBUR!J-EN0+G^@_J??NO==^_=>Z][]U[K@9(U=(V=%DDU&-"RAW"
M`%RBDW;2"+V^GOW7NN?OW7NN.M/]6OZM'ZA^OZ:?K^J_X^OOW7NNR0H))``%
MR2;`#^I)X`]^Z]UW]??NO=>]^Z]UP62-RZHZ.T;:)`K*QC>P;2X!)5M)!L>;
M'W[Y^77NN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__4V5_C?44.
M.ZAR596RT]'1KVOWU)63S:8X;S=T[W@+3FW[CS%E3D$M<#G@>\=/<F@YSW@G
MA2+_`*M)U*?)H9N7MO515JR?]7&Z%/:LN.&6W!28*2!MOPP8B>DCHI)*G'QU
M\R5,>0$$TEQ23:88@]*I*@`2#3K*^P(M*MI^''0JE#:(S)7Q,UKQIY?Y<_ET
ML*JFBK*>2GFUA'*,LD3M%/!-#(LU/4TTR6>"JIIT62-UY5U!]NH[1LKHQ#J0
M01Q!'`],8(((!!%"#P(/$'Y'H4MB[VK:ZNDVUN>JBGR[*)\%E%HVI/X_21Q2
MRUD-2(5_AZ9K&B.[K'X_/$?(J"S6DC8-\.XAK:[91>CA04UK3)IP!'F!]O01
MW;:UM`+BU4_3?B!-=)\OG0^1/#A7IT[!W748&DIL3AI0NY<V#]I*OB<X;%12
MQID<_-'*KIJ@C<QTBLI$M6R_54>RO?=V&UVOZ9_QR3"#T]6(]!_,T'KTQM.W
M_73%I1_BJ?%\SY*/M\_0?ET7C:FWY=O4V82>H6HGRVX,GF799)I0D=4ZI3*\
MM1^[+5-!$'G<_KF9B.+>XL9WD8N[$N>)/$GB3^T]#EV4Z`JT55`'Y=*GW7JG
M7O?NO=>]^Z]TT9JLHZ2A:.LI&R7\0)Q]-B$A6HDR\\T;DT2Q2`Q>-HE9I7DM
M'%&I=B`/>B13(KU9`2V#2F:^GSZ2U/UUM>NK-G[AW7MG;>=WCL1LD=F;BKL?
M!E,QLZGR5XWHL'FZR!:Y6CH@D+SC0TNC58'GWI5H!J`J/Y='UES7S+M>U;[R
M_M._WEMR_N807EM'*R0W7AFJ>/&ITOI-2H8&G#ACH0/=N@_TDHLKN.MKLO%C
MJ'`RTF,R<F,5ZROR,$S-%2TU09_)3T5333W:?0\:%6A<%6)(/NM6)-`*`].Z
M8E5-1:I%<`?Y^F3-U>YX:W$?QFBPL.WDS>"JJC*8VKJ'?%24U6UC6K7+%YJ:
MKJ&B76L:I3H69F+:1[JVJHJ!IJ.G(Q$5?0S>)I.#Y_9^7[>A(((-B+$?4'VY
MTFZ][]U[KWOW7NDKNR6FDI*#$O)$U;E<SA$I*)G3S5,=-E:6JJI!$Q+?;004
M[&23246UC]?=7I0#S)Z=B!!9Z=H4Y_(]3TVSMN&0RPX#$1R?>ID%D6@I_(E;
M"[/!4Q,4+0O"[$H$TJI-P/?M*_PCJIEE.#(W"G'RZ>_=NJ=0\A1C(T%=CR64
M5U%54ETD:)P:F"2$%94]49N_U'T]Z(J".MJ=+*WH>H.W:L5N"Q4^E8W6CCI*
MB)(TACAK*`F@KH(XXP(ECAK*9U4)Z=(%N+>_*:J#U:0:9''E7^1R.GKWOJG7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-%1N
M3`8ZK^WJ\K2K5P30K)0PL]77AW`D2,45*DU27="+#3:[`&UQ[H[*%:IS3IQ(
MY&*E5Q7CY?MZ7_\`+ME:?H7<DS0S4S3?('Y%2&GJ`JU$!?M[=3>*=49U69`;
M,`38\>\N-I_Y(FP_\\,'_5M>H)NL;AN@K7_&I?\`CYZ/=[7=-=:DFZMR[[PG
M9/R,^!=7U1\B*KOSN3^=IU9\HNOJJAZE[/J^ILC\89>X^E>SLOV,_=]%@Y^L
M,/MO!;0V%EEK:"JRE-5BHC\"P.6/M_E:5+P>V,.8WV2;</K/$&G2$_><L;+J
MIXJSBY@$.C426&I5H*O<USI`>>9T!==SY<LK2UT48O<-:0VS"@/Z?A2JYE9]
M.E59EU4ITPYO=/\`,@Q>S>T^Q,_WA\H.T<=W[T=_.OVQ)T;O'JS;^5Z_ZN_V
M7W([M7XI5FS,+3=:4^=&YMT06AHVR]1D8MQ430P4T+1K^X36HE7E.&&[_6W%
M]BV>],C#]1;N3<[:*>)0,`+:.?%C*EPZO.Q%0$/8$MS[@6C1R+#MEMS5#:Z4
M-(Y+.2P>5I&8FH$=PG]JK!:LJ&A7N,MMG='\P^G[V^/7Q(QFZ>\J+8/R53XB
M?**+NR+;E-C\1T7T?UETY3/\J_C=)F*?:\&*VAEM[=G[2P]-C:&I6*NBHMVU
M?@XI``*;DQOS1S+:=KQ;-NFYWFIR=-];S@C;+8N&(=8KZ21)0*$V=NA+!G+]
M`=%:'EC:;E)&-WNNVVMH%44:TNHI`;RY"G3X>JPTO$Q#J;S4"FDZ4('\=_EM
M_.7W%W3\_:'M3<7:F%S.SOCI\V,_F^L*W8W;-5B^O-Y[*P6YE^-U?\<@OQ0V
MSU=B,D*Z*@98J3LC>LNY(JA91"DX:-`?#)(WMSO5_%<2ONBV5L5D8?KQW[3H
M)TT,L),:CZA#"D+JBHC+(RJ)&&#Q6P]Q-BL&C1=L?=`ND&L#V&GXV8:^YAX3
M+,\D1U,ZLE7HHD_([L#^8S\3\S_*ZGQ/R9^='R1I>R]I;'W_`-P]<8[:.7P_
M8F_.U-\;OV!6[DVS7[OVC\-NTNG*;9.WL%D)J"EV?N;([/EQT`EJ)\M,9BZ#
M./Z2+W$W#98[83;3`Z01$LNDH9+A))YF=H8Y?B21I8YHC%%%H2-GTE@A']3/
M[?#=YK@Q;O*)9).VA4K;HT44(&N2+O5P`\4@DDDJTBJA42<E4?(S`_+7H[N;
M?N?^9N"Z^V]_,3_FQ;1_T7=+]?QIL_><%-]OD?C_`(O=NWJ#K+,XC(T'9Z3U
MF%AW+FFDQU321JWWL>J6>0(VBFUMMED>V-Z\G(&XG2R@`7,5XP*1"10D,TMJ
MSW")(H9Y;>`*""\4HGWQ?JYE6&<VT"<P<ONS`DLL<FUPF4N4.IXX[H+;RZ<1
MI//E2L;PD`V%OCYJ]L?'#Y-5^X]U?S#^I^D]B_*'^7?V]L.KH-B9=.^Y.GLC
MV!N38G<F$R\V"^)'2];O;%].46W\4[8+$;9R&(Q5?01>&HR6/(#']I"D=S[7
MRW4\<\D'-@28J28FM9;-9;>Z<-W-JGA(2:5(Z$L'CU"%@2;H[7-OSK;[;;O&
MUSRU<Z4<J&CN(+N/5;Q$=J?IW$Q*+++K15*N/U58T_=?=7SNWKV%_.9^/F[,
M_P#*SY#=>Y[XG?*>JZI-#L'LC9/5_6F,H,7@ZCJ;`0]?;M^*_7[5F_,_ALD*
M"CK]H[_W2V9JEGJIJ&&.0"$IL?'GY;4W-NIW:#>-O=I&-%:5-VC5X8Q598D*
M=Q7PYXHH86+35T%Q18S6]ISGRC+:S$;7+$%*@"H1MO+&>5Z.C_K+E@T$GBS*
M@B`#H!?K<S\S-ZUOP\;O'9O;5+\@>G_D-\UJ7L';F+P>X=U=/[&VGD/Y:G9-
M1T`>H\D=G8J@S76.9Q.0Q4#2Y2&>KJ]Y'(4]2/,4IPJWQ@+;F2^M97DW"3EW
M?5F9E!/UPW2R#1(HU*8?#4-9``E[8JYU2&2A-RH(TVB#;[A@MK^].5&A4$C_
M`!+QQJ=S74MP&67ZT,08V5<+%X1.39.Z/YD1V;U;VAA.[?D_U]COC]T-_).K
M*'H#;W5N`H.N.TMR]ZU&#VC\IL?OO!3];G/RT6W]OU,TV2QN'J<;'A*I5FJ$
M1(EC`EE6W7W`OO'<3[5<\V3605CV1V7[MAE,H?C4W##PYF8JA61`"SU0LODD
M?E^9+1_`O(]GW>[#H!XC7-ONES]-&P8%2)+=0H32'=620%@.X(^R,[\_-M]S
M;([/ZNV!VK,=F;R_G`XSM/<.U-GUVU>P=K?&&+YV]/5==G.E<?2[$K-M[G[I
MR'5.*J)=J+74S5&7I_N*R":IGB36%^7'C2PV/]ZRRQ;7/L/+PO72HE4_77P9
M0F-"!FB-YHI)#:ZV1=3*P$/,@:5M_BVT1ON*[T'M%<@1%OZN)4L[$*0',JPF
M1C']3X<;G35>AE^9OSP^;FR,[\GNB.H:WYBOV7%\PL%O[I'=>VNCM];@V32_
M#?,_#.3,8&FB[*79%;MG[?+=PTYD;'SU#9G^*W614&H!/<27<]A)'X1AW6RD
MWU+H4"C6+ASM_A<1*@B91`8]0I&VK&@NQ$+&.:&XC#2[7=[+M)MZUU&;Q%%[
M))6C1OI&B;7I.MU"*>_3*Z'SO\T38/=W1^1W=\LOF%VQLC%?)/\`EW[?W/LW
ML3J[97]W]W;1^7'QEKM[?)5]XY#;_4^!R:;7ZKWWC:>EQ*PU<$6UYWECK9)Z
MJ82`6RVUC9<R36@*3;?^]=^L4)(`6WM+5KFTN25(#RO.PCCD-(V11&BFE.@X
MLD]WRA;[M5XMS.P;=?&,#(NI-Q%I);YJQ1;4&2:,CQ&=O&9E44Z5W\U_;.X,
M=_-P^)O:NV.M^XNY][XI/C1MS9/6V0ZM^15/LZEH?].F5J][[[^-GR@Z-W:N
MPNG][X7!Y*1^P,9V#BEQ&;P%)34Z-,DQ,0>Y0DEM^:=T$<8/CSJKNY$;P1&R
MD1I*RU@N=O!;5);DK/\`4I(8EU%6)SS-HFY3@CD!*0P7$B(O>DTYEB,:,B4G
MBOE\,?3SC])8W%34.O0)=F]E_+_MKJ'^:#UYV1V1\]=T=\U?47RKH-X_&W._
M&J"F^*_4E%@>Z,;B_C7FOCYVIC=L;=S6<S&Z.M7IZB"AQ&0W@^X$FJIZY<::
M4`H=OCEO.6^7VMKJMT;G96GGF4+-;[BVX0?611H=.NW@`D)1HO!2*-)?J"6T
M.<)(+7G(HZ)%:5OU@2(^)%+9#;93!+.Q`T2R2%-;!A()V,"Q%/U>AUW#M7YF
M[6[RZGZ=W/O[O_Y.T'0G\UGXV;KZN['[9VK2TE4^W.P?Y?/;F\=W8O(YS8.S
MMF[7_P!$VW.WLG'CJ=FA$.(,J4DU2T]F)P+B9II-PV^V7][0V/-MM$7.9?"2
MV^@,Q)"M)(7<+)1!-3L`"T!#M*1+R_<PW4K1V=UM'+TSQJ!^C+^^(X[E(A0N
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MR.YMIXLPSRK$_P!S#X']K]QB,U_MUO$?`2ZVOQ@.P%)-LN3<2:F5Y%#;I:+)
M`BD([($=H5F*DEMBZQ6^\7%SJG%G>Q`A3I,J;A:&T"IK4$"PO9+:Z>@D45E(
M=HU;2J).\OYF^]8.H/DEM_;_`&;6]H;[ZP_FB93K+KK='6,<U-UYG>C?CQU1
MUCU-2FES>U:+);6K.S.X-E[AW'CZ*IJZ=,^]?"MY8"JJS=S1)8<P7=N)(1<[
M+#>G2`9K>&_WV.46Z@:A)/8;0Z@14=A(K:HRX(Z,]LA!(L;B59C:;[M]F-9T
MQ3M;[9?BXG=EJ1#<WQ599@#X:8C(4JO0K?RXOE9\VNQ-W_*C:/Q\[+[+^8F4
MZ^Z2^$VXMAX#^8S_`!CXPY+'9OL:;MZ7O7)5LVT.A5W:@@S6&6GQ35.VECJZ
M>B2-*F>&&.KJ#V>WA_=UU-;0QMMR<R2VRS:OUOH$L+.2!BH)4S,TA=PWA,?$
M,C(A(4AR&:7ZW;8K^66/<9-GDFEAT`1K>?6&-T4X;P40$(0'4$:%=N[PR]8_
MK?\`F.39'L'(55-UO0?&^L_X4`;7WEN'K0=5=XY#Y`32GY#=?5V4W;M?L\;K
MQVR9N@J>L0RQU<NU=#XN&65JE`UD*-@)M[;VOUMXO@V>X_3"@B*-X.\^`+P.
M7H68C4%9!^I$%)I5A#S%KGBY]*R)&TFP;>LX%9`2+/;A*MK0(3(I%!75W(X*
M*:]!KN[N/^8/VQU=\U^O]W[L^:W8O9>Y_B1_,*H_F1T#V+T!-M3X_?'S<F#Q
MN:Q_Q;QWQ$WIANO\%6;LRF]*-XHHJ;%YW=CYFCDDJYS1RQHC%=DL5QL5G(C2
M3[>%V>5YY@8[M=T.XVAN;98@J?XNB_5Z_P!/1%'!"XD;60IEM\GTO/FTARD%
MP-XE1(HF+VK;4()RER\I!_6J+,JQDC=I)IH_"<+K)B:/M7YWQ_S,:/XV0]E?
M+C*=+]E?%S"[1V?MWJ;;.\>N]I_':GK_`(F4E4V^<]6=@_%7,]9[QW%@^R\?
M,]/G\;V:F53+5U-2C$L:>6)EF[^/N-M[N0M(YO1)NCQ3BBA/"E,EK'$A\.16
MF4+;H8!<>,7,W:C%XPUL[1[=MWM3<-"HA$6VK-"14R%W,=PTK?J*4C0B:1)1
M`8TB*]S4+5LU7R/_`)K73GQV_ET[%Z)[+^6&+VY!TSF(J_=_9_7W==1N++_,
MC&=O97#[OZF[EQNT?AOWKN_=_5VT<4^/7%4.2CVU1Y;'U4U0FX*IP3$JL6-U
MO_+T'@0QPG:MG^GA`TPR0F!5O3(M$598IU:U_4GB>&!()/"?Q6F?4D$=GM.\
MM<RS&0;ONGU3A@98_P!4O:^"W=V2PM]15(IA).\T;%/"6(6Z9B#YU=F_)#>W
M3>%[7[X^-&%[6_F>;@VEO_M#HGK_``6+KJ3J+&_RV=C[RJYMN;FWCUMG\0^W
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M"/"_/]).I6Y.*IRU84_M&,OY#Q&_F<_8.C2_[UR;`6%S]38?D^P3T(>O>_=>
MZCU%/YQ$4FJ:6JI9EJZ"MHIVIJVAKHE=8*JDJ%/[<J:R#JNC*Q5@5)'MR*:6
MWD2:"0I,IJ".(ZJRHZLDB!HV%"#D$=-&W*NIR>.CRV4JJBOW#6JL.XJVM9FK
MCE*#53ST4ZLD:TJ43`A((U2&/42@LUS:>ZN+R0W%U*7G/$GY>0'`#Y#'6_!B
MMAX$$86`<`.%#Y_,GU.>G_VSUOKWOW7NO>_=>Z1N2W+*<Y_=C#OCH<J(Z=YZ
MS+K7"E@>IU3)3T4$$*1Y.O\`L89)A&9X4M8:B=0%"V=(X]/+$/#\5ZZ/E3_4
M!7Y'J(^V-PT,[Y7&;F.9S"P9!*>'=T!DQ%--D'BD>3'PX<4L^,3]D1Z;SJ(/
M2+$DG6EAD-4_/_8ZWXL;#0T6E*CX>./6M:_RSTY;6W'-G%R5%D:&/&9W!51H
M<M0PU2UE.SK=1744ZJC/15#HU@PUQ\*Q)][5M5011AU66(1E2K51A4'_`"'Y
M]*OW?IKI.XDM29?<&'<V!J8]P4*G3K>ERXT5OZ0"13Y6"0<BX61.3>_NHP6'
MY]./W)&_RH?RX?RZ>ZNG6JI:JCD"A*JFGI7\D22H%J(GB)>&56CE50]RK`JW
MT(M[L14$=4!H0WH>D5M:JRF)DH-IYRDIJ:1<2)<)4TV0>N^ZI\<(J:MIJR:I
M*RRY'R-]P@C!44[Z2!XR2VA(HK#RQT]*JN&FC)(KG%./I\O+[>EY[<Z8Z][]
MU[H/*?(2P[QW6:#;^3R,GAP-$TZ)314C5T-`]55'^+U3A*&FBH:FG4P_VY@2
MJ:BQ]MU[WHI\NE!4&&'5(`,_LKZ>>:Y].E519NGJJAJ"J@J,1DQ&LJX_)_;Q
MRU,+'3YL?-!//2Y"%)/2QB<LAMJ5;B]@P)IP/331D#4#J7U'^7TZ>?=NJ=,V
M?KJK&XFIKJ/PK-"]*&FJ(I)X:2FEJHH:FNDIX98):E:*&0R&-74L%^OO3&@)
M'5XU#.%/#/\`Q7Y]0L#C,C0U66JJVGQ>/7(O3.V-Q4DL]/\`Q"G66.MRWEDA
MIUB?*ZE+1*A(T`NS,3[TH())IGJTC*RHJDFGF?3R'Y=*;W;IKKWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@YQD&7H]^96MV]
M&^0P];E:*FW$M?7I34V+RICII,G48>,!IZFH^T%/Y00J!ET#4265D@@N5X'C
MTJ)1H8ED-'`[:#B/*OYUZ'3^7K_S(S=?_BPWR-_]_!NOWEWM/_)$V'_GA@_Z
MMKU`5S_N=N?_`#U2_P#'VZ/1[7=-]$)['_F!=5]7;N>BW91KA^LL=W+GND=R
M=Q9C<F'Q.U,!NK9G3.[^YM^U,U-.'K*C&;0H=LQ8J=M22396J:&%7:GD!1I>
MPCPY)V"6TEM>SQL*L72RD6"2B@5U27!>&)069VC8T`:/6I-K,QNDMT,DT)M`
MX%!I:\D4(I).-$+QW$C-I58Y$R:L5R0?//9.`CI).V]H9OJ^MW'M;!;TV#LM
MY:[>79N],%OG>^2V;UI0T&RMLX"H5MZ;W7&M5K@J6MKLA0IJ6H1?%*Z&4MO/
M;E[:>%_WK&\4<D"#6T<KI/(\9(^+P$@<RNH,:T?OTJK.RHCDMAN$,Z':6:;P
MYR=,;QQ"V`D%<J)9+E$B#49ZQD"KE4$KI_Y;==]Y]CS;$Z^ILG7T4'5=)V34
MY[(0S8>JQ>1_TC;OZSSW7^X=JY.FI<]MW>&U-P[-J(Z^GJTCDAD.@H"+G<<'
MBVUY=)*C6\3P!65@R2K/'*ZNC#!"^$RL.(:JFC*P%7[([1F5A))+<QLC#2T;
M6PM20X.>];I&3R*`."5=3T]=W=[9KKC<NP>M.N^N9^U^V^R:3=><P6UYMTT.
MQ=LX79NQ%PHW?O3>N]:W&9YL#A,?6;EQM#`M/CLA5UE?7PQI"(Q--"C5I99Y
MX8(P5AB$LK,=*HC.(T%:$M)(VHQI0`I%,S,HCS=E2*W2XF9@))A#&`*EY"CR
M$<0%58XV9F)P="@,S@=!95?.C8VQ]I;=K^\=D;ZZQ[`R\F^):_K3!8FJ[<R=
M%MCK>JHJ?>/:N-R77M'D5RO2N-3*4DHW'+34482JCCF@@J=<".O):AH:7&F,
MP"65I!H%LID:(?4M5HXM3HWAMK99$I(I*AM-%CN"+C5#5EN#%&%.HW#>&):6
MXH'D81FKII#QL&1A726B;I_F-_&#:^9K,*N6[$W6]/N[:/7E%E>O^HNR-];=
MW%V)OW:4&_-F;#VIN#;.V\CB=S;HW%L^KAR%/!12S+]O,A=U+6]["N6D3PF$
MBR7*:2"&)LE9[LJ.++;HCM(PP%4D5IU77%X<<PG3PF@@FKJ%`ES(L-OJ_A:6
M1U15-&JPU`#/7>Q_YB_QM[+V[E=Q[`;MW=J4&%V1N7%X/#=%=M5&[-X;=W_E
M,[@L'G]E;8;:4>9W'A*;/[6RE!D:N&+[?&5>/GCJGB*KJO+$\2H]-0,BIVYH
M)(/J89#3"PSV_P"K!*:)*N$);MZU"_C,RZ60A)#W@IW0RK!-%W4)FAF=(Y8@
M"Z%U)&DUZ9XOYG?Q"J(=FU5)N_>U91;PVS@=Y3Y&EZD[-EQNQ-K[A[-W%TS3
M9GM'(#:WV?7-+0=I;5KL)6C*O3R457`3*JQ?N>[6UO)>2Q16U&60VJJU1H9K
MZ)9K-`QQJN$8>&O$M5#1@1U>96M[6YNIT*B%[M72E9%-B$-V3&*MI@61'9J4
MT'4I(Z7VXOFYT_2;*EW=LU\QOVIIMK]E;\K=L8_$YC$YV@V1TAOZFZ_[HRV0
MI\IBHQBLGL7+?=)'CZS[:?)U%(T%.23K"2.>)X[>Y+TL6@M)VDI4)#>X@>GX
MB37Q(Q^I&J2LRCPG`MX;^*UN%)NC/<0(HSKN+>,R&*HK02+H\*0]D@EB*%A(
ME3:8?+8W/XG%YW#U<.0Q&:QU%EL57TY+05N-R--%64-7`Q`+0U--,KJ;"ZL/
M:NX@EM9Y[:=-,\;E6&#1E)!%1C!'ECI/!-'<P0W$1K%(@930C#"HP<C!X'/3
MC[9Z=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IAW5M;;N^-L[AV9
MN[#T.X=J[LPF4VWN3`Y2!:G&YK!9NBGQV6Q=?3MZ9J2OH:EXI%_*L?;%S;07
MD$MM<QAX'%"#^WRR"#D$4((!!!'3UM<SV=Q#=6TI2XC8,K#B"#4$=%Y^+OPG
M^*?PKP6Z-N?%KH_9?3.*WKEJ7.;N3:\%?+7;DRE!1+CJ"HS.8S-=E,Q7KCZ)
M?'3Q23F*!6;QJI=B5[75P]M#9&0_2H[.JX`UO34QIQ9@J@L:FB@5H`.D2VL"
MW,EV(Q]2Z*A;).A*Z5%>"@L3I%!4DD5)/1I/:?I_KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__];9B^,G_,J9?_$I
M][?^_GWS[QT]Q_\`E<]X_P";7_5I.I1Y/_Y5VP^V3_JXW1@/8'Z$W7O?NO=>
M]^Z]TDLA'DL!4U^7Q%`<M0UX>MS&*^^2EFIJV!%:?,8YJ@21RO5T<6B:G&DR
M2QQLI%W]T-5)(%1T\I6151VHPX&GEZ'[#P/2EI:JFKJ6GK:*>.II*N"*II:B
M%U>*:"9!)%(C*64AE;^O!X]W!!`(X=,D%25(H0>I)5AR00/ZD$>_=:ZZ]^ZW
MT'^2K*C/[@Q]-M[(TQ;;)S-96+48^IGH3FX%3%0XVLJ[0>%3%6U%FA9RLB$D
M-I*ELG4P"GA_AZ4*HCB8R+\=`,YIQK_(=89=S[@Q>7K:"OQG\6KJG&467Q>"
MP<<CK14,=554V7:?,2T\9K9J9(XW`$:F2618XU%_?M3!B"*GT'6_"C=%96HH
M)!)\_,8\O]BIZ0.`@QM7'4P8G"[JJ<!AY*YMG[NHH*E\M%6U.5J:^L>II9JF
M&/,QTE=#,ZU%0HF]30R)K<$MK0X"G2.!_/\`GTHD+"A=T$AIJ4\*`4_*H\AC
MS'#I;U%5N;+8]6P.:BW!1UF6@Q.1E@QC[:RV%$51#)E)Q*9XF1*>-&B:+Q+.
MJ2@ARPO[<)8@:345IZ4]>DX$2-^HFE@*C.H'T_U<,=*([+P4<[55!_$<972)
M+3U65H<E4IELE12R"1Z/)9&<U%35P74:;D/%;T,OO>A:U%0>FQ/)2C4*^A&`
M?4#J'/4C9E100O4TPVQE,E2XZG&2R-0*W!U=3',66GJ*I9EJL-^SY'\\RM37
M:S%2`/5T4_A)_P!7Y=6`\8,0#XH%<#!_V?L&>L&3;.;IQT=1@\?BHZ2*MHLC
MAJK,U=535E=+05D4L=;2K2TTXQM'51QNB-(6DFA<DJBMSHU85`QUM=$34=CJ
MI0T\J^7S/^#IRQF\<36A8,C54>(RRSU5+4T-3-+!3_=4M6]+)'0UM=#215@>
MRNJK^[XY%)47][#@\30]4>%URJDI2O\`Q8'#I\R.3I,7%')4F5Y:B3P45'2Q
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M!1TE+0QB@+3UD)2LK*V=Y::H7)4*5:)'$`4CD1&/!;T^H6K6H'6]2PZ"H5FR
M?/AP`^1]>/7#*TV1V[BYLR=R[DRE11ST4TM)(:2>FKS4U]-#64L&+CHS([U8
MF84\*RZHW*HC`>]$%1742>O(5D<((E`-?RQZ_P"$]+VX/(!`(!`868`BX##Z
MA@#R/P?;G3'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7>D\\'CD\>_=:ZZ
M]^ZWU[W[KW77/-K7L;7O:]N+VYM?ZVY]^Z]TAL+65V$K)JG<V.KUR&7R.-@K
M<KC8J:IVZ9?.E!CEI8Z>1*ZDAM4(A>IB,[L;,S!!9K(#%@:G]G2E@KZ!$PTC
M@#Q]3\OV8Z&C^7HI7HK=&HW)^0OR./\`K?\`&8MV"W^PM[R[VK_DB[%_SPP?
M]6UZ@.XS?;G_`,]4O_'ST>CVMZ;ZK*I/@EC]W[]RN&[6PV)S_5.Q?EUOWY:=
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MD\RR.`JHJAE5:M7IF0%[<*NE;B.6XD2B@)6Y:R4JW%R(X;32K,SNSL*D*H4"
MWWKT!D>TL]LGL'8W8#]8]I;`QF[]M8G/UNT\9V!L_<6R.P8\*F]-B=@;#R==
MAAN7;>6GVYCZN(4^1QU735M#$ZSF(SP3(1&RRW+H5,-Q`(9HW74DB!M:$BHI
M)&=8C>I`269&1A)A_P`75!'"VH-%.LT3*VEHY55DU#!!#1NRLI'\+*5=%(KZ
MB_DY=:XF+%;@V_NOK9NR&S/9^1W/6;T^+'3.^.G6H.V!LQ\WBNM^AJVGQ^UN
ML/[N5FP,;/AJF*KR%0DC57\2;*+52*'UHB6UNM3:+;K$Y:C3/IGGN-2RD4C_
M`%+FX41B,Q")T3P]42.*R2&>1[B=0;@2B1--4C%(EA(=`=4FI(XV=S()#*FI
M7569";*D^#FU\?D=MUM#O;)4M-MCY/[1^3%!CJ7;6W,;1"OVCTVO3M+LR&AP
ML&+Q.-PM30+][KHZ6G2"7]F&!(@H%;:MO<O=`DL1N8H2Q_Y*8D#=S%F/@A^T
MEB7TC4<GI*T6JWF@+4UVUA"2%51_B,\4X8*H"CQ6BHRJ`%#=O#HOVY?Y5^)R
MN#V+B\1W9DX'V/UEUCUA+B-U;$I-T]>]@8/K??/9V]EH.TMC4.ZMK-O7;&=J
MNRW%1AI,A#0M/C::685""2!G-=+F:<HC+(;.JLH91]'9O:*ZJ>P3=WBQR.KK
M$X-(WK532\O7O/J2=<;R75[-J1RCJ;VYM[ET#CN$?^+^$VDJ[HV'0C,?9/\`
M*;V?LKJ7?74M-W+N*IQ>].J\9U4E?3;$V=M],%BL9\DNRODA!5XS`;<7%[>I
ME3+]EU&*BI:>GIJ:"AIHRB@W4*[&^>RDM):&26*ZVB;4S$LW[HC\*)6)J298
MPHD;CJ!8#-`@F'CF_9E53<)NH8*`JJ=U@@AE**/A6(PZXUJ<-H).G47C`?$_
MLG;E7_,&[(VSM>JH=V?*++56Q>HMB[GSVTJB@Z\VMF<?-A=\=@+4X?*U^-H,
M/O\`W[N7*;UKL<E1+D9X8:>)X4K#]NA*+)9^5X^7)9-(O;N5KAB#^C:2,WAV
MQTD:OITENVC\/4%EO'`=D&H+5NO`YB@WN-%)L+2,0@#2)KB-%9I*<0)S#9P.
M9-)I;%P(P]#9+UULRCZYZ^V+U]CJB6KQ^Q=G;9V=0U4X(GJ:3;.%HL+35$P+
M.1+/#1!F]1Y/U/LXW"Z^NO[V]T:1-,[TK6FIBU*XK2M*TST46%L;.RM+5F!:
M.-5)%:$@`$BM30G-*]++VCZ5]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=?__7V8OC)_S*F7_Q*?>W_OY]\^\=/<?_`)7/
M>/\`FU_U:3J4>3_^5=L/MD_ZN-T8#V!^A-U[W[KW7O?NO=8+TU:E13!H*N,K
M)35<,<JRV25&CEAG$3EH]:$@@V/O6#4=;RM#PZ2FV\+68K-;7V!%#5?W<S&<
MFBI,IC)UBS&.PR4U9ELA25<3K+4$1U06)LDA]$<ZZ@KV;V8[+9I>;E;6DJL;
M<DDT]`"<GR%:`GY^O36XW)CL[F\5A]0JC!X$D@"GSIG3\O3H9MU]91XRA;,[
M$I2<MCJ:N>LQ.5S68JH,]0"#[@4L-163Y!J3)T]13JU.P4(VMT>P8$#7=.6+
M66W!VV)8IT)/F=0I\.2<X&G\_7H,V&^3"8I?R%H6H`0`-)KQP!C.?/I!457#
M64-+DE)CI:FB@K]<OH$,$T"SL9C>R>%2==SQI/N.:XJ<="M@0Q7SK3I&[,S>
M(FV_-D&RE,TDF6J3FJZ>HIHJ"7.5)B,GV$Z&.ADI983%XO"3<'U?N:_=(V4K
M4&I/3T\;K(%*F@&/6GS\Z]+OD?X'_?'@_P!/;G3'7@/PHL!<V4``7-R;*``2
M>3_C[]U[I#Y*NJ-K9:):6"7*T>X*ROR57AJ:('*XS[6D6;+YN@)D45E#J2,R
M4Q42-+(?$Q)T>Z$Z3C(/^JO3ZJ)4-31E`%?(^@/H?GZ<?7IS_OEM,1RS/N/#
MPP0IY9)JBL2FC,00NTD35'B^Y1`I#&+7I8%39A;WO6G\0ZIX,U0!$U?LZ3CK
MN7<4T&XJ"HH3@\?D'K,'M^>B05.>IHJ6?&333Y2?P_:4^6BJ9Y8$*,MO"6;2
M6'NG<W<.`/#UZ='A1`QL#XA%"?3->'G3'\^GO^/YZ6HJ%I=E9,T5.D`66OR&
M.Q=7+*R%YDIZ-VJ(I8H$`4,LOJD(%E6["VIJX0TZIX<8`U3C4?0$_P`_]CKC
M69>LC3[G<>V8(]NJ)'EGEFAS=;C4/I^ZRN)CI9(X*3P$B8T\E2T7]JZ:B/$G
MBR]O[>O*BG$4OZG[*_8?7TK3J%M#&5J3R9>=84Q4N.2DVK33EYLO08*:JDKJ
M:.KE.J&$2P3*%1&9_`(TD):/G2`\3P\O6G5IF6F@5UU[O0G@:?ZN-:<>EY[<
MZ3]>]^Z]U[W[KW7O?NO=0LA04V3I)**K60PR-#)>":6FGBFIYDJ*>>">%DEB
MF@GB5U8'@C\^]$`BAZVK%"&7CTPX+*P1U&4P==FEJLECLE7+3QY&JIQE9,0D
M=)/3U-398/.J_<D"70-2@?6Q/O2GB"<UZ<D0T1U2BD#APKTJ4=)$62-TDC<:
MDDC=9(W4_1D="RLO^(/NW37V]<O?NO=>]^Z]U[W[KW7O?NO=)K)9>KEJYL'M
M^.&HRWV7W$]?+-#_``[!+,_A@FK57RRU-:W,D5*J7=5NQ5.?=234JO'IQ4&D
M225"5X>9^SY?/J"FS(-=Y\]N*J2G\,N,$V09JC%Y!1`:G*053^4U%35O!?1,
MCP1+)(B(%<CWK0/XCU;QCY1J">..(]/]6>'4/.9/-[-IA5H9-T8^KKJ:C@AR
M$QARE!65ACC7S5U/3M%4XR5XW*@0"2&1E4:E/&F)05XCK:*DQI\+`>7`_EZ_
MGGIT^^S6:E--C4JMMPTT*-D*W*XD35GW[NP&,QT%0ZT-1'"B:YJD&6,JRJGJ
M)*VR<#'6M,<8JU&)X`'R]3_FZZCQ6YJ1HZ],]#E,B_W*UU%D$J*7;\D4C!Z5
M,9248DJ,:]"5MK9IGF#MK;A;:HXSJS_+K1:(X\.B^5./YGSK^5.LM!@LO4RT
M+[ASTE<B5U+D9,31TM+34,5=3U*5--`M<D,=?5XZAF13&CA&=ENY8>GWHJ2I
MU-Y=;\1`WZ<=/*OG3[.`)Z%;^7KST3N8_P!?D%\C?_?Q[N]Y<[5_R1=B_P">
M*#_JVO4#7'^YVY_\]4O_`!\]'G]KNF^JD3_,V[,W#\A,QL7J3X%][]R?&?9G
MR(@^+'87RLV5NK8<T&W>VH*ZGPVZZ[%=*2U1W_N7JCKW/5T-)G=T)+34E$8Z
MEQ%(E.3)O9@-SCVNYN6%K8;AX_TLCY618/&422:?["&:2"2.&1ZZCHJ%+A1K
M=6&WC<(K:MS?V2PM<Q**%!,L3B.,G^VGCCF5Y80%9,@%NECG_P";]\)-HYKY
M+;?WKN;M?8>7^*&Q<KV?VE1;\Z`[HV3-D.M\'O*BV!EM]]:1[GV5BI.T]J46
MZ<G2TYK<$M;"ZU4,B%HY%8IH[F&7:6WI219K<VT#`@B1)+MRENKQ$>(OB,K`
M57%#6G2Q[&YCW&+:W0"=XIW5M2F)A;1>-,!,"8BR15?2&)(#$5TF@)=V_P`]
MKX=]4[&Q&?P6#[NWIO;<.`Z_W5C.M\GT?W'UWD<+MWLWLZ#K38N3[1SFZ.O/
MX7TW'OJ9*W(;<7<HQ[;@HJ,O2:EEB=C2SL;B[W_;-@50L\][;6KN2`D4MP`W
MA$D@-<Q1D22VJGQD!&M5)Z+WN((]JGWB20BS6VNID-"3(EK%K,B@`GP))"L"
MW%#%XC8+4/3!W9_/)ZCZ=[5VAU)1=)=K]HY[</R6^0/Q_P`Y7=9[3[6W=C=I
M4OQMQV.R786?J1@.G,K79[=D4.3C,6`QL-33I"?N)LI'2_O^RB*\CD%I(586
M\FRW>Y%O+P[6:2'0@-"^IHVUNPC2$E%DH98?$,[ZQ>R#(S@W1N;"!$P*O?VZ
M7$9<@MI4*XI36\@#%4_3E"+/I_\`G`8#MKX>?'+YAQ_'O?.UML_);Y;]8_%[
M9^S=PY;)8?<.,H^TNQ8^O\+V5DIMR;$V[!D<;32.:IZ;&I6T<ZJ8Z?(RE693
MV#;9)+_E';WE03[K9M<5!#"(+9W%YI)!!>JP:5:BA@ZRIKB*,Y8)D>SYVOX0
MQM]F25C4:6F\*6*)@!4A#605&IBA5HW"R*R*)O8G\V;X[])[U[RVCW7AM_[2
M'4_R*VQ\:-IR;-V7O/N+<7;O8&Z.@<-\@:2DVML;K7:N<W-2U+;?R4M%#3M%
M.U154XTL/(%4D@NX9K.QN>[QYYMP58PI8Z-N>-9Y"P%`H63Q6K0)&KL312>C
M"ZLY;6XDB+*84LK*X9R0H!OIY[>&(`FK.9(=(I7474`5XMK?SC/AUIV7NJ#=
M>2K.I-]=`;(^0.+WY1[4[$GR^-VUOWOJF^.F,7=&S5V&&VO18GLBK6ARU179
M"&IQ4ZN*FDCA1J@&XV^?ZUMO8K]0UY86T9#*8W;<H)KBU8R5"JDL<78U2K%T
M4LKLJL@DE1=J7=U5S;AK\.-)#K^[?#^J`3XV:/Q"6&D=B,ZEE#%1`[=_FL?#
M+I2H[2Q^[MY[WR><ZF[@Q70>:VSL+J7LGL7=6Y>W<AL6@[,R&RNN=M;+VUFL
MUV%D=H[$R<&3SKXJ&I@PU/(/NI(V]/LH2ZCD@L[A$<Q3S72)12<63+'<S,!\
M,$<K>`9FI&9PT0)<$=*G@>.6YB=E!AM[:9CJ6E+LO].@-:&:14,@A_M!$5D*
MZ&4EKRO\W/X-X_=72.T,?V'O#=]?\@.J9.\=A9#874G9^]MOT?4U#FLMM_<6
M^]^Y[;FULACNML#LO+8.KASDN=>@_A,D#)4!'&GVIGI;7.\VUPZI]!;1W$[D
MCPDAFB>:"02C]-A.B'P=+$R,51`68#IB/5):[?<I&VNZNI+:.(@B9IX6B66+
MP320-&94UU4!0220H)Z3&W/YOWQ:[#ZNV%W%UE3]GYC8N_?D-UO\?,/7[YZ:
M[PZQJ]Q9;L[!Y?<>VL_UOC,]U955W9>-R^)Q#OCY,>BT%8[+&U9"[QB1^2VG
M@:S%Q$R^-!>2Z`"9E^BMVN)5:'#AM*\#0FO8'8%.G8U24;UX4Z-]#'$[L"/"
M(EN4M5(EKH*AWR5U4`!8*C:PBOC_`/SP?AEWIU75]I5T'</4<$5-G<KC=L=F
M]2[XP>XMSX+%=X8GH&BKMG1-A/L]Y5]?OS<N)IIZ+%2UDV.FR"Q5!5XI=+5E
M')?6FQSQ:&GOEL"J(VLJ=QDGCM:LHTE&-O*6F4F$*ID#F/2Y8N7%K=;W!(K:
M+*6^4L01J&W017%TP'$%8YEI&?U"P*:0ZLH.OWM\OMA]"YS.X?/XG+YM=F]4
M5?;N]GPLE(U;A,-7[DI-C]=X"CQU0T9RFZ>T-\U+XW%T[2TT"&FFEFF1$&IA
M6N)S=I8V_CRQ2V\`56`9[F[<I;PBN!J5))9)&(6.-`:-JP^%C"VC2S+&LB7$
MI+8T6]K%XMQ.P.2$U(@5`S,S$4&G+5A_DKVQMJGW;/W_`/%[>^P$P>V]N[FV
M_6]0YJK^1F-W6^X<RV!.R8$VUL[:NY<?V-A:QHIJVD_A<^(BH9?N5RCQQS&-
M0XB1'7QM5R+E8@H!TN'4L)8W-!X2Z'$AE$)0Z.T^(*-QAYI4\)?\5>&20,Q"
MNOAZ:I+'G3(X=?#6-I=9$BU!0:DIBOYD?Q>S&-VWE:7+[[CI<WA^TMQ9QJOK
M;=U)_HTP'26YJG9O:^:[4EGQR4VQL?LG<].*.J>JDO)+-$8!,CAO;)EC"^('
MK";2&Y#"I#1W#2);JH`U-+-)%)''$`9&D4J%R*W\.3Q&@,9^K%VUN8_QB1(H
MYG)'`1I#-'*TA.@(P)/$`**C^:CUM%E.UJ3_`$1=P8Z#J_';7KUQFZMF[IVE
MO_>+;GZ4[E[P@H]M;!RVV%K_`#+MCI^4Q2U513TDRUA/F2:!J9Z;F\NU[/NF
MZS0$R6HO=40(U_XE#92R:CP3-X%:M2JH9%#HV%%K;)=WVWVL-RC6UQ;V\RS#
M,96XOFLDT'BX+`.A4=Q8(=.6"Q^$/SSW/\Q=T;WV_D_C=O3I*EV!UOTWO3,Y
M;>&:R%6M9GNYML?WWQ&U<'35>Q]MID*?#[3J*:>IKVFB9IY_&E,8@M1(:SV#
M6XWCQ9`)+3<I+(CS:2&&&2=AYA%:=$0TJX[R$J%)';;C'=MMP@4-'<62W50:
MA8Y9)$AX"A+K&S'("D%07TDAU[,^>M'UG7;DQ60ZCW%DLKM#Y+8;I#<E#1[A
MH/)C.N\EM+:V^*WOV33C9F;:F(VUNF.:6@TB<O!*GF!4D%NW2+N%WLEL&")=
M3W44CDU%N\$PMX1(*58W,T^WHFGX#N$);"L>C&^#64.[2=KR6\%O-&NH`S)+
M&\LNDG"FWCM[YV5LNMHV@?J)UDI/YB?4M'N2KPF]-G]G[4PL_?5=T)MKL6'8
M^YMQ=8Y?._Z0$ZHVUD\GOS&89=MX*/=W8L51CZ6G%15/3HD,]4\$=1'[]:M]
M7#MS)B>ZC=T4XU`">2,*Q^+Q;:$3@@:5\18BWB`CK=Z/H5W2>0AK2S56D=3J
MT`10O,7493P))3$X/<6BD(6BFD78O\RKX^[FH]CKN27-;.S.Z?X,FY(315&X
M=L=5U6[]WYK9O7]%V9O7'TT.&VK5;^R>&/\`#5J`FL31E]",KLZH1S#ID`1X
M86#-VJ99K:.Z^G1CAYUCD6J+DDJ!W.JE[<8&VVYO;:4ZGAGF0@"K>%#.\!N"
MO%82Z-WY"Z7)-$9@8+H/Y0=8_).FS61ZQ@WU-@\9X:G&;FW'L#=6U]K;SPU3
M6Y''4VX=B[CS&-I\/NC$2UN)GC;[>8U,.A6EAC62)G<$$WTD-XZ:%>G:Q`D&
MI%D4E*UHR.K!A5<Z20P("621([N:RU:I(VD4E>Y-44ABD74,!D=2"IH3\2ZE
MSTI-P=PTF![RZ_Z2?!5536;]ZU[.['@W"E;#'28RGZTS?76%J,5-0-"T]1/E
MW["CDCE615B%*P96U@A$TP6WYAN-.-OM(IR/XQ(\J:1Z$>$34U!K\NE$D12V
MLKFM1->"WIZ$PRS:OF*1%:>IK7'1&M@_S/\`:G94U#M':W6%3/W)O+`=.97J
M;J:KW_@:/+=@57:NR<KO[+R/D9L:/[O;5ZOVYAYJG-Y9J:J185`A@DJ)(:>1
M:D)DO&L8V!E2\>*0^44$5O8W$MT]*T11?)$B`%I)@D:_VE5W=Q"R$[W#Z8U$
MP0_[\FCO+RSC@3--<KVC25)`CB9G;MC8D\O5G;\'8F?[3V7DL&=K;YZAWC#M
MC=.`_B7\8IY<;FL11[DV9NK%9/\`A^+-7B-U;=KTE0-!')3U44].X8PZW;C"
MRV4%['J\-I)(V#"A66(C4M*FH*/'(K<&604R"`S+JBNC:NN?!BE5LZ661372
M:9T2I+$WG6.I`U``9?=>O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7_]#9B^,G_,J9?_$I][?^_GWS[QT]Q_\`E<]X_P";7_5I.I1Y/_Y5
MVP^V3_JXW1@/8'Z$W4>JJ8J.FJ*N;7X::&2>3QJ7D*1J6(C0$:W:U@.+D^_9
M)``R>O<>A`PG655DJ<5F[J^NQ_G53%MW`UXI!2P,+Z,OFH(S5U==(I]:4KPP
MQ'TJ\GZO8_V[E*!(P^YL7F/X%-%'R)&6/KP'IT&+O?WUE+%0$'XF%2?F`<`>
ME:G[.EI/USL:HI\?3/MJ@BBQE*M%1FB:IQTZTJJJB&IJL?/35%>ITW)G:0EK
MM>Y)(AEVK;9TB26QC*H*+BE!Z5%"?SKT41[E?Q-(Z73AG-3YY^PU`_*G4[![
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M<^U$6WV$$CS0V<:RMQ(49_R"OG2E?/IF2^O9D6.6[D9!P!8^7#YFGE7AY=`;
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M%/@ZVECJZNDI8%81I#4_<W4"TB6M[T`RC!K]O^3J[/'(3J0@^HR?S'G]HI]G
M4V+<DE1%$U/MK=$E1.J^.FDQB4B^72#/$]775%-2PBGDNFN0HLA'HU`@^]ZN
M':>M>%0FLJ4^VO\`@ZCXG=:5L=%)E,;+@$R7G2AGK*ZBGI):NEDD2IQLU1$Z
M?:9*$Q-^W(JK(4<1L^FYT'K2HI7KSQ:=6EM5..#Y^?V?ZCTKK6X/!]WZ:Z][
M]U[KWOW7NH59C<=D51,A045<D<J3(M730U"K-&K(D@$J,"R(Y`O^"1[T0#Q'
M6PS+\+$?9TG1B,[AY:M]O56*DQCU!JJ;;-;2-101O4#5D(J;+TS2-1)),!)`
M@@,,;.X86(*UHPKII3T_V>G-:.%\0'7_`!#/V8\_GFO3UB<JF5BJ6^TK*"HH
MJIJ&NHJU8Q-35B0PSO$)8))8*B/QSJ5D1K,#]!]/=@:UQU1TT$=P((J*=.OO
M?5>O>_=>Z1V4&3S&5J*3$ULV.&W:<S-4)4F.*JW#5P4U9B::H@B#&IQ]-2:O
MN5E]!\XTJ64,*&I.#P_P]/+I1`76NH_R\\^OI]G4[:V,GQ.-J()Z*CQS567R
MN4%#1.DRTRY.J:K\,]3''''55"22-=U%M)47-K^]J*`XIGJLK!W!#$T4"I^7
M2C]VZ;Z\"1]#;_6]^Z]U[W[KW7O?NO=9(?\`/1?\M$_Z&'O3?"WV=;7XA]O2
MK_EZ_P#,B=R_^+!?(W_W\>[O>6VU?\D78O\`GB@_ZMKU!=Q_N=N?_/5+_P`?
M/1Y_:[IOJI6;^5OG\5\@<QV%UK\W_DQU+\>=X_(6G^5'87Q-V,=BT&U-T=TM
M6Q9?/U5#VPVWF[>VMUUO;.4<%7FMK4>3&*KY/,I5$G*IK:@-NAV^TF'U%E8K
M<+:H^!"+@2U4E:>,D3SRR0)+J$;E6%2M3O<S]>UU/`/I[VZ$"W+IGQ5@$2J0
MK5$4LB0HDTR4DD%:D=$_PG_"=_K#&[F^4>\<O\KNZ=X[H^4G5V_.F]S;DW7M
M;K[(;GQ>Q=U]O;*[?P$5=NB'&TNX-];@V37[-3%4F0S=35RMAY(Z95A2GB'N
MNV*^V[/:;0&#QQW.VW#M329)MLG\6*1@#35*E4N&R\LA\9F+8Z4W5T]SNHW,
MU`7ZX(A)8(E]:S6\D88]WAQM,TD*"BQT\,+I)),Y\MOY1%%\F^T][=@;;^5W
M<71FV^Z-H]#;4^1/6&S]J]:;EVSW0OQKW>=W=39"NRV[]O9#=6RI<9+//35\
M>$K:-<G3M&)B1$`RW;;J3;][CW0@2V:;S'NB6YPJWB+'&SZUH[(\<,*F-BRA
MHQ(!7'18UK'^Y[3;8OT[N/:IMN-PO]H]I*LGZ9!JH*O+*P<`-HEDCJ`U>A`V
M;_*TV+LSNO%=U4G;.\ZO)XOY/_,7Y/+@IL-@XL?/G?F)L#%[!W'M:2HCO4KB
M-ETF+6HH)A^]42N5F]('LFFL(YMOV[;V8Z;?8;[:PWF8[Z]BO7E]-:-$$5>!
M4DG/1O>7\EY=)=.@#+?[7=4\M6UVCVD:?Z657+N>*D`+CJ7F?Y7VRLG\`NF_
M@S0=R=B;;J_CYDNNMX].]^X+'[97?NS^T>IMWOO?K_?PV]E:#*;0RSXC-L!/
MCJJ"2DJZ?5&]M6H+Y7N?'Y:O+&Y-O>[7!:Q1LH#!EM[);!U=7!#+/!K$B\`7
MQ72*H[8QPV_,MG-%XMGNK7GC*25(%W<M=$*RD$>'(RA3Q*KG))Z3'3_\JK'[
M!W1USVCV1\DNR>].\=N_+;-_,'LGM7=NT.OML5':V^Z[H3+_`!TP.WI=G[&Q
M&"VAL7:NT]@5M**2'%4J,U32>1R3*UG[>2*S%@EI`$A@L-RMZ5+%GW.5);B<
ML<ZZH%1?A"=HH!3IBY6>]AW:.\N3))<OM^DT`$4.VS>-#"BC&EG+L['N+2,W
M'I/=;_R:.D]EXW*;>W)V)O#L':V>^'/:WPVSF"S&(P>-2NVEVMW[O+OZNWC%
M68\>>BW/@,[O!J6B\?[:+2Q3W\H/M/=:[C:+[:TD,<DL6TA)5^.&79[8V]M,
MG]/5IG-<*Z`#'1R=TD.X6U^84*IN>Y7;1D`I(-S\(3P."#6/1&4]65VKY=`U
MV]_((Z*[A^(?3OQMW+W%O++]A]1=P;][X;Y#;XV#UKV;G.QNSNU%R-'V+N'L
MGK+>V%R?7&YFSV&JX*6!7I5././I9("K16.K\?5WNRWEND<`L[1[?0J*RNDS
M":X;N!999KL&Y,JG6&9T)96/199%K:SW:TN)'F^JN(I0Q8JT9MT$%L@H>Z.*
MU`MPC5!4!L$``W/QW_E@=6_&_<VR-P[,WC7I3;,^%TGPW3;V/V#UMMO;=;C:
M_L3,]FYWL6':V#VY3[-QF8RVXL]47Q4>+?$B-@KQ2W?6]N+_`%Z<U1`:(=SC
MLXZ']3P8[*&XAC4:]6L,MPQ8,--115`-`GLX3:CEIBVJ;;KR[N=0&@RR7GTX
M?5HTE-'TRZ2I#9RQ(!Z*#\:_Y"76'QTIJ!:/Y"[US\V/^7_0ORVIL9@^KNI^
MI]@4V5Z`IMVT^"VMC^L.KL'MO9..K=U_WOE_C6?BI5R=:E)2Q^F.%5*JPO6L
M/W.44N]HMV.YF8'ZNS-F0BL6$*(K&31'022DO(6-"%-RQN9N8)3VB_M%@(``
M*JM[%>ZV(`\5]<2QJSY1"P7C3I.9'^3_`+JV_P!C?`CK?"[QWCV9TE\:?E=W
M9\E\_P!A[QJ-@;53;W5>\LPW9>W?BO)M[:LU'N?M"BE[VHL7N"/(Y*C,-.M`
M7FJ3)'3T_LKY8A78=PY;D10MOM'+CV"O^.ZE4>#8R%0=,;V<;.Q>BAAVK5Y'
M(IOH;<[/FA48^+O&^1WC)^&W1M1OPK88B[!\,!=3"M&*HJGJRSN;XHKVOW9O
MK(9ZBGRG4W?_`,>\5T_V;48W-4N(W+L7<W5>],QOOJC>>V34PS-45`K]XY'E
M$E^VKZ*CEDBDA,@%;:*2!-YBAG>&::ZM+V"9:%HKJU_3I0^3IX3BH92(9(V`
M$HU*)IB_[I<HLB0QWEO)$P[7@O4C$A)XD_I&)@"A"RAU)*FB/W]\'NV>X-E9
M_;G</R^WEOK(UJ[!I<+1)UW@=L]3R8W8^YX=SUM-V+U)@<_3479DW8$L(H\_
MY\E0TM3CU%/3T]+$TRS*&"&6*Y6"(W`NEE8.OB1!5CDC6..)B0@4RM*K,9&\
M986<NL*ITTI*1W%NDLBVS0-&A5M,REFC8NTR@%VTQB/"H`CS4`>36J:ZK_E<
M=8]?;%WUUSF=^Y[=&U>PM@]_;`S.+Q&U=F=<T.+QWR%[%A[-W'+M/%[*QE!A
M]M1[9W`)$P]/#3F*GIRBR^9D+NW<1F:.(+,XGB@LHXY"=;J=ON;JYM9#J&EW
M5KA0P*A&\)>P!BO5ED*WDEX43]2>:21`*(PN+.VLI8Z9(1HK:M=1>LC'74!N
MN+?RX,ONC.;KW;VY\EMX=D;NW3#@L>V5BZ_V=M"AQ>(VWT1WAT/C*.BP^)DJ
M(FJ:G%]X5N7K9Y)&\^5IQXT@II!3Q6OE%_MVZ6,@"R7D5^LKKPU;A!:0.44U
MTK$MHAB0LQ[CK=CW&]G-]"^VK`";6TAM8HU8U8K:WRWRM(^-<DC*L;L%0%0"
M%!'0_P#3WQ=R706X,EE^OM[KEH-Z2=&87?5/NO$1:AL[I+IJGZII8-N-BY(?
M#G-PRXFCKI99RT4+>5%4J5]K[B]:ZO=PGF0"WNMRO+UP/B$ES;P1(BDXT1R6
M\;,3W,I88-#T1V6UKM]K916\M9K>PM+121@QV\TSLYS\3).Z@#`(4^O6#>WP
MMV1OON[M7N?+;FSRMVQ\>\KT+F-G1T]`V#Q\F;U463[$H)W4U9W3/MV"DQP5
M[PI!2*5LSO<G:WF_=W,-C#>O%)>M$\4JT$EH\:FKP-3#22K:SN37]6S@/X>A
M`EV5ON7[QH49+%F+(1VW%6)3QO,B))+J)`*=EU*#7'11LW_*,VOF:_J^HJ>\
M,]D8>MJ'H.II\CNKKC9>\]YQ[QZ(W]1=DMN79.Z=Q/5P]8T_;.ZZ/[K=T&(H
M8ZW)R%=%=#&@C]FD5P(-R:_M[>.*,3J\<<8TA4%O]*UN6J6-OX1=HXE*+'++
M)(==0H+)K?Q]IN-JEGD836EQ!(S&NHSN[F?1A/J1J5#*P;5'&H"HQ+%3;._E
M3]>;`[#VYOS;6\]NU<B'9TN_3OKH/I[LG=.XJO8FX,UF,#7;(WIO;"YC(=65
M-5099,?7_9PUB20TT<]*M'6EJHMVDIM&B50/`C6,KIHK^*EK#:ZS*!J*L((I
M-&"DBG1(J,R%;NT@W:>]NIDI<SM(&KW((Y+B2XT",]NI#-*@<U#(X\1'*(0*
MO2'PEW#\?NR>Q^V=H]FX'*[M[3RNT:+=./H^LL!U=LK(;6Q6[*W.[CW+N+9'
M7531;4W1WEG</7G'ONI*+&O-!3PB6G-G+I[$&RLH-N4+]*UPLDH%0H"6[Q`6
M\99E@\24I+/0D2:0`%TJ.F[X_674]]6EP(W6,G+'Q)HG(FDPTJQ1(R0:AK34
MQ9FUL>AL[VZ`W1V9N_KSLSK/MJKZ;[-Z]Q&^=I4NXO[F8;L#$9C9'8T>`?<V
M!R6W,Q78I4K8LKM3&5U!6PU4;4U326ECJ(9'B+$EL7:_3Q2+6\M?IYU'%HP^
MM&1C41R1L6"OI<:9'4J:@AXS5MHH&0%HKI+B,G@)%22,AU_&CI*P9:J:A2K+
M0U*\G\K'IG&8_<\NU]T[BVWOLX+XY4G4W:E+C,)4;_Z<W/\`&3;^6PNQ]UX/
M-/!$^<7,R9RM?,XNJ"XS(TM?5TCQ>"H<`R%S)'>-?6U$N/WF]WPJI62VMK-[
M:1<"2![>!D8-G]9V72ZHP:JLUNEK?AIX3:/#)4T9W>\EOS<*]"8IA<R+(K)@
M&*,$,FI29[HSJ[>.W^S_`)"=O[^CIZ+.=K;BV;@,+BZ:6CF\>QNI=MOMC`YZ
MM_A]564=-D-Z9:NR66^U621Z*CJJ>"1O-'(JLPB&*R=$B"37%Y-<R*"3HUI#
M!%%4X9HX+:/6ZT5G9J"@U,W*)GN;7Q9A)';64-NKZ=)<ZI)YG(X`&:=T44%`
ME<AAT:#W7JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__1
MV:_CKA<CBNDANQ)6K=O5':/>8S,+7-7MZ1.[=^TW\4@TH!/@9"(_N$-Y*5B9
M03&6"0C[E[*YWR_W6W)8:8_$7S%(U&H?("E1^?4@\E[A&=LMMOE%)`[Z#Y&K
MDZ3_`$JUH?/AQZ&^"2LK_OCA<3DL]%BU9\I4XF.":EHM$?E>$U,M1#%65RP^
MO[:G,L^FUU!*@QQ:;9?WT<DUI;%XEK4X`QF@KQ/R'0OFNK:V9$N)@CMP!K7/
MF1Y#YF@Z<\+LW-;_`,'-D*?(4FW\!E(9J?'/68V;(93)P>2:FFR#4WWE!_"(
M4DBO3J^N62P=E5;`GFU\L37ENEW/<>"&H4`6IH#Q:M*&O`?MZ+KW>H;*<P)#
MXKK\6:`'T!H:XXG\AT.5?ELIC<CMS%4VW<OGZ?):H,GN"EEQT%'A!2QQ(U=E
M8YYH99#5L2X2!3]"%N;+['TDLL<EO$ML\BM74X*@)0<6J0<^@!Z"<<44D=Q(
MUPB,O!36K5\EH#P^?2(W+V96[:WE3[;J=OP/C9Y]MJF3_B4K9&LI,_5OCY:O
M&XB"CE-2<57H5ECUZ_&-5K$6*KS>FL]TMMO>T)CE*T<'UP>T"N#QSPST86NU
M+=6$UXMS1T#56F`5%0"Q/F.&...EOMO=>)W4N9.+%9'+M_.5NWLM2U],:2JI
M<E0Z3(C0EW/BFBD62-K^I&!L/9I;7<-T)O"U5CD*,"*$,O'\CQ!\QT@N+66U
M\'Q:4D0.I!J"I_U4/SZ4GM3TGZ\-(Y8D*H+.0+D(H+,0/R0HX'Y]['7NBY;9
MW-O+>>Z<!(N>JJ7'M_$MWU6WZ**CHZ&+#T]/-2X/"U]<M+)D9H<E65,.OS.!
M(T<K`#0%`+VO==RW7=9$$FFQC+-I`I4"JJI:E:$Y-?3H47UC8;?8$^%JN6H@
M8DG)H68+6F`"!3U'KTS5%1FJC<.X:C<F%CVYG,@V&R=1A8:Z+)PTU-)B8*"G
MECR,2HE:TLF.D#N%4`J%L"#[#W,0N3N;2W,`C=XU-`:^5./`FH\OET:[9X`L
MHTMYC)&K,-1%,UKP\N/6+!Y;-[8W[1YYYZ&3:%;C:3;66HA#)_%(Y\AE8A2Y
M2.;B-X<=6R(62]VAEDL-0!.^7-P:QW)%:AMYJ(?4$GM/Y$T/R/6MUM$O+!E4
M'ZB,EQZ$`9'YCA\P.E=W[@ZE,-!NW%4`R>=H)<3M5Z*HE"TYP&7W-BZ_(&E1
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MR:3IDHY*:G+19U<G2EZ*L*,"JH62XO\`0>[%:4H2,_ZN/3:/K$FM%:BU&*</
MLIQ'2MQF+IL33O!3F262>:2JK:VH*/69"LE-Y:NLE1$#R']*@`)&@"(`H`]W
M``X=-,Q<U/Y#R`]!TY>]]5Z]<WO?GZ_[$?3W[KW23Q]%3R'<.VJVDI*R)*R;
M*4M/5PB6DGH-P/4U,.J)PXC^TR`GA)2S`*&6Q;B@`[E(_P!1Z=9B/#E5B#2G
MV$?[%#U)VC(9-M8A6:9Y*6G?'SO/*)W:HQD\U!4:)P\OGIEFIV$3EBS1!2WJ
MO[VF5'6IA25_F:_MSTH@0>001<@E2#8@V(-B;,#]1]1[MTWUW[]U[KWOW7NL
M4U13TJJ]14TU*K,4CDJIHH8VE"%PH\KQB0JJEBH-](/OU:=>`)P`3TFMDJB[
M8QA4,3)]W-+4FY&1FDK:AI,K$[JDLM-DC::%I!Y#"R:KD7-4^$=.S_VK_P"J
MF.'Y>?SZ57NW377O?NO=)3$:#N3<CU$,]-E*DP"G@>G\<-1M_&A(*6OAGC7P
MULDM75/Y'+&6)6CC(`4#W4?$U>/^3IU_[*(`]@_PGR^6/\_2K]VZ:Z][]U[K
MWOW7NO>_=>Z][]U[K)#_`)Z+_EHG_0P]Z;X6^SK:_$/MZ5?\O7_F1.Y?_%@O
MD;_[^/=WO+;:O^2+L7_/%!_U;7J"[C_<[<_^>J7_`(^>CS^UW3?55-1_,\H(
M>O.\-^ITQ7RCIC^8QMO^7W)BO[\TJ-N*OW%VGUCUDG:4=8=L%<714LO9*UAQ
M+1SR,M(8_N@9`Z.V,7UJ<A/JTC?'F4>?@^"]ZM3_`!ZOHR?PT\0#.GN>W*']
MW2<UH6U?NO9XK\GAX@EMH[GPAQTD!]&LUK2ND5ITF8_YV/PTS62[NVUM6?M1
MMR=-=:_)SL$9#>_3W9^Q^M-\S_$B;*4O=>U]D=E5.T<GB-V9O9<N.6:NAQ,6
M1G@HYXY%BD=A$4$%TEWLIWVUH;/PK6:C55S!=W"VL<RH06:,7#>"6`IXJLM:
M*S!2+!UYBL.6YS2]GOOI`4&M5G\+Q_"9JA%?P2'"LRU!'J.A8Q'\T_XNUNUZ
M_,Y"KWS29_$=M_';HFMV;2;$W+5[@RO9WRAVGM3>?4='LZ@JL?C:_<NUMQX#
M=D55'EQ!3TT=-35+S"(T\JH;2VC+N%M81L/$FW2^L1J*J4EV[Q&NFF&H^%%%
M#&;AG)*^`5E!*,I)''>HUA=W[J1%!MMO>FF=<-RWAQ"&M#+(\U8!&HUF96CI
MK!'2.VI_.<^!N]=V]S[1V_OW>M0_2^Q^V^PZC<]3UAO3'[&[1VUT-15U=W%-
MT=O&NQE/@^UZOKZ/'2K7PXR5W#+>/R("P)Q?0G8KSF)E=-N@@CG;4I63Z>5Q
M''<"-J.879D*M3X9$8@!NCDV-P-[M.7Z`W\UR+8$$&-;@C5X#R"JK+0/VDY,
M;@$E>D]M7^=C\-]Y9SX_;9PNV?E2^XODNBY?K+`U/Q4[GI\T_7]5N3%;3P_;
MVXL.^V3D]O\`4VY,YEECQN;FB-/6I#++&#&@<G46W74NZ2;/I"WT<:M(&.D0
ME_%*1S,:"*5UA=U1Z'1I9M(->BAKZV7:VWE7U6&ME1E[C-H1'=H0*F5$$B!F
M6HUMI!+`@(?=_P#.YZ2V)W%MKJ#*=-=[;SJ,]V]\NNK:_=G4/6^^.P=M[7/Q
M!::/?-5F)5VEAZFKS#O&LE324*5-'CJ-UJGK9(7C:0CM[^*:&UN7(BLVV&3=
M7D>H40QS-"1&*%I*%6UL50(YBBH7GB#'%_8RV5Q%:*/$NY-RLK-4''7>VT=R
MC-DA0%E6@&HLBRR'2L,H4VC_`,RCXO5/2WR.[[V[G]R;KZ[^,'7>TNQ^P<I@
M]MU4@R5#OKJS$=P;5P&SY*N6DI<_NC);1W%C==*LD8IJJOAAE=&8E5F[+=;3
M!=R-:/+<1[D^WI&M`9;I)((0D9:BLC37$<2RUT:]8K5&HBVUHMSFLXTF$44V
MWK?:Y*JD=LPG)DD-"4*+;3.Z$:E502.X=`)L+^9MV;LW9W;78WS^^%/87PBZ
MYZ^ZYV3VCM;L"+L/`_(;:O8&-[!W%%M/;76E'-U[M[$YFB^0=9N"LI*8;/I:
M+*2LU9%HJG#IK>NUCLDNK:9F?>XKZ*U%O&C2-/)*K%3:$`&X561UE(1?#`5V
M[&)6EJS7\MM-91_[IIK.2Y$\C+&88XM+-]4A)$!*.K)WN'.M!WK0L6<_G.=+
M5B=,2=9]9=DYZM['[#^0?5W8&RNU,%N?H'MCHS>O0WQHW?\`)>3!=A=7;^VB
M=T4==O';6W*6.B\B4\0ILE'5I).J-"4M[(;.TOKU=$MO%L]Y?!D<,&-G<6]O
M);L1_9RAY^\&K)I%4(=6Z,-OM1?))5GBG7<=LMM#H063<YS#%<H21KA%&966
MJR%60,K*U)&ROYW?PUR<?QBPG860W?L/?_R)ZBZ![1SV,QFTMU;[Z[Z%JODA
MMW#YKK#:7<G;V&V_2;4VADMUU>82DQLE:M+]VQ61HX$D7V=W&V,O,VZ<LV<A
MEGMKIK82%?#CEG5-9@C9CI:8*5+(&-"Z*3J-`4R7#0;=^\KB(K%6X.E>]Q!;
MSR0-<,BY6&L;MJ(PJN<JNHBGA/YNWPJSG<^9Z3AW5V#CLGA]T=U[17L7/=3;
M]P?26<R?QQVGG-W]ZR[5[?R>&IMD;HH.K:3;E72Y>6AJIOMJ^+PV)96));W$
M-QM<^\!]%E'8M>=X*NUJLT4"SI&1K>.6295A95/B9T^55]Q;RV]_#MFG7>/<
M06X"=P$\Z-(D+..Q9!&NN12P**03P:BM^)7\SKXK_-F3L;']%9;?9W%USMJE
MWS/MGLKKC=_5N9W7UYEC60[<[,V12;PQ=!)N?KK<E7020TF5I@\1<`,JEE#>
MW%[C;^7]TW][5M-HK>+$Q"2QR")IEBE0U,;.JL!4$51QQ6G5+4176[6>UK+4
M7#4CE4%HI`)%C=HW^%]!="P!!`=#P;J#U]_,GZ=R7\OCKC^89W#C,IU'U]O_
M`&I@\['LNA&2[+W;_']T[G?9^U-@[5H-LX*GS&^MX[JW"]/1XZCHL>L]54U*
M(J#EO:[>8?W1>6%B!)<75RMMX21HS2.]S`DX1$6I)168L>`2-Y#I4&E;%6OO
MWJP*1P6<MT)'=@J*EK-)"TC,:!0Q0$#CJ=4%32H69S^=1\+L!UML[L.JHOD;
M493>?8G8O44/3./^-';U9\A=M]J=6;/I>P-X=?[TZ23;8WYM?<5%LNNAR:+4
MTBP244HF$HC#,$ES+#:FS+3H\,]I-<K(A#QK#;2)%=-(ZU$?TS/^N'TE`I8X
MTZK012SQW;F)HWAN+>$HX*.[W:NUJ8D.9$N`C>$R5#D:1W!@`^^1O\]?X@]+
M]1[:[(Z]QO9O?>5WST'LGY&[6P6QNN]_';>%ZZ[(W*NT]A9#N/L2@VAN'`=(
M_P![\_!6T6/.=2(3UM!+"=)TL5XL;G^L4/+C)28[A9VCR_Z"LEX8VC59#19)
M3!(LZPJ=;(4':7'3$,]M+M0WAY2MLT-Y(JE6\739*_C,T7QK$LJB%I2-*L2:
M,%;HQ\'\U/XBS?).;XN?QSL4;TIMZ575$_8"]3;_`'Z!'>-!MF7>%=T-#WO_
M``->N)NXJ7;\#SG""M%0=)C%Y?V_:""6.Z@W"Z@),$$=S(A8%#<QV=1<O:JU
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M6,D)Q6X-W92NHJ`_=AVI\>*IAIJ$C5-8M]:%.I0K[7]>E"36![BV@AK@:6E2
MX$],Z$T*:NS"-R\K:22QD:C'N"6;^5)3;7-Q+^4+6Y@;AJDUE>Q5:1UW9\W^
MDME]EYCK;.KOF&/;V>79.<[&AV;D9NJ<7V9-L_\`O[1]6U>]@ZTB[\R&U7BJ
M(:98VIS+40TS3K52I`S+7<"6MS>RL4MT2=E+`UF%JKM<>"`"9#"L4I;`KX4H
M368W`?:WE6>WM@-4S^#J`SX0N'$<#2_P+*[*%.::T+Z5=20OVK_,W^.6\=OS
M9C$8CN2'+U^,ZESNP=@YCJW-83L+MW;_`'E_&?\`1?G>L=L92:EGSN-W+_=K
M)DFH>CDHDQU1)5I!&@=C&6UGB<PF,M<+=-`Z+W-&Z0"Y8R4J%1;<^*6J0!V&
MDE$*=FCCE>.655B$;N)#7PVT3BU94:G<_P!0R1!0*LTB,M4;4$YL/^:+TUN7
M8F+WMN?8O:VTEER?9U1O/'4VS,UN)^G.O.N^ZMX]*0]E]SRQX_%S[%PF<S>S
M*N=J8P5-7214]4S))3TLM3[H(UT[6QF0)<6UG(9":0I+?1J\%OXIH#(^L`&@
M`JK2^$&6MKA9K>\W>S-NYFMKJ:)4`K+*MND3S2I&*G3&)D!`+%B:1ZVJ%&GK
M+YT]']L]O/TWM>#L.GS-1GNVMI[<W7G]B9?"]?;WW7T;FQ@^T=N[+W75?Y/G
M:_;$CBH,BQI25=)JDIIIO'*$U:PRW=HMVD95#;"X"L-+F'QOIS)I.0$G(B93
M1PQ';I[NM7>FSDAC=@X=XTU)W*KS6WUD2LPP#);UD6E1@@D-CI#_`"Z^;Z_&
M3M3ISJM:'I&AJ.V=F]I;R3>7?O?%9T7LO%Q=95VPJ&7!4.1Q_5G:%5G,_FVW
MRLL<7AI4BAI)&+,6`".WG^HO]SL@47Z:TBGJ6[G\69H=*+3BFG6Q)^$\.E3V
MVC;H;_O.N[$%`N%K#+-J9JX'Z6E10U)XBF9T7\PCIK%[YV]UANZFW$FZ*E^E
M<5O+>FQL%G]Y]";-W/W_`(1,KU502=PU6&VS2Y3#[XJ":;'5ZX^(%WB:KBHQ
M/%J72)$L][&KLD4,]S#64"-C+:6PO+B/35J-';?JG.FG:&+]O24I,EA:[@56
M2*:%)AX1,E()+DVJ2D@"BF6B^O%@&168(U_YG/3.5R]%MS9^S.TZ_.9:7J;-
M[;?>6S,UU]MS>W57;'>>U.BL5VQL?<N6H*RES^WH\]NE*N"F:.GK:FEC5VCA
MCGAE:]I:37,]I`\;1L\\<4BL")83-:W5U$6CXG6EJXH#56[6HZL@]=-':V]S
M<"9)8UM;R6-HR&CD:Q1'GC#@T!4NJZJ%374FM:$O69_F9?';;&;["VSNS!]U
M[5W-U]2;,R;;7SG4NX8=T[NPW8/:F+Z8VEEMH[7IC5[@FBRV_P#.T%,*;(4V
M.KXX*V&I>G6G8RJEM-=ZMI]-$S7$T\$*QXUB6YAGGA1LZ59DMIM0+5C9=$FA
MB`5%S;/:7+07#JJ""ZE$E?TV2S5&N"K<6"JZE2`5E']DS])7L[^:7TIL;I[=
MO96W=@]Q[[W;LW:'=6Z=S]/X[8V1I-][!'157-A=YKVK2PKE3L?$4^Z!!0+7
M1QY)93/YJ>.HACD9-@%WL1"0]O/],1+D1J+JX:VC#,0*.9(YP$-#^BY)5*.;
M6=J;N[>R9_#N1*R!".]RD*7!:->#)X4L+:Z@?K1CXFT]&[ZE[RINRMV;_P!B
MY#;[[7W3LC&[`W9%1?Q+^+4N>V!V?@9\KM#=5#6?P_&Z3)D\1E<95TVA_MZS
M&.1))')$[*9K?POK0'J]M>S6L@I2DD81U(SE)898W5L=_BQ9,3$E-I>"ZMMI
MN?"9$O+&*Y2O"CU$D=?-H9!1AQT/#(0OBA0/7M-TLZ][]U[KWOW7NO>_=>Z_
M_]+;8^&*))\?J&.1$DCE[+[\66.1%>.1)>[-_+)&Z."KQNI(((((-C[!/,P!
MWF[!X:4_XXO1QLI(V^`@YU-_Q\]&BHZ.CQU-#18ZCI:"BIP1!245/%2TT()U
M'Q00*D:%FY)`N3[(%544(BA4'``4`_(=&S.[L7=RSGS)J?V]2223<DD_U)N?
M]O[MU7KWOW7NHLM%1355+734=)-6T`F%#62T\,E51"H4)4"DJ'0RTXG10'T$
M:@.?=2JEE<J"ZUH:9%>-#Y5ZV&8*R!B$/$5P:<*CSIUSAIJ:G>IDIZ:G@DK)
M_N:R2&&.)ZNI\<</W%2R*K3S^&)4UM=M*@7L![V%4%B%`)-3\SZGU/7BS,%#
M,2`*#Y#T'IUG][ZUT%6[M]9G!;D?!4>!H,I0-MR*MF>JRDV-J9*K)5-;21-%
M(E-5(<?3)1NLZA1.SN"AL""'=WW[]TW4<#VA>-HBU0:&M:4^SU\_3HZV_:DO
MK9IOJ-$@DIPJ*``_+.<>7KU@Z5Q46.V<\A#R9&?+5]#D:UB/'5K@9FQ>/6B7
M2K0XVDHXQ'&C7?R>1F+,Q/NW+,4*;5'+%&5,CLS5-:D$C!]`!05SUK?I9'W!
MD9P4113Y5%37YDY/Y=1^TZ/PY#:N=55"2/7[8K9`;,171C)XD/<:3&E90S*O
M.H/-87U'V7<XVVJVM;L#*.5/V-P_*H_GTJY>FH]S;$_$`P^U<'^1_ET&61=(
MHJ.:9UBIZ?-;=J:F9[^."EI\_C9JF>:P)$,,",SG\*"3Q[!FW,J;A8L[`()D
MJ3P'<.A'.&:WN%4$L8W``XUTGAT:+-XBBW#C<GA,@C2466@EI)_&X655E(:*
M>"3D)/!*%DC;\.H/N8)X([F*:WF6L3@@CY'_`%8ZCR&9[>6*>,TD0@C\O]6>
MB/X#<+U&\LICI(:I6:ISN"FKJFG^SI]Q2[.J_L:;=&-@=F9%JX1+3SQ7!#QJ
MPN@O[AN]M6L[EX\F'4P5B*:M!I6G\CU)<;++:QR5`>BL5!KIUBND_P"$=*G<
M,D<<VV'8J"-U8U-0*M*@J:3)4X58;EG6I=A&Q"G2C%^`I(2M^'[>MQ@D2_Z0
M_P"3J3N:AJ,GMW-T%'''+65>-J8J-9=.G[HKJ@=&<A4GCD4-$Q*Z9`IN/J/,
M"58#CUJ)@LD;-\(.>O8'/8S/BI@QDM9//C#2TM?%54572U,-3+3"412)4QHT
MDX`(DTEK.#R>"?*P:M/+KTJ&$!I*!3YU%*=/GNW5.O>_=>Z#2?(U&2S^Y*?$
M5STE=C*C'X[(9*.*DEI-N[?Q<8R61GK15ZXVK,A6U,JI'H+>.'5=4]9:J2S!
M>(_D.E.D)'$7%5()`]2<"GV#^?2OZ]VSEMR_QA\-N&FFP=7)4YIMST&WTEHF
MJZJEI88,=@Z=ZZ.@R%=5M$]5/(CFGB>RD:I2`(=DV&7<S+)*S1V@%0P7XCZ+
M7!]2>%<=%6Z[I#8^$OA!KCAI+<`/-J`D>@'$_ET&/6>4R]!!DX=U)3X=Z_.9
MS(U7\>^XV_GSEYJ]*,J=M5M/3K0T%;'2&H\@8(SR^C4IO[*9K=K=VC,<@()K
MJ4J>/'[#_JKT9R,DP1XG5NT4TD,*4KQ'F.'^;H4YMP8&GI(Z^;-XE**:HCI(
M*K^(4LD-35S$+!1TK12.:JKG8@1Q1ZI')LH)]L^@'$F@^9]!TT$<DC0:@5/R
M'F3Z`=/5-C=TY"18J#:.:A1H7J&R&X$AV]B8(8T$CO45%7)+6(WB8,J+3LS"
MXX*L`>0<N[O.P4VOAK2NIR`!_A/\NBZ7=-OB!)N@S5I1*L3]GE^=>@EJJ7(9
MG/Y2;&97:&ZHGI8:>"HBQ>=RF'P25-/2,AI,CF108BIBJXX9)95IZ26H+LBZ
MBA)5%<V5G;,:[BL[TX1@D?+O;`X&N">`'KTOAGE:-:VCPBN=1`)_VJU;TI4@
M<>A0IHY8J:FBGDBFGBIX8YI8(!3022QQJCO#3!G%/$S"ZI<Z1Q?V@Z\<DD=9
M_?NO=>]^Z]TR9/;^-R]31UE8:]*BA2>*%Z')UV-+1U&DLDYH9H'G6-U#1@FR
M/S[J5!()ZNDC("!2A]0#_AZ:<-N&CA?.8C)9BFGGVQ5)3S9">:)&EH9X?-1_
M?2`K'_%X%5XYT`#N4$FGU^]*V2I.1_J_;U9T-$=4(##A_A_+S'2ZI<+NW(8^
M3,XW;4]1C$8>&&IJEQN>R<-AKJ\7AJ^"`-3`GT"IFII)@"46UM0AAY;W6>U-
MRL04^2,:.1ZT.!\@2">BF3=MOBG$#S9\V`J@/H2/YT!`Z;W3+4&1.(SN-AQF
M3_A=+F!3T^3@RH2CJZB>FC2JD@AA%+5B:G8>,Z@P!*L0I]H-PVVYVR2**Z*:
MW75136@X9QC/2FVNH+M'DMRQ16TU(I4TKCU'6?V@Z4=>]^Z]TE<KN6DIZZEP
ME+FL%A\GD6KH*?+;BKI,9AZ"IH8HY9?\I>AJXLA51:[&&(-I86<JVE656]HU
MPRJ\J11L&(:0E5.GX@&H<_ZN/6F;PU,@B>32154`9L\*BHH/G_DZ$O\`EQ3"
MI^.^6J%G@JEG[W^0LHJJ:K^_IJD-V]NP^>GKO'%]Y!+^I)-*ZU(-A]/>6%@%
M7:]G5*:19PTH=0IH'!C2H]#3/4%S5^LW+4#J^IEXC2?C/$>1]1Y='U]J>J]4
M][B_E#;:SGR%SW95-\H>\\+\?-Z_*+:'S0W_`/#RCQG64_6&[?DALO)8+<.+
MWF^^JS9LW;>&P57NO:N+R=9A*/,18^IJ:2SKH?2MME>39VVTF0SI8/=-9AZ?
MXL;M9@X72!XBQFXG:%9-0C+]O"I]O+/NZ7Z^(87O+2WM;DH36:WMPJ+'DD1B
M2)%CE,>DNNJO'&;<'\GSJO</7.&ZYJ.W^Q8*'#[8_F*[83)08S:OWM5!_,9J
MLS5;^K)XVQ_VXJ.O&S+KAM("S!%^Z\G/M*MNJ[=!MH-(H]GL-O!\]%A=P7B2
M>FN1X`K^6EB0*T/1G#NDD._2[\L2^.V^P[GISI$D-K):K%ZZ"LA8GXM0`!IC
MI>X_^57TG1?)SXV?)V3=^]ZO-_'3J39/7*[&D.(39'96ZNKMC;DZXZN[?WI0
MI1?=?W^V#L_>^<HZ%Z:2*GT9`:D)@B(-)+QY=YYNW>1`?WMXS&,Y6"2Y"1W4
MD5<AY[:*.V<\?#3!J3T1M`6V;E[9?%(AL-"E@`&FBB8300RTH"D-R#<H,TE-
M>`'1-.H/^$[7Q7Z3WS\E=T[+WUF8,/WYU=WUU?MS$2]0]!)N[J2B^0N.S.+W
M?E<5W12]<T_<6]IL71[@JHL?!F\U4P1P,D,HECC5031V97E>\Y9><LLL,4`E
M`",((9%=8RL82-V(CB5Y&4E]!<C6Q8&YOB>:-NYG6%1);W?U7A'N1IZ?$"VI
MXTU%V5$("ZJ`Z10C=\N?Y+W57R^A^'6/W;W-O3:V*^(FU]E;1Q,F"ZUZ.RN\
M]T8S957M*LI:[#]I[HZ\S/9O4NX,F^TXEJ*O;.6H?2]XXT==;')O&?G"\YO=
M/\8FF$GAJS1@%9'E"^)&4E:(LU'C+D.FI#VNP)3#;^!RDG*<;DVZQL@=@&P\
M7@D^&U8]87*N%#*U#6H72JJ;^57MG8>_MB=R[`[C[0CW9UC\J_EA\JQMFGQ/
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M[$QM$I`\NLN+_DV[2JLCM3?79_R<[I[A[NI>T>Y>V^RNY-VX7KC$YGM#<?;7
MQBS_`,4:/'3[5V;MC;FRME[9Z_ZYS*28NBQ%#`C5L!DG,GE<>T=Q:VK[?>[;
M:0"WMKC;[VVDTU)>2_GMII[EBU29:VL4:J*(L:JH7MJ5]I>W,$DD]Q+XT_U>
MURJ2`-$6TSO/;6XT@:E+R2&21JR,7)U84`"*K_A.G\5Y^YOC7W)_?W,5M?T3
MUE\<^L]UX;=W3W0/8Z]L4WQEVWB=J;&SW]XNQNNMT[GZIR^4P^%ITRAVO54"
M5+Q)(H25%D!M%N#Q<S;US&(E)O+M[KPOA\.X=`K.)4TRLM5C<1L]%=6*E1(P
MZ+KZ#Z[:XMNDE8.HF0O@ZHI9Y)_#*-6.J^+)&)-.HQE0P)4'H"^L_P"51\IL
MW\Z\W@NS]KY#;/\`+DVCOCYQ[NV9MO,?(#8>_8*_'_,C9&Z-H;PP?7.U-I]1
M[)[+VG)N',[]R&9>;=.=S(P4:-14(L_ED)]KMDGY9O=IWV1RXV,[9`M0SI$+
MVVGA`956'3!':BCM&9I2T8D)5&7I?N5TT&]6U[L*!4DW2"_N#0+$\T5M(DK-
M'4N7G>8JRA_"`$DHTNZ]'^_EL?R:>D?Y:LW;%7U]O23?.1[+VOC=AT>8K.F.
M@NM,_MS9&+:ID@Q&0W'U)UUL_<'8&1J)I(9*C(9VJK)YYH!(P\CNY47S2;CR
MW?;!=,/$N@WC2H`FLF)HP5A6D2!=<C*%6@+Z1110I+>*.UWJTW>$'1;G]*-C
MKTU<.:R-61B0J+EN"U()-0'?7_\`)=W#MGXYS_%/>7\P+Y&=A=*;1I=E9/X[
M8!^O?C[L_,?''LCK+L.B[+ZY[)V?NS:_6]+N+=^4VSGZ(1M0[CJ,ICZVED>.
M>)@5*NS7-Y*^VWXNBN_V<MN\%S12T8A@>U9/#IX3I-;.89-2$A:E2');JS1V
M[3;K&UNIV>^6Y$]L:E)#<3+<:@_]HC0SJ)8BC`!Z$@@``<NHOY5>U^NM[=9=
MN;R^0G;?<_=NU.VN[^[.Q^T]\8O8.,R?;^^^[.D:3H*H?);>V9MO;NU-E;?V
M5L/&4D>)QV%HZ6"-X"9-?D;VEN;:UDVV[VFTMQ;V<VV7EHP4EB7O[BWN;FY+
M.23,\ENB@801T6G;4NQSW!:6:ZE\:Y:\L)@Q"KICVY)DMH`%`!0"=RSM61F)
M);@`6+=O\A'8V5ZWVAU=L3Y@_(;JC:Z?&_K;XP]U4.T\+U3D(/D!L'IW?.>W
M_P!:U&[1N?9N:K-I9?!YG<U;#4R[?GQS9&AE%/,2BG4:0[A/#O*;G\5H+ZPO
M?ISB,W>WPV]O%*6%)"'BMH@\18QEE#!01FMT1="YE`\/<)?WC&9U_M!;[E+-
M/-;BM1I22>1HWIK76XKWX,1#_*1V73_(BM[5B^1?>"]'5G?V1^6Q^(OCV%_H
MGC^4>4V]-@*GM7^](VH.TY<8LDYR,>VVS/\`!$R@%1XC8)[*;>`0V;VDCF7P
M;>]ALF:E;)+\3"?P](`D(%S<B(RZS&L[@$\2W,HD*E%6/QC9F\T@?XX;(PF%
MGK7PV)MK8RM%H:3P5!(!IT+OQ=_ES["^+>Z^@=V;;[#WCN>IZ`^(^2^(F$I,
MY0X*FI]P;7R?8^%[(FW?ESCJ2&2'<:Y'"I3B.`I2F&1B5U6/LW?<'<;H#$H6
MZ@VZ(C^%=NBGBC*_\U!.Q>O`J--,]6N_\<-N7P8]SW&]%/-]Q=7D3_2QE0$/
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M^M6X$YK3]:ANKEXM8&AIB3K"1A=03SQ2P7)<&Y;Z87!H`)UM)(GA&G(C/Z$"
M2,M6=(E4%.XEGJ_Y:FTX:_KS=6V>W-Z[=[#Z@Z>^./5W5^[VPVW<K'M[)?&Z
MIW__``'>&3P-1!#0[A;>&)['R-!F,=*\=,],X:G:"95E4UDOKCZG<;R!A'/<
MWSW#8#`++:BSEA`/X7B&H-76D@5@2`59(]O#-#:6UPI>"))@`#0EY+N*\22M
M#0Q2PJ``-+QLZ,.ZH8*'^6/'C]J9#:D/R5[-FA[)PV^]H_(W*U>V-C2Y;NO9
M>_>W]^]Q9'$P2P8REINN<O19+LW-8J#(XR)W&(JPAB-1%#41I2(&CL[%X-6S
MQ)9_HDGOEL8XXHI&D%&I(L48N(Q19`H"^'5BRJ:>YEO;S=1*$W:228I(JBD4
M<Z1J\2HVI2$\(-`6KX;/)4.K:0*^"^#.*Z^KMD[GZXWWDZ3=75F\OE;V#U]!
MG\;CZK;<&X?E!-D:N?'YNGI84KJC;^Q:BM5:-8G6>HBCM,[$D^[1W-Y!816L
M4BM<+MOT9=A\2M?)?/*0*#664H`*(`:TQTV\<$K%64I!]5;3@+FAM=N?;XTJ
M>*E&#L3W:A0&G2X[G^-G8/8W:'4?=77_`'D_4?8_6.P.P>O:JH3K?;W8&WMR
M8CLFNV%ELT\F(S^1QU1C*JBRFP:=Z:2*I/[<KI(K<$-*BV^Y;Q>6;$6]W!'"
M4:A(2&9YHSJ%.ZKT;!!`P`<]6$C2[9965V@,\-P)]2D@>)X,D+"GFI$A(X$$
M#YCI!Y[X(8K>D^]LUV!V;G=U[H[&W_\`%GLK>E938#";;Q&8W!\7*C%U6,I*
M7$THR!Q&(W[)C`N1199GIDD;[=A8>Z>%%'$8XX`T?U5[/H9B`S7NV+MLD98`
ME4"`R*0"P9J9`'3QN9Y;66UEFHSV26OB*HU(D=])?(ZJ3I+JS^'1CI95!-"3
MT3KH[X"=W;N[`_B_?.7WCL#8?5W6O5O4G4&VY=R]9;JRV-PO5/R%VOW=@8L'
MN#96-C?.X%*+8N.Q39G.4^+SU9"4=\=32P/+4+H+F22WFN[Z5WW6::UD9L(Y
M,-E?6TA?P_TT9FOV=&A9JNCN?#0QQJBECCB>WV^QM8TVB"'<8U6I=2+[P(QI
MUT<HD<!/AR*`@=(P\E'?I=;!_D_[#V3GJ3/2]S;CKZC'T6P\/$V,ZZZZVWD<
M]C>O._MA?(3$9?L+<E!C)]S]A=AYC=&QEI<KG<C6,]52U3>&GIG2[4L;A[-]
MMD*H3;W%K/I5?#B\2TCNXD\.-<1HZ7DA=:L2]&U4`4/7_P#CXNE=GI(E^@9C
MKDIN"*DNIVR_AZ$\$85`I!!U$]+_`+!_ECXK<B]R5.PN_NPNJL]W\/D!@>T<
M_AMN;/W!597KOY!YR+<N;VCB:3<%%44&$R6U,S&[8K+K')4)!55$<\<VN-HD
M]O6&#;K,L6L81;ZT-!XC6EU<74#%@*K0W4L3J,/&1\+J&Z417`BW0[RL0.X(
MX,9/PH/I;6U<%<%]7TD,RDL"DJG3VDJ3/=-],[@VOW1VUVIN6**BI\ALOJGI
M'KG'I5T]95S=>=34VX\D=UYB2D=H*?)[NW3O:M*TOZZ:CH8"UI)715(FU)O$
M[*!=[AN#7,H%:(J((8(P3Q(_6F+"F+A8S4Q:B6I:BWCV.RCE,EKM]@($8BC.
M\A5YV;Y4C@C4?Q1RO4K(H4U7M/TIZ][]U[KWOW7NO>_=>Z__T]MKX7_\R!QO
M_B3.^/\`W]N_?8*YE_Y+-W]B?\<7HWV7_DG0_P"F?_CYZ-3[(>C7KWOW7NO>
M_=>Z][]U[KWOW7NNKJ`6=@B*"SNWZ4106=V_VE%!)_P'OW7O\/12,CN-<[69
MW<U$\=37;A:F_NUCED-14RXQ3_!MK1Q0EO*T.7K`:BRJL:O4,/PQ]Q-NMT^[
M;K(;<%M3!(QQJ!@$?::MU(-E;BPLHHI<!`6<\,GN:OV#'Y=&;VU@8-LX2APT
M,LU0:=9)JNIJ)%DEJLC62O5Y*I8HJ1JLU;,Y54541;`"P]RA9VD5C;0VD-="
M"F<FO$G\S7H"W5P]W<2W$E-3'R\@,`?LZY[CP=/N3!Y+!U4C01U\`2.J1%>6
MBJX9$J:&OA5B`9J*LA211<7*VOS[W=VT=Y:SVLOP2*1]GH?M!R.M6T[VMQ#<
M)\2&M/7U!^1&.BYU-)5T]7F,!G(J22MQ[K15YHS)]AD*7(4:5%/64R2WF@AK
M:2?U1.6:*0,NI@`QB3<;"3;;N2TE8,0`01Y@\#\O\_0^M;E+J"*YB!"GR/$$
M'(^=/7S'0@;!WGE9,AC=D9*B&2>DQ#/%GZ%ZAI8,?1*T%!-N2EE@^WI9:L0^
M!)HIV\\Z7\:W)`ZY?WR?<-%G-:L71,R#X<8&H>1;\ZGTZ#6[[7%;*]Y%,`K/
M\!XU/'2?,#C2F!Y]1.V^NFR:#L+9^-@;L3;-//.L$-,C2[WPJ4WCK-I5ANI-
M7/3Q@T$XL\-2JJ24=A[?Y@V5=RMVG@3_`'81Y6@^,`?`?M_"?(_+JNR[H;24
M6MPY^@D-#4_`2<./D#\0\Q\^BYX@4M-N;`9?*Y&GRN=W=0)KI:FFI?/MV6&B
MK)Z$XZHIJ2+[2*2+RT4B3L))9`!&6*L#%@&EQK/>>(/$'_)Z=#ES6*14!$2'
MB.#<./KZBG0M1213*DL4D<T,G*RPR)+$ZW()22,LC@$$<$\CV[TD((J",]%D
M[.Z\W9V9L/M+9=%OG>VPZ[=E90TU?NO8-9#2[SV;4XNNCJHJO"XJ9*6.MILY
M@(J593!51S34UP-4@-V2&(<`G/IY?ZAU(OMKSI8>WO._+?.%_P`H[?OMI8EV
M-E?*6M;@/&R4DH&H8V;6E58!P*BG0X[8K<51X/%87^\LV9J]OX/'X^OR6?D^
MTW!7_P`(H*>DJ<UG*:KBHYHZNM:+SSR&-4+N2.#[<4BE*\.@9NUS^\-UW/<H
M]NBM8KFYEE6&$'PH1([.(HLFD<8.A`22%`ZFTNZ=N5D\5-3YBD:><@01R>>F
M\[-8HD#U4,$<TD@(**I+.IU*"O/OVI>%>D)AD`)*&G4&7KC+[XRF9I-OQP4>
M-DIUBW'DZC+Y6A2DS^1AA2DR&/QM.7Q^5K<?B(B]3#(@,GEA!:Q:QQMFPW6[
M!Y(G"0*P!8D^?'2!Q('\R.DEUN\&W+&)@6F()4``X'DQX@$\#\CT</'T4.,Q
M^/QE-?[7&T-+04P*HA\-)`D",R1*L2NX34VD`:B?<L(H1$C7X5``_+'4>NYD
M=Y&^)B2?SZ!_MB#=)4ULU>9-A-20XS*T&*$=)EZ5Z]_LY:K,54RS293`3O,D
M/AIFAD@,FIDE'J0-\R?O9+=I[.X`LU7O4`:J'!))K5?*@H?MZ/-C^@:4130D
MWA-5))*XR``*4;SJ:@T\NB[+AL%U]V7LO?"[8HJ[:M-#5XG,8V""AGDV_D5B
MDJ-N;HP&-KIX8HZNAJT9&:GL\22/+P-;>P9LM]%97\$ES&7@"D4TZBOF"!Q[
M3Z<*D]"B^BFO;"Y@CFTW!(())`8<&5C\QZ\:`=#Y5_(;924^:CIZ'<51G,?3
MAJ3#-B7JAE:BJ&FC@BR&+?)XY!("9)!)(I6.-QR]E(V/-.U&&256?6%)56%"
M],8.1Q]?GT%QRYN'B1(VCPR15@?A]:@T./D/3H-\!BJ_&0U39+(4M95U]0*N
M>#&8V+#8.@E8$/#A\7'),:.F86U!G)9EU6%[>XWGG:XE:9XT5FXA%TK^S_+T
M+0J(JHFHJN*L=3'[3T_^VNO=>]^Z]U[W[KW6&1Y5>EAIJ2HKZRNK*?'T5%2^
M`3U-74EO'&KU,T%/$H2-F9G=5"J?S8>WK>WENIX[>!=4SF@%0*GCQ..J22)%
M&\LKZ8U%2<F@_+/2]V+UH:+-5V\-TXK$19:JIXZ3&XJ,0Y`4,(:"67(Y:5HC
M15&XWDIU1980X@@&@2,23[D+8-@.W>)<W@5KIP`!Q"CCQI\5?,>7#H+;MO'U
M21VUJ[BW4U)X%CZ#ST_(\3DCH3]P;CQ6VJ2.OS,]0D=35+1TL5-25-?6UM8\
M<DXIZ6EIDDEFE$,+R,39512S$`>S^[O+:QA-Q=RZ8JTKDDD^0`R3T3VUK/=R
M>#;I5P*\0`!ZDG@.B][@W/%N7>TT]-0Y6&@I]NT=+CJFLQ<]`K`5<E3D5K&F
M%_N6JI4$"AF7Q(QX)/N..8MQ@W*Z@DMG#0(E!@AJDU-01PX4\N/0RVFSDLK5
MTFH)F>IH012E!2G\^L;,%5F8V5%9V)^@5068\<\`>P_T9=)J"MR^?2&7%J<+
MAZA8Y8LM5PQS9>NIY`'27&8R0M!0131D%)JK5)8@B$?7W6I;A@=.E4CPW<_I
MY#[3Y_E^WJ/B*',)F>I*.H&,W/M[*T]+%'M_<4,E2:^/.;WRK[BJX:BF"0R9
MW#214E2TDD0)6GLS!69?8QM_J8GY;M3&LUC-!32PJ*EBS-Z:EP?RZ)9C`\>^
M3AVBNHY*ZE-"*(`HS^%NX?GT./P/5$Z>WJD858U^1WR55%151`B]T;P"A44!
M54`<`<#WDHO^X]C_`,\\?_'!U"\/Q7-?]_/_`,>/1U/?NGNJ1MU_SSOCGU#D
M>V<5WCUQW%@\AU]\C?E+TC@*#J/8VY^],AN/:OQ,PVQ-Q]F=MYZBVK@:&?9.
MW,3M_?"U]8M0*B"AHZ.:1ZI@`/;=O/;S;?LU[)+X8N;+ZJ4L#X=O$=QFVU6D
MD`(TF6($G2#WA55FIJ6WEA<6NZ-ML:>(2MJ(Z4URRW-D+T0I'4LS!3H6E=;"
MI""M%Y2?SO/A-E-BY+?6`H/D=N/[3NW9W0F(V-A?C?VA/VIO/>79G6N2[:ZI
MR.R>LJC#4V\MQ;3[3V-C&K,#7Q4@%7'+&S)&CZQ>031?0(]K)]3<27<8C`U2
M))9*LEQ'*JD^&R1.)>^@T5-013I#&\4D5[<"9!:PVUO<>(31)(KF<VT3Q,<.
M/J`833A(I`K2O3?N[^>Q_+\V9L;IW?F3W3VI5TO;F%W1N>MVWA^H-XY+>W2^
MUMA;KJ-B]B;D[_VK#2C)]5XOK[>5#48W*BL5ZB&HII?'%*BZ_=@8FOH+2&XC
MDMY(8)1<*:VVBY)6`F:E*RE9*+34OAR:PM!6VB?P+B0VLHNH[F6W\`J1<-+"
MJM(JQ&C'2KQFN`PECTDU-'3O3^<M\:^IMR=X;'V[MOMC?N<Z"VIU9O3L'?>-
MZRWI-T#M[!]QP[(R77;YGN3`X7<.)HZ_>6&WO!+BZ1*>:JJY8I%\:QH\JO[?
M:SW^X#;_``S$Z[RNVOXG;_C1DCC>*.N)'3Q%8@$*%(9F4$'JR>#(M@T4PE%U
MMDM_'X?>?IXXKF022#!C1C:R)5LZAI4,W;UE^07\XCHGHS=7RAZEGZW[L'=_
MQV^.W=7R(V[MGL3K?=G577O>VW^CMK4VYMUTW5':6<PM?0;@H(TKH4_B4%#-
M2LFN2#[A4`8N6=IK.\N[>(GZ:ZMHI48Z)$2YO$LTE*'.C6X91AF4J:`,6"W;
MK#ZS<^6]OGET0[FZ)',BF2(/)`9PA84&O0K`J2"'1T-&4CI=?('Y[]J;._V6
M3KOXS?&$?(_Y)_)KK#+=TX?K#,]O8CIS8NQNK]J8/:>0W=N/>/:V5VGNOPS0
MYK>^-Q6+I:?#32Y*KF8L::*-G"[<+>YM=^YBV6UA\:+:HFDGDKIHIG:W@5$[
MBTL[I(56H55C<LX[0Q1M]U;7.R;'O%W)X+;BRI!&.XE_`%Q*6/;2*&,J'<`M
MKDB58VU'2A=S_P`X7IOIK8_4%;\FND?DKTYW#OGK')=O]K]%X#J/<_=.Z/C)
MUEM_<U;L_<':W>>7ZSH,MB]G]1T^;QTK4N<J!$U51VF^UC(=$JTFWR;@+6TO
M@;(1VK/<2*88H&O%!A@N7:JPW!)96B+$IH8L0M"7(XMP%H);BP/US3SQ1PQ,
M)I+@V_\`:/;*M'FBH5*OI75K4*":T8E_F][.3Y#?Z'JSKC&TFQ$^6.\OCG4=
MR-V1!)@J?9^T/@[0_->;N1L:NT]#8JKP56<7]@M8=$:?>?<M?[8;A5%MKBYW
M-C:K#9[M/+J%='[KOXK%DH,DRF76*"JD:`KZ@W2J6$/$LNV-]4)(-GDCTX$G
M[WGFA4`DX$(B#DFFK400FDDN6P_YY/P#[!ZT[J[2QFZ>T<1A>E,!M;=]3@]R
M]0[RP^]>S]F]@;II-C=:[MZ5VE)1RY?LK"=C[TR%-BL.:1%GGK*F)9(HE<-[
MHT=T+.WN!8S-=27<5M].J$W*W$R-)%$T0R&9$E;B0HBD+$:<LIX3WDEJ;F-8
M%AFE\=FTV[1V_P#;LLIP1'5"1ACXB:0Q;J3G_P"=G\+-L]7Y/LC,4?R`H\KC
MNYZKX^KTQ5=#;XH._LAVQAM@;=[-W=M:CZER=-0[CCEV+M'<L,^8FJ5IX:5H
MI$#2'Q^2MRR0#;6CD6:*Z6Z=&B.M1%:3-;SS.1\$2S`1@M1BS*NFM0-1`R"]
M+J8C;K;ZA(-!+709X(U!RSNBM(`,:!JK0BHT;P_F)]7KU]\'.VNG,?'W!UI\
MX/D)U]T?M'=%-EJC:_\`=FCWS@=\9:?=-9C,AA*RMK*_;M?LB:@JL3*M%,M2
MSJTJ&(JRQ;.8<QVO+\Q4&6PN[I9%.I2EO;"ZCTT^)9T9=+5&D$$J35>FO&4[
M-N.[!6#VUQ;PO$P*NKS726KJX/PM$SDD4.K30&A#==_*[^9Y\7OASV/B^KNU
M3VWG=R#9M/V=V%4=3=.[[[4P/174E7FY=N4O;G>^;V?BLA1=:==SYBDJ(EKZ
MLEB*69_'XXRWLOLYXKV^FLDD")'+#%),_9;QS7']A"\S=BRRBC*I.%*LVE64
ME7/;7,%K!<BW>62996CBC&N>5(0#*\<2][)'4`L!EJJNI@0$E3?S</B)4_**
M/XGI)V\N\7[2/2LG9+=1;L;H"F[1J>MZ?MG;^RZCNJ&GEV6F=W=L69ZW&4XG
M,E1'3RLPC10[.6S+<Q;C*Q\%;5+UG\4&,G]VN5O@NH=QM@!)(!P1ESJ.GI/=
M.EJEC(K>,EPEDZF+]2B[@:6C,%RHF;M4GS!].@#V?_/9^*.]>Q]RT=+M[M':
M?Q_V=\:.S_DSE/D1V9UYO[K_``&Z]F=?=E;.ZUQ.5Z=V]G-H)4]O[.W]E-TN
MN+RV(JI&EJJ9:;[4O.C#T9<;;NVX7-M-%-;FP5+<H3=2R;BTX@C\`?J*T@B0
MQ`@^)XAKH"$E1-$$O[#;H9HY)9;B[C>0,/IXULXEDN)/'S&PA)9)14:"*@N"
M.A('\Z/XBP=9UO8&9VC\I=K[CQO;W7_2&1Z%W3\9^SL'\DJ3??;>V<UNWJ>%
M.E:S%KN[)8CLO"X&=\-64<=3#5/9"4.K3N>L+;?&H\6:YEN80L?>R3VD1FGA
ME49CD2$>+1J*8SJ#4!HG@99H[^=F\.W@MHKC7)V))!/.EM'+"QQ(C7#^"2IJ
M'!!`Q4Q>T_GQT]V=\3=K_+/JNBW/N#;O8&>H=@[%V/NG$56P-]5O:^2[#?J>
M#K3<V$SL+5>T]Q8OL&*6ARB31RFA6FGDTR".S/W5K-#<[-9PRPR2[BL+6[A_
MTI(YH3<++K"FB"!7E)TUTH0`6(!I!/#)%O,THDC3;S,LZLA#H\+>&8])IW/(
M4C0FBUD5F94JP7_7_P`HMN9_K[Y`]E;\Q\'7VU_COV;VYL'=^3;)5&?I9L7U
M#'3S9G=<"T^(HJU8JV%W:*C2":?T!5+NP7VC:>(;;8;DH=DN&F5$"EG+1WUQ
M91HH%=3RM"I51^*0("::BJBMYY=QN-M"KX\8@J:]OZMG;W;&I`HL8G*EC3M0
MN0H-`#M9_,@Z>QZXO#UO6?R&INT<YO#$[,PO1LO5Z#MO(U>X]@[I[,VMF4PJ
M[A;`TFU]R;1V5E98*^IR<$-/4T,M)5FFJU,/N[,JO)'4&6)+AI@"#X!M5ADG
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MZ;L3;?5N1SO2]/0559E=VTN-W?O#%I)!/3T-;)1U\-;#!+2/YO:2`M<26EM'
M&W[QF>W58"-,VF[;1;2,IH%29Z("S!HV9%F6(NM51@83SQ%U\&(7(:6OZ2O:
M1237$1;_`'Y''#*10:9/#?PF?0Q!G^B.^=I?(';.X=P;8Q&[MKY#9F^-P];[
MXV7O[#0X'>.S=[;9%%/DL%G*"CR&7QC2/CLI25D$U)655-/2U43I(;D*\T1%
MO9W2NK03HS*17_0Y9()%-0"&2:*1#Y56JDJ0Q3:Z7%U:NC+-$4J"*562*.:-
MQYZ7CD1A6A%2K`,I`(OU;_,B'8?:':>ULC3?';;6VNINQ?D+L_<&VU[XW7FO
MD148+X^UV[*/,;FHNHX.E*3;TDV8IMK&N2C.Y?V:*75YI)%T,@M+VW?ER'F2
M\8K:MM[7;",>(8E61HRLGPTIIJ2H8]R@*:X7W5E+'O<6Q6Y!NI)[:%#)^F)'
MN((9^RFJH`E*K6FHH2=(X"/MG^9;T9NS!FOQ.Q^^%W-EJ;JC*=>=99#K)L;V
M3VWMWNS&[CS'7.Z.OL!69J*EEP.7Q.S<S45$F6JL3+C(L54?>QTY\8D,9K:>
M">2U:(M=Q7$L,J+W&%X(4GE,A%5TK%(C54L2S"(`RD1](M<(D423HD+1:TD8
MD))^L;?3&:59S,`@%,AA*"8:R!OV;_,GZV[`H\YN;9G6/;FX]F8SKK;>]J44
M6UGQ^_GR>2[C[FZ:W-@MQ[/W-+M_%;#QVR\UTQ75%=E\WF*''QPR`2/&_C$S
M933;-=%@T1>VT,I!1HKJQ%\DK.Q4)^F50(>YW940%CIZ4&WD\86U"+I)KV*1
M".Y9;-[-&1`NHRES=@]HHJHSDZ`S*WT?\USXNY/#[0W)B<?V_EMK[CV3M7L3
M<.Z,=UQ4U&WNK=G[M[6W5TC29?LC*#)+3X]<=V=LROQU7%C3E)D2+[N-):+5
M4J_:VDMY=16L'&22SC5C55,FX0+<6:=P#*TT;@#4H"."LI3%4L[_`$UG=7<B
MG5"UZ'C6C2#]WZ#=L`I*E8UD5P0QUJ>S401TYY+^8309SN'"=0]/],[ZW\VY
M<!\CJ_:O8F:(VCUKOO<'QQ_@M#N3;6P-R0T6XFSTE9NC(5&),]3#0*M32-+3
MK5TVN:-##*DFV[INT@9+.UL(KRFD^+);R3K&'CCP3JB)FB!(+@Q!A&LR/TK:
M`+/M\`G1C-N"VCD$:89&MYYZ2,:4TF$(]*JI+]Q>)HR>'K#L3;G;G7.Q^T-H
M3S5&V.P-K83=V#DJ8_#5+CL[CX,A3PUD%V-/6TRS^.:,DF.5&4_3VMO+5K.Y
MEMV8-I(HP-592`RNI\U=2&4^8(/2"VF,\*N\31R@E71A1D=&*.C`THR.K*P]
M0>EU[3=/]>]^Z]U[W[KW7O?NO=>]^Z]U_]3;:^%__,@<;_XDSOC_`-_;OWV"
MN9?^2S=_8G_'%Z-]E_Y)T/\`IG_X^>C4^R'HUZ][]U[KWOW7NO>_=>Z][]U[
MKP)!!'!'(_UQ[]U[I(4FP-DX_)P9FAVQB:3*4U745U/6PPNLL%551M%-+$IE
M,48*.VE`HCC9BR*K$GVCCV^QBE$\=I&LP8M4"AU$4)^TCI6]_>R1F%[IS$5`
M()Q0&H'[>E?[6=).O>_=>Z!3M?$TE'4X3>*/4TL_W=+MS-3B55Q38>=*^HHY
M<I$8S:HBRACB@J2P\0E*'TO["/-ME$]HE^(R9T(6HX!236H\\TH?*O0BY?N9
M!+)9EAX3`L!YZA3A^62/.G2"^]JL+7T.>QM51T>5HG:EIQ7RB&ART%;838*N
M;4KO#7-&K1LMWAF59%!LRL"]NW&?;+I;F"A\F4\&7S!_R'R/0BN;6*\@>WE!
MTG((XJ1YC_+ZC'1C]N9ZCW+B*'-8\/&E2"LU)*RFJQV0IW\5;C*P+;15T-2I
M1A8:@`P]+#W+5I=17EO#=0-6-Q7[#Y@_,'!Z`-S;R6L\MO*.Y3^1'D1\B,CH
MG.\L/244/9<&)_B%;%E-XM%@$C>*DR<>:6HHZ<4M#4HT*I0X[-B;[5I&#+$'
MU'D'W%&^I`FZ;@MN6*F3-?XCQ`^0/"OSZD+:Y99+7;VGT@B//$C3FA/S(I7I
MK@PF[\%0923`T&"I*.KPLJ4>T\?6U=+_``?*"F,<5=254M+5TU17>)%$D<2P
M133^H7:[L4Z64'2!PX=+2\4C*)&:H;+$<1_J^W'2VVY38N##T4F(TO2UL$-:
MU46J))JZ>6&-9:NIEK)):N2=V2Q\C%DTZ>`+>[K2@(X=,2%RY#\0?V?LZGUN
M.Q^2\/\`$*"CKOMY!+!]Y30U'BD7@-&948J;?[`^]D`\17JJLRUTL17K%F88
MZZ@;'3TD.2.5J*3#TE#4R"**HK<G/'14J"8I*U.8FD\GD16>-4+*+CV]!`UU
M/#;)37(P45X5/^;CU4RB!7F)(5%+$CT&>AWZYVI7;/VX<;EJI:W+U63R&2R-
M4M4U;K:=T@HH35M347W!H\930PZQ#'JT7M<DF5]FV]MKL([61@TH9BQ%:$D_
M/Y4'0%W2]6_O&GC4K%I``.*`#/KQ-3Q/2\]FG1?TP[EV[1[IQ$N'KIZRFA>H
MHZR.HH)5BJ(*J@J$JJ24"6.6"=(YHP3%*CQO;D?0A+>VD5_;26LY81-QH:'&
M1_/UQTHM;J2SG2XB"EQ7B*C(H?\`BQGINV_L;;6W2M12T$=;ES]P9]P9.."K
MS=2:M1'4!ZPQ)X8'B'C6&)4B2/TA;$W:LMLL=O14MH%U`'N(!<UXU:E<^G#R
MZ<NMPN[PGQI3H-.T844X4'^7CUBS^Q,'G*>D2FC3;U?CW)Q^6PE%0P5--$_D
M\]%+`8!35F-J#*6>"0:==G4JX#>Z;AM-GN4"PS)IH<,H`9?LQP/F.'5K/<;J
MSD:16UJ1E6)(/SXU!'D>/Y=`C54>7PE>F%W#2Q4^1>G>IHZRDE$V,SE+`XBG
MJL<QM+!-"65IZ60>6$2*;NAU>XSW/:KK:IECG`,;5TL.!`_P-3)'0SM+VWO8
MS)`34893Q4G_``@^1''Y'KOV6]*NO>_=>Z][]U[ISV><<^^,8F:-8FA5;::Q
MPHV*J<^U)7FK;)5*OYX\E2T*-]C$5$+ZG;49`H`HY5%C]?6=C]9GPQ3MX'4:
M_P`5.`]*^?11O9N18MX('@?Z(:]U*B@`_AK\1X\/+HQW^O\`3\^Y(Z!?18M]
M1[QJ=Z8V3<"T5!1T=7FCMB:FIEFILC@=4'WM(D\=>[C+O2M"TIJ*>.2/U^)B
MFI3'O-#;@75;R!/I=9\)E)^5=0K0DCU&,D'H9;(+(0,;:1C-I'B`TXYH1CX:
M^A-<5ZQ^PCT<]=J`2`?H2`1^"#P0?\"/?NO=)W:A*X"@IS?7CGKL4Q/UOC,A
M54:W_P"G4*^ZK\(Z<E_M&/K0_M%>N5+C\]2;FP>8Q63H**+`Y+)9#$I544F4
M2";/0Q1Y.),<\M)3TX-4)*A9!*^MY;%!IN32#=KBT6S,0!>`R:=65HX'X<9!
MKY^?222TM[A;F.4&DP0-3![#C.>(H.'EQZ%#^7O45=7T1N*JKQ3K75'?_P`C
M)JP4GD^U^YD[DW>933B4F00L_*AKD`VN;7]Y4V4S7&V;1.P`9[2%C3A4QJ3U
M"$D:PW6X1(246YE`KQH'-*]'E]J.M=5"9_\`DX=&;@WAVQO.I[1[:@KNW<K\
M[,MFZ2"79WV>-F^?&P=G=?=CQ8L2;8>;P[-QNRX)\'YFE(GED^Z-0FE5:CB$
M>U?NE6/@_NV.RK^+PX]V.[AO369CX1QI\+RU]W2JXNGN-_V3F%E`NK"[M[A%
M%=):VL38(&\Z-&=;4(.O@0N.@5^0W\G[/9G=/4^=^/'=?9.P<Q/\D/B_V'V-
MV'09O96*WCUAM'XP?$_>OQTVGN'JJER6Q<[M[-[CRCU>-GR6.R]'68^L6>I3
MQK!^R5+3W$^^S;@T[0PS7>\7KLF3X^Y00Q>#I8$-!^E3N[UKK#:E4A+'%!#L
M+[;I\2>+;-OL8@U0#':;E]:9792K"4"1RNDA6*(I%"U4OVG_`,)R_B!VG@^D
MH\MV%V7/O[JVEWU3[V[3WGL[H'N?='>L_9W8-5VGOW-=@8GNWI_L/9F&W)F]
M[9*LJ(\AM[&8BHI*:J:EB84ZI&K=NEM9;E97-E:1Q;7!;6\`ME'9HMF9HJ2F
MLZD^)+XA64"0R:B*HA6]Q-<W=K>)<W#-N$UU-<&?`823HB/V+2(J!'%H#(=!
M0FI+N6.?V!_*LZ2W[LCYA=?G>>_MM[<^8]9\=ZC=='M^/:-+#L*G^-N"V'M[
M9N.V'2';;4-)09.@Z_I/O8ZJ*H4&200"%="HHMKJ:WO-NOF<R7%MS`^[@L2=
M4[M`QC8DU,0,"@9UT)JY-*6MI!:&'P(U")L;;6!0`>"RWBF2@H/%_P`=D.`$
MJJ]G&I4<]_PGZ^-NX.[?D;WM7=W]\S[N^1VR/DUUMG!6#JVOFVQL?Y3;;J<)
MO;`8O=%1UV=][BI=KUU2:S;JY[*Y6/#`&F@1:9Y(V+MNMAMVU2;3&Y:!Q$&8
MTUL+>^BOK?410,Z/%X;2L#)+&P61CX<>EZ*\DAW79MU4`O8W,,\:&I4/';M;
ML!YI'*K*QBC*HCK5%74U3L_(3^7A@.YL;\?,OL'OWN_XU=U?&C9>1ZWZW[[Z
M:K=EG>LG7NXL!@,#O'9NY]O[[VEO#K_<F&W.-JXZK85.*::BKZ..>D>%KW67
M\LM[O6\[VLSQ2[A&\=PB'LDC:5ID4@U96BD9FBD1ED34XU=QZ0V$4-ELVV;*
M\0E@LFC>!F`UQR1Q>#KJ!D21$K+&08Y**66J+0N.]?Y*O6&Y-L]>8';/RM^8
M6P,EA>ALE\8>YM[XKLG`;GWS\F>BL[NO+[VSVR^UMQ;^VCNJJQU55[AW%DC3
M93;W\'R.,HZZ2EI)88%C1*3):SW5RLMG&=@G2S66QI_B\OT,8BMF<_VI80UB
ME/B?K(Q$@/5H7NH(;66.[;]_6\MS)%>%5,T9NV$DRJI'@^&90LJ1F,I&ZZE%
M225S)_)V^-4W8;[SFS^_6V_+WANONB3K=:K!Q;3,>[OAK2_".NZ^6HCQ`W#'
MM*EZOI!5PR"L&17*'6:@Q6C]VN&-[;W]ON!,PN;7<X)"<$C=+V.^F<::`-'+
M$HBH*!?B#'/3]O,;**UAL%$4<$.U1(!FB[3+++!\5:^*966:N"OPZ<]$=7_A
M/WU)\;_BA\I>O/C1+E>S^T^RL!UPG3[9V#X\_'#<^PLKU#V#A>P^O3CN\>J?
MC54[BR^9P6X<'1UO\0W=0[I_B%10HE6K"HJ)362_W:WL]F6RFINEMN,%T9UT
MQL7C4Q%A"J&WIX<DU4$2@B5@A0A*4AM=KEOK][^`/M4UE<P&W8>*A68%M.MC
MXP[UB"OXA,>A7TL5ITC^M/Y$^Z_DW\;=VXW^8EN^IPWR*W/\N=V?)[;^ZMOY
M/J?Y(97:TNX.J=C=09?&;SJ.TNC:7I3L2HWCB=F&NEBBV+CJ'#224Z8Z*`TP
M8N7=M8B'ECZ`A+FSBOEDH@*LE]>2W9A'B^(X,;&)O'5UD9U<`B)RG3%O<7S3
M;XM[J>UG^C6/4Y+@V<1C66J:%`</(GA:=)32SAI:MU9GV9_*UV#N_P"*_P`6
M_C#UOW1V9\?5^(O86R^T^I^T^H=K=+83=E'O;9N(W7C4RLNT9^L9^I*2',5&
M\JVJJ*6CV]3T@F<!(U6X-KZYGN]_MM_AE:">*WF@5%)9?!FA6!HR9-;$>$H4
M&H.32F`/6445IM.X;3+&)H[EXY'=AI;Q(YUN%<>'H%0ZCR.``:G/08]F_P`G
MC%]O/B\MO?YK_+:HWMN?J%?C[\G-]82NZ@VWFOEITA3;MSFZL7L/M&CPW5E+
M@]K/B4W+7XV++;2I<!EFQE5)#)4.6U^V%BM!=7!>S1]HGDMII[1JF">YM%"1
MW,E3XFMD54E176*1$52@H:N"6[6&V:.[*[K;BX2"ZTIXT,%RVI[=:KX;Q*Q+
MQ"1&*.S,"2>AM7^6!TE%FGR=-N?>]-C3\U-L?->/;<1V]_!X-U;5Z+@Z`QW7
M$8?"M6'KYMGTZRNK2G(_<\BI">CW=V^H5$OOUU,.\1R:L>*-Z>5[HOIIE3,P
MC*TH*:M5.O)2`GZ(>`HL]LMD"D_IIM4\4]N5+5.HM"H?42*5T@'/15=F?R&N
MA\'BMV;-WK\C/D_VSU=7?'+=_P`5NLNN-Z;FV-2XSHGI_</8FT^T,!CNM,[M
M78FW]T'/[#W5LRADQV4R]9DZR2*"..I>9(D4;DN+Z:TN?%OY#ODDFWR"]P)T
MEVLR-9R**>""AD)<>'ID.6&>K%;0749CL8EV97O";(#_`!9EW"/P[N-D.2D@
MJ5&K]/X4HM01MZ[_`)36R=LY[;'8G9?R1^0?R![MPOR)Z9^0>;[F[4K.O?[T
M;KDZ"V?O'976'6M7AMG[&VOL_"[#PN,WS7SRC'8^ER%97S-43U+R.Q+]O<K:
M3VMQ;6L:.KWLDE!_;37UJ;-Y7S@Q6^F.%$TI&J`!:$CI@)(8;R":=I(WM;:V
MCU4K#!;7D=^J*::G,EPA:1Y2[D.0"*+02Y/@E2]9_%JGZ7Z:W'D\]NC8?R%R
M_P`J>O:_?M91TD.0[&K^^LSW[5;4S57@\92PTVVLA7[@K<-#,('EIJ66.63S
M/&VM*LLD!Y.9(]<>SP06X6NDS01VSV<FIC4"1H)9&!`"^*%^%:T67#F]FYOE
MDE\.3>#(SD"HCD;PF33Q.@20QZ_B?PR^GNTD.]-\'LK4'NW;V2[ZWT>D_D5N
MCLW>G9'2$FTNM6BI\GV[BOM-S4&#[)H]NP;UH8<97%:BBE%0\L4L2@LR>GW1
M(([>TBV]9VDCMI)'MI0-#Q.;R2^BE`H0S13R%D5PP("JX:F6S<2O=C<4C6*:
M581-&:2)(B6L=H\3!OPRPQA7TTXL5IJIU(V=\"L+B^S=F]V=@=R]C=K=O;/W
MAB=Q)O3/8_9>!_BN!VSU=V!U9M7955@MK;>Q>&I<1BL?V5E,E-44\45;796;
MR2RF(+"OGCC=[R54"S74-TLQ'!WNXX(FD`X)X<=NBQ1KV+JD9@S.3TSH_P`5
M6QUL;6,6Z1`FICCM[CZE5U?$YDD_M'<EB``NFF0OP_\`*TV1M7"[0VALOO3M
M[:NQL;D>BLWV+M2BI]B5=/V[G/COO>BWGU_D-R9#);5JJ_!1U28^'&YB#$-1
M19*A@AU!)8S*ZU;DF[AGN(UEM8V+K$<()'L5L)7)%'(DA1&*%M*RKK4`$J;2
M@M'NYB8QWMY'<1O*/B6.>YFNM*`X5HI)Y522A8QMH<L`"':K_ED;&S6-H=M[
MI[E[3W'L[8M#3X'HS;-5!LNEAZ9VNW:VQNU\MAL7DJ/;<62WA49.KZ[Q>(2M
MS4E954N%B:&)A+)).S%K(]O?[;NTKF;=K>6S/BL?[2*QD66&)D6B#6Z1M/(@
M5Y3''E=)!O,5D2^MXHUCL9UO"8U`HLM[!/;RRJ?B&A+F?P8Z^''XA&E@%TFH
MZTZ(K.H]];\SVS]W5-1MGMSM??\`W)V1@\[0T-562[IW7MC8FV<-C]LUU)24
MCXS"X.+9K3,)FFFF:I968@)HW%(RVUK929MK>"=8Z8;Q)[Y[LNQX%5$TT84`
M8*,:E236Z+7%Y)?J=,\AMU<?A\.WM!;*%\]3&.)V)]&`H#3H$MM_"K>.U(^T
MMIXGY/;]'37;6\.\=W;BZLJ>O>J9Q2R=\Y+=.;W1C,9O<;8CW9#28O-;KFGH
M7DEDF01)'(TB:@2Q]OCFY>@Y;N9&>RBL7M4;`<(_B$-4"A96E)&*&@!''I<+
MZ2/>DWVV18[OZBVF8996:W2"("AX"1(%#4-02Q4C%`E[A^"^9V=0;&[%^/T^
M\-T]P=9;'^.'5NSJEMX;$VGE]N[:Z&I>R\-'N[!_WMV-N'96Y-S;DP/:60HL
MKC,NE-C*FD?R4\E-4PQ%S:YW"\;<[V_B72;R_N+B4K3'CVJ6[1!7K6%C%$Q(
M/BHZAU+`&-B[Z2UFM+&WN`&%G;E(E.H:G-RDPD++E9(Z/H%/#=2T4@H^M0[Z
M\_E14]5TWL#%]F]I[D@[7Q38[/[BFEQFQ.RMFUV?INY._NY8H-W;6WAM&3:G
M83PY+Y!5T-1]S11T'WV.I:RD@@:-0=LT=NVVQVFGP[:&SC^&H)M=OBL6:+Q-
M31D^%XD4C5FCKQ&IEZ=-S/=KNCW::7NKZ\N.TZ6`NKBVF$;%"%*A+2))$7].
M34]:T0@3ML?RINHML=5;ZZE@[.[0K\+OOK?"=8UN3JTV/3Y/'87!?('L3Y%4
M]7CH,3M+&X:&MEW9V36T944HITQ\42)&KJ7+MC?26$MG-&@9X;K;)QJ)-3M4
M0@MU8UJ0\0593\3%=0*DGJD];AKUWP]PFY!J``5W2*&.X90!1=)BUQ*!I4L0
M0R@`+"C^#^5ZIWG2]J=6=F[XW0>K,5\@JCH'X_[DEV=B>LMJ[E^0]?!G]U+E
M-T4^V3O?+8JAW0DD^/\`O*Z=L;15,]-&)%\00L"SQ[3N&V12@RW%A#8K*PJ8
M+:)T\,J@H':%$1>[NE2)$9@Q:0J8OI6N+4S*R6@OOK)54FLLPAFC85.(TE,S
MN54!5F8R`4[>C=?'[J:EZ)Z2ZNZ?I,@V77KS9>#VU4YAHA3G,9*BI$_B^7^W
M!84XRF5>:H$8)$8DTWX]F%Y+#+,!:Q>'9QQQQ1+QTQ0QK%$I)))*QHH))-2*
MUZ+[99PDDMVRM>32RS2E113+/(TTND>2^([:1Y"@Z&#VEZ4=>]^Z]U[W[KW7
MO?NO=>]^Z]U__]7;:^%__,@<;_XDSOC_`-_;OWV"N9?^2S=_8G_'%Z-]E_Y)
MT/\`IG_X^>C4^R'HUZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;LKE<=@\
M?4Y7*U24=!2*AFG=9)#JDD6*&&&&%))ZBHJ)G5(XXU9W=@%!)]M3SQ6T4D\\
M@6%14D^7^KTXGIR&&2>5(84+2,<`?ZOY]8\-G,/N&C7(8/)T>4I#XP\M',LI
MIY)(UE6GJXN)J.J$;`M%*J2+]"`??H9X+F,2V\JO&?,&O$5SZ&GD<]>F@FMW
M,<\3(_H13Y8]1\QCKK/H)-O[@0P?=*^!S(:FTZ_./X;5$QZ+-?5;^A][F_L9
MNVO8V/7!Z]":30'53O7/ID=%[Z[QN%RV5&(W)BX<W%F-FP##5$S22P4='2TU
M)%GH?!9325F1>JBDCK4?R%4$0*$>L`<I)93R7EM/;!I6CXG(T8#+\B2>/GP\
MNA=OSW44<,\$Y15ER!@ELE3\P*$4\N/GA;;%VSNK;U=V%"L4\%%.):?;$V0K
MH)ILK7T_\03#Y>2HC\Q4QXV6EIYYYHQ+*\*EE;0681[/MUSMTN[1*--HSUA!
M-?(Y\Z#@,YQGHHW*]MKQ-M=C6<#]2@I05%13S\R`,9XYZ+_DYWCP&,QE)(_]
M\DK(:BBH:B+[FN.YL75/+FJK+TLE2DOVB58J#5S/(JG7Z7U,EXQNA.DTJ7%?
MJM9U5XZJYK_GZ&L'AM1TI])IP1@:2,`?.E*#IZJ6W3`C23Y?:6/C8I21.]'D
M]#3SEHX:A:BHR-/XJIG8>.GTR*S+;R<\-]P\QUH>$>".3QXC_-_/^739`F9V
MW04>+AS.U*H8^"&FIZ2MCGQ5?7O'&'>F>5\O/!1U$Z*\@E974LWJ4*+^]#4H
MI48Z<[)6+E'%?3('\JG[.L69W]!C\:M12XVK;(RMH6BR234-/3@!_)4'(K#+
M09.*-E58UI)9#4O(BQD%KC32`"H&>O);EFH6&CU&?Y<1^?#I8[4ES]!V+LZ;
M*08&NH:JJJ\*M?$DU(,=+DJ"JDC,-%7R5SC*2U=#$D%1'+&VF9X&!#`^Q%RQ
M*T6\0(RH1(I6IX@T)&FOF:4QQ!IT4;RD<FUW)1G#K1J>H!`-:4Q0U(-:4!Z-
MB1;@\$?4'W*70#Z][]U[KEXY+7T/;ZWTFUOZWM[W0\:=:J/7KC[UUOKWOW7N
MF#<NV\?NG%OC*\RP,DJU6.R5*(Q7XC(Q`B#(4+R*R>1`Q5XV!CGB9HW!5C[2
M7ME;[A;O;7"U0^?F#Y$'U'^P<=*+2ZELYEGA/<,$'@P\P?E_,<1GHK.0PV_-
MF55+09JLI<PU6[Q4-97Q04E!G7BD)9<;E,;$HPN3EISY/L:V"7BXBD=5+>XN
MW39;[:GK)1[<DZ7'`^E?X2?0X]#T/+/<++<$)B!20#*^8_(_$`?,'[0.N+Y^
MHQS@[BQ@PU'(&\64AKAE,<DBV/AKY8:6&3',Z&ZO(OA8@C6#8$IU$?$*#I7X
M88?IM5O2E#^7KT[IE<5)6#'QY3&O7GZ4*5U*]8?VQ-Q3+*9B?$0WT_2;^]U%
M:5SU0HX&HJ=/K3K%F-:T2U$4$E3)05^)R:11(TLO^XW*4E;))%&A$KO'!"YT
MH?(PNJW)`*FTE$%U:SL:*DBDG/`$5X9X>G5'3Q(Y8QQ9&7]H(''Y]&OIZRER
M-/3Y&AF2IH<A!%6T51'S'/2U2":GF2X!TR1.#SR/H>?<SJZR*LB&J,`0?4'(
M/[.HW961F1Q1U-"/0CB.DUO+:Z[LPXQZ5<>-R%-6TF0Q66>C^^;'5=+,K2.*
M<5%*\L592&2GF02IKBE()]H=RL(]RM'M9&TU((:E2I!X@?94?8>E=C>-8W"S
MJNI:$%:TJ".!X\#0\.(Z`;(4N:V]54U#NBCH,?)54M=4TM?1Y2GJ\?5Q8QJ=
M:R=D=8*K&1D54;JLP(&HKK+#F,MSVBZVK0;DH8W)"D'C3U'$8_S5Z&EG>VU\
M'-L6JM*@CA7AG@>!_P`/350[AP.3G^VQV8QM=/8LL=-512&4*2KFG8'14^-E
M(;QE])^MO92&4\&Z7-'(@JR$#INQ]738L[O:LE6FI,;F9LE+(]RL5+E*"BR`
M(50S,6J))`JJ"6;@`D^]`@:Z^1ZLREO!TBI(I^PD=-%+0[NSNX8,R^0K-M[>
M-*L&/Q(E\&<I:DK#*F6K:5378FL%<\KQO2U`#T\<:,I61G`J0[!C6BT_/IT&
M&-5CTAI=63Y?9Y$4]1QZ&S^7@)EZ!S:U$B33KWS\AUFFCB,,<LH[AW<'E2$O
M*8ED;G3J;3>US[R[VK_DB[%_SQ0?]6UZ@.Y_W/W2@Q]5+_Q\]'J]K>FNJ9<O
M_-GJ\3_,[SG\OZKZ6VCA-L;53!IG.R][]_[2Z^[/S%%F>I\OVK5=D=9]#[PP
M.)E[4Z:VM%BCBLOEL)N"JRE'D!)_N,:*)W#6T7%ON%CS%N%Y.MO;;>MR7SK:
M,6WAG7<(`'ABG5RT$H$B&@\1DU84;K:S6+;#%:QF:XO1"<]B-X\S0"."3N66
M>)E#31-X9"GL+L`&?-J?SN_A;NS:O9^]4QGR$VSM?K[KENY=K9G?716[ME8_
MO_IB+>N$V!4]M?':LW%]A2=F['I-R;EQZ23H]+4+!6PS^'Q-K]J[:VN+A+77
M`T-Y)<6<)@E&B>(W\BQ6KRQ'N2.1VTELZ""K@,55FM&J\:UB=9(=%V5G0ZH)
M&LHGFN8HY1VO+'&C-I'Q#*DJ&(>/D9_-RZGZ([:VETQ@^E/D#W#N[*_+GK+X
MC;PJ.O=A39+";(W9V9UE@>W<9FYZ^*HJ),O2KLS<<$L5-'%'+.]/6>I$I'=D
M^W^)N6Y[#M\.E(KZ7<(Q)(=*JVVAA..!J0X#'@%MQ+.QI'I9B_E6PV3<-Y96
MD\&TL;D1(*R/'?S-%%0?Q5C=0N2TS0PC,NI4I\3_`.<OU%\D,_E^O<WTQWQL
M/LVAH?D]EMNT..ZSWEO'8':U/\7.Q,QLW>^V>ENP8MOX6'M#LFGP]/CLC4X7
M&T3_`&TN32D2>:9?4U8SKN'+=OS%;1R,#M=I>O"%/BZ+H^'6)30RQ1W%;<R]
M@9@7TB,%@NW*V_=W,MSR\\Z,J[H]DLU:1ATA$X\=OA@+1ZW"EF.E":^72=B_
MGV?#2?K^#><'7/RXJMRMW#O'HJOZ2H/CUFLIWKA.PMC]62=T9F@S'7F+S%;4
M4U!_HY@ER`J5J)$ACAD^X\&AK.RR11165SXJM9S6ES<^*M6CCAM)X;>Y>5@.
MP1-/&Q)[2A)4EJ*6%BE\::VDA:.X2>WBTN-+,UTDS0:%.7UM`\0"@MXM`5TU
M8/.#_GN?!G<G7>\>S,)C_D;78':FX?CKA,=C#\?-]4>[^QL;\JVR--TAO/JO
M9V0@I-Q;ZV9O+*X:LHH*NEI_(]53,(XI$:*21^2WN(S:((&>YGOY;-(U&J3Q
MH[8W:AD'<BSVX$D)<+J5@7"`-I9CDC=+N6201P0V+W;.]53PXITM;@!Z:2]O
M<.L4R@]KU`+4-&O&_P`\7X_;C[3^-77.W>DODW!2]W[@[\VQV9GM[=39?8]1
M\6L]\=<6^3[%P7>VWLFT^1VWF-NT+P9'))J,./P=3%7-+(LBQE*)H#<RZKVW
M&U)LT^XFX+GPVCMY!%(B46K/%+J@F!`,=PUO#1FN$(O*)DMXC':RON+[M;6/
M@::2!KJ(3Q2D'_0Y(F66(\'A6>6JK`U5-A/YXOPLRO6W:O:>2PGR2V3MOK+8
MVSNV\92]@?'W>VSL_P!S=*;^W_ANL]J]T]#8?,105'9W7.4W7N"CB6HI2E8(
MZB-S36=`STB3PP6[W%K)'>-=VUL]NR_XS#-=XMEFA%743,&C4C4!(C(U&`!W
M%X<US)#%.C6H@NY5N`?\7E6Q0R70CF^%FAC"NPQ5'1EJI)!ENFOY@/5_R$^/
M'R![XZTV7VI@*_XYUG:&V^PNI>[]C9CI[LW;V^.M-GP[UEVWN7;6:AKJ_`IG
M\'D*&JI9V24FEK4<QA@T83[U))M'+XYA4)-;-;S2(%;\4#R12Q,0#I>.6)XW
M%"`1@D=/;+''N^_P;#J>*=I[="2I^"Y6-XI4K0.C)(&4@@$@BHIT6^7^;;M/
M;'6WQ,[@[*ZLK]M=??(/X`]I_/'?==@=Q2;IS/6&W^J]E=0;TRNRL+A1M[$M
MOVLK*7M)XHZHRXLZJ$'P'S6C,]^@MM@WKF_:[JY)@VJ*V;Q-.9#<W@LP"@)T
M!68.2"YI@#UIMT$^YVNV36Z#ZBZWF>P"DT`\&*\E\4M_2%I313&OXCISSVW_
M`#D_C]V'C]O3['V-W5@<]6?*#IOXVYG8'<_5&\NK.PC/WIL'<G9'66\=M;6R
M6/K*K)X#L#:^W7GPE15M0P52G]YX+IKI):7$!B,L3-^GN>N-!JF2;:K?ZBXM
MVCQ28*4HNK.L!26JH3VD\%[#N$L,GZ<-I:7*R'$3PWEVEI%(KYJFMFU%0=.G
M(`-0NX_YP/PN78O6G9&1W%OG";/[&^//;/R@JLIEME5,!ZSZHZ8SU#L_>59V
MK1T];4UNU-P/OK()@:'&)'55=9EU>G1;QNRH[J1+8WVEA,L%C8W(,1#B5=R=
M4L8H2#^I-<DMX:CM(BE)<:<OP12S&T1HS%-+?W=H4DHK1O8H[W;RC\$,"H/$
M?.DRQ"E9!T%N._GI?"O+=(Y'NG'[?^1M;5XCNCKSH7(])4'2F5RGR!@[`[=Q
M69S?55/!UGBLI75&3QO86.P4[XR>DJ:@R,`CI&X=5?>*97V:*.%I);Z>>&-4
M&HB:VB,\T;C\+)"!(3E-)!U8;2S%)$\>Z322K%!:6T=PSR'2KP23);I)&3\0
M,T@C(PP8$$974J,3_..^..[]V_)'KG9^P^_HMY?&'ISL#M'L[(;RZCSFW]@;
M5S77/7>-[#W/UEN;<U%/F*W$[ZV_19B"EKJ<T3P+6B2G@GGF\:2,7#"+:=VW
MF*6-[&UF\/74Z9J7!MB\)`.M1*K`<&8*6"E`6"VRM7NMWY;V=T=+O<FA"K3N
MB$ZF2/Q02`A:.C`$XU*&TDD`-^HOYWO378'<M?U1NGH_OS8FW:#;7Q'KE[TK
MMB5[]-U>?^7N&AR6P(9=P5HQU5A=JUM77TM)C\E51"3(RO-:GB6!F92T03<N
M8MNFD6&6RW:>P59#1WDMK26\E+`5"5AB+("3J5X7)`FCJ62W(BBVN8*7BGVW
MZQF4$A$-['9**4JU))*NU`%T2C/A,>CS87YL;`W_`-*]#]R=68;-Y^D^3._\
M3L+IO";IB.T:W/M6Y3/_`,1W-7J$S-1C]N8W9^TLIGED6*66HH(([(KS`+1(
M9I+O9[+3HN+NU6Z*N"KQV_TRW<A=2*B5(65?#-/UV2-F4$L'YG$,.^2L*FRN
M9+8_PO.EP;155A4:'GX2&@\,%A4T4@/U]_,?ASW9/8^'WUM3KW9.P>M<9V[G
M-\T3=I2-\@^I-O=3UF7IEW1VST1G]H[<RK;=WO'@9SC:C:E=N<))-2K+Z)_*
MC-FS3[0^YS(2QCB95B!D/B321)':.M`Z79,RKI*>&98Y8_$U>%XC]U!+%NT6
MV0Z3JF:.KG1K14:0W,1(T/;!4UEBRR".2.4QZ1(4'/97SMZEW9O+:G6N7VIV
MOUMV=N[=]!M*AZ[[&VC08?=%"F<ZWW=VIMG=.4CQ.X,]BX-J;EVML;*+3U$=
M5-/#D*5Z.JAIJA'C7;NJ-<)J!DABN7E`SX36BPR2Q.1@R>'/$\>@O'(K$I(=
M+`,:P;?ZL`_2L(&C:A`E2XF\".2.H!T^)VN'"2)C4@JM2GU_\VS%5>XD_N'\
M<>V-[[#RF4^*%#M#<M(<'19G>D?R<W!O_;\4."VPV1J*J+-[9JMD'3!7/144
MZF>6HK:.&$226MUFEODL9(M,K7K0`5%2O[H.ZK+G2H73IC<%@4#:QJ(*=/2*
MBF]"R@BWL[B9R0=(>VW-=MDBQ5B2VJ2,JK%RH0*"P/0W;S_F<=#;#ZKVCW1N
M+9W<]'UWN"KSF,W/GZC:&WL9!U=G=K;^KNL]S[7WO_'-Y8I,IO'`;LQ%='48
M;;#;BRII:&6KCIY*7QS2.6\?U5]M-E`P(OELS!)0A)1?%1!H!`D(&I?&81Z8
M`P,I6HZTT<JP;M*8SX]C)<)-%4:XS;)XDA;.@*RD&(LX\8G3'J8,`Q;@_FJ=
M"[=S6[L9/UI\C*_%[,J>X%R6\<=UECI-H56)^/F^Z#K[O#<N-RE7NVCJ)L!U
MKF,M22U;R013UM+4!L=%6R)-%&U8O'?16$_B+%#<);.#)VA8[NX>T@D:E:*U
MS&82!5U)61D$)\3JLJ2K*T-O"\\FHH/#%=4HM4O/!4MI'B-:OXJ:M*.$D17,
MBZ.FSM;^:AU=L;8W;VZ-K=3]S[LK-@4?>N/V)-DMLX[:FS>YM_\`Q[GR$/8>
MQ]B[HR6;DJ34XREQ=3D(ZRLHJ6BK\?2U!H9:JH@DIU8N998+""\$!\61(I%B
M8Z9#`UTEI),!D4@ED`D4D/E6"F,^(%<5JDEPD1N%,)"5D4%E5YK,WL"-@&LT
M5`"`55SH=E8@$4V_F%]08RN2DW1M+M7;N+I1%@-P;ZJMK8R;KW`]MKUF.U:[
MI*IS]+N.HJY^PJ/;09-4-++A'R`%$N1:K982JW)K;;7W4R3_`.*V[7?AN5(^
MI2R:1;AX5%21'X,QH^@N(93%X@C8A#MRW%_%M!$!6XN4M"Z\?IS>^&+<3&E`
M'::(537H\6,R:`ZU$?XU_,#KGY039RCVAM;L[963P^S>MNR:;$=I[3@VGE-P
M=:=O8_,9#KO?N$I*?,9A_P"";A7;M?#X*PT>3I*BD>.II83HU*9[*>W%WXNG
MQ+>Z:VE4&ICF6..4HQ%5-8Y48%689*DAE*AMIXUN(+>M?&A:6-@.V1$E:%RA
M-"=$BT-0`0R.FI&#=%Q^3/SZS?27R7'QXQ%-\><&T73>SNUO[T=[]O[[Z_.;
MFWAO?>VS8]O;:P^R^F^RA5G$ML\33U%14TY)K$18B%9_:#:W.XW6Z04`%M=V
M\%!F1_'B,FI5-`-.G2`6RQ&0.EM[$EE8;=>N6T3BZ)-`$06WT]:M6I+>/7X:
M`(<DG`A57\Q7HW`]@;CV!O+$=C[7I-F;NWCUONCM>MVBQZ<@[,V#U0.ZMS;,
MQ&Y%R!W)FJL==QSU])40X<TE2:=Z;RK6@4QWXT+V\]W"6,02Y>-2/U95M;H6
M<VE%U=RSLJ!6*ZR?TR]#1N2&6`6:S,A>1;4L5-4C^K1GA+NP4!&"&K?@!5I-
M"LI*6Q'\R39&Y=[[?Z_Q/3O=6V]TS;XZWP.[-O\`9>SWVSN#&;1[7ZH[K[4V
M1O#:>+V]4;T_OS49G']+U-.,73R0UT,]6L,RQ5D<E*%7T\J-<>(I/@B]61$[
MY4GLH+>=H=`PQ=;F,*Z.R')4LN>K:$8`I,I62W@GA>NF*2&>_AL/$UM0HJO*
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M_C)T2&2-A_!-`YCE3U(!`>-B%+PR1N57507G'@WL]F0<1Q2(?)XI5JKCRPZR
M1,`3IDB=:XZ&?WKK77O?NO=?_];;:^%W/0&,-K7[+[X(_P!8]V[]M[!7,W_)
M:N_L3_CB]&^R_P#).A_TS_\`'CT:GV0]&O7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW33G,)CMQ8R?$91)GI*AH)0]-,U-5TM32S)44E;1U">J"KI*B-7C:
MQ%Q8@J2"Q=6L%Y!);7*:H6XCA\P0?(@Y'3T$\MK*D\#4D7AYCT((]",'HM`H
MLC@LYD,:V3R6&W-0R&(Y+$ROBVS^)CE9L7F9*/0V*RD4L53:4/%*(*AI$](*
MCW&%P-PY?OIX;>=T4FH/X77R)'PD@8/H>AQ$UINEK%+)"CI3(.2C>8K\0X8S
MD4ZEM3]M[OQM+"M0-P[&S-140!*Q\7C,S5/CLE$L55E\I2I230[3JIXI@Z0P
MS5<T<"J55)+,>HO,^Y[;"/&C,,YXX5E6OQ$BF#Z**T'SZ+V.Q6%W(?#9;F(<
M!5EJ1P`->X"F20*GY=#)LSK_`!&THJ6L\:U6Y/X;)09/,)/7""J$]2M5,E+0
M5%3)34=-&8XXHPB(WAA0'Z'V)-LVBUVR./PHQ]3HTLXJ-6:DTKZ_RZ(K_<KB
M^=PS$6^NJKC&*<:5/^<GI>,JNCQN+I)&\3@$J2DB-&X#"Q4E6/(Y'LUXU!X=
M%W`@^?1+,=MC;G66ZLEL.'*?Q#+5$,.3Q]74R^>OJ<--"]9]K41I+.,9/254
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M&IQUI(Y62-FY#>Q?MNRG;K2X.YNK6XHY"U+`H0:U`!*FF4H0<5S7J';[=H[R
M>WCVM764U2K&BD."*4)(!%</Q%33%.@^W[EI8<M@ZW:NV*^MK,UN>KRVV,'C
MJ.JPNRL]MQZ/&Y*CWC4_>Y$+C*S"4]=/#,T$"4U15FPA+K?V1<P16;>'=QPZ
M)))"5*K1'0A65R":@K4@E5R?+'1MM!FTRP33@HD8#:FU.C@D%!09#4!%34+Y
M]*3&3XW-MF\?NK.5VTVIQ2ST%1E<)%)M+(R%7FGQ3N]-#DH*S%/``7%8CU+.
MDT#+81AJPL=FN08WW-H[L*"K<%)]`"`05I2FJIXCTZU<S7\!22&S62$D@J#5
M@/6M2"&_TM!0@^O3GL;LS?,5,V.AJ:;<-#$*FLQ65W%A\O2156'DK"V-$.52
MNFR,DE122J$%8LTJHI.IM)4JXN9[RR'@:H[J$&BLVI7(!XMY@GRK7[3TQ<;)
M9W!\4HT$IIJ52I4&GEY8\Z?LZ6^9WUN?/".FHXYMG8\0@5S4E;25^;KZDGUQ
MTF12#Q8K&QK]'1?NI2?K$!8VW'FR>=%CV]#"".YC0M7T7R`^?$_+IBTV*W@9
MGNF$K5P,A0/F.)/RX#Y]([^&4XF%4L^42O5M:9,9O,G)QR7OY(ZZ2N>=6_J+
ME&_*D>PV+Z^$@E%[+XH\];?Y^CCP82AC,$?A^FE:?X.GZAW=NW;)R59!4S;N
M@J:>.>6AW%DZIJNFJ*(.7DQ$U-2O'_EM+^V:<HB&54?5<N">6'-%];&7ZNLX
M8CB:%?(TH.%/+UZ+;G9;.Y$8B`A*U^$8->%:GR/GZ8Z'/;NZ]O[LCJ)=OY%*
M_P"T>)*F(PU-+4P&>(30NU-5PT]0T$JDA)54Q.5(#$@@2#:WMK?*[VDZR*IH
M:>1X_P"H\.@E<VES9E%N8BA85%?/\Q_@X]*+2UB=+6'U-C8?ZY_'M5TFZ#/M
MZMQF/V%E9\G61T<J3XVHPOD-Y*C.4>0IY\?'!"+O,-:D3$`K%`7=B%!/LFY@
M-N-GO1<.%4KCYL#5:>IK_*O1KLJS-N5MX*:C4ZODI%&K^7\Z=`;0;CP&:J)J
M#&Y&"MD>FDD,*QSJE32L-$Z1-/#''5^%7`GC74T08:P`1[B4,K8!Z'31R(-3
M+05_U?['4++8C:]'AI*2JBP^"HF04M+5^&CH7HZD,9:66CG*QNM533_NK9K@
M@D\7/OQ"`9H!U9'E9P02S>G'ILI=U5U!DZK&YU:)Z:AJ*:$YZG:2BD>"JIZ=
MZ7+U6)D%1#'B):N84[5<-3)&LI4NL:GC08@D-P]>K&)64-'6I\O\E?6F:4Z$
MOKG?BXG*2;8\:5>S)LF*3&[@BF8P83<&3E?R;?C]+05F#:ML%GB?325-4(3=
M;E!MRSON@Q;5<_V9)"/7@3P0_+T-<5IT&][VKQ$>_CQ.%JR^H'X_MIQ'F!7H
MR1!!((L1P0>""/P?8]Z"/0`=V[5H:^NV-NS,+]UM;#;@P^*WOC)7:.@J<!7Y
MJCEH\EEW0AVP^$R=GJ8@51EE#R:EC(]A[?-OAN)]LO9PIMX9`)`W`HQ&3\E:
MA/RX\.CW9KR2&+<+2$D7$D9,9'$,H-0/FPX?,8R>DWV3M?;N%(GHZC;XVUN'
M)0T.-Q>(FI(LG@MPPP4\,U9M:GI==-4)%)'#4SQ0&.:G<M(5=&(`?YFV>&,M
MN%O)$L34!04&0,E*8)I0E1GSST:;)N,TH^EE20S*"=1J05/D]<CS`)J#PQTA
MIMN;DKCF4K\QA(8LSCZ7&5PI,15U;U8HXJJG&0+3Y"DCHJF>*IOH02"-T72Y
M'L&Z6-:L,]"$2QKHTHV#49'GY<.EU11O$*.*2:2IDB6FB>HE"++4/&$1IY%C
M"QB29EU,%`%SQQ[VWPG[.FAEP0*"O2R_E[?\R&W!_P")]^17_OX]W>\N-K_Y
M(VQ_\\4'_5M>H*N?]S]T_P">J7_CYZ/+[6]-]5<]M_RJNK>\?E;MSY+=F]W_
M`"&W=MC:^]\9V?B?C/G]V;8SG1^,[%Q.QLSU_3;AVY+F-GUW:6S,7/ALY/-4
MX+#;CH,#55KO-+1LTDFI-:V=K`MXMQ"+GQ([N-3)75&E[&8IU#(5:1-#.L23
M&1(0WZ:KI32_=7,TZQ+"Y@(:V9_#-!(UI*LT#%6U*CAT0R/$J-+I'B%B6)!?
M;W\C;X^8[K_LGK#=??'RC[,V;N'H/<7QCZ6Q>^=^;7J_]E7Z6W#N3"[M.U^E
MI\3LC$3U-;C,[M7#FGR>YFS^2^TQ-/2O,]/Y(Y'IC=7-I*MQ>R-O4DEDSWW:
M+I_W?*LULI8#PPJRJ)'TQ@R.`S$D`BML\5IN%M<6]M&FUPM=,EFHI;HU[$\%
MRR@?J+KA=HD42:(E8^&JG(4&W_Y-^Q,+M^89#Y9?+#=W:E1\L>H?F//WQNS<
M'5V3[+F[5Z@ZYH^J\=02QQ]74NRWV=GME4STE70?PG]I)C]M)#I6RN.=(KGE
MJYBMHU_=EU?SJH';,=R1DNTE'\$@=Z",QE`U$*@*`7S6GCV6\64D\FB[L;2V
M!K0PK8S>/:O#CM>)]/Q:E<KJ<,[,Q563_D_]`97KC9O64W8W=-%AMD[0^;^S
ML7D\-N+;^%W"U'\[MR#='9&1;+8[;,$M/D]GY%5&!>$1QI$--8E6"URIK)3M
M?[K25E0;/8;>K"A*Q[=/%<024(*L[20J)593%(A92E&/1R]_)+NFX;K*BF6Y
MW4W[KD#Q&M)K-D4@ZE7PIW96!\1)`K*XIT$/QQ_D._&3XSU&`J]F]I]T9:IP
MW8.]^TJPY2'J/"TF<WOV'\<L[\9]TY6JP^P^KMH8+'05NSLV:\04-+2I_%X1
M.^L23)(NO#];87VW2#3;S;=?68T_@BW"6TGG*UJ`PFM`\8IHC$KQJ@C6-4+(
MXRE[M=^TA:XM;ZRN@3G6]A]4(0YXD%+HK(U=;^&C%M9D9T)\AOY*M+6=:]:;
M3^.7:?8>&W)A<Q_+<ZZSVZ\QN_!;:SVTNF/@CNK/5E%OK8.3P^QJF./N"?$[
MEGJ5%1`^,J:V")1##&7#*WNYKKF,;Q-.\`FW:6_E:*FI)3M,^WQ+&K:E:(L8
MO$CD#!D:0&J]I>*P_N7<[%H1+/\`NF\M(5>NAS>;C#?R>,5(849&560@@4J"
M3J`]X'^33TEAX^ILC7]W_(?=>^]D=J]]=J]J]D;IW#LG);J^3=7\F=ITNQ.Y
M]K=RQQ[%I<%!M3<^S<918V&#;='@9,;2T<:TDD)U$ETMIM\HA@-@@VU=GO-N
M,%6*/'?2I<W$S,6,AG:[C6Y#AP/$%"I3MZ\);L-+<?6/^\#N5G>K-1`R/8PM
M;6\:J%$9B%L[0,K(2R$DMJ.KI-[7_DB='XC9&ZMC[N^0_P`H^V:6KV#UCTSU
M;D^R]X[*S&1Z%Z)ZG[9VCW#MGJ+K5<;L'#T-3A:C<.Q\;35N3SD.7SU5CZ6.
M%JW]M2#&"_NH[JUW.Y<3[T+^TNY[EP/%NGLBS0I-ITJ(_$>65UC6/5+(SDZJ
M'IE8(8A);VL8AVH6E];PVR`"&W&X0F"X:*M7U>%H2-6=DC6-55`-0-@O6WQ-
MZXZXJ?E6\=;N#<^.^7W9V>[/[-PVXJBA;'TE9N3K;:/5N6V]M\XR@QU538"H
MV[L^%K3R5%0)YY2)=)15+;BWBN^7XN6YUK8+]74U(<B\GEN)!4<-+2LJ$`$*
M%J217HP6]G3?(>8(FTWT<5JB^:CZ-=,;4-<GBU30G@`,=5V[._D=]+;>VCOK
M8FZODK\J>V-IY#XQ=C_#WI/"]C[JZ\R--\8>@^T),0NY-I]2/ANM\'4Y&K&,
MVSB*""OW,^>JXJ+%P1:R->I0\L\]O=+=S--?W#V#37#T,LPVZ83PJ_X*/+WS
M,JAY&RS5Z9M)39;E87]NH6VMKBYN$@!/@B>Z5U>4BNMF59)%CU.0@D?2,GHP
MVYOY7G2VZ.WJ3N2LWSV=3[@H^\_B;WW%C:2NVPN&.Z/B!UKNGK#8&),4NV9:
MS^`[APN[)Y\N@F%1)51QFGEIT#(R^+<IHK]MP5%,INMRGH:TU;I;16LPXUTH
MD2M%FH8G46%`$\*"#9TV5"?IUVFVV\-^+PK6]^N1_3Q&E[6--.C`4-W=(VC_
M`)-WQ%1?G'09E=^[EVW\Z\%D]J;SVMF,_0G#=3;0SVX-Q;\W%M3I-:+$4E5M
M3`YWM7===NNIIZF2O1\S-J_S"B'V0BR5>6EY9BD*PK=).DI"O*AMR#91_J!D
M:*RH5@C92NABD@<=&!OIFYA',,@#2_3M$T61$QE18[J4JI!$UTB1K-(I#'PT
M*E2*](3X\?R2?CC\==B;'V7M_L#?^;J=C_*3JGY4P;J78_QVZYS&;W/TYB<]
MB-G;.S]%TMTGUI@,IM%(=RU<E0\M(^5DEENM6B^GV=?6R>/LDX0![(W;`#5I
MD>\MY+:1F6NE=,<G8$"@%1JU"HZ)_I$-MOEJ78Q7UO#":T+1QP7$-RH1J:B6
MDA767+U!-*&AZF]H_P`ECX^=O_+'MSY<[R[0[;FWGVOU9VMU:=NXK%=*;?QF
MU<?V]U;5=1;AR5)N[`=28SM7>`Q>V*^=\9CMS;@S>)HZMUD%,WBA"$UO90V^
MV[QMP+$7@8,]2"H>:.9NQ-,3L3&JB25)'1=6AE<E^CP[E,VY<N;D44OMMQ;S
M(IJ0SVQ8QU))=5JU72-T5SQ%,=!%\E/Y/(_T%=];/^.&^>Q-P;M[T^(WQZ^'
M<FT=];[VMM3KO`3_`!\CQ6%ZK^3LV8Q'7U5O6C[2ZUQ./^X6#%54%)72:A'3
M12LLT;V^+)O=YOLK!(GW?F&WW.>4#4ULT:1Q3?3K4%EF@A6)HW;N)!+JH/23
M;C!8-MEPRLYL-IO+-$%`+B.Y>654E)!`\*:9Y%=0M`*$,:=6#Y_XI5&T.H?B
M%L[I]L<V;^'&XNKZO9E#E:F3#XO<^V]N;(R'4>^,97U5/#6?8U^;V!N?)5-/
M*8I5&26+6-+,P-MROUO^:WY@\`K;3&YA>,-\%M=+HTIPJ;8K`\:U6HAT`KJ!
M!1MUE+9<KOL;SZKOPH7+^4EQ!*EP2]03IGD5]5,@R:JT!!26X?Y=>RNP,O$G
M;?<7</:VQ=OXOM/%=<[+W?D-L29/8--V]@<YMG<D4/:=#MNE[8W;28S![CJX
M,73YO,5\5)^P[B:2EIWC+8/%A623QF.Y>`L*3BBNB)+#-&=(`C>5)+>!A+(C
MMJ0N>Z20L<23F2440"R-QX[PGNC:32RL.ZI2)A)(&B0JA5O#IX2A.H\W\O.A
MK<GC^P\K\B.XLM\@<+O+9^YL%WU6XWK#^\F*PVR-E[OZ]Q&R(]G0;$AZXJ-O
MU&U>P,T*N67%-75%?7M5F=98X?'Z2..1Y90@26?ZCZ@KCQ_JHHH9<&HB`CAB
M\(1:1&REA4N^I/&JI"+5RSV<<4,<*,2?"6";ZB/N^.4^+W.9&;Q!13@#J%L3
M^67U7U[/U@N'[+[4J\7UC3_'MZ7&9:HV?5'<6:^-NX]\;@V-G\]D8]J4^0^\
MR*]@U]-DXJ5Z>FJ(_&Z1Q2J7*CQJ;DVY","3QO$5<Z5/[K;:6`\R&M]#]Q)$
ML8((5G4Z8%ENUU4$\<ZO\_J-Q3<R1_"4G5E4#'AR%6!*JP#GLC^4'TOV,F9I
M:CM/M'#T.Z,/VE@-Q)%B^J\_D1B^T^X]]=WY5-FYK=W7F?R'7%=!N[?M13S5
M6$:DJ,EC*6FIZQYC$)"UM[R[:VW&W<`6L6WJAH-6K;?"\!F<#6R'P8VDAJ(6
M<%P@9FJLN;HW5U?W<B#Q+F>[D<5.BEY$D,P"$Z=0C0K'*0945RH>@72->4_E
MV]4YC:.Z-GUV].Q7H]V[1^5FS\I7)6;;2N6C^7?86"['[`K:8_W=--'78/-8
M&.+$WC:**GD<3I.VEA25$D@@M@NF&.*QC4#R7;[M[N'C7+.Y1SYH!2C58ZM+
MJ2SE25`"ZW*SY_B6P_=X&*8,7>?/Q,UT]O0"==_RQJW.[9[3V]\@^W-];@V_
MG>Q/ESE>J-A83([5;;?5F(^16X=VX^#>6%R:[,H-PY+=T>PMP.$H<M49+%XR
MLK:KPQ/J5EK*AO-FVN*Z:F^+8^"\J@?I5O/JV2,&JNI:.W77(I<1HT0.EC6I
ME$.XLUL/]U2&T(C/^BM;;=#9!Y#\2M43'3&RJ24>E13H:<I_+KV?N"JJZ+<?
M</:68V#ELNW8&<ZU:GV'0[;RO=TO6!ZMG[>-=0;0I]QT5?)CB,H,'#6+MY,T
MJU(H[`1^];E#%ND>XQ3@B.07H@"D_P"*B_,YN!'6NNOU-P(S-K,8F<*?ATL[
M>\FWMMKQR%I(A9B4G_B3]`T+6_B`4"D&VM_$,01I!"@8TU`BKU_\4*/I[<V%
MW7UCOC.4V3AZP^-_1NX$W/38?+4>3ZK^/$N^FHX::*FQ-'+2[JW73[[J(ZNK
M618HFBB>&./2ZR&$][-<76XS2!1#>;E->3*/XY+06ZHA-=*))'#*:U8Z74M1
MJ!AX$:+;`"1/9VAMXCY:9+N.XE9QYL4$D:TH!J!I45'#LKXM[KW1WCDN^^M/
MD7V)TINO/=7[5ZHW'C=N;/ZEWC@LQ@MF[GWANK!5_@[%V-N>MQ^5AKM[UL<C
M03I%+%XP8]2ZB7VD;6?[V6.4F&\GBE=2!AX8FA72:5`*,:@DU.<=+)Y5N(MN
M1XAXEKXX1@34K<&`N"*TP8$*FE15@:U%`WWY_+\Z]W7MW=4>1S&Y-ZYC-]R]
MA?(:IP^X<OC=N8#=78>^N@,QT+7[<S.0V]MB?(X#9M=ALJU5Y:&%ZZCK2)8V
M=$$!:EB:"U=+"+O2VO8XQJH5^LO/KBP<@T>*8#P68%0`/$5\UL)/JG$=_+6.
M0V(E;2#5;(:15,`B5:B91IU`D(4P06/IW^7-V-V-/V9N_P"6>^NQ<?N'=\'5
MN`P%#B^Q-E;@W7AL-UCT]WAU$'.[=D]:;"V[2T==0=\9&HI#38V/)-4T<=56
M3O)-+`#.ZDCN+6[J0;VYNKR9V*C_`(E064'ZB5,;.#9ZRB@0%'$;*XU$LV=Q
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M6N$"QUF1EA4LD2NR2U46VUVMB,RF::XE-.,UPRU49R(H8X(`U%U^%XFD%R.M
MW5)=RFN5(\!8(8(L4/AQ:W+-_2>>:=Z5.E65*G3T8OWOJO7O?NO=?__7VV_A
M?_V3]B?_`!(_>O\`[^S?OL%<S?\`):N_L3_CB]&^R_\`).B_TS?\>/1J/9#T
M:]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&.Y*?`;^JZG"X/<^/I
MMY;)J'=T"??MC/XE$(*FDRV,+T\M1CJP1J&:*16CFC6SA@5))N=I9;VDMB+H
M"Z@:N,E"1YCT(_XOHUL9[G:RET]L3:S"F<!J'BIS0C[.'ETL]MX.#;6"QN#I
MII:A*"%A)4S?YVKJZB:2KKJME'IB^ZK9Y'$:^F,,%'`]F=I;1V5K!:Q5T(H&
M>)]3^9STAN;A[JXEN'`#.:T'EZ#\A^WI[]J.F.NQ:XN+BXN+VN+\B_X]^Z]T
M2'.P9F#=6YZ_')3Y#?TV[<[05LN3PG\(HLOM3'0X6+&SU^6=::4+BA.JT8HT
MJC)%(VME!O[C;?HXP99+F1C??4.`1'34@"T#$TKI'PD5K6O0\VQ]44*(H%D(
M4-->HJY+5H,_%^*M*4Z#O>4^4RS8G,2J]+N/9\XSM-L[R0Y&DR-?A&^YJ:W'
M1Q(E;)6T<5IGI9-2U%.(VA,A^I&NJT,%VI#+6JD4-&4UTLIX'`J/2A4GHV0)
M()K<U"L-)/#M84J#PIY5\C4$#H[.P]]U_8"PYS'XFDAVE/CZNGEKC7/+DH=V
M4&1--7XP4;01";$RT4BRQ3%4D#$I(BGCW*>WW\FXHERMOHMF4UJ>X.&H5IYK
M3(;^74>WUDE@6@>;5<AAP':4(J&KZUP1^P]`AV)/NL;^K,JS40VNU5MW:^(R
MV#KL?50)"F2?[O%Y>B=YZM<O'5U$T4T,8@BC0"4ER@7V$^98)I9;F[EB4V\:
M*L;*_`ENX,O$L"3@4%..1T(ME>W2VAMT9A<,6=U93GMP5;`TD4SDUQY].S>H
M,C"Z,"K(WJ1E_*,K75E_P/'L&\>/1S_AZZ4!55%`5$%D10%1`.`%4650!^![
M]U[KOW[KW7O?NO=>]^Z]U"J\=0UTD<U73)+41#3#5!GAK(+,'4P5D#QU,)20
M:ETL-+"XY]V222-@\<C*_J"0<?9U[!&D@%?0BH_8>LC05+S154F;W/+6TY#4
MM?-N3+RU=(X^C4Y:I^W%_HP:-E<<,"/:X[KN9D64[A+XB\.X_P"#@?S'2<6E
MH%9!:1!#Q&D9_/C_`#Z]]L'K&R5745F3RCH8VRF5J9*^N$1^L$$LOHHZ<W-X
MX5C0WY!]I[F[NKR3Q;J=I)/F>'V#@/R'3D444">'#&J1^@%/V^9_.O3%O&A@
MK]MY<S0R2ST5!5Y&@DIY'@K*6OI*>2:&>CJ8FCF@E)32^A@7C+*;@V]I6`*F
MOETIA8K*E.!-#\QTT5.T\-D,(:K`T6,3-BA2IQF4QT\B>')O2<21U8EF<)4"
M=ED\A;RQN%FU+[J4!6JCN\NKK,Z24D8Z*Y!]*_ZOL\NG/;5!MR2E&6P^(@H6
MJHI\?4J88T8-2U#05U,T4,LU!H:K@.MH+Q3:5(+*%MM0OQ`=4E:2NAWK3/[>
M'S_;D=*%J"DEI#CC31I12H8OMX%%,BJSZKP>#Q^"1)?4K)8JXU#GVXI*D%30
M@U%/(^O31))).3\\]#QU]D,CEMFX+(Y6J>NJZJ&J(KI0@GK*2+(5=/05528U
M1'J9Z*&-I'"KK8ZK7/N7]IFGN-MLI[EJSN@)/"OH?S%.@#N,44-]<Q0+2)6H
M!Z8%1^1KUQ[#QN0R^R\]C\72-D*R>"F<8V/Q>?)4U-74M568ZE\Y6#[NMI8'
MCBUE5+D`D7N-;O!/<[9>V]L*S.A`'KZC[2,#Y];VR6*"_M9IVI$K9/I@@'[`
M<GY=%GV]!@UJ\PM#@L1ALIBLC+29"GQS450:6IK*:"KF!FHHUIX*I_(8JD1_
M6:%U+.%!]Q/<V\EK*UM(P++Z&H!(J?E4<&^8(Z'JRF:-)06*,,5%"0#0?.GF
M/D1PZ5?MCKW62#_/0_\`+6/_`*''NK?"WV=;'$=*W^7J".A<\2;W[\^19_\`
M8R;P'_$>\N-K_P"2-L?_`#Q0?]6UZ@J?_<[<_P#GJE_X^>CR^UO5.JC*C^9W
MF8>MN^=^Q]-8UY^F?YF&V/Y?=+BVWQ4I%N''[B[:ZJZR/:,];_==FQE92Q]D
MM6?PE8YT9J01_=@2%T>L(A>I[>.S:?WX\RGS\'P7OEJ.'B:OHP<Z:>(1G3E_
M=(1MTG-Z!M8VO9(K\&E/$,EK'<F(\=(4OHU]U::M(K0),_SO_C#F:ON[`;<V
M'\@L)E>J>L/EIOW;^].R.G\OMKIWLW*_#.;+4G=>TM@[YHLGE&W1F=J2XY*F
M>.FIPIHYDTR?<7@4O@N1=['^_;?%N;>TN`CU61K:\N4M$F5<U19V\%LX<$@,
M@+=*4L"O,UARU,VJYFW`61:/N1)S#]0(W;&EFA[EJ*-P&:]"YAOYL7QUJ<!/
M+E,!VK%O:A[>^,O1(V'C]F4TFX=U[\^5NR=L;]ZLS&PZ"MS]*^8Z[R.W-Q25
MD^6J7I!24V,KFEC#4SCV<36>G<8+!)%#2;KN%CWLJF)]M626YDGSV1);)]5J
M&HF!TD"]X'1%#>:]ON[]HSX<.V6U[C_1H[I_!A2"M"\KW&JV$9TDSJR`DBI#
M;9/\]+X%]@[V[KV5MG/=BU1Z;V!W3V30[HEV?00[4[FV[\>*#(9'N%>F*W^\
M;9+<&1V?#C)0\64I,,M7IUTK31WD!(+Z(\OWO,;1R+8P6\=PRE:2FVED$<<X
M0_Z&Q>,T)$H61"T8[M)S]%-^_;+E\,INY[L6H8&L2W)!/@,X_'VN*J&C)C<!
MR=.J!@/YXWQ@S^ZOC7L<=*?,;";Q^5-+3[AZRVMN;HNEV_N&'K;)[GQ&TMN]
MM[@PV1WK#DHNO]UY;+@XUZ"+(92IIX))OLEC\;2'L.VW$V[S;)J1+Z%`9M1H
M(&;QBL4U`2DA6!W(H512ID9,@$[7T"[,V_(2^W&1TC*Y,WAI&[M%Y,BB5%J2
MNIC1`U"0C=T_SM=I;-[IVSU"OQI[\[3@SG=7S/ZKRV\^G-FOG\1MB+X<F1=U
M>6ES-?B)LWGI_1/5I$\-)244B3K+)K6/V00[A#);V=Y,PBLVY>EW5W:HK%'.
M8"(E`+.%9:2$T*R26\:JQF!4[W#;Y;2XBM(AXEW)N=A9JGF&O;1+I7<TP`KU
M`%28XYG-/"(8[>R_YD?Q8WQU;W[WA0;JS6+Z=^-FRMD[][-['S6!E@VY!A=\
M]28/NJB@P?V-1D<IFLOB-E;EH#7TL=,LD5;51T\?E<FQANJOM%M>75S&S+%N
M$UFH12[330O%%2``?JK+-,L,)'QRATH-/1=MA_>UQ86UN-#W%C%=UD(18X9#
M./UB3^FT:V\CRJW]FFEB<TZKY[S_`)\NR-F])5&\NI/B1\L=P=V#N'HKJL_'
M_MWI_<'5F^L+AOD'DYZ;K;MG,XN`[FK*WK[>E/C*ZGPC8\5-77YB!:&:.D=B
MR^$<S;QRSM-$#7VYM93$L*VDRPF<Q2J*_K-$/$C4'1)$LKK(?"9>O">V7;=[
MW.5G$%KMPO(L4%U"91!XD+-0&-)6"2L0&1FC71^HIZLHV;\K,ON/YK[H^(.1
MV'38O^ZWQ-ZQ^255O09JJ-5-E=_=A;PV)6[+;;-1B(&I(,.=J_<+5O5M+(TQ
MC:!-&IG[:)+J'FJ>.3]/;MS@M5IGQ%FMGN/$J,"FG2`*A@=51PZK*SPQ\L&1
M")-PL[B9@008S!);QZ*')U>,2:T*Z:4-:BN;OK^>%T[T[M7;N5JZ]HMU_P"S
M8]\]4YO8V%ZZSF^<SE.F?BQV6^P>]-YPK4[SZ_CVM-A8ZFF>GR;/E8I*MA%!
MCZM&>2$NMKN&0\LW#D_0W>UK>SFA`@BG:6&!RV2*S1DB/0SR1QRT*4#$QW"Q
MEM6WNUCS?0RP0P*>,LTEM;W90+@,/"ETE@ZA&>,DL25)@-L?SH_AKOOMG:?6
M>P:?NW?&V]\]F]=]-;6^0.W>ILM+\;\MVCV/L/\`TFT6R(NUZ^LQ]!#GMN;'
MD@K\M#)`AIDJ$6/S2+,D2]8'$MU%<T@\);YP93I66+;D=[N:$Y$D,;1O%K'Q
M2*:#1W]%K3((898ZR%EM]:H"SPO=31P013*/[.61I%;0<A/BHQ564WP^_F^?
M#CYO]S;BZ.Z5S&^4W308+<&[=CY;>.UZ3`[7[GV5M/-T^W]S;QZJKZ;.97(Y
M+"87)UU,LJY6DQ%8\53'+'`\>MUK803W^W3;BD+1B)(I'C<:94CGKX4C+D!6
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MUVTL7C,U%69';-7\<I*`14==4QUSUYDIY9%CB\]U@=3=B='U(K,BJI+R5M=O
MN8%",$823?7I'X;`,KJ`14D*J6W,ML)(&'CB5XW5BH5'BW"&QEK(&9"B>(TW
MB`E"J<:'4!6K/YCO6N.J<+MBOZ7^1U)VYN3=VVMI;?Z+FV3LL=GY8;UV!O+L
MG9^Z(P.QFV)0[1S^W.O\PGWE7G*=L?7T+TE?'23V0IR:2RP#NGB6X,R@@^";
M6.*69'-=+,(I4D3PC(LHU")G=64,1!98'NS($LS'#)'(U0LR3SK;HT8IK_M6
M57618WC!#.JKGK%COYC76&:VGF^Q=L[,[!WELV@V;U#O:*'"8[;&W<UA</VG
MC=[5[UF_<QV=O+876NRJ+;<^R:BDJYJ[/01"N*T\3S2RPJ^[HBSBEFF-8EF=
M=8H$*K:VUVK#7I8M(ER@CC"F1V(4)J#!78('N?`2,%;AA,#&P)<2073VDB40
M,.QT8NQ.A44N7"9Z-KT+W9L;Y']-]<=Z]:3Y"IV)VCM?'[MVS)EJ-:#)C'9!
M6M!D*2.>K@BJZ::-XY/%--"S(6CDDC*NRJ\LYK&?Z>?X]"/YCMD19$PP#`E6
M%58!E-0P!!'2*"=9UE*@@I+)&PP:/%(T3BJEE(#HP#*2K#*D@@]5@[?_`)J[
MM\A\QUGO+$=+X+8F)^17>/0N2-/V%O6+M';..Z8Q^\\I4]F[AQV?ZYPO7-1A
M*^AV7)/)C<?GJG)I%51_;I4RI)$"O;;VWN=JL]SO6,4<UA=71*C4L2VKRJRR
M?C8NL1*E%-&8:AI#,##<;2:UO#96D9DG\;;XU5J*9&OHK=QHIJ4",W%/U"H8
M1MD,R*PCXS^;5\=]X4NWZK8KK4)6;OZO_CB[AW5L69Z'IOLQ=SO0]R4(ZWW3
MV2$Q],-KS!L-E3B<]`S*M51TQ>/6NT",L;LF/PA-XZT+/"T=I/<HK:-4;F7P
M&1?"DD`8.#W(5Z9@6.Z^J6WDUL(/%A(PDP%U;VTE-6ET$?U".QD1*J5*@JQ8
M*2+^9QU=69-\1/UEW1L'(T,'4VZ*JD[0V50863/=;=QXSM'+;+W9LZ3;^Y]R
M4];-E*+JC(.U'7/0U=`6CBKHJ:=C$M+O_=?!N%Q>@H;1KE)XQF6*2UL_K'0@
M=A_3H*J[*6#*&)4].0PBYELXK6594NH%E@E6OA2(;VVLM52`X'B7*$50$KWT
MTD$JW<W\R#I'`2;"H,;L[N/>VX^S]K=![KV-M/9^TL#59W.T_P`D<?V1DNM\
M8IS6[\'A\?DVI^J\I_$6JJN"CH/VF><HSO'>XADMKN_LF0M/;7%S"^G(U6MH
M+V8@XJJVYJOXG<:%4L5#)E9#;V]RSA898O$4FO#ZR*Q`-`:$SS(,T4)5V90#
MTD<#_,UZUWSL;+]A;-ZY[.Q>#VILCK3NS<5-V7@J+:&7ROQ^WUNK.;*SG8^R
ML=B\ON:IK:O86>V[7"OQV57$S314,DE,989:6:9WZ;3)`99D%LUU:P,U?@^O
MC$EA,U:`07`=23420H)3+&LD9B/E\=A/&+&?ZL1711-(!::P=5O+8BM1-#72
M``4ED:(1.\;&1;+8Y(YHXY8G62*5%DCD1@R21NH9'1A<,K*001]1[8961F1U
M(<&A!X@CB#U6.1)8TEC8-&P!!'`@BH(^1'7/W7J_7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=?__0VV_A?_V3]B?_`!(_>O\`[^S?OL%<S?\`):N_
ML3_CB]&^R_\`).B_TS?\>/1J/9#T:]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U$CH*"*JGKX:&BBKJI%CJ:Z*DIXZVIC725CJ*M(UJ)T4J"`[$`@
M?T]U"(&+A`'/$T%3]IXGJQ=RH0N2@X"IH/L'`=2_=NJ]>]^Z]U[W[KW0/]OP
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M%3SI30-5PA)'-*H\<H#E6:Q`Q@VV.S6V2WN70JX+5(_4HND@@X%10]M,BO0;
MFW&2[-PUQ;JX*$+C^SJVH$$"IH:CNXC'1>=V[0V_M_<>,W3AL=V`*S,[KS$5
M3)G</)3TE9F6S54LT<66I_W,735[2L](LM,M+6TL7,R%SJ"6^[?;Q127<1G7
M4SZM:55FUUX\5+'X#2C*,G.1+M=[/,/II3`0J+30W<%T^APU!\6=2L>!ITN3
M]3S?D\_U_P`?80Z-.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[H(YMKU-3E<_E,;//CLEB,U1)!A]OR+AZ>HQL-,M52U_B>0XVMST\5:SI-/
M$(6:-H'!1M09TFK$8(/`?ZJ5Z6>*`L:ME67B<Y]/4#'E]O4?!U6Y,=F),9B*
M#,5=%,F6B8YG&56+Q--732T59C\Y.#3PT]$(XYJB&LIJ0F.>ICU1*/(67RE@
M:`&G[/S_`,_7G$3H'=E#8X$$TX$?/RH3P''AT[U516[=S5=3_P`0GR=1E-LB
M:'^.UGVF/RVXVR"T<:THA!2@I:.B>\\5)&IAI[.PE:S!V.-I)HX0W<Y`J>%2
M:?L^SILE3%XA2BHV=/$*!7\R?*O$^G1T]M8NIP>W,!A:R2*:LQ.&QF-JY8#>
M!ZFCHX8)V@;QPEH/*AT$JI*V)%[^YKMHF@M[>!C5D15)^8%.HRN)5FN)YE%%
M=V(^PFH]>GP$@@C@@@@_XCD>WNF>B^;WV?M_:53@*W;5`N(;/9S,0YN.&:62
MFR+3T62SGFFIYS*?O4KE;Q2HR^*&\5BFD*!^:=NLK:UANK>W"3&4@D>>JK&H
M\S7@?+APZ%6R7US<R30W$I=%C!6OE2BBA\A3B/,YX](FNSF/H*A:.1JJIK3&
M)VH<;1562K(J<W"U$\%)'(:>%R"%:0KK(]-['V!2P&//H2+&S"HH%]2:=0Z/
M,YU)J6?(;6J8J*<)(BXRL3*96F<NCQID,<8J-8M4+6;PR3E)5*V((/NK%M+5
M7%.K:$K191JKYX'Y'/\`DZ%'^7C)YOC_`)B7QRQ>7O?Y$2>*>,Q3QZ^Y-X-H
MFB))CD6]BI^A]Y=;5_R1MB_YXH/^K:]0/<"E]N8_Y>I?^/GH]'M;TWU4[N'^
M4)T?N#Y&93O$]T?)7%=?[E^0FU/EAO/XF8O?FV4^-&\?D;LRJQ.5PO:F9V]5
M['J]_P`.2.X=O8W)U%#1[BI<54U]!%))3,-:M;9W?9FLVA<RBT>Z>V$G<+8W
M:RK+X5-.!X\[1*^M8C*V@`4`KNX.\+="9C&US;6]O<&,E3/!;!5CBD.:*418
MY/#T&1!I:NIJN.=_E'?'C<&P<3UW6[U[?3#X?;?STVQ3U=/F]J+DI:+^894Y
M>J[CGGD?9LE,U7MJ3,R_W=(B5:4*OW2UEC=,MNBV$.W`GP$VJRL`?/P;&ZAN
MXF]/$:2!5D--)0L%530@TBW.>'>Y-]5$^J;>8MS*YT>/#;26JI2M?",<C$BN
MK50AP*@KF@_E@_'&A^2/QT^4'W6_:G??QLZ@V]U'MG!5&<Q9V/O`[+VGFMC;
M!['W_M^/!1MF>S-A[3W7FJ'%9&">DBIX,Q4J86'B\9B]W))NW->[LJF7=Q)X
MJ&ICC:8KX[P@DZ&GBCBMY22=4,2+QJQ)7MP^T\O[.TC?3;<1H(PTB)1XHY2*
M:XXIA]1&M!2;NS0`%8ZO_D&?#'I_=OR*W#L7.=DXO"?(7KCNSK-MEC%](_9=
M68CORDRM'OS(=>;XAZ<@[?J<D(LY5BA&X=R9VEI4F\?A:-(U0ICLPO+5WRP\
MSO;2Q11>(:+(L,+AXXAH"HP`6-"\B/(RH"S%RS,:F^D_K)8<S+&BW<%S]1X8
M%8GFI0NP-67.I@D;(@+'2```!4^5'\G7X\?+O&_%K;W9G8O<=#M/XK;<VAM7
M;>VMO/U,\6\L3LRHVQ48]]P[CW/U3N7>^U,Q7':M.E77[0RFVJR>)BOD&F/0
M;M=L_-5SS;+&K7TDRRZ*LJ!UD:5:%&672':IC,I1@*,I#.&*X(!;\LIRM$["
MR$;)J-"Y5XO!:H8&(G172WAZU))5ABCX/Y5_4VT=Z['[=Z][![KQN_NK/D]\
ME_EE@L71;KV508;?.X?E$E++VGTKO*3*]>9R,]0[D_A=+2IXHTS%)"NK[Z1B
MVHNIX$>WO])'=/:['=;8(Y<)-!=3?4L9:#$BSA7C=`JJ46J,`05UTPW#7&\K
M6^J\V^X66,GQ(7VZU6RA,9)-0UN&64-J+ZV*E<43'PC_`)8.S^HOY??9OPX[
M^PN+S5#\CMR=V[G[FVWMC=6:RN/P^+[>SE>N%V'MK?4M!M[/5M-UIL*'$XC'
MUZTU(8FQRM#''&J*+7=LL_+O+&P&]F:7;K*W3ZA>R1KJ*3Z@W2Y;3(MQ1D8U
MU>$C,HJ4#=M<20\Q<R<P+;1A;Z]F<0L`Z+;.GA"W<4`:-HR^M:`4E=0?Q')L
M_P#D\=,83"U";[[\^47>>_ZSM3XW]DU/;_<6^MG;@[".(^*6Y:G=73?5=,^'
MZ^V_M:@Z[P^4R%6]6D&,CRN1DJY9:BM>;1(BH3%;W9=Q"(+VTW4[B[@4-S=&
MVEM`]Q3!5(966-(_#5*DJ!J?4BDM%ELMSVYY'-E/MOT,:UJ+:V-Q%<LD)-35
MYHD9FE,A(`&`!02OD+_+@I>[OD_C_ECLSY=?++XR=D)U?M7I_<F/^/\`N'J;
M&;8WQL?9^],[OG$X[=-%V%U%V'D)7.7W%4I(U)54FJ!](L;L4^VAMMGW"1',
MEK=74-Q)"^8VD@C\)<#2U#'56[N#&E,46[@_[PL[&U=1'-;13QQRIB15N"C/
MDU7#(K+5<$"M>BO=W?R"/A_WGA\%!G=Z]OX7=FWNZOD7W1C^P*2EZ1W=GS/\
MH=]0=B]G['GPO:G378.PY-IMN:C@EQTHPZYFA6+2E<1)+Y*PQ);R[(\*A8;.
MPCLR@`I-##-)-")&-75HVEE"M$T9*N0VK%'KRZEOA?M<4,T\D4@?-8WBM(;,
ME172?$C@C:17#J9!J4+0`%FI/Y/GR%VU\_=B9_K.;:'7OP#V5\B^M_DO5[)_
MT];CS]+N#>^Q.F9>MLOE<;\;Z+HW:NW-I[T["8P4V3J_[Y5^%I:>G>HH<;3S
M5$B!7M<JR2;@^_1![<0;M#!$*R!8MS61&A1V*F.'5/+,RL)9-1,:2A3TAW*-
M5AL$V:JWC?0?4S&D32-9S1SB618ZB68>!%"CCP@R@/*C-&FD_'P6_DU_%K^7
MUW#O+MWI'+;VKGW#ALUMS:VS]V8+I8XGK/`9_.KG<CB]K[NVEU)M/MC/1,\:
M4RR;DW%G)A2H%+LPU^]6%Q<66TOM33&4N(U:5J!V2(41"(PD9_"68QZV*!F8
ML6)W?0Q7NY+N.@1T>1Q&GP:Y*ZF&K4XXOI56"J'*@::`"M1_!#";FV,_3W9.
M2KAU[UQ\K<C\B^F,IM/+QPYZKQ&X=R9?L'+["WM!EL-7Q)A3N+>F:Q-5'32E
MJ_$-"ZR4\VH*QMU;$<J7*DB^VI&A&=230JC1P>+@%M*-"Q3`%Q:12ABM%#]]
M)+=2<RH)2(-S$3LPQ)'(#$91&:44$Q%5:A/T\\D3=U7//L'^6WU#O?=>[]]T
M6\=];8W;NON_#=\)6+0=<[UP6`W3B=E9S9CXW$[*[(V'O#9\V'JWW3E,RC5E
M%55M%GZYZZDJ()%C"LV\`MX;:`2,R)+=L6)K(R7AC+Q"3XXUB\,"W:,I)%&\
ML2OX<KJ7;BX>ZEGEE'<\-JE`2%'TA[&TUH?$`03(U8Y#%$Y0/&K!*[7_`)4'
MQSV[MC`;,J]R]K[HVW@-O+M1:+<.Y,(U3DL$FW_D%MM:;(Y+$[9Q5>:D4'R/
MS3"HADAG6>DHG#`QR^989Y?#"HY641*BNN&4QP6=O'(OD)(UL8'4T*^(&)4@
MT&Q=2`W!TJ1+/+*X(!#&:[CO)5*_#HDDCTLE*>&[H*=I43-G?`K9F#[!V9V[
MO/M?MGM?M?9.\-O[EQ^^]Z5&R*/(5N&VAUMV!UCM+8U=B]H;+VUM]=N8;%=F
MY:N>6GI8,E7Y6?[BJJI@!&&B%,MS<!0+BXCNA,0*"5[J**%Y"OPH4BA58DC"
MQ(2[:"SL>D1C!M?H0S?1HL"1*34Q1P7"W*H&-6<O*H\1Y"[LH`#"@Z"E_P"5
M+TM28S8=)M[L3LW$9+KB;8TVV<KDJ'JK?%-')L/%]BX;&U-=M3?G6VY-EY#*
M/1]F5[Q5LF/-7CZF*">BDIY5=I+2.9675\!5D:F&*-:VEHP5_CB8QV41\2(I
M)W2IJ\*1DZ5/,7296&6N99_/^TENY;P@C@\8EE8"-PR46-B#)&K@V7QI^/0^
M,6P]L=-[3WKG=Q]2;`V9B=K[(QF[H\37;MI:R#-[DRV7R^:W+C,3AAE'KH,O
M34\<9A"QK2:_UNY9Z:ZFNB[W5&E"01H1BD<%ND/</-G*!V;`!P`!TE,86>26
M(D++)/+(#3,L\[S,5]%&M@%\OL`Z`.?^73L3.9O<-%OKMCM#?_2^X.Z^P_D#
M-\?MP4765)L6G[(['J]Q9#)5:[GV[U_A>U*K#8G);JK:BBHI\])$LCIY?*L:
MJ"ZWM+>+;;';94\1+6VG@@8DAHUN/'$K#3I5G*7,R*SJVE7J!J4,%TMY<->3
MWMN_@S3-:F33D/\`2);I&"'U45OI8&<+345(%%9@8E!_+HV70]<P]=9SLWL3
MM#;6VJ_9==L;:F\XNMMM8*@Q_7&%W%AMK[1SN0ZXZSVSF]P8_)4.?-+E<Q7O
M79^IIX(B*H2(2ZB^EGNX9Y9E6;<W6X+.Q*>(]Q;O`U0E$C_M#(/#0`2G4591
MHZ:L!!8SLEN&AV]HEBT+WZ(Q<13]OB$LY'@K&JNY7PZK@L7Z`3X_?R[NP,[N
M7<6]?EAN+<=5)#@^A-E[.V?!V9M_?STNV^B:/MVCH\;4;HV_U%U+3#:>7I.W
MZJF57QS[CJ%I4J:W)O.U@_<F&^L]S2\U275]<7,DS'#,+JP6RD,A4Z#)3Q)`
M8ECB5B.QJD!B"6>UNK`6<4<%E9V8@A5:L%I?07H*:ZOI4VL$8$S2G2'`(%.A
MVZY_EJ=<[$W9L'>F4[@[H[`S?6#=*T&R&W55]?4M'A]I_'[&=LX7K/:#4NUM
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MUZULEI*6"AI::BI8Q#34E/#2T\2WTQ04\:Q0QK>YLD:`#_6]ZFFDN)I9YFU2
MNQ9CZDFI/YD]%\$$=M!#;0BD4:!5'H%%!_(=2/;?3O7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=?_T=MOX7_]D_8G_P`2/WK_`._LW[[!7,W_`"6K
MO[$_XXO1OLO_`"3HO],W_'CT:CV0]&O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'JZ6FKZ6JH:V".JHJVGFI*REF7
M5#4TM3&T-1!*O&J.:)RI']#[TRJZLCK5&!!'J#Q'6U9D971J.#4'T(X'I(;2
MVI0;/K]PO%5T#U&Z,O%74-)'3PX]H,3A\92XW&8>*E6=AD!AZ.(J9U02/&Z^
M2Y`/M):VJ6KW!#+JD>H``%%50JK3ST@<>-*5Z57-R]TD`*FD:4)J35F8DM7R
MU$\.%>'3'G.J<5G:#;-!59?)U#;5SV2S^*R^:CI-Q9^BJZV.J:B&/RN0B$U&
MN%KIHIH`1()(Z=890Z$^VIMMBF2W1I&/AN6#-1F!-:48\-)H1QJ``:CIZ'<I
M(7N'6-1XB!2JU52!2M0..H5!X9)(H>DGV#M3M?<NSJ/#XC*4D=1B*VNI<O'G
M:_&5]=OW#T7V<N'SQRD>-H*/:^Y)ZNG>7TF..C1FLQ;3I1[C9[C>6)MXY!45
M#:BI,BXHU=(5&)%?1?MITKV^ZVVUO#/)&Q!`*Z0P$;9U+2I+J`:>K?MZ#';F
M4W%5XI<KN+"M0T=7GZ_!4&1H9J#(T*5='4_9"DR51B\AD8J.6JJ4+4TSE8JF
M-TM9B`8]N=LNK>$W?A5LPQ75J5J$&G=I)`J>'\^A2MS;O+].LOZ^@-0@K4$5
M[=0!-!Q].E#4UD-(T*2K4N\_F,<5)1U==-XZ:+S54[PT<,\J4U+%ZI)"NE`1
M<\CVBBAFG8I#$SN`3114T'$X].G&94&IW"K4"I(`J>`SYGRZSPS15$,513RQ
MST\R"2&>%UDBE0_1XY%)5A_K?0^V^K<,'CUD^O`Y)^@]^Z]UZW^\?7_#W[KW
M7O?NO=>]^Z]UV%8\A21_4`^_=:Z@U.1QU%I^]R./H];M$GW5;2TY>12JO&HF
ME0M(C,`P'*DB_P!?>B0.)ZL%9OA4G\ND_!.*?>5:K2PO!FL;30TQIZR)XDR&
M$3R55/6TWJ9,I+25JM$58:J:,W3TZO=:]Y^8_P`'3A%81C*GT\CZ?+U^?2MN
M?ZGW?IKINRV+I<SCZG'5D4,L4Z,8C-"LXIJL(WVM;$C_`*:BDF(=&!#`C@CW
M[."#D9'VCAUM6*FH_P"+'F/SZ%C#=IT(CQ='N7&Y+#5#Q4U%7YN=Z"HP"9((
M(?-)60UC5E/0UTJ`I/-!&B-(%D*GGW)EES/M]RUO!*6CG8`$L!I#>FJOF>!(
M`Z!]UL5U$)I865X@20!75I^RG$>8!)QCH6D'D57CM(C`,CQD2(ZL+JR.FI65
MA]""0?8E]".'1%PX\>@:[=S6`_@%31QY_#1;JPE539O$XR::2JEFJZ420S8Z
MK@H!+/3_`,3Q]3-"H<QEI&2Q]ASF-K*;;Y[:2[C2Z'<@+"NI<TI\Q4='FR1W
M27D4RVSM;-VL0,4/F">-#0^?06XC'R8]*V6HJ%JJ[*USY*OGCI_M8C,T,%/%
M!!`SS2QT]+34Z(@=W:]R3<V$7J*`UXGH9NP8J`**!0=/<'^>A_Y:Q_\`0X]^
M;X6^SJ@XCI6_R]O^9"9W_P`3W\B__?R[Q]Y<;7_R1MC_`.>*#_JVO4%S_P"Y
MNY_\]4O_`!\]'D]K>J=4]U/\SC=T/6??V_(^I=N-5]-_S/MK?R_<=C9-UY)*
M;/;>W%V]U-UD_9-95##-)0YJFINR):L8Y$D@:2E5/,`Y97MNB%['[=.YT_OQ
MYP],^$(7OU!7AJU?1@FM*:SZ"K^Z0_NZ3G%`=2[7L<5^O_#&DM([DQG^%07T
MZA4T%:>722E_GA_'W+3=VX;`]0_)+:]5UEU=\P]];/[$[*ZJH,7T[VKG/A/+
MEZ3NG:.P]QX??-?D]P97;CXY*HJU/0T]12S!$J5J0\*%\%R+O8AOL';$;:SN
M51\2-;7ETEHDRJ*@JL[^$U6!U#4H:.C%4EA3FBPY9E;7-+N(LF>/*1SF#Z@(
M[$`J6B[D.DAC4#(-!=PO\VOH:HPI@RNR>WAV)#V[\7.C:3K['[5V\NX-[[P^
M6.P]N=A]:[KV%15>]_#6=8OMK,U=96Y.LJ:62@@P]?Y(BU,0QQ/9A-SBV])%
M5GW;<;%M;`>`VV(\US+/3X8A:H+I2H9VADC81AFT]$$-VS[==;@\1T1;7:WH
MH/[9+N7P(8X*_%,USJMPC:!XRE0Q%&(2;!_GY_`OLK?O>&P]JUW9-6_3?7?>
M/9N(W(V&V8V"[JV]\<L=DLGV[#U31TN_:K=T.2VY3XJ8PING%[9CR2KKHWGC
MNX(UOT/+M[S*T,BV<%M'<,A`\4V\LBQQS!02NDEXR4+"95D4M$*/H._H9?W_
M`&'+VM#=7%X+4/7]);DJ6\%F^(GM<:T5XBT;`2&J:N.,_GH_'>MW=\7M@Y+X
M[?,':.]/EM24FY.L=K;WZ]ZQVEGJ;K3+[HPVTML]IYS%YKN2EJZG:^Z\GF!)
M04.'7+;C>D@>:3&1HT/E/X-LGGWN?E_4B[A"@,P)-(7;QBL4FD%@^F!F8JK1
MQJ5\5T.H*3/?0KL9YA34^VM(Z1E1_;>'''([1DT72HE1079"[$Z`P!;KCB/Y
MPG\2^4?5/QKPWQK[<["B[*^3'S"Z!R79FQ<%CQMC9'^RH9"+&9FJK:+);GDR
MN>K#+50U60D@2".''R)+!%-*_@4FVV;]X?NTG]..?EV;=`6XR".X:`11+\W4
M1DL<3S6R"JRN\1IOD/[G++0O)^\]OM*?P?6VD=UXCF@PB.7H!_90W#$ZHU64
M+-\_\*`NK:'9W853UQ\1?E?NOM?J;Y)="_'?LCI;.[>ZSQ>\]JU/?>?R>&VK
MNJL?;':&\\*J9&?;]=04F*GK*7+?QD04];!112F=7[3_`!V?DKP9$^BWC=39
M>)7^RD2-)I%-.UY#$^J/0QC.B35("FEF-R#;7;<T27*D7&W[8]XJ^4Z+*(04
M/Q!`[1EF95)26,H&UDJ..!_GF_#+=GR2WQ\6]IXCN/='8^U:KLK;&W7P.VMF
M9&A[5[7ZBP.2S_8'2W76'A["_OU-V!A8L+6TT<N7P^(P%;5TDD=-DYAH9V;2
M<7^W7NYV2-+;QPO/&%I6XMXY1$UQ"20HBSXH\9HG,-90FD=.7$1L[VUL;QEA
M=Y8HI&<T6WFF4,D4YXZ]1$3>$)564B-F!Z%+H7^;C\6.]_BA\BOE_'1=F=9=
M>_%/.[TVUWEMCL/`;;J=^;1SFR-O8C<]=C::CZUW?V)M;<E5E,9GZ,4:XW+5
M1>IF$$GBE5T53N"FQVK:=W0&XMKXA8%B!9Y)6N/I5B56"U=YRJ(:Z&UJP?22
M16TBDN=WN]EE3Z>[@C620S$(B1%'D:5VJ=*1K'*9-0#+X;57A4JE'_/GZEVS
MC?DUO;O?H'O;H?:O3&XOC)L7KSKCL;;6`VO\A^S>P/D9L[=V[L;MB7:><WA1
M]:8"%:#:S5-%DY]U)B9*(N]14T\J>'WJ4&WL[)Y!KW*?=+NT$*%28Q9P6T\S
MREBH4QB=O$"E@0(Q$9&D535#'-)JA8K9)ML=TTCJP5A+=36\(AH&+B7PU*U"
MNK%Q*L8C8@:.V_YM.T*W^69N7^85\2]FP]MS46Y]L;`PO6/8&539]52]CY?M
MW;G4.<V5N[+[8DWAC:3);<SV=(DGQE1DJ"HT*]/4RPNLI8WCZK;9.6UAC69-
MRFA$;+JS'+KRJE0^M6C:/0R@ZP>*T)?VE;?<#OPN9&@;;[:XDD!`)5H(?'`)
M5BNET*."I)",*@,"H+'O?^?ELCKONCXX8?>77V#P7QXW[\4:WY`_(+MR3<67
MK\]TYOB/K'>'9%/U+AMJ46#9=SYB.'9\E-,TDU/()*F'T*"3[4N]JFX\ZQ"1
MGV[;XH39NM"]Z\S61154D(H:+<;0@EZ+)(5<JJE@E2*];;>69GC1-RN[F6.Y
M1B=%M'$]Q"\I<`D@36=T`NG48XPP!+!>A+V1_P`*"?AYV?MO&+UGU=\G>PNZ
M,MO:NV?#\9-A[`V+O_NZCQN.V75=AUW8]=2;%[1W'U])UYCMFTIKJF:EW#4Y
M./\`X#_8FL_R?VEW![BTLIKR&'Q$BM[B65LB.V6W,:,;AJ5"&2:%5:(2A_$[
M-120+>W,<T@C=]#.\2PJ2`]T9B]%MU)RRB.1I!+X7AJFJ0JC(S1NJOYWNQ,M
MU7M7LWM;K'=E%D]T?$_XR?(#%=5=1;=R6_-_;JWS\H.YNP.F>O\`JC8,>4R.
MWH=P;AS.X-G1I'#60XQ*4RO)4U*Q*2AM?V9M;B\LK1)+F^6_M;6-(P-4CW&V
MIN3D5(71#%XKLY=0(XR:%B`?(8G@CO))E@L2^Z%GEU*%CVZ[BM5+#3J629ID
M58@&8RL$`'F*6Z?YQ?5FQZ>AW;O[IWY`]8[9Q_Q3^0?R:WYUMV9U'6;2[ZVG
M3_'SM+8/6&Y]LS;:R.Z(MNUM?-D=[)+1O1U==CLI!IFI*]X^'0RR6L,&YW2W
M*SVT(VW2T08U;<;F>U12C!9`T<D)#J55A0LH=60E3;V<UTM@B+X<\M_<6Q\3
M"CP+!K\L&74I5HEPREA4Z&"NK!4CV3_..Q-9\5/D1WET_P#'OY&;;[%^-O9&
MS-D=@]4=V]0X#![FV[A]Y;9QG8&`[%W3C*CN;:6%PO6.Y]A9..KI,G+GHJZ"
M::&*:A$TBPEG=O%VRUVN]ED1;6:ZN8)3\1@EM#HGAD`(_55V0(L?B+*3I4TU
M,J?:FCW6:]MK>-VF%C#<PG@LT=P3X3QT!+J`DAD!T&-4=B:H4(G]G?S??CET
M+\%_BW\UM^0]@=B[6^4=+UUB^NL7UMM#;^W<_N?=>]MH9'=<R28[LSL+;&S]
MBX^AH\%722#+[E5(S$(8IZF5DUF&\V_[JYC3EP*SW+J[J001X4:(YD).FM5D
MC(1`TA+45#I8AK:%EW+:+W=7*HEL=,H-323QS;^&NG76D@*ZR0E!J+"H!';J
M7YQ83N#N7L;K'`[:RV*79_Q+Z)^4M%0[EQ:XW/18ON^3L@8S`YVJH,YF<1_$
M*!=AE)HZ02Q1NY:.HJ(V1@DW59-KVKG"_.F27:;U[<@:@KLMHEUC4H;.K3D*
M5X,@(Z?M1'=R<HJ`Z+ND=PXU`5407$,!."5SXM11F#"A!`XUB?R^?YV'9GR^
MP'9_8N?V-\6]X;<ZSZ3RG;6<Z*^)'<?9G;?S"P=;%N&BPN*VKNCK/L7J7J?K
M/%UCF2=*R:/=\M-23HA:7PEY8[G1!LDN\SZI80MJ`\&EH0]PHD[WD:,JB1B5
MBVD_V3"AQ6LR,>9&Y?MY$259KQ:3$I(T=JS1ZXU02!C))X2H"17Q4X&H!AMG
M_P`]'XT]D]>_'_>G5O1ORP[1W#\B^V>YNE-I]4;`Z_Z\W)V'MW??0D&)K^R(
MMX-1]LG8M-M_$87,PUXRV/S>2Q[4H8F57&@VDA,=SMT&L&&YVMMP$N1&EM'.
M+>1I"P5E*RL!32=6-!:J@U(,=ON4]R/":UOX+0HQ&MYKF%YX0@!-=2(U:E64
M@AE%#0+Z#_A1;\/ZN)*^J^/_`,X\3@)<?CMU0[KK^A</+M:;JYNX:GH7<_<:
M9K&=AY"F7K78G:D46*R56^FKFFJHS04U8!*8[V%NU_/MD",(S=26:@R518QN
M,22V+R$C"W.K1&%#.65F*"/2YK-XL4-Q*+=W,?U@TI1BSV&HW<2$'07@B4S/
MW!0G:6\4&,&5WM_.1^+_`%7\B^[_`(V]P;,[SZHW'TCTYV3WQ-O'=^S]JS;-
M[(ZVZKH\77;GS?6]+M??>X]_UBU4&6C_`(5_%L%ATS!#"C:8CE##,)]MWB_C
MC8S64D,;P4K,SW%P+6!$450O+,T:JC.K`2(S!020H,!$^R1AT-I?BL<]0L*C
MZ=KEVD9M+*L4:2>*P5E1HW4FM*P</_-JV+FFZ'K-S='_`"'^-M+VEW5O#JW<
M>`^4O4-9U_NG"X+:_P`>-Z?(B/?V(J,+NC<&U<OM7([2VFSK5T%=E)()1)25
M--3U0TJJF^GLY+SZVZ1$MMMO;F<"NN![)[=9(I%IEJ3J08P\<E0(Y"P90W`K
M7EK<S6<;2.)K!8B!V2K?7!MXV4FE,JVI9#&\8`9TTLI*J^!W\WWXC_S#MW[_
M`-C=)S;YP.X]C[3H^R**C["H-H4/]^.ILCE'P^/[/VN=H;VWHV/V]49`(C46
M>&%S].)HVGQ\:L2-&.2+:+O>+M?!BMBHG1R-<.N-I%UZ=2,"J2`F-Y`K(0VG
M4FIEY4&XV^VQ?J-.7$+K\$S1LJNL8-)*C4C`,BZE:J:M+Z2?[D_GT[&R>3WI
ME^L^A.X*+IC:OQ3^5GR7P?=/;6QJO:^WNW,1\<=R['VO1YGI/&T.=GEWQL?<
M62W'6I/)7U&"RE-]M`_VHAJ8Y69M3)+;7ES>1-;.@VDK$X_6T;I=>!$\BBH1
M&C*RQD,S9(D12`":0V<4V[;1M4,PE-QN%Q:M+&=4(-M;2S3!)`#J>.2+PF&G
M2W<8V?2U#0XW^<)T'/\`)/;GQBKNI_DC'F<MVKUQT1E^ZJ7K'&2_'K;O<?;'
M4V$[>Z^V7E=\+O.;-4]=N_`9CPTJIBYC!4PL*HP1-%-(8VMF;Z]O[2W.CPI]
MPB3Q,>*^V%C=)&14%DC'BBND,I`!UU0$#7JQ;7M>Y2#6+BSL;EEC%3%%?R>#
M`\@--*F4%6(+:?,Y%6WO_P"=GS*IOD%W3U/\*_AWLKY(;9^*%'U9-\A*K=_=
M3]7[]W/GNU<;3[JQ^POC_M]MH9S;VXMRX#8LR9"MJ=P9/"8TR5$<$<K.K^RW
M:W-Y_NPO(RFPG=/H0Z4>4N@@-Q-X9T@0VQN(PX+>(X#F-6`KT8WX6$?0V<JM
MO9L/J]+U6)59IEAA9@&8RW'@.4*J444#D$@%6Y3^:QL6#L/Y4]=;8^*WS'[%
MJ?AU3RT_<&[=C====U>P/[VQ[?V;NA=@[6W7G>V=OTF7W2V!WDE9+YEI*"CI
M**HGJJF"(0M-H3Q':[K>E;_=;'>R6RLU%\1H9FAE=`Q'Z<=!([.5HKH`#(2@
M<^GF&X6&TNH_>4]E'<F,=QC6:)I(D<J"/$D*-%&J:M4F`=/=T#&T/YYWQ3WI
MMCKSN.#^^&U.D-T?'CY0=X[GGW3M)*S?FUJOXP=I[%ZFW7L]J796Z-U8#+YR
MMW3O*.FH8<5-E:?)O)"U/5A";J[B)K6._DT-.RVFV30)$I+SMN<TT%O$B,%)
ME:2+1H;1I:I)TY%(U$L:EF$+IN<UK,9654A6"R:^>9W!*K&L*ARU2:570'P!
M8Z[_`)O?1>],OL_:NZ^D_E+T9OO<7>O6_0>X]@=Y=8[?V5NCJ_/=T[5W!NSI
MC>/8*4N^\WAZ7KOM*';-50XO(XVLR4D>5"T=7!33-I]VBMS-=6EFDT?BR_6(
M>X4CN+*`74EK)YB>2V)G@"AHY8E=ED[3TBDN?#MI[MH)/!1+:530#Q+>ZG^E
M6Y2I'Z,=S2&;5ID1V7],@UZ0?;'\[_XT]/=*[,^26Y.F_D]7_'_>O;78O5-'
MV[A]E=<KM+'+UQOQ^NZO?M8V=[7P>6R6S=U9RCK9L%'BJ7(YO)X^@GJDQPB$
M9D3[;3<KGE.T5A%+O-M;S6^LXTW3TMU?1K(=T,<YTAECBFC,C(Q95,)[>:(\
MRK$GC2;7=202K'DEH8U>5DU:5T)(6MF+E#]0CQ@$49K?_P"\6&_Y7%_XLG]X
MO\U-_P`6;_E<_P`W^G_:?U_X>UO[OO/]\_Z-X7$?VG\/'^?#Y]$/[^VO_E*_
MXA_5<#_8?Q\/Y<?EU__2VV_A?_V3]B?_`!(_>O\`[^S?OL%<S?\`):N_L3_C
MB]&^R_\`).B_TS?\>/1J/9#T:]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!QOGK7&[WJ*+)/DZ[#9K&4KTN.
MR5-%35:4P:H%7',M/4(LT%1%4J&$M/-!(5]+%EL/95N6T0[D\$S3R1W$7PLI
MX5-<@\<CY>G1E8;G+8I+$(D>!_B4^>*<1\O4'UZ0L6X.YMHG3EML5^]Z(5!^
M[GA:BJZM5*/$:C'9'$.DJT,E4(Y%IZG'&H1'=0QTBQ7%<\RV+.MY9"ZAJ3J0
MJ&IY4`IBM,$5`KDTZ,&M]BO`#;W?T\E!AJZ?SKYTKD-0FGKT)L])N/<+8,5\
M%'BML9;:V8I]Z[:G?[C,KD\O1TL5!1TN4IU$:0X])*A9V0H6?3:_X/F6>?P0
MX"VS1,)$.6JP%`&'IFM/.E.B@-;P>-H):X653&XPNE2:DJ?7%.I5+LK;5'MA
M]GP8[_<!*DBS4TE1.]1--+,M0U;+7%Q5-D!4HLBS!@Z.JZ;!0!J/;[..R_=R
M0#Z/21I]0>.>-:YKQKUI[ZZ>[%ZTQ^JK6O\`*E.%*8IPZA;>V#A]MY89JDK\
M_6UR4-3CX6RV46MC@@JYJ>:H:%$I:<K-+]I&I8D^E?I<DE-8;+8;;,T]JKB0
MKIRQ.*U_R=/W>Z75[$(9]&@-7"TR!3_*>DONWK^I^^7-;-H*(3UCR+G<&:M<
M92U\\T@DCS=')*'HJ3(Q.6%2H114QMJYD0:BK?.71?,MS8*B75>X'M#U\Z^3
M#[,CY]+MKW@0*8+QV,0':>)6GX?4@^6<'Y=-./ZXW%7U4:[G..Q&"@F5JZ'%
M9>LJ,CEE`/CHHZY*3&C$T<TS*)7#&H<*433JU>R^PY2D2X$FY21M;J?A4GN^
MTXH/YGI5=;_%X16R5_'(P6``7YTJ:G^72,[/P%%U_2X^N_O!EYJ?(5\]+AHJ
MR57FQ4M'3/EGIHTII(:C=F0R4-*:.FCJQHCCD8OY)2C>T^_;18;3;27$2,QE
M8*H8XCXM5:98FE`#P'2K9[^YW*80N%7PUJQ`^/\`#FN$`K4D9)X4'24Q6.W1
M-CJ/^)[AKZ)ZBFIIZZFDH,=)FZ2K>-364<>40O1PTPF%X[4[RQ*=.LV!`.`:
M@JW1\[Q!CHC!H<&IH?3''^?4Y*#<U.)((-P4,]-K<T]1E,1+69:*-VU".>>G
MR%%1UC0@D*YB0D6U`V).Z-_$*=5U1&A,9K\C0?X">FO+8BEHJ:"HJ'S&<RU?
M7T.+@FJ,_78LS5%:[($8XYH:2@QZ1J[.D,!.D6%SS[T0!DU)/SZNCLQH*!`"
M>`/^'B?M/4C;VS\5ATJZF?'8R7*9.1I:]TI_/30HRZ$H:,U@DE:!(@/+*_[M
M5*6DD))`7RH!4D9/6I)G<@!CI'#_`#FG\O3RZC9#96*IBN7V[BJ6DSF,-+5X
MN"(M!0RS4+3%J?[598J6*?(TM3+3O.0)"C@%M(M[\4`RHSUM9W/9(Y,9X_G_
M`)N-.E3C,KC\Q20UV.J(YH)D#:!)$T]/)I5I*:JCC=_#54Y8+(AY5O=@014'
M'33HR,589Z</>^J]=$*RLK*K(ZE71@&1U86975@596!L0>"/?NO=-T6)H:='
MCHQ5X^&52DM/C,GD\;2RH228Y*6BJX*?QW/T"@>U$=Y=PJ4BNY53T#,!^RO5
M'CBD(:2)&8>952?YCJ524E+01""AIH*2$$MXZ>-8E+,;L[Z`#)(Q^K,2Q/U)
M]ISDDG)/5R2>)ZD>_=>ZRP?YZ'_EK'_T./=6^%OLZ\.(Z5O\O;_F0F=_\3W\
MB_\`W\N\?>7&U_\`)&V/_GB@_P"K:]07/_N;N?\`SU2_\?/1Y/:WJG53FZOY
M2?QOROR)S'R"R'<?R-P6S<OWSM3Y7[X^+E'VM@J+XK[I^0FSJC%Y#!]O[EV3
M7[/J=UQ9M<_M['Y*:"GW!28JIR&/ADDIFLZMO:)#LK6K02&06CW+6XD.H6S7
MBRK+X5--!^O,8U?6L9E?0`*`>W5&WD7*S51[FV@@G,=5:X@M@H2.0Y[-"+')
MHT:T72Q-6U.^3_E/?&+=W7>#V.=X]M5.VL?MGYU;=QV2QV[=J2U55C/YA51E
MJKNNI:M79D]'45&%DS$O]W'2,)1`+]RM;8W8%NJ6,.W9\%-JLK`>O@V-S#=P
MMZ>(TD*"1J:60D*JDA@80[I/'O,F^QA#=MO,6Y$9T?40V\EJJT!KX6B1BRUU
M:P"'`JI75+_+.^,F+^1WQR^4,LN]Y.Q/C=U'@>E]E8RMW)BQLK=<6UMK9G96
MQM\;[VXN"A&X>S]E;5W/FJ'$Y&":D6FI\Q5J(&#)XS!KN5]VYJW8J#/O"OXR
M9**9&4SO$I)T--'''#,26#PQ(I%06).]N'VG8-G:1OH]M8%#6C.JT,<<K"FN
M..8">-:"DW=F@`+5UI_(@^%O4FZ/D-F]CY;MC%X'Y"]=]T=:U6PO/U*VW^KL
M+WU392EW]7=8;BCZBB[0@RLD>;JQ1G/;ASU-2+,4$)C6-4*4LU7ENZY9>9WM
M)8HHO$)'BK#"X>.(%0%*@*B%G1Y&5%U.6+,QI]=*.8[#F9$1;R"Y^HT`?I/,
M1EV4U(J=3:8V1`S'2H%`!+^4?\G[XW_+G#_&7:O:6_>[Z?9/Q?VYM/:FV]F[
M<SG746)WMAMGS[9GQPWED-P]8;CW1B,G6?W5IHZRNVKD-M5M3%=&E`6+QFQN
MV?FFXYMFB5[^2=9M!J(PZ2&92NDK*%$A#:#(4;2`RFK:BV"$6W+:<L0.RV0C
M9->#(5>+P6!J#&3H)HWAZE))4CKAN;^49\:ZNOP^YE[/[\V1/M[Y`?*3Y"UM
M?MOL';&`CS,_S"Q\>)[OZSW!5S;)F<]69G'PQ14T,,E-EZ41*1D6;46*Y;6W
MFMK2VNAKBBV.ZVKN--=O=S?4.STI^LDX66)DTJK(H9&6H)B]U,\JRPJ$G6\V
M^Z1EJ2DFVVJV<(746JCVX9)@VK6'<J4)&DNG3O\`(&^$_6?479_6W5?<_P`D
M:>'L_,?'G.Y/LO!=@]51[\VWO'XL;NRN[^GMT;8RFW>I*#;%)N+!',M15<E7
MC*S^(4J1R5*R5>JJ8R:>X8[#+*:R6&ZIN,1H`&N5@-O*64`(8YTIXL:*J*RC
MP1$"P8L:W@E7<H9!JAN-NGL64DFD$\L<U`Q)<O$\2F*1V9J5$ADQ1]W-_P`)
M]?@YNKL+OG?E9GNZJ"E^0V-[$_O?LS$93J>BP>$WEVI3%=Z=E;0W*>H)NU,9
MNW)966?(K!4;BJ\''554JC'_`&S"G4LALX[;:Y]IMF,=MK0P$4K:I'<+<QQ0
MBFEHD=0@6X6<F'])BRTHOEN)9[Z#<)VUW&FDM:_XPQA,#22D$%9&4ZRT!A/B
M@2BC5)'KH#^3Y\3OCY\7_DI\1<-6=G;VZC^6%1D,EV_%O7/;7IL]6YW,;%P.
MPLQG]NUG7^R]AXW;&0KZ+;5'6A:2C2FI\C'Y8(HE8Q^U^Y32[EMMAMC2-%':
M7!F@>,D20R&=+I61FU9CN5\:/4&TLQ7,81%3V`^@W-]T`$LSVR02+(JM')$B
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MLX3:VN^VJ2,XW"WN(96--02YB,3:-(`!2,TC)!II!;5FI<\Q_(>^#&Y:+=>(
MW4>W]S[?WGV9\@^S,S@,UO;$SX])_D/UVO6F8V;BY(=IT^1Q6P^N\*OGVI00
MSJV,K"7EEJHV,1+DMQ'M5IM4;D+!8-:I)CQ16\@O8YR2"K7$+VMO#&SJR?3P
MI')&^6*Z2[EEO[F_DTDRW,$S)2D9\&">$QZ13].<W-Q-/GQ'GE:19$P`F-F?
MR#_BYU[LO:V$V/WE\K=D]C;*WWF]Y;9^0G7^[.FNM.[,9B-T;0?8FZ^MAE^N
M.B]I[-K=@[EVU(T52E3@YLJLI\T-=%*%8/W@-["MO(Q6![::WN%4D+=0SNDC
M).N5HKQQLGA"(H4%#EJHX$%OXQ6C-XD4D)8!C:R0AE62!B"0S*[I)XAD61&T
MNI`%!!B_DD?$NGZ]H>OJ7>?R!H5P'0/QYZ"V5O+'=@X+';]V%3_%WM?=O<_3
M_:6U=Q46RH/M^U\'OG>%1-/65,-5C*N"*.*2@*F7RJ;J[N;B>XO()C;W[WT%
MVLL5`T4D%B-N"QAM2>'+::HY4=7U>(Y4KVZ7$$0MHK*>!9[,"_#)+J<2?O">
M*YE+FH8M%-#')`X*NC*&+,U"'[.?R=N@]X[6.![%[K^5G:6?KOCQW9\<-R]E
M=D]KX?=_8N[MK=]]D;)[0WMN7,YG)[)?'T>Z*+.[`H*;$PXVCH,%C<?KACQO
MJ5UJ)4C:0V]M'%&S[:^E:TU;9<R7<+$L6=C+-*YG+LQ9:+&8PH`>MKF:W$'Z
MA=H[NXN`6_CN+%MO90HHJQI`W8JJI\0>(Y<EM7OD]_)J^+'RPR6_\OV-NKNK
M%9#L;N'JKNC.2;4W-LR*DASW5'3)Z'Q^"I,-N?K[=."J-L;CV`[ID8ZVEJZQ
M*US44-312!=*&2VBE-MX@JD=QN$I7R<;F83<QMYJ@,$9B:,I+'0@2D,P+-NS
MVME;V4+D)%96ELC?B5;.6>6%_1GU7,@=7#1.--8M2AN@_P#F'_*URFZ?Y8.Q
MOY?WQ/WGFL$_4-/LW!=5YOL7.;-KZ2/!;7GK4HJ?L2#.=5[TVWO'&XZ@K`BQ
MC"PUI>**>*H2="\E]Y-WON[;-?WEP*QO&L[:0=42Q+"[!133,R+570H$=FHO
MADQE3LSVVT6V[6Z1L4G\5E`-"KRSF<J#7,89B-#ZM2@*QU4<&:^)O\M?HGXA
M^*MZXKM[I7U/Q5Z8^*&4Q^2W#1Y7!1[-Z:J=^Y7&9O%B;!4V6CW-FLUV5E)J
MR:6H>D*>!(*6F6,JR[>9(-SM>9-JC1DVK<+@/2I+QHEHEC$BL2V%MXDJ7UNT
ME69VK3HNVT7%JG+T]P4;<+'ZAR1\+RWEQ'=7#$8&GQH_TP@0*A*TX4S[L_EJ
M]`[P^`=!_+GR&:[+H^EL7L+:>P,;NS%;@P-)VI2T6R<YCMQ[=R\F<?:T^U\C
ME:;,8N*66*KPU1CJI=234KHS*4F[AMXN+"[F?P[BVEMY(R@%`ULBQH2KAT8%
M%HX92#J)`4Z2%MK,;63=W5`PO6NC*#4?[F2/+*%92KH`SG058,`JJQ8:M09_
M&#^4!\8/B7DNFLEUAN/MZJ?H[L;Y!=I;1I=R9_9L]#6;K^3.S-M[,[/?-4>`
MV#MVG?&30[:CK:"EHEHH:&LGE"`TWBIXGIY6GB\%@!$-JFV]0*]EM-=K>:02
M22T<B!4=BQ\,D/K:CA*4+1S))(6,E]:W;&B@F:TMY;=#V@`"1)6:50!5P"N@
M54IY/Y+OQ43K'_10-W=X?W<_V7_(?&\51W;M(Y@;$R7R4/RFGK_N?[A?:_WE
M7L3_`"99_!]N,3^R8#-_E'NZ7$B"T`I^C)LSK]NQ1>%9U^3KFXX:SE/#X=/0
M,;>*6%/@>3>'-?7>O]RZ4IA/]`\T_&9.@ZQO\@7X,4G<O=/=&3R7=NY\EWMA
MOD%MC>>T\_O3;#[9@VI\EZ**/LO;N(R&*V)BM_"E7,0)D\345N<K:[$U:!8)
MUIKTY0VT!M-IN=H@F=89$10X-)(S#=I>VKHP`'B6LZ5BD8,S@D3F:B%;/(9+
MZROI%5FAE5]#`-&]+9[25'5JUBN(7TRQ`K'VCPEC!8,,VSOY2/2N'H^KH.R^
M]OEG\D:_JGM#<G9>'S/R&[<Q>^JW*4VX^C-U_'ENM\C1T&R]NX'%==8SKS>=
M;XJ;"T>*R%1D6%565E3)JU*K@QWBW0NX$D>XL;NUG8UU3"]:!II78$$2?XO&
M(Q'HBC%2L08ENF[8O91S0V<C1Q&2R9`#B'Z"<W$"Q@U!!<D2M()'D2B%Z*M'
M7X#_`,IGXU?R[,KO_)=*YOL3<L&^,'0;1HL7V-#U14T^Q]DXVJEJ:7:&V<GL
M/JK8&Y<IBB##')-N"OSE?,E-&7J&?R/)MI9)]EEV6];QXY2/%D<`/-1#'1PF
MB.A#,3HC2K,3Z`-&)!NB;I!6)TU&-%/9&6?660MJD!%`HJYHHH//H!\5_(=^
M+&*Q_8NV_P#35\N,KL'>G1/>WQMV?UKG^U]K9O8_1/3_`,A<_A=S[WVQTMC<
MAUO-6X#[/-8.*2@GR=3EYHT/BG:HCCA2)F$.EHUM<2M/,W[O#32&LK)M<PFL
MXRPTC1&5$9[0S1\6U4<&,5XT&[66[6\,<7@7<]RD*`K`)KF&2&X?0""/%$C.
M0&`5\QA59U8U</\`+2Z$@SC;@3<':)K6^5G2_P`P3&VX=OFF_P!)_174^W>G
M-GXO0-IA_P"YE9M?;-/+D*75]U-6L[QU,,9$2KXK^>&YM[I0OB13[G*,&FK=
MA*+D'/!?&;P<U6BZB]#4KCMDCL&VY2?`.V6-C7S\';YUN(37AXC.H$AII9<*
MJG/2(^4'\I_HWY1=L[J[9R7</RDZ8J.UL+LG;7R'V/T!W%_H\V%\DMO]<S`[
M+QW;6,FVYG<NDV#QS24"UNW:_`9&6@D,,M0X6,H76,4=C.'"^+9B]CO/`DS"
M+F/PR)0HTL"QBB9UUZ)&C5G4FI*NZD>Z@5`1%>+;/;+.@`F6WD,C/$"04(+2
MR$,R-(FHA'5<=2^XOY47QQ[JZJ^4O4FY-T=PXC!_+'O+9OR%WME]O;IVXF=V
MIV'L+"]?X+;C;+.<V;G<'-@(J3K>@:HH,_0YV&KDDF,VM718VY+<26VT6_B$
M&RW*YOHVHI)ENWD>964J4,9$LB*H0%%:JL'57%TF\.6[D2,!9MKM[`J"P`@M
M:^$58-K$@-"S:Z/32RE2RL#NR?Y%'PCV7L&@ZL^X[?W)U[C^J_DMU%!MG.[P
MP%-`NVOE1V'LKM3L&OAK]K[-VWE*#<&#WSL6DK<#44D].F-+NACE01+$KN))
M)[:6!)6BE\"RBCD1B)8!MUS-=63Q,2:20/-I#N'+I&FO4VMG;A;PB^M$EC>]
M>YD5U!29I;']WS1R)0*8IH"Q=`%I(Q*%%H@7V)_E"=!#HKY!],[^[B^47<VY
MODI)U_/O[Y'=J]IXC.?(G%5/3\D-1TQ5;%W?B-E8':^SZKJ6MA^ZPTE-A-?W
M<DDU4:F21V*?<(8]PM+>V*B&1+QKII8NV22=U6.1Y&R&#P*+8H`(Q;EHU5=1
M)U8L]C=/<!O%3Z(VBQR=T<=L2[>$@P=/BNTQ+LS&6C,2%4`+_DG_`"%OA!\G
M]J_'S8^[Z_N3:>TOCAT6WQ[V;@MA[HV=0T69V*E3BLK0UVY!N7K[=,L.[Z#<
MF(CR8RN';$5535/(E29Z9S![6R7=PW,EUS1')X=_(;9E50/#B:SD9[8Q*:LH
MA#M&(RQC=*"1'9584M@UMM=IM7BO)'').[.[%I)6NE47!E).ES*RB0OI#J]3
M&R!F!MQ_N'3_`/.\S?\`QXG]P_IA_P#@/_SO/^+3_P`7O_U3_P";'LS_`'W+
M_P`H</\`N;]3^/XO]]_'_9_\;_I]!S^JUC_O^;_DF_0\5_LOXOA_M/G\/]'K
M_]/;9^%@M\?,-S>_8O>A_P!OW7OT^P3S+_R6;O[$_P".+T;[+_R3HO\`3-_Q
MX]&J]D71KU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7@2.1P?\`#W[KW7O?NO=>]^Z]U[W[KW09]CIO
M=H:%MJR9(8W[?(1YR'`)BSGV>00+2249R@):G$!F4BF*U*RE'4\<$N]#>##'
M^Z2*]VL8U$4QIK^?#-:'HUVH[;XCC<!G&DFNGYUI^7'%*CI'[8ZXS.5S&-S.
M_(\E5X7"P>7;NV]P[GR>7JJ'-05E/-19>OQT4\F)9Z:&-Q$L\U7+&Q5CI;@(
MMJVS<BR3;U,9%4#0A8DJP.&-.UC3A6M.E=_N-FB20[8@5W/>ZJ`&4C*@GN&>
M-``>I_=%30XO^YV=RDRTE#2Y/,T$^1GUO34\F1Q1FIX9$6.0I+53X\%90!H$
M9!(#'VQSB@-C:RE<++2OD*J>(^9''R_/J_+=6GNH5^)HP0/,T;_)7AY_ETBN
M"`0000""""""+@@C@@@W!_/N/>A1UW[]U[I.[C420X6%_P#-S[IP*26`UVBJ
M)*N+QN?\V?N*5-1')34H^ONK?A^T=.1\7/HAZ47NW3?7O?NO=(/^'XVJ[#%?
M1T-"U9@\&T.8K1H2>"IS))QT42P!7EKGHJ9_*TI*K3NH4:O=*`R5`R!_AZ?U
M,+;2S&C-@?(<?RKZ>?2\]WZ8Z][]U[KWOW7NO>_=>Z][]U[K+!_GX?\`EK'_
M`-#CW5OA;[.MCB.E9_+U-^@\X1]#WU\B_P#W\N\?>7&UXV;8Q_RY0?\`5M>H
M*G_W-W+_`)ZI?^/GH\OM;U3JBO=]#7[LW#O7?W<.ULSV#UCM7^89V'@_E;L+
M'[3RV^ZV3I+9W6N6P'Q?BSG76$I\UF=Y]5;>R6;V]N>LQL%#5Q3RY*6ODI95
MCF(8VU;<6W*M[?6U1-;;F6?35$W+ZR2%&FH&)\.SA:UMW:JQ,]M+6/6'"F]5
MGGWZWVZ5AN*?NL1YT,;+P(I[M8R2!WW,DSR,.Z9(I[:KZ`@6NV\)CZ[=_7)^
M,FP/E'TQ\;*/-_*;M&MV5L^'=?5>"[2W;M;;G4];LA]G[4R[QUW777.Y-SMD
MEP^W*NBP.,S%='62G&S4=1(T_GEO88[B2X+M';[#<26\98,ZR&_B6,,2'5G:
MWDF>"&36T$)4>$GAHJM)':W+Q06[1H;C=K2.:4*43PQ97/B$4T%561(%N9D"
M^)**^*[,7)(^I>QOFYN?=^;?;=)WKG\+D<G\8M^;"PG9.+[LW[C]I=CRU'R%
MH>Q=MYS?_=W76QJ9,WBY(=K)N2+`8W"[4Q\[QBABBA9Y77!3%9W!MY%>>-[D
MQNHP\3[1((VA,I,LBM<QOH,_>TI`:.,2B(JE:WDO(I)5:.UFM'\=#@K*FZ[>
M45U0>&C?3R3'3!K`B#$R3-$).A;Q79?RRVMM'*]M]+Y3Y>=PX+I#KWI+N#N[
MKKM7;V]X=Y=@=X4V=W#@^_.D.N\/O+;N(RF2HY>O\L^6.(V]#-MVCRV*QR8Y
MP]1*C-W4D5K-=3[<GB[%]6MO9%]3.\=U!<PFXFXS,EK<G;IV><!T5KT(I5`J
M%]M%)=I#;[@Y@WTP2RW(6@C1[:6VFBCBT`Q`W,(O[=5CKKK:M(H8ZV3N_=\?
M-C9797QGVJ^:^2E?V/M#<'Q"R':^4CD[CW+M+L3`=F]AX;*=_18#86P^OHNF
MXMF;`Q.[<AB<SE-W9K(Y6CCQU,F-HJ&.`5$IAMMK9Q\RIMYN!)MT%T;1V9M>
MM8]N>&.X>1M,:17-V(Y5:+7*9F=Y98T41]-7TTL_+.XWD<)CW*:SN+NW"@KH
MD>[>5+8+W2-+#;KI\.4I$L6E`DKR%EL]^>U)-WO\*MYT'5.(QG9<FZ=[=18_
M&8?);:S.Y=MYD83Y![$HMPTVZ-M4E*N6R6UL=_":O^+1",#[*"9B=`+>PQ<Q
MM=WG),T4:O;R;MML]74F/P7EBE$D@\H_#8.Q:@"GNIT9P2+!;\T(\CK*FV;E
M%V$!_%6VN(M"'_?GB#0M*U:@6M1U7+C-L]P=([Y[UVON[KZK^.>V,KW%\?V[
M/'P2ZM[`VQUGD_BY0;:[!CB[=ZZSFU,+4[EC[/W%V368W!;[@PU-%N'!86@I
MC"U11N,C[-;*2WEL8%W":9(5O[PR*6;LG-M$+%$T`GZ.=8S*[@JIO289PBBL
MR"[CG2_D>RB@:<[;;^$P`J\?UA^L,RL"OU=NDCK$K$UM")XB90$C:,3C_F_V
M+D9,AENSOF'M7;.V!\8<?U'-B_[P;7RN[NKM]_-SLK8F?W;VCC%P*_QCL*I^
M+IQLV:&1BBK\53-396JAI*\>97=IAED_=K[V%7<);VWBNXP55$0[7<23A/#.
MB/7.+<R20M2"Z#QPN`2A<OE@\"[7:IW^DCLMSF@<BKM-`;1[8-X@UNID^IBB
MCE!\>W-2K-23H+>X.UOFWMS;.+VKMBI^6=)V'U/NG=D6P-QY*7O[<57VILS;
MOR^WY@\;24VT-C=>U6V.R\]C>E=L4<F;S78F=DI:C"5--+C\=43U$M8^N7)U
MOKGE"^W0*DDB;4;R/30!&*I<.R46*&-]3"<@/<>*A(%N@1G5;O:P6L7,6WV6
MIXS'?M:R!ZE9?I8GAB,E6ED<7#'P%JD*HU)&F`98AAWI#\Q:3!;EW+2Y_P"3
M&\*SM:I_F"8G/[0W1BMP[GVAMS!]=_(;`+\:UVIL>IV^V+VK*^R))X\74I!]
MSG,:S-))5+'&\=-@#"WY:COO[;Z7:)9BU-7U'[RBCN:L?A/TY8R(I555?%(#
M`OU6:;Q-T:2/2D(NO!&D:5,,FQS2LQ`P:7J)1^*RN8N#!.G/86]NY.R_EYO7
M;_9]/WGA_C3O?KGYA[>[IV7V>_<6X]M[*K=G9?;,W6V;SF9W1L#9_1W6536;
M>HLM7[:IMD_<JN-6-ZW)U]8!($.J-.5N9[N:Z9)H]JCN()`3KBN8[@M*4=@)
M&N8`Z:E1$A4H#"CK&)2Z%F&X\M+9P@W*[DD$JC"2V[V<@J44Z/`EE11J=WF<
MN=9B$C0I<3\0MQ;VW;\6OCWN?L9JN7>^=Z@V%E-QU60#KD<A7U>W*"7^*Y-)
M%22+)Y:!DJ:A&4%)Y64@6]G^\)HW"8-"L4Y"&6-358YF16GB4^:Q3%XU.:JH
MR>/1'MWA_3%;>9I+-995A<FID@25U@D)HM3)"(W+4&K56@K3HQ?LLZ7=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]3;:^%O_9/F%_\`
M$B=Y_P#OZM^^P3S+_P`EF[^Q/^.+T;[+_P`DZ'_3-_QX]&I]D71KU[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UX"_`Y)X`'Y]^Z]T4KLW.5>6WE
ME,/0309"NIZD[=Q%'7(9:+;V/./2+=NX9<="C?<E,@YI1+.R>5QX4.A75HQY
MJO9)]R>T66L,5!I\@Q'<3ZGRS]@Z'.P6T<=A'<LE"_<6'%J'M%?+UH/M/EU*
MHJ2+'T5'CX&D:"@I*>CA:9@TS14T2PQM*P`#2%4%[`"_T]AP"@`'#HS8EF9C
MQ)KTW5V;AIZEL;00/E\R`I;&TDB(*-7%TGS%8P:#$TS#D&2\KC_-QO[T6H:`
M5;JRH2-3&B>OK]GKUCIL3535-/D<W7?>U=-(9Z2@I%--A<;.T;PB2"%@:FOJ
MHHI643U#$C42B)?WX`\6.?Y=;+@`JBT!\SQ/^;[!_/I_]VZ;Z][]U[I)TO\`
MN#SV32JACCHMT9.*JQU?`H6!,B*"&GDQN2U?N15U8:5I(9+F*8DH`CBST':Q
MJ,$].GOC2A[D&1\J\1\A7/2L]WZ:Z][]U[KWOW7NO>_=>Z][]U[K+!_GX?\`
MEK'_`-#CW5_A;[.MK\0^WI6_R]?^9`YC_P`3O\BO_?S[R]Y<[9_R2-D_YXH/
M^K:]05/_`+F[E_SU2_\`'ST>3VLZITB<=@]@8?<6ZM[8NCVWCMR[IFP>$WCN
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MM#X:5O'#5P2:C+%8.K7+`&_O0H%B`^$KV^A48&GY"E,8%*=;8$,Y;XBU6KQU
M-W5/S:NJIR:U\^G;WOK74+(9+'8BCGR.6KZ+&8^F4/4UV0JH**CIU9E16GJJ
MF2*")6=@`68`D@>]5`H"<DT'V];`)X"O3=D-T[8Q+0+E=QX'&-50+4TJY#+X
M^B:IIVX6H@%341F:!C]'6ZG^OO9PS(?C'$>8^T=:&55Q\!X'R/V'ISHLA09.
M#[K&UM)D*8NT8J**IAJX#(ALZ>6!Y(]:$\B]Q[V012HI_JI_AZT"#P/^HBH_
M:"#]G35NK:NW=[[>RVT]W8>AW!MK/4C4&9PF2B\^/RE"[*TM'6TY(6HI9B@#
MQM='6ZL"I(.J#5&].Y'5U^3(P96'S5@&'H0#TXDCQ$M&Q#%67'HP*L/S4D?G
MT^QQQQ1I%$B1Q1(L<<<:A$CC10J(B*`JHBBP`X`][9F9F9B2Q-23Q)Z:5515
M1%`0"@`P`!P`ZZFFBIXI9YY8X8(8WEFFF=8XHHHU+R2RR.52..-`26)``%S[
MJ2`*DT'5P"Q"J*D]>AFAJ88JBGECG@GC2:&>%UEAFBD4/'+%(A9)(Y$(*L"0
M0;CW8@J2K"C#JH((J#CK%-6T=,Z1U%734\DA41I-/%$\A>1(4"*[JSEYI%06
M^K,!]2/=006T`]_IYYK3'Y']AZV10:C\/K]G']E1^WJ3[WU[K#+4T\,D$4U1
M#%+52-%2Q2RI')4RI&\SQP(S!II%AC9R%!(52?H#[\,F@XTK^7K]F1^WKWD3
MY?Y^'[>LWOW7NO>_=>ZBUM;1XVDJ*_(U=+04-)$\]56UL\5+24T$8N\U143O
M'##$@Y+,0`/=694&IV`6H&<<30?M.!\^MJK,:*I)^7RR?Y=8\;E,9F:*#)8?
M(T.5QU4&:FR&-JZ>NHJA4=HW:"JI9)8)0DB%258V8$?4>[E67#`@]5!!K0UZ
MG>]=;Z][]U[K%//!2PR5%3-%3P1+JEGGD2&&-?IJDDD*HBW/U)'OWF!YDT_;
MPZV`3@#/67W[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_U=MK
MX6_]D^87_P`2)WG_`._JW[[!/,O_`"6;O[$_XXO1OLO_`"3H?],W_'CT:GV1
M=&O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2;WE5+1;/W95--5
M4XBVUG+5%#.:6NIWEQM3!%-0U0!:FK8YI5,,@!*2Z2`2+>T]W*(;6YF-:+&Q
MQ@X!X'U].EVUN8]SVV40QR%+B)M$BZD?2ZMI=?Q(U*.OXE)'GU6/\;>I,STW
MM>@VKBMV9'>YI</+FJG<>^ZV3([FW2=R;GS%=-19O-A)ZNDJL,\)$#CS1CR%
M7CO<^X0C#ZBQ:K$5).2:GS/K\^LC/=CW"_UT><MQYQGY8V[9WN%BC^EV^/PK
M6/P8EC#)'PU/2KG%<4X=&55-PYH!*B.7:U%PL\5/4T]9GJQQQ(D%;`)*/%T9
M/Z9$#U+KR/"?;O<>(H/Y]1I^FF1WG^0_+S/\OMZ:JEL+L[+XYZ;P45)E()<;
ME:.F6:JJ_+2I+74&=K((14U\_A/EAJ:F0,0LR%VLH]ZPA%.'^K/5QKG1JY(-
M0?MP1Z?,#Y=+.EJZ2O@2JH:JGK*:2X2HI9HYX6(^J^2-F4.OY4\C\CW>H/#I
MD@J:,"#U(]^ZUU[W[KW4#)8RCR](U%7QR24[2P3CPU$]+/%44LJSTU1!4TTD
M4\,T$R!E96%B/>B`10]65F0ZEX],<E5E=NF)\I6197;^M89LK+3O%F,4KQVA
MJ,H*1/LZS'K.FB2H5(Y$\@=QI#-[U4KQ-5ZN`DE0BD2>GD?L\P?ETJ_=NFNO
M>_=>Z][]U[KWOW7NLL'^?A_Y:Q_]#CW5_A;[.MK\0^WI6_R]?^9`YC_Q._R*
M_P#?S[R]Y<[9_P`DC9/^>*#_`*MKU!4_^YNY?\]4O_'ST>3VLZIUJ=[IV]W7
MB.Q?D1\'6^,/R6RG8/=O\ZCJ[YB[-[1QO4&[*_XU/\;T[@Z8[5S>]\SW[1TE
M1U[@JS`;;ZZR<%3AJRJ@R;5XB@CA<RJ2_P`L2I./;.*6L!V*;</J3)VBB_O.
M6)HJT\47'U4"Q:-3:BVM5T$=.\U7`5N>)H4,PW3EVRLK<1T8F<VD-JX<#^R6
M&16:1I"O8NI=55!3.4V?_,OPNU>T.Q:KL[YT=E5W?G27\Z7:6:Z4WKM[,;EZ
M[ZX/6.2W6_PL?8.RGV4*_`;LWA&Z)@JFIFJIMQT<D5-2K)`B(2BU65.58+6X
M!EOWV+9[IG85E6^.YVR7,:GBI6S9O'A-3V/</1LJ>0BU?GZTN!,D.U6W-4,`
M5"%ADL9+"1WD<UH4CN4%)00H9PA-0`3([=P'\QV#O?H#XP4>=^2^/Z9^0[_$
M?Y2;J[R#Y_'8WX^;#Z<Z?HZ?Y,?%&KW)'001[`K^U^TMK8(46&)IJAJ'<66$
M0`I67V)[AXFYFYC@`C:VVG=-SO87<DI?PW0*[=:EPY$J6UZ\K2ID"RAA4K1]
M?0)5&AY:VJ5#(U]NFVVMFZ`%7LYX9`UW=`8\%I;'2L3T-;T,2&U,JD,^//87
M\\&O[C^>Q[>R_P`C<9F<9\>?FM65FRYMC]^UNRH]\XC";EC^,<_Q3S,O4&*Z
M/PNXJ*K_`(>])#LW<^:J\XDVJHC-3&X0'QF9O;K>)XY)VW?Z*VTE@1<K?F=1
M<%58(YB`^H4QQ(UN(_#9"5$3$7%;4>X.QP.(AM)W0`TS;&PT\)"-2AR/"(EF
M9)M8D5UJSJ!%^1.VOYD_QFR_\L6NZX[C_F3_`"=BW!M+9&]>\.L6J>X(MP;B
M[?WAN_8&3WC0[_[9V1TMOCK+:NU<%B:FHQ\&T=^P87!XFBBFE^ZGDEJ#&,XF
MM8?<&_VZ*WCEV.%TAA=BHB\+Q+A9)I'D*PSFCK*SB2.4)$L4*J3&W04C6XN.
M0!>W$KQ;[+XLD@53K#?3IX4,2*6FA'B*RBB.KO(6D8:*=2<W\?\`Y6;\^6/1
MF[M\;@^?O56W<E_,*_FI]8X[,=)XO?6%VGL3"=@2T</QI[-W=CMM;3FCHNN,
MU45M53G=]41C:C&4J**Q%/D8*V5G>&'8HK*=/WC+R+?(LLU`L-]%?%HT(84@
MDFM]4HB<`RRPVW'3I81[]<VWB?42V[/M\._;#-)'$5>1H3M40N:::^*L-T!#
M*5JL:2W(-*U0Y7PU[B_F*]X?RW_G;\@<!F-TYOY631[VZ=^.&S<_-C,EC<;O
MWXQ=<XSIG<^Z]G8G+21[7EK^S^ZMM[AS<)F;P5E3+3I4&RD!3OES#=\I;/OE
MA%/%'N\IW%EA`:>WL+JYC0V]N"/[2"TAE>!"#^M)4#NTA'LUN+3FO<=EO9XY
M1M,8V_7,S"&XO+=)I!<3Z154FDGMXYV7_0XS3AU6KO+HCY8_+KH6JZRGW9_-
MAWA\9J;Y;?R^:_&UORHVOF-G?(BNWEF=ZY"E^5T=1A\MUY2[DS?Q\ZWH!A\O
M05&5QC;?Q.:ADEHY:BEA<^UZ0P+S)R!>E(C80\SN+=JEF&W?03/X]\&^"1;M
M5BMY90LABFF20#5$>BV2YN4V#FZ&%I?WI+RZ/J5I1?K_`*V%5BLRN&1[5I'G
M2%G35'$U01(&N)_FY_`#I3Y(YO\`E]9S<7Q;V_WQG=J_,CX\=;[YW#6]>-O/
M*XCXTA]WU6]\/NZJQU!(F.ZQDK6@FR9J%BQZ2NI?3J`*2PCAEY[LKZX@1;:Y
ML]S,[4HC2)8SM:!R:BJSL/`#$GQ"`M2<KIFD@Y0W*PAF=GM_I?`6O>"UY9I.
MR4H=36ZL)2M/TP2:`5!`_CY\=OF_\7.TJK.?&2?Y&[8VSO7Y7_S5=@[9^-&7
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MXB%&`+(E5!W%VO\`S63\1/Y<'8&W<5_,/Q6Z-O[I[APO872N"'R)K.V>]),+
MV+@!UOO;LGN#`_'C)[RV5BMP;?IJNGQN"[4VSAJ`T56*C(U<OA8,9B1$YOV:
MX-H)()MOM28*Q+%%()F20RO4V<CRQ>'+(&DB>!:C2LK2%4L2+)R[S#;F5HYT
MW!]$Y#,\D36Q<+$E!<1)',Q161)!*Z88)X8*[^0^_P#^9-V5_,$^2&V<#U%\
M\=L?&S<_Q]^873_9/7V]:OL#L[HO-[BK_B)NW(]-Y;J/&;>Z?P'4>%QVZM[8
MZGI:*HPF>W!EY,R9J>NEA-=#3L&UACFY<Y\@G;Q?%M[GZ574F43P;E"**6HP
M5[0/+"J*8S`X36\J'H_VR\C@Y@]N[H@P7,&X[2T[!E$1@E5?&:0*"I:*1F6X
M=VC*R1B7PDC()-/\#*[YA;1^8OP\^'6YMU]MX3IK:OPLZ:^:6Z<!N"OKL9_=
MRDG^.6T?C/4?&C<.*K$I\UB\9M_O/$U6Z8L/4QQP0S>4$>6)@!K>RVU_S3[F
MW3W0E3;;ZZ6)JAEN%W:XCFM'Q57^DCM=RCB<$NH>(DE2@4'/"]GM/*,*!TEW
M(@L`"A@_=CW/U-*C*WGUFV^(":L4D(H`*&T^4]1G\GV?\GLYG<'NW<>4ZI^0
M7\NZMVQB=J[.W+OC<&&^.F+WALS?FY=T[?VQL_&[@W1DL74]AC<[962BHG9O
MX-&L@84R:0EMCB)^7-RG0B5.:;A;A@I.B%-O46BOI!_2_7:1&:BB6>;AI)Z.
MMSB$T.YV<)J[\MDQ*:+JF>^E^I"$Z0[^'!;!A5F51&!3Q*,@_P"8]\A.ZNQL
M)15_Q$Q_RJQ63QW5.[]R[`W9MC97RSV=2Y_L[!9^%DV-1]0;6ZXVA+N+>/VF
M.AF%5V#E(=HC%U$B4N+RE1-(85=@GA[U;3W34M5GL&9?CUV_UE+EPIK"B+$)
M%G$@DN'4((8HU/C%5$UK/9-:LH+/]4A;*%)1;+X`9Q^JVN20>#X?AQ!U=YIF
M\/PNE)OO:GR8KY<QV#2;W^4.$W#N7Y(_*W%T><IML[R[#@ZGZEQ70W:T?56?
MZ_Z:J8X,+#!3[EJJ:2AFI(:7(YFLEAHQ5N131HW!^A:M'<.JDV.YM*QUL=:;
MPL<*:XSXJ*]C&-"P,&:(FXB#2:7Z:VYS<0M/=1AIP-F"QU6-27M+.2Z8J1X;
M.MPTI<R`JCJT;Z4UCHON0WW\M8>I>O<Q0UGREJY]D]E]DX_;^T\5D/FDL/R5
MO3]99'`Y[:79^X.L,CW3U#7X>O?)T&(VUW%A]S;(R%949%)<C+04M)4P*8;A
MQ?<OSO9QF:0*C0:E_35;ME:8N=-O/&ZL@*W0M[E;2-7219'>=T0B3Z+<(#>'
M0I0^.5<%B;5U,;Q"LT#K02E[1I(3=L%,97]%1LV5W!\CX?Y@&W]X[@QWR,V#
MTC3;F^2N([QV=O*/O[?6SMN[6VOL;(Y3KC=>5K*K:N#^-NTMO97([76;;D&Q
MJ7,9*6&4_P`3S=3459I?==K>SM;+>)[ZY#6XVZ9E9@>V=;ZV;23(!(9A`TZJ
ML21P>$-""=@)>E%^DUQ%MR6]NPW!+NT5M)6CPO9R"5@(Z)H$YB\1Y2TIEJZK
M!&K1J?3YI8J#=V.^..[,]LW<';'QQP':L.[N\=C[8VQEM[39K:57L#=$.P]T
M9SKO%4U5FM_[+VAONOQN2R6'AHZ^:1$CG^SJ/MS'[:DA6RW=H]R@IX=O<Q+J
M&N.*Z)C"-(@U:NQ9X8W`(BFECEJFGQ4W',MULMT;"0F>1[>12&\,O;J^N55)
M(^(:&,?&1%:.A+4Z(=TYMOM;>6^<7L[8'6^\NB/CUFOE)7[CDW-T%M3O[XO[
M4[2V]3_'K<^1E3+=?[NRU/N_JG:^.[*P^(H,E68NFVY0;ER<;R)%*9I7G3:]
MRBMML9%!O(K;=&CBD8/$91]*;:1ZDE4DF>Y,5K,[*%4N(PKYI=?2>+N30*3%
M-)MRR2*M)5033)/&OPJTBVR0F2XC4-1U1I*H-)?]N;C_`)DS=5=BY1>S.U7[
M;7"[9B^0^QZGH?Y3U#;0>;N[;M'V%N'JG<F=WT=IRYC`=8-F4QV+Z@2(97$L
M*ZD$>0@HVD4(+4VNWZIV.RF6U\60B1)58PRM-4#_`!S2UP(HYU2D5NAUPD1E
M@VY4N5N[\1(HW-8[P6Z`H\3JK(+:I;_%]0A/B0O+^I/)6.XJ^LJ/W5>8[[@W
METC'VQVU\L=R]"39KL2IZQSG5/5'R:V?N.I[0INP>K8MF[![;7L]]]]N;RZN
M_NQ+N$TN6W\*?"5=+)5+42^2CQ\_LPL5)O(UN0IW+P(3%J\)8'C-Q=K<&9$`
MB21(1:`%V$[0EIH@LY=ND5X&6QO&M=7T7CN9M.MITI:QM#].6)D=7F,Q=8PR
M).(H7K"2O3MT5#\CM[=^]KX'Y2;]W9#M2OK/D]BNZ^K,]U%\@I.IING5S.:I
M>HZS`]C[MW9/\:ML4..V2,;64>0VE1#,9825,>305$<TD0?2B<H7L]W<L)X]
MK$DS_#+#?J4:1X6<&2L+"7PD@K`4$<ZD,BEC>Y:X3F6W_=L0T?O$+;`=R2VA
MC.A90A5?U#I\1YZ2K+JARCTZLY^%F=WGN;XF_'O/]@RU]3NW*=5[3JLE797R
M?Q7*0-C8UQ&8RPF2.897,85:>JJ=0#>>9K\^Q'NGB?5AIXU2]:&%ID4U5+AX
M4:X134U5)S(HR<#HGLA;K'<1V<IDV]+F=(&)J6MTGD6W8D@$ZH1&:D"M:TZ,
M][+NEG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__6VVOA;_V3YA?_`!(G
M>?\`[^K?OL$\R_\`)9N_L3_CB]&^R_\`).A_TS?\>/1J?9%T:]>]^Z]U[W[K
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MMOI?#2*%CW::DL/(5/`5I6G'H]V_:+.SF>==4DRJ=.JE`>!-!Q-*TKPZ2VS<
M,N&K-RTT=2]=%!5X^E6LE@@IY#4"EDR&0I]%.+2,*G)":61B7DGF<GZ``.HN
MDMT;3OK6(TH2"?YT'^"@^74C.0/%DXZK+U^2?;%6E/1O!25DN.I</7ERD<^1
M:@\%75XW)LZHTCRZ::8"X\;W7S8-2>S_``?;UJ.A6B*/%'RK4?*O`C^8Z4M!
MBL9BM7\-Q])0LXTR24\*)/+8W/EJ+&>6Y%SJ8W/NP`'`=-L[/\3$]0:S!Q/4
M/D<7.V&RSV,E921(U/7:?I'E\<2E-D8S]-9T3K_8D7\^(\P:'K8D-`K#4G^#
M[#Y?X.L!S5;CU/\`'L3/!'&/7EL.),IBBH^LTL"+_%J!+<L'AD1/^.A'/O6H
MCXA^SK>A6_LWK\C@_P"8_MZ4,4D<\,51#(DT$\:303Q,'BFBD4/')$ZW5T=2
M""/J/=NFS4$@C/7/W[KW37FZ"7*X?)8V"6.&:NI):>.28.85=[6$PC!?PO;2
MU@3I)X/T]Z(J".KQL$=6(P#TUP[JQ\6&&6S,M/C&@KWQ&1@B>:KCH\I%524I
MIU*PK4>*01B5&>-/V&#$`<^_+5@:#(K7\N/[.MM&=>E<@Y'S!_U4^WI1K/`\
MTM.E1!)40)%)-!'-')+#'.&,$DL:,62.8*2A(LP''O?3="`"1CK+[]U[KWOW
M7NLL'^?A_P"6L?\`T./=7^%OLZVOQ#[>E;_+U_YD#F/_`!._R*_]_/O+WESM
MG_)(V3_GB@_ZMKU!4_\`N;N7_/5+_P`?/1Y/:SJG2?BW;M68XX0[FV_*<OD*
MW$8D19G'2'*97&F<9'&8X+4G[W(4!II!-#%JDB\;:@-)MY>XH%R60N*>:"E7
M'JHJ*L,"HSGKS=FO7C2P4UQ1CD*?1B.`XGRZ<L=D\;EZ45N)R%#E*-I:B`5>
M.JX*VE,])/)2U<(GII)8C+2U4+QR+>Z2(5-B"/>Z&BM3#`$?,'((]01D'SZ\
M11G0X=30CS!]"/(_+J8S*BL[LJHJEF9B%55479F8V`4`<GW5F55+,0%`J2>`
M'6P"Q"J*L>N$$\%3#%44TT513SHLL,\$B2PS1N`R212QEDD1U-P02"/>^J@@
MBH-1UE]^ZWTVYG&XS,8C*8G-00U6&RF.K<?EJ:I8I3U&-K*:2GKH)W#(5AEI
MI&5B&%E)Y'MFXBAG@EAN5#0,I#`\"/.ORIQZ<A>6.6-X21,&!6G&OE3YUZ#G
MI7#=*;1V!AMA=`4_7F*ZVV/$V"PVV^LI\&^V-M@R25TV/AIL!-+1T=3-/5O/
M*&M+))*TCW9RQ5R233K#-(Q9-"JA\M"*$15\M*(%50,*H`&*=)UCCB>:-124
MNS./Q%G8EF:N:LU22<DUZ7F7W/MK;Y(SVX<'A"N/K\LPR^6H,:1BL4(6RF3(
MK:B&V/QJU$9J)O\`-PAUUD:A=H$$D#B--?\`;'2O^]-VKZG`ST\$=M.E"=34
M&.)H30>IH":<:`G@.I6/S&(RS5B8K*XW)OCJA*3()CZZEK&H*J2F@K(Z:L6F
MED-+4/1U,<H1]+&.16`TL"=E6`#%32I'YJ:,/M!!!]"*'/5`0=-#Q4,/FK?"
MP]0:8/`^73E[UUOIKFSF%IZRJQT^8Q<&0H<:,U6T,V0I(ZRCPYDFB&6JJ5YE
MGI\:9:>1?.ZB+4C#5<&VB0$DD)_30T8^2FE<G@,9SY9ZL$8F,!35R0O](BE:
M>M*BM/4>HZF4E729"EIJ^@JJ>MH:V"*JHZRDGCJ:6KI:B-98*FFJ(6>&>":)
M@R.I*LI!!(]W961BKJ0PX@X(ZH&#"JD$=2/=>M]!1C>N>FNONP=T=H4&V-D[
M5[-[@GV]M[=&]7@QU!NO?LV`I:W^[.W9\M5.M?E5QE,U2])0QL52\LBQW+M[
M];CP8I;*VJL4DC3,B\&<"C2$>95<%C\*XP#UN6L[I=359XHQ&&/X$+*`H/!0
MS:1Y:F"UJ:=+"#;FTJK<W]_:7%86HW6,'+M$[JIX*:3+';\.4.1EV^^2BO*^
M/I\PC2^!F*QSZC8,6O6/0!+)%2DP0L1P?1KT$^NG6X4^6I@./6G%2BN.Z,M2
MO%2VG4/45TK4?T1Z=.]%EL5DOOQCLGCZ\XNMFQN3%%6TU5_#LC3)')44%?X)
M'^TK8(YD9XI-+JK`D`$>[$@()":1D$@^5`2":\,$$'T((\NMT.OPZ'Q*`T\Z
M-D8XY'#U\NHT6X]O3P3U4.=PTU+2S4E/55,64H9(*:>O6G>@@GF2<QPS5JUD
M1A5B&D$J:0=2W\`6$945#FB_,TK0>IIF@\NM>;#S`)/R`K4GY#2U3PP?0]3Z
MRNHL=3O5Y"KI:&EC:)'J:RHBI:='GF2G@1YIW2-6FGE5$!-V=@!R0/?O-5_$
MQ``]2<`#U)/`>?7J&C&F`"3\@!4D_(`$D^0SUEG@@JH9::IABJ*>>-X9X)XT
MFAFBD4K)%+%(&22-U)!4@@CZ^]$!@0P!'6U9E(920P].L-164&/6E6JJJ2A2
MIJ(*"B6HGAIEGJY@1345*)&02U$H0A(TNS6X''NU2[>9<U/S-`2?V`$GY`GJ
MJJ%2BK2-0.'`#`'V"I`'Y#J7[UUOKHD`$D@`"Y)X``^I)_I[T2%!9C0#KP%<
M#CU@I*NDKZ:"MH:FGK:.JB2:FJZ2:.HIJB&0:DE@GA9XI8G!N&4D$>[%2IHP
M(/7O4>8)!^T&A'V@X/H>FS<NVL!O'`9?:VZ<10Y[;F?H*C%YK"Y.!:K'93'5
M:&.JH:ZFDO'44M3&2LB,"KJ2""#[J0"4)%2KJP^3(P93]JL`1\P.KQR21-KB
M<J]"*CY@@_M!(ZG338[#T!EJ)J+%XR@@13)-)!14-%31!8HU+N8J>G@C6R@7
M"@6`]W9GD<L[%I&;B<DL3^TDD_:2>FXXPJK%$E%44``X`#R`\@!^0ZR4E;1U
M\/W%#5TU;3^6H@\])/%4P^>DGDI:J'RPNZ>6FJ87CD6]TD4J;$$>Z^0/D14?
M8>!ZWYD>8_RBH_D0?L/4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U]MG
MX5G5\>L(UK:NP^\C;_`]U;]]@KF7_DM78^2?\<7HWV7_`))T/^F;_CQZ-5[(
M>C7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!SM:@CII-O[H2/QB&J;`
M9NK!M&,7D8II,6U8+:1#2YM(U24D>+[AA^ES8)<W68ELX;Q(ZRQM0D?P'U^0
M:GV5/0AY>G(FFM"W:ZZ@/Z0XT^96N/.GRZ"S.TB5N&RE++*E-KHIW2ID)5:2
MIIU^YI:LD$,II*J%)..;K[CLBH(\^A8ATNAI7/[1Y_RZ3>Q\W1Y+`39FIJJ2
MBGR5?E,UDJ.HJ8(I\.99C'+!7PM()::2".DU.'`*7M]`![T*KJ#BC@FH/$'T
M/3DR$.%0$K0`'U^SK-HRNZZ2G^Y@I<=MNNE%1-!]S7C-9/%#RB*CK(D@IZ>D
MILJ"KRH)';P$(>6;WK+CT7^?^H]>[(F-"3(/LH#\O6G^'I9`!0%4!550JJHL
MJJH"JJ@<!546`_I[OTSUW[]U[KP)!!!L0;@_T/OW7ND0L>,VGF#)IK*#"UF(
M90P.5K\9#D8LB961D!K(L6$HY/0;10B,,!]+"F%;Y4Z?JTJ4P9`WR!I3\JY_
M/I8T]13U<*5%)4055/(+QSTTT<\+CZ^F6)F0\?X^[\>'3!!!H00>D]F:L39?
M%;>CRC8N2>&IRN3D@K*6DKEQL*-3T<$#U"2/&]=7R7!5;F.![$>ZD]P6O3J+
M16DT5'`8Q7_8'^'I1=.]>4]1N'=FX=Q9.;.-CLA2X_$8+(U%7438V"&.LDH<
MEG5EM19^2MH*]A2S,'$<>J-AK0^QSRKMEI(C;A)I>93I`S530U+`FC%@<&E*
M=!WF#<)D6*TB4HC#46Q1N&%IE:$9%>-#PZ%7<W6N)EQDE1M#&TF#W#CH:V?%
M18V*GHJ'+33O'4S8C+P$)!-39&6!424E7I6LR,%!4GFZ;%:7MJR0PJEPH8II
MHHU')!'`AB!6O#HHL=WN+><&XE+P,0&U5)`&*@\:KZ>?`]!#CJ^+)TB5<4<T
M%WF@GI:E1'54572S/3U=%517;QU%-/&RL/R+$<$'W%SH\;O'(M)%)!'H1QZ&
MF"`5(*D5!'`@Y!ZG>Z]>ZRP?Y^'_`):Q_P#0X]U?X6^SK:_$/MZ5O\O7_F0.
M8_\`$[_(K_W\^\O>7.V?\DC9/^>*#_JVO4%3_P"YNY?\]4O_`!\]'D]K.J=:
M?';OQ;^3^Q?D%\K\_L[X[=K[@V=_+K[TW5\Z_AA+M?967K\=W-O+Y2=C]9=@
M=D]<=1C'TJG=&=VOM+![NQM724PFDAJ\V(VTB3DKVA[C;>7;'<$0KN6VO+LD
M,7<SFQNI[YVNJ4J4"7UEK<=M+205!1E!EN,4&X;Y=6/UJ+8;I;IND\C5*I?6
M=O!#$DAH0'>2VN&2).X":-J#4H("=D]/_P`WGXY;^^#/3?1$_?VQNNL?T-T=
MN7:^6ZXVQ\@L]UQC_DMV5V%N'?WRD?Y';6Z;VON+9>9:;.;I$,L'9+TV(I:1
MWGHV5TJ&42[;'!#SI-M,UQXNW;=)8VD!D:MO)M=E9PV[4=J0>)*\5P6D#"XH
MT+Q@?IGHAOY%GY<&[1V[1S7[;A=S(E1<1WEW=23PJ:?K%(HY(0B`&$E94D_$
M.C$]B;(_F([_`/F?_,_Z.R[?._LKJGN#H7Y24W76^\+N'Y`]+=2]3,NQL/FN
MH-A]7X7.X6JZ$WM49K<-,-OT.1V7EXMQ5]/4SS91$66K@`-OH+F[]M^<[:*!
MGW:*&66(R@,]S-%<N8K?P&TR:9XV"RQPE[4PQLA!\6-@*;>:.VYMY%NI)46V
M9K6.<1T6.)7M3'<W!D6JUCF!E0S:9DED0K_99*C-2?S<ML;A_E[;.^/TGSKZ
M]Z;P?QS^-&"ZNE[&V=\ILA5[<[<H-TY'&?(S%_*K9FS-G9;`9#&P5<$='BX>
MSOM<11;9--/C&"++(L@B2"[]Q-TEN)4>Q-U:-$6/Z+[9])%4.6I$MX[BX%TV
MH7:S:"*?I'H"V\+V7(^V0-#(MZD5X)PF)5OC<R%#'HK(UJH,36RH#;/$&5B:
MN.K'M]?'[YW[N7Y1[_I^\_YA6U-X]D?S7]C=([+P.T-_]BX[:'6'PI;MS8$N
MYNQ>G]DM2RXK&;8J]OU>2,VXWBJ:.''(T:E(4<$-;)!&]GR+:7DLHCN;Z^DO
M6=J2B&([M]-`S\8$D1;4!AW,SPNIQ'T(MSEE67G*YA6(SVG+UI](J+^E)>26
MMB;A@M?UI5F\>B\4[P06U'H5,]T1\Y-V?RC_`)??'"BR_P`B^U.SME?)_N+8
MW7I[<WAE*/O_`+S^(FQOD5C,H-J4G:6XZC;V2W+E.SNCZ7(XO%YJHJX1DXJE
M(Q4)&ZLNKN:"\L?:S==YVX36Z?1S;K;Q*$:58IYED#1`KW`+!-)#QE1"-+M)
M1G;>WDM-PY[LMIW3P;F:&1=ON)"7CMYI["W8:6R0B3//"DE?T)")"08R00SK
MVCWYUY1?S'NT/AY_*@[[^-'Q_P!P=(=2;!V-C?CYM/Y#_"?Y,Y_<6,[`P5%D
MY8^I9L%GH,GOO:&VMPY+)9;=_7^WLMD<OBZ*.BIZ_P"[,C"\[W*\NRK<73!K
MW?;=T\(N46'3<*LS0*OU$$4>FW6>W1(1(T[,08HV*)X!;+O-A)'9!I+;:[E7
M\0*78E8:Q"<MX,TS2>*UO*[R/$L>KN:1%<$=O];?S-]W_'':.X.U^L_EAN;O
MSK;X??SH>N-J;EW;M+M;=G95!!OC*]!Y3XW;>?=F\\-)OC<V=W7@X:I,`V5,
MF9KDI)8'4S4TL<9@?#5OJ(PBWDNW<OQ3E=`U36W,$GU8(4Z#HMPLDC)5&AI-
MJ*-K*_99(&OK6*1C^[$YGCGB\1B=,#['=`O632RI]0ZJP8!8YG\(A31>A#^5
M6Q?YG?7.V_E!FOCWL3Y'[4V1V5_,6PVZN[<EU1A.\]N]N[PZY7X-_'W!;/W%
MLC(=$[?RG>%?LM>X<%6467K-JT\RBKI6IZYEIEJ`"Z_;2>7+36Z[<MSS`RB/
M51;B7=II+5I@E3X+VID>'Q:0.Q4L2QBJ@L0&VNSF95_>XY=V&.0N%KIC2Z%T
MB:J`3I(T0E4?KJA[!0OTS_*#(_SV(L;\!8*+>/R->>I^-6VYX-_=5[!^3]*D
M'R3G[/S06O\`DSUUU9L6NS&2^PZPEV_'68[LJCHMO5!2LEF45AJ])C&BGGFZ
MA=D#C]WZ#VFS9!$OUYQ6U5I+C7J!8-&A7Z8!`U$FJ,<LP2A)#9F6]UK5Q>*N
MH?2+J/\`C+*D==#*#XC`^/4E*V%?.'XU?S!^S?G)WOO3X[[ZQ?4='D?Y0NW>
MO>QMY;@^,N7[OVCW1NZ+L/NG(9GICKJN3>^PZ/:F^Y1E141E),K4QT]?`31,
M"I8BOX@-F]UDMT+;5/N,316U*33HMC(FJ.7N8A5_1.E&_48'4#CH3;/<2"+V
MG%Q<QIO$%Q=--.::(&9ML.J2/%%=T9U!>/MBD`)H:$\Q>#_F5;'W1\<-FXC#
M_P`Q+:F]MI]%?RX-N_"S9W3V%K<;\+<;@\1L/KK'_,##?..DEI$VWB=R8NL@
MS$$T.[_%74M+'",,IG"CV*WGBNN>]_N/%#L_,4QG,YK:?N<JOAM:,,-<:/J"
M3'^N;SP!B$B@*EA>#EF&,H50;9<&#P`1<G=3<7)0W*Y(MRYMB@/Z!M3*9"'U
M=,'8'9G\QSI7=7\Z&NW/N3YL9C:.(Z&^26]>K_D;NS+=]=2]:]4Y3&[[QE;U
M3MGIW8F_,4O3%3G$VYDGH<5F.NLU(IH\;)4Y-2]4%A"5K))_4NV@<3+?C<=M
M42'2;F=WOTAEC6.73+&TL3,[KW68HL(-&1F'(@CFYWVHPPQR63P3AHEIX$2K
MMY<2.RUCE"SQ@+K*W!:0N:!)`1)Z>VM\Y^P]U=<X?`R_S,:[XLY7Y^_&PTVZ
M/EO!N>D^2FUX,M\;>\<9\GMS8G-R4LNX-I_'W&;YKL`^#RI$.!I<Q(3B9#3%
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MM97;^3S72V[-K="XS>_8VTH\E!CIZS%Q[*IL[)3UT!TI-12:&$D1`?D2U38_
M;O;;UD%HFX&*Z6H(6"7?[@NL@K3PY8)`7)P8)"^5(K6*:ZNMZN]S4,=P;E:P
M,;*E6-]#L[E45*$&:.Z"KX1!(DI&RYIUWV[T#V'M+<'R?WITSU'NG/[([F^5
M_P`.]FY+;>SL%65>,R'5VP<3\4*WK_N?9F+I@F.RFU.O),#F,3F*RC)C7%,9
M&8C'$>W-JEN[6]Y6M]PA*G]][E<RZ@%:"X5[G07#4\*.ZB"Q5(TK*ELU%0R$
MZN4L)K&XFL)D,,/*?T\>EM0E25;Y="D$F2>)I4E1:%W224$L3&`6;M3#?+;N
MS<G<VW(]C_*W%;`[-V/G:/=6PJT?)G>$VT>QML?,;XYY?:M>F\.S*+']6T&\
M:?KIMR9'&#K7;E!MS'8B+Q-D,L]**A$VPP15Y=-S.61=QV&97;4OAK'=SB]J
M[Z;GQ(U>W-S*QA1B"\,2QQZ^E>XW'A27,EK"GBK#O,#BBLLL;[5<+:G0OZ/A
MRSH%A0&6:K`2R!I_"Z&GY&TGRMVMM'N/IO9V,^6M1087M_Y,M\>NR?[X_+S=
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M(].NNDZC0`IV225+.)]TCUS0[+MX*-0:Y_K%^J#:?[24Q`ZBVLJH#BE*]!0O
M8ORN[)Z3H\[OO'=]5-?D^W9_C?4YG9^Y/D/#MO:];\9=FYW86[NW\IM_XK2P
M=M[PI^\>Y(LLV-CI\QMK%M4TU%-ELI'2P)3S%5^[[G86>Z6*-!=;M9W6X11K
M6L1ECABMK-$(6&*3LEN(WFD^G6.36JRRM&I,+6*#;MQO]NN)5EM=MFMK)V-0
MTP$DMQ)=.6#NRB)[>*3P4:=VK$3$H>5;6_@IOC?FY_B;TGMCNFHWFWR*V_T)
MUU5]R8GL'!9C#;XIMRYC"U]`U3N6+)4X27,Y*OP-49@L]3-K75*[&17D6\XB
MTO(.83LRA[4V^@!!_HDEG%,4H`HUTF4LJJ`K,4TJ5**5[.)K6XB@O6(<74[)
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M=ZQF%@\B3XGNG*`UMXEC<H(UDDY?D$]6W&YL[^0,.PQW(B*V\95:2!R^AH`O
M@VR`EI&F;6B0-\;2^:&_]M?*?`[[S_;V?W]EL'\A:+=W4-#T?\C<ILS<^VV[
M-I#TA%L[?.YNQ\O\=:8XS98Q]1BSL'`PYC(Q_=19B)9DGD"'9$,<7+S3.'T3
M[<USJ[2MXEY;M<2`R5D*1E9Z+"1:&W*2@J40$SLYBF_QS.WAVS-.(CVE3:M8
M3Z%<)I56=S'K:<?4+<!HEU*YZN*^,)J:+N_YH[?PJE.N,3VOL&MP<$0*XW']
MA;CZEVMF^V\?BT""&)9,[4TM=6+&;#*5U46`D+WW;/XFT`EM4:;E>)"226,"
MF%J4/PHET]W'&``NA!2O'HG0:9[$,6^J.U6;3J<:9@9XUQ0`,;6.U+9)."V3
MT=CW3I5U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__0VV_C!X]DKVS\?,M_D>[N
MH.U-]Y:*@J#HJ,SUKVCNO+;^V'O3'HUC58BMCSM1CY94U+#74,D3D/Q["7-%
MNZWZ7M/T9D6A\@R@*R_:*`_8>C+99E\"2T)I+&YQZAC4'[,T^T'HU'L,]'77
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MKZB?\7FJZW[BKE/_``9S;\>_:%_A'7C++C]0BGIC_!URP$>4V5EL?N*CR>1S
M--B*2?'U>#>''PSY+;CJS/1&N$:3UV0Q6E9J,S/ZI(RI(\C'V:[-N+;5>I.2
MS6Y%'4>:^OS*G(_V>DFX6R;A;/;Z564FJMG#?Y`>!I]OET:S%9?&9V@@R>(K
MJ7(T-0B-'44D\4Z*SQI(8)3$[B*IB60"2-B&0\$>Y:CECF19(I`T9\P0?\'G
MU'\D4D+F.5"KCR(I_J'SZ#W=^PJ_(Y:3/;;J,=3UN06*/.4&4-3%15\M/&(J
M;+05%'!4S4^3C@40R@QLE1$J7*L@)#N]\O#<Y5N;>58[FE&J#1@.!QP(X?,<
M>'1SMF[BSB-O<(S1#*TI5:\1GB#QXX/V]!;EH\EMFH2FW51PX<3Q"6CR,58:
M["58#,LD`R8IJ:.EK82H8PS!&*,&75S8$;AL]]MA7ZB,-&1\2U*_833!\\]"
M2TOK:^!-NYU#BIPWVTJ:CYCIJW%N;![+V[F=Z[FR$&+VSMG%U.>S&4G<"GI\
M=0PFI=U>]I9:@*$A1;M-*ZHH+,`45M:7%_<P6-I$7NIG"(HXEFP/\Y/D,]/3
MW$-I#+<W$@6"-2S$^0&3_J]<=#O\&]F9_9GQLV3_`'JQM1A=Q[UR6\^TLMA*
MM=%7A)>T-Y9W?-+B*N/ZQ5F.QV<ABF0@,DJLI%P?>74<`M+>TLE;4((8XZ^N
MA`I/YD&G4%JYF::X9:-+([T]-;%@/R!Z-Q[MU;H-3W/T\NZ'V.W;'6HWK'6R
M8U]GG?>UQNA,C"CRS8]]OG*_Q9:V*.-F:(P^154DBP]Z1ED1I(R&1022,@!:
MZB2.`6AJ>`H:];D5HBHE!4G32N*ZJ::5_BJ-/K44X]*7![TV=N:84^V]V;:W
M#4'$X[/B#!YW%Y:8X+,/518G-"*@JJASB<I)13+3U-O#.T+A&8HUG"C@.2A`
M5@IQP8J&`/H2I#`'.D@\".M,"I`;!)8"OF4;2X^U&[6_A;!H>E+[IU[IMQV9
MQ&8->,3E<;E#BLC4XC)C'5U+6G&Y:C$9J\77BFEE^SR-*)5\D$FF5-0U*+CW
MX95''P-6A\C0E30^=&!!]"".(Z\1I8HV'`!(\Z$5!I\P01Z@U&.G+W[KW22W
M?O\`V)U[14V2W]O7:6Q\=6U/V5'D-W[DPVVJ*KK/&\WVE-59JMHH)ZGPQL_C
M5BVE2;6!]U+H&5"PUD$@5R:4K0?*HK]HZL$=E=U0E%I4TP*\*GRKY>O3IM_<
M>WMVX>AW#M7.X;<VW\G&\N-SFW\I0YG#Y"*.62"22AR>.GJ:*KC2>)D)C=@'
M4@\@^W7C>,A9$*M0&A%,$5!SY$$$'S!KU0,K5TL#0T_/TZ>?=.M]>]^Z]U[W
M[KW4#*97%X/'5N8S>2H,/B<;3R5>0RF4K*?'XZ@I81JEJ:VMJY(::EIXEY9W
M954?4^]$@4J>)`'S)-`/M)(`'F30=656<Z44EO09X9/\L]<ZK(X^BH*C*UM=
M1TF+I*27(562JJF&GH*:@@A:HFK:BLE=*>&DAIU+M(S!%0%B;<^_2$1:C*=(
M7C7%/+->&>JQ_K:/"[M5*4S6O"E.-?*G27W7M/K_`+?V)EMH[SP.U^Q^M]^8
M,T.:P&<HL=N;:.[=N96%)#3UM%4I5XO,8C(4[*P#"2*5"#R/>Y(BLBK+'26*
M57`(H5DC<.C9R&1U5E/%64$9'5[>X>,B>UF()4@,I\F!5A4>14D'U!(Z?J;)
M8*+(';%)D,4F5QV+I*YMOP5E(,E18:626BH:U\6DGW5/C99J22**4H(F>)E4
MDJ0+,[S--*S%FU=QX]S5;N/JPJ<Y/'IF.&.VB@ACC"0A:(`*#2E!11Z+51CA
M4#S'3M[KU?J/5TE+D*2JH*ZF@K*&MIYJ2LHZJ))Z:JI:F-H:BFJ()5:.:">%
MRKHP*LI((M[;EBCGBDAFC#0NI5E(J""*$$'B",$=61WB=)(V*R*001Q!&01\
MP>FK`8[;FW,?0;/VU38G$8W;.*QN/QVW,4M-34^#PM/":/$TE-C:?2*#'14]
M(8J=0BQA(]*\+8.M*9GD9I-4@(#$FIK3%3QJ1G.3QZ;6-(51$0*IJ0`*"E<D
M#TKZ8!QT^^]=6Z][]U[I,U.<VAE!E\#59O;U:T>,R#YS$OE<?+-!B(Y)L;E)
MLC2"H,M/00S+)!,\@5$<,C$$$>VG6&X@F#Z7MB-+^:T;4M">`J4<9\U8?A-'
M8S-%-"8PPGU=M..H!&%/F`Z-]CH>#"L?9^!V1L796"P.Q\;M[;&P-NX2GAV]
MC\#'14&VL5M^GI_-3G'BET4,.-2F/D#J=!4ER3<GVINII-<DEVY#J*,6QI"B
ME#6E`H%*8``IBG3$,2X2W3XV)HN=3.Q8G'$LQ))XDDGB>E#0OCJN),KC7HJJ
M'*4]-4QY*A:":+(TK1!Z.H2L@+)5T[02`Q.&92C74V/NA4HS*RT:N1P->&?G
MBGY=;U!]+5K04'V5)H/E4DT]2>N5?D*#%4=3D<I6TF-Q]'$]165]?4PT='20
M(+O-4U50\<$$2#ZLS`#WKS4>9(`^9)H`/F20`/,FG5E5F-%4D_+J4""`0001
M<$<@@_0@_D'W[A@\>J@A@&4U4]=^_=;Z2^T\1L[!T>3QVRJ+`8ZB&X<[79FE
MV^E%'"-TY?(2Y?<=1DTHN!G*[)5SSU1E_>:274_U][&H0VT8KX"1A8Q^$(I(
M"KY!0VH4&*U\Z]6D+--+))_;N06)XGM4*3YGL"@$_A`IBG2H]ZZKUT2`"20`
M`2238`#DDD\``>],RJI9B`H%23P`Z\!7`X]->*SV#SL<LN#S.*S,4(IC-)BL
MC1Y&.(5M'!D*,RO233+&*N@JHIXKD>2&176ZL";%6`J5(%2/S'$?:*YZV05;
M2PHWIY\2O_'E9?M4CB#TZ^]=:Z][]U[KWOW7NO_1W=NZ?CMM?M^NP.[:7.[C
MZW[7V=!54VS>V=B5%+1[KP]#6L):W`9*"OIJW#;JVCDIE#5.*R5/44KL-:".
M3]SWMA')$]O/$LENW%6X5]0>((\B,]-M&2ZRQN4F7@PX_8?(CY'H&O\`1)\U
M*&]+2]\=#9^GB)6'*9[HK<&-R]3'_8:OIL%V4F*%1;]30I&C'D(HX]E3<O[*
MQ)"3K\@X(_FM>E(O]T44\6(_,H:_R:G7O]%_S<_Y^_\`&[_T36]O_ME^Z_U>
MV7_EX_WM?^@.M_O#=/XX?]X/_077O]%_S<_Y^_\`&[_T36]__ME^]_U>V7_E
MX_WM?^@.O?O#=/XX?]X/_077AUC\W;"_;?QK)_)_T.;Z_P#ME^]?U>V;_EX_
MWM?^@.O?O#<_XX?]Y;_H+KO_`$8_-S_G[7QK_P#1.[Z_^V7[]_5[9O\`EX_W
MM?\`H#KW[PW/^.'_`'D_]!=>_P!&/S<_Y^U\:_\`T3N^O_ME^_?U>V;_`)>/
M][7_`*`Z]^\-S_CA_P!Y/_077O\`1C\W/^?M?&O_`-$[OK_[9?OW]7MF_P"7
MC_>U_P"@.O?O#<_XX?\`>3_T%UU_HR^;P/';'QI86_/3^^UY_P!AV2??OZO;
M-_R\?[TO_0/7OWAN?\</^\M_T%U[_1G\WO\`GZWQH_\`10[]_P#MD>_?U>V;
MUN/]Z7_H'K?[PW+^*'_>6_Z"Z]_HS^;W_/UOC1_Z*'?O_P!LCW[^KVS>MQ_O
M2_\`0/7OWAN7\4/^\M_T%U[_`$9_-[_GZWQH_P#10[]_^V1[]_5[9O6X_P!Z
M7_H'KW[PW+^*'_>6_P"@NO?Z,_F]_P`_6^-'_HH=^_\`VR/?OZO;-ZW'^]+_
M`-`]>_>&Y_Q0_P"\M_T%UX=:_-^W/:7QE/\`C_HE[`%_]A_I&]^_J]LWK<_[
MTO\`T#UK]X;G_%#_`+RW_077?^C7YO\`_/T?C+_Z*7L#_P"V-[]_5W9OXKG_
M`'I?^@.O?O#=/XH?]Y;_`*"Z]_HU^;__`#]'XR_^BE[`_P#MC>_?U=V;^*Y_
MWI?^@.O?O#=/XH?]Y;_H+KW^C7YO_P#/T?C+_P"BE[`_^V-[]_5W9OXKG_>E
M_P"@.O?O#=/XH?\`>6_Z"ZZ_T;?.`'_F:'QD(M^>INP1S_L.Q??OZN[-_%<_
M[TO_`$#U[]X;I_%#_O+?]!==_P"C?YO_`//SOC'_`.BH["_^V+[U_5W9?XKG
M_>U_Z`ZW^\=S]8/]Y;_H+KW^C?YO_P#/SOC'_P"BH["_^V+[]_5W9?XKG_>U
M_P"@.O?O'<_6#_>6_P"@NH-3U)\SJVIH*RLW]\5JNLQ4KSXRJJ>GM^35&/GD
M3QR2T4TG8324TCH;$H1_M_=6Y9V)VC9UG+(:J2R$@^H.C'5EW7=T5U22(*PH
M0`U"/GW9Z3F:Z!^9F;S#9V?M7XWPULN.@QM2(.J]^B*JCI)Y9J2:?R;_`))#
M44XG>,-?_-M8C@>RG<^0>6MUECGN)+Q9%73573(K45JAX9IT867,N]V,+0Q"
MV*%JY5\&E#2C#CCJ#_LNGS(_Y^K\<C_C_HPW]_Q&_/99_K7<K?\`*5?_`.]Q
M_P#6OI7_`%QW_P#WU:?[P_\`T'U[_9=/F1_S]3XX_P#HL=__`/V>>_?ZUW*W
M_*5?_P"]Q_\`6OKW]<=__P!]6G^\/_T'U[_9=/F1_P`_4^./_HL=_P#_`-GG
MOW^M=RM_RE7_`/O<?_6OKW]<=_\`]]6G^\/_`-!]>_V73YD?\_4^./\`Z+'?
M_P#]GGOW^M=RM_RE7_\`O<?_`%KZ]_7'?_\`?5I_O#_]!]=?[+I\RK_\S3^.
M!'^/678`/^\;[/OW^M=RK_REW_\`O<?_`%KZ]_7'?_\`?5I_O+_]!]>_V77Y
MD_\`/T?C?_Z+3L'_`.SKW[_6NY6_Y2[_`/WJ/_K7U[^N._?[ZM?]Y?\`Z#Z]
M_LNOS)_Y^C\;_P#T6G8/_P!G7OW^M=RM_P`I=_\`[U'_`-:^O?UQW[_?5K_O
M+_\`0?7O]EU^9/\`S]'XW_\`HM.P?_LZ]^_UKN5O^4N__P!ZC_ZU]>_KCOW^
M^K7_`'E_^@^I.#Z!^:NV\E/D</VQ\<:=*ZYRF+;K/L%\3DIA'%%%624O]^@*
M;(PQPJOGAT.Z#2^H`6--MY%V+:RPM[V^,3<49H]-?4404/S\_/I'>\Q[M?*H
MF@M=:\&"OJ`]*ZLCY'\NEK_H[^<?_/POBV?\?]&G9?/_`*_WLW_JYL_^_+G_
M`'I/^@>B_P#>6Y>D'[&_Z"Z\>NOG"RLC]@?%EHW&ET?K+LJ1&7Z$/$^_BD@L
M?H18^_?U=V?_`'Y<_P"])_T#U[]X[EZ05^QO^@NFG9?P;ILCNO"[X^06\\=V
M?5;:R<.;VQUOM7:O]P^F\'FZ:;[BBR]9M9\QN#)[OR6-G59*;^)5C45/(`Z4
MBN`P=VW8]BV:22?:MK2*[8$&4]TE#Q"F@"`^>D"OKUZ[W#==R1(]RW!Y8%((
M3@E1P)'%B/+43T?[V9=)^O>_=>ZTU^G_`(Y]D;._FI_)/>6^OB=V+50;Q^;'
MR%W=L7L&J_E&[$[-IZ_:V\=MU5)L[>.'_F.Y7?F/WYUOMV2M=GA^SP=3%0'5
M#&S"J9E)[**0\BW>V11%=S;9]SATT^F82RM=L@9UU&XUHRJ-07Q=:PX5028;
M^T;\P6-X'#V8;:"U/\8!$,-HD@$;:1"4=6UD$^'H,N6J`FMB=8_S!NCOA]6;
M-QOQM^9N10_R[_Y;G4U!MGJ+<O:G4.^.N^QL?V7WW+VUF<#4=<QTO8V3R^PX
M*S!3;JP.WZC'9>LQ=2B25=+$QD`DYBF-W)N$5O*=4V_6WAR`DJD2;%;("RH0
M7MVNT:!BS+#%,?$E)"%3IC!%=M=%%>)9-_=T`35()]YB>)D=@P60VI>:!M+O
M(@98E8MT\]>X#^:5%U=\%*/Y58+^;+DJ[:76'8^U<5%\1MWIB]_T'REPGRJR
MR;&RORTR._\`,Y&DW;U%6?'^'$I29C>4N<VY-1BJ:L-362-+[4+);R<QVT]O
MI%[+9[1X32!!9*J1-'O(N4H(UG:81LM8U>2+6]H0Q#=%$NI=LW.%?^2<MY?E
M@/$-V0\,3V'T[DF0P*S7`HK$QSB-)OTE"]&JZ^^-GS+Z:^6N[OD=L''_`"YD
MI]^?S./F)_>_HO&[ORNW>@]U_'O</QLW!F]J[_K-GO1#9\.0WQW%M[$TF.WM
M61S24U8T<4!2*\9(;)YK#8&M#$UPK[#OC^'J*/'<KNDDMA!;NU3;R/$[O&0-
M<JR$OK`4`VOHH[_<$NWO!%/%+R\JOI5M2BUMX;[QPE%N$B!82(*)&T9TZ17H
MBWQ\V)_-N[&ZX^26S=TX3^93T5LCM_Y)?R_LWUK3[C[2[XW+W7U9UYF>VMZ8
M'Y9TN"[9[$RN1W70TVV]M1T+966FI\3@9Z)(LA18R&FDU,;6=K97%OR587MX
M6BCWV0SR*&@9MODVUS")2:R!?J4*NLKO-#*REBADC'1??W<J2<RWNWV@2Y?8
M;K1&U)4%_'>6WAB)0!'J,4DQB\$!7B!75)X1;JV[^;%\`^R/D)M_^6+\>>G:
M&/>^`ZP[]W!_>KL?Y)=4+\T]F[;VY@_C=V?BL)NOY";6[,RRTO84&X=R_9T+
MY',UAE7*UD-2IDG2.-D3^/N',TNYA+2(ILU_I#1*(3*7LO"A2@_1>30Q5T5G
M`1Z*U6Z60F&RY1WBP$L\DTE]M]*2'QBGU9,S@UJZQ(Q9TJ%,8T$JAJ*4^P?C
M[_-+Z(^&7QMZDZ"ZO^4'4%#M;OWY?5?RRV;\=]C=G[8HJ7O[<&Z<+F>K=W_'
MK:/Q5SG6NX9/A=6X^6OJ]LT>/F?;U/+(:7-4\DJQJ&IKF:_N^5"DMPEHNPPQ
M6WBEGD@NTN)/JUOR_P"D7&H?2M,KV[6P[#J-2WX<4$?,B/';O<_O<-*T2+$D
M]G]*B6S6ND>('94'UWAL+@71JQH&'1^\_A?YJFT_YC7P&W-FF^6'?6!R/2?Q
MTV_W-B,)2=L]-?&/9>[?[I;CQ?<_8F\LKL;?62Z+SE?+E:M,OE\#O#`39AJJ
M!:'$S1AZ2H4WC:-N8.?(;1(D@E-SX$LA!AB!M%,8A1P4DC6Y0B+P/#G)EK(V
MF,JR"77_`%7Y7DE,AN8F!>-,32CZT,JS.*21R?2D)(9B\/Z98Y=PI</B!'_.
MPV=O;YM;H^0.VOE_V;5XSHWOX[WZAI\CW/LC&=N=CU.XYJ'K27XD]R;IW+N_
MK#K_`#V%P$DTN,_T9X.D@J*9D\M.]4D#*00&W7D:ZK#<&5UL$`8R"\BF,JB\
MGQJN)8T7QFECC;PI5""V*AHST9W'B?UQMVC>`1I/=N"%#6DENL3FW@()6%&D
M?P0CR@S(=?C-B2KW\0NC/YGW;W7W0W2OR$W!_,7ZGZ[R7\QO?F;W'N.F[0[\
MVEVKB?B#F?B?'N;:F&W;VUO'=&?[6I=G57<D,N/G7+91J_'Y.5H8A1.T$<8C
M@CM6W#E"2\E1GM=LW;ZBE$BDN8[B&7;_`!%7MD#1/^F"7+A9('=BDH!7=3.M
MGS1^[8G59WV<PAZO(BO-<17_`(;,`59(UC,I140=LRQ@2"JFWEU!\W=Y[&_F
M9]7[^V'_`#0=\]Y;PZ4^9&U*B'=FX<1O+X$;RV9D-UQ0?%.C^.>W,E/EJS)=
MEMU\E'&8=KQ4E>M5]^VX'J)&C'L-PK-?<L[:FMH;XS[:UV95'C)N(W&%[J:S
MID6D<0E=:$6:PK&-'B@%1)92)M_-]DWC)^ZXY9EMVB8Z/H?W?*D8NR_Q3M*8
MQ+JK<-<%F1O`U#H^W4/QT^476G3G\WGX[YS._*7NKK[.?'K:;?&C(=];DW'V
M5N'=&^>Q?B9GZ;MG:O6><S,?FDQ$?9O@I$P6/5,?B:IQ3TT,08J57.NG<.4M
MYMK6`27D>\WR1`=TTEH'M)+=G;XIAJ:?1*U68`@L=(H3\GHMCO'(MY<.8XY-
MJL&N4-%B@N8[BXCD54^&$^`L+2)_I6P".BK]K?(+Y0]G?RKND_CWTE\%/YGW
M7/;O5VW_`(U=.[TRZ;<[>^+>X]N9+#]85>&EWIMFLZJW!2]G=K=:8?>6W(*3
M-4.*R."CC@K(*FKJHZ9'1UO.LT^]\RW.Z[3,4M[N^O&C9F(*NRM)")HL*J2A
MF033/X$,RKX@<E`4O*R0[+LQV[<H?$F@M8@X5005\8"1H9""?$CTJWAQH998
MF94T@NRDBWCU9_,VJ,9\?>RMP=;?S.$^8-5_+:^/74N%[$Z(FK-O8<?+[8OR
M([>J:/%_,+.5>4Q\6Z.N\7MBL@K<G)E'R&#J*6K-37B62II)O:EY0W,V]3[$
M88UN[[9IXQ.NFQ,0LE7<C-%0:9`"Z:2H=7.B`))4%P"']R;7!O(F>TM9=^0B
M$LUTOB26_P!!X3ZC(8F*$Z@YUHBERRKU8;C<%_,J'\Q-JK<5'\[I>RO]FDH*
MH[FPVX84_E;_`/#>PZW@3+85-OG+_P!V_P#3DVZ/NA"@H/[Y#+&"59_LP5)3
M:^"(=V^E640>'NWU7U%3*Y/U'[L_=M,A@O[OTF/2%(O/J14X:N_JVBL/J=!O
M?"VSZ4P8190;?]XF_P""D$"_U%M2,#:BW4'2>B3=]]'?S.]B_P`MSXZXOK3#
M_P`T;M/YB?("K[/[`[$WN?DY\A*?)=!=E[6I,C1=:[#W%UUM'/[?R.'V%N7"
M3%:%,CDJ/;E/D:>.IRD>1DF2+VU++/;W7+%G;*1#:[3:SR3$>*9[AH[1KZ&4
M$%/%0J[1K*&K22"",RNS='RK8O?<SW5T5>WGWNX@CC7]-8K5;BY%I-'I[C%(
MK(LIBTMIT2O)&B+5<;FZ-_F`[2[#^9/9FSMK?S%7W]\@.H/Y;._NTMS;#SN>
MILCG>GZ#;VWJ3YM=?_'R3/Y*CP>S/E+MS+&JBPF%HHJ/,X['25D>,:$S*"KF
MCL+2^YHLM,O]4_Z[O,PAK]1+8R6&JTDB8$2/;QWS>%>:")%M(X(<I$H4BA-[
M<0\OW@,?[^'*+01F;^RCO(KTB99U^%9Y+)5DM&E!C:Z>:5JO(Q8>NH_C[\Y>
M]\E\/>MM[[O_`)F_4WQ)R'R@^6V9H\AO7M[?G7_RJQOQCQG3VRZWI?;'RH[#
MVSG)=ZXU,YV[2YB/#IFZY]Q_8,D4M0K,I+\$)>[VN3=I(C<1;+>%A$=,32G<
M+86`FT]CW:V1D:4+VM2CU83`[GD2/;M[7:$E\*3==L5?&!:8+]+=?O)X=1++
M:FY\+PSP%:J`AC/1M_Y8=9\LLIOSY\8;L3L3L7?D'P]J*OX3=(S;SWIEMU8S
ML;<>PLEOOM.'MC,#*5,D&6WOE=J=C;/P60KZUY\BS8B19IB'(]E<MU>7GMY>
M;VL?_(DO?%CTH!5)=KM_H'>)``%^KO4N+AM`5)&T4'8.EQM[*VYWM=F:1OW-
M;*L[L[,"T>ZRI>1QR'S^CM@L,;`DHK,`34T"O;O2/9&X-J;9^1?4'7VZ-Z;S
MVU_*XQ>W)9J.GD1^V>QMZ;Y[8K/DOTY6U@J(Z7(]F97<.1;*1TM1(73<-)2>
M4KK9P8[NL=K:\T1[?"IV^[;;H41`OZE@;5_#GC44!:`O%.2M2RO-&H+34*_:
M)5GDY5%[.$W"UWW=+B1I**8[CQK-*3A1VK*J3PFH`33K`'@TZ3V=VU\P)=\=
M-8;;75WR/VKC=J;:V=U3O[:T.-^1&Y=J[NZLK/A;F=O569R2S[FP/Q<VCM=>
MU*Z@Q[;?QV"W-O2+-TLM;75V,B*QA/S.@W"3W!*.9H[N'?$11W#QF#FSH[@F
M43*FN`VZI!%K6)Y9)G>,E^T3""VY:(4Q7%O<;3(K&BGPS>QO=@JE-!AA=TF^
MH9FD5?TH0B),5A@>K/DCT+U'MWJ["[+^4F;ZYW%\>O@:FY9LIO/Y/;M/67:2
M8SMN@[HS:X;J#)5?>>0Q>$BVYMBFS.R-CU>`IC-44K228ZD:JF)KNTR7NZ[F
M'G_17?9O!>C/JM_H8-"X96D62?Q3'+<S+!%.-4C@:4*:WUPI:7,4*EY+"<2Q
M#1&-9W%?#*EE9(2EN[U\*-II+<457==:PNLNJ_FMNSX[;DE[1B^6-9O_`*X^
M+G=&&ZXP>:SG:&V),[V.OR=[HQFP*S*[6_OUN2HWMNG_`$%G!+00Y[*;CF7'
M2PR33U52BU(31N@GL+K3^IX7+2MJTL0R^*N[$@(D9;Q(D:>58U)!212%DJQA
M9^`-V\!F`VD;ANTB'N4&)HK![&I9FE"5>X$<4CG2WB1LM4*J*&>RGRGI:[Y6
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M+-<@F,N&%[<1*7:,"-F*&$*4+UCTG7(`9&9F"P;GN;(3^[YKB(0'OTD_10-*
M%#]Z@3+,6U*@+5*HBLJ`E/:6P_DGLGM/.[LV1M?Y`Y-ZKY<=S[MV_P!2[7PW
M>.U=B]E4&<W=U&<7O!NX.F\K_!-@;C7$T56M%-V-A,WL#)XE:Z*0TE2!,6ML
ME,5QRK$41P(0DBR86%&W#<&D<%JV[C3+#)/#*$G>((;:126JOWTQ3Q[H\3Z?
MT(M+)5C(Z[=;($(0B96#H\<,L6I(IB?J(W4(5<.Z.O\`Y%T75JP_P#Y493?7
M;W>7RAR&X-Y4N^/ECNJFZ[QFW]V;NH^A<!B>J>@M\;+S4.'W!MW)Q0;=JFSF
MU-H4/ACK\W65`2GC8.TO&V';;2%I%W%=HG?50^)+=L[``M(?#@F"B-E:X)14
MU+#!+*Q'2NVEMQN^XW5["IL#N%K&5!71';"W1I&"H-<L8D5E<6Z^+-(0&EC0
MEND5T=@?G]GNP>G,KWCO+Y"[1WF=L_%Q]N4"]$=U;UPM=M"'IS:=/WE@NS]U
MX+O;:/QOVAN#*=DT>Y(]Q'>6VZ_<\!J*:HPTM6&HXXQ#OD=G//S8+%5DBFFW
M!C'31&]I)"[6<4;.&0'04`%K&EPEV&25`G<0Z@NX[&PCD9E$4,2HP(>1;A+M
MTE9E0AVJGAD-/(]M);4=6\02`G#^#.V-V=?=B?'_`&/-@<IM;(4/\NWK"#OC
M:^0I)L?-A=\;?W5183J]-PT31((-VIB!N6D_>M4&CI`I]$2`+KJ99[[FDPLC
M;>O[M*D&M+EK>=9PHKI%8HX/&*YU)`'/P]+]R,9O;>1"?J7W+=R.-#:-=B2)
MAY%?%D)B)/"24H*%R+=/95UKKWOW7NO>_=>Z_]+?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7"31H?R:?'H;R:[:-%CK
MU7XTZ?K?\>Z2:-#^)3PZ&M>%/.ORIQZLFK4NBNNN*<:^5/GT"G0-/\=:78M5
M!\8&Z?;K=-W[M->W253M"LV@=^OF9WWU]_4;*EGQ3[N&?:3^*>5C6+57$]G%
MO;JZOH]M"5_=_@#Z>G]GX.IJ>#^'P]>OX.W7K\Z]4:GU-Z7_`-S#+^M7X_$T
MK_:>>O1H^+.G3Y4Z7FR$V`F-RG^CD[2.(;=&Z'S']S9,3)C?[YMFZP[S&0_@
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MW8_\&?%-N45PP=,FVAO%:-CDHJC^[BQ?8BL`8TFDQ#0;G::OI@(Z_2>+)2GP
M>+1/%IY:Z>'K_%31JQIZM(6+1>+77X0TUX^'KDTTKG1XGBT\M?B4SJZ6/O75
,>O>_=>Z][]U[K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g912919dsp_277.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_277.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X1IE17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-3HP-#HR
M,B`Q,3HR-3HU.0```````Z`!``,````!``$``*`"``0````!```!6:`#``0`
M```!````\``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!DO````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`;P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[+IW1^E#ZM8F2SI6+E9(P:[&UFJL.L>*
MFN:S>YG^%?[=RYVGJ/2<+IKLV_%PNJEP)N8,-F,,:\8N1F_L\W^E97<Y^1C,
MPV8_]-Q++OUKU[;::UV71;13]6\"T@N;7A5/(:"XPVIKO:Q@>][OY+&KGL+Z
M_P"7E'"9]@:;,JQS2QMA#G,;=C8OJ8M;J_>[T<W[8_U'U[*L>_\`ZTE(3G8N
MZUS/JW@/JK9G6M;`]5S.GNKHL:RK['_/95U[/09O_FE6NZMC'%#L?ZO=.?<^
MF6O:UES'66?M)N*^D44?IL=[ND^H_P#2LL_6O3^FSWW\+Z^Y^;359C]-;>;:
MWWQ38]X+:Z*\U^)5^@_3=0;ZOV?T_P":]3T_TGTZF$;]=LRS[/4,:I_VDW,=
METO>:6BIK'59-+K<<>I5DW6?8*/6]#?U&JRBOUDE(K\KH^-7T`'H^#D6=8%)
MO=72T,:+?0J=;CO=1ML8R[*:_P!-_P"F]!5,/K/2[V]/-G0,%GVO)=CW[6,?
MLCT=GV?93^NN_6?TOV;U/1]+]893^E^S7L+ZZ=4?]E;9@M=78:F6VE[Q89?T
M[&OM]$8[6;O4ZS78QF__`+37_P!@0^O?4WL=DUX3'45#+!8"_=::6861BFK<
MQOHO]'-N?E4V,]7T\3*_/I]%)2+`ZMTO,KJ<WZNX9^T9AP:7-8W:7EN-E4N>
M'8WJ5L^Q7YEUV]GZ)^!Z7\Y=^B+A9_1\GH.=U2SHF#3=AVBH5"MME1+S6VK]
M991L=[KOTVS^9_[4_9??Z=GJGUB=1T?I_P!8+NG56Y31D%ECK`ZJIK*KKK'T
M93&6?\HUXC*<5VS_`+4_]:N"_P"M_5JW64?9P]]EF4VBPM<'EK;LJFG[+4UG
MI9+.G58U5_4'V6U?H;ZOWV>JE-&WK6",$YU?U;P!6/LS8L#&Q9D8S>I%MCW8
MK:J:F[OL%5N_WY;Z_P"HKG6;<#IW4G8]'1,.[=C56LKMJK8&N-?5,N[>^K'O
M>YVSI==.S]^W_MQ\#Z]9UE/2VW8K++<R^O'NNK+PQS7,Q/5RJ"^EC?U;)SO1
MRL7_``;\:_\`X3T;O_.;JE/2^C6MP_MN3G=.?G9,%S';J::+[*:*:ZK=]^39
MD;*:_P!&DIRG]6Z3LR;&]$Z=4VNRJMHO8&FEMDQE]3VXKV8V);'ZI959=ZOJ
M4[_2_264LSJN`^]K3]6<6FLFL6-MK:+F3^R_7::?LVWU&?MRO8SU/^TMWJ;/
MS+%OUUZK8.GBK&K8<BQCG&MQN^T5^M?1=5TW:WTG.]/'K?<Z^ZK[-]KH_KOL
M8GUUR[Q@^IC4M&9D^@ZUMEI8VLC%?]I:[[+]"JW+_9=WK>A_E7TZ/]/]F2G#
M_;N%;55FU=!PG4-;999532VT/BB^\8C\AV/3Z.5BVT,MR]E=OZM=4B6]8QZ&
M776=`Z;8T,QG4,:U@9%PS"^]^9Z3Z'49-F"S'PWM_P`-D4^K[UJO^LEO1NH]
M0Z55C5?8<$'[+76UX-+&XV+?6^ZJJMS/L+\O(?3Z_J?H7_\``5OMJ!5]>NHM
M%>3=BRS*?A-KQMK@:Q<P_;OUC;LLLJL_25,L]/\`1>I_PFQ*;'7,GHG2NH8&
M&WH>+:<MKGV@TM:Y@#7%FUPI?39^E9Z=K&6;ZUC976L<XU;6=`P,2^RRD"TU
MLL9ML_9N0,>ACL:MUV8[&ZK9OK_1>G]DNO\`^*UW?7CJ+6C?@54A[F%EUEMG
MI,K<[.JC(+,9UK;[K>E^ECLJJMWV9E'Y_P#2-CH?7<GJF=U'&MQ1CLPK/38=
MX<\P^ZG;?5#74O>RAF75^99CY57_`!EB4X?6<_I73,_+QF_5_$O9B4NMV^DU
MMKPVEV7]I:W[.^O]G^HS]GOR/4W_`&Y_I^BJK^I8=-N7=9T##LJQ&BE]#*F3
M]H^T=1Z?4^FPT;K:LS*PL&C9L_5_M?K>_P!->@(.1AXV5Z7VFIEWH6-NJ#P'
M!MC)].UL_GU[O8DIIU_5_HGIM]3IF&+(&\-IK(!_.VN-;?:J'UCZ'T6KZN]4
MMJZ?BUV,P\AS'MIK#@14\M<UP8N@6;]:/_$SU?\`\(Y/_GJQ)3__T/1?J_\`
M\@]-_P#"E'_GMBG3;TG)R?M=%E%V2RK9ZS',<\5/<YVS>WW>D^W&?_;H_P"#
M4/J__P`@]-_\*4?^>V(#_JG]77[MV$SW;]Q#GM/Z0;+=6O'TVI*=&EF-C45T
M4[*J:FBNNML-:UK!M;6QOYK:VM2OR<?'J==?:VNMGTG.(`&NS_JCM6=_S3^K
MQ#VG":6O:YI:7/(A_P!/8TOVUN=^_6C?\WNC12W[*W;C.>^ELNAKK'^O86MW
M?Z9OJ?R/S$E-XVUC4O`UV\CG]U#KR\2ST_3O8_UF[ZMK@=S2-V]G[S%0R/J]
M]7MUF3D8[&EY>ZRQSW`3:YMEOY_Y]C&/5)G3_J7N<QK:I?`<7/?K`:QOZ1[O
MS6UMV>Y`RB-R!YE3L9^-TO,I;5U&NF^G>"UMP:YI?_-C1_MW>[T__`T?U*H^
MFV/B%G_\V^@OHJI&(ST:?4=2UI<`/6<VZ[;M=_A+&,<F9]5^@UW"ZO#;78UY
ML#F.<V'.+G$^UP_?>BIU(2A.DDI;YI1YJMU"]]&,YS-'$AK3X3^<L$^X[G$N
M<>2222LWXA\6ARDXXSC.24AQ[\`$6?#RYR`FZ`T>GA*/,KEP&'B)'(T[)`,(
MEL$>(@JC_P`HQ_XG/^/_`.@,OW(_OC['J(2A<QL'@D6M`DZ`<DI?\HX_^)S_
M`.&?^@*^Y']\?8]0DN7V#P_U"6P1,:)?\HX_^)S_`.&?^@(^Y']\?8].LSZT
M?^)GJ_\`X1R?_/5BS*W/K>'U.+'#@A7NO6F[ZI=3M(@OZ?D$CS]*Q:'P_P")
MPYPSB(''*%&B>*XGQ8LV`XJLV"__T?1?J_\`\@]-_P#"E'_GMBT%G_5__D'I
MO_A2C_SVQ$S^IX^$&A^ZRUX)92P2X@?G?R6H$@"R:"FXF)TGLL#_`)T7;OZ&
M=OAO.Z#_`-;VK1Q>H8_4L>QE)++=I:^M^CFR-L_U4R.6$C0-E-/-=1S[.H9!
MM<?T+2?19V#>SH_TC_WE6D<)ZPUH++6$[?:0#M(<-'=G(SLACV;'BQS?#>T?
MDK6>29$F1U*YN]`ZA9CY+<5Q_07':UIX8_\`-V_R7_0VKJ%QF!6;>I8[*P?Y
MUK@"9(##O=KI^:U=%U'K>-@N]*#;?$FML")X]1_YBM<ODK&>(Z1-`E:7227/
ML^M+MWZ3%]O\A\G_`*36M6QAYN/F4BW'=N;P0="T_NO;^:IX983-1-HI#U?^
MB_VV_P`5BK9ZO_1?[;5C+E_^,'^ZX_[*/_3R.AR?\V?[S3R,;"-DWV['/)<U
MI<&P7:.<W\[Z6U#IQNG565O9D26.+P"\08]CM/W6[4^7=A?:'#*QR[T@&^H)
M,[MIV!HC]]#99TAS]*MK@\;?%VOJ[M7?0W!4XB?`+.2B.G"8MX<7#^G5=-DK
ML3$+1=ZKW5.=(VP[<23M'L;O?])"=B]+VZWD[HV@NF-6C;M(/[JE7F].%(J%
M3VLD>P<@_3W3O]NWZ>YJE<<"NVQMF-[:X!L;,$EH=M_-_,_E?X/_`(M(<8-'
MW!V^3Y5`R!HF?A79:VOIF3<^PY$$[@Z'#;+MIX=['?11L3$QZW"ZFQUC=I`.
MX%I![_UO9]-51D=(;7+<9VG+(\8]I<;-OTW_`.>K6)E8MKW58["TMESS$:F/
M\_Z:;D$Q`UQ\(%>KAKA1+BJO70_>;?=6^L?^(WJ'_INO_P#/5BIJYUC_`,1O
M4/\`TW7_`/GJQ:?_`!=_GLW]P?FT>=^6/F7_TO1?J_\`\@]-_P#"E'_GMBY>
M_)LR<NS))(<]WM(,0T>UC=-OT6+J/J__`,@]-_\`"E'_`)[8N:S,1^'G/H<-
M-VZL^+"?;M_ZE5>;OACVO7_N4A?>Z=;'S_7/_DU#$R7X^95D@DN#@'DZES3[
M7M/]E2<[:TA\ZC@SK^/N0J6[K0XUN?7619:VH%Q#`071"K1$C.(CK(D<(\4D
MT-7H>J]!&38<C%<*[G?SC'?1<?WM/H/6-5TK-MRGXC6M%U0!L!<(`=]$R-WT
MEN6?6;I#,$YHNWU;S4UK`2]U@`?Z3*S#M^URP<7ZR8U'5LGJ-F/EBK):UCFE
MS'!H;]%_I-AW_@EFSWJ]/!AXI>X3"=?+MZ^*/S?N^CB7XL&?-$3PXSDA?S#;
M_`_?=W$Z:SI&+?EN/K9#:W.+HAH`&_TV#^LN:ESWR]TO>9>]W&X_2>XKI,[K
MG27X+0;A8W.J?Z#:P2YX_FW;1'MV.=[]ZYP>M186NFNU@AP(@B1^ZY0<UC,(
MXR`1CUX3T)8P1Q2B?FC\T?TH_P!X+NK+6[BYA'D]I/\`FRKO0LAU'4ZV@PR^
M:WCQT+JS_9<J9R+R(W_@W_R*O?5_$??GMNC]%C27'MN(VL9_6UWJ''_.1X;N
M_P`$EW.K_P!$_MM_BL'(MMK8TU5^JXN#2WB`?SG'W>UJWNK_`-%_MM_BL#+.
M;Z;?L88;-PW%Y@;5D_'`#SL`:_FX_,>&/S9/TF_R7R5I\W5%]LR/:#B.DF#N
MG3S?[/S6_P"O\YZ<6YM[@",,P6[I,]QZG^C_`#W>W_6M*L=8+R;#5#:[`V."
M\_S3G_U?Y*C'7B]COT(;ODMG7;^[NA9XC#;]6/\`JLFYPC^I_CR7;FY1;+L)
MP)U\P"Z-OT/I[?<BV9%XRV4,H)J+F[[B"6P?I'^P@C]O;(F@NC3L"81<?]J"
MT#*]/88G9VT.[_I_00E&`L_J]`=!D,E2$=3Z.N@D41SLMME@&$ZQ@(V.;I(C
MWMX=[VN;L2/4,P.AO3["7:S,#3][V;E,_M<@_P`V-.1SK_T?ZG_@B0'62V'.
MK:01$020(F3"/ZNM1C[?SDD^GMC^LI-FFQUE;'O8:W.U+#R#/R5_K'_B-ZA_
MZ;K_`/SU8J%'K>DWUX]7\[;QRK_6/_$;U#_TW7_^>K%I_P#%\5S&<:?+TU'S
M-#G=H_WCL__3]%^K_P#R#TW_`,*4?^>V(^;A8F75LRFAS6R0Z8+?Y37_`)J!
M]7_^0>F_^%*/_/;%A=7ZA;G93J0?U6IVT,!`#MIAUCI^E_(4>;((1U%WI20&
MS^S.@^IM_:!C]W>S_J]JV\3#Q<2K9C-#6G4N&I=_*<_\]<CZ6/,0^/":^/\`
M.1>G]0S<4FC&<TMN(8QEL[&N)VM?I]#^7^8J^+)`3`,8PXC7%>WFH[%#UVFA
MOUA;C[!3CTTM=6RL!HFPO-ML?1W6/:UCW_\`!HMF'CBJ9=M',%A,!7,OZJYE
M^*Q[\WUNHTN<:[K!#36Z#]ELC<_8Q_NJL_P:RJ^D==OO?A-;0VZJ/5)N:[8'
M?0<ZNN;O=^;^C4\XR$Y?Y07\PNJ=?E>8PSY?"/=C@.,<,\4R(^/I_>XF]]3*
MJG9&:US&O&-8Q^/80"YCK0]MP8_Z3=[6,WKH.H=/P,EGJ9<,+!`OW!I`_KGV
M[?ZZRJ^AYW2J:K<#,'Z$/MRF6-AM[S`<]VT[F>G4W957N_<_XQ9F;FWY]OJW
MGVC^;K'T6C^2/WOY:&60QXH"1$S+]']RN_\`C.=S.6.7F<LX`B)(J7^<]/#Q
M_P"%PNG1TKH3[=@SC9KHS>QL^4M:USO[*WJ,>G'J;30P5UMX:%PQVNT,'R6Y
M]7NI6BX8-KB]C@323J6EHEU?]3:H<&6/%P\(CQ=1_:PD.GU?^B_VV_Q6,MGJ
M_P#1?[;?XK&6!_Q@_P!UQ_V4?^GD;_)_S9_O-:W&OLO+VY3JF[1MK;V/&[GW
M(;L<BAK!F>F6$[G-=R7NW^[>Y_YOL]RGF481)LR7FO=I,^`_JN_,_P!?458U
M=%]_Z7:``2Z8;'(<';=FWV_U%1QDF,3ZM*^7$)#3Q_2;T;H;Z?NPO\4[<2]K
MX^UZD[RW63PS]_=M_J_G_P#!^Q0'3[B'5?;'.@!@:"=(#9W>_=[VJ-N+TFJT
M-N<YCF0X-<28U]3]W][<INMZ8;G9!MVVV`EW(`!;M+G-C<WV?Z_S:=<M#'B.
MF_M#?]%-RW%G30\'V,K,;?4RNS*UK>7%X<03N(VL):[_`#43&Q[:K[76Y!O<
M\`!I_-`/[NYWTG;U3KQ^DMK+GW[MON?8/:.?8[9L<UN[\S_2_P#"*[B8>/C;
MW4%Q%L$N<[=H/H[?O3<IJ$A<M>^/@&O#*7J1+2)%GZPX>O[S8[JWUC_Q&]0_
M]-U__GJQ5.ZM]8_\1O4/_3=?_P">K%I_\7/Y[-_<'YN?SORQ\R__U/1?J_\`
M\@]-_P#"E'_GMBY:MCJ[[*G:/87-=SR"1V74_5__`)!Z;_X4H_\`/;%7ZKT1
MV38<K$<UF0?IM=]%\<'AVRQ0<QC,P"-3&]/-(+ARZ"0'$\P`9_ZI##'W9%3&
MAVZQ[6M#A&N[\W^2U63T;JY>?U<SXA[`W\'+6Z9T88&[,RG!]S&D@-U:P1[]
MN[Z5CF_G*M'%.4J,3$=2=$VV\_JF+@`"TEUCM6U,U<1^]_(;_66#B]4Q\?J>
M3U#[+!R@T$-V[F[?I>Z&[O4^D]4C>[(R/M%QEUKMSY!(C]W:/=L:WV*;ACQ!
MV,<1SMM^]LE//-Y/5P'AB=/[POBU08`U?34/3/R:>I=,R/LCMSG5O9L/T@XM
M^@YJY)A88+@2TCAL`_BKG1\E^-U"ES=&VN%5@\0XPW_,>M+J?U>L=8Z_!CWG
M<^AQCW'GTG?ROW'(2XLT1,#U1],@$[.1;?7:T-=ZA`U'T.?DU%Z-6ZSJF.&\
MM)>X^0:9_P"JVJ3.A]5>[;Z&S^4YS8_Z)>Y;_2>DLZ>PN<[U,BP`/?$``?X.
MO^3_`-6ABQ3E,$Q($3U42SZK6Y^([8)+"'$#4P/I+$!!$C4=B%T\!!=@X;G%
MSJ*RX\DM"A^)?"?O>2.2.3@D(\!!'$*'_HS-@YCVP8D6+MYRRNNP;;&AXUT<
M)Y4/LN*23Z+)//M72_L_!_[CU_YH2_9^#_W'K_S0J0_XO91H.8`_P9?]\S??
MOZI^UYQU%+R2^MKB1!)$R/!0^Q89YH89$?1[+IOV?@_]QZ_\T)?L_!_[CU_Y
MH2_Y/Y1_X)'^++_OU??OZI^UYHXN*1'I-B(C;V\$4``0-`.RZ#]GX/\`W'K_
M`,T)?L_!_P"X]?\`FA`_\7LAWY@'SC+_`+Y7WX']$_:\_,?P\SX*]URMU?U0
MZDQ^CF]/O!'@?1LT6I7AXM;M]=+&N[$-`*H_6<?]C/5__".3_P">K%H?#?A?
MW,SD9^Y*8$=!PQ$6#/G]VA5`/__5]%^K_P#R#TW_`,*4?^>V+07/=#Z]@U]%
MZ?6ZO,)9BTM);@Y;FF*V?1>S%<Q[?Y35>_YQ=/\`]%G?^P&;_P"\B2G2@)GM
M#V.8[AP(/P*SO^<73_\`19W_`+`9O_O(F_YQ=/\`]%G?^P&;_P"\B2GF;*'X
MU[L>W1])VGX?FO\`ZKVJ3W5'0C=X.;R/+W-6IU/K'U;R2UF8,NJT#V/^QY;'
M@>6[%]S5F-R/JWN]V9F%G@,+)!_SOLI5&7+3!J%&*ZT_1\9^3U&H-'MI(ML/
M8!OT/\]ZZ]873^N]`JI+,&O+<P'WEF%F.)=_PCQBGW*W_P`XNG_Z+._]@,W_
M`-Y%9PXO;C74ZE!=*$ZS/^<73_\`19W_`+`9O_O(E_SBZ?\`Z+._]@,W_P!Y
M%*ATTEF?\XNG_P"BSO\`V`S?_>1+_G%T_P#T6=_[`9O_`+R)*=-)9G_.+I_^
MBSO_`&`S?_>1+_G%T_\`T6=_[`9O_O(DITTEF?\`.+I_^BSO_8#-_P#>1+_G
M%T__`$6=_P"P&;_[R)*=-)9G_.+I_P#HL[_V`S?_`'D2_P"<73_]%G?^P&;_
M`.\B2G369]:/_$SU?_PCD_\`GJQ+_G%T_P#T6=_[`9O_`+R+.^L?7<&WZO=4
MJ;7F!UF'D-!?A9;&@FIX]]EF,RNMO\M[MB2G_]G_[1\(4&AO=&]S:&]P(#,N
M,``X0DE-!"4``````!``````````````````````.$))30/M```````0`2P`
M```!``$!+`````$``3A"24T$)@``````#@`````````````_@```.$))300-
M```````$````'CA"24T$&0``````!````!XX0DE-`_,```````D`````````
M``$`.$))300*```````!```X0DE-)Q````````H``0`````````".$))30/U
M``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(`
M```!`%H````&```````!`#4````!`"T````&```````!.$))30/X``````!P
M``#_____________________________`^@`````____________________
M_________P/H`````/____________________________\#Z`````#_____
M________________________`^@``#A"24T$"```````$`````$```)````"
M0``````X0DE-!!X```````0`````.$))300:``````-/````!@``````````
M````\````5D````-`#D`,0`R`#D`,0`Y`%\`4`!A`&<`90!?`#,````!````
M``````````````````````$``````````````5D```#P````````````````
M``````$`````````````````````````$`````$```````!N=6QL`````@``
M``9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````
M``````!,969T;&]N9P``````````0G1O;6QO;F<```#P`````%)G:'1L;VYG
M```!60````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2
M````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I
M9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4
M>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P``
M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`
M`````````$)T;VUL;VYG````\`````!29VAT;&]N9P```5D````#=7)L5$58
M5`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`````
M``9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(
M8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E
M2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI
M8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````1
M15-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````
M``````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``
M```````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``
M```````X0DE-!!0```````0````!.$))300,`````!E+`````0```*````!O
M```!X```T"```!DO`!@``?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E
M7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!O`*`#`2(``A$!`Q$!_]T`!``*
M_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``
M```````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H`#`,!``(1`Q$`/P#LNG='Z4/JUB9+.E8N5DC!KL;6:JPZQXJ:
MYK-[F?X5_MW+G:>H])PNFNS;\7"ZJ7`FY@PV8PQKQBY&;^SS?Z5E=SGY&,S#
M9C_TW$LN_6O7MMIK79=%M%/U;P+2"YM>%4\AH+C#:FN]K&![WN_DL:N>POK_
M`)>4<)GV!ILRK'-+&V$.<QMV-B^IBUNK][O1S?MC_4?7LJQ[_P#K24A.=B[K
M7,^K>`^JMF=:UL#U7,Z>ZNBQK*OL?\]E77L]!F_^:5:[JV,<4.Q_J]TY]SZ9
M:]K67,=99^TFXKZ111^FQWNZ3ZC_`-*RS]:]/Z;/??POK[GYM-5F/TUMYMK?
M?%-CW@MKHKS7XE7Z#]-U!OJ_9_3_`)KU/3_2?3J81OUVS+/L]0QJG_:3<QV7
M2]YI:*FL=5DTNMQQZE63=9]@H];T-_4:K**_624BORNCXU?0`>CX.19U@4F]
MU=+0QHM]"IUN.]U&VQC+LIK_`$W_`*;T%4P^L]+O;T\V=`P6?:\EV/?M8Q^R
M/1V?9]E/ZZ[]9_2_9O4]'TOUAE/Z7[->POKIU1_V5MF"UU=AJ9;:7O%AE_3L
M:^WT1CM9N]3K-=C&;_\`M-?_`&!#Z]]3>QV37A,=14,L%@+]UII9A9&*:MS&
M^B_T<VY^538SU?3Q,K\^GT4E(L#JW2\RNIS?J[AG[1F'!I<UC=I>6XV52YX=
MC>I6S[%?F77;V?HGX'I?SEWZ(N%G]'R>@YW5+.B8--V':*A4*VV5$O-;:OUE
ME&QWNN_3;/YG_M3]E]_IV>J?6)U'1^G_`%@NZ=5;E-&066.L#JJFLJNNL?1E
M,99_RC7B,IQ7;/\`M3_UJX+_`*W]6K=91]G#WV693:+"UP>6MNRJ:?LM36>E
MDLZ=5C57]0?9;5^AOJ_?9ZJ4T;>M8(P3G5_5O`%8^S-BP,;%F1C-ZD6V/=BM
MJIJ;N^P56[_?EOK_`*BN=9MP.G=2=CT=$P[MV-5:RNVJM@:XU]4R[M[ZL>][
MG;.EUT[/W[?^W'P/KUG64]+;=BLLMS+Z\>ZZLO#'-<S$]7*H+Z6-_5LG.]'*
MQ?\`!OQK_P#A/1N_\YNJ4]+Z-:W#^VY.=TY^=DP7,=NIIHOLIHIKJMWWY-F1
MLIK_`$:2G*?U;I.S)L;T3IU3:[*JVB]@::6V3&7U/;BO9C8EL?JEE5EWJ^I3
MO]+])92S.JX#[VM/U9Q::R:Q8VVMHN9/[+]=II^S;?49^W*]C/4_[2W>IL_,
ML6_77JM@Z>*L:MAR+&.<:W&[[17ZU]%U73=K?2<[T\>M]SK[JOLWVNC^N^QB
M?77+O&#ZF-2T9F3Z#K6V6EC:R,5_VEKOLOT*K<O]EW>MZ'^5?3H_T_V9*</]
MNX5M56;5T'"=0UMEEE5-+;0^*+[QB/R'8]/HY6+;0RW+V5V_JUU2);UC'H9=
M=9T#IMC0S&=0QK6!D7#,+[WYGI/H=1DV8+,?#>W_``V13ZOO6J_ZR6]&ZCU#
MI56-5]AP0?LM=;7@TL;C8M];[JJJW,^POR\A]/K^I^A?_P`!6^VH%7UZZBT5
MY-V++,I^$VO&VN!K%S#]N_6-NRRRJS])4RST_P!%ZG_";$IL=<R>B=*ZA@8;
M>AXMIRVN?:#2UKF`-<6;7"E]-GZ5GIVL99OK6-E=:QSC5M9T#`Q+[+*0+36R
MQFVS]FY`QZ&.QJW79CL;JMF^O]%Z?V2Z_P#XK7=]>.HM:-^!52'N86766V>D
MRMSLZJ,@LQG6MONMZ7Z6.RJJW?9F4?G_`-(V.A]=R>J9W4<:W%&.S"L]-AWA
MSS#[J=M]4-=2][*&9=7YEF/E5?\`&6)3A]9S^E=,S\O&;]7\2]F)2ZW;Z36V
MO#:79?VEK?L[Z_V?ZC/V>_(]3?\`;G^GZ*JOZEATVY=UG0,.RK$:*7T,J9/V
MC[1U'I]3Z;#1NMJS,K"P:-FS]7^U^M[_`$UZ`@Y&'C97I?::F7>A8VZH/`<&
MV,GT[6S^?7N]B2FG7]7^B>FWU.F88L@;PVFL@'\[:XUM]JH?6/H?1:OJ[U2V
MKI^+78S#R',>VFL.!%3RUS7!BZ!9OUH_\3/5_P#PCD_^>K$E/__0]%^K_P#R
M#TW_`,*4?^>V*=-O2<G)^UT6479+*MGK,<QSQ4]SG;-[?=Z3[<9_]NC_`(-0
M^K__`"#TW_PI1_Y[8@/^J?U=?NW83/=OW$.>T_I!LMU:\?3:DIT:68V-1713
MLJIJ:*ZZVPUK6L&UM;&_FMK:U*_)Q\>IUU]K:ZV?2<X@`:[/^J.U9W_-/ZO$
M/:<)I:]KFEI<\B'_`$]C2_;6YW[]:-_S>Z-%+?LK=N,Y[Z6RZ&NL?Z]A:W=_
MIF^I_(_,24WC;6-2\#7;R.?W4.O+Q+/3].]C_6;OJVN!W-(W;V?O,5#(^KWU
M>W69.1CL:7E[K+'/<!-KFV6_G_GV,8]4F=/^I>YS&MJE\!Q<]^L!K&_I'N_-
M;6W9[D#*(W('F5.QGXW2\REM74:Z;Z=X+6W!KFE_\V-'^W=[O3_\#1_4JCZ;
M8^(6?_S;Z"^BJD8C/1I]1U+6EP`]9S;KMNUW^$L8QR9GU7Z#7<+J\-M=C7FP
M.8YS8<XN<3[7#]]Z*G4A*$Z22EOFE'FJW4+WT8SG,T<2&M/A/YRP3[CN<2YQ
MY)))*S?B'Q:'*3CC.,Y)2''OP`19\/+G(";H#1Z>$H\RN7`8>(D<C3LD`PB6
MP1XB"J/_`"C'_B<_X_\`Z`R_<C^^/L>HA*%S&P>"1:T"3H!R2E_RCC_XG/\`
MX9_Z`K[D?WQ]CU"2Y?8/#_4);!$QHE_RCC_XG/\`X9_Z`C[D?WQ]CTZS/K1_
MXF>K_P#A')_\]6+,K<^MX?4XL<."%>Z]:;OJEU.TB"_I^02//TK%H?#_`(G#
MG#.(@<<H4:)XKB?%BS8#BJS8+__1]%^K_P#R#TW_`,*4?^>V+06?]7_^0>F_
M^%*/_/;$3/ZGCX0:'[K+7@EE+!+B!^=_):@2`+)H*;B8G2>RP/\`G1=N_H9V
M^&\[H/\`UO:M'%ZAC]2Q[&4DLMVEKZWZ.;(VS_53(Y82-`V4T\UU'/LZAD&U
MQ_0M)]%G8-[.C_2/_>5:1PGK#6@LM83M]I`.TAPT=V<C.R&/9L>+'-\-[1^2
MM9Y)D29'4KF[T#J%F/DMQ7']!<=K6GAC_P`W;_)?]#:NH7&8%9MZECLK!_G6
MN`)D@,.]VNGYK5T74>MXV"[TH-M\2:VP(GCU'_F*UR^2L9XCI$T"5I=))<^S
MZTNW?I,7V_R'R?\`I-:U;&'FX^92+<=VYO!!T+3^Z]OYJGAEA,U$VBD/5_Z+
M_;;_`!6*MGJ_]%_MM6,N7_XP?[KC_LH_]/(Z')_S9_O-/(QL(V3?;L<\ES6E
MP;!=HYS?SOI;4.G&Z=596]F1)8XO`+Q!CV.T_=;M3Y=V%]H<,K'+O2`;Z@DS
MNVG8&B/WT-EG2'/TJVN#QM\7:^KNU=]#<%3B)\`LY*(Z<)BWAQ</Z=5TV2NQ
M,0M%WJO=4YTC;#MQ).T>QN]_TD)V+TO;K>3NC:"Z8U:-NT@_NJ5>;TX4BH5/
M:R1[!R#]/=._V[?I[FJ5QP*[;&V8WMK@&QLP26AVW\W\S^5_@_\`BTAQ@T?<
M';Y/E4#(&B9^%=EK:^F9-S[#D03N#H<-LNVGAWL=]%&Q,3'K<+J;'6-VD`[@
M6D'O_6]GTU5&1TAM<MQG:<LCQCVEQLV_3?\`YZM8F5BVO=5CL+2V7/,1J8_S
M_IIN03$#7'P@5ZN&N%$N*J]=#]YM]U;ZQ_XC>H?^FZ__`,]6*FKG6/\`Q&]0
M_P#3=?\`^>K%I_\`%W^>S?W!^;1YWY8^9?_2]%^K_P#R#TW_`,*4?^>V+E[\
MFS)R[,DDASW>T@Q#1[6-TV_18NH^K_\`R#TW_P`*4?\`GMBYK,Q'X><^APTW
M;JSXL)]NW_J55YN^&/:]?^Y2%][IUL?/]<_^34,3)?CYE62"2X.`>3J7-/M>
MT_V5)SMK2'SJ.#.OX^Y"I;NM#C6Y]=9%EK:@7$,!!=$*M$2,XB.LB1PCQ230
MU>AZKT$9-AR,5PKN=_.,=]%Q_>T^@]8U72LVW*?B-:T75`&P%P@!WT3(W?26
MY9]9ND,P3FB[?5O-36L!+W6`!_I,K,.W[7+!Q?K)C4=6R>HV8^6*LEK6.:7,
M<&AOT7^DV'?^"6;/>KT\&'BE[A,)U\NWKXH_-^[Z.)?BP9\T1/#C.2%_,-O\
M#]]W<3IK.D8M^6X^MD-K<XNB&@`;_38/ZRYJ7/?+W2]YE[W<;C])[BNDSNN=
M)?@M!N%C<ZI_H-K!+GC^;=M$>W8YWOWKG!ZU%A:Z:[6"'`B")'[KE!S6,PCC
M(!&/7A/0EC!'%*)^:/S1_2C_`'@NZLM;N+F$>3VD_P";*N]"R'4=3K:##+YK
M>/'0NK/]ERIG(O(C?^#?_(J]]7\1]^>VZ/T6-)<>VXC:QG];7>H<?\Y'AN[_
M``27<ZO_`$3^VW^*P<BVVMC357ZKBX-+>(!_.<?=[6K>ZO\`T7^VW^*P,LYO
MIM^QAALW#<7F!M63\<`/.P!K^;C\QX8_-D_2;_)?)6GS=47VS(]H.(Z28.Z=
M/-_L_-;_`*_SGIQ;FWN`(PS!;NDSW'J?Z/\`/=[?]:TJQU@O)L-4-KL#8X+S
M_-.?_5_DJ,=>+V._0AN^2V==O[NZ%GB,-OU8_P"JR;G"/ZG^/)=N;E%LNPG`
MG7S`+HV_0^GM]R+9D7C+90R@FHN;ON();!^D?[""/V]LB:"Z-.P)A%Q_VH+0
M,KT]AB=G;0[O^G]!"48"S^KT!T&0R5(1U/HZZ"11'.RVV6`83K&`C8YNDB/>
MWAWO:YNQ(]0S`Z&]/L)=K,P-/WO9N4S^UR#_`#8TY'.O_1_J?^")`=9+8<ZM
MI!$1!)`B9,(_JZU&/M_.23Z>V/ZRDV:;'65L>]AK<[4L/(,_)7^L?^(WJ'_I
MNO\`_/5BH4>MZ3?7CU?SMO'*O]8_\1O4/_3=?_YZL6G_`,7Q7,9QI\O34?,T
M.=VC_>.S_]/T7ZO_`/(/3?\`PI1_Y[8CYN%B9=6S*:'-;)#I@M_E-?\`FH'U
M?_Y!Z;_X4H_\]L6%U?J%N=E.I!_5:G;0P$`.VF'6.GZ7\A1YL@A'47>E)`;/
M[,Z#ZFW]H&/W=[/^KVK;Q,/%Q*MF,T-:=2X:EW\IS_SUR/I8\Q#X\)KX_P`Y
M%Z?U#-Q2:,9S2VXAC&6SL:XG:U^GT/Y?YBKXLD!,`QC#B-<5[>:CL4/7::&_
M6%N/L%./32UU;*P&B;"\VVQ]'=8]K6/?_P`&BV8>.*IEVT<P6$P%<R_JKF7X
MK'OS?6ZC2YQKNL$--;H/V6R-S]C'^ZJS_!K*KZ1UV^]^$UM#;JH]4FYKM@=]
M!SJZYN]WYOZ-3SC(3E_E!?S"ZIU^5YC#/E\(]V.`XQPSQ3(CX^G][B;WU,JJ
M=D9K7,:\8UC'X]A`+F.M#VW!C_I-WM8S>N@ZAT_`R6>IEPPL$"_<&D#^N?;M
M_KK*KZ'G=*IJMP,P?H0^W*98V&WO,!SW;3N9Z=3=E5>[]S_C%F9N;?GV^K>?
M:/YNL?1:/Y(_>_EH99#'B@)$3,OT?W*[_P",YW,Y8Y>9RS@"(DBI?YST\/'_
M`(7"Z='2NA/MV#.-FNC-[&SY2UK7._LK>HQZ<>IM-#!76WAH7#':[0P?);GU
M>ZE:+A@VN+V.!-).I:6B75_U-JAP98\7#PB/%U']K"0Z?5_Z+_;;_%8RV>K_
M`-%_MM_BL98'_&#_`'7'_91_Z>1O\G_-G^\UK<:^R\O;E.J;M&VMO8\;N?<A
MNQR*&L&9Z983N<UW)>[?[M[G_F^SW*>91A$FS)>:]VDSX#^J[\S_`%]15C5T
M7W_I=H`!+IAL<AP=MV;?;_45'&28Q/JTKY<0D-/'])O1NAOI^["_Q3MQ+VOC
M[7J3O+=9/#/W]VW^K^?_`,'[%`=/N(=5]L<Z`&!H)T@-G=[]WO:HVXO2:K0V
MYSF.9#@UQ)C7U/W?WMRFZWIAN=D&W;;8"7<@`%NTN<V-S?9_K_-IURT,>(Z;
M^T-_T4W+<6=-#P?8RLQM]3*[,K6MY<7AQ!.XC:PEKO\`-1,;'MJOM=;D&]SP
M`&G\T`_N[G?2=O5.O'Z2VLN??NV^Y]@]HY]CMFQS6[OS/]+_`,(KN)AX^-O=
M07$6P2YSMV@^CM^]-RFH2%RU[X^`:\,I>I$M(D6?K#AZ_O-CNK?6/_$;U#_T
MW7_^>K%4[JWUC_Q&]0_]-U__`)ZL6G_Q<_GLW]P?FY_._+'S+__4]%^K_P#R
M#TW_`,*4?^>V+EJV.KOLJ=H]A<UW/()'9=3]7_\`D'IO_A2C_P`]L5?JO1'9
M-ARL1S69!^FUWT7QP>';+%!S&,S`(U,;T\T@N'+H)`<3S`!G_JD,,?=D5,:'
M;K'M:T.$:[OS?Y+59/1NKEY_5S/B'L#?P<M;IG1A@;LS*<'W,:2`W5K!'OV[
MOI6.;^<JT<4Y2HQ,1U)T3;;S^J8N``+276.U;4S5Q'[W\AO]98.+U3'Q^IY/
M4/LL'*#00W;N;M^E[H;N]3Z3U2-[LC(^T7&76NW/D$B/W=H]VQK?8IN&/$'8
MQQ'.VW[VR4\\WD]7`>&)T_O"^+5!@#5]-0],_)IZETS(^R.W.=6]FP_2#BWZ
M#FKDF%A@N!+2.&P#^*N='R7XW4*7-T;:X56#Q#C#?\QZTNI_5ZQUCK\&/>=S
MZ'&/<>?2=_*_<<A+BS1$P/5'TR`3LY%M]=K0UWJ$#4?0Y^347HU;K.J8X;RT
ME[CY!IG_`*K:I,Z'U5[MOH;/Y3G-C_HE[EO])Z2SI["YSO4R+``]\0`!_@Z_
MY/\`U:&+%.4P3$@1/51+/JM;GXCM@DL(<0-3`^DL0$$2-1V(73P$%V#AN<7.
MHK+CR2T*'XE\)^]Y(Y(Y."0CP$$<0H?^C,V#F/;!B18NWG+*Z[!ML:'C71PG
ME0^RXI)/HLD\^U=+^S\'_N/7_FA+]GX/_<>O_-"I#_B]E&@Y@#_!E_WS-]^_
MJG[7G'44O)+ZVN)$$D3(\%#[%AGFAAD1]'LNF_9^#_W'K_S0E^S\'_N/7_FA
M+_D_E'_@D?XLO^_5]^_JG[7FCBXI$>DV(B-O;P10`!`T`[+H/V?@_P#<>O\`
MS0E^S\'_`+CU_P":$#_Q>R'?F`?.,O\`OE??@?T3]KS\Q_#S/@KW7*W5_5#J
M3'Z.;T^\$>!]&S1:E>'BUNWUTL:[L0T`JC]9Q_V,]7_\(Y/_`)ZL6A\-^%_<
MS.1G[DI@1T'#$18,^?W:%4`__]7T7ZO_`/(/3?\`PI1_Y[8M!<]T/KV#7T7I
M];J\PEF+2TEN#EN:8K9]%[,5S'M_E-5[_G%T_P#T6=_[`9O_`+R)*=*`F>T/
M8YCN'`@_`K._YQ=/_P!%G?\`L!F_^\B;_G%T_P#T6=_[`9O_`+R)*>9LH?C7
MNQ[='TG:?A^:_P#JO:I/=4="-W@YO(\O<U:G4^L?5O)+69@RZK0/8_['EL>!
MY;L7W-68W(^K>[W9F86>`PLD'_.^RE49<M,&H48KK3]'QGY/4:@T>VDBVP]@
M&_0_SWKKUA=/Z[T"JDLP:\MS`?>6868XEW_"/&*?<K?_`#BZ?_HL[_V`S?\`
MWD5G#B]N-=3J4%TH3K,_YQ=/_P!%G?\`L!F_^\B7_.+I_P#HL[_V`S?_`'D4
MJ'3269_SBZ?_`*+._P#8#-_]Y$O^<73_`/19W_L!F_\`O(DITTEF?\XNG_Z+
M._\`8#-_]Y$O^<73_P#19W_L!F_^\B2G3269_P`XNG_Z+._]@,W_`-Y$O^<7
M3_\`19W_`+`9O_O(DITTEF?\XNG_`.BSO_8#-_\`>1+_`)Q=/_T6=_[`9O\`
M[R)*=-9GUH_\3/5__".3_P">K$O^<73_`/19W_L!F_\`O(L[ZQ]=P;?J]U2I
MM>8'68>0T%^%EL:":GCWV68S*ZV_RWNV)*?_V0`X0DE-!"$``````%,````!
M`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2`$$`9`!O
M`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-!`8`````
M``<`"`````$!`/_A%_QH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_
M>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z
M>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^"CQR
M9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC
M;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U
M:60Z8C%B-&9E.#@M93AB,RTQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@('AM
M;&YS.F5X:68])VAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*("`\
M97AI9CI#;VQO<E-P86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*("`\97AI9CI0
M:7AE;%A$:6UE;G-I;VX^,S0U/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\
M97AI9CI0:7AE;%E$:6UE;G-I;VX^,C0P/"]E>&EF.E!I>&5L641I;65N<VEO
M;CX*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F(Q8C1F93@X+64X8C,M,3%E-"TY-V)F+3DV.3(W8S8W
M-60V9"<*("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\G/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70])W5U:60Z8C%B-&9E.#@M93AB,RTQ,64T+3DW8F8M.38Y,C=C
M-C<U9#9D)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y/CPO<&AO
M=&]S:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IB,6(T9F4X."UE.&(S+3$Q930M
M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I
M9F8Z3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I;VX^,S`P+S$\+W1I
M9F8Z6%)E<V]L=71I;VX^"B`@/'1I9F8Z65)E<V]L=71I;VX^,S`P+S$\+W1I
M9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF
M9CI297-O;'5T:6]N56YI=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F(Q8C1F93@X+64X8C,M,3%E
M-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIX87`])VAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#$U+3`T
M+3(R5#$Q.C(U.C4Y*S`U.C,P/"]X87`Z0W)E871E1&%T93X*("`\>&%P.DUO
M9&EF>41A=&4^,C`Q-2TP-"TR,E0Q,3HR-3HU.2LP-3HS,#PO>&%P.DUO9&EF
M>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^,C`Q-2TP-"TR,E0Q,3HR-3HU
M.2LP-3HS,#PO>&%P.DUE=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4;V]L
M/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD;W=S/"]X87`Z0W)E871O<E1O;VP^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#IB,6(T9F4X."UE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D
M-F0G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O
M<VAO<#IB,6(T9F4X-RUE.&(S+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0\+WAA
M<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IB,6(T9F4X."UE.&(S+3$Q930M
M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\
M+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)
M3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P
M35-&5`````!)14,@<U)'0@``````````````````]M8``0````#3+4A0("``
M````````````````````````````````````````````````````````````
M`!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B:W!T```"
M!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD
M```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#U````"1L
M=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#```$/```
M"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H
M8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2
M<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N
M,0``````````````````````````````````````````````````````````
M````````6%E:(````````/-1``$````!%LQ865H@````````````````````
M`%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``&-I865H@
M````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE
M8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M``````````````````````````````````````````````````!D97-C````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92`M('-21T(`````````````````````````````9&5S8P``
M```````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$``````````````````````````````````'9I97<`
M`````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0
M````5Q_G;65A<P`````````!`````````````````````````H\````"<VEG
M(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W
M`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`
MJ0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?
M`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!
MP0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$
M`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#
M?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:
M!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%
M]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T
M!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24)
M.@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB
M"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-
M6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S
M#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D42
M9!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T
M%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`8
M91B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR
M&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?
M:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X
M(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG
M>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1
M+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PP
MI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'
M-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z
M[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D
M0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&
M9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR
M3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3
M$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX
M6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@
M_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_
M:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P
M*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1
M>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`
MJ($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDS
MB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2
M>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INO
MG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BE
MJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+
ML`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z
M.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.
MQ4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0
M.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`
MW`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_G
MJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G
M]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____
M[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!
M`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P/_P``1"`#P`5D#`1$``A$!`Q$!_]T`!``L_\0!H@``
M``8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$````````````&
M!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!
M,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='
M8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZ
MA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;G
MZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A
M%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#
MDT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:F
MML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ
M>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P"Z/^4I_*5_EE]R_P`LKX+=J]K?!?XS
M]@]D]@?&?J[=>]]\;KZLVUF-S;KW+FMNTU=EL[GLO5TDE7D\KD:N9I)IY6:1
MV/)]^Z]U8$W\D_\`E&K)I/\`+H^(OJ>1"G^AW:VMI-.N%4<T85+QJ2PM[]U[
MJE?OG=?_``G$Z.[)WWUW1?RN=J=W4/4.<FP7='9O1/PW@["ZJZDR=&JODZ/>
M6]\=2BAAJ,/J/W<<8D$`4WX'OW7NK3.FOY6_\DCY!=8;([FZB^"/PSWGUSV'
M@J?=&T=Q8OI_;4M/E,74*'-X7@BJ8JM5;2T#QW@<%6Y'OW7NA*7^2S_*&BDT
MC^79\1"9!J0OU'MF4&,*6"J&IGB^XC7ZH&#R`:K>_=>ZP-_)G_D_%?NE_EZ?
M#AZ/5$K5"=5;/,11W$,(C981$9IZYO$MOJ?2Q!X]^Z]U*_X9?_D^_=4]%4?R
M]OAW35<R>6.@EZGV=%72*?HT4)C2>6,'\Z"#[]U[KA4_R8?Y/U)JEJ?Y>WPZ
M@IQ,:8O4=2;2HRDQ&D0#SP(LU1/(/VAZ2P/IO]??NO=%]WY_+Y_D/=;]X]2_
M&_>'P=^'N/[F[PQ6XLUUWL^/I7`R3Y3;FV8/N<WG:BHIZ3[/'8ZD-H%FE=9'
MG-D#<^_=>Z,3)_)8_E%P48J)_P"75\0*,*A>2>IZ?VF:.EB0*QDJYF@B"*R'
M@L1_C[]U[K'2_P`F#^3Y4X\9&G_EZ_#R7'E-0J1U/LZ2)4/UE:M"21!!R?U7
MM[]U[KCC_P"3#_)^KX'DH/Y>WPYR<<+%9),=U+LRM0?U<RKY-"?\&-^/?NO=
M<:#^3)_)[R9FCH/Y?'PWK9:*7P5:T74^S:WQ2@D&*5:199(9018B0"Q^OOW7
MNLR_R8/Y/LLCTT?\O+X?/5PR!9Z*/J3:$E73DD_\"(Z:GGDIQ?\`#@`>_=>Z
MY2?R5_Y1.B37_+M^(*%2K@'I_:<.B(R^.)GD$2ZA),-%P0&/'/OW7NN"?R8/
MY/AF^U'\O?X<M6.ID2C/4FTHJF2P.HQ024S2O&"+70%??NO=26_DG_RBY:<2
MO_+G^(\(53(]^H=KQ:``3=BM+"Q2P_M%01^/?NO=0*?^3'_*`K8X'I/Y>7P[
MKHY9Y(3-C^I=IU4(>']5ZFEI988F7^TCNO/%_?NO=<I?Y,/\GV)JE9_Y>GP\
M4TIAAJG3J;:B)`9T\J?<!*9OL!I^CR%0?ZCW[KW6>G_DM_R@\A!'48[^7A\/
M\A1EBHGI.H]HR+,4X/V]1##(LC(P(8$W]^Z]T7387\NC^3#V7W?W-T'@_P"5
M[TG@]R]'Q86?<FZMV?&/%8'8&YSG%8PTVP]TU5(:7<_VW`J'IV!IV_K[]U[H
MP2_R7_Y0GEJ:2#^7?\0):FB,(J8O]$VTI62:=0:>!@L<L\+RCZ:T`;W[KW7*
MF_DQ_P`GZIJ)Z6'^7I\.IJZ!%EFHH.IMESU<*,;'RTD2R2)I/!8@#W[KW7/_
M`(9A_E`+D/X;_P`-X_#^2N<&1:./J39;50A'UD-,ZB?0/RRH1[]U[K'6?R8O
MY0%$L/W?\NWX?TYEJHZ:,3]5;.IU\\I98$,S4_[CRD<):YO]/?NO=9(OY+_\
MH.5I8H_Y>7P\FFI6O74L74&U35TD3G2C2P"D:H0EN!=0#]1[]U[K@?Y+G\H1
M:_\`A_\`PWO\-ON9H(YJ>E;J7:2U<ADD-V$#)YVA,8XTH!<?7\>_=>Z*E\5O
MA3_(A^8-;WS1]3?R\OC*DGQP[7R?3/9/]Y>A]HXE:;>&'@^ZJVQQ66I6KQ+Q
M']NH<1E_]3Q[]U[H0^_/Y<_\B7XP=0[E[V[M^#/PZV;UAL^*CDSFYI.FL!DJ
M.#^+5R8_%QP?98V8U\M75R!0J`LM_H`/?NO="EB/Y/O\FW.;=P6Z:7^7U\/5
MV]NC$8W-8NOGZDVC1))196AI\E33&HJ$B$8EHZI'"+ZE#6/OW7NEC#_)+_E%
M/%&X_EU?$6174,LD?3FU&1T;E'5C1N65E(-[F_U]^Z]TTS_R8_Y/]+D$QL_\
MO/X=K6U%VI:$]2;)CK98Q]9%IYE2>2,?DJA]^Z]UQJOY,?\`)]H_75?R]OAQ
M3^H1EJCJC9U.BWN8](>`1R22$<"Z.5!XM[]U[K#6_P`F+^4)24:5M1_+R^'<
M5,B/,W_&(MIJU4(E,C1T3O'3(\K1\JC$W!'U%O?NO=%=^''P=_D8?.3K3<O;
M'2_\NKXQ_P!T=I=K]@=-98[EZ'VSALA_?/K;*C$9T4L?BG2HQYJF'C>_K4W^
MGOW7NC5R_P`F;^3Q3UE+C:C^7M\.XLE6IKIL=)U-LB*NJE'ZI*6EE1:B6,'\
MJI]^Z]UPJ?Y,'\G^C\DM5_+U^'=-3PR+!,]7U'M2A%/(]QI=JBG1)6F)`C_2
M"?H3[]U[HI/<7PN_D2='_(3XX?&#?/\`+N^-$7:GRHK<_2=1Q8?H3:^3P-2-
MM+&^4GW!DU^U.,2.*4$>F:Y_/OW7NC>2_P`EG^41"`W_``W5\1&U%(RQZ>VD
MB&HE8I!'&)XHXSYB#8*Q)_I[]U[IQI_Y)G\HJ2%''\N?XD^H&^KIK:P(;40X
M_<HB]@P('XM]./?NO=9O^&2?Y1?_`'KG^)'_`*)O:?\`]0^_=>Z]_P`,D_RB
M_P#O7/\`$C_T3>T__J'W[KW0`?+#^37_`"J-G_%CY,;LVO\`R_/BI@MR[9^/
MO<^?V]F\=U!M2GR.&S>(ZWW+7XK*XZI6AUTU?CJZGCFAE6SQRHK*00#[]U[K
MY`/^DCL3_GO=Z?\`H4YS_P"KO?NO=?_0VL?Y)/\`VZ+_`)<__BI'3?\`[R=#
M[]U[JR7,4\E3C\M#2:4K:JAR$%&TH_9BR!IIJ>FFD/U7R&91?ZE1[]U[K49_
ME5?.GXC?RZ_AG\D_C-\Z]]8#KGY(=4]Y_(?<7;'66]<'6)NKNW'[OW-D\SMK
M([>H*G&RC?%)NW!5D-#1,'D#\*?2/?NO=<.W/D?UO@OGW_(S^2%#MS</PS^)
MN^>M>_:EMG=B1+U9M3:M15[8S5=B:3>6#@K:?;&-CSOW4$U")R*J:7Q_M*>/
M?NO=5`;G[*SW<'PR[XJ=L]K]C4VW.TO^%'VRMGX+?>U-\;EQF;H>M]T;<IJ*
M"+;^8DGA?$4*#-,\21*L0TJ0OOW7NK'N\_Y970]/_.!^#?\`+FPN]^^]O_&&
ML^#7:N_=[;4QG>O9,>X^Q,R_<.Y,Y61[AW4N6&::DJ\]/'4>42JL?@2.'2@M
M[]U[HA/R/PG:6=^4O\P+&;_[]ZN^-G;'0/R)V-U[\3]\=W=Q=K[?[*ZRZ9PW
M]VZ/JY.F.N=J39&'LC#[SI(WAK*F3'5TD\DSR3E2;^_=>Z/-VSU!0_([^8'_
M`#L:#O3/;QSL?2W\N;XY]I[.PFW]Y[[PFRZ7MO'?'VKRT>]J;#4%71R+D(\Q
MBONJ<R(A224EU)X'NO=$J^/VR^M>W/E3_P`)_.Z/E-NK<E14]C_%.II]P;]W
MAV/D]NG<&]NM-PU\'6]/6Y]\E%3SUM.(Z19(HV27)R-'Y%;R-[]U[K:&_GN]
MU;0Z:^#^`HNP-A9KL7%]M]W]6]4TE!CNP]R]/[#QN5W/FC38C.=P;]VQ50YG
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M74.XZF/%?)*?=&9JJ+'[_P`;41QNE.D$/VZ<*H6WOW7NC@=3P=N[J^2?4W\C
M'-;G["GD^.'SU[&^2'8N[I\UG!G,U\0]LH>T.J169IIQ_%\%FMW;BIZ`T+OH
MDIH`A4A0/?NO=$G[QW'B/C_\S>X.^\SV'UQ\T\)2_-C$U$AP'R#[8Z,^<W6%
M;59^.B_T7;6ZMDR=#@MT]?8HLJ5`I:6:CJ44`<$^_=>ZVX?YP'R`VYTC_+)[
MG[7WILK?^\=JY?:FS,2VV=J;RS'7&?H_[ZY#&P0U6X=_[91,]M'$8<52ID:N
M'U%`5X\AM[KW6HS\;=W;HV;MO^>IU_LC=NR,=UY1?`SI3LO:VT>A^TM\;YZ^
MVKNS+5Y\N2V?NW<^6_C55GZ>.15SE=2,L0J5/]/?NO=##W[\>,K\8/Y4GP%[
MFZTW3V/D9OFMV+T+/\]^SNT>Y.QJC;^XMOU5`*C"8_=F;QV6KXMB==97+,U/
M7O0FFB:FC76??NO=7@_R&L!FME5GS,VUMOOCI;M#H8=LT-=USL'I/>V_^RMF
M=#9U<<E%N+:&WM];UI6ARFW9@(:J*.CK*N$RNY#_`%]^Z]U21_,5[-[#P>]O
M^%)K8+L'=6"GVIMKXMY3:TE%NK,T$N!JCN*EHJT;<2"H"8V>MBD)<4S)Z1=K
M^_=>Z,_%L;<OP_\`YE'1>&^*F:WVFY_D#_)F[?[>W?MW/;YW3NE>Q^[<!M*B
M?:FZ,A2U-;-XMU4=83)3SJ%`?@#FQ]U[J5_*;K_@G)0?`;LF@[O[;S'\U/LW
M:G8U;VYM'"=@[ISHW;VO'C\]+G]K_)+`U=574>U-JXC(0I]E')%"OD`"W/OW
M7NB`8?>V(E^,^!^1M)VYORI_G:Y/^91-LG(;/;?V\%[7FVLG<L^)EV/_`**8
MZN2BQ_5?]QXH_+*V,C@:BO,7!]^Z]TK?EWLB7LS)_P#"DGM7L'.;ZFW_`/%W
M+=>;TZ9I</V%O/'8#JSL.6DV;_$,YMG'8O.04`K8:B618G9"/&H)'/OW7NC%
M;$VJ?CO\V/B+)UMOCL-:[Y3_`,ECY*]K]]5N>WYG]S5O8G:&%V#DLAAMZ9V3
M*5E13C-T-8%-.U-H:$H`"#[]U[HC7PNW=LB#XQ_R>NU_CCW1O?=O\R/.?+/"
M;#[+V[)OW>FY]X9?J"7<-5%O+;F[MEY#(U$0ZXP.`J))X)VIC3"=R1*3P/=>
MZ<^Q-[]L[-^+/\RFGZVR%1MGKW=G\ZC;VTN_LY%E<WM[%/U?EKI-1[JW3MG[
M[)[>V-69&-(LI6TTB`4K$,1S[]U[K%\G>BJ#(_RZ/YD%'ANWNHNTNANM.U.E
M.Q=@]1_'3M#M;LG970.]ZO)X_%;[.-W?NDG&9;;N?V[)]V*=*JN@HZN\AC5O
M?NO=#I\QL%M>+O/X/]!8;??5<?P0?^7?E]V])97N?OS>^W>F,YV@V)I*C>N?
MA[&VCF(4SO:.V:J5CBJ*>JE"R(42+C0/=>ZVI?Y.,W9:_P`N_H.C[$[GPO?N
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M,[DQN3Q]+6;\VK24-.,;!4RK)/>RQN00?=>ZM_\`^$MIQ!_ET=B0X.LR.;V^
MOS;^43X7)Y-IY,GE<'7;JQ/\'S&0EJ`IJGR.."S2R&Y9V8GGW[KW5+'R4W7L
M3.8;^<+V7\H>T=W[._F==)=Z2T'P>VW#OG=.U]WXC`Z<='U'0],;"3(T>.W+
MMG<3J&K?MH:B.H9G$OTL?=>Z,I7]5Y?Y7_S./D%LKY85&^*B?"?R4^A.T]U=
M>X[>N[L)ML]QTFT\E62Y[-8G"5U$DF5Q^:5JE44*8ZA=/JT6]^Z]T5?X;;KW
M/WCF?^$V;]IY_)[KJ\KAOE9U_F-Q;GS$]9N*KVY]_6XNEHYLZX>KGR<./F*T
MU1(WD`B12;K[]U[HQG12=M]B_)CH'^23N7<N]WK/A]\X>U>_.U]S3Y?,/_>'
MXA[-4[TZ5V[D,VM0TE=49O);@%.\DDC1RO%I_%O?NO=;P%.GC@C3T@(NE%1=
M"I&"1'&%!8#QQV7Z_CW[KW6;W[KW7O?NO=%F^:G_`&1O\M/_`!6;OC_WUFZO
M?NO=?"@]^Z]U_]':Q_DD_P#;HO\`ES_^*D=-_P#O)T/OW7NK0S%&VK4BG6RN
MUQ^IDTE6/^*Z1_MO?NO=!!O/X]]$=B;JP^^M]=.]8[RWIMQT?";HW-LK;V:S
MN,>)]<?VN3KJ">KC\3BZ^HA3R+>_=>Z?-^=/]5=I8C'X'LKK?8V_,+BJN"NQ
MF)W9MC#Y_'8ZLI0HIZF@I,G1U,-)+"$`4H%L`/?NO=)(_&'XZ_8R8L=(=7IC
M)=_X[M63&Q;+P,6/;LG$Q1P8S?'V45$E,-S4,,2K%5A?*BJ`#Q[]U[I:U?57
M6M?OZ@[4K=B[7JNRL5A?[N8S?4^&HI=U8_`?<SUG\&H\T\1KZ;&&JJ9)#"CB
M,NY)%_?NO=,.ZNB>D-Z[VP'8>\NH^N=T[_VY&8MO;QS^S,!E]R8>,,DBK0YB
MNH)ZZG5'C4K9QH(N+>_=>ZGR=+=23;BWSNZ7KC9S[H[,P=)MGL+/G`T'\5WI
MMZAQTN(H\+N6M\/FR^,I<9,\"0S%T6)BH%C[]U[HM79%#\%NK=R_'#HSLG;O
M2>V]PYK<M=2?%WKO-[2P\DHW)MVF&3JX^N:1<;+3XNMQT0$ALT2J0".1[]U[
MHU>[>O=B=A[3K=D[_P!G[>WIM'*0)3Y/;>Z,109W"UT:2"54J\?D(:BDGT2\
M@E>#]/?NO=)3;_Q\Z(VL=S-MKI_K;`IO+#8O;F[:?$[-P-#2;BP6$IFH\3B,
MS14]#'25]!C:5S'#%(C*B&P'OW7NF;;O470'0NU=S1;(ZUZJZKV541U>6WLN
M'VYMK:6WZK%14DDV5K]P>.B@HJRCIJ4%Y/->,+>]KGW[KW35T;U5\8,-@&[$
MZ!ZZZ?QF%[,I8\Q4;OZWVOMBDH]YT-:2T>0_BV$HXXLM05>FX(=HGM^;>_=>
MZR8OXR_'C;>6QV<VSTKU=MC<>#W!D-S;>S^!V1@,9E,5NJMIIJ*JS]#74-'#
M6#*STLA2H.JTL=U-P2/?NO=$K^'/\NS<71WR:^0?S5[X[K;Y`_)7O3%X/8L>
MZJ+8^-V+M_9G56SZB3^[^SL!MVCD=),C]MXTJZUB&JC&&(]^Z]T8;=$7P<I_
ME7M+9.ZMM]&GY<[QVCD][[/QF9V?MZ;M#,[/VY5_;U6X,=728Z64T=%6L8_.
MT@D#<7X]^Z]T:O<.V-K;LPN8VWNS;V(W#@,[1G%YC#;@H:7,87+4-4//+0UM
M!61RTU52J5)TLI4$<?0>_=>Z*%TW@_@?W-2=I8?H_8W2&[*78]54=#]L8C9^
MR\%3_P`+EH"E94]?;FCIJ&!'IJ))Q,:=]:`M?W[KW1JAUAUK4]?4O5U7L/9U
M3UQ!B8<%3[#J<#C*O:<6'I4\5-C8L'4TTF/^S@061/'9?Q[]U[H#MI;S^*/3
M?9^#^'_7$G6G7?:5?M#)]C8/I/9.*QN`R<VS,74P4-?NJ'#8ZEI:/[6GGK%4
MR&[\\>_=>Z$/,?&_H+<[[]JMR=.=;YZ?M6''0=DSY+:N'R$F^XL0X;%IN>2>
ME?\`C*T+`-%YM6@_3W[KW2G/4G52;NVYOO\`T?;2_OMM;;4FS-L;J_@-!_'\
M#M.98EEVYB\IX/O*'"R"!`U.C+$=(N./?NO=,6`Z*Z:VGO+<._MH]3]>[9WS
MN0A<_NO`;.P.&W)EWU,5GR&<H:.&LJE=6N0SZF(N>??NO=`[TCDOAI\B=QY_
MY!=)XGI_L#>>U=QYOKG<O;&!VO@YMVXC<VT*V2CS.WJW.MCDRGWM!5JZL1*6
M'TN1[]U[H8ZWX\]%9:'L>/)=2;`KXNY#3R=K+6;7Q4W^D5J8Q-3/O+73'^/M
M"84TFI\FG2/Z>_=>Z1?9WQJZLWYMO<&,Q^QMF;>W9_H9WWTILG?B;;QQS&Q-
MJ[ZP=;@JS";?ECB6:BPS"J65J>-DCDT<CW[KW1`_Y?OQ<^)O\MK;?QD^$&Y-
M[=9[R^6V.ZQW5-L/<]=M+%8GM3>6P,5FY9\]5XFLCI'KOX)AZJJ6)KS@K[]U
M[JS[&=&],8G$[WPF.ZNZ_I,)V7DJG,=@XB':N'&+WGE:N/P560W)0O2M2Y>L
MGB&EY)D=C_7W[KW0$=HI\,/B7T?D<7V5MWIOIKX]9[.8K9F5Q57M?"8GK[+Y
MS>F33&8;#Y/&T5`E-45F8R3*JAT:[$<^_=>Z%6O^.GQPWEUWM78.8Z8ZFW)U
MI@:>DJ]G;4R&R-N9':^&@8)5TLV`QE7CY*7'(Y82`PJFJ]S?W[KW0T8C#8G`
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M[=Y8+L3=/4W76X]^;8##;^\<WL[`9/<N(UH(S]CF:R@FKX"J`!2'NOXM[]U[
MIP?J#JV3>>;[%?K_`&FV_-R[7@V3N#=YPE#_`'AS.T*59UI]M9+*>'[NKPL"
MU,@6G=C&-9XY]^Z]T@L9\;^B=OQ[0BVCU)UMMN;J^/,P]:U>+V;AJ<;`JLP&
MEJGVLL<*?PNHFJV$LXA""7Z'Z^_=>Z)5\,OY>.X>B/DG\D_F3W;W0OR!^1/R
M&HL'LBIW9!L7';`Q.S>J]HUD];A-CX/!T!=7TS&%YJHD--+'J-[\>Z]U:E3G
M5!$;ECH4$DZFN!9M1!-W!'/^/OW7NLWOW7NO>_=>Z+-\U/\`LC?Y:?\`BLW?
M'_OK-U>_=>Z^%![]U[K_TMK'^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZLKJZW[
M1*VLEFE2GB2I<-&AE$<5/3HU1.R,ME^V:-B%%]?XO?W[KW6C'BOYC7R7K_GO
M\1.X.COD%\K=]_&KY'_./>/0V<J^V-P;4QW1^\\#C\PN'R&UNL^GZ-FRVW:7
M:57&Z196I1)JH#4>3[]U[IZWU\IOFGNW8W\ZWO[&?S">XNOLG_+S^9&\J#H?
MJO#9S#+MB79V.W1C*6DP.]:*N`J]R[,KVE>@I\?,&2-HV,?+V]^Z]T.X^2GR
MY^8O\P#M/HW<GS2[B^'.Q9/Y;W3ORC.S.M,_18G,[3[(EV)29C,U&(J\A1EJ
M#"0U.7-9EJ1&,E;'&BGA>/=>Z+IM;YV_S&/FAM;^2MU/M[Y4]B_'O=WS!R/R
MOZE[7[.V=00TF8W7BNF,OE:?;O9<-)7Q""3<F7V_M/[J&IC70&K&8<-[]U[H
MTN[]Z_+3LKY#_P`P;HG+?S!?D/TEA?Y6'Q7ZTS_6.<Q6?P^#W3WKNJ;K_/;A
MS_;'?!J(9(=ZXO<&=Q,40A@>(1B71920/?NO=!9\Q_YJ7S2ZR_EN_P`N7^91
MM/N!ML=T]F;+W#U[V!\8ZQZ@[2[Y3*;<R\5+W7MO:M-'4U-!7;(K*1,S/*!I
M-+(L>JPY]U[H<-Z=F=M[,WS_`,)Q8JWY29?Y&57R![*[EW9VKVWE)*+(T^^S
ME^J\5N:&DP^2FI)JK![9PF4KI*2DIHF1U2/2Y^H]^Z]U6F_S`_F*9#X1;;^9
M&/\`Y@/?%)V&O\U,_#;;NUEFQ#]9Q]?[UWINK!QS[JP<^.EDW5D,`U(CTHG)
M$-,B1CD#W[KW5CFW/F=VQ\,.Z_YTW1'?/S3[SWKTO\;/CET+VWL7N?<5)C=_
M]M];[M[MQ9H<]!L?&54,6-KJ.+<F2BAQU-*$2CNC@C3[]U[HAO7_`'Y\QM\5
M7\TWX@=F]U?*["=;3?RYJSO[:L???8>Q]^]Y;6J)-J1;BJ:N+.[;IZG$X/!]
MM88-&^)A=I,?CYB+Z_I[KW3CL#N3Y7?''^6__)#^._2O<OR2SN#^=L$N8W5E
M.O<_M+`=D;7VYMO9%-E<;T#T7NO-1X^EV;"]2?+!+4SB22*Z\LUA[KW6QY_)
MN[!^8&X>G^Z-E_,2LW!G\QUAW=G-N=7;JWGNK9.]>P\KU5/1TE1BJ'LG*["S
M&5@;?6%JJB2EKEGTRZX[L/?NO=50?)KY`_+/N#Y,_P`X'<M!\Q>SOBW@?Y:O
M5^)J>@^N=EY?%8O9VX<QD-LUV0_OMV3A\C1>7=M)N.H004@DU10O*AC)9`#[
MKW14NF_DCVOF?EQ_*<^6&[*C*]I]VO\`R$.]NX<U79-VR&8WAOFAW%N/*TM9
MD2J^:NFKLC31!T47*\`6]^Z]T(G5?RU^8W6O4/\`*Z^>_P#LYW9O>F_/GQ\D
ML%U[V[\6-S9/'93J;%[=WM75%'F=N=?;3IT:NVCG>JZ8:Y*B,"6RD2V'U]U[
MHE.P,SW=TG\??YW?S`Z.^8O9'3N]_B[\^MQ[MVIT]L_*82@V9VAE:K(;;PK4
M78N&C(JMUTN;IJXT\%/%Z0U.]@2Q(]U[HW?\V+^8;\@<O2]E[N^.?>7RZVWW
M+\;/B!T+W7V-L?JC<&RNK^A^D\[V!3X7)R[A[&&9(SO;U9N:MJ9(EPT",M+3
MFUK>_=>Z-CT+V%N#M[^?7\`NT-X20U&ZNPOY-6=W5N6IAAB@CJ\SF<IM>JR5
M2L4%HHEJ:F1G"KZ5U6%O?NO=&G_GO=T_*S8W8_\`+#Z5^*WR$W+\>,O\G/DS
MO3J7>^Y-M4U-.]9MRIV)CYHI)H:Y'IY:C!1UDU32$6$=:8W_`+-C[KW59'R@
M[-_F&[1^96]?Y>W77R-^9?8\'Q`^'&U.SMM=H;$[`Z^V-OOM3M#=U/7Y*3L7
MY!;GWK48_&;DV!@ZF&&FFHJ:6."F37Y1?W[KW0W4?R1^=?R=^3O\LSXF]Y?(
M7=GQ'GW7\)-[_);O??O1VZ-J0Q]I=R;%R"X/&4M'NS&UF3V_DMD045JJMHZ6
MHECJ)5=@VGD>Z]U63\'_`)"]Y=+_``AV!T=U1W5E.L<?\MOYO_=/2'9_RFVU
M]C1;AV;LZ/+5V5R>;Q>1K#58K&;G['R-J>AJXT1HM5EY(O[KW5P75O9/R:P_
M9W\V[^7IF?F]VG7==?&+H[9O;'4/S1W=N2BE[*Z>W+N3"5F6K]C;PWLBP-G1
MBGH4F9)29Q#*8PH#(#[KW7?_``GL^;/R3_F$[K[\[U^1GR%GRF5ZPV]L'IO#
M?&_;\%=@]JU=#CL=(G^S'97%Y=8ZRHK^SI(1)%.JF.,LPOR`?=>Z:_YHNQ:[
ML_\`GT?RR]A8_O/=/QZGW9\1/D+BZO?^QLA187?+T4V[C-+MO9V=JT,>"S^9
M9"D-;8NBHQ`N3?W7NBO[%_F']Z5'P>WMT=VU\E?DQN?LRC_F-;E^(OQR[7Z0
MJMFP_(+Y%X+;-5/E'VG5=@;C,6W-L5N'H@M/D,U))Y944Z;D^_=>Z(5VC\F_
MD/W[_*'^8?7OR'WEOK?>=^-7\V'XN]:;?RG96X:'>.^\1MF;?V/S$>#W-O*@
M!HMQ5N$FD,+SQ:D5KJIL/?NO=&P_FY_/GOW9&_N_=W_$3Y#_`"VCR7PQI>@=
MO;[PVU]S;$V+\8^L]SY"@P];/LW<6VZ]QN;MG+;RH:L"4JFB%3]>/?NO=&Y[
M&[N^8/R;_F0=[_';&_+OO3HCJC&?RLNE/E!!@^ELOC<+F:#L_(;)K-P9"IP&
M6FH*B?:YS&5(^[12351H%N%/'NO=%XZ%^>?S1^8W6W\F_P"-N\_DKVAU2GRH
M@[WG[T^1G7^2Q6U^S=\3=*9&?#;:V?C=U".*CPN=S<02IKGB"5=48V)!!]^Z
M]T.OS:^4_P`G?C?\7?B-T%TE\W-]?+&H[U^<FZ?COOCY+==5^U<+W%MW:F%H
MJC*1=4T&^JEGV[C>R\=DHQCY<K7N))N02#[]U[JSC^3?O/YJ2XKY0=6?+.MW
MYF\%UKVW24G0FY.V]];`W_W.-AY'"1U60VYVUFNO\O7A=T8?-L-`J887^TD6
MRVY]^Z]U>#`&$,8<DOI]=VU'422PU6%P#P./I[]U[K+[]U[KWOW7NL300NP=
MHT+*;@D"X/\`7_7X]^Z]UT:>`ZKQJ=:A&^OJ53<`\_0'W[KW68`#@"P_H./?
MNO=>]^Z]U[W[KW19OFI_V1O\M/\`Q6;OC_WUFZO?NO=?"@]^Z]U__]/:Q_DD
M_P#;HO\`ES_^*D=-_P#O)T/OW7NK07IX9!(LD2.LH"R*PNKJ/PP/!'/^Q]^Z
M]U5/0?R8_P"7%C>PE[,PWQRV_MS>F+[;INY<1F,'FLUC_P"Z^_*2O7)15>VJ
M:"J2BPM!F:]ON*REIXUCDE/JO[]U[HB?Q;_D9]6CO?YP]N_-[J?K7M:M[K^<
MF^OD3T978[/YJIIH^O<VF)KL3@NPL%&^)H:[[7,T1J1CZF.KACG):_-_?NO=
M/_:G\F3:OR)_FA=Y?)_Y'[)Z_P!Y_%7>GQ^ZNZZV3MVDW/GMO;YP.\METT-!
M.RTF(.)&-P4]&I@T"K>.>)M+1VX]^Z]U:1%_+_\`B/2;N^+N],9U%A]MYCX;
MX_,XOXUT^!DK\3C>M*'<.,EPN:BHL;03&AJ!DL;,T<C3!F97)8DF_OW7NDY\
ME?Y9'PB^7^^L/V5WYT1M[>N^L51T^(R&XXZG)X#(;AV_1RF>DV[N_P#@U31I
MNS`0RW*TE5Y8A<@<<>_=>Z56X?@1\3-X=G];]M;BZCP>;W1T[UUD^K^L\7,D
MYV5LC9&=QSX3*XC;FS9E.`Q9J,7*T+RQQ?<%"1?W[KW0:[%_E7_"GK^G^.]-
MM3JZ>CH_BOOKL#LCH*DJ=TYRLH.N]S=F>4;L;"4574-IH*J.0K%2L/'3*`$`
MM[]U[J,O\J;X.)TU'T!_H@1>IJ7Y`XSY-46V8]QYJ]-W+CLI5YF'>-/7I4?Q
M#7%EJV63PZO"=9%K<>_=>Z7>Z_Y='Q%W[O3Y"[]WYT_B=X;A^577FT.LN]9,
MS4U-?BNP-H[&B\.U,=4XII!24D^!T(T,R!65E#?4>_=>Z#;I7^4[\$_C_N;*
M;JZIZ,QF#S&>ZHRW1VXEJ<OELW0;UZ\W#++/D\/NY<C454F<,=+*U+'43,Q2
M&T:V46]^Z]UEH_Y2'\O^#X_T_P`7&Z$Q-5T[CMXU'8>VMM5N7SU96;/W7(IA
M3+;*W"U8,CM(PTUXHTHY852(:0+>_=>Z-5\9?BOT-\1.M:?JKX\=?8?KS9HR
M%3F*F@QCU%94Y/,US:Z_-9G+ULM17YG+5K\S5,\CR2'DGW[KW5#7\T?^5!\E
M?E]\@NQMZ]>=._#/?>![*Z\H>N\7V-V/D=^['[)ZZ88ZNH9LWN7%[2ECPO<D
M>WQ5*^*@R89:20*RCCW[KW5E'Q5_EA]`?'7;'Q$RF7PZ;P[N^)_Q=@^+NT.R
M9ZO(&-]FY!6J-QT?\`D+4\]+D<K/++K=20&L??NO=*CJW^5/\!^D^\3\@^N/
MCELO;/:#563RN'S$4F2J<3M;-YQB^<S&S=I5%3-@]K97(,S&2KI(8Y26//OW
M7N@[K/Y*_P#+6RG8M3VID_C5@,UO/+=D3]J[FK\EE\U6T.XMZ/5KD:;(;JPK
M5J8W<%/0UR++31SPNL+BX]^Z]T('?O\`*E^`7R9[0RG<7=OQYVGNSL#/;*I^
MO,YE=61H8L_MRBI10X&'.XNAJ*>AR=1MND41T,\T;_;*!;Z>_=>Z7G7GP$^,
MG5W:_57=NSMC3X[M/ICI&K^/77F[*S<64RU7A^K*R:*8[9FAJ&892"&6!"LS
M>I=(%^/?NO="'W9\2NCOD/N_HSL+MS:/]YMS_'#?%7V/U)EQ7Y&B;:V]*['I
MC*_+BEB<)6"LI8PA1P1I`X]^Z]T&/RK_`)<'PV^;&X-N;M^1/2>"WSNS;&/;
M"T&Z*?(9C;&XI=NR5!JZO;.4R&%JZ*IS>V*R=BTE%4&2%KD$<^_=>ZA=W?RU
M?A1\AME]0[![(Z#V;D=L]%0TN/ZDI\`M?M:LV)MN.G^UK,!A,EB9Z2MIMO5T
M,:I448D\<P!U"Y)]^Z]TP;8_E9?`?!?'S=7Q?QOQ^V<>C-X[UJ.P\EL.J^\K
M,51;WFF$[;CVW]Y)]W@\I',H>.>E=722Y!O[]U[J'C_Y5'P4PGQVWG\7<)TQ
M387I[M#*4>7['Q%#N+<<6?[&R%%4I/$N^-X5%9/GMP4Q\2J8:F9E9%"VT\>_
M=>Z%[8?P?^,/67=]!\A>N>M*+8?9V/ZQPO3;9;;5?6X?&938>UZ=*3!X',;;
MH&AQN<AQD**(JB:-I01?5?GW[KW2*^4O\N'X=_,?L#:/:GR+ZHHNPMX]>[/S
MNQ=I9^HRV9Q4^U-MYRK^^R<V*FQ]13U%)F(:X>2&9&#JQX]^Z]TR9[^5C\#M
MV_&[:?Q0R_Q\VDG2VQMPTF]MK8*@ER..RV&W5'-YVWI3[KII8<PVZ<BQ+5=5
MYO-.'(<D>_=>Z2,/\HC^7[1=:=D]+XSH[&X'J[M'M'8/;^^=FX?.YFEP];V%
MUT\%1L[<E/$)':DK&J8!)4J&/E<EG_4??NO=<>[/Y0'\N_Y"[^WQV7VK\<-J
M[CWIO[;M-MS=U=%7Y7%+GDHZ>&CQV;RE'2U,-+_>?&4E*D<.3=&G"*`#;W[K
MW0Z[>^!_QFVUVOF^\<'L"6F[%W5T!MSXTY_<[9K)/5Y;J':F,.&PVVGI2Z1O
M446.)C%61Y&7DD\>_=>Z"W*?RH?@=F/CMLCXMY#HK$9+J+K7<=?O'8&*FRV8
MHL]LW<N6K'K,IF-N[MHZF#+XBKKI)6$PAF42+Z3Q[]U[I;5?\MGX05WQOIOB
M;4_'C9"=`X_,R[@H-DICY:;[3=TM0U;4;YHLQ2R+F%W;55C>1\CY14N_);W[
MKW0H?%SX??'7X=[%R'7WQUZXH-@;=SF7?<.XZA*G(9+,[FS+CQOEMQ9W+U-5
ME\SDFB71Y9Y"^@`?0#W[KW1IQ:PM]/Q_K>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[HLWS4_[(W^6G_BLW?'_`+ZS=7OW7NOA0>_=>Z__U-K'
M^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]UC,4;,'**6"LH:W-G(+#_8E1
M[]U[KB]-!(29(D<E&C)90?0_ZU%_H&_/OW7NO?;0:!&88VC!)",H=;DAB=+7
M%]0O[]U[KF(T!4A0-(TK_@"+6_VWOW7NNGBC=2CH&4FY!O:][W_V_OW7NNS&
MA*DJ+H25_P`"?J?]?W[KW41M!DD']K4/(@*L\?/HFTWNJO;_`&(]^Z]U(2",
M)I94)-RQ5=(8L;L1;Z!CS;W[KW73Q1LNAD#)<$*S674IN+`?3D>_=>Z[\,3)
M8QII:UP/IPVL`$6X#\_Z_OW7NN0BC`("``L7('^J/)/OW7NN8``````^@`L!
M_K`>_=>ZQF&(DDHI)%B3SQJU6_Y*]^Z]UV8HR&!068,&_J0WZA?ZV/OW7NO+
M#$BA510!>W'TO]>3SS[]U[KH0Q*4(108Q9"/JH/X'^'OW7NNUBC0$*@`.J__
M`"%RW)YY]^Z]UV(HP+!%'##Z#Z-^H#^@/OW7NNU15`"BP'T'/'^W]^Z]UX*H
M^@%_Z_GG_'Z^_=>ZX&")E*&-2K$L5MP2Q!)M_B1[]U[KEXX^#H7TC2OI'I7^
MB_T'OW7NO+&BJ$50%!N%/(!^M^;\^_=>ZZ6*-;611I8L.+D,W)()N1?W[KW7
MC#$>"BD:@UB+C4+V)'T)%_?NO==F.,E24!T?I_PO_0?3W[KW730Q,;M&A/(Y
M4?VA8W_K<>_=>ZZ,$)%C&I&G1R/[/TTD_4C_``]^Z]UWXH[%=`LW!'^L+?[#
MCCW[KW7?C2X.E;@6''T'^M]/?NO=>*(;W4'4`I_Q4?0?ZWOW7NNRB$$%000`
M1_@/H/\`86]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M19OFI_V1O\M/_%9N^/\`WUFZO?NO=?"@]^Z]U__5VL?Y)/\`VZ+_`)<__BI'
M3?\`[R=#[]U[JT?W[KW6N!\N/DA\XNKOFKW]MKK2N[*W#U3VIA=B_'3JS'XS
M&U-5@NG.W]];/P.5HNV*!DB:..BPF+DS62K9;E3-04\7ZI;>_=>Z3WQW_FD?
M*38^,^._4_:/4>[M^28CHG:&?[9[0W1@=U2[RWWE*C8NY]U9S?NVGAGI8,K#
MB)<(*?(8XTKN:@%140EX5?W7NE#M'^<E\A-PQ[2R&0Z0P=#MJ?Y`Q]4;FW7%
MM#?XEJ<#F]K=?[AVKD]M=?PYK(9RK=Y=\-3Y"N2OK::FDHY/V#8^/W7NEYLO
M^;#W[V_N/K39/4W3NV9=V[JK>F=O[RBW1C.P*'";!WAORO[G.]<+F*N>DAGJ
M3MS&];4)CB@;7#)D5$[IP/?NO=!]6?S@?EG%@N[MP)\9,/BH.N,YB\?2+GJ/
M=25&`HX=U;DVWN2BS&%_BM)4;OW7)%@XJG&TU-4XI)XJE6&L`-)[KW1UOE__
M`#`^Q_CYL3HW=NQ]DX"LINV>O]U]E9'<'9F'WW3[9H&VK@=NYBDZPQM/M:EJ
M,]C^PM_R9B6+%Q5Z&&"6+2PFL1[]U[H+/C/W+\E)<W_,A^1W:&U=R9J3:$&R
MLGU9T=B9-T1UE#B*7H_![X39V*H,A65>*AR]169'_<C44$1EEJ-=E#?M#W7N
M@:R7\WKY#X?K"?=-#TMLOM'<&/['Z_VFC]98;MA<)E,)O;8D^\,YD(J+/8\9
MB&IZ:8)'N=@LM.T(+1&*9DA]^Z]T$?R*_F+_`"4PG6'>6V]D0_W8K]Q1?)NM
MVQVSNN3LS-T=34;2FB@VGM_H8[=Q\\]-N"$5ZUM''./M8J5`@60ZBGNO=*/L
MS^:=\JJ3'=K];]-;0PU+D^KNO=H5M-V;OGK_`'Q514>7VCN38&%["CS4%)E:
MR#<1W!C<]45,-5%'0&.F228(YT/[]U[H8<#_`#$OD7L3.08*3J;(=H-W%WKO
M;K+K_.TU9O7(XU=ZX?.[;G:2GI:RG<[/ZGGV/DZS)8QG8ZQCGCU:G'OW7NC`
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MCMH=@U]+B-PX`9I,')@J:EW#63U^T2U!&U?G(/OE745%)#^H>Z]U>9T[N^OW
M]U?LC>63KL!DLAN/`4F3K*_:U+FZ';M5/-KURX>DW)%!GH*$E?0*I%E_J/?N
MO="5[]U[KWOW7NO>_=>Z][]U[J+ZQ(Q,ATWMIO\`3_6'NDBF72(V*TX])0LL
M4K2.Y,1.!Y#I";TWW@=AXZ?,[ERW\/QT9TK-J$A:1CZ8$IU4NSM]+CW&'N%[
MS<F>W-LS[W>(LR^1*?Y74]"7;-AO^8FCM=MA8RM3*@U_D#T5?*_-*BHJAH\=
MLFMR=&7(IZO^-4].\T5_1+)`]#(T18<VN;>\#=]_O.?;K:MYW+;8]N+I!,R!
MA&Q!IY@B>A_+J2[;V(YN:")C(E2/-\_GV=1/]G7E/Z>M:QU_##<=&+_XV-!<
M>RC_`).E>WO_`$:F_P"<3?\`6_I[_6(YL_WY%_O?_0G6)OFO57-NM:JU^+[G
MH@?]M_#O9%<_WK_)$,\L2<N.R*:`^!(:_/$].KCV(YIH*O'7_3_]"==?[.O5
M_P#/M:K_`-">B_\`K=[9_P"3LG)7_3,O_P`X)?\`K?UO_6(YI_CC_P![_P"A
M>O?[.O5_\^UJO_0GHO\`ZW>_?\G9.2O^F9?_`)P2_P#6_KW^L1S3_''_`+W_
M`-"]>_V=>K_Y]K5?^A/1?_6[W[_D[)R5_P!,R_\`S@E_ZW]>_P!8CFG^./\`
MWO\`Z%Z]_LZ]7_S[6J_]">B_^MWOW_)V3DK_`*9E_P#G!+_UOZ]_K$<T_P`<
M?^]_]"]>_P!G7J_^?:U7_H3T7_UN]^_Y.R<E?],R_P#S@E_ZW]>_UB.:?XX_
M][_Z%Z]_LZ]7_P`^UJO_`$)Z+_ZW>_?\G9.2O^F9?_G!+_UOZ]_K$<T_QQ_[
MW_T+U[_9UZO_`)]K5?\`H3T7_P!;O?O^3LG)7_3,O_S@E_ZW]>_UB.:?XX_]
M[_Z%Z]_LZ]7_`,^UJO\`T)Z+_P"MWOW_`"=DY*_Z9E_^<$O_`%OZ]_K$<T_Q
MQ_[W_P!"]>_V=>K_`.?:U7_H3T7_`-;O?O\`D[)R5_TS+_\`."7_`*W]>_UB
M.:?XX_\`>_\`H7KW^SKU?_/M:K_T)Z+_`.MWOW_)V3DK_IF7_P"<$O\`UOZ]
M_K$<T_QQ_P"]_P#0O7O]G7J_^?:U7_H3T7_UN]^_Y.R<E?\`3,O_`,X)?^M_
M7O\`6(YI_CC_`-[_`.A>LJ_->HTB_6E9?\VW)1$?[?[`>SRU_O3^0)[>*:39
MF5V&1X3BG[9Z]4/L1S74TDBI_I_^A.NC\V61XQ)UU6J'/JMN&C;QB]O5;'W]
MJ/\`DZ3[??\`1I:G_-)_^M_6O]8;FT\)(O\`>_\`H3H<>NN_]I=A21XY*M\1
MN&:)I1@IZ@2/H5OUQ5@CCC<6_%@?>37L_P#?-]N?=*#;WCFC@N)J]ATJ:UH*
MJTI(Z!N_>VO,7*LQFOXW>`^E60?GI`_GT/:%VB`69F8_V[C_`!O8V]Y<^+'>
M0Q7=K)^BRU%"*$?ET`KE];&*(:7KT7#YGW_V3/Y9:CJ/^RR]\W)YO_QBW=?M
MR-Q(BN.!Z]&CHBI(U7'$]?"D]WZOU__6VL?Y)/\`VZ+_`)<__BI'3?\`[R=#
M[]U[JT?W[KW4!\7C9)WJ9,?1O42/%*\S4T+2O+`K)#*SE-1EB1BJM^H*;`V]
M^Z]U'DV_@II*6:7"XJ2:BIY:2BF?'TK2TE)/I,])2R&+73TL^D:XT(1[<@^_
M=>ZCP[5VO3?:_;[<P,'V,PJ*(0XC'Q"CJ`-(GI0E.HIY@O&M+-;\^_=>ZSQ;
M>P$$CS083$03/-)4O-!CJ.&9JF7RF2H,L<*R?<.9WN]]1+GGD^_=>ZQ2[7VU
M.*\3[>P<XRLT%3E!-BJ&49*II55::HKQ)`WWD].J@(\FIE`%CQ[]U[J158/"
MUT*T]=BL=74\<T=1'!6T=/5P1SPR>6&:.*HCDCCEAE]2,`"I^EK>_=>ZF1T5
M'"T[PTM-"]3(LU2\4$<;U$J(L:2SLBJTLBQJ%!:Y"BWT]^Z]U`BV_@8(_%!A
M<3!'IK$"08^DA4)D0!D`HCB4+]\!^];_`#EO5?W[KW6-ML[;>G@I'P&%>EI9
M/-2TS8NB:GIIBGC,M/"8#'!(R>DLH!(X/OW7NN']U-L"6LF&W<&)<C&(LA(,
M50AJZ,1^(1UA$'^5((AIL^H:0!]`/?NO=38\+AX1"L.*QL(IYON*<14--&()
M]'C\T.B)?%+X_3J6QT\?3W[KW7.#%8NFGJZJFQM!3U->P>NJ(:2GBGK7'T>K
ME2-9*EQ_5RQ]^Z]U`&U=L"!*4;<P(I8ZEJR.F&(Q_P!O'6.)%>K2#[?Q)4NL
MS@R`:R'//)]^Z]U)DP6$EGI:F7$8R6IH(G@H:B6@I9)Z*&1=#PTDKQ&2FB=.
M"J%01[]U[J)!M+:M*U&U+MK`4S8XU)Q[4^'QT+4#5FK[QJ(QTZFE:KUGRF/2
M9+G5?W[KW3Y%%%!&D,,:0Q1J$CBB18XT0<!410%51_0>_=>ZR>_=>Z][]U[K
MWOW7NO>_=>Z:9Y?$]1(7(1&1F%^`JH6<?[&WMJ25;6VO;F3X41F_8*].PM%>
M'Z51^HIH?SX=5+]T;WR&]M[YRLDE88W'O+C<)"DA:(I#(5-0T5S'Y"0>2+^_
MF8^_![V;[S%[EW^P6=_(MK%*:@,>%<"E3^SK,SV=Y4BV>.*\N(AK8#]G\N@D
M2ZJ!JN;#4P'!-N3_`+$^\$)+6"5VDN;AO'8U:M.)^W/4]-)J8E5[:XZ]Q_C_
M`+S_`,5]U^BLO^4D_P`NJDUR4ZXFGC8ZBUB>3=O:=I#$QCCM0Z#@:'/SQCK8
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M4$?L/7O'?_?7^'KWVT7^J_Y.]^^HD_Y01^P]>\=_]]?X>N055&D7L/\`7/\`
MQ/M0EO:RJ))92DAXKC'[<]5+:LF//78]))%P3]?=OH[+_E)/\NMZS2FC'62C
M>IHZB2JIIY()U\4])+$YB:.HC8,/6FEUOI_K:WL6\D\[;MR)S%M-]M=W(MO'
M,I-"15:BIQQZ(>:[*#=]CFLI(P7(/'JVCI7>LV^-@8C*5;+_`!."*2BR2QL"
M/N:8:02;\ED"G_7/OZKONR<]/S[[3;1NLKZIP@!)X_"/F>N?O-FQ_P!7]VN4
MD2@XC[/V#I&?,PW^&/RO/UO\8^]^?\?]%FZK_P"\^YZM`1;Q!N-.@J)%F_53
MX6R.OA3>U'7NO__7VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6$EB6`)%C[JU)%94:C#IGOUD5Q7H+>T
MNW-E]/[=J=R;TSU/BJ6+5]M3R.KU>1F4$BCHZ?\`SC22G@$"P]@[>>88^6PT
MM]/5?0G_`&1TM2+7Y=5-]F?S'.QLW63TG66*IMHXO]U4J<[3KDLM-`;B.:.,
M66&9AR!^/<%[U[K7D]S>_0;E)'"7.G2:4'RST91VT8"EE!/1:9_EQ\CJV;[K
M_2UNZELVJ2G@800DD\JD&CT)_0?CW'.X^X?.DC'Z;F>[49X/_L=7^GA_WT.A
M+V1\^^_ML30',YBEW;B$G45%-FZ$1Y66,$`I!7BQ)8?DCV+MG]SM[BM+..]W
MF>2<(`Q9JDGU/2%HPKO2,4KU:'T!\P^O.[[88SOM7>R1WEVQEID$M5Z0348^
MHL$FA8_1;ZK>YMY5Y^LKZ-5N[G4Q\R1_E/3;14R%Z-[&6\:EFNUA<CZ$^Y'`
M-RHGMYCX3Y&?(],D9..LH^GU_P!YY]NH'B'ZC5ZJ>/#KE[>!J*CAU7KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z9J]$,=8"H(:"<L/ZGPOR?95NQ+1R0,:PO;R57
MR.#QZ<LE6*\A>-=+LZU(\\CCU257,RUF29203E,@";F]OOJ@6_VWOY)/O#@2
M>_ON/$^8XKV4(/)0N5`^SRZZ-<D1I)L%D[J"^CC^7450%4*O`'T`]P%,S22N
M\AJY.2>)Z%Z`!5`&.N[G^OMJ@].K]`WD^U4QVX>RL))C%<;#VY19U)S.R_>&
MIP]9E2A7^GDIQ';W,^P>V]UNVV\LW<=^52_K45'8/$">GYTZ/(>7[FXV^TW"
M.8TEE*`8\J#A3^?2,I/D_L*:GQ]+6O)09VIQ^(JIJ26AR/V4>2SN".5QN,^^
MA4Q$SE2![.A[+<P^-(T=T[6@:0:M2_#&Y5F`I6O1^?;C>F1Y4GJ@8"@8:OC"
MDTT\!7I/X'Y5X+(5^"H<M04>.&7CJGKIX*AY%Q#T6&_BT,++,0\CUDBB/_:@
MUO9KNWL5O%EM+[K;;B[HFC2#0>()"5/`<5X]*-Y]J]ZMXHXX+N42]P)!'$.$
MK\/#-0>A.Q?>FQLENA=KI6A\O*_V\=++19"@IAD6`E>DJ*Y_\GCJ8E<6C7TV
MM[!][[8[[9;9]<]P?@!^(''J<5KT3[C[?[W!L,U[X\@C0E2ZD%\8#*`F5)XL
M3T_;L[6VEM#*4>)RU7-'D\@*>ICI(,56U?CQ_F%,]1(:4/'&K2M8L.#;V'-J
MY(YBW.`3QN1`M0S:P.[B`-5*XR*5Z(^7^4MUO+5C]:\OAIEF8`LP!..W\CTF
MZSO[KO#X^ERF1R,B4=35[A@24X[(-Y7VU`E55(B6!`:.47'L2Q>U7-%W!*]J
M6++I![@/C-%-:4S_`"\^C:?D;>);E+&.=DF9(F%&'"4TSV^5.FU_DGUDLF6@
M>LK86Q='C:VNG;%9&T$&<62;#PHD@54JZGPD`7N1[<C]I>:C;6-Q*Q"R%Z$.
MM#H[6!^P^?#TZ50^VG,!5$2]+N7T"KBI9?B/PY4#_9ZP5/R@ZKI7H4?*3&IK
M:!LM)",+D9%I\?#60XJK><1!DIW@J*A2>>&/MQ?9WFI[1;I)F,'B:*^(OQ?%
M3(SV@_*G3B>VG,+W-U9FX(DBQ\8%3I+"G9D'ATH.M.XL3V%C-]YJEQU?CL9M
M'<=9A4K*RFD:.N@Q=)'5355/#+:55FCD!YN?9=S/[=;OL8V:/ZT/-<6XD(5@
M`-;$!21YBG^#HHYGY(W/:[[E^V_>;+)+%5E5Q5BS`#7V^1P/SZ8J[Y)=:08_
M"Y`Y.NAILO4DV.'J6\M+'6"A-7#,"&@I#.]B5!%Q[-;/VIWYX)O&<B[0?#J'
M$#5DT].C?:O:OFB[O=]1+OQ!$A--8HIT5HHT$U\P/7IJSWREV#C-W8[;%-:H
MI*Z?,T=;GO#DH\;CEQ.+&3=Z*<T<@R,UPJ7U'U.1^/:VP]E^8+S:Y]R-V59%
M1PNM2'UL4T^J@<>'IT5V/MQS&-F@O)[V9JJ*"M9<M0:TTU%?\'2DH/D=UC51
MR54V5-'!#Y!-'D,?/0U,52D$U;#32PRI$R-D8H3]N+#6HL/K[*Y/:3FA&"*'
MH:BOB`\*#!`(-*YI^?3%W[>\R6JD-?LTH"D!6!!#&@/P^7XO3H:L?7QY2AI,
ME#&\$-?!'5Q0/<20QSJ)$ADOSY(E;2W^(]Q+O&WS;7N=YM]RP:>)Z$\:X!X_
M8>B@VLMD3:7#EIXSI8G-2..?MX?+J9<_U]EE!Z=:ZXH3Y?%<^-[LR?V68+PQ
M_P`?:LFME(Y^-&4*?0$Y`Z:GAB:"1C&-7KU9!\1HHTZMR<B(`_\`>G*)JYOH
M$=)9?K]!J/OZ>?N%RR+]VGE&[5J74FG4WFW=3)^S'6`ONW(\G-%S%(Q,86E#
M]O3Y\SP%^&?RR`%@/C-WR`!]!_QBW=?O.]@`2`,=1=H2/L10$'`#KX4GO77N
MO__0VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW2-WGN[%;%VWFMTYJJBI<7AJ.KK*J:H;2-<:%XH5O8?N
M/Z1_K^P_ONZ)L%I+?2GL.>GHX]1`ZUN.\^[]R]Z;TRNY<S5-X(7>+:^!.O[:
M@QHE;Q/XF_;6K,0N38GWAS[A<\2<URS6MI(:Y&/^+/1S!``%`7H(#9W\I!$C
M`"['UCBUB?K[C*';;R)$$A.H#/\`JITXPHQ%.N_Z<GCZ<GC_`'GVK53'35U7
MKBP5A9O4-5^23S_47^A]MW5I<:?&0D*V1TX(`PK3CU-H<M687(4^6QF1DQ>0
MH)*2IQN2A9EJ8:Z!U9HUECLXA8BQ'TM[,]DOKZW;2)6_;UOP`#PZV`/B+\B%
M[MV`(,W401[UVH5H-Q0QDLU92("M+EX5/-JH`$_X^\S^0^:HKS:=KM9369(5
M4_:,>O1#.*334\FZ.)#K\*^0@OI!)'T_UQ?GZ>Y'NJ&-RG#IHFI!ZSK]!_K>
MZP5\&.O&G53Q/7?MWK77O?NO=>]^Z]U[W[KW7O?NO=--=^BK_P"H>?\`ZTO[
M*=T^+_J'D_P'IZV_W*MO]./\(ZI&R'_`O(_]K7(?^Y]1[^2;[PG_`(D![G_\
M]T_71OD7_E7K+_2'J,/I[Q_?XCT+5^$==^Z]6Z`K?73V1W1G<SFL%NV;;+[A
MQ5)B=T8_^$XS)+EL33J\2R4]37%:BBJ9()&2\5R%/N9.4?<<[-M-M876W^*+
M4'PGUR*5-=5"%(!%<]'%IS!<6:[=;ZR8(92P'D6/X308^WI-U?QPP4L>6I:/
M,55)1Y'-;,S<41@$AI1LK#2XR.`3.NNU2LHO:P_'L3VWOE=Q[<MHZ?J:9@3W
M'NF<,#6OEFGIT);/W#O;7<+;<I80\D<;I0$@'6WIP^9^SI#1_#C:=;.DV;S4
M]51Z9FIZ=J6_VU93X63&4]4-!5P8JB1)@2;:D'L0[E]X:[?9MML;2,)(A0EA
MJJ0KU89-,K5?F">ENY^\5XLQ8+5SBA8THSZC^P"G2FVU\:,7MWL5-ZS9F'(U
ME14IGJREK,333U60W(:6GI9ZM\_-+;&0O'3JW@"`7)/Y]DN_>[=QO?*IM5A*
M3`!%*ZZ"-2:"E:5SFN<=%]_SW?S;.\%L66S6%HR`U!I)+!M-*DYH*&@Z$#>G
M459G-R0;HV]NZOVG55^.;`YF.CQ^)R/\?Q`KX\J8\=4UY9L1DTDA,+2P"Q0\
M>PQRG[D0[;M36%_MBW#ABP9BX*-31D`@::&HU>8Z`^U<PW.F$,:01N)`*D`M
M2G=ZBOGT$U?\6ILY7QQOOG(#!0Y#<60QF$DQ%`YQPW9304M?$<B&^^GEC%/=
MG<7YX]C=?>>WL-OGACLU76L>IJN=1C)-::J"M?+J0?\`7"DCGAW![<&[1$4D
M&E1'D`?+TSPZ5FY?CA@MSQ;RIJ_),Z[DFV550M54L:?8UVS*2HI:-13U)C2N
M2:20&UP#[*+?WJN[:WVR"T4D()0?B'9*RDY!-*`'/ET7VON'<VUQ:7<:Z?#\
M488G^TS7[:^7RZ9<-\7<7AJ:O2/-0)49/9N3VI7BBQ%-CZ:>LRF:IL]+E$HH
M'F@IIGEI%A(C:Q(_Q]JKSWPGFMIK+P:0B^605+,5C6/1X8).5J:YS\Z=7C]P
M[TW=C=S322S1,'U,V6(#*":4R`<#H2^N>L8=GXO>6W8\DN8I<QD&ROD>):&?
M&5%3BZ:AJZ:('BN,@@NU_K>WL"\X\\S;E-R_>0,ZJL(6E&H:.2#QQ@^6.B7F
M+G2YW+?N6KYX-+A&!J:ZM,E5/R_PCH(=X_%;;^;AV/7?QE(*G:=!)MQI\A@J
M&NI\GCJS-C--%)35DL9I*B)KPJ\0)`-_<B;-[S7EO9[M%+;:H)3J!!<$,(]`
M(H:T\_3H3;+[D;G!NF_26\LJ2ES(?#;.$H0#0@@\3P/4C-_$VBKJN'&-NK)4
M^R*"OS5=1[4^PI(Y,;4[DI$CUP9UV^[GIJ&<>582;6.GZ>Z;?[ZLFTL_[O0;
MBPCX&0J?#-&\Z58<:#/ETSMWNG=1FWND35,841BS?&$8L"0,ALTKUPR?Q?BW
M/2UK;QWAD<U4U.2H<AD,A38C&[?$];MJGD@V94-1QW,"[35VDE0<9'59O9E'
M[[0[=-`NW[6K6R0E=+M(VHR:?&KFN0,>G13_`%OW,`I;J%9BP!U5(61RSD4'
M&I`7T\^C78:FEH\50TM141U=1!3I'45<018JF<7\U1'''^W#'-)=EC'$8.G\
M>\:>8+\;GO6Y;@H(264L*UK3RK7/"G'H.R2R3.99:^(0*UXX`%3\S2I^?3G[
M)^F^N*?\"%_X*W_0I]J?^6?<_P"G7KTO^XTG5DGQ(_YE5DO_``Z\K_UKH_?T
M[?<-_P#$8.2_]K_Q[KG[[K_\K7=?9_EZ>/FA_P!D:?++_P`5F[Y_]]=NOWGH
M_P`1ZC1_B/7PI/=>J=?_T=K'^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]
MU[W[KW7O?NO=<2UO;#2."0$QUNG7M7^M[UXK_P`'6Z=<;\_4_P"\<>Z"*<L7
M\4Z2:T]/EUNF.'7,>WU!0=S$]5ZK-_F5;Z?$=<[3V)!/-"V]]PRR9$12%%?%
M89561)P.6BFFK5;_`%XA[A'WPOIH=CBBBF*J5\NE4)((]:=4M>1Y`KO^NY-P
M`""/3>X`-R![Q`MXO"@>YA&F?/<.->CRW8E>/7J>*HR%72T=,#YZNII\?"@^
MKU%?4&EIV`_+"1>/\?9O;RW%Q#$'E8R$9/J>J/EVJ?/I]7:^XI1Z,#E9EK#X
M::>GI*]X4J8'*2)JC4I=F0WMQ[6+LEY<CXC_`*ORZITT92BK</5S4&4@>CJH
MXDJ98I%>-X1+P(V1_6NG^AY]EL\=[!));22L50Z:>6.K!V'!CUAB01#BQ)Y+
M'G42+W-[\F_ND9>.I#4/7C(_\1Z-Y\'-^R;+[_VS0O(\=#OB*OVQ71ZM,`F4
M/+CII5^A9!3C2?\`FY_C[D+VRW2__?[0M>/X(8"E<`=)IHXRKOH&L\3UL+H`
M%L!8!>!_3WFTE7M8]7$J/\'10V.O7_Q;_6]T6YC50@0U'RZ\.'`=<KV_XW[M
MXS'(3K5.O?XW/^L/=FG"K4H:_9U[Y4ZX%P/]5[03;JD5?TS^SJP6OIUE4W4'
M^H]F$$OC0QRTIJ%>J$4)'7?MWK7337?HJ_\`J'G_`.M+^RG=/B_ZAY/\!Z>M
MO]RK;_3C_".J1LA_P+R/_:UR'_N?4>_DF^\)_P")`>Y__/=/UT;Y%_Y5ZR_T
MAZC#Z>\?W^(]"U?A'7?NO5N@^[!WK2[$VME=Q&,5?\-UU,D,S-31:C*M*(?N
M/'+4%3*X_P`U')S]/<B<G<K3;]=V=LTM(I2!04/GY@D>7E48ZURURU<[EO=R
M[[K+].SD^'C2H"ZC04X8\SQZ*7B_F@DU#09([&D6BESN1Q.7%3EJV/%4K87(
M1TM7+!DWPK54)FC?R&*IIX6)')`L?<];U]W^SAF6V7<8T?P%DU*BEB2M54+K
MX'AJ!;/`=21/[<2R;1/N5O.I4T\$`KK82`E2ZZ<%2#@<!QZ5D?ROIQNC=&$G
MVPE#!CZ*LJ<5)D,V,?+G**GIH:MJB@GDHOX>]'40U"J56HDE8"X7FWLBC]AJ
M[59WAO=1:FL!5K&U3CXJL1YX&:CI(_M6SP;<9#'+>.`<=ZA6-*O1:JP(-`1C
M!X=-NW/EY09>BR&2R>TYL<U//6XI!'+4R05N8HXXI\9C:8U=)13J,DDP4>2%
M&9E/%K$WW'V-OMNN3ML>]!HRBL*:1AL\`6%5&30G[>C#_6RDELK":SO*P2D4
M#,HI&6*NST&`K*1G'KTLM@?(H[M[`K-F97;";>J&DJHHC7Y">2OF.-IX*FL%
M'B:W'PTU0FJ2Q>GG(`'U]E/,WM.^T\L+NEO=DS&,:Z`+J!8JI9@QXD8!`)X=
M$W,?(`VC;K;Z"Z1Y:59DTE1JK3N4<0N2#PKT*7;V[LAM+9\]9@XEI\C55]!A
M\?52H[+0/E*U(*G(U3,S.!3QGTQL;?B_N/\`D[EFVW3>DMMU8?2(I8KQKH%:
M4\B3Q/09Y3V#ZB_6'<+HSP`%B&(-:#`&!6O0+57:F_.J\I5TV[,Q/V!0P;9J
M-US5XQ&-P>3P%-C,G!0RN^-U2?Q2CK$J/\F)LWD4GW,TWM7LN[V<-SL=K%9R
MF0)0.2CZ@:#4Y.EC3"C!!KT+!R19[RNK:]$0>3P@FI#EE+`@JHX4I(?PCY],
M@^362R>4QLNWML5&1;=-#02;2PPRU!2TE2*W+RPPY+)9:2F;P-))"76`\DGV
MBVSV@VZ.XEM-QN%U(YUL5K1M`.AEJ,`8+"G[.C5/:Z:&R:ZG>$10,PF.H515
M4$F(::N<CI#TORRS.U,'0U.Z-N0U>1EW#D9<]XZU4FQM.<Q_"*=`:&@JX))(
MY)5`+&,'@^Q))[,;=NNXRV%G,HCC4"--((:JZB%U,-*D@^O#HVW#VGC:=)DN
M%,(@7P&)4`$J'8?#C'&GKU-VI\F-Z%*>?=^`\M?-B=PS8['T%9B_X?5R4W8"
M8'#R54[03B@-E"3G5^D\V]^WKV=VBPCD@VZ[\-?&CC9J`E2T`=U`KW+4^5#Z
M=%5U[67"W,@VBY3PQI,E7"$H82[D`#N(%-(X$\>A"?Y-;DBR$^!AZYIY]T4+
M[ICSU&FZ:$T6';:M#'DJY**H:D:/*K5T\WZOZ'3^/82F]D;564IOVA'$?AD1
M5#B1M(P&[*'R)-?+HBC]K5M=N;=GN%&S4C*-4"3]6H6J::BA%?D>/0Z;"[(V
MYO\`AHIL=4++D1@Z+,U^*=#%+BES5#!7/2S5/C6GJM*5`L5%M-@/<4\S\H7_
M`"U=20NQ^G$CHKU`#%&*D@<1PX'H(W.W2[3#*9Z:PVG!U5"G!Q3)XGYUZ$\:
M=*Z+:=*Z=-K!;"P!``-A[CVX+F:0R&K^?GTGBD66-9%X-GKOVSTYUQ3_`($+
M_P`%;_H4^U/_`"S[G_3KUZ7_`'&DZLD^)'_,JLE_X=>5_P"M='[^G;[AO_B,
M')?^U_X]US]]U_\`E:[K[/\`+T\?-#_LC3Y9?^*S=\_^^NW7[ST?XCU&C_$>
MOA2>Z]4Z_]+:Q_DD_P#;HO\`ES_^*D=-_P#O)T/OW7NK1_?NO=>]^Z]U&U:9
M&;5(]N-%@$07^I/%[#\^_=>Z0>Z.T.O=EHTVZ=Y8/!K<C_+LA`HX-CZ48M]?
M\/8:N><MBLYYK6>Y`FC8JPQQ'Y].A3IKBGV]!E#\K?CW/4FDA[>VG-4EM*PK
M4R`%K_I60TI4@?UN?]?VQ_7KEW'^-_X/^@NMZ2:</V]##MW=NW]UT:5^W<[C
MLW2-RTF,JH*D#4+KY61M<)_Y!'M3!S38W)!B8%#P(]/GGK15N%>E9$P:-2#<
M6'.K4?\`DK\^SR&9+E-2\.FZ4/5/'\SZ"HESG6$QN*)J+-4J2_A:@.'>,?@,
MP`]XY^^LS"T2('`Z40CN'57-!"M94T<%1+]NE1.D$S_3PH2%,O/TL.?>.FVQ
M"2P:HK7_`#='MO@`]#(O5T&/KZ'+;>[`VRR45;324YK:@?>09*DE\],[GZ!H
M)V+`_2_LVL[81+$Q&*=5?XF^WH2,?3]B4E+)A_[_`&V,=14F3ER$M30Y&AC/
MW59.:9XH_(^I:=5;SV_!-_8NLMTMX%&H#'5>D9N/JW(9_*5.0S_8&TLAE*VM
MQU&XCR^/#FGJXS)(\SZK6I"H%_Q?V4[A;)<22W2+VR$L/SZ]T#FY]N3;9R$6
M/GS&.R/DC+DXMTFCIY%)40-41EHW%@.1P?8/O%\,D4ZUY]"+\<*:KJ^[NKA"
MA:J?>=(?#]=,4"KKEX_`2,<_X>Q9[89W]R/XATW+\'RZV<D(*W!OP>?>=L6;
M6+UT#_!T2OY]-E76K1QRU$\\5)#"&>2HJ)8UI(XD^K322,HA-O;#7VWVX'C.
M!3CPK7]O6@"0.@6S7R8Z,V[-)2YKM3:U#,CLFDUWW'J4V(#0P2@V/^)]DMUS
MKL%J2)+H?R_Z"Z<"'Y?MZ=ML_(+IK=DT5+@>RMKY6HDL(XJ>O2.5[\"Z3"*Q
M/]+#VE@YZV"Y?0ER"/R_S]:\,U.1T+$<T=2GEBJ%EIW_`'$FB:-H2GXTS1LV
ML'V)+:?;;U=<85A\Z?Y^M<.G%+Z%O8&P^AN/]@?:T*B@+&.P<.FSQ/7+WOKW
M337?HJ_^H>?_`*TO[*=T^+_J'D_P'IZV_P!RK;_3C_".J1LA_P`"\C_VM<A_
M[GU'OY)OO"?^)`>Y_P#SW3]=&^1?^5>LO](>HP^GO']_B/0M7X1UW[KU;I*;
MKVSM?>.&K\#N.D:JQ=4@CR`BE!,0259XS#(DL=3357G4,=!N"/8PY5W/?MHO
M[._L*F.)J@9S6M0<<*&G5=MGWO;[V:>S;0LA.D5(U"E*\/\`8Z#"B^.'4J4B
M4JXB=*=*VMR=7X,G5N^6J,H`M93U[3S--5I4K;R>2Y/N1][]U.9XW9YQJ?PU
MC2I:D87*:,8T'AZ="4\[<Q642^"]-"T2@(TT\\?\5UEJ_CEU14UV5FJML1R2
M9"G-++025E35T,$!@AI_N,9"S^#&5QIX$0^$"P0>T]K[R\QP[=81^(QF2M7J
MVI\DT/RJ3^WIS;^>N8X(E>"\,9-"2,$D5PWJ,\3TS5'QMV.S;?IL33P8["4>
M]L+N_.P5\TV2J\ED\'1RQX4_>5$C3RI6U)7[@MQZ0#]/:]/>K=G7<I+B,K<M
M:O'#I+$+K(U5]-"@Z?M/1:_.W,5L%$,[Z1$\8`J`%9BS4`'&I)S]O2H_T*["
MH]P9?<\5)446=R<LPGDEK:N48RHR=.:>2?$*7=*.JRH!+"*P98QQ[)[[W.WO
M<-IV_;Y(BUNGQY;]5%?4J/ZJAX>E>KP\V;E+8?0/(-!H6IQ9J4)/I04%?GGH
M0JO;FW\GA)L#D:(9C$U>,CQ%=2U99Y*N"+2?)*TK"1IC,NO5P^K\^X\@WS?+
M7<WOK"9X)_%+J%K0`GX>'"F/LZ)$>[MWCEAPZFH(/"O\N'2'Q_276>&I:NCI
M\/)-+DFA>MJ\E55V3KZZGIG#T^+:2HDE$5#3,H*Q`A`1<\^QK+[J<X;@]M$L
MC1)`P8(A(7Q`*>+2GQD>?3^V\Q;U97#06SA(%)IQH"_Q-7U-:'UZ@U/1?5E<
M:R$86G"U34Y\<=7(JXY:6H:L@FQZT<@-!XJMV=0M@')]FDGN-S9"Z73LS3&K
M2$LQ,I.#KQYC!^70DDYOYECME26Y;P144((!J*$9`XBG#IA_V67I2HCI:(;9
MEEBH@IBH4R5>JR:*U,B)JZ\BFO;[^,37?5Z@/;P]Z.:[=IKE12YDX,&:J=NF
MBXP-..K3^X/-+V<*27A:*(4%1@8I0?ECI0-T%U8GWJ?P-#%DH:^GECGE?QBG
MR=?'E,C#0)Z3315>4C$[CZ^8:A[)+SW?YONC;:[AB8V5R=9.IU&D,WS"=OV=
M%<'N'S&\P(8ZP`*T(P%T@?8%-/LZ<L?TWUMC(H:>AP\5/+%3Y>C1ZFIEDJZP
M9FD>DSIJZ@$M+555$X\1OSH']/:P^Z?,DQ245`&@JJLVE3&VI0OR)K7TJ>F+
MKF_FNZ@FM)[@FQ8KC-`%^'RX*?V5STN\%M_#[<Q5!B<+1BCQN.Q='B:%C##"
MT6,H*>.FI*>KGD59ZIQ%$/UDG\>P1OG,',',%Q-/?2NR-(SZ:DA6=BS:<?/H
MIDGDF8O=$,6:IJ?/Y=/*L&4,"2+6!*>.X'`]'X%A["TBNKLK@Z_/IR-55%5:
M:1Z=<O=.K]<4_P"!"_\`!6_Z%/M3_P`L^Y_TZ]>E_P!QI.K)/B1_S*K)?^'7
ME?\`K71^_IV^X;_XC!R7_M?^/=<_?=?_`)6NZ^S_`"]/'S0_[(T^67_BLW?/
M_OKMU^\]'^(]1H_Q'KX4GNO5.O_3VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[
MJT?W[KW3%D,K#C8*ROK*J*FQU)%//45LS+%!1QTPO-YR]A8+<@^R_=+^':+1
M[NX:B4\_]0Z9`D:0C50=4]?('YN[MW[GINOND*BMQ6'J*B;&3;GB_:K\G/'*
M\-L;,2?'35!^GY(]XX\U>X>Z[E+);\O;O+`P/%&H?\O2](PP`ICU\^B"9'8_
M9V4W#546?QNX<CEFJ*])9Z\U%9%]S0$M5:3*[1F9F'-A]?<23Q[I//+->7DD
MEVS$NS$59CQ)QQ/1DMO#I%8UKTG8MH[IR=.M3!MW+1JJ^M30".4D$@^(*JFW
M'%O;7TUW_OYNK?3P?[Z'2KVI6]P=;I_>?:LV\ML&F-34K54J5"T[24E0"?OZ
M76R3Q:`0UU^GM4N^;SMYC2'<I4513!]/RZ\((@:B,=6^_%;YGT?;7AV-OR:G
MQ.^FA5\7DJ<I1XS<\:@,5HT?_@-6QV_<0_4_3WD/[<\]Q/"L6ZW9D:G%J'_*
M.F)(%#*ZH"!Q'3W\^>L9M[=,Q;DH*3[_`"^PLBN=6&%"\T]`R&/(*`IN4(`9
MO];VO]T^78=\VEKV"(.I%0?M''%>BYF(=BN!7^75#T8UQJ6UN64&\EP]FYLW
MT-UO;_8>\0=N9MEOFBW`$V]::3P_R=&MM(]!W'AUVL,:KI5`!?58$_J_K]?K
M[O=[A)+<SO;2%;8L=*C@%\@.E!->LK>L2!O4)5TR:N=:^+PV:_U_:]/^M[1F
MXG.#*>O=<1''I*^-+%2ANBDZ3:XO;5S;VLCOKV-$#7#>$!@5Q3K77*,".-H4
MXC8W*#Z?[SR/]A[3SW<3Y,88_/KQ]>C[?R]^L9MU]M'>U11RC#=?T=5XJF9#
MX*G,9$6IXXV(L7I8B;?T'N7O8KE*]DWV]WB^0OMTC%D5N"BGECU^9Z0S.U6%
M32O5KO>?>NUNA]J3[AS\\E7D:L-3X#;U+,@K,M6`72*"(W,:(QN[GBWO(?G/
MF^RV!(K5)=$E/+_B^F-(8U(QU15V]\E^V>XJ^HDW%G:VCPZR3_:[7PK2XW#0
M4CDLGW\L+JU;41+PS$FY'O%3?.;]\O=SW"2+=IA:M*2J@X`^72](8C&H*`XZ
M+U$(V1'!6:XNLA)E!N2;J9-1(_Q]AB:]N[@DSW#,?GUOZ>#_`'T.I.IM:RJS
M1RQ_HD@8T\BV^A#P&-K_`.Q]IKN[N;2&*6VG9&IY=:-O!7^R'1E>DOE7VETU
MEJ&CI\K/N3:DTL?\0P&:JY:O[>C##6^,,S,8I`M["_L;<E>X&Z6CJEWNDK(/
M(G'7C;Q%2-`'5[74'<>U^YMG4.[-H51GCF;[:OQTSI]]A:]+B>GKT!U60C@V
MLP^GO+;E[F2UW6SM760%F4?;_AZ+98M+-@<>A@5B4!U:N/U`6!(X)`_'/L6X
MZ1RDC@>FVLYCJO\`J&G_`.M+^R;<^(_YYY/\!Z46F;BU_P!./\(ZI(R'_`O(
M_P#:UR'_`+GU'OY)_O!_^)`>YW_/=/\`Y.NCG(O_`"KUE_I#U$T/>^OC^E_>
M/S2"I[>A8L\84`C/7((WY)_V_NFOY=>\9/(=$I^3.V,MNG>G5&*H,+A=R325
M&_J],)N"JS>*QF5?#X*EGI*-&P%;2R3UL4A+QR2\%R>/>7OLU>;58\K;O=W6
MXR6TOT]LH>-(W85F8,M'K0,/B.#T+MAAVN6%CN=T4CJH!`U%=?F:\`#BF0!G
MH$SV3VOL+!;#PFR<G%2P57\9S%1#628]8*?(T^3>#_1I#/NBGK*WQ4H4B-TE
M^]*L+\6]CV;8^0-XFW6[WC:X;EV(569'8TH/\9;PV"@'@01X=?/H>7G+>Q;A
M=M$C)'!"8XR%*=Z%*B2E:ZB>(X#KANCM3L;*9_#Y.7<T467Q68W#*G75'C)P
M^"?#8&+("K.3)6MSE165$K"2*<?:V4>`D@^_/R=R#!L:IMNSHLDRQAI:+H<2
M2%2HJQ550`$%>ZIH]!T<6'M]LKRWHN)(6V]K:/0YT@ARQ!%/+AQKY]"`W?\`
MNG.9:3'8C>>-Q6$J</M@5F]EP%+6T>V:O*8`Y7+O/3U`6BJ"V03P$5!`1N%]
M7L';A[=<K6$EK*=HCF>LGZ()4RZ9-`':=8HN:IQ^SH)1<DV;[5N-T\[?41RR
M:%)4$A&TBE?4?;CH/LEO_L:CWEN+,P;J&ZX*S<?3]1MW;<F"--#7H<+GQD:G
M%QAUJ*&LR\U(D<+MZ(BQXUE?<@[/RC[>_P!7=KLWV=5O!:7HDDJ**3)'H5CJ
MH0H)9M5#0?;TR.5]F40QN((V&O4]07;*X8G%*'BOGTH:/M7MO-5.VL%A^QJ2
MH?<V8VR*O=,&TZ*HDVQ_&?(^:V?38V733FJP#)HDJJTB>]^/I[)OZG^WMG?W
M:W6Q6PC@MY-*ZF7Q63A+J+5HQX!.T^71F>7-B;:)]QC#JZ2R:8^PAEC-`&H,
M!^(H.C.;)W7G-R=*RY+<50,AN.'&[KII*X4W\)_B-1CZC)4<-4D=*?'"TD5.
MA]'IO]/<%[MR_M-C[C[@MEHCVT3Q%4#`@!@A(!.3Q/0#OMHMK3>I8%?5:,ZX
MH#04!I0<*$TZ*ULK;F]=D;)INS</@L?MNLI-L54]3!093-9G);MFS=1'0Q93
M+4<\LU$W\*\KU"QOHL5O]/<V;A=<O[U-<[+N-Q%<5D58M:H@C4$E@I4@@L!H
MSY'UZ&EW'RQ/-'M+2.UQ)+4'2NF/0M2JL>(;\\]->5[*[6I]Y4F5INPZG<F/
MVO3;IAH:FEP&.QF,W[.,,*B@HHXHH'9)=KU3$2O3:FF(N?S[46?+G(4NUPQS
M\I6T<D\2$@LY:*CT)8%LF4&@UTIY='UCRQRO<<OQP3!#<S3H6+:"T8+D-D$`
M"@!%1D'IUVWVU\@=S2[8VV=\4N-K,W79F67<M#B-KY^K:DH]I39B**7'Q4XP
MM-$:Z$+&2_E0/:<`^V9N2?;*S;=+P<JV_A0"+]&0R1DZY`M0=>LU!R?AK\/0
M>ON5M@LXC2;]?2<J%T_VN@9/G0U(I7\NDKM_L'LBNW7D<SF=V5.5^ZSG4TLV
MW&V]2^%8Y:7<AR.9PSH8JF"2%<5XY5B4THEE%[G1<1Q\F\D1[)90Q;-;1/(+
MS2RN"10(5A<%J!234$G45'V]*MVV79(;:V@M=`$-M(LCD`>*QD0!C2N<FE/2
MM#U)P?;W9>]<O)@\UN67+XJ7<VQ,S@9DI:"AJ8L-D\YXLECWCPD%/%2I%0L!
M)'7RR5`MZN>/9'NW*')]EMSW=GM<%M>QV,ZR("S`S*N"ID8UKQ!0!?3K4W*/
M+]C;F:5%E#33(M0M-"QAD<TS742!Y=6ATK25%/#,9"?)&I7U:K(!9`#H2X5`
M!]/Q[PDWS1'NU\B'4H?!_(=0\+BV0^$B`!<4^SC_`#ZEA2!<F_\`L?\`C7LK
M$JCB@ZN'5_AZZ3_@0O\`P5O^A3[4U!L+H@4&M>O2XMI!7JR3XD?\RJR7_AUY
M7_K71^_IU^X;_P"(P<E_[7_CW7/[W7_Y6NZ^S_+T\?-#_LC3Y9?^*S=\_P#O
MKMU^\]'^(]1H_P`1Z^%)[KU3K__4VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[
MJT?W[KW56/\`,2[LGV[C,?U+M^H>+(;EA?*;@EI9V21*&F8+3X^HT$%8JT'4
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MV>61I!33P1AV^UB4VO\`ZD>X>]U/;XPH]U;+0-D4ITOM6!J!Q'1)PX<!Q(DH
M;D21(8XW_P!J6-N4!_H?I[@!(6MU6!OB3!_+I9UW[MU[KL?\3[?NG_0B7^CU
MX]"!U9U7O7M_=<&U=H8RIR4L\\1KZI8GIZ7#4`<"6MFK&`B?0IY6]S[%O)_)
MTN^N`%K7K18**L:#K82Z;ZJVST1UG3;>I)(95H(GRVZ,VBK3BLJHH7JZBODN
M22D,4>A>>$'O,OE^RM>5>7;>!5`DBAHQ^=.BR1R\C4P/+JA;Y#]P97NCLW<F
MY*BH4TM'-4XW:6+5G,4.(@J'2*6Q;QI42(MR1R;^\,^?=_O-^YDEMXY#IU8_
M;U<>70(-%$^DE&`%B%9F])`'!%[&Q]D!C:$F)_C7!Z7Q_`OV=9/]@!_@``/]
M@!8#WKJ_78^GM-<N+A1".(QUH]</&A.HKZOZ_G_;WN/:`;;/&VJ.O6ST:7XC
M]S5?3O:V)6IFD_NQO&MI-O9>C,[)2`UK@196>.^D2T<E@'XX//N5/;+FR=-U
M3:7D-83I/1=/@O\`;UL6I)')%&\3!XY(TDC=3=61U#*RG\AE-Q[S9@.J&-O5
M1_@Z*IN'3?6?YJI_ZAI_^M+^RO<^(_YYY/\``>E%I_N1:?Z8?X1U21D/^!>1
M_P"UKD/_`'/J/?R3_>#_`/$@/<[_`)[I_P#)UT>Y$_Y5^Q_TO4<N%'^'^\^X
M$%G(_<HP>CY;9I)&)8T)Z9X\Y25*5+TLH?[.IK<?5,Z2J(:R"5(/&.0)2KR#
MD7Y]F7[CGC\`2K1I$5Q_I3Y_GZ=&<%G4D"N".%,XJ?LQU-B%#4*DU1%3/44K
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M,1@(X2RWA&'IOLYPHM$M32K&(JUPOT=@P%_:J3G'GV:\LKX[W>?5P`F.3\2$
MC.GMX'&>F3=<PNLOZI.JM>]JC/#Y?RZBUL&V*6KI(JN#$TD];.M#2J8*!YY%
M@`DA@I9`!/\`<0-RH!!3\6]TCWOG[Z2ZMH-QN?I9`Q=030E^U]7;^(8/2V"+
M<;B..:92TD?=4EL$_;Y?X>I4>,V]36=\9C*<)-)422TV-ITIZAY"5,M0:=`H
MJG_+L2U_S[I>;MSO?>']7N-Q((X!$I8UTQC\`[<+T]')N:JRQSL7<\-1#5]0
M/,?9CIRI*>A$34R4D/@TRA**%(HXC#,#Y&E4*([.K&_'/L.WU[O[WSW,TTIO
M"02QJ2"H`%,>0`Z*[H;DKNX<$5XDG/\`J/2;W!GMH;5H()LI4X_$XR2I3%11
MS"%Z62HEII&AIT\3%0LD,3^EA_9^GLVV7;N;]^O3)9&:2[)UEA6N#ECCRQT8
MV=CNUZZ:@QD5=7G4"M*C'J>L:S;,;;U'N.@APT.&:&FK*2K^TII*80UQ%)2U
M./`0+#YHY@24"E[^J_LS?=^?H=\W/:Y]TN6O]2I(*U)T$$!NW\)'\ND*#=5W
M>\L'C8.&H<L"=(U$$?RZ;-IY#K[</WD>U1@<BN!S-;0U2XZCBI/M<TB!,O')
M%#%%'YE@(,@7]0/JO[/.8Y_<01BYW:]N3)/#&:L>YHT-8B*+E00:='%\NYP(
MOB%UU`4U$E:<5R>!J:=+%,9M^.H2J6AQBU"6$-0V+B9$`)9$\J(7I@";A;A0
M>;>PE#S1S<8C:'=+@VOB%R#PUL*%CCB1CHJN)]W\*%%8ZR*$:CPKP'J/GTV4
MV)P%-6WBQV&I],YF910X](RX+%IG4*H:!JB4,&(OK_/LPW+F'G2[B$US?3NV
MC34G.FFFG#A3'1A</NDFVR1B:0$I0`%J!N(I_2H"*>G2@6L@63P*1Y:=P93.
M6"%%4(4&E@MF8$J!^+>PW^XKFX@6ZD_M'%3^W'Y]$]GMDS6=O/=*?&89IDZJ
M\>'4I)5;4`K*/KI>^H`\\ZC>W/'^'L/75J\#T9:=*'C\!*AJ]=+_`,"5_P""
MM_T*?;B?\DZY_P!.O6RVNT=O4=61_$C_`)E5DO\`PZ\K_P!:Z/W]/'W#?_$8
M.2_]K_Q[K`'W7_Y6NZ^S_+T\?-#_`+(T^67_`(K-WS_[Z[=?O/1_B/4:/\1Z
M^%)[KU3K_]7:Q_DD_P#;HO\`ES_^*D=-_P#O)T/OW7NK1_?NO=:W7S(W'/N'
MY&]F2RNY&+RE+M^EUFX'\,U0A8Q_9L!^/>%'N'?7B\P[^@N&"BYD%/SZ.X57
MPHVTYTCHL<*H(XB0@"5-.OG*GP1EG`:"LC/+P_ZK^H]Q3&!<3'Q^[/GTH#L#
M@]#'3T<CQU0I:/8$FBI9C#Y?!0&GX(>-/U(Y'X))!]BN.V@6-%6(``=:))))
M.3U)\E)(U=0QXKKV.&DHZ>KC<U#'[NHG`\L#'6=9A)]W\"'_`'V.M=(?=C14
M]1BHGAP$)5I0ZX-6(F@8?LK*Y=M87\<#VAF@A745C`->M])-$*JH<>I+BS6:
MU_K];C\^RNX\NM>?5J/\L?.SOD>TMHL\JTL5#A\]$FH^+[F:HK:1Y0IX60T\
M*(2/JJCWD/[&3.]RT<K:D4=H/E3TZ*[A0#(0,D]6YUF.H,A1245?1T]71U:.
ME32U,230S+("L@DC<,K!@?>16XV-GN#+#?6ZRP^C9'2)Y9$RCD'HA7:OP!ZF
MWI73Y3:L];L+(3R32O!C!Y<*9I3JU&A:XB0,?TJ0/<0\Q>R'+^ZP[M/8;@UK
M=2L672$`C)_"">`'SZ-=LOE19GN4\0?,\.JHNZ.E9^G-_P!5U_6[FH\M6108
MV?'Y!(/M5JER#)-'YH"27O*WAL/];V->2_N57/,?M7O&\)S'(V[JL@24F+4I
M530@T\CD8Z!-YS]M^W[R;:=QX8;X?*G[>K!NM?Y;^VG@Q.6WSO6OS?F@I:^3
M&8B+^'0,M1$DYI9IC=Y54OI)%N![BS9?9R':K&QVW>(%N[NW0(\KBK2,N"S%
M:"I^6.A4+WZL"Z@EI!)W*!P`.13JQ_8'66Q^M<+3X+9NV\?@Z&%0&%-$OW-0
MX`#2U54;S5$KD7)8\GW+W+_+>U;(JBRVV.$CS4&O57ED84+DCH)_EKG)=L?'
M?M7,4;20U";>:BC\+:"4K*RDH9@+6LLM/4,K6_LGVGY^D:#9)I(FTNRG(^SJ
M\1JXKZ=:W\>I(XU/!6Q^@N">;7M?@<>\$YY'&[27&H^-K/=Y\>CB&*-AW(*]
M8E=ON9%G+QQ.U(D+(AE8K*ZK/*%4$WB4D_X6]F/T]Q/(9I)&)8U)ZVP"D@#`
MZ'!^M=D9#(Q08#LNE?'>6BCJ)ZO'3-*E:5$%321R"H0/$H)E-@.1?V9P[:64
M57K74.OZUPM-3>23L/!35$E)+74T5%"8D$<;.J4\^IWTSN([V)OS[8DVL([N
MB4:O'KWSZ"!&#J&N#<FQ`L"`2MP/\;>R^:*]2H69J?;_`+'7NL1D>+R3H")Z
M<":F*DA@(:F.1BG]";?CVCVG7M^]13VS:+IWJS#B3ZD],2HA4DKUM%=)9Z3=
M/4G7>?G9GERFT\14.SF[EOM5C.H_D^CWT`Y8GGN-@LIIY2TICXGCT42*M2*8
MZ7M9_FJG_J&F_P"M+^WKXDI&2<_32?X#U:VQ=6P'\8_PCJDC(?\``O(_]K7(
M?^Y]1[^2O[PG_B0'N?\`\]T_71OD7_E7K+_2'J`DL;^="NIXR0.";<?@W]PL
M+@VPM"Q_3(%?V]"D6DZ/#-]4WAMG3BGV=5XYGJ_LW<.\>R:NMI=S1X]?](>8
MV6:?)5D5!59.3<-//M^>.""JC195IH+)<``?CWFK:[WR#9\I<J/%8V@O9HK:
M.1Z*6[D[]56P%J<FF>/4M;-?<J[=MT<NX6-M+<^(FO6.X)X9J./XNI%-LOM[
M[K<H3![W/8=719!Z;=;[C&.VW%A9\3BV7%P22U;1-7P6J(HXFA+FLD#:[>U5
MK<<G3;%M\RV5B-E^I"$>(HE\19&6NC5JT-1=1K33D=%U_O/)Z6UM)':6GTI$
M6A=&ILL=7G4'@*_PCIKVML??F0W103U&#WQBNN,:=X5]+B-Q9>KI:K!Y:AV*
M6QU7FHTJIFGIZ[/K)(J:V!E`;Z&WLQW6/E.TL]XAECLSOU(5JFAU;7+P1@:4
M"4!(%?(]'7,+<K16W)*[=9VJ[C(Z_5-%^.)IP`'SW,$-"/3CTE]L[6['RFRM
MN9K;F`[%BQ%5B:"K[`%9FRM;OZ-<Y52U='M6:JJI99IFQV@&0"&Z\6%K^T]Y
M#RU;[[;Q[G'M[+-(1`JN@$?8H42`$>&-520]<YZ/]RON2MNYNYPVX;59_H2L
MMFK(3&C&,=S4:@`:I!Z7FT^N>Q),IF<GE<!O&3&TG7VY5V!AZ_-U=)DJ)YMP
M`XS!UZQUMCN#&4&M0&D?5$P&KGVQS!<<JVVC;(([,WIW*-)2KH5+&,:B'!H8
ME)!J*+JK7H&W.Z\KIN-FZQ6T<!*&<K'5*@=U%)_T0^?[.@KV=U1VU/N?&9C+
M[=WA3X_!Y^FR.UXJ^AFHXJ',Y3:M329&?QSY2>5(J/<#Q/=V>Y!;\^Q1OEQR
MELNU-;"2TFN)@RW$BO$VJ*.0!54JU":>0H33CU(<V^>WDFVF&"SM(YQ;`4H2
MQ(EU5:AI_9U7'ECCTH<;UIW4VW-SC,3;]I:VH6B&2I:3'!_XMEZ;,&?(UV+I
M7R$IW''648\;!#`%3\>PU<S<MVUUM,$*6,IN64P$RIV(P("R:6I&5.3JJ:\>
MBA]V]O;C=(I8-MM1&/$R<47P^P@D]N>%>C==7TF\J3JB/'Y7!U5!F$QV:H<5
M23UYAK)J:(R/CI*@%I9\965C.5>%II#2V%B;V$%\SOLL'N'?637BSPB6,24H
M$#FFM5(.EE'DXH"/LZBG=+W;)>:;Y;4(FT+.K*!W#2%%<?,U-/,\.B13]=]T
MY:2M6KVINN#'U>6VUF&QF4IUIHJ;(0)E<;55$+SUT[5[F.J!$GI\BD&W/O)C
M8GV'EF>*6::T$B12JICEC:J-I900&%,8\Z<.IKAWSD3Z*(6_@"Y.H,U""`-+
M:<$T`(K3UZ-OD,3FL3T5U)MZ:AJ::JP%=U[C]\4YB$53'M^F=!7Q-$C2*/MS
M"K,`3R/>/%O<[5<^[G.VXWMR/H96N&B`92#(`-!&>%:^9X]1"S22<\\S[I;W
M@ELYY9'@#$:`*`$#_!T1NFZE^0N'RG<53#@]QUN&W+ENU,EL6'"SK1I@\_5T
ME&V%W%7-'50/4+NF-?%2<?MR(21;WE*+OD7<-JY9GDGMVN$M[5)=3)\#RLJJ
M`7IVY+^BFIZG?<^9/;2_L-HL#86ANH_`,Q=35U5*R`&O$/2OJ0.E:>L_D/B*
MZOH,;1]@5&TGPO2F2W3CXLEJJLS74^,>'L+$XB62N9H,L]85^ZD!"MH'LKO$
M]NKIK&X%CMOBB2_B1JQJP99`82W=0(!4(Q'#AT%K'=?;==KCGNMJL_WX&G\.
MJLR%37PM1J*`8('KZ],6>ZF^2,F)IXL!-O'$T6Y=R[JV_#C:K*0G<&R>OYQ%
MD-OY#(U#RRM*8LM3&*/EF"2M]1[;M[SVY-W.U]9;>\MG"DK#M99I*E6%0X![
M&!%/Q#AT)MAYD]KS.(-QV:U=5C@D:BGPS,JTD11JK1JEF/H!3SZ<=M]/?('<
M&3V5F]\4>_7;-X3MC([KQ-#E`D>/RU#MQ,?L>*J\5=$DD0R%!]S3Z;"\W(/O
M>Y;S[<V%KNUEMVV;<IM'LXU8:`3XTJLY74Y)[&*R$8&:TZ2[OS7[06.V\PVN
MW[-92WL>Y6*PNR-40M(3<`4:@#*P3Y@#@>C]=!4^\Z/J7JJFWQ+D6W3%M!4W
M,,G)Y*Z7)HT@5JZ34^N=8]/.H^\-O=]MDBYPYJM-GMH4MX[RB&.A73@T4@D4
MSY=8V^Y>X[/-S;[F1<I*L6R0[O;K:J@(6.)U0NB`U(4DM6O0W4S%GB9C<E'_
M`-Z/N*V`%C=`<-:]-W"+'#,B"BCJRGXD?\RJR7_AUY7_`*UT?OZ=/N&_^(P<
ME_[7_CW7/SW7_P"5KNOL_P`O3Q\T/^R-/EE_XK-WS_[Z[=?O/1_B/4:/\1Z^
M%)[KU3K_UMK'^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]UK;?,S"5>V_D
M-V;%44_IKLQ1[CQQM_P(&5)ED*&_)C#>\'O<4?\`(DY@_P">J3_CW1[#_8Q?
MZ4=%K17$C31M'+JGIT:IFM]I'$6'IJ(^/+;\^XTM/[8_;TX.A9ADC1:O'RC8
M\E-5R7IW%.Z"-TL7D0:M2DCZB_L8)\"_9U[IV@2*&"<BFZXFBA2)X'=BK^LB
M[GFX9OR.?=^O=!UN+"PK)DLL^5V\A=T:+&XR5E2%6(-XKW(4?CZ>T%QP?[>M
M^0Z3G`N%?6/P^K7J']=7]J_]?9-/UKSZM1_EE8.O7)]K;G>!CCVI-N8.BJ>;
M25<#5-?60*?H=$=8@(]Y!>Q(K>S9\CT6W'X\>?5OMB$C!))`')^OY^OO)J4U
MG0TZ+9>'4*6\?D1+DRZF%QQK-Q:_X'M$VTQ2"\9[]A')(6([:+\O^+Z=@CK!
M(X7-#^>.M93^8KVSN.@^8NRJ.OZVW5CI=M2[;I:&@22BJW[4HX-S)44=5M.5
M('%.:U3]MXY"6BE]3<>^@GL'L%B_LKS(TNZQ5`E$(U)D^!_HF<=__&>L0>>H
M;V3F>1M)5C2H_/RQZ=;('7&9S6=V)MG.9S;=5M/*9#$4-34[:KYX:G(85I84
M)H*RHI[0RU5,ITN4&DD&WO![<EACO[J)90U'-2.%:^7RZRBY:9SR]LQD6C_3
MI4?ETO@;#GV7$:NCO[.BV?++;=;NSX\]HX7'J9*V?!S5$!4794QU52Y.;3P?
M]T4;#_6/L#^X8`V%P!Y?Y.E,/QC[.M;O6TBAW72S6++]+&P%O>"4_P#R4)*?
MQ'H\M_A'V=*_8NX<7M_)RU>5QBY&..`QQ+&@:19'R,<DK#7<:GHH9$/'Z2?8
M@M[Y$1(_,=:<]S?;TO*#>?4M/4BHGV!FY8Q)55*Q1U<4<*U$V+EI8Y8X]-U*
MS."+WY]G=O?H!7JGRZ@S[IZB?'_9KU]EX`U-D3'"E=PU;4%#0SSF]Q+#8VY`
MY^GMF>^2K\./7O\`#T'VX:S"Y"N>?;N*JL72+CJ>&:GJ95>.*MC4"=XB/U,U
MKD^R2>_A!K7/7NF'7YZBDCIE$KRL:=#;DBHGCB"V_'J/LKMG$FZV[C@6'34O
MPGK:#Z/P4^V>HNN\#4IXY\9M3%4TJ?32XI@Y'^PU^\^.4O\`E6[$?\+Z*)/B
M/0@5G^:J?^H:;_K2_M7>_P!G'_SS2?X#UZW_`-RK;_3C_".J2,A_P+R/_:UR
M'_N?4>_DL^\)_P")`>Y__/=/UT;Y%_Y5ZR_TIZBHJIJD)C@5VD#25#&&-_&-
M3$2+<D$>X%E)E>%&!(``%,\>EVXW>X%XH+4$@'RKZ]!.W=W6-#D,Q2U.[]NT
MD^#C6LS41JF4XFF:I6CBJCKYD\E01S]"?<K6_M?S1N.PVUU:6S,&/:/XB,T&
M,FF2/3H7S<J[Y?;6=$-R)94H&5&-3IK3X>`&!UTG<W6$^+W#GVW;MZ;#8W*4
M^'DG6JIHO-G'8S-01-->J2NDC99/&%MX^?;"^V/.<";>BV+`R(9.)^'A7"TH
M.@Q/R%SA#N7*&W"*Y"R094HPU:6P1V]P(P2,5QTW]>]R;%WCUE4=G05`QVWJ
MO^*Q5E3D;.BIC*FHQGFD348]$A1@.+%3[=WOD?GC8.8CL:.TEY%H*Z/4JK@+
MV\14?GT,=_Y2YAL.9[3:YH2DD8!*@GB:,/*N,'Y=.*]N]2X*&#"2[MVSC$Q8
MP]/%!)_DD4*YNCDJ*"&F"7"BNUW%A<_CVU_K;\][M=2;H\#M)/J=F)R=)HS'
MM_!P)\ND=[RYS)/(V[M'=.MPS$G2QU:6IQ"\?,>O21;Y(]3IN[;6V4R=/4TV
MXMO9_<%-N&GF^XQ-'C=M3)0YPU*O<SR_<$")%`D##\^Q%/[+\[KL=_NK1J!&
MZ1:2W=5S7&,5%*]&LGMWS5+MMUND=M,!&Z*W:0Q9Q6*@TUH<U/`=*R'NCJZL
MW)4[;IMVX2KSD]5%C5Q,-9!%5K6M1K4T4;I4,$I7J\;)Y6B-FXO[(I/:WGBW
MV^TF^B?P-#,":T`K0GX<@'%>'SZ)1R=S0=M2[:*X`55+-I;214@D,%S0BF.I
M;=T=0U2Y*./>6`EGQJM2U<\58T*4:0JM!/2R4\;".1TJG13)$;7;D^RV'VWY
MW1X%&WN)9J,#FO\`%CM\U!X^726'E/F&-W%S:SM;M@AE;)!J"3IX#CU'J>YN
MK:"!WK-VX*%5K#BZF.6J\,29';<*U-?3)9F2GEQ\<H=I"`&OZK^S"+VPYZF*
MS_1%D`U`^95S1:]M:$C'S'2S^HF\B[DNEM+GQ7S4(QP11?+-?Y=2,5VOUIEX
MVK,)G,/F,;/G,?A,KD**J>JI]OY"KE#T"5M--=VCK)"+.MEM]./:2_Y&YSVY
M7^KC=9/!>0<:N@XT(%*CR'&HZ*MPV3?;)6A@AGB914*5*DXR0-.:#B/GTI=U
M;IV7M6BFR6Z*[&X[$2U#4\CY1VBIJUZB0LD$<R:FAJ];7"6(`M[#>S[!S+N5
MS#'8VTK7034-(-:CXJU'"G'KUE;;S)##`C.;D=I*U+`GY`9'SITQ5G9>Q*+'
MU%6N7QDZ8[QS'34A_%%'2^=*>-1ZJH?:@`.;A?\`7]G"<H\WW#I'1@":`>=3
MBO#R/2Z+E#FDR+)X=QW5^)6`XYKVXKTF\AWEUIC,_AL%+DZ/[S-R4T<-!#7P
M"KPRY2C&6K\I7U!)6:E%&RDQ?K`/L1M[6\W-82S-$-4<9)!)()KI`II[23P/
MKTN7D_F^^VZ2^BAG,**6+:6`*QG2N@Z>XU\AY=*&3N#JF7'29F'=^!FHXJV+
M'FND<I!)5TZ.8*.:..\DLDM&Y>F/TU"_)]D=IR%SK%)]/+9R*<L!7A3S&*4/
M!OET3Q\I<UQ3JI2Y$C*#A6K1_.FGUP?3I)CY!=2R9JNPT>Y*`?9;?QN<&0)D
M_AHQL\\U+CH36VO55U1,6U?F_%N/9Q+[5\X/;1[A/:9>5EI6I+`!F%*5`&,\
M/GT:1>W^^&*XNY[>9EGF4$:3K5T\].FM!QJ>A6VYG,/N+%4N3P5935^.FBDD
MI:RDU""6)Y'!$6H!@L;`I_KK[CG?=GW#:KZYAOHRLP;N!\C0=!N[V=[7<-P$
MJ'5>2I(:\:Q`+4_;2N>GRF%GB']%?_>C[+2:V-T?Z:]'5R:Q3'JRCXD?\RJR
M7_AUY7_K71^_IU^X;_XC!R7_`+7_`(]US[]U_P#E:[K[/\O3Q\T/^R-/EE_X
MK-WS_P"^NW7[ST?XCU&C_$>OA2>Z]4Z__]?:Q_DD_P#;HO\`ES_^*D=-_P#O
M)T/OW7NK1_?NO=56_P`Q/HRHSM#A^W]NT3/4X*08S>'@C:2H.'D4F#*1(H8L
M]&?23:P4^X$]U.3;:6VN=RM;-1<2DLS`9)/F>E\$S452<#JF]2DJ12`KX8ZB
MF\<NDK2P('%A/#PSE1]?>)%C/^[K]UOX]2!N!KT;1,C4U**]"_#423Q596MV
MQ,:*:5X_]QM@\9^ND:=5G'L9"99:2QBD39`\J>G6GIJ:@Q7J;0UM%514NG(;
M#"5T<R5=%-C#'+1?;*3&`3:[.1]?S[?6:('N`ZK]O059?(-D\@\[4>/IH8X/
MMF^RB6.*H\5U614L?20+CV&-SOS922R.?TB:@?+IN0D+4'IIA%5,M/#3!9ZA
MI-,5(5>.>I4FTBIH4E_`O]![5['9R\S'39QFOR_U'HJEGF#&DAZ/S\4OF%L'
MX_Q/UKOF(8S!9?+R9&/=T+-%+29.95BJHLV)E#2Q01H$5P`"JCWU1Y%^ZONE
MK[;\K<S[##&+^>PBFFHRASJ6K8`)+?*G4,;M[HP\I;KN,._NS6GC$+4$@#RI
MP%.K9^H>]MA]T;5S>\-A;DAS>`P>>RVWZG*R.D=)Y\-5&*JK%E.A%I9J8>6-
MFL-)O[#G,'+FX<H^$N]1,)S$)!49TGU%!0CS'ET,^5N<]L]P87/+L))U:>U3
M6OH,M6OEZ]5@_)W^<)L+JO<6=Z]Z:VV_<F\<979'%U^5@JIL7M7;-?0NT,D&
M1R4L8^_FCE'*TVL-;@^X>W7G_8X!);)`K3,:D`'2U?XC7C3CUT%]C/N2\Z>X
M%O8;UO.Z/:[!.M3K:-95/HL3J#I/D3U4MNW^8S\N=_[MVUO:MQ74<5?M&NJ<
MCM5*_K&'<-5AYJQ3'-_#,U7O'5TNJ(Z=4JD@^H`'GV@3WCYDVRQNMKV>1X-N
MF4!XXV8*P'`$9X?D3P..LJ;G^[#]IKB-;R\YH9[Q<EG2WK7SS7HZ_1O\Z;?&
M"K\;AOD3UU2U6'EJHZ"JWQL>28##)?2]1E]O2J9FABOJ9Z?4EAQ[7<J<[6EZ
M\_[^.EFR#Q(/YTQU$_/']WYNVW;=<-R'N(N5C)":VB0:`.(T@Y]!U>CUSW;L
M7M+KR/M#8^\:3<&S:O&R9*/+4TJ^"GI(KS3U$P<)44KQ4RDF*5592.?<FV$L
M6\W4<=CI,=0!H-=1/`&E<GS'7-KG#EC??:B_W#^MOU(@@)++,I!`!R5JJU7&
M",'HGG:O\Q+I&'8*8_8^<IM_;@WCCJZ@I<8Z%$HTJ!-15:[B5;?P]S&6])YL
M1_7W).T^PW,&_2[M^^86;;4<ZEDPJ]M0L55&I/*M>H<N/>WEZ6<_NU0R-\-`
M?A/"M":'Y=4Y912LK3H(X8:NHDFH1$\TJ3RRL6:@C=XU21*>]EL?H/?.OWL]
MM)^4^:;A=O/@V>LT"TIQZE'D[G>UW(QF:U#*?4'J*BNBA9%*R?60'TL'TNIN
M!^0)&'^Q]PJ+I8Y#&V7!I7UZ&=P\<T\LL2!8V:H`\AZ=<K`?U_'Y/]DW'^V(
M]G=O*SC'3/7:V4N5X,C*[G\LZ<*W/Y6_M'<7#I)(K'`/7OMZQB.-0`%-@Q8"
MY_43<GZ_4GVD:]MU)#1`G\^M_GT9KXG=*UO<G;&&IWII'VCMV<YS=M887$6F
MBE1J##PR`!&>ND`+@?@>Q_R%R9>;IN,.X3(6L)#J0'@%^7_%]%$LDGC2)XAT
MUZV-Z2"."EIX8H_!%#%'''$/I'&B!43\\*H`]YN[9;)9V$-N%HBKPZ3LU6)Z
MA5O^;JK?\J\__6E_;&Y:>W2.WZ>3_`>KVW^Y5M_IQ_A'5(^0_P"!61_[6N0_
M]SZCW\E/W@L_>!]SA_R_S_Y.NCG(@KR_8C^CTVY*EK6I=-'424\M1ZHJ@)'6
M4]*K0NDLD]+(";%R"1_A[AGE[<;&RW%9KZRCE@0T(>N<XH`<]&^W[I;MN%Q;
M305$9I7@20010]5<9GX4=H[AKMS9#/;^P62R>Y-M_P!W9,E+3Y!:RO6GWI'G
M\?4"A"PT5,T>-4PJJW`4?GWG9:>^/MGM^V;7:[;#)'X4WB:!$VE:VQC:AU?[
M][A7[>LG+3WDVW;;2QM8;'3#"5;!(`.GNJ:FM>!IY\.E?6?$7>M)O#+[HQ63
MVW]VO8%!O+!8/*4%3)AJP':\.U:A,E0Q$TDCQQ:Y5(^AYO?VLVCWRY0N-GV^
MTFDTW$=J8Y#X9U)W$A$JU"IK4U^SJ]S[L;)OFU[;%>12FY@L7ABG#DO;_K&:
MJ9!JWP]"S@?C5DL7\:<]TI6YR@;)9>BW!3)EL=%6P45-4Y/)3UL<B1%&D6GH
MFDTBQ^@]P_N/O5LDONBN\PEVV99XS5E(K154DK7U&/7J/;CW)6]YSMM_W"=Y
MIE(UZJ%F4+2GK4@YZ!"A^'?8.6W+3YO<&ZMJ5E1'FNK<@M%#15BTT]!U[2&C
MJ%F1D*E\A'8M]+GZ^Y%W;WVY)VN&!;0.J"WN4HL;8,L@>.G=YT(;TKT/9?>'
M8MNV*'9[>&9HD\9E=A0J9*X%#^$FJ?,9Z3E9\#MXSYW$UJ[WQF/JL)N3LG<F
MWDIHZU*>;)[GS=-E,+33H(]`Q&(CC,59"?VY48`#V(KK[RWM_-L=)[9W5X84
MD'A,?7Q&`KEDQH]:=&2_>#L$VF^L_IM0FA@4L:ZD\&$QL_'+L3J7YUZ6.9^'
M^ZZ_)[FSN1S.WZ?(9GNO;._ZJKH:2H@K9J*EVZN(JL;BI4B$E/-'.6(YTB$@
M6]A__@B>5'V>WLPTCJ-KE15*-\9<Z5.>U2`"3Y''2;:O>W8UV_E;;A;&1$VB
M:!@:T=UD\19'&KCZ'UZGT7POW(\>+PF:W'M:?&[?V7NO9^VJK"TV33(9"NRM
M;)F:?);H6;Q05=5AJI(RKWXD'^P]W;[P?(TEO#/9+(=QDD@\35"R^"H4`F%@
M>XD$I0\5Z"]M[W;-#9;G<3;<\QFW*&4EF-(T'8T(J?@DXD"AQ\^D+B/@AO*G
MQ&[Z?(;YQF2RN[-@-B':MIW*4N^LM4L=T;EJXF9],69IU6%M!#60?3V97'W@
M^1H;NR^ECECACN&5B$8'P%_LP,FI4U(^VO0OO??;9IKZ+Z?;HT@@NED`74?T
M4'8@S4T.:?MZ%_&_'/<>UY-[1T]=!4P=@#JS!T\.%ACIH\`-GTL%/D<I(H4#
M54>(L7_5I(N?<;[I[R;-O$NT*M'2S2[=]8(UJ[UC3CW&GD,@]1[OWN-M][';
MSNC&6-YC4ZB?U*T6M:Z17'1@>U>MMP;FFVE6[8R.#CS&V9LW4P4N?I):[;>7
M2J@^W:EKZ$QO%)4T\1,L,G]B0W!]QUR-[H;3L]YO3;K&Z6L@0)*BEI(J&I"+
M6E'^%J^70!VCFFQMK+?&HZSR-&J.H(9<ZB:@UH?AJ.'1?:+XI;CH,S_$8\[!
M55>-PF2V]1XJIUR4[4NXH*Z:NK-+Z5DJL?D:Z]*S`F.DB*?T]R5<^^/*U]:1
MBWVV.">6=&+(K5TII09)QJ4%V_I8ZD.^]WHH>6]LMZRR7#2H\KFI8T8:D^:L
MJ]WSX=<)OB[OV./!X_%9K9GCH,G)F*3/?PRO&Y'R=7MR/`U4#R.KX^KQ<4T&
MN-G8,B,`!Q[/MO\`?+DBVM;J6ZO+N2<R"D+PDQ:$D)KKJ&)TT-.%1T;;7[Q;
M?MUY>ONL+';)+81I`&(CCC$GB`KGM8UH1Q.<]<=@_%?=&`R[YG=VXMNY<U.Y
M=F9<T4<5=4Q#^Z.,KZ"25O+`B,U9/4>HE`#:W(`]DG./OMRK?Q11\LK+&\*S
MT)B*DF4II!J3B@)^75M]]YMFW=[D;3:M$KVSH"E5TAI`P"]QROEGY]3)/BWF
M*6CK:/S;7J:*HACGIX:ZCRB_:UN,W#E,Y0&FK:']VD\:5RHH*E1H'%O;5G[P
M\O[G=0SW6[7$`UY58ZAD,:*PR?-E;AY'I-9>Z<T*6[&ZE:9"0S:@2?$0(2RG
MB`,GSK\NC'=+;0S^TMO+B,[F#F9GJZZJ'VYFJHL93->=*09:IAIYJR&)G-BR
M*1^G\>X=]X]_V+?M[NMRV"T6.T;1@5&0JJQH2>)%33J,>;]RM+^3ZZU6A2+2
M&("DDDU;34D<*=#$-/W*:"A7Q@@QFZ&Z&Y4_F_N'4K^[KFM:^(O'CQZ#5D\C
M[1&\K:I"N3^?5D7Q(_YE5DO_``Z\K_UKH_?T[_<-_P#$8.2_]K_Q[K`OW7_Y
M6NZ^S_+T\?-#_LC3Y9?^*S=\_P#OKMU^\]'^(]1H_P`1Z^%)[KU3K__0VL?Y
M)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW3'D\3C\M19'&Y*".LQV1IJBCK
M*2=?)#)#4@I.C(>"KAN?Z?CVDO[2#<[.6TD4'!'5!,0]",#'5,?R5^">Y]M9
M&OWGU!12;@VK)))DJO;=+;^-XN42-(5QE(?178^*WI3]5N/>-/.GL\997GM8
M\$^5,?X>C.&XH!T10[MW3@:BHI*W%1T>1EE8319'`005,*@Z7@GHY='V\B6L
MR'D'W%%Q8MMJ?1,.Z'L/VKT8@U`;UZ3><S,V8JHJFNIJ"G58T@5:6@CQ^LIP
M"#%J4F_]/84O;YHW(KD=>ZF[2V-NO?\`E8,)LS"5^9R<]4(_]QT,]=3QN6`M
M75IC6&B87]0^@]GVW\M2<VQVD4:U.D=-R_!U<O\`%3X4T76<M+O_`++I:/-;
MW\;-C\):*LH=O&K'[WD\@,<]8`Q#-:W]![R=]M?;%.542>Y4:Z>=.B:2A8GK
MG\R_A)L[O_9F6H]G;<VGMGL>KEIHEWK40RT<>-HPX:26IHZ11'7HPN%15!_)
M/O,;VV]ZN:>4+AK+]XRMLD0TK$:E:#AI/$?8#3J&O=GVYM.>=N@MX(5%V3W'
M%?Y]4_?);&;O_EV]$UOQCV=VY6;CWY\B\Q49;+5>-QQQ\6U-LTN)%'7-CY!=
MX(<Q)$8=7#$(XO<^PA[Y^[5MS;#]==6XCOWB9`2VHZ2?/./]D]9\?W:_W6-C
M7?K*7?T\6PM91)(I52K,*T7R-1@_;T0'K'8,%1CZ2:1))&F6&5WFURN96"^2
M1GEUNSNUSJ)O_C[PVAV7;)6%R6'=GR\_SZ[C<P"QY<FFM+#<?#AB)55!4!0.
M"C/ET9^EZXHUIP3&PNO/[98MQ_:)N6/^O?V([6PV6,C5I/V@?Y^H@W'?+J\+
M0Q;ZX7T#*>@YWKUECYXI28QJ6`A65`&2RW"ZE((`_P!3]/9#=[%<3W%]+9$^
M"6-/L\J='?*//F^[%N-IMURYDL*A0Q)R*X-`*5Z<OAIW'NKJSL#<GQ^GWE4[
M7ZW^1]-D^O/XC4025]/M'<N8QSXJFS]+`S::>5GE\=Q8$RI_3V//9[F8<J[]
M%;[D=4/BJZ@F@U(?RI7UZ@_^\#]AMI]V/;2\YEMK55W:*U99&4`LT;`D`UK@
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MK?#J4KW;QL1Y5L!%"LDTS<?1DC5KL?\`#VS:;>^Y.KC@^>O<>C&=*_%GM3NS
M)49QN)KL!M%IXY\CO#-T[T%.E*6]=+BZ251)7R%0=+V`/N0]K]K9MS56"?X.
MJ,ZH,GJ^3IGIC:736RZ/:VUJ9E<"&HR>7J8ECK<I7QC2U95%"`7;\*/2![RJ
MY3Y=M=AV':;)HQKBA"GUKGHFF:LLA'F>AF33H4)^FW'U_P")Y]B1W#@JIZ:Z
M;*W_`#=5_P!0\_\`UI?V6[B*!1_R[R?X#T[;_P"Y5M_IQ_A'5(^0_P"!61_[
M6N0_]SZCW\E/W@\?>!]SO^>^?_)UT;Y%_P"5>LO]*>H#"1B2!;TM'=69;HWU
M4V-B#[@M([50#))DYI0'/0FCM=O1O%*+XI-2?GUEB::(EK`WT'U!7MH3QI;6
M&`TH;<>],\;?V,I`X=7DBLYE*=M.@I[5[=VUU?CJ*KS6/RE6E4M4M5_#5IVB
MH8:.,RFMJ4FJJ:5(A$2"8U?CW(GM][;<P<[2;F^VB/P+=0Q9G"L=>`%J.XU\
MAT9<G\G[KO.Y7,%@Y8.]$!X4\^`H/S/2$H?E-L>MF=&I=Q4F$@GR.#3<YQXD
MV_75L&/CR34%+5FIB>*HFA8*$9`2?S[%]_\`=ZYIM!#>2^"879&(UC6"<`E*
M<`>)X#HP;VMW::^^JMXE,]-00$:J:RA)%*@5!H?/J;UAW/7;WWCGL0^`RVW\
M3C\)BLDB9JA^VJJF/*)KI)*=HY'\:216(Y/!]I/<#VOEY:V[;6NG3ZTN58`@
MD:>-:8S7!Z7\R\D1V>S6,\MR))GD92%*LM5-#4\:CS'D>F;<'RBVGMV6NJ*[
M$YJF6ESN2VW"9#3(N;JL9)'/7Q8>6MK(J4G'!E=YBZ,0+%3;V;[#[%;WN^W;
M;'$BM)<PK.I!4@(U=.K':30C3TQ8>U=YNEK<1V31%A&K%20#Z`$"ITFN#TQ[
M@^3^(>DQN8VSB\ON#'5VY-MXVNW!#$\N`QTF7\C20560BG6)LBWVS`B-=)/T
M/NFW>Q>Y%=P>ZD2&"VAE+*2OB$K2@"')7.#T:;'[65WC;+&^`BN%LKFBBE>W
M%0#FE3QIPZ6-=\A-JQ3X4RT.>JJC<>V:C(87&4F/E:OSDU?N#^&P8BCIS-:F
MK*NKC)+']2@>]Q>R6X-;CZ>2.OCJI)90N%U5+>2JIX^N.@YNGMNUMLU_'11%
M'?0J^5[2JZP3Z_Y./3+/\EFI]VU>W*K96>Q5'C]C#>%5555!$E=2UQS"8UL0
M]')-$DKQ2-RY>P/MO_6&WF6S^JBO%>Z^O-N$J-%/#+>)XG#2:4KT?6OM:;E8
M[I98&>=^TA@0PP?P@D-3-#Y=-M#\K]KY&,2XK`;HKY4AS:YBFH:#R+A8,'+%
M3Y5ZB>.HDCD\*U"$E6-@;>U$_P!WWF:WDDAN?!5T"G,BT8,*C2:9&#GR/1K/
M[5W"EHYF@\,,H4D@$LX[5(-*$T-!Y],N(^6%&9=PME,!G:2"#>]3MC;K1"*$
M9C'KB*#)?>U4V5J8*.B+I5B\:2!R!<#GV)KG[O<YVO9H;=0=SGLA<-732H9P
M16GX=/#CZ]7WKVP_=EOL,ELUNYN;4R2+J`T=Y4$!<L#0Y(XXZ&7M/M6JV%U!
ME>RJ#$566FI*&BJ8<:CWFE@KJFEIG35<EC'YOJ"?IP;>XFY+Y"BYAYNCY8DN
M0C>*ZU(%%*JS$G\UZ!&S<M6U_P`P7&R2:1'&2/+BHJ`/MZ#K:/R1\V[-V;<W
M%MG.8V*CW=G-MT.5AH34X:9L=@<9EI,%4SS3QO39I&JS::)##:P)^ON4^=?9
M-+;DWEW?-M85:*-G)*KW2N5[0*EAC/H#GH^W_P!L);[;]FFM)89$GM1(ZAE$
MB_J,BDK0]A`J#Q)K3J!0?*VEW/O;;>U-M;5S59+D<\^U=S":HBDGPJ5&*FRN
M/KWDI*AJ66-%I&(:,VY-^;^TUS["-LW*&\<P7LL=;:/6-5`')(!"DT.H5P.C
M*#V;N.7.69-TW1HXR+<3KIHW:'*$'`PQ(!\^CAN0@>!C8+)K9;L"S`DJ[DL6
M9M)_)/O%Z='2<R)73P!^7IU#D%O/(1>0G]%\@5ZQ:5T@`D*-=E#%5L_+\`@'
M5^?=6N)G`5GJ!TODADN`1(*G'^QUTC:JA#Q^@J+``65"!P+#@#V^"38718YU
MKTJ6+P+$Q#@!U9)\2/\`F562_P##KRO_`%KH_?T[?<-_\1@Y+_VO_'NL`_=?
M_E:[K[/\O3Q\T/\`LC3Y9?\`BLW?/_OKMU^\]'^(]1H_Q'KX4GNO5.O_T=K'
M^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]UB*+=FTC5]+_`-1_3VS#022T
M'GU[0M02,]<$B0&^@`@L0>;C7]?]@?;TH#J58XZ<8^AZ#C=/4/5^\_(VZ]B[
M:SKLTA:6JQD#U#&0W<R31>*9W8\DEK^P=<\F<GW<LLUUM=N\[-5B>-?4]W5A
M/<`4$AIT&U-\1OC?!+]Q%U-M82"0RHLD=4Z!OK=86JW1`/Z?3V6O[:>W4I_4
MY?M&/^K^EU[Q[C_?K=#9MW9VT]JTBT6V]O8;!4T48C$>+Q]/2>D#2`SQ(LLA
MM^6)/^/LXV?ECE/;':+9-J@@F3%4&0?VGK;23L%!D-.E'$D2V"'@"P_UO]<F
MY]B<12IJ,LS,OH>FW#TSU$(B8R*%`TSL?438EN6-F)!!)]OPPE%+-(6C85`/
MD/0=%@:28S?3QZ9(Y*:A\NM2W^:S5U66^>&8Q-694H=N;*V;CL5&\C>&6CRT
M"9:M\*EK!:;(#62.=1_Q(]X_\[P2[ES";47!\.@HN*#_`%<>NZ'W`[#9HO8[
M<MX.W1_OWZB8F:AUT44`XTX8X=+_`*/3KZ3!8"AJ=L_Q/+-4M'5B(%6FC05?
MK'J'I/AN/^63_P!1[,+#;MLAMX;::`/(BT)]2`>@[[@WW-LE]N%T;]A;O(3W
M$>96GE]H_9T:X87;$=-)7+L3*34=+35<BQ4]/2D.OVRO"TLCS@LRDW!-O9O#
MMNRM\=DA6GI_L]0C-OW,%BY5+QA*2*Y^>:8].@RW;2;&P]53U6;V*]+325&1
M$Z2@"E1)8_\`)ER"*Y#F`B+])M^XWLYL7L+:*Y7P@(E+!1Y`4P/]7KT/>7M]
MYOWC;W-OO#F9`NG(JI!&1CTK^P=4_P#;#Q8;>&.S&($?W>+W'09G&_9>2-9*
MFCS$,E+2P`-J4,\A86YX']/<,S7D,N^D^&&TN:?+Y=9M\N6ESO7L_N[\T3M=
MLT!!\7S4*1FE.MXG8\JU^RMHU-6K_<5FUL!456O7J,TV+I99+FX.H2.;GZD^
M\DOW5#>06K7`UH%4@'RP,=?.GS!;"+?-[%L`B?52@4]`[`?RZ5KQ1*=>D-Q:
M]K_BW/\`L/:N6]%JJQA#I&!0'H.2"<J4DD)C]#UBFH*"NIWIZRBIJNEF!\L%
M5`E1#)J%B'BF#QD$?BUO:.;;=MOT,US:HVO)U=*8=21H(WH*<!T"V?\`C'T!
MN:HDJ\YU;M*IJ))&D,D=&U(2[<DZ*66&-+G\*`/86O\`DGD&;-[LEJQ/K_T5
MT[XUP?\`16ZS[9^.71FU*M:O`=9;6H:J$WBJ!CA,ZD<@ZZB6?7_L1[:VWD'D
MJV;Q[?;+81$U51^$>@[NM^-<"H\5NAF@HZ:EA2&"*&""-0L4%/$D<,:CZ*D4
M85$`_P`![%P&V[6G^*VZJ*?A%>JZW8_$:]38T41HH'I`X!O_`,3[6QR+<Q)*
M5PPKTTU=1KQZYV']/=A&@X+UJO357?HJ_P#J'G_ZTO[+-T^+_J'D_P`!Z>MO
M]RK;_3C_``CJD;(?\"\C_P!K7(?^Y]1[^2;[P?\`XD![G_\`/=/_`).NC?(O
M_*O67^E/4<$V]X_.!J..A/\`3P.*O&"3UW<^ZT'IUM+:"/X(@.@*[?Z.VYVO
M+12Y?(9"@JHZ&MQ>NAFIP:R#)((Q%)]Q!/XQ31@J-.D@'W-GME[M3<BPW-NN
MVI*ATG4=5>PU`QY'H5\F\]W.P7-[;V)8"*340*K0@5)!'$GCZ=-E)\9=B1;>
MBQ%53U\F-&Y:C<<OEEBG8Y6;'1XV:"7C0U.:6-2&M?G@^SB_]_N8+_?#<LQ6
M(VXB`#,:"OQBH^+RIPZ=F]V-WM-U\=)W%V4""E::=>L"H\JFM.GWKSI;';`R
M-?FJ;<>XLQ5U=!3X?7F:E:C[?'T`,>/I($955:>@C],?!(`^OLMYV]W?ZTO#
M'+MD89//NJQH!J:OGBOIT@WOGV&^M5LFV[1&LS2&@8]S&KG_`&QX])S<7QTV
M9EJ2&*HGF:HI,]E=QP5\*T<[15.>"+E:2*EK:>II3]XJ`.S1E[?1A[..3OO`
M<Q\MW=O);EEB2V6`+5J44&C4H<BN/+I7M/N(T=Q/)%9L$DC5"*.M0AJM6%#0
M>E?MZC5/QDVW5R4<(RV?@QO\2Q.;K=OPUM%3X>KJ]NQR+2UD]%3T\=/]S(DY
M`(`O[47?OU+)+N$MQMJR7DP=&F8OXFF6F*`4[:>GV]+?]=XV]ZUR^WI^](8I
M(HY*.2JOQ0$GX3YUX]-L7Q8VUY::J3/;I-71T<.*VQ6'*0FHVTM'G&W)0S8^
M0QW@:CJ2R(QN?58W'M<OOS#+;M:2;/%])JU.E7TR?I^&5;Y'XC3\0ZU<>Z4-
MZD4<VSQ/"\H>8%6H[:-))SQ^SRQU*RWQGVYDHZJLJ\IN>:LR.'K<=DJZ7++/
M49&5LM%F_N9O,LB@PS0A`JA5Y^GM#:^_5Q;+]%#8+]&LRNJ$N%4!2H3A\)8Z
MSYU^75[#W)N+:Z9=KA2WC60%%C!&D:-+4K4U(QGRZQ[:^,&S-NT^;_AT^6KA
MN/&;OIZSS311DT^[&I:C<:!:=((@\$=-&L6E1RO'/M5S![_[UN\UC));JAMS
M"``6HWA]NDDCX7XM3IN\]P-P(U3R.!XBL:DL0R5\(BN:Y/'@#UD_V5G:D5)5
MXF#*YR/%U]?09AE>IHJF*.JAV]38>61*:MIJF..:LAI(C(^G7J^A!]JX/O*[
MO'-9W0M1XT44L=*O2DCL3Y>5=(_H];'N.US%8F>W62ZA@\)6-=042%U%1P`J
M33UZ$*NZIPN2Z_'6U3-D:?`_PJEQ33O5>:IH8*:6.H\L,K%F:>>IC#&][?06
M''N,+3W#?;^9'YHM=MC^N:8NWQ#56H*FGE0TX<!Z]$L&^&VW*;=;:W"7+,S$
MJ""Y;`).>`X?/I)S_';:N1I,I35U9EIIJ[=>5W77Y%:D&J;(Y[%T>)DDB(_2
M4AHED:P`NQ]BN]][MTFMMEMY[539PP*BQ$MHHCER>'%JT/R`IGHT'N#?;,8[
MBK&V$*1(IKA48MIQG2"QI7SZ8-I?%K:>RMUP[FHLCF*C+4N2P63-;-54L2U%
M/AJ&KP[XTPPPQQB.>CK6+<7/UO[/N;??>3F_E"79);!3"8V4*=>D.Q!##YI0
M!?Y]'6^^ZNZ;]L<FW@%;"2%T*@EN+!Q6M30D9\J\.C3-:1V<KS?2#<,66/\`
M;1KK8'4J@^\8_%DTA=1T^GI7-/RZB_;CIL;9432@7`],]=_X?CVW0>G2OKA&
M+3J!]-+?]"GVI_X@7/\`IUZ]-FWD/5DOQ(_YE5DO_#KRO_6NC]_3M]PW_P`1
M@Y+_`-K_`,>ZY^^Z_P#RM=U]G^7IX^:'_9&GRR_\5F[Y_P#?7;K]YZ/\1ZC1
M_B/7PI/=>J=?_]+:Q_DD_P#;HO\`ES_^*D=-_P#O)T/OW7NK1_?NO=16D5Q=
M3(5UNC%/3I:,G5J)_%Q[:D_Q</(3\^M^G1&OD7\U]I]/R3[=VP*7=>\],D+T
MJ3*N(Q=1$2DBUN00E'JXG^L(Y_'N(.;_`'(AV4LFJA'EGJY(2F*GJJ;?7R[[
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MVOVUL_IW;M3OC?N5;!;1Q]8M/DLW-#-/18MYV`CFR9B4M'3.U@&`.G\^Y.Y.
MV7=>9KO<-LL(A)<1%M*UHQ11G2*9(]!T2;CO6U<M[/N^ZWCA8HJLQ^=/MZUQ
M?YL$.Q]^[PZW^5W4.Z,+O7960H8]B[\R>WJW[K^!UT1EJL?6UJ(A,`JJ%M(+
MV(6"WY'N$_=/D/?.6[D[VUM-%3#:E*D>A%1G'75/^[`]]-@YQY>YBY)M[E):
MDO$/+-"R\?7U]1T7;J#LJ:@6ARU+5TZ5$=/%3QP&GU"(,MM:FX!U*U[_`.)_
MJ?8!V_=I3'#.P[RN?MZS8]P^2+6]>^M*=@E-"*>1K3[*@?LZ-_CN\=PP8V;'
M#)X^>FEC,512RTA,3JRZ60M<,05X^OT]GD&Y-2@/;UCAN?M@MU<ET2D@.#Y_
MYN@B[/[BRF<HOMLG44'@CNBQ4E*PL$%E+$MRR@#ZW^GOR[LSQWL*\:G_``=#
MWVP]NS;ON1DK^FVGRR`*YZ*CU9L:;O7Y*=>[66IIJ;;]#G\=NG=^7RCTE-AL
M%M[`5RU59-E)6D585K5IQ!9RMQ4)_3VCY"Y6;?-_/B1EHE;4U!6N?3^74A>]
M_/\`;>UOL'S1?>)HD2W*K3CW`TI]E-7[>MO+K/Y`],=B9>HV1UKO?!;JK]NT
M,<-1!@)GKZ3'4]*HITCJ*N%3"C1^/2`"?>2]QRKO=A:#<9A)'8ZJ*&&G'```
M@5Z^<>QY]L]]W6Z`D#2/(6J,@ZC7[//[.A8S^Z<)L[!U>X-QY>GQN%Q]-)45
M%95S*J.L:%[1E]+,[6L!:Y/L);KS!L^TBFX3!&''_42.AA.JRQ,RJ*TZJ/[B
M_F-;FRM568?I>BI<7B$>HA&YLSIGK:J!6*I68ZE`M%>WI#`GWCCS/[L[@NY;
ME!MDI-B)2(R"?A'"@H>G[>V'@0F@KIZ(]F>\^W]TRO6YCLG=E=).YE9QDZJB
M0LQN=%/3-"L2C\``6'N)MUY^YFNV)\9Z?;_L=/\`TYZD;>[][KV?40R[<[)W
M/23^45#+4U\^5IZB,<_;S0U/FLK?0CZ^VMN]P^;;)XO&F?Z<'&3P_P!YZ]]-
M\NC_`/2'\Q3)S5U'M_N:AI88*N6*FI]SXBE9*F%S9-5?B;D^$_5IA8#ZV]Y$
M\E>Z.T7<21[M,`].)_U#JC6AXKQ].K8\%G<7N+&8_-X2NI\KB<G3I/0Y"BG2
M>EG@<:DE5E^C-]"/P1;W.5I<V]Y;0W5JP-M(H93\CPZ+G%'8?/IZ1UD4.INI
M^A_V-O\`B/:CJO377?HJ_P#J'G_ZTO[*=T^+_J'D_P`!Z>MO]RK;_3C_``CJ
MD;(?\"\C_P!K7(?^Y]1[^2;[PG_B0'N?_P`]T_71OD7_`)5ZR_TAZC#Z>\?W
M^(]"U?A'7?NO5N@>[6WQG]L/M3![?@P\>2W3E*NFI*G<%2*/$T*4](TU36/+
M835DTVFPB#J$/-O<P>W7)>U\Q,\VXSR)"J#5I776O#Y*`>)/1CRQLMI>7F\3
M32E8EBUMH`9RVH"@7B<</7H!ZOY);GI(JZOAH=J/@\`-L87<4?\`%\A65N8R
M.YX:B.BJ=MF!%CEHZ&2G5F15)G)(N+>Y/M/9KEQE4S7$IW,S2&%50!65&%2Y
M)[>/^JO0SM?:^SWK>K5(+B33.KNK-&HT+'0G77@QX4.1TC<I\@.X:ZDVLKKM
M3!56XQ@\TN01LG)#C</4[KEV[5X^M>Q#U<D<7EO]%U@?CV(1[.\@B]N_'NY&
MA77&5$8U>/X0=<5KIJ<GTZ$]K[>;%:[ENMI</)*]KK#`J@4Z4#U4US4&@^?3
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M4,1``%6H0.`K2HR.A+<^UNP0W;VL5P^F&,LYTJ`U'""ASDL:<*4%>C8IO_=&
M<Z)J-]TN.;;FXY]F[AR<%%D45WH\M1BN\<*QH\P5:IJ='(+,1]#S?WCM<\B[
M?M?NQN7)]_)&UI;7L:-H(*LAT&@SQ"L1@]18G+NTVW/%[M<,K/`MVL=:"I#`
M9/E@]`1LCY`;\%-MA<RVVJ\45+UU0[DE6JGI\IELYORF8P3X6B5@)*?&S\R(
M!:I:X-K>Y7YE]I^51:;M)MY<%6G,(T5&B)LZF\L<3Y=#/F?DC;;2W\?QY0TI
MEHNA=($5/B:O:QR%!\L]"?W-W+N?8N0K\3M>CVV:S#[1K-TUDFZJG(X^2MI:
M'(08^JI,;`A,;UI5VF"`G3I`]A/D+VSY<WZVDO-SN9(XQ+H`1`Y+%216IQD4
MK_EZ#?*7(]INLNW,Y8&YE"*44.`>/<1\*TQJ/0';9^16^IVW%$@Q53/1YO<^
MZIQNFIK:-H=M0/MZEQ>'VPM.--54M+72R*DUF*_X>Y8WGV4Y1M]HLKF8K!+]
M''A%#&24L^6!.*@"I\J=2+=^W-A;W<<<DLHCD98HC&@92Q5RQD880`K0'A4]
M>V_\DMW;9@R^X=PRX&KP55NC=..H(\AE:FFW%@?\AH:S'UN7A1)Z5<9$LY1:
M9%U?VM7X]EVY>S'+.Z[+L%C;%DW@1*'5$U(:,VIM=<UH*'UQTUN_MI8[C)#;
MV@<(D,!?M4HVMRO97)<$=PZ=>O\`Y";Q[#[.V+MRNBDQ?V.Z=Y8_-P4BS44&
M?B;9$V0PM14XFK\U331Q31>6-"_YU?0V]ZYG]H.6.0N3^;;R>)9_"CMS%(R]
MT9=U9@*&A.DZ2?3Y](.:_;"+DW9[.[\8&*6#52JD460HV5^?^#H_I1T)22VM
M25("Z0`#95"CZ!5L/>%EQ)#+/++`*0LQ(^SJ'8'BDAC>$UC(P?\`5\^NO;/3
MO7%/^!"_\%;_`*%/M3_RS[G_`$Z]>E_W&DZLD^)'_,JLE_X=>5_ZUT?OZ=ON
M&_\`B,')?^U_X]US]]U_^5KNOL_R]/'S0_[(T^67_BLW?/\`[Z[=?O/1_B/4
M:/\`$>OA2>Z]4Z__T]K'^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]T1WY
MJ?("IZ;V(F"V]5Z-[[ZJY<1A_%(J2XO'RQO]]EG/^ZO`EPC$?J]Q)[N\QWFS
M;3&FV7K0W#+DK2O\Z]&=O#&ZJQ0::?SZH&J:V2MJ:BMJ*N2KEJYI*B6:H#SU
M$\TCEGGGUZ@9Y'Y+6N;^\4[FYN-YMGFW65IWSEO]BG2CZ>#_`'T.ACQ]/U+4
M8?&??9/+T&2EHHS]Q34\M;]UET0&OHZV)B1%31N+)]/9C9V-A]);`6B4T#U]
M.GE`4``8ZSR8WHWPTYFW=N2F\-+]Q-]MB(!JJY%NM)('<LL*/QSS;VJ^AL/^
M41/Y_P"?KWY=)#=U#L'[#%R;-R^2K<A]O$^3@R$0BB2JM^Z(EL0%O]`"1[#>
M_P"U;<\8=K1#3[?\_7O+AU@Z]["WAU?NZDWKM'+1X?+T\"4TT<<;5$-=`H]4
M533(1&0XX-Q?_'V(O;WF*'ER7_%'\&GIUZBL*-D="]NO:_RC^?><?:TVYJFC
MV4J)69J'PRTNT:&*8AJ9$I4TI4UG`UHY?3_3WV3]E?<7VNY9Y)V'F@[5"_-9
MM06G4-XQD<9'Q%?SIY=8?^X6P\W<T[SS#LL%_*=EDN'4Q8T%.%#BM/SZ/7\9
M_P"7UM;KSXQ=H]%]M8S$;O'8>[LQ7[CGIX!#"U&D<6-V_E*"Y#4U128NEAJ$
MTD:95Y!N;Q'[O<XO[B;O)<W=Q)-9RQA=+FN":T(\BIX_9QIU//W9TWCV#:"^
MY7NVVW<(Y?$UQ'22:4S6H-1C((ZI(^1'P#^0_P`8L[D*S:&*S7:'5WWU4^/S
MFVHZC*;EQ.,1V:DI,WBRD<DDD<%@\T`8<7`]XC;MR!NNV7%[>0/KL"Q**M*(
MODM...N]OL?]Z7D/G[;-OL.;;M$W\H!(TQ[I'\W#5537\NBJ)VUFL4L6.R6.
MSN.KA>,T&3QV6I:]G7T^.F@FI!-4D?3U6)]QS;[GNVV;B6O-N>6S!^$AR/Y#
MK(N-N1]UN42QW2!-1P0R`?S?H1>O.H/DG\F,[0[?ZVZ]W.]%550AKMP9W'UV
M"V[BJ5S9JVIR==#'*TL:&YBA5Q_0^QXVW3;W$ESLUF8?&`9@`12OKJ_XOH(<
M\>[_`+8>S%G<3;A>6LMT2U4!U%VIYB-B:^5<=;`7Q^_EI;-Z<^/G8NR<[%1[
MM[,[3V7FL3NO>CRF1X*R:E>;$T&'FD$=1!C*3*Z)$O9]2^HD<>YR]K;->439
M7-S1[GQT,A(^)`V1]E.N+OWI_?SF+[P:[GR_L%_+MNQ,C+%%&V%+`JSMJJ*D
M&E#@"M*=5\;6^(7RH^%*X3L':6XJB*FR-+3MNU]I0F=\;/$QO19RFT.E921@
M`LZ@7N?>=VU\^>VG-^U;MM/,FW0R^&K&'Q`W91</'W`8]#GKEHG)?.O).X16
ML&Z2_I,$9U*G50^9`IGY8Z5G=GR4[-[LQN)V[O'(4#8K'0Q-418E)*&DR]=$
M.*R6F!#(6(Y0FP/X]\7_`+P>]6TO/4VV[;.6VM&"T\CW4J1]GSZS-Y26XDV)
M)]T8R3%<D_(?ET7C07822QJLM@ILJC2!QI&FPL!_3W$+W=M"S1(H"K@#H\C*
M&-2HHM,=9``O`^@^@_Y'[3-=DCM/5NNO[+)R%9BQ`)4D_P!;BQ]JC-)-"D<C
MDQTX'K?6,1(K:@/7_P`=-3&3_6\A.NW^%[>TJVELA++"`>O=6-_`SY#U>T-V
MTW4VY\A-)M/=[53;9GJY_P!K#;AH[+)0(&MX*6O^J"]B?I[G3V3YNWE]WN]G
MW7=9)-IA(2&-J:8U`P%P,?:3TDN($(+A!JKGJ[J/59.?Q<VM8D\GZ?Z_O)QY
M9'O4,;GZ?T\NBPZ:&@Z;JR_CJK_7[>?_`*U/[:W7XO\`J'D_P'JUM_N5;?Z<
M?X1U21D/^!>1_P"UKD/_`'/J/?R3?>$_\2`]S_\`GNGZZ-\B_P#*O67^D/48
M?3WC^_Q'H6K\(Z[]UZMTG=P[6VWNRC;&[DPU%F:(RI-]M71F2))HQ99HK,I@
MFMP70JQ'U/L4;1OW,.Q0N^T;O)`KK0A2N1Z9!ZO837NU7K[CMMX\5T?-:5H/
M+SZ3U1U-US6UN.R,VU,%][B:=J3'3?:HOVL!C,018@ZQ2&.-B$9U9H[G21?V
M(;;W9Y^METKN\["A\AP8U;.CS(STM/._,-GX\2W]SID-6H6[CZU`K]M.N%?U
MKUNE%34=3M_`QT./Q<%'&U7&!3PT$>1#Q44;&51Z:]Q(#<MKYO[;B]Q.<Y;N
M2\^JG-S)*3@5);10M\/\..F++G3F2\W"_N)+RY\61ZDT-2:#)J/04^SK)4=3
M];UF.AQE7M3"55#2QU\,$,T1:.-,EI&1T_N\"N"#R\^L`7]NP>ZW/]JKQV^[
MW*(Q4D#STFJ_A\CGHMGYOYCFWH,\TS%F4DFOX1V^5.WRZAS=6]44^)CQ=1LS
M;AQL56^0/W4#I&E8PTO4K5>5I3=/3;5HT^FUN/=(^>O<2XD9H^8KB.-B#I!7
MUJ!0K7CG[>A+#S'S7!>27J<P70.F@5:&B^E*?Y.L"=/=2Y2EF0;2VY54%;24
MU&T<:%Z1Z6CF,],:91*J020RWM+&$EMZ=5N/;[^Y_N18&YA7>[H%ZZS0=U>-
M3H\^F;_G?F>U>'<TW&Y:[0'2<@BO$4`_D01TN8,/@J7&KMF@AQB8ZCI6H)\'
M`(5@HL?4ZFI`T`/H6LB,B'\MJ)^O/L.'F#>'O_ZP312G=I&#&8J=3,M!6M*5
M6BCAT%$WC=+JZEWF2-Q?3OK9^[4S^IJ.(H#TDZ;JWJ_"5>+S%+MG;-'78)(L
M?BJJJIXR*1*]I$I(X7F=@TU*K$0LVIXO[!7V(4]T.?Y(Y;0[C<M;.DH*@5JK
MYD![>#<3Z]'&X\V\S[M;36E_>W$L4K!G!KW$"A)H/,<:=!SVGT%1=I9&CJ:[
M<5518^@@JJ2MQ8PU#DXZVCEJ(%FIZ&NJIH:G#UD]/$RO57D1E-@M^?8LY2]S
MI^7=I^EAV)7F&F369)$.L`Z20`0P%:TQGHWV+G_>N78([?:[>")PU=1<JQ%*
M:6!K@&E,5Z6D74'5T<5''/L_$U*T%8:ZD=J"0.M3XHJ99Y&UAYY&IZ>-6UZD
M8J#;V1;G[M\[WC&,;G((12@)&!Q'%?*IZ=;GCGIQ(8]UHSII:DH`H232E*"A
M)^?SZG#ICJR>HK\BNR\`M1F(:N+(O]FJ-515RB.K2:/6%O.B`,;`V%AQ[+HO
M=SW"L]`@WRX30-*D4H%K6@.GA7/1?'[H\YVSQ;?+N=R!;NI4J20&7*D,%S3U
MKUSV[U)UKLNNI<GMO9^'Q>0HYI*FEK:>.9JJ&>6CEQ\DRS2S2N7>BF:*[$^E
MO:+=_<OGSF>PGV;=N9+B7;)::HF*Z6TFHKV@X.>/1CNW-_,G-=HEMO&\SSVZ
MH5"N10*QU$`4&"17H2`VL:^?5<\DDW)YN3S]?8$:,Q,8S2HZ#%M:Q64$=K"H
M$2"@'\^N_=>G^N*?\"%_X*W_`$*?:G_EGW/^G7KTO^XTG5DGQ(_YE5DO_#KR
MO_6NC]_3M]PW_P`1@Y+_`-K_`,>ZY^^Z_P#RM=U]G^7IX^:'_9&GRR_\5F[Y
M_P#?7;K]YZ/\1ZC1_B/7PI/=>J=?_]3:Q_DD_P#;HO\`ES_^*D=-_P#O)T/O
MW7NK1_?NO=:[GSPWE)NSY#;NH#)++0;:H\=MRGB9R8Z>6,WKA"`1H\TJW:W/
MO#3WCW]YMXO;+5B.8K^SH\MQIAC'RZ+QM3PO%&#/MT2S9:-`N45J>OE5J?(/
M]O#-S']N6A7FWX'L!0*1LP<^:]/>5.A$\=1%3N:C"]?>&KB1*A),R%=YE^C.
MT94B2_U*VN?:NUN"+:`>BCKWY=-FBLIDJ*V&#8-+1M]O1U-%-4QU$#%2%,NI
MU:1A;^U>Y]J/JCU[J+N3`-EXXTBJ-GT8I*MM%3B*\0//&Y_8C<&X$'/!_I[1
M7K_51^$./7N@VR>,?%Y)\9-40R2QQEZB>EE$L"S@7:*&=;"1+_0_GV$YMLN(
M6+QG'6NK9?Y9N\)*_;_8VQ'U,,#D<?GZ9V(YAS%.L3PB3];A*NFD-B2`2?>4
MGLKN^[-!'8S.3;(N%KC_``=%#V=K9R2W3*`\CEB?MZM1\:R($4W<7;5]`"PL
M?\#_`+'WD%]3_CZ^(M`.'17?-]=&R6[=WKTV5-$OA=9HTGB19'D5KS:D47**
M@8&YM]/;>Z7OA7-G"K%8W(KCC4TZ;V^7>=MAD8.3HJ1G-!D4QUKZ_*KYA=C;
M,^66T-L;1^/N*J]E86JCHJ_;FX=E8J7<7:=1F,DN-@R^+KIT,^(Q5,P+TTA(
M:8BWO,'DGV.Y7WSVXO\`?MXW.-;MB155C<0Z<BA)&2/B!X5Z@OF;[QGN?L&_
M-:[:;CZ=#@>+*M1]@&.KY>MI:+)[4P>9IMJ_W1_BF)I:UL%44ZT-;BI*B(-)
M0UE(ITP3T[$JP]XH7FT1;1N%_$LX>)92!2FF@."*8..ILV;F_F'FW;[+<]]#
MCQX@Y+LS'/KJ`/2YAIXTA>,0Q!0.!Y"P/-QJ8DGZG\^T\\QN$*6\QU_X.C1(
M;:V+2V"#Q3QIY_X>@/\`D/N:'9G2'9.X6A0B@VYD:=45595GK(30T\HN"&9:
MFI1@3?D>P=SMOU]RQL8NHY3XA2A/G4UKTDW6TBG@BFN(1XK4K^?^;K6L>1J@
M!Y/49+2M<`'R.-3DD6-RQ/O!3=IKC?=VFW*<EF+5-?MZ&D%ND?+_`.FM*+CK
ML"P_UOI]?][/LL^DDDN'Q@MTBM:_3P@\=(Z7FW>L=U;KHZ+(X@X]XIFKH4AE
MR5)3M+())UA\BRKJ5D-.?8GL]C>10Q&.E%.H&Z=@;NV=3B?/4'V<4^6EP$+1
ME*K1DJ6-)*B9WB.EJ-U<:7``/X]IIXOIYI8?X33KW2/5E90R,77Z:BI0L0;$
MZ3R.1[:Z]UFHLG/B,CC\M2-)'5T60HJN*>)BLD,F.JHVC="/T,BWY'U_-_;N
MU[PW+^YQ7"-I\1@3^VG3<OP'K::ZVW)'NS8.T-R1DL,UM_&UVHF[,TM,FMC^
M"6=2?>>/+5S];L-E?L.YXZ_RZ)G4ZCZ=**L-XJD_UIIO^M+^W[Y_$CCD];:3
M_`>MVPI=6P_IC_".J2,A_P`"\C_VM<A_[GU'OY*_O"?^)`>Y_P#SW3]=&^1?
M^5>LO](>HP^GO']_B/0M7X1UW[KU;KJ;2(21;5;_`&-_Q[=M"PN8]5?#U9^S
MHNLOJSN-UXO^XU<=5Y=D;J[>QD&]<I09S<4&-A[7K\!72//5X^#;6RXHH3C,
MAC%H,96Y!:>:H)4U,*3>3D,`.?>;W)6P^V,PY8BW':;9Y38)-)W5,KL&[7[Q
MI/\`1%"*=3KR=!R;*%&]A`ZVQ8`H&+O4`CN8`Z1FAIQKT'>ZMT=N9/:U%2;R
MS.X9<O)#L>;:V*PN-R,>&W;C:_*(=R93(4]+1/*U715"PV:9XC3K=F7U6`U@
MV/VLC>;]U[;;1S/-*1*6'Z00$>&*N1WBO')I@]"3:[3DFPYAW-%\&;;%64%V
M"B1&"#PPH#TIFF.-,=*N3?/<Z4&33#;@W+D=Y)CY_P"*[=R6,:##XC=ZY>>F
MVMA:*>6B6DAH,M01@54(E</"?/K5K*2BXY?]KH6L%GV*W6`%E,JR:C("JNS%
M0_"(?"1\1[".B$6?)LVY&V::*.`.M'"C4T96K.1K^,'('ET:S:F1W#5=$#+9
MB:OJ-Z/M3<%5EH:FGCCFI=RPX^OD@QU##IT&F@R$:QPM;UJ%8\GWC5N5MM:^
MZ=U8V<21\N?6QI'0U#1%D[V/`$@U(K1>'EU%NZ-]/S?O,5B@^A6X'ATX:*+D
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M`]1:SL'M;<^7R^+>HW;D\8D]!D*W#S4]1593"YG$;K%,M.87QU)B\<9<=>0"
MGGG3QD&][^RZ^Y?]N]JM=N:"TMXKIE*EPPI*C1ERY.LYIVZ:#../1AMMER/+
M'&_T]NNX1*X=,!26CHH#:ZL-5&U&AKY4Z<,;VCWEF]V93%46X=YTN&JI,"M4
ML='4UN0V[KW?_"<A3">JQ45%2(N&D$Q\#2J%-QS[L_*7M6NPVUVUA:/>*,U:
M@E73K#_VE0?PD#SQQZ,I-@]M6ALYSROMDERB3&0LVDNP@J`U)*M1Q4'!/I3H
M2\9OKL6ESE;A-X=@;[Q>U\1GMR8/:^8H<7)69O<F4Q&1QBX^FR-8F-=:VEJ\
M?52,#4+!"-%@QM["^Z\L>UYAGOK#E>RFDDB5V3Q#I@1@P+"K@D@J,&ISPZBJ
MXV?9I)9+K;N7-M*SQ1Z8VD"!"R$DJ-9/'TKD#J7M;>_=-3W9F*+-YZ>'!45?
MEJFLQ-30Y"&"/95%CZ6:AKUITH?X10UE15R2+]S'423-:PCMS[UN/+WM1#[=
M;3<Q[3`-S=/B!))9BPT4U^6"!3[>CJ^VGDJRY+LV,Z)O2Q(6*A&&LN04#:]3
M+09J`.CZ8F9*G'TM89C/#4T\4\4K1-"7CE0.A,;A76RM:Y`+?7\^\+]\6W3=
M+B&P33&K$4'J.(\^H0NI7=_#M6!?4>!'KCABG4\:?['Z?Q[+"'!(D^/SZO&)
M`BB8_J>?7?O75^N*?\"%_P""M_T*?:G_`)9]S_IUZ]+_`+C2=62?$C_F562_
M\.O*_P#6NC]_3M]PW_Q&#DO_`&O_`![KG[[K_P#*UW7V?Y>GCYH?]D:?++_Q
M6;OG_P!]=NOWGH_Q'J-'^(]?"D]UZIU__]7:Q_DD_P#;HO\`ES_^*D=-_P#O
M)T/OW7NK1_?NO=:TOROQ]7C_`)%=M0U<;1F7==9E(M5[S4=12^>FM?ZJ&:X_
MQ]X%^[ME=+S1NTM3H:Z8CH]A_L8_]*.@SV751*](]1+MRDB;)P4ZC+T;U-?,
M_P!IE`(H3RL<5S8&U_:2S"OL:X_#_DZ=\ATM/&9HS3A.O)O'4E8J1XG24`-P
M'+']5OKS[56T=N+>$%!\(Z]UG$D6/R$]%7KU^D=13^448B9X(G`X62][%#_C
M[>T6_P#`.O=-U3&,I392F4[$I4K:>G@%?!((VC"$"0TXO8`C_"_O4L5LB:XX
MP'IGKW0793%08JO;&QUD571+'Y4KZ9S(LA'^H>Y)5B./85OY;@.1',0O6NK,
M?Y8E%.=R=K5WC9<>N&VPB2,+:Y369-I`?I<W-S[R#]BIY;N:6(,=40R>D]\D
M$\*QRH&/`=7$PA/&&"`,UP47@!;\%M1X/O)"Y2*"833/4?/HD^E2V8K;H%^S
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M=&'04S1VB]4,H!6:-T:)S_9!TD^G_8^Q187UE<`/9LO#R_XOI^.%;8UA72?E
MT6#YDXZJK/C9V9!21#R+AHFE@CO:5(\MCF#!?J;:;CV!O=*`W>PNCG6M#U=R
M9Z^-W4/^#K78C)*+<6-K$'Z@BX(_V!]X*,;VWO98A*PBU''ET=6\\I@%N9#X
M-.'ETK-E8O`Y7+U-/N3+Q4%`E,[Q"6H7'Q&954K_`+E7#1B4F8_LVN='U]B.
MW\,!2%&NG3P"J`%%`.A:PVW]K118VA@[AI*>C,U5*F/CFK8YJ*3[2>4+(\,6
MEI!+*SW!L2U_8BMKN1``KT/6^HN8V_MS*)/%DNY8JX2460K'DJY)YCY,9H2G
MI27"_N52_FP8V^ONMVMF^J5X5,QR3YD]>Z!_<&+H<-7-1XS.4><I!CJ7(Q55
M,A!D>H"ZJ2_TO#?Z?7CV$;UM#'PC0=>Z8I4T0R^,%C&)44'DRR3RQA2?K<AF
MMQ[3[%9MNNZK%>KXJ*PH#Y?LZ;E^#K9O^.>.JL7T?U=CZY&2JI=FXB.9&X*N
M8`Y!_P!@WO/+DZ.6':;6V)/TZQT`\@.BF8Y-.A7K(R\-4D=PXB?3].0T;63G
MBQ]G.]6LC;-N"V?9<K`X0CB.T\.DZLQN+70U&!%?V]4EYNDJJ;-Y:DF1H9(,
MKD5F@/&AOO)FMSS^EA[^3W[SNUW7+GO3S)=WT!,D\[.Y/XR3W5IZ^=.NC?M[
M<PR\J;>-0,P2A/G4CJ$4L2"S`_T`N!_K'WC[<1&\GENK:&*.W<U5=5-(],Y_
M;T,$?2BJ14CSZ]I'^J?_`))]L?0W'_"O]['5O%'\/7`Q*3>['_8>U*6URJ@:
M(O\`>QU;QZ>777@2ZMSJ3]+`68<DVU#DBY^GMT1W@72%BT_Z=>O>/Q%,'K@:
M2$B,:3:&9)X[`J4E358AEL=+:CJ7]+G]0/M0DVZ1QM$CQ",BE-:\.DY2W:5Y
MC%^JQ!)SDCA7/EUW]LGB,%Y/"5G5HM3^-A4%6E+)JTLY900Q]2V])'NBMN*Z
MM)BS_37RZJT%H\\=RT`,Z<#FHK@^?GY]>^VB(4%00A!`*`BX?R78$>LZQ<DW
MO[VLFYK32\8I_37I0)54DJM#2GGPI3_!UY::-#=`4Y!LEU7@$`:19;$,01:Q
M'U]MR+?2FL@B)_TZ_;_AZU(Z35\5-7#C7RX==&EC;7<R_N.KM:2469?TE+./
M&%MP%L`./I[LIW!``OA`#^FO5`L`#*(A0@@_GQ_P==_;1^C]8$9!106"*5!4
M$("%^C'\?7GZ^]EMQ)))BK_IUZOKCJ6T=Q^WKD8$*",WT*AC"Z18(;7']3]!
M_L??M6XTTZHM/^G7K9D0MK*]_KUC-)$S(YUW3]/J<`\$>M0P646/T8$>Z@WZ
MEB/"J?Z:]59HW\,LF5-1QP?EUZ*CAA\?C#CQ,70.SRKJ(L2R2LZR"W%F!'NS
M/N+:=1B-#4=ZXZJXAD30\0*4(IGS-3_,GJ1(&EN'=F!^HL`/]8````#\#@>T
MR6UQ')XJ10B2M:ZQQZU"MO;FL$(4_+KBL:J`H9@!]`%X'MJ:UNY9'D<QER<]
MXZ?,VHDE<]<M(_U3_P#)/MKZ&X_X5_O8ZKXH_AZ\T3*%D4_3^U^;'@W_`*>U
M$DL=PMCM4%FJW(.ERI),C$X)\L`^73<;T-QXSUB.0#P`IGJR3XH4U73]9S/,
MC1T]1G\E4PK;BHC9(%\G/U]2'_;>_I[^X;L6X;;[*;38;@6-BBKX<9X+BN,`
M\<\>N>GN_*S<WW,L+GP=7`>E>G;YH6_V3/Y8D?0_&3O=N?\`:NK-U'_B?><.
M3QX]`(MJ.H<#U\*3W[K77__6VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W
M[KW5)G\Q[J^IP^^\/VI2P2RX+=,`P6=J((F_W&9"@A$-/4RMR`M3&`MSQ[QK
M][=ACC4;@%%9#J_/HZMB3$JDY`Z(1LFJEIYH?)5X:%TRD<WVM52":NL()?4\
MCJR?9E96X6S6/U]PEMY!V[1Y4_R=*.E76S25STCU&X=A0LUJ^`T-(T)$1.I:
M>4L"RD`6-R3[:$VD!:\.O=2(J^GK:V:.;)[!1:RG,9D>E+M&[K:^NY!()^OO
M?U'SZ]CI%5^SJ.FC9ANS;CM'4,H$,=H@"W*H!_8`/'OQN-6-77L=,60PL6(^
MRT9G&9"#(3R)(M"CFII6_P!U(BW8#RG@"WMEX%DJ2>O=7J_!#JFJV#TS%N'-
MT4M-FM\,^8G2?T3T^%B9WQ$+Q^DH[Q,9""!8M[RJ]H>61L&TC>7-/JH@_EP/
M^QT323GQW'FK'H*/EO\`-*38DV3ZVZLK::7<M+"8]S;G+JU-@ED]!I,>RZE;
M*(QL3Z@I]A[W%]U;.&Z;:K*3@:'CTLBB\8ECU4/F\[F=SUTN4W'D:[,Y&HD>
M>6HRTS5LWED.IV'F+I&6/-D"@>\;>;.;=XNY(E:5OIZXSY?LZ>%@JG4>!/32
M4#!PR^EXO$P'%X[W*\$$7(^HY]FWT&U[CL(:^G`)7Y>GVCI6BVT=`ZCKM1:5
M)D`2>,AHZA`(ZB-EX4I,@65"+?@CV&0+O9X(6M9#]$JC1P^'RZ12P*\CN@&D
MG'1V/CE\T-X]3Y2EVYO.LJ]S=?LU)!6)65#U.8P$,I$<%902R7>2CN;NK%C8
M>Y<Y#]R9;8"*>2O^3^73?TU12G5UV3BV[V_UY7TM'5P93;^[L&T4&0II%:-Z
M:OIQ/22HRDCR4\VDL/J&'O)7>M.]<LVMT!V31!A^8Z+M)$LD9]:=:T6^=F9O
MK[>.Y-HYRGE@R.`R-9!*DZE4GITJ'6*HIS8:T>,@W''/O#GF3:UM;R9@M#7H
MSM@10>=.DH\44JJDBI,BD%5E170D:B&,;`H7'D/-K^PLD[*_R'2KKFC-$;QG
M006L5`6Q:/PFUOI>/T_ZWLY@GU`>O6^N'CB,9C,<90LKD,BL2R_0EB"Q_P!O
M[17%\WBR(3P/7L]<U5570JJJZBU@JCU'ZG@<?ZWT]HF;Q<D]:Z$WI7KG)]J]
MF[3V-C8)77(Y6*?,5`4M!C,-0RK4-42-]%-3I(Y^OL=^W.VK<[R13)(Z;E("
M$UZV=\11TV-Q=!CJ10M-04=/1P@+I`CI8DA7T_CA/>;=K;I9VD:J*40?X.B9
MZEL]<WL0_'U<"_\`L!_Q'LPBTO$FHX9>DUF`T\['\)ZKU^1G2F?H\U7[XV7C
MSF,?7,\^<PU*&.2BJ7(::NHSRIA"BY6WODU]\K[F%U[C7DO,NQP!;@L6!&FM
M3QK4\/RZG'VU]UGV_<+?9)Y:QUT\3Y=$RDR-(I/FK9:3FRQU$<<,P(X9)$E(
M<.&!!N/?%+F'V5YSY>WW==CFY5W.62UF:,NEK.Z,5\U=(RK#YJ:=97#GO88^
MUYAKIGY?SZBMEJ0,1_%:<6/T:>G5A_KK?@^R;_6NYO\`^F-W?_LBN?\`K7TX
M.?N6Z"LZU_U?/KO^+T7_`#MJ7_SHI_\`BOMAO;/F]6(_J;N__9%<_P#6OK7]
M?N6_]_C_`%?GU[^+T7_.UI?_`#HI_P#BONO^MIS?_P!,;N__`&17/_6OKW]?
MN6_^4@?ZOSZ]_%Z+_G:TO_G13_\`%??O];3F_P#Z8W=_^R*Y_P"M?7OZ_<M_
M\I`_U?GU[^+T7_.UI?\`SHI_^*^_?ZVG-_\`TQN[_P#9%<_]:^O?U^Y;_P"4
M@?ZOSZ]_%Z+_`)VM+_YT4_\`Q7W[_6TYO_Z8W=_^R*Y_ZU]>_K]RW_RD#_5^
M?7OXO1?\[6E_\Z*?_BOOW^MIS?\`],;N_P#V17/_`%KZ]_7[EO\`Y2!_J_/K
MW\7HO^=K2_\`G13_`/%??O\`6TYO_P"F-W?_`+(KG_K7U[^OW+?_`"D#_5^?
M7OXO1?\`.UI?_.BG_P"*^_?ZVG-__3&[O_V17/\`UKZ]_7[EO_E('^K\^O?Q
M>B_YVM+_`.=%/_Q7W[_6TYO_`.F-W?\`[(KG_K7U[^OW+?\`RD#_`%?GU[^+
MT7_.UI?_`#HI_P#BOOW^MIS?_P!,;N__`&17/_6OKW]?N6_^4@?ZOSZ]_%Z+
M_G:TO_G13_\`%??O];3F_P#Z8W=_^R*Y_P"M?7OZ_<M_\I`_U?GU[^+T7_.U
MI?\`SHI_^*^_?ZVG-_\`TQN[_P#9%<_]:^O?U^Y;_P"4@?ZOSZXG+T=_^+M3
M?^=%/_Q7V^OM?S@R@_U-W?\`[(KG_K7UL<_<M_[_`%_U?GUG3)T3:;Y12[#T
M*K4[!_\`@IU>KW;_`%KN;_\`ICMW_P"R*Y_ZU=4//W+V:3+3_5\^A(Z^V'NW
MLG*0XW`XZ1,8)HURFY:V)EQU&`P9X8E6PEJ'C_25)%S[S7^[5]R7F?G>^Y?Y
MKW6PEBL9&UB*5-#+I>G<CA74XX-Y9ZC7W)]T+39=KC>QFJ)L`\,</GU;3LS;
M&/V;M[#[;QH;[/'TOA1G-WDD8LTTK'\F25B?\`??T1^WO*%MR/RIM_+UN@40
MJ*T]:#YGK$'<=R;?GN-QE;4SDGH'/F?_`-D9_+'_``^,O?`_VW5NZ_8P;XCT
M30&L*$^G7PI/=>GNO__7VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW0
M9]G]<[9[4VAG]D[EI(JF@S-.R!I%+&FJE4^"JA((*RPO8\'\>R#F?8+'?=M,
M5_:+*`,!J_Y".GEDD6FER,=:_P!W5TKV!\<]P/C\M2"MVQ)D):K;^[JBB^[Q
M\Q5F%)!6&&/RQU9CL&#'1_A[Q-YIY4N[!Y8MKA\&.IPO#^=>K&XN`:&0]`]5
M;YRV5I)*.IQVW_W`?/-1XF!9H&/ZA$X07L3Q^/8";<(;1!;W-CJN$&EB0U2P
MXG'1G%*#&A8]U.DDL404*%5U'T=X41W_`-J90H`8_P!/99-OUNI(%A3\FZOX
MB]81`DI-H`0T^@(CZY9)+VU)"JDW/]/?C#?[VL2[3JBE(S3_`&1U[Q$]>K"/
MB5\.\[OS,8OL'L+'S8K8M#4155!C:Z+17;BFIV5Z.;051DI"0"#8<?U]S1[?
M^W>XKIEYBC,\/H_^Q3JDDZJO:>[JR/Y1=IGI7IS,9G'EJ'*5T<.U]K4L3HLE
M-6Y&G>.*J@B`T+_#J9)#]"+JO'N9/<C<Y.7>4[.'9)3;QB$(`ODHP`*U\NBY
M45Y"S*"3Y]:\-1/+6SS5U2YJ*FKEEJ*B>5C*\\T[EY992^KR.[L22;\GCWAK
M?Q17PGO[A-=Y7XSQ_P`W1W;JH`%.ESLB;:=-B]S#=&'FK8ZAL%2X_*)'//\`
MPC56Z*J.B$;>BNK(QI+/J'/%O9SMMK:W]O:I?PB0!12M?\E.K/(]2FHZ:]+-
M:+IUHWK/X/O.GTU$DD>&K*^:/(U-'(9!%94I&1#_`).+6)'[GLRO]MVQ;;P5
MM4\*G#-/\/3#(K985Z2>[HNOQ1Q#:>*W7B\X0"^,SM1]]&8#R95*0QE9`/Z^
MR>=$:SCM"M;5%HJ^0`\AUL`*``,=!PL:%%!5C9BUY`!(2?J)+?4#_4_0>R40
M0VC:[:,(Q].O>?5J7\NSN:L.1S'2^8JY9J?[*IW#M59Y],=/*CH*W&4S'D),
MDB2:;FQ+6M[R.]K.9]SW7Z79]PW!Y;.-0BHU**HX`4`/\^DD\484R*M'KQZ,
M!\P_B;_IGHX]];'--C]_XJF,-3%47-%G,?`I=J32MKUMQ9&_)]C3W)Y#L[O;
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M>3/)')]CM&V[9,]BB[IX0UOFI;-2<T_ET632N7D&OLK@='8"Z5`']+>Y@C!:
M,+)G'2>M3U[QI;](YY_V-OK[L```H&!PZHH$9<I@DY^?6'[*EU.WA4M(6+DZ
MCJU\->YM9A^/I[M(QEB,,AK$12G2:*SMH;CZN*$+<U^(<>DM6]=;"R4GFK]G
M[<JI=1?R38FC=RQ^K,QBU,3_`(W]LQP111I%&@$:B@`\AT<#=-P%3]6]3ZFO
M^'K!_HQZZ/UV/M4G^IP>.)/^N33W/NWAIZ=;_>NX?\I3?R_S=>_T8=<_\\-M
M7_SQ8[_ZG]T,$)-2@KU[]Z;A_P`I3?R_S=>_T8=<_P#/#;5_\\6._P#J?W[Z
M>'_?8Z]^]=P_Y2F_E_FZ]_HPZY_YX;:O_GBQW_U/[]]/#_OL=>_>NX?\I3?R
M_P`W7O\`1AUS_P`\-M7_`,\6._\`J?W[Z>'_`'V.O?O7</\`E*;^7^;KW^C#
MKG_GAMJ_^>+'?_4_OWT\/^^QU[]Z[A_RE-_+_-U[_1AUS_SPVU?_`#Q8[_ZG
M]^^GA_WV.O?O7</^4IOY?YNO?Z,.N?\`GAMJ_P#GBQW_`-3^_?3P_P"^QU[]
MZ[A_RE-_+_-U[_1AUS_SPVU?_/%CO_J?W[Z>'_?8Z]^]=P_Y2F_E_FZ]_HPZ
MY_YX;:O_`)XL=_\`4_OWT\/^^QU[]Z[A_P`I3?R_S=>_T8=<_P#/#;5_\\6.
M_P#J?W[Z>'_?8Z]^]=P_Y2F_E_FZ]_HPZY_YX;:O_GBQW_U/[]]/#_OL=>_>
MNX?\I3?R_P`W7O\`1AUS_P`\-M7_`,\6._\`J?W[Z>'_`'V.O?O7</\`E*;^
M7^;KW^C#KG_GAMJ?^>+'?_4_NPB0"@7'7OWIN'_*4W\NN)ZNZY+I)_<?;&N/
MF,C#4(T_G@"$#W;0OIU[]Z[A_P`I3?R_S=*BCPF'QT/V^/QM%0P7#>"DIXZ:
M'4!8'QPA$O;_``]UBAC@EDGB0+*_$CB?MZ17CON$:Q7KF6->`8U`S7'Y]3DI
MX4"A4`"7T\DVN;GZD_GV\69C5C4]-1*L$?@Q#3%Z=%K^:8`^&WRT`^G^RS=\
M?^^LW5[KQZV`%``&.OA0^_=;Z__0VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[
MJT?W[KW6+QJ2;@6U%O\`8W_XK[\7#`J3Y4ZL3@#IES^V,#NG'5&)W#B:#,XV
MJ1HYZ/(TT=3`ZNNEK+(#H8C\K8C^OLAO=CMKQJO&#UO7BAX=$5WY_+NZ/W14
MU%5MVIW#L:KDGEF,.'JON\='K8MXHJ.J/[<*WL%\AL/8%N_:C9KF::X\)0SL
M2<>OY]7\6@`&.@MI?Y8NW/NE>M[1STE$K<1PX6CII&0'@-*9Y`6M]3[(I_9[
M9R<H*_9_T-U[Q6_BZ,?U7\)ND.M*R/)K@Y]TY:FD6:+*[DJ$K?'.IOY:>BBT
M0Q`L+A2'`]FW*WM?:['?R7;(#"35>'#\CU8RXPQKT<"F@CAABCB2*."-%6**
M&)8HHU`]*QQ*`L:@<``<>Y>9(S&8E`TTITV6!X<>JD?YF^7FCJNJ=MQR2QT2
MMF<Q(-1,;3C3''JO<LR^,6)O;_;^\?O?"[\':H;<'X5IT[":L.JG8AIAC4KI
M('Z?Z&]_S_K^\8+5C+9.`>(/1[;_``_ET)>QMP[MPU)6T.W<909"ES3A,DM?
MC!.'6E8R4VEY"0#!)RKI8D_GV9;3,5T1URO57^-A\^E1DNP^S,)3T,U?B<+2
MQM0P4=)5OB1++X(-!TW)+\B,?X\>S/<9RL9/E3JIZ8:SNS<^1CK*:>CVY-25
ME.]*?M\.BU1+J5^X:9E,Z2$F_##V6AM5NC>HZ]Y=!;'&8HQ&S:BMP6YY)-_[
M1)_/Y]EEQY=:\^AX^+N8J,#W_P!6U].TBR2[I6AF1#R\%3#)"I;ZZDTRG@\>
MY`]J[TV^_$EJ`..FIA6-AZ];*D--%#Z40!;D@7)`U&Y^I/O.$NMS"K/E6`Z*
M'-1\^@8[1^/W57;U-)%O/:M%75@$BP9:E`HLM3%^2R52%?(]_P`N&]@[<.1M
M@W!I))+91(YJ33_9Z\)&"C/1*\Y_+*V)42:]M]@[EQ,(8F.DJJ6BRGA0FZQ-
M*&C:33>UR`3[CW<_9W9+EV*QKGY?]#=;\4_Q=2=M?RU.O<?615>Z=\[DST*$
M:Z"EIZ7$026^JM)$:B4<>R.Q]G4L[K4JCP`<8'#]O6_$.*OT>3K/I3K/J;')
M2[%VKC<3(T:I-DS%]SEJO@@O4Y&?74,7_(4JG^T^YJV/EVSVR!%\%=0%/]6>
MM&0L?ET*RA5`](!`MP![$(MXU)*J*=-D5->N?ZA[=X=:X'KE[UUKKWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBS?-3_LC?Y:?^*S=\?\`
MOK-U>_=>Z^%![]U[K__1VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW7
M5A[IX:5KISUZO7=K^[C'#KW6-8HUUV7]9NURS`G_`%F)`]^ZU0'KWBC`(T"Q
M^H/(_P!@#P/=&1&^):]>H/3KRPQ+RJ*O_!1;_>O;E3I"5[:<.M^G7/2!^/=%
M14J5%*]:IU4W_,ZVU4U>-ZWW2D4@H<?793$9*H53:`5ACFHF=APH/@E`O];^
M\=OO`V-Q/M=I)9U$E*M3SX]*H*:AU49Y%E'D6^EN1<6-OH./];WC':I)!LSJ
MQ_QFASYUIT>V_P`/2TVQ3U%1%`W@S%EKJN)*REK##0&,4(D6G5`P85>L\'Z7
M]G6V)&MG:NZ_K%!J/F3U5_C;[>E=482AR#I2U>![#)HR5C\U6)E1B/65)8J0
M?]M[7.(I!1Q7JO2$S6TLO1U-9-AL%N6BQU+3QEYLE2I(MK^MT*$%M0/U]IY!
M$J:54!!U[I,CZ`>K_'4I1K_XH22I_P`+^R.X#$X/;UKHQWQ&VY4;I^0G7T%-
M%+,<?E/XO6D*2*6BQ$<GE>]K*DS2QW)_I['7MCM\[;X)9`3$S"G2&X=QJ`;%
M>MD)6)0,+J".`?K_`+$?ZWO.6)56!%44HO\`DZ*I6(X'/7,(K!2PN;?F_P#O
M5['WI8U(!(J>O+D`GKPBC%[(JW^ND:2?]B+'W;PT_A'6Z#KRQ1K^E`+BQ(^I
M_P!<_4^W*F@6O:.O4'7,*```.!].2?\`>^?>NO4'7K#^GO=3U:IZ[M;WKK77
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T6;YJ?\`
M9&_RT_\`%9N^/_?6;J]^Z]U\*#W[KW7_TMK'^23_`-NB_P"7/_XJ1TW_`.\G
M0^_=>ZM']^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!GR`ZIQ_<W66Y
M=E50TU-9"U7B9B#>#+T$<AI'6Q%M18K_`,A'V%]_V2+F"SNHI14I4#]GY=*(
MC0KZ=:UFXL#F]G9[+;4W%3?:Y[`U$M-D:)X9(B&BD,1>!C8/&;7!%P?>#F^6
MXL^9I=J"T772GY]'UOD#[.IN+K<=CZ=!6T>0J'%0TG^29!HG*2((W8PAO&KM
M%Q>U_P#'VW*3!+)`."&G[.JO\39\^G7-9[!RP5W\&_O5C*N2G@%"DN9G:-)%
ML)"29&)O;F]_;?CMZ]5_/I--ELO+&R39/(GR1K'-&V1JI8V"C]!_>*,`?Z#V
MB:Y)D8,:BO7NFJ67P*[.Q"*4)=P\LCO,;)&@%V8W^GU]KHX?$%3\/7J=7/?R
M^>A:W:F$K.V-TT9IL[N:!J+;:21O'+3[?E*2?<F-B-+UHC4D$?V?>2OMYR]'
M!8[;?!:,\0/[>BVX8!G`]>K.[@H"+V('U^O''_$>Y\C'8H^717+PZR+]!_K>
M]TICJR?"O7?OW5NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBS?-3_LC?Y:?^*S=\?^^LW5[]U[KX
M4'OW7NO_T]K'^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]UB*J=1(O8W'^'M/;-^K<*/XNG`2*4/'HDWR?\`
MB-@.\:>HS^'F@VUO^"#Q4N9\"R4>4@4NZ4-=2H5D:5[!1-?@GW%O.'MOL5]<
M'=K7:8QN1-3)4UK^VG\NGEN)U&E9B.J7.Q>B^T^JLC-!NO:.:IH5+QC(4]))
MDL;/H.D3IDJ93'3Q/]06'`]XO;ORQO,&YWZM"Q`E;R^?V=&,<E8T+GO(ST$"
M3K"-#M31278M&\J3%V/U)D>Q8D_FP_UO9*^WWL&'M2?V_P";JWB)Z]*3;6UM
MT;OJX<7MG;N5RU;43A$3%4,^1CLQL%>HC4140_P8FW]?>[?E+>[R1;B+4(9#
M4"@P/3UZWXB>O5G7QP^!60CR%+O+N>%(J:G:"JQ>QDE1ZQIZ=TDIZK+5W^:T
M`_6`"_%B?>0/(_MO%<1Q_O:S$B_TO]@CIJ6X"X3+?RZMUH*6"DHZ6FIXHX8:
M>&.*&**,11QQQ@*B)&OI1546L./>0EIM5CM\$-K;6ZI%&H50*T`'D,]%4K,7
M:IS7J80#]?:\8Z:(!XCKOW[K8%,#KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBS?-3_`+(W
M^6G_`(K-WQ_[ZS=7OW7NOA0>_=>Z_]2U[^5+_.[_`)4W0W\MGX1=,=P?-7JS
M87:/6/QOZQV7O[9>:H]Z_P`7VONG`[>IJ#,83)K2;5JJ9*W'UD+1R!)'4,."
M??NO=6!?]!"W\E__`+V!=,_^<>_O_L-]^Z]U[_H(6_DO_P#>P+IG_P`X]_?_
M`&&^_=>Z]_T$+?R7_P#O8%TS_P"<>_O_`+#??NO=>_Z"%OY+_P#WL"Z9_P#.
M/?W_`-AOOW7NO?\`00M_)?\`^]@73/\`YQ[^_P#L-]^Z]U[_`*"%OY+_`/WL
M"Z9_\X]_?_8;[]U[KW_00M_)?_[V!=,_^<>_O_L-]^Z]UQ_Z"%/Y+_/_`&,"
MZ9Y_Z8]_?_8;[:CC\-W<>9ZW7AUC7_A0A_)>5F9?Y@/3%VO<_9[_`+\_XG9I
M('^'M\L"-)K3JQ8'B.HE5_PH$_DJUT+TU;\]^CZRED&EZ>KQV^ZF%Q_1XIMD
MNC#_`%P?:*3;=NF),MJ"Q^W_`#]7$@``%:](FH_G<?R#JJ99ZCY>_&.29>1(
M=G;GO?\`J;;!`//LENN4=ANC5K)0?S_Z"Z]XK#S/2GQ/\^S^1W@5*8/YQ_'_
M``ZM^I<7@=Y8X-_P;[38T5_]C[46O+VVVBHD<"Z5P./#]O6C*Q\^G@?\*#OY
M+MB#_,!Z8L6U$?:;_;U?UYV;Q[/(UC@73$M!UK7Z<>LR_P#"A3^2\JA1_,"Z
M9L!8?Y'O[_B=F^]UKGJA-37KE_T$+?R7_P#O8%TS_P"<>_O_`+#??NM=>_Z"
M%OY+_P#WL"Z9_P#./?W_`-AOOW7NO?\`00M_)?\`^]@73/\`YQ[^_P#L-]^Z
M]U[_`*"%OY+_`/WL"Z9_\X]_?_8;[]U[KW_00M_)?_[V!=,_^<>_O_L-]^Z]
MU[_H(6_DO_\`>P+IG_SCW]_]AOOW7NO?]!"W\E__`+V!=,_^<>_O_L-]^Z]U
M[_H(6_DO_P#>P+IG_P`X]_?_`&&^_=>Z]_T$+?R7_P#O8%TS_P"<>_O_`+#?
M?NO=>_Z"%OY+_P#WL"Z9_P#./?W_`-AOOW7NO?\`00M_)?\`^]@73/\`YQ[^
M_P#L-]^Z]U[_`*"%OY+_`/WL"Z9_\X]_?_8;[]U[KW_00M_)?_[V!=,_^<>_
MO_L-]^Z]U[_H(6_DO_\`>P+IG_SCW]_]AOOW7NO?]!"W\E__`+V!=,_^<>_O
M_L-]^Z]U[_H(6_DO_P#>P+IG_P`X]_?_`&&^_=>Z]_T$+?R7_P#O8%TS_P"<
M>_O_`+#??NO=>_Z"%OY+_P#WL"Z9_P#./?W_`-AOOW7NO?\`00M_)?\`^]@7
M3/\`YQ[^_P#L-]^Z]U[_`*"%OY+_`/WL"Z9_\X]_?_8;[]U[KW_00M_)?_[V
M!=,_^<>_O_L-]^Z]U[_H(6_DO_\`>P+IG_SCW]_]AOOW7NO?]!"W\E__`+V!
M=,_^<>_O_L-]^Z]U[_H(6_DO_P#>P+IG_P`X]_?_`&&^_=>Z]_T$+?R7_P#O
M8%TS_P"<>_O_`+#??NO=>_Z"%OY+_P#WL"Z9_P#./?W_`-AOOW7NO?\`00M_
M)?\`^]@73/\`YQ[^_P#L-]^Z]T`ORI_GV_R?]\_&#Y(;*VG\[^H,WNG=_0G<
M.V-M8:EI=\)59?/Y[KS<6*P^+IFJ-HPP"HK\A51Q1ZW5=;BY'OW7NODT?Z$>
4Y_\`GT79_P#Z`.Z__K3[]U[K_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g912919dsp_280a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_280a.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0Z<17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-3HP-#HR
M,B`Q,3HR-SHS-@```````Z`!``,````!__\``*`"``0````!````TZ`#``0`
M```!````@0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```UF````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`8@"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2DDDDE*0[KZZ6[K#IV`Y
M/]5-D9#*&;G:D_1;W)5&NNS(L]:[7]UO;Y)*2?M6O_1/`^7]Z<=4I_<L^X'^
M*S,CK_36Y#JV56W-K)#K:F-<QQ&A8USG-<[8[\Y)O7NE'Z5%P^-/_D7%)3JC
MJ='[EG^;_M3_`+1H/9X_LK,'6NB'D/;\:GA$;U7H9U]7;\6/'\$E.@.H8_\`
M*'Q:4_V_&_>(^15#]I=#/&2P?-P_@B-R^D.XR:_\_P#O24W/MV+^_P#>"G&;
MB_Z0?BJH?T]WT<BL_P#7`G<V@B*G"UY^BQKVR?WO\UJ2FU]KQO\`2-3_`&G'
M_P!(W[PJ]E%+&%Q)(X`TDD\`(-=.X`.AQ'TB`DIT!=4[A[3\"%->=_6?Z_/Z
M=F/PND8]65]F,9#[2=A<W^=Q\;T_SZ_S[G?X5=7]5^NX_6^EU9N/.RQLAKC+
MFD>VVE__`!5B2G__T/54DDDE*22224I!R<FO'9N=J3]%@Y)4<S,KQ6;G>Y[O
MH,')_P#,5FUMLR'^OD&9X'`C]UO\A)26MEF39ZUVH/T6C_J6_P`E976>L>J7
MX.&Z*F^S(O:>>QQZ'?\`GZS_`*VMJQ@MJ=6X'98TL=!+3!$>US?HJDWH/2FM
M#64EC0(`:YT1\TE.#6T`!K1`&@`X`1F!;7["P/S38W^U/Y0E^Q*!Q:\?$`H4
MIR@#*(&RM`]&_=N^]O\`<4OV1:/\*PQX@A%32#!X*7I,_=!^2M_LS(&LL/SC
M\H3GI^6!]#\0DIJ>A4>6-/R"TNGX%6./7<QK;7#F![6_N_\`DDV)A/:_U+VQ
MM/L:8Y_>_LHU[_4<:AJQI_2'Q=SZ7_I1"E+%YM<'_F\5M^/^$_K._P"H6%]<
M_K`>C=.&+B.CJ&6"*W#FMGT;<F/_``.C_A/TG^"6SEYN/T["MZAE&*ZA.G))
M^C6S_A+7^QB\FZQGY'4LZW-R?YVT_1'#&C^;I9_(K:G4IR;H:V!PV(79_P"*
M+,<R_/Z>3[&6"Q@\!8UV[_I4KBLLPU=-_BK?'7\[X5#_`*5C4B@/_]'U5)))
M)2E4S\^K#KD^ZQW\W7X^9_D*/4NIU8->OON?_-U_]^=^ZQ<Y]H?;>;[SZCG'
MW3I/@T?R?Y*2F_2VS)L.3DG<#V\?Y+?W6(V9D7U,;Z+"=QVN<!NVB.=JKLZB
MR-6$1X%.R^G<'"VYH[MF1\$E)*:;W/;8XNALDA[HW^#"W\W]_<K+;+])QR)Y
MVO!0VY6.[\\?,(K;:7<.'R*2O%(+-)>TU@`DEQ$``;C*QZOK0S)LK.!C_:*+
M"W8[>!8]KN'UTM#MK'?2]ZUA967EC;&EXT+0]I(^+)2IPJ,8$X^.RDNDGTV!
ML_YH24PZCU7`Z75ZN;>VED[0YW=Q^BP!L^]_YC5-]EKJR:O:XB6[P1$^+4&]
MK)WVUA_N$;A,:[FNVG_1H'2\KJ>3C^KU#%;A7.)BAMGJF)T]1P'M?_(24Q8W
MJM&!;2_,JRNJO+GU.@5#87-]C*MS]OH5G9ZCOS_YU2Z?T_-%[<C(>6;#+@;#
M8YX(^@?S-J+7TG!^VCJ#J0[,#=C<ATE[6:_HV'\QGN5VRUM->\C=&C6CESC]
M%B2E7W%@#&'](_@_NM[V?^0_EH=-8(`:/:.!W)/_`)D@M#G.)=[K'F7D<?U6
M_P`AGYBQOK9UW[%C?LW%=&5DM_2O;S74=)_XS(^BS_@_TB04XGUMZY^T\L8U
M#IPL1QVD<66_1?=_4K_FZ?\`MU<O:))5LEH`C0#0`>"KV`&2BARL[2/,KH_\
M5)GKN9\*O_/CUS74#+VCS'Y5T7^*<SUS+\VU_P#5O2*7_]+U59_5>K5=/K`$
M69#Q^CK_`/1EG[M:AUWK%72L06&'7VG;16>Y&KG._D5M]RXU^<;[777.+[;#
M+WGD_P"O[J2FY9?9?:ZZUV^Q_P!)Q_)_54FN51N16>\(K;&GNDIM!RF'*NUT
MHC2DIL-*S.N=;^P5BC',YMH]O?TVG_"N_P"$_P!"Q-UCK%?3:&[0+,N[3'JY
MD_Z1_P#P3/\`P1<!F]0RLFZRO'+K[WD_:<D>)^DQK_HM_K_];K24ESNK4XEC
M88;MY<'O#H.\:O\`?_A'>Y%QOK6VJ"Q^53_5>3_U+EDV=-LS*F44O8UU3CJ3
M#9<![6D?NPLFVJVIVUCP^--S"8.OTO=^:DI]!P_KOD.L975U*YK["&L;8)DG
M\WWM>MFOZV=;9^>R\Z!K34TN<YWMKJ9MV_I'N7!?5K`,'J&2==1C[N`!_.Y'
M]G\U>A?5KIL!O5,EI#G#]2K=H6L=]++L;_ILAO\`-?Z*C_C$E/54YMWI,^T5
MM;<6M-K&&6A\?I&M=^ZUZ:VPVV"P\-$,;X3])W]9RKAT(C7!H-CB&AH)+G:`
M`:N>[^2U)2/J?4Z.D=/LS+@'.'MJJ[OL/\W3_P!^M_X->;9&9=E9%F3DO]2^
MYQ?8[S/A^ZQK?8QBM_6'KAZOF^I62,.F6XK#X'Z=[Q_I+_\`SW^C607%%29U
MJ`^WD*+G%!<\B=>$E-/-?-K?B%TG^*0_Y;R?-M7_`%;ERN78!;J=?!=1_BG,
M=;N\VU#_`*;DBI__T]#ZZ9=EW7WU2=F+6RMH[2X>O8[_`*=?^8L07/"]`ZI]
M3\'J.5;F>M=3?<07P6N;(#:Q['#]UG[ZR,CZ@YK9.-EU6#L+6N8?O87I*>:&
M0X(K<MP[J_?]4NOT2?LHM:.]3VN_Z+MCUG7X69C&,G&NICN]C@/\Z-J2FPS.
M<.Z)9UAF/19?<3Z532]\<P!Q_:6:',.@<"LKZRV$=-](&/7L:T_U6_I#_P!2
MDIS?VX,[,OS.IN<77Z"MA(#6?FU;V^YM+&^WVHKLBF^L54W55UCZ%+1L:/#=
M'TEA&J-05`UN24[N/@9))%ES?2+2-U)EQGEM;?S?;^<E9116YE3F"BIQB.Y`
M_.+W?SCEAM=<PRUQ'P)1JK<C)OJJ>]SC,"=8'TG)*?0/J]TROJ-@?8T#IN,0
M'-[6V-U9B_\`A:GZ>3_I'_H5V>[<9/*Y7!R&X>+5BU:,J:&CX\O/]IRNU]5(
MY/"2GH`1J3]$<E<O]<>N:'H^.[D`YKAV'TF8G_?\C_MM7NK=;/2^EMR)!RKC
MLQ*S_I'#<;7-_.;0SWKD\/H/6NH.WLI<W>2YUU\MW$_2?M_G'[DE-`O\TS/4
ML=Z=3'6/.@:P29_JA=MTS_%R'0_->ZWQ;]!G_1_2.76]/^K73L)@;76UH'9@
M`'_DD;4^9X/U1ZUFD%S1C,/=_N?'_%M_[\]=3TS_`!;8-</R]USN_J&!_9K8
MNWKJKK$,:&CR4T%/,._Q;_4VUOZ;IS'./+VNL8?_``.QJGT?Z@]`Z)F_;.FB
MZEQC=6;"]AVG<S^<W/\`I?RUTB22G__4]522224I,4Z22FGD=)Z9E`_:,2FR
M>26"?\[Z2PNK_P"+GZN]4K:T-MPRQQ<UV._N1M]S+A:Q=2DDI\OS/\35XDX'
M50X]FY%4?^"4N_\`1:P\S_%=]<,:?3IHS&CO3:`?\S(%2]L31*2GYWS/J[U_
M`DYG3,JEHY>:G.;_`-N5;V*OTXU_M'':XAI]0`@Z'_I+Z05>[IO3[[!9?BTV
MV#A[ZVN</[3FI*?*Y!$@_,*3)<]K0>2!]Y7HF1]4_J_D278;6./YU1=7_P">
MW-:L^SZB8`L:_&R;JMI!VNVV#3Y-<DI-TSH^-F!N5>T.=4377(!(`C=M/YNZ
M%MU8F/2/8P#SY*CA8C,/';2UQ=!)+CW+C)5A)2DDDDE*22224I))))3_`/_5
M]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9_^T33%!H;W1O<VAO<"`S+C``
M.$))300E```````0`````````````````````#A"24T#[0``````$`$L````
M`0`!`2P````!``$X0DE-!"8```````X`````````````/X```#A"24T$#0``
M````!````!XX0DE-!!D```````0````>.$))30/S```````)```````````!
M`#A"24T$"@```````0``.$))32<0```````*``$``````````CA"24T#]0``
M````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R````
M`0!:````!@```````0`U`````0`M````!@```````3A"24T#^```````<```
M_____________________________P/H`````/______________________
M______\#Z`````#_____________________________`^@`````________
M_____________________P/H```X0DE-!`@``````!`````!```"0````D``
M````.$))300>```````$`````#A"24T$&@`````#3P````8`````````````
M`($```#3````#0`Y`#$`,@`Y`#$`.0!?`%``80!G`&4`7P`T`````0``````
M```````````````````!``````````````#3````@0``````````````````
M```!`````````````````````````!`````!````````;G5L;`````(````&
M8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````
M````3&5F=&QO;F<``````````$)T;VUL;VYG````@0````!29VAT;&]N9P``
M`-,````&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@``
M``=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I
M;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP
M965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```($`````4F=H=&QO;F<```#3`````W5R;%1%6%0`
M```!````````;G5L;%1%6%0````!````````37-G951%6%0````!```````&
M86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E
M;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO
M<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E
M5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453
M;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P``````
M```*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````
M````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````3_P````
M````.$))3001```````!`0`X0DE-!!0```````0````!.$))300,``````V"
M`````0```*````!B```!X```M\````UF`!@``?_8_^``$$I&248``0(!`$@`
M2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,
M#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!B`*`#`2(`
M`A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+
M`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,
M,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*2222
M4I#NOKI;NL.G8#D_U4V1D,H9N=J3]%O<E4:Z[,BSUKM?W6]ODDI)^U:_]$\#
MY?WIQU2G]RS[@?XK,R.O]-;D.K95;<VLD.MJ8US'$:%C7.<USMCOSDF]>Z4?
MI47#XT_^1<4E.J.IT?N6?YO^U/\`M&@]GC^RLP=:Z(>0]OQJ>$1O5>AG7U=O
MQ8\?P24Z`ZAC_P`H?%I3_;\;]XCY%4/VET,\9+!\W#^"(W+Z0[C)K_S_`.])
M3<^W8O[_`-X*<9N+_I!^*JA_3W?1R*S_`-<"=S:"(J<+7GZ+&O;)_>_S6I*;
M7VO&_P!(U/\`:<?_`$C?O"KV44L87$DC@#223P`@UT[@`Z'$?2("2G0%U3N'
MM/P(4UYW]9_K\_IV8_"Z1CU97V8QD/M)V%S?YW'QO3_/K_/N=_A5U?U7Z[C]
M;Z75FX\[+&R&N,N:1[;:7_\`%6)*?__0]522224I))))2D')R:\=FYVI/T6#
MDE1S,RO%9N=[GN^@P<G_`,Q6;6VS(?Z^09G@<"/W6_R$E):V69-GK7:@_1:/
M^I;_`"5E=9ZQZI?@X;HJ;[,B]IY[''H=_P"?K/\`K:VK&"VIU;@=EC2QT$M,
M$1[7-^BJ3>@]*:T-926-`@!KG1'S24X-;0`&M$`:`#@!&8%M?L+`_--C?[4_
ME"7[$H'%KQ\0"A2G*`,H@;*T#T;]V[[V_P!Q2_9%H_PK#'B"$5-(,'@I>DS]
MT'Y*W^S,@:RP_./RA.>GY8'T/Q"2FIZ%1Y8T_(+2Z?@58X]=S&MM<.8'M;^[
M_P"238F$]K_4O;&T^QICG][^RC7O]1QJ&K&G](?%W/I?^E$*4L7FUP?^;Q6W
MX_X3^L[_`*A87US^L!Z-TX8N(Z.H98(K<.:V?1MR8_\``Z/^$_2?X);.7FX_
M3L*WJ&48KJ$Z<DGZ-;/^$M?[&+R;K&?D=2SK<W)_G;3]$<,:/YNEG\BMJ=2G
M)NAK8'#8A=G_`(HLQS+\_IY/L98+&#P%C7;O^E2N*RS#5TW^*M\=?SOA4/\`
MI6-2*`__T?54DDDE*53/SZL.N3[K'?S=?CYG^0H]2ZG5@UZ^^Y_\W7_WYW[K
M%SGVA]MYOO/J.<?=.D^#1_)_DI*;]+;,FPY.2=P/;Q_DM_=8C9F1?4QOHL)W
M':YP&[:(YVJNSJ+(U81'@4[+Z=P<+;FCNV9'P24DIIO<]MCBZ&R2'NC?X,+?
MS?W]RLMLOTG'(GG:\%#;E8[OSQ\PBMMI=PX?(I*\4@LTE[36`"27$0`!N,K'
MJ^M#,FRLX&/]HHL+=CMX%CVNX?72T.VL=]+WK6%E9>6-L:7C0M#VDCXLE*G"
MHQ@3CX[*2Z2?38&S_FA)3#J/5<#I=7JYM[:63M#G=W'Z+`&S[W_F-4WV6NK)
MJ]KB);O!$3XM0;VLG?;6'^X1N$QKN:[:?]&@=+RNIY./ZO4,5N%<XF*&V>J8
MG3U'`>U_\A)3%C>JT8%M+\RK*ZJ\N?4Z!4-A<WV,JW/V^A6=GJ._/_G5+I_3
M\T7MR,AY9L,N!L-CG@CZ!_,VHM?2<'[:.H.I#LP-V-R'27M9K^C8?S&>Y7;+
M6TU[R-T:-:.7./T6)*5?<6`,8?TC^#^ZWO9_Y#^6ATU@@!H]HX'<D_\`F2"T
M.<XEWNL>9>1Q_5;_`"&?F+&^MG7?L6-^S<5T962W]*]O-=1TG_C,CZ+/^#_2
M)!3B?6WKG[3RQC4.G"Q'':1Q9;]%]W]2O^;I_P"W5R]HDE6R6@"-`-`!X*O8
M`9**'*SM(\RNC_Q4F>NYGPJ_\^/7-=0,O:/,?E71?XIS/7,OS;7_`-6](I?_
MTO55G]5ZM5T^L`19D/'Z.O\`]&6?NUJ'7>L5=*Q!88=?:=M%9[D:N<[^16WW
M+C7YQOM==<XOML,O>>3_`*_NI*;EE]E]KKK7;['_`$G'\G]52:Y5&Y%9[PBM
ML:>Z2FT'*8<J[72B-*2FPTK,ZYUO[!6*,<SFVCV]_3:?\*[_`(3_`$+$W6.L
M5]-H;M`LR[M,>KF3_I'_`/!,_P#!%P&;U#*R;K*\<NOO>3]IR1XGZ3&O^BW^
MO_UNM)27.ZM3B6-AANWEP>\.@[QJ_P!_^$=[D7&^M;:H+'Y5/]5Y/_4N639T
MVS,J912]C75..I,-EP'M:1^["R;:K:G;6/#XTW,)@Z_2]WYJ2GT'#^N^0ZQE
M=74KFOL(:QM@F2?S?>UZV:_K9UMGY[+SH&M-32YSG>VNIFW;^D>Y<%]6L`P>
MH9)UU&/NX`'\[D?V?S5Z%]6NFP&]4R6D.</U*MVA:QWTLNQO^FR&_P`U_HJ/
M^,24]53FW>DS[16UMQ:TVL89:'Q^D:UW[K7IK;#;8+#PT0QOA/TG?UG*N'0B
M-<&@V.(:&@DN=H`!JY[OY+4E(^I]3HZ1T^S,N`<X>VJKN^P_S=/_`'ZW_@UY
MMD9EV5D69.2_U+[G%]CO,^'[K&M]C&*W]8>N'J^;ZE9(PZ9;BL/@?IWO'^DO
M_P#/?Z-9!<45)G6H#[>0HN<4%SR)UX24T\U\VM^(72?XI#_EO)\VU?\`5N7*
MY=@%NIU\%U'^*<QUN[S;4/\`IN2*G__3T/KIEV7=??5)V8M;*VCM+AZ]CO\`
MIU_YBQ!<\+T#JGU/P>HY5N9ZUU-]Q!?!:YL@-K'L</W6?OK(R/J#FMDXV758
M.PM:YA^]A>DIYH9#@BMRW#NK]_U2Z_1)^RBUH[U/:[_HNV/6=?A9F,8R<:ZF
M.[V.`_SHVI*;#,YP[HEG6&8]%E]Q/I5-+WQS`'']I9H<PZ!P*ROK+81TWT@8
M]>QK3_5;^D/_`%*2G-_;@SLR_,ZFYQ=?H*V$@-9^;5O;[FTL;[?:BNR*;ZQ5
M3=576/H4M&QH\-T?26$:HU!4#6Y)3NX^!DDD67-](M(W4F7&>6UM_-]OYR5E
M%%;F5.8**G&([D#\XO=_..6&UUS#+7$?`E&JMR,F^JI[W.,P)U@?2<DI]`^K
MW3*^HV!]C0.FXQ`<WM;8W5F+_P"%J?IY/^D?^A79[MQD\KE<'(;AXM6+5HRI
MH:/CR\_VG*[7U4CD\)*>@!&I/T1R5R_UQZYH>CX[N0#FN'8?29B?]_R/^VU>
MZMUL]+Z6W(D'*N.S$K/^D<-QM<W\YM#/>N3P^@]:Z@[>RES=Y+G77RW<3])^
MW^<?N24T"_S3,]2QWIU,=8\Z!K!)G^J%VW3/\7(=#\U[K?%OT&?]'](Y=;T_
MZM=.PF!M=;6@=F``?^21M3YG@_5'K6:07-&,P]W^Y\?\6W_OSUU/3/\`%M@U
MP_+W7.[^H8']FMB[>NJNL0QH:/)304\P[_%O]3;6_ING,<X\O:ZQA_\``[&J
M?1_J#T#HF;]LZ:+J7&-U9L+V':=S/YS<_P"E_+72))*?_]3U5))))2DQ3I)*
M:>1TGIF4#]HQ*;)Y)8)_SOI+"ZO_`(N?J[U2MK0VW#+'%S78[^Y&WW,N%K%U
M*22GR_,_Q-7B3@=5#CV;D51_X)2[_P!%K#S/\5WUPQI].FC,:.]-H!_S,@5+
MVQ-$I*?G?,^KO7\"3F=,RJ6CEYJ<YO\`VY5O8J_3C7^T<=KB&GU`"#H?^DOI
M!5[NF]/OL%E^+3;8.'OK:YP_M.:DI\KD$2#\PI,ESVM!Y('WE>B9'U3^K^1)
M=AM8X_G5%U?_`)[<UJS[/J)@"QK\;)NJVD':[;8-/DUR2DW3.CXV8&Y5[0YU
M1-=<@$@"-VT_F[H6W5B8](]C`//DJ.%B,P\=M+7%T$DN/<N,E6$E*22224I)
M)))2DDDDE/\`_]7U5)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]DX0DE-!"$`
M`````%,````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``
M```2`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`````0`X
M0DE-!`8```````<`"`````$!`/_A&`5H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z
M;65T82\G('@Z>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A;65W;W)K
M(#$N-B<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O
M,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N
M<RYA9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70])W5U:60Z-#9F-&0Y-S,M93AB-"TQ,64T+3DW8F8M.38Y,C=C-C<U
M9#9D)PH@('AM;&YS.F5X:68])VAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q
M+C`O)SX*("`\97AI9CI#;VQO<E-P86-E/C0R.30Y-C<R.34\+V5X:68Z0V]L
M;W)3<&%C93X*("`\97AI9CI0:7AE;%A$:6UE;G-I;VX^,C$Q/"]E>&EF.E!I
M>&5L6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^,3(Y/"]E
M>&EF.E!I>&5L641I;65N<VEO;CX*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C0V9C1D.3<S+64X8C0M
M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIP9&8])VAT='`Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\G/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z-#9F-&0Y-S,M93AB
M-"TQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.G!H;W1O<VAO<#TG
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O
M<VAO<#I(:7-T;W)Y/CPO<&AO=&]S:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C
M<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT
M-F8T9#DW,RUE.&(T+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z
M=&EF9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F
M.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E
M<V]L=71I;VX^,S`P+S$\+W1I9F8Z6%)E<V]L=71I;VX^"B`@/'1I9F8Z65)E
M<V]L=71I;VX^,S`P+S$\+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z4F5S
M;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(#PO<F1F.D1E
M<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED
M.C0V9C1D.3<S+64X8C0M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN
M<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX87`Z
M0W)E871E1&%T93XR,#$U+3`T+3(R5#$Q.C(W.C,V*S`U.C,P/"]X87`Z0W)E
M871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`Q-2TP-"TR,E0Q,3HR-SHS
M-BLP-3HS,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^
M,C`Q-2TP-"TR,E0Q,3HR-SHS-BLP-3HS,#PO>&%P.DUE=&%D871A1&%T93X*
M("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD;W=S
M/"]X87`Z0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT-F8T9#DW,RUE.&(T+3$Q
M930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$
M/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HT-F8T9#DW,BUE.&(T+3$Q930M.3=B
M9BTY-CDR-V,V-S5D-F0\+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C
M<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HT
M-F8T9#DW,RUE.&(T+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z
M9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z
M9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0]
M)W<G/S[_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`"!`-,#`1$``A$!`Q$!_]T`!``;
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<6#$#2;'4";_T_(]^Z]T@MU]B[*VA
M(L6X,[2T=7*!XZ0OYJD*1<2_:QDR*C#\VY_'OW7NDA%WKU?.2HW?3II%[O39
M&('FU@6AL3[M4=,>&WKTZP=R=:2>/3O7$V<@!9/O48W-K,7B""_^)`]Z/3JB
M@`/3HO:G7$E_]_AA!;_IL2/Z_P"N>?I[UU;J7%V/L20J(MUX!@WZ"<C!J/%_
MRU[GW[KW4P;UVE/S%NK``+P?]R=`O/U_W=("?]A[]U[J3'NG;C%=.>P[\7&C
M*TLA(M]0B,;C_6^GOW7NI/\`>'"ORF6QK#Z7%=$.?Z6UCW[KW4O^)8YN!7T?
M]?361W_Z&]^Z]US6JIFL8ZFF=;\$3!R3_KAK$W]^Z]U+61'-E=6(YL#?CW[K
MW7/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]#?X]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%[[9[:3;:R[;V[(DN?DC(J:Q2&BPB
MD:;6`.JMDN!&O^)]^Z]T"."ZPDW)2U.9W+)*:VL7SP3N/+7!W!-I5<DK8GZ7
M`M[]UL9('49NI<<<E58@U^0::BI(9VKI<3!%1%)B+4D3P%BTRDZK'^R/?J_+
MI1X(]>ID/2$+QH5R=(4:]FFQCL;7(O(;<@?[U[]TPXTL1UD/1JK^C(X:6_U_
MW$R>G^GX/U]^ZKUW_H5G0>BHP;E?TK]JR,?Q^GC20/Q[]U[K/#TS6D,6@Q$O
M/ZE7QVX^A!)O[]U[K(_3N05;I2X]CQ94JC$;7MPVH6`]^Z]UA_T0Y7_E1I1_
MK95A_O4GOW7NN?\`HJRL7J^PJ.>/^+I(?KS_`*O_``]^Z]UX=;9Y/\W2Y%47
MD"/)R:1^3;U_6_OW7NNQL;<T/,,>8B)X)3)N;@<\VDX'OW7NL@VCNZ.S+-N5
M"O(*5TC!2/RMW(//OW7NFFJ;<.*R\.%K,]N:AK:NEEK(#/)6%'I(YZ>GJ6,]
M.'6`))4I;5];\?3W[KW3ICJ;>U95+3KO3-Q0+9JB?S^:.-";,ZLPU.5_LD\D
M_7W[KW0*]U?.#HSXU9+;FW^X/D-MCKG<&Y'BIMOT>]=Q4L>5RU1,Z)`7I8VU
MT=-4L]P\X$`_)O[]U[H\'3_;&,[+QJRT]91552M+%74U905453C\UB)Q:ER^
M-EA9HIH)C]66Z_D>_=>Z&GW[KW7_T=_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7!]6FRZ;D@#5]/K_O)]^Z]T73MSN&+;\<VW-MU0FW!*!%7UL0U
M18B,WN(QR&K9;6"_CZ^_=>Z"38NRI9C'GLUK\DLIGA26\E0Q"NXG&NY:;4+"
M]P-7OW7NBS?,7Y93];I6=-=25L?^DS(P"/<6Y(IA64W6^*JD6,S32QW6IWA5
M*^BDA_Y1`3*XM;WH\#U[JLK&;Q[VI`SP?(CMM6D<2N6W(*@M);3I8>`\`?GZ
M>RZI]>O5/KT(V*[4^35/'$:;Y#]AE6X_RH4E<0"3S(9(E\P_P-KCCWZI]>O=
M+BD[Q^6%+XP.\ZVLC3]!R&V\3*3_`%\EH)O'J_V%_:FW)[\]:Z6-#\B_EB@4
M_P"DW;-2%M;R;3QK22_3]3)2QMJ/Y(8>U/6^E72?*CY64Y2/^+;!R'^J6;;X
MB64_@N868`\?X>_=>Z4E/\N?E-&FJ3`]5UVEE!=Z?.PS`7_0MJL1@?@V%K>_
M=>Z5U+\POD$F@5/6_7-8Y0%DAJ,Y&"3?U6-;]?\`'VCGKK'V=>/2FI/F-VTH
M#5_4>W'!.EDI-PUBR#D<FZGT#^G^/MFI]>M=/Z?,G<H`-?TR[A3=C2[DA,)`
M^H`J*229N.#<_7Z>_%B`34XZV.(Z$#8W;TG?>3R6R*_K#.X;!FC,^YLU'GHJ
M:FI5B:.:BHXI((*:5Y)GL"%:]O9OM.YJA4D+J`Q45'2:\C:4=I/Y=&JR65Q^
MV<+)7U:H(*&"GI:.G>0F6=@HAQ>.IB3^Y4SN@74;V/)^GNURVN>5Z@U-<?/J
M]NI2"-3Q`Z!-%RF1KYLIDO5F,NZI,H<M#11*Q$.*I.;"EI`>3;]V1FDY!'MC
MI[HM?SL^66Q_@M\=-T=G[G%+EMQ^O%;+VQ-.(JS>&_:VE?\`A&WI$#!ZC!XX
MA*C(RIQ#2*$-BWMR+,B]-R_V;=?-W^3W8F[/D7O'>6^NY,Y6;JW1V#DJNNS&
M3R,OW$E)D*V0S8VGQ5]2T.)Q,K"*"*+2%AC6XO?VMH/3I#4^O6R7_P`)COG1
MNK-8?/?&7LG/5F3SG2><H8MIU.2K&J*A^MMSSO028]_(SRRKALD`HN3I#C_#
MV7GB>C$<!]G6\IH6_P"K^S_A_F[6_P!\?>NM]?_2W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=%:[D[NBV_+4;3VE.M5GI2\60R"V,&#C9-+I"1Q)
M7`7.G\>_=>Z!_K_9,E1/'N#/O/,)'-5#%5`FJJ7)U>>I1KG7*]R+_@CW[KW0
M`_+SYDTW4\3]5=7U%%7]OY6B#U];3J*FCZLQM2RALS6P*#YMQ5E/?[6B/JBD
M`)%O?NO=5(XB*5:FJDJJNIR60J:N:LR64KI#/6Y3(5+R35.0JZEBS5%14/)J
M9KV!)46`M[T>!^SKW0F8V$26``!`OP/\0/Q_K^RWK72TH:8AU^HY'Y_UN/Z<
M^_=>Z5<-+81VN-7UM?U6M;5;ZVO[56_X_P`NM]**DI>+?C_??2__`!/M3U[I
M44=(+IP!?GZ"Y_QM_7W[KW3[2THNW']K_#^OT_I^??NO=*".D`5387M:]N;?
MT^H-O:.?X_RZ]TZ14OKY4#@\^G_#^G/MCK73_A=MY#<>2I,+BH?N*ZL<:`!<
M01Z],D[#FXC%V_V'O=-7;ZXZ\<`GJPK9&S,-L/;\6-QRP,D,/W==65!`CEK%
M775SU+GDTJJCZR3Z1[<^B>#ATIM(Q*,GH/<AG3N_*QY.Q&WL=)4MM^ED-VE+
MG1_>"M0\3/5?YJA0"\5/>4_6_M7'70M>/59X_"F>/T/2B%=BMG[?RF\]U9&C
MPV/P^/K<K79BO8)0X;%8NFDK*_+59;TK34-'"6)^FK2/=^F>M`7^:?\`.3.?
M-SY"Y#.8^JK:?IGK_P"_VWU%@)ZC_-XS[ATR6Z\E""%J,UO"KB,[2V/CH_%#
M]5/MR+^T7IN7^S;JFO>DWCI:@?[46!_H1?D'@@W]K>D/1Q/Y,O851UW_`#,-
MLT]!(U-3=C;0W3BVCU$"6=,=1;FH68"P?]ZC>U_9>>)^WHQ'`?9U]03^^D/U
M\HT_Z)?[[VU-_F[Z/)]?IY>?>NM]?__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]UTU[&QL?Q_QO_`^_=>Z)SWEW_%@WJMF;%J5GSS`4^6S<3ZZ?`J_HEBQQY6I
MR?\`99/[`-_J/?NO=`UU_LR>LD_CN?61O)+]Q34\Q+333L&9JF5FNS^0G5S?
MZ^_=>Z,']QITG4K-87"\".P"A++P+`>]:Q'^H>'6M0C[SP'10I/@O\?ILCE,
MU)@L^N6SV5K\QE<H=S9.>NK\G75+5#558]1/.Z+I:T2_10+"WOVOQ?U!PX=;
MUB3O'#K*/@GTXX)I:[<U%)]`8LDD\04$Z54SH"6YY!%O>^O=<'^"NT(@IQN]
M-P4H).E*FBQ4GXO8"*.(@@_U)'O5!Z=>ZQ?[)6\`M1;YB?2?T5E"H<_X3"&Z
MV-_Q^/?J#TZ]U@F^(>Z8;?;[BP,U[B(-#5TVFUOIXU;R7O\`0_3WOKW3>?BW
MV=3N325.WIU0G4175*F06M<)-&J*3_C]/?NO=>_V7GL^B.J3"4\YMQ)2UJNC
M?XL;\$G_`'CW[KW7?^A[L*B%Y]L9+1;46A2E=KGZ:?$[2L+_`)M]/?NO=>&R
M-V4_JFVYF`R^GU4$C\#Z&ZBWOU!Z=>ZCC;V?CM"<5DPS,``<=*?*Y-DC)MP&
M<CZ?T]ZH/3KW1U^I.NH-H8G[[*(IW)F(1+4S")M-!2GD4?C_`,XLIDLS`6)'
M'O=!Z=>ZX[YW#_'*N;9=`O\`N-QYA?=<^O2*PO'Y:7:7W"$>59X[RY!U/[!"
M1MR??L^O7@2.!ZY8+'0UCG6"**D6)I+*$:T**L:A5M8-"`ND?538>UT0'AKC
MK=2<GCUKQ_SP?G>])C:[X@=999(:J2*FJNZ,G02N$@HV1*S$=9B1&5@KHT=5
M6&]UC1(GO8CW8*/3I-<$]O6HQFU"R,!?C4H+`*UM1-K#Z"Y^GO=!Z=)JGA7H
MM78\WBA8?U8FW/\`JB.?Q[]UKH:?Y8]8P_F:?':-+ETRN1CX_"S==9$:?];\
M_P!/9>>)^WHQ'`?9U]-W^\+_`&7GL?\`LC+[OZ_[M_O!_#OZ?['WKK?7_]3?
MX]^Z]U[W[KW7O?NO=>]^Z]UBETV4-;DG2IX!<#4"3QP`#[]U[HAWR&^2\6+F
MK-B==U@GRH'@S>X:9O)!C%D_;GQ^/MZ9J@V(E(_S9/OW7N@2ZPV(\QIMQ9T2
M-"W[M/0SW:I>4W;[Z?7=B9&-[F]Q[]U[H0]X]J;>V5+0XZH\M9F:]'%!B<>-
M=54PJWC^YJHU_P`S3JWH4_D^_=>Z#N?NS?R_PJHIMO8F5,EE<;BUQ<0:;+PC
M+5S45+/2QK_G:BEF0252G]%*KM[0;Q(8=M:5>(;_`"=(-W=H=L>5>(;HR]'F
M:9D6(YW#RU,6E*Y8ZJACM,HL;/%(SZ5:X`/%OK[ILDIGVTRG^+_/U39)3/MO
MBGCJ_P`_2DIZLR-JBJ*&=;`!EG$JDC^R'4V)N/\`8>S+HRZ<8JNJ+'5%$.+^
MEM9O?_&]O?NO=)+<':>P=G5T5!NK>.T<%7S@2)CLKN'%X^K?Z:9)H9ITJ8%`
M(/TO;GW[KW0BT>0AGB6:FF6H@D6-X*E7$RSPR('CDAF4^.6!@WI8?4>_=>ZX
M5V;IX$(3EE`$]^?7<`WO<?7W[KW0#=U_(W:O2.SLEO/<T>;K:'$4<M?)C-O8
MG*9S)RJ#X8C38O#PSUN0GJ9SXHHE727(,A"<^_=>Z#SJGYBXC?GQTD^2^>VW
MN?KC8\6V=R[OKL1O'$5.#W=A\;M_*9.B:/<.'`%11Y&N\*M%$A4".06-A?W[
MKW0&U/S?[.W34FMVMCMC;9P4T:5E)2Y*IGRN=:E=1XX<E.`D4U:(U!81J`H(
M4W;43[KW5C/56>SF[NOMJ;FW/A/X%F,SC8JZIQ,D:QFD:0R*)(Z>0>:E@K8H
MXJB*%_7$LO/U]^Z]UFW[NZ3"P0XC#R1'=&:66.@,C#3BZ6`+)69JM3@K3T4;
MW@O_`,":@^-?T'W[KW09X?&&G2DQ=*SOJ>:26287GK*R637D:^I)NPJ*QVU,
M#]1;^GOW7NB]_._Y;X/X<]#9#<&->&I[$W6E1MWK/`-/'Y<EN:52E7GGA:[Q
M87;"NM35NUUD=%0>UT7P+ZTZWUHN]CYO,;GRV8W%N/)3YK<&X*_(9S.Y>M=Y
M*W*9?)3O-D<A5&4LZO4U);0OT6+2!Q[</26YXIT6;.TNKR-_JED(_P"0@3]?
M>NDW11NV6^W8(?[31M^;?I`X_P!>WO?7NA4_EA3^?^9O\?W4D:=VYI+WMP-D
MY-0./P![+CQ/V]&(X#[.OICW/\%^I_[(C_K_`-G][UUOK__5W^/?NO=>]^Z]
MU[W[KW71^AYMP>3^/\>>./?NO=5L_)SY7+2SUO6_6->KU@O2;DW53-Y(Z-2P
MCGQ&*96/FGG!*NZFZ'CW[KW1?.JNOY*AXMP[AA=$U_<TE$Y9GDD>[?<2:B3)
MY+W)-[GW[KW1B\KN7$;?@2HR-68:.2\44<4%7*T0AC+^0M2QLJK';Z&U_?NO
M=`'EMM];=E;VQ^XL1V%44.Y):*EQ;8^ACFFDK*>@EJ\A"D*24B&%J5,A4&7U
M#^S>^D>_=>Z,#M;8V(V[+#71T<F4R"!X(\M7U225<%/,7CJ1!$AM"TJ$A6L'
M!8\V]Z(#"C"H^?6B`PHPJ.G*3KO8]55/D9MJ0P5LDL>J>$"E5&I6#."8IK,7
MCU"Q')Y/OP55%%``^6.O!0HTJ`%]!CJ?B]B[+Q\=.E%1Y6B2F2K0++5U/IBJ
ME*JI]9.I238_7WOJZ&C*?F.DYW-1=E_Z%^U*+X^9'$8_N+);1R5)U]4;FKJG
M^$8[<B4A3'5-;5S)JH5$2MHE0,ZS%#I//OWY=+KV9):Z`/RZJ?Z>^%/?6^'-
M1VUL[!;2K:P13YW>.Y]P)N#=M55.`:VMAEAEJUK*BI]4ID98U=FN0OT'NBY1
M0`>?5P-;3S]7]<;;V+L=*G(#;>$P6`AJJIII\A]A14BXY:X()%J:J5U@:5D5
MP[I?\CW[K?11?BYC/FA/NSM'<?RHW7UT=N+N27$]3[;ZSQE?34+;/@#5$&Y=
MV567EDR5-N.N:1:8TEWC5(PP8\$>Z]T='*PX62`5M=#2UIH:>:<'0SU:QPH9
MG2()^I&(Y_J??NO=$?J_D5V'O3OJ?X_XGXS;AW'T/D]M2TN^.WZE<<FR8,IF
M1>DP4&*KW2KSE.N*,B9*:GB$<<SHC$GW[KW1T>LOCITMLZ>ER.W.MMMXRKIH
MD=5BQSSK$I4:(X_OZF9$6,<%6YU`GW[KW0Y[FW+C=I8>?+Y(.Z*8Z2CI*8VK
MJ_(U(%/0X_'(/K4U#@)>Q$409SZ4]^Z]T7NFER%979#+Y4K)GLY+$]7HNU+C
M*>"2]%A*!GNQH\<JA`?[;W?ZGWM?B7[>O=+;.[HVWUALG<&^]Y92DPF&P&)K
M<UGLO7L$@HL;21^>HO(UK352IXHOR964?GV8T'IUOK2M^:'R@W1\KNY<SV/D
MS44VV:,U.`Z_V].7$>!V>E2TE#Y(R="5F3A7[FJ:P;[E@A_I[U2G2"4GQ&ST
M1?=$/E1VL"=')MR>!:_Y-O>QT];YUUZ`S.TA\#$6^K\V%[`-Q_C]/>^E%!Z=
M$-[MJ=.25+FRR1CC_6_I[]UZ@].A2_E<50D_F8]"R`<#?.XT`_I?:^847_IQ
M[+6^(_;U[KZ;^D_P2W_@$O\`7\_Z0;V]ZZ]U_];?X]^Z]U[W[KW6.4A4+LP5
M4!=F:P50H)+L2194`N??NO=53_+7YD12#*=6]2Y3TGS4.[=W44G-VNE7@\(Z
M&ZO)&Y\U0#902BG4/?NO=5RXRNTR)(TC(ZRK,DQ]<@E#%M=F)+LS<F]R3[]U
M[H<,3V]O2B:+_<KY(P%1%F@`!0+8!T`N!Q]![]U[I?TO>&XPJQU<>,K*=K^2
M%Z5KGC3PI%CP>??NO=*?#=OT5)4QU4.TZ**=-1$]&(HJA6E33(T1T@IK4V/^
M'OW7NA%HN\L&2/N\3D8M7+"*:,@D&_)L+GW[KW2TI.X=ISH(S4U<`8@EZBGU
M1W/X-N=9_K_A[]U[K-N?OOJ+8>W:C<N^=]X/:F#H@%DRF:D^VIY9Y'#1P1"3
ME\B5_1'SJCN;>_=5<T1CZ`])G;'R\^,6\UC;`]Y=99#S%6CAFW#08]U:X".L
M>02ET-<V!)-OZ?GW[I'97!G(J>AUQ.]=D9=(_P""[LV?F"ZV9L?N/!Y0%9+C
MDT%0SA>?\3[]T8,*,1TW9&DJ&DBE;UV@,;21DO%>`NU.T3W/-I2+_@'W[JO5
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MD[,RH':-;1U(,&[=W4KJZ;=@R$;"&KPFT00LS`F.>I;\Z/9EZ];ZI#GRP:.0
MEI'.C2Q<AB2MM7(4@@NMQ_7@^]=()?[1OMZ0^6R`E@D0`79E'//'/^`_V/OP
MZ>M_Q]!/NJ:G2D*J;2!7'`MZ@+'G\<^]]*>JX^ZI?/G$B']J2'_8_NQBW]?J
M??NO="=_*TF\O\RCH.0<!^Q-Q)_U+PN:0_[>WLM/$_;UKKZ?O_+H_P#+'?\`
MY=_>NO=?_]??X]^Z]UBD9(5DFD<*BHS.S$*J*BEF=F)LJJHN2?H/?NO=4X_+
MWYLMF)\EU9U)E77%P-/CMW;THF;16SG]M\1A6C8/]BS>B>H!%[W4VO[]U[JM
M.FJ`KM<*&M9@K:@+\M&'Y:558\,;EOJ?K[]U[I34=4!H_K_K_P#&AR#[]U[I
M44]=I5G-SI']22#].#_C[]U[I^I<@9"AN>+<W-^;?7F_OW7NGREK+$V+`:CS
M<@_4_P"W]^Z]TIZ2JN5OS_K_`)_WGZV]^Z]UPW#O?!;2P65W)N3)TV%P6%H9
MZ_)Y6M<I34%)3H9)9G9K`DHI4+]9"V@<L/?NO=:VWRU^7^1^1.ZJS)3S_P`(
MZEV;]Y+M3$U;GPLE,^C^]N?%_&^6RD5HZ6)@=*6`Y!]^Z]U4IF_FWU[L_>.;
MVCFML;AJI,)72TTV5H32M3R+Y72&IBI)F1UU117XY]^ZT%4<%`Z%W:'SYZ=I
MUB>BWGO#;3FUF\>8QZ1MK/\`G6H)U"JI^I2_'OW6^CA;#_F.I`:,;8^4^>PT
MBZ/%'/O'*4RDC]'IR/G`T?[4!]??NO='OZ[_`)C'RA-##E]N?(+*;JQ1,L,%
M1)48;<&.F6G(\\1J!#K>826+(UC^;>_=>Z-;UW_-9^5G\=VGBGQ>U.PZ[<FY
M<-MK";<AVU!19?<-?7UL$592PUM*R-2+28LRU4M5H:.G$=V(U#W[KW6PM1]L
MJ4'W./56LG[<$]W^@X5VL&"GBY^OOW7NF'?N[Y=XXNDP5-Y:#&S525.:A\@:
M;+T=':H@Q,DJ$"+$S5BH]8I]4D2V'%_?NO=-.+C:MJ4A31''$ADE`%T$"E0Z
M1@@!021:WX'MZ#X_RZ]T0C^9Q\XZ?XM=3)LC9-=''W%V;0U>-VO'2R`U6S]L
M,!2YK>54I_X#Y&=F%/CKV#RG6.(V]K*#T'6F^%OLZU!I<\SS2RU=3+53U3O4
MSO5RBIJYJJ:666MJZRH!(-15U$I9E_V/O71?4^IZ;ZO/J!P;"X%@3:W'O?2V
M(`QK4=(C+Y\*>"?[7-S_`%X^G^'O?3F!P'0;Y[.+41O^?&C#_8CZDF_T)]^Z
MWT0/LJO\NX%:Y-J^!>26_P!V\#Z_3CW[KW0I?RJ9BG\QOX].23??&Y#_`*[-
MA<KS_O/LM/$]:Z^HSYA_";_^`+Z_I^/[[:?>NO=?_]#?QJ7$<$DI=(UB4RN\
MK:8E1`69Y6)`"(HU'_6]^Z]U1Q\S_G7%NNMRO4?4&X)*7;U--4T&[=XT%4JU
M.XVIK1U.(P,T;`4V($MUJ);AY3PAL#[]U[JLRCK:=P%$^L$^I4XOQ:[\\@W_
M`#[]U[I2TU2@U!.5"<7_`*6/TYMQ[]U[I]I*H^CZCZ?U_P!A_C^/?NO=*:GJ
M_0_X%OZ_XC_8`>_=>Z?J.KY6W^]CGC\_CW[KW2HI*H6_V(_WOZ_GD>_=>Z=*
MS.4F*HJNNKJV+'T=+2-554\DT=/$E/2_Y3/4551-Z(*6ECCU,?SS?W[KW6O'
M\X/G#)W=E,KM#:V:?!]);/FEJ,GGJF04\6ZJVF;Q5.8S`5E67"1M&?X=2CF2
M3D@V]^Z]U0YV/WE6]F91=M[4&1I-ET=;]Q%%%:#);CGIE(I\GEWXCIZ.2Q,<
M+#T`BXO[]U[HB'R:AS='VSG\ICJ2MJ5K*7"50F2E:IC:1\52^8B>(>-Q`Z,I
MM_:)/Y/OW7N@7DWUF<;]LH-/6QRTB33021S4L]-)'(04<N0KL;7LO%O?NO=*
M+9^<W=V/NK!;)VQ@(ZS<.YLE2XG&P1M?7+5RI&9:A@#HHZ=?7,YL$B5C?W[K
MW6SQT7UU@NB>K<5M`Y!%H=N4D^4W#GGU3/5YRJDU9BHIZ=?5.,E7#QTT:\N&
M55^OOW7NMC#^7M\7:_9F(I_D!V;ADQG8N[,0:;8>U:R/74=;;&JFCJ*>EJ5G
M#%=TY^!A55DB@,H=8KV!'OW7NK58ZI6D!M>^H@_D@@_@V^O^O[]U[IQAFFFD
MC2G4F0L>"/[-@#?GGB_^P]^Z]TP]T=W;$^.75.[.T-Z5HI\+M7'R54M-&P&0
MW)F9E:'$[>PRGEJS+U3"(?B--4AX0^WX/C/V=>ZTD_D1W_O+Y"=J;N[8WY5B
M;-;FK3)!0PN[8_`X:#5'B=O8Q78Z*+$4EHP0`'DUO]6O[6=>;X6^SHO<N50`
M:05NQ)L2+FWU.GZGW7HMZ::[+60D:OH?[1O]/Q^?I[WTOB_LUZ0F2RU[\D\'
M\DV^GTYY/O?3G2)RN5'@FM<'0?R?]Y/Y_P!C[]U[HF&\JT3[ABXOXZ\.;_FS
MKP?Q^/?NO=##_*LDT_S`OCE.3R-WYB0FYN0=O9ICS]?9:>)^WK77U!/OO]P5
M[M_V0-]U]3^G_2-H_K];?GWKKW7_T=GG^;O\MJWX[](X;KW:65DQN_\`NFNR
M>*I:ZF8BKPNSL9"'W-DHU4B0-72UL&/1@1H\[$?0>_=>ZU<L9V:8P$^XT6^B
MW)5`+'QH][S1PM=0YN6M>]S[]U[I>47:3#215VN1]&/XO_0^_=>Z6V,[;G4H
MHJKIJ4$EB;J6%_J;_G_>/?NO="/CNV(_3JE#_0\'Z?UOS_7W[KW2^Q?:>.D:
M-)7`#D!^3_C?^I%C[]U[H1,?V%AI+'R6`M_KV_'OW7NEQ1[SQ;*EIXY`S1WB
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M4]3C-HBH4P1XK!/(J5.4&L$EJY&\3..4AUGW[KW6QA_+[^-"=Z[JHNY=ZT`G
MZ4Z]RTC;)QF0IVCI.T]^XFH$=7N2I@8:I]C[.EB\-"MB*VM#2BZ@>_=>ZV$Z
M:M9V0EV<%003="6);45A/,4=B`@/U4>_=>Z=#6.!^V#J^@%R?KP>+#\>_=>Z
M4])60XVE:NJI88IDII9'>JE\-/34<$,E1/4R/]%`6,\_CVK@`*&H\^O=:HG\
MS3YP/\D.T_[B;%RDW^A?K*OJZ'#_`&S/%2;SW7'>ES.[)X6(D^UI2AI*#5=3
M$CN.7O[?H/3K?55<^34H1S^MU'YX+$"WUX%_>^O=-TM2-#<6/X^GU_VWOW6J
M#T'2>JJL#ESZ026Y_`/^/T]H)2?$:A/7ND9DJEZNHIZ+'02U5542:(HX$,\\
MCW4+#%2H?),TM_Q[I4^IZ]T..TOA9\J^T\9+E-F]+;LKH71A3P5%%#AY:Q60
MM$8$K9%=]2D'D7M[]J/J>O=%C[&_E6?S38\A/E*?X6]PUN'3SR?<[=Q=/G#+
M`"2)2M+4JP>QX']/?M1]3U[K-_+^^.?R&Z5^=?Q]R/;72?;'7%#0;RR!K<IO
M+86XL)C*`R87(01?>UIHWQ\,+5#A+M)R387O[UU[KZ/6NN_N[_F\[_V[JO\`
MYJ?S?>?Z4_I;[>_WU_\`=?U\'-K>_=>Z_](^?\\G=.5W/\R\5MD3%Z#KKJ3:
M..I(@YTK5[KK,WN'*5"K<JOD2.D4V^MA?Z#W[KW5-ZT];$`ND67Z?7@?T7Z`
M`>_=>ZDPU-7&Q-FY6PL;?D'^I_I[]U[IV@S%9$J"[^DW/K_VHGGW[KW2E@W5
M51"(@N+GFSD#@#_'Z\^_=>Z4E'OFKB).I_1]?4U_Z?7Z<`^_=>Z5E%V15QE`
M)F34`3=VN;<?UO[]U[HM7S4^8V9Z,^/>[\Y@,HE-O+.1G9^T;NVNGS6;B:*3
M)+8W/\-H-<P_Q7W[KW6LIU'W]7]7YR;<\-*F>W#,[M%E<T!-+3?<R>2MK*B.
MHU_<9.:I#%2]W!LU[\^_=>Z,E_LW6U-W5KUN]L1DIJ\VC^ZCJI99$3^@\SL%
MCY^@X'OW7NIE7F?C3V/)!)E<_GL371AH*29*H+#322"Y9P"H#E3]?K[]U[H=
M.L<'U!M+'2+L7<V$S>XZFLK9*;<6Y:J!ZS&4M7!'%)3X6&?731UA$=EF<7`O
M8W]^Z]T@^S:NCV37X2ISU;2UG\;K#4FHI<@E;5U5-2R?Y3).SL\LLLAE]5R;
MM_L/?NO=69_#G:%5\OMY87K_`!\U3MKK+'4M+E.TMP4A\<F/VFKI!%LG;]0A
M7[7,[JJ(C'+*"!3TZR'B_OW7NMMW9K[1VIMO";3VI2T&$P&`QE'B,'BJ"..*
MEH*"@A2"G@@6,*#HC3U-:[L2QO<GW[KW0@TN4@E*N:M+V`+<:C^!<GDA?Q[]
MU[I2X^IC5)*^KE*4T;@+&B>1Z_ZGQP_ZD@CD_CW[KW5./\V#YOR=>[3JOCSL
M#)-3]B;ZH(JCL#)T-6DLVS-IU/C:'!TKT[!J?*[B@O'.+AHJ,O:S,/:RW^`_
M;U[K66K<HJFZK;Z*-))](YTW/)`^OM_K?3++7>5[BX+$*JWTW8\``D@`L??N
MO=#?UA\:N_.Y*FGBV%U]N#(0SEHAD*S&S8G"QJUE\\]76%&GC6_$L.H,?Q[]
MU[JVKH#^1QV+OF:DK.T]RUPAD*>7;^T4EITF+A-?\0S=7%8,JW&I`+#\>T$O
M]HWV]:ZOW^,O\FOICJB*GFHM@8*BJHXU67*9FD@RN8GD&EFD:LKDJ"\R\Z6C
M"%;_`.V;Z]U;3L?XS]9[*IXS38*"IFC",GECC)#!`I*AD(0V_`]^Z]T8"@H:
M2@ITIZ.FBIHD4*L<:J-('T!(`^GOW7NHN2V_@<RGCS&$Q&5CU*^C)8VCKDUH
M04?350RKJ0BX/U'OW7NI/\+QEK?PZAM]K]C;[2GM]EJU?:6\?_`75SX_T7_'
MOW7NO__3VU/D[_+-^/7RJWW6]D;SGWM@-]93'XS&U><V[FTIHI:;`T[T6/IY
M\5+#+$=$4E^&%^/?NO=5P[W_`)"SR+/+UQWM(K:C]O1;UVPLJ@"_ZJB@E5B+
MV]7U_/OW7NB<[Z_DO_,;:1FGPN/V%V#20@G7@-POC\C*H4MZ**OB%1*#IMI)
M`N1S[]U[HFF^/AA\I^O`\N[?CSV+CJ-"X^\I<!4Y*D=4%W>*?$-5$J.3J=0/
MZ^_=>Z+9DL378*LEIMPX[+81XF"FERV/K,=+$[$@"7[R&(VO_3Z>_=>ZR!*:
MP*R1LY%_VF+1L3_J3>S`^_=>ZBU<HB0?BX//]+?TM[]U[JF;^9OFJC-YWKC8
MQGO08O&Y3<\Z@FSU.1GBQU`9`#9W6&EFL3R!?W[KW54=5M?T$H==V#ECR2_]
M23<AA_7W[KW2?J</6A^/R/\`$<?XG\^_=>Z;GQ];$Q47%B&TJ2`3;B]K`GW[
MKW4FEKLW0L9%FGI^``8RY_2VH"VO@`\^_=>Z?H-P[BW)D<+CILC65DTE;38S
M':]<STLU=.D*.K.6*A7<,;?4#W[KW6WC_+_I<?TET;A8,<!%D-T2G-9>I<VF
MK(!&*#%1RG]3(,?2"0@D@M,3:Y]^Z]U8MBN]ZQ&9A6<(W%I&%AP!87LH`]^Z
M]T+6"[_K',%.M4&DGJ(8XKN6)EE<1(.2?Z^_=>Z&CY'_`">QOQ?Z&R/:FY3!
MD,Y3T4.$V%M^><Q?QS?&4@\M)13K<`4=!J%3.WXBCYX/OW7NM3A:3N;Y';[S
MV<QF"W%V3O+=^7K<EELECJ"IEIZFKR,QD9GKI0*&"AB/$:^0&,"P``'O=2.!
MZ]U8;T7_`">?D!V;4T-3OZKCV?CI8XBN,Q="V7W'X?H[5,ZM]I`]F(-KM]..
M#[]J;U/7NKZOC#_)!ZHV4,9DLEM2ES.5C,=LWO.5\O6W(#2M14I04437_4DJ
M'2>![]4^IZ]U=1UO\,>L]CTE'$^.AG:D58XH8XHHJ>&-#=5AAC58XUX^@`'O
MVIO4]>Z-/B=KX3!Q1TV,QM-##$%51I4E0/R?3RWO77NE%I7_`%(X^G`]^Z]U
MW[]U[KWOW7NO>_=>Z][]U[K_U-_<`"Y``N;FP`N?I<_U-A[]U[KOW[KW7K?G
M\^_=>ZZ(#`JP!!!!!%P0>""#P01[]U[H.-U]2=6[S@DI=V=<;*W'!5+(M0F6
MVKAJ]Y-0'+5$U(T\9_Q#`GW[KW1,]_\`\KWX3=A^2:KZ9Q^W*Z=WO4[0KZ_`
M.)FY,JQ)+)`+?@:0O^`]^Z]T2WL;^0_T7FXJB;8';&_]E5(#^&GKH,?N*BB+
MFZ\U/BE`0<6%[^_=>ZUY_GQ_PF4^=&\^PSO'H;=O5O;VW:/:U#C(*;-9E-D9
M]9Z2:LJ&5**O63'3SO\`<7)U`%B=/-O?NO=41=P_R9OYF72(K*K??P][0FHJ
M<^O*[1HTW7BZ@*2ADII\&]1(02AX$?TL?S[]U[JNK=W66^=E5,E)O;KC>VSI
MXET3T^Z-H9W"&,4Y(E;17T-,P>Y_5JM[]U[I`O1T$S!DD5P5725TO86X!*\`
MC^AY'OW7NN)PM*?KS_KH/^*^_=>Z>]HX*B@W=MJHIXR:M<S0-%:P0S&:6./T
MCBX8C_8CW[KW6U#LZA3%;:P=!"=*46(QE&H7TC33T,$!-A8#UQ'W[KW2HCR%
M5"X"\(IL#J^H`-KB]S]??NO=#+TA)-N#M#9^(J"3!)E8JJ87+*$H2*A.";>I
MUM_C[]U[JY7,?R_\1\T,EL[<N_L,V>V?L>KRXV_B)\C4IMI\ODFAIZ_)5-%"
ML;5U53I0^)"=0C+$?I)!]U[JS;IW^7OU;UK14=!!A<50T5/`D:X_$4%)1TP1
M56P=((8_*UQ^IKL??NO='<VQUIM':E.E/BL32Q!'$BRK%&)-2\`ZE4&X'Y]^
MZ]TO4C2,61%C!Y(556Y^ESI^IL/?NO=<_?NO=>M[]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW70`%[`"_)M^?]?W[
MKW7?OW7NO6_WGZ_X^_=>Z][]U[H-]]=0]5=E4LU+V#UML+>T$XTRQ[KVG@\]
MY1I9-.O(T51(#I8@$&]C[]U[JM;N#^1U_*V[L6I?=_Q&Z[PN0F20?QG9460V
MED$DJ6)+0'%U$5(KJ3P?$=)]^Z]U5CW'_P`)(_@;NV2LJNH^T.[^HJJ6[4U&
MV6H-YX&*3GQQO#DZ>FFC4.02RN6(X_/OW7NJS]U?\)"/D'M[=N$R75?ROZTW
M'MNFRU/-.-X;8S6#S%/3PU:3&=I,8*BGGGB52`$L#8?F_OW7NCA;M_D_?-[K
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M?Z_GW[KW75A]+"U[VL/K_7_7]^Z]UW8#\?7Z_P"/OW7NNM(O>PO_`%L+_2WU
M^OT]^Z]UPEBBG1HIHHYHW!5XY461&!^H9'!5@?\`'W[KW0<U_3W5&0R4.9K.
MM]BS9:!F>'(OM?#+6ZR=9\E2E$LTBEN3J)Y]^Z]T(D$$-/%##!##!%#$D4,4
M$:1Q11(H58H40*L<2@`!0``/?NO=9O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=?_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_U
MC_O7OW7NO#Z#_6'^]>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
1]U[W[KW7O?NO=>]^Z]U__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g912919dsp_280b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_280b.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0B&17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-3HP-#HR
M,B`Q,3HR.#HR,0```````Z`!``,````!__\``*`"``0````!````D*`#``0`
M```!````+0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```=0````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+0"0`P$B``(1`0,1`?_=``0`
M"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]$ZAE68X<YNNT3`67^V\LZB/Q6AU5^P.
M=&[3A8;KI,[&H%(;@ZUF>2?]LY?DJ7J3^8U+>/W&H?5)VV;5_7KZ:G66$!K1
M/=9/_/J]I_FI'C*;K'NZ?;[6C3LN3))5GE\0F"3J'-^(\WEPY1'&1$5>UO7?
M\_;?]%_TD_\`S]M_T7_27(*3&ES@!R5,.5QDUP_\Z31_TES7[X_Q(?\`>O6_
M\_+/]%_TDO\`GY9_H3]ZQ</H.5EC]$TOCF-/Q*;+Z'E8W\ZUS/"1I]Z'W;#M
M0_QI*_TESG#Q<1X=K]N/_>.W_P`_+?\`1?BE_P`^[O\`1?BN6./<+!6&ESCP
M&ZRM;'^J?5KF!Y:VH'@/,%*7+X8FB`/\*2Z'/<]/Y#Q>4(?]ZZ?_`#\N_P!%
M^*7_`#\N_P!#^*H_\S>I_OU_>G_YF]2_?K^]#VN7_D9,GWCXEV/^)C_[UNCZ
M]W'_``/XI_\`GQ=SZ/XE`QOJ5>;!]JN:VL<[-25K#ZJ]&:W;Z1/\HN,RFR'+
MC:_^=_WS+CE\2F#ZA'SCC_[UH?\`/F[M4/O*U/J_]9?VIDBES36\2=LR"%@]
M9^JQQJG9&&XV,;JZL\@>2A]2O^6F^.TI2QXS#BCT1BYGFQS$<>8WQ>GY8?7H
M_P#_T/0.K/%;7.+=P`X6#Z@<?H-6]U9[6-<YPW`#A8/JL=KZ8^:!2%][>];4
MMS?]&U,7M_T;4X>W_1M02T^KQ]@MAH&G9<FNLZN1]@MAH;HN3T\5<Y3Y#YN+
M\6_GAY*5G":TVC=W,?>JT*3'.;]'NK+FD7H^FXU==&/735`:&B=.21RGOJ9;
M2YCQN:1W7-=*^M>.:&49SO2LK&T/(T("GU/ZTX;*2S$?ZUKA`/#6^:H>W+B.
M^I>A&?E_9CZ@(B%&%Q/$V^F8'V;-WN?6\,!:`T@GYK:WRO/ND]89B9WK6;G,
M(+7D<ZZKL<;JV!D,W5WM\PXP?Q1RQE8W.BSD<N+VY"`$/5\GZ7]]O[BE*K?;
M<7_3,_S@G^V8O^F9_G!15X%M\<?WOM,6T''@:#P3^2!7D4O=[+&NCF""C@MY
MF!XI'Q58(-?AJL]K7`M(D$01XRN5^K-3:?K196WZ+38!]ZW^H]0HP<9UUCN!
M[1XG^2N<^I]CK?K`;'<O#G'YJ?&",4KV:?-3B>:P1'S"1D?*3__1]!ZJYK&O
M<X;@!PL$VUNU%0CXKH>H>CN/J%P$:P`1'S*RB.DR?<__`#6_^20*0TM[/]$/
MO3BRO_1M^]7(Z3^\_P"X?^231TG]Y_W#_P`DDDN3U?WX%H:P`QV.JY*!S*]#
M(Z1M.YS]O>0(_P"J5!P^J?J&7">_M;_Y)6.7G*,#43+7H'.Y_EXY)@G-''IM
M,T\7HGCP*[./JE^]_P!%O_DDX'U3[._!O_DE-[TO\W+[&E]RA_XHQ_XT7BBP
M.&O*@:AQ.B[J/JK^]^#?_))B/JM^]_T6_P#DD/>E^X?L7#DX].9Q:^,7B6-:
M%,0/HZ%=G'U6_>_Z+?\`R2<#ZK=G?]%O_DDO>EUQG[$?<H?^*<?^,'BY<EN<
MNUCZK_O?]%O_`))/'U7_`'A]S?\`R2'O_P"K_!7W*'_BG%]O_H3QM&1=18+*
MGECAW!6D/K/U9K(]1CCXENJZ"/JM^\/N;_Y)*/JO^\/\UO\`Y)`YH=<19<?)
MY!$\',CAZ\!N+R%^9D9=GJ95IL/:>!\`MSZDL)ZR+`#M#2)^2U`/JO\`O#[F
M_P#DEI=('2_69]C).IB`T"8[PY-EEO&0,9'Y+L'*B',"<L\9S_=OUO\`_]G_
M[0TL4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``````````````````````
M.$))30/M```````0`2P````!``$!+`````$``3A"24T$)@``````#@``````
M```````_@```.$))300-```````$````'CA"24T$&0``````!````!XX0DE-
M`_,```````D```````````$`.$))300*```````!```X0DE-)Q````````H`
M`0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!
M`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T````&````
M```!.$))30/X``````!P``#_____________________________`^@`````
M_____________________________P/H`````/______________________
M______\#Z`````#_____________________________`^@``#A"24T$"```
M````$`````$```)````"0``````X0DE-!!X```````0`````.$))300:````
M``-%````!@``````````````+0```)`````(`$0`4P!0`%\`,@`X`#``80``
M``$``````````````````````````0``````````````D````"T`````````
M`````````````0`````````````````````````0`````0```````&YU;&P`
M```"````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO
M;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```"T`````4F=H
M=&QO;F<```"0````!G-L:6-E<U9L3',````!3V)J8P````$```````5S;&EC
M90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG````````
M``9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D
M`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/
M8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG``````````!,969T
M;&]N9P``````````0G1O;6QO;F<````M`````%)G:'1L;VYG````D`````-U
M<FQ415A4`````0```````&YU;&Q415A4`````0```````$US9V5415A4````
M`0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L
M`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU;0````]%
M4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI9VYE;G5M````
M#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU
M;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO
M;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/=71S971L
M;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$*```````#```
M``$_\````````#A"24T$$0```````0$`.$))3004```````$`````3A"24T$
M#``````';`````$```"0````+0```;```$OP```'4``8``'_V/_@`!!*1DE&
M``$"`0!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`
M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,
M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`
M+0"0`P$B``(1`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($
M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"
M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'
M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]$ZAE68X
M<YNNT3`67^V\LZB/Q6AU5^P.=&[3A8;KI,[&H%(;@ZUF>2?]LY?DJ7J3^8U+
M>/W&H?5)VV;5_7KZ:G66$!K1/=9/_/J]I_FI'C*;K'NZ?;[6C3LN3))5GE\0
MF"3J'-^(\WEPY1'&1$5>UO7?\_;?]%_TD_\`S]M_T7_27(*3&ES@!R5,.5QD
MUP_\Z31_TES7[X_Q(?\`>O6_\_+/]%_TDO\`GY9_H3]ZQ</H.5EC]$TOCF-/
MQ*;+Z'E8W\ZUS/"1I]Z'W;#M0_QI*_TESG#Q<1X=K]N/_>.W_P`_+?\`1?BE
M_P`^[O\`1?BN6./<+!6&ESCP&ZRM;'^J?5KF!Y:VH'@/,%*7+X8FB`/\*2Z'
M/<]/Y#Q>4(?]ZZ?_`#\N_P!%^*7_`#\N_P!#^*H_\S>I_OU_>G_YF]2_?K^]
M#VN7_D9,GWCXEV/^)C_[UNCZ]W'_``/XI_\`GQ=SZ/XE`QOJ5>;!]JN:VL<[
M-25K#ZJ]&:W;Z1/\HN,RFR'+C:_^=_WS+CE\2F#ZA'SCC_[UH?\`/F[M4/O*
MU/J_]9?VIDBES36\2=LR"%@]9^JQQJG9&&XV,;JZL\@>2A]2O^6F^.TI2QXS
M#BCT1BYGFQS$<>8WQ>GY8?7H_P#_T/0.K/%;7.+=P`X6#Z@<?H-6]U9[6-<Y
MPW`#A8/JL=KZ8^:!2%][>];4MS?]&U,7M_T;4X>W_1M02T^KQ]@MAH&G9<FN
MLZN1]@MAH;HN3T\5<Y3Y#YN+\6_GAY*5G":TVC=W,?>JT*3'.;]'NK+FD7H^
MFXU==&/735`:&B=.21RGOJ9;2YCQN:1W7-=*^M>.:&49SO2LK&T/(T("GU/Z
MTX;*2S$?ZUKA`/#6^:H>W+B.^I>A&?E_9CZ@(B%&%Q/$V^F8'V;-WN?6\,!:
M`T@GYK:WRO/ND]89B9WK6;G,(+7D<ZZKL<;JV!D,W5WM\PXP?Q1RQE8W.BSD
M<N+VY"`$/5\GZ7]]O[BE*K?;<7_3,_S@G^V8O^F9_G!15X%M\<?WOM,6T''@
M:#P3^2!7D4O=[+&NCF""C@MYF!XI'Q58(-?AJL]K7`M(D$01XRN5^K-3:?K1
M96WZ+38!]ZW^H]0HP<9UUCN![1XG^2N<^I]CK?K`;'<O#G'YJ?&",4KV:?-3
MB>:P1'S"1D?*3__1]!ZJYK&O<X;@!PL$VUNU%0CXKH>H>CN/J%P$:P`1'S*R
MB.DR?<__`#6_^20*0TM[/]$/O3BRO_1M^]7(Z3^\_P"X?^231TG]Y_W#_P`D
MDDN3U?WX%H:P`QV.JY*!S*]#(Z1M.YS]O>0(_P"J5!P^J?J&7">_M;_Y)6.7
MG*,#43+7H'.Y_EXY)@G-''IM,T\7HGCP*[./JE^]_P!%O_DDX'U3[._!O_DE
M-[TO\W+[&E]RA_XHQ_XT7BBP.&O*@:AQ.B[J/JK^]^#?_))B/JM^]_T6_P#D
MD/>E^X?L7#DX].9Q:^,7B6-:%,0/HZ%=G'U6_>_Z+?\`R2<#ZK=G?]%O_DDO
M>EUQG[$?<H?^*<?^,'BY<EN<NUCZK_O?]%O_`))/'U7_`'A]S?\`R2'O_P"K
M_!7W*'_BG%]O_H3QM&1=18+*GECAW!6D/K/U9K(]1CCXENJZ"/JM^\/N;_Y)
M*/JO^\/\UO\`Y)`YH=<19<?)Y!$\',CAZ\!N+R%^9D9=GJ95IL/:>!\`MSZD
ML)ZR+`#M#2)^2U`/JO\`O#[F_P#DEI=('2_69]C).IB`T"8[PY-EEO&0,9'Y
M+L'*B',"<L\9S_=OUO\`_]DX0DE-!"$``````%,````!`0````\`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-!`8```````<`"`````$!`/_A
M&`1H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T
M;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^"CQR9&8Z4D1&('AM;&YS
M.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^
M"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z-#9F-&0Y-S<M
M93AB-"TQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.F5X:68])VAT
M='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*("`\97AI9CI#;VQO<E-P
M86-E/C0R.30Y-C<R.34\+V5X:68Z0V]L;W)3<&%C93X*("`\97AI9CI0:7AE
M;%A$:6UE;G-I;VX^,30T/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\97AI
M9CI0:7AE;%E$:6UE;G-I;VX^-#4\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@
M/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70])W5U:60Z-#9F-&0Y-S<M93AB-"TQ,64T+3DW8F8M.38Y,C=C-C<U9#9D
M)PH@('AM;&YS.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#HT-F8T9#DW-RUE.&(T+3$Q930M.3=B9BTY-CDR-V,V-S5D
M-F0G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H
M;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H
M;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C0V9C1D.3<W+64X8C0M,3%E-"TY-V)F
M+3DV.3(W8S8W-60V9"<*("!X;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N
M8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/
M<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU=&EO;CXS,#`O,3PO=&EF9CI8
M4F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXS,#`O,3PO=&EF9CI9
M4F5S;VQU=&EO;CX*("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E
M<V]L=71I;VY5;FET/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z-#9F-&0Y-S<M93AB-"TQ,64T+3DW
M8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,34M,#0M,C)4
M,3$Z,C@Z,C$K,#4Z,S`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z36]D:69Y
M1&%T93XR,#$U+3`T+3(R5#$Q.C(X.C(Q*S`U.C,P/"]X87`Z36]D:69Y1&%T
M93X*("`\>&%P.DUE=&%D871A1&%T93XR,#$U+3`T+3(R5#$Q.C(X.C(Q*S`U
M.C,P/"]X87`Z365T861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O;VP^061O
M8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2=U=6ED.C0V9C1D.3<W+64X8C0M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*
M("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM
M+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P
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M;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_N``Y!9&]B90!D0`````'_
MVP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__`
M`!$(`"T`D`,!$0`"$0$#$0'_W0`$`!+_Q`&B````!@(#`0`````````````'
M"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@!"0`*"Q```@$#
M!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1AB
MD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$
M9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6F
MIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"
M!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$D
MP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.S
MP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(
M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$`
M`A$#$0`_`-S/Y!=H;@Z[AR^2H#/5)BJ9:B.EIWDC>1GOI&J,AM*_G\'VGN.'
M3\'Q=$0'S7[6JU:6`XI0%C=#,]=#*BR7O&X:?U,MN3[*2[*Y*\>C98T90IX=
M<H?F;VZSV>7%$6/Z*FKO?_SH''OWCR_/KWT\(].I7^SD]L7`UX[DVYJ:K_ZI
M]^\>8X%>F9[2.94C!`)8>OKTF-\?._?.QML9G=&XZVB@QV)HI:@F&2L>26H_
MW1``M2=/E?C4;@>S7:/J;BY6)>/1;[E[[M_MARS^^KI*H%)XTX#YAO\`!U7V
M/YZF^L?521OL;[RA\TD<-4,G-3R%%75&^MUE],GTM;W,L'M;>\R[:(8KH6\A
M(.LJ6`IFE`PX]8+-]_+8K"XEDFY6EW*!21X,<R1,:X#:S$:!3Q'GU,7^?+NI
M3<[`E/\`Y,#_`/U)[3_\#MO`X<T1_P#.)_\`K9UO_DX7RD>/LKN/_<PC_P"M
M'67_`(?GW,?U]?3:?]IS[W_WBE]^/W==Y84_K3'_`,XG_P"@^O#^\+Y17/\`
MK*;C_P!S&/\`ZT=9D_GQ;C8^GKV=UL?^8B<'_#@TOOW_``.&]<?ZUQ_\XF_Z
MV=5/]XCRAP/LGN/_`',8_P#K1UT_\^+<9!0=>U43_@MGY"MA]?\`E$'OQ^[C
MO1_YVJ/_`)Q/_P!;.O'^\0Y0`J/93<*?]+&/_K1UB_X?=W4>%V',3_3^/2?_
M`%+[U_P-^]?]-5'_`,XG_P"MG6O^3B7*'_A$]Q_[F,?_`%HZ['\]O=O_`#P,
MP_U\])_]2^W(ONW[UK'_`"*8S_S:?_K9UIO[Q+E$*?\`F"FX?]S&/_K1UR_X
M?;W=_P`\"Y_P;/2$?^XGM5_P.&]?]-,G_.)O^MG3/_)Q3E+_`,(IN'_<QC_Z
MT=<7_GN[PTG1UV';CTG.3$'^O_*.O^]^_'[NF]1C7_6Z&+^DT#,H^U=>:]>_
MY.#\I[A_BH]E=P[O3<8_+/\`O@?X>NXOYZN\)R%?KR!+?4/G*I+#_76`BX'X
M_)]^3V'W6V;5)[A6)_Z@V_Z"Z\?[Q3E;;1X8]D]P('KN$7_6@].'_#X6[M/E
M'7GCCMZ7?)9-6D)X_9!@\;@7Y.H6'MP>TDEM^I+S=;78'^A);&-VKC#:L4XG
MU`ITU+_>1;&8SI]C;X?/]Y1$#[3]/_@!ZBK_`#R]YH2(NOZ75(0E_P"-5LE@
MYTEV7P(1I!O]?Q[53^S\MQ%K56K3''_H+I%N']XURU?6Q@/LO?J*9/[PB\O3
M]#H_'\O[^90_RP[+I-B9/&Y/;&;H(Z^J?&2UYK:7+4BT\R)4I=(VAC5AJ`;5
M]/<:;WR!=<OZ[V4G0A^?GC^(^O62OL[[^[#[G;8EC9>V=[M\\J5%Q)>)*B$4
M8U0(I.H5`]#GK__0W!/E1EDP$&=RTE$F2CBHX;T4BEEEU*?2;?3Z_7Z#VGN.
M'3]O\?55-9O,552)1MS:_,2R"(PR+(%DY".OE6[16Y/LL2GB-4=&I5G0!6H>
MN/\`'TG6S[9VOI//^:F7D?[4M0/;]8_X/Y]-^#-_OX?LZY)E::_.VMK\`GA:
MEC_L`*KV[$T2L28ZBA\^BK=[.\EMHE@NU1_&C-=-<!LCCY]%F^8#QUWQ_P!^
M2)BL'0,*6G"-2152U"D2W!#M4LNC^HM?V*O;\Q;GO:0"/11AQSY]1O\`>TG6
M?VL%I*A,@C/=6GEZ=:^$]3-,0KD*BK$BK'<$,D0U-R2"&]YR6UKM8V<;7<6C
MME3J5RIQ]F?Y]<*4M8(FF0*?$U'-?*O6$ZK7#2$W^EQ_Q3VB.R;`/^(=Q_SF
M;K3(JFAZ=L3CJK(UM/1T>N6IJ7\*1D:@&?@%[#A1]2?Q[.=AY3Y=W;<%LW$T
M(,;MJ:5V':*TH#7/#I)(=8*+&2>/'TZ/+U!\#>SNWHI)=HXO*;E$`+UDF.IQ
M24U/)&I=H17ULT-+(5_(#7/X'L);E><C;7N$NWW"354TU>-(`?RH3U[D_9>?
M.=MY.V;/R5<?3@D>+KB*_;IU`YZQ=L?!WM+JO_CZL%F]MZ@!22U]&U3CZACP
MJ/DJ1I::!G/"W)N?;\=QR-/-##;^*Y?S$SX^WI?SKR?S_P`AWXAWGDRX_=M0
M&GUQA03_`$=3,>BKR]=[NIMQ0[9APV1R>7JG2.BIL33SY%JOR@"-HEIH'8*7
M-B2++]20/9SO.U<I[-MW[P*RRXKI$K@_M-1T7[=9R;T8[?:D\:\8TT#!!KPJ
M:#JP/K_^5%\KM\82CSM;AL#LB"NC$U-0[NS4%'E9HG74DD5%3)4DJ003K9"!
M^/<;KSMR;&IF?8[H*/\`EY;S_+J>>6/NU\[\R;?]2P^GO2>V!D#,R^;!A(%P
M,YZ$$?R;_DQ?U;@Z]5?R3FW_`/J?^OO7^N'R/_T9[G_LI;_H'H1?\"%[C?P?
M\8'_`%MZRQ_R;_DGY$']Y>O0"P4D9F5M(8VU$"G!L/S[<B]T>6]L<7FS[3,-
MP7X2\WB+G!JC+I.*\>''I^#[H//QE47=XMM;^<C1DA?3"RUR<="_UK_);WU/
MN&$=M=E;>P^VZ>025,>SYGR>8R40!(IZ6>6,4M*'>PD+ACHO;FWLCWGWVW21
M&\/;T#?Z2+_H'H?<K_<UOQ=)+N?-T$L=1@02#_K(>K`J?^5G\-,=B_X4^Q<O
M6>:*"%LM5;FS,E<:HLJ_<BG6H%$&>3FP2P]QO/[Q;U?S_3S0((6.:*@.,\0M
M>LF[3[JG*#;%)8M,GU;`4DH]!2GX:_Y>JU/F/_*XJ.JMLY3LOI;+97<^W<,*
MF?.;3RC)+D\720^H24-5!I$D?]05)`')]R7R5[CC>BNVM9LDG\18$?L`ZQ+]
MX_NN76Q;Q);[1NT95(]51&U#45I0OTGOY*81/FAA'T'[D[:S44CEGN*>GIYT
M:)D8_KCFD`)_P]HO=)639;PM*K5*<!3\0Z/?N276Y7_->XV$ESH@VZ,ED(J7
M\0,HH1\.DK7-:UIU_]'<$^5N:@V_0YS*5.-3+PPT$:F@=2PF+K86M]&']?::
MXX=*+?X^JF#N.ER$S2#:NV4#HLP2:*H$X63D1DB9?\V/K^/96O\`:'HW3@.I
M!S%"J!9=I[;9;CA34J;\V-S4?2WM[J_7,9#&N!HVI@$-QRDE06M>Q'_`BWNR
M_B_TIZ1WO]E'_P`U%_P]%P^7;02=![Y>'$XR@'VD`+TQF,W^<^@+SNND_GCV
M+?:G_E8Q_IA_AZAO[U__`$[H_P"D;_!UKRM^K_D(?]:A[SG3@/LZX<M_N1-]
MI_P]<@;:2&"V8&Y%[@']/^%_>S]O2>?B<5QT-?2='15>Z(6KB5CJ:N"BC8.(
MS&U7-'`&,ECI'JY/]/::Z-U]-.;)]-QI-#_A_ET&]ZL]VOH[.RV5"VX/-&`!
M3@7&KB1Y=;I776`V_L'KS:FR=I14N.P]#@\7]\D%%$1FLA54,514Y&=WN9=)
M>T;7-FY]X,\U?OL\SSL9V^,_X?MZ^@_V)]JOZK^RVV;W^[(WWDVRN3H2IQ\Z
M\#TY;ZVSAMU[-RF#S&-BRN-FHIHE6O:.<4KNI6.K2`V0_:R,'%N1;CVXESO5
MC>6]RDQ+`\!\_P`Z=%>^;3#SUR;O>T<R;-&BR:1KT("/,94:AGT/5<?QGZ%?
MK+NB3/UVX^O\]#@<-F\/346`S5!F,W#4SU++'5UU/''Y*&'P2A2K7L1IO[DG
MF#F#>3R^!*6TZ/EUBS[5^P'+'MY[B'F::19H#+7PSKIQ_I%E_EU9N^4:0HRF
MTCK^Z8U2%'`^@"1+]1[ARUW"\W"WFM2Y#,0?V9ZS]W.7:[^:TW?EO;T2[C4@
M(`IJ&H#B@7`]?RZXM6RL""SV/^UM[M^[KS_?Y_G_`)^D?UW-7_1L7_>(^N*U
M#Z@/+*@/ZB)"#I_M+]/[0X]OVT-S93+<R2U5:_SQZGKQ;>MQ'TFZ6"I9-\1T
MH.&1E<\>G.*ME<K302FGI_\`CBC:A(0+WE)N2>+BUN?;EQ>>*".FSLMI`3X:
MCIR6\BB)V()*G6/P5.JXO?GCV5"-FE)09_V.B[<"UO:LR<`R_P#'ATU9S'4>
M1HZ['U5-%4T-=2S4E32.-1JXJJ-H:B*75=&,L3D*2.#S[.N0-RN;??A&K9J/
M\/0AW[E;9MU6\N;U09/"^?\`#U0;_+.VW0[-_F?[OVQBY$?'X:N[+Q].L:%8
MX85K5F@IP+D717(O_M/N<?<&2:XV&ZE?X:K_`(1UR]^Z?!'M_O;[BVEL/T*L
M!]@:2G7_TMP3Y6Y>BP5#G<ID,><K34^/C+4`%S.Q7TJ#R%/^)N/::XX=/V_Q
M=5+MNS%Y9GGBV3AXHM*2".HE<S$2$E4*QO&1XP.?98O]H>CA."]89,OC-(_W
MYF"'J']NI_U_^5CV[U?J3'EL84'^_.PM[V!CEJ%?^OU-0>/=E-`Y_HGJC6ZW
M)BC>8(-8-2*C!^7KT73Y<34TG0>^O%A*''L:2!A-!),T@'D-U&J5U*M^>+^Q
M3[5/_P`B/"U.H=0C]Z@_5<BR6D`U,$;(^SK7PT1LI;S*'#J#'I;5S&.;_3CW
MG$D[AD#P$(5K6HIUPWN3/;WD\4EN:@GS'KUT8T(`9P0"#]#^/;QEC/XNDSR2
M$DB(\.GS$9.MQS2I0&1VG`NL#^.950AB\3D>F1"H(/MN2=4C>D@%12ISQ'3E
MA+):;A:7GU:VS(V)'76H/E5?/J^KXJ?S5^OI-CX'8/?F:FV-N?;&.BPE)N/+
MT4SXC,8^B4)1!ZBDAFFAK/&H6[*P<_D>\6.:>3MR?>)-QAO4:-FX!#_A)ZZN
M>R7WC-OVSEFVVGF'W+L1`L?P&!P:4]0AQT^?)7^:1U!AMGY'"=.;AEW_`+TS
M%)/14E6L%51;=V]-(N@Y*KJ)=$E8\$;%HT4+J>P/M5RSRU>W6^V8NUK``Q(I
MQH/MZ5^Y7WH.3;?EO=;3EN]CW*_>BK'#6-CY:P7C`HO$BM3U5Q\3_F'BNG>\
MX]Y;E7.9O#5>)R6"SU;2S>6KF_BM5]]'5U,)4BH:ER1OJ^HB%O<A\S[8MQMT
MEBEF1B@..L.O9?W2WW8_<B#F3G"9[G9'DU-;@A&I7`#]P&/EULG=;_*WH7LC
M")E=N=G;9M%%$U31YC*4N$K*>20"\;1UTL:,R$V/J'O'V[Y7W.QCG,$9\2HI
M@>OV]=0Y?<WE'FG<MOYBY:W*/:[5(F5H)=4S$L..H*%Q]G0C)W-U<[!?](VQ
M^;_IWAM]CP+_`$^_'LH_=/,/\)_8/\_1K_7ZV_Z:ZT_YPM_FZE1]P=8!@1V-
ML>__`#=W=@E3GBQ*5TC7_IP>?=X]DWR=Q'-VQGSH/\AZK)[@;$B%MYYXLX=O
M_$YB>@/X?A4G)H.E9MOL/9>=K=."W5@,RL!(JSC,O0UC0:@5&F*GFDFGY/\`
M97_>/=+C9;NU4EGU4^5/\O2FSYLY4W!E7:.:8+TG@$5UK_O2CH4XJK'LKS/7
MPT]/H+133&-#(%%W/@,OW*JJ\DA#[10W,EK<([VC,HKYCS'1CN+7K6+37.UO
M%MNI=4Y*E5JPH2!W9-!PZ+Q\BOD!LGH3KC.;ZW#FJ>-8<=.^"A\B15.9KW_8
MI8L7!)^]4E9Y%+'0`J@G\>Q][<<I/O&\F]%VL2UK0J3\^(/0`]^>?;'VUY7F
MYF7<%O$D0@0)5&KI`^)@1G[.J5?Y/NY,EO+Y^UNXLD/)7;AHMV9^LE?TNLE8
M\\NKGEV=9E!M_3W*WN6\%AL5SMU=<CZ*,,`48'@?LZP#^YI>/N/N3S!OC0FE
MZ'\_@IJ:A]>-,#K_T]PWY4Y''82CS^3RE`^4I*7%+*]!XC:J8+Z8D<N%5C^"
M>/\`#VFN.`Z46_Q=5*3;IVYE!]U1]?T"Q.J2$39*.*1==RL;*LJFZ?[;V6+_
M`&AZ-T^$?9U$?,82WJV+BHA<79\JS#_6LDK-<^W>K]9X<[@>$39F%#_U.2G`
ML/\``GW=(VDUJHSI/^#IJ:`W"K&K4.H'HOWRT?\`BW0^^8<3MC'P3BBB=C05
MLD]4D,3EY2L<A",@4<_GV)O:R>*WYCK(<5'4#_>*6^M>49#'"9**WIZ?/K7H
MCBA8>;SKZPC^(J1,ATZ&1HD+."I']/>;B[O879ALU<`Z:U^S\NN+.[WNZW6X
M747T5'\1L47R^?631#^9"/\`725?]Y=47_>?;VBS_P!_C^?1;X.\^5H?V+UF
M$11?)3U)1_TZE57.D\.+&3\C\^VY;K;]O0W,LP*#'GY].013B4'>-K>2Q`-0
MK!37\)J/0]8*C"4M?'(U5+%)+I9897,T<T)8<L'1RO\`O'M";S9+PAVCKCC6
MG^3IQ>8+"QE,=ML\HA]#)JX?ETD:O:T(<Q+D:@4]H[IY%.N2-KEGE:SE>/I[
M4'<=@M(]<*J)QCC^WRZ$,',VWO'JL=GD7</(EP5`/'M(IPZ4^(QE%1JNIT4Z
M2&>*3QLY`-@QO<\_7VW^]]KN:!](7Y_\5T'KW^L.X2Z[>U?5Y4H/\HZ4<4D<
M2E*"\4KD:O#,-,GY8R(6]9'^\>W3#RU<+2X9-'YC_)U>1.;[&S=]UFN8MJ!&
MIM9%#7MRK5XTZR&?)H-19S;_`&I1]?\`%6!]M_NWDS_?B_M/^;HL&YQDXWFX
MK_S5F_S]>2OKPP+LP`-[Z_H?[/ZW*_7WX;%RA?'Z:&51(WS;RSZ=7^K:X_2C
MW:X9CY&67_*>EALGL'>6PL_3[CVANC*[9S,$AECKL;7%&#6(*^$N8FCD4Z7!
M!NI]M7'(_+3"GB*Q_P!MT)^6^;N=N5YQ+LT\K%3@$ZN'^F;H[</\SCY7X_%_
M;1[QVKD:A(8X(JROVU239*%1I3RQ5@LZS!>3^&^AX]DC>V_+LKD=HKYYZF6?
M[R/OAN.RR[!>PG]UR::D1Q`]I#+W`UX@=%(WWW!O_N+<$VX>UM\Y7<]60YIE
MR51HI:,N"/#0T,%J*F5@=(*I?V_R_P`M[5M=U+#:RK6ASGJ'/<CW!Y_YNM[2
MPW0R&V5@=./EG!\O3JTW^2E@ZNJ^8U)N"FH:X8BFP67I?OYDO")IZ"5Q3"8$
M+(4$/X'Y]Q[[P6EM':ETFK(-.,^9ZS'^Y-M%_MLXDO;8J7#D'&13CQ/'K__4
MW-/D%'M!ZZJ_O/5[AIZ3[./[\4V.Q=9C?M;'5ZLCE*&,,1_A<?CVGGI05KT_
M!75CCT0">#XF^>>^5W5?7Z_%@-L6^O%BNY=-O9:H3Q#W&OV?[/1LA?2.T?M_
MV.L+0?$VWIRF\;_X8';U_P#K#N37_P`1[=[?4_L_V>KU?^$?M_V.L+P?%+3_
M`,73>WU'Z,#B-7_O1_3VNV_3X[>?8WR\OSZ0;A]48%^GQ)K7AG%?0T_P]=SP
M?$;[*H_B64W;_#?#)]Z<E@L%]E]O8^7[@5.X_%HM_C?VCY9$HWPFS9C)JX$4
M'[:G_!TNYK;8?ZNH.988_!T9.LUX9QHI_/HHV3I_Y3G\=K?/EJ05VIONO'M[
M:C07OQX?]_.J6U7O[EJ]_K69(_I!26AX$G'GQ`ZQ6E/W>M4U43ZG5_%^W\/^
M7K@*?^4W?C+PD_\`-O;FT0W^W&Z3Q[24Y_\`XF_9_L],5]@?X4_;_L=.M-!_
M*CL/%E8]=N->`VI:UOZ?WD]LS_UV\/\`QLGP*BN/]GJC_P"L/I'TPC$E?.A%
M//C0?SZGI!_*QU'QY6FU6_&W]H_2W^U[ETVM[.+4\S_3=BYIZG_-T*-O/W?A
M;?XQ'9F7YL@/#TTG_#U#FI_Y7&KG+P_[#;NRB/\`#_F*1[#Z_P!:_P!Y@N6\
M.AQY?M_V.BLGV`^O4NEM]+0U"E>-,9`K_+J6E/\`RM?&+Y:G_'TV]LJ_^V_O
M/;V8/_6:A\,&GY_YNEY/W?\`3_B<<0;_`$U?\*CKG#3_`,K?6OCRT.KU6MM[
M95[6-_IN>_T]I?\`D8:AI+4^P_Y^D%M_K-?6H;KP#94-0^@+PQ4FOGPQQZGQ
MT_\`*_UC_<M!^?\`.;?V7I^GY_W\Q]V/]<O,G]G^ST=ZON^_[[L/]ZC_`.@.
MI:0?RO=0OE<=;F_DP&R]/T/UMN0GW1QSQI/TS,)O*@K]OF.D&Y-]W'Z23]X1
M6IM*BOALH;CBFA"W'C3RX]9/!_*[M^WE,3J_&C`;,U_[#5N3^GNJCW)K_:/7
M_2_]#=$]N?NXD+^ZXU#>6IB?^/*.NE@_E@WYRN/MS?\`W`;+_P!C]-R^U]L/
M<;QAJ9N!\OE]IZ7S?ZTGTS^(;?Z*HK3P]7$4R#J_EUGB@_E?:A;*8C59M/W&
M!V9XM6DZ;VW'^J_T_P`?91MH]P?WK(0\A-3Q6@_;J/\`@Z25^[]0?4)%J^9'
M_0/1W_B'%\7%W;MX](U];,?NZ_[:.@Q&U:6A-5_#ZK[G^(S8W-U=<L?@U:+1
MGU6OQ[+N9AS3^\[<[NS>!0U%,<,5-<?D#U)?*9Y!_3_JHJUIVT/E3/D/+K__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g912919dsp_283.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_283.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X1G$17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-3HP-#HR
M,B`Q,3HS,#HP.0```````Z`!``,````!``$``*`"``0````!```!H:`#``0`
M```!```!&P`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!B.````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`;0"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[SH_1^D6=(P7OP<9SG8]1<XTLDDL;_(7
M.XO4L1O3F]7R\+I5E.54ZS'Z=56RO)K<[(IP,:K(R+W&A];+<CTNHY'HXOV+
M(_P=ZZ[HG_(V!_X6I_ZABD.D]+:[)>W#H#LT%N8X5,FX&0YN3[?T_P!)W\ZD
MIY,]<Z4;:Z&?5['=;+*\@'T0UEUF5?T:NNMWI[\BK[?C?S[:OZ+^G]/U?U=!
M/UDZ+=2QV/T3&9ZV-7:VRQE9#;;\?(SL6MU+*VV6T_J5]5]N^K_S[Z/9MZ5T
MM@8&8=#16VME<5,&UM+O6QF,]OM;CW?I:/\`16>^M5*/JQT2C.NSF8E1MMJ9
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M5;BUX=N%CV8M)!JQW5,-;"`6AU=3F^FSVO?]%(])Z622<.@EVX.)J9J+&,HN
MGV_X6BJJFS]^JNNM)3RC,W&'0<_J&1TSIM.3C=0=@,W5M]"N<BO`KNRKMH=9
M7C^MZU^ST/4V?]IT'(ZU@=,.5BY72,//R<*RX.NQZJZ*GUX^/1U+(>*[3EV-
MOJJR/1]'?;^G_P!#ZOZ'LZ.F].Q\5V%CXM-.(\.#L>NMK:B'Z6-=2UOI^_\`
M/]J&WHW1V4,QV8.,VBMMC&5"I@8UMVF0QE>W8UF1_A_]+_A$E/+W]=Z#3=EM
M/1,<U4&YF/9%`-EE%V+T^QES'-_4JW9F?7LNO?\`T;]:_FT/]M=+^T^G^QL;
MU/T>/]F-=8`RGY=_27_KFWWXK;\;^<^Q_P`W_P`+^KU]%5]6.E,ZIE=3>PW6
MYM;J;:[8?7Z;Q6VZO8YNY]=K<>EOIW/M96QGIT>E7O5QO2>E,]/9AT-]$,;5
M%3!L%3O5H;7[?8VBUWJ4[?YNQ)3RF#U_ZOYN3@U5]$H%>:,9KK"VK<RW*KOR
MJZ_2]/\`2TLJQ+=V1N_G/^N^FW5LNKI_6;*1TSIS\%A-53?2K+[+OL[\RO%M
MR66N=@Y-EC/T;,CIOV=^+^F^U[W^FM]WU5Z.>J8O4F5>F_"8&8]#-K:6;1:U
MCF5M9NKV?:+?T=;V4_X2RKU*ZU?=TWISLQN>_%I=FM;L;E&MIM#2"-C;]OJ[
M/<[\Y)3Q^-]8OJ\<!N3E='QP]C&/R&U,J=]+I[^OO=2UP&YOIU?9V;_\)_A%
M6?\`6#!Q7WOSNC8=8I=:UN-377=);7TDT-=FL]G])ZO^DLKQK/T/\NG]-VS.
MC])KMJOKPL=EV.P546-J8'5U@.8*JGANZNO9;8WTV?Z1ZC5T/HE-9JIZ?BUU
MN:]A8RFMK2VT,KO86M9MVWUTU,N_TC*J_P!Q)3SE'5NBOS>G8N3T.C#;GRQ]
MM[&,#+]]]%>-6UU'Z1U]F(]V-]H^QV9%+Z_1I?9Z]5/2?L3HW_<#&_[9K_\`
M()ZNC](ILINJP<>NW%::\>QE3&NK8=TUT/:W=4SWO]E:N)*:7[$Z-_W`QO\`
MMFO_`,@J?6.C](KZ1G/9@XS7-Q[2UPI9((8[^2ME4NM_\C9__A:[_J'I*?_0
M](Z)_P`C8'_A:G_J&*ZLSI>2VGH_3P6O=.+4?:)_,8K'[09_HK?\W_:AQ#N$
MT>Q;:K9SG-J:6N+3ZC!(,:%P4?V@S_16_P";_M0<K+%K&,;5;N-C(EL<.W=W
M?R4#(="%<)[%S<KJ/7:<VQM."<G!8QNRQMI;:ZPM=;9M;^D8ZFO9Z/T/YZVK
M^<4!U?KKG/=^R<AM=51<0;`7N?-7IM9^;Z>Q]UENQM]_\VRJKU_7IKT]MW^@
ML^YO_I19W5>BV=3LQ["[)QCCBUH-0:"?5:&?2]9NS;M_]5IHOLI@.J]?&QS^
MG6-D7/=6"YY.USOLV/ZM;W-Q[74[;K;KZO2M_F,.NQZ7[:ZW!_R-E3IL;ZHE
MTN:SG;L9MW/M?O=_-_S?J6>IZ8;/JWU&RUES^I=1]6L$->T5@@$C<T?I7-VO
M:SW?X3_A/\&M/"Q,K%QA1:<C+<USW>M<&%Y#W.>UCOTG^":[TV):]D(>F]3S
M\YEME^);@U!C74&Q[BZS=ZOJ&"VO9Z>RO_/_`-%Z5BCFY_5L>G'.'0[*+Z7.
M<?>^;&L8ZFC]$YGH>ONL?]IM_1?HO0_G;5><V[:[]#9J#V;X?\8HTMN]&K]!
M9]!G9O[H_P"$0]78J<QG7.NZFWHV2`*RX;;))>`X^D(:[;O_`)7LK_T]C_2K
M4K.K=>9C47CIEMC[66/MQVO/J5ECOT=+]?YS)I=7Z7\OUOS%:ZITZSJ/3[L$
MLMI%P;^D:UI(VN;9QZK/W/WEGV_5K-MK-)S^H>@7;@P[#!W>KJ?6]WO^C_@?
M^!_F_2(![)79UWZR0`_HM^X[@`+"!)=%3B??MK]/^=_PG_%L]/U3X75^LWV4
MUY/2[\=MABZ\V>UDB0_TW#?]+^7_`.#>ICHG3NF9V$ZQUV3F9X>QC0W(V':Y
MI>YUK(L^E9ZFU_\`Q:O;;O\`06?<W_THD;[(8UVVEULO<8L(&IT&UFBS\[JG
M7,?(L;BX+\NICJ@P-WRYCF[KKQD;O0;Z=GZ#[-Z?J^S[1_-VL5ZIMVZ[]#9_
M.'LW]VO_`(1$:+@0?0LT\F_^30]78I<A_7/K`VFPCHV2;@[;4P/)!'N_2N=M
M_FVN9^]799_HJE/J/5?K!C7W58?3;,IM;@&OEX#FN:QU;F:_I/TOKU7M]GH[
M*O\`2*OC?5?-Q:Q7CY^=4V"'!H;!&ZRQO^']ONL][_YU_P"D_2?S?HEZ?]7\
M[!LH<W.S[::';OLUFSTW-V/K-3F^I]#<_P!7^NC10V>E=4ZGENMKS<2S!LI#
M7$E[G-=O+]C&[@/TC65^I=[W_P`Y3^^K6>YSNC]2W.)C%MY,_F6(FVZ`/1MT
M\F_^E$+.#QTCJ6^MS/U6V"X#7V6?NN<D+O8J?__1[BH91Z#@?9',;D?9:=AL
M;O;]&K=N9OJ_,W?X10Z39UJQEW[7III>'Q1Z)G<R7^ZP;[MOM]+\Y'P0?V1T
MT[]@&+5X?N,_>1S5:-2YP'FT?^15?)\TF>'RC528_P`Y3_QK?^_);7@P7N!'
MDW_R*;:[U*?>?YUO9OG_`"4V/S#S'YIE\I\GB\[K/UA9GY;*\G*%;+[6L`9(
M#0][6!OZ+Z.U!_;?UE_[E9?^9_ZB7:7?6GH5%UE%N<YMM+W5V-])YAS3M>V6
MTEOTE#_G=]7O^Y[O^VK/_2"MJ$S0_5?@\=^V_K+_`-RLO_,_]1)?MOZR_P#<
MK+_S/_42['_G=]7O^Y[O^VG_`/I!+_G=]7O^Y[O^VG_^D$M5<9_S/X?V/&GK
M?UE@_K67Q^Y_ZB3-ZW]9-C8RLJ($>SR_XI=D?K=]7X,9[I@Q^BL_](J-/UMZ
M`*6`Y[I#6AWZ)YUC_B4M5<9_S7X/(_MOZR_]RLO_`#/_`%$E^V_K+_W*R_\`
M,_\`42[*CZU]#R,NG%HS2]UY+6OV[6AVFQCG6,9[K?\`!K9V/_TCON;_`.12
MM!R@;XP'S3]M_67_`+E9?^9_ZB3?MOZR_P#<K+_S/_42],V/_P!([[F_^12V
M/_TCON;_`.12M'O1_P`W%\R;UOZR2XC*ROI:^SR;_P`$A_M[ZW^I8/6R/3&W
MTG$$$@M._</1=[FV;5Z92UY?=^D=I9X-_=K_`)*+L?\`Z1WW-_\`(H*]Z/[@
M?*Z.N?7&R^DY%ES7->TTM@DNM(VMK;`;OW[GM=2__!_YZ]1Q'9+\6IV6QM60
MY@-U;';FM='N:U\-W*1I+BTN>26F6DANA@MEOM_=<G]-_P#I'?<W_P`BDLG,
M2JH@4S5+K?\`R-G_`/A:[_J'JUL?_I'?<W_R*I]9:1T;J$N+OU:[F/W'_N@)
M+'__TNT?AX>?]7<#"S#%5F-CN(#@UTUBJUA:7;OSV*H/JWT8/+C?>X;@YK3D
MG31[7-<[Z=OJ>J]WZ56[+<RKZMX#\%]#,GT,<,.2=M1!%7J,<[]^RO<VO^6J
M]&3]8#D4"]_3_LY]ESF6>YY:'>K=5]+9_P`3L?\`]MJ"=\1U_E3-&N$-_#KQ
M</%JQ*K9KH:&,-EF]\#]^QWTT4VU>I3[V_SK?SAYK-:?K74UC-N'E$-.ZQY=
M4XN]GI^RK]%_I-^U'PG]<.74WJ->**`019CN?N-F[V-].PNVU^EOW>[Z:;$>
MH&^H3(^D^3G9GU+9DYF1E?M-C!?:^W9Z8.W>XOV[O7;NV[D+_F(S_P`M6?\`
M;0_]Z$#(^O/6JLBZIK<;;7:]C98^8:YS&S^F_DH?_/SK?[N+_F/_`/2RM4N`
MST*/Y-O_`)B,_P#+5G_;0_\`>A+_`)B,_P#+5G_;0_\`>A5/^?G6_P!W%_S'
M_P#I9+_GYUO]W%_S'_\`I9*BJL_?\FT?J(P`G]JLT$_S0_\`2ZKT_P"+G#]&
M1U%@%H+W`USK:&NL_P"U'YVQ1_Y]];.FW%UT^@__`-+*M1_C$ZV<=I&-4P-&
MV'5N&C2VO_3_`,KU6_\`!I*(S]2/P;V+_BYP*,JLOS*[L=Q<[(]H981I^BJ?
MOLV5V[OTNS_K?_!]NRW'8UK&V-#6@`#<.!IXKS[%_P`8?6K>HTMMQFOJ!<UU
M=+3^E#H%?I[R]WJ_Z#^OZ5B]$8XN:'$%LB=IY$]B@Q9./3B^E,?7H_TC?\X)
M>O1_I&_YP1$R3&UZ+Z=]WZ1NMG[P_=K1?7H_TC?\X*-'T[_^,_[Y6C)*1^O1
M_I&_YP2]>C_2,_S@B))*1^O1_I&_YP53K%E;^C=0V.#HQK9@@_X-ZOJEUO\`
MY&S_`/PM=_U#TE/_T^WKQJ<OH?3J,BIE])QJ7.982!+6UN9]$?O*LSZM](8W
M:W$K^DUTE[R8;8W):W5NUK/4JKW[&^^K]$CG'R\CZNX%6'D?9,@XV.67Q,!H
MJ>]L#_2,;Z:#]@^L,5@=6;[#+B['8=WTP&G;Z?MV.9_UQ03^8ZTS0^4:.D3:
M220V3_*/_D$Q-OJ4^UO\ZW\X^?\`(2QV7LQZF9%GK7M8T6W!H:'O`]]GIM]K
M-[OS5,_SE/\`QK?^_)D?F'F/S72^4^2G=,Z6YSG.P<,N))<2UDDDRXN_1)?L
MOI/_`'`PO\QG_I)<OU#ZK=;R!D#%8VBRRQSJ[MS'1+_4G8[]]OM0,GZG_6.W
M^8<*72X@RR()&UCF@^[T_P`VS^<6C[6.OYP?\W_OFMQR\7KJNF=)M8+*L##>
MPR`YK&$2#M=_@OS7!2_8W3?_`"NQ/^VV_P#I%4?JKTOJ&#2\Y3W-8X!HH=R7
MM]K\EW[GJ1]!OYBWU%,",B`>(#JN$CW+G.Z/TT-)_9V)H#_@V_\`I)0HZ1TY
MU-1/3\0DL;)V-\/^*6D_Z#O@5#&_H]7]1OY`FJXCW+4KZ3@U9%>35A8]5U0<
M&.8-L;M'?0K;_G*Y-W[C?\X_^01$DD7:/==^XW_./_D$MUW[K?\`./\`Y!$3
M)*:]!NWW^UO\Y^\?W*_Y"+NN_=;_`)Q_\@HT?3O_`.,_[Y6C)*1[KOW6_P"<
M?_();KOW6_YQ_P#((B22D>Z[]UO^<?\`R"J=9-AZ-U#>`/U:Z(,_X-_\EJOJ
MEUO_`)&S_P#PM=_U#TE/_]3N:+<>CHG3;<AXKK&-2W>XD"7,9M'M_>4<7J/2
M<R\X^+DLON%?K;&.>3Z8>ZCU/[-['5(F)0R_HG3ZK*?7K=BT[FEH<W1M;V;@
M[]U[=Z)CX-.*'-Q<04!YEXJK:R2-)=LA03!XCH6:!T&H9>FSP/\`G._\DF]-
MGJ4\_P`ZW\YWGYHFRW_1O^[_`&IBRW?6?3?#;&N.G83YIL8RL:'<)E(4=7'S
M/KCCX3;[+\4MIQW.:^SUG<!WI[MK:W(%OU\PJ3#\5Y,N!V6O=!9MWMTK^DWU
M6+:LZ#T2QSW68CW%Y+G2;""2=SO;OV_2*B[ZN]"<9=AN<0($FPZ'EH]ZT.+!
M^X=OY?IM;U=V/0>M8_5F$$%EVT6M#7.VNJ=_-V-U\_>M?T6?RO\`.=_Y)5.G
MX6)TZDU8U3P''<YQ;)/[H)_=8WV,5OUA^X__`#2HIF)D3$5'Q7"^JSZF!CN>
M#^<[^]0QZF''JY^@W\YWA\5-ULM<`Q\D'\TJ-%FRFMKF/!#&@C;WA-4S]%GG
M_G._\DEZ+/Y7^<[_`,DEZP_<?_FE+UA^X_\`S2DI?T6?RO\`.=_>F]%G\K_.
M=_>EZP_<?_FE+UA^X_\`S2DI%14S??S_`#G[SOW*_-&])G\K_.=_Y)"J>6OM
M)8^'/D>WMM8U$]8?N/\`\TI*7]%G\K_.=_>F]%G\K_.=_>EZP_<?_FE+UA^X
M_P#S2DI?TF?RO\YW]ZI]98&]&ZA$ZXUW))_P;_WE;]8?N/\`\TJIUAX=T;J`
M@B,:[D1^8])3_]7T3I+VLZ-TW<]K)HI`#M-Q-8VUMU^EN50=1ZZ,=EC*,3+W
M`2^F[:TDZ;:_4^F[>[;]/](I](MZL.D86S&QRS[-5!=D/!C8WZ0&&Y93;>F?
M96?JN-]FVU^CNR<J(EOI>COPO^*]7TO^!^T?X))3L-R^NDAUF)CL;O+2/7W2
MTDMJ<VW8S:YWL_1^B]+[=UHUXQ^R4"QX<,IIO!#+!M-=-+MGZ7UF>I^YZ:Y_
M`M^KWVJC[%BX?VB6>A&3DS,U^G&_"_>]'_T8D+>A_9V^CBXOIP?3V9.3'!W[
M-^%Z?J;/^N?S7_`I*=H=3Z^YFQN%C.R&,W6U?:!H2`^MOT?HN;ZGZ5'LS>LF
MRQN-BT6LK+M3=#G!I.QC6M#_`-)97Z?T]BS,JW!^U6?:\7"]::]_J9-VV=K?
M1VSA>GO]+9]'_!?SBHV6_5STAZF+@;99]+)R-\R/2YPO6^G_`.I$E.[5G_6!
M]S6G#QO3)`<X7RX-(]UNP-/\U9^C]/=^D_TJBWJ/U@:QMF3B8M#/I6O=>-K6
M^T-&[^U_._\`6_3_`,*LC.MZ/Z-/K8N'MEWV79DW1N]1T^AMPO2W?:=VS\S_
M`*VETZWI?V2_[+BT;MH^TQDY/VF?T7^APOM'J[_1_HO^$_FDE.P.J]5;74;\
M?&;=8YH..,AH,#>S(]*QW\ZYEWH5-;LK_G$[<SZQ65S7C8LR`8M+OY?T6PWW
M5N9L_2_\+_P:J6VU_J_J8N-Z<N]",G(]*=_Z7Z&%Z'\Y_.>I_@O5_P"T_J*S
MTNV[;?\`LW%Q-GJ_I]N3;_.[*N=^%_H?124W^G7=4M:\]0QZ\5PV[&5V>KV_
M2?I(9^=_P:N*EZO6?^XN-_[$V?\`O$EZO6?^XN-_[$V?^\22FZDJ7J]9_P"X
MN-_[$V?^\27J]9_[BXW_`+$V?^\22FZDJ7J]9_[BXW_L39_[Q)>KUG_N+C?^
MQ-G_`+Q)*;J2I>KUG_N+C?\`L39_[Q)>KUG_`+BXW_L39_[Q)*;JI=;_`.1L
M_P#\+7?^>W)>KUG_`+BXW_L39_[Q*GUBWJ_[(SM^-CAGV>W<6Y#R8V.X!PVI
M*?_9_^T>6E!H;W1O<VAO<"`S+C``.$))300E```````0````````````````
M`````#A"24T#[0``````$`$L`````0`!`2P````!``$X0DE-!"8```````X`
M````````````/X```#A"24T$#0``````!````!XX0DE-!!D```````0````>
M.$))30/S```````)```````````!`#A"24T$"@```````0``.$))32<0````
M```*``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O
M9F8``0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````
M!@```````3A"24T#^```````<```_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@`````_____________________________P/H```X0DE-
M!`@``````!`````!```"0````D``````.$))300>```````$`````#A"24T$
M&@`````#0P````8``````````````1L```&A````!P!$`%,`4`!?`#(`.``S
M`````0`````````````````````````!``````````````&A```!&P``````
M```````````````!`````````````````````````!`````!````````;G5L
M;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@
M;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG```!&P````!2
M9VAT;&]N9P```:$````&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L
M:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````
M````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T
M960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD
M<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE
M9G1L;VYG``````````!"=&]M;&]N9P```1L`````4F=H=&QO;F<```&A````
M`W5R;%1%6%0````!````````;G5L;%1%6%0````!````````37-G951%6%0`
M```!```````&86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O
M;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M````
M#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T`
M```/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E
M;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T
M;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E
M=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,
M`````3_P````````.$))3004```````$`````3A"24T$#``````8J@````$`
M``"@````;0```>```,Q@```8C@`8``'_V/_@`!!*1DE&``$"`0!(`$@``/_M
M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+
M"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`;0"@`P$B``(1`0,1
M`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!
M`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1
M`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2
M!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+2
M1)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[SH_1^D6=(P7OP<9SG8]1<XT
MLDDL;_(7.XO4L1O3F]7R\+I5E.54ZS'Z=56RO)K<[(IP,:K(R+W&A];+<CTN
MHY'HXOV+(_P=ZZ[HG_(V!_X6I_ZABD.D]+:[)>W#H#LT%N8X5,FX&0YN3[?T
M_P!)W\ZDIY,]<Z4;:Z&?5['=;+*\@'T0UEUF5?T:NNMWI[\BK[?C?S[:OZ+^
MG]/U?U=!/UDZ+=2QV/T3&9ZV-7:VRQE9#;;\?(SL6MU+*VV6T_J5]5]N^K_S
M[Z/9MZ5TM@8&8=#16VME<5,&UM+O6QF,]OM;CW?I:/\`16>^M5*/JQT2C.NS
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M_?75V=)Z5;BUX=N%CV8M)!JQW5,-;"`6AU=3F^FSVO?]%(])Z622<.@EVX.)
MJ9J+&,HNGV_X6BJJFS]^JNNM)3RC,W&'0<_J&1TSIM.3C=0=@,W5M]"N<BO`
MKNRKMH=97C^MZU^ST/4V?]IT'(ZU@=,.5BY72,//R<*RX.NQZJZ*GUX^/1U+
M(>*[3EV-OJJR/1]'?;^G_P!#ZOZ'LZ.F].Q\5V%CXM-.(\.#L>NMK:B'Z6-=
M2UOI^_\`/]J&WHW1V4,QV8.,VBMMC&5"I@8UMVF0QE>W8UF1_A_]+_A$E/+W
M]=Z#3=EM/1,<U4&YF/9%`-EE%V+T^QES'-_4JW9F?7LNO?\`T;]:_FT/]M=+
M^T^G^QL;U/T>/]F-=8`RGY=_27_KFWWXK;\;^<^Q_P`W_P`+^KU]%5]6.E,Z
MIE=3>PW6YM;J;:[8?7Z;Q6VZO8YNY]=K<>EOIW/M96QGIT>E7O5QO2>E,]/9
MAT-]$,;5%3!L%3O5H;7[?8VBUWJ4[?YNQ)3RF#U_ZOYN3@U5]$H%>:,9KK"V
MK<RW*KORJZ_2]/\`2TLJQ+=V1N_G/^N^FW5LNKI_6;*1TSIS\%A-53?2K+[+
MOL[\RO%MR66N=@Y-EC/T;,CIOV=^+^F^U[W^FM]WU5Z.>J8O4F5>F_"8&8]#
M-K:6;1:UCF5M9NKV?:+?T=;V4_X2RKU*ZU?=TWISLQN>_%I=FM;L;E&MIM#2
M"-C;]OJ[/<[\Y)3Q^-]8OJ\<!N3E='QP]C&/R&U,J=]+I[^OO=2UP&YOIU?9
MV;_\)_A%6?\`6#!Q7WOSNC8=8I=:UN-377=);7TDT-=FL]G])ZO^DLKQK/T/
M\NG]-VS.C])KMJOKPL=EV.P546-J8'5U@.8*JGANZNO9;8WTV?Z1ZC5T/HE-
M9JIZ?BUUN:]A8RFMK2VT,KO86M9MVWUTU,N_TC*J_P!Q)3SE'5NBOS>G8N3T
M.C#;GRQ]M[&,#+]]]%>-6UU'Z1U]F(]V-]H^QV9%+Z_1I?9Z]5/2?L3HW_<#
M&_[9K_\`()ZNC](ILINJP<>NW%::\>QE3&NK8=TUT/:W=4SWO]E:N)*:7[$Z
M-_W`QO\`MFO_`,@J?6.C](KZ1G/9@XS7-Q[2UPI9((8[^2ME4NM_\C9__A:[
M_J'I*?_0](Z)_P`C8'_A:G_J&*ZLSI>2VGH_3P6O=.+4?:)_,8K'[09_HK?\
MW_:AQ#N$T>Q;:K9SG-J:6N+3ZC!(,:%P4?V@S_16_P";_M0<K+%K&,;5;N-C
M(EL<.W=W?R4#(="%<)[%S<KJ/7:<VQM."<G!8QNRQMI;:ZPM=;9M;^D8ZFO9
MZ/T/YZVK^<4!U?KKG/=^R<AM=51<0;`7N?-7IM9^;Z>Q]UENQM]_\VRJKU_7
MIKT]MW^@L^YO_I19W5>BV=3LQ["[)QCCBUH-0:"?5:&?2]9NS;M_]5IHOLI@
M.J]?&QS^G6-D7/=6"YY.USOLV/ZM;W-Q[74[;K;KZO2M_F,.NQZ7[:ZW!_R-
ME3IL;ZHETN:SG;L9MW/M?O=_-_S?J6>IZ8;/JWU&RUES^I=1]6L$->T5@@$C
M<T?I7-VO:SW?X3_A/\&M/"Q,K%QA1:<C+<USW>M<&%Y#W.>UCOTG^":[TV):
M]D(>F]3S\YEME^);@U!C74&Q[BZS=ZOJ&"VO9Z>RO_/_`-%Z5BCFY_5L>G'.
M'0[*+Z7.<?>^;&L8ZFC]$YGH>ONL?]IM_1?HO0_G;5><V[:[]#9J#V;X?\8H
MTMN]&K]!9]!G9O[H_P"$0]78J<QG7.NZFWHV2`*RX;;))>`X^D(:[;O_`)7L
MK_T]C_2K4K.K=>9C47CIEMC[66/MQVO/J5ECOT=+]?YS)I=7Z7\OUOS%:ZIT
MZSJ/3[L$LMI%P;^D:UI(VN;9QZK/W/WEGV_5K-MK-)S^H>@7;@P[#!W>KJ?6
M]WO^C_@?^!_F_2(![)79UWZR0`_HM^X[@`+"!)=%3B??MK]/^=_PG_%L]/U3
MX75^LWV4UY/2[\=MABZ\V>UDB0_TW#?]+^7_`.#>ICHG3NF9V$ZQUV3F9X>Q
MC0W(V':YI>YUK(L^E9ZFU_\`Q:O;;O\`06?<W_THD;[(8UVVEULO<8L(&IT&
MUFBS\[JG7,?(L;BX+\NICJ@P-WRYCF[KKQD;O0;Z=GZ#[-Z?J^S[1_-VL5ZI
MMVZ[]#9_.'LW]VO_`(1$:+@0?0LT\F_^30]78I<A_7/K`VFPCHV2;@[;4P/)
M!'N_2N=M_FVN9^]799_HJE/J/5?K!C7W58?3;,IM;@&OEX#FN:QU;F:_I/TO
MKU7M]GH[*O\`2*OC?5?-Q:Q7CY^=4V"'!H;!&ZRQO^']ONL][_YU_P"D_2?S
M?HEZ?]7\[!LH<W.S[::';OLUFSTW-V/K-3F^I]#<_P!7^NC10V>E=4ZGENMK
MS<2S!LI#7$E[G-=O+]C&[@/TC65^I=[W_P`Y3^^K6>YSNC]2W.)C%MY,_F6(
MFVZ`/1MT\F_^E$+.#QTCJ6^MS/U6V"X#7V6?NN<D+O8J?__1[BH91Z#@?9',
M;D?9:=AL;O;]&K=N9OJ_,W?X10Z39UJQEW[7III>'Q1Z)G<R7^ZP;[MOM]+\
MY'P0?V1TT[]@&+5X?N,_>1S5:-2YP'FT?^15?)\TF>'RC528_P`Y3_QK?^_)
M;7@P7N!'DW_R*;:[U*?>?YUO9OG_`"4V/S#S'YIE\I\GB\[K/UA9GY;*\G*%
M;+[6L`9(#0][6!OZ+Z.U!_;?UE_[E9?^9_ZB7:7?6GH5%UE%N<YMM+W5V-])
MYAS3M>V6TEOTE#_G=]7O^Y[O^VK/_2"MJ$S0_5?@\=^V_K+_`-RLO_,_]1)?
MMOZR_P#<K+_S/_42['_G=]7O^Y[O^VG_`/I!+_G=]7O^Y[O^VG_^D$M5<9_S
M/X?V/&GK?UE@_K67Q^Y_ZB3-ZW]9-C8RLJ($>SR_XI=D?K=]7X,9[I@Q^BL_
M](J-/UMZ`*6`Y[I#6AWZ)YUC_B4M5<9_S7X/(_MOZR_]RLO_`#/_`%$E^V_K
M+_W*R_\`,_\`42[*CZU]#R,NG%HS2]UY+6OV[6AVFQCG6,9[K?\`!K9V/_TC
MON;_`.12M!R@;XP'S3]M_67_`+E9?^9_ZB3?MOZR_P#<K+_S/_42],V/_P!(
M[[F_^12V/_TCON;_`.12M'O1_P`W%\R;UOZR2XC*ROI:^SR;_P`$A_M[ZW^I
M8/6R/3&WTG$$$@M._</1=[FV;5Z92UY?=^D=I9X-_=K_`)*+L?\`Z1WW-_\`
M(H*]Z/[@?*Z.N?7&R^DY%ES7->TTM@DNM(VMK;`;OW[GM=2__!_YZ]1Q'9+\
M6IV6QM60Y@-U;';FM='N:U\-W*1I+BTN>26F6DANA@MEOM_=<G]-_P#I'?<W
M_P`BDLG,2JH@4S5+K?\`R-G_`/A:[_J'JUL?_I'?<W_R*I]9:1T;J$N+OU:[
MF/W'_N@)+'__TNT?AX>?]7<#"S#%5F-CN(#@UTUBJUA:7;OSV*H/JWT8/+C?
M>X;@YK3DG31[7-<[Z=OJ>J]WZ56[+<RKZMX#\%]#,GT,<,.2=M1!%7J,<[]^
MRO<VO^6J]&3]8#D4"]_3_LY]ESF6>YY:'>K=5]+9_P`3L?\`]MJ"=\1U_E3-
M&N$-_#KQ</%JQ*K9KH:&,-EF]\#]^QWTT4VU>I3[V_SK?SAYK-:?K74UC-N'
ME$-.ZQY=4XN]GI^RK]%_I-^U'PG]<.74WJ->**`019CN?N-F[V-].PNVU^EO
MW>[Z:;$>H&^H3(^D^3G9GU+9DYF1E?M-C!?:^W9Z8.W>XOV[O7;NV[D+_F(S
M_P`M6?\`;0_]Z$#(^O/6JLBZIK<;;7:]C98^8:YS&S^F_DH?_/SK?[N+_F/_
M`/2RM4N`ST*/Y-O_`)B,_P#+5G_;0_\`>A+_`)B,_P#+5G_;0_\`>A5/^?G6
M_P!W%_S'_P#I9+_GYUO]W%_S'_\`I9*BJL_?\FT?J(P`G]JLT$_S0_\`2ZKT
M_P"+G#]&1U%@%H+W`USK:&NL_P"U'YVQ1_Y]];.FW%UT^@__`-+*M1_C$ZV<
M=I&-4P-&V'5N&C2VO_3_`,KU6_\`!I*(S]2/P;V+_BYP*,JLOS*[L=Q<[(]H
M981I^BJ?OLV5V[OTNS_K?_!]NRW'8UK&V-#6@`#<.!IXKS[%_P`8?6K>HTMM
MQFOJ!<UU=+3^E#H%?I[R]WJ_Z#^OZ5B]$8XN:'$%LB=IY$]B@Q9./3B^E,?7
MH_TC?\X)>O1_I&_YP1$R3&UZ+Z=]WZ1NMG[P_=K1?7H_TC?\X*-'T[_^,_[Y
M6C)*1^O1_I&_YP2]>C_2,_S@B))*1^O1_I&_YP53K%E;^C=0V.#HQK9@@_X-
MZOJEUO\`Y&S_`/PM=_U#TE/_T^WKQJ<OH?3J,BIE])QJ7.982!+6UN9]$?O*
MLSZM](8W:W$K^DUTE[R8;8W):W5NUK/4JKW[&^^K]$CG'R\CZNX%6'D?9,@X
MV.67Q,!HJ>]L#_2,;Z:#]@^L,5@=6;[#+B['8=WTP&G;Z?MV.9_UQ03^8ZTS
M0^4:.D3:220V3_*/_D$Q-OJ4^UO\ZW\X^?\`(2QV7LQZF9%GK7M8T6W!H:'O
M`]]GIM]K-[OS5,_SE/\`QK?^_)D?F'F/S72^4^2G=,Z6YSG.P<,N))<2UDDD
MRXN_1)?LOI/_`'`PO\QG_I)<OU#ZK=;R!D#%8VBRRQSJ[MS'1+_4G8[]]OM0
M,GZG_6.W^8<*72X@RR()&UCF@^[T_P`VS^<6C[6.OYP?\W_OFMQR\7KJNF=)
MM8+*L##>PR`YK&$2#M=_@OS7!2_8W3?_`"NQ/^VV_P#I%4?JKTOJ&#2\Y3W-
M8X!HH=R7M]K\EW[GJ1]!OYBWU%,",B`>(#JN$CW+G.Z/TT-)_9V)H#_@V_\`
MI)0HZ1TYU-1/3\0DL;)V-\/^*6D_Z#O@5#&_H]7]1OY`FJXCW+4KZ3@U9%>3
M5A8]5U0<&.8-L;M'?0K;_G*Y-W[C?\X_^01$DD7:/==^XW_./_D$MUW[K?\`
M./\`Y!$3)*:]!NWW^UO\Y^\?W*_Y"+NN_=;_`)Q_\@HT?3O_`.,_[Y6C)*1[
MKOW6_P"<?_();KOW6_YQ_P#((B22D>Z[]UO^<?\`R"J=9-AZ-U#>`/U:Z(,_
MX-_\EJOJEUO_`)&S_P#PM=_U#TE/_]3N:+<>CHG3;<AXKK&-2W>XD"7,9M'M
M_>4<7J/2<R\X^+DLON%?K;&.>3Z8>ZCU/[-['5(F)0R_HG3ZK*?7K=BT[FEH
M<W1M;V;@[]U[=Z)CX-.*'-Q<04!YEXJK:R2-)=LA03!XCH6:!T&H9>FSP/\`
MG._\DF]-GJ4\_P`ZW\YWGYHFRW_1O^[_`&IBRW?6?3?#;&N.G83YIL8RL:'<
M)E(4=7'S/KCCX3;[+\4MIQW.:^SUG<!WI[MK:W(%OU\PJ3#\5Y,N!V6O=!9M
MWMTK^DWU6+:LZ#T2QSW68CW%Y+G2;""2=SO;OV_2*B[ZN]"<9=AN<0($FPZ'
MEH]ZT.+!^X=OY?IM;U=V/0>M8_5F$$%EVT6M#7.VNJ=_-V-U\_>M?T6?RO\`
M.=_Y)5.GX6)TZDU8U3P''<YQ;)/[H)_=8WV,5OUA^X__`#2HIF)D3$5'Q7"^
MJSZF!CN>#^<[^]0QZF''JY^@W\YWA\5-ULM<`Q\D'\TJ-%FRFMKF/!#&@C;W
MA-4S]%GG_G._\DEZ+/Y7^<[_`,DEZP_<?_FE+UA^X_\`S2DI?T6?RO\`.=_>
MF]%G\K_.=_>EZP_<?_FE+UA^X_\`S2DI%14S??S_`#G[SOW*_-&])G\K_.=_
MY)"J>6OM)8^'/D>WMM8U$]8?N/\`\TI*7]%G\K_.=_>F]%G\K_.=_>EZP_<?
M_FE+UA^X_P#S2DI?TF?RO\YW]ZI]98&]&ZA$ZXUW))_P;_WE;]8?N/\`\TJI
MUAX=T;J`@B,:[D1^8])3_]7T3I+VLZ-TW<]K)HI`#M-Q-8VUMU^EN50=1ZZ,
M=EC*,3+W`2^F[:TDZ;:_4^F[>[;]/](I](MZL.D86S&QRS[-5!=D/!C8WZ0&
M&Y93;>F?96?JN-]FVU^CNR<J(EOI>COPO^*]7TO^!^T?X))3L-R^NDAUF)CL
M;O+2/7W2TDMJ<VW8S:YWL_1^B]+[=UHUXQ^R4"QX<,IIO!#+!M-=-+MGZ7UF
M>I^YZ:Y_`M^KWVJC[%BX?VB6>A&3DS,U^G&_"_>]'_T8D+>A_9V^CBXOIP?3
MV9.3'!W[-^%Z?J;/^N?S7_`I*=H=3Z^YFQN%C.R&,W6U?:!H2`^MOT?HN;ZG
MZ5'LS>LFRQN-BT6LK+M3=#G!I.QC6M#_`-)97Z?T]BS,JW!^U6?:\7"]::]_
MJ9-VV=K?1VSA>GO]+9]'_!?SBHV6_5STAZF+@;99]+)R-\R/2YPO6^G_`.I$
ME.[5G_6!]S6G#QO3)`<X7RX-(]UNP-/\U9^C]/=^D_TJBWJ/U@:QMF3B8M#/
MI6O=>-K6^T-&[^U_._\`6_3_`,*LC.MZ/Z-/K8N'MEWV79DW1N]1T^AMPO2W
M?:=VS\S_`*VETZWI?V2_[+BT;MH^TQDY/VF?T7^APOM'J[_1_HO^$_FDE.P.
MJ]5;74;\?&;=8YH..,AH,#>S(]*QW\ZYEWH5-;LK_G$[<SZQ65S7C8LR`8M+
MOY?T6PWW5N9L_2_\+_P:J6VU_J_J8N-Z<N]",G(]*=_Z7Z&%Z'\Y_.>I_@O5
M_P"T_J*STNV[;?\`LW%Q-GJ_I]N3;_.[*N=^%_H?124W^G7=4M:\]0QZ\5PV
M[&5V>KV_2?I(9^=_P:N*EZO6?^XN-_[$V?\`O$EZO6?^XN-_[$V?^\22FZDJ
M7J]9_P"XN-_[$V?^\27J]9_[BXW_`+$V?^\22FZDJ7J]9_[BXW_L39_[Q)>K
MUG_N+C?^Q-G_`+Q)*;J2I>KUG_N+C?\`L39_[Q)>KUG_`+BXW_L39_[Q)*;J
MI=;_`.1L_P#\+7?^>W)>KUG_`+BXW_L39_[Q*GUBWJ_[(SM^-CAGV>W<6Y#R
M8V.X!PVI*?_9.$))300A``````!3`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`$,`4P````$`.$))300&```````'``@````!`0#_X1?\:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X])^^[OR<@
M:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\>#IX;7!M971A('AM
M;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM<'1K/2=835`@=&]O;&MI="`S
M+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F.E)$1B!X;6QN<SIR9&8])VAT
M='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G('AM
M;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.CEF.3DY,38W+64X8C0M,3%E
M-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIE>&EF/2=H='1P.B\O;G,N
M861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X:68Z0V]L;W)3<&%C93XQ/"]E
M>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX96Q81&EM96YS:6]N/C0Q-SPO
M97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X:68Z4&EX96Q91&EM96YS:6]N
M/C(X,SPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\+W)D9CI$97-C<FEP=&EO
M;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HY9CDY.3$V
M-RUE.&(T+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@>&UL;G,Z<&1F/2=H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*(#PO<F1F.D1E<V-R:7!T
M:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.CEF.3DY
M,38W+64X8C0M,3%E-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIP:&]T
M;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\G/@H@
M(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H;W1O<VAO<#I(:7-T;W)Y/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M)W5U:60Z.68Y.3DQ-C<M93AB-"TQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@
M('AM;&YS.G1I9F8])VAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O)SX*
M("`\=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@(#QT
M:69F.EA297-O;'5T:6]N/C,P,"\Q/"]T:69F.EA297-O;'5T:6]N/@H@(#QT
M:69F.EE297-O;'5T:6]N/C,P,"\Q/"]T:69F.EE297-O;'5T:6]N/@H@(#QT
M:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B`\
M+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TG=75I9#HY9CDY.3$V-RUE.&(T+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G
M"B`@>&UL;G,Z>&%P/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O)SX*
M("`\>&%P.D-R96%T941A=&4^,C`Q-2TP-"TR,E0Q,3HR.3HU-2LP-3HS,#PO
M>&%P.D-R96%T941A=&4^"B`@/'AA<#I-;V1I9GE$871E/C(P,34M,#0M,C)4
M,3$Z,S`Z,#DK,#4Z,S`\+WAA<#I-;V1I9GE$871E/@H@(#QX87`Z365T861A
M=&%$871E/C(P,34M,#0M,C)4,3$Z,S`Z,#DK,#4Z,S`\+WAA<#I-971A9&%T
M841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W`@0U,@
M5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@/"]R9&8Z1&5S8W)I<'1I;VX^
M"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z.68Y.3DQ-C<M
M93AB-"TQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.GAA<$U-/2=H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C
M=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z.68Y.3DQ-C,M93AB-"TQ
M,64T+3DW8F8M.38Y,C=C-C<U9#9D/"]X87!-33I$;V-U;65N=$E$/@H@/"]R
M9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M)W5U:60Z.68Y.3DQ-C<M93AB-"TQ,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@
M('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R<^
M"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^"B`\+W)D9CI$
M97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP86-K
M970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT
M<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`````
M`````````````/;6``$`````TRU(4"`@````````````````````````````
M```````````````````````````````````18W!R=````5`````S9&5S8P``
M`80```!L=W1P=````?`````48FMP=````@0````4<EA96@```A@````49UA9
M6@```BP````48EA96@```D`````49&UN9````E0```!P9&UD9````L0```"(
M=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``!`P`
M```D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E120P``
M!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ````
M```````````2<U)'0B!)14,V,3DV-BTR+C$`````````````````````````
M`````````````````````````````````````````%A96B````````#S40`!
M`````1;,6%E:(`````````````````````!865H@````````;Z(``#CU```#
MD%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D97-C
M`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)14,@
M:'1T<#HO+W=W=RYI96,N8V@`````````````````````````````````````
M````````````````````````9&5S8P`````````N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````
M`````````````````````````&1E<V,`````````+%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````
M``````````````````````````!V:65W```````3I/X`%%\N`!#/%``#[<P`
M!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,``````````0``
M``````````````````````*/`````G-I9R``````0U)4(&-U<G8````````$
M``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H
M`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`
MVP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@
M`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"
M%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K
M`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#
M^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K
M!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&
MG0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R
M"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*
M$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2
M#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.
M9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7
M$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3
MI!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/
M%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9
MW1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU'
M'7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A
M'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4)
M)3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I
M:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA
M+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILR
MU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7
M.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]
M83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W
M0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)
M'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])
M3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6
M#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES6
M72==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD
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MC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26
MGY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_Z
MH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ
M'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0E
MM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^
M_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFY
MRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O5
M3M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]
MX43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M
M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX
M^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!
M&P&A`P$1``(1`0,1`?_=``0`-?_$`:(````&`@,!``````````````<(!@4$
M"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$`0,#
M`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.A
ML?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#
MT^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJ
MM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%
M!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R
M\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S
M*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(
MF*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1
M`#\`NC_E*_RE/Y97<O\`++^"_:W:OP6^,_8'9/8/QGZLW7OC>^Z^KMNYK<NZ
M]S9C;5)5Y?/9W+5U--5Y'*Y.KD:6>:1BSR,3[]U[JP[_`(9)_E%_]ZY_B1_Z
M)O:?_P!0^_=>ZB/_`"3_`.49'+H/\N?XCL6N88X^FMJM(Y7_`#ER:-8U"DC@
M^_=>Z1%1_*8_DET^X8=H3?"3X*0;OJT$U-MJ;KSKTYHT_P!?.^*$@K?$P%E8
M(`3[]U[I?0_R2_Y1CQ1L?Y<OQ)4LH)4].;28B_\`M0HW!!_')X]^Z]UD_P"&
M2?Y1?_>N?XD?^B;VG_\`4/OW7NO?\,D_RB_^]<_Q(_\`1-[3_P#J'W[KW7O^
M&2?Y1?\`WKG^)'_HF]I__4/OW7NO?\,D_P`HO_O7/\2/_1-[3_\`J'W[KW7O
M^&2?Y1?_`'KG^)'_`*)O:?\`]0^_=>Z1<'\H;^2M6[IR.RJ#X+_"*JWEBZ5*
MO);8@ZUV14YW&TKD:*FOPD,?WE-`]^'=4'OW7NEC%_)*_E&M&K/_`"Y?B0C$
M7*_Z'-IM8_X'[(W!]^Z]U`G_`)*O\H>-Y$?^73\1D19H(&,O4.U*:\E39D\4
MS4H#&WT0<D\>_=>ZG1?R3/Y1,D:NO\N?XE:6'&KIG:BMP2.0U%<?3\^_=>ZR
M?\,D_P`HO_O7/\2/_1-[3_\`J'W[KW25W/\`R=?Y,VS,75Y[>/P)^%NU=O4C
M1K5Y?<'6&S,/0TKS2!(3-DJR."FA$SFR(2I)X]^Z]T^X[^2S_)\RU!29/%_R
M]/A]D<=74\5515]%U#L^II*NFE4-%44]1%1O'-#(INK*2"/?NO=3?^&2?Y1?
M_>N?XD?^B;VG_P#4/OW7NO?\,D_RB_\`O7/\2/\`T3>T_P#ZA]^Z]U[_`(9)
M_E%_]ZY_B1_Z)O:?_P!0^_=>Z]_PR3_*+_[US_$C_P!$WM/_`.H??NO=(8?R
MB?Y+51NZKV-1_!7X/3[PH:-*VOVFG6VQY-S45&YN*ZHP<<7W\5$8R")"@'/U
M]^Z]TL5_DF?RC!9&_ES_`!&,VG5H'3FU0`/H6)-&P(O_`+'W[KW2"SW\I?\`
MDE;6RE+A=S_"7X(X++Y2018K%9;8O7^(R5<Y-EAIZ*N:*>:0GZ,BV;Z6]^Z]
MTOZ?^2;_`"BY8(I1_+I^(KB1`ZO'TWM,QNK<JR'[1]2LMB#<W^OOW7NLW_#)
M/\HO_O7/\2/_`$3>T_\`ZA]^Z]U[_ADG^47_`-ZY_B1_Z)O:?_U#[]U[KW_#
M)/\`*+_[US_$C_T3>T__`*A]^Z]U[_ADG^47_P!ZY_B1_P"B;VG_`/4/OW7N
MDKNG^3G_`":-FXFMW!N[X$?"W:F#HB@J<QN+K'9V&Q5,LC".)JC(5<=/20>5
M^%!()/'U]^Z]T]XO^2Y_)ZS6.HLMB?Y>GP^R6,R-/'5T&0H>HMGU5'64LRAX
M:BFJ(J-HIX)4-U9200;CW[KW4_\`X9)_E%_]ZY_B1_Z)O:?_`-0^_=>Z]_PR
M3_*+_P"]<_Q(_P#1-[3_`/J'W[KW7O\`ADG^47_WKG^)'_HF]I__`%#[]U[I
MKJ_Y+7\H*ACJJJL_EV?$6EI:%6FJ9ZKI_:-+!'"`-4[U51!'2)`@Y;4PL!]/
M?NO=(_;?\I'^2KO5JN/9GP>^#&ZSC:AH,M_=KKK8FX'H9%<#PU,.+>:HHYK'
MZ,I%_?NO=*R3^2O_`"C(JFGA7^7/\0]%4S"$/U'M(U$LD9U5"QPO3@D00+K8
M+JL.;#GW[KW3I%_),_E$R1JZ_P`NCXCL&%P5Z;VI;ZV_-%>X]^Z]UD_X9)_E
M%_\`>N?XD?\`HF]I_P#U#[]U[I'[N_D]_P`F+8^-GSN\/@7\+=J8*FE@AJ,S
MN/K'9V$Q4%55W%-'-DJR*"E0S,NE(R;LQL/?NO=-5;_*2_DF4-=M7$5WP?\`
M@Y29C?,-)4;2Q=3L'9%'7[KI:L1&"?:]-(J5&62<3KXS`&U`CGD>_=>Z$-/Y
M)7\HLJ#_`,-T?$<\GD=,[4'T)'T:B)X]^Z]UR_X9)_E%_P#>N?XD?^B;VG_]
M0^_=>Z]_PR3_`"B_^]<_Q(_]$WM/_P"H??NO=>_X9)_E%_\`>N?XD?\`HF]I
M_P#U#[]U[KW_``R3_*+_`.]<_P`2/_1-[3_^H??NO=>_X9)_E%_]ZY_B1_Z)
MO:?_`-0^_=>Z]_PR3_*+_P"]<_Q(_P#1-[3_`/J'W[KW7O\`ADG^47_WKG^)
M'_HF]I__`%#[]U[KW_#)/\HO_O7/\2/_`$3>T_\`ZA]^Z]U[_ADG^47_`-ZY
M_B1_Z)O:?_U#[]U[I"=I?R6?Y2^(ZQ[&RN._EW_$VCR&,V)N_(4%7!T]M:*>
MEK:+;^0J:6HAECHTDBE@GC5E92&4BX-_?NO=?&C_`+R;B_YW^:_\^E=_U_\`
M?NO=?__0VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW5'?\`PH0^;^_/
M@=_+;[1[.ZIRIP/:._<[MGI?8>=B$K5VWLQOR2O6LSU`D5M-708;'5#0R$C3
M,5/U`]^Z]T0#:'_"9'XC=A_&#`9_>G9W?6:^:6^^N<#O&I^5%;W'OR+,P=FY
M_'4>X/XO#M2/.K@IL70Y&I"I"].9="']P$W]^Z]T=?M_Y3=I?R3?Y9>PZSY3
M]DU7S7[YV[G\;T[UWE<5CYMF9CM;=&Y9Y(NO,+74\]3EJJKFQ=%3B/(5TLX>
M14U$@N/?NO=%<ZY_G,?/_HGOCXT]??S1_AYU[T+UA\P=Q4>UNG^R^J=W9;.+
MMC<>:AI:G$[<[`BR=954,62T5D"R&)](:3BXN/?NO=*7Y#_SEOF7B?YCO?O\
MM#XC?$7:O=7;NR-E[3WQU[NC<6\J[;^VHL=78F'-;JR'8DDIB--BZ5*^FBHE
MH75I68K^1[]U[HE/6'_"B+^8]\B/CGW?OGHKX&];5?9'PWR6YF^6^XMT[[R\
M'6F,Q.TZZ<U6*ZUP=/)'N?([JJ<=22NPJ)&AC0!K$>_=>Z.+WS_PH+KNL_Y6
M'Q*_F1[8Z6H-QQ=_]C;=V-OOK=\_5?=[32:MJZ3=@VWD*,$5>0I31-'2+4`6
MEE35[]U[IBVO_.N^=73ORA^,VR/GO\+MJ]'?&[YJ;CI]N=`[\VKO'(9[>&WJ
M_.QP5>VJ#LN2JJ/X,N9DH*^G:IAIE54,HT@\V]U[HMO0^_Z#JW_A3#_,XWYN
M_+UM-L;8'Q+FWMN(O7N]-!BL#M>@SE;5Q0F44T9-)13:4`%IG`')]^Z]TX1_
M\*!?YB>;ZCSW\PK:/P=ZFK/Y8>U=QR8W*YJO[*J:?Y!5>S\?GUV]6[TQV)2N
M&+@AE,JRI324KRCZ7_/OW7NBN_SK/YE/SRSGS._ENM\1-G9G+_&_M"+K;M+H
M^@PV_4P.,^6.[=RXR#*9?96\*6'*4T=-2[1FD^Q0U2K'Y[R`_3W[KW5KWR4_
MG!_.$?(3KKX&?#+XH=<;V^:Z]&8#NOY#83M/>TN'Z]Z83)PTE;-LR#(4.0@;
M/YB.CG`$T=0T>I@;$`GW[KW0R?#G^=A0=I?&[YL=@_*3JX=*]Y?R^:W/XOY'
M=;[;SD.X\(]7BZ1FQ]5L_+-42K-292LTP`F1E61AZB;^_=>ZUOOYHW\SC^9/
M\T_Y1W8/<_:_PMVCU7\->^-U[2GZ@[3V9OBL&_MO8>EW!5)MS([^PN2K*T93
M$;QBA_8JJ&*'Q2+8@"WOW7NMW/\`EY.9/@M\27:6:=FZ!ZR+3U!<S2L=KX_5
M)*TD4+L[MR25!/U]^Z]U6!_,.^?/\T;K+O+?_6GP>^&.R=V]8].]<TW8_9?>
MOR!W#EMH[-W%1P055=FMM=:SX_)4$57EJ.@A*^5M9\Y''X]^Z]TA.L?YY^>[
M,_DL]K?S0<5T]BZ3L/ID;CV_NOJ"ISM6VW9-T;8W'C=OU;)GQY,BN-G@K_-$
MPO(SKS?Z>_=>Z)5O_P#X4+?/[K;KSXW?,W>WP.V1M'X`=\;AVCL^AW5D]_U=
M3W!4Y#=%1!2Q[IHJ*!CAL5MDM'4-!#64DM1,(_\`/*3[]U[H_O\`,4_F[=[=
M-_(#XY?"GX%](;8^0?RK^2.RH>T</2;^W!58+K_9'7U6D=939#<4V/J8,G45
MM5CY"\<B5*P(=),;?3W[KW51G\M/MSOCN'_A3-\ALO\`([J=NA^VJ/XJS[:W
MKUM1;GEW3A*?+83&8>G_`(YMS,`QT]3BLO$XGA?3^3^;GW[KW6S?_-3^568^
M$?P`^4'R/VS:7=_7G6=>VTS41-44_P#>O+>##[>F*D^F**JJS+(WTUH+^_=>
MZH,_EZ_R$?C#\S_B!UO\L_G7O?O;OWY-_*#:O^DS/]D'N3L'`KLL[AJ)IL-B
M=L8S"Y:"ATX32@5I%.I1IX4>_=>ZB_RO/G%W9\,)?YOGP2[.WQN#Y&R_RP*#
M/=D]);CWMEZZ7*9#KBD3Q4FR,QG*F6>LDIJ*IJH!"')T*&MP>/=>Z2FXO^%%
M_P#,6R?POZ\_F)]?_P`O_85/\1\3D<?MOO/<FZNP\D-VY'./EGQN2K.J\32M
M2G&[8I9C'`N2KHJ\23,3X5"^_=>ZL^^>?\Z;,=&=-?"=?BEU`G>7R<_F"4."
MJ.@^J<WDI:;'XZGS&)HZRHR&Y:V@:BJZFDQ5=.],TD03R&%G](X]^Z]T`G0'
M\Z#YHU'\R#X__P`M7Y?_`!/V3TWW!OO:^>SG8NYMI[SRF8VA6PT]#)E-I9OK
ME*SR3OC:^AADCJHJAR_W*6'`]^Z]U#[,_G)?S`^^OD-\CNJ/Y5?Q#Z^[_P"N
M?A_G9]L=T]K=L[MK,'3;CW3CUEJLIM'KNCQ-;C8/XK#34DJQFH%07922?Q[]
MU[H._E__`#4?C_\`.7^1'WM\E]_?'S)[MBV=O/`]:=Y_&?,;ZW#LS*;8[$P6
MY(:+)TTF]=D34.=BQ\-5&\]+41&-9%0JP.DW]U[I;]^?SE]S_`7J/^5#L#IW
MXL/V-@?ESU'A*';FP\;N_(3;EVS518G&4>U-JX7)Y1I9\S41U%;"E155;$O&
MKN23S[]U[H1_AE_-]^9V?_F02?RX/Y@OQBZ^Z.[)WMU[5]H]6Y7K7=^0S6/_
M`+NPT+Y`8S-U5;/-!D<DE)!('-.4M,I`''OW7N@MR'\[OYQ]V_(;Y04WP2^&
M&W^\OB?\*MU5FVN]M\9_=U1MWL#=%7@*2MJ-S)UE254J8PU=/#03S1TE2CRZ
M*<V/K`]^Z]U9)_)D_F8[@_FF_%K<_P`C,[UW0=9MC.X=]=>8G;V/R-37RRX;
M;8HZC%UM:*E0\.3J*6K43KRHEU!>+>_=>Z(3_P`*==L?*G<OQ*ZEJ.C,-VKN
M?IS`=PXW+_*O9O2U7E*'LG<75CT\:U&.HCB(ZNIJ*'S:C*PAL@%RWOW7NJ+_
M`(K4_P#)W[.^1WQ@W%_+=^5O=W\L;Y1;7[*Q,>Z>N?DF_:N\,=W/B4G05O7U
M2V6WF-K8W(Y,HZ&>:>*,F10([@#W[KW1D_DY\]/YJ&-_X46[!ZCV1TGE]YXG
M:6S*ZAZR^-2]F4^.V+NWJ;<5)4T.X/D3F((LW1XR+.QXC[NM6G=HYHUH`N@W
M.KW7NM@+XH_S3-Z?(O\`FM?.3^797=98/;VU?B1MO"9O&]E4>3KJC-;JFRDV
MU8##68=E:@I*9GW,2CQF^F,%OZ^_=>Z+K\4?Y[D?</3/\UOO+NKK3%[`V5_+
M<[-W#L6.#:>9K<ED]_4&"K-YXZDJ7%8$DHLCEJ_;4*:8RRJ)C;Z<>Z]UKW?S
M=OYCO\ROY?\`\GW<O9_?'PPVMU/\4OD#OSJ?.=,]I[-WS5U6[MHPX+>AR%(>
MR<+5R^4T._(:8T^.GIM`64`,+'GW7NK1>^>T^E]M?,K_`(37;-[`^/\`#V7V
M7V!TMU,.L^TY>S=^[1DZAKZ+;O7D=-5-M7$5J8#?=/\`?U`ET95)7F*:;V?W
M[KW0X]O?SI_GKW!\D_DOU=_+$^)/4G=G5_PTS;8/O'L3N#?F1VS/NC*X6FJ:
MS<6'Z\QM'D<;'2SP"GFBCDJ!+K>$DBUO?NO=+[?_`/PH9VIC/Y2^+_F-;)Z?
MJ<AOS*]@+T96].9?,E<)L_ND96'$5>/W-NJC@$,.VZ.:5914&6'7&^D-J'OW
M7NEQ_+J_F)_S4N^^VMI;>^3/P\Z#R71V^\%-N&D[\^*G<6*WAMK8D<\*3T.*
MWKCLUNS*5U37QA]$GV0(#@CZ@@>Z]UL/0,7B1BRO=?UK]&%SI8>I[W'YOS[]
MU[K+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#?N3_F4/:O_`(C??/\`[S&4
M]^Z]U\$_W[KW7__1VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW53O\`
M.4^!&4_F-?!+MKXZ;<R-'A^PIZW![[ZGR60+/04N_-FU1R&*2O7DB/(QRU,"
M,MM!D'XO[]U[JEFN_FP?S9MJ_'JD^'V._E4=^X_YIXSK^#JO!]R8<?<='0UM
M%0P;2H^R*?<<=*,=0RP1QI60PR5A9'%]-N/?NO=*;YZ_RP?YAGR*_E+?%ZB[
M&WNGR#_F`_%WL[`?(*OQ%=4TM%3;L>BJ:6NS'7*Y&!*2DSF8Q--0T\4%8R)Y
MBCJ+:K^_=>Z+_P!SM\V/YYO=WP,ZRW1\$>V_AWU)\0>TL7W+W;V=V^_VE#G=
MR[27"0/MS8U*D.--31U-9A%\3J\@9)/U6%_?NO=&L^.'1W<6#_X4_?+'N3(]
M7=AXOIS<OQ:PN$P79E=M/.0;#R>4CPNU(7QE%NV6F;!5.1AJ**5?`LTCW4_[
M'W7NB;_RL_CA\@MH?"/^?SMC?'2O:NVMS=L=F]TUW6V,S>RL[B<IONEK]H9R
MBQT^UZ:LHJ:HSU/6U3HL34JRH^H:2??NO=5M?+GK/L[IS_A,]_+[V/O?KC<W
M7W9V-^8%,PV?O;$UVV\U1Y*MSV8GHER^*S4,%111Y658I`)8E"\-;CW[KW5C
M_=V)^='\XKY"?RT.AMY_!'LCXQ[)^&&_=H=Q=S=J[WS%/)MC+U6'P^VA"-A9
M2BCCAS-!7PX.FE@(9G;RL#:WOW7NAAH/AMVUV[_/)_FM-FNN=_[;ZB[]^'&>
MZJVEVQ6X#+XS8N4W)N':U%C88*+<E11?8SU2U[KJ6)F'#\<V]^Z]U2GTK_+_
M`*CH#8O^R>?(O^2?\LODI\EL!N3<F*H^SMC?(+MC:OQU[%V9D\ZL=!D:Y</E
MJ79N%F2#3R2EI`)O$+$'W7NK>/YMGQ![LZ6I_P"3!VE\>/B/V1NCK_X3Y##4
M6]NC.LLY7]K[JZ^HVCI,G2;3;/U<:3[D7R224IR9B].DZK"Q]^Z]T`?\S7X$
M;AQG\QBI_F,=K_!#Y%?++XG_`"9Z9V94;AZOZ.W]O38W<O3W;4&&QU&<?N>+
M:%?2YZIQ\=0QB:&+_)"6((`2WOW7NC=?$#^6%MSNSX'_`,QO:/7/\OOL3^7U
MG_EGUQ4=:[)'<W?&Y^R=\]FTV`KANG;4F[,/N.6<;4KFW!2K"M23Y)(GL?2/
M?NO=5;?(;>W\S#L#^2S0?RJJG^61\@<'O+XRXC:>WNP>UZ>@CS6VMT[2V%FJ
MMJ,;$P%!BI<INK-Y1:U'88V63QQKJ/U/OW7NMZ3X&X'.;6^%?Q7V]N3%Y7;V
MX\)T5UYB\I@LW%44N3QF2I=M4,4U#E*2I2.HIZRED32\<BAT8%3R/?NO=:@'
MSGZJ^;6^/YG/RZVE\IOAY\G_`)L]0=F[<&U?@IANM>Q-S;1Z$ZOERD34=-GM
M]C&U]%M=EI))_N:F&LD$K30EM'J'OW7ND;\:/BU\B]D?\)K?YB/Q7S?Q^[7Q
M7>F+[9WU2477S;!W&^;W1'6[LPE13U>RZ9J"1]VXI8*1Q%5T2NKQK=3_`%]U
M[H=?YE/QN^0>^/\`A./_`"]^H]J]+=F[B[4VEFOCF^Y.L=O[(W'E-W[?..DS
M4>6;/[5IL=+G<9!0+(C5#SZ5CU>JPY]^Z]T./S@Z%^57Q"^?GP-_FL](?'+>
MWR6VML_XK[4Z&[[ZMV(/-O\`VQ.=FXS$QU^*PSPN[PI1>EB`&CJ$:X'U]^Z]
MTAOY:V!^8O;W\_WN?YK]^_$;L_XT]>]K?&NM&SH]V8>HJ\=C\'!34-!@,5NG
M=)48>AWA/#"QFI%&L:AP.??NO=;-'SO^+&%^;7Q$[_\`BSFJPXZ/N3K?*;9Q
M.6DA>48+)R!:G#99W:0"6*ES5-$1:S+&Q(^OOW7NM;KXE_S!?YFO\M#X_;*^
M#_?_`/*T^0/?N_NFZ&LZ[Z?[=Z8^WRG7V^MM4$\Z;9KMP5%)35R8I!$5+/4O
M3D1_4`B_OW7NE+\4_P"7S\M]J?$S^;C\S/E?LA,+\R?Y@^P=\9&DZ=VK3Q[@
MR^U=L08JI.U]KU%+BJ>I$VX:R81:XHY9AJ0']7T]U[HKV/\`C5\@(_\`A)ID
M.A'Z5[6C[G9JB5.K%V-N5^PGFDWTF16-=H18W^-&*2E4N3XRH3DCW[KW3U\M
MOBM\E.N.KOY%7\P'J7IG<'9G:/P.ZXVU0]C_`!PCJ_X-V?EMO/$F0K(L%MJO
MB;(5V1IZR66*6)83/&I_3[]U[H)^N_D;W9\M?^%+GPN[D[8^-&^?B_C\IT;F
M:78G778)2KWU/M;$XZN$VX=QT8I:2JP_FRE2VE98HF6*/Z6-S[KW0[]&'YJ?
MR*_D1\^.M-H_`KN#YA]0?,3N#+=R]%=A]-R_Q1,?NW*QY.E?;6_2E/6C"X^D
MJ,NQ=Z@P^A`0W/OW7N@,WC_*U^37Q]_X3^_-ZAW;UKNK+_*3YA=[X/O[='1_
M7=%E-\Y;:E+E-RSU&#VRN.P5/5S'*8O'9"9\A]J9(ETKJ/ZO?NO="_\`++XX
M_(#<':W_``FRK</TOV3D*'J;"[,I^UYL?LW.5]/UVU'%A#4+O9XL>_\`=XPH
MCEON]&DWO<_7W7NCB?(#HWMW,?\`"GWXP=PTG578&2ZAQGQ9RFWLMV?0[2SM
M5L3%9BHP^:IXJ/(;NAHFP.-RK33*@A=U<@@VY%O=>ZKY^/F7^:O\H[L+^9M\
M7]B?"?L3Y5[/^4F_^R>UNG^[.N,[CIME[:@S>"W-'6T_8.0AHLA28?\`A0R\
M]X:O[69OMP!P0??NO=6&_P#"0ZFR<7\L_?53D:)Z.JJOE/V^TRE6\#5$<F%2
MKCIW);RK350DCU:CR/K[]U[H_O\`.`J_YF6Q]L=.=T_R[EI]_)UOV!%7]Z?'
MH4>`CJ^X.N?VR^+H,CF4$ZU\)\@:..HBUJPLI^A]U[K7-^<<7R#_`)U>Z.A>
MI^G/Y079?Q/[-VCW!M'<W8?RI[-VKCMF5&Q<%A*^"LRN)PV63`;>FS5/,\9<
M.DU6'(4@WO[]U[HX?S%ZN^47Q:_G\?$#YH8/X[=M_)GJ.;XL;;^/.;W)UO@J
MS)R8?<TV-R.RL]N;<E=0(L=%3QMF!5R>?2AC5R![]U[I(;\H?F1_+"_GI?,O
MY:;,^$/;WR\ZM^<6Q]O8CKW+=2_:QTV!W1C*?;E2<9N.M,=:,13459MT02R5
M?V5+*)5(E9E/OW7NB_?RW?Y<_P`G>\OA?_/S^//=/3V].BNW/DSVY0[WV!A]
MT4%?B,?6;HSN.WKOG$XG#YFLAAQVZ,/C,IE%H:R>EGD@:6P+GW[KW1:/F!V+
M_,Q[Y_DO[>_EG5G\LCOO;&[_`(Y+LC%]L]GC$5.8VWN#"]2YQLE@$Z[P6,HJ
M[,Y_*Y680J_VIJ80JLP<7L/=>ZLF^7/Q\[OSW\P3_A,?N[!]1]FYO:?2?5?5
M\/;>Y,7LC<=5C.M'Q>+ZU+4N^,A28ZKHMM3TYHY1/%6-%)>)AQS;W7NJYNX_
MY;-1\)_FE\R:GY'_`,MWY2?.+J;OGM/-]N?'CLWXQ=J=A;3@Q<NZ<ED<O5;8
MW[@=G9.*259:_-R1325@(C5./0;#W7NK@-O_`!8[%Z*_DX9O;?17\HO:)B['
M[`3?7;/P5[D[=W+VYN#(;+,U-)4;MP.7K*NDGQF_8HH!-#C]4QCD"FY;CW[K
MW57?PB^)7=.Y?YC_`,4^S?Y>GP;^8G\N;IW9.ZI,K\N(N[=_[CKNN,W@8:J*
M:IVQM;;VYI(FJJ'(4J2QI''#I76`#P#[]U[KZ"E.BI"BH25&HW;7^HNS,!Y/
M4%#$V'X''T]^Z]UG]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!OW)_S*'M7_
M`,1OOG_WF,I[]U[KX)_OW7NO_]+:Q_DD_P#;HO\`ES_^*D=-_P#O)T/OW7NK
M1_?NO=<="7U:5U$@WL+W7@&_]0/?NO=>5%4!0+`"P%S8#_6^GOW7NL34T#KI
M:)"H^@(^EB#Q_3E1_MO?NO=9617_`%*&M?AA<<_7@\>_=>ZZT):VD6^NG^SP
M=0]/Z>#S[]U[KE8'Z_[[F_\`O8]^Z]U5K_-4_EI[3_F@=-[!Z<WCV;N#J_'[
M`[9V[VI!F]NXO&96LK:G`/:+$RT]<I6&"?R`>4>L>_=>ZLJVIAX\#M?;F`5W
MG3`X3%8:.:4HTDRXFAAH$GD*>CR2K!J-N+GW[KW2@*J18@$?T(N/K?Z'_'W[
MKW7!88T30JZ4M;2"0MK6M:]N1[]U[KRPQ*P9456`(NHMP;7'%K_0>_=>Z]X8
MM?DT#60H+<W(5M:@\\V;G_7]^Z]UQ-/"6D8Q(3+I\A(!UZ%*K>]_TJ;#W[KW
M60J"`+?3Z6)%N".".0;'W[KW7M"\>D&QN+\\VM?G\V]^Z]UP,,3:;HI"APHM
MP`_Z^/H=7OW7NN>E>./T_IY/'%N/]A[]U[KH1HK,X4!WTZF%[MI%EU'^T`/I
M?W[KW781!]%`]6KCB[<BYM]?K[]U[KQ16!5@&4_56]0/^N#<'W[KW7!H8F&E
MHU*V(L1Q8C21_K6]^Z]UR6-$X1=(LHL+@650J_G\*+>_=>ZX-3PM?5&IOIOQ
MSZ+:.?\`:;<>_=>ZRZ1>]N>.?]:X'^]^_=>ZK3_F._RUNKOYB^SMBX?>>_\`
MLWJ'?/4^YI=V]7=L=2[DJ=M[MVIGI81"Q#QR11UM*=*MH>ZDCW[KW17O@;_)
M2Z\^'GR0K_ESV?\`)/OGY@?)RJVI4[&P_:'?&>HLG6[7VK51^&;&8J*$"=/-
M!^V26MHX]^Z]U>/"J^(61DOJU`^DEM1NS:3SJ(O_`*WOW7NN2PQ(VI8U5M3O
M=1:[N+.QM]2UN??NO==M%&ZNK(I60$./]4#]0?SS[]U[K$R!G-F)1%T^);J5
M?BSJ>+D#W[KW6NK\D?\`A/IM'M/N[MGMOH_YQ_+GXGXWY$9:>N[QZUZBWNE+
MLK>9K(A!D(X,=50S?9BNB,@EA8^.\K,!S[]U[JVCX._"OIO^7Y\=-D?&CHJG
MRM-L+9CU=:^1SE5%7YW<F;R=0T^4S67J8$BCGRF2GLTKJH!"J/Q[]U[HXB00
MCU:`S-9BSV9R;DK<F]RM^/?NO=9BH/!%Q>]CR..1Q]/?NO==:%L5T@!KW`X!
MN+'Z6^H]^Z]UC2G@C%HXD0:8UL@T^F$6B4VM=4'T'T]^Z]UYZ>"1M<D2.X30
M&8:B$U!]()O8:E!]^Z]UD*J2K$7*DE3<\$@@_P"W!]^Z]U[0H!`4`,22!P"3
M]20/J3[]U[KP55N5`&IBS6XNQ`!)_J;#W[KW77C2Q&D<DG_&Y.HF_P!>6Y]^
MZ]UYXT>VM0VEE8:N;,K:E/\`KJW(]^Z]UVB+&H5%"J"2`/I=B6)_V+&_OW7N
MN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H-^Y/^90]J_P#B-]\_^\QE/?NO
M=?!/]^Z]U__3VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW6&6G@F!$L22`V!U*#<*XD7_`&SJ#_K^_=>Z
MS6MP.![]U[KJQ_K[:9'))#&G6\=>L?Z^ZZ)/XSU['7K'^OOVB3^,]>QUZQ_K
M[]HD_C/7L=>L?Z^_:)/XSU['7K'^OOVB3^,]>QUZQ_K[]HD_C/7L=>L?Z^_:
M)/XSU['7K'^OOVB3^,]>QUZQ_K[]HD_C/7L=>L?Z^_:)/XSU['7K'^OOVB3^
M,]>QUZQ_K[]HD_C/7L=>L?Z^_:)/XSU['7K'^OOVB3^,]>QUZQ_K[]HD_C/7
ML=8S$A8L5!9@`21<D#Z?[:_OVB3^,]>J.O&&,DL40DBQ.D7(_I>WOVB3^,]>
MQUR5=("KP!P`/H![]HD_C/7L=<K'^OOVB3^,]>QUZQ_K[]HD_C/7L==6_/Y]
M^T2?QGKV.L34\3ERT:DR*$<D?J4?0'_;^_:)/XSUZHZY+$B"R*J@&X``X-@+
MC^AL/?M$G\9Z]CKDJ!!I4:0+V`^G))/^\GW[1)_&>O8ZY6/]??M$G\9Z]CKU
MC_7W[1)_&>O8Z]8_U]^T2?QGKV.O6/\`7W[1)_&>O8Z]8_U]^T2?QGKV.O6/
M]??M$G\9Z]CKUC_7W[1)_&>O8Z]8_P!??M$G\9Z]CKUC_7W[1)_&>O8Z]8_U
M]^T2?QGKV.O6/]??M$G\9Z]CKUC_`%]^T2?QGKV.O6/]??M$G\9Z]CKUC_7W
M[1)_&>O8Z]8_U]^T2?QGKV.O6_Q/^W]NJ0H`9A7KWY=!QW)_S*'M7_Q&^^?_
M`'F,I[W6HP>M=?!/][Z]U__4VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[JT?W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!-W%V9%U3M:'<ST+Y
M3S[AP&!^S20HP?.UHH(7!XM:5Q_L??NO=)UNXIT9D_@+KI)4K)6C6"IL0U[\
M@CV'[G>5@GEA/%6I_JSUOKK_`$R3_P#.B_\`5U?^*>V?W\G^JO\`GZ]U[_3)
M/_SHO_5U?^*>_?OY/]5?\_7NO?Z9)_\`G1?^KJ_\4]^_?R?ZJ_Y^O=>_TR3_
M`/.B_P#5U?\`BGOW[^3_`%5_S]>Z]_IDG_YT7_JZO_%/?OW\G^JO^?KW7O\`
M3)/_`,Z+_P!75_XI[]^_D_U5_P`_7NO?Z9)_^=%_ZNK_`,4]^_?R?ZJ_Y^O=
M>_TR3_\`.B_]75_XI[]^_D_U5_S]>Z]_IDG_`.=%_P"KJ_\`%/?OW\G^JO\`
MGZ]U[_3)/_SHO_5U?^*>_?OY/]5?\_7NO?Z9)_\`G1?^KJ_\4]^_?R?ZJ_Y^
MO=>_TR3_`/.B_P#5U?\`BGOW[^3_`%5_S]>Z0TOR7$'8]/U\^VI3+/LR;=[U
M2UUS'$,TN(CC'%@AE/\`Q3W[]_+Z?ZOV]:Z73=R37.G!,!>PU5JWXXYX^OOW
M[^3T_P!7[>M]=?Z9)_\`G1?^KJ_\4]^_?R>G^'_/U[KW^F2?_G1?^KJ_\4]^
M_?R?ZJ_Y^O=>_P!,D_\`SHO_`%=7_BGOW[^3_57_`#]>Z]_IDG_YT7_JZO\`
MQ3W[]_)_JK_GZ]U[_3)/_P`Z+_U=7_BGOW[^3_57_/U[KW^F2?\`YT7_`*NK
M_P`4]^_?R?ZJ_P"?KW7O],D__.B_]75_XI[]^_D_U5_S]>Z]_IDG_P"=%_ZN
MK_Q3W[]_)_JK_GZ]U[_3)/\`\Z+_`-75_P"*>_?OY/\`57_/U[KW^F2?_G1?
M^KJ_\4]^_?R?ZJ_Y^O=>_P!,D_\`SHO_`%=7_BGOW[^3_57_`#]>ZS+W"K([
M-AIA(#"@1:X69R6+:1;^@_V/OW[^7T_U?MZUT@]B_)3^_%+N"J3;,U$N#W5F
M-N*PKKI4##_;//-I`U7T3\_ZWOW[^7C3_5^WKW2V_P!,4BEA%B#/&'?1*:P`
MNA8E201<6''^P]^_?R>G^K]O6^O?Z9)_^=%_ZNK_`,4]^_?R?ZJ_Y^O=>_TR
M3_\`.B_]75_XI[]^_D_U5_S]>Z]_IDG_`.=%_P"KJ_\`%/?OW\G^JO\`GZ]U
M[_3)/_SHO_5U?^*>_?OY/]5?\_7NO?Z9)_\`G1?^KJ_\4]^_?R?ZJ_Y^O=>_
MTR3_`/.B_P#5U?\`BGOW[^3_`%5_S]>Z]_IDG_YT7_JZO_%/?OW\G^JO^?KW
M7O\`3)/_`,Z+_P!75_XI[]^_D_U5_P`_7NO?Z9)_^=%_ZNK_`,4]^_?R?ZJ_
MY^O=>_TR3_\`.B_]75_XI[]^_D_U5_S]>Z]_IDG_`.=%_P"KJ_\`%/?OW\G^
MJO\`GZ]U+H>V9JRNQ](<,Z"MJA`7$NL(IL+AOH;'VF&[&6=J<*_ZO/KP/ETI
M>X/^9/\`:GUO_HWWR>3<\[9RAM?^@O[$EH^M*];;KX*?M7U7K__5VL?Y)/\`
MVZ+_`)<__BI'3?\`[R=#[]U[JT?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7$_GVVA)D<$XZV/+HJ'S(53U%3L0"R;]V(ZM^5>+-1R1L#^"D@N/\?:
M7<9'CB!C8@_+KQX'I$R<R,3R6.IB>26878D_U)-_<8RR2M?7#22$U<\>M>76
MLW\Z/YC?S`ZG^97R+Z7Z1[&I*2'JG;O2>4ZOZ>H?C7F>U<GVON;>>,ILEE-G
M5V^\4II]FC,5!(CJ:@VAA!YM[%-C%9M$C20J21YT\CY=:Z.U'_-;J,=2]KON
M/XX;O%7U+VKU[\<JPTVZ\'0OO/Y#=C8>AR.)V1A<14T1;&8FAK*B1JZO>I$E
M+%3F-89=7MB>R4RN\:`(2:`>0Z61HA525S3IX'\U;!9"&#8NV^@MZ;D^2.-W
M3V_MGL3HQ=UX3&UFQJ3HO"4^;[)SPW9)%38?)45#15,,^*18UJ,@LQ5PNGVW
M]`:$Z<#_`"]6T)_#Y]!=T[_,RSW</RQW-N'-;BVQU!\&ME_%SK+O$YW>,NWL
M-7U];V-E*G&4,F[,AEZ6'(XJ#^(4$L"14DCZBE[V/M,85#%`M7K2E.O:$_A%
M.A<S?\UW8,6^,WC]F]99C=O4U#VQ#T%A.^X-QXU=D9WNG-[8EW1C]LQT*4=5
M/%M,/"E%_%%9VC>34I(O[IX:U(TC'7M"?PCH"/CY_,]W/MSX+[M^0WRJW;U_
M_IUW)1=G=@=0]-P9#!8K*Y_;.SLWF,#C,)MG%XN@QF1R^&HZJB!KZV5:B8!&
M(E_H8BVA1::%8"F:=)&H&(`Z&GJWM_YI]-]>9/Y7?,#N3H[?GQSR'1==W+DM
MF]<;!J=N[RZ_K4QE+F\=MS:5=#6U,N\Z=H:Z*"66KU*O+DCZ#S16U3IC73U7
M'3'EOYNN'VOC)\;NWXV=@XCMR3,=%+A>HGW=@*V;,[2^1VM>LM[TFZ,702T]
M-BJ]`'KH:AR]`38>V39JQJJBAZ]CITV[_-;CWPVU]F=?_&OL'=_>V;S?<^,W
M)T[3;FVK0UVUL7T5E:?"[\R])N:M6#!YK[>>J1,?%#::OJ752T7)]^^AQ\(Z
M]CKAD?YPO3F,^0-9TE/UKNJBCP64BV/G\QELO14N3P?82;.GW?6[1RVV?')D
MDIHH8!#4Y=7,=+5_LIJC-_>OHOZ(Z]^70!]C_P`Z;<=%T5N#>FT?C7FMI[YS
M_1F3[LZ6.]-VX:OP^[=LT&^:39N8RV06@Q\E/30[9EJ!(Z:OW5E0<E3[N;`!
MM+`4]1GK7Y=7@]8YW<&ZNM]A;GW9@X=N;FW#L_;F:SF#@K5R,&.R62Q-+5U,
M,-:B1)40N\NM6"CTL!;CV6RH$D9:<#TM1$**2HKTBYN?DS1@V(_T#,MK?V1O
MX.!_K:N?]?W2@].K>&G\`Z#CYT_(C,_%7XP]E]U;>P-'N#=6'3`87:6.S+U/
M\%J,]NK<=!MO'U^:DQW[^+Q&%K,D)YI6MY8HRK<>S."*%HXZQKJ(\^O>&G\`
MZKZ[D[9_F/\`Q,Z/WQV3VIWAT%VM'5Y#HQ]GUNT^L(]O[AVO5[O["PN"WECI
M\35SRXO-[97"91EI*J9?--(H8'GV\D$#L%\-17K7AI_`.@VV3_.4S>VMBUTV
MZNG-P]O9?;6UNZ>V]];IP&:P&RJ+;O5/7/<<_6!J!A,ICYJFLS2QLDU)#"Y^
MZ=6'T`]MFQU*950:"U.DC@!R`,="7L7^:;N',]@]D];;<ZNW-WKV1G.Z=VX;
MIK8&(;![&K,-U1LWKC;F^<UDZ[,SQ?PW-Y&EH\VL=/#4T[3U5>_C+A!?W4V-
M/PCJOV="5W-_-6VOU#V?LCJ3-=2Y['Y;L*BP>&IZFJW3MNHW)L_>^Z]DY7<6
M,Q>[=IX]LB*&''RT%I7>MI)/*K`0R+8>[_31A0#&"0/3I7&B%5)45Z$SI#NO
MY"=[_P`LC#]^;6S&VE^1&?Z<WINW`Y5\!%_=Z3>&)S&XHL;!6[>4O')25F,P
MT<<$:_64E[#40"ZX2-7(0=O5Q&G\`KT4S:_\T?>>_/\`1#OG:=#@J_8.ROC%
MC.TOD_AZJLVYM7)-VYNK/+LG:/7$.;W&#C=MRY#.4%?7E(2U9]K"$\1N/:F*
MT#Q(X&3U[PTK\'1=^W?YTF_-TP;%W/TY@5Z^VY+MWN[$]@[;SE+CMS9"+>W6
M&[MK8#%5F!S]5B\+438FLCSY>1FI8;BPL19BZ+&I`"]:\-/X1T8S.?S3]^;O
M[9^.V-ZRZ_R.*Z2W)WOV+TYOWLS--M11V56]8[);*;FQNVZ2J*P[!DILW'>"
MJG)^ZC#:C&+$V_=YH6(%``?V]))*"0BF*])K?'\YK<VX-K;KH>F.AL7/V;L_
MN3HK9>6I*WL?#Y_:^8V/W!N"3"19;!;BH,;#CQE:'1IJ130UL5/(X*2S:3;R
M[>2*]O`_RZIT\=9?S;<U%M;=='G>K\]W-V'LC/\`?^\=^4&#J<3LW'=<=)].
M;I7;<V9GJ_#3KNBKH,G(:6(:$?(&/6ZJ#;W7Z`TKH%*];_+H5Y/YP/7];V*N
M$VQTGOG</4T>_>B^O\QW0^9Q%'CL9D_D/M^#-]?S';=-CWKHE5JH+4J6;3IM
M>UO>OH?Z(Z]U<=&+:`3&[Q5"1-)&C1H\D)DA>1%>.)PLC(2+J+WO[0RQA)'2
M@P>E<:(44E17H`NAG>+$=@-&Q1E[:WT`5-K"2+'"0#_!Q]?;=!Z=7\-/X!T.
MS`7/`^OOU!Z=>\-/X!T7+Y=]XGXV?&7O#O>EV\=Q9#J7KK.[QH,`U9-21[EK
M*"$/2X^H:,&KI(4JV3]VGYD34OOP4$@4Z]X:?PCJL;=G:?\`,OZ+^+':GR<[
M.[M^/_96,R?QTI>U=F[<VKUA+MC/]=;OS38"OH\%00353T>YMNXS"YB1'K<@
MIEDGBU`VM[,K>R2:-#P<G\J9_P`O2.0:78`8Z#?JK^<-O2EV[D:7/]39[O[>
M#Y_Y$9BG;:U=M[8>/PNQ^A,#M3*Y['SQ_P`/DDKLO)#FI9:)F8BJD4QGA1[W
M]#2E5&>J="#L#^;=+N7LK>&&VQL3/]NU78&Z>G,3\<^J47`[-R*P[]ZAR79F
MXZ/<N^(J<8XIBX*51KFIGF%4G@5M+^TSPJCLI48Z72QH+2)PHU'H:^X_YJ>W
MNCMP=0;<WWT?NC`5/88Z^I-WX_);GVU/O7K+/]DY&3#8S'9?96+;)9/)TM)7
MP$3R>2AC@C(D620L8UJ(U-:*,"O2:T"O,H85'0J_$'Y']H=R_#K?W;^]*C;]
M7OW;NY/D/C\7/0X^&BI2NP=T;JQ&VHDHZ5WAKH(*'#P7N;LY8M8D^UXMX4"J
MR*6H/YYZO<*JS2*HH`>'1/,1\_/D1_LO_P#+=[-=-JYO=?R.PW:F3[3QL^,H
ML;C,SD=E=?[NW'A\/CC2NU5@98<O@(X*HZ0K7N;7][$5OBL:],4Z)@?YP'RQ
MS-'TQD:W#;?Z]S&_]I]);DS.UDP>+S./J*/?W968VIDZ_'Y:>\]$L..I3Z>1
M(R*?S[>3;HY:LH&BA/\`J^WI5&JE%)45Z&;H_P#G&=TC*463[;ZCI=X=,83J
M3J/>>].Q\#68_;^?Q$79?:&8V54[VRN"I:&>&/;>"@QRF2"%ON3%&TI.E_>_
MW8M,**].:$_@'5U_QE^0F'^3_7>7[3VYMK)X/:8WIOC:.VZFKK(IQOF@VGF)
M<3'NW;TD,4,=+BLAD*.980%!,5@>;^R>XB$4TD=.!Z2R`:R`,=&)>Q9CZ>3<
MJJZ0A/ZHK?UB/I/^(]LZ1Z=4Z=\"2<Y@E))49&,6OQ8D7]J]O53<@$8KUKSZ
M,1W$`O3_`&H``!_HVWQ]/_#7RGN04140:%`Q_DZ]QZ^"C[=Z]U__UMK'^23_
M`-NB_P"7/_XJ1TW_`.\G0^_=>ZM']^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]UQ/Y_V'MJ/^TDZL/+HJ7S'_P"900_^'WL?_P!V\?M'N?\`8C\^M'@>
MD.WZC_K#_>A[C>X%+B8_TCUKH$=E_'WKG9G<_;/?NW\;DF["[NQ^V,#O>:IR
MHJ*2HQ^QL><)BQ@Z292,97M&X5G6Q*"P/O0O6C%`QH.M@=`UN#^7]\=MV;>[
MGV_G,+N22+OCN/$=[[JR-)G,E29_#=O[=,,>`[!V9E8C_OU:W!?PT"F>+U1%
MFM>_LPCWC]-:G-.EL=="_9TB,C_+#^+U;M#`[?IZ/LG"YK#;C[`W!F.W-O\`
M9&<QW:FZ,QVO3QTN]:[='92?[E<VFX*&,05T4EUFB])L/=_WQQ%>K9Z<<!\9
MO@O\=]SA:@=;;0K=_P#66S.EZ+8'8&[-OU>"W'L/KJ>2?!4&UMF[FR5+-5[B
MAKZR65F@ADE\C%B3?WY9F9A.C48Y!ZUQX]98_P"7I\3Z_N>I[.QV'S466I]V
M8WL?*=68C>%5'UG3;_BP%1M_:O8%=UK0!,/3[HJ,,_EIZ\1JP)U`$\^]:C5C
M7)X]>Z$?9WQ#^-G6?46,ZK_T<[;SNP=N;6WIBX6W_2T>=R$.WMP5U=F=YT)W
MADJ>7)XC$5;9&<N$=%Y]T:ZD&I"YH3G\ND4E-;8\^BT='_RXO@IMRNW=5;$W
M#N'MS%YWKG)]=R;4W)WAF^U-O;%ZXW;%-+'M_9>U*[+C'8'"UV.ETQ2+'^VD
M*VX7WM[O4J+I`('$>?V]5P*YZ6NV_P"5W\7<'20TBXWL/<>4I^P.IMY46X-U
M=DYO<N\XO]#GDDZ\VDF;EDD(V'@3(6CHPYBA%A^/=EW18P$)&!U[J/E/Y8'Q
M?R9FK<0W8^U<\_8'9N_WWILOL3/[4W$,SW%5QU&^MNR9VFM54FTLA+3CS4"V
MBE//U-_>_P![KZ]>ZSR?RQ/B]C][9GM/:N&S^(WAD,3414F/K-U99MFUN\%V
M36;/HNQ,U@IJLR9C/P4]05\\C`N"202;^_?O9?7_`%?MZ]T!WQ__`)071/77
M1)ZP[JRVY^V=V9KIZ?I[.YYMV9REQ6"VG6[IGW55XOJ+$M)-'LTU>2,$M5'$
MQ61X0Q]^&[KZ]>QU:GL+:-/L'96UMD4>3S69H]J8.@P-%D]Q9.?-9VKHL;`M
M-2/E<K4_OU]8E,BHTC<G2!^/:=Y/&8RC\6>ET?P+T'TW_935'_X@=_\`WNU]
MUZOTM.T>K.O^YNN=Z=7=F[<H=V[(W[AI\%N7;LXK9!68^5PYG:H0A:&IAD17
M1H_T.@8<^[>,RC2#CKW1`]M?RE?B?B-O;MV_59/NG>]+O-M@BIS>_P#M[=N]
M,EM_#];[EI=P;1VK@:C(U#_PC!MG:"%7B1?3"@YL/;K7;,^M5"_9UJGSZ>\9
M_*S^)>+P>[\'28'=DF)W_P!;=E]69V`[VS-7)6;;[#WR.RMUT5-4R#6,C1[M
MGT4LO'[%POMS][!5\,T%/\U.D4@_4;J-5?RK/BF&JZC`0]H;)W.-U56]8=[[
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MQNO`9>??65H]UKVAE-U)FX]^U^'KM^U?\<@:2')23Y;;],T<BFQD#@?3W;][
MCU_U?MZUGI>Y#^5%\2:W=<^ZZ[;O8(QT.YMR;RH]@)V=GZ;J[#[CWAMMMI;K
MR&-VK':GILYN#'2AZF9?5(1<^]C=U&:Y_P!7SZ12_&WK7IDP/\H7XA;<VYNC
M;-,>URN=I.KT?/UW9>:FR^VYNI:Y\EU9+LZKBCC./DPS>2-"G,<5KW^OOW[W
M4^>>J=/3?RF_B<^WL;MNEHNT,96R9#L+^-9B@[)SV-W3OO&=NUM/F=Y;3W7F
M(B'W)LK+U='YZFFF.B1R3P?>_P!\"FFN*]>Z7];_`"W_`(LU]1N%(]L;CPT>
M?WWTKV'5XK#[ARL%'#D>@\/_``?KJ'#XZ,K!18AHX(X9XQ>ZK>_/O7[W7.?]
M7[>O='T&O]OR6$ID@:55$@6.5E+21`2_N6B<E1?DV]IWD$S-*.#9Z71?V:?9
MT7SHG_BS]@_^);WO_P!:\=[KU?H>C]3_`*Y_WOW[KW2?W=M';O8.T-S[(WI@
M*+<VSMT8BKPFZ-OU,,51#G\-7P/3S4%5--?[=560E0OT//OW7NJW]M?RB?B)
M@</O?#257=.Z,/OW9-=U-#3;Z[HW=NFDV/L/(9.DK9-N==XR>J:CP?\`#JN.
M*.$JI"074&P]JEW-8E2+`*BG^STAD_M&^WI18W^6I\/>KAE=VS4N=Q='3;=[
MII,[E\]ONOQN+Q^-[IQ&,Q.^ZZ;*39&EH:%L=1XI%8S*#3ZBZ@EO?OWNM:UZ
MIT'VR_Y<GP-RVT!G.KMX9@4@W%UM68+MGK_N;1EMO;EZRVM+L#"#9.YL/42Q
MT5108>N-/6)&=>0247!(/O1E\<^-7XL]+Y3_`(C".E+N7^41\0]RYS%[BJJ+
MM:GKL5C]K4-;/2=H;AFI=R5VQMR-N#9.:WH]09:K,YR/,35$K3,_I$GTM[]7
M!%.DEE_;KT9[J?K?X\_&;951T#M?=>WL-BJ[.[ERU3LW>6\L57;AR]1V=N;(
MY7,1.F2KHLN*/<>4R4\%+H52Y:RW]MO<-J-34].75/J)1\^@!ZE_E3_$GICL
MF#L_:V'[*K*C%46^*/9&U-T]A;EW7LCK7']D05L&YZ3K_8>2GGH]LG)4&2EB
MDDC)8!VM8'W=[PM&B!`M!DCBV:Y^SI-05)Z1V'_D^_#K%U6'J6QO95?1[>H-
ML8S;]/G.S,]D?[MX'8NYZW>&)V[C'E%X,.,GD'DCIQ<1P(8Q]/:^/=E2-$-!
M0=+H@/#7I.[^_E3]38SJ+=NTOCRU;M;=.Z.A)/C;+-OW<6[,WL-^LJ3)U];5
M2[CP6-KHH,YN?#C<4TF,GJ%#1RJ+'@>[C>4KQ'^K\^KTZ/Y\<NC=O_&WHCJK
MH;;<JU>&ZLVAB-JTN0%-]H<K/CH5^[S3P>69DGRU<7J7)8NSR%F-R?99<3"X
MFDF'!CTDD^-NAO)+,S$W9F9F)^I9B68G_$L;^V>J=.^`_P"+[@_^UE'_`+V/
M:O;O]R1]O5?/HQ/<?_,H.U/_`!&V^/\`WE\I[D(?`OV?Y.O#KX*'N_7NO__7
MVK_Y)-S_`"B_Y<_-O^<2.F__`'E*+WL4ZW@"O5H37_U9'^Q]Z*%L@D=5,\2?
M$,]=AA8>HG_'WKPC_&>J>(&R`:'KO4/]4?>O"/\`&>O:_D>O:A_JC[]X1_C/
M7M?R/7M0_P!4??O"/\9Z]K^1Z]J'^J/OWA'^,]>U_(]>U#_5'W[PC_&>O:_D
M>N"ZM1))*D\#_>O:>.WF2:1VE)0GA7K0D-1QIT57YC@CJ&+U&QWWLC_8?[ET
M^GMC=740!:=W2^W>$,#(@*_9TBW(U'_67_H4>XVGE'BR`C-3TU-I,KE!1:XZ
MPND<@(=`P(C!_'^:D$T=B+$%)1J'^/M@M$>,8Z:IUD)N&!)LX`<7-F`)8`B_
M(U&_O7Z/^^QU<.X%`QIUQ;2T@E87<(8P;FV@_5=-]%C_`*WOU8?]]CKVN3^,
M]:K?\X'8&&E^5^[]\UW6G9.6W9E>E]E8?84&8Z5K>^.L^Z:W%9&:<[*V5E-J
M8Y-Q?'S>463ECI9\NN1IFE@_RAQ9?9MLDRO.Z2H&@1JT/`#A2A/^#I4A)52>
M-.F#=&7^1O3'=G>W9&,;Y(=>;CS.[/@#NS=6SJ&I[&WCM#!=(T>!I<=W#B\8
M]-19&/-#;]:RTDGV<E55TE/&=:"Y;V=[V]KX'^)P(DE#PQP_/J_3OOCO_P"4
MW8V*W5-O[>_RAVE\<-\[]^;.&Q>Y]J;/W<FZ*VKQV)@'0&Q,GA<5AJC<B[$S
MT3MX(#`:>K5B9)`;@4VVZVWZ"V-Q:1M,$&HD9)/GQZ0R?VC?;T4[KS='S>Z>
MV%AJ;KW`]K;#V/DMK?%C;_:F[\-@-X;:W7M[;\77FX7S*XVJP>%K]U1J,V88
MLD]+#52P!]$F@<A7]9LW_*#%^S_9ZIT:?=?R`_F([<W9\2\QO+</=VYZ[(=?
M=>KE>K-J8'>NPJO<M1E]Z-B,IF9*S%XW/[0W=5S[;,4^3H]QQ4/VT8$BS:W(
M!-.=MDDE=+5*EN%,4IUO/6UI%*:B"&5Q*#+20I)'*B(Z`Q)KIYDB2.$R0M=6
M*J`66XX]IO\`$?\`E%3]G7NI'GDN3JN=`CN54G0""%Y!L`1[+)O`\5],2A:^
MG7J=<%<I;1Z=+%UM_9=OJR_ZDG_#VW^C_OL=>IUU?_>>?]B>3_M_;@F"@*HH
M!U<,X%`QIT"$Q_YR:H__`!`[_P#O>#WOZCKVN3^,]#>3=@Q)NA8*;G@:CQP?
MI[]X_7M<G\9ZZ.DN)+6=00"/3P18BPL#<>_>./3KVN3^,]=V4LS_`-IS`S$<
M7-,"(#8<`Q`\$?['VTS1,23&">E**K*"R@GJ/D)=&,R!BHZFMJ(J&L2DIJ&:
MGHZFOJ:XMY:!)JX^!*J:2QBD^@DM;WK5#3^R'[.K:$_@'6FOT%U9D=N?*2':
MG4'3_;LV\<U6_)C$]AT.Z>G=P;-[9Z03=VW=S@;ID^1^&J*+"=VXBJRKP_:T
MLWW$B0RZ$_18"J&XB:",E`M5%`.'25F96*J30=*GK'O;Y,_'OXUX+9VS=S_*
M22DK?A%F\3L?"MM3L_<F8PORTP7="X_=N/QK9?#_`'F)KH-KRM-2L_\`N+6"
M4Z">?;KFU<%C$FK52GY?ZOSZIXC_`,9Z4G?FX?DIV7O_``V%[6S7R(SV_P#:
M_P`FNI<SLCJZFV=N3_15'TK3]1-6TW8#Y./%K@J/<%5O"IGCR56]0E0U5^SX
M])%VECL"6*VZ:BAK4<?7K?B/_$>DWT/VY_,>P.Z?C%LC'?Z3=CXJEVQU)!L;
M9O\`=S>%/MC=&+R&]=V+VMD-U[9I]O08"MJL#2>,B/)5E'/2H%9(YE8>VS#M
MVE6%JE:YP/RZ]XCU^(]'Z_ER]V_*K._-;M/8'<6<[I[)VW+1]@98[BSM%O';
MNP=I-B-T55!M>DS.R]XXZ#'[5W-6X>5/M8MO9%Z.OB59&4,S`+?"VD0)6RCU
M4R=/GUJI)J3GK8+(#`!E4:'=E4.[@,4-.9/W`'622+AE/Z"2OXO["U\+8$F.
M!1]@ZUUVMD70M[:%C^I-D6(PJJDDE0(CIXMQ[1H8M*DQBO7NO+9%TI=5\0@L
M&8'PBUHKWU:!I'%_Q[O6'_?8Z]3J6'+:&8EF,L-R>2;!AR3]>/;BS!0%44`Z
MN&<"@8TZ+WT2?]P_87_B6][_`/6O'>]_4=>UO_&>AZ)%S_KG_>_?OJ.O:Y/X
MSUQ<*X17&I8W\B"Y`5_]5P1<_P"O[]]1U[7)_&>N9LQU'ZZ-'X`"\FP`%AR?
MQS[;9XV)+1@GI0BAE!903U7'_-<V=!O[X/=J[:R.V.Q]WX)*K:L^7H^J#1U&
M],7C8,[25.2SU-@98JM-\XC;U+!Y,AA'CUUD!*\W]^21%=66,!JXZN8TH>P=
M:]&TMG;JJ.H-Q5.V=H=E[<Z1VK\YOC'N>7N+K/JGLWX]R]AX>6:2CW'5U73M
M(`<)!LFCEI_OJVBHXJ2JJID<J=-R*+800V\0FC75I(IQH?+@?GTED=C6,,?#
M'`>7Y=&CP7RE^>$E?MCK?:6:[ZSG<&U]Z_->IKTW1M/<"8>NV_0;5RE5TGC]
MP9C+[>H]L9"C2&>";"JAFFGG`4^M2/=QX&DMX:X%?\G3:MH(*&AZ*/(_=^X^
MV\;V+LJJ^0_:>[<AL[X,G=NY.U]@[SJ\M1]@P]@S56^=NT5=E]O45+#B-I;@
MGOXXHUCAITL+H`351:.6)C7@3P].O,Q8ZF)+'H9NN>^_YF^>ZU^3-1N'L'N;
M;&X<9LH5>_9CM/?.\:KKWL$=LM0+3;+IJ/#8G)[8P]1LN*4SP[>;(R4U`?N_
MU)I%0+4F@@6OV=>IU=O_`"J^RNVNT?C375'<=#OUMQXCL#=6#Q.9[&W%6YA]
MZ4>$2.:ASFT\_N;%83>E=M2HFGD2`9"EBF">@Z@`Q+;I+=925C4J0"/]GJRR
M,!0,:#JRF/6/W+VD;2T@$;P!7#%S%XFYTP2$JM[W`!]IZ0?[Y'6_$?\`B/7A
M87X')9C_`(EF+,?]B3[8>8*Q510#JIJ36O7KC^GNOU'6J'UZ=L`?]SN$_P"U
ME'_Q'O6WM=/N#LLC".O#KWGT8GN+_F3_`&I?_GVV^/\`WF,I[E>W#>"FLU-.
MMGKX*/M_K77_T-JS^26VG^43_+I(%R/B/TX>?_#4HO;,KF%2_EUI3K;1_J].
MC6[E^1=1M[.9;"KTYVIFSBJZ>A_B>)H-NOC*_P`+:?NJ&2HS]/.]++_9+HC6
M^H'L/77--M9L5?\`U?SZ.(.6KN]"O&H(/^KTZ2S?*ZM4D?Z`^Z.#;C&;8(_V
M!_O)]/=4YNL756KQ_P!7KTN'+%]&-&A<?/\`V.NO]FOK?^?!]T_^>S;/_P!D
MGNW];+'U_P!7[>O?U;OOX%_;_L=>_P!FOK?^?!]T_P#GLVS_`/9)[]_6RQ]?
M]7[>O?U;OOX%_;_L=>_V:^M_Y\'W3_Y[-L__`&2>_?ULL?7_`%?MZ]_5N^_@
M7]O^QU[_`&:^M_Y\'W3_`.>S;/\`]DGOW];+'U_U?MZ]_5N^_@7]O^QU[_9K
MZW_GP?=/_GLVS_\`9)[]_6RQ]?\`5^WKW]6[[^!?V_['78^6-</KT)W1;_M6
M;8_^R/\`I[37'.%C&M%^+_5\^MGEB^"ZM"_M_P!CHOWR7^0F7WKUYCMO8[H[
MMZ"MK]][,%.U12;7CO*F71O'8[C^O%K>VK/<QO#T4FA/2-]GN(JB0"@],_Y.
ME<V:[3+&_P`?.SR>`2M-MI5-@!<#^\?%[>_3;`S2R-IXG_5Y=$[@!V"M5>N/
M\9[2_P"\>^T/^I&VO_LC]M_U?;^$_P"K\NJT/\77OXSVE_WCWVA_U(VU_P#9
M'[]_5]OX3_J_+KU#_%U[^,]I?]X]]H?]2-M?_9'[]_5]OX3_`*ORZ]0_Q=<_
MXYVII"_[+[VCI#B0+]MMG3Y!'X@]O[Q6U>/TW^MO>X]BDMW,JJ?]7Y=*XW4*
MH+9IUP&9[1U*_P#LO?:!=.$8TNV24!1HRJZMPG2K(Y!`X(/-_;DNURW0T,II
M_J^75_$3^(=9!F^TU_3\?.SUM&\0`I-KJ%22/Q2*H&X!IU1BUQ8@?3VR-@G4
M!54Z1_J].D<F78@XZ[_CO:FG3_LOO9^GTFPI=KC]">-;$;@N+1\<?4?7WO\`
M<5S_``G_`%?EU3/7'^.=JA]8^/O:(<&`AQ3;8UC[8WIPK_WAU!8C]`./ZCW8
M;+(,%37_`%?+K8'7#^-=IW)_V7SM&[,S$^#;/+,2S'_CXOJ6-_?OW,_\)_U?
MEUZGSZ]_&>TO^\?.T/\`J1MK_P"R/W4[`S9TG_5^77J?/KW\9[2_[Q[[0_ZD
M;:_^R/W[^K[?PG_5^77J'^+KW\9[2_[Q[[0_ZD;:_P#LC]^_J^W\)_U?EUZA
M_BZ!*IR/:B_(^EJX^A>R6F'1KQBE8[8!"?W]4%BG\6DLP'^)]^_J^?,?ZOV=
M>Z&]\MVDC%?]E^[.>Q_4L6V64D\FS#<$=Q<_ZD>_?U?;^$_ZORZ]0^O7'^,]
MI?\`>/?:'_4C;7_V1^_?U?;^$_ZORZ]0_P`77?\`&>TO^\?.T?\`SGVU_P#9
M%[U_5YOX/]7[.E2.H106SU[^-=I'5?X^=H'4(@UZ;;+`^!_)#P=PD7BDY']#
M[]_5YOX/]7[.K^(G\0ZY'-=I,TCGX^=H>24JTD@IML)(Q5653K7<(865B."/
MK[6Q[*Z(JZ3C_5Z=))#5V(..N#9;L][ZOCSV<UUD6YIML$A9F5Y@K?WBNOE=
M06M;41S[O^Z'_A/^K\NJ9]>LCYSM20*)/CYV?($_2'I=KO;]KP`>O<!N%B](
M!N!^.>??OW0_\)_U?EU[/KUQ&9[2"J@^/G:.A7655\&V2%D10BR+?<5U8(`+
MC\#W[]T/_"?]7Y=>SZ]<3F>T;,O^R]]GV:0RL/MML7>0WN[G^\-W8:C8F^F_
M%O;#[=+4II-!_J].M@'UZ]_&>T_^\?.T/^I&VO\`[(O;+;$\F=)_U?EUZGSZ
M]_&>TO\`O'OM#_J1MK_[(_=?ZO,,:#_J_+KU/Z77OXSVE_WCWVA_U(VU_P#9
M'[]_5]OX3_J_+KU#_%US&<[3`7_G'SM$6EB/%/MD\*&N>=Q?2_OW]76/X3_J
M_+KWY]`;T97]I1X7?VGH#M!I9>V-[%T9=J+XKICA]#F)--_]<^_?U>8\!_J_
M9UO\^AQ;+=I(Q3_9?NT)+']?BVP][\_J7<$8-K_T'OW]7F_A/^K\NM4^?7'^
M,]I?]X]]H?\`4C;7_P!D?OW]7V_A/^K\NO4/\77?\9[2_P"\?.T?_.?;7_V1
M>]?U>;^#_5^SI4CJ$4%\]>7,=HHX=?CWV>K@ZM0I=L7O;3<C^\-B2O!)^H]^
M_J\W\'^K]G5_$3^(==?Q?M`@J?CUV>RLN@H]-MEXRH-P#&^XF0@'_#\#^@]K
M8]E=$5=)Q_J].DDAJY(..LASG:AD:4_'WM$RN_D:0T^V&<N+V?4VX20RZC8B
MQ%^/=_W0_P#"?]7Y=4SZ]<#F.T6C6$_'KL\Q))Y43[;;&E90ND2<;BN74?0D
MW'X]^_<[_P`)_P!7Y=>SZ]>;+]H.Z2-\>^T-<;.ZLM/ME&#RKHD<LFXE+M(G
MI8FY(X/!/OW[H?T/^K\NMU/KUYLQVBRA#\>NS2@B\"K]IM8!83IO&MMP`JIT
M#Z<\>VFV1R2='^K]G7NO?QGM/_O'SM'_`*D;:/\`O>XK^Z_N-_X/]7[.M4^?
M77\9[2_[Q\[0_P"I&VO_`+(_;+<OL6)TG_5^76Z?/KW\9[2_[Q[[0_ZD;:_^
MR/W7^K[?PG_5^77J'^+IVVUE.R9=RX1:GHWLO&TXR"-4U]9'@TI*%./W)$AR
M\QD11SP3[4[?M8ANBI7(Z]GHVW;,IEZ8[0=BVH]:[Y+:E1&!_NSE;JRHSJK+
M:QL3[%Q7PUI\O\G6Z=?!8]VZUU__T=JK^23_`-NC/Y<_^/Q*Z<!_]!>D]^TJ
MZD.*CJDO88RN"3_F/^7HS.YP%W+G"``?XE4_@?\`'0?X>X!YB9OW]+#7]+5P
M\NIRY?C0;#;RA1XFCCY],OD<?\B7_BGLIEAE$CB-R$K@=*TDC**7`+TR3U[R
M/_O@O_%/;?A7'^_3U;7!_`O7O(_]1_ME_P"*>]ZG7!8U'6]*'(44Z]Y'_K_O
M"_\`%/>];?Q=>T+_``CKWD?^O^\+_P`4]^UM_%U[0O\`".O>1_Z_[PO_`!3W
M[6W\77M"_P`(Z[+'CZ<_7@<_[Q_C[]:_JM<^)W:>%?+IL`,64Y`Z"?M]5:@V
M,65"5[2V$%.E;@29)2]C;^T?K[..2+JY._)`9V\'5\-<<>@WOBJD<A04-.CP
M[Z["V;UOB3N#?6Z,1M3;XK8<:<MF*ZEH***LJ_*:>%Y92-+GPMI!///O(18P
M34J#7J,8HVG=EC4LP]./0/#YC_%^0`#O?K4<<,NZL<`;<7Y>_/MSZ<#.A2.G
M9]@W5QJBBG`^2M_FZ[_V<CXOKZ3WIUHQ'%SNK&W/_63W[Z8'.D#IR+8-T$:!
MH)RU..EO\W7O]G*^+W_/\^M/_0JQO_7SWKZ7Y#IS]P[E_P`H\_\`O+?YNO?[
M.5\7O^?Y]9_^A5C?^OGO9M:BA`IU[]Q;G_OB?_>6_P`W7O\`9ROB]_S_`#ZS
M_P#0JQO_`%\]U%HJ\%7K?[BW/_?$_P#O+?YNN_\`9R_B_P#\_P`^M/\`T*L;
M_P!?/=_`;Y=:_<&Y?\H\_P#O+?YNO?[.7\7_`/G^?6G_`*%6._Z^>_>`WJ.M
M?N#<O^4>?_>6_P`W77^SE?%__G^?6G_H58W_`*^>]?35R0.M_N'<O^4>?_>6
M_P`W7O\`9ROB]_S_`#ZT_P#0JQO_`%\]Z^E^0Z]^X=R_Y1Y_]Y;_`#=>_P!G
M*^+W_/\`/K3_`-"K&_\`7SW[Z7Y#KW[AW+_E'G_WEO\`-U[_`&<KXO?\_P`^
MM/\`T*L;_P!?/?OI?D.O?N'<O^4>?_>6_P`W7O\`9ROB]_S_`#ZT_P#0JQO_
M`%\]^^E^0Z]^X=R_Y1Y_]Y;_`#=`B_RT^-I^2,69_P!.'79QHZ/;'B9=RX]H
MS7KOT530JVLW/VQY_P`/=Q;8(TK4].CEO=&B\7P90-5*4-?MI3AT-W^SD?%]
M/2>].M21^6W3C@W//(,EQ]?=3;9^$=-?N#<O^4>?_>6_S=>_V<KXO?\`/\^M
M/_0JQO\`U\]Z^E^0Z]^X=R_Y1Y_]Y;_-U[_9ROB]_P`_SZS_`/0JQO\`U\][
M^E^0Z]^XMS_WQ/\`[RW^;KW^SE?%[_G^?6?_`*%6-_Z^>_?2_(=;_<6Y_P"^
M)_\`>6_S==_[.7\7_P#G^?6G_H58W_KY[W].?EUK]P[E_P`H\_\`O+?YNO?[
M.7\7_P#G^?6G_H58W_KY[]].?EUK]P;E_P`H\_\`O+?YNO?[.7\7_P#G^?6G
M_H58W_KY[]].?EU[]P;E_P`H\_\`O+?YNO?[.7\7_P#G^?6G_H58W_KY[]].
M?EU[]P;E_P`H\_\`O+?YNNO]G*^+W_/\^L__`$*L;_U\]T-H":E5KUO]P[E_
MRCS_`.\M_FZ]_LY7Q?\`^?Y]:?\`H58W_KY[L+:G`#KW[AW+_E'G_P!Y;_-U
M[_9ROB__`,_SZT_]"K&_]?/?OIJ^0Z]^X=R_Y1Y_]Y;_`#=>_P!G*^+W_/\`
M/K3_`-"K&_\`7SWKZ7Y#KW[AW+_E'G_WEO\`-UQ/S'^+KE?^,Z];`I)&Q5=T
M8_U:KA=5GY!_'NPMN.%Z]^X-RJ/T)_\`>6_S=`=T=\M/C3B<;O\`&0[NZWAE
MK>U]ZU],/[U4)\U)(N.TO?6/2BBW^'O9ME)[57IV7EO<X65/"F-0#A2>/EP\
MNAU7YB?%S3<=\];M>YN=U8W\DG\O?VT8@#30G2%N7]UU$^%<4_TK?YNN_P#9
MQ?B]_P`_VZU_]"K&_P#7SW[PA_"O[>M_N+<QQBG_`-Y;_-UQ;YC_`!=N?^,Z
M]:_^A3C?^C_=A;U`[5ZN-AW5LK'/0_T6_P`W7'_9Q_B[_P`_VZU_]"G&_P#1
M_O?T_P#07KW]7]V_WW<?[RW^;KK_`&<OXP`V'>76IM_V=&/Y_P!L_NPML>7[
M>GEY>W/2";><G_2M_FZ+CE_YF?16*^2&`Z3DW1MZOVSNO;N.KL%V'A<O#68F
MGW)65<M+)@LL5)A4!`K*UQ8MS[\(!6AI7I='R[?-`9O`8$$U!!!QZ"G5D%#,
M:RF@JTD1HIT\D;)+'*DD9)\<J/'=&25`&!'%C[;<*I*E<CH+7-M<Q7<HU$(#
MP],?9TX@#^@O[8ZL"<5.>N8`_H/]M[]7JXX=>L/Z#_;>_5/KUOKVE?Z#_;#W
M4@')'7NO:5_H/]L/>M*^G7NN!BC8AB@)4W!_H?Z_T]Z$:!M04:O7KU3T'7<:
MJO4':H4`#_1OOG@``<[8RA^@_P!?W<YX]>Z^"A[]U[K_TMJK^23_`-NC/Y<W
M_BI73G_O+TGNR\#U2?\`T+[1_@'0\]GP[@GK-ZTVU,CC\1N&J3(QX"KRU%+E
M<;19=KBGK\I0Q215U1CTE(+1P2QW4<>\?^8-/[_N"W'4*=33L9N!LU@(QJCT
M$M7`IY4^?6N%V+\S_P"97T[UU\R-Y[E[*^/F]9/CMW#U_P!%;=Q>R>G-VMN3
M.;NWU5;:KL9N''X:MS$D&3H(\5FG1<9YUEK2O,\?T]GT>UV=P]NL4C5=LE@`
M`OK7UX]$\UXZ&96-"*C'KTJ_BC_,R^3W8G;/672?;U)MJEW)D_DDO66YJC,]
M4;GZAWC5;*SG5]?O'!5F6ZQS&1S&3VN\.<@$-+615U9'D8`&:-0+^_7VTVUO
M<M%;N7C]33_)TVE^QB#.Q5A^?^'K84!#`$+(O`!64%9`P%GU*0"/4#;_``]@
MZZ3P[B9/1B.A;:-KMH'!XJ#UW[8Z4=>]^Z]U[W[KW7(_1?\`??T]VL?BO.FE
M^-_MZ"KMW_BW[(_\2GL#_P!V(]F/(_\`RL:_Z;_+T'-^_LI/L_R=!3_.PCC/
MPCR@*)<]F;&>^E;WU9>YO];\^\D(:Y/H.@MR19BYWV*-AVFI_P`'6G<:>`$`
M1(`%6P"C_4CV_P!96W.S6=K8HY05TCR^777V\7_'-/\`DGW[I#!;V1BC(C7A
M\NO?;Q?\<T_Y)_XU[]7IWZ:S_P!]KU[[>+_CFG_)/_&O?J]>^FL_]]KU[[>+
M_CFG_)/_`!KWZO7OIK/_`'VO7OMXO^.:?\D_\:]^KU[Z:S_WVO7OMXO^.:?\
MD_\`&O?J]>^FL_\`?:]>^WB_XYI_R3_QKWZO7OIK/_?:]>^WB_XYI_R3_P`:
M]^KU[Z:S_P!]KU[[>+_CFG_)/_&O?J]>^FL_]]KU[[>+_CFG_)/_`!KWZO7O
MIK/_`'VO7OMXO^.:?\D_\:]^KU[Z:S_WVO2=2-%W:ED0:,(%4V_2LN6_<4?D
M!R.??NO?36?^^EZ40AC;DQH22>2/\3[]U[Z:S_WVO7OMXO\`CFG_`"3_`,:]
M^KU[Z:S_`-]KU[[>+_CFG_)/_&O?J]>^FL_]]KU[[>+_`(YI_P`D_P#&O?J]
M>^FL_P#?:]>^WB_XYI_R3_QKWZO7OIK/_?:]>^WB_P".:?\`)/\`QKWZO7OI
MK/\`WVO7OMXO^.:?\D_\:]^KU[Z:S_WVO7OMXO\`CFG_`"3_`,:]^KU[Z:S_
M`-]KU[[>+_CFG_)/_&O?J]>^FL_]]KU[[>+_`(YI_P`D_P#&O?J]>^FL_P#?
M:]>^WB_XYI_R3_QKWZO7OIK/_?:]>^WB_P".:?\`)/\`QKWZO7OIK/\`WVO7
M)8T5HBJ(&\A%PHN1'S&#QSI)-O?NO?36?^^UZ3FVD1J:O9D0LF9S3*=(N&FC
MC,I'`YDTB_\`6WOW6OIK/_?:]/Z0Q!$_:3E%)X'U*@D_3ZD^T,N9&Z5?NRR:
M$.8Q4]!3W=ORMZOZSW%O;!X>CR^:PL$9H,94EGBK99*J$3QRPBVJ1L>9/`/S
M,![;-:&@J>@U?0VD1(5`2.@_V1\AL'N3KG=W9.4P[)@MN[IDVWC8L5)3#*5%
M--C,37&;(G+9+'T9K*&HK)(7LPTLA!Y'M=":QC'#I`FXV,8,9C%5Q_JSTV=G
M_(R';.V=@[FVK@\?,F]<I401TVY_N72FQV-62:LJ)6VG4Y)&F\,1.J.5X`+:
MC>X%U8,`1P/7EW;;W`94%#\O]GI-9;Y*YW*YSL'!]7[2QF\*C:U'M&3$S15@
MR$M?4Y60KNRI@QM#44!R&%Q%-*##>2.194(,I8$>]2$JK%5J0.F)-_M%,D21
MJ67R_P!1Z&3JCLW<V]I:N7*;9Q^/P-)CL%D]N[PQ3UU/2;HJ*UTBJ_M\563U
M-7CYL7-&4=6E8B6-F#$$'W8<,]'5M:6]^`PC7K:R_E2_S(<]ELCM_P"+W<SY
M;-5TE2V.ZTWE%'-D)FHH&9HL%N.15>19XP?VYF.D1Z1?CVF=P7</U%O/?*"6
MLDM]:1@5XC@.&3PXUZV/D8,PLVKD\VL."0?]M[:IVUZ@S4/'*CUZD`W'MOI6
M>N_?NO=>]^Z]U[W[KW7O?NO=!OW)_P`RA[5_\1OOG_WF,I[]U[KX)_OW7NO_
MT]JK^23_`-NC/Y<W_BI73G_O+TGNR\#U2?\`T+[1_@'1FMT<;GSCCAOXC4C5
M^;:_I_K>\?.8O^5BE_TW4Z[!_P`J[;?Z3HG/9'P\^//:VT.WNO\`>6R8:[:O
M?.XJ'<W9]/'E<MB:S-[HQ/VHH,LE51R1O#44HH8A!+$R&,1BQX]LF_O89F\*
MY9:'&>'37T5HZJ\ENI)%3CC7I&=._P`OCXE]%5FWLAUMU4,;GMJ;S;?^(W)E
MMS[BW1NB7=W\&?;J560S67JJROF^QPDC4T!,FA(B0H'NC;E?,03=.2/GUL;;
M9E3KMHZ$<*8!Z.T!8`>K_D,NS#_`F3]PV^ESS[1N[2.SN:N3D]+HT2-$CC`"
M`4`'7?NO5^O>_=>Z][]U[KD?HO\`OOZ>[6/Q7G32_&_V]!5V[_Q;]D?^)3V!
M_P"[$>S'D?\`Y6-?]-_EZ#F_?V4GV?Y.DU_-VZ\WYVA\1:S:O7.T\SO'<;=@
M[2R(P^#IONJN2BH&R`J7,7U*#[@<^\B0S*"`>/06Y*W!+#>TN9&`1<&OSZU9
M8_A!\MPJJ?C[V=(0`+OB5#G_`%P"0+?\1[\7D'XCUE%)S_R]]"D=RD3G2.)!
M_P"?NN?^R0_+;_O'OLP?^0D>]>)+_$>@X>==B)K&D:IY`4Q_/KW^R0_+;_O'
MOLS_`,](]^\27^(]>_KILOI'^T?Y^O?[)#\MO^\>^S/_`#TCW[Q)?XCU[^NF
MR^D?[1_GZ]_LD/RV_P"\>^S/_/2/?O$E_B/7OZZ;+Z1_M'^?KW^R0_+;_O'O
MLS_STCW[Q)?XCU[^NFR^D?[1_GZ]_LD/RV_[Q[[,_P#/2/?O$E_B/7OZZ;+Z
M1_M'^?KW^R0_+;_O'OLS_P`](]^\27^(]>_KILOI'^T?Y^O?[)#\MO\`O'OL
MS_STCW[Q)?XCU[^NFR^D?[1_GZ]_LD/RV_[Q[[,_\](]^\27^(]>_KILOI'^
MT?Y^O?[)#\MO^\>^S/\`STCW[Q)?XCU[^NFR^D?[1_GZ]_LD/RV_[Q[[,_\`
M/2/?O$E_B/7OZZ;+Z1_M'^?I)R?#+Y4#?(Q"]"]BIE/[DU&7CISAP9&IQG4Q
M\<C?UT3DD'^OOVN3^(];_KILO$!/Y?\`072N;X0?+4&W^R^]EM:URN)&DFPN
M1_L??M<O\1ZU_739?2/]H_S]<?\`9(?EM_WCWV9_YZ1[]XDO\1Z]_739?2/]
MH_S]>_V2'Y;?]X]]F?\`GI'OWB2_Q'KW]=-E](_VC_/U[_9(?EM_WCWV9_YZ
M1[]XDO\`$>O?UTV7TC_:/\_7O]DA^6W_`'CWV9_YZ1[]XDO\1Z]_739?2/\`
M:/\`/U[_`&2'Y;?]X]]F?^>D>_>)+_$>O?UTV7TC_:/\_7O]DA^6W_>/?9G_
M`)Z1[]XDO\1Z]_739?2/]H_S]>_V2'Y;?]X]]F?^>D>_>)+_`!'KW]=-E](_
MVC_/U[_9(?EM_P!X]]F?^>D>_>)+_$>O?UTV7TC_`&C_`#]>_P!DA^6W_>/?
M9G_GI'OWB2_Q'KW]=-E](_VC_/U[_9(?EM_WCWV9_P">D>_>)+_$>O?UTV7T
MC_:/\_7O]DA^6W_>/?9G_GI'OWB2_P`1Z]_739?2/]H_S]<E^$7RW5T3_9?N
MQM,PD"L^&!,+A;EK_@D>_:Y?XCU[^NFR_P!#^7^?I';.^&/RFR=+FY,?T7V+
M+%2;@S6/JM.(!\%9%]F"M_PVEC_M_?M<O\1ZV><]F!H0E?\`5\^EBWPB^6I9
MK?'OLH`$J`F(`2RDJ-(_I8>Z'422:UZO_7K:M.C6FCTJ/\_3%N3^7U\H=W8>
M;`YGX\=GU%'4U%#6,$Q*!DDQ=0M50BYXO35*:TO]#];^_4/25^;>7I#62*(G
MYT_Z"Z2^T/Y:'?VQ<7G,+@?B]V)%A-U;EJMQ;BH\QA*7+TU5DJTJ]9/2XZHC
MDA@%94+Y'L`"Y)]V#.HT@FG2;^L'*;5)LH#^0_Z"ZP[T_EH_(#?F)H,1N#XU
M=FT%/@:ZIJ,,=MXQ\)+0BKC,%33M3T*1TR4]93-ID2,:2K&_-_?@T@P"0.JC
M?^40`!8VX'Y?]!=)K(?RE>V:JJRM?%\6^T<#5Y7"4&(JZ[:5'D<;6O!CYO/2
MQ4,]/5P^/*&<>2232$)8W'OQ:4J0'8'IL[QR>2SKM]N)#Y@"O_'NGK'_`!7[
MEZ^W1L'HF#JG=.W-U92FI(-K;-RF.DDS64@<K!*R)^[I@13Y:BK=K:RWO>N3
M^(]&</.&Q6RU@2-%'I3_`#];<W\NK^79LWXF;0I=X;GHJ+<?=>YJ*-LUFZ@+
MD(]KQ2.['!8&HE!:GIJ<$"0@7,@:QM[T2P8U/=U!7.'--_O&[[D(K^4[6SC0
MA-%``'`>E:GJTQ0A]2@?GD?X&Q_WD>]5/"O0'T+JU:1JZY^]=6Z][]U[KWOW
M7NO>_=>Z][]U[H-^Y/\`F4/:O_B-]\_^\QE/?NO=?!/]^Z]U_]3:H_DE\?RB
MOY=%O^\2NF__`'EZ3W9//\^J3_Z']O\`D'0U;ZW[M;%[MSE#7U=<E:F4JHBD
M&'SDT?D#V]4L&/DAD%_RK%3_`%]X^<PD?UAEKQU?Y>ITV$-_5Z"A&G1^?#I.
M+V/M:1)@,G5:8E$58),!N%B#'_9COC/HOXM[+9_[:7[>E,5/#C]:=8U[*V6^
MJ1,G6D31+$S';^XPSQ+^E&(QP-E_V_MJO3FD$4ICKI^R=G!HP,I5C@<?P#<9
M)_I]<:3_`+W[]UX``4'#K(>R=F@D?Q*K_P#0?W'_`/6T>_=;ZZ7LG9Q$A.3J
MN/I?;^XA;_UF?X>_=>ZXKV5LXJ/]R56?\?[O;B_^MOOW7NNY.RMG`QVR=6+@
M7']W]Q?_`%MX]VL?BN^F4^-_MZ#+MCL;9S4FS`:VO8#L[8!!&"W"%!_B*^JW
M\,X'LQY'_P"5D7_3?Y>@[OW]D_\`J\NK#U[+V4QJ&7)5FJG9DGU8'<6H$?41
MVQEB./Q[R(:H8]1.P:)W8=8%[2V.4#QY*O%Q?4<#N+4?]>^,]^K7!)(Z9=[B
M840D=<G[3V/"T"39*O9ZGF-A@-R,+$V&LC&$+[UJXT)IU97G151OB'6<=F;)
M3R*V1K"4-F/\"W&1_P`@G^&&_OVH_P`1ZMXLO6.+L[9,JRO'DJPK"2)=>!W&
M&%A?T7QGOVH^IZWXLW6,]I;%_8)R5?\`NB\>G!;DL1>W[G^XSZW]^U?TCUKQ
M9>LTG9VR4=5;(UNK_:<#N.Q_]9GOVK^D>O>-+UV.SMD>O_<A6^GZ_P"X'<?'
M^M_N+]^U'^(]>\6;K@.T-C6_XN-=_P">+<G_`-;/>M1]3U[QI>N_])^QO^=C
M7?\`GBW'_P#6SW[4W\1Z]XTO^K_BNO-V?L<%/]R-=S]+8'<G/_K,][U?TCU[
MQI>N0[.V1Z_]R%;Z?K?`[CX_UO\`<7[]J_I'KWBR]<8^S]D%6(R-:0/K?`[C
M_P!X_P!QA]^U'U/7O%E].@)D[/V9_LSE$!DZO2W14Q`."W&;WWX/K_N-X-Q[
M]JSQZWXTP!4?">AX/9FRONA#_$JWS&,R`?P/<?AT`W)/^XS3KM[]J^9ZUXLO
MRZQP=G;)F25H<G6E8F82^7!;CU<7N$OC`>/?M7](];\6;KBO:.QGA,BY.NTE
M[`G`[CU7O]/^+9]/?M7S/6O&F].N9[/V/Y%'\1K?];^`[CM_A_R[/?M1]3U[
MQINN3=G;'#$'(UM_\,%N.W_NL]^U'U/7O&EZZ_TG[&_YV-=_YXMQ_P#UL]ZU
M-_$>O>-+_J_XKKW^D_8W_.QKO_/%N/\`^MGOVIOXCU[QI?\`5_Q77O\`2?L;
M_G8UW_GBW'_];/?M3?Q'KWC2_P"K_BNO?Z3]C?\`.QKO_/%N/_ZV>_:F_B/7
MO&E_U?\`%=>_TG[&_P"=C7?^>+<?_P!;/?M3?Q'KWC2_ZO\`BNO?Z3]C?\[&
MN_\`/%N/_P"MGOVIOXCU[QI?]7_%==)VAL<L1_$:XG^AP.Y+6_\`/8?>]1]3
MU[QI>N?^D[9)D*?Q*M!N@M_`=QZ1J#<?\6SC5;GW[5\SU[Q9:\.B]]`=F[*.
M"[*G;)US0'N#>D;L,%N3SEU;%K&@7^&DF)5/%O>@?GU8W%PQ#,:D=&%;LW94
M8@+Y&K(G53$?X%N(L5(%C);&<'GWO5\^J^++Z#KB.S-D^::G;)5ID0^M?X'N
M,Q@V##01C+6L?]O[]JIYGKWBR^F>O-V=LD$H^1K;C@@8+<=K6^@_W&7^GO6H
M^O7A++Z"O7'_`$E;%2---?6JJ`A+8/<MU%R3_P`NVYN?Z^]ZC_$>O>++UTO9
M^QK7&1KKG\_P+<?]?\<8??M1]3U[Q9?/H+CC^C*KMF7N&;'RU?8=/MBFVO39
MVLV]GY9<=M]JEY'3%R/BV-+)*['R%+,1[T#3-<]6%Q.$*`]OIT*4?9VQX5$2
MY&L18R0%CV_N'0-)(!'^XSDD?7^I]Z.37K8+-EN/7,=I;)`L,GD`/Z?W?W#^
M>?\`G6?U]^Z]UVG:FR2Y'\4R!/\`3^[^XK?0?]6RWU]^Z]UR;M/908C^)UXM
M_3;^X;?^ZP>_=>Z[;M+9(0-_$Z\#^O\``-PW^MO^=6/S[]U[K'_I4V19/]RF
M0YO8_P!W]Q<V/YMC/?NO=9(.R]HUM7]C1Y.N:KG95C#8+.Q1H6`MJDJ<9'`/
MK_6WOW7NHW;@D'3?:/ED,K_Z-M\DR%50M?;.5(.A`%7TD>_=>Z^"K[]U[K__
MU=JC^2;_`-NB_P"7+_C\2NF[_P#H*T?_`!7W>+@W26Z9@T0!Z--NX6W%E+%A
M:NFM9FX]7XYX]X]\Q'_D1./+5_EZG38"?ZO1&N?#_P`G2=\D@N!(X%_IK/-_
MZ\\^RV>0":4:?/I9!!,\,3^(<CKWEE'`D<#_`(,?^*^V?$7^'IWZ:?\`WX?]
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M;%F_Q].2`Y'NXQ^%>K+L&ZR4:-9J?Z4_YNO?[,%TBOI';O7)`_)WMMN__NTX
M]O"V9@&[<_/I4O+VZ`"L,I/^E/\`FZ]_LP?27_/W.N?_`$-MMG_Y*>]_2M\O
MV];_`*O;G_OB7_>3_FZ]_LP?27_/W.N/_0VVW_\`73W[Z5OZ/[>O?U>W/_?$
MO^\G_-U[_9@^DO\`G[G7'_H;;;_^NG'OWTK?+]O7OZO;G_OB7_>3_FZ]_LP?
M27_/W.N?_0VVW_\`73W[Z5OE^WKW]7MS_P!\2_[R?\W7?^S!])?\_<ZX_P#0
MVVU_]=/?OI6^7[>O?U>W/_?$O^\G_-UU_LP?27_/W.N?_0VVW_\`73W[Z5OZ
M/[>O?U>W/_?$O^\G_-UW_LP?27_/W.N/_0VVW_\`73W[Z5OZ/[>O?U>W/_?$
MO^\G_-UU_LP?27_/W.N?_0VVW_\`73W[Z5OE^WKW]7MS_P!\2_[R?\W7?^S!
M])?\_<ZX_P#0VVU_]=/?OI6^7[>O?U>W/_?$O^\G_-UX?(#I'Z_Z7^N^>;?W
MVVT0/]:^4]^^F?A1?V],GEW==1/AS4_TI_S=`3)W?U`?DW!7KVUU_P#8_P"@
MF2E24[VVWX#6+OY:EX]0REO-]K]1];>]+"<@J*]7_JYNF@2E9-(-*4-?MI3A
MT.D??_2`0#_3#UX]K^IM[[:+&Y)Y/\4'T][-L_\`"O[>J?N'<_X)/V'_`#=<
M_P#9@>D/^?O==?\`H;;9_P#KI[U],_HO[>O?N#<_X)/V'_-U[_9@.D`+_P"E
M[KD_FW]]]M#_`!_YVGOWTS\*+^WKPV+<M5#')^P_YNBT;^_F#=']?=\]==/Y
M?=NWJK%=E[;KZ_#[TQ.?H<MB:#<U'F(L=2[?R@QLU1]L:^GD,B,3S;W[Z>F#
M2O1A!RY?R122>"]4\B#G[,9Z/A15"U5%35,<HE2HA29)8V+1R)*-:O&Q-S&P
M8$?X>V'70[+3AT234@FDB92-)ID?X>I:W'U)/^Q_XW[H<\!U34K_``]<QR/=
M>M4ICKOW[KW7O?NO=>]^Z]U[W[KW7K?Z_P#MS[]U[K`"3/:YMH8VOQ=74#C_
M`%C[]U[HOOQ[)_A?97)X[EWV@Y)LH.-('U_K[]U[HQ`^G^Q/^]GW[KW7?OW7
MNO>_=>Z][]U[KWOW7NNK#_>OR?Q]/?NO=>``X'^/^\FY_P!Y]^Z]UW[]U[KU
MO]?_`&Y]^Z]U[W[KW7O?NO=>M_K_`.W/OW7NO>_=>Z#?N,6Z@[4`_P"?;[Y_
M]YC*>_=>Z^"?[]U[K__6VJ/Y)W_;HS^7+_XJ5TW_`.\K1>[Q<&_U>9Z1W?Q1
M=#GW9NF/96/[&WI/3UU5!M+";CW)+C<;"*G+UL6WJ"LR4B8C'R/.F1JZA:-E
MBBTKYY/1Q;WC]S`!_6&4TK1J_P`^IJV1Y#R_&H8CLH/S''\O+\O7JG'XX_SB
M^L>TNO.S.S>W]B5G1^T-@4VU:[&YJJWQM;?,&Y7WEEJO;^(VS74&%FH<WMG?
ME)F*)@^'JH(9)$8AI3I]F3;&LRK<(*Z_+\JG'^7SZW#N,T,:0_4$@*1D#!\J
M?;GCPZ&VJ_FS?#%<?M+(T6\=WYRBW=M>KW:M5M_9.8R/]SL%AMSR;4SVX-^-
M2?<TNW\;MG<2M!6I+(P,:WU$"_MI=B&:I4=/3;I(55HYZ-PIC.*?M\Q\^INX
MOYH_QD1>\\7L+,9;>NX.A\+797=E72XW[?;,E1C_`.&PUE!1[@D-524=52ME
M(Y'-53"G*D!&<\^RR79RLD@IP/3O[V9@@UTX5H?V]"9TK\\OCYW]VGGNFNO,
M_E\OO[;--*^X(UQ;T^VH<KCJ&FJ,CA<7GP\E.U502U*B66ICIZ9^=!DX]U_=
M!J*CCU5]X=4:CY'`^M?4>5#T<^$NT4;2,K2,H+LFG26(N=)2.)"!]+A0#]0+
M>T$L?@R/%_":=&%M*9X(IC6K+7/63W3I_KD?HO\`OOZ>[6/Q7G32_&_V]!5V
M[_Q;]D?^)3Z__P#=B/9CR/\`\K&O^F_R]!S?O[*3[/\`)TW_`,W!RGP9[=",
M5+#!J2I(;3)DHTD`(-UU*;&WX]Y$4[6/V=!7E"U%UN\,9&"#_DZTJE%E4`L`
M%4`:F^@4`#Z_T]TZREM=FL[:T5GC%=/7?/\`M7_)1_XK[7Q_`N?+JHM;$BOA
M#KWJ_P!J_P"2C_T=[OCUZW])9?[Z'7O5_M7_`"4?^CO?L>O7OI++_?0Z]ZO]
MJ_Y*/_1WOV/7KWTEE_OH=>]7^U?\E'_H[W['KU[Z2R_WT.O>K_:O^2C_`-'>
M_8]>O?267^^AU[U?[5_R4?\`H[W['KU[Z2R_WT.O>K_:O^2C_P!'>_8]>O?2
M67^^AU[U?[5_R4?^CO?L>O7OI++_`'T.O>K_`&K_`)*/_1WOV/7KWTEE_OH=
M=B_]6_Y*/_%??NE)VNR:%7\,<.@-[I[&FZHP6<WY38L9B7`;;IYEH74N]142
M9^G$E)$`=;15&.9V8?F4#WXF@)'09O8;.(D!!4=0=F]^;?W/LC=78#TU1%M[
M`;IR&%HFH7CJ:ZJA9*&JB^YIJF>CB26E-4T>G7QI]U#`UIY=)8UM'6H1>IN[
M>[*'![$VUOO;^`S.Y:#<^YL)BG#^*CEPM%452T,TU7##45,"F2>0:M,C@V'/
MNU>K>%:_[[7H+MR?)G=&$W)O3;/]RZ"GR<&X&PFP\972Y*FJMS4\52T,^9CK
MIE%!'2+H=0%-KJ??@:UZ+&:S%PX*BH-.GS`_(S>N9DQE5C.HL]/05U=MU(L_
MCZW724Z5ATU5;#4+<E<7.K%6C(Y'O71K`]ICL%.MM;^5E_,QR?WNU_C/W?75
MV4CKY5Q/5^\6-1D:W7&QTX#/26>9C%J]$C$V%A?VDD;5(^KC7J-><^1)"DN^
M6D8$,I+4X"GF1CCCK92060"][B]R;_F_^V]U\_F.H71?#E*]9DX4#W0\3TZW
M$]<O>NM=>]^Z]U[W[KW7O?NO=>]^Z]U''_`C_IV__0Z>_=>Z+]\?/^+7V7_X
MF??G^]XWW[KW1B!]/]B?][/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0;]R?\RA[5_\`$;[Y_P#>8RGO
MW7NO@G^_=>Z__]?:I_DF_P#;HK^7/_A\2>F__>6HO=HO/\^M(B2/WK6@_P`I
MZ'WMO:N.WNF^-GY*6JH*'=6.W!M^OFQ<AI<I!39:EGHIJZ@K(RLD%28JA[$$
M$$W'/O'SF$_\B.4>6KJ6.7F=K."(FL>D8/"G5)^'_DC](+B>R:?>W<7:V_MR
M[PQ^U</AMP[@H]JQU>PL?LK/3;BVM4OC<9CZ*CW?EJ*LG99*K))/4R4#%&8L
M;^SP[V8U6-*(P/EY"E*?9U6XVYFN;DJ#X(/^SC'I_/'47<G\IO,9OMG;=#1]
MQ;IVYTG_`++=F.E^T*[;-%M'$[A[)R6YNP\AN[.8'+[8CQ\>*Q>%W'35`M54
MA23'QG2;L;^V_P!],`09".F3MQ;3IR>(],<?+]GJ>A`W/_)YZ3W1V%V+O>;L
M7?.+3?\`L3.;"3$X&@P./&&V_5T.`@5I<S&L%5N^#&S;?1:2DRL;/%Y&*N;C
MV@?=`9')D.:]+DV]O"C8VZ$U7^?^QGH5^IOY<G5O4OR?/R>QN_=VY3<<^!R6
M`H=M2XG%X3'_`.YJDI*7[C,Y;&T\5;N>DQJ8HF&BKX/#3-,VASQ[J-R-<OGJ
MSVD-`5B&DFE:5K3!'\\=61"02@2`L0P!!:3R'Z6_7I2XXXX%A[)IW\2:1_4U
MZ.K==$$2`4H.N_;73W7(_1?]]_3W:Q^*\Z:7XW^WH*NW?^+?LC_Q*?7_`/[L
M1[,>1_\`E8U_TW^7H.;]_92?9_DZD?S2MK[CW=\,.U,'M?"9/<V=J:C!O18?
M$T-37UE8B9.,O!'34*O42!!RUAP/>1))(H.@5RC=26F]K*\A$8/[!CK3]/QP
M[^+'3TKV:@OQ'_<S</I_J/W,>S\?XDGW2C>G639YTVF.S5)I(V:GJ#_EZ\?C
M?\@?^?+]G?\`H&9__P"MWNP>0``$TZ2ISEL9132+]O\`L]>_V6_Y`_\`/E^S
MO_0,S_\`];O>_$E_B/5OZX['_P`*_;_T-U[_`&6_Y`_\^7[._P#0,S__`-;O
M?O$E_B/7OZX['_PK]O\`T-U[_9;_`)`_\^7[._\`0,S_`/\`6[W[Q)?XCU[^
MN.Q_\*_;_P!#=>_V6_Y`_P#/E^SO_0,S_P#];O?O$E_B/7OZX['_`,*_;_T-
MU[_9;_D#_P`^7[._]`S/_P#UN]^\27^(]>_KCL?_``K]O_0W7O\`9;_D#_SY
M?L[_`-`S/_\`UN]^\27^(]>_KCL?_"OV_P#0W7O]EO\`D#_SY?L[_P!`S/\`
M_P!;O?O$E_B/7OZX['_PK]O_`$-U[_9;_D#_`,^7[._]`S/_`/UN]^\27^(]
M>_KCL?\`PK]O_0W7O]EO^0/_`#Y?L[_T#,__`/6[W[Q)?XCU[^N.Q_\`"OV_
M]#==CXW_`"`_Y\OV=_Z!F?\`_K;[UKE_B/6FYYVBGA^(FCTKC_#T%^]?B9W+
MO;,OM+-=/]F>"JV[05[4=+M7/)6)24.XTJ9:TQMC#Z):B`0D_2QM[]KE_B/2
M1^:N7I>YX8C_`*OMZX;/^"/8^R-M;AVMC?CWV97[=S>ZZW>-9B\KLK-UE%%6
M9602RT5/"^,;5`&`8CZ7]ZUR"M&.3TVO,_+2@@00@5_U?BZ?\Y\,^V<WM:/9
M<O1'9&.V]2U=/61T>%V-GJ.."2FJ5K:>GIXTQJJL4<ZAQ;^U[MXDO\1ZW_6C
MEO\`WQ%_J_VW0:YG^7+V5NG)9O+Y?JGY`5%?E6B>DR$V&W!Y]EQPRF<#;*-C
M2*4U-0S.X`()<_U]^URTPQZ2-O?+DDID\"')^7^?I:T_1W8'77]R.M*GKG>.
M`KJ^F6FV;MK.82KQ>6R\=#418Z;[1&A26OHY9IP\C,B^HGWK7)YL:]',&Z;`
M4!6VBIZ_ZCUM6_RT_P"6IC/C_B<?W%W/0T&:[FRL*U>,QKTZMCM@T%2MXDB@
M.I/X]HMY)1<@&WU]V`(;4WQ5ZA_F_G"_N[J]VVSW&3]SJQ"(#V@#\*CTK6N>
MKLE!$2\:?Z<ZC:YMS^;^ZUJQZBBX)RR_%UF2^D7^ONK<3UZ,L44L<]<O>NK]
M>]^Z]U[W[KW7O?NO=>]^Z]U''_`C_IV__0Z>_=>Z+]\?/^+7V7_XF??G^]XW
MW[KW1B!]/]B?][/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0;]R?\RA[5_\`$;[Y_P#>8RGOW7NO@G^_
M=>Z__]#:H_DG_P#;HC^71_XJ1TW_`.\M1^[Q<3^?5H/[0_ZO,]&'WKF<#'NC
M,4U9G,-33"KJ!)33Y:""8N&Y62-JE'1Q_3CWCWS#_P`K'+_IO\O4J\O#]&$#
M^'I-1[AVVB`#.;?8JBI(QR]*SQZ6U!=9JRPTG_'_``]EMQ%(TTK`X)Z$Y:-"
MRT`H>NUSVV`0Z9_`M9)D#?QFF(9*A0L^J]99S*HL202?Z^VO!E.:]55H%4*J
MJ`!3RX`U_P`/79W!MB-X;YW;P<O%+&3F*74'B`6)FO6>KQA1:]QQ[<6QD(U#
MSZV;B*@0C`Q2GKUTN:VQ$AA7/8`+JD9KYN$NQE8N^J0UID969B;$V'X'NQL9
MB2237JBRVR*JK&`H-0*</Y]94W#MIE)&X,`!%=3_`+F*6WI'Y_RL^VBGADH>
M(QTX6+G6#@]<1N;;3`,,_@+'D?[F*7_ZK]Z_+K5#_%US;<VV8_&IS^W[R"ZW
MS%+<7_ZJ_=K'XKS_`%>732UUOGH*^VLW@):/9D:;AP.J/L[8$IMF:8G2,D#_
M`,K7Y]F/(_\`RLB_Z;_+T'M]_L9/7JPU]T;5<LC;FV]=&.L#,XL%&!N0W^5@
M@@_U]Y$UTDTZB[7X9)X'KR;LVI&FI=U[?91Z?^+WBR+_`(]1K;<_Z_O3,6X]
M-L[25T@=<VWCM6,JK[EPFI_TG^-XP!K_`$*@UPN/];WJOR'6U#A0",]=_P![
M=K,Q3^]."1E&IE.9QFH#ZV/^6DC_`&/OU?LZW1AG2/V==)O#:CKJ7<V$<<W8
M9O&$"WUN16V'OU?D.MT;^$=>.\MJ+I']Y,*VKZ,,WC"#_L?OA?WZOR'7J-_"
M/]7Y==G=VU0XC.ZL"K.-2J<UC`0/\0:VY]^K\AUJC?P_RZ\N\-JD&VY,*VCZ
ML,UC"&_Q%JVWOU?D.MT/H/V?['72[QVJ1?\`O'A?]CFL9_\`5WOU?D.M4;^$
M?LZ[&\-J6_X^;"#_``.;QE__`'-]ZJ>MT;^`=<6WAM52`=T8+U?3_<UB_P#B
M:X7][K\AUZC?PCKE_>[:QU?[^G!>C]7^YG&?T_ZC>/?J_(=:HW\(_9UY=X[6
M8$KN/!L%^I_C>,Y_VU:0/>J],L[@D:1T`<^Z=N?[,_15`W#@PDW1$T2ZLW26
M(;?JD`JM;XB=7YY/^/OU:>?7O&F`T@#1Q_/H>O[T[81EA?<^WUEC!.DYS'ZE
M_P!=6K`QX_J/>Z_/K6N6N5'7EW;M7277=.WV`OS_`!W&D)?Z@G[TCZ_U]^K\
M^O:Y?X1U@;=NTV2.0;EPC*C\,F;QI4L;^H$5VD_7^OO88];6ZH2I&>@:W+U=
MTINKMO;7<FX:G:F5WOM#;-?MG:51D<OC*C^#TV3R$5?6UE%%)4.D-34",*7L
M38<>]ZR2&/$=&UON=S%"88W(C)J?V=#+3[FVG3H(CN7;T;1:U=6S.,8C4Q:S
M%JO4;@_GWIB6))\^BN>Z!D<5\^I']\=II#K&X\$8U;3=<SB]-R?P36:?K_C[
MKPZ8+!_LZY#=NV"`1N7"`'Z#^+XK@?\`G;[T>G5%%`Z[&\-K$Z?[T[?##@@Y
MC%:O]M]Z>??NK==_WNVO_P`]7M[_`,_&*_\`JOW[KW79WCM9%N=QX)O]J&9Q
M0#?ZUZP#W[KW7`;OVP_J7<N$`/T'\7Q7'^VK??NO==_WSVJI5#N+!ECQ?^,8
MKD_^=M_?NO==?WLVL)&ONC;RN`HL<SBPP#<D?\#+\VO[]U[H`>@-V[73"=DR
M'<6`*KW'O=3(N8Q05R[8OUZOO2MS?^OOW7NA\&\=KDA3N3!J;*5MF<5Z]0!N
M/\LN3?\`WGW[KW67^]VUR_C_`+T;?$HY:,YC%:QQ>S)]X6''OW7NNO[X;6(+
M#=.W@!>X.9Q1M8F][5EA]/Z^_=>ZXG>.UE59!N7".LG*L,QBBMOI92:P"P(_
M'OW7NNUWGM9G$0W%@]94L/\`<SB?H/\``5I/T_P]^Z]UV=W[7//]Z=OI_M)S
M&*N+<<_Y7[]U[KQW?M91<[KV[;_',8H?[S]X/?NO==#>FU;?\?'@V_VI<SBK
M'_6M6^_=>Z\-Z;49BHW#@[C^N9Q7^V_X&WO[]U[KD=W;7O\`\?3M]/\`:3F,
M5<?Z_P#E?OW7NNCN_:RBYW5MZW^.8Q0_WG[P>_=>ZX_WRVN`#_>3!,&/!7,8
MFW].":VWU]^Z]UU2[JP$]:*2+<N#J9IO\Q2PY3&S5#<#@103O,;D^_=>Z3_<
M)+=/]J$Z23UOOG]-[?\`'LY3Z:N??NO=?!1]^Z]U_]':H_DG?]NB_P"7*/P?
MB3TW<?U_WZM'[]`2==?4_P"$])IW>-HS&Q!/0_;^V7L[(;NS>0K<#A7K6JII
M'J*BAIIY=2,&EJYYI`HB5K78L>![@;?44\Q2$C\7^7J;-B5!L<$P3];175Y_
M+I!MMWKIH1+%C]G@96.K>DDIX\1-#D-+A5.-C21CE*@6Y2(L4_/M!<6UPTTI
M1B%J>C"&XMC%&9D!D-*GS)\Z_;UEJ-B[#H%43;=P-.EU2-YZ2BA#`.L;TS+-
MH1<A45I\4"7N1P/;?TMU2FMJ]>$]J9"?"31QI\Z8'V'B?GUD_N)LB:I:!MO[
M;FR"4Z^''4]%0/50QQOI-5)&A:P^Y_98_2XM[<N(+Y(8]$S*:>73,%U9O/(I
M0:`>FU<%U=+424T5+L>KR$@"_8Q28QZHD&SBEH896J):J)A:10MQ;Z>TMFNX
MR24:X<BO#_4.G[J:SCB#*B_Y^GI-A;,52!M?;[Z^7>+&11QR'\D)(FM?]8\^
MW)[&Z,TAU&M>K02J\,;C`(ZZ&P-D@6&T\"`/P,=3\?\`)OMKZ&Y]3T[K7UZ[
M?8.R6*%]J8(F/]!..I_3_@/1[2-87\3.T<K`,?+_`(KKT3)K:O#H,>V-D;/C
MHMDRIMC"+*W:/7Z,PQ]/J9/XDHTFZ?0^QMRIM9AN%G44GK\7GT'.870)(5'E
MU84-@;'CDJ4&U]N*TS,\H?%4P1PQYULT?JD8G\'W-0+%%UBK^9ZBUF\44$=6
M]:=<EZ^Z_$7@&R]N"+5K,?\`"J(+K_U5M%[W]^T^9!_9TP!/'\"4!^WKE-U_
ML2H>&2;9NWI7IP!"S8NC)C"_0+Z>+>]:/F?V=:,MU4]I_GUD_N+LCRO/_=#;
M_FD4K))_"J+4ZD6*DZ/I;WK1_2/[.O>)=?PG^?6*+K[8<"/'%LS;T:27UJN+
MHPK7^MQI]^T?,_LZ]XMU_`?Y]>_T?;#M&/[F;>M$+1C^%T?H']!Z?>]'S/[.
MO>+=?P'^?7)M@[%>5)WV;MYIHT\:2'%46I4_U(.CZ>]:/F?V=>\6Z_A/\^NU
MV%L9`P39VWU#_J`Q=&-5_P"OH]^T?,_LZ]XEU_!_AZZ78.Q5%EV;MX#^@Q='
M;_H3W[1\S^SKWBW7\!_GUQ_T?;#_`.>,V]_YZZ/_`*-]^\/YG]G7O%NOX3_/
MKD=@[%;1?9NWCX_T7Q5%Z?\`6]'OVCYG]G7O%NOX3_/KF-B[(&NVS]OCR&[_
M`.XJB]1M;GT>_:/F?V=>\2Z_@/\`/K$FP=B1^14VAMY=?ZE&+HP/^A?;PCPO
M3DBR^"&"?J'[>B^U.P=ER?)ZCB&TL($BZ)E96;%T_P!K%;?H*J'`"K)<_3VX
M$73737/3=J)RS>-"=/V'HP8V'L:205,FT\!)4%-!F;%T3.5^A&K3R+>Z,F30
M4_U?9T](&#L%BQ_J^77DV#L2*.2*/:&WECEOY$&)H;/?ZZO3?F_O6C_5_J'5
M:/\`[[_U?LZZ38&P(X%I4V;MU8$;4L0Q=$$#7O<#3];^ZE,\#^SIHP.6+>$*
M_GT">Y-Z_'_;'<&VNFMST>V<3V!OG`5FXMH4^0QM%14^<H:"K&/FQF/JS^W)
MD*=VOI-B0?=:4Z<6"Z*EDB)`]`2/\'0VT^PMBO&';:FWY'D4"65L32:I"@T>
MO]KDKIM?\V][T^?2-O#61A+%^IYGK,>N]A/3FF_NAMTP%M9B_A5)HU#Z&WC^
MM_>B/4=.CPV%(QUE7KW8P4#^Z6W^``+8ND^GX_W5[J>G%!"@'CUQ'7&P0YD&
MSMNZR;EOX31W)^E_\U_A[]U;KL]=;#8DG:&W23]3_"J/_KU[]U[KMNO-B,@1
MMH[>*#Z*<51V'_6+W[KW7EZ\V(BA4VCMY5'T`Q=)8?\`6+W[KW7$]<;"9UD.
MS]NEU-U;^%4EP?ZC]OZ^_=>ZX'K_`&,]47;:.WBQ0L6.*I"2R,JJ3>*UPIM[
M]U[HOWQ^Z_V,^"[+HVVCMXTO^FC?1,'\+I=!*MC"O'COZ2/?NO=&#'7.PKQ-
M_<_;MX++$?X5270*;*!^W^+>_=>ZR#KW8JU3UHVCMX54@L\_\*H];#3IL3XK
M?I%O?NO==?Z.]AZ63^Z&W=#WU+_":.S7-S?]K^I]^Z]UU_HZV'XHH/[H;>\4
M((BC_A5)I0$EB%_:X]1)]^Z]UY.NMAQS+4)M#;RS(NA9!BJ34%/U`_:^A]^Z
M]UT>N=ADDG9^W23R3_"J3ZG_`*=>_=>Z[;KK8;*$;9^W2H^BG$T=O^M7OW7N
MN*];[!4!5V=MP`?0#%4?_7KW[KW7EZXV"C:UV?MU6)OJ&*I+_P#6OW[KW7)N
MN]AL2S;0V\6/U)Q5)<_]8O?NO=>;KK8;*$;9^W2@OZ3B:.W/_3KW[KW7O]'6
MP],:?W/V[HB_S:_PJDLER3Q^U_4^_=>ZS1;"V73UL&1I]KX2GKJ;_,5<&/IX
M9XOSZ9(D1O?NO=,G<G_,H>U/_$;[X_\`>8RGOW7NO@G^_=>Z_]+:H_DG?]NC
M/Y<O_BI/3?\`[RM%[U;\)/M/_'FZ1W?Q1?;TN_F!192IZC^1V/P460GS%;U3
MV(F$I<6DD^7K\_-M;)/AX,:T#)+%.^2DC6,*;ZE'N"M[_P"5AE^W_+U-^R5.
MP6A%<*<>61Q_*G\^M1GX[=,_,+&[H^#.S*[9W=T--\7=Y4-=A<GDSE_#E]P]
MX[3WQO*J_C%1-4E*W&;0IQCZ:2:?R)05'HM?V::\,YTFJD\<X('#U]!YC/2(
M0.Z_T?\`/T8+.=K_`#,^0.S.M=E9F@^0=1_<W:OQG?L]<EM?+;?J:CN/%=_[
MEHM^92FS%/!"<@*?;#TTCS*?')"BL1;VTTL2H6/Q:J?RZN+:3`IY="1\&?\`
M9W=H[ZJ:3:&WMU]J;_Q_5.:QF8H/DOG]S[;VPFZ8>_-U-E:'"[DCI4FR)H]G
M)3R4B@&)UTC41S[O>7<31HPC"@C`'`=(;:VE^JF#OBISTJ?DG\+\9UY\C/D7
MW;TMU9N_;W8^"^'%?V;L?<.S\[O7+IB?DEEMX9)\EE=K4<F4GQ>3W!_#B%6`
M0F..(`Z/::QW`L1"SUC%*"@_XOI7N-JXB##B.FCMKL;Y_P#6?R%^,NPMC;U^
M0NY=OT^-Z/K-XU6Y,97[CQ79]+V'#/7=FU&:JZ"ACQF/AVI55"4ZR5#PUE!H
M"QHXY]J)+B+Q)JI6E?\`5\_LZ4VD^FU@6N5%#^7'I$9;Y)?S"=U[;PNQL#E/
MD+MO>&W>N8MN]D;L.R<ACXJ7L"3Y(08>KJL;E*R@:CR&0I>L:L".I2Z-3(#:
M]S[:%Q%2I&.E7U`Z=\=V;_,=ZM'8F2DW;\C^VZ6+#_*K:V/Q>?P](_\`#\;L
M/<NW\1U7NRAK*;'THH]S5N.RU74I6(TCU"TZA4/M9*T'T\<FG!4?MZ9CN3XK
M@'SZ.;_+Q[`^1V^NAZ]/DGFM];KS6WOE3AZ#9&Z.Q<'D-O9G-[)EK:23!.LV
M5IJ3(9*&E8N%>6-78@GZ6]F6SWD,3(%]/Y]!_?YVTN">(Z.=_.JWOO78?QUV
MOE=E[HSFU:ZL[&QE#-78+(U&.JIJ*2ED>6E>6G=&,32"]K_7W)R2+);0.IR1
MGISD*#:KJ^:*^520M,_::^?IUK"-\D._]1/^F;LB]_\`GK,M]!_U4_X>[>(_
MFQZR#;DOE`6RN+6/A7@/\_7+_9D?D#_S^?LG_P!"S+?_`%3[7Q1LT:-7B.B[
M^J/*1S])'^S_`&>N_P#9D?D#_P`_G[)_]"S+?_5/MSPFZW_5#E/_`)1(_P!@
M_P`_7O\`9D?D#_S^?LG_`-"S+?\`U3[]X3=>_JARG_RB1_L'^?KW^S(_('_G
M\_9/_H69;_ZI]^\)NO?U0Y3_`.42/]@_S]>_V9'Y`_\`/Y^R?_0LRW_U3[]X
M3=>_JARG_P`HD?[!_GZ]_LR/R!_Y_/V3_P"A9EO_`*I]^\)NO?U0Y3_Y1(_V
M#_/U[_9D?D#_`,_G[)_]"S+?_5/OWA-U[^J'*?\`RB1_L'^?KW^S(_('_G\_
M9/\`Z%F6_P#JGW[PFZ]_5#E/_E$C_8/\_7O]F1^0/_/Y^R?_`$+,M_\`5/OW
MA-U[^J'*?_*)'^P?Y^O?[,C\@?\`G\_9/_H69;_ZI]^\)NO?U0Y3_P"42/\`
M8/\`/UQ/R/[_`/K_`*9NR>?S_>S+_7^O_`GWK4Z]NKATK@Y-Y1D&GZ6.H'H/
M\_0*]B?,_M7K3=>W,KN;N/LU'W(,7LF#))N+*$Q29G,O64%/45#50_W&1SQZ
MYK'AO;9:A!)R3T4;SRYRMMR=L*::^G^STI</\Z.RLEM#%[UJ._M_8;#9F6I@
MI)<QNO+4ZU,U+D*G',*21:DJB/-2L4_JI!]V$C$8;'35GR]RG<VL$YM4)=:U
MI_L]<=P?.#M;;^=V/MZ?O/LJIRF_,BM)@XJ/=F9GI'A:GF(::J\]I',B:K^_
M:W_B/2K^K'*7_*)'^S_9Z1V\/Y@G<VS-W5^T<]O_`+XHY(MMON./+T^>R%5C
MZF@Q[T\0GHI?XDI49&KJDA]0%WN/:&25Q(1J/'I#+M/)T+F)K2.HQP_Z&Z0$
M?SDS6_.Q>M*?(;H[&R>_9XJZOP]7ELLU5F]DS4N3+24L%54U3O02_P`0I-3P
M![E;<<^VRQ)!)STXEERHB&-+>,(?*GK^?6XY_+5_F84'?^'QO3G<64I\3W'B
M:.DI\5DY_'2TG8-"B`1G'\Z!GDBMYA?U$7]N#OJ=7?\`X>HEYVY'^F,F[;?"
M/W9,:K3\-<"@SVBAJ>KKH>-(]0#*#9N6'`_5_M0_/O1R*^?41Q*8)RAX=2A]
M/;9X]+CQZ[]ZZUU[W[KW7O?NO=>]^Z]U[W[KW4<?\"/^G;_]#I[]U[HOWQ\_
MXM?9?_B9]^?[WC??NO=&('T_V)_WL^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!OW)_S*'M7_P`1OOG_
M`-YC*>_=>Z^"?[]U[K__T]JC^2=_VZ,_ER_^*D]-_P#O*T7O5OPD^T_\>;I'
M=_%%]O0H?*'L:KZBZ_[O[2I:*#)UW6FR]Y;[HL5723TM+D9ML;8R6X*6E:2C
M269Q-48X*+CDM]/<%[T*\QN`,ZA_AQU-VS5_J]`*T!B/S^W]H\^JL]N?S<^L
M<O\`W?PN;ZW[#Q6XLG#LG#Y3=>-P;UG5.W^P=[]7U';.W=ISYJ6:/)"#(8Z!
M_,RP^0_2]N/:EK9]6ME%#4C\C_EZLC*+=$0@L10U\OF/FOE_/I==8?S1NH=]
M[!P>XMPXK<%!FI*CI'!Y:GP]'5G%C/\`?U)6S;8;&FMTUDN.BCHC=I074_T/
MMCZ:3-!TN\>WJ`R`FG'_``_MZQ8#^;%T?G,.-U;CV%VGLK8=9B.T,AM7?>\,
M)28_`;P'3S/0;JP>VI:>K^_R.;R%1#HQJV5IW/Z2?:6>WF."Q*#RZ+&EC:20
M"BU8Y&3Q!'G^WJQS8FYDWGLG:N[X,?D\-!NS`X;<E/C,M#)29:AILI0PUE%3
M9&!SY:>KCI)D$B'\WO[)7ANX6)AE93\NCM);*<#Q(U.//I6"1QJL1ZFB9O2O
M+P/Y8G(MRZ2<@_6_NRSW%!KE)?S/6FM[9JZ8AX9_P=>:1W&EW=T)8F-V+1$L
MAC8M$Q,;$H?J1_C]?=O'F_WX>JFTMCQA'7;L9`@D/D5=!$<GKA&A%C7]EKQ<
M*H_L\VYY]O6MW<RK<1R3,43@#Y=-+:V_B2MX0J>/05]O.S46R&9BQ_TJ]?'U
M'58C(@`@&X!`/%O:SD^:6YWT07#EX:\#PX]![?H(1%(1&*@=%:_GJ2P)\9ME
M).DAC_TIXS3X2$;6:*4@NTH*:%/)/X]Y!:%C150448`]!T2\CV<!W4RR.!6A
M\NM3LF/4VJ=6-SZHVBEC//\`9DC<(PM^1Q[U]G#K)]UV\V:CQ4^$>8_S]>O%
M_P`=F_VR_P#1_LW@=1%&"<TZ31IMGAI5TK3U'^?KUXO^.S?[9?\`H_V[XB^O
M5]&U_P`:?M'^?KUXO^.S?[9?^C_?O$7UZ]HVO^-/VC_/UZ\7_'9O]LO_`$?[
M]XB^O7M&U_QI^T?Y^O7B_P".S?[9?^C_`'[Q%]>O:-K_`(T_:/\`/UZ\7_'9
MO]LO_1_OWB+Z]>T;7_&G[1_GZ]>+_CLW^V7_`*/]^\1?7KVC:_XT_:/\_7KQ
M?\=F_P!LO_1_OWB+Z]>T;7_&G[1_GZ]>+_CLW^V7_H_W[Q%]>O:-K_C3]H_S
M]>O%_P`=F_VR_P#1_OWB+Z]>T;7_`!I^T?Y^O:HO^.S?\DK_`-'^RJ:1_%?2
MQI7IRFVHNI)4#4]1_GZ`7N'JO'=P9#;>W,M6O2XF@AJ<G5DPJ\];>I>GI8L8
M!,'AJZ:LE#>7C]/'MOQ)/)ST0[A:[==]LTBL/F1_GZA;;^/^V:#IG:O5.Z,Q
M6YZAVI)IBS..JI<?42S05]3.AK/(DJDVD`<KP2"?>E>4*`7)/KTC@VZVBACC
MCN0(P,<.EING85%DO[@5&+K:*E;KG,+F<=4U*I62U&C&5$*8[[J\;RPBHE5B
M;#U>]^+)_%T[]##_`,I(_:.D3ENGLAO6'>&2W3G::FS^Z]D87;=(*&D6KHMO
MG`9&GR%:(X7D+QC*9RG@D=0?4`?QQ[;;OKJ\^DTNR;?,6:1T+'B:C_/TR83X
M_9FER.T9ZC=.-KL?A,^^\MQ1X[;U(F8S.Z(LE-6UV-QV1@)R%#290U"Q-3G4
M&T<6O[\16F>JML6W&G<@S\O\_6VI_*V_EL9,5NU/DIWGC:V@6FEBS'5FQ9Q+
M25JI/$HCW!FU4Q3PTWCL(H6L?3J/U]NJHIJ;H$<Y\X+;67]7;*<E804-#A1Q
MH/4FO6R?`%2/2"2(TTJ223QP!<\D#Z#_``]^/E\SU!,+">=VI7J2ANBD_D>Z
M,*,1TK848CKG[UU7KWOW7NO>_=>Z][]U[KWOW7NHX_X$?].W_P"AT]^Z]T7[
MX^?\6OLO_P`3/OS_`'O&^_=>Z,0/I_L3_O9]^Z]UW[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#?N3_F4/:O\`
MXC??/_O,93W[KW7P3_?NO=?_U-JC^2=_VZ,_ER_^*D]-_P#O*T7O5OPD^T_\
M>;I'=_%%]O0Y]X[&Q'9]!V+UWN,U$.!W[A-P[0RSTL\]%D5HMP8N3#23TM0%
M*`0PRNRGZ>H^X+WNG]87!'XNIMV16_<$#K(?[/A0$8X_F>'Y=5K;X_EE]+KU
MSNW$=;1[@Q^[JW*;8WOM2??&Y\H=O0[]Z_ZHJ>G]H5M>V-C:JJ\9C<17F2KI
MQI,CD6][EW41NT)8T4D?Y^FXK=I$#USIJ1Z>G\ND7UU_*6Z7PNW.GIM^;N[`
MGWQL+;?4>,WQ#L[>F3V[USOS=G4'GJ=F9JKV564$M>[)%520QS&5-"`7'NG[
MWC"`4[M7'S^S[.O"W=G903\(((R/3CPJ#Y>G3GWE_+.V9V?U_P#&3HC:+XJC
MZ6Z9[RJ.Z=Q/N7(9_*=C9$TN5J-Q3[9VE6T"0XX4N8W'5K#719`+#+3H`+^W
M?KXWC&KB5J.DYM61Y:&I!SY?G^S/5J4<>F*):>%8H(XXHX884T10Q1(L<<$:
M2D2(D*H$L?I;^GLGGOD5F!&>C>TL244@]I&.N6B8_P!E_P#;1_\`1_M"6UG4
M//HQ5/#4)Z==W<<&-KC_`&E/^CC[]U;KLK,;$(UOK]$_Z.]VLOBN^FD^-_MZ
M"SMA":39@<3&W9O7[6"I8,,D.1ZKV]F/(_\`RL:_Z;_+T'-^_LI/]7ET?3/[
M5VSNV!*/=.W,'N:BIJE:N&CS^,H<M31U,2LB3I3UT4\22JK$7TWL?>19TX]>
MHE$FXVTLDD+$(>%#Y=(H=%])_4=-]8BY)_X\?;(Y)N>!CP!S[]4?Q?R'2K]_
M;\!I\>6G^F/^;KK_`$%])_GIWK%?Z`['VUS_`(C_`''CCW83$``/_(=7&^;X
M1_;2_M/^;KK_`$%]*?\`/G.LA_@=C[9O_P"Z\>]^,W^_/\'6_P!^;Z>$TO\`
MO1_S=>_T%]*?\^=ZR_\`0'VS_P#4'OWC-_OS_!U[]][[_OZ3_>C_`)NO?Z"^
ME/\`GSO67_H#[9_^H/?O&;_?G^#KW[[WW_?TG^]'_-U[_07TI_SYWK+_`-`?
M;/\`]0>_>,W^_/\`!U[]][[_`+^D_P!Z/^;KW^@OI3_GSO67_H#[9_\`J#W[
MQF_WY_@Z]^^]]_W])_O1_P`W7O\`07TI_P`^=ZR_]`?;/_U![]XS?[\_P=>_
M?>^_[^D_WH_YNO?Z"^E/^?.]9?\`H#[9_P#J#W[QF_WY_@Z]^^]]_P!_2?[T
M?\W7O]!?2G_/G>LO_0'VS_\`4'OWC-_OS_!U[]][[_OZ3_>C_FZ]_H+Z4_Y\
M[UE_Z`^V?_J#W[QF_P!^?X.O?OO??]_2?[T?\W78Z,Z3_P"?.=9?^@/MK_ZW
M^Z$U-2V?L'5!OV^LQ7QY<?TC_FZ`F;I/IH?)NDI3U+UP*1^C9*AH!LO;7@%1
M'OL+'*$^PLDJJ;:AS;W3BW2Z/>-^,6+A](/'4:@^G#H=1T1TH?4.G^M+<@?[
M\C;6D@DW](H-!O\`ZWN^H#CQ^P=)VY@WU-40N9=-?XCUX=#=)'Z=.]8^@DV_
MN)M@@,P&KC^'6!.D>]ZQ_J`ZI_6#>Z4-Q+_O3=>/1'2;EG_T/=9W<AF9=C;:
M4L0"H+%<>+FQ/O1<'C_DZ\O,.^)\-Q*/]L>BR=@?`?HWL7OOKGN++[-P&/QO
M66!K:#';,P^"Q>*PF6W)495*RBW#N*EQ\%.M=%0TBE(M?(/UO[J:%@3PZ>BY
MHWV)619WH2?,D@_F.CU4='!24L$$"QP1PQ)$D<:JB1JBA52)2WHB`4:5'`%O
M>ZU-:9Z*9Q=7K--*YUN:G[>IBV4%1<W_`"`MCS?_`%?NI.?LZW!!].*GCUE5
M[*``>/\``?\`1_NI-23TZ3J->N7D/]#_`+8?]'^]=:Z]Y#_0_P"V'_1_OW7N
MO>0_T/\`MA_T?[]U[KWD/]#_`+8?]'^_=>Z]Y#_0_P"V'_1_OW7NN"DF8'2;
M>-A>P')D4#\G\<^_=>Z+WT`S#$]E64C_`(S-OK_4?F3&`'ZW^GOW7NC"I(="
M<&Y52>!]2`3_`&QS?W[KW7?)YUL+_CTBW_)WOW7NN]9'')M^;+S_`,GCW[KW
M7O(?Z'_;#_H_W[KW7O(?Z'_;#_H_W[KW7O(?Z'_;#_H_W[KW7O(?Z'_;#_H_
MW[KW7O(?Z'_;#_H_W[KW7O(?Z'_;#_H_W[KW7O(?Z'_;#_H_W[KW7O(?Z'_;
M#_H_W[KW7O(?Z'_;#_H_W[KW7B_'U*DWM<`D\'Z+J-_?NO=!UW#?_0_VIJ-S
M_HWWS<VT_P#,,Y3\?CCW[KW7P4??NO=?_]7:I_DG?]NC/Y<O_BI73?\`[RM%
M[M$``]/G_A/2.[^*+H8^P]@XG*;ZSF1DS6ZJ66HK*IIZ>EW%6P4K:[*R04XB
M=((M(L%7@>\?N8&;^L<E&X-_EZG78-*\N1"F2G28BZYP-ZJ=L[NQIJ]HY'=M
MR51,31HD4>D&FLC(D2W(L6M<W/LNN&A\:36@+%OY]*K>.5H4(E8#3_+TZPP=
M6;>IX/`FX]Y,NAXV>3==?+(RR2F9QYI8GF%Y3?\`5Q^./;9:!CJ9!7K<=N\4
M?A1.RQ^E/7KA5]8X&H-.C9S=S1PM&[$;FK`6:(KH+LL`9U7Q@@$D7%[>U2+&
M54A12G2CPP54.*D=9GZVP;.S#.[P(+$W_O+6,3?\ZFA)-_=&MK=S5H5/3R.\
M8`1J`#KC_HUP?_.\WA_Z$E7_`->/:5E5&*H**.'56)8DL<GKW^B[;K<MGMW!
MCR1_>>L'^\>'WKJM>N1ZSP*@*,YN\@#@_P!Y:P\?]2.1[M9?%=]-)\;_`&]!
M1VOUSAEI]FD9W=P"]F;`M_OY*OZC)#_IG_I[,>1_^5C7_3?Y1T'=^/Z3_P"K
MRZL/7K+`ZZ@_W@WKJJ9&=S_>2JLK,2"(_P!GTK[GP;PINI;8PU*M0X)ZC&2:
M7!,AH.'7$=68&-0HW+O@A>`3N>IN1_C^Q]?:B:ZTC4MN/R!ZJ+I_-AUU+U5@
MYVII9-Q;V1H`!"$W/4`2J#<&2T)N3_C;W=9E>)',"U(]#7KWU3"H5^LK=881
MFE:3<&]%=V)*C<U393]+)IALH_V_M%/-)D+#FOE7_-UH7#>4F.N"=6X*-"#N
M+>TA>_JDW/4EDO?A2(1:WNQ:7P8SX7<1U[ZEZT\3INR^PMHX+%SY7*[OWC0X
M_%K]Y5U<VYZI46&%M+_<N8+>$EAJ^GM18+-*RH8`SDT%:GKWU3#C)CJ9!UKM
MW)PTF3@W1NYZ.J@CGI9*'=$YI*F*90\<J:8G!5D86Y]VDK'/*'ATT/"G#\NK
M_5,1A^I?^BK"C@YW>W^N-SU)'^W\?OU5;@H_9U0SRGX9#U[_`$5X3_G>;W_]
M"6J_Z]^ZT'IUKQIA@R'KO_17A/\`G>;W_P#0EJO^O?OU!Z=>\>;^,]<#U7@K
M\[AWL#_3^\]4+?\`6+WZ@].O>/+_`+\/7(=5X2W&>WNP_K_>:J-_^L7OU!Z=
M>\>7_?AZ[_T686UOX[O>W]/[RU7_`%[][&.'6O&EK76:]`%4]2X*?Y0T'^_@
MWC&T71,AT#<E5KD4;]'ZAXB&'^Q'NVI@:USTZ+RZ52@F.@GAT/8ZOP)E61=Q
M;T2/0R^)=RU0B!O]0AAU`_['W4YR>/332R,2S.2>NX.K\+%'-''N+>TGF+>5
MFW/5%X[_`$*,81;C^@]^ZKK8T[NN,75.$BC2-=P[ZE"BPD?<U46:YO<GPKSS
M_3W[K?B/_%UU)U-A7GAJSG][^2#1P-S5(5UC!$:R+X2)`H)X/OW6M;_Q==OU
M?@:AVF?/[T1I#J*KN:J50?IPHBL!Q[W4]7$TH%`YZY+U9A``%SV]R`.#_>:J
M/'^OXO>NJ.[2?&:]<O\`1;AO^=[O?_T):K_KW[]U0``4'#K@>K<'^=P[V!_I
M_>>JX_ZQ>_=;Z]_HMP?_`#T6]O\`T)ZK_KU[]U[KO_1;A6`"Y_>Q_P`1N>I!
M_/U)B_'OW7NNQU9A@+'/;W-OS_>:I/\`O/B%_?NO==?Z*\."6.?WN03>QW/4
MV''TMX@??NO==+U=A?,-.XM[J=!-AN:JL/W4-N(OPWOW7N@`^/O5F%?"=EPI
MG=ZH6[FWTQD_O+4^0J)L:;AO#8*3^+>_=>Z'Y^J\.1"HW'O1/"JJX&Y*J\ME
M'ZCX3<\?7W[KW71ZKP1D:8[BWOZ^?'_>>J$:V`%D3P@CZ>_=>ZY'J_`OPNXM
MZC_!-S58M_2Q\7OW7NN_]%F%*A1G][DC^U_>:I#'_7/AYM_K>_=>Z['5F&`L
M<]O<V_/]YJD_[SXA?W[KW7$]6X/\[AWL#_3^\]5Q_P!8O?NO=>_T6X/_`)Z+
M>W_H3U7_`%Z]^Z]UR'5N%MQGM[L/Z_WEJC?_`&/B]^Z]UU_HKPX)8Y_>Y!-[
M'<]38<?2WB!]^Z]UX]6X,FYW#O8?X?WGJA;_`&'B]^Z]UU_HNP1&D;CWM?\`
M-MS55Q_3GP\_7W[KW73=58>T87<&^"`?41N>I!/U^MX#JM[]U[K-2]9XNCR$
M.0BSV\G:G=6CAGW!)54SL+<-3M&"+D?GZ^_=>ZE=P$MT]VF2&4_Z-M\\.+-Q
MMG*#U?XFWOW7NO@I>_=>Z__6VJ/Y)W_;HS^7+_XJ5TW_`.\K1>[Q<&_U>9Z1
MW?Q1=&3WW6?:[AW#45,B45/C9ZF>:L>II@K4'B\^0JIA6/##CJ;"T8\KS,;!
M>?>/^_`'F&8D?B_U?LZF?:9'3E^!4DH"E>'"GE7SU''RZ+UL3Y)?'_M>@W-E
M^K^[NK]^8G:V8IML;FR&V=\X*MHMMYJKJ*>GI8<I,M2K0U=57/\`;HB@JS2`
M`FQ]L3;6[/(Y4@MG]OGTJAW4(L,>O"TK^501_L]#D(Y`(1)3OY)9'5:7R+#4
M^-!'IEIKEXZV5OW"T3,I4)Q[;&T,1GRZ=DWD*XHW:>'S.<?(?/I+4V\-O5>Z
MLYL?'[BQE?NK!8R@S64V]3SRKGL'A,N\RTF5R>)?29(*ZHB>*D*GG0?K;V[X
M8C414RN.E,4DCCQFD.AJ4&*5IP!\N%37UZ4^H(BO.)`DB*0T;3@P16_;F;4#
M',TI^IX'X]ZQT^"Y/'A]F?\`-UV&<\MK4_D,HC8?ZZ*2%-OQ?V72_P!H_P!O
M5UKI%34]=6OR2?\`;G_BONG5NN=R`HN;6_J?\/=K'XKSII?C?[>@J[;)%#LD
M@D%NTNOU)N>1_$1Q[,>2/^5C7_3?Y>@YO_\`8R?9_DZ4/S^[P[#Z'ZNP^Z^N
M<G%B<M5[JAQDSU./AR$4U.]+(]C$[AM&OGBQO[R_]O\`EO;=ZWF2*Z1>X`GY
MU.:Y'4-WDSJ#I;SZJ(3^8S\JU55GWOB6ET@R%-LTRJ6(N=*&8D#GWDU/[,<L
MQ6GC"V35I]/7\^@I>[O)%J`?ATELS_--[_P-9)BLQVOM#$Y%L<V?%)6XFC@J
M3@*>K7'5E<L;SWT154@!-N"?9!'[:<K:@CVL988.//\`WKI1;[HSP1,6-2.E
M./YCWRE>&*2EWMB9T:-'1X,%23QRQNH:.0N;&`2(0?[5A[,H_:KE.72?I4'Y
M?]#=/?O%OXCT'L_\WCMJ@W!6[8R'=.Q:+<F+I*W(YO!U\-)2U6-Q^,6.2IR+
M/)H5Z;P.HL/K*X'M%>>W/)UK*\9M8ZC'#_H;\NM_O)J4U'I(;O\`YI?86]=I
MU>U]Q=Z;*R&!WOMBLR51045%14TV8VG`TZY#)X6HIII*Q(**"$O/$RB64J2O
MMS9>0>45O8;D1)J2M!3%3P/Q>7EUX[D2"M3GH\?P&^?']V:;;W6G968&4V+D
MH*'^YV[7GEEDQ.+K$1L4*R2<+)_!ZB.1?$&]:7Y/L&^X_M=+`UUO>V+^BYU!
M<`%?,UR:^G5(=RU2F/RKU?M1S4]=3Q5E+-#4TE1"LT4\4@D22.10\<B2(Q5D
M9""+>\<W0PRZ6%/MZ$ULVI0:U'4Y(4"@$$FWU)-_][][)!)(X=/GB:=<O%'_
M`*G_`'EO^*^]=:ZY:%_I_O)_XK[]U[KHQH>2O^\G_BOOW7NNO%'_`*G_`'EO
M^*^_=>Z+S5>GY2TY4D:>@9[6)X_XR'`O^WLQ]^Z]T82(`QB_^J<_['4WOW7N
MLFA;@VY'T-S_`,5]^Z]UT8T))(Y/^)_XK[]U[KQC0VN/I].3_P`5]^Z]UWH7
M^G^\G_BOOW7NNC&AY*_[R?\`BOOW7NNO%'_J?]Y;_BOOW7NN6A?Z?[R?^*^_
M=>Z]H7^G^\G_`(K[]U[KCXD!U:>3_BW^]7M[]U[KLQH>2O\`O)_XK[]U[KQC
M0BQ''^N?^*^_=>ZPHH$P47L(WL+DVM(A'U/OW7NB_P#Q\YQ?91)8D=R[\078
M\+JQIL.?I?W[KW1A@BV`M^DD#D_@FWYY]^Z]UWI6][<WO]3]??NO=>"J"6`Y
M/U-S[]U[KKQIJ+6Y/U-S_K?2]O?NO=>,:'DK_O)_XK[]U[KO0O\`3_>3_P`5
M]^Z]U[0O]/\`>3_Q7W[KW71C0\E?]Y/_`!7W[KW7C&A%B./]<_\`%??NO=>$
M:*+`6`_Q/_%??NO==A%!U`<_UN?^*^_=>Z\44DDCD\'D_P#%??NO=>"*!8*/
M^)_V_P!??NO=!QW$H7J#M0`6'^C??/\`O.V<H3]?\3[]U[KX*'OW7NO_U]JC
M^2=_VZ,_ER_^*E=-_P#O*T7N\7!O]7F>D=W\470J?(_;59N_;'=&TL;B\?F,
MCN[:^YL)CL3F,C/1468R>8VS+A,5B,EDJ!9)\/B\M6'Q--QXUL6]X_<Q#5S!
M*!_%U-6PMX6Q12.`*QTX^0J:_,\,#K4IV=_+>^5^5ZT[5VWF?BT-O;9H).@)
ML'M7-[PV)!O_`'-6=4]FPYW=VV-K;XZZGP$NY-CP;8J*IZ6;/4L60F#@/*[*
MMA:^YVSF)G(+Z:'!Q04IGC]O2!-O=P6K@Y_(GCT=Z7X2]ZXWJBIW%5];=E[P
M&?\`EYV+OON+I^C[ISN'W9V'\>ZA,LG4NV,9NH[D";<Q6VYJR!Y*6C^WE98K
M.[CVQ^\+$%6$8#"G5OW5.3ANPCCT&>Q/@W_,-VSWQTWVWNZJK]PX':W7O5.'
M[`V8^ZIJW-[P?#YS>2X.*OW+1UT$^<CZ/I\S0%XVD/\`%2C.VH#VAFN-L8L[
M1`SEC^S]OKTH2&[C3PDN&$7"GV_EYCHX7\L#XQ?*_I/M+M?<OR-SW9%36;AP
MF7PF=EW)E-KS]>[LW5D-TY?(1;NP4=)N'+YZMJ:?#S0112F"AC"H`8@1S5[G
M;"M3`H8`#SX?ZL]:T7\C1!+EBHJ:^E/3'Y=74Q&\<9(D!"*I\I0R70:27,?[
M9+6OQQS["UV8S<SF(?IZL?9T?VOB?3P^,?U=.?//7/VQTHZY'Z+_`+[^GNUC
M\5YTTOQO]O05]N_\`-C_`/B4^O\`_P!V(]F/)'_*QK_IO\O0<W[^QD^S_)TD
MOYK85NB]N$JNI=[4^EB!]31R?DCWFW[40:]_=C+I`4'R]?GU"U\IH3Y5ZU]B
MD9(+*M[`DD#ZV'_$CWFS=BW.W(IO!A1YC_/T`-RLY'9J#JL/YN?&WM'MW?:[
MZZOHW.2VMU51;5BI_O5@AS_\:WX*O/X6:/A33+@56JO^L2(+'\>X;GVC<9=P
MN)H=R(A+U`JM*=/VD,RP0H[$*!T93?'2N\=T[GZNW!B=\#;..VC@,#29O`&I
MR,:U]70RT8G"K25,,,[-21,A+*00?8LV_:+VE&W(_M7IW1/_`!'H'_D-\?-U
M]N9SO//T6"HZ>NDV%M+9_6]=2FBQN9R%%_>#%[LWQD(:IX&=JMUQYIU\NLE(
MU'TO[#6]\OWCW,["_.6]5Z>218Z"1:D<>@,ZX^+O=:=D],YK/X$X;%XK+8?=
MF[JJ;^[];35&%V^<S2X_`3321P5\6Z:W&UZBHI:>$TF0#?2XO[IM'+=[K`^M
M_FO5?%3TZNRZHZNW5VWO'%["V+BI9<O4M3/24:0HL6/I%===15U%,HI::BHJ
M>VB/@(18<CV*N;N8MNV[ER+;]PF5C;QZ6)_V/MZW;V[//K"FA..MJSX_]6U_
M3W5VVMCY'=&6W;6XFCA^ZRV2F\Q:0@ZJ"C)&L4-,S%4#7:P^OO!S?K^TOKZ:
MXBMA'$20!FO'B>AQ9)HCH>/0Z)?0NHW-N2/]]_3V4`@BHX=*3Q/7/WOK77O?
MNO=>]^Z]U[W[KW1=:S_LJ6#_`,0#/_[\2G]^Z]T86'_-K_KO_P!#M[]U[K+[
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MHX_X$?\`3M_^AT]^Z]T7[X^?\6OLO_Q,^_/][QOOW7NC$#Z?[$_[V??NO==^
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7N@W[D_YE#VK_P"(WWS_`.\QE/?NO=?!/]^Z]U__T-JC^2=_VZ,_ER_^
M*E=-_P#O*T7N\7!O]7F>D=W\471I-X(IW)EFMI9JJJB8H2A>.4V=9"A7R"PX
MU7T_BWO'SF%B.8I0#@M_EZG'8X8WV"WD9*NJ5!],=)QPKM(61"95\<A\<=W3
M1HT,0H)4)Q;^GLKN&D\>7/GT;6DL$=M"F,*.N"1K&%5=5E"@:G=^$%E#%V8M
M8?UO[:+S$DDFO3RRVJ(L:`!!P'7+Z%B!8M+'-<6%I(HS"C+;]%HS:PL#^?:5
MA<%F(;%>O&2U)!-*TIQ/7$*@TVC0!->E`B"/5(+.YB"B-I6_U1!;_'W6ESPU
M8ZUKM-6J@U?G]O7?/YN?]<DG_;FY/M6FK2-9[NJC0/[,=GEUU[MUOKD?HO\`
MOOZ>[6/Q7G32_&_V]!5V[_Q;]D?^)3Z__P#=B/9CR/\`\K&O^F_R]!S?O[*3
M[/\`)T<7M?IK8/=F"CVSV+@AGL135HKZ>!YI*815*J469'C=27"$B_O(O:MZ
MW3:[^9[5BHK0'Y>7EU$TL2R"AZ+^G\OSXGJBJ>NHV90`2V4KG)MQRRRV/T_'
ML7S^XW-AC*/N)TTX:1_FZ2/M\+X*]>/\O_XH\?\`&.HN&5Q;)UX.I/T$D2`F
MP_K^/=8O<?F:../_`![R_A'3/[OC7M"X'SZX'^7Y\32;GK>#@EN<E7GDBQ(O
M(;7!_'M2ONMS7&*+N6/](.O"P3^#^?7C_+\^*!=)3UQ`SH_DC9\E7L58H8R5
MU2D"Z$@CZ$>]2^YW-$J:Y-PP?Z(Z2OLR.[-HX_/I!]C_`,O7HJOV+N>AZ\V1
M28_=\V/D7;65J<E5U*T621HUC/[LYEA%&A)325T?0>UFT>YW,$4\;/>5@KW5
M%/Y]-G8^-$SY9Z&7XO?%W9?QSV72X['1QYC=F3CB?=.[9(`M765.D--302->
M2&@24V"K:_U/LBYGYJOM\N)9[ECX1)HM:U/J>'Y=&MOMRPQHI^,#HV*1J%2Z
MA='T"DV7\<?UX]@D:[AZDXZ5JHC6@ZD*`%`'`_'^QY]JPND!?3K?'KOWOKW7
MO?NO=>]^Z]U[W[KW1=:S_LJ6#_Q`,_\`[\2G]^Z]T86'_-K_`*[_`/0[>_=>
MZR^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[J./\`@1_T[?\`Z'3W[KW1?OCY_P`6OLO_`,3/OS_>\;[]U[HQ`^G^Q/\`
MO9]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z#?N3_`)E#VK_XC??/_O,93W[KW7P3_?NO=?_1VJ/Y)W_;
MHS^7+_XJ5TW_`.\K1>[Q<&_U>9Z1W?Q1=#CV#C-U3;VR[T.\HJ&C:NJ)$HC@
MJ*?P(6NL33O.'E*_U(N?>/?,()YBES^+_+U.FPNHY<B4_%H_R=)9,'O5EE;^
M_:$2$M%_OV<,=*GZ!"U<K,!?\B_NKSVBNZN@U@YZ5P1H883H!J.L:[?WR%&K
M?H+6Y/\`=G"<_P#J_P"Z_4V7^^A_/I[P8_*,=>DV_ODO&4WZ%50-8_NQA#KY
M'U/W_LOE*M(S)\)..O"&/SC'7-MO[V))&^U`OP!MG"<?^K_NE!Z]>\)/]]C_
M`%?GUVFWM\%9+[[!YX_WZ^$N/]8_?CW[IP44*`,=8UV]O@@7WYS^?]^UA!_\
M?^_=;SY#KG)M[?(,(&_."/\`GF,(;\?U_B'NUC\5WTTGQOT&7:^$W<M/LMI=
M\0M''V9L!61MN8X?O#(CDA*HKJ/^!M[,>1\<R+_IO\O0<WXUAD-.K"1M_?;O
M,R]BQJLC-XE;9V,?Q(2;(KFN&K3_`%-C[R!6^1KB2`085OGU%KD!B1PKUP7;
M6_UC\8[*CUWU:ALS$:M/]+#(:;>U$TK4U+#_`(>O"=!2JCK*=O[^D,3+V.J+
M'PRIL_$Z9;?4M>O)%_:83DK1H`3^?5"Z$DCAUV,!OXF4_P"D:)0Y)13LW$GQ
MBWT4BOYM_C[KK0@`VP_GU[6O7"+;G8"HX?L=9&-[,=GX@6_Q`6O/^\^]RL_A
M*$A`7K?B+TR9FBW3M_$U>9S'9]-08[%1O6UU;)L_#H$C4A9Q,XR&D(^H:C_A
M[>VWQG(C\"I8T`SQZMXRKG5CIQH</N_)T]%E<?V?3U%!5TT<U-+2;3Q+TT\,
MRB2.567(.&!5AS[],'21UE0X/`UZ]XJG-`3]O4W^[G8%F_XR.#<FW^_/Q''_
M`*O<CVBD=B*0]OV=4(KP/70VWV'87['_`/70Q'_U=[4Q:O#36:M3K77?]V^P
MO^?C_P#KH8C_`.KO;G7NO?W;["_Y^/\`^NAB/_J[W[KW7-=M]@@&_8X_P_WY
MV(N/I]#]]8^_=>ZZCVYV$JR!NQPY8G26V=A[KQQIM7G_`'GW[KW0!3[<WXWR
M;HD_T@:IEZ)E$DO]T,1ZX_[_`*L5:]?8791]/?NO=#\=O;^,XD3L6*.`(5\`
MV;BB@<G]6K[\L3_O'OW7NO+MWL$1&-NQXS*0UG.S<5J%R;6_R_0;?X^_=>ZX
M1[<["6!8I.R%>>^HR?W/Q`8BYXL*[38^_=>Z[?;G832(Z]CV06NB[/P^D_2]
MR:^_OW7NN9V]V`6<KV1&H_"_W-Q)T?['[_D\>_=>ZQR[;[">FT1]D`2EPPF7
M9^(#Z;\J%:O\>G_>??NO=<QMWL$``]B`D`7)VAB+DVY)M76^OOW7NO';G8/_
M`#\=1_A_<S%&W^%Q7\^_=>ZZ_NYV#_S\A?\`T"\7_P#5_OW7NNWVYV`R!5[&
M`87NR[.Q()_V!K[#W[KW72;<["50&[%#$?5CM#$`GG\VKK>_=>ZXKMOL(2%C
MV/=2>$.S\.5'^VKK^_=>Z[_N[O[[@D=CQ#T'T_W-Q1('D0GG[_\`P]^Z]T`/
MQ^V]OK^!]EQ#L1#*W<N^W$PV?B@P'EQH-E^_*Z;<?U]^Z]T8(;?[`O%_QD%"
MJJNN^T,3ZS8:BUJ^]R?Z>_=>Z\VW>P#/)(O8R)$Q&B'^YN*94%@"`QK]9YYY
M]^Z]UY]O;_=6T=D1)_BNS<42O`/]JOM[]U[K"NWNP?%$C=CJ9/4&<;/Q`+V8
M\D&OL./?NO=9?[N]@#_FHBG_`!_NAB1_O'WWOW7NNCMWL'_GXZC_``_N9BC;
M_8BOY]^Z]UU_=SL'_GY"_P#H%XO_`.K_`'[KW7+^[O8`_P":B*?\?[GXD7_V
M'WW'OW7NNDV[V"'+-V*"OX4[/Q&D?[:OOS[]U[KD^WNP"Q*]C(@/T4;,Q;`<
M#\_?\^_=>ZXMMWL!D"KV0BM]"XV7B[_[$&OT^_=>ZX';W8:K$O\`I##,GZW&
MS\0/)S?U#[^PXXX]^Z]U)I\)O2"I^ZK]_P#W%'&PO1)M7&TNJP&I6J(ZR5S?
M^MO?NO=0^W9!+TYVC(&U!NMM\^JUKVVSE03;\<CW[KW7P5/?NO=?_]+:H_DG
M?]NC/Y<O_BI73?\`[RM%[O%P;_5YGI'=_%%T9W>KI_>/,^.:*E=*J=VEJ9"8
MA"MC7SR,7CC@2E@]::CQ[Q\W\_\`(BF%/Q=3=LH/]7H#KH/#_9Z?MX=)\21)
M)%Y"E.BW^U>I8MY$*W%160WN*.%>9)0V@,1S[036$LDTDE,%NC"-_P#%DTOW
M:1P_U<?EUA^ZB4JTTB4\#AM,TS($"*2*EII96BC66G?@:2PL1[9.VS`XX=/+
M(&137/#\_P#9ZD#6HLPTGZD<->XX-_H0PY]T*&,F,\1CIX9%1UZ]OZ?[8?\`
M%/?NM]=AB`0+`-]>!S_O'OW7NN@;<`#_`&P_XI[]U[KD3?23;CZ<#CZ>[6/Q
M7G32?&_05=ND_P`/V2-36?M3K_4`[`&^27\`BWLQY(_Y6-?]-_EZ#F__`-C+
M]G^3I3?S`>YNP.DNK,'N;KS-+A,K4[ICQ\\Y@2J$E,U*[^%HF1[`R6)_/O,K
MVZV+:M[W>:VW"-672#GU)^T>74-WDI054YKU3T/YAORJ-F;?],'*\@8&C`'%
M[6D`:W^N+^\HKGV?Y-CLA(MA&&T@\#_T%T%+W>9(BP\0])7._P`SSO\`V[64
MN.W#W%@<)55N/R^3HDK*''4]1/28BF^\R4D<;L+_`&=&/(?P!S[#)]KN5?\`
ME#C_`&?]#=*;?<V>")M1R.E+1_S%OE/D,=2Y>A[!I9\9504\T%6F#I:B.J@J
M(DEAJ8Y5`6-9HG#"VH<^_?ZUO*O_`"A1_P`_^@NGOWBW\1Z#W/\`\V?N+:VX
M)-MY_O/;6+S]'0+DY<148P5%0M$VMZ=ZJ*&D+*U2C@_TLOM/<^WG)L*A#8QA
MP,X/_077OWDW\1Z1E?\`S5]V=QX([&?O_:&XL/V-%7;=HZ:@CHZ.JW!!3.R;
M@I*(2"*6DK:2N0T\1?3JTD#GVJV7D/D]+A)1:Q^(IJ#0X_XUU[]XM0C4>CX_
M!OYU9'KRKQ/4_;M<\VR*GP8_;VX*B435NVI[B&EHLC(I*G%.ME0W+*QY/L*>
MY/M//$DF_;4OZ3Y"X`*^9K6M1Y#SZK!N8,IC/"O5^N/JJ:MHX:RFGBFI:J-)
MJ>>GF$L<D4H#Q,LBLR,KJ000?>,L\)AFHP(->'#H36SZT]>G14&D7'X_J3_Q
M/NYI7'#IXTJ:<.N]"_T_WD_\5]ZZUU[0O]/]Y/\`Q7W[KW7M"\\'GZ\G_BOO
MW7NNM"\<'C_%O^*^_=>Z+S5,R?*6GTDBW04Y'/%QV'"M[?2]F/OW7NC!P@>(
M#_%_^AV_/U]^Z]UEL";_`)'OW7NN/C37Y+>NVG5<_3^EKV]^Z]UX(H70!Z?Z
M7/\`O=[_`)]^Z]UVJJ@LHL/]B?\`>3<^_=>Z\$4'4!S_`*Y_XK;W[KW7'Q)_
MJ?\`>3_Q7W[KW7,```#Z#W[KW7?OW7NN.A;WMR?\3_O5[>_=>ZZ,:'DK_O)_
MXK[]U[KO0MK6_P!Y/_%??NO=85%I[?TC?_'^VG]??NO=%\^/B+_#>RWL=7^F
M7?BWN?TZL:UOK8#5S[]U[HQ(`M;\<C_87(_WKW[KW7=A:WX_V/OW7NO!0M["
MU_K[]U[K@88RVLKZKWO<_7_;V]^Z]UV8T))(Y/\`B?\`BOOW7NN0``L/H/\`
M8_[W[]U[KOW[KW7`QH221R?\3_Q7W[KW77B2UK&W_!F_XK[]U[KF`%``X`_U
MS_O)Y]^Z]UW;\^_=>ZXZ023_`%^O)_WJ]O?NO==&-&`!!X_VIA_O1%_?NO=!
MSW&`.H.U`/H.M]\_X_\`,,93^OOW7NO@H>_=>Z__T]JC^2=_VZ,_ER_^*E=-
M_P#O*T7N\7!O]7F>D=W\470O?(;8M'VAMSM7KBNK:O%4F^,+N+;,N3H9IZ2M
MH$S6#FQ<V7I:FFDBJ(JC%/40RQ%6'KCYO[Q\YASO\X_I?\7U-VQT_<EN:<8L
MG_`!_.O6J;GL]\T.P>FMWTF3V#W/-W'@-N["_ER;1VQB\GF\%6;RR=)GJK<_
M='=./W%D*BEQ.&QV3V=1)BZ3)OY/)5VT,OU]B@36$11"`0%&3Y^>1ZU\NBT0
MWY[HYF`K4<,4!`_8.DID.HOF-\N=M_$'X[9GK[<6.[1Z+V7\CNJ^PL7VWV'V
MIM+`4S;$GPE-L7?>0WGUU.G]]=SR461BEA8M)1U4J/ZR/:B*ZVM#)XE!VXHM
M0:\>/#_#ULQ[F"2+IJL:G(KC`ZVD_CAUUO'J#H7J#K'L3>DG8F]=A[`V_MC=
M.]Y#,S;GS6-I%BJ\F&J6-2ZNY"!I"794!;DGV`+THUY<F,4CUFGV=">V\3Z>
M'Q6+2:14^IZ&JX;E?H?I[3=/]>]^Z]U[W[KW7(_1?]]_3W:Q^*\Z:7XW^WH*
M^W?^`&Q__$I]?_\`NQ'LQY(_Y6-?]-_EZ#F_?V,GV?Y.DE_-<`;HK;J_2V]Z
M<\$J2?LY+&XL?>;/M3:K+O[LTE`%!\O7J%KY31CY5_R=:^^E;BZJ>!<LH8DZ
M1]6:Y)_U_>;-U%;?NY5-ROPCS'^?H`;E:2.ST'5<_P`Z/CQVCW;D,#ENLJ>F
MI\WM/KWL"GQ56*F*&2NSN=QD>&H<'*I71]IFL?-/'-<7`B6Q!Y]Q--;7SWD_
MA[D1#J.D=M*>G3]I',D,*LQ"@"O0N[N^/>\=XXGIEJ;=,6V7V#MO:%!F\*BY
M.5*JJQ&'H*:LA23&Y6CI@HF@9;RQM[$VW[:SH#+>5/SIT\4FU&C&E>D'V+U3
MV1)\B9NQM@;)G:H3:_CK-RY#<%/687>-'C=J2X?';3AVU)Y6I:ZCW,Z2"52`
M5%S?V0[QR]-+/,\=W1"<?#_GZN'"C2P[N@<JOB3O:BWA\?J?9V$_A=/20;5J
M^TMTTLVV*[&0YG&;JR&YMPQ5G\3>ER45?/5UC*[40_<`T\A+>V]GY:N-6+S/
MVKUL2Q^G5R?5O5N[^Z-XT.R-A8V>KR576K4AF@D1:6,3:*FKGJ&18TH88EUH
M&%_R/8JYOYIM-MY<BVR^N@5MH]+5_P!C[?+K5O`SSZU&&..MJGX_=55'3G5>
MU]@U>X,ENF7%44<=3DLA,9=$@&IZ>E+WE^TAD8JFHDV'U]X+;_N-M?W\US'`
M$B)(`XDYXGH=62^'%0G/0YQ7\:WY-OQ_O'^\>R4$$5'#I2WQ'K)[WU7KWOW7
MNO>_=>Z][]U[HNM9_P!E2P?^(!G_`/?B4_OW7NC"P_YM?]=_^AV]^Z]UE]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4<
M?\"/^G;_`/0Z>_=>Z+]\?/\`BU]E_P#B9]^?[WC??NO=&('T_P!B?][/OW7N
MN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW0;]R?\RA[5_\1OOG_P!YC*>_=>Z^"?[]U[K_U-JC^2=_VZ,_ER_^
M*E=-_P#O*T7N\7!O]7F>D=W\471J-WD_WDRC\%A530@D`_MB82Z+$6L7%S_7
M_6]X]\PDCF*3_3?Y>ITV%%/+L1(SHK^=*=)5D0^,$`^&;SQ#_43:@PE']7!4
M$$\CV6SM*)I-)--71Q:QPM:PZE!J@!ZZ95==#EG6Z'2\CL#H70`=3&X*<,/H
MUA>]A[;USTI4TZ<^EM-:R>&-8X'/7;68!;*%`LJJJHJBWT54"J!_@![U4G)X
M]-D*I(7X>N@```/H/?NM==^_=>Z][]U[KD?HO^^_I[M8_%>=-+\;_;T%7;O_
M`!;]D?\`B4^O_P#W8CV8\C_\K&O^F_R]!S?O[*3[/\G1S>T.G^N^Z,-%MOL?
M;U-N3#TM9][3TD]1-$L-8JE%G'V\L+ZPAMR;>\B]JWK==JOI9+1B@K0'Y#\N
MHFEB$@H>@!'P`^*JC3_HKQ[Z1;4:_(ZC;^I^^'/L:3^Y7-1BT-?'33R4?YND
M;[=%(*%>NC\`OBL01_HIQH#``VKLB&X;6/4*X$$-R#]1[3Q\_P#,6A6^K.1Z
M#_-TP=O13I"X'7!OY?WQ49PYZGQFK\D5N1&K_%]-<`Y_U[^U*^YG,T0"B]_X
MR/\`-U[Z!/X>N!_E^_%.\A_T2XH&4PEBE;D(F!I^83&T=<K1%3R=.G4?K?W6
M?W3YDT#Q+['^E'^;I,^RB1BX6E?GTB^QOY>70&1V/NBBV)UUB,+O*NQ%=2;?
MR!K:Z..ER=44"5C@U9@,D*%M+%2;W/))]J=H]T^8$GC;ZPF$-D4IC]G5#L=`
M:+GH9?C-\8-E_'G9E-A\7!_$MRY""G;<NYIU1ZZKJHX466FAJ19XZ%)`0H2U
M_P`^R;F?FJ_WVYDN+J0^&3737B3YG`_V.C6WL$AB13\8'1H8H%0ARH#A-!*L
MVD*#P`M]-_\`&U_8*[[AZGATL55C%!U*'T%OI[5JND!?3KW7?O?7NO>_=>Z]
M[]U[KWOW7NBZUG_94L'_`(@&?_WXE/[]U[HPL/\`FU_UW_Z';W[KW67W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1Q_P
M(_Z=O_T.GOW7NB_?'S_BU]E_^)GWY_O>-]^Z]T8@?3_8G_>S[]U[KOW[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT&_<G_,H>U?_`!&^^?\`WF,I[]U[KX)_OW7NO__5VI_Y)X8_RBOY=(1AY?\`
M91>G3&I_3J_NK1Z2?]CP?>V+"-M`[NJU@9U65:G_`%#_`"=&EW)L?N'(9RMK
M<=#U\]!/632J:[(YV.L6)FNOE2GHG@66WU"L5_Q]QIO'*LUY<M=1Q@2D\:YZ
M'VV\Q16MLEJ9#X(%*4Z;5Z[[@<3-)%UQ&Q)^T5<GN(B5?[)D_P!QYL2?;$?(
MUW)&LCR]Q&>'^?J[<SJK$1N0GD*<!UC3KKNHJIDINM5<CU*N3W'8'^@_R#Z>
M[_U#N?\`?O\`@_S]:_K.?]_']G^QUVW7/<UTM3]:B_UOD]Q\_P#JA[U_4*XK
M4R?X/\_7OZT'_?S?L_V.N1ZY[FN?\GZV_P#/EN/_`.H/>OZ@W'^_!_+_`#]>
M_K0?]_-^S_8Z\O7/<MFO3]:GGC_<GN/C^E[4''OW]0;C_?G^#_/U[^M!_P!_
M-^S_`&.N(ZY[FL+P=:_^?/<7_P!0>_?U!N/]^#^7^?KW]:#_`+^;]G^QUVW7
M'=%TM!UJ!;D')[B%_P#8?P^Y]JHN4(K=2AA&L_$?7^?6OZT`5/BM7[/]CI*;
MVZ1[JW/!@HX?]&T'\(W;MO<3+_$]Q`21X63RRQW-`>6<7']?;MGRO%83BZLX
M1'/ZCC_,])Y]_M[E66:K`CS!Z,E3U7;_`(Y3487KL2@L*8KFLZOW%OHTE\;Z
M"Q_'L>P-+X$7BM62F?MZ!\ND2N(SV5Q]G7`5G<WAU2;>Z[674`RC/9TKR;<$
M8RY/MW4?7JFIO7KG45O<B24ZT^`Z[EC('W3/G<XAA/`8*/X9Z@/?JGUZU4^O
M68UG;_F=8\)UZT(6\;_QO.7;_77^&<<^]=:ZPT];W`\<C5.#Z[CENWVRIG,Z
MRS?TU$XWTGCVV\4<GQK7K>IN%>L)J>YV\1&WNNKM;[H'/9_]MUXM';'`<+;_
M`%_>XXTB_LUIUO4WKUF-5V^)D$."Z]\10V/\=SHO8W(T#&6X/YM[NW?\6>O%
MF.2<]<UK>Y2'_P!P77E@2!_N=SI_V_\`N+X]Z50F%%!U4YX]=1UW<Q4DX+KS
MCZ6SN>(^GYOBS;WOKW7:U_<I4$X+KV__`&O<Y_Q.,O[]U[KS5_<P*6P77I!/
M_.^SH_(^EL7;_>_?NO==BN[F]?\`N"Z]X/'^YW._T!Y_W%\>_=>ZZCKNYBI)
MP77G%[6SN>(^GYOBS;W[KW07R[8[N;MV#L:/%]<S4K[`CV/44<N;SX:E;^\W
M\;FJHB,;Z]42K]?Z>_=>Z%)JWMZ.J"QX?KUL>$:\W\:SHE,QY"A#C;:23]??
MNO==0UO<Y@G,V"Z\2==7VZ)G,ZR2V_268XRZW'U]^Z]U@CR7=0IHWJ<!UU'4
M%M,J)GLZ8U.HV"M_#+GBWOW7NLCU_=)F01X+KLT_^[7;.YX2+]+Z0,:![]U[
MK(U?W)K?P8+KV2&_[3MG<ZK,+#]:_P`+-C?_`!]^Z]UC>O[G6$M_`NO/)>Q'
M\=SND"]OK_#`=7OW7NN8K^X["^$Z]!MR/X[F_P#B<;?W[KW7%:_N9G;_`'!=
M>Z0?J,[G2;?UM_#"/?NO==FN[IN=.`Z](_!.=S@/^V_A?OW7NN35O<HC!3!=
M?&8CE&SN=T@_T'^XS^GOW7NN*Y#N72/)@^O%?^THSN;(!_P)Q@/T]^Z]UP^_
M[G\@U8'KP0GZ.,]G=7^O88RWOW7NLGW7<7E8C!]>Z=3A9/XYGK^,J"I(_AO!
M,@M[]U[H,>N=K]W[,Q6Z8GPO7<M;F^P-Q[EC@&>SPB^RR\-*(9&E..)\GF@-
MU_I[]U[H2S7=S#[<183KR7TI]X3G<Z#$]AK"#^&F_-_]?W[KW7/[WN?[N15P
M?7C4/^Z9QG,]Y6]()U(<:0+-<>_=>ZZ:O[E*%H<%UZYYTAL[G0"02#S_``S_
M``]^Z]UU_$>Y1#$6P?78J6_SL?\`'<X(U.HBRL<82>+>_=>Z\F1[D,JQO@NO
M1="QTYW.,18VX'\+%^/?NO==FN[HN=.`Z\*_@_Q[.\_^LOW[KW79K>Y]-S@>
MO0WY'\=SH'Y^A&,]^Z]UTN0[CTC5A.O0?R/X[FS^?\<;?W[KW7ER'<NLZ\%U
MXL?]EAGLV6/]?3_#/Z^_=>Z[>N[FU'Q8'KUX_P"RQSN<!(_Q`Q9MS[]U[KSU
MW=`C!3`=>&3\J<[G0H_V/\+Y]^Z]UP&0[F")Y<%UVLC?J49[.6')M:^+Y%O?
MNO=9Z:O[<%9$*_$;"3':E%1)1Y7.3542_4V26@BB/'^/OW7NLO;[^3IWM)R5
M);K;?!.@W6_]V,H#I)^HO[]U[KX*?OW7NO_6VJ_Y)2+_`,-&_P`N<WY_V4CI
MP?\`KJT9_P![/OPJ,^73+0:CJIG_`&:_Y>K.JA"?2'FLKI80V211<WU,]U>,
M@?Z_OPN8D-2`3\^G4UIBM1UQ1I6L5,<FFUS=A8?[2NGAF'X_K[0O/=F1_!2L
M9.,^756\4DD'J2GD*@V87'T>X8?\&!Y!]T\:[_@_GU[O_BZ[(<VX^GT]7OWC
M7?\`!_/KW?\`Q==_N?[X^_>-=_P?SZ]W_P`76.TP+&]U)O8#G_;W_/OWCWG\
M'6JO_%UR426%O][]^\:\\TS]O7N_^+K,`U@3]1_C[,(B3&A<=U,]5/B5.>NO
M&+ZK<^KFY_MVU?G\V]WQUK]3UZXW922`9?J.-(,?TXN?=3T\M:"O'K,EB@)'
MUYL;,;_XD<$^_=;ZCDL7)(>-(W9G)*%9$(%N`"UN/I]??NO=2([%%((:XX8"
MUP?I^!^/?NO=<M*\<#CZ<#C_`%O?NO=<&#`'01J+7]7T`/U^GUM[]U[K'>[`
MV8\D*8BI4C_$_5>??NO=9`_T7@2%2]OJ..+DC_'W[KW47R274"^I6UL00(3&
M3:Q>UKC\#W[KW6=2+*M_W"I<:@#P#^2!:W/OW7NLB7*J6TDV^J\K_L#[]U[K
MD>`;6!_QX%_\??NO=>7Z#]/_`"#]/]A[]U[J&^IGE56*JPT!RR`K(#RJ!AS<
M>_=>ZE(`46ZD<"ZL!?CCD?2YM[]U[J'/<&0^>2-.+$!2D9"F/2/SR[`^_=>Z
MR(+1H'U2L`+):Q8BP,CAN0=5^??NO=25L1<`"_\`2W_$<'W[KW7*UOI[]U[K
MJP(L0+?TMQ[]U[KUA_0?[8>_=>Z]8#Z`>_=>Z[]^Z]U[W[KW76D?T'OW7NO:
M5O>PO[]U[KQ4,""+@VO_`(V]^Z]UQ,2&_I^NF_)_L_I_/X]^Z]UV$0,S!0&;
M]1_K_K^_=>Z["@?06_UO^*?3W[KW7K`"P``YX'`Y^OT]^Z]UQ\:6"Z00/H#S
M_O)Y]^Z]UX(@((4`@6!_-C_C[]U[KG[]U[KWOW7NNK#^@_VP]^Z]UQ"("6"B
MY^I]^Z]US]^Z]UX@$6/(/OW7NN.A+`:18?2XO_O?OW7NNC%&=5U#!N&#>I2/
MZ:3=?]X]^Z]T''<*)'T_VHB*J(O6^^;*BA5'^_9RAX4``<GW[KW7P4??NO=?
M_]?:O_DDJO\`PT7_`"YS;_N4CIO_`-Y2B/\`O9]^.10\.MZCZ]'\["V+1[\Q
M=)B:G+[EQ$=%G\?DTJMKY.2AKVD@D\STM6Z`WQLEK2(?JOMEK>%_BC!Z]4^O
M1$?YAM!W-G\;T)L[IV'?^4KMR]I'';@H>O\`L"'K6NGP./P==6(U7N^JQF3I
M<?3"LBC$ID0>2UEL3[O9,$W9K;7IMAM\K`4J`PH%/V^0_;U8BJJ:>?12,QWA
M\X_CWLS-;3WWV]LG;V,ZMVUUIMO<W8V[>OLCVA5[3S'9,DM6-Y[KSE#7X3^]
MV-V+3P+12K!3Q+62522R21K&02R::9-J@N_'83->QQ\`>T@%J_MZ\*YJ,]!%
MF_YI?RSV]N_;/WV.V#6[9SO0>\]UXBDQ&S<E+4[@W#M?#9[*8_M&M@KJZDW+
MA-@YJ##I-X8Z26"(2^/SZK7.YU"32*OP@XZK7I-;P_FJ?,7;FR.LJW9L77_;
M^)W7O7[.F[UP&RQLW8V^S+MC;.X6Z]P&*WAEZ54R-%F\Y+@Q74TD\D]3`2(P
M_'MKK6?7H=-Z_+SY*;SPF],@W=FT>J\SLGO3K/$[PZNH.H,]7;CZQV)D:RLH
M:G"[KW)5UL=+N!NP96IS'54T:+0:O27%B=ABIJ#GKU>O9#Y[_,'9O4&8@P/7
MU'O7L'9?5#=OM4U>WLG3T>5V1F32X_`TDC3-#3C/8W+/6>4RRQF2*@)=4$A(
M\6+$DG/7NCP?R[?ECOCY&=)8;.=T2X/&=G5N7W.N*Q^..&I*G=FT\+7-34&Z
MJ?#8#(YO'4U/D8KE4AJIDNOZB;CWZ;L12O$CK?5:77G\QWYL]U]S]D].[%RF
MP=M-ENP=E[:Z^W/G.JJS+?Z,://[NWA@LS1;UP])GH),MDL;0;8CF"5,E#*J
MU2M(%](*>U=I6(<XZ]CI@[(_F<_+F+L3KKK>F.U*!-S]7Y3$;_Q&$V=D%ST6
M\LIL+?&4QO9.SLS/4/F,;08S/;=IE%)+CI:6)J@1R2WM=2X`=@.'6NAOW]\Y
M/F#L;J[?F!V^FQ\=N[I;KC8^^MU]B;WP2+@:S;W9L&#EV+"CRY2DPT6YL9C?
MNI\NU5-'$T\\2V0\>Z]>Z!/<_P#,U^5F$VOLKLO$8S$XO&;NW-TI3;GQVZ]J
MM%DLOC=P["QV6SN.V!B<ED*#;RY#-9FI?4(JVIJ&#Q_:Q27('NO=6:=[?*;L
MW87R%ZBV5A=Q;9V7L_</4%7V''M/>>R,_E=P=S;Q#Y2&3JW:>XL:PI]H9[`T
MU/354XEBGD=9BND"Q]^Z]T0#'?S!_FKO"'.4'6FZ>LM[34>#WEO3+;GQ_36\
M8\3L#,;4V=4;HJ.BZZEJ:B!L_NNFK:,TDE4ICF=9@PC5TT&D!+SNC9%>O=9]
MT?S"_EYLG/[1V/OS?/4N`W)D<9!NVDA7J/=LD_:K96LV\^/ZBVS3_?NN$W#3
MTV<DIZC(:IF+0ADBU:PK]PH1-2=;Z#F7^8/\Z<#VULCI/";0C@IMVX[/)%7[
MQQ>'CW5FLOGZG/QPU&+BR>1QE;)#UO\`:0^*CIJ:5\@JVF>*_+;U%M#(/B*Y
M^WIJ`EYW1OAKU)ZJ_F7?,6B[6ZPZCS]#@.PMMR];8^/-[W;;=%M[*[^R^1PN
M?ER&_,7AYLFFY:*BVMN2DIZ*MIZ:CGHXR_,P:WMFT9I7TNU<]*[I5C%4%#3I
MH[F^?WRYV?VGO_XX8;<]'!B\%U9/`^=K=D+7;XVAO/'P;7W,W8=?+A:VLKZK
M:59%E*FBCBGHH4ECALC%KV4/0.P`Q7I+&244GC3I=Y'^99\IL1DNA\?C]R];
M;XV!N_LG.]<U?:F`Z[K<=D^X*=!3T-#EM@;&SV7Q]8:/;=15L<B:%JJ8R4[#
MQK$2XKU?J/C/G-\T-D?'K>VZY^SMI;HDZZPVT=L1[GRG2\\&2JM^=@;JW#2'
M,[F@EW!08?&X#8^.HH1,J.T3B1?+*G!/NO=*KKGY\_*3O#K22;+=E=?].[XK
M_C5G]TX':Z]3[CRFX]^;MH\)FY\EVELNI^[EBP^V]F9#$(CT$\<XJI:A`)`E
MBWNO=#E\C?FEW_T5UK\$MR;2W#M?=V$[2@V50=N;FJ-HJV;W549K$89'EVW@
M*C)4K8[(5.0K))9Z>'S52$-ICTCCW7N@+[6_F(]P;LQ6RL#M_?NW>E]R;*W9
MLNJ[YW=D^M]S9K#==5U7VUNK:-=C=V8BNBHTEPB[*I**NKZ:*;7$\B-Y%!M[
M]U[J90?./^8'ON(Y?:<W6&V-O#;VWZ>@K,YU+NVJFSN5GZ_W7O"?=M&DU?2L
MF&W!)MN`4M&462,5P!>ZJ&:@+-<2+(?T@>M^F.@AW=\I/F)E=Q[GW+#WO!U-
MA)\5)G#M:HZDJMRT>3JL3V3U:,]%@LI65]'+B#CMK;@JS+:.<&E(9@I!/M7>
M!4A`C2CCY]:\^G38G\TWYB[IR?=]#N_"[$ZPVUMO>^W\#4=D9S:HW-CN@,!F
M.P<MMU:O>>T-N963<6YFR&V,;3Y&,U:4)B6O74"H#,DAU&)"YJU.O=76_!'>
MF[^Q/B7TQO;?F:J-Q[JW'@\QD,IG:G&SX>3+*V[-P1X^N3%U4<5304U1BXX6
MABD4.D)4-<W)=Z]T;?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=!OW)_S*'M7_Q&^^?_`'F,I[]U[KX)_OW7
MNO_0VL?Y)/\`VZ+_`)<__BI'3?\`[R=#[]U[H^?9>3[!P^$6JZ[VO0[LSC9:
M@@DQ^0S2;=@CQ575^#+9'[KP5!DJ,-1'RP@BTC&UO?NO=$;^5?S:W'\3>J>L
MM^=E[!V3C-T;\WI+LJ?#;A[$H\)LW;,T25]719*;=+T%3]S45M'"I6)81(2Y
M'%O:58D?>R#,RJ-ND;`K6A&/L)P?3IS510/7I<;*^7M%NSK_`'IOS,[/QX&R
M>DL%W-DXL!FJ7<.&R>-R5)D<K'C<)E3!3BKC$.,\BR.G+MP`?99/$6VBVDU&
MAOXUIY#AG^?6U;#8Z1?R"^97Q_V^VQ]B]H;:RV_]B]R["W1E=RR]?8RNWO)L
M7%XG#;=K<]1;]I]FR29O;&*BQNXDEJJZ8P"FIT(/%R!!**22`$D`^?31XGIM
MS/\`,M^&G6>4[`ZUK\KN*-NG-J8C.5M'2]>9BNH,UMQZC%X6+^Y5?2Q/3[K:
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MD`SD5Z]7AT/^R/D!U5VGN!<-U]'7[MJ$H\+D<M546V,C)A\)%N7%)68V/<>3
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M[[6J<F&KG@=5/'MJW_MY`.->O8J.@X?^8Q\%,[FMJ=S8J3?>Y-TS0Y_KK%OM
M[JK=FZ-VX':N/IZ7>62S.:V[B161[<V)48JK@R<&7J(T26D8NI"B_M3<A@K:
MA2O6ZY'0M?[/IL2?HGNOY`X[K?L.JVQTQV2.NACZO:-?B]R[K\FX=O8H[IVK
M1UT<4V5H*U]P(\,<%W>VE?4P'MEL6L1!K5>FX`#<.#Z]-]7_`#*_AU1Y786)
MK]YUV`RF^ZC(8DTV1V'D,)D^OFH<T^W:J'MFFR--35W7$<FXU6B7[I")GD50
MMV!]M6?]H=/'I^X!"D'T^WKV4_F<_$V@PO8FYJ^'LY8.M*?$5E6?]"V[UJ-V
MX/*92LP]/FNO4EQT<F^MOU%=C:B\E"7&B'41I]J7!#L#Z],1?V:?9TJMB_/S
MXN]K=@[&ZZVC6;NS>9WGCL#E=L[HI^LL\FRD?<^%GW+BL%6[W%(^'P^9J<53
MNTM(\Z3"1&5N01[KU?IG[)^9N=V7N7?U?@>@LUO#HCJK=N)V1VUV?1[DVYBI
M\'GZFHQM!DDP&S*P_P`2W%C,+5YFG2J:$:IF>\88`V]U[H<NK.]L?V3VGW;L
M:#8VX-O5G1<FTJ.#*9>FH:5=T8K>^`DSJ5V&A!\D5(O@6&.(E07/TO[]U[HH
M6=^>?;N(W-G-B5GP^RU1V9+FL92=<[2DWIM9J//;=J#D*[+39[,N)(-L[IQ.
M)H%KIL8_[IAFB;GD^_=>Z&G:/S1V;O?=&SMOG:.3VQ@=Y=-YCN6OWSN^GQU#
MLW!K@YY*?,86"K?6,SD-OU--/]]5(&B5T"7!8>_=>Z$SXK_)#`_*/9.]MXX3
M`U6"QFTNU]W]:0"NGIJP9B#9AH4I]QPT]&]\;2[@I<DLT,;'4L96WO<J^#&)
M/45Z]T:.+%XZ:G5:C%T@!8NT,D44JEP0@=_3HD:1$4L2#JL+WM[303^,2#U:
MG#J6<;CW,C/0TK--8RLT$;-(18+Y&927T@"U_H!Q[44ICJIZF(B1J$C54119
M54!5'YX`X^OOW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z#?N3_F4/:O_B-]\_\`O,93W[KW7P3_`'[K
MW7__T=K'^23_`-NB_P"7/_XJ1TW_`.\G0^_=>ZM$,:-]5^C:^"0=7UO<$'GW
M[KW17OD3\<<=\@Z79M.W9/:W468V%NP;CV]O/J#,X;#[MI\A)134$D<K[FVO
MNO#U5!)22L@,M+)I!N#?WI5"S&=<3&,QU_H-DK]AZW4]`5NG^7SLW>E3A*G<
M'>GR0JJU=NXK979-=#OC;=+4=V[9P5?/D:/"=P+2;(@HZ^@7SN#-BX\5-,DA
M5F*\>VS#&85M]/Z(D#@>6H4H?RH/ECKU3GIX[6_E]]`=CY#"UVWSN'I*H$&X
M\9NL=+2;;V3)VAAMTX['X7/8WL1Y-NY%]T)E\/BTIGK)66O2%;1SH?;[,SL7
M8U8\>M=`G+_*,^.!W/V%N;%[I[=P+[^PNZ=OS8/&Y/95;A]OXK=T^&J*^#`4
M^0V-D/XQXY,/'89J3++#'(Z*`M@*]>ZX8C^3G\.<1NC:NYH\3N'+U>U-I+M&
MNQV9CV)D8]YT46&K<%19/<V0;8']X<=58_'9"9*:/"5>,H8[@+"``/?NO=&,
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MO9._\)L9)JC:&5DW342-M[9^.J,Y2+E_[M[.H](I`PBD1F8?IL/=R234\>O=
M)W._!O"9+>_96<H_D#\C<!LSM?);MS>_ND<+N79475F<J-^86NP.ZZ=\?4]>
M5.Z(Z'*TE87$<>5#1U<:E&`NIUU[I0S?"CIZ3=*;GJ(]RU53+UO6]8O1RY=:
M>EEVUE>K\9U%5TP6.DAJ8ZR'9>+0K(LD>F<LX&JUO=>Z"#&_RR^F*"@,.Z-^
M]Q]@9IJD2/O3>&[\159^KQE!1[3QFU-O5;XS"4%"<)M3";)HZ2@)A\X4.\SR
M.VKW[KW2V/\`+Z^/]5@%VC6P;KJL-44>`QM;0Y#/4]0F0QN&I]U4]%2U#Q8Z
M`305L>[JN*M`(615C6WI-]*`K%EPW7ND%TQ_+#^._1."DP^UY-TD5.+[#P-3
M55E-L7;M4V*['VK!LJ7&K2[,VEMZDGJ]N;;QZ#&2R0M/87E>5KGW=V:04<U'
M7NAEJ/A9UU-U'V/TE%O/M.EV=V=N/%[K^YQVXZ.+/[,SN/DPE7!D=GU'\!2+
M%0+D=O4]04G2J43%OJIT^Z$554/P@8ZTH",6448]%]S?\I[XP;JW?LO>>YZS
M?^[MY[/K:W*Y_=F[Y-G;IR_;N9R^X/[QFJ[#S6:V'65$M<N3C5R,&N&>)$"A
MROI]^11&VI!1NK,2P"L:CH`>O/Y3FZ-WMV%2?(SN#=U;MNHR^)I>G,3U]OUM
MSG8.U]KYO,Y6CQ<:[[ZX;%T--/\`QJ2,4KTF4:-1Z:K@6L26)).>J@```<.C
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MJ*EP>7J'J\;F-N;H,;Y>7<$K)%53Y2MKH?N)9D:.\SE@`+`>Z]T[?''XJ=2_
M%#"[YVUTQ@JS;N#W]OG.=A9K"SY6MRT(S67H:.B:FQ35M14ST>+A6D#(KNSW
M8W)XMMR9%5'-5`H.O=&AIM)IX2`/\T@(4Z@"%"LH/-]+`CVTD4<?P+3K=3UG
M^GMSK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW0;]R?\RA[5_P#$;[Y_]YC*>_=>Z^"?[]U[K__2
M,]_+M_V9_P#V1;XG_P!RO^@AS^Z/^@SK_P#NW_LLO_#/_P#LO/\`!OX'3?8?
MZ%/]/_\`QF[_`$9_;Z?X/_>O_<]]CX_O/W]?OW7NCF?\YC?^%1W_`+0A]^Z]
MUP_YS$NW_<4C>XO_`-N);7MQI_%OZVX_K[]U[K@_^SAZEU?]!25]?I\7_#%%
MKZ/]V>+TVM_JN/I^??NO=>;_`&</TW_Z"D_HMM'_``Q1;Z-:^CC_`&_^%_Q[
M]U[KF?\`9Q+&_P#T%)6T<V_X8EO;GZ6YU_ZWJ]^Z]UQ3_9P[>G_H*3MY&_7_
M`,,47U?G_.<^/^G]G^GOW7NN+?[.'I:__04K:_.G_ABG5?6/TZ?7;5_3BW^%
M_?NO=<_^<Q+C_N*2_/\`WHEM_L?Q?_7]^Z]UX_[.)^?^@I+\?3_AB;^O'Z?\
M?K_A_A[]U[K@W^SA?G_H*5_S;?I_X8J_3^?T?[L_I_;_`*>_=>Z[3_9P[26_
MZ"E/HNK7_P`,4W_3QX]?-[?73^?KS[]U[KH_[.%I:_\`T%*VNM[?\,5:KW%M
M-O7;^MN/Z_GW[KW7)O\`9Q/3?_H*3_6+:?\`AB?ZWXU:/['];^GW[KW71_V<
M/F__`$%*?I6]O^&*/IJ%K:?[5_K;FWUX]^Z]UU'_`+.%8:?^@I6WKMY/^&*K
M_P"U7\OJ_P!:_P#L/?NO==_\YAZ3_P!Q2MN+_P#;BG5]?Q_;^O\`3W[KW7,?
M[.)J?_N*1O8:K_\`#$NFUN-%_3>WUT\W^O/OW7NN+?[.'IY_Z"D[<?I_X8GU
M?C_4>N_OW7NN+?[.'I>__04K;U:M/_#%.KZ\Z-/J_P!;3_L/?NO=9#_LXGCY
M_P"@I'3I_'_#$ODM;_:?W=7^\^_=>ZXO_LX=A?\`Z"D_TO;1_P`,47MHYOHY
MU6^E^;_3GW[KW7E_V<.Z6_Z"D[Z?3J_X8HM;0/UZN-5O]5S?_'W[KW72?[.'
M9=/_`$%*?I:VO_ABB]K\ZO)SJO\`35S;Z<>_=>Z[?_9P[-J_Z"D[72^C_ABB
M][C3I\?JM_6W']??NO=9?^<QO_"H[_VA#[]U[KW_`#F-_P"%1W_M"'W[KW7O
M^<QO_"H[_P!H0^_=>Z]_SF-_X5'?^T(??NO=>_YS&_\`"H[_`-H0^_=>Z]_S
MF-_X5'?^T(??NO=>_P"<QO\`PJ._]H0^_=>Z]_SF-_X5'?\`M"'W[KW7O^<Q
MO_"H[_VA#[]U[KW_`#F-_P"%1W_M"'W[KW7O^<QO_"H[_P!H0^_=>Z]_SF-_
MX5'?^T(??NO=>_YS&_\`"H[_`-H0^_=>Z]_SF-_X5'?^T(??NO=>_P"<QO\`
MPJ._]H0^_=>Z]_SF-_X5'?\`M"'W[KW7O^<QO_"H[_VA#[]U[KW_`#F-_P"%
M1W_M"'W[KW7O^<QO_"H[_P!H0^_=>Z]_SF-_X5'?^T(??NO=>_YS&_\`"H[_
M`-H0^_=>Z]_SF-_X5'?^T(??NO=>_P"<QO\`PJ._]H0^_=>Z]_SF-_X5'?\`
MM"'W[KW7O^<QO_"H[_VA#[]U[KW_`#F-_P"%1W_M"'W[KW23W]_LW_\`<7>G
MW7_03W]M_=+<?W'\:_X8R_@_@_@]9YOXM_!_]RW\,\=_/]K_`)1XM7C]>GW[
4KW7R]?\`<'_V9?\`[$3W[KW7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g912919dsp_284.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919dsp_284.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X1DK17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-3HP-#HR
M,B`Q,3HS,3HP-@```````Z`!``,````!``$``*`"``0````!```!H*`#``0`
M```!````_P`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!?U````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`8@"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[GH/2.DV="Z;99A8[WNQ*"YSJF$DFMG)
MVKD\7J./5=U>[)^P6MP#F&K$M=AC^8R'4T4G!Q\)G4Z7/H;Z=5K\K(WV^G^A
ML]>M=O\`5W_Q/],_\*4?^>V+)J^N),-NQ!ZE#<HY]=3]YJ=CY#>G8[&.L917
M^NV'UV/R+,:NFBJRRS]])3@.ZVUMQR+.F]-IH?A5VC&LK:U]5UN:[IMCKWW,
MHW?LNL?Y4J_5_2O_`$?K55_IT>CKF,^_I[;.B8-;,K[&VYNUCB'9PS!2^FVI
MEE3J?U)EV_\`T%W^D6X?KATW(9CNPZGVC*KQ;O5M86U,KR\AN`QM]K19LO>_
MU?3KV?I/1^GZ/Z5$Q_KGT>]U30V^LY-E->-ZE9:;69+K*\7-J;._[)<^BS])
M8VNS_@O3MI]1*>6HZVW+HQ;:.E85F4;LFM^)0REU5AKPSU*G'.0RO+9<_P#-
M8_#RJ_\``_:/3]^(K3.N8=O4>G45]%PAC]1VV5&QE==EF/=?9BXUM#;`S=97
MC5,ZCD5-9;^BOKI_0_SJZ'IOUOZ1U#/Q^GXC+?4R\=N76YS`QNRP/L:?<X6/
MW;';[::[:&6_HK;O7_1K-Q?KVVSK&5AY./77C83\SUKF.N?953A&QMN;;7]D
M;CNIL=4RO;C9=UOJ7UU[$E.1U+)&/]8LS"H.)8&>L,7!%%!#7LPCE559F&_&
MJZFVMU_ZS^U,3+R\2W^B^E3ZGZ*6!]8NGG$I;=TK!RLL5UO-=3&>I>#TZ[J]
MMM%(K_[F8_V+VLV>I_PBZ+'^N_1<BS$8QEHOS;G8H8YK`YCVFF6V/]7T[/;E
MX]VS%LR;/2L]3T_T5_IQ;]>N@G%S,G'%EM>%&[TPSWUE]N/]HJ+[6,;3Z]%[
M/UA]#_\`@_UC&]=*><QNMU5LR;KL#IW419>S$PQAUL=4W)MQ<;(PJ*[/2WV8
M^5EOR:KK[W_J]JU^MYG3^F=8Q\$=+P'5O&.7->QK;[SDW'"-?3:O3V6.P8^U
M96]_\UZ?\U_/HV7]8_J]FVX]XP\O/=A/JLP!54\L?=?C_;:O0J<^JF[)IZ:^
MS)_3L_5?\'^L65>I=Q?K/C7]:?TJZBVM_K&G%O+2:WN&-1U!U;W.#7XV3Z&1
M;^AL9_@?I^I^C24\A=?G-^JV#U!M>([/RNIW4O<S&I+#12<W=BTL?C[F5/;@
M_H_IY'_#(/\`SFIP<'(S<C!PLHVYAMP\>ZFNMWV!].'G545/JJ97Z]6/U&MS
MWVONO_X#(_2^AMXO^,;ULC'KMPFTLMRKZ;[#;(KHI;OKS-OI>[U]M[=G_=6U
M6<C_`!A8!QF9&%B79.ZC+O(=#?2.+17G,%Y;ZK6MRJ,FG:YCM]7J^E;7ZWJT
MUI33LZKC4Y%[KNC8!PJCDV%S&3:RC!S:^FY]]U?H[?Z-=]LK94[_`+3V5_X5
M3SK,%W3>AYF57B]!JZG>[[1<VO&]E+J,K*Q*WVY^/;1799Z6+ZWZ+^=_1,5_
MJ/UGZ'E]/NQ>HXN66$V-SL3TWMLKJH;1DY5^3Z3V?J;*<K%?9MM_6:LCT/0N
M_2TJ5_UYZ?3DO#*;;.GX]6399F-:=KCB.QZ;&X3&@_:6,NRO2NO_`$5%/H^I
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MCTLG9^G]_K5=/L_H[/2RUI()`D<'P3;&1&T1,Q'>=VY)3QW6;\3!ZRW"Q>G8
MEGVD8553+JF-K8_*?U!CKW-91]H<YOV*K]'ZO_;/\XKE5/2>I?4\]5;T[&HL
MR<!]VUM3#M<ZISB&NV?FN73JEUO_`)%S_P#PM=_Y[>DI_]#T3ZN_^)_IG_A.
MC_SVQ1N^K?1KK,RU^.1;U!]%N58RRQCW/QBUV)8Q]5C'4/H<S_`>FA=(S<;"
M^KG2K,I_IUOQL=@>02T$U-/Z1S0?29[?YVS]&CCZP]"-=MC<_'<VAK76[;&N
M+0_^;W-:=WO_`#&I*8X_U:Z+C4BBC&V5-&.T-WV&!B6OSL,>Y_\`@<JVRW_A
M/H6_HT)OU2^K[6.8W&+6N?6]L6V@UFES[L9N(X6[L.JBRVUU5.)Z-/Z3Z"/9
M]8.BU;O5S*JG,+@6/=M=[26.VUOA[_<W\SZ:>KZP=$N<QM>=0Y]I(K9O&YQ`
M+MK:_I[O;]%)2/&^K/1L6W$MHI>W[`T,Q6&VUU;(:ZEKVX]EKJ?6]*RQGKNK
M];^6G=]6^B/C?B,?%F1=[BYWNS`]N>/<X_HLIMS_`%:/YCZ'Z/\`15)\7ZR=
M!S!5]FSZ+#?M])F\!Q+Q+&^FZ+/4_P"#V^HH-^M'U>=4RW]H4-988:7O##,;
MO>VS:ZO_`*XDIB[ZJ]$?33195;93CO\`4:Q^1>\.=NKM_6?4N=]K8VS'I>RO
M*]9C/347?5'H#FO8<=X;9<,C:+K@&6`W/_5PV[]68YV9E;Z<?TJOT]B)=]:.
M@4`&[.J8'5^JTDF',G9NK,?I/</HL_[^K^+EX^76;<=^]@<6DP1J/)X;XI*:
M'_-CH@Q/L;*'5TAS'M].VUCVNJI9TZMU=U=K+J_U&IN,_P!.S])5_.?SEB+5
MT#I%%]615CAEM%GK5$.=#7^@SINYK-VS^A55T;-NS_"?SOO6@DDIR*_JE]7J
M]FW#;%9#FASGN$M=DV#<U[W->W=U',]K_I^M_P`'5Z</^9WU>.,S&=CO=56V
MQC-U][G!EU;,2^GU77>KZ+\:JJKT=_IL]*M;222G*ROJQT3+-CK\<EUSW66N
M;;:PN-E=6-=6]U5C-V/?1BX]=V-_1[O2_25)'ZL=%^T69+:7LMN%FXUW7,#3
M<:[,A]#*K6,QK+[**K+;<=M5F]:J22FO@8&+T[%;B8C"REA<X`N<]Q<]SK;'
MOLM<^RQ]ECWO>][U82224I))))2E2ZW_`,C9_P#X6N_\]O5U4NM_\C9__A:[
M_P`]O24__]'T+H-5=OU<Z;7:P/8[#H#FN`((])G+2KK<3%:-K::P(`@-`$-U
M;V_-53ZN_P#B?Z9_X4H_\]L5B_(R:[0VO&=<PC5[7,$'^K8YJ2F?V7%EWZ%D
MO,O]HU),R[3W>Y,:<1GN-;&P9!+6C4=_Q6%UKZPV-M=BX#MI9+;+^2'#1S*I
MEOM_/>N;R2;6O?:38XM(+GDN,1^\^5G\Q\4Q8I\$0<D@:->F`/\`><KFOC6'
M#D]N$3EF#PRH\,(R_=XGOQB8#VL`HJ<UA;97#6P',_FGLC\ZO\Q.W$PN&TUZ
M0(#&Z>'9>*XF7E85GJX=S\>S]ZIQ8?[6WZ3?ZR[;ZM?67#ZQ>W`ZY2Q^8\;:
M<F-K;"1#J[&-VLJO=M]NS]%=]#]'9L]6QBYJ$SPD<).W9ZWGO@/,<M`Y82&?
M''Y^$<,X#][@]7I>W;C8X!VU,`(VF&C4<;5-E==<[&ANXR8$28#?^I:G;]$1
MPG5AQU))))*4DDJV3B67/:]F3;C[1&VO9!_K>K78DILK'I^K73L=U1HLR6?9
MWM?6T9%I:"R&QZ;WN9LL8WT[/^#4^JY%73:'9F5F7,K:X%E;0R7'\W'K;LW/
MW;?WO^$^@N(ZI]:NK=0>X-L.)03I32X@_P!NYNVRS_H5_P#!JURO)9>8)X*$
M1O.7RMSD_AV?FR3C`C"/S9)?+Y?UGKKND=-Q<@$G/#7%KZZ\>S(]%FSBMM>(
MX,:USOTCV6)_V3T6O?2:<IPLN%CS^G+2]NVW?[?T36.W?FMV?SB\OSB2YEA)
M+]3N/,Z?G*]TGZV];Z78WT\AV10#[L>\E[2/!CG?I*?^MN_L/53G)#E>9ER\
M_5P\/K']>/'\KI3_`.+>?VS/%ECDD/T"/;O^[+U/J6#=CUU48M-=K:VLVUFQ
MCFPUFD.W!JNK*Z3U_"ZETUN?_1V@`W,MT+"3'N=^=4__``-O^$5QO4>GN8+&
MY5+F$D!XL:1(&]PW;OS6>]*,A(6#8+A$42.L28FM?5'TR;*I=;_Y&S__``M=
M_P">WH@ZETXAI&520\`MA[=03M]NO[R'UO\`Y%S_`/PM=_U#T4/_TO1/J[_X
MG^F?^%*/_/;$WU@S78?3G.K.VVTBJMPY!<"7.'\IM;7[/Y:?ZO?^)_IG_A2C
M_P`]L65]<\BNAF(+7BMCC8?<0`2!7'_5*#FYRAR^24?F$?37>7I:_.2R1Y?*
M<0,LG"1`0'%/BEZ?3&+SX```&@'`4;?YM_P/Y%5=U;I[3!N'R#C_`-2U"MZS
MA^E:6;[!76ZRPL;]%C1[K';MOM7,0PY92%0EOV>8Q_!OB<JF.2YD8P;,SARQ
MQ@?[24>!YY:&%TRY[?M%SSBTLAPM)VN$>X/9N^A_QCE/&Z7U%];#BC$&2^"W
M[1<-PD;JW45.:RJS]_U&69*AF_4CZZ9;P[(#;SR/TS=H_JL.UC/[#5T>'D,)
MF(\WS_+?#O#/.)YCA[PP\48?X^5]*^,?'^;R@X?AT3BQS&O.2C[D\D#UY3%\
MG#+_`#^7_P`)?3^D=1RNK=.HS,+)I<T@UVDL+P;*W.98]OINI^GM6ICMR&L(
MR'LL?.CF-+1']5SK%R7U`Z#G]/Z'?@=3#Z;!ENNK]*W7:ZNMGTJ7?O-L]BZ7
M]F50&^OD0WB;7'@;9U5V8Q1D8X<HYC%$U#/&B,T?W[CZ/4X4`1&(E9D``;WM
MNI*JS!:Q['^M<[89VNL<6G0M][?SN5:35RDQ,)TSC#2?`)*?-_KAU*W,ZLZE
MVX4XOZ.EI!;)_P`-<-WTM]GM:_\`T=:Q%Z2<>C)QF5Y%;;6%H.UX#A,?RECY
MGU/P+I=BN?C//;Z;/\QYW_YMJB^%_P#'?D(PC@YG#/EN#TC+#]?BE_7R1CPY
M8<7]6&9Z7D?B>'%BAAEC,!$5Q1]8/>4OTO4\)F\,^?\`!6>D=-^T/%]K?T+3
M[0?SB/\`OC43ZR8#^A.H=GCUJK=_I>B?I%NWV6%X:ZKZ7_"+F^H]=S<UOH[Q
M3C`;115+6QX/_.?_`-0KV3X5G^-\U+F>2G`<GE$0.<.L?1",)QQ8_P"<GDC+
M_9_WVG_Q@^-Y#@^Y\A/@GF'Z_FO\QBE_D\,?F]^?[W^2A_K/YOM<?ZW],Z5U
M.C])ZH>\5Y.S5C:W$![['>YKO2_G-C/]&O3A76!`:(\('P7S4OHGH=S[^C8%
M]D^I=C4O?/.YU;'.E6>?^!X?A6#!##.>3C,_<ED_?]/R1C\D7FN0P1P8CBB9
M2`/%ZOZS;]*K4;&ZB#H-0JO6_P#D7/\`_"UW_GMZNJEUO_D;/_\`"UW_`)[>
MLUN/_]/O^BWNI^KO3'BI]P^R42*X+OYIGYI+5C?7RBS/Z$<AE-E3L*UMKO4:
M)-;PZJS9L<_Z.ZM[UO?5W_Q/],_\*4?^>V*SE6X+FOQ<I]</9%E5C@)8^6:A
MWYCOHILX\43$]13-RV<X,^/,-3CD)5W_`'@^.]+Z1E]3N+*1MJ:1ZM[OH,'_
M`'^S]RIJ+]<;<3IG3?V/@:![@<NP_3L<WW;;'?NU;_YO^;]3_A%VO5:F=!P!
M]F8/L^C,)S=6%S_H.M=^_P#GO>_^D?\`4>4_6/)]7)>V=PK.R3K);+K7'^M<
M]ZAY7#$<S@PC6<I1EDE_JXR^4.CSOQ/-SIF3^KY?%&4XXOWI?+CEE_>GQ\#U
M'U0R*.K]&.#D^Z[!.QKOSA6_6EP=_(VNJV_\%6K[G]9Z.9Q[W_9QHTCW,&OT
M74V;V5KA_JGU7]F=:IL>[;1?^@O/`#7D;7G_`(NW8_\`J+UW`Z<<YQ]1OZJ#
M%I/#OWJ6_O;OS_\`R:Z+F1B$90SXX9L)U]K+&.6!_NQG^D\ER_/\_P##OB(P
MX(#FN3YD^[+E<NN&!E_/Y,<_5]VG'Y^/^O\`S>1T>B,?G=*HNZBUGK7GU@QL
MMAI]E+F^]SO?2U:6+AX^(PUX[=C"9VR2-!M_/+E%^!@7[3;1786#:V6@PW]P
M?R4>NME5;:ZQM8P!K6C@`+$C"$!PXXC'C'R0C\L(_NQ=B<N*<I`</$2>$?HW
M^BR220[WVLK+JJ_5>.&2&S_:<BM2)BJC<K/+'$X3@X`%K397J27!S=P/YK6M
M=_;2&3G$&<-P,Q_.,XB=W^=[$E-5C=@-9YK)8?EP?[3?<I(MM-S_`-/Z>Q_%
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MLLD_GK][AX%V*)B+/5MJEUO_`)&S_P#PM=_Y[>I,JZIIOR*3JV=M3AH!^DYN
M=]-_T?\`1_\`"('4VY#>@YXR'MLL^S72YHVCZ#OS5C,C_]3T3ZN_^)_IG_A2
MC_SVQ7;**;"'65M>X<%S02/O5+ZN_P#B?Z9_X4H_\]L6BDISS7U!M09>VG*J
MV['T,KVEP.G^%L]';_(7,YW^+OZL]1R&M/3\KI^XN<;,>QHK_>]U;WY#*]W[
MM=2[9)&),9"4=)#:0W2"0"+TEOXO$]/^H?U`Z=9NM#<NZI\$9EN^'`[-K\<>
ME0_W?Z2E=6R[IV6/L];ZKVM;)K:0X;0=GT1^;N;L5J!X)FL8P0UH:!V`A&<Y
MS-RD9'^L;12U555+!74QM;!,-:(&IW.T'\I32235*22224I))))2R!;A4V.+
MQ-;SRYFD_P!8:L<K"29EQ8\L3#)$3B=XR'$$@D;//]?^J./U[%KQ,O)L957:
M+9J:T.)#7UQN=O9_A/\`1J/0_J)]7.BV-OQ\<WY+-6Y.0?4>#,[F-AM-;V_Z
M2NGU%T22DP2GR_+_`'7!*6+E[,O:@3&'%/YD&B>(ZGNM"=),2`)/`04NJ76_
M^1L__P`+7?\`GMZN`AP!!D'4$*GUO_D;/_\`"UW_`)[>DI__U=CI?_)>%_XH
M/Z/3_,_S?\VS^:_D*S_]<B\)224^[?\`UR)?_7(O"4DE/NW_`-<B7_UR+PE)
M)3[M_P#7(E_]<B\)224^[?\`UR)?_7(O"4DE/NW_`-<B7_UR+PE))3[M_P#7
M(E_]<B\)224^[?\`UR)?_7(O"4DE/NW_`-<B7_UR+PE))3[I5_-L_P#%']$?
M1XX_-0L_^@97_BB_F;?YSZ'T'?3_`)*\022"G__9_^T=SE!H;W1O<VAO<"`S
M+C``.$))300E```````0`````````````````````#A"24T#[0``````$`$L
M`````0`!`2P````!``$X0DE-!"8```````X`````````````/X```#A"24T$
M#0``````!````!XX0DE-!!D```````0````>.$))30/S```````)````````
M```!`#A"24T$"@```````0``.$))32<0```````*``$``````````CA"24T#
M]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R
M`````0!:````!@```````0`U`````0`M````!@```````3A"24T#^```````
M<```_____________________________P/H`````/__________________
M__________\#Z`````#_____________________________`^@`````____
M_________________________P/H```X0DE-!`@``````!`````!```"0```
M`D``````.$))300>```````$`````#A"24T$&@`````#3P````8`````````
M`````/\```&@````#0`Y`#$`,@`Y`#$`.0!?`%``80!G`&4`7P`V`````0``
M```````````````````````!``````````````&@````_P``````````````
M```````!`````````````````````````!`````!````````;G5L;`````(`
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG````_P````!29VAT;&]N
M9P```:`````&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````
M$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R
M:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````
M5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,`
M```!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG
M``````````!"=&]M;&]N9P```/\`````4F=H=&QO;F<```&@`````W5R;%1%
M6%0````!````````;G5L;%1%6%0````!````````37-G951%6%0````!````
M```&86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````
M"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC
M94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L
M:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````
M$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P``
M```````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`
M````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````3_P
M````````.$))3004```````$`````3A"24T$#``````8$0````$```"@````
M8@```>```+?````7]0`8``'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`8@"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`[GH/2.DV="Z;99A8[WNQ*"YSJF$DFMG)
MVKD\7J./5=U>[)^P6MP#F&K$M=AC^8R'4T4G!Q\)G4Z7/H;Z=5K\K(WV^G^A
ML]>M=O\`5W_Q/],_\*4?^>V+)J^N),-NQ!ZE#<HY]=3]YJ=CY#>G8[&.L917
M^NV'UV/R+,:NFBJRRS]])3@.ZVUMQR+.F]-IH?A5VC&LK:U]5UN:[IMCKWW,
MHW?LNL?Y4J_5_2O_`$?K55_IT>CKF,^_I[;.B8-;,K[&VYNUCB'9PS!2^FVI
MEE3J?U)EV_\`T%W^D6X?KATW(9CNPZGVC*KQ;O5M86U,KR\AN`QM]K19LO>_
MU?3KV?I/1^GZ/Z5$Q_KGT>]U30V^LY-E->-ZE9:;69+K*\7-J;._[)<^BS])
M8VNS_@O3MI]1*>6HZVW+HQ;:.E85F4;LFM^)0REU5AKPSU*G'.0RO+9<_P#-
M8_#RJ_\``_:/3]^(K3.N8=O4>G45]%PAC]1VV5&QE==EF/=?9BXUM#;`S=97
MC5,ZCD5-9;^BOKI_0_SJZ'IOUOZ1U#/Q^GXC+?4R\=N76YS`QNRP/L:?<X6/
MW;';[::[:&6_HK;O7_1K-Q?KVVSK&5AY./77C83\SUKF.N?953A&QMN;;7]D
M;CNIL=4RO;C9=UOJ7UU[$E.1U+)&/]8LS"H.)8&>L,7!%%!#7LPCE559F&_&
MJZFVMU_ZS^U,3+R\2W^B^E3ZGZ*6!]8NGG$I;=TK!RLL5UO-=3&>I>#TZ[J]
MMM%(K_[F8_V+VLV>I_PBZ+'^N_1<BS$8QEHOS;G8H8YK`YCVFF6V/]7T[/;E
MX]VS%LR;/2L]3T_T5_IQ;]>N@G%S,G'%EM>%&[TPSWUE]N/]HJ+[6,;3Z]%[
M/UA]#_\`@_UC&]=*><QNMU5LR;KL#IW419>S$PQAUL=4W)MQ<;(PJ*[/2WV8
M^5EOR:KK[W_J]JU^MYG3^F=8Q\$=+P'5O&.7->QK;[SDW'"-?3:O3V6.P8^U
M96]_\UZ?\U_/HV7]8_J]FVX]XP\O/=A/JLP!54\L?=?C_;:O0J<^JF[)IZ:^
MS)_3L_5?\'^L65>I=Q?K/C7]:?TJZBVM_K&G%O+2:WN&-1U!U;W.#7XV3Z&1
M;^AL9_@?I^I^C24\A=?G-^JV#U!M>([/RNIW4O<S&I+#12<W=BTL?C[F5/;@
M_H_IY'_#(/\`SFIP<'(S<C!PLHVYAMP\>ZFNMWV!].'G545/JJ97Z]6/U&MS
MWVONO_X#(_2^AMXO^,;ULC'KMPFTLMRKZ;[#;(KHI;OKS-OI>[U]M[=G_=6U
M6<C_`!A8!QF9&%B79.ZC+O(=#?2.+17G,%Y;ZK6MRJ,FG:YCM]7J^E;7ZWJT
MUI33LZKC4Y%[KNC8!PJCDV%S&3:RC!S:^FY]]U?H[?Z-=]LK94[_`+3V5_X5
M3SK,%W3>AYF57B]!JZG>[[1<VO&]E+J,K*Q*WVY^/;1799Z6+ZWZ+^=_1,5_
MJ/UGZ'E]/NQ>HXN66$V-SL3TWMLKJH;1DY5^3Z3V?J;*<K%?9MM_6:LCT/0N
M_2TJ5_UYZ?3DO#*;;.GX]6399F-:=KCB.QZ;&X3&@_:6,NRO2NO_`$5%/H^I
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MCTLG9^G]_K5=/L_H[/2RUI()`D<'P3;&1&T1,Q'>=VY)3QW6;\3!ZRW"Q>G8
MEGVD8553+JF-K8_*?U!CKW-91]H<YOV*K]'ZO_;/\XKE5/2>I?4\]5;T[&HL
MR<!]VUM3#M<ZISB&NV?FN73JEUO_`)%S_P#PM=_Y[>DI_]#T3ZN_^)_IG_A.
MC_SVQ1N^K?1KK,RU^.1;U!]%N58RRQCW/QBUV)8Q]5C'4/H<S_`>FA=(S<;"
M^KG2K,I_IUOQL=@>02T$U-/Z1S0?29[?YVS]&CCZP]"-=MC<_'<VAK76[;&N
M+0_^;W-:=WO_`#&I*8X_U:Z+C4BBC&V5-&.T-WV&!B6OSL,>Y_\`@<JVRW_A
M/H6_HT)OU2^K[6.8W&+6N?6]L6V@UFES[L9N(X6[L.JBRVUU5.)Z-/Z3Z"/9
M]8.BU;O5S*JG,+@6/=M=[26.VUOA[_<W\SZ:>KZP=$N<QM>=0Y]I(K9O&YQ`
M+MK:_I[O;]%)2/&^K/1L6W$MHI>W[`T,Q6&VUU;(:ZEKVX]EKJ?6]*RQGKNK
M];^6G=]6^B/C?B,?%F1=[BYWNS`]N>/<X_HLIMS_`%:/YCZ'Z/\`15)\7ZR=
M!S!5]FSZ+#?M])F\!Q+Q+&^FZ+/4_P"#V^HH-^M'U>=4RW]H4-988:7O##,;
MO>VS:ZO_`*XDIB[ZJ]$?33195;93CO\`4:Q^1>\.=NKM_6?4N=]K8VS'I>RO
M*]9C/347?5'H#FO8<=X;9<,C:+K@&6`W/_5PV[]68YV9E;Z<?TJOT]B)=]:.
M@4`&[.J8'5^JTDF',G9NK,?I/</HL_[^K^+EX^76;<=^]@<6DP1J/)X;XI*:
M'_-CH@Q/L;*'5TAS'M].VUCVNJI9TZMU=U=K+J_U&IN,_P!.S])5_.?SEB+5
MT#I%%]615CAEM%GK5$.=#7^@SINYK-VS^A55T;-NS_"?SOO6@DDIR*_JE]7J
M]FW#;%9#FASGN$M=DV#<U[W->W=U',]K_I^M_P`'5Z</^9WU>.,S&=CO=56V
MQC-U][G!EU;,2^GU77>KZ+\:JJKT=_IL]*M;222G*ROJQT3+-CK\<EUSW66N
M;;:PN-E=6-=6]U5C-V/?1BX]=V-_1[O2_25)'ZL=%^T69+:7LMN%FXUW7,#3
M<:[,A]#*K6,QK+[**K+;<=M5F]:J22FO@8&+T[%;B8C"REA<X`N<]Q<]SK;'
MOLM<^RQ]ECWO>][U82224I))))2E2ZW_`,C9_P#X6N_\]O5U4NM_\C9__A:[
M_P`]O24__]'T+H-5=OU<Z;7:P/8[#H#FN`((])G+2KK<3%:-K::P(`@-`$-U
M;V_-53ZN_P#B?Z9_X4H_\]L5B_(R:[0VO&=<PC5[7,$'^K8YJ2F?V7%EWZ%D
MO,O]HU),R[3W>Y,:<1GN-;&P9!+6C4=_Q6%UKZPV-M=BX#MI9+;+^2'#1S*I
MEOM_/>N;R2;6O?:38XM(+GDN,1^\^5G\Q\4Q8I\$0<D@:->F`/\`><KFOC6'
M#D]N$3EF#PRH\,(R_=XGOQB8#VL`HJ<UA;97#6P',_FGLC\ZO\Q.W$PN&TUZ
M0(#&Z>'9>*XF7E85GJX=S\>S]ZIQ8?[6WZ3?ZR[;ZM?67#ZQ>W`ZY2Q^8\;:
M<F-K;"1#J[&-VLJO=M]NS]%=]#]'9L]6QBYJ$SPD<).W9ZWGO@/,<M`Y82&?
M''Y^$<,X#][@]7I>W;C8X!VU,`(VF&C4<;5-E==<[&ANXR8$28#?^I:G;]$1
MPG5AQU))))*4DDJV3B67/:]F3;C[1&VO9!_K>K78DILK'I^K73L=U1HLR6?9
MWM?6T9%I:"R&QZ;WN9LL8WT[/^#4^JY%73:'9F5F7,K:X%E;0R7'\W'K;LW/
MW;?WO^$^@N(ZI]:NK=0>X-L.)03I32X@_P!NYNVRS_H5_P#!JURO)9>8)X*$
M1O.7RMSD_AV?FR3C`C"/S9)?+Y?UGKKND=-Q<@$G/#7%KZZ\>S(]%FSBMM>(
MX,:USOTCV6)_V3T6O?2:<IPLN%CS^G+2]NVW?[?T36.W?FMV?SB\OSB2YEA)
M+]3N/,Z?G*]TGZV];Z78WT\AV10#[L>\E[2/!CG?I*?^MN_L/53G)#E>9ER\
M_5P\/K']>/'\KI3_`.+>?VS/%ECDD/T"/;O^[+U/J6#=CUU48M-=K:VLVUFQ
MCFPUFD.W!JNK*Z3U_"ZETUN?_1V@`W,MT+"3'N=^=4__``-O^$5QO4>GN8+&
MY5+F$D!XL:1(&]PW;OS6>]*,A(6#8+A$42.L28FM?5'TR;*I=;_Y&S__``M=
M_P">WH@ZETXAI&520\`MA[=03M]NO[R'UO\`Y%S_`/PM=_U#T4/_TO1/J[_X
MG^F?^%*/_/;$WU@S78?3G.K.VVTBJMPY!<"7.'\IM;7[/Y:?ZO?^)_IG_A2C
M_P`]L65]<\BNAF(+7BMCC8?<0`2!7'_5*#FYRAR^24?F$?37>7I:_.2R1Y?*
M<0,LG"1`0'%/BEZ?3&+SX```&@'`4;?YM_P/Y%5=U;I[3!N'R#C_`-2U"MZS
MA^E:6;[!76ZRPL;]%C1[K';MOM7,0PY92%0EOV>8Q_!OB<JF.2YD8P;,SARQ
MQ@?[24>!YY:&%TRY[?M%SSBTLAPM)VN$>X/9N^A_QCE/&Z7U%];#BC$&2^"W
M[1<-PD;JW45.:RJS]_U&69*AF_4CZZ9;P[(#;SR/TS=H_JL.UC/[#5T>'D,)
MF(\WS_+?#O#/.)YCA[PP\48?X^5]*^,?'^;R@X?AT3BQS&O.2C[D\D#UY3%\
MG#+_`#^7_P`)?3^D=1RNK=.HS,+)I<T@UVDL+P;*W.98]OINI^GM6ICMR&L(
MR'LL?.CF-+1']5SK%R7U`Z#G]/Z'?@=3#Z;!ENNK]*W7:ZNMGTJ7?O-L]BZ7
M]F50&^OD0WB;7'@;9U5V8Q1D8X<HYC%$U#/&B,T?W[CZ/4X4`1&(E9D``;WM
MNI*JS!:Q['^M<[89VNL<6G0M][?SN5:35RDQ,)TSC#2?`)*?-_KAU*W,ZLZE
MVX4XOZ.EI!;)_P`-<-WTM]GM:_\`T=:Q%Z2<>C)QF5Y%;;6%H.UX#A,?RECY
MGU/P+I=BN?C//;Z;/\QYW_YMJB^%_P#'?D(PC@YG#/EN#TC+#]?BE_7R1CPY
M8<7]6&9Z7D?B>'%BAAEC,!$5Q1]8/>4OTO4\)F\,^?\`!6>D=-^T/%]K?T+3
M[0?SB/\`OC43ZR8#^A.H=GCUJK=_I>B?I%NWV6%X:ZKZ7_"+F^H]=S<UOH[Q
M3C`;115+6QX/_.?_`-0KV3X5G^-\U+F>2G`<GE$0.<.L?1",)QQ8_P"<GDC+
M_9_WVG_Q@^-Y#@^Y\A/@GF'Z_FO\QBE_D\,?F]^?[W^2A_K/YOM<?ZW],Z5U
M.C])ZH>\5Y.S5C:W$![['>YKO2_G-C/]&O3A76!`:(\('P7S4OHGH=S[^C8%
M]D^I=C4O?/.YU;'.E6>?^!X?A6#!##.>3C,_<ED_?]/R1C\D7FN0P1P8CBB9
M2`/%ZOZS;]*K4;&ZB#H-0JO6_P#D7/\`_"UW_GMZNJEUO_D;/_\`"UW_`)[>
MLUN/_]/O^BWNI^KO3'BI]P^R42*X+OYIGYI+5C?7RBS/Z$<AE-E3L*UMKO4:
M)-;PZJS9L<_Z.ZM[UO?5W_Q/],_\*4?^>V*SE6X+FOQ<I]</9%E5C@)8^6:A
MWYCOHILX\43$]13-RV<X,^/,-3CD)5W_`'@^.]+Z1E]3N+*1MJ:1ZM[OH,'_
M`'^S]RIJ+]<;<3IG3?V/@:![@<NP_3L<WW;;'?NU;_YO^;]3_A%VO5:F=!P!
M]F8/L^C,)S=6%S_H.M=^_P#GO>_^D?\`4>4_6/)]7)>V=PK.R3K);+K7'^M<
M]ZAY7#$<S@PC6<I1EDE_JXR^4.CSOQ/-SIF3^KY?%&4XXOWI?+CEE_>GQ\#U
M'U0R*.K]&.#D^Z[!.QKOSA6_6EP=_(VNJV_\%6K[G]9Z.9Q[W_9QHTCW,&OT
M74V;V5KA_JGU7]F=:IL>[;1?^@O/`#7D;7G_`(NW8_\`J+UW`Z<<YQ]1OZJ#
M%I/#OWJ6_O;OS_\`R:Z+F1B$90SXX9L)U]K+&.6!_NQG^D\ER_/\_P##OB(P
MX(#FN3YD^[+E<NN&!E_/Y,<_5]VG'Y^/^O\`S>1T>B,?G=*HNZBUGK7GU@QL
MMAI]E+F^]SO?2U:6+AX^(PUX[=C"9VR2-!M_/+E%^!@7[3;1786#:V6@PW]P
M?R4>NME5;:ZQM8P!K6C@`+$C"$!PXXC'C'R0C\L(_NQ=B<N*<I`</$2>$?HW
M^BR220[WVLK+JJ_5>.&2&S_:<BM2)BJC<K/+'$X3@X`%K397J27!S=P/YK6M
M=_;2&3G$&<-P,Q_.,XB=W^=[$E-5C=@-9YK)8?EP?[3?<I(MM-S_`-/Z>Q_%
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MLLD_GK][AX%V*)B+/5MJEUO_`)&S_P#PM=_Y[>I,JZIIOR*3JV=M3AH!^DYN
M=]-_T?\`1_\`"('4VY#>@YXR'MLL^S72YHVCZ#OS5C,C_]3T3ZN_^)_IG_A2
MC_SVQ7;**;"'65M>X<%S02/O5+ZN_P#B?Z9_X4H_\]L6BDISS7U!M09>VG*J
MV['T,KVEP.G^%L]';_(7,YW^+OZL]1R&M/3\KI^XN<;,>QHK_>]U;WY#*]W[
MM=2[9)&),9"4=)#:0W2"0"+TEOXO$]/^H?U`Z=9NM#<NZI\$9EN^'`[-K\<>
ME0_W?Z2E=6R[IV6/L];ZKVM;)K:0X;0=GT1^;N;L5J!X)FL8P0UH:!V`A&<Y
MS-RD9'^L;12U555+!74QM;!,-:(&IW.T'\I32235*22224I))))2R!;A4V.+
MQ-;SRYFD_P!8:L<K"29EQ8\L3#)$3B=XR'$$@D;//]?^J./U[%KQ,O)L957:
M+9J:T.)#7UQN=O9_A/\`1J/0_J)]7.BV-OQ\<WY+-6Y.0?4>#,[F-AM-;V_Z
M2NGU%T22DP2GR_+_`'7!*6+E[,O:@3&'%/YD&B>(ZGNM"=),2`)/`04NJ76_
M^1L__P`+7?\`GMZN`AP!!D'4$*GUO_D;/_\`"UW_`)[>DI__U=CI?_)>%_XH
M/Z/3_,_S?\VS^:_D*S_]<B\)224^[?\`UR)?_7(O"4DE/NW_`-<B7_UR+PE)
M)3[M_P#7(E_]<B\)224^[?\`UR)?_7(O"4DE/NW_`-<B7_UR+PE))3[M_P#7
M(E_]<B\)224^[?\`UR)?_7(O"4DE/NW_`-<B7_UR+PE))3[I5_-L_P#%']$?
M1XX_-0L_^@97_BB_F;?YSZ'T'?3_`)*\022"G__9`#A"24T$(0``````4P``
M``$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!(`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,````!`#A"24T$!@``
M````!P`(`````0$`_^$7_&AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`
M/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60G/SX*/'@Z>&UP;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@
M>#IX;7!T:STG6$U0('1O;VQK:70@,RXP+3(X+"!F<F%M97=O<FL@,2XV)SX*
M/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R
M+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG
M=75I9#ID.&(Q.#$Q."UE.&(T+3$Q930M.3=B9BTY-CDR-V,V-S5D-F0G"B`@
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M,2XS+R<^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TG=75I9#ID.&(Q.#$Q."UE.&(T+3$Q930M.3=B9BTY-CDR
M-V,V-S5D-F0G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O8F4N
M8V]M+W!H;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P
M:&]T;W-H;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F0X8C$X,3$X+64X8C0M,3%E
M-"TY-V)F+3DV.3(W8S8W-60V9"<*("!X;6QN<SIT:69F/2=H='1P.B\O;G,N
M861O8F4N8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO
M=&EF9CI/<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU=&EO;CXS,#`O,3PO
M=&EF9CI84F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXS,#`O,3PO
M=&EF9CI94F5S;VQU=&EO;CX*("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T
M:69F.E)E<V]L=71I;VY5;FET/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z9#AB,3@Q,3@M93AB-"TQ
M,64T+3DW8F8M.38Y,C=C-C<U9#9D)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,34M
M,#0M,C)4,3$Z,S$Z,#8K,#4Z,S`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z
M36]D:69Y1&%T93XR,#$U+3`T+3(R5#$Q.C,Q.C`V*S`U.C,P/"]X87`Z36]D
M:69Y1&%T93X*("`\>&%P.DUE=&%D871A1&%T93XR,#$U+3`T+3(R5#$Q.C,Q
M.C`V*S`U.C,P/"]X87`Z365T861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O
M;VP^061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O
M;#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F0X8C$X,3$X+64X8C0M,3%E-"TY-V)F+3DV.3(W8S8W
M-60V9"<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO
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M"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/
M1DE,10`!`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C
M<W!-4T94`````$E%0R!S4D="``````````````````#VU@`!`````-,M2%`@
M(```````````````````````````````````````````````````````````
M````$6-P<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0`
M``($````%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M
M;F0```)4````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````
M)&QU;6D```/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\
M```(#&=44D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT
M("AC*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C````````
M`!)S4D="($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M
M,BXQ````````````````````````````````````````````````````````
M``````````!865H@````````\U$``0````$6S%A96B``````````````````
M````6%E:(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA9
M6B`````````DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N
M:65C+F-H```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````
M`````````````````````````````````````````````````````&1E<V,`
M````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@````````````````````````````!D97-C
M`````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0``````````````````````````````````=FEE
M=P``````$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6
M`%````!7'^=M96%S``````````$````````````````````````"CP````)S
M:6<@`````$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R
M`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`
MI`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9
M`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!
MN0'!`<D!T0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z
M`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#
M<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,
M!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%
MY07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A
M!W0'A@>9!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`)
M)0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+
M"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-
M0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6
M#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B82
M11)D$H02HQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42
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M-8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0Z
MLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C
M0&1`ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&
M(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ
M3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2
MQU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI
M6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@
MJF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I
M:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAO
MT7`K<(9PX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S
M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`
M1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.
MB3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2
M$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"
MFZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E
M.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6
MKXNP`+!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JY
MPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11
MQ,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/
MN-`YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[
MVX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G
M'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9
M\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW_
M___N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!
M`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`__``!$(`/\!H`,!$0`"$0$#$0'_W0`$`#3_Q`&B
M````!@(#`0`````````````'"`8%!`D#"@(!``L!```&`P$!`0``````````
M``8%!`,'`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q
M%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&
M-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X
M>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3E
MYN?HZ>KT]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$'
M,F$4<0A"@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*
M<X.31G3"TN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&
MEJ:VQM;F]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*
M6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`+7_`.2)_*F_EM=]?RI?A3V]W1\(
MOC=V=VCOKJNMS.\]_;SZOVYG-U;HRQWQNVF.2SN9K:22LR5<:>GC0RRLSZ$4
M7L![]U[JU+_ADG^47_WKG^)'_HF]I_\`U#[]U[H'.^_Y5G\FSX_=.=F]V;J_
MEN?%K(;8ZLV7N#?&X*'#=*[-FS-1BMN8^IR=;'CH*O\`A]/-4-!2MH!E74??
MNO=:T&%_F:?\)HMS8J/-;<_DA[ZSV)J9)DBRF%^'G6.5QM1%2GPUS4V0H-Z3
M4_FI)VTNJL2I^I!]^Z]U>Y\"/AA_)/\`Y@WQYQWR)ZR_E6=,]=[9R&Y=Q;<7
M;W;?QTVQMW=T,NVJS[2>>7%PO5W@KN#"\<LJ'^I]^Z]T>*'^23_*-,2%_P"7
M-\1PQ4$@=-[6-K\@7>B+W`/Y]^Z]T5#'_"#_`(3_`.6^5U9\*\3\+/AKEOD3
MB]GUV_LYL3'=+[<J*C!;9HA2VJ,I4+0FFI:B05B?MDAC?Z>_=>Z-<G\DK^4<
MR@_\-R_$@7O<-TWM0$C_``'V;:;_`.O[]U[K(/Y)/\HNW/\`+F^)`_P_T-[3
M/^\_9>_=>ZXM_))_E%FX7^71\1]7UYZ;VK;_`&-J,&WOW7NL?_#)7\HW4S?\
M-R_$BP%M1Z?VH%)_J$^R*V_WGW[KW00]X?RHOY/W174O9/<&>_EE_&O<>"ZU
MVEE]YY;";1Z*VOE=RY;'X*CDJ*O&X#'S&B%3EZO3:!0X5C]>;>_=>Z!#X._!
MK^2U\Z_CEMGY)]?_`,JKI78&U-U9?<.*H-L=J?'G;&V]ZT3;<R'\+GGR>,'W
MB1PUM3ZH'21T>(%@3[]U[HZ*?R2OY1912?Y='Q&8D<E>F]IE;_FQ-$>`?\??
MNO==_P##)/\`*-YM_+F^)%K_`)Z;VI<_ZUJ+CW[KW48?R3/Y1NIU/\NCXC:V
MU"-?]#>UQI5?J7;[0KQ?ZJ![]U[J@CYO=O?\)\_B/W]N3XO[&_E!['^67=NQ
M:>FG[!VU\??C5M7<]!L,2Z354VX\A&CU$60I(V!:-:8J";&0>_=>Z-C_`"Y>
MNO\`A/3_`#,-M[ZJ^G/Y=7QVV+V%UA4:.R.H>UNAMH;:[`V?%&YA-;DL/$U4
MJ4+.K#6'^H]2@_3W7NC+_%_X/_R`?F+-V^/CI\*_AOV-C.DM^+UKO'-XOIK`
M2XNGW<E&U76XVGJIJ-#7?:,"C.GI#"PO;W[KW1N5_DD?RC-(O_+G^)%[<_\`
M&&]J'G\\FB)^O^/OW7NNO^&2?Y1?.G^71\1^#S?IK:AM_7_E"'OW7NJT/F+T
MG_(4^$_R&^+7QL[0_E?](9[>_P`M]PR;<ZXK]D]"]=Y'!8RKCR46+:?<]1D\
MAB:JCI_N)E/^3Q5#:;FW!]^Z]U9>G\DG^4:5!?\`ES?$=6MR!TYM0@?[$T(O
M[]U[KE_PR3_*+_[US_$C_P!$WM/_`.H??NO=<#_)*_E%D$)_+F^([$&Q'^AW
M:BV/^N*`GW[KW6/_`(9(_E%DZ#_+G^)0#)]1T]M?@@\C4*0'Z'ZBWOW7NJ(>
MXMT?R,=B_.3<'P2ZD_DFX?Y*]D]=YW;>W^W\WTU\8MK[AP?6DNY*JCH8<KF8
MG6&H;`XB6N1JVM;PTR+>TA(]^Z]T?/Y^_$7^1I_+E^,F<^5'>'\LGX^;@V/M
MS<.UMM9+$=>]&[(R>Y3DMVUKT-!]O19>?#T3PQS)ZRU0`OX)^I]U[HNWP*P/
M_">K^8=\<>^/D]TY_+/Z*VMLCX\3YB#L3%=D=%]>XC<%.N)VK5[MAJ,=2XC)
M9J@FBR&-HW2,/-"3-P??NO=`G_+5[6_X3E?S2>[LST-T'_*HZ]VWO#![/K=\
M5>1[%^/?5^)VX^+QM1%35,<=9AMQ9JJ$IDE&A6@"M^>>![KW5[R?R2OY1KJ1
M)_+F^)"L261%Z=VQ&Y`^M]5$KCG_`&!]^Z]UG7^25_*,*@G^7+\2%-N5/3>T
MR1_L?L>??NO==_\`#)/\HRYO_+H^(UK\?\8:VF#_`*Q_R+Z^_=>Z[_X9)_E%
M_P#>N?XD?^B;VG_]0^_=>Z]_PR3_`"B_^]<_Q(_]$WM/_P"H??NO=46_S'M\
M?\)Y_P"6?W[MSXZ]N?RD]D]B[^W7LVBWMB(.G_CCUSN.GDQE753TP@:.NR^)
MK7K8V@9F2.)U"VN1?W[KW2/^'OR"_P"$Q/R[[?PW1<?\N7JWH'LS=LQ@V9@_
MD/\`%[:NP*;<U:&$0QV+R-)D]P8^:N>1P%C=X=1X^OOW7NCR[X^,W\D38WSP
MV'_+^K/Y3'6-?VIV#LD;UQ/8&-^-6TJKI?'4;4M;4QX_/[Q6N$^/RO@Q\FJ%
M**H]3)=P6'OW7NK%(_Y)?\HZ2%)$_ES?$@&10^E^G-L+<,H8:0U$'4V/Y`(_
M(]^Z]UE3^25_*+,8+_RYOB2A'U4].[4)%C^6^RN;^_=>ZZC_`))W\H>4,8_Y
M='Q)8*;$_P"AG:@N?\-5#<^_=>ZX_P##)7\HXFX_ER_$=038Z^GMJW:W^H`H
MK`\>_=>ZR+_)*_E&%>/Y<_Q(4@V8-TWM1K6^O/V7/^W]^Z]UTG\DO^46_*_R
MZOB*X!L=/36T^#_2_P!F>??NO==C^25_*+/Z?Y<_Q(M?ZGIS:AO_`%M_D)MS
M[]U[KP_DD_RC"./Y<_Q(!!-]73>U&M_7_E"_I[]U[KI/Y)?\HM^5_EU?$5P#
M8Z>FMI\'^E_LSS[]U[HL_P`N?Y<O\E[X>_'_`+(^1.^_Y8/0&[MI=;8N/*97
M;_7'06U]Q[RR]/-,E.M/@L1IH5GJQ,XO^X++<^_=>Z?_`(M_RROY,_RJ^/O5
M?R'VA_+$^/.T=L]K[8BW1AMM]@="[0P>\\11R5E71)2;AQ*)7+15X:C+%1*]
MU8&_/OW7NA[_`.&2/Y1A/_;NCXCV!^G^AK:E_I_44?\`Q'OW7NN7_#)/\HO_
M`+US_$C_`-$UM/\`^H??NO=5X_S:_P"4K_++Z:_EE?.GM7JGX+_&?K[LGK_X
MS]H[KV1OC:G5FVL/N;:FY<+MVIKL3G<#EZ2DCJ\9E<=5PK)#/$RR(PX/OW7N
MO__0V8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW1$OYFB+_P`-[?-DZ1<?
M&OMM@;7(/]RLJ21_0DL??NO=:3/\DOY+?SJ^M_Y>/5^T?A5_+3Z<^2G15+NG
ML:HV_P!M;JWSLS$9C,YJLW-//GL174&6WWB*NG3#5^JG5Y((KB,+?@>_=>ZV
M?]^;%_F(_,#^5;N>IW::W^7E\[L?%NO>6(PO4V[8UQ-!D-DS5\VW]OY++8G*
MS47\(WOCH@DY6IDBBDD$C,0O'NO=42_RF?G3_,+_`)Q/ROZ;ZYW7W%NGHWJ3
MX&=<8N+Y5T/7V](<1G/D?V;C,W58S'KD9**H6KBQ6;R&-T530^2/QQ/J)\Q]
M^Z]T5SXX?";Y$YG_`(4I_)'JC'?.CM[!;UV5A&[9W9W'C:03;IWSLF3,8/<,
MO46;@:I2-MO38VK3'M8D-#&+*38>_=>Z1^^?YKU7\T>^?FEOOO/^:WW;\!X>
ME-W[TV7\/NBNEMN=@2X?==1M"ER--B,QV+7;/VUG<;6X[/9VB6DJEKI*>:!Y
M?(HT#W[KW1B_D!_.#^8_;/\`PG#VW\F\;V_N[K#Y4[#^5^Q.D=Z]B[&J*K:^
M=WEAJ1=RK29AH8Z>@FI*?<^(IH9JE8U`FE0%O4>/=>Z=OG'V3_,>_EX[K_E1
M_,G+_P`PKN3M?,?+KL7K7:79W2N4%)0=,T6#R6%V75Y&FPVSZ33!D4J,5N,A
MZBJ!JGJP9"U_?NO=*7^=[\R_E1U[_,NH^NOD#WQ\SOB!_+F7JW;];UWVC\1L
M+.E1E=_93$4V1?(;HST3I%EH:7)321UE%).LL42J$3GW[KW5BGP9^1.Z\O\`
MRD_FKN[8G\RFF^>65ZVZZ[$S?6W;%1M?+[*[7ZHD;:]=5T&W]]0[C*Y7-Y?&
M>$3T]9/$`'!2.XM[]U[JHK9/S+^?FVOY)?P#_F38CY&]HY:IZ6^7VY\5\GZ*
M;-5U13]B]/Y??U/AHEW-CX#'2Y&GP4:2@R2#2BS(`!;W[KW5O\7S:[C^7'\Z
MI\+TOW!O3`?"?X._$G'=\]Y;9V=E9(MN=B[QW7MJ?=>#VQN:.DE$=3-3+5&*
M2-B0HIK:3]![KW6NB/YKN\_E90?*?Y4=N_S>N[/BGWWM#?6ZX/B3\4.JMH]A
MUG5>4PFVIZJ?;6/WC3X/:%?M;)S[@^U2%/NZM&<R$S\<>_=>ZW:OY-_S8W=\
M_/Y>W0_R,[,HH\?V+EJ#-;0[%2EBDHZ2LWEL^L_@V>R34\J0I0)EF"2)!ILC
MN0K6X'NO=4$_(;X+_P`VG^7Q_,2^3_SC_E;X?JGY/;%^2&97=7;72^[:K`_W
MSP<SR+556%CH,]DL57_PN-D9:>MH\@U3,?28C8#W[KW63X#?(OJ#YR=C?S#.
MH\E\;-S?RN/YM/8G2.:J^S-_;9J=Q'*Y_%4$U-69#<>W=MUCTCT&6Q,5&"\3
M#]Z*HUJ[:N?=>ZKR_P"$]'37?6TOC=_,W^4FR?ECV;MS$=%3_(O:^3Z<QD,U
M%M[?6_\`_1KF*K#]L[@?[A98-XX2HIO-2NJ%Z=V-F!]^Z]T?SXI?.#Y;;K_X
M2J_(_P"6&;[W[%R_R-VM5=Q4V#[>J<_65&]L1!A>QMMXS'24N8GD:I@DQ^/F
M=$9"`JR-8<D>_=>Z"WY&?S*_FA6?RL/Y*W1'6/>V[MN?)+^89!@<-V?\@Y*P
MU&^J;;,^Y:C#568HL[((YZ?<4M7*1(\;A_#`/4"UA[KW1<_YC?Q'^1'PZ_F?
M?R>NN^T_F+V5\M=IU/9F%R6S-Q]OQT51OO9F8?>,%-NJ@GW`_GR67P>:GO)1
M1RR::4@@<FY]U[JZKXS?,GO;X>?S6OYFWQ,^6?<F[.PNJZ;IW(?,#XQU>^LM
M4U8Q&Q<)05F6S&TL-65THBAIL?0H8VA@8CS*-0!(]^Z]T.?_``GE[)^4_P`D
M?C1V]\Q/DKVCV'O6B^1O>>^<OTGM3=-=5OA]D]083)U6.V]_=F@GD:/'T.0D
M82*4(UQQ<CW[KW0!?S;/EI\H^Y/YE'Q2_E!_%CNK/?&VB[:VM-V%W[W;MBU#
MO6CVH1)5P8K8N5E*&GKCBJ4L7BD#^:0#Z`CW[KW0&;.[$^7?\J7^:K\</Y='
M9WS+[=^67QQ^?.P=T8WK_=?<,SYOMSJ/>S#)8.CR-!N-9)34TU%ED$BVTJ]A
M>Q%_?NO=5S?RCOAOWYDOY^?\Q;:E#\VNV,5GOC?O#"Y_M7=U+1.,O\F<)-NJ
MDA&U=^EJI&IL6HFCU*QD#-&#;ZV]U[J\?_A6:T9_DT=JRP1A?^,P]'`L`%8*
MNZ9$0K;]/B/T_I;W[KW6KMUSVBW\NKH+^:;\>,35I@XOEW\$_B]VSTEC*8?9
M2Y'?7<6,QNV*NEQD$9A2:5,>:MB$.HRRF_UL?=>Z-C_(GZ.3XI_SJ>Z.F,)/
MB=MUFR?@I05-179<1T&*Q>?S&Q-O[LGK,RR",10X_)9$M6RLURD;7]^Z]T7?
MY[_-7MKH?:W97=NT/YWW=/>7S;VSW"ZGJ#H2DW?_`+*;MG9,F>:&+%UU;-A8
M-JMD$HU\*Q1U4J.RW!8GW[KW5KG\W;Y_?-FFZA_DE;RZ%[VW-TEO?Y63[(_T
MAY#!UYH=N9O,YR@V]&7SU"DLM%D:-JJJFD>GD#1'6`PY]^Z]T]S[K^<'\O7^
M>]\0/C/O/YP]V?)[J?YN;>RT^^-L]BU],,7M[,9.;(4F6EV?BX3]AM>EPE;&
MKT!HUA*0J%'/OW7NAR^&7\P/O#X:]K?SH/C1\T>ZMT=DYKXEXW<?R)Z&W9O[
M,K4UE5U'F<=D#MO#8RIR4@GJZ>BRE?1PJ!>QB?@_4^Z]U81_PG\R7RKW_P#`
M7;?R!^77:>^>P^RODONS<';>W*'=>2KLC'L?K?)Y"II]G[=Q<=<W^XVD>%))
MFA14'B\9M[]U[JJ3YUTE-7_\*KOY=U)D*6FKJ:;I:$3TU7!%44TI$6XF]<$Z
MO&P#*"+@V('OW7NA/_X5I=>[%V]\->B.[L#MS"XCN;K7Y1=;-UIN7$4=#B]P
MO)E<@G\3Q%/4T,4-?44[B!)&6Y&H7]^Z]TEMZ_+SY1TO\_CX.=*T/8.YZ/8>
M]O@UM#?6X.GEK_!MG/=C9#K+)92=,E3S*WAKAE5`+W`L%#`WN/=>ZH_SWSM^
M0.Y/D3\B,7_,'_F6?.K^7I\CL)VUN"BZ6Q>(V;DV^+.W]IT.<>'#MN7:>!FC
MR.?HIJ.-%$E-"\+*Q9I.2![KW5ZW\X+^:?W9\3OY:GPHH.IOE?L[?/97ROSV
M&V)NKYH[#V?68_"P;`H<>T^YNQ]L;>A&XI:'<$U*OB,<9-3'.K.$5C;W[KW1
M!/AA_,V?XU_S-?B%TAT#_,I[E_F1?%[Y2Z]A=T#O##;ZI\SU5V'5U0H\5F-N
MY'?FV=M55%BYZUC-`M/(ZRQ@QOQ8>_=>Z?OYMGR(S^W/D?\`+:N[-_G2=G=;
M]B[*@J/]E=^)GPK&\9Z?;550T*5%'MWO'(;<QE5AXLHU0NJK\U0M0HD]3:0%
M'NO=/66_F6_S/NW/^$[/2WR+Z>S6^-V=S5'=&4ZF^0?<>RL6V3[/P_5VU*I8
M9=UXC'8VFBBBSM4*N.FJ*H1!P$\K$,;^_=>Z4O\`)K^5VP]\_,CK'#]5?SEO
MD9V-29[%U--V7\2/FYL_.5F]=U;AJPBU=-L'>330;<PM515@_8IP))U7@`^_
M=>Z`+Y=_S18ODW_,J^6?3???\S;N3^71\>/C-597K_I>AZ*PF^9,]O[L+'R0
M0RY/=U3L_;F>F.)HLLL@J?O#%YX-*P:3<^_=>ZC;1_F[_P`T#O;^2YWID>E=
MQ[T[+[K^.GR4P?4/97R,V;M:KB["R_QOS5)DZ_;_`&/@-N5%,*T;AK*/&%*N
MJ=8:B*&9'D(D5C[]U[H;_P"3?\MMB;P^7?3U%UG_`#F/D7OEMRXR"D[9^(_S
M?V=G:O<F[]T5H6.MQ'7F[)\C4[<VQ44TZNT($DTMR%4W^GNO=;$W\\[MCLCH
M_P#E6?++M?J/=>3V-V-M#8M/5X#=&%GDBRV'D.7HX)9:2>1=<,Q1F4O;U?7\
M^_=>ZUA/F)\\?G?MO^7M_(5W7T_\FNPMC]I?(S+PX?L;>29!J2FWI5Y/<U70
M4<^[H&<P9J.B07>*13&R`7^OOW7NC79G??S<_ER?SU?@_P#'_>?SC[E^4'6G
MS:@J'[$VMV354<>V]M9K(SU&-=MI8&G)Q>%QM!-.K4RT\<8"(-0+?3W7NMTV
M)@R`@JP):Q5_("`Q`]5A?Z?[#Z>_=>ZJ\_G;?]NB_P"8Q_XJ1W)_[R==[]U[
MK__1V8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW19_E_U-F^^?B_\`(+I#
M;5918_/]L]3;XV)B,IEW>+$4&2W'@ZK%4LE?-%>=8%DJ@3I!X%O?NO=:GWQ)
M_E*?\**/A+TEMSX\_&SY_?%K8W5.UJK-Y'$[:.P\5N>:@K-TU;Y',Y*HR>X-
MAU>0EBEKF=T4RR:&8E0?K[]U[JR7?'Q+_G<]F_R[NROC/V'\LNA]P_)SMG=5
M?@LIWICJ"?9F/VWTC74'@RNW\%BMJ[<Q[UV:R+220O/)'&WV\A4MS[]U[HJ?
M6G_"?OL[X+?(+X7_`"1_ES=G[3V/N'JS96(V#\O=O]AY'<=/@._,;(*=]R;@
M@IX*25(LOEWDFC2%QH2>.&:^HM[]U[H5>Z?Y6_\`,/Z^_G!9[^9E\)=[?'3^
M"]R;0VML;L_9G<]9NB++[;Q/@Q%)NZJP4>+P60I<H\U-B6^VUO3E)6^EN1[K
MW0*Y3^3=_,Y^(G<_RDK/Y9/:_P`6,/T?\Q]Q56^-VXKO'!Y*;??4&],W22)G
MLEUS4Q;=S]/7I0U53-)2F6>"]TU"X!]^Z]T9/YX?R=ODO\I?Y1VQ_@,WR)VQ
MV'\@Z#LSKGLG?O=_9./;;N&S]=MB+.IEZ),=MS%RU-/1QC,1QT;2%Y'"FYYX
M]U[I0?S3OY1G>7SCZ<_EH];=:[WZ[VUE/A=V!LC>'8E5N>?,PTVX\3MK";.Q
M55#MEZ?&S2^>6JVW,Z^8+PR:KGW[KW2J^<7P^_FRY+Y`3]N_#7O_`*.[*ZCW
M1LFEVKNCXA?+'%C+]6X^L2@HJ+)9S:TM/M^MGTDP&54;02Q.IC>WOW7NB_?`
MW^1SW!\:/CY_,4C[*[`ZQJ_D?\]]H9[#UFV^L\/D-M=*=9?=4V43$T&$I:5"
M?M(,MDPWEBI(W$*6T6]^Z]T9[X-_RD,_TI_)FW7_`"R_D5N38V\\WNK`=NXC
M,9[;$=5DMJTU3ONMGRFV*J(96C@JGFPF3-/)K,(*^*XM[]U[J+_)&_E%;D_E
MM]%=Z;6[[WKMWMON/OG>%7/OO>>%J*HT]7L.EPR[8V]@*C(5L1K9GCQ2F1H&
M`C61C;ZGW[KW5>&W_P"3#_-@^'P^0'0G\O\`^0OQCQWQ@[_[(RN_:'>79^V*
MNG[SZ..?RD%=7)LZ==LYW'Y=H(-:1AIX48GZ)<GW[KW6T=\9NG=Q]']$]:]8
M;XWW5=L[UVAMNEH=V=DUN+H<)D-Z[C>[Y7.U&.QR14E+)5SM<!>;*I)O[]U[
MK7"[T_E(?S/OC)\R>^OEK_*7^4/66UL?\E:^HR?8/3'?\-34[>QV8JIQ4S5&
MVIJG'[@HVIJ:=FEBO"CHS$<K8>_=>Z,-_+*_E'?(SI_Y/]Z?S!/YB'=FT.[_
M`)<]T[%DZY6?KC'1X_:6QMI5U(E)E:6@$>-Q<57>D@CAB"4\($:?I)]^Z]T7
M/^71_*!_F&_"C?WRTZ`RO8?QPW5\#/ECN3MK<FZ\FE;NC_3C35&^-NYK;V&?
M&XM<)38FFI8*?+JU1&:Q[M&2#S;W[KW18.N_Y$G\VK9'P'^07\L:F^1_Q@PG
MQ5W'DMU9WKG(T&+W)6=C;QR&X]P4.8AP.\:B>EBQVU\#))3^6=Z<UE1(Z+R?
MI[]U[HX7>O\`(F[B[)_EA_R].A=H=K;-VE\S/Y=\&'S?7'8L"5O^CS-[FQN5
MJ*VMQ%;)4TD&6_A-0(X"C/$OKU$J;\^Z]T$?:'\GC^:W\Q?E'\&?F+\M?D;\
M<LKO/XU[OQ59GNN-@8_/8G;>%P6(S,&4J#MS)QTM2<YN?*RQEYQ**6(L>+#W
M[KW13_\`A4CB^MN[/D;\*=A_&OMS$U7S9WKO3<_Q>WUL3KO/4&3WIB^K]_?P
M^HKX=_T5#7_Q/"TL=1.X\$SW$"&P"GCW7NMS/XN]";4^,WQTZ4Z`VCCZ2CP'
M4?6^U]CT4-+&%@:7$8F"FR=3&+L0*_(F:4\G_.?4^_=>ZJ/_`)HG\JSN/Y&?
M)+X\_/KX5]K;7ZE^9'QD@J,9@(=^T4^0ZWW_`+8D:21-O;KCH4^ZA754R(6(
MD7Q&UOH1[KW0._%C^5S\U.V/GELC^8O_`#3>TNGMU=K=$;8K-K?'OIGH>#*M
MUSL:6I>62HW579C.1I7O554TS3>/26\K7O8#W[KW0L_!/^6)W%\4OYJ_\QWY
MQ;OW=L/,=:?,F/&_W#VS@Z[*2[KP=51YS'YNJCW!'44'VJHOV[6\4CC2PO[]
MU[H<?YVGP.[/_F3_``&WO\6.J=Q[5VGOG<>^.NMS8_+;UJJ^EVW'3;5S$M?5
MK6U-!C:BJ62='M&BQM=@/H/?NO=5`_-+_A.QVE\H>VOY:^_\5V+UU@L=\9^J
M.G>K_D935TF6!WO%U#E\5D:'^[Z0P1ID*-XJ.2*,3HI]9Y'OW7NC94G\F+MA
M_P":)\Y?F+E.P=G87IKY6_'O='2>U\1MF?+TG8&UJW<NT*?;464:*&@_AT-#
M1R4X#!9+F(V%A[]U[JJ;:G_">#^9T?@[VK_+<S'>_P`1=L?'F3=E?V+L'>.W
M=E97)=L=E[QH:]*[!X7L+,5>&Q\VW-NT[IS4TTE7*MS8$'W[KW5A_P`J?Y+7
MR=^175O\HK:=/O?J;`;E^`N1VQ5=MF3)YN?';BH\%)C$>+9LSX-)*B2>EQE@
MU1''9G/^!]^Z]T:+YE?RP.Z?D9_-X^!'S_VOO'9>$ZO^*U.:3>6ULI-D4W=G
M8IJ^KJ%;`P4U'5TDT!-4+M*U.UUX^GOW7NJ"/^%#G76P?EO_`#/_`(;=,?$O
MMS#[C[[^0>+J?C9\HME];YBFRKCK3$[JH*Y%[(DQKSG'''8D5*_;U<EXK!AI
MN/?NO=;V/5_76V>K.N-@]:;5HH*;;?7>T,!LO`PQPI$(\7MW$TV%ICH465YJ
M>D!?ZW9C]??NO=:V/\U;^45\_/DE_,9Z=^>7P;[^Z;Z3WKU'U?2;.V]6]@45
M1ELK2YB*IK6EJZ?#S[>S^(J:-Z>K*7D35S8#W[KW2+VS_)1_F(?+[M[I?L+^
M;_\`.?:_?O6_1N[(=][9Z.ZJV91;9VYG-U8^97I*W+-18K!4%33H\*WO1*P`
ML!^3[KW1N>Z_Y4_;G87\Z;IC^8QM_>NRMN].]8]%+U37;?-3DX=^TN6&$S.,
MQ^6P4!QM1AYH<?+D8V1))5N8_I[]U[HB?R/_`)7'\[C?^+[Q^/,?>_Q#^4_Q
MQ[GS^XGPO97R>VM53=Y]68'<<RZJ?;LM'MRI@2?`TY9:589E1=((`)/OW7NA
MI[8_X3WT^X?Y77Q?^&G6_<T&.^0?Q#WK#W%U=VSN3$ULVV:[LMZJ4YW'Y;!R
M:E.S<G!*:<0Z&5=(E*DD^_=>Z'+X7?#S^;'7?*':_?/ST[U^/6"ZTZ^V?/MS
M"]`?&3:U$-M]AY&%1#1;NW?D,S@\=+C,DTA:;11R672$4J./?NO=5T[3_D0_
MS&NE^]OG%M/HKN_XQ4WQ=^>>Z-V9?L'LKL':N5W#\A-DX7=!R]:FW-G4U939
M&G/V<^9:%F;)Q*%B214U*![]U[HS?QM_D_\`\P7XS_RJ<#\..GOEIMCI?Y'=
M>=Y;S[&V;OS8O\0R_7W86U,K54512;6[%CS.'-?3TM7%2,9HH$,<<CV&JUS[
MKW0<]4_R:_Y@'R'^>/QG^8?\P++?#WK5?BIN&GW1@*#XD[8K\1N/MS.4,\55
M3Y3>V:J<;C)+&>(,;CTZV55L??NO=++OK^4O\\^A?F]\D_F!_*]["^.(Q_R_
MIJ7&=N=<_)'`54^.V?NP"`2[TV-64V#R@FGADB^X2Q4F=FN);D>_=>Z,LG\M
MW^8WBOY=N,Z:V_\`S!:S&_-UM[4._LMW1!MFFQ^P\W&I'W?5=;B<7AZ2ODV>
MM(SQI72HTQ=RY0"R>_=>Z)'LK^3%_,)^3_S:^,'RF_F$9?X>;`QOQ1W-2[KQ
M_P#LJ^U:[&[T[DR-!54U9!-O3)U.-QR1I+54JL3I%E8@+R??NO=7F_S3OB?O
MWYR?!'Y"?%CKO,[>VYO'MK:L6&P&>W//4QX.DFIZ^EJ5_BC4=#/)X?'';C42
MWT]^Z]U27W?_`")ODKV5\7/Y0_26&[+ZKI=Q_P`O?<D&4[1S,U=F?L=U8^/.
MS96>'9Y&':0RRQ$1VG5`"/\`#W[KW1U?F[_*Y[K^2W\V/^7U\[]D;TZ^V[UW
M\405WEMO+U%<N\,T%RB9-8]OTR8J2@GIQ3AE/DD4BYMQ[]U[J_V$DQ@LNDZG
M].HM;UM;EE4\CGZ<>_=>ZJ]_G;?]NB_YC'_BI'<G_O)UWOW7NO_2V8/^$]/_
M`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW0)]X][=/?';869[6[ZW_M[K+K3`5%'1
M9?=NZ*V.DP6.GR$ZPT0J*N.-YH)JF:P`(L/Z^_=>Z5N`[!V3NG8F,[.V[N;`
M9C8&7VXF[<7O*AJXJK`UVVI:;[Y<M25T16.:@:B'D#_33[]U[H/NA_DET/\`
M)W;67W;T!V3M?M3;>#SM?MK+YC;54U;0T&=H',&0Q-142(JK/3NI#*EP+>_=
M>Z'-*>CJ$AE,44P4*8W(\EM!;3I9A?TDFWOW7NNV18]2A%\1=`RD>@1A"6)!
MX"@CGW[KW1=>L_E;\=>ZM_\`:/4O4_;&TM\=E=-U<-!VALW`9.*?-[&KJNM>
MABI<Y2$6IJL543"QO<J!_A[]U[HR$48$2JY\K:0'>18]4A4_J<(`A-Q?CCW[
MKW7:0Q1BR1HHN38*/J?K_M_?NO==F*,W!C0WU`W4?VQ9_P#DH?7^OOW7NN)I
MX6TWB0Z61UNHX=%*HP_Q520/\/?NO=<O%%:WC2VO7;2+:[6U6_K;W[KW1*?D
M+_,&^$7Q3WE2;(^17R-ZJZ?WG7X^'-T>"WMFX\?D:G$RWCBKX(`A)1]-E9OQ
M_7W[KW4;I'^8G\'ODKNVEV7T;\J.F.RMW9!96H-I;>WQB9=TU7VZ^65Z3`:X
M,G60"+U%E!6WOW7NCNPF*2.-T=)DY*2#203<@E2O'UX]^Z]US$:`6T+:Y/T!
MY/)/^N3[]U[KHPQ$W,:7U*]](OK0$*W^NH/'OW7NND@A0L4C12[%G(479C]2
M?\3[]U[KD(HPS,$34Q4L=(N2@TH3_BHX'OW7NN)AA/UC0V%N5!XN6MR/]42?
M?NO=>$$(U:8HUU$%M*@`E18$@`7('OW7NB:4'P!^'6-^2F8^7-+\=NM/]F-S
ME7]U6]KS;?QU5NI*]*=:89N+(3PO-39.2G41^5"'TBU_?NO=&XK\G3XVBJ\E
M6U"T]#C::KJZRKD(6FI::CB:6IFK#JU*(8T+&PX'OW7N@$Z)^2O0GR?Q6Y=S
M=`]J[5[9V[L_/5.U=PY#:58U?#B-STBR2UF*R51,%9:B)$LR@<`>_=>Z,&J*
MY1B?3-"K*RV_;95!8J0`;D>_=>Z)#E/YCOP3QO>$_P`;<E\H.I:'O>AW0-ES
M]93YR)=U0;IFAB,6WZBEEB*Q9*HBE3T7N0P_K[]U[I\^1/SO^'7Q'W!A=K?)
M/Y#];]0;CW5B9,YA,%OC/PX^MKL'15/VU364,:HTDD<=390S?G_#W[KW1JMH
M;FVQOW:VW]Z[2RM!N/:^ZL1C\]@,[0.D]#EL3D*=:G'5]+,HM)#/33!E;^A]
M^Z]TZF*-)6#@",&1X_W/"KN0"8FBX24*!?4QM[]U[H,-P]L]7X3:N]-\9_?N
MUJ+9W7\=3+OO/39W&3X[:\6,43Y.#.24,D_V4M!$RLRN=04\^_=>ZP],]X=3
M_(;KW&]J])]@;=[-ZWSOW5+A-V[8J!68K)RXV;[2N-%6#3YA!*=)-KA@??NO
M=#!$B!`B@JR``D\L=("W9OJ2;`^_=>Z*!UW\!/ASU/WCO'Y(;`^//5^V.]-^
M9+(97<G9E!MJ@7=5=79>-(LI419#Q?<4K5Z1CR^-EU&Y/U]^Z]T;AG<-)'&_
MCE=+(TQ#(&5PBE4!`]1<\?FWOW7NB]]4?*/X[]Y;U[,ZZZI[6VIV+O[I_*KA
M.T]K;>K14Y;9V1DD^V%'GJ60*M/*DR'TJQM[]U[HR"J"%+!"RWL5%P+<"Q/-
M[#_;^_=>ZZ$,09G$:!G_`%'2+M;D7_KS[]U[KLQQLNAD4J005(!%C]1_L??N
MO==&&(Z+QH=!NEP#I-@MQ?Z&P]^Z]UQ>FIY='DAC?05*74>DJ=2V_I8\^_=>
MZ[\,)8,8TU*FA3I%PG!TC^@X]^Z]UR,<;!0R*0I!4$`Z2O((_I;W[KW7O&EP
M="W"A0;#A0;@#_"_OW7NNC%$3<QH3:W*CZ`$`?X6!]^Z]UWXH[*-"V4:5%AP
MMM-A_A;CW[KW77AB_P".:?JU_I'ZP;AO]<'W[KW7C#$593&A5OU+I%FO8\CZ
M'Z>_=>ZY:5%[*HOP>!R/Z'^OOW7NN+0Q-^J-";:;E03:UK7M?Z<>_=>ZY@!1
M8"PYX'^)N?\`;D^_=>ZJY_G;?]NB_P"8Q_XJ1W)_[R==[]U[K__3V8/^$]/_
M`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW1#_`.95\8<3\O?@S\HN@JVA2JKNP.JM
MS?P(/3)4NFZ<'C9,KMN2F1D?35/DJ".-"/4-?OW7NM6'XA_S*\GUG_PEX[QR
M.9SCTG='QMQN]/AI14E1/-_$:7=63R;[8V7C:9&9IXLM_=:OEG1K:Q+#J%R.
M/=>Z.9\9=A?-_P#EC_R>/AYU=\)OC9M[M+Y.=QU>,WSW%N?L'*T-!L3JG*]C
M/!GLUOKL&HGR.(S.2I<?29.+0L;3F)4>ZM;W[KW3[_+;_F]?,_>O\RS='\LC
MYL2_&#L/=U!UKD]_X7MWXKY^OSFUA4T,5)738#(Y&1XZ`U--1U926,0K/',F
MD\\^_=>Z+#T=_.L_G!_,CYA=^_&'XQ_&+H/<&"^/'?.,Q>_>P*N;<6,CP72]
M+O.HVQE)\A2Y[<2PYO<.7QU)/.B4J1,CQ$A+$7]U[I6?`_\`F(=2]1?+[^>E
MV5O/XT])]/XOXC4D>ZM]=E]38?-8GL#NMDW5FZ*EI=^U&<SV3I*[*566CC-/
M-!'`$>H-@;<^Z]U#H/YK_P#/3W-\7G_FE[;^-7Q;H_@]34DV]X.DZ_/[B?NS
M-]-K7B)-[TF8G9,8U4M`#*56HB#,#:$_3W[KW1DOG3_/RWGU;\8?Y8/RG^*N
MS=@;EVM\].U\=L/=6#[+AW%4U6S,?4)MZFRT6+;"YC`SC-8>OR<R%WBFA!52
M5/(/NO=&&_F$?S5>_?B9_,1_EM_$#K_9_6V=V-\R/".P-P[HH]PUF?P0.9J,
M5+_=6IQF<Q5&C>"$2*9J>4%CS?W[KW5<'R0_GA?/+L+^8#\HOA[\1,Y\+N@,
M9\4\NF%1OE]N^OVCG^\LS2S2Q/CMEY&J:EPT<V2E0)'3RRP.%=&UB_OW7NMC
M_P#E^]P_*CN[XV[/WS\P^FMO](]VUTM53[@VMLK=6.W5L[*T<4X%%NO;F6QV
M4SL<&-RD-F2G-;,R@_6QX]U[K3#_`.%`6]OCAU]_/S^+N[OEIT]F^[NC<;T3
MAG[#ZTVWMT;OR>Z:.1\PE''08%ZB@^^:FE*.ZB4&R'D#W[KW1;'H/B/_`#"O
MG#\)Z;^1Y\(^UOCEO3HWNO$[N^27;U1MI-A;:VUL%<ICJ@X;<N.I]QY6AA(I
M:.I7R-)%42BH\8BL+^_=>ZV8OY@?\V#Y6T/S[P/\L/\`EYX3X_8_N6DZ\3LS
MM;N/Y'[DJ\/L#8V&GH8LG08G'4]/+3I496KIW0:+5,G[MO$MM7OW7N@V^-O\
M^[M"?XS?S(JOY2=3;1E^7/\`+8QWWV_]K=,9FOR'7'8]!5Y.+`;;W#MNLGJ*
MZMIJ*;,U")6%6\+17==/T'NO=%T^$W\W/^<3\H:SH[MS:>W?@3W_`-6]M;GQ
MZ[ZZ`ZG[0AV_\B.EMISUDD65.=P&ZL_AJF7+4%,I*A5K3(4NJV86]U[H^?\`
M,Z_FT_(;J3Y>=*?RYO@UM[I^?Y.]J[)/8N\=Z?(+<$F"ZZZEVQ+"]3CTR\T$
MT/W5;74L;,/KI(!`:_OW7NI7\M+^;-\B>]^V_EA\,_E;U]UQ6_+GXN;<7=F,
MJ?CSN.+-]?=V;;DHW>B&T:K(Y#309&HR*(CS3L(O'+>R^_=>ZJ_^6O\`.A_G
M1_#/:`^6OR`ZN^&/6?4E1VE3[*/P_P`KOFHK_DUB]K5N7DI<=ESC\1E:V&OF
MR%!`TKUPD:GIR1=0./?NO=&R_FB?SR/EY\6>_?Y>75GQ3Z1Z][9IOF]T?C^P
MJ+:6XAF*S>$V[-QU<5!AL#@<QA\Q18Z"&BGK(VE>:%U9(GOI]^Z]TW]K?S9O
MYIG5.-^&GP?SG1G1*_S3/EIF-X5V4QN:R=71=/=6=;XW*O3;<SN;?%Y3(FMS
M%93I(742*EHP?$2>?=>Z/M\.N^/YJNXE^3W2'\Q?XQ[%P$>P.N-W5.POD[T]
ME8I.J>Q&?;N2\V'EQ&3K8-R_Q!48'S0T%/"=)!6_J/NO=:GO\G+Y#_S/NB/A
M#\[^P_@]UO\`'RKZPZ:[]WQVIVMNWN'+YV3<>YOX9!6RY'9NP]O8N,(TL>)@
M:1JFH,;7]((/'OW7NMV;^4U\Z*K^9#\%^F/E9E,%C]J;CW;%G,+OC;N#>K;#
M8_=>`K3CLE3XDUCR5+40O&PU,3=B+V]^Z]U\[#YV;"S5%_.!_FC?+#`3U460
M^%GRSZ8[7JHZ"1X@,!ENR-M[?S]9*T?J$-'0J"Q^EF/]??NO=#M_PH]S<WS4
M^4GR7[^QF1FJ>O\`XB_';XDX'&)32F?'P;N[XF7+9?'HX+0K)&M>DCJ/4%4$
M_7W[KW6Q9VS_`#6.\?C'U!_*Q^`WPQVQU;N'Y3_(SXT]7Y^'=_<V??!]5=:;
M:I-L8^*"JW,]/)"P-<T3\L2`H'!)]^Z]U,ZD_FW?/_LN?YU?`'LO9OQCJ?Y@
M72_1V7['ZCWMU_NO-U/0W96TJC#2U.XYS74=6,M0Y#`8=II(9H&`:=%#*/S[
MKW5)O\GG>WSFS_\`*]_F92Y_"]79SXDYG:/R.K^P.PLQN7<61[JC[@BP4<E'
M08MLK-48&LVK//(49IE,S+8@W]^Z]T]?R^/G5_->^#_\E7KKY*=`]0_&NK^(
M'2.\=U0;N7L/+;BJNU]]'+;AB.1R^*QV,:+&8G`T\D_C61JA)F:Y\;"WOW7N
MMBGYD_SR\SU'\2O@QO\`^//56/['^4_\PW%[6BZ4ZSS-?5?W8P>3S%+2TN5S
M&>DH_M:^;"8W,3L@L`2J$D\>_=>Z"K"?S1?YEWP9^5_QPZ!_FR=:?'>7K#Y<
MYX;0ZZ[C^.&5W)+!LO?4KQ0KM_="[A:.%X_O)40Z%)T'4I(]^Z]UB[9_FI_S
M&/DM_,L[P^$W\L/K/X]5^U_AW24TO=N_/D%E,]28G<V=+TIJ,1A:S;QTXZG^
M]JTH86TLQJ&+L0%]^Z]U49_)%^4N[>@^U?Y_?RT[0ZHJJ3LOK#%9GLG>'4.V
MZZ;*Q0[GPFXLJ^0V]B\K3JU35TK9I;K*JEVIKL>??NO='!^&O\Y'^<+\LX.J
MN[NJ]O\`P&[PZ][$W5'0;J^*^R.TZ7`_)'KO:;5SPY#*U]'N7.8(K745*NN-
M5-27%K+<V]^Z]UN?8>IJ:S$8NKK*&;&5=5CJ*HJL;42B>HQ]1/312S44\Z^F
M::ED8QNPX9E)]^Z]TX^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJX_G;?]NB_P"8Q_XJ1W)_[R==[]U[
MK__4V8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW4653+Y([S?YMU)C/CNL
MH*^EN?W8ARI_!]^Z]U\^GLK^3G\Y9/YJW9'Q7VIU'N&/^6'W7\U^O?EIO+=%
M)28]=EPTVW:>;/M023#(Q3/4U,S28VHA\8.J74`/?NO=6P_\*2?CI\M>U,#\
M-*CHGK;L_N;XK]=]C23_`"*Z!Z3W'D-K[GW3@Z),52XNEEJ\;6PU(QRX>!J)
M%5G$,Y,EKF_OW7NB,_RW_@=WMU5_.VZ=^76VOY>6\?AY\1=\]#Y_:V`V@^YJ
M/<M7L?)K@J?#TF7[-R4DSY'^\FZ:O&M4U,4FIVEE5RUSS[KW5@_\@OX@?(GX
MX_+;^:IO;O3J7<O7&V.X>[WSW7&:W$E+'%NW"ON#+5<.0QKTS.LU+IJ$92=.
MDM;3S<^Z]T2SXZ_RH/D=W-W1_P`*%>L^U>M]T]4[+^:,*X_H_L?<U+21[=W/
M6XW?^1W'B<ABQ#))*JM5TT`UE4(@E;BWU]U[I%[9[2_FS;#_`):#_P`F*G_E
M@]DY[NVAZ\J_CMMOO>#/8N'HN/K".K-)'OK)9EVIR*PX^5I/":I6_(C)_;]^
MZ]T^?S'OY,GR-Z=_E/?RQ^K>@MH9#O3L_P""7<='VUV=L_:$AJ*W=>8W+)B<
MQN<;>6=8Y'I:'*8OQ+91Z3?3S;W[KW6/Y$;+_F'_`,P'^9G_`"E?EKF/@#VE
MT1U%TYD*7$9D[BW#@J[=.$I:?+2U^:W+O#'QA*;;.+,DEL>CHU9-%^JQL/?N
MO=/'\U;I+=_8ORF[J'S(_DE)\I-E9N44'QT^3OPUW'N':'9.;_9:/&-VO6X_
M*5^4%;BIRC3-/0K3:D_W8OOW7NK1O^$XWQ'^6_Q$^&>[-F_+./=FVZS>?:N9
MWKU3U5O3<XW=N#JSKM*1(<9B*_(P5,]-!/7,!))!'91)<Z5)('NO=`=\MOAU
M\A=^_P#"C?X4_)W"=,[BW#\==C=4/A=Y]E"CH*S:N)R38W-+]GE%JW:42*]8
MEB(V-_H1;GW7ND#_`#"?@Q\DOA-_,JZ2_F=_RUNI,QV#@NQ=S4FT_F3\<^N'
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MKK[<]=M_?DV[]F[;@PM/O7!R8N2.O:/(1>2H)U']QB-)O?W[KW0F_P`N/X1]
MW2=;?.[Y"],?R]-J_P`O#LK>'4F\^N?AUDLSNW>N5[VRSYNC*%M_T^>W#F<?
M1+"L*PTU6D%(RU#"0(H&KW[KW6OUG/Y9'R^[H^!6_P#I>#^5CW74_.;:V_\`
M^^?='RX[2[,DSF0WE18K,US1;7ZIQ6X,A5)6UVYON+5L5%*L!BA#$W/OW7NK
M]OD%\-?E-V3_`#&_^$]?=>VNA-]-UU\?.D-E[?[TW,]#3K!UOF,0DD5?B]T4
ME1.LU#44XB-B%<$.#<6'OW7NC"?SD_B3\HNN?YBOPI_FS?%CIK*_(V'X^4E1
ML[N+I3;U>M+O'*[;9JV2#,[82?5%+_N/K9(R+-:>)25L??NO=&%^&7R&_FH?
M,GNKY)]D=O\`1>5^,'P8FZ;SV!Z6Z3[.P>WX.Y=V]AY+;M;1QUARE'$F5IL6
M9IO(5FTC6P7D>_=>ZK\_E`_"3Y8]'_RG_P":%T[V=T;N_9/:W<.\^XJKKG:6
M9IZ2/*;OI<]MNOQN-FQA6OO41SS361G\9L;_`)]^Z]U9Y_PG$^/'=7Q8_E9=
M7]0]^[`S76/9>$[![1R.3V?G(X5RM/2Y//)4XV2H6*2:)&K(%NNEB+?GW[KW
M5,%!_*Z^3/:GS6_X46'>W1VZL)UK\M.F<GAN@MWYBFH!B.PMV1;EPFX\,NUZ
MO^(>6/)138HA&=8[7/\`L?=>Z(;L[^5'_,&RG\C[YL4W9/0/9F?^9?R#^2W1
M572;(K(\?)OJMZXZ>I8<!2U8A.4%*<''21)HNP-HE-OZ>Z]T<?\`F)?RL.[J
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MWA2Y*EJRIRII5:JHD+V$K#FU@/?NO=1/D5_+"^9TGPE_DS_)WI'J.;/_`"M_
MEQ;:V])OKX_;BJJ>CW'FMOG+'-9+$XX_=M22Y:DJ(=0C,AU*X`O8CW[KW2B[
MHV/\U/Y[?RZ^$;=@_"WLGX6?%7XC]E2=M]F;E[CJX/[T;IWABJBEJOX!M*EI
M!!-/33/1+#&Q4K<EKVX]^Z]T^X3JSYJ_RF?YNWS![PZC^%G8/R_^/_S[J<3G
MMF93KG+XS'5.QMTU%9#F*O#[OJL@LK8NGH\G`6:>=%IO#(-)UCW[KW2,_E"_
M$;^9+TQVC_.)[=['^*^V=L]M?(2GK,_U1L[M.KCKNHM^YO*9K(YBLVA65N,K
M)ZG(X],;7"GE,@A22758:;>_=>ZJ:[Z^!O</R2IMJ;,Z+_DK]T?"#^8B^_MN
M5FX^]>J.P,IM'XU8NDH\]+)F\_@,=_%#@\=3342H8%-1-.K`L#<@#W7NOHS=
M%[=W?M#I;J7:?8&=;=&^ML=<;+V]O+<;LTCYS<^&V[C\=G<I)*]VFEK<E322
M,YY=F+?GW[KW0J^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZJX_G;?]NB_P"8Q_XJ1W)_[R==[]U[K__5
MV8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW7$HI()4$J=0X^C?U_U_?NO=
M8WIX'(9XU8AQ(+WX<*4#6O:^@V]^Z]UR6*)6U+&BL5TDA0"5O>QM]>??NO==
M^-`6;2+N07-OU%1I!/\`K`>_=>ZZ>*.12LB*ZM8,K#4"`0P!!XX87]^Z]UYH
MHW!#H&!#`AN19ETL+'Z`KQ[]U[KF%`4*`-(``'XL.`/?NO=<?%'K+Z%UE0A8
M"Q*ABP6X_&HW]^Z]UV41KZE4ZAI:XN&']"/H;>_=>ZX&"$ZOVT]:&-N+%D;@
MJ2.;'W[KW7<<,40TQQJ@_H`/S:_^WM[]U[KPBC%@$`"_0#Z#@CZ?3Z'W[KW7
M((@O9%6]KZ0!>WTN1:]O?NO=>T)<G2+L-)(%KCG@V^OU]^Z]UC:G@;]42,=*
MI=A<Z%;4%)/)4-S;W[KW7)H8F!#(I4J%*D>G2&U`:?IPW/OW7NNE@A1F9(T1
MFTZF4:2VB^C41:^D'CW[KW73T\#L&>)&95=0Q%R%D70ZW^MF4V/OW7NO&"$K
MH,:%0$`6W`\=O';^FBPM[]U[K)H0_P!D?VO]CJX:_P#6_OW7NN/BCOJT+?2$
MO;G2""%O_2X]^Z]UYH8G8.\:,ZBRL0"5%[\'\<^_=>Z[\::E;2-2W"D\E;BQ
ML3]./?NO==Z$OJ*@L+`$\G@ZOJ?\??NO=<!#$"[:%N^G6;?70"J_ZQ`/OW7N
MNS%&>2BDZ0E[<Z`0P6_UTW%[>_=>ZZ$$0O:-1<$$@6)#-J:Y%CRW/OW7NO>"
M$N9#&A=D,98BY*%@Q2Y_LEA>W]??NO=<O&E@"H(!#`&Y`(^G^V]^Z]UT8HRR
ML474H`4VY4`W`']`#[]U[KMHT>VI0VE@P)^H9;Z3?ZW%_?NO==Z%X.D'2+"_
M-A_A?W[KW721QQ@"-%0"_"BWZCJ/^W/OW7NO>-->O2->DKJ_-B;V_P!O[]U[
MKWC31X](*?ZD\CZW_/\`C[]U[KF`!P!8?T''OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJX_G;?
M]NB_YC'_`(J1W)_[R==[]U[K_];9@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5Q_.V_[=%_S&/_`!4C
MN3_WDZ[W[KW7_]?9@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5Q_.V_[=%_S&/_`!4CN3_WDZ[W[KW7
M_]#9@_X3T_\`;E_^7[_XAFL_][[>7OW7NK(>]OD/U1\;-E5_9'=N]*/K_8>/
MR%'BYMT9.ARM=00Y/*$K00SPX2BR-6*<O9&<Q@!SR1[]U[I0[%[4V7V+LG:_
M8>T-S4.8V?O''T^5V[G$EEHJ?+4%5$'IZJFBS'\/K8_$O,\4L4<BW%U'OW7N
ME9+F4@:\E?3%(((9:G54T,/IGDLCS"2=32K]L?*&%@R\CW[KW7*KS]%C8)*B
MLKJ>"&&&KGEJIZI885IZ"`5%34QQRH6FC6F5GNFL$`D'W[KW18]U_-KXU[/V
M-LWL_=/=FU-O]>=F95\#UWN2M2O@IMSY2.LCHZEL:1`\\])03,JS2F,11EM;
M,(_?NO=&7I\_05</W5%DJ2KI?M*>I2M@R,<L#0RTYKTJ6<:J;P5%(RNK`^I&
MX^GOW7N@^WGWCUSL7-83;.Y=XXS$YS<U-D*S"8MFK:[(5M/11P3UDYHZ*GFK
M*2BI8IP14MIA(-[V'OW7NG?:/:^Q.P8):_9>ZJ#.T-&,-Y:^CJI/X8RY:F>K
MQ\E-5/$D63%9&"+(Q/\`7Z>_=>Z6KYNB)>U=21JCQP7DKZ5%6L<L8H68SHYD
ME&FT;`,P/T]^Z]T7K/?,7XY[8[NPWQMW#VS@L;WCF6Q2XWKZK@RE'DJVISN/
MJ<GA8%KS0?P5)<C0TLLL<+U`F9$N$/OW7NAO7>NWSF(,,V52/)5&+?,B%I&^
MR6A@JFQ[EJUXT@AD-3&P"-9F(/%O?NO=.53F:.ECJ)9\G2PQT=)49,F:I$;Q
M4%-&9ZBOK!Y27H4A!8-I"V'OW7N@!ZO^7_QN[G9EZO[KV1NR==QUVU4I:/+&
M.HJL]CJ;[VNQM#25?V\U?-3T2&37#KATF]_?NO="9O;M79/6>"I]S;]W92[?
MP=3FZ3;D=;7`D56>R7D_A>&BCHHY6&2JC"P5(QI-O61[]U[ISJ-][=AV_)O"
MIW)24.UZ?$U.<JLC4RP4U+1X>EIVK'R%?)4(E71J88V]+"_I-O?NO=!GNWY2
M]`;"PVS-R;O[>VGMS";[QU-D-JUN8R4M/'N+&5]73T=%D,?KC0Q03UM;'&DL
MH4/J`'OW7NE)#WEU=5;/SV_(NP<&NTMK39JFSV?DKXX:*BDP+/\`?Q7=`E3-
M"486C#N]N+W]^Z]T!]/_`#`?B952;)AC[IQ3-V+1Y&OV97+AMT083,4E%$'R
M$DV>FPLF#Q-3AZ<>6>&KJ*>6,$$H`03[KW1T<=54]?CZ*NI*N*OI*RDIZNDK
MH'22&LI:B))J>JBDC_;DBJ(75U9>"#<>_=>ZF>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJX_G;?\`;HO^8Q_XJ1W)_P"\G7>_
M=>Z__]'9@_X3T_\`;E_^7[_XAFL_][[>7OW7NK$/E'TV_?W1O8O4D53C:*LW
MIAHZ"EJ<E1QUM+3?;9"FK?/XY8W5)BL!4,.1?W[KW5$?>?\`+I^1&_NW=XY/
M;>'I,AU9MGO;J-.GME=C3UHV+#1YK:&6JOD/V#E\#M[/X^KS.RLQNU:6*@I$
MECJECB31$%!'OW7NDYV!_(K[NW9/6UZ_*"GW)FJ?%[:CP.<W;N#MV):(8K`_
M9R;?S>$V]NW%[:W!M+%U;>6@@K8)-%.BQN203[]U[H_7R0_E[]E=[[EZ?R\?
M;6$%'L?I_;'66XYZG&YBEK\1DMO559F*[?'6M-A\Q38>BR.Z8J\XJNIZU)(F
MQ@T+SS[]U[K#E/@!V=M#8'Q2Q_06[^B<7NOXZ[$W5U3F<9VGL2OWEU_D=M[_
M`)*2?/YW;V&Q^6IZK&;N@^T#TZS/)3SEK.I46/NO=%UJ/Y1/9V[,[F:C>G<&
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MVOF]A];9_8M3G,1B*;,TO6F3G,V>,U.];2220:28GU`>_=>Z#+K[^2UV%AZ'
M;F(W7W/CLKMZBS&#JMUX-\CV-NG';IHL+F=P9.JGFAW+N5Y:"IW0^8AFK$IW
M$0EB?39;#W[KW6;X,_!#Y+]&?*'>>/WYCY<EL/`[*[BV_!W5FH<G7-OJ?L6I
M@CV3@H8J_=N:@W'M?8N.1H:.FEH*%Z&(E9))K^_=>Z3&$_DM]VQT+0Y;M?J5
MY=O=F9O>_7F.P&W]]46)V/%5;-;`Q9?;*Y'/OD\5EJFN@C^YHH9EQ:I)((D%
M_?NO=/>Y_P"3_P#(CL"I&3WIW=U7N;/9?<NZ]PS5M1B-_P`5'U]+N;.5681N
MO**/<DL%-+6450*&I>H\K+'%964&WOW7NDM0_P`D7NC'46](<IW]MK?^2W'5
MA9*#?U7V96[7WGA)Z++XM<!O;;M'NJ''04^$2O22A:BT2AZ===Q[]U[HTO=G
M\MO=W;E%U!U%N7*X^HZ[Q7Q<ZZZ;W=N<8]I*?#9GK#L.#=,U7A<96SU%523[
MGQ1%+12F0RPO&KNQ(]^Z]T`,/\A:HSVR\5+N_P"2<M;V'MI=]TN)K7ZQV=E\
M?E:/+U^2EP5/E<SE(&W+2ST^-J(:>IFHY4DUHSHUS[]U[H?>O?Y;_9/3?2$F
MW,EN/"]E56SOC3W=UYL+9&WZ*OAHL1V7W'(^.J=Q8[)[BGK,E,E'@7AA66H=
MYQXF`(&GW[KW5Q/3NV\CLWJ/JW9^8E$^7VIUSLC;65F#^02Y+!;:QF+KY`_]
MO754KF_Y]^Z]T(WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NBQ_*KNO<?Q]Z,[*[9VYM>3?F:V=AY,CB=
MI453!#59FI-524J8ZG%550":M1*EIUAC;RU`B\,2F1UO[KW5<G5_\YGK'*Y;
M8^U.Q]F[ICR^X>L]S;[R.]]DX]VZ^Q^0V97UU+N#:>1H-WU&VMX8#=BT5*)7
MH*ND>6GJG6`:P1)[]U[IWD_G+=&U78VUL31[8[)H^F\YMS(UN9[ESFVZ?$XG
M`YJF_@-5)2_:R9J&K7$X&CW%3#)ULT*)3SN(T\P-_?NO="YW'\T>S,+C_B]O
M7J+;FWLMUSW^NZ*NH3>M!GZ3?U+0[:V]5[Q@JL+A\/D6I9ZG-[>QLDD%-,=+
M":+Z$V]^Z]TAX?YS?Q*K-Y9C;M)%W#78+;,.WI-S]B8_8=-/U[MRKW-0I6T^
M(RN8&;7(&MQKG[.I$5),(:W4C,"I]^Z]UWU5_.<^)O<^_>I.N=ET7<L6<[GS
MU3@=JY#<'7L>$VWAI/#32XJMW5N*IS9QE!2;FBK8_P"'")JRHE<V:%3Q[]U[
MH!^\OYQF7ZGW3E\5-U2M1M!*/L@X'?:96I@HX<[LSM#:/5VTL3N.":6DIHWW
MUG,Y64T0201BI@CN0&]^Z]T9_=W\R[;#]-_);?VP^M.T*?<'QTQ,DM;0=F8"
M+:F#W+DES\.W((=L93'9G)2[C5\@Q=8XE6>HC(1+,X]^Z]T7VA_FC=T5>!V#
MV4.M.OI^N:[J7)=M]L4E/E,Y#NCKO$8OLNHZA10E74QP5$^7W4D=1'1N@GA@
M+QO=XV/OW7NKSZ9WD@C>1'20K9UD4(VI259M(>0!7(NOJ/I(]^Z]UG]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW57'\[;_MT7_,8_\5([D_\`
M>3KO?NO=?__2V8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JY>P^MA?\`UOZ_7W[K
MW6)Z>&2Q>)'T\KJ4-I/]5!N%87^HY'OW7NL?V5*0Z^"/3(`KBW#`/Y`&'Y&O
MGW[KW63[>"ZGQ1C0;K90H!MIO86!]/'/OW7NN#4=(S!S3PZEU6(C4&[J$8\`
M7)0`7^H'OW7NN1I:=B&:)"P#J"1<A770X!O<!E%O?NO==FG@+*YB34FD*;?I
MTWTV_%Q<^_=>Z[:&)K:HU:Q!%Q]"%*C_`&RFW^M[]U[KC]M!^Y^TG[H"R<7+
M`)XP+_463CCW[KW7OM:?2J^%-*,&5;>D$7L;?0_7W[KW60QH;$HIL+#@<`BU
MA_06]^Z]UP6GA7],:+ZU?@6]:@@-Q]2`??NO==-2T[JJ-$C*K:E!'T;U<C_D
MH_[?W[KW70I:<!0(8P$U!0%L%U6U6`L.=(]^Z]US:"%B&:-"5U$$J+@L-+'_
M`%R.+^_=>Z]X8A_NM>"I^GY467CZ>D?3W[KW7(1QB_H7DW/'YM:X_IQ[]U[K
MKPQ6`T+92"/\"/I_MO?NO=<U4*`J@`#Z`<#GG_>_?NO==^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z26
M]MA;-[(VSF=F;[VWB=U;6W!12X_,X/,4J55!D*.8HTD,\9L>6C4A@0RL`001
M[]U[HL6:_EY_"+<6,V_A\[\8NI,KCMK8NKPN`IZW;,$QQN,KZN2OK:6*9G^X
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M3)9O$`ZXZ;(54T:L7`)1AZ;>_=>ZP4OPI^.5M]0[AZSVWOB#?V>S61S$&[<5
M2YBDAH\[G,-NN7;M'2U*/#!@Z3=V#@RL:*`5KAY0=7OW7NA\W)UGUYOG:F;V
M;N[9FW-P[7W1CY<7N/"9+#TCT&:HY/3-#74XB02*[KJ!X96LP((!]^Z]T!^<
M^&_0%7LFKZ[V_P!?[?V;MO(8_:V"KJ#;6,@HEKMJ[0S!W!0;7J_U&?"RY-VE
M>(\/*Q=B6-_?NO=&JB`6-`%91I'I8W87YLQYN>>??NO=9/?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5Q_.V_[=%_S&/_`!4CN3_WDZ[W[KW7
M_]/9@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]TW+-(9YE)(5&(7ZV_V-^`/;*7<3RM!H.I32M.DZW$GB21S0A80<,*U(]<X
MZRK,X#:RG^!#7'^Q)-O:J6+4M(R0>E(52I,$FMOM'^3IO:6=?)(:L*A8K:0W
MC7_@DD=BI'^)]H#=O`WA3Q*$7&HUS\SY=>N)&B@4S)&F,FM/\/0?[C[/V-M5
MA#N3LC9FV)2YAB&X]V83$/,X'ZHUKJ^-F7GZM;V77>_\K1G3><S6]LXX@SPK
M_)F'07?F3DZVD:/<><K>"4<0]Q`M/R9P?V](.+Y+]*RY4[?C[SZDJLK`(Y*F
MFI>SME3UJJ`2C-219?RI%4&PL1<_CV_9\P\NR*O@[O!-%@*XDC8,#^*H:A_+
M'0NY<Y?FYUL+K<N5;J\O=OBN%7Q;=?&C)%"5#Q!U-1Q%:]"?B]UT6XX:+)8/
M.4V6I)H7DD?!5U'DZ(*'(#&>DGF4%E%P`>?8A@NMLD5UBEB<5P=2US]AX=%^
M_P!EN'*W-21[E8[@+(VSG0T+A=0X&A"FOITKZ>K>:F$J.Y5Q<>0,DP%R.8VL
MRG_7]MO"GBXDQ\B"/V]6M[ZRW6%7@9XM0KW#2P^T'@>F++;EH\+09+(Y7*TF
M(QV+1)JNKRE5!0QPHQ"!ZBHJ6$4-/(S#0WY/'MT1*&6H%.K2V]U81^)!6Y)S
M3+'_`(STX4F?QBXB#*U>9HTH)*:&H%?-54:TTL-1;PSPU"2:)(IKC2WT;\>T
MTH`D<`4%>MPR231)+-`8Y6%2I!&D^E#D?GTZM4@`OJ8Q,H?6A+K)&PNHIBC7
M:4"Q-A]/;?3G4^/5XTU&Y(O?GF_(_5ZKV_K[]U[KG[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NF9:B7[RI4R_MQGA-7/T!L%_KS[I(MZ@UB!#">!J:TZ9@
MNII[B6U-GIC3@]"*_.O#KA]P\C,Q```Y\MU)4<V%_KR/>BUK=H(TNBDGR(K7
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M]TO]OAV:":QC)59>\EJT->`%1D#'1E.UX_E+5XO8T?6N\=O8K))N>IDWEE6H
ML7)4KLEMN2?8"?%96.LH*S,3[@T>62D2"-58Z`+>SB&VM[@YFTBE<9Z:GO9H
MX=3;5+2M*K&Q_GT@=X4'S\J=S8VMV3N_KV+;V.Q6U*JMQM?3XY)<ED,G04AW
MK0UZ"DE:@IL)54\_\-E4LU09.0`H]TE\.%6C$09P>/K3_/U>UCA>*.[FN70,
M*E&%"/D0>N6?/S9;;6.HX=Q82GW55;QS,(W!B\?@V,.WTQ-3_=B>HQ<M#)C!
M25^1,6I)8GD1BPE;2%]DLU[)"?\`<:J_8>M3W=NH*P*'/\_Y=*JHVQ\M5V'3
M5N=[+QNY=VTF9Q=5_=[9-'1[)@RF+6@FIJS!Y+.RPU<]'6-4Z:B2HB6-&D]*
M@)I]J89#-&DA6E?+K2,S(K,*,>A/^.47:N.Q>X<7V/D\OE(Z'^!IBZW<]9]Y
MG1F)8J^HW;CYJH,PJ:'&-)1QTLESK74WY(]N=7Z,\IN`?I<`V_I_A_L/?NO=
M=^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJN/YVW_;HO^8Q_XJ1W)_[R==[]
MU[K_U-F#_A/3_P!N7_Y?O_B&:S_WOMY>_=>ZN8]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW2.R^56CI\E4355)CHJ*5GEJ'J(?''31*TDDU<97"T\;(I_Q'O5U<[=M
M4*WEU4+IJQH,?,9&/4]%YW,6'U<_,D<<&RJ>V1C1=`XEF<J@_;3JK+OW^9YL
M[:,4VT^E,?2]A;I$U51U6XZYZZBV9BJRF.AHUJ$C6MSTL;WN(O%#QQ(P]XG>
MYOWM^3N1KJXM5;Q+E&```K4>?PR?L]>L)?O$_?9]L_:S;KN/D?<8;_F!''9&
MR/&:<>Z"4FH]*=54;_\`E/\`(OM51#O?MK<C8>M28R[6VK(-IX*6&9F_;FH\
M2L556+"OI5G;40.>?>`'/GWUO=+>=ZW0[+$8=E>0^#I:8=GD:5(!/GGKE=SO
M_>(>_7,5Q=BWA^AM)?A$<DX`'`4JQ&1GHOW\+QY3PFG^ZB%]/\3DJ<A(022;
MG*25,H))_K?WB]S)[H\^<T7\TVX;].)"QJ"YIG[<]8A\T^]GN=S1N<]SN7-E
MYXK,:@R&E?G7/5)WRYI*;&_)#>_\.BBQS+A-FQZL>BT;*DN$2HE`:F\36DG.
ML\_7WG%[;;[OD7MUR5,]_)XYM35@?BHYH:_9U^B3_P`RRG+GMW[H?W?.Y;MS
MCRC;;CO.W;VT4TTT1=G*VXD+*U>\T.2*9QT'FP^Z>XNKLA397KGMOL39&3AG
MCJX:O;V[LU27DB(*(\+5DM+86^FBWN5[#W'YHL!2.^D8#&6/[,>77>/F?[HG
MW9?<"/;MYW7VHVMC)&=+?2@L0QXM4X/RZN;^,W\_CY=]0U.+H.YX</\`(#9%
M.U)2UQS3_P!VM^8Z@+$29!-TT<,\6=K46Y9:F"5I+`>GZ^YDY<]]+IH;';MQ
M2C*`&<%BW^'KG-[_`']TG[?[@O,?,OM)NLMON[!GCLBD$5M&V*("L;.!G[1U
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M_<D;UER`/K[]U[H@>#_F@;?FDD7=/5>\MOM/OO)]<X=J/(467H,QG,=1RUDC
M3U'VU,V%0T]-*\3-(R3)XVU>H>_=>Z,U+\N-L0];T_9*8#<51#E,SA,-0;>M
M/#DGCS=3/0XFNDGFI!C8!/4P-Y1'42V`!+"_'NO=!_F_G=M]=LXO-XK9NYXL
MED(Z*MBQ.X5_NU05Z')/CZS!X;<-2DF/R.Y8Y(BW@%D"$$FQ]^Z]T+/17R4?
MN'<F9VU4[2K=N5]!CGR\+??P9:G-&E>N.TU$M,JP0S),X#A;V86^H]^Z]UF[
MZ^2O3OQQPN2WEW'OW![*PT<WAI!)4+5YS)U02P@PV"I5FRF6JI&X\:PM&O%V
M`Y]F_+'+O/O-^[KM6S;`TVW^($615E;CYL55E&>/0EY=Y/Y]Y[OK39.4]FFF
M+R!`R)*0*^99$8`#S/EU0]\AOYY^[\R*_;WQLZZBPE#%(ZTW8_87@JLE4TI0
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M'^X_E7_3=`7M#NKN/8AA?9?:G8N`DADDJ(/M-\;G?PS2E9'=/NLI..74&QN+
MCW\PDWN9S.+VXGM]SF6(N:=QX5X=3?;_`'.ONHWZ^&GW?.7=39U?28K2FH-6
MAIZ]6$='_P`YCY\]+34L=5VNG;&%A:&*LPO9^-H\Y524:&WVU+G)52OI08^`
MT=R/8TVKWQYIM`IDNI&4#S9NL4?=?^ZD]G>=[AYM@WZZY>1F)"6<=NB_EXBM
MPZO[^)'_``H$^//;+8[:'R,VW+T!O(SP4E-GM%?F^O\`.U<Y\,6C,0Q-68:1
MPX01U<3!3<ZP"/<_\C>[^S[\+2UW&XT;FX[J_#6O\3-UR,^\;_=Q^X_M))O^
MX[#-<;OR;:N/"N#WW,J$#N>.&'3754$*:``=7_[;R^VMWX2ASNU\E0YO#92G
MI:O'YBAK*:OH:J(#53K%5TDTJ,J@\6/^!Y]S.;FUG59#)&8CZ$&O\^N>C<N3
M<OWDMON22+,I^%U*L/R8`]+>DI(5AB9HH_(%;40=5RSEFN?[?)_/MDF(FL-/
M"\J=4E*&1BGP>769Z.ED"AX(V"EV4:;6,@M(>+<L.#[UTWU(`"BP%ASQ_KFY
M_P!Y/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW57'\[;_MT7_,8_P#%
M2.Y/_>3KO?NO=?_5V8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW7O?NO=%
MJ[\[6WAUNV"I]IT&)K9LK1[BK9),O#E9%FJ<-#25&+VW028Z)Z>GRN[)YFHZ
M22>R1S#4W'OW7NBF[3^?._ZZ/"1[G^/N]*6KW#%134J8.>.KCQ450*N+*19F
M>JHQ!%DL154;+#$I(JUNP(]H)EN-NF2:Z<M;S&JCR`./ETS=RB,0Q+_:/3^9
MIT=JF[6QE)UR-^;TFDV=1P85<SGS655+41[=A9#($J*N+1%*6C(-T'ZN+<>U
M&_W]MRUM\F\[@R+9H*DL:+2GF308^WI/O=U:\D;=+O7,-XHL$`+%R`H\SDZ1
MC@<]4`_+GY@[B[^RN7V=L^MJ,/TVDX4QQ%Z3,=@UE%*?'D,K4Q-%/1XN1?4D
M-_4/K]??*;[P'WPVWJ7=MDY2W&:"*.1HT:.HJ*4(KJ8::CB.N&OWV?OWWW/)
MO_;SVUW>>UV>.0QL\990Z<&'Q,A'&E.B31B*2.*4(H$+ZXE!N(P!IT@\:E`%
MA^/?-F\YCW'<MV-]OD[7;L>[Q#JJ*U_EURD37-9;A<RM2X9R=6*D\>/S/74K
M>4M?]+$FWT(!'T#"S`?['W6XW>Z>1UMIVCLZ]B`T51Z`>G1=^]MT>*.*2_D9
M%%`"<=8U145446518`DFP_UR23[*Y&:5B\A)<^9Z1.[2,SN:N>)ZI&^8X'^S
M';X_[4VRO]XV]'[Z*>VCLWMGR.&-0+5@/L\0]?IG_P#,K%;P0_W;TXBB"B;F
M,ZZ?BU0@-7UJ,'HM4=OTV&FX-O\`'V-'8@+0^77TL;=&D46YVT:@00R$1J."
M`+4`>E#UR<E^&)(`L.2+`?TL00?];Z^W(R11Q\7KT[MEO!+#(\D(,DAJQ\V/
MS_9TN>O^Q>P.L]V83>_7&[LMLO=^WJR&MP^X\-4205-!/"Q8QU"PF-JJCJ`-
M+Q2:XR/Q[%&R\W<Q['(&VW>;B!:4.AJ8].HH]X/97D'W7VB3;.;^4[/<H#2B
MSIK"LH.E@*\5K4?/K=._E6_S>MO?*G![6Z*[DR,.W?DQB,?*$DJ6BH<#VS34
MX++DL'5,1!#N2>!=4N.%FLMUO>PS9]N_<;;^9=JVRVN)`V["("6O$L,5&:DG
MB<=?+)]^+[E/._L+S/N_,_+=O/+[?/<:HBBDE%/<RR)''I11\*DMD<<]7UQU
ML-0E-(9ZA?+`TJA8M'*!A>12+J\9%K'^GN7!$4C=M"L`1QZP)@#7]M%O"3.D
M,0J\?`&F2"#GIZHV5J6!ED>53&"))`!(X_U3@<:C[2R$%V(4`5X#ATIBNHKZ
M-+N!-,,@J!PH.I/NG3G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]TWY'$8K,4LM#EL=0Y2BG_SU'D*6&LI9;$$&2GJ$
MDA<J1<$BX/T]^Z]TUG9NT6C\3;6VXT7E2?Q-A,:T?G2+P)/H:F*^98?0&MJT
M\7M[]U[K)DMJ;:S&*@P>3P6+K,-35%-54V+EI(?L*>HI)/+2RPTJJL,302>I
M=(`!]^Z]TQ9+%8*::'&U&(H:FEAE<T5)48BBGI**<`-Y:".2G>"G?\E@`;^V
MH[8;>+G<+N\>6.5UTH2*)Y44"AH?/I5#8E4>^>74B@G144(^8XU]*=50_/;Y
M_=9_#J*3"];8O#;I^0.X,14XF@V_AY,73P[4@JZAJP;@WM40A1$L-4HFAH&`
M:JD'-AS[R*]D/N]<V>[^[_4P6TD'+Z./$=@44`C_`$,LA5_V]9(_=C^ZOSS]
MY#F3]Z6Z26'*%HP\8FL893YH)(V#GY`]:G':_<_:?>N[*O??;N\*_>6ZZZ:6
M>6OJB8J6D:4:3%B<>C?;XJG6,!0D(46'ON#[9>SW)?MQR[M>U[5R]:Q7\<2B
M65%HTKCB[$8)/KU](WM']WWVS]J.7MDL-@Y0L8=V@MU22X1`))7`[I'88+,<
MD]!HQ+1B)N8UM93^+?3G]5_]C[E5H(G4J\8*TI3J;WMH)$:.2,&-A0@\".%.
MN!53R1<@Z@223<?0\D^RN"RM)I;N*6!6CB8!`1A12M!^>>FK*"&TC:VMHPEN
MIH%&`!\ND%VA^]LW+F4!RST3&X')5FL>/Z6]XG??LM;>Y^[)SY]1"KZ+8E:^
M1H<CI$L:'<T0J-(8`#Y5Z*FC$!3<WL.?]@/?QI$"I^WK*S;8TCV^TCC6D804
M'EUE$L@##5^NVJX!)M]+$BX_V'NP9@"`<'IZ6TMIZ":%6`]>NKZM0<LP9=+`
MLW-C?GU7)!_/MV.>:W=)H)"LH\QQZ".Y;5;<P/<[#=6$3;!&-,JFN?Q!=/`J
M?//5G?P,_FF]^?!_+T^*ILK5[\Z9K<C2'<?6V6J9JAX:,2JL]9M'(5#.,-E8
M8V+%!Z)``+>YJ]O?<3<K2ZBAW?=I9;0<5<X%<"G#KF/]\C^[O]M_=W;I^8N3
M-MMN7-\LE8QM9K$@OI#0QI=-(&HNKMJF:$^?6]1\9?E#U3\J.IMN=K]/[QDS
M6W,GXHLA23:/XW@<GIM4X#/TI`;'Y"FD^I'I<68&Q]Y:;/S-MG.-J-OY?NA'
M?1(I<(0"OF:98Y^8Z^:?GWD/=>1.?^:>0M]G@CYFVFX,-S;PR*Z1R:5?2,!@
M"K`C4JD@UI3HQT=;Y*M$^ZJ;D-I32!$^F_U/Y^GU'U]CE8A9V4<4S*TM*:B1
MJ)]>HZBY@A_>)V>6RI.6(U:6_P`)Z?X'\D2/SZA?GZ_4CVF6-XE$<C5<<3T;
M2)X;LGIUE]VZIU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5<?SMO^W1?\QC_`,5(
M[D_]Y.N]^Z]U_];9@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/?NO=>]^Z]U'F
MI*6HT>>GAFT/Y$$L:R!7N#K`8$!P0"#]0?I[]U[I/34.$#N)*.D5:><,+001
MQP-"KLL@`"HIC\K6/U&H^V95CW.-H@U3`W[",TZ8B7ZJ2:=J4M_\F>M?3^8-
M\HH^R=UU'2NP)((^O]H9&H?=60QK&$[HW'1L8I\7'+%:(T6WG)^XC>Z3M^GW
MS+^]S]Y:2:"_]L]FF83IV2%:Y)\N)!'Y=<>?O^_>X%_:;C[1\MWCB=:K,RDB
MM?PUU$$8]*UZKL>GA8)KLQ`2]K*O`NM@I%A8<>^40$L5\\=T*$,=7^7CUQ5A
MM;9PSW%TZ3BNH4''SXYZS$AM0ORW'``_I^!_K>SB[_=,T0,8I+3C0?Y^D=U=
MF8+:6@)0MGU)_+K%:W']./9$0%)`..D+H\3M'(*.,$=>]ZZKU2)\Q_\`LH[>
M_P#VI=E?^\]'[Z)^V7_3M.2?^>9O^KAZ_37_`.96;_Y&\O\`XL?_`%A'1:8_
MK_MO8UD^%?LZ^E6RX[Y_S6/_`!WKL_7VXGPCI;MB!+.%J\5KUTQ+6O?A0G''
MI'T!M:]O=^'2H^`2:TK7UZ5&T=U;CV+N3`[VVAEZS#;KVKDZ/<.W,UCYWIJO
M"YC#S++2U,<B'4"=.EB/JK$&_L0<L<Q7'+NZ17L,A721_/\`V.HR]R>0.5_<
MOEG?>3^:=MM[G;;V)T*24(/;0-0D5(/#RZ^@%_*S^?V(^>70:9/*STV.[LZ]
M;'[?[/Q(8+%)7I3@T^Z*.GNIDP^<@!9](LLU[^\].3.>HN:[.(0$>)0*0#FM
M./$_\7U\?_WKONV[W]V?W*WGEF^B9N6[MW>"2E5*,2--554!4&@`)-.K8Z(!
M:6`!=`$8LOUL/]AQ8_7V.BI3M)J1UBQ#%#!$D-O3P5%%IZ=2O?NG.O>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[JL/^9#\Y<#\-^L<F^,R%/5=O;SI9\=U[MW]NI^TEF40U.[<K
M2\R?PK#*VITX,C6`]R[[(^RW,GN_S?#8+;5V**0.SFNG2.(RI6OJ*\.I_P#N
MX?=]YO\`?+W"V_;K%9!RU&X:Y?(18P<@$H4).:J3UI5[KW3N7>FZ<UO/=F7J
M,[NK<M=4Y/.9NLE::IR%36W=Y=<EW%.58"*,_P":CLH^GOZ`>2N4-CY$Y,LN
M7-@M(D\.W`"KC4].)I\_.G7TY\D<B\K>UW)^U\M\C;';QQJD:R!!IUD#+OI.
M&/'RZ822;$_6P'^P4!0/Q]`/8OV9+N/:[)+ZGU83OS7-3YGCCJ7X%"PQ*$"B
M@P.`_;U[V9]/=>_'^W]H+/\`W(W/_3C_``=,Q_'+]O2`[,_X\S+?\&I/^AG]
MXE_?F_\`$9/<'_GE/^7HO3_DJK_IU_R=%27]*_\`!1_O7OXS#Q/65EA_N';?
MZ0=<O>NE?7N?K[LJZJCH,[E<S[/)+<I;>+;SR*&H"6!-%P!Y>I/#H;^D.F-P
M=T[JAQ.-#QX:A\<FX<GI*I14$;!I(*66Q7[^0$V'UL?85YMYOL>3]KDW&[),
MP!\-?XF/#5D$)\^N+_\`?"_WG7ME_=X^R>_&/>(-V]U]WJFW[<KK*UM(**KS
M);S+/;A699%9T()%>'6Q=\2^T:KX=[BV_4[$HC/LFG@@P^[=J+=#G-OHY>NK
MHK6A.<IV<R)*P+M^F_X]@+[OWWG+WDSW#O\`<MYN&?:;QE4*2Q"C@*"HX9I4
M]?GF>V_]XU[U;W]XKFOW@][.9;W<9>:;_P"HNVG>20:R%C6A.@NL:*J@L<!0
M#UL&=G[EWQW'\?\`;6Y/C5N*HDRNY,KM>NQ6:Q5>N)R:[<BKF;<%(:MTD%-4
M4]/>*6-EU,4/]??9C8MSBYZV^RYDL)@+(@-0<#7/S_//7>_EG>^6.?MAM.=]
MBE22":$2*XTU!(J%P6IZ4KT`4+_S0TK,C11577)VK3;=QE!AFE;$09=LSC\-
M!#E*K(YZHA>H(JLF!*)F4F=F=5"VO[$\C:G9AYGI7;7+7D$=TRT+BM/3HQ^>
MJ_EID^D(VVUE]O4?;SY':JI-58>E@\%)'G!#O&OK*&5WQDM`M`Q%(J*#(J!C
MZF/NG3_0>=FTWSXK=OXO';.SVU<5D)\),,WG1_`Z3(TFX(-SU>/H4HZ.2F>A
M>ER>`:'(L5X0PFG/,I(]U[IPH,A\W<1L[>DN?R6&S^=3JMJG;E4<5@,,D6_6
MFH$C`I<5%)/*XI&J9"G^:#*H/Y]^Z]TVKM_YXY78]=4MV3MJHK)\U1T^)PG\
M&QNW=PU^V?#C:BJR7]YL0&BH<BD35`5%CNS(+\GW[KW1JNBZ[?\`4;'F7L9:
MJ#(TN0EI<7-654M3EZS#P4E`LU97S2JDLU3_`!9JE%<J-4:K^+>_=>Z'9+Z1
MJY///]1?CZ_FWOW7NJNOYVW_`&Z+_F,?^*D=R?\`O)UWOW7NO__7V8/^$]/_
M`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW7O?NO=>]^Z]T0#Y[=X?Z#^G<S%BZEAO
M/L[(/LC9\<$BQU&/DR5%+_'-P`@%U7!8P&57^BS21^XF]V><(_;OV_YNWR*Y
M$%ZT;&-@:-K*$`C.2./G3J!?O`>[-A[(^V?-7,E]=Z+JXC<0>NHH5[<@U!R*
M5SUK:P1:$8%FE<O')+-(Q>:IJ(;D550Y):2HE8ZW8\LQ)-_?SR7F_;GS'OFZ
M[KNE_)<;E,S/XCT+D@D@U]1U\L&\;_O/.&^;]S5NM])//-([EWRU22RU-/+R
MZY:;<$?DD_ZY-S_O)]ANXDGFE>2Z8M.3DGC7Y]`:21IG:61BTC&I)\SUX<&X
MX/MC2I\NMQN\3K)&Q$@-0?3KOW;A@<.MRRR3R/+*Y:5C4D\2>O>_=4ZI$^8_
M_91V]_\`M2[*_P#>>C]]$_;+_IVG)/\`SS-_U</7Z:__`#*S?_(WE_\`%C_Z
MPCHM*?4_[#V-9."?9U]*UC\6^?\`-8_\=ZYW%SP#_K_[X>ZKK-`I/1793W\5
MK*;)C/20:EE[0B@=PBH*L*9'J<==?7Z"UK?X?Z_Y]KXK.9J,YHO2F.ZDN)A<
M6EM6R`.OQ`5<$9[5\\?SQTYT5/%/+&'IYWJIX_M*(T\<CR5!D(`IHZ.._P!S
M)(Y`U6]B+8=JY;O4W,<P[S):Q0]RLN@Y`KDL13J,_<3GKV_]O[9N<^>N>[+:
MMI@A>4)>7-O;51`6(C6>2,L33`!J3CSZN5_E?IW+\1N[-N]^Y>JDVQLC(TPV
MYO/9-4Y%9N#:&7K8H*RHRU%9H,?7X?4*ZFG)+K%&RVY]A[D7[Q?+/(/N)9[!
M!+-<V!FI-($+(B,.QD9&TDD?%7`..OC0_O/O[[GV+^\'[V;)[!>RW*MONFWV
MUP()-SNXYH)5E$FF18&2=X9$TGL8?%UNF]N]QYC8>P]K[IV@VW\F-P[BP=)3
M5>XY,A2XFIVU7XO)Y)*VC-!(DC9"L2CB2(!@KM,/3^/?3';M_L=XM;?=;)M5
MC<+K0^JMD'C3J)+10EK`%^'0*5].(Z+,W\PIY,?C)H.K=RR5*46R:[<4C.*6
M*CBW?/7P2T--0U$8K5RV.DH3HA<>6K1E,5^?9[`L4WPMTHZFX7Y[U^<K:"#_
M`$'=G4U!F\K58/""DGP];E?]QVUZK=4V<RM*SQ-1XJ7P+3%S(K*[%2NI6'MN
M12KLI\CUKH^_7&\8>P=B;5WK3TWV<6Y<-2904AJ(ZLTKSK^[3M40JD4K0RJR
MDJ--QQ[IU[I:^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z@S5*Q,RL_P!6"BUKJ2/I[07%^EO>6MLRFK@^6.-./3D2+<ZEB;N0
MYZ#_`'COK%;%P6Z-U;BR,E%MS:F$R.=S5<[*GVM%BZ66IJ?%?2#,T:>@7NS6
M`]WCV+G'>^<.7-OV&VB>SN)4C*%R"S.P454`^9SZ#/5-AO%YCWU>6MNL&?=2
M^E0J,=1KPQ4U^0'6A=\LODANCY7=\;P[@SM752T5945&+V'BYG-]N;,IJC5A
M5D5_1YI:=1,X`OJD(:]O?T/?=_\`9N'VFY1V/;[BSA3=A!_C+1FH>5JECJ%-
M0\J@#`Z^H/[GWLW:>V'LWR;$NU1VG,5W9![UE!#O([,?U*BI(6@R`>BW:@;G
M7Y"227MIU$DDM;\:C_K>YXGM[=U+V2!;NE`PX@?;UF':V-K8JTT,`61@-1'$
M^6>NQ[66:31VL,=RY:<#N)XD]+4;4H;UZ[]JNK]>_'^W]H+/_<C<_P#3C_!T
MS'\<OV](#LS_`(\S+?\`!J3_`'M_>)?WYO\`Q&3W!_YY3_EZ+T_Y*R_\U%_P
MCHJ8_2I_VD?[U^/?QGT#=H'=UD9+??N+:I+^6=YM970A%=-<!5`SIKQ].N=A
M_3_'^G^]^]B!SQX=*[>XN)K:WO+FX$5T\9815`!.:#-&]*]+_KKK7</:6Z*#
M:.VH9%JJY$GR.19"]+@<8LEI<M4R7TZ&`(6/]1/O7,>\;-R5L'[_`-TEC>(Q
M$E*@MJK0!5!!)^7IUS?_`+Q7^\9]M_N'^PV_<[<^[Q##S[/:R"PLHV61WGH0
MM4$B3A*D$,JG/5Y_5?5^W.I]D4&T]NPC0BQ5.3R2Q@5>:R84&7(UTH]9D<FR
MC@!`!;WS]YQY_P!\YVW2:\EVH_N\'2L:AR@4'`X'\Q7B>ORNOO@_>S]SOO;^
M]_-WO7[I\R7-YNVZ7+-!#*Y=88OA5`6`=0H`H&J?GT))B9TC!6-M:(6.OEU@
M8L@:QXL3_L?8>MK>_P"81<0;1LJ0O;BK%`U13.:@YQUBOO%YND<EL]_<^);K
MA(]094''2/0'B>K(OY<??]3L_?TO1><R<D.U]_C*9C9,;JE0:3>\*1+EL53K
M/(OVT.5IM,L:KZ6F32!<^^HGW%OO`WEYLVY^V7,Z2R-;IK@E0/)*00:J5&``
M.&*D@#KMS_=R^_NZ;K:P>WVX0/'M2"D:C48S04(J33AY>9ZV"L;3K_#Z=)HH
MRQA"2*#Y$(4L`I)%F`'U_J??23;='T-KHN)I4TX>5=,C?-U\C\O3KL#-';PR
MO%:IIMU/:.%!]G4Q:6G2Q6%`0%4&W.E#=%O]=*D\#Z>UW3771I*8A0T$;!3=
M=:A])N3<:KVL3Q_3W[KW7OM:<LK&)-22&56YN'8:2P-_R#:WT]^Z]US\,5@H
MC0*`0`JA0+BQMIM:X]^Z]UUX(=8D\:ZP&4,>39K!AS?@Z1[]U[K-[]U[JKC^
M=M_VZ+_F,?\`BI'<G_O)UWOW7NO_T-F#_A/3_P!N7_Y?O_B&:S_WOMY>_=>Z
MN8]^Z]U[W[KW7O?NO=:VG\ROM&;?7R:J]GT-1)+@^IMO4^WO&LI>E.Y]R)'E
M<U.D?T6LBHS%22'_`%$8'OE-]_\`]RKV*]V[D6SN6$.C4X!]>/RSPZX9_P!Z
M?[I2;KO?+7MS93'P+.K2J/-^.1P\P/RZ(.K!40VO<WO_`%YL1_L+>^9[65WL
MT^WW<ZT250P^RO7)N22;;MI.WLE)KJC?EPZZ<W9C_C[27LBS7=Q*GP,Q(Z#A
MC:+]-QW+@]<?:;KW7O?NO=>]^Z]U2)\Q_P#LH[>__:EV5_[ST?OHG[9?].TY
M)_YYF_ZN'K]-?_F5F_\`D;R_^+'_`-81T6A/S_L/8UDX)]G7TJV/Q;Y_S6/_
M`!WKD>.?S_Q3_'W>"01/J(J.@K-NTQ>UVY!+!.,B1%.DH#W:W/:M?/Y9Z%+K
M'J#??;>32@VCA)ZR"*58\CF*C51XC&IP9'EKG73-/$O/B6]_95S'S?MO+EE+
MN&Z782V7@JD,Y)X=E0:?/KF/_>+?WOOW9_N$\B[K>;WSA9[M[F"`FUL+1X[R
ML@)&BX%M<>-""U*U2M/+JVGH_P",>RNFECR_HW-O"LIHFFSN1A2H6FJEN)UP
MU+.&3'4A/T%BW%[^\1/<#WJW7FA+C:=J@-I8?`"FK5.O\3ZN);@:=?GN_P!Y
M9_>Y_>,^_IS'!?[QS--M7*5V^NWVJUN'EMH8B:",K,ID0EAJTDDU->'0D=A]
MN=8=98FOR'8V\ML[<H(*.:IE@R^4II*^I,H)D>EQ<$KU]4#I&D!3'<6^GL9>
MQOW?_?WW,NDMN0?:K=+Y9`!XIL[X1_(^+';NE*_EUS,Y1]M?=G=^;>7DY9V6
M^7F%Y!+#<1QNL:2`U61YBFA.[SSC-.MBG^4G\GNM?F1\+MGYW;U;'N[&]=;J
MS76LU7FZ."HJ9Y=JU3'%9NIHZM)TIIZJBJ-41^JHHM[[J\L>UG,WMER-R9R9
MSE8-;<RV>VQK/&U=22K76I#*K"A(XJ#\NOJ7]F;/G2S]J.0K7W#NDGYXBVZ-
M;UUD\96G%=3"6@UC3I[J#->K1$VOMR1TGFP&%DJ!)3U`F;&4;.9J2XHIV8PD
MO+1J?V6-S%?TV]J;1FA<Q-Z]241Y]2_[M[>]/^X+$`K(904QU&A\C>34]TA4
MZF\K7_KJ-_J?9F34UZITYTM)2T-/#1T5-!1TE.@CIZ6EACIZ>"-?I'##$J1Q
MH/P``/>NO=2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=,4].)'J6+J;3+(/4ITZ5%U(_LW]H[V.*YNK!'4KI4]U/G7B<=,[;'
M+MUQN%S.WZ$S`C[*4ZI<_G1]R9C8OQLFZXVUC,_E,GW)G(<1GZG;]#75K8#9
MN+C6LRM?5MC4D-)35,RI"));*9+@^Y3]D;CD:+W;Y:GYJ]XK?9$@F#('N[.(
MAP<56>1"!\^LO?N0\O<EP^]^U\U<QA&L87\0:@I&L8%:L*4X\?MZU"X)$FB(
M699X:<,K26"-5*KLAG@%E)B)!_%@>/?T1<O<U;%O-K9P[/O,6X6S1@">)TEC
MF%/C22)FC>IXE"16O7TZ;+O^U;K:P7.VR*UI*H*$4*D>5""1CA@]<ROU(-[V
ML?\`"W'^Q`]BZTM5M0S,W0H<ZXJ*,$==J+`#Z^U.L2=Z\#UZ$:8T'RZY>_=.
M=>_'^W]H+/\`W(W/_3C_``=,Q_'+]O2`[,_X\S+?\&I/][?WB7]^;_Q&3W!_
MYY3_`)>B]/\`DK+7AXB_X1T512-*WMPH_P!?Z"WOXT8%K*3Z=9*(('M(VNX8
MVE1*Q`G+4%>''C3ATI]M;8S6\LWB=M[:H3DL[EJE(*+&HC%V!;]VMGF_3%21
MJ;D&W(]M;EN5M8VL]U=2^':1@DMCTX+4Y8^0ZQ.^]I]ZGVU^ZG[-[Q[Q>[VX
MVUG+9VCR0Q%U+O(M3HB1I(Y'!(`.BI%>KLNA>CL-TUM>EH(84K<]D'CJ-U9\
M6662?2SM1PZO6M'`YT!/H=-_>$?/G.>X<_[Y>6:-39K4_IH*D&GXR#P8^?EU
M^6I_>:_WCO/G]XE]X/G;W-YHEF7DN.\/[GL`9'AM+<(JC0LE9(RY4NP+&A8^
M70ZUV3I<-C)LGD:NCQ^*I(Y9\CD:J>*EHZ6!-1_RB29U"LL8_'LLY&L^=.>-
MRAY+Y!Y?DGW29@J+"DKL37XB$5R*^M.N<NW\M;KS/N>WR;;8S7]U<$!E1&D\
M+4P4%M`)4+QJPH!GAU6)\AOYI/3W5B9#!]84Q[-W5`KTJU'EEH-FT50`0TKY
M>(??5DL;$>F-?&2""??<S[B7]Q-]ZWW[YDBO/<S<+CD_VZN%#W%S:S)]<RGX
MJV]Y`JL=)-`#UGO[;?<*YIW?<S><Z.L'+:LIC:HE:53YJE%'$&IK3JG6I_F%
M?(RJ[XZT[^J][5])D^KM[;;W;A=NX,S8_;=&-O9**O-%]I3R(LK5U(KQN[:M
M98%A?W]4'(G]SU]SG[M?L7N_+?)'M5MG,7N8+=UAWRZM52_:4H0'=[=O##`]
MU=-*\1UU2]H/97VV]J;6S/+>UQ0WZG+A0&-!45R:5/IP]>OK7_'[M;`]Z=']
M3]R[9:^"[/V#MC?&.34'-/%N/%4^3DHW()'DHIZAX6'X9"/?S[\T\N[ERCS'
MO?+&[JR[E8W+PR!L'4C$>8'$4(P*BAZS-L9VNK.WN'-6=:]#![(.E?7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U5Q_.V_P"W1?\`,8_\5([D_P#>3KO?NO=?_]'9
M@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/?NO=0W=QKLQ_SMA_@MOI_K>V[HE8
MTT&C'JER2JPZ,$\>H$]3)%*\CRND"'UD,`B*@,CNQ(](&FQ_P][OG%OMY<8D
MQGI9(T,5J'=0#QKUJ"]C[RD[`[-[%W[(IBGW?O\`W+N&JC+%DAE;(34:)#?E
M8U2D&D?0#W\\'WE>9-QYC]Y^?#N5VTJ6VXRQ1U-0L:&@4?+KY2?OB\S[AO\`
M]Y'W8-Y=,\=KO4\<534*B$!0/V=(Q/TK:X%R0/Z$FY_WGW"-YN%]?K!'>W+2
M)$NE`WX1Z#K&.YO+JZE22XN&>1,*3Y"M<?GUXDW/^/M$```!PZ22222.SNQ+
MDU)]>N6H?T]^I\^KI*J\8P>NP/SQ8_0$CCV\ML64,9:`]+TL9RBW($/AL*@%
MQ7]G'KL_\%_VW(]V5(4PSUZ>CO(X3I;9X9"/],?\'5)'S%B:3Y'[YT+R,-LM
MB#P++MY+B_\`7_#\^^BWLI8S;W[>\IV\$D:Z(9161P@H)2,%L'Y=?IA?\RR-
MXD/]V]%=<NVBON*[GJ>W:J0B015J'%6U4`Q_+HN5%22Y!Z:BQ])45>1J"`M#
M11O55\S_`$_9B'Z03^/8]W"SM+:]CM8;Q=0<(S2,J0@D\?$K2GJ:TZ^@'F+W
M<Y'Y"Y-O^9_<GFK;=@_Q26:5;BY@MR2D;,PMQ<21F9P%.@+EFHO$]'IZG^(\
M2TE!OGO/(T>SMI?;)7P[>K<A!C\E6H5UI+E\E-(BXU"!=Z:VJW^O[`_,/-T]
M_O=]R7R1R??;OS1;JT9&U6T]\K2$8*M;B0-0TH0*=?%=_>5?\S*'-?,-KOWL
MG]Q*;>!<P7+VK;QX%U:7E,HS!5$T)S73@`C/2M[)_F(?%GH/#G:778FWC78:
M)J.BQ&R,=`VW8:I+JD.1S4^E"^KAG597/)U>\O?NY?W'/W_OO7[79\[;OLVW
M;=R7.:,VX7ZV.XH*54+9W4"MVUS44KBO7S0VOW6OO(?>(YJN/=#WLWN:>ZW#
M]2XO[F17NSJ.K5X?AKG)/=2AX]5;]T_S2?D%V-2U.-VM68_JG$W96H]MQRU&
M?F1U92#NB=&:DB*_6(H#R;&WOZ'_`+L/_,MA]VKV\MN6MX]Z>9YN9=SAA4SV
MEY!92VZ2`ZBD<D3HS(#P;B>LR/;_`.YE[-<N6EFF[<O0;MNL)6D\Z4:0C.J0
M*U&;YC&.JSMQ[GW#NO)29O<N?RVX,M*3KK<K6U%9/I9M113/(WC2Y_2H"_X>
M_H7]G?8_V:]C]@3E[V8]O[#9K-(1&%MT=$;2*"I+N/GUE]9;'8['MUO:;;!'
M;VL:@(B4`4#@!Y_MZW9?^$A/><U;C?EU\<Z^JFD>GJ]F]QXP2%?%30UZS[0R
M5+2H`%C$\D"S.`.3S[^?W^^7]I[7E#F?DOGW993:;]N[2F\,5#J<,&\1FR2S
MC!J`*#'4S\E;N[V,%G+-70N/L]/L\^MG7L/YDYSKO?VX]LY#K_(U.W]L9VKQ
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M"K1RC=E773U3XBEA>UJC2B22!E`]/OW7NA!D^:&)3.5>$@V5NN9Z/?.6V0N1
MFJ\508"KRV)PV-RD\XS%89(Z3!R+76@JIO'#4.OI/(]^Z]UBP?S?V[FNP]B]
M?-LC>T5?V'D7QV'>-,<4I33)6M49.LACE>J@QC2T>A6=U+7#`6(]^Z]T>NCE
M,U-#*S:F=;L2NCU7(*Z;"VD\?[#W[KW4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U#:FA'G/B75.0SFWZF%@"?]A[U*XF:&"4:D`-`>G)#]1''%-W1+Y'H@
MG88H]Q]X;XIZFFBEH-L;5VWLZGC:-*C'U[;D\^:S4=5!('A>:AGIXE8$7&H`
M^_G1_O:.8X]A]R]EMN6)A:;JL:L[1TU'@36M?.GEU+/MZ3:0AK<E`&QIQYXZ
M)3W)_+^^+7<:5LN4Z^I=I[KR:.8]T;%G?;>X!,ET\@:EB.)^V<C4T#QC5SR+
M^X=^[Y_>Y_?D^[J_*L?+_OKO>Y\G[9"(XMHGN0EDD>HD1KX<7B!22<5\R>LI
M^6/?_P!Y.4/HK#:?<'<HMHM@%C@\0>&JUKI':2!]AZJC[:_E"=LX$U>2Z<WQ
MA^P,72&1&P6Z(%VQNGT6*TU--2B7#5-400`S_K/-Q[^C;[L/_,T/RYO]SM'+
M?WGO;:TV)3&JR7&UI?;A(U136WB,B:CQ(%!7K./VQ_O`/H+:.RYVBEFN0N92
M6E!(XT"Z33YGJM#L3J#M/J#)RXGL_KS=6R*N-GCC7/T+14=0RC_.09RG\F#F
M1KW6TZEA]%O[^B3V7^_I]V+WJY>Y:W?DKW3VYH-R@$L$4]Q:P7FDD@"6V:X,
MD;U&585I0^?6<'(?WH/:SGK8]KW6QW]4GN5)T,%0J02"-+OJ'#S'GT&<+I,F
MH2`LGZUX#7^MBH"CZ?T^OO,&"XBO[**^M;XM;N*AH]+`@\*$5!_+J==IWNTW
MBS2XVZ=)JCB""/Y$]9->KD#2&OQ_2W_%?:"PW:*[&[6NW0R&^MV`9I4,:NQ&
M"&.&'E4=)["\W5]RW"VN+)%@1NU@2=6/LI^SH/NRV1-H99I'<1EZ$!0`>69A
MP/K:_O$O[[N^3V/W:^?K3>-K'BO9D5C#.JG.2P%!CS/3=IXQWY);R9H[;Q0?
MD14<:TZ+A04$N2JJ+&45%/5Y*M,%/CZ2EC+RU%7,X1$:,7+(HY/]/?Q\F3:K
M"WM;^UE,[E&\=)1I5#FGAD&KX]?/H?\`NM[S^V_M/R-S3[I<^[S!MW*FP0L[
M74K)&2N@OH@,CHDI<C2%5JDX&>KC/C;T'C.FMJ2[CW0:*3=.11:K-92H:"FI
M=K4Q36^->NJ)$^WTI8D+^3[Q(YRW3F[W0WYMAY'@,EG$V@6R:C<3R9-4MP&D
M=J5`T`^77YCO]\Q_>E^XG]XG[S;G:\O[YN">R^UW3P[9MB"0V]Q$77_&&C=6
M=979<JCLN>@!^1_\SCH_IVKR6VMCB3LC?5+Y*?1CI_)M2DF6,%36YN)BDTD9
M8'2GY%K^^I?]WY_<@>_WWM;N'F+GF/<^3.0YE)\9T6VOF0-23Q+:^A323^$5
M[@:CK"WV>^Y3SUSM!MW-V]?[J=DNE#M%@LJDZ='A,`^0*T/KU1!\@/F3WK\B
MZN6/=&[JZCVV9=5+LS;[38G;\)1@4>I,+QM6N@')8L#_`$]_8;]RS^YC^Z#]
MSN+;]VVOE&SYFY]B1:;I>V\<=TK#).NWDT$U\].3UT^]K?8?VZ]H(UN>6^6H
M(]W:+1+<:2KNM*$4K2AKY=%5J\I7U4LKSU33-(RESZ6!**%%CH%K6_%K^^OU
MK96=O;QPV\`6%5H`*T`X$=3.UU*UO%:JQ6T045/)1Z`>G43[F?G]PV974BRZ
M2KV+@K;3ZM(_Q]Z@VVPMH_"M[54C]!4<?SZ3_BU_B]?LZ^G)_P`)H^]\IW)_
M*XZTP.5RRODNF=[;ZZFA@$IFJX<)BJN#.866L9RS_NQYN41W/"1@#@>_C\_O
M..6(N4OOH\]C:HC!M%Y+%<,BBB,[Q('IZY6ISQ/4\\H7,LVT;?XDA.*?L)ZV
M$*621X(G+NVH.;L02?6UC>WTM]/\/>#-P95WF*-6I;Z#51PK3H<3*@:2B@4Z
M<%OI%^3[5GCCATD4U4'KE[UU;KWOW7NO>_=>Z][]U[JKC^=M_P!NB_YC'_BI
M'<G_`+R==[]U[K__TMF#_A/3_P!N7_Y?O_B&:S_WOMY>_=>ZN8]^Z]U'91J/
M_!PWMN8U,2GAUJ4:A'7RZ#7L[,P[>V'O/,2'1#C]OYZOF-R+I2XRJJ9"3>X]
M,1]E7-<QM]DG>OX3_@/1!SG?M8;-*^JGZ9_D#UI]X];T@9^?-/550)^I6JJI
MJE#?\^F4>_G"]X)S<^Z//DY-2^YS'_C77R7_`'A;IKWWO]T;LG,F\W!_:W3A
M]?<<=0YQZX_4^]]4XFG7FCD8`(5#-Z4LR,Q8?JNC%;6'O885^'RZ-[7:9[D`
MJE1]O7)E\,:RRSPB+1>0SH*<@_G3('*?CZ^S>WV+<+X"2&$T.1QH1^S_``='
M\7)W,%PL?[NY3W*Z+#!CM9Y%/^E9$(8?,=)VJWGM+'!UR&ZMNX]48@+5Y[%4
MT@_VD^6L66X_VI0?8CM?;+F:_'BP;<Q)&!W$?\=Z&NT>S'O9?@-M'L_S'*I'
MX-LOV_FMN:]4??*_L;9^6^4>^,;M[)5N\:]MM[,JWH-CXG+;QK*2"BP*)55(
MIL#35PJWE;CZB-#^KWUB^Z[]VCW!]TN3>4>7-MBV;;KA('!FW>^BVRWS(<K/
M<Z8RH&:]?<K_`'*'WOX_N6?W<'-=GSMRC=Q>Z4.Y2&RVLV]SX4TO@D1MN+Z5
MELIG<!9%9040!J9Z#1ODUOGJK'JG3'QUW!BMRF*0S=C]L[0S$FY)T93YQM_;
MQH*?#8^G1?5&6+RJ0/J??8GVA_N9O9;FJ]M+GWW^]]RK:;<L(67;K'?.7MRM
MG)_$[?4HX(.*D]<_/O5\X_>A_O`.>[SW)]\?<&\BY%@5Y+/E>VG\7;K3%3X3
MS0BX;2P+*0QJ3T1WM?LKY,=S5ZR]@9GL/=4$4-1)'35-/FEQ\:2R,]HJ6FHZ
M:G/CO94*FP'OO-]V#[L7]V!]U_;MBW'VH3VXVOG"SACC.[0;G81WERZ"AEE`
MOB@9SEJ`J#PZA;DKV1Y.Y?LHEY&Y`AVS=O"U7;F%DDN)!Q=FDU%G/]&GRZ`N
M#:>^C2/31;<W6L$=0DC(VWLI&VI2&NA^T$C"WX!M[SJF^\+]W#=ITM']Z>5O
MW@$*K*=UVZH^>HW5!GJ2[7;>9H[:2"1&7;@0)(34%QQ(T$:F!&,=)'*154>0
MJZ:LCDIZJ&<I/25:&EGBE0?IJ*67QR1RJ#]'4-[7V'NW]W_P8K2?W/Y>NG44
M,G[PL2KG^(,MQI/VC'3%UL=X9GN;2R:W@8U5*%="^2T85%/0]0O4'+2-$23<
MDR1#\#Z>H6X]B(^Z/M`;<Q[5[O[!;1^03<K&E?SG/15-M>Y2L5:-B?S/^3K:
MG_X27;HBQWSK[JVVD`F&Z>A-=34>5(Z:G7`Y]:[]@@$U%5HG`91<@'WQ&_O;
MN?/;'FSE_DO;-NYKM+_?[28!WCEAE24,2:^)'(0P7U7'KT/^4-KGA9!*K!M/
MYCUQQZ^AE48?#5"-/48?&5#URL:B22@IY#,)(A`QF,D)>4M``IUW)46^GO@C
MO/,&X;#+8VVU6ADC:G`MVY\BM?MZE^*140:GH%'[>I='M?;5-#II\!A(EDA6
M*0Q8J@B\L2WLDGC@76@)/!N/9Z9YKG_&+FOCOEJDG)^9R>DS2"5FD'`GK$-E
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MW)`CH,%XU#?72FHV'T%_?RE_WIFZ7%_]YF]LFE.B./13[6'4P<B@?3("/]5*
M]*E(HB(V8`2HI4&YX!^H*ZM+?[$>^?%X=HA9]NN86AEB(!=$U%B,U-<=#R59
MVE:@_3\OLZP24M.Y)DC5KMKY=DLW]1I86''T^GM%MZ++NB+MSK.E/]&I&#\N
MFI+.!R&>6CTI7'#I,9;;6W-S1U^(W)@L1G\16@15.)SF.I,KBY%TV!%'7Q3T
MRNH)LZJ&']?8_P!LYUWWVPWNVYHY"YHN-JYU@-=5J$*Q'TCE(;4*`&M./3EE
M9#:YHKVTW1E96U*`5&DCA2F>/5=7=/\`*[^,79-=4UNV*++]1;FF\LYK-EDU
M&-JRY`\]5@*_R8V6,$?\=$8`<#Z>^PGW6/[^_P"_Q[%6^V6W,?-]YSWLT#C3
M;[K>21Q!1QC`MH58+04K6O61G(WWP?=OV\4V]G?R7NWA=*QFH8MY&J+4CJKC
MN'^55\B-@_>9#KP8ON+;5.KU22X2J7$[KCHHVTWGVUE+#)S,U[M1RB,`<#W]
M&GW5?^9C[V*]RH;:+[PNR+RS=SJ*QV,5S=K'+G].L[H1'P.LC\NLSO;[^\8D
MN]OV>RYSY>BMMT)TR,OBR`BM`=6,D<0<CJJ'O[!978."S&+WUM[+;2K:0TKU
ME'N6AJ\1-1.:J.!8`,BD-+D?W"&,D$C*M[?CWT=]X?O->W?WCON^\U;I[2<X
M;?O/+4]MW6JW,#7CI\1!L8Y))BU."@5ZS9L?O#>U.Y;"-WWK?X8K4Y.HQ`C@
M0:-("/,$'[>@?VQ\A.D/C-2Q;RR$([8[FR=-656V]L82OIY,'L>EBUQQUV;S
M-0WC7+$@'QPA_2P`Y]\=_N\_W7WO[][CF.QDM=CN^6?9ZXDUM>%3!?1KXA!5
M;2\B"LH3*G5W=?*!_?!?>>]W_OK^Y7,'W;>3=^EV7[IG*=Q]+<"-ZKODK&.Y
MBN#;R*RR"V8M$DD$@05.K/1'._?F_P!\?(&5*+.[GGVSMJJ6HEEVAM`5=!CI
M#>\2Y9I-,M3,`O+$@->]K6]_3+]S;^Y/^YY]UZ6#F/<.6+;G7GV"=98MWW:U
MCM[RVD&5:%K>4(:'-2O$4ZYS>TOW4?:+VO6SW1K-;MO!+03R*DACH36,*#HA
MU'RRWH>B02^02$M4'RJ3?3H*7N6L00`YNW)(O[[,7NQ_O78[?:;3>Y%9*?J*
M59V`/!@:CAC[!U,@W"42-);P:+4_"N0`/+J&S-<7+<-K#+?]7Y;2/2#Q[7V&
MWVEE8_NB&>1;I$H92*$G^*OPDY^SI0]Z+H_XP,?MZQR.TCL['4Q/)(`)L+?0
M``?3V9[9:R6-A;6DMZ]S(BT,K4U/DFIICSICTZ2/IUG1\/7#VNZKUOS_`/"0
M#<,-9\<_EMM7[V>27!]O;+ROV+F\,$>>VME8I)(1;TB9Z,:OZE??RZ_WSFQ+
MM'OERWOL2XO+0LQ_I!XUI^SJ;N1])VRT[JZ:U^63_GZW&855*>-%%@@T"WTL
MI*_\1[Y.3+JGDG/Q`'_!T/Y.+>E.I41O&I_J/^)]I[27QK:*7U'3`%`!UD]J
M.M]>]^Z]U[W[KW7O?NO=5<?SMO\`MT7_`#&/_%2.Y/\`WDZ[W[KW7__3V8/^
M$]/_`&Y?_E^_^(9K/_>^WE[]U[JYCW[KW6(B^K_`^TL.IIYA(:@''RZV0&`'
MGT@]^[?I-R[2W-@*JD6MASF#S.+DHY#=)DK\95TI0JK*VF<2%38WY]E/-2-/
MMQA*ZD(X?RZ+[_:$W6)X+U!+`0<'A2E/+KYWFX_G!V#M[*9O;&/V%MA)-OYS
M.8&6KR]9DWJHUP^6K,=&6I(0J)(L5,..;6]\C^<?8SE7<.?>;+V^F=&EOI&T
M",,!4\*DUIU)OMQ_S*]^V/WG[+;/??=?O`<R[,G-4?[Q-E;V%A)!;^.2?"C>
M9];HM.TM1CY]!M7?-WNRM9HZ([7Q"7.F=,%]\A'X*">=9K?\&%S[0#V*Y&@)
M^HVT2Q>1!*G^1/66G)O_`#*0?=3VUZ;U[]\R7DJCA+M>WZ6_-913I!9CY5=^
MY4-&=_FB!-M>"P]!BI/^0?/Y@O\`O/M='[3^W$&A(^4X7"^;ER3]N1UEK[=?
M\RS?W`^3[A/ZT\I6F^6\>`;JSC4R_-Q%<BA/H.D14=X]TUA*5_9F],D`S,D5
M17T\:Q%OKI-+!"I_V_LWC]O_`&[MR#;\GV43\#12:_;J)ZS!Y<_N+/[KOEV-
M-'W*^2;[MIJEAN`3\\7)'2*K]T;GR;%\EN/<=342R.[QOG<M)Y#(?2D4,56B
M:_Z`+_L/8OL]JL[00P[;M$+(RT55C4Z?(<`2/7J>.7_[L7^[X]OK+ZBP^[!R
MEMME;BJ!5F1(D45TH6N*4\_M/1M^N/BK?K'+?(WOZGK=J]5X7'2UVV<1DFT[
ML[-R-(M14BDI/O@\N+QI6E;R5$@)E12.-0]S1RO[>[CM"VW,&[6ZFTK4Q:AW
MUX*4%#^SKG']XW[POL=[>\SR>V/W?N5K79]QB?0+BT656&:89I)$-#^P=%6_
ME8=F[3[3^27:72FZYY=GY7LC)[CW[TOO#:4[8',[:W-CE`3;V/K:1Z>>NPN6
MPY6^/=W3RP,0O/OM+R/[+^VG.?L[R'=>Y_M7M>Y<IWM@A6"X#M&J-J%%(936
M@P"2*UKU\T7W\O?7WF]A>9=R]YMCWR^WSE^#>TGW[9G8_2;LSD$RWG@1F8,`
MOANT94Z#G/5\N8^2GS#^*V1Q>,WVVU^ZNN(JFVW\OV)M+#;NI'CA4A:23<34
M2U^W)I%4JL15V4_VB?<%\\?W,OW0/>FVW63V1YH'MWN+QDRKMD%H&#$Y[KJ5
M]5.../RZZ)?W>?WION9?WD_)$<)M-H]KO=_;R\"[79G3:W&I"R:;C<IUE<E^
MQ@B&@/KT<#IG^:+\<]Q4[KV]\?\`#=<UYGAITRN/VKM_<^U7DE_SE6\]-BUR
M5%1J3<>=&8#Z^^/7W@/[D'[]_M=O>_-['\ZGF_D:T)\.XW"\M+6X>-5KJ2"&
M)@Y)X!33\^LQ.<?N%^ZNUQ3[IR[86FX_3'X);A(T"@:CX.D$R#^&G$GJS+KG
M>?QO[?IL?D.NVZ6WA3U5.)S_``K#;5:L2[V\?\$&.CR[FWU=H@@_/OB#[D\L
M_>H]I=PW_;O<R#G#9[VWG95;]W3_`$+!>)6[DMUC*@XU`TIGK%;=/;QMNOTN
MN;N5Y+/>H@:!HW3O4U[7D"Z@".(X^70H-TITQ4U,M56=)]/SU<[F2>IK.L]A
MU=9-(>#)454N`>6:0BUV9B?<3V/WL_O0[;$FQ[3[U;K%8VJZ$020A%4<`M8^
M&>D-QRURY?EKN^V^.2XD[FU`UJ?7/6"JZ+Z(/$O273AO?Z=2[`<7_P!?^[WL
M0;?]\/[QT>J/=??_`'Z.YKPC\%P?S\/HCGY>Y:LVU6O*T#G[&'^#I[Z<ZNZS
MVUW[MFJV=U[L7:.0Q^P=WU:56UMF[=VY/5?Q.2EH3!DI,+CJ*1J6,PAHPQMK
M)]];/[K_`-]/=3WUYKYUV'W;Y]W'F+:=KC5;);S3^@M`3I"HNDDDFA)Z"?..
MU;5M^WVVX6&UQVUU(.[36N13SZ.91=F;6RF3S.W\?N?%3YC`U[XK,TTTSTM/
MBJZ%8Q)1M+-!%%6U5[@PPR/*E^1;WVIV^#<(MZOWEG=MN4G0GDHICRZC]%6:
MS1G6K4X]<6[IZNCFR&/7L7:<5?B9HJ7)PC.XQH<5/)51TBTE9.\PIX*QYIE`
MB=A+<CCV<LVHEJUKU6+^S2G"G0JQ544Z,U/415+1.8CXY$*^72I\<I4L%?2=
M5OZ&_O73G4U?H.;_`.QO_O(`O;W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[K!,+@C_``-O\#;@_P"W]I6G9;RWC5NTUJ.G8\$'
MY]5RX8-%O3N9I/J_;VZS<\7;[#!W;_8^_DH_O-%O8OO@\_BX+?1B:(PCR52D
M9.G'FQ)/SZF'D8#P`1P+&GR%.EHJJP#E1<W-_P#'W@%O>X7$NZ7S+.V@O_D'
M4ALS`E:XZ[:-'_4H/^O[)#)(34L:])W@BDS(@/7#[>'_`(YK_MO>Q+(,ASTR
M;&T/&!>O-30.K(\89&-V5BQ4G_%;V_'M=!N^Y6O^X]XZ?9TJA`MR#!VD>G7%
M((H%(B0(NH'2+V%[?0$D*/\`6]UEN+B\,UY=2EYR15CQ/3=P[.REC4DU_/JK
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M/M<;4V]F#&,?"2.!I\NH;N\CM(YU.WZF-KGBWX_UO?K/:MNV\DV5FD9^5?\`
M/UH.XC6(-^F.`Z]K;^OM7+!#,NF6,,OSZ;TKZ==7)YYO_7V7"(PN8H1IA'`#
M@.MTI]G7B2/9C&%*BHSUX4ZWS_\`A'_MR*DZ/^8&ZQ4R&7,]E=>8MX3$P@CA
MP^!RS.RR6TM,S5G-OH"/?S%?WVFZQ7'NGR1M<)4F&V)?U!,D=!^P=37R,JKM
ML##SK7]M.MS)5TP*!Q:_%[_5CR2?R?S_`(^^0DA5C*/,C_)U(+?BKZ=2HA:-
M1_A_Q)]HK)/#M84IP'^7I@&HKUD]JNM]>]^Z]U[W[KW7O?NO=5<?SMO^W1?\
MQC_Q4CN3_P!Y.N]^Z]U__]39@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/?NO=
M<+#U&_U/N@&@LQ\^M!:&O35+3++4^35H,4L)U`_JC16+)]?P[>_30K=(%88K
MT\M]%&K(WH?V]?-,_F`]:5W37S1^2'7571K2T^+[/W1781/$$2HP64JI,SBJ
MV.XU&.NAJ&L23JL??/7W*M9;+G?F81*0GU;4-*>?^#KZ[_N$^Z/+F\_=G]EM
MBA:4[E:[##$P6-BM8Z@]W#!Z)Q)<@`MQ8?I51:X!M<6/Y]QXMW<$D:B<]9MW
MNX6\:1Z6F1O/2A-?MQUTC7X(5@+`!D4G_>5)]UDDD!!#$,>/26^W"WF%G;1P
MR%G([BC"F:?9TX4E#4Y.JI,=14U37Y#(5,5+04M$C^>6>5@B4\-)$I:H9V8#
M4+#V;[+L\N[SB-$K4Y-<_/I#S=S#LW*FQW5[O7,T>WVL2G]1WB3APIK91U>;
M\*OY:E-C&PG;/R*H(Y,@D"9K:O5T\#EX(XE^X&4W/&73[V6E5=9I0R^/ZF_O
M,3V$]M=KV6??-]YWME&VB.L#-FM%K4"JT]!DUZ^<_P"_G_>)\S[M:7WMU[4[
M\\WA2&&2:-_[3C5JJKHWR(QT3#^<7\K!N#`U^SMFY.DAVEAYZC9VUUIC''!F
MWIX8YMZYB@AC58DIZ.EIUHJ?C0%!`%R28ZL>;[[W$]XY^7-JJ.4H9BO:<+1@
M%-#7C0^?EUSU]J^7[>\LUYWYQFU<SR$N=5"P-*DU[34_9UK`]9]D9;JKLG9/
M9>"DGQ>7V5O'%;EH*WR2QU(BQ%6E?)`DL)3T30$Q6%M0)4W'OZ1N5.68#[,\
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M(Y&8`X`*8TD?/KZ_O[IS_F96?ZWE?V6^_P`;I=RA(H[6UWP)<7UQ<SE@L3W*
MHD-O"N0&D':JBIZ(U19/([<RD5=C:_+[9W%BIRZ5..KJ[!YVFE4@>-ZBCEIJ
MHQQ/]4<LO^'N3^>O:+V7^\IRTFT>ZO*UKS+RD]2+2_0^&-0SV!T)!&,U'7V)
M[IRY]WS[Q^W;1S1+<[/S/8-%&T;03Q77AK(`RAOIIFT'/<">TU!ST=SJW^9#
M\M>J5IH)-^P]AX:.6,-BNP*"FRE3]FEE6EHLS"*>MI$""P8B1O\`'WQG^\G_
M`,RZ?W$O>?<]VO\`D[;6]OQ=$E$V6RCE6-J8(-Q.U`6R10#TH.H#Y]_N^?;C
M>GO+KEK>I-MN#(76*.*/2%I_9@NY.D>O'JS[IW^<7U%N0147<VT=Q]<5XE2F
MDS&+CEW-M8R&P:I,U*J5]'27_P".Z:P+W_'OYU?O4?\`,NA]Z'V)@W;F#VHA
MV_FGD2!R5N)KVWCW$**D,+*W5R305IDUQU@SSY]TCW)Y4NYXMHLOJ[($Z'Q5
M@.&$!IU;/\0NP=@=Y[T[`[8ZUWC3;LVAC=N[9V#B,WBH9(Z2KFKI)=U9"53,
MJ-Y<=,_VL@T@CZ'W,']W#]USF+V*L^:-TYOV]X.9INRX652DH?!TNI"L"JX`
M*@TX]<__`';LMQVFY&S;K;/#N<1;Q$84TD&E#4`@GC0CH2M\_$/KC?[YXY.7
M,Q+GM\9;?M;54=?DHWFR>6HTCO3QPY*&.F?"U$(DIC&J$L2'U#WU$VS<HYDW
M70`VD%?SIU$ULE+(@\-/0<5/\O+J>7-[TW&^6SE6=\2XJ;)X=<=0#$1-AYJ"
ML$TU(&59JFJFQP,LK#REY"=7MBV!$$0/'3TU'30M.%.C<]*=8CJ[K_%;3J,W
M7;ARHGJ\ID\_6M(U57UE963U$;R>1W"?:T<D=.JC@)$/;W5^AD`L`/?NO==^
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH\S>,,Y_P!A
M[0F,QR75V<Z$8C\A7IZ,:R%Z('N2C_A?=':&*\7V=#F(-L[MQD0XCJ*O*8^>
MDW)E4O=FDDR%+`DAO:X'`]_-/_>W\F)MWN)[<\^T_6WVRE=C3CX4RH#]M,?E
MU+?([`1:`#56_P`''IW@XBC!-R%"DGZL5])8_P"+$7]\=]R%+ZY%/Q=2.U0Q
MKUD]H>J]>]^Z]U[W[KW7!OH?^#+[6QD?1S+YZATS-Q3JO[^:B/\`L73\S6'Z
MCT5O".X)Y1XZ<,O'X/OH3_=1PS3?W@/W7X8^+<S6?_5Y.@G[A_\`*K7_`/I1
M_AZ^6\Y8L=1N1Q_L%&D?[8#W^VG8HT=G;(_Q!`#USMNC6XF/](]<?:OICKWO
MW7NO>_=>Z]?W0HIJ:9ZUUG4!EN5_:!'D?^UJ_P!0A^ER/:*60Q5SUL#AZ]?2
M@_X2Y]09+K7^6I1;QR%!/357<W:^]=X8]94535[>QHI<+AJL/I!>*6:"HTWO
MROOY#?[VOG%MZ^^!O'+H?5!9I$G'@S)&Y4CR(QCY]3CR7&5VFR:G$'[.)ZV6
M*8_LQ)>_I))YN2";DW)^I]\^IYRN]K;#X60G^70\F6FL]3U_2/:\`+@<.DJ?
M".N7OW5NO>_=>Z][]U[KWOW7NJN/YVW_`&Z+_F,?^*D=R?\`O)UWOW7NO__5
MV8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JP[NO>?8.T*C;>2V9+]W0BISAS6#BP
M4>4GR\>-PM;7TU%35LDL4F-GEJ:949@K@ZN.??NO=%BD^=VY8MYY#9$72^YL
MC7Q9^/;]%7Q4F4I\5452;<3,ULYKI*$Q?9PU;?;A[V+CZ^_'/'KWR\NECL3Y
M5[OW3O3KK:.>Z<SFWI=]Y!8YZQ#D9J/"TE1B:G)35%=4RTL<`>GGI1$1<`%Q
M_7WM69?A-.F&MH'^.('K6A_X44?')]G=[[)^3.%I=>#[,PXV5O"?[=P*+=NT
M84?%,[`F.V0P%2%1C^N16'X]XM_>'Y<:!++>[2((\PJY4_%2HJWSX5'IUWS_
M`+G;WKVWF;9>=_9*\5;7>]H:1[.?N\0Q.`650]$(1S50NHGK7#D"JS!+$%@4
M87'H(!M_3Z>\6[&[MH;>036X:X\B:UZ[S;>+RSVRWL_WF]Y?Q*-4CZ0S4XZM
M.`?ETK]B[`WEV=NG%;+Z]V]6;EW3FY8Z:@QE+%(ZS-K"U$LDZCQTJ4JG4Q8B
MX'L0\M<K;AOUS%*8"T+-7[17[.HI]W??+E+V8Y6N^9.;=V1&`++%530T^&@(
M8#\NMDWX6_`':7QVACWSOLT.[NV:VCCCJLP::.LV]LBC9`XI\7#4K(HR0D)1
MGTD@CCWF5R'[:;'MUO%+<;1%XI&30U)_;U\P?WU?OK<P>_NZ7^T;7OLXY+UL
M/I^$14X([EK2G]+H4/F;W<_6?7:;4PU4E)OGLJ.?&4\?F9LEB]K4O&7S]/.I
M,M)62*;0D%=:L1SH]DGWE?<6UV?V]BY;VBX\+<(WCC4+Y**U7-<$8/7/CEK:
M[:PAN9]MA$5R[?ILO$"E,<1QZTK_`)Z=@QYO?>4V]`Z28_8V)BQ$"1$&^1R!
M\F28N!H:=`?W&'ZBUS[!/W4.7?J>:_;CPK:EUN6X6PN*`UD3Q!KU_)@2/+'6
M?'*G+6SVGL/O7,7,NVI-S%';N4G>OB+5#2E"!@YX=5:?Q&HDT15#,\$3QQB&
M2S@1I)Y(OQ_8;G_>_?U(Q[)MEO`=KMK-4LH4T(F:*J\`,_Y>N:C[M>7^\V-W
MO=PUP%J$+_A!;RI3SSUM=_R"?DK_`'@V+V!\9<WE%7+;1R']\]ATM9*+2X7+
MS^/-8['QDJ6BHV7SNJWTF4'@>X7YUVYK"Y(L(!&/#J:'CGCFO=\O(=<'_P"]
MR]D#:<Z[+[TV5B&VJX7Z>X50?C7N21B/)OA\LCK8W:%)$96#:;!=`=UT@-<!
M2I4AKCDCDVY]@A8_"M/&I^N]"Y\V(\SUQ&O=XN]Q:*UMH0D45="C-`!D`$'U
MZ*MWO\6MH=N&JS^.FCVGOR*%GBW#24L7\.GO8QT^X<6BWK8ZBUEF325/)]C[
ME#W%WO8!;1_6/)8K4%:BH^RN33T\_+KL?_=:?WO_`+Y_W>O-?TB;Q=7WM;-I
M:;;7=DA)3@-,,)E(8\:-CRZJ9W]U_O;JO<-3MG>F%J<5.QM1Y5(C7X>MC!(2
M:BK5C"3O.GJ\(97C_/T]Y8<K^X^SW=I;M-?AI)N!/$'A3)%#7%".OT5O[OC^
M\Y^[O_>(>U=ESMR%S3:[?SS"`EYMLY6UE2X9:E+6*YD6>ZC'^_$CH3CCTB"B
MHOFBCGJ"JLX@C)GJIHT!>2*'ZO-52J`L:\G4P'L6[T;3EV%^:5=8XE6KD4HV
MKUSY4ZZ'W',7[IY<N[U.XVJEG60%309-/.@&?\/6\[_+-^/0Z`^'G5FV\I&:
M;<^Z:"?L#=Z&#QRQ9G>ZQY.&C<V#G^&4C1+8\J^H>_GU]\=]L.9/>3W-YDV@
MCZ*_W664$5[L*E<_Z6GV=?*7]XSG"7G?WJ]RM]&ZO=V5QNLQC=J"J5````&!
M2@^0'5AJ4L*J@,:EDMZC]2P%BQMQ=OJ?<0V]I;VGC?31!/$-6IYGU/4)ABJZ
M`:)Z=<A30+](E'IT_GE=>NQYY]?/M\```#AU4``4'#K,%4#2``/Z`6'^\6][
MZWUW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I
MOFNS2!C=0U@I^@NOU_V'LLW(RP/;S^(19T(D7%&!QGSX=/DE(U*8<^?10OD'
MA3A]V]>;ZB732UGW/7N?JPQ/VU-EJ@93;LDBWTBGGS=/XYV_LQD<CWRQ_O3O
M9*/G[V;V3G#8=OC(V!)"A'&-&(8A<GM)6IXYZ&G).X2P7NB24@-_/_5CI/Q"
MT:`$D"_)^IY/_$_[Q[^7$SB6XEDN5U._G\^IK#!QJ]>LOMF2%HF!9>SKW77N
MDK*TC,BT4G`].O=>]M]>ZX?74/Q<>U<&553\)=:_MZ\ZJ0I(ST2G^8EM^+=?
MP7^5>WJJ9X:;*]+[VIII$_6ICQXJ8RO'"EH?>;OW".8KKDK[\7W;][VNX,+P
M<Y[4BZ3^&2\@1EX'#!J'H'>XBA^5]R0MI'A&A'D?+KY6LP`ED`^FLV_Q%^#_
M`+$<^_W"8_@7[.N=ET`+B8#AJ/\`Q?Y]8_=^F.O>_=>Z][]U[K.BJ0+@?[S[
M*[AI;><W4MRRVJBFG%"3Y^O33,U30]+78^S\SV)NO9^P=JX^6OW)O#<^'VOA
M<;%Y)9\AE]P9"#'T,D,<:EUCIGEU-P;*"3[BGW3Y]V_V[Y!YNYXW2^;Z&"W:
M1":40Z2%"TS\617->C;;+1KR5$H,BG^SU]B_X8_'K!?&+XL=#]#XJEBC3K#K
MG;VW:XQ.S1OGX:?[K<D\37`>*?<%54NAMRA'OXI_=OFN_P#=/W,YG]Q.9[MK
MW?;V\>7QY#5RI("<`!B-5%*8I3K('9[9+3;;2&-*!4`Z-"L4:VTJ!I%A_@/8
M#:"%[@7;1@W(%`WG3HU+LU03QZR?3V]U0``4'#KWOW6^O>_=>Z][]U[KWOW7
MNJN/YVW_`&Z+_F,?^*D=R?\`O)UWOW7NO__6V8/^$]/_`&Y?_E^_^(9K/_>^
MWE[]U[JY'[:`R/*8P9'*$N2Q(*+I4I<VC(7\K;W[KW65D5A9A<?ZY'YO]00;
MW'OW7NL9IX6*LT:LR,S(S>ID9[:RC-<KJM^/?NO=$'_F'_$O$?,GXS=A],U\
M,*[@E@DW5UODY="-B-^X"FJ)]N/'*``L-5,6AD#7!CD-P;#V'^<>6K?FG89;
M/0/%533SJ>IE^[[[V7_L=[U<D<W;=*UO:(ZI<."15'<*U<$'MSC-!CK0#ZB^
M)W<_</9N9ZLP^V:G"Y7:.5EQ._LWG8IX,%L^IQ]4])E#75+QQ_Y0[Q,T%..3
M<?CWA-M7M9N6[\S_`+GBBH/$*^7D:</GU]07NU]^/VC]E/:VRY[&\I=[YN\*
M2PQTKXCR+C48V++F@';]O6S+\8_BEU3\7MKIB=J4"U^[*RGA;<^^<LB?Q[<#
ML@UTE%3F\F+I1)RJQZ'TVN3[R]Y/Y&M.7I(MHFB'BVHT-]HX^?7S$?>&^\][
MT?>;YFWYMVNITV!KIBL9:JK'7`&J-3P^?0_[JW!C=I8#);CW#(])A<!CJW)Y
MFIF=(3%B::-FE>&(%4DKTFTK"""6!_/L4<V\P6_+UL-%%`^WJ%[:#E^'97Y=
MMY`V]LI%:9U</(TQ]G6M[\C^\*[=5;V-W7N"IAA\.,KI<!@I&)&/PE(CQ8/'
M@N;025,5I"%L69C>]S[Y=>ZV[[ESA[M;?M<;LUG<SI@9&6R>'ET,]DV"3;MX
MY!V&Y4>-/%'KKYGQ-/6KKW+GLAD:*JR61ED:JSF2J\I,9&#2F3(S&24,]M36
M!`YX`''OJA]RSE2#<?>;8K0Q`0[>%(%.'AD4ZS\^]-8I[>>RME86@TK=0!3]
MI%/GQKT7`1SJQLMU`"CGG3]0W^N/??Z*:.2_NA7!?KCVJ/?6J31C^Q%#^6>C
M<?"?Y"Y7XQ_)?JGMVFED7&;;S$5+NFFC8A:[:>;ECQVX(I%%O*T-!.\R"_#Q
M+[CCW'V]Y+.:6W'ZJ]P-:8P"/]7D.H@^\;[;[?[X^RO-?)DMNK7SVQ\-B*D3
MHK-&14C)8:1Y=W7T.\!F,=N+"8?/X:MAR&(S>,HLMBZZF=9(JO&Y"GCJJ&<.
MI969J65=5C^N_N'\30+'Q-/^+Z^03G3ET>W',NX[4\I;>K6=HY(S2D;*:,M1
MQH13AT[%5;1>Q:-BZ&YN&(L=7^K6W]DW`_I[1BQFC)*/0=!@[_/<2&YNMJ$R
M'C753]H'27WIL?;'86VZ[:^[L5!F,+7&[P/&#/2U:AO%5TTX*ST\L;->Z,M_
MH>/;Y%SXMM);R:9XB*FM*4(/^#J9_9'WM]TON_<][5[O>TG.UURSSQ9-XMI<
M6AC,D:C.@&5)`H)%#52?/HMOQD_ET93=7ROV9!CJB@W7U%LVKI-][J^^#15M
M*N&JXZG&;9KIET0O6Y3*11B#3P(HVU`@^UOOC]Y6,>W-QR<TICW2:/P\'4:4
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M@W_P_P!Y]H;^-;^VEV\-21Q3IY&)TBG`]!QOW:&.WOM?,;9KV)ARE'+24TC7
M_8K90'I*F,J0T;TM1&K*P_3[CWW$Y5VS??;3>?;C<]+G<;1X0#YZJBO$<*_9
MT9V\[VSB0+1JUZ)GMJOR51!/B\K)X]P;9KZS;^Y*+2$E_BF+($55`3_G*+(T
MS1N&`LS,;>_D&^])]WV[]@O<7F/EBXB4P07.A<@@!@&6FDD$4(\SU.FRW<EY
MMME/(*%HP1\QP_;CI8QZM"ZP0Q`+!B"RD\D$CCCWCE(5O-KG"K22)P/RZ.!P
M'7+V&>M]>]^Z]UP_U?\`K^UUN.P'RUK_`(>MM\*]%-^;W_9(7R4?^U_H?WNE
MSR-(P=7Q8\>\I?NC2D??!^[T2<?UVV;_`+N%MT#_`'$`'*NX_.,]?*1F-Y&/
M^M_O"@#_`'CW^Y[$0T:,.!'7.NZ_W(EKZ_Y.L?MSI/U[W[KW7O?NO=9%8VM_
MOOK[)-U-M=E-I>2EQ*-0'R3CU73J8#K:>_X2_P#\OVM[X^3E?\O-_81AU7\<
M;P[0:NH2:7<G:V2IW&.GI_N56.KAVO1L]3KC)5:@*C"Y]\+_`.]F^\S!RSRM
M']W38;IOWI>LC7-*J1$K!@OF&J2*4H1]G4H\E[1'-(+AE%5X=?1DHM/VD&AM
M:",!&N3J0<(Q))+$K:Y_)Y]_/B(WB`CD-7''J5VC$1,8%*=2O>^M=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW57'\[;_`+=%_P`QC_Q4CN3_`-Y.N]^Z]U__U]F#
M_A/3_P!N7_Y?O_B&:S_WOMY>_=>ZN8]^Z]U[W[KW7O?NO=19:*EG$@EB#B4A
MGNSBY5=*D$,"I"_TM[LKLFK2:5%#TU<P0W<:17,8>-6#`'R(X'\NJOOE+\?\
M9U_FLKW!L#`T-+AMS9"2J[7HZ*CAC6EG<(%WK'%#&9*LA[+D!)K*\3+8:@$%
MCMUCME_^]+"V6+<*UUBM:^N:C^72[?KRZYHM=FL>8)C=6NWZ?IE?A#H.I=-*
M'!R*D]%22SA*M(C>HB!H*J(I(IU"_F\SAV82H002>0>/9I'97R7]WS!N5Z7C
MG;6Q.G->->'3EKS!OT,UQ'%N,BQ.<@4S7\NJI/GQW9'D,A2]%[9JI'IL=)0Y
M[LBOAG9E64V.`VZ7#'R0R7)JD_VM+^\./O1>X4'[M:TY:W'P+]:U*$5/[:\.
MEFS<M;-%N*[U#MT8W75J\7.K4<UXTX_+K7^^=._TPVRL/L''E4FWODH\EF(E
M(66/%;=72E),W^<6.L>:Q`(OX_>-?L/;76_;ANW,N]_K[I9:5AF?XD+_`,%*
M+Y>8/677W7N4+;G;W`W+<>>;(;BMG(#;&6OZ2@AJ+H*_BSFO5)';M69OL*$M
M<QN]E^H$=P47_6'ON3_=Y[##>\R[SS#<6X>]K3Q#QI0:OED_+H0??VYEOI8K
M/8&O6.WPT"1XTK3.,5_GT"35=0&-IFL/2/I^D<6^GT]]B1;6RR-+'$`Q->N7
M=M-+:Q21P.51_B`\ZBG^#K$U1,P`:1B%<.`;6U*;@_3D`_CZ>VKFPM+Q62Z@
M#J>-:]5C8Q(T<9HA-2/6G6[A_)#^4W^G7XK_`.C/<&2+[VZ(J:?;$@GE5Z[(
M;0JX#4X7(H2%9Q1LY@O8Z0H%S[QHWW;)+'?]W@@JMH)V"#R4<0H^7')/7S;_
M`-YQ]W&V]L?=5?=#:;=#LO,DIN9(UH%6:H\4$`DC614\.)H.KIBHU?T/'(_-
M@!?_`%S]?]?V5^'=%12<T_+KF?N',;7`MX=OM5LK!1I=(R6!J:ZNZIK3TZS8
M[&Y7<.9Q6WMOTL^4S^8JTH<5AJ1+U-79M-5*LH&F*EI@VN6=AIIP.;W]A#FK
MF*#E[;+R4W`%R.)Q6M./GGJ6?:OVIWWWPYSV/E/E;9C(LE$,@U`D:AWFH*AJ
M5&FH'5VOQMZ4Q_2NQ8-OL(:_=&6E;,[OS,4:D5>6FC*BG@F`):EHXB$3FUP6
M')]\_P#FW=SNVY7&Z7<A>5GP3Q(K^77U^?=E]B[;V#]F-GY'@"K<K%J<"E-9
M7Y$\.C/TE.@IXO(B/)XU5F(O?3]/K?Z6'^Q%_9"7#G6.!ZFRQ1TM+=)/C"YZ
MR"CI@+>%2#>X.IE;4Q=BP8D,68\WO[UTJZR)#%&I5%LI+&VIB/7^H"Y-@;?0
M<#\>_=>ZR````"P'``^@'OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"^].\.
MN]B[@_N]N7=%+B*Z/[(U1JHJPT=&V35OX=#5U=-#+!2R54:,ZB1E)"W^GOW7
MNL6,[YZFS-5!3X7LC:V5EGDFBC@I,HM5)4+!%)42O2^%"DPCB@8E[Z`H//OW
M7NGG;_;O7FZ=MU^\L!O3#Y+:F-JI<=7Y^.KB3$T==3R(D].]8]@*B%V6-D^H
M9K>_=>Z2L'R,Z=J*N6*#LK;4\M)7#%SXY<@D>1&6G=1%3O2LI9:7P796-KV)
MO[]U[I\QO=W6&X,S087`]@;;RN3K9Y8:/'8[(0U%3D:F%W44U+&A8R(S(;N/
M20.#Q[]U[KEC.XNM\[5Y"@H=_;6GK<3'/49B"#)TL@HJ:FJOL*B&H,TL>BIA
MK`8W":O6+#^GML0Q"87`0>,!2OGU8,R\#TE<9\A.E<K404U%OS%>5\CE*/QR
M+4PE*G;YB&5HY/-`"K!*F-C>W#`C@^TMWMMC?7=M?7=LLEW#\#&M5S7'Y]7,
M\QK60YZ#WN_9-?25W^E39F.J,ID*>GAHMW;>QL:^;*;7A_?GR%(687S>*2TT
M/%ZJ%6B_`/OG1]_K[FVS_>#Y,W+F?E;;H[?GNQ4RRRK0/=:%JJMK;20H%.Q:
MT^?0TY=YFN+80VLURPMP:<>!)X_['#I$8C(P93&4-?CZJ/(4M=2B2DR%.=-)
M*K,S(YB>\J2A3I8'D,"#S[^6O>MMN^6]QW#EK=]K>ROXG\-R0X8NN.#`8)Q4
M#AGJ9(9#+"K*X((K7IY6^D7-S^3;\C@\?Z_L"SQ-:W$D,J#4IH17_+TH`(`!
MX]=^W%\"0`+&`>M]<2.#_B?9@SVJVB0I&!<!UJ?SZ;=CJ4`XZ`GY)8O'YKX^
M]XXK*4L=;CZSJS?L=32S:O',@VIE9`K:65N'0'@CD>YH^[M>7=C]Y3V1O;*X
M:.\3F_:"KCB"+^VH17'0=YZ19.6K]7%5\)OY`D=?).1F9(V8W9HXRQ/Y)07/
MO]U/EJ::YY>V6XN)"\[VT98GB25%3USDO@!=S@<-77+V>=)>I`"%%]/JMR>;
M_7V"8-\FWO=>8-AM7EMI+.15\4*<U4-VEAI(S2H)Z9)8,>['7`+8_I#<_0FW
M^\^SY)7L8(K22[:>\I\1`!/VTP.E$4D:TUK7HZ/P1^%O9GST^1NP/C]UEBI&
MFS]9'7;QW3HG7#;%V1CJF-]P[CR]7XV@5H*0F.&.X:2=T4`GCWA[][?[R_+?
MW8N1KGGW?FBDWX(\5O'6K!V%-(*U(!-#4KT<;)MHW'<HTTGZ=F\^`&/Y=?6"
M^)OQ<Z>^'G0W7O0O4>(AP^SMC8H(:D1H]5FLI(4.6S.9G+2-59+*5+%Y7N1_
MJ;"WOY!?>?W'YK^\9[G7?O5S'O\`++N<\A-:*`J#"QJ"!10J@</GUD3:6-GM
MMJ4L;58T4#AT`V[LK\U,-7TO^C['Y7(Y0[GJH=RP9FDQ-9L:BP$V;EI</)M"
M-33UOVL6W9$EF\CLPJ(V'TL/896Z2]474?P/G_9_/K8:1QJE-9#QZ@S]@?S`
M<9LOM62JVEB)-YX_,4])U9'2;<H\ACL_BGR3P39;)A\E3M33I301@4::G*3O
M,#Z-/NW6^E?V-O\`^;N*Z#Z_RNQMAX*M[PR,%++N[$NE+EL)0.N)BR.1AJ'-
M331TM0,F[TL<88W518GZ^_=>Z0^_^Q/Y@*UV#CV!M3#R08[:F8SN8JLYMR&C
M&5S3X^"GQN$FQT5?*:6-*F>:8,K\-3HI)\EA[KW2WW3O?YF'*;7Q>UJ;;AR4
M&UL/E-PRRX&)L?E)ZZER,5>ZTM151OBYJ3(FB_:,A*J[WX'OW7NF?L+,_*ZE
MW%MJE3+;G@ARN`@QVZJW9>'Q-;A,7D:;)QU,F:PL8^Z>66FHD85L44DDI@/"
M@`D>Z]T=KJ7+;KS&R:*OWDKC+-79N,5,M*M!-6T5/G<E!C:MJ%2RTR5..BB=
M!S=&!_/OW7NB#_SMN?Y17\Q@_P#@)'<G_O)UWOW7NO_0V8/^$]/_`&Y?_E^_
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M*Q5M6[S9)<A3SI#)0&$^AHV!$12PL`/?&KW"7F"7G6_L[IY#=+(U`:4XT&:9
M^SJ0=K@8%1^$]44_)_?[=@]T;GEIIEGQ>W"FW<>8Y!+!4)1LP>>)U`!UL3<C
MZGWF#[:<N?U;Y-L$=0+F<^(YID$C`/73/[LG*<.W\O)ORI^I<19^=<>OIU7Y
MV/5FHS6@$_L4Z7'^I>WJ(_UQ[[N_W=7+L2<D[[NNCN(<U^S/KU@3]]+?&O><
MS:,U0&(_R#_!T&,EM;6^E_?1&U?Q;:&3U6O6$J5TBO'KA[4=6ZM0_E*_)^7X
MU_+/KW^(U9H=C]DU4/7^[HFY2?\`O#,4Q&9E#?MJV'R?C5&)`$<K$W]PUSSM
M\<37=\9C5G%13!J>!->`\OGUBG]\KV8LO=7V/YMENMNCNMPVZV>XMU;BK1H:
MJM"/CXFM:4P.M]7;&#W%OO<=%M'96+J<_N"KF"RP8V-JJDQL3V*SYFN6\&)I
M54Z_*S$.O`]XS<V^XEGRV)%DER.''A_D/7SI>P/W0>?_`'VYJ?9['9Y+?:XR
M?%G/:$-*@*)`JL/]M\^K?.A?C;@>BL+5;MW#5TF4W[68UZG<&YYF5<=@*."'
M564.!U_\!,8(E+2']4C`EB1;WA]S;S]<<S[G>O)(PM&D)"^M.%<`]?3E]TG[
MG_MO]W+EW9IK6WCGYJ6`"6<J`[.<_AD921PJ!T96#/X7S6ILYB4ITIHZP/\`
MQ6BB9:*II4JX*V:.290D$].RLK-8:6O[CR]MENQXKDF2OIP'64LMYO,V^*TR
M,NW`G[/YC_+TLL7D*2MI(?LZ^DK%YC>:FJX:H+,`'*"2)FC>RM^#]/;:H(U"
M#@.CJ5T>1WCIH)Q3IWC;6BM9A?\`#"QX-N1^/I[MTWUS]^Z]U[W[KW7O?NO=
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M[KEL;X2='=:;OVKOK9%)N'`Y[:&WZ+;V(FILL98FV_CWK)%H:R*IIYTE:1:U
ME:86G90/7[]U[KAMWX6](XY*R3.;>7=$F4JLI4O45M541PP0Y'/3[BC1DI9J
M:JEFARE09%DU6U``BW!]U[I75GQJV94X*;;U+)EX1-E<MFVSLE?32U\5;G),
M?2Y6(-!#"3%58W&11@?V54?FY/NO=&&DI:9C,!`FIT2!S<AFBBL8PYO=C':P
MO<V_P/M)!<N\UTMR`D$;:5S\8(R<_LQT[%$L;&8DYST4GL7JW+;7J\GNOKZC
M.1QU153UN>V13L(I)F($L^0VP[%8:?*L_+TSZ86%R#J/OE']^W^[]Y=]YX+O
MW.Y`467.,2:GB15_Q@CS9I9*C/\``GV=#WEWFMH#]/.U8A_J]/+H.-N;DI<_
MCSD(*R.;PU$D&2C4:),7)&/5396%E63'5T375HR"&(N#8CW\Y_N![6<P\F[K
MN&W;]:F/>+>33,I/!AQK4`C[".I5L[N.X@CE1NTCS%/V5Z5$3F2-7*LA(O9O
MK:Y"D_\`!AS_`+'W$+AK><CS!Z7`U'79'U_U_:A4:5_&_#K4?M/5'^).@4[_
M`'?_`$']SHJ,SMU9V))$JBYEDAVGE=$`'-S*"1[FKV7;]W^_?M+>`YBYKVHT
M\\7UN>B3G-%?ES<03D0L?M[2:?GPZ^2!3L6@A8JR$QH3&P(:,E1>,@\@H>.>
M>/?[IG(%U]=R1RI>?[]L8F_:H/7-_<!2^NO].?\`BORZS>Q?TCZR\A5^O/LJ
MED#RSPVI*S`C4>'E\\''5%&I]/1Z_@Q_+_\`D7_,#[/QO5_0>QZO+(U2O][.
MR,A#64FP>OL>A#551NK+>+[=9O";Q1Q,T\C$!4//O#;[S'WN/;?[N&R7^Z;O
MO4<O,B@B*$#496I4+6,L58C`[?MZ$VU\MW&Y-ICCP!DU&/V]?3/_`)9O\LGI
M+^6YTG3==[$H*;<O8&?I::I[)[.R%/!'F]Y9N!?N'I*`LIGH-MT<KD0P@H)`
MBR2#7]/E=^\O]Y;G'[V//F]<R\Y1F#EKQ*6EJ7+)#&0H(RJ$DTK4U(J0#3J8
MMBY<CVNUMO\`?M*L:>=3PZLX@HH6CAE:&-)5B9%1;JB!P`Z:;Z2%(MR/Q[QX
M^FAL=N;:]F51;T(4`X%:Y\_7H3M)0%*DCSZ<(8(U1+JI95TW^MQ<GG\'W7:;
M-[#;K2SD-7C6A_:3TTQU,2!CKA48^CJD,=13I,A*-9]1*M'?QO&U]43K?@J0
M?9CU7K(:6F.J\$9#,&92HT,P72&9/T$A1];?CW[KW7?VL'I_:7TDD'DGDZB"
M;W*D\V/'`_I[]U[KLP1$J2G*W(.IOS<$?7D&_P!#Q[]U[K#_``^C*E/MX]#*
MJ%`"$T*2P70#I"EC<BW)Y//OW7NI010"H'!))!)/)-SR23]??NO=5=?SMO\`
MMT7_`#&/_%2.Y/\`WDZ[W[KW7__1V8/^$]/_`&Y?_E^_^(9K/_>^WE[]U[JY
MCW[KW7O?NO=!_O\`ZLV!VECX,3O_`&W2[FQE/))(F/K:BOCHW:4P&1:BGHZN
MFBJXV-,AT2ATNOT^OOW7N@?'Q!Z`&2.1;8--+'3XRDPV-QLV2S'\-Q-)0U,=
M7"U!3_Q$+$340JQ8W)TV)MQ[]U[IPV!1]$;#S&X\#UU)LW;V<DR<T&;PV-RL
ML,LV5Q"(E3#)35,[0^?%I.-<=.+J7]0'OW7NA.J-Q;<:J2/^,XLNT"5T8-?3
M>!H?,E(9//%)H=(IY0+$E=3"_P!?=T2.%9&B72[Y)'F?7HN%S<K<R*LQ"5QT
M1?Y:_P`M+XW?*ZBR%=E</4]8]F5U#7)2]A;"\6*S0J9XI(A/EL>L?\,S4%VN
M_D4.POZO<1[Q[2<@;MNDN\WW*UO)NC&ID)?43ZT#@?RZ%ECN][;@!9R13Y?X
M>M-/Y*?\)B?G/U9D<IF.BL_L+Y)[9$]=6:Z;)P;(WE#`TTDU/')@\FYI\ED=
M+\K2NZLWT/LJYKY,>T2Q>PCT6KJ.U145X#B:\//RZSR]C?O:<G<N<M0\I[W:
M*MW91&,L1(=3"M"2HH*UX=:\W?G\N'Y_=1;ESB]B_$#O?`4T59#3Q9"7K_-5
M]%5(S$&:BJL9#5K+3R_V6MR![Z__`'4^>>5/;WVSCL!!%!<2)1\FK=O=7)_P
M=8'>^?,;>X'N/=WMG*?HG8Z!Y9-:Y'^$]%\I?BG\EJVII:6E^-W=E3)73"GI
MXZ;K3=\L\LY-D"O/BX8;.?\`&P]Y+0?>!]O[?;H(A;0&5$%35R2?GF@ZB2?9
M;JWGEAK4*U/+H^G1W\B7^:1\@<E24FTOB!V-M;%UZ0NFZNTDI>NMK11RVO41
M9K,RBDG5`;^+B5OP/<>[U]Z7DNQD$58U?+$#66I\E`-?\/6UVBX()H3ULC?!
MO_A(4^)R6#WM\Y>\5J&Q]90Y!>K>DI33^26"2.7['/;WR2K4(L3Q@%:"%D:_
MID_/O%OW*^\W>[R]_#L4LGT+L:$C2`M/(%=6/0TZ$47+]A<[<MMN,"21..Y"
M*@UJ"#Y$$&G6ZQU-TOUATYM'%;/ZZVM2[?P^.QU#C48":7+5E/CHEIZ9LKE*
MAWR&0F")<F5VN3]/>(FZ<WWN_P!ZTVXW3S2?,8'V`"G2;E?D?E3DJSNK#E78
MX;*RG8LZ1ZJ,3@DZB?V"@Z4&[=N)N+;^Y=M1RBA7/X7+8`UL:),E%'E\5/0B
MKJ*6=T$XIO*;!67GZ^TP"$EP,MT=Q6-I!I\*!5IPIY=%/SOPEV1NZ/<]=NG=
M&<R65W3UI@.M<T].LF(PQH,#34E!%E:;#454):3*U&,HUB,B36T"_P!;^WQ-
M*!0.:=&<EW<RVYM))B;8_A\O\_1I>J>M<#U1L;`;)P"S/C,#104E)45LOW-?
M4+"I5)ZNJ8M)/.Z6NQ)-A[H2222<](T1(D6.-:(!0#H25_2.+?X>]=7ZY>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ^*/4'T@,+FXN`2UKE@"`Q-O
MJ;^_=>ZY%%/!!_VY_P`?\?\`'W[KW701```/H-(/.H+P+:OU6X]^Z]UX1H/H
M#^/[3?V;V_/XO[]U[KB88R0UC<.)`=;_`*AP"?58CGZ?3W[KW7,(@^BJ.+<#
MFQY(O];>_=>ZQF"$_P"ZU'(/I]-R+V)TVN>??NO=="F@4DB,7:Q8W))*@`$D
MGD@#VGNK6WO5B6ZB#JAJM?(_ETYXLFE5U'2!0=<9*.FE(:2%6(-_R`W&GU@$
M"06_#7'N[PQ2213.E9$^$^GV=-(!&24%">BW=@]$[?W+F:S<&#R&0V=N3U$Y
M;;R0I3SR"((B[DQ<[&DW%1NP`,91)1;B3WAQ[W?=!]F_?BXYJFN^0K6+G:\E
M#3[C^KXLCZ`H8AI%B)"@#`\L]"NQYAWB%+>);U_"7@*C_-T!V1QO9NR86?<F
MT:G<V%1RB;FV%"^3:.-.6GR&UIRN8A#$$L8!+%']+FWOBI[\?W4O/WMO#>;_
M`,O[D^X[=K+!/T00*X72CLU`,5IT/[#F^&BQW;]X&3TG*+L;:N0J/!!N+%HQ
M9Q)35]73X6JI-`%UGCRAI9)9%/U$8)!X_'O`I_9/GO:-SN+7=.3IUC2*1E33
M(5.@$ZJA>*TJ!Y]"6UWJRNB71P5J!^WIK[-J*:?JS?S"II*NBJ-D;L<UL<L=
M;1.C[?R:,J5"-901];@WM[][?;1OFV<]^VV_2\J3M$F_[;*)BDP=M%Y"U"NC
M&K25X5].DW,&X6DENT+E:Z2*'AP/H>-,?GU\F#<=/CY]RYJ+&/',&S67@2CH
MQ+-/%-'DJF*.GCCDCC:74J@@1JW!M[_;+]DO=;9=T]E?;SF6\W*QMH)]IMI/
M#,\8=%:,55D=@ZLIQ1@&]1US_P"8]M)W[=/IE/@"8T\O3]O1DN@_@/\`,GY/
M92#%=%_&KMG?C25<5)49BDVAEZ/;6-\QL)\IF,E3T5)24Z`W9]1`'/L(>YWW
MW_N_>VEK)_6'GDP3$T!CB:6A_P!IJKTB@Y?OY5JD))_R=;.?P:_X2@]AY7+8
M/>GSJ[&Q6V\#124]=5=0=99%,MG<L-8D.-S^Z%3['%43);4U&9JBY*E1]??)
M/[Q/][+?RR[MLOL?NUS]*31;]E$3$$4)\"6-B6!X<%(S7H8[5RK:K'&][`#+
MYBAK^T8ZW2_C1\8.B/BGU9A>I.@.M-N]:[$PT)6/$8*`^:NJBS&HR&7R<I?(
M9?(U4I+/-/([F]N``!Q3YUY^YQ]U.:;WF/G/?I[^\F<L[R4%3\E4*J_8H'4F
M;=:6]K"B11!<>7IT8-*&D:,W@7]P,&-V#6("$*P(9`54#TV]DLT4<D/TKK6W
M`II\NC%Y9/@UG0/+J4L,:((U6R```7)X`L.223Q[;MK>&T3P[:,(GH.FBQ)U
M$YZY@!0`!8#Z#V^22:GCUXDDU/'KOWKK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U5Q_.V_[=%_S&/_`!4CN3_WDZ[W[KW7_]+9@_X3T_\`;E_^7[_XAFL_][[>
M7OW7NKF/?NO=>]^Z]U[W[KW6%D1BY`&I@%?D\@?BQNOOW7NB&;Z^%.%WKV#N
MK>]1O;+4YS\.Y*=,1C\92T\.,?<];CZK+5=/-/D[QYTPX^..&NIT@*1@^0/?
MW[KW25SGP-VK6-C\J^_]VIEJ6EK,5E(:..>FP-?CY\DV8IJ"/;M#D*2&@IXI
MV/[\4AU,RFQLH%0U6T]->`I8L>)ZF8+YC2XBHP.V=V=>UKTE5!*8,MLZMR&:
MH<5BL=AJ^7&T^>?*4]-4-FZB7$O%/"MUB-BS&Y/M>ED[BJBIZ>#A*=8'^<^W
M<=DJ=(^N=P14U12Y>6M6GR&&JHJ6JQ<-+/#!#D**5\="]7%(]Q(RQL5`1B6`
M]T:.#<4^C9ZF+RI2A'^;K<>QV%A+)NIE`EN!J/VGB./RZ6G5WS/V9VQV#3;'
MQ&T]T4-=E,;393$Y#(4^/7'Y&@.)CRU3//-'4-48BJQ]+,GEIIU296D''M"U
MQ/$PLT&0,9Z9FM&4_709'1R71YZ2F\3I$NI9?(0LBB-E=-"LURK^1Q^>2./:
MJ)V51K?OI0_;TXDPD17?XB.G.GTK'''=I&1560LS7#`6)=&9M))%[>T\II\+
MT/6B4)KUPD9/(MXP9)':)2S*CE5Y9D;ABO\`A?W8*DL6B1J@#JXI04/65'2R
M)'I%P2HN`2`;'BWTO[;6VM86+*J@_P"KY]6%/,XZX/X5\CRQ"4HEW9RK@*S7
MT@&]N>?I[<J#D<.J&E33AUF^W@<1.4%T&J,J60`,NGZ*5!&D_0^_=:ZSJBJ%
M"BP467_`?T]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4!X$>60F-
M68\:F^MK#@_U'^!X]DUQN.XO+-96L6C2</7^>13I2K:40UZY+"(TT`V`^G]H
MK?GB]S^?;MN9XHI!N<QE!\L'_CO3$K22,"G#I*9W8FSMT>-]T[8V[N$16%.V
M:PF.RAB'/$0K*>;Q<_TM[#V[\J\C7W^[#<-BB>:5&340]:-@B@(I7I9#=3Q(
MB(Y##CT'N0^-O260:26?8>+03/(\E-3565HL<_F@:FF3^$TF1I\:(I('*F,1
M!#?Z>X]G]@?;-[3;);?E>!)+2>.9#WU5HG$BD5?B"`1QZN]]<7)I.Y=?GT'N
MS_@S\.-D$/M;XO=%XZH^X6K&1/66TZO)_=*VH5(R=?BZK(),&%]0EO?WD;<^
MZ/,7,,R3R\TWIQ10`R*`?]*%!^T]%4FW6WBR2&-06-3BO^7HS5-18G"TB46.
MH:7&TL2A(Z7'T<5-3QJ@TJJ0TR)&JJ!8`#V'=T&[7X9ANK22GB785_:QKTIA
MV^)L+$M/V=2X8:>4"=4+%Q_:#+Q<_@D:2+?TO[06.PP6ZK->!6N3\1J"*_:#
M0]5EM%1RIQ3TSU/CC6.((@L%O;U%O]NS$GZ^S&0:8V2TIJZJJA//'69;Z1?Z
M^W8!*(D$Y_5IGKQ())'#KE[=ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW57'\[;_MT7_,8_\5([D_\`>3KO?NO=?__3V8/^$]/_`&Y?_E^_^(9K
M/_>^WE[]U[JYCW[KW7O?NO=>]^Z]UT``20.3]??NO=<3'&6+%%9B"+L-7!&D
M@7OI##ZV^OOW7NL'V5+<DPJ]R3:0M(`2P?TK(65;,+BWTMQ[UI`-:9Z]4]-G
M]U]MVE'\`PUJBJDKIU&,H],];*'$M9,OATRU4HD8-(UW8,;GVZ)I5X2$=>(!
MX]1CLO:!CFA_NQ@?!41QPU,`Q5$(*F*(((HJF`0B*HCB$:Z5<,%L+6]L1QI%
M-+<1BDSFK'S)]>FI88IU19D#*O"OETG-M]/]9;1S59N+;>S<1B<YD*G)5E;D
MZ9)C55-3F)(Y,E-*TLT@9ZHPH";>E%"K91;W<YD,I_M#Y]*(Y'BA%O&U(1Y=
M)[NG:>Y-\]<;MV?M#)U.`W%D!BH,5G*"66*IQ,IS6/JYJM')`9DQL+W_`%"[
M6]U**221D]-%5-21T4#&[-^=&!DQ'VN]]OY"(5FTJ.IQ%1%B_'+C*/*U)W?D
MWKJRH^YEKY,8(R`Q&K4+`6]Z$:#@O7@BC@.FW+==?.<9^'*1=B8^MI:3"92/
M1+6X:F_W+5CK)CH<;'%2O#1UE+361YIC+%(5>P]2VT(HP:Z<]6].L.VJ7YOY
M?L;?IR-=44FT]O;DPF.QU/5OC,&F:I5QT=97Y+9]7)35$TVUC4@Q5;3*9W8_
MLW`]U>WA>FJ.O6ZGHP7QBV?\@,!!V35=\9M<K69O>L=9LV!<A391\9M%:-[8
MZKJZ:GIH)_\`*GN6"*VD`'F_MQ$5%5$%%'6N/1O4MH6UK:0./IP+<>[=>ZY>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN(102P')^I_K[V22*$XZ
MW4\*]=%$/U4?[S[92"*)RZ(`_KUL,PX'KO0M@MA8?0>_30Q7%!,@;-?V=:U$
MDFN>N#P1/^M`W^O?_B#[>+$JR$]I%"/D>K([QBB&@ZYJJJ-*BP^EO:>&V@MX
M$MH8PL"B@'D!U4L2:DYZXF*,_50?]O\`\5]II-JV^4EI+52?S_S]6#N.#=<@
MB@6`%O:E;>%(5MUC`A48'6BS$U)SU[2H%K<'W:*"*#^R0+UHDGB>NP`!8?3V
M[UKKOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5<?SMO^W1?\
MQC_Q4CN3_P!Y.N]^Z]U__]39@_X3T_\`;E_^7[_XAFL_][[>7OW7NKF/?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6+PQ^3RV;R:2M];
MVL3J/HU:+W_-K^_=>ZX?:4_H)B!,9NERQTFQ!M=CP0>1]#^??NO==_;4]W_9
M3]PH9!I]+^-=*:E_20J_CZ>_=>ZQS4%'4'5-3QNVD)J-PPC!!\:LI#+&UN5%
M@WYO[]U[K,((@-(2PM:P+6`)O8<\#CW[KW60````6`^@]^Z]UW[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NJN/YVW_;HO^8Q_P"*D=R?^\G7>_=>Z__5V8/^$]/_`&Y?_E^_^(9K
M/_>^WE[]U[JYCW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U!FJHX-;/-&J*VEC(ZH%8@634UA<W]IYKR
M"$48]PZ89GU&AQUDCE+B][7YM<'_`'D7!O[U:SB?40<=:9F'GU)7D#VJ/'IY
M"2H)X]=^]=6Z][]U[JKC^=M_VZ+_`)C'_BI'<G_O)UWOW7NO_]:V+^23_,4Z
MSZ6_E4_"SJW/?'OY_;PS.RNKJ_#Y+<G3_P#+]^7/<G6N5J8]\[ME:HVAVAUM
MU-N386]<25E`6MQ60JZ1V#*LA96`]U[JT_\`X=DZ<_[Q5_FC_P#IK'YW_P#V
MB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW
M_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#I
MK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC
M_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q
M5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ
M<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_
MX=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?N
MO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#V
MB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW
M_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#I
MK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC
M_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q
M5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ
M<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_
MX=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?N
MO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#V
MB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW
M_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#I
MK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC
M_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q
M5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ
M<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_
MX=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?N
MO=>_X=DZ<_[Q5_FC_P#IK'YW_P#VB_?NO=`)W_\`S->I=W[)J*6@Z`_FD;7K
M*.NIZZG9_P"6!\X,;292:,JBXVLK*SIBC2&*4/K!UJ;J!^?87W2RAEFDD^L1
M9"?A)4>GF6K_`"Z8E6H.?/Y="5L?^:7T]@-J8'#R?&_^:=N&2@QT$$F:J?Y6
MGSHDFR#`%C.[P](21L"6L+$C2!R?9KM<*0Q@+*'-,TH?\!/6M(TJ*_X/\_2P
M'\V3IRP_YQ5_FC_^FL?G?_\`:,/LT/'IY<*.N_\`AV3IS_O%7^:/_P"FL?G?
M_P#:+]ZZMU[_`(=DZ<_[Q5_FC_\`IK'YW_\`VB_?NO=5X_S:_P"9/U;VG_+*
M^=/7.(^.7\P[;&5WI\9^T=N8_/\`9G\NOYC=8[`Q-7E=NU-)#7[O[#WQT_A-
:F[+V_2M+KJLCE*VEH:6)2\LJJ+^_=>Z__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g912919g06e15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919g06e15.jpg
M_]C_X0L"17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP-#HR,B`P-3HP-3HT-P```Z`!
M``,````!__\``*`"``0````!````U:`#``0````!````/``````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```G,`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+0"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I5>I=0Q^FX=F9
MD[O3KB&,&Y[W..RJFFO_``EUUCFU55_Z16ESOJ5=2ZO=U3,<UG2.@&QN.YY<
MUKLIC2W.SW[MM;JNGU^IA4?3_3_;_P#1U)*5TOJ_7;_K$>GYU5-5)POM=M%8
M+G8[GV"K%HNS?4=5D7W5LR7VLKHJKK]+]#;?_.V]$L+ZIT76X^1US*K->7UJ
MS[1L<`'5X[1Z73<=VPN^ABAMS_\`A\B];J2E))*`NJ-KJ0]IM8T/=7(W!KBY
MK'N9]+8]U=FW^HDI=[V,:7/<&M'))@!)CV/:',<'-/#@9"P^L_5KHV?=;U*[
M"'5>H8S'&C%R+GFK?M]E(Q[7V8>/Z^RO=^K_`/"K+^H_2JGV.ZRUU&)>UIQ<
MOIF!CG$JKO:?4R*<YC[+WY61COLVX]OZ*NNO^:_17)*>R53JG5NF](Q'9G4L
MAF+CMTWO/)@NV5L'OMLVM_FJV^HK%[;74V-I>*K7-(KL<W>&N(]CW5RS?M=^
M9O7#=/Z9B]2ONZIU;.;F=)QP*[NH94,;F65N-EGI;W_9,7H55WI[<?$8ROJ&
M11^M795-?Z5*>VP\JK,Q*<NG=Z60QME>]I:[:X;F[F/]S461]W*P.I_6O#.$
M&]!OHZEU'+M^R85=3Q8SUBWU'6W&G?\`JV)3^LY#_P!SV(6-TCI'U3=^UKLQ
MN-5]F=5U*ZXP<K(+_M+,VXN<[?E[W9OL;ZEEGVKT*OT=%5:2GI4ESP^N>&WJ
M-.-E46=.P\BJZZK.SW,Q6O\`1=76X549#FY/N]7U/UFO&L]/]+Z3ZOTBBWZ_
M?5LY!:[(]/#]%]U?4+6FO'M=4_TLC'P[+@S[9=5]+]5]9)3T:9TEI#3#HT)U
M@KBNA_7S-^L'477XF+7@_5O"+W9G4LQT%P#?T=-<%M-%WJ.]6W?;9^K>_P#1
M_H_6G]8_K3EYW3K,7H%#K*,VYG3V=8?8*:?4OL&([[$Z'Y&7LW?TK%I?0SWW
M5V6^C[TI#C]>Z_U;*^Q/S*L3I%E[L:KK^)26C)M'I,^Q8;<NW*9C;K/M=3.I
M?I\;(OK^SX?Z?^=GU#H70KL[]E=&J-W6P^JS,ZH^VRV_#K#O4^T69UKK;&9U
MS*W,Q,3?^E_PU7V#U%?K^JW4\SIS>G]5SFXV"RIM5?3NF-].MC62VKU,W*];
M,R/3;Z7T/L?O9[Z[%I?5:JBOZO8'HTLH]2BM]C*Q`-CFM-SY/OL<^SW>K9^D
ML24__]#U5)"R<G'Q*+,G)L;314TOLL>8:UHY<YQ6.1USK3G;++.B],F*W-:/
MMU[2UP+_`-.U]?2ZM[F^FQ]-N?\`^$+/T:2F[U?J73NFTC(SLVK".UXI==9L
M:YT?Z,G].YO[FUZXAE]^9AX/U;Z9T[(ZE@=,:T]6(K]&O(S:]MYP;[NJ?9O2
MHLRG?;<[]!?=;^AJ]#]+8MC*PL+'ZH[IGU;QVNZ[<T.SNKWEV19ATO&SU;LK
M*==D6Y=]3=F!@^K[_P">N_5*??TW3NGXW3<*K!Q6[::1#9,DDG>^RQWY]MMC
MG66V?X2Q)3D.Z+UGJYW=<S'8N-(+>F].L<QI'O:YF;U#;5EY6]C_`'5X_P!B
MI_XY+_F5TVEK1TW+S^F%KMQ=CY=K@[2-EE6<[,H<W_K*Z!))3SW_`#&Z'96T
M9S\S/M$[K\C,R"]T_O-INIH;_P!;IK6CTSH'1^DUV,Z;BLQ?6TM>R?4='T?4
MO=-S]O\`*>M!))3S.+]0NGX[SNZAU&ZE^[U*#DFIMA=^?D/PF8N1DV?R[[[%
MH87U8Z3T[+IR>G,?AMI8YAQ:7EN.\N#&>O?C?S;\EK*OZ1_.V?X?U?T7IZR2
M2E+%Q_J9]5,>YU]72L7U'&9=6UX:9+OT3+-[*/<[_`[%M))*<_#Z#TK"ZAD=
M3Q\<-S<MK66W$EQ#&!K645;C^@I]C/T5.QG_`&W6@X7U7Z1B98S2RS*RF%WH
M79=K\AU+7$N]+$^T.L;C,9.S]%^DV?SCUK))*07X.%DAHR:&7AC_`%&"UHLV
MO_?9ZF[8[^HN&_QB"OKN;7]6FP+ZVLMQJPZP6VY%_K54>G4T?9_L6#51=E=1
MS;F7^G5^JX_H9%_J+T!0]&GUO7V-]8-V>I`W;9W;-_TMF[\U)3A=)^HGU8Z9
MC4T-PJ\EU('Z3)!N]XCU+ZZ\@VU8]ESF[[/L[*O_``-BL_6;IV1G=+'V.MMN
M9A7TYN)4XAH?9C6,R!3O/\WZ[&/HW_\`"+7224\[=]<^G6X>SIV^[K%WZ.CI
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M2,/H^&,3$#B"XV776NWVW6N_G<K*N/NNR+?SW_\`6V?HMC%=2224I))))2DD
MDDE*22224I))))2DDDDE*22224I))))2DDDDE/\`_]G_[1+D4&AO=&]S:&]P
M(#,N,``X0DE-!`0```````\<`5H``QLE1QP"```"AL0`.$))300E```````0
M%O\:1<PIE@Q(A\\:]MO64#A"24T$.@``````Y0```!`````!```````+<')I
M;G1/=71P=70````%`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E
M`````$-L<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA
M;65415A4`````0``````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O
M`&\`9@`@`%,`90!T`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE
M;G5M````#&)U:6QT:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M
M````$`````$``````!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB
M;V]L``````!#;&)R8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L````
M``!#;G1#8F]O;```````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$
M8F]O;```````26YT<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,`
M```#`````%)D("!D;W5B0&_@````````````1W)N(&1O=6)`;^``````````
M``!";"`@9&]U8D!OX````````````$)R9%15;G1&(U)L=```````````````
M`$)L9"!5;G1&(U)L=````````````````%)S;'15;G1&(U!X;$!RP```````
M````"G9E8W1O<D1A=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G
M4$,`````3&5F=%5N=$8C4FQT````````````````5&]P(%5N=$8C4FQT````
M````````````4V-L(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN
M=&EN9V)O;VP`````#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E
M8W1,969T;&]N9P`````````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R
M;W!296-T5&]P;&]N9P``````.$))30/M```````0`2P````!``(!+`````$`
M`CA"24T$)@``````#@`````````````_@```.$))300-```````$````>#A"
M24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))32<0````
M```*``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O
M9F8``0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````
M!@```````3A"24T#^```````<```_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@`````_____________________________P/H```X0DE-
M!`@``````!`````!```"0````D``````.$))300>```````$`````#A"24T$
M&@`````#10````8``````````````#P```#5````"`!$`%,`4`!?`#``,``U
M`&$````!``````````````````````````$``````````````-4````\````
M``````````````````$`````````````````````````$`````$```````!N
M=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O
M<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````\````
M`%)G:'1L;VYG````U0````9S;&EC97-6;$QS`````4]B:F,````!```````%
M<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P``
M```````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R
M871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U
M;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````
M3&5F=&QO;F<``````````$)T;VUL;VYG````/`````!29VAT;&]N9P```-4`
M```#=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$58
M5`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,
M8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T`
M```/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU
M;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP
M965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S
M971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T
M<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@`````
M``P````"/_`````````X0DE-!!$```````$!`#A"24T$%```````!`````(X
M0DE-!`P`````">@````!````H````"T```'@``!48```"<P`&``!_]C_[0`,
M061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+
M$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"T`H`,!(@`"$0$#$0'_
MW0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!
M`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$
M(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F
M1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!
M46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD23
M5*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54DDDE*57J74,?IN'9F9.[TZXA
MC!N>]SCLJIIK_P`)==8YM55?^D5I<[ZE74NKW=4S'-9TCH!L;CN>7-:[*8TM
MSL]^[;6ZKI]?J85'T_T_V_\`T=22E=+ZOUV_ZQ'I^=5352<+[7;16"YV.Y]@
MJQ:+LWU'59%]U;,E]K*Z*JZ_2_0VW_SMO1+"^J=%UN/D=<RJS7E]:L^T;'`!
MU>.T>ETW'=L+OH8H;<__`(?(O6ZDI222@+JC:ZD/:;6-#W5R-P:XN:Q[F?2V
M/=79M_J)*7>]C&ESW!K1R28`28]CVAS'!S3PX&0L/K/U:Z-GW6]2NPAU7J&,
MQQHQ<BYYJW[?92,>U]F'C^OLKW?J_P#PJR_J/TJI]CNLM=1B7M:<7+Z9@8YQ
M*J[VGU,BG.8^R]^5D8[[-N/;^BKKK_FOT5R2GLE4ZIU;IO2,1V9U+(9BX[=-
M[SR8+ME;![[;-K?YJMOJ*Q>VUU-C:7BJUS2*['-WAKB/8]U<LW[7?F;UPW3^
MF8O4K[NJ=6SFYG2<<"N[J&5#&YEE;C99Z6]_V3%Z%5=Z>W'Q&,KZAD4?K5V5
M37^E2GML/*JS,2G+IW>ED,;97O:6NVN&YNYC_<U%D?=RL#J?UKPSA!O0;Z.I
M=1R[?LF%74\6,]8M]1UMQIW_`*MB4_K.0_\`<]B%C=(Z1]4W?M:[,;C5?9G5
M=2NN,'*R"_[2S-N+G.WY>]V;[&^I99]J]"K]'156DIZ5)<\/KGAMZC3C95%G
M3L/(JNNJSL]S,5K_`$75UN%5&0YN3[O5]3]9KQK/3_2^D^K](HM^OWU;.06N
MR/3P_1?=7U"UIKQ[75/]+(Q\.RX,^V75?2_5?624]&F=):0TPZ-"=8*XKH?U
M\S?K!U%U^)BUX/U;PB]V9U+,=!<`W]'37!;31=ZCO5MWVV?JWO\`T?Z/UI_6
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M_P#3M?7TNK>YOIL?3;G_`/A"S]&DIN]7ZET[IM(R,[-JPCM>*776;&N='^C)
M_3N;^YM>N(9??F8>#]6^F=.R.I8'3&M/5B*_1KR,VO;><&^[JGV;TJ+,IWVW
M._07W6_H:O0_2V+8RL+"Q^J.Z9]6\=KNNW-#L[J]Y=D68=+QL]6[*RG79%N7
M?4W9@8/J^_\`GKOU2GW]-T[I^-TW"JP<5NVFD0V3)))WOLL=^?;;8YUEMG^$
ML24Y#NB]9ZN=W7,QV+C2"WIO3K',:1[VN9F]0VU9>5O8_P!U>/\`8J?^.2_Y
ME=-I:T=-R\_IA:[<78^7:X.TC995G.S*'-_ZRN@224\]_P`QNAV5M&<_,S[1
M.Z_(S,@O=/[S:;J:&_\`6Z:UH],Z!T?I-=C.FXK,7UM+7LGU'1]'U+W3<_;_
M`"GK0224\SB_4+I^.\[NH=1NI?N]2@Y)J;87?GY#\)F+D9-G\N^^Q:&%]6.D
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M?JN/Z&1?ZB]`4/1I];U]C?6#=GJ0-VV=VS?]+9N_-24X72?J)]6.F8U-#<*O
M)=2!^DR0;O>(]2^NO(-M6/9<YN^S[.RK_P`#8K/UFZ=D9W2Q]CK;;F85].;B
M5.(:'V8UC,@4[S_-^NQCZ-__``BUTDE/.W?7/IUN'LZ=ONZQ=^CHZ2]A9DLN
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M$Q`X@N-EUUKM]MUKOYW*RKC[KLBW\]__`%MGZ+8Q74DDE*22224I))))2DDD
MDE*22224I))))2DDDDE*22224I))))3_`/_9.$))300A``````!5`````0$`
M```/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X0DE-!`8`````
M``<`"`````$!`/_A#W9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C`Q
M,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C
M(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP9&8](FAT='`Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X
M;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E
M+U)E<V]U<F-E4F5F(R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B
M92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&5$871E/2(R,#$U+3`T
M+3(Q5#$P.C0R.C,V(B!X;7`Z0W)E871O<E1O;VP](D%S<&]S92!,=&0N(B!X
M;7`Z36]D:69Y1&%T93TB,C`Q-2TP-"TR,E0P-3HP-3HT-RLP-3HS,"(@>&UP
M.DUE=&%D871A1&%T93TB,C`Q-2TP-"TR,E0P-3HP-3HT-RLP-3HS,"(@<&1F
M.E!R;V1U8V5R/2)!<W!O<V4N4&1F(&9O<B`N3D54(#DN-RXP(B!X;7!-33I)
M;G-T86YC94E$/2)X;7`N:6ED.C%!1D4X-31#-39%.$4T,3%!.45"0D)$0D$P
M144Y,S0T(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C$Y1D4X-31#-39%
M.$4T,3%!.45"0D)$0D$P144Y,S0T(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240](GAM<"YD:60Z,3E&13@U-$,U-D4X130Q,4$Y14)"0D1"03!%13DS-#0B
M(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB
M,R(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F.E-E<3X@/')D9CIL:2!S=$5V=#IA
M8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C$Y1D4X
M-31#-39%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=$5V=#IW:&5N/2(R,#$U
M+3`T+3(R5#`U.C`U.C0W*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB
M+R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R
M86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T
M:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HQ049%.#4T
M0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T-"(@<W1%=G0Z=VAE;CTB,C`Q-2TP
M-"TR,E0P-3HP-3HT-RLP-3HS,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB('-T179T.F-H86YG960](B\B
M+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I=F5D
M1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C$Y1D4X-31#-39%.$4T
M,3%!.45"0D)$0D$P144Y,S0T(B!S=%)E9CID;V-U;65N=$E$/2)X;7`N9&ED
M.C$Y1D4X-31#-39%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=%)E9CIO<FEG
M:6YA;$1O8W5M96YT240](GAM<"YD:60Z,3E&13@U-$,U-D4X130Q,4$Y14)"
M0D1"03!%13DS-#0B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`#P`U0,!$0`"$0$#$0'_
MW0`$`!O_Q`&B````!@(#`0`````````````'"`8%!`D#"@(!``L!```&`P$!
M`0````````````8%!`,'`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%
M$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V
M@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(24I8
M65IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*
MU-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2
M!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R
M)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75
MY?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9
MJ;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`-_CW[KW7O?NO=>]
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M"220`!<^_=>ZA8C+XG/XR@S>"RF.S>&RM)#7XO+XBMILEC,E0U*"6GK*"OHY
M9J2LI)XV#))&[(ZFX)'OW7NG'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TQ;
MIJ-QTFV=QU6S\;B\UNZFP67J-K8?.9.?"87+;CAQ]1)A,;F,S2X_+56(Q==D
MUBBJ*J.EJ9*>)V=8I"H0^Z]UK+;Y_GT?+'`]XS?R]:G^7UL'K7^95O+=G7^T
M.K\!N;YB]7]E?$?"XWLG![CR>([![A[>VK0[.WAM3+TL6VIJZBZY_@T&\=ST
M,D"8MGGJJ59O=>Z.+COY.%7\CP^]/YJORP[W^:F]\W0`5/3/7_8G8/Q7^&W6
MDE4:R6?"];=.]%[LV9N7<JX^ER#8R3.;MS>7R.:HJ>.2IAA:22+W[KW51&&^
M)O\`*UA[?['2JZSW#3?R0<EWWTI\8,'M27M#M[(_$_,?S&,)1]_8/=7RFH*J
M3L!\GL_I;;=9N##=-U>9AJ(]E[D[&RM-73))_`X,Q'[KW7__T-_CW[KW7O?N
MO=>]^Z]U[W[KW5;O\R'Y2=A]+[)ZO^/WQIEPU5\V_FMO>KZ/^+M'FHX:W#['
MFIL2^>[>^2&\\7>:MJ^N?C7ULE1N#(""EK?NLH<9CGA*Y#4ONO=5/_S"?C/M
M/XT_!?XS_P`E?XM9S>E5W-_,\[\3KGLCM_,9%]T=R[_VDF8PO;/\P#Y>=M[D
MS5749'>6Y\MLNF>/.2SO.%I,U#04RQ4L%-%%[KW6RULC9NW>NME[0Z^VACHL
M/M+8NU\!LW:^)@%H,7MW;&*I,)A,="+"T5%C:&*)?\%]^Z]TJ/?NO=>]^Z]U
M[W[KW43(2UD%!6SX^D3(5\-)4RT-!+5"ACK:R.%WIJ22M:&H6D2IF"H93&XC
M#:M)M8^Z]U0_O]?^%!7<&;W/EV[`_EO?RU>BMN23Y%]P(V_OF'W!1X+#4WWF
M;SN=W!O/!=0=-?W26A$DWDDQ^'K:?[=_-HCTR^_=>Z(9\;OYL/S)POS'Z&^,
MFU_E[\4OYT>$[)[&Q>WNZ&^''QZWQLK>7QTZDW'6U5%1_(7=/<^R,WNCXNTV
MTMH5"(,QA*^MCR3EXH:>?7)Y_?NO=;;WOW7NB)_.3^8-TM\#<+UB.Q\-OS?'
M8O>V[JCK_HKJGKW$8O\`CG9>]J2.@J:W#_WXWSFME]/[`I<9CL@M945FY]QX
M:%Z2&8TOW4\?@/NO=:R_R7J?FS_.T[XK/@)4_(*BZUV9]]LC=/RBZX^#W8LN
M]/C_`/"WIZC&1FW-UQ\K_D[3;:Q<7RT^8_;V2DJ<!C>N</%A]@[3?"R96ICS
M4E,]92>Z]UN`='=*];?''I[K3H;I[;=+M#J_J39F!V'L?;M(6D3';?V]014%
M&*BID)J,ADJH1&:KJIBT]752232LTDC,?=>ZI+[_`/GM\Z?D+W5\K-J_RKGZ
M%KNJOY=.U<XG?V_^Y]G;CWCBOD7\KMNQ?WHR7PSZERF`WCM3';6BVCLS&34^
M[-S233U.,W!E**B6"&)7K']U[JZ3XZ]T8'Y']`=(?(3:^,RV$VWWEU)UUV[@
ML+GH!39S#XGL;:.(W=08G,P+=(\IC:;+K#4!24\J-I)6Q/NO=#)[]U[KWOW7
MNF#<>ZMK[.QXR^[MR8#:V*:IAHUR>X\QCL'CVK*C7]O2"MR=12TQJ9_&VB/5
MJ;2;`V]^Z]T%7Q[^370'ROV1DNROC=VULONC8&(WEN;K^NWCL++1YO;R[NV?
M51TFX,33Y.%135WVC3Q21U$#24M53315%/)+!+'(WNO=%O\`YH/S*R/P3^&/
M9_>.T<!3[Q[?KJG:W4_Q[V-53TE-2[S[_P"X-Q8_8'56(KYLA5X['IA*#<>:
M3)Y3S55*IQ6/J0LJ2%#[]U[J@/KGL/\`E>]0_#_L/X"8N'LO^<Q\ROD5-#V?
M\T\E\*MKY'Y$=B[_`/DCO"OI9*KN?<?R(P:T/671^&ZJWZ\*;4RE3N"AK-GQ
MX^*L6'[Y:R>7W7NC'_%+IW^85_,9P.ZOCG_,<[HW/T)TY\4<WA^EN[_C)UEG
M,3!\C_F'!7[6VKOS9^Y_EE\DNO*^IVC2=8]D=2[EI*+/[<ZRGBIMRUU1EHZ[
M*4XC_A\/NO=;"W^@+HO_`$-?[+I_H9ZK_P!E_P#[I_W#_P!!_P#H_P!J?Z(_
M[D^+P?W1_P!'7\*_NC_=KP^G[+[3[:W]CW[KW7__T=_CW[KW7O?NO=>]^Z]T
MU#.X-LY)ME<SBFW)%BH<[+M\9"D.;BP=163X^GS,F*$WWR8J>OI98$J#&(6F
MC9`Q92![KW5/?P$W#M/Y1=F?)#^;MOO,8RCV!N!>P?C5\0L]GLKC<=M;8'PC
M^/6_,W0[][4_B$TE!1XUOD?W;M',;KR60R*K+'M;#[=A$HIZ4O+[KW0=?RXL
M=G?G=\O>Z_YPF[:',8[I7-[(F^*?\M_:&Z*3+460@^.FVMTMD^U?DO\`P'*2
MP4V$K?D[V)B8YL/*<?299=IXNECFEFIJB(GW7NC&_(K^=K_*T^*_85=U1W#\
MOME1]D8>FR%5N/9G6&T^T/D!GMGIB93#DX=]470.Q>S7V)78]P#-39C[&HC5
ME9D"NI/NO=*OH+^<-_*_^3<-8_3OSAZ`RU90+3-5X#=^\HNIMW0I51B2-_[E
M]MP;&W:Z)?1*RT1$$O[<FE_3[]U[H)NU_P"?G_)^Z9W14;,W7\Y^K\_N2DJZ
M?'U&/Z=P?9'R$2+(5,C018]J_H/9'96-^_%2OA>$3&6.<B)U60A3[KW21W#_
M`#T?C-N+$3P?%'I#YK_,;L2?(T.&P.Q>LOAE\G=AX_(92LKJ&D,6;[%[GZEZ
M_P!C;,HH(ZF9Y*K)54,$1IG\K1H5D/NO=6`?)WYI_'[X<=:;3[,^1N[_`/1Q
M3;]W)@-B;$VC6Q4^3WSO/LK<]++4X;KC;6%PM7D:3)[GF:"1)I$JOX72+&\U
M1614JF<>Z]U6A\L/YGG\GWO7X;]C=7_-GY&;#ZDV9W9M3-[%[%^/U9V]L3=_
MR;P&/K*V6+'O-L'XG;_[SW12Y.M^SI<ICUHFKTEAE@2JB/DEI??NO=$K_D[_
M`#YZV^(^W]Q?#3Y8Y?,=(;3J^Z.LM@_RUM[][?%@_$KMGY;=!]G9&AV!U;4Y
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M3+[@[O\`D/E^U]Y[FQ6Z.U*+8FW</N+?/=&[^P^RL?EGR5)@*/-5>-0Q131P
MT@I2WNO=!FG=?\SSYZXV>;XX;&;^4S\,<=1//%\C/D?USAMZ_-/L3:F'\;23
M=0_$[)3ML?H+;=728NKIDR>^Y:_+?85-)7T.'!O&ONO=%1Z2^/G\S'^6/\M?
MF=E>DNC_`)2_S7.M?DMM?XXS_'KO+Y&_/_KBEK]A5FT=NY;&=DX'O:+LNHVW
M78N*#=>>JLK056U-IUZ+@(J+&TJ"4U"P^Z]TF_G/V;_-L^$U+L3^;C\P>]OB
M31=9_%:NWSMG+?RX.B]^]\]?]6]F;-[EVY_=+`93*]YY?:&Y<KW7\D:7>5;C
MH\=@\QLJAV?BXL<V0HJZBE>M>H]U[K3@^6_\PKY"_P`_KYRXK8O>78NZ/CK\
M6J3<,LG675N%V5VUW7@.@\)`D&-CW/+U1T;L',[[[X[TW123U%#1O/1T8J<O
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MQY?N3=%+%D:IUADQ..D`JF")(DSI?W7NM:3MCNCN3Y7]+]-?R6?Y=OP?^3G9
MWQP^+^P^DNM?Y@VY-RPP_`VOW=LG!;'PV6V=TM09[Y#*V_NKL'WQ-34&Y-W5
M;X^JWRVU:N6GIL?52UE46]U[JW^A_E^_S#/E%@L3UU\R_E5U_P#$_P")VW\3
M@ML8GX5_ROZ;=6PESFQ=O4-#1X78W87RSWOC,)VC!M&'%4QP^2P6S\+MG'Y'
M%GPB:-;>_=>ZM<^.?Q1^-'Q#V0O7/Q@Z(ZKZ(V:R8O\`B&(ZQV7@]JON*LP^
M,@P]#FMX93&T<68WKN;^'TZI-E<O45N2J3=YIY'9F/NO=,/R!^$WP[^5\V*J
M_DS\6^@.^\E@:9Z+`9GMKJ38V^\_@**6J@K:BAP.X-Q82OS>%HJRII8VGAI:
MB*.<+:166X]^Z]T*75'2O3?0^UH=C='=2]9=,[)IG\M/L_JC8>UNN]K026MY
M(=O[0Q6'Q,3VXNL(/OW7NA-]^Z]T%G;W1G27R"VLFQ^^NG>K.[ME1UZ96/9_
M;W7VTNRMK1Y2*EJJ*/))M_>>(S6)6OCHJZ>%9A#Y!%,Z`Z78'W7ND#T]\-?B
M#\><E-F>@/BI\;>C<Q40"EGRW3W1O6'6>2GI@TCBGFKME[7PE5)`&E8A&<K=
MCQR??NO="EOWJ?JWM4;47M#K78'9"[#W?B>P=CKOW9NW=X#9F_<`*A<%O?:@
MW#CLB-N[OPJU4HI,E1^&MIA(_CD74;^Z]TO_`'[KW7O?NO=>]^Z]TW4N'Q-#
M7Y/*46+QU'D\V]))F<C2T5-3U^7DH*9:*@?)UD425%>]%1H(H3*SF.(!5LO'
MOW7NF3);"V-F=U[>WWE]F;3RN^-HTF4H-J;RR6W</7;KVQ0YQ84S5%M[<551
MRY?"TF82GC%5'331)4!%$@:PM[KW2L]^Z]U[W[KW6LE_/4^:5'L?NOI[X8=A
M[YW_`-;?'G>GQX[2[_[?VOU/BC)WS\[LY3;WVETITY_+X^,^>BVYGL_@.P.V
M-_[VCJ]R5>W5BW!2;95I(JS%P>:K/NO='1_DD?RV\/\`R_?C#E<SNOJKK?J_
MY*?)W>6:[R[VVSUQC8(]N]7'=5;/7[`^.6TLD_W62EV3T/M"HI\2D;UE=%-F
MCDJU*BH^[,[^Z]U<Y[]U[JM;^9[\7.V/D)T_UCV-\:Y,4ORQ^'/>.S/E7\<<
M;G<C!A,#V%NW8='FL-NWI#<N=J6BI\-MSO#K7<N8VY+53214U)5UM-4S21Q0
M-(ONO=`KM_\`GH_!],32[=[;3OCHGY0*T&&R7PCW_P#';NBL^5%3OJH^YCHM
MF=>]>[3V/GXNY3G9:8/C,MM6IRN&J:2HAGEJ:96D6+W7NC:_!WK/LW`[2[,[
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MHE7;_6WQV_E_;MP?P/\`Y./Q[Z8PG\S;Y5XW+9#,=K;@@RO:&\_CET;65U*_
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MWBO\FJWHY86J:?\`;D+)Q[]U[I5^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
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MITR$.0C]U[H5/A%\#M@_#;$;]W36;KS_`'M\I>_,W2;W^5/RV[(HL9#VGWUO
MNFI%HZ+S4F+08CKSJG9%`!C=G[(PPBP6UL/%'!"LU2U56U7NO='J]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7__U=K'X%+1?)OLWN_^9#E*^BS]!VKDMR?'3XHFGHI(*?9_Q*Z1[#W!@9\K
M025M%09*3+?(3N/"93=V3GEB3RXF';](ODCQL<TONO=%^^27\P/O;Y0=J;O^
M#G\H-MJ;R[;VEF8MH?*;YTY^CQVZ?C?\&(:UIJ?+46*@JYEP_?\`\G<73Q2G
M'[/H#6X[&9-8QG"L,&0@IO=>ZL&^%OPDZ9^#G6%9L3K"/-[GW=O+-U>]^[N]
M.PJ]-R]U_(7M/+SU-;N'L[N#?4T,>1W1N7*Y"NG:)&*T>.@D%/210P*$]^Z]
MT<+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U__UA%^.?\`LYG^@#;G^S6_\.`_\,&?W%;_`&7?_9.O
M]EY_TU?Z!O[RYS^[W^SR_P"RV_\`.7/^BK_1MY/XW_H]_P"4'1_>#C[OW[KW
M6X7\)_\`91?]E=Z=_P!D3_T7?[*O_=#'?Z)O]#_VG]SOX)XAY/)X?]R/]Z?O
M/)_&OXK_`+G/XK]Q_$O\N\_OW7NC4"WX^G^'OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g912919g10v78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919g10v78.jpg
M_]C_X1$/17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP-#HR,B`P,#HQ,SHR-P```Z`!
M``,````!__\``*`"``0````!```"B:`#``0````!```#2``````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```_9`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`H`!\`P$B``(1
M`0,1`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]43I))*4F3I)*4DDJV5D
MEA%5<^H[N()`,[=C3[?4?M=LW_HV?I+K?T=22DMEU59#7'W'4-`+G1X[&[G(
M)SZ@2-IT_E5C\MBKMI]A<Z'!QDS[A.GN]P=OV^S]8O99_P`'732BM<\UM)EK
MW.B-SM!K$-:6U[D+329N701).P'\X_1_[=;NJ_Z:,L\F7$O&QX`ATF>-[FMM
M:/4]FWW[_9_P7Z1*JYV*[:[^9&A!TB/=+6_1:]C/=94S]%;5^GQMGZ2E(&U$
M.BDDDBA22222E)DZ9)3_`/_0]1MOII:'76-K:=`7D-!(!?\`G?R&N<JW[;Z-
M_P!S\;_MZO\`\FJOUB<X,P*P2&79;:[&@QN8:[RYCOY+MJN_LW`_T#/N24P_
M;?1O^Y^-_P!O,_\`)*=75.F7$BG+HL+=7!EC'0//:Y+]F=/_`.X[/N4F8&)7
M)JK],GDUDL)^.PM24R^UXO\`IJ_\X?WJDRQEH=D$AS7R1J`#(;[=Q.SW-^S8
M_P#8M5W[-7XV?]N/_P#)H62::O=8_P!"EC/IB!`!:(U!_>0.R1NQI9M;O@DO
MC0Z21^<]@]GJ(5@M>07!P["!.OS5EKPPM;`F=LD<^XMTCVM0=C=0&@@R0=T&
M)]OYCO<AT4II?9%=K"`>Y&FG^OYOT/\`C%!K2/T`]NV&M,:B""Q[Y=[W,O>U
MW^C^G_Q:.US:V%I`!+C(G0:#;M_L[5"PTFUT/`N+217^=MW>G/[VSU/S?](E
MXI98>50*C6Y[6>F8#7.`+00'M9_UK=Z/_6T9V9B-:7.OK:T:DE[0!^*D^BM[
MR\[@X@`EKG-F/ZCFJ#\2A["RP.L8X0YCWN<T@]G->XM<G+6'[4Z;_P!RZ/\`
MMQG_`))/^TNG?]RJ?^W&_P#DD/\`8W2?^X=/^8W^Y+]C=)_[AT_YC?[DE)Z\
MO%M,575V&8AK@=8+H]I_=8Y%6+E8N-A=7Z6,2IE`NNL;:*V@;@W'RK&[M/S7
MK:24_P#_T>]^L7/3/_#S/_/60MA9?7,>RX83F1&/DBZR3'M;5?NV_O.]RU$E
M*22224Y-'UAHMR?LQHL9;ZYQ]AVAS2&VW"RQECJ_T-E&-;=3?5ZU%U?\U;ZG
MZ-"N^LO3MC+V-M=6&&W>&B-HL&'<QS'O99OKO?L>S8M/[!@P&_9ZX!D#8(!(
M<SVZ>WV6VM_Z[9_I$CT_!)).-42XDN.QLDEPN<3I_I6,M_XSWI*<O+ZY3C;_
M`+1OKL;LL>*P#`L]6S&K][AON?7BN;:QGL8__@TCU=C['-JJ<6U4C-L.YH#:
MGO?6RQDA_P"E=Z%]NW\RO_A+O31LM_0F9!HM]%M[&;36^O<"QP+=FW;[O;>]
MOL_T_P#PJ#9D]'=9ZUE]#C2-F\N#@)+;S^D]/V^INK]N[_1_\&FI8U_6#!+G
M[W.J970_)?N;,5AM63ZA=[G6664WM?Z-;?S+/]'^E)7US&.;7T^UCV9`LV>D
M!)!AEM+'>[WN;CW59-_I>IZ7_6[$U9Z$QFYQQVUTDOW%H);NV._G7L;L;MJJ
M_P"M5U_X-7Z^G]+LI868U+JG-!9[!$$ML;R/WFL>B`II6?6OI-=/VEQL^SAH
M<Z[;HTN?=CMK<V?5]3U\6RK^;^FM'$S:<L6BL%K\>PTW,<-6O`;9M.W<QWZ.
MRM_L=^>F_9W3][K/LU6]^[>[8V3NW!^[3W;][]W]=Z-5352S94P,;),-$:G5
MSOZSD4,TDDDE.3U3_E?HW_ABW_VVRUJK/SZ'V]2Z;:T@-QK7V6`S)#J;\=NS
M3]^YJT4E/__2]+ZA_,C^W_Y[M5I5LQCK&,8WZ3BX#PUKMY5E)2DDD-U]+0TN
ML:T/T;)`G^JDI(DA-R<=T;;6&2&B'#Z1X;_64O6I+BT/;N!@B1(/@DIIV=6Z
M;6]_JOV^FY['/+21OJ9ZUS9:#_,U>Y4G9O2R]SVY][!<2X,:';8]-M[FU33]
M'T7MO]O[ZU`,"ZQP`JLLY=]%SM/;+OSOY*C/3=-:.X'T.XVO'^8DI!1U#IM>
M/2SUS?O:TUO<TN>]I<UE=OL9[F.LLK;ZNS8KN/?5D45Y%+MU5K0^MT$2UPW-
M=[D)HZ>X^T4DMEQC;IK[G?YRFRW%K8UK'UL9`+&@@"#QM24F24!=2=I%C2'F
M&ZC4_P`E,+Z""18PAO)#AI*2DB2@+J3,6-,"3!''BI-<UP#FD.:>"-0DIK7_
M`-*I5I5LAI]>E_;<&_/5RLI*?__3]43IDZ2D#K[P7;<=SH^C#FB=?Y3E#<\U
MN/V0RV"UDLDDG:[\[;]%0)RO4>1ZVV3&E<1/YOY_^>F+LQU)`-K'UQ[PVO<^
M=(V..SV_V$E)*W6.<&NQ-C29+B60#^][2FW6.)+L/SDEFOXJ%@S)@.N'M&K1
M40#`W?2^F[_H)F/S6O#W"]S3^813`T_DOW?224E)>P->W$EQF0TL!$:<N+?I
MI&1`&).@=IL@&?H_UU$.R]I!%LMK?[@VO5Q(V;=?YQG^#_P7^F29;E-:2]MC
M@Z0`6LW"/S_8_:DI</>&DC"(DF6S7KY_24W3[_U;=LVAGT?<)_-_=V*NY^:P
MN8#=9+8#PRJ`3[@[Z3-SF?02%N;L+=M^[4[]E7?RW?FI*3!Y`K<,0@^[]SV:
MGS_/_D),<"7`XA8#J3#-=NK?HN_S$&QV<V&AUSC'TFUU<F#KN<IFS*<38/5:
MQL.]+8R2#'L;[DE)):&M/V4^^0X0V0)_/U_/1ZS-;?;LT'L,:?R?:A>GDN8X
M^L6.<=S06M.T1_-_ROZVY%8'-8T/=O<!#G1$GQVI*9))))*?_]3U5))))2DD
M$UY/N_3`2Z6PSANOM^DF%>5#YN!)C9[(CQ_.]R2DZA8XMK<6@DQI`DS\$)U6
M7^;>![8U8#[H^G]+_HIW5Y1>7-N#6GZ+=@T^+MR2FN7YK8,VNC0@5LUTY^FI
M%^4*29L+Y=!%;9B/;[=VU%=5F%K0V]H<)W.-<S)]D>\;=C4GUYAL);<UK)T;
MLDQ'[V[_`+ZDI`+,S<!-L'G]&S\N_P!J-CON-KFV;R(!!<P-`\?<"G;5EC=-
MX((AGL$@_O<^Y(UYDMBYH`:`X;.7?O?2_P"BDIL)(5#<AL^O8VR>"UNV/^D]
M%24I))))2DDDDE/_U?54DDDE-2R[(+BVLN:07`N-1<#K[(][/_,U%EV5ZA!<
MYS9@#T'#G1OO]3;[9W.1G86*YVYU8))))D\D[O%+['C0X;-'P7:G4M.YO_22
M4@%V5N<PN=,D"*3&GYV[?[DSLG*):&[QI[MU!()GD18W:K/V/&AS=@AQ!<->
M0D</&+=I9+9W1)YB/^^I*0^IENVAKB-XVC=49#F_2?8=^QK70EZN2ZPP7-;)
MAIJ.@`[NW>Y'9C4L>'L;M<`1()X/^Y%24TC=D[06DB)W%U+I/[NUH?[=JE9;
MDBT-8\`.@M_1.<(/T9L#FM;_`"U;224U3=D#U"2(&C0*W'7Y._2-_J)C=>US
MF[@72`W]$^`=-TO!]S5;224Q9OVCU(W:SMXYT4DDDE*22224_P#_UO4+KA2&
MN(EI)W'P`:^S_OB*JN?_`#3?[?\`Y[M5I)2`X=#MQ(=[B20'O'/TN').Q*7/
M:\[I:T,$/<!`U$@.]R.DDI&**FN8X`@LW!ID\..Y_?W>YJC7B8];@YC2"W4$
MDG6-OYQ_E(R22E))))*4DDDDI22222E))))*167!CV,`ESB/NG;**JN1_2JO
MA_WYBM)*?__7]&ZKD5TLH:^9OM--<"?>ZN[;N_=;[5?6/]8N>F?^'F?^>LA;
M"2E))))*4DH66"MLQ))AK1W)53)R6,:[?876;7/#*S#6AOTGN?+7;:_SW;O^
MMIT8&2V4Q'=O)(#;W"HV6-=L`:&$Z/>3[=:_;Z>]W[__`%STD%V>6/+'!A=`
M]C7$EI>=M7J$-_.][W^W]&RI]B0A([!1G$;ENI*E7U*HEX+VV[7;=U?$P"?I
M';[7.95ZF_\`G?8FQ.J4WASGOK8P&&.]0>[Z7YKMOYK=Z/M3HFMOVH&6%@6-
M?V-Y),'-=,$&-#"=,7J22224TLNZNO-Q:WF'7DUU""9<T?:'#3Z/Z&FQWN5U
M975?^5>C_P#ABS_VVREJI*?_T.]^L7/3/_#S/_/60MA4>K8-N971Z.T6X]OK
M5EQ(`<&6,9(#;-_NL]S%7_[*?W<+_/M_](I*=90LK<^-MCJXYV[=?^W&O69_
MV4^&%_GV?^D47&'7B\_:_L[61[?1>[=,_G>K1MV[4E-IV,]PVNOL(/((K(_\
M](3NGMA[@][G.AQ'L!<6C]'[A7^9_@_]']-3V9O[P_SA_P"\Z=HS&F2&O\B^
M/^IH"()&Q00#N`YHZ5Z.Z,;U'6-W/-?HL;,$>BW]&QW_`)VC5XU[+G/;18UU
M@][PZGL-&QL_.5[=E?Z.O_MP_P#I)/NRO]&S_//_`*21,Y&[D=?%$<<!51&G
M@Y[L:Z/Z,YQ(!C]7Y`'M_F_S6UL:K+NFT/<'OU>!`)942`8$3Z/\E'W9/^C9
M_GG_`-))G'*((#&M)_.#S(_SJD.*7<_:GACV'V(Z<"NB10XU!VK@QE39^.VI
M%%5@()N>0.Q#(/W5H>S,_?\`^DW_`-(IG,SMIV.E\':'.:!,>W=%'T=R!).I
MU4`!H!3:260'?6F-:<.?^/L_]XD^[ZT?Z##_`/8BS_WA22KJO_*W1O\`PS9_
M[;9:UED,Q.KY.;BY'4&4,;B6%]8IN<\DNKNH<Y_J8M7T?5;^CW_\)ZGZ+TKM
M=)3_`/_9_^T9LE!H;W1O<VAO<"`S+C``.$))300$```````/'`%:``,;)4<<
M`@```H;$`#A"24T$)0``````$!;_&D7,*98,2(?/&O;;UE`X0DE-!#H`````
M`.4````0`````0``````"W!R:6YT3W5T<'5T````!0````!0<W138F]O;`$`
M````26YT965N=6T`````26YT90````!#;')M````#W!R:6YT4VEX=&5E;D)I
M=&)O;VP`````"W!R:6YT97).86UE5$585`````$```````]P<FEN=%!R;V]F
M4V5T=7!/8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O
M9E-E='5P`````0````!";'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O
M;V9#35E+`#A"24T$.P`````"+0```!`````!```````2<')I;G1/=71P=71/
M<'1I;VYS````%P````!#<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB
M;V]L``````!#<FY#8F]O;```````0VYT0V)O;VP``````$QB;'-B;V]L````
M``!.9W1V8F]O;```````16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG
M3V)J8P````$```````!21T)#`````P````!29"`@9&]U8D!OX```````````
M`$=R;B!D;W5B0&_@````````````0FP@(&1O=6)`;^````````````!"<F14
M56YT1B-2;'0```````````````!";&0@56YT1B-2;'0```````````````!2
M<VQT56YT1B-0>&Q`<L````````````IV96-T;W)$871A8F]O;`$`````4&=0
M<V5N=6T`````4&=0<P````!09U!#`````$QE9G15;G1&(U)L=```````````
M`````%1O<"!5;G1&(U)L=````````````````%-C;"!5;G1&(U!R8T!9````
M````````$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O
M;6QO;F<`````````#&-R;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T
M4FEG:'1L;VYG``````````MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``
M````$`$L`````0`"`2P````!``(X0DE-!"8```````X`````````````/X``
M`#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)
M```````````!`#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`
M+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@``
M``8```````$`-0````$`+0````8```````$X0DE-`_@``````'```/______
M______________________\#Z`````#_____________________________
M`^@`````_____________________________P/H`````/______________
M______________\#Z```.$))300````````"```X0DE-!`(```````(``#A"
M24T$,````````0$`.$))300M```````&``$````".$))300(```````0````
M`0```D````)``````#A"24T$'@``````!``````X0DE-!!H``````\D````&
M``````````````-(```"B0```$H`4@!/`%,`10!7`$D`3@!$`"``0P!/`%(`
M4`!/`%(`00!4`$D`3P!.`"``+0`@`$,`3P`@`"T`(`!#`&4`<@!T`&D`9@!I
M`&4`9``@`&\`<@`@`%``;`!A`&D`;@`@`$,`;P!P`&D`90!S`"``+0`@`$0`
M;P!C`'4`;0!E`&X`=``@`%(`90!T`'(`:0!E`'8`+0`Q`````0``````````
M```````````````!``````````````*)```#2``````````````````````!
M`````````````````````````!`````!````````;G5L;`````(````&8F]U
M;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````
M3&5F=&QO;F<``````````$)T;VUL;VYG```#2`````!29VAT;&]N9P```HD`
M```&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S
M;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N
M=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N
M=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```T@`````4F=H=&QO;F<```*)`````W5R;%1%6%0````!
M````````;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT
M5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q4
M97AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!
M;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R
M=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC
M94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*
M;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````
M"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````C_P````````
M.$))3001```````!`0`X0DE-!!0```````0````".$))300,``````_U````
M`0```'P```"@```!=```Z(````_9`!@``?_8_^T`#$%D;V)E7T--``'_[@`.
M061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8
M$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.
M#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`S_P``1"`"@`'P#`2(``A$!`Q$!_]T`!``(_\0!/P```04!
M`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#
M!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84
MD:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E
M\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>W
MQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(C
MP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#
MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`
M#`,!``(1`Q$`/P#U1.DDDI29.DDI222K9626$55SZCNX@D`SMV-/M]1^UVS?
M^C9^DNM_1U)*2V755D-<?<=0T`N='CL;N<@G/J!(VG3^56/RV*NVGV%SH<'&
M3/N$Z>[W!V_;[/UB]EG_``==-**USS6TF6O<Z(W.T&L0UI;7N0M-)FY=!$D[
M`?SC]'_MUNZK_IHRSR9<2\;'@"'29XWN:VUH]3V;??O]G_!?I$JKG8KMKOYD
M:$'2(]TM;]%KV,]UE3/T5M7Z?&V?I*4@;40Z*222*%))))*4F3IDE/\`_]#U
M&V^FEH==8VMIT!>0T$@%_P"=_(:YRK?MOHW_`'/QO^WJ_P#R:J_6)S@S`K!(
M9=EMKL:#&YAKO+F._DNVJ[^S<#_0,^Y)3#]M]&_[GXW_`&\S_P`DIU=4Z9<2
M*<NBPMU<&6,=`\]KDOV9T_\`[CL^Y29@8E<FJOTR>362PGX["U)3+[7B_P"F
MK_SA_>J3+&6AV02'-?)&H`,AOMW$[/<W[-C_`-BU7?LU?C9_VX__`,FA9)IJ
M]UC_`$*6,^F($`%HC4']Y`[)&[&EFUN^"2^-#I)'YSV#V>HA6"UY!<'#L($Z
M_-66O#"UL"9VR1S[BW2/:U!V-U`:"#)!W08GV_F.]R'12FE]D5VL(![D::?Z
M_F_0_P",4&M(_0#V[8:TQJ((+'OEWO<R][7?Z/Z?_%H[7-K86D`$N,B=!H-N
MW^SM4+#2;70\"XM)%?YVW=Z<_O;/4_-_TB7BEEAY5`J-;GM9Z9@-<X`M!`>U
MG_6MWH_];1G9F(UI<Z^MK1J27M`'XJ3Z*WO+SN#B`"6N<V8_J.:H/Q*'L++`
MZQCA#F/>YS2#V<U[BUR<M8?M3IO_`'+H_P"W&?\`DD_[2Z=_W*I_[<;_`.20
M_P!C=)_[AT_YC?[DOV-TG_N'3_F-_N24GKR\6TQ5=789B&N!U@NCVG]UCD58
MN5BXV%U?I8Q*F4"ZZQMHK:!N#<?*L;NT_->MI)3_`/_1[WZQ<],_\/,_\]9"
MV%E]<Q[+AA.9$8^2+K),>UM5^[;^\[W+424I))))3DT?6&BW)^S&BQEOKG'V
M':'-(;;<++&6.K_0V48UMU-]7K475_S5OJ?HT*[ZR].V,O8VUU88;=X:(VBP
M8=S',>]EF^N]^Q[-BT_L&#`;]GK@&0-@@$AS/;I[?9;:W_KMG^D2/3\$DDXU
M1+B2X[&R27"YQ.G^E8RW_C/>DIR\OKE.-O\`M&^NQNRQXK`,"SU;,:OWN&^Y
M]>*YMK&>QC_^#2/5V/L<VJIQ;52,VP[F@-J>]];+&2'_`*5WH7V[?S*_^$N]
M-&RW]"9D&BWT6WL9M-;Z]P+'`MV;=ON]M[V^S_3_`/"H-F3T=UGK67T.-(V;
MRX.`DMO/Z3T_;ZFZOV[O]'_P::EC7]8,$N?O<ZIE=#\E^YLQ6&U9/J%WN=99
M93>U_HUM_,L_T?Z4E?7,8YM?3[6/9D"S9Z0$D&&6TL=[O>YN/=5DW^EZGI?]
M;L35GH3&;G'';722_<6@EN[8[^=>QNQNVJK_`*U77_@U?KZ?TNREA9C4NJ<T
M%GL$02VQO(_>:QZ("FE9]:^DUT_:7&S[.&ASKMNC2Y]V.VMS9]7U/7Q;*OYO
MZ:T<3-IRQ:*P6OQ[#3<QPU:\!MFT[=S'?H[*W^QWYZ;]G=/WNL^S5;W[M[MC
M9.[<'[M/=OWOW?UWHU5-5+-E3`QLDPT1J=7._K.10S22224Y/5/^5^C?^&+?
M_;;+6JL_/H?;U+IMK2`W&M?98#,D.IOQV[-/W[FK124__]+TOJ'\R/[?_GNU
M6E6S&.L8QC?I.+@/#6NWE64E*220W7TM#2ZQK0_1LD"?ZJ2DB2$W)QW1MM89
M(:(</I'AO]92]:DN+0]NX&")$@^"2FG9U;IM;W^J_;Z;GL<\M)&^IGK7-EH/
M\S5[E2=F]++W/;GWL%Q+@QH=MCTVWN;5-/T?1>V_V_OK4`P+K'`"JRSEWT7.
MT]LN_._DJ,]-TUH[@?0[C:\?YB2D%'4.FUX]+/7-^]K36]S2Y[VES65V^QGN
M8ZRRMOJ[-BNX]]6117D4NW56M#ZW01+7#<UWN0FCI[C[122V7&-NFON=_G*;
M+<6MC6L?6QD`L:"`(/&U)29)0%U)VD6-(>8;J-3_`"4POH()%C"&\D.&DI*2
M)*`NI,Q8TP),$<>*DUS7`.:0YIX(U"2FM?\`TJE6E6R&GUZ7]MP;\]7*RDI_
M_]/U1.F3I*0.OO!=MQW.CZ,.:)U_E.4-SS6X_9#+8+62R22=KOSMOT5`G*]1
MY'K;9,:5Q$_F_G_YZ8NS'4D`VL?7'O#:]SYTC8X[/;_824DK=8YP:[$V-)DN
M)9`/[WM*;=8XDNP_.26:_BH6#,F`ZX>T:M%1`,#=]+Z;O^@F8_-:\/<+W-/Y
MA%,#3^2_=]))24E[`U[<27&9#2P$1IRXM^FD9$`8DZ!VFR`9^C_740[+VD$6
MRVM_N#:]7$C9MU_G&?X/_!?Z9)EN4UI+VV.#I`!:S<(_/]C]J2EP]X:2,(B2
M9;->OG])3=/O_5MVS:&?1]PG\W]W8J[GYK"Y@-UDM@/#*H!/N#OI,W.9]!(6
MYNPMVW[M3OV5=_+=^:DI,'D"MPQ"#[OW/9J?/\_^0DQP)<#B%@.I,,UVZM^B
M[_,0;'9S8:'7.,?2;75R8.NYRF;,IQ-@]5K&P[TMC)(,>QON24DEH:T_93[Y
M#A#9`G\_7\]'K,UM]NS0>PQI_)]J%Z>2YCCZQ8YQW-!:T[1'\W_*_K;D5@<U
MC0]V]P$.=$2?':DIDDDDDI__U/54DDDE*2037D^[],!+I;#.&Z^WZ285Y4/F
MX$F-GLB/'\[W)*3J%CBVMQ:"3&D"3/P0G59?YMX'MC5@/NCZ?TO^BG=7E%Y<
MVX-:?HMV#3XNW)*:Y?FM@S:Z-"!6S73GZ:D7Y0I)FPOET$5MF(]OMW;45U68
M6M#;VAPG<XUS,GV1[QMV-2?7F&PEMS6LG1NR3$?O;O\`OJ2D`LS-P$VP>?T;
M/R[_`&HV.^XVN;9O(@$%S`T#Q]P*=M66-TW@@B&>P2#^]S[DC7F2V+F@!H#A
MLY=^]]+_`**2FPDA4-R&SZ]C;)X+6[8_Z3T5)2DDDDE*22224__5]522224U
M++L@N+:RYI!<"XU%P.OLCWL_\S46797J$%SG-F`/0<.=&^_U-OMG<Y&=A8KG
M;G5@DDDF3R3N\4OL>-#ALT?!=J=2T[F_]))2`796YS"YTR0(I,:?G;M_N3.R
M<HEH;O&GNW4$@F>1%C=JL_8\:'-V"'$%PUY"1P\8MVEDMG=$GF(_[ZDI#ZF6
M[:&N(WC:-U1D.;])]AW[&M="7JY+K#!<ULF&FHZ`#N[=[D=F-2QX>QNUP!$@
MG@_[D5)32-V3M!:2(G<74ND_N[6A_MVJ5EN2+0UCP`Z"W]$YP@_1FP.:UO\`
M+5M))35-V0/4)(@:-`K<=?D[](W^HF-U[7.;N!=(#?T3X!TW2\'W-5M))3%F
M_:/4C=K.WCG122224I))))3_`/_6]0NN%(:XB6DG<?`!K[/^^(JJY_\`--_M
M_P#GNU6DE(#AT.W$AWN))`>\<_2X<D[$I<]KSNEK0P0]P$#42`[W(Z22D8HJ
M:YC@""S<&F3PX[G]_=[FJ->)CUN#F-(+=022=8V_G'^4C))*4DDDDI22222E
M))))*4DDDDI%9<&/8P"7.(^Z=LHJJY']*J^'_?F*TDI__]?T;JN172RAKYF^
MTTUP)][J[MN[]UOM5]8_UBYZ9_X>9_YZR%L)*4DDDDI22A98*VS$DF&M'<E5
M,G)8QKM]A=9M<\,K,-:&_2>Y\M=MK_/=N_ZVG1@9+93$=V\D@-O<*C98UVP!
MH83H]Y/MUK]OI[W?O_\`7/2079Y8\L<&%T#V-<26EYVU>H0W\[WO?[?T;*GV
M)"$CL%&<1N6ZDJ5?4JB7@O;;M=MW5\3`)^D=OM<YE7J;_P"=]B;$ZI3>'.>^
MMC`88[U![OI?FNV_FMWH^U.B:V_:@986!8U_8WDDP<UTP08T,)TQ>I))))32
MR[JZ\W%K>8=>374()ES1]H<-/H_H:;'>Y75E=5_Y5Z/_`.&+/_;;*6JDI__0
M[WZQ<],_\/,_\]9"V%1ZM@VYE='H[1;CV^M67$@!P98QD@-LW^ZSW,5?_LI_
M=PO\^W_TBDIUE"RMSXVV.KCG;MU_[<:]9G_93X87^?9_Z11<8=>+S]K^SM9'
MM]%[MTS^=ZM&W;M24VG8SW#:Z^P@\@BLC_STA.Z>V'N#WN<Z'$>P%Q:/T?N%
M?YG^#_T?TU/9F_O#_.'_`+SIVC,:9(:_R+X_ZF@(@D;%!`.X#FCI7H[HQO4=
M8W<\U^BQLP1Z+?T;'?\`G:-7C7LN<]M%C76#WO#J>PT;&S\Y7MV5_HZ_^W#_
M`.DD^[*_T;/\\_\`I)$SD;N1U\41QP%5$:>#GNQKH_HSG$@&/U?D`>W^;_-;
M6QJLNZ;0]P>_5X$`EE1(!@1/H_R4?=D_Z-G^>?\`TDF<<H@@,:TG\X/,C_.J
M0XI=S]J>&/8?8CIP*Z)%#C4':N#&5-GX[:D456`@FYY`[$,@_=6A[,S]_P#Z
M3?\`TBF<S.VG8Z7P=H<YH$Q[=T4?1W($DZG50`&@%-I)9`=]:8UIPY_X^S_W
MB3[OK1_H,/\`]B+/_>%)*NJ_\K=&_P##-G_MMEK660S$ZODYN+D=090QN)87
MUBFYSR2ZNZASG^IBU?1]5OZ/?_PGJ?HO2NUTE/\`_]D`.$))300A``````!5
M`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X0DE-
M!`8```````<`"`````$!`/_A#W9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT
M87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP9&8]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N
M<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&5$871E/2(R
M,#$U+3`T+3(Q5#$P.C0R.C,V(B!X;7`Z0W)E871O<E1O;VP](D%S<&]S92!,
M=&0N(B!X;7`Z36]D:69Y1&%T93TB,C`Q-2TP-"TR,E0P,#HQ,SHR-RLP-3HS
M,"(@>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP-"TR,E0P,#HQ,SHR-RLP-3HS
M,"(@<&1F.E!R;V1U8V5R/2)!<W!O<V4N4&1F(&9O<B`N3D54(#DN-RXP(B!X
M;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C$S1D4X-31#-39%.$4T,3%!.45"
M0D)$0D$P144Y,S0T(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C(V,D4R
M,$8V,#9%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240](GAM<"YD:60Z,C8R13(P1C8P-D4X130Q,4$Y14)"0D1"03!%
M13DS-#0B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R
M36]D93TB,R(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F.E-E<3X@/')D9CIL:2!S
M=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED
M.C(V,D4R,$8V,#9%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=$5V=#IW:&5N
M/2(R,#$U+3`T+3(R5#`P.C$S.C(W*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G
M96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA
M;F=E9#TB+R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%
M=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%
M=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HQ
M,T9%.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T-"(@<W1%=G0Z=VAE;CTB
M,C`Q-2TP-"TR,E0P,#HQ,SHR-RLP-3HS,"(@<W1%=G0Z<V]F='=A<F5!9V5N
M=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB('-T179T.F-H86YG
M960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$
M97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C(V,D4R,$8V
M,#9%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=%)E9CID;V-U;65N=$E$/2)X
M;7`N9&ED.C(V,D4R,$8V,#9%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,C8R13(P1C8P-D4X130Q
M,4$Y14)"0D1"03!%13DS-#0B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F
M.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X
M<&%C:V5T(&5N9#TB=R(_/O_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("
M`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`T@"B0,!$0`"
M$0$#$0'_W0`$`%+_Q`&B````!@(#`0`````````````'"`8%!`D#"@(!``L!
M```&`P$!`0````````````8%!`,'`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU
M`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!
MT34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J
M.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$
MQ<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!
M`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3
M&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D
M])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y
M25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`-^R")9(
MHY'5=3)R`D9`!.K2"4+%0XU<G]7)]ZH*::#3U[K-X(^.`2-7)2/Z.077]'`=
MA<VM<^_:5%*`8Z]UQ-/&2^H`ZSR-$?T/ZE/H]0D_M7O<#WX@'B`>O==F!3]3
MP;:@4C(/ITM<%#_G%X/^`M[KH!:IR/3RZ]UAEH8IHO%)I9;HW,,!YC8-&P#1
ME5:,`!2!=;7%C[M0&E1CKU2.'4G0WYD8CZ@:4X_UO3[WU[K']NHEDF#/KD2-
M3^DJ#%KT.JE;!AK/^'NNGNU5/#AY=>Z]]OR2)&4$GTB."P!4#1<Q7TZAJ_U_
M\/>V%:9(SU[KM8```S:SQ=F2/4WI"OJ*H/\`.V]7]?I]/>^O=<O#%_QS2_)O
MI6]RNAC]+79>#_4<?3W[KW70@B``T*;6L2JW%KZ+64`>,&R_ZD?3WJ@H!3'7
MNNOMX@`-*@@KR$0<(;JMM-@J_@#Z'D<^_$`\0#U[KWVZ"^FR$WY"1_4MJ!%T
M_LM<C\:C<W/O6@$EFR2?/R^SKW6/[0`L5DTZB]QXH"+-R%YC)LLGJ_Q;ZW][
M`HS-4FO^K'7NN0I_U7DU%B;GQQ`D$#4.$'ZV%V_K_K>]]>Z[$']9";D%O1$"
MQ_M7(3^WQ?\`UO?NO=="G8?\I$O)!/IA&KF[7TQ#EQ8$_4`<6]MF,E0/$;CU
M[KS4VM65II&#JRFXC)LX*L!Z/RO'O>CL*:CGS\^O=<UB**J(Y5$5410J655`
M50+K^`/=P*`#KW6)Z0-/]P)I5D\2PFWC*F-9&DMI9"`3J()'X]UIW:JGAP\N
MO=<C`]K"=QQ:^B&X.JX8?M@`JO`'TM_CS[\HI7).>O=<O`IOR+'7QXX[:7L=
M!]/*AA?_`!/)]VH!P'7NN0A`N+WN;GTH"219B2%%RY%S?Z^]4&13!Z]UV(D^
MI1"UPQ8HMRZBP<V`]0'T/X]^H*`4P.O=>\4=N$5?Z$*O%CJ'%K&S&_\`K^]]
M>ZX&&[$ZR+ZM("1634!:WHN=+W;DFY//X]^Z]UR6*Q<EM1;Z71!IN!JMI47U
M,+F_Y]^Z]UT(W`6\I:VG5=(QK(!#D@+P9`>;?2W'OW7NO&(E2%<HQ*W8)$2=
M-P;@H0=2>G_`?3W[KW7A"00=?T73_FXQR&NK<+]57@#Z>_=>ZX&!C<>9@#Y!
M81Q?1QZ!<H2?&W(_J?K?W5EU4[B/LZ]URBA:.*.,3.WC14U,L>IM(L&:R`7(
M'X]VZ]UAFHA/)'(\TA\:2QF,K"T4@DTD%T:-O4C("+$`_0W]T=!(%!/`]>ZY
M"E47!8,";D-##SJ73*6]'J,MO43_`*WT]^6-54*14?/KW7`T2$6+*3^USX(`
M1XKA2+1\$*;*?[(^EO=?!7N^8^6*_EU[KWV*`JR%$9+!66GI[JBR>0(I\=U4
M'D`?GGZ^]>`N*,:_E_F_U<>/7NLOV_I*ZEYN!^S%8#5K"VTV(#?[<\^W0JC@
M,^OGU[KBU*&#`LI+`@$PQ-96MJ4@KZ@Y'-_K^??J`5H./7NNS2KQIT+8D_YF
M(_5-!Y*\7''^MQ]/=2BE=-*"M<=>ZX?:&ZV>,!?%8?;0\>($+I-AITJ;+_J1
M]/>C'Z.0OIC_`#=>Z[^TL+!T'`'%/`.%?4HMH^B_@?@\_7WHQ`^>/3&/Y=>Z
M]]IQS(I)#@DT\'(=@P!&@<*PO_B>3[V(Q6K,3]O7NN+499BQD3D."#30,#KM
MJ+76Y+6Y_K^?>R@+:CGY>77NN9I`?JRGZFS00D79-#']/U9>#_AQ]/>FC#-4
ML?Y=>ZXTU(U+30TR5#LL*!%8QQ`E020-*(J*`IL````/?O#HJJ'(`Z]UZ:C\
M\E-*\\EZ9I2%58PLGE305D!1C91_2QY][>,/IJ34=>ZY"EMIO("5$0'[,0MX
MR2+`*+6!L/\`4_4>_!#1AK.?Y?9U[KG]N+\E2+6(\4?^K+@WT_AC?_7Y^ONQ
M%5TU/#CY]>ZZ^W^OJ'(8<QQGDMJ!Y7D@_7^I^OO2KI%-1/V]>Z[\'ZKN#J)-
MO''87'J^@Y+'ZD_7Z>[=>ZZ-/Z@0RJ!:X$4?-ETWU6N#:]OZ`V%O?NO==?;$
M&X=+`1Z5,$9TF-B5(/'Z03I'&F_'OW7NN2TZ`\K$>;\1*M@"6`%C^&-_]?GZ
M^]%5-"0*]>ZXFG8V_<7Z6.J%&N+WT\GZ7_WGGZ^]D`X(J.O=<VA+?VE_/UB0
M_4AC?CFY%_\`7Y]Z(R#7AU[KH06O8H+@C_-+]6(9VX(N787/]?S[WU[KW@-R
M=4?J9F/[*<EQ9K_UU`6)^I'OW7NNH*?[>*.&-E$<:LH58D1;%BUE1+(BJ#8`
M"WNJ*$4*#@=;))-2<]>E@,CHXDTE$=+%`R,'T'U+<7L4^GNW6NO&!B2VM+W.
MD^(74$6/.JY+?D_D<>_=>Z\8#86,0(T6)@4VT`A0!J%@M^/Z>_=>Z\*>UO\`
M-<*`+0``%264BS<!6-P/P>??NO=>^V7Z:8;68$>!;>KDBVJVDOZB/R?\?>J#
M../7NN_MU-KB,C_&,$E2/6I.KGR'ZG\VL;^]:5I32*=>ZX?:@6($`8%26^W%
MS8%3_NS@^/TC_4CCZ<>]E5(H5%.O=>%,18WAN/R(`/H2!;]SC3&=(_H/I8<>
M_:5QVCKW7+[<Z@UXN"EAX?IH;BQ$@L57A?\`4GGWOKW78A>_J="HY"B*WJU$
MJ?UD:47Z#_5<^_=>ZY&%2I`L#:R\7`L;K<?4@-S]>3[]U[KD4)%BUQ8@@WL0
M1S^;@EN??NO=8XH/")0A4>2628G1SKD:Y+>JS6%A^/=572`*]>ZX5%,\_@O*
MH\,ZSD>.XDTI(H1AY!87<'_8>[=>ZY^%@39TL68_YHWTLEB&/D]3&07)_(XX
M^OO5!4&F1U[K@('XOX/]UAM,+*2%Y8K:4Z64_H/.@>]T%2:9Z]UV(9`3_P`!
MP/VQZ(F4\$M)SY/KJ-U_H;DW/O05020`#U[KQ@8WNM-8J`?VV]5W8RA_7ZT9
M3]#_`&N3[]04I3'7NN1B?G2(?5K)NC7)L%BO9O4-(LWY(X][Z]UR",/KX_U*
M;A2.%6P/U_4..?Z>_=>ZY:6`X$=R$N=%@2#S<`_0#Z?T/OW7NN*K+8:O"3I`
M-D:UPW%KL;*$_']??NO=<$?]]X&1>(EE5Q_J'=U$9!N;@I?CC_#W[KW4GW[K
MW7__T-^^C.JE@)^IC4_0C_>#R/?NO=2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=10
M/\M<V_Y18A>W_-V8VO\`7\_3W[KW4KW[KW7_T=_&E_X#P\W_`&U/^W%_SS[]
MU[K/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
MXZ1J+\ZBH7ZFU@21Q>U[M]?K[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC`C[QU
MMS]M&;_X>646]^Z]U)]^Z]U__]+?QI;_`&T%R"?&G(Y!X_'OW7NL_OW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z9MP;CV]M+$5NX-U9[#;9P.-B,^1S>X,I0X;$4$(^LU;DLC/345
M+$/]4[J/?NO=$[R/\QCX>19FHVUM/MO_`$P;DIT8_P`#Z`V3V#W_`%4LHL!3
M+5].[5WIB(:AF(73-4Q`-PQ'OW5&D5,&M?L)ZATOS)[`W4)XNMO@O\PMQ3H1
M]O5[YVWU;TAAJA""?(TW;/:>VMPP*/\`4MBS)_M-^/?NO*^H,0I%/7%>HT7?
M/SKK92*3X!8'&T^HZ7W5\O>OJ"?1JL#)!M;K_>L2R:>2%E8#_5'W[JNJ7_?0
M_;_L=.[]O_.I(Y''PMZHE,:ZO!%\QH_/(;7TQ^7X\Q4]S^-<B#_'W[KVJ7_?
M8_;_`+'3?3?(3YF4E3IW#_+ZS<]$I/DJMA?)SI#<L^@"Y>&BW?/UHTQM]%UJ
MQ_I[]U93(3W(`/MK_DZS'YTX/`U-1#VE\:OF+U)1T,)FR6X<YT#F^PMJ4*QV
M65Y=P]#9'MVC%.C'B0Z5(YX_'NMLX6E0?V="%UG\VOB5V_708?8'R#ZORNXZ
MF<4T.S\GN:DVIOIZAOI#_<3=QP6\$E_&EJ$$'CZ^_=;#`C4.'1H_?NM]>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW4<#_*V/Y^W0?\`623_`'KW[KW4CW[KW7__T]_"D8-2P,I)
M!B2Q-KVM^;`"_OW7NI'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
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M-'3^#^_/R@WEN?Y`9R0@$+-38[LG)YS:&!DB4@1C%8N@CB`&A%M[]U[0I()%
M6'F>C:5==L7K+;$<M?6;3Z]V9@X8Z:*2KJ,/M/;&(I[GQ01O,]!BL?#J)TJ-
M"W^@]^ZOT6#=W\PWX2;+JEH,E\E^K<SDV++_``?8&<;M/-JZL%,<F%ZSI]VY
M6*4,0-+0AO\`#W[JK.JTU'IO@^=O3^?+56R>O/E+V%%0>5C5;5^)WR&BHOW*
M>*1/%6;FZ^VW1U0J89QXRCNK6-K:3;W55D5FT@'[:&G3'A/F;5Y:NR.0HOA9
M\[HT)#M5YOJ#:^#@=UITI:>+'XS.=G8_+?Y:8D!/VHCB8ZYFB74P]U9FT+JH
M3]F3UF3^8M\><12SOV-A?D/TY6450]+D,=VE\6OD'@_L)ET,?+G<7UUG=H55
M+ID!2JILE/22IZDE9>??NFQ.AXA@?F#T*_7GS1^)/:TU'1[`^2'3.X<OD)/%
M2[<3L#;F.W:\U@?"^T,O7T&Z()N?T24BM?\`'OW3H8,`P..A.[*Z7Z?[EQJX
M?MSJSKSL[&1HZ0T6_MF[>W;!2B0,&:C7.X^N^SE&LE7BT.K&X(//OW7B`P((
MJ.BHM\`MI[$1:CXN]V=^?%>KI(ZR3'[=V/O^K[!Z>;(51O\`<9+I3NF/L/8L
M=,JV0Q8B+#/H4!)$(#>_=>()!`-#U%E[.^=/0WD;MOIK:/RRZ]HO)Y.Q/BVS
M[&[DHL=14@_W(;B^.?96X:K"[EKJZ<AG7;&\*BHN'\.+/H3W[K?1@NC_`)3=
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M7[]U[K__U-_&E`6F@4"P$2`"Y-AI'%SR??NO=9_?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UXFP)YXYXY/\`
ML!^3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBQ]]_*WKCH?)
M8#8TE%N7M#O/?-))5];?'KJO'0;E[9WQ2Q57V51G%Q<U908?9NP\74!_XAN?
M<-;B=O4`B=9:P3>.%_=:+`$`\3T!,7QU^0WR?B_B7S-WW#L#K+)1B6'X@?'C
M=.>Q6`EH:B.H*XSOGOZA_N[OWM>L^UKS3Y#$8"/;>U9)(`LD>4BM,_NO$`@@
M\#T;JDH^D/C+U=X*2'K#H3IG8=#K:W]U^M.N=I4$LZJT]1,YPVW</#45DXUR
M2,GEFDNQ+M<^ZV/(#HJ,7S9W?W+(E'\+_COO?O+$51C2#O?L>HJN@_C5'#4?
M<4YRN%WCNW!U_8O:%%CJR&TC;5VOE**<*P2M7AO?NJZJTTBHK3TZDQ_'OYC=
MJ1^7OKYC3=<XJNI`E;UQ\.-@8KKBEI)P39#W+VBW9W9F1NEM<^.AVV[M<K'&
M+`>Z\5)(.H@>G2FP'\O;XIX'(U&YJ[K9>R]_U-#)1S]A=][CW3\@]U5#S"/[
MBJ>J[ES6]*2DFJS%^X*2&F32S!%0&WOW7BBE@Q4$CHT.V-N;;Z]V[2T.,P6S
M-GT<,-*M?2;6Q..VIMR*=4"32TM)!'%'%"G/C5R6"@"_U/O1(458@#JX!)H!
M4]=5/9775%J^ZWYL^$A@I1MRX@R!R0H41"L:2]R.`/;)N;<:B9TH./</\_3@
M@F-/TF_8>L"]I=;2RK"N_=I)*2Q"2Y[&0E]!LX4SU,:G2?K;GCW1+ZSD-$N4
M)^T=>\"8?Z$W[.GFEWIL^N=(J+=>VJN20:HXZ;.XNH=UY&I$AJW9A<?4>W$N
M(),).A^Q@?\``>J^')348V"_9T''8'1/6W;E?)_I1Z]ZR[&P7@HS14F]M@;2
MW=-&RM4BL@\FX<+DO%2U5-)$`\3I*IB%B!];T;5J\3L],?X>FV4,"K#'0`1_
MR^NG]HN:GH+>W>GQ?JON9JXT?27;6Y*38\];)=HY:WJ3?K[\ZCGBA<\(F#B]
M)*W`/N_7@`H"J*#J!4XO^8GT^OW6$W1T9\RMLTB5E558'>.'J_C/W55`DK28
M_#[PVJ-[].YVKB4*P^[P.W(96+*T\0TL/=:4,*ZGK^72DV)\[NG\SNW&]7]O
MXK>_Q9[DRM4^/Q'6WR+PM+L@;OKH9H*22/K#LBCR.9ZB[7CGKIC'3I@,]75L
MJKJ:FC!M[]U;H4.\_BOTA\B/X/D.Q]G@;WVI>38?;.T,IE-B=Q]<UH%2U/7;
M#[2VE5XC>FW#3U-4TQIHJLT%3(!]S!,ET/NO=%PJ-]_*;X?J1VU0;A^7WQNQ
MY`;NG8NW:8_)[JG!)4O%'5]N=1;6H*?&]ZX+%T<T)J\_LJDH\\D4$LTVW:K]
MRJ'NO='<ZU[-Z][CV1M_LKJO>>W>P-A;JHOO]O[KVKE*7+X;)TZR203K%5TD
MCK'5457#)!4T\FB>EJ(WAF1)4=![KW2Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U$'_`]O^H2/_K=)[]U[J7[]U[K_]7?RI_\
MQ#_RS7_>A[]U[K-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZKW[$^1O:O>._MT_'SX0M@6R&R\M/M/OGY;;EQB;DZCZ`SJ1K_%=@]?X4
M3P47>7R0P]/,KSX2.==O[3F>)MPU!GT8:L]U[HP'Q^^+W57QPQ^??9=+F]Q;
M[WS5TV5[1[F[$S$F\NY.V<[2P^"#+]@;[K88JW))1HS+0XVECH\)B(G:''45
M)3VB'NO=`%N/YE;G[<W%F>L?@?L?#][;EP>5JL!O3O\`W76Y/#?$;J?*T"/_
M`!;%Y#L'#13Y/NC?^&FD@27;&S5JO!+*8\GE,0RDGW6B2"M!45STH=E_!O:5
M?N7$]G_*3>>9^7O<6'JVR6#S?9^)QV/ZFZZKV6.(-TU\?L?+5]=[`:&&FA"Y
M*I3,[F=X@\V7F8D^_=>H*ZO.G1L]R[]VOM66*CR>0,V8JD+T&W<535.9W'D3
MHE:,4>#QL53D)$E:$J)618`W#.OM/-<PP4#M5SP4`EC]@&?\G3J1.X)4=H\S
M@?MZ"?>'<&;P%,F0R\>Q^I\'(U-+39;M?<M/_&\G221%ITQ>R-O59JILA"Y"
MB%\@DI/!CO<!!=;D;;NN#%;Q'X3(XJWF=*J:DCTJ?LZ40VC3,4C1Y&_H`D5^
M9\A_+H-(=\;@WK+')MRG^0?9J('J:*LP>`H>B>O:^+]+(N=W3_=S/Y"#6I"M
M%-5`CE+_`%*,W\\\8%K;W-R6R"%$*$?Z9]/'RXDCI5](D;:9IH(J<:GQ#7[$
M##_!GI\H.ONT,A,M5%U7TCM2":-O*-];DW;VYN".=](>1]6.Q&/Y5>0M:[,?
MJUN3LVVZ2F-TL+2,TI^HSRL/V!0?V\>M^+8)J5[F>2G#0%C'\RQ_EPZ5B=6]
MO(#)CNUMD;/=X[>':/2F%C6![#_-5&:W)DWD0$?1HQQ_K7]O"PW72NG<XHSY
MA(!2ORU.<?;4],FXL:$?22,2>+2?Y`H_S]2*KK/NNH$:O\@8:N(6\M-E>G]E
M5M+,0@7F."JH)44L-7#WN?K;VZ++<PS%MXU#R!B3'[*'J@N+/SL?V.W^STS5
M?57;$,:&',]#;KE2((4W1TM4XM9'NS,RS8;>55X-9:W^:<#ZV/T]LO8[HM-$
MMG(/1X2O\U<_X.G8[BPX/%<*/Z,@_P`J])5]H]C;;E,S]*XV>65I6J<WT;W!
MD]L54,;!7=X=I;LAVSB9F<@CQ&IF4?103[3B+<H2%;:4->+03:?^,N%^SB>G
MB;&6FC<''RECK_QI2Q_XR*==4W;]3MZ:.GR6^-R['DDF6AH<)\D-@R8*BJ9%
M<^1Z?LG;8H<!)KL?&\E35\<6/U]V&ZI!X8FN9(2QH!<1E03_`*=0%_:>'56V
M]Y-7A(DH'$PMJ.?Z![OY#H;*;L^JH:6.NW7M>LI,+*'>GWAM"J3?6T:BEBBU
M/D)*G#0+F\=2.XLKS4(B7\R<,0:I>]@DDB/@G@Z$.I'\51FGY=%Y@.HHI[Z\
M&[6_8<?SZ=]S[5ZI[UV/7;:WCM[8G;776XH_#D<'N'%X/>FU,J(7#!:K'Y"'
M(8V>:EE`*ZE\D,@!&EAPK21)5#QN&0^8STTRLATLI!^?1,S\9>]OC,@RGPK[
M(?<NP,>%EG^(?R*W3N+<G7TF/IUI`<1TGW56+N/LKI&M:FII(Z2DR"[IVO%+
M,%3'T48,BWZKT-?07RTZ_P"\<UG>N*_$[EZA^0>QZ!:[L?X[]I4E/A>R=JTG
MWKXS^\>&-+4UNW>R^MZZN510[IVS6Y7!52S1*:B*H9J=/=>Z#3M#XE[GVGOC
M<'R#^%NY-O\`3?>.XZV;+]E[`W%#D7^.?R8J'"/*O;VT\-%45.T.PYGB`I>P
M-NTZ;AIRY7(PYJC_`,@/NO="5\<_E7M;OBIW+L/.;9S_`$U\A^M8*+_2_P#'
M?L"6@&^-E-6224U'N7`Y#'3383LOJ?<=53R'![NPDE1B<E&IC<TU=%54--[K
MW1I_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW407^^;@V
M^T3G\7\TG'^O[]U[J7[]U[K_UM_*G_S$/_+-?]Z'OW7NLWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK+WOV%V#\Y-];JZ(^/6[,UU]\8MAYS(
M[.^2?RDVAD9L;NC?^Y\34O0[H^./QBW#2$28_)8J>.2BWOOVE>^W9A)B,,[9
MQ:RKP7NM$!@0>!Z-_++\??AET%K?^X_0_P`>^DMJ(BK&D&!VEM#;U)*L4,$$
M,2M-69+*Y.K5(XT6?(97)U051/5U`$GNM]$WI=C]U_S`U;+=X8;?7QP^&-6I
M;;OQW:NR6SN_/DEBJ@W3-?);)8N>DS74'5>4H;>'KK'SQ9W)13'^\E73H9<`
MONM$!@5/`]6`1CKKIK9>&PV-QVW.OMC;<I<?MO:^V-M86EP^&QU/%'X,3MK:
M>UMOT<<8TQ1Z*6@H*8MI6T<=APU-/%;IXDSA5J!]I.``!DD^@ZO'&TAT1K4_
MZOR`Z!???:N1IVHJ3/56:V-%G$+[:Z^VA11;F[ZWU3Z*@&6EPU&*VFV9BG%O
M).VJ2E9#YZNB>Z@IO+\Q,BS.T>H]L:#7-(*'@`#H'^S5EZ,+:QDF#-$H.D]S
ML0L2_:QI4_+S\@>N.W.O.R]P0U`/VG06U\C*[UF,VM44FZ^XMQ0NTMYMU]C9
M)<ECL+62EM>BB7)5,.LA:Y2.&+>TW.X[G"V,!))5"))FX_'*:JOKVZS0TU"G
M3S3[?:GL'U4PX%@5B'^E3#,./'2*_A(Z%/:'2W66Q:R3,X/:E'/N29A-5[NS
MLM5N?>=?4*EFFJ=U;BJ,EG&>4W)59UC!/"@6`,K?:["U?QHK9?'K76U6>O\`
MIVJV?MZ137UU.H228^$!0***H'R5:+_+H%,)\C=[]G[PW=U_U3U@F'W#L>*D
MEW/5=RYJ7::XDY+[C^%1#;6WJ'<F<KVR"4YE1P\,(@*,7NZCV30[]>;C=WMA
MMVV&.X@IJ-P=`[@=)"IK8@T-.&!\QT9S;1;V5M;W=[>AHY2=(A&NM.-6;2HI
M7(R:X\NAJZ;SO96?V8)^V]LT>UM]8_.[AQ&4I,5<X'(4^/RU3%BLUMYWKLA4
MRX7)XLPO$\[K.Q#%XXSZ`=;;+?36JMN4"QW@9@P7*FA(!6I)HPH<GHMOH[..
MX(L)WDMBH(+"C5(R"!BH-1C%.E?MK>>T]Y)EI-J;CPVXDP.9K=O9EL/7T]>N
M,S>.95K<96&G=Q!5TY8:E///M1!<V]SXOT\Z/H8JVD@T8<0:<"/3IB6">#0)
MX60LH8:@14'@17B#Z]%IW=V9OOLGNK*]!=3YN/9%'LO"4>>[2[-..HLUE:,9
M557&[2V5C\C'/B(\Y*DZR5%951SI3*"%B+KZ@[<[E>7V]-L>V3")84#SRT#,
M*_"B*<5:N6-=-,`]',-C;6>VP[M?Q&7QG*Q1@E5.G#,[#N`!X*M*GB:=3*KI
MOMW:^_>M<]L[N[LG=&U(-SZ>R]L;ZS&W:^"KV^^*R3"NQLL.W*"2,IE%IXWI
M8M)*RZXV3QE6>.U[G:WEA-9[K/);>)^JDK*PT:3E:(#JU4%/0U\NFTOMOFM;
MR*ZV^)9_#_29`PHU1AJL:BE37Y4\ZB?N+Y%UN0[#RO5'2VQ)^TMW[9%M[92?
M-P;7V-LB<N@CQ^9W%-1Y&:KR\EG7[6DIY75T*DZDD5/3[\\FX2;7M-D;BZC_
M`+5BP2.+/!F-27X]JC[3@]4BVI5M(K^_N1#;R$A!0M(]/Q!*CL\M1(^0-1T[
MX[N*M@W=ANK^ZM@P['R^^(ZRFV?DJ?,4V\>OMZU5'`)Z[;T.7?'8NIQFX13$
MR)0U]'$*F-&,,DA&GV]'NK+<P[=NUH()YPP0Z@\<E.*!J"CZ<Z645%:$\.JM
M8`V[WNWW7B)&>X4*R*/X]()[/+4#@TJ!TZU_0>SZ2KJ,MUQ79CJ#<E1(U6U;
MU_5QX_#5M2!99,WL6KBK-EYJ!I2#+Y*%9G_$J$Z@XVR6J%I-O+6LYS6+"U_I
M1D&-OG5:^A!SU1-SG*B*[59X:\'RWSTO\:_D:?+H+<O3;PV!5UN8WSAGQ.@M
M*_>/2&.J33U(!FTU/:W4$RY6:6($M/5U=,,O"H(M+1@74OD>\L&:2^@HF*W$
M`.:><T-"17)++K`%,J."E([>\HEG+W<?!E(_,1RX!\@`=!/HQZ%W!]K+3X_'
M9'=<V&K=K91(?X/VKM&J&0V%E!-4M2Q-EM$U74;/F,K(C-42ST`EU+]TK#1[
M-X+ZJ*\S(86IIE0U1Z_973G&21_2\ND$UJR.T81EF7BCBC#S^5?V`_*G3-W]
M\:>JODM@L!3[XILOB]T;,K:C<'57;FP,U-M+MKJ3<M;2I3MNCK/?F-5Z_!UE
M3#'&M72R"IQ.7@C%/D:2LI2T#&0((!'#I'T778?R,[5Z`WSM?H;YQ5&"E3>F
M7IMJ=$?,+;V,@VUU9W;N"?3%B>N^U\#$[X_HKY$9I!>CH3)_=;=\X=<'40UI
M_@<'NO=#=\D?B[M?Y`4VV=T8S/Y3J;O[JZ:NRW1GR'V72T<F^^K\Y6QQI7T,
MU+6@8W??66[(X$I=R[1RPFPV>H1:1(JN&CK:7W7NDY\;/DEN+?NX-S=!=_[9
MP_5_RSZNQ--F-Z;+PU36S[%[/V+45HQ.)[_Z`RN6/\1W+U#N;(V@JJ6=I,QL
M_,.<1EP9/LJW(^Z]T<+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=1Q_P`"F_ZAU_ZV/[]U[J1[]U[K_]??OHS>EIR"2#$A!8W)](^I_)]^Z]U)
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7'WIOK>WRJ[2W/\,.@MS9K
M9>R=FKBXOFK\BMJY"7&9O8&%W!CH,OC?C3TQG*6TM+\@.SMN5L57FLS3N'V!
MM.KCJT*9G*X5X/=:#`DJ#D=&IRN5Z$^&O0#U]<=I=)?'WHK95)204]%1G'[<
MVCM7"Q08W$8;"XC&P5%=D<C6U$D-'04%'#4Y'*9"HBIZ>*>JG1']UXD*"S&@
M'16.I>I.Q/E-O[:/RI^6.T<GLK;&S<K#NKXF_$3<GAD_T1SI'*N&[\^0.,IY
MJG%Y_P"4N4H:@R8S&LU3CNLJ28TU&TN;>OR;>ZWT=K>&]WPE;0[9V[C&W/OK
M,PM4XW`15`I:6@QJ2^&?<FZ<EXYEP6VZ24%/*4>>KF'AI8II;JJ6>Y\-U@A7
M7=,*A:TH/XF.=*^GFQP*GIZ*(/WR-IA'$_Y!ZD_RXG'1;L)6;L[#SE5+UOF:
M;<6X*.LK,;N;Y"YW#"?8FTX]9I<GM/H;:DU3+1Y_)4QC:&:N+2T",C&LK*Z8
M?:*'EEN=QGD3;)`9%)#W3+5$-!V6Z'M<^1:NE<ZBY[>C4Q06J$WR%:$%8,AF
MJ/BD>G:.&/B/D%'=T8O8'5FT>N4KI\-35>1W#FG6;<N]MQU;9O>FZ*E0@$V<
MW!4J*J>&/0/#2Q"&BI1Z8(8E]/L]LMNMK`/X*DS-34['4[D>;,<GY#`'D`.B
MZYO)[LKXK`1K\*J**H]%48'^$^9)Z`7[K+?(CM;LS9<VY<YMKJ#I^MQFU,KB
M=I9:NV[N'L3?>0QYR.8&<W)C'I\OC=G[<H9XZ>*BH9X):ZK>22>3QQQQ$C$C
M;_N.XV?U$D>UVCB-E0E#+*1J8,XHPC0$`*I&IB26*@#HS:(;5965P84>\N5+
MJS=PC0&@[3VEF(K4@Z10`5)/05=R=<[I^+-!!W?TENW>,^U-LY"@E[+ZMW3N
M?-;MP6>VU45<=)/68N7<%;D:[&9"B^X55:-BT8?R`Z4>.4KWJTNN68CONTW4
MQM(B#-`[LZ%.#.NHE@PK6E<_(#*_;;FTWEQMNZ6ZB9Q2.6-55@P!HK4`!4GU
M''\B(N^I\[C/E3USO'KK<U-LR+Y-]6T>$3=&:VR^Y:"&LV[3_P`=H*9,1_$\
M73R9RMQ$E*M,TDK)$0X='5K>ZWWU$?-.VWFW7(B3<K71J92XK'WBB5`#:6%"
M21Q!!ZO:_3-R_?6]Y"SS65R&TAM-0Y","<F@(S3/#(Z.%TML/=_7.T\AMS>>
M^)^P\@^Z]RYFAW)605-/D)<7G,@V3AI,A%45E:B5-+55$P"0,M-'$4CB1$0#
MV+=ILKJPM6M[J^:X?Q&(=A0Z6-0IR>!K3Y4`&.@[?W-O=3K+;6BP1Z%&D&HJ
M!0G@./$^=<GI:;8V3M'92YE=I;<Q&W5W#FJS<6;&)HH:,9/-U^C[O)58A5?+
M4S:!<_06X`]J[>TMK42BV@2,.Q9M(`JQXDTXD],SW5S=>$;F=Y"B!5U$FBC@
M!7@!T2C(U>0^-WRBWSV)O#%Y"3I7O#%82*3?M!1SY.BV#O#"11P_9;P6BIYJ
MS#87*:I&BK&7[13(NMU\<A`/93R_S-?[E=*W[JODC'B`%A'(F*24^%&&0Q%*
MFA..A$H7>=EM+.WE'[SMBY\,XUQG-8R31GK@IQ(%17AT97;WR"ZMWEOS%]>[
M(W+0[TR]?@<SN.LK=L5%-E<-@L?B)\;3(N9R-/,T--5Y6?)6I8EUNXAD+!0%
M+"&'?-MN;Z+;[6X$L[(S$IW*H6F&88!.K`XX/#S)I=LO(+9[JXB,<8<*`V&8
MD$X!R0`,GAD=`3\&Z1,/MCN';>89!V#@.[]Z4V]X9HTBR>NI-)58*LJ;LT\]
M!D\=(9Z69R1*KNP/U]DG)<;06N[V\]/KUOI?$_BR05)\Z%:%3PIP\^C;F=Q-
M<;?<19M6M8])'PDJ*.!\U:H8<0>HOSIRL=7MSJ3K_#3.W8.[.X]EUFT*6C!?
M)0'!5<D]9DHA$ZS00PF=(V?A=$C7.E6(;YWDU6VTV5O4[C+>Q&.@JPTFK,/0
M!:@GY_;U?E:(_47]U(VFTCM9-9/`U7"U]6\NH_:./J^ZOE-MO86SL_G-FOT]
MLBMS?8'8.TZXT>?HGWE4T9P.RJ)Y5J,:\E=%CONY?/#,J1%KH3;W3=$EWCFF
MRVZTN'B2S@:2:1"0RF0KHC!RM6"DD,"=.1\_;?(NU['>7=Q`CM<R*D:.H92%
MJ6?U%*@*5(-?V]'PB3QQQQEWD,:(GDE(:232H77(P"@N]KD@"Y]C@"@`X]!<
MFI)I3H"=R]+M29:LWEU)EH-@[KKFGFS^#DI6K.M.PS*J^2FWOM*)HX(:ZIT%
M/XQCA3Y*+RL9#4I>%B:XVDH[W6TRB"Z)JRTK#)ZB1.`)_C2CBM3JX$SBW'6B
MP;BAF@`H#4"1/30Y!-!_`U5I@:3D!]L+>U?@\EF<%@MNY7"93;H.2WGT!EJB
M.IS&'QDTYAFWGTCEW,-)NK957579*2)EI2Y,4:T%7>CE8L+U@WTXB\*XC'?;
MFA*CAJA.`\?F*8R!V-V].3V2A0_B!K=O@F'PD_PR#.AO(UR./<O=T.&ZMJ]6
M?(+K'/;,WE@=M=F]6=AX2KP>Y-MY^@ARF"SN*J;Q5F-RN-K(P\%725$=FCD6
M*JHJJ+_=<T8TGD,T5Q&LT+AHSP/^K@1P(.0<'/12Z-&S(XHPZ(7M'?6_/@+O
M3:W3/?.[MP=B?$/?>?Q6S?CY\F-YY&HS&[NE-V9RLBQ>T_CS\FMT5KR56;P6
M>KIX<?L;L*ND,U?5R183/RG*24&1S#O5>C2_)SXWX_Y`;:P&0P.Y:OJ[O;JK
M*5>\OCYWI@Z**MW%U5OV2A:BF:HH))::'=_6V\Z`?PO=VUZN5<?N/"RR02&&
MH2DJZ7W7NFKXI_(W)]X8/=VSNS-K4G67R6Z0R]!LSY!]3TU?-D*#`;AKZ.2M
MV[OO8>3K(J:MW/TOVQB::3*[4S+1(U13+/152PY3'Y&DIO=>Z-=[]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[J.`/NV;F_P!N@^@M82.?U?6_/T]^Z]U(
M]^Z]U__0W[J+_@)3<`?LIP/H/2.!_A[]U[J5[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z)S\N^[M\;&Q.Q^E^A3C:GY1?([*9;9_39R]`F6P'7N'PE)2UO9WR
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M,3ELVG2U77M)OGL+[A\?NOY+9RG4T==1XW(T?@J,)TY1B(TWDH3`F4A'VM`8
ML<KRU9#!'^^6F$0(V=B-4E:/=$>0(R(!\-<:Q55I'EC5B-M6.1RIW(BJI2JP
M`^;`X\7S"YT?$W?0*<C&XW'8?'T.)Q%!18O%8RDIZ#&XW'4L%%C\?0TD204M
M'14=,D5/2TE-`BI''&JHB````>Q.B)&JQQH%110`"@`'``#``].B5F9V+NQ9
MB:DDU))\R3Q)]>DSC.Q-D9G>>X^N\7N;%5V]]I4.-R>Y-M4\^O)XBAS":\=4
MU<6D*$J$*FRLQ0.FH+K6Z=+VTENI[&.X4WD0!=*]RALJ2/0^73S6TZ6\-T\1
M%O(2%;R)4T('V'CT3/*9'='Q;[R["WID]K[BW/T7W'44NX\MG]K8J?/9+8^\
MH08*DY7$X])LD^.J1*QU1Q,LD4B:6,D#QN#I9+KEG>=QO9+62;9;QE=GC4L\
M4@&FA5:DJ>-0*BORR(QX&^;796J2I'NEJ"H5F"K*AS@G`9?0D5_/I_[;[%H?
MDML7)],]*46X]POV$E#A=V[]J-N;AVWM'KK:=164T^>RE?EMPXO&#)[EDQ<,
MD./Q=&)IY*EPTIBA1W]K=SO1S#8W&U;,&<S#2\K(RQQH3W'N"EW*U"(H/<07
M*J#TFVZ%]FO(=QOM"F$ZE34K,[9T@:20`#0L2>'"M>E/WCTST]EJ;KBN[0[*
MS6R-J=78QZ7:.-I-VX_9[/E:2FHJ>+-0YR*GBW/49FCQE"D4:451&PU%@NH^
MWMYVG:94L&W._>*VMUH@\3PNZ@&K4*,6``H`1_/IO;;_`'",WBV=FLLTQ[^P
MOC.-/``D^?2]QO>.*RE)20]?;#[6[!HQ30Q46;IMKU>#PE:D:1QI.=R]A56U
MX<@'^K3Q&?6;M=KW*Q-XC=46PL+J=:4#!"JD#%=<I0'[<U\J])6VYT8FZN88
M3QH6#$?[5-1'V&E.N<&]._<DVFGZ/V[@49-0FW1VW0M(C!K%):3;&U=P)<KR
M"M0POP?Z^WENMW?33:D0$?CF%0?(41&'VT/[>M&WVU2*[B[#^C$?^?G7KE)F
M/D>J,7Z\Z?K(V60/31]E[JA>1=141^2HZV>']V(\W%@;CD<^Z>)OU,V=H1Z>
M*_\`UJZJ$VO41]5/3U\-?^MM>HM-O;M;!:WR7QUE\`3553[`W[LS-32:0O\`
MF:'-Q[)JJDER;+];>Z+>;G#J+["=/$^'+&W\F\,D_P"'JYMK*0#1N@U>CHX_
MF-706;LS/2&Z=T46ZMQY;LSXY]E3TRX<[HKJ3*]8Y',XRG<F#%YW,U]!DNO=
MUXVFF-X!52U7B(O"R#GV77<FS7%RMS<2SV&XL`@D-868<0I8@Q/3RU:M-<4Z
M6P+ND=LUO"D5S9UJ$[9*-PJJU$BD^>D#53-:=*["=)[?V5'E^W=@K6=X=O5>
M'^WVWNWL[?AR355&T@C;'XC/4F-J</MZ@:F>0!J*B0R#]MG"NQ]J8MF@L1/N
MMBK7F\&,A'FE))!H=*M0K&II^!`/+@3TW)N4UR8=OO2+;;E;O2)--#_$5)!=
MN%=3?9Y=`=T3V=LCHS"[[J.]ZW,[-[O[`[#SFY-UX?<&!K8Z[=%;65HH=LX_
MKN7'Q5F.W;A8L;XXZ1**>66.2219%0_4BV3<[38[>^EW]F@WJXF:20.IJYPJ
M+"5J)45:*FFK<13HRW2RNMTDM1M*";:X8E1"I%%H"S&0-0HW%FU8I2A/2AW6
M-]?)/O/=_6&.W=GMC],]2#'X_?3;7KIL5G=Y;DRU&E:F*&6II%GIZ2*)V`"W
M6'P,[*TDD7B4W9O>8M[N]JBNI(-GM`OBE#I>21AJ"AAD*!QIQI]E-6ZV>R;1
M:[E-;)-NESJ\-7&I(T4D:Z<"3BE?7A2M5-OGJ.J^/^R,[V9T=N+>=/DMC8V7
M<^<V-NC>.?W?M+L+`X.'[S.X:LH]S9#(M@L_68FGD^RR-`].\-4$\B2Q,Z%;
M=;9^XK.XW':)I0\*%VC>1W215[F!#LVER!VNM*&E05J.D%O?#<KA+3<HT*2L
M%5D1%=&)HI72`"M2`RM6HJ11@#T-6<VMM3O?96R]VT=3D,'E&QV.WGUUOC#M
M%2[JV;6YK&T]5%54%01+#+3U5-*L.1Q\XEH:^$&&HC=;6-I(;;>;*UN8V9'*
MB2*0?&A(J"/R-&4U5A4$$=((IIMMN9XF574$I(ARK4)!!X<#E3Q!H1T#&U]T
M[TP.\,UB\EMZDQ?;>.@.<WMLS#LT.TN]MGTLD>//:'5TM7((J#>5"AB2NQ\S
MB>.8I1UCO%)09`%<%Q<07DD3H%W(#5)&,)<+@&:&I/>HH&6M:]K8*/TLN+>*
M2&.6"2MB<*S9:)LD12$>1SI:E"*LHPR@Q&<P76O?/6.;VONC"8+L/J[LO;64
MV[N7;6X,<E?A-Q;>S%/48K.8#.XBOB!%T:6FJJ:=$F@F5D=4D0@"6*5)HTEC
M-485'^R#D'U!R#@]$\D;Q.T<@HZFA_U<#\B,'B.B6?'K>>[_`(Q]K8CX.]W;
MDS&[=N9[&YG+?"CO+=>1J,EG.S-A;8HWR.X/CWV7G*UGGRO??1V#C\U)D)Y'
MJMZ[,B3)L9LEC-P2*YU3I9?+CJ;>N-S.T?F!\?L#-F?D+T)B<E0Y78^,*4M1
M\D_C_7U<65["^/>4F],=1N(O3?QW8=54:EQ.\*6*+7%093+K4>Z]T:?JKM#8
MW=?6^R.V^M,]3;FV%V)MK%;LVKFZ59(EK<1EZ5*J`5-+.D=7CLC2ES#5TE0D
M=31U4<D$R)+&Z+[KW2_]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1P/\`*V/_
M`$S*/^LK_GZ>_=>ZD>_=>Z__T=^V@O\`9TUQ:T,8_I_9'T_/OW7NI?OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z9]Q;AP6T=OYW=>Z,OC\!MK;&'R>X=Q9[+54-#BL)
M@L+13Y++Y?)UM0R04>/QN/II)II78)'&A8D`'W[KW1&/A=MK*=IY;>_SN[%P
MU=C-Z?(_&XO&=,[=SU,M/ENJ/B+@:NJR'4.U&H9)*F3!;G[2:NEWSNJ$2"89
M+,4V.J-2X6E$?NO=)OY)35GR\[H'P5VS65,73>T\3M_?GSRW#C:QZ0Y78NXE
MEJ^NOB30Y"BD%73Y7OF.CDR.\E1HIJ3KVG:D8HVY:*>/W53I?4A/V]'QW%F\
M5U_MFF^QQ<12`8_;NT]KXF*"B&0R,RK18';F)IXHUIJ&"T86X004E+&\K!8H
MF(8N)O`B9PNJ3@H_B;R'Y_R%3Y=/11F5PNH`<23P`\R?]6>'17Z+:V;[(W/G
MNOILRM?@8:VGJ_DOO?$&II$WGN`TJS8?H#9U9K\V-V;@<75)_'!&PF6@F2D9
MON\CD)8@\89-PNY[`-6U%/JI`:%VIBW4T!"`&KD&H4A.+N>CA9#8PPW;(!.0
M?`4CX14?K$>9)J$)_$NJA55KWVCW5MZO[(VO\6-A[RI>OLGEBF-WCN[&PTM%
M)L_"TV,CJJ+86QVJ$CQE)O[=-&\-/2S!)(\12R>2-'JVI8_;.Y;Q;MN-KRO8
MW(AFD!#NM!X:A:B./\/BL*:1G0O=0G2.G+';IOHKG?;B`RQ1D:5:O>Q/QMYE
M%.6_B-`<:CTH.J]Q]7]-]AGXK83-;ZK,A!A:?=NVO[V91=SXVAI\BE9+4;,Q
M>:U2YBBEH:7&/D4I\D/5#4L8)611&BK;KO;=NOSRS%<2M<*GB+K)>@.=`?)P
M!J`?-#@D4HGO8[V^@.]2Q1K$S:#I`6I'XM`IQJ`644KC!Z,CC<)M9<I7[MQ&
M*P(S.=IJ6DR6Y,=1T'\1R])CFD2D@K,M31_<5T-&Q945Y&"6L+6X/8XK8R/=
MQ1IXS@`N`*L!P!89(&:"N.BII)2BQ,[>&I)"DF@)XT'`5\_7J+O'>^U.O\)+
MN+>.;I,%B8I8J99ZGS2SUE;/J^VQN,H*2*HR.7RM64(AI*6*:IF((1&/NMW>
M6UC"UQ=S!(AYGS)P``,DDX``))X#J\%O-<R>%!&6>E<>0'$D\`!YDT`Z!23+
M]R]H1PS4)?X^[!K)/`N1W%18W(=QYV.9O%",=A:V6KVQU]]XC'QFN7)Y($#5
M2T[\`L,FZWY7PA]%:5XN%:9O32M2D?\`MM;'^%>EQ3;[0`NWU-QZ*2L8^UL,
M_P#M=(_I'IVQW6NQNL,U2[@IM@YC=^3JHUDS'9N7K)=^;XHZV)X:>.:HES4]
M7N"*BEA=I)/X4HBBT6%.%L0[#MEE92+,+4R3GC*Y,DE?],U6`S^&@'I3IJ?<
M+NZ7P3+HM_)%[$_WE:`GYFI^?2K;>-73RU&Z,=74^\]ASM`*V'"4HGW#LYA3
MQ>6I:BI=55F<<?\`.U-.8ER5)J+(DZ>B-?XC"LBL&A/IQ&!^WU/GGI&4H2K"
MCC_5_J\N@PW9N3^&X#*U><W'7Y+;6%V[N#<<6>QM?&O]\NK*VEMGI*62E44\
MN^M@RM!+3-&$EJ56()ZZF942W5VMO%<7$YI"D;-4>:4.H`"M7&*#B20!Q/3T
M,+32);(A\1V"C_3GA^7'_#Y=`5!E-T;=SLF_MV9O/TN8WQ%2;6[0I4EKFVWL
M6?<7\)P6Q\OLS&"_W^<VA3F/;6XE@>T>XL]#,Q2.,D$,<UW:R0[C=N^F:@F2
MITQ:Z")E!\T`$<P&0[ZN`Z.)(K6>%[.WC4O""8WIWR!:F4,1CNR\5172A'GT
M8"/>N=IZ>429.HP\&3K!10&CACSU1018;51Q;%ZYQ:K63[SW>"I3+Y5O/CJ6
MJ+JAE6(",_$\P+:ZBK>A-.%%44.H\=3<`>B(II^8_P!5.A#.[#3">7L*3!;>
MQF3IA38K9-3HSNYJI))2AJ<M%0O615D]2B6^SHX*B.+4=4\AX52TBT99].@^
M7$GUJ/\`)3K:JU5,5=0/'A^P_+I`TG3.W:Z.HW1U2^[^@L_-6S/;"T-/C,!F
MGA'C2JW!U=D6J=KUU%4ZV.LTM!DB23Y8S8^RL[+:@F?;GDM)RQ/8:*3_`$HC
M6,@^?:&/DPZ7_O.8@0WJI<1#^++"N3ID'>/VD`^1ZQ9+?U3MJ7'X+Y);/VY'
MA4R>-EP?:N.HERW6,^9IZJ.3&5&X*3+)593J_-0U?B:&:M:?&^8?MY`/:/VP
M]]);4MN8K2/P-8TS**PDU&G6IJT+5S4U0>4E<=.+:I,6FVB=_%TFL1-)*$=V
MDB@D%.-*-3\'GTGJH/\`'WM'L;L.HP&<SG5'<+8#<.<SNU,57;ER6P][X>@_
M@]7/F,!B8ZO,5FT-RXE89UKJ2&?[*LBD69%BFCD5A5_<FY;EN+(TFUWA1RR`
MN8Y`NDU"U9HW&DJ5!TM6HHU>G"W[RL;2T\15OK;4JAB%#HQU4!)`#JQ-0::E
M(H>WH*NXN\,O\@L-D>D?CYM7=V9GW@1A-U]B97;N:VWM7;&W:AHSD:F.NS%+
M025#5%.=#'1=HV9(4DE8:"K>=XGWZ+]R<O6\CF>HDF962.-/Q98`LQX%:<*C
MB<&6V;=;;1*NY[U.@\*A2)&5G=O+X20H&":_X.GOL;L?=>W9.NOCE\8YFW-V
MAL@[<;<M:])33;)PFVMJ8Q(Z[!]B973,F$?=2&)&2G(K(&E4QVD,:.IOMPNK
M0[?R]RROC[C!HUEJ>&D:`569\Z6DQ0*-0XBF*L65E;S"\WC>E,5A*'T4J6,C
M'!1:@L%-:D]OKT,W^_>^1VRC/2S5^P^R^O=R55-'4Q&EJ]U]/]J86'PU5/)H
M=:3,XNHIZH"6%C]CGL+5"X\<X*G`-OO]HQ6L.X02$>1>"910BHPPSG\,B'T/
M1<#-M%R`P\2TE0&APLL39!IY'%1^)''J.DILG?N5Q%=N'.;@Q5/MK-;=R$&-
M^0>RZ&:>?$8FNF@8X7NW8Z2CSS[-W110^:K<C6:6-S-:MQM6LK=G=S@RS31+
M%,C`7$0.H*3\,R'B584)J,J#^-&!M/;!XX54ZE=:POZYS$QX:ES0>M*=K+TN
M_DCT#M7Y-]297KK-Y2OVWE!6X;>7679FVQ3G>'4G:FTZN/-]==L[$KI/13;E
MV;GX(JF-2WVU?2F:AJEEHJJIAE$71/TB_B+WUN7N79&XMK=LXG%;2^2716YV
MZI^16R\1).,12[ZQ^,H<IBM^[,BK@N1FZL[CVID:+<^V)Y=;ICLC]G.YKJ*L
M2/W7N@=V(I^)'RRRO4$H-%\>OF1G=U]E])G_`"A<1UK\H:>BK=V]X=0TQ:.6
MFQ^)[RPM)6=@X*G$D2#.4.ZU"_Y11Q#W7NK$_?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW4:W^6$_],P'Y_P".K'_6_P")]^Z]U)]^Z]U__]+?LH.**E_Y81_X
M?V1_7W[KW4SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5[_`#(/^G7L/I3X,4$B3X+M
MV?(=N_)F&*=?)#\6NI<IAY,MLVOC@KZ&N@IN^^S<GA-J2A2?NMO/G@H;PM;W
M7NC%_)OO&C^.'2&\NT5V]5[QS^+@Q6W>NNO,2PBR_9/:>],QC]G=6];833'*
MT=?O7?6;H,<LJQNM+'.\[KXXG(]UICI!.DGY#IE^)G0]?\?^H*/;^[<W3;Q[
M?WQGLUVO\@.PJ:(PQ]@]X[]D@R.^]PT4;P4\M-MK'S108?;U&Z*<9MK%XZA4
M:*9??NM])S>V\,YFLU0Y#:DL#[IW=D,KUWT-%*M-5T.-ABB/^DGNW(TYD>.H
MQ^`Q\+K1AO\`/100P);^*GV'+V[E=T%LP^JF)CMP<@4KXLY'D$6M*\:!?]$'
M1Q9VXTR&<?XI$`\Q\R/P1#YL<8X5+'"'IYWIE!T%U_LCJGIZ@H,MV7O#(5&W
M^N\9N:>6HCS.;M4[DWMOK>U;3RTE74PQ0?>9/*52D2U%;.JJI:4#W:\F?9K*
MUV_:8%EW*4E8ED8@,U"\DDC#-!EW(R6-!QZW;Q'=;JYO;^1DL8U#2,@%47"(
MB`XXZ40'`'R'2BWAU+0=^]64F#[?VG1[2W950?>O)MS+P9?(;-W)`S0P97;F
MYEH*%ZCTPI)9X562)A'(ITW#][M4>];:EON<(CN31JH:F.08#QO09'D:9&#T
MS;W[[9>O+MTQ:`$@:A34OHRU(_8>.0>BC]<[]WU\:LYNCH[</5TG8G:V\,E4
M[@ZYW?MJ4_=]SU.0:6&3-=D9S*5%548"#;\%*J5E;,7AH:&`1+&S)$]0%-LO
M[_E^>?8;K;3<;G(2\,B?\2/Z4K$DH%X,S$Z5%`/AU'E_:6N[PQ[O!=+%9(`C
MHP(\-J5TQ@8;7\0`I5JD^=!RV/2)\5^M]N=>^2J[,[<WYF,YE\)L';<S8[%5
MNX\I4?Q/.T^V*6N\\&Q>J=HM5K]SD*D%(8K2R++6U*02G5C$G+5C!MX<S[G.
M[LL8)`+GN8*,B.%/-C@#.78`E=PS;Q=/=L%ALXU52].``HNJGQ2-3`&2?102
M!'VIU'FJ;(R]D]@9;$[X[F>CJ$P]954]:FP>NTJXPDN"Z[P4LDE5B:%HP(ZO
M)R%LODP"9I$B*TT1I:[:ZR?77\BS;C0T-"$CK^&)372,"K_&WF:8".>]!C^E
MM5,=E7(_$]/-R*5/&@^%?(5R5KDZ7>60Q\E%G=I;%W52NRL^/;*5D$,C(;I)
M]OEL!D*8NAY4EP0?H?9@1,PH\:$?:?Y8_GTD(BQ1F!KZ#_/TBJ;;F5QH;^%[
M+WKM**.4SE=G[]Q&1II"MB-&$S];_"RI`MH$"W^GMD*ZY$+K]C`_R)Z=JE-/
MB*?+*TI^?'I.5U!GFJYLO/2;BBS0:1AN$;.J=L[A%.HA,%+5YS95;F\1EX8C
M`J^.NQE1`5N+"_NE65M94ZO721Z>:DC]HKUY0*&/6"/M_P`X'0)5E57;TW94
M8.:#&18+:&9P6Z,XD+SR8?/=G24QR>SJ7.8**BI5PM?MRCIIMT;@CHA'#D:>
M&@BFAUU1#$]Q_CUZMIX=+:!@\E?A>6@:)/(C33Q9!3%$4@U/1E#_`(I:-.KD
M7$P9$-,JG"1L^O\`9K7U8@X'4[<';G6^7QU;L.HIL?E:;:U5+M7<%))F*RIS
M&1AWA25D6=VQNNM3#TV&FW)V'1"LE^WH<A*T>3BCF65Y(@GNL^[;/.+O;YIT
M<1'PY5)-:R`]KD@`F3)PWQ"M:CKRV&XVJVMW'$ZF0:T8`8T$=RBI("F@-0.T
M\*=9]E9'-05&2V]D*G-5>6VQ1XG''>=)D*/#5>]-BURQ5_7^XCEQ$V>Q>)R^
M(IU2MH,7_#*>')4E6C,6]9MM]Q-&TME<ZFN8:*7P/$C(K'*3Q[EP0I`#JQ/$
M5K>Q1,8[F!--O-4@`5TL/CCXYTG()J2I!IT*^%FJL1Y/X,M%MZ9F>.KEPF/V
M''D\C=_(9*G.;R[!R^4K%9E%GEA)'!T<>S=6>A\("OR"5_,EST@<5%"U:_;_
M`"``ZFA,ED9*A:Z@W'N&&<:6I<OW%@\?1NCJ?U4.TVI:<(+_`$TL./I[V=1P
MRDCT+C_)_EZW1<T8#_:'_+T*F*;.5U/2X>LVYM.FVP:/^&UM')N2?/SRXUJ%
MZ<T@I&P4='5Q-Q%(LTQ#Q%B;G@OJTL@`D1`AJ"*ZL</2AKTR``*]WB>6,?Y^
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M23P2?L0321NDP(/L-P6-_MF_?NKER=`Z6>NX:8%A+(S]K-0ZM9SW9`4T(..C
MR:\M+_9VO]YA.DW.B)8B%,:!,JFH$%!BH-"6H:@UZ-9\>.F-Q=5P=@;@WQN>
MFW5O_M3=G][]VUF,IGI,-2U4=''04E#C(Y4BEEB@@0CR-'$`FB-4"1J2*N7]
MGNMK6_GW"Z67<+J8R2%%TH#P`6N2`,5/R%!3H@WC<X=P:TBM;8Q6<$81`35B
M.)+>52:UICIZ[AVIE89L7VSLN@-?O38M)64^4P$,2,>Q^NJQEGW1L&K72?N*
MWQQFOPI<,L.5A5.(:FI#O[O;RIHW:S0M>0*=2C_18N+QGU/XDXD.*##-5BQN
M%*R6$[4MY34$\(Y!\+U\A^%_53Z@=9.I=PX>*GQ^VL/D?XGM+,X&'>74^5)G
M*5NQ:W[9WV\KSH)!5;+GKHH%BD/F3'STRL-<<I#^W7$3QQK"^JU=`\3>J'\/
MVIPH<Z:5R#TU>QR"1VF%+D,5D&/B'GC^+)J,$U(QT5_Y70_[+AW!UK\ZL,QH
M=HT$>!Z$^8%+&TJ462Z"W3N21.O^V\E$DC1OD?C7VAN/[Z2H$#O!M#<6XF=K
M1PZ#3I%T83Y6]#M\B^D-U=>8K-IL_L"EFP^^>F^PQ31U-5UGW9U_E:7=W56_
MJ56IZB5H=O[RQ5*U?!&`U?BGJJ)CXJF0'W7NI'Q7[S/R+Z)V-VC78&79^[ZV
M#*;9[0V%4E_O>NNX-AYK(;)[9Z^K%F8U'DV?V#@,C0QR2`&IIXHYP-$JD^Z]
MT83W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71
M8+8DVN0H_P!=C8#C^I/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6#C[H\<^`<\_
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M[W4K6U4!'/M%>2&D=LC$2RFE1Y*,NWRH,#^D1T_`HJTK#L05_/\`"/S/\J]!
MYTECZ'=>5S?<%/3)3X"KH4Z[Z?H45EI\7U5M2L:F&5H8R$\:[^SU&U>K%=;X
MRGQRDGQ^R[:`MW+/NPIX##PX!Z1(2-0_YJ-5OFH3I?N+&".+;B?U%/B2_.5@
M*@^7Z8[?],7]>@1JN@=P=Y]B=OYSN.FW?LC=>WLW@:7H[=>U,Y(-O[<V11T[
MUN&J\!-!/`N5W)5[A@J*O/)501.GEIX(G6-5<DLO+\N\[ENEQNJ30W,3J+61
M).U(P,%`#\1:IE##-5`-*=&4>ZQ;7:;?'821S0.I,\;IQD-*AJBFD+01LIP=
M1.>N8[^[9^.,IP/R:V]/NW:1,E/M7N38-&M4<S+'&[T>%W%MUFII*;<59%'I
M304,LB'2)KF0>3>]TY?`M^9(#-;UI'<1"OB')"NF-+G@*8-,GB>KC9[+>09M
MCF$<W%X9#30":51C74H\ZY`(^SHR&\=U[/V?A\=W#7;-JGWUG<'A]F;6P\V-
MI:;L+-5NY*I,GANMH;O4&CJ:C,'RU<?D:GI!!+4S,(H'=1)>7-O9Q+N+6I:[
M=515`'B,6-1$#Y=V6SI%"QPM>B2V@FN)&L?J`MLK%F-:HH7!D^>/AIEJA1DT
MZF=8=>9#;KY/>N^*RESW:V\4BDW3F:97.-PF/C=IL;L+9RSJ)J'9NVA(4CN%
MFR%3Y*VIO/,0E=LVYK9IKZ[(?=9Z>(PX*!73$GI''6@X%C5V[F--7EV)0EK;
MDBQC)T`\23@NW])J5/DH[1@=.&<PE!0%JO/=G[GP\%14.\0J-P;?PE*MW+BE
MIV3$4;-%&IT@%W?2!=B>2N=`M2]PP!^8'[,5_P`O24,2`%B7'R/^?I(0U&U:
MV)),/D^V]]1M.].ZX?+[H2B9I/KY<E+5;?Q)@'-B*C2/;5(S30\K_8QI^9J!
M]N>K:F*D409]!7_/_DZ#O)Y3:7\43!1X_;%-N2I]:;7J=[[C[(WI54ZJ&1UV
MO@<S%34PD@N5>;))&2#=@!<L$P,QC&@2"E5+%FSP[0WGY5(_9TXC/I.JNG[`
M!^TC_)T@=Y53XBBR7\*V]2YG,P05L>/V_BXMO8^IR&0HDD:?%M'BY*K'I/0M
M$/N5K,]4>")9#4&$@>T\[>!#/)%;ZY@#I0!06;R!\O75J;@#7RZ=MD!=%,I5
M"PU-G`\SC^5%XT^SI)[=H)CM/#8/$;1['\[T,>4RL_\`HUH5RF2W#G*Z:OWI
MN0XR'L3%9!L!N.IDI:>F$L,4E+C:&EABE>$DR$]D[QVB6PLKKQ#5G)C74SL=
M4A_M0W<::10:55:&G1G<A7E,RWMO0451K+:%&%'P4JHJ2:\232O3TFV\M%DH
M\U%UQOE<U#2C$Q9.?I+!SEMO45)+30;?GHO](+4=7'^\S0U<L`>.X2-(T"@6
M=F9S(NT3B8KI+_3IJ*_PL3+0\33&*FE.M+&ZH81NMOX6K53Q9*:OXAV8/V'/
MG6G2;W#@-PXO&[2S&WNK^T*W+[)K9Z)),EU]"'/7F<>EGW1CI)I-YY+*5^3P
MN=#9K$*D3)3$3T<<;"?4$\AEMFL[FTVN\\6#L[HU-87(UJ>\EM)_44@$BA4#
M/3\,4+I<VUQN%MX3]R@2,-,J@Z6'8!W#L88!J"3CH4MO[O%;)&9\?C*V>H:*
MFH_XAM;;V[L=D:J>-P@CJHH=K[FK'#*`SI-7322ADBBET^Q(DBL3(0I6M-1`
M(./D`WYU/I3HBIBOPMZU(_SC_!TOJ[>.T\#M/,[MSG56!W!C<#`*>LFV)M:?
M,Y5\^*J&B7#5>T<CMJ@W#@&3[C7+/5*::FIP9)943WZYNX+2VN+J2SUQQBI"
M*6?C2FC2"/4DX`!/6X8YIY5B6?36F6:@I3C6M/L`R:T&>HVV,'O7?V+7<&$I
M/C9@]N9#1)BZ;![:JNS7$:+IFHLCN&BR>S,2]73S7CE6GIF$3*5#-:_M+:F]
MOXOJ89+)86^'2IEH/FU4!(\P`*=*)_!M9##*+DR#CJ/A_L4AC0^1)SZ=./\`
M>W</1&-K<AV)M/95%UPM9]WEM\==5590T^W7JI*6D^_W)LK/RRY+[`D@R3XR
MLR,L2+=J<(K2"\M_/M,4DVZ1Q"P4YDCJ`M2!5D8DT->*%O2GGU2*UCOG6&R:
M0W1X(PKJH*T##SH#A@!Z&O43.TYZ+S-5VOL\&KZ5W;4+FNV-M4&N>EVA49$+
M-+W1M*DB++#BV602[HHH%T34]\G$HGAJA5-7`.RRON5O5MJD.J9!4^'7_1XP
M/P\#*H%""9!D,&=C8[DB6<H_W8*-,;<"X'")N`K_``,<_@.-.ECW1/L+X^=F
M;K^0VX,[F<EMWNJ@V9M>08S;U3N48G,X6AR$F*JZ7-XV5_M]N9[&QQ104QBD
MUUVDQ.1+H5)>&QV'<[GF*XGD:"[2.*BJ7HRZBI4C@KB@IFK4H<TZ5VXO-XLH
M-F@MT\>V,CCN"EE--2D&E64U-:X6HICIXH?DQF=VY/)X/KGHGL_/YC#1XNHR
MU-NX[<ZRCQE!FXZ^7#Y2LCW3EAF%QV4CQDQ@DCHY"YC8:05(]NP\QS7LDT.W
M;)<O)&%+>+I@H'J5-'.H@T.0OD?/I@[1%!&DUYN<*0.2%*:I22M-0[0`"M16
MK>8\NNOC[W_N[N7=78F+R>QL3B]L;0J8<=C-X[6W')NG;=?FZ>>2'+X,9R;'
MXB'*U<$;Q31RT4#T_BOK<%HM?N7]_N=ZN=SBDL%C@@<*'5]:,V=0#:5#4]5!
M'SX5WN^TP;9%9LMTS3RKJ*,FAU4_"2*M2OH2#\NF;)8.NV1O3-[)PL!:5JK*
M=Y]$Q>0PI_&Z:9U[:ZLII/)&(J#,MF#504R`((<W,19:-=-A#]'>RV<:@*29
M[<>6K(GB^0);4*#A(U/@Z\TB7%G%=..Y:0S'C4<8GX8("Z2?Z`_B(Z,5DL9L
MON?K3)X//XNGW)U]VCLK(X/<&!R:'[?-;3WCA9\9FL'E(H)@\:UN+R$M-4QJ
MX9"S+<$>Q%%(LT<<J?"P!'Y_Y>B5U*,R-Q!IT5OX%[LW-_HGW#T'V-E*S,=J
M_$7?>3^.N[LSE?$F6WEMG;&,Q&<Z6[/JX?O:VJDD[*Z1W%M_)U=1(UI,P]=&
M"3"UG.J])'8X_P!EZ^?'8G6W[%#UI\VMG57R!V%3!Z*FI<;\B^H*+;.Q>_,)
M144%.LQF[$ZUK-I;C36P\M;B,W4>IY)&'NO=6&^_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[K#8?<$\7\`'U-[>0_B]K>_=>ZS>_=>Z__]3?NH?^`=-_RQ3\W_LC\GGW
M[KW4KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1.OGQV/O7K?XI]HR=5U:4G<W8M-@NCND9?X
ME#BJF#N#O3<>*ZGZ_P`M154T<RB?:^>W;'EW&AK08^1B`JL1[KW0W[#VCL3X
MY=([1V1CZN'!=;=']8X7;L.3RDJ1Q8S9_7>V*>A;*Y:I`"EH,3B3454QY9M;
MFY)]^Z]T6S^7CA<M5_'I.\=U4-1C]\_+??.[?E1NBCJJYLC+C<=VO44LW5>W
M%G<>2*'9O1N)VOAQ"23$U`PX-U'NO=*3M?)Y/.U&XZ/#2U--GNRMRXWXY;%G
MA6=:G%X1_/F>W]VTT1DT?[CL119%A4(MUEP]/R"1["^Z22S^-!`Y$MS(+9#Y
MJM"T\@'R`8>7P*0<BIU8)'%)'),M8HD,S#U/"-3]K%>/DQ\NE[W#V[M[XU;.
MV-#1[)S.:P]5D\3L7!X?;HBIJ3"T5+C'@QD4^1R#+CJ-`*6"DI8IYHVJ)9%1
M&+"Q5;ONUOR[9V9%G(\)=8E6,?"*8R<`````D5)`'3.WV$F[W,Z&Y59=)<EJ
MYSW'''B6/R!/0=U'S$AP[T<6Z^AN]MLS5]7!C:..LVI12&LRM33R5-/BZ#_<
MI"<A73I!+HBA#R,L3-IT@GV7-S<D*HUUL=_'J?2*Q5JWD!1LDT.`*X/2Y>77
ME9EM]SM'HNK#THHXDU%`/F3TJ=A=H=?_`"AK\UA9>M]P2[>ZWS&SMQ?>;]QD
M&*:FW_0U]7E<31IMYJJ:L3);=%#!6>26\8::/TW`NLV[=K'F-[B-;&3P;=T)
M,BA:2CN`"U)U)AJGA4=)[O;[W98X)GN%62=7`"FM8R-):HQI:I4>M#U/ZZ5N
MW]_UG=M;)Y]E[6?-[.Z0HE:)Z2L@$SXO>_:IT-(9*O=%9328O$N2OBPU,\J"
MV1D]NV`;<[U]V=JV<=4@'D>(DF^US5$]$6H_M#TU=?XC;+8**7#@-*?/R*1_
M(+\3>K&A^`=*++5F,FEK$R'8>[=UU4%9/)'MKKM(X*B&%IB(\;4C:D#9-6@0
M6=ZFNA%@2=/LT9EJ09F8CR7_``8S^TCI`JMIKH`'J?\`9_R#J)C]N344<^2Q
MNQ=I[!QM.'KI]S[]K(]Q[E@A$1E->\*UE3%0-2"[L:C+$*?U(+'WK25&L1JB
MC)+&I`_R4XY/6Q3"!F8D\!PK_J^70>;VW7M]Z:OIAN*H[+S0>AH*)Z_.T4&R
M$S=?ICQ]11;(VE*^7WE#BVE$]72T]%D&^WBEN^L>T-S=Q!&\*=))SA1J%-7E
MV+5B!Q(TDT!Z4P0L\@#H8XJ&I`J:`5XF@!/`$D9(Z2VUL+A=ATN1H\]@GWGL
MG<V0J:S><=3@=X;AW)A]PY:=!5[FP<K=:;<F@VQ3L[&2AB:^)@C$U&RI$\12
MV\7T7:RF6&0ZG)U%@QXLI\,=M?(FJBA6@!'3MPSW+(RZ1*H"@#2`0!BO>:L<
M>7<>.>N.[I*_#9+)83';FJ=WTDR8R*@WFF3VO69&BC^X@R&UNO*FFK=LUE%F
M-P5.H_8U=55?P]?-!59-#,T+5=YS<P.T`9WC.!("M0>*Q%2-)8BNDDA?Q/FE
M6E$/A^*P"LI^&C?86J#@`\0!7R'R<LS0X?<9P^-VWM^MV;@<74T>0DW-%'N?
M%]D9[=<%=19)GQ^],=LC>$[X2&KAEBKZX5,AS,@>`.:/6U1Z6);E?#A@9$4@
ME^Y9-:D'#!&QBC&I#BJY6M7HA-%J=F#.5^'M9=)'F-0H1Q`I5>)H:=-5%F<)
M_<K9F5QM37TW97]Y<17;EW13QY:DR^0I=Q9/-4-1'5[EDVMDTRRU"4\:34RX
M^H%.NG32TU@8:PS1FWLW,A^K#@L:,"=189.FI!S3%,#AU8QD37,1`\#PS05%
M`0%X=U`:GUK]O#I0;;IMO46:JZ;>-+4YO&[IRD>0I]_5=5NROWIM+=%3+)]N
MM7N^?9>SY,)M5O##%C):=Z>+&U`$!3Q2QLNH-$,A%R&>-VJ)"79T9C0`MH4*
MG`*00%.#@U%95D:,O'1'4&J]@4J``2!K:K$Y(IGB.D!DGR6#W3G\;!GYJJOH
M\@U#_?%,]MBGI]VR5"5]968W'[?7;M'!MZIQPHXVSU=#.T,4U/-+CU%>T_VM
M&>Y2>:'Q&=AVAJH`^"U`ND:0`.]ZGN';W$TKHB*0L811N`[JCRK6N<_"I'VX
MXM&._O%!#MK*/N5MF57]Z(XJ3=#466VQEXOXW4Y*#(/N!]S[;I*/<6PHL>@_
MA6-R.32ID=HJEI]4=.OM,R24M72=D_56CG4KT-:A]2]T=!A6;4:UU`@#I96G
MBCZ<2#PR"N"*^3J5;M<>H6@X4H3TM]D;WP6U-U[$W1!N.FCE[%JHMJ=I8N?*
MX*LH9\__``W*?PK=--D,3/'15V8P&=P3XVOKI=4E909"!S)41PTTOM0MW9VU
MS9W44BJ)W\.4:ER[`Z'(K\09=!;BRL*EJ`]5$4]Q:W-I+$Q,*>)$2#4**:UJ
M17258,%_"RFE*D=*O;]?M7L3+)V;V#E,QBY\D[UG4)F1Z?"[#V6F4KL=C=P4
MTCP5V'Q^[=[QXQJVKR->MQ054%'3.$BF,CEJL&X2?O.Z<D,081Q6-`2%8"A`
M>2FIF(P"J`]IJEN'>U06,2Z6`_4/F[<2*_PI73I!R021G!E,#C*\Q5;5^ZDW
MC@,E3*M!'5XS$:A2RJZ2";(8M(*++4U3`P!O3K?DDD&WL_56SJ?4A'F!_A&"
M*?+HM)HP(&DCH!]F[=P^(RVX?C1OW%T6?V9%#3;YZ=AR\)J:6KV%C,UCJIMG
MVG,C2Y+I[=0I$IGUZUQ55C&'KCE;V0VEO#`\VP7:![2FN'4*CPPP.BOK"VG2
M:UTE#Q!/1K,[M%%NMLVB:NB2GD^FFK[)%J3BFH-Z]`-VC6YKY"=VMUGUKBMY
M==;@VICMP;&[PW]6FDQT*=59BK@JX,)C88):TY>JW/+3QU>&J`T,D"33G_-/
M4@!_<VEW_>VVO;HY8)85:.ZE-!^BU"$49U>)Q1A0@$^1;HZL%CV?;1?WQBGA
MD*O!'DUE&"QX`:.#J:UHOH.CX[+V9M3K/:.)VAM/'4N!VQMVB,%)31D)'%$F
MN>IJZN=R#-4U,K/-/-(=4DC,S&Y]CBSL[7;K6*TM(ECM8UHH'`#_`%<2>@M=
M75Q?7$MU=2E[AS5F/$G\O\`Z!WL[(X?L/JC!]Q];U,6YZK8-=3=K[#R&/:II
MQFH=OK6TNY,-"6BAJWAW-M2;)8TQ,JAI9D8@E%]E>X2QWFVP[KM[AS`WC(17
MN"5$BC%>]-:C'$@YZ76<<EM?2[=>(4$OZ;@T[2::6].UM)^RH\^E3U=EL;'D
M<]@<77QU>!S<%!VGL5@RKKVEOWR5U5#2P+%%XJ2BW(M3(BGF.&MB6P`%UMC,
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MU[KWOW7NL'_*2?\`E@/^MA]^Z]UG]^Z]U__5W[J+_@)37^OA3_H4>_=>ZE>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZK_P#DM$_8_P`P/@CTM]I1Y/!;5W%W!\MM[4[N?N*&
M#I;95)UMUO4R1JX(@;LSO>BK(M0*M/B@1RGOW52P#!?,]3OYD>6KY_BUG^I,
M%E5Q&ZOE!OCK+XJ[=J6B>4>/OG>^'V1O:4^,%XEQO5];GJUI`+QK2EAR`??N
MMMJH=--7SZ.!FZO%=<["R%3BZ&@QV(V;MB1,/BHE6DQU/38;'>##XBGCB`6"
MF_8BIXD4<`@#\>V;B40033'\*D_L&/Y].PIXDL<9X$@?EY]%\ZZVS)4=OX/%
MUHCGAZ(ZIHJ:J,DS5$H[3[AJWS&ZZ\3?2:6FP6#&ER2`F7<`"]_9#9Q>)NRQ
MDC196X!'_#9^YF\^"KPK3O-.C.X<K8,Q8UN)JC_FG&"J@_+4:4_HCTZ7E#V;
MUAW+N3LGI.IV]F]PQ[<?(;;WI%G-G9*38V0:&''-78V'<4M/+@JVIC_B<8\/
ME6I5T9E0:-06)N&W;I<7VTF)I/#JLE4/AGA5==-)(U"JUJ/3'336EYM\=GN"
MRJI:C+I8:QQH2OQ`&G&E.BQ[QQ^8^-&[]C;N[%R&\.POCMUC1;LEZ]R%##)G
M=T]<[FW#CXL1C<;V`9ZC[K=&"H<))5XO;^5-IZ-J[[>L=M44S!J]#\N7=G>;
MC)-/R]!J,9'>\+OVJ),ZI$"DI$V2NJC$X/1W;,-ZAN;:S2.+>)R@=<*DJK5F
M*XHC%@K,H(#::J.*]#UV+D_-USB,3LO"/LG>GR/S&%P\L:TE)3;@P\^Z<!%4
M[SW/F%Q\O[V=VEL##U),XD<)5T\":[:;B"^>MC'#9P&&YO9`O`!E+K61V`/Q
MK&I-:GN"@GHHLA2[:6[EUV]JI/$D'2>Q5)_"TA&,8)/'H5,]@>N-O[+Q&W<_
M%CL3LO;U-C*#$XN:NJ:*C6GPM*M/C,=%34U1%-E%BIH0JTI$WE*CT,;>S40P
M0P10A:0HH`&>`%`,<<>71<9I6DDF)K(Q))IYDU)^6?/IKQ^0W!74T..ZWVAC
MMG[>\C$9W<N*DP\`C,I22?"['HA09.J>:*TD;UKXY#^5;Z>]*SL=,,06/U./
MV+Q^=33JI\RS5-/]5>D5N'!8?/?QC:T=;N;LS>M5%34N2R/\33'[=VE+3Y''
MY",5K4])+M3`I%D,/',U"M'79"H6+1-%+&S$MSQQSA[=M3.:5IP4@U!],&AI
MDGS!'3B.4TL0`H_::BA^?#YX\NDCO_!5$U#444.Z<KO#/[-7&[MSV+QNT]K?
MP&@&$(K*NAR60P>)V[E_O*BFCGFH,;!D:>MJ9XHA*4IW<L77EJ2CCQ&D="'*
MA5`P:Y*A2<5(74"2!4TK51;RJLHHH16[:DGSQ7S_`#-#3B!4#ILP&/JM[Y"+
M";1%.L`AI:C<6ZGQA_A^V\76!F?'8S)8'M'<--)OVHIRK04SATH8W%15+8PP
MSZB5IY%CMU`92-3$5"CB5&F1OU*$?$.T'4:X!>>98U;7_O-<GYFJ"J^M"*^7
M2'FI.O\`&[@-)!4T>5Z@Q,=?MO+9?';APN.JX<!"L_\`%,73X9\Y_%-Q8F#,
M1SMG,]1P)E<BLIB5IXH9G=.5MXI"D*D[:JE7(:M%XE0NK416I9P"Q':"0.KA
MIG;Q2U+PD,*C%132<+0&E`JGMQG)'2WR6`CV-5XNCF-)E-E9-:>79&]Z>&2L
MH/X<E*DM-@MVYNM[.VI@J3(-&RKC*U52FR,`6.PJ5'F=,*P-&ITFU-/#<<`H
M`HK,9%%?X3^(4&6XM^(LZ2$K^KG4">)).5`0G'F*X^SI*4FW9J#K?8N\Y<Q1
MO1Y[*["Q,-%X8Z*.CFPV>W1/'739"IWSC</6TM<M8%CB2LI@C<BKJPRAF0@%
MM!>*5"2/&*'RTL]34R9!K7344]6Z?+#ZFZC"$41C^T+Y:308]/3AU$W;DER&
M(R,5-C:>NP06MH<MDZQLG@\;E?MZ6-LA18S<U#V=NK$)A,2E1JS=?&)GAI=<
M5(KSB62GW/I>-\:H=)!;*JP(R`XD;M\G(!-,)4U(:J0ZXK.#@4!TFOXE**?L
M'#U\NN>TL%M#<56FV-^UU#2[>W108W%[1S.&SNVZ2AW!N%2<CAZ>IQ5+E:C*
MX!<2U/'-@,9)3Q4%1(DSU$(GECIO;=O'!<ZK2[6-;=U4+I9:,W$=M=2@4!1<
M*3EE#$#K<K20L7ARXKJ!'`$4;RIFO<1D>1H*]9MVQ9#`9&EQ^[8Z;#9?:N<Q
MV8R6:H\5"^*SNWW?(TT>>VK1[T["S]+EJFIBD6&HQPP]5-15LEB\49@J_;\_
MBHT4<[A)5D!+T&E@:Y0/(:G(!&EM+'T(;K<9$H?P5)!6E/,9%`Y5!C&#45IG
MS'6;-8_/5M/U/D-Y;FH\7ALKO;"5^5W51[>V%1T.SZ^AVUF,S@,-NNC&'6?&
M9JNK6HZ1C42S8Z-I?&X61X-::[BFC3:&O9PD;3J7;0@5"`S(#VXU'2I)-`3]
MG3UJR,^Y>##JE$+!5#,2U2%8@USI6K4\Q\@>N/5.QL7_``';$29>3#9.029'
M8M%G<++LZC[`QU'N7-1X;*UVZL)!C=QY/#[FVS44U4-L35!^T\H,]-44Y6,;
MV>PK96KR2L&75HKV%^]]+,R@,RNE&T8'#!'7MRO&^KN"@&IR"^=84E5U*`U1
M56J-?'&*'/0\+%MW&5BQ5M%G>DL[/,K)68:KI_[C96H05"4ZBI6FGV=6%D&L
MQ5M)15CER`M[GV?DHK4;5$U?+X3Q_P!K\S6G1/K8TU48?/C_`)^F[M["[NH=
MFT/9"S8[<&\>FLXF_-OU6%H),=4[@VE3T)H]^;=JZ9ZC(*:G<.SZFN5$@?PR
M5L5)*J*T:J$>[QR+:)?(:SVK^**#BH!$B\?Q1EAZ5H:8Z6[=)$;AK60Z;>==
M!KG23E6\OA8`_94=!YWKNCL':V\^J-T=(2;`B3OB2GZ^RFX\]M[SPSY!L74[
MBZ]SU;N"DFBK:BDHL6N2CHZ1U=)9*C2`S.H4HWRZW&UN]KN-E%M6\/A%W3!.
MDO$2ZD-0+KTBAR:>?1AM<%I-;[A%N8ETVH\0*K4/$(ZJIJM2=%3Z+UZ#XJ;U
MWX?NOD+WUO??JSR4]1/LS9;_`.C_`&'%)3REOMOL\;(^0R%'41FTHD>-G!M]
M`/=SRU<WP_W>;W<3J34I'2&.OI1>X@>56^VO38WJ&U4#;-LBAD!^-OU'_P"-
M8&:'`P>E9\;(:?:.6[MZ3I)6J<%UAOZGJ-K":H:KDH]J=@X.EW32X.HDD+N[
MXC+RU\2ER7:`QEKDDESEP+9S;SLD=3#:3@H:DT291(%J222I+5/H0/+JF\:Y
MX]LW.2GCW$1U$"E6C8IJQBI`%?4])CJS3L:MP^TY*B2C3J/M3=732TT[K55E
M;L#L"FIMW=7M/42LTZTU%'5XNC@Y`_8<`<6-MMK;%("*+;7+P#U\-P'C_95`
M#PH#3JE_68BY'^CQ"0^0UJ=+@?F"37/GPZ3G\R?$9*#XK;C[>VYBURN\_BSO
M#K[Y6[1@9Y4O+T1NO';RWG2?LO'))'GNK:;/XN1`1KBKF'-[>Q/T2,H<`$\"
M#^SHX^:Q.U.TMAY;!9)*3<>QNQ=HU^)KXXY/)0Y[:F[L-+1U21RIQ)293#Y!
M@&'U1[CW[JW14OY<^X,_F/AMTSM_=^A=Z=1X_<GQ[WC#Y_/4Q;C^.^\MP])U
MTN08LT@R&138D=9)JLS?<!OHP]^Z]T=OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%K**
MER%.U+6PI44[202M$]])DIIXJJ!CI(-XIX58?XCW[KW4KW[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U@_P"4D_\`+`?];#[]U[K/[]U[
MK__6W[:'FCIOS^RG/_((_P!Y]^Z]U+]^Z]U[W[KW5"_\X?\`F*_(CX0]A]!;
M:Z3R'7-#B^QME=DY[<?]^-D9'=E0]?M7.;'H,6:"IH]S[>BQU*M+GJGS*ZRF
M1BA!7206IG=%4HM37IJ9W0*46I)_U<.I_P`J_P"8-\BNI_Y4?QF^8FRJ_85%
MW%VM+\>VW=5Y79%9E]IF#LC#U-?NC^$[5_O)15="998E^VU5LQIU^OD^ON[$
MA"P&:=69B$+4[J</GZ=4M-_/F^?Q):/>?2?B/$<G^@ZM;UW0%&5-_P`C%_5P
M!P?]A[3>/-_OK_#TT)SI-4.ORP:=<O\`A^7Y_P!W3^^72)*:O4G1N0:P!"JQ
M/]__`!A6(_U^??O'E_WU_(]4\>;_`'U_AZ[;^?)_,`1K-O/I"-B-0BGZ/KU;
M3ZK%K=@*R!B.&(TD?X^_>/+_`+Z_D>O>/+_OK_#UQ'\^?^8!=6.\>C--P65>
MD:X@C3J`$G^D0*"5Y-_I[]X\W^^O\/7O'E_WU_AZXR?SZ_GXVH0[RZ-#(`Y"
M]'Y![*&"Z3?L2QUD_4<<>_>/+_OK^1Z]X\M/[+^1ZS#^?3\_%!63=_1?DMJT
M#I2N\@5@`@"_Z1/JYN5N.;>]>/+_`+Z_D>KB<U75&U*9P>/R^76!_P"?7\_U
M;6-X=%&*YT:^DJ]2UA8"1CV*JH+_`%YX/O?CR_[Z_D>JF>2ITQ]OS!ZY_P##
M]GS[9F']\^A5,>E7T=+9!E+.0=:L_8UV*(;:1^IC]??O'E_WU_(]>$TQ4MX8
MH"/7SZ\W\^SY]A;#>/1)<V7GI2N6[K<R)&K=C79]-OK;G\6M[]X\W^^OY'K<
MDTBNRK'50>.>L47\^O\`F!721]X=$O'R..E*Y$)/(69O](A,,R_@7]?]/>O'
MF_WU_(]:,LP56\,9^W^?65/Y]'S_`)'<#>/15E_3XNDZZ0,-7U4CL5B[?BP^
MMOZ^_?42_P"^O\/6TG;/B1D#Y`]1&_GV_P`P36$&\.BAJ*:".C\BQ-R04L.P
MV`DO;4/Q?CWOQYO]]?X>O&=](I'W5S@TIY=9E_GS?S!T:\N\.CO&XL"W1N01
M5!OZD;_2%^X\>GE?J0;^_>/+_OK^1ZT)Y-0#1]OV'H^G\O;^8=\^OGQWCN+I
M9N]>H^JEP'5V6[)CW+BOC<FZIZY\1N?:NW&PTV.RW:&,IJ:"J3<S3>99&=6I
MP@4ARRN12.Y(9*"GS_R].I(7=@%(0#S%#U<Y_H0^?1"@_/+KH$?K*_##!#5]
M?TAN\G"GZ?6X]O\`3O7ATA\^@P(^>?73+ILRR?##!&[<693'WE%I'UXY]^Z]
MUR_T(_/@D'_9\.N@+"X'PRP?)`_J>\6-F;DCZV^A'U]^Z]UR;I/Y\%;#YV];
M*;<LOPQP_P!>>0&[W8#_`'GW[KW78Z3^>P4C_9[.N&8A?4_PSPWI('J*A.]$
M%F_H;V_K[]U[KK_0G\][@CYV=;6!!*GX98<AAQ<'_C.P8`V/T(//OW7NN7^A
M7Y[7;_G.KK;21Z1_LF>)U`_XM_IWLP_V`]^Z]T3/8G5?RRWS\Z._:JB^7NQ8
M^R>A.C.DNKLIOFI^*V.JL3DL+VWGM_\`:M5M:@VDO<T$.$KL2F"Q-355Z5DK
MY&.KIXWAB^S22;W5*5D#`B@%#^?1P:'XK_('=G9_3&]/D%\H]L=M;-Z3W[D>
MT]O]>[<^.N)ZR_B>_P#^XN\-A[7S&4W2G9F\:W[+:E%OBNJXJ6.G03UH@=W`
MB"GW5B*D&O#HTO;*_>X7;NW&@6HAW7OO9^%K49BI_AL&6CW!E--KZFDQN#E0
MCZ:6)_'M)>4:..)N#R*/YZC_`"!Z?@^)V_A4G^5/\O2(Z6KXEP';?9V1J&J*
M3='9_86=AJW1%E7;&R)5V-BH%;59Z>&AV:\D5S:TI_K[+=J<>#N>X2<'N)37
MST1DHH^P!#0<!TMOU;Q+*S4=\<2+3RU/WG^;T_+HJW2LWR[VUU[0;XV/M[K7
ML/:G9E=G^U8]M9G.U&)W=C)-^Y:JW1)1-F%6GQ=1/IK@B(S2^#B,GTV`5VB7
MFV';_P!X6<%K=074C3A&8QR`2-JIJII)H?/X::3Z]'VXKR_)<"TN);B&YMP(
MV8!61M`TX7XA2ASC5QIT(G^S)[LW1NC8?3G8?QIR^V\MV-N.'#9*BWS78S)[
M/K=OXVEJ<MN7)8>:*@K(=Q5.(IJ%94IVB6.Y5GD2P)-?W_/=75EM%_R[)%)<
M.01*5:,HH+,0PJ&-!4+0>1)IGI(=EMX[.[W*TWJ.2.$#"AA)5C1:@TTJ2::J
M\<`'H<(F3=OR/K"9$J,?T[US2P)"4M]KO'M/(S3U$ZN`/)/2[1VG$H!)$<>1
M;B[W]FPTW?,#$/5;."E/Z<QJ:_,)&M*^3]%1`AVM<?J32U_VL8I^PLY^55^7
M2TS"[!V7E3N+)P&KW5F9IDQ:L*W<6Z*^6TC?PW;./D:LJZ6F19=!2E2&FC4@
MRE5NWLU;P8F!;,AX<23Q./E_(=(06(":NVOY=-65BSF>Q]5EM^Y0=>;(I`]1
M4X6BS$=)EZVB6554;LW332I'BZ>H50&H\9*'/DT-5R7*>ZL6TL\[!(1Y5\OF
M?\@_;Y=>[1@"K4_U4ZQ8BBR&YL=3XK:]%4]<];PJZ4M30T_\&W5N*G+G]S$4
MAB2?:F)K&+2&KF492I#:D2G+"9O*"ZA8P4A'[2/EZ#Y\?LZWVJ`2=3_R'^?_
M`"?/H4,+A,3MW&TV(PE!38S&T::(*6E30BWY>21B3)/43/=I)9"TDKDL[,Q)
M+Z(L:A5%%'5"2<DYZ++VYDNM\3D*FH_AFR*`TN7Q5%NO<6Z\CEL)LR;,9*:'
M[3:M72[?E4;EWGE*%C+('IJI<=01_<5?[2QQ.27US9V[2R$1J@8"1V)"ZC2B
MT7XW(XFAT@=WITKMEGE=436:`D`<0!FN?(?:*G`ST(6"WKMZMI:">7KG)0P2
M4T;T64VS@\;OC;$].G[438?.[/\`XFE12HL85=4,#J!8QBWLQCN(V1)%B-"*
M@J`PQZ%:C[.J-"RLR^**CU[3^8-/\O2;KL7L#[FIK,-TWN+,5:RR9+[+*8BK
MVKLU:R%ON_XC7TN[:K&[:IC!-")Q,M%-,DJB1%,@!]L.+9]1^B8Z:X8:4]:G
M51?G6AH<C/5AXRE3]0HQ3!J:>@I4]!CMS+;*RN[0N)K>K-_U=/D:RI3K7#9V
MNI\1A<CDWJ5KJGKW)9VJ78V^\LE/63#)K%3TIIIBRHU,6:)RZ.>VFN5A:2VE
MD`KX0.!6H_3)['-"=6`1GAP*Q[>ZCMA,8I4C."YR32F&`[D&`17!\J]"5A-O
M]88V/'43=>]CT.)V]/2MMW9V4VSO+,[1VW-1PO%2#;V!QHS6V**&C1B(/'>&
MGO:'0+>S.%+6..-%MY%C3X5TM1:<``*J`."@8`X8Z3-)<.SR&X0R/6K:AJ->
M-2<Y\_7KAOWL+:^+P%=65FRL#MG&UT==!5;@[:H:#:N%9Q`]2PCP++-O#=-5
M(\0/VM-2QO(;?NH?4&;ZXM+:"6>5(HP5/=)11PSCXV^P#\^M6]M/-*L<.IY*
MB@0%CDT&1@?;Y=2-A[:ZZW56XM<SB4K-Q[+6CSV#V_EMPUN\=L8^#(4E31XK
M?_7+Y>JKH*S;^>H*F5:2MB]4&MX'6*:-D&[:*RND@UQ(S1@,N=:BHHKQDUJK
M`G2P^PT(Z\\MS;^*BLR:@4>@TGCE'X9!&0?3I;[^ZVH=PPY.NH,5B,E/E:,4
M>Z-I9N"*3:G8F-A*20X[<E.\$\<63I6B'V62$;RT[`)(LT%XO:Z>WBGCD22)
M'1Q1E8`JP]&!!K\O3IB&:2!TDCD9'4U#*2&4^H((ITE8U>MH<H<9BYMY[5^Y
MT;OZMW*89MV;-R!U5$XVX];+)'/&@D$D%!+-X&0+)CJI8]$3M``1D(FJ,8*&
ME5^0_P`@X4IIIU8AE8$M1CD,///$_P"7^?3KA9*[^$35FPLDG8NT&EJ*"NV=
MN>L>//XEHVECK,-19;,1"J2>E$BHV.SB^156QJ8U('NZDNI:-M<7`J>(]1GS
M'"A_;TT3DDX/R]?]7ITL]D1;4?#5E'MO%U.)H/O*A,GMW(TM=1MB:ZIBCEJ\
M<V*KV>GH8#',#XJ7_(V#:HM2MJ+T>@I^FM%J<4\_,4_U#TZT:@UKGHM6V.N3
MV%TEN7I;^,5.WMR=+=C9#;NQ=SJ@GK]M5NQLS2[JZCW`M*Q02Q4VT\CC(WC8
ME9H/(MS>X"T>V'<=CN]F,S1S03LL<E*E#&^N%Z'C1=((_$*C@>CY[SZ/<H-Q
M\,-#<1`R)Y,K@I(OYD,1Z&GF.DK7]K?.+&TQVJ_Q_P!GY#<ZP^`;_P`9NNGE
MV5*JJ8CEFHZ^LQ,U-(UA,8I9(PG(*$#3[3/N7.<:FU.Q0M<!?[82CPCCXM)T
ML,\5)Q\QTI6QY98_4-O$BQ$U\/PV+`<=)85KZ5`IYUZ'/XZ=197J_;6>RF\,
M[#NGLCL?<$^\=^;@IV\E+/D9X4IZ#%T$HC@$^/PM"@BC<1QAV+E41"B*:\N[
M1+MEO<3W<XEW*Y?Q)7'PD^07RHHQ6@KQH,`%F[7Z7LL,5M$8["!=$:$U(%:D
MD^K&I/[/+I"=D4%1B^T.S(,>_P!HV\NF]N]B4U1=6E.YNE=W%I9:*$7D:I?$
MYJ@1BJECXDY%A9J[0Q;K?!302VBR</Q0/D@^NEE'Y#\K1%9-NMB?CCG9/]K(
MO^<-^WHRNZ=N;?[*V-N/:.<@&0VKO[:>7VYEZ8@`5VW]U8>HQF0@*R*P`J<=
M7NMF!_5R/8D1@ZJXX$5_;T4$4)!X]$2ZJZ6_F"]0=8]>]58'OGXF[@PG6.R=
MK]>[?RVY_CWVZ^?RN"V=AJ+;N&R6XZG&?(RDI*C/U&+QT3U;P0PPRU)=E1%(
M46ZUT6_XN[<^:FU^U?FAU'L?M7XLX[*[6^12=H;UCW#TGVYF,?7YOY"=;;'[
M,J<ILVGH^]\-)@=JU&5JJZ+[2IER%3_%*>LF-1XI8HX_=45B6D4^1_R='17;
M_P#,850I[8^%LA46,IZ"[O0O_M9C7Y'LJ$_T!(]^ZOUQ?`_S&U5?#VI\*97L
M`PGZ%[RC2_-V4Q?(QF'%N+'_`%_?NO=8/X)_,FU'_C)OP>T<V/\`H,[ZU?BU
MQ_LP]C^?S_Q3W[KW48X;^9E^.QO@K^.3TMW^?R;C3_I\'U7_`!^OOW7NN1Q/
M\R\?3?WP7?T_0]1=_16?_7_TW377_8`^_=>Z\,7_`#+_`%7WQ\%SQZ+=6=_+
MS;G5?N)K`G^GT]^Z]U&7'?S.[C7O#X'6YU%>M_D$#^LZ;`]JG_==K\_J_P`/
M?NM&M#3CUKKR_P#"D'Y)4];EJ)NK?B=,V'SV>P52Z[KW_3EI<!F*_#5$_A;.
M3M&)9<>SZ"VI`P4W()]IGF<,0B'3\P>DWCN*,P73JH?7]G6(?\*2?D=Z&_T4
M?%/QGDVW=OXN1^?IF/V[?ZS7'NGCR_[[_D>M&YP:#NK_`"_S]3%_X4A_(Y@S
M#IOXM,B<F3^_6_$5P`2ZQ@U#'6/KS^/?O'E_WU_(]7$X4#Q.)SC/^H]<H_\`
MA2-\BV4L>E/C`UM5E7?V_5,A`XT75P/\;_CGW[QY?]]_R/6A<KW5&?+_`&>L
MO_02%\BRUEZ4^+Y^EU._^P`UR`0.(#8J/KQ[]X\O^^OY'KPN4TBM==/RKU[_
M`*"0OD9J8_Z#OC)XU6^D]@[_`/*2+EF&FE90BKS?WOQY3_H?^'K0N02E1BF?
MM^7RZEI_PH_^0YC5FZ(^-;7YUQ=C;]:-DM>Y`QC/$S'@`W_WCW[QY<?I?R/5
M_J8OG^SJ7'_PH[^0#!`W0?QR9F;QC3V7OM-4F@M95."D*@?U/X][:>34=$9T
M_,'KWU,?H?V=<O\`H(\[_OS\>_CV%M>Q[,WT7O;F*PV]8R*?]@1[UX\O^^OY
M'II;DU&L#3\NLR_\*.>_AI+_`!Y^/K@J&+1]G;Z')O<`';;6TCDDGD<"Y][$
M\FEJQG5Y8/\`/IYIXU)!J?LSU+@_X4;=[L2\OQUZ$,2Q:F\?:>]U<,2""#_=
M.6X*`^D+>_NOCS?[Z_P]:,ZJ[`Y6@I3J6O\`PHV[M!)?XU=)E0`=*]L;T5SJ
M)TGU;'(`T"_NRSR5&J,Z?/!Z]]3%\_V=9Q_PHS[LTK_SC)TSJ-R?^,N;TLR?
MV9$7_1^2$O\`U_'N_P!1'Z-^SJOU*:C6NC_57K#6_P#"CSN>CQN2K?\`98NF
MIY:.CJ*F&,=O[SAC=Z:GDJ&CF?\`T=S,%DT`*5!L?J/?HYM5`R$$GTQ\L]>:
MYC`;2#J^SJV_YE?S(=U_%KXA?&GY+XKJO;&[\QWS5=;TV2VGE]XY;`8K;9WU
MU9E^PZEJ#,4FVLO6Y0X^KQ@I(Q)2T_DC<R-I(T%YB0CL!D#JTLK(BL`*G_-T
M:'X%_*/)_,GXR[+[^S&S<?L'([IS&^<34;8Q6>GW+04?]S]Z9W:D<\&8J<5A
M9ZC[^+#K.RM3(8FD*7;3J/E-54GC3IY355/J.CC>]];Z][]U[K#;_*+_`/-D
M#\?ZL_['W[KW6;W[KW7_U]^ZA_X!TW_+%/\`>!;W[KW4KW[KW7O?NO=5(_S)
M_P"9W@_@'N_J/:>7Z`J^YV[0VQO;<45?!O?#;33`1[0RNUL8U"U-E-L;@?(/
ME'W*'#JT*Q""Q#%AIH\BQ@%JT/5'D6,`M7/16.]/DW\DOD/UU_+V[9I/B/L;
M:NP=]?*GH#LSI^&?Y,XO+U^\J_,[`[#R6T]E;JQ,/3U%1[%BRN(R$SU%8)LI
M]A44RPFGD9]27!\^JR9,)\M0_P`!ZL6B[-^<HC4CX!])0-<_M?[.-CO3Q]=4
M7QM9?43^/?JGIP%C75@U]>O)V=\YCZ#\`^DTC-K_`/.8V-/J+<DHOQNMI`%[
MWO?\>_5Z\2]308IZ^?IP_GUU+V9\X]?/P!Z3G]%O(OS%QAX^NC][XWQOIO\`
MX6]^J>M@F@KQZQIV9\XF4J_\OWI1%*L60_,3$-J)`&A0/CD58L/ZE1_C[]7K
M0+&M13/7E[-^<@8A?Y?G2J+8#5_LXF'%P+@#2GQR;](_V'OU3Z];J>NG[,^<
M0-Q_+[Z4D=@NIA\Q,.!9?TC6WQR#L5_X+8?CWZI]>M`MW5&*XZZ;LOYQ%6!_
ME]])LOU\9^8>')8\'])^.7COJ_J?Q[]UXE@.T5/V]>3LGYOD!O\`AOKI2-KC
MAOF#A;@C^T#'\<W'%^/S[]UHE^ZBUSC/EZ\,=>_TE?.`NU_Y?72G"ZA)_LX6
M%.J0_4#_`)QSU`6`]1Y_P]^J>M@M4@\/+_5Y==GLWYR6*?\`#??2IB+!F7_9
MQ</RP:P<1GXYZ"0.;D@^_5/KUOKM.S/G&@_;_E^=)Q>H\?[.)B$MSPW[?QQ;
MZ_[?W[/6@6J01V]=IV=\Y-=O^&_NE474;O\`[.+B?IR=05?CC<ZF_P!8^_5/
M6ZGKF_9OSETK?X!=)R+JX0?,7&DIZ"=;!_C<J#U>GTDG_8>_=>J>I%)VO\[*
M8^2G^!73M%(0J$P_,G'1/H8W<%H/CH+HK"]K\^_=>ZE_Z:/GW=A_LB_58`_2
MQ^:5%ZN2/H/CT2H^G^W]^Z]UP;NKY_*1_P`X)]5N#KN8_FI0>D+;1<2?'J*Y
M>_XO:WOW55+DG4H`^W_8Z['=7S[+,#\%.KU46TN?FCC?4+7-PO0!*F_`_!_J
M/?NMFN*"N>N0[J^?)`/^R*=9`DGTGYGXNX4$`$D=!D:B+FPN/\??NM]=-W7\
M^`UO]D3ZU8$\,GS.Q.D+?ZL'Z'1@;<V`/^O[]U[KH=V?/G\_!+K2US]/F?B2
MVD?0V_T"A;G^E_\`8^_=>Z]_IM^?%O\`LA#KF]SQ_LYN$Y'X-_\`09^?Z>_=
M:S4"G;T[_$GK3MS";V^4G=O=^QMK]:;W^0G:>R\YC]C;7WV.RH,!LKKGI?KS
MK/!)D=W)MK:<-9D<GF-O92N:".C"4T=4BZW;4??NO``$D#)Z.Q[]UOH'NQ,J
M<=O/K-I#(:+'#L#=%7$KHL<@P.S:NEC,B,"6T?QIBI'Z6(/LMOI-$UH?X1(]
M/+M0C/\`O72F!-:2@#)TC]K#_-T%O7.6VIUM\/-J[A["AGKMIIUE2;@W73+C
MY,M49"CWJO\`%<A2MC8@7K7KIMP%&B`LVLCZ>RZTFM-MY8@N+X_XF+8,]17#
MBK"GG752GGT87<<MYODT-J*3&;2OE0J:#]E.E%U]N[H[JWIF3>6#QF0ZFZO&
M4R602@W;A]Q;:J8ZZOK_`+=SC=N[A#Y6&'+U:`T=/31+%*K!H8]+7-[.ZV3:
MMG%Y%&;7;2:T960U8TIH;NJ?(`?8.J75ON-YN9M9'$]^2%JA5P<4^)<&GF?V
MGIYZG[QZB[[FJ*S9\KU>=V>_W0H-R[?J,-N3$4N6BJL?%F\9!E*=:E<9EX(Y
MH!54S%)%#1L1?27MJWS:][UFSD)ECSI=2K@'&H!@#0Y&H8\NM7^U[AM0`N%I
M%)455M2DJ:E21BJFE0?//39U!%6YZ3OO<5+7KCLKN+N/=>$H<O'2T]:]'1;%
MQF$V%CV6"<M!5&EJ,!.X62Z:I""+7!KM`>1MYN2:/)=N`>.(PL2_\<)SZGRZ
MKN%$7;H1\*VZFGS<LY_X]TLI$VWUU-HQM!E=X=@9Z$B(2U$>4WCGHEEBC\V2
MRU68:?";;HY0FMV--CZ8*!'&9-,;&A\.(G2-4Y_:?M/D/Y#RZ0"KUR`H_9^S
MUZ<<;LRORN1I=R=@55-E\M1S+4X;;U"TS;0VQ(@(@J**EJ423-9Z,,Q.2JD#
MH3_D\5,MPUU0L0\OQ>0\A_G/S_93JNJ@*CA_/H2/;O5>D;V!+N"':67FVS]S
M_$HXHGD_AT44^9&+6>(YEMO05`:DFW(F*\QQZ3*T+58C#J5)'MFX\7PF\'XO
MYT\]/EJIPKBO'JZ:=0U&@_U4K\J\?ET5+9F)J)MX9ZMV[18O.;GVQ'CCU;35
MM?(<%@>F-]4M34S]D;6I\J(Y-Q]C[ORM)4TV?KLA)'4BJB,'D6E9OO""T!EO
MKE@H:6,*81^!89`3XB5%2[D,)"V010'2>XSG81VD$<>I87_M#3)D4_`?Z*@A
ME`]:GN&&[+[*VQAMXX.ERNP,8V7E>:LJL=M2.JVEO:HQ-06IURU%%TYE(:&J
MJZBNUJ3EXZ2"58I#',GBF(U/9V2W"5LU,U#4)57TGS_28`U.!J"C!-<'K:W=
MP8BJW!,?EJHRU].\&GY'Y4Z4M=@/CM0[8J]S;LVAF:_+8')18"NV'OK<NZ-X
MYF+=E1%%44>W),/N+<N<P5<M9%*D\5:?)C/L":QIUI4DE3RV^RK`9)K5M:$!
MHY&>0A_(%69E/&NK*T[JT%>O";<BPABE[&R&556H'F"%4CTIQKBE:=..>I=Q
MP[:P.V]V;+ZBW1@][5.&I]A8=,;C4VCL/*5%,TL^V(IJJ2FH]P>7!PR38:MI
MACWK*\2P'P1R4Q*N=:I#!/:0R6\@&C`T(U/A'#XA\#"F:C`*],QN=;RPS2K*
MHJQJ:M_2_(TU`UQG.>DY6=7+M(T%15[;R]+M*7(T5'FJ*;L?+[3\<%48Z)/[
MMT^S-ZB3)[@K)Y`E+C!3^.KD*01".1A(4QVFU@4:HI!#48\5UX\`H1^XD\!2
MI.!T]];-(*"16DH37PU)QG-5X>IK@9ZG[0BVMM6N3<6U^LMHT=:TIGHJ;/1[
MVK.P*2D>D,1\^\LW@<Y38_)30R:I:5)_$@O"TSO=@HMX;6WD\:&T17-14AB]
M/0N0?MI7'#CTW/<7-P-,URQC^5`O^\K3]M.DICFIXMS9J3K"ESV+P>/.(J]G
MX:KI#15>S.Z]XSKD,IUOMZFJ(E6+KG-[;C&7W7BY7^RQBO%5T&F5@*9%&$CN
MIH[*HMU;M!K5)WSX:_\`"F0EW2M$.5I4!54Q:2TMI)P/J&#5..Z)>T.W],-5
M5;BPXUI4GT@\WAA^Y\7W'BC\_@U^'S:!Y?#Y/7XM=].KFWU]B@5H-7Q=$1I4
MTX=([<^TY<E54^XMNUJ8+>.-C$5)E#$TM#E:%6:1MO[FHXWC;)X.=W8K9EJ*
M.5O+3NC:P]&2IUKB0?S^1^7\QY=75J#2?@_U9'SZ1L4%/NK*5-50/-UQVUC*
M:EER]*/!7QY&A3R4U,<I3#[6DWMM&=M24]6OBJ:<C2DE+,'C#(*222&/MN5`
MK7S'E7U4T-#Q^SKU2%IQ0\/]7ET,<'G\$/W1B-3XH_N#`'$!GT#RF$2%I!$9
M+Z0Q)M]>?:D5H*\>J=`9M*(X?Y`=P8XO^WNO:/66^(([%0*FE3<FRLG(.-+L
MU/MZA#&]P`H(M;V36P\'?-S3_?L,4G[-<9_XZO1E/23;+%Q\2/(A^SM<?S9N
MBX8;JS+?+[)9KLWLO>&YL;U`<_F\'U9UGMK(_P`)I:S"[9RU=@)MX[EJH?/]
MY7;BR./FGA2Q:*F,8#J/3[#T>TR<U23;CN=W*-J,C""%&*#0C%1))0U+.06`
M\A3[.CE]PAV".*SVZ%&W$HK2RL-5&(#!(P:`!00"V:FO3O-U95?$>MQ&_>O-
MZ;LR74E3N/!8/LWKK=N2DW'!08_=.6H]N4&[]FU4B15.-K\%E\E2-4T_JCGH
MO*;ZU7VH&U#E<PW>VW$K;>9%6:)V+@*YTAT)^$JQ%1P9:^8'5?WB-_6:VO[>
M,7^@M%*BA"64:BLE,,&4&AP5:GD3T,7;-&LW;W1`/C09^E[BV/+*[!3XLYL,
M9X16M>16EVBK6_VGZ>SC<(PVY;23\+B:-OF&CU4^>4%!T56;4L=SI\2^$X_)
MZ?\`/W^'H4NKLB,KUOL2O]>J;:F"64.-+BH@QU/3U(8?@BHB;V8V+:K.V)XZ
M`/V"G2"<4FEIPU'I>>U7375;FZ\5\D>C_ESWIVQU/\9:OOW8??76705+59'"
M=O\`6O7=;MC?/4T_:V$S=+E,1O[(8^HKXLMMK<V&>"II2Z#[9XW`8"_NM4`)
M(&3TM%^1OS'LNO\`EU;Y#6]07Y*?&]U#<\*S;P0L#;ZD+]?I[]UOKH?(_P"8
MP/K_`)=&_;>K_-?)/XUNW'Z>)-Z0BS?Z_'OW7NN7^S(?,/\`[UT=AWX_[F/^
M,UN;?G^_E^+_`-/Q[]U[KL?)+Y>Z;G^7-V>&L"5_V8GXM_6]F`/^DRQ(^H^E
MQ_3Z>_=>ZS#Y(?+0#U?RZ^UCP"!'\@?BNWY]0;7VM%8@?2UP?\/?NO=2#\C?
ME4+?]B\NW#_73WQ\5>/I_JNWEO\`7_>/?NO=93\COE""=7\O3N<J#8%.[OB<
MQ;_$#_38I"G_`!L?\/?NO=`)44LSR2RUO\F0U%1+/+4-)'5_`NM,TU5,]145
M$L\G:D;>>:I=GD9KLS$L22?>ZGUZIX<9SH%?LZCO1Q,0K_R7)'4V60_\X#MI
MB8D/Z3VQ^Y8#](^OOU3Z]>\./^`?LZX?PS;EO7_)<K`&UH`,#\"G_:5@!K'^
MEP:0X-PO/OU3Z]>\./\`@'[!UT^+V>K*)/Y+N2<V4WCVG\#9513J%K_Z75]2
MG\#\'WZI]>O>''_`/V#J,^-V,4)G_DJYEXV`\BIL?X%U#Z2P7_-?Z8`7(/)'
M].??JGUZ]X<?\`_8.N`QG7/K`_DJ9\(+!O\`C''P,&OZ#A/],=V47_VP]^J?
M7KWAQ_P#]@Z[_A?4Y<_<?R5]S+)=`[KU+\$JA2%3TE94[C_<T*;#^GT'OU3Z
M]>\./^`?LZX-B^E"K--_)9W>55`=*](?!B5S;Z(JKW+^H'Z<V]^J?7KWAQ_P
M#]G70Q'1@TE/Y+.\C<I8MT1\&E87N-3!NYKKH_/Y]^J?7K7A1_P#J)+B.A`S
MI+_)3WVY\CW\70?P>EB=RH#.K+W4JE67B]A]/?JGUZ]X4?\``.F^7`_&QK_<
M_P`D_LD:"=)A^.?PJF+2%;'3X.[@=.D6U&P]^J?7KWA1_P``ZC?W5^*QT:_Y
M*G9R:CI)/QH^'S%!J!4OXNZ7+*2;\:K6YMQ[]4^O7O"C_@'4'^ZWQ*5W'_#*
M?;`8MK=A\7_BF074FUG7N(JW^&DE>?;81`&`44/'Y]>\*/\`@'0==N[2^)<G
M7'8"Q_R9^U,#7_W"W?%0;CG^,7QJCH,%.=OUY@RU=68#MJLR-+2XR9EF>2&-
MYXUC)C4L`/=_EY=:,<2@DQB@^72#?YJ_%G:'P6^(6'^<GPR[XWGUI@^L^BMO
M;6WUV!TCUKV!UCNWL.AZ=BI\?N79,E5V'D\DS;BV]09.LQ]74X^BJ)<>TA=8
MV8Q^Z/(L8#-6E>O2&,(I=>W[.K8?@?V5\<NV_C/LS?/Q1Z]/5O2.2R^]Z3;6
MRSLC'==G&Y'$;SSF+W14?W5Q4T]#1?Q+<M)55/D1B:CR^5O4Y]V!!`(.#U9'
M5UJO#HX7O?5^O>_=>ZP?\I7U_P!T#TW%O\X>;6O_`,1[]U[K/[]U[K__T-^V
MA_X!TU_^.2#_`&PM[]U[J7[]U[KWOW7NM2+_`(4F%AW'\1="ZG_T8]V%5YY/
M][.JQR!]1_K\>TMU\"?:?\'26Z^!/M/^#H^&TRA^"'\CPZR5/?\`\,[%+69O
M]#?90"G4OZ`W^%^/:E?A7[!TX_"#[1_@/5]OO?3W7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%[[N?PU(J1'(9:+
MI[O6LIYD`TQ318?:J`,UB5=TE.FW]#_3V2[J`6%3GZ>>GS[5&?V]+]O%9H%(
MJIGCJ/S/35+L/(=C?%/:VS,'7T>-S5?U;US5[?K:V*2;%Q9W;V.VYN'!+DH5
M'EEP\^5Q,,=4H!9J9W`!/'MA[*3<.6K>TBD"S-;Q%214:E"LNH>:DJ`?E7I0
M+H6N]373JVD3/J`-#1BP:A\C0FA]>@@BZE[T^0F^=HYGY(8':NR>N.O9SD8.
MM-O9E=S0;UW5$72'+Y"K`,<6&CM8)->5J?5"L:B>>0E3;3O._7MG/OR1P;7`
M0PMU(<O(.#.XQH_H^@I05/1F-RV[9[:XCV65Y+R;!E9=)1*951YDUX^OK0="
MMAZ7<FXOE`^XDZ\W'L_:6PNKMQ[%_O7F*;$4M!ONORVZ]MY"AI\#'C<K6U4N
M"PM-A99J>2JB@?54N%C07U&D<5S+S*;GZ)H[2&U:/Q#I`D+.C`*`2=*Z3Q`H
M3\^BYWABV46_U2R32W"R:!7],*C+4U`&IM0!`K@=*;XUWDZQEK'71+DNQNXJ
M^=?5J\DW;&\UNY8DLQ2-23[4[%FP+U^*>8_MF?CTQNN+L#R$47_5M>AY$<8D
M:4(@E9%C:0*OD:-&=D1GMJ*(TC$"]@6/]?9Q05K3/1;TUS;@P--EJ;`U&;Q$
M&=K8?N:/"S9*CBRU73@R#[BFQSS+63PWA<:U0KZ#SP?=#+$KK&TBB0\!45/V
M#JP1F4L%)4<3Y=._MSJO7O?NO=$ZW6F0ZX[*P&3V]BJS(RT6Z:K`XW"4<E#3
MQ9/;?=V/RE;!CJFIDC0T.*V]VOLH598EA24-5,8T8A8Y`]=^)9W=I+!&2/$*
M:10U$P)R>*JLJ`U\@30>71O;Z;FWN(W=02@8EJU!C.:>I9&H/4BGSZ%;`]6;
MKP]/E,NG9F6AWON/)/G-PY!,+@*W;=1D)(8*:'&PXBLQXRYV_AJ"GCI**+^(
M)-'#'J,GD>5G,H+22$2.UR3<NU6;2M#Z"E*Z5&%%:T\ZD](I9XY"H%N%B`H!
M4U^9J3Q)R<4]!3INK^O.P5W'2=F_QK;.8WMBHJK"MM^'`P8O;N;V+4BF>JVY
M#E*TY3/XK-RUT+5T5:]3-`)]-.\0IVE<M/:7+3Q7GB1_4K52-/:T9.5J:LI\
MP02*X(()ZLL\*Q26^AC$14$ME6'GC!%,$4SQK4#K'O'I^&=<='LG"XFBH<[4
M2XG=F&RY;(;<Q.'K0,G'N+#[6K:BIP,.>V[F:"-J2*DBIU,M7)(7]/JO/9*=
M(@C70:JRGX:'-:>JD8I3CQZ]#=,M3([:@,$<:\*$\:$<>/`=)O(]1[[C$%+N
M*OQ_<&UL325U#@\5DZFLP&[L/'F/-%59:BR%=79+!9O=&)CG5,=65K4TU)30
ME8Y5FDDED2MMLV5GD%Q`*A%/:R`X)!)8,P_"S4(&`:DDW6ZC"Z8E\*0\2,@T
MX"E*J/4"M?2F.EWLGL'(XS$Y?`=FP/AMW;+Q-7E*AYYH)FW=M'%TBRIO#&2P
M2/2UE08E\63AA=OLZ\$$+%+3M(HMKN1(YHKU&6>%:DX_44"NM:'\F'X6^14F
MDT"%HFMW#1R4]1I8FFDU_:#YCY@](/X]8:;)04&Y\O!KKX,'!N.JJ6I8X$JM
M\=NQQ]@;LKR-/E>JQF"RN*QD3M9HX(Y(U`1K>TNS0#P899'+S!=1)%*M-WL:
M>H4JH]`*=/[E(3-(@P@.D`<-$?8O[:$GU.>C4^SWHLZ][]U[I+;GVI1;EBI)
M3/48K.8B62JV_N/'>-,IA*R6/QR/`TBO%5457&`E523*]-51C3(ALI6CQJ]"
M<,.!'$=65M)^7F/7I[QJY%*"D3+RT<^32!%K9\?%-3T4U0HL\M-!/+/-!'(1
MJ",[E+VU-:YL*@`$U/5>@,DD\?RHI(A&_P#E7Q^R$DDPD/C/\/[&QBPQM#>P
M=?XDY#?D$C\>R8XYB4^MD?Y2C_H+'VGHS!KLSBG"Y'\T/^8=`5%V#NKXB5>6
MV1NKKC=N\^DI<YG,[USOOK_%KFJS:N.W%E*O.U>QMWX5989HY</E<A.*&L5Q
M'-1%%(UQM8G%]<<L>-:W6WS2[0'9HI(E#:%=JF-T!KVDG2WX@1Y@]&1M;3>H
MX;BWO8XMQ"*LB2$@,R@*'1J$=P`+`THU?(]03V%O+Y@9C!;0VOU]NS9'16,W
M+@]Q[_WOO&D;#9'>,&U\G29W&[+VYCM3$09',4-.U;.LDNFG4BZ7"R-F\N^:
M)K>U@L)8=E617E>5=)D"$,L:K6NEB`7/IC'FX+6UV*.>>YNXIMQ:)EC2,Z@C
M,"I=VX54$Z1YMG@.C%=R+X]X?':K4$RP]S/3!@R+IAK^LNQH)[ZP68,`!9;$
M_P"M[/MT"BXV5R<BZ`'YQR=$UB-46XK4T\`G]CI3I1]'OKZLVE8$".GR,`!D
M\MEI\UDJ=?W/[0M'Q_0<>U6V?[@V_I0_X3TFN?[9Z?+_``#H5_:[ICKWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN@"+W-^21Q:P_`_P`;>_=>Z[]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]T%/>XU=']RK]=75/88M_K[1S`]^Z]UK*_S4&9?Y-'\L5^%TT7Q
M7+?6W/Q3W("O'`!)M_3VFNLQ!3PU#^6>DUU\"_;U:!_(GD\G\M?J!C8VWGW<
MM^23I[BWJ`23^HV'U]W@4K'GS->GHP%1:#RZN`]O=7Z][]U[K#;_`"C5_P`V
M;?\`)]_]?W[KW6;W[KW7_]'?OH[_`&L%_KXUO_OOZ^_=>ZD^_=>Z][]U[K4<
M_P"%)U_]-'Q$(#-_QBSNY0!P!KW=U2#K:_`8"P^EOZ^TUU\"?:?\'2>X!81J
M.)/^3H^6T?\`L@[^1P%:X/?_`,,N2J\J.FNRF(_%B`.".;CVH7X1]@ZM)CP1
M_2'^`]7X^]]/=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]T`7<0-5F\!A%N)-R=?=SX.$J0"9:C;F'J54%FTABM(2
M+@_3\6]D^Z(SO$%&3#,OYE!0?RZ761T.LE:%98S^QNE3T74K6=)]0U*NLGEZ
MRV(6=3J4R+MC%I+9@`&`E4B_T/M1M#!]JVUEX&"/_CHZUN7_`"4;_'^C/_QX
M]"I[,.D77O?NO=`%\=':'9V[,([*TFV>X>X\(VDL;1_Z1,_EJ746/+-1Y6-C
M;CGCV3;'06MS%^)+J<'_`)RLW^!AT9;KFXAD\G@B/_5-1_A!Z%7>NYX=G;6S
M6Y):=ZU\;2%J+'1$B?+9:IDCHL-AZ8JDA%5F,M40TT7I/[DHX]F%W<"UMY9]
M)9@,`<68X51\V8@#[>D4$1FFCBU4U')]!YD_("I/V=![A^JMJ4&S,DW8M!B,
M[GLXDFYNQ-RUB-YJC."$5=758_*7CR.(Q>W%B$&*6"2)J"DIX_&5<%BFAV^!
M;<_5QJ\[]TC'B6.20>("\$`/:H`'#IYKF03`V[L$&%'R^8X$GBWJ2>@]Q\6_
M-NU^R=T4^[-ZRX[>.]L-MG%=?[NJZ#.G^Z%=%D:[(9S+U38V+-4FXQA\::^*
M,53"ABC\,_ED>8JQHG@:S>*ZD8/(%TO1JJ:DFM`P(`KQQ2A&3T\#%.)T:-%*
MH6JHIW#R&:4-:</F.C6>SGHNZ*OW;50XS<<V?J,I@L1#MK']59=*K<55D8,7
M4Y6G[1GJ<9AY#A\?E\LE=F:6EJX*9H*.I/D;U(5O[(]VE\$B5Y42-&B-34U;
MQ,)106JWE0'/ET8V2EM**A9GUKBE0-&3D@8P34CAQZ@)\F4E9!'/UZ?+,\40
M-?VP"Q50UFOTZH1OK]>#;@D\>V?WY\XN'I-_UJ_V>G_W:G_#OV1_];.N+?)B
M0.463K<L93$@;+=LAV<`G2$'3+%FLK?0VX^OOPWLMP,7[)A_ABZU^[5K_HNG
M[(_^MG7.3Y)U%/(Z50Z\@$2*\BRY+MN&4!SH1M$O2X_;9^`>;^]_OH@D$Q#\
MIO\`K5U[]VH>'BT^R/\`ZV=8W^3L2:BU3ULJQR,DS'-=J'0%34VD#IKU.EQQ
M?D'ZCW[]]'^*+_JM_P!:NO#;13(EU?8G_6SI$=F]P[4WSM/-X7<LO5-,IQ&9
M6ASM9F>S]6W)JK%U%,V8CJTZEH9:-:6*75.JU$2RP!D=M!/M-=[G#<VTJ2-;
MZF1@"3*`"01Q\($#.:$8Z<M[.2":.15DH&!(HF:&M*:Z'HS'4\<5/2[LIHJR
M&NCCW)024U7`\)AK,;-L?9W\,KZ=86:-*2MHT5X@.`O`^GL[L1I^HC_A<#'"
MFA--#YBG#^?19<-K\(TH-)QZ=S&GY5Z$'<.<H=LX+,[BR7F_A^#QE=EJT4\8
MEG--04TE5,L$99%DF9(B%!906(N0.?:N6188I9F!THI8TXT`J>F44NZ("*L0
M/VXZ!Q=U]P[ER=5M6#;VT>L\DV,ARL>5R^<J-]5O\'KFDI36XC$8S&X3$3Y;
M$5:Z*B*>N>"&5XB/N(I`60+/N$[>&((X:@&I8N2#Z`!14'C4T''(Z4O':QY$
MK2"M.&D?M))H?LK]G66II\]UIN39=94[ZW)NO";TW(NT-Q4.Z?X94K2Y?*8N
MOK<#G<!+C<?BUPBG*XS[.:B57I9$K59%1X1Y-E9;2:W/U3O%(^E@U#D@D%:`
M4R*$<*'`J.K@QW,4Z^"JR(NI2,8!`(:M:X-0>-1YUZ';V9=(>@`C1JCY2U4J
MKJCQ'05%#,X9?VY=P=AUTD$;+^J\B;;<C\67_'V2@5YB8T^&R'_&I3_T#T95
M`V<"F6N?^.I_T-T/_LZZ+>O>_=>Z`KM=EGW_`/'C&!2\DW9V:R:H`?3%A^K]
M^2RS,?TA(C4*.>26%N?9+N9U7NQQ>MR33_2Q2&OY?Y>C"S!%ON4@/"$#_>I$
M'2CZ5B$75NS=)8K-C9:M6==#,M=7U=8K%>;:EGN/Z@^UNW*5LK<'C2O[23TF
MN?[9_P#5P'0I>UO3'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
M%@QMI;39@3P#=1]5Y^EQ^?Q[]U[KE[]U[KWOW7N@L[S%^DNX@#I)ZL[!`8?B
M^TLN+_[#W[KW6LC_`#3RX_DQ_P`L15/J:D^**Z](`4_[*IN0ZCJOIO\`2WU)
M/M-=?V0K\.H?['\^D]P"0@'$GJS[^1(?^Q;/4OITD;X[Q#*;75O],>];@VXO
M_K>]VW]F?MZ?`HJ@\:=7!^U'6^O>_=>ZQ<^?Z&WA_58:;Z_I?ZW]^Z]UE]^Z
M]U__TM^^C_X"P<W_`&U%R`";<7-N+GW[KW4GW[KW7O?NO=:C7_"E'6.YOB(U
MB8_]%_=8](&H.-W=5$/]"2(UN>/H?K[2W?P)]I_P=,7":U5:]U<?,^GRZ/KM
M`ZO@=_(Y950`]_?#$D%0HYZ:[*&H(#8.6-^.`?:E?A7[!UM\"$?TA_@/5^'O
M?3W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=!=V!'2TNXNJ\[/&TC4>]9\'QX]`AW9MG.XG]W7R4-?\`;"PY)XM[
M0W?;-8R^DFD_8ZD?X:=/PAF6=%_@K_O)!_P5Z2WQF6>DZ;VU@*R377[.R.[M
MD5J%M4D$FT-X9W`4\4W`TR?84,+6L.&'M'R^2-IM8F^*,O&?M1V7_)7[.E>[
MYOY9`,.$<?[=%;_+T*>]-WX+8&T]P[UW-5&BP&V,55YG+5(4.\5%1Q&64QQE
MD\LK`:42X+L0!R?9G<W,-I!+=7$@6"-26)\@.)Z10PRW$L<$*%I6-`!YGI1P
MS1U$,4\+K)#/&DT4B&ZR1R*'C=2/JK*P(_P]O\>'39!!((ST7'8^2IMA=C?(
M;!UT-:,?+N#:/:6+IJ"BK,OD:R#?>W*?;^2%!B\935.1J2^ZME57"1N`\W-K
MD^R.Q(M;_?(-!":DF``J2)%TL0.)J\;8]?+AT9W8\>UVN44U:#$37S1B17T[
M77\ATPY#<V_=YU,N]LAL3)[2VILB#(YW;.'W_'3XN!LG0T%:U/O?=]-0561S
M53/1PAEQF&IH%-.\AJ*FH6H^WCIK-]3=LMU+`4ACJR(V#J`(#O0DX_"@X5+,
M=5`-#P;=7MHW#S/16=3BAI54Q3)^)SQX**:B11W#DY=Q46V]FY*2DHLEE<5B
MMT]@0K+]M#A-KT/CJLFLXEJUJ:.#-Y>E-!#Y"VJ!:EB3X7]K6DU+%#*Z>)H#
M29I1?,T)J`2"*GRKFHZ1H-#-(`:`D+]OE^SC^SUZP;QJQ+VAT:\$BU%!65._
MIHIX0L]-)(=ERR4<J3H6C`DI7F*,#9E)MP?;=R6-]MA4_IU>OS[#3_+U:,`0
M76KXQI_PY_R=#-[,>DW12*6F@W[W-B89_MI*:BSV<[0KO$)Y!+C>OIZGJ_K2
M@,IF")]QN.HS69]*V+4R*;@D>R)U^HW2W04TJ6E;YZ?TXA^TNWVJ/3HS4^#9
M2O\`B-$'^V[W)_+2HSZ]&8W+N7%;3Q,V8R\LJP)+3TM-34L+U60R>1K9EIL=
MB<5117FK\IDJJ18H(4&IW;\`$@VN+B.VB>:2M!Y`58GR51Q+'@`.)Z+D1G;2
MO_%#U/R'1?MT8_LO=NX=GX+/;LR?7R;MDR]<F#V3DEI*G`[>V_#35&2I<CN.
M%&JLWO',+E((%>F>#'8Y%FDC2JDCCF8KN%N[E[>&65X?%#&B-0H%XU8<7-0/
MX5R1JH"5L;0Q*[HBOIIEA6I-:8/X13SR3Y@8Z'O;FU\3LW$-BL!#7&!7FJ;9
M/-Y?-5M75R*-<U7E<[6Y/(335#(-3O(Q_/LUA@CMXA%$#H'J23^9)))^9/2.
M21I7,DA&H^@`'[!0#\AT!^U<QOR;%Q[^I<]E]V9>CEGQ_9_5-3CZ'&OAZZG;
MR5&.V;1O''68O.;<AF!@6>HGI]PT>B02!IH*A2R%[Q8_JS(TKBOBQ`#M(S2,
M?Q+@`,2'&:@D'I1,B(PC9`$([6'F/4^H/F.(X>1'0YT&0V]OK;2U=#/!F=N;
MBQU33LRB6-*FCJ4FHJZCJ89%AJJ2IB;R05$,BQSP2J\<BHZLH,E:&[@P0T$B
MD?:"*$'S!\B,$'!H>D_=&X(PP-?\W1=.B9:C;68?9M?5)45>)I<KUK7U4U.U
M-593(=2S4";6S'C266`RYWK'=.-DJ#P3+2'BQN2C:7>/_%7:OA5AX<?"II(_
MTT;+J_I#&.C#<$!"3J*"0"0#C3774/R=6I\B.C$[QAI:G:.ZJ>MM]E/MO.0U
M>H77[67&525&H&P(\3&_LYG"F"8/\&@U^RF>B],.A'&HZ"?'SUU+UOU#V%IJ
MJZJVUM/;=7N&/R.]55;:SNW,7#N>=D0.:JIQK)#DBM[R?9LJW9A[1VY/T6WS
MBK$1H2?,@J*G_+^73TH3ZFZC![=;4^T''^KY]+KL==MY/957'FMPP8"@KY<0
M^&W-'*C_`,+SW\0HZK:V8H)%;QRS4F9CIYX_4(W"V8Z"Q]NWT<4]JZ22:0:%
M6'X6!JC"GHU#Z>N.JVS.DRLB:B.(]1YC\Q7_`"9ZQ]<[\CWECJBFR"4U!NW!
M2+0[EQ4$HDIC-I5J7/8*;6XR>T]Q4Y6JQ]7&SJT3F*0K40SQ1^L[DS*8Y@%N
MDPP_Y^7U1O(_D:$$=;N(/"8.E3;ME3\O0_TAP8>O#%"4;UF5S7:G?.[8:C[J
MBASNT.N:)BJ:89-D;:7)YF&!^7,<><WC/&XX7RPL/J#[1;>/%W+>+H&J:TB'
M_-M:M_QISTJO/T[/;(#QT-(?]NU!_P`90="IN?=N"V=28ZNW!6I04N5W!@ML
MT<T@]#YC<F2@Q.)IW8D"-:BNJ434>%O<^S*>YAMA&T[Z0[J@^;,:*/S/2*&"
M6<NL2%BJ,Q^2J*D_D.E)[?Z:Z*_V]62MVSL:2D8>;8'5'=W8E2+VD#/C-O[6
MQ(B]0L\DN3J3<CZ1^R#<7/[UL0O^@V\\I^1HB+_QYJ?GCHTM01M]Y7A))$@^
M>68_X!T.>P:";%[%V9C:F/Q5./VIMZCJ8S]4J*;$4D,ZFW]H2H;_`./LWM4\
M.UMT`I1%'\AT7S-JEE:O%C_AZ5OM1TWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%_=ZZNE^WETAM75^_UTDE0U]J98:2
MP((!_K[]U[K6+_FG@M_)5_ED2>3QVI/B/K"ZB&23XK[C#+J'`%[<GVFNO[,$
M<:C_`&>D]R"RHHXD]6>?R'VU?RU^IC>_^_Z[RXOJT_\`&8MZ60-_:"#B_O=M
M_9G[3T^!15!XTZN(]J.M]>]^Z]UBM^_>Y_S5K7]/Z[WM]+_X^_=>ZR^_=>Z_
M_]/?OHR#2P$?0QJ?H!]?\!Q[]U[J3[]U[KWOW7NM1+_A2FQ7NSXB%;E_]%'=
MUE8W1@=X=5`C1^&/U)XX'U]I;KX$^T_X.F+AW15*-0U_R=6![/*_[(E_(Y*$
M,I[Z^&NDV7U!ND>S1=0+C\_4?CGVI7X1]@ZV^?!/](?X#U?5[WT]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO==>K5^--OK<ZM5S?BUK6_P`??NO==^_=
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MJ33XY3,B>0`GG=]PMY$M/WDTEA=`_HZ1J&FA.574R$TH./D:CH3\KK93@SBS
M$=W!3]340IU5`J":!J5^1^1Z,#\*LOV[V#LK$;UW/VE29+8F*%9M3!;*QVW\
M`U<\FW2,0U1N#=,=(:V6.`4ZM31PD2S1LLD\S%M`/.3YMVO[1+R[W!38K5$C
M"BO8=-6<]WE@?F3Y=%7,D5A;736]O9LMP:.SEC0ZA6BKPH:UKZ\!T.'8*'9_
M<W4W8P:*'$[FARG2V[)'!+>3<D]/G^NZKTH3^QNO%3X]22`'S(_U_9W?4M=U
MVR^K1):P/_MN^,_DZE1_S4IY]%MKJN+&]M*Y3]9?]KVN/S4U_P!ITI^Y)\E!
MMF.:.IPV+VU0529K>6:S4$^2BI<-AFCK:>AH<#2A9\YD<EE5@"4[21PR)&\;
MZ_(L;K[V3PH3(Q40C+DYHHS@>9)P!_AX=)+9=<@10QD.%`]3\_(=!3B>G,EO
M6LRFX=PT.3VO09#;PH8,5N+(T^9W/O//4^77<&W=X=F0X]OX/'3[8KEO0;?C
M>>CC6>6.=1&L=,B`;?\`63?4W$12(I30Q#%\U4RTJ*(<JE2`22?3I8URMK'X
M,,BO)7X@"`E11A&3GN&&8@'`IZ])RG?/XJKV9BL#A9TI9^T,;6[<I:">F-+U
MUO")\C1=M]?Y>C2>>KI=AU6UI<GD<1/!&T43520D11_9AV"D\,L2PQL\9F4H
M`?[-C42HWI$%JRT\R%'X>K+)%(LKROW^&0U?QC'AE?Z8(%:\1GUZ.K[$713T
M57IZ2*B[/R6(J$"5W^BC'Q0ZT993)MWN#MC'[A34;AO%6Y&E+"]P7%_J/9%8
M`)N,H];=0/M264/^PD5^T=&5R==G&PX>,U?]LD=/Y`]/6\<KG*[?U?3T]#F8
M,SAGPNW>LVEVQF\I@*?(;ICI5W9V355<6-;!2/MW#UDE-3">J7Q"FJD*VJB"
M[=S-]24"MXRE5C&DE:M35)PIV@D9.*-7!Z:AT+&"S#PV!+48`T'!?E4@>534
M>G4;>>R]P;7GQFZ*S>VZ,]A=K!ZO$9G))2UN7Z]RDPJ8\CN7+TN*H\='O;:>
M4Q]7)1Y.&=!/BZ`M)3%1KE@<>V>.5)Y9WDB0U6M`4.=3$BFI2,$$=HX?*AN*
MJRK$JZL-3@0*4P:T(.:CB>/2G?N(28RHQT5#14F^:*CBK<S25=?')M?;V"GC
MJ9(>PJW/(T,5;L.K@I)):&6(K45SK]OHBE2<P+#<Q@'N&L*"17@I_%_I<&A\
MR*<>F='F3V>O^3I-[;V9NV65NR-LULE#G:B*/3!NB&2AJNT,?--'+55W8214
M\E3A&$":=MP01+)@*<Z9(Y(YI:.-*+>7Q3=PL!(0,>4@QE_G3"&E4\Z@T#RR
M(!X,H/A$^62I_HG_``CS^1ST)_7^V,MA9]V9W-QT&-R&],Y%G)]N86IEJL-A
M&BQM)C_142T](*[-9+[;S9"J2&&.:8BRG1Y)%%M"\9FDDH&=JZ1\*XSY"I/%
MCYGR]69&!T*M2%%*GS\_\O0/;7\5=W=NJJH5CEI8^T\^VJ%U(AJ,1TCUW@\_
M42*#QKRM;34[VO\`N0W:Q(]EELRR;E=LIP+@_F5@16^RA/YTZ73J4M;;4*5@
M_P`,KD?R!Z%_MVIK8NO=P4&-TKDMS)0;*Q\\A=(**MWQDZ/:5-D)Y$1RD5!+
MF1-]/44"_GV97S,MI,%IJ:BBO],A:_E6O26U`^HC)-`M6_WD%O\`)T"8;<^]
M,_28;K_=N5VS@MH/%AME/0S4M1B,CC=E(^.W-N'>&.DIW7<6`S^XH8MNT%/K
MB/CI:ZOIVUI&ZEZBXN'*6TS1Q1T6.AXZ*AF8?B4L`@%14!F'ETM+QV_^Y$*2
M22`LY-21JX`<-+`$O7.2`<5'2<P.Z<W083<6UMPXY<%E-M;ER.Z=N[0F'W65
MZYH<'FXI\#&*B**./=G6F;,1\>8H(Y5PM)D4IJN-%B;P-Q7,NB6*8!9E8L$R
M3'0XSP=".#J#IU`,,&FI80K1RQ9MF`&K^+&0<G2_]$\:5!((Z&K)4?4&+VTO
M>4NV,#3IMG:];NRESN.I*"'*4N-BH),K5T--58R413/4.I5J=9'BFJ3R&8@^
MUUPUC'`=TDB%(D9@<:@*5(!^9XBM">DL/U,SK91R,1(X%*FA/`$CY>OD.I?2
M6U,QMOJS#T^<_P`@WEN?^,[VW;+'$C24F\-^9*MW1F4,4PDBD?$UV5-.H8%"
MM.HM;VWL]M-;[=$+C%W)623_`$\A+M_O).D?(`9Z<W"59;R70:PI1%IPTH-(
MI\C2OY]5C_,C<_<VVMP8+K?LOL+;^YMNU55#O_:M5MO;M/M[-0?P2LDH:"LS
ME#%+5R1UN+J9FD1X7>G=U\RB,Q%$C+G"YWVVN(=NO;^.2V-)8RJ:6!0T!DH:
M8)J`#0TKBF!QRS%M\D4U];6A285C8,Q92'&0*BF0!4G(K0='I^*F8[8[`V7C
M^T.Q.S<;NC&;DIZH;<VQMW`X/'T.-IJ>LDI'JL]E*6ACKJW/B:F>-Z>-HZ:G
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M,]MJW`;K'?H)O;@[5RH//XX]^Z]UK%?S2O5_))_EE2C5K%'\/BERI8^3XL;C
M5E=S8`D'D\#VFNO[('^D,_ZO7ATFNO@7[?\`)U9M_(9_[=J]4+ZKIO[O1#J8
ML;CN/>A/)`L+G@<V][MO[,_:>GT^!/L'5QOM1U;KWOW7NL//W'^'A_WG7_K_
M`-/?NO=9O?NO=?_4W[Z+_@+!^/VQ_OOS[]U[J3[]U[KWOW7NM1+_`(4INP[L
M^(X7DCJ;NUE)*(L;_P!\>JM#%V!/-B`![2W?P)]I_P`'2>Y)41LI[@3_`(.K
M`=HW7X)?R.`&"D]^?#4$D7N/]"79K,%O]-0'!_I[4K\*_8.K.:B`_P!(?X#U
M?9[WT]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW6*>&&IAFIZB*.>GJ(I(9X945XIH94,<L4B,"KQR(Q!!X(/O1`
M((/#KPP:CCT3;'N^PM[]4;@J9&T8/*YSXQ;UJ9HS&[8S+3TN>Z>RC11@H(FJ
MZ:AI$D?2=>;;Z_4AD5M+W;;@N-*DVLA^VC0GRR3I6IKEZ#B>CJ)3=6E]`@)8
M+XZ_[44E_E4^E%-.C.G8.T7WN.QZC"4E9O6+"KMV@W!6I]U78?!^66HJ,9A'
MFUKB*>OJ)F>J\`1ZDZ1*65$"G_TEN;KZTQ`W032&.2%XT6O`$G-*5Q6M!T5>
M/,(3;B0B`M4KY$C@3ZD>5>'EUBVAUYM/851N:;:.+3!TV[<T=QY;$T+M#A1G
M9:2"CKLGC\6MJ3&U&4CI8VJO`J)/*GD9?(SLVK:SM;/Q_I8502.78#`+&@+4
MX`F@K2E>/&IZM-<SW/A>/*7*(%6N2%%2!7C05-/3APZZ[(V11]C;'W)LRMJ)
M:$9O'M'0Y2F++5X7-4DL5?@<]1,CHRUV!S5+3UD!!%I85_'NM]:+?6D]J[%=
M:D`CBK<58?TE8!A\QUNTN&M;B*=<Z3D>JG#+]C*2#]O2-Z^W!!W+UAD<1O*@
MCI=P0IFNN>T]O0RA7Q&[<;"<9N&FIY(R6AI:^.:/(XV8<O05=-.OZP?::RE_
M>6WLEW'2;NBE7T=>UJ'T/Q*?X2IZ>NH_H;P-`WZ?:\9/FARM?GY-_2!'3WUG
MN"NJ:+(;,W)5&HWML!Z3#YZ:4VES>.FB=MM;QCN\AD@W3C(/+*0=,5?'50?6
M%O;UC,S++;2_[D0G2:^8_`_SU+FO\08>1ZI=Q*K)/$#]/(*CY'\2_:I\OX=)
M\^D?N;.[-V9VW!E!68R;<&3VB]9NS!HOW&?QFUL?7Q4,6_\`'P78Q4&/J*E*
M7+B(":>B2&8ZDH`IJ\MM#?:1(/J&CU,N2=((&H#T!H&IQ%#Y9JD4SP,X0^"&
MI7RU4P"?6G"OV>?0]0S15$4513RQSP3QI-#-"ZRQ312J'CEBD0LDD<B,"K`D
M$&X]F'2;HJ._(,CUYV5B]WXS&UU>D=3GLU1XW%HTE3N/;6>HL>_:^T:*G+.V
M1W/AY]OT6[,51I:?("FKZ>!2X/L/WB2VEVE[&K,$U,0,ED8#Q4`\V72LJ`9-
M&'1M:&*>":VE(`90`?X9!\!)X!6!,9)X5!/#HSF"SV&W/A\;N#;V3H\SA,O2
MQ5V-R>/G2HI*REF%TEAE0D'FX8&S*P*L`01[.X)X;J&.XMY`\#BH89!'19)&
M\+M%(A6130@\1TE-\;U3;D1QN--#+N"HHI\AJR4IAPFW,-3ZEK-U;IJE=#28
M2B*D)&&6:NG'ABM^Y+#J:98E))`-*YP`/4GR'^'@.O*M<GX?\OIT78[0S6+V
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M!&J1O)1_A9N"K5FP#T_;6SW+L`0L:BK,>"@>9^?D!Q8T`R>@QZ'VO54T%5N7
M(UE/E)G3*TB9ND-Z+<FX=PYZHW/V-NK%D0P"7;^5W+)#0XMRNI\;B('!,;QG
MVEVNW,<>MV):K5/DS,VIV&,C5VJ?X5'E3IZ^G$CZ5`"=M!YJJC2BGY@5+4QJ
M8^?0N[]?;`VAGH-Y4B9';F0H)<7D<487J9<PF3'V,6(HJ6%EJ*G(Y.>=8:>.
M(B5IG700UB#&=8GAD29-43"A'K7%/SZ1QLZNK1FC@U!^SIEZOV:^T=N0)6Q>
M++UL-*M3`9:>H.'Q-!&]-MK:D-3304T-12;5PQCI1*J#[B<2U#:I)W9F[.#P
M($6A!H,8[0/A04Q11@>O'B2>MR2&1M1X_MJ3Q/VDY_ETPY]8]Z]H[6PM!$OV
M_5U2V[MR9V(:*FCR^6Q%9C<!LZCK(Y5ECDRN.R,M?DHM)7[*.F20::I#[22L
MMWN$,,8J+<ZG;T8J0J`^I!U./)=-?B'3\3>#;RL14RC2/2@():GGD4!]:^8Z
M1&^-OX+/;QVIT3MK%I0[=GR<7</:M+01R18J#;V)S(JMNX&2%HVHJ=NP=^4"
MR24T)0346+KRR?N%F2WD4<]U:[3`M(M8FF`X:0:JI\OU)`.WS57_`#5VC-;0
M3;B[?JT,<7KJ(HS#Y(AX_P`3+^1GO9_T4]![%U;LE-_9?LVIP\63WIE\+1[;
M_B^58Y`XK;U'',APN"IZC73XBAKI:F66K$*J]5)(?*S*$540VZS%Y+?F$&[=
M0I8YHH_"*X`R:TR:YKCI1]7<BW6T$Q%N&U:1@$XR:<2*"E:T\NH.+VYU_P!%
M[0WGD\)01[8V;0R;C[!S&+HB5Q&)84;93<,^&QY98,935;TDE2U-#H@%1([(
MJZR/=(X+':+6Z>"$16P+RL%X5IJ8@5H*TK047T`ZL\MUN%Q%XLADN&TH">)\
MA4\2?*IJ:4Z!CI7!Y*:382YN.6#/5&/W'WUV!`D`2F7>?;597)M_$UT4I,D%
M9@,+4UU,B@#2M"EN+'V6[3#($L_%%)F#7$F/QS$T'VJ"R_[4?+I9N4B&:=8V
MK$E(D_TL8H2/DQ&KS^+CT;?V(NBGKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@W[D%^H>U0?H>M]\@_[';&4]^Z]
MUK"?S21?^2'_`"S%+`J:+X=!R;:67_96-RDDDCZ&W'^-OQ[37?\`8?[=?\/2
M:Z^!?M_R=68?R%3?^6UUE:X4=C][B-2P<JB]O[O`4D?GCG_'WNV_LS]IZ?3X
M$^P=7)^U'5NO>_=>ZP,BM41N=6J.-BMF=1ZCI.I58*X`/`8&QY'/OW7NL_OW
M7NO_U=^ZB_X"0?\`+,>_=>ZE>_=>Z][]U[K4/_X4K$-W9\18PKE_]%'=CW%@
MI5-X=6`A6?T%P"21_3VEN_@3[3_@Z2W?P)]I_P`'5@NTS_S@G_(V+&[MWU\,
MR#RWJ;H_LUCSI-O1?^EOZ^U*_"OV#IQ^$'^F'^`]7U^]]/=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71(`)/T`N?]
M8>_=>Z['//\`7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<1J
MNVHJ5N-``((&D7U$L0Q+7^@''OW7NN7OW7NO>_=>Z+?W!L:CSM9EL#55!QF(
M[FP`V?4YB(A)-O=C[<2;-]:[H@;S1N*V&>GD$;+IU55#1I<E@/9+N5H)S);_
M``I<H5+#BLB]T;>@I0YI6JJ.C"RN6MVCF45DB;53R9#AU/R-:'Y$]"%T_O>L
MW]L+$9C,T\6/W90/6;:WSB(RO^X?>^VJJ3#[GH`BLS1TQR=*\U+JL9*.:*0>
MEP2HVJ]:^LXY94"W2DI(H_#(ATN/6E15:\5(/`]4W"U%I=/'&2;=@&C8_BC;
M*G&*TPWHP(XCH3O9ETBZAT&1H<I3FJQU73UM.M15TC34TJRHM5054U#74SE2
M=$]'6T\D4J&S)(C*0""/=597%48$5(QZ@T(_(X/SZV01@BAZ+_V)'-U-O1>[
M<72R2;2S5/CMO]Y4-)"9)*;#4-X-M]JQ4\*F:>HV.)FI<MI#O)@I3*0?X=$C
M$-^#M-V=YC#&T<!;A14X&$F"CB4PLGK'G_0QT:6S"]MQMTC*)E-82?4\8J^0
M<FJ#`#_Z<GI;;]VYD\K%CM^]?R4LN\\+CYUQPCK8:6BWIMC(QK/6[4J\JJ3P
M015UDJ<96LLL=!D4CF*O`]1%,87=N\FB[LZ?5*,9H'0\4)'EYJ<Z6SP+`I()
M537;W`/@L<^JL/Q`>ODP\UJ.-""4U,ZX'<5/NW"YC=6)QT>P*39<N]LH=L97
MO/=O<.XMS+7;QV1@=E30SK7=NU<&U\91,M5#!A<+0R/)!$:#UH&I6:&[2[21
MQ$(!'K.DS/*7J\:QTS*0JC@$522*J,'<8CDMGA?3XIEUA!J6)8U%%9G_`-]C
M4W"KL<'-`1YZGW?O#'PYZC.UTK(=LUD=/O?:FSI9<MMS:>?KON,A7XKK/.U"
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MC<XF,DBPRJ`*UUQUH<$T\1*@?EP/EUL"RD`0/(G'AI8#UH#H:G\_VTZ7$WR9
MQ=3"N/PVT\A)NVCBI9=TXK/Y2APNWMHQY$*^$DK=W4:9NAW*-W4VNIP46`AR
MU3E:6-Y5BC"/IW^_`]8HK5OJUIK5F"K'J^&KC4&U\4\,.6&:#K;;;X?>]RIM
MS\++4EO7M-"M.#:](!\^D3A,+W.99\AMS&TNT7:DK:+'T>&VI75,&"QV2R$>
M0KJ3`?Z3=S;8H\:*JLACE:/^$O3IXE$<*+=#I$W:0L5=(C2E51FIY]OB,HX^
M>FGRZVS62]IJZ\<D"OI70K'[>['D>EYA.C:[+9*JSF_<I6UE7DZ`8S+5-5E_
MXWN_,8:2H^[J=LS[CI<;@L3L[:-9/_P+Q.W*"ABKA85-3.@*L_%M*B4W$TKO
M*PH2QU,1QT@T`1/5(U4-C42,=-S7[/$L$<:I$#4*HHH-*:CDEF]&8FGD!T-.
M=W1M_9=)08_P2S5DL(I=O[2V[1)5YK(1TD#!*7#X:F,0CHZ6"&S2N8:.F1;R
MR1H+^S1Y$B"BF3P`XFGH/]0'2``L2:_:>BI[@[8RAWGMK+UU!)D8X-RY#;^.
MAQ5!!N'#8[?>*K3C\AT[A#4Y3`0Q=JYK&^:=]Q9+QXJ&DCDI<:)7EEDD(+O=
MS#-"NDE3(5JBZJR*U/`R5TNRYUM1<42I/1M;[?JCDUGOT:J$THA&)2<U4?P#
MNKQIT.F>[9I,KC\=B^JYZ'=F\MUSYR@V\NFH.%PL.WLQ4[=W)O'<\H2.2';&
MV,M22Q>DALG6+'2TS%I?+&92WX=(UL:27$E0O\(`-&=C_"I!&/B.%]0CCM2K
MNUT"D*4U>IJ*A1_2(_8*D\*=9\AD=J]`=;U63RE1D,M)#4>6HECIXZO=W8^_
MMPU*0P4U'1TR1G*;KWAG)D@IH(PL46I(U\5-"/'6:6UV:QDE:I[JTXM)(YP!
MYEW8T`\ODHQZ..7<+D(@`%/]JB#).>"J,_/YDYS=1;(RFV,5F-Q[O%/+V3V)
ME!NO?U12SO54E%7O2Q4>(VGB*B1G9L!LK"00XZEL0LS125)`DJ)"?;7:301/
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MD6+S4FW8Z>*@VC0.T1*DIM^FAJ)`;%:BJE!Y]F%DI*27+5U3-JSQ"\$'R[0"
M1Y$GI%<45Q$IJJ"GY^?\Z]";[6],=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'G;J>3J?L]/]7UYO5/S_:VWDA^
M`3^?>B0`2>`Z]UJ__P`T-M?\CO\`EGO=2PIOAJ`RV*#_`)Q?W*A8`6)6WX`_
MU_:>Y-8UIQ)'^K\QTFNO@7[>K*/Y!I!_EM=<@$MI[/[\!)^I/^F#=QN?^#7N
M/\#[M;_V9^T].Q/K08X8_9U<W[?Z<Z][]U[K%8>?5;GQ6O\`FVN]O?NO=9??
MNO=?_];?OH_^`L%_^.8_%O\`>/?NO=2??NO=>]^Z]UJ&?\*5RY[M^(2Q_J'5
M?=):X)NK[RZM2]KZ0%OSP20;>TMW\"?:?\'26Z^%/M/^#JP7:+,_P2_D:,``
MQ[[^&EPJ<"W1W9P<`$W0``\\V]J5^%?L'3C\(/M'^#J^[WOI[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[J-6UM'C:.KR.1JZ:@Q]!33UM=75L\5+1T5'2Q//55=753O
M'!34U-!&SR2.RHB*22`/?NO=`]U]\D_CIVUGZ_:G57?O2O9FZ,4LSY3;?7W:
M>QMYY[&I3G3.]?A]N9W)9"D2!N',D:A3P;>_=>Z%K&9;%9NE:NPV3Q^7HEK,
MECFK,964U?2KD,-D:K#Y>A-12R2PBLQ66H9Z6IBOK@J89(G"NC*/=>Z</?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]TG-V[<AW9MW)X&6IEH9*R%6H<G3C558C*TDL=
M9B,Q2#4@-5B<G3Q5$8)`+Q@'@GVS/"L\3Q,2*^8P01D$'U!SU>-S&X;R\QZ@
M\1^8QT6':^Y:K9W85)NW*4]/B,+VEE:3KOMO'PI(E)M/OW;]+!B]M[DU&5UB
MP?9>!AI\?',R@2,N&);54O[#\,C65\+MAIAN7$<P%=*3KVHX%.$PHA)](CYD
M]&QC%S9&`+^M""\9\WC8]Z_\VV[@!ZR_+H?NR=]9#8&"_B^,V!O;L2J9WCCP
MVR*+'UM=&RIK66K6OR-`8J5CQJB6>0'Z(?9S?W;V4#31V<L[#\,8!;A7S(_E
M4U\ND%I;I=3K%)=1PJ?Q.2%'Y@'_`#?/JF3!?(+MK&;ZWQAMI[NI>HJ;N3M2
M7)9H[LI$S476=3GLH*/*5E''FJ>"&BRM%32HE=JI/"T\4;NL=GD,/VG,.Z1[
MA>0P7(MH+VZ)/B+4P%VH:`T`8?CJ*:N[UZD6YV:SDLK9Y[<S7%O;*%*'$FE:
MBM,E3Y$'53SZO$PF$BP^`QV`EKLEG8J''0XZ?);AJAE,KF-$(BGK,Q5/'''5
MU=<=3S$(D99B%15LHF>&$0PI`79P%H2QJS>I8^9/GC\NHR+5<NHTYJ*>7V>>
M.BXT-0WQBK3B,M+(?CGDZQ%VUGI6FG_T&Y2OJ+?W5W'(5=H>I:ZJE_W%9)V\
M>`E?[*I*41II8"-6.P.8Y68[*[=K<?IR?P.>/@D_"_"(G2W9I*FKEMW(=5_W
M9TR`/[7^D/\`AG\0_&!J'=6JT[&ZI&XZMM[[(GI,?O&6CCBJ]52])BMUT:T5
M10T=4V1I8*R?;N\\/C:Z9,+N2DBDK<>)3&ZU-&STS&%W9"<FXMWTS%:5'!@1
M0&M#1U!.B096OFM1TDM[@1TCES%6O"M,UX&@920-2'!^1SU$Z!KJ/$;<;K2I
MEIL7G]FZXTVE689<!NJ@P<CH4RNX%ARF5Q6[LEE,K-/-5Y_%2''9.HF\VB*=
MY8E:VC1#`+*@1XN"4HP7^)J$AF8U+.M%8FM`21TYN'B2R?5L2RO^*M02,4`H
M"H```0Y4"E2*=-._ZV>G[8PN!VU@'Q>X<WM^FS,N[,3G8,)F<[34NXZ'!Y>D
MH<96T<^W-VML:@K:?)9*FR;"4T$Z+27D!TMW=VR;C%:00_JN@;4&"E@'"L%J
M-+&,$,RL:Z3VYX>@@1[.2Y>84#Z*4K0Z"RUH=0U4*@@4!X]9-F=VU.=:@I:8
M8G=$U7MZ#=R432+L'>R;(^^K,.V]:C:NZ*C^%5VWJC)4+"*MI,F*>1)(W"J)
M%`>M=UM[DHB.#(T?B!3V/X>K3KTM^$D88&E"/7JL]D\-=0-`^FH[EUT!*AA^
M(5`(I4&H\NA+D[2VIC\?-E=T/D=CXRF`>IRV\L?-A,!31LVE)JC=$AEVO##*
MU@CM6A7U#23<>UPN(R*D,!ZD&GVUX4^=:=)3&0*U'[?\AST7GK3LSX^U_9>X
MH-J=Z=&[VI<<X?KS8FP>P-L;PW;MVMW`LLF]))-N8&LR.2#5-;&(\:E,CBDH
MI*F)!'',Z$OMO`6XE=;B-K=?[-5R4U9DP*_$<@TP"16AIT^XD:-%$;"0CN)P
M&'D/R\_4Y\NC!2=I8">KR.-P-'F=R9?#BF&:Q=!1)CZO!-74SUF/.?3<,^%;
M#15](AFA><*)(/W$U(+^S'QE/P*Q_*G^&G2?0174P!'SK_@Z">7N@;IGS>-Q
M.]MFX6?#[*_O^V&VIDZ7=V[,SMM*>IK14X;/U]+3;%C@R%+"NF>G_BBP:U9R
MH(/LN_>MM)))!'=Q^.L/BA5():/-&5CVD$C)&JF*TJ.ER[?<#PWD@<1&41EF
M!`5C3##X@16M#2OE7H$(M.^\+M.I7+9'8.W^]<%0T&'RRYS+T._<#WCM6LJL
MA-L?L?L&')PY?-T&YXJ">DAHJ1:.GAFQDL4,3-/"Q)6GDW"&U:1Y(+*[CTCN
M*2)<!CV22*:T:A4!:94CS'2[PUM)9TC42S6[L2>*M$<:D0K04XU-:ZAZ'J9A
M=KY7<?\`>?;-#4;J[&;?VVJ'![XZ_P"U8*&%.NZ_#Y4G&YS?W9>SSC,GF*^C
MI(W6@QR(=P9&B%(\U12QQ&:.L5E-+XL(DEN8IX]$D4^G],AL,\JT8E172N7<
M:266E>K/.D0AG:-(VCDJLD9/>*"JI&U0/4M32&J*&M.C.4U)L+X_[,R^ZMT9
MF.-C#CO[R[KK**-<GG:JF04&!P.%PN)IV,5)3&84>$P.,A*1>0101/-+(\I^
M/I-ELWGGDP`-34RQX*JJ/]YCC0>@45.2L^/N,XB@B-*DJH-0HXDDGTXL['YD
M@#">V/L_<?8&[,;W/VGBJG!U.*@J5ZHZPKI8*@]>T.1@>FK-U[G6G>6CJNT-
MPX^5HI-#2182AD:C@=I)*N:9/9VMU=W0W3<@5*U\&+RC4XUOZS,*@^4:DHM:
MLS/7$\-O`;&T(8D_J2#\9\E7TC!SG+MW&E%`X_)W)[MVGUM5]A[*W]#LC-[$
ME3*BFRL=#5;:W?1U,D-%4[6RU#6P2M-7Y!90,:\#13K7^-0VB1_=>9)[JSVJ
M>_M+P0RP=_<`585H58'C4'MH0=5!7/5]DA@N=Q@M+BU,L4ITX)!6OXP1_#Q-
M0017HA'1_P`E=U5/>6[>P=T[/WCV+7;TVQA=IQXSKG%MEY-G46WJROKZ>#&X
M.6J].'R4U>\K.*@%JDR.[/=0@`Y>YJO)]XN;N^LI9GG15"PKJ\-025QQ*FOK
M6M3D=#'?=@M;;;+:VM+F.,12,29&"E]5,GY@#TX4IY]6PU6Z,3C-JU6\L\\V
MW,)CL'4;BS$N=B-%/A,7143Y"OERL`,III*"EB9I5!8KI(%_<L23QPP/<3-H
MB5=1)\@!4U^SJ.UC=Y!$@U.6H*>9K04^WRZ*9L[%9S?V1K,EN"DK,?G^\GQN
M[]VXNL$D=7L7X^[=EJ*;K[KVI19U:BR^]6GFER$0*NL^0RHM_DR>P[9I-=LT
MDZ%;B[H[J?\`0X%Q'']K_C'JTGH.C:YECM_#BMV!C@J`?XY3\;_8N`I]%3U/
M1U%54554!54!550`JJ!8*H%@`!]![$_1-UW[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND#VN0.K>R2;D#8.\
M20"5)`V[D;V8<@V_/O1(`)/#KW6KQ_-!4C^1I_+3_25\7PTU>.Q#(WQDW.1$
MA(L6DX'X)M[3W-/"5AG(_GY_EQZ377P#[?\`)U9+_()`_P"&VNOB'$FKM3OU
MR0ND!CV[NO4MOR0?J?Z^]VW]F?MZ=B5510OI7JZ#VHZ<Z][]U[K'_NZ__-O_
M`**]^Z]UD]^Z]U__U]^^C_X"P?G]L?[[GGCW[KW4GW[KW7O?NO=:A_\`PI20
MR]X_$:,<?\8D[K8<FQ)WGU8`"OYL0/:6Z^!?M/\`@Z9GC:0(JCSS\NK"=IG1
M\%_Y'"IJT_Z>?ANA!NQ(_P!!79_U)YX(O_L/:E?A7[!UZ3'@C^D/\!ZOG][Z
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZU<?Y^'R%DQ'R%^'_QP[,HMRYKXG58Q/>/
MR'Z[VI55E'7=U[7PW:&&V]D]DY)*6KH#N'#8';M'65!PYGBBR%7D(`]Y5IFC
M9F-!&:XU#IIC+XBA%[//'5J%3\4OY;GSV^/N(J>FMK=.KM:GH%3JON7XXXK`
M];]F=+;AI*31BZ_8^ZMFT&!W=UUN7;[NAGQ-2*=7533UU(\3/$7*AU.EL''3
MO1,^F-W?._XD?'+^77\,NG^L>J\YW[OW>GRJV3V;E^^%WQ1;:V_LSIS?6\\Q
M4=XR2;5RM-F*O&;YCRV-R<",U54Y$YZE17#2R5":"LJ*H(J*=:8D#`J?]6>@
MP^7W\U3Y\_#/Y"[*^.&\ML_#SL#<N],-UCF4W9M?:/=NW<!AE[1W_D^O,?25
MN,R_9N6R%4^%KL8U;/)#-:>FD6-%2759N:5D=%4"A_S]:!;"E<TX^5?\/5AN
M([T_F!]9?+[XX](_(?:_Q=W1TE\@E[6Q5'VOTKA^UMO9_;V]^O\`K;-=A8O:
M&8V]O;>.YJ*BDW!CL!5ST]6DU3%/#1SQE8)5C,KQU:@133_/KP+=H*U-,D<.
MGC^9I_,0PG\OC972VXY\31;ER_9/<>W,)F,!/'62UE'TOMVIILSWIO;%K25-
M(G\8VILV15QRSOX9LK6TL3*P<CW2218P*\3Y=6Z&[YH_)+<70?PU[3^273.'
MV[V5NG`;-V]G>K<#D6KZO;V_<UO+.[=P6S<4DF&K*"MGBW/6;CIXJ5XYXE,D
M\;,ZIJ/MSY=:8D`D*2?3JL#YF?/#^9?\%^K^JNR>X=K_``?S>0[6WE'LB'86
MR\1WG/5[/R[[0SN\*@Y#=^3WU3XW<<./AP+T<AIZ&D\D\JR1ZH@UFY6*1LPX
MCK?61?G+_-'R/P1PW\P'9O6_POWYU[5]8S=PY_J>@QG>&#[+V_L3%I556YZN
MARE7O3);>W/E-K8O'5-7/2I'1M40PN*=I)0D<M^ZJTI3S_V.JEAI+(-7V>?0
M`?S*/YC7R/\`B)W/C.L*[8GQH[?V=\A.DMO;RCRW\'[+VG,^#K]U5NW*!,_#
M0;[S=/-N#:]21+C,W02T\LE.ZEHHY*:G92R^M(9/J/%4&&:/0XX5`R&KY,M3
M0^6,B@(4)>7-L(I(`#+&X9:U_P!Y^QC2H\\^N3@]N=]?S:.B.N>TZO"8;X0]
MZ[RZ'ZU??N1V/'B^]=H]@]G["Q&"-94=@[)JJ[==7MS<U:)Z*JIJS&(U-,,C
M3&(2J:NB$[=E=N#)MLC%KV!0:MDS1T`652*"I-5<9TL,T#+6]U&5B%ZD8\%J
M]JU[&&2F<\,J3Q'S#4.[\=>F.L^T.IH.X]];:VOOK(_*#![6[ES4&1Q2Y'"X
M2CWYM;%[@IMM[7_BBRUM-B:,Y65Q/^U4U!F_=)"H%3V_+>V(^Y375ND\MU(S
M/K4,`#P10:T`\Z9)))\J+9M[OI4L$BE:)8(E1=!(K3)8TXDG]@QZU!3Y]?S&
M>GOY:VP-D[(QVV,MVCV_N?$O!U3TKB<W/_$!MO&5,6'BW'NO<.2&7R&)VI29
M&:'&4"^.LR>7KV2CHH962>2G-U$=K'%;Q*2`*`5)-/M8DGTR>BQW:1VD?XR:
MG[>N:3_S<\YTI+O[(X;X)+V7E-NMF9?BOE=K]O5&*FHZS&_=3];9GO>7L=L8
M-X3Q2-0S5W]U9,&M6Q#*],#.7G"O&RNFI2,J?,$9!KC/#TZJ"5(8$@@]%?\`
MY?/\P[_9A=J[\P73&S,SM;>W7N(K:[?_`,4MZUHW3N3J5DKZW!'>?0F4^[VU
M+V;U7BMQTCT.5V965&(S&#R<1HJ::G2:BBJ"&*.?:A2PC:7;EXPU_4C%?]"8
MFC(/]]L012B&E$Z,S-%N.;MA%?'_`$3\#8_T0`5#'^-0:D]PXMT4_=7\U#Y7
M]A?-2B^$,76'Q3RFZW[FGZLV!W-)_I[V2<=7U&T)=YT^Y?X13YB/?NT*K[.D
M.-KJ!*IG%?$VIYJ2SLK,D.X+&P%8B3I8!D<>1H31D8<#4<?(](W^JM&EA.)!
MQ!(93C%:$@BAJ"#Y^1Z,;\I,G_,?^,FT:+M+>W7_`,/^QMFY/>.WMD=@=I=8
MYGNO![[ZEQ7=.Y=M=5;A[-H.MMXYJ;:&;SLU%N"&&MRE#44\ZE1/-2I3BID5
M-/LQ,,VBX9KM@X$@`#`N-)8(3X8<J-)8::\:`DU4IN#B6*L2>`"O820.W(!<
M#6%#$M3-.&:#HV?R#WAUWU)L#?G:FZ,ECMFT/3U-55&>V_78_<6`S\GQD7KV
MBV'GMB8VCW-CHL9N#=U4X:HQ%/0S5E'/E)*<@MJ;V575JLLL'@!%NED\,(^I
M#].\8C=!J%&90#(JJ2&(^?1A#((H[@SM(T!BU%E*N!,&+(YH>T$]I)HV<^G5
M!'PZV-V'_.9^9>^*_P"1F6W1M?XP]=47^DC.=#;"R>7P?7&(AR572;8ZSZ7I
MH\154^'HLA78?"256X,X8!D\LN+J(\>]%%4NU.?6EO#%-(L$3*DAU'370"H5
M0/1>VE%X&C'HBD>XG2$S.A2,%:8U9):OJPJ35C6AH/3K8#[Q_EC_``AKM@;#
MZYV3\:^N.JWDW1'M_;N_.GMAG9_8>R*NJVWN"7%YVEW[L*GQF\*!8<W14BSU
MM17J(P^ORB0+?6[12R+9BVGDAN/%[70'!T,1J`%"A(`<&F.!!ITHLDB+7#20
M1O&(SJ!H"1J6NEN(:AJ*5)]*=$C^#VTMU_"G+_-'>/R8SNY,G6]*?(6CW7NG
MMOMC<[Y#=F]OCA5?&C`X_';@I]Y;NF\G8$>RZRCIX$@HJEY6:DF@BC%9,:4H
M*SR';-PGM"-QA=T>/4*T9=+M%J8:TJ%=.!*DBFH4Z?54@.XVBSAK-T1EDH:$
M@U770$HX!9&&16A':0>DQTW\C?D%_,+KMS)\2.C=M=8?'WJZLSVQ]I]W]R+N
M_<?9V7W!DZO(9_&XG:.U=HYK9VU>MIMO;0W5)#D?XCF:Y3CLHM!5032,(HF[
MK;;2\@\)HI_JP'"-&`I0,Q*D2-A2`S*ZBH9200<=7L]PN8IC(AA\$E3()2Q#
MZ1PTKEJFC`\4(!!KTNMW_.'>OQ)^3.W?CG_,(V3M;JK8W=E53[^VY\@_C?NO
M<]3U5ELK75&'V1D*G>.,[&2?>?3&)Q%0M%0YD[9J]-(V37(5-0*.KGEA7BP"
M4\29HXI3J=%/XZ`'OXJI`&(PA)J2<FJ8WC+I``8I558C\%215?,U)/<6'#&.
MA8_F/_.[NC^7&_6474&Q_C3O;K;?N=K]LX_960J=\;:W]L^JI-K2;F?<F:EP
M-9E<+G,1FJNDEB,I@HJLSU4#WJ;SR(J,UK:.MA;&,3!:E!\04?B(&1]K<3ZF
MO3,OU$BBZF#%':@8@T+>@/"OR'#HS_P8S':WRJZWZK^8/R*I^LWJ>P-D[?WW
MTYUSL2'=TN#Z@I,]35K3S5D^Y<I/0[GWS6XRHB$N8%#2S4>J:FIK0$M)4;:D
MMX+Z\F,SJ08U(HD6,E5J=3G_`'XV1P72,=."\=;?Z:%`BGXR,L^<5/DHX:!@
MT!-3T???&]]H]:[.W1V%O[<.+VGLG96!RFY]U[FS=2E'B<%@,+1RU^4RE?4O
MQ%34=)`SM:[&U@"2`3(D`$DXZ2=4@=8_+GO/^:GNG=<OQO\`CUT_MKXP],[L
MCH:7M[Y:U'9.XI=_;[6A3(T--MWHKKO+[.Q8J*';N5I:Z5\WFYJC#I70J].M
M7-+3TZ"[L;#=HECOK82P*]0K94D<"5X-ZC4#0Y&>E%K>W%HSR6<Y1R"I9>-/
M,`\1\Z4KPZ2&T/F94?`_YQ9+IOYO]4;#Z@A[XVGLT=>=V]!YO-9'X\9*FCW+
ME,0N9W#M#>$,.Z^JX_[P9>GQF3C2:NQN$J6IZF1_L\C]Y$7V>T6VT[G?7]N@
M2*Y5`RJ**&35W`#AJ!%0!Q%?,]*KK<Y[VSMK:Y)9XF8ZR:DA@*`DY[:'/G7Y
M=*[^:-\\^W/CS_`<MM+9'3/<?0@[@Q/7F6H,WEM_[5RM1VG@=G9'?L6TLYD\
M2V5PV\MJ8:LPHK,@*.G2G6MBIL;5>0BL3WNZDBW662VTL;&"1=9J-,L@J?"\
MRR)AI#P+@)Y,.MQE]MB2X5U%Y*IT#-8T./$]`S951Q"DOYK2/LKYB?S$3\18
M_G_M3X\?$_L?K_?FPXN[MV;&PW9W<&![DQNQ\;15,U='129G96:VIG)=C;9H
M)"N/I9*7[@0RR0++4SLLIK!%X2RRLVJ1SJ)I3'DOV*,#]IR3T7NY?2H6B**`
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MEEHZ2N6HEB4F!9G`C:HDK'K5"?EY]51PZAP*`]';^"?\POHCY^;'RVXNK)LK
MM[>.STPP["ZOW6*%-T[3.>I9:G"Y>FJ<955N'W3LS/BEG_AN9Q\TM+5&"1&$
M,\<L$?HY%D%1Q\QZ=:1PU12C#B/,=%?[,_FEYS>_RH_V2?X']38/O_N3%5NX
M*/L;L[?>Z\ALWH'JD;/EI*7>LV7S.WL'N7<^[I-G9&O@H*Y,?3PP?QB>/'15
M$E49UIME^\(!4^?R]*_;U8D@J-)H?Y=8?D-\[/F-\!Z/:'8?R^Z)Z;[4Z`W5
MNK%;)S/8WQ3W3O2AWGUMN',*9,5_'^L>UJ$P;EQF<^UGIZ&6ASL#RY#PTKI'
M+44XFV[!%9CP'6B2"H"DU_EU:=U%VUUYWOUILON#J?<]!O+KOL#!TVX-J[CQ
MWE6"OQ]07C>.:FJ8X*S'Y+'U<,E-64E1'%54=7#)!-&DL;HNU8,`5..K="-[
MWU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z0G:1(ZQ[&("DC8F[R`W"D_P!W\A8-_M-_K[]U
M[K5W_F;1K+_(S_EJ:8Y50+\-C:0H9(B?C1NJY\@&D%3?38>K@>TUS\"_;TGN
M5)04&!Q^SJR7^07_`-NW=@<L;]J=]_J`!_YFWNFQXX]0Y/\`B?>[;^S/VGIY
M?@3[!U<][4=6Z][]U[KA8>2_&K1;\WM?^GTL"??NO=<_?NO=?__0W[Z,WI8#
M];QJ?I;_`'@^_=>ZD^_=>Z][]U[K40_X4H+_`,9S^(TA'I3J/NOU?TU;RZN!
M^G(U+Q<\?C\^TMU\"?:?\'2:Z)"+0^?5AFU%5?@U_([5067_`$\?#@BQ)T_\
M8*[/>Y8C^R1S_MO:E?A7[!U=^$'^F'^`]7Q^]]/=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=5D?S$O@STI_,,P-'U37[\INO_D=U#B:?L/KC=^,AILOF]J8'?%7E<`]
M+O#:<M31MN;J_?U?LRHIZFG\U/*E;BHZBEGAJ*92S<D8D6A_U'JKKJ`H:$</
MM^?R^76ICV1T'_,#_E0=GTN_JB3='4M15YBFQ6#[ZZCR,NZNDNQ9_NG_`(7@
M=YP5M(N,J)\T*`F'`[SQD-0\:B*CGDD*R>TACFB-5J?/'#\^JLY44;XJ<?(G
MTZVXOY8WS37YX_'RE[.WAMC`;>[EZVW'ENM.R*+#1^7&19L8_"YJ#<NTVK9*
MK*8G;>_=O5U!7"BEF>6EG#TTCS?;K,ZR-@Z*:@GSIZ]>C<NIU"C#!^WK7E_G
MED_\.B=*A=-_[F_$LDDG@+\C-SFQ!X);_8\>T]Q_:Q?ZO/ISY];FD]'254E)
M-4TM-42T%0:NAEG@BEDHJIJ>>D:II'D5FIJAJ2JEB+H0QCD9;V8@J^O=:K/\
MQGHW>?SIZ+^3/\PC;:UN5Q'0'8$VR?C/M^AC>MBW5\4>C\KD]N?);?E%1X^M
MEILK4=F=F?QK/8R:6%99]O[)Q!B8Q5;!F)X]2Z@*N.J`*Q60'R_+H]G\BSY&
MT??OPT'2.\9J?<&[?BYG,=UW*F5#91LKUE4K_>7I7.3/7B6.K?$X>G?#+(HL
ME5M]F6S6/OUN^I-.:CJP#``.06Z`[_A1^/\`C`OQ=8%KI\B<FRJ"%#D=0=A<
M,3^FWX/X/NT_]B_6^K"?Y1-)25_\L'X>4-9##D*&MZ2Q]+5TM;3QS4U72U-=
MEXJBEJJ68213P2Q.T;JX(=2=0Y(]N^G5$"A0$-5ZU]/^%%E/3TGS0^.L4`AH
MJ:E^-V(AI8(Z>(4L:4W=.;%/1I`%$,=/(%6*Q!C12"5*BQ2W>44$5&?\'6V0
M,5)\L_ZO\GSZLBZKW/\`(/LG^81V!L'NOK=/BGD.IOB5M23XT;=R.]*?MC:<
MT'87=B+GUW#OC"KC<%NW9^_JS;5'M>3#?;PSX^@ITIU(JVHYW+;ZT)B@CB?P
MIHGU029(1R/@8^:2"JLIQ0`*0P4]&EI.S2SF:/Q+=U`E3`+*#\2_TUXU'KG!
M/5V/2^]L#N#;8VE1[9@ZYW+UM38O:FYNJUBIJ8;%^RHQ28:FPL5)#345?L:O
MQ]&'P>0I(UHZNB0!!'+%-!"LL+];U)%>,QWD9I)&>*-_S\C4JCC#+D9J`GNK
M,VC*$8/:L*HXX,O#\F'!E.5.#Y$Z;WRGR63[3_GO4N$[&1Y\51_,WXP=;T5/
M7AA1P;`VE%UEN#;6/IZ:9C'%25.9S%36ZELLM17R/8ES[MJ+7"U\FI_AZ1EB
M&"B,D'S\NMOSNKOF/HG.;*KMW8&IJNL=URU^$RF[,1'45>1V?N.GA;(4$N6Q
MBH5K,!E,=%.-<#&JAEIS:*4.`J#>-[79)+.6[A/[MD8JT@R8WI5`5I4AZ,*C
M((\Z]&VV[7)NGU$=M(OU2+J"DTU#@:'U&..*>8ZT^_BKO7^`_P`].#/=8O/#
MMW?/R^^06W*2"E@EABK>NNRL!O[=&>I*S&D((*/^(8ZFR&EQJBEHXI&"NE@H
MM+I+E8;J`DPS`,*^:L<8\NBQX6MYKBW<4DCD*MFO<.-/ETW]S5&Z<?\`SX=[
MU^R=N9;>6](_EMCYMJ;3P6Y\)L?/[@S<'QWPXIL=A]Y[IAJML[:JC2QN_P!Q
M7124TT$3TI75.A&YHS,TD0F=&9J:D(#+GBI((_(@@C'6HZQSK-H5E`^%JT/V
MT(_:#4'/5VOPM[C^3?=O<_SVPWR7^/5;N#*;,S7QZZYW!T)O'+['3*X'8N*V
MQN_=>U-V4>/O5=4=A9#>U;F*G(55=C:V@QU1/3PI2JIIC%'5I=UM%4"`72*#
MJ8$1R'."JG],X_I)G\ATM065P\A9FMSB@H73AD:OCK7/PF@IU&_G<=O-O7^7
MGO?!X?";_P!DY>3L_I2IW1MS?.S<WMRLGV?CNSL!59>5,@]/5;:R%#3U5/!+
M(T%=*C1QGDW`+/[WM;ATM&CEBO&.$DC92:>C4*'Y$.?EUZ:PGBCDG1DD@3BR
M.I`KZBH;_C/1(_\`A/#@.M-QXKYE8OL.#"2UXW=TO7XE,KDSC*C^$UFTMV4#
MIC94K:2H:!<GCYS(L;D(\@O8L+O^'924^JT:O*IH:?+(QTU!)<H'-N6TU%:#
M_#ULL_Z(>CH8Y0V,Q@AGCTS+-NW-/#+!^HI(LN>:-X2!<J1I-N?=OI-K`^%*
M$?Q<1^W/3[7M^_:7;_>0/\`ZI`_GXY[8&V/A7M/976,^R*=MU]_=>X?>4.V:
MS!5.:7:V)QV[=\P8^O%+)496+$9'>&U\:TQ8B-W0(]_)8MA=I1V2U\#ZJG!=
M)>GY=P'\L_/IN7Z\Q%YO&\!CQ.K23_@KT)?\DO>5+L/^7WUY@]H==[[W[NO<
MW8G=VZ,S'MG#04>W:7+Y'LO/QTR9K>VXJO#[9HY#B*6E70M1//$J:&C#)I]U
M?<S#_B\%A//.,=JT4'CF1RJ`9S0DCTZ<AL?$C6:6[ABB/\35;''L4%J^E0*X
MSGHF?_"A>#?N=V-\0L[V?MS9VW&JNSNU=OXC;&"RE7NC*4N%SG6\%7F(-Q[@
MJJ/$XVM%5)@H`]+1TIA#:"9I--O=HWW%J2WT44:D=J*2S*?Z3F@/I15XYJ>F
M+PV,;116;R.Q8U9@%!']%06(^TD_8.BJ_-'*5&Y_Y0O\J3>.7H88MT;QW7+D
M-TYD1.,INC)83I[L';F/W'FJN9Y:K(Y+(8;$4[B261@BE5C"QJBKY+2"TMA'
M!"$:236WJQJ22Q-22:^9P,"@`'35Q<75P\/BR%P,9X**8H!0+^0^W)/5VW\O
M3Y5;9Z9^$?Q:V9VKBLQC*:D^+/5>]MEY[#P29R/<^"S&.JZ>DP=5"C)+C]S4
MT^.:-9)66BJEN_EB*E?97=\U6>U7MS8[FCKIC62-E4D2*P^$4_&""#^$TXU!
MZ.;/8KC<K*UO+$@ZW9'4D#0RGS/F",T&1Z<.@)_G?=M]A[A_EK]?9.?#U.QL
M?W;WWUMC]S;>^Z>HF7KY*3=N_MM;=W3(`D$]3G<CM'%RUD*`TQ?]@%U]3&EO
M=3WFWVUU/!X32]P6M2%-2@:F-16A8#`.,TKT6W<,=M<S01RB14:FJA`)'&@.
M:5X5Z,1_(8PV-Q?\NC8U;01)'4;D[4[US^88$,\V4E[2W'B]<S#ZR)CL53QC
M^B(H^@'LPMO[/\STBC0H"":Y)_;U7;_PI`RNTMPU/Q0Q>,J(,EN/;.Z.WMN;
ML%+`TL-#CMT;-VEF(]M9/)1J(?XI5IBZ>L&/UF9*5A.Z(DD32)9;N)YI+>%Z
MS14+$<%)X*3Y,1G3QTY."*J7MY(X89W4".0D*#Q('$@<=-<5X5P.!H63YN[F
MW?O?^3Q_*\WOO/(>26OW'MG"T5%0T\%/!E8L;U;V70+O?-`4M+*^Y,_3XB*1
M5&I(TJ9WD>6><NC8@$48T((X`>Q%X9RSM_29B33RKG)-*-*#&BNY>4G+M@^B
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M6)@R,7DT&H_@E74`'S`E/;L03&P.K_!UY45`0M?SST<C_A1H2/BUT"?5;_9F
ML2/20+,>J^T=)-_U6/X_/MV?^R;[1U;_`#='>_DX*DO\L+X=HX62-^JY$=62
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M^Z]U[W[KW7O?NO=>]^Z]TA>T/^9:=B6`)_N+NW@C4#_N`R'!'Y!_I[]U[K5\
M_F8I'_PQI_+81E98BGPW1E4_N*&^-6ZN(R.`0?\`;#VFNO@4^5?\/#IF=M*@
M'X2:'[/EU8[_`""B#_+?V&`Q;1VOWXNHW)-NV=T'DDW8B]KFWT][MO[,_:>G
M5II6G"G5T'M1UOKWOW7NL=CY;VX\=K_XZAQ[]U[K)[]U[K__T=^^D+&GBUIH
M-F&D/K](9@K:@!RZ@&WXO;\>_=>ZD^_=>Z][]U[K45_X4FJW^G+XCN&"J.H^
M[+@$!VMO'JXV0&RMI-B1?Z`V]I;KX$^T_P"#I/<*75`,"IJ?(8XGY=6#;35?
M]D:_D<A`I4=\?#AK%BW'^@CM`W5_R03<?U''M2OPC[!U=Q3P1_2'^`]7R>]]
M.]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=4>?+?<?R^ZA_F?]>=Y_'#XZ;_`/D'UKA_
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M&[`HJ#)U_7_;^>WMN^/;5/GL/BLCFHL=@:V,13K`D=35DQ1,X764\ZLTD9"D
MC_9Z;D,BRH44D4H?3CU>_P#/?Y1=C8'XGYK_`&5SJCY%=A=Q]VX3+[)Z^FZ^
MZ1[(FW!U/!D,A3[7WGVGNRBRF#PM3M'*];86OK,GA:"N$=5G,O1TT%-%+!)+
M/&I9M(KI)SY=.L:#X2?LZ9>O?Y=O\LZ;J;";IQOQ-V^VV-M[4CHY&W[U=O\`
MQG8,M#M''?P^LDW%L_<6)Q^\LIN&HCQ[M4:L<\^2G8NBS&0%M];50JA1P`ZH
MG^"6S/D7\"?Y@>^-Y;8^-'RVWA\/MRY_?75-?OR+H'L>>NR72F0S[[GZE[%.
MVY<%!N2J'6^5,=%-HH!D*C$3UM2D#,ZQ,E1&2<A0?#Z:C9@?#*MI\B?\IZ/]
M_/=PO87?^QN@NLNB.E^].X-U[-[3F[!W9_<+IGL'-X';FVLEU=N/&XN;(;B.
M"IL+-E,G6[DIDCHJ:>>IB*S?<)"864O3`F)@!4]79RM*(3]G1[_Y1];D]N_!
MSH#I/>NQ>S>M>T^GNNJ#;>_MF]E];;UV+6XS(QYC,QQS8^OW%A*'";AH:](_
M/#+CZJI_9D0R",MI%E;4H.DC[>JP@B-010Y_P]47_P`[?KGNKY1_*_KW=WQ_
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MU21;C;N)+>19FCN$HL4YS@D-X4XKW*QJ`2>.05>FHRLI!X,T3+KB=BTD8QFA
M_4BXZ2HXBG#B"M:5I?S/?AIW9VUW?MCY8?''8_\`#_E[L%=BYOM?X^G+T4==
MV8G3.<HL]UWW;T1N'*S8W%;]HJ*/')ALWBTDILG)C#3(\,%=2)#6OVMY]1<&
MUN(_!W2/)4_"Z_QQ&@UH?,_$OPN%-*L7EDJ+'<6TIDLR:AN!4_P2`5TMZ`X8
M=RDC@8/O#YC]==V[1?>6XJGY=XCN3"85*S;'P1_V3_NM]UXGL6"D%/-M3)Y:
MFV*NW\^]7D_-"^Z3DTQ4&.D,\7C`:-R??^6KK?2\K[JZ(BG1%H&@,!EF-:L3
M3#?A'`5K4RVC>H=JTZ;`,Y/<^HZB*\%\AY8\Z9/H$_\`*I_EW]K];[YW/_,5
M^6:5G6.ZGI]S;IZTZ\H:6GWAN;'X'?451D=][PWICL-1YQX*_.;>JUQ>(Q=`
MLF6I:0333,DU3]I$=V5H!;V/TTY%O&JZ2`.]`M!6HP",XHWSZ*))&:>ZDN81
MX[LQ(K\+$Y(H<D<,U'1(\IM?M.7^<Q%\LU^/OR7_`-E]7Y;XO??^D27X\]PM
M0G85+U/3;"EWK#B1LX[@_@*[@1G%Z7S_`&2FH$6DV]J=#^-JT&FK_+TFKW4T
MGAQ\NME+M#<LN'[CZ1W?T57T>,W/\I:C:^`WQ7Y+:]74UV9ZXZWAR&Y,+F*K
M$9Q<?D]O/@,/NK,06DIX)GDKT$H5H`/9-OEYN=ON6P6VVRJ!/,1*I4$^&H!+
M`\1IX8'XOET=[79V4MGO%W>1O6*(:""0-9)`!]:UK^6?+H;?EO!TCEOCWV9L
MWY#P&OZH[&VY7]>;DP]/`U3E<TFZZ:;'P8_;\,:22C<*R-YZ*5`&I9X%GU+X
MM0-MTW.RVFS>[OY"(>&!4L3P50.)-,#I!96-SN$ZV]JE9"*\0``.))/`#SZU
M).D.H_D7_*P^3*;L[)^-N^/DM\9NQ,17;&RU6_7-'EMU;VV%35Z9G;.\Z383
M-F%V[W;LL+Y:_$A32Y:GJJV.GGB'VK0%4=SMU\T`OK!HW>HCCN$&L\/@K522
M*$@$,*T(KTH>VO+3QI+2Y$D*JI=X6.D"M.\=K"C<"00>(.>KG!_,0_EW9W%4
MTG7'Q.[P[*W[71K%A.L:#X6;]VKNBIR44>BGQ]57=B[2VGM/&4M,[!:FI:O>
MFI(B7<Z0`7+FSY=LO#:XVR%=0)'Z:ENWR"@:B?D`?G3IR"XWF[#BWNI6(\M9
M`SZD]H'S)'2#R/7-1\U^A.Q/BU\BNO-O](=O_(+=VY=\=&TG6G4]#CME?&)>
MNL?A\]UKM^MW9546W<]W7EL3E\&]7N[.T]'3XBMJL]4XVB6GHUIW**RWO9IK
M^VV^UVB>"2?7I9H!$&\,58^M!]GF!Y]*+S:=PCLI+N?<H)HX]-52;Q""QH*^
M5?7[#Z=%J^`G>?=G\OK8W8'PA^3F'K?C[5[2[/W3N_`=]1=9]A_(3JV6DWO#
MC\_6[2VW7]:8NMQ^,J\MFJN7,8F?<+8_7CJN6EEI5KZ<QL8237UU<2;=M5W`
MK0C]5BI=D+9152J@DBIJ3BG#HMA6"UC^IW&UE*.:QT.E'488EJ$@J:8`SZT'
M2*^2G7GRP_G#=J_'WJ3:.T=YXGHOI*I[$.^_F5O;K+<?4>Q-SG>V9Q4,^[^J
M=G[VQ.U]T;HW%A.N<='B\320X\4LF:K9:JHJ(Z*`R3*;.#=3;"+=0OU2.XU\
M/$75V-I`&GMXCUZ:O#9/=,^W@_1E5(#996IW#5Y@'@V*^G0M?SL>NZ*LZ<^)
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M:^%`CDC5EG]78Y-6-3W$D@!C2ND)+JXENI=;/74HJ0**!P"IPII%`*"@X"O'
MH:OYVVU-MT_0?Q<^)/QYZ[[,W?D.@=][8DJ-I]?=3]D[SI-E]<X3IS<NU]NU
M67W'@-JUV":IK7RU#"H%1)43S2.SJ"DA"RX5F0!03GRZ891^F"":$</\O2FZ
MJ^(FS?GG_*/Z/^-TE!GNN?E?\7^M\;7;-F[!Z_WOL;+===J4RYJD7;>=.Z-O
M86?)=>]F4%(U!E?L6J8S13PUL8-32TI6QC\2)5:H-/Y].X_+H)OY0_S&[<^)
M.WM[_%KY;=*?([9W66S9=PYCJW/S]$=P;IAZVW-C\A5KO?HUJW;6S,M2YC`9
M3.B6MVE54!EH))I*FEAD^WDQP]^B+C]-UX>?ETVI:CU6@!Q]G1O?A3T+\9/G
M3B^TN^_D;USVDWRA[0[*W7OSLO8V^ZKOSIG</5&QFSN2V?T7U<*+&5G76&W#
MB]F=3[7QJ)6PBN$V0J:V=9@*C0'NMH,5S4YSY?+JG/Y_]'U/Q3^?&V^RO@-L
MSM?<%'L*?:O8-1B=H]<]R[VQG7?=NQ<W/A]T;0S>]Z_;^Y)-Q4'<&W+)6M-7
M5[)%59'65CEANCE1A('C4YR:=-RB0,LB9IBGVGC^71[_`.<5\@]L?,#XI?&J
M@Z:V3W7G]\57;6#[$W7UNG1'<C;LZXQ,'6F^,5G*+?E"=B)_`\AAMQ9ZGQP5
MB!55#%Z?RP`R!V8LT8"HU3_+[>GO7H9OA+\X:'XU_P`MSI'IO;?1/R8[6^6'
M7W6N7VQ0=![>^-G>5+5S;W&;W#/AAN'>>:V+A=B839LTE53U%1DFRG%&Y,:/
M./#[W'5(5JIKZ>?3,=4A6JFH\O/CTFOY0/\`*@[+ZCW'OGY-?,W;V(HNP=_[
M.W=L_:G4\];19O(83%]KUAS';F\]^U>+JJS%T6Y]_-(**GP]-55:XC&M4+-.
M]15/'3ZAB,98L02>KKJ:NH=I\O\`/T7[XS]-]C_R3OG!O;(]G[#["WE\(NUM
MJR=<;?\`D+L#:.X>P,9L+;6/W$^YNK'[4P&S,3F=Q[<RVR8:BOP>8J'H_LJN
MEEARD,Q"U-/!I8VBD&D5C;]HZTIT$1A6IZ]&F_F<_,S:OS,^/U1\.O@?B-W?
M*OLSO'<.T:'>/^C+:&XI-D;(ZZP6XL1NC*R;R[-SN-PVQ=IUFXZ_%TM`BU->
MK4U)+55,X18%CG<E!93&!EL5\A]O7I6D4#PUJU>K$_Y9'PF;X+_&/$=<;BK\
M5G.VMY9JM[&[FW!A?))AJG?&:I:*ABV_MZIJ:>FKZK:^R-O8RBQ-#+.JRU0I
M7JF2)ZAHULB!%"CAUM$""@'5AWNW5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I$=F"_7'8``
M8D[(W6++^HWP-?PO^U'\>_=>ZU?/YEUC_(N_EO,SW%_AJNI2%)9OCCNL!/[1
M5A8@V^A!]IKK^S`\]0_V?]CIF=&=.WB,]6-?R"S_`-BXMD"XNO;7?@.D$*#_
M`*5]RFRW`8BQO<_D^[6W]G^?3J_"M>-.KH/;_6^O>_=>ZX\Z_IQI^O\`C?Z>
M_=>ZY>_=>Z__TM_"E-Z>(_6Z#_B??NO=2/?NO=>]^Z]UJ)?\*3XV?O+XD'3=
M!U)W23?2%UKO/JYH^3S=;$VO8CZ^TMU\"?:?\'3$XU)0!B?E_E^75AFTR!\'
M/Y';$@@][_#NQTFS:^A^T55@`%"W+`_2P]J5^%?L'6WX0?Z8?X#U?#[WT]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==$V%S<\@<`D\D#Z`
M$_GW[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC5E'1Y&DJL?D*2FK
MZ"MIYJ2MHJR"*JI*NEJ(VBGIJJFG5X:BGGB<JZ.I5E)!!'O3*KJ5905/$'AU
ML$J00:$=%EWWU$U-C*7&+B,KOW8>*J(J[`8NBRLF/[1ZBR-*',&X^J=Y/4P9
M6JCQ\/HCQTE2E5'&HB@FF@/V))[RP5HU4Q-)`M2*$B6,U%#$]00`/PUK2@!(
M[2807KJ[/J"RD9J*I)\G7AGUIQS@YZ;MN=L;PV51O4[E>?N/JZCE>D7M/9F(
MGDW]M1J=P*JB[;ZSH:5,EY\3%J-1D<33"4(@:?&P7,C,17MY9"ER#<V8-/%0
M?J)_S6C&:CS9!P%60<>GY;:VNCJA*P71R8V-$;YQ.:BA_A<\3ACP!C]H[KVG
MO7`4.X-DYW#;BV[5QA:+)8&MIJ['VC50U,'I79*>HIKA)(6"R0L-+JK`@'-O
M<6]U$DUK,KPG@5((_E_@XCHLF@FMY#%/$R2#R(I_J'H>E(2`"3]`+G_6'M_I
MKJOGJK>NU>_/F5O'?.'S,59A>G>KJ3:>RZ"H@JL7DZZLW3F*@[KW0F)R44&0
M;&PR47V$<[11AM0^JLA((VZ\M=YYMO;F&2J6=L(U!%"2[DNP!H:#2%K3.,TI
MT*;ZTGVSEZUAEB(EN+@LQJ"M%4:%JM14U+$5)X8%#T_?.&NV[G]O;#ZE@HMS
M9CMC>.ZJ?-]58W:RXP2TF;VVK>;+YVJR\L5%0;?@I:Z1)9>9H[F6,7A+!SG(
MQ7-M9[6B2MN<TFJ`)04=,ZF+8"BN?/S'GU3EI&BN+C<9'1=OA2DI:N5?&E0N
M6<TQY>O0.TVY^T=V]\]'=9_*@#9,^S\K1;SV15;4I*88CM#L3'T-;#C'R.X(
M:B>*AIZ:GJ)0U/11P++5L89%C66)6)XKK=;K>MEVOFA5B,?ZD6C(FF089FX"
M@J0J@=Q((%1T8RVUA;;7N-[R](TJR+HD+X:*,FK*J^>J@JQR`,5SU976[9V[
M6[@PV[J_%451N';6/S6.P>9J$U56'Q^X#C7SL%'(S:*=,G_!Z;S,!J98%!-A
M;W(KP0--'<O$IG12%8@54-34`>(!H*^M!T"Q)($:)6.AB"1Y$BM/V5-/MZ*%
M\9J\=R]G=R?(VM+U>.DRQZDZI\OE,.+V'MAXZS+U=!#/J%//NO.31U-4\=@Y
MA122$``5Y<D7>+_=^86-4,G@0C/;%'\1%<?J.=1IZ`5H.A!O"_06.V;0%H^@
M32X%?$D%`//X$`'YDT'0.U^W:_#?,/L+K;/=A[MZQV=W='B>Q,?E=K9!=M97
M?N6P>-H\5!L['[U4?Q#`&BJ#6/.E#)%55,<<40=!(FHGEMVBYMO["XOY;:SO
M%212C:&E91I\,2?$H!U&BD$X%<BI@DH;ENUO8K-)I[>1HVU#4L:MW:RAPVK`
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M$Y.E%\^YC0#U`K4^0/1?MW9C>F_9TP^_SEMC[9R__%KZ0Z_KQDNXM_XF>7Q:
M]^;GQ%9#1[`VS4(A%5#05,:+"\B3Y5;&$D]R]Y>_I7NJ*!O]`B.J9P2!^HZD
M!$_B"GA4&0\.EL9M;,EK>DLZG^U<?I*:?@0BKD5P6\Q4)Y]#'L/KBJQ:X>MS
MJT&&H<%2K2;/ZQVH?L]B;'H8["E4PP14J[HW'#&HU5T\:002%OM((CJFE-K:
MR2)(0T:K'&*)&N$0#A08JP'GP'X0.)02W+L9:.2[GN<_$V:G[`?3S\^AD]F'
M27KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1/98OUQV`/I?9.ZQ<'3:^"K_[7X_U_
M?NO=:NW\RNTG\B7^7!+QZ1\,_P!`]%G^.NZD8D*+:;$W-O::Y^!3Y5Z:FD,:
MAE`K7JQ_^07*9?Y<6R&)OI[;[[0?D!5[6W)H"D^JP4CZ\^]VW]F?M/3BDE5)
MXD=70>U'6^O>_=>ZQ_[N_P"G?_17OW7NLGOW7NO_T]^^DL::$CZ%!;Z_3G^O
MOW7NI/OW7NO>_=>ZU$O^%)G_`#/3XEVD"$=/=TLVKE2!O;JW3<&XMJ^MA?\`
MU_:6[^!/M/\`@ZJ]2*!J#S/F!\OGU83M6_\`LC?\C@ZB_P#QGGX<W8DW>_0_
M:(+&]B0;W^GM2OPK]@ZI)_H6?Q#_``'J^3WOIWKWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7ND!N/KO$9O)_WDQM57[4WE'`*>/=>W98Z7(5$,?C,%'G
M:26.;&;FQD;PI:GKX9U0+^V8R=7M-+:QR,)%)2;'<N":>3>3#Y-7IU9F4!&[
MHO0_Y/,?:*=%VW#UCD<%GJW=,N"S>U]RU;+-5]P?'\"BKLW.D@6&;LOJ.LCR
M..W3J8F:>04^9>P"QF#@@FFV_1(UR4>.Z)S+;X+9_P!$B.H-ZDT<^A'1A%>@
M!495EAI31+4T'HC@@K\J%?G7I_VQVAVG2P-*M%M#OG;]/XC)E^MZ^GV?V/0T
MREEGEW#UINRLBQWWBFUD@RE-(Y^E,MU!<CNMWA:CQ17</K&?#E`IQ:-^TD\*
M!U^SR'FM]OETA9'@E/'Q!JCKY!60%J?,J<9KTHL=WET?_>*.KW!+#UMOJNQZ
MX^4=F;6JM@;C;'^99DQC9W/T%'0Y"D\\:NL=/73PEM+"Y*GW9-ZVKQ0UPWT]
MU2GZR&-J$\*L`"#@X8CJK;;N`CI$OBP:J_IL'%?6BDD&GJ`>G+LGJG:?=0VA
MNO#;KJL!O+8F2?,;$[%V;5XO(5>(FJXEBKJ.>"ICK\1G,'EJ8!*FEG1DD3]+
M*22;WVVVF\?1W45RR7-NY:.6-A5210@\596%-2D9'IU6UO;C;_&@DA#6\M`\
M;@@,`?R92,T8$$=)5/C]N7<^_>O]]=O]H?W^?JRNR&8V7@L)LK'[&Q<>X*^&
M&G&;SLD&7SN0RTU'#`IA@2:GIEE4.R-8#VF_<<UQN%G?[GN/CBVJ8D$:QA78
M4+DAF+&F`*@"O#I0=TAAM[NWV^R\(3X<ERYT5J%6H`&1EJ%J8J,U,%NC$3[A
MVSN'`4N0?$U.;P>6Q%/E8X1428R;)4$]%'D(Z<RP">2C>82*A=`Q6UQ]?9Y<
M1--;SPI(49T*AAQ%12H^8XCHJB=8Y8Y&34JL"1PK0UI7/'H->@>G*7H?K/$=
M<4NX*W="8NLRM:^;KZ*GQ]15296OFK2GV=+)+#!%3+*(D`9CI0$DF_LNV/:(
M]DL(["*5I%#,Q8@`DL:G`QTLW3<&W.]EO&C":J`*"2```*5/3IVOANG-PX#^
M%]S1;%J-OK+'4Q)O>LQ-#3T\Z2(8ZFDJ\E44LE'.)(UM)%(C$BU_;NY1[3-$
M(]U$!BKCQ-.#\M7`_9GJEE+?P2,^WM*)""#HKD'B#3B#Z'H)-H]D]*;'QC;9
MZ"Z\S6[X7JV,U#U'LF7^"O7RDA:O-;URHPFU'=R;&>?)2R!!^0`/9;:WVT6J
M?3[-9-)5B:11D+J.:M(0$SZEB?RZ5W-ON,[>/N=P$(4`>(V:>BH*M\Z:0//J
M)G]\=EYNK7$[BW'ANI4K(G6/8O6ZIVIW;7E:=Y*FDDKTQTVV-I/+`=23)0UJ
MQ,015);5[W+<;C<-X<MPELA'P1_JSG&16FE#GB%:GDWGUY%L(`#'&T\M1W/^
MG$/7MKJ:GGW+]AX=.6Q>HLG0RUM?@,3)U><V;;AWGG<A#O[OC>5-^V&7+[KR
MTV9H-M05:1I)X8YLA]M*G[4=.;$/66VF$NT47@ZAW2$Z[B3A\3FM*^E30_#I
MZ9N;PRB,/,9`N0H&F)?D%%*_;1:^=>C`;8V=MW9]/40X.@\,]?+]SE<I53U&
M1S>:JRTDAK,UF:Z2HR64J=<SD--*^@,50*M@#>&"*!2L2T)XGB3\V)R3\R>D
M,DKRD:VP.`X`?8!@=*?V]TWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TC.Q
MUU=>[\6P.K9FZ%L;`&^#KA8DV%C[]U[K5N_F3&_\A_\`EO.S%627X8D:OU,?
M]EYW:A4E+`K8_3Z$>TMW_8T_I+_AZ8N-/A]U?E]OS^75D'\@<$?RXME@N'MV
M]WZ+C5^>UMR&W(%R"?QP?=K;^S/V].K\"?8.KI/:CJW7O?NO=8_]W?\`3O\`
MZ*]^Z]UD]^Z]U__4W\*7_@/#?ZZ!>WTO_O/OW7NI'OW7NO>_=>ZUG_YU?Q.[
MN^9ORS^-?5GQ_P`/M3-;UVO\<.Z-_9>EWANS^YF/3;([0Z@V])-1Y5L-FUJ:
MX9+)1+X?$I"$MJ^@+$\;2*H6E0?\G3<H=D*H!G!KT;[=_6.\.E/C1_)UZAW_
M``8^CWQUM\H_BILG=M)A\F,UBZ?/[<Z5[7QN6I\=EVI*(Y*BBJZ9PDXAB,J#
M5I6]O;P%%`^759,>"/Z0_P`!ZNB][Z>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z26?V)M#=$\57F\!0U61@*?;Y>)9*#-TPC_`$K3
M9O'24F6IT'^I295-AQP/;$MM!.5:6,%AP/`C["*'^?5UDD0$*YT^GE^SI(9#
MK;.&F>AQ>_\`*5>,GD9JO![]P^)W_B*F.WHIG:O3'9LP`VN'K9";?@\^T[6<
MFC0ER2OI(`X/RS0_(Y/3JSH#J:$:O525/V^8_ET#E=\=L9-72Y.OZ<Z>K*I2
M@AK>O\SNSJ;+2JLBR!YA@J>2)F5D#6:J-V_M?4^RMMDB+&1MNMBPI3PV>$T_
MVN*_\5TN3=+E::;V7YZZ2#_C7^"G4*#J;/P2S)2XCY"[;I0+Q4^W/D?+EZ!-
M(%EI:;<VXV>,&Y%BH''NAVM@:QI>1*<T2Y)'[&;_``8]>K"^%&9_IW8G\4(!
M^VJ@?L'3C+USN$PB./*?*V5F2-2!VILFF<%38WG_`(TA!]5F8'U`7^OUL-ND
M;56YW+\Y4'^`]>^O3_E&L_\`G&W^;J%_H@R.0?QYC9_<.Z(%"A8=\?)/.Q41
M*WYEHMLY^J@?5?U!D=6_H?=3M9<*LUK<2T_WY<M_@5J']G6SN)'=&]NC?T8%
M_P"?EZ46'Z!I,;5?<8GKCH_;$SMY1F*_!97LG<E+(`7C>')9\823SQ2A3<RE
M+CZ'CV_!LT$5"FWVJ$>>DR,/S:A_G_@Z:EW.XD`#W<S?($(/V+4="=_HOJ<M
M'$F\]^[QW)"L;P38G'5D.R]O5$#A@()L=M.+&U]1"H:VF>LF#``&XX]F0LV?
M^WN7<4(H.U:'Y+0X^WI#XM#5(U'\S_.O2[P&V-N[6I&HMN83%X2E<JTT>-HH
M*0U,B+I$U7)$BRU=003>25GD8DDDDGVIBABA!6*,*/D./EGU/S/3;,SFK&IZ
M??;G5>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I(=@@G86]P
M+W.T-R@6L3<X:M'%^+^_=>ZI&W/\(=T?/W^4!\`>F]G=A[<ZSRNWNN?BMV<^
MX-T;9RF[,=4T>V>F)\148A<=B,]MRJBJZQMR*ZS><QH(F4QMJ!6K*'!4C_8Z
MJR*^G5P!KT8O^3?UU7=,_$_>/2F4RM)N#*]-_*?Y0=:Y/<6/H)\5C=P5^V^V
M<[#49;'8RJJJZJQ]%4M-9(I)YG33R[?7WI(Q&ND''6HV+!J@8)'[.K7?=^K]
M>]^Z]UQMZ]5O[-KW/];VM]/?NO=<O?NO=?_5W\*3_@/%_P`%_P")/OW7NI'O
MW7NO>_=>ZK\S7_;U+K2P:P_E^=X:FYTC5\C/CWI`%].HZ3?\\#W[KW4?Y^,5
MSOP#`!N_\POI=>#:P'7/=+DG^HLEO?NFI>,7^F'^`]6%^_=.]>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7"16>-U20Q.R,J2J%9HV*D+(JN&1BA-P""#^??NO=:\/
M4ORD_F%]M;Z_F@[<V;WOUC+EO@#V348KJ[;^[.B,14[?[CP^.Q6]]PR[5[-R
M.V]UX//XBNRD6U8\>F3P;T)I9)C4&EFT^`M"0F.1J94G^75-7ZACIY`]"5M3
M^<7G.Q>EOY?':NQ.G-HO7_.+M>K^/.9P&Z=_9C#Q=+]P86FS4^X*W(9"@VCE
MX]U['I3M^7Q>,45<\=53N0/WEC\LJ,JG.33AY];9@NFO$FG0U_(#^89W#\=?
MBUN/Y+;FZ4ZTW?B,+W!UKLG;%1LCMG.UNS.VNN.VZS:&WML=D;)W'6]=T^3Q
M>2PF[=SU%+E,+7XXCQXJ22FK)EJ:=B[ULD*"QX#H2>HOYA.*S>__`)M=1=U[
M.QNP-\?!+&[3W+V?N'8VZ_\`2)UON?:&]]B/OW;U?M[+?P?!9W!;Q-!#)3U.
MV<G11Y))O$\#5,4\;^]$T!/7B:`D\.G7%?/:@WY_+HF_F`]9['BK*3']-YWM
M[-=4;OW#)A<QB*S8M)D9^Q.K\IG\9ALNF,WI@,I@Z[%"62B:G%="&D58B2-!
M@5U#A3KP8%=7E2O0';5_F<[]KM]?&;KK/_'/&5FZ/FK\5M\_)7XTX[9/;,&1
MJJS+;+V)A-^?Z)NT*'<>S=N9'9QRM#N&EIX=V4D.2P8J'*R)%^V9-"16*@5J
M17\NO*0RAAP/3A@_GS\G<Y\D>\?BKBOBSUUN3MCXY=<]']K;^I<!WQE8,5NS
M;O<M:8ZS!==5V<ZGQHEW-L3&4M54.<F**ERSQ1PQ-3F4M'?_``];Z5W3'\R*
MCW9\O?D-\0.Z>N,?T[N#IG9N=[,V5V&-\#/;0[DZYVEN'(X'>NX,%2UFW,!6
MXBMV6]-$V2HTDR)IV\X>1?!=Z!CK*L./#[/GU[HNY_G";J?XU_/GY.M\:J/%
M[<^".\/[NY;8>6[4D3>'9>,7&X+<J9*CKJ?83XC9>2K]K;KQ[Q4-2*YHJ[S4
M\TB!%E;QD5==:]O'\^M*=2A@#0]'!VS\I/D3G=L;RW4O1G5E?@,+T/)VWB-P
MX/NW*38ZAWY3X+:&^6Z)['H,IUGC<GLS<F3Z[WG2Y.CS,(R-`P#K+#%I&N_6
M^@=^-_\`-!?Y/]?87([4Z9FZY[MVMW[LCHGY*_'KM?=5=AMZ=$56_*ZJIL'N
MIJN@VC5#=.*R--`LE"'I<9'6U'DIO-%)"2]$D62NFM1ZXZ]\O/K'E/G]\F<5
M\@=C_%NK^).QZ;O'L?XT;\^4.V-J3_(.I^QH\+LK/+@(.IMQY^'J.2AHNQ\]
M5S1+]Y`*C"4<K.C3RI&)9+]:KDKYTZ,G\IOFCB_C'LCH^6KZXSN\^\/DIV'L
M?J'I;HBCSV'P.5SW9&\(H*O(4.X]X5ZU.$VOM786-^XJ\YEO%5^""GM3T]3-
M+#"_JCUZT6"E0>)-.DMCOF;NC:_RFPGPN[LV#M?9O<O:/4V?[6^/N\-K;LRN
MYNI.TEV?)-!OG966JZW;6$W=L3>6T=4%6(IJ&KI,KBY))Z6H$\$M&F@P+%/Q
M4K^77BP!4'S/0:?%7^8+VM\JMC=2]I;7^-^V\9M#LCMSL/K7-;:;O"*K[/V7
MM?JS?>1ZTWQW!2[?J.M\9A-[[*P&\8Z"*L@I,C35E+2Y2&5@TBM`=*P<$CUI
MU;!X'JT_W;KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TDM_7_N+O2PN?[I;CL#^3
M_!ZSCW[KW17_`.7-?_9`OA5=BQ_V5GH@EBP<F_6FVSRXX:W]??NO=(3^7=J.
MV/EH6=F_[&$?,[2&%M"CM[)@(O`]/%_\2??NFHO]$_TYZL(]^Z=Z][]U[KC?
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M?NO=>_V%^?\`?'W[KW6.5I$BD>*/S2K&[1Q:Q'Y9%4E(_(P*IK86N>!>_OW7
MNJ!>J_AC\_NJ-Z_S+MS[.VI\>Z++?S!=WUFX-CY_<O;&Z:_'=$4]5C=YX66L
MWW@,)UI3Y'?>5IZ+=8J:6DQ-=3T\E5#X):J*)ON`V(P$=-1[B3^WIO2?%9J8
MT@=,F]_Y1^^NN.GOY:_0G2&+V1W'LGX<]VUW=W>N4[8W#!LU^]Y]P8C<.-WQ
MM^DVM3[6WKB8:C=5=N-I(:>LE3'4F/IHZ6269SYO?O"6B`8`-?MZ\ZEC'3R:
MO2[^3WPR^8'>_P`(MS?$O8W6G3?6&T-N[\^/6$^/6R:_M_*YF3:'4'266P>[
ML[DNP-Z4W7\ZSYK<E1C3@,+AL913T^+Q])2SS5CN\Z*YUM]6DZ5!KY''1V=[
M?'3-?8]']8]+]/[<Z.ZJS_8^([9^1>>ZKW;M'9F]L+N39-/1;BV724U$VPL]
MC>U*BO["QN-DS-=6RP3/C<5XU\QF"Q^ZL,`"E.B'[&^!7RMZ:Z7_`)F_Q9V%
MM[9>YNAOD]6=H;F^+\FY>VDH]U;(WCW%MHX+LA.PXZ;KUZ*FVQGMW54FY*=L
M>]5/"K3T[0++,'6BH%UYJ&-3^?6M)HX+$U_EU[XP_P`OGY-_$3NGXQ]^]4;7
MZSK8\]T#L[X[?.;IS<O8]=DC#F-BT-+1XGY"?''?N1VCE'Q-7G<I'-69W:JP
MX#&Y2!HV95K0)HO:`&5A@`4IUM1I55\@.C4]*_&?O?9O\TGY=_+/<VU]ITO3
M/?'3_3?5^S:R@WTN1WC05_3L>36JS&X=JG;M)2TF,W8<FOV:P9&IGIO`QG1?
M(`EJ"NJG=2G6^@XW]_+^[%^0G8GQW[9WI#BNG]S=`_++O_=F;I<7NR+=55VS
M\3>[\GN?=FY.II<QA\%B9\*=Y;M7`_Q3&SO+2+0C*0BHE^Z5CZBDAB.X<.M$
M$E3JP/+UZ*SNK^7;\R-U?&7^</U)#L_K+"[S_F#=Y[A[,Z8K9NV9*C#;0PNZ
MX]NXV-.PJFEV2:O&Y?;:[;^\ECQL63BJ14)#%(K([EMH@WB=Q[J?RZ\Q:A*B
MK=&TZOZ%^3O5_4^\^G.N?C3U)UILS=?3N_\`-=ETU/W!C\C6]M_)+<O5^R^J
ML9#M>+';*H\7L'9>5;!5.?SV;K$GKZBK6-(L>6GG97>M].G8O\OC/;L^3/PT
M^;&P&I.L>Y=AUVQ=L_+;9@W-+587N7JW";-R^*QT>6RV,QPH]V[\ZLW;-0U.
M*K:JGA2OQL+PNT4D%#X*:!JU@T/G\_M^SK04`E@,GI6;V^.7>^<_FQ=._+?'
M[/VP_1G7OQ=WQT%E\M/OR"GWG4[AWKNVDWE#N''[-&"F@FVYB!1&BG$F1AK)
M)Y5DCA,<9UWZT-6MB?AH*?;Y]*O^8+\0]\_(FJ^+G='3==MP=Y?#/O[`=Z[`
MVKO?)9##;([-PRQIB>PNL\YG\7C\M7;4R&Z-M7_A.7%'6PT&3@A^XIY*>24K
MHJI()%2.'6F0,4)/`UZ#*O\`C'WQWQ\\.H_FWVUL?#=8[/\`BGT]V%M3I[I*
MDWOA]X;\[-[4[%IFBS&[]V[EQ5-3[-V;M+`8:3[#$T<577U597225=6:6&**
M&;04!_$KW::?Y_V];9`Q0D_":])W^5'\!MR_%785+N/O#KW:FU/D7BLIWOM>
MIW9LG><.],;N_J3M?N`]M[:PN3R#8/`U*U>T)(*2E"&FC\=1%4%'EBF4CR+H
M!%:Y)_;U6)2BD'^(G]IZN)]VZ<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDMOD:M
ME;P7D7VMN`7`N><35C@?D^_=>Z*U_+F`'P"^%@!4@?%SHP72^DVZWVZ.+@6_
MUOQ]/?NO=('^760=M_+H#1Z?YAGS,!*%B23VM6/Z]0%G&NUAQ8#W[IJ+A)_I
MCU89[]T[U[W[KW7O\?S_`,5M_P`4]^Z]U[W[KW7_U]_"E_X#Q?\`!?\`B3[]
MU[J1[]U[KWOW7NJ_\V3_`,.G]9#4;?\`#?\`WH=.D:;_`.S%_'?U:K7!'TM^
M?]A[]U[J%\_1?._`'\6_F&]+F]@;6ZX[I/(-OU?2_P""??NFI>,7^G'^`]6&
M^_=.]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT2O^8CF/DKM_X:=Y9GXBX_+Y3OG';=QU3M:AVS1462WG/AX]Q88[[78&/R5+
M7T%7V#_<+^)_P-9:>JMD_"R4]3(J4\NB:`D<:=>.,]5K_"SY/4GRSR&^)_A=
M\JNS=K]GX/IZ@VKO'XJ_-7^\/9^4ZFW_`#=@;"CR'>>-DRN4Q^]M[T6,VK'G
ML;4T"9]*$Y1\>):;$M43)+6.02+J`IUH$,`PX'H7OB;\E?FM\A?D'\L^M1OW
MI-]M_"[Y=;0Z2W+35G5.;Q>4[8ZGRFU,9N'=N?7,T/8-9#M'LG%#+NV.$-'-
MBIUHUCFB#3F2'R.69Q3@:=51]32"G`TZ$_K+YW;Y[7^7_P`R?B9A-N8+:^>V
M3T]M?M'X;[@WKB\I0X#N;$R4&>V=O7>=7D*3+RG<NP\-W/0PT4,N+2*9\=%.
MYL=#&P)JP(`'E\^K]`EM'Y&_/S<_S9^07PGQ'9_QYR>Z_CW\>^@^\:/=^7Z5
MW-A\/V3N'L7-U--O/9&8H:#M2OJMI;76CQ4L>)KJ5JFOI9:I9*D5*PE)M]45
MJLZTX4_GTD-D?.SY.]G?)CY@?&##=R=$[([/Z>^0<O3/QAVSN/J#,9R3N]H^
MG\AW9DI>P(L?VCC,MB</MG&8N?&U^7PT21TD`CJGIWE;[<T5B7=:<*?SZ\K5
M9UIPI_/J^.DDGEI::6JIQ254E/#)4THF6H%-.\:M-3BH142<0R$KK``:UP!?
MW?J_4CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M2;WD0NS]UL?HNV\Z3;C@8NJ)Y_'OW7NBH_RX6#?`#X6L'\@;XP=(L'L03JZ\
MP!Y!YN+V]^Z]TA/Y=8`V_P#+_EB3_,-^8Y(:UE/^DV4`)8#TV`//Y/OW347^
MB?Z<]6&^_=.]>]^Z]UQXU#GDJ>+_`(!'-O\`B??NO=<O?NO=?__0W\*3_@-%
M_P`%_'/Y/Y]^Z]U(]^Z]U[W[KW5?^;(_X=.ZS6W/_#?_`'D;\\C_`&8KX\"Q
M_'I_XGW[KW47Y]FV=^`E^0?YA73`M:__`#3GNBW/]FS6-_\`"WY]^Z:EXQ?Z
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M-*5I<'C1.HDK)*E7I=:5+!B.X"E>J%`7#UR!3H/^D?@SWWT-N+^81OO9O>?7
M:;[^<&_)NU-MYB7K7<(I>C][2;:I]E4:Q4@WTS[_`,5A\-3)7P&1\5-)DP5<
M?;D*M5327->)KUY4TES7B:])C<O\L.?!=O\`PU[U^..[=D]([^^+='E</NG[
MW#[_`.Q,=VYL;=>'BP6[NJ9YMP]@1UVT]GUB2U&3I:F(U53!E_',\<G[FNQ4
M$AB.X=>*`NKUR`?Y]#3UM\,]^;'_`)B7?OSBK^Q-G9/!=Y]1[!Z;DZTH]H9F
MCS.V,-UA55E?MW<$>\IMSU-'F,IFZG(RK7T[8NGAABCB\+EA(9-]6"@$D#)Z
M+YM+^7I\DNL^U/F#W!U]W#\?#O7Y4]QX[N[;.6WMTUO3<G^R\[ZP'7>0ZMV]
MG=H4,/9N.I=[Y"EVUDI9IA6G'P5$\TL+H:5_&**FEG:O&G\NJJFEG:O&G\NK
M<MIX>NV]M7;.W\IGLANG)X/;^&P^1W/EEB7*[CKL9CJ:BJ\]DU@`A7(9>H@:
MHF"`*))#;CW?J_2@]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]TGMV_\>IN;Z?\`'O9KZ_3_`(MM3];\6]^Z]T4G^6V0W\OWX6E;
MV/QCZ6M<AO\`F`<'^5X(_P!;W[KW2'_EU`#`_,)0"+?S#_F*?46))?LEI"?5
MR`2_`^@'TXM[]TU%PD_TYZL/]^Z=Z][]U[KA?]P#_:&/^\J/Z7_WGW[KW7/W
M[KW7_]'?OHSJI838BZ?0C21R1]"`??NO=2??NO=>]^Z]T0#-JW_#IO6;^3T?
M[(!WDHBTCAO]F*^/!,FKZBXL+?X>_=>ZA_/P$YSX"6!('\POI8L`VG@==]SV
M)L1J`8@V]^Z:EXQ?Z?\`R'JPOW[IWKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN$AD"_M*K
M/^`[%5'^)(5C_O'OW7NN0O87M>W-N1?\V-A<>_=>Z[]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,>Z!?;6XA_7!98<BXYH*C
MZC\^_=>Z*%_+:T_\-^_#`(`JCXT].A54DJH78^&``))-A;W[KW2*_EV_\67Y
MC#\C^8=\OKGG\[^A8?7^BL!_3W[IJ+_1/].>K#O?NG>O>_=>ZQG_`#J_\LV_
MZ&3W[KW63W[KW7__TM^^C)--"3]2@^AN/J?I[]U[J3[]U[KWOW7NB!9L'_AT
MOK$Z>#\`N]!JO^1\B?CMZ=-_P#>]O?NO=0?GXH;-_`4D*=/\POI5KL;%3_H]
M[F4%/ZM=K?ZQ/OW34O&+_3C_``'JPOW[IWKWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NNK\VL?I>_X_P!;_7]^Z]UW[]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZK6_FB_S`J+^7Q\?H-]X?;N.WQV]OW,5.T^H]D9:IJ*;
M$U^7H<559S/[DW`:*2"OGVYM'"TAFFIJ:2*IKZN:EHXI(6J?/%21BJ]OQGA\
MSU2218U+'CY#U^727Z/^+?S7W'UA@>SN[_Y@?=.)^2&[MNTNXJC;VQ-A](X_
MX\=:9/-8NGJ:39M-U'E>NLGE-XX[;8F^WK:JNW`M?7S*\L-12$H5L*T%>-.M
MI72"QJ3G_8Z+EVA_,%^5G\OKXT=;;[^6W4^'[R[&W?W]VYU!N^KVQN63J2C;
M(X[=_8N1Z]WCUWM[(;1W73OU!N'K/:M#/1)4UKY:G>K5:AZB02R>ZN^DH*5J
M:=:=Q&M3Q\OGT>_'_)'Y*4/>76_3V]OC9L.#;_96+WW3#MWKCOJK["V]USO[
M;6QY-^[6V9V=M.NZCV7N'!0[ZP=)4R461BDG@/V^G3JEA$E^K`U`/J.BL=3_
M`,S7OWNOL#Y:=5];_#O:VX=]?#3-9';_`&'CI_DB,)2]@Y''YO>&"1>K*NMZ
M9FAD?(S;+J)H4S+8Q%6:&.256+.M%<L'HN0:?;UXD`$GATM>@OYF.Z/F'U]T
M7OCXG?&/-[T/8^0[2Q7;E/VGV/0=6XKX[9+JZAV542T&ZLYAMH=DQ[OKMY5&
M_:#^"0XN'55T;25+&)8*A(MJP8'U'$>A].O`@@$<#T"O1G\W;N7Y&===[=G]
M3_!FKW+AOC=VAC>N>S-LTWR!Q[[^KZ5LG3P[FW;UY@8^IGH-UT6UL']QD/LI
MZW'5N02G:*!?*55M*^HN*<#3JJ/J+BG`TZ'CKG^8;V+V'\\.V/@3#T)MG#[O
MZ?VY6[SS_:%3VY4UFT,OMHXS8F3PO\$V[!UW'N`9RO'8M#%44T\D<=*:>H<2
MRJ(O)K6?$T%*#R->O%Z.J4XBO2"Z$_F<]S_(OM7Y,=-;#^*.QZ+>'Q3S=9M_
ML.NW?\FUV_M?.UM)NS>6SEJ=I96FZ2S<PH*BNV345!?(0TAAIYH@_K+!=J^I
MI%I\)IU?I.=O_P`V7M3H_&?&5]_?#6HQ.[ODIVOO;HM-@5/=^,CRW5W9VP.U
M,;U=EDW1FJ?KVNP>YMD9M\S39C%9?#O-]SC'#-`KO&&K++X>GMK7K1(!"DY/
M#HS7R-_F`T_3?<74_P`3.K^K*SY$_,CM;#1;A3J3:>[<=M+9/7FU8:6LGRF_
M>U.SMP8ZI&T]GQ?PNK>D2'%9#,5T5.3'0@R0^1WKQ8`@$Y/2TPWR1^0>UN[^
MENCN]?C;B<)'W2V]*;#=U]2=I-V!U-B,WLS9><WU4;2W'2;EV3L#?F#W+E<3
MAI!C]6-FQM8M/4N*R.2-*:7W6^E/W%\S>L.E_D[\7_BUN4B3>OR@/8G\`K4R
ME#34^UH]CX%,GBI<Y0S`U<T>^LN7Q6,,9425T3+S8@:+*"H)R>'7N@4^3/SJ
M[9^/^3^268P_Q.RN_.F_B]UKM?L#>_:^0[9Q.PUW16Y[#Y/<.4V?UQM6LV7G
MJC<N6VOAJ6EDJZB:LHJ,S5\<*R>1)0M'<H)&*=H%?M^77ND7T3_,0[M[UV?\
M:^TL5\-JC"]0?)[-;BVOM??8[PQ>X:KK[<.,Q>^*G`-VIM3&==Q9#";:W3FM
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M>Z][]U[KWOW7NO>_=>Z][]U[IDW*=.W,^U@=.$RILPU`VH9S8CBX_P`/?NO=
M$\_EI*5_E\?"X,YD;_9:>GR7(5;EME8AC95"JJB_``X'OW7ND9_+K5EQ/S,U
M$D-_,1^73+<W.D[UHN/TKP&O;Z\?GW[IJ+_1/].>K$??NG>O>_=>ZX'_`#J_
M\LV_I?\`4G^Q]^Z]US]^Z]U__]/?OH[_`&T-_KHY_P!>YO[]U[J3[]U[KWOW
M7NB!9L?]C2^L2!]?@%WJ&;5]=/R)^.VD:;_C4>;?GW[KW43Y]?\`%[^`_K*?
M]C".EK675KOU]W*-!X-@0;W_`,/?NFI>,7^G'^`]6$>_=.]>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UZXO:_/UM
M^;?UM[]U[KWOW7NO>_=>Z][]U[K7!_X4<?'_`+,W[T;TKWYU]@,GNS%_'S<>
M^%[!P^'I*K(U^(VWO[%X!\7OF2AIHIG&WMM[KV;0P9BH56-%C\@]7(/MZ:9T
M9G!T:U:A7/3%P*QGLK^?#Y_/JY'H/YC_`!X[S^.&T?DGMOM_KE>MLGL_%YW<
MNY:_>.WL9B-DU_V<2Y_"[QKJW(04FVLGM[*K-2U<56\1BEB/U6Q+JU*J3Q(Z
M<C8,BE34=49?S[^Z>O.WO@]\3.W-FY.:78>\ODK!D-IY/<^+R>S9]R8*EV#V
MC14^Y,;A]TTN(S9V_F*:D^_Q]6\$<=5CIH*M;P3(S-2_%#_IATS<TTI5J#5Q
MZLVZ6W'MGX?[^W9L/LCO+)]\[T^9/RIP5=T5DL[N78N>[AW1A<STML^GRU!F
M<1M&DVUBDV/TUANL,O4C(46/@IDP\<6I7JI2]0]T^M:9:O\`FZH,Z[QWRHW3
MWA_/?J?A%VN^W^Y=I]MY3)U.R\)MC9>[\MVGLRH[&[QH=T[;VSDLQ]QF=F]@
M8C%)4S;=GQXT5V5M2U&AS!/`E59&$VAQ\1Q3_+UJ2NDT_/YCT_/JZK^1AOOX
MG[M^!FRL/\6<3'M*3:>6KZ/O'8N1W76;PWE@NYJ^"EFW#EMSYK+>/,92CW70
MT]-5X6JFAIU.'%/3K%`]++30/1D:`OF,'Y'K4;*R+HX#R]/ET2K_`(3?9"AR
M&%_F%O1U]+6F/Y:58E%-6052HK4&6:&0"!W"0U"W*-PKV.GZ>ZQ?%-_INMKH
MJ^@YKG[>E/\`&.NI9?\`A1)\YZ**MI9*B'H#'M/31STSRH%VY\8[J\8D:57C
M,RE@`&4,-5A;VRG^Y+_G_DZL5!8-3N`IT1/XP]&=A?)_Y+_SE>M.H.X<[UWN
MNG[JH\W)B-NUNUVP/9V,PWR;[:RV5ZS[$J:['5><Q^U=U46!J<9+48BNQE3#
M'D)_+),@\)>C_M+C_3#_``=>!)+`K0#A\^CS?SYZ^GHN\OY3235=/2O4?*W1
M%YYX86<C?G0B7C$TB!P))54_@%P+W(!:NC3P_P`_\G533Q(CJSG'KTCL'6S?
M&K_A1)O#+]]9&GP.W/E3UAFZ'H'L#=M3!B=O9ZJK-F]4T..Z_P!NYO(21T,V
MY,5D>KLMCFQPD%0&J:,HA^_A#O+VRR:L:J4^=!GK3`F2(@8%:];$.X>X>I]N
M]B;8ZIW!O;;='V5N3";@WC@-G3U23YY=L;6I'?/[OK*6%)FV_MO'13&%LE6F
MFI'GD%.DK3.(R[TYUJ]?S"-E_(#OWHK=7\Q#9'3U5@LAUUV_M[Y3]$?(&E[&
MQD^1A^*?7&+@QW6E#_HWI\?/NG'[<R%#`.QYH8:H1BHR=34R,8V^W1J:,R(0
MHJX%1_J^SJKMH4M2M.K3OEI\B-H_*/\`DI=[?(?:=5218/LGXF[HW!64\<Z.
MFW\_'C'H-W;8JI)F736;6W11UF.G#D$2TS>ZR,KV[LI!!'5&*O$QUT4CCZ="
M-_)=GBJ?Y8GQ-F@E6:-MH[O42(Z2`F/M'?43KKC+*2CH5/Y!%CS?V\I)5213
M`_P=>@_LQG%3^RIIU2'_`"I.G]]=K;N^0&\]E]H'![4Z#_FKQ]E]J]=&JV[1
M[/W]M+$XK>M#49S<>9J*5=RT62V+49B'*X^G@KXL94SXI1/32RCR1M0?`W^F
M/^'KRB8DEF`%>%/+K:IZ7[DV'WYL"A[0ZORD>X-@9K,;JQFV-STCTLV)W72;
M4W1E]IU>Y-O55)/40Y#;>6RN$J),?5J0M92:)T'CD0E[IWH5??NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]TR[D%]NY\?UPN4'X_Y49_Z\>_=>Z)U_+1!'\OCX7*3<K\:
M>H%)`(!*[*Q*D@$DV)'!^A'TX]^Z]TD_Y>)7^$_,<*'&G^87\MP==KZCO:D<
MD6_L7;T_X>_=-1?Z)_ISU87[]T[U[W[KW7#CR#ZZM#6'XMJ6_P#L;^_=>ZY^
M_=>Z_]3?QI?^`\7_``0?3W[KW6?W[KW7O?NO=$#S:#_ATGK*0`7/P#[S0FYO
M8?(CX[LHTWTV!)Y^OOW7NH?SY75G/@/P#;^81TNW/XMUYW-<CD<@>_=-2\8O
M]./\!ZL(]^Z=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KK2+ZK#40%+6%R`20+_`%L"3_M_?NO==^_=>Z][]U[K
MWOW7NNB`P*L`00001<$'@@@\$$>_=>Z*Q-\&?A=/NYM^S?$[XYOO&2I2MGW"
M>F>OAD:JOC=)8<C62C;X6MR4$L:O'4RAYXW4,K`@'W[KW#AT*V_>CNENU*ZB
MR?:'4?6G9&0QM')C\;5[^V-MG>,V.HIFF:>EH&W%C,C]E#.:A_((M'D#$-<>
M_=>Z2VW/BM\8=G9R#<^T/CIT7M/<U+CLAB*/<NV>IMAX#<5%BLM0SXS)XRAS
MF)P-)E**@K\;524\L,4J1O#(R$%21[]U[IQV5\;OCUUKN&'=O771O4FP=U04
MU51KN7977>T]K9Z2DK1+]Y3567P>)H<A6P533.\BS22!Y'+GU$GW[KW63#?'
M/H#;=9O');8Z2ZIVMDNPZ.NQ^_LGM;8&UMM9+>U'D\A-EJ^GW9D,'BZ"LW"E
M7E*F6H?[MY29YI'OJD<M[KU`.'6;K_X]]#=392IS?572_5?666K:-L?7U_7F
MP-K;)J<A1,\<HILB^V<7C/XA%')$"@FU^,WTVN;^Z]TR8_XL?&G$;B?>.(Z#
MZ@Q.\Y9ZZJJ-Z8OKW:V.WG55&3B:')2UF[:+&0;BK6R$+:)_+4OY5`#7"K;U
M!U[J;LCXT_';K+<$6[>M^B^H^OMTQ0U5.=R[(Z\VGM3/U$%<96K8J[,8+%4&
M0R,=7).\D@J))-<KLYNY+>_=>ZR;]^-WQ\[5S@W-VATAU1V1N%*:"CI\UO[8
M.U]XY.@IJ9D>&+%UNXL9D9\2J21H_P#DS1%GC1C=D4CU`>(Z]TZ]@=%],=L[
M(I>M>TNJNO\`LC8%#%20T.T-][3PF[,#0_84XI:":BQ^>HZ^&CK*&`!89XPL
MT5KJP//OW7ND7LWXC_&+KW9V[NO]E=#]7[<V?V!0KB]^83';1Q*0;UQ4?F$6
M*W;/)3R5FX\5!'4R)'35DDT$<<CHJA'8'W7NE-'\>NBX>N1T]#U)U_%U,M4M
M4O646U\5'L!2DJS+1IM!*88!,2K*`*(4XHP@T>+1Z??NO=)N'XD?%VFV1E.L
MJ7X^=/TG6N<W)%O#-==4G7^VJ38.8W/%3?9C-979M/CHMMY&MD@`$C34SB5E
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MQH"?R?S[]TU%PD_TYZL,]^Z=Z][]U[KWOW7NO>_=>Z__U=_"E_X#Q?\`!?\`
MB3[]U[J1[]U[KWOW7NB!YLK_`,.D]9#^W_L@?>1'/]G_`&8CX\7XMSS;\\?[
M'W[KW4+Y]$#-_`:X!_[&$]+`<L"">O>Y0"-/%_ZWXM?\V]^Z:EXQ?Z?_`"'J
MPGW[IWKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ75;U6O<_
MIN!:YM]23>WU_P`??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNFK/"^#S(_KBLB/H3]:.;\#D^]$@`DG'7NB9_P`M`L?Y?/PS+ZM7^RY=4WUD
M%N-IXX#5I)%[>_`A@&4U4]>Z2?\`+Q`7'_-`*KC_`+&&_*XDM]&+[GQ#EH^2
M0EVM^/4#_KG?3<8`UT8'N/\`Q75AOOW3G7O?NO==?G_8'_B/?NO==^_=>Z__
MUM_"E_X#Q?\`!?\`B3[]U[J1[]U[KWOW7NB"9L_]C2.L5_(^`G>I/^.KY$?'
M4+Q?FVD_C\^_=>Z@?/R_\:^`UK_]O"NE+V)M;_1_W(>0"-0X_P!8'G\>_=-2
M\8O]./\``>K"O?NG>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NFO.7_@N8M>_\
M+R%K?6_VDWTMS?W[KW1,/Y9JJG\OCX9JMK?[+EU4>.1<[4QQ;^O]H^_=>Z2?
M\N]0N.^:!"A2_P#,/^6+-]?41NK$H&-V;DJH^EA_A[]TW&*:^X'N/_%=6'^_
M=.=>]^Z]U[_>_P#D5_?NO=>]^Z]U_]??QIA:"(?T7_#^I_IQ[]U[K/[]U[KW
MOW7NB!YQO^QI/6"\<?`/O9CSR;_(CXZ`<6M9;'\_GW[KW1R-X]<[%["EV=/O
M?:V&W/-U]O3%=C;)DR](E6^V-]8.BRF.Q&Z<07_X"9G'4.:JXHIARJ5#C\^_
M=>H#Q'2T]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UAJ:>.JIZBEEU>*IA
MEIY-#:7\<T;1OI8<JVEN#^#[]U[H-^ENH]H=!]2]<]*[`7+)LCJW9^#V/M5,
M[E:G.YE<%MZABQV.&3S%:35Y.M%/"ODFD.N1N3S[]U[HGG\NTL<?\TPS:M/\
MQ'Y8`?064[EPS!>+?0-^>3[]U1`HU:3YFOV^?5B/OW5^O>_=>ZXG]0_UF_%_
M]3_:_'_$^_=>ZY>_=>Z__]#?RISJAC/]5O\`[R??NO=9O?NO=>]^Z]T4?*]6
M;]J?GAL3NR#$T;=883XC]L=69/.G*T29"#?NZ.X^F-VX/$IA"_\`$9Z.JV]M
M#(S-5*OAA>%8V.J1??NO=&X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%CZ.W'VSN[>G<%1NOL#9>X]B[(["SO
M76V\3M_KFMVQFI*W$XS:^5R&0SF<J-^[FIJF3#Y/+5F+6&"D@$\=,E0Y1W:)
M?=>Z,Y[]U[H"?D1OO<G7^P*/([2SNU]L9S,[UV5MB+<F\<34Y[`X'&9K/TD>
MX\M-A*/.[:J,M74&VHJR2CIEK(C/6+$EGU:&]U[HK>W_`):[MS^R>S.[,MD<
M1UQU+@NAMD[HQVW-Z[.IH.S]D]Q;VKLYBZ#9VZZ^#L0[*R%>K8S'^3%%J)Z?
M(9R"FFK%$4A'NO=*;:G?7<>[OB=N#LS#YOIO/=N=6[AR6,['R6TZ+)YOJS/4
M?7>Y:2I[+CV7#!O&HKX<A4[`6I_ASR9.JBBS"H)$>'5$/=>Z2>[ODI\ATV+3
M=\[#V_LVNZPWQV+UG)U#L'<FSMS8O?VX.@:3#Y#=_<G8VZ\K4;LH&VSG\]UU
MA\IG-IX^7$1U%"E#1T^3IY*FNFIZ/W56U8TTXYKZ=<NU/DWV/LO&;KW+3=A]
M<8O9,GR#Q6Q=J9\]-]B[]RU'UC2].'LC>%>^W=C[NKLING<$>4?[;'5\-/28
M]45!50KY?*GNK='*ZA/;G]V\DO<E5L[(9]-S9E=OY+9N'RNWH<ALAF@DVU5;
MAP&6R^>?#;L:&21:VG@K)Z9&52C`EE'NO=`E\@/D+FNG.R=@8Z'[*NVC-A3D
M=V[:HL-35V]]QUVY-^;,Z\VHNW\MDMW;>PVV=M;6&XLEN'<F0J*6N%-B,*X4
M1M(&/NO="G\?=R=@[OZ[_O'V+DMNY;(9+=N^$VWD-M[6R6SZ6NV%C-UY;#;*
MRE9A\GN3=,HR6=P..BR$DL=2L+K5KHB0#GW7NAN]^Z]T1'LOY0YGKSO7=.QL
MQF,)0;)AV_@\#@A0[-J<ON';.[\UL3L'L&O[+W[E:S?&'H6ZSQ$&T,=A*.CI
M*%*K);@SD-,*E2#I]U[J;5;\^2<V`^*N*&\NJ]M]F=RT7^__`*#)]2;KR&*Q
M?V6R<EO[<N3P..7M6@K\//@HJ*FQ"TE94UBR558)6E4*(_?NO="G6[O[4;Y(
MP[#I,ULNDZJPW5%%V'NJ:JV?EY=SC*5FX<IMV@Q$.YSO2GP>.QV63&5E:7DQ
MDLT`QYC!=96>+W7NLAWIV1/\CLSLZ#/;!INGMI=9[:WAN45&WLBV\H=R;LRN
MZ<)AL&^YVWG#@J'&S0[<DR&I\2\^E5BOIE$H]U[J'NS=G;K_`"(VCUMLW=/7
M5#LZMV%DNP=WT.>V'N+,;KH,;@=S[=P,-'A\_0=@8;$++O%\U5)&\^-<4`QS
M/:H+Z![KW0<T_P`E\]7_`"_'3F$W'T]GNK(!F=A[BHH,O!3]Q;;[GQ>PZ;M'
M[*FQU/N_)19O8^/V3#*,K/-B<?-19/(4<$<DWCJ=/NO=`-M7YL]X;LPNPMET
M6U^J$[QW+WGMK&[K1$W56;0V+\9NQ-V5]?U-VAF-NT6;J-RP;O[/ZSA6'%4<
MM='0R9RDR,YD%#031^_=>Z'+KGY!=G;[[T.P:VIZUV9#C\]O2'=/3.]=M=@[
M:[DQFQ=OTV4HML[[V;NRKJ)-@]GC<>=6@J:R'%TYH,=ALA$XK9*E&BF]U[H\
M?OW7NFC/Y&JP^!S>7H<17;AKL7B,ED:/`8QJ9,EG*JAHYJFGQ&/>MFIZ-*[)
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MW7ND9_LX'9,GQ\[`[9HJSHK(4>!["V)M;KONJFDWU/T-VG@MV;OPFW<_F,+C
M\7)E]]QG8?\`$:FFK*BE?(X^IK*&1H)BB5"4_NO=++(=R?*>#I?*=FX3#]$;
MJHJIGWWL_?5##V%A]H5?2%-U)4=@?WDS^S\O7IO*BW-F=S0)A:*E@GF'AJDK
MI8U5&@;W7NH.].]OD_UW\?Z_<N],3\=MO]Z[@WWL79?4.(S69WGA.L=\Y/>6
MV-LYF7$9"JKJD[IP-3@\G49V&IJF5RE!@YJXTNC]H^Z]U%[4^8>6VWUS\:][
M[?W=T%LJD[KQV9K=Q[G[:RFYQL;"G";*DSE5_=[)8.?'FOCDW-&E!":J6`SQ
MU"/'JE`AD]U[I2Y_Y1]B["V_T?V%V1UM3;<V?V9@L]MO-;2Q]/N/+]EGO*NF
MI?\`1#LS:5%-28N`XKM2*CKH:9<K34-;1UD]%%5K3EJGP^Z]T:?JN?M"IZ]V
MI4]T4&RL5VC48Q9]YXOKJLS.1V7C,K-/-(,?@<CN"&FR^0IZ*D:*)YYHHO-,
MKNJ(A51[KW02;T[+[DS6>WOANB]L]>5E%U@::FW3N7M#.9O&8C<&Z9,53[AJ
M=B;63;E)5ST,N-PE;2MD,W6%Z6AJ*R.*.DJVBJA![KW0*;D^4?:6>[&V#L7J
MJ?H7$9+L?H_979^U-I=IY'L*7>N;W-O3';VS<.UZ-MF8JHVVF+Q.$V9-/65K
M532PI=_`8BLA]U[H]&UJG<-;MC;E9NW%T.$W55X'$5.YL+C*\Y7&XC<,^/IY
M<UB\?E&AIFR5#09)Y(HJ@QQF:-`^E;V'NO=%.K_D/V%7_("JZHVQC.J,71X+
M<."PM?M+LC<^Y]I]K;SP%=)C:G</8W6\(V_4[3S>!V_AJJJJ*6@BGJZG)G'S
M"6;'FRCW7ND]F^ZOEN.U\GL_:O4?5.2P5#)BMQ)BLMNC=F.WS_H\R';S=:P9
M.KFBQ,^U:;+93;V,R6Y8%\Y2*CIEII$:5FD7W7NE[M_Y!;BR?R8W#U'-1[`R
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M*0]775.CQP0KZYIF5%NS`>_=>Z`?;7:_<*;VVGA^S.LMK[,VYV?BLO/LO^';
MVDSFZ]H9_;^`.XJS;?9M`V'H<.TN2Q4%3*E7A:JMIJ*>E>FD,HDAJ7]U[H/O
MCS\CNT>\)MJY>GV]T?E]HUU3+0]AOUGVSEMY9SJFKKMG3[OVQ#G?NMFX;$92
MLRT+X^.>BCF@K:-,K!*\9C5B?=>Z-7O_`#FYMN;1R^6V;M1M[[IA6BIL%MC^
M)QX6#(Y#)9&CQL#Y'+RT]8,7A\<:S[JNJ%@J)(J.&5HXI7"QM[KW1.:GY8]L
M83K??W9NX.F]C)M;;>UJO,[6W13]O5F*V7N/,X[M*NZR?"9O<6Z.N\-)M2#+
MQ4:YJEJVIJJ.&@G1*@1R>H^Z]TI-P_++(4.([SW'M/;/6V^-M=0P=58_#[DH
M.Z\5C=N;RWCV#48R',[;R&XYMJUF"V1!M-,Q22?=U%15BI2KB,D=*"2/=>Z&
M3IKLO=_9*YZNS6UMGTNU(8,!6[%[#Z][#7L/9'8]!EHLB<G48*NDVUMBL@3`
M5="D3R&*:FJUG22"5EO;W7NIG>/<&.Z4V93;JKZ&EKI,IN7`[2QG\6S4&U=L
M4F4W!4O!2UV\-Y5M)78_9^VJ98G,U=/#*!(8X8XY)IHHV]U[H(=Q_(CMS;/7
M$&\ZGX])D,D*K?=;6''=M;9J>O'V)L[`5&>P^_\`'=B4>(KUDQ_9$?V\.#HJ
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MBM[#Z#W7N@FW[W7N7$9K<.`ZNZKR?;]=L2EIJSL-\=NO;VUJ/;SUE$N6I=L8
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MB?Q/;F;A1FI*R*\,ZH=)-C[]UZ@'`='Q]^Z]U[W[KW77Y'^L?P?\/S]!_P`3
M[]U[KOW[KW7_T=_&F-Z>(C_4#^O_`!//OW7NL_OW7NO>_=>Z][]U[KWOW7NO
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M;AH]U;8@S0IB#D\'%G<?!/443GPU7A5)`R:E/NM]!53_`!&ZOHLAB*NARF_:
M:BQW?F_/DCD]OR;KDR>WMV]E=@U.1K,BVZ\;FJ/)_P`0VW@JG)O)A\;$]/3X
MR2.%X0'AB9/=>ZS2_%C:HVIW'L[%]@]K[=P_=V\LAO+=']W=Q8+%U&%?+82@
MV[EMN[,:+:S0;:VUDL/C(8I8HXWJ"ZM*LZS.\C>Z]TH9OC_BJFNZ/KZSL3M6
MLDZ+BS4.*IZG<F+>AWZF=V\VUZL]H4(V\M-NEX<1+(D!B6C,+RNPY8^_=>Z#
MNC^&.R<'3=>TNT.SN\=EIUK/O^KP3X'?6/J)\A6]CY.;(9JLW'/N3;>?DSDV
M.I9%Q^-$Q\=!C88X(E"HI]^Z]T87K3K_`!?5VR\1LG$93<>=IL9)E:RHSV\,
MQ+N#=.>R^>S.0W#G<YG\Q,D)K<IE\UE:BHE*1Q0H9-$4<<:HB^Z]T'':GQFZ
MQ[DSNX-Q[V7<LV2W#T3V5\=YCB]R9#$P8S8/;+X\[TK,%#2,JXG>-;%BX(H<
MO%:KIH4*1LJNX;W7NGO-](X7+9+HNLQ^].T]GXWH/*RY+`[4V1O_`#.V=I;Z
MI3L;+;"H]N=N8.A;P]C;5Q%#E?OZ2@K6,,67I::KL9($]^Z]T,_OW7NBP[W^
M(G3O8FX>S]S;J@W7793MS)]#9#=CQ;MR])#%3_'/=M-O?KW!8&&GEC&"V[4;
MBADFS%)`5CRZU4Z5&I)+#W7NE%N/H&BW-W/M+NNK[-[7H\ELF"KI<!LC'9O;
M<'7L%/E8,=3Y^*;$3;2J<Q4?WACQ,`JF;(:QI(A:$.X;W7ND7N;XDX#=V[-^
M[FSO<'>]3C^S*O`KO'9$6\=OTVS,EMC;LU9+C]@P44&SH\QB]FRIDZN*IAI:
MZ&JJXJN435#ZKCW7NN&7^(NW,_O7>>\,WVSW9E*'L'<^U]Q;OV'5;DVD=B9>
MBV;5)5[>V<<;'L:/+T6SZ-HPCT]/715%2FH33R%Y"WNO=+S&]$QX[M[.]R?Z
M5>V:[+Y[`S[8?:U?E=H2[)QF#^[R>0QM#B,7%LJ#)TPPF1RTT]/(];)*[E14
M-.B(B^Z]T%A^$VP8=A;#V1C.Q.W,+7[%W#N/=$G96-S&RAVOO;,;KI-V46:J
M=^[XK=@UM=GC60[VR!D,:4SS/(C2M(T:$>ZT16F3@]+BF^,.SZ0]1+#NS?J0
M]/X3^"4,4-;M>BFWM]ML3-=<X'+=@Y7'[3H\YFLOM+;6XJT8F2FJJ&.CJ9VG
M$9DL1[K?4OK?X[X_8>6VKF,YV9VGVQ6=>[;_`+I]=R]H9S#9JHVIB9<918G(
M5[U^)V]@\CNO=^8HJ+Q5><S4V1RDT4CIYE\LQE]U[K+\?NE,SU'1=A9G>G8>
MXNS^RNW>P\YV/OK<F7K\P-O8N:M6#%[7V'UMM/(Y?+4.Q>N^O]H8ZBQ=#14C
M*:R:"?)5AER%=53/[K0%*Y)J>A&[/V%3]H;!W/L&IW1O;94.YL?]@=V=<;BF
MVGOC`2+4054.2VUN*"&H?%Y*":G4JYCD1ENCHR,RGW6^@'W+\4*/>FW=[T.Z
M^W>SLGO#L*FVKA=Q]C4\6P<=N*+9FT,TV>QVP]O8R'9+[4P&U\AD))),BL5`
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M/O1?Q3M*/&5^V9JJCWS-24"T:-#4)1PT$U1!'`JU,^OW6^@YV#\0,3LNBVQM
MW(=B[AWAL';W7G976DW7N5VIUSB-L9/;_:FX(MR;D18-J[3P4^#6GJZ.FIJ*
MGQ[TU)34%+'`(B07/NO=*S(=![MK*7I"A3OC?34G2]3C:]VRVW.OL_D.P\GB
M:&IP='E-Z9/);9DJ6R']V\C5T[RT/V;/53+6<5$2'W[KW1F/?NO=%JW+\<AG
MMP;SDH>S]];9Z][/KUR_9G6F$7`0X[<F4.+Q>%R$N*W/+B9-V[1H=TXK#PP9
MFGH*M!5C6\+4LTT\LONO=/\`L+I>KV+V7O\`WS'OJNRNWMZ1X),9UY-M;:&-
MP>R!MC!T&VL%%MK*XG$TF=^THL'330^&HGF4FJD(TKI0>Z]T.WOW7NBJ8/XT
MYA,_M6?L#N[?_;.SNO\`>M7V-L7:V]<;M,Y7';REK-P56(K\_O?%8>@SVX\?
MLZ+<DU/AZ2U*L,$4"U+59B!/NO=+3!=3[UPV^^VM\S=OY7*3=CX:EPVWL54[
M+V=!2]<P85LN^UOX35TE##D-P1X2;/5<KQY.2H6IEF);2/2?=>Z#39_Q$PNR
MJWI'/X?<V-BWQU=G=Q9_?78J=8]?0;[[PJ]V8;,XG<?]]]RPXE,ECGS]3FFR
M%>^/DA-57P0.0J1+'[]U[I8;2Z6[)VU3=WSU7>=9E]S]N5CY3#;J_P!&NRL7
M7]>9*/;T&U\3)CZ6BC%'N:CP>(QE#]M!DEE_>AEDD=_N'4>Z]U"Z;Z`W;UAD
MMM/F^X:_>.WMG;*H]H8';-#L?;>QJ.HEH<7AL#29_=53MZ5IMTY*@P>%6FI$
MG"0THFE9%N4\?NO=#;V%L?#]E;)W+L3/25L&*W/BI\;45>-F2GR6/D?3+1Y3
M&SRQ5$$61Q=;%'40&2.6(31+K1UNI]U[H`,A\==^[EV_O([T[VR>XNQLUL7<
M77NR]\Q=?[8Q6)ZUQ.Z:*FH\]F\'L..HJL/E-X9A:934U];/(FA%A@AIZ<S0
MS>Z]T,W46P*GK/8&`V?D<QC-QY7$45-19'<N,VGBMEKG?X=2T^)Q555X+#2S
M4$%71;?Q]'1%U<AXZ5+!%"HONO=*O==!N'*;<S&.VGN&GVGN.LHI(,/N2JPD
M6Y*?#5KV\==+@IZ[&PY01"_[33QJ2>3Q8^Z]T7M_CYN>HZIZDZKKNR\76T'7
M^\MF9_>%7+UC@_L^S-N[,S(SM/M>OP!R[XS`397(TM+/55\'F9YX6=85$A5?
M=>Z3N7^,.\*W$;BQ&-[8P&*I=P_(.#NNHHATWMR;#3;>Q.(PF-VUUEE<-2Y[
M&TV8HL/4;;H)Y,K(4K*LTJJZK^KW[KW0Y=3;!W#U]A<EC-Q;PH]U/4Y.*7"T
M6"VE1;#VCL[;M#B<;B,3M3:>TJ')9B+&8RCCQ[3R,U3*TU342,!''XXD]U[K
M!VCLSL/=<NW9]B]@8C:U+C!N"GW1M'=>Q:#?6R^P\7G<2<;!CMR4C9+!9ZB3
M"5#?=P-05].)WO%4++"Q3W[KW039?XSY->@Z3HK9N]\'M^DK,K/E]W9W([`B
MR5'EI\ANB3>V9I<!M#";EVIA-IXC)[@<Q+10-)3TF-=H8E$EIA[KW2@[-^/4
M/<N\]HYCLW,XO<^Q-D[=K9\%UM_!<UBJ.#MJN1Z#_2F^XL5N^DKY)<;MJJK,
M718YH6%/3Y*J?[AI)!H]U[I'XKX\]H[9Z?Z4ZJV[VEM'1U7NO$9[,9')]?[@
MEI-T87:^YVS^T]HT./@[(6LPF/P]*8:9IZFLR<TYHH)6`)D5O=>ZG=J=$=A[
M[[.J]_8G.=+QI0;8P.#Z]GWOU)DMZ;KZUSF.K\OD\AOC;&=??&,HZ/<515Y2
M,P&"DIP@H8!*TPN![KW1I</0S8O$8O&5&2K<Q48['4-#/E\D8#D<K-24T5/+
MDJ\TT-/3&MKGC,LICC1/(QTJHL![KW16JWH#L3'[C[6HMB]G8O;?6G>>Z)MZ
M[\IJO:\V1[#VWG*_;VU]J;EI>O-RQYBDQ%+C]V8/;2`2Y&AJZG#54LDM,TJM
M#%2^Z]T[['Z"EV_W+N#L+/XSJO+X*AQNW,3U%)3[/R9[$ZWQ>V=L2[1I,-3[
MOS.<RT38RIQ.5R9E6DIZ-F>O<-K!=G]U[HS_`+]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNB`6#?D`@?[&W_`!3W[KW7
M?OW7NO_2W[Z,6IH1>_H^I^IY///OW7NI/^^^G_$_0>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZXD>I3^0&_K_A_L/]O[]U[KE[]U[K_]/?QI?^`\7_``0?[[_8>_=>
MZS^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;:
M[,X?&5.-H\EE<;CZO,U34.'I:ZNI:2IRM:L33M28V">6.6NJEA0N8X@SA03:
MP]^Z]URGRV*I:['8RIR>/I\EF%JVQ&/GK::&NRBX^))Z]L=222+45RT4$BO,
M8E;QHP+6!'OW7NL%)N#`5]?4XJ@S>(K<I1B<U>-I,E15-?2BFG6FJ34T<,SU
M$`IZEQ&^I1H<A38FWOW7NLQR^)&67`'*8X9U\<^77"FMIAEFQ,=2E%)E%QWE
M^\..2LE6(SA/$)6"EM1`]^Z]U@QFX<!FIJNGPV<P^6GQYB%?!C,G15\U"9_)
MX!5QTL\KTQF\+Z-875H-OH??NO=9*7-X6NIZNLHLOBZRDQ\E3#7U5+7TE13T
M4M'J^[BJYX97BII*70?(KE2ECJM;W[KW76)SN$S\$M5@LQBLU305#TD]1B<A
M29*"&J2..5Z:6:CFFCCJ$BF1BA(8*X-K$>_=>ZR8_,8G+-D$Q64QV3;$Y"?$
M91<?6TU:V-RM,D4E3C,@*:60T>0IXYT9X9-,B*ZDJ`1[]U[K+7Y''XJE>MRE
M=1XVCB*"2KKZJ"CI8R[!$#SU#QQ(7=@!<\DV]^Z]U!FW)MVG-8M1G\+`V.6F
M;(+-E:&(T*UEOLVK`\ZFF6KO^V7T^3^S?W[KW4>/=^TYL<<Q%NC;LN(6<TIR
MD>;QKXX5(C,IIS7+4FF$XB!;1JU:1>UO?NO=2JG<6WZ+'4^8K,[AZ3$5<4<]
M)E*G)T4&.JH)H?N(9J>NEG6FFBE@]:LK$,G(XY]^Z]U'?=FUHL=#F)-R[?CQ
M%1Y33Y1\SCDQTX@OYS#7-4BFE\.DZ]+'3;GW[KW3BN5Q;C',F2H'7+H)<25K
M*=AE(S"*D28XB0BM0T["2\>H:#J^G/OW7NLM+745<LS4592UBT]1+23M2U$5
M0L%5`0)J:8PNXCJ(2PU(UF6_(]^Z]U@RN8Q&"HGR6<RF.PV.BDABDK\K74V.
MHHY:F9*>GC>JJY88$DGGD5$!:[.P`N2![]U[K!D]P[?PK(F9SF'Q+RA6C3)Y
M.BH&D#EU0HM5/$7#-&P%OJ5/]#[]U[K)+G,+!5TU!/F,7#75C1)1T<N0I(ZN
MJ>9'EA2FIWF$T[2QQLRA02RJ2.`??NO==5N=PF-G%+D<QBJ"I:%*A:>MR%)2
MSM3R3BFCG$,\R2&%ZDB,-;27.D&_'OW7NN=5F,10R^"NRN-HY_'%-X:JNI:>
M7Q3S_;0R^.:5'\<U3^VK6LS^D<\>_=>Z]4YG#T4Z4M9EL;25,C*D=/4UU+!/
M([Z-"I%+*DC,WD6P`N=0_K[]U[J2U92*LSM54RI3L4J':>(+`X^J3,6M$P_H
MUC[]U[J3[]U[K`E5322/#'40/+'(T3Q)-&TB2HD<KQN@8LLB12JQ!%PK`_0C
MW[KW63R1F]I$-BH/J7@MIT@\_5M:V_K<?U]^Z]UR!#"ZD$7(N""+J2"+C\@B
MQ_Q]^Z]UZX/T(X_XJ1_O8]^Z]UW[]U[KWOW7NN@0>001<BX-^5)5AQ^018_X
M^_=>Z[!!`(-P>01R"#]"#[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO__4W\:7_@/#_P`$'^^_U_?NO=9_?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5CU"]%;[[*[^V#\J-EMO+M#>6
M_<CU]L;:&4V1N_<.43HC*8.#$[+J^J\CC**LBV_ALE2UN4R69SN%J:">AR<E
M1]]40R4,'A]U[I&Y?$;$WPN\MF_W5RE9\PLKW/3^.NKL#N&/+=';3Z[[%Q]1
ML?=N`WR^)HZ;:'5FV^JL?0U]%/CZE8MQ5>0>!UJ*NOJH??NO=*CHONWHJM[A
M[6W+UIL_;F:[C[P[IK=L8RIV]L7([<S4_6^U=K4%`F^-U;AR&U,35U>T9LYM
M>ORE1-]Q,E5)5QF`R2-&I]U[I`[.J^DLEANK]R8?#Y^O[_V9OBA[J^37;>X]
MI[RQ^_>J9=I4]9E>ZL/OO<\V`I,I3T64I\?5;4P^T:4S4M9CY(OLZ22AIC4I
M[KW04]`;EVWT:NU?D#VGAMEX78=/T7V=WAU9NKH7J;>&$W#V3)OK==3F.Q^N
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M#0?WUK>O<'B\A'5Y]A4&2;.&F^YFFBJ$@]U[IR^><^W,]U)M3I?-Q[;J*_Y`
M]Q=4=88&GWALS,;\VO\`=2;WPVYLC4YW;V(A`J*"/$;>FC#5-7CJ99YH]=5'
MQ?W52P6E?,TZKQWKOCK/+=?=U93L&MZ,R&^/D#\SMO=0;DW35]([^I>O*K:7
MQ8;9\TC;KVK4I7[IRV'Q46U*B%JB7-#'S5&90T58D;QI[]U;I794=1[HZOZH
MVKU;B>DT[+[X^1?6V&W'E]W]*;PQ'QX[:WK\>-H4&<W5G]F;'Q]`[8#9DNXJ
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M]S/MG<F^=X[6WQNKL:'=&$;<&['I:3I[%=5==;>V]NS)[>KZ3`&/`[HS&X:6
M@6K35D(JO)>-IK,/=>Z?-Q8_XK[K^7/Q[Z;JH=D[AW+T3UIN[&T=!N;:XW/E
M9\KC:+:^%V'M*LW3E\54P5>3V[A'S&96FEJ9)HY]%6J*Y\OOW7ND;MK9G6/R
MF^5_R8D>EZ`WYU]3M%U7V?B-P=?9RH[PAEVCL2FVSBZS:>\,D8,1B=LINW<6
M=@:MHZ?[S[G%QFGJRH*Q>Z]TX;9V+T7VO\L^ZNEL-N3:F9ZRVENC8'R)[,Z:
MBP%4DVZODGC"=I25NY<O6T"8O<^S=EIL+;F;JZ")YYFW;)!-5SF)32R>Z]U:
MC[]U[JGKJ+K7X>3]C]T[VQ69VTN!^+FX^N-ZQ;^PM6TF^\AE=DT._M_]@[N[
M#W*<6^3W7'GMV[_KJ3)24[7KSATI')%*(O?NO=`QU#N7KGJ67H#=_=6;Z2I=
MD]-]`=T?-_;U!UYM7>T.]:63NG<^,Q^,KLM3YZIKL3E\WEHMZ9*F6&D^WJ5R
M]#&L<,-.(U3W7NA/^.-#-M[N7N[8'<>%V?T7N/Y2?'K=7=79,.Q.X<=N#(QU
M1W'E,*^9PDV/Q&+QFPX.O^N=V4])2UR1O_%)Z*:O9II(9YG]U[H;/A#TO\:<
M[7Y3Y(]-G:TTU)V%W7M':59UY6RT>&@V`]?M?96!V_N/'*?)7-!M[K>@RM!'
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M[J#F\1\3-MY_;,FS]XQ[$^+O>/9FYZ?N#))N[>VU>D,_OSJG9-+B]E[`P&9K
M\CB]C;,V/ON9ZNOKFPTU)A=WY'""G:6KDJJF&J]U[H(MWXS9VZ9>O.J>F]C=
M=[HQ.[.[^S>^OC=TMV_V)N[K;;F>Z^V#T[)A,]7;8CQHS>Z<;LGLON3=%1D,
M-0SXV3!O01SU:TQII$1/=>Z==LY+XH9_'?%?:_;_`&/M*OVCM'JSN_NB3:F\
M-T9;$T>`R&[MTT&P\=U)MO:^3W#4[FRU/UG7MG\#CL5.V1KZ:3!I'$OF""/W
M7NA6WY1=4UG2?QCZB[OK,#B<KO#N'$5NUME]P=A3XKL?:O3E5O3=.\<'B,A5
M93<F-W5+64W6VWZ/;-4]9)+,SS-0SM)4N0WNO=)_Y`;NV%LGM_MS?&!S=%0[
M9Z/Z/VI\6NS=FT&X\ED,!)A>ZL'N?)=>5.\]J8_*VP9VKOL[9QE#DE@6NBQ^
M?R:F;QV4>Z]TC-WITSL'KW?^SNQ=OP]J[OZ,I<'TSL3X^;D[UGZIW%1=>X'K
MK;JR;_ZLI<UEZ'-;DWAVMNR>6HQ^>A>?*U4D]-105T,U#,GOW7NKB-BX*/:^
MR-G;:BBRL$6W=J[>P4<.=S]9NO-PQXC$4>/2+,;HR,U3D-R96-:>U17SR235
MDP:9V9G)/NO=5H[ZZ+^//<?RVWCUMEM^56=[`R'76]-_;BKJ+MVJI]^;,W!G
M\UL7;6SL/MO:^!W%CTQ--L#:6U\C-0+48^=J*3)"J9O+,'D]U[I*Y++;'[0V
MY-O"KW9E,I\X=R=PY'!=>;!H-]Y:GWCTCF-I;_R&$Q^UZ/8V*GBBVCUYM38^
M"GR>YJW)X\T6?IZBJGJ)ZB*OHHO?NO=7!>_=>ZJHV#U!\==P_(KMRNH^TSF-
MU=&9#KCL7=N[9>XZVORL&\CO_=G9F^<KN7;M#NZ';&W</3X.EQFW*AI\='!3
MXA:BC&@`Z/=>Z#KI:LQQW-T#6[XS?2.*ZY>3Y$?.2AS>WN^=Z97<#[.R%9)#
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MV?HMQ3IV7LG!U&>I*/&UKXZ/$9*GE@O]Q51CW7NA&FS='`W:O6O2/?L%%MK=
MN\^N=I]6IO[N/,5=/NCL+$4&?WC\@>I>F>W:VIW/O7%3U?6&&IF-10OFY=LY
MG^(2P0HT$T%/[KW1B/B%58;(;&WA6X-=\8VDC[%S6#J=I[I[1/<FV]HY7;&+
MPF!R6-ZN[!FJ<A6YO8U?447WSB>IDEILS4U\#)3-&:6'W7NG+N7,5.X.T>L>
MEZC?E=UOMK=&W=\=@;CK\-EHMN;GWY1;`J=L0'K_`&SN9:NGR>"IQ_>/^*9N
MHQVC(C&T8BBFABFJ)4]U[HFVZ-W;GR.R-N;-Z<W)V)V5C,G\GMT3](X^D[[K
M>NMS]E]4=9=<U6:W?MBB[AJS493<O74?:"U6&H:JHFKI*K&_;'[QPD55[]U[
MJP[J'KNOZ[P^:@R&[=\;DDW+FJ?<RXO>^]<QV`VQY)]MX#&9#:.W-S[B>?/U
M^W(<OBZBLB-5*[^:LDTA$THONO=`;\FMC9_<6\.IJC']K]I[5BW-O?9.PJ':
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<3;4O];-;D_3B_`X/^Q]
M^Z]UR]^Z]U__U=_&E-X(C:UU^GUMR?S^??NO=9_?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==6']!];_[&
MUK_Z]O?NO==%58$,JL&!!!`(((*D$'Z@J;?ZWOW7NNPJJ6*J`6.IB``6(55!
M:WU(50/]8#W[KW7%XXY+:T1[?36H:WT^EP;?3W[KW6%Z.DDAJ*>2EII(*Q94
MJX'@B:&J2H5EG6HC92DZS*Q#A@0P)O?W[KW7!\=CY,>V)DH:-\4]&<<^,>E@
M;'OCVA^V:A:C*&F:C:G/C,1704]-K<>_=>ZQU6)Q==CSB:W&X^LQ92",XVJH
MZ>HQYCI7CEID-'-&]/HII(4:,:;(R`BQ`]^Z]UG>CI)*A*QZ6F>KB4)'5/!$
MU1&@\ED2<J944>5^`;>H_P!3[]U[K!+B<5/40U<^,Q\U532^>GJ9:*FDJ*>?
M4[^:&9XS)%+KD8ZE(-V)_)]^Z]UQK,-A\A,E37XG&UU1'&L*5%90TM3,D23"
MH6))9HGD6-9U#A0;!Q?Z\^_=>ZS1X^@BEJ:B*AHXYZPH:R:.FA26K,?^;-3(
MJ!YRE^-1-OQ[]U[J%5[<V]7Y;'Y^NP.&K,[B(YH<5FJO%T-1EL9#4?\``B+'
MY*:!ZRBCG_MK&ZAOS?W[KW3S[]U[IC@VQMJERT^>IMO8.GSM4\CU.:@Q-!#E
MJAYHH8)GGR,=.M9*\L%/&C%G)9$4'@"WNO=9H<!@J;,5NXJ?"XFGW!DJ6GHL
MCG8<;1Q9BOHJ3_@+25N32%:VJI:;_=<<CLB?@#W[KW3M[]U[I+TNQ]E4,V5J
M*':&UZ.?.P5=+FYJ7;^)IYLQ35\TM174V5DAI$?(05M1.\DR3%UD=V9@22??
MNO=8CL#8A2.,[*VD8XL-+MR)#MO#%(]O3O+)/@8U^RTIAII*B1GI1:!B[$K<
MF_NO==;>Z_V'M*MK<GM39.T=LY')PQT^2R&WMMX;"UN0@AD:6&"MJL;14T]7
M#%*[,JR,RJQ)`N??NO=/6:P>%W+BZS![BP^+S^%R$:Q5^'S6/I,KBZZ))4F2
M.LQ]=#/25,:31*X#HP#*#]0/?NO=,^1V%L7+T%/BLMLO:>3Q=+C*?"TN-R.W
M,/6T%-AZ2JH:VEQ-/1U-'+3PXRFK<7331P*HB26GB<*&C0CW7NL&WNN>O=HT
MV5HMI[#V9MBCSL:19RDV]M?"86FS,444\,<>5@QM#319&..&JE11,'`61@.&
M-_=>Z]B>N.O,#M:LV-@]A;,PNR<C'70Y#9^)VO@\=M:NBR:&+)15FWZ.AAQ-
M5'D(SIG5X6$J\-<>_=>ZCOU;UC)A\#MV3KG8C[?VK7+E-L8)]H;?;#[<R:&8
MID<#C&QYHL/7(:B2TU.D<@\C<^HW]U[KCN3JKJ_>4DLN[^M]A;JEGR$.7GDW
M)L_;V<DFRM-B_P"!T^3E?)XZJ:3(084_9I,;R+2_M`B/T^_=>Z[R?5?6.:VY
MC-G9CKG8N4VEA5TX;:^0VE@*S;V''BE@_P!Q6&J,?)CL<1!.Z#PQH0KL/H3[
M]U[I483!X7;6)Q^`VYA\7@,%B::.BQ>%PF/I,5B<;1Q"T5)C\=0PP4='31#]
M,<:*J_@>_=>Z8MZ==[!['H*3%=@[)VIOC&4%='DZ''[MV_BMQ4='D8DDB2MI
M:;+4M7%!4F"5XF=0"\4CQM='93[KW3=F.H^JMPUFTLCGNM-@YK(;!BB@V)7Y
M79^WZ^MV5!`]#)%!M&KJL?+4;;A1\93$+1-"O^3Q\>A;>Z]T(7OW7N@ZW7U%
MU;OK<6W=W;SZ\V=NK=.T)(9MJ;BS^WL9E<UMN:"L2OBEP62K*:6KQ4BUD8<M
M`Z$G@W!(]^Z]TUY_H;I3=4F^YMR]4]?YV;M!-LQ]D2Y3:F&K9=^)LR;[C:*;
MNDGI'?<*[8F&J@%4912G_-Z??NO=<,CT)TOEM]X_M#)]8[,K^Q<548^KQ>]:
MK!T<VY<=/BJ6FH:!Z++/&:NE6GI*.&/2C*K+"FH'0MO=>ZYTW0W2M%OV;M"C
MZKV%2=@U%74Y*HW92[8Q-/EZC,U@C2JW%//%3(LVYZFGB6%\HRG(-3CPF;Q>
MCW[KW0L^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KW^^^O\`Q'T/OW7NO>_=>Z__UM_"D.JGB((-TO<?0\GD<#_>O?NO
M=2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>_KP>#_`+?@&X_V_OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z\.>1]#[]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KHGD#CF_];\6
M^GX_/OW7NN_?NO=?_]??PI3>GA/^T#\W_P!Y'OW7NI'OW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBK=G?)7)[-R^[:;8_3V[^V
M-O=4Q05_=6Z\!F=M8+';(H?X8FX,EB]O0[BK:2?L3?&#VLZ9.KQ%!X_#33T\
M;5`JJB*G;W7ND3O+Y;[SHM\;QVCU;T/+V]3[4VWM3<]#68GN'K;;>?WM2;FV
MP=WM1[,V-FZK^\N0R6-PI20I4QTB5!FB\3L&8I[KW4?<7RX[$HMW=H;9V;\<
M:[LA.L=U_P!VYX=K]R=8OO3=-+24.S,CG<UMOKV6M;/M#MZGWO3)5059IIEG
M4H`0\+R>Z]T*2]W[]_TY[@ZKJ.F)*38^U,#CMU[B[CJ>S=D183$[<S2;@BPU
M76;5:4;F@JZRNVM7*T3HD4--")VELP3W[KW3!M+Y);YWGN3:,^'^-_9,O3O8
MTE;!L3N`YC:2PR1T^V=P;FQ>YM[[$ER46Z]B[`W?#@%I\1E)4JIY:C(42U=)
M1?<*5]U[I/\`Q[^5'8/>&5V;_$OCMEME[/WEM#)[E&]<;VOUMV5C]I9&DI-N
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M5U<D<(="X8>Z]T`'8WS3&T>F^MNW=I],;W["AWULK=?8.=P]'F]I[>H>M]M[
M`VXN8WM'O'>>9R0VK'G\=FIHL+0T5/43'*Y%W-.Y@BEF7W7NDUN+YK]D;:V=
M5YJO^)780W7A,_O_`!NY]JR=@==46*Q6(V%2;!5\OC]_9+(T>UL_6[GW'V5C
M</BL?3N*BLKXJW2?%1R2'W7NGC?'S+W?L'J#;_9N8^-._)L]7]K;MZRSO6-+
MO+8<.Z<;1['RFYZ7<^_=OUF4R6-PV\=I8G`[1KLY*\$T$JX:EFJ`IT!6]U[H
M7.PN_LOC,[0;*Z7ZQRO>V^JC;&+WUEL=BMRX+9>UMJ[*SD]52[>R^X][;D+8
M^GR>[)Z"J&(QM/#4UE9'1U$SK!3Q&8^Z]T$\7S6KG."DR70>_=AKD_CUV#WM
MF,+VSNOKCKK?&T:S8N8K<#3]=[AV=D=S5M9'EMTY"D#4>4IYI\,M*_FEJ$&E
M6]U[IAS'S4[/I8ML1X3XG[FS^;SW0NS>\*O:H[FZ?Q>YZ&HWE3[MJJ/K#&8:
MMSGWFZ=]QQ;-JQ']BLF/J71UCJ3XV]^Z]THMU_,3>&W=R;ZI<?\`&?L'<NR^
MIMF;%WUVSN?'[RZYI-P;-Q.[]J5^\<K00=>Y'/4VX,_N+9.%QSRUU!`ZU%3J
M1:$54KK&?=>Z.MA\OC<_B,7GL-5Q9#$9O'4.7Q5?!J\%;C<E315E#5PZU5_%
M4TLRNMP#9N1[]U[HO^].[=_[<[PV?T]@.B\WO/'[KPM5N>7?]#V#U_A\7M_;
M>#RVW</NO*Y;;N9RU-NF3^#UF[*%:>*FIIVKV:4)H$+$^Z]TF8OE3-FNSZ[9
MNP^G=]]D[)VWV=1],[^[)V=E=EU0V#V#/*J9%]Q;#KMP4&\X-B[9\T0R69^W
M&CR>2FIZJF4U'OW7NC;^_=>Z++L;Y)T^\OD1V?\`'NHZZW5@*KKO$4^7Q_8M
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ML;#GJ)6EIA69.$K%I>7QAA[]U[H0>G^Q*KMCKG:W8T^RMQ[`I]X8NDS^(V[N
MRJVY59],#E:>*NPF0R`VMF]PXJCFR>-J(YOM_NGFI]>B55D5E'NO="7[]U[H
M%>\>[,7T=MS&YZNVGNS>U3ELCDJ*CP.SDP`R*TF!VKN+?&Y<U75NZ<]MG`8W
M$8':NU:VHDDGK(VEE6*GA62>>)&]U[H&*#YD-E=MX;+XWXY=_P!9GMP=F83K
M#$[+2AZQCS<N0W+U50]RX3<E1D)NS(]KP;1&RLBG\0JA7O+BJZ.:GJ84,3-[
M]U[I8;<^4^W=VYSJ3;N!ZZ[/J,MVEF.VL'D::JQNU*'_`$59'I'*4V`["B[)
MDEW@8D3&[DJX\=!-@VSE/5U3KXI&B=)&]U[I(8KYF4VX\/UIE-K?'[O?<%1V
ME%VE48G'01]0XX[<HNI=TTFT,WD=ZY;,=MX_!83'[@R]=&N%DBJJO^(!T6T<
MCI&WNO=&:ZVWS1]F;`V?V%C\'N?;5#O/;V+W'1X#>F(.!W9B*;+4L=7#0[@P
MWW%6,=E((Y`)8A+(JM]&86)]U[H*^Z?DKM3HS=_5&TMS[1[`SG^EG/O@J+<&
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MDONM$A:5]:=/6`^8NP,UOR?9%=L7N/:=&.W-S=&XWL'=FP_X;USG>RMM5LV/
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M&U\U16THR4%351>?'U#05\*2!FA`#$>Z]T->^M][3ZTVKE=Z;VS$>#VWAD@:
MMKFIJVOG>:LJH:#'X_'8O%TU;ELQE\KD*F*FHZ*C@GJZRIE2&&.21U4^Z]T`
MN!^8?4&0@WN=UTW8G4V2Z[VYMK=^Z\#VQUMNW9^8I=M;WS^;VML3)8N.3&UE
M%N:JWMN+;E=0XW&XN>LRTM;3_;O2QSR11R>ZKJ&HKYTZE4GRSZWEV?VKNS)[
M=[8VS4=,X*#=>^-D[GZNW9B.PXMH5L%=4XW=N!VA+0OD=T[?R<.*K1%-CON2
ML]#4TTBQU,$L*^ZMURQ_RQZWK:6)JG;O;N#S']^^O-@9#:>X.HM]XG=>#KNU
MLS6[?V!N3.XBHP^K&[!W#F,?-3)GG?\`A<-1$\,TT<R/&ONO="CL/MC:/96:
M[&PNTCG*P]7[OEV)N3,5>W<SC-MU>ZJ*C@J<UB]KY_(4=/C-V?W;GG^SR4V/
MDJ(*+(QRTDKK40S1I[KW67LKM79?4^)H,GNZNK149S)+@]K[=P6(R>Y-V[PW
M#)35%9!@-J;8P=+79C.966FI))&6&(QP0QO-,\4*/(ONO=!I-\K>HXMH;.WG
M`^^LI1[VWCE.N<9@L#UCO_<&],9V'@J3-5N>V-NK9>%V]7;EVEN7"0[<K_NH
M,A34XB^U8ZM+1L_NO="1U?VSLON'!Y3/[)J<Q+38+<V:V9GJ'<&V=Q[1SF#W
M3MZ2&+,X3*8+=.+Q&5I:NA:H2Y\1B<."C,/?NO=(OLOY,]0]3;JH=D[ORNYG
MW1D*;;U1!B=J]==A[\EC?>&8R6`V;0UTVR=K[@IL;DMW9?"5T.-IZAXI:K[&
MH=1XX7<>Z]U"H_E?T+D:4UV/WM5UM".CO]F1%;2[+W[/2-TOKEB_OBE3'M=H
M9)/)`X_ABDY@^-O\DLI(]U[J)G/EUT1MRFJ*[*[BW9%04.P]M=G97(TO4O;N
M1QV#V'N^BK,CM_<>X*_';%JJ3`4U;28^=GBK'@J*=H72:.-U*CW7NC)1NLJ)
M(AU)(BNC6(NK@,IL0"+@_GW[KW7/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW75^0..;_GGC^@_/OW7NN_?NO=?__0W[Z,AJ:$
MBX!0?7Z_D&]O\??NO=2??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=$URGQZ[2GR79^Q\7V/MVAZ*[DW=F-Z;Q4[>KAV]BH]UQ8
MZ+>^P=LY^"OCVS_=W=`H)53*55')D\;1Y":GA5Y(Z6K@]U[ITZF^/F3VOW'V
M/VUO[;71>3S^2RN2AZOWCLW9>4Q'8NUMB5N*VYMF#8N;S^6KL@M3B:?;NR,3
MJ2B^VIFJDE98$!%_=>ZX_'#H#.=;YW??8':&W>B:WMK=^X=Y9&7LKJW9N:P>
MZ,K@=[[KDW57;;W1F]S9#+YK)8_#-18NBHHQ4^`08R-O&A.E?=>Z:-C]&]QU
MV[_D3D>Y\QU15[;[]VE1;6J3UI0[WQNZ<+18G;U1M#%T`J]TY;*X>:BCQ&4K
MZPO%30R)D*MA9XU!]^Z]UCI^KOEQ'UKN#81[5Z6I),5UME.N.OJS%=>[LH8<
MS55%#0X+#[_WYHW;][@J_!X:FDE3#X&6."2NG)-8(DCC3W7NFSH#I#N#H#';
MLJ1C>F$VWBNOG&V>E.@=I?Z/<9V!VA2T%#!5[TW7G]W5\D%-NK/XG:F+Q--)
MKBI(_+43UDDK:'3W7NAO^-F"[XP74>W_`/9F-\8/?'=6>JLSNS>9VGM_';=V
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MZ&IGQD#PT<;N[+[KW1T_CGU[OWK'KF#:F_\`)[$EGH*]*/:>U>KMO5FVNM^M
M.OL'@\)M?9G7FS,?DYZK+28G"X?`I/)-5.7>LJYQ&L<`BC3W7ND7WGT!G>]N
MRNK6W97[?J^C.NXLQO*79]/E>P-K;XR'=4,;4.PMWP;KV9N/!I!@-F8RIK/'
M1LK/)6UPJM0DI*<>_=>Z`-?BS\AL9\3ML?&K`9GX_P`$-%NO,5&<7+4O<>8V
MY'U[#V.O8NU-CXNIK]X56]LG.(E_@F2R.0R4D\U%>H4&8E#[KW1BOD5U_P!Y
M]E[4V%MGKO)]/T$,&\]D;I[0C[!QF]<C1YBAV/N;;F\J;";4CVUEL9-2QY7-
MX+Q5$E<TZ"D;3XG+-[]U[H)^_/B7NCY![_[$W%OVNV?F]J8[I[+=?_'?;E/N
M;N38M7M'<N^<=/2=IY[L3)]=[SV])N2BWE''044:TG@FHL;0&.,ZZNI<^Z]U
M"V3\=_DQU14XS*]==A=+39_?'6'4^R>ZLKO+:6^<I'CMW]3[4&R\;O\`ZSHZ
M'=-)+D<=EL(X:?`9:H@1*RG$RU_^43I[]U[I)]\_#GMCNU.[ZC<K?&#?FXMS
M=3=4=3=-;M[-ZLSF8R^U*#$5F:K>YL[N.&DROV^-R>_*G<=1)CUVZV.%&]-1
M^=IQ`MO=>ZY;N^+/R-W%WSO#M['97XR8?)Y7);7Q76_951L?>6=[BZ/V%BMJ
MY'9>=I]@U>4KY-M-N#+X?=VX9HXGC@Q2U.10ST]1H9G]U[I55'QX^2^Y=S=[
M[=W-O_IK!=0=\]@Y+-[LS>R]L[QD[GJ.M%PFV]DXOK2FKL]EYMHXBKR.P=LI
M05V:2&H:G-=524-)!4&*IC]U[H_E)24M!24M#0T\-)145/#24=)3QI#3TM+3
M1K#3T\$,85(H88D"JH`"J`![]U[HK&#Z][_'RCRG;&Y:GI6;K!]D5O7>#H,0
MG8`[(QN!BSN1W+15LU16U/\`=":NSF2EHDR,2TRB*.@1H9FUE![KW08==?&C
MNJH[7V1V=WKG.A\MN[KK*Y[(_P"EWJ'8.>V!VMVY15^)S.VL'MCLF^4DPU'M
M/$;>R-+]U0"7+PUU=BZ6>'[!4\7OW7NCO;L&ZCMC<(V,VWTWF<+DAM1]V)D9
M-L)N(T<PP[[ABP[Q967"I7^,U*TSI.T(8(RL01[KW1`>H_A_V?U=V3\>.P(=
MU;<R-?M[!]L5WR5KLGOKN'<`W[V/VZE%F=V;AZTV?F\M-LC:=+EM]T*9%Y):
M5:JGH43'PD0(K>_=>Z/UO(;N;:6Y5V`VWDWRV"RB[0DW:,B=K1[D:BF&&DW$
MN(5LH^%CR!C:I6G_`'FB#!"&((]U[HC'67POJMH_%WL3JF+'=5=7]Q]I[.QF
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MN'?.[=Q8[;6X),(^;SZ5NX%IHC+#@,(D="LU8^F3W7NC0=<8C>N`V!LS"=D[
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MJ8F&?>.,S6VNVL'AL!AJA\UN3.XK;]')N;`NV*IJK)@&FR4,2$R>Z]T@][_#
M7M-MR=72[3V_T5OO#]"=4[<VQTMN/M/=_8^$W/MSMC%UM/N+)]N97;VTMG97
M;N5ER.[,-BZJ3&25#PSFBU-)'J"+[KW5ENWJ7,4.`P=%N'*Q9W/T>'QE+G,Y
M!018N',YBGHH(<GE8<9"\D..BR-:CS+`C,L(?0"0+^_=>ZK,[U^''??>62[Y
M[$S.\L5ANR\@V%V+\=,%M?N?L3;'5&,ZCVON'%;RPC=O8&CZVJZC(;RRN]H*
MG)9R.CCK:?(TJ46-6IBAI%G;W7NE+NOXJ]W=AY'?.=W'6]58'-[Z[PBJLU48
MK.[KS<.4^,^X-L]:;5WGLBNBGV=@"F^Z"BZPH:G$W,^,%;JDD=/+(#[KW3MA
M/CWW]N2D[`Z]["INI]L]:=I]Y[D[;[(S6V-X;NWEO+<FVZG=&*RFVNO,+C,I
ML?9V)VV:G;NU<7C,UD9JK(6I?N(Z.G5Y(JF#W7NK$/?NO=$]Z/V#\@NK<-M#
MIN;'=4IUCL6HSE!4=E4^X=T5>]M[;8K*O.UF"DH-BK@<?C-I;U\M93OF:RHS
M.2HY*@2R4T#"8+3>Z]T#N2Z6^557TOC.BH,!TG1[8ZOVU4XS#5V*W;N/&+WE
MD]OXQZ?JT9K'C9D_^B3$4F<^TS6Z'C?<%569&A-/1`03M4>_=>ZG;:^+N]-@
M]M]7;[VKM7#5N*I<14[R[+@W!VC7UTF(["Q72L?7.W.ONL\.=B)C*'8.5W0D
MVX,U7.]-+6;AJ1DC3,\20I[KW3K\?_CINW9&SY.P.TM@P[I^0>V=Q=C[PVMA
M*SOO>.]NN1N[?^0S&Y<YG-ET^?V_B]L]:U.>R6Z:V@,T&`DJJ2D5M#E)Y$;W
M7NDWM#97S<V_U#7[%I=L]=83/8K8O;-5)4Q=J#-0=F]M]KYRORV/KI,Y5]7P
MY/9&W=B9/<60R,U1]O5560=((!#I+L/=>Z5/Q@Z=[+Z2Q&\-L8KIO:NQ>M8=
MI2Y'';$K>Y-P=K[A[`[37$8+`4TIW=N?&-#L78U/MK:%-1QX\)501SUS/%#!
M%!XY?=>Z;:;K7OO_`&6GO3`_Z&=E4/<_:^^>UJYL(_;\63P<N"[BS9_B]?!O
MM]B4U9BWP.RZN.@%*N.O45.,1E9$='3W7NA0^(_7V^.LL!N3:.4ZKI.GNOJ'
M(/7;,VO5]OYKO+=V2S>X,UN+<&\,YG-\YU#7PX2`9&@QV'QTDU3)1TM$R^18
M?!%'[KW2]^1&S=[;HP&Q<[U_A<)NO<O5W9VW>SJ;9&X,L=OT.]H<%C,_BY\#
M3[@:EKJ;"YN$9T5^,GJ86I1D:*!)FBB9IH_=>Z##?N&^06_]N["W]E>H]B-N
M'K'MK$=DX+I"?L"&NKL_AZ+9FYMKO#E=[S8.+:-!O_!YS<W\:Q"QK+BTFH((
MY:Q)&^YI_=>Z`_O3IKY!]K;-[&W=DNK5DWWW'2]9=5_W$V%W%@]J[EZEZ*V9
MN>HWYN2MB[(S6%GV_G>TMVY^JK(U%)2+0T"RT,:3RBEJ*FI]U[H1.TNA-P;8
M^.?9^!ZNZZW?W+V]W;BL?AMWY#L'NNGI-[8ZHDQ^07"YU>RLZLU'BUZ@JZOR
MX*'"TU.M-7JM53QK.\U0WNO='&ZVVQBMF["VEMG"[8BV;08K!4$2[8CJH,@^
M'JYH159*FK,K3O+'FLHV2GE>LKR\CUU4\E0[N\C.WNO=`5VY@^T\!W-L7N/8
MO7Q[DQN*Z^WAUY+LB'=&V-HY;9^8W)F=OYU-]X?(;MFI<55T.7I]O)C,LD<Z
M5T$*4[T\52IGB'NO=%FW=\:^W-T;AZWV]N?![WCPF]MZ]J=M]V;_`.C>XL9U
MT^Q=]]AT.+V5@=OX&IKGPV]]S[5VIUS'54-9-#3Q2Y&31.(%9S!![KW5GT%-
M3TJ,E/#%`C.TKK$BH'ED-Y)7T@:Y9#RS&[,?J??NO=%6[8PN^,KWKT>NWND9
M<_L7&;LAWCV1VK1;EV'A):*HPVU-[[;V5C*O#UV9HMX[GIMN9+=TM>R)`\,*
M-^QY9&DC'NO=%B[UZ#[E[%S7?62VWLSM7:=%#B^D^ENH-N]==T[,V'M'>?4^
M&RE;7;XS6:VM2YB/$4V)PR;KRU.,?DDBK:W':::!(Q)^W[KW2NKMA=TO\@-]
M=J8OJ'M%9ZK=.$V1L_!Y+N7KFB^/>9ZWHL'M_:DV_NP.O,5N:KW'5Y3$09+<
M-?CJ>.BEJ]#T\4D2R:3#[KW5CWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZXD$LIN0!>X_!O:U_];W[KW7+W[KW7_]'?
MOHQ:FA'ULOU_V)]^Z]U)]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]T2#N7Y)YK8WR1ZGZMVIO+J23#U-9LNF[DV1NNIAI>PXL;
MVMN+([)ZWK.MYX-WT556[AGW/3&KK**;#UD$6"H*F9I8I)J6_NO=(NH^3^_9
M?E3F>F=L[UZ\W4<?V5@-LQ]04_66]Z;>\?72;;V%E^SNQZSL]MU?W.BAZZJ]
M\0>F.@ECJ"R4,B154\4J^Z]U,Q^^OG)F.Z=P[2I:/I.AVQMZDV/N_)8J?`Y7
M(56-P>\>Z=Q;37951NVD[#B6;<6-Z0VO+NF>L&*16RE9!1Q0-#<GW7NA*JNQ
M^S,3WGV^F7[!V)%T7TOU]@.P=V8R'KC++O:GDS^,WK72[=.['WY)B9(,)A]I
M195ZA<4LLHKD@T*!Y/?NO=9>NLQ\LMUUO6O8F5J.F*'K?L"67+;JZT&*W2-Y
M]:[$R6UMR9?9=7A-^1Y67%;ZWY-FI\)3Y^CJ,5C<9#"]6:&H<P1M5^Z]TG^J
M.W.RZ[XX;Z[@W]O_`&5F<Q4X#MG=77J8CKBLV=#C]L]=S;CQN-RN2V]7]A[B
MK=SODH<12Y.J\570Q1BL%.C*NB9O=>Z0'1G=_P`EM[]=9CMU)-H]PX3$]/[G
MGK-@87J?>_2>\ZCY$[;QFU\G_<7:0[`W)DI\OLVJJ:W*8UZVKI*=Q6T\'A>9
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MLBD@W_E]];)[$Z3W?LW'9?K_`''0]3[RZ;WU/GTW-N;'90Y39^ZMS[AJ(-L5
M>`H:"IHGJ8Z*N9YV+PJME7W7NE[\D]Z;JZXZ.[([`V7F]MX+<FS-LY'<F+FW
M;@*W<F#R=;BX'J*+;=3CL?N#;%8K[GKEBH(YTJPU.]0'".0%/NO=%S[9[J[_
M`.@Z+X]+NK*]9;ZR6;W+N?<7R*>@V7N3;-#@ND-MX"*HWCN+K>*EWAN>N7</
M76X,]B&"UPK(,MBFJV?[.98F&P`:U-.O=8MH]N_);?F[=T]7X?+]4X[,3[^[
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MM=X[R[3P6_=D[T[@R6`W)MO$;">GVCLVBV/NK:E5E*C^]&[GHY@Z2RU-/$QI
MOWT"O[K?3KB.Y?E5V7LVOW)MW"=4=,U/6?7V+S/9D?8E#N/=<>:[>;:E!O;+
M]84-+19O:E7L39N$V_E*+^*YRL.0R-'6UKTB4+28^I>7W7N@+WI\]=_-V-C]
MM;$W+UC0;EW)UQT)O'K/X\;FZS[!S^_NU-X=J[6S^]MP]:XSM+`;LQNT\+4X
MS:&&^[AR$F*D_ARI/5U],U!`7?W6B0"`3D]#_P!N?*O-;*^5W5W3>UMW=+U>
MV))]CXGNG96YLG#1=LT61[@R6X,!U8_6;4^](9<GDGR>)-?EJ"IP,T<."IGG
M2J62HB">Z\""2H.1TU[\[1^:Z=L[FV-U[A^BHZB+'[MWELG8NX<)N?+YG+==
M;6W;UML_`9G<&_J+L3;NWL+D^Q:C<VX*Y:88]Y<52X.&+QU4TTC>_=;Z%S*[
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ML_R=J)=Q]$9K;&Q=@[H[2Z(W/L&LSF?_`(AL':U9N_;=7G^VL-3;CR+4JU^Y
MMLBHQL..JH),AACYB*>5Q''[KW3,_P`P^_CUMM+>.2VYTML;=N+^,O<V]^\>
MN]SR;YR=9LGY"]8S[:V;C=DX+.XFJIJ:NV5FNSMQI3$5-/'DCC466-B\R@>Z
M]T9KJGLGO"G[8GZ:[XQ_5E9GLAU@G:.`W+U$NZJ##TM-CL[BMK;DVSN#"[PK
M<K7I51Y?+Q38S(05/CKJ99UDIZ:2`&;W7NA>[G[%Q74G4_879>:SN!VWC]E;
M3S&>?,[G+'!4E31TDAQZ5\25^*EJUK,@T4$=/'4P2U,LBQ1NKNI]^Z]T4#%?
M*7MRL^'G8G;]92=(#O#J[/Y[:&X<9MO.;DWETWD=VXG/XVFHL)A<WAY5W#-+
MD\=GJ&CE8-**/,/*I\T,0+^Z]T-/=>^.^^ONB:+-[/3IW/\`>@S?7NVJK&YN
MGWE1==97-;TW9A]IM3XJEQN2K-VT*^?-QS0"22H;QQ/J!!U+[KW1C\(<O_!\
M6NX)<7/N&/'4"9^3"1U,&';-"DA.4;%T];/55M/CGK"[0)-))*L)4.S-<GW7
MNBS?,#NW>72/6>.R?6%=TX>UMS[D3!;"VWW?N>MV;LS=E1C\%G-V;DH)]T4$
MZ3;>;%;1VY79%ZUXJF**&C9/#)))$I]U[H+-S_->3;'8_7)FV_@:[I?L;X\T
M78>-R='DZP]BQ=R;J(S?5_55+BY(5P.8E[1VE0Y,8N*&49`Y#'-^TU/(9(_=
M>Z`^B^:'R=K*KHW9N5Q_Q7V/V]W?U!6;]VWU[F\KV_GUS&^,KFMVR[-Z^VSN
M##X:BQN0Q[;1VS)49#-SFF@+TTU33P-1LKI[KW0NYWY6]T;5WQOO8NZ=F=3X
M6;#_`!QQ6],-N`;CW?E,9MSY(8_8&X^Q=\=.[YI:'!F2NVG'L_"-F,3FL;.)
MJFBI:J%Z83K&6]U[IG3Y+?+6'%[VWO4=<=$U6SNF.M.J]Y]J8&+<?86+W?F,
MYG^L:;LGL_;^P<IDL&VWZ>;:V/R%.,0F1CU9*1UAJFH=8F7W7NFW?WSPW_LK
M&?(7#4O6.U=P]E[5[.GVM\=L)2[CSM)ANQ>NE?$;?S/;&_#+@9<]M[;'5N^Q
ME\9N.7%TN2C>>CI*>E<U60AB7W7NE71?)OO/<_?O8_3?7_\`LL^Z\GUCN;:E
M-E]AONGL;#]G9'9/VW5\_96[C]UMZ7:V!BVU-V#-!CEDFJX\E44?BUQNSB/W
M7NLD7RS[;RTG<&UL5LGK;%;\V'\G-G=5;!FW#G-Y/L[L[J+?F]QL?&;_`*.J
MQFW9,QBMS[?W'B-R8G)4?AJ*`9':]0T=3X*J$I[K0)-:K3/^H]3,!WU\N<YV
MF^WVZ5ZSQ>S:?/[*KLG@ZW<N[I>VMO\`6V]^U=R=?X_-9VAH,)6;(I<U3[5V
MA7[IF1<DT24GBHP&F<3>_=;Z=.G/E/V'W#W%5[6PFU.K4V3C-R[WVYO7:M=V
M#E<#\C.GZ/:$62H\7NW?G6&;VU3T^8Q&]=RT-/1PQ8RH\5##DZ:H%96*)53W
M7NCP9.LDQ^-R%?%0U>3EH:&KK(L;0+&]=D)*:"29*&B2:2&%JNK9!'&'=%+L
M+D#GW[KW1%^M>_\`Y0[DW0]+O?IOK/;.U<171XC?5;BMY[QR^;Z]R>2Z6F[@
M@7<4$VRZ3"S4^UZBOQ&`RGVM7+)/D,BTE,OC@96]U[IAZJ^:>;[/I^N$Q57\
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M]XLA72-/18K`UR2U#"2-D?W6E)(J5H?3H=.KNX-Z;@[#W?U+VKU_A^O]^;?V
MOMSL#"_W7WI/O[:^Y]C;FKLKB5J:;,U6U=GU^.S^V,_AYJ#(TE11+')>&III
M98IF2#W6^E5VUVG)UQ2;;Q^"VM6[^[`WWG&V[L/8F.RF.PLV;KZ;'U68S&1R
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M?NO=>]^Z]U[W[KW7K_[Q]?\`#W[KW7O?NO=?_]+?NH;?:06N1H_/U_4?K[]U
M[J5[]U[KWOW7NL!B+L'9G0HY($4CJKJ+:1*.`?\`$>_=>ZS^_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z*C5?$+8E?@.PL+7;W[7K:SLKMFC[>SN[JO
M=>.J-\8_+8[([8R&.VKMK=,NWVR.WM@XX;/H*:GQE.5%/1Q&&*1$=@?=>Z?<
M'\8MGX08Z4[Q[.S&3P_>V>^0&'SF9W53U&9Q>Z-T19.DW#M:CJZ7$4:IUUE\
M9FZRDFQ+(R&FJ&42`K&4]U[IZZ\Z$Q7779W9?:M+V!VCN?-=J#&C<&%W?N/&
M93:N/_@KRIA/[N8BCP&,DPXQ&/F:CA59G5J<DR"28M*?=>Z9MA_&C;^S,YV7
MFLMV'VMV=#VWBSB-[;?[.W#@L_MK(4W\.I\(I@Q.-VO@THRN`IA0E$80O3N^
MM&D<R'W7NF?;GQ4Q>V,+E<)C^[OD7-"^U)]D[-JZ[LN&IJ^K]O3.FB/9*_W>
M2AJ\Q24L$5-!E<]#G,M%3Q!%J0&D+^Z]TBQ\%=AOLC-;#J^W?D-7XW)=<8SJ
M3#92I[&H%W#L;KRGK\+6[@VYLK*4FUZ4XJ/?\6W,?29^HF2IK,A1T<<7E0`D
M^Z]TI9/B#MVMAWG-G.YOD3G=R;QHMA8R/>]1V:F'W=M#&==;Q&_L)CMEU^T\
M#MRBPU)DMT*LN662FJ#EZ=%I*LRT8\'OW7NA?ZOZBQ'6'\?KDW+O7?>Z]US8
M]]R[Y[#S5/F]TY:FPZ5<>#Q6K'8["X/$X/!KD*DTM#CZ&CI8Y:J>8H9IYI']
MU[J3VKU3A>V<+B,;D<WNW:>7VSN*BW;M#>FP\W_`-W[2W'14M?C/XCB*Z6ER
M&-J(J_"9:MQ];1UU)64%;05DT,\$B/Q[KW0(9SX9;$S.T<?MJ#L7NG`YI.QL
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MT."QNRL518JCRVW\C1?QZNG%:*Z6J^ZJVFUATA,7NO=*+`_'>BP7:VWNW3VO
MW-FLU@.ML'U?)@,[NG"5VT]P83!P5>G+[CQJ;6IZ^OW3E,I6'(5M<E5"T]8B
M'2L*B'W[KW37O/XJ[%WQNC=>:R.[>T<9M?L*JQ60[*ZIV_O23#]9]AY+%8ZF
MPS5FY,3!0-G8H\YA,?2T68I,?DJ"@S=+2I'7P5`:7R>Z]UQG^*NS:Z@[.H,M
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MLY_`Z)EAIE54!]^Z]T];"^*776P=Q=,;MILQOG<6Y.C.I<ETWM/*;ESU'/\`
MQ7;=?+BS39?=N/Q&(PV)S6[L'14$])0Y`4\+P4V4KU*LU4[^_=>Z%/M[KB/M
M[K3>764^\-Y["I-[86?`9#=77E?BL5O+&8RM:-,FF"R>9PVX*#'U.1H!)2O,
M:222.*9VB,<H21/=>Z+9O3X+=;[HGRTFWMV[NZGILUTNW1V0QG4^"ZEVCC*K
M;,^=P&>J\M50IUG63UNX'DVY#2P>:63'45#45<-/21_=2L?=>Z>-]_#+8^^L
MCVAFY-]=C8+.=M4O5U)N6NQ51LZ>DH$ZPS=/N,OMO!9O9V6P6(D[#S6/HI=S
MG[>49,4,*J(-+%O=>Z%[K/I?$]=YO=6\Z_=.\.QNQ-[1XJCW%OW?E;BZK,?P
M3!"KDPNT]OXS`8C;^V-I[/Q5;DJRJBQ^.H:='JZV:>=IIG,GOW7NH_<W1^%[
MO?KNCW5GLQ#M78N_<9O[*[&@H=LY+:?9%7A(*A,-@]_X_<.!S$N2V]BZZI^_
MA@IY*4C)4]-4%F:GC`]U[H(:OX>8^+!;WVQM3M/=6Q-N;Y[FQ7=-=M[:VQ^F
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MWA=P9W$;<I=T;BV-MK&;;QU,N*FJE7(1T4:5LM1`9()/=>Z:,=\.OM=L=;8;
M(=K9+.;DV9O:/<N[NQ\EUIU.=]=I;9B[2/<[=;[DR]/M*%,/M"O[&C@R-:N+
MCI)JR6!2[ZB[-[KW67:/Q7W[M[<.,K<O\D]Z;@VM1=E[F[6K]KTVQ.N]I5>?
MW%N+<V1W@N,S&[-KX?'YV?:E%N"JI7>@5E%=38ZGIZJ26(2"3W7NN.Q?AKC]
MK5_2F:S_`&IO#>6=Z>R^]\E6Y&;![*V['V=3[JRV;W-A<=OVAV_@:2GFAV)O
M'/39?&R4/V<C5Q+5!E5Y%?W7NECLSH#>^WM_]Z;VSW?&YMR1=TX>EP]-C*/9
MFR=J5O74>'I\ECMM5.U-R8?'MEJNHP&+RD@B_B!JE:L9JBP+%/?NO=0^K?C9
MN':V\-H;Y[7[HW+WMN7K':>3V3UCFMR[5VEMC+X7$9^CPE%NC,[JR6UJ.EGW
MMO/<T.WJ;[NLD%)0!O(\-!#)(7'NO=&IE61XI%BD\4K1NL<I02"*0J0DAC)`
M?0Q!L2+VM[]U[HHF$^-O9&/ZF[\Z\ROR!K<WN;O&MW1DD["_T6[*QM5LNMW?
MA*?`99Z';=)(<1N"&#'TL:4JUYD>)$57>4+[]U[I.;F^(.YLU#V)%B.YJ3:W
M]]OCWLGX\8E\7T]LB0[.V[@:B=]WY+'K-4>/)-OFER%5#]E4`TF+5H6IU+0W
MD]U[J%E?B+V;FMF]H;8G^1[8:;L+;5#M2@CVATSLO;>RMN8Z?-QY/>>2JNO8
MLG687=>Z-Z8FE@Q,V0K9-=+C8S'$NIW8^Z]TY[N^'=15X3L[;G6G9-!U9M[M
MG/=8;QW1M?'=6[5R^T8MZ[*R5+5[UW#B=N_=XBDI#V]0X+$4^9@D:9`U#)4(
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MIJFEJ*1;^2&2:&3W7N@7W/\`$[/;BBV/%DNP]J[W@H]_Y_LKN#'=M]3X[?N'
M[CW'FMH5&P\?2SXN+<^!Q^T-L[,VOD:B#$8Z.&NBA,5(TK2O!))4>Z]T<K'8
MZ@Q&/H<3BJ*EQN+Q='2X[&XZA@BI:*@H**!*:CHJ.E@5(::EI:>)4CC0!410
M``![]U[J9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__T]_"E_X#
MQ?GTG_>S_K>_=>ZD>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_U-_"
ME_X#Q?\`!?\`B3[]U[J1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z;$S6&DR)PZ9;&/EE221L6E?2MD5CB"&5S1"4U(2,2+J.FPU"_U'
MOW7NI$E?0Q5E/CI:RDCR%7#45%)0R5$*5E53TC0K5ST]*SB>:&E:IC$C*I5#
M(MR-0O[KW7'^)8[^(_PC[^B_BWV7\2_A?W4'\1_AWG^U^_\`LO)]S]E]S^WY
M=.C7Z;WX]^Z]UZ+)8Z>?[6'(44U4$,IIHJJ"2<1C@R>%)#)H!_-K>_=>ZR1U
ME'+H\5732>1IDC\<\3^1Z>015"II8ZF@E(5P.58V-C[]U[KM*NEDMXZFG?4)
MBNB:-M0IG\5019C<02^E_P#4MP;'W[KW6?4+D7%P`2+BX#$A21];,0;?UM[]
MU[KRLK"ZL&`++=2"-2,59;C\JP((_!'OW7NN_?NO=<$DCE77&Z2+J==2,'75
M&[1R+=21J1U*D?@@CW[KW7,$$`@W!Y!'((/T(/OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KU^;<_P!?H;?[?Z7]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]7?OHU"4T2CZ!3_
M`&BU[L3?422>3[]U[J3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNK>J]S]+:>-/UO?Z7O[]U[K
MOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U3)3T^#[`^0^1[?Q>W^JJ/J[?7RXVSLO*=M;
M8Z^W@/D'@M\]8[>V;A>O<15;CJ<5146'ZX[+W1M2KQM;F:+6&HLW34<K2TM=
M4U%'[KW2RVW'UOV51X[&QX>KR/S;R?:^/W3OS<&0P&;K=Y]&5^U-[0U^6JLG
MGZY%CV#UI@=B47\(PM#2U$..W%354,<4=9]]55#^Z]U'ZOK^D]Z=V87L2DJ=
MF=JXQMR;_P#D1D-Y;FV)V)UQ\C?CG(V#S]908WL[/U30TU?L7;5!EI]N4.VL
MM3XBHAII:5EHZX4$]7[]U[H*.DMP](96EW;O.IPO4==OC*T'=GR/ZXK^I>K-
MVT?9/7B5NWNT,GN?-=Z9M(9JMHZC";YQ^+Q^-I8(X:RM`1*.24#Q^Z]TOOC)
MMB&OS_3^.WWLZ'9_6W2'4_7'RQZSPN<V+1X7&])[3WKU'ENKJ'KR3<`P.->?
M?3[BVON#>^Z&EF>LAR&2@2=%6*`^_=>Z>-L[O^+-+U;\ZODAM/;/6$,LV5WU
MLV3-8G:U/41UFUZC;.$V-@8YZ.FQXF?;W8V\Z2IR-68$\64^X-1*9+!A[KW0
M5[LP>PNO-A[AZQSM-39>E^,'QUKOCKLWL#>+YJHJ\GL/Y.YO:FQ>HZR7>TFD
M9_P=:XZO@J`E1.]!+2S2S&,S*Q]U[H[OQSVWU53]Q[ISGQOP\.$Z6QG6."V=
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MU#\8OC[U9E\CUO\`WE[0^2J9BKZ>[)WCF=D[%V%F>N-S9'<_9'26V,C7Q;BW
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M*3,9>KFR\^8\573RRNU&:I5`4-[]U[I%[T'6O8[=AY#,Y_,[D^67^E?<VR>I
M=G8G=&9Q.]^G*_;^X6Q>PZC:^WJ&KAI\'LZDP-#!NC.9Z>D;'Y:DK9UJJB>D
M:GIE]U[H.*_&;%WRN[,-3YF3=/7GS<^3F3@PC;7WCN_-8[!=A=3]B8G#9BHV
MW/A,\E'LBEW5TIUKDL]6QTM12Q5&2HYI7CUU4GD]U[JY!$6-%C0!4151%'T5
M5`50/\`![]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[K__6W[J,WIHN+<-Q>_T=A];F_OW7NI7OW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO6M?Z\F_U)_VU_I[]U[I([TWWM7KW%4N9W=EHL51Y#.8
M+;&+3PU-979C<FYLG3X?`8+$8VAAJ<AD\KE,C5(D<,$;L%U2-IC1W7W7N@R[
M`^4'0O5F;J]O[^['Q.VZ[&56VJ'.5-519NHP.V*_>5?!C-IX_=^Z:#%U>V=G
MU^XJZKACHX,I5TDM1]Q$44K+&6]U[ITROR&Z:PO8%#U=DM]4%/O2OR^/V]'C
MUH<S4XREW'EZ>2JP^VLMNBEQLVU<'N7,01WH\=6UM/6U1DC6*)VEC#^Z]TY[
M2[KZTWSOW??6.UMPS9/?'6<M+!OG"-M_<V/&`FK522BCFR>3PU%AZMZV"198
M13U$WE@82I>,AO?NO=-]+\@NFZWL,=5TF^\74;X;(Y'"QXV.FRC8Z?<.(HS7
MY7:]+N?[#^ZM5NW&42/+48F.M;(PI#*7A`BDT>Z]TV]:?)GHWM_+?P+KS?\`
M0Y[+/%F9J6BEQ>X,'+DX]NY6HP>X&PC;BQ&)CSO\"RU))!6?9M.:5U_<T@@G
MW7NG';'R#Z:WE5=KT.V]^8K)5W1M0*;MNA^WR='6[$F;%5.;C&<I*^@I:F-)
M\/1R5,3QK(DL*ZD+`B_NO=8^M_D3TIVY1UE?U]V%A<[2T.WJ#=U2\J9#!NNT
M\G#)44&Z8X-PT6*GJ-MU,43%:^-7I!:QD!X]^Z]U/ZX[VZC[<R.=Q/7.^<1N
MG([;2FGRE)1K6T\O\/K9)H:'-8W[^DI%SFW*Z:FD2#)4)J,?.Z%4F8@CW[KW
M2^W+N#;NU,!E]Q[MR^*P.VL/0SUF:S&<JZ:@Q-!01K:::OJZQXZ:*"S:3J-F
M)`Y)`]^Z]T$>VOD9\?-Y;=W;DL)V9LN?![$Q='4;YI,E4K@ZC9^&RJU-/AY]
MU;>S\&-RF!QF?2DF7'-5TT4616)Q3&4(UO=>Z;IOE/\`'1-E0]E579>WH]IM
MO&BZ]&4J:/+15U+OC(OJQ>U*S"38M=Q8W.9+T24M//2QR5$<L4D89)8F?W7N
MGK+]_P#16+ZXQO;N5WYME>N<OE\3AJ#=/CJ*RCFW#F<K3XG%X9Z:FHZC(4^=
MJ,XL5**66%*F.L"Q,BR@+[]U[KA6=_\`0L_7M'VE6]@;3J]B?QC[/'9B4M63
M-N?'--(<1083[67//NR@%/)(:&*E.0B2-W\8568>Z]TSY_Y2?&O:E+LW/YOM
M;9-!1]DX*NW'LS,I.]53[EV_B6HH<QE:/(4-+41M085JF`5KR.@H@1YO&%-O
M=>Z6&[.TNF=D3["QV[]U[-P([>S6-V_U\V1EI$QF^,_4_;5&$Q6(R`C?&5V1
MKC51-0QF774,P\&L_3W7NF'L+OGX]]6;DBQ/8>_=D[7W8:7&SQ461,;9H05:
MY4X:)5IJ6HJEGJXL=6O2P<2R103/&I1'(]U[J+N7OCXX;.S&RY-R;XV)B\WV
M7C\=N;8=5+%%-6[RH*^F6#'9;`5M+1SOE1+CY05>-V=:4ES:(%O?NO=*3<_:
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MJ-UYC=O8^6HH)J@9*CQG\#>JFURRR0P";W7NGCK7.]]9/(;RPTO4V_\`8-=V
MCV;V#NZOWSOF?8%3B]D[!&TO[J["2ACVQV'GJ^3>Q_N]A"E#]I/3PQ/4&9P8
MP6]U[I.8?;_9$_7'4FQ9/C]N'`T'QY7#[WW(KYS9#5?8'8?6N$FJL#@.K!29
MBHCS;;_WC5C(U>=RTF'583+'.K5=3.*;W7ND'UIUQW5T[MW;78<VQ.W>[MR4
M'1N8R^P^N]\;HZUBRW3O>64J))-Y[1ITH*_;V'K,+V!+GV$&7J<IEZO%X_%S
MTJ5(CK%23W7NF&#JKY#=25'96.4]E_(.;?/QISF*J,_C=A]<;`0]G;KWQ6Y+
M(2O5579?W6:W171[SRM8T-1!#0XBCQE/315<QG6-/=>Z&7?.R.P>T<!5Y.DZ
M<RN.V;L38>'V%M?K?>&7VW0[^[8VKD=^]:9_M?;N1^SSM;@MN8?.[-ZVCQ-#
M!75L3Y&JJ)&JOMJ70TGNO=#1UP=V=C=FQ]M9GKW-=7[3VWL#(;#V-A-Y4^(H
M]^9]]TYG;N<W3E\WA\17Y-=KX3%3;/H:3'4<]0]14.:BH:*&/P&7W7NG'Y%8
MK,U6#V#N#'[(RO96(V!V=@-^;KV+@'Q[;ASF'P&)W!_#ZK`X[+55%CL]E=K;
MKJL;F8<>\L<M4^/`IV^Y$*M[KW07=@3;DW2>N.XYN@]WG";9[$QF9W7L$8G9
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M%-M[!T^'I<Y14./:FK:^HR:2-(IA]^Z]U[N/:G;.\MK;Q_T<;-[(ZZZ_Z`ZI
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M[]B9CKJL+N#=^XJ^BQDQ`%7C\3#5QEH*F%C[KW1N_?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7%=5O65)N?T@@6N=/U)-]/U_Q]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO==&_%A?GGFUA_7Z&_OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U__T-^ZBM]M%8W'KL?^GC^_=>ZE>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZZ551555"JH"JJ@!54"P50+```<#W[KW7?OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NNB;6X)N;<?C_$_P"'OW7NN_S]?]A_7_D7
MOW7NO>_=>Z__T=^VA)-+$2&'^<X8`-_G'^H'`]^Z]U+]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=?_2W[J+BFB_/Z^?Z_N/[]U[J5[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD';GR5S.R_DSUAU7MC
M>74DNWY:O96.[@V5NBH@INR$/;.7S6U^M).M)X-Z4E569V3.T'WV1HJC!U4$
M6"HYI1.DU13Z?=>ZX[D[L[9A^0N)ZZ3.]?=:XV??^-VYM[9O9>Q-]LW<NQ&P
M^&SVZ=V=?=PXJNCV-'OVAIS7Q8K;7BGJ2:*9JY45XW@]U[H\/OW7NJZ=A]Z]
M]=I=L]I[1V5O;K.2;K?M;)T$>P<KTKV7BZ2NZ?PG9=#L/*9>M[CJMW#;55O.
M1<7N/[./%4-;!+48N,3Q0!I%]^Z]T/'7>>[SW#W7W9B,YNO8,W5/7V:Q^"VI
M#C.O\M2;HR.6W)M;&;N>AS>XIM_U^+E78])FZ*%FI\=`^1:=F<4Q50?=>Z0O
M5?<79U5\7-Z=W=B[RV)E,_)L[M+?FRTPFQ*[:^)QNU]BQ9RGP^2R.%JM_P"Y
M<CN*+(PXNFR56T5;2(@KA3H5`25O=>Z!S:OR1^0E9TEOOO.7=?5NYMK8CJ+,
M4=`TW379G6]7A_DYCZO;N&I-LP[?W=O!,_NKK!]RY6KH*BI=<96--2H*=Y%9
MI/?NO=&<ZQWIW#BNWLSTOVUD]D;XG3K/%=G8??FQ=JYC8T5(*O<V0VUD=J[B
MVQE=T[TCUFHIUGQ==!7J:F"&H2:GC>$2S>Z]T.N^*NOH-G;GR&-W#B]IUN/P
M>2KX=SYO#3;AQ&`%%2R54V6R.#I\K@I\I24,$32/"M93EPMM8]^Z]T0W,=X?
M*?:OQ8ZJ[8DDZDWOW%V9N7KC-T.S,=L?=>W]I2]?9G#2;WWQM>FG7L#<&=CW
MC0]887+9#'Y$&H@_B\$-,]#+`SR>_=>Z,-T;V;O?M#>W;N4FRNT<OTU0-UE+
MU#6X;;6:PNYZBGWEUO@>Q<PN[:[([CR=%DGI\=N[%FE^WH<<Z1S,)D9K'W[K
MW35\LNQ^Z^K=AR;OZDH=@K0X#";SS^[<YORCRV;ABJ\1@';K_9V&VWA,_MJO
MK:_L3?-528V6M^Z,>-I3)(8G=HRONO=`MO+O_OOI3(]28/N_<74V*JMZ]][D
MV_/E-L=6]C[D.Y^C-J]8IN_)YK#;:VMO/=>:VIO2HWC2S8V">J_B%!%CZF"6
MHA2I(CD]U[KG1=_][;J^)V0[]V%N?J#/YK<G:5;3].2OUMONGVSNOJ[,=I'K
M#K6GSF`KM_8K=./W;N>.JI<I4U`FA%.9OMOL$8-I]U[I6_(#N?M;I/%]>8S<
M&[]I[2Q-?AMPY#L+Y'Y+I;?N[^N<-FL-4XQ<)MJJV5L_=U?5]>TVXXLA)45&
M9SN7&(I:''U"+/\`=2P^/W7NC7=:Y'=67Z[V-EM\U.R:W>63VEM[(;IK>M:[
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M-MJ=E[NJ-[;6R,E)UW%`V+R0VU2C#YDY%Z:*2MDI(JH"G]U[I`['^2_=G9?>
MW975>R<WTKD*GK+NF+%Y[8^2Z^[5PVXJ;X_4&Y\=M?<6^/\`2)5;I?9=?OF/
M*1Y6GQU'1T512U<F-;R_;-Y8XO=>ZL:]^Z]T0OJCY4;DWY\INX.J*G<?1V5Z
MFP&+W72]:9?:^5R:=FKO7J?.8?`=RXSL/`U&?RF/IMM;7S.Y(,=29&-*!JK(
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MJ=HJ>GK8_P`L=[]S[T^1QZLEZCQO3O4W66P]R;![%W;)N_,S[SR6[X,_N'_2
M)+3[;-/@J_I/(;1P4DV'J<=7RY')6^Y(BII(?)[JW7=7W1\O<?\`&;;';$VT
M.BJ_?>X<=7=C9:7&R;[7K;8G4]'UED^P85SGWU?3[OS6\LEDJ"GP\1HXEIDG
MKUG:(QP.LGNO=,>^.^?FIL#IC)[WW#UGT1C=Q8.HS&?RV=R&8WS3=?1[0I.J
M=FY_!8*GQZM-O-]Z[H[?W/4[8@F:,4L4&+EK'AO+#`WNO=-?9ORH^0O3-!UY
MC>W%^.76>X=Y=O;YV)'N#<)[2R6U,_M/#X#"U>S]Q;1Q&WH\AG1E]Q;IRPQ!
MHJ^>`R.\4T1)=8&]U[I?2]J_,VNW)U_UGCMH?&["=HU'6/8/8/9=#N+<78V0
MVU1'"=BT>S^O(=J9'`8R:H7';WPT\E=4R5:R5&,DA:(0U!!(]U[HU?3G8\7;
MO5VQ^RHL)6[;_OC@*/+S8#(3Q5=3B*N0-#74`KJ=8Z?)4U/60R+!5QJB5<&B
M954.%'NO=%F[G[C^4NW^WL;L/J[873T&V-P5]%MW:6<[/S>\FS6\,O2=>;T[
M(WKF\)A]ET-;HV]M:DV]18E(J@Q5%7E*UO7%$L9E]U[IDR?R.^1^2V9F]];*
MZHZRAQG2^U*3)=\X_>6]LQ2UF;W_`(39^.W=VCU;U#6X3%U]%3S[#$TN..<S
M86CJ<O\`Y.*=8H)ZI?=>Z/+MS.4>Y]O8+<N.2ICQ^X<-B\Y0QUD/V]6E'EJ&
M"OI4JH-3^"I6"H4.FHZ6N+FWOW7NJ_)OF/ON'Y";DZMH/]`&[,3@N\L-U%3]
M?;:WSNM_D7DL1D]O;'S6?WZFQI=O3XBCP76PWPDN8GJ9X<=)1T,S)6Q3R4L$
M_NO=2=K_`"H[CWWW_P!@=4[$C^.&Z:7K+MBFVYNW9E+O3?5+V]B^ITW%MS`Y
M[L>NHJO;B;7Q];@FS-64HI)C%DI,5-'2SLS6C]U[I=XOOGY"[M3!=H[)Z<V!
M6_'K-;DH,;'7;F[*JMJ=G)UK-G8J/*?("6@KMN2;3I-HXW;ZSY:GV[)5G,U^
M.2.3ST]1-]G'[KW7'%_)/M>;(]6[\S?56W,+\?\`N/>>&V)LZM;=]74=P40W
MJU4O6G8NX=J?P6+;%-M?>4L-.LN*@R4V7Q5-D8*FHN\=71T_NO=!]\;OFGN[
MN/>>VMOYG'=%Y_%[MA["FDJ>D.TLQOK-]74?7V1S%"N>[?Q&5VIA8-K;>WFU
M!3Q8]I*B&MBKJI*<TTP6HGI_=>Z6W27R0[MW75=(U7;O4NR=L[7^15#GJGK_
M`"_7V^LUN6OVU5XG:V5WYB*/?>(W-M':<WV&\-E8:IJZ6OQS5$5+51QTT\?^
M40S'W7NCR^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_3W[Z/_@-'P1^O@_\`
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M:::FIXZ:,00Q$$M[KW0?2_`W8=5M#+;,R'<'R&R-#7=<[>ZBP^2J-_8.+-;-
MZSPN6Q67R>S]IUM#LVCBHZ#>[8#'4V=GJ(JJMR%'00P^=%5M7NO=/^?^&FWM
MTP;C;<?=?R"S&;W)/UOY=SU6\=J1YC%8GJ[<]5O7;^W,-2TFPZ?;M)ALANNI
M%;D]=!+59!H88I9S3Q)"/=>Z&7JCI7;74O\`>+(46:WAO3>&\JC'S[P["[#S
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MU]?UMD(-Q9+$9"$.@2&FIIV.NHBFE"N/=>Z5>_\`XOXKL#=.Y]RU'<'?.V:;
M?6T]J[(WQM+:?8%/C=H[CVYM67/R1PPXVKP.0JMH9;/1;DJ8,KD]OU&)R5=3
M>.-YP((#%[KW1B,#@L/M?!X;;.WL;28?`;=Q..P6#Q%!$M/0XK#XBCAQ^,QM
M%`GHAI*&BITBC0<*B@#Z>_=>Z+CV!\3]E]@[RWANBHWOVMM?$=H4&WL;W#U]
ML[=\.&V3VO2[9HSB*`;GADQ-9N/#RUVVM&(R4F`R6&DRV*AAIJMIDACT^Z]T
MI=F?'S#;$[=W?VS@=^=BQQ;QP&U]LS]7RUVU5ZHP.&V5BOX1M6CVIMZDVA29
MG`P8:GFJ7CBBR7@:6LF9T8>-8_=>ZS[(Z&Q^Q>X.U.XZ'L3LS,9#MZ;%U&Y-
MF9_*;8K=B8Z?`XC$8'`R;:Q]-M*ASV(&(Q6)\<:?Q*2.1JJ>29997#K[KW4"
M/X]QKWVOR`D[<[;J,U'@*O:4&Q9Z_8QZXIMJ5U3%DJC`P8I-AQ[A2)\U30UI
MJ?XH:UIH(T:8P+XO?NO=,VW/B_BMH[BDK-M]J]P878<6]<SV+A^G\9N3$X_K
M_![MW#45F1RPHVH=O4^[JK9TF>K9,G%MNJRD^!AKY9&%*82D$?NO=,_7?Q*H
MMA5&R$K^\N]>Q,#L'=^Y>PL-MG?69V"U!7[ZW76;IR63W)N3);2Z[VGN3<,J
M97>F1JH:2HK6QZ5$L;F!C!#H]U[HRN[\%5[HVKN3;5#N7/;-K,_@\IAJ;=NU
M7QD6YMM39*BFHX\[MZ7,XW,XF'-XMIO-2O4TE3"DR*7B=05/NO=$Q?X`]:T^
M,ZTQ^W=\;[V95]:]5[QZKCW/M+%=58?>&]Z;?6UCL_/[L["W'%UL]9N3=<N.
M=JQ7'@HFS6G(2TTLZ*1[KW3KDO@SL6OQ&1HXNQ>S<9F<O\=Z/XVY'<..?8<4
MLVU::.FQ=1O*/"S[&J-NTO9>1VA3#!RY.*E6$8PB-*962-T]U[H8NMNB*78^
MYGWUN7?N].TM[Q;>?9^#S.[_`.[6,Q>S-HR5=+5U.W]D[/V5M_:^U-O0Y:3%
MT)R-4M+)7Y!J&G$LYBAABC]U[IV[UZ@B[SV$_7==N_/;2P.0SVW<GN9,#0[:
MR(W?@<#E:?,5>P]PTNZ,)G:*HV;NR6CCILQ3QQQ35N/,M+Y5BGE#>Z]T`FX/
MA+@:K/[_`,SL;L;,=346^<]TYN,;6Z]Z[Z:Q6V,3E.D<O6[CVI/-CI>OIY-S
M35^X:T3Y";*2551-#2TM/')##31*/=>Z?Z+XDT\&Z]F[TR?;F_=T9W%[GSF[
M.R)MTXK8&9INXZ_,[)J^O*;$;FHI=I)2;:VAM3:>9RE+A\5@$QE+2C+5CRBH
MEJ)9']U[J$_Q)R</7?:W7>%[MW+MO']LYX_Q&MP/7'3>,?;'6<>Q*;K;&=/;
M/Q5)L6'!XS9V`VCC:2GQ\LU-4Y"E:)W$Q\KCW[KW2J[`^/.ZNP.@L7T9-WCN
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M)QV"PF+I0PIL;B,11PT&-H*<.SN(*2CITC2Y)TJ+D^_=>Z`;=_1N[=U]]]==
MS+W#E<7@NMJ;*TF(ZRCV-LFOQ%1'N:@BQ^[9IMSU^/FW535V9@HJ9(YJ>>(T
MD22QJ&6=P/=>Z1N<^)9S6ZMY1)W%O_%=(]C[J7?W8'1F-I=O0XS<N[JFJQ]1
MN.C;?C8Y][8WKG?#8J)LWMZGJ$BKVEJH_N(Z.KGI']U[HX"HJ(J1JJ*BA$55
M`5%465546`50.`/Q[]U[HF&S?B`VV#MK<5?V?5YCM?:_=6]^VZ;MBBZZZ]VU
MN7+8GLJ:L;?G5^Y(<3B!3YO96X:6O\3>0BJB:@QDRR>?&4DB>Z]U!ZP^*'9>
MS=P;9R.\_DQG^P,)@MW;LWSE,/2=7;`Z[R.\\]NS+[IW'54>Z]R;.BI:[(;3
MI]R;OJJT8E8XZ::2&G$NL1-Y/=>Z4^POC+NK:4&.V5GN^]Z[TZ.VUB,KMG:O
M4M=MO:.+>3:-?@:W;&/VEOS?=!0'<V]\'MG!9!H*`(<;4NT-/+6S5DT1D?W7
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M-554%$DU1)).[L?=:`(`!-3T+'OW6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KB?U+R?SP/H?I]3_`(?C
MW[KW7+W[KW7_U-^R@_X"1<D_YSD_7_.O[]U[J9[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KH&]^"+$CD6^G%Q_@??NO==^_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]7?MH1:EC%K?YSZ`@?YU_\`5<\_
MX^_=>ZE^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KJQN#<VYXXL;VL?I?CW[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NN"!E#:G+DNQ!TA=*DW5./J%'%_J??NO=<_?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]UP2-(P50:069R!_JG8LY_UV8D^_=>ZY^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_5?3?Z\_ZGC_B??NO=
M=^_=>Z__UM_"E_S*V_U4G^'^[7_Q/OW7NI'OW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K__7W\*1@T"$?0M);Z_\=7%_58\^_=>ZD>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"/?W>?6O66Y]H[-WEE,
M[1;CWX]1%M+'XK8F_MTKF9J..:>L@BKMJ;8S>.IYZ*DIY*B=)I8FAID:9PL0
M+^_=>Z%SW[KW1;<_\N.@]KY3=V)SN[LY0/L+=N,V+O+*'K7M*HVOMO=F9;!+
MC,-E=Y4FRY]I4TU7_>:@*N:WPA:I&+A3<>Z]TZP_)WI6HAVO41;GRYI]Z=L9
M;H_;-0^P.Q8J?*=G8*LK\?E-NI/+M-(J:FI:W%5<?\2F,>*D:EFT5+>*33[K
MW4/:WRP^/^\:BMIL/V#%3FBQ>\\T:C<FV]W[,QU?B^NZZLQN_*W!93>.W\%C
M=QQ;/JZ"89+^'RU+4B1F20+'9C[KW2<V]\VOC1NBM3'8C?V5-9+@-P[FIH<G
MUKVK@?OL/M79.&[)SL^.DSNR,;%DJJDV%N*@RRTL#254]%60R0QR"1;^Z]T_
M0_+3H*>BQ61CWK7_`&6:Z.ROR1QU0^Q>PXEEZ5PJ129#>\RR[41Z**..>-HZ
M"<1Y2<2(8J9PRW]U[J!2?,;X[5F%W%N`;WRM%C-K=?83M;,/F.NNSL%5IUQN
M2N?&X3>>.Q>:V9093.X+(5L;(LU##4A;$MI7GW[KW0H]<=P]=]LC<2[%STV1
MK-HY.#$;HPV4P6XMI[DV_7U=(E=0IF-L;NQ."W#009*B?RTL\E*L%5&&:%W"
MM;W7NE!O??6T>M]LY+>.^<]0[;VWBEA^\R=>TFCS54\=)0T5)301S5F1R>1K
M9HX*6DIXY:FJJ)$BBC>1E4^Z]T!$?S.^.,F.W'D#OK)0U&SMW[(V%NW;D_7O
M9<6^=L[O[*C6;8.$SNP&V?\`WVQM1NZ%U>@>6@6&H1T97(=2?=>ZE5/S"^/-
M)@(MR3[WR:XZ7M&3I7[=>O.S)<]#VI%A(]QMLBKVK#LZ3<]#F6PDJ5"+-1QQ
MR(ZA6+$`^Z]U)W!\NOCMM;9^V=]YKLBFI]N;O;=2X*2FV]N_*9B4[$H*S)[Y
M_B.U\5M^MW1@5V51T$K9@U]'3#&,`E3XG9%;W7NN%7\O/CY0];9KMRJWS6Q;
M`VWNZ?8FY,Q_<7L1ZO;FZZ6GIZJIQ6X-NQ[2?<V$-/3UD+R355'%3H)H[R#6
ME_=>Z=]Q?)SIC:F/ZVR.?W#N"A7MV7,P=>8X=;]FU>X=P3[>H9,GF83M:AV=
M4[EQ$M!CXFF=:ZDI28U++<#W[KW7+8OR<Z-[(S.+V_L_?*9',YC$=BYRCH*S
M;N[,#*F.ZDW=0;$[(;(-N'`XJ+#U>T=UY2GI*NEJV@J@9ED6-HCY/?NO=+WK
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M24."K=RUL%!6U^&I\;29>CP>/EJ)<?5305\:`!H0SH&]UHL`0"<GI![P^;GQ
M=V%N[-;&W7VM18S<FW<M+@\[3IMK>N2QN)RM,FV7R%'7;BQ6VJ[;D#X<[SQ*
M5[&KT8^7(01U)B=POOW6^C5>_=>Z`BJ^3?1%%V31=25?8^'I]^Y+<T>R<?BI
M:;+KCJ[?$F&K]Q+L>DW1_#O[J5.]EP>+J:ML0E<<DD$$C-"`C6]U[I]VUWKU
M+O#M+?72>W=ZX[(=K=:XK#YW>^QS3Y.CS>!PFX*BKI,+F)8Z^AI8*O%9.IH9
MHX:BF>:)GC8:KCW[K51737NITG\#\G.C]S=C[LZCP6]_XCV+L5LHN[MLQ;:W
M?'48(XB&6HJVK:V?`18L1RP0.]*RSLM:J,:<RZ3;W6^N/4GRBZ"[UKOX;U1V
M7A-W5[X&DW51TD%/E\7/EMLUKK'#N#`QYS'8P[@PR221K+4T/W$-.TT0E9#+
M&&]U[H7-V;JV_L;;&X=Y[LR<&$VOM3#9+<.X<Q5+,]-BL+B*26NR>1J5IXYI
MO!1T<#R/I1B%4\>_=>Z+?1_.;XF5V!WCNB+N[:L&W^O]CT/9N\<MD8,YB:3!
M=<Y"M3'4V_*E\IB:-I=G_=R`29&(24D"^N21$!;W[KW2TW3\HN@-EY[=.V-S
M]G[>Q6?V7LK;_8NX\9(N1J*BBV5NO.4.V=L9^#[.AJ(\I2;@W#DH*&B6D:>6
MIJI1%&C/<>_=>Z;MG?+CXW]A;>W9NK9';.W-T8'9&#IMS;GK<-'E:U\;M^LK
M\MBJ7,)11XXU^0Q\V5P-;2K)2Q3+]S22Q?YR-E'NO=1Z7YB?&:NZSC[DI.X-
ML3]83[ECV?2[SC7*G#U^XY:,Y$8[&/\`PX3Y/1CD>H>6G26".GAEE9PD4C)[
MKW3CM?Y7?'3>M'M6OVMVWM/-4F]]]P=9;3EI*BJ_W.[\JMK#?%'MFA26ECD>
MOK]G$92GN%CJ*`B>-FC.KW[KW0C;&[2Z][+J-ZTNP=VXC=<W7.]<QUSO<8>9
MJF/;F^=OB`YW:U?.(U@&8P[5*)51(SF"4E'LX91[KW47<_;_`%GLO>FT>NMT
M[RP^%WSOW%[KS6S-L5DDHRVY<7L;&C,;OK<33QPR?=1;>QC+-4Z3>-'7B[*#
M[KW2&IOE7\<ZK;_4F[(NXMCC:_?.8CV]TYN*?++2X3L3/5&0CQ-'AMM9.J2&
MCK<GDLG*L%)!K62LE8+`)#[]UHL`0"<GI2=G]]],=+MCU[7[+VCL$Y."HK:<
M[DR]/CTAQ5&RI7Y[)/(2F'VUC6<"JR=68,?2EAY9DN/?NM]"O35-/64\%723
MPU5)50Q5-+54TJ3T]33SHLL,\$T3-'-#-&P964E64@@V]^Z]T$V^?D!TAUEN
M#'[6[#[6V'LO/9.*.>#'[EW)C,0U-3S^5:*IR]163Q4F!ILK-"\-%)724Z5U
M0IAIS)*"GOW7NG#/=U]1[7WI@^NMQ=C[.P^^=QRTT.'VM7YV@@S-3-76&+AE
MI&FUT,V:D_;H%J/$U?*#'3B5P5'NO=0JGOWH^CV/N3LNL[<ZYH^O]G;FR.R]
MU[RJ]X8*FV[MO>>)W%'M#([0S>4FK4I<;NJFW7-'C3CIF2L:OEC@6,RR(K>Z
M]UP?Y`=(1=B3=22]L;!A[-I\A18FHV+-N;%1;FI\MDL=#E\7BI\5)4+4PY/*
MXJ=:FDIV`FJH#KB5U!(]U[IZVAV[U?O_`#FX]L[(W_M/=>X=H324VZ\+@,W0
MY/)[;JHJVIQTE+G*.EFDFQ=4M91R(8I@DGIO:Q!/NO=1,5W;T]G-ZU76V&[/
MV'E.PJ&KR=!6[&H-TX>JW;15>&2>3*0U>WH:M\K3-1)2RER\2C]I[$Z&M[KW
M4#;GR"Z)WAF(]O;4[DZPW)G9H\I+3X?![ZVUE,E51X-)I,VU)1T62FGJOX+'
M3R&K$:L:81OY-.EK>Z]T\;%[BZD[0EJH.MNS^ONP)J&EIZ^KBV7O';VYY*?'
MU9TTF0D3"Y"M9<?5/=8I_P#,R,"%8D$#W7NEGG,YA-LX?);AW)F,5M_`8:CG
MR.7SF<R%)B</BL?2H9:FNR62KYJ>BH:.GC4L\LKJB*+D@>_=>Z3479_6LU?B
M,5#V'L:7)Y_:K;ZP..BW;@)*_-[(2/S-O'$4:Y`U&2VJL7J.0A5Z0+SY+>_=
M>Z:\3W7TUGL9GLW@^V^LLSAMK4<.1W/E\3OS:N1QFW,?4&44]=GJ^CRLU)B*
M.<T\FB6H>-&T-8FQM[KW6&F[TZ2K<;G\Q1]Q=65>(VI34];NC*TW86TI\;MN
MCJZQL?2U>?KHLN]+AZ:IKT,$<E0T:/,"@)86]^Z]TKL9O39V;S%7M[#;LVSE
M\_08O&9ROP>,SN+K\Q187-1F7#9BKQE+52UM-B\M$-5+4.BQ3KRC,/?NO=.F
M6R^)P&-K,SG<ICL+B,?":BORN6K:;'8VAIU(5IZRNK)8:6FA!8`L[*MS]??N
MO=,V1WULC#[?H]V9;>.U<7M;(I2R8_<N1W#B*+;]='6PM444E'F:FLBQU2E7
M3H9(BDC"1`66X%_?NO=<LOO?9>W\-1;CS^[]KX/;V2^W..SN7S^)QN&R`JZ6
M2NI#192MJX:&J^ZHHFFC\;MKB4N+J"??NO=**GJ*>KIX*NDGAJJ6JABJ*:II
MY4FIZBGF19(9X)HV:.6&6-@RLI*LI!!M[]U[K-[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZZOR!8\WY_`_P!?_7]^Z]UW[]U[K__0W\*1@T",I!!:2Q%R#^Z_////OW7N
MI'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBP9
MN+L//_)K8%=4]2;CBZUZ]VSORDHNQ1NS8:XRLW9O&GVM%3UQVJNY6W6^'QV$
MQM?1^5J-9_O*L6B\`:;W[KW1GB;`FQ-@38?4V_`N0+GW[KW1&OCAT[O:FW-V
MOVIV3BNV=F[KWSN7?M1'U;O?LS:6^^F8*;/;S3-;6W)MO:6T<GEZ7'9_';;V
M_AJ2LFJ)8I%GCJ33I:9Y7]U[I*]:;,[ZPFW.F<?D>JLCB4^->S-W93*8.IWK
ML_+/WIW3E-J9?;-`^S,FF;-/B=IU<FX<EDOXKG3CJN*3(1T[TB-'4.GNO=,7
MQV^-6_NL\ELO+]A[?W;V;@:_HC-QU>T>R=Y[+W?6=']M9BJ-5V5LS95)3&CV
M[EMF]R4N9>F2HEJ<C+CTQ`IWJ(J.ND0>Z]T[2[+[GKOCCW]4+T#EH.[]^[E[
M7CV5MG,;SZH.:PFW^T(J/:=#/M_>N,W5D<'@:?:_7U+11S0&LA>2HQGAC1X1
M`[>Z]T'&Y?C]W-LS&?)G"]<[)[F[`7.]/]-="=1Y[??>VS,_FLAM#+3[@3N?
M,;=JMSYJAFV%48##YNGC<5A\V3K\7!-3Z@05]U[I59+KKO"NZ1W%U/2=6]VU
M=!NCL/8NVZC?>].].MLQ\C8NO\OO>7>W:F^:W>G]XJ_;=/BMG8Z1,)M7&4U3
M+7Z8@\E,L:AY/=>Z,E\:.JMW=4OVMBM\U><WMG*W?;U&([KW;G,;FMX]I;":
MB2NV=2[G3')04^'R/6T63J<`*:GQV.H:B.D%?'$T];52-[KW4SOS;^]Y-T=(
M]A[8VA5=E87JW>F=SFY^O,9DL+C<[6+F]HY7;.+WIML;DK\5@,QG=C')U#Q4
M%154KSQ5LLD$HJ888I?=>Z!+OK#]R]QX'86%?HOMC9%+DNPLON+=>Y>GNXNJ
MMN]I[2VYL_!9VBZXJ_XYE<[B*!=SY[<F:@JI**CFRM'CJ&FFCEJ)'E">_=>Z
M3VXNNOD-V9'TEL-]N=F]";?Q^5[-W/G.T^M]]]5UV_\`953CMK9CK?IFIWY5
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M44$$4<,$,:10PQ(L<444:A(XHHT`2..-``J@``"P]^Z]T4GL/;6X\S\C>JQC
M^GLU6]<48WMF.R]\TDW7]/M[/;ESVP&Z_P!HKN+%56Z:3=^XZ?"[8R.7HYI6
MQM0*5)X(H]<<CF/W7NBT]J?'WLS?6X.T<[BL#\A-DTFX>W^D^L<%LOK[L_K/
M`=<9'X\[$7;4>X=\9'9Z9R))L%6TK[AI*O#R34V4K,?-1T\5*HU./=>ZD[_Z
M]^4>\-_5W>C8?=42XWOSJ;`;/^/BX7IK(5)Z<ZIWO4Y.LWS_`*3<AO"G?:L7
M8D&3J\Y710RR9)6I,=C'IV$4C-[KW1@J'9U7G_DQNFER_2^:QO4%+UEE,52Y
M?*T>Q)-@[P[`W1V#C]Z;XSDF#H=TU^;J*W*C!85UK*[%1254]-,'*B)#)[KW
M1P969(I71#*Z1NR1K8&1E4E4!)`NY%N3[]U[JM3JK#=QX+=IWSB.D>Z>M\92
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M^5%;O&#H;L/&;"VCN_>FZ=V8679./Q>QX\6^X**#=_\`N!RFX*:3,9S;U%3#
M;V)K9ZL2&I#K)$NA)&(0^Z]T3ML)O?(=09[KFOZ7^1>_ML9G?'6W7^0WEVL.
MOJGN+<_6F].SJS=7<.!R>*PV;PE#C>F=G=:4E#@(1"T4^0DJ)@:&5HGJ*GW7
MNEWMK:79&P=M=U9?>O5.X.PFZNDZ\V)\?\'BX-M[CSN^Z#JI]P;EZZ[$Q>%D
MS6,Q6&;&YGL=*!Q65%+4PR8"6I;T>"1_=>Z45,V:ZM^*N%W3LWISM;+=W9KI
MG:_5L6-Q^WL++VA2;BPF`W+'MRIW;'4[KBQ.(P.'WGF*ZNGECR,D,#Y)Y@6,
MC-[]U[K!V0N0Q?P_V9'@.F.WMZ;ZQ/7\/7FRL#1;5P</:6S<KD]B9;K7(;SK
ML77;QHL5@*BEV[45C/(F4F8)5+&A<RV/NO==?*':IIOC[#A>K^M.W$WAO+-]
M=9O%9OK#;V"R'977.9VQ3;1H%WS6MG\O28VDW7M78.WOLJ97>H2>>G2CT2)(
M5;W7NCB;`VIMK8^R]M[5V?A'V[MS#XJGAQF'F\S5E(DP-74-E)ZF>JK*W-5=
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M6.*&*-0JJH"JH``M[]U[HC6QZ&*FR'9?4'8OQLW;O7+=F]M[LSG8&Y\SM?;>
MX.G=Z[0S&YVJ]J;FR&YMR9BKHJW$[6Z_CQU#%@IX'R5)5XTTT-*81'5/[KW0
M:TN&W8_7W972F:Z%WID.P=S;_P!Q;P[A[/FVI056R-W86EWP=UT>]MI[D;(K
M5;XW.^RZ.@Q^UL)`JU^)KX::EE6BIZ)ID]U[H,J'I?=N9G^/^8S>QNPLCM[N
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MMP;WR&5VYM_;E)MC`;=KA3;B_NACX,=+DJ^:MAAI),BE&*99WCEE@]U[H5?E
M_'N6;XW=IP[.V)E.SMT3X?&P83K[$TD-;4;OK9MQ8:),%5PU$]/"F$KE8KDI
MF<?;X_SRV8II/NO=`1TKL_=O7V[>ZM^=WXG?.Y*?J3<&]MF]:[HEV]7[SR^]
M=F=RY3:W<^\9]D[8V_09W<YV=M+=6XDVAAJ*FB5*3$;=$'A\</D/NO=/?3>%
MV#%\6:K-=B=1Y])ZS<N8['[%V)+U!N+$;MS.^I^R*CLZ@QT^QJ';]+EMT/C=
MQU])'!XZ>HH)A3A;FG1P/=>Z`;*]$;)F^*NQ<5BNM\KANU/D10;`ZGWMN>7H
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M_=>Z][]U[KWOW7NO_]'?NHK_`&T=_K>3\W_W:_Y_K[]U[J5[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H`NP>ZLOL/M?K+8$76
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MSNY.S-P[VVQ@L_\`'+L#9VSMZ8?-YK#;[KL[M+(+MQ,12X^LH\3VAMBCR"Y?
M9&X-QQ9`BAIH#E466GFBJI::551_=>Z1VROE/7[IZ\[TWKD^I\QMG(]-XK,;
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MM-0U4DE)41S11.D\1*ET8-[]U[J1W?VGE>IMM[=R^"V4V_\`,[GW]M#8&,VZ
MFZL#L]Y*W=^0;'05W\4W$ZT4D6/?]V:",/4O`KM$CLNAO=>Z!*M^6^77KS`;
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MM]K,9I8`%+>Z]TR;R^6>=Q^3V'C>N>F:S?L_874>,[9PF/SG9FP.L=RO%F:I
M*?&;.CVONNM;*U>ZJY95\:1!J8RK)&9@R#5[KW7JWYH8';7^E8;_`.J^R]H3
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MS=>2PFT\CD(-Q9K'4>X=ZBEQLT40CS`QU5-"RQ+"\WNO=+BB^2E3N#LRMV;L
MCJG=>^MH[=WZ>L-][^V_GME"?8V\8Y98JNISFPLEGJ#>"[*QDJ!*C*K#K8MY
M::FJ:4?<GW7NC0LRJI9B%5069F("JH%R23P`![]U[HL=!\E4K=R;1+]8;XHN
MI]_;A39FS^XJML*F(S&Z*V:MBV_*VTER#;QH-D;M:@:/%9R:E2GJYIJ8^-::
MIAJ6]U[IEV_\E]YY_<U)BX/CQOB3;=1V5D>O)]UXK>W5^X7QM)CMW[CV4W8.
M2VQAMUU6XJ+8<V7VQ4L*F2%:A(%+-`"K*/=>Z,QNO<5-M#:VY-V5M'D\C1[8
MP&8W#5X_"43Y+,U]-AL?49&>BQ&.C99*_)U4=,4IX5(,LK*H-S[]U[HIN&^7
M.;J9=YQ;C^/'9NV5V5M;LW-Y"L7<76&Y,7)G^J]O;7W'G]F29?;V]*[&8S+5
M<&ZXJ2EJ*N6&B>OIJF%Y4$0D?W7NA/VSWGD]S[EQ&U(.IMZT&4R?1&$[LJ7K
M\KLC[+#56XJ^MQN)ZRR512;GJV_OG-4XZ?5/"DN'5(7(K&M8^Z]TF]M?)Z"M
MZFW/W)O;K#>77FU<!D(L/C:?(YG8.X\IN[,-NN;8;4.`7:F[,MBXTJ-YQQT5
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MU3[AKNP<=L"BVXE5UK415O\`%-BU?8<&\:'=D6_O[F5VRJ+`T4JUM7#7R2T=
M2C(\.E2_OW7NIU9\BLE0[-DW9/T7V[]W3=A+UK5;3_XQY!GYLS69#%8G"97!
MS5^_:+`[EVOG,CFH$AK:.MD5(UFDD5$A<^_=>Z?MV]XS;=K*?!87JWL3?^[Z
M3;5%N_>>U-F1;8JZW8F$J_T4^;RF2W)C-O9#<]:8:D4&)QU965V1^TD>)/#H
ME;W7NDSE_DQ)1-3_`,)Z([VW(K]0[=[GKEH]O[.P=;AL'N49'[+:.6PN\M];
M:SM'V;%)B:F-\$:7[@RPNB,SHZK[KW1C,)E(\YAL1FHJ3(4$68QE!E(Z#+4C
M4&5HH\A2Q5:4F3H7+/1Y"F68)-$23'(I4_3W[KW3G[]U[H#LKWUMS#][[;Z`
MK-L;Y;<.Z=K5NZJ#>%)A\=6==T45*M>]-@\]GZ?,R5^!W'G(L/7OC:6JHHQD
M(\=5-"[B"2WNO=(]OE;LZ2A[1FQVQ>U,QENHNZ,%TANK:V/VUB1N.ISNYZG;
M%/M[=6W*6NW)146XMAY<;MI'CKJ:H>9=%1')`DU+411^Z]TXXKY,[:R&Y6P5
M?L'M;;>'D[2SW3N/W]GMJT$>QLKO;!9:?`)#29'&YW)Y:GPV>SU+)0X[(5=#
M34=36`0&1)71&]U[HR'OW7N@.VQWE2;I[7WAU+3];=JXO(;(:F_C&[\SM[#T
MFPY8<C!75&'J<9FX=QU597PYF+'R&`+2"1/3YDBUK?W7NH^S_D%MS>V[,)MS
M#[+[37#[JI,_7;1[(JMC5HZSW-2;=6EDJ*BCW323U8Q4&5IZOS8J3*08],Q#
M'(]$9U0GW[KW0\^_=>Z+AA/DGB\W5=M4R]3=Y8U.G,;FZ[<%9D]@PQTF>K<'
MAL=N%MO;(:DS=9/NC<.3PN6IYZ2"&,++Y/&768-&/=>Z?-D_(/8O8N3ZRHMG
M4.[\QC.V>JSW!M7=:;8KJ;:\.U=>(B^SW#D:SP3[=W1Y,Y3*<950QU2NSJRA
MHI0GNO=";O'>.W=A;=R.ZMU9`XW"XQ8/N)HZ2MR-7-/5U,-%0T&.Q>,IJS*9
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M['VSV7BJW)[<?*4\V(R<N#W#@=PX;);<W/MG.04U+6RX?<.`S%/2Y'&5IH:Z
M"HCU(8JBFGBGA>2&1';W7NEY[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQS2Q4\4L\\B0
MPPQO+-+*P2.**-2\DDCL0J(B*22>`![]U[KDCI(B21LKI(JNCJ059&`964C@
MJP-Q[]U[KE[]U[KWOW7NO__2W\:8:85%K>J0V_I>1S_Q/OW7NL_OW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB%;G^(.Y=W9W<?
M9N9W7LV?O+(]P;)W;MGL`8CL"#$[1ZQZZS=+DMF;$AV91]CTF(S&6PE(V0C%
M94?Y)-5Y>JJGI=4AB/NO="ILKX]I1=U]D]Q]B8CJ?=N=W#N"AR>P-QT.R<C2
M;XVAB<7BJ;;^*PU=F,QG\YCZJ7&XG'1M'54--02&IJJHZ0D@7W[KW39U!\<I
M]E9O?N_]\XCI[<W:^Y=Y;JWGA-]8/9>>Q]=05FY&E6"FR$FXMS[GJE;#8J&B
MQD<^/DH6DH*6Q16D>_NO=8>K>GN^-J9>EDW3V+UM_`CO;L#L_<E%L#9V\<#D
M-[;QWLV<:BQ>=J\[OS<$%/LO;G\<33311-453XJB9I4M,K^Z]UQQG1':>Z-E
M=X[-[@WYLVJ;M^I&8H<_UOMK<&$RFU,U_#<?BZ11'NK<VYZ3+XG;T.W,8])"
MZQ),4G2=#')I'NO=<-[=7_*C?W76[]IY3N;J[!Y;=6-QNTI7VSUKN6CP\&V)
M,JW]]<Q#53[]DW11;OWAM:23'4IIZV.FP;2_<1_=3(C^_=>Z"_/_``ERN&I.
MV-K])9KK[K_KGLCK[JCK]-FY[!]A;NCBQ_7.5K'JQE:^K[(A>7%9':5=)@J?
M'T245/#1MJF^X_S?OW7NE5%\8-_XW9W9U+M;-]+['W;VY%MG![DH-D]79;:W
M66-VO@(<G1UE13[8PN[Z/*[@WWG\=7BDJ,O65B$4$5/2B$Q4L>OW7NG/>G1O
M?>^Z)FW%V+UAE'KNP-H;ER>R,OLC<^8ZN7:VQ<75C&;7H=OU6[UJ_N]P;EJD
MR63K)Y987-+3Q)3`Q^4^Z]T/?36R]V[#V<,#N_.;;RE1#7LN"P^RMLKM+9&Q
MMI4&/QV%VUL;:&&>JKZV+"83%XI&#U$\DC5$\NG1"(HH_=>Z2G=_3M;W+E^K
M<9F*;KK.]6[7W96[HW]LO?>U*W<LNZY5V]EL#@8\1*F7H\3BY<++G9ZX/54E
M:&JH*<H(RFOW[KW0$;G^)V]:O:/577&-JNC]Z=;=3IO;$X;9W;_768W)C*[;
M>45,1L"FK:?&Y^AQYS6PMG23T!KOMFFK9'%1>!VEU^Z]U`W]M#YE;#W5U=O/
MJF@V#W1O?*[,W5M'O7<.\\G3;$VIB<1%N'([TVE)UIM.FEJ<YE-PX_,[@FQ=
M'15N5HL=-AZ</75Z5:1/)[KW2PQ?0_<6#I-F[GZ_[#I-M;YR&S=WX#L:I[/V
M[BMX5U-GNQMQQ[VW)V+A:79E?@]LG>M#N.".-<;>7!34,--3*4BHX_+[KW2E
MW?T;V&,7T?L[KC<.P:+8W3>1V;GF@WQ@MQY7<.Y<SL^ARF+IGJJO;>>V]C::
M.;[^/),_V\A;)P`E/$Q`]U[IC[>^*2]Z;]W]N'L!NOIL;/L':>W.EL]!M&JR
M?8/5&[MK9^?>D&\A5YS*UFV<PDN])*6JDH5H8(*J#$TM/4^:-YE/NO=->]/C
M_P!W;M[(G[%FS7QVFW"NW]F;;VCO#+=3YS+;VZD;$XO<5/NK=G7&0R6Z:Z"C
MW#E<KO/(STL4FB!8(J:"J-4JR,WNO=->[?B?O3=^+W;E<GE>LJCM.I[1[.SO
M7>]:C'=C/0;%Z][5P^*V5N&FFP%/OBEI<[V)#U[B8Z&ER,ACI:2I)GIH(+ND
MGNO=>R/QK[BJ.T=Q]@8JL^.6WLMFMYXQL#V5CNL,U4=Q]>=64.`P&TJG9NT,
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M8>Z^TY:G*UJXR+`0::F7%8=6@GR3"I$RQP0TWOW7NE%\6NB*CI'9533;FP?5
M\/9.:EACWGO+K3$9K&+OI:&JR>3H<ON2;<=5D,W69HY;<>3F;S5-0J?<D*Y!
M-O=>Z,AE#DQC,B<*M"V9%#5G$KE&J$QC9/[>3[!<B](DE4E":K1YC$K2".^D
M$V'OW7NB;5O3/?\`E/C5V#UE7Y/I*/M'L?=>Z:_<66HJ/?R=>5VVM_[J;,[P
MH:B@DKCNAJZ7;^1K,3`OW)A:%86<V+Q>_=>Z<]C=#;SZ?W%\B=Q]1[=Z*VS_
M`'__`-&5)U5@:3%;GP6%Q^.V7B:O'9'_`$AQ8=6BEJ#/EJN6C&)AA4(R1RFX
M,GOW7NN\-U1WM@OC[L+K*D;H+(;CV]5)C-]8/<6"W?N'K/LG91QV7ILIBIER
M4TN;V]F=R9:NAR,U1)!E:>GDB>#[>>*34ONO="C\?>J*OI_9%;MZM.WZ.;+[
MFRNZ/[K[+7,P[`V0,K!00-M;8E)GJRLR%'MZ&:A:L=?\GADR%952PTU+%(E/
M%[KW6'M[8?8.:W+UQV'U?5[+.[NO9-U4!P?8$>7BV[F\!O6AQE)E_%F<#3UV
M6P6<QTV&IIJ:9:6JBFB\U/(BB831>Z]T`G8OQ=W[V%3;/Q&[VZB[0V_GM_YW
ML/OW#[[QNY\?0[AK\EM+^X6WL%U[3X=JU\1@=B;6KIEH/OY:BJEJJ2"=I4FD
MEE7W7NEQW=\>LCVGN/I7;1VOU/GN@-BP9JFW?L7>3;IAR<GWF*HMLX.JVA%A
M8GQ"2[;VT]?#$E6P\AJPH>(*6;W7NE?W3LOM_=^XNK4V%!U<=F;.WEA=[;AA
MWED]WT.;K*[!19:GQ]!A8-NXNJQR4U++7P5BR5$A!FI1&8M#ZU]U[K%E-D]X
M;?[&WYN'K7*=85.W.S*K:61R,V^8-S+GMD9+`X3'[6R<F(H,#&U%O3%UV&Q4
M%134E168=Z:O:<M/+%*JQ>Z]T$&ZN@NZLUW1O'M^FQ_0M7NB"7;>*Z6WON"I
MW]6;CZVV_0;?S.W<S75>W:?'1;?S66E&[\U6TM&9UI%J*M5>3TF7W[KW0\BI
M[WROR&6FIZ?;NVOCAM#KR1<E59"CBR>]^UNV-RY"GEH8\#44^56/9^Q>LMN8
MYS625%))59W*9E(X?MX,9*U9[KW0[-JTMI`+6.D,2%+6X#$!B`3]38^_=>ZK
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MJPU#N2/'XG.XN3&0YFFI:Y<5E8CF1544TT$M-]W31K*$1FD3W7NBVXSJCY`-
M39O?68J9=QY:'M_;'9^SNE^Q^PZ7=&.P&(P6%S^.S&W\-O3#[/Q,&"R>0R>X
M7K\5',F4HJ.7'T:23(K2M#[KW3SN+K[O3-[CPO>E5MG9M7O3;6>P2XCI5-W5
M*8F7KZCP>YJ:OI<EO.IQ#XBL[0AW-NMLI1U`HHL93+CH*1)@TDM?[]U[INW9
ML[ONNW-MCLFLZUV_O#*U.]L3N6OV-C>S*';\.QMN=>;3W=1=>;>.;R6V9(-Y
M9G([QW[797)3)]G2T;1QPP_<+&)9O=>Z,=U7M#<6!CW=N?>S8?\`OOV+N;^\
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M9O3K^BV7C\='!V7MCLSK';V*W'O/*SYBEW;6QY/9,`JYL1)#4X>CJH\U3S!)
MVAA`E]U[I/;#^0'=6[H]H8:NSNQ\7N"J[\B?[V/95:*'>GQ>S4'8NZ-MYEJ>
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M@H-KRY?L3`X++YFMVC+O>9,')C,[EJK$87`1Y[;B2[EW55XB#$8V26=HHJZO
MB+QR#CW[KW05];=T]D=I[,[M[/&X\?L#8N'VKMZJVK39+9&*SVY>L-X8O9L>
MY>W]L;M_AF^JC%;UR6P<G.N)G2$T$*Y*FJHTEG1%<^Z]U+;>'R+H_C/M_LNK
MWKL2?=&3VVG:.\-QGK>JH,=LK8L'7-?O:;;V$V1)ON>HW%GJG.45+B_/492$
M1P5LU1XR\$<3^Z]TEZSM7Y%]=8/J1^V-U;'3*[Y[>V?3U7]V.G-\9_,9'K,]
M1G>_8^&BV3MC<VX<Y@<UA]XX^LQM)EB:Z*GIS`U52LSAV]U[H=?C'V'NGMG8
M.8['S>X,5N#;>Y^P=_\`^B^HQVRLQL6JBZUP6Z<GMO;39W$Y_)UV7ES=<F(D
MJ)99X,>Y25`:2%@5]^Z]U%^2>Y^Z=J;?H,KU+6[2Q,<.FEKZS<>VJO=]7E-U
M;AW-M'9VQ-L8["4FY]JM#05U9N6KK*ZL\\DL2X^*&.,_<.\?NO=`[N3O/M+J
M#=77F`[DWCMH4=-M7Y![R[%GV+TSV#O+(YC9^SMPX_$=3;BIJ7:.2W(VQ*JO
MQ&66NRD-3%64M1-2RT\$L+7T^Z]U)R6_?D&G1WQOS\?9>Q\?V7VYN39.%R]8
MW2V4K<%5)V7$V<IUI-KOV73Y#;E3L/:$53/*TU?6)6U5':00QR$+[KW3A\A^
MW.W.K1MG#4NY]N;&H8-DT^3K^\MW]3[NWGU=N'LJ.K7$4NS-Y4FR\X*KIW:&
M2J=%?7Y>MJ'AAHI_%3U*202.WNO='(P#9I\%A7W(,2NXGQ..;/C`25<V"&::
MCA.5&%EKXXJZ7$BN,GVS3*LK0Z2X#7'OW7NBG[Y[,[HW!'VUNKJK-=<;0V#T
M?)N*EJJK>NW<]N/*]E;LV)AY,ON[!2R4F9V]1[%V-2S2#''*1+E,B];3SS)`
MM/"B5GNO=!IG/D+VEOOM;'=<]7;RPVPLYG^HMA;RP.U-T=%;TW]'3;TW=M7>
MV\ZO![T[%P^[-O;3VMB\7AMOT"213K#D&GK1XUD5X_?NO=<:ON/Y&9ONG>G3
MF`WKUSM[>^`V)MJMVUMZKZ+[*W+LW<.^J?KJ@W3OR'+=L0;PQ.WL+MBDW!G\
M334\-OXQ'35US!,=,@]U[H<*C<_=#?(U-EQ[OV'0=8XCK/#]D[MHYNOLM5YN
MCEJ\I4;;BV]1;T;?E!CH:3,U6%RM>M5-B3+31TJ1>.0%Y![KW3/M/=GR?['I
MMC]J[27J;!]<;MW'@*I>M-XXO<Z[O7I;*Y*BFFWV=\X;+55!#V96;:U5M%@3
MB3BXUJ$IYZXRHTWOW7ND7T7WAV_W%O;<,&$WEU5N';NQ^TMQ[?WUMZ/J7L_9
MF2Q/7393?^+V3E\'OK.;NR6WMU[SKY-J4<U5'0T<^+-+5LZS1%HA[]U[H]_O
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KJ_('/-_QP+?U/X]^Z]UW[]U[K__U-_"EN(5O_JI?^MK^_=>
MZD>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+A
M!\8=D1;US.[)]V=L9+$Y[?"]E9#K3+]CY[*=9-O>*?'5M-F(-M5DDM134%'D
M\5!6PXA*H8..NC%0*+S7?W[KW2BHNCZ"A[$[`[*B[%[9DR_8>V(MIUF'GWBL
MNUMN8ZB>OEQ,^SL$V,\&"R6%J<M62TTX:1A)5R&3R>@+[KW20H?BKLG$[5Z:
MVEAMY]K8>DZ1&7?;F5QN]#3[CW)6YK;6>VM4Y7?^=_AC5V[LFE'N:NJ!+.RF
M2OG-3*))@&'NO=1J?XA]6PXO9M(^6[&JLWL/I'>70.WM[U.^LL=Z1[&WK%B(
M*RLKLO#X8,EO'"T^("8O+SP/6T`J:KQM>IF+^Z]T\=?_`!EV?UY05$=%O'M/
M<F?3955U[MW>V]-[U&Y-V;'VG4TM+3'';)J*JC3$8&99,?33R52T;U57-2P&
MJDG6&-5]U[I*#X?[<;J+=G357W-\BJ_`[OW%1;GK-QU?9X.^L;DX-SC>617"
M;H@P4%1CZ+<>XV>HR$)1TF$KQ*(XCXQ[KW2MRWQ>ZSS.0[.S%14;SILSVHNP
MJC+97&;ORV-K-M[AZW6I?;&\MAFC>*#:.[!D*A:RNJZ9`,G4PQFK29`4;W7N
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M`TZ$*^Z]U`W/\;\;N;.=:YS_`$M=X[?_`-%='A*;;N'VUOFDQN!KJC#8W(X2
M;+;DQDF`JH\]ELY@\K44=;+,;&&0F%89/7[]U[K#N[XO;0WCOG=&\Z_??<E!
M0;].WAV!UUB.RLS2=:;TAVUBTPM'1Y';,R5,F&QV2Q$2TV5IL/4XRGS4*Z:]
M*D%K^Z]T9-5"@*H"JH"JJ@`*`+``#@`#W[KW1;,Q\6>O<WNO/9VKSG846U]V
M[@@W=O'J2BW;-2=4[MW9"E.)<[GMNQ4@R-0,G)14\N0Q\==%A\G-`'K*.=I)
MC+[KW2SV1TY0[&["[*[#I-]]DYVI[0R<67S&V-S[BHLIL_"UU-08K$TC;4Q,
M>'I*K"PTF)PL%,D?W,D>@,S!I7:0^Z]UPZRZ9HNK]Q=D;BH=_=F[K/9NZJW>
M&3PV^=RTF>PFW\M7/IDBVC31X>@J\-C(:"*GHXJ9IYHHJ6DA10"K,_NO=,FQ
MOC]0;([+WKV>W9_;N\,EOVA@Q>:VYO;<N%S&SH,=055?4X2BQ.%I=L8V3'4V
M`7+5<5,J3D,E5(9_,Y#CW7NH&T/C9A]D&.EP?:7=@VYB,=G,7L;9U9ON*JVU
MUU29FEJ:&EBVW`V%7(Y>#:U%5&'"P[@JLW3XN*.-88U6*,+[KW33U3\4]M=4
MY'KZMA[/[IWU1]6;>RVWMBX'?^\,3DL'AQFZ.EQM=F:FFP6V-N5.>SO\,IY*
M>*?)35BP1U4YC19)-8]U[H4>J>K(>J,?O*@AW]VGV$=Y]E[Y[,FKNUM[U^^<
MAMN;?.8?+OL?9M1710C;?6FT@PI,%A8%\&-HU$:ECJ9O=:`I7).>A3]^ZWU[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW77-S]+?C^O^-_?NO==^_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z__5W\J<6B7ZCU2<&WYD8_CCW[KW6;W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7!&<Z]:!+.52SA]:`"SFP&@DD\<_3W[KW7/W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
M_];?QIO\RO)/JDY/_+5_?NO=9_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7_]??OHR#3I:_ZI?K:_\`G7_IQ[]U[J3[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KBSJBZF-A<#@$\L0HX4$_4^
M_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__T-_"D-X%_P"#2_@#_=K_`(''
MOW7NI'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNB];I^473FS-]9_K[<68W'0Y;:"[1?>F:&PM\U&QMEIOTR)LZ7=>_P"FV]+L
M["4^=EB9$EFK1%`P_P`H:($'W[KW0[C)XULBV'7(4)RR4@KWQ8JZ<Y%:`RB`
M5K40D^Y6D,S!/(5T:C:]_?NO=)S"]A;&W'G=P[8P6Z\%E=P[4RBX7<.'H\C3
MRY#%Y4XC'9TT,].'UM/'B<O332!-0C$H#68$#W7NE)%DL=/6U>,@KZ*;)4$=
M--7X^*J@DK:**L$C4<M72)(9Z:.J$3F-G50X4Z;V/OW7ND#N#M7;>W=\=?;!
MFI<[D\IV+GMQ;9H<C@L8<M@=MYS;FR\COZ6@WODZ:8C:\V6V[B9WH/.EJJ5`
M@L635[KW0E^_=>ZQS2K!#+.RRNL,4DK)#%)/,RQJ7*Q00J\TTK`65%4LQX`)
M]^Z]T#O2_P`@.JOD!MS([HZQW#5Y3'8;>.?Z^S%-F]N[DV=FL7O3:]SGMO5>
M"W?B<'E_O,>JLQ>.%X)45GBD=58CW7NA0IL_@JS%Q9NCS6)J\-.XC@R]-D:.
M?%S2&K^P"15\4S4DCFN_9L')\WH_5Q[]U[K))F,3#3UM7+E,='2XV=J7(5,E
M=2I3T-2GBU4U9,\HBI9U,R720JPUKQR/?NO=!I4]NPT?3#=T5'7?:D=-'M*/
M=\_6S;0"]N4],\*5$F%J-E-D08MRTL+$RT9J=:%64G4+>_=>Z6VR=VXG?^S-
MH[[P*URX+>NV,#NW"KE*&HQ>37$[CQ5)F,<N1QE6J56.KA1UB>:"4"2&2Z,`
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M=>Z1O7W4W?V5^5/77;/9/6,&"I\/-W+/O+=>)RG2:X2*KJ\:-I]88K;7\`P<
M7<NY=J5FS)R:J?-Y8,<E30/-B8_'!/3>Z]TO.I^G,QL+?G:+XGXW[/VCO#>O
M87>N\Z;Y&1KU;50T+;UJZB;9L^-H<68^Q\@<G0QT29>EJH:%5JH9R99XWC=O
M=>Z+OUK\4NXL358W.';&]]K=R[;ZJ[4Q[]M9/<7Q_P`;C=P]O;NVG4X"IS^1
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MNC(XO'9[-=?X:66NQV-$A:MR*0(RF+RV]U?JI'?_`%'FNL]Y[8^,V]<1CNU]
MH[K[BZ!WAU'M[>V[NG>M,_VCMGX^;`RJ;NVSUU@=IU^'EQV;P=?B\#-'-EUQ
MJ;C$M9CZNHBIIE$WNO=#]O7XY]A5'1WR8PFQ?C1A]KX[Y)Y/9.T<7\>]K;EZ
MVPV,V#M'`QOA]R=L98568H^M]M=D[FP[>9(MM&IFHJG'8J<5+UL<U3![KW0Y
M=@]04&W?C'O?9?3GQ!Q\^Y.VMBUVW,[UR^1ZAC--GJ+:E;B=IY_L_.[HW15;
M>WOD\;5T]()<B:G-9"9DC>5Y3'J7W7NGG>=%W#AOB)B^L.NNBMV9K>=;U9-U
M'!MS(;\ZLQE;M.AH]MC9M+N'/;@J-X28*L:IQ<9JH%Q\M=)YBB3)&"Y7W7NC
M6[`26'9.U::;:N0V.U'@\=01[0RM=A<ED=O4^/ITHJ3%UE=MS)9C!5,]-2P(
M"U+53P_T<^_=>Z+_`/*?:FYMV4/7Z;(Z^[)W/OC;^YJG<&SMW=>=D;-ZNCV1
MECBZG;^07=^Y]T#-5D&T]S;;SU;258H-O[@J?$&:*F2J6FD'NO=!=BJ3LSXE
M=2?&CX\=/[%7N+M7?F_WI-W[BSF6WI%L'9^"RNX\EV;\B>Y]\[YR5-NG<%1'
M0/G:NGP%%6U+93<.X<KCJ9Y(H6K:JE]UHU\AU8![]UOH@GR(3Y(=D;]R?5M-
MTSO*I^-4-/MJ+/9SKWL?K'!;J[R;.&#^\NT,WD-Q;SVWN3JKJG;E++)'FGQM
M/5[BW(`::C>DI3*:SW7NN':?6/<$&]>SMJ=8];8*KVKW!U!UETMM'?$5?MC!
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MLP/NO=6`^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZKZ^"%/#!N_^848HXHS/_,%[(J)C&@7RS/T9\=E:22P&J70BJ2>?3[]U[JP7
MW[KW7O?NO=>_IQ?G_;?X^_=>Z][]U[K_U-^VB18Z:-$4*BF0*HU6`\K_`.J)
M;W[KW4OW[KW7O?NO=5^YL#_AU'K,^FX_E^]Y`_ZH`_(SX\E?Q^DD'\^_=>ZR
M?.VMR%'N+X$K09'*8]:WY_=34607&Y3(8Q,ACY>K>[Y)L=E$H*FF7)XN:6%'
M>EJ!+3R21HS(612/=>Z/][]U[KWOW7NO>_=>Z][]U[KWOW7NH=>,@:248MZ.
M.N_;\#U\<TM(/W4\OECIY89FO#J"V86:Q-Q<>_=>ZF>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NN-FUZM?HTD:-(_5<$/J^O`XM]/?NO=<O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=$<_EL]B;[[8^$?0O879F[,GOK?.Y,)N>?/[KS"XU<EF)Z+
M?V[,92S50Q%!C,<'@Q]##"/%!&-,8N"UR?=>Z8_@M_Q]_P#,$]*K_P`Y_P#8
MUM+Z[_\`&#OCSZF_U#'_`%/X]^Z]T?\`]^Z]U[W[KW7O?NO=>]^Z]U__U=_"
ME_S"_P#!I/\`K:_OW7NI'OW7NO>_=>ZK^S1'_#I_6@XN/Y?W>)_M7`/R+^/7
M^&FQM_K\>_=>ZP_/75_>7^7\%OS_`#!^IM5FTV4=3=[$WX.H<6M[]TW(I8QT
M'!J_X>K!_?NG.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKH_E+<_P`O
M#XU&][[>WB;V1?KV;O8V*H64$?D`_7W[KW3[\&U4;Q_F!:3>_P`^NP&8:=.E
MCT5\=KC]*ZKCF_/U^OOW7NC]>_=>Z][]U[KWOW7NO>_=>Z__UM_"E_S"?Z\G
MXM_NQ_Q[]U[J1[]U[KWOW7NJ_<V1_P`.I=9C4;_\-^]XD+;BW^S&?'D,U_ZC
MCCW[KW6/YYV_O+\`+KJ_[&#=36^MU(ZF[V(86_I;G\6O[]U[JP;W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5T?RE[?\-Y?&RVC_`(L6]/T6T7':
M&^+Z;<$7_/Y]^Z]T^?!HR'>'\P+R<:?GWV$$].G]O_09\>"G]HEK@_4VO_2U
MO?NO='[]^Z]U[W[KW71-K<$W-N/Q_B?\/?NO==^_=>Z__]??QIA:%1Q^J3Z<
MCF5R/]X]^Z]UG]^Z]U[W[KW5?^;_`.WI_6?*6'\O_O'TZ?W.?D7\>>2]^4-O
MI^#_`*_OW7NL/SS-MR?`#Z\_S!NI18&U_P#C$_>MK\&X!Y_'OW6BH:E?(UZL
M&]^ZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<_P#*5##^7C\:]8LW
M\!WF6!M]3V?O<D\``WO?W[KW3Y\&@R[P_F!ABI_YS\["*VO^ENBOCLP!O_:%
M_?NO='\]^Z]U[W[KW7O?NO=>]^Z]U__0W\*7_,+^?5)_UM?W[KW4CW[KW7O?
MNO=5^YIF_P"'4>M$TMH_X;][Q8O?TZO]F,^/0"VM^JW/U]^Z]UP^>94;F_E_
MZK\_S!>J``"1=O\`1)WN5Y!'`(O;Z&UO?NM$@4J:5ZL%]^ZWU[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ5M2
MAK,M[\,I5N"1R#SS;_;>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NNN>.+W//^`L>?\>??NO==^_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[JNK^4R2?Y>GQNO^K^![UU<!?4.T-\!O2+@<^_=>Z?_`(0:AO+Y_A@01\]M
M^?4DC2>A_CJR%;_@H1_L;^_=:&K.HCC_`"Z/M[]UOKWOW7NNC?BPOS_MA_7W
M[KW7?OW7NO_1W\*7_,+_`,&E_P"MK^_=>ZD>_=>Z][]U[JO[-#_L:AUJW'_;
MO[N\'ZW'_.1?Q\(_-B#S_K6]^Z]UB^>E_P"\O\O^Q(_[&#=3W_Q'^B7O>X/^
M'Y_V'OW5'+#11:YS\AZ]6#>_=7Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[JN?\`E*BW\O+XVBQ6V#WM<,03?_2COFY)'!)/-_S[]U[I_P#@[?\`OE_,
M"!U<?/G?OZB#P>AOCHPTV/"V;Z'GW[KW1^??NO=>]^Z]U[W[KW7O?NO=?__2
MW\:<6B4<CU2?6U^9'/XX]^Z]UG]^Z]U[W[KW1`,V#_PZ=UF=0M_L@'>(*ZC>
MX^17QY*MI^EK$\^_=>ZC?/:_]Y?Y?VFW_;PCJ2X.GZ?Z)^]KVU6Y`YXY]^Z]
MU81[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJY?Y2:E/Y>'QM0LS
M%<+OA;OJU>GM3?0L0Q+`"U@/P/?NO=*+X/+IWG_,#'UO\^-]M?C^UT'\<F^@
M^FF]OZ\>_=>Z/Q[]U[KWOW7NO>_=>Z][]U[K_]/?PI#>!3:WJEXM;_=K_@>_
M=>ZD>_=>Z][]U[H@.;_[>E]9_7CX`]Y<W-N?D3\>/J/H3QQ_3W[KW4?YY_\`
M'R_``6O_`-C!NIO]A;J;O4WO;BP'^']/?NM'5C33CG[.K!O?NM]>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=<=:A@A90[*S*EQJ*J5#,%O<JI87/XN/?NO=<O?NO=>]^Z]U[W[KW7O
M?NO=>'T%Q;_#^G^'''OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZKK_E-:?^&]_CEH!"?PG?9740S:3VKOL@LP^I(Y/OW7NGWX/W_O
MG_,"^O\`V7OOJQ)!N!T'\<AP`?2!:UC8\7_/OW7NC[^_=>Z][]U[KWOW7NO>
M_=>Z_]3?QIB#"I`(&J3@@#Z2.#]..3[]U[K/[]U[KWOW7NJ_,VW_`&-2ZS2X
MX_E^=Y,18WY^1GQX`(:^FW!N/K]/?NO=<?GEI_O-_+_!!)/\P7JG39;Z67J/
MOA[GG@64B_\`4^_=:+`4J#DTZL%]^ZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71N`;"Y_`O:_P#L
M>;>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]UT+&S:;'3Q<>H`V)7^HY'(]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MBB"-=*EB+L?4S,;LQ8\L2;7/']![]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[JNK^4R;_R]_CF=.G_`'%;]]-PUO\`C*^_.`0`+?X?CW[KW3]\
M(`!O7^8):US\]]\%@/P?]E^^-UM7X!*V/'X//-_?NO='W]^Z]U[W[KW7N>+?
MUY_P'OW7NO>_=>Z__]7?QIBQA4LI4ZI."`#;R/8V4D<CGW[KW6?W[KW7O?NO
M=5_YL`_S3^LC<W7^7]WH+6&DAOD7\=^2WU!&C@?F_P#A[]U[J/\`/4'^\W\O
MRQ`M_,(ZH)N;7'^B+OD$?4<\^_=>ZL(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW5=/\I@D_R]OCGJTZAB]_`A+Z05[8WX"!?GBUN>??NO=*#X0J
MR[V_F!AOS\]M[,O`OI;X_?&XK<@"]P>/S:P_'OW7NC[>_=>Z][]U[KHFUO\`
M$V_'^/\`7W[KW7?OW7NO_];?SA%HP`-/+\6M]78WM_4_7W[KW67W[KW7O?NO
M=47_`,PKYL[+^!'SOZ'[@W]LK>>_\+NWXB]W=<4.$V&^VX\U2927N7H_<QR5
M6VZLYM_'-C?M,,T7[<SS"5E]&DEEH\B1@%SCK18`J#6I-/\`5Z=#CW]V[AN_
M.O/Y5/=NW,5E,)@>VOF3\?>P,/AMP?8#.8G';KZ,[MS5+09/^&5M?C3DJ2&J
M$<W@GFBU!M#L+$W&0#UOJU_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=59?RT^RNO^K/Y:?QZWCVIOO9O6^U:>'>F/JMS[\W/A-H[>@K\EW)ORBQ
MM%-F<_6X_&PUF1JY%B@A:022RL$4%N/?NO=+G^7UN?;N]<Q\\MV[0W#A-V[4
MS_SNWK6[>W3MK+X_/[<SN/7X_P#QOI6K,)FL345>-R5'#6TTU.TD,KJ)X9$)
MU*0/<>!Z]U8I[]U[KWOW7NO>_=>Z][]U[K__U]_*`:8P/]JD/^WD8_X_U]^Z
M]UF]^Z]U[W[KW6HS_P`*2(3/WC\3E5M)7IWNLDZ@&0?WTZM]48:X+G3;^H'M
M)=L`L0/$L1_+^76B0H9CP`ZL.VRH/PL_D:C4`$[T^(UC'I93I^-?;ZVN%^C?
MFP%O:I?A7[!_@ZWU>Q[WU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM
M3#Y0TWF_X3K].02TT$MNW.O]<,Z13Q>GY7;B]7(>,G\AO]C[9N'1(9#)\-/2
MOV?SZ]T=S_A.7$L'P0WU`D:11Q?*7M98TC"+"JMMCK>3]E(P%2,LYXM];^Z6
MM/"J.%>JJX>I'D:=7Y^U/5NO>_=>ZZ-^+6^O-_Z?X?X^_=>Z[]^Z]U__T-_2
M+]'_`"$__0[>_=>ZR>_=>Z][]U[K41_X4FJ[=Z_$L770O3G=K`%@K-)_?3JP
MBU[J0+<WL!?\_3VDNV"K$#Q)('[.M$A5+'@.K%MKJS?"S^1F0R\=Z?$=W-SR
M/]EI[ANJ76[>L@?CBY_P]JE^%?L'6_('J]CWOKW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=:FOR;IS_`-`[73<"MX6';77Y0L>%/^S6;A9=>D#TV^H_
MV_M+>/H@9JT%17[*CKW1V_\`A.?%XO@IOU2RL?\`9I^V"2IXXVSUPHX_L\+P
M..+'Z'W:V-8JCUZT&#5IY8ZOO]J.M]>]^Z]U[W[KW7O?NO=?_]'?SA_S8_UW
M_P"AV]^Z]UE]^Z]U[_8?['^G_$^_=>ZU#?\`A2E")>\_B238A>G>[RRO>Q7^
M^75GZ2"`AUVU$_4?3GVEN_@3[3_@Z]U8QM/6WPJ_D9,ZHCKWC\2+J0R?]RT=
MPQG2""Q;2;_X_7VI7X5^P=>ZO:][Z]U[W[KW7%@Q92KZ0+ZET@ZKVMS<%=/^
M'OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+
MKV%\HNJ]A9R?9E'59OL?LB%$9NL^J\+5[YWE`9C(D'\8I,5JQ^V(I98RHDRE
M31I^;V!/N0N7?;'FKF&PBWIX8-MY:;_B;?RK:6Q&"3&TE'G(!KIMTE/E2M.H
MVYB]U>4]@W!]C@DN-SYE"@_1V$374ZU)4>*(_P!.`%AIK/)'DUX5/0??WA^:
MO9$<DFWMD]6?'O"U"1-1UG866K>T-^"*3DRR[:VH^'VOC:GQL&,,N1J2CC2Q
M/)]B+Z#V2Y:=1N.];OS)>*3J6SC2PM*C&D37(DN'6H^-8$#`U`'0:_>7OKS.
M)#MVP[1RWM[`:'NY'OKNASJ,$'AP(U#F-Y6*G!)ZP2?&WO[).E;FOFQVLF2X
MD=-L;$ZRV]A/->["/$28/+/]J.`L;3L;?5C?W>+W&]O+9##;>QFT-#ZSW=_-
M+2GG()HP3\P@'H!TVWMA[BW/ARWOOMNXN0*GP+6RAC+&I-$,4G:*T"ZL4%23
MU"ZW[![DZV^0V.^.'<6\L3VQCM[]?YOL#K;L>DVO3;0W+3+M3(8[&Y[:V\L1
MB99<%5N(:Y*BFKZ=8&D.I'0FQ5_F/E[D[F7VZN?<CDS8YMHGV_<8K.]LVN&N
M86^H21X;BVED`F450H\,A?3AE:G&G+',7.?+7N/%[:<Y[W%N\-[MTEY9WBP+
M;S*L#I')!<1H3&YR'650I-2#7&D[_N$>IUZ][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4V^3D/_;.WT[&72/Q]M]?
MD.S!D4I\KMPV(((UJ#]/R1_C[27S:+=FIP(_PCKPZ.O_`,)S5*?!7L!"^LK\
MJ>U`3]?KM+K)@+VN;!OS<_UY]WM36*OJ>J(^O4:4H2/V=7Y>U'5^O>_=>Z][
M]U[KWOW7NO_2W](OT#_@S_\`0[>_=>ZR>_=>Z][]U[K4+_X4IZ3WK\1U>58U
M/3W=WH>ZB1O[Y]6"RN"!?3>X/!!_K;VEN_@3[3_@Z]U8WM(D?"O^1EJ<*3WC
M\2@-3%RW_.,_<5D#"YN5_P!X%C[4K\*_8/\`!U[J]GWOKW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&':/<.PNGL11Y3>N6D@J
M<Q5-CML;;Q5'4YO=^\<R(S)'A-H[8QL<^6SV4E%O1#&5C!#2,B78";E?E#?N
M<+R:TV2S#1PIKGFD98K>VCK3Q;B=R(X8^-"Y!8C2@9L=!3FSG7E[DNTM[K?+
MLB:=_#@@C5I;BYDI7P[>!`9)7]0HHH(+%1GHOYV9WS\B0*SLG+YSX]=35+>2
MCZMV1F(8NV]UXZ6$JG^DCL+&O*FS::K20L^(P3?=1A@DU?J5D]CX[QR%[=J\
M/+=I!S'S>N&OKJ(G;K=P>%E9O0W+*1BYNQX9(U1VU"&ZCL['[@^Y)\?F>^N.
M6^3V(*6%K(!N%PE,_6WB5%NKU/\`B]J1(HH))]0(Z,IU[UCU]U1@8ML]<[1P
M>T,+&S2O28:B2!ZRH>2266MR=:VNNRV0GEE9I*BJEFGD9B6<DGW&_,/,W,/-
MFX-NO,N\3WNX$`:Y6+:5``"HOPQH```B*J*``%`ZE'EWE?EWE';DVGEG9K>R
MV\$G1$H6K$DEG/Q.Y))+N68DY/2[]D?1]U[W[KW1&NI`W<_RM[6[VAM/L+JC
M;A^/'6U=XB(,WN*FS+9KMS/X^;6RU-%0YN"FQ,4ZWCE--+I/I]SAS:#R9[4<
MH<BRT7?]WN/WQ>I4ZHH6C\+;HF!`HSPE[AE(!7Q$]>H$Y0C'._N[S;[@(P?8
M=GMSM%BP%`\PD\3<)`W!U64)"CJ2K`-3(P>7W!_4]]-F8S6'V]CJK,9_+8W"
M8FBC,M;E,O74N-QU)$/K)4UM9+#301C^K,![46EG=W]Q%9V-K)/=R&BI&K.[
M'T55!8GY`=)+V_L=MMI+S<;R*"T059Y'5$'VLQ`'YGKCA,[A=S8F@SVW,OC<
M]@\I`M5C<QAZZFR6,KZ9B0L]'74<LU-4Q%E(U(Q%P1]1[M?6-[MEW<;?N-I+
M;WT3:7CD5D=&]&5@&4YX$=:L-PL-UL[?<=LO8KBPE74DD;J\;CU5U)5A7%0>
M(ITZ^TO2SKWOW7NL4DT<,<LT[I##"KR2RRNB1QQ1J7>621B%CC1022Q``'/O
M:@LRJH)8F@`R2?0#JKND:/)(X6-14DF@`&223P`&2>BI[[^;_P`8]@96HV_7
M=G8W<FY*10U3MW8-'DM^Y>$$.=,T6UJ7)P4\@T$%))%<'ZCW+.Q>QGNEO]G%
MN4'*DMMM+G$]VR6D7Y&=D+#YJI'G7J)-]]]?:[8;E["7FB*[W)30PVBM=2"O
MJ(0X'YD=0-B_.7H/>^ZL3LN>OWEU_N+<-1'1[:I.T]A[FZ_I]RUTP#04&$RF
M>H8,56U]0I!B@\RRRW`12Q`]O[[[%^X&R;1=;[%;V6X[7;J6G>PNX+LP(O%Y
M8X7,B(#Q<II6A+$`5Z2[#[]^WN^;O:;%--?;;N=RP6%;^TFM%F9JZ4CDE41L
M[?A775J@*"Q`Z.![A[J9^DOO'>^S^O<!6[IWUN?![1VYCD+UN:W#DZ3%8Z`!
M68*U362Q1M*X4Z44EW(L`3[,]GV7=^8=QM]IV+;+B\W.4T2*&-I';[%0$T%<
MDX'$D=%.][_LG+6VW&\<P[M;V6UQ"KRS2+&BCYLQ`KZ`9)P`3T32;Y^[$W#+
M51=+]3]Y]\14DSPOF=@=?UT6V9R+")Z+/;ADQ-/6Q3_56C1E*B][>YF3[O\`
MS#MR0OSQS9L'+Q=0?#O+Q#.*\0T,`E=6'HU,XZ@^?[Q6QW\DL7(W)7,',!1J
M>):V;K;G^$K--H#*^:,JGY]9Z/YV;<P-?04O>/37='Q\QN4K(*"BW;V'M>.7
M9:5-3+X:9,MN/!560I\(L\A"B2I5(E)]3J.?>I_8;=+^&XEY#YTV+F.>&,N]
MO9W!%U115C'!*J-+09I&6<^2FO6X?O"[9MMU;6_N!R+OW+<$T@1+B[M]5K5C
M1=<\+.(J^1=0HSJ(IT>B&:&HABJ*>6.>">-)H9H762*:*10\<L4B$I)'(A!5
M@2"#<>X(((+*P(8$@@BA!&""#P(/$=9!1R)+&DL3AHF`((((((J"",$$9!&"
M.LGO75^O>_=>Z8=S;HVWLO!9+<^[L[B=L[=P].]7E,YG*^FQ>+H*9+7EJJVL
MDBIX5)(`NUV8@"Y('M=MNV;CO-_:[7M%A-=;E.X6.*)&DD=CY*J@DGSP,"I.
M!T7[INVV;'87.Z[SN$-KML*ZGEE=41`/-F8@#Y>IP,]%TV#\R>D.S-Z;=V9L
MZOW;D1O&3,TVSMX5&Q-UXK8.[<A@,?)ELKC-N[MRN,H\=E*VEQD,D]H[HT<;
M%6-N9&Y@]F>?.5MDW#>M]L[2'Z/PS<6XN[>2[MUE?PXWGMXY'>-6<JO=D%@"
M!U&7+OO?R#S7OVW;#L=S>2M>&5;>X:TN([2X>%#)(D-Q(BI(P0,W;52%.:T!
M,+'O':,NXY-G1;IVY)NZ*E:NEVM'G,8^XXZ)-&NLDPBU1R:4J^1;R&((-0YY
M'N/#M&[+MR[PVU7(V@OH$YB?P2^>P2Z?#+8/;JK@XZDE-[V63<WV6/=[5MX5
M2Q@$L9F"CBQB#:PHJ*G33/2D]EW1IU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6II\GQ'_T
M#M]-I(XTGMSKY-0Y`)^5NX56WIM93_4`6'M-=`F$T'`@_P`QU[H['_"<QBWP
M6["N4(7Y4]IJ-`LO_'H]8EB`;-ZG)//]?Z6][MO[,_:>M`DUJM,]7Y^U'6^O
M>_=>Z][]U[KWOW7NO__3W\X;^,7^NJ3_`*V-S_L??NO=9??NO=>]^Z]UJ%_\
M*5K#O#XDL%4LW3_=Z7DB$R!#O3JG5920BR!22"UP1<#GVEN_A3[3_@ZTQ"@L
MQHHZL9VDO_.%/\C(:78+WE\2?T.LFE1\:>X@K.Y(UJ.+VY]J1\*_8.M_/J]O
MWOKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%J[?[TRN
M"W-1]-]-X*A[`[YSF.BRD>%KJB>GV?UQMJJEEITW_P!KY>C#SX?;JRPN*.BA
MODLQ.GAI4`US1R1RCR-:7VUS<Y\Y[B^W<@V\IC,B@&YO9U`)L]OC?MEG(93)
M*WZ%LA\25JZ4>+.=>?[O;]R3DGD>PCW+W$GB$@B9J6]E"QI]7N$@S%"*'PXA
M^M<L-$2T)=9_4_Q]Q&Q,U6=C;TSE;VGW=G*=H,YVCN6FIXZN@HIBSMMC8.%B
MUX_8.RZ9I&$=#1`23`ZJJ:HD]?MCFWW`N]_LX>7=EV^/:>1K=@T5A"259P*"
M>[E/?=W1`S++VKPACB7MZ4\G^VUAR]N-SS3O5])NW/MRFF:_G`#*G'P+2(=E
MI:@UTQ19:M97D;/1AO<?=25U[W[KW0'=O_('873;XC#Y89K=78&Z!(-E=5;%
MQC[D[%W@\<@BEEQ6!@DB6CQ%*Y_RG)5TM)C:55)EG4V!&W*'(&_<Y"\N[,P6
MG+]H1]3?73^!9V]14"24@ZI&%-$$2R3N2-$9X@!\Y^XG+_)1M;.[$]YS%=#_
M`!:PM$\>\N,TK'""-,8/QS2M'"E#JD!QT!G<':W;\NS<%U3B*;!;*^0'=?\`
M%FQU'29&/+4?1/5E.JC='8^]L[&[8NLR&U,26BADA,5'69VHBIZ5IHXFE<;<
MG\I\GIO.X<W;G--?>W&R&,.6C,;;K?M_N/86T9_4"W$M&<,#)'9H\LPC9@HC
M[G+G#G-]BV_E&WBM[#W'WXR:$202+M.WC^WO;J:NAGMXJA64K')=NL4'B*A=
MA^Z*Q?4VS>OMO]8]1[DVYG\!UYBZ/!R#";AQFX*V.I823U60S\V.JZIUS&<K
MVFJZAY=+33RNUN?8$YZO.;=ZYBW'FCG';[F#<]RF:6LL,D*D8`2$.J_I1+IC
M0+4*BJOEU(W(%OR?L_+FW<J<F[M:W.W[7"L)$4\<S*0*EI2C-221BTCUI5F)
MIT&W>ORAH>N,]CNJNM=M5/;O?FY8)7P/6^!JH$CPT'@,J9_?F4+^';.`@0B4
MF4I)+&+C0K"0";D/VNN.9MON>;.9-T39O;RU<":]E4DR&M##:1\;B8_"`M55
MCFI!7H+>X'NQ!RQN5KRARMM3;U[BW2DPV43!1&M"1-=RGM@B%"W=1F4&FD'5
MT&&UOB#N7M#)4N_?F3O2;M3/_<)D,5U+A:NKQG3.RVT_LTL>$@-,=T5]*-.N
M>J!1G#:A,+.1/N?O#MW*]K-L'LMLO[GVT@K)?RJLFYW6<EICJ%O&<TCBH0*9
M4U7H,[=[+7_-=_%S)[S[])NU^&UQ;?&S1[=:U&4$:Z3<,#0ZY.!J.\=Q.]M7
M:>VMC;>Q6TMG8+%[9VQ@J446'P.%HX<?B\;2AWD\%'1TZ)##&99&8V'+,2;D
MD^X0W3==RWO<+O=MXOYKK<YWU22RL7D=N%69B230`9X``#`ZG7:-GVO8-ML]
MFV3;X;7:K=-,<42A(T6I-%44`R23ZDDG)Z4'M!T8]%`[I^6V%V)NI.HNJ=IY
M;O7OJMA9XNNMFS0BBVI$_C6++]E[G<28W9>(4S!R)BU3(@)6,*0_N7.2_:6^
MW_:).<>:MXAV'V^B8`WMP"7G;-8K&W%'NI,$$K2-:Y8D:>H9YW]XK#E_=TY-
MY2VB;?\`W!D!I9VQ&F"@!#WLYJELF1\7<16H4=W2`B^*_:W>4D6;^7?;-=D\
M14)'-'T'U!69'9W5>.#'S?9;ER\<XW-OV>+RM&[3RPQ&WIU)8>Q"WNIRKR*O
MT7L]RE%#>*2#NVXHES?R>6J&,CZ>T!H&`1&;/=0]!R+VDYMY^$=][S\W236S
M@-^Z=O9K:PCSJ\.9P3-=%:E2S.`:8)6E#<=?=0]7=4XNGPW7&P=J;,Q]*C)%
M'@<+144S!_UM45J1?>U<CC@O+([$?4^XDYAYNYIYMNWON9N8;R^N6-29I6<?
MDI.E1Z!5`'D.ICY<Y,Y3Y0M4L^6>7;2RMU%!X4:JQJ:Y>FMO]LQZ*W_,2&'R
MOQPRFPWQU/E=\]I;KV9UWU52"GAGRL&_,_N*@%%F<.S`U-'4[?QU/4ULE1#9
MHXH6!(5C>4_NZ&YL_<RSY@-PT6Q;39W5Y?M5O#-I#`^N.4"BLLSLD01L,SBF
M1U$_WE$LMP]LKKEI[:.;?-XO+:RL5(!<74LR%9(Z]RM$BO*73N55)KT-'=G<
M6)^-'2DF]-QQ9/=N4Q-)@-J;<P5`&?-[_P!^9408?;N`HF99/'69_+$&25@P
MAB\DA#:=)`_(W)EY[F<Y1[%MLD-C:RM+/-*_]E9VD=9)IG'FL,?!:C4VE:BM
M0-N>N=;/VLY%_?>Z+->W<*0V\,2YEO+MP(XHE)&&E?+,?A74U"10@;UU\1*O
M?&<Q_<WS`R<';G:M0D&0Q'7\QD;IOIY'*U$.W=H[3,KXW/5^-!\51E:])Y:N
M34P%K,1YS#[O1;'87')GLW;/LW*8+))=C&Y;C^$RW-Q0/$C_`!);PZ%C%`<U
M``/+/LQ+O]]:<[^]5TF]<WD+)':-4[=MQ/<(K>`DI*R`Z7FE#ZSJ-#4-T>JB
MHJ/'4L%#CZ2FH:*EC6&EHZ."*EI::%.$B@IX$CAAB0?15``]P5+++/+)//*S
MSNQ+,Q+,Q/$DFI)/F2>L@8((+6&*WMH4CMT4!54!54#@%4```>0`IT7'YD;J
MVWL[XO=W9;=.-@S6.J-@9W!4F"GACJ&SN?W+2M@-M8BFII`3/6UN?R-.L00>
M17LRV*@B1O9S:MRWGW2Y$L]JN6@NEW*&4RJ2/"B@;QIY"WDJ0HY:N"*@X-.H
MR][-XVW8_:GGJ\W2".:%MOEA2)Z$2S3CP8(P,DLTSIITC4"*BA%0L_COM#/[
M`Z'Z=V5NJIJ:O<FU^M]GX7.2UDGEJ4RE!@Z*"LI99;MY#0S*80US=8P?9-[A
M[QM_,//O.>^[3"D>V7>Z7,L0444H\SE6`\M8.LCU;H\]MMDON6O;_DS8-SE9
M]QM-MMXI"QJ0ZQJ&4GST'L'R7J%WIW[L_HC`XRKS-)EMT;QW9D!@>N.LMIPP
MU^^>Q=SR!/#A=N8V6:"(1Q>17JZR=XJ2B@]<KCTJS_(O(.\\^;A=P6#Q6VSV
M<7C7M[.2EK96XXRSN`3GA'&@:25NU%.2$ON![B[+[>[?9RWT4UWO=[*(+*Q@
M`>ZO+AOABB0D``<9)6(CB7N<\`5SNWL+;?7G7^6[([$K8=F;<VY@/[P;FJ,I
M/#*,)#'3QRU%)-)1M/%5UD=1(($2`R&>8JL6HLMR':=@W+F+?[+EOEVW:]W2
MZN/!@5`1XK$T4C532I'>2^D(M2]`#00[SS)MG+7+=YS1S-.MCMEK;>-.7(/A
M``%E)6H9@QT`)76U`M21T2+8_66;^5.;QOR*^3&-_A?4^)\N>Z-^/VX`L6"P
M^#4&HQ_:?<%!4D4>7WIE,>HJ*>AJ0]'AZ9Q<-,7(G#?^9['VGL[GVW]L+HR\
MW34BW7=X<R22_"^W[:Z]\=LC]KS)26YD!H1&%!@;8>4[[W<W"'W*]U+41\FQ
M#Q=JV>:@BBBIJ%_N2-5)+IU[HXV)BMXB*@N6(+1B^S>S?F=\B=R4OQXJ8=E]
M;=>X*;KO;O<JT`FBZXV9EJ@#>&[]@8B=(J,=H=IKBX<?A96"G%[=I#4`1M4R
M!I.N^5.5O93VUVB;W'A:]YGW*?ZR;;=6DWEQ$*6UO>2*2WT-@9&FNER9[N3P
MZL(ETQ/!S)S;[Y^Y&Y)[9W,>W<L[9";.'<=&KZ&VE8BYNK2,A5^NW`1K%;''
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MTE!Q>_MN4`Q2`\*=>].CK?\`"<8K_LBO8@5M=OE5VCJ:][LVS.K6/-A];W^G
MT]MVW]F?M/7NK^?:CKW7O?NO=>]^Z]U[W[KW7__4W](_T?\`(3_]#M[]U[K)
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MO8RY!Y4_KGS5MNR377T^V4DFNIO.&TMXVGN9%&076&-_#4X:0JIX]`7W(YQ'
M(O*.X[[%`LVZ%H[>TA-:37ES(L%K$:9"M,ZZR,K&&;RZB]#=,T_3^U*I,IDV
MW9V7O3('=G;?8E5';);YWQ60JM96'4`U%MW#16HL-CD"P8[&PQQ(NK6SN<]\
MYR<X[M"]I:_1\K64?T^WV2_!:6JGM7^G-*:RW,QJ\T[.[&FD"GM[R-#R3LTD
M5S=&\YGO9/J-PO6'ZEW=,.YR?PQ1C]*WB%$AA5$45!)'+V">A[TTYS/8/;&*
MKL]N3,XK;^$QE.]5DLQF\A28K%8^FCMKJ*W(5TL%)2P)?EG=5'M396=YN5Y;
M[?MUI+<7\S:8XHD:21V]$1`68_(`GI'N&X[?M-G<;CNM]#;;?$I9Y976.-%'
M$L[D*H'J2.B?5G=_:G?3RX7XM8:'`[):4T^4^378>(G&TDIU=HZI^H=CU@H\
MGV7D$TL(LC4_:8".1"?)5CT&8(^1^5N00M[[K7C3[VHJFR6<J_4%L:1N-TNJ
M.QC/%HH_$O"#\$)[NH:EY\YJ]PM=G[468MMA-0^^7L3"W`R"=OM7T27K_P`,
MTGAV@I77-A25\=_=-]![DR'77QIQ&<^6'RLW_7_P?<V^LGFES=7FMP4P(DBW
MCV`RK24>`P+H)GQ.%2'%8NG5BWVQ!+2D/;[G/W!VV'F;W0O;?E#VBVU-<-M'
M$8UAB?@;:R^)Y915/J;EFN)W('ZH("Q./<+D[V[OWY8]KK.?G'W<W*3PY[N6
M42/+*O'ZJ\H`(HOC6VM@EO$@)K%EB+.SO@;0;PRN5[5^76[Z[MKLS=D%))N7
M;V*R63VQU3@<70G[B@VA0X>@JZ:JSNW\$URGWLHADD+RM#K=G8)[Q[^3[):6
MG*OL[M";-RM:,W@S2(D^X3R/VM<R2.K)%-+P_174JZ4#T4`#+9_N_0;W>7?-
M?O'ODF\\RW11I849K>QA2,$I;JB%6EBCJ?[1@C$L3'4DDF/7>[(=P_*/N3"_
M!C86W-NMD]H;;Z?V_O'`XJDQO6^R-H8;-35N_.Y]P1TD1I]P9VLR92CVW3WU
M54=+YBLJ2.ON:>8]H>Q]J>2]Q]^N8;JZ$=[/N,UM-(SWMW<R1!+/;(&:C0Q+
M'JEOGI^DTF@%"%/4#<M[N^Z>ZO.MC]W_`)=M+6*>SAV^WNH8T2SM+:.0/=[G
M)H!65Y'I'8H::Q'XFEU8CJW;HGX^;'Z%P%518'[W<&[MP3')[][)W)(*_>N_
ML_,1)69;/9635+XWFN8:5"(*=+!06U.V(//GN#OO/^X17&Y:+?:+=?#M+*$:
M+6SA&%BACX8'Q.07<U)-*`9G^WWMOL/MWMLMOMWB7.\W!UW=[.==U=RG+22R
M&II7X(P=$8P!6I([>P+U(/7O?NO=$[^:?;>]>N>N=L[2ZJEBI^W>\M_[=Z?Z
M[KY@"F!K]S22',;KLZ-"S[:P-/45$8<A1-H)N`09>]E^4]DYDYDW7=N;(W?D
M[8=NFW&\1>,R0@>';@_\.F9$:F2FH#)!ZA7WSYPW[EGEG:MGY/(7G+?MQAV^
MS<\(7F)\2<UQ^E$&8$X#4/ET)GQ]^._7WQSV9_=?9E+/6Y;*3_Q7>V^<W(:[
M>&_]RS:GKMP;GS$[2U=743U$CM'"7,-.KE4`NQ8.>X'N+S'[D;R-UWV9$M8E
M\.UM8E\.VLX!\,%O$**B@`:FIJ<BK'``%7MW[;\N>VNRG:]DB:2]F;7=74IU
MW%W,:EI9I#5FJ2=*UTH":9+,P\>P)U('08]L]Q];='[2K-Z]G;KQ>UL)3*Z4
MYK9T.0S%:%O#B<!BT+5V;R]4Q"Q4U.DDC$_0+<@3<I<F\R\];S#L/*NTRW>X
MODA1V1KYR32'LBC7BSN0HIQK0=!7G#G;ECD+9YM\YIW6.ULE!T@D>)*X%1'#
M'\4LK<%1`3G-!4]$D^..=SWS-[2QORIW;L^NV?U1U;'N':_QYVGFY8JO(9K<
M&4E:@W=VSF(T1::GKXL="N*HXHA)'2O]R%FD="[37[D6%C[,\KW/M1M.\I><
MW;HT,^\7$0*K%#&-=MM\=>XH7)N)6:AD7P2R*#H$&>V=YNGO3S9;>[6_;&;+
ME3:5F@V:WD99'DED)2YOI:559511`@2JQDRJ'<KJ+-_,?W[0;"ROQ>W5224N
M\MU=?=QKOZ@Z.HJF3^]78M-1;>R^.ILEB:2EAKJE(MK92H2<RM32(6)"W92/
M9A]VW8+CF&T]U]J=&L]JO]D-I)NCJ/`LBTT3M&[,44FX13'IU@TI6@->BC[S
MN_VVP[G[/[I'*EYN>W;Z+L;6K'Q[I5AE1)450S!;>6C%RA7)I5EIT*?Q8^8N
MPNR.OL6_:/>O2,G;%;59"OSFU<%D#LW^ZD60JY:S&;/J,7N_(QY2OR^VJ&5:
M2JJE"QU,T1=5L;L$_=/V>W_EKF*\'+'(F_#E)%189YH_J/'TK1K@26R&-$F8
M&1$J3&K!6-<`8^TWO7R[S+RY9MS=[@[$>;Y)&,L$3_3"W+&JVVFY</(\([6D
M``<@D`TU$?=X?)GX];!H?XCN[NGK3#TY<QQH^[\+5UD\H4OX*7'8^KJ\C5SE
M1PD43N?P/8"VCVR]Q-_G^FV?DC=)Y:5Q;2JH%:5+NJHHKYLP`\\=2%O'NQ[9
M[!;BZW;GS:HH22!2YB=B1FBI&S.Q^04D^0ZIB^2GSZVSVQWCU[1[4QD.:Z8Z
MIS5%NBBGWA!N+'[7SW8CRF@PG9&^MO8JBDW1DNONM6J?O*'')'3U.1KTU,53
MQCWFE[;?=\W;E+D+F2ZWBZ:WYTW:V>!UMV@>>"SP\MG:RNP@6\O@OA2SEG2W
MA-`-18]8->ZWWB]JYOY\Y<M]HLDN.2MGN([A#=+.D#WA+)'?7D,:_4/:V%1+
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M5H'KW19`R@6(MJ,GM%[76^_VX/\`KC\X0O%:L/CLMJ#>'--'@E9KYQX<;+1Q
M"&92K="3=FC]XO=:[V"Y8'VSY.E22\5B!%>;J5+QPR`_%#9)^I*K=OBD!@RD
M=%R^9'R4WM\B*;;O07QF@EJMD=H;];JO(=GL9*7&=EYRBBEK=T;3V%,ICJ\G
MU]M/%4DM3NC.4]J:2&(T<$C*\IDDGV8]LMB]N9=QY_\`=1PF][7MOUT=@*-)
M8Q,=,%Q>#*QWERY5+"T?]16832(K*@6,?>OW3W[W*3;/;SVJC9MAW7</HFO\
MK'?R+F:"S8$-)96Z_J7]TE$9`84<HSEEKM'-QX#8]1\1_@[D*!YMK15,7?\`
M\KZJ*FCV'USDZBG`W9EL?DEE%'NKM&HBIV%'102O286FBA$DH2']L@WNT?<M
M\3WD]^8)/`O"O[IV%23=WD2G]"-TIJM[$$_J2LHDNF9RB%Y.X]V._3:MDF]F
M?8.:-I+,-^^.8'HMI9R,/UY%DKIGO2`1'$CE+6-$!>D=4'[XV=R_%?9N>VO\
M1NA,YD=\Y'"8;/Y?,[HV[C:O<F`_BU#*U7GLYOSL&GC&-K-S[JR,DLHJ0\T=
M3/>)74A(_8#]R^3?=O>K'<_>#W"VV.PM+B>&.*&9U@E\-AIAAM+-B9%@MHPJ
MZ"$9$HQ4@ENI%]K^>?:'8MQVCV9]NK][^X@AF>2:WC,T`=.^66ZNUHC2W#%B
ML@+I(U4#@@+T?!Y(X]`=T0R.(X];!=;D$A$N1J<@'@<\>X'\Z>=*_EUD&S*M
M-3`5-!7S)X#[>N?OW5NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM2[Y-6_Z!TNJ26CD"]P;-*V:\
M<B_[-YN4(NKDZ=)Y`-^+>VYJ^%)0YIUX='5_X3B,6^"O8M_HORJ[00"Y)`79
M?5@O<_AC]/KQ[;MO[/\`,]>ZO\]J.O=>]^Z]U[W[KW7O?NO=?__5W\X1:,#_
M`&I_^MC>_=>ZR^_=>Z][]U[K4,_X4K:&[P^(:F/7+_HD[Q*$W]*_WOZKU6`Y
M))`_K[2W7P)]I_P=>ZL2VG&W^R3_`,BQ';U#O3XBLQ2SAM/QH[BD`)!M^.2#
MP?\`;>U*_"OV#KW5\/O?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7N@!^2'5>=[6V!CJ3:%7C*7?&Q-\[+[4V-'GO/_=K)[JV!FH<WCL'N44R2
M5*X3.1QR4LLL:M)3-*LZJYB",/\`VVYJV_E/F&XFWF"5]AO["YL+HQ4\>.WN
MXS&\L&HA3-$2LBJQTN%,9(#U$=>YW*-_S?R]9Q[/+&N_;;N%MN%J):^#)<6D
MGB)#-3(BE&J-F7*%A(*Z:%!Q_(?N6E@%'F?AUW(NY(T"U-/M_<W56<VPT^GD
MT&ZI]YXD5%*7'I:6D@DTV+1CZ>SQO;SDZ1S-9^\6S';2<-+!?Q3T\M5N+:2A
M]0LCCC1B,]!J+W,Y\CC\#</8_>QN8P1#<;?+;DCB4G:YC)4GX2T:L10E0<=<
M)=R_,O?T7AVWUSU=T+0S1QG^.=D;GJ.TMTPI(H9GIMG;&&'V_%5QWL5J,TZ`
MWX/T]^7;?9OE]PVY<R;KS!."?T[*W%C;DCR:XN_$F*GU2U!ID$=>_>WOAS+"
M@V[E;:N6X'I62]N#?W"J>.FWM!'`''H]RP&:Y%.DCO?ISISK3!U'=ORZ[)S7
M<LVT)$R5/D.ROMX]B83*RL(J6EV+TYM^&+:W\7KIA''31R4V2R,DJKIF)%_9
MQL?./.?,FX1\C^S_`"U#LJWP,9CL=1NYHP*LUWN,I-P8XUJ78/!"JDU0`]%'
M,')/(_*NWS<^^\O,\^]M9$2*U]I^DBEK1%L]MB`@$KM01J4GF9J4<G/1(\_W
M+WG\\-R9/KKJO$Y3:/4\+T].=M4M948*F.%82)%FN^-\X9S5X:BK$3R4FS<$
M[UU9'I%5+X@S"==LY(Y"]@=NM.9^;[R*\YN*DB4HLI,AH?#VFUD[9&4FDFYW
MBB*)J^%'K(!@C<.=_<+[PFYW?+G*EA+9\GJZKX`D:$>%D&7=KF,EE4C*[9:G
MQ'%/$D902+(_C1\4.O?C;A9#AH*?-[YRM%!2;BWK-CJ>@FFI82)(L#MW&0M+
M3[8VG1R\PT4#,7*J\\DTBAQC5[F^[7,WN;?@[A,\.P1.6AM0Y8!C@S3.0#/<
M,,-*P&*A%125ZRA]L/:+ESVSLF:S1;CF"6,+-<E`E5&1#!&"5M[93\$*D\`7
M9R`06'Y0]U[V[_WEDOA;\7*D5.X:Y5H?D'VQ32,VW.I=F5?DI\KMU<C2S(:C
M=V7B#T\L,+%XD+TZVG:1Z62_:[DK9>0-EM?>WW4B*;;$=>T;><7&X7*T,<VA
ME[;>,T=68:6.F1OTPHFB;W8YVWWW*WJX]C?:J1C=2]N[[BN8+&VJ1+;AU(+3
MRT,<BJ00"T*GQ"[0O&<WGT)_+/ZDVYUOLS$C>G8VY)X:JBVL<UAL%NK?=;Y8
MJ?+;UWGN*LA.*VCM3#4JR+%/4(M)!'"M-3(S!R$NW[-[A?>@YPW/F3>+T67+
MUJK![CPY9;:T3+1VMM"AUW%Q(:%D0F1F8RS,`14QW#?/;[[KW*.V\L[%8?O#
MF>Y9"+=7BBN+IJJKW5U*PT6UO$M0A8!%51#"K48A@C_FL=+5?9M7M/&;:W+E
MMC4>WJBII]]XT-69+=N]&^U_A>R=@[%BHOXUN6?*/)+''5M)2PEHS(0*?]\F
M#_=0YYBY7AW>ZW*UAW]KA0]H]%2WMCJUW%W=E_#@\.BEHPLC48+7Q"$Z+V^]
MKR2>:9-JM=KN9N7$A(^K2K2SW+:?!M[2S"&6;Q274.605&NGA`OT$M1_.'V]
M38C=E34])9FDS=+EZ6DV5@YMX8V1,CB%@G.9RN[\I38N:GVY/C*B%56FI5R3
M3^2RN!&S^Q?']S?<Y+S:(5Y]MFL7A9KF5;9ZI)4>%';1M(#.)`35Y#`$TU(.
MI5Z!LOWT+!+/=W?DEX]R6=4M8FND*N@J)GN)4C*Q-&0-,<0F+EM.H:&;HW.W
MOF!O67>G2F$["^.^Z^L]L]]Y>JVUL7,YG=VW,GN://TNWJ[<W^Y_9>,C:IP^
M&J,=CY2D[U+3HNEI88]5EA_<O9[9H]DYUO>7/<NSW;=>7XEFNXX[6>*`PM*L
M-8;J0Z9)%=UJ@0*<A7:E3,6W^\^__OSD2QYD]LKS:]IYAG:"VEDN899UE$33
M`S6T:ZHXR%(U%]2BC,H%0$3\@.Q?C?\`)+=NS.B]K=V-M[O;;.]VW/U%O_:.
M*K-P8/;':>T\=55C8*IW`M%+M+*UE1AY)Q68O[ORM"K!BDBJC'GM]R][E>VN
MT;SS[N?(OU/M_=V/@;A:W$BPRSV%PZKXHBU?4Q*)`ABN/"H&(*ZE)((?<3F7
MVQ]T-ZV/D#:N>&M^?K2_^HV^\M8VEB@OH$9_!:XT&W=FCU"2$2:J"A(8:2S4
M7?'S`VEV_@?C=73?&[N;M&LVA7[SR==A)]_[+_NW@,:U-!#6;]AI,7N3&[?K
M-Q25"G'QJL8J#JTH%T,ZV3D+V<WCD^_]R[<<S[)RI'>I:HDHL[DSS/J)6T+/
M`\RP!?UB2VD4R3J`06ON![U;1SI9^V%S+RQOG-CV3W4CQ?5VXMHEH%-YH25(
MFFK^C14U_P`(!4D6-T5/S+;`9?/[V[)^-WQ[V=B,9/D\[N3"8/=79.<P5#2I
MYJRK^\W?5[5VLGAB!"F2DF!:WI8G3[".V1>RYOK3;=EY7YGYBWB>4)%#)-;V
M44K$T5=-LMQ<=QI73(I`KD9/0MW:7WU^DO=RWWFKE7EOEN"$O+/%%<WL\2C+
MMKN6M[<4&`3&^?(X'5.&_P#)TW<6VNT>SML5.\LGUUMC&MMW<?RB[N4[G[<[
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M-HDAU3W=QQ2$$B+6`W:@4Y<V//%_[8<C>WWMC9V:;O[RR[9#''81T"Q,$!>6
M[=,0VMN#1YFHTNFHRY8"Y\?OB]1=;;@K>W^VMPQ]I_)C>].[;I["R2(M'A8G
M$C/M/K+$3*%VSM+#TLPI8Q$JSS0I>0J',8"GN#[IW/,VW6W)G*FW_NGVPL&'
MT]E&26E(_P")-](/]R+F1AXC%NU&-%!TAB-/;SVGL^5]UN.=>;MR_>WNE?H?
M'O)*4B4Y-M8Q\(+>($(H4:F458@,5Z6_=75_Q>?:^Y=\=Y[`ZG_NUB:.HRVY
MMT;MVU@E,%.I1I)ZG*M1KD)JF>4*D:([33RLL:*SL%)'R1S3[IQ[KM>Q\A<Q
M;Q^\IG$<%O;SRT+'R6/5X8`%2Q("*H+,0`3T><]\I>TTFT[IOWN!RWLYVN%"
M\\]Q!%@5&2^G669J!0"79B%4$L`:LNO>E-N?+K/9)?CUT5M;XP?%R0O19WN;
M^XN(I^WNX:.FF9)\#U^,G#4':6U\DR@5%;&'D*Q\L7)IQE9S#SMN?LY8VLGN
M+S]=\U>ZXH\.V_5R';ML<C$UYX9'U%PG%(F(4:OA``E.(7+?(6V^].Z7:>W'
MM_;\H>TB]DNY+:QIN.YJ#4Q69;4+>W<XDD4$FE#(36$//9=+\=]G[LEZFPV&
MP_7OQ4^,6XMH[C[ZW'3(]?N[O'O"&.?,=<=$XB8M-N;?&7IJM8\KE85DD344
MA80(`WLLY8E]RMZVE.;KZ[GW+W;YKMKB#:8F(2#:]K)$=]NS@`06D;+JM[=V
M"XU2#Q&-.C'F:V]L=EWV7DRQL8=M]H^4[FVGW:507N=WW6C266TQL:S7;H0+
MBXC5F`;2C")`#T)N[\UO]=K[D^>GR-VI4XJ?KS#U(^*GQFR++.=K[BW+/!@=
MI[FWM%':.N[1W;E*^FC6,`_PBF8B.TPN@8V>SY?.Z;7[!>VN[+*FYS*-_P!Z
M7M%Q#!66X@MV-=%A:HCMJ_XE2`%JI\0LY@OM^3:-U^\+[H;3X,FVQ?\`(>V6
M4@BWGG/A6UQ<@?%?7#O&--*VR5"T<#2N>N<KT]\/<=0U/8=;4]K_`#4[IIJ;
M+;_HMGXS^^'<&]-R9:6&L?;F.H*:2:7:W7>VZZ9*6D6JFHL53Q0"0D-P"'F.
MVYP]Z)IEY9A7:/8_8V:.SDN'^GVVT@C#*)Y'8`3WLZ@R2Z$EN'9RM--.A!RM
M<<F^R=G&_,=R^\^^V^)XUVD"_4;E=3R4?Z=%6I@LX&T11AC'`H4.<]5^]-[M
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M*5C:9B0-(KT+N>.4_=CW"WOE+?\`EKVQNMKY*AV][&TLTN8K29;9R-9N54JU
MC'<*%1EB#/X*A:ACE)_+3IOLKJ7HK85!VMO#"["V;N/>VW]C;=Z:Z.V[DL?T
M)U+A*BDFK<WN+?4B,-S]O;RDHZ22.E2N8"OKY&-V9O9O[/<[<M\V<_\`,%SR
MQLLNX;U;[?/<S;ENDR/NM_("$BAMA_N/MUN&(+F'^QA"X`'1+[R\C\S\H\A<
MMV?-F\0;?L]SN,-O;;=M<3Q;3MR!"[RW5")]QN2%(B675XLK$DGR5I[\W5\6
M/CI-7?&7XZUO6/4U)-@\74]\=\4<&-WEV1N;.3?P_&Y?&=?0RTN4R5165.LQ
M-6RPT%'`="11JJH25?;W9O=7W(6#W3]RX]SYM<2.NU[43);6<,8\1XY;PAHT
MTK0-X2M-(V6=CW='8Y_Y@]J_;5YO:7VO?:N5:Q1_O3=55+J\N)#I21;,$,^M
MJZ-<@AB2H"H**2`;Z[$[>[@WAUVN7[=[7[.["W&9,UAJ/;L&=I:'#U[U8BH*
M7J7%8ML92;@RU!+(WGKJ&"GHZ68>,3,(Y']Y$\O<M<H<F;-S*;7DW9]HY=M2
M(Y6F>)GD0)5CN,DOB&-'QX<;LTDB]QC%5'6.',',O.'.>\<KQ7O.6\;QS'=:
MGC5%F55?5QVR.+PQ*ZYK+$D<,;@(DAHS`^79G_#@>Z=\=!]/D;RH,A1[=V_O
MS%;5P&XLE&U#B=EY2@Q])N;Y`=R4:4E%E]SY7*4*RUV/IIOM8_*(TAGDF#''
M_E8?=SVC8O</G%C:RP/=2VKSS1(?$>ZC=C!M.W.6>.!$8B*9T\0Z=3/&J$=9
M"<TQ_>-W3?\`V_Y+7ZQ)8;6&[@MHYI*JEK*B+/N^X+I$D[.JM)$)"BZ@H21W
MJ>;?*_YR8?\`T:MW7NS`=(;#WCWGE*:K[/SVP<=A*VFVOLUOO-R[6&WLFE4Z
M;/\`#02PTM=/`M?7SS!%J6A!D]MCVB]A;O\`K..1=JNM_P"8+/8(V2QANY)5
M:>Y!2&<S)I'U-75Y(HW,,**=4(DHG6W]X_?JS_JK_7K>4V#E^]Y@D#7\EE&C
M"WM:-<6YAD!TVP"LL<A0S3M55E93J#;\N/Y@TO<L><V+U#O/=/5NP,9CZB6A
MW%BX,GANS.W]VKH_A6%VZM.8:W96Q*(ZJJKKJAX:NJC1-":'"2+_`&@^[O'R
M8^V[_P`Z[%:[MOTTJAH7*266W0?Z)+-6JW5V<1QPJ&BC9CJ8L*JU[S?>//.H
MW#ESD[?+S:>7X8F/BQK)'?7\YQ%'&%H]M:"I=Y6822*!10IHQS.L/YC_`%93
M["V#A-RXGN[?&_Z3:NVL9NS([;Z?W-70Y3=<.,HJ7,U%-(?&M2M5D];K*MDE
M4ZP`&"^X5YF^[7S<V_\`,%YMESL5CR\UY.\"S[E`ACMS([1JPR5*QZ05.5I0
MUI7J;N4OO-<JQ<N\N;=NMCO^X<R1V<$=P\.WROXEP(U61@=6=;AB#7N!U>=.
MK%]E[EDWCM7![HEVWN;:$F;H8ZYML[RQ\&*W1AO(S`4>;QU-69""BKE"@M&L
MTFD$7-[@8Y;QMR[1NE]MB[C:W:P2%/&MW,D$E/Q1.50LGH=(K]G63.Q[H^];
M18;K)M=U9//&&,%RBI/%7\,J*SJK>=`QXCI4>RWHUZ][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4O^3SA/^$Z?5A-E8]P;.LH?4%E/R\W
M*2BL!ZM+W'TY`]MRU\*2A\NO?;T=+_A.$YD^"G8KEM1;Y5]H'Z$`7V7U:;+>
MS:>>+VM[;MO[+\SUH!A74037^75_WM1UOKWOW7NO?[?Z^_=>Z][]U[K_UM_2
M+]'_`"$__0[>_=>ZR>_=>Z][]U[K4+_X4KAO]-WQ':UT3J'O`C0UI0_]\>J^
M>2`(^!?\D^TMU\"?:?\`!U[JQ+:*F/X2_P`BQ$T?\SU^(U]+*%L?C3W&SZ3P
M&/\`@/K[4K\*_8.O=7Q>]]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z(3\B/A_NWY,=S;3RN^^T9,;T!LS"T]7C^N=N4
M<U'N3(;UGJ:J',UM?F)6DH(:.KQ!ABAJE1ZRF0S10K%YGF,\^W'O%MGMAR=O
M%IR_RMXGN#?3E7O9F5H4M0JF)4C`UETEU,T9(BDJCR:S&J#'KW+]D]S]U.=]
MEON8^:VC]OK"%62QA5EE>Y+,)7>2N@*\>E5D`:6.C"+PR[.3D;&V%LWK3;..
MV=L+;>+VKMG%(4H<1B*<4]/&6L99Y6):>KJYV&J6>9Y)I6]3LQY]PYOF^[SS
M+N=SO6_[E+=[I,:O)(:L?0#R55X*B@*HPH`ZFS8.7MDY7VNVV7E[;(K3:XAV
MQQB@J>+$Y+,W%G8EF.6)/0>_(C:G<.^.J\YM/H[>V"Z[WOGJC'8V3=N=HJZL
M_A6V:RJ2GW1+A#0:IJ+<HP\DAH*@HPBJ`#Z&TRQG_M]NO*&R<TV&[<\;'/N6
MQ6X9_IXF5?$F5=4`DUX:'Q`OBI4:DJ.X51@[[D[1SGOW*6X;/R'OEOMV^W#)
M&;B56.B!FTSF(H"4F\,MX3Z3I<#X31U8.E/CCM?XW]/UG7/4!AIMPU&.R594
M[VW-3C)93<V^JJBE2GW1N^2G\$^2CBKBA^W1U6*F3Q1D<L5_/'N/NON5SA'S
M-SBI:R$B*MM`=$<%JK`FWM@U0E5KW$'5(=;>@+^2O;;;?;7DN?EKDUU&Z&%R
M;JX'B//=%"%GN=.EG`>G8"*1C2IKDE(Z&_ET4M+N:L[A^6FZH.^.X<Y70Y3*
M4=0LU1L&ER-+.7HYGHJ^FIIMPQ42)&*.DGA@QF/C'BBI6TB0S#S[]X^2;:8.
M3?:#:'Y>Y-AC,:."%O&1A1EUQL1#J)/B2*SSS-21Y@3IZACV]^[/#%ND_.OO
M)NB<P<[W$@DD3N-FLBGM8JX5I](`$2NB0PK^FD-%#=/W<^PNI.M^P,[MWX^=
M%[:WA\KN]\=DVGJYAE1M_K?:N5I7P6?[.WEF(WJX.NMMI'(\<,6-6DKLY7'[
M>G#GR-&6\F;USCS+RW8;A[A<]7=G[0\OR(`!X?BWEQ&1+#8VR$*;RXJ`S-,9
M8[2(>++I&@,LYZV+D;8>:=QV3V\Y&L[[WCY@@<MJ\4PV-LZ^%-?7,BEA8Q:7
M*QB'P9;J5A'%7N*E1ZQ^%'5V-[HZV^.&V<4^^J3II,+VE\I^XLGCY9(LUN2C
MIXY.LND<)(\TU!@L765SMELGCXF>IFH:>+[AW+M>6.:?>SFZZY(YE]RMVN&V
M^3??%L=BV]&`,4+&E]NDO:K2R*H^G@F8!$E=C$J@#J)>4?9+DZ'GCEWVOVF,
M[F-B,=]O^XL!2290?H=J4`Z8T9B9IHAJE>-!XS,2>CQ?(CXA;J^2/>W7NYMV
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M\MIYPV?:]MYQ]M;.Z.V/*+".WNKBRLK>&332)[6#,OAZ`%<31LP)UDDL61;%
M[![MR;O&[[ER5[FWMH=T2(WTMQ;6][>S2QZZR)=3XC\4R%F4PR*I50HTA0IC
M>_OCOM7Y&[(P/7V^\_NZFVSB]T[>W+F:/;^67$G>,6`:1_X#N62"GO/A\C*X
MDE6'PNDR(\;(R*1&OM[[@[M[;;[><Q[#96DF[26DL$;31^(+<RT'C0@M194%
M54MJ!5F5E8$]2A[@^W.T^Y.P[?RWS!?78VJ*[AGD6)PGU(AJ?"F(7,;FC,%T
MD,%92I`H0KY'=0_)#-]_=(]<=!=3[6VUTOTWMU-Q]:[DR8QZ]5[/[$KTR&*.
M^]P;;I)8JO,[BZWI9/-A,4\$R5-=5-5R.3J*S[[:\W^VEA[?<]\Q>X'-5[<\
MZ[U<F&]AC+?77%FA23Z6*9@5C@O3VW,^I2D48A`P`<?/<SDOW-W'W$Y&Y<]O
M^5[2TY'V6W6:RE=4-C;WC:T^KEB&7GLUJUO`5</(_C$U)(/)\>/C-LSX_8S*
MU5+D,MOKLW>,L>0[*[=WA+]_O7?F8-I)JBMJY'E_AN)2H)-/00,((%L/6PUF
M#?</W+WKW"NK.&>"&QY7L5T6.W6XT6MI'Y!%`&N4CXYF&MS7X0=(GCVY]K]D
M]O;>\N(II+[FJ].N]W"<ZKFYD)J=3&I2/5\,2G2`!4LPU=+ZMZ>V=D>X,)W?
M7?QRJWOMO9F7V+@4FSV2?;>)P^>R%)D<Q4T6VC-_"8,UDI*&&.:L$?G>"-8R
M2J@`@@YNWBVY1O\`DF`P+LEU>QW4I$2>,\D*,D:M-3Q/"0.S".ND.2U*D]""
MXY+V6[YSV[GNX\=M]M+*2UA!E?P4CF=7D98:Z!*^E5:2FHJH4U"BC9W/T'UE
M\@,9M;"=I86HW#A-I;NQV\Z'#C)5U%B\AE,9!504]+GJ*EFC@S6(<599Z:<,
MC,JG\$%5R9S[S/[?W>Y[ARK?+;7]W9R6S2:$9TCD*EFB9@3')V@+(M&`)Z2<
M\>W?*GN-:;58<W6#7-A:7:W"Q^(Z1NZ`@+*J,!+'FI1Z@D#YU%NBHJ/&T=+C
ML=24U!04--!1T-#1P14M'1TE-&L--2TM-`D<-/34\**B(BA44```#V$9999Y
M99YY6DGD8LS,2S,S&K,S&I9F))))))))->AE!;P6L$-M:PI';1J%1$`55511
M5510*H``````P.BE;3^#_1&U.Z]P]\#%9C<&\,SN3);QQ>/W+E/XKM?9^Z\V
MVO-;BVOA'IXX*;,UTANE3.:B6E!M`T8M:6]V]\.?MWY$VSV]>]AM]CM[9+9W
M@3PY[FWC_LX+B8'4T2XK&@17XR!^H;V3V$]OMDY^WGW&6SFN=]N[EKA5G?Q(
M+:=Z^)-;Q$465Z_&Q=D``0J.AQ[@ZBV9WEL#,];[]IJ^?;V9>@J&EQ61J,3E
M\=D<374^3Q.6Q.3ICYJ+)8W(4L<L4@#`,O(()!`_*'-N]<C[_9\R;!)&NXPA
MP!(@DC=)$,<D<D;8>-T8JRXP<$&AZ'W.G)FQ\_<NWO+',,<C;=,4:L;F.5'C
M<.DD<BY1T900?VU!Z3_3GQSZ<Z&I:V/K79E#B,IE_&VX-TULE1FMX[EJ$5`U
M5N#=.6EJ\SDI97365:41!R2J+[,.<_<7G+G^:W?FC>Y)K6`$0VZA8K6!2:Z8
M;>,+$@'`$+JI@L>B_DOVTY*]OXIQRQLD<-W-3QKAB9+F8C\4L\A:1R>)&H+7
M(4=+D];]>G=)WP=C;0.\SIONP[;PQW'=%5$;^-&C_B.M8U"AO)J"@"]O9!_6
M#F#]UC8_W]>_N0&OT_CR>`/LBU>'2I)IIXFO'H^/*_+1WC^L']7[+]_?\I/@
M1^/Y#^UTZZT%*UK3`-.EK[*.'#H]ZC5=%1U\0@KJ2FK81+%,(:N"*HB$T$BR
MP2B.9'02PRJ&1K75@".?;D4LL+:X9&1Z$54D&A%"*CR(P1YC!Z:F@@N$$=Q"
MCH"#1@&%0:@T-<@Y!X@Y'35N3;&W-XX>JV]NS`87<^`K_']]A=P8RBS&+J_!
M*D\!J,?D(*BEF:&HB5T+*2KJ&%B`?:C;MQW'9[N'<-HW">TW",DI+"[12+44
M.ET(85!(-#D$@X/23=-IVO?+*;;=YVZ"[VZ2FJ*9%DC:A!%4<%30@$&F"`1G
MKG1[:VYCGQLF/P&$H9,-0OB\/)1XJAI7Q6,D*&3'8UX($:AH9#&NJ&+3&=(N
M.![]-N&X7`N1<7TT@FD#R:G9O$<5H[U)U.*GN:IR<YZM!M>VVIMC;;=!&88_
M#CTQHOAI_`E`-*?T5H/ET]6!^H'M%05!IGI=\O+I*[LV+LO?E-CZ/>VT]N[N
MH\3DH<SC*3<F&Q^:IJ#*TT<L,&1I8,A3U$4-7%%.Z!U`;2Y'T)]FNT[YO6PS
M3W.Q[O=6=Q+$8G:"5XF:-B"48HRDJ2H-#Y@=%&[[!L?,$5M!ONSVU[!#*)46
M>))52100'4.&`8`D`C-">D[2]+]346^Z[L^FZYV=%V%DJ&BQE9O$8#'-GY:'
M'4J4-'3)7O`TL$<%%&L(\>@F)0INH`!C+SES9/L-MRO+S'>MR[%([K;>,_@A
MI&+.=%:'4Q+&M1J)(R>BJ'D3DVWYBN.;H.6;)>9Y8EC:Y$2>,410JJ'I50%`
M7MIVX..A+1$C4*B*B@`!44*H`X``````]AD@,26%2>A4JJ@THH"_+'7+WOJW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ6?*"5
MXO\`A.EUC(/%(3W+M$'QQO*A\GS&W*MT!U.K!F'/X/NDG]G)]G7NCI_\)O\`
M5_LB?8NL*)/]FL[0\@1@Z:O[E]6$$'^K*03_`(^VK;^S/VGKW6P![4=>Z][]
MU[KBS:=/^U,%_P!X)_XCW[KW7+W[KW7_U]_.'_-C\>I_^AV]^Z]UE]^Z]U[W
M[KW6H9_PI7.GN_XBLMA(W4?=\89=#2!6WAU66LCBPN!8&]B>/:6Z^!,^9_P=
M>_P]6*[1!7X3_P`BY23)_P`9R^(^I[^HV^-'<3"2[:3RP%[?BX''M2/A7[!U
M[J][WOKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW1?N]OBQ\?_DTNU$[VZSP_8J[&GS%3M09>LS=(,+4;@@H
MJ;,2TW\'RF-\CUL&.@4^37I\8TZ23?W7NB^G^5?\`64JWQNVNP9M3`[BW\=3
M6MJ8G=MV8#\GGW[KW7A_*P^`2_I^-^VDX`(3<O8"!K`@:PF[E#D`V%[V]^Z]
MUD7^5I\!5"JOQQVR`E]-MR;_`.+D&X/][;W!%P?J/Q[]U[KIOY6GP(8$'X\8
M3E=-QO#LE2!J#&S#>89;LHO;Z^_=>ZQ/_*O^`[C2?CYC%4J5*Q;Z[2A4@@@D
MK#OE%+$'Z_7_`!]^Z]UA'\J?X!@W'Q\H`;A@R]@=L*P8*%#*PWX"K6'U%C[]
MU[KL_P`JGX",=3?'ZB=KW+/V#VRY)`(N2V_22;'\^_=>ZY?\-6?`:Q4?'^B5
M2"-*=A=LHMF`4V";]4"X4?3\\_7W[KW7'_AJGX#\6Z$B4BP5D[+[A1U`_LJZ
M]@AU7^H!`/OW7NNS_*L^!9N#T2Q!*FQ[1[G(&GZ:0>Q++_L+7]^Z]UF'\K3X
M)BVGI*J4*_D54[8[L1%;T_IC7L<(H](X`L??NO=<#_*Q^"6K4.DJU6YN4[<[
MPC+7+,0^CLE=8U.3S?\`W@>_=>Z`+Y&?"#X)=([&HJ_#_'RNWAV5O#-T6Q>G
M^O5[I[S@J-\=@YP2KB\=.X[,U18/&0QRUV4JG!2DQU/*Y(;2"/O;GDC^O&_2
M6M[??1<LV4#W6X7A!*VMG%3Q)!_%*Y(BMXZUDF=%&*D1Q[G\^'D3E^*7;[$7
MO->X3K:;=:5I]3>2U\-6H:B",`RW#CX(48UJ5!`S>G\OOXJ_'S8.T-B1]6UG
M>7S3[RJGH\(&[:[NQT62SH0UF5W!FJFA['I,GB>B^H*>8FGCJYF9:>&*%&^Y
MF9UD':MCV'W+W[<=ZDM9-B]C.7E#N`[N8H2:)%$KL4DW7<6'>8Q36SN0(4"F
M/MUWKF+VUY:V[E]+U>8/?7F&JJQ6./Q)@H\2>0JBM%M>WC,8<DZ51`?$<D&M
MZL_E`?"W8VRL-B-R=?Y_>&]GITKM\[\E[<[LQ.4WKNJI'DR6:R?\([%QXJ52
M9VBHQ,)):>E5$+LVMVBGG/F./FG?KK<+/;ELME0Z+2T1G:*UMUQ'%&'9J&@#
M2%:!Y"S4`(42WR/RW=<J\N6>V[GNK;AOS#Q+R\=(TDNKALO+)X:(#0G1'J!9
M8PH8LVIB(B_RL_@RE]/4&?%R2;]X_($C43<L`>TR`]Q]1S["W0MZY?\`#7'P
M@X_XQ3NKT_3_`(SW\B>+&]Q_QECZWYO]??NO=9!_*]^$J@JG5V[XU9@[+'W_
M`/(V-6<+H#.$[:4.VGCF_OW7NNS_`"O_`(4&Y_T8[R#$:2R_(/Y(*X%@+JZ]
MN!U86X(((_'OW7NL@_EB_"T!@>MM[MK"JWD^0_R2E)"W"W,G;K&X!^OU]^Z]
MUT/Y8?PL!!'6V]QI%E`^0_R3"J#8'2@[="+>W-AS[]U[KH_RP_A:591UOOE-
M8LS1?(KY*PR?6_IDB[?21"3^00??NO==?\-A?"\#3_H][!(U:KGY)_)TMJ_K
MJ/<9;G_7]^Z]UD'\LCX:K?3L3LE`5*Z8_DU\HD0*3<Z43N944W_(`/OW7NO#
M^61\-U_1LCLY.2;I\H/E0C<BQ]2]TAK$?47L??NO=9/^&S?AW^=E]HGTZ;GY
M0_*@DK8+8D]TW-@/]A[]U[J0?Y;/Q&.F^U.V/0%5?^<I_E8`JI^E0!W7:P_I
M_3W[KW7A_+9^)"`"/;/;T7ZKF'Y6_+&%FU&[!VC[N5G!/X)/OW6BH)4YP>N?
M_#;OQ,-K[=[B-@`M_EC\M"5`)8:">\+H03]18^_=;Z\O\M_XI+],-W;^";_+
MKY='41;EK]Y<WMS[]U[KB/Y;_P`5UXCQ_>L2DEG2/Y??+H+(Q!4-(#WB2S*I
ML.>/?NO==C^7!\61RM#WNC?AU^7_`,NM:D6*LK'O$V9"+@_U]^Z]US/\N;XQ
MD>H?(%FL07/S$^76MM7ZBQ'=XN6_/OW7NLH_EX?&]`JPU?R)@56=BL/S%^6R
MJYD`#ZP>ZVU7`'^M^/?NO==O_+R^.K+:/)_(^G8$E):?YC_+2.6,DW;0_P#I
MH.G5]#_A[]U[K%_PW?\`'O4S?W@^3ERMO^RS?EI9>`-2#_3-96X^OOW7NNO^
M&\NA>0-W?*A8C8>`?-'Y8>$`"Q`4]PEO5]2;W)]^Z]UW_P`-Y]$@JR[S^5:.
MO]M/FC\K@Q%K:6)[?(86`^O]/?NO=9E^`'3:D%>QOEN-(LG_`#FC\I2$%K`*
M#VN?H/ZW]^Z]UB?^7]U,_'^EGYD*``JA/FM\GTTJ&U!01VA>W%N;FWOW7NL;
M?R_.JB5T=Q_-"$`,-,7S9^3JJQ;Z,P/9C$E/Q_3W[KW7F_E^]8%M2]U?-9/2
MJZ4^;/R9"\']5CV2?4WY/Y]^Z]UR'P%V$M[?('YR6)#6/S8^1A`L"`!??I(`
M7C_8>_=>Z-+U;UOCNI]EX[9&*W-V'N^BQM3DZF/.]I;^W1V;O.I;*9&IR4D6
M1WAO'(Y7/Y"FI)*HQ4L<L[+34R)%&%1%`]U[H0_?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:E7R>*C_A
M.CU64TJB]R;-!/+`@?,+<JLW)U79N3^1?_#W27^SDKZ=>J!DG`Z.G_PF]96^
M"78I6UA\K.T5U*F@-IV7U;;T_@@'G^OMJV_LS]IZ]@Y'#K8"]J.O=>]^Z]UP
M<@:?45NX`X)U'GT\?U]^Z]US]^Z]U__0W\X?\V/^#/\`BW]MK?6_OW7NLOOW
M7NO>_=>ZU#?^%*PD/=GQ,`4M$W3_`'<&O9H]:[SZJ:-3&1]2?JUQ8"WTO[2W
M?P)]I_P=>ZL2VDID^$_\BUB`-/>GQ'<B,"1!;XT=Q@"X(L`2!<7L?\/:E?A7
M[!U[J^#WOKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4YK\AJ;??RA[&WWMK`3=Q]I;!R^
M<Z#^+_2V%JR*?;<=&(HNUN]^RLK-!_#=A[=SN<0XV'(SG[M\90/3P12-.2,P
MG]NY]A]K>6>7]VW!-EY4W**+=M\W.5>Z<M4V&TV40.N[GAB_7,"_IB:99)70
M(!UA6GN5!O\`[K<S[YM>W'>^<-ON)=IV/;8F.F!4`^NW6^D(\.UBFEK$DS5E
M,,311JQ>H/ET)T'7]?Y'</:7:.X8.P_D#V'3TL6]MZQP2P87!8BF<SX[KOKC
M&U):3;VP<%(UTCXGR%0#551:5E6.">?N?K?F*VVWE7E;;6VWV[VUF-K:DAI9
M)&%'O+UUQ->2C!8=D,=(80$!+9">W_M]<<N7&Y<U<U;DNY>XFY*HNKH`B..-
M22EG9HU3#:1$DJOQRO666K$!04^5'R_WKT+W1U7U3C-K]?X+$]GX*2HVCV9W
M7N7.;*ZQ[$[.3<,>/@^.6WM_XK$97;VQNX<_M]7R&#3<+0T^X)G2BH$GFCJF
MIXSZE#ILPGS`W[E/DIV?TG6GI+"4'6G=M'U\F.R5?V6N]MV;"?H[:W>.8WEC
M*JFVO5;.Q>8P&!W#5Q_85%2T56<+4,)H6GIT/NO=/G4OR,^1O<?4VS/D9@>K
M>L\#TYVEL[-=A[.PFX=VY\]E[8Z^JMDYW=/6.[]Y)C,75;=RE3OIZ+&-78?'
M.E1@Z?,`?<5TE'-Y/=>Z+KU%_,E[0[*Z,[T[0@ZFV%GJ[J/X@;;^47\?V/O#
M/9#J[%[[S/7^4[!S/Q1W[F\C@:;+X3N3:.$QM-6UDE+#5(N+S=#55%)2&2&*
MJ]U[H4W^7_=M?\?NU^\MD8WXZ]A474&U\MO_`'3'A]T]GXBFIL'MSINJ[0RF
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M.:Z`J9)!NO%TT60DIZ:HQ-6CF/-4T<?NO="[V=W_`+RHN]ME?%WJ7!;3RO;F
MXNH]T=X[ES^^:S-4.Q=F;`VSN?;FR*1C286FFS6XL_N_=^X?MZ.EBEIXZ6DH
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MPG^VB]U[I84WRQW)O3NCN?X]];["P*[_`-D;1VQNKK#<.]=W3T>R>SJ:FWH=
M@=ZNO\!P64S.(7H+=$])19"(H\F3K*Z&.G,:%IE]U[H`<?\`.[O,?&>3Y09[
MJSIO%;(K>RL%UEBH5[(WO+48_(S_`"FD^,&XLWN0GKK53X+'.Z;GIWIDGFEH
MX)J&2..<Q5#^Z]T?3H3L?,=K;!_OCEINOLA#/N3<V*PV<ZRW#F-Q[4S^*P.7
MJ,/_`!"&;/X';V5QF3ILG15-%6T<D4J0U5(YBGFB='/NO=#3[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K4K^4"ZO^$YW65G4Z>XMH^O3J#`?,3<BFRK
MJ.L@_0?GZ_GW27,<GV=:*A@5/`]'0_X3=JR?!/L96.JWRJ[-Y!8J3_<CJN]@
MPXM]#_K>VK;^S_,]4C4HI4FN<?9UL">U'3G7O?NO=8I3;Q?7F91P2/J&^MOJ
M/\/?NO=9??NO=?_1W](OT?\`(3_]#M_O?OW7NLGOW7NO>_=>ZU$O^%*/I[M^
M)3(JM(>HN[0=1^J?WRZL`5%/IU,6/)X''M+=_`GVG_!U[JQ3:*Z_A5_(RU60
MKWC\2F"N"I)7XT=Q<64D!]-S_0GVI7X5^P=>ZO9][Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW2;P.S=H[6J,O6;:VOM[;]7N"NERF>JL)A<=BZG-9*=VDFK\K/0TT$N0
MK)9'9FDE+N22;\GV87N[;MN<=I%N>Z7%S';H$B$LCR"-!P2,,2$4`"BK0"G#
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M`[=PNW]Y?%K'_$3LF&BSVVO^,E=;[?VI/L'9^\=UTTVTI,:W=FT-B54N'I=T
MTD%+4U-`ZPUT57'2T"T?NO="[7_&6+/]8=H=4[N[?[4W3@>S^K)>F9ZJMFV3
MCZW:FQ:K`Y7;>2.V(,-LW'8D[JRN-S,QGRN1ILA4-*D.D+'$(C[K1R".FS(_
M#GJ[<N,?![\DK>Q<'%T!C_COB,1O7$;/S-%M[:L&.KL7F]PX-&VW$V/W=O*D
MJH4RU0A%/4KCZ14@C6``^Z\!0`5KT%V1_ET=6[@Q]'1;K[/[SW)68GX^=8?'
MO`[IJMYXG&[YV_3=*[KJ=]=4]QX?>.!VSB<S1]][-WA5&OCW`KB&IF7344<L
M;S)+[K?1AZWH6ES':W2W<FX-^[PS&\.D]C;\V-BD:#:E!AMU0]FQ[2&\\YNO
M'8[;=,3F:V;8N+EIACI,?24C1S!82DQ5?=>ZX]G=`8G?O8.R^X=O;LW)UGV_
ML/;NY]E8??6U8L+6ME-B;SJ\+D-P[*W=M_<6,RV$W/@'RVWJ+(T2S1+/CLE3
M+-3RHLE3%4>Z]TA]A?#KK[K7=_4NZ]K;FWPHZFVKW1MN/%9G(XO.Q;_R/R(W
M?@>P>Y-\=D9;)8>7/[BWMO/?.UJ')R5,=52TT,PG2.G$4VB/W7NA)[GZ;JNW
M*7%P4G8V[-C+0X[=6!RV)QF/VCN?9>]]M[UQM/B-P8'?^Q-\[=W'MK=="*"`
MFD$\0%/,[%A+#)-!+[KW0<8GX>=?;:S'Q5R&TMP[RV]C/A[UYN7K3JG;L=;C
M,KCJK`[FV-ANOYIMVU>:Q60S&8K\9@]OTK4KQ5-*JSJYD61'\8]U[IIV_P#"
MG8&U]R?'W?6!W-N7%=A=#?W\6KWSC<?M#'Y[NBG[-Q;4>^J3N::CVW"-T4NX
M<R(,[,L'V;#/T5-5J1XO&WNM$5(-3CINI/A%MO'?''!?&S&]H=@TFW-N=O4/
M<V,W8:39$^[4W+B^\#\BL=CY3)M7^[[8.G[15)#&M"DTF+3[,R^II3[KRC2*
M5)Z,WUWLS-[,QN5AW'O_`')V-F<UG*S-569W#2;?Q45!'41P4]-A<#@]KXG#
M8C$X:BAI@UO'+4U%5+-//-))*2/=;Z$'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW6IC\G;O_P`)UNL6*HNCN7:990``OC^8FYDL`"/5?@V_Q]TD_LY/
MLZJY(5BHJP'1S_\`A."H3X+=D*ND)_LU?9Q`!:X9MD]5EP48MX_5]!_3G\^V
MK;^S_/K8KI4GC3J__P!J.M]>]^Z]UAF_W5]?\\GTO_C];?C_`'CW[KW6;W[K
MW7__TM_2+]`_X,_XM_;;\>_=>ZR>_=>Z][]U[K46_P"%*!MW7\2+N`K]3]UK
M:Q8AAO'JQ@X`'^%OJ/:6[^!/M/\`@Z]U8EM-7_V2S^1HH1F8=Y?$LD`<A5^-
M'<;&0C^BH-1_P_K[4K\*_8.O=7K^]]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNE8,+J;BY%
M_P#$$@_[8CW[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM3/Y,B(?\)U>M@P]([EVP(QI=27_V<G<V
M@:;DJQ/];B_NDG]G)]G7N'1S_P#A.*KK\&NR2XTEOE1V4;`6!/\`<?JP$DV&
MI^+$_P"'MJV_L_SZ]U?[[4=>Z][]U[K@X8Z=)M9P6Y(](O<<?4GW[KW7/W[K
MW7__T]_6/]/Y^K?6_P#JF_K[]U[KG[]U[KWOW7NM1G_A28%_TW?$DZ0Y/4?=
MP*E'867=_5TB$A>#ZE(_V/M+=_`GVG_!U[JQ/:R>+X8?R-4E32P[Q^)ED5[@
M,WQD[D(Y2X8!3>WT'^PM[4K\*_8/\'7NKT_>^O=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7CP">3;\#Z_[#_'W[KW70-P#8BXO8_4?X'_`!]^Z]UW[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU//DNL;?\`"=WK
M@?K5>Y=M-9?KJ3YC;GU``ZKNC`W!_(]TE_LY/LZ]T<C_`(3D*5^#W909T<CY
M3=D<QBRV_N/U=8`?7@?UY]M6W]F?M/7NK^_:CKW7O?NO=8Y&T^/_`&J15^MO
MK?\`V_\`K>_=>ZR>_=>Z_]3?TB(*7!)&I_J2?H[#ZMS[]U[K)[]U[KWOW7NJ
M-/YMW\LOO;YZ=@=&[MZ?WCU-MK']:[+["VSN"F['K]W4-;656[,YLW*XVHQ(
MVWMG<%/+24\.W9UG$S0N&D32&&K2GN(VD50H\^O=!EV-U_\`-_HKK/\`EJ=*
M;HV7\5<O3]._)'H_8G6.9P7;O;DE1O7>^S^D.W,'B)]]4F2Z4IH]H;<RF&IJ
MZLJJB@FRU13UD<,45-+#(SQ/C``^77NK+?[S_P`RV[#_`$,?"/A;JW^S&=XD
M.Q'TM_LLH*`'B_-_>^O=>_O-_,N)/_&&/A&@L"-7R,[Q<B[6*G3\95Y"\W_/
MOW7NNQNC^96JE6Z5^$SR$E@Z?(_N](PH)M&R/\9&<N1_:!M_A[]U[KB=S_S+
MVU%.E_A$GT*B3Y'=Y.2/[2DI\8P`W]#]/?NO=<O[S?S+#<?Z&/A(+W"G_9C.
M\&"V^A8?[+,I.K^@^G]??NO=='='\RQ;C_0I\)I+:N5^1_=Z:B?TD*WQC;2!
M^;F_]/?NO==G<7\RE?7'TY\)M3V:6.7Y&]ZOZ@H7]H_[+0T<2@#Z`6/U^OOW
M7NNEW%_,P>]^H?@[#]+%OD+WO*"+<WT?&A2"#[]U[KH;E_F7@6;ISX0.P+79
M/D3WHJ,!^DJ'^,Y8:_\`'Z?X^_=>Z[;<O\R_EEZ:^$)'`$;?(SO,,";>LN/C
M(5*KS<6!/]??NO=<1N7^9@Y!'3?P?A!O<2?(KO65DL#8DQ_&95:[6^EO?NO=
M>.Y/YF/U'3WP=L+"Q^1'>VIB.&86^,^E58\@<D#Z\^_=>ZYG<W\RV/D],_".
MHNP`6+Y&=XP$*"=3$R_&60$L`-(`X)Y]^Z]UV-T_S*=5VZ3^%)2ZDA?DAW8'
M*G]2@GXQE=:_@_0_X>_=>ZS_`-[?YCI)MT7\.%!+6O\`)?N(E5%M(:WQA`9B
M?K;@?X^_=>Z]_>_^8VH]70_P[E+%M.CY-=OQB(*!82Z_C`QD+DG]/TM[]U7N
MU4IV4_GUR_OA_,8X/^@3X?6MRO\`LSG;A:Y`X#?[*^%X-_?NK=<?[[?S%[`_
M[+M\1[V-U_V:?M3@CZ"_^RM?VO\`>/?NO==/OG^8L@]/QQ^)<S6!]/RJ[/B4
MDGE?7\66(('Y^A]^Z]UU_?[^8J"2?C-\4V52"0/EGV.KRK^5CO\`%<JCB_!;
M@V]^Z]UQ;L#^8J0?'\8?BL#?TB3Y:]B?IXX8I\5SZO\`6X]^Z]UR_P!(/\Q%
M/U?&#XM3FQYB^6O8,2W_`+(_=^+!/YY_UN/?NO==?Z0_YB2MJ;XN_%N2/3^B
M/Y<;_2;R,!8@R?%?Q&.-OU<@D?07]^ZJNH@:A1NLC=C?S"P`5^*WQF8@V9?]
MF[WNNK_:D;_962`/]<`^_=>;4%.D5;HS/5.7[4SFSJ:O[EV1M'KW?+9#*PU>
MVMC[\R'9&WH<;!72Q8>M@W3D]E[`K)ZG(X]4FF@;&QBFD8QB24+Y&]U;H2/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1>N]
MNP?D)L:3:J]%?'7$=])E/XQ_>F3*=UX'J#^ZGV8QQPYA3-;3W.=PC,M45`;Q
M>'[7[8:M?D&GW7N@!'R`^?P#:_Y>.V2P4E1%\S>OW#M<64&7K.`BXOR1[]U[
MK+'W_P#/<\R_R]-OH/5<1_,?KN1[`>C2&Z[B0EC_`%86_P`??NO==_[,!\\^
M?^Q>F&XM;_G,/K7GGG_F!3]!_O/^W]^Z]UA_V8;YZ"0H?Y=5"4`)$R?,+JDH
MUC8`*^THY02.>5M_C[]UI22`6%#UYOD/\\U4L/Y=-*YN`$3Y@=2ZC<FY]>UT
M0`?Z]_?NM]='Y%?.\`_]BY&)%K6^7G35B22&N3A@0%'/TY]^Z]UR'R-^='&K
M^7'7_D-H^6G1["_]4UT\9:,_U.EO\/?NO==GY'?.1>6_EPYAQQQ!\L.AW;ZD
M&XG>F7Z<_4^_=>ZY'Y'_`#@O8?RX,_8_D_*SH$`?3ZC[PG^OTO[]U[KK_9D_
MFY<`_P`MS==B5]0^4_QU(`_M$WSBGC\6!O\`X>_=>ZYK\E/FM>TG\MS>@'%F
MB^4'QND%KB^L2;H@8&WTL&O_`(>_=>ZZ7Y*_-4VU?RVM\J+"_P#SD_\`&HM>
MY!`'][@#QR.>?S;W[KW6?_9E/F5R?^&W^P@!>P/R5^,FH\\<#?94`C_'W[KW
M7?\`LROS'!L_\M[LHBUPT/R1^+KK_K?N]BP-?_86]^Z]UT?DQ\Q0?^W;/:9`
M"DE?D=\5+FX]2H&[00%A_B5!_K[]U[K,OR7^7AO?^6[VXI_L_P#.0WQ.*D6-
M[D=N:@;@?@_7W[KW62+Y+?+=A^[_`"X>WXSQPGR"^)LHY_J3W!'R/S[]U[K*
M/DK\L+G5_+E[D`L.5[[^)3$DDW`![H4<`?U_/OW7NN?^S,?*;\_RY^\0H*@D
M=W_$=C=B%]*CO(EE7DD\<#B_OW7NL3_)[Y0QG2W\N3OQV!Y\'<WQ%E33^&5V
M[YCU&Y^EA[]U[KE_LT/R9747_ES?(30ND7C[<^(\DC%O]3'_`*?%NJGZDD<?
M2_OW7NNT^4OR/;2?^&ZOD>JEK7?L_P")(94_#LH^01//]!<^_=>ZR'Y3?()5
M&O\`EX?)C66*Z8^P/B;(``"2Q<?(8#38<?DD^_=>ZX?[-=WRK)K_`)=_RGT.
M=.J/>7Q.E9.?J\?^S&K9;?0W/OW7NJ()MI_([Y4?R@>O?BWTW\3^W-R9";>\
M6ZL9VC4[JZ-PW7.6IMK_`"3W+O;-4U*,CVO3[T6JIXH)Z#3-B*=6K8F(<PZ9
M7JX+(X'$CKW5H?\`).^-?=OQ:^*.]^ON^MAUG7>\,M\@=];PQ^!KLOMS-33[
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M$"4)8%NY)&6RDD6/^E&_K/)7D$_X>TVF[_C_`)CILF334(-5>%?+U^WKL]2_
MSTZK4'_X<2`N'`?N;P-<<V#CM(`6YXM8WM[]IN_X_P"8ZL2X`*J"W\NN)ZI_
MGK0'Q!OYBBQ>5681=Q>?R*`/W"3V?(59>/3<`D<CW[3=_P`?\QUH&6@)0:J^
MOEZ_['6.3J?^>F-3HO\`,6=B-1([C*`,>-8![0U"1+$V4?FWOVFZ_B_F.O,9
M`>Q`1\S3K@W6'\]>;C1_,790`I\G;KQNP4Z2=7^DY"/2+?0EKW/OVFZ_C_F.
MMJ7()=0&\A7K@.K?Y[,:HBC^8R(T64NJ=P,"Y8JRQHQ[/=BH7BY-SR/?M-UY
M/_,=5+2T6D8)IG/`]=#J/^>O)(U0\?\`,24(2X([GD\P6P](C/:8$QLW-@;_
M`(^GOVFZ_C_F.KBI`+"C>?66/IK^>G-I:2/^89*48.3+W>]/R+:0L0[535&5
M/J4W/'OVF[_C_F.JDR=U%%:XSQ'S].O'IK^>C&QB7_AP\*W%H^ZY'4MJ>]YO
M]*A$:!>!8VY^GOVF[_C_`)CK0:4D!HU"_;UT>G/YZZ(LP/\`,.\K*86`[K9C
MI9;'T_Z4VM8"VNU[^_:;O^/^8ZN2U5HO;Y]<3T__`#UY@S11_P`PYF+1(L=1
MW8]-HB].M?(>U/H!?D`_Z_OVFZ_B_F.M]</]#O\`/5+W(_F),O$:G_33*'6-
M?HO/:H`4$?JY-OR??M-W_%_,?YNFV:4'LC!7YFG68=2_SUJ4)+&?YBM[R,&B
M[F:64WL0IB?M"7QG4/R+$<>_:;NGQ?S'7@TQ(#1*%]:]#]\6,3_."ZK^1G37
M8O>6V?YB>]>F]G[LK,SV1LY][4^^DW+@)MI;FQ<&/EVC7=GBGSP&X\A03-3L
M;HL1F4%H@ILJW.I=3=M<Y'5U+$=RT-?Y=;"3?/BN`!'P:_F!-<,1IZ%V\#Z?
MP0W9:D$_@'Z^U/6^N:_/:K-M7P@^?\=PQ`;H+"M^D7(/B[%D"D_07M?\>_=>
MZX_[/S5$*?\`9'_Y@-B0/^9`8<%;FUV4]B:["USQ]/?NO=9S\\Y%*`_"OY]>
MLL#;X]TK".VKERF^&%FT\6O]1[]U[KK_`&?8A@K_``M^?:$GZ_[+H)5`M?46
M@WE*H'XM>]_Q[]U[KC_L_*BY/PN^?H"GD_[+A(WIYNX5=W-(P']`"W]![]U[
MKB/GW&02/A?\_P#_``!^-E2I(O:X#;K%K_XV/OW7NO'Y^0!2S?#+Y_@@7T#X
MSY!V/%[#Q[E=+_['W[KW7%OG_3KI)^&/\P&Q'J*_&3)OXS>P#+'N1G8G_:0P
M'Y(]^Z]UTW\P&E4*?]DS_F!,&_U/Q?S)*\$V8'/@\6_V_OW7NLB_/^@8*3\.
M_G\A)LP;XM[DO'P#=BN696'-O26Y]^Z]US_V?S'`D-\0/GVMA<'_`&5G=+!C
MJTZ1X\D]B!SS86_/X]^Z]US3Y\XUSI'Q$^?"F[`:_BSNQ`=()OK:O"`&UA<@
MD^_=>ZZ/S\Q(%_\`91_GR1Q]/BEO8FY_%ON+BWY/T_Q]^Z]UU_L_^$%M?Q*^
M?2$W]/\`LI?8,EK6^K0^5!]?Z^_=>Z]_L_\`@_4!\3/GT=/U_P"<2>PQ?B]U
M)4!O]A<W]^Z]UW_L_P#@--_]E0^?/]GT_P"RB]EAO4;?0TXO;ZG^@]^Z]UD7
MY^;=+,C?%;YZQE0I!;XA=I,K:K?I>*AD2ZD\@D'_`&'OW7NN7^S][;#JI^+7
MSSLQ(\G^R@]KE%L0"6TXTN!S_0W`X]^Z]UFD^>VV49U'QA^=L@1M.N/X@]N%
M6^O*:L0K,IM];?GW[KW7-?GIM@IK/QE^=2,`"8F^(/;Y<7/TO'A7B8C\@,;>
M_=>Z\OSTVN2;_&7YU*`+DM\0.W[?3\`84L3S^![]U[KH?/;:I%_]EG^=8LRJ
MP/P[[FN-1M?_`(L'K4?DK>WOW7NN1^>NT1JO\;?G2&5RA4?#?N]KV%]2NFV6
MB9#]+AOK[]U[K(OSRV@S(&^./SEC$FL!F^&_>3*I0Z1K$>UI&37^"1:W]./?
MNO=<3\]=F\V^.?SG-N./ACWT+FP-AJVB/K?Z_3_'W[KW64?/+9!56'Q\^<-V
M5FT?[)=\A-:%?JCC^Y%@_P#A?GW[JJL&%1Z]<D^>&Q6%WZ"^;L"WMJF^%WR'
M`OZ;CT;$<_VOK]#8V/'OW5NN8^=VPBAD_P!!'S855%V#?"_Y%AU!OI.C^X.M
MM6GBP/\`O(]^Z]UP7YZ];LJM_H4^:`NJMI;X6_)-657%U+*>N@5/]1]0?K[]
MU[KDWSTZTC"F?IKYF4S.K.L<OPO^2AD9%_M:8NN)=-SP`;,?Z>_=>ZX?[/UU
M8-)?J+YD1HZ:U=_A9\F]-K7867K-G#(O)%KV]^Z]UQ?^8!T^GUZQ^7K#3JU)
M\+?E$ZWO8K=>JSZUO<C^GOW7NLJ?/WIHQEWZ^^64##GPS?#+Y2+/;BS",=4-
M<,#<<^_=>Z[_`-G^Z5`8R;$^5L2I;49/AG\I@!<7'Z>IF)X_H#[]UH,"6`\C
M3KP^?_1Y-O[F_*7Z7N?AO\I@`!];D]26'^]^_=;ZX-_,$Z%U>([<^3<<@*$J
MWPX^50N";\,>GS&00.3?B_\`7W[KW7$?S">@>"^W?DW$EB3))\-_E:$4BX9&
M(Z=8AUL;BWOW7NN?_#A?QRLW^2?(:ZFS)_LG_P`L=0)74!;_`$+\FW]+^_=>
MZY_\.%?&H*6>3OF/2H+J_P`1?ED&C8V!C=1TH;2*2+@7M?W[KW6)_P"8G\7H
M>9\AWC`O%GE^(WRVTDFWI!3I!_58^_=>ZXG^8M\6UO?)]WC2VDG_`&4?Y;D:
MKVL".CS?_7''OW7NL9_F/?$\,JMN'N%&8$A7^*'RR0\*6.H/T@"IL/H;'W[K
MW51?\S+^8+\DLINGII_Y>N[>_8]LQ[>WXG:RX#XI]CR?[GILAL]MCM4-VGT=
M-4AVH%RH04=H@`QF]7C]L3LRJI0YKUH@G31B*']ORZK#D^>G\Y]'CMO3Y0&]
MT_[))H;.=-R0O^@HWT*+ZN"1^/:7Q):?&?\`5^75NO#^8)_.5-Y7WU\DT0$$
M?\XAT8'BL0"R_P"@JU[CEAQ_O7OWBS?Q'_5^7568+2OF>LB_S$_YRU,QCEWO
M\@6#%G$L_P`/J&^@*8U$8_T'!26=?S]#_K^_>+-_$?\`5^76M6FNL4S0>?\`
MQ77%?YCW\Y!`5.^.^C)^N[_#VCLMK*H=#T=95/YN;$_GW[Q9?XC_`*ORZJ\@
M1PK`Z2.(SUR'\RC^<:1&$WOWFPXU@_#G'>2U].HLW20]+.WXX%O?O%FSW']G
M^QUM6%$%225K6GIZ^A^77$_S,OYQD!CB???<RF87O-\-\<TI=F9!XP>E0OC&
MGZ?T-[^[+-(K5-2/3_4.M&5`JDUH>&#UEB_F>?SAUC\K;W[>?0LFMW^&F.$0
M\9"261NFE#E6(MS[V)Y!IP33^?V_9UY9`QI3!^'YCSKZ=>/\T_\`G`E5\&]^
MSCI#@^3X78]GTN05<C_1`JM:W^!`_%_=3-+114@CS]>K.Q6BJ*N>'^R?+KQ_
MFK?S?H&\+;\[!:6-M++/\*Z%&8DBP=UZG0`D.""%X`_/OWC3?Q']G^QU3QX_
MZ7[#UP/\US^;ZCC7OO?RJHU.7^%E`D86Y7UD]5JP76/J#].?\/=OJ)-6JG;Z
M?[-*];6:-B%%:GY'KE_PZ]_-[&H_W\WJ_J!2WPOHA=68<LHZR9@JC])^K#_'
MW9KER"`E#ZYZV[K&`6)SZ"O6%_YM?\W.)GCD["W(@LJQM)\,:=)2[&XNC;!5
M5D`/((M;W59Y5)U"OY4_P#K32HATL37[#UPB_F[?S;ED1I.P,N8V<0L)OAK&
M%&DW,L>C9U.[._TTZC8&_P#3W9KE])I'0_GTTMP"6U*0/+!->K6L;WE\@_C-
M_(8^/':_13Y/:W<\O^CB6M>NZJKMW9"C/97=]94;]>3KC)XPUE&*R//5;(LE
M,HH(Y`R@*@/M26(CU<2%KTI&:4Z/)_)Y^2WR$^5'QAWCV'\E,N,WOW#]Z;UV
M5CJQ>MCU:!M7#[:V/D,;`=NM!3&I>+(9FKO6:1Y;Z/\`=?O43F1=16AKU56#
M5T^1IU:Y[<ZMU[W[KW6"<D>&Q(O/&#8VXYN/\0??NO=9_?NO=?_6W](B2@+?
M74_YU?1V`Y_UO]M[]U[K)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K!/?]FW_*Q'?Z
M?3F_U_P]^Z]UG]^Z]U__U]_6.VGCZ:G_`.AVOS^>??NO=<_?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
C]U[W[KW7O?NO=89B!XKFUYXP/\2;V'^N??NO=9O?NO=?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g912919g15i50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919g15i50.jpg
M_]C_X1O=17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP-#HR,B`P,#HQ-3HR.````Z`!
M``,````!__\``*`"``0````!````F*`#``0````!````<``````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``!JG`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`<`"8`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))<O_C!NLJZ7
M@BO)LP_6ZCC5/MJM=2=CW.;:'W5EKVU[/<DIZA)></ZIDY+\G"/6LC'Z=A-R
M[NF]2WAHR74MIV5/S?\`M95T^ZR[U6;?US_2W^E8K%77OK#DTU^K?;A_;KJ@
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MX9)3J_5=W4'=(8<[U9]2P8YR=,@X^]WV1V8(;^L^ALW_`.$_TWZ;U%K+G\KZ
MQY5743@TU56G*^ROZ6\./Z6NXN;FVO$?]H:ZOM'Z/_!V4K.QOKWD7XUV6W%J
M-.'C_:LMK;';VM;=;1D4L#JFM?=315ZWTO3];]6_X5)3V*2Y-GUWR++KL>OI
MVZUV0W&P6>L&NM<\O>QU]3ZVV8K/L5?[0]3;;3]G]/\`2>JB5?7B@=0;T_*Q
M_1L+\C'-N^:QD8WN-3O8-M.13^DQ[OS_`.9]%)3U"2H]$ZA;U3I&'U&VG[,[
M+J;=Z.[?M#QO9^DVLW>P[OH*\DI22222E))))*?_T-Z[ZP_6/*Z[UVO!NIQZ
M?J^QA;A6L#_M.YKK+'V7>V^CVL_0OJ_1,W_I?40+/KKU_&Z93U*UN+;^U<2[
M+PJ&-=MH-!K=Z.19ZV_);;1;^DN:RG9D_H_SUUN?]7>A]1R696;@TWY%9!%K
MFC<=NK&V.;'K5MC^:MWUH)^J?U;C)'[/I`S`!D`-@.#7>OL@?0K]9OJOKK]E
MEG\XDII]3^L'5J,ZW`PL:BRW`PVYV=9<]S6N:2]OH8;&!UF]_HV_I[/T=7YZ
MK8GUVKZAU_'Z/^SS9C9=#<MF5,BNJRH9%7VFE];6U^Q^RS9=9L6M?]5>A7G=
M9C2YSK'6$66`V"YPMR*LB'_K&/;8QCG8UV^C_@T+*^I_1<FJQD74NMM=<^VJ
MU[;"7U_9;*FV%SO3QG8S64_9JME/IU5?Z-)30_YW=/S.G&W%P6Y36Y]?3Z*'
MN:UKQ8YHQ,QDL?LQ[?;;5^C2L^MV.RO(95TPV78;;K^L8[7UCT&5N=5;8YWT
M<JW(K99=17_AZ/I^FKV3]3^D7.#JO5Q"UN.U@QG^FUOV0O?AEK(+/T3K7*)^
MI?1Q2*JG9%)<RRO)MKM(MR&W.%M_VV]VZV]]C_\`"[O49ZEGI>FDI:_J_2*>
MHXN)5@&]V?77ETWUUUAK@WVU6-WEEEMF+7Z;W^FW?C4/J56CZS=$ZE77;7T_
M[3?U'T&UU@46&UP#\IM5MK;'UUOZ>RM]]K,I]?H_X'](M/)^K>#D9%%KK+F5
MXOI.Q\=CP*JW4"QE%E+"USJ7[;OTGI/9Z^ROU_48JE7U/IH]!V/F75V87I_8
MW[:_::V.Q[++]E=?VJS*JL>S(]3\S^9]%)2*SK?U;LMOQ\W`LI=FNQVYC;Z/
MI/M=9C8#,EK/4?9ZCL/94[:^O^;4*NK?56ME.8S#M%;Z[,C[0*'.:W[6_P!.
MW[0]N_\`6<RUK*]K_P!-_P!85B[ZI-MSJNJ/S'OZGCLI91F/KK+F^FZU]^YC
M&UM?]KKR;:+&>S95_P`+^D58?4=U71\OI./F,IJR:F,;8W&8'A[+#D?:+[`_
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M?J&)8RX66A[K(O-EW47M>TWOS*<QW\\_^9]/^;_1J\_ZLY[OJSTK`+J!U+HU
MM&35LW"BRS&)AKW;?4;]IK+O5M]/^>L]54J/J?U.[K(ZAE6-PJ[WWY&0S"M>
MQ];[/0;7BUW;/T]5GV;U\[^8KNOL_F?](E/259G2.E8S,&S-IK&#2QC_`%K6
M-<UC6AC'W26;-S46KJW2KFO?3F46MJ>*["RQCMKW:,J=L<=MC_S&+E<OZJ&[
MZW7]5LZ3790YKS;<ZRNYEP]+;3Z6'>S=CY]60QC6V_S'H^JL8_5'K=G0>D].
MJP_V9DX3'9V;D5-I=ZE]'J-Z;0[[.YC\K*V_3]3V,_TOJ)*>^MRNB6Y%=UN3
M0;L-S]A]5H+'$&FW<T/_`'7;/TBM59>)<_TZKJ['EOJ!K'!QV$[?4AI^AN_.
M7GG4/JU]NS<_-NZ$:!D]'<Z^MM3+?3S[;/48_#L&RR_+979:^_TF?X/T_46C
M_BYZ6_#MR[;\&S$R#1C4N>ZAV/6?3:YKV,98]_J7.</6RK:?T-EK_P!])3W"
M2222G__1]522224I))))2DDDDE*22224I)),'-/!!24NDAMOH?8:F6,=8!)8
M'`N`XG:B)*4D@Y.7BXE1NRK645`@&RQP:T$Z-E[_`&I\7*QLRAF3B6LOHL$U
MVUN#FN$Q[7M]KDE)4DDDE*22224I))))3__2]57'YS>JX'6Z,V_J+_M65D6^
MGTYEA.&,&JM\Y-F-::GLOJ9Z-F0]EMK/M'\W38NP7)XN!]9']9RLK*Z?C"O.
M=Z%N0Z\.L9ACVLQZ::\=E=CMQLR-U_\`I/1L_FTE."ZWJ73.D8^8[JV;;=U?
MH^5?8W*M#O3LKKHO8_"8UU7V>QOKO_2.?;^C_P`)ZBU\;I^5@=8=TWI_4;MW
M4>F675OS+GY0%[;*VM?3N>U[6LKNL]38_P!_Z-_^#56CZJ=?R^G4=-ZG31CT
M=/P,C#Q+JKO4LL=?6S'9ZFZG]#7M9[MG_;:NU]#^M]SGYV4<"KJ-.&["PO0?
M>&`6/K=:Z]SF>JVQM=7Z"W'<S98DIHMHRZ,3KF'T%]UF!7532ZPV>KMO(<[J
M=M#\ZS>ZMF(ZGZ%FS_N-^F6R_I[.H_5/IC<C.LQ^GUX]%^<XDBRZEE0?Z-N4
MUU5E.]VRRZUGO?\`S?YZ'@=!^LN'T7(Z2W(P12,4T83:Z7L`>Z=]N2=[_4=9
MO?ZCV?X7],HO^KWUCL^K.%T5]^&'8Y97?+;75NHI`^SX[@'UOO;9Z;&9GJ>R
M^KU$E.,ZO)_YN]-M;8]O1\?J`MQGV1Z@J^TU5=+K+'UOO_PMGOL_2_Z=$^N/
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M/'JM8Z8+1ZF1[O\`!O9^@]]5S+*[5J=*P,3`IMIPWN?2ZZRS87;FUN>[<_'I
M:WVTTUN^A1_@TW6NE5]6P'X;['4.+F65WUQOK?6]MU=M6Z=MC7,3](Z55TK#
M&+78^]Q>^VV^W;ZEEECC8^VYU;:VNLU_<24W4DDDE*22224I))))3__3]57#
M8GU@ZC?]=#7]IQ&UFRW".&]]C7BNFQQ:YM4OK_:-GNL_T-F)L7<KDLKZK]7S
M/K0S*RLL6]+K<S):/38UX?58;,;!:ZIS+FMH<[U_M?\`A?Z.DIZU))))3A_6
M_&S\CIE8P69-MK+V.?5AW?9['5ZMM'K>I3^:?W_YST_8N88W=1BX->9U3%MR
M^J,Q,^G(RW/R*=M%^36RG*I>[TJ\AOIW?X3UUVO6#UH8@_8@QW9F]NF7O]/9
M_A/YGW[_`-U<ZWZO?6$@=6VXS>MNS_MEE3K'>@:Q2[I]%/KLJ]?912[U6,_T
MEEB2G0^J9=59U;I_KWY%>!F>E6[*>;;8=53<[=:\E[Z]]CO35?J^`SJGUG9@
MYKWOQ:NGV7>G3=9CD/-S6,?;]GL9N_1-V?I'?Z3V*K?]7OK4<=EV+?5A]0R.
MI#-ZAZ%U@I=6UM6/Z3-U/JV,?53O]&S\_P#[;6GUGH_67=5;U?HEF*S+.,<2
MP9C;'L-8?Z[6L%#J]GO+M^_U$E/,],Q&=7PLC)R\K*K?C=(Q',%6393PS*FS
M*]%S:W>KZ;?>_?\`HOTB[+ZL9%V5]7>F9%[_`%+;<6I[WQMDEC23M7-,^J/U
MAZ=AG%Z,<#9F8%.)U'[:;7R^IEE.W&;2UC?1_3V>^[>_^PNNZ7A-Z?TS$P&D
MN;B45T!QU)%;6U^#?W4E-I))))2DDDT@$`G4\!)2Z2BY[&-+G.#6CDDP$O49
MOV;AOB=LZP3MW0DIDD@NR\1NW==6-PELN&H'=NJ*US7-#FD.:X2"-00>X24N
MDDDDI__4]57'MZW]:<CJ6;;B'%?T_!S_`+(,)PV9%K6^BV\LONM9C^SUW7,_
MXK8NP7`]6P;,OK>34_HCV]5=FT.Q.N44$U,I:ZA]-EU]MA_3LJKMJR'45>G5
M[$E-KHV9U^\49V=]8:6UA]S[NF_9:VVOKH?:VRO=ZGKL_1U[W;*=[/Y:)T?+
M^MMV(WJ^3D^OT_J.+?<RIE=+'XG^&Z?8QWTLWUJ/;L>W]'9_.*G]7L+(QF4X
M]OU:M;=<^ZB_K!-++FUW6WS;N+GYOLI?7[__`##U#=&H^M-73CT2W#=1B8&%
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MJ5MM;[_?7_A$E-%_6NN8'2\;-NOLN=UO!?AXLO\`:,NM_H=.RJGA[JZGY^):
M_,N]_P"EMI_G*5WV!C.Q,''Q7V.N?14RMUKR2YY:T,=8]SMSG.?])8`Z)UF[
MHW0,6\5#(Z9ET6Y$V$CT:/4K9M>VIOJW^EZ6[V5,]1=.DIX*R_J%639]8?VA
M?8P]8/3S@^J[[*S&<\=/]S`[95D,?^L?:-WZ.Q$^I57U?R;\4M.=?U?#I=8^
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MM;LJ9E/OWY1MV_IF8VRK;Z?_`!:CU<=&^LOU9Z5UO)Q6Y6:^_%Z??<'.EH]=
MM64*VU^VUMS]_I_G^ED+J:_JO4+^COM>RZKI.'9ANK?6#ZN]M%7J'<7-9M^S
M_1_X1!;]4=O2W]/&2&[^I?M(O;7`:/M`S?L]3=_L]K?2]7_P-)3SV7TOHF-]
M9LKI[/J_^TZ&48=3&U@/%#1ZKA9=ZON9OV_X-UGJ^BO0:JJZ:F4U-#*ZVAC&
MC@-:-K6A8/4_JOG9?4\C/P^K6]-&56RJUE%59>?3;:UGZQ;N?_A]VUBW<>MU
M./54]YM=6QK76'EQ`VE[OZR2DB2222G_U?55RW4/K3U;$R<ZZO$HNZ7TRYM6
M79ZCVW`%M+W>E6ZOT;K/UCVM;;_(74KSWKN3=0SZQ]'OKO?E=3R:GX)94]]+
MV/;CL])MOIOIHN8RFWUG6/\`^%8DIV6?6GJI^L+L!V+2<(9IP0UKG?:Y])N1
M]J=C/V5_8V[VV67M?_,_X-=#GY3</!R,MQ`;CU/M)=H(8TO]W^:O/WU7U]2+
MF4Y=GU@_:HLD-R/L0K=9Z?J/,?8F_P"3O8^Q=!E_4+H;,6ZW#H>[J3*K1BWV
MY%[BVQ[;`TF;'MV[[?\`1?V$E.;9]</K-@8GK=3KP769/3SFX0QA;[7;L>MC
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M\-D[&MES[G[K:6LL94^[[,__`+D^DL[I]>;@7=-S,+H>9Z&'7DX3<:STAD%U
MKL?(_:-UAM9CM;E>E9ZW_=C>DIG3U/ZS]2RJ^GXG5:\:W'HO=EY/V46MM]&]
MV*VZFEVS8_;_`('<]-U'K?UES/J]1UC`R6=-Q:<$Y-U[F5V.R,EI-?[/;3;[
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M0+V[O09N_1V>GN#K?;C[MG_")*<?`SOK&.B],MZ679E)S+*G6/`O=9@A[VU9
MEU]M]5GJ^FS?O_/W_P!&5?ZW]/SF]1S>H/QNHVX)HK_6</-]$4-8#]LLKQ=_
MO_1>_P!/T+?4]_[ZW.J]$ZD1T:GHF0<3&Z;;6+ZO5>P/QF;&^@6L99Z[ME?^
M$<Q1^LG3?K1U-M^%@9.)C]-R:A587ML^T>X_IS7;6[TF;J_8S]'8DIIGJ=%?
MUEQ=U[V]/Z?C4XU1+GN=?D9^W[.;V_G-JQL5UGJY'^D21>J?47I-]F)=A8>,
MRZK*Q[<I]S2XV44@5V4?G_2K97[/YI))3__9_^TD@%!H;W1O<VAO<"`S+C``
M.$))300$```````/'`%:``,;)4<<`@```H;$`#A"24T$)0``````$!;_&D7,
M*98,2(?/&O;;UE`X0DE-!#H``````.4````0`````0``````"W!R:6YT3W5T
M<'5T````!0````!0<W138F]O;`$`````26YT965N=6T`````26YT90````!#
M;')M````#W!R:6YT4VEX=&5E;D)I=&)O;VP`````"W!R:6YT97).86UE5$58
M5`````$```````]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0`'(`;P!O`&8`
M(`!3`&4`=`!U`'````````IP<F]O9E-E='5P`````0````!";'1N96YU;0``
M``QB=6EL=&EN4')O;V8````)<')O;V9#35E+`#A"24T$.P`````"+0```!``
M```!```````2<')I;G1/=71P=71/<'1I;VYS````%P````!#<'1N8F]O;```
M````0VQB<F)O;VP``````%)G<TUB;V]L``````!#<FY#8F]O;```````0VYT
M0V)O;VP``````$QB;'-B;V]L``````!.9W1V8F]O;```````16UL1&)O;VP`
M`````$EN=')B;V]L``````!"8VMG3V)J8P````$```````!21T)#`````P``
M``!29"`@9&]U8D!OX````````````$=R;B!D;W5B0&_@````````````0FP@
M(&1O=6)`;^````````````!"<F1456YT1B-2;'0```````````````!";&0@
M56YT1B-2;'0```````````````!2<VQT56YT1B-0>&Q`<L````````````IV
M96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`````4&=0<P````!09U!#````
M`$QE9G15;G1&(U)L=````````````````%1O<"!5;G1&(U)L=```````````
M`````%-C;"!5;G1&(U!R8T!9````````````$&-R;W!7:&5N4')I;G1I;F=B
M;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`````````#&-R;W!296-T3&5F
M=&QO;F<`````````#6-R;W!296-T4FEG:'1L;VYG``````````MC<F]P4F5C
M=%1O<&QO;F<``````#A"24T#[0``````$`$L`````0`"`2P````!``(X0DE-
M!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-!!D`
M``````0````>.$))30/S```````)```````````!`#A"24TG$```````"@`!
M``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`
MH9F:``8```````$`,@````$`6@````8```````$`-0````$`+0````8`````
M``$X0DE-`_@``````'```/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H`````/____________________________\#Z```.$))300`````
M```"```X0DE-!`(```````(``#A"24T$,````````0$`.$))300M```````&
M``$````".$))300(```````0`````0```D````)``````#A"24T$'@``````
M!``````X0DE-!!H``````\D````&``````````````!P````F````$H`4@!/
M`%,`10!7`$D`3@!$`"``0P!/`%(`4`!/`%(`00!4`$D`3P!.`"``+0`@`$,`
M3P`@`"T`(`!#`&4`<@!T`&D`9@!I`&4`9``@`&\`<@`@`%``;`!A`&D`;@`@
M`$,`;P!P`&D`90!S`"``+0`@`$0`;P!C`'4`;0!E`&X`=``@`%(`90!T`'(`
M:0!E`'8`+0`R`````0`````````````````````````!``````````````"8
M````<``````````````````````!`````````````````````````!`````!
M````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````
M!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG
M````<`````!29VAT;&]N9P```)@````&<VQI8V5S5FQ,<P````%/8FIC````
M`0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)
M1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U
M=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@
M````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`
M`````````$QE9G1L;VYG``````````!"=&]M;&]N9P```'``````4F=H=&QO
M;F<```"8`````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````
M37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X
M=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI
M9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!
M;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#
M;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)
M=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O
M='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))
M300H```````,`````C_P````````.$))3001```````!`0`X0DE-!!0`````
M``0````".$))300,`````!K#`````0```)@```!P```!R```QX```!JG`!@`
M`?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,
M#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!P`)@#`2(`
M`A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+
M`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,
M,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C
M<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"
M$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#
M!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))))2DDER_^,&ZR
MKI>"*\FS#];J.-4^VJUU)V/<YMH?=66O;7L]R2GJ$EYP_JF3DOR<(]:R,?IV
M$W+NZ;U+>&C)=2VG94_-_P"UE73[K+O59M_7/]+?Z5BL5=>^L.337ZM]N']N
MNJ#7"IH?C7545Y'4^G7MO;9L9:SU<G$W?I?993:DI[]<KUCI.3G_`%K-AJ=]
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M59_ADE.K]5W=0=TAASO5GU+!CG)TR#C[W?9'9@AOZSZ&S?\`X3_3?IO46LN?
MROK'E5=1.#355:<K[*_I;PX_I:[BYN;:\1_VAKJ^T?H_\'92L[&^O>1?C79;
M<6HTX>/]JRVML=O:UMUM&12P.J:U]U-%7K?2]/UOU;_A4E/8I+DV?7?(LNNQ
MZ^G;K79#<;!9ZP:ZUSR]['7U/K;9BL^Q5_M#U-MM/V?T_P!)ZJ)5]>*!U!O3
M\K']&POR,<V[YK&1C>XU.]@VTY%/Z3'N_/\`YGT4E/4)*CT3J%O5.D8?4;:?
MLSLNIMWH[M^T/&]GZ3:S=[#N^@KR2E))))*4DDDDI__0WKOK#]8\KKO7:\&Z
MG'I^K[&%N%:P/^T[FNLL?9=[;Z/:S]"^K]$S?^E]1`L^NO7\;IE/4K6XMO[5
MQ+LO"H8UVV@T&MWHY%GK;\EMM%OZ2YK*=F3^C_/76Y_U=Z'U')9E9N#3?D5D
M$6N:-QVZL;8YL>M6V/YJW?6@GZI_5N,D?L^D#,`&0`V`X-=Z^R!]"OUF^J^N
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MHGZE]'%(JJ=D4ES+*\FVNTBW(;<X6W_;;W;K;WV/_P`+N]1GJ6>EZ:2EK^K]
M(IZCBXE6`;W9]=>73?776&N#?;58W>666V8M?IO?Z;=^-0^I5:/K-T3J5==M
M?3_M-_4?0;76!18;7`/RFU6VML?76_I[*WWVLRGU^C_@?TBT\GZMX.1D46NL
MN97B^D['QV/`JK=0+&464L+7.I?MN_2>D]GK[*_7]1BJ5?4^FCT'8^9=79A>
MG]C?MK]IK8['LLOV5U_:K,JJQ[,CU/S/YGT4E(K.M_5NRV_'S<"REV:[';F-
MOH^D^UUF-@,R6L]1]GJ.P]E3MKZ_YM0JZM]5:V4YC,.T5OKLR/M`H<YK?M;_
M`$[?M#V[_P!9S+6LKVO_`$W_`%A6+OJDVW.JZH_,>_J>.REE&8^NLN;Z;K7W
M[F,;6U_VNO)MHL9[-E7_``OZ15A]1W5='R^DX^8RFK)J8QMC<9@>'LL.1]HO
ML#]^2YL^C37^CKIK24Z&`[ZO^M@XE-)HRL;%L=AT6,>VVK'#F8UVWU/>SW,J
M9MW>HLC#'^+W/QZSAV-MQZG8N":FF[:?TCWX.)DTO^G5;DVO?9Z[?TUO])6E
ME?5S*MZI^UZLMK,YF0Q]+C7N:W%;6<>W`=[]WZQZEM[[?]+Z7Z/]$LWI'U!_
M9?3^H=/;=3;3U3&+<B:RTC)!?Z&34[>]U=.RS?Z6[]%D5^KC^FDIL.P/JF\'
MKGVBQHKM;C49!<]Q9;1?8T4X7JML?9ORGWU?H_69<RQ]5?Z%4[>E_49N%?ZO
M4)Q^H8EC+A9:'NLB\V7=1>U[3>_,IS'?SS_YGT_YO]&KS_JSGN^K/2L`NH'4
MNC6T9-6S<*++,8F&O=M]1OVFLN]6WT_YZSU52H^I_4[NLCJ&58W"KO??D9#,
M*U['UOL]!M>+7=L_3U6?9O7SOYBNZ^S^9_TB4])5F=(Z5C,P;,VFL8-+&/\`
M6M8US6-:&,?=)9LW-1:NK=*N:]].91:VIXKL++&.VO=HRIVQQVV/_,8N5R_J
MH;OK=?U6SI-=E#FO-MSK*[F7#TMM/I8=[-V/GU9#&-;;_,>CZJQC]4>MV=!Z
M3TZK#_9F3A,=G9N14VEWJ7T>HWIM#OL[F/RLK;]/U/8S_2^HDI[ZW*Z);D5W
M6Y-!NPW/V'U6@L<0:;=S0_\`==L_2*U5EXES_3JNKL>6^H&L<''83M]2&GZ&
M[\Y>>=0^K7V[-S\V[H1H&3T=SKZVU,M]//ML]1C\.P;++\ME=EK[_29_@_3]
M1:/^+GI;\.W+MOP;,3(-&-2Y[J'8]9]-KFO8QECW^I<YP];*MI_0V6O_`'TE
M/<))))*?_]'U5))))2DDDDE*22224I))))2DDDP<T\$%)2Z2&V^A]AJ98QU@
M$E@<"X#B=J(DI22#DY>+B5&[*M914"`;+'!K03HV7O\`:GQ<K&S*&9.):R^B
MP37;6X.:X3'M>WVN24E22224I))))2DDDDE/_]+U5<?G-ZK@=;HS;^HO^U96
M1;Z?3F6$X8P:JWSDV8UIJ>R^IGHV9#V6VL^T?S=-B[!<GBX'UD?UG*RLKI^,
M*\YWH6Y#KPZQF&/:S'IIKQV5V.W&S(W7_P"D]&S^;24X+K>I=,Z1CYCNK9MM
MW5^CY5]C<JT.].RNNB]C\)C75?9[&^N_](Y]OZ/_``GJ+7QNGY6!UAW3>G]1
MNW=1Z99=6_,N?E`7MLK:U].Y[7M:RNZSU-C_`'_HW_X-5:/JIU_+Z=1TWJ=-
M&/1T_`R,/$NJN]2RQU];,=GJ;J?T->UGNV?]MJ[7T/ZWW.?G91P*NHTX;L+"
M]!]X8!8^MUKKW.9ZK;&UU?H+<=S-EB2FBVC+HQ.N8?07W68%=5-+K#9ZNV\A
MSNIVT/SK-[JV8CJ?H6;/^XWZ9;+^GLZC]4^F-R,ZS'Z?7CT7YSB2++J65!_H
MVY37564[W;++K6>]_P#-_GH>!T'ZRX?1<CI+<C!%(Q31A-KI>P![IWVY)WO]
M1UF]_J/9_A?TRB_ZO?6.SZLX717WX8=CEE=\MM=6ZBD#[/CN`?6^]MGIL9F>
MI[+ZO424XSJ\G_F[TVUMCV]'Q^H"W&?9'J"K[355TNLL?6^__"V>^S]+_IT3
MZX]/Z.>J]1R^MX-V6VS%J;@WU,M>RC:+O4LMMI].FEOKOJ]CWVVK;SNC?6CJ
M'1J<2_,PZ<RO(;>;*J7^D&U$6XU5;'6M?[;6,WN_<6AU;H]W5<;"HOO:QN/D
M4Y&4T,);<*O>ZB-[=E=ENWZ7JI*>:JZSBXWUCPG]9R&_;.G=-QZ+F-<UKAD9
MA;]KM?4?2<^FBO'9;<[_`+35V?S*GG?5CZN,^M/2*^FXC&9EMMG4LJ]CGN(J
MI!<PG<Y[&UY6;?2M[K7U:P^ININKKHHRF9%-]N0:6O?8RH@OQW/FM^VUC?2]
M^_V?X-6*.D^EUS)ZJ7APR,>G&KKVP:VU.ML=MLW.]MKKOH,97]!)3Q7U5PZ<
M7J_2NGT]/=B]6PVW6=4R[:35]HK(LQWV4V[VWVU?:GU^GZ^+Z5W^#V+T99V)
MTDT=:S^K66BUV8RFJIFS::JZ0^:_4W.]3U;;7V_1K6BDIY[ZXAMM72L2RL74
MY?4\>JUCI@M'J9'N_P`&]GZ#WU7,LKM6ITK`Q,"FVG#>Y]+KK+-A=N;6Y[MS
M\>EK?;336[Z%'^#3=:Z57U;`?AOL=0XN997?7&^M];VW5VU;IVV-<Q/TCI57
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MT]G^$_F??O\`W5SK?J]]82!U;;C-ZV[/^V65.L=Z!K%+NGT4^NRKU]E%+O58
MS_266)*=#ZIEU5G5NG^O?D5X&9Z5;LIYMMAU5-SMUKR7OKWV.]-5^KX#.J?6
M=F#FO>_%JZ?9=Z=-UF.0\W-8Q]OV>QF[]$W9^D=_I/8JM_U>^M1QV78M]6'U
M#(ZD,WJ'H76"EU;6U8_I,W4^K8Q]5._T;/S_`/MM:?6>C]9=U5O5^B68K,LX
MQQ+!F-L>PUA_KM:P4.KV>\NW[_424\STS$9U?"R,G+RLJM^-TC$<P59-E/#,
MJ;,KT7-K=ZOIM][]_P"B_2+LOJQD797U=Z9D7O\`4MMQ:GO?&V26-).U<TSZ
MH_6'IV&<7HQP-F9@4XG4?MIM?+ZF64[<9M+6-]']/9[[M[_["Z[I>$WI_3,3
M`:2YN)170''4D5M;7X-_=24VDDDDE*2232`0"=3P$E+I*+GL8TN<X-:.23`2
M]1F_9N&^)VSK!.W="2F22"[+Q&[=UU8W"6RX:@=VZHK7-<T.:0YKA((U!![A
M)2Z2222G_]3U5<>WK?UIR.I9MN(<5_3\'/\`L@PG#9D6M;Z+;RR^ZUF/[/7=
M<S_BMB[!<#U;!LR^MY-3^B/;U5V;0[$ZY1034REKJ'TV77VV'].RJNVK(=15
MZ=7L24VNC9G7[Q1G9WUAI;6'W/NZ;]EK;:^NA]K;*]WJ>NS]'7O=LIWL_EHG
M1\OZVW8C>KY.3Z_3^HXM]S*F5TL?B?X;I]C'?2S?6H]NQ[?T=G\XJ?U>PLC&
M93CV_5JUMUS[J+^L$TLN;7=;?-NXN?F^RE]?O_\`,/4-T:CZTU=./1+<-U&)
M@863C5V_HXRG#]'@65&NSUL.ST_I^IO_`.W$E.7^W/K">EBVOKGVRZS#JNRG
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MXEK\R[W_`*6VG^<I7?8&,[$P<?%?8ZY]%3*W6O)+GEK0QUCW.W.<Y_TE@#HG
M6;NC=`Q;Q4,CIF71;D382/1H]2MFU[:F^K?Z7I;O94SU%TZ2G@K+^H59-GUA
M_:%]C#U@]/.#ZKOLK,9SQT_W,#ME60Q_ZQ]HW?H[$3ZE5?5_)OQ2TYU_5\.E
MUC[<A^2:FN<756B;7?8['V^OO]F]C_YRM7'_`%7ZJ>J?9V>B.@C//5"'6.]=
MUQ:;F4^BRIN.W";G_I75;O4_PF];GU=Z?D=-Z'A8&26F_'J:RTUDN9N'TMCG
MAKMB2FK]<Z;;_JUFUU5FTD,-C&R3Z;;*WY!&S])[:&V._1?IO]%^D7+'I?U=
MR^E=9.'3E^A@4',IZ?F"^IS<@57LKRZKLA_VNRNZJKTO2L_5OT?T%VG7L'+S
M^DY&+A7''RG@&BX/<S:]KFV,+GT_I-GM_2,_PGT%FXOU=ZG9C]5=U;,JOS>J
MXXQ/5IK<QE=;66L9^B?8_=^DR+'_`)B2GG>H8?0,3ZL]*Z)C6,Z;3U]S,N^U
M]Q:UNRIF4^_?E&W;^F9C;*MOI_\`%J/5QT;ZR_5GI76\G%;E9K[\7I]]P<Z6
MCUVU90K;7[;6W/W^G^?Z60NIK^J]0OZ.^U[+JNDX=F&ZM]8/J[VT5>H=Q<UF
MW[/]'_A$%OU1V]+?T\9(;OZE^TB]M<!H^T#-^SU-W^SVM]+U?_`TE//9?2^B
M8WUFRNGL^K_[3H91AU,;6`\4-'JN%EWJ^YF_;_@W6>KZ*]!JJKIJ934T,KK:
M&,:.`UHVM:%@]3^J^=E]3R,_#ZM;TT95;*K6455EY]-MK6?K%NY_^'W;6+=Q
MZW4X]53WFUU;&M=8>7$#:7N_K)*2))))*?_5]57+=0^M/5L3)SKJ\2B[I?3+
MFU9=GJ/;<`6TO=Z5;J_1NL_6/:UMO\A=2O/>NY-U#/K'T>^N]^5U/)J?@EE3
MWTO8]N.STFV^F^FBYC*;?6=8_P#X5B2G99]:>JGZPNP'8M)PAFG!#6N=]KGT
MFY'VIV,_97]C;O;99>U_\S_@UT.?E-P\'(RW$!N/4^TEV@AC2_W?YJ\_?5?7
MU(N93EV?6#]JBR0W(^Q"MUGI^H\Q]B;_`).]C[%T&7]0NALQ;K<.A[NI,JM&
M+?;D7N+;'ML#29L>W;OM_P!%_824YMGUP^LV!B>MU.O!=9D]/.;A#&%OM=NQ
MZV-RVWV,]ECLQC&-I=^8MOI/4NMU]9LZ3UQV-9;9C_:L=^*U[&!K;/0LJ?Z[
MWOL?[ZUC](;;UC,Z=AWX671B8/3;</J#,NA^/78;&X],4O<7>MN]%WL_,K_2
M^HK/U;^JW2W4=8Q\GI_H85^9Z-6'9OVFK$(&/D3:?4L=?;ZEWJ^I[ZO224[W
M6K>I_8'#HX:[,L>RMMAVN;6'.`LO>Q[F>HVIGTJ]V]<YB=5^LN3U"OI-.?4;
MZGY8OR[,7V6FG[-M97CUVUOQZJOM3F>LZU_KV,5KJW3<?ZO8%Y^K72GMS>H;
M:7OPV3L:V7/N?NMI:RQE3[OLS_\`N3Z2SNGUYN!=TW,PNAYGH8=>3A-QK/2&
M076NQ\C]HW6&UF.UN5Z5GK?]V-Z2F=/4_K/U+*KZ?B=5KQK<>B]V7D_91:VW
MT;W8K;J:7;-C]O\`@=STW4>M_67,^KU'6,#)9TW%IP3DW7N978[(R6DU_L]M
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M7_Q7Z-)3+ZP]2ZT?J4+[:78V?DX^[+].:Q2`QUM_Z1UN_&<YK?2J=NNV6O53
MZT9M+<OHN/G=3RND]-NQK+/M&(YS'/N;]G]*JQ[69'L])UMGN9_UQ:G4>F=>
MS/JA7TNT4Y74+ZF4YQN>6M((_6'UW5U._3_Z)_H?35C,Z?UO*^JS^GAV-1U6
MW']`O;N]!F[]'9Z>X.M]N/NV?\(DIQ\#.^L8Z+TRWI9=F4G,LJ=8\"]UF"'O
M;5F77VWU6>KZ;-^_\_?_`$95_K?T_.;U'-Z@_&ZC;@FBO]9P\WT10U@/VRRO
M%W^_]%[_`$_0M]3W_OK<ZKT3J1'1J>B9!Q,;IMM8OJ]5[`_&9L;Z!:QEGKNV
M5_X1S%'ZR=-^M'4VWX6!DXF/TW)J%5A>VS[1[C^G-=M;O29NK]C/T=B2FF>I
MT5_67%W7O;T_I^-3C5$N>YU^1G[?LYO;^<VK&Q76>KD?Z1)%ZI]1>DWV8EV%
MAXS+JLK'MRGW-+C912!791^?]*ME?L_FDDE/_]D`.$))300A``````!5````
M`0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`
M;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V`````0`X0DE-!`8`
M``````<`"`````$!`/_A#W9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O
M`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@
M,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M
M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SIP9&8](FAT
M='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&5$871E/2(R,#$U
M+3`T+3(Q5#$P.C0R.C,V(B!X;7`Z0W)E871O<E1O;VP](D%S<&]S92!,=&0N
M(B!X;7`Z36]D:69Y1&%T93TB,C`Q-2TP-"TR,E0P,#HQ-3HR."LP-3HS,"(@
M>&UP.DUE=&%D871A1&%T93TB,C`Q-2TP-"TR,E0P,#HQ-3HR."LP-3HS,"(@
M<&1F.E!R;V1U8V5R/2)!<W!O<V4N4&1F(&9O<B`N3D54(#DN-RXP(B!X;7!-
M33I);G-T86YC94E$/2)X;7`N:6ED.C$U1D4X-31#-39%.$4T,3%!.45"0D)$
M0D$P144Y,S0T(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C$T1D4X-31#
M-39%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240](GAM<"YD:60Z,31&13@U-$,U-D4X130Q,4$Y14)"0D1"03!%13DS
M-#0B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D
M93TB,R(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F.E-E<3X@/')D9CIL:2!S=$5V
M=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C$T
M1D4X-31#-39%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=$5V=#IW:&5N/2(R
M,#$U+3`T+3(R5#`P.C$U.C(X*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT
M/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E
M9#TB+R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z
M<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HQ-49%
M.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T-"(@<W1%=G0Z=VAE;CTB,C`Q
M-2TP-"TR,E0P,#HQ-3HR."LP-3HS,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB('-T179T.F-H86YG960]
M(B\B+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I
M=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7`N:6ED.C$T1D4X-31#-39%
M.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=%)E9CID;V-U;65N=$E$/2)X;7`N
M9&ED.C$T1D4X-31#-39%.$4T,3%!.45"0D)$0D$P144Y,S0T(B!S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z,31&13@U-$,U-D4X130Q,4$Y
M14)"0D1"03!%13DS-#0B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$
M1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X<&%C
M:V5T(&5N9#TB=R(_/O_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#
M`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`'``F`,!$0`"$0$#
M$0'_W0`$`!/_Q`&B````!@(#`0`````````````'"`8%!`D#"@(!``L!```&
M`P$!`0````````````8%!`,'`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#
M!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34G
MX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(
M24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'
MR,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1
M!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$
M\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D])6E
MM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI
M>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`-_CW[KW7O?N
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MW_D?B-MN?Y!+VN]<O8';U/TU7?(2`TGR5S'QD@[*W)'\=<Q\CZ`XO"R8_N;(
M=5KCGRD532PY81>`Y9?XP<A[]U[JPGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=?_T-_CW[KW7O?NO=>]^Z]U1!_PH)WGN/:/Q@^*5%MSO#L;
MX_?Z0OYDOPYZNW)O[K7N'=?16078V^MS[AQ&^<;N'L;9>9P>?PFTQM9JJLJI
M8IB*:2CBJBMZ<,ONO=5)Y?Y.]C=FYKNWHR;^9U\A>JOBC\;,%\X^X?A/\VHM
M[XO;N/\`E[N3H7:?3M)M_8.Z/DQ&E!D/D=L3XA=E;LW-#G<6**IB['IZ>F:H
MR><AQE<&]U[H7]K?/+^8+V=M':K;Q[4[:^/Z?)ONSI#&XG)8GJ#8>-WM\2>[
M.I?C#L/MSYQ?"[M;"=G[8W=#M;;G8.`HMP;UZZK*ZG.<H$QE=B<K54<FA&]U
M[IVV[\POYD.Z_BOL;NK)_-Z3KG?>]^Z_Y<>Q:39"=6_!SLK*S=8_/E?CO@,9
MW#!MO8TF;W+M/"568W[NVJVMA<U2G-57\&667[ZABD9_=>Z-Y@N^/FQ\>_E5
M\G<?\H/YA_76[_C3\#^@^HOD[WS-)\5.K-HYCLW;W<_^S*8ZGZMV_3X'LRBS
M_6>5VY0=186JQ%;)59RHW#GJR>!84IZFGH:;W7NL777\UKY$;H_D^_,3Y3[A
MVQL39WSB^&<W:^T>T=@;JV?NO';%PV_-OSX;?77_`-[L?+97:/8,>%S/3V_<
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M\8MFS=P)F?LMP[=K]H9"@IZ/(S9.=Z>+W7NE;MK^>%L2#O\`PGQP[:ZC7KC=
MF0W7\L>CLCOA.PDS/7.'^3OQ0FJ,S7[`RE:VT,?DL/UOW#UN]'FMG;EJXXLA
MDJV>;$OA8ZNDF8>Z]U9Q\)OD%N7Y8?$?XZ?)S=O6*]-YCO[J39G;J=:KO&GW
M^-L83?V(@W)M>([MIL%MA,LV2VQD*.L.K'TDM.:DPR1K)&WOW7NC1>_=>Z][
M]U[KWOW7NO>_=>Z__]&V?>'\PK^8OV]\YOYJ^W/C]V-TOU%U]_*>V7U]6X7X
MQ=C[!Q>\8?E\FZ=L[HWKNW<F]>PZ>NQ/:7552<+MV.';>1P228'&SY*D.6IJ
M]/*[^Z]T&&?_`)U7SUZP^,W6?RFW?B?B[O67YR?$+Y$?*;XP=2[9VANNGV_\
M:LA\><YUGE:3KOM_>G^F&+=/=F)WSU-OV=LKN*@Q^V8\5O>CAH(*04E=$J>Z
M]U9]\F_Y@7RSZ\[MW]\?.C>D^D-T;N^+GPZVE\UOE%O+M7?&[]J;8WGM+(Y/
M>F,J^J/C9M?;^+S.[:_<>Y).LL_]MNC,&3"X">"FIJVEJIJA;>Z]T"/5/\ZW
M;_R3^>G3_P`)(_AUF=X=3=Z=`;1^4&![W?/_`,5H^M.J>S^B,1W-L*L[QZTW
M3USC<'M3(UNW=R?PS,28[<V6IL775U+3!JHU1T^Z]T\M_-M^/W=7QTKMW=2_
M%O;7=N,Q'\P'JSX*]3]6;KW'LK;FU]\4?9V[]N4'0'R.VU59+9FZ*3;G4&_\
M=646?P,DN*6<T-*9H2WAC9O=>ZY9[^;IL+![;[DP&U/@[E=W[_\`C[M[O?NC
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M`?&KM&BVIG^O.S^]5[<I_CIOK=6W-F-\S>P*+9V__P#2YN3%-N2/'=V?(OL#
M`X[$&AR?W6XZZCDB<>/!I55$/NO=&YZ)R?P";=WQ<Z@V-US5]:]Q=+_%/L_/
M_&SK'L/8'8^T^YNGOC#CMV[.Z1[(HL0-V4LNY-L4CYW;^"QKT$]9_%9J>"FE
MAC,*EQ[KW5<W4<7_``GO^1.P=HS]([PP6].L-C;D^%7PIKMCX+._(ZHVIEX9
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MC!U#UQM'<:=L=R]9;9W=M79&V-HX;`;7W3V73Y#+;?CV\,[AZ*"H-9/2T-)4
M-+KA5490/=>Z7^V?EG\6=[8S<N9V3\DNAMZ8K9F[L%U_NZOV?VYL'=--MG?N
MZ:N&@VOL;.R8'/Y`8K>6Y:ZIC@QV+GT5U=-(J0Q.S`'W7ND5NOM#X4[M[`V=
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MY/\`\,NSML[OP`QW<'7N5WYVUO'N'=78/6O>79>WNR*S+]@]10]!;SV/B=W5
MV>S-9L[IG/=*XW%;9?9>#7&[9@Q6`Q,<%%$V-I'B]U[K#V-_*!^(F^,G297:
MH[3Z%FQ.%^+F$VY0_'S?:]9X';$7PSSF^MQ_'6MPNV*7#9#;@R/7N8["KY8)
M*FEJ5?3$C*45E?W7NF&7^3%\0J39E%L_9^<^0/7%3E]G=G;#[O["V+W3G\=V
M[\K=N]U;TQO8/;)^4':F3ILQO;M3<6]MTT=5*V;>LI,WBJ;+5])BZN@HZ@P+
M[KW0P]D?RV^C^R]^]4[PKMY=U;<VWT;4=-Y?IWIO:F^L?0]/]6[MZ"V_V'MG
MJ_>W6VVLCMK+9?KK<6-PW8T]-E5P.2QN/W11XW'T><I<E0TQII/=>Z`';7\H
M+9W7Z]5Y#KGY(]P[8W9\<H>I7^-VYWVMTP\^R\YUSU?N3J/>.[NT*3;W76U1
MWONOOO8^\\GC-X5>9EA+8Z2"+$+B9:?[B3W7NN]V_P`I6@WCWAL3Y99_Y([Q
MW'\PNHMD]![/ZE^1>Z>K>JJS<FVO]%F\>U\_VA69S`;9PNS\)N.A^0.TNZ<[
MM3+XZ%<;28S!?9/1JN3HHLB?=>Z`BE_D?5NUOB!\@/AWUG\C]B=?;-[BZKZ^
MV9AMV8/XC]>4F^Z+L+8G=F6[AH^W.U]W4&]*+<7<V5PM%D(=M[8Q,M5A\5MK
M#4<>B*KF+R'W7NC&]F_RY.T=W?*"7YI[4^0.U]M_(K;OR0Z^WEUGELMU--N'
M:^V_B3MOIO(=1[^^)F2HJC?$.7J:;MNLW;F]T97<-'548AW!_"IH,>AQB/+[
MKW1*/B/_`"$/]E.Z`^7WQSQW8O3^^]C?-KXVYG;7<CUG56X]NY*A^6&%R>]*
M;K#N?K_*/OO=&>VKU[CMN[O@KYL!)75U7@-X8>++;=K,:E7/21^Z]T.66_EH
M]]Y+^6;\`_CY5Y/H&G^5_P#+Q[3^,GR#V%_=(;QQ'Q_[.[.^+.X,A]ABMRY2
MKP4>\<2.Z=EY"L7<&=_A%344NY<K49.*CET(A]U[HM6R/Y/?R;WS\Q\?\DNV
M]W;?^.NT^T=[?(GO[M[;OQ![S[&V=V#UIO#M27HO&;4Z%VAV,^T*>O[.V!O$
M]+MNWM.JDBVMAMS[JS,D=-B$I:5GR7NO=0.V/Y54N^?YN':/R[W!_+TV#N?K
M;)[7WS6[^[-W#V9TYW7L_P"0U`WQ\IL;UW5;'^-_;&TYLST]\N-D=R;;Q5!0
MYOR)M>;;U3E7EJS452JWNO=5I5/\I+YN;C^!W\OSXQ[/^-4WPS[8^.FT-U?-
M;Y.]N==;.^/6XV[-^0'QSJM_X+X2=69:?J+=.V=T]^]^U^(J(9\I-EGIL;BH
M,BM2<I-7K)2M[KW2W[__`);8^0/=?RT[RWK_`"GJSJ^G[H_DS[AS?:&S]N]/
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M=?_4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==$@`DD`#ZDFP'^N
M3[]U[KK6NK1J76%#E+C4%)(#:;WTD@B_TN/?NO=1H,A053O'35M)421.(Y(X
M*F&5XY"AE$;K&[,CF,:K'G3S]/?NO=)_&[\V/F<_5[4P^\]J97=-!0ODZ[;6
M-W%B*[/T6-BJTH),A5X>EK)<C34,==(L+2O&L8E8(3J('OW7NE7[]U[I`]E=
MJ]9=,[5GWUV[V#LSJ_9-)78W&UF\-_[EP^T-K4-=F*R/'XJFK]P9ZKH,30OD
M*Z9(8O-*@>5U4&Y`]^Z]URZQ[2ZV[KV'MSM+J#?NT>S^MMX4DU?M3?NP]P8O
M=6T=R4-/6U..GK,'N'"U-9B\I2Q5]%-"9(97021LM[@^_=>Z7GOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z__5W^/?NO=:X/=]!\J_CS\U>K^\^P?F/NY^Y^ZOD7WD
M=I_"_:7;><S'PDQ_\O[IWIW?--D.\-X=,;WR'7NY=K]I;'V[_=O,;MR&+W!F
M\7!N[(+-C\/D$=DB]U[JLJLW1\E/BO\`$3IONO*?S!/G#OG??SY_DP?,CNW>
MN&^27<U%N6#JOLGK/IWH3M/:NYOB_M[&[FZ_J.HMV8R;M;*O)EJ[)YVNAPRP
MQG(P5\-*\ONO=6(=9]`]H?'7Y?YWXL_&_P"9/=;Y+Y>_RO\`LWM_:F?^6O>_
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M'RZU=5A8'F@F/NO=*KO'^65_+IP?\T;^7;MWXN_';9.`[VWEVYV7_,3[U[7V
MQO3L#<^;Q_3_`$K19+-[<KZZDRFZ-S8'$[3[R^3W9^W:1:F."FI*FGH*R&G\
M@C%.WNO=%._E7=1;/ZC^77P$^.6ROA]FND_FY\=]L?(+L/YY?(3L3HNLZE3Y
M1]69?![_`.I,]O3K+?9W9B^T-^=?MWWN+$2XB;=6Q<?M_<3T$-7CIJ$TD2R^
MZ]UN@>_=>ZIX_G$T]!NO;7\OWIC<FS\5OW87?O\`,[^*O6W8.V,P^0CQU9M?
M#1[][?JY,I&:]=H9_`E^K%I\C@=PX_+8K/T51)1BG6JDIIH_=>Z/A\6NB.I?
MCOLW?NQ^E=U9S/;(RW=G;&_1MS([PI-T;=ZHW#OC=$^=W1U)UMB<;#2XKK7K
MC9F=J)TQNUZ6*.'#F:5=.MW)]U[HR_OW7NO>_=>Z][]U[KWOW7NO>_=>Z__6
MW^/?NO=:^W5_1/\`,>S/S([Z[;[8^'GQFHMK?)?<$_378/<>Y/DU0;L['V-\
M'\/'48/;/4?7G76S?CUM[9N\\Q3YG)9?=T==NUJJOF3-_P`'KJBHIZ"D6+W7
MNB6[*_E4?/7N+X\]2_%KY6=;='=4]=_$KX#?*_XB]`=A]<=\-V/V=V9NOY`]
M4;(Z<VV-Y5&=Z1IAUUM.3%[=,U:^*JWBU)#3RT%1!'$\/NO=&AV]\(_YO.\L
MAN'Y`]NY'X!;+^5NP?A7NSX?_&>3I?L+Y/8W8=%A.T.P.MLEV#F^VLYDMI?W
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M-\L?A[NSY@]=?%_86_\`M+";>QW5'R&Z$[\[ZPF)V+D,QMCOVCZ;:HW!E.J(
M\?4[UQ#;7V5O+?BT=9.:\9Z(T%']I-23^4RI[KW2)^:?\M7I[Y6Y/KS>VW]H
M]%];=P;<^1?0O<F_^X<G\?\`:.]^P>T-A]0;CQM?N#J+.;IBR&U=PRXKL#:^
M,CP=1-7U>4HH\7JIY*">-E$?NO=#!L3XG?W.^;W>7S!J-U8?+0]J?'OH7X_[
M2V4NU*NERG6N!Z<W1VMNO+KC-UU6Z,G1R8+?&4[(@FEQM!B\1!%-BXI)?NI2
M)%]U[K%U/\3*K8'S.^6?S"W+OO%[UR_R'V;\?NLM@[<38JX+)],]:=(X7=DF
M0VBF\'W/F9-XT^^NPM\9'/3NE!B1`[0P.E0((I5]U[HYOOW7NBL?,WXL8'YD
M=!Y[I',[RW'UGD*K='7&_-D]K;)I<-4;_P"J^P>J^P-M]B[,W]L&HSM%D,?B
MMW8/-;:C^UJS$[0"5R`02I]U[J7\1?BWM3X@=.4_4NV=V[Q[(KZS>._.Q=^=
MK]DC:TO9W:_8?8^Z<ENK=._.Q\GLW;6T,#G-V9&HKTIY:U,?!+-3TL/EUR!I
M']U[HSGOW7NO>_=>Z][]U[KWOW7NO>_=>Z__U]_CW[KW6JWU3\_?D1O[^=!5
M;;/>7Q%PVU\AO[N;X;9#XX[LWOVUM/?&/ZWZ([EW/78?-8K8C9#<^U,E\R=V
MQ3UN7AGA>#;N7ZZAH:C73U-12TX]U[K:D]^Z]U[W[KW55W\WCK3O7LGXT;2@
M^/VWOE#O?=NW.\>NL]N'K[XF_(`?&OL?>779.7Q>^*"?L@=A]8O3T-#ALB]5
M1PMD9X$S<-#4ST-;%3O%[]U[JC/#8TUVRNBN@]O_`"*_FI]([V[[_FL[`^+'
MRSZ\[]^=NZ=\_)KX^TVW_C'WMW3L[:_6G>G76],S3[#VEVWBZG$[B>!9,O!N
M@3O`DL8I/-%[KW5S_P#*?FK-H9_^8+\;H^V>].W=J_%[YDR=;;.SGR5[%S/:
M_<5+C]P]#],]E9>+)[]W)DLEN#<&U*O<N\JR;#2U7A9(6DC5+1ZW]U[H'/EK
MT5A?EQ_,WVO\?^]=S;VSO3>Q_P"7IVCW#'M/J+Y$=V?'"JPF_P#,?)/;>W]K
MY_?'^B+?VUILO15^QL4^/HZG+5L](:K'Y"HAHE0RK![KW547QEZGQ'S0Z5[;
M[3[B[]^46U\_TO\`R@/A%N'`8WKOY<]L=&1U5-CM@?*FJK]U]\OUUN+$;2SF
M2WX-GT$AR60;))6X.D6N5U2KJ%;W7NMEG^61V!N[M?\`EV?!_LS?VY?[X[UW
MY\6.C]U[IW0,&NW(\YG,YUY@:_(9"GQ*4])#%235$[>&6*)(:J(+/&`DB^_=
M>Z/+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__T-_C
MW[KW6O5VC_*^^7?>'\T';W;G;WR)I=Z?#/:NY=@?(["PMUIU]MC>>.WCT]VM
MEMU](_%;!YO9&XML=C8G%]7YG)S;JD["F>MKL]2U`V]60?:0(3[KW6PK[]U[
MKWOW7NBL?,&H^9]-U)3R?`^@^.N1[T.]MII-3_*&;L"GZM_N`U9+_?222;K2
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M3VG@L9M6@ZHW-M*7`U57N'(UK92MKQEWGC6DB@BITCG-1[KW5;&)_E&_S!OC
M+U!5=0_!R?X$/@_D'_+^Z(^+WS+'R\RGR`W]#D-]=1=8]A==2X?I+&=:8#:V
M-BZUKZ7L_-RS9+<Z9/*54M7"C4:45)'1M[KW6Q)\8.EJ/XW?&KX]?'?'9&LS
M&.Z&Z0ZIZ9Q^5R%5'6UV1H>L-B8'9-)6UE;%C\3'65%33X17>44M/Y&.KQI?
M2/=>Z'/W[KW7O?NO==,RH+LRJ+J+L0!=B%47-A=F(`_J3[]U[K%)4T\4L%/+
M/#'/5&1::&25$EJ3"AEE$$;,'F,40+-I!TKR>/?NO=1,CE\3B**;(Y;*8[%X
M^FDAAJ*_(UM-145/-4U$-)3Q3553+%!%)/55$<2*S`M(ZJ+D@'W7NL;9[!IE
MGP+YG%)G8\?39:3"MD:-<M'BZVNDQE'DGQQF%8F/J\E"]/%,4\<DZ&-26!'O
MW7NDG6=M]58Y,;)D.S>OJ&/,T53DL/)6;SVY3)E<=10U5165^-:?)(M=14D%
M#.\LL6J.-(7+$!&(]U[I;8_(4&6H*'*XJNH\GB\G1TV0QN2Q]3#6T&0H*V%*
MFCKJ&LIGDIZNCJZ>19(I8V9)$8,I((/OW7NI?OW7NO_1W^/?NO=:Y&/^:G\T
M3L;Y'?)O>'3N1^*.?^,'QB^?+_%:E^-.XL1'U_\`*#NS;FVJ?I[$]G9#;G:/
M8W:>U^I,?2;=I^T:[<6,JETUE:<#]D*>>:H6D;W7ND;\.>X_GIV!2]5=_=^_
MSD.E,7MC'[O^0^ZNPOA:GPFZBVYVMO?KOXY]A]FX?>6T1F8.PJ[M;;M92;,V
ME3Y"ODQ>VJK)8M6"K]Z%\]5[KW2H^(/:W\V;>W5&"^9?:O=<W9_Q?^7'Q0^3
M/<.U]B[0ZE^/>S]^?!5Y*:L[,^(.]-N92%(<Y\GZWL;JBJBH9\7D*&D_A68%
M&]?`Z259B]U[JL=OF[_,%F^+L.Z=N_S3Y?D/OO=WPXZ?[@[XRW7FT?AGM7_9
M".Q:COCXZQ938&Z]U;0VHNT]L;XWIL+LG-4F8;L.CH*3"4&W,E54KU#3104G
MNO=6Z=4[.WKVC\5ODMO#HC^>SWI\P\-LRM;(#L;H?&_!W=V\MBY#J_;FY-P[
MOZPVUN3;G6E9M"?,]H8?)X[QSY6ZTWVU+5T4D,51/)+[KW064F[/EMA/Y.?5
M592?-OOWM/Y;_P`RG$?&O#?&CL/>6S.O]N=@=([M^0FQ]F[HR>-Q%#USANML
MG6[?Z_VE09W,UV5ECJ\C1Q1R5#ZX(V;W[KW1:OE5\]9NU-N?RK.S>]?G1WY_
M+.ZC[FZE^66QOE=NKJ3?>RMLU&`^2/0.XNIMJYCK/*0YW:7;%1CM_8WL;#;B
MHA&M!*]+1/4H:Q]#)4^Z]T%&7^:/SA^/7Q?Z4[VWIVQV/V#DOYDOP2W[\1.C
M8\IV1$VWL%\V>NNQ(^K_`(7]^[$W)0[[RNS-D9[Y7_'K?&1[&W/60Y%CG<[M
MU&6NQ*I2TB>Z]UMU]"=;Y+ISH[ISJ3,[OSW869ZQZNV#L#,[_P!TY3*YS<V^
M<QM':V+P.5WEN+,YVNR>:RN<W17T$E=5U%743U$T\[-)([$L?=>ZU?\`<F^N
M_P#:G9.Z_P"9*WS#[YW9A:W^<IF/@I7?%>+NO=4/P_V/\6]T[_QGPZJ:7-;8
MQ^=H,!L7N/;FXHUW?3[RI:[[+#Y>M2EEHY:GSS'W7NE?_)7VQ\`^SM]]"U.)
MK_GEV3\X?CUTWN#?&Z=[]^[W^;^1ZIV;G\_D-S;&WY0T>1[`W+'\<]Y[DWU3
M=I3Y-9,7!D\;DX*HUV-DC,<T<7NO=6U?SFMG[JWY_+4^36V=I[3RV]Y:G&=<
MY3=>W<'3Y.LRU1U;MKN#K[<_<==CJ/;M13[PJZ_#=48;,UD$6`+;BDGIT7%J
M]>8%/NO=4'U'Q=_EY=S_`!6_F5U'277/R\/6OQ=Z"KOE?UK\._EQBOE!U#GM
MF?)#$="=X[:V5\A=A=E]Q[TK/D%O39W8^R-CKA#M_+25VS(I,1%**%JG4(?=
M>ZR?(#IWX#=,?RT/@'\#.L-W;1^'&P/YK6Z.N?E!VEV%O/Y`UVU]N;._N+TA
MLCOO=7;5+NKO7,;]Q^$KJOLW:NR*7&;?@H*/$5E5.XA..F3S'W7NF+Y;Q_#C
M^:9_++^`WSV[-Z)P/>?R"W+WU\+_`((=L]ETN[=VIF]MT0^5VW-C]\T.U<3M
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M]Y=B=M;Y[$K\E5]H;=V)L[<&`W?7;4PCXG;\L=#))3+-^XWNO=.G\OGIGL/J
MK"]>=;[I_DB=H8C?V_MW=Z],=H?S(J_,?&?87>.T^N>\>^.^:6OW]29:OW'N
M'Y/UN-VQUGG\.XR%5!0UE>))G6%::*BER/NO="A\-=B?S2=G_'G(?`K=OQUW
M-UKTK\7?A)\MOCQM+?\`*.FZ?"?-7<]%%2;,^)NZ]BU^U.R:?LSXW[TJME+-
M5Y(9:GR5%6S5<[U=11Y%8F]^Z]T5_=?\HWYD8OXV=>XK9?QLVOO?>O;O\K7X
M*].?)'KK<.\NBML5FV_D]\'?D5TYW93;$3<5;5YS;E?LGY`XR?<N/W:U!]UA
MJJIQ$62KQD*RHBBD]U[JZ[XVT?S(W+L'Y1;$[,_EM?'#X/TF[^L,[4[$;IWY
M!=?]G0=H]E9K:V2V=C,1O6FVITYU_1X^3`[>Q>+I9,Q705*/3B.".$PP:1[K
MW15-P_RG-U]W]'_R1/C?\E=BT^_^I?B+TSD=I_,7!0=V[KP/CW50?#REZSVN
MF`R^SLCMG=>[DI.X:>/[>KQM?0O0T<)L7I)I8G]U[H!>AOY._8NU>ZNF.OM_
M]*8\?$;9O:'\[W:]5B\SW'0=C38/X]?-V@Z9VWT?&K9''2[EW&V[-HX+.T#T
M>1E?*8>G)^^K*B5@9_=>Z.1%\)?F)O3X<?RD>I.P*'J^'M+X7_+OXS]G]R&K
M[2R&8I4Z5^.2=B;4V[4XC/X7JC!8[L'M.NZ_J\#)74AQN$QAS;U3PU1CABEE
M]U[J\_W[KW6O'F/Y8/RFJ_D\O7&&FZ:I?Y9]%_,#RO\`,GK\=G.TM]2]^[K[
MXKMG9+L7`]90==[?ZMQG4&,^+V!^6$M+G*[;]57U.7KEIOOA7&H=XC[KW5IW
M\N[H+?\`\6OA!\8_CSVI4[8K.R.H^J-O;.WM5[*SN>W)L^IW)CUF;*3[7R^Y
ML3@L[-@):F8M215%)`U+`5@5=$:D^Z]TZ?._I#M;Y%_$_M[J+HKL6NZF[HW)
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M,,J-P8CJY*6CVY0P_+K$_)VEZ<V/@X=ZTO\`=QJ;&X*#`19T5$H@\DU0N/,;
M+2K[KW3G\F?Y8?>?<_R:[:^0O2G\PSMCX?4_=/6O7'76^\!TMT_U7D-YYJGZ
MPVWVG@MM5$_;>]HLYN6@QU'5=I559%18ZGH!3U,?GCE6L6FK*3W7NK6^O]MY
M'9NP]D[0S&Y,AO++;5VCMO;>4W?EED7*[JR.#PU%C*W<F36:KKYER&<J:5JJ
M8-/,PDE-Y'/J/NO=*[W[KW7_T]_CW[KW5"OR`_FD?*[I_LCY6[TVO\>NC.P?
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M&Y-J[ESV`H=Z8/K_`&[/-65V'IZV')5%*6>E66:-(9/=>ZI@ZK^5'\RKM#O[
M9GPWV3\L^I:WLC8>^_F]BNS_`)$[\^&XJ=A]SU70@^,\>&VSM3IW:/:^T<]U
M#L?8^0[SK,6-PUV?R9W5E<5(U'++3^A?=>Z1>SODK_,U^4O9NS/CCTW\_NN>
MGMY]1=(?)#</R`[K@^$^)[9P'<-1TM\JL[T+B.Q^M>M\I5[>K=K[HR6$HS55
M.V8:[)T\=3311Q^5*J.>7W7NH?R*^;/\R7N[^7QUA\VOCUWAM3X=]-;`^".4
M^1G8W:N>V-T[V'NKY3?*+!9_([5@^(6$ZY[`6BR_0V4W)DMCN]/EL=1;BJ*_
M);MI\-0T;5F/'WGNO=;.VP]QUF\=C;,W=D,%7[6K]U;3V[N.NVSE(ZV')[=K
M,YAZ/)U."R,.2QV(R,5?B)JIJ>9:BDI9UDC(>&-KHONO=/68R(P^)RF6:BR.
M27%XZMR)QV(I&K\M7BBII:DT6,H497K,C5"+1#$"#)(RJ#S[]U[JC3^5S\R>
MZ-Q=+?S&^^/FO+OG8LO4_P`C^R.V!U/V)5S4FZOCOT/E^DNO^Y-G=35V`W=M
M'8.3VAD]I[+R@6KHZ^MK*23+-4U%+4)0SP._NO=</AW\F?D?0?RQ^^]X;9J-
MV_)G^8KUIM3=W>>[_C]V1D\_O3/[!W[\AMN?[,E\?N@:MJ'#]>1Y&FV]T7O[
M;*#!X*H58JCRT%/4I*5*^Z]TDOY@_P`D/FC-_)5Q^_\`=G66YNE_DEW%\>ZK
M-_(J78T&0Z\Q?QWQ%%UCG-_]IK4;NR_:U)G^CL[EL9A7P.`KJNLW'+C=PY*F
MI:RGE!EEC]U[HO\`_-![JV9B>U_Y9G6O?GSA^5WP-^)>_OB_V[OX]Q?%?=>Z
M=G[F[$[SVG#\>I-A[#W7N+";0[;:JP..V#E\]F'CK,6R1,OF^_1_5[]U[I7]
M$=V_S%J7X6?!K>'Q)JMQ?(/8M=\RNT>MLINO=>"H_D#NCMC^7]0=H[SPVP?D
M9V1VEOGN_8>ZYM\S[+V_%D!DJ1:.MR53DXT7;,4<24WOW7N@>_F[?'ONW&?(
MGY1?)'.]+_S&M]_'*;H7JZ5>Z?B=_,6I^A<;\<-L;-H<R/D?O':O1";KFK-R
MUE%L"AAR*X9]I9ZGS-=3US6\U=`8/=>Z-95?)78^WOYDW1*Y+MG?>-^,?Q1^
M-70GQQV#45&Z>P=R;K^1_P`E?YBU9@I^H*_M3$4@IOXG@M@=*]"UF9J<_O"/
M[:FR&:K*PO35$#%_=>Z__]3?X]^Z]UIV?.KLC=_7N%_G/_"?L+9O>>?[D^:7
MR=Z3W3\5JW9?1O9'8'1F_MA;]VA\==OTFP<9OBCZZW'USUAV1@<!UUG9MR5V
M:RE(L9@_B5#)#/!&/?NO=!GF-I[VVW\CY\M@NO/EQNK^:'_P[9AM[-68_:/S
M(I_@1A>L=U]KG9<>\-PY&'#1_%W$9/(?#6H.-RN7IEKIA+3OXY)FA)]^Z]U<
M/VM_(;^$.(ZP[%W=TAU9O')?*_;_`%-WA2]!=J=H_)[Y/;FJMN]I=@;([!Q^
M(R.1&1[#W3A%P<NY=[U$]12#`UU&K3R3+0R3$Z_=>Z*9\2J+=?S<[?\`AITE
MOSXO_+[K#HWXP_RS>[_BA\O-N?*OXU]H_&KKCM:L[2VQ\=^N8L;USN+)93)G
ML>JRE7UI65=-C9I*7^&8@ODX,@:U5@?W7NAA_EQ?RN/C'D-B?S&NN.SOAU'U
MO\>NR/F)3]1["^.6^:?L88+,],_"G(XR@Z:[BJ*_?.7KMW;LSO:/8$N8W(NX
M4RU=293!28NDBD-)3M"?=>Z$?Y6_&[KS^6UT3VG+_*O^`^]L3\A/EHNW>J]Q
M[E^)/7='D9-C[2V_59?*[E[(W)#D^U>N,3M;=>U]@;CW(VR\A3O.\^]9\7%5
MT]52JT7OW7NB8_'S;W<_QXWC\*^[>C?Y5GS*EZWZ`V!\Q?AO@^CM_P!5T?B_
MDUE]W]P[R^/_`')_LYO9.[:_M;:_3F(P?>PV-EDW'(TE&F/W=-6PTR-13TTK
M^Z]U'Z+ZH^='Q.[%Q?R\P?PN^0/=F,^3?4'SMH=X]%[0R?0>R/D!\8<KV=\W
M=T?([K.OW)EMZ=F8+:@W'F>K-[1XVNHMJUM5-F,IM^A>>`RT=,6]U[I"8WX]
M?S$.MNEOY>/QHRO\MK>'R-Z*^'G174V_=X=*;"[TZ$ZKZM[]^3NY,-DMUMB>
MZW[S[#W9B]X[)^/^[(I)JW&5^!DJLAV`]#N:@RE-#1QT-7[KW6VQMC(Y?+[:
MV]EMP8"7:F>R>#Q.1S>UYLC1Y>;;>7K:"GJ<E@)<MCB<?E)</6RO3M40?LSF
M/6GI8>_=>Z?/?NO=:_7QW^`'=79'9/\`-\ZC^:O0=+L?XZ?.3OW%=N[<[1Z?
M^4>1&X-];>P,6V=H[:VA0XK:&&VEV'U^8=M]:X_*YF>KKHXJR;,U&-2"6D60
MGW7ND_U7_*0[+^)F[_YFV[?A"Z=(;J["Z*Z@Z@^`>\L]W7V%V55;=Q.V^M<'
M7[\P&\,=VOD.U,)0R/VO@A#@]P9O%;ARN%I*R5:93C(H<=[]U[HPOR&^,GSM
M[N_E%;/^)&[Z7IONSY.]G=5;#ZK^5N0[5["R6W,!E\'D\.Z=MY[9_8>U>L<O
M3TG:%-4PP_P/*':T^/ILG:L-(Z1*K>Z]T,?;W0'S6[>_E:;C^.=%G?C7U?\`
M-3?'Q_\`]#M7N?;<&^ZCH+KT[JCIMF;U_N759+%9O?@DQ?4M96TN-JWHSKS:
MQ3-#%3'QI[KW22^4_P`)ODE-2_RU]C?`ON"NZ!ZA^'/:G5^/[5V.>Y]_;%PO
M8?Q<Z]H]DX-NKJ_!;:V-O,=HY:3;FT5HZ2/-5V,I(8IJGR2R/4ZX?=>Z9?YC
M_P`;_P":!\K,;VOT-\>^Z?B1U-\3^Y.J:+K#>,^ZMN]U#Y,P4^Y:\4G:F0V?
MO[:F:&Q=L2Y;9M348['"IPN7B4,YGC;S7A]U[H*_E%_(M^)G86>^/>]>B/CI
M\;-O[\V7\L?B[V=WINKM;;&2W57]E_'GI/&8K:F[NK:4ST.X8I*O-;.VQB$H
2\8R4."J*^@2>L!+3>;W7NO_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g912919g23c35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919g23c35.jpg
M_]C_X0;E17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP-#HR,B`P,#HQ-CHQ,0```Z`!
M``,````!__\``*`"``0````!````2Z`#``0````!````(P`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```6O`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`(P!+`P$B``(1
M`0,1`?_=``0`!?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`\SRLK*&3:!=9`>[\]WB?
M-0^V9@XOL[?GN[<=UH=+Z?A]2ZZ["R[;*66OL#'U!A.\$N:UWVBW&J:S^4ZU
M=7A_XMND9F57C5]0R`ZTD!VW$>!`+Y<S'ZA==^;^94DIX3[;F$0;[(F?INY\
M>4AFY@XOL$<>]W?YKJ.H?5[ZD=/S+L+(ZSF>K2XUNC#TEIA[P76MWUZ;5RGI
MM=?Z;'2POVM?'8F`[:DIG]NS1'ZQ;I$>]W;CNI?M'J'_`'*N_P"W'?\`DEUW
M6?J?]4NA9K>G]4ZUD5Y88VRUM>-ZC6APG;O;8L^KZI8N11TE]&58+.KYCL:L
M65;6BO=LJN#M_OW;DE.#^T>H?]R;O^W'?^22_:/4/^Y5W_;CO_)+8ZC]4LUW
MUDS>B]#INSOL;]A,`$0/<;'>VMON67=T?JE'4/V;;C6-S2[8*(EQ/\F/I)*1
M_M'J'_<J[_MQW_DE>^VYOV2?M-T_9=W\X[G[3L_>_=6GC_4K*QND]7S>MTVX
M=F#4QV,QP^D]Y[_F[=JQ?^T7_H)_[M)*?__0\U%_V?JAOTBNXN,L98(W>[]%
M>'TV?]<:O6OJO?A_;,?J%MC,>K8;:WW#I#`[<TM8T_86UY^-9MLW[?\`K5B\
MASFAN=D-'`M>!\G%`24^A_6:[ZX6T9]^3?TY^(\V`[3ANO\`1<7;&ML9^G<[
M9_UQ8_3<_P"KG5.J=/P:^DT]*W9-1LS!?8[]&W<;6/\`M#W5L]3]Y<HDDI[3
MZ[_77J.5UGJ6%2<9^&'.QV6"FFQQ8WV;V93JW6^[Z7LL72T7=)'U@^J_2?M=
M+</I6&[+9?ZK8]9X_F+3_-L<U]>__2+R9))3ZQT?J%?4_JYFWT,Q;<_J/5++
MLK'MRW8A:S3T[/7JLIR+*:/;^C_XQ&Z7UVK-^MO43=E83,[%Z<[%P\JI[C4;
MR[W.;=FP][ZW_H_^+_KKR%))3Z5U>S*P/\6V3@]4ZA7F]1R,L/#6WMN=6W=6
M32YPLLW?1LM_1_Z1<'K]CY_[2^'_`':5%7I/V2-/Z+'/_=F4E/\`_]'SC*]'
M[9D;O2GU7_3]6?I.Y]/VH7Z#?_@8C_AHF?\`/W*LDDILN]"6QZ/.L>M_TI_[
MZA_HO3/\WNG3^<W1Y?X-"224S.R=-ORW?Q3L]/>-VR.^[?'SV>Y#224G/HZ_
MS7TNWJ\:?]'_`*:=_H[/;Z.[^3ZL_P#3]BKI)*9>W^3_`-)6_P!']F_,GT/Y
M?/K_`.O_`)VJ222G_]G_[0^(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<
M`5H``QLE1QP"```"AL0`.$))300E```````0%O\:1<PIE@Q(A\\:]MO64#A"
M24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%`````%!S
M=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/<')I;G13
M:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``````#W!R
M:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T`'4`<```
M````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT:6Y0<F]O
M9@````EP<F]O9D--64L`.$))300[``````(M````$`````$``````!)P<FEN
M=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R8F]O;```
M````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```````3&)L
M<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT<F)O;VP`
M`````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D;W5B0&_@
M````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!OX```````
M`````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L=```````
M`````````%)S;'15;G1&(U!X;$!RP```````````"G9E8W1O<D1A=&%B;V]L
M`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N=$8C4FQT
M````````````````5&]P(%5N=$8C4FQT````````````````4V-L(%5N=$8C
M4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````#F-R;W!2
M96-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P`````````-
M8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N9P``````
M.$))30/M```````0`2P````!``(!+`````$``CA"24T$)@``````#@``````
M```````_@```.$))300-```````$````>#A"24T$&0``````!````!XX0DE-
M`_,```````D```````````$`.$))32<0```````*``$``````````CA"24T#
M]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R
M`````0!:````!@```````0`U`````0`M````!@```````3A"24T#^```````
M<```_____________________________P/H`````/__________________
M__________\#Z`````#_____________________________`^@`````____
M_________________________P/H```X0DE-!`````````(``#A"24T$`@``
M`````@``.$))300P```````!`0`X0DE-!"T```````8``0````(X0DE-!`@`
M`````!`````!```"0````D``````.$))300>```````$`````#A"24T$&@``
M```#R0````8``````````````",```!+````2@!2`$\`4P!%`%<`20!.`$0`
M(`!#`$\`4@!0`$\`4@!!`%0`20!/`$X`(``M`"``0P!/`"``+0`@`$,`90!R
M`'0`:0!F`&D`90!D`"``;P!R`"``4`!L`&$`:0!N`"``0P!O`'``:0!E`',`
M(``M`"``1`!O`&,`=0!M`&4`;@!T`"``4@!E`'0`<@!I`&4`=@`M`#8````!
M``````````````````````````$``````````````$L````C````````````
M``````````$`````````````````````````$`````$```````!N=6QL````
M`@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG
M``````````!,969T;&]N9P``````````0G1O;6QO;F<````C`````%)G:'1L
M;VYG````2P````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4`
M```2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&
M;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9```
M``!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J
M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO
M;F<``````````$)T;VUL;VYG````(P````!29VAT;&]N9P```$L````#=7)L
M5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`
M``````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$`
M```(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L
M:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%
M4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T`
M```115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG
M``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N
M9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"
M/_`````````X0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`
M````!<L````!````2P```",```#D```?+```!:\`&``!_]C_[0`,061O8F5?
M0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/
M%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!
M#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`",`2P,!(@`"$0$#$0'_W0`$``7_
MQ`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!````
M``````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@`,`P$``A$#$0`_`/,\K*RADV@760'N_/=XGS4/MF8.+[.WY[NW
M'=:'2^GX?4NNNPLNVREEK[`Q]083O!+FM=]HMQJFL_E.M75X?^+;I&9E5XU?
M4,@.M)`=MQ'@0"^7,Q^H77?F_F5)*>$^VYA$&^R)GZ;N?'E(9N8.+[!''O=W
M^:ZCJ'U>^I'3\R["R.LYGJTN-;HP]):8>\%UK=]>FU<IZ;77^FQTL+]K7QV)
M@.VI*9_;LT1^L6Z1'O=VX[J7[1ZA_P!RKO\`MQW_`))==UGZG_5+H6:WI_5.
MM9%>6&-LM;7C>HUH<)V[VV+/J^J6+D4=)?1E6"SJ^8[&K%E6UHKW;*K@[?[]
MVY)3@_M'J'_<F[_MQW_DDOVCU#_N5=_VX[_R2V.H_5+-=]9,WHO0Z;L[[&_8
M3`!$#W&QWMK;[EEW='ZI1U#]FVXUC<TNV"B)<3_)CZ22D?[1ZA_W*N_[<=_Y
M)7OMN;]DG[3=/V7=_..Y^T[/WOW5IX_U*RL;I/5\WK=-N'9@U,=C,</I/>>_
MYNW:L7_M%_Z"?^[22G__T/-1?]GZH;](KN+C+&6"-WN_17A]-G_7&KUKZKWX
M?VS'ZA;8S'JV&VM]PZ0P.W-+6-/V%M>?C6;;-^W_`*U8O(<YH;G9#1P+7@?)
MQ0$E/H?UFN^N%M&??DW].?B/-@.TX;K_`$7%VQK;&?IW.V?]<6/TW/\`JYU3
MJG3\&OI-/2MV34;,P7V._1MW&UC_`+0]U;/4_>7*))*>T^N_UUZCE=9ZEA4G
M&?AASL=E@IIL<6-]F]F4ZMUON^E[+%TM%W21]8/JOTG[72W#Z5ANRV7^JV/6
M>/YBT_S;'-?7O_TB\F224^L='ZA7U/ZN9M]#,6W/ZCU2R[*Q[<MV(6LT].SU
MZK*<BRFCV_H_^,1NE]=JS?K;U$W96$S.Q>G.Q</*J>XU&\N]SFW9L/>^M_Z/
M_B_ZZ\A224^E=7LRL#_%MDX/5.H5YO4<C+#PUM[;G5MW5DTN<++-WT;+?T?^
MD7!Z_8^?^TOA_P!VE15Z3]DC3^BQS_W9E)3_`/_1\XRO1^V9&[TI]5_T_5GZ
M3N?3]J%^@W_X&(_X:)G_`#]RK))*;+O0EL>CSK'K?]*?^^H?Z+TS_-[IT_G-
MT>7^#0DDE,SLG3;\MW\4[/3WC=LCONWQ\]GN0TDE)SZ.O\U]+MZO&G_1_P"F
MG?Z.SV^CN_D^K/\`T_8JZ22F7M_D_P#25O\`1_9OS)]#^7SZ_P#K_P"=JDDD
MI__9`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``
M(`!#`%,`-@````$`.$))300&```````'``@````!`0#_X0]V:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60]
M(E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`U
M+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@("`@("`@
M("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+R(@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM
M+R(@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&AO
M=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X
M;7`Z0W)E871E1&%T93TB,C`Q-2TP-"TR,50Q,#HT,CHS-B(@>&UP.D-R96%T
M;W)4;V]L/2)!<W!O<V4@3'1D+B(@>&UP.DUO9&EF>41A=&4](C(P,34M,#0M
M,C)4,#`Z,38Z,3$K,#4Z,S`B('AM<#I-971A9&%T841A=&4](C(P,34M,#0M
M,C)4,#`Z,38Z,3$K,#4Z,S`B('!D9CI0<F]D=6-E<CTB07-P;W-E+E!D9B!F
M;W(@+DY%5"`Y+C<N,"(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HQ-T9%
M.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T-"(@>&UP34TZ1&]C=6UE;G1)
M1#TB>&UP+F1I9#HQ-D9%.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T-"(@
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED.C$V1D4X-31#-39%
M.$4T,3%!.45"0D)$0D$P144Y,S0T(B!D8SIF;W)M870](FEM86=E+VIP96<B
M('!H;W1O<VAO<#I#;VQO<DUO9&4](C,B/B`\>&UP34TZ2&ES=&]R>3X@/')D
M9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS
M=&%N8V5)1#TB>&UP+FEI9#HQ-D9%.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%
M.3,T-"(@<W1%=G0Z=VAE;CTB,C`Q-2TP-"TR,E0P,#HQ-CHQ,2LP-3HS,"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN
M9&]W<RDB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I
M;VX](F1E<FEV960B('-T179T.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O:G!E
M9R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A
M;F-E240](GAM<"YI:60Z,3=&13@U-$,U-D4X130Q,4$Y14)"0D1"03!%13DS
M-#0B('-T179T.G=H96X](C(P,34M,#0M,C)4,#`Z,38Z,3$K,#4Z,S`B('-T
M179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(
M:7-T;W)Y/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N8V5)1#TB
M>&UP+FEI9#HQ-D9%.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T-"(@<W12
M968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HQ-D9%.#4T0S4V13A%-#$Q03E%0D)"
M1$)!,$5%.3,T-"(@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED
M.C$V1D4X-31#-39%.$4T,3%!.45"0D)$0D$P144Y,S0T(B\^(#PO<F1F.D1E
M<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_[@`.061O8F4`9$``
M```!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P/_P``1"``C`$L#`1$``A$!`Q$!_]T`!``*_\0!H@````8"`P$`````````
M````!P@&!00)`PH"`0`+`0``!@,!`0$````````````&!00#!P((`0D`"@L0
M``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2
M<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D
M@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9
MFJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$`
M`@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6
M,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58W
MA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'
MU^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`
M#`,!``(1`Q$`/P#1T[,[/[-I>Q^P:6#LCL%8*?>^[((E?>NYIF$<6>R"('EF
MRDDLK:5Y9V9F/))//OW7NDE'W)V]%K\7:O9$?DEI)Y/'OG<Z>2:@D\M!,^G*
M#5+12C5"QYC;E;'W[KW7*3N?N&6,0R]K]E20K639$12;ZW0\8R%0S/45P1LJ
M5%9.[DO+;6Q)))O[]U[KC%W)V]`T30]J]D0M!%50P-%OG<\;0PUVK[V*(IE`
M8XJS6?*HL)+G5>_OW7NLZ=W=SQ)!''V[V?''2K1I3(F_MUHE.N/9GH%@5<L%
MB6A9R80MA$2=-O?NO=.7^S#]_P#_`#_+N'_T9F]?_KW[]U[KC_LPG?NHO_IP
M[?UE0I;_`$E[TU%020I;^-7*@L2!_C[]U[KE_LP_?_\`S_+N'_T9F]?_`*]^
M_=>Z]_LP_?\`_P`_R[A_]&9O7_Z]^_=>Z-/_`*;.ZO\`1)][_IF[>^Z_V5?^
M-^7_`$G[YO\`Q3_9W?[O_>:?X]H\G\'_`&+6TV]5M7J]^Z]U_]#4'^+O074/
MR?\`G+F.CNY=^=@==8+?6[NS*+;N?ZZP75V;R\F\:+)Y+)XG&Y.3N3MGI/K[
M!8&KHJ.J,]?79^F6&1(T56,EU]U[K8,Z;_X3<?$;NOM'9756V_F+\@*++;UK
M\A1T^5_NQ_+ZWS18J+%X/*9^JK<GM_IW^8EV;V+44+4^*:#RX[!9#P331O,L
M=.)9H_=>Z(MW[_+X_DD?&_N/L;H[L?\`F6_,B+>G7.Z<EL7+OC/@0\F&&9P&
M6JL?G]SXVNRG:6(GW%LNAJ<=4T2RTT$;U%1$:BF>HIM)?W7NJ`$P.+R6^EVQ
M@<Q)686OW8N!PV?FQ]2DM5BZK,#'X[,2XI5^\22>DD29J<#R`G1;5[]U[K9;
M^8_\G[^4K_+[[HQ/QM^6O\S3Y#[.[MI=I;2WKOC#['^'L'8VUMOX[=6-CK*/
M$Q[BQ/9%+*^0J?#++%*M-/IIY8C)"IY?W7NBB;4_E,=7=E[%_EZYG87>_9-'
MNKY_?,K=?QXVI2[[Z<@V[MG`]8P;HHL!LCLR@RJ;NFFW%D<[39*EEEI2M)$:
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MW7__T=(.DWS_`*-/E%4;^*4$D.U.Z<MF*Q,EL78/9E(<=3;NK/XE?8':6'S_
M`%WNRH6@:0PT>9HYZ"68)Y5`&H>Z]U]#_P#E@;XZ?D[BZ9^1^Z]X[2ZLV@VR
M:WL79>XNU,+_`,)X=@T&\8]W[%R.*VY@LA5_%+:^S/EATQO!L9N]<G+11E)H
M/MIL9D71)*F%O=>ZI@_F:;R_F^;JV5\K]_\`9_;'\MO.='[ARG:E).FV\[_+
M;W5W\.C,]F\^-O8?"[OVO25O;.3S1VK50Q4OVU4<RTPC9)#5V]^Z]U7-\<>]
M/Y=7RX^3GP^Z"VQ_+]Z7^#,>1^3W2>4WA\CZ3Y*=R;@D/76UJK-5G8&W=SKW
M)NW,[*V_3;RIQ1^.NC6.6BJJ?TR%90J>Z]T-?\[;^=+\B^U_F7\U>B=EUWQG
MW-T'2[AW7T!MS==%\?\`X\=D;HSW7^U_N]L0Y[;?>F6V%G=_0/E#YJRCJ:#,
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M!^2?RF[=^6N`W7#@MM_)G:_>^>ZEP,N[M@9#)=<Y7+X[L#>"9D.,-E<VJ8<R
M4$"9IO,T<T#*_NO=:E^J?_0_;[J#Q_[*=I\7VDGD\'^SSZ_M?-KT^?[G]_RV
MT^+]JVKGW[KW7__2T4N\Z*#&=V=PXVE\GVV/[3[!HJ?S/Y)?!2;MR\$/EDLN
MN3QQC4;"YY]^Z]T%GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ-3]U4_Z)/%:E\7^RK?:_P#%S;R_;?[.[]Y?[7PV^Z^\_P"475;P?Y1JOZ/?
MNO=?_]/2Q[3_`+G_`.F+N#^*_P"BW[K_`$G]A>7^^7^G7^-^7^_&X=7\1_N7
M_N(_B/BT^3P_L:=-OW/)[]U[H.A_<3^,M_S)+['^$+:_^S'?P;[S[UKZ;?[^
M'^+^#ZW_`,@\%K?O7]^Z]UW6_P!Q/N,9X/\`0CX_NG^[^R_V8_[?Q:8]/\3_
M`(C_`)7]K>^G[+]^][\:??NO=)<?W9_NY77_`-'/\3_B:_;W_P!+?]X_M/1?
M['3_`+]+^&?6_P!S_EOUM^/?NO=,57_"?.?#_=;Q^."WVG]]O!J\$7DM]_\`
MY3Y/)?R7]'DU:/1I]^Z]U+PO\#_BM!]]_<O[3[A?N/XU_I$_A7CYO]__`'=_
MW.?;_P!?MOW?Z>_=>Z4=1_=#74^/_11;^.OXOM_].6C^'_[CM/VWW?[G\"_S
MNGS?[D_\]?\`W1[]U[J3FO[E_P`#?['_`$/_`'_DAM_!?]/O\<T^=]>C^\7^
M_;\?CMKU>K1;1Z[^_=>Z#_\`W'?]F_\`^O5[]U[H?O\`<#_H[_YA+S_Z`/\`
;OY/G^]_V:7_SW?>_P[_J@^W_`.FWW[KW7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g912919g75a85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919g75a85.jpg
M_]C_X0I"17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP-#HR,B`P-3HP,SHR-P```Z`!
M``,````!__\``*`"``0````!````S:`#``0````!````-``````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```D,`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`*0"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I!S,O'PL6[,RG
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M6O;[458'U+I:WH[\QEU=K.IY-V:RNAYLII%SOZ+0\MK_`)K;^F_1U_K7VCV+
M?24PNNJHJ?=<]M5532^RQY#6M:T;GO>]WM:QK57Z7U3!ZM@UY_3[/6Q;I].S
M:YL[26'V6M98WZ/YS5S'7.H])S_K&_I77<NK"Z1TNNK(?BY+V5-S<BR;:=+'
M?K>!A,9[J?YNW-_GO6]!:G3OKC]6\[(MJP[B*VTNS+<I];J:#6U_V9]OVC(;
M4Q_Z1CF>I_-_H;/TGZ))3H=:ZOC=&Z;=U')#G,J`#:V"7V/<17314W\ZRVQS
M6*ZTDM!(+21):8D>1V[FKE;NHX.395]9>N/&#T;")/2J<C<UUMK@?\I/Q?IN
MM]+>SIN-Z5F1Z3[<G^=N_0H_6K-IZ[C/ZI6.C]`R<>T8UN8`Q]F0TUO:W*<X
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M``:ESB5PF%E])=U6SKW5;MF%=E'(Z'C/#SDY5EC*,&OJ#>G5&RV^NFNO[/TC
M]5]7[/=;F65_I:[4;`^KE77GF\Y'43]7K2]S&96;DEV6QX#:VMH=:WT.F,]U
ME+K_`-<S/I_T;9ZW4]-Z'TCI0/[/Q:Z'O`:^T";'AOT1;D/W7V[?^$L24YHM
M^LO6FM]%AZ!@/@FRT-LSWM.Q_P"BI_2XG3_;ZE?ZQ]JR/^Z]"P*/JWU.GZPW
M9.!TS])B.:W%ZCU*[U&OL-;6974<E[;+>HYUWIN]#!Q?U?`Q_P!/=^@ROT=7
M?I)*>>^P?7?&!^S]5P\[>03]LQ75[-/>VIV#=5^CW_09<RRS_A[%*K'^O%E]
M3,O+Z=5B[@Z]^+3:+X:6N]*G[5;?1^G]U5MCV?HF?S7Z3^;WTDE-'J_3'=4Q
M!C#,RL"'AYNPWBNPP#^C]1[+?T;MRS6_4CH[V5LS[<SJ;:SNVYV5=>QQ[>I0
M]_V=VWZ7\RN@224YS,#J%'4J[<;+`Z86;;.GOK;#-K6UT_8;:A4^GZ/Z5E_V
MFO\`T7I+12224@MP<*Z^O)NQZK,BC^9N>QKGLG_1V.&]G]E9MOU3Z-?UBWK&
M36_(OM](FFU[G4!]+7UTV_9)]%UC&6NV>JVSTG_IJ?2N]2Q;*22D5F+BVWU9
M%M+'WX^[T+7-!?7O&RSTGD;J_49['[%-[&/:6O:'-/+7"1^*DDDIYCZT?6$X
M.37TJG)'3W>G7<^YC6VY%C7V.HIZ?T;!=O\`M.=D/J]-]CZ;*<*OTOT5GK?H
M2_53ZL8?3L.O,RL*MO5\AUE]]UA]:]AN>^YN._-MW76OQZGUT66;_P!-97ZJ
MZ`L87AY:"]H(:Z-0#&X`_P`K:I)*8LKKK;MK:&-DNAH`$N)>]VG[[W;G*222
M2G__T>GZ+USI&!TK]LYMK7=1Z\]V8W&IB[)M:X^G@8=%%/Z6W[+BMHQ?]'5=
MZOJ[/TJN#I?4/K"66]?K&-TUEGJ4]&!#C9L@T6=7N:75W>\>M^SZ?U;^;^TV
M9?\`@^3_`,7O_P"43ZT_\;D?^W+EZ<DI22222E))))*4DDDDI22222E))))*
M4DDDDI22222E))))*4DDDDI__]G_[1*H4&AO=&]S:&]P(#,N,``X0DE-!`0`
M``````\<`5H``QLE1QP"```"AL0`.$))300E```````0%O\:1<PIE@Q(A\\:
M]MO64#A"24T$.@``````Y0```!`````!```````+<')I;G1/=71P=70````%
M`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L<FT````/
M<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4`````0``
M````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@`%,`90!T
M`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````#&)U:6QT
M:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$`````$`````
M`!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L``````!#;&)R
M8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#8F]O;```
M````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```````26YT
M<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#`````%)D("!D
M;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@9&]U8D!O
MX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5;G1&(U)L
M=````````````````%)S;'15;G1&(U!X;$!RP```````````"G9E8W1O<D1A
M=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````3&5F=%5N
M=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````````4V-L
M(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O;VP`````
M#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T;&]N9P``
M```````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T5&]P;&]N
M9P``````.$))30/M```````0`2P````!``(!+`````$``CA"24T$)@``````
M#@`````````````_@```.$))300-```````$````>#A"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#R0````8`
M`````````````#0```#-````2@!2`$\`4P!%`%<`20!.`$0`(`!#`$\`4@!0
M`$\`4@!!`%0`20!/`$X`(``M`"``0P!/`"``+0`@`$,`90!R`'0`:0!F`&D`
M90!D`"``;P!R`"``4`!L`&$`:0!N`"``0P!O`'``:0!E`',`(``M`"``1`!O
M`&,`=0!M`&4`;@!T`"``4@!E`'0`<@!I`&4`=@`M`#4````!````````````
M``````````````$``````````````,T````T``````````````````````$`
M````````````````````````$`````$```````!N=6QL`````@````9B;W5N
M9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG``````````!,
M969T;&]N9P``````````0G1O;6QO;F<````T`````%)G:'1L;VYG````S0``
M``9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````!W-L
M:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU
M;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E96YU
M;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`````
M``!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````````
M`$)T;VUL;VYG````-`````!29VAT;&]N9P```,T````#=7)L5$585`````$`
M``````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A;'14
M86=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E
M>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L
M:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T
M06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E
M0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG``````````IL
M969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P`````````+
M<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"/_`````````X
M0DE-!!$```````$!`#A"24T$%```````!`````(X0DE-!`P`````"2@````!
M````H````"D```'@``!,X```"0P`&``!_]C_[0`,061O8F5?0TT``?_N``Y!
M9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1
M#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.
M$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#/_``!$(`"D`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!
M`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$
M!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21
MH;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7R
MLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'
MU^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!
M4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3
M=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,
M`P$``A$#$0`_`/54DDDE*0<S+Q\+%NS,IXJQ\=CK+;#)#6M&YSO;[D9<I]:N
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MW1NFW=1R0YS*@`VM@E]CW$5TT5-_.LML<UBNM)+02"TD26F)'D=NYJY6[J.#
MDV5?67KCQ@]&PB3TJG(W-=;:X'_*3\7Z;K?2WLZ;C>E9D>D^W)_G;OT*/UJS
M:>NXS^J5CH_0,G'M&-;F`,?9D--;VMRG..SIS_1;<[&HN?\`IF>IZGZQ^@QT
MIZM)>=U?6C-_YS/S'YN1;TYN3;4UV-2_(Z?9BBMGV;&Q/LM%MEW5[,BS=?D_
M:*ZJ/1NJ_34^E5;TN%]=NAWXF5F95AZ93BY#\6,V*;'OK97=9Z>.\^MO_2_S
M.SUOY"2G?7`WNN^N'46M#['X#['?8V5/].NG%I?Z5O6\AS'[LC.S\FB[%Z)4
M]NS&8RS/]*STKEH9O5L/ZU>CC=!9;FBMPL/40^_&Q<=Q8'[[+L=^+DY.977:
MS]1H=_A_UJW%4_JUT+J?U<O=TO%QV78+[!99U:ZTNL?2UOITXK\;Z3<K&8VK
M'J=5Z>%]FK]7]'=^@24__]#U5)9G4NIY%>0SIO3:VW]1M9ZA]0Q5143Z?VK*
MVP][?4]M.-7^ERMEG\U75?D4TA]7&UU69G6>LYV18UFZ^X9+\*A@8)L?7CX#
M\:JFK;]/UGW?\:DIWGO96QSWN#&,!<YSC``&I<XE<)A9?27=5LZ]U6[9A791
MR.AXSP\Y.598RC!KZ@WIU1LMOKIKK^S](_5?5^SW6YEE?Z6NU&P/JY5UYYO.
M1U$_5ZTO<QF5FY)=EL>`VMK:'6M]#IC/=92Z_P#7,SZ?]&V>MU/3>A](Z4#^
MS\6NA[P&OM`FQX;]$6Y#]U]NW_A+$E.:+?K+UIK?18>@8#X)LM#;,][3L?\`
MHJ?TN)T_V^I7^L?:LC_NO0L"CZM]3I^L-V3@=,_28CFMQ>H]2N]1K[#6UF5U
M')>VRWJ.==Z;O0P<7]7P,?\`3W?H,K]'5WZ22GGOL'UWQ@?L_5</.WD$_;,5
MU>S3WMJ=@W5?H]_T&7,LL_X>Q2JQ_KQ9?4S+R^G58NX.O?BTVB^&EKO2I^U6
MWT?I_=5;8]GZ)G\U^D_F]]))31ZOTQW5,08PS,K`AX>;L-XKL,`_H_4>RW]&
M[<LUOU(Z.]E;,^W,ZFVL[MN=E77L<>WJ4/?]G=M^E_,KH$DE.<S`ZA1U*NW&
MRP.F%FVSI[ZVPS:UM=/V&VH5/I^C^E9?]IK_`-%Z2T4DDE(+<'"NOKR;L>JS
M(H_F;GL:Y[)_T=CAO9_96;;]4^C7]8MZQDUOR+[?2)IM>YU`?2U]=-OV2?1=
M8QEKMGJML])_Z:GTKO4L6RDDI%9BXMM]61;2Q]^/N]"US07U[QLL])Y&ZOU&
M>Q^Q3>QCVEKVAS3RUPD?BI))*>8^M'UA.#DU]*IR1T]WIUW/N8UMN18U]CJ*
M>G]&P7;_`+3G9#ZO3?8^FRG"K]+]%9ZWZ$OU4^K&'T[#KS,K"K;U?(=9??=8
M?6O8;GON;COS;=UUK\>I]=%EF_\`365^JN@+&%X>6@O:"&NC4`QN`/\`*VJ2
M2F+*ZZV[:VAC9+H:`!+B7O=I^^]VYRDDDDI__]'I^B]<Z1@=*_;.;:UW4>O/
M=F-QJ8NR;6N/IX&'113^EM^RXK:,7_1U7>KZNS]*K@Z7U#ZPEEO7ZQC=-99Z
ME/1@0XV;(-%G5[FEU=WO'K?L^G]6_F_M-F7_`(/D_P#%[_\`E$^M/_&Y'_MR
MY>G)*4DDDDI22222E))))*4DDDDI22222E))))*4DDDDI22222E))))*?__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P`V`````0`X0DE-!`8```````<`"`````$!`/_A#<YH='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC
M,#$Q(#8V+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@
M/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R
M+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O
M(B!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM
M;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X
M;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E
M+U)E<V]U<F-E179E;G0C(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UP.D-R96%T941A=&4](C(P,34M
M,#0M,C%4,3`Z-#(Z,S8B('AM<#I#<F5A=&]R5&]O;#TB07-P;W-E($QT9"XB
M('AM<#I-;V1I9GE$871E/2(R,#$U+3`T+3(R5#`U.C`S.C(W*S`U.C,P(B!X
M;7`Z365T861A=&%$871E/2(R,#$U+3`T+3(R5#`U.C`S.C(W*S`U.C,P(B!P
M9&8Z4')O9'5C97(](D%S<&]S92Y09&8@9F]R("Y.150@.2XW+C`B('AM<$U-
M.D1O8W5M96YT240](GAM<"YD:60Z,3A&13@U-$,U-D4X130Q,4$Y14)"0D1"
M03!%13DS-#0B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z,3A&13@U-$,U
M-D4X130Q,4$Y14)"0D1"03!%13DS-#0B('AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#TB>&UP+F1I9#HQ.$9%.#4T0S4V13A%-#$Q03E%0D)"1$)!,$5%.3,T
M-"(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!P:&]T;W-H;W`Z0V]L;W)-;V1E
M/2(S(CX@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T
M.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]J<&5G(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#HQ.$9%.#4T0S4V13A%-#$Q03E%0D)"1$)!
M,$5%.3,T-"(@<W1%=G0Z=VAE;CTB,C`Q-2TP-"TR,E0P-3HP,SHR-RLP-3HS
M,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H
M5VEN9&]W<RDB('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM
M<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(O/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\
M+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@
M96YD/2)W(C\^_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`-`#-`P$1``(1`0,1`?_=
M``0`&O_$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!
M````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042
M!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"
M\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA9
M6F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4
MU=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%
M,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F
M-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E
M]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FI
MN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]UJ3?S)_FSW_`/)OY5_&OK?XD=M;LZ^Z(ZF_F;_%OXTX+(=9
MU2T&<^8GR=V_O*?>ORPP%7F\?N"FW)3_`!>^''2F&FI-TS_PV3";AW;G#2O+
M5Q8EA'[KW6VS[]U[KWOW7NO>_=>Z][]U[KWOW7NH>0R%!B:"NRN4K:7&XS&4
M=3D,CD:ZHBI*&@H**%ZFLK:RJG>."FI:6GC9Y)'8(B*22`/?NO=%5Z.^?7P=
M^3.X!M'X\_,#XS]V;P9*R9-G]8]W=<[SW=)3XZG-775<6UL%N*MSTM%24H,D
MDZTYB5%+%K`V]U[HVWOW7NO>_=>Z][]U[IGSFX<!MB@&5W+G,/M[&&MQV-&1
MSF3HL30'(9BOI\5B:`5E?/3TYK<IDZR*FIHM6N>>5(T#.R@^Z]T\>_=>ZX2R
MQPQR332)##"CRRRRNL<<4<:EWDD=R%1$4$DD@`#W[KW1??BW\J>B/FCTMMOY
M#?&S?479'4.[LENS$;>W=#A-Q;?AR5?LC=>9V3N2.'';IQ.%R_@HMQX"JACG
M,`@JHT6:!Y(9(Y&]U[HPOOW7NO>_=>Z][]U[KWOW7NJI?YH/R[[JZ=HN@_B?
M\.!MVH^<WSEW[E.L^D<MNG&'/[8Z3V%M?%)G>[OD_O+`!)(LMM[I?:51'-34
MDZ2PUF8K:-'IZR%)Z27W7NM9_%?"[I>FFWY\YZCNSYKTWQYS?=W4WQUQ/\TS
M'?)/L(]V9KM7:]#W33;B_FP[PDJ,B>N!\3-L=K;OQ?2FV\921+MD]?9?.;CJ
MY6IQ19!?=>Z__]#?X]^Z]U[W[KW7O?NO=>]^Z]U5;_-![W[9Q.%Z+^$WQ:W9
M/LOY9_/K?^2ZKV5V#C8&JLK\?^B-H8I-T?*+Y0TE.U3BZ.7*=3=;R+1X"*3(
M4,T^[L_B!`TCJT9]U[H@7\O7X_\`5/;_`,^*7>G0>U5V[\`_Y-?7.^?@M\,H
M(L@M?C]\?*K?R0'YB=R8O*^2JK=TK@]N3TNU*S+5$SKE<U5Y.I5Y9C4>/W7N
MMD_W[KW7O?NO=>]^Z]U[W[KW7O?NO=1JRCI,C256/R%+35U!74T]'6T59!%5
M4E9254305-+54TZO#44U1"[(Z.I5U)!!!]^Z]U4E\QOY5O\`*CW'TSN'?7:O
M1/2'Q6HNF-LU^\\%\H^CL1MWXO\`9_QZ_NCC:NLQ/8&UNV>L:3:62Q/]PZ@"
MOHZ.N>MP[5,*>6BG!\;>Z]TO_P"3=W'\@._OY:7Q2[8^3?\`$ZWMC=.Q\J*C
M=F=PU5MS</9NQL)O'<FW^J.X=P[=JWFEPV<[?ZNQ6'W)4QB65)9,F9T*+*(H
M_=>ZLW]^Z]TA^S>RMA]-==;Y[;[1W1B]E=;]:;3S^^=];NS4CQ8K;>T]KXRI
MS.=S-<T4<T[04&.I))"D:22R:=**SD*?=>ZUP>D?C-W/_/'WI%\WOG%6]C=1
M_`:AJDW3_+:^&V"W!3[8SV5IY<9+!M#YN=]OCJ&7^+;ZR*RPYS9&$R+5]!B4
ME!>":ADE?-^Z]ULS8F@?%XK&8Q\AD,L^.Q]'0/E<M+#/E<F]'31T[9#)S4]/
M24\V0K#'Y)FCBC1I&)5%%@/=>ZIB_F,]L;A^6W9.-_E"_%_?V6P?8'<6$_BW
MSR[CZ]^SR&1^(/P\KJ-9\]AJ[,5-)D\)MCOCY28^8[9V;CZF&IK:7%5M;G):
M:.FAI*B;W7NA^[K[_P#@E_)"^#6SEWAD*'J7X_=(;3Q/7/4?6>"JJ/,=C]@Y
M#'0`4>T>OL'G,SCLGV)V'G9GFR&1J)JD.[O59'(U,40J*E?=>Z$[YC_.G8GP
M_P#B1/\`*O+[)WOOS^.-UE@.J^H\50KMGL+LGLONG.8+;'6'72TFZ5HEVEEL
MMGMQTZY%Z]`^*IHJF1X9)81`_NO=!'\!?G_V;\I>R_D=\<_D;\6JCXG?)WXO
M4G4N>['Z\P_=FQ/D;L=MJ]X8O<^8Z_JJ/L_KVBQ5%C-UM0[3J7K\%E*"AKH8
M)::J@^YI9Q*GNO=6=))'*H>-TD0E@'1@ZDHQ1@&4D75U(/\`0BWOW7N@S[GG
M[&INKMZ2=2YC8VVNP3AIH]N[L[,2MJ=A;,FE>..LWKNC&8^HH*S/XO:&.:;(
MMC$K,:,HU,*5J^@29JR#W7NM%K)]F?*KYX_S*]D[B[X[R^'.'^-?R'ZVS?\`
M+@P7SAZ*H/DQL?XT=PX;KON"K[?[^^-'QSW1NW?F(R$';'R7P4])@*W=F/SP
MP>>QV#R6WMK;AJJ]*EO?NO=;@W^GC^7D>IS\>/[_`'QV_P!!R]F+_+=/6'^_
M='47^E!NM60?$<8<P?W-;)#KE#CSMT$PB.V.*B<BG/NO=?_1W^/?NO=>]^Z]
MU[W[KW7O?NO=:@W9O?/>O=/S4^0^\_CY#4M\Q?F3O;L?^6S_`"X\S48_^+8_
MX;_";XC[MK=I_.?^8)N&LH))\718+=GR/DR<.!BKX:#(YK);=PU!2RUT<4D'
MOW7NMFGXA?%CJCX3?&OJ#XM=)XJ3%]<]/;2IMN8EZHH^5S^3GJ*G+[JWGN&>
M)4BJMT;YW7DJW,9.5%2.2OKI61$0JB^Z]T0+O?\`G.]#[;W-O+J/X<[#WO\`
MS!N]MD>6DWKC?C])20_&_I+(+2U]6:OY1?,K+05'0_1&VL9%B*W^*S25N7RF
M*:CE2HQHD`0^Z]TU?RSOYDO;'?\`\1.Z_E[\^<9\:_C3TYL_O7L+:W4O>6U^
MPLU@.B>S^C]N9NAVMM_MC&[F[B;`Y!MJYS=SU&.Q.<K$Q"[ET)/!BZ)9(4F]
MU[JV3K/M;J_NG9V([#Z>['V)VML'<%.*K!;VZWW;@-[[2S-,7>/SXO<6VJ_)
MXBNB$D;*3%,P#*0>01[]U[I59;.87`XW)YG.Y?%X7#X3&U^9S.5RV0I,=C<1
MB,7!)59/*Y.NK)8:6@QN.IHFDGGE=(H8U+.P`)]^Z]TT;%WULWL[9>U>QNN]
MSX/>VPM\[?Q.[-F;QVSD:;,;<W3MC/44.2PFX<!EZ*2:BRN&S&.J(ZBFJ87>
M&>&171BK`GW7NJ<-Z_\`"A;^63MGLS?/36U-_=W]W=I]:[SW;U[OG9?1?Q6^
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M%B?W7NB+;<Z>_P"%!7<VWEP/9'RE_EW_```Q-#3XC&8N;XD_'??WR9WR*'')
MXL@T!^1.[=M];;4AJQ2)%04\6+S"TM'/=R9H@K>Z]U4__+4^1?\`-9[3P/R:
MZ[^-DWS'[9[`[S[]WIB<3\H/YEF,R-%T=_+\Z,ZVW;NCKK&'&4<.U=B[?^17
MRNW9CJ.7,UVS]A8^#9V'K*S"_P`3J76ERT#^Z]U>[MKXA=P?`+XIKUA_+JVC
ML+N+Y(]I]I4>=[T^17RUWYG#N'>&\]]S5<_9GRK[EJL%C)=S]V[HQ58(S!M6
MGRF!#4<BPTM;$E,(*CW7N@&W/_(FZJ^075G<\?SM^0O;/S(^5W=FQO[DM\K=
MV8G:^R9>@*.@S&%W#MV#X?=(X:'*=<?'+$8S<.U\=D:P4/W^7S-:E2]=DIHZ
MMXE]U[H+^UOY=W\X;Y;]1UGQ/^8?S?\`A#N;X_Y@;<I-U=M]?_$#<\'R@W"N
MU,S092AWMMR#-]C4_3O4W;U3)1BJHL]AL;*NW,FD5304S&,*?=>Z*]VA_+GZ
MM_E@[(W;B]T_SL?YA/6?6_=&_P#M/N2DZAZS;J'(?-KY,=NY/!4%9O;<$/:F
MP^B-X?(SN_=<=+0TTV:RD>&K(\/0!:F>3'P1M4CW7ND5_)7P?\Y^G_EO?$?K
M7X^==?'?H[KC=N(W-W?O7Y=?-7L+=_R"[([2HOD+OO>?:_\`>;I?X^=2;FQ`
MPSP4F[**I$F]-U8Y\O)--4RTD,\[N_NO='JVK_*0^:GR>D_N5_-__F!Y'Y6_
M'7K_`#LM/L?X^_'S:LGQLV7\A<;25PR>.WY\QJO:*XW<FZLC/-.L2[(Q-?\`
MW;QK8REJDKJJ6:IC/NO=7.]@?%GXV=K=)4OQK[(Z'ZEWI\?L?B-OX+%],[@V
M%MO(=;X;$;22FCVI18/:,N/.&PD6UTHX?X::2*%J'Q(8"A46]U[IA_V3#XC_
M`.R\_P"RE?[+/T7_`++#X/!_H!_T7[._T2W_`(]_>O[O^XO\(_N__%/[U_[E
MOO/!]W_%/\L\GW/[OOW7NO_2W^/?NO=1JVMH\;25.0R-72T%!1P25-96UL\5
M+24E/"I>6HJ:F=XX8((D!+.S!5`N3[]U[I&T/:7664K8L;C.Q=B9'(S:_#CZ
M'=VWZNME\<9ED\5+3Y"2>3QQ`LUE-E%SQ[]U[HFWS^_F1_'/^7UT'E>Y>R=W
M;6SNX<GD:39G4'5M'OC:N"SW;?:F>_R?:VRZ#,9NOBPVU\1-62)-F,]D&3&8
M#%)-6U3:(PDGNO=:_?\`+0^2G4O3>2^1V^/BC\>]W_S1OYE?R,[1[`W/\E=V
M?#G;<>S?@M\=<]N#=67[(PGQ<VK\Q.X&VWTUMCIO`9?=M;E'R6V9MUU^[L[5
MUN7GCK":5:?W7NK6<G_+M^5WSD2LF_FG_)I&Z4SD,T=3_+T^$N5WEU'\?:S'
MR+GZ`8GO;Y#BHP'R0^1D%?A\I22UV-AJ-F;8_BE"DB8R6,>KW7NEW\__`.65
MD^_O@;5?!7X3[YZ_^$NP=QYSKO;F\<3MGKZL;8%=T7AMQOFNP=@8_9>Q\_L?
M[2LWT1!_%IXJJGFW#003XJNJ$I<C43)[KW3;TS_)FZ$QF[]D=P_,;>>Z/GOW
MAUS3XFDZUK.Y<-M_:/QMZ-QF!P,>V,)MWX[?"_KZ'%?'CJ[;V&Q%+`:1ZK%Y
MW-T];%]TF2$QU#W7NFG?'_">_P#D_P"^]Y3;^E^&^`V'N6IKJG)54_279_=_
M0.-GKZB85`J3@.D^R]@X&!J2?4U.(::-(#(^@*&(]^Z]T'<7_":?^3A0YS";
M@Q'QBW-CJS&[IHMR9JEJOD5\D-VX;?U'25\.6EV7V'@=_P#:^[<-NO8F5R]'
M355=CIH`M9)3(LKM$TL<GNO=7J8_'T&)H*'%8JAH\9B\91TV/QN-Q]-#14&/
MH**%*:CH:&CIDCIZ2CI*>-8XHHU5(T4*H``'OW7NLL%+34OF--304YJ9WJ:@
MP0QQ>>IEMY*B;QJOEGDTC4[78VY/OW7NL_OW7NBP;]^%_P`7.S_DAU)\O=^=
M-;6W'\D^BL'E=M=4=N54F7@W+M'!9E<NE;C((Z')TN)R=.HW!7_;_?4U4U(:
MZH,!C,\I;W7NC/\`OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K%.9EAF:FCBE
MJ%BD,$4\ST\,LP0F*.:>."I>")WL&=8Y"H-PK6L?=>ZU#=D?%3Y=?-396^^O
ML[\4^Z.B/EA\I3ENN_YE_P#,N^4%'M/;64ZTZ:J=TK-OSXE?RW=J-N_L+=N8
MZRSFR<K6[8P.0QV.PNQY<)&V3R5=D\[5ZX/=>ZVS-B;'VGUCL?9O6VPL'1;8
MV-U[M3;NQ]E[:QJ-'CMO;3VGB*/`[=P>/1WD=*+$X>@AIX@68B.,7)]^Z]TJ
M_?NO=>]^Z]U[W[KW7__3W'_FK\S<;\3MN[#V[M#KO,_('Y1]_9[-;&^*_P`7
M-H9["[:W=W;OK`X"HW-N&6KW1N`G!==]6=>;=ISE-W;NR2MCMOXS22E165-#
M15?NO=$JQG\HA?E!)%V+_-K[KWC\U=\96LQ6Y:?XU;>W/O3J?X#=(Y6CJJG+
MX[;O7/0^T,]A:CMJHVG+DYL9_>KL.JSF3SM'!#/+1T+DP+[KW0._-WX"?R1O
MCQL?;>R\Y_+.^.?:'=W>^3JMF?'+XT]*=5[5VUWUWUOC#04^6K<?LO+[=;;N
M6V5LK:-(T-=O#>5=7X_;FU,*S5.6K(XI(HI_=>ZQ_P`O;^0Y\7NI<QN[Y+_+
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M<R$>7&]>_"GH;LS-[$I,CM2.HC2JHLC\E^UMF9+?&<J6`>MHFPE.+T^/IRWN
MO=+/Y)?S.<1MWM[+_#KX0]:3_-SYST%)33[GZOV9N.@P'3_QOQM?55-&N\_E
MOWE4)5[7ZHQF.%'/,FVZ<9'>F6:.&GI<6OWM-4'W7NA"^%?P1/0>[>Q?D_\`
M(+>E#\@OGM\@:+'4O=7?CX7^$[?VAL_'-#4[?^.GQOVQ5O55/5WQSV)41*U/
M0^:7+;DR*?Q;.5-76&G2C]U[JQ3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__54GQH_P"'0/\`0-TG]C_L
M]7_#"WW>;_T$?[)?_H-_X<$_V5[^]^XO]#W^F3_1)_SD!]A]A_#OXE_H_P#]
MS7\!\_\`$_W?)[]U[K:^_E<?\-V?[*AMO_ALG_1I_LOO\7J_XQ_<;[W^]_\`
MI*_A>'_O'_IX_O/_`,9/_P!.'\,^P_B_]\/]_']O]KYOV/M_?NO=6+>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
)]U[KWOW7NO_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g912919img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919img001.jpg
M_]C_X``02D9)1@`!`0$"6`)8``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`!I`L8#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4Z:74=2!VZTI;!Q7RQ^V1\>]6^'L5CX2\"7$ECK&IPFXN[]%!>UM
MR2H$9/1V.>>P%;8>A.O45.&[,,3B84*;J3V1]-W>M:?8.$O[^SMG/19IU0_D
M34UM?6UZFZSN()U]8I`P_2OS'^%'PFU[XO\`B06RW4UW+CS;O4;]VF%NN>68
MG))/85]6:=^SGX;^&D$-SJ?CK5=)G;D2).ELCL.X3N.>]>CC,NH87W9UES=K
M,\K"YK6Q"YXT;1[MI'TB'4C((QZYI00WW2#]*\Y\(:XRK'!8^+M*\2Q?PF9U
M28^P*G!_$5Z#:NSQ9==C$\KG.*\IQMUN>M2J^T5TOZ^1-1114FP4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`&-XG\8Z+X,M(;GQ1J$&
MGQ7,OE0F3),K[2VU5`))VJQP!T!I+7QEHE]KSZ+:ZE;R:I'&SM;`G=A=I8#L
M2HD0E0<C>N0,BN0^-V@W6OZ/I\6D6'BF75;>>673-0\/Z@EK)877E,L;2EG4
M-$V\JP*NO]Y2*Y3P;\-_$NF^-]!&M6Z,NC:_K&N7NKQLHCNQ>Q,J0(,[N'F;
M((P!;ISR!0!W%_\`'7P%IF1?>)M/C<37</E@.S^9:R".X7:%)RCE5/'5E]1G
MJ?#_`(DTWQ58O>:!=+=VT5S-;/(J,NV6&1HY$PP!RKJRGW!KY^^*OP:\6/\`
M$*]UKX?Z7IU]:0:C9^++1+F<1[]4A3[-<6@&00MQ`(7W'Y0\.3DD8>/A[X]\
M/7GB32K.]\;R6ZV2'1+[2+ZU2T0-;H)W>*1Q(]R;GSY<<`[UQ(N3@`^D#P*Y
M?0?B?X8\3:A'8Z+JT4UW-)<QQ1/%)$9'MWV3HN]1N:-N&4<CO7#?"3P]XNT?
MQG>7GCB'4Y$O_#FG11S#46GMXYX);H2AEDD+AW62%^C8R07)7)\VL_A+XYEU
M^\U/3]+\2Z)?QZQXGNDGFUJUDA-I?>>T"VL:R,8;EI&MV+_+L$<@+'?@@'U7
M4%_>Q:;8W%W=>9Y-K$TLGEQM(VU1DX5068X'0`D]J^>=/\"?$6SL]/0R^))-
M8-GI+V-[<ZUYL>GW0F+ZI]J'F%95<$[0%<%=J)LQPS1?#OQ422;_`(2/3_$,
MFC37\DMU8VVOP_;)T>T,2%9A,H&V92[JIC4F1&084H0#Z%TC5;77=*LM2TJ4
M3V6H6\=Q;2A2OF1NH96P0",@@X(S5NOE_3_AM\7]*TCPK%HUS>1;-&T]=2M[
MKQ`RK972VYLKF)4C<JR;9(KM<'&^U<#F48J^-?"GCWPU<>*M2FEUP:/I4$-W
MHLMQXG=I=5O;2\22W@;$N0+B)GA*[`#D!@S`,0#Z<UO7+'PYI<^HZU<):V=L
M`9)&!/)(55`&2S%B%"@$DD``DU'H/B"Q\2V3W6D2O)%'/);R"2%XGCEC8JZ,
MC@,""#U'OT(KS4VC^*_A3XC\+W?AW5?$CZ7=_P!F7T&K7HB;6/FBDGF@N`_!
MQ(^P[EVR1A<KMR/.=<^&_P`5+;PS/;>'IO%.JM=:7?Z?IBZAXCBAN]//GV\M
MC/<RHX61TV3IN7>Y5E#ELDT`?35G?17\;/;^:`DKQD21-&=R,5;`8`D9!P1P
M1@@D$&FZGJ=IHNG7-_J]S#9V5E$TUQ<3.$2)%&69B>@`KYHU?X8?%"XN-6N=
M*34X;N[@UZ"RE?Q`%,"7.HQW,*EMYQNM@\*'#>4P'`4`UWVJ?#O5M6^#VFZ/
M#9ZLLMEK5IJ4VD:KJ44\\]M#>I<-:&6,B,#:NU!G:-JJ6QDT`=XWQ*\.QWME
M:37SPSZA%!+$DMK+'M6=V2#S"RCRS(R,JA]I)!`&:M^&?&VB^,4D?PY?)=B.
M-)?]6R%HG+!)5#`;HVV/M<95MIP3BO"4^"_C36++7;#Q))<2?\)G+ISR7[WR
M2S:/!9:E+/'#(^=TK_9VB0%=PWAR3@[CW_PC\!:QX:O;.X\101VK:3X3TWP^
M@CN1*+IK8REYN.BG>NW.&Y?('<`]3HHHH`0BO@S]KK1I+CX\332(6631[;R@
MW((#.#C\:^\FSD`=.]?/G[3_`,/SK5UHWB&%#NLV-G<8_N,=RD_B,?C7IY-5
MC2QD92VU7WGE9U2E4P<E'?1_<-_9!\.P:/X$U>X1"+B]O?WQSR%5!MQ^9KRF
MWL-3^*WQ!EGU.<-<ZAJ#Q0[\E(45B``.P"K]":^@O@58-I.F7=LXVQR;9%&.
M^,&N<\$>"&T#XC7`*%1;W\ABSS^[8D@Y_P"!&L,UN\9-W/`Q=&57!X:G]F^I
MW_A[X1>%_#UJB0Z?'++&H#3RL6)/3/MFNMLK*#3E"VC,D8'$>\L!]*\3^/7P
MA\2Z_)JOBOPA\2_&/AF73=,EFATJQE3[([Q1L>AYRV,'ZU\)?#OX_P#Q6\>>
M,_#F@M\1_$]C%KVH6]HUPDHD:(2D#<H(YQGO6^"RN6*IN<*L5;=/FT_`]:OB
MJ.7S5-4&D]FK:GZRHY;U'L1BCS%9CM))4X/UKS[X1?"J\^&B:BNJ>,_%/C"3
M4#&QDUNX#BWVC&(U`&T'.36%\<?@SJ'Q`CFU;PYXZ\8^$M2T^S98HM+O2EK-
MMRX+QX'S$\;@>E<"A%SY>;3N>NYU%#FY=>QZ\)@6QD[O2E\T#&<\\#(ZU^0_
M@WXY_%;QGXDT3P_)\1/%%H-8U"&R$\5UN,1=PI;U('.,]:_1OP)\";OPAX6U
M_2-0\?\`C?7[SQ!!Y)U#4;[=)8D(5#6X`PAYR3GJ!7=CLJ>"4?:5%=^K]3@P
M6:+%N7)!Z>AZV9PO4D?44JS!CWX]B*_/']IJP^(W[,P\-'0?BYXZUJ/7Y+A&
M-Y(,0^4J'@C.2VYNM=+^R?X6\4_M`^'K[Q)XR^*/Q"AFT77!;?9;'4=D4Z*D
M<G.03ALX.,<9%:/*&L,L3[1<GS]-B/[6OB/J_LWS>=O4^[5.>AIU,C7"KDDX
M'>GUY"/9O<****8!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5P7QJ?53X(,'A/4
MK&PUJZOK>.R@O+YK)-38.':R$Z?/$TR(Z!UY!.<&N]JGJVC:?KUI]EURQL]0
MMMZR>3=0+*F]2&5L,",@@$'L1F@#Y]T3X^JUCX>\+_8-7M9=9COK"[DU35Q)
MJ&FW4:WVY"\8(=(WLI(UF+@OE67<5<CI/V;OB+KOCS0!I_B"&WEMM&T+15&J
M&_>2[OIKC3+:XDDD4J,$F9OF#9R.G>O2IOAYX5N#&9_#6@2F*(11E]-A8H@+
M$*,KP`7<X_VV]35K3/".A:)G^QM&TJPW6R6I^RV<<68$!"1?*!\B@G"]!VH`
M\F^'_P`2I-`^"EAJ>J:G;ZGK5[J=];6W]KZH5,^R_EB7YL,S!(U7Y44LV``"
MS5RGA_\`:':W\<ZIJES#/>6&M^%=*U=;-=0:2*T"VEY//';?*5DG;RP!$-A?
M8S?P$5[L/AIX0!C(\*^',Q1>2A_LJ'Y(]P?8/EX7<JMCU4'J*MV/@OP]ID<4
M>FZ%HUHENRO$L%A'&(V4L5*@+P07<@CIN/J:`/,-9^+/BO4O@#XO\6>']#MK
M37K'3);C28+>^AU$2*8%D67]T6&5W-\I/S;`<8;%.\1WND^!+'PQ=:'KVJ:_
M<:K>Z39B.Y\3RD744U]#']M(!.X[I1D*%1E?:1C:!ZKH7AS2?"]D;/PSI>G:
M1:-(TA@L;5+>,NW+-M0`9/<]ZY?Q5I?A;P!H=YJ]KX6T:6[EN($@M[>QABDO
M+MY52W3=MX)E=1N/W<ENU`'G7AG]H/Q+J=EX-EU70O#]N/%NG_:8YEU1PL,D
M=P@NHV!C^7RK=VFR3SY;#CJ.L^*D\4?Q%^$_VJZ>*RO/$%S%*AN"L,[+I]S+
M"&7.UF$L:,N><J,5Y-J'B[2O$NO^(;"_T;28F@,V@#PY9^7']EU#4+Q;)[F[
M<P[E:X23S(V`8-"KD@LU=_I?Q"M-5MO"G@T^$=/FL[K4]0\.W,5U<"6VL[C3
MH)V555U+R(PMU*L0"%=3R>*`,J3XKZMX(U^[MK1]/U'1[F]\17\MSK&L.FR.
MR-M^Y@D;<JJ&FD&"<*$8#&VN9U#X^ZG:>)++Q>@L+FVT[PCK$FK:<FIRPPRI
M::I!$9HHF4D2E"Q4.JD!]I->U:9<6/BSX?0WT7AG1DO-/$\']EZ@J"&QN8W:
M&=-X1L(&5_F5?F7G'->=6OQ`MM4\+>&_$MMX"\(7FDZQ<V^G7LD4R-)+)<7W
MV4QVR&'<^W:L[K($(48(W*V`!_[2?B?6-'U_18_#LM^4L])NM0O1:79MY;6)
M)[=#=0`_)<SH'=1;OPPD/?"M@W_CSQ)KWCCXI6FM3^*_#5M%X&-SIT'EBVCT
M]8KB\59ED)($DRHC%^H'R@@IFO0?A9\4K/XO>(-6L;S1-+$OA8H7`D6>72[D
MS31FVF5E'ES*(%?*Y!##!P`3+/\`%[0=0\;^+M%O]&%QINAZ/;M-J31+*-3D
MDN)H#:1)C,FV6,Q\G!D=E`X)H`\YNO%>NW$&F7D.H7<FH6>A^#9-%Q=N!=O>
M7K1WQ*AL3%HE`8D'`&>.M>H?!#4+B\/CV"]U6[U5M/\`&E];QO=7/G/%&$B(
MC&.%4;CA0``*Y+0/CG97VB:-JDGA;3K2/2[+29+N&)P[V`U&\>SBCMSL`.QH
MR7^Z".!71?`_XFVGQ!U#Q-%I^EZ58R:?<(VH-IX*M#=L\J26MR"JL;B,1*6;
M&TB1<'C)`/6****`$K.\0:-!K^D7-A>J'BN4*D=P>Q'OFM*D---IW1,HIIIG
M,>$-$_LF'9)_K(P48X[#IBM4Z3"VH"]`'FE<.<=?2KI&-Q*@8'6N=L?$2V^L
MFPNY#_I#'R7<\`_W:TDJE9N6[.10A1BH2V)/'4@;P)XD48R-)NA_Y":OQ^_9
MYE6+XP_#MY"J)_;]EEF8*!E@>3VZ?K7ZP_$_4;C3O#VL#"M'/IETC8&,GR7Q
M7Y&?"/PM;>+/B#X2T74I9H[35=5M[.<POLD".P!V''!&1@U]+PW9T<0F[*WJ
M?-Y_6C*K3C%7<7WMV]3]J5U:UZ>?#Q_TT7_&J>MZY91Z7=B2ZMH]UN^"\RC/
MRGWKYT;_`()X_#B3C^T_&8P?^@O_`/8U#??\$\OAW'9R.FJ>,7>)"T8;5<C(
M''\/2O$5'!:/VS_\!_X)[[KXU*WL5_X%_P``_/SX._NOB]X)<C('BBR/O_Q\
MJ:_:PH"0?2OQ,^%*FT^+/A($X6#Q'9(`.^VX0`_7%?MH.E>UQ1%*=*W9_F>5
MPYK&JFNI\/\`_!3Q#'X=\`3J1N75+T#Z&V'^%:G_``3&F:7X9^,$<X=/$`)'
MIF!/\*J_\%.DW>#_``(RJ&*ZQ<@?C;U8_P""9(">!O'2@[O^)[$=WKFW6E"*
M_P!7W?O_`.W(<G_PO1]/T/L[O2T5\Q?M+?'+5/!/QC\">"I?$$W@7PMX@MY)
M]1\2PVL<L@D!94A5I59(U#!-S8)`D'0=?G\+A9XBI[.&]F_N5_4]_$8B%"'/
M+R7WGT[17A_[,7Q)\1^+O!&NWGQ&O8;RPTO7;FRT3Q%-"EH-9LD.$N"HPO/(
MW*`&QQZU[5:7MOJ$"SV$\-S"^=LD,@=3C@X(XJ:]"5&HX2Z%4:T:L%-=2:BJ
M&OZW:>&M#U'5]7E$-CI=K)=7,A_@CC4LQ_(&OCW]C'XW^)=9^,/CSPE\4'O8
M+_Q`_P#PD.DVM[*6-ND@5_)C!.`ODR0L%'3:WO6U#!5*U&I5CM#^OPZF5;%P
MI584Y?:_K\3[1HKY=_;#^*S>!_&7PTT'Q-J6L:%X#\0W=PWB*_TJ9H9I4C"A
M(O,3YTCW.&?80Q7..E=)\&_`FGV'Q,D\4_"#QQ/X@^'>IZ/)#=:7)X@EU*.U
MOO,C,;Q[V8J"@<$%L@^QXMX%QPZK2E:Z;6FFCM:_1^1'UQ.LZ45>S2>NNJO>
MW8]^HKX4\%>/_"'QG^)7Q"TS]H/QGX@\,>(+/79['0-.'B"?2;:SM$)11'Y;
M+&TVX$MO)S\I&1FO7M;\?^(/V6_V5CJ/CC4H/%?B/3'>STR\ENGG&HF6=_LS
MR.>3B(AF`[(0#WK2ME=2G*--.\VTK6WOV?5+J9TLPA.,IV]U)ZW[=UT\CZ-H
MKY;^`/P9?XN?#"Q\;_&SQ!XKUWQ%XP@-TOE:W<V$.GP,Q\I((H'15^7#9P?O
M>W/+>!OBUXC^`/[4;?!_QKKVH^*/".NM$=`O=4E\Z[L3,O[F-I3RZ[E,9SWV
ML,<BG_9O-*I"G.\H)MJV]M[/K;S2']?Y8PG4C:,K6=^^UUT_$^S:*^._B/\`
M%#7_`([_`+4,'P9\'ZQJ7AWPIH8>7Q->Z7,8;J]\M`TD2RCF-`S)'Q@Y9B>@
M%=OX\_8ZTQ-*BO?@?K>N^"O%>G2)-:W)UR\FMKQD;.RY1I&W*>>1R,]#TJ7@
M(4^15Y\KDK[7LGM?72_DF-8R=3F=*',HNV]KM;VT_P`CZ-HKXA_X*(V=SX9L
M/!FNZ#J&LZ7K>M:E]CU"33]7N88YD6(841APHY[@`GN:^P?!/A6P\%^&;+2=
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MB)H/BDVW]HI+XHN9)&WW31MM<ME?E`Z5[WHG[)5CHGQ4N]:EUO7M:\-:GX>>
MPNK35M=NIKN.Y-Q'('BF#!E0B,9`8<CN#Q=7+Z-*G&<JOQ*ZT\[=]R:>-JU)
MRA&G\+L]?^`?0E%?GM^R_P"%[;Q=^T'\4?#'Q"U?7M1TCPY)<)I\$OB.\B2'
M;=E%P1*"<)@<DU[_`/#WX6^&)_C+!XJ^#6KZG;Z=X5O+O2/%%E-J]S=6^HS-
M:JT3Q[Y'#-&TH!)(Z''*\O%9=3H3E!U'=*]^73572O?KMMN+#XZ=:*DH+5VW
MUT=GTZ;[GT/)*D0!E=4!X&XXI]?`EO\`$_X>:_\`'KXF:+^UX)1=PZJUEX>^
MW23&QTZS7("Q["!$[C8_F8&=WWA7U7^SEX)_X0#X:1Z5:>)H_%NDG4+JXT;4
M4N3<?Z%)(6BC,A)W%1D$@X]/2L\7E[PU-.3=W;IH[J^COK8O#8WV\VHI6UZZ
MJSMJNESU"BBL:^\:>'M+U5-,U/7=&M-2D*!+.>_BCF8N<(`A;<<GIQS7GJ+>
MB1W.26[-FBHKFYAL[>2>\EC@@A0O)+(X544#)))X`'K5#1/%&C>)EE;PWJ^F
M:JL!`E-C=QSB,GINVDXS[T)-J_0+J]C4HJGJVL6&@Z?-?:Y>VFGV5N,RW-U,
ML4:#W9B`*H>&O&_A[QD+C_A$M<TG6#9L%N!8WB3&$D9&X*3MR.F>M-0DX\R6
M@G**=KZFW1114E!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5S7BGXD>&/!-_8V/BO6[
M'3+W4TD>SMYY,27"QXWE%'+!=RYQTR*Z6O)_BEX7OM?^*OP\N]-@UF!-.BU6
M&YU;3T3_`$%+B!47);(Y=$_A)&T'@9H`],TC5[+7]+M=2T6ZAO;"]B66WN(6
MW)*A&0P/<5SOQ4L+BZ\&SW6G-;+=Z)<6^JPBYE$43FVE69D9SPH949=QX7=D
M]*\@U/2_B-#J/B;2]/;QPMI#I8@T;4HY[?$MY%)$(9BH8`(WSF08RZ;B2&*J
M.FU(:HOP(TK_`(3J+4;>>WU&Q;Q*-1G65C`E]&;IMPR#`5#,`<'RN"`<B@##
M3P-X$U&XN]2'BVQMY](,FHVS-%`)M/DDOX[PM,_6;9<(B!2?EW%3\S9K?&@>
M'+74O`NH67BZWEO+;5]6UJVM_P!T9==N)8)Q<*@+`J(UDDX'W0B@G@Y\U;X5
M>,#XONM0@L=2GL[/7Y=4FT^;8;:WB76;>[5-.<G<WVF*-II58D"50!L^Z>PT
MGP3K-IXM\#:Y+H=\4E\9ZWJUR72(2:59W5O=)$LGS9&YYD<JN<%VSR#0!VWA
M.WET;X73:M/K%CHD^KW$VN7-X&6[M[87$QG,8).UU",$W*1GJO45PJ:7X2TV
M\\-7&G?%!K"37KF[FM3%';LEY>7=RS3SIN1A#(SDP*>-O*+\S-GM/AK>/!\.
MM2NK.TN=0TV?7=1DTB/347?]C>]D\N2,2,`5&2ZXXVA2H/`KS.'PKXHTW0-)
M\+:UX+U[7=!_M.34)[B-[22ZG@CU)I]/M+F5Y5.5)6>5P'./EY9G-`'6?#GX
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M+NO%_P#;6FKIT5WXBFGT_9(C+-;>3"B2`*3M)*-D'!]J`.THHHH`****`$/0
MYKR'XN:3<V2M?0,Z0LZD2H<&,^OM7K]4]4TV'5K"6TO$#PSH4=3Z&ML-6]E5
M4GMU.7&8=5J7+UZ'BEU\4-*\7?#+Q#:ZY=V=KKFE:3<MMEE">=B-@KH6QG)P
M".Q.*_,WX"7J6OQ9\`W-W)';I%X@LY)GDRJ1+Y@R2QX["OL;]H']G&P?Q`]_
MK%C<W22@)#<"X=8Y$`^Z5!P&'ZU>^''P(^#/Q,T5M'N?"5IH'BBW3@QSS`3X
M_C3<^'XZC'%?5X6>%P=&=2+<HS_E5[?BCY'%T\3BZT8RBE*'?2Y]D:9JEIJL
M'G:=>6MY%_STMY5D7\P2*H^*/$>G^'],NI=6O;.R00.RM<7"1AB`>!N(S7SO
M\*O`EO\`LT^(K^TTO2F@TO5V4W061I`X0':\88\8!.0*].\7_!#X;?'#4;/Q
M!XQT.U\0SQ6XMX9);B3:B9W8V*P`.3Z9KY-J@IN/,^7O;7[K_J?34,;.O!I1
MM/LW^MOT/R6\"7\=E\1?#=[<E8((O$-K++)(P"QI]H4ER>FT+DD]J_:S1?$&
MG^(;<7.A:A8ZE:-]V>SG69/S4D5Y(_[&/P:/W?`>D`?]=)O_`(NM/P3\.OAE
M^SW)>W'AN+3/"J:_)'%)]IU(JES(N=BH)&QN^;MZBO9S?,</CDI04E**VMO^
M/Z''E>"Q&#G+GY;2=]]OP/!?^"G(_P"*#\%OSE=<E7CT-NV?Y4[_`()B1X\"
M>.G4L8WUV(*3[6ZTW_@I=-YOP]\$A`<MKLL@W$#@6[=_^!5V'_!/?PO/X6^"
M`N=1B,4_B6_DU&$$$$VXQ$C'/KY98>S"MXU8_P!@V[RT_!_H82A)YXI6VCK]
MQ]25^?>B:EH_[:7Q#^(OAWXSZ]/H-_HLLEOX*TKSEABL=KNDLNTX\Z;*(&#?
MPLV`,9'W3XB\7:3X9%L-=OH+$W;E8?.;`<CD@&O"O&_PR_9Z^(/BB37?&%AX
M<N]9ED#7$T=U)";AQQF18V`8\=<9/>O-RW%4L.YN=U)K22M=:^=M]GY:=3T<
MQA[1QCS*RW3=DU_P.A\K_#WQ1_PF%W8?L[_'S6-$_L30-?#0:ZUWYF8H`<6,
M$P.U0Y(57)!5"Z==H'Z%_"^?P=_PB4-E\)CI7_".Z1/+8PII8'V>.2-L2*I'
M#88G+#.3GDUY=XE\'_`+Q5H>F:/X@T7PE/INCJ5L($@,(MU/4*8]IP3R03R>
M3S79^&/&OP[\':#9:)X2OM(TO2M/B\NUL[5"D<2]<`8]223U)))K;,<=1Q45
MR)Q=[M:<M^K]7VZ=S#`0^KR?-.+\[ZVZ+T1S7[4,\OBO2O#?PPTB_6PU+XCZ
MF+::4*KM!80*9[F382-P*HJ8Z'S,5\U?M5^#O$OP"^*'@#XP7OB)/$,MM?Q6
M5VT6F16&R.($K'MC)#!XC,F>V`/2OI'7]!^"'B?Q(^O>(K#PY?ZY)(LAOIDD
M:7<H`!#=N@Z8J[XI;X->.=;74?&MKX=UO4;>`0)+?6;7&R/)(`!4CJ3SC/-/
M!YA3PS@MXV?,K+6_9WO:UON\Q8JBL1S/F2EIROFVMY??]Y7^+/B?X6?$R/P;
MX,^(\-KJFE?$2VFN]#OGF6.)9(E1EV2[@R2,)/EQU(*GK@^":%^S\O[-_P"U
MEX!M?@WXAOK^S\3?:CK6CW$@DDM+%$&YYBN,QDD;&<`AU`!->YW>@?`:\T%M
M%NM$\*R:29VN%M/[+;9%*P4,\>$^0D*N=N.@K5\#7_PB^&L4T?@.#2](-R`)
MYK:RF:68#H'E*EV`QT)-31S"G0I2ITY2LTTXNUG>]GOHUILM;;E5:4:M13J.
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M8LQINJ6;R!);9X<J"RGD`H%;/U]#7B>KZ6W[1O[=^FZOX%9+WPO\.%M1J>LV
M_P`T!F@9Y/*5^C,9&"<9X5CT&:]X\3:!\$O&FJ-J7B7PSH>H:@Y)DNFT*422
MD]=[*@+9_P!K-=7X=\:>`O">F1Z;X6MXM(T^+[EK8:)-#&I]=J1XS[UBL?1I
M5*M6DGS336MK*^_KY;%NFJD*=*I4CRQML]7;;T\]SY5>S;]G/]O:Z\1^.R+/
MPI\0!<+9:S,-MO')<!&V._W5*RQA3D_=8-TYKZH^+_[0'@[X,>#I=?\`$NIV
M]SN&VPL+.9)+B_E/W4B7/.>,MT`Y)J37_'7@;Q-IDNG^)8%U;3Y>9+6]T2:>
M-_JC1D9_"N0T30?@CH6H)?Z'X,T6UO(GWQSIX6DW1MQRI,7R]!TJ:N,H8ATY
M5T[Q23MU2V]//<JFO8*<:52-I-O5[7_/\#P[_@I/K]I<^#?AO]JFBM;MM5-S
M/9^>IFA1H02<`YXZ9]:^A/CM\8]-\"_!>^U/P_K.G-JFK6R6&A,UXA\RYG81
M(^<\A"VYCVV'-3:SJOPKU_49=0U_P_IVJZA,%62YN_"DMQ*P48`+-"3@#WJJ
MD/P@>WBB'@_1FA@WB&-O!S$1AF+,%!AX!9B<#N31]<P\J5&G*+]QM^MW>PN5
MJI5G&I'WTEOM;0^;?VC?V4F\,_LYP7:_$;4];MO`]KY^E:?>+:0VV"1Y_E.B
M*[,5W,,LQ)'<FOHS]DGXSV7QB^#.@74FH6]SK^FVHL]7@\T&598L)YC+G.'&
MU\_[5:]]K?PWU#2;32]1T"VNM,L#FTLIO"TLD%N>>4C,.U>IZ`=33M!UKX<^
M%[I[OPMX<CTJZEC\MYM.\*2V[NF<[2R0@D9`./:GB,QC7POLJNLDVT]%ONK+
MOOZA1I4Z.(]I3FE%I)J]]MG\MO0^5_VK_%NAW/[:'P@EM]:TF2+29+--0D6]
MC*VC"]8D2G.$(')#8P*^[FU>Q33A?O>VBV!0.+HS*(MIZ-OSC'OFO*)K?X3W
M$LLMQX$TZ629R\KOX)9F=B<DDF#DD]ZUG\5^!9=`&A2>'[E]$5`@TQO"LQM@
MH.0OE>5MQGG&.M9XO%4J].E!)KD5O76Y>&:I5*DW->\[[_(^-/V<=.\`^,?V
MI_C`OQ"7PQJFFR75W+IYU*6%XG8WA^:,L<-\O<=J^B_"WC;X;_!CQE9>"?A+
M=Z+K%W\0_$HGBT;1[F,Q:1$+=%N)3Y98!1Y)8*<$ER!P":Z9;/X1RL(Q\/=-
M;'0'P,<?K!5W3)_AMX:U"*]T'P3%IM[#DQW-CX.:*1,@@X=8@1D$CKWKHQ>8
MT<1)N2E:R5KZ72T?WZG-AH0HI)3C>[=^NKU/,?$5O\#OVGM>\7:9\2K+2]$\
M5^#M4GTN:YEU)+.]:&(X2X1\C?&>>&#!<$>F><_93U"R_9^^'7Q;UB_U74=8
M^&'A_6M^@ZC'"9/MD:C;*\*C`8%VC7<N$9E8@@9->W:[??#KQ/=_:]?\&?VG
M=G@W%[X->>0CTW-$34GB'X@6L?A2]L?">@W]S<"T:&QLK[0+B*R;C`20"/B/
M'4`=.*S^OP]C[!7Y';1O:V]GTO\`@NY3=%5E4<XJ2OJK:WVNK]/ZL=+\)?BU
MX=^-7@NV\3^!IYYM.GD>%TN(O*E@E0_-&Z\X89!X)&"#FO(_C)+HMM^UC\&;
MC5;G1[1X++67GENC$&P($\L,6Y'/W3[''>K7[/>G:+\"OAQ!X<\KQ#J-W-=S
M7U]<P>'KB*)YY2"PC0KE44!5&>RYKLM1\0^&=8N&N-6\&ZO?SL`#+<^%3*Y`
MZ#+*3BL%4H4<5-TV^6TDO1IHVGB8U*$54DE+1O56NFGW.@L_B_X)U746TVV\
M2Z--</<SVBI]I4K-)#"DLRHV=K;(Y%+8/&2#T-?/_P"R%\1_!_P]^!.L7WB+
M6='TV-?%>IG8)D\V7=<8140?,Y.0``#GM7KT6M>%XHHXX?!6J(D8D$:+X4("
MB0!9`!MP-P`!]0`#2)J_A2W\K_B@-58POOB,?A(?NVXY'R\'@=/2G"K0C2E3
ML[-I[]K^76X/$*=2,U.-U?\`&WGY'EW[0_BC3O%?CCX/:S#?V^I_#G1_&-Q;
M>(9UR]I;7T7R0FX.,!4E#C<WR@]37K4OQ+^&'A[Q!XAU5=5T*"_TO2()]=U*
MU`=8;3S66$321@C.]GVJ?FP2<8JW_P`)SIJ64MLG@_Q-]EN"QE@&B*$DWG+;
MES@YR<Y'.>:KV/B?1-/LIK33O`>O6MI<_P"NMX=`CC27M\R@@'\:F>(ISIQ@
MT[1TT>Z;OKIO_P`#L7&<8SE)35WKZ:6TU_K4]'CE2:-)(F#(ZAE8="#T-.S7
M$#XDQ@8'ACQ>`/\`J%C_`.+H/Q*0#(\+^,&]AIBC^;UQ6.SZU2_F1W%%<-_P
MLUP/W?A#QFP_Z\(Q_P"U*0?$^<]/!?C;\;*+_P".T68_K-+N=U17##XF7!(`
M\&>-,D@<VD(`_P#(M#?$N[$1<>"_&!(8C;]G@SP>O^MHLP^LTNYW-%<-_P`+
M+N^W@KQAGM^X@_\`CM*/B-?[<GP5XI!]"MM_\=HL'UBGT9W%%</_`,+%U`_=
M\$^)S_X#?_':8?B1J?\`T(OB?_ONU_\`CU%A^WAW_,[NBN%'Q$UAON>`O$Y!
M[F2U'_M6I%\>:RV?^*&\0CZSVH_]JT6%[>'?\SMJ3-<6/'>M$X/@;7U]VN;0
M#_T;3'\;:VS<>"-:QZ_;;0?^U:$@]O'^D_\`([?-&:X=O&NNK]SP/K3_`$OK
M08_\BT?\)GXAVY_X076`/4ZA:#_VI3Y27BH+>_W/_([C-%<*?&WB$=/`^IGZ
MZG:?_%TG_";>(NW@;4O_``:VO_Q='*R?KM/L_P#P&7^1WE)D>HKA/^$T\2'@
M>!]1!]]6M?\`XJE_X2_Q*?\`F2;K_@6L6W^-+E8?7*?9_P#@,O\`([NBN`?Q
M=XL8?\B0Q_[CD'^%,/BOQ=V\##'OKT'_`,33Y6/ZY3\__`9?Y'H5%>?+XJ\6
M]_`ZK_W'H3_[+0WBKQ<HS'X*AS_M:]$/_9*.5A]<I^?_`(#+_(]!HKSY?%?C
M%ASX,MA_W'XS_P"TZ4^(_&4O^K\'V+8ZY\0*/Y1T<K&L5!Z*_P#X#+_([_(H
MS7!+KGC)CA_!VG*/7_A(0?\`VE3QK'C%AD^$],!_[#Q_^-4K%?6(^?W/_([K
M(]:,CUK@WUCQIC]WX3TG/^UKQ_\`C-*NL>-B!O\`">C9QS_Q4!_^,T6!5X]G
M]S_R.\HKA5U?QRPY\,:"/0'76/\`[1H&J>.>WAOP\OUUM_\`XS0'MUV?W/\`
MR.YHKA_[3\='@>'_``V#[ZS)_P#&:!?^/3TT/PJ/^XO*?_:-`>W79_<_\CMV
M;"G;@G'`)Q7B.F?M,?VMXN'A:U\,2#Q%M"G3Y-3C#K*MS+!.APIP(UB$Q;HT
M<L;#K7<+>>.V./[(\)C_`+BLY_\`:-92>'_$\&MR:O;>%O`,>IRR-(UZ+R;S
MF9HTC9B_DYR4CC4\]$4=J+#]NNS^YG,Z/^T^GB2XNM/\-^%[G4-=M;5+E]*7
M4$654^S2RR*QV[5=)H6MF7/$C)G`8&GZ=\>K'XH0ZYHVA6,)MUTZ\^TW@OU;
M9$;2&6"1%V8?S1<,H&008),@[2!TEAH7BO2K^2^TSPQ\/[2]F\WS+B&YE21_
M,D\R3+"')W/\Q]3R:H#P%K&`#X*^&:JO3:\@Q\LJC&(?2XG'_;5_[QHL+VZ[
M/[F<!X1^.UY9^#/!*>*-)U6*71-.TJ\U*?3]15UGM9])NIEEE01C>2]K(ODC
M&&,;;B.*[*_^->OR)H]J/!FDW3^)-'OM3MX6\2H8Y+2"&VDPS^25WO\`:2N.
M5&S.XJ<B%/A-J]IJ&E7>B:!X#T5M,EMSLLI)T\Z.WCDC@B8B,?(@E?`QQG'<
MU2G^".K)KFA7>CZ!\--/T_1TO5DT]+.5DG^TI&I(.SY<")1@#!''08HLQ^V7
M\K^XI:Y^T9'JGAG6=+^&^FI87L7@TZQI3/=1PFUCQ;!4D0(RPN$ND95^;`7E
M5RN=+PE\3-:T3Q+%X+T;PQ?ZK)%KMU87=_J7BIKKR!%:VERS^;+&9'R+HA4Q
M_P`LSRH/&M<_#/4;V\GN[SPM\+I[JZ#B>:6TE9Y0ZHKAB4Y!$<8(/!V+Z58C
M\!:[#>I>6^@?#2.[CD,J7"P3"19"H4N&V9W%552>I"@=`*+$/$I?9?W'+^%O
MVF-:\0#3+BZ\'V-K9ZAIVFZH3%KGFRQVMY=FT'R^4H+I(-Y&<%`>=W%==XH^
M-O\`8NM>(8M)TZTU+3/".DQZGJ]Q_:`262)TN&`M8PK"5@;9E(+*"S8!RIJE
M%\,]4A"B'PS\+8ML21+LT^08C1_,1/N?=5_G`Z!N1S3H/AOKD%W9W$&B_#*&
M73PXM)4TN4O;AV9V"-C(!9W8XQRS'N:+"^MK^27W%%_CQK_]M0>'X/"^FSZ]
M=?9)58:R5LXH+JVNYH6:4Q;BX-FZLJJ>&5@<'`W_`(1_&*3XF3".\TJ'2WNM
M`T[7K-(KW[2?LUV955)#M4!U:!LXR"&7GK5$_#C6S'''_9?PU\N*83QH='D(
M24)L#CGA@A*@]0#CI71_#[P4_AB>6:ZTKPG82_9([6)M$TS[*5B0DB,_[`)R
M%Z`D^M%BH8A2=N5KU1V]%(.G-%(Z!:***`"D(SUI:*+`9NLZ'9:]I\UGJ=ND
M\$WWE;U[$>A%?.?Q!^#%SX4O8]1T-[F6%)0\%PC$2VY'8D?SKZ=Q[TUXA(I5
M^0>H(R#75A,;5PWPJZ['#C,!2Q.LM'W/$/`OQ#'BJR&B?$N)&N(VQ;WX&WSA
MV+8^XWOT-=]I/A.7PY=&71Y\Q2/GRP?E;Z_XU7UOX5:9=3M-91K'YS[I(B<`
M_P"Z>WTK:T#3;S2HH[625Y(%/`?DI[9]*O$^PF^>EI?='%1H554M65VMI+]3
M=@=GBS*-K#K7QE^W9^SMXZ^*NK:'X@\!6SZY;:;8R6ESI7F`21EGW"6($C.<
MX.#D;17V=]T8KS_QE>^*]*=I=%M7O(U&0T17/_?)K#"XN6&JJK!)M=SIS&$)
MX9PG>W6Q\I>#_P!G+XM_&W0O"/AW]H<PZ/X/\'3%H@9%DU#45*A1&Q4D*`HV
M[B=V*]TTKQ7:^&_%'B&WTAEM]&\+ZEIT`5&/EQ02Q+;R(/0*P0CW4URFO_$K
MXHZO<-ING:=J5MY@*?N-.\MCGC&_H/K6-XV\/W/P6_9R\2R^*Y%'B+Q3=1^7
M&LN\HP;<HSW90I9C[UTU<15QM>%.UHWV6UWN^]SQ,-B:<*B]BI-+64I=DK)'
MUX8$DQYBJ^/[PS5>_ET_2;&YOM3:TM+.SB::XGFVHD4:@EF9CP``"23Z51\&
MZB^K>%M&O9AA[O3X)F^K1@G^=5OB3X(MOB7\/_$7A34KBXL[7Q%IL]C+<6Y'
MF0B1"N]<\9&<X/!Q7#;E;78^IBHS2DT<K=_M!_#VPO;2SNM2NTO;^6**UM?[
M"O#+,TJR/%M00Y(=8I2IQAA&V,X-2?\`#0GP]%[<6<FLR0W%O*83'+I5U&9)
M1"L_E1YB'F2>4Z2!$RQ4Y`(S7*>/_@1XG^*_A+P]I?Q`UOPS=3Z'JD%W*+?2
M9XX;](H)X2'Q.)$+^>6^5\*5&,Y)J#PY^SGK6C?%*3QQ<>(=+;41JD4XABL)
M3#<6HTZ&SDC>-I2%FS`KI,OS*&=#N5C2*4(KH=?8?M$_#[4VL5LM4O)#JE_+
MI]EG0[U?M-S%YOF1)F$993;S`CL8V!IEO^T=\.[K2K'4X-6O#I^IVTMU97)T
M.]5+B"*$S22(3#RHB5GSZ`XK`T#X"ZWHGA7PMIO]N:1+=^'/&%_XD:4Z>Y28
MW37;&`?O,KM-XXWYY"#@9-8&F_LF7&@?#3POX5\/Z[IUK+HMAJ-KJ5XVGR.-
M1>ZL6L_."&7]VP4JQ`)!*`<9H'RKL>BWG[0'@2R%H9;^_;[=I\VI0"/1;MR]
MG$D;R7``BR8U6:(DC^^/?%GQ5\<?`_@W3M%U#6=6#V'B&TEO=.NK.TENXI[:
M*+SI9]\:L!&D7[PDG[N3VK@?#'[._B;P@?"YT#Q1X?M'\-Z7?:?$W]@RR<72
MVP>50UP?FWVWF;3\I:0C``%:^I_LUZ;>_P#"K]-%S;7/ACX=6-S9RZ;J%KY[
M:G'+:BW`=@RJ,`%B-I#9Q@"@+(Z&U^.G@Z^T4ZKIDNHWMFNK3:2[6^ESN4NH
MHC(Z%0F<;5.&^Z3@`G(JIX>_:0\"^*#X?71;S4I7\37D-GIZ/I-Q&6DFMC=1
M%@R#:CVX,JN?E*@\Y!%9T?P%N[&]UJ+2==@@T74==O/$%O:M8L9(KZXMFA*.
MXD`>!7<R!-H.0J[L#)XKP=^QW=>"KGP[>:+XPM[:\\,RZ>]N%T8O!<M9Z?/9
M+-+&9\^<\=QERK`?NHP`,'(%D>KVWQP\*WM]>6-B^JW.H6.IW>FRV<.ESM,9
MK5$><J@7)15EC^<?*3(H!)8"M/4/B?X4T?P'!XTU+58;3PS<Q021W\T;Q@K,
MRI&2K`,,LZC!`([XP:\ZTCX!^*]"\6W?BK3O'5I_;\^IW<QDFT(-!/:7,5JD
MD,L0E4[PUE#(KHRX.X%2#QT?Q4^"%O\`%_0M(T7QGJ<E[I-A#<&\M?+:#^T+
MEX&A25FB="JKYDAV#AMW/04!9'1:Q\3/#^B:M<Z?>S7+RV$EO'?RP6<DL5DT
MY'E"9U!";L@\]`P+8!!K+E^.'@Z"UANKB]NH[.\@>;3[EK";RM059$CQ`P7$
MC,\D:JHY?>I4,#FN0^''P)\8^`YI6F^(::@FLV=E'X@+Z(/,NKBUA2W%Q"[2
MMY32P11+(&#C<FY=I)IZ_L\:K-X`M/!NH^-II](\/26TOAJ4:3&+BS>UGCFL
MVN'+$3^48E3`6,.N=W)R`=CK(?CAX3F\36/AV2;4(-;O]3;35L9]/ECDBN!;
MFX"R97"JT*NZL3M8(V"2"*JP?'SP5<:U-H[7-[%K,>F7&I1Z?-82I-<P6\LD
M4QA4C]XZO#("BY;"YQCFL35/V?;G6?%UKXVN/$,$'C>UU*UNTO(M,+6BQ06U
MQ;BW^SF7)!6[G;?OW;F7LN*K>(?V8+/Q1I5_8:OXBOP9["(6-_;VZQ7FFZFE
MQ=7'V^&8'@E[R5?+QMV?(<@G(!T>C_'OPGKGB6RT'3K?Q$VHZA`ES"K:#<JI
MMVE$(F+%,"/S"%+'@=>G-3W7QZ\`6.A6^NRZ[;_V-<:^V@G4%B<PPWRR-&4D
M;'R+O7&\X3!!S@@UF7?P2U%?%`US0?%)TVZA\#GPM;'^S!(T)WAUN@?,'SA@
M,+C'O6/IW[,5KI-_>6]EK$$OA34KFRN;SP]>Z<;J&5X;-K.8[WE)Q-$4#`@@
M>4N,\Y`.BO?VA/"5E??8Q%XBN;C^TY-+*VNA7,P%XAD!AW*F-W[F0C!Y`![C
M.[X.^*7AWQYJ$UIX:GO)WA25B\EI+$A,4GE2IN8`!T<A60X89!Q@YKA;']FJ
M+0-`\&Z3X7\3:A;P^#_%\GB))K^#[;->!Q,GV>1V<$@1SE`YRWR*>H.>E\,?
M!RW\+?$'7O%]A>P+J6NVTL%PT5B(3<%I`\3W.U@LSQ`>6C[5;82&9NM`#O$7
MQU\&>&]+\6W]_J$TUKX&OH;+Q`;6W>9K%I5C8.RJ,E`)5R5!QM8=5-0ZG\=_
M"NEZC96$":OJ5SJES#!IHTZR:X2_:6V:Y1H9`=C*88Y'W9QA#WP#Q^G_`++]
MUHE\+W0O%YM[O4-,M[?7VFTLSKJUW#>F[2\93-^[?>\P*KQB9O1<+#^RO#X?
M\1:?J7@/Q+-HUMI7B4ZY8Z9<6`N[>SW64MLUK"-ZE(<SS2*N3M9\#Y0!1<#T
M)?BYX9G\*Z7KVE3W6I6^MW;66GVMK;NUS<7*[_,@$38*R)Y4N\-MV^6V<8K(
MN?V@O"MO:74_V?7YO[*@DN-:AATF5Y='BCD>-GN4`RHW12D;=Q949E!7FJMY
M\`8$\.>&K;0/$&H6.O\`A779]<L]:GA2X,]Y<F;[5YT/RJT<@N9EVJ5VY7:1
MMHNO@EJ1U?6-6T[QC>6^I>*M,73O$,SZ='(MS&AD\IX%!`ADC6:1%)W@KMW!
MBN2`3:;^T3X)UFZU6UT:XOKZZT;4[*QO(8+8LZK>;/LUT.?GMG\Q,2KD9.#@
M@BI/#7Q]\*>+-2\/VFC0:S*OBB4QZ9=_8&,$W^C-<@F0$A08T?KR&1E8`\5S
MMC^RGH%D^BM;ZC=V<GA;5X;K0IM/C%O);V,:P+]@E;+>=$3;1N2P!WJK#!'*
MZ3^S%;Z%>)J^B^(9=.\11ZW'J_VVSTV*&WFN!:26LKRVP.QGECE8R.-NYPC8
M&W%`7.@T3X_^&?$-_=V&C67B"ZO+/3&U%K>/3&9Y(UO)+,JH!Y?SX9%QZ*6S
MCFJ]C^T9X/NO!M]XKU*'6]'T#3[G[*][J.G-$DDHN7MG5,$EMDL;A_[JJ6^[
MS570OV>Y/"OC"SUWPSXKU"P:/2HM.O(?L,+F[07DMY*^XCY&DEGDW8&`K87!
MP:I6G[,%C)X0T[PQXEUN37=#L;K5[N2SNM/C5+B?4#*Q=@I'^K-Q.%`ZK(0<
MX!H'=G0>(OCYX8\,>)/$7A^^MM8DUKPYID6J-9PVJLU]9N0&FMB7"R"//SKD
M,HYQ@J3CW/[3?AZPO-;AU?PUXQTZ/P[9P7FIW-U80K':P3B4PR.?.)17\AQE
M@`O&_;FL_P#X96M=7\+_`-C^.?%>KZ]-;0V*:=JHMXK6]LGM8S%Y@E0?,9(F
M,<@(PZLP(YKLI_A`LWBGQIKR:]J$-WXQM+*U=8X(MEJEH7,04%3O!,L@=7R'
M5MN`*!'5^%O$%IXNT6+4["WN8()9)$5;E`K'8Y4L""5925RK*2K`@@D&M8PH
M?X17.?#GP%I_PT\)6N@:$D4=I;2S3!((%@B5Y96E<1Q+\L:;G;:@X48`Z5TU
M`#!$BC`44NQ?[HIU%`#=B^@HV#T%.HH`;L7T%((D'113Z*`&&-3U%+L7TIU%
M`7(S!&6R4&?6@P(>J@U)10.[&>2G]T4H10,`#%.HH%<;L7^Z*:+>(-N"+GUQ
M4E%`7&^6O]T?E1Y:_P!T?E3J*=V`WRU_NC\J:84/\(J2BB[`C^SQ_P!Q?RH^
MSQ_W%_*I**5P&>3'_<7\J3[/'_SS7\JDHHN!'Y$?]Q?RI1#&O1%'X4^B@!HC
M4'(4`^PI=H/44M%`#=B^@H,:GJ*=10#5R,PQGJHI?)0]5%/HH%9#!"@Z**7R
MU]/UIU%`60W8/2CRU]!3J*`LAOEKZ"CRU]*=11<+(9Y2^E'E+Z4^BG=BY8]A
M-HQC`HVCT%+12'9#=@/:C8OI3J*!C=B^E*`!TI:*`"BBB@`HHHH`****`"BB
MB@!",^GXTF#Z"G44F@.6\53:K:0O-:0F>&-<L(OF8#UV]3^%>*^)?CWJGA2Y
M,:E/E_Y97T15L_C@G\*^DBH/7/YUF:QX7T?Q#%Y>N:98WR8QBX@5\?F*[</B
M:<+*K#F1Y^)PE2>M*;BSY-UC]MC6[&%XX-&T@S`_ZYWD"#W(_P#KUXO+J_C;
M]K#XC6&E75S<7ELMR/M"Q0[+33[;</,8?W6(&`2<DU]P7G[-'PROIVEN?".F
M,S')`+J/R!Q78^&_!6A>#=/^P^%-)L=)M.OE6<`C!/J<=?QKTH9E@J"<L/1]
M_I?H>9++<=6M"O6]WK;J:6FVD>GV-M:VXQ%;0K$@_P!E0`/Y5;IJ(%``&,#`
MIU>`O,^B2LK!1113&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
<%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g912919img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g912919img002.jpg
M_]C_X``02D9)1@`!`0$"6`)8``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"``P`L8#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]4LCU%!8#J0/QKG=;L?$;W>[0+[2;>U*#,=S9/*V_N=P<<=.,5G1Z
M9XQWYEUCP^R]U_LJ3_X[32,I5;2MRMG9A@>A!_&C</45QSZ9XN)^36-!0>@T
MR3_X[33I'BUQ^\UK0^.F-+D//_?VGRD.NU]B7W+_`#.SW#U'YTF]?4?G7%C0
M_%G?7=$S[:.__P`=H_L+Q9@_\3[1MW8_V.W'_D6CE(^M/_GW+_R7_P"2.TWJ
M.K#\Z#(HZLOYUQ<>A>*O^6^O:.Y]1H[#_P!JTC>'O%+29_X2+2U3'W!HV?U,
ME'*'UJ7_`#[E_P"2_P#R1VOF+_>7\Z/,3^\OYUQH\/\`B7OXATW\-'Q_[4I#
MX>\2Y_Y&.P'_`'!Q_P#%T<HOK<O^?<O_`"7_`.2.T#`]"#^-&1ZBN(D\.>*6
M(\KQ391CN!HJG/\`X_1_PC'BGOXLM_\`P3)_\71RC6*;_P"7<O\`R7_Y([?<
M!U(_.@,&^Z0?H:XC_A&/%.>?%L&.X_L5/_BZ>/#?B9#^Z\5QJ#U`T>+G\S1R
ME+$2;_AR_P#)?_DCM:3('6N/;0/$K(0/%6W/<:5#Q1'X?\2H"'\62-SVTJ`?
MTHY67[5_R/\`#_,[`D`9)Q1N&.HKC!X=\4`\^,9B/3^R;<?TI?\`A%?$\C!O
M^$SN`/3^RK?_``I6:W'[67\C_#_,['>O]X?G1O7^\/SKDSX4\1-]_P`7W9QZ
M:=`/_9:B;P7KK$D^,M3&?2RML?\`H%`O:R_D?X'9`@]#03CK7&?\(3K9_P"9
MSU;_`,`[;_XBEC\$ZRC9?QAJSCT-I;C_`-DH:%[6I_(_P.Q\Q<XW#/UIU<<?
M!>K'/_%7ZPH/9;>W'_M.D_X0?5/^AQ\0?]\6_P#\;I![6I_(_P`#L2P'4B@$
M'H1Q7(#P3J0(W>+_`!"<>T'_`,;HD\$:B[$CQ?XC4'L#!_\`&J=@]K/^1_@=
M;YJ#JR_G2AU(X8?G7'1^!+Y6)D\8^)I!Z;H!_**B3P#=N<CQAXJ3V6:#'_HJ
MBPO;5/Y/Q1V.]?[P_.CS%_O+^=<9_P`*^N_^AR\6?]_H/_C5(?AW,P^;Q=XL
MR>I%U&/_`&G18/;5/Y/Q1VGF)G[Z_G2>:G]]?SKC8_AT\9R?%7BI_=KN,_\`
MM.F?\*SE/WO%OBUO^WU!_)*$A.M4Z4_Q1VX93T(/XT9'J*X,_#DK-D^*?&)V
MKMVC4@`1_P!\=:7_`(5XAZ^(_&#?752,?DM5R,GZQ5_Y]/[U_F=T74=2/SH\
MQ/[R_G7#)\-K61L-KGBQB?[VL28IS?"JS<Y.M>*1]-9E']:7+;<I5ZK_`.7;
M^]'<;AZC\Z-PSC(S7$1_"NP0Y_MGQ6_LVN3_`/Q5/_X5=IQX.J^*#_W'+C_X
MJBR'[6I_)^)VF:,UQ!^%>F'_`)BWBH?37KG_`.*IP^%NFCIJGBAO8Z[<?_%4
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MO_X!]?T5X_\`#G3?AA\6?"EOXE^'$UOX@T*[DDCAOHKJYVNT;%7`WL#PP(Z5
MTW_"I?"W_0*3_P`"9_\`XNJ42'/$7TBOO?\`\B=U17##X2^%L_\`(*3_`,")
MO_BZ'^$OA5\;](A;'3,LO_Q='*+VF)_D7_@3_P#D3N,CU%&X>HKA?^%2>$Q_
MS!+8_P#;63_XJC_A4GA/_H"6W_?V3_XJCE9'M<5_)'_P)_\`R!W.]?[R_G33
M/&I^:1!]6%<+_P`*?\'_`/0`M/\`OM__`(JI4^%/A2-0J:%8!1V*D_S-/D8>
MVQ/\D?\`P*7_`,@=I]IA_P">L7_?8H^U0_\`/:+_`+[%<8?A5X4/_,!T[_OR
M*/\`A57A7_H`Z9_WY%'(Q^UQ/\D?_`I?_*SL_M4/_/:+_OL5&=1M%^]=6X^L
MJ_XUR(^%?A;'&A:8/^V&:1/A+X1C)/\`PCVBMGL;%:.4I5,3_)'_`,"?_P`B
M==_:EE_S]VO_`'^7_&C^U++&?M=KC_KLO^-<H/A5X1!X\-Z&/^W%:>/A?X4"
ME1X>T7:W4?85YHY`Y\1_(OO?_P`B=/\`VM8_\_MI_P!_E_QH_M:Q/2\M/^_R
M_P"-<W_PK/PIM"_\(YHF!_TY)_A2K\-?"JC">'=%`]!91_X4N4KVE3LOO_X!
MT1UBP7K?68^LZ_XTW^W-._Z"%E_X$+_C6%'\-?"F3GP[HGXV,?\`A2GX8^%"
M<_\`"-Z!^.GQG^E*Q2E5?1?>;9U[3!UU&Q'_`&\I_C31XCTDG`U33L^GVI/\
M:R8_AKX5C!V^'=#7/]VPC'_LM/\`^%<^%Q]WP]H8/K]@C_PH"]7R-(^)=(4X
M;5=-!]#=)_C0WB72%^]JNFCZW2?XUFCX=>&._A_1<^UC'_\`$U)'X$\/0$F#
M1-'0GK_H,?/Z4!>KY%MO%>B+G=K.E#'7-Y'_`(TW_A,-!_Z#>D?^!T?^-5_^
M$&\/[M_]C:3O]?L4?\L4X>#=$'_,(TC_`,%\?^%%@O4\OQ)/^$R\/_\`0=T?
M_P`#H_\`XJFMXW\.J<-K^B@^]_%_\52_\(CH_P#T#-._\`T_PH_X1#1N^E::
M?K9Q_P"%!-Z_E^(W_A.?#?\`T,&B?^#"+_XJAO'7AM1EO$.B`#N=0B_^*I3X
M2T9>FE:7^-E'_A3QX:TL+@:?8`#L+5,?EMHL%Z_E^)"_C[PS'C?XBT-=PR,Z
MA%S_`./4T_$+PN.OB/0__`^/_P"*JR=`L>B6>GJ/^O1#_2I5T/35.18V6?:W
M0?THL'^T=+?<S-?XD>%4)!\1Z+QZ7B'^M,_X65X5/W?$>C?^!:?XUL?V38CA
M;6W4>@A7_"E&EV8_Y=K?_ORO^%%@MB>Z_$PV^)_A09!\1:/QW%VN:0_%#PD/
M^9CTS_P(%;W]FV@Y6W@!]?*7_"E%E`.D<0^D8HL*V)[K[F<[_P`+8\(]O$.E
M_P#?ZD/Q6\)EOE\1Z4,]O.KI/L<7]R/_`+Y%+]DB_N1_]\"BP?[3_=_$YI_B
MKX50@-XATW)Z8DS_`$II^+7A,==?T\?\";_"NF^R1?W5_P"^:46R#H$_[YIV
M"V)\OQ.7'Q:\)GIKUDWN`W_Q-6++XD^'=4O8+2PU>&:XN'VQHB/EC]2N!70?
M9T/55_#BE6V"<X`_W>*+(J/MMW:WS+"G(]:*1/N],>U%2;H4@'K2;%]!3J*!
M-)[C=@'0"EP!VI:*`LA,48I:*!B8HQ2T4`)1BEHH`3%&*6B@!,4%0>H%+10`
MW8OH*-B^@IU%.[)Y5V&[%]!2@`=`*6BB['RKL)BC%+12"R"BBB@84444`%%%
M%`#=@]!1L7T%.HH`;L7T%&Q?04ZO&OVR==O?#?[+?Q-U#1I+B&^B\/SI;RV\
M[0R1N^$#HZ\JPW9!'<4`>Q[!Z"N-^,'AGQ#XS\`W^A>!M570M2U1XH6U/>ZO
M:0&13*\>PAM^P,!AEY/45^;GQ-^)WCBX_9L'PH?Q)KEIXK^%=QK-[XGU2&]D
M2\ET_3EC:S+R!MV)C>P+G)W>4>M?6'AKXJ?%#XW?$SQ!H?P@UKPOX3\-?#I=
M+@U*75],?4+S6)[BWCN&4`2*L,8C;:&^9BV3TZ`'4S^!/C3JWAK6[?6O$^D'
M4;J6QFTS[,QA2UD@O4DDPZQABCPK@JV[)R"<,:R]<^''QROM5TEXO%&FW":-
M=37-K=O.D3$&WFCV2Q+`%D=FF7:<A4\O)4G!KYJCU;0O&WP4U[X^_'>Q^(7Q
M"U&W\37T%UI'A[Q))IT/@VUMIV6-$@$\(!`CCW-\SL90<8R:^K_@U\:M5\7_
M`!.^-&F^))K6'PWX$ETI]*Q"$D@MY[`7$OFOD[R#W[4"LBH?!WQQO)X7M_&$
M-G%#JL*W?VB"!I+JWC_CB58]L:MU="6+X."G0M\0?"KXR:BEF+/Q[;>?9YF@
MN'D"+%.UM(KEXU@Q*OG2?("5$:H"0YX'S5X,_P""A7C+Q?\`!OXX:W'>>&E\
M1>&+.WUSPDMO`LJP:=/="'RKA-W,L?R[@<']ZI]*U?C-^U+\:/@A8>,?"_B'
MQ%X7U?78-!T?7='\1:?H!C>UANM0BM)H9;-G=78!F9"#SZ<X`,]UU[X._&?5
M;!;=?B'%/'.C?;(II3!N(MFB1%:*$$(7<R..22%P1@5<N/AK\2O&O@O3AXIU
M2WN+Y-1OV-C?3M9^5`R>397#/;@YFBV"<IG!:5N5*KCY6D_;!^,^N^"O!MOX
M>\274M_JOCS6]!;5]+\"I=:CJ-I9V\4D;G2V;,4H9W#1Y4A1D].?5-5^+?QW
MTOXM^%/AI::CY[_$RSTW5=&\2:CH$%E-HUI;Q;M7BGM.?WQ(0JK9V&8+GC(`
M/6'^%7QMDU2^\[XIVS:4TLALHH;)(9T0+*(@[F-@3N6U9N.=TX_NTD'PD^*N
MH>)_#5SXM\86FJ:7I.O1ZA<P>;Y6!$7Y14A&\.&4>6[8C(8[GW`+Q_\`P45^
M(=MH'PV\*^"[N]UFPA^(7B.WM-2N-&MY9[R'3(")KMXHXOG9L+&OR_WS7G7[
M-7[3?B?7M!_9O\,V>H2H+G6-;\,^*X;ZT!N+@:?:;[8L7&^-_+,3-T))(-`'
ML'AK]GSXI>&+F&>S^)$N56.U<&1IG6TWM*RJTR.OF"::4[BN61(D)`&1<O\`
MX%?%*^O4ENOB/+>0Q7#W,,;W$L#0S>2JQLC(G`61[ABF,,K(AP%&%\+_`!@\
M5ZEX^_:4TR]OH'LOAU'9MX=06B`VQDTUIWW'&9,R`'YL^G2OF;Q?^WKXO\+6
MO[/5YJ?B73(!J'AZPU[QY"UK$CZM#=W"0>7$NPA&11-,0NWY5^@H`^R?AK\.
M/'WA_P`97>J_$'QQ+XAT]ENA;649:*-6DD0QL4`"X6-"`,G!8D'GCUJOSC^)
M'[:GQ'\%>//B[X=OM0\K2)?%\&D>!]:ALXF^Q7,<MH\]F_RD,LEK,SJS9.5?
MGICUOP7X\^)OQ@M/B1\1[+XA#PQH7@G5]:TRQ\&6>C6TV4L4D0/=S2`R"9V`
MD&W`4;>#F@#[!KS'QY_R6WX6_P"YK/\`Z31UY)^P-X\\>?$CP"=>^*FJ>/=5
MGU33;.YAFUW1;*RL&+[RS6,EO\\J$;<F0`@;<#DUZYX\_P"2V_"S_<UG_P!)
MHZ`/D+_@LFN/A+\/L#C_`(227_TF>OR>K]B_^"L&E>';_P"#GA&?QWK^K:%I
MMMXE`4Z=IBWS32M;R[04:6,``!CG)^E?ES_8_P`'?^B@>-?_``CH?_DR@#]7
MO^"<'B*U\(?L)6.O:L)FLM$DUF^N1"FYS'%/*[;1D9.%.!FOH+X"?'GPK^T=
M\/H?&'PZ>^_LR2ZEM7AOX!#/!+&1E70$X."K#GD,#WKYL_91@T.W_P""<'B*
M/P9J5_J^E#1?$GE75]8K:2LV+C<#&LC@`'(!W'/7BO-OAE\1[G]D_P"'NC:S
M81O/:?&#X6Z=?:!;=?-\56UO#;"$#UGCEMV]S$U`6/LOX7?M+^#/B_\`$GQQ
MX(\&-J<VK>`)UAU2>:U"6TC%W0^3(&.\!XV4\#D=Z].U+4;31].NK_5;B&TL
MK*%Y[FXF<(D4:`LSL3P``"2?:OS/GTW5_P!FKQ/\1]`\+ZK+I.HVWA+P1I.K
M^(8V`>R-[>R)?7X;!`;=-*P8C@L#VKUW]I'X/V'@GX9_$SPQ\*O''B&YU#6_
MAU/>/X)O]5GU-KN."XB\[4(Y)G=T9H]\3*N%D+\`$4"LCU-/VV?"JI8ZQJ/A
M/X@Z;X`U.>*"T\<WNBB+2Y#*X2*0Y?SDA=B`)6C"\@]"#7KGAGXE:/XL\;^+
M_"NEI>#4O!+V::DTL06)C=0^='Y;9.X;.O`P?6OG?X__`!5UW2_V6K#XC?!'
M4/AYJO@+2O#<%U?:5K6D/>B^3]R(XHRLJI&5S@JRL0P'3%>?>./B0OA_QC^T
MKYEUKVF2^(?^$+M+&3P_/'!>FZO;58TACFD^2(-]PR'[@8L.0*!GWK@5QWC#
MXG:;X,\:>"?#6HVU[->>.KVYM+&6%5,<+P6[3L9"2"`50@8!YKX+UKXB^._@
M?J_QQT3PY;7'A'^ROAG::M#I,7BR?Q+_`&9=O>"![U9IAOC<02%S'C'[M&[Y
MKTV\^&?A7X:?M"?LTQ>"_%6O:Q+J[ZG<SPZGK\^I?V@HTU\7^)7;8Q+;24VJ
MVX#'RT`?;&!1@5^:^E:7JGA7]D7PGXYL/$?C*^\0?$;Q1;Z#K^I77B:=#9Z4
M^IW"^1!*[%+1&9(XS,!N`D8YZ`=#!\+O'-KKOQ%\&_#V2T\"W%KX.M?$.D^%
M=/\`'MYKD\&K6UYYL%P7D1?+BN`KPNA;#<,5(YH`_0?`HQ7R]^SQ\4)OVG/B
M]<_$+1[F\M_"'A/PM::3!9+,Z12:Q=JES?!TR`S0*(8?F'!9\=Z^HJ`L)BC%
M+10*R$Q1BEHH&)BC%+10%A,48I:*!60F*,4M%`60F*6BB@8FT>E&!2T4`)BC
M%+10`F*38/04ZB@5D-V+Z"C8OH*=10%D-V+Z"C8OH*=10%D-V+Z"C8OH*=10
M%D-V+Z"E"@=`*6B@+(3%+110,****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*Y3XI_#31_C!X!U
M?P?XO-Z-'UJ-([K['<&"4JLBN`''3E!GU&1WKJZ*`/(O%7[*WP[\7WGCZ]U+
M2[B'4/B5HL&C:_>6UTR22VT*[4"=0C8"Y('.U<YQ6?XE_9!\`^(_%FF^);>7
MQ3H&MV,%K;W-UH&OW&G'58K8!85NQ$P$VT`#)&<<9QQ7MM%`'@GCK]A_X3?$
M#Q%K6L:MI.L6$OB9P^NVFD:[=V%IJS@YWW$$4BQR,>Y(YZGGFG^)_P!BSX=>
M*?%&N:]/+XQTZ\\2PQPZK%I7BF\LX+N-+<6ZJ\4;A&'E#;R#U/K7O%%`'AGB
M#]BOX3>(K"&SN/#TEG!#X8'AIET^\DM?.L!)'(%DV$;WW1(=[9;KSS3++]BG
MX56?AO5=';2=5O#KES93ZCJ=]K5S=7]R;259;=&N9'9Q&CHN$!"\<BO=J*`/
M!/&G[$7PL\=ZA?7VKV.NVMUJ&OW&ORRZ=KMS:,M]/$D4TB&-P5W+&N0,#.3W
MKM]'^`OA'1-<\$:Q:V^HRZC\/=)N-*T.>YU&:9H[>=463S"S$RN1&OS/D]?6
MO1**`.6U7X9>'-;^(.A>-M4T_P"T>)/#5I<6FEW;3OBVCN`!+A,[,L`!DC..
M,UYWXP_8S^$OCG7+[6-?\-SG4=1U5]6GGM-6N[5C>/$L3S+Y<B[69$4';C.,
MFO;:*`/#]/\`V+_A1I?B%=<LM$U2/4OL\<$LO_"07Q%PD<'D()5,V)"(_ERX
M)[]:T=(_9,^%>B^'-<T*S\+0OIGB+1K;1;^*XNIIBUC;QM'#"C,Y9`JLW*D'
M)R23S7K]%`'D5Q^R?\+;OPSJ&@7?A>.?3=4UBUUFZ22\G=WOK:-(XI]Y?<&"
M1J#@C(SG.3F35_V5?A;KGQ!N?&M_X5@'B&^)>\FM[R>"*[D,9C,DL*.(W?8S
M#<RD\GG->LT4`>;_``H_9T^'7P.N;VX^%7AFW\/RZA`D%QY-U/('C0DJH61V
M"@$GH!5CQEHE_??%KX=ZC9VDTUCIBZH+RX4?+!YD"*F[_>(('TKT"B@#PO\`
M:\^$'Q!^,W@#2](^"WB?2_"FL6FK)=7%WJ$9=)(!'(I0`1OSN93T['FODC_A
M@O\`:G_Z+-X,_P#`5O\`Y%K]*Z*`/'/V>?A#XD\$_`F/P1\<=6TWQ?JEQ]MB
MU*YM4*PW-O.[XCQL0_ZMMIX%=BWP=\%/H?A/1Y?#6ERZ;X%G@G\.6\L6]=-D
M@0I$\><D%5.`3GUZBNRHH`Y&^^$O@[5-:\0ZMJGAW3+V_P#%FG1:;K<ES#YH
MO[6+=Y<4B-E2HWMV[^PJG\.?@;X$^$L]Y<?#SPU8:1=:A&L5Q<H7EF>)3E8O
M,D9F$:D\("%'8"NZHH`\;OOV.?@IJ.OSZQ>?#?PS)>7,AEF3[.5@D<MN+-;@
M^46)&2=F377ZO\%O`FOCQ&-;\*:)?#Q=#;PZX)[57%^ENNV`2`]=@X7T[5VM
M%`'`>#_@%\.?`$UU+X.\&>']*EOK%["[>&S7-S;.VYHI"<[U)ZAL^G2JWA']
MG#X8>`]3LM2\'>!O#NDZAIL[SV=S;6@62W=HS&VQNJC8S+M'')XKTBB@#F;/
MX9^%+#P,_@RU\/:4OA22&6%]':V5K9HY&9W4H<@@LS$^YJGX#^$7A#X4:;?6
MOPO\.:-X;^WG=,]I:@&5P,(9&^\X7L">!G&,UV5%`'F7[.GP6@^`GPML?"RW
M<.I7YN;F_P!5U"*W\A;V\N)6DED"9.T98*!DX50*]-HHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
'`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
